Fetal	O
and	O
neonatal	O
mortality	O
were	O
similar	O
in	O
those	O
groups	O
;	O
however	O
,	O
selected	O
maternal	O
and	O
newborn	O
morbidities	O
were	O
significantly	O
greater	O
in	O
women	O
with	O
hypertension	B-DISO
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
only	O
V	O
(	O
T	O
)	O
was	O
independently	O
associated	O
with	O
the	O
development	O
of	O
AL	O
in	O
children	O
with	O
primary	O
severe	O
respiratory	B-DISO
disease	I-DISO
(	O
r	O
(	O
2	O
)	O
=	O
-	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

Sepsis	B-DISO
,	O
MOSF	O
,	O
and	O
lung	O
superinfection	B-DISO
with	O
Pseudomonas	O
or	O
Candida	O
species	O
may	O
be	O
also	O
important	O
factors	O
in	O
the	O
development	O
of	O
AL	O
in	O
critically	B-DISO
ill	I-DISO
children	O
.	O

The	O
study	O
was	O
carried	O
out	O
on	O
71	O
faecal	O
samples	O
of	O
pups	O
with	O
enteritis	B-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
cleavage	O
activity	O
of	O
the	O
first	O
papain	O
-	O
like	O
proteinase	O
domain	O
encoded	O
by	O
open	O
reading	O
frame	O
1a	O
of	O
the	O
coronavirus	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
and	O
characterization	O
of	O
the	O
cleavage	O
products	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
sialic	O
acid	O
binding	O
activity	O
of	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
by	O
analysis	O
of	O
haemagglutination	O
-	O
deficient	O
mutants	O
.	O

TITLE	O
:	O
Initial	O
severity	O
of	O
metabolic	B-DISO
acidosis	I-DISO
predicts	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
in	O
severely	O
traumatized	O
patients	O
.	O

Initial	O
base	O
deficit	B-DISO
was	O
significantly	O
lower	O
in	O
patients	O
who	O
developed	O
acute	O
lung	O
injury	O
than	O
in	O
those	O
who	O
did	O
not	O
(-	O
8	O
.	O
8	O
+/-	O
4	O
.	O
5	O
vs	O
.	O
-	O
5	O
.	O
6	O
+/-	O
5	O
.	O
1	O
,	O
p	O
<.	O
01	O
).	O

Our	O
results	O
provide	O
evidence	O
of	O
oxidation	O
occurring	O
early	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
major	O
trauma	O
patients	O
,	O
with	O
protein	O
carbonyl	O
measurements	O
providing	O
a	O
sensitive	O
index	O
of	O
this	O
process	O
.	O

Six	O
patients	O
with	O
acute	O
HPE	O
and	O
mechanically	O
ventilated	O
in	O
the	O
supine	O
position	O
(	O
Group	O
2	O
),	O
20	O
patients	O
with	O
ARDS	B-DISO
(	O
Group	O
3	O
),	O
and	O
5	O
patients	O
with	O
pulmonary	B-DISO
fibrosis	I-DISO
(	O
PF	O
)	O
(	O
Group	O
4	O
)	O
served	O
as	O
control	O
patients	O
.	O

Fifteen	O
of	O
20	O
patients	O
with	O
ARDS	B-DISO
(	O
75	O
%)	O
improved	O
oxygenation	O
when	O
in	O
the	O
prone	O
position	O
.	O

Patients	O
with	O
HPE	O
and	O
early	O
ARDS	B-DISO
responded	O
better	O
to	O
prone	O
positioning	O
than	O
did	O
patients	O
with	O
late	O
ARDS	B-DISO
and	O
PF	O
.	O

ABSTRACT	O
:	O
Changes	O
in	O
the	O
alveolar	O
hemostatic	O
balance	O
in	O
severe	O
pneumonia	B-DISO
were	O
compared	O
with	O
those	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
contrast	O
,	O
PCT	B-DISO
is	O
generally	O
not	O
induced	O
by	O
severe	O
viral	B-DISO
infections	I-DISO
or	O
inflammatory	O
reactions	O
of	O
non	O
-	O
infectious	B-DISO
origin	O
.	O

PCT	B-DISO
may	O
be	O
helpful	O
in	O
the	O
differentiation	O
between	O
infectious	B-DISO
and	O
non	O
-	O
infectious	B-DISO
origin	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
pancreatitis	B-DISO
,	O
cardiogenic	B-DISO
shock	I-DISO
and	O
acute	O
rejection	O
of	O
organ	O
transplants	O
.	O

PCT	B-DISO
monitoring	O
may	O
be	O
useful	O
in	O
patients	O
with	O
high	O
risk	O
of	O
bacterial	B-DISO
infection	I-DISO
(	O
major	O
surgery	O
,	O
trauma	O
,	O
immunocompromised	O
patients	O
).	O

Outcome	O
results	O
by	O
diagnosis	O
were	O
pneumonia	B-DISO
,	O
73	O
%;	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
67	O
%;	O
and	O
airway	O
support	O
,	O
60	O
%,	O
with	O
overall	O
lung	O
recovery	O
occurring	O
in	O
77	O
%,	O
and	O
hospital	O
survival	O
in	O
71	O
%.	O

ECLS	O
provides	O
life	O
support	O
in	O
severe	O
respiratory	B-DISO
failure	I-DISO
in	O
children	O
,	O
allowing	O
time	O
for	O
injured	O
lungs	O
to	O
recover	O
.	O

ABSTRACT	O
:	O
Prone	O
ventilation	O
improves	O
oxygenation	O
in	O
selected	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Our	O
objective	O
was	O
to	O
critically	O
evaluate	O
our	O
experience	O
with	O
prone	O
positioning	O
in	O
patients	O
with	O
severe	O
postinjury	O
ARDS	B-DISO
.	O

We	O
have	O
reported	O
alterations	O
of	O
cellular	O
functions	O
by	O
macrophages	O
(	O
Mphi	O
)	O
exposed	O
to	O
cocaine	O
in	O
vitro	O
,	O
including	O
the	O
inhibition	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
replication	O
.	O

ABSTRACT	O
:	O
Hybridomas	O
secreting	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
the	O
Nebraska	O
calf	O
diarrhea	B-DISO
strain	O
of	O
bovine	O
rotavirus	O
(	O
BRV	B-DISO
)	O
were	O
characterized	O
.	O

Indirect	O
fluorescent	O
-	O
antibody	O
assay	O
,	O
immunodot	O
assay	O
,	O
and	O
immunoprecipitation	O
were	O
used	O
to	O
select	O
hybridomas	O
that	O
produced	O
anti	O
-	O
BRV	B-DISO
MAbs	O
.	O

Seven	O
of	O
the	O
MAbs	O
were	O
shown	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
Western	O
blot	O
assay	O
to	O
be	O
reactive	O
with	O
the	O
BRV	B-DISO
outer	O
capsid	O
protein	O
,	O
VP7	O
,	O
which	O
has	O
a	O
molecular	O
mass	O
of	O
37	O
.	O
5	O
kDa	O
.	O

Both	O
were	O
subtype	O
A	O
specific	O
(	O
G6	O
subtype	O
)	O
but	O
did	O
not	O
react	O
with	O
all	O
isolates	O
of	O
BRV	B-DISO
group	O
A	O
.	O

TITLE	O
:	O
Short	O
-	O
term	O
effect	O
of	O
inhaled	O
nitric	O
oxide	O
and	O
prone	O
positioning	O
on	O
gas	O
exchange	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
short	O
-	O
term	O
effects	O
of	O
inhaled	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
prone	O
positioning	O
in	O
improving	O
oxygenation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Four	O
proteins	O
processed	O
from	O
the	O
replicase	O
gene	O
polyprotein	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
colocalize	O
in	O
the	O
cell	O
periphery	O
and	O
adjacent	O
to	O
sites	O
of	O
virion	O
assembly	O
.	O

On	O
Day	O
1	O
control	O
animals	O
had	O
significant	O
leukopenia	B-DISO
,	O
whereas	O
anti	O
-	O
CD18	O
-	O
treated	O
animals	O
had	O
a	O
moderate	O
increase	O
of	O
the	O
number	O
of	O
circulating	O
WBC	O
compared	O
with	O
baseline	O
values	O
(	O
p	O
<	O
0	O
.	O
05	O
between	O
groups	O
).	O

The	O
lungs	O
of	O
the	O
anti	O
-	O
CD18	O
-	O
treated	O
animals	O
showed	O
minor	O
signs	O
of	O
inflammation	B-DISO
and	O
PMN	O
infiltration	B-DISO
whereas	O
controls	O
had	O
interstitial	O
and	O
intra	O
-	O
alveolar	B-DISO
edema	I-DISO
and	O
a	O
large	O
number	O
of	O
granulocytes	O
.	O

In	O
this	O
particular	O
model	O
of	O
ARDS	B-DISO
the	O
monoclonal	O
antibody	O
against	O
the	O
CD11	O
-	O
CD18	O
complex	O
had	O
a	O
beneficial	O
effect	O
,	O
reducing	O
PMN	O
infiltration	B-DISO
and	O
oxygen	O
radical	O
release	O
in	O
the	O
lungs	O
,	O
preventing	O
alveolocapillary	O
membrane	O
damage	O
,	O
improving	O
gas	O
exchange	O
and	O
,	O
finally	O
,	O
significantly	O
reducing	O
mortality	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
turkeys	O
with	O
the	O
haemorrhagic	B-DISO
enteritis	I-DISO
virus	O
(	O
HEV	O
),	O
a	O
type	O
II	O
avian	O
adenovirus	B-DISO
,	O
results	O
in	O
varying	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

Recent	O
studies	O
indicate	O
that	O
immune	O
responses	O
play	O
a	O
central	O
role	O
in	O
disease	O
pathogenesis	B-DISO
.	O

Treatment	O
with	O
thalidomide	O
,	O
which	O
is	O
a	O
potent	O
TNF	O
down	O
-	O
regulatory	O
drug	O
,	O
prevented	O
HEV	O
-	O
induced	O
intestinal	B-DISO
haemorrhage	I-DISO
and	O
treatment	O
with	O
an	O
IFN	O
-	O
inducing	O
chemical	O
prevented	O
HEV	O
-	O
replication	O
and	O
inhibited	O
HEV	O
-	O
induced	O
pathological	O
and	O
histopathological	O
lesions	O
.	O

The	O
antibody	O
responses	O
to	O
BCV	O
were	O
followed	O
in	O
milk	O
and	O
serum	O
from	O
six	O
dairy	O
cows	O
and	O
in	O
serum	O
from	O
four	O
calves	O
for	O
a	O
period	O
of	O
1	O
year	O
after	O
an	O
outbreak	O
of	O
winter	B-DISO
dysentery	I-DISO
(	O
WD	O
).	O

TITLE	O
:	O
Characterization	O
of	O
the	O
stunting	O
syndrome	B-DISO
agent	O
:	O
relatedness	O
to	O
known	O
viruses	O
.	O

ABSTRACT	O
:	O
A	O
582	O
-	O
base	O
pair	O
segment	O
located	O
in	O
the	O
nucleocapsid	O
protein	O
terminal	O
part	O
of	O
the	O
S1	O
gene	O
of	O
26	O
Arkansas	O
(	O
Ark	O
)-	O
type	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
from	O
Mississippi	O
broilers	O
was	O
amplified	O
and	O
sequenced	O
.	O

Turkeys	O
inoculated	O
with	O
only	O
R98	O
/	O
5	O
did	O
not	O
develop	O
clinically	O
apparent	O
disease	O
,	O
and	O
only	O
mild	O
disease	O
and	O
moderate	O
growth	O
depression	B-DISO
were	O
observed	O
in	O
turkeys	O
inoculated	O
with	O
only	O
TCV	O
.	O

Turkeys	O
dually	O
inoculated	O
with	O
TCV	O
and	O
R98	O
/	O
5	O
developed	O
severe	O
enteritis	B-DISO
with	O
high	O
mortality	O
(	O
38	O
/	O
48	O
,	O
79	O
%)	O
and	O
marked	O
growth	O
depression	B-DISO
.	O

An	O
apparent	O
synergistic	O
effect	O
in	O
dually	O
inoculated	O
turkeys	O
was	O
indicated	O
by	O
increased	O
mortality	O
,	O
enhanced	O
growth	O
depression	B-DISO
,	O
and	O
enhanced	O
AE	O
lesion	O
development	O
.	O

Both	O
patients	O
had	O
severe	O
gastrointestinal	O
tract	O
hemorrhage	B-DISO
complications	O
at	O
their	O
nadir	O
.	O

Marble	B-DISO
spleen	I-DISO
disease	I-DISO
and	O
pheasant	O
coronavirus	O
-	O
associated	O
nephritis	B-DISO
,	O
two	O
viral	O
conditions	O
capable	O
of	O
causing	O
high	O
mortality	O
,	O
were	O
diagnosed	O
in	O
a	O
few	O
birds	O
in	O
1996	O
and	O
1997	O
.	O

A	O
lymphomatous	B-DISO
condition	B-DISO
of	O
uncertain	O
aetiology	O
was	O
detected	O
in	O
a	O
small	O
number	O
of	O
birds	O
.	O

ABSTRACT	O
:	O
To	O
group	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
,	O
a	O
genetic	O
grouping	O
method	O
based	O
on	O
hypervariable	O
region	O
1	O
(	O
HVR	O
1	O
,	O
nucleotides	O
168	O
to	O
197	O
)	O
was	O
compared	O
with	O
that	O
based	O
on	O
the	O
whole	O
S1	O
gene	O
.	O

TITLE	O
:	O
Right	O
atrial	O
pressure	O
predicts	O
hemodynamic	O
response	O
to	O
apneic	B-DISO
positive	O
airway	O
pressure	O
.	O

Pulmonary	B-DISO
interstitial	I-DISO
emphysema	I-DISO
,	O
serious	O
intraventricular	B-DISO
hemorrhage	I-DISO
,	O
and	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
occurred	O
more	O
frequently	O
in	O
patients	O
with	O
early	O
neutropenia	O
.	O

All	O
cis	B-DISO
-	O
acting	O
frameshift	B-DISO
signals	O
encoded	O
in	O
mRNAs	O
are	O
minimally	O
composed	O
of	O
two	O
functional	O
elements	O
:	O
a	O
heptanucleotide	O
""""	O
slippery	O
sequence	O
""""	O
conforming	O
to	O
the	O
general	O
form	O
X	O
XXY	O
YYZ	O
,	O
followed	O
by	O
an	O
RNA	O
structural	O
element	O
,	O
usually	O
an	O
H	O
-	O
type	O
RNA	O
pseudoknot	O
,	O
positioned	O
an	O
optimal	O
number	O
of	O
nucleotides	O
(	O
5	O
to	O
9	O
)	O
downstream	O
.	O

To	O
determine	O
the	O
stimulus	O
for	O
systemic	O
inflammation	B-DISO
,	O
rats	O
treated	O
with	O
cryoablation	O
had	O
either	O
immediate	O
resection	O
of	O
the	O
ablated	O
segment	O
or	O
delayed	O
resection	O
after	O
a	O
15	O
-	O
minute	O
thawing	O
interval	O
.	O

These	O
findings	O
correlate	O
the	O
clinical	O
observation	O
of	O
an	O
increased	O
incidence	O
of	O
multisystem	O
injury	O
,	O
including	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
after	O
cryoablation	O
but	O
not	O
RFA	O
.	O

RESULTS	O
:	O
Histologic	O
lung	O
sections	O
after	O
cryoablation	O
showed	O
multiple	O
foci	O
of	O
perivenular	O
inflammation	B-DISO
,	O
with	O
activated	O
lymphocytes	O
,	O
foamy	O
macrophages	O
,	O
and	O
neutrophils	O
.	O

The	O
putative	O
virus	O
was	O
isolated	O
and	O
cultured	O
in	O
epithelioma	B-DISO
papillosum	O
cyprini	O
(	O
EPC	O
)	O
cells	O
.	O

The	O
majority	O
of	O
scientists	O
consider	O
disorders	O
in	O
the	O
ventilation	O
-	O
perfusion	O
function	O
of	O
the	O
lungs	O
the	O
main	O
factor	O
in	O
the	O
pathogenesis	B-DISO
of	O
burn	B-DISO
shock	I-DISO
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
indicated	O
that	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
interacted	O
with	O
specific	O
sequences	O
in	O
the	O
3	O
'	O
non	O
-	O
coding	O
region	O
of	O
IBV	O
RNA	O
.	O

ABSTRACT	O
:	O
Involvement	O
of	O
the	O
central	O
nervous	B-DISO
system	O
in	O
patients	O
with	O
essential	B-DISO
mixed	I-DISO
cryoglobulinaemia	I-DISO
is	O
rare	O
,	O
and	O
there	O
are	O
few	O
cases	O
described	O
in	O
the	O
medical	O
literature	O
.	O

Classical	O
studies	O
of	O
pathogenesis	B-DISO
have	O
revealed	O
different	O
lung	O
cell	O
tropisms	O
and	O
replication	O
kinetics	O
for	O
each	O
of	O
these	O
viruses	O
and	O
they	O
suggest	O
the	O
involvement	O
of	O
different	O
lung	O
inflammatory	B-DISO
responses	I-DISO
or	O
mediators	O
.	O

The	O
proinflammatory	O
cytokines	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
),	O
tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
have	O
been	O
shown	O
to	O
play	O
key	O
roles	O
in	O
several	O
respiratory	B-DISO
disease	I-DISO
conditions	O
.	O

Starting	O
from	O
literature	O
data	O
and	O
the	O
SARs	B-DISO
developed	O
in	O
this	O
work	O
,	O
a	O
putative	O
binding	O
mode	O
of	O
styrylquinoline	O
inhibitors	O
to	O
HIV	B-DISO
-	O
1	O
IN	O
was	O
derived	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
clinical	O
profiles	O
and	O
therapies	O
instituted	O
for	O
patients	O
with	O
severe	O
malaria	B-DISO
admitted	O
to	O
an	O
ICU	O
.	O

Four	O
patients	O
required	O
mechanical	O
ventilation	O
because	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
of	O
whom	O
three	O
died	O
.	O

TITLE	O
:	O
Zinc	O
chloride	O
smoke	O
inhalation	O
:	O
a	O
rare	O
cause	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
probability	O
of	O
cardiopulmonary	O
complications	O
increases	O
significantly	O
when	O
patients	O
develop	O
class	O
1	O
HELLP	B-DISO
syndrome	I-DISO
.	O

Exposure	O
of	O
the	O
liver	O
to	O
pancreatic	O
elastase	O
results	O
in	O
hepatic	O
inflammation	B-DISO
and	O
injury	O
which	O
appears	O
identical	O
to	O
that	O
seen	O
during	O
severe	O
AP	O
.	O

In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	O
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	B-DISO
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
PVL	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

TITLE	O
:	O
Elective	O
high	O
frequency	O
jet	O
ventilation	O
versus	O
conventional	O
ventilation	O
for	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
in	O
preterm	O
infants	O
.	O

From	O
1	O
/	O
RD	O
the	O
number	O
needed	O
to	O
treat	O
(	O
NNT	O
)	O
for	O
benefits	O
and	O
number	O
needed	O
to	O
harm	O
(	O
NNH	B-DISO
)	O
for	O
adverse	O
outcomes	O
were	O
calculated	O
.	O

Data	O
regarding	O
clinical	O
outcomes	O
including	O
the	O
incidence	O
of	O
pneumothorax	B-DISO
,	O
patent	B-DISO
ductus	I-DISO
arteriosus	I-DISO
,	O
pulmonary	B-DISO
interstitial	I-DISO
emphysema	I-DISO
,	O
pulmonary	B-DISO
hemorrhage	I-DISO
,	O
necrotizing	B-DISO
enterocolitis	I-DISO
,	O
retinopathy	B-DISO
of	I-DISO
prematurity	I-DISO
,	O
intraventricular	B-DISO
hemorrhage	I-DISO
(	O
any	O
and	O
severe	O
IVH	O
),	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
,	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
,	O
neonatal	O
mortality	O
,	O
mortality	O
prior	O
to	O
hospital	O
discharge	O
,	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
or	O
death	O
,	O
and	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
or	O
death	O
were	O
excerpted	O
from	O
the	O
reports	O
of	O
the	O
clinical	O
trials	O
by	O
the	O
reviewers	O
.	O

TITLE	O
:	O
Histoplasmosis	B-DISO
presenting	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
exposure	O
to	O
bat	O
feces	O
in	O
a	O
home	O
basement	O
.	O

None	O
of	O
the	O
patients	O
had	O
evidence	O
of	O
immune	B-DISO
deficiency	I-DISO
.	O

ABSTRACT	O
:	O
A	O
human	O
tumor	B-DISO
xenograft	O
contaminated	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
was	O
implanted	O
in	O
a	O
nude	O
rat	O
in	O
order	O
to	O
decontaminate	O
the	O
tumor	B-DISO
line	O
.	O

The	O
difference	O
between	O
the	O
two	O
trials	O
was	O
the	O
duration	O
of	O
implantation	O
of	O
the	O
tumor	B-DISO
in	O
the	O
nude	O
rat	O
,	O
i	O
.	O
e	O
.,	O
12	O
days	O
in	O
the	O
first	O
and	O
24	O
days	O
in	O
the	O
second	O
trial	O
.	O

ABSTRACT	O
:	O
We	O
have	O
isolated	O
the	O
virus	O
from	O
a	O
fecal	O
pellet	O
in	O
the	O
colon	O
of	O
a	O
BALB	O
/	O
c	O
mouse	O
with	O
X	O
-	O
linked	O
immunodeficiency	B-DISO
(	O
xid	O
)	O
housed	O
in	O
a	O
room	O
in	O
which	O
there	O
has	O
recently	O
been	O
an	O
epidemic	O
due	O
to	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
designated	O
it	O
as	O
the	O
MHV	O
-	O
TY	O
strain	O
.	O

All	O
the	O
cases	O
were	O
heavy	O
drinkers	O
and	O
died	O
of	O
liver	B-DISO
failure	I-DISO
or	O
variceal	O
rupture	O
.	O

Histopathologically	O
,	O
the	O
appearance	O
of	O
Mallory	O
bodies	O
increased	O
significantly	O
as	O
VOL	O
became	O
more	O
severe	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
the	O
VOL	O
severity	O
did	O
not	O
correlate	O
with	O
sinusoidal	O
neutrophil	O
infiltration	B-DISO
.	O

The	O
pathologic	O
change	O
induced	O
by	O
the	O
direct	O
viral	O
invasion	B-DISO
cannot	O
be	O
responsible	O
for	O
all	O
of	O
the	O
symptoms	O
,	O
especially	O
for	O
the	O
rapid	O
and	O
severe	O
clinical	O
course	O
of	O
the	O
disease	O
within	O
24	O
-	O
48	O
h	O
after	O
the	O
initial	O
respiratory	B-DISO
symptoms	I-DISO
.	O

During	O
infection	B-DISO
,	O
the	O
bacteria	O
produce	O
leukotoxin	O
(	O
LKT	O
)	O
and	O
lipopolysaccharide	O
(	O
LPS	B-DISO
),	O
both	O
potent	O
inducers	O
of	O
inflammation	B-DISO
.	O

Nonetheless	O
,	O
it	O
has	O
also	O
been	O
demonstrated	O
that	O
an	O
exacerbated	O
host	O
'	O
s	O
inflammatory	B-DISO
response	I-DISO
is	O
responsible	O
for	O
the	O
severe	O
lung	O
damage	O
.	O

We	O
demonstrate	O
that	O
in	O
this	O
case	O
PEEP	O
alone	O
was	O
not	O
adequate	O
to	O
recruit	O
the	O
injured	O
lung	O
and	O
that	O
a	O
high	O
-	O
pressure	O
recruitment	B-DISO
maneuver	O
was	O
required	O
.	O

The	O
FeLV	O
infection	B-DISO
was	O
self	O
-	O
limiting	O
because	O
all	O
seven	O
of	O
the	O
initially	O
viraemic	O
cats	O
died	O
within	O
five	O
years	O
and	O
the	O
remainder	O
were	O
immune	O
.	O

Although	O
different	O
to	O
the	O
G	O
/	O
UUUAAAC	O
frameshift	B-DISO
sites	O
and	O
'	O
H	O
-	O
type	O
'	O
pseudoknots	O
of	O
nidoviruses	O
,	O
in	O
vitro	O
transcription	O
/	O
translation	O
analysis	O
demonstrated	O
that	O
the	O
GAV	O
element	O
also	O
facilitates	O
read	O
-	O
through	O
of	O
the	O
ORF1a	O
/	O
1b	O
junction	O
.	O

To	O
improve	O
the	O
immunogenicity	O
of	O
the	O
chimeric	O
fimbriae	O
,	O
the	O
in	O
vivo	O
inducible	O
nirB	O
promoter	O
was	O
inserted	O
into	O
pCS154	O
,	O
upstream	O
of	O
the	O
fas	B-DISO
genes	O
,	O
to	O
create	O
pCS155	O
.	O

Hence	O
,	O
immune	O
responses	O
to	O
heterologous	O
chimeric	O
fimbriae	O
on	O
Salmonella	B-DISO
vaccine	O
vectors	O
can	O
be	O
optimized	O
by	O
using	O
promoters	O
known	O
to	O
be	O
activated	O
in	O
vivo	O
.	O

TITLE	O
:	O
Use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
to	O
rescue	O
a	O
child	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Several	O
gene	O
1	O
proteins	O
have	O
been	O
shown	O
to	O
localize	O
at	O
sites	O
of	O
viral	O
RNA	O
synthesis	O
in	O
the	O
infected	O
cell	O
cytoplasm	O
,	O
notably	O
on	O
late	O
endosomes	O
at	O
early	O
times	O
of	O
infection	B-DISO
.	O

In	O
this	O
study	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)-	O
infected	O
cells	O
were	O
fractionated	O
and	O
analyzed	O
to	O
determine	O
if	O
gene	O
1	O
proteins	O
segregated	O
to	O
more	O
than	O
one	O
membrane	O
population	O
.	O

2	O
,	O
Fig	O
.	O
1	O
,	O
Ref	O
.	O
28	O
.)	O
CONCLUSIONS	O
:	O
Early	O
use	O
of	O
HFOV	O
within	O
the	O
first	O
24	O
hours	O
of	O
acute	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
in	O
pediatric	O
patients	O
is	O
associated	O
with	O
better	O
survival	O
.	O

ABSTRACT	O
:	O
Systemic	O
hemodynamics	O
,	O
oxygenating	O
function	O
of	O
the	O
lungs	O
,	O
and	O
oxygen	O
budgeting	O
were	O
studied	O
in	O
32	O
patients	O
with	O
acute	O
bowel	B-DISO
obstruction	I-DISO
(	O
ABO	O
)	O
with	O
severe	O
endotoxicosis	B-DISO
.	O

TITLE	O
:	O
Acute	O
lung	O
injury	O
in	O
two	O
experimental	O
models	O
of	O
acute	B-DISO
pancreatitis	I-DISO
:	O
infusion	O
of	O
saline	O
or	O
sodium	O
taurocholate	O
into	O
the	O
pancreatic	O
duct	O
.	O

The	O
severity	O
of	O
pancreatic	O
and	O
pulmonary	O
injuries	O
was	O
evaluated	O
1	O
,	O
3	O
,	O
and	O
8	O
days	O
after	O
the	O
induction	O
of	O
acute	B-DISO
pancreatitis	I-DISO
by	O
morphometric	O
and	O
pulmonary	O
mechanical	O
studies	O
.	O

On	O
day	O
1	O
,	O
there	O
was	O
an	O
increase	O
in	O
intraalveolar	O
edema	B-DISO
in	O
both	O
groups	O
(	O
p	O
<	O
.	O
02	O
).	O

Expression	O
of	O
the	O
reporter	O
genes	O
was	O
under	O
the	O
control	O
of	O
a	O
transcription	O
-	O
associated	O
sequence	O
(	O
TAS	B-DISO
)	O
derived	O
from	O
the	O
Beaudette	O
gene	O
5	O
,	O
normally	O
used	O
for	O
the	O
transcription	O
of	O
IBV	O
subgenomic	O
mRNA	O
5	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
is	O
the	O
leading	O
cause	O
of	O
death	O
among	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

A	O
specific	O
cause	O
of	O
the	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
was	O
identified	O
in	O
38	O
percent	O
of	O
all	O
episodes	O
and	O
70	O
percent	O
of	O
episodes	O
with	O
complete	O
data	O
.	O

Infection	B-DISO
was	O
a	O
contributing	O
factor	O
in	O
56	O
percent	O
of	O
the	O
deaths	O
.	O

TITLE	O
:	O
Localization	O
of	O
linear	O
B	O
-	O
cell	O
epitopes	O
on	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
nucleocapsid	O
protein	O
.	O

Myocarditis	B-DISO
was	O
detected	O
by	O
histologic	O
examination	O
in	O
18	O
of	O
31	O
cardiomyopathic	O
cats	O
and	O
in	O
none	O
of	O
17	O
control	O
cats	O
.	O

Myocarditis	B-DISO
and	O
or	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
genome	O
was	O
detected	O
in	O
felines	O
with	O
idiopathic	O
hypertrophic	B-DISO
,	O
dilated	O
,	O
and	O
restrictive	B-DISO
cardiomyopathy	I-DISO
,	O
suggesting	O
a	O
possible	O
role	O
of	O
viral	B-DISO
infection	I-DISO
and	O
inflammation	B-DISO
in	O
the	O
pathogenesis	B-DISO
of	O
cardiomyopathy	B-DISO
in	O
this	O
species	O
.	O

Furthermore	O
,	O
the	O
SRV	O
infection	B-DISO
may	O
compromise	O
the	O
lymphocyte	O
-	O
mediated	O
immune	O
defenses	O
by	O
reducing	O
lymphoproliferation	O
and	O
the	O
CD4	O
-	O
CD8	O
+	O
(	O
presumably	O
T	O
-	O
cytotoxic	O
cells	O
)	O
lymphocytes	O
during	O
the	O
acute	O
stage	O
of	O
SRV	O
infection	B-DISO
.	O

This	O
review	O
details	O
our	O
knowledge	O
of	O
the	O
involvement	O
of	O
MMPs	O
,	O
namely	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
,	O
in	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
effects	O
of	O
separate	O
virus	O
or	O
LPS	B-DISO
inoculations	O
were	O
subclinical	O
and	O
failed	O
to	O
induce	O
high	O
and	O
sustained	O
cytokine	O
levels	O
.	O

These	O
data	O
show	O
that	O
exposure	O
to	O
high	O
endotoxin	O
concentrations	O
in	O
swine	O
buildings	O
can	O
precipitate	O
respiratory	B-DISO
disease	I-DISO
in	O
PRCV	O
-	O
infected	O
pigs	O
,	O
and	O
that	O
TNF	O
-	O
alpha	O
is	O
probably	O
an	O
important	O
mediator	O
of	O
these	O
effects	O
.	O

All	O
were	O
TIA	B-DISO
-	O
1	O
(+),	O
CD56	O
(-).	O

Although	O
cytologic	B-DISO
atypia	I-DISO
is	O
minimal	O
,	O
studies	O
for	O
T	O
-	O
cell	O
clonality	O
confirm	O
the	O
diagnosis	O
.	O

We	O
describe	O
a	O
patient	O
who	O
had	O
acute	O
and	O
severe	O
lung	O
injury	O
from	O
malaria	B-DISO
.	O

She	O
was	O
given	O
doxycycline	O
and	O
quinine	O
,	O
but	O
as	O
her	O
parasitemia	B-DISO
resolved	O
,	O
dyspnea	B-DISO
and	O
hypoxemia	O
developed	O
and	O
she	O
consequently	O
required	O
placement	O
of	O
an	O
endotracheal	O
tube	O
.	O

This	O
report	O
shows	O
that	O
patients	O
with	O
P	O
falciparum	B-DISO
malaria	I-DISO
should	O
be	O
monitored	O
closely	O
and	O
transferred	O
to	O
an	O
intensive	O
care	O
unit	O
for	O
additional	O
management	O
if	O
respiratory	B-DISO
distress	I-DISO
develops	O
.	O

Nevertheless	O
,	O
regional	O
increases	O
in	O
vascular	O
resistance	O
can	O
occur	O
that	O
may	O
predispose	O
mammals	O
to	O
organ	O
dysfunction	O
,	O
including	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
addition	O
,	O
an	O
overproduction	O
of	O
nitric	O
oxide	O
(	O
NO	O
,	O
examined	O
by	O
its	O
metabolites	O
nitrite	O
/	O
nitrate	O
)	O
by	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
,	O
examined	O
by	O
western	O
blot	O
analysis	O
)	O
is	O
attenuated	O
by	O
pretreatment	O
of	O
LPS	B-DISO
rats	O
with	O
terbutaline	O
.	O

A	O
total	O
of	O
61	O
infections	B-DISO
with	O
rhinoviruses	O
and	O
coronaviruses	O
were	O
identified	O
from	O
1198	O
respiratory	O
illnesses	O
(	O
5	O
.	O
1	O
%);	O
in	O
addition	O
,	O
9	O
additional	O
infections	B-DISO
associated	O
with	O
>/=	O
1	O
other	O
respiratory	O
viruses	O
were	O
identified	O
.	O

Because	O
of	O
the	O
potential	O
for	O
acute	O
respiratory	O
compromise	O
,	O
any	O
child	O
suspected	O
of	O
having	O
GBS	B-DISO
needs	O
immediate	O
hospitalization	O
.	O

Another	O
clinical	O
variant	O
is	O
the	O
Miller	B-DISO
-	I-DISO
Fisher	I-DISO
syndrome	I-DISO
characterized	O
by	O
ataxia	B-DISO
,	O
ophthalmoparesis	B-DISO
,	O
and	O
areflexia	O
.	O

To	O
determine	O
the	O
separate	O
and	O
combined	O
effects	O
of	O
HFOV	O
and	O
PLV	O
when	O
initiated	O
after	O
the	O
establishment	O
of	O
acute	O
lung	O
injury	O
in	O
severe	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
we	O
studied	O
the	O
effects	O
of	O
these	O
strategies	O
on	O
gas	O
exchange	O
and	O
histologic	O
signs	O
of	O
acute	O
lung	O
injury	O
in	O
premature	O
lambs	O
.	O

Pulmonary	O
injury	O
was	O
assessed	O
at	O
24	O
hrs	B-DISO
by	O
histology	O
and	O
leukocyte	O
and	O
protein	O
concentrations	O
via	O
bronchoalveolar	O
lavage	O
.	O

Inhibition	O
of	O
p38	O
mitogen	O
activated	O
kinase	O
decreases	O
the	O
pulmonary	O
injury	O
through	O
attenuated	O
production	O
of	O
TNF	O
-	O
alpha	O
and	O
NO	O
suggesting	O
a	O
primary	O
role	O
for	O
these	O
mediators	O
in	O
pancreatitis	B-DISO
-	O
induced	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Pancreatic	O
elastase	O
induced	O
pulmonary	O
IkappaBalpha	O
/	O
IkappaBbeta	O
degradation	O
(	O
30	O
minutes	O
),	O
NF	O
-	O
kappaB	O
activation	O
(	O
60	O
minutes	O
),	O
and	O
TNF	O
gene	O
expression	O
(	O
60	O
minutes	O
)	O
with	O
subsequent	O
neutrophilic	O
inflammation	B-DISO
(	O
4	O
hours	O
)	O
and	O
microvascular	O
leakage	B-DISO
(	O
24	O
hours	O
),	O
whereas	O
amylase	O
,	O
lipase	O
,	O
and	O
trypsin	O
did	O
not	O
.	O

In	O
this	O
study	O
,	O
the	O
individual	O
roles	O
of	O
CD4	O
and	O
CD8	O
T	O
cells	O
in	O
MHV	O
-	O
induced	O
demyelination	B-DISO
were	O
investigated	O
using	O
recombination	O
-	O
activating	O
gene	O
1	O
-/-	O
(	O
RAG1	O
-/-)	O
mice	O
infected	O
with	O
an	O
attenuated	O
strain	O
of	O
MHV	O
-	O
JHM	O
.	O

Adoptive	O
transfer	O
of	O
CD4	O
T	O
cell	O
-	O
enriched	O
donors	O
resulted	O
in	O
more	O
severe	O
clinical	O
disease	O
accompanied	O
by	O
less	O
demyelination	B-DISO
than	O
was	O
detected	O
in	O
the	O
recipients	O
of	O
undepleted	O
cells	O
.	O

Patients	O
with	O
pneumonia	B-DISO
and	O
pleural	B-DISO
effusion	I-DISO
should	O
undergo	O
therapeutic	O
thoracentesis	O
;	O
the	O
pleural	O
fluid	O
should	O
be	O
Gram	O
-	O
stained	O
and	O
cultured	O
,	O
and	O
the	O
differential	O
cell	O
count	O
,	O
glucose	O
and	O
LDH	O
concentration	O
,	O
and	O
pH	O
should	O
be	O
determined	O
.	O

The	O
infusion	O
was	O
temporarily	O
discontinued	O
and	O
rigors	B-DISO
subsided	O
following	O
administration	O
of	O
25	O
mg	O
meperidine	O
im	O
.	O

The	O
systemic	O
(	O
intravenous	O
or	O
oral	O
)	O
application	O
of	O
vasodilative	O
agents	O
in	O
sepsis	B-DISO
and	O
chronic	O
pulmonary	B-DISO
hypertension	I-DISO
has	O
,	O
however	O
,	O
important	O
side	O
effects	O
:	O
Antagonism	O
of	O
the	O
hypoxic	B-DISO
pulmonary	O
vasoconstriction	B-DISO
aggravates	O
the	O
ventilation	O
/	O
perfusion	O
mismatch	O
(	O
decrease	O
in	O
arterial	O
oxygenation	O
).	O

The	O
data	O
indicate	O
that	O
residual	O
virus	O
from	O
a	O
primary	O
CNS	B-DISO
infection	I-DISO
is	O
a	O
vital	O
component	O
in	O
mediating	O
local	O
retention	O
of	O
both	O
CD8	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cells	O
and	O
that	O
once	O
minimal	O
thresholds	O
of	O
stimuli	O
are	O
lost	O
,	O
T	O
cells	O
within	O
the	O
CNS	O
cannot	O
survive	O
in	O
an	O
autonomous	O
fashion	O
.	O

Spongiform	B-DISO
encephalopathy	I-DISO
has	O
not	O
been	O
reliably	O
reported	O
in	O
ostriches	O
,	O
while	O
anthrax	B-DISO
has	O
occurred	O
rarely	O
in	O
modern	O
times	O
but	O
was	O
reportedly	O
an	O
important	O
cause	O
of	O
death	O
approximately	O
100	O
years	O
ago	O
in	O
South	O
Africa	O
.	O

The	O
persistent	O
presence	O
of	O
viruses	O
in	O
the	O
upper	O
respiratory	O
tract	O
of	O
asthmatic	B-DISO
children	O
shows	O
a	O
possible	O
connection	O
between	O
viral	B-DISO
infections	I-DISO
and	O
asthma	B-DISO
.	O

RESULTS	O
:	O
Adenovirus	B-DISO
DNA	O
was	O
found	O
in	O
78	O
.	O
4	O
%	O
of	O
asthmatic	B-DISO
children	O
,	O
rhinovirus	O
RNA	O
in	O
32	O
.	O
4	O
%	O
and	O
coronavirus	O
RNA	O
in	O
2	O
.	O
7	O
%.	O

Tuberculosis	B-DISO
can	O
be	O
a	O
life	O
-	O
threatening	O
infection	B-DISO
.	O

TITLE	O
:	O
Drug	O
-	O
induced	O
respiratory	B-DISO
disorders	I-DISO
:	O
incidence	O
,	O
prevention	O
and	O
management	O
.	O

Bromocriptine	O
is	O
mainly	O
associated	O
with	O
pleural	B-DISO
effusion	I-DISO
,	O
while	O
methysergide	O
is	O
usually	O
associated	O
with	O
pleural	B-DISO
effusion	I-DISO
and	O
fibrosis	B-DISO
.	O

Recently	O
,	O
outbreaks	O
of	O
TGE	B-DISO
of	O
reduced	O
virulence	O
were	O
reported	O
in	O
the	O
field	O
.	O

119	O
ferrets	O
with	O
epizootic	O
diarrhea	B-DISO
of	O
presumed	O
viral	O
cause	O
and	O
5	O
control	O
ferrets	O
.	O

Results	O
strongly	O
implicate	O
a	O
coronavirus	O
as	O
the	O
causative	O
agent	O
of	O
epizootic	O
catarrhal	O
enteritis	B-DISO
in	O
ferrets	O
.	O

TITLE	O
:	O
Pumpless	O
extracorporeal	O
lung	O
assist	O
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Severe	O
respiratory	B-DISO
insufficiency	I-DISO
treated	O
with	O
CPAP	O
].	O

The	O
case	O
of	O
a	O
55	O
-	O
year	O
old	O
male	O
patient	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
a	O
bleeding	B-DISO
diathesis	I-DISO
is	O
reported	O
.	O

Pulmonary	B-DISO
insufficiency	I-DISO
was	O
treated	O
non	O
-	O
invasively	O
with	O
CPAP	O
and	O
the	O
patient	O
recovered	O
from	O
pulmonary	O
distress	O
one	O
week	O
later	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
with	O
viruses	O
and	O
Pasteurella	O
spp	O
.	O
were	O
determined	O
sequentially	O
among	O
26	O
cattle	O
that	O
died	O
during	O
two	O
severe	O
epizootics	O
of	O
shipping	B-DISO
fever	I-DISO
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
patient	O
was	O
admitted	O
to	O
our	O
ICU	O
for	O
ketoacidosis	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
(	O
ARD	O
).	O

Correction	O
of	O
the	O
metabolic	B-DISO
acidosis	I-DISO
by	O
insulin	O
therapy	O
resulted	O
in	O
intracellular	O
penetration	O
of	O
phosphate	O
and	O
potassium	O
,	O
causing	O
severe	O
hypophosphataemia	B-DISO
and	O
hypokaliaemia	O
responsible	O
for	O
ARD	O
.	O

Bovine	O
coronavirus	O
can	O
be	O
detected	O
in	O
populations	O
of	O
feedlot	O
cattle	O
in	O
the	O
form	O
of	O
viral	B-DISO
shedding	I-DISO
as	O
well	O
as	O
seroconversion	O
to	O
the	O
virus	O
.	O

Bovine	O
coronavirus	O
infects	O
feedlot	O
cattle	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cattle	O
developing	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
and	O
pulmonary	O
lesions	O
.	O

Titers	O
were	O
detected	O
for	O
antibodies	O
against	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
canine	O
herpesvirus	O
-	O
1	O
,	O
and	O
canine	O
parvovirus	B-DISO
-	O
2	O
but	O
not	O
for	O
antibodies	O
against	O
canine	O
adenovirus	B-DISO
-	O
1	O
,	O
canine	O
coronavirus	O
,	O
canine	O
parainfluenza	B-DISO
virus	O
,	O
rabies	B-DISO
virus	O
,	O
feline	O
herpesvirus	O
-	O
1	O
,	O
feline	O
calicivirus	O
,	O
or	O
feline	O
coronavirus	O
.	O

The	O
28S	O
rRNA	O
cleavage	O
occurred	O
as	O
early	O
as	O
4	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
,	O
with	O
the	O
appearance	O
of	O
subsequent	O
cleavage	O
products	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
intact	O
28S	O
rRNA	O
with	O
increasing	O
times	O
of	O
infection	B-DISO
;	O
almost	O
all	O
of	O
the	O
intact	O
28S	O
rRNA	O
disappeared	O
by	O
24	O
h	O
p	O
.	O
i	O
.	O

Furthermore	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
occurred	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
that	O
do	O
not	O
show	O
apoptotic	O
signs	O
,	O
including	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
DNA	O
fragmentation	B-DISO
.	O

Instead	O
,	O
at	O
high	O
levels	O
of	O
expression	O
,	O
a	O
helicase	O
mutant	B-DISO
dominantly	O
interfered	O
with	O
the	O
function	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

To	O
provide	O
definitive	O
experimental	O
evidence	O
for	O
the	O
neurotropism	B-DISO
and	O
neuroinvasion	O
of	O
HCoV	O
and	O
its	O
possible	O
association	O
with	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
),	O
we	O
have	O
performed	O
an	O
extensive	O
search	O
and	O
characterization	O
of	O
HCoV	O
RNA	O
in	O
a	O
large	O
panel	O
of	O
human	O
brain	O
autopsy	O
samples	O
.	O

However	O
,	O
the	O
molecular	O
determinants	O
of	O
MHV	O
-	O
induced	O
demyelination	B-DISO
are	O
still	O
unknown	O
.	O

When	O
HCoV	O
-	O
229E	O
was	O
applied	O
to	O
the	O
apical	O
or	O
basolateral	O
surface	O
of	O
well	O
-	O
differentiated	O
primary	O
cultures	O
of	O
human	O
airway	O
epithelia	O
,	O
infection	B-DISO
primarily	O
occurred	O
from	O
the	O
apical	O
side	O
.	O

We	O
also	O
constructed	O
a	O
mutant	B-DISO
in	O
which	O
translation	O
of	O
the	O
intraleader	O
ORF	O
was	O
disrupted	O
.	O

This	O
mutant	B-DISO
had	O
a	O
wild	O
-	O
type	O
phenotype	O
,	O
indicating	O
that	O
,	O
at	O
least	O
in	O
cell	O
culture	O
,	O
the	O
product	O
of	O
this	O
ORF	O
does	O
not	O
play	O
a	O
role	O
in	O
the	O
EAV	O
replication	O
cycle	O
.	O

Reactivity	O
of	O
anti	O
-	O
rotavirus	O
,	O
anti	O
-	O
reovirus	O
,	O
anti	O
-	O
adenovirus	B-DISO
,	O
or	O
anti	O
-	O
enterovirus	O
antibodies	O
with	O
the	O
IBV	O
antigens	O
coated	O
in	O
the	O
commercially	O
available	O
ELISA	O
plates	O
coated	O
with	O
IBV	O
antigens	O
could	O
be	O
utilized	O
for	O
detection	O
of	O
antibodies	O
to	O
TCV	O
in	O
antibody	O
-	O
capture	O
ELISA	O
.	O

TITLE	O
:	O
Morphologic	O
observations	O
on	O
respiratory	O
tracts	O
of	O
chickens	O
after	O
hatchery	O
infectious	B-DISO
bronchitis	B-DISO
vaccination	O
and	O
formaldehyde	O
fumigation	O
.	O

Postvaccinal	O
and	O
fumigation	O
effects	O
on	O
the	O
upper	O
respiratory	O
tract	O
were	O
temporary	O
,	O
whereas	O
in	O
lungs	O
,	O
increased	O
emphysema	B-DISO
,	O
cartilage	O
nodules	B-DISO
in	O
the	O
interchange	O
zone	O
,	O
and	O
general	O
lymphocyte	O
infiltration	B-DISO
had	O
caused	O
intensive	O
injury	O
.	O

TITLE	O
:	O
Hypoproteinemia	B-DISO
predicts	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
development	O
,	O
weight	O
gain	O
,	O
and	O
death	O
in	O
patients	O
with	O
sepsis	B-DISO
.	O

Regression	O
analysis	O
to	O
compare	O
outcomes	O
in	O
patients	O
with	O
low	O
serum	O
total	O
protein	O
levels	O
with	O
outcomes	O
in	O
patients	O
with	O
normal	O
serum	O
total	O
protein	O
levels	O
with	O
respect	O
to	O
weight	O
change	O
,	O
development	O
of	O
ARDS	B-DISO
,	O
and	O
mortality	O
.	O

In	O
multivariate	O
analysis	O
,	O
two	O
variables	O
were	O
predictive	O
of	O
failure	O
of	O
CPAP	O
:	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
(	O
58	O
+/-	O
14	O
vs	O
.	O
41	O
+/-	O
11	O
)	O
and	O
a	O
hepatic	B-DISO
failure	I-DISO
at	O
the	O
entry	O
into	O
the	O
study	O
.	O

TITLE	O
:	O
[	O
Microcirculatory	O
and	O
hemostatic	O
disturbances	O
in	O
patients	O
with	O
influenza	B-DISO
and	O
respiratory	B-DISO
infections	I-DISO
aggravated	O
with	O
coexisting	O
diseases	O
].	O

The	O
antitumor	O
effect	O
of	O
the	O
corticosteroid	O
might	O
have	O
some	O
effect	O
on	O
the	O
recovery	O
from	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
primary	B-DISO
macroglobulinemia	I-DISO
.	O

Survivors	O
often	O
are	O
impaired	B-DISO
after	O
hospital	O
discharge	O
but	O
tend	O
to	O
improve	O
over	O
time	O
;	O
however	O
,	O
ALI	O
does	O
confer	O
a	O
significant	O
additional	O
burden	O
on	O
survivors	O
with	O
regard	O
to	O
pulmonary	O
function	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

It	O
is	O
possible	O
that	O
therapy	O
with	O
beta	O
-	O
adrenergic	O
agonists	O
might	O
be	O
useful	O
to	O
accelerate	O
the	O
resolution	O
of	O
alveolar	B-DISO
edema	I-DISO
in	O
some	O
patients	O
.	O

These	O
approaches	O
may	O
be	O
useful	O
in	O
reducing	O
mortality	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Fibroblast	O
growth	O
factor	O
2	O
(	O
FGF2	O
)	O
and	O
FGF	O
receptor	O
expression	O
in	O
an	O
experimental	O
demyelinating	B-DISO
disease	I-DISO
with	O
extensive	O
remyelination	O
.	O

Evaluation	O
for	O
infectious	B-DISO
or	O
noninfectious	O
aetiologies	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
unrevealing	O
.	O

TITLE	O
:	O
Survival	O
of	O
human	O
coronaviruses	O
229E	O
and	O
OC43	O
in	O
suspension	O
and	O
after	O
drying	O
onsurfaces	O
:	O
a	O
possible	O
source	O
ofhospital	O
-	O
acquired	O
infections	B-DISO
.	O

To	O
evaluate	O
possible	O
sources	O
of	O
infection	B-DISO
,	O
virus	O
survival	O
was	O
studied	O
in	O
aqueous	O
suspensions	O
and	O
on	O
absorptive	O
and	O
non	O
-	O
absorptive	O
surfaces	O
representative	O
of	O
a	O
hospital	O
environment	O
.	O

Premorbid	O
lung	O
conditions	O
,	O
i	O
.	O
e	O
.	O
asthma	B-DISO
and	O
airway	O
hyperresponsiveness	O
,	O
might	O
have	O
been	O
risk	O
factors	O
for	O
illness	O
severity	O
but	O
not	O
for	O
persistent	O
complaints	O
.	O

TITLE	O
:	O
Regional	O
distribution	O
of	O
gas	O
and	O
tissue	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Physiological	O
correlations	O
and	O
definition	O
of	O
an	O
ARDS	B-DISO
Severity	O
Score	O
.	O

(	O
b	O
)	O
To	O
propose	O
a	O
new	O
ARDS	B-DISO
Severity	O
Score	O
to	O
identify	O
patients	O
with	O
a	O
high	O
mortality	O
risk	O
.	O

TITLE	O
:	O
Detection	O
and	O
isolation	O
of	O
coronavirus	O
from	O
feces	O
of	O
three	O
herds	O
of	O
feedlot	O
cattle	O
during	O
outbreaks	O
of	O
winter	B-DISO
dysentery	I-DISO
-	O
like	O
disease	O
.	O

ABSTRACT	O
:	O
Clinical	O
signs	O
of	O
a	O
winter	B-DISO
dysentery	I-DISO
-	O
like	O
syndrome	B-DISO
in	O
6	O
-	O
to	O
9	O
-	O
month	O
-	O
old	O
cattle	O
in	O
3	O
feedlots	O
included	O
acute	O
onset	O
of	O
diarrhea	B-DISO
with	O
high	O
morbidity	O
and	O
low	O
mortality	O
,	O
respiratory	O
tract	O
problems	O
that	O
included	O
dyspnea	B-DISO
,	O
coughing	B-DISO
,	O
and	O
nasal	B-DISO
discharge	I-DISO
,	O
and	O
high	O
rectal	O
temperatures	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
supportive	O
therapy	O
used	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Adverse	B-DISO
effects	I-DISO
possibly	O
caused	O
by	O
steroid	O
therapy	O
were	O
not	O
observed	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
effect	O
of	O
vitamin	O
A	O
supplementation	O
on	O
the	O
risk	O
of	O
diarrhea	B-DISO
and	O
of	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

Incidence	O
and	O
duration	O
of	O
episodes	O
of	O
diarrhea	B-DISO
and	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
during	O
the	O
year	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O

Vitamin	O
A	O
supplementation	O
was	O
also	O
associated	O
with	O
increased	O
risk	O
of	O
acute	B-DISO
diarrhea	I-DISO
among	O
normally	O
nourished	O
children	O
or	O
children	O
with	O
stunted	O
growth	O
but	O
was	O
relatively	O
protective	O
among	O
children	O
with	O
wasting	B-DISO
disease	I-DISO
(	O
P	O
value	O
for	O
interaction	O
=.	O
01	O
).	O

Serologic	O
and	O
virus	O
genetic	O
analyses	O
of	O
rodents	O
trapped	O
in	O
the	O
area	O
showed	O
Oligoryzomys	O
fulvescens	O
to	O
be	O
the	O
likely	O
reservoir	O
for	O
the	O
HPS	B-DISO
-	O
associated	O
Choclo	O
virus	O
.	O

TITLE	O
:	O
[	O
Dengue	B-DISO
:	O
a	O
new	O
approach	O
].	O

Patients	O
with	O
viridans	O
streptococcal	B-DISO
bacteremia	I-DISO
(	O
VSB	B-DISO
)	O
who	O
developed	O
serious	O
complications	O
were	O
compared	O
with	O
patients	O
with	O
VSB	B-DISO
without	O
complications	O
.	O

The	O
initial	O
reports	O
of	O
the	O
use	O
of	O
ECMO	O
in	O
ARDS	B-DISO
patients	O
were	O
quite	O
enthusiastic	O
,	O
however	O
,	O
in	O
the	O
following	O
years	O
it	O
became	O
clear	O
that	O
ECMO	O
was	O
only	O
of	O
benefit	O
in	O
newborns	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

These	O
""""	O
treatment	O
related	O
clinical	O
fluctuations	B-DISO
""""	O
are	O
more	O
frequently	O
seen	O
in	O
relatively	O
young	O
patients	O
with	O
severe	O
motor	O
and	O
sensory	O
involvement	O
associated	O
with	O
a	O
preceding	O
and	O
possibly	O
ongoing	O
cytomegalovirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
[	O
Hemiparesis	B-DISO
as	O
a	O
sequela	O
of	O
traumatic	O
pseudoaneurysm	B-DISO
of	O
the	O
carotid	O
bifurcation	O
].	O

At	O
that	O
time	O
no	O
central	O
-	O
nervous	B-DISO
symptoms	O
could	O
be	O
found	O
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
systemic	O
reaction	O
after	O
intravesical	O
administrations	O
of	O
bacillus	O
Calmette	O
-	O
Guérin	O
(	O
BCG	O
)	O
for	O
polyposis	B-DISO
.	O

A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
was	O
treated	O
by	O
monthly	O
injections	O
of	O
intravesical	O
BCG	O
immunotherapy	O
for	O
polyposis	B-DISO
of	O
the	O
urinary	O
bladder	O
.	O

The	O
clinical	O
status	O
of	O
the	O
patient	O
quickly	O
worsened	O
,	O
with	O
the	O
appearance	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
acute	O
anuric	O
renal	B-DISO
insufficiency	I-DISO
,	O
rhabdomyolysis	B-DISO
,	O
hemolysis	B-DISO
,	O
and	O
cytolytic	O
and	O
cholestatic	B-DISO
hepatitis	I-DISO
.	O

BCG	O
instillation	O
is	O
a	O
valuable	O
tool	O
in	O
the	O
therapy	O
of	O
bladder	B-DISO
carcinoma	I-DISO
,	O
but	O
increasing	O
reports	O
of	O
severe	O
adverse	O
reactions	O
should	O
continue	O
to	O
remind	O
practicing	O
urologists	O
to	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
common	O
and	O
uncommon	O
reactions	O
after	O
its	O
use	O
.	O

ABSTRACT	O
:	O
A	O
coronavirus	O
was	O
isolated	O
from	O
feces	O
of	O
a	O
diarrheic	O
foal	O
and	O
serially	O
propagated	O
in	O
human	O
rectal	B-DISO
adenocarcinoma	I-DISO
(	O
HRT	O
-	O
18	O
)	O
cells	O
.	O

A	O
total	O
of	O
106	O
patients	O
were	O
identified	O
from	O
hospital	O
notes	O
as	O
having	O
at	O
least	O
one	O
of	O
eight	O
major	O
complications	O
(	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
sepsis	B-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
coagulopathy	B-DISO
,	O
wound	B-DISO
infection	I-DISO
,	O
pneumonia	B-DISO
,	O
fat	B-DISO
embolism	I-DISO
or	O
pulmonary	B-DISO
embolism	I-DISO
).	O

ABSTRACT	O
:	O
The	O
case	O
of	O
leptospirosis	B-DISO
with	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
severe	O
jaundice	B-DISO
in	O
young	O
abattoir	O
worker	O
has	O
been	O
presented	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
noncanonical	O
signal	O
for	O
transcription	O
of	O
a	O
novel	O
subgenomic	O
mRNA	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
:	O
implication	O
for	O
the	O
mechanism	O
of	O
coronavirus	O
RNA	O
transcription	O
.	O

Region	O
I	O
of	O
the	O
3	O
'	O
UTR	O
,	O
adjacent	O
to	O
the	O
nucleocapsid	O
protein	O
gene	O
,	O
comprised	O
212	O
nt	O
and	O
could	O
be	O
removed	O
without	O
impairment	B-DISO
of	O
replication	O
or	O
packaging	O
of	O
D	O
-	O
RNAs	O
.	O

Our	O
purpose	O
was	O
to	O
determine	O
whether	O
the	O
onset	O
of	O
the	O
HELLP	O
(	O
hemolysis	B-DISO
,	O
elevated	O
liver	O
enzymes	O
,	O
and	O
low	O
platelet	O
count	O
)	O
syndrome	B-DISO
in	O
women	O
at	O
<	O
or	O
=	O
28	O
.	O
0	O
weeks	O
'	O
gestation	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
adverse	O
maternal	O
and	O
perinatal	O
outcomes	O
in	O
comparison	O
with	O
the	O
risk	O
for	O
women	O
with	O
severe	B-DISO
preeclampsia	I-DISO
but	O
without	O
the	O
HELLP	B-DISO
syndrome	I-DISO
at	O
a	O
similar	O
gestational	O
age	O
.	O

Hepatic	O
resection	O
(	O
n	O
=	O
21	O
)	O
resulted	O
in	O
slight	O
perivascular	O
edema	B-DISO
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
post	O
-	O
resection	O
,	O
but	O
there	O
were	O
no	O
other	O
significant	O
changes	O
.	O

This	O
study	O
suggests	O
that	O
a	O
soluble	O
mediator	O
from	O
direct	O
liver	O
injury	O
leads	O
to	O
neutrophilic	O
lung	B-DISO
inflammation	I-DISO
and	O
this	O
is	O
associated	O
with	O
the	O
thawing	O
phase	O
of	O
cryoablation	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
infections	I-DISO
of	O
the	O
lower	O
respiratory	O
tract	O
first	O
require	O
a	O
weighing	O
up	O
of	O
risks	O
,	O
which	O
is	O
of	O
importance	O
in	O
particular	O
for	O
the	O
decision	O
for	O
or	O
against	O
antibiotic	O
therapy	O
.	O

In	O
combination	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
serious	O
underlying	O
disease	O
such	O
as	O
left	O
heart	B-DISO
insufficiency	I-DISO
or	O
diseases	O
of	O
the	O
lungs	O
,	O
may	O
become	O
life	O
-	O
threatening	O
.	O

Bacterial	B-DISO
infections	I-DISO
are	O
frequent	O
during	O
the	O
first	O
weeks	O
.	O

Alternatively	O
,	O
antigenic	O
epitopes	O
derived	O
from	O
the	O
viral	O
proteins	O
may	O
exhibit	O
sufficient	O
homology	O
to	O
host	O
components	O
that	O
the	O
immune	O
response	O
to	O
the	O
virus	O
activates	O
autoreactive	O
T	O
cells	O
,	O
i	O
.	O
e	O
.	O
molecular	O
mimicry	B-DISO
.	O

Positioning	O
therapy	O
was	O
administered	O
in	O
group	O
3	O
in	O
order	O
to	O
prevent	O
atelectases	B-DISO
,	O
and	O
respirator	O
-	O
induced	O
lung	O
injuries	O
during	O
a	O
foreseeable	O
,	O
relatively	O
long	O
period	O
in	O
the	O
intensive	O
care	O
unit	O
in	O
view	O
of	O
the	O
severity	O
of	O
the	O
trauma	O
.	O

No	O
patient	O
of	O
the	O
prophylaxis	O
group	O
developed	O
an	O
ALI	O
or	O
ARDS	B-DISO
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
initial	O
vWf	O
:	O
Ag	O
concentration	O
and	O
ISS	B-DISO
,	O
APACHE	O
II	O
,	O
LIS	O
.	O

22	O
.	O
5	O
kPa	O
by	O
6	O
hrs	B-DISO
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Anti	O
-	O
Mig	O
-	O
treated	O
mice	O
displayed	O
a	O
significant	O
decrease	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
in	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cell	O
recruitment	B-DISO
into	O
the	O
CNS	O
as	O
compared	O
with	O
normal	O
rabbit	O
serum	O
-	O
treated	O
mice	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
Mig	O
is	O
important	O
in	O
contributing	O
to	O
host	O
defense	O
by	O
promoting	O
a	O
protective	O
Th1	O
response	O
against	O
viral	B-DISO
infection	I-DISO
of	O
the	O
CNS	O
.	O

Thus	O
,	O
the	O
extent	O
of	O
replication	O
and	O
the	O
degree	O
of	O
hepatitis	B-DISO
in	O
the	O
liver	O
induced	O
by	O
these	O
recombinant	O
viruses	O
were	O
determined	O
largely	O
by	O
the	O
spike	O
protein	O
.	O

Multicenter	O
,	O
double	O
-	O
blind	B-DISO
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

Eighteen	O
patients	O
with	O
pneumonia	B-DISO
and	O
hypotension	O
,	O
or	O
in	O
the	O
absence	O
of	O
shock	O
,	O
two	O
or	O
more	O
end	O
-	O
organ	O
dysfunctions	O
,	O
were	O
enrolled	O
and	O
treated	O
.	O

There	O
were	O
no	O
differences	O
in	O
types	O
and	O
occurrences	O
of	O
adverse	O
events	O
,	O
including	O
ARDS	B-DISO
,	O
or	O
in	O
outcome	O
between	O
the	O
two	O
groups	O
.	O

TITLE	O
:	O
[	O
Emergent	O
riboviruses	O
implicated	O
in	O
gastroenteritis	B-DISO
].	O

Enteric	O
coronaviruses	O
have	O
most	O
frequently	O
been	O
associated	O
with	O
gastrointestinal	B-DISO
disease	I-DISO
in	O
neonates	O
and	O
children	O
younger	O
than	O
12	O
years	O
old	O
.	O

The	O
role	O
of	O
toroviruses	O
and	O
picobirnaviruses	O
as	O
causative	O
agents	O
of	O
gastroenteritis	B-DISO
is	O
still	O
emerging	O
.	O

A	O
69	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
cough	B-DISO
and	O
severe	O
dyspnea	B-DISO
.	O

The	O
cause	O
of	O
death	O
in	O
the	O
three	O
nonsurvivors	O
was	O
intracranial	O
complications	O
leading	O
to	O
total	O
cerebral	B-DISO
infarction	I-DISO
.	O

A	O
high	O
survival	O
rate	O
can	O
be	O
obtained	O
in	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
using	O
ECMO	O
and	O
pressure	O
-	O
supported	O
ventilation	O
with	O
minimal	O
sedation	B-DISO
.	O

ABSTRACT	O
:	O
The	O
relevance	O
of	O
an	O
elevated	O
base	O
deficit	B-DISO
(	O
BD	O
)	O
during	O
the	O
fluid	O
resuscitation	O
of	O
a	O
thermally	O
injured	O
patient	O
is	O
not	O
completely	O
understood	O
.	O

The	O
incidence	O
of	O
Hellp	B-DISO
syndrome	I-DISO
among	O
women	O
with	O
severe	B-DISO
preeclampsia	I-DISO
and	O
/	O
or	O
eclampsia	B-DISO
(	O
164	O
cases	O
)	O
was	O
9	O
.	O
7	O
%.	O

General	O
anaesthesia	B-DISO
was	O
used	O
in	O
all	O
patients	O
.	O

Six	O
perinatal	O
deaths	O
were	O
related	O
to	O
abruptio	B-DISO
placenta	I-DISO
,	O
intrauterine	B-DISO
asphyxia	I-DISO
and	O
extreme	O
prematurity	O
.	O

CONCLUSIONS	O
:	O
The	O
high	O
maternal	O
and	O
perinatal	O
mortality	O
and	O
morbidity	O
reported	O
with	O
the	O
presence	O
of	O
Hellp	B-DISO
syndrome	I-DISO
requires	O
maternal	O
-	O
fetal	O
follow	O
-	O
up	O
in	O
a	O
tertiary	O
centre	O
where	O
intensive	O
maternal	O
and	O
neonatal	O
care	O
are	O
available	O
.	O

ABSTRACT	O
:	O
A	O
10	O
-	O
year	O
-	O
old	O
cat	O
was	O
diagnosed	O
with	O
chyloperitoneum	B-DISO
based	O
on	O
the	O
effusion	B-DISO
characteristics	O
.	O

Necropsy	O
revealed	O
vasculitis	B-DISO
with	O
multifocal	O
areas	O
of	O
necrosis	O
and	O
lymphocytic	B-DISO
-	I-DISO
plasmacytic	I-DISO
inflammation	I-DISO
in	O
multiple	O
solid	O
organs	O
,	O
most	O
likely	O
due	O
to	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Notwithstanding	O
,	O
the	O
final	O
diagnosis	O
of	O
FIP	B-DISO
was	O
based	O
on	O
the	O
characteristic	O
histopathological	O
lesions	O
.	O

Viral	B-DISO
shedding	I-DISO
may	O
be	O
intermittent	O
.	O

Viral	O
inactivation	B-DISO
is	O
all	O
the	O
more	O
easy	O
when	O
there	O
is	O
an	O
envelope	O
.	O

Virus	B-DISO
shedding	I-DISO
in	O
nasal	O
secretions	O
of	O
the	O
majority	O
of	O
the	O
cattle	O
ceased	O
between	O
days	O
7	O
and	O
14	O
with	O
the	O
appearance	O
of	O
HE	O
-	O
and	O
S	O
-	O
specific	O
antibodies	O
.	O

We	O
present	O
a	O
patient	O
who	O
developed	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
including	O
severe	O
ARDS	B-DISO
,	O
after	O
severe	O
skin	O
injuries	O
and	O
septic	B-DISO
shock	I-DISO
.	O

Accordingly	O
,	O
values	O
for	O
gamma	O
min	O
were	O
significantly	O
improved	O
upon	O
secondary	O
supplementation	O
of	O
LSA	B-DISO
with	O
DPPC	O
up	O
to	O
control	O
values	O
.	O

We	O
conclude	O
that	O
marked	O
changes	O
in	O
the	O
FA	O
composition	O
of	O
the	O
predominant	O
surfactant	O
PL	O
classes	O
occur	O
,	O
both	O
in	O
ARDS	B-DISO
triggered	O
by	O
nonpulmonary	O
events	O
and	O
PNEU	O
.	O

Bacteremia	B-DISO
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
lung	O
injury	O
.	O

An	O
increased	O
level	O
of	O
IL	O
-	O
8	O
in	O
the	O
donor	O
BALF	O
was	O
associated	O
with	O
the	O
development	O
of	O
severe	O
early	O
graft	B-DISO
dysfunction	I-DISO
(	O
p	O
=	O
0	O
.	O
027	O
)	O
and	O
with	O
early	O
recipient	O
mortality	O
(	O
p	O
=	O
0	O
.	O
0034	O
).	O

CONCLUSIONS	O
:	O
It	O
is	O
likely	O
that	O
the	O
hepatitis	B-DISO
B	I-DISO
may	O
have	O
been	O
the	O
trigger	O
for	O
the	O
Schönlein	O
-	O
Hennoch	O
-	O
purpura	B-DISO
.	O

The	O
cellular	O
absence	O
of	O
hnRNP	O
A1	O
had	O
no	O
detectable	O
effect	O
on	O
the	O
production	O
of	O
infectious	B-DISO
virus	O
,	O
the	O
synthesis	O
of	O
genomic	O
RNA	O
,	O
or	O
the	O
quantity	O
or	O
quality	O
of	O
subgenomic	O
mRNAs	O
.	O

ABSTRACT	O
:	O
Practitioners	O
may	O
be	O
called	O
on	O
to	O
treat	O
rodents	O
with	O
respiratory	B-DISO
diseases	I-DISO
or	O
to	O
advise	O
clients	O
concerning	O
the	O
care	O
of	O
these	O
rodents	O
.	O

Respiratory	B-DISO
diseases	I-DISO
of	O
mice	O
,	O
rats	O
,	O
guinea	O
pigs	O
,	O
and	O
Syrian	O
hamsters	O
are	O
well	O
known	O
because	O
of	O
the	O
use	O
of	O
these	O
species	O
in	O
research	O
,	O
whereas	O
few	O
or	O
no	O
reports	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
rodents	O
of	O
other	O
species	O
exist	O
.	O

TITLE	O
:	O
Fatal	O
neonatal	O
echovirus	O
6	O
infection	B-DISO
:	O
autopsy	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Experimental	O
introduction	O
of	O
the	O
A528V	O
mutation	O
into	O
the	O
wild	O
-	O
type	O
spike	O
protein	O
resulted	O
in	O
the	O
loss	O
of	O
MAb	O
binding	O
of	O
the	O
mutant	B-DISO
protein	O
,	O
confirming	O
that	O
the	O
single	O
point	O
mutation	O
was	O
responsible	O
for	O
the	O
escape	O
of	O
BCV	O
from	O
immunological	O
selective	O
pressure	O
.	O

The	O
largest	O
RNA	O
-	O
protein	O
complex	O
formed	O
by	O
the	O
cis	B-DISO
-	O
acting	O
element	O
and	O
the	O
lysate	O
from	O
uninfected	O
mouse	O
fibroblasts	O
has	O
a	O
molecular	O
weight	O
of	O
about	O
200	O
kDa	O
.	O

It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	O
-	O
6	O
may	O
be	O
more	O
important	O
.	O

CONCLUSIONS	O
:	O
It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	O
-	O
6	O
may	O
be	O
more	O
important	O
.	O

Much	O
further	O
investigation	O
is	O
needed	O
,	O
however	O
,	O
to	O
determine	O
the	O
effects	O
of	O
colloid	O
administration	O
on	O
clinically	O
relevant	O
outcomes	O
in	O
a	O
broad	O
range	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

The	O
ability	O
of	O
administered	O
colloids	O
to	O
increase	O
colloid	O
osmotic	O
pressure	O
(	O
COP	O
)	O
constitutes	O
one	O
mechanism	O
by	O
which	O
colloids	O
might	O
reduce	O
interstitial	B-DISO
oedema	I-DISO
and	O
promote	O
favourable	O
patient	O
outcomes	O
.	O

Attempts	O
to	O
increase	O
COP	O
might	O
also	O
be	O
less	O
useful	O
in	O
states	O
of	O
increased	O
vascular	O
permeability	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
although	O
this	O
issue	O
has	O
by	O
no	O
means	O
been	O
settled	O
by	O
empirical	O
data	O
.	O

A	O
serological	O
survey	O
of	O
antibodies	O
to	O
CCV	B-DISO
among	O
different	O
dog	O
populations	O
.	O

In	O
comparison	O
,	O
for	O
those	O
dogs	O
presented	O
without	O
any	O
history	O
of	O
gastroenteritis	B-DISO
only	O
15	O
%	O
were	O
positive	O
for	O
IgM	O
and	O
30	O
%	O
positive	O
for	O
IgG	O
.	O
Serological	O
evidence	O
indicates	O
that	O
infection	B-DISO
with	O
CCV	B-DISO
in	O
dogs	O
is	O
widespread	O
throughout	O
the	O
Australian	O
mainland	O
.	O

The	O
most	O
common	O
complication	B-DISO
is	O
anaemia	B-DISO
accounting	O
for	O
76	O
.	O
56	O
%	O
followed	O
by	O
cerebral	B-DISO
malaria	I-DISO
(	O
59	O
.	O
38	O
%).	O

TITLE	O
:	O
Lymphocytic	B-DISO
hypophysitis	I-DISO
in	O
a	O
man	O
presenting	O
with	O
hypercalcemia	B-DISO
.	O

E	O
was	O
retained	O
in	O
the	O
pre	O
-	O
Golgi	O
membranes	O
,	O
prior	O
to	O
being	O
translocated	O
to	O
the	O
Golgi	O
apparatus	O
and	O
the	O
secretory	O
vesicles	B-DISO
;	O
M	O
was	O
observed	O
to	O
exhibit	O
similar	O
localization	O
and	O
translocation	B-DISO
profiles	O
as	O
E	O
when	O
coexpressed	O
with	O
E	O
.	O
Deletion	O
studies	O
identified	O
the	O
C	O
-	O
terminal	O
6	O
-	O
residue	O
RDKLYS	O
as	O
the	O
endoplasmic	O
reticulum	O
retention	O
signal	O
of	O
E	O
,	O
and	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
-	O
4	O
lysine	O
residue	O
to	O
glutamine	O
resulted	O
in	O
the	O
accumulation	O
of	O
E	O
in	O
the	O
Golgi	O
apparatus	O
.	O

Mice	O
immunized	O
orally	O
with	O
a	O
Salmonella	B-DISO
vaccine	O
strain	O
which	O
expressed	O
chimeric	O
fimbriae	O
from	O
the	O
pagC	O
promoter	O
elicited	O
significantly	O
higher	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
to	O
both	O
the	O
987P	O
fimbriae	O
and	O
the	O
TGEV	O
epitopes	O
than	O
mice	O
immunized	O
with	O
the	O
same	O
strain	O
hosting	O
a	O
tetA	O
or	O
nirB	O
promoter	O
-	O
driven	O
expression	O
plasmid	O
.	O

This	O
indicated	O
that	O
the	O
pagC	O
promoter	O
can	O
be	O
used	O
successfully	O
to	O
improve	O
epitope	O
-	O
display	O
by	O
chimeric	O
fimbriae	O
on	O
Salmonella	B-DISO
vaccine	O
strains	O
for	O
the	O
induction	O
of	O
a	O
desired	O
immune	O
response	O
.	O

Moreover	O
L	O
-	O
Arginine	O
,	O
the	O
precursor	O
for	O
the	O
formation	O
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	O
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	O
and	O
administrating	O
L	O
-	O
Arginine	O
smooth	O
muscle	B-DISO
relaxation	I-DISO
occurred	O
,	O
and	O
consequent	O
weaning	O
from	O
iNO	O
was	O
achieved	O
.	O

After	O
calving	O
,	O
the	O
physical	O
condition	B-DISO
of	O
the	O
cows	O
deteriorated	O
for	O
reasons	O
unknown	O
.	O

Nine	O
patients	O
recovered	O
successfully	O
;	O
one	O
died	O
from	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
soon	O
after	O
the	O
operation	O
.	O

In	O
most	O
cases	O
this	O
resembles	O
reactive	B-DISO
airways	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
,	O
and	O
the	O
role	O
of	O
immune	O
mechanisms	O
is	O
uncertain	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
health	O
of	O
United	O
Kingdom	O
Gulf	O
war	O
veterans	O
,	O
to	O
compare	O
their	O
health	O
to	O
that	O
of	O
similar	O
personnel	O
not	O
deployed	O
,	O
to	O
describe	O
patterns	O
of	O
ill	B-DISO
health	O
in	O
both	O
groups	O
,	O
and	O
to	O
estimate	O
their	O
extent	O
.	O

Those	O
who	O
had	O
been	O
to	O
the	O
Gulf	O
were	O
more	O
troubled	O
by	O
every	O
symptom	B-DISO
with	O
a	O
mean	O
severity	O
score	O
(	O
3	O
.	O
0	O
)	O
substantially	O
greater	O
than	O
in	O
the	O
non	O
-	O
Gulf	O
cohort	O
(	O
1	O
.	O
7	O
).	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
(	O
APACHE	O
)	O
II	O
score	O
>	O
17	O
,	O
serum	O
albumin	O
level	O
<	O
25	O
g	O
.(-	O
1	O
),	O
and	O
diagnosis	O
of	O
P	O
.	O
carinii	O
pneumonia	B-DISO
were	O
the	O
only	O
factors	O
at	O
entry	O
associated	O
with	O
ICU	O
mortality	O
(	O
p	O
=	O
0	O
.	O
02	O
).	O

Patients	O
with	O
bacterial	B-DISO
pneumonia	I-DISO
are	O
less	O
frequently	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
after	O
the	O
introduction	O
of	O
highly	O
active	O
antiretroviral	O
therapy	O
with	O
protease	O
inhibitors	O
in	O
1996	O
.	O

On	O
the	O
assumption	O
that	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
initiates	O
ARDS	B-DISO
by	O
occluding	B-DISO
the	O
pulmonary	O
microcirculation	O
with	O
microclots	O
,	O
the	O
patients	O
were	O
treated	O
with	O
plasminogen	O
activators	O
.	O

However	O
,	O
no	O
extreme	O
and	O
severe	O
cognitive	B-DISO
deficits	I-DISO
were	O
recorded	O
.	O

ABSTRACT	O
:	O
Faecal	O
samples	O
from	O
suckling	O
(	O
n	O
=	O
205	O
)	O
and	O
weaned	O
piglets	O
(	O
n	O
=	O
82	O
)	O
with	O
diarrhoea	B-DISO
from	O
24	O
farms	O
in	O
Southern	O
Germany	O
were	O
examined	O
for	O
shedding	O
of	O
important	O
metazoic	O
parasitic	O
,	O
viral	O
and	O
bacterial	O
pathogens	O
using	O
culture	O
,	O
microscopic	O
and	O
electronmicroscopic	O
methods	O
.	O

He	O
was	O
also	O
complicated	O
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
and	O
pseudomembranous	B-DISO
colitis	I-DISO
.	O

The	O
underlying	O
lateral	O
musculature	O
was	O
edematous	B-DISO
and	O
possessed	B-DISO
markedly	O
atrophied	B-DISO
muscle	O
fibers	O
.	O

TITLE	O
:	O
Identification	O
and	O
analysis	O
of	O
the	O
Georgia	O
98	O
serotype	O
,	O
a	O
new	O
serotype	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

TITLE	O
:	O
The	O
exacerbating	O
effect	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
on	O
the	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
-	O
induced	O
suppression	B-DISO
of	O
opsonization	O
by	O
Escherichia	O
coil	O
antibody	O
in	O
chickens	O
.	O

Many	O
viral	B-DISO
infections	I-DISO
develop	O
in	O
an	O
epidemiological	O
way	O
(	O
influenza	B-DISO
,	O
VRS	O
bronchiolitis	B-DISO
,	O
rhinovirus	O
infections	B-DISO
...)	O
and	O
several	O
epidemics	O
by	O
different	O
viruses	O
overlap	O
from	O
September	O
-	O
October	O
to	O
March	O
-	O
April	O
making	O
it	O
very	O
difficult	O
to	O
decide	O
the	O
precise	O
cause	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
effects	O
of	O
infusion	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
versus	O
the	O
inhalation	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
patients	O
with	O
an	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Immunodeficiency	B-DISO
was	O
present	O
in	O
60	O
patients	O
,	O
including	O
38	O
with	O
AIDS	O
.	O

TITLE	O
:	O
Maternal	O
antibody	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
:	O
its	O
role	O
in	O
protection	O
against	O
infection	B-DISO
and	O
development	O
of	O
active	O
immunity	O
to	O
vaccine	O
.	O

This	O
system	O
is	O
based	O
upon	O
the	O
in	O
vitro	O
transcription	O
of	O
infectious	B-DISO
RNA	O
from	O
a	O
cDNA	O
copy	O
of	O
the	O
human	O
coronavirus	O
229E	O
genome	O
that	O
has	O
been	O
cloned	O
and	O
propagated	O
in	O
vaccinia	B-DISO
virus	O
.	O

Arterial	O
blood	O
gas	O
tensions	B-DISO
,	O
hemodynamic	O
variables	O
,	O
and	O
the	O
oxygenation	O
index	O
were	O
recorded	O
after	O
each	O
dose	O
of	O
5	O
mL	O
/	O
kg	O
.	O

CONCLUSIONS	O
:	O
Perflubron	O
is	O
more	O
uniformly	O
dispersed	O
when	O
dosed	O
in	O
a	O
rotational	O
fashion	O
with	O
alternation	B-DISO
between	O
supine	O
and	O
prone	O
position	O
during	O
incremental	O
dosing	O
.	O

ABSTRACT	O
:	O
Malaria	B-DISO
is	O
one	O
of	O
the	O
most	O
common	O
infectious	B-DISO
diseases	I-DISO
in	O
the	O
world	O
,	O
and	O
severe	O
respiratory	B-DISO
complications	I-DISO
have	O
been	O
described	O
mainly	O
in	O
association	O
with	O
Plasmodium	O
falciparum	O
.	O

Then	O
,	O
it	O
was	O
used	O
during	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
to	O
improve	O
gas	O
exchange	O
.	O

The	O
interest	O
on	O
prone	O
position	O
during	O
ALI	O
/	O
ARDS	B-DISO
progressively	O
increased	O
,	O
even	O
if	O
the	O
mechanisms	O
leading	O
to	O
a	O
respiratory	O
improvement	O
are	O
not	O
yet	O
completely	O
understood	O
.	O

The	O
possible	O
mechanisms	O
involved	O
in	O
oxygenation	O
improvement	O
during	O
prone	O
position	O
in	O
ALI	O
/	O
ARDS	B-DISO
patients	O
are	O
:	O
1	O
)	O
increased	O
lung	O
volumes	O
;	O
2	O
)	O
redistribution	O
of	O
lung	O
perfusion	O
;	O
3	O
)	O
recruitment	B-DISO
of	O
dorsal	O
spaces	O
with	O
more	O
homogeneous	O
ventilation	O
and	O
perfusion	O
distribution	O
.	O

TITLE	O
:	O
Experimental	O
reproduction	O
of	O
winter	B-DISO
dysentery	I-DISO
in	O
lactating	O
cows	O
using	O
BCV	O
--	O
comparison	O
with	O
BCV	O
infection	B-DISO
in	O
milk	O
-	O
fed	O
calves	O
.	O

These	O
findings	O
shed	O
light	O
on	O
the	O
apparent	O
epidemiological	O
differences	O
between	O
WD	O
and	O
calf	O
BCV	O
diarrhoea	B-DISO
suggesting	O
that	O
,	O
(	O
1	O
)	O
the	O
same	O
strains	O
of	O
BCV	O
cause	O
natural	O
outbreaks	O
of	O
calf	O
diarrhoea	B-DISO
and	O
WD	O
,	O
(	O
2	O
)	O
seronegative	O
cows	O
are	O
more	O
severely	O
affected	O
by	O
the	O
infection	B-DISO
than	O
seronegative	O
conventionally	O
reared	O
calves	O
,	O
and	O
(	O
3	O
)	O
unaffected	O
general	O
condition	B-DISO
in	O
diarrhoeic	O
calves	O
may	O
lead	O
to	O
underestimation	O
of	O
the	O
occurrence	O
of	O
calf	O
diarrhoea	B-DISO
in	O
WD	O
outbreaks	O
.	O

In	O
broad	O
-	O
spectrum	O
antiviral	O
assays	O
,	O
the	O
3	O
-	O
arylsulfonyl	O
-	O
2	O
-(	O
trifluoroacetamido	O
)	O
thiophenes	O
(	O
8c	O
-	O
g	O
)	O
and	O
2	O
-	O
acetamido	O
-	O
3	O
-	O
arylsulfonyl	O
-	O
5	O
-	O
nitrothiophenes	O
(	O
9f	O
-	O
g	O
)	O
proved	O
considerably	O
active	O
(	O
IC	O
(	O
50	O
)=	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
mL	O
)	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
and	O
/	O
or	O
varicella	B-DISO
zoster	I-DISO
virus	O
(	O
VZV	O
).	O

With	O
isoflurane	O
anesthesia	B-DISO
,	O
the	O
decrease	O
of	O
Rint	O
,	O
L	O
(	O
0	O
.	O
2	O
+/-	O

TITLE	O
:	O
Recombinant	O
equine	O
arteritis	B-DISO
virus	O
as	O
an	O
expression	O
vector	O
.	O

Confocal	O
fluorescence	O
microscopy	O
of	O
BHK	O
-	O
21	O
cells	O
electroporated	O
with	O
capped	O
RNA	O
transcripts	O
derived	O
from	O
the	O
resulting	O
plasmid	O
(	O
pBRNX1	O
.	O
38	O
-	O
5	O
/	O
6	O
-	O
GFP	O
)	O
demonstrated	O
that	O
the	O
GFP	O
gene	O
was	O
expressed	O
in	O
the	O
transfected	O
cells	O
,	O
while	O
the	O
gradual	O
spread	O
of	O
the	O
infection	B-DISO
through	O
the	O
cell	O
monolayer	O
showed	O
that	O
the	O
recombinant	O
virus	O
was	O
replication	O
competent	O
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
decade	O
,	O
cases	O
of	O
babesiosis	B-DISO
in	O
humans	O
have	O
been	O
reported	O
with	O
increasing	O
frequency	O
,	O
especially	O
in	O
the	O
northeastern	O
United	O
States	O
.	O

Feline	O
coronavirus	O
(	O
FCoV	O
)	O
genomic	O
RNA	O
was	O
detected	O
consistently	O
in	O
this	O
study	O
in	O
biologic	O
samples	O
from	O
adult	O
cats	O
,	O
kittens	O
suffering	B-DISO
from	O
FIP	B-DISO
,	O
and	O
their	O
siblings	O
.	O

TITLE	O
:	O
Echinococcal	O
hydatid	B-DISO
cyst	I-DISO
at	O
the	O
right	O
ventricle	O
outlet	O
with	O
leakage	B-DISO
to	O
the	O
pulmonary	O
artery	O
outflow	O
causing	O
follicular	O
airway	B-DISO
disease	I-DISO
and	O
sudden	B-DISO
death	I-DISO
.	O

ABSTRACT	O
:	O
Postmortem	O
examination	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
parous	O
woman	O
who	O
died	O
suddenly	O
revealed	O
a	O
hydatid	B-DISO
cyst	I-DISO
mass	O
located	O
at	O
the	O
right	O
ventricular	O
outlet	O
,	O
with	O
a	O
grossly	O
discernible	O
defect	O
opening	O
to	O
the	O
pulmonary	O
outflow	O
tract	O
.	O

These	O
observations	O
indicate	O
that	O
local	O
infections	B-DISO
as	O
caused	O
by	O
TGEV	O
,	O
FECV	O
and	O
CCoV	O
do	O
not	O
strictly	O
correlate	O
with	O
apical	O
release	O
,	O
as	O
suggested	O
by	O
earlier	O
work	O
.	O

A	O
few	O
days	O
after	O
the	O
second	O
gemcitabin	O
cycle	O
the	O
patient	O
developed	O
severe	O
respiratory	B-DISO
distress	I-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
synthesized	O
and	O
tested	O
dicaffeoyl	O
or	O
digalloyl	O
compounds	O
joined	O
through	O
a	O
five	O
-	O
membered	O
heterocyclic	O
ring	O
as	O
HIV	B-DISO
IN	O
inhibitors	O
to	O
explore	O
the	O
SARs	B-DISO
of	O
this	O
family	O
of	O
compounds	O
.	O

An	O
IBV	O
monoclonal	O
antibody	O
neutralization	O
-	O
resistant	O
mutant	B-DISO
(	O
NR	O
18	O
)	O
had	O
an	O
unusual	O
substitution	O
of	O
Ile	O
for	O
Arg	O
at	O
the	O
fourth	O
position	O
,	O
giving	O
the	O
sequence	O
Arg	O
-	O
Arg	O
-	O
Ser	O
-	O
Ile	O
-	O
Arg	O
,	O
which	O
likely	O
prevents	O
cleavage	O
and	O
,	O
thus	O
,	O
destroys	O
the	O
conformationally	O
dependent	O
monoclonal	O
antibody	O
binding	O
epitope	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolates	O
foreign	O
to	O
the	O
United	O
States	O
and	O
comparison	O
with	O
United	O
States	O
isolates	O
.	O

ABSTRACT	O
:	O
Eleven	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
foreign	O
to	O
the	O
United	O
States	O
were	O
analyzed	O
by	O
using	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)/	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
and	O
S1	O
glycoprotein	O
gene	O
sequencing	O
.	O

In	O
particular	O
,	O
rhabdomyolysis	B-DISO
associated	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
is	O
frequently	O
observed	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
with	O
a	O
6	O
-	O
16	O
%	O
reported	O
incidence	O
in	O
Intensive	O
Care	O
Units	O
.	O

The	O
mean	O
time	O
of	O
presentation	O
following	O
surgery	O
was	O
4	O
days	O
(	O
range	O
1	O
--	O
10	O
)	O
and	O
6	O
days	O
(	O
1	O
--	O
13	O
)	O
for	O
ALI	O
and	O
ARDS	B-DISO
,	O
respectively	O
.	O

RESULTS	O
:	O
ALI	O
/	O
ARDS	B-DISO
occurred	O
in	O
2	O
.	O
2	O
%	O
of	O
our	O
operated	O
lung	B-DISO
cancer	I-DISO
patients	O
.	O

An	O
infant	O
with	O
in	O
utero	O
arteiro	O
-	O
venous	B-DISO
thrombosis	I-DISO
is	O
reported	O
.	O

She	O
had	O
no	O
malformations	B-DISO
.	O

Pain	O
was	O
treated	O
with	O
analgesic	O
therapy	O
,	O
and	O
motor	O
impairment	B-DISO
required	O
physiotherapy	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
three	O
aspects	O
of	O
non	O
-	O
invasive	O
pressure	O
support	O
ventilation	O
(	O
NIPSV	O
)	O
applied	O
by	O
face	B-DISO
mask	O
to	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
due	O
to	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
):	O
(	O
1	O
)	O
the	O
initial	O
acute	O
effects	O
on	O
respiratory	O
rate	O
,	O
gas	O
exchange	O
and	O
hemodynamics	O
,	O
(	O
2	O
)	O
the	O
clinical	O
course	O
and	O
outcome	O
during	O
ICU	O
and	O
hospital	O
stay	O
,	O
(	O
3	O
)	O
the	O
nursing	O
workload	O
as	O
measured	O
by	O
the	O
daily	O
PRN	O
87	O
(	O
Project	O
Research	O
in	O
Nursing	O
)	O
score	O
.	O

No	O
complication	B-DISO
occurred	O
during	O
NIPSV	O
.	O

It	O
is	O
autocatalytically	O
released	O
from	O
the	O
precursors	O
pp1a	O
and	O
pp1ab	O
by	O
one	O
zinc	O
finger	O
-	O
containing	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
in	O
IBV	O
and	O
by	O
two	O
paralogous	O
PLpros	O
,	O
PL1pro	O
and	O
PL2pro	O
,	O
in	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
application	O
of	O
the	O
immunoperoxidase	O
(	O
IP	O
)	O
plaque	B-DISO
staining	O
procedure	O
(	O
IP	O
test	O
)	O
to	O
the	O
diagnosis	O
of	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
infection	B-DISO
was	O
investigated	O
.	O

The	O
genome	O
of	O
coronaviruses	O
has	O
been	O
engineered	O
by	O
modification	O
of	O
the	O
infectious	B-DISO
cDNA	O
leading	O
to	O
an	O
efficient	O
(>	O
20	O
microg	O
ml	O
(-	O
1	O
))	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	O
of	O
the	O
foreign	O
gene	O
.	O

ABSTRACT	O
:	O
Antiviral	O
roles	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
subsets	O
were	O
examined	O
in	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
murine	O
cytomegalovirus	O
(	O
MCMV	O
)	O
and	O
other	O
viruses	O
,	O
including	O
lymphocytic	B-DISO
choriomeningitis	I-DISO
virus	O
(	O
LCMV	O
),	O
vaccinia	B-DISO
virus	O
(	O
VV	O
),	O
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

To	O
follow	O
the	O
spread	O
of	O
virus	O
in	O
the	O
central	O
nervous	B-DISO
system	O
,	O
4	O
-	O
week	O
-	O
old	O
rats	O
inoculated	O
by	O
the	O
i	O
.	O
c	O
.	O

By	O
immunohistochemical	O
analysis	O
,	O
virus	O
-	O
specific	O
antigen	O
was	O
found	O
first	O
in	O
the	O
pyramidal	O
cells	O
of	O
the	O
hippocampus	O
and	O
cerebral	O
cortex	O
,	O
and	O
later	O
in	O
the	O
large	O
-	O
sized	O
neurons	O
of	O
the	O
pons	O
and	O
spinal	O
cord	B-DISO
.	O

In	O
two	O
patients	O
,	O
antibody	B-DISO
-	I-DISO
mediated	I-DISO
rejection	I-DISO
either	O
was	O
the	O
immediate	O
cause	O
of	O
death	O
(	O
hyperacute	O
rejection	O
,	O
one	O
patient	O
)	O
or	O
preceded	O
a	O
fatal	O
case	O
of	O
pneumonia	B-DISO
(	O
accelerated	O
antibody	B-DISO
-	I-DISO
mediated	I-DISO
rejection	I-DISO
,	O
one	O
patient	O
).	O

ABSTRACT	O
:	O
Western	O
blot	O
experiments	O
showed	O
that	O
sera	O
from	O
mice	O
infected	O
with	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
contained	O
autoantibodies	O
(	O
autoAb	O
)	O
that	O
bound	O
to	O
a	O
40	O
-	O
kDa	O
protein	O
present	O
in	O
liver	O
and	O
kidney	O
extracts	O
.	O

TITLE	O
:	O
Comparative	O
examination	O
of	O
cats	O
with	O
feline	B-DISO
leukemia	I-DISO
virus	O
-	O
associated	O
enteritis	B-DISO
and	O
other	O
relevant	O
forms	O
of	O
feline	O
enteritis	B-DISO
.	O

ABSTRACT	O
:	O
Cats	O
with	O
feline	B-DISO
leukemia	I-DISO
virus	O
(	O
FeLV	O
)-	O
associated	O
enteritis	B-DISO
(	O
FAE	B-DISO
),	O
enteritis	B-DISO
of	O
other	O
known	O
viral	O
etiology	O
(	O
parvovirus	B-DISO
[	O
PV	O
],	O
enteric	O
coronavirus	O
[	O
CoV	O
]),	O
and	O
enteritis	B-DISO
of	O
unknown	O
etiology	O
with	O
histologic	O
features	O
similar	O
to	O
those	O
of	O
FAE	B-DISO
and	O
PV	O
enteritis	B-DISO
(	O
EUE	O
)	O
and	O
FeLV	O
-	O
negative	O
and	O
FeLV	O
-	O
positive	O
cats	O
without	O
enterocyte	O
alterations	O
were	O
examined	O
.	O

PV	O
and	O
CoV	O
infections	B-DISO
were	O
confirmed	O
by	O
immunohistologic	O
demonstration	O
of	O
PV	O
and	O
CoV	O
antigen	O
,	O
ultrastructural	O
demonstration	O
of	O
viral	O
particles	O
in	O
the	O
intestinal	O
content	O
,	O
and	O
in	O
situ	O
hybridization	O
for	O
PV	O
genome	O
.	O

In	O
cats	O
with	O
EUE	O
,	O
myeloid	O
/	O
histiocyte	O
antigen	O
-	O
positive	O
macrophages	O
were	O
relatively	O
numerous	O
,	O
suggesting	O
recruitment	B-DISO
of	O
peripheral	O
blood	O
monocytes	O
.	O

He	O
presented	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
following	O
a	O
very	O
long	O
hyperbaric	O
oxygen	O
therapy	O
(	O
using	O
a	O
US	O
.	O

pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Management	O
of	O
respiratory	B-DISO
failure	I-DISO
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
typically	O
requires	O
ventilatory	O
assistance	O
.	O

Some	O
cases	O
of	O
severe	O
angioedema	B-DISO
have	O
been	O
recently	O
reported	O
after	O
treatment	O
with	O
fibrinolytic	O
agents	O
.	O

ABSTRACT	O
:	O
Serological	O
evidence	O
of	O
previous	O
viral	O
exposure	O
(	O
titer	O
at	O
arrival	O
)	O
and	O
current	O
viral	O
exposure	O
(	O
titer	O
increase	O
)	O
during	O
a	O
28	O
-	O
day	O
study	O
period	O
,	O
was	O
used	O
to	O
determine	O
if	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
or	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
(	O
BVDV	O
)	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
undifferentiated	O
bovine	O
respiratory	B-DISO
disease	I-DISO
(	O
UBRD	O
)	O
in	O
feedlot	O
calves	O
.	O

+/	O
p	O
mice	O
were	O
intermediate	O
between	O
+/+	O
and	O
p	O
/	O
p	O
mice	O
in	O
susceptibility	O
to	O
liver	B-DISO
damage	I-DISO
,	O
virus	O
growth	O
in	O
liver	O
,	O
and	O
susceptibility	O
to	O
killing	O
by	O
MHV	O
.	O

There	O
was	O
a	O
trend	O
toward	O
higher	O
pneumonia	B-DISO
rate	O
in	O
the	O
severe	O
group	O
,	O
with	O
50	O
%	O
of	O
patients	O
in	O
the	O
severe	O
group	O
developing	O
pneumonia	B-DISO
as	O
compared	O
with	O
28	O
%	O
in	O
the	O
moderate	O
group	O
(	O
p	O
=	O
0	O
.	O
20	O
).	O

ABSTRACT	O
:	O
Stunted	O
growth	O
of	O
poults	O
afflicted	O
by	O
enteritis	B-DISO
mortality	O
syndrome	B-DISO
(	O
PEMS	O
)	O
may	O
be	O
associated	O
with	O
depressed	O
digestive	O
capabilities	O
.	O

TITLE	O
:	O
Fas	B-DISO
/	O
Fas	B-DISO
ligand	O
system	O
mediates	O
epithelial	O
injury	O
,	O
but	O
not	O
pulmonary	O
host	O
defenses	O
,	O
in	O
response	O
to	O
inhaled	O
bacteria	O
.	O

ABSTRACT	O
:	O
The	O
Fas	B-DISO
/	O
Fas	B-DISO
ligand	O
(	O
FasL	O
)	O
system	O
has	O
been	O
implicated	O
in	O
alveolar	O
epithelial	O
cell	O
apoptosis	O
during	O
pulmonary	B-DISO
fibrosis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Alveolar	O
permeability	O
changes	O
,	O
as	O
determined	O
by	O
bronchoalveolar	O
lavage	O
fluid	O
HSA	B-DISO
concentrations	O
,	O
were	O
less	O
severe	O
in	O
the	O
lpr	O
mice	O
6	O
h	O
after	O
the	O
challenges	O
.	O

Intracerebral	O
injection	O
of	O
MHV	O
-	O
2	O
into	O
4	O
-	O
week	O
-	O
old	O
C57B1	O
/	O
6	O
mice	O
produces	O
acute	O
meningitis	B-DISO
and	O
hepatitis	B-DISO
without	O
encephalitis	B-DISO
or	O
chronic	O
inflammatory	O
demyelination	B-DISO
.	O

ACP	B-DISO
was	O
defined	O
as	O
a	O
ratio	O
of	O
right	O
ventricular	O
end	O
-	O
diastolic	O
area	O
to	O
left	O
ventricular	O
end	O
-	O
diastolic	O
area	O
in	O
the	O
long	O
axis	O
>	O
0	O
.	O
6	O
associated	O
with	O
septal	O
dyskinesia	B-DISO
in	O
the	O
short	O
axis	O
during	O
TEE	O
examination	O
.	O

RESULTS	O
:	O
Normal	O
right	O
ventricular	O
function	O
was	O
present	O
in	O
56	O
patients	O
,	O
whereas	O
right	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
was	O
observed	O
in	O
19	O
patients	O
after	O
2	O
days	O
of	O
respiratory	O
support	O
.	O

ABSTRACT	O
:	O
The	O
paper	O
provides	O
evidence	O
for	O
the	O
pathogenetic	O
approach	O
to	O
treating	O
acute	O
lung	O
lesion	O
(	O
ALL	O
)	O
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
involves	O
earlier	O
(	O
the	O
first	O
days	O
following	O
the	O
onset	O
of	O
respiratory	B-DISO
failure	I-DISO
)	O
use	O
of	O
surfactant	O
,	O
its	O
combined	O
bolus	O
intratracheal	O
or	O
intrabronchial	O
administration	O
in	O
doses	O
of	O
200	O
-	O
400	O
mg	O
/	O
m2	O
,	O
followed	O
by	O
continuous	O
(	O
5	O
-	O
day	O
)	O
aerosol	O
inhalation	O
in	O
doses	O
of	O
20	O
-	O
30	O
mg	O
/	O
h	O
for	O
children	O
and	O
30	O
-	O
75	O
mg	O
/	O
h	O
for	O
adults	O
until	O
pronounced	O
clinical	O
and	O
X	O
-	O
ray	O
effects	O
are	O
shown	O
.	O

ABSTRACT	O
:	O
Episodic	O
wheezing	B-DISO
associated	O
with	O
viral	B-DISO
infections	I-DISO
of	O
the	O
upper	O
respiratory	O
tract	O
(	O
URT	O
)	O
is	O
a	O
common	O
problem	O
in	O
young	O
children	O
but	O
also	O
occurs	O
in	O
adults	O
.	O

It	O
is	O
hypothesized	O
that	O
an	O
experimental	O
infection	B-DISO
with	O
human	O
coronavirus	O
(	O
HCoV	O
),	O
the	O
second	O
most	O
prevalent	O
common	B-DISO
cold	I-DISO
virus	O
,	O
would	O
cause	O
lower	O
respiratory	O
tract	O
(	O
LRT	O
)	O
changes	O
in	O
adults	O
with	O
a	O
history	O
of	O
viral	O
wheeze	B-DISO
.	O

Twenty	O
-	O
four	O
viral	O
wheezers	O
(	O
15	O
atopic	B-DISO
)	O
and	O
19	O
controls	O
(	O
seven	O
atopic	B-DISO
)	O
were	O
inoculated	O
with	O
HCoV	O
229E	O
and	O
monitored	O
for	O
the	O
development	O
of	O
symptoms	O
,	O
changes	O
in	O
airway	O
physiology	O
and	O
provocative	O
concentration	O
of	O
methacholine	O
causing	O
a	O
20	O
%	O
fall	O
in	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
(	O
PC20	O
).	O

The	O
fall	O
in	O
PC20	O
affected	O
both	O
atopic	B-DISO
and	O
nonatopic	O
subjects	O
equally	O
.	O

The	O
most	O
frequent	O
signs	O
were	O
meiosis	O
,	O
change	B-DISO
in	I-DISO
mental	I-DISO
status	I-DISO
,	O
hypersalivation	B-DISO
and	O
fasciculations	B-DISO
.	O

Three	O
patients	O
with	O
intermediate	B-DISO
syndrome	I-DISO
died	O
due	O
to	O
delay	O
for	O
endotracheal	O
intubation	O
.	O

APRV	O
increases	O
cardiac	O
performance	O
,	O
with	O
decreased	O
pressor	O
use	O
and	O
decreased	O
airway	O
pressure	O
,	O
in	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
A	O
nucleotide	O
variability	O
in	O
the	O
sequence	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
transmembrane	O
protein	O
M	O
of	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
is	O
described	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
demonstrates	O
the	O
use	O
of	O
stochastic	O
genetic	O
epidemiological	O
models	O
for	O
quantifying	O
the	O
consequences	O
of	O
selecting	O
animals	O
for	O
resistance	O
to	O
a	O
microparasitic	O
infectious	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
The	O
hypothesis	O
that	O
the	O
changes	O
in	O
the	O
respiratory	O
system	O
pressure	O
-	O
volume	O
(	O
PV	O
)	O
curve	O
during	O
pulmonary	B-DISO
edema	I-DISO
mainly	O
reflect	O
distal	O
airway	B-DISO
obstruction	I-DISO
was	O
investigated	O
in	O
rats	O
.	O

In	O
keeping	O
with	O
this	O
explanation	O
,	O
the	O
lower	O
Vuip	O
and	O
Crs	B-DISO
were	O
before	O
HV	O
,	O
the	O
more	O
severe	O
HV	O
-	O
induced	O
edema	B-DISO
was	O
in	O
alpha	O
-	O
naphthylthiourea	O
-	O
injected	O
rats	O
.	O

These	O
studies	O
have	O
indicated	O
that	O
adhesion	B-DISO
molecules	O
such	O
as	O
intracellular	O
adhesion	B-DISO
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
neutrophils	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	B-DISO
),	O
substance	O
P	O
,	O
and	O
chemokines	O
acting	O
via	O
the	O
CCR	O
-	O
1	O
chemokine	O
receptor	O
play	O
a	O
pro	O
-	O
inflammatory	O
role	O
while	O
complement	O
factor	O
C5a	O
plays	O
an	O
anti	O
-	O
inflammatory	O
role	O
in	O
pancreatitis	B-DISO
and	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Studies	O
were	O
performed	O
to	O
investigate	O
the	O
contributions	O
of	O
the	O
CC	O
chemokine	O
receptor	O
CCR5	O
in	O
host	O
defense	O
and	O
disease	O
development	O
following	O
intracranial	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

For	O
PCT	B-DISO
,	O
no	O
significant	O
correlations	O
(	O
Spearman	O
rank	O
)	O
were	O
found	O
to	O
the	O
lung	O
injury	O
score	O
(	O
p	O
=.	O
93	O
),	O
the	O
abbreviated	O
injury	O
scale	O
-	O
lung	O
(	O
p	O
=.	O
33	O
),	O
or	O
the	O
sepsis	B-DISO
-	O
related	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
-	O
lung	O
(	O
p	O
=.	O
38	O
).	O

The	O
average	O
size	O
of	O
these	O
defects	O
was	O
512	O
cm2	B-DISO
.	O

Interruption	O
of	O
further	O
epidermal	O
detachment	B-DISO
occurred	O
after	O
an	O
average	O
of	O
4	O
.	O
8	O
days	O
from	O
the	O
onset	O
of	O
IVIG	O
therapy	O
.	O

No	O
hypertrophic	B-DISO
scars	I-DISO
were	O
observed	O
.	O

Substitution	O
of	O
two	O
amino	O
acids	O
that	O
inserted	O
an	O
N	O
-	O
glycosylation	O
site	O
at	O
amino	O
acid	O
291	O
also	O
resulted	O
in	O
a	O
mutant	B-DISO
hAPN	O
that	O
lacked	O
receptor	O
activity	O
because	O
it	O
failed	O
to	O
bind	O
HCoV	O
-	O
229E	O
.	O

Information	O
was	O
collected	O
on	O
weight	O
gain	O
,	O
clinical	O
signs	O
,	O
and	O
treatments	O
for	O
enteric	O
and	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
during	O
the	O
study	O
period	O
.	O

TITLE	O
:	O
Neutralization	O
of	O
the	O
chemokine	O
CXCL10	O
reduces	O
inflammatory	O
cell	B-DISO
invasion	I-DISO
and	O
demyelination	B-DISO
and	O
improves	O
neurological	O
function	O
in	O
a	O
viral	O
model	O
of	O
multiple	B-DISO
sclerosis	I-DISO
.	O

ABSTRACT	O
:	O
Intracerebral	O
infection	B-DISO
of	O
mice	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
followed	O
by	O
a	O
chronic	O
demyelinating	B-DISO
disease	I-DISO
with	O
clinical	O
and	O
histological	O
similarities	O
with	O
the	O
human	O
demyelinating	B-DISO
disease	I-DISO
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
).	O

The	O
results	O
of	O
randomised	O
clinical	O
trials	O
investigating	O
selenium	O
substitution	O
in	O
critical	O
ill	B-DISO
patients	O
with	O
inflammation	B-DISO
are	O
reviewed	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
serology	O
in	O
broilers	O
and	O
broiler	O
breeders	O
:	O
correlations	O
between	O
antibody	O
titers	O
and	O
performance	O
in	O
vaccinated	O
flocks	O
.	O

Significant	O
correlations	O
measured	O
between	O
antibody	O
titers	O
and	O
production	O
parameters	O
within	O
and	O
between	O
the	O
generations	O
strongly	O
suggested	O
negative	O
effects	O
of	O
IBV	O
infections	B-DISO
on	O
laying	O
percentage	O
in	O
the	O
breeders	O
and	O
on	O
mortality	O
and	O
daily	O
weight	O
gain	O
in	O
the	O
broilers	O
.	O

Economic	O
losses	O
associated	O
with	O
IBV	O
infections	B-DISO
in	O
the	O
broilers	O
occurred	O
predominantly	O
in	O
flocks	O
hatched	O
with	O
low	O
and	O
erratic	O
maternal	O
antibody	O
titers	O
.	O

Ventilator	O
inspiratory	O
flow	O
(	O
V	O
(	O
I	O
))	O
and	O
trigger	O
sensitivity	O
settings	O
should	O
be	O
optimized	O
to	O
limit	O
the	O
increase	O
in	O
work	O
of	O
breathing	O
and	O
dyspnea	B-DISO
.	O

However	O
,	O
every	O
effort	O
should	O
be	O
made	O
to	O
maintain	O
plateau	O
pressure	O
and	O
V	O
(	O
T	O
)	O
goals	O
by	O
buffering	O
severe	O
acidosis	B-DISO
and	O
treating	O
patient	O
-	O
ventilator	O
asynchrony	O
with	O
sedation	B-DISO
.	O

Most	O
of	O
the	O
affected	O
herds	O
had	O
been	O
vaccinated	O
with	O
modified	O
live	O
-	O
vaccines	O
(	O
MLVs	O
)	O
against	O
PRRS	B-DISO
.	O

The	O
complete	O
ORF5	O
gene	O
of	O
eight	O
acute	O
PRRSV	O
isolates	O
from	O
herds	O
experiencing	O
acute	O
PRRS	B-DISO
outbreaks	O
in	O
Iowa	O
and	O
North	O
Carolina	O
was	O
amplified	O
and	O
sequenced	O
.	O

The	O
data	O
from	O
this	O
study	O
do	O
not	O
fully	O
support	O
the	O
hypothesis	O
that	O
the	O
emergence	O
of	O
acute	O
PRRS	B-DISO
is	O
due	O
to	O
reversion	O
of	O
MLVs	O
to	O
a	O
pathogenic	O
phenotype	O
,	O
as	O
only	O
one	O
of	O
the	O
eight	O
acute	O
isolates	O
was	O
shown	O
to	O
be	O
very	O
closely	O
related	O
to	O
the	O
RespPRRS	O
MLV	O
.	O

Four	O
rhinovirus	O
,	O
four	O
coronavirus	O
,	O
three	O
RSV	O
,	O
one	O
Mycoplasma	B-DISO
pneumoniae	O
,	O
and	O
one	O
influenza	B-DISO
A	O
/	O
enterovirus	O
double	O
infection	B-DISO
were	O
confirmed	O
.	O

RESULTS	O
:	O
Four	O
rhinovirus	O
,	O
four	O
coronavirus	O
,	O
three	O
RSV	O
,	O
one	O
Mycoplasma	B-DISO
pneumoniae	O
,	O
and	O
one	O
influenza	B-DISO
A	O
/	O
enterovirus	O
double	O
infection	B-DISO
were	O
confirmed	O
.	O

CONCLUSIONS	O
:	O
Prolonged	O
nasal	O
eosinophil	O
influx	O
was	O
observed	O
in	O
allergic	O
patients	O
after	O
common	B-DISO
cold	I-DISO
.	O

In	O
cats	O
with	O
FIP	B-DISO
,	O
the	O
precardial	O
mediastinum	O
(	O
including	O
site	O
of	O
the	O
thymus	O
)	O
and	O
mesenteric	O
lymph	O
node	O
parenchyma	O
were	O
often	O
affected	O
by	O
granulomatous	O
-	O
necrotizing	O
processes	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
man	O
with	O
mild	O
pulmonary	B-DISO
emphysema	I-DISO
had	O
been	O
followed	O
for	O
two	O
years	O
.	O

A	O
few	O
cases	O
have	O
been	O
reported	O
of	O
progressive	O
pulmonary	O
cystic	B-DISO
disease	I-DISO
associated	O
with	O
PCP	B-DISO
pneumonia	B-DISO
in	O
patients	O
with	O
AIDS	O
,	O
in	O
which	O
the	O
cause	O
of	O
bulla	B-DISO
formation	O
was	O
thought	O
to	O
be	O
lung	O
parenchyma	O
destruction	O
induced	O
by	O
HIV	B-DISO
itself	O
,	O
or	O
increased	O
elastase	O
release	O
from	O
HIV	B-DISO
-	O
infected	O
macrophages	O
.	O

TITLE	O
:	O
Sequence	O
analysis	O
of	O
the	O
S	O
gene	O
of	O
recombinant	O
MHV	O
-	O
2	O
/	O
A59	O
coronaviruses	O
reveals	O
three	O
candidate	O
mutations	O
associated	O
with	O
demyelination	B-DISO
and	O
hepatitis	B-DISO
.	O

Bullous	B-DISO
impetigo	I-DISO
is	O
also	O
due	O
to	O
exfoliatin	O
.	O

Scarlet	B-DISO
fever	I-DISO
is	O
related	O
to	O
the	O
streptococcal	O
erythrogenic	O
toxins	O
.	O

Toxic	B-DISO
shock	I-DISO
syndrome	I-DISO
is	O
defined	O
as	O
a	O
multi	B-DISO
organ	I-DISO
failure	I-DISO
syndrome	B-DISO
with	O
a	O
rapid	O
onset	O
,	O
fever	O
,	O
rash	B-DISO
followed	O
by	O
desquamation	O
,	O
vomiting	B-DISO
and	O
diarrhea	B-DISO
,	O
hypotension	O
,	O
conjunctivitis	B-DISO
and	O
strawberry	B-DISO
tongue	I-DISO
.	O

The	O
disease	O
is	O
related	O
to	O
an	O
infection	B-DISO
or	O
colonisation	O
with	O
a	O
toxin	O
(	O
TSST	O
-	O
1	O
)	O
producing	O
strain	O
of	O
Staphylococcus	O
aureus	O
.	O

At	O
the	O
age	O
of	O
20	O
,	O
in	O
a	O
seven	O
months	O
period	O
,	O
she	O
precised	O
urgent	O
abdominal	O
surgical	O
intervention	O
in	O
three	O
occasions	O
for	O
acute	O
diffuse	O
peritonitis	B-DISO
related	O
to	O
jejunal	O
and	O
ileal	O
diverticula	B-DISO
.	O

In	O
the	O
cerebral	O
MR	O
leukoencephalopathy	B-DISO
was	O
detected	O
.	O

TITLE	O
:	O
Lack	O
of	O
CCR2	O
results	O
in	O
increased	O
mortality	O
and	O
impaired	B-DISO
leukocyte	O
activation	O
and	O
trafficking	O
following	O
infection	B-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

TITLE	O
:	O
Chemokine	O
expression	O
and	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
:	O
regulation	O
of	O
host	O
defense	O
and	O
neuropathology	B-DISO
.	O

Throat	O
,	O
rectal	O
swab	O
and	O
cerebrospinal	O
fluid	O
samples	O
were	O
subjected	O
to	O
viral	O
isolation	O
and	O
viral	O
isolates	O
were	O
identified	O
by	O
immunofluorescence	O
,	O
micro	O
-	O
neutralisation	O
using	O
human	O
rhabdomyosarcoma	B-DISO
(	O
RD	O
)	O
cells	O
,	O
and	O
reverse	O
transcritpase	O
polymerase	O
chain	O
reaction	O
.	O

Echovirus	O
7	O
was	O
the	O
sole	O
pathogen	O
isolated	O
from	O
three	O
cases	O
of	O
acute	O
encephalomyelitis	B-DISO
,	O
two	O
of	O
which	O
were	O
fatal	O
due	O
to	O
severe	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
resistant	O
to	O
inotropic	O
support	O
.	O

Echovirus	O
7	O
infection	B-DISO
associated	O
with	O
encephalomyelitis	B-DISO
could	O
be	O
fatal	O
due	O
to	O
indirect	O
involvement	O
of	O
the	O
heart	O
resulting	O
in	O
severe	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
.	O

The	O
survivor	O
had	O
residual	O
bulbar	B-DISO
palsy	I-DISO
,	O
but	O
is	O
considered	O
to	O
have	O
had	O
a	O
good	O
neurological	O
outcome	O
.	O

TITLE	O
:	O
Intranasal	O
inoculation	O
with	O
the	O
olfactory	O
bulb	O
line	O
variant	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
causes	O
extensive	O
destruction	O
of	O
the	O
olfactory	O
bulb	O
and	O
accelerated	O
turnover	O
of	O
neurons	O
in	O
the	O
olfactory	O
epithelium	O
of	O
mice	O
.	O

Biopsies	O
of	O
the	O
olfactory	O
mucosa	O
in	O
patients	O
that	O
complain	O
of	O
dysosmia	B-DISO
after	O
viral	B-DISO
infection	I-DISO
fall	O
into	O
two	O
categories	O
:	O
one	O
in	O
which	O
no	O
olfactory	O
epithelium	O
is	O
seen	O
and	O
another	O
in	O
which	O
the	O
epithelium	O
is	O
disordered	O
and	O
populated	O
mainly	O
by	O
immature	O
neurons	O
.	O

The	O
damage	O
to	O
the	O
bulb	O
indirectly	O
causes	O
a	O
persistent	O
,	O
long	O
-	O
term	O
increase	O
in	O
the	O
turnover	O
of	O
sensory	O
neurons	O
in	O
the	O
epithelium	O
,	O
i	O
.	O
e	O
.	O
the	O
relative	O
proportion	O
of	O
immature	O
to	O
mature	O
sensory	O
neurons	O
and	O
the	O
rate	O
of	O
basal	O
cell	O
proliferation	B-DISO
both	O
increase	O
.	O

Thus	O
,	O
damage	O
to	O
the	O
olfactory	O
nerve	O
or	O
bulb	O
may	O
contribute	O
to	O
a	O
form	O
of	O
post	O
-	O
viral	O
olfactory	O
dysfunction	O
and	O
MHV	O
OBLV	O
is	O
a	O
useful	O
model	O
for	O
studying	O
the	O
pathogenesis	B-DISO
of	O
this	O
form	O
of	O
dysosmia	B-DISO
.	O

TITLE	O
:	O
Antibody	O
is	O
required	O
for	O
clearance	O
of	O
infectious	B-DISO
murine	B-DISO
hepatitis	I-DISO
virus	O
A59	O
from	O
the	O
central	O
nervous	B-DISO
system	O
,	O
but	O
not	O
the	O
liver	O
.	O

TITLE	O
:	O
Pulmonary	O
oxygen	O
consumption	O
:	O
a	O
hypothesis	O
to	O
explain	O
the	O
increase	O
in	O
oxygen	O
consumption	O
of	O
low	O
birth	O
weight	O
infants	O
with	O
lung	B-DISO
disease	I-DISO
.	O

VO2lung	O
was	O
not	O
correlated	O
with	O
clinical	O
measures	O
of	O
acute	B-DISO
disease	I-DISO
severity	O
.	O

From	O
1	O
/	O
RD	O
the	O
number	O
needed	O
to	O
treat	O
(	O
NNT	O
)	O
for	O
benefits	O
,	O
and	O
number	O
needed	O
to	O
harm	O
(	O
NNH	B-DISO
)	O
for	O
adverse	B-DISO
effects	I-DISO
,	O
were	O
calculated	O
.	O

In	O
the	O
subgroup	O
of	O
six	O
trials	O
where	O
a	O
high	O
volume	O
strategy	O
(	O
HVS	O
)	O
was	O
used	O
for	O
HFOV	O
,	O
this	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
CLD	B-DISO
in	O
survivors	O
at	O
28	O
-	O
30	O
days	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
53	O
(	O
0	O
.	O
36	O
,	O
0	O
.	O
76	O
)],	O
of	O
'	O
death	O
or	O
CLD	B-DISO
at	O
28	O
-	O
30	O
days	O
'	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
56	O
(	O
0	O
.	O
40	O
,	O
0	O
.	O
77	O
)	O
and	O
oxygen	O
use	O
at	O
36	O
-	O
37	O
weeks	O
postmenstrual	O
age	O
or	O
discharge	O
[	O
five	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
72	O
(	O
0	O
.	O
56	O
,	O
0	O
.	O
93	O
)].	O

In	O
this	O
group	O
of	O
trials	O
HFOV	O
is	O
associated	O
with	O
a	O
strong	O
trend	O
for	O
an	O
increased	O
rate	O
of	O
gross	O
pulmonary	O
ALS	B-DISO
(	O
four	O
trials	O
,	O
summary	O
RR	O
1	O
.	O
54	O
(	O
0	O
.	O
98	O
,	O
2	O
.	O
42	O
)]	O
In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	O
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	B-DISO
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
periventricular	B-DISO
leukomalacia	I-DISO
(	O
PVL	O
)	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

ARDS	B-DISO
is	O
a	O
widely	O
disseminated	O
syndrome	B-DISO
caused	O
by	O
severe	O
etiologic	O
factors	O
.	O

ARDS	B-DISO
progresses	O
through	O
three	O
clinical	O
phases	O
:	O
1	O
.	O

definitive	O
therapy	O
to	O
interrupt	O
mechanisms	O
of	O
inflammation	B-DISO
and	O
pulmonary	O
injury	O
;	O
4	O
.	O

The	O
cat	O
was	O
negative	O
for	O
feline	O
immunodeficiency	B-DISO
virus	O
,	O
feline	O
leukaemia	B-DISO
virus	O
and	O
feline	O
coronavirus	O
.	O

The	O
ear	B-DISO
disease	I-DISO
responded	O
rapidly	O
to	O
treatment	O
with	O
prednisolone	O
and	O
,	O
apart	O
from	O
slight	O
thickening	O
and	O
curling	O
of	O
the	O
pinnae	O
,	O
the	O
cat	O
remained	O
normal	O
and	O
pain	O
-	O
free	O
.	O

TITLE	O
:	O
[	O
Tracheal	O
gas	O
insufflation	O
avoids	O
hypercapnia	B-DISO
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
].	O

This	O
hypercapnia	B-DISO
is	O
extremely	O
dangerous	O
for	O
severe	O
head	O
trauma	O
patients	O
because	O
it	O
increases	O
intracranial	O
pressure	O
.	O

Histopathologically	O
,	O
no	O
significant	O
difference	O
was	O
revealed	O
between	O
wt	O
and	O
srr7	O
-	O
infected	O
mice	O
on	O
day	O
2	O
postinoculation	O
(	O
p	O
.	O
i	O
.),	O
with	O
only	O
scant	O
inflammation	B-DISO
and	O
a	O
minimum	O
degree	O
of	O
neuropathological	O
changes	O
.	O

Twelve	O
animals	O
had	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
50	O
%	O
to	O
70	O
%	O
FiO2	O
at	O
sea	O
level	O
to	O
maintain	O
PaO2	O
of	O
50	O
-	O
70	O
torr	O
[	O
6	O
.	O
65	O
-	O
9	O
.	O
31kPa	O
])	O
induced	O
by	O
intravenous	O
oleic	O
acid	O
.	O

Three	O
stem	O
structures	O
were	O
chosen	O
as	O
targets	O
for	O
the	O
introduction	O
of	O
transversion	B-DISO
mutations	I-DISO
designed	O
to	O
destroy	O
base	O
pairing	O
structures	O
.	O

Infectious	B-DISO
IBV	O
RNA	O
was	O
generated	O
in	O
situ	O
after	O
the	O
transfection	O
of	O
restricted	O
recombinant	O
vaccinia	B-DISO
virus	O
DNA	O
into	O
primary	O
chick	O
kidney	O
cells	O
previously	O
infected	O
with	O
a	O
recombinant	O
fowlpox	B-DISO
virus	O
expressing	O
T7	O
RNA	O
polymerase	O
.	O

In	O
patients	O
with	O
major	O
trauma	O
,	O
IL	O
-	O
8	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
that	O
progressed	O
to	O
ARDS	B-DISO
compared	O
to	O
those	O
that	O
did	O
not	O
(	O
n	O
=	O
56	O
,	O
P	O
=	O
0	O
.	O
0001	O
).	O

Hypoxia	B-DISO
downregulated	O
a	O
range	O
of	O
other	O
proinflammatory	O
mediators	O
,	O
including	O
MCP	O
-	O
1	O
and	O
TNF	O
-	O
alpha	O
.	O

Recently	O
,	O
a	O
withdrawal	B-DISO
syndrome	I-DISO
has	O
been	O
described	O
for	O
GHB	O
.	O

Patients	O
were	O
discharged	O
on	O
tapering	O
doses	O
of	O
benzodiazepines	O
or	O
pentobarbital	O
and	O
were	O
free	O
of	O
psychotic	B-DISO
symptoms	I-DISO
at	O
follow	O
-	O
up	O
.	O

CONCLUSIONS	O
:	O
GBL	O
discontinuation	O
can	O
result	O
in	O
severe	O
withdrawal	B-DISO
,	O
necessitating	O
ICU	O
admission	O
.	O

In	O
patients	O
who	O
are	O
overtreated	O
,	O
decreasing	O
the	O
SNa	O
by	O
giving	O
hypotonic	B-DISO
solutions	O
(	O
eventually	O
with	O
DDAVP	O
)	O
so	O
that	O
the	O
daily	O
increase	O
in	O
SNa	O
stays	O
under	O
10	O
mEq	O
/	O
l	O
/	O
24	O
h	O
could	O
protect	O
them	O
again	O
ODS	O
.	O

RNA	O
was	O
extracted	O
from	O
the	O
intestines	O
and	O
stool	O
samples	O
that	O
were	O
collected	O
from	O
the	O
swine	O
with	O
diarrhea	B-DISO
.	O

This	O
duplex	O
RT	O
-	O
PCR	O
may	O
be	O
a	O
useful	O
diagnostic	O
method	O
for	O
the	O
rapid	O
,	O
specific	O
,	O
and	O
sensitive	O
differential	O
detection	O
of	O
TGE	B-DISO
and	O
PED	O
viruses	O
using	O
clinical	O
samples	O
.	O

In	O
contrast	O
,	O
the	O
L2	O
-	O
MHV3	O
strain	O
induces	O
the	O
development	O
of	O
a	O
fulminant	B-DISO
hepatitis	I-DISO
,	O
leading	O
to	O
death	O
within	O
3	O
days	O
.	O

The	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
integrity	O
of	O
intrahepatic	O
immune	B-DISO
tolerance	I-DISO
mechanisms	O
and	O
immune	O
-	O
mediated	O
viral	O
elimination	O
.	O

They	O
all	O
recovered	O
from	O
aplasia	B-DISO
,	O
but	O
soon	O
after	O
they	O
died	O
from	O
brutal	O
and	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
),	O
a	O
severe	O
respiratory	O
syndrome	B-DISO
,	O
develops	O
in	O
response	O
to	O
numerous	O
insults	O
and	O
responds	O
poorly	O
to	O
therapeutic	O
intervention	O
.	O

The	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
were	O
chosen	O
as	O
antigens	O
,	O
because	O
antibodies	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
FIP	B-DISO
virus	O
(	O
FIPV	O
)	O
are	O
known	O
to	O
precipitate	O
pathogenesis	B-DISO
.	O

for	O
2	O
h	O
)	O
provoked	O
pulmonary	B-DISO
hemorrhage	I-DISO
and	O
edema	B-DISO
,	O
protein	O
leakage	B-DISO
and	O
massive	O
neutrophil	O
infiltration	B-DISO
,	O
resulted	O
in	O
severe	O
hypoxemia	O
and	O
impaired	B-DISO
lung	O
compliance	O
,	O
accompanying	O
the	O
increase	O
of	O
phospholipase	O
A	O
(	O
2	O
)	O
activity	O
and	O
interleukin	O
-	O
8	O
,	O
and	O
degradation	O
of	O
surfactant	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

TITLE	O
:	O
An	O
autopsy	O
case	O
of	O
primary	B-DISO
biliary	I-DISO
cirrhosis	I-DISO
with	O
severe	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
A	O
74	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
postoperative	B-DISO
pain	I-DISO
and	O
its	O
therapy	O
is	O
a	O
great	O
challenge	O
for	O
all	O
health	O
-	O
care	O
providers	O
in	O
operative	O
medicine	O
today	O
.	O

Many	O
of	O
them	O
consider	O
pain	O
is	O
a	O
natural	O
and	O
physiological	O
consequence	O
of	O
different	O
diseases	O
and	O
pathological	O
conditions	O
and	O
moderate	O
to	O
severe	B-DISO
pain	I-DISO
is	O
considered	O
as	O
acceptable	O
consequence	O
of	O
surgery	O
.	O

Introduction	O
of	O
the	O
""""	O
fifth	O
vital	O
parameter	O
""""	O
would	O
solve	O
many	O
problems	O
in	O
postoperative	B-DISO
pain	I-DISO
therapy	O
,	O
because	O
healthcare	O
workers	O
take	O
vital	O
signs	O
very	O
seriously	O
both	O
for	O
monitoring	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
1	O
7	O
-	O
year	O
-	O
old	O
female	O
with	O
acute	O
extra	O
-	O
pyramidal	O
parkinsonism	B-DISO
complicating	O
a	O
suicidal	O
attempt	O
with	O
the	O
organophosphate	O
insecticide	O
chlorpyrifos	O
,	O
who	O
was	O
initially	O
suspected	O
to	O
have	O
developed	O
severe	B-DISO
depression	I-DISO
or	O
psychosis	B-DISO
.	O

Following	O
atropine	O
and	O
toxogonin	O
treatment	O
along	O
with	O
mechanical	O
ventilation	O
she	O
developed	O
overt	O
extrapyramidal	O
parkinsonism	B-DISO
and	O
encephalopathy	B-DISO
,	O
characterized	O
by	O
impaired	B-DISO
sensorium	O
and	O
agitation	B-DISO
,	O
mask	O
facies	O
along	O
with	O
a	O
muffled	O
voice	O
and	O
swallowing	B-DISO
impairment	I-DISO
,	O
a	O
resting	B-DISO
tremor	I-DISO
with	O
cogwheel	B-DISO
rigidity	I-DISO
switching	O
to	O
bradykinetic	O
choreoathetotic	O
movements	O
.	O

Together	O
these	O
events	O
orchestrate	O
the	O
principal	O
clinical	O
manifestations	O
of	O
the	O
syndrome	B-DISO
,	O
pulmonary	B-DISO
edema	I-DISO
and	O
atelectasis	B-DISO
.	O

Enhanced	O
expression	O
occurred	O
mainly	O
in	O
genes	O
associated	O
with	O
oxidative	B-DISO
stress	I-DISO
,	O
anti	O
-	O
proteolytic	O
function	O
,	O
and	O
repair	O
of	O
the	O
extracellular	O
matrix	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
viral	O
agents	O
in	O
two	O
farm	O
populations	O
of	O
captured	O
guanacos	O
(	O
Lama	O
guanicoe	O
)	O
in	O
the	O
Argentinean	O
Patagonia	O
region	O
,	O
that	O
developed	O
severe	B-DISO
diarrhoea	I-DISO
outbreaks	O
.	O

In	O
addition	O
,	O
95	O
%	O
(	O
38	O
of	O
40	O
)	O
of	O
the	O
sampled	O
animals	O
were	O
positive	O
for	O
RV	O
antibodies	O
,	O
suggesting	O
a	O
high	O
prevalence	O
of	O
RV	O
infection	B-DISO
in	O
the	O
populations	O
tested	O
.	O

ABSTRACT	O
:	O
A	O
serodiagnostic	O
ELISA	O
utilizing	O
the	O
recombinant	O
nucleoprotein	O
(	O
rN	O
protein	O
)	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
was	O
developed	O
,	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
141	O
virus	O
neutralization	O
(	O
VN	O
)	O
positive	O
and	O
101	O
negative	O
sera	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	O
of	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
localized	O
to	O
the	O
Golgi	O
complex	O
when	O
expressed	O
exogenously	O
from	O
cDNA	O
.	O

Under	O
identical	O
conditions	O
,	O
TGEV	O
-	O
GFP2	O
spread	O
throughout	O
ST	O
cell	O
cultures	O
,	O
expressed	O
GFP	O
,	O
and	O
formed	O
viral	O
plaques	B-DISO
.	O

Patients	O
who	O
died	O
before	O
or	O
on	O
admission	O
and	O
those	O
with	O
prior	O
chronic	B-DISO
renal	I-DISO
disease	I-DISO
were	O
excluded	O
from	O
the	O
study	O
.	O

A	O
total	O
of	O
639	O
patients	O
(	O
291	O
female	O
and	O
348	O
male	O
)	O
with	O
ARF	B-DISO
due	O
to	O
crush	O
injury	O
were	O
hospitalized	O
in	O
35	O
hospitals	O
.	O

Mortality	O
,	O
when	O
it	O
occurs	O
,	O
is	O
mainly	O
associated	O
with	O
thoracic	B-DISO
and	O
abdominal	O
trauma	O
and	O
medical	O
problems	O
such	O
as	O
DIC	B-DISO
and	O
/	O
or	O
ARDS	B-DISO
/	O
respiratory	B-DISO
failure	I-DISO
,	O
often	O
in	O
conjunction	O
with	O
sepsis	B-DISO
.	O

Flocks	O
had	O
an	O
ongoing	O
history	O
of	O
bacterial	O
-	O
complicated	O
respiratory	B-DISO
disease	I-DISO
with	O
mortality	O
rates	O
as	O
high	O
as	O
28	O
%	O
in	O
spite	O
of	O
receiving	O
live	O
vaccinations	O
for	O
Massachusetts	O
and	O
Connecticut	O
strains	O
of	O
IBV	O
.	O

This	O
is	O
particularly	O
true	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
in	O
whom	O
the	O
most	O
significant	O
changes	O
in	O
thyroid	O
function	O
are	O
observed	O
.	O

Clinical	O
trials	O
indicate	O
that	O
transient	O
severe	O
hypertension	B-DISO
,	O
antenatal	O
hospitalization	O
,	O
proteinuria	O
at	O
delivery	O
and	O
neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
may	O
be	O
decreased	O
by	O
normalizing	O
blood	O
pressure	O
,	O
but	O
intrauterine	O
fetal	B-DISO
growth	I-DISO
restriction	I-DISO
may	O
be	O
increased	O
.	O

Acute	O
leptospirosis	B-DISO
period	O
was	O
characterized	O
with	O
polymorphic	O
clinical	O
picture	O
impeding	O
precise	O
diagnosis	O
and	O
threatening	O
with	O
such	O
complications	O
as	O
bacterial	O
shock	O
,	O
acute	O
renal	B-DISO
failure	I-DISO
,	I-DISO
acute	I-DISO
renal	O
-	O
hepatic	B-DISO
failure	I-DISO
,	O
DIC	B-DISO
-	O
syndrome	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
.	O

This	O
can	O
be	O
explained	O
by	O
disorders	O
in	O
immunity	O
,	O
especially	O
structural	O
immunodeficiency	B-DISO
,	O
and	O
commissures	O
at	O
the	O
sites	O
of	O
hemorrhages	B-DISO
.	O

The	O
K	O
(	O
m	O
)	O
values	O
of	O
the	O
MHV	O
-	O
like	O
esterases	O
for	O
the	O
latter	O
substrates	O
were	O
two	O
-	O
to	O
tenfold	O
lower	O
than	O
those	O
of	O
the	O
sialate	O
-	O
9	O
-	O
O	O
-	O
acetylesterases	O
of	O
influenza	B-DISO
C	O
viruses	O
.	O

Another	O
unspecific	O
esterase	O
substrate	O
,	O
alpha	O
-	O
naphthyl	O
acetate	O
,	O
was	O
used	O
for	O
the	O
in	O
situ	O
detection	O
of	O
the	O
dimeric	O
HE	O
proteins	O
in	O
SDS	B-DISO
-	O
polyacrylamide	O
gels	O
.	O

Time	O
onset	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
is	O
variable	O
,	O
although	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
onset	O
precedes	O
initial	O
manifestations	O
of	O
polymyositis	B-DISO
/	O
dermatomyositis	B-DISO
in	O
roughly	O
half	O
of	O
the	O
patients	O
.	O

Moreover	O
,	O
clinical	O
presentation	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
can	O
be	O
dichotomized	O
,	O
according	O
to	O
patients	O
'	O
pulmonary	O
manifestations	O
,	O
into	O
:	O
1	O
)	O
both	O
acute	O
and	O
aggressive	B-DISO
lung	B-DISO
disease	I-DISO
similar	O
to	O
Hamman	B-DISO
-	I-DISO
Rich	I-DISO
syndrome	I-DISO
;	O
2	O
)	O
slowly	O
progressive	O
lung	B-DISO
disease	I-DISO
;	O
and	O
3	O
)	O
an	O
asymptomatic	O
pattern	O
.	O

The	O
association	O
of	O
cyclophosphamide	O
and	O
corticosteroids	O
may	O
be	O
the	O
most	O
effective	O
in	O
patients	O
with	O
steroid	O
-	O
resistant	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Regulated	O
and	O
prolonged	O
expression	O
of	O
mIFN	O
(	O
alpha	O
)	O
in	O
immunocompetent	O
mice	O
mediated	O
by	O
a	O
helper	O
-	O
dependent	O
adenovirus	B-DISO
vector	O
.	O

The	O
helper	O
-	O
dependent	O
adenovirus	B-DISO
vectors	O
meet	O
these	O
requirements	O
,	O
as	O
demonstrated	O
in	O
various	O
studies	O
in	O
the	O
literature	O
.	O

Herein	O
we	O
show	O
that	O
transfer	O
of	O
CD8	O
T	O
cell	O
-	O
enriched	O
splenocytes	O
from	O
MHV	O
-	O
immune	O
IFN	O
-	O
gamma	O
(-/-)	O
donors	O
resulted	O
in	O
a	O
substantial	O
decrease	O
in	O
demyelination	B-DISO
(	O
4	O
.	O
8	O
%	O
of	O
the	O
white	O
matter	O
of	O
the	O
spinal	O
cord	B-DISO
compared	O
with	O
26	O
.	O
3	O
%	O
in	O
those	O
receiving	O
cells	O
from	O
C57BL	O
/	O
6	O
donors	O
).	O

Diarrhea	B-DISO
was	O
observed	O
in	O
32	O
%	O
of	O
the	O
pigs	O
and	O
virus	B-DISO
shedding	I-DISO
was	O
demonstrated	O
in	O
100	O
%	O
between	O
postinoculation	O
day	O
(	O
PID	B-DISO
)	O
1	O
and	O
8	O
.	O

In	O
the	O
systemic	O
lymphoid	O
tissues	O
the	O
number	O
of	O
IgG	O
and	O
IgA	O
ASC	O
detected	O
were	O
lower	O
than	O
in	O
the	O
mucosal	O
tissues	O
,	O
however	O
,	O
in	O
the	O
blood	O
,	O
presence	O
of	O
IgA	O
ASC	O
was	O
constantly	O
detected	O
from	O
PID	B-DISO
14	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

Symptom	B-DISO
diaries	O
were	O
kept	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

TITLE	O
:	O
In	O
vitro	O
and	O
in	O
vivo	O
expression	O
of	O
foreign	O
genes	O
by	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
-	O
derived	O
minigenomes	O
.	O

Recombinant	O
main	O
proteases	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
,	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
were	O
tested	O
in	O
peptide	O
-	O
based	O
trans	O
-	O
cleavage	O
assays	O
.	O

ABSTRACT	O
:	O
We	O
present	O
an	O
extremely	O
rare	O
case	O
of	O
hemophagocytic	B-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
)	O
induced	O
by	O
fulminant	O
Mycoplasma	B-DISO
pneumoniae	O
(	O
Mp	O
)	O
pneumonia	B-DISO
in	O
an	O
elderly	O
adult	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
immunosuppression	O
on	O
protective	O
immunity	O
of	O
turkey	O
poults	O
against	O
infection	B-DISO
with	O
turkey	O
coronavirus	O
.	O

Turkey	O
'	O
s	O
were	O
experimentally	O
immunosuppressed	O
with	O
cyclosporin	O
A	O
(	O
CsA	B-DISO
)	O
or	O
cyclophosphamide	O
(	O
CY	O
)	O
and	O
infected	O
with	O
TCV	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
adenovectors	O
could	O
efficiently	O
transduce	O
injured	O
alveoli	O
by	O
exposing	O
adult	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
100	O
%	O
oxygen	O
for	O
48	O
or	O
60	O
h	O
before	O
endotracheal	O
instillation	O
of	O
either	O
1	O
x	O
10	O
(	O
9	O
)	O
or	O
4	O
x	O
10	O
(	O
9	O
)	O
plaque	B-DISO
-	O
forming	O
units	O
of	O
an	O
adenovirus	B-DISO
that	O
expresses	O
an	O
Escherichia	O
coli	O
lac	O
Z	O
gene	O
(	O
adbeta	O
-	O
gal	O
)	O
in	O
a	O
surfactant	O
-	O
based	O
vehicle	O
(	O
Survanta	O
).	O

To	O
examine	O
the	O
role	O
of	O
other	O
host	O
factors	O
in	O
MHV	O
infection	B-DISO
in	O
mice	O
,	O
IFN	O
-	O
gamma	O
-	O
deficient	O
mice	O
with	O
a	O
BALB	O
/	O
c	O
background	O
(	O
BALB	O
-	O
GKO	O
)	O
were	O
infected	O
intraperitoneally	O
with	O
MHV	O
and	O
compared	O
with	O
B6	O
-	O
GKO	O
mice	O
.	O

The	O
relative	O
risk	O
for	O
combined	O
morbidity	O
(	O
death	O
,	O
intracranial	B-DISO
hemorrhage	I-DISO
,	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
)	O
was	O
increased	O
(	O
3	O
.	O
0	O
,	O
P	O
=.	O
019	O
)	O
when	O
compared	O
with	O
matched	O
control	O
infants	O
.	O

Chicks	O
were	O
first	O
infected	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
by	O
injecting	O
a	O
high	O
dose	O
of	O
vaccine	O
(	O
attenuated	O
virus	O
)	O
into	O
their	O
air	O
sacs	B-DISO
and	O
then	O
were	O
infected	O
with	O
pathogenic	O
EC	O
introduced	O
intratracheally	O
.	O

Within	O
each	O
line	O
,	O
Ab	O
levels	O
were	O
higher	O
in	O
chicks	O
exhibiting	O
colibacillosis	B-DISO
than	O
in	O
healthy	O
ones	O
,	O
suggesting	O
that	O
these	O
Ab	O
were	O
produced	O
as	O
a	O
result	O
of	O
ongoing	O
infection	B-DISO
but	O
were	O
too	O
late	O
to	O
fully	O
prevent	O
morbidity	O
and	O
mortality	O
.	O

TITLE	O
:	O
Indications	O
for	O
mechanical	O
ventilation	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

However	O
,	O
IPPV	O
has	O
not	O
proven	O
to	O
be	O
beneficial	O
in	O
traumatic	O
brain	O
injury	O
and	O
flail	B-DISO
chest	I-DISO
,	O
in	O
the	O
absence	O
of	O
other	O
indications	O
.	O

Based	O
on	O
the	O
pathological	O
findings	O
or	O
on	O
the	O
immunohistochemical	O
distribution	O
of	O
viral	O
antigen	O
,	O
FIP	B-DISO
-	O
affected	O
cats	O
were	O
divided	O
in	O
the	O
following	O
groups	O
:	O
subacute	O
against	O
acute	O
lesions	O
;	O
low	O
against	O
strong	O
intensity	O
of	O
positivity	O
;	O
intracellular	O
against	O
extracellular	O
positivities	O
;	O
positive	O
against	O
negative	O
lymph	O
nodes	O
.	O

While	O
cellular	O
immunity	O
initially	O
eliminates	O
infectious	B-DISO
virus	O
,	O
CNS	O
viral	O
persistence	O
is	O
predominantly	O
controlled	O
by	O
humoral	O
immunity	O
.	O

Serum	O
antiviral	O
Ab	O
and	O
CNS	O
virus	O
-	O
specific	O
ASC	O
became	O
prominent	O
only	O
during	O
final	O
elimination	O
of	O
infectious	B-DISO
virus	O
.	O

Mandibular	O
distraction	O
is	O
a	O
safe	O
and	O
reliable	O
procedure	O
for	O
treating	O
patients	O
with	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
.	O

ABSTRACT	O
:	O
The	O
beneficial	O
effects	O
of	O
nitric	O
oxide	O
inhalation	O
on	O
oxygenation	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
are	O
well	O
described	O
.	O

Seven	O
hundred	O
and	O
twenty	O
patients	O
were	O
selected	O
on	O
the	O
basis	O
of	O
seasonal	O
or	O
perennial	B-DISO
rhinitis	I-DISO
,	O
or	O
asthma	B-DISO
,	O
or	O
both	O
.	O

Respiratory	O
and	O
food	B-DISO
allergies	I-DISO
were	O
studied	O
in	O
all	O
patients	O
.	O

Specific	O
IgE	B-DISO
levels	O
to	O
P	O
.	O
acerifolia	O
pollen	O
extract	O
and	O
food	O
allergens	O
tested	O
were	O
measured	O
.	O

By	O
electron	O
microscopy	O
in	O
situ	O
hybridization	O
(	O
ISH	B-DISO
)	O
using	O
MHV	O
-	O
specific	O
RNA	O
probes	O
,	O
DMVs	O
were	O
highly	O
labeled	O
for	O
both	O
gene	O
1	O
and	O
gene	O
7	O
sequences	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
patients	O
with	O
acute	O
hypertriglyceridemia	O
-	O
induced	O
pancreatitis	B-DISO
.	O

CEACAM	O
binding	O
did	O
indeed	O
alter	O
S1	O
conformations	O
,	O
generating	O
alternative	O
disulfide	O
linkages	O
that	O
were	O
revealed	O
on	O
SDS	B-DISO
gels	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
pharmacodynamics	O
and	O
pharmacokinetics	O
of	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
in	O
dogs	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ARDS	B-DISO
,	O
induced	O
after	O
iv	O
injection	O
of	O
endotoxin	O
,	O
was	O
evidenced	O
by	O
reduction	O
of	O
paO2	O
/	O
FiO2	O
from	O
(	O
62	O
.	O
5	O
+/-	O

iNO	O
had	O
no	O
adverse	B-DISO
effects	I-DISO
on	O
surfactant	O
phospholipids	O
and	O
lung	O
fluid	O
balance	O
,	O
but	O
attenuated	O
expression	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
,	O
beta2	O
integrin	O
CD11b	O
,	O
and	O
interleukin	O
-	O
8	O
mRNA	O
in	O
the	O
lungs	O
by	O
22	O
%,	O
44	O
%,	O
and	O
25	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Pressure	O
-	O
controlled	O
inverse	O
ratio	O
ventilation	O
(	O
PC	O
-	O
IRV	O
)	O
was	O
used	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
after	O
failed	O
volume	O
-	O
cycled	O
conventional	O
ratio	O
ventilation	O
(	O
VC	O
-	O
CRV	B-DISO
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
outcome	O
of	O
early	O
PC	O
-	O
IRV	O
in	O
severe	O
ARDS	B-DISO
.	O

Twenty	O
patients	O
with	O
severe	O
ARDS	B-DISO
were	O
switched	O
from	O
VC	O
-	O
CRV	B-DISO
to	O
PC	O
-	O
IRV	O
if	O
they	O
failed	O
to	O
maintain	O
SaO	O
(	O
2	O
)	O
>	O
90	O
%	O
by	O
the	O
following	O
criteria	O
:	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	O
)	O
>	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FIO	O
(	O
2	O
)	O
=	O
60	O
%,	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
10	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
The	O
values	O
of	O
PIP	O
,	O
mean	O
airway	O
pressure	O
,	O
minute	O
volumes	O
,	O
and	O
lung	O
injury	O
score	O
in	O
VC	O
-	O
CRV	B-DISO
were	O
43	O
.	O
9	O
+/-	O

RESULTS	O
:	O
The	O
values	O
of	O
PIP	O
,	O
mean	O
airway	O
pressure	O
,	O
minute	O
volumes	O
,	O
and	O
lung	O
injury	O
score	O
in	O
VC	O
-	O
CRV	B-DISO
were	O
43	O
.	O
9	O
+/-	O

TITLE	O
:	O
Detection	O
of	O
infectious	B-DISO
agents	O
in	O
laboratory	O
rodents	O
:	O
traditional	O
and	O
molecular	O
techniques	O
.	O

Molecular	O
methods	O
to	O
detect	O
infectious	B-DISO
agents	O
in	O
laboratory	O
animals	O
are	O
being	O
used	O
more	O
routinely	O
.	O

ABSTRACT	O
:	O
The	O
nucleotide	O
sequences	O
of	O
the	O
coding	O
region	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
12	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strains	O
recently	O
found	O
in	O
animal	O
facilities	O
in	O
Japan	O
were	O
analyzed	O
.	O

The	O
insertion	O
in	O
two	O
different	O
positions	O
allowed	O
stable	O
plasmid	O
amplification	B-DISO
for	O
at	O
least	O
200	O
generations	O
.	O

Concomitantly	O
,	O
ExPLIs	O
inhibited	O
the	O
LPS	B-DISO
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	B-DISO
but	O
not	O
its	O
activation	O
by	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
1	O
.	O

Neuroradiologic	O
investigations	O
showed	O
bilateral	O
cerebral	O
sinus	B-DISO
veinous	O
thrombosis	B-DISO
without	O
any	O
brainstem	O
lesions	O
.	O

Ischemia	B-DISO
of	O
central	O
chemoreceptors	O
or	O
integration	O
of	O
their	O
informations	O
could	O
be	O
one	O
of	O
mechanism	O
.	O

5P	O
(	O
m	O
)	O
(	O
25	O
approximately	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
may	O
be	O
the	O
optimal	O
pressure	O
of	O
SI	O
in	O
rabbits	O
with	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
:	O
report	O
of	O
a	O
clinical	O
look	O
-	O
back	O
investigation	O
.	O

TITLE	O
:	O
Genetic	O
evidence	O
for	O
a	O
structural	O
interaction	O
between	O
the	O
carboxy	O
termini	O
of	O
the	O
membrane	O
and	O
nucleocapsid	O
proteins	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

Analysis	O
of	O
multiple	O
second	O
-	O
site	O
revertants	O
of	O
the	O
M	O
(	O
Delta	O
)	O
2	O
mutant	B-DISO
has	O
revealed	O
changes	O
in	O
regions	O
of	O
both	O
the	O
M	O
protein	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
that	O
can	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
last	O
two	O
residues	O
of	O
the	O
M	O
protein	O
.	O

TITLE	O
:	O
Clinicopathologic	O
review	O
of	O
pulmonary	O
silicone	O
embolism	B-DISO
with	O
special	O
emphasis	O
on	O
the	O
resultant	O
histologic	O
diversity	O
in	O
the	O
lung	O
--	O
a	O
review	O
of	O
five	O
cases	O
.	O

Apart	O
from	O
producing	O
emboli	O
in	O
the	O
pulmonary	O
vessels	O
,	O
subcutaneous	O
injection	O
of	O
silicone	O
can	O
obviously	O
cause	O
serious	O
pulmonary	B-DISO
disease	I-DISO
due	O
to	O
its	O
ability	O
to	O
induce	O
acute	O
to	O
induce	O
acute	O
pneumonitis	B-DISO
and	O
even	O
possibly	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Other	O
viral	O
agents	O
that	O
are	O
recognised	O
in	O
these	O
animals	O
,	O
including	O
adenovirus	B-DISO
,	O
parapox	O
,	O
foot	B-DISO
and	I-DISO
mouth	I-DISO
disease	I-DISO
,	O
bluetongue	B-DISO
,	O
epizootic	O
haemorrhagic	O
disease	O
,	O
bovine	B-DISO
virus	I-DISO
diarrhoea	I-DISO
,	O
rotavirus	O
and	O
coronavirus	O
,	O
are	O
also	O
discussed	O
.	O

Ectoparasites	O
of	O
importance	O
in	O
this	O
group	O
in	O
various	O
parts	O
of	O
the	O
world	O
include	O
a	O
variety	O
of	O
ticks	O
,	O
as	O
well	O
as	O
lice	B-DISO
,	O
keds	O
,	O
Oestridae	O
,	O
mange	B-DISO
mites	O
and	O
fire	O
ants	O
.	O

TITLE	O
:	O
Cystic	B-DISO
fibrosis	I-DISO
and	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
coexisting	O
during	O
pregnancy	O
.	O

An	O
18	O
-	O
year	O
-	O
old	O
primigravida	O
with	O
cystic	B-DISO
fibrosis	I-DISO
was	O
admitted	O
at	O
term	O
with	O
pulmonary	O
symptoms	O
,	O
hypertension	B-DISO
,	O
and	O
thrombocytopenia	O
.	O

CONCLUSIONS	O
:	O
Cystic	B-DISO
fibrosis	I-DISO
,	O
a	O
disease	O
once	O
managed	O
predominantly	O
by	O
pediatric	O
subspecialists	O
,	O
will	O
be	O
seen	O
increasingly	O
by	O
physicians	O
caring	O
for	O
adults	O
,	O
including	O
obstetrician	O
-	O
gynecologists	O
.	O

There	O
are	O
two	O
main	O
conditions	O
,	O
namely	O
critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
and	O
neuromuscular	B-DISO
disorder	I-DISO
related	O
to	O
the	O
use	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
.	O

Mortality	O
is	O
as	O
high	O
as	O
60	O
p	O
.	O
cent	O
and	O
relates	O
to	O
the	O
medical	O
,	O
rather	O
than	O
to	O
the	O
neurological	O
condition	B-DISO
.	O

A	O
purely	O
motor	B-DISO
deficit	I-DISO
is	O
usually	O
first	O
noticed	O
when	O
curarisation	O
is	O
discontinued	O
.	O

Electromyography	O
discloses	O
fibrillation	B-DISO
potentials	O
in	O
all	O
muscles	O
,	O
as	O
well	O
as	O
myopathic	O
changes	O
.	O

ABSTRACT	O
:	O
From	O
January	O
1999	O
to	O
May	O
2000	O
(	O
17	O
months	O
),	O
21	O
strains	O
of	O
streptococci	O
and	O
four	O
strains	O
of	O
enterococci	O
have	O
been	O
isolated	O
from	O
74	O
blood	O
cultures	O
in	O
25	O
infectious	B-DISO
episodes	O
in	O
hematologic	O
patients	O
.	O

These	O
patients	O
suffered	B-DISO
from	O
acute	B-DISO
leukaemia	I-DISO
(	O
14	O
cases	O
),	O
chronic	B-DISO
lymphoid	I-DISO
leukaemia	I-DISO
(	O
two	O
cases	O
),	O
non	B-DISO
-	I-DISO
Hodgkin	I-DISO
'	I-DISO
s	I-DISO
lymphoma	I-DISO
(	O
two	O
cases	O
)	O
or	O
myeloma	B-DISO
(	O
three	O
cases	O
).	O

During	O
16	O
episodes	O
(	O
64	O
%),	O
the	O
bacteremia	B-DISO
occurred	O
within	O
15	O
days	O
after	O
the	O
onset	O
of	O
neutropenia	O
consecutive	O
to	O
antimitotic	O
chemotherapy	O
,	O
and	O
in	O
nine	O
episodes	O
(	O
36	O
%)	O
it	O
has	O
occurred	O
after	O
a	O
period	O
exceeding	O
15	O
days	O
.	O

Occurrence	O
of	O
negative	O
middle	O
ear	O
pressure	O
in	O
winter	O
-	O
spring	O
colds	B-DISO
was	O
significantly	O
greater	O
than	O
in	O
fall	O
colds	B-DISO
for	O
unexplained	O
reasons	O
.	O

Cox	O
proportional	O
hazards	O
regression	O
analysis	O
demonstrated	O
only	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
to	O
be	O
significant	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
predictor	O
for	O
late	O
mortality	O
.	O

TITLE	O
:	O
[	O
Adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
--	O
etiology	O
and	O
pathogenesis	B-DISO
].	O

TITLE	O
:	O
Virus	O
-	O
provoked	O
rhinitis	B-DISO
in	O
patients	O
who	O
have	O
allergies	B-DISO
.	O

ABSTRACT	O
:	O
The	O
most	O
common	O
illnesses	O
in	O
humans	O
are	O
the	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
caused	O
by	O
viruses	O
.	O

Caused	O
by	O
immunosuppressive	O
therapy	O
he	O
got	O
a	O
severe	O
broncho	O
-	O
pneumonia	B-DISO
.	O

Given	O
the	O
seriousness	O
of	O
septicemia	B-DISO
caused	O
by	O
viridans	O
streptococci	O
and	O
the	O
potential	O
for	O
selection	O
of	O
other	O
resistant	O
microorganisms	O
,	O
the	O
routine	O
practice	O
of	O
antimicrobial	O
prophylaxis	O
for	O
neutropenic	O
patients	O
with	O
cancer	B-DISO
should	O
be	O
reconsidered	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
the	O
clinical	O
manifestation	O
of	O
severe	O
,	O
acute	O
lung	O
injury	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurs	O
most	O
frequently	O
in	O
the	O
setting	O
of	O
sepsis	B-DISO
,	O
aspiration	B-DISO
of	O
gastric	O
contents	O
,	O
trauma	O
,	O
or	O
multiple	O
transfusions	O
.	O

ABSTRACT	O
:	O
Analyses	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
in	O
a	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)-	O
infected	O
macrophage	O
-	O
derived	O
J774	O
.	O
1	O
cell	O
line	O
showed	O
activation	O
of	O
two	O
MAPKs	O
,	O
p38	O
MAPK	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
),	O
but	O
not	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
).	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proved	O
useful	O
for	O
the	O
detection	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
rat	O
coronavirus	O
(	O
RCV	O
)	O
in	O
acutely	O
infected	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

TITLE	O
:	O
Extracorporeal	O
respiratory	O
support	O
and	O
minimally	O
invasive	O
ventilation	O
in	O
severe	O
ARDS	B-DISO
.	O

Surgical	O
complications	O
are	O
amenable	O
to	O
surgical	O
treatment	O
during	O
ECLS	O
and	O
bleeding	B-DISO
problems	I-DISO
can	O
be	O
controlled	O
.	O

TITLE	O
:	O
Bronchoscopic	O
administration	O
of	O
bovine	O
natural	O
surfactant	O
in	O
ARDS	B-DISO
and	O
septic	B-DISO
shock	I-DISO
:	O
impact	O
on	O
biophysical	O
and	O
biochemical	O
surfactant	O
properties	O
.	O

Severe	O
biophysical	O
and	O
biochemical	O
surfactant	O
abnormalities	O
were	O
encountered	O
throughout	O
in	O
the	O
ARDS	B-DISO
patients	O
.	O

The	O
bronchoscopic	O
application	O
of	O
a	O
high	O
dose	O
of	O
natural	O
surfactant	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
septic	B-DISO
shock	I-DISO
is	O
both	O
feasible	O
and	O
safe	O
,	O
resulting	O
in	O
a	O
pronounced	O
improvement	O
in	O
gas	O
exchange	O
.	O

As	O
all	O
recombinant	O
deletion	O
mutant	B-DISO
viruses	O
appeared	O
to	O
be	O
viable	O
,	O
we	O
conclude	O
that	O
the	O
MHV	O
group	O
-	O
specific	O
genes	O
are	O
nonessential	O
,	O
accessory	O
genes	O
.	O

Both	O
patients	O
were	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
intracranial	B-DISO
hemorrhage	I-DISO
respectively	O
,	O
secondary	O
to	O
leukostasis	B-DISO
.	O

Trauma	O
,	O
emergency	B-DISO
vascular	O
,	O
and	O
general	O
surgical	O
patients	O
with	O
PaO	O
(	O
2	O
)/	O
FiO	O
)(	O
2	O
)	O
(	O
PF	O
)	O
ratio	O
<	O
200	O
were	O
entered	O
into	O
a	O
protocol	O
designed	O
to	O
maintain	O
mixed	O
venous	O
saturation	O
(	O
SVO	O
(	O
2	O
))	O
>	O
70	O
%	O
with	O
FiO	O
(	O
2	O
)	O
<	O
0	O
.	O
50	O
.	O

The	O
prevalence	O
of	O
FIV	O
antibodies	O
was	O
significantly	O
higher	O
in	O
entire	O
males	O
and	O
neutered	O
males	O
than	O
in	O
females	O
,	O
in	O
cats	O
over	O
two	O
years	O
old	O
compared	O
with	O
younger	O
cats	O
,	O
and	O
in	O
cats	O
suffering	B-DISO
disease	O
of	O
non	O
-	O
traumatic	O
origin	O
rather	O
than	O
in	O
healthy	O
cats	O
or	O
cats	O
suffering	B-DISO
only	O
from	O
trauma	O
.	O

TITLE	O
:	O
[	O
ABO	O
-	O
incompatible	O
liver	O
transplantation	O
and	O
patients	O
with	O
hepatopulmonary	B-DISO
syndrome	I-DISO
].	O

TITLE	O
:	O
Site	O
-	O
specific	O
recombination	O
in	O
eukaryotic	O
cells	O
mediated	O
by	O
mutant	B-DISO
lambda	O
integrases	O
:	O
implications	O
for	O
synaptic	O
complex	O
formation	O
and	O
the	O
reactivity	O
of	O
episomal	O
DNA	O
segments	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
multiple	O
organ	O
dysfunction	O
following	O
postoperative	O
epididymitis	B-DISO
].	O

However	O
,	O
spontaneous	O
left	O
scrotal	B-DISO
pain	I-DISO
with	O
tenderness	B-DISO
,	O
intense	O
heat	O
with	O
swelling	B-DISO
developing	O
on	O
the	O
tenth	O
hospital	O
day	O
,	O
and	O
hypotension	O
,	O
dyspnea	B-DISO
and	O
oliguria	B-DISO
were	O
noted	O
on	O
the	O
eleventh	O
hospital	O
day	O
.	O

These	O
findings	O
provide	O
additional	O
evidence	O
suggesting	O
a	O
possible	O
role	O
for	O
EPEC	O
in	O
the	O
pathogenesis	B-DISO
of	O
PEMS	O
.	O

TITLE	O
:	O
Genetic	O
and	O
antigenic	O
diversity	O
in	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
isolates	O
of	O
the	O
1940s	O
.	O

TITLE	O
:	O
Anaphylaxis	B-DISO
to	O
rocuronium	O
.	O

Severe	O
haemodynamic	B-DISO
instability	I-DISO
and	O
bronchospasm	B-DISO
occurred	O
after	O
rocuronium	O
.	O

The	O
activities	O
of	O
these	O
cytokines	O
have	O
been	O
studied	O
extensively	O
in	O
vitro	O
and	O
in	O
rodents	O
,	O
but	O
in	O
vivo	O
studies	O
on	O
the	O
role	O
of	O
these	O
cytokines	O
in	O
infectious	B-DISO
diseases	I-DISO
of	O
food	O
animals	O
are	O
few	O
.	O

The	O
role	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
in	O
the	O
symptoms	O
and	O
pathology	B-DISO
of	O
porcine	O
pleuropneumonia	B-DISO
has	O
recently	O
been	O
proven	O
by	O
use	O
of	O
an	O
adenovirus	B-DISO
vector	O
expressing	O
the	O
anti	O
-	O
inflammatory	O
IL	O
-	O
10	O
.	O

Out	O
of	O
three	O
respiratory	O
viruses	O
-	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
),	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
and	O
swine	B-DISO
influenza	I-DISO
virus	O
(	O
SIV	B-DISO
)-	O
only	O
SIV	B-DISO
induced	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
and	O
severe	O
lung	O
damage	O
by	O
itself	O
.	O

Disease	O
and	O
lung	O
pathology	B-DISO
were	O
tightly	O
associated	O
with	O
the	O
simultaneous	O
production	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
and	O
IL	O
-	O
6	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
lung	O
transplantation	O
following	O
Mycoplasma	B-DISO
pneumoniae	O
infection	B-DISO
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
:	O
chemokine	O
-	O
mediated	O
regulation	O
of	O
host	O
defense	O
and	O
disease	O
.	O

Obesity	B-DISO
-	I-DISO
hypoventilation	I-DISO
syndrome	I-DISO
must	O
be	O
distinguished	O
from	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
,	O
although	O
the	O
two	O
conditions	O
are	O
often	O
associated	O
.	O

Infection	B-DISO
was	O
allowed	O
to	O
progress	O
for	O
24	O
h	O
before	O
treatment	O
was	O
started	O
.	O

The	O
results	O
indicate	O
that	O
intestinal	O
mucosal	O
IgA	O
antibodies	O
to	O
TCV	O
are	O
elicited	O
in	O
turkeys	O
following	O
infection	B-DISO
with	O
TCV	O
.	O

ABSTRACT	O
:	O
Previous	O
reports	O
on	O
the	O
spread	O
of	O
bovine	B-DISO
virus	I-DISO
diarrhoea	I-DISO
virus	O
(	O
BVDV	O
)	O
from	O
animals	O
primarily	O
infected	O
with	O
the	O
agent	O
are	O
contradictory	O
.	O

In	O
contrast	O
,	O
it	O
proved	O
impossible	O
to	O
prevent	O
the	O
spread	O
of	O
BCV	O
infection	B-DISO
between	O
the	O
experimental	O
groups	O
and	O
consequently	O
all	O
20	O
study	O
calves	O
became	O
infected	O
with	O
the	O
virus	O
.	O

TITLE	O
:	O
Adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
the	O
tropics	O
.	O

In	O
particular	O
,	O
malaria	B-DISO
and	O
TB	O
are	O
important	O
infections	B-DISO
that	O
predispose	O
patients	O
to	O
ARDS	B-DISO
in	O
the	O
tropics	O
.	O

Recently	O
several	O
congeners	O
of	O
GHB	O
,	O
gamma	O
butyrolactone	O
and	O
1	O
,	O
4	O
-	O
butanediol	O
,	O
have	O
emerged	O
as	O
drugs	O
of	O
abuse	B-DISO
and	O
show	O
toxidromes	O
similar	O
to	O
GHB	O
.	O

Severe	O
dyspnea	B-DISO
developed	O
after	O
the	O
bronchofiberscopy	O
,	O
when	O
the	O
chest	O
radiograph	O
revealed	O
bilateral	O
ground	O
-	O
glass	O
shadows	O
and	O
the	O
oxygen	O
saturation	O
in	O
the	O
room	O
air	O
fell	O
to	O
60	O
%.	O

TITLE	O
:	O
Assessment	O
of	O
static	O
isolator	O
cages	O
with	O
automatic	O
watering	O
when	O
used	O
with	O
conventional	O
husbandry	O
techniques	O
as	O
a	O
factor	O
in	O
the	O
transmission	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

TITLE	O
:	O
Management	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

It	O
is	O
now	O
recognized	O
that	O
ARDS	B-DISO
is	O
a	O
manifestation	O
of	O
a	O
diffuse	O
process	O
that	O
results	O
from	O
a	O
complicated	O
cascade	O
of	O
events	O
following	O
an	O
initial	O
insult	O
or	O
injury	O
.	O

Cytoalbuminous	O
dissociation	B-DISO
was	O
seen	O
in	O
the	O
cerebrospinal	O
fluid	O
.	O

A	O
diagnosis	O
of	O
severe	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
was	O
made	O
.	O

A	O
repeat	O
screening	O
test	O
for	O
urine	O
porphyrins	O
was	O
positive	O
,	O
and	O
AIP	B-DISO
was	O
confirmed	O
by	O
specific	O
porphobilinogen	O
deaminase	O
in	O
the	O
blood	O
.	O

TITLE	O
:	O
[	O
The	O
pathogenic	O
role	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

CONCLUSIONS	O
The	O
serum	O
level	O
of	O
MIF	O
and	O
PBMC	O
MIF	O
expression	O
increased	O
in	O
ARDS	B-DISO
patients	O
with	O
enhanced	O
pulmonary	O
MIF	O
expression	O
and	O
macrophage	O
infiltration	B-DISO
,	O
which	O
suggests	O
that	O
MIF	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
.	O

METHODS	O
:	O
A	O
24	O
-	O
year	O
-	O
old	O
female	O
with	O
cystic	B-DISO
fibrosis	I-DISO
underwent	O
double	O
lung	O
transplantation	O
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
sclerosis	I-DISO
,	O
a	O
chronic	B-DISO
inflammatory	I-DISO
disease	I-DISO
of	O
the	O
CNS	O
,	O
is	O
characterized	O
by	O
immune	O
-	O
mediated	O
demyelination	B-DISO
.	O

These	O
findings	O
demonstrate	O
a	O
novel	O
mechanism	O
for	O
immune	O
-	O
mediated	O
neuropathology	B-DISO
and	O
show	O
that	O
activated	O
CD8	O
T	O
cells	O
may	O
serve	O
as	O
important	O
mediators	O
of	O
bystander	O
demyelination	B-DISO
during	O
times	O
of	O
infection	B-DISO
,	O
including	O
in	O
patients	O
with	O
multiple	B-DISO
sclerosis	I-DISO
.	O

During	O
his	O
hospitalization	O
,	O
he	O
developed	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Recent	O
evidence	O
suggests	O
that	O
progressive	O
ARDS	B-DISO
is	O
closely	O
linked	O
to	O
activation	O
of	O
inflammation	B-DISO
and	O
coagulation	O
.	O

Air	O
cysts	B-DISO
,	O
bronchiectasis	B-DISO
,	O
and	O
the	O
percentage	O
of	O
normal	O
and	O
abnormal	O
tissue	O
were	O
quantified	O
for	O
each	O
segment	O
and	O
correlated	O
to	O
the	O
duration	O
and	O
variables	O
of	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Coccidioides	O
immitis	O
causes	O
a	O
benign	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
endemic	O
areas	O
.	O

The	O
patient	O
subsequently	O
developed	O
severe	O
ischemic	B-DISO
necrosis	I-DISO
of	O
the	O
skin	O
and	O
soft	O
tissue	O
surrounding	O
the	O
catheter	O
site	O
.	O

ABSTRACT	O
:	O
Sleep	B-DISO
apnea	I-DISO
syndrome	I-DISO
(	O
SAS	O
)	O
is	O
a	O
condition	B-DISO
of	O
repeated	O
episodes	O
of	O
apnea	B-DISO
and	O
hypopnea	O
during	O
sleep	O
.	O

It	O
can	O
cause	O
life	O
-	O
threatening	O
morbidities	O
,	O
including	O
cardiac	B-DISO
arrhythmia	I-DISO
and	O
ischemia	B-DISO
,	O
hypertension	B-DISO
,	O
and	O
respiratory	B-DISO
arrest	I-DISO
,	O
and	O
even	O
death	O
.	O

TITLE	O
:	O
In	O
vivo	O
evidence	O
for	O
the	O
role	O
of	O
GM	O
-	O
CSF	O
as	O
a	O
mediator	O
in	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
.	O

Increase	O
in	O
respiratory	O
rate	O
resulted	O
in	O
significantly	O
higher	O
PEEPi	O
(	O
1	O
.	O
3	O
+/-	O
0	O
.	O
4	O
versus	O
3	O
.	O
9	O
+/-	O
1	O
.	O
1	O
cmH	B-DISO
(	O
2	O
)	O
O	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
trapped	O
volume	O
(	O
70	O
+/-	O
43	O
versus	O
244	O
+/-	O
127	O
ml	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

External	O
PEEP	O
needed	O
to	O
be	O
reduced	O
from	O
11	O
.	O
9	O
+/-	O
3	O
.	O
4	O
to	O
9	O
.	O
7	O
+/-	O
2	O
.	O
9	O
cmH	B-DISO
(	O
2	O
)	O
O	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
safety	O
of	O
long	O
-	O
distance	O
ground	O
interhospital	O
transport	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
the	O
most	O
severe	O
unstable	O
respiratory	B-DISO
failure	I-DISO
after	O
establishment	O
of	O
a	O
dedicated	O
transport	O
system	O
.	O

We	O
discuss	O
this	O
concept	O
of	O
ECMO	O
use	O
in	O
the	O
context	O
of	O
accepted	O
indications	O
for	O
ECMO	O
in	O
cardiac	O
patients	O
and	O
encourage	O
an	O
expanded	O
role	O
for	O
its	O
use	O
to	O
prevent	O
cardiorespiratory	O
collapse	B-DISO
in	O
planned	O
interventions	O
on	O
compromised	O
patients	O
who	O
are	O
at	O
risk	O
of	O
acute	O
deterioration	O
.	O

CONCLUSIONS	O
:	O
During	O
HFOV	O
in	O
burn	O
patients	O
,	O
postresuscitation	O
edema	B-DISO
of	O
the	O
supraglottic	O
upper	O
airway	O
may	O
cause	O
expiratory	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
.	O

Sequencing	O
of	O
various	O
regions	O
of	O
the	O
spike	O
and	O
polymerase	O
genes	O
confirms	O
that	O
UWSMN	O
-	O
1	O
is	O
widely	O
divergent	O
from	O
other	O
CCV	B-DISO
and	O
feline	O
coronavirus	O
strains	O
.	O

ABSTRACT	O
:	O
Three	O
unrecognized	O
field	O
isolates	O
of	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
(	O
IBV	O
)	O
were	O
recovered	O
from	O
commercial	O
broiler	O
chickens	O
vaccinated	O
with	O
live	O
Mass	O
viral	O
strain	O
(	O
H120	O
).	O

Gerhardt	O
'	O
s	O
syndrome	B-DISO
frequently	O
induces	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
requiring	O
ventilatory	O
support	O
,	O
and	O
this	O
condition	B-DISO
might	O
be	O
mistaken	O
for	O
a	O
severe	B-DISO
acute	I-DISO
asthma	I-DISO
attack	O
.	O

We	O
hypothesized	O
that	O
alveolar	O
macrophage	O
(	O
AMPhi	O
)	O
chemokine	O
and	O
cytokine	O
release	O
after	O
hemorrhage	B-DISO
and	O
sepsis	B-DISO
is	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
.	O

Adult	O
male	O
rats	O
underwent	O
soft	O
tissue	O
trauma	O
and	O
hemorrhagic	B-DISO
shock	I-DISO
(~	O
90	O
min	O
)	O
followed	O
by	O
crystalloid	O
resuscitation	O
.	O

Serum	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
levels	O
and	O
spontaneous	O
AMPhi	O
TNF	O
-	O
alpha	O
and	O
MIP	B-DISO
-	O
2	O
release	O
were	O
elevated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
HCLP	O
,	O
concomitantly	O
with	O
the	O
development	O
of	O
lung	B-DISO
edema	I-DISO
and	O
leukocyte	O
activation	O
.	O

These	O
cases	O
were	O
classified	O
as	O
follows	O
:	O
two	O
monophasic	O
acute	B-DISO
disseminated	I-DISO
encephalomyelitis	I-DISO
;	O
one	O
recurrent	O
disseminated	O
encephalomyelitis	B-DISO
;	O
three	O
recurrent	O
ONM	O
associated	O
with	O
Hughes	B-DISO
syndrome	I-DISO
,	O
autoantibodies	O
and	O
polyarteritis	B-DISO
nodosa	I-DISO
;	O
six	O
recurrent	O
ONM	O
with	O
endocrinopathies	B-DISO
;	O
and	O
finally	O
,	O
four	O
multiple	B-DISO
sclerosis	I-DISO
cases	O
.	O

At	O
24	O
,	O
48	O
,	O
72	O
,	O
and	O
120	O
hr	O
postinfection	O
(	O
HPI	B-DISO
),	O
bursa	O
,	O
lung	O
,	O
spleen	O
,	O
heart	O
,	O
and	O
thymus	O
were	O
collected	O
,	O
fixed	O
in	O
10	O
%	O
neutral	O
buffered	O
formalin	O
,	O
and	O
paraffin	O
embedded	O
.	O

These	O
results	O
indicate	O
that	O
in	O
situ	O
hybridization	O
can	O
be	O
useful	O
in	O
detection	O
of	O
IBV	O
-	O
infected	O
chickens	O
and	O
in	O
understanding	O
the	O
pathogenesis	B-DISO
and	O
virulence	O
of	O
IBV	O
infection	B-DISO
.	O

Histologic	O
analysis	O
showed	O
significant	O
increase	O
in	O
extravascular	O
(	O
migrated	O
)	O
neutrophils	O
only	O
in	O
severe	O
pancreatitis	B-DISO
.	O

TITLE	O
:	O
A	O
novel	O
animal	O
model	O
of	O
sepsis	B-DISO
after	O
acute	O
lung	O
injury	O
in	O
sheep	O
.	O

The	O
sheep	O
developed	O
a	O
hyperkinetic	O
cardiovascular	O
response	O
concomitant	O
with	O
a	O
decrease	O
in	O
Pao	O
similar	O
to	O
severe	B-DISO
sepsis	I-DISO
in	O
human	O
patients	O
who	O
meet	O
the	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PaO2	O
/	O
FIO2	O
<	O
200	O
).	O

ABSTRACT	O
:	O
A	O
23	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
with	O
macrohematuria	O
and	O
systemic	O
edema	B-DISO
appearing	O
after	O
an	O
acute	B-DISO
upper	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

Many	O
interstitial	O
infiltrating	B-DISO
cells	O
were	O
positive	O
for	O
interferon	O
-	O
gamma	O
,	O
but	O
their	O
number	O
diminished	O
after	O
treatment	O
.	O

Remarkably	O
,	O
most	O
of	O
the	O
postmortem	O
lungs	O
with	O
ELS	O
exhibited	O
no	O
significant	O
acute	O
inflammatory	O
cellular	O
response	O
such	O
as	O
neutrophilic	O
reaction	O
,	O
and	O
little	O
evidence	O
of	O
widespread	O
edema	B-DISO
except	O
for	O
focal	O
intra	B-DISO
-	I-DISO
alveolar	I-DISO
hemorrhage	I-DISO
.	O

TITLE	O
:	O
Reversible	B-DISO
posterior	I-DISO
leukoencephalopathy	I-DISO
syndrome	I-DISO
and	O
silent	O
cerebral	B-DISO
infarcts	I-DISO
are	O
associated	O
with	O
severe	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

As	O
'	O
diagnostic	O
#	O
10	O
;	O
PCR	O
',	O
a	O
set	O
of	O
consensus	O
nested	O
primers	O
was	O
selected	O
from	O
highly	O
conserved	O
stretches	B-DISO
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
.	O

TITLE	O
:	O
Enhanced	O
green	O
fluorescent	O
protein	O
expression	O
may	O
be	O
used	O
to	O
monitor	O
murine	O
coronavirus	O
spread	O
in	O
vitro	O
and	O
in	O
the	O
mouse	O
central	O
nervous	B-DISO
system	O
.	O

Expression	O
of	O
EGFP	O
remained	O
stable	O
through	O
at	O
least	O
six	O
passages	O
in	O
tissue	O
culture	O
and	O
during	O
acute	B-DISO
infection	I-DISO
in	O
the	O
mouse	O
central	O
nervous	B-DISO
system	O
.	O

They	O
caused	O
encephalitis	B-DISO
and	O
demyelination	B-DISO
in	O
animals	O
as	O
wild	O
-	O
type	O
virus	O
;	O
however	O
,	O
they	O
were	O
somewhat	O
attenuated	O
in	O
virulence	O
.	O

To	O
better	O
assess	O
the	O
role	O
of	O
apoptosis	O
in	O
MHV	O
infection	B-DISO
,	O
we	O
used	O
three	O
different	O
biologic	O
phenotypes	O
of	O
MHV	O
to	O
examine	O
their	O
differential	O
effect	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

The	O
study	O
showed	O
that	O
the	O
two	O
groups	O
were	O
of	O
similar	O
birth	O
weight	O
(	O
mean	O
+/-	O
SEM	B-DISO
):	O
control	O
901	O
+/-	O
73	O
g	O
vs	O
iNO	O
874	O
+/-	O
70	O
g	O
;	O
and	O
gestational	O
age	O
:	O
control	O
27	O
.	O
2	O
+/-	O
0	O
.	O
5	O
wk	O
vs	O
iNO	O
26	O
.	O
8	O
+/-	O
0	O
.	O
5	O
wk	O
.	O

The	O
incidence	O
of	O
other	O
acute	O
complications	O
as	O
well	O
as	O
early	O
neonatal	B-DISO
death	I-DISO
,	O
were	O
comparable	O
between	O
the	O
groups	O
.	O

All	O
studied	O
variables	O
were	O
significantly	O
associated	O
with	O
ARDS	B-DISO
in	O
univariate	O
analyses	O
.	O

Stepwise	O
logistic	O
regression	O
,	O
however	O
,	O
demonstrated	O
age	O
>	O
65	O
years	O
,	O
ISS	B-DISO
>	O
25	O
,	O
hypotension	O
on	O
admission	O
,	O
24	O
-	O
hour	O
transfusion	O
requirement	O
>	O
10	O
units	O
,	O
and	O
pulmonary	O
contusion	O
as	O
independent	O
risk	O
factors	O
,	O
whereas	O
admission	O
metabolic	B-DISO
acidosis	I-DISO
,	O
femur	O
fracture	O
,	O
infection	B-DISO
,	O
and	O
severe	O
brain	O
injury	O
were	O
not	O
.	O

Using	O
a	O
model	O
based	O
on	O
the	O
logistic	O
regression	O
equation	O
derived	O
yields	O
better	O
than	O
80	O
per	O
cent	O
discrimination	O
in	O
ARDS	B-DISO
patients	O
.	O

Independent	O
risk	O
factors	O
for	O
ARDS	B-DISO
in	O
blunt	O
trauma	O
include	O
ISS	B-DISO
>	O
25	O
,	O
PC	O
,	O
age	O
>	O
65	O
years	O
,	O
hypotension	O
on	O
admission	O
,	O
and	O
24	O
-	O
hour	O
transfusion	O
requirement	O
>	O
10	O
units	O
but	O
not	O
admission	O
metabolic	B-DISO
acidosis	I-DISO
,	O
femur	O
fracture	O
,	O
infection	B-DISO
,	O
or	O
severe	O
brain	O
injury	O
.	O

They	O
argued	O
that	O
""""	O
not	O
all	O
SIDS	B-DISO
victims	O
were	O
normal	O
","""	O
and	O
referred	O
to	O
their	O
hypothesis	O
that	O
SIDS	B-DISO
results	O
from	O
brain	O
abnormalities	O
,	O
which	O
they	O
postulated	O
""""	O
to	O
originate	O
in	O
utero	O
and	O
lead	O
to	O
sudden	B-DISO
death	I-DISO
during	O
a	O
vulnerable	O
postnatal	O
period	O
.	O

Bergman	O
(	O
1970	O
)	O
argued	O
that	O
SIDS	B-DISO
did	O
not	O
depend	O
on	O
any	O
""""	O
single	O
characteristic	O
that	O
ordains	O
a	O
infant	O
for	O
death	O
","""	O
but	O
on	O
an	O
interaction	O
of	O
risk	O
factors	O
with	O
variable	O
probabilities	O
.	O

It	O
seems	O
likely	O
that	O
the	O
""""	O
acute	O
control	O
""""	O
group	O
of	O
Kinney	O
et	O
al	O
(	O
1995	O
)	O
died	O
too	O
quickly	O
to	O
develop	O
gliosis	B-DISO
or	O
severe	O
depletion	O
of	O
the	O
neurotransmitter	O
systems	O
.	O

We	O
can	O
conclude	O
that	O
the	O
acute	O
controls	O
had	O
no	O
previous	O
episodes	O
of	O
severe	O
hypoxia	B-DISO
,	O
unlike	O
SIDS	B-DISO
or	O
their	O
""""	O
chronic	O
controls	O
.	O

There	O
are	O
difficulties	O
with	O
Filiano	O
and	O
Kinney	O
'	O
s	O
(	O
1994	O
)	O
explanation	O
of	O
the	O
age	O
at	O
death	O
distribution	O
of	O
SIDS	B-DISO
.	O

Our	O
objective	O
was	O
to	O
determine	O
if	O
fAPN	O
can	O
serve	O
as	O
a	O
receptor	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
A	O
field	O
-	O
based	O
case	O
-	O
control	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
strength	O
of	O
association	O
of	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
)	O
and	O
some	O
major	O
swine	O
viruses	O
with	O
postweaning	O
multisystemic	O
wasting	B-DISO
syndrome	I-DISO
(	O
PMWS	O
).	O

Further	O
analysis	O
of	O
the	O
genome	O
of	O
one	O
of	O
the	O
viruses	O
revealed	O
that	O
it	O
contained	O
genes	O
3	O
and	O
5	O
that	O
are	O
typical	O
of	O
IBV	O
but	O
absent	O
in	O
both	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
and	O
murine	B-DISO
hepatitis	I-DISO
virus	O
groups	O
of	O
mammalian	O
coronaviruses	O
.	O

This	O
work	O
:	O
(	O
a	O
)	O
confirms	O
that	O
coronaviruses	O
are	O
present	O
in	O
pheasants	O
(	O
indeed	O
,	O
commonly	O
present	O
in	O
pheasants	O
with	O
respiratory	B-DISO
disease	I-DISO
);	O
(	O
b	O
)	O
demonstrates	O
that	O
their	O
genomes	O
are	O
IBV	O
-	O
like	O
in	O
their	O
organization	O
;	O
and	O
(	O
c	O
)	O
shows	O
that	O
there	O
is	O
sequence	O
heterogeneity	O
within	O
the	O
group	O
of	O
pheasant	O
coronaviruses	O
,	O
especially	O
within	O
the	O
spike	O
protein	O
gene	O
.	O

BOS	B-DISO
did	O
not	O
occur	O
any	O
earlier	O
in	O
the	O
DAD	O
group	O
(	O
median	O
953	O
days	O
,	O
range	O
152	O
to	O
1	O
,	O
393	O
)	O
days	O
compared	O
with	O
the	O
non	O
-	O
DAD	O
group	O
(	O
median	O
665	O
days	O
,	O
range	O
52	O
to	O
4	O
,	O
299	O
)	O
(	O
p	O
=	O
0	O
.	O
48	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
).	O

However	O
,	O
adenoviral	B-DISO
infections	I-DISO
still	O
play	O
an	O
important	O
role	O
in	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
.	O

Variety	O
of	O
antiviral	O
drugs	O
with	O
controversial	O
effects	O
have	O
been	O
reported	O
in	O
management	O
of	O
adenoviral	B-DISO
infections	I-DISO
in	O
immunocompromised	O
persons	O
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
pancreatitis	I-DISO
is	O
related	O
to	O
increased	O
early	O
urinary	O
levels	O
of	O
the	O
activation	O
Peptide	O
of	O
pancreatic	O
phospholipase	O
A	O
(	O
2	O
).	O

RESULTS	O
:	O
The	O
median	O
maximum	O
PROP	O
values	O
were	O
significantly	O
elevated	O
48	O
h	O
after	O
symptom	B-DISO
onset	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
[	O
1	O
.	O
52	O
(	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
2	O
.	O
9	O
)	O
nmol	O
/	O
l	O
]	O
as	O
compared	O
with	O
patients	O
with	O
mild	O
acute	B-DISO
pancreatitis	I-DISO
[	O
0	O
.	O
72	O
(	O
0	O
.	O
55	O
-	O
1	O
)	O
nmol	O
/	O
l	O
,	O
p	O
=	O
0	O
.	O
002	O
]	O
and	O
controls	O
[	O
0	O
.	O
49	O
(	O
0	O
.	O
22	O
-	O
1	O
.	O
2	O
)	O
nmol	O
/	O
l	O
,	O
p	O
=	O
0	O
.	O
001	O
],	O
but	O
not	O
before	O
or	O
after	O
this	O
time	O
point	O
.	O

Upon	O
infection	B-DISO
of	O
cells	O
with	O
Albany	O
4	O
followed	O
by	O
transfection	O
with	O
synthetic	O
RNA	O
transcribed	O
from	O
the	O
DI	O
-	O
like	O
cDNA	O
construct	O
,	O
recombinant	O
mouse	B-DISO
hepatitis	I-DISO
viruses	O
as	O
the	O
large	O
plaque	B-DISO
forming	O
phenotype	O
were	O
isolated	O
by	O
plaque	B-DISO
assays	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
of	O
391	O
degrees	O
C	O
.	O
By	O
RT	O
-	O
PCR	O
and	O
sequencing	O
,	O
those	O
large	O
plaque	B-DISO
phenotypes	O
were	O
confirmed	O
to	O
have	O
contained	O
the	O
thermostable	O
phenotype	O
marker	O
derived	O
from	O
the	O
transfected	O
RNA	O
,	O
demonstrating	O
that	O
recombination	O
occurred	O
between	O
the	O
Albany	O
4	O
genomic	O
RNA	O
and	O
the	O
in	O
vitro	O
RNA	O
transcripts	O
.	O

This	O
study	O
redirects	O
our	O
current	O
approach	O
of	O
utilizing	O
the	O
MHV	O
targeted	O
RNA	O
recombination	O
as	O
a	O
means	O
to	O
study	O
bovine	O
coronavirus	O
genetics	O
towards	O
the	O
construction	O
of	O
an	O
infectious	B-DISO
cDNA	O
clone	O
.	O

At	O
admission	O
,	O
nonsurvivors	O
had	O
significantly	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
,	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
and	O
McCabe	O
scores	O
,	O
and	O
lower	O
oxygenation	O
and	O
pH	O
.	O
During	O
the	O
first	O
week	O
,	O
Pao2	O
/	O
Fio2	O
,	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
,	O
pH	O
,	O
base	O
excess	O
,	O
and	O
driving	O
pressure	O
consistently	O
discriminated	O
between	O
survivors	O
and	O
nonsurvivors	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
a	O
frequent	O
syndrome	B-DISO
in	O
this	O
cohort	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
effect	O
of	O
repeated	O
prone	O
positioning	O
(	O
supine	O
-	O
prone	O
/	O
prone	O
-	O
supine	O
)	O
on	O
oxygenation	O
in	O
children	O
suffering	B-DISO
from	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Herein	O
we	O
report	O
a	O
description	O
of	O
gross	O
and	O
microscopic	O
lesions	O
found	O
in	O
specific	O
pathogen	O
-	O
free	O
chicken	O
embryos	O
caused	O
by	O
UNAM	O
-	O
97	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
variant	O
strain	O
after	O
the	O
eighth	O
passage	O
.	O

Surfactant	O
dysfunction	O
probably	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
severe	O
paediatric	O
ARDS	B-DISO
triggered	O
by	O
pneumonia	B-DISO
,	O
as	O
it	O
was	O
found	O
that	O
surfactant	O
instillation	O
rapidly	O
improved	O
gas	O
exchange	O
in	O
the	O
majority	O
of	O
the	O
affected	O
infants	O
in	O
our	O
study	O
.	O

In	O
general	O
,	O
it	O
is	O
a	O
well	O
tolerated	O
cytotoxic	O
agent	O
and	O
myelosuppression	B-DISO
is	O
the	O
major	O
dose	O
limiting	O
side	O
-	O
effect	O
.	O

Pulmonary	B-DISO
toxicity	I-DISO
has	O
been	O
described	O
and	O
dyspnoea	B-DISO
occurs	O
in	O
approximately	O
8	O
%	O
of	O
patients	O
in	O
whom	O
,	O
for	O
the	O
majority	O
,	O
it	O
is	O
mild	O
and	O
reversible	O
.	O

We	O
present	O
a	O
case	O
of	O
Gemcitabine	O
toxicity	O
in	O
a	O
patient	O
treated	O
for	O
a	O
lung	B-DISO
cancer	I-DISO
.	O

Conversely	O
,	O
CD4	O
(+)	O
T	O
cells	O
from	O
CCR5	O
(-/-)	O
mice	O
displayed	O
an	O
impaired	B-DISO
ability	O
to	O
traffic	O
into	O
the	O
CNS	O
of	O
MHV	O
-	O
infected	O
RAG1	O
(-/-)	O
recipients	O
,	O
which	O
correlated	O
with	O
increased	O
viral	O
titers	O
,	O
diminished	O
macrophage	O
accumulation	O
,	O
and	O
limited	O
demyelination	B-DISO
.	O

Mechanical	O
ventilation	O
with	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
is	O
a	O
cornerstone	O
therapy	O
for	O
ARDS	B-DISO
patients	O
.	O

CONCLUSIONS	O
:	O
our	O
case	O
suggests	O
that	O
Mycoplasma	B-DISO
pneumoniae	O
should	O
be	O
considered	O
as	O
an	O
aetiological	O
agent	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Brachial	B-DISO
plexopathy	I-DISO
after	O
prone	O
positioning	O
.	O

Histopathologic	O
changes	O
included	O
characteristic	O
tubular	O
epithelial	O
degeneration	B-DISO
and	O
sloughing	O
with	O
lymphoplasmacytic	O
interstitial	B-DISO
nephritis	I-DISO
.	O

TITLE	O
:	O
Chicken	O
egg	O
yolk	O
antibodies	O
as	O
therapeutics	O
in	O
enteric	O
infectious	B-DISO
disease	I-DISO
:	O
a	O
review	O
.	O

Mice	O
deficient	O
in	O
IL	O
-	O
2	O
,	O
IL	O
-	O
2Ralpha	O
,	O
and	O
IL	O
-	O
2Rbeta	O
are	O
each	O
characterized	O
by	O
a	O
rapid	O
lethal	O
autoimmune	B-DISO
lymphoproliferative	B-DISO
disorder	I-DISO
that	O
complicates	O
their	O
use	O
in	O
studies	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
these	O
cytokines	O
and	O
receptors	O
for	O
immune	O
responses	O
in	O
vivo	O
.	O

The	O
use	O
of	O
NIV	O
is	O
increasing	O
for	O
patients	O
with	O
acute	B-DISO
and	I-DISO
chronic	I-DISO
respiratory	I-DISO
failure	I-DISO
,	O
because	O
of	O
its	O
convenience	O
,	O
lower	O
cost	O
and	O
minimal	O
complications	O
.	O

ABSTRACT	O
:	O
Using	O
isogenic	O
recombinant	O
murine	O
coronaviruses	O
expressing	O
wild	O
-	O
type	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
4	O
(	O
MHV	O
-	O
4	O
)	O
or	O
MHV	O
-	O
A59	O
spike	O
glycoproteins	O
or	O
chimeric	O
MHV	O
-	O
4	O
/	O
MHV	O
-	O
A59	O
spike	O
glycoproteins	O
,	O
we	O
have	O
demonstrated	O
the	O
biological	O
functionality	O
of	O
the	O
N	O
-	O
terminus	O
of	O
the	O
spike	O
,	O
encompassing	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
).	O

ABSTRACT	O
:	O
The	O
primary	O
target	O
in	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
is	O
believed	O
to	O
be	O
either	O
myelin	O
itself	O
(	O
myelinopathy	B-DISO
)	O
or	O
the	O
myelin	O
-	O
forming	O
cell	O
,	O
the	O
oligodendrocyte	O
(	O
oligodendrogliopathy	O
).	O

Neurofilament	O
immunostaining	O
of	O
spinal	O
cord	B-DISO
sections	O
demonstrates	O
that	O
axonal	O
injury	O
with	O
oligodendrocyte	O
apoptosis	O
also	O
precedes	O
demyelination	B-DISO
in	O
an	O
animal	O
model	O
for	O
MS	O
,	O
Theiler	O
'	O
s	O
murine	B-DISO
encephalomyelitis	I-DISO
virus	B-DISO
infection	I-DISO
.	O

Sequence	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
gene	O
encoding	O
the	O
M	O
protein	O
revealed	O
that	O
the	O
viruses	O
detected	O
at	O
the	O
onset	O
of	O
the	O
infection	B-DISO
were	O
very	O
similar	O
to	O
typical	O
strains	O
of	O
CCoV	O
,	O
whereas	O
from	O
42	O
days	O
after	O
infection	B-DISO
in	O
pup	O
A	O
and	O
40	O
days	O
after	O
infection	B-DISO
in	O
pup	O
B	O
the	O
viruses	O
had	O
nucleotide	O
and	O
amino	O
acid	O
mutations	O
resembling	O
sequences	O
in	O
feline	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Dengue	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
(	O
DHF	O
)	O
is	O
caused	O
by	O
dengue	B-DISO
virus	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
STAT	O
activation	O
will	O
predict	O
the	O
host	O
immune	O
response	O
to	O
viral	B-DISO
infection	I-DISO
and	O
possibly	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
viral	B-DISO
infection	I-DISO
.	O

These	O
results	O
suggested	O
that	O
ratio	O
of	O
activated	O
STAT1	O
alpha	O
/	O
beta	O
and	O
STAT3	O
alpha	O
/	O
beta	O
in	O
mixed	O
leukocytes	O
from	O
spleen	O
predict	O
the	O
outcome	O
to	O
MHV	O
-	O
3	O
infection	B-DISO
,	O
and	O
may	O
be	O
an	O
important	O
marker	O
and	O
therapeutic	O
target	O
for	O
modification	O
of	O
host	O
immune	O
response	O
to	O
virus	B-DISO
infection	I-DISO
.	O

We	O
included	O
children	O
aged	O
2	O
-	O
16	O
years	O
with	O
active	O
asthma	B-DISO
,	O
defined	O
as	O
three	O
or	O
more	O
recurrent	O
episodes	O
of	O
reversible	O
wheezing	B-DISO
.	O

Atypical	O
bacterial	O
pathogen	O
infections	B-DISO
were	O
linked	O
with	O
prolonged	O
asthmatic	B-DISO
symptoms	O
.	O

We	O
surveyed	O
70	O
free	O
-	O
living	O
Rio	O
Grande	O
wild	O
turkeys	O
from	O
Bandera	O
and	O
Kerr	O
counties	O
,	O
Texas	O
,	O
for	O
evidence	O
of	O
exposure	O
to	O
Salmonella	B-DISO
typhimurium	O
,	O
S	O
.	O
pullorum	O
,	O
Mycoplasma	B-DISO
gallisepticum	O
,	O
M	O
.	O
meleagridis	O
,	O
M	O
.	O
synoviae	O
,	O
Chlamydophila	O
psittaci	O
,	O
and	O
the	O
avian	B-DISO
influenza	I-DISO
,	O
Newcastle	B-DISO
disease	I-DISO
,	O
turkey	O
corona	O
,	O
and	O
reticuloendotheliosis	B-DISO
viruses	O
.	O

Two	O
adult	O
females	O
sampled	O
in	O
Kerr	O
County	O
,	O
whose	O
body	O
mass	O
was	O
significantly	O
less	O
than	O
that	O
of	O
other	O
adult	O
females	O
trapped	O
in	O
the	O
area	O
,	O
tested	O
positive	O
for	O
reticuloendotheliosis	B-DISO
virus	O
(	O
REV	O
)	O
proviral	O
DNA	O
on	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
PDGF	O
and	O
FGF2	O
regulate	O
oligodendrocyte	O
progenitor	O
responses	O
to	O
demyelination	B-DISO
.	O

Ten	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
on	O
mechanical	O
ventilation	O
.	O

The	O
purpose	O
of	O
the	O
experiments	O
presented	O
here	O
was	O
to	O
examine	O
the	O
in	O
vivo	O
effects	O
of	O
thymulin	O
on	O
avian	O
NK	O
cell	O
activity	O
in	O
response	O
to	O
a	O
viral	B-DISO
infection	I-DISO
.	O

The	O
greatest	O
enhancement	O
of	O
NK	O
cytotoxicity	B-DISO
was	O
observed	O
at	O
10	O
days	O
post	O
-	O
infection	B-DISO
in	O
those	O
chickens	O
that	O
began	O
receiving	O
thymulin	O
after	O
infection	B-DISO
.	O

ARDS	B-DISO
is	O
a	O
biphasic	B-DISO
disease	I-DISO
that	O
includes	O
an	O
acute	O
phase	O
,	O
consisting	O
of	O
severe	O
leukocyte	O
infiltration	B-DISO
,	O
edema	B-DISO
,	O
hemorrhage	B-DISO
,	O
and	O
the	O
formation	O
of	O
hyaline	B-DISO
membranes	I-DISO
,	O
and	O
a	O
chronic	O
phase	O
,	O
which	O
is	O
characterized	O
by	O
persistent	O
intra	O
-	O
alveolar	O
and	O
interstitial	B-DISO
fibrosis	I-DISO
.	O

CBA	O
/	O
J	O
mice	O
infected	O
with	O
1	O
x	O
10	O
(	O
6	O
)	O
plaque	B-DISO
-	O
forming	O
units	O
(	O
pfu	O
)	O
reovirus	O
1	O
/	O
L	O
develop	O
follicular	B-DISO
bronchiolitis	I-DISO
and	O
intra	O
-	O
alveolar	O
fibrosis	B-DISO
similar	O
to	O
BOOP	B-DISO
.	O

The	O
concentrations	O
of	O
surfactant	O
proteins	O
A	O
and	O
D	O
were	O
measured	O
in	O
pulmonary	B-DISO
edema	I-DISO
fluid	O
and	O
in	O
plasma	O
.	O

The	O
use	O
of	O
a	O
low	O
tidal	O
volume	O
with	O
moderate	O
to	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
improves	O
the	O
survival	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
prevalence	O
of	O
enteric	O
pathogens	O
in	O
dogs	O
of	O
north	O
-	O
central	O
Colorado	O
,	O
fecal	O
samples	O
were	O
obtained	O
from	O
client	O
-	O
owned	O
dogs	O
presented	O
to	O
the	O
Veterinary	O
Teaching	O
Hospital	O
at	O
Colorado	O
State	O
University	O
for	O
evaluation	O
of	O
acute	O
small	O
-	O
bowel	O
,	O
large	O
-	O
bowel	O
,	O
or	O
mixed	O
-	O
bowel	O
diarrhea	B-DISO
(	O
n	O
=	O
71	O
)	O
and	O
from	O
age	O
-	O
matched	O
,	O
client	O
-	O
owned	O
,	O
healthy	O
dogs	O
(	O
n	O
=	O
59	O
).	O

Interaction	O
with	O
nascent	O
2a	O
also	O
may	O
be	O
involved	O
in	O
1a	O
recruitment	B-DISO
of	O
2a	O
polymerase	O
to	O
membranes	O
.	O

ABSTRACT	O
:	O
CD8	O
+	O
T	O
cells	O
control	O
acute	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
by	O
neurotropic	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
but	O
do	O
not	O
suffice	O
to	O
achieve	O
sterile	B-DISO
immunity	O
.	O

However	O
,	O
use	O
of	O
this	O
technique	O
has	O
adverse	B-DISO
effects	I-DISO
,	O
including	O
increased	O
risk	O
of	O
pneumonia	B-DISO
,	O
impaired	B-DISO
cardiac	O
performance	O
,	O
and	O
difficulties	O
associated	O
with	O
sedation	B-DISO
and	O
paralysis	O
.	O

ABSTRACT	O
:	O
Renal	O
involvement	O
is	O
common	O
in	O
leptospirosis	B-DISO
.	O

17	O
.	O
5	O
yrs	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
of	O
28	O
.	O
6	O
+/-	O
7	O
.	O
1	O
)	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
lung	O
injury	O
score	O
,	O
3	O
.	O
5	O
+/-	O
0	O
.	O
4	O
)	O
with	O
Fio2	O
of	O
>	O
or	O
=	O
0	O
.	O
6	O
and	O
mean	O
airway	O
pressure	O
of	O
>	O
or	O
=	O
28	O
cm	O
H2O	O
.	O

Ultimately	O
,	O
studies	O
of	O
lung	O
injury	O
markers	O
may	O
help	O
define	O
interventions	O
that	O
prevent	O
or	O
moderate	O
ARDS	B-DISO
.	O

In	O
the	O
murine	O
coronavirus	O
a	O
selective	O
interaction	O
between	O
the	O
viral	O
transmembrane	O
envelope	O
protein	O
M	O
and	O
the	O
viral	O
ribonucleoprotein	O
complex	O
,	O
composed	O
of	O
N	O
protein	O
and	O
viral	O
RNA	O
containing	O
a	O
short	O
cis	B-DISO
-	O
acting	O
RNA	O
element	O
,	O
the	O
packaging	O
signal	O
,	O
determines	O
the	O
selective	O
RNA	O
packaging	O
into	O
virus	O
particles	O
.	O

Decreasing	O
recruitment	B-DISO
of	O
patients	O
led	O
to	O
a	O
preliminary	O
end	O
of	O
this	O
study	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
impact	O
of	O
bronchoscopically	O
guided	O
percutaneous	O
dilational	O
tracheostomy	O
(	O
PDT	O
)	O
on	O
oxygenation	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
ventilated	O
with	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
).	O

Furthermore	O
,	O
oxygenation	O
did	O
not	O
deteriorate	O
with	O
PDT	O
even	O
in	O
patients	O
with	O
gravely	O
impaired	B-DISO
gas	I-DISO
exchange	I-DISO
(	O
lowest	O
quartile	O
)	O
with	O
a	O
PaO	O
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
averaging	O
130	O
+/-	O
42	O
mmHg	O
(	O
range	O
45	O
-	O
192	O
mmHg	O
)	O
at	O
a	O
PEEP	O
of	O
17	O
+/-	O
4	O
mbar	O
.	O

ABSTRACT	O
:	O
To	O
estimate	O
the	O
prevalence	O
of	O
infection	B-DISO
with	O
human	O
herpes	B-DISO
virus	O
type	O
8	O
(	O
HHV8	B-DISO
)	O
and	O
the	O
incidence	O
of	O
Kaposi	B-DISO
'	I-DISO
s	I-DISO
sarcoma	I-DISO
among	O
HHV8	B-DISO
-	O
infected	O
individuals	O
,	O
we	O
conducted	O
a	O
population	O
-	O
based	O
,	O
cross	O
-	O
sectional	O
study	O
in	O
Latina	O
.	O

The	O
title	O
compounds	O
were	O
synthesized	O
through	O
a	O
highly	O
convergent	O
,	O
one	O
-	O
pot	B-DISO
procedure	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
liquid	O
-	O
phase	O
blocking	B-DISO
(	O
LPB	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
chicken	O
and	O
rabbit	O
affinity	O
purified	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
has	O
been	O
developed	O
to	O
detect	O
and	O
estimate	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
antigen	O
concentration	O
directly	O
in	O
infected	O
allantoic	O
fluid	O
.	O

The	O
relative	O
sensitivity	O
of	O
the	O
test	O
ranged	O
between	O
10	O
(	O
5	O
)	O
and	O
10	O
(	O
6	O
)	O
median	O
egg	O
infectious	B-DISO
doses	O
(	O
EID	O
(	O
50	O
))	O
for	O
chicken	O
IgG	O
and	O
between	O
10	O
(	O
3	O
)	O
and	O
10	O
(	O
4	O
)	O
EID	O
(	O
50	O
)	O
for	O
rabbit	O
IgG	O
,	O
depending	O
on	O
the	O
test	O
strain	O
.	O

ABSTRACT	O
:	O
Fibrinogen	O
-	O
like	O
protein	O
2	O
/	O
fibroleukin	O
(	O
Fgl2	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
both	O
experimental	O
and	O
human	O
fulminant	B-DISO
hepatic	I-DISO
failure	I-DISO
.	O

We	O
have	O
reported	O
recently	O
that	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
from	O
strains	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
-	O
3	O
,	O
MHV	O
-	O
A59	O
),	O
which	O
cause	O
massive	O
hepatocellular	B-DISO
necrosis	I-DISO
but	O
not	O
from	O
strains	O
(	O
MHV	O
-	O
JHM	O
,	O
MHV	O
-	O
2	O
)	O
which	O
do	O
not	O
produce	O
serious	O
liver	B-DISO
disease	I-DISO
,	O
induces	O
transcription	O
of	O
fgl2	O
.	O

Following	O
stimulation	O
with	O
MHV	O
-	O
A59	O
,	O
it	O
was	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
that	O
HNF4alpha	O
binds	O
the	O
HNF4	O
cis	B-DISO
-	O
element	O
in	O
the	O
fgl2	O
promoter	O
.	O

ABSTRACT	O
:	O
To	O
report	O
two	O
children	O
admitted	O
to	O
our	O
emergency	B-DISO
department	O
with	O
respiratory	B-DISO
failure	I-DISO
,	O
one	O
for	O
status	B-DISO
asthmaticus	I-DISO
with	O
pneumomediastinum	B-DISO
and	O
requiring	O
mechanical	O
ventilation	O
and	O
the	O
other	O
for	O
high	O
suspicion	O
of	O
foreign	O
body	O
aspiration	B-DISO
.	O

She	O
was	O
diagnosed	O
as	O
M	O
.	O
pneumoniae	O
pneumonia	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
treated	O
with	O
clarithromycin	O
and	O
methylprednisolone	O
.	O

The	O
authors	O
studied	O
56	O
patients	O
with	O
pathologically	O
proven	O
appendicitis	B-DISO
.	O

Blood	O
was	O
obtained	O
before	O
the	O
induction	O
of	O
anesthesia	B-DISO
,	O
when	O
82	O
%	O
of	O
the	O
patients	O
met	O
the	O
criteria	O
for	O
SIRS	B-DISO
.	O

Patient	O
plasma	O
inhibited	O
LPS	B-DISO
-	O
induced	O
stimulation	O
of	O
a	O
monocyte	O
cell	O
line	O
,	O
and	O
this	O
inhibition	O
was	O
accentuated	O
by	O
complicated	O
disease	O
.	O

Because	O
neutrophils	O
appear	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
development	O
of	O
ALI	O
,	O
we	O
examined	O
the	O
relationships	O
between	O
clinical	O
outcome	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
peripheral	O
neutrophils	O
from	O
patients	O
(	O
n	O
=	O
30	O
)	O
with	O
sepsis	B-DISO
-	O
induced	O
ALI	O
.	O

TITLE	O
:	O
Perforin	O
-	O
mediated	O
effector	O
function	O
within	O
the	O
central	O
nervous	B-DISO
system	O
requires	O
IFN	O
-	O
gamma	O
-	O
mediated	O
MHC	O
up	O
-	O
regulation	O
.	O

TITLE	O
:	O
Neutrophils	O
promote	O
mononuclear	O
cell	O
infiltration	B-DISO
during	O
viral	O
-	O
induced	O
encephalitis	B-DISO
.	O

ABSTRACT	O
:	O
Neutrophils	O
are	O
the	O
first	O
infiltrating	B-DISO
cell	O
population	O
to	O
appear	O
within	O
the	O
CNS	O
during	O
infection	B-DISO
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
).	O

Thirty	O
percent	O
of	O
the	O
patients	O
(	O
66	O
of	O
220	O
)	O
were	O
identified	O
as	O
having	O
a	O
history	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
based	O
on	O
a	O
positive	O
response	O
to	O
an	O
alcohol	O
screening	O
questionnaire	O
.	O

After	O
adjusting	O
for	O
differences	O
in	O
the	O
source	O
of	O
infection	B-DISO
,	O
sex	O
,	O
age	O
,	O
chronic	O
hepatic	B-DISO
dysfunction	I-DISO
,	O
diabetes	B-DISO
,	O
severity	O
of	O
illness	O
,	O
nutritional	O
status	O
,	O
and	O
smoking	O
status	O
,	O
the	O
effects	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
on	O
the	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
remained	O
significant	O
(	O
p	O
<	O
.	O
001	O
;	O
odds	O
ratio	O
,	O
3	O
.	O
70	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
83	O
-	O
7	O
.	O
71	O
).	O

This	O
sheep	O
model	O
was	O
characterized	O
by	O
a	O
rapidly	O
evolving	O
massive	O
anasarca	B-DISO
,	O
hemoconcentration	O
,	O
cardiac	O
dysfunction	O
,	O
multiple	B-DISO
system	I-DISO
organ	I-DISO
failure	I-DISO
,	O
and	O
severe	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Susceptibility	O
of	O
three	O
genetic	O
lines	O
of	O
chicks	O
to	O
infection	B-DISO
with	O
a	O
nephropathogenic	O
T	O
strain	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Mortality	O
rates	O
were	O
compared	O
in	O
three	O
genetic	O
lines	O
of	O
specific	O
pathogen	O
-	O
free	O
chicks	O
inoculated	O
with	O
one	O
of	O
two	O
doses	O
of	O
a	O
nephropathogenic	O
strain	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
virus	O
.	O

Furthermore	O
,	O
the	O
absence	O
of	O
CCL3	O
impaired	B-DISO
the	O
cytokine	O
production	O
and	O
cytolytic	O
activity	O
of	O
CD8	O
(+)	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
CCL3	O
not	O
only	O
mediates	O
macrophage	O
chemotaxis	O
but	O
also	O
significantly	O
enhances	O
differentiation	O
of	O
primed	O
CD8	O
(+)	O
T	O
cells	O
into	O
effector	O
cells	O
and	O
their	O
release	O
into	O
circulation	O
,	O
thus	O
potentiating	O
effective	O
migration	O
to	O
the	O
site	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Engineering	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
genome	O
as	O
an	O
expression	O
vector	O
inducing	O
lactogenic	O
immunity	O
.	O

ABSTRACT	O
:	O
The	O
genome	O
of	O
the	O
coronavirus	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
has	O
been	O
engineered	O
as	O
an	O
expression	O
vector	O
with	O
an	O
infectious	B-DISO
cDNA	O
.	O

Expression	O
levels	O
driven	O
by	O
this	O
TRS	B-DISO
were	O
higher	O
than	O
those	O
of	O
an	O
expression	O
cassette	O
under	O
the	O
control	O
of	O
regulating	O
sequences	O
engineered	O
with	O
the	O
N	O
gene	O
TRS	B-DISO
.	O

Extension	O
of	O
the	O
complementarity	O
between	O
the	O
TRS	B-DISO
and	O
sequences	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
viral	O
leader	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
noncanonical	O
core	O
sequences	O
.	O

TITLE	O
:	O
Differences	O
between	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	O
in	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
replication	O
in	O
primary	O
hepatocyte	O
culture	O
.	O

TITLE	O
:	O
Memory	O
T	O
cells	O
protect	O
chicks	O
from	O
acute	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
.	O

It	O
is	O
characterized	O
by	O
increased	O
expression	O
of	O
TGF	O
beta	O
and	O
other	O
cytokines	O
on	O
airway	O
epithelial	O
cells	O
,	O
increased	O
expression	O
of	O
class	O
II	O
antigens	O
in	O
the	O
airways	O
,	O
lymphocytic	O
bronchiolitis	B-DISO
,	O
and	O
bronchial	O
epithelial	O
cell	O
proliferation	B-DISO
mediated	O
by	O
numerous	O
cytokines	O
.	O

During	O
48	O
hours	O
,	O
control	O
sheep	O
developed	O
multiple	O
signs	O
of	O
ARDS	B-DISO
.	O

These	O
included	O
decreased	O
pulmonary	O
gas	O
exchange	O
,	O
increased	O
pulmonary	B-DISO
edema	I-DISO
,	O
abnormal	O
lung	O
compliance	O
,	O
and	O
extensive	O
airway	B-DISO
obstruction	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
,	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
are	O
syndromes	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
that	O
result	O
from	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
and	O
inflammation	B-DISO
.	O

This	O
mutant	B-DISO
(	O
Delta	O
E	O
)	O
was	O
obtained	O
by	O
a	O
targeted	O
RNA	O
recombination	O
method	O
that	O
makes	O
use	O
of	O
a	O
powerful	O
host	O
range	O
-	O
based	O
selection	O
system	O
.	O

The	O
illness	O
is	O
being	O
referred	O
to	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Astrovirus	O
,	O
calicivirus	O
and	O
enteric	O
adenovirus	B-DISO
are	O
also	O
important	O
etiologic	O
agents	O
of	O
acute	B-DISO
gastroenteritis	I-DISO
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
.	O

TITLE	O
:	O
A	O
cluster	O
of	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Hong	O
Kong	O
.	O

There	O
was	O
no	O
evidence	O
of	O
infection	B-DISO
by	O
Mycoplasma	B-DISO
pneumoniae	O
,	O
Chlamydia	O
pneumoniae	O
,	O
or	O
Legionella	O
pneumophila	O
.	O

Fever	O
followed	O
by	O
rapidly	O
progressive	O
respiratory	O
compromise	O
is	O
the	O
key	O
complex	O
of	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
from	O
which	O
the	O
syndrome	B-DISO
derives	O
its	O
name	O
.	O

The	O
acute	O
colonic	B-DISO
pseudo	I-DISO
-	I-DISO
obstruction	I-DISO
,	O
Ogilvie	B-DISO
'	I-DISO
s	I-DISO
Syndrome	I-DISO
,	O
most	O
often	O
appears	O
as	O
a	O
complication	B-DISO
of	O
other	O
clinical	O
conditions	O
.	O

This	O
report	O
also	O
describes	O
an	O
unusual	O
cluster	O
of	O
cases	O
associated	O
with	O
a	O
hotel	O
in	O
Hong	O
Kong	O
and	O
identifies	O
the	O
potential	O
etiologic	O
agent	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Preliminary	O
clinical	O
description	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

We	O
report	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiologic	O
features	O
of	O
138	O
cases	O
of	O
suspected	O
SARS	B-DISO
during	O
a	O
hospital	O
outbreak	O
in	O
Hong	O
Kong	O
.	O

From	O
March	O
11	O
to	O
25	O
,	O
2003	O
,	O
all	O
patients	O
with	O
suspected	O
SARS	B-DISO
after	O
exposure	O
to	O
an	O
index	O
patient	O
or	O
ward	O
were	O
admitted	O
to	O
the	O
isolation	O
wards	O
of	O
the	O
Prince	O
of	O
Wales	O
Hospital	O
.	O

Cough	B-DISO
and	O
headache	B-DISO
were	O
also	O
reported	O
in	O
more	O
than	O
50	O
percent	O
of	O
the	O
patients	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	O
elastase	O
in	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	O
elastase	O
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

The	O
total	O
protein	O
concentration	O
in	O
the	O
epithelial	O
lining	O
fluid	O
also	O
is	O
increased	O
in	O
these	O
individuals	O
with	O
a	O
history	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
compared	O
with	O
healthy	O
controls	O
,	O
suggesting	O
alterations	O
in	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
.	O

Published	O
articles	O
on	O
experimental	O
and	O
clinical	O
studies	O
of	O
coagulation	O
and	O
fibrinolysis	O
during	O
infection	B-DISO
,	O
inflammation	B-DISO
,	O
acute	O
lung	O
injury	O
,	O
and	O
evolving	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Fibrin	B-DISO
deposition	I-DISO
is	O
an	O
important	O
feature	O
of	O
pulmonary	B-DISO
infection	I-DISO
or	O
severe	O
inflammation	B-DISO
.	O

HPA	O
axis	O
activation	O
is	O
an	O
important	O
component	O
of	O
the	O
compensatory	O
anti	O
-	O
inflammatory	B-DISO
response	I-DISO
to	O
critical	B-DISO
illness	I-DISO
.	O

During	O
critical	B-DISO
illness	I-DISO
,	O
neurohumoral	O
factors	O
,	O
cytokines	O
,	O
endothelin	O
,	O
and	O
atrial	O
natriuretic	O
peptide	O
all	O
may	O
participate	O
in	O
HPA	O
axis	O
activation	O
,	O
resulting	O
in	O
elevated	O
plasma	O
cortisol	O
production	O
and	O
plasma	O
concentrations	O
.	O

Current	O
evidence	O
indicates	O
that	O
short	O
-	O
duration	O
,	O
high	O
-	O
dose	O
glucocorticoid	O
therapy	O
is	O
not	O
effective	O
for	O
early	O
ARDS	B-DISO
or	O
severe	B-DISO
sepsis	I-DISO
.	O

CONCLUSIONS	O
:	O
Current	O
evidence	O
indicates	O
that	O
short	O
-	O
duration	O
,	O
high	O
-	O
dose	O
glucocorticoid	O
therapy	O
is	O
not	O
effective	O
for	O
early	O
ARDS	B-DISO
or	O
severe	B-DISO
sepsis	I-DISO
.	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
using	O
an	O
open	O
-	O
lung	O
strategy	O
has	O
been	O
demonstrated	O
to	O
improve	O
oxygenation	O
in	O
neonatal	O
and	O
pediatric	O
respiratory	B-DISO
failure	I-DISO
,	O
without	O
increasing	O
barotrauma	O
.	O

An	O
activated	O
complex	O
of	O
tissue	O
factor	O
and	O
factor	O
VIIa	O
triggers	O
procoagulant	O
activity	O
in	O
the	O
lung	O
,	O
with	O
subsequent	O
thrombin	O
formation	O
and	O
fibrin	B-DISO
deposition	I-DISO
.	O

Soluble	O
thrombomodulin	O
has	O
been	O
shown	O
to	O
improve	O
ALI	O
in	O
animals	O
,	O
and	O
it	O
is	O
currently	O
being	O
evaluated	O
in	O
humans	O
with	O
sepsis	B-DISO
.	O

TITLE	O
:	O
Synergistic	O
antiviral	O
effect	O
of	O
a	O
combination	O
of	O
mouse	O
interferon	O
-	O
alpha	O
and	O
interferon	O
-	O
gamma	O
on	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

SARS	B-DISO
is	O
thought	O
to	O
be	O
caused	O
by	O
an	O
unknown	O
infectious	B-DISO
agent	O
.	O

A	O
novel	O
coronavirus	O
was	O
identified	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
Control	O
of	O
communicable	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
The	O
Public	O
Health	O
Service	O
Act	O
authorizes	O
the	O
Secretary	O
,	O
in	O
consultation	O
with	O
the	O
Surgeon	O
General	O
,	O
to	O
make	O
and	O
enforce	O
regulations	O
as	O
are	O
necessary	O
to	O
prevent	O
the	O
introduction	O
,	O
transmission	O
or	O
spread	O
of	O
communicable	B-DISO
diseases	I-DISO
from	O
foreign	O
countries	O
into	O
the	O
States	O
or	O
possessions	O
,	O
or	O
from	O
one	O
State	O
or	O
possession	O
into	O
any	O
other	O
State	O
or	O
possession	O
.	O

To	O
facilitate	O
the	O
genetic	O
manipulation	O
of	O
the	O
viral	O
genome	O
,	O
genes	O
were	O
separated	O
by	O
duplication	B-DISO
of	O
transcription	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
and	O
introduction	O
of	O
unique	O
restriction	O
endonuclease	O
sites	O
at	O
the	O
5	O
'	O
end	O
of	O
each	O
gene	O
using	O
an	O
infectious	B-DISO
cDNA	O
clone	O
.	O

Interestingly	O
,	O
in	O
vivo	O
infections	B-DISO
with	O
rTGEV	O
-	O
delta7	O
showed	O
an	O
additional	O
reduction	O
in	O
virus	O
replication	O
in	O
the	O
lung	O
and	O
gut	O
,	O
and	O
in	O
virulence	O
,	O
indicating	O
that	O
TGEV	O
gene	O
7	O
influences	O
virus	B-DISO
pathogenesis	I-DISO
.	O

Based	O
on	O
these	O
data	O
,	O
he	O
was	O
diagnosed	O
as	O
having	O
acute	O
mixed	O
lineage	O
(	O
myeloid	O
and	O
B	O
-	O
lymphoid	O
lineage	O
)	O
leukemia	B-DISO
.	O

Despite	O
therapy	O
with	O
prednisolone	O
and	O
FK506	O
,	O
he	O
died	O
on	O
day	O
400	O
post	O
-	O
BMT	O
because	O
of	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
BO	O
.	O

TITLE	O
:	O
Coronavirus	O
as	O
a	O
possible	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
reported	O
in	O
Hong	O
Kong	O
.	O

By	O
use	O
of	O
serological	O
and	O
reverse	O
-	O
transcriptase	O
PCR	O
specific	O
for	O
this	O
virus	O
,	O
45	O
of	O
50	O
patients	O
with	O
SARS	B-DISO
,	O
but	O
no	O
controls	O
,	O
had	O
evidence	O
of	O
infection	B-DISO
with	O
this	O
virus	O
.	O

A	O
coronavirus	O
was	O
isolated	O
from	O
patients	O
with	O
SARS	B-DISO
that	O
might	O
be	O
the	O
primary	O
agent	O
associated	O
with	O
this	O
disease	O
.	O

TITLE	O
:	O
Blockade	O
of	O
tissue	O
factor	O
:	O
treatment	O
for	O
organ	O
injury	O
in	O
established	O
sepsis	B-DISO
.	O

We	O
tested	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
obtained	O
from	O
HSCT	O
recipients	O
with	O
acute	O
pulmonary	B-DISO
infiltrates	I-DISO
for	O
HRV	O
(	O
n	O
=	O
122	O
)	O
and	O
coronavirus	O
(	O
n	O
=	O
46	O
)	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O

The	O
fatality	O
rate	O
in	O
HRV	O
-	O
infected	O
patients	O
was	O
high	O
(	O
83	O
%),	O
but	O
all	O
patients	O
had	O
significant	O
coinfections	B-DISO
,	O
and	O
the	O
overall	O
mortality	O
rate	O
was	O
not	O
different	O
from	O
that	O
of	O
patients	O
who	O
were	O
negative	O
for	O
HRV	O
in	O
BAL	O
samples	O
.	O

Microscopic	O
examination	O
of	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
showed	O
an	O
eccentric	O
fibroatheromatic	O
plaque	B-DISO
complicated	O
by	O
thrombosis	B-DISO
,	O
endothelial	O
erosion	B-DISO
and	O
extensive	O
T	O
-	O
cell	O
and	O
macrophage	O
infiltration	B-DISO
.	O

Enteroviral	B-DISO
infection	I-DISO
may	O
play	O
an	O
important	O
role	O
in	O
coronary	O
plaque	B-DISO
instability	O
and	O
may	O
precipitate	O
thrombotic	B-DISO
occlusion	I-DISO
.	O

Pending	O
development	O
of	O
confirmatory	O
laboratory	O
testing	O
capacity	O
,	O
CDC	O
'	O
s	O
interim	O
suspected	O
SARS	B-DISO
case	O
definition	O
is	O
based	O
on	O
clinical	O
criteria	O
and	O
epidemiologic	O
linkage	O
to	O
other	O
SARS	B-DISO
cases	O
or	O
areas	O
with	O
community	O
transmission	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
short	O
-	O
term	O
outcomes	O
of	O
144	O
patients	O
with	O
SARS	B-DISO
in	O
the	O
greater	O
Toronto	O
area	O
.	O

In	O
the	O
event	O
that	O
contact	O
history	O
becomes	O
unreliable	O
,	O
several	O
features	O
of	O
the	O
clinical	O
presentation	O
will	O
be	O
useful	O
in	O
raising	O
the	O
suspicion	O
of	O
SARS	B-DISO
.	O

Future	O
studies	O
of	O
infectious	B-DISO
diarrhea	I-DISO
in	O
cattle	O
should	O
also	O
include	O
assays	O
for	O
this	O
etiologic	O
agent	O
.	O

TITLE	O
:	O
Haemorrhagic	O
-	O
fever	O
-	O
like	O
changes	O
and	O
normal	O
chest	O
radiograph	O
in	O
a	O
doctor	O
with	O
SARS	B-DISO
.	O

His	O
condition	B-DISO
improved	O
with	O
intravenous	O
methylprednisolone	O
500	O
mg	O
daily	O
and	O
ribavirin	O
1	O
.	O
2	O
g	O
orally	O
thrice	O
daily	O
.	O

All	O
patients	O
were	O
hypertensive	O
and	O
comatose	B-DISO
with	O
an	O
average	O
GCS	O
of	O
8	O
+/-	O

ABSTRACT	O
:	O
To	O
retrospectively	O
analyze	O
the	O
thin	O
-	O
section	O
computed	O
tomographic	O
(	O
CT	O
)	O
features	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
at	O
the	O
authors	O
'	O
institution	O
.	O

Group	O
1	O
(	O
n	O
=	O
23	O
)	O
patients	O
had	O
symptoms	O
of	O
SARS	B-DISO
in	O
keeping	O
with	O
criteria	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
a	O
positive	O
chest	O
radiograph	O
.	O

Preoperative	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
and	O
bronchoscopy	O
showed	O
that	O
from	O
the	O
level	O
of	O
12	O
mm	O
beneath	O
the	O
coricoid	O
cartilage	O
,	O
the	O
trachea	B-DISO
tapered	O
and	O
continuing	O
to	O
the	O
tracheal	O
carina	O
and	O
that	O
the	O
smallest	O
tracheal	O
level	O
was	O
located	O
18	O
mm	O
distal	O
from	O
the	O
coricoid	O
cartilage	O
,	O
the	O
area	O
of	O
which	O
was	O
4	O
mm2	O
.	O

TITLE	O
:	O
SARS	B-DISO
Web	B-DISO
information	O
.	O

The	O
emotional	O
and	O
behavioural	O
reactions	O
of	O
patients	O
and	O
staff	O
are	O
understood	O
to	O
be	O
a	O
normal	O
,	O
adaptive	O
response	O
to	O
stress	O
in	O
the	O
face	B-DISO
of	O
an	O
overwhelming	O
event	O
.	O

The	O
structures	O
reveal	O
a	O
remarkable	O
degree	O
of	O
conservation	O
of	O
the	O
substrate	O
-	O
binding	O
sites	O
,	O
which	O
is	O
further	O
supported	O
by	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
Mpro	O
-	O
mediated	O
cleavage	O
of	O
a	O
TGEV	O
Mpro	O
substrate	O
.	O

TITLE	O
:	O
Postoperative	B-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
transfusion	O
-	O
related	O
?--	O
a	O
case	O
report	O
.	O

Without	O
identifying	O
the	O
blood	O
donor	O
implicated	O
in	O
the	O
disorder	O
,	O
transfusion	B-DISO
reactions	I-DISO
or	O
TRALI	B-DISO
will	O
be	O
inevitable	O
.	O

RESULTS	O
:	O
Specific	O
fragments	O
were	O
amplified	O
from	O
the	O
sputum	O
samples	O
of	O
SARS	B-DISO
patients	O
,	O
which	O
were	O
confirmed	O
by	O
DNA	O
cloning	O
and	O
sequencing	O
to	O
belong	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

CONCLUSIONS	O
:	O
Sequence	O
analysis	O
has	O
confirmed	O
the	O
existence	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
the	O
sputum	O
samples	O
of	O
SARS	B-DISO
patients	O
,	O
and	O
nested	O
RT	O
-	O
PCR	O
is	O
a	O
quick	O
,	O
easy	O
,	O
and	O
convenient	O
way	O
for	O
the	O
detection	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
[	O
Clinical	O
detection	O
of	O
polymerase	O
gene	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
].	O

Specific	O
amplicons	O
can	O
be	O
amplified	O
from	O
the	O
sputum	O
samples	O
,	O
throat	O
swab	O
and	O
plasma	O
of	O
most	O
SARS	B-DISO
patients	O
,	O
and	O
8	O
were	O
random	O
selected	O
and	O
sequenced	O
.	O

Among	O
the	O
patients	O
with	O
a	O
nonruptured	O
aneurysm	B-DISO
,	O
two	O
deaths	O
(	O
9	O
.	O
1	O
%)	O
occurred	O
because	O
of	O
aorto	O
-	O
broncho	O
-	O
esophageal	O
fistulae	O
or	O
cardiac	B-DISO
arrest	I-DISO
due	O
to	O
severe	O
asthma	B-DISO
attack	I-DISO
within	O
30	O
days	O
,	O
and	O
the	O
other	O
three	O
hospital	O
deaths	O
were	O
due	O
to	O
aspiration	B-DISO
pneumonia	I-DISO
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
with	O
preoperative	O
renal	O
dysfunction	O
,	O
or	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
due	O
to	O
perioperative	O
myocardial	B-DISO
infarction	I-DISO
.	O

Bovine	B-DISO
spongiform	I-DISO
encephalopathy	I-DISO
and	O
outbreaks	O
of	O
virus	O
infections	B-DISO
in	O
the	O
bioindustry	O
,	O
such	O
as	O
swine	B-DISO
fever	I-DISO
,	O
foot	B-DISO
-	I-DISO
and	I-DISO
-	I-DISO
mouth	I-DISO
disease	I-DISO
and	O
classical	O
avian	B-DISO
influenza	I-DISO
,	O
have	O
led	O
to	O
massive	O
killing	O
of	O
cattle	O
,	O
swine	O
and	O
fowl	O
in	O
the	O
Netherlands	O
.	O

No	O
cavitation	B-DISO
,	O
lymphadenopathy	O
,	O
or	O
pleural	B-DISO
effusion	I-DISO
was	O
demonstrated	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
identified	O
as	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
in	O
Asia	O
early	O
in	O
2003	O
.	O

During	O
November	O
1	O
,	O
2002	O
-	O
April	O
30	O
,	O
2003	O
,	O
a	O
total	O
of	O
5	O
,	O
663	O
SARS	B-DISO
cases	O
were	O
reported	O
to	O
WHO	O
from	O
26	O
countries	O
,	O
including	O
the	O
United	O
States	O
;	O
372	O
deaths	O
(	O
case	O
-	O
fatality	O
proportion	O
:	O
6	O
.	O
6	O
%)	O
have	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
CDC	O
'	O
s	O
interim	O
surveillance	O
case	O
definition	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
updated	O
to	O
include	O
laboratory	O
criteria	O
for	O
evidence	O
of	O
infection	B-DISO
with	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
(	O
Figure	O
,	O
Box	O
).	O

Transmission	O
rates	O
fell	O
during	O
the	O
epidemic	O
,	O
primarily	O
as	O
a	O
result	O
of	O
reductions	O
in	O
population	O
contact	O
rates	O
and	O
improved	O
hospital	B-DISO
infection	I-DISO
control	O
,	O
but	O
also	O
because	O
of	O
more	O
rapid	O
hospital	O
attendance	O
by	O
symptomatic	O
individuals	O
.	O

ABSTRACT	O
:	O
Hong	O
Kong	O
has	O
been	O
severely	O
affected	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

We	O
prospectively	O
followed	O
up	O
the	O
first	O
ten	O
children	O
with	O
SARS	B-DISO
managed	O
during	O
the	O
early	O
phase	O
of	O
the	O
epidemic	O
in	O
Hong	O
Kong	O
.	O

Persistent	B-DISO
fever	I-DISO
,	O
cough	B-DISO
,	O
progressive	O
radiographic	O
changes	O
of	O
chest	O
and	O
lymphopenia	B-DISO
were	O
noted	O
in	O
all	O
patients	O
.	O

The	O
children	O
were	O
treated	O
with	O
high	O
-	O
dose	O
ribavirin	O
,	O
oral	O
prednisolone	O
,	O
or	O
intravenous	O
methylprednisolone	O
,	O
with	O
no	O
short	O
-	O
term	O
adverse	B-DISO
effects	I-DISO
.	O

These	O
results	O
indicate	O
that	O
stem	O
-	O
loop	O
III	O
in	O
the	O
BCoV	O
5	O
'	O
UTR	O
is	O
a	O
cis	B-DISO
-	O
acting	O
element	O
for	O
DI	O
RNA	O
replication	O
and	O
that	O
its	O
associated	O
intra	O
-	O
5	O
'	O
UTR	O
ORF	O
may	O
function	O
to	O
enhance	O
replication	O
.	O

During	O
the	O
surveillance	O
period	O
,	O
15	O
individuals	O
(	O
10	O
hospital	O
staff	O
,	O
3	O
patients	O
and	O
2	O
visitors	O
)	O
were	O
identified	O
as	O
meeting	O
the	O
case	O
definition	O
for	O
probable	O
or	O
suspected	O
SARS	B-DISO
,	O
in	O
addition	O
to	O
our	O
index	O
case	O
.	O

TITLE	O
:	O
Effects	O
of	O
albumin	O
and	O
Ringer	O
'	O
s	O
lactate	O
on	O
production	O
of	O
lung	O
cytokines	O
and	O
hydrogen	O
peroxide	O
after	O
resuscitated	O
hemorrhage	B-DISO
and	O
endotoxemia	O
in	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
mechanisms	O
leading	O
to	O
ventilator	O
-	O
induced	O
lung	O
injury	O
after	O
hemorrhage	B-DISO
differ	O
from	O
those	O
after	O
endotoxemia	O
.	O

We	O
have	O
used	O
convalescent	O
sera	O
from	O
several	O
SARS	B-DISO
patients	O
to	O
detect	O
proteins	O
in	O
the	O
culture	O
supernatants	O
from	O
cells	O
exposed	O
to	O
lavage	O
another	O
SARS	B-DISO
patient	O
.	O

Blood	O
tests	O
showed	O
lymphopenia	B-DISO
,	O
mild	O
thrombocytopenia	O
,	O
and	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
with	O
normal	O
d	O
-	O
dimer	O
level	O
.	O

His	O
chest	O
condition	B-DISO
gradually	O
responded	O
to	O
ribavirin	O
and	O
corticosteroids	O
,	O
and	O
serial	O
chest	O
X	O
-	O
ray	O
showed	O
resolving	O
pulmonary	B-DISO
infiltrates	I-DISO
.	O

TITLE	O
:	O
Hiding	O
in	O
the	O
bunker	O
:	O
Challenges	O
for	O
a	O
radiation	O
oncology	O
department	O
operating	O
in	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
outbreak	O
.	O

The	O
time	O
between	O
onset	O
of	O
symptoms	O
and	O
admission	O
to	O
hospital	O
did	O
not	O
alter	O
outcome	O
,	O
but	O
shorter	O
intervals	O
will	O
be	O
important	O
to	O
the	O
wider	O
population	O
by	O
restricting	O
the	O
infectious	B-DISO
period	O
before	O
patients	O
are	O
placed	O
in	O
quarantine	O
.	O

SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
faeces	O
was	O
seen	O
on	O
RT	O
-	O
PCR	O
in	O
65	O
(	O
97	O
%)	O
of	O
67	O
patients	O
at	O
day	O
14	O
.	O

Evidence	O
of	O
infection	B-DISO
with	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
human	O
metapneumovirus	O
was	O
sought	O
by	O
reverse	O
-	O
transcriptase	O
PCR	O
and	O
serology	O
.	O

All	O
six	O
patients	O
had	O
serological	O
evidence	O
of	O
recent	O
infection	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
was	O
common	O
but	O
not	O
universal	O
.	O

The	O
presence	O
of	O
haemophagocytosis	B-DISO
supports	O
the	O
contention	O
that	O
cytokine	O
dysregulation	O
may	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
the	O
severity	O
of	O
the	O
clinical	O
disease	O
.	O

Common	O
variant	O
sequences	O
at	O
four	O
loci	O
define	O
two	O
distinct	O
genotypes	O
of	O
the	O
SARS	B-DISO
virus	O
.	O

TITLE	O
:	O
Survival	O
of	O
severe	O
ARDS	B-DISO
with	O
five	O
-	O
organ	O
system	O
failure	O
following	O
burns	O
and	O
inhalation	O
injury	O
in	O
a	O
15	O
-	O
year	O
-	O
old	O
patient	O
.	O

ABSTRACT	O
:	O
To	O
show	O
the	O
effectiveness	O
of	O
an	O
integrated	O
therapeutical	O
approach	O
in	O
a	O
severe	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
following	O
burns	O
,	O
inhalation	O
injury	O
with	O
therapy	O
-	O
refractory	O
oxygenation	O
under	O
maximized	O
ventilatory	O
settings	O
,	O
and	O
an	O
overall	O
complicated	O
clinical	O
course	O
.	O

TITLE	O
:	O
Detection	O
of	O
a	O
group	O
2	O
coronavirus	O
in	O
dogs	O
with	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

Serological	O
analysis	O
showed	O
that	O
the	O
presence	O
of	O
antibodies	O
against	O
CRCV	O
on	O
the	O
day	O
of	O
entry	O
into	O
the	O
kennel	O
decreased	O
the	O
risk	O
of	O
developing	O
respiratory	B-DISO
disease	I-DISO
.	O

CONCLUSIONS	O
:	O
With	O
careful	O
monitoring	O
and	O
adjusting	O
of	O
the	O
nutritional	O
plan	B-DISO
,	O
a	O
hypermetabolic	O
complex	O
trauma	O
patient	O
with	O
an	O
open	O
abdomen	O
can	O
be	O
fed	O
optimally	O
,	O
safely	O
,	O
and	O
successfully	O
despite	O
increased	O
bowel	O
edema	B-DISO
and	O
multiple	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
chemotherapy	O
for	O
lung	B-DISO
metastases	I-DISO
from	O
non	B-DISO
-	I-DISO
seminomatous	I-DISO
germ	I-DISO
-	I-DISO
cell	I-DISO
tumors	I-DISO
.	O

During	O
a	O
10	O
-	O
year	O
period	O
,	O
16	O
consecutive	O
patients	O
with	O
diffuse	O
lung	B-DISO
metastases	I-DISO
from	O
a	O
NSGCT	O
were	O
admitted	O
to	O
the	O
ICU	O
for	O
respiratory	B-DISO
distress	I-DISO
and	O
high	O
-	O
risk	O
chemotherapy	O
.	O

Nine	O
patients	O
developed	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
within	O
3	O
days	O
of	O
the	O
initiation	O
of	O
chemotherapy	O
,	O
while	O
the	O
respiratory	O
status	O
of	O
the	O
seven	O
other	O
patients	O
improved	O
.	O

Refractory	O
hypoxemia	O
and	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
were	O
the	O
leading	O
causes	O
of	O
death	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proven	O
useful	O
for	O
detection	O
of	O
Sendai	O
virus	O
and	O
PVM	O
immunodeficient	B-DISO
animals	O
and	O
contaminated	O
biomaterials	O
.	O

ABSTRACT	O
:	O
Gamma	O
interferon	O
-	O
deficient	O
(	O
IFN	O
-	O
gamma	O
KO	O
)	O
mice	O
developed	O
a	O
wasting	B-DISO
syndrome	I-DISO
and	O
were	O
found	O
to	O
be	O
co	O
-	O
infected	O
with	O
Helicobacter	O
sp	O
.,	O
and	O
a	O
new	O
isolate	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
designated	O
MHV	O
-	O
G	O
.	O
The	O
disease	O
was	O
characterized	O
by	O
pleuritis	B-DISO
,	O
peritonitis	B-DISO
,	O
hepatitis	B-DISO
,	O
pneumonia	B-DISO
,	O
and	O
meningitis	B-DISO
.	O

Initial	O
experiments	O
used	O
a	O
cecal	O
homogenate	O
inoculum	O
from	O
the	O
clinical	O
cases	O
that	O
contained	O
H	O
.	O
hepaticus	O
and	O
MHV	O
-	O
G	O
to	O
reproduce	O
the	O
development	O
of	O
peritonitis	B-DISO
and	O
pleuritis	B-DISO
in	O
IFN	O
-	O
gamma	O
KO	O
mice	O
.	O

This	O
result	O
confirmed	O
the	O
importance	O
of	O
IFN	O
-	O
gamma	O
in	O
preventing	O
chronic	B-DISO
infection	I-DISO
and	O
limiting	O
viral	O
dissemination	O
.	O

SARS	B-DISO
and	O
safety	O
.	O

Screening	O
programs	O
in	O
cheetah	O
populations	O
for	O
feline	O
coronavirus	B-DISO
infection	I-DISO
may	O
be	O
most	O
reliable	O
if	O
a	O
combination	O
of	O
serologic	O
analysis	O
and	O
viral	O
detection	O
by	O
polymerase	O
chain	O
reaction	O
is	O
used	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
major	O
histocompatibility	O
complex	O
(	O
anti	O
-	O
MHC	O
)	O
antibodies	O
(	O
Abs	O
)	O
and	O
antipolymorphonuclear	O
neutrophil	O
(	O
anti	O
-	O
PMN	O
)	O
Abs	O
are	O
generally	O
considered	O
as	O
the	O
main	O
causes	O
of	O
the	O
development	O
of	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
),	O
which	O
is	O
one	O
of	O
the	O
most	O
severe	O
and	O
sometimes	O
lethal	O
side	O
effects	O
of	O
transfusion	O
.	O

The	O
binding	O
for	O
one	O
protein	O
-	O
protein	O
interaction	O
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
.	O

The	O
probable	O
genomic	O
packaging	O
signal	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
analogous	O
to	O
that	O
of	O
MHV	O
and	O
BCoV	O
,	O
with	O
the	O
corresponding	O
secondary	O
RNA	O
structure	O
locating	O
at	O
the	O
similar	O
region	O
of	O
ORF1b	O
.	O

ABSTRACT	O
:	O
To	O
constructed	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
model	O
for	O
the	O
3C	O
like	O
(	O
3CL	O
)	O
proteinase	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
to	O
design	O
inhibitors	O
of	O
the	O
3CL	O
proteinase	O
based	O
on	O
the	O
3D	O
model	O
.	O

Targeting	O
to	O
the	O
3D	O
model	O
and	O
its	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
main	O
proteinase	O
(	O
Mpro	O
)	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
virtual	O
screening	O
was	O
performed	O
employing	O
molecular	O
docking	O
method	O
to	O
identify	O
possible	O
3CL	O
proteinase	O
inhibitors	O
from	O
small	O
molecular	O
databases	O
.	O

RESULTS	O
:	O
Sequence	O
alignment	O
indicated	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
proteinase	O
was	O
extremely	O
homologous	O
to	O
TGEV	O
Mpro	O
,	O
especially	O
the	O
substrate	O
-	O
binding	O
pocket	O
(	O
active	O
site	O
).	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	O
inhibitors	O
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	O
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
proteinase	O
.	O

In	O
particular	O
,	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
SARS	B-DISO
E	O
protein	O
is	O
much	O
more	O
similar	O
to	O
that	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
other	O
mammal	O
coronaviruses	O
.	O

Magnetic	O
resonance	O
angiography	O
(	O
MRA	O
)	O
showed	O
significant	O
narrowing	O
in	O
the	O
distal	O
abdominal	O
aorta	O
with	O
bilateral	O
renal	O
and	O
common	O
iliac	O
artery	B-DISO
occlusions	I-DISO
.	O

The	O
initial	O
presentation	O
of	O
Takayasu	B-DISO
arteritis	I-DISO
as	O
a	O
pulmonary	B-DISO
-	I-DISO
renal	I-DISO
syndrome	I-DISO
with	O
severe	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
diffuse	O
pulmonary	B-DISO
hemorrhage	I-DISO
is	O
unusual	O
;	O
to	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
been	O
described	O
previously	O
in	O
the	O
literature	O
.	O

TITLE	O
:	O
Recombinant	O
platelet	O
-	O
activating	O
factor	O
acetylhydrolase	O
to	O
prevent	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
mortality	O
in	O
severe	B-DISO
sepsis	I-DISO
:	O
Phase	O
IIb	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
clinical	O
trial	O
.	O

ABSTRACT	O
:	O
Platelet	O
-	O
activating	O
factor	O
(	O
PAF	B-DISO
)	O
is	O
a	O
potent	O
proinflammatory	O
mediator	O
implicated	O
in	O
the	O
pathogenesis	B-DISO
of	O
both	O
severe	B-DISO
sepsis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISO
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
.	O

A	O
total	O
of	O
127	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
,	O
but	O
without	O
established	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

TITLE	O
:	O
[	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
November	O
2002	O
an	O
epidemic	O
of	O
a	O
new	O
severe	O
respiratory	B-DISO
infection	I-DISO
has	O
taken	O
place	O
primarily	O
in	O
South	O
-	O
East	O
Asia	O
.	O

The	O
ascending	B-DISO
aortic	I-DISO
aneurysm	I-DISO
ruptured	O
in	O
the	O
ambulance	O
while	O
she	O
was	O
transferred	O
to	O
our	O
hospital	O
.	O

In	O
this	O
article	O
,	O
we	O
present	O
a	O
brief	O
summary	O
on	O
the	O
biological	O
characteristics	O
of	O
coronavirus	O
with	O
its	O
associated	O
diseases	O
,	O
and	O
make	O
some	O
suggestions	O
on	O
how	O
to	O
curb	B-DISO
this	O
outbreak	O
and	O
how	O
to	O
cure	O
SARS	B-DISO
disease	O
based	O
on	O
the	O
potential	O
targets	O
of	O
this	O
novel	O
virus	O
.	O

TITLE	O
:	O
A	O
recombinant	O
fowl	O
adenovirus	B-DISO
expressing	O
the	O
S1	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
protects	O
against	O
challenge	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
and	O
cystic	B-DISO
fibrosis	I-DISO
(	O
CF	O
)	O
are	O
progressive	O
and	O
frequently	O
fatal	O
disorders	O
,	O
which	O
have	O
,	O
at	O
present	O
,	O
few	O
effective	O
therapeutic	O
methods	O
.	O

SARS	B-DISO
originated	O
in	O
Guangdong	O
Province	O
,	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
at	O
the	O
end	O
of	O
2002	O
.	O

Identification	O
of	O
the	O
SARS	B-DISO
causative	O
agent	O
and	O
development	O
of	O
a	O
diagnostic	O
test	O
are	O
important	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
three	O
decades	O
we	O
have	O
seen	O
several	O
viral	O
(	O
and	O
bacterial	O
;	O
i	O
.	O
e	O
.	O
TB	O
)	O
epidemics	O
which	O
took	O
place	O
at	O
an	O
era	O
where	O
we	O
would	O
have	O
expected	O
the	O
eradication	O
of	O
many	O
infectious	B-DISO
diseases	I-DISO
.	O

Is	O
it	O
a	O
mistake	O
or	O
a	O
terror	O
acts	O
of	O
leakage	B-DISO
of	O
viral	O
mutant	B-DISO
from	O
research	O
or	O
other	O
laboratories	O
?	O

TITLE	O
:	O
Update	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
United	O
States	O
,	O
June	O
4	O
,	O
2003	O
.	O

TITLE	O
:	O
Update	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
United	O
States	O
,	O
May	O
14	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
The	O
Singapore	O
Ministry	O
of	O
Health	O
(	O
MOH	O
),	O
with	O
assistance	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
),	O
has	O
been	O
investigating	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

This	O
report	O
updates	O
information	O
on	O
reported	O
U	O
.	O
S	O
.	O
SARS	B-DISO
cases	O
.	O

TITLE	O
:	O
mRNA	O
cap	B-DISO
-	O
1	O
methyltransferase	O
in	O
the	O
SARS	B-DISO
genome	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
viral	B-DISO
disease	I-DISO
,	O
observed	O
primarily	O
in	O
Southern	O
China	O
in	O
November	O
2002	O
,	O
with	O
variable	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
and	O
pneumonia	B-DISO
,	O
in	O
approx	O
.	O

TITLE	O
:	O
Hemophagocytic	O
lymphohistiocytic	O
syndrome	B-DISO
:	O
Unrecognized	O
cause	O
of	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

After	O
admission	O
to	O
the	O
PICU	O
,	O
seven	O
patients	O
(	O
63	O
%)	O
were	O
diagnosed	O
as	O
suffering	B-DISO
with	O
HLS	O
and	O
each	O
had	O
one	O
or	O
more	O
organ	O
failures	O
(	O
patients	O
3	O
-	O
7	O
,	O
9	O
,	O
and	O
10	O
).	O

TITLE	O
:	O
Glycyrrhizin	O
,	O
an	O
active	O
component	O
of	O
liquorice	O
roots	O
,	O
and	O
replication	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
SARS	B-DISO
warrants	O
the	O
search	O
for	O
antiviral	O
compounds	O
to	O
treat	O
the	O
disease	O
.	O

Of	O
all	O
the	O
compounds	O
,	O
glycyrrhizin	O
was	O
the	O
most	O
active	O
in	O
inhibiting	O
replication	O
of	O
the	O
SARS	B-DISO
-	O
associated	O
virus	O
.	O

Within	O
1	O
h	O
of	O
CEES	O
infusion	O
at	O
4	O
mg	O
/	O
kg	O
,	O
high	O
levels	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
ceramides	O
,	O
and	O
nuclear	O
factor	O
kappaB	O
accumulated	O
in	O
lung	O
and	O
alveolar	O
macrophages	O
.	O

TITLE	O
:	O
Update	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
United	O
States	O
,	O
June	O
18	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
clinical	O
and	O
radiological	O
features	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
evaluate	O
the	O
accuracy	O
of	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
guidelines	O
on	O
defining	O
cases	O
of	O
SARS	B-DISO
.	O

Of	O
the	O
556	O
people	O
,	O
141	O
were	O
admitted	O
to	O
hospital	O
,	O
and	O
97	O
had	O
confirmed	O
SARS	B-DISO
.	O

Between	O
November	O
16	O
,	O
2002	O
and	O
April	O
16	O
,	O
2003	O
,	O
there	O
had	O
been	O
13	O
index	O
cases	O
of	O
SARS	B-DISO
including	O
3	O
cadres	O
,	O
3	O
farmers	O
,	O
2	O
retirees	O
,	O
2	O
workers	O
and	O
1	O
shop	O
attendant	O
,	O
reported	O
from	O
13	O
cities	O
in	O
Guangdong	O
province	O
.	O

All	O
of	O
the	O
cases	O
had	O
no	O
close	O
contacts	O
to	O
similar	O
patients	O
but	O
6	O
of	O
them	O
later	O
caused	O
2nd	O
or	O
even	O
3rd	O
generation	O
cases	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
epidemiology	O
and	O
measures	O
for	O
control	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Guangzhou	O
city	O
].	O

Relevant	O
research	O
also	O
indicated	O
that	O
SARS	B-DISO
could	O
be	O
classified	O
as	O
an	O
air	O
-	O
borne	O
infectious	B-DISO
disease	I-DISO
,	O
transmitted	B-DISO
through	O
aerosol	O
and	O
droplets	O
,	O
but	O
close	O
contact	O
also	O
played	O
an	O
important	O
role	O
in	O
the	O
mode	O
of	O
transmission	O
.	O

Onset	O
of	O
symptoms	O
in	O
4	O
of	O
our	O
patients	O
who	O
could	O
clearly	O
identify	O
only	O
a	O
single	O
contact	O
with	O
a	O
patient	O
with	O
SARS	B-DISO
occurred	O
on	O
average	O
4	O
(	O
SD	O
3	O
)	O
days	O
after	O
exposure	O
.	O

At	O
a	O
follow	O
-	O
up	O
examination	O
3	O
weeks	O
after	O
discharge	O
(	O
5	O
weeks	O
after	O
onset	O
of	O
illness	O
),	O
all	O
patients	O
were	O
no	O
longer	O
weak	O
but	O
continued	O
to	O
become	O
fatigued	B-DISO
easily	O
and	O
had	O
dyspnea	B-DISO
on	O
minimal	O
exertion	O
.	O

Clinical	O
laboratory	O
features	O
of	O
SARS	B-DISO
include	O
lymphopenia	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
lactate	O
dehydrogenase	O
levels	O
.	O

ABSTRACT	O
:	O
The	O
Authors	O
report	O
a	O
case	O
of	O
acute	O
White	O
-	O
Spirit	O
poisoning	O
with	O
pulmonary	B-DISO
hypertension	I-DISO
associated	O
to	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
mRNA	O
was	O
successfully	O
amplified	O
and	O
encapsidated	O
,	O
indicating	O
that	O
the	O
first	O
649	O
nt	O
of	O
TGEV	O
genome	O
also	O
contained	O
the	O
5	O
'	O
cis	B-DISO
-	O
acting	O
replication	O
signals	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
children	O
:	O
experience	O
in	O
a	O
regional	O
hospital	O
in	O
Hong	O
Kong	O
.	O

This	O
insertion	O
resulted	O
in	O
a	O
frameshift	B-DISO
event	O
and	O
therefore	O
,	O
if	O
expressed	O
,	O
a	O
C	O
-	O
terminally	O
truncated	O
protein	O
.	O

We	O
showed	O
that	O
the	O
frameshifting	O
product	O
,	O
cloned	O
in	O
a	O
plasmid	O
,	O
was	O
expressed	O
in	O
vitro	O
and	O
in	O
cells	O
transfected	O
with	O
the	O
mutant	B-DISO
construct	O
.	O

Of	O
the	O
three	O
enveloped	O
viruses	O
tested	O
,	O
human	O
herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
),	O
bovine	O
parainfluenza	B-DISO
virus	O
type	O
3	O
and	O
porcine	O
respiratory	O
corona	O
virus	O
,	O
only	O
HSV	O
-	O
1	O
proved	O
sensitive	O
to	O
the	O
3	O
-	O
HP	O
-	O
proteins	O
.	O

However	O
,	O
to	O
achieve	O
HSV	O
-	O
1	O
inhibition	O
,	O
significantly	O
higher	O
concentrations	O
of	O
the	O
modified	O
proteins	O
were	O
required	O
if	O
present	O
before	O
infection	B-DISO
as	O
compared	O
to	O
during	O
or	O
after	O
infection	B-DISO
.	O

(	O
3	O
)	O
Timely	O
administration	O
of	O
Ribavirin	O
,	O
Methylprednisolone	O
,	O
immunoenhancer	O
(	O
such	O
as	O
interferon	O
alpha	O
-	O
2b	O
,	O
thymosin	O
-	O
alpha1	O
)	O
to	O
SARS	B-DISO
patients	O
was	O
efficacious	O
to	O
certain	O
extent	O
in	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

Early	O
discovery	O
of	O
SARS	B-DISO
,	O
early	O
isolation	O
of	O
SARS	B-DISO
patients	O
,	O
and	O
early	O
treatment	O
are	O
very	O
helpful	O
to	O
improving	O
patient	O
'	O
s	O
prognosis	O
and	O
controlling	O
SARS	B-DISO
overspread	O
.	O

(	O
3	O
)	O
Timely	O
administration	O
of	O
Ribavirin	O
,	O
Methylprednisolone	O
,	O
immunoenhancer	O
(	O
such	O
as	O
interferon	O
alpha	O
-	O
2b	O
,	O
thymosin	O
-	O
alpha1	O
)	O
to	O
SARS	B-DISO
patients	O
was	O
efficacious	O
to	O
certain	O
extent	O
in	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

RESULTS	O
:	O
The	O
following	O
factors	O
were	O
associated	O
with	O
a	O
significantly	O
higher	O
mortality	O
rate	O
in	O
the	O
SARS	B-DISO
with	O
ARDS	B-DISO
patients	O
,	O
including	O
age	O
increase	O
(	O
OR	O
=	O
1	O
.	O
203	O
,	O
CI	O
=	O
1	O
.	O
036	O
to	O
1	O
.	O
396	O
,	O
P	O
=	O
0	O
.	O
016	O
),	O
long	O
-	O
time	O
hypoxia	B-DISO
(	O
OR	O
=	O
1	O
.	O
067	O
,	O
CI	O
=	O
1	O
.	O
014	O
to	O
1	O
.	O
122	O
,	O
P	O
=	O
0	O
.	O
013	O
),	O
thrombocytopenia	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
hypernatremia	B-DISO
(	O
OR	O
=	O
26	O
.	O
667	O
,	O
CI	O
=	O
2	O
.	O
242	O
to	O
317	O
.	O
147	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
and	O
elevation	O
of	O
serum	O
creatinine	O
levels	O
(	O
OR	O
=	O
111	O
.	O
932	O
,	O
CI	O
=	O
6	O
.	O
096	O
to	O
2	O
055	O
.	O
252	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

From	O
December	O
2002	O
to	O
April	O
2003	O
in	O
Guangzhou	O
Institute	O
of	O
Respiratory	B-DISO
Disease	I-DISO
,	O
38	O
patients	O
with	O
severe	O
SARS	B-DISO
were	O
retrospectively	O
studied	O
to	O
evaluate	O
the	O
relationship	O
between	O
treatment	O
strategy	O
and	O
prognosis	O
.	O

Thirty	O
cases	O
were	O
cured	O
(	O
78	O
.	O
9	O
%),	O
of	O
them	O
11	O
cases	O
had	O
pulmonary	B-DISO
fibrosis	I-DISO
(	O
36	O
.	O
7	O
%),	O
8	O
patients	O
died	O
(	O
21	O
.	O
1	O
%)	O
in	O
all	O
cases	O
.	O

It	O
is	O
appeared	O
that	O
corticosteroid	O
therapy	O
has	O
no	O
marked	O
effect	O
on	O
the	O
development	O
of	O
chest	O
radiogram	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

The	O
clinical	O
data	O
from	O
all	O
patients	O
with	O
ARDS	B-DISO
in	O
medical	O
ICU	O
(	O
MICU	O
)	O
during	O
May	O
2000	O
to	O
Aug	O
.	O
2002	O
were	O
collected	O
.	O

The	O
percentage	O
of	O
patients	O
died	O
primarily	O
of	O
ARDS	B-DISO
was	O
low	O
in	O
both	O
groups	O
(	O
7	O
.	O
0	O
%	O
and	O
11	O
.	O
1	O
%).	O

GC	O
could	O
be	O
one	O
of	O
effective	O
treatments	O
for	O
ARDS	B-DISO
,	O
and	O
it	O
should	O
be	O
given	O
without	O
hesitation	O
when	O
refractory	O
hypoxemia	O
and	O
shock	O
were	O
found	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
epidemiology	O
,	O
clinical	O
presentation	O
,	O
management	O
,	O
and	O
infection	B-DISO
control	O
measures	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
recognized	O
febrile	O
respiratory	O
illness	O
that	O
first	O
appeared	O
in	O
southern	O
China	O
in	O
November	O
2002	O
,	O
has	O
since	O
spread	O
to	O
several	O
countries	O
,	O
and	O
has	O
resulted	O
in	O
more	O
than	O
8000	O
cases	O
and	O
more	O
than	O
750	O
deaths	O
.	O

Hematological	O
changes	O
in	O
patients	O
with	O
SARS	B-DISO
were	O
common	O
and	O
included	O
lymphopenia	B-DISO
(	O
68	O
%	O
-	O
90	O
%	O
of	O
adults	O
;	O
100	O
%	O
of	O
children	O
,	O
n	O
=	O
10	O
),	O
thrombocytopenia	O
(	O
20	O
%	O
-	O
45	O
%	O
of	O
adults	O
,	O
50	O
%	O
of	O
children	O
),	O
and	O
leukopenia	B-DISO
(	O
20	O
%	O
-	O
34	O
%	O
of	O
adults	O
,	O
70	O
%	O
of	O
children	O
).	O

Systemic	O
toxic	O
changes	O
included	O
degeneration	B-DISO
and	O
necrosis	O
of	O
the	O
parenchyma	O
cells	O
in	O
the	O
lung	O
,	O
liver	O
,	O
kidney	O
,	O
heart	O
,	O
and	O
adrenal	O
gland	O
.	O

Among	O
the	O
207	O
contacts	O
of	O
the	O
index	O
cases	O
through	O
different	O
generations	O
,	O
there	O
were	O
36	O
cases	O
of	O
SARS	B-DISO
(	O
attack	O
rate	O
17	O
%)	O
patients	O
with	O
one	O
death	O
.	O

The	O
characteristics	O
of	O
SARS	B-DISO
distribution	O
in	O
time	O
,	O
place	O
and	O
population	O
in	O
Shanxi	O
were	O
described	O
.	O

In	O
Shanxi	O
province	O
,	O
the	O
SARS	B-DISO
epidemic	O
seemed	O
to	O
have	O
had	O
the	O
following	O
stages	O
:	O
importation	O
of	O
the	O
first	O
case	O
,	O
gradual	O
increase	O
of	O
the	O
number	O
of	O
cases	O
to	O
reach	O
the	O
peak	O
and	O
decreasing	O
.	O

CONCLUSIONS	O
:	O
In	O
Shanxi	O
province	O
,	O
the	O
SARS	B-DISO
epidemic	O
seemed	O
to	O
have	O
had	O
the	O
following	O
stages	O
:	O
importation	O
of	O
the	O
first	O
case	O
,	O
gradual	O
increase	O
of	O
the	O
number	O
of	O
cases	O
to	O
reach	O
the	O
peak	O
and	O
decreasing	O
.	O

The	O
first	O
SARS	B-DISO
case	O
was	O
reported	O
in	O
Inner	O
Mongolian	O
Autonomous	O
Region	O
on	O
March	O
27	O
,	O
2003	O
.	O

Another	O
131	O
cases	O
were	O
excluded	O
the	O
original	O
diagnoses	O
of	O
SARS	B-DISO
including	O
10	O
confirmed	O
cases	O
and	O
121	O
suspected	O
cases	O
.	O

One	O
of	O
the	O
major	O
features	O
was	O
that	O
hospitals	O
had	O
become	O
the	O
important	O
sources	O
of	O
secondary	B-DISO
infection	I-DISO
.	O

Finally	O
,	O
the	O
third	O
phase	O
was	O
between	O
April	O
29	O
and	O
May	O
20	O
,	O
with	O
small	O
wave	O
crests	O
of	O
cases	O
,	O
spreading	O
to	O
38	O
counties	O
in	O
10	O
prefectures	O
with	O
a	O
high	O
proportion	O
of	O
cases	O
with	O
no	O
history	O
of	O
direct	O
contact	O
with	O
diagnosed	O
SARS	B-DISO
patients	O
.	O

The	O
main	O
symptoms	B-DISO
and	I-DISO
signs	I-DISO
of	O
the	O
SARS	B-DISO
patients	O
would	O
include	O
fever	O
,	O
cough	B-DISO
and	O
chest	O
X	O
-	O
ray	O
changes	O
.	O

IFA	O
can	O
be	O
used	O
to	O
assist	O
diagnosis	O
of	O
SARS	B-DISO
after	O
10	O
days	O
of	O
the	O
onset	O
of	O
disease	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
pneumonia	B-DISO
can	O
manifest	O
as	O
focal	O
peripheral	O
consolidation	O
that	O
clears	O
relatively	O
quickly	O
and	O
does	O
not	O
cause	O
secondary	O
complications	O
or	O
that	O
progresses	O
to	O
bilateral	O
consolidation	O
and	O
a	O
more	O
protracted	O
clinical	O
course	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
clinical	O
features	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
the	O
value	O
for	O
caring	O
of	O
patients	O
suspected	O
of	O
having	O
this	O
disease	O
.	O

TITLE	O
:	O
An	O
adult	O
model	O
of	O
exclusive	O
viral	O
wheeze	B-DISO
:	O
inflammation	B-DISO
in	O
the	O
upper	O
and	O
lower	O
respiratory	O
tracts	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
an	O
experimental	O
infection	B-DISO
of	O
young	O
adults	O
with	O
a	O
history	O
of	O
episodic	O
and	O
exclusive	O
viral	O
wheeze	B-DISO
(	O
EVW	B-DISO
)	O
using	O
human	O
coronavirus	O
,	O
in	O
which	O
16	O
of	O
24	O
with	O
EVW	B-DISO
(	O
15	O
atopic	B-DISO
)	O
and	O
11	O
of	O
19	O
healthy	O
controls	O
(	O
seven	O
atopic	B-DISO
)	O
developed	O
a	O
symptomatic	O
cold	B-DISO
with	O
evidence	O
of	O
infection	B-DISO
,	O
but	O
only	O
those	O
with	O
EVW	B-DISO
developed	O
lower	O
respiratory	O
tract	O
symptoms	O
and	O
increased	O
airway	O
responsiveness	O
.	O

TITLE	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
a	O
liver	O
transplant	O
recipient	O
and	O
guidelines	O
for	O
donor	O
SARS	B-DISO
screening	O
.	O

We	O
describe	O
a	O
patient	O
post	O
liver	O
transplant	O
who	O
contracted	O
SARS	B-DISO
and	O
died	O
during	O
the	O
outbreak	O
,	O
with	O
subsequent	O
infection	B-DISO
of	O
family	O
and	O
several	O
health	O
-	O
care	O
workers	O
.	O

A	O
screening	O
tool	O
based	O
on	O
potential	O
hospital	O
SARS	B-DISO
exposure	O
,	O
clinical	O
symptoms	O
,	O
and	O
epidemiological	O
exposure	O
was	O
used	O
to	O
stratify	O
donors	O
as	O
high	O
,	O
intermediate	O
or	O
low	O
risk	O
for	O
SARS	B-DISO
.	O

A	O
web	B-DISO
service	O
is	O
provided	O
,	O
by	O
which	O
a	O
user	O
can	O
obtain	O
the	O
annotated	O
result	O
immediately	O
by	O
pasting	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequences	O
into	O
the	O
input	O
window	O
on	O
the	O
web	B-DISO
site	O
(	O
http	O
://	O
tubic	O
.	O
tju	O
.	O
edu	O
.	O
cn	O
/	O
sars	B-DISO
/).	O

ABSTRACT	O
:	O
To	O
assess	O
serum	O
antibody	O
responses	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
nucleocapsid	O
(	O
N	O
)	O
antigen	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

These	O
findings	O
may	O
provide	O
useful	O
information	O
for	O
optimizing	O
supportive	O
care	O
for	O
SARS	B-DISO
-	O
related	O
critical	B-DISO
illness	I-DISO
.	O

Thirty	O
-	O
six	O
cases	O
developed	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
of	O
whom	O
11	O
died	O
.	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
life	O
-	O
threatening	O
respiratory	B-DISO
disease	I-DISO
which	O
has	O
its	O
origins	O
in	O
Guangdong	O
province	O
,	O
China	O
,	O
where	O
the	O
earliest	O
known	O
cases	O
were	O
identified	O
in	O
November	O
2002	O
.	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
the	O
first	O
transmissible	O
disease	O
of	O
the	O
21st	O
century	O
].	O

These	O
ranged	O
from	O
dyspnea	B-DISO
to	O
severe	O
bronchoconstriction	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Our	O
data	O
emphasize	O
the	O
particular	O
prevalence	O
of	O
respiratory	O
involvement	O
in	O
the	O
case	O
of	O
GERD	B-DISO
complicating	O
type	O
2	O
hiatal	B-DISO
hernia	I-DISO
,	O
and	O
also	O
the	O
excellent	O
symptomatic	O
results	O
obtained	O
by	O
surgical	O
therapy	O
for	O
this	O
condition	B-DISO
.	O

In	O
all	O
patients	O
,	O
surgical	O
repair	O
of	O
the	O
hiatal	B-DISO
hernia	I-DISO
,	O
together	O
with	O
an	O
antireflux	O
procedure	O
,	O
resulted	O
in	O
complete	O
resolution	O
of	O
the	O
respiratory	O
complaints	O
for	O
follow	O
-	O
up	O
periods	O
up	O
to	O
160	O
months	O
.	O

The	O
syndrome	B-DISO
has	O
been	O
defined	O
as	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
)	O
by	O
WHO	O
,	O
and	O
is	O
characterized	O
by	O
an	O
incubation	O
period	O
between	O
1	O
and	O
10	O
days	O
(	O
average	O
5	O
days	O
)	O
and	O
by	O
a	O
febrile	O
phase	O
that	O
usually	O
lasts	O
approximately	O
3	O
days	O
.	O

The	O
laboratory	O
findings	O
in	O
SARS	B-DISO
cases	O
include	O
leukopenia	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
a	O
rise	O
in	O
transaminases	O
and	O
lactic	O
dehydrogenase	O
levels	O
.	O

Alimentotherapy	O
,	O
respiratory	O
auxiliaring	O
ventilation	O
,	O
anti	O
-	O
infective	O
and	O
glucocorticoid	O
methods	O
were	O
used	O
in	O
western	O
medicine	O
;	O
Chinese	O
herbal	O
medicine	O
was	O
used	O
according	O
to	O
syndrome	B-DISO
differentiation	O
in	O
traditional	O
Chinese	O
medicine	O
.	O

8	O
.	O
99	O
days	O
,	O
2	O
of	O
whom	O
showed	O
fibroid	B-DISO
cord	B-DISO
-	O
like	O
changes	O
.	O

This	O
patient	O
suffered	B-DISO
from	O
severe	O
ARDS	B-DISO
due	O
to	O
sepsis	B-DISO
.	O

The	O
macrophage	O
-	O
inducible	O
Salmonella	B-DISO
ssaH	O
and	O
spiC	O
/	O
ssaB	O
promoters	O
were	O
compared	O
for	O
their	O
ability	O
to	O
express	O
the	O
TGEV	O
C	O
and	O
A	O
epitopes	O
in	O
the	O
context	O
of	O
the	O
heterologous	O
987P	O
fimbriae	O
on	O
Salmonella	B-DISO
vaccines	O
.	O

The	O
Salmonella	B-DISO
cya	O
crp	O
vaccine	O
vector	O
was	O
shown	O
to	O
incorporate	O
into	O
987P	O
partially	O
degraded	O
chimeric	O
subunits	O
lacking	O
the	O
TGEV	O
epitopes	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
gene	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
Chinju99	O
which	O
was	O
previously	O
isolated	O
in	O
Chinju	O
,	O
Korea	O
was	O
cloned	O
and	O
sequenced	O
to	O
aid	O
in	O
the	O
development	O
of	O
genetically	O
engineered	O
vaccines	O
and	O
diagnostic	O
reagents	O
against	O
PEDV	O
.	O

A	O
retrospective	O
study	O
was	O
conducted	O
on	O
78	O
cases	O
of	O
SARS	B-DISO
referred	O
to	O
the	O
Guangzhou	O
Institute	O
of	O
Respiratory	B-DISO
Diseases	I-DISO
(	O
GIRD	O
)	O
between	O
December	O
22	O
,	O
2002	O
and	O
near	O
the	O
end	O
of	O
March	O
2003	O
.	O

The	O
prevalences	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
,	O
in	O
37	O
cases	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
,	O
21	O
out	O
of	O
37	O
cases	O
)	O
were	O
considerably	O
high	O
among	O
the	O
patients	O
.	O

Seven	O
patients	O
who	O
developed	O
ARDS	B-DISO
complicated	O
with	O
multiple	O
organs	O
dysfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
)	O
died	O
.	O

(	O
5	O
)	O
Leukopenia	B-DISO
was	O
observed	O
in	O
67	O
.	O
7	O
%	O
of	O
this	O
cohort	O
.	O

Early	O
recognition	O
,	O
prompt	O
isolation	O
,	O
and	O
appropriate	O
therapy	O
are	O
the	O
key	O
to	O
combat	O
this	O
infection	B-DISO
.	O

Chest	O
radiography	O
and	O
CT	O
were	O
performed	O
in	O
28	O
patients	O
with	O
SARS	B-DISO
within	O
one	O
to	O
three	O
days	O
after	O
onset	O
of	O
the	O
disease	O
.	O

CT	O
showed	O
single	O
small	O
focal	O
patchy	O
opacities	B-DISO
in	O
23	O
patients	O
(	O
82	O
.	O
1	O
%,	O
23	O
/	O
28	O
),	O
including	O
oval	O
ground	O
-	O
glass	O
opacities	B-DISO
in	O
20	O
patients	O
,	O
lobular	O
distribution	O
ground	O
-	O
glass	O
opacities	B-DISO
in	O
2	O
and	O
small	O
patchy	O
consolidation	O
in	O
one	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
poses	O
a	O
threat	O
to	O
most	O
countries	O
because	O
of	O
easy	O
and	O
convenient	O
travel	O
across	O
the	O
globe	O
in	O
a	O
matter	O
of	O
hours	O
.	O

This	O
report	O
describes	O
the	O
quarantine	O
measures	O
used	O
in	O
Taiwan	O
and	O
discusses	O
the	O
need	O
for	O
further	O
evaluation	O
of	O
quarantine	O
and	O
other	O
control	O
measures	O
used	O
to	O
prevent	O
SARS	B-DISO
.	O

Adverse	O
drug	O
reactions	O
,	O
although	O
frequent	O
,	O
are	O
mild	O
,	O
and	O
include	O
acne	B-DISO
-	O
like	O
skin	B-DISO
rash	I-DISO
and	O
diarrhoea	B-DISO
.	O

A	O
low	O
intensity	O
anticoagulant	O
regimen	O
after	O
mitral	O
valve	O
replacement	O
is	O
advisable	O
in	O
lowering	O
the	O
incidence	O
of	O
anticoagulant	O
related	O
bleeding	B-DISO
,	O
while	O
optimizing	O
sufficient	O
protection	O
against	O
thromboembolic	O
complication	B-DISO
.	O

The	O
exudated	O
organization	O
tended	O
to	O
become	O
glomeruloid	O
organizing	O
pneumonitis	B-DISO
in	O
a	O
few	O
avaoli	O
.	O

The	O
typical	O
pathological	O
changes	O
of	O
lungs	O
were	O
diffuse	B-DISO
hemorrhage	I-DISO
on	O
surface	O
.	O

Pulmonary	O
alveoli	O
became	O
thick	O
with	O
interstitial	O
mononuclear	O
inflammatory	B-DISO
infiltration	I-DISO
,	O
diffused	O
alveoli	O
damage	O
,	O
desquamation	O
of	O
pneumocytes	O
and	O
hyaline	O
-	O
membrane	O
formation	O
.	O

The	O
specific	O
changes	O
included	O
reduction	O
of	O
lymphocytes	O
and	O
hyperplasia	B-DISO
of	O
histiocytes	O
,	O
depletion	O
of	O
the	O
follicles	O
of	O
small	O
intestine	O
and	O
colon	O
wall	O
,	O
decreased	O
hyperplasia	B-DISO
of	O
the	O
bone	O
marrow	O
and	O
increased	O
number	O
of	O
the	O
megakaryocyte	O
.	O

According	O
to	O
the	O
virus	O
-	O
like	O
particles	O
found	O
in	O
lung	O
of	O
the	O
SARS	B-DISO
case	O
,	O
it	O
is	O
considered	O
that	O
these	O
virus	O
-	O
like	O
particles	O
may	O
be	O
a	O
new	O
kind	O
of	O
coronavirus	O
which	O
caused	O
the	O
""""	O
atypical	B-DISO
pneumonia	I-DISO
"""."	O

The	O
supernatant	O
and	O
cultured	O
cells	O
exhibiting	O
identifiable	O
cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
were	O
prepared	O
for	O
electron	O
microscopic	O
study	O
.	O

RESULTS	O
:	O
Examination	O
of	O
CPE	O
cells	O
on	O
thin	O
-	O
section	O
revealed	O
characteristic	O
coronavirus	O
particles	O
within	O
the	O
cisternae	O
of	O
endoplasmic	O
reticulum	O
,	O
Golgi	O
apparatus	O
,	O
vesicles	B-DISO
and	O
extracellular	O
space	O
.	O

When	O
this	O
infection	B-DISO
occurred	O
in	O
IFN	O
-	O
gamma	O
gko	O
mice	O
,	O
the	O
virus	O
was	O
unchecked	O
,	O
and	O
the	O
infection	B-DISO
led	O
to	O
death	O
.	O

However	O
,	O
only	O
the	O
presence	O
of	O
diabetes	B-DISO
mellitus	I-DISO
and	O
/	O
or	O
cardiac	B-DISO
disease	I-DISO
(	O
HR	O
7	O
.	O
3	O
,	O
95	O
%	O
CI	O
3	O
.	O
1	O
to	O
17	O
.	O
4	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
associated	O
with	O
adverse	O
outcomes	O
as	O
a	O
whole	O
.	O

TITLE	O
:	O
[	O
Chlamydia	O
-	O
like	O
and	O
coronavirus	O
-	O
like	O
agents	O
found	O
in	O
dead	O
cases	O
of	O
atypical	B-DISO
pneumonia	I-DISO
by	O
electron	O
microscopy	O
].	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
causative	O
agents	O
of	O
the	O
atypical	B-DISO
pneumonia	I-DISO
(	O
also	O
SARS	B-DISO
)	O
occurred	O
recently	O
in	O
some	O
regions	O
of	O
our	O
country	O
.	O

Since	O
the	O
novel	O
Chlamydia	O
-	O
like	O
agent	O
was	O
found	O
co	O
-	O
existing	O
with	O
a	O
coronavirus	O
-	O
like	O
agent	O
in	O
the	O
dead	O
cases	O
of	O
SARS	B-DISO
,	O
it	O
looks	O
most	O
likely	O
that	O
both	O
the	O
agents	O
play	O
some	O
roles	O
in	O
the	O
disease	O
.	O

METHODS	O
:	O
Organ	O
samples	O
of	O
7	O
dead	O
cases	O
of	O
SARS	B-DISO
were	O
collected	O
from	O
Guangdong	O
,	O
Shanxi	O
,	O
Sichuan	O
Provinces	O
and	O
Beijing	O
for	O
electron	O
microscopic	O
examination	O
.	O

This	O
study	O
delineates	O
clinical	O
characteristics	O
of	O
such	O
fatal	O
cases	O
of	O
SARS	B-DISO
for	O
the	O
purpose	O
of	O
identifying	O
patients	O
with	O
poor	O
outcome	O
.	O

Patients	O
with	O
the	O
diagnosis	O
of	O
probable	O
or	O
suspected	O
SARS	B-DISO
admitted	O
to	O
the	O
Taipei	O
Veterans	O
General	O
Hospital	O
during	O
the	O
period	O
from	O
March	O
26	O
,	O
2003	O
to	O
May	O
25	O
,	O
2003	O
were	O
included	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
,	O
thirty	O
-	O
six	O
probable	O
cases	O
and	O
17	O
suspected	O
cases	O
of	O
SARS	B-DISO
were	O
identified	O
.	O

Common	O
laboratory	O
findings	O
were	O
lymphopenia	B-DISO
,	O
and	O
elevated	O
serum	O
levels	O
of	O
lactate	O
dehydrogenase	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

Otherwise	O
,	O
SARS	B-DISO
easily	O
induces	O
hospital	O
-	O
acquired	O
first	O
then	O
community	B-DISO
-	I-DISO
acquired	I-DISO
infection	I-DISO
.	O

Patient	O
3	O
was	O
a	O
19	O
-	O
yr	O
-	O
old	O
male	O
with	O
pretransplant	O
Hct	O
of	O
43	O
%	O
who	O
received	O
a	O
cadaveric	O
renal	O
transplant	O
after	O
23	O
.	O
5	O
-	O
h	O
cold	B-DISO
-	O
ischemia	B-DISO
;	O
3	O
.	O
5	O
L	O
normal	O
saline	O
was	O
given	O
during	O
surgery	O
.	O

Preferential	O
distribution	O
of	O
nitric	O
oxide	O
and	O
PGI	O
(	O
2	O
)	O
to	O
ventilated	O
areas	O
of	O
the	O
lung	O
causes	O
selective	O
pulmonary	O
vasodilation	B-DISO
,	O
improved	O
ventilation	O
/	O
perfusion	O
matching	O
,	O
and	O
decreased	O
hypoxemia	O
.	O

The	O
damage	O
of	O
liver	O
function	O
in	O
the	O
severe	O
SARS	B-DISO
patients	O
may	O
have	O
close	O
relationship	O
with	O
age	O
.	O

The	O
important	O
chest	O
X	O
-	O
ray	O
imaging	O
features	O
of	O
36	O
patients	O
with	O
severe	O
SARS	B-DISO
included	O
small	O
patch	O
of	O
infiltration	B-DISO
(	O
n	O
=	O
27	O
,	O
75	O
.	O
0	O
%),	O
large	O
patch	O
of	O
infiltration	B-DISO
(	O
n	O
=	O
22	O
,	O
61	O
.	O
1	O
%),	O
large	O
area	O
of	O
lung	B-DISO
consolidation	I-DISO
(	O
n	O
=	O
10	O
,	O
27	O
.	O
3	O
%),	O
interstitial	O
lung	O
lesion	O
(	O
n	O
=	O
26	O
,	O
72	O
.	O
2	O
%),	O
ground	O
-	O
glass	O
shadow	O
(	O
n	O
=	O
28	O
,	O
77	O
.	O
8	O
%),	O
irregular	O
linear	O
opacity	B-DISO
(	O
n	O
=	O
15	O
,	O
41	O
.	O
7	O
%),	O
diffuse	O
lung	O
lesion	O
(	O
n	O
=	O
12	O
,	O
33	O
.	O
3	O
%),	O
with	O
single	O
lung	O
involved	O
(	O
n	O
=	O
9	O
,	O
25	O
.	O
0	O
%),	O
and	O
both	O
lungs	O
involved	O
(	O
n	O
=	O
32	O
,	O
88	O
.	O
9	O
%).	O

Decrease	O
of	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
lymphocytes	O
of	O
patients	O
is	O
related	O
to	O
onset	O
of	O
SARS	B-DISO
.	O

RESULTS	O
:	O
A	O
significant	O
decrease	O
was	O
observed	O
in	O
all	O
SARS	B-DISO
patients	O
in	O
their	O
peripheral	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
lymphocyte	O
absolute	O
counts	O
[	O
256	O
(	O
104	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
and	O
256	O
(	O
117	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
,	O
respectively	O
],	O
which	O
were	O
also	O
lower	O
than	O
those	O
of	O
the	O
patients	O
infected	O
with	O
HIV	B-DISO
,	O
CMV	O
and	O
EBV	O
.	O

All	O
patients	O
infected	O
with	O
HIV	B-DISO
,	O
CMV	O
and	O
EBV	O
had	O
significantly	O
higher	O
CD8	O
(+)	O
T	O
lymphocyte	O
counts	O
in	O
comparison	O
with	O
normal	O
controls	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
and	O
imaging	O
characteristics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
to	O
study	O
their	O
relationship	O
.	O

After	O
treatment	O
,	O
most	O
lesions	O
were	O
absorbed	O
completely	O
,	O
but	O
slowly	O
in	O
patients	O
with	O
multi	O
-	O
lobe	O
consolidation	O
and	O
/	O
or	O
extensive	O
interstitial	O
infiltration	B-DISO
.	O

After	O
treatment	O
,	O
most	O
lesions	O
were	O
absorbed	O
completely	O
,	O
but	O
slowly	O
in	O
patients	O
with	O
multi	O
-	O
lobe	O
consolidation	O
and	O
/	O
or	O
extensive	O
interstitial	O
infiltration	B-DISO
.	O

We	O
studied	O
interactions	O
between	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
E	O
and	O
M	O
proteins	O
using	O
in	O
vivo	O
crosslinking	O
and	O
VLP	O
assembly	O
assays	O
.	O

RESULTS	O
:	O
Five	O
children	O
and	O
3	O
adults	O
with	O
traumatic	O
injury	O
and	O
ARDS	B-DISO
received	O
ECMO	O
support	O
.	O

SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
was	O
diagnosed	O
in	O
329	O
(	O
75	O
%)	O
of	O
436	O
patients	O
fitting	B-DISO
the	O
case	O
definition	O
of	O
SARS	B-DISO
;	O
human	O
metapneumovirus	O
was	O
diagnosed	O
in	O
41	O
(	O
12	O
%)	O
of	O
335	O
,	O
and	O
other	O
respiratory	O
pathogens	O
were	O
diagnosed	O
only	O
sporadically	O
.	O

Replication	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
macaques	O
of	O
pneumonia	B-DISO
similar	O
to	O
that	O
in	O
human	O
beings	O
with	O
SARS	B-DISO
,	O
combined	O
with	O
the	O
high	O
prevalence	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
SARS	B-DISO
patients	O
,	O
fulfill	O
the	O
criteria	O
required	O
to	O
prove	O
that	O
SARS	B-DISO
-	O
CoV	O
is	O
the	O
primary	O
cause	O
of	O
SARS	B-DISO
.	O

Five	O
months	O
later	O
,	O
the	O
patient	O
returned	O
with	O
another	O
episode	O
of	O
severe	O
bronchospasm	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	O
disease	O
,	O
which	O
was	O
first	O
recognized	O
in	O
Guangdong	O
Province	O
,	O
China	O
,	O
in	O
November	O
2002	O
.	O

A	O
broad	O
body	O
of	O
knowledge	O
originating	O
from	O
research	O
in	O
veterinary	O
medicine	O
indicates	O
that	O
development	O
of	O
vaccines	O
against	O
the	O
SARS	B-DISO
-	O
coronavirus	O
may	O
be	O
problematic	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiologic	O
features	O
of	O
34	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Beijing	O
.	O

Fever	O
,	O
lymphopenia	B-DISO
,	O
low	O
serum	O
iron	O
and	O
chest	O
radiograph	O
are	O
helpful	O
to	O
diagnose	O
SARS	B-DISO
early	O
;	O
age	O
is	O
the	O
independent	O
predictor	O
of	O
an	O
outcome	O
.	O

A	O
total	O
of	O
106	O
cases	O
of	O
SARS	B-DISO
were	O
analyzed	O
prospectively	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
effect	O
of	O
glucocorticoid	O
(	O
methylprednisolone	O
)	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Before	O
treatment	O
by	O
methylprednisolone	O
,	O
the	O
counts	O
of	O
CD	O
(	O
4	O
)(+),	O
CD	O
(	O
8	O
)(+)	O
and	O
CD	O
(	O
3	O
)(+)	O
of	O
27	O
SARS	B-DISO
patients	O
were	O
(	O
401	O
+/-	O
203	O
),	O
(	O
340	O
+/-	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
190	O
cases	O
of	O
outbreak	O
with	O
atypical	B-DISO
pneumonia	I-DISO
in	O
Guangzhou	O
in	O
spring	O
,	O
2003	O
].	O

ABSTRACT	O
:	O
To	O
study	O
methods	O
of	O
diagnosis	O
and	O
treatment	O
for	O
atypical	B-DISO
pneumonia	I-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
),	O
outbreak	O
of	O
the	O
illness	O
in	O
Guangzhou	O
during	O
Jan	O
.	O
-	O
Mar	B-DISO
.,	O
2003	O
.	O

Other	O
46	O
cases	O
were	O
accompanied	O
by	O
diarrhea	B-DISO
.	O

Of	O
these	O
cases	O
,	O
36	O
cases	O
develop	O
to	O
ARDS	B-DISO
and	O
11	O
cases	O
died	O
with	O
severity	O
ARDS	B-DISO
.	O

The	O
possible	O
death	O
-	O
related	O
risk	O
factors	O
including	O
age	O
,	O
underlying	O
diseases	O
,	O
leucocytosis	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
lymphopenia	B-DISO
were	O
analyzed	O
by	O
the	O
Mantel	O
-	O
Haenszel	O
chi	O
(	O
2	O
)	O
test	O
.	O

Clinical	O
symptoms	O
of	O
these	O
patients	O
were	O
fever	O
(	O
100	O
%),	O
coughing	B-DISO
(	O
88	O
%),	O
and	O
dyspnea	B-DISO
(	O
80	O
%).	O

A	O
history	O
of	O
close	O
contact	O
,	O
fever	O
,	O
X	O
-	O
ray	O
signs	O
of	O
pneumonia	B-DISO
and	O
normal	O
or	O
lowered	O
WBC	O
counts	O
are	O
favorable	O
for	O
the	O
diagnosis	O
of	O
SARS	B-DISO
.	O

Recognition	O
of	O
ALI	O
as	O
the	O
important	O
index	O
for	O
critical	O
SARS	B-DISO
and	O
comprehensive	O
supportive	O
management	O
are	O
of	O
paramount	O
importance	O
in	O
decreasing	O
the	O
mortality	O
of	O
patients	O
with	O
SARS	B-DISO
.	O

The	O
patients	O
with	O
SARS	B-DISO
were	O
found	O
having	O
damage	O
of	O
cellular	O
immunity	O
markedly	O
.	O

CONCLUSIONS	O
:	O
The	O
patients	O
with	O
SARS	B-DISO
were	O
found	O
having	O
damage	O
of	O
cellular	O
immunity	O
markedly	O
.	O

CT	O
scan	O
was	O
performed	O
in	O
16	O
SARS	B-DISO
patients	O
in	O
the	O
recovery	O
phase	O
,	O
of	O
whom	O
13	O
showed	O
lung	B-DISO
fibrosis	I-DISO
.	O

The	O
count	O
of	O
T	O
-	O
lymphocyte	O
subsets	O
of	O
SARS	B-DISO
group	O
decreased	O
to	O
the	O
lowest	O
level	O
during	O
the	O
10	O
(	O
th	O
)	O
and	O
12	O
(	O
th	O
)	O
day	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
levels	O
of	O
CD3	O
(+),	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
-	O
lymphocyte	O
subsets	O
in	O
peripheral	O
blood	O
of	O
SARS	B-DISO
patients	O
decrease	O
significantly	O
and	O
go	O
down	O
to	O
the	O
lowest	O
point	O
at	O
days	O
10	O
approximately	O
12	O
after	O
onset	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
[	O
Epidemiologic	O
features	O
,	O
clinical	O
diagnosis	O
and	O
therapy	O
of	O
first	O
cluster	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Beijing	O
area	O
].	O

The	O
oldest	O
patient	O
(	O
74	O
year	O
old	O
,	O
male	O
)	O
received	O
the	O
healthy	O
convalescent	O
plasma	O
infusion	O
(	O
50	O
ml	O
)	O
from	O
recovered	O
SARS	B-DISO
subject	O
and	O
completely	O
recovered	O
within	O
21	O
days	O
,	O
having	O
a	O
shorter	O
disease	O
course	O
.	O

The	O
main	O
clinical	O
manifestations	O
included	O
fever	O
,	O
cough	B-DISO
,	O
pectoralgia	O
,	O
chest	O
distress	O
,	O
headache	B-DISO
,	O
etc	O
.	O

CONCLUSIONS	O
:	O
Prevention	O
of	O
infectious	B-DISO
diseases	I-DISO
calls	O
for	O
macro	O
and	O
integrated	O
strategies	O
as	O
well	O
as	O
effective	O
surveillance	O
.	O

The	O
transmission	O
chain	O
of	O
this	O
outbreak	O
could	O
be	O
clearly	O
delineated	O
,	O
and	O
all	O
the	O
41	O
cases	O
had	O
close	O
contacts	O
with	O
their	O
infectors	O
,	O
SARS	B-DISO
cases	O
of	O
the	O
previous	O
generation	O
within	O
the	O
symptomatic	O
period	O
thereof	O
.	O

TITLE	O
:	O
SARS	B-DISO
outbreaks	O
in	O
Ontario	O
,	O
Hong	O
Kong	O
and	O
Singapore	O
:	O
the	O
role	O
of	O
diagnosis	O
and	O
isolation	O
as	O
a	O
control	O
mechanism	O
.	O

Our	O
best	O
estimates	O
are	O
consistent	O
with	O
SARS	B-DISO
eventually	O
being	O
contained	O
in	O
Toronto	O
,	O
although	O
the	O
time	O
of	O
containment	O
is	O
sensitive	O
to	O
the	O
parameters	O
in	O
our	O
model	O
.	O

It	O
is	O
shown	O
that	O
despite	O
the	O
empirically	O
modeled	O
heterogeneity	O
in	O
transmission	O
,	O
SARS	B-DISO
'	O
average	O
reproductive	O
number	O
is	O
1	O
.	O
2	O
,	O
a	O
value	O
quite	O
similar	O
to	O
that	O
computed	O
for	O
some	O
strains	O
of	O
influenza	B-DISO
(	O
J	O
.	O
Math	O
.	O

ABSTRACT	O
:	O
Since	O
May	O
8th	O
,	O
Beijing	O
'	O
s	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
is	O
on	O
a	O
continuous	O
decline	O
.	O

The	O
desquamation	O
and	O
hyperplasia	B-DISO
of	O
alveolar	O
lining	O
cells	O
was	O
also	O
apparent	O
.	O

Micro	O
-	O
thrombus	B-DISO
were	O
easily	O
found	O
in	O
these	O
lungs	O
.	O

Upon	O
admission	O
into	O
ICU	O
,	O
all	O
patients	O
had	O
poor	O
nutrients	O
intake	O
for	O
an	O
average	O
of	O
11	O
days	O
and	O
16	O
patients	O
(	O
76	O
.	O
2	O
%)	O
were	O
diagnosed	O
as	O
malnutrition	B-DISO
.	O

RESULTS	O
:	O
Upon	O
admission	O
into	O
ICU	O
,	O
all	O
patients	O
had	O
poor	O
nutrients	O
intake	O
for	O
an	O
average	O
of	O
11	O
days	O
and	O
16	O
patients	O
(	O
76	O
.	O
2	O
%)	O
were	O
diagnosed	O
as	O
malnutrition	B-DISO
.	O

TITLE	O
:	O
[	O
Viral	O
nosocomial	B-DISO
infections	I-DISO
:	O
the	O
problem	O
of	O
contemporary	O
hospital	O
management	O
].	O

Influenza	B-DISO
and	O
parainfluenza	B-DISO
viruses	O
as	O
well	O
as	O
RS	O
virus	O
affect	O
frequently	O
respiratory	O
tract	O
.	O

The	O
present	O
work	O
was	O
based	O
on	O
the	O
first	O
-	O
visiting	O
case	O
records	O
of	O
these	O
SARS	B-DISO
inpatients	O
.	O

The	O
clinical	O
features	O
including	O
fatigue	B-DISO
(	O
60	O
%),	O
dry	B-DISO
cough	I-DISO
(	O
68	O
.	O
9	O
%),	O
dyspnea	B-DISO
(	O
53	O
.	O
3	O
%),	O
joint	B-DISO
pain	I-DISO
(	O
26	O
.	O
7	O
%)	O
and	O
diarrhea	B-DISO
(	O
26	O
.	O
7	O
%).	O

Serum	O
antibody	O
was	O
not	O
detected	O
until	O
on	O
the	O
9th	O
day	O
of	O
the	O
course	B-DISO
of	I-DISO
illness	I-DISO
;	O
CT	O
is	O
a	O
more	O
sensitive	O
method	O
for	O
detection	O
of	O
the	O
abnormal	O
chest	O
radiographs	O
than	O
regular	O
X	O
-	O
ray	O
test	O
.	O

CONCLUSIONS	O
:	O
Exposure	O
to	O
the	O
SARS	B-DISO
patients	O
happened	O
in	O
most	O
patients	O
.	O

Plasma	O
anti	O
-	O
SARS	B-DISO
coronavirus	O
IgG	O
antibody	O
was	O
not	O
detected	O
in	O
normal	O
subjects	O
and	O
the	O
clinical	O
personnel	O
.	O

RESULTS	O
:	O
The	O
typical	O
signs	O
of	O
SARS	B-DISO
are	O
multifocal	O
air	O
-	O
space	O
consolidations	O
,	O
and	O
progress	O
over	O
a	O
day	O
from	O
small	O
shadow	O
to	O
becoming	O
generalized	O
.	O

The	O
ill	B-DISO
-	O
defined	O
and	O
variable	O
opacities	B-DISO
showed	O
to	O
be	O
dominant	O
.	O

The	O
improvement	O
of	O
acute	O
stage	O
lesion	O
in	O
17	O
cases	O
is	O
related	O
to	O
the	O
usage	O
and	O
increased	O
dosage	O
of	O
corticosteroid	O
,	O
some	O
cases	O
showed	O
non	O
-	O
parallel	O
with	O
symptom	B-DISO
and	O
chest	O
X	O
-	O
ray	O
.	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
45	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

TITLE	O
:	O
[	O
Mental	B-DISO
stress	I-DISO
and	O
crisis	O
intervention	O
in	O
the	O
patients	O
with	O
SARS	B-DISO
and	O
the	O
people	O
related	O
].	O

The	O
infection	B-DISO
rate	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
average	O
rate	O
in	O
our	O
country	O
.	O

RESULTS	O
:	O
Except	O
for	O
4	O
fellow	O
-	O
doctors	O
were	O
infected	O
by	O
close	O
contact	O
in	O
a	O
same	O
dormitory	O
,	O
all	O
others	O
were	O
infected	O
on	O
work	O
-	O
station	O
of	O
close	O
contact	O
with	O
SARS	B-DISO
patients	O
,	O
there	O
were	O
no	O
more	O
cross	O
-	O
infection	B-DISO
among	O
the	O
health	O
care	O
workers	O
.	O

The	O
forecasting	O
for	O
SARS	B-DISO
epidemic	O
situation	O
is	O
also	O
given	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
SIR	O
model	O
in	O
forecasting	O
and	O
analyzing	O
for	O
SARS	B-DISO
].	O

CONCLUSIONS	O
:	O
EIRIS	O
was	O
an	O
effective	O
method	O
to	O
break	O
the	O
transmission	O
route	O
of	O
SARS	B-DISO
within	O
the	O
hospital	O
.	O

Group	O
A	O
referred	O
to	O
the	O
stage	O
before	O
the	O
declaration	O
of	O
infectious	B-DISO
area	O
was	O
made	O
.	O

CONCLUSIONS	O
:	O
The	O
trend	O
of	O
the	O
in	O
-	O
hospital	O
medical	O
staffs	O
infection	B-DISO
rate	O
changed	O
with	O
different	O
style	O
of	O
prevention	O
and	O
protection	O
measures	O
.	O

(	O
2	O
)	O
Set	O
up	O
a	O
special	O
laboratory	O
or	O
area	O
for	O
detection	O
of	O
specimens	O
associated	O
with	O
SARS	B-DISO
,	O
appoint	O
the	O
staff	O
specially	O
assigned	O
for	O
the	O
task	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
awareness	O
and	O
practice	O
of	O
SARS	B-DISO
in	O
community	O
residents	O
in	O
Beijing	O
.	O

CONCLUSIONS	O
:	O
Most	O
of	O
the	O
residents	O
believe	O
SARS	B-DISO
have	O
influenced	O
on	O
regular	O
life	O
,	O
stability	O
of	O
society	O
,	O
development	O
of	O
economy	O
and	O
international	O
communication	O
.	O

CONCLUSIONS	O
:	O
There	O
was	O
the	O
condition	B-DISO
to	O
avoid	O
the	O
SARS	B-DISO
to	O
diffuse	O
and	O
extend	O
in	O
the	O
rural	O
area	O
as	O
Pinggu	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
is	O
a	O
new	O
kind	O
of	O
pneumonia	B-DISO
.	O

While	O
limitin	O
has	O
antiviral	O
activity	O
as	O
strong	O
as	O
that	O
of	O
IFN	O
-	O
alpha	O
in	O
vitro	O
(	O
the	O
concentration	O
that	O
provided	O
50	O
%	O
inhibition	O
of	O
cytopathic	B-DISO
effect	I-DISO
is	O
approximately	O
30	O
pg	O
/	O
ml	O
),	O
IFN	O
regulatory	O
factor	O
1	O
(	O
IRF	O
-	O
1	O
)	O
dependencies	O
for	O
induction	O
of	O
an	O
antiviral	O
state	O
were	O
different	O
for	O
limitin	O
and	O
IFN	O
-	O
alpha	O
.	O

ABSTRACT	O
:	O
The	O
putative	O
NTPase	O
/	O
helicase	O
protein	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
postulated	O
to	O
play	O
a	O
number	O
of	O
crucial	O
roles	O
in	O
the	O
viral	O
life	O
cycle	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	B-DISO
therapy	O
.	O

All	O
eight	O
common	O
NTPs	O
and	O
dNTPs	O
were	O
hydrolyzed	O
by	O
the	O
SARS	B-DISO
helicase	O
in	O
a	O
magnesium	O
-	O
dependent	O
reaction	O
,	O
stimulated	O
by	O
the	O
presence	O
of	O
either	O
single	O
-	O
stranded	O
DNA	O
or	O
RNA	O
.	O

SARS	B-DISO
epidemic	O
was	O
very	O
rampant	O
in	O
March	O
,	O
April	O
and	O
May	O
2003	O
in	O
the	O
mainland	O
of	O
China	O
and	O
Hong	O
Kong	O
.	O

In	O
this	O
paper	O
,	O
we	O
briefly	O
review	O
the	O
current	O
status	O
of	O
SARS	B-DISO
in	O
China	O
.	O

Among	O
32	O
patients	O
,	O
24	O
were	O
cured	O
,	O
2	O
died	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
6	O
died	O
of	O
their	O
primary	O
diseases	O
,	O
and	O
the	O
overall	O
mortality	O
was	O
25	O
.	O
00	O
percent	O
.	O

(	O
5	O
)	O
The	O
ratio	O
of	O
severe	O
pneumonia	B-DISO
and	O
mortality	O
in	O
SARS	B-DISO
was	O
much	O
higher	O
than	O
in	O
CAP	B-DISO
(	O
both	O
P	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
(	O
1	O
)	O
Fever	O
above	O
38	O
.	O
5	O
centigrade	O
,	O
dry	B-DISO
cough	I-DISO
,	O
short	B-DISO
of	I-DISO
breath	I-DISO
,	O
headache	B-DISO
,	O
myalgia	B-DISO
,	O
diarrhea	B-DISO
in	O
SARS	B-DISO
were	O
more	O
common	O
in	O
SARS	B-DISO
patients	O
than	O
those	O
in	O
CAP	B-DISO
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
[	O
Retrospective	O
analysis	O
on	O
clinical	O
features	O
of	O
35	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

SARS	B-DISO
is	O
a	O
serious	O
respiratory	O
illness	O
,	O
the	O
most	O
common	O
symptoms	O
are	O
fever	O
,	O
cough	B-DISO
,	O
headache	B-DISO
and	O
myalgia	B-DISO
,	O
other	O
common	O
findings	O
are	O
lymphopenia	B-DISO
,	O
the	O
CD	O
+	O
4	O
and	O
CD	O
+	O
8	O
in	O
T	O
cell	O
in	O
peripheral	O
blood	O
decrease	O
and	O
multi	O
-	O
infiltrate	B-DISO
through	O
out	O
the	O
lung	O
fields	O
.	O

,	O
the	O
most	O
common	O
symptoms	O
are	O
fever	O
,	O
cough	B-DISO
,	O
headache	B-DISO
and	O
myalgia	B-DISO
,	O
other	O
common	O
findings	O
are	O
lymphopenia	B-DISO
,	O
the	O
CD	O
+	O
4	O
and	O
CD	O
+	O
8	O
in	O
T	O
cell	O
in	O
peripheral	O
blood	O
decrease	O
and	O
multi	O
-	O
infiltrate	B-DISO
through	O
out	O
the	O
lung	O
fields	O
.	O

T	O
cells	O
participate	O
in	O
both	O
defense	O
and	O
disease	B-DISO
progression	I-DISO
following	O
MHV	O
infection	B-DISO
.	O

Expression	O
of	O
chemokine	O
receptors	O
on	O
activated	O
T	O
cells	O
is	O
important	O
in	O
allowing	O
these	O
cells	O
to	O
traffic	O
into	O
and	O
accumulate	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
of	O
MHV	O
-	O
infected	O
mice	O
.	O

Significantly	O
enhanced	O
activity	O
of	O
the	O
macrophages	O
occurs	O
in	O
SARS	B-DISO
as	O
the	O
major	O
reactive	O
cells	O
,	O
but	O
T	O
lymphocyte	O
subsets	O
are	O
obviously	O
decreased	O
,	O
indicating	O
the	O
important	O
roles	O
of	O
the	O
macrophages	O
and	O
T	O
lymphocytes	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

ARDS	B-DISO
treatment	O
is	O
frequently	O
complicated	O
by	O
significant	O
extrapulmonary	O
comorbidity	O
.	O

Finally	O
,	O
severely	O
impaired	B-DISO
renal	I-DISO
function	I-DISO
(	O
urinary	O
output	O
)	O
was	O
associated	O
with	O
adverse	O
net	O
fluid	O
balance	O
.	O

Leukopenia	B-DISO
was	O
observed	O
in	O
67	O
.	O
7	O
%	O
of	O
this	O
cohort	O
.	O

Ninety	O
-	O
five	O
patients	O
(	O
99	O
.	O
0	O
%)	O
had	O
a	O
complete	O
clinical	O
recovery	O
,	O
and	O
1	O
patient	O
died	O
of	O
progressive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
collected	O
epidemiologic	O
data	O
on	O
128	O
probable	O
and	O
suspect	O
cases	O
of	O
SARS	B-DISO
associated	O
with	O
the	O
hospital	O
outbreak	O
,	O
including	O
those	O
who	O
became	O
infected	O
in	O
hospital	O
and	O
the	O
next	O
generation	O
of	O
illness	O
arising	O
among	O
their	O
contacts	O
.	O

Of	O
the	O
128	O
cases	O
,	O
120	O
(	O
93	O
.	O
8	O
%)	O
had	O
documented	O
contact	O
with	O
a	O
SARS	B-DISO
case	O
or	O
with	O
a	O
ward	O
where	O
there	O
was	O
a	O
known	O
SARS	B-DISO
case	O
.	O

Evidence	O
to	O
date	O
suggests	O
that	O
SARS	B-DISO
is	O
a	O
severe	O
respiratory	O
illness	O
spread	O
mainly	O
by	O
respiratory	O
droplets	O
.	O

A	O
SARS	B-DISO
-	O
CoV	O
whole	O
-	O
genome	O
approach	O
has	O
been	O
developed	O
aimed	O
at	O
determining	O
the	O
crystal	O
structure	O
of	O
all	O
of	O
its	O
proteins	O
or	O
domains	O
.	O

ABSTRACT	O
:	O
The	O
genome	O
organization	O
and	O
expression	O
strategy	O
of	O
the	O
newly	O
identified	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
predicted	O
using	O
recently	O
published	O
genome	O
sequences	O
.	O

SARS	B-DISO
in	O
children	O
appears	O
to	O
manifest	O
as	O
a	O
milder	O
form	O
of	O
the	O
disease	O
as	O
compared	O
to	O
adults	O
.	O

Metabolic	B-DISO
acidosis	I-DISO
and	O
hypoglycemia	B-DISO
are	O
common	O
systemic	O
complications	O
.	O

The	O
first	O
SARS	B-DISO
case	O
was	O
identified	O
in	O
Foshan	O
municipality	O
on	O
November	O
16	O
,	O
2002	O
,	O
followed	O
by	O
1	O
511	O
clinically	O
confirmed	O
cases	O
(	O
including	O
58	O
deaths	O
)	O
up	O
to	O
May	O
15	O
,	O
2003	O
.	O

Earlier	O
use	O
of	O
glucocorticoid	O
therapy	O
with	O
suitable	O
doses	O
could	O
alleviate	O
their	O
clinical	O
symptoms	O
,	O
improve	O
their	O
clinical	O
courses	O
,	O
and	O
promote	O
the	O
absorbance	O
of	O
infiltration	B-DISO
in	O
their	O
lungs	O
on	O
chest	O
-	O
X	O
-	O
ray	O
films	O
for	O
the	O
cases	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Clinical	O
features	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
forty	O
-	O
one	O
confirmed	O
health	O
care	O
workers	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
features	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Ten	O
patients	O
complained	O
inertia	O
and	O
myalgia	B-DISO
.	O

TITLE	O
:	O
[	O
Effects	O
of	O
surveillance	O
system	O
and	O
preventive	O
measures	O
on	O
the	O
control	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
a	O
university	O
in	O
Guangdong	O
Province	O
of	O
China	O
].	O

A	O
series	O
of	O
control	O
measures	O
benefited	O
the	O
early	O
diagnosis	O
,	O
effective	O
isolation	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
SARS	B-DISO
control	O
.	O

The	O
source	O
of	O
the	O
outbreak	O
was	O
later	O
traced	O
to	O
an	O
individual	O
with	O
SARS	B-DISO
who	O
spent	O
two	O
nights	O
at	O
Amoy	O
Gardens	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
challenge	O
for	O
public	O
health	O
practice	O
in	O
Hong	O
Kong	O
.	O

Maintaining	O
a	O
healthy	O
and	O
hygienic	O
environment	O
can	O
be	O
one	O
of	O
the	O
effective	O
public	O
health	O
measures	O
to	O
combat	O
infectious	B-DISO
disease	I-DISO
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
are	O
to	O
describe	O
the	O
clinics	O
view	O
of	O
acute	O
infectious	B-DISO
gastroenteritis	I-DISO
(	O
GE	O
)	O
at	O
the	O
community	O
,	O
in	O
primary	O
and	O
secondary	O
attention	O
health	O
centers	O
,	O
with	O
special	O
references	O
to	O
viral	O
aetiology	O
(	O
VIGE	O
);	O
to	O
correlate	O
with	O
drinkable	O
water	O
and	O
excrete	O
treatment	O
;	O
to	O
develop	O
for	O
the	O
first	O
time	O
a	O
fast	O
diagnostic	O
using	O
electron	O
microscopy	O
in	O
Río	O
Cuarto	O
,	O
Córdoba	O
,	O
Argentina	O
,	O
considering	O
the	O
university	O
and	O
community	O
collaboration	O
in	O
the	O
viral	O
diagnostic	O
.	O

The	O
microbial	O
findings	O
has	O
been	O
:	O
pathogenics	O
bacteria	O
(	O
31	O
.	O
7	O
%),	O
fungus	O
(	O
17	O
%),	O
parasites	O
(	O
1	O
.	O
2	O
%),	O
rotavirus	O
(	O
16	O
.	O
4	O
%),	O
calicivirus	O
(	O
1	O
.	O
6	O
%),	O
adenovirus	B-DISO
and	O
coronavirus	O
(	O
1	O
.	O
6	O
%).	O

There	O
are	O
statistics	O
signification	O
:	O
the	O
NOVIGE	O
in	O
summer	O
period	O
(	O
49	O
%)	O
against	O
the	O
VIGE	O
(	O
12	O
.	O
5	O
%)	O
(	O
p	O
<	O
0	O
.	O
0003	O
);	O
the	O
VIGE	O
in	O
winter	O
period	O
(	O
87	O
.	O
5	O
%)	O
against	O
the	O
VIGE	O
in	O
summer	O
period	O
(	O
12	O
.	O
5	O
%)	O
(	O
p	O
<	O
0	O
.	O
0003	O
);	O
the	O
GE	O
aetiology	O
(	O
VIGE	O
and	O
NOVIGE	O
)	O
in	O
associated	O
with	O
age	O
groups	O
(	O
p	O
<	O
0	O
.	O
0003	O
);	O
the	O
vomits	B-DISO
preceding	O
diarrhoea	B-DISO
in	O
VIGE	O
was	O
58	O
%	O
and	O
in	O
NOVIGE	O
(	O
19	O
.	O
5	O
%)	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

there	O
are	O
not	O
a	O
strong	O
relationship	O
of	O
diarrhoea	B-DISO
by	O
shortage	O
environmental	O
health	O
in	O
this	O
study	O
;	O
6	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
principle	O
of	O
thermal	O
physiology	O
,	O
especially	O
on	O
the	O
effect	O
of	O
the	O
ambient	O
temperature	O
on	O
head	O
-	O
neck	O
skin	O
temperatures	O
,	O
the	O
paper	O
discussed	O
some	O
general	O
problems	O
about	O
detecting	O
the	O
suspected	O
patient	O
of	O
SARS	B-DISO
from	O
large	O
number	O
of	O
transferring	O
people	O
in	O
public	O
place	O
according	O
to	O
the	O
head	O
-	O
neck	O
skin	O
temperature	O
during	O
recently	O
fight	O
against	O
SARS	B-DISO
.	O

The	O
ability	O
of	O
several	O
porcine	O
viruses	O
to	O
cause	O
transplacental	O
fetal	B-DISO
infection	I-DISO
(	O
parvoviruses	O
,	O
circoviruses	O
,	O
and	O
arteriviruses	O
),	O
emergence	O
or	O
recognition	O
of	O
several	O
new	O
porcine	O
viruses	O
during	O
the	O
last	O
two	O
decades	O
(	O
porcine	O
circovirus	O
,	O
arterivirus	O
,	O
paramyxoviruses	O
,	O
herpesviruses	O
,	O
and	O
porcine	O
respiratory	O
coronavirus	O
)	O
and	O
the	O
immunosuppressed	O
state	O
of	O
the	O
transplant	O
recipients	O
increases	O
the	O
xenozoonoses	O
risk	O
of	O
humans	O
to	O
porcine	O
viruses	O
through	O
transplantation	O
.	O

siRNA	O
may	O
be	O
effective	O
in	O
inhibiting	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
replication	O
.	O

CONCLUSIONS	O
:	O
siRNA	O
may	O
be	O
effective	O
in	O
inhibiting	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
replication	O
.	O

The	O
autopsy	O
revealed	O
severe	B-DISO
bronchopulmonary	I-DISO
dysplasia	I-DISO
(	O
BPD	B-DISO
)	O
in	O
his	O
lungs	O
with	O
secondary	O
pulmonary	B-DISO
heart	I-DISO
disease	I-DISO
;	O
a	O
tracheotomy	O
was	O
carried	O
out	O
to	O
enable	O
his	O
survival	O
.	O

ARDS	B-DISO
were	O
observed	O
in	O
23	O
cases	O
,	O
showing	O
speckled	O
SP	O
-	O
A	O
immunostaining	O
.	O

ABSTRACT	O
:	O
The	O
oxygen	O
regulated	O
protein	O
150	O
-	O
kDa	O
(	O
ORP	O
-	O
150	O
)	O
is	O
only	O
induced	O
in	O
hypoxic	B-DISO
conditions	O
.	O

Moreover	O
,	O
both	O
groups	O
of	O
litters	O
from	O
primed	O
gilts	O
suffered	B-DISO
less	O
clinical	O
illness	O
(	O
as	O
measured	O
by	O
the	O
extent	O
of	O
weight	O
loss	O
post	O
-	O
challenge	O
)	O
than	O
control	O
litters	O
.	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
discovered	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
which	O
can	O
readily	O
spread	O
in	O
the	O
healthcare	O
setting	O
.	O

A	O
recent	O
community	O
outbreak	O
in	O
Hong	O
Kong	O
infected	O
a	O
significant	O
number	O
of	O
pregnant	O
women	O
who	O
subsequently	O
required	O
emergency	B-DISO
caesarean	O
section	O
for	O
deteriorating	O
maternal	O
condition	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
severity	O
and	O
outcome	O
of	O
this	O
syndrome	B-DISO
varies	O
.	O

Over	O
the	O
years	O
a	O
variety	O
of	O
""""	O
lung	O
protective	O
""""	O
treatment	O
modalities	O
have	O
been	O
introduced	O
and	O
proved	O
as	O
effective	O
and	O
safe	O
in	O
the	O
treatment	O
of	O
this	O
syndrome	B-DISO

TITLE	O
:	O
[	O
The	O
treatment	O
of	O
molecular	O
adsorbents	O
recirculating	O
system	O
artificial	O
liver	O
in	O
severe	O
liver	B-DISO
failure	I-DISO
patients	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
].	O

Abnormal	B-DISO
liver	I-DISO
function	I-DISO
mainly	O
resulted	O
from	O
ALT	O
elevation	O
(	O
70	O
.	O
7	O
%),	O
then	O
both	O
ALT	O
and	O
AST	O
elevation	O
(	O
22	O
.	O
4	O
%).	O

Ultrasonic	O
examination	O
and	O
pathological	O
observation	O
showed	O
no	O
special	O
features	O
,	O
compared	O
with	O
those	O
in	O
common	O
acute	B-DISO
hepatitis	I-DISO
patients	O
.	O

TITLE	O
:	O
[	O
Initial	O
analysis	O
of	O
complete	O
genome	O
sequences	O
of	O
SARS	B-DISO
coronavirus	O
].	O

In	O
some	O
regions	O
of	O
the	O
genome	O
,	O
the	O
genomic	O
sequence	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
significantly	O
different	O
from	O
that	O
of	O
other	O
coronavirus	O
,	O
and	O
has	O
a	O
self	O
-	O
conservative	O
genomic	O
sequence	O
.	O

TITLE	O
:	O
Case	O
report	O
of	O
the	O
first	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
patient	O
in	O
China	O
:	O
successful	O
application	O
of	O
extracorporeal	O
liver	O
support	O
MARS	O
therapy	O
in	O
multiorgan	B-DISO
failure	I-DISO
possibly	O
induced	O
by	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
.	O

The	O
diagnosis	O
of	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
)	O
was	O
made	O
in	O
view	O
of	O
the	O
severe	O
hypoxemia	O
and	O
the	O
characteristic	O
symptoms	O
exhibited	O
by	O
the	O
patient	O
.	O

Despite	O
the	O
best	O
intensive	O
therapy	O
,	O
he	O
clinically	O
deteriorated	O
into	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
)	O
including	O
additional	O
dysfunction	O
of	O
kidney	O
,	O
liver	O
,	O
and	O
heart	O
.	O

In	O
contrast	O
,	O
the	O
degree	O
of	O
(	O
1	O
)	O
pancreatic	O
inflammation	B-DISO
and	O
tissue	O
injury	O
(	O
histological	O
score	O
),	O
(	O
2	O
)	O
up	O
-	O
regulation	O
/	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
E	O
-	O
selectin	O
and	O
ICAM	O
-	O
1	O
,	O
and	O
(	O
3	O
)	O
neutrophil	O
infiltration	B-DISO
was	O
markedly	O
reduced	O
in	O
pancreatic	O
and	O
lung	O
tissue	O
obtained	O
from	O
cerulein	O
-	O
treated	O
5	O
-	O
LO	O
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
disease	O
of	O
multifactorial	O
etiology	O
characterised	O
by	O
rapid	O
development	O
of	O
severe	O
diffuse	O
and	O
nonhomogenous	O
inflammation	B-DISO
of	O
the	O
pulmonary	O
lobules	O
causing	O
life	O
-	O
threatening	O
hypoxaemic	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
model	O
was	O
defined	O
by	O
investigating	O
,	O
during	O
the	O
natural	O
history	O
of	O
ARDS	B-DISO
,	O
the	O
relationship	O
among	O
the	O
three	O
fundamental	O
elements	O
of	O
a	O
disease	O
process	O
pathogenesis	B-DISO
,	O
structural	O
alterations	O
,	O
and	O
functional	O
consequences	O
.	O

In	O
a	O
small	O
randomised	O
study	O
of	O
patients	O
with	O
unresolving	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
the	O
current	O
authors	O
have	O
shown	O
that	O
prolonged	O
glucocorticoid	O
supplementation	O
improved	O
all	O
aspects	O
of	O
glucocorticoid	O
receptors	O
function	O
and	O
enhanced	O
glucocorticoid	O
-	O
mediated	O
anti	O
-	O
inflammatory	O
action	O
by	O
interfering	O
with	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
hemolytic	B-DISO
anemia	I-DISO
,	O
severe	O
secondary	B-DISO
infections	I-DISO
,	O
or	O
hematemesis	B-DISO
,	O
but	O
patients	O
in	O
the	O
PS	O
group	O
had	O
less	O
hyperglycaemia	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
children	O
.	O

Diagnosis	O
was	O
characteristically	O
delayed	O
until	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
complicated	O
a	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
at	O
13	O
months	O
,	O
prompting	O
high	O
-	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
of	O
the	O
chest	O
.	O

The	O
concerted	O
efforts	O
of	O
a	O
globally	O
united	O
scientific	O
community	O
have	O
led	O
to	O
the	O
independent	O
isolation	O
and	O
identification	O
of	O
a	O
novel	O
coronavirus	O
from	O
SARS	B-DISO
patients	O
by	O
several	O
groups	O
.	O

ABSTRACT	O
:	O
Reductive	O
metabolism	O
of	O
carbon	O
tetrachloride	O
(	O
CCl	B-DISO
(	O
4	O
))	O
is	O
thought	O
to	O
cause	O
lipid	O
peroxidation	O
which	O
results	O
in	O
hepatic	O
injury	O
.	O

CCl	B-DISO
(	O
4	O
)	O
treatment	O
(	O
1	O
mL	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
produced	O
severe	O
hepatic	O
injury	O
in	O
rats	O
as	O
revealed	O
by	O
significant	O
increases	O
in	O
serum	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
(	O
EC	O
2	O
.	O
6	O
.	O
1	O
.	O
2	O
)	O
activity	O
and	O
hepatic	O
malondialdehyde	O
(	O
MDA	O
)	O
content	O
,	O
severe	O
liver	O
cell	B-DISO
injury	I-DISO
,	O
and	O
increases	O
in	O
hepatic	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
).	O

These	O
findings	O
indicate	O
that	O
induction	O
of	O
HO	O
-	O
1	O
is	O
an	O
adaptive	O
response	O
to	O
CCl	B-DISO
(	O
4	O
)	O
treatment	O
,	O
and	O
it	O
may	O
be	O
critical	O
in	O
the	O
recovery	O
of	O
hepatocytes	O
from	O
injury	O
.	O

TITLE	O
:	O
SARS	B-DISO
vs	O
.	O
flu	B-DISO
:	O
can	O
you	O
tell	O
serious	O
disease	O
from	O
common	O
malady	O
?	O

ABSTRACT	O
:	O
Health	O
officials	O
caution	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
may	O
return	O
this	O
fall	O
with	O
the	O
flu	B-DISO
season	O
,	O
and	O
the	O
serious	O
disease	O
may	O
be	O
difficult	O
to	O
distinguish	O
from	O
the	O
common	O
malady	O
.	O

Confirming	O
a	O
flu	B-DISO
diagnosis	O
means	O
you	O
'	O
re	O
relatively	O
safe	O
in	O
ruling	O
out	O
SARS	B-DISO
.	O

Factors	O
that	O
may	O
alter	O
future	O
estimates	O
of	O
case	O
-	O
fatality	O
rates	O
,	O
reasons	O
for	O
heterogeneity	O
in	O
doubling	O
times	O
among	O
countries	O
,	O
and	O
implications	O
for	O
the	O
control	O
of	O
SARS	B-DISO
are	O
discussed	O
.	O

He	O
later	O
developed	O
a	O
myocardial	B-DISO
infarct	I-DISO
and	O
coagulopathy	B-DISO
,	O
and	O
succumbed	O
to	O
his	O
illness	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
JHM	O
,	O
causes	O
acute	O
and	O
chronic	O
neurological	O
diseases	O
in	O
rodents	O
.	O

One	O
strain	O
,	O
JHM	O
.	O
SD	O
,	O
caused	O
acute	O
encephalitis	B-DISO
,	O
while	O
infection	B-DISO
with	O
JHM	O
.	O
IA	O
resulted	O
in	O
no	O
acute	B-DISO
disease	I-DISO
.	O

The	O
increased	O
neurovirulence	O
mediated	O
by	O
the	O
virus	O
encoding	O
glycine	O
at	O
position	O
S310	O
was	O
not	O
associated	O
with	O
a	O
different	O
tropism	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
but	O
was	O
associated	O
with	O
increased	O
lateral	O
spread	O
in	O
the	O
CNS	O
,	O
leading	O
to	O
significantly	O
higher	O
brain	O
viral	O
titers	O
.	O

In	O
vitro	O
studies	O
revealed	O
that	O
S310G	O
was	O
associated	O
with	O
decreased	O
S1	O
-	O
S2	O
stability	O
and	O
with	O
enhanced	O
ability	O
to	O
mediate	O
infection	B-DISO
of	O
cells	O
lacking	O
the	O
primary	O
receptor	O
for	O
JHM	O
"("""	O
receptor	O
-	O
independent	O
spread	O
""")."	O

Use	O
of	O
products	O
with	O
fish	O
oils	O
,	O
borage	O
oils	O
,	O
and	O
antioxidants	O
should	O
be	O
considered	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
[	O
Organism	O
distribution	O
and	O
drug	O
resistance	O
in	O
7	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
death	O
patients	O
with	O
secondary	O
bacteria	O
infection	B-DISO
].	O

ABSTRACT	O
:	O
At	O
the	O
13th	O
European	O
Congress	O
of	O
Clinical	O
Microbiology	O
and	O
Infectious	B-DISO
Diseases	I-DISO
,	O
held	O
in	O
Glasgow	O
,	O
Scotland	O
,	O
May	O
10	O
-	O
13	O
,	O
2003	O
,	O
the	O
latest	O
developments	O
in	O
clinical	O
microbiology	O
and	O
the	O
treatment	O
of	O
infectious	B-DISO
diseases	I-DISO
were	O
presented	O
alongside	O
recent	O
progress	O
on	O
molecular	O
aspects	O
of	O
diagnosis	O
and	O
emerging	O
patterns	O
of	O
infection	B-DISO
.	O

In	O
addition	O
to	O
a	O
historical	O
session	O
looking	O
at	O
Scotland	O
'	O
s	O
own	O
contribution	O
to	O
the	O
control	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
the	O
meeting	O
involved	O
up	O
to	O
six	O
parallel	O
sessions	O
a	O
day	O
,	O
looking	O
at	O
all	O
the	O
major	O
aspects	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
treatment	O
,	O
surveillance	O
,	O
epidemiology	O
and	O
drug	O
pharmacodynamics	O
and	O
pharmacokinetics	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
recognized	O
infectious	B-DISO
disease	I-DISO
associated	O
with	O
severe	O
morbidity	O
and	O
mortality	O
.	O

TITLE	O
:	O
[	O
Preliminary	O
result	O
on	O
the	O
nosocomial	B-DISO
infection	I-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
one	O
hospital	O
of	O
Beijing	O
].	O

One	O
of	O
the	O
epidemiological	O
characteristics	O
of	O
SARS	B-DISO
in	O
Beijing	O
was	O
noticed	O
that	O
the	O
disease	O
clustered	O
in	O
families	O
and	O
hospitals	O
.	O

The	O
incidence	O
rate	O
of	O
SARS	B-DISO
was	O
18	O
.	O
0	O
/	O
100	O
,	O
000	O
with	O
case	O
fatality	O
rate	O
as	O
6	O
.	O
7	O
%	O
in	O
Haidian	O
district	O
,	O
Beijing	O
.	O

Seventy	O
-	O
two	O
point	O
seven	O
percent	O
of	O
the	O
SARS	B-DISO
cases	O
had	O
been	O
exposed	O
to	O
the	O
injection	O
in	O
the	O
hospital	O
settings	O
.	O

When	O
the	O
epidemics	O
came	O
to	O
a	O
rapid	O
decline	O
,	O
85	O
.	O
7	O
%	O
of	O
the	O
patients	O
diagnosed	O
during	O
that	O
period	O
could	O
be	O
traced	O
down	O
to	O
have	O
had	O
the	O
history	O
of	O
contacting	O
SARS	B-DISO
cases	O
within	O
their	O
own	O
families	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
epidemiologic	O
characteristics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
evaluate	O
the	O
effectiveness	O
on	O
its	O
major	O
control	O
measures	O
in	O
Tianjn	O
.	O

From	O
April	O
13	O
through	O
May	O
8	O
,	O
2003	O
,	O
there	O
were	O
175	O
SARS	B-DISO
cases	O
including	O
imported	O
ones	O
,	O
were	O
identified	O
with	O
an	O
incidence	O
rate	O
of	O
1	O
.	O
9	O
cases	O
per	O
100	O
,	O
000	O
.	O

The	O
whole	O
process	O
of	O
epidemic	O
in	O
Tianjin	O
was	O
less	O
than	O
one	O
month	O
with	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
93	O
.	O
7	O
%	O
of	O
the	O
total	O
SARS	B-DISO
cases	O
in	O
Tianjin	O
were	O
directly	O
or	O
indirectly	O
transmitted	B-DISO
by	O
a	O
super	O
-	O
spreader	O
.	O

Among	O
the	O
total	O
number	O
of	O
1	O
975	O
medical	O
workers	O
who	O
participated	O
in	O
the	O
SARS	B-DISO
medical	O
cares	O
and	O
treatments	O
,	O
3	O
.	O
4	O
%	O
of	O
them	O
got	O
infected	O
.	O

During	O
the	O
outbreak	O
,	O
all	O
index	O
cases	O
and	O
chains	O
of	O
transmission	O
seemed	O
to	O
be	O
clear	O
,	O
with	O
only	O
3	O
patients	O
not	O
able	O
to	O
be	O
traced	O
for	O
the	O
source	O
of	O
infection	B-DISO
,	O
taking	O
up	O
2	O
%	O
of	O
the	O
total	O
SARS	B-DISO
patients	O
in	O
Tianjin	O
.	O

Among	O
the	O
10	O
index	O
cases	O
,	O
only	O
the	O
super	O
spreader	O
and	O
another	O
one	O
index	O
case	O
transmitted	B-DISO
the	O
virus	O
to	O
their	O
contacts	O
but	O
the	O
rest	O
of	O
index	O
cases	O
did	O
not	O
cause	O
any	O
secondary	B-DISO
infection	I-DISO
.	O

Diagnosis	O
was	O
made	O
on	O
the	O
basis	O
of	O
viral	O
culture	O
and	O
electron	O
microscopy	O
findings	O
that	O
exhibited	O
typical	O
crown	O
-	O
like	O
particles	O
and	O
through	O
amplification	B-DISO
of	O
the	O
viral	O
genome	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

On	O
the	O
basis	O
of	O
this	O
report	O
,	O
coronaviruses	O
should	O
be	O
considered	O
as	O
potential	O
causative	O
microorganisms	O
of	O
pneumonia	B-DISO
in	O
immunocompromised	O
patients	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
prognosis	O
factors	O
of	O
alcoholic	O
patients	O
hospitalised	O
in	O
an	O
intensive	O
care	O
unit	O
with	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
SCAP	O
).	O

We	O
then	O
synthesized	O
new	O
derivatives	O
that	O
,	O
in	O
our	O
hands	O
,	O
were	O
endowed	O
with	O
in	O
vitro	O
antiproliferative	O
activities	O
as	O
low	O
as	O
3	O
.	O
4	O
microM	O
against	O
a	O
panel	O
of	O
cell	O
lines	O
derived	O
from	O
hematological	O
and	O
solid	O
tumours	B-DISO
.	O

The	O
symptoms	O
mostly	O
often	O
revealed	O
in	O
patients	O
of	O
early	O
stage	O
were	O
fever	O
in	O
56	O
patients	O
,	O
cough	B-DISO
in	O
41	O
and	O
weakness	B-DISO
or	O
heaviness	O
of	O
limbs	O
in	O
40	O
,	O
which	O
in	O
patients	O
of	O
middle	O
or	O
crisis	O
stage	O
were	O
cough	B-DISO
in	O
53	O
and	O
weakness	B-DISO
or	O
heaviness	O
of	O
limbs	O
in	O
43	O
.	O

CONCLUSIONS	O
:	O
ICWM	O
can	O
improve	O
the	O
symptoms	O
and	O
regulate	O
the	O
immune	O
function	O
in	O
uncertain	O
SARS	B-DISO
patients	O
.	O

Forty	O
-	O
six	O
patients	O
with	O
established	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
were	O
studied	O
prospectively	O
.	O

ABSTRACT	O
:	O
A	O
remarkable	O
collaborative	O
effort	O
coordinated	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
team	O
at	O
WHO	O
resulted	O
in	O
discovery	O
of	O
the	O
etiologic	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
less	O
than	O
2	O
months	O
after	O
the	O
announcement	O
of	O
global	O
alert	O
.	O

Cases	O
of	O
more	O
than	O
10	O
days	O
'	O
duration	O
exhibited	O
organizing	O
-	O
phase	O
DAD	O
,	O
type	O
II	O
pneumocyte	O
hyperplasia	B-DISO
,	O
squamous	B-DISO
metaplasia	I-DISO
,	O
multinucleated	O
giant	B-DISO
cells	O
,	O
and	O
acute	B-DISO
bronchopneumonia	I-DISO
.	O

SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
identified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
7	O
of	O
8	O
cases	O
in	O
fresh	O
autopsy	O
tissue	O
and	O
in	O
8	O
of	O
8	O
cases	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
,	O
including	O
the	O
1	O
negative	O
case	O
in	O
fresh	O
tissue	O
.	O

ABSTRACT	O
:	O
The	O
S1	O
and	O
S2	O
subunits	O
of	O
the	O
spike	O
glycoprotein	O
of	O
the	O
coronavirus	O
which	O
is	O
responsible	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
have	O
been	O
modelled	O
,	O
even	O
though	O
the	O
corresponding	O
amino	O
acid	O
sequences	O
were	O
not	O
suitable	O
for	O
tertiary	O
structure	O
predictions	O
with	O
conventional	O
homology	O
and	O
/	O
or	O
threading	O
procedures	O
.	O

SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
is	O
spread	O
by	O
multiple	O
mechanisms	O
,	O
including	O
direct	O
contact	O
and	O
large	O
-	O
droplet	O
aerosolization	O
,	O
and	O
may	O
be	O
spread	O
by	O
droplet	O
nuclei	O
as	O
well	O
.	O

The	O
SARS	B-DISO
-	O
associated	O
coronovirus	O
infection	B-DISO
may	O
cause	O
complex	O
cytokine	O
cascade	O
.	O

This	O
paper	O
outlines	O
our	O
experience	O
with	O
public	O
health	O
issues	O
that	O
have	O
arisen	O
during	O
this	O
outbreak	O
of	O
SARS	B-DISO
in	O
Hong	O
Kong	O
.	O

This	O
procedure	O
,	O
when	O
performed	O
without	O
protection	O
,	O
may	O
lead	O
to	O
infection	B-DISO
of	O
the	O
medical	O
and	O
nursing	O
staff	O
taking	O
care	O
of	O
the	O
patient	O
.	O

The	O
possible	O
origins	O
of	O
these	O
marked	O
SARs	B-DISO
are	O
discussed	O
.	O

Two	O
were	O
infected	O
in	O
second	O
trimester	O
while	O
the	O
other	O
3	O
in	O
third	O
trimester	O
with	O
2	O
hospital	O
-	O
acquired	O
infections	B-DISO
and	O
3	O
community	B-DISO
-	I-DISO
acquired	I-DISO
infections	I-DISO
.	O

Common	O
diagnostic	O
criteria	O
were	O
Suitable	O
for	O
SARS	B-DISO
-	O
complicated	B-DISO
pregnancy	I-DISO
in	O
second	O
and	O
third	O
trimesters	O
,	O
but	O
attention	O
should	O
be	O
paid	O
to	O
the	O
interaction	O
between	O
SARS	B-DISO
and	O
special	O
pathological	O
changes	O
during	O
pregnancy	O
.	O

The	O
use	O
of	O
corticosteroids	O
and	O
psychological	B-DISO
supports	O
need	O
further	O
study	O
.	O

RESULTS	O
:	O
SARS	B-DISO
-	O
CoV	O
minus	O
-	O
RNA	O
was	O
detected	O
in	O
PBMCs	O
from	O
SARS	B-DISO
patients	O
.	O

Demonstration	O
of	O
recombination	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
lineage	O
indicates	O
its	O
potential	O
for	O
rapid	O
unpredictable	O
change	O
,	O
a	O
potentially	O
important	O
challenge	O
for	O
public	O
health	O
management	O
and	O
for	O
drug	O
and	O
vaccine	O
development	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
nucleoprotein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
detection	O
of	O
antibodies	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

This	O
case	O
series	O
is	O
the	O
first	O
report	O
to	O
describe	O
the	O
clinical	O
course	O
of	O
the	O
first	O
cohort	O
of	O
liveborn	O
infants	O
born	O
to	O
pregnant	O
women	O
with	O
SARS	B-DISO
.	O

The	O
presence	O
of	O
fever	O
in	O
conjunction	O
with	O
a	O
SARS	B-DISO
exposure	O
history	O
should	O
prompt	O
one	O
to	O
consider	O
SARS	B-DISO
as	O
a	O
possible	O
diagnosis	O
in	O
children	O
irrespective	O
of	O
the	O
presence	O
or	O
absence	O
of	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
nasopharyngeal	O
specimens	O
seems	O
to	O
be	O
of	O
little	O
utility	O
for	O
the	O
diagnosis	O
of	O
SARS	B-DISO
during	O
the	O
early	O
symptomatic	O
phase	O
of	O
this	O
illness	O
in	O
young	O
children	O
.	O

The	O
complete	O
sequence	O
of	O
SARS	B-DISO
genome	O
has	O
provided	O
an	O
opportunity	O
for	O
the	O
development	O
of	O
molecular	O
diagnostic	O
assays	O
.	O

To	O
restrain	O
further	O
outbreak	O
of	O
SARS	B-DISO
,	O
the	O
World	O
Health	O
Organization	O
has	O
posted	O
several	O
pairs	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
for	O
early	O
diagnosis	O
and	O
urged	O
more	O
research	O
to	O
be	O
done	O
on	O
PCR	O
protocols	O
.	O

TITLE	O
:	O
Dynamic	O
changes	O
in	O
blood	O
cytokine	O
levels	O
as	O
clinical	O
indicators	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Observing	O
the	O
dynamic	O
changes	O
in	O
blood	O
cytokine	O
levels	O
can	O
provide	O
a	O
scientific	O
basis	O
to	O
assess	O
pathogenesis	B-DISO
and	O
efficacy	O
of	O
clinical	O
treatment	O
of	O
SARS	B-DISO
.	O

SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
strains	O
would	O
be	O
grouped	O
into	O
two	O
genotypes	O
(	O
C	O
:	O
G	O
:	O
A	O
:	O
C	O
:	O
C	O
/	O
T	O
:	O
T	O
:	O
G	O
:	O
T	O
:	O
T	O
),	O
and	O
abbreviated	O
as	O
SARS	B-DISO
coronavirus	O
C	O
genotype	O
and	O
T	O
genotype	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
valid	O
measures	O
for	O
preventing	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
among	O
protected	O
healthcare	O
workers	O
in	O
isolation	O
units	O
.	O

Numbers	O
of	O
SARS	B-DISO
cases	O
in	O
the	O
wards	O
mentioned	O
above	O
were	O
1	O
,	O
1	O
,	O
1	O
and	O
96	O
,	O
respectively	O
.	O

The	O
infection	B-DISO
rates	O
of	O
the	O
healthcare	O
workers	O
in	O
the	O
areas	O
mentioned	O
above	O
were	O
73	O
.	O
2	O
%,	O
32	O
.	O
1	O
%,	O
27	O
.	O
5	O
%	O
and	O
1	O
.	O
7	O
%,	O
respectively	O
.	O

RESULTS	O
:	O
Four	O
types	O
of	O
isolation	O
wards	O
were	O
analyzed	O
,	O
including	O
the	O
ward	O
where	O
the	O
thirty	O
-	O
first	O
bed	B-DISO
was	O
located	O
on	O
the	O
twelfth	O
floor	O
,	O
the	O
laminar	O
flow	O
ward	O
in	O
the	O
Intensive	O
Care	O
Unit	O
where	O
the	O
tenth	O
bed	B-DISO
was	O
located	O
on	O
the	O
fifteenth	O
floor	O
,	O
the	O
ward	O
where	O
the	O
twenty	O
-	O
seventh	O
bed	B-DISO
was	O
located	O
on	O
the	O
thirteenth	O
floor	O
of	O
the	O
Lingnan	O
Building	O
,	O
and	O
thirty	O
wards	O
on	O
the	O
fourteenth	O
to	O
eighteenth	O
floors	O
of	O
the	O
Zhongshan	O
Building	O
.	O

Pyridoxylidenephloroglucinol	O
rearranges	O
to	O
light	O
-	O
yellow	O
(	O
4	O
'	O
RS	O
)-	O
1	O
',	O
4	O
'-	O
dihydrobananin	O
by	O
refluxing	B-DISO
in	O
5M	O
hydrochloric	O
acid	O
.	O

529	O
-	O
bed	B-DISO
community	O
hospital	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Given	O
the	O
low	O
mortality	O
and	O
morbidity	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
compared	O
with	O
other	O
public	O
health	O
scourges	O
,	O
is	O
the	O
attention	O
devoted	O
to	O
it	O
misdirected	O
?	O

TITLE	O
:	O
Increased	O
expression	O
of	O
19	O
-	O
kD	O
interacting	O
protein	O
-	O
3	O
-	O
like	O
protein	O
and	O
the	O
relationship	O
to	O
apoptosis	O
in	O
the	O
lung	O
of	O
rats	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Pancreatitis	B-DISO
was	O
induced	O
by	O
retrograde	O
intraductal	O
infusion	O
of	O
4	O
%	O
sodium	O
taurocholate	O
(	O
100	O
microL	O
/	O
100	O
g	O
of	O
body	O
weight	O
).	O

This	O
virus	O
was	O
possibly	O
transmitted	B-DISO
from	O
an	O
animal	O
reservoir	O
to	O
humans	O
,	O
and	O
from	O
February	O
2003	O
,	O
the	O
epidemic	O
was	O
spread	O
internationally	O
by	O
further	O
person	O
-	O
to	O
-	O
person	O
transmission	O
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
information	O
of	O
protein	O
-	O
protein	O
interaction	O
between	O
the	O
SARS	B-DISO
-	O
CoV	O
proteins	O
and	O
caveolin	O
-	O
1	O
,	O
identify	O
the	O
possible	O
caveolin	O
-	O
binding	O
sites	O
in	O
SARS	B-DISO
-	O
CoV	O
proteins	O
.	O

On	O
the	O
basis	O
of	O
three	O
related	O
caveolin	O
-	O
binding	O
motifs	O
,	O
amino	O
acid	O
motif	O
search	O
was	O
employed	O
to	O
predict	O
the	O
possible	O
caveolin	O
-	O
1	O
related	O
interaction	O
domains	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
proteins	O
.	O

Caveolin	O
-	O
1	O
may	O
serve	O
as	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
proteins	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
replication	O
,	O
assembly	O
,	O
and	O
budding	O
.	O

RESULTS	O
:	O
Thirty	O
six	O
caveolin	O
-	O
binding	O
motifs	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
proteins	O
have	O
been	O
mapped	O
out	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

New	O
imported	O
SARS	B-DISO
cases	O
therefore	O
need	O
not	O
lead	O
to	O
major	O
outbreaks	O
if	O
systems	O
are	O
in	O
place	O
to	O
identify	O
and	O
isolate	O
them	O
early	O
.	O

Using	O
seroconversion	O
to	O
CoV	O
as	O
the	O
""""	O
gold	O
standard	O
""""	O
for	O
SARS	B-DISO
CoV	O
diagnosis	O
,	O
WHO	O
-	O
HKU	O
and	O
WHO	O
-	O
Hamburg	O
RT	O
-	O
PCR	O
assays	O
exhibited	O
diagnostic	O
sensitivities	O
of	O
61	O
and	O
68	O
%	O
(	O
nasopharyngeal	O
aspirate	O
specimens	O
),	O
65	O
and	O
72	O
%	O
(	O
throat	O
swab	O
specimens	O
),	O
50	O
and	O
54	O
%	O
(	O
urine	O
specimens	O
),	O
and	O
58	O
and	O
63	O
%	O
(	O
stool	O
specimens	O
),	O
respectively	O
,	O
with	O
an	O
overall	O
specificity	O
of	O
100	O
%.	O

She	O
developed	O
cardiogenic	B-DISO
shock	I-DISO
.	O

Left	O
ventriculography	O
showed	O
severe	O
mitral	B-DISO
regurgitation	I-DISO
and	O
global	B-DISO
hypokinesis	I-DISO
.	O

ABSTRACT	O
:	O
Pulmonary	O
gene	O
therapy	O
offers	O
the	O
hope	O
of	O
treatment	O
for	O
conditions	O
such	O
as	O
cystic	B-DISO
fibrosis	I-DISO
,	O
lung	O
cancer	O
,	O
pulmonary	B-DISO
fibrosis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
for	O
which	O
current	O
therapy	O
is	O
inadequate	O
.	O

In	O
France	O
,	O
5	O
probable	O
cases	O
of	O
SARS	B-DISO
were	O
diagnosed	O
until	O
May	O
2003	O
.	O

The	O
clinical	O
symptoms	O
of	O
SARS	B-DISO
are	O
unspecific	O
and	O
its	O
evolution	O
may	O
be	O
misleading	O
.	O

The	O
positive	O
ratio	O
of	O
IgG	O
was	O
higher	O
than	O
that	O
of	O
IgM	O
in	O
SARS	B-DISO
patients	O
during	O
the	O
first	O
stage	O
.	O

TITLE	O
:	O
[	O
Detection	O
and	O
analysis	O
of	O
SARS	B-DISO
coronavirus	O
-	O
specific	O
antibodies	O
in	O
sera	O
from	O
non	O
-	O
SARS	B-DISO
children	O
].	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
presence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
-	O
specific	O
antibodies	O
in	O
the	O
sera	O
from	O
non	O
-	O
SARS	B-DISO
children	O
.	O

Indirect	O
immunofluorescent	O
assay	O
and	O
double	O
-	O
antigen	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
were	O
used	O
to	O
detect	O
the	O
virus	O
-	O
specific	O
antibodies	O
in	O
sera	O
of	O
1	O
,	O
060	O
non	O
-	O
SARS	B-DISO
children	O
in	O
Guangzhou	O
.	O

CONCLUSIONS	O
:	O
No	O
SARS	B-DISO
coronavirus	O
-	O
specific	O
antibody	O
are	O
present	O
in	O
the	O
sera	O
of	O
non	O
-	O
SARS	B-DISO
children	O
.	O

Detection	O
of	O
SARS	B-DISO
-	O
like	O
coronavirus	O
has	O
been	O
reported	O
previously	O
in	O
masked	O
palm	O
civets	O
(	O
sometimes	O
called	O
civet	O
cats	O
)	O
and	O
a	O
raccoon	O
dog	O
for	O
sale	O
in	O
a	O
live	O
animal	O
market	O
in	O
Shenzhen	O
municipality	O
.	O

TITLE	O
:	O
Establishment	O
of	O
persistent	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
antibody	O
-	O
free	O
and	O
antibody	O
-	O
positive	O
chickens	O
.	O

These	O
findings	O
indicate	O
that	O
,	O
unlike	O
the	O
mammalian	O
coronaviruses	O
,	O
propensity	O
for	O
frequent	O
genetic	B-DISO
change	I-DISO
may	O
not	O
be	O
inherent	O
in	O
the	O
IBV	O
genome	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
diagnostic	O
test	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
with	O
the	O
use	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technology	O
.	O

Hepatitis	B-DISO
B	I-DISO
virus	O
nucleic	O
acid	O
testing	O
has	O
not	O
been	O
implemented	O
,	O
and	O
the	O
risk	O
of	O
transfusion	O
-	O
transmitted	B-DISO
hepatitis	B-DISO
B	I-DISO
virus	O
in	O
the	O
United	O
States	O
remains	O
relatively	O
high	O
at	O
an	O
estimated	O
1	O
:	O
205	O
,	O
000	O
.	O

The	O
risk	O
of	O
transfusion	O
-	O
transmitted	B-DISO
human	O
T	B-DISO
-	I-DISO
cell	I-DISO
leukemia	I-DISO
virus	O
I	O
/	O
II	O
is	O
1	O
:	O
2	O
,	O
993	O
,	O
000	O
,	O
based	O
on	O
Red	O
Cross	O
estimates	O
.	O

Prevention	O
of	O
these	O
potential	O
transfusion	O
-	O
transmitted	B-DISO
infections	B-DISO
is	O
addressed	O
by	O
deferring	O
potential	O
donors	O
whose	O
personal	O
behaviors	O
or	O
travel	O
histories	O
place	O
them	O
at	O
risk	O
.	O

With	O
high	O
morbidity	O
and	O
mortality	O
,	O
SARS	B-DISO
is	O
an	O
important	O
respiratory	B-DISO
disease	I-DISO
which	O
may	O
be	O
encountered	O
world	O
-	O
wide	O
.	O

For	O
the	O
respiratory	O
physician	O
,	O
detecting	O
SARS	B-DISO
in	O
its	O
earliest	O
stages	O
,	O
identifying	O
pathways	O
of	O
transmission	O
,	O
and	O
implementing	O
preventive	O
and	O
therapeutic	O
strategies	O
are	O
all	O
important	O
.	O

Ten	O
of	O
48	O
animals	O
tested	O
at	O
more	O
than	O
one	O
time	O
point	O
by	O
RT	O
/	O
nPCR	O
were	O
shedding	B-DISO
virus	I-DISO
at	O
multiple	O
time	O
points	O
possibly	O
indicating	O
persistent	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
A	O
previously	O
undescribed	O
coronavirus	O
(	O
CoV	O
)	O
is	O
the	O
etiologic	O
agent	O
responsible	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Using	O
a	O
panel	O
of	O
contiguous	O
cDNAs	O
that	O
span	O
the	O
entire	O
genome	O
,	O
we	O
have	O
assembled	O
a	O
full	O
-	O
length	O
cDNA	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
Urbani	O
strain	O
,	O
and	O
have	O
rescued	O
molecularly	O
cloned	O
SARS	B-DISO
viruses	O
(	O
infectious	B-DISO
clone	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
contained	O
the	O
expected	O
marker	O
mutations	O
inserted	O
into	O
the	O
component	O
clones	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
affected	O
many	O
areas	O
of	O
the	O
world	O
recently	O
and	O
is	O
becoming	O
a	O
global	O
problem	O
.	O

Also	O
,	O
the	O
worry	O
and	O
fear	O
of	O
an	O
outbreak	O
of	O
SARS	B-DISO
among	O
staff	O
working	O
in	O
the	O
nursing	O
home	O
was	O
considered	O
to	O
be	O
high	O
.	O

TITLE	O
:	O
[	O
Preventive	O
and	O
treatment	O
effect	O
of	O
composite	O
Rhodiolae	O
on	O
acute	O
lung	O
injury	O
in	O
patients	O
with	O
severe	O
pulmonary	B-DISO
hypertension	I-DISO
during	O
extracorporeal	O
circulation	O
].	O

(	O
1	O
)	O
The	O
time	O
for	O
improving	O
symptom	B-DISO
in	O
the	O
ICWM	O
group	O
was	O
5	O
.	O
10	O
days	O
and	O
that	O
in	O
the	O
control	O
group	O
was	O
7	O
.	O
62	O
days	O
,	O
the	O
difference	O
between	O
them	O
was	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
);	O
(	O
2	O
)	O
The	O
days	O
and	O
amount	O
for	O
use	O
hormone	O
before	O
subtract	O
in	O
the	O
two	O
group	O
were	O
similar	O
,	O
with	O
insignificant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
3	O
)	O
The	O
days	O
and	O
amount	O
for	O
use	O
hormone	O
after	O
subtract	O
in	O
the	O
two	O
groups	O
were	O
significantly	O
different	O
(	O
P	O
<	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
The	O
time	O
for	O
improving	O
peripheral	O
WBC	O
count	O
and	O
absolute	O
value	O
of	O
lymphocyte	O
,	O
as	O
well	O
as	O
for	O
absorption	O
time	O
of	O
shadow	O
in	O
chest	O
film	O
were	O
not	O
different	O
significantly	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
In	O
treating	O
SARS	B-DISO
,	O
ICWM	O
was	O
superior	O
to	O
the	O
treatment	O
with	O
western	O
medicine	O
alone	O
in	O
aspects	O
of	O
improving	O
clinical	O
symptom	B-DISO
,	O
promoting	O
recovery	O
of	O
immune	O
function	O
and	O
absorption	O
of	O
lung	B-DISO
inflammation	I-DISO
,	O
decreasing	O
the	O
dosage	O
of	O
hormone	O
used	O
and	O
shortening	O
the	O
therapeutic	O
course	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
on	O
effect	O
of	O
integrative	O
medical	O
treatment	O
on	O
quality	O
of	O
life	O
of	O
rehabilitation	O
stage	O
in	O
85	O
patients	O
with	O
SARS	B-DISO
].	O

Quarantine	O
of	O
the	O
close	O
contacts	O
of	O
confirmed	O
and	O
suspected	O
SARS	B-DISO
cases	O
seems	O
to	O
be	O
the	O
most	O
effective	O
intervention	O
against	O
spread	O
of	O
SARS	B-DISO
in	O
the	O
community	O
.	O

Infections	B-DISO
within	O
hospitals	O
can	O
be	O
reduced	O
by	O
better	O
isolation	O
measures	O
and	O
protective	O
equipments	O
.	O

METHODS	O
:	O
To	O
use	O
a	O
back	O
projection	O
technique	O
to	O
construct	O
the	O
infection	B-DISO
curve	O
of	O
SARS	B-DISO
in	O
Hong	O
Kong	O
.	O

The	O
infections	B-DISO
among	O
the	O
medical	O
and	O
health	O
workers	O
are	O
high	O
.	O

RESULTS	O
:	O
The	O
best	O
parameters	O
to	O
fit	B-DISO
Canadian	O
data	O
as	O
of	O
6	O
April	O
2003	O
(	O
before	O
infection	B-DISO
controls	O
took	O
effect	O
)	O
are	O
R	O
(	O
o	O
)	O
=	O
1	O
.	O
5	O
,	O
F	O
=	O
30	O
%,	O
i	O
=	O
5	O
days	O
,	O
d	O
=	O
14	O
days	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
false	O
-	O
positive	O
of	O
serological	O
diagnostic	O
testing	O
for	O
coronavirus	O
antibody	O
in	O
patients	O
with	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
SLE	B-DISO
),	O
66	O
normal	O
individual	O
and	O
31	O
SLE	B-DISO
with	O
non	O
-	O
SARS	B-DISO
patients	O
were	O
detected	O
for	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
antibody	O
and	O
RNA	O
by	O
enzymelinked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
ELISA	O
kit	O
coated	O
by	O
non	O
-	O
purification	O
antigen	O
may	O
induce	O
the	O
false	O
-	O
positive	O
of	O
SARS	B-DISO
-	O
CoV	O
antibody	O
in	O
patients	O
with	O
SLE	B-DISO
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
development	O
of	O
IgG	O
and	O
IgM	O
against	O
SARS	B-DISO
CoV	O
and	O
characteristics	O
of	O
changes	O
of	O
antibody	O
titers	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
search	O
the	O
opportunity	O
for	O
collecting	O
specific	O
anti	O
-	O
serum	O
from	O
convalescent	O
patients	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
can	O
be	O
associated	O
with	O
various	O
disorders	O
.	O

In	O
this	O
review	O
,	O
we	O
present	O
animal	O
models	O
and	O
techniques	O
for	O
the	O
study	O
of	O
ARDS	B-DISO
,	O
and	O
discuss	O
the	O
roles	O
and	O
possible	O
mechanisms	O
of	O
various	O
chemical	O
factors	O
,	O
including	O
nitric	O
oxide	O
(	O
NO	O
).	O

TITLE	O
:	O
[	O
Genomic	O
variations	O
in	O
the	O
locus	O
for	O
aminopeptidase	O
N	O
:	O
a	O
putative	O
cellular	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
spike	O
glycoprotein	O
].	O

We	O
described	O
the	O
clinical	O
course	O
of	O
the	O
first	O
long	O
-	O
term	O
hemodialysis	O
patient	O
who	O
developed	O
SARS	B-DISO
in	O
the	O
literature	O
,	O
and	O
our	O
experience	O
in	O
performing	O
hemodialysis	O
for	O
this	O
patient	O
.	O

In	O
this	O
patient	O
,	O
the	O
course	O
of	O
disease	O
and	O
duration	O
of	O
viral	B-DISO
shedding	I-DISO
was	O
apparently	O
prolonged	O
,	O
thus	O
highlighting	O
the	O
need	O
for	O
increased	O
infection	B-DISO
control	O
.	O

Difficulties	O
of	O
diagnosis	O
,	O
infection	B-DISO
control	O
,	O
and	O
treatment	O
of	O
SARS	B-DISO
in	O
renal	B-DISO
failure	I-DISO
patients	O
are	O
discussed	O
in	O
this	O
report	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
fever	O
(	O
100	O
%,	O
46	O
/	O
46	O
),	O
cough	B-DISO
(	O
72	O
%,	O
33	O
/	O
46	O
),	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
46	O
%,	O
21	O
/	O
46	O
),	O
and	O
diarrhea	B-DISO
(	O
39	O
%,	O
18	O
/	O
46	O
).	O

The	O
case	O
fatality	O
of	O
infantile	O
beri	B-DISO
-	I-DISO
beri	I-DISO
fell	O
from	O
almost	O
100	O
%	O
to	O
7	O
%.	O

A	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
),	O
was	O
isolated	O
from	O
specimens	O
from	O
three	O
patients	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
persistent	O
airway	O
neutrophilia	O
observed	O
in	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
of	I-DISO
prematurity	I-DISO
(	O
CLD	B-DISO
)	O
may	O
reflect	O
inappropriate	O
suppression	B-DISO
of	O
neutrophil	O
apoptosis	O
.	O

134	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
were	O
obtained	O
from	O
32	O
infants	O
requiring	O
mechanical	O
ventilation	O
for	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	B-DISO
):	O
13	O
infants	O
(	O
median	O
gestation	O
26	O
weeks	O
,	O
range	O
23	O
to	O
28	O
)	O
subsequently	O
developed	O
CLD	B-DISO
(	O
CLD	B-DISO
group	O
),	O
and	O
19	O
infants	O
(	O
gestation	O
31	O
weeks	O
,	O
range	O
25	O
to	O
39	O
)	O
recovered	O
fully	O
(	O
RDS	B-DISO
group	O
).	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
serious	O
respiratory	O
illness	O
that	O
has	O
recently	O
been	O
reported	O
in	O
parts	O
of	O
Asia	O
and	O
Canada	O
.	O

In	O
this	O
study	O
,	O
we	O
use	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
and	O
docking	O
techniques	O
to	O
screen	O
29	O
approved	O
and	O
experimental	O
drugs	O
against	O
the	O
theoretical	O
model	O
of	O
the	O
SARS	B-DISO
CoV	O
proteinase	O
as	O
well	O
as	O
the	O
experimental	O
structure	O
of	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
proteinase	O
.	O

Moreover	O
,	O
chloroquine	O
has	O
immunomodulatory	O
effects	O
,	O
suppressing	O
the	O
production	O
/	O
release	O
of	O
tumour	B-DISO
necrosis	I-DISO
factor	O
alpha	O
and	O
interleukin	O
6	O
,	O
which	O
mediate	O
the	O
inflammatory	O
complications	O
of	O
several	O
viral	B-DISO
diseases	I-DISO
.	O

We	O
review	O
the	O
available	O
information	O
on	O
the	O
effects	O
of	O
chloroquine	O
on	O
viral	B-DISO
infections	I-DISO
,	O
raising	O
the	O
question	O
of	O
whether	O
this	O
old	O
drug	O
may	O
experience	O
a	O
revival	O
in	O
the	O
clinical	O
management	O
of	O
viral	B-DISO
diseases	I-DISO
such	O
as	O
AIDS	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
which	O
afflict	O
mankind	O
in	O
the	O
era	O
of	O
globalisation	O
.	O

In	O
particular	O
,	O
the	O
number	O
of	O
CD4	O
+	O
lymphocytes	O
in	O
tissues	O
decreases	O
during	O
the	O
evolution	O
of	O
FIP	B-DISO
lesions	O
.	O

In	O
contrast	O
,	O
cats	O
infected	O
with	O
the	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
develop	O
a	O
follicular	O
hyperplasia	B-DISO
in	O
the	O
peripheral	O
lymph	O
nodes	O
.	O

The	O
results	O
of	O
the	O
current	O
study	O
suggest	O
that	O
cats	O
recently	O
infected	O
with	O
FCoV	O
that	O
do	O
not	O
develop	O
the	O
disease	O
have	O
a	O
transient	O
increase	O
in	O
T	O
cells	O
;	O
cats	O
from	O
groups	O
with	O
high	O
prevalence	O
of	O
FIP	B-DISO
have	O
a	O
moderate	O
but	O
persistent	O
decrease	O
in	O
T	O
cell	O
subsets	O
;	O
cats	O
with	O
FIP	B-DISO
have	O
a	O
very	O
severe	O
decrease	O
in	O
all	O
the	O
subsets	O
of	O
lymphocytes	O
.	O

This	O
article	O
aims	O
to	O
provide	O
an	O
overview	O
of	O
the	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Sixty	O
-	O
nine	O
patients	O
(	O
26	O
%)	O
required	O
intensive	O
care	O
because	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

For	O
members	O
of	O
the	O
Princess	O
Margaret	O
Hospital	O
SARS	B-DISO
Study	O
Group	O
,	O
see	O
the	O
Appendix	O
.	O

ABSTRACT	O
:	O
In	O
cases	O
of	O
tracheal	O
compression	O
by	O
a	O
mediastinal	O
mass	O
or	O
aortic	B-DISO
aneurysm	I-DISO
,	O
muscle	B-DISO
relaxant	I-DISO
might	O
induce	O
fetal	O
ventilatory	B-DISO
failure	I-DISO
.	O

After	O
the	O
induction	O
of	O
general	O
anesthesia	B-DISO
for	O
video	O
-	O
assisted	O
thoracic	B-DISO
surgery	O
(	O
VATS	O
)	O
for	O
high	O
-	O
pneumothorax	B-DISO
,	O
she	O
was	O
placed	O
in	O
lateral	O
position	O
.	O

Suddenly	O
it	O
became	O
difficult	O
to	O
ventilate	O
her	O
and	O
her	O
oxygenation	O
saturation	O
declined	O
with	O
bradycardia	B-DISO
.	O

We	O
managed	O
successfully	O
to	O
keep	O
spontaneous	O
breathing	O
intact	O
under	O
proper	O
sedation	B-DISO
by	O
three	O
sedative	O
drugs	O
;	O
propofol	O
,	O
midazolam	O
and	O
morphine	O
for	O
5	O
days	O
until	O
the	O
next	O
operation	O
.	O

Interestingly	O
,	O
infection	B-DISO
with	O
live	O
and	O
ultraviolet	O
light	O
-	O
inactivated	O
viruses	O
equally	O
repressed	O
BNip3	O
expression	O
,	O
indicating	O
that	O
the	O
down	O
-	O
regulation	O
of	O
BNip3	O
expression	O
does	O
not	O
require	O
virus	O
replication	O
and	O
is	O
mediated	O
during	O
cell	O
entry	O
.	O

Journey	O
through	O
an	O
epidemic	O
:	O
some	O
observations	O
of	O
contrasting	O
public	O
health	O
responses	O
to	O
SARS	B-DISO
.	O

Active	O
and	O
empowered	O
involvement	O
of	O
the	O
general	O
public	O
in	O
implementing	O
and	O
cooperating	O
with	O
public	O
health	O
control	O
measures	O
supported	O
by	O
national	O
and	O
international	O
authorities	O
has	O
clearly	O
helped	O
to	O
bring	O
SARS	B-DISO
under	O
control	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
public	O
'	O
s	O
knowledge	O
and	O
perception	O
of	O
SARS	B-DISO
and	O
the	O
extent	O
to	O
which	O
various	O
precautionary	O
measures	O
have	O
been	O
adopted	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
features	O
of	O
recurrence	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
therapeutic	O
response	O
.	O

Recurrence	B-DISO
was	O
analyzed	O
retrospectively	O
in	O
SARS	B-DISO
patients	O
referred	O
to	O
our	O
hospital	O
from	O
April	O
to	O
May	O
this	O
year	O
to	O
understand	O
the	O
clinical	O
features	O
,	O
the	O
recurrent	O
related	O
factors	O
,	O
the	O
response	O
of	O
treatment	O
and	O
the	O
outcomes	O
.	O

RESULTS	O
:	O
In	O
recovery	O
phase	O
,	O
the	O
rest	O
heart	O
rates	O
in	O
64	O
%	O
of	O
patients	O
with	O
SARS	B-DISO
exceeded	O
90	O
bpm	O
,	O
and	O
the	O
heart	O
rates	O
after	O
mild	O
exercises	O
in	O
72	O
.	O
1	O
%	O
of	O
patients	O
with	O
SARS	B-DISO
exceeded	O
100	O
bpm	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
,	O
which	O
mainly	O
resulted	O
in	O
pulmonary	O
damage	O
,	O
may	O
involve	O
heart	O
.	O

Young	O
patients	O
start	O
with	O
fever	O
,	O
chills	B-DISO
,	O
malaise	B-DISO
,	O
headache	B-DISO
,	O
or	O
myalgia	B-DISO
;	O
cough	B-DISO
and	O
dyspnoea	B-DISO
follow	O
.	O

TITLE	O
:	O
[	O
Rational	O
therapeutic	O
regime	O
of	O
glucocorticoid	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
its	O
receptor	O
mechanism	O
].	O

ARDS	B-DISO
patients	O
were	O
stratified	O
into	O
three	O
groups	O
,	O
i	O
.	O
e	O
.	O
mild	O
,	O
moderate	O
and	O
severe	O
by	O
clinical	O
indices	O
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
diagnosis	O
,	O
treatment	O
and	O
influential	O
factors	O
in	O
fever	O
patients	O
during	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

CONCLUSIONS	O
:	O
During	O
epidemic	O
of	O
SARS	B-DISO
,	O
the	O
etiology	O
of	O
fever	O
is	O
influenza	B-DISO
or	O
other	O
virus	B-DISO
infection	I-DISO
in	O
90	O
percent	O
of	O
patients	O
.	O

TITLE	O
:	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
employing	O
a	O
recombinant	O
antigen	O
for	O
detection	O
of	O
protective	O
antibody	O
against	O
swine	B-DISO
erysipelas	I-DISO
.	O

This	O
test	O
has	O
important	O
potential	O
for	O
the	O
effective	O
control	O
of	O
swine	B-DISO
erysipelas	I-DISO
.	O

Three	O
of	O
the	O
patients	O
were	O
homozygous	O
for	O
the	O
'	O
common	O
'	O
1528G	O
>	O
C	O
mutation	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
MTP	O
,	O
giving	O
rise	O
to	O
long	B-DISO
-	I-DISO
chain	I-DISO
3	I-DISO
-	I-DISO
hydroxyacyl	I-DISO
-	I-DISO
CoA	I-DISO
dehydrogenase	I-DISO
deficiency	I-DISO
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
a	O
critical	O
care	O
perspective	O
.	O

This	O
was	O
supplemented	O
by	O
epidemiology	O
information	O
obtained	O
from	O
other	O
Web	B-DISO
-	O
based	O
sources	O
.	O

The	O
mortality	O
rate	O
of	O
SARS	B-DISO
patients	O
admitted	O
to	O
the	O
ICU	O
ranged	O
from	O
5	O
%	O
to	O
67	O
%.	O

ARDS	B-DISO
,	O
kidney	B-DISO
failure	I-DISO
,	O
and	O
shock	O
occurred	O
within	O
4	O
days	O
,	O
encephalopathy	B-DISO
within	O
6	O
days	O
(	O
average	O
4	O
.	O
8	O
+/-	O
0	O
.	O
9	O
days	O
),	O
abscesses	B-DISO
after	O
14	O
days	O
,	O
systemic	O
bacterial	B-DISO
infection	I-DISO
and	O
fungous	O
infection	B-DISO
within	O
half	O
a	O
month	O
(	O
average	O
14	O
.	O
6	O
+/-	O
1	O
.	O
1	O
days	O
,	O
14	O
.	O
8	O
+/-	O
0	O
.	O
9	O
days	O
respectively	O
),	O
and	O
death	O
within	O
6	O
days	O
.	O

Acute	O
respiratory	O
viruses	O
commonly	O
induce	O
inflammatory	O
chemokines	O
such	O
as	O
CCL3	O
(	O
also	O
known	O
as	O
macrophage	O
inflammatory	O
protein	O
-	O
1alpha	O
)	O
and	O
CCL5	O
(	O
RANTES	O
),	O
which	O
can	O
amplify	O
inflammatory	B-DISO
responses	I-DISO
leading	O
to	O
immunopathology	B-DISO
.	O

With	O
regard	O
to	O
blockade	O
,	O
combination	O
antiviral	O
/	O
antichemokine	O
therapy	O
is	O
a	O
new	O
strategy	O
worth	O
considering	O
as	O
a	O
general	O
therapeutic	O
approach	O
to	O
viral	B-DISO
infections	I-DISO
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
To	O
check	O
the	O
feasibility	O
of	O
expression	O
of	O
the	O
immunogenic	O
gene	O
of	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
plants	O
,	O
the	O
transformation	B-DISO
of	O
S1	O
gene	O
of	O
IBV	O
into	O
potato	O
and	O
the	O
immunogenicity	O
of	O
its	O
expression	O
product	O
was	O
studied	O
.	O

ABSTRACT	O
:	O
Herpes	B-DISO
simplex	I-DISO
virus	O
(	O
HSV	O
)	O
is	O
occasionally	O
detected	O
in	O
the	O
lower	O
respiratory	O
tract	O
of	O
patients	O
in	O
intensive	O
care	O
,	O
but	O
its	O
clinical	O
importance	O
in	O
such	O
situations	O
remains	O
unclear	O
.	O

A	O
neurosurgical	O
patient	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
received	O
two	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
postoperatively	O
.	O

CONCLUSIONS	O
:	O
The	O
clinician	O
should	O
appreciate	O
that	O
erythrocyte	O
transfusion	O
to	O
prevent	O
or	O
treat	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
may	O
cause	O
transfusion	B-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
,	O
a	O
condition	B-DISO
that	O
mimics	O
,	O
exacerbates	O
or	O
possibly	O
triggers	O
the	O
syndrome	B-DISO
it	O
was	O
intended	O
to	O
treat	O
.	O

ABSTRACT	O
:	O
This	O
exploratory	O
,	O
cross	O
-	O
sectional	O
,	O
quantitative	O
study	O
investigated	O
the	O
relationship	O
among	O
hospital	O
nurses	O
'	O
willingness	O
to	O
provide	O
care	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
,	O
their	O
attitudes	O
toward	O
SARS	B-DISO
infection	B-DISO
control	O
measures	O
,	O
and	O
nurses	O
'	O
health	O
status	O
and	O
demographic	O
characteristics	O
.	O

In	O
addition	O
,	O
vaccination	O
for	O
influenza	B-DISO
and	O
the	O
use	O
of	O
rapid	O
diagnosis	O
kits	O
for	O
influenza	B-DISO
are	O
recommended	O
.	O

ABSTRACT	O
:	O
To	O
prevent	O
SARS	B-DISO
from	O
spreading	O
through	O
air	O
travel	O
and	O
in	O
order	O
to	O
rebuild	O
the	O
confidence	O
of	O
the	O
traveling	O
public	O
in	O
the	O
safety	O
of	O
air	O
travel	O
,	O
ICAO	O
has	O
set	O
up	O
an	O
""""	O
Anti	O
-	O
SARS	B-DISO
Airport	O
Evaluation	O
Project	O
.	O

By	O
mid	O
-	O
July	O
,	O
five	O
international	O
airports	O
in	O
Southeast	O
Asia	O
had	O
been	O
inspected	O
and	O
found	O
to	O
be	O
in	O
full	O
compliance	O
with	O
the	O
ICAO	O
anti	O
-	O
SARS	B-DISO
protective	O
measures	O
.	O

Monkeypox	B-DISO
:	O
beware	O
of	O
exotic	O
pets	O
.	O

Such	O
an	O
analysis	O
,	O
embodied	O
within	O
the	O
DS	O
GeneAtlas	O
pipeline	O
,	O
has	O
been	O
used	O
to	O
critically	O
evaluate	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
genome	O
with	O
the	O
goal	O
of	O
identifying	O
new	O
potential	O
targets	O
for	O
viral	O
therapeutic	O
intervention	O
.	O

This	O
increase	O
persisted	O
only	O
in	O
cats	O
that	O
developed	O
FIP	B-DISO
(	O
in	O
spite	O
of	O
a	O
decrease	O
in	O
alpha	O
(	O
2	O
)-	O
globulins	O
)	O
but	O
it	O
was	O
only	O
transient	O
in	O
FCoV	O
-	O
exposed	O
cats	O
,	O
in	O
which	O
a	O
long	O
lasting	O
increase	O
in	O
alpha	O
(	O
2	O
)-	O
globulins	O
was	O
observed	O
.	O

Cellular	O
infiltrates	B-DISO
in	O
cats	O
with	O
FIP	B-DISO
included	O
lymphocytes	O
,	O
plasma	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
and	O
eosinophils	O
.	O

Principal	O
components	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
find	O
the	O
least	O
number	O
of	O
'	O
components	O
'	O
that	O
would	O
summarize	O
the	O
cytokine	O
profiles	O
in	O
cats	O
with	O
neurological	O
FIP	B-DISO
.	O

Between	O
April	O
17	O
and	O
April	O
26	O
,	O
2003	O
,	O
32	O
consecutive	O
patients	O
with	O
SARS	B-DISO
were	O
encountered	O
.	O

Neither	O
the	O
pharyngeal	O
wall	O
nor	O
the	O
tonsillar	O
area	O
demonstrated	O
hyperemia	B-DISO
.	O

RESULTS	O
:	O
Clinical	O
manifestations	O
included	O
fever	O
in	O
31	O
patients	O
(	O
97	O
%),	O
followed	O
by	O
cough	B-DISO
,	O
dyspnea	B-DISO
,	O
chill	B-DISO
,	O
headache	B-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
diarrhea	B-DISO
,	O
rhinorrhea	B-DISO
,	O
and	O
otalgia	B-DISO
.	O

Although	O
the	O
initial	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
has	O
been	O
controlled	O
by	O
conventional	O
measures	O
,	O
the	O
animal	O
reservoir	O
for	O
the	O
coronavirus	O
progenitor	O
has	O
not	O
been	O
identified	O
.	O

Forty	O
-	O
one	O
patients	O
(	O
66	O
.	O
1	O
%)	O
were	O
in	O
close	O
contact	O
with	O
other	O
probable	O
,	O
suspect	O
,	O
or	O
quarantined	O
cases	O
;	O
10	O
patients	O
(	O
16	O
.	O
1	O
%)	O
had	O
recently	O
traveled	O
to	O
WHO	O
-	O
designated	O
affected	O
areas	O
within	O
10	O
days	O
;	O
and	O
7	O
patients	O
(	O
11	O
.	O
2	O
%)	O
were	O
transferred	O
from	O
other	O
hospitals	O
that	O
had	O
SARS	B-DISO
patients	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
nucleotide	O
sequences	O
showed	O
the	O
clear	O
separation	B-DISO
of	O
sequences	O
analysed	O
on	O
the	O
basis	O
of	O
virulence	O
and	O
geographical	O
origin	O
.	O

In	O
situ	O
hybridization	O
was	O
used	O
to	O
detect	O
the	O
expression	O
and	O
location	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
polymerase	O
gene	O
in	O
autopsy	O
tissues	O
from	O
SARS	B-DISO
-	O
Cov	O
-	O
infected	O
subjects	O
,	O
including	O
the	O
lung	O
,	O
spleen	O
,	O
lymph	O
nodes	O
,	O
pituitary	O
,	O
pancreas	O
,	O
parathyroid	O
,	O
adrenal	O
glands	O
,	O
gastrointestinal	O
tract	O
,	O
skin	O
,	O
brain	O
,	O
liver	O
,	O
kidney	O
,	O
blood	O
vessels	O
,	O
striated	O
muscles	O
of	O
the	O
limbs	O
,	O
bone	O
marrow	O
,	O
heart	O
,	O
ovary	O
,	O
uterus	O
and	O
testicles	O
.	O

SARS	B-DISO
-	O
CoV	O
invades	O
various	O
organs	O
of	O
the	O
body	O
and	O
distributes	O
in	O
a	O
similar	O
fashion	O
to	O
CD13	O
,	O
the	O
receptor	O
of	O
human	O
coronavirus	O
229E	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
the	O
monoclonal	O
antibody	O
against	O
nucleocapsid	O
antigen	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
autopsy	O
tissues	O
from	O
SARS	B-DISO
patients	O
].	O

Immunohistochemical	O
technique	O
was	O
applied	O
in	O
4	O
fatal	O
SARS	B-DISO
cases	O
to	O
examine	O
the	O
autopsy	O
tissues	O
including	O
the	O
lungs	O
,	O
spleen	O
,	O
lymph	O
nodes	O
,	O
brain	O
,	O
pituitary	O
,	O
heart	O
,	O
liver	O
,	O
kidney	O
,	O
pancreas	O
,	O
trachea	B-DISO
,	O
esophagus	O
,	O
gastrointestinal	O
tract	O
,	O
adrenal	O
glands	O
,	O
parathyroids	O
,	O
skin	O
and	O
bone	O
marrow	O
.	O

The	O
2003	O
SARS	B-DISO
outbreak	O
was	O
an	O
extraordinary	O
event	O
in	O
the	O
life	O
of	O
Ontario	O
hospitals	O
,	O
especially	O
around	O
Toronto	O
,	O
and	O
in	O
the	O
lives	O
of	O
the	O
healthcare	O
workers	O
.	O

ABSTRACT	O
:	O
The	O
risk	O
of	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
on	O
airplanes	O
is	O
of	O
major	O
concern	O
to	O
the	O
public	O
and	O
airline	O
industry	O
.	O

TITLE	O
:	O
Air	O
pollution	O
and	O
case	O
fatality	O
of	O
SARS	B-DISO
in	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
:	O
an	O
ecologic	O
study	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
claimed	O
349	O
lives	O
with	O
5	O
,	O
327	O
probable	O
cases	O
reported	O
in	O
mainland	O
China	O
since	O
November	O
2002	O
.	O

Partially	O
ecologic	O
studies	O
were	O
performed	O
to	O
assess	O
the	O
effects	O
of	O
long	O
-	O
term	O
and	O
short	O
-	O
term	O
exposures	O
on	O
the	O
risk	O
of	O
dying	O
from	O
SARS	B-DISO
.	O

Our	O
studies	O
demonstrated	O
a	O
positive	O
association	O
between	O
air	O
pollution	O
and	O
SARS	B-DISO
case	O
fatality	O
in	O
Chinese	O
population	O
by	O
utilizing	O
publicly	O
accessible	O
data	O
on	O
SARS	B-DISO
statistics	O
and	O
air	O
pollution	O
indices	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
recognised	O
and	O
highly	O
contagious	O
respiratory	B-DISO
infection	I-DISO
caused	O
by	O
a	O
new	O
strain	O
of	O
coronavirus	O
.	O

TITLE	O
:	O
SARS	B-DISO
virus	O
:	O
the	O
beginning	O
of	O
the	O
unraveling	O
of	O
a	O
new	O
coronavirus	O
.	O

However	O
,	O
distinct	O
patterns	O
of	O
several	O
open	O
reading	O
frames	O
in	O
the	O
SARS	B-DISO
virus	O
genome	O
may	O
contribute	O
to	O
its	O
severe	O
virulence	O
.	O

The	O
life	O
cycle	O
of	O
the	O
SARS	B-DISO
virus	O
is	O
largely	O
unknown	O
;	O
however	O
,	O
based	O
on	O
the	O
analogy	O
with	O
other	O
coronaviruses	O
,	O
several	O
potential	O
targets	O
for	O
antiviral	O
development	O
are	O
identified	O
.	O

The	O
stability	O
of	O
SARS	B-DISO
coronavirus	O
in	O
human	O
specimens	O
and	O
in	O
environments	O
was	O
studied	O
.	O

A	O
total	O
of	O
10	O
(	O
6	O
)	O
TCID50	O
viruses	O
were	O
placed	O
in	O
each	O
tested	O
condition	B-DISO
,	O
and	O
changes	O
of	O
the	O
viral	O
infectivity	O
in	O
samples	O
after	O
treatments	O
were	O
measured	O
by	O
evaluating	O
cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
in	O
cell	O
line	O
Vero	O
-	O
E6	O
at	O
48	O
h	O
after	O
infection	B-DISO
.	O

Emerging	O
infections	B-DISO
are	O
a	O
serious	O
concern	O
for	O
both	O
the	O
public	O
and	O
healthcare	O
practitioners	O
.	O

The	O
recent	O
global	O
diffusion	O
of	O
SARS	B-DISO
highlights	O
the	O
ease	O
in	O
which	O
diseases	O
can	O
diffuse	O
from	O
place	O
to	O
place	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
antibody	O
titer	O
between	O
patients	O
of	O
bacterial	B-DISO
pneumonia	I-DISO
and	O
patients	O
of	O
atypical	B-DISO
pneumonia	I-DISO
,	O
which	O
was	O
-	O
1	O
.	O
99	O
+/-	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
observed	O
in	O
serum	O
levels	O
of	O
interleukins	O
(	O
ILs	B-DISO
),	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	O
-	O
8	O
in	O
SARS	B-DISO
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
,	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
in	O
8	O
-	O
14	O
days	O
group	O
and	O
in	O
over	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
than	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
The	O
mean	O
concentration	O
of	O
serum	O
IL	O
-	O
6	O
in	O
SARS	B-DISO
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
as	O
compared	O
to	O
the	O
control	O
group	O
,	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

B	O
cells	O
,	O
B1	O
cells	O
and	O
the	O
expression	O
of	O
CD40	O
on	O
B	O
cells	O
were	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

The	O
monitoring	O
of	O
B	O
cells	O
,	O
B1	O
cells	O
and	O
the	O
expression	O
of	O
CD40	O
on	O
B	O
cells	O
is	O
useful	O
in	O
the	O
differential	O
diagnosis	O
of	O
SARS	B-DISO
.	O

It	O
was	O
suggested	O
that	O
the	O
causes	O
for	O
cardiac	B-DISO
arrest	I-DISO
in	O
SARS	B-DISO
patients	O
may	O
include	O
:	O
(	O
1	O
)	O
the	O
lung	O
injury	O
caused	O
by	O
the	O
SARS	B-DISO
virus	O
leads	O
to	O
hypoxemia	O
and	O
thus	O
an	O
unsteady	O
state	O
of	O
the	O
myocardial	O
electricity	O
;	O
(	O
2	O
)	O
SARS	B-DISO
virus	O
directly	O
causes	O
injury	O
to	O
the	O
myocardial	O
cells	O
and	O
/	O
or	O
the	O
conduct	O
system	O
;	O
(	O
3	O
)	O
SARS	B-DISO
infection	B-DISO
aggravates	O
the	O
original	O
myocardial	O
pathological	O
change	O
,	O
worsening	O
the	O
conduct	O
block	O
;	O
(	O
4	O
)	O
extreme	O
anxiety	O
leads	O
to	O
extra	O
secretion	O
of	O
catecholamine	O
,	O
which	O
causes	O
instability	O
of	O
myocardial	O
electricity	O
;	O
(	O
5	O
)	O
defecation	O
worsens	O
hypoxemia	O
,	O
which	O
induces	O
arrhythmia	B-DISO
(	O
ventricular	B-DISO
fibrillation	I-DISO
)	O
and	O
causes	O
cardiac	B-DISO
arrest	I-DISO
.	O

Consequently	O
,	O
we	O
thoroughly	O
investigated	O
the	O
immunoreactivities	O
with	O
patient	O
sera	O
of	O
a	O
series	O
of	O
synthesized	O
peptides	O
from	O
SARS	B-DISO
-	O
coronavirus	O
structural	O
proteins	O
.	O

Four	O
epitopic	O
sites	O
,	O
S599	O
,	O
M137	O
,	O
N66	O
,	O
and	O
N371	O
-	O
404	O
,	O
located	O
in	O
the	O
SARS	B-DISO
-	O
coronavirus	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
screening	O
synthesized	O
peptides	O
.	O

In	O
this	O
study	O
,	O
we	O
immunized	O
cats	O
with	O
cell	O
lysate	O
with	O
recombinant	O
baculovirus	O
-	O
expressed	O
N	O
protein	O
of	O
the	O
Type	O
I	O
FIPV	O
strain	O
KU	O
-	O
2	O
with	O
an	O
adjuvant	O
and	O
investigated	O
its	O
preventive	O
effect	O
on	O
the	O
progression	O
of	O
FIP	B-DISO
.	O

This	O
study	O
showed	O
that	O
immunization	O
with	O
the	O
cell	O
lysate	O
with	O
baculovirus	O
-	O
expressed	O
N	O
protein	O
was	O
effective	O
in	O
preventing	O
the	O
progression	O
of	O
FIP	B-DISO
without	O
inducing	O
ADE	O
of	O
FIPV	O
infection	B-DISO
in	O
cats	O
.	O

During	O
URTI	B-DISO
,	O
also	O
respiratory	O
syncytial	O
virus	O
(	O
approximately	O
20	O
%)	O
and	O
coronavirus	O
(	O
approximately	O
10	O
%)	O
infections	B-DISO
were	O
found	O
,	O
which	O
were	O
rarely	O
detected	O
in	O
infants	O
with	O
rhinitis	B-DISO
.	O

The	O
parental	O
history	O
of	O
atopy	B-DISO
was	O
not	O
related	O
to	O
the	O
prevalence	O
of	O
rhinovirus	B-DISO
infection	I-DISO
,	O
indicating	O
that	O
the	O
genetic	O
risk	O
of	O
allergic	O
disease	O
does	O
not	O
seem	O
to	O
increase	O
the	O
chance	O
of	O
rhinovirus	O
infections	B-DISO
.	O

TITLE	O
:	O
Nosocomial	O
Transmission	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Are	O
we	O
ready	O
for	O
pandemic	O
influenza	B-DISO
?	O

At	O
the	O
same	O
time	O
,	O
an	O
old	O
foe	O
has	O
again	O
raised	O
its	O
head	O
,	O
reminding	O
us	O
that	O
our	O
worst	O
nightmare	B-DISO
may	O
not	O
be	O
a	O
new	O
one	O
.	O

Together	O
our	O
data	O
indicate	O
that	O
ACE2	O
is	O
a	O
functional	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O

The	O
cDNA	O
library	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
PUMC01	O
isolate	O
)	O
was	O
constructed	O
by	O
means	O
of	O
random	O
-	O
priming	O
strategy	O
.	O

In	O
phylogenetic	O
analysis	O
of	O
18	O
SARS	B-DISO
-	O
CoV	O
isolates	O
,	O
two	O
classes	O
were	O
observed	O
and	O
there	O
is	O
different	O
differential	O
time	O
between	O
these	O
two	O
classes	O
and	O
the	O
different	O
isolates	O
in	O
each	O
class	O
.	O

TITLE	O
:	O
[	O
Cloning	O
,	O
expression	O
and	O
purification	O
of	O
SARS	B-DISO
coronavirus	O
PUMC2	O
strain	O
nucleocapsid	O
protein	O
].	O

Prokaryoticly	O
expressed	O
and	O
purified	O
N	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
PUMC2	O
strain	O
was	O
obtained	O
.	O

The	O
numbers	O
of	O
blood	O
vessels	O
decreased	O
in	O
the	O
fibrotic	O
and	O
consolidated	O
lung	O
tissue	O
,	O
and	O
the	O
vessel	O
cavities	B-DISO
enlarged	O
,	O
losing	O
the	O
normal	O
contour	O
of	O
alveolar	O
septa	O
.	O

RESULTS	O
:	O
The	O
patients	O
had	O
a	O
moderately	O
degree	O
physiological	O
impairment	B-DISO
and	O
increased	O
SGRQ	O
score	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
pulmonary	O
function	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
during	O
the	O
convalescent	O
period	O
.	O

No	O
gender	O
difference	O
in	O
SARS	B-DISO
cases	O
was	O
found	O
.	O

People	O
were	O
all	O
susceptible	O
to	O
SARS	B-DISO
,	O
which	O
mainly	O
threatened	O
the	O
young	O
adults	O
and	O
the	O
middle	O
-	O
aged	O
,	O
as	O
well	O
as	O
health	O
care	O
workers	O
and	O
the	O
retired	O
workers	O
.	O

Flow	O
cytometer	O
with	O
multi	O
-	O
color	O
flouroscence	O
and	O
hematology	O
analyzer	O
were	O
used	O
to	O
detect	O
the	O
expression	O
of	O
T	O
lymphocyte	O
and	O
its	O
activated	O
a	O
subsets	O
in	O
240	O
SARS	B-DISO
patients	O
including	O
50	O
cases	O
of	O
critical	O
type	O
and	O
190	O
cases	O
of	O
common	O
type	O
.	O

TITLE	O
:	O
[	O
Clinical	O
diagnosis	O
,	O
treatment	O
and	O
prognosis	O
of	O
elderly	O
SARS	B-DISO
patients	O
].	O

Elderly	O
patients	O
diagnosed	O
as	O
SARS	B-DISO
in	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
were	O
compared	O
with	O
younger	O
patients	O
.	O

These	O
results	O
also	O
confirm	O
that	O
ACE2	O
is	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	B-DISO
virus	O
and	O
may	O
help	O
in	O
the	O
elucidation	O
of	O
the	O
mechanisms	O
of	O
SARS	B-DISO
-	O
CoV	O
entry	O
and	O
in	O
the	O
development	O
of	O
vaccine	O
immunogens	O
and	O
entry	O
inhibitors	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
the	O
""""	O
Chinese	O
Chernobyl	O
""""	O
emerged	O
against	O
an	O
alarming	O
background	O
of	O
rising	O
infectious	B-DISO
disease	I-DISO
in	O
poor	O
rural	O
China	O
and	O
to	O
a	O
backdrop	O
of	O
interregional	O
and	O
global	O
polarization	O
of	O
population	O
well	O
-	O
being	O
and	O
vulnerability	O
.	O

SARS	B-DISO
has	O
added	O
its	O
own	O
dissonant	O
note	O
to	O
""""	O
health	O
disturbance	O
""","	O
caused	O
fear	O
and	O
panic	O
and	O
disrupted	O
international	O
commerce	O
.	O

This	O
essay	O
presents	O
a	O
qualitative	O
flowchart	O
that	O
follows	O
SARS	B-DISO
from	O
its	O
origin	O
in	O
China	O
to	O
the	O
accumulation	O
of	O
global	O
damage	O
.	O

TITLE	O
:	O
Molecular	O
diagnostics	O
of	O
atypical	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
global	O
health	O
concern	O
.	O

Our	O
results	O
suggest	O
that	O
designing	O
anti	O
-	O
SARS	B-DISO
therapies	O
can	O
benefit	O
from	O
successful	O
experiences	O
in	O
design	O
of	O
other	O
antiviral	O
drugs	O
.	O

Gene	O
recombination	O
and	O
fusion	O
of	O
more	O
than	O
one	O
virus	O
in	O
ecosystems	O
should	O
take	O
charge	O
with	O
the	O
origin	O
of	O
a	O
SARS	B-DISO
virus	O
.	O

In	O
particular	O
,	O
a	O
common	B-DISO
cold	I-DISO
or	O
influenza	B-DISO
virus	O
can	O
acceleratedly	O
changed	O
into	O
a	O
superpower	O
common	B-DISO
cold	I-DISO
or	O
influenza	B-DISO
virus	O
through	O
genetic	O
mutation	O
and	O
gene	O
recombination	O
by	O
increasingly	O
combined	O
pollution	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Toronto	O
,	O
its	O
impact	O
on	O
anesthesia	B-DISO
practice	O
and	O
the	O
infection	B-DISO
control	O
guidelines	O
adopted	O
to	O
manage	O
patients	O
in	O
the	O
operating	O
room	O
(	O
OR	O
)	O
and	O
to	O
provide	O
emergency	B-DISO
intubation	O
outside	O
the	O
OR	O
.	O

TITLE	O
:	O
Laboratory	O
-	O
based	O
surveillance	O
for	O
influenza	B-DISO
:	O
role	O
of	O
the	O
Wisconsin	O
State	O
Laboratory	O
of	O
Hygiene	O
.	O

Influenza	B-DISO
viruses	O
also	O
cause	O
pandemics	O
,	O
during	O
which	O
the	O
rates	O
of	O
illness	O
and	O
death	O
can	O
be	O
expected	O
to	O
be	O
much	O
higher	O
.	O

Effusion	B-DISO
RT	O
-	O
PCR	O
was	O
performed	O
in	O
6	O
cats	O
;	O
it	O
was	O
positive	O
in	O
all	O
5	O
cats	O
with	O
FIP	B-DISO
and	O
negative	O
in	O
the	O
cat	O
with	O
another	O
disease	O
.	O

The	O
pulmonary	O
alveoli	O
were	O
thickened	O
with	O
interstitial	O
mononuclear	O
inflammatory	O
infiltrates	B-DISO
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
desquamation	O
of	O
pneumocytes	O
and	O
hyaline	O
-	O
membrane	O
formation	O
;	O
fibrinoid	O
material	O
and	O
erythrocytes	O
were	O
present	O
in	O
alveolar	O
spaces	O
.	O

Severe	O
immunological	O
damage	O
in	O
lung	O
tissue	O
is	O
responsible	O
for	O
the	O
clinical	O
features	O
of	O
SARS	B-DISO
.	O

More	O
attention	O
needs	O
to	O
be	O
given	O
to	O
the	O
identification	O
of	O
the	O
underlying	O
causes	O
for	O
the	O
emergence	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
which	O
are	O
often	O
related	O
to	O
anthropogenic	O
social	O
and	O
environmental	O
changes	O
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
nucleocapsid	O
protein	O
was	O
employed	O
to	O
establish	O
an	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

ABSTRACT	O
:	O
Two	O
cases	O
of	O
severe	O
community	O
-	O
acquired	O
pneumococcal	B-DISO
pneumonia	I-DISO
(	O
CAP	B-DISO
)	O
admitted	O
to	O
our	O
hospital	O
within	O
24	O
h	O
are	O
described	O
,	O
both	O
in	O
young	O
males	O
.	O

These	O
two	O
cases	O
illustrate	O
the	O
usefulness	O
of	O
the	O
British	O
Thoracic	B-DISO
Society	O
severity	O
criteria	O
and	O
serve	O
to	O
emphasize	O
the	O
importance	O
of	O
early	O
recognition	O
of	O
adverse	O
physiology	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
still	O
empirical	O
and	O
controversial	O
.	O

Paediatric	O
nephrologists	O
should	O
be	O
on	O
the	O
alert	O
for	O
SARS	B-DISO
in	O
order	O
to	O
care	O
for	O
immunocompromised	O
patients	O
.	O

TITLE	O
:	O
A	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
the	O
diagnosis	O
of	O
turkey	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
RT	O
-	O
PCR	O
was	O
sensitive	O
and	O
specific	O
for	O
TCoV	O
and	O
did	O
not	O
amplify	O
other	O
avian	O
RNA	O
and	O
DNA	O
viruses	O
tested	O
except	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

The	O
closely	O
related	O
bovine	O
coronavirus	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
of	O
pigs	O
were	O
differentiated	O
from	O
TCoV	O
using	O
the	O
same	O
RT	O
-	O
PCR	O
with	O
slight	O
modifications	O
.	O

The	O
results	O
of	O
RT	O
-	O
PCR	O
correlated	O
well	O
with	O
the	O
results	O
of	O
the	O
immunofluorescent	O
test	O
for	O
the	O
same	O
samples	O
tested	O
at	O
the	O
Purdue	O
University	O
Animal	B-DISO
Disease	I-DISO
Laboratory	O
,	O
West	O
Lafayette	O
,	O
Indiana	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
a	O
young	O
African	O
male	O
with	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
who	O
developed	O
an	O
acute	O
,	O
severe	O
Guillain	O
-	O
Barré	O
-	O
like	O
peripheral	B-DISO
neuropathy	I-DISO
associated	O
with	O
ascites	O
.	O

All	O
vaccinated	O
animals	O
showed	O
strong	O
neutralising	O
antibody	O
responses	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
vitro	O
.	O

The	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
were	O
presence	O
of	O
diarrhoea	B-DISO
,	O
high	O
peak	O
LDH	O
and	O
CRP	O
,	O
high	O
AST	O
and	O
creatine	O
kinase	O
on	O
admission	O
and	O
high	O
peak	O
values	O
.	O

TITLE	O
:	O
Revised	O
U	O
.	O
S	O
.	O
surveillance	O
case	O
definition	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
update	O
on	O
SARS	B-DISO
cases	O
--	O
United	O
States	O
and	O
worldwide	O
,	O
December	O
2003	O
.	O

ABSTRACT	O
:	O
It	O
is	O
unclear	O
when	O
,	O
where	O
and	O
how	O
novel	O
pathogens	O
such	O
as	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
),	O
monkeypox	B-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
will	O
cross	O
the	O
barriers	O
that	O
separate	O
their	O
natural	O
reservoirs	O
from	O
human	O
populations	O
and	O
ignite	O
the	O
epidemic	O
spread	O
of	O
novel	O
infectious	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
deadly	O
form	O
of	O
pneumonia	B-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
a	O
viral	O
family	O
responsible	O
for	O
mild	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
a	O
wide	O
variety	O
of	O
animals	O
including	O
humans	O
,	O
pigs	O
,	O
cows	O
,	O
mice	O
,	O
cats	O
,	O
and	O
birds	O
.	O

ABSTRACT	O
:	O
With	O
the	O
hospital	O
-	O
based	O
transmission	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Ontario	O
,	O
acute	O
care	O
hospitals	O
severely	O
restricted	O
visitor	O
access	O
.	O

TITLE	O
:	O
The	O
secret	O
life	O
of	O
ACE2	O
as	O
a	O
receptor	O
for	O
the	O
SARS	B-DISO
virus	O
.	O

Now	O
,	O
Li	O
at	O
al	O
.	O
identify	O
and	O
characterize	O
an	O
unexpected	O
second	O
function	O
of	O
ACE2	O
as	O
a	O
partner	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
glycoprotein	O
in	O
mediating	O
virus	O
entry	O
and	O
cell	O
fusion	O
.	O

After	O
Koch	O
'	O
s	O
postulates	O
had	O
been	O
fulfilled	O
,	O
WHO	O
officially	O
declared	O
on	O
16	O
April	O
2003	O
that	O
this	O
virus	O
never	O
before	O
seen	O
in	O
humans	O
is	O
the	O
cause	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Vaccines	O
against	O
infectious	B-DISO
bronchitis	B-DISO
of	O
chickens	O
(	O
Gallus	O
gallus	O
domesticus	O
)	O
have	O
arguably	O
been	O
the	O
most	O
successful	O
,	O
and	O
certainly	O
the	O
most	O
widely	O
used	O
,	O
of	O
vaccines	O
for	O
diseases	O
caused	O
by	O
coronaviruses	O
,	O
the	O
others	O
being	O
against	O
bovine	O
,	O
canine	O
,	O
feline	O
and	O
porcine	O
coronaviruses	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
together	O
with	O
the	O
genetically	O
related	O
coronaviruses	O
of	O
turkey	O
(	O
Meleagris	O
gallopovo	O
)	O
and	O
ring	O
-	O
necked	O
pheasant	O
(	O
Phasianus	O
colchicus	O
),	O
is	O
a	O
group	O
3	O
coronavirus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
being	O
tentatively	O
in	O
group	O
4	O
,	O
the	O
other	O
known	O
mammalian	O
coronaviruses	O
being	O
in	O
groups	O
1	O
and	O
2	O
.	O

Adoptive	O
transfer	O
of	O
IBV	O
-	O
infection	B-DISO
-	O
induced	O
alphabeta	O
T	O
cells	O
bearing	O
CD8	O
antigen	O
protected	O
chicks	O
from	O
challenge	O
infection	B-DISO
.	O

Patients	O
usually	O
present	O
with	O
high	O
fever	O
,	O
chills	B-DISO
,	O
myalgia	B-DISO
and	O
dry	B-DISO
cough	I-DISO
,	O
with	O
or	O
without	O
chest	O
X	O
-	O
ray	O
evidence	O
of	O
pneumonia	B-DISO
at	O
the	O
onset	O
of	O
disease	O
.	O

Researchers	O
now	O
think	O
that	O
the	O
SARS	B-DISO
virus	O
split	O
from	O
group	O
2	O
coronaviruses	O
,	O
and	O
that	O
this	O
happened	O
relatively	O
recently	O
on	O
the	O
scale	O
of	O
coronavirus	O
evolution	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
based	O
elderly	O
studies	O
concerning	O
microbiology	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
are	O
scarce	O
.	O

In	O
a	O
1	O
-	O
year	O
community	O
-	O
based	O
study	O
,	O
we	O
prospectively	O
investigated	O
the	O
possible	O
virologic	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
107	O
symptomatic	O
case	O
episodes	O
and	O
91	O
symptom	B-DISO
-	O
free	O
control	O
periods	O
.	O

In	O
contrast	O
,	O
another	O
flight	O
carrying	O
four	O
symptomatic	O
persons	O
resulted	O
in	O
transmission	O
to	O
at	O
most	O
one	O
other	O
person	O
,	O
and	O
no	O
illness	O
was	O
documented	O
in	O
passengers	O
on	O
the	O
flight	O
that	O
carried	O
a	O
person	O
who	O
had	O
presymptomatic	O
SARS	B-DISO
.	O

Using	O
twelve	O
gene	O
prediction	O
methods	O
to	O
predict	O
coronavirus	O
known	O
genes	O
,	O
we	O
select	O
four	O
better	O
methods	O
including	O
Heuristic	O
models	O
,	O
Gene	O
Identification	O
,	O
ZCURVE_CoV	O
and	O
ORF	O
FINDER	O
to	O
predict	O
SARS	B-DISO
-	O
CoV	O
(	O
BJ01	O
),	O
and	O
use	O
ATGpr	O
for	O
analyzing	O
probability	O
of	O
initiation	O
codon	O
and	O
Kozak	O
rule	O
,	O
search	O
transcription	O
regulating	O
sequence	O
(	O
TRS	B-DISO
)	O
in	O
order	O
to	O
improve	O
the	O
accuracy	O
of	O
predicted	O
genes	O
.	O

We	O
reviewed	O
the	O
HRCT	O
findings	O
at	O
presentation	O
(	O
n	O
=	O
12	O
)	O
and	O
after	O
hospital	O
admission	O
(	O
n	O
=	O
25	O
)	O
of	O
29	O
patients	O
with	O
SARS	B-DISO
and	O
compared	O
the	O
HRCT	O
findings	O
with	O
the	O
radiographic	O
findings	O
.	O

Follow	O
-	O
up	O
CT	O
scans	O
obtained	O
in	O
hospitalized	O
patients	O
show	O
findings	O
consistent	O
with	O
fibrosis	B-DISO
in	O
a	O
small	O
percentage	O
of	O
patients	O
.	O

TITLE	O
:	O
High	O
-	O
resolution	O
CT	O
findings	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
pattern	O
-	O
based	O
approach	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
serious	O
atypical	B-DISO
pneumonia	I-DISO
caused	O
by	O
a	O
novel	O
pathogen	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
an	O
acute	O
enteritis	B-DISO
in	O
pigs	O
of	O
all	O
ages	O
,	O
often	O
fatality	O
for	O
neonates	O
.	O

Since	O
Germany	O
was	O
exclusively	O
confronted	O
with	O
imported	O
SARS	B-DISO
cases	O
,	O
the	O
surveillance	O
system	O
could	O
fulfil	O
the	O
requirements	O
.	O

Extensive	O
laboratory	O
studies	O
of	O
the	O
two	O
molecules	O
zanamivir	O
and	O
oseltamivir	O
have	O
shown	O
that	O
they	O
block	O
all	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
yet	O
tested	O
and	O
would	O
,	O
in	O
theory	O
,	O
even	O
inhibit	O
the	O
1918	O
pandemic	O
virus	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
mitochondrial	O
-	O
aconitase	O
binds	O
specifically	O
to	O
the	O
3	O
'	O
terminal	O
42	O
nucleotides	O
of	O
the	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
RNA	O
along	O
with	O
three	O
additional	O
proteins	O
of	O
70	O
,	O
58	O
and	O
40	O
kDa	O
to	O
form	O
a	O
stable	O
RNA	O
-	O
protein	O
complex	O
.	O

We	O
report	O
a	O
girl	O
born	O
at	O
37	O
weeks	O
of	O
gestation	O
presenting	O
12	O
hours	O
after	O
birth	O
with	O
hypopnea	O
,	O
bradycardia	B-DISO
and	O
a	O
decreased	O
muscular	O
tone	O
of	O
unknown	O
origin	O
.	O

Paroxetine	O
withdrawal	B-DISO
syndrome	I-DISO
should	O
be	O
considered	O
as	O
one	O
of	O
the	O
differential	O
diagnosis	O
of	O
neonatal	B-DISO
encephalopathy	I-DISO
.	O

There	O
were	O
two	O
major	O
manifestations	O
of	O
near	O
-	O
drowning	O
in	O
the	O
Dead	O
Sea	O
:	O
electrolyte	B-DISO
imbalance	I-DISO
and	O
acute	O
lung	O
injury	O
.	O

45	O
unweaned	O
crias	O
with	O
diarrhea	B-DISO
.	O

TITLE	O
:	O
Neurotropism	B-DISO
of	O
swine	O
haemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
coronavirus	O
)	O
in	O
mice	O
depending	O
upon	O
host	O
age	O
and	O
route	O
of	O
infection	B-DISO
.	O

To	O
follow	O
the	O
spread	O
of	O
HEV	O
from	O
peripheral	O
nerves	O
to	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
),	O
the	O
virus	O
was	O
inoculated	O
subcutaneously	O
into	O
the	O
right	O
hind	O
leg	O
of	O
4	O
-	O
week	O
-	O
old	O
mice	O
.	O

The	O
brain	O
titres	O
became	O
higher	O
than	O
those	O
of	O
the	O
spinal	O
cord	B-DISO
,	O
reaching	O
a	O
maximum	O
of	O
10	O
(	O
7	O
)	O
PFU	O
/	O
0	O
.	O
2	O
g	O
when	O
the	O
animals	O
were	O
showing	O
CNS	O
signs	O
.	O

In	O
this	O
preliminary	O
,	O
uncontrolled	O
study	O
of	O
patients	O
with	O
SARS	B-DISO
,	O
use	O
of	O
interferon	O
alfacon	O
-	O
1	O
plus	O
corticosteroids	O
was	O
associated	O
with	O
reduced	O
disease	O
-	O
associated	O
impaired	B-DISO
oxygen	O
saturation	O
,	O
more	O
rapid	O
resolution	O
of	O
radiographic	O
lung	O
abnormalities	O
,	O
and	O
lower	O
levels	O
of	O
creatine	O
kinase	O
.	O

TITLE	O
:	O
CXC	O
chemokine	O
ligand	O
10	O
controls	O
viral	B-DISO
infection	I-DISO
in	O
the	O
central	O
nervous	B-DISO
system	O
:	O
evidence	O
for	O
a	O
role	O
in	O
innate	B-DISO
immune	I-DISO
response	I-DISO
through	O
recruitment	B-DISO
and	O
activation	O
of	O
natural	O
killer	O
cells	O
.	O

ABSTRACT	O
:	O
How	O
chemokines	O
shape	O
the	O
immune	O
response	O
to	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
has	O
largely	O
been	O
considered	O
within	O
the	O
context	O
of	O
recruitment	B-DISO
and	O
activation	O
of	O
antigen	O
-	O
specific	O
lymphocytes	O
.	O

TITLE	O
:	O
An	O
indolent	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

MHV	O
replication	O
is	O
impaired	B-DISO
in	O
autophagy	O
knockout	O
,	O
APG5	O
-/-,	O
embryonic	O
stem	O
cell	O
lines	O
,	O
but	O
wild	O
-	O
type	O
levels	O
of	O
MHV	O
replication	O
are	O
restored	O
by	O
expression	O
of	O
Apg5	O
in	O
the	O
APG5	O
-/-	O
cells	O
.	O

ABSTRACT	O
:	O
Two	O
cases	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
that	O
occurred	O
in	O
Singapore	O
General	O
Hospital	O
are	O
described	O
.	O

In	O
contrast	O
,	O
the	O
plasma	O
concentrations	O
of	O
other	O
key	O
proinflammatory	O
cytokines	O
,	O
including	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
,	O
were	O
not	O
overtly	O
increased	O
in	O
any	O
of	O
the	O
patients	O
throughout	O
the	O
course	B-DISO
of	I-DISO
illness	I-DISO
.	O

SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
an	O
enveloped	O
RNA	O
virus	O
,	O
which	O
contains	O
several	O
structural	O
proteins	O
.	O

Focusing	O
on	O
tests	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
we	O
attempted	O
to	O
determine	O
the	O
optimal	O
specimen	O
types	O
and	O
timing	O
of	O
specimen	O
collection	O
.	O

TITLE	O
:	O
Infliximab	O
:	O
a	O
new	O
therapeutic	O
agent	O
in	O
acute	B-DISO
pancreatitis	I-DISO
?	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
therapeutic	O
effectiveness	O
of	O
monoclonal	O
TNF	O
antibody	O
(	O
infliximab	O
)	O
in	O
acute	O
edematous	B-DISO
and	O
severe	O
necrotizing	B-DISO
pancreatitis	I-DISO
models	O
in	O
rats	O
.	O

Chimeric	O
TNF	O
antibody	O
,	O
infliximab	O
,	O
should	O
be	O
evaluated	O
for	O
treatment	O
of	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Items	O
with	O
significant	O
differences	O
among	O
symptoms	O
,	O
signs	O
,	O
and	O
laboratory	O
tests	O
on	O
presentation	O
between	O
SARS	B-DISO
and	O
non	O
-	O
SARS	B-DISO
groups	O
were	O
determined	O
and	O
used	O
to	O
develop	O
the	O
scoring	O
system	O
.	O

ABSTRACT	O
:	O
On	O
March	O
13	O
,	O
2003	O
,	O
Singapore	O
physicians	O
were	O
alerted	O
about	O
an	O
outbreak	O
of	O
atypical	B-DISO
pneumonia	I-DISO
that	O
became	O
known	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

No	O
patient	O
contracted	O
SARS	B-DISO
as	O
a	O
result	O
of	O
an	O
ED	O
visit	O
.	O

The	O
total	O
points	O
of	O
the	O
scoring	O
system	O
for	O
SARS	B-DISO
at	O
initial	O
presentation	O
were	O
significantly	O
higher	O
in	O
the	O
SARS	B-DISO
group	O
(	O
median	O
9	O
;	O
range	O
6	O
to	O
11	O
)	O
than	O
in	O
the	O
non	O
-	O
SARS	B-DISO
group	O
(	O
median	O
4	O
;	O
range	O
3	O
to	O
7	O
;	O
P	O
<.	O
001	O
).	O

RESULTS	O
:	O
The	O
scoring	O
system	O
for	O
SARS	B-DISO
was	O
defined	O
as	O
radiographic	O
findings	O
of	O
multilobar	O
or	O
bilateral	O
infiltrates	B-DISO
(	O
3	O
points	O
),	O
sputum	O
monocyte	O
predominance	O
(	O
3	O
points	O
),	O
lymphocytopenia	B-DISO
(	O
2	O
points	O
),	O
history	O
of	O
exposure	O
(	O
1	O
point	O
),	O
lactate	O
dehydrogenase	O
more	O
than	O
450	O
U	O
/	O
L	O
(	O
1	O
point	O
),	O
C	O
-	O
reactive	O
protein	O
more	O
than	O
5	O
.	O
0	O
mg	O
/	O
dL	O
(	O
1	O
point	O
),	O
and	O
activated	O
partial	O
prothrombin	O
time	O
more	O
than	O
40	O
seconds	O
(	O
1	O
point	O
).	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
the	O
scoring	O
system	O
for	O
SARS	B-DISO
were	O
83	O
%	O
and	O
100	O
%,	O
respectively	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
chronologically	O
document	O
the	O
time	O
sequence	O
of	O
symptom	B-DISO
development	O
in	O
probable	O
SARS	B-DISO
cases	O
and	O
compare	O
that	O
of	O
the	O
febrile	O
non	O
-	O
SARS	B-DISO
cases	O
,	O
thus	O
providing	O
valuable	O
information	O
for	O
early	O
recognition	O
of	O
the	O
disease	O
.	O

Probable	O
SARS	B-DISO
cases	O
were	O
determined	O
by	O
the	O
Center	O
of	O
Disease	O
Control	O
Taiwan	O
.	O

The	O
major	O
clinical	O
symptoms	O
of	O
SARS	B-DISO
patients	O
on	O
ED	O
presentation	O
were	O
myalgia	B-DISO
,	O
loose	B-DISO
stool	I-DISO
or	O
diarrhea	B-DISO
,	O
nonproductive	B-DISO
cough	I-DISO
or	O
dyspnea	B-DISO
,	O
headache	B-DISO
,	O
and	O
chills	B-DISO
.	O

When	O
the	O
clinical	O
score	O
was	O
applied	O
to	O
patients	O
with	O
a	O
positive	O
symptom	B-DISO
score	O
,	O
the	O
combined	O
sensitivity	O
reached	O
90	O
.	O
2	O
%	O
(	O
95	O
%	O
CI	O
82	O
.	O
0	O
%	O
to	O
95	O
.	O
0	O
%),	O
and	O
the	O
combined	O
specificity	O
reached	O
80	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
73	O
.	O
2	O
%	O
to	O
85	O
.	O
6	O
%).	O

Travellers	O
were	O
asked	O
about	O
contact	O
with	O
SARS	B-DISO
and	O
possible	O
symptoms	O
,	O
were	O
screened	O
for	O
high	O
fever	O
,	O
provided	O
with	O
health	O
information	O
and	O
observed	O
for	O
any	O
clinical	O
signs	O
.	O

The	O
use	O
of	O
these	O
primers	O
allowed	O
the	O
detection	O
of	O
viruses	O
that	O
have	O
undergone	O
recombination	O
around	O
this	O
hot	B-DISO
spot	I-DISO
.	O

We	O
compared	O
the	O
abilities	O
of	O
conventional	O
and	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
to	O
detect	O
SARS	B-DISO
CoV	O
in	O
clinical	O
specimens	O
.	O

To	O
investigate	O
the	O
nature	O
of	O
viral	O
RNA	O
molecules	O
in	O
these	O
clinical	O
samples	O
,	O
we	O
determined	O
copy	O
numbers	O
of	O
ORF	O
1b	O
and	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
sequences	O
of	O
SARS	B-DISO
CoV	O
.	O
The	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
was	O
more	O
sensitive	O
than	O
the	O
conventional	O
RT	O
-	O
PCR	O
assay	O
for	O
detecting	O
SARS	B-DISO
CoV	O
in	O
samples	O
collected	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

RESULTS	O
:	O
Since	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
March	O
2003	O
,	O
the	O
weekly	O
outpatient	O
clinic	O
attendance	O
has	O
declined	O
by	O
59	O
%,	O
the	O
number	O
of	O
operations	O
performed	O
by	O
79	O
%,	O
the	O
average	O
ward	O
bed	B-DISO
occupancy	O
rate	O
by	O
79	O
%	O
and	O
the	O
daily	O
admission	O
rate	O
by	O
84	O
%.	O

This	O
was	O
a	O
three	O
and	O
a	O
half	O
year	O
retrospective	O
study	O
comprising	O
of	O
98	O
patients	O
who	O
died	O
of	O
ARDS	B-DISO
in	O
the	O
intensive	O
care	O
unit	O
of	O
Apollo	O
Hospital	O
,	O
a	O
tertiary	O
care	O
referral	O
centre	O
between	O
January	O
1999	O
to	O
June	O
2002	O
.	O

The	O
present	O
study	O
looked	O
at	O
only	O
those	O
patients	O
who	O
died	O
from	O
ARDS	B-DISO
and	O
did	O
not	O
evaluate	O
the	O
clinical	O
outcome	O
or	O
survival	O
pattern	O
of	O
ARDS	B-DISO
patients	O
.	O

The	O
criteria	O
used	O
for	O
diagnosis	O
of	O
ARDS	B-DISO
was	O
based	O
upon	O
American	O
/	O
European	O
consensus	O
statement	O
for	O
definition	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
ARDS	B-DISO
.	O

Primary	O
pulmonary	B-DISO
infection	I-DISO
was	O
associated	O
with	O
ARDS	B-DISO
is	O
one	O
-	O
third	O
of	O
patients	O
.	O

This	O
case	O
is	O
the	O
first	O
description	O
of	O
successful	O
early	O
and	O
long	O
-	O
term	O
management	O
of	O
severe	O
lung	O
involvement	O
observed	O
in	O
cryoglobulinemia	B-DISO
.	O

Although	O
she	O
has	O
been	O
free	O
of	O
chest	O
symptoms	O
for	O
seven	O
months	O
,	O
further	O
follow	O
-	O
up	O
may	O
be	O
necessary	O
to	O
assess	O
the	O
potential	O
danger	O
of	O
relapse	B-DISO
.	O

TITLE	O
:	O
Hericium	O
erinaceum	O
(	O
yamabushitake	O
)	O
extract	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
monitored	O
by	O
serum	O
surfactant	O
proteins	O
.	O

Strategies	O
,	O
devised	O
using	O
information	O
about	O
the	O
coronavirus	O
available	O
at	O
the	O
time	O
,	O
as	O
well	O
as	O
epidemiologic	O
and	O
infectious	B-DISO
disease	I-DISO
containment	O
measures	O
,	O
were	O
initiated	O
to	O
protect	O
obstetrical	O
patients	O
and	O
staff	O
.	O

A	O
relationship	O
between	O
the	O
level	O
of	O
fecal	O
IgAs	O
to	O
CCV	B-DISO
and	O
the	O
degree	O
of	O
protection	O
against	O
CCV	B-DISO
infection	B-DISO
was	O
observed	O
.	O

Subsequent	O
follow	O
-	O
up	O
of	O
the	O
2	O
(	O
7	O
%)	O
patients	O
with	O
normal	O
HRCT	O
on	O
admission	O
showed	O
that	O
they	O
were	O
having	O
nonpneumonic	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
infection	B-DISO
only	O
and	O
were	O
eventually	O
denotified	O
from	O
having	O
SARS	B-DISO
.	O

SARS	B-DISO
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
presumably	O
originating	O
from	O
wild	O
cats	O
.	O

The	O
WHO	O
has	O
implemented	O
a	O
number	O
of	O
programs	O
to	O
eradicate	O
or	O
eliminate	O
targeted	O
infectious	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Accurate	O
clinical	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
based	O
on	O
the	O
current	O
World	O
Health	O
Organization	O
definition	O
is	O
difficult	O
and	O
at	O
times	O
impossible	O
at	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

It	O
is	O
characterized	O
by	O
a	O
rise	O
of	O
temperature	O
to	O
at	O
least	O
100	O
.	O
4	O
degrees	O
F	O
,	O
associated	O
offensive	O
or	O
purulent	O
vaginal	O
discharge	O
and	O
lower	B-DISO
abdominal	I-DISO
pain	I-DISO
and	O
tenderness	B-DISO
.	O

Induced	O
septic	B-DISO
abortions	I-DISO
were	O
analyzed	O
between	O
April	O
1992	O
and	O
September	O
1999	O
in	O
TU	O
Teaching	O
hospital	O
.	O

ABSTRACT	O
:	O
Whether	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
can	O
be	O
asymptomatic	O
is	O
unclear	O
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	O
factor	O
plays	O
a	O
key	O
role	O
in	O
the	O
induction	O
of	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
,	O
leading	O
to	O
the	O
synthesis	O
of	O
cytokines	O
,	O
adhesion	B-DISO
molecules	O
,	O
chemokines	O
,	O
growth	O
factors	O
and	O
enzymes	O
.	O

Circulating	O
lymphocytes	O
had	O
the	O
highest	O
percentage	O
of	O
infection	B-DISO
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggested	O
that	O
lymphocytes	O
,	O
particularly	O
T	O
cells	O
,	O
were	O
probably	O
the	O
target	O
cells	O
of	O
SARS	B-DISO
CoV	O
.	O
The	O
viruses	O
may	O
actively	O
infected	O
the	O
immune	O
cells	O
during	O
SARS	B-DISO
CoV	O
acute	B-DISO
infection	I-DISO
phase	O
and	O
the	O
destruction	O
of	O
target	O
cells	O
may	O
be	O
one	O
of	O
the	O
important	O
reasons	O
for	O
the	O
death	O
of	O
the	O
circulating	O
leukocytes	O
in	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
which	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
virulent	O
and	O
highly	O
contagious	O
organism	O
.	O

By	O
5	O
days	O
postinfection	O
,	O
these	O
mice	O
showed	O
significantly	O
(	O
approximately	O
20	O
-	O
fold	O
)	O
lower	O
titers	O
of	O
infectious	B-DISO
virus	O
in	O
the	O
brain	O
compared	O
to	O
control	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
gp33	O
-	O
41	O
-	O
specific	O
cells	O
failed	O
to	O
protect	O
perforin	O
-	O
deficient	O
mice	O
from	O
infection	B-DISO
by	O
the	O
recombinant	O
MHV	O
expressing	O
gp33	O
,	O
indicating	O
that	O
perforin	O
-	O
mediated	O
mechanisms	O
were	O
needed	O
.	O

This	O
paper	O
aims	O
at	O
providing	O
an	O
overview	O
of	O
what	O
is	O
known	O
about	O
SARS	B-DISO
and	O
the	O
impact	O
it	O
has	O
had	O
in	O
Hong	O
Kong	O
and	O
to	O
highlight	O
from	O
the	O
perspective	O
of	O
a	O
school	O
of	O
nursing	O
the	O
major	O
clinical	O
,	O
educational	O
and	O
public	O
health	O
implications	O
.	O

The	O
index	O
patient	O
presented	O
with	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O
initially	O
without	O
changes	O
to	O
his	O
chest	O
radiograph	O
.	O

TITLE	O
:	O
Telehealth	O
responses	O
to	O
bio	O
-	O
terrorism	O
and	O
emerging	O
infections	B-DISO
.	O

Three	O
major	O
lessons	O
were	O
learned	O
as	O
a	O
result	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
2003	O
,	O
involving	O
communication	O
,	O
evidence	O
-	O
based	O
action	O
and	O
global	O
partnerships	O
.	O

Bronchiectasis	B-DISO
was	O
seen	O
in	O
2	O
cases	O
,	O
atelectasis	B-DISO
and	O
mosaic	O
perfusion	O
were	O
seen	O
respectively	O
in	O
one	O
case	O
.	O

Chest	O
radiographs	O
showed	O
hyperinflation	B-DISO
.	O

METHODS	O
:	O
Clinical	O
manifestation	O
,	O
chest	O
X	O
-	O
ray	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
pulmonary	O
function	O
of	O
4	O
cases	O
with	O
bronchiolitis	B-DISO
obliterans	I-DISO
were	O
retrospectively	O
analyzed	O
.	O

For	O
this	O
need	O
,	O
we	O
purified	O
recombinant	O
proteins	O
including	O
the	O
nucleocapsid	O
(	O
N	O
),	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
truncated	O
forms	O
of	O
the	O
spike	O
protein	O
(	O
S1	O
-	O
S7	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
Escherichia	O
coli	O
.	O

(	O
2	O
)	O
When	O
iNO	O
was	O
connected	O
to	O
the	O
ventilator	O
circuit	O
,	O
the	O
connected	O
site	O
should	O
be	O
placed	O
before	O
humidifier	O
to	O
minimize	O
fluctuation	B-DISO
of	O
iNO	O
concentration	O
,	O
and	O
sampling	O
site	O
for	O
iNO	O
monitoring	O
should	O
be	O
placed	O
adequately	O
to	O
eliminate	O
artifact	O
.	O

TITLE	O
:	O
Understanding	O
SARS	B-DISO
with	O
Wolfram	O
approach	O
.	O

ABSTRACT	O
:	O
Stepping	B-DISO
acquired	B-DISO
immunodeficiency	I-DISO
syndrome	I-DISO
(	O
AIDS	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
as	O
another	O
type	O
of	O
disease	O
has	O
been	O
threatening	O
mankind	O
since	O
late	O
last	O
year	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
lessons	O
learned	O
from	O
other	O
coronaviruses	O
.	O

As	O
a	O
result	O
of	O
the	O
SARS	B-DISO
epidemic	O
,	O
coronaviruses	O
can	O
now	O
be	O
considered	O
as	O
emerging	O
pathogens	O
.	O

The	O
genotyping	O
and	O
phylogeny	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
analyzed	O
and	O
reported	O
in	O
this	O
paper	O
.	O

For	O
patients	O
with	O
fever	O
,	O
normal	O
or	O
low	O
count	O
of	O
white	O
blood	O
cell	O
and	O
with	O
suspected	O
pneumonia	B-DISO
suggested	O
by	O
X	O
-	O
ray	O
,	O
it	O
was	O
urgent	O
to	O
determine	O
the	O
etiological	O
agents	O
of	O
the	O
diseases	O
before	O
they	O
were	O
admitted	O
to	O
the	O
hospital	O
.	O

These	O
data	O
indicate	O
that	O
the	O
patient	O
was	O
a	O
confirmed	O
case	O
of	O
SARS	B-DISO
.	O

The	O
data	O
mentioned	O
above	O
indicate	O
that	O
antigen	O
and	O
gene	O
detections	O
for	O
those	O
common	O
respiratory	O
viruses	O
are	O
useful	O
methods	O
for	O
the	O
differentiation	O
to	O
avoid	O
the	O
spread	O
of	O
SARS	B-DISO
.	O

All	O
the	O
5	O
cases	O
developed	O
nonproductive	B-DISO
cough	I-DISO
;	O
on	O
auscultation	O
,	O
both	O
moist	O
and	O
dry	O
rales	B-DISO
could	O
be	O
heard	O
in	O
3	O
out	O
of	O
the	O
5	O
cases	O
.	O

IgG	O
and	O
IgM	O
antibodies	O
to	O
Mycoplasma	B-DISO
pneumoniae	O
and	O
Chlamydia	O
pneumoniae	O
as	O
well	O
as	O
blood	O
culture	O
for	O
bacteria	O
were	O
all	O
negative	O
.	O

CONCLUSIONS	O
:	O
Patients	O
presenting	O
with	O
normal	O
findings	O
or	O
focal	O
air	O
-	O
space	O
opacity	B-DISO
on	O
chest	O
radiographs	O
had	O
a	O
good	O
clinical	O
outcome	O
.	O

Knowledge	O
of	O
the	O
ecology	O
of	O
influenza	B-DISO
in	O
wet	O
markets	O
can	O
be	O
used	O
as	O
an	O
early	O
-	O
warning	O
system	O
to	O
detect	O
the	O
reappearance	O
of	O
SARS	B-DISO
or	O
pandemic	O
influenza	B-DISO
.	O

Median	O
maximal	O
respiratory	B-DISO
dysfunction	I-DISO
score	O
was	O
3	O
(	O
interquartile	O
range	O
3	O
-	O
4	O
).	O

Increased	O
age	O
,	O
severity	O
of	O
illness	O
,	O
lymphocyte	O
count	O
,	O
decreased	O
steroid	O
dose	O
,	O
positive	O
fluid	O
balance	O
,	O
chronic	B-DISO
disease	I-DISO
or	O
immunosuppression	O
and	O
nosocomial	O
sepsis	B-DISO
were	O
associated	O
with	O
poor	O
outcome	O
on	O
univariate	O
analysis	O
.	O

76	O
male	O
wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
five	O
groups	O
:	O
A	O
)	O
control	O
group	O
;	O
B	O
)	O
endotoxemic	O
group	O
,	O
receiving	O
intravenous	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
8	O
mg	O
.	O
kg	O
-	O
1	O
;	O
C	O
)	O
pretreatment	O
group	O
,	O
treated	O
identically	O
to	O
endotoxemic	O
group	O
with	O
the	O
additional	O
administration	O
of	O
propofol	O
(	O
5	O
mg	O
.	O
kg	O
-	O
1	O
bolus	O
,	O
followed	O
by	O
infusion	O
at	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
)	O
of	O
1	O
hr	O
prior	O
to	O
the	O
injection	O
of	O
LPS	B-DISO
;	O
D	O
)	O
simultaneously	O
treatment	O
group	O
,	O
treated	O
identically	O
to	O
endotoxemic	O
group	O
with	O
the	O
additional	O
administration	O
of	O
propofol	O
simultaneously	O
with	O
the	O
injection	O
of	O
LPS	B-DISO
;	O
E	O
)	O
post	O
-	O
treatment	O
group	O
,	O
which	O
was	O
treated	O
identically	O
to	O
endotoxemic	O
group	O
except	O
for	O
administration	O
of	O
propofol	O
1	O
hr	O
after	O
the	O
injection	O
of	O
LPS	B-DISO
.	O

Our	O
findings	O
also	O
suggest	O
that	O
while	O
respondents	O
unanimously	O
agreed	O
that	O
they	O
would	O
inform	O
their	O
parents	O
,	O
spouse	O
,	O
siblings	O
and	O
employers	O
if	O
they	O
were	O
tested	O
positive	O
for	O
SARS	B-DISO
,	O
they	O
were	O
more	O
ambivalent	O
about	O
disclosing	O
such	O
information	O
to	O
their	O
neighbours	O
and	O
colleagues	O
.	O

TITLE	O
:	O
Bystander	O
CD8	O
T	O
-	O
cell	O
-	O
mediated	O
demyelination	B-DISO
is	O
interferon	O
-	O
gamma	O
-	O
dependent	O
in	O
a	O
coronavirus	O
model	O
of	O
multiple	B-DISO
sclerosis	I-DISO
.	O

TITLE	O
:	O
Do	O
men	O
have	O
a	O
higher	O
case	O
fatality	O
rate	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
than	O
women	O
do	O
?	O

Thus	O
,	O
among	O
SARS	B-DISO
patients	O
,	O
males	O
may	O
be	O
more	O
severely	O
affected	O
by	O
the	O
disease	O
than	O
females	O
are	O
.	O

ABSTRACT	O
:	O
Inflammatory	B-DISO
response	I-DISO
leading	O
to	O
organ	O
dysfunction	O
and	O
failure	O
continues	O
to	O
be	O
the	O
major	O
problem	O
after	O
injury	O
in	O
many	O
clinical	O
conditions	O
such	O
as	O
sepsis	B-DISO
,	I-DISO
severe	I-DISO
burns	O
,	O
acute	B-DISO
pancreatitis	I-DISO
,	O
haemorrhagic	B-DISO
shock	I-DISO
,	O
and	O
trauma	O
.	O

Acute	O
lung	O
injury	O
that	O
clinically	O
manifests	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
major	O
component	O
of	O
MODS	B-DISO
of	O
various	O
aetiologies	O
.	O

Inflammatory	O
mediators	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
,	O
which	O
is	O
the	O
primary	O
cause	O
of	O
death	O
in	O
these	O
conditions	O
.	O

This	O
review	O
summarizes	O
recent	O
studies	O
that	O
demonstrate	O
the	O
critical	O
role	O
played	O
by	O
inflammatory	O
mediators	O
such	O
as	O
tumour	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	B-DISO
),	O
IL	O
-	O
10	O
,	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
),	O
C5a	O
,	O
intercellular	O
adhesion	B-DISO
molecule	O
(	O
ICAM	O
)-	O
1	O
,	O
substance	O
P	O
,	O
chemokines	O
,	O
VEGF	O
,	O
IGF	O
-	O
I	O
,	O
KGF	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
),	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	B-DISO
)	O
in	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
.	O

However	O
,	O
much	O
of	O
the	O
biological	O
behaviour	O
of	O
the	O
virus	O
is	O
not	O
known	O
and	O
data	O
on	O
the	O
tissue	O
and	O
cellular	O
tropism	O
of	O
SARS	B-DISO
-	O
CoV	O
are	O
limited	O
.	O

These	O
findings	O
indicated	O
that	O
tissue	O
responses	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
are	O
distinct	O
in	O
different	O
organs	O
.	O

Fourteen	O
cases	O
had	O
close	O
contact	O
with	O
SARS	B-DISO
patients	O
.	O

All	O
the	O
18	O
patients	O
but	O
one	O
presented	O
with	O
fever	O
and	O
cough	B-DISO
.	O

Between	O
the	O
end	O
of	O
February	O
and	O
the	O
end	O
of	O
May	O
2003	O
,	O
a	O
fowl	B-DISO
plague	I-DISO
outbreak	O
occurred	O
in	O
The	O
Netherlands	O
.	O

Sedation	B-DISO
was	O
initially	O
achieved	O
with	O
propofol	O
up	O
to	O
standard	O
doses	O
into	O
a	O
nonfemoral	O
venous	O
site	O
.	O

ABSTRACT	O
:	O
In	O
April	O
2003	O
,	O
the	O
Ontario	O
Legislature	O
amended	O
the	O
province	O
'	O
s	O
public	O
health	O
legislation	O
as	O
part	O
of	O
a	O
package	O
of	O
amendments	O
related	O
to	O
the	O
recent	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
[	O
Clinical	O
characteristics	O
and	O
prognosis	O
of	O
33	O
children	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Guangzhou	O
area	O
].	O

Five	O
(	O
15	O
%)	O
cases	O
had	O
an	O
evident	O
history	O
of	O
contacting	O
SARS	B-DISO
patient	O
before	O
the	O
symptoms	O
occurred	O
.	O

Antibodies	O
that	O
specifically	O
recognize	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
and	O
nucleocapsid	O
proteins	O
may	O
provide	O
a	O
rapid	O
screening	O
method	O
to	O
allow	O
accurate	O
identification	O
and	O
isolation	O
of	O
patients	O
with	O
the	O
virus	O
early	O
in	O
their	O
infection	B-DISO
.	O

Three	O
patients	O
had	O
evidence	O
of	O
fibrosis	B-DISO
.	O

Cysts	B-DISO
were	O
present	O
in	O
one	O
patient	O
who	O
received	O
only	O
short	O
-	O
term	O
low	O
-	O
pressure	O
and	O
low	O
-	O
volume	O
ventilation	O
and	O
in	O
one	O
patient	O
who	O
received	O
no	O
mechanical	O
ventilation	O
.	O

The	O
pathophysiology	O
of	O
ARDS	B-DISO
includes	O
abnormalities	O
of	O
surfactant	O
function	O
as	O
well	O
as	O
pulmonary	B-DISO
inflammation	I-DISO
.	O

Adolescents	O
infected	O
with	O
SARS	B-DISO
may	O
develop	O
severe	O
illness	O
as	O
adults	O
,	O
and	O
close	O
monitoring	O
for	O
disease	B-DISO
progression	I-DISO
in	O
terms	O
of	O
both	O
clinical	O
and	O
radiologic	O
deterioration	O
is	O
warranted	O
.	O

TITLE	O
:	O
Current	O
challenges	O
in	O
lower	O
respiratory	B-DISO
infections	I-DISO
in	O
children	O
.	O

The	O
diagnosis	O
and	O
clinical	O
management	O
of	O
lower	O
respiratory	B-DISO
infections	I-DISO
pose	O
challenges	O
to	O
pediatric	O
health	O
providers	O
as	O
new	O
technology	O
is	O
developed	O
and	O
new	O
pathogens	O
emerge	O
in	O
the	O
spectrum	O
of	O
clinical	O
disease	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
on	O
structural	O
proteins	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
.	O

Three	O
structural	O
proteins	O
named	O
S	O
,	O
N	O
and	O
M	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
uncovered	O
with	O
the	O
sequence	O
coverage	O
of	O
38	O
.	O
9	O
,	O
93	O
.	O
1	O
and	O
28	O
.	O
1	O
%	O
respectively	O
.	O

However	O
,	O
administration	O
of	O
anti	O
-	O
IP	O
-	O
10	O
serum	O
caused	O
no	O
difference	O
in	O
clinical	O
signs	O
,	O
inflammation	B-DISO
,	O
demyelination	B-DISO
,	O
virus	O
persistence	O
or	O
anti	O
-	O
virus	O
antibody	O
response	O
in	O
TMEV	O
infection	B-DISO
,	O
while	O
levels	O
of	O
virus	O
specific	O
and	O
autoreactive	O
lymphoproliferation	O
increased	O
.	O

TITLE	O
:	O
[	O
Morphological	O
study	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)].	O

In	O
order	O
to	O
understand	O
the	O
personal	O
need	O
of	O
being	O
quarantined	O
and	O
to	O
estimate	O
the	O
risk	O
of	O
developing	O
SARS	B-DISO
during	O
the	O
quarantine	O
period	O
,	O
a	O
survey	O
on	O
the	O
quarantined	O
residents	O
of	O
Haidian	O
District	O
,	O
Beijing	O
,	O
China	O
was	O
carried	O
out	O
.	O

Of	O
those	O
who	O
completed	O
the	O
questionnaire	O
,	O
2	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
5	O
%	O
-	O
3	O
.	O
5	O
%)	O
developed	O
SARS	B-DISO
while	O
under	O
quarantine	O
.	O

Persons	O
who	O
looked	O
after	O
the	O
illed	O
SARS	B-DISO
patient	O
(	O
s	O
)	O
during	O
their	O
symptomatic	O
period	O
,	O
had	O
an	O
highest	O
attack	O
rate	O
of	O
31	O
%	O
(	O
95	O
%	O
CI	O
:	O
20	O
%	O
-	O
44	O
%).	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiologic	O
features	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Beijing	O
.	O

Totally	O
,	O
2	O
521	O
portable	O
cases	O
were	O
diagnosed	O
and	O
verified	O
according	O
to	O
the	O
diagnostic	O
criteria	O
of	O
SARS	B-DISO
issued	O
by	O
the	O
Ministry	O
of	O
Health	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
analysis	O
of	O
SARS	B-DISO
genome	O
using	O
gene	O
prediction	O
method	O
GeneDecipher	O
developed	O
in	O
our	O
laboratory	O
has	O
been	O
presented	O
.	O

Each	O
of	O
the	O
18	O
newly	O
sequenced	O
SARS	B-DISO
-	O
CoV	O
genomes	O
has	O
been	O
analyzed	O
using	O
GeneDecipher	O
.	O

Detailed	O
results	O
of	O
GeneDecipher	O
analysis	O
of	O
all	O
the	O
18	O
strains	O
of	O
SARS	B-DISO
-	O
CoV	O
genomes	O
are	O
available	O
at	O
http	O
://	O
www	O
.	O
igib	O
.	O
res	O
.	O
in	O
/	O
sarsanalysis	O
.	O
html	O
RESULTS	O
:	O
In	O
this	O
paper	O
,	O
a	O
novel	O
analysis	O
of	O
SARS	B-DISO
genome	O
using	O
gene	O
prediction	O
method	O
GeneDecipher	O
developed	O
in	O
our	O
laboratory	O
has	O
been	O
presented	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
without	O
respiratory	B-DISO
symptoms	I-DISO
or	O
abnormal	O
chest	O
radiograph	O
findings	O
.	O

TITLE	O
:	O
Expression	O
cloning	O
of	O
functional	O
receptor	O
used	O
by	O
SARS	B-DISO
coronavirus	O
.	O

Intensive	O
care	O
unit	O
(	O
ICU	O
)	O
nurses	O
and	O
other	O
healthcare	O
workers	O
who	O
care	O
for	O
SARS	B-DISO
patients	O
are	O
at	O
risk	O
of	O
contracting	O
the	O
disease	O
.	O

TITLE	O
:	O
Mild	O
illness	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
:	O
lessons	O
from	O
a	O
prospective	O
seroepidemiologic	O
study	O
of	O
health	O
-	O
care	O
workers	O
in	O
a	O
teaching	O
hospital	O
in	O
Singapore	O
.	O

There	O
was	O
a	O
trend	O
towards	O
protection	O
for	O
HCWs	O
who	O
,	O
while	O
fully	O
protected	O
,	O
had	O
had	O
contact	O
with	O
patients	O
with	O
SARS	B-DISO
.	O

HCoV	O
was	O
detected	O
in	O
28	O
(	O
11	O
%)	O
of	O
the	O
261	O
clinical	O
specimens	O
obtained	O
from	O
patients	O
presenting	O
with	O
symptoms	O
of	O
RTI	B-DISO
ranging	O
from	O
common	B-DISO
cold	I-DISO
to	O
severe	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
associated	O
viral	B-DISO
hepatitis	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
:	O
report	O
of	O
three	O
cases	O
.	O

Here	O
we	O
report	O
the	O
clinical	O
course	O
and	O
liver	O
pathology	B-DISO
in	O
three	O
SARS	B-DISO
patients	O
with	O
liver	O
impairment	B-DISO
.	O

Immunohistochemical	O
studies	O
revealed	O
0	O
.	O
5	O
%	O
to	O
11	O
.	O
4	O
%	O
of	O
nuclei	O
were	O
positive	O
for	O
proliferative	B-DISO
antigen	O
Ki	O
-	O
67	O
.	O

With	O
better	O
knowledge	O
of	O
pathogenesis	B-DISO
,	O
specific	O
therapy	O
may	O
be	O
targeted	O
to	O
reduce	O
viral	O
replication	O
and	O
modify	O
the	O
disease	O
course	O
.	O

Nineteen	O
patients	O
with	O
ARDS	B-DISO
and	O
10	O
with	O
ALI	O
were	O
included	O
in	O
this	O
prospective	O
investigation	O
.	O

The	O
assay	O
will	O
permit	O
further	O
studies	O
of	O
the	O
cellular	O
immune	O
responses	O
in	O
cats	O
during	O
natural	O
and	O
experimental	O
viral	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
usefulness	O
of	O
ascites	O
as	O
a	O
material	O
for	O
viral	O
tests	O
in	O
cats	O
with	O
effusive	B-DISO
feline	I-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
we	O
attempted	O
to	O
detect	O
anti	O
-	O
feline	O
coronavirus	O
antibody	O
,	O
anti	O
-	O
feline	O
immunodeficiency	B-DISO
virus	O
antibody	O
,	O
and	O
feline	B-DISO
leukemia	I-DISO
virus	O
antigen	O
in	O
ascites	O
from	O
88	O
cats	O
clinically	O
suspected	O
with	O
effusive	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
acute	O
respiratory	O
illness	O
,	O
which	O
has	O
broken	O
out	O
in	O
China	O
.	O

GPs	B-DISO
who	O
were	O
exposed	O
to	O
SARS	B-DISO
or	O
who	O
had	O
worked	O
in	O
high	O
infection	B-DISO
districts	O
were	O
less	O
likely	O
to	O
quarantine	O
themselves	O
(	O
10	O
.	O
8	O
%	O
versus	O
33	O
.	O
3	O
%;	O
p	O
<	O
0	O
.	O
01	O
;	O
6	O
.	O
5	O
%	O
versus	O
27	O
.	O
5	O
%;	O
p	O
<	O
0	O
.	O
01	O
respectively	O
).	O

Exposure	O
to	O
SARS	B-DISO
,	O
the	O
infection	B-DISO
rates	O
in	O
their	O
working	O
district	O
,	O
and	O
anxiety	O
levels	O
had	O
significant	O
impact	O
on	O
the	O
level	O
of	O
protection	O
or	O
prescribing	O
behaviour	O
.	O

According	O
to	O
this	O
structure	O
model	O
,	O
the	O
leader	O
TRS	B-DISO
is	O
located	O
in	O
the	O
loop	O
of	O
a	O
prominent	O
hairpin	O
(	O
leader	O
TRS	B-DISO
hairpin	O
;	O
LTH	O
).	O

RESULTS	O
:	O
Sequencing	O
analysis	O
confirmed	O
that	O
the	O
desired	O
DNA	O
sequence	O
in	O
recombinant	O
plasmid	O
was	O
correct	O
and	O
had	O
the	O
same	O
sequence	O
of	O
natural	O
N	O
-	O
terminal	O
of	O
SARS	B-DISO
virus	O
S1	O
subunit	O
.	O

The	O
idea	O
of	O
more	O
frequent	O
biological	O
""""	O
invasions	O
""""	O
with	O
economic	O
and	O
societal	O
impacts	O
comparable	O
to	O
SARS	B-DISO
,	O
presents	O
stakeholders	O
in	O
and	O
the	O
global	O
economy	O
with	O
unprecedented	O
new	O
risks	O
,	O
challenges	O
and	O
even	O
opportunities	O
.	O

TITLE	O
:	O
Sabadinine	O
:	O
a	O
potential	O
non	O
-	O
peptide	O
anti	O
-	O
severe	O
acute	O
-	O
respiratory	O
-	O
syndrome	B-DISO
agent	O
identified	O
using	O
structure	O
-	O
aided	O
design	O
.	O

Previously	O
,	O
we	O
found	O
that	O
MHV	O
-	O
JHM	O
neurovirulence	O
was	O
marked	O
by	O
diminished	O
expression	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
mRNA	O
and	O
a	O
reduced	O
presence	O
of	O
CD8	O
T	O
cells	O
in	O
the	O
CNS	O
concomitant	O
with	O
heightened	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	B-DISO
)-	O
1	O
transcript	O
levels	O
and	O
greater	O
macrophage	O
infiltration	B-DISO
relative	O
to	O
MHV	O
-	O
A59	O
infection	B-DISO
.	O

However	O
,	O
despite	O
the	O
absence	O
of	O
detectable	O
viral	O
titers	O
,	O
approximately	O
40	O
%	O
of	O
S4R22	O
-	O
infected	O
mice	O
succumbed	O
within	O
3	O
weeks	O
,	O
indicating	O
that	O
the	O
enhanced	O
mortality	O
following	O
S4R22	O
infection	B-DISO
was	O
not	O
associated	O
with	O
high	O
viral	O
titers	O
.	O

These	O
observations	O
indicate	O
that	O
differences	O
in	O
the	O
severity	O
of	O
viral	B-DISO
encephalitis	I-DISO
may	O
reflect	O
the	O
differential	O
ability	O
of	O
viruses	O
to	O
stimulate	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
within	O
the	O
CNS	O
and	O
subsequently	O
the	O
character	O
of	O
infiltrating	B-DISO
leukocyte	O
populations	O
.	O

TITLE	O
:	O
Infection	B-DISO
control	O
for	O
the	O
otolaryngologist	O
in	O
the	O
era	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Here	O
it	O
is	O
hypothesized	O
that	O
concurrent	O
with	O
emergence	O
of	O
chloroquine	O
-	O
resistant	O
malaria	B-DISO
(	O
presumably	O
with	O
enhanced	O
anti	O
-	O
apoptotic	O
capabilities	O
),	O
other	O
intracellular	O
parasites	O
have	O
evolved	O
to	O
enhance	O
their	O
ability	O
to	O
prevent	O
apoptosis	O
in	O
host	O
cells	O
.	O

The	O
mortality	O
of	O
SARS	B-DISO
is	O
in	O
the	O
region	O
of	O
10	O
to	O
15	O
%;	O
the	O
presence	O
of	O
underlying	O
disease	O
,	O
high	O
initial	O
C	O
-	O
reactive	O
protein	O
levels	O
,	O
and	O
positive	O
SARS	B-DISO
-	O
CoV	O
in	O
nasopharyngeal	O
aspirate	O
samples	O
are	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
mortality	O
.	O

All	O
cases	O
of	O
malaria	B-DISO
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
from	O
January	O
1996	O
to	O
December	O
2001	O
were	O
identified	O
from	O
the	O
intensive	O
care	O
records	O
and	O
retrospectively	O
reviewed	O
.	O

A	O
total	O
of	O
31	O
cases	O
of	O
malaria	B-DISO
were	O
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
in	O
the	O
six	O
-	O
year	O
period	O
.	O

CONCLUSIONS	O
:	O
Several	O
infections	B-DISO
of	O
P	O
.	O
falciparum	O
are	O
still	O
associated	O
with	O
significant	O
mortality	O
.	O

Most	O
patients	O
were	O
youth	O
and	O
adult	O
aged	O
between	O
18	O
to	O
40	O
years	O
old	O
,	O
the	O
initial	O
symptom	B-DISO
was	O
mainly	O
the	O
high	O
fever	O
,	O
accompanied	O
with	O
general	O
soreness	B-DISO
,	O
chest	O
stuffiness	O
and	O
cough	B-DISO
,	O
etc	O
.	O

TITLE	O
:	O
Very	O
diverse	O
CD8	O
T	O
cell	O
clonotypic	O
responses	O
after	O
virus	O
infections	B-DISO
.	O

Avoiding	O
secondary	O
insults	O
is	O
the	O
cornerstone	O
of	O
supportive	O
care	O
,	O
and	O
this	O
is	O
based	O
primarily	O
on	O
aggressive	B-DISO
immune	O
surveillance	O
,	O
full	O
nutrition	O
,	O
and	O
unrelenting	O
oxygen	O
delivery	O
.	O

Informants	O
perceived	O
themselves	O
to	O
be	O
suffering	B-DISO
as	O
they	O
suffered	B-DISO
the	O
same	O
anxieties	O
,	O
fears	O
and	O
grief	O
as	O
the	O
patient	O
.	O

The	O
RM	O
was	O
performed	O
with	O
stepwise	O
increases	O
of	O
5	O
cmH2O	O
of	O
PEEP	O
every	O
2	O
min	O
and	O
thereafter	O
with	O
stepwise	O
decreases	O
of	O
2	O
cmH2O	O
of	O
PEEP	O
every	O
2	O
min	O
until	O
a	O
drop	O
in	O
PaO2	O
>	O
10	O
%	O
below	O
the	O
recruitment	B-DISO
PEEP	O
level	O
.	O

The	O
PaO2	O
of	O
recruitment	B-DISO
was	O
225	O
+/-	O

TITLE	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
child	O
with	O
malaria	B-DISO
:	O
favorable	O
response	O
to	O
prone	O
positioning	O
.	O

TITLE	O
:	O
A	O
combination	O
of	O
mutations	O
in	O
the	O
S1	O
part	O
of	O
the	O
spike	O
glycoprotein	O
gene	O
of	O
coronavirus	O
MHV	O
-	O
A59	O
abolishes	O
demyelination	B-DISO
.	O

The	O
antiviral	O
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	O
inactivation	B-DISO
and	O
cell	O
cycle	O
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
Effective	O
prophylaxis	O
and	O
antiviral	O
therapies	O
are	O
urgently	O
needed	O
in	O
the	O
event	O
of	O
reemergence	O
of	O
the	O
highly	O
contagious	O
and	O
often	O
fatal	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
genomes	O
in	O
Taiwan	O
:	O
molecular	O
epidemiology	O
and	O
genome	O
evolution	O
.	O

ABSTRACT	O
:	O
Since	O
early	O
March	O
2003	O
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
has	O
claimed	O
346	O
cases	O
and	O
37	O
deaths	O
in	O
Taiwan	O
.	O

SARS	B-DISO
-	O
CoV	O
viruses	O
isolated	O
from	O
Taiwan	O
were	O
found	O
closely	O
related	O
to	O
those	O
from	O
Guangdong	O
and	O
Hong	O
Kong	O
.	O

The	O
in	O
vitro	O
susceptibility	O
of	O
the	O
prototype	O
of	O
SARS	B-DISO
associated	O
coronavirus	O
to	O
a	O
panel	O
of	O
nucleoside	O
analogues	O
and	O
protease	O
inhibitors	O
currently	O
licensed	O
for	O
clinical	O
use	O
was	O
studied	O
.	O

Forty	O
one	O
patients	O
with	O
SARS	B-DISO
followed	O
for	O
3	O
weeks	O
were	O
treated	O
with	O
a	O
combination	O
of	O
lopinavir	O
/	O
ritonavir	O
and	O
ribavirin	O
.	O

In	O
vitro	O
antiviral	O
activity	O
against	O
SARS	B-DISO
associated	O
coronavirus	O
was	O
demonstrated	O
for	O
lopinavir	O
and	O
ribavirin	O
at	O
concentrations	O
of	O
4	O
micro	O
g	O
/	O
ml	O
and	O
50	O
micro	O
g	O
/	O
ml	O
,	O
respectively	O
,	O
only	O
at	O
48	O
hours	O
.	O

The	O
adverse	O
clinical	O
outcome	O
(	O
ARDS	B-DISO
or	O
death	O
)	O
was	O
significantly	O
lower	O
in	O
the	O
treatment	O
group	O
than	O
in	O
the	O
historical	O
controls	O
(	O
2	O
.	O
4	O
%	O
v	O
28	O
.	O
8	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
at	O
day	O
21	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

To	O
date	O
,	O
no	O
effective	O
and	O
specific	O
therapeutic	O
method	O
can	O
be	O
used	O
to	O
treat	O
patients	O
suffering	B-DISO
from	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Recently	O
,	O
this	O
technique	O
was	O
employed	O
in	O
anti	O
-	O
virus	O
infections	B-DISO
in	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
and	O
hepatitis	B-DISO
C	I-DISO
/	O
B	O
virus	O
.	O

All	O
sputum	O
samples	O
from	O
patients	O
with	O
SARS	B-DISO
from	O
the	O
four	O
major	O
hospitals	O
in	O
Hong	O
Kong	O
were	O
reviewed	O
;	O
abnormalities	O
were	O
sought	O
in	O
the	O
cellular	O
component	O
,	O
including	O
abnormal	O
numbers	O
and	O
morphology	O
of	O
the	O
component	O
cells	O
compared	O
with	O
those	O
from	O
age	O
matched	O
controls	O
taken	O
over	O
the	O
same	O
period	O
one	O
year	O
ago	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
became	O
a	O
worldwide	O
outbreak	O
with	O
a	O
mortality	O
of	O
9	O
.	O
2	O
%.	O

The	O
pathological	O
features	O
were	O
dominated	O
by	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
with	O
the	O
presence	O
of	O
multinucleated	O
pneumocytes	O
.	O

Viable	O
SARS	B-DISO
-	O
CoV	O
could	O
be	O
isolated	O
from	O
postmortem	O
tissues	O
.	O

These	O
various	O
cholesterol	O
levels	O
had	O
no	O
effect	O
on	O
the	O
binding	O
of	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
to	O
cellular	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	B-DISO
molecule	O
(	O
CEACAM	O
)	O
receptors	O
,	O
rather	O
they	O
correlated	O
directly	O
with	O
S	O
-	O
protein	O
-	O
mediated	O
membrane	O
fusion	O
activities	O
.	O

TITLE	O
:	O
Infectious	B-DISO
salmon	O
anemia	B-DISO
virus	O
specifically	O
binds	O
to	O
and	O
hydrolyzes	O
4	O
-	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
physiological	O
effects	O
and	O
the	O
clinical	O
efficacy	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
vs	O
standard	O
medical	O
treatment	O
in	O
elderly	O
patients	O
(>	O
or	O
=	O
75	O
years	O
)	O
with	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
related	O
to	O
cardiogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
.	O

Study	O
groups	O
were	O
comparable	O
with	O
regard	O
to	O
baseline	O
physiological	O
and	O
clinical	O
characteristics	O
(	O
age	O
,	O
sex	O
ratio	O
,	O
autonomy	O
,	O
medical	O
history	O
,	O
cause	O
of	O
pulmonary	B-DISO
edema	I-DISO
).	O

Within	O
1	O
h	O
,	O
noninvasive	O
continuous	O
positive	O
airway	O
pressure	O
led	O
to	O
decreased	B-DISO
respiratory	I-DISO
rate	I-DISO
(	O
respiratory	O
rate	O
,	O
27	O
+/-	O
7	O
vs	O
35	O
+/-	O
6	O
breaths	O
/	O
min	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
and	O
improved	O
oxygenation	O
(	O
PaO	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
),	O
306	O
+/-	O
104	O
vs	O
157	O
+/-	O
71	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
compared	O
with	O
baseline	O
,	O
whereas	O
no	O
differences	O
were	O
observed	O
within	O
the	O
standard	O
treatment	O
group	O
.	O

Noninvasive	O
continuous	O
positive	O
airway	O
pressure	O
promotes	O
early	O
clinical	O
improvement	O
in	O
elderly	O
patients	O
attending	O
emergency	B-DISO
departments	O
for	O
a	O
severe	O
pulmonary	B-DISO
edema	I-DISO
,	O
but	O
only	O
reduces	O
early	O
48	O
-	O
h	O
mortality	O
.	O

CONCLUSIONS	O
:	O
Noninvasive	O
continuous	O
positive	O
airway	O
pressure	O
promotes	O
early	O
clinical	O
improvement	O
in	O
elderly	O
patients	O
attending	O
emergency	B-DISO
departments	O
for	O
a	O
severe	O
pulmonary	B-DISO
edema	I-DISO
,	O
but	O
only	O
reduces	O
early	O
48	O
-	O
h	O
mortality	O
.	O

TITLE	O
:	O
S1	O
glycoprotein	O
gene	O
analysis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

ABSTRACT	O
:	O
Different	O
tree	O
-	O
building	O
methods	O
consistently	O
place	O
the	O
SARS	B-DISO
corona	O
-	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
as	O
a	O
basal	O
Group	O
2	O
coronavirus	O
rather	O
than	O
as	O
an	O
ungrouped	O
species	O
as	O
concluded	O
by	O
others	O
.	O

The	O
first	O
was	O
prior	O
to	O
the	O
closure	O
of	O
the	O
ED	O
due	O
to	O
SARS	B-DISO
and	O
the	O
second	O
was	O
after	O
re	O
-	O
opening	O
of	O
the	O
ED	O
.	O

TITLE	O
:	O
A	O
retrospective	O
study	O
on	O
clinical	O
features	O
of	O
and	O
treatment	O
methods	O
for	O
77	O
severe	O
cases	O
of	O
SARS	B-DISO
.	O

Our	O
findings	O
indicate	O
that	O
the	O
SARS	B-DISO
outbreak	O
had	O
significant	O
psychosocial	O
effects	O
on	O
hospital	O
staff	O
.	O

TITLE	O
:	O
Tracking	O
the	O
evolution	O
of	O
the	O
SARS	B-DISO
coronavirus	O
using	O
high	O
-	O
throughput	O
,	O
high	O
-	O
density	O
resequencing	O
arrays	O
.	O

However	O
,	O
animal	O
models	O
suggest	O
a	O
role	O
for	O
T	O
-	O
helper	O
(	O
Th	O
)	O
1	O
lymphocytes	O
,	O
known	O
to	O
be	O
activated	O
in	O
psoriasis	B-DISO
,	O
and	O
a	O
role	O
for	O
tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
,	O
a	O
major	O
Th1	O
cytokine	O
,	O
in	O
alveolar	O
damage	O
.	O

TITLE	O
:	O
Surviving	O
Sepsis	B-DISO
Campaign	O
guidelines	O
for	O
management	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

Children	O
(	O
aged	O
5	O
-	O
17	O
years	O
)	O
with	O
sickle	B-DISO
cell	I-DISO
crisis	I-DISO
were	O
randomized	O
to	O
receive	O
oral	O
sustained	O
-	O
release	O
morphine	O
,	O
1	O
.	O
9	O
mg	O
.	O

New	O
onset	O
of	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
was	O
3	O
-	O
fold	O
more	O
prevalent	O
in	O
the	O
oral	O
group	O
(	O
57	O
%)	O
versus	O
the	O
continuous	O
intravenous	O
infusion	O
group	O
(	O
17	O
%)	O
(	O
P	O
<.	O
001	O
).	O

The	O
acute	O
paediatric	O
wards	O
were	O
stratified	O
into	O
three	O
areas	O
:	O
(	O
1	O
)	O
ultra	O
high	O
-	O
risk	O
area	O
,	O
(	O
2	O
)	O
high	O
-	O
risk	O
area	O
and	O
(	O
3	O
)	O
moderate	O
-	O
risk	O
area	O
according	O
to	O
different	O
risk	O
levels	O
of	O
nosocomial	O
SARS	B-DISO
transmission	O
.	O

ABSTRACT	O
:	O
Nosocomial	O
transmission	O
of	O
droplet	O
-	O
borne	O
respiratory	B-DISO
infections	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
may	O
be	O
influenced	O
by	O
the	O
choice	O
of	O
oxygen	O
face	B-DISO
mask	O
.	O

To	O
investigate	O
the	O
role	O
of	O
viral	B-DISO
infections	I-DISO
,	O
allergen	O
sensitization	O
,	O
and	O
exposure	O
to	O
indoor	O
allergens	O
as	O
risk	O
factors	O
for	O
acute	O
wheezing	B-DISO
in	O
children	O
0	O
to	O
12	O
years	O
old	O
.	O

In	O
children	O
under	O
2	O
years	O
of	O
age	O
,	O
infection	B-DISO
with	O
respiratory	O
viruses	O
and	O
family	O
history	O
of	O
allergy	B-DISO
were	O
independently	O
associated	O
with	O
wheezing	B-DISO
(	O
odds	O
ratio	O
,	O
15	O
.	O
5	O
and	O
4	O
.	O
2	O
;	O
P	O
=	O
.	O
0001	O
and	O
P	O
=	O
.	O
008	O
,	O
respectively	O
).	O

A	O
retrospective	O
,	O
observational	O
study	O
was	O
performed	O
in	O
an	O
adult	O
medical	O
intensive	O
care	O
unit	O
of	O
a	O
university	O
-	O
affiliated	O
hospital	O
involving	O
consecutive	O
patients	O
with	O
varicella	B-DISO
admitted	O
over	O
4	O
years	O
(	O
1997	O
-	O
2000	O
).	O

Four	O
patients	O
had	O
underlying	O
pulmonary	B-DISO
pathology	I-DISO
:	O
past	O
pulmonary	B-DISO
tuberculosis	I-DISO
(	O
2	O
),	O
emphysema	B-DISO
(	O
1	O
)	O
and	O
recurrent	O
right	O
pleural	B-DISO
effusion	I-DISO
from	O
autoimmune	B-DISO
serositis	B-DISO
(	O
1	O
).	O

ABSTRACT	O
:	O
The	O
recent	O
worldwide	O
epidemic	O
of	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Disease	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
over	O
800	O
deaths	O
and	O
had	O
a	O
major	O
impact	O
on	O
the	O
health	O
services	O
in	O
affected	O
communities	O
.	O

Numbers	O
of	O
unstimulated	O
and	O
mitogen	O
-	O
stimulated	O
cytokine	O
-	O
secreting	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
measured	O
repeatedly	O
during	O
and	O
after	O
hospitalization	O
in	O
13	O
patients	O
with	O
SARS	B-DISO
using	O
enzyme	O
-	O
linked	O
immunospot	O
technology	O
.	O

Together	O
,	O
these	O
studies	O
describe	O
important	O
tools	O
that	O
can	O
be	O
used	O
to	O
study	O
SARS	B-DISO
-	O
CoV	O
S	O
glycoprotein	O
structure	O
and	O
function	O
,	O
including	O
approaches	O
that	O
can	O
be	O
used	O
to	O
identify	O
inhibitors	O
of	O
the	O
entry	O
of	O
SARS	B-DISO
-	O
CoV	O
into	O
target	O
cells	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
the	O
most	O
severe	O
lung	O
injury	O
caused	O
by	O
many	O
pathologic	O
states	O
.	O

On	O
ICU	O
day	O
3	O
,	O
the	O
bilateral	O
infiltration	B-DISO
shadow	O
on	O
her	O
chest	O
X	O
-	O
ray	O
was	O
pointed	O
out	O
,	O
and	O
she	O
had	O
a	O
low	O
central	O
venous	O
pressure	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
epidemiologic	O
features	O
of	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Dongcheng	O
District	O
,	O
Beijing	O
occurred	O
in	O
a	O
period	O
between	O
March	O
and	O
May	O
2003	O
.	O

There	O
were	O
34	O
.	O
7	O
%	O
of	O
SARS	B-DISO
cases	O
without	O
any	O
histories	O
of	O
contact	O
before	O
the	O
onset	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
a	O
major	O
antigenic	O
determinant	O
for	O
use	O
in	O
the	O
development	O
of	O
a	O
rapid	O
serological	O
diagnostic	O
test	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	B-DISO
infection	I-DISO
and	O
to	O
study	O
the	O
immune	O
response	O
during	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
humans	O
,	O
we	O
cloned	O
the	O
full	O
length	O
and	O
six	O
truncated	O
fragments	O
of	O
the	O
nucleocapsid	O
gene	O
,	O
expressed	O
them	O
,	O
and	O
purified	O
them	O
as	O
glutathione	O
S	O
-	O
transferase	O
-	O
tagged	O
recombinant	O
proteins	O
.	O

TITLE	O
:	O
[	O
Some	O
research	O
clues	O
on	O
Chinese	O
herbal	O
medicine	O
for	O
SARS	B-DISO
prevention	O
and	O
treatment	O
].	O

According	O
to	O
the	O
experience	O
and	O
information	O
,	O
to	O
select	O
several	O
perspective	O
candidates	O
from	O
anti	O
-	O
SARS	B-DISO
effective	O
TCM	O
prescriptions	O
and	O
drugs	O
.	O

SARS	B-DISO
-	O
CoV	O
protein	O
-	O
derived	O
peptide	O
-	O
1	O
(	O
SSp	O
-	O
1	O
RLNEVAKNL	O
),	O
induced	O
peptide	O
-	O
specific	O
CTLs	O
both	O
in	O
vivo	O
(	O
transgenic	O
mice	O
)	O
and	O
in	O
vitro	O
(	O
human	O
PBLs	O
),	O
which	O
specifically	O
released	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
upon	O
stimulation	O
with	O
SSp	O
-	O
1	O
-	O
pulsed	O
autologous	O
dendritic	O
cells	O
(	O
DCs	B-DISO
)	O
or	O
T2	O
cells	O
.	O

SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
also	O
lysed	B-DISO
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)-	O
matched	O
tumor	B-DISO
cell	O
lines	O
engineered	O
to	O
express	O
S	O
proteins	O
.	O

ABSTRACT	O
:	O
Following	O
intranasal	O
administration	O
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
replicated	O
to	O
high	O
titers	O
in	O
the	O
respiratory	O
tracts	O
of	O
BALB	O
/	O
c	O
mice	O
.	O

Thus	O
,	O
antibodies	O
,	O
acting	O
alone	O
,	O
can	O
prevent	O
replication	O
of	O
the	O
SARS	B-DISO
coronavirus	O
in	O
the	O
lung	O
,	O
a	O
promising	O
observation	O
for	O
the	O
development	O
of	O
vaccines	O
,	O
immunotherapy	O
,	O
and	O
immunoprophylaxis	O
regimens	O
.	O

TITLE	O
:	O
Overview	O
on	O
SARS	B-DISO
in	O
Asia	O
and	O
the	O
world	O
.	O

The	O
genome	O
of	O
SARS	B-DISO
-	O
CoV	O
has	O
been	O
sequenced	O
and	O
it	O
is	O
not	O
related	O
to	O
any	O
of	O
the	O
previously	O
known	O
human	O
or	O
animal	O
coronaviruses	O
.	O

Seroconversion	O
for	O
SARS	B-DISO
-	O
CoV	O
using	O
immunofluorescence	O
on	O
infected	O
cells	O
is	O
an	O
excellent	O
method	O
of	O
confirming	O
the	O
diagnosis	O
,	O
but	O
antibody	O
responses	O
only	O
appear	O
around	O
day	O
10	O
of	O
the	O
illness	O
.	O

The	O
role	O
of	O
cytokines	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
is	O
still	O
unclear	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
originated	O
in	O
Southern	O
China	O
in	O
November	O
2002	O
,	O
and	O
was	O
brought	O
to	O
Hong	O
Kong	O
in	O
February	O
2003	O
.	O

The	O
characteristic	O
HRCT	O
feature	O
in	O
the	O
acute	O
phase	O
is	O
ground	O
-	O
glass	O
opacities	B-DISO
with	O
smooth	O
interlobular	O
septal	O
thickening	O
,	O
sometimes	O
with	O
consolidation	O
in	O
a	O
subpleural	O
location	O
,	O
which	O
progress	O
rapidly	O
to	O
involve	O
other	O
areas	O
of	O
the	O
lungs	O
.	O

The	O
major	O
clinical	O
features	O
include	O
persistent	B-DISO
fever	I-DISO
,	O
chills	B-DISO
/	O
rigor	B-DISO
,	O
myalgia	B-DISO
,	O
malaise	B-DISO
,	O
dry	B-DISO
cough	I-DISO
,	O
headache	B-DISO
and	O
dyspnoea	B-DISO
.	O

Less	O
common	O
symptoms	O
include	O
sputum	O
production	O
,	O
sore	B-DISO
throat	I-DISO
,	O
coryza	B-DISO
,	O
dizziness	B-DISO
,	O
nausea	B-DISO
,	I-DISO
vomiting	I-DISO
and	I-DISO
diarrhoea	I-DISO
.	O

A	O
retrospective	O
study	O
carried	O
out	O
of	O
72	O
probable	O
SARS	B-DISO
patients	O
has	O
shown	O
that	O
cases	O
who	O
received	O
pulse	O
methylprendisolone	O
did	O
not	O
differ	O
in	O
cumulative	O
steroid	O
dosage	O
or	O
adverse	O
reactions	O
,	O
although	O
the	O
former	O
patients	O
had	O
less	O
oxygen	O
requirement	O
,	O
better	O
radiographic	O
outcome	O
,	O
and	O
less	O
likelihood	O
of	O
requiring	O
rescue	O
pulse	O
steroid	O
therapy	O
than	O
their	O
counterparts	O
.	O

Despite	O
concern	O
about	O
potential	O
aerosol	O
generation	O
,	O
non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)	O
has	O
been	O
reported	O
to	O
be	O
efficacious	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
-	O
related	O
ARF	B-DISO
without	O
posing	O
infection	B-DISO
risks	O
to	O
health	O
care	O
workers	O
(	O
HCW	O
).	O

The	O
long	O
-	O
term	O
sequelae	O
of	O
SARS	B-DISO
are	O
still	O
largely	O
unknown	O
.	O

Hospital	O
outbreaks	O
of	O
SARS	B-DISO
typically	O
occurred	O
within	O
the	O
first	O
week	O
after	O
admission	O
of	O
the	O
very	O
first	O
SARS	B-DISO
cases	O
when	O
the	O
disease	O
was	O
not	O
recognized	O
and	O
before	O
isolation	O
measures	O
were	O
implemented	O
.	O

In	O
the	O
majority	O
of	O
nosocomial	B-DISO
infections	I-DISO
,	O
there	O
was	O
a	O
history	O
of	O
close	O
contact	O
with	O
a	O
SARS	B-DISO
patient	O
,	O
and	O
transmission	O
occurred	O
via	O
large	O
droplets	O
,	O
direct	O
contact	O
with	O
infectious	B-DISO
material	O
or	O
by	O
contact	O
with	O
fomites	O
contaminated	O
by	O
infectious	B-DISO
material	O
.	O

In	O
Hong	O
Kong	O
,	O
where	O
there	O
are	O
few	O
private	O
rooms	O
for	O
patient	O
isolation	O
,	O
some	O
hospitals	O
have	O
obtained	O
good	O
outcome	O
by	O
having	O
designated	O
SARS	B-DISO
teams	O
and	O
separate	O
wards	O
for	O
patient	O
triage	O
,	O
confirmed	O
SARS	B-DISO
cases	O
and	O
step	O
-	O
down	O
of	O
patients	O
in	O
whom	O
SARS	B-DISO
had	O
been	O
ruled	O
out	O
.	O

In	O
conclusion	O
,	O
SARS	B-DISO
represents	O
one	O
of	O
the	O
new	O
challenges	O
for	O
those	O
who	O
are	O
involved	O
in	O
hospital	B-DISO
infection	I-DISO
control	O
.	O

The	O
distribution	O
of	O
FCoV	O
types	O
in	O
cats	O
,	O
which	O
had	O
succumbed	O
to	O
FIP	B-DISO
,	O
however	O
,	O
was	O
fairly	O
unknown	O
.	O

For	O
the	O
efficacy	O
test	O
,	O
eight	O
dogs	O
were	O
vaccinated	O
by	O
intramuscular	O
(	O
four	O
dogs	O
-	O
group	O
A	O
)	O
or	O
by	O
oronasal	O
route	O
(	O
four	O
dogs	O
-	O
group	B-DISO
B	I-DISO
).	O

TITLE	O
:	O
Comparisons	O
of	O
envelope	O
through	O
5B	O
sequences	O
of	O
infectious	B-DISO
bronchitis	B-DISO
coronaviruses	O
indicates	O
recombination	O
occurs	O
in	O
the	O
envelope	O
and	O
membrane	O
genes	O
.	O

TITLE	O
:	O
Simulating	O
the	O
SARS	B-DISO
outbreak	O
in	O
Beijing	O
with	O
limited	O
data	O
.	O

There	O
are	O
many	O
challenges	O
in	O
preventing	O
and	O
managing	O
community	O
-	O
acquired	O
pneumonia	B-DISO
in	O
the	O
elderly	O
.	O

Because	O
SARS	B-DISO
is	O
a	O
new	O
emerging	O
disease	O
,	O
this	O
review	O
describes	O
the	O
current	O
understanding	O
about	O
the	O
etiology	O
,	O
clinical	O
pictures	O
,	O
laboratory	O
and	O
radiological	O
findings	O
of	O
SARS	B-DISO
.	O

Using	O
barrier	O
precautions	O
,	O
the	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
can	O
be	O
prevented	O
.	O

SARS	B-DISO
is	O
an	O
infectious	B-DISO
disease	I-DISO
with	O
high	O
contagiousness	O
and	O
a	O
high	O
mortality	O
rate	O
.	O

However	O
,	O
neuraminidase	O
inhibitors	O
can	O
only	O
be	O
applied	O
in	O
specific	O
infections	B-DISO
and	O
the	O
spectrum	O
of	O
agents	O
with	O
antiviral	O
activity	O
is	O
broad	O
.	O

We	O
have	O
shown	O
previously	O
that	O
fracture	O
hematoma	B-DISO
can	O
activate	O
neutrophils	O
and	O
is	O
thus	O
a	O
putative	O
mediator	O
of	O
the	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
(	O
MOF	B-DISO
)	O
in	O
those	O
patients	O
with	O
severe	O
skeletal	O
trauma	O
.	O

ABSTRACT	O
:	O
Public	O
health	O
measures	O
have	O
successfully	O
identified	O
and	O
contained	O
outbreaks	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
but	O
concerns	O
remain	O
over	O
the	O
possibility	O
of	O
future	O
recurrences	B-DISO
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
DNA	O
vaccine	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
induces	O
T	O
cell	O
and	O
neutralizing	O
antibody	O
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	O
,	O
in	O
a	O
mouse	O
model	O
.	O

In	O
this	O
issue	O
of	O
Critical	O
Care	O
,	O
two	O
groups	O
that	O
have	O
frontline	O
experience	O
of	O
SARS	B-DISO
debate	O
the	O
role	O
of	O
steroids	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
transmissible	O
febrile	O
respiratory	O
illness	O
caused	O
by	O
a	O
recently	O
discovered	O
coronavirus	O
.	O

The	O
C57BL	O
/	O
6	O
mice	O
also	O
developed	O
subclinical	O
intestinal	B-DISO
infection	I-DISO
,	O
but	O
only	O
transmitted	B-DISO
virus	O
for	O
two	O
weeks	O
.	O

The	O
T	O
cell	O
-	O
deficient	O
mice	O
developed	O
severe	O
disseminated	O
disease	O
by	O
two	O
weeks	O
and	O
transmitted	B-DISO
virus	O
for	O
four	O
weeks	O
.	O

Non	O
-	O
infectious	B-DISO
RNA	O
was	O
detected	O
in	O
a	O
few	O
mice	O
for	O
several	O
days	O
after	O
transmission	O
had	O
ceased	O
.	O

ABSTRACT	O
:	O
A	O
new	O
respiratory	O
infectious	B-DISO
epidemic	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
broke	O
out	O
and	O
spread	O
throughout	O
the	O
world	O
.	O

Our	O
results	O
indicate	O
that	O
these	O
animals	O
do	O
not	O
play	O
a	O
role	O
as	O
amplifying	O
hosts	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
We	O
studied	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Taiwan	O
,	O
using	O
the	O
daily	O
case	O
-	O
reporting	O
data	O
from	O
May	O
5	O
to	O
June	O
4	O
to	O
learn	O
how	O
it	O
had	O
spread	O
so	O
rapidly	O
.	O

Our	O
results	O
indicate	O
that	O
most	O
SARS	B-DISO
-	O
infected	O
persons	O
had	O
symptoms	O
and	O
were	O
admitted	O
before	O
their	O
infections	B-DISO
were	O
reclassified	O
as	O
probable	O
cases	O
.	O

We	O
conducted	O
a	O
case	O
-	O
control	O
study	O
in	O
Beijing	O
that	O
compared	O
exposures	O
of	O
94	O
unlinked	O
,	O
probable	O
SARS	B-DISO
patients	O
with	O
those	O
of	O
281	O
community	O
-	O
based	O
controls	O
matched	O
for	O
age	O
group	O
and	O
sex	O
.	O

TITLE	O
:	O
Lack	O
of	O
SARS	B-DISO
transmission	O
and	O
U	O
.	O
S	O
.	O
SARS	B-DISO
case	O
-	O
patient	O
.	O

Residual	O
respiratory	B-DISO
symptoms	I-DISO
were	O
still	O
present	O
in	O
recovered	O
SARS	B-DISO
case	O
-	O
patients	O
2	O
months	O
after	O
illness	O
onset	O
.	O

TITLE	O
:	O
Probable	O
secondary	B-DISO
infections	I-DISO
in	O
households	O
of	O
SARS	B-DISO
patients	O
in	O
Hong	O
Kong	O
.	O

We	O
conducted	O
an	O
investigation	O
of	O
healthcare	O
workers	O
exposed	O
to	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
patients	O
in	O
the	O
United	O
States	O
to	O
evaluate	O
infection	B-DISO
-	O
control	O
practices	O
and	O
possible	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
transmission	O
.	O

Despite	O
numerous	O
unprotected	O
exposures	O
,	O
there	O
was	O
no	O
serologic	O
evidence	O
of	O
healthcare	O
-	O
related	O
SARS	B-DISO
-	O
CoV	O
transmission	O
.	O

We	O
conclude	O
that	O
activities	O
related	O
to	O
intubation	O
increase	O
SARS	B-DISO
risk	O
and	O
use	O
of	O
a	O
mask	O
(	O
particularly	O
a	O
N95	O
mask	O
)	O
is	O
protective	O
.	O

TITLE	O
:	O
Atypical	O
SARS	B-DISO
in	O
geriatric	O
patient	O
.	O

Inconsistent	O
use	O
of	O
goggles	O
,	O
gowns	O
,	O
gloves	O
,	O
and	O
caps	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
for	O
SARS	B-DISO
infection	B-DISO
(	O
unadjusted	O
odds	O
ratio	O
2	O
.	O
42	O
to	O
20	O
.	O
54	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

No	O
significant	O
differences	O
existed	O
between	O
the	O
case	O
and	O
control	O
groups	O
in	O
the	O
proportion	O
of	O
workers	O
who	O
performed	O
high	O
-	O
risk	O
procedures	O
,	O
reported	O
minor	O
protection	O
equipment	O
problems	O
,	O
or	O
had	O
social	O
contact	O
with	O
SARS	B-DISO
-	O
infected	O
persons	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
for	O
detecting	O
SARS	B-DISO
coronavirus	O
,	O
Beijing	O
,	O
2003	O
.	O

TITLE	O
:	O
Serologic	O
and	O
molecular	O
biologic	O
methods	O
for	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
infection	B-DISO
,	O
Taiwan	O
.	O

The	O
assay	O
,	O
based	O
on	O
multiple	O
primer	O
and	O
probe	O
sets	O
located	O
in	O
different	O
regions	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
,	O
could	O
discriminate	O
SARS	B-DISO
-	O
CoV	O
from	O
other	O
human	O
and	O
animal	O
coronaviruses	O
with	O
a	O
potential	O
detection	O
limit	O
of	O
<	O
10	O
genomic	O
copies	O
per	O
reaction	O
.	O

TITLE	O
:	O
Ultrastructural	O
characterization	O
of	O
SARS	B-DISO
coronavirus	O
.	O

We	O
show	O
that	O
infection	B-DISO
with	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
resulted	O
in	O
distinct	O
ultrastructural	O
features	O
:	O
double	O
-	O
membrane	O
vesicles	B-DISO
,	O
nucleocapsid	O
inclusions	O
,	O
and	O
large	O
granular	O
areas	O
of	O
cytoplasm	O
.	O

In	O
addition	O
,	O
ultrastructural	O
examination	O
of	O
a	O
bronchiolar	O
lavage	O
specimen	O
from	O
a	O
SARS	B-DISO
patient	O
showed	O
numerous	O
coronavirus	O
-	O
infected	O
cells	O
with	O
features	O
similar	O
to	O
those	O
in	O
infected	O
culture	O
cells	O
.	O

When	O
combined	O
with	O
clinical	B-DISO
findings	I-DISO
,	O
these	O
epidemiologic	O
features	O
provide	O
a	O
possible	O
strategic	O
framework	O
for	O
early	O
recognition	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Clinical	O
description	O
of	O
a	O
completed	O
outbreak	O
of	O
SARS	B-DISO
in	O
Vietnam	O
,	O
February	O
-	O
May	O
2003	O
.	O

Cerebrospinal	O
fluid	O
tested	O
positive	O
for	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

Antibodies	O
to	O
SARS	B-DISO
virus	O
were	O
detected	O
in	O
cord	B-DISO
blood	O
and	O
breast	O
milk	O
.	O

TITLE	O
:	O
Atypical	O
SARS	B-DISO
and	O
Escherichia	B-DISO
coli	I-DISO
bacteremia	I-DISO
.	O

In	O
April	O
2003	O
,	O
in	O
response	O
to	O
the	O
SARS	B-DISO
outbreak	O
,	O
the	O
federal	O
executive	O
branch	O
acted	O
rapidly	O
to	O
add	B-DISO
SARS	B-DISO
to	O
the	O
list	O
of	O
quarantinable	O
communicable	B-DISO
diseases	I-DISO
.	O

Since	O
the	O
emergence	O
of	O
SARS	B-DISO
,	O
CDC	O
has	O
increased	O
legal	O
preparedness	O
for	O
future	O
public	O
health	O
emergencies	B-DISO
by	O
establishing	O
a	O
multistate	O
teleconference	O
program	O
for	O
public	O
health	O
lawyers	O
and	O
a	O
Web	B-DISO
-	O
based	O
clearinghouse	O
of	O
legal	O
documents	O
.	O

TITLE	O
:	O
Crisis	O
prevention	O
and	O
management	O
during	O
SARS	B-DISO
outbreak	O
,	O
Singapore	O
.	O

RESULTS	O
:	O
Of	O
36	O
patients	O
with	O
probable	O
SARS	B-DISO
CoV	O
infection	B-DISO
,	O
30	O
(	O
83	O
.	O
3	O
%)	O
were	O
positive	O
for	O
IgG	O
antibody	O
to	O
SARS	B-DISO
CoV	O
;	O
in	O
contrast	O
,	O
only	O
3	O
of	O
48	O
patients	O
with	O
suspected	O
SARS	B-DISO
CoV	O
infection	B-DISO
,	O
0	O
of	O
112	O
patients	O
with	O
fever	O
but	O
without	O
SARS	B-DISO
,	O
and	O
0	O
of	O
96	O
healthy	O
control	O
individuals	O
were	O
positive	O
for	O
it	O
.	O

ABSTRACT	O
:	O
Current	O
treatment	O
schemes	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
include	O
broad	O
-	O
spectrum	O
antibiotics	O
,	O
glucocorticoids	O
,	O
and	O
ribavirin	O
.	O

For	O
a	O
sample	O
application	O
,	O
homology	O
modeling	O
of	O
non	O
-	O
structural	O
proteins	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
is	O
discussed	O
.	O

They	O
also	O
suggest	O
that	O
the	O
success	O
of	O
efforts	O
to	O
educate	O
the	O
public	O
about	O
the	O
risk	O
of	O
SARS	B-DISO
and	O
appropriate	O
precautions	O
was	O
mixed	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
and	O
studies	O
,	O
we	O
propose	O
that	O
HAART	O
should	O
be	O
considered	O
for	O
patients	O
with	O
SARS	B-DISO
and	O
their	O
close	O
contacts	O
when	O
the	O
SARS	B-DISO
epidemic	O
reemerges	O
.	O

Aggressive	B-DISO
quarantine	O
measures	O
,	O
possibly	O
aided	O
by	O
rising	O
summer	O
temperatures	O
,	O
successfully	O
terminated	O
the	O
first	O
eruption	B-DISO
of	O
SARS	B-DISO
and	O
provided	O
at	O
least	O
a	O
temporal	O
break	O
,	O
which	O
allows	O
us	O
to	O
consolidate	O
what	O
we	O
have	O
learned	O
so	O
far	O
and	O
plan	B-DISO
for	O
the	O
future	O
.	O

TITLE	O
:	O
Studying	O
the	O
global	O
distribution	O
of	O
infectious	B-DISO
diseases	I-DISO
using	O
GIS	O
and	O
RS	O
.	O

ABSTRACT	O
:	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
monkeypox	B-DISO
are	O
infectious	B-DISO
diseases	I-DISO
that	O
have	O
recently	O
been	O
introduced	O
into	O
areas	O
far	O
from	O
their	O
region	O
of	O
origin	O
.	O

TITLE	O
:	O
Multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
.	O

Just	O
three	O
decades	O
ago	O
health	O
in	O
China	O
was	O
characterised	O
by	O
high	O
rates	O
of	O
infectious	B-DISO
disease	I-DISO
and	O
early	O
mortality	O
(	O
diseases	O
of	O
poverty	O
)	O
in	O
a	O
mainly	O
peasant	O
society	O
.	O

Demographic	O
data	O
and	O
complications	O
were	O
described	O
and	O
severe	O
preeclampsia	B-DISO
and	I-DISO
eclampsia	I-DISO
compared	O
using	O
t	O
-	O
student	O
'	O
s	O
and	O
chi2	O
tests	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
identified	O
respiratory	B-DISO
disease	I-DISO
that	O
threatened	O
Taiwan	O
between	O
April	O
14	O
and	O
July	O
5	O
,	O
2003	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
investigation	O
of	O
nosocomial	B-DISO
infection	I-DISO
of	O
SARS	B-DISO
in	O
medical	O
staff	O
of	O
a	O
hospital	O
].	O

The	O
medical	O
staff	O
associated	O
with	O
nosocomial	B-DISO
infection	I-DISO
of	O
SARS	B-DISO
in	O
a	O
hospital	O
were	O
investigated	O
with	O
standard	O
procedures	O
of	O
epidemiological	O
survey	O
.	O

The	O
clinical	O
presentation	O
is	O
highly	O
variable	O
,	O
from	O
a	O
mild	O
fever	O
to	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
An	O
assessment	O
of	O
World	O
Health	O
Organization	O
criteria	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
patients	O
with	O
cancer	B-DISO
.	O

The	O
authors	O
report	O
their	O
experience	O
with	O
the	O
exclusion	O
and	O
quarantine	O
of	O
patients	O
with	O
cancer	B-DISO
during	O
the	O
peak	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Beijing	O
,	O
China	O
.	O

All	O
11	O
patients	O
met	O
the	O
WHO	O
diagnostic	O
criteria	O
for	O
probable	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Positive	O
-	O
microscopy	O
TB	O
is	O
a	O
real	O
issue	O
for	O
the	O
respiratory	B-DISO
diseases	I-DISO
department	O
of	O
N	O
'	O
Djaména	O
General	O
Hospital	O
,	O
with	O
a	O
prevalence	O
rate	O
of	O
37	O
cases	O
in	O
100	O
patients	O
.	O

Increase	O
personnel	O
in	O
the	O
respiratory	B-DISO
diseases	I-DISO
department	O
at	O
the	O
N	O
'	O
Djaména	O
General	O
Hospital	O
.	O

The	O
use	O
of	O
an	O
antiviral	O
is	O
logical	O
although	O
there	O
is	O
no	O
effective	O
agent	O
against	O
SARS	B-DISO
-	O
CoV	O
,	O
with	O
the	O
widespread	O
use	O
of	O
ribavirin	O
in	O
2003	O
attracting	O
considerable	O
scepticism	O
.	O

8	O
samples	O
per	O
pool	O
)	O
were	O
spiked	O
with	O
plasma	O
of	O
an	O
imported	O
case	O
of	O
SARS	B-DISO
or	O
of	O
a	O
subsequently	O
infected	O
contact	O
person	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
S	O
(	O
spike	O
)	O
protein	O
of	O
the	O
etiologic	O
coronavirus	O
(	O
CoV	O
)	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
plays	O
a	O
central	O
role	O
in	O
mediating	O
viral	B-DISO
infection	I-DISO
via	O
receptor	O
binding	O
and	O
membrane	O
fusion	O
between	O
the	O
virion	O
and	O
the	O
host	O
cell	O
.	O

Synthetic	O
peptides	O
can	O
elicit	O
specific	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
study	O
provides	O
insights	O
for	O
the	O
future	O
development	O
of	O
SARS	B-DISO
vaccine	O
via	O
the	O
synthetic	O
-	O
peptide	O
-	O
based	O
approach	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
this	O
case	O
is	O
due	O
to	O
noncardiogenic	O
pulmonary	B-DISO
oedema	I-DISO
without	O
hypervolaemia	B-DISO
.	O

ABSTRACT	O
:	O
Focused	O
efforts	O
by	O
several	O
international	O
laboratories	O
have	O
resulted	O
in	O
the	O
sequencing	O
of	O
the	O
genome	O
of	O
the	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
novel	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
,	O
in	O
record	O
time	O
.	O

To	O
investigate	O
serum	O
total	O
LD	O
,	O
LD	O
isoenzymes	O
,	O
and	O
other	O
parameters	O
including	O
blood	O
lymphocyte	O
subsets	O
as	O
prognostic	O
indicators	O
in	O
SARS	B-DISO
patients	O
for	O
adverse	O
clinical	O
outcomes	O
in	O
terms	O
of	O
admission	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
death	O
.	O

A	O
total	O
of	O
109	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
according	O
to	O
the	O
modified	O
World	O
Health	O
Organization	O
case	O
definition	O
of	O
SARS	B-DISO
were	O
recruited	O
from	O
two	O
major	O
acute	O
hospitals	O
in	O
Hong	O
Kong	O
.	O

This	O
technique	O
is	O
reliable	O
and	O
its	O
application	O
for	O
screening	O
large	O
number	O
of	O
clinical	O
samples	O
would	O
improve	O
the	O
diagnosis	O
of	O
HCoVs	O
respiratory	B-DISO
infection	I-DISO
and	O
our	O
knowledge	O
of	O
these	O
viruses	O
epidemiology	O
.	O

People	O
'	O
s	O
fears	O
of	O
SARS	B-DISO
appear	O
to	O
have	O
had	O
strong	O
impacts	O
on	O
access	O
to	O
care	O
.	O

Adverse	O
health	O
outcomes	O
resulting	O
from	O
accessibility	O
barriers	O
posed	O
by	O
the	O
fear	O
of	O
SARS	B-DISO
should	O
not	O
be	O
overlooked	O
.	O

CONCLUSIONS	O
:	O
The	O
N	O
protein	O
is	O
a	O
highly	O
immunogenic	O
protein	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
Conformational	O
epitopes	O
are	O
important	O
for	O
this	O
protein	O
,	O
and	O
antigenicity	O
of	O
the	O
COOH	O
terminus	O
is	O
higher	O
than	O
that	O
of	O
the	O
NH	O
(	O
2	O
)	O
terminus	O
.	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
latest	O
information	O
on	O
the	O
risks	O
of	O
acquiring	O
SARS	B-DISO
,	O
review	O
recent	O
recommendations	O
from	O
the	O
U	O
.	O
S	O
.	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
),	O
discuss	O
the	O
role	O
of	O
hospital	O
facility	O
and	O
clinical	O
engineers	O
in	O
SARS	B-DISO
preparations	O
,	O
and	O
update	O
ECRI	O
'	O
s	O
recommendations	O
for	O
infection	B-DISO
control	O
procedures	O
during	O
equipment	O
servicing	O
.	O

During	O
the	O
period	O
of	O
the	O
outbreak	O
,	O
10	O
patients	O
with	O
SARS	B-DISO
with	O
psychiatric	O
complications	O
were	O
referred	O
to	O
our	O
Consultation	O
and	O
Liaison	O
Psychiatry	O
Team	O
for	O
assessment	O
and	O
management	O
.	O

Also	O
presented	O
are	O
hypotheses	O
about	O
the	O
human	O
immune	O
response	O
to	O
SARS	B-DISO
infection	B-DISO
,	O
as	O
well	O
as	O
immune	O
therapies	O
against	O
botulinum	O
and	O
anthrax	B-DISO
toxins	O
.	O

ABSTRACT	O
:	O
Despite	O
significant	O
progress	O
in	O
our	O
understanding	O
of	O
their	O
pathogenesis	B-DISO
,	O
nosocomial	B-DISO
infections	I-DISO
remain	O
a	O
major	O
problem	O
in	O
hospitals	O
.	O

TITLE	O
:	O
[	O
Glucocorticoid	O
-	O
induced	O
diabetes	B-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
the	O
impact	O
of	O
high	O
dosage	O
and	O
duration	O
of	O
methylprednisolone	O
therapy	O
].	O

After	O
adjusting	O
age	O
and	O
sex	O
,	O
the	O
daily	O
maximal	O
dosage	O
of	O
methylprednisolone	O
was	O
the	O
only	O
factor	O
that	O
might	O
predict	O
the	O
occurrence	O
of	O
diabetes	B-DISO
.	O

Decreasing	O
the	O
daily	O
maximal	O
dosage	O
may	O
be	O
beneficial	O
to	O
the	O
reduction	O
of	O
corticosteroid	O
-	O
induced	O
of	O
diabetes	B-DISO
.	O

Only	O
two	O
patients	O
had	O
mild	O
elevated	O
intraocular	B-DISO
pressure	I-DISO
at	O
baseline	O
and	O
at	O
subsequent	O
follow	O
-	O
up	O
.	O

There	O
was	O
no	O
loss	O
of	O
visual	O
acuity	O
,	O
cataract	B-DISO
progression	O
,	O
or	O
increased	O
cup	B-DISO
-	O
disk	O
ratio	O
.	O

Our	O
study	O
did	O
not	O
demonstrate	O
any	O
ocular	O
manifestations	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
An	O
epidemiologic	O
investigation	O
on	O
infection	B-DISO
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
wild	O
animals	O
traders	O
in	O
Guangzhou	O
].	O

Infection	B-DISO
rate	O
in	O
traders	O
only	O
engaging	O
in	O
civet	O
cats	O
was	O
58	O
.	O
54	O
%,	O
significantly	O
higher	O
than	O
that	O
in	O
traders	O
engaging	O
in	O
snakes	O
only	O
(	O
9	O
.	O
46	O
%).	O

During	O
the	O
period	O
of	O
SARS	B-DISO
epidemic	O
,	O
detection	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
antibody	O
in	O
people	O
with	O
symptoms	O
of	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
was	O
higher	O
(	O
30	O
.	O
70	O
%)	O
than	O
that	O
in	O
those	O
without	O
such	O
symptoms	O
(	O
20	O
.	O
08	O
%).	O

ABSTRACT	O
:	O
To	O
know	O
their	O
real	O
epidemiological	O
histories	O
in	O
1	O
,	O
091	O
probale	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
without	O
definite	O
history	O
of	O
contact	O
with	O
SARS	B-DISO
patients	O
in	O
the	O
first	O
survey	O
.	O

SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
stool	O
specimens	O
with	O
fluorescent	O
quantitative	O
polymerase	O
chain	O
reactions	O
(	O
FQ	O
-	O
PCR	O
)	O
in	O
101	O
SARS	B-DISO
patients	O
on	O
the	O
10	O
to	O
55	O
days	O
after	O
onset	O
,	O
27	O
non	O
-	O
SARS	B-DISO
patients	O
and	O
400	O
individuals	O
with	O
health	O
check	O
-	O
up	O
.	O

SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
positive	O
in	O
stool	O
specimens	O
by	O
FQ	O
-	O
PCR	O
in	O
58	O
of	O
101	O
SARS	B-DISO
patients	O
(	O
57	O
.	O
4	O
%),	O
and	O
all	O
negative	O
in	O
27	O
non	O
-	O
SARS	B-DISO
patients	O
and	O
400	O
healthy	O
individuals	O
.	O

Positive	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
100	O
%	O
(	O
8	O
/	O
8	O
),	O
67	O
.	O
7	O
%	O
(	O
21	O
/	O
31	O
),	O
47	O
.	O
4	O
%	O
(	O
27	O
/	O
57	O
)	O
and	O
40	O
.	O
0	O
%	O
(	O
2	O
/	O
5	O
)	O
on	O
the	O
10	O
-	O
19	O
,	O
20	O
-	O
29	O
,	O
30	O
-	O
39	O
and	O
40	O
-	O
55	O
days	O
after	O
onset	O
of	O
fever	O
,	O
respectively	O
,	O
with	O
values	O
of	O
logarithm	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
load	O
of	O
6	O
.	O
06	O
+/-	O

CONCLUSIONS	O
:	O
Positive	O
rate	O
and	O
load	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
in	O
stool	O
of	O
SARS	B-DISO
patients	O
was	O
the	O
highest	O
at	O
their	O
acute	O
phase	O
,	O
and	O
decreased	O
with	O
the	O
extension	O
of	O
its	O
course	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
diagnostic	O
value	O
of	O
determinations	O
of	O
serum	O
acute	B-DISO
phase	I-DISO
reaction	I-DISO
protein	O
,	O
such	O
as	O
complement	O
3	O
(	O
C3	O
),	O
complement	O
4	O
(	O
C4	O
),	O
prealbumin	O
(	O
PA	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
etc	O
.,	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

During	O
the	O
three	O
months	O
when	O
SARS	B-DISO
was	O
explosive	O
in	O
2003	O
,	O
524	O
questionnaires	O
were	O
collected	O
from	O
Xuanwu	O
Hospital	O
,	O
You	O
'	O
an	O
Hospital	O
,	O
Xiaotangshan	O
Hospital	O
,	O
Renmin	O
Hospital	O
and	O
Ditan	O
Hospital	O
in	O
Beijing	O
.	O

Doctors	O
/	O
nurses	O
having	O
SARS	B-DISO
had	O
less	O
emotional	O
and	O
depressive	O
conditions	O
than	O
the	O
others	O
,	O
which	O
might	O
due	O
to	O
the	O
difference	O
in	O
medical	O
knowledge	O
,	O
working	O
condition	B-DISO
and	O
the	O
route	O
of	O
infection	B-DISO
,	O
suggesting	O
that	O
psychological	B-DISO
intervention	O
in	O
the	O
post	O
-	O
SARS	B-DISO
period	O
called	O
for	O
attention	O
.	O

ABSTRACT	O
:	O
Transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
can	O
be	O
a	O
life	O
-	O
threatening	O
complication	B-DISO
of	O
transfusion	O
.	O

In	O
its	O
severe	O
form	O
,	O
it	O
is	O
clinically	O
indistinguishable	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TRALI	B-DISO
has	O
been	O
reported	O
after	O
transfusion	O
of	O
all	O
plasma	O
-	O
containing	O
blood	O
components	O
.	O

During	O
a	O
SARS	B-DISO
epidemic	O
,	O
we	O
also	O
strongly	O
advocate	O
isolating	O
all	O
suspected	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
with	O
a	O
low	O
PCT	B-DISO
level	O
.	O

ABSTRACT	O
:	O
During	O
a	O
natural	O
outbreak	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infection	B-DISO
in	O
an	O
animal	O
facility	O
in	O
Rome	O
,	O
6	O
-	O
week	O
-	O
old	O
,	O
outbred	O
,	O
immunocompetent	O
Hsd	B-DISO
:	O
ICR	O
(	O
CD	O
-	O
1	O
)	O
and	O
immunodeficient	B-DISO
Hsd	B-DISO
:	O
athymic	O
nude	O
-	O
nu	O
sentinel	O
mice	O
(	O
barrier	O
maintained	O
)	O
were	O
exposed	O
to	O
MHV	O
in	O
order	O
to	O
study	O
tissue	O
distribution	O
and	O
duration	O
of	O
the	O
virus	O
in	O
naturally	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
seven	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
,	O
including	O
six	O
in	O
-	O
house	O
assays	O
and	O
one	O
commercial	O
assay	O
for	O
the	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
RNA	O
in	O
clinical	O
specimens	O
.	O

The	O
results	O
demonstrated	O
good	O
performance	O
for	O
all	O
assays	O
,	O
providing	O
laboratories	O
that	O
need	O
to	O
do	O
SARS	B-DISO
RNA	O
testing	O
with	O
a	O
choice	O
of	O
assay	O
formats	O
.	O

This	O
fragment	O
was	O
highly	O
expressed	O
,	O
and	O
the	O
purified	O
fragment	O
C	O
could	O
detect	O
all	O
33	O
SARS	B-DISO
patient	O
serum	O
samples	O
tested	O
,	O
collected	O
from	O
7	O
to	O
60	O
days	O
after	O
the	O
onset	O
of	O
fever	O
,	O
but	O
had	O
no	O
reactivity	O
with	O
all	O
66	O
healthy	O
human	O
serum	O
samples	O
tested	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
identify	O
general	O
properties	O
of	O
emerging	O
infectious	B-DISO
agents	O
that	O
determine	O
the	O
likely	O
success	O
of	O
two	O
simple	O
public	O
health	O
measures	O
in	O
controlling	O
outbreaks	O
,	O
namely	O
(	O
i	O
)	O
isolating	O
symptomatic	O
individuals	O
and	O
(	O
ii	O
)	O
tracing	O
and	O
quarantining	O
their	O
contacts	O
.	O

We	O
conclude	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
smallpox	B-DISO
are	O
easier	O
to	O
control	O
using	O
these	O
simple	O
public	O
health	O
measures	O
.	O

The	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
late	O
2002	O
and	O
the	O
recent	O
outbreaks	O
of	O
avian	B-DISO
influenza	I-DISO
in	O
Asia	O
are	O
timely	O
reminders	O
of	O
the	O
ever	O
present	O
risks	O
from	O
respiratory	O
viral	B-DISO
diseases	I-DISO
.	O

Apart	O
from	O
influenza	B-DISO
,	O
there	O
are	O
no	O
vaccines	O
and	O
very	O
few	O
antiviral	O
chemotherapeutic	O
agents	O
available	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
-	O
the	O
most	O
common	O
cause	O
of	O
human	O
illness	O
.	O

TITLE	O
:	O
Obesity	B-DISO
-	O
related	O
excess	O
mortality	O
rate	O
in	O
an	O
adult	O
intensive	O
care	O
unit	O
:	O
A	O
risk	O
-	O
adjusted	O
matched	O
cohort	O
study	O
.	O

Obesity	B-DISO
was	O
significantly	O
associated	O
with	O
intensive	O
care	O
unit	O
mortality	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
6	O
).	O

All	O
four	O
patients	O
suffered	B-DISO
from	O
fever	O
,	O
runny	B-DISO
nose	I-DISO
,	O
and	O
dry	B-DISO
cough	I-DISO
,	O
and	O
all	O
four	O
had	O
underlying	O
or	O
additional	O
morbidity	O
.	O

The	O
farmers	O
were	O
asked	O
to	O
collect	O
faecal	O
samples	O
from	O
each	O
heifer	O
calf	O
that	O
had	O
diarrhoea	B-DISO
between	O
birth	O
and	O
90	O
days	O
of	O
age	O
,	O
and	O
also	O
from	O
a	O
healthy	O
calf	O
of	O
the	O
same	O
age	O
.	O

G	O
.	O
intestinalis	O
was	O
found	O
in	O
42	O
(	O
29	O
%)	O
of	O
the	O
diarrhoea	B-DISO
samples	O
and	O
in	O
29	O
(	O
23	O
%)	O
of	O
the	O
samples	O
from	O
healthy	O
calves	O
.	O

In	O
addition	O
,	O
rotavirus	O
is	O
a	O
major	O
pathogen	O
in	O
neonatal	O
enteritis	B-DISO
in	O
Sweden	O
,	O
whereas	O
coronavirus	O
and	O
E	O
.	O
coli	O
K99	O
+	O
seem	O
to	O
be	O
of	O
less	O
importance	O
.	O

Lack	O
of	O
a	O
suitable	O
assay	O
has	O
been	O
a	O
major	O
hindrance	O
for	O
enzyme	O
kinetic	O
studies	O
and	O
a	O
large	O
-	O
scale	O
inhibitor	O
screen	O
for	O
SARS	B-DISO
3CL	O
proteinase	O
.	O

The	O
pK	O
(	O
a	O
)	O
values	O
measured	O
for	O
the	O
active	O
site	O
residues	O
and	O
the	O
activity	O
of	O
the	O
C145S	O
mutant	B-DISO
are	O
consistent	O
with	O
a	O
general	O
base	O
catalysis	O
mechanism	O
and	O
cannot	O
be	O
explained	O
by	O
a	O
thiolate	O
-	O
imidazolium	O
ion	O
pair	O
model	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
Beijing	O
,	O
2003	O
.	O

The	O
proportion	O
of	O
case	O
-	O
patients	O
without	O
known	O
contact	O
to	O
a	O
SARS	B-DISO
patient	O
increased	O
significantly	O
in	O
May	O
.	O
Implementation	O
of	O
early	O
detection	O
,	O
isolation	O
,	O
contact	O
tracing	O
,	O
quarantine	O
,	O
triage	O
of	O
case	O
-	O
patients	O
to	O
designated	O
SARS	B-DISO
hospitals	O
,	O
and	O
community	O
mobilization	O
ended	O
the	O
outbreak	O
.	O

TITLE	O
:	O
Amino	O
acids	O
270	O
to	O
510	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
are	O
required	O
for	O
interaction	O
with	O
receptor	O
.	O

Chest	O
radiographs	O
at	O
2	O
to	O
3	O
weeks	O
of	O
infection	B-DISO
revealed	O
an	O
atypical	B-DISO
pneumonia	I-DISO
with	O
pulmonary	B-DISO
consolidation	I-DISO
,	O
a	O
clinical	O
characteristic	O
of	O
SARS	B-DISO
infection	B-DISO
.	O

Expression	O
of	O
SARS	B-DISO
virus	O
-	O
encoded	O
RNA	O
was	O
detected	O
in	O
all	O
3	O
cases	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
the	O
SARS	B-DISO
viral	O
signal	O
was	O
localized	O
in	O
pneumocytes	O
by	O
using	O
in	O
situ	O
hybridization	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
noncanonical	O
interactions	O
,	O
potential	O
inhibitors	O
,	O
and	O
binding	O
pockets	O
in	O
the	O
main	O
proteinase	O
of	O
SARS	B-DISO
-	O
CoV	O
based	O
on	O
its	O
recently	O
determined	O
crystal	O
structure	O
.	O

These	O
findings	O
provide	O
a	O
wide	O
clue	O
to	O
searching	O
for	O
anti	O
-	O
SARS	B-DISO
drug	O
.	O

A	O
significant	O
association	O
between	O
the	O
history	O
of	O
positive	O
exposure	O
to	O
pesticides	O
(	O
i	O
.	O
e	O
.	O
the	O
women	O
themselves	O
or	O
their	O
newborns	O
who	O
showed	O
acetylcholinesterase	O
activity	O
levels	O
lower	O
than	O
20	O
%)	O
and	O
the	O
presence	O
of	O
IUGR	B-DISO
was	O
found	O
.	O

Diabetic	B-DISO
neuropathy	I-DISO
""""	O
is	O
commonly	O
considered	O
untreatable	O
.	O

In	O
some	O
of	O
our	O
patients	O
,	O
especially	O
ones	O
having	O
a	O
strong	O
type	O
-	O
2	O
diabetes	B-DISO
genetic	O
background	O
,	O
the	O
intravenous	O
immunoglobulin	O
-	O
G	O
-	O
responsive	O
neuropathy	B-DISO
preceded	O
the	O
diagnosis	O
of	O
type	O
-	O
2	O
diabetes	B-DISO
by	O
5	O
-	O
10	O
years	O
.	O

Intravenous	O
immunoglobulin	O
-	O
G	O
is	O
herein	O
suggested	O
as	O
a	O
treatment	O
for	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
a	O
recent	O
,	O
and	O
feared	O
-	O
repetitive	O
,	O
pandemic	O
with	O
many	O
fatalities	O
caused	O
by	O
a	O
highly	O
-	O
contagious	O
mutant	B-DISO
coronavirus	O
,	O
for	O
which	O
there	O
is	O
no	O
definitive	O
treatment	O
.	O

This	O
is	O
in	O
marked	O
contrast	O
with	O
epidemics	O
of	O
sexually	B-DISO
transmitted	I-DISO
diseases	I-DISO
or	O
computer	O
viruses	O
to	O
which	O
scale	O
-	O
free	O
network	O
models	O
often	O
apply	O
.	O

Like	O
other	O
known	O
coronaviruses	O
,	O
SARS	B-DISO
-	O
CoV	O
is	O
an	O
enveloped	O
virus	O
containing	O
three	O
outer	O
structural	O
proteins	O
,	O
namely	O
the	O
membrane	O
(	O
M	O
),	O
envelope	O
(	O
E	O
),	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
.	O

The	O
economic	O
and	O
psychological	B-DISO
impact	O
of	O
this	O
mysterious	O
illness	O
was	O
profound	O
.	O

ABSTRACT	O
:	O
Whether	O
subclinical	O
or	O
atypical	O
presentations	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occur	O
and	O
whether	O
clinical	O
judgment	O
is	O
accurate	O
in	O
detecting	O
SARS	B-DISO
are	O
unknown	O
.	O

With	O
the	O
SARS	B-DISO
coronavirus	O
serologic	O
test	O
as	O
the	O
gold	O
standard	O
,	O
the	O
clinical	O
diagnosis	O
of	O
probable	O
SARS	B-DISO
at	O
hospitalization	O
had	O
a	O
sensitivity	O
of	O
0	O
.	O
96	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
91	O
to	O
0	O
.	O
98	O
)	O
and	O
a	O
specificity	O
of	O
0	O
.	O
96	O
(	O
CI	O
,	O
0	O
.	O
92	O
to	O
0	O
.	O
97	O
).	O

Intranasal	O
or	O
intramuscular	O
inoculations	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
MVA	O
/	O
S	O
produced	O
serum	O
antibodies	O
that	O
recognized	O
the	O
SARS	B-DISO
S	O
in	O
ELISA	O
and	O
neutralized	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
.	O

TITLE	O
:	O
Laboratory	O
safety	O
aspects	O
of	O
SARS	B-DISO
at	O
Biosafety	O
Level	O
2	O
.	O

Airborne	O
spread	O
of	O
the	O
virus	O
appears	O
to	O
explain	O
this	O
large	O
community	O
outbreak	O
of	O
SARS	B-DISO
,	O
and	O
future	O
efforts	O
at	O
prevention	O
and	O
control	O
must	O
take	O
into	O
consideration	O
the	O
potential	O
for	O
airborne	O
spread	O
of	O
this	O
virus	O
.	O

Therefore	O
,	O
IL	O
-	O
1beta	O
induces	O
both	O
a	O
pro	O
-	O
and	O
an	O
anti	O
-	O
inflammatory	B-DISO
response	I-DISO
in	O
pediatric	O
PMs	B-DISO
,	O
whereas	O
adult	O
PMs	B-DISO
produce	O
only	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
response	O
to	O
IL	O
-	O
1beta	O
.	O

ABSTRACT	O
:	O
An	O
effective	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
vaccine	O
is	O
likely	O
to	O
include	O
components	O
that	O
can	O
induce	O
specific	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
responses	O
.	O

Risk	O
factors	O
for	O
SARS	B-DISO
patients	O
who	O
had	O
been	O
healthy	O
prior	O
to	O
their	O
illness	O
included	O
old	O
age	O
,	O
high	O
peak	O
fever	O
grade	O
,	O
increased	O
neutrophil	O
count	O
,	O
increased	O
neutrophil	O
percentage	O
,	O
and	O
close	O
or	O
prolonged	O
contact	O
with	O
a	O
SARS	B-DISO
patient	O
.	O

Randomized	O
controlled	O
trials	O
which	O
compared	O
partial	O
liquid	O
ventilation	O
with	O
other	O
forms	O
of	O
ventilation	O
,	O
in	O
children	O
(	O
28	O
days	O
-	O
18	O
years	O
)	O
with	O
acute	O
lung	O
injury	O
or	O
acute	O
respiratory	O
syndrome	B-DISO
,	O
reporting	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
mortality	O
;	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
respiratory	O
support	O
,	O
oxygen	O
therapy	O
,	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
or	O
stay	O
in	O
hospital	O
;	O
infection	B-DISO
;	O
or	O
long	O
term	O
cognitive	B-DISO
impairment	I-DISO
or	O
neurodevelopmental	O
progress	O
or	O
other	O
long	O
term	O
morbidities	O
.	O

TITLE	O
:	O
Impact	O
of	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
on	O
a	O
hospital	O
in	O
Taiwan	O
,	O
ROC	O
.	O

The	O
study	O
estimated	O
the	O
utilisation	O
of	O
resources	O
related	O
to	O
infection	B-DISO
control	O
,	O
SARS	B-DISO
related	O
medical	O
services	O
,	O
and	O
routine	O
medical	O
services	O
,	O
and	O
SARS	B-DISO
related	O
medical	O
outcomes	O
at	O
National	O
Cheng	O
Kung	O
University	O
Hospital	O
(	O
NCKUH	O
)	O
from	O
25	O
March	O
to	O
16	O
June	O
2003	O
through	O
a	O
cross	O
sectional	O
survey	O
of	O
hospital	O
records	O
.	O

No	O
cases	O
of	O
nosocomial	O
SARS	B-DISO
transmission	O
occurred	O
.	O

ABSTRACT	O
:	O
Some	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
have	O
recently	O
become	O
endemic	O
in	O
Germany	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
detected	O
in	O
Singapore	O
at	O
the	O
beginning	O
of	O
March	O
2003	O
.	O

In	O
addition	O
,	O
heparin	O
(	O
100	O
microg	O
/	O
mL	O
)	O
inhibited	O
infection	B-DISO
of	O
Vero	O
cells	O
by	O
50	O
%.	O

While	O
it	O
is	O
generally	O
agreed	O
that	O
we	O
underestimate	O
the	O
proportion	O
of	O
nosocomial	B-DISO
infections	I-DISO
that	O
are	O
viral	O
,	O
due	O
to	O
a	O
lack	O
of	O
routine	O
monitoring	O
,	O
viruses	O
easily	O
account	O
for	O
more	O
than	O
30	O
%	O
of	O
the	O
cases	O
of	O
hospital	O
-	O
acquired	O
infections	B-DISO
in	O
many	O
paediatric	O
settings	O
.	O

We	O
show	O
a	O
potential	O
role	O
of	O
dendritic	O
cells	O
(	O
DC	O
)	O
in	O
murine	O
coronavirus	O
-	O
induced	O
immune	O
modulation	O
and	O
pathogenesis	B-DISO
by	O
demonstrating	O
that	O
the	O
JAW	O
SII	O
DC	O
line	O
and	O
primary	O
DC	O
from	O
BALB	O
/	O
c	O
mice	O
and	O
p	O
/	O
p	O
mice	O
with	O
reduced	O
expression	O
of	O
the	O
murine	O
coronavirus	O
receptor	O
,	O
murine	O
CEACAM1a	O
,	O
are	O
susceptible	O
to	O
murine	O
coronavirus	B-DISO
infection	I-DISO
by	O
a	O
receptor	O
-	O
dependent	O
pathway	O
.	O

ABSTRACT	O
:	O
Microorganisms	O
are	O
transmitted	B-DISO
in	O
hospitals	O
mainly	O
by	O
contact	O
,	O
droplet	O
,	O
and	O
airborne	O
routes	O
.	O

Orthopaedic	O
surgeons	O
have	O
a	O
substantial	O
occupational	O
risk	O
of	O
contracting	O
a	O
blood	O
-	O
borne	O
infection	B-DISO
because	O
of	O
frequent	O
handling	O
of	O
sharp	O
instruments	O
and	O
objects	O
during	O
operative	O
procedures	O
.	O

Pathogens	O
that	O
can	O
survive	O
in	O
these	O
small	O
airborne	O
particles	O
may	O
cause	O
infection	B-DISO
if	O
they	O
are	O
inhaled	O
.	O

Aerosol	O
-	O
generating	O
procedures	O
in	O
patients	O
with	O
tuberculosis	B-DISO
or	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
may	O
facilitate	O
airborne	O
transmission	O
.	O

TITLE	O
:	O
Stability	O
and	O
inactivation	B-DISO
of	O
SARS	B-DISO
coronavirus	O
.	O

These	O
are	O
:	O
Hendra	O
virus	O
,	O
formerly	O
named	O
equine	O
morbillivirus	O
,	O
which	O
was	O
responsible	O
for	O
an	O
outbreak	O
of	O
disease	O
in	O
horses	O
and	O
humans	O
in	O
Brisbane	O
,	O
Australia	O
,	O
in	O
1994	O
;	O
Australian	O
bat	O
lyssavirus	O
,	O
the	O
cause	O
of	O
a	O
severe	O
acute	O
encephalitis	B-DISO
,	O
in	O
1996	O
;	O
and	O
Nipah	O
virus	O
,	O
the	O
cause	O
of	O
a	O
major	O
outbreak	O
of	O
encephalitis	B-DISO
and	O
pulmonary	B-DISO
disease	I-DISO
in	O
domestic	O
pigs	O
and	O
people	O
in	O
peninsula	O
Malaysia	O
in	O
1999	O
.	O

One	O
Clinic	O
employee	O
was	O
thought	O
to	O
potentially	O
have	O
monkeypox	B-DISO
because	O
of	O
her	O
direct	O
contact	O
with	O
one	O
of	O
the	O
patients	O
.	O

We	O
describe	O
the	O
aetiology	O
of	O
viral	B-DISO
diarrhoea	I-DISO
and	O
the	O
characteristics	O
of	O
rotavirus	B-DISO
infection	I-DISO
in	O
Shahrekord	O
,	O
Iran	O
.	O

If	O
host	O
genetics	O
could	O
be	O
shown	O
to	O
play	O
a	O
role	O
in	O
disease	O
,	O
it	O
may	O
allow	O
the	O
detection	O
of	O
cats	O
with	O
a	O
susceptibility	O
to	O
FIP	B-DISO
and	O
the	O
development	O
of	O
increased	O
population	O
resistance	O
through	O
selective	O
breeding	O
.	O

TITLE	O
:	O
Disease	O
outcome	O
and	O
cytokine	O
responses	O
in	O
cats	O
immunized	O
with	O
an	O
avirulent	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)-	O
UCD1	O
and	O
challenge	O
-	O
exposed	O
with	O
virulent	O
FIPV	O
-	O
UCD8	O
.	O

Tissues	O
from	O
five	O
control	O
cats	O
and	O
from	O
15	O
cats	O
with	O
FIP	B-DISO
were	O
examined	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
antibodies	O
against	O
human	O
AGP	O
,	O
FCoV	O
and	O
myeloid	O
antigens	O
.	O

Diffuse	O
fAGPrP	O
positivity	O
within	O
the	O
lesions	O
,	O
likely	O
due	O
to	O
vascular	O
plasma	O
leakage	B-DISO
,	O
endothelial	O
and	O
epithelial	O
lining	O
were	O
detectable	O
.	O

Most	O
previous	O
vaccination	O
attempts	O
against	O
FIPV	O
were	O
unsuccessful	O
because	O
IgG	O
antibodies	O
against	O
the	O
surface	O
protein	O
enhance	O
the	O
infection	B-DISO
.	O

In	O
our	O
study	O
,	O
we	O
report	O
the	O
construction	O
of	O
another	O
poxvirus	O
,	O
the	O
modified	O
vaccinia	B-DISO
virus	O
Ankara	O
(	O
MVA	O
),	O
as	O
an	O
expression	O
vector	O
for	O
the	O
FIPV	O
M	O
protein	O
.	O

Proceedings	O
from	O
the	O
2nd	O
International	O
FCoV	O
/	O
FIP	B-DISO
Symposium	O
,	O
Glasgow	O
,	O
4	O
-	O
7	O
August	O
2002	O
.	O

We	O
report	O
a	O
woman	O
with	O
HIV	B-DISO
infection	I-DISO
,	O
who	O
developed	O
hypocomplementemic	O
acute	B-DISO
nephritic	I-DISO
syndrome	I-DISO
10	O
days	O
after	O
an	O
upper	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Thrombolysis	O
for	O
central	O
venous	B-DISO
occlusion	I-DISO
causing	O
bilateral	O
chylothorax	B-DISO
in	O
a	O
patient	O
with	O
down	B-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
woman	O
with	O
Down	B-DISO
syndrome	I-DISO
(	O
trisomy	B-DISO
21	I-DISO
)	O
and	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
presented	O
with	O
severe	O
respiratory	O
compromise	O
secondary	O
to	O
bilateral	O
chylothorax	B-DISO
as	O
a	O
result	O
of	O
central	O
venous	B-DISO
thrombosis	I-DISO
and	O
extensive	O
upper	O
-	O
limb	O
deep	B-DISO
venous	I-DISO
thrombosis	I-DISO
.	O

It	O
is	O
recognized	O
that	O
there	O
is	O
an	O
increased	O
incidence	O
of	O
congenital	O
lymphatic	O
anomalies	O
in	O
Down	B-DISO
syndrome	I-DISO
,	O
which	O
may	O
have	O
been	O
a	O
contributing	O
factor	O
in	O
the	O
development	O
of	O
chylothorax	B-DISO
in	O
this	O
patient	O
.	O

This	O
report	O
illustrates	O
the	O
angiographic	O
findings	O
,	O
demonstrates	O
the	O
successful	O
vascular	O
recanalization	O
,	O
and	O
discusses	O
the	O
etiology	O
and	O
management	O
of	O
central	O
venous	B-DISO
thrombosis	I-DISO
and	O
chylothorax	B-DISO
.	O

With	O
the	O
advent	O
of	O
the	O
droplet	O
-	O
spread	O
disease	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
or	O
SARS	B-DISO
,	O
a	O
review	O
of	O
the	O
infection	B-DISO
control	O
procedures	O
for	O
aerosols	O
is	O
warranted	O
.	O

The	O
airborne	O
spread	O
of	O
measles	B-DISO
,	O
tuberculosis	B-DISO
and	O
SARS	B-DISO
is	O
well	O
-	O
documented	O
in	O
the	O
medical	O
literature	O
.	O

The	O
average	O
age	O
of	O
SARS	B-DISO
and	O
non	O
-	O
SARS	B-DISO
patients	O
were	O
(	O
40	O
+/-	O

CONCLUSIONS	O
:	O
Some	O
patients	O
with	O
other	O
respiratory	B-DISO
diseases	I-DISO
were	O
misdiagnosed	O
as	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
covert	O
infection	B-DISO
in	O
health	O
-	O
care	O
professionals	O
and	O
its	O
relation	O
to	O
work	O
intensity	O
and	O
type	O
of	O
work	O
.	O

Medical	O
examination	O
was	O
also	O
carried	O
out	O
for	O
313	O
people	O
who	O
had	O
close	O
contact	O
with	O
the	O
29	O
antibody	O
positive	O
health	O
care	O
professionals	O
,	O
but	O
no	O
clinical	O
SARS	B-DISO
was	O
found	O
.	O

Covert	O
infection	B-DISO
can	O
be	O
found	O
in	O
the	O
health	O
-	O
care	O
professionals	O
and	O
it	O
showed	O
no	O
contagiousness	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
During	O
inhalation	O
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	O
,	O
blood	O
arterial	O
oxygen	O
partial	O
pressure	O
fell	O
gradually	O
,	O
and	O
eventually	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	B-DISO
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	O
-	O
8	O
in	O
serum	O
rises	O
significantly	O
after	O
inhalation	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	O
-	O
6	O
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	O
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	B-DISO
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	B-DISO
,	O
edema	B-DISO
and	O
atelectasis	B-DISO
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	B-DISO
in	O
other	O
organs	O
.	O

Here	O
we	O
report	O
a	O
method	O
for	O
eliminating	O
false	O
-	O
negative	O
results	O
and	O
increasing	O
test	O
sensitivity	O
,	O
based	O
on	O
the	O
hypothesis	O
that	O
the	O
message	O
encoded	O
by	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
is	O
the	O
most	O
abundant	O
during	O
viral	B-DISO
infection	I-DISO
.	O

In	O
conclusion	O
,	O
the	O
nucleocapsid	O
gene	O
represents	O
an	O
additional	O
sensitive	O
molecular	O
marker	O
for	O
the	O
diagnosis	O
of	O
the	O
SARS	B-DISO
coronavirus	O
and	O
can	O
be	O
further	O
adapted	O
for	O
use	O
in	O
a	O
high	O
-	O
throughput	O
platform	O
assay	O
.	O

ABSTRACT	O
:	O
The	O
new	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
),	O
described	O
in	O
February	O
2003	O
,	O
infected	O
a	O
total	O
of	O
8	O
,	O
439	O
people	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
damage	O
of	O
liver	O
in	O
patients	O
with	O
SARS	B-DISO
].	O

Alanine	O
aminotransferase	O
(	O
ALT	O
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	B-DISO
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
relation	O
between	O
the	O
use	O
of	O
corticosteroids	O
in	O
the	O
treatment	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
and	O
arthralgia	B-DISO
as	O
a	O
sequela	O
.	O

The	O
information	O
about	O
arthralgia	B-DISO
was	O
investigated	O
one	O
month	O
after	O
discharge	O
of	O
SARS	B-DISO
patients	O
from	O
the	O
hospital	O
.	O

In	O
3	O
.	O
6	O
percent	O
of	O
patients	O
arthralgia	B-DISO
occurred	O
within	O
one	O
month	O
after	O
SARS	B-DISO
,	O
53	O
.	O
85	O
percent	O
of	O
the	O
patients	O
experienced	O
low	O
-	O
grade	O
arthralgia	B-DISO
.	O

Pneumothorax	B-DISO
and	O
mediastinal	B-DISO
emphysema	I-DISO
occurred	O
in	O
7	O
of	O
27	O
serious	O
cases	O
of	O
SARS	B-DISO
with	O
NIPPV	O
,	O
and	O
mediastinal	B-DISO
emphysema	I-DISO
occurred	O
in	O
1	O
of	O
189	O
cases	O
of	O
SARS	B-DISO
without	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

So	O
when	O
NIPPV	O
is	O
used	O
in	O
the	O
treatment	O
of	O
serious	O
SARS	B-DISO
patients	O
to	O
improve	O
hypoxemia	O
,	O
optimized	O
mechanical	O
ventilative	O
pressure	O
should	O
be	O
acquired	O
in	O
order	O
to	O
avoid	O
pneumothorax	B-DISO
and	O
mediastinal	B-DISO
emphysema	I-DISO
.	O

Seven	O
cases	O
of	O
pneumothorax	B-DISO
and	O
mediastinal	B-DISO
emphysema	I-DISO
improved	O
gradually	O
.	O

CONCLUSIONS	O
:	O
Intravenous	O
drip	O
of	O
the	O
oxygen	O
-	O
enriched	O
liquid	O
effectively	O
helped	O
correct	O
the	O
hypoxemia	O
of	O
SARS	B-DISO
and	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
cases	O
by	O
bypassing	O
the	O
diseased	O
alveoli	O
through	O
which	O
oxygen	O
would	O
not	O
pass	O
into	O
the	O
blood	O
by	O
conventional	O
oxygen	O
inhalation	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
correlation	O
between	O
positive	O
rates	O
of	O
RNA	O
in	O
clinical	O
confirmed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
and	O
its	O
appearance	O
in	O
relation	O
to	O
the	O
development	O
of	O
the	O
disease	O
in	O
order	O
to	O
provide	O
scientific	O
basis	O
for	O
early	O
diagnosis	O
,	O
effective	O
prevention	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

We	O
show	O
here	O
the	O
three	O
-	O
dimensional	O
appearance	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Enhanced	O
detail	O
of	O
the	O
ultrastructure	O
reveals	O
the	O
trimeric	O
structure	O
of	O
the	O
10	O
-	O
20	O
nm	O
spikes	O
on	O
the	O
virion	O
surface	O
.	O

These	O
results	O
contribute	O
to	O
characterization	O
of	O
the	O
SARS	B-DISO
agent	O
and	O
development	O
of	O
new	O
antiviral	O
strategies	O
.	O

Expression	O
of	O
SARS	B-DISO
protein	O
3a	O
was	O
detected	O
at	O
8	O
-	O
12	O
h	O
after	O
infection	B-DISO
and	O
reached	O
a	O
higher	O
level	O
after	O
approximately	O
24	O
h	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Our	O
study	O
demonstrates	O
that	O
SARS	B-DISO
-	O
CoV	O
indeed	O
expresses	O
a	O
novel	O
protein	O
3a	O
,	O
which	O
is	O
present	O
only	O
in	O
SARS	B-DISO
-	O
CoV	O
and	O
not	O
in	O
other	O
known	O
CoVs	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
multiplication	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
cell	O
culture	O
can	O
be	O
strongly	O
inhibited	O
by	O
pretreatment	O
with	O
interferon	O
-	O
beta	O
.	O

In	O
contrast	O
,	O
during	O
FIP	B-DISO
disease	O
,	O
fAGP	O
underwent	O
several	O
modifications	O
in	O
the	O
sialic	O
acid	O
content	O
,	O
including	O
decreased	O
expression	O
of	O
both	O
alpha	O
(	O
2	O
-	O
6	O
)-	O
linked	O
and	O
alpha	O
(	O
2	O
-	O
3	O
)-	O
linked	O
sialic	O
acid	O
(	O
76	O
and	O
44	O
%,	O
respectively	O
when	O
compared	O
to	O
non	O
-	O
pathological	O
feline	O
AGP	O
).	O

Proliferation	B-DISO
of	O
polyclonal	O
plasma	O
cells	O
of	O
recipient	O
-	O
type	O
that	O
was	O
documented	O
postmortem	O
,	O
was	O
most	O
likely	O
responsible	O
for	O
excessive	O
antibody	O
formation	O
.	O

ABSTRACT	O
:	O
This	O
study	O
adopts	O
the	O
concept	O
of	O
the	O
three	O
levels	O
of	O
prevention	O
from	O
traditional	O
Chinese	O
medicine	O
to	O
discuss	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
prevention	O
and	O
nursing	O
.	O

ABSTRACT	O
:	O
Spotted	O
hyenas	O
(	O
Crocuta	O
crocuta	O
)	O
are	O
abundant	O
predators	O
in	O
the	O
Serengeti	O
ecosystem	O
and	O
interact	O
with	O
other	O
species	O
of	O
wild	O
carnivores	O
and	O
domestic	O
animals	O
in	O
ways	O
that	O
could	O
encourage	O
disease	B-DISO
transmission	I-DISO
.	O

Some	O
problems	O
in	O
the	O
rational	O
exertions	O
of	O
TCM	O
in	O
preventing	O
and	O
treating	O
SARS	B-DISO
were	O
also	O
discussed	O
.	O

The	O
clinical	O
illness	O
is	O
similar	O
to	O
many	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
,	O
although	O
a	O
large	O
proportion	O
of	O
patients	O
show	O
a	O
rapid	O
deterioration	O
with	O
respiratory	B-DISO
distress	I-DISO
towards	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
illness	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
HLA	O
-	O
A2	O
-	O
restricted	O
T	O
-	O
cell	O
epitopes	O
in	O
the	O
S	O
protein	O
of	O
the	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
of	O
human	O
coronavirus	O
strain	O
229e	O
(	O
HCoV	O
-	O
229e	O
)	O
was	O
analyzed	O
for	O
the	O
elicitation	O
of	O
a	O
T	O
-	O
cell	O
immune	O
response	O
in	O
donors	O
who	O
had	O
fully	O
recovered	O
from	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
a	O
newly	O
identified	O
group	O
2	O
coronavirus	O
,	O
is	O
the	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
a	O
life	O
-	O
threatening	O
form	O
of	O
pneumonia	B-DISO
in	O
humans	O
.	O

SARS	B-DISO
-	O
CoV	O
nsp13	O
unwinds	O
its	O
substrates	O
in	O
a	O
5	O
'-	O
to	O
-	O
3	O
'	O
direction	O
and	O
features	O
a	O
remarkable	O
processivity	O
,	O
allowing	O
efficient	O
strand	O
separation	B-DISO
of	O
extended	O
regions	O
of	O
double	O
-	O
stranded	O
RNA	O
and	O
DNA	O
.	O

Furthermore	O
,	O
we	O
established	O
an	O
RNA	O
5	O
'-	O
triphosphatase	O
activity	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
nsp13	O
helicase	O
which	O
may	O
be	O
involved	O
in	O
the	O
formation	O
of	O
the	O
5	O
'	O
cap	B-DISO
structure	O
of	O
viral	O
RNAs	O
.	O

Finally	O
,	O
we	O
established	O
that	O
,	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
nsp13	O
localizes	O
to	O
membranes	O
that	O
appear	O
to	O
be	O
derived	O
from	O
the	O
endoplasmic	O
reticulum	O
and	O
are	O
the	O
likely	O
site	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
replication	O
in	O
actively	O
growing	O
DBT	O
and	O
17Cl	O
-	O
1	O
cells	O
resulted	O
in	O
the	O
inhibition	O
of	O
host	O
cellular	O
DNA	O
synthesis	O
and	O
the	O
accumulation	O
of	O
infected	O
cells	O
in	O
the	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Conjugated	O
and	O
unconjugated	O
oligomers	O
were	O
tested	O
to	O
determine	O
sequence	O
-	O
specific	O
antiviral	O
efficacy	O
against	O
a	O
member	O
of	O
the	O
Coronaviridae	O
,	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

These	O
results	O
suggest	O
that	O
this	O
composition	O
of	O
antisense	O
compound	O
has	O
therapeutic	O
potential	O
for	O
control	O
of	O
coronavirus	B-DISO
infection	I-DISO
.	O

We	O
also	O
identified	O
a	O
novel	O
dibasic	O
motif	O
(-	O
KXHXX	O
-	O
COOH	O
)	O
in	O
the	O
cytoplasmic	O
tails	O
of	O
S	O
proteins	O
from	O
group	O
1	O
coronaviruses	O
and	O
from	O
the	O
newly	O
identified	O
coronavirus	O
implicated	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
previously	O
identified	O
the	O
major	O
pathological	O
changes	O
in	O
the	O
respiratory	O
and	O
immune	O
systems	O
of	O
patients	O
who	O
died	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
but	O
gained	O
little	O
information	O
on	O
the	O
organ	O
distribution	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

These	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
the	O
respiratory	O
system	O
,	O
the	O
gastrointestinal	O
tract	O
and	O
other	O
organs	O
with	O
detectable	O
SARS	B-DISO
-	O
CoV	O
may	O
also	O
be	O
targets	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

In	O
addition	O
to	O
viral	O
spread	O
through	O
a	O
respiratory	O
route	O
,	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
intestinal	O
tract	O
,	O
kidney	O
and	O
sweat	O
glands	O
may	O
be	O
excreted	O
via	O
faeces	O
,	O
urine	O
and	O
sweat	O
,	O
thereby	O
leading	O
to	O
virus	O
transmission	O
.	O

This	O
study	O
provides	O
important	O
information	O
for	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
sheds	O
light	O
on	O
possible	O
virus	O
transmission	O
pathways	O
.	O

Recently	O
,	O
a	O
metallopeptidase	O
named	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
the	O
functional	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
Although	O
ACE2	O
mRNA	O
is	O
known	O
to	O
be	O
present	O
in	O
virtually	O
all	O
organs	O
,	O
its	O
protein	O
expression	O
is	O
largely	O
unknown	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
first	O
recognized	O
in	O
China	O
in	O
November	O
2002	O
and	O
was	O
subsequently	O
associated	O
with	O
a	O
worldwide	O
outbreak	O
involving	O
8098	O
people	O
,	O
774	O
of	O
whom	O
died	O
.	O

TITLE	O
:	O
[	O
Clinical	O
observation	O
on	O
treatment	O
of	O
SARS	B-DISO
with	O
combination	O
of	O
chaihu	O
droplet	O
pill	O
and	O
huoxiang	O
zhengqi	O
droplet	O
pill	O
].	O

Early	O
applying	O
of	O
CH	O
-	O
HZ	O
treatment	O
showed	O
good	O
effects	O
in	O
improving	O
CK	O
,	O
LDH	O
,	O
oxygenation	O
index	O
and	O
absolute	O
value	O
of	O
neutrophils	O
,	O
and	O
could	O
reduce	O
the	O
daily	O
maximal	O
dosage	O
of	O
glucocorticoid	O
needed	O
for	O
SARS	B-DISO
patients	O
.	O

RESULTS	O
:	O
Early	O
applying	O
of	O
CH	O
-	O
HZ	O
treatment	O
showed	O
good	O
effects	O
in	O
improving	O
CK	O
,	O
LDH	O
,	O
oxygenation	O
index	O
and	O
absolute	O
value	O
of	O
neutrophils	O
,	O
and	O
could	O
reduce	O
the	O
daily	O
maximal	O
dosage	O
of	O
glucocorticoid	O
needed	O
for	O
SARS	B-DISO
patients	O
.	O

To	O
rapidly	O
identify	O
anti	O
-	O
SARS	B-DISO
drugs	O
available	O
for	O
clinical	O
use	O
,	O
we	O
screened	O
a	O
set	O
of	O
compounds	O
that	O
included	O
antiviral	O
drugs	O
already	O
in	O
wide	O
use	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
a	O
peptide	O
with	O
fluorescence	O
quenching	O
pair	O
(	O
Dabcyl	O
and	O
Edans	O
)	O
at	O
both	O
ends	O
of	O
a	O
peptide	O
substrate	O
and	O
used	O
this	O
fluorogenic	O
peptide	O
substrate	O
to	O
characterize	O
SARS	B-DISO
main	O
protease	O
and	O
screen	O
inhibitors	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
radiographic	O
findings	O
and	O
evolution	O
of	O
round	O
pneumonia	B-DISO
found	O
in	O
eight	O
patients	O
with	O
confirmed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Radiologists	O
and	O
physicians	O
should	O
consider	O
the	O
possibility	O
of	O
""""	O
SARS	B-DISO
pneumonia	B-DISO
""""	O
when	O
spherical	O
air	O
-	O
space	O
opacities	B-DISO
are	O
noted	O
on	O
chest	O
radiographs	O
of	O
febrile	O
patients	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
and	O
change	O
of	O
people	O
'	O
s	O
health	O
behavior	O
in	O
China	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
become	O
a	O
new	O
worldwide	O
epidemic	O
whose	O
origin	O
was	O
until	O
recently	O
unknown	O
.	O

Most	O
respondents	O
took	O
action	O
to	O
avoid	O
being	O
infected	O
by	O
SARS	B-DISO
,	O
including	O
,	O
most	O
commonly	O
,	O
efforts	O
to	O
improve	O
indoor	O
ventilation	O
,	O
to	O
disinfect	O
the	O
indoor	O
environment	O
and	O
to	O
increase	O
hand	O
-	O
washing	O
frequency	O
.	O

With	O
the	O
aim	O
of	O
developing	O
therapeutic	O
agents	O
,	O
we	O
have	O
tested	O
peptides	O
derived	O
from	O
the	O
membrane	O
-	O
proximal	O
(	O
HR2	O
)	O
and	O
membrane	O
-	O
distal	O
(	O
HR1	O
)	O
heptad	O
repeat	O
region	O
of	O
the	O
spike	O
protein	O
as	O
inhibitors	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
of	O
Vero	O
cells	O
.	O

The	O
inhibitory	O
potency	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
HR2	O
-	O
peptides	O
provides	O
an	O
attractive	O
basis	O
for	O
the	O
development	O
of	O
a	O
therapeutic	O
drug	O
for	O
SARS	B-DISO
.	O

Proper	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
and	O
scrupulous	O
attention	O
to	O
hand	O
hygiene	O
are	O
critical	O
to	O
reducing	O
transmission	O
of	O
SARS	B-DISO
,	O
especially	O
in	O
health	O
care	O
facilities	O
.	O

Health	O
care	O
workers	O
bore	O
a	O
large	O
burden	O
of	O
illness	O
during	O
the	O
2002	O
to	O
2003	O
SARS	B-DISO
epidemic	O
.	O

TITLE	O
:	O
Effect	O
of	O
temperature	O
on	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
fecal	O
samples	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
Antibiotic	O
-	O
resistant	O
bacteria	O
are	O
an	O
increasingly	O
common	O
problem	O
in	O
intensive	O
care	O
units	O
(	O
ICUs	O
),	O
and	O
they	O
are	O
capable	O
of	O
impacting	O
on	O
patient	O
outcome	O
,	O
the	O
ICU	O
'	O
s	O
budget	O
and	O
bed	B-DISO
availability	O
.	O

A	O
new	O
coronavirus	O
(	O
SCoV	O
)	O
that	O
evoked	O
a	O
rapid	O
outbreak	O
of	O
disease	O
described	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
the	O
first	O
half	O
of	O
2003	O
may	O
serve	O
as	O
an	O
example	O
.	O

Hantaviruses	O
(	O
Puumala	O
,	O
Hantaan	O
,	O
Sin	O
Nombre	O
and	O
others	O
)	O
infecting	O
field	O
rodents	O
may	O
be	O
a	O
cause	O
of	O
hemorrhagic	B-DISO
fever	I-DISO
with	I-DISO
renal	I-DISO
syndrome	I-DISO
(	O
HFRS	B-DISO
)	O
or	O
pulmonary	O
syndrome	B-DISO
(	O
HPS	B-DISO
)	O
in	O
farmers	O
and	O
laboratory	O
workers	O
.	O

TITLE	O
:	O
Bioinformatics	O
analysis	O
of	O
SARS	B-DISO
coronavirus	O
genome	O
polymorphism	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
tree	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
isolates	O
has	O
been	O
produced	O
using	O
the	O
CLUSTALW	O
program	O
,	O
showing	O
high	O
compatibility	O
with	O
former	O
qualitative	O
classification	O
.	O

They	O
were	O
euthanized	O
at	O
5	O
(	O
n	O
=	O
2	O
)	O
or	O
9	O
(	O
n	O
=	O
2	O
)	O
days	O
post	O
-	O
infection	B-DISO
(	O
dpi	O
),	O
or	O
monitored	O
until	O
14	O
dpi	O
(	O
n	O
=	O
2	O
).	O

TITLE	O
:	O
Glycan	O
arrays	O
lead	O
to	O
the	O
discovery	O
of	O
autoimmunogenic	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Using	O
carbohydrate	O
microarrays	O
,	O
we	O
characterized	O
the	O
carbohydrate	O
binding	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
neutralizing	O
antibodies	O
elicited	O
by	O
an	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
.	O

Two	O
regions	O
within	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
have	O
been	O
identified	O
,	O
showing	O
a	O
high	O
degree	O
of	O
sequence	O
conservation	O
with	O
the	O
other	O
CoV	O
,	O
which	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
heptad	O
repeats	O
(	O
HR1	O
and	O
HR2	O
).	O

TITLE	O
:	O
Serum	O
hepatic	O
enzyme	O
manifestations	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
retrospective	O
analysis	O
.	O

Purified	O
N	O
protein	O
was	O
used	O
to	O
measure	O
the	O
SARS	B-DISO
-	O
CoV	O
specific	O
IgG	O
antibodies	O
from	O
16	O
SARS	B-DISO
-	O
CoV	O
infected	O
patients	O
'	O
sera	O
and	O
from	O
131	O
control	O
subjects	O
using	O
ELISA	O
assay	O
.	O

TITLE	O
:	O
S	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
mediates	O
entry	O
into	O
hepatoma	B-DISO
cell	O
lines	O
and	O
is	O
targeted	O
by	O
neutralizing	O
antibodies	O
in	O
infected	O
patients	O
.	O

Coexpression	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
with	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
-	O
based	O
reporter	O
constructs	O
yielded	O
viruses	O
that	O
were	O
infectious	B-DISO
for	O
a	O
range	O
of	O
cell	O
lines	O
.	O

Since	O
its	O
discovery	O
in	O
2000	O
,	O
ACE2	O
has	O
been	O
implicated	O
in	O
heart	O
function	O
,	O
hypertension	B-DISO
and	O
diabetes	B-DISO
,	O
with	O
its	O
effects	O
being	O
mediated	O
,	O
in	O
part	O
,	O
through	O
its	O
ability	O
to	O
convert	O
angiotensin	O
II	O
to	O
angiotensin	O
-(	O
1	O
-	O
7	O
).	O

Once	O
this	O
technology	O
is	O
adapted	O
to	O
SARS	B-DISO
-	O
CoV	O
replicon	O
RNAs	O
,	O
it	O
will	O
allow	O
high	O
throughput	O
screening	O
for	O
SARS	B-DISO
-	O
CoV	O
replicase	O
inhibitors	O
without	O
the	O
need	O
to	O
grow	O
infectious	B-DISO
SARS	B-DISO
-	O
CoV	O
.	O

There	O
was	O
no	O
transmission	O
of	O
SARS	B-DISO
within	O
the	O
operating	O
room	O
complex	O
.	O

The	O
only	O
recent	O
innovation	O
is	O
the	O
hypothesis	O
that	O
pulmonary	O
ARDS	B-DISO
and	O
extrapulmonary	O
ARDS	B-DISO
could	O
be	O
different	O
clinical	O
entities	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
disease	O
that	O
caused	O
large	O
outbreaks	O
in	O
several	O
countries	O
in	O
the	O
first	O
half	O
of	O
2003	O
,	O
resulting	O
in	O
infection	B-DISO
in	O
more	O
than	O
8000	O
people	O
and	O
more	O
than	O
900	O
deaths	O
.	O

A	O
similarly	O
consistent	O
picture	O
of	O
the	O
SARS	B-DISO
patient	O
with	O
respiratory	B-DISO
failure	I-DISO
has	O
emerged	O
from	O
studies	O
from	O
Toronto	O
and	O
Singapore	O
.	O

ABSTRACT	O
:	O
Organophosphates	O
may	O
cause	O
serious	O
life	O
-	O
threatening	O
conditions	O
,	O
such	O
as	O
an	O
initial	O
acute	O
cholinergic	B-DISO
crisis	I-DISO
and	O
intermediate	B-DISO
syndrome	I-DISO
.	O

Sometimes	O
the	O
diagnosis	O
may	O
be	O
difficult	O
,	O
as	O
in	O
case	O
1	O
,	O
identified	O
initially	O
as	O
brainstem	B-DISO
stroke	I-DISO
.	O

Intraperitoneal	O
injection	O
of	O
cerulein	O
in	O
mice	O
resulted	O
in	O
severe	O
,	O
acute	B-DISO
pancreatitis	I-DISO
characterised	O
by	O
oedema	B-DISO
,	O
neutrophil	O
infiltration	B-DISO
,	O
tissue	O
haemorrhage	B-DISO
and	O
necrosis	O
and	O
elevated	O
serum	O
levels	O
of	O
amylase	O
and	O
lipase	O
.	O

Its	O
etiological	O
agent	O
has	O
been	O
convincingly	O
identified	O
as	O
a	O
new	O
member	O
of	O
family	O
Coronaviridae	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
smooth	O
vesicles	B-DISO
fused	O
with	O
the	O
cell	O
membrane	O
,	O
and	O
the	O
mature	O
particles	O
were	O
released	O
.	O

A	O
specific	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
SARS	B-DISO
-	O
CoV	O
yielded	O
positive	O
results	O
for	O
<	O
50	O
%	O
of	O
children	O
.	O

Sore	B-DISO
throat	I-DISO
and	O
initial	O
and	O
peak	O
neutrophilia	O
seem	O
to	O
be	O
predictors	O
of	O
severe	O
illness	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
hypertension	I-DISO
is	O
a	O
common	O
finding	O
in	O
pulmonary	O
circulatory	B-DISO
disorders	I-DISO
of	O
different	O
origin	O
.	O

However	O
,	O
randomised	O
controlled	O
trials	O
performed	O
to	O
evaluate	O
long	O
-	O
term	O
effects	O
revealed	O
different	O
results	O
:	O
thus	O
,	O
in	O
chronic	O
pulmonary	B-DISO
hypertension	I-DISO
inhaled	O
vasodilators	O
improved	O
outcome	O
whereas	O
the	O
results	O
for	O
the	O
treatment	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
revealed	O
beneficial	O
effects	O
only	O
when	O
used	O
as	O
a	O
rescue	O
and	O
/	O
or	O
bridging	O
therapy	O
in	O
severe	O
hypoxemia	O
.	O

It	O
was	O
shown	O
that	O
kit	O
was	O
able	O
to	O
detect	O
10	O
TCID	O
/	O
50	O
ml	O
of	O
SARS	B-DISO
-	O
Cov	O
virus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SCV	O
).	O

Type	O
I	O
interferons	O
(	O
IFNs	O
-	O
alpha	O
/	O
beta	O
)	O
were	O
suggested	O
as	O
potential	O
candidates	O
to	O
treat	O
SARS	B-DISO
.	O

TITLE	O
:	O
Detention	O
for	O
tuberculosis	B-DISO
:	O
public	O
health	O
and	O
the	O
law	O
.	O

Of	O
14	O
attending	O
physicians	O
,	O
four	O
became	O
ill	B-DISO
during	O
the	O
outbreak	O
.	O

RESULTS	O
:	O
Toronto	O
Public	O
Health	O
investigated	O
2132	O
potential	O
cases	O
of	O
SARS	B-DISO
,	O
identified	O
23	O
,	O
103	O
contacts	O
of	O
SARS	B-DISO
patients	O
as	O
requiring	O
quarantine	O
,	O
and	O
logged	O
316	O
,	O
615	O
calls	O
on	O
its	O
SARS	B-DISO
hotline	O
.	O

Instead	O
of	O
chelating	O
therapy	O
patient	O
died	O
due	O
to	O
respiratory	B-DISO
failure	I-DISO
.	O

In	O
our	O
case	O
the	O
appearance	O
of	O
the	O
encephalopathy	B-DISO
was	O
the	O
key	O
to	O
the	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
new	O
corona	O
--	O
virus	O
SARS	B-DISO
-	O
Co	O
-	O
V	O
was	O
not	O
identified	O
at	O
humans	O
and	O
animals	O
up	O
to	O
this	O
time	O
.	O

TITLE	O
:	O
Outcome	O
of	O
coronavirus	O
-	O
associated	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
using	O
a	O
standard	O
treatment	O
protocol	O
.	O

One	O
patient	O
(	O
1	O
%)	O
died	O
of	O
SARS	B-DISO
-	O
related	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Occult	O
pneumomediastinum	B-DISO
in	O
a	O
SARS	B-DISO
patient	O
presenting	O
as	O
recurrent	O
chest	B-DISO
pain	I-DISO
and	O
acute	O
ECG	O
changes	O
mimicking	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
emergent	O
disease	O
due	O
to	O
a	O
novel	O
coronavirus	O
,	O
which	O
caused	O
outbreaks	O
worldwide	O
.	O

We	O
report	O
a	O
SARS	B-DISO
patient	O
who	O
had	O
developed	O
recurrent	O
chest	B-DISO
pain	I-DISO
and	O
acute	O
T	O
-	O
wave	O
inversion	B-DISO
over	O
the	O
precordial	O
leads	O
on	O
electrocardiography	O
(	O
ECG	O
).	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
clinical	O
staging	O
system	O
for	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
based	O
on	O
clinical	O
feature	O
,	O
laboratory	O
tests	O
as	O
well	O
as	O
dynamic	O
changes	O
of	O
chest	O
X	O
-	O
ray	O
images	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
SARS	B-DISO
coronavirus	O
by	O
a	O
short	O
hairpin	O
RNA	O
expression	O
plasmid	O
targeting	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
produces	O
six	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
,	O
each	O
containing	O
a	O
64	O
nucleotide	O
(	O
nt	O
)	O
leader	O
sequence	O
,	O
derived	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
by	O
a	O
discontinuous	O
process	O
.	O

The	O
Western	O
blotting	O
demonstrated	O
that	O
SARS	B-DISO
patient	O
convalescent	O
serum	O
could	O
recognize	O
the	O
recombinant	O
fusion	O
protein	O
.	O

TITLE	O
:	O
Sensitive	O
and	O
specific	O
monoclonal	O
antibody	O
-	O
based	O
capture	O
enzyme	O
immunoassay	O
for	O
detection	O
of	O
nucleocapsid	O
antigen	O
in	O
sera	O
from	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
was	O
84	O
.	O
6	O
%	O
in	O
13	O
serologically	O
confirmed	O
SARS	B-DISO
patients	O
with	O
blood	O
taken	O
during	O
the	O
first	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
(	O
11	O
of	O
13	O
).	O

TITLE	O
:	O
High	O
-	O
efficiency	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
genetic	O
material	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
spread	O
to	O
a	O
global	O
pandemic	O
,	O
especially	O
in	O
Asia	O
.	O

Patients	O
with	O
SARS	B-DISO
had	O
significantly	O
higher	O
IL	O
-	O
8	O
levels	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
in	O
early	O
stage	O
,	O
and	O
higher	O
IL	O
-	O
2	O
levels	O
(	O
p	O
=	O
0	O
.	O
039	O
)	O
in	O
late	O
stage	O
than	O
normal	O
controls	O
.	O

As	O
long	O
as	O
no	O
cases	O
of	O
person	O
-	O
to	O
-	O
person	O
disease	B-DISO
transmission	I-DISO
are	O
reported	O
anywhere	O
in	O
the	O
world	O
,	O
efforts	O
should	O
be	O
aimed	O
at	O
early	O
detection	O
and	O
notification	O
of	O
cases	O
and	O
of	O
groups	O
of	O
people	O
who	O
are	O
in	O
contact	O
with	O
one	O
another	O
and	O
who	O
have	O
severe	O
respiratory	B-DISO
infections	I-DISO
of	O
undetermined	O
cause	O
,	O
such	O
as	O
pneumonia	B-DISO
,	O
which	O
could	O
signal	O
the	O
reemergence	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
express	O
S2	O
protein	O
of	O
SARS	B-DISO
virus	O
fused	O
with	O
Trx	O
and	O
then	O
detect	O
its	O
reactivity	O
to	O
the	O
sera	O
from	O
convalescent	O
SARS	B-DISO
patients	O
.	O

The	O
fusion	O
protein	O
could	O
react	O
with	O
all	O
the	O
sera	O
from	O
convalescent	O
SARS	B-DISO
patients	O
but	O
not	O
with	O
the	O
sera	O
from	O
healthy	O
donors	O
.	O

The	O
convalescent	O
SARS	B-DISO
patients	O
'	O
immune	O
function	O
gradually	O
recovers	O
,	O
and	O
the	O
effect	O
of	O
SARS	B-DISO
virus	O
on	O
activation	O
of	O
T	O
cells	O
gradually	O
disappears	O
.	O

The	O
downstream	O
targets	O
of	O
p38	O
MAPK	O
,	O
MAPKAPK	O
-	O
2	O
,	O
HSP	B-DISO
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
were	O
phosphorylated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

The	O
p38	O
MAPK	O
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	O
of	O
HSP	B-DISO
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
A	O
novel	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
protein	O
,	O
U274	O
,	O
is	O
transported	O
to	O
the	O
cell	O
surface	O
and	O
undergoes	O
endocytosis	O
.	O

TITLE	O
:	O
An	O
exposed	O
domain	O
in	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
induces	O
neutralizing	O
antibodies	O
.	O

Monoclonal	O
antibodies	O
raised	O
against	O
this	O
fragment	O
recognized	O
the	O
native	O
spike	O
protein	O
of	O
SARS	B-DISO
CoV	O
in	O
both	O
monomeric	O
and	O
trimeric	O
forms	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SCoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
major	O
surface	O
antigen	O
of	O
the	O
virus	O
and	O
is	O
responsible	O
for	O
receptor	O
binding	O
and	O
the	O
generation	O
of	O
neutralizing	O
antibody	O
.	O

Recombinant	O
SCoV	O
S	O
protein	O
appears	O
to	O
be	O
a	O
suitable	O
antigen	O
for	O
the	O
development	O
of	O
an	O
efficient	O
and	O
sensitive	O
diagnostic	O
test	O
for	O
SARS	B-DISO
,	O
but	O
our	O
data	O
suggest	O
that	O
assay	O
format	O
and	O
choice	O
of	O
S	O
antigen	O
are	O
important	O
considerations	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
3	O
(	O
MHV3	O
),	O
a	O
coronavirus	O
,	O
is	O
an	O
excellent	O
animal	O
model	O
for	O
the	O
study	O
of	O
immunological	O
disorders	O
related	O
to	O
acute	O
and	O
chronic	B-DISO
hepatitis	I-DISO
.	O

Whether	O
or	O
not	O
our	O
patients	O
had	O
been	O
suspected	O
of	O
or	O
treated	O
as	O
having	O
SARS	B-DISO
,	O
was	O
recorded	O
.	O

The	O
patients	O
filled	O
out	O
questionnaires	O
regarding	O
lung	B-DISO
cancer	I-DISO
treatment	O
and	O
the	O
risk	O
of	O
getting	O
SARS	B-DISO
from	O
the	O
hospital	O
.	O

Thus	O
,	O
a	O
clear	O
differentiation	O
between	O
the	O
two	O
conditions	O
is	O
needed	O
,	O
especially	O
for	O
those	O
patients	O
who	O
are	O
under	O
active	O
anti	O
-	O
cancer	B-DISO
treatment	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
patient	O
who	O
suffered	B-DISO
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
presented	O
with	O
an	O
uncommon	O
chest	O
X	O
-	O
ray	O
finding	O
,	O
lobar	B-DISO
pneumonia	I-DISO
,	O
which	O
was	O
never	O
reported	O
.	O

Acute	O
lung	O
injury	O
and	O
respiratory	B-DISO
distress	I-DISO
are	O
among	O
the	O
most	O
frequent	O
and	O
serious	O
complications	O
related	O
to	O
severe	O
brain	O
injury	O
that	O
benefit	O
from	O
the	O
use	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
and	O
ventilation	O
to	O
protect	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
The	O
PiCCO	O
physiological	O
monitor	O
(	O
Pulsion	O
Medical	O
Systems	O
,	O
Munich	O
,	O
Germany	O
)	O
was	O
used	O
for	O
hemodynamic	O
diagnosis	O
and	O
monitoring	O
of	O
4	O
patients	O
:	O
a	O
polytraumatized	O
female	O
patient	O
with	O
septic	B-DISO
shock	I-DISO
and	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
;	O
a	O
man	O
with	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
and	O
cor	B-DISO
pulmonale	I-DISO
who	O
developed	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
while	O
recovering	O
from	O
anterior	O
resection	O
of	O
the	O
rectum	O
;	O
a	O
man	O
with	O
severe	O
head	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
;	O
and	O
a	O
polytraumatized	O
male	O
patient	O
with	O
a	O
myocardial	O
contusion	O
.	O

All	O
were	O
in	O
a	O
life	O
-	O
threatening	O
situation	O
,	O
either	O
immediately	O
as	O
in	O
the	O
case	O
of	O
the	O
patient	O
with	O
myocardial	O
contusion	O
or	O
eventually	O
as	O
in	O
the	O
patient	O
with	O
septic	B-DISO
shock	I-DISO
.	O

One	O
example	O
,	O
the	O
PiCCO	O
monitor	O
,	O
combines	O
arterial	O
thermodilution	O
with	O
analysis	O
of	O
the	O
pulse	O
waveform	O
,	O
providing	O
a	O
series	O
of	O
hemodynamic	O
parameters	O
useful	O
for	O
managing	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
.	O

TITLE	O
:	O
Hospital	O
preparedness	O
and	O
SARS	B-DISO
.	O

Given	O
the	O
difficulty	O
in	O
implementing	O
several	O
of	O
these	O
measures	O
,	O
control	O
measures	O
were	O
frequently	O
adapted	O
to	O
the	O
acuity	O
of	O
SARS	B-DISO
care	O
and	O
level	O
of	O
transmission	O
within	O
facilities	O
.	O

TITLE	O
:	O
Laboratory	O
diagnosis	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
transmission	O
,	O
risk	O
factors	O
,	O
and	O
prevention	O
in	O
Hong	O
Kong	O
.	O

This	O
is	O
the	O
first	O
case	O
series	O
reported	O
with	O
the	O
detection	O
of	O
the	O
SARS	B-DISO
coronavirus	O
from	O
tears	O
,	O
and	O
has	O
important	O
implications	O
for	O
the	O
practice	O
of	O
ophthalmology	O
and	O
medicine	O
.	O

The	O
positive	O
specimens	O
were	O
found	O
in	O
cases	O
sampled	O
early	O
in	O
their	O
course	O
of	O
infection	B-DISO
.	O

We	O
studied	O
SARS	B-DISO
case	O
reports	O
through	O
April	O
30	O
,	O
2003	O
,	O
including	O
data	O
from	O
case	O
investigations	O
and	O
a	O
case	O
series	O
analysis	O
of	O
index	O
cases	O
.	O

Clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
differed	O
between	O
children	O
(<	O
18	O
years	O
)	O
and	O
older	O
persons	O
(>	O
or	O
=	O
65	O
years	O
).	O

The	O
pGEX	O
-	O
2T	O
/	O
N	O
has	O
been	O
constructed	O
and	O
expressed	O
in	O
the	O
form	O
of	O
fusion	O
protein	O
GST	O
-	O
N	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
.	O

We	O
correlated	O
positively	O
reacting	O
peptides	O
with	O
the	O
in	O
vitro	O
SARS	B-DISO
-	O
CoV	O
neutralizing	O
activity	O
of	O
the	O
samples	O
.	O

TITLE	O
:	O
Avascular	B-DISO
necrosis	I-DISO
of	I-DISO
bone	I-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

CONCLUSIONS	O
:	O
AVN	O
can	O
occur	O
in	O
the	O
patients	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Hypoxemia	O
occurred	O
after	O
induction	O
of	O
anesthesia	B-DISO
and	O
repositioning	O
in	O
a	O
patient	O
undergoing	O
hip	O
pinning	O
.	O

The	O
patient	O
was	O
returned	O
to	O
the	O
supine	O
position	O
,	O
but	O
despite	O
maneuvers	O
to	O
improve	O
oxygen	O
saturation	O
,	O
the	O
patient	O
'	O
s	O
saturation	O
remained	O
below	O
87	O
%	O
and	O
pulmonary	B-DISO
thromboembolism	I-DISO
was	O
suspected	O
.	O

TITLE	O
:	O
Contributions	O
of	O
the	O
structural	O
proteins	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
to	O
protective	O
immunity	O
.	O

ABSTRACT	O
:	O
Situations	O
of	O
cardiac	B-DISO
arrest	I-DISO
have	O
been	O
reported	O
in	O
under	O
-	O
nourished	O
patients	O
with	O
protein	O
and	O
calorie	O
deficits	O
when	O
the	O
provision	O
of	O
nutrients	O
was	O
initiated	O
in	O
an	O
uncontrolled	O
manner	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
dialysis	O
patients	O
.	O

In	O
all	O
seven	O
patients	O
with	O
PD	O
effluent	O
tested	O
,	O
SARS	B-DISO
-	O
related	O
coronavirus	O
(	O
CoV	O
)	O
could	O
not	O
be	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
or	O
viral	O
culture	O
.	O

Despite	O
dosage	O
adjustment	O
,	O
ribavirin	O
-	O
induced	O
hemolytic	B-DISO
anemia	I-DISO
was	O
more	O
severe	O
in	O
the	O
dialysis	O
patients	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
replication	O
by	O
niclosamide	O
.	O

TITLE	O
:	O
SARS	B-DISO
in	O
newborns	O
and	O
children	O
.	O

Some	O
newborn	O
infants	O
,	O
however	O
,	O
developed	O
severe	O
intrauterine	B-DISO
growth	I-DISO
retardation	I-DISO
and	O
life	O
-	O
threatening	O
gastrointestinal	B-DISO
complications	I-DISO
.	O

TITLE	O
:	O
Generation	O
of	O
the	O
transgenic	O
potato	O
expressing	O
full	O
-	O
length	O
spike	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

In	O
vitro	O
secretion	O
of	O
interleukin	O
2	O
and	O
T	O
lymphocyte	O
proliferation	B-DISO
of	O
spleen	O
cells	O
from	O
the	O
immunized	O
chickens	O
varied	O
with	O
the	O
dose	O
and	O
the	O
manner	O
of	O
vaccination	O
with	O
S	O
protein	O
derived	O
from	O
transgenic	O
plants	O
.	O

TITLE	O
:	O
Mucosal	O
immunisation	O
of	O
African	O
green	O
monkeys	O
(	O
Cercopithecus	O
aethiops	O
)	O
with	O
an	O
attenuated	O
parainfluenza	B-DISO
virus	O
expressing	O
the	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
for	O
the	O
prevention	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2002	O
was	O
caused	O
by	O
a	O
previously	O
unknown	O
coronavirus	O
-	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
continues	O
to	O
cause	O
sporadic	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
China	O
.	O

The	O
data	O
generated	O
in	O
this	O
animal	O
model	O
show	O
that	O
administration	O
of	O
a	O
human	O
monoclonal	O
antibody	O
might	O
offer	O
a	O
feasible	O
and	O
effective	O
prophylaxis	O
for	O
the	O
control	O
of	O
human	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Expression	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
receptor	O
by	O
central	O
nervous	B-DISO
system	O
microglia	O
.	O

Receptor	O
expression	O
on	O
microglia	O
was	O
reduced	O
during	O
acute	B-DISO
infection	I-DISO
and	O
restored	O
following	O
immune	O
-	O
mediated	O
virus	O
control	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
lung	O
assist	O
has	O
been	O
proposed	O
as	O
an	O
invasive	O
measure	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
when	O
oxygenation	O
is	O
critically	O
impaired	B-DISO
.	O

In	O
30	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
multitrauma	O
,	O
pneumonia	B-DISO
or	O
after	O
surgery	O
(	O
p	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)-	O
ratio	O
67	O
+/-	O
23	O
mmHg	O
)	O
pECLA	O
was	O
established	O
by	O
insertion	O
of	O
cannulae	O
to	O
the	O
femoral	O
artery	O
and	O
vein	O
followed	O
by	O
connection	O
with	O
a	O
membrane	O
gas	O
exchanger	O
.	O

pECLA	O
represents	O
a	O
feasable	O
and	O
effective	O
treatment	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
associated	O
with	O
a	O
new	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
Pulmonary	B-DISO
involvement	I-DISO
is	O
the	O
dominant	O
clinical	O
feature	O
but	O
extra	O
-	O
pulmonary	O
manifestations	O
are	O
also	O
common	O
.	O

Remarkably	O
,	O
endothelial	O
cells	O
,	O
which	O
express	O
ACE2	O
to	O
a	O
high	O
level	O
,	O
have	O
not	O
been	O
shown	O
to	O
be	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
There	O
is	O
also	O
evidence	O
that	O
cell	O
types	O
without	O
detectable	O
ACE2	O
expression	O
may	O
also	O
be	O
infected	O
by	O
the	O
virus	O
.	O

The	O
mutation	O
rate	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
was	O
estimated	O
to	O
be	O
0	O
.	O
80	O
-	O
2	O
.	O
38	O
x	O
10	O
-	O
3	O
nucleotide	O
substitution	O
per	O
site	O
per	O
year	O
which	O
is	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
other	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
Successful	O
therapy	O
of	O
severe	O
pneumonia	B-DISO
-	O
associated	O
ARDS	B-DISO
after	O
pneumonectomy	O
with	O
ECMO	O
and	O
steroids	O
.	O

These	O
results	O
indicate	O
that	O
,	O
at	O
least	O
as	O
observed	O
in	O
this	O
study	O
,	O
outbreaks	O
of	O
increased	O
mortality	O
resulting	O
from	O
colibacillosis	B-DISO
are	O
not	O
necessarily	O
associated	O
with	O
IBV	O
,	O
NDV	O
,	O
APV	O
,	O
M	O
.	O
gallisepticum	O
,	O
M	O
.	O
synoviae	O
or	O
O	O
.	O
rhinotracheale	O
infections	B-DISO
.	O

Cotton	O
swabs	O
dipped	O
in	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
or	O
avian	O
pneumovirus	O
(	O
APV	O
)	O
were	O
allowed	O
to	O
dry	O
.	O

Among	O
them	O
,	O
three	O
of	O
the	O
five	O
flocks	O
had	O
been	O
vaccinated	O
against	O
infectious	B-DISO
bronchitis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
seroprevalence	O
of	O
antibody	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
cohorts	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
with	O
subclinical	B-DISO
infection	I-DISO
in	O
SARS	B-DISO
and	O
non	O
-	O
SARS	B-DISO
medical	O
wards	O
was	O
2	O
.	O
3	O
%	O
(	O
3	O
of	O
131	O
HCWs	O
)	O
and	O
0	O
%	O
(	O
0	O
of	O
192	O
HCWs	O
),	O
respectively	O
.	O

Job	O
that	O
dealing	O
with	O
palm	O
civets	O
was	O
the	O
main	O
risk	O
factor	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
animal	O
market	O
workers	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
impact	O
of	O
effective	O
interaction	O
between	O
public	O
and	O
media	O
on	O
the	O
prevention	O
and	O
control	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

In	O
the	O
late	O
period	O
of	O
SARS	B-DISO
epidemic	O
,	O
investigation	O
on	O
knowledge	O
,	O
attitude	O
and	O
practice	O
on	O
SARS	B-DISO
prevention	O
and	O
control	O
among	O
general	O
population	O
was	O
conducted	O
.	O

RESULTS	O
:	O
During	O
the	O
3	O
month	O
period	O
of	O
SARS	B-DISO
epidemic	O
in	O
Shenzhen	O
,	O
techniques	O
of	O
the	O
""""	O
E	O
-	O
health	O
and	O
public	O
health	O
informatics	O
""""	O
as	O
an	O
emerging	O
fields	O
were	O
used	O
to	O
focus	O
on	O
population	O
to	O
eventually	O
improve	O
the	O
health	O
of	O
entire	O
population	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
hospitalization	O
would	O
cause	O
the	O
situation	O
of	O
SARS	B-DISO
patient	O
to	O
deteriorate	O
,	O
losing	O
the	O
best	O
chance	O
for	O
treatment	O
and	O
increase	O
case	O
fatality	O
.	O

The	O
medical	O
expenditure	O
on	O
SARS	B-DISO
patients	O
at	O
the	O
hospital	O
was	O
higher	O
than	O
that	O
on	O
patients	O
with	O
common	O
diseases	O
which	O
was	O
associated	O
to	O
the	O
following	O
factors	O
as	O
:	O
days	O
of	O
hospitalization	O
,	O
severity	O
of	O
disease	O
,	O
stage	O
of	O
the	O
disease	O
break	O
-	O
out	O
,	O
patient	O
'	O
s	O
occupation	O
,	O
baseline	O
disease	O
status	O
,	O
medical	O
insurance	O
status	O
etc	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
warrants	O
the	O
search	O
for	O
effective	O
antiviral	O
agents	O
to	O
treat	O
the	O
disease	O
.	O

This	O
study	O
describes	O
the	O
assessment	O
of	O
the	O
antiviral	O
potential	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
against	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
strain	O
Frankfurt	O
-	O
1	O
replicating	O
in	O
African	O
Green	O
Monkey	O
(	O
Vero	O
E6	O
)	O
cells	O
.	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
an	O
efficient	O
3	O
'-	O
noncoding	O
region	O
based	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
RT	O
-	O
PCR	O
assay	O
for	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
.	O

Efforts	O
to	O
control	O
future	O
SARS	B-DISO
outbreaks	O
depend	O
on	O
the	O
accurate	O
and	O
early	O
identification	O
of	O
SARS	B-DISO
-	O
CoV	O
infected	O
patients	O
.	O

TITLE	O
:	O
Development	O
and	O
characterisation	O
of	O
neutralising	O
monoclonal	O
antibody	O
to	O
the	O
SARS	B-DISO
-	O
coronavirus	O
.	O

Two	O
of	O
these	O
Spike	O
-	O
specific	O
mAbs	O
demonstrate	O
the	O
ability	O
to	O
neutralise	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
while	O
another	O
four	O
Western	O
immunoblot	O
-	O
negative	O
mAbs	O
also	O
neutralise	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
inhibitory	O
effect	O
of	O
serum	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
-	O
specific	O
antibodies	O
from	O
convalescent	O
patients	O
after	O
half	O
an	O
year	O
of	O
onset	O
on	O
SARS	B-DISO
-	O
CoV	O
-	O
mediated	O
cytopathic	O
response	O
.	O

TITLE	O
:	O
Sequence	O
comparison	O
of	O
the	O
ORF	O
7	O
region	O
of	O
transmissible	O
gastroenteritis	B-DISO
viruses	O
isolated	O
in	O
Japan	O
.	O

Since	O
then	O
,	O
a	O
large	O
body	O
of	O
research	O
on	O
the	O
syndrome	B-DISO
has	O
been	O
published	O
;	O
the	O
most	O
updated	O
developments	O
are	O
summarized	O
here	O
.	O

It	O
has	O
been	O
shown	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
is	O
typically	O
relatively	O
inefficiently	O
transmitted	B-DISO
,	O
with	O
the	O
notable	O
exception	O
of	O
transmission	O
during	O
superspreading	O
events	O
.	O

One	O
,	O
four	O
,	O
and	O
one	O
of	O
the	O
six	O
patients	O
who	O
died	O
did	O
not	O
produce	O
any	O
IgG	O
,	O
IgM	O
,	O
and	O
IgA	O
antibodies	O
against	O
the	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
respectively	O
,	O
although	O
these	O
antibodies	O
were	O
detected	O
in	O
all	O
six	O
patients	O
by	O
the	O
indirect	O
immunofluorescence	O
assay	O
.	O

Further	O
studies	O
should	O
be	O
performed	O
to	O
see	O
whether	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
antibody	O
positivity	O
has	O
any	O
prognostic	O
significance	O
.	O

ABSTRACT	O
:	O
A	O
newly	O
developed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
specific	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
further	O
validated	O
to	O
confirm	O
cutoff	O
values	O
and	O
evaluate	O
its	O
diagnostic	O
performance	O
with	O
clinical	O
samples	O
.	O

TITLE	O
:	O
Kinetics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
-	O
specific	O
antibodies	O
in	O
271	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
SARS	B-DISO
.	O

The	O
ELISA	O
was	O
capable	O
of	O
detecting	O
this	O
protein	O
in	O
SARS	B-DISO
CoV	O
cell	O
culture	O
lysates	O
at	O
15	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
/	O
ml	O
but	O
did	O
not	O
produce	O
positive	O
signals	O
when	O
tested	O
with	O
cell	O
culture	O
lysates	O
of	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
.	O

VeroE6	O
cells	O
,	O
fetal	O
rhesus	O
monkey	O
kidney	O
cells	O
,	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
the	O
only	O
cells	O
known	O
to	O
be	O
susceptible	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
developed	O
a	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
assay	O
to	O
analyze	O
the	O
susceptibility	O
of	O
cells	O
derived	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
species	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
Additionally	O
,	O
productive	O
infection	B-DISO
was	O
determined	O
by	O
titration	O
of	O
cellular	O
supernatants	O
.	O

Mink	O
lung	O
epithelial	O
cells	O
(	O
Mv1Lu	O
)	O
and	O
R	O
-	O
Mix	O
,	O
a	O
mixed	O
monolayer	O
of	O
human	O
lung	O
-	O
derived	O
cells	O
(	O
A549	O
)	O
and	O
mink	O
lung	O
-	O
derived	O
cells	O
(	O
Mv1Lu	O
),	O
are	O
used	O
by	O
diagnostic	O
laboratories	O
to	O
detect	O
respiratory	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
influenza	B-DISO
virus	O
);	O
they	O
were	O
also	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
indicating	O
that	O
the	O
practices	O
of	O
diagnostic	O
laboratories	O
should	O
be	O
examined	O
to	O
ensure	O
appropriate	O
biosafety	O
precautions	O
.	O

Mv1Lu	O
cells	O
produce	O
little	O
SARS	B-DISO
-	O
CoV	O
compared	O
to	O
that	O
produced	O
by	O
VeroE6	O
cells	O
,	O
which	O
indicates	O
that	O
they	O
are	O
a	O
safer	O
alternative	O
for	O
SARS	B-DISO
-	O
CoV	O
diagnostics	O
.	O

Evaluation	O
of	O
cells	O
permissive	O
to	O
other	O
coronaviruses	O
indicated	O
that	O
these	O
cell	O
types	O
are	O
not	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
,	O
providing	O
additional	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
binds	O
an	O
alternative	O
receptor	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
public	O
health	O
concern	O
worldwide	O
.	O

TITLE	O
:	O
An	O
efficient	O
method	O
to	O
make	O
human	O
monoclonal	O
antibodies	O
from	O
memory	O
B	O
cells	O
:	O
potent	O
neutralization	O
of	O
SARS	B-DISO
coronavirus	O
.	O

We	O
used	O
this	O
method	O
to	O
analyze	O
the	O
memory	O
repertoire	O
of	O
a	O
patient	O
who	O
recovered	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
and	O
to	O
isolate	O
monoclonal	O
antibodies	O
specific	O
for	O
different	O
viral	O
proteins	O
,	O
including	O
35	O
antibodies	O
with	O
in	O
vitro	O
neutralizing	O
activity	O
ranging	O
from	O
10	O
(-	O
8	O
)	O
M	O
to	O
10	O
(-	O
11	O
)	O
M	O
.	O
One	O
such	O
antibody	O
confers	O
protection	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Potent	O
and	O
selective	O
inhibition	O
of	O
SARS	B-DISO
coronavirus	O
replication	O
by	O
aurintricarboxylic	O
acid	O
.	O

Our	O
data	O
indicated	O
that	O
ATA	O
should	O
be	O
considered	O
as	O
a	O
candidate	O
anti	O
-	O
SARS	B-DISO
compound	O
for	O
future	O
clinical	O
evaluation	O
.	O

TITLE	O
:	O
Correlation	O
of	O
high	O
-	O
resolution	O
CT	O
,	O
symptoms	O
,	O
and	O
pulmonary	O
function	O
in	O
patients	O
during	O
recovery	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
therapeutic	O
effect	O
of	O
integrative	O
Chinese	O
and	O
western	O
medicine	O
(	O
ICWM	O
)	O
in	O
treating	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
its	O
influence	O
on	O
T	O
-	O
lymphocyte	O
subsets	O
.	O

ABSTRACT	O
:	O
The	O
case	O
of	O
a	O
72	O
-	O
year	O
-	O
old	O
woman	O
with	O
probable	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
is	O
reported	O
.	O

The	O
recent	O
infections	B-DISO
in	O
December	O
2003	O
clearly	O
document	O
that	O
SARS	B-DISO
will	O
be	O
a	O
major	O
topic	O
also	O
in	O
2004	O
.	O

The	O
optical	O
density	O
value	O
of	O
the	O
immunological	O
reaction	O
of	O
synthesized	O
8	O
peptides	O
with	O
SARS	B-DISO
patient	O
serum	O
was	O
1	O
.	O
5	O
-	O
2	O
.	O
6	O
times	O
higher	O
than	O
that	O
with	O
normal	O
serum	O
.	O

In	O
contrast	O
to	O
Vero	O
cells	O
,	O
SARS	B-DISO
-	O
CoV	O
did	O
not	O
produce	O
cytopathic	B-DISO
effects	I-DISO
on	O
LoVo	O
cells	O
.	O

Furthermore	O
,	O
the	O
recent	O
development	O
of	O
influenza	B-DISO
-	O
like	O
clinical	O
syndromes	B-DISO
with	O
novel	O
aetiologies	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
SARS	B-DISO
)	O
has	O
increased	O
the	O
need	O
for	O
rapid	O
and	O
accurate	O
near	O
-	O
patient	O
diagnosis	O
.	O

Three	O
separate	O
studies	O
were	O
conducted	O
in	O
adults	O
presenting	O
with	O
(	O
1	O
)	O
a	O
flu	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
,	O
(	O
2	O
)	O
a	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
the	O
community	O
,	O
and	O
(	O
3	O
)	O
a	O
severe	O
pneumonia	B-DISO
requiring	O
hospitalisation	O
.	O

In	O
adults	O
,	O
RSV	O
is	O
a	O
frequent	O
cause	O
of	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
case	O
of	O
a	O
19	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
sudden	O
severe	O
left	O
-	O
sided	O
tension	B-DISO
pneumothorax	I-DISO
in	O
the	O
recovery	O
room	O
after	O
undergoing	O
a	O
6	O
-	O
hour	O
open	O
reduction	O
and	O
internal	O
fixation	O
of	O
an	O
anterior	O
and	O
posterior	O
pelvic	O
fracture	O
sustained	O
in	O
a	O
motor	O
vehicle	O
accident	O
4	O
days	O
prior	O
to	O
surgery	O
.	O

Contingency	O
planning	O
for	O
future	O
infectious	B-DISO
diseases	I-DISO
outbreaks	O
is	O
required	O
.	O

Respiratory	B-DISO
failure	I-DISO
is	O
the	O
major	O
complication	B-DISO
of	O
SARS	B-DISO
and	O
approximately	O
20	O
%	O
of	O
patients	O
may	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
invasive	O
mechanical	O
ventilatory	O
support	O
.	O

Treatment	O
of	O
SARS	B-DISO
was	O
empirical	O
in	O
2003	O
due	O
to	O
our	O
limited	O
understanding	O
of	O
this	O
new	O
disease	O
.	O

There	O
were	O
49	O
(	O
27	O
.	O
7	O
%)	O
cases	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
detection	O
positive	O
in	O
177	O
patients	O
,	O
including	O
31	O
(	O
17	O
.	O
5	O
%)	O
cases	O
with	O
one	O
sample	O
positive	O
,	O
14	O
(	O
7	O
.	O
9	O
%)	O
cases	O
with	O
two	O
samples	O
positive	O
,	O
and	O
4	O
(	O
2	O
.	O
3	O
%)	O
cases	O
with	O
three	O
samples	O
positive	O
.	O

Sample	O
Ten	O
pregnant	O
and	O
40	O
non	O
-	O
pregnant	O
female	O
patients	O
infected	O
with	O
SARS	B-DISO
.	O

Clinical	O
course	O
and	O
outcomes	O
of	O
pregnant	O
SARS	B-DISO
patients	O
were	O
compared	O
with	O
a	O
group	O
of	O
non	O
-	O
pregnant	O
SARS	B-DISO
patient	O
.	O

In	O
this	O
study	O
,	O
sera	O
were	O
collected	O
from	O
healthy	O
donors	O
,	O
patients	O
with	O
SARS	B-DISO
,	O
patients	O
with	O
severe	O
SARS	B-DISO
,	O
and	O
patients	O
with	O
SARS	B-DISO
in	O
convalescence	O
.	O

These	O
results	O
suggest	O
that	O
there	O
are	O
different	O
immunoregulatory	O
events	O
during	O
and	O
after	O
SARS	B-DISO
and	O
may	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
this	O
syndrome	B-DISO
.	O

TITLE	O
:	O
Pulmonary	B-DISO
pathology	I-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Toronto	O
.	O

Eight	O
of	O
20	O
patients	O
showed	O
predominantly	O
a	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
pattern	O
of	O
acute	O
lung	O
injury	O
,	O
six	O
showed	O
predominantly	O
an	O
acute	O
fibrinous	O
and	O
organizing	B-DISO
pneumonia	I-DISO
pattern	O
,	O
and	O
the	O
remainder	O
showed	O
an	O
admixture	O
of	O
the	O
two	O
patterns	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
lungs	O
of	O
patients	O
who	O
die	O
of	O
SARS	B-DISO
are	O
almost	O
always	O
positive	O
for	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
by	O
RT	O
-	O
PCR	O
,	O
and	O
may	O
show	O
features	O
of	O
both	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
acute	O
fibrinous	O
and	O
organizing	B-DISO
pneumonia	I-DISO
patterns	O
of	O
acute	O
injury	O
.	O

Antibody	O
-	O
response	O
kinetics	O
were	O
evaluated	O
in	O
4	O
patients	O
with	O
SARS	B-DISO
,	O
and	O
production	O
of	O
IgM	O
,	O
IgG	O
,	O
and	O
IgA	O
were	O
documented	O
as	O
part	O
of	O
the	O
immune	O
response	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
prognostic	O
implications	O
of	O
chest	O
radiographic	O
findings	O
in	O
52	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
effect	O
of	O
provision	O
of	O
information	O
about	O
the	O
infection	B-DISO
control	O
in	O
the	O
specific	O
infection	B-DISO
disease	O
treatment	O
unit	O
in	O
a	O
city	O
hospital	O
on	O
the	O
outpatient	O
'	O
s	O
intention	O
of	O
outpatient	O
service	O
use	O
,	O
respondents	O
who	O
underwent	O
outpatient	O
medical	O
care	O
at	O
the	O
hospital	O
(	O
N	O
=	O
821	O
)	O
were	O
asked	O
whether	O
or	O
not	O
they	O
intended	O
to	O
continue	O
the	O
outpatient	O
visit	O
at	O
the	O
hospital	O
if	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patient	O
was	O
admitted	O
to	O
the	O
unit	O
.	O

ABSTRACT	O
:	O
This	O
study	O
established	O
a	O
modified	O
alkaline	O
phosphatase	O
-	O
labelled	O
avidin	O
-	O
biotin	O
-	O
complex	O
(	O
ABC	O
-	O
AP	O
)	O
method	O
for	O
diagnosis	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
Mycoplasma	B-DISO
pulmonis	O
infection	B-DISO
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
wax	O
-	O
embedded	O
sections	O
,	O
murine	O
antibody	O
-	O
positive	O
serum	O
being	O
used	O
as	O
the	O
primary	O
reagent	O
.	O

Hypercapnia	B-DISO
(	O
Pa	O
(	O
co	O
(	O
2	O
))	O
12	O
kPa	O
)	O
with	O
severe	O
acidosis	B-DISO
(	O
pH	O
<	O
7	O
.	O
20	O
)	O
ensued	O
.	O

This	O
is	O
the	O
reason	O
why	O
the	O
most	O
important	O
international	O
organizations	O
recommend	O
that	O
the	O
dentists	O
adopt	O
a	O
unique	O
preventive	O
approach	O
to	O
the	O
problem	O
:	O
SARS	B-DISO
patients	O
should	O
not	O
be	O
treated	O
in	O
the	O
dental	O
office	O
.	O

It	O
is	O
therefore	O
necessary	O
to	O
adopt	O
protective	O
measures	O
for	O
the	O
dental	O
personnel	O
and	O
to	O
implement	O
and	O
enforce	O
infection	B-DISO
control	O
measures	O
in	O
order	O
to	O
eliminate	O
the	O
risk	O
of	O
viral	O
contamination	O
.	O

During	O
major	O
outbreaks	O
of	O
infectious	B-DISO
disease	I-DISO
,	O
continuing	O
education	O
providers	O
should	O
maintain	O
regular	O
contact	O
with	O
public	O
health	O
authorities	O
and	O
learners	O
,	O
enact	O
a	O
rational	O
process	O
for	O
postponing	O
or	O
canceling	O
courses	O
,	O
and	O
implement	O
a	O
disaster	O
plan	B-DISO
flexible	O
enough	O
to	O
ensure	O
the	O
deliver	O
,	O
of	O
education	O
using	O
technological	O
advances	O
.	O

ABSTRACT	O
:	O
To	O
analyse	O
the	O
lung	O
pathology	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
correlate	O
the	O
findings	O
with	O
the	O
time	O
sequence	O
of	O
the	O
disease	O
.	O

Ten	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
,	O
and	O
virological	O
confirmation	O
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
were	O
identified	O
.	O

Electron	O
microscopy	O
confirmed	O
that	O
HCoV	O
-	O
229E	O
was	O
localized	O
near	O
or	O
at	O
the	O
orifice	O
of	O
caveolae	O
after	O
incubation	O
at	O
37	O
degrees	O
C	O
.	O
The	O
depletion	O
of	O
plasmalemmal	O
cholesterol	O
with	O
methyl	O
beta	O
-	O
cyclodextrin	O
significantly	O
reduced	O
the	O
HCoV	O
-	O
229E	O
redistribution	O
and	O
subsequent	O
infection	B-DISO
.	O

We	O
highlight	O
the	O
need	O
for	O
clear	O
and	O
easily	O
accessible	O
information	O
on	O
dealing	O
with	O
infectious	B-DISO
diseases	I-DISO
.	O

Practical	O
advice	O
on	O
coping	O
and	O
stress	O
management	O
techniques	O
for	O
health	O
care	O
workers	O
are	O
needed	O
in	O
preparation	O
for	O
potential	O
future	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

Anti	O
-	O
viral	O
IgG	O
,	O
IgM	O
,	O
and	O
anti	O
-	O
nucleocaspid	O
antibodies	O
were	O
detected	O
7	O
-	O
30	O
days	O
in	O
patients	O
after	O
the	O
onset	O
of	O
SARS	B-DISO
symptoms	O
.	O

Analysis	O
of	O
serial	O
tenfold	O
dilutions	O
of	O
virus	O
stocks	O
revealed	O
that	O
the	O
sensitivity	O
of	O
the	O
mouse	O
antibody	O
production	O
test	O
on	O
day	O
28	O
(	O
10	O
(-	O
10	O
)	O
dilution	O
)	O
was	O
at	O
least	O
10	O
times	O
higher	O
than	O
that	O
of	O
the	O
viral	O
plaque	B-DISO
assay	O
(	O
10	O
(-	O
9	O
)	O
dilution	O
)	O
and	O
10	O
(	O
4	O
)	O
times	O
more	O
than	O
that	O
of	O
the	O
RT	O
-	O
PCR	O
(	O
10	O
(-	O
6	O
)	O
dilution	O
)	O
for	O
detection	O
of	O
MHV	O
-	O
A59	O
.	O

ABSTRACT	O
:	O
To	O
define	O
the	O
origin	O
and	O
evolution	O
of	O
recent	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
in	O
Japan	O
,	O
a	O
genetic	O
analysis	O
was	O
performed	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
are	O
an	O
important	O
cause	O
of	O
mortality	O
.	O

Considerable	O
efforts	O
have	O
been	O
made	O
in	O
the	O
past	O
few	O
years	O
to	O
develop	O
novel	O
therapeutic	O
interventions	O
to	O
reduce	O
mortality	O
in	O
sepsis	B-DISO
.	O

The	O
complete	O
genome	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
(	O
SARS	B-DISO
coronavirus	O
)	O
has	O
since	O
been	O
sequenced	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
SARS	B-DISO
-	O
CoV	O
N	O
)	O
protein	O
shares	O
little	O
homology	O
with	O
other	O
members	O
of	O
the	O
coronavirus	O
family	O
.	O

Active	O
fluid	O
transport	O
of	O
alveolar	O
epithelium	O
might	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
lung	B-DISO
edema	I-DISO
in	O
acute	O
lung	O
injury	O
.	O

Four	O
of	O
the	O
7	O
patients	O
(	O
57	O
%)	O
who	O
presented	O
in	O
the	O
first	O
trimester	O
had	O
spontaneous	O
miscarriage	B-DISO
.	O

No	O
newborn	O
infant	O
had	O
clinical	O
SARS	B-DISO
and	O
all	O
investigations	O
were	O
negative	O
for	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
during	O
pregnancy	O
is	O
associated	O
with	O
high	O
incidences	O
of	O
spontaneous	O
miscarriage	B-DISO
,	O
preterm	B-DISO
delivery	I-DISO
,	O
and	O
intrauterine	B-DISO
growth	I-DISO
restriction	I-DISO
.	O

TITLE	O
:	O
Recombinant	O
scFv	O
antibodies	O
against	O
E	O
protein	O
and	O
N	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
.	O

TITLE	O
:	O
Potent	O
inhibition	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SCOV	O
)	O
infection	B-DISO
and	O
replication	O
by	O
type	O
I	O
interferons	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
but	O
not	O
by	O
type	O
II	O
interferon	O
(	O
IFN	O
-	O
gamma	O
).	O

Overall	O
,	O
73	O
.	O
0	O
%	O
of	O
the	O
total	O
subjects	O
knew	O
that	O
SARS	B-DISO
was	O
highly	O
infectious	B-DISO
;	O
69	O
.	O
9	O
%	O
knew	O
that	O
it	O
could	O
spread	O
through	O
close	O
contact	O
;	O
67	O
.	O
4	O
%	O
were	O
aware	O
that	O
high	O
fever	O
was	O
the	O
early	O
symptom	B-DISO
;	O
and	O
60	O
.	O
8	O
%	O
thought	O
SARS	B-DISO
could	O
be	O
cured	O
.	O

The	O
level	O
of	O
awareness	O
of	O
SARS	B-DISO
among	O
Qataris	O
was	O
poor	O
(	O
31	O
.	O
7	O
%)	O
compared	O
to	O
that	O
among	O
non	O
-	O
Qataris	O
(	O
68	O
.	O
3	O
%).	O

ABSTRACT	O
:	O
Sepsis	B-DISO
and	O
other	O
critical	B-DISO
illnesses	I-DISO
produce	O
a	O
biphasic	O
inflammatory	O
,	O
immune	O
,	O
hormonal	O
,	O
and	O
metabolic	O
response	O
.	O

The	O
combination	O
of	O
severe	O
inflammation	B-DISO
and	O
secondary	O
changes	O
in	O
endocrine	O
profile	O
diminish	O
energy	O
production	O
,	O
metabolic	O
rate	O
,	O
and	O
normal	O
cellular	O
processes	O
,	O
leading	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

Fever	O
(	O
ie	O
,	O
temperature	O
>	O
38	O
degrees	O
C	O
)	O
was	O
the	O
most	O
common	O
symptom	B-DISO
(	O
98	O
%)	O
and	O
the	O
earliest	O
.	O

Only	O
two	O
patients	O
with	O
preexisting	O
illnesses	O
had	O
cough	B-DISO
on	O
the	O
same	O
day	O
the	O
fever	O
began	O
.	O

The	O
majority	O
of	O
patients	O
(	O
63	O
%)	O
first	O
developed	O
unifocal	O
infiltrates	B-DISO
at	O
a	O
mean	O
time	O
of	O
4	O
.	O
5	O
+/-	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	B-DISO
-	O
CoV	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

Intracellularly	O
retained	O
S	O
proteins	O
only	O
contained	O
endoglycosidase	O
H	O
-	O
sensitive	O
N	O
-	O
glycans	O
,	O
whereas	O
mutant	B-DISO
proteins	O
that	O
migrated	O
to	O
the	O
plasma	O
membrane	O
acquired	O
N	O
-	O
linked	O
oligosaccharides	O
of	O
the	O
complex	O
type	O
.	O

Corresponding	O
tyrosine	O
residues	O
are	O
present	O
in	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
S	O
proteins	O
of	O
other	O
animal	O
CoV	O
but	O
not	O
in	O
the	O
tail	O
portion	O
of	O
the	O
S	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
.	O
Changing	O
the	O
SEPV	O
tetrapeptide	O
in	O
the	O
cytoplasmic	O
tail	O
to	O
YEPI	O
resulted	O
in	O
intracellular	O
retention	O
of	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
As	O
the	O
S	O
proteins	O
of	O
CoV	O
have	O
receptor	O
binding	O
and	O
fusion	O
activities	O
and	O
are	O
the	O
main	O
target	O
of	O
neutralizing	O
antibodies	O
,	O
the	O
differences	O
in	O
the	O
transport	O
behavior	O
of	O
the	O
S	O
proteins	O
suggest	O
different	O
strategies	O
in	O
the	O
virus	O
host	O
interactions	O
between	O
SARS	B-DISO
-	O
CoV	O
and	O
other	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
important	O
pathogens	O
that	O
cause	O
acute	O
respiratory	B-DISO
diseases	I-DISO
in	O
humans	O
.	O

That	O
is	O
,	O
it	O
suggests	O
that	O
combining	O
traditional	O
Chinese	O
medicine	O
with	O
Western	O
medicine	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
.	O

I	O
discuss	O
what	O
we	O
have	O
learned	O
about	O
the	O
movement	O
of	O
viruses	O
into	O
humans	O
from	O
studies	O
of	O
influenza	B-DISO
A	O
,	O
both	O
how	O
it	O
crossed	O
from	O
birds	O
to	O
humans	O
and	O
how	O
it	O
subsequently	O
evolved	O
within	O
the	O
human	O
population	O
.	O

The	O
disease	O
had	O
the	O
propensity	O
to	O
cause	O
clusters	O
of	O
pneumonia	B-DISO
,	O
particularly	O
in	O
healthcare	O
workers	O
or	O
close	O
family	O
contacts	O
.	O

These	O
animal	O
models	O
allow	O
comparative	O
pathogenesis	B-DISO
studies	O
for	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
and	O
testing	O
of	O
different	O
intervention	O
strategies	O
.	O

The	O
first	O
of	O
these	O
studies	O
has	O
shown	O
that	O
pegylated	O
interferon	O
-	O
alpha	O
,	O
a	O
drug	O
approved	O
for	O
human	O
use	O
,	O
limits	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
lung	O
damage	O
in	O
experimentally	O
infected	O
macaques	O
.	O

ABSTRACT	O
:	O
The	O
search	O
for	O
animal	O
host	O
origins	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
has	O
so	O
far	O
remained	O
focused	O
on	O
wildlife	O
markets	O
,	O
restaurants	O
and	O
farms	O
within	O
China	O
.	O

TITLE	O
:	O
The	O
international	O
response	O
to	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
2003	O
.	O

ABSTRACT	O
:	O
In	O
this	O
survey	O
of	O
infectious	B-DISO
diseases	I-DISO
consultants	O
,	O
90	O
%	O
reported	O
that	O
their	O
health	O
care	O
facilities	O
have	O
plans	O
in	O
place	O
to	O
address	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Of	O
343	O
patients	O
who	O
met	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
case	O
definition	O
of	O
probable	O
SARS	B-DISO
and	O
who	O
had	O
been	O
admitted	O
to	O
a	O
regional	O
hospital	O
in	O
Hong	O
Kong	O
,	O
201	O
patients	O
had	O
laboratory	O
evidence	O
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

Frontal	O
chest	O
radiographs	O
on	O
presentation	O
may	O
have	O
prognostic	O
value	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
MLV	O
(	O
SARS	B-DISO
)	O
pseudotypes	O
are	O
highly	O
valuable	O
for	O
functional	O
studies	O
of	O
viral	O
tropism	O
and	O
entry	O
and	O
,	O
in	O
addition	O
,	O
can	O
be	O
a	O
powerful	O
tool	O
for	O
the	O
development	O
of	O
therapeutic	O
entry	O
inhibitors	O
without	O
posing	O
a	O
biohazard	O
to	O
human	O
beings	O
.	O

In	O
fact	O
,	O
an	O
autopsy	O
also	O
subject	O
prosectors	O
and	O
others	O
to	O
a	O
wide	O
variety	O
of	O
hazards	O
,	O
including	O
bloodborne	O
,	O
aerosolized	O
pathogens	O
and	O
others	O
(	O
for	O
example	O
SARS	B-DISO
).	O

TITLE	O
:	O
[	O
The	O
changes	O
in	O
effective	O
local	O
blood	O
perfusion	O
and	O
compensatory	O
ventilation	O
in	O
different	O
lung	O
areas	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
rabbits	O
model	O
].	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
mechanism	O
of	O
severe	O
hypoxemia	O
that	O
induced	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
by	O
way	O
of	O
observing	O
the	O
effective	O
local	O
blood	O
perfusion	O
in	O
different	O
lung	O
areas	O
of	O
ARDS	B-DISO
rabbits	O
.	O

The	O
moist	B-DISO
rales	I-DISO
were	O
observed	O
in	O
43	O
.	O
3	O
%	O
of	O
patients	O
.	O

Hypoxemia	O
was	O
a	O
common	O
characteristic	O
in	O
SARS	B-DISO
.	O

Abnormal	O
chest	O
X	O
-	O
ray	O
including	O
infiltration	B-DISO
and	O
consolidation	O
shadows	O
were	O
seen	O
in	O
100	O
%	O
of	O
patients	O
.	O

The	O
main	O
clinical	O
manifestations	O
of	O
SARS	B-DISO
included	O
respiratory	O
and	O
systemic	O
toxic	O
symptoms	O
.	O

RESULTS	O
:	O
The	O
initial	O
symptom	B-DISO
of	O
SARS	B-DISO
was	O
pyrexia	O
and	O
the	O
temperature	O
was	O
>	O
38	O
degrees	O
C	O
.	O
The	O
natural	O
course	O
of	O
fever	O
was	O
about	O
14	O
days	O
.	O

Among	O
them	O
,	O
1084	O
cases	O
(	O
83	O
.	O
96	O
%)	O
had	O
used	O
GCS	O
and	O
207	O
did	O
not	O
in	O
the	O
course	O
of	O
SARS	B-DISO
.	O

There	O
was	O
no	O
significant	O
difference	O
of	O
average	O
age	O
(	O
t	O
=	O
-	O
1	O
.	O
08	O
,	O
P	O
=	O
0	O
.	O
2808	O
)	O
and	O
the	O
time	O
from	O
SARS	B-DISO
onset	O
to	O
hospitalization	O
(	O
P	O
=	O
0	O
.	O
2797	O
)	O
between	O
the	O
two	O
groups	O
.	O

In	O
the	O
treatment	O
of	O
SARS	B-DISO
,	O
GCS	O
seems	O
to	O
be	O
effective	O
.	O

Bio	O
-	O
statistics	O
with	O
regression	O
analysis	O
and	O
ROC	O
is	O
applied	O
to	O
analyse	O
the	O
data	O
collected	O
(	O
502	O
)	O
from	O
the	O
SARS	B-DISO
hospital	O
in	O
Singapore	O
and	O
conclusive	O
results	O
are	O
drawn	O
from	O
them	O
.	O

The	O
results	O
are	O
vital	O
in	O
determining	O
two	O
very	O
important	O
pieces	O
of	O
information	O
:	O
the	O
best	O
and	O
yet	O
practical	O
region	O
on	O
the	O
face	B-DISO
to	O
take	O
readings	O
and	O
optimal	O
pre	O
-	O
set	O
threshold	O
temperature	O
for	O
the	O
thermal	O
imager	O
.	O

TITLE	O
:	O
Oligomerization	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
glycoprotein	O
:	O
dimerization	O
of	O
the	O
N	O
-	O
terminus	O
and	O
trimerization	O
of	O
the	O
ectodomain	O
.	O

Nodules	B-DISO
less	O
than	O
10	O
mm	O
in	O
size	O
in	O
immunocompromised	O
patients	O
are	O
highly	O
suggestive	O
of	O
viral	B-DISO
infections	I-DISO
.	O

Small	O
cysts	B-DISO
may	O
be	O
seen	O
in	O
a	O
minority	O
of	O
patients	O
with	O
subacute	O
hypersensitivity	B-DISO
pneumonitis	I-DISO
and	O
centrilobular	B-DISO
emphysema	I-DISO
in	O
chronic	O
farmer	B-DISO
'	I-DISO
s	I-DISO
lung	I-DISO
.	O

Reversed	O
halo	B-DISO
sign	I-DISO
has	O
a	O
high	O
specificity	O
for	O
cryptogenic	B-DISO
organizing	I-DISO
pneumonia	I-DISO
.	O

In	O
permissive	O
cell	O
lines	O
,	O
effects	O
of	O
SARS	B-DISO
-	O
CoV	O
on	O
cellular	O
gene	O
expression	O
were	O
analysed	O
using	O
high	O
-	O
density	O
oligonucleotide	O
arrays	O
.	O

ABSTRACT	O
:	O
To	O
contain	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
the	O
Hong	O
Kong	O
Hospital	O
Authority	O
set	O
a	O
policy	O
that	O
stipulated	O
there	O
should	O
be	O
no	O
visitors	O
to	O
hospital	O
wards	O
.	O

However	O
,	O
about	O
half	O
of	O
these	O
relatives	O
complained	O
of	O
insufficient	O
information	O
regarding	O
the	O
patient	O
'	O
s	O
condition	B-DISO
and	O
progress	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
principal	O
etiologic	O
agent	O
of	O
SARS	B-DISO
.	O

NAbs	O
to	O
SARS	B-DISO
-	O
CoV	O
are	O
broadly	O
elicited	O
in	O
patients	O
with	O
SARS	B-DISO
and	O
,	O
according	O
to	O
their	O
kinetics	O
,	O
may	O
correlate	O
with	O
viral	O
load	O
during	O
the	O
early	O
stages	O
of	O
the	O
disease	O
.	O

APC	B-DISO
regulates	O
the	O
coagulation	O
system	O
by	O
inactivating	O
the	O
activated	O
form	O
of	O
factors	O
V	O
and	O
VIII	O
in	O
the	O
presence	O
of	O
protein	O
S	O
.	O
Tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
plays	O
critical	O
roles	O
in	O
the	O
development	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
in	O
sepsis	B-DISO
by	O
inducing	O
endothelial	O
cell	B-DISO
damage	I-DISO
through	O
activation	O
of	O
neutrophils	O
.	O

APC	B-DISO
reduces	O
the	O
pulmonary	O
endothelial	O
cell	B-DISO
injury	I-DISO
and	O
hypotension	O
in	O
rats	O
administered	O
endotoxin	O
(	O
ET	O
)	O
by	O
inhibiting	O
TNF	O
-	O
alpha	O
production	O
through	O
inhibition	O
of	O
its	O
transcription	O
.	O

Furthermore	O
,	O
APC	B-DISO
reduces	O
the	O
ischemia	B-DISO
/	O
reperfusion	O
-	O
induced	O
renal	O
injury	O
and	O
the	O
stress	O
-	O
induced	O
gastric	O
mucosal	O
injury	O
in	O
rats	O
.	O

Furthermore	O
,	O
APC	B-DISO
reduced	O
the	O
spinal	O
cord	B-DISO
injury	O
induced	O
by	O
compression	O
-	O
trauma	O
or	O
ischemia	B-DISO
/	O
reperfusion	O
by	O
inhibiting	O
TNF	O
-	O
alpha	O
production	O
in	O
rats	O
,	O
suggesting	O
that	O
APC	B-DISO
may	O
be	O
a	O
potential	O
therapeutic	O
agent	O
for	O
spinal	O
cord	B-DISO
injury	O
in	O
which	O
only	O
limited	O
therapeutic	O
measures	O
are	O
currently	O
available	O
.	O

We	O
describe	O
the	O
environmental	O
findings	O
and	O
observations	O
from	O
this	O
response	O
,	O
including	O
the	O
rapid	O
reconfiguration	O
of	O
medical	O
facilities	O
during	O
a	O
national	O
health	O
emergency	B-DISO
,	O
and	O
discuss	O
environmental	O
challenges	O
should	O
SARS	B-DISO
or	O
a	O
SARS	B-DISO
-	O
like	O
virus	O
emerge	O
again	O
.	O

Longer	O
durations	O
of	O
quarantine	O
were	O
associated	O
with	O
an	O
increased	O
prevalence	O
of	O
PTSD	B-DISO
symptoms	O
.	O

TITLE	O
:	O
Model	O
parameters	O
and	O
outbreak	O
control	O
for	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
features	O
of	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
elicited	O
in	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
were	O
studied	O
by	O
ELISA	O
and	O
western	O
-	O
blot	O
competition	O
assays	O
.	O

Results	O
indicated	O
that	O
MHV	O
-	O
infection	B-DISO
triggers	O
at	O
least	O
three	O
distinct	O
Ab	O
populations	O
:	O
anti	O
-	O
MHV	O
,	O
anti	O
-	O
FAH	O
and	O
cross	O
-	O
reacting	O
Ab	O
.	O

TITLE	O
:	O
Pathogenic	O
role	O
of	O
HMGB1	O
in	O
SARS	B-DISO
?	O

Passive	O
immunization	O
with	O
anti	O
-	O
HMGB1	O
antibodies	O
confers	O
significant	O
protection	O
against	O
lethal	O
endotoxemia	O
,	O
sepsis	B-DISO
,	O
and	O
acute	O
lung	O
injury	O
,	O
even	O
when	O
antibodies	O
are	O
administered	O
after	O
the	O
onset	O
of	O
these	O
diseases	O
.	O

ABSTRACT	O
:	O
""""	O
Emerging	O
infections	B-DISO
""""	O
have	O
been	O
defined	O
as	O
infections	B-DISO
that	O
have	O
newly	O
appeared	O
,	O
that	O
have	O
appeared	O
previously	O
but	O
are	O
expanding	O
in	O
incidence	O
and	O
geographic	O
range	O
,	O
or	O
that	O
threaten	O
to	O
increase	O
in	O
the	O
near	O
future	O
.	O

These	O
viruses	O
illustrate	O
how	O
such	O
agents	O
emerge	O
:	O
by	O
encroaching	O
on	O
previously	O
unvisited	O
habitats	O
(	O
eg	O
,	O
hantaviruses	O
),	O
by	O
air	O
travel	O
(	O
eg	O
,	O
SARS	B-DISO
),	O
and	O
by	O
accidental	O
importation	O
(	O
eg	O
,	O
monkeypox	B-DISO
).	O

Additionally	O
,	O
the	O
example	O
of	O
SARS	B-DISO
demonstrates	O
not	O
only	O
how	O
quickly	O
emerging	O
viral	B-DISO
infections	I-DISO
can	O
spread	O
but	O
also	O
how	O
quickly	O
they	O
can	O
be	O
identified	O
and	O
contained	O
with	O
motivated	O
cooperation	O
.	O

Age	O
65	O
years	O
and	O
older	O
and	O
younger	O
than	O
18	O
years	O
and	O
the	O
presence	O
of	O
sputum	O
,	O
abdominal	B-DISO
pain	I-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
and	O
rhinorrhea	B-DISO
were	O
inversely	O
related	O
to	O
having	O
SARS	B-DISO
.	O

In	O
step	O
2	O
,	O
haziness	O
or	O
pneumonic	O
consolidation	O
on	O
chest	O
radiographs	O
and	O
low	O
lymphocyte	O
and	O
platelet	O
counts	O
,	O
in	O
addition	O
to	O
a	O
positive	O
contact	O
history	O
and	O
fever	O
were	O
associated	O
with	O
a	O
higher	O
probability	O
of	O
SARS	B-DISO
.	O

RESULTS	O
:	O
Predictors	O
for	O
SARS	B-DISO
on	O
the	O
basis	O
of	O
history	O
(	O
step	O
1	O
)	O
included	O
previous	O
contact	O
with	O
a	O
patient	O
with	O
SARS	B-DISO
and	O
the	O
presence	O
of	O
fever	O
,	O
myalgia	B-DISO
,	O
and	O
malaise	B-DISO
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
acute	O
methemoglobinemia	B-DISO
in	O
a	O
patient	O
treated	O
with	O
celecoxib	O
for	O
osteoarthritis	B-DISO
.	O

Although	O
acute	O
methemoglobinemia	B-DISO
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
several	O
drugs	O
,	O
including	O
sulfonamides	O
,	O
as	O
of	O
August	O
13	O
,	O
2004	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
severe	O
methemoglobinemia	B-DISO
manifesting	O
as	O
ACS	O
with	O
celecoxib	O
therapy	O
.	O

Within	O
each	O
infectious	B-DISO
agent	O
session	O
the	O
presentations	O
included	O
those	O
describing	O
the	O
development	O
of	O
new	O
and	O
novel	O
anti	O
-	O
infectives	O
,	O
including	O
research	O
based	O
on	O
the	O
preclinical	O
development	O
of	O
new	O
molecules	O
,	O
and	O
the	O
results	O
of	O
animal	O
modelling	O
and	O
clinical	O
studies	O
on	O
advanced	O
-	O
stage	O
antiviral	O
agents	O
.	O

ABSTRACT	O
:	O
We	O
demonstrate	O
the	O
feasibility	O
and	O
utility	O
of	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
syndromic	O
surveillance	O
using	O
a	O
regional	O
emergency	B-DISO
medicine	O
Internet	O
application	O
to	O
minimize	O
impact	O
on	O
ED	O
and	O
public	O
health	O
staffing	O
.	O

There	O
were	O
differences	O
in	O
the	O
way	O
that	O
Taiwan	O
and	O
mainland	O
China	O
responded	O
to	O
the	O
SARS	B-DISO
epidemic	O
,	O
however	O
,	O
both	O
employed	O
techniques	O
of	O
hospital	O
quarantine	O
.	O

RESULTS	O
:	O
There	O
were	O
differences	O
in	O
the	O
way	O
that	O
Taiwan	O
and	O
mainland	O
China	O
responded	O
to	O
the	O
SARS	B-DISO
epidemic	O
,	O
however	O
,	O
both	O
employed	O
techniques	O
of	O
hospital	O
quarantine	O
.	O

Autopsy	O
demonstrated	O
severe	O
hemophagocytosis	B-DISO
in	O
the	O
bone	O
marrow	O
and	O
histopathology	O
indicating	O
a	O
marked	O
increase	O
in	O
vascular	O
permeability	O
in	O
both	O
lungs	O
and	O
kidneys	O
.	O

In	O
this	O
patient	O
,	O
active	O
SLE	B-DISO
and	O
associated	O
hemophagocytic	B-DISO
syndrome	I-DISO
may	O
have	O
induced	O
an	O
increase	O
in	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
which	O
immediately	O
induced	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
is	O
an	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
new	O
type	O
of	O
coronavirus	O
.	O

The	O
prevention	O
and	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
can	O
be	O
under	O
the	O
guidance	O
of	O
the	O
doctrines	O
for	O
treating	O
febrile	O
diseases	O
of	O
traditional	O
Chinese	O
medicine	O
,	O
treatment	O
based	O
on	O
syndrome	B-DISO
differentiation	O
,	O
such	O
as	O
syndrome	B-DISO
differentiation	O
of	O
triple	O
energizer	O
,	O
syndrome	B-DISO
differentiation	O
according	O
to	O
defensive	O
phase	O
,	O
qi	O
phase	O
,	O
nutrient	O
phase	O
and	O
blood	O
phase	O
.	O

ABSTRACT	O
:	O
To	O
find	O
out	O
the	O
timing	O
of	O
serologic	O
responses	O
after	O
illness	O
onset	O
and	O
distribution	O
of	O
IgG	O
antibody	O
to	O
SARS	B-DISO
-	O
CoV	O
in	O
SARS	B-DISO
cases	O
of	O
transmission	O
chain	O
or	O
non	O
-	O
transmission	O
chain	O
.	O

The	O
cumulated	O
positive	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
IgM	O
during	O
days	O
0	O
-	O
7	O
after	O
onset	O
was	O
the	O
same	O
to	O
that	O
of	O
IgG	O
.	O
During	O
days	O
8	O
-	O
14	O
,	O
55	O
.	O
17	O
%	O
of	O
cases	O
had	O
seroconversion	O
for	O
IgM	O
which	O
reached	O
a	O
peak	O
(	O
86	O
.	O
96	O
%)	O
during	O
days	O
21	O
-	O
30	O
.	O

CONCLUSIONS	O
:	O
More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	B-DISO
could	O
produce	O
IgG	O
antibody	O
when	O
they	O
were	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
Detecting	O
SARS	B-DISO
-	O
CoV	O
IgG	O
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
difference	O
and	O
significance	O
of	O
T	O
-	O
lymphocyte	O
subsets	O
in	O
differential	O
diagnosis	O
between	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
SARS	B-DISO
)	O
and	O
common	O
atypical	B-DISO
pneumonia	I-DISO
.	O

Totally	O
100	O
patients	O
hospitalized	O
in	O
Beijing	O
Ditan	O
Hospital	O
since	O
March	O
to	O
June	O
2003	O
with	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
were	O
involved	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
[	O
Studies	O
on	O
IgG	O
antibodies	O
of	O
SARS	B-DISO
patients	O
].	O

The	O
production	O
of	O
SARS	B-DISO
IgG	O
is	O
not	O
notably	O
correlated	O
with	O
sex	O
,	O
age	O
,	O
seriousness	O
of	O
symptoms	O
,	O
and	O
steroid	O
treatment	O
.	O

RESULTS	O
:	O
Out	O
of	O
121	O
patients	O
studied	O
,	O
71	O
.	O
1	O
%	O
were	O
SARS	B-DISO
specific	O
IgG	O
positive	O
.	O

The	O
clinical	O
manifestations	O
of	O
SARS	B-DISO
at	O
the	O
early	O
stage	O
were	O
complex	O
.	O

Persistent	O
Lymphopenia	B-DISO
and	O
thrombocytopenia	O
may	O
be	O
associated	O
with	O
the	O
prognosis	O
.	O

RESULTS	O
:	O
The	O
average	O
minimum	O
amount	O
of	O
interferon	O
alpha	O
2b	O
,	O
alpha	O
1b	O
,	O
beta	O
1b	O
or	O
omega	O
1b	O
to	O
inhibit	O
50	O
%	O
CPE	O
in	O
Rda	B-DISO
cell	O
culture	O
was	O
(	O
160	O
.	O
5	O
+/-	O
129	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
149	O
.	O
0	O
+/-	O
71	O
.	O
7	O
)	O
IU	O
/	O
ml	O
,	O
(	O
69	O
.	O
5	O
+/-	O
61	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
87	O
.	O
3	O
+/-	O
47	O
.	O
1	O
)	O
IU	O
/	O
ml	O
,	O
respectively	O
or	O
(	O
0	O
.	O
6	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
(	O
10	O
.	O
6	O
+/-	O
5	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
3	O
.	O
5	O
+/-	O
3	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
0	O
.	O
9	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

TITLE	O
:	O
[	O
Development	O
of	O
the	O
cDNA	O
chip	O
for	O
SARS	B-DISO
virus	O
and	O
a	O
primary	O
study	O
on	O
the	O
possible	O
molecular	O
mechanism	O
of	O
interferon	O
alpha2b	O
inhibiting	O
the	O
SARS	B-DISO
virus	O
replication	O
].	O

TITLE	O
:	O
[	O
Clinical	O
pathology	B-DISO
and	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

The	O
distribution	O
and	O
quantity	O
of	O
lymphocyte	O
subpopulations	O
in	O
the	O
lungs	O
and	O
immune	O
organs	O
from	O
SARS	B-DISO
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
.	O

SARS	B-DISO
coronaviruses	O
were	O
mainly	O
identified	O
in	O
type	O
I	O
and	O
II	O
alveolar	O
epithelia	O
,	O
macrophages	O
,	O
and	O
endothelia	O
;	O
meanwhile	O
,	O
some	O
renal	O
tubular	O
epithelial	O
cells	O
,	O
cardiomyocytes	O
,	O
mucosal	O
and	O
crypt	O
epithelial	O
cells	O
of	O
gastrointestinal	O
tracts	O
,	O
parenchymal	O
cells	O
in	O
adrenal	O
glands	O
,	O
lymphocytes	O
,	O
testicular	O
epithelial	O
cells	O
and	O
Leydig	O
'	O
s	O
cells	O
were	O
also	O
detected	O
by	O
electron	O
microscopy	O
combined	O
with	O
in	O
situ	O
hybridization	O
.	O

The	O
semi	O
-	O
quantitative	O
analysis	O
of	O
lymphocyte	O
subpopulations	O
revealed	O
that	O
the	O
proportion	O
of	O
CD8	O
+	O
T	O
lymphocytes	O
were	O
about	O
80	O
%	O
of	O
the	O
total	O
infiltrative	O
inflammatory	O
cells	O
in	O
the	O
pulmonary	O
interstitium	O
,	O
with	O
a	O
few	O
CD4	O
+	O
lymphocytes	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+	O
or	O
CD20	O
+	O
lymphocyte	O
subpopulations	O
were	O
obviously	O
decreased	O
and	O
there	O
was	O
imbalance	B-DISO
in	O
number	O
and	O
proportion	O
,	O
while	O
CD57	O
+,	O
CD68	O
+,	O
S	O
-	O
100	O
+	O
and	O
HLA	O
-	O
DR	O
+	O
cells	O
were	O
relatively	O
increased	O
in	O
lymph	O
nodes	O
and	O
spleens	O
.	O

There	O
were	O
varying	O
degrees	O
of	O
decrease	O
and	O
imbalance	B-DISO
in	O
number	O
and	O
proportion	O
of	O
lymphocyte	O
subpopulations	O
in	O
the	O
immune	O
organs	O
of	O
the	O
patients	O
with	O
SARS	B-DISO
.	O

In	O
logistic	O
regression	O
models	O
,	O
both	O
older	O
age	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
severe	O
lymphopenia	B-DISO
(	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
significant	O
predictors	O
of	O
clinical	O
deterioration	O
.	O

Older	O
age	O
and	O
severe	O
lymphopenia	B-DISO
seem	O
to	O
be	O
statistically	O
significant	O
for	O
predicting	O
the	O
clinical	O
deterioration	O
in	O
SARS	B-DISO
patients	O
.	O

Delegates	O
(	O
n	O
=	O
99	O
)	O
suggested	O
that	O
temperature	O
-	O
taking	O
(	O
32	O
.	O
2	O
%),	O
improved	O
screening	O
vigilance	O
(	O
14	O
.	O
4	O
%),	O
SARS	B-DISO
screening	O
forms	O
checked	O
daily	O
(	O
9	O
.	O
1	O
%),	O
strictly	O
controlled	O
entry	O
(	O
8	O
.	O
1	O
%)	O
and	O
adopting	O
hospital	O
screening	O
procedures	O
(	O
7	O
.	O
1	O
%)	O
should	O
have	O
been	O
instituted	O
.	O

CONCLUSIONS	O
:	O
Wearing	O
an	O
N95	O
mask	O
for	O
4	O
hours	O
during	O
HD	O
significantly	O
reduced	O
PaO2	O
and	O
increased	O
respiratory	O
adverse	B-DISO
effects	I-DISO
in	O
ESRD	B-DISO
patients	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
fusion	O
core	O
.	O

This	O
study	O
investigated	O
stress	O
reactions	O
among	O
338	O
staff	O
members	O
in	O
a	O
hospital	O
in	O
East	O
Taiwan	O
that	O
discontinued	O
emergency	B-DISO
and	O
outpatient	O
services	O
to	O
prevent	O
possible	O
nosocomial	O
outbreak	O
.	O

We	O
further	O
assessed	O
that	O
the	O
putative	O
origin	O
of	O
the	O
SARS	B-DISO
epidemic	O
was	O
in	O
late	O
October	O
2002	O
which	O
is	O
consistent	O
with	O
a	O
recent	O
estimate	O
using	O
cases	O
from	O
China	O
.	O

Data	O
on	O
the	O
EMS	O
volume	O
,	O
the	O
transport	O
category	O
,	O
the	O
final	O
SARS	B-DISO
status	O
of	O
patients	O
,	O
and	O
the	O
EMT	O
responsible	O
for	O
the	O
transports	O
were	O
collected	O
.	O

Of	O
these	O
,	O
1	O
,	O
760	O
(	O
22	O
.	O
1	O
%)	O
were	O
SARS	B-DISO
-	O
related	O
.	O

Two	O
EMTs	O
working	O
in	O
team	O
C	O
,	O
the	O
team	O
with	O
the	O
lowest	O
risk	O
,	O
developed	O
P	O
-	O
SARS	B-DISO
.	O

During	O
the	O
outbreak	O
of	O
SARS	B-DISO
,	O
the	O
overall	O
EMS	O
volume	O
did	O
not	O
change	O
significantly	O
,	O
but	O
the	O
non	O
-	O
SARS	B-DISO
EMS	O
activities	O
decreased	O
.	O

During	O
the	O
five	O
peak	O
days	O
of	O
SARS	B-DISO
-	O
1	O
,	O
the	O
total	O
number	O
of	O
HQ	O
days	O
was	O
664	O
.	O

ABSTRACT	O
:	O
We	O
have	O
developed	O
a	O
new	O
experimental	O
system	O
based	O
on	O
a	O
microfluidic	O
chip	O
to	O
determine	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
test	O
results	O
showed	O
that	O
17	O
positive	O
samples	O
were	O
obtained	O
among	O
18	O
samples	O
of	O
nasopharyngeal	O
swabs	O
from	O
clinically	O
diagnosed	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
A	O
universal	O
microarray	O
for	O
detection	O
of	O
SARS	B-DISO
coronavirus	O
.	O

There	O
are	O
many	O
point	O
mutations	O
among	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequences	O
.	O

It	O
was	O
found	O
that	O
the	O
bases	O
of	O
six	O
nucleotide	O
positions	O
(	O
nt9404	O
,	O
nt9479	O
,	O
nt19838	O
,	O
nt21721	O
,	O
nt22222	O
and	O
nt27827	O
)	O
with	O
high	O
-	O
mutation	O
rate	O
have	O
an	O
important	O
relationship	O
with	O
the	O
SARS	B-DISO
epidemic	O
.	O

We	O
describe	O
the	O
kinetics	O
of	O
these	O
efficient	O
viral	O
inactivation	B-DISO
methods	O
,	O
which	O
will	O
allow	O
research	O
with	O
SARS	B-DISO
-	O
CoV	O
containing	O
materials	O
,	O
that	O
are	O
rendered	O
non	O
-	O
infectious	B-DISO
,	O
to	O
be	O
conducted	O
at	O
reduced	O
safety	O
levels	O
.	O

TITLE	O
:	O
A	O
large	O
outbreak	O
of	O
acute	O
encephalitis	B-DISO
with	O
high	O
fatality	O
rate	O
in	O
children	O
in	O
Andhra	O
Pradesh	O
,	O
India	O
,	O
in	O
2003	O
,	O
associated	O
with	O
Chandipura	O
virus	O
.	O

Our	O
findings	O
suggest	O
that	O
this	O
outbreak	O
of	O
acute	O
encephalitis	B-DISO
in	O
Andhra	O
Pradesh	O
was	O
associated	O
with	O
Chandipura	O
virus	O
,	O
adding	O
to	O
the	O
evidence	O
suggesting	O
that	O
this	O
virus	O
should	O
be	O
considered	O
as	O
an	O
important	O
emerging	O
pathogen	O
.	O

Administration	O
of	O
dexamethasone	O
improved	O
LPS	B-DISO
-	O
induced	O
ALI	O
and	O
retained	O
expression	O
of	O
AQP1	O
.	O

ABSTRACT	O
:	O
The	O
human	O
coronavirus	O
,	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
was	O
identified	O
and	O
molecularly	O
characterized	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
chloroquine	O
,	O
a	O
4	O
-	O
amino	O
-	O
quinoline	O
,	O
as	O
an	O
effective	O
inhibitor	O
of	O
the	O
replication	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
vitro	O
.	O

One	O
patient	O
was	O
confirmed	O
to	O
have	O
coronavirus	O
pneumonia	B-DISO
while	O
the	O
other	O
had	O
active	O
SLE	B-DISO
with	O
lung	O
involvement	O
.	O

The	O
available	O
epidemic	O
curves	O
for	O
SARS	B-DISO
show	O
marked	O
differences	O
between	O
the	O
affected	O
regions	O
with	O
respect	O
to	O
the	O
total	O
number	O
of	O
cases	O
and	O
epidemic	O
duration	O
,	O
even	O
for	O
those	O
regions	O
in	O
which	O
outbreaks	O
started	O
almost	O
simultaneously	O
and	O
similar	O
control	O
measures	O
were	O
implemented	O
at	O
the	O
same	O
time	O
.	O

The	O
effective	O
reproduction	O
numbers	O
revealed	O
that	O
epidemics	O
in	O
the	O
various	O
affected	O
regions	O
were	O
characterized	O
by	O
markedly	O
similar	O
disease	B-DISO
transmission	I-DISO
potentials	O
and	O
similar	O
levels	O
of	O
effectiveness	O
of	O
control	O
measures	O
.	O

In	O
controlling	O
SARS	B-DISO
outbreaks	O
,	O
timely	O
alerts	O
have	O
been	O
essential	O
:	O
Delaying	O
the	O
institution	O
of	O
control	O
measures	O
by	O
1	O
week	O
would	O
have	O
nearly	O
tripled	O
the	O
epidemic	O
size	O
and	O
would	O
have	O
increased	O
the	O
expected	O
epidemic	O
duration	O
by	O
4	O
weeks	O
.	O

For	O
avian	B-DISO
influenza	I-DISO
aspects	O
of	O
the	O
agrarian	O
economy	O
in	O
southeast	O
Asia	O
enabled	O
the	O
virus	O
to	O
reach	O
the	O
human	O
population	O
.	O

Most	O
recently	O
,	O
outbreaks	O
of	O
measles	B-DISO
in	O
Chinese	O
orphanages	O
have	O
been	O
documented	O
.	O

No	O
effective	O
treatments	O
have	O
been	O
developed	O
for	O
viral	B-DISO
gastroenteritis	I-DISO
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
environment	O
and	O
occupational	O
hygiene	O
factors	O
of	O
hospital	B-DISO
infection	I-DISO
on	O
SARS	B-DISO
outbreak	O
].	O

Warning	O
of	O
atmospheric	O
conditions	O
favorable	O
to	O
SARS	B-DISO
,	O
and	O
improvement	O
in	O
occupational	O
hygiene	O
management	O
is	O
the	O
key	O
to	O
prevention	O
from	O
SARS	B-DISO
outbreak	O
.	O

All	O
hospital	B-DISO
infection	I-DISO
could	O
be	O
attributed	O
to	O
defects	O
in	O
the	O
key	O
links	O
of	O
occupational	O
hygiene	O
.	O

Infected	O
mice	O
had	O
a	O
relative	O
failure	B-DISO
to	I-DISO
thrive	I-DISO
,	O
gaining	B-DISO
weight	I-DISO
significantly	O
more	O
slowly	O
than	O
uninfected	O
mice	O
.	O

These	O
data	O
indicate	O
that	O
C57BL	O
/	O
6	O
mice	O
support	O
transient	O
nonfatal	O
systemic	B-DISO
infection	I-DISO
with	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
lung	O
,	O
which	O
is	O
able	O
to	O
disseminate	O
to	O
brain	O
.	O

The	O
synthetic	O
peptide	O
S	O
(	O
603	O
-	O
634	O
),	O
which	O
overlaps	O
the	O
site	O
IV	O
sequence	O
reacted	O
with	O
all	O
the	O
convalescent	O
sera	O
from	O
42	O
SARS	B-DISO
patient	O
,	O
but	O
none	O
of	O
the	O
30	O
serum	O
samples	O
from	O
healthy	O
blood	O
donors	O
,	O
suggesting	O
its	O
potential	O
application	O
as	O
an	O
Ag	O
for	O
developing	O
SARS	B-DISO
diagnostics	O
.	O

This	O
study	O
also	O
provides	O
information	O
useful	O
for	O
designing	O
SARS	B-DISO
vaccines	O
and	O
understanding	O
the	O
SARS	B-DISO
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
on	O
hospital	O
surfaces	O
.	O

We	O
explored	O
the	O
possible	O
contribution	O
of	O
contaminated	O
hospital	O
surfaces	O
to	O
SARS	B-DISO
transmission	O
by	O
swabbing	O
surfaces	O
in	O
2	O
hospitals	O
and	O
testing	O
the	O
swab	O
samples	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
viral	O
culture	O
.	O

Although	O
the	O
viruses	O
identified	O
may	O
have	O
been	O
noninfectious	O
,	O
health	O
care	O
workers	O
should	O
be	O
aware	O
that	O
SARS	B-DISO
coronavirus	O
can	O
contaminate	O
environmental	O
surfaces	O
in	O
the	O
hospital	O
,	O
and	O
fomites	O
should	O
be	O
considered	O
to	O
be	O
a	O
possible	O
mode	O
of	O
transmission	O
of	O
SARS	B-DISO
.	O

This	O
period	O
was	O
characterized	O
by	O
the	O
upgrading	O
of	O
infection	B-DISO
control	O
precautions	O
,	O
which	O
included	O
the	O
wearing	O
of	O
gloves	O
and	O
gowns	O
all	O
the	O
time	O
,	O
an	O
extensive	O
use	O
of	O
steroids	O
,	O
and	O
a	O
change	O
in	O
antibiotic	O
prescribing	O
practices	O
.	O

Data	O
on	O
MRSA	B-DISO
acquisition	O
and	O
VAP	O
rates	O
were	O
collected	O
prospectively	O
.	O

In	O
March	O
2002	O
,	O
Esteve	O
and	O
Hemispherx	O
Biopharma	O
entered	O
into	O
a	O
collaborative	O
agreement	O
under	O
which	O
Esteve	O
will	O
be	O
the	O
sole	O
distributor	O
of	O
Ampligen	O
in	O
Spain	O
,	O
Portugal	O
and	O
Andorra	O
for	O
the	O
treatment	O
of	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
.	O

Under	O
this	O
agreement	O
,	O
in	O
addition	O
to	O
other	O
terms	O
,	O
Esteve	O
will	O
also	O
collaborate	O
in	O
the	O
drug	O
product	O
development	O
by	O
conducting	O
clinical	O
studies	O
in	O
Spain	O
in	O
patients	O
coinfected	O
with	O
HIV	B-DISO
/	O
HCV	O
.	O

Hemispherx	O
has	O
developed	O
a	O
'	O
ready	O
-	O
to	O
-	O
use	O
'	O
liquid	O
formulation	O
of	O
the	O
drug	O
and	O
has	O
begun	O
treating	O
patients	O
with	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
in	O
ongoing	O
clinical	O
trials	O
.	O

In	O
May	O
2004	O
Hemispherx	O
announced	O
that	O
it	O
had	O
filed	O
an	O
expanded	O
US	O
patent	O
application	O
covering	O
the	O
use	O
of	O
Ampligen	O
for	O
the	O
potential	O
treatment	O
and	O
prevention	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
dreaded	O
emerging	O
viruses	O
.	O

With	O
these	O
highly	O
infectious	B-DISO
SARS	B-DISO
-	O
CoV	O
pseudotypes	O
,	O
several	O
cell	O
lines	O
derived	O
from	O
various	O
tissues	O
were	O
revealed	O
as	O
susceptible	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
were	O
highly	O
corresponding	O
to	O
the	O
expression	O
pattern	O
of	O
virus	O
'	O
s	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

In	O
addition	O
,	O
we	O
also	O
demonstrated	O
angiotensin	O
1	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
the	O
homologue	O
of	O
ACE2	O
could	O
not	O
function	O
as	O
a	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O

Therefore	O
,	O
this	O
study	O
not	O
only	O
established	O
the	O
quantifiable	O
and	O
reliable	O
assay	O
for	O
the	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
measurement	O
of	O
the	O
3CLpro	O
activity	O
,	O
but	O
also	O
characterized	O
the	O
molecular	O
interaction	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
with	O
the	O
substrates	O
.	O

At	O
3	O
months	O
after	O
hospital	O
discharge	O
,	O
46	O
survivors	O
of	O
SARS	B-DISO
underwent	O
the	O
following	O
evaluation	O
:	O
spirometry	O
,	O
static	O
lung	O
volumes	O
and	O
carbon	O
monoxide	O
transfer	O
factor	O
(	O
TL	O
,	O
CO	O
).	O

We	O
questioned	O
whether	O
CKLF1	O
could	O
be	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
inflammation	B-DISO
and	O
proliferation	B-DISO
in	O
the	O
lung	O
.	O

We	O
report	O
5	O
children	O
with	O
magnetic	O
resonance	O
imaging	O
evidence	O
of	O
osteonecrosis	B-DISO
.	O

In	O
view	O
of	O
the	O
high	O
prevalence	O
and	O
asymptomatic	O
presentation	O
of	O
osteonecrosis	B-DISO
,	O
we	O
suggest	O
magnetic	O
resonance	O
imaging	O
screening	O
for	O
osteonecrosis	B-DISO
in	O
children	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
During	O
the	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
the	O
spring	O
of	O
2003	O
,	O
strict	O
infection	B-DISO
control	O
measures	O
were	O
implemented	O
in	O
Toronto	O
and	O
surrounding	O
hospitals	O
.	O

TITLE	O
:	O
[	O
Pathological	O
changes	O
of	O
lungs	O
in	O
patients	O
with	O
severity	O
acute	O
respiratory	O
syndrome	B-DISO
].	O

Four	O
cases	O
of	O
SARS	B-DISO
with	O
lung	O
tissue	O
samples	O
available	O
(	O
including	O
one	O
for	O
ultrastructural	O
examination	O
)	O
were	O
enrolled	O
into	O
the	O
study	O
.	O

The	O
principal	O
lesions	O
consisted	O
of	O
acute	O
alveolar	O
exudative	B-DISO
inflammation	I-DISO
,	O
hyperplasia	B-DISO
of	O
alveolar	O
epithelium	O
,	O
necrosis	O
,	O
alveolar	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
alveolar	O
desquamation	O
and	O
focal	O
fibroplasia	B-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
effectiveness	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NIPPV	O
)	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
the	O
associated	O
infection	B-DISO
risk	O
.	O

Patient	O
outcomes	O
and	O
the	O
risk	O
of	O
SARS	B-DISO
transmission	O
to	O
health	O
-	O
care	O
workers	O
were	O
assessed	O
.	O

Among	O
these	O
biomarkers	O
,	O
one	O
(	O
11	O
,	O
695	O
Da	O
)	O
was	O
identified	O
to	O
be	O
serum	O
amyloid	B-DISO
A	O
(	O
SAA	O
)	O
protein	O
by	O
peptide	O
mapping	O
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
.	O

Increased	O
SAA	O
occurred	O
in	O
three	O
of	O
four	O
patients	O
at	O
the	O
time	O
of	O
extensive	O
pneumonia	B-DISO
as	O
indicated	O
by	O
high	O
x	O
-	O
ray	O
scores	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
SARS	B-DISO
virus	O
-	O
specific	O
IgG	O
antibody	O
and	O
was	O
transcribed	O
reversely	O
into	O
cDNA	O
.	O

ABSTRACT	O
:	O
We	O
have	O
expressed	O
and	O
characterized	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
in	O
cDNA	O
-	O
transfected	O
mammalian	O
cells	O
.	O

Using	O
S	O
-	O
protein	O
-	O
pseudotyped	O
SIV	B-DISO
,	O
we	O
found	O
that	O
the	O
enzymatic	O
activity	O
of	O
ACE2	O
made	O
no	O
contribution	O
to	O
S	O
-	O
protein	O
-	O
mediated	O
infection	B-DISO
.	O

TITLE	O
:	O
The	O
battle	O
against	O
SARS	B-DISO
:	O
a	O
Chinese	O
story	O
.	O

SARS	B-DISO
required	O
the	O
health	O
care	O
system	O
to	O
respond	O
quickly	O
and	O
efficiently	O
.	O

The	O
potential	O
danger	O
of	O
haemorrhagic	B-DISO
fever	I-DISO
viruses	O
and	O
eradicated	O
viruses	O
such	O
as	O
variola	B-DISO
virus	O
being	O
used	O
as	O
bioterrorist	O
weapons	O
has	O
also	O
increased	O
the	O
profile	O
of	O
antiviral	O
drug	O
discovery	O
.	O

ABSTRACT	O
:	O
The	O
adhesion	B-DISO
of	O
microbial	O
pathogens	O
to	O
host	O
cells	O
is	O
mediated	O
by	O
adhesins	O
.	O

RESULTS	O
:	O
SPAAN	O
had	O
optimal	O
sensitivity	O
of	O
89	O
%	O
and	O
specificity	O
of	O
100	O
%	O
on	O
a	O
defined	O
test	O
set	O
and	O
could	O
identify	O
97	O
.	O
4	O
%	O
of	O
known	O
adhesins	O
at	O
high	O
Pad	B-DISO
value	O
from	O
a	O
wide	O
range	O
of	O
bacteria	O
.	O

The	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiologic	O
features	O
of	O
138	O
patients	O
with	O
SARS	B-DISO
were	O
analyzed	O
.	O

Patients	O
with	O
bilateral	O
pneumonic	O
changes	O
at	O
presentation	O
were	O
more	O
likely	O
to	O
have	O
an	O
adverse	O
outcome	O
than	O
were	O
those	O
with	O
unilateral	O
pneumonia	B-DISO
(	O
P	O
<	O
.	O
001	O
).	O

The	O
predictive	O
value	O
of	O
these	O
characteristics	O
for	O
end	O
-	O
expiratory	O
atelectasis	B-DISO
,	O
overstretching	O
,	O
and	O
optimal	O
end	O
-	O
expiratory	O
pressure	O
was	O
assessed	O
.	O

Understanding	O
its	O
pathogenesis	B-DISO
and	O
developing	O
specific	O
diagnostic	O
methods	O
for	O
its	O
early	O
diagnosis	O
are	O
crucial	O
for	O
the	O
effective	O
management	O
and	O
control	O
of	O
this	O
disease	O
.	O

Of	O
these	O
104	O
compounds	O
,	O
2	O
target	O
the	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
7	O
target	O
helicase	O
(	O
Hel	O
),	O
and	O
18	O
target	O
spike	O
(	O
S	O
)	O
protein	O
-	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)-	O
mediated	O
viral	O
entry	O
.	O

127	O
patients	O
(	O
33	O
%)	O
met	O
the	O
clinical	O
criteria	O
,	O
and	O
112	O
(	O
29	O
%)	O
had	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
during	O
severe	O
ARDS	B-DISO
maintains	O
oxygen	O
and	O
carbon	O
dioxide	O
gas	O
exchange	O
while	O
providing	O
an	O
optimal	O
environment	O
for	O
recovery	O
of	O
pulmonary	O
function	O
.	O

The	O
indication	O
for	O
ECLS	O
was	O
acute	O
severe	O
ARDS	B-DISO
unresponsive	O
to	O
optimal	O
conventional	O
treatment	O
.	O

TITLE	O
:	O
[	O
Occupational	B-DISO
asthma	I-DISO
].	O

The	O
incidence	O
rates	O
of	O
avascular	B-DISO
necrosis	I-DISO
of	I-DISO
femoral	I-DISO
head	I-DISO
and	O
of	O
osteoporosis	B-DISO
were	O
higher	O
in	O
convalescent	O
SARS	B-DISO
patients	O
than	O
in	O
general	O
population	O
.	O

Statistics	O
showed	O
that	O
serum	O
IgG	O
was	O
not	O
related	O
with	O
avascular	B-DISO
necrosis	I-DISO
of	I-DISO
femoral	I-DISO
head	I-DISO
and	O
osteoporosis	B-DISO
.	O

The	O
incidence	O
rates	O
of	O
critical	O
conditions	O
and	O
MODS	B-DISO
in	O
SARS	B-DISO
cases	O
were	O
34	O
.	O
86	O
%	O
and	O
13	O
.	O
71	O
%	O
respectively	O
.	O

ABSTRACT	O
:	O
Some	O
of	O
the	O
structural	O
proteins	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
carry	O
major	O
epitopes	O
involved	O
in	O
virus	O
neutralization	O
and	O
are	O
essential	O
for	O
the	O
induction	O
of	O
protective	O
humoral	O
responses	O
and	O
the	O
development	O
of	O
an	O
effective	O
vaccine	O
.	O

TITLE	O
:	O
[	O
Current	O
topics	O
on	O
SARS	B-DISO
coronavirus	O
].	O

In	O
order	O
to	O
investigate	O
the	O
maturation	O
and	O
proteolytic	O
processing	O
of	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
CoV	O
,	O
we	O
generated	O
S1	O
and	O
S2	O
subunit	O
specific	O
antibodies	O
(	O
Abs	O
)	O
as	O
well	O
as	O
N	O
,	O
E	O
and	O
3CL	O
protein	O
-	O
specific	O
Abs	O
.	O

Evaluation	O
of	O
sera	O
from	O
healthy	O
controls	O
(	O
n	O
=	O
60	O
)	O
resulted	O
in	O
two	O
weakly	O
positive	O
ELISA	O
results	O
with	O
the	O
remainder	O
being	O
negative	O
while	O
the	O
S2	O
protein	O
WB	O
demonstrated	O
three	O
positive	O
results	O
from	O
the	O
20	O
controls	O
with	O
a	O
history	O
of	O
SARS	B-DISO
contact	O
and	O
no	O
positive	O
results	O
in	O
40	O
noncontact	O
controls	O
.	O

TITLE	O
:	O
Small	O
molecules	O
blocking	B-DISO
the	O
entry	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
into	O
host	O
cells	O
.	O

Two	O
small	O
molecules	O
,	O
tetra	O
-	O
O	O
-	O
galloyl	O
-	O
beta	O
-	O
D	O
-	O
glucose	O
(	O
TGG	O
)	O
and	O
luteolin	O
,	O
were	O
identified	O
,	O
whose	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activities	O
were	O
confirmed	O
by	O
using	O
a	O
wild	O
-	O
type	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
system	O
.	O

TITLE	O
:	O
Macaque	O
model	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
macaque	O
model	O
as	O
it	O
currently	O
exists	O
will	O
have	O
limited	O
utility	O
in	O
the	O
study	O
of	O
SARS	B-DISO
and	O
the	O
evaluation	O
of	O
therapies	O
.	O

Influenza	B-DISO
and	O
tuberculosis	B-DISO
(	O
TB	O
)	O
surveillance	O
were	O
used	O
as	O
models	O
.	O

ABSTRACT	O
:	O
The	O
international	O
consensus	O
definitions	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
have	O
formed	O
the	O
basis	O
for	O
recruitment	B-DISO
into	O
randomized	O
,	O
controlled	O
trials	O
and	O
,	O
more	O
recently	O
,	O
standardized	O
the	O
protocols	O
for	O
ventilatory	O
treatment	O
of	O
acute	O
lung	O
injury	O
.	O

Lessons	O
learned	O
while	O
using	O
the	O
cyberspace	O
method	O
are	O
discussed	O
,	O
including	O
guidance	O
for	O
organizing	O
a	O
long	O
-	O
distance	O
research	O
team	O
,	O
the	O
central	O
place	O
of	O
trust	O
,	O
and	O
the	O
time	O
when	O
e	O
-	O
mail	O
communication	O
demands	O
to	O
be	O
supplemented	O
with	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
interaction	O
.	O

TITLE	O
:	O
Effect	O
of	O
intranasal	O
vaccination	O
against	O
bovine	O
enteric	O
coronavirus	O
on	O
the	O
occurrence	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
a	O
commercial	O
backgrounding	O
feedlot	O
.	O

ABSTRACT	O
:	O
In	O
March	O
2003	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
issued	O
a	O
global	O
alert	O
recommending	O
active	O
worldwide	O
surveillance	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
Heat	O
stroke	B-DISO
(	O
HS	O
)	O
is	O
a	O
serious	O
and	O
potentially	O
life	O
-	O
threatening	O
condition	B-DISO
defined	O
as	O
a	O
core	O
body	O
temperature	O
>	O
40	O
.	O
6	O
degrees	O
C	O
.	O
Two	O
forms	O
of	O
HS	O
are	O
recognized	O
,	O
classic	O
heat	O
stroke	B-DISO
,	O
usually	O
occurring	O
in	O
very	O
young	O
or	O
elderly	O
persons	O
,	O
and	O
exertional	B-DISO
heat	O
stroke	B-DISO
,	O
more	O
common	O
in	O
physically	O
active	O
individuals	O
.	O

TITLE	O
:	O
Multi	O
-	O
phase	O
approach	O
to	O
eradicate	O
enzootic	O
mouse	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
algorithm	O
was	O
tested	O
on	O
42	O
patients	O
with	O
affections	O
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
due	O
to	O
severe	O
craniocerebral	O
trauma	O
,	O
spinal	O
trauma	O
,	O
cerebral	B-DISO
stroke	I-DISO
and	O
multitrauma	O
.	O

ABSTRACT	O
:	O
Food	O
associated	O
viruses	O
are	O
responsible	O
for	O
a	O
high	O
number	O
of	O
infectious	B-DISO
diseases	I-DISO
in	O
man	O
,	O
mainly	O
gastroenteritis	B-DISO
and	O
hepatitis	B-DISO
.	O

The	O
three	O
most	O
important	O
viral	O
agents	O
are	O
noroviruses	O
(	O
NV	O
)	O
(	O
formerly	O
known	O
as	O
Norwalk	O
-	O
like	O
viruses	O
),	O
Rotavirus	O
(	O
RV	O
)	O
and	O
Hepatitis	B-DISO
A	I-DISO
-	O
Virus	O
(	O
HAV	B-DISO
).	O

Overall	O
,	O
42	O
.	O
7	O
%	O
of	O
nurses	O
had	O
a	O
positive	O
intention	O
to	O
provide	O
care	O
to	O
SARS	B-DISO
patients	O
,	O
and	O
25	O
.	O
4	O
%	O
of	O
nurses	O
would	O
volunteer	O
to	O
care	O
for	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Efficient	O
assembly	O
and	O
release	O
of	O
SARS	B-DISO
coronavirus	O
-	O
like	O
particles	O
by	O
a	O
heterologous	O
expression	O
system	O
.	O

TITLE	O
:	O
A	O
novel	O
auto	O
-	O
cleavage	O
assay	O
for	O
studying	O
mutational	O
effects	O
on	O
the	O
active	O
site	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
proposed	O
as	O
an	O
attractive	O
target	O
for	O
drug	O
design	O
.	O

Combination	O
of	O
an	O
effective	O
antiviral	O
,	O
acyclovir	O
,	O
with	O
steroid	O
in	O
the	O
treatment	O
of	O
varicella	B-DISO
zoster	I-DISO
virus	O
may	O
be	O
associated	O
with	O
a	O
lower	O
mortality	O
than	O
acyclovir	O
alone	O
(	O
0	O
%	O
vs	O
.	O
10	O
.	O
3	O
%).	O

Those	O
who	O
received	O
formal	O
education	O
demonstrated	O
that	O
they	O
acquired	O
greater	O
knowledge	O
of	O
the	O
sources	O
and	O
precautionary	O
measures	O
for	O
SARS	B-DISO
.	O

Here	O
we	O
introduce	O
a	O
probabilistic	O
model	O
that	O
describes	O
the	O
worldwide	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
and	O
demonstrate	O
that	O
a	O
forecast	O
of	O
the	O
geographical	O
spread	O
of	O
epidemics	O
is	O
indeed	O
possible	O
.	O

The	O
analysis	O
of	O
extensive	O
morbidity	O
rates	O
among	O
different	O
age	O
groups	O
of	O
the	O
population	O
showed	O
that	O
children	O
were	O
affected	O
by	O
coronavirus	B-DISO
infection	I-DISO
5	O
-	O
7	O
times	O
more	O
often	O
than	O
adults	O
.	O

New	O
technology	O
related	O
not	O
only	O
to	O
genetics	O
but	O
also	O
to	O
satellite	O
and	O
monitoring	O
systems	O
will	O
play	O
a	O
role	O
in	O
weather	O
,	O
climate	O
and	O
the	O
approach	O
to	O
environmental	O
manipulations	O
that	O
influence	O
factors	O
contributing	O
to	O
infectious	B-DISO
disease	I-DISO
emergence	O
and	O
control	O
.	O

TITLE	O
:	O
Thrombocytosis	B-DISO
after	O
trauma	O
:	O
incidence	O
,	O
aetiology	O
,	O
and	O
clinical	O
significance	O
.	O

Despite	O
the	O
fact	O
that	O
patients	O
with	O
thrombocytosis	B-DISO
had	O
a	O
greater	O
severity	O
of	O
illness	O
,	O
the	O
ICU	O
mortality	O
was	O
comparable	O
among	O
patients	O
with	O
and	O
without	O
thrombocytosis	B-DISO
(	O
8	O
vs	O
14	O
%,	O
P	O
=	O
0	O
.	O
34	O
).	O

Patients	O
with	O
SARS	B-DISO
-	O
related	O
psychosis	B-DISO
received	O
higher	O
total	O
doses	O
of	O
steroids	O
and	O
had	O
higher	O
rates	O
of	O
family	O
history	O
of	O
psychiatric	B-DISO
illness	I-DISO
.	O

The	O
results	O
suggest	O
that	O
optimization	O
of	O
murine	O
mAbs	O
for	O
neutralization	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
will	O
likely	O
be	O
possible	O
,	O
and	O
will	O
aid	O
in	O
the	O
development	O
of	O
diagnostic	O
tools	O
and	O
passive	O
treatments	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
High	O
-	O
throughput	O
screening	O
identifies	O
inhibitors	O
of	O
the	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
.	O

ABSTRACT	O
:	O
To	O
analysis	O
the	O
relationship	O
between	O
glucocorticosteroids	O
(	O
GCS	O
)	O
usage	O
and	O
side	O
effects	O
in	O
the	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

In	O
this	O
structure	O
-	O
activity	O
relation	O
study	O
,	O
the	O
molecules	O
with	O
the	O
highest	O
predicted	O
binding	O
scores	O
were	O
identified	O
and	O
assayed	O
for	O
ACE2	O
enzymatic	O
inhibitory	O
activity	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	O
fusion	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
interesting	O
enteric	O
symptoms	O
of	O
the	O
medical	O
care	O
workers	O
who	O
were	O
evidently	O
infected	O
with	O
SARS	B-DISO
by	O
means	O
of	O
respiratory	O
transmission	O
.	O

RESULTS	O
:	O
Among	O
16	O
non	O
-	O
ICU	O
cases	O
,	O
SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
plasma	O
since	O
day	O
3	O
-	O
4	O
after	O
fever	O
onset	O
;	O
viral	O
concentration	O
peaked	O
in	O
the	O
first	O
week	O
,	O
which	O
then	O
rapidly	O
declined	O
in	O
the	O
second	O
week	O
of	O
illness	O
.	O

TITLE	O
:	O
Partial	O
liquid	O
ventilation	O
for	O
preventing	O
death	O
and	O
morbidity	O
in	O
adults	O
with	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
are	O
syndromes	B-DISO
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
only	O
outcome	O
we	O
considered	O
to	O
be	O
of	O
clinical	O
significance	O
and	O
reported	O
for	O
all	O
enrolled	O
patients	O
(	O
i	O
.	O
e	O
.,	O
patients	O
with	O
ALI	O
and	O
ARDS	B-DISO
and	O
less	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
)	O
was	O
28	O
day	O
mortality	O
.	O

TITLE	O
:	O
Print	O
media	O
response	O
to	O
SARS	B-DISO
in	O
New	O
Zealand	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
media	O
response	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
related	O
risk	O
perceptions	O
,	O
knowledge	O
,	O
precautionary	O
actions	O
,	O
and	O
information	O
sources	O
were	O
studied	O
in	O
the	O
Netherlands	O
during	O
the	O
2003	O
SARS	B-DISO
outbreak	O
.	O

Although	O
respondents	O
were	O
highly	O
aware	O
of	O
the	O
SARS	B-DISO
outbreak	O
,	O
the	O
outbreak	O
did	O
not	O
result	O
in	O
unnecessary	O
precautionary	O
actions	O
or	O
fears	O
.	O

TITLE	O
:	O
CD209L	O
(	O
L	O
-	O
SIGN	O
)	O
is	O
a	O
receptor	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Group	O
1	O
was	O
the	O
indicators	O
of	O
impact	O
on	O
patients	O
,	O
including	O
visitor	O
'	O
s	O
condition	B-DISO
classification	O
,	O
number	O
of	O
patients	O
that	O
died	O
on	O
arrival	O
(	O
DOA	O
),	O
received	O
cardiopulmonary	O
resuscitation	O
,	O
underwent	O
endotracheal	O
intubation	O
,	O
needed	O
mechanical	O
ventilation	O
,	O
discharged	O
against	O
medical	O
advice	O
(	O
AAD	O
),	O
died	O
in	O
the	O
ED	O
,	O
and	O
the	O
admission	O
rate	O
to	O
wards	O
.	O

There	O
were	O
significant	O
differences	O
on	O
condition	B-DISO
classifications	O
(	O
p	O
=	O
0	O
.	O
000	O
),	O
increased	O
rate	O
of	O
patients	O
that	O
underwent	O
endotracheal	O
intubation	O
(	O
p	O
=	O
0	O
.	O
003	O
),	O
needed	O
mechanical	O
ventilation	O
(	O
p	O
=	O
0	O
.	O
020	O
),	O
and	O
admission	O
(	O
p	O
=	O
0	O
.	O
000	O
).	O

Currently	O
,	O
the	O
DHSS	O
is	O
evaluating	O
these	O
efforts	O
and	O
recognizes	O
several	O
issues	O
that	O
need	O
to	O
be	O
addressed	O
,	O
including	O
:	O
assessment	O
of	O
the	O
timeliness	O
,	O
completeness	O
,	O
and	O
accuracy	O
of	O
surveillance	O
data	O
;	O
validation	O
of	O
surveillance	O
data	O
through	O
comparison	O
with	O
hospital	O
uniform	O
billing	O
data	O
;	O
characterization	O
of	O
the	O
sensitivity	O
of	O
alerts	O
through	O
examination	O
of	O
reasons	O
for	O
identified	O
aberrations	O
in	O
disease	O
activity	O
;	O
evaluation	O
of	O
DHSS	O
staffs	O
and	O
LINCS	O
epidemiologists	O
'	O
follow	O
-	O
up	O
efforts	O
in	O
response	O
to	O
alerts	O
;	O
evaluation	O
of	O
cumulative	O
data	O
trends	O
to	O
determine	O
patterns	O
in	O
baseline	O
disease	O
activity	O
(	O
e	O
.	O
g	O
.,	O
variations	O
in	O
disease	O
activity	O
attributed	O
to	O
seasonality	O
);	O
development	O
of	O
methods	O
to	O
integrate	O
data	O
from	O
all	O
surveillance	O
efforts	O
to	O
provide	O
timely	O
,	O
comprehensive	O
,	O
and	O
coordinated	O
summaries	O
of	O
disease	O
activity	O
and	O
to	O
distribute	O
these	O
summaries	O
regularly	O
to	O
all	O
New	O
Jersey	O
public	O
health	O
partners	O
to	O
better	O
inform	O
public	O
health	O
and	O
clinical	O
management	O
;	O
and	O
development	O
of	O
a	O
coordinated	O
multi	O
-	O
agency	O
response	O
plan	B-DISO
in	O
conjunction	O
with	O
adjacent	O
states	O
.	O

TITLE	O
:	O
Viral	O
loads	O
in	O
clinical	O
specimens	O
and	O
SARS	B-DISO
manifestations	O
.	O

ABSTRACT	O
:	O
A	O
peptide	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
can	O
be	O
used	O
for	O
retrospective	O
serosurveillance	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
by	O
helping	O
identify	O
undetected	O
chains	O
of	O
disease	B-DISO
transmission	I-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
antibody	O
prevalence	O
in	O
all	O
Hong	O
Kong	O
patient	O
contacts	O
.	O

TITLE	O
:	O
Characterization	O
of	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
and	O
identification	O
of	O
biologically	O
active	O
small	O
molecule	O
inhibitors	O
using	O
a	O
continuous	O
fluorescence	O
-	O
based	O
assay	O
.	O

The	O
identified	O
inhibitors	O
have	O
Ki	O
values	O
at	O
low	O
microM	O
range	O
with	O
comparable	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activity	O
in	O
cell	O
-	O
based	O
assays	O
.	O

TITLE	O
:	O
Management	O
of	O
inpatients	O
exposed	O
to	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
Large	O
artery	O
ischaemic	B-DISO
stroke	I-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Four	O
patients	O
were	O
critically	O
-	O
ill	B-DISO
and	O
three	O
died	O
.	O

TITLE	O
:	O
Laboratory	O
diagnosis	O
of	O
four	O
recent	O
sporadic	O
cases	O
of	O
community	O
-	O
acquired	O
SARS	B-DISO
,	O
Guangdong	O
Province	O
,	O
China	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
SARS	B-DISO
coronavirus	O
excretion	O
from	O
patient	O
cohort	O
,	O
China	O
.	O

ABSTRACT	O
:	O
This	O
study	O
investigated	O
the	O
long	O
-	O
term	O
excretion	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
in	O
sputum	O
and	O
stool	O
specimens	O
from	O
56	O
infected	O
patients	O
.	O

TITLE	O
:	O
Silencing	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
gene	O
by	O
small	O
interfering	O
RNA	O
in	O
HEK	O
293T	O
cells	O
.	O

The	O
plasmid	O
pEGFP	O
-	O
optS	O
,	O
which	O
contains	O
the	O
codon	O
-	O
optimized	O
SARS	B-DISO
-	O
CoV	O
S	O
gene	O
and	O
expresses	O
spike	O
-	O
EGFP	O
fusion	O
protein	O
(	O
S	O
-	O
EGFP	O
)	O
as	O
silencing	O
target	O
and	O
expressing	O
reporter	O
,	O
was	O
transfected	O
with	O
siRNAs	O
into	O
HEK	O
293T	O
cells	O
.	O

Glutaraldehyde	O
cross	O
-	O
linking	O
SDS	B-DISO
-	O
PAGE	O
and	O
size	O
-	O
exclusion	O
chromatography	O
results	O
show	O
that	O
,	O
similar	O
to	O
the	O
full	O
-	O
length	O
SARS	B-DISO
3CL	O
(	O
pro	O
),	O
the	O
N	O
-	O
terminal	O
deleted	O
SARS	B-DISO
3CL	O
(	O
pro	O
)	O
still	O
remains	O
a	O
dimer	O
/	O
monomer	O
mixture	O
within	O
a	O
wide	O
range	O
of	O
protein	O
concentrations	O
.	O

Enzymatic	O
activity	O
assay	O
using	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
method	O
reveals	O
that	O
N	O
-	O
terminal	O
deletion	O
results	O
in	O
almost	O
complete	O
loss	O
of	O
enzymatic	O
activity	O
for	O
SARS	B-DISO
3CL	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
The	O
recently	O
emerged	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
contains	O
four	O
structural	O
genes	O
,	O
two	O
replicase	O
-	O
transcriptase	O
open	O
reading	O
frames	O
,	O
and	O
more	O
than	O
five	O
potential	O
genes	O
of	O
unknown	O
function	O
.	O

These	O
findings	O
advance	O
the	O
understanding	O
of	O
the	O
morphogenesis	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
enable	O
the	O
generation	O
of	O
safe	O
,	O
conformational	O
mimetics	O
of	O
the	O
SARS	B-DISO
virus	O
that	O
may	O
facilitate	O
the	O
development	O
of	O
vaccines	O
and	O
antiviral	O
drugs	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
vaccination	O
with	O
rMVA	O
expressing	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
is	O
associated	O
with	O
enhanced	O
hepatitis	B-DISO
.	O

Efficient	O
activity	O
of	O
TGEV	O
replicons	O
was	O
associated	O
with	O
the	O
presence	O
of	O
the	O
nucleoprotein	O
provided	O
either	O
in	O
cis	B-DISO
or	O
in	O
trans	O
.	O

TITLE	O
:	O
Expression	O
,	O
purification	O
and	O
sublocalization	O
of	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
insect	O
cells	O
.	O

Mild	O
pulmonary	O
abnormalities	O
were	O
detected	O
on	O
HRCT	O
in	O
16	O
(	O
34	O
.	O
0	O
%)	O
subjects	O
,	O
including	O
residual	O
ground	O
-	O
glass	O
opacification	O
(	O
n	O
=	O
5	O
),	O
air	B-DISO
trapping	I-DISO
(	O
n	O
=	O
8	O
),	O
and	O
a	O
combination	O
of	O
ground	O
-	O
glass	O
changes	O
and	O
air	B-DISO
trapping	I-DISO
(	O
n	O
=	O
3	O
).	O

Highly	O
conserved	O
HR	O
regions	O
between	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
SARS	B-DISO
-	O
CoV	O
spike	O
proteins	O
suggest	O
a	O
similar	O
three	O
-	O
dimensional	O
structure	O
for	O
the	O
two	O
fusion	O
cores	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
epidemic	O
raised	O
tremendous	O
challenges	O
for	O
the	O
Canadian	O
health	O
system	O
,	O
challenges	O
for	O
which	O
the	O
country	O
was	O
not	O
adequately	O
prepared	O
.	O

A	O
critical	O
review	O
of	O
problems	O
and	O
solutions	O
encountered	O
during	O
the	O
2003	O
-	O
2004	O
SARS	B-DISO
epidemics	O
will	O
serve	O
as	O
the	O
basis	O
for	O
considering	O
national	O
preparedness	O
steps	O
that	O
can	O
be	O
taken	O
to	O
facilitate	O
the	O
early	O
detection	O
of	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
a	O
rapid	O
response	O
to	O
an	O
influenza	B-DISO
pandemic	O
should	O
it	O
occur	O
.	O

Other	O
than	O
fever	O
(>	O
38	O
degrees	O
C	O
),	O
the	O
patient	O
exhibited	O
a	O
dry	B-DISO
cough	I-DISO
,	O
myalgias	B-DISO
,	O
arthralgias	B-DISO
and	O
mild	O
lymphopenia	B-DISO
and	O
the	O
chest	O
radiography	O
showed	O
an	O
opacity	B-DISO
on	O
the	O
right	O
lower	O
lung	O
.	O

TITLE	O
:	O
Canine	O
coronavirus	B-DISO
infection	I-DISO
in	O
Turkish	O
dog	O
population	O
.	O

At	O
the	O
time	O
of	O
mobile	O
team	O
visits	O
,	O
5	O
(	O
25	O
%)	O
hospitals	O
implemented	O
infection	B-DISO
control	O
practices	O
consistent	O
with	O
World	O
Health	O
Organization	O
recommendations	O
on	O
visitor	O
policies	O
,	O
private	O
negative	O
-	O
pressure	O
rooms	O
,	O
and	O
personal	O
protective	O
equipment	O
.	O

Our	O
findings	O
reported	O
the	O
views	O
and	O
satisfaction	O
levels	O
of	O
the	O
front	O
-	O
line	O
staff	O
of	O
an	O
obstetric	O
unit	O
concerning	O
precautionary	O
measures	O
against	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
reported	O
the	O
views	O
and	O
satisfaction	O
levels	O
of	O
the	O
front	O
-	O
line	O
staff	O
of	O
an	O
obstetric	O
unit	O
concerning	O
precautionary	O
measures	O
against	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
alone	O
can	O
mediate	O
the	O
membrane	O
fusion	O
required	O
for	O
virus	O
entry	O
and	O
cell	O
fusion	O
.	O

CONCLUSIONS	O
:	O
Integrated	O
traditional	O
Chinese	O
and	O
Western	O
medicines	O
has	O
some	O
positive	O
effects	O
on	O
lung	O
infiltrate	B-DISO
absorption	O
in	O
SARS	B-DISO
patients	O
,	O
and	O
is	O
recommended	O
as	O
an	O
adjunct	O
treatment	O
for	O
SARS	B-DISO
.	O

These	O
species	O
will	O
be	O
useful	O
for	O
the	O
evaluation	O
of	O
the	O
immunogenicity	O
of	O
candidate	O
vaccines	O
,	O
but	O
the	O
lack	O
of	O
apparent	O
clinical	O
illness	O
in	O
all	O
three	O
species	O
,	O
variability	O
from	O
animal	O
to	O
animal	O
in	O
level	O
of	O
viral	O
replication	O
,	O
and	O
rapid	O
clearance	O
of	O
virus	O
and	O
pneumonitis	B-DISO
in	O
AGMs	O
must	O
be	O
taken	O
into	O
account	O
by	O
investigators	O
considering	O
the	O
use	O
of	O
these	O
species	O
in	O
efficacy	O
and	O
challenge	O
studies	O
.	O

Coronaviruses	O
including	O
SARS	B-DISO
-	O
CoV	O
encode	O
an	O
envelope	O
(	O
E	O
)	O
protein	O
,	O
a	O
small	O
,	O
hydrophobic	O
membrane	O
protein	O
.	O

Thus	O
,	O
CNS	O
persistence	O
of	O
increased	O
numbers	O
of	O
secondary	O
CD8	O
+	O
T	O
cells	O
reflected	O
differences	O
in	O
the	O
initial	O
pool	O
size	O
during	O
peak	O
inflammation	B-DISO
rather	O
than	O
enhanced	O
survival	O
.	O

Two	O
major	O
immunodominant	O
epitopes	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
362	O
to	O
412	O
)	O
and	O
middle	O
region	O
(	O
aa	O
153	O
to	O
178	O
)	O
reacted	O
with	O
more	O
than	O
75	O
%	O
of	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
Israel	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
SARS	B-DISO
-	O
CoV	O
inactivated	O
by	O
beta	O
-	O
propiolactone	O
elicited	O
high	O
titers	O
of	O
antibodies	O
in	O
the	O
immunized	O
mice	O
and	O
rabbits	O
that	O
recognize	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
especially	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
region	O
.	O

It	O
first	O
occurred	O
in	O
Southern	O
China	O
in	O
November	O
2002	O
and	O
was	O
transported	O
to	O
Hong	O
Kong	O
on	O
February	O
21	O
,	O
2003	O
by	O
an	O
infected	O
and	O
ill	B-DISO
patient	O
.	O

TITLE	O
:	O
Clinical	O
picture	O
,	O
diagnosis	O
,	O
treatment	O
and	O
outcome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
children	O
.	O

TITLE	O
:	O
Post	O
-	O
SARS	B-DISO
infection	B-DISO
control	O
in	O
the	O
hospital	O
and	O
clinic	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
has	O
almost	O
mandated	O
a	O
re	O
-	O
evaluation	O
of	O
infection	B-DISO
control	O
practices	O
in	O
hospitals	O
,	O
clinics	O
,	O
schools	O
and	O
domestic	O
environments	O
,	O
especially	O
for	O
patients	O
with	O
respiratory	O
tract	O
symptoms	O
.	O

Unlike	O
adult	O
patients	O
,	O
no	O
fatalities	O
were	O
reported	O
among	O
the	O
paediatric	O
SARS	B-DISO
patients	O
.	O

Lastly	O
it	O
is	O
of	O
utmost	O
importance	O
that	O
international	O
research	O
collaboration	O
should	O
be	O
strengthened	O
to	O
deal	O
with	O
SARS	B-DISO
and	O
any	O
other	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
that	O
can	O
seriously	O
threaten	O
our	O
future	O
.	O

TITLE	O
:	O
A	O
study	O
on	O
SARS	B-DISO
awareness	O
and	O
health	O
-	O
seeking	O
behaviour	O
-	O
findings	O
from	O
a	O
sampled	O
population	O
attending	O
National	O
Healthcare	O
Group	O
Polyclinics	O
.	O

Television	O
(	O
91	O
.	O
6	O
%),	O
newspaper	O
(	O
65	O
.	O
2	O
%)	O
and	O
radio	O
(	O
30	O
.	O
4	O
%)	O
formed	O
the	O
top	O
3	O
sources	O
of	O
information	O
on	O
SARS	B-DISO
.	O

A	O
diagnosis	O
of	O
SARS	B-DISO
was	O
based	O
on	O
the	O
demonstration	O
of	O
serum	O
coronavirus	O
antibodies	O
.	O

Two	O
women	O
experienced	O
motor	O
-	O
predominant	O
peripheral	B-DISO
nerve	I-DISO
disorders	I-DISO
.	O

The	O
rSCoVN	O
protein	O
has	O
a	O
high	O
specificity	O
against	O
SARS	B-DISO
-	O
CoVN	O
-	O
mAb	O
and	O
SARS	B-DISO
positive	O
sera	O
,	O
but	O
has	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	O
.	O

This	O
provides	O
a	O
basis	O
for	O
further	O
researches	O
on	O
the	O
early	O
diagnosis	O
of	O
SARS	B-DISO
and	O
the	O
mechanism	O
of	O
SCoV	O
.	O
RESULTS	O
:	O
All	O
of	O
the	O
recombinants	O
were	O
His	O
(+)	O
Mut	O
(+)	O
after	O
transformation	B-DISO
of	O
P	O
.	O
pastoris	O
with	O
linearized	O
plasmids	O
.	O

Its	O
incidence	O
rate	O
was	O
high	O
,	O
the	O
patients	O
'	O
condition	B-DISO
was	O
severe	O
,	O
and	O
the	O
mortality	O
was	O
higher	O
.	O

The	O
peripheral	O
blood	O
picture	O
and	O
liver	O
function	O
of	O
169	O
cases	O
with	O
SARS	B-DISO
were	O
analyzed	O
.	O

Serum	O
of	O
60	O
SARS	B-DISO
patients	O
,	O
20	O
samples	O
of	O
serum	O
and	O
20	O
samples	O
of	O
gargling	O
fluid	O
of	O
medical	O
staff	O
of	O
the	O
""""	O
Fever	O
Clinic	O
""","	O
and	O
one	O
cDNA	O
specimen	O
obtained	O
from	O
one	O
SARS	B-DISO
suspect	O
patient	O
were	O
examined	O
with	O
F	O
-	O
PCR	O
diagnosis	O
kit	O
and	O
gene	O
-	O
chip	O
technique	O
for	O
SARS	B-DISO
coronavirus	O
.	O

RESULTS	O
:	O
Three	O
methods	O
,	O
including	O
DR	O
Chip	O
and	O
two	O
F	O
-	O
PCR	O
kit	O
from	O
Zhongshan	O
College	O
Da	O
'	O
an	O
gene	O
stock	O
company	O
and	O
Shanghai	O
Fortune	O
industrial	O
joint	O
-	O
stock	O
Co	O
,	O
Ltd	O
,	O
were	O
used	O
,	O
and	O
the	O
results	O
were	O
all	O
negative	O
for	O
all	O
specimens	O
,	O
except	O
one	O
cDNA	O
specimen	O
,	O
which	O
was	O
obtained	O
from	O
one	O
SARS	B-DISO
suspect	O
patient	O
,	O
virus	O
could	O
be	O
amplified	O
by	O
F	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Various	O
low	O
triiodothyronine	O
(	O
T3	O
)	O
states	O
have	O
been	O
described	O
in	O
severe	O
nonthyroidal	O
diseases	O
and	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
cardiovascular	B-DISO
disease	I-DISO
patients	O
.	O

Findings	O
have	O
significant	O
implications	O
in	O
enhancing	O
the	O
effectiveness	O
of	O
SARS	B-DISO
prevention	O
programs	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
new	O
,	O
highly	O
contagious	O
,	O
viral	B-DISO
disease	I-DISO
,	O
emerged	O
in	O
China	O
late	O
in	O
2002	O
and	O
quickly	O
spread	O
to	O
32	O
countries	O
and	O
regions	O
causing	O
in	O
excess	O
of	O
774	O
deaths	O
and	O
8098	O
infections	B-DISO
worldwide	O
.	O

A	O
community	O
-	O
wide	O
eradication	O
of	O
SARS	B-DISO
is	O
feasible	O
if	O
optimal	O
isolation	O
is	O
combined	O
with	O
a	O
highly	O
effective	O
screening	O
programme	O
at	O
the	O
points	O
of	O
entry	O
.	O

TITLE	O
:	O
Use	O
of	O
viral	O
lysate	O
antigen	O
combined	O
with	O
recombinant	O
protein	O
in	O
Western	O
immunoblot	O
assay	O
as	O
confirmatory	O
test	O
for	O
serodiagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

We	O
assessed	O
longitudinal	O
neurocognitive	O
,	O
emotional	O
,	O
and	O
quality	O
of	O
life	O
in	O
ARDS	B-DISO
survivors	O
at	O
hospital	O
discharge	O
,	O
and	O
1	O
and	O
2	O
years	O
after	O
hospital	O
discharge	O
using	O
neuropsychologic	O
tests	O
and	O
emotional	O
and	O
quality	O
-	O
of	O
-	O
life	O
questionnaires	O
.	O

ARDS	B-DISO
results	O
in	O
significant	O
neurocognitive	O
and	O
emotional	O
morbidity	O
and	O
decreased	O
quality	O
of	O
life	O
that	O
persists	O
at	O
least	O
2	O
years	O
after	O
hospital	O
discharge	O
.	O

Recombinant	O
human	O
activated	O
protein	O
C	O
is	O
recommended	O
in	O
patients	O
at	O
high	O
risk	O
of	O
death	O
(	O
septic	B-DISO
shock	I-DISO
,	O
sepsis	B-DISO
-	O
induced	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
Acute	I-DISO
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
of	O
>/=	O
25	O
,	O
and	O
sepsis	B-DISO
-	O
induced	O
multiorgan	B-DISO
failure	I-DISO
)	O
and	O
no	O
absolute	O
contraindication	O
related	O
to	O
bleeding	B-DISO
risk	O
or	O
relative	O
contraindication	O
that	O
outweighs	O
the	O
potential	O
benefit	O
.	O

The	O
role	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
and	O
airway	O
pressure	O
release	O
ventilation	O
in	O
ARDS	B-DISO
is	O
uncertain	O
.	O

TITLE	O
:	O
Antisense	O
downregulation	O
of	O
SARS	B-DISO
-	O
CoV	O
gene	O
expression	O
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
define	O
the	O
clinical	O
characteristics	O
and	O
clinical	O
course	O
of	O
hospital	O
-	O
acquired	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
most	O
common	O
presenting	O
symptoms	O
in	O
our	O
14	O
patients	O
with	O
hospital	O
-	O
acquired	O
SARS	B-DISO
were	O
fever	O
,	O
dyspnea	B-DISO
,	O
dizziness	B-DISO
,	O
malaise	B-DISO
,	O
diarrhea	B-DISO
,	O
dry	B-DISO
cough	I-DISO
,	O
muscle	B-DISO
pain	I-DISO
,	O
and	O
chills	B-DISO
.	O

In	O
those	O
receiving	O
mechanical	O
ventilation	O
,	O
pulmonary	O
function	O
was	O
only	O
mildly	O
reduced	O
at	O
6	O
to	O
8	O
months	O
after	O
acute	O
illness	O
,	O
consistent	O
with	O
the	O
natural	O
history	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
other	O
causes	O
.	O

Optimal	O
correlations	O
were	O
found	O
between	O
conventionally	O
measured	O
body	O
temperatures	O
and	O
IRT	O
readings	O
from	O
(	O
1	O
)	O
the	O
front	O
of	O
the	O
face	B-DISO
at	O
1	O
.	O
5m	O
with	O
the	O
mouth	O
open	O
(	O
r	O
=	O
0	O
.	O
80	O
),	O
(	O
2	O
)	O
the	O
ear	O
at	O
0	O
.	O
5	O
m	O
(	O
r	O
=	O
0	O
.	O
79	O
),	O
and	O
(	O
3	O
)	O
the	O
side	O
of	O
the	O
face	B-DISO
at	O
1	O
.	O
5m	O
(	O
r	O
=	O
0	O
.	O
76	O
).	O

IRT	O
readings	O
from	O
the	O
side	O
of	O
the	O
face	B-DISO
,	O
especially	O
from	O
the	O
ear	O
at	O
0	O
.	O
5	O
m	O
,	O
yielded	O
the	O
most	O
reliable	O
,	O
precise	O
and	O
consistent	O
estimates	O
of	O
conventionally	O
determined	O
body	O
temperatures	O
.	O

In	O
addition	O
,	O
chest	O
radiography	O
showed	O
decreased	O
spread	O
or	O
density	O
of	O
lung	O
infiltrates	B-DISO
,	O
and	O
the	O
physiological	O
effects	O
remained	O
after	O
termination	O
of	O
inhaled	O
NO	O
therapy	O
.	O

SARS	B-DISO
related	O
perceptions	O
,	O
such	O
as	O
perceived	O
risk	O
of	O
transmission	O
and	O
efficacy	O
,	O
etc	O
,	O
were	O
associated	O
with	O
mask	O
use	O
and	O
not	O
visiting	O
crowded	O
places	O
,	O
but	O
not	O
with	O
hand	O
washing	O
,	O
which	O
was	O
associated	O
with	O
duration	O
of	O
stay	O
.	O

TITLE	O
:	O
Public	O
health	O
interventions	O
and	O
SARS	B-DISO
spread	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
The	O
2003	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
contained	O
largely	O
through	O
traditional	O
public	O
health	O
interventions	O
,	O
such	O
as	O
finding	O
and	O
isolating	O
case	O
-	O
patients	O
,	O
quarantining	O
close	O
contacts	O
,	O
and	O
enhanced	O
infection	B-DISO
control	O
.	O

N	O
protein	O
can	O
be	O
used	O
as	O
an	O
early	O
diagnostic	O
maker	O
for	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
After	O
severe	O
trauma	O
,	O
decreased	O
plasma	O
concentrations	O
of	O
the	O
soluble	O
adhesion	B-DISO
molecule	O
L	O
-	O
selectin	O
(	O
sCD62L	O
)	O
have	O
been	O
linked	O
to	O
an	O
increased	O
incidence	O
of	O
lung	O
failure	O
and	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
).	O

Three	O
of	O
four	O
studies	O
showed	O
lower	O
early	O
sCD62L	O
concentrations	O
among	O
individuals	O
progressing	O
to	O
ALI	O
and	O
ARDS	B-DISO
(	O
WMD	O
=	O
-	O
229	O
microg	O
/	O
L	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
476	O
to	O
18	O
microg	O
/	O
L	O
).	O

More	O
importantly	O
,	O
this	O
classifier	O
accurately	O
distinguished	O
acute	O
SARS	B-DISO
from	O
fever	O
and	O
influenza	B-DISO
with	O
100	O
%	O
specificity	O
(	O
187	O
of	O
187	O
).	O

This	O
method	O
is	O
suitable	O
for	O
preliminary	O
assessment	O
of	O
SARS	B-DISO
and	O
could	O
potentially	O
serve	O
as	O
a	O
useful	O
tool	O
for	O
early	O
diagnosis	O
.	O

RESULTS	O
:	O
The	O
discriminatory	O
classifier	O
with	O
a	O
panel	O
of	O
four	O
biomarkers	O
determined	O
in	O
the	O
training	O
set	O
could	O
precisely	O
detect	O
36	O
of	O
37	O
(	O
sensitivity	O
,	O
97	O
.	O
3	O
%)	O
acute	O
SARS	B-DISO
and	O
987	O
of	O
993	O
(	O
specificity	O
,	O
99	O
.	O
4	O
%)	O
non	O
-	O
SARS	B-DISO
samples	O
.	O

The	O
frequent	O
substitution	O
of	O
the	O
external	O
masks	O
with	O
a	O
new	O
one	O
will	O
improve	O
the	O
filtering	O
activity	O
against	O
droplets	O
produced	O
by	O
cough	B-DISO
or	O
sneezes	O
of	O
the	O
patient	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
factors	O
in	O
relation	O
to	O
severe	O
acute	O
respiratory	O
syndromes	B-DISO
(	O
SARS	B-DISO
)	O
among	O
health	O
care	O
workers	O
and	O
to	O
develop	O
related	O
protective	O
measures	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
infection	B-DISO
in	O
heath	O
care	O
workers	O
was	O
related	O
to	O
many	O
factors	O
during	O
the	O
process	O
of	O
diagnoses	O
and	O
/	O
or	O
treatment	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
risk	O
factors	O
related	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
close	O
contactors	O
in	O
Beijing	O
].	O

One	O
of	O
the	O
epidemiological	O
characteristics	O
was	O
that	O
SARS	B-DISO
were	O
as	O
clustered	O
in	O
the	O
family	O
among	O
those	O
close	O
contacts	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
dynamics	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
Initial	O
viral	O
load	O
and	O
the	O
outcomes	O
of	O
SARS	B-DISO
.	O

Compared	O
with	O
the	O
2000	O
-	O
2002	O
data	O
,	O
we	O
found	O
no	O
differences	O
in	O
visits	O
,	O
admission	O
rates	O
or	O
length	O
of	O
stay	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
period	O
in	O
2003	O
.	O

The	O
up	O
-	O
regulation	O
of	O
LIX	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
2	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
our	O
study	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
temporal	O
expression	O
of	O
inflammatory	O
genes	O
during	O
LPS	B-DISO
-	O
induced	O
ALI	O
and	O
suggest	O
that	O
early	O
therapeutic	O
intervention	O
is	O
crucial	O
to	O
attenuate	O
lung	O
damage	O
.	O

To	O
assess	O
the	O
adherence	O
to	O
PPE	O
and	O
the	O
possibility	O
of	O
transmission	O
to	O
exposed	O
staff	O
a	O
structured	O
questionnaire	O
was	O
administered	O
and	O
serum	O
samples	O
tested	O
for	O
SARS	B-DISO
coronavirus	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Moreover	O
,	O
MVA	O
is	O
considered	O
to	O
be	O
a	O
prime	O
candidate	O
vaccine	O
for	O
safer	O
protection	O
against	O
orthopoxvirus	O
infections	B-DISO
.	O

The	O
SARS	B-DISO
outbreak	O
has	O
demonstrated	O
the	O
vulnerability	O
of	O
an	O
organ	O
transplantation	O
service	O
and	O
reminds	O
us	O
of	O
the	O
fearful	O
possibility	O
of	O
zoonoses	B-DISO
in	O
future	O
xeno	O
-	O
transplantation	O
.	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
flu	I-DISO
].	O

And	O
group	O
3	O
corresponds	O
to	O
the	O
avian	O
pathology	B-DISO
....	O

In	O
June	O
2003	O
,	O
SARS	B-DISO
affected	O
over	O
8	O
,	O
000	O
people	O
and	O
774	O
were	O
killed	O
.	O

ABSTRACT	O
:	O
A	O
survey	O
was	O
conducted	O
to	O
measure	O
psychological	B-DISO
stress	I-DISO
in	O
hospital	O
workers	O
and	O
measure	O
factors	O
that	O
may	O
have	O
mediated	O
acute	O
traumatic	O
responses	O
.	O

RESULTS	O
:	O
Higher	O
Impact	O
of	O
Event	O
Scale	O
scores	O
are	O
found	O
in	O
nurses	O
and	O
healthcare	O
workers	O
having	O
contact	O
with	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
have	O
replaced	O
the	O
ectodomain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
Beaudette	O
strain	O
(	O
Beau	O
-	O
R	O
;	O
apathogenic	O
for	O
Gallus	O
domesticus	O
chickens	O
)	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
coronavirus	O
(	O
IBV	O
)	O
with	O
that	O
from	O
the	O
pathogenic	O
M41	O
strain	O
to	O
produce	O
recombinant	O
IBV	O
BeauR	O
-	O
M41	O
(	O
S	O
).	O

TITLE	O
:	O
Overexpression	O
of	O
7a	O
,	O
a	O
protein	O
specifically	O
encoded	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
induces	O
apoptosis	O
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

TITLE	O
:	O
Genetic	O
screen	O
for	O
monitoring	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
SCoV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
Singapore	O
,	O
the	O
military	O
was	O
actively	O
involved	O
in	O
the	O
containment	O
of	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
last	O
year	O
.	O

This	O
review	O
reconstructs	O
the	O
events	O
that	O
took	O
place	O
during	O
the	O
SARS	B-DISO
outbreak	O
,	O
focusing	O
on	O
the	O
special	O
support	O
arising	O
from	O
complementing	O
the	O
military	O
-	O
affiliated	O
laboratory	O
with	O
the	O
public	O
health	O
laboratory	O
.	O

A	O
series	O
of	O
keto	O
-	O
glutamine	O
analogues	O
with	O
a	O
phthalhydrazido	O
group	O
at	O
the	O
alpha	O
-	O
position	O
were	O
synthesized	O
and	O
tested	O
as	O
reversible	O
inhibitiors	O
against	O
SARS	B-DISO
3CL	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
Clinical	O
application	O
of	O
arteriovenous	O
(	O
AV	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
requires	O
assessment	O
of	O
cardiovascular	O
ability	O
to	O
respond	O
adequately	O
to	O
the	O
presence	O
of	O
an	O
AV	O
shunt	O
in	O
the	O
face	B-DISO
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

A	O
severe	O
ALI	O
(	O
arterial	O
oxygen	O
tension	B-DISO
/	O
inspired	O
fractional	O
oxygen	O
<	O
200	O
)	O
was	O
induced	O
by	O
lung	O
lavage	O
(	O
repeated	O
three	O
times	O
,	O
each	O
with	O
5	O
ml	O
/	O
kg	O
saline	O
)	O
followed	O
by	O
tracheal	O
instillation	O
of	O
2	O
.	O
5	O
ml	O
/	O
kg	O
of	O
0	O
.	O
1	O
N	O
HCl	O
.	O

TITLE	O
:	O
Bench	O
-	O
to	O
-	O
bedside	O
review	O
:	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
how	O
neutrophils	O
migrate	O
into	O
the	O
lung	O
.	O

The	O
molecular	O
mechanisms	O
of	O
neutrophil	O
recruitment	B-DISO
in	O
the	O
lung	O
differ	O
fundamentally	O
from	O
those	O
in	O
other	O
tissues	O
.	O

These	O
results	O
suggest	O
that	O
SARS	B-DISO
-	O
CoV	O
,	O
like	O
human	O
CoV	O
OC43	O
,	O
poorly	O
infects	O
human	O
PM	O
,	O
and	O
production	O
of	O
IFN	O
-	O
alpha	O
by	O
these	O
cells	O
further	O
limits	O
the	O
infection	B-DISO
.	O

TITLE	O
:	O
[	O
Dynamic	O
changes	O
of	O
immunoglobulin	O
G	O
in	O
convalescents	O
who	O
have	O
suffered	B-DISO
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
].	O

The	O
large	O
-	O
scale	O
cultured	O
SARS	B-DISO
-	O
CoV	O
F69	O
strain	O
was	O
inactivated	O
with	O
0	O
.	O
4	O
%	O
formaldehyde	O
and	O
purified	O
,	O
then	O
used	O
as	O
the	O
immunogen	O
combined	O
with	O
Freund	O
'	O
s	O
adjuvant	O
.	O

The	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
made	O
from	O
F69	O
strain	O
owns	O
strong	O
immunogenicity	O
,	O
and	O
the	O
cross	O
neutralization	O
response	O
between	O
the	O
two	O
different	O
SARS	B-DISO
-	O
CoV	O
strains	O
gives	O
a	O
hint	O
of	O
the	O
similar	O
neutralizing	O
epitopes	O
,	O
which	O
provide	O
stable	O
bases	O
for	O
the	O
development	O
of	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccines	O
.	O

TITLE	O
:	O
Plasma	O
proteome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
analyzed	O
by	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
.	O

TITLE	O
:	O
Diagnosis	O
and	O
pharmacotherapy	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
what	O
have	O
we	O
learnt	O
?	O

The	O
incubation	O
period	O
of	O
SARS	B-DISO
is	O
usually	O
4	O
-	O
6	O
days	O
and	O
patients	O
commonly	O
present	O
with	O
high	O
fever	O
(	O
temperature	O
>	O
38	O
degrees	O
C	O
),	O
dry	B-DISO
cough	I-DISO
,	O
chills	B-DISO
and	O
rigor	B-DISO
,	O
dyspnoea	B-DISO
and	O
diarrhoea	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
pathogenesis	B-DISO
,	O
disease	O
and	O
vaccines	O
:	O
an	O
update	O
.	O

Rapid	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
clinical	O
disease	O
of	O
SARS	B-DISO
in	O
adults	O
and	O
children	O
.	O

SARS	B-DISO
is	O
much	O
milder	O
in	O
children	O
younger	O
than	O
12	O
years	O
old	O
than	O
it	O
is	O
in	O
adolescents	O
and	O
adults	O
.	O

Numerous	O
approaches	O
to	O
the	O
development	O
of	O
SARS	B-DISO
-	O
CoV	O
vaccines	O
have	O
been	O
undertaken	O
,	O
and	O
there	O
is	O
evidence	O
that	O
antibodies	O
to	O
the	O
spike	O
protein	O
may	O
be	O
protective	O
from	O
replication	O
and	O
pathology	B-DISO
in	O
animal	O
models	O
.	O

ABSTRACT	O
:	O
This	O
special	O
supplement	O
of	O
Nature	O
Medicine	O
,	O
directed	O
at	O
the	O
topic	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
is	O
very	O
timely	O
.	O

By	O
the	O
late	O
twentieth	O
century	O
,	O
however	O
,	O
an	O
increase	O
in	O
the	O
emergence	O
and	O
re	O
-	O
emergence	O
of	O
infectious	B-DISO
diseases	I-DISO
was	O
evident	O
in	O
many	O
parts	O
of	O
the	O
world	O
.	O

ABSTRACT	O
:	O
The	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
difficult	O
early	O
in	O
the	O
illness	O
,	O
because	O
its	O
presentation	O
resembles	O
that	O
of	O
other	O
nonspecific	O
viral	O
fevers	O
,	O
such	O
as	O
dengue	B-DISO
.	O

Features	O
independently	O
predictive	O
of	O
dengue	B-DISO
were	O
modeled	O
by	O
multivariate	O
logistic	O
regression	O
to	O
create	O
a	O
diagnostic	O
tool	O
with	O
100	O
%	O
specificity	O
for	O
dengue	B-DISO
.	O

Laser	O
capture	O
microdissection	O
of	O
tumor	B-DISO
cells	O
can	O
provide	O
an	O
adequate	O
number	O
of	O
cells	O
for	O
whole	O
genome	O
amplification	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
overview	O
with	O
an	O
emphasis	O
on	O
the	O
Toronto	O
experience	O
.	O

No	O
transmission	O
occurred	O
before	O
symptom	B-DISO
onset	O
or	O
after	O
recovery	O
.	O

These	O
data	O
suggest	O
that	O
limiting	O
inducible	O
NO	O
synthase	O
-	O
generated	O
NO	O
availability	O
with	O
the	O
exogenous	O
NO	O
donor	O
,	O
sodium	O
nitroprusside	O
,	O
may	O
reduce	O
lung	O
injury	O
after	O
severe	O
hemorrhage	B-DISO
,	O
possibly	O
,	O
among	O
other	O
effects	O
,	O
by	O
downregulating	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
.	O

RESULTS	O
:	O
Sodium	O
nitroprusside	O
significantly	O
increased	O
MAP	O
and	O
reduced	O
fluid	O
requirements	O
during	O
resuscitation	O
after	O
hemorrhage	B-DISO
.	O

Collaborate	O
with	O
your	O
infection	B-DISO
control	O
committee	O
,	O
disaster	O
management	O
committee	O
,	O
local	O
board	O
of	O
health	O
,	O
and	O
other	O
providers	O
to	O
develop	O
protocols	O
and	O
policies	O
.	O

ED	O
staff	O
,	O
particularly	O
the	O
triage	O
nurses	O
,	O
need	O
training	O
in	O
early	O
recognition	O
of	O
presenting	O
symptoms	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

More	O
importantly	O
,	O
the	O
immunized	O
mice	O
produced	O
strong	O
delayed	B-DISO
-	I-DISO
type	I-DISO
hypersensitivity	I-DISO
(	O
DTH	B-DISO
)	O
and	O
CD8	O
(+)	O
CTL	O
responses	O
to	O
N	O
protein	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
life	O
-	O
threatening	O
disease	O
,	O
is	O
caused	O
by	O
the	O
newly	O
identified	O
virus	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

These	O
""""	O
exhaled	O
bioaerosols	O
""""	O
may	O
carry	O
airborne	O
pathogens	O
and	O
thereby	O
magnify	O
the	O
spread	O
of	O
certain	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
influenza	B-DISO
,	O
tuberculosis	B-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
False	O
-	O
positive	O
results	O
in	O
a	O
recombinant	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
due	O
to	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
229E	O
rectified	O
by	O
Western	O
blotting	O
with	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
spike	O
polypeptide	O
.	O

Compared	O
with	O
the	O
community	O
sample	O
,	O
SARS	B-DISO
survivors	O
had	O
significantly	O
more	O
distress	O
and	O
poor	O
quality	O
of	O
life	O
.	O

Thus	O
,	O
the	O
nomenclature	O
,	O
risks	O
,	O
and	O
pathogenesis	B-DISO
are	O
not	O
well	O
defined	O
.	O

Chemokines	O
and	O
their	O
receptors	O
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
several	O
diseases	O
.	O

A	O
multicenter	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
corticosteroids	O
for	O
late	O
SARS	B-DISO
is	O
justified	O
because	O
of	O
widespread	O
clinical	O
use	O
and	O
uncertainties	O
about	O
relative	O
risks	O
and	O
benefits	O
.	O

The	O
membrane	O
-	O
bound	O
proprotein	O
convertases	O
(	O
PCs	B-DISO
)	O
furin	O
,	O
PC7	O
or	O
PC5B	O
enhanced	O
the	O
production	O
of	O
the	O
approximately	O
80	O
kDa	O
protein	O
.	O

In	O
agreement	O
,	O
proS	O
processing	O
,	O
cytopathic	B-DISO
effects	I-DISO
,	O
and	O
viral	O
titers	O
were	O
enhanced	O
in	O
recombinant	O
Vero	O
E6	O
cells	O
overexpressing	O
furin	O
,	O
PC7	O
or	O
PC5B	O
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
focused	O
on	O
severe	O
imported	O
malaria	B-DISO
in	O
patients	O
admitted	O
to	O
intensive	O
care	O
units	O
.	O

All	O
patients	O
,	O
more	O
than	O
15	O
years	O
-	O
old	O
with	O
falciparum	B-DISO
malaria	I-DISO
who	O
were	O
admitted	O
to	O
intensive	O
care	O
units	O
between	O
October	O
1997	O
and	O
April	O
2004	O
were	O
included	O
.	O

Criteria	O
of	O
admission	O
were	O
impaired	B-DISO
consciousness	I-DISO
in	O
69	O
%,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
19	O
%	O
and	O
isolated	O
high	O
parasitemia	B-DISO
in	O
19	O
%	O
of	O
the	O
cases	O
.	O

Seven	O
patients	O
(	O
22	O
%)	O
had	O
community	O
-	O
acquired	O
coinfections	B-DISO
and	O
six	O
(	O
19	O
%)	O
had	O
nosocomial	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Expression	O
of	O
cellular	O
oncogene	O
Bcl	O
-	O
xL	O
prevents	O
coronavirus	O
-	O
induced	O
cell	O
death	O
and	O
converts	O
acute	B-DISO
infection	I-DISO
to	O
persistent	B-DISO
infection	I-DISO
in	O
progenitor	O
rat	O
oligodendrocytes	O
.	O

Thus	O
,	O
the	O
establishment	O
of	O
a	O
persistent	O
,	O
nonproductive	O
infection	B-DISO
in	O
CG	O
-	O
4	O
cells	O
may	O
provide	O
a	O
useful	O
in	O
vitro	O
model	O
for	O
studying	O
viral	O
persistence	O
in	O
animal	O
CNS	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
of	O
golden	O
Syrian	O
hamsters	O
.	O

were	O
completely	O
protected	O
from	O
virus	O
replication	O
and	O
accompanying	O
pathology	B-DISO
in	O
the	O
respiratory	O
tract	O
.	O

Comparing	O
these	O
data	O
to	O
the	O
mouse	O
model	O
,	O
SARS	B-DISO
CoV	O
replicates	O
to	O
a	O
higher	O
titer	O
and	O
for	O
a	O
longer	O
duration	O
in	O
the	O
respiratory	O
tract	O
of	O
hamsters	O
and	O
is	O
accompanied	O
by	O
significant	O
pathology	B-DISO
that	O
is	O
absent	O
in	O
mice	O
.	O

Sivelestat	O
Na	O
,	O
is	O
available	O
for	O
ALI	O
.	O
ARDS	B-DISO
in	O
Japan	O
,	O
is	O
needed	O
further	O
prospective	O
randomized	O
studies	O
.	O

This	O
observation	O
does	O
not	O
support	O
the	O
use	O
of	O
inhaled	O
nitric	O
oxide	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Both	O
methods	O
detected	O
influenza	B-DISO
viruses	O
A	O
(	O
H1N1	O
and	O
H3N2	O
)	O
and	O
B	O
,	O
human	O
parainfluenza	B-DISO
virus	O
types	O
1	O
to	O
3	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)	O
types	O
A	O
and	O
B	O
,	O
and	O
human	O
adenoviruses	O
.	O

In	O
the	O
great	O
majority	O
of	O
infected	O
children	O
,	O
hRSV	O
and	O
hMPV	O
were	O
associated	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

In	O
lung	O
transplant	O
recipients	O
,	O
viruses	O
present	O
in	O
bronchoalveolar	O
lavage	O
appeared	O
to	O
be	O
associated	O
frequently	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

The	O
model	O
'	O
s	O
use	O
in	O
the	O
design	O
of	O
strategies	O
to	O
minimize	O
the	O
risk	O
of	O
SARS	B-DISO
in	O
a	O
previously	O
unexposed	O
community	O
is	O
demonstrated	O
.	O

TITLE	O
:	O
Structure	O
of	O
a	O
proteolytically	O
resistant	O
core	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
S2	O
fusion	O
protein	O
.	O

TITLE	O
:	O
Acquired	O
but	O
reversible	O
loss	O
of	O
erythrocyte	O
complement	O
receptor	O
1	O
(	O
CR1	O
,	O
CD35	O
)	O
and	O
its	O
longitudinal	O
alteration	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Abstract	O
Serum	O
levels	O
of	O
IgG	O
,	O
IgM	O
and	O
IgA	O
against	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
detected	O
serially	O
with	O
the	O
use	O
of	O
immunofluorescent	O
antibody	O
assays	O
in	O
30	O
patients	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
to	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
membrane	O
protein	O
M	O
were	O
prepared	O
and	O
used	O
for	O
the	O
comparative	O
assessment	O
of	O
three	O
blocking	B-DISO
ELISA	O
variants	O
to	O
detect	O
PEDV	O
.	O

Its	O
specificity	O
was	O
verified	O
by	O
inclusion	O
of	O
control	O
samples	O
containing	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
and	O
rotavirus	O
A	O
in	O
each	O
analysis	O
.	O

The	O
fear	O
,	O
uncertainty	O
and	O
stigma	O
caused	O
by	O
SARS	B-DISO
are	O
associated	O
with	O
psychological	B-DISO
distress	I-DISO
among	O
some	O
of	O
the	O
primary	O
healthcare	O
providers	O
in	O
Singapore	O
.	O

This	O
chapter	O
focuses	O
on	O
some	O
of	O
the	O
known	O
features	O
and	O
presents	O
some	O
current	O
questions	O
regarding	O
genome	O
replication	O
strategy	O
,	O
the	O
cis	B-DISO
-	O
acting	O
elements	O
necessary	O
for	O
genome	O
replication	O
[	O
as	O
inferred	O
from	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
molecules	O
],	O
the	O
minimum	O
sequence	O
requirements	O
for	O
autonomous	O
replication	O
of	O
an	O
RNA	O
replicon	O
,	O
and	O
the	O
importance	O
of	O
gene	O
order	O
in	O
genome	O
replication	O
.	O

With	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
genome	O
the	O
efficient	O
(>	O
40	O
microg	O
per	O
106	O
cells	O
)	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	O
of	O
the	O
foreign	O
genes	O
has	O
been	O
shown	O
.	O

In	O
addition	O
,	O
there	O
may	O
be	O
a	O
demand	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
antigens	O
,	O
hepatitis	B-DISO
A	I-DISO
,	O
B	O
and	O
C	O
viral	O
-	O
selected	O
antigens	O
,	O
HIV	B-DISO
retroviral	O
antigens	O
,	O
influenza	B-DISO
antigens	O
,	O
trypanosomal	O
antigens	O
,	O
and	O
foot	B-DISO
and	I-DISO
mouth	I-DISO
disease	I-DISO
antigens	O
.	O

Screening	O
of	O
400	O
NPAs	O
,	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
from	O
patients	O
with	O
respiratory	O
illness	O
during	O
the	O
SARS	B-DISO
period	O
identified	O
the	O
presence	O
of	O
CoV	O
-	O
HKU1	O
RNA	O
in	O
an	O
additional	O
specimen	O
,	O
with	O
a	O
viral	O
load	O
of	O
1	O
.	O
13	O
x	O
10	O
(	O
6	O
)	O
copies	O
per	O
ml	O
,	O
from	O
a	O
35	O
-	O
year	O
-	O
old	O
woman	O
with	O
pneumonia	B-DISO
.	O

The	O
pathogenic	O
phenomena	O
described	O
here	O
likely	O
bear	O
relevance	O
to	O
other	O
severe	O
coronavirus	B-DISO
infections	I-DISO
,	O
in	O
particular	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
for	O
which	O
multiphasic	O
disease	B-DISO
progression	I-DISO
and	O
acute	O
T	O
-	O
cell	O
lymphopenia	B-DISO
have	O
also	O
been	O
reported	O
.	O

TITLE	O
:	O
Effect	O
of	O
soluble	O
porcine	O
aminopeptidase	O
N	O
on	O
antibody	O
production	O
against	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
quantitative	O
assessment	O
from	O
chest	O
radiographs	O
with	O
clinical	O
and	O
prognostic	O
correlation	O
.	O

Three	O
radiologists	O
who	O
were	O
blinded	O
to	O
the	O
identity	O
,	O
diagnosis	O
,	O
treatment	O
protocol	O
,	O
and	O
outcome	O
of	O
each	O
patient	O
independently	O
evaluated	O
serial	O
chest	O
radiographs	O
from	O
67	O
patients	O
with	O
confirmed	O
SARS	B-DISO
.	O

TITLE	O
:	O
Lipids	O
in	O
the	O
nutritional	O
support	O
of	O
the	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
the	O
debate	O
concerning	O
the	O
use	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
as	O
opposed	O
to	O
physical	O
mixtures	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
specifically	O
regarding	O
their	O
effects	O
on	O
gas	O
exchange	O
and	O
pulmonary	O
hemodynamics	O
,	O
still	O
remains	O
unresolved	O
.	O

Studies	O
suggest	O
that	O
lipid	O
use	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
may	O
be	O
improved	O
by	O
increased	O
knowledge	O
of	O
genetic	O
determinants	O
of	O
severity	O
of	O
injury	O
and	O
response	O
to	O
therapeutic	O
agents	O
as	O
well	O
as	O
by	O
the	O
development	O
of	O
tools	O
that	O
allow	O
better	O
timing	O
of	O
immunonutritional	O
intervention	O
.	O

Overall	O
,	O
lipids	O
,	O
in	O
particular	O
n	O
-	O
3	O
fatty	O
acids	O
,	O
emerge	O
as	O
powerful	O
nutrients	O
with	O
pharmacologic	O
properties	O
potentially	O
improving	O
prognosis	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Consequently	O
,	O
larger	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISO
trials	O
with	O
comparable	O
methodologies	O
are	O
necessary	O
for	O
detailed	O
evaluation	O
of	O
the	O
pharmacologic	O
impact	O
of	O
lipids	O
.	O

Current	O
trends	O
in	O
the	O
management	O
of	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
consist	O
of	O
maintaining	O
acceptable	O
gas	O
exchange	O
while	O
limiting	O
ventilator	O
-	O
associated	O
lung	O
injury	O
.	O

Mechanical	O
ventilation	O
with	O
airway	O
pressure	O
release	O
ventilation	O
permits	O
spontaneous	O
breathing	O
throughout	O
the	O
entire	O
respiratory	O
cycle	O
,	O
improves	O
patient	O
comfort	O
,	O
reduces	O
the	O
use	O
of	O
sedation	B-DISO
,	O
and	O
may	O
reduce	O
ventilator	O
days	O
.	O

Good	O
outcome	O
was	O
defined	O
as	O
discharge	O
by	O
day	O
22	O
following	O
the	O
onset	O
of	O
SARS	B-DISO
symptoms	O
.	O

TITLE	O
:	O
Clinical	O
manifestations	O
of	O
two	O
cases	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
I	O
-	O
Lan	B-DISO
County	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
respiratory	O
tract	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

As	O
SARS	B-DISO
becomes	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
in	O
the	O
21st	O
century	O
,	O
its	O
clinical	O
manifestations	O
and	O
treatment	O
will	O
be	O
discussed	O
.	O

The	O
evolution	O
of	O
these	O
viral	B-DISO
diseases	I-DISO
was	O
probably	O
not	O
directly	O
affected	O
by	O
climate	O
change	O
.	O

These	O
infections	B-DISO
concern	O
human	O
but	O
also	O
animal	O
viruses	O
affecting	O
wild	O
or	O
tame	O
animals	O
.	O

TITLE	O
:	O
RT	O
-	O
PCR	O
-	O
based	O
dot	O
blot	O
hybridization	O
for	O
the	O
detection	O
and	O
differentiation	O
between	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
fecal	O
samples	O
using	O
a	O
non	O
-	O
radioactive	O
digoxigenin	O
cDNA	O
probe	O
.	O

Reverse	O
genetics	O
system	O
for	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Guidelines	O
issued	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
the	O
World	O
Health	O
Organization	O
state	O
that	O
healthcare	O
workers	O
should	O
wear	O
N95	O
masks	O
or	O
higher	O
-	O
level	O
protection	O
during	O
all	O
contact	O
with	O
suspected	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Three	O
epidemiologically	O
relevant	O
microbes	O
are	O
the	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)-	O
associated	O
coronavirus	O
,	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
and	O
Clostridium	O
difficile	O
(	O
C	O
.	O
difficile	O
).	O

TITLE	O
:	O
Surgical	O
treatment	O
of	O
tracheoesophageal	B-DISO
fistula	I-DISO
in	O
a	O
patient	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
complicated	O
with	O
extensive	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

She	O
was	O
intubated	O
for	O
ventilatory	O
support	O
3	O
days	O
after	O
admission	O
because	O
of	O
progressive	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
patient	O
was	O
previously	O
healthy	O
and	O
acquired	O
SARS	B-DISO
from	O
close	O
contact	O
with	O
an	O
infected	O
family	O
member	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
complete	O
genomic	O
sequence	O
of	O
rare	O
isolates	O
(	O
minor	O
genotype	O
)	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
from	O
SARS	B-DISO
patients	O
in	O
Guangdong	O
,	O
China	O
,	O
where	O
the	O
first	O
few	O
cases	O
emerged	O
.	O

Phylogenetic	O
tree	O
building	O
based	O
on	O
the	O
variations	O
of	O
the	O
M	O
protein	O
appears	O
to	O
support	O
the	O
non	O
-	O
human	O
origin	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
To	O
investigate	O
its	O
immunogenicity	O
,	O
we	O
synthesized	O
eight	O
oligopeptides	O
covering	O
69	O
.	O
2	O
%	O
of	O
the	O
entire	O
ORF	O
and	O
screened	O
them	O
by	O
using	O
ELISA	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
with	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
The	O
structure	O
analysis	O
and	O
antigenicity	O
study	O
of	O
the	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
Coronaviridae	O
family	O
is	O
characterized	O
by	O
a	O
nucleocapsid	O
that	O
is	O
composed	O
of	O
the	O
genome	O
RNA	O
molecule	O
in	O
combination	O
with	O
the	O
nucleoprotein	O
(	O
N	O
protein	O
)	O
within	O
a	O
virion	O
.	O

The	O
substitution	O
rate	O
of	O
the	O
R	O
protein	O
is	O
close	O
to	O
the	O
average	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
.	O

ABSTRACT	O
:	O
The	O
article	O
discusses	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
an	O
important	O
disease	O
frequently	O
seen	O
in	O
veterinary	O
practice	O
.	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
review	O
recent	O
knowledge	O
and	O
to	O
increase	O
understanding	O
of	O
the	O
complex	O
pathogenesis	B-DISO
of	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Pena	B-DISO
-	I-DISO
Shokeir	I-DISO
syndrome	I-DISO
is	O
a	O
rare	O
,	O
autosomal	O
-	O
recessive	O
disorder	O
that	O
usually	O
affects	O
newborns	O
.	O

Whether	O
the	O
N	O
protein	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
antigenic	O
remains	O
to	O
be	O
elucidated	O
.	O

ABSTRACT	O
:	O
In	O
the	O
face	B-DISO
of	O
the	O
worldwide	O
threat	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
human	O
life	O
,	O
some	O
of	O
the	O
most	O
urgent	O
challenges	O
are	O
to	O
develop	O
fast	O
and	O
accurate	O
analytical	O
methods	O
for	O
early	O
diagnosis	O
of	O
this	O
disease	O
as	O
well	O
as	O
to	O
create	O
a	O
safe	O
anti	O
-	O
viral	O
vaccine	O
for	O
prevention	O
.	O

Using	O
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
),	O
these	O
peptides	O
were	O
screened	O
in	O
the	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

The	O
analysis	O
of	O
TRS	B-DISO
supports	O
the	O
minus	O
strand	O
extending	O
transcription	O
mechanism	O
of	O
coronavirus	O
.	O

The	O
results	O
indicated	O
that	O
the	O
multiplex	O
PCR	O
technique	O
could	O
be	O
applied	O
to	O
detect	O
the	O
SARS	B-DISO
-	O
CoV	O
specific	O
target	O
cDNA	O
fragments	O
successfully	O
.	O

ABSTRACT	O
:	O
The	O
sudden	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2002	O
prompted	O
the	O
establishment	O
of	O
a	O
global	O
scientific	O
network	O
subsuming	O
most	O
of	O
the	O
traditional	O
rivalries	O
in	O
the	O
competitive	O
field	O
of	O
virology	O
.	O

Within	O
months	O
of	O
the	O
SARS	B-DISO
outbreak	O
,	O
collaborative	O
work	O
revealed	O
the	O
identity	O
of	O
the	O
disastrous	O
pathogen	O
as	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Antibodies	O
against	O
SARS	B-DISO
virus	O
were	O
screened	O
by	O
biopanning	O
with	O
immobilized	O
virus	O
antigen	O
.	O

Human	O
phage	O
antibody	O
library	O
against	O
SARS	B-DISO
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	O
anti	O
-	O
SARS	B-DISO
virus	O
antibodies	O
were	O
obtained	O
.	O

N	O
protein	O
expressed	O
in	O
E	O
.	O
coli	O
was	O
recovered	O
from	O
SDS	B-DISO
-	O
PAGE	O
gel	O
and	O
served	O
as	O
immunogen	O
in	O
the	O
preparation	O
of	O
the	O
mAb	O
.	O

And	O
the	O
expressions	O
of	O
TCR	O
Vbeta4	O
,	O
Vbeta22	O
and	O
Vbeta23	O
in	O
SARS	B-DISO
patients	O
treated	O
with	O
glucocorticoid	O
(>	O
1	O
000	O
U	O
)	O
were	O
higher	O
than	O
those	O
in	O
SARS	B-DISO
patients	O
without	O
treatment	O
.	O

ABSTRACT	O
:	O
We	O
have	O
solved	O
the	O
three	O
-	O
dimensional	O
crystal	O
structure	O
of	O
the	O
stem	O
-	O
loop	O
II	O
motif	O
(	O
s2m	O
)	O
RNA	O
element	O
of	O
the	O
SARS	B-DISO
virus	O
genome	O
to	O
2	O
.	O
7	O
-	O
A	O
resolution	O
.	O

Here	O
we	O
have	O
extended	O
this	O
approach	O
to	O
RNA	O
by	O
proposing	O
potential	O
functions	O
for	O
a	O
rigorously	O
conserved	O
set	O
of	O
RNA	O
tertiary	O
structural	O
interactions	O
that	O
occur	O
within	O
the	O
SARS	B-DISO
RNA	O
genome	O
itself	O
.	O

(	O
2	O
)	O
Specific	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
assayed	O
with	O
two	O
methods	O
,	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
for	O
detecting	O
IgG	O
antibodies	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
mixed	O
antibodies	O
.	O

According	O
to	O
our	O
survey	O
,	O
there	O
was	O
no	O
latent	B-DISO
infection	I-DISO
among	O
close	O
contacts	O
.	O

Potential	O
possibility	O
of	O
aerosol	O
transmission	O
might	O
exist	O
within	O
1	O
meter	O
square	O
area	O
around	O
SARS	B-DISO
patients	O
.	O

Six	O
strains	O
of	O
hybridomas	O
that	O
produced	O
the	O
monoclonal	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
obtained	O
.	O

Brown	O
particles	O
were	O
seen	O
in	O
macrophages	O
and	O
pneumocytes	O
in	O
autopsy	O
lung	O
tissues	O
from	O
SARS	B-DISO
patients	O
.	O

The	O
recommendations	O
in	O
the	O
CDC	O
document	O
were	O
based	O
on	O
some	O
of	O
the	O
important	O
lessons	O
learned	O
in	O
healthcare	O
settings	O
around	O
the	O
world	O
during	O
the	O
SARS	B-DISO
outbreak	O
of	O
2003	O
,	O
including	O
that	O
(	O
1	O
)	O
a	O
SARS	B-DISO
outbreak	O
requires	O
a	O
coordinated	O
and	O
dynamic	O
response	O
by	O
multiple	O
groups	O
;	O
(	O
2	O
)	O
unrecognized	O
cases	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
are	O
a	O
significant	O
source	O
of	O
transmission	O
;	O
(	O
3	O
)	O
restricting	O
access	O
to	O
the	O
healthcare	O
facility	O
can	O
minimize	O
transmission	O
;	O
(	O
4	O
)	O
airborne	O
infection	B-DISO
isolation	O
is	O
recommended	O
,	O
but	O
facilities	O
and	O
equipment	O
may	O
not	O
be	O
available	O
;	O
and	O
(	O
5	O
)	O
staffing	O
needs	O
and	O
support	O
will	O
pose	O
a	O
significant	O
challenge	O
.	O

Healthcare	O
facilities	O
were	O
at	O
the	O
center	O
of	O
the	O
SARS	B-DISO
outbreak	O
of	O
2003	O
and	O
played	O
a	O
key	O
role	O
in	O
controlling	O
the	O
epidemic	O
.	O

Recommendations	O
in	O
the	O
CDC	O
'	O
s	O
SARS	B-DISO
preparedness	O
and	O
response	O
guidance	O
for	O
healthcare	O
facilities	O
will	O
help	O
facilities	O
prepare	O
for	O
possible	O
future	O
outbreaks	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Rapid	O
creation	O
of	O
a	O
temporary	O
isolation	O
ward	O
for	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Taiwan	O
.	O

Of	O
the	O
34	O
patients	O
with	O
probable	O
SARS	B-DISO
,	O
13	O
were	O
transferred	O
to	O
medical	O
centers	O
to	O
receive	O
mechanical	O
ventilation	O
due	O
to	O
rapid	O
deterioration	O
of	O
chest	O
x	O
-	O
ray	O
results	O
,	O
and	O
three	O
patients	O
died	O
of	O
SARS	B-DISO
despite	O
intensive	O
therapy	O
in	O
medical	O
centers	O
.	O

Twenty	O
-	O
three	O
percent	O
of	O
Hong	O
Kong	O
and	O
11	O
.	O
9	O
%	O
of	O
Singapore	O
respondents	O
believed	O
that	O
they	O
were	O
""""	O
very	O
likely	O
""""	O
or	O
""""	O
somewhat	O
likely	O
""""	O
to	O
contract	O
SARS	B-DISO
during	O
the	O
current	O
outbreak	O
(	O
P	O
<	O
.	O
001	O
).	O

TITLE	O
:	O
Limitations	O
of	O
forehead	O
infrared	O
body	O
temperature	O
detection	O
for	O
fever	O
screening	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
airflow	O
obstruction	B-DISO
is	O
a	O
common	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

The	O
ventilatory	O
pattern	O
should	O
be	O
directed	O
toward	O
minimizing	O
dynamic	O
hyperinflation	B-DISO
and	O
auto	B-DISO
-	I-DISO
PEEP	I-DISO
by	O
using	O
small	O
tidal	O
volume	O
and	O
preserving	O
expiratory	O
time	O
.	O

LSA	B-DISO
and	O
vertebral	O
column	O
neoplasia	B-DISO
were	O
the	O
most	O
common	O
diseases	O
affecting	O
cats	O
between	O
2	O
and	O
8	O
years	O
of	O
age	O
.	O

Results	O
of	O
this	O
histopathologic	O
study	O
showed	O
that	O
FIP	B-DISO
and	O
LSA	B-DISO
were	O
the	O
most	O
common	O
disease	O
processes	O
affecting	O
the	O
spinal	O
cord	B-DISO
of	O
cats	O
.	O

The	O
intent	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
recovery	O
of	O
individuals	O
who	O
had	O
been	O
hospitalized	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
the	O
year	O
following	O
their	O
discharge	O
from	O
the	O
hospital	O
.	O

In	O
addition	O
,	O
we	O
explored	O
the	O
incidence	O
of	O
femoral	O
head	O
necrosis	O
in	O
some	O
of	O
the	O
individuals	O
recovering	O
from	O
SARS	B-DISO
.	O

The	O
subjects	O
of	O
this	O
study	O
were	O
383	O
clinically	O
diagnosed	O
SARS	B-DISO
patients	O
in	O
Beijing	O
,	O
China	O
.	O

Some	O
patients	O
who	O
complained	O
of	O
joint	B-DISO
pain	I-DISO
were	O
given	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
examinations	O
of	O
their	O
femoral	O
heads	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
individuals	O
who	O
had	O
lung	B-DISO
fibrosis	I-DISO
showed	O
some	O
spontaneous	O
recovery	O
.	O

TITLE	O
:	O
[	O
The	O
genome	O
comparison	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
other	O
coronaviruses	O
].	O

ABSTRACT	O
:	O
High	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
)	O
is	O
a	O
novel	O
late	O
mediator	O
of	O
inflammatory	B-DISO
responses	I-DISO
that	O
contributes	O
to	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
sepsis	B-DISO
-	O
associated	O
lethality	O
.	O

Although	O
acute	O
lung	O
injury	O
is	O
a	O
frequent	O
complication	B-DISO
of	O
severe	O
blood	B-DISO
loss	I-DISO
,	O
the	O
contribution	O
of	O
HMGB1	O
to	O
organ	O
system	O
dysfunction	O
in	O
this	O
setting	O
has	O
not	O
been	O
investigated	O
.	O

After	O
hemorrhage	B-DISO
,	O
in	O
addition	O
to	O
positively	O
staining	O
endothelial	O
cells	O
and	O
macrophages	O
,	O
neutrophils	O
expressing	O
HMGB1	O
were	O
present	O
in	O
the	O
lungs	O
.	O

Plasma	O
concentrations	O
of	O
HMGB1	O
also	O
increased	O
after	O
hemorrhage	B-DISO
.	O

TITLE	O
:	O
Duration	O
of	O
RT	O
-	O
PCR	O
positivity	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Decreased	O
production	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
ARDS	B-DISO
may	O
favour	O
vascular	B-DISO
lesions	I-DISO
,	O
since	O
VEGF	O
promotes	O
endothelial	O
survival	O
by	O
inhibiting	O
apoptosis	O
.	O

SARS	B-DISO
manifests	O
clinically	O
as	O
atypical	B-DISO
pneumonia	I-DISO
and	O
ranges	O
in	O
severity	O
from	O
minor	O
nonspecific	O
symptoms	O
to	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
main	O
clinical	O
manifestations	O
were	O
fever	O
,	O
cough	B-DISO
,	O
minor	O
or	O
serious	O
dyspnea	B-DISO
,	O
nausea	B-DISO
,	O
signs	O
of	O
injury	O
to	O
other	O
organs	O
,	O
and	O
so	O
on	O
.	O

The	O
treatment	O
regiments	O
included	O
oxygen	O
,	O
small	O
dosage	O
and	O
short	O
period	O
of	O
methylprednisolone	O
(	O
1	O
to	O
2	O
mg	O
/	O
kg	O
),	O
use	O
of	O
ventilator	O
,	O
psychological	B-DISO
intervention	O
,	O
and	O
treatment	O
of	O
underlying	O
diseases	O
,	O
after	O
which	O
,	O
all	O
the	O
7	O
patients	O
recovered	O
.	O

TITLE	O
:	O
[	O
Potent	O
neutralization	O
antibody	O
elicited	O
in	O
mice	O
by	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
spike	O
protein	O
S1	O
domain	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
related	O
factors	O
of	O
the	O
X	O
-	O
ray	O
outcomes	O
in	O
recovered	O
SARS	B-DISO
patients	O
.	O

RESULTS	O
:	O
Among	O
all	O
the	O
patients	O
with	O
abnormal	O
X	O
-	O
ray	O
result	O
,	O
19	O
were	O
male	O
(	O
54	O
.	O
29	O
%),	O
16	O
(	O
45	O
.	O
71	O
%)	O
were	O
female	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
7	O
(	O
58	O
.	O
33	O
%)	O
were	O
above	O
the	O
age	O
of	O
45	O
;	O
28	O
(	O
34	O
.	O
57	O
%)	O
were	O
below	O
the	O
age	O
of	O
45	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
hyperpyrexia	B-DISO
(>/=	O
39	O
),	O
26	O
(	O
50	O
.	O
00	O
%),	O
below	O
39	O
,	O
9	O
(	O
21	O
.	O
95	O
%);	O
multiple	O
-	O
lesion	O
,	O
22	O
(	O
52	O
.	O
38	O
%),	O
mono	B-DISO
-	O
lesion	O
,	O
13	O
(	O
25	O
.	O
49	O
%),	O
P	O
<	O
0	O
.	O
01	O
;	O
glucocorticoid	O
administration	O
time	O
within	O
5	O
days	O
,	O
22	O
(	O
38	O
.	O
60	O
%)	O
after	O
5	O
days	O
,	O
12	O
(	O
33	O
.	O
33	O
%),	O
P	O
>	O
0	O
.	O
01	O
;	O
within	O
7	O
days	O
,	O
21	O
(	O
30	O
.	O
00	O
%),	O
after	O
7	O
days	O
,	O
14	O
(	O
60	O
.	O
87	O
%),	O
P	O
<	O
0	O
.	O
01	O
.	O

TITLE	O
:	O
Prokaryotic	O
expression	O
,	O
refolding	O
,	O
and	O
purification	O
of	O
fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
S450	O
-	O
650	O
was	O
expressed	O
with	O
a	O
histidine	O
tag	B-DISO
in	O
Escherichia	O
coli	O
BL21	O
.	O

We	O
report	O
a	O
16	O
-	O
year	O
-	O
old	O
adolescent	O
with	O
SARS	B-DISO
who	O
presented	O
with	O
diarrhoea	B-DISO
.	O

Treatment	O
directed	O
against	O
SARS	B-DISO
was	O
prompted	O
by	O
an	O
epidemiological	O
link	O
and	O
the	O
clinical	O
picture	O
as	O
the	O
disease	O
evolved	O
.	O

TITLE	O
:	O
Susceptibility	O
of	O
different	O
eukaryotic	O
cell	O
lines	O
to	O
SARS	B-DISO
-	O
coronavirus	O
.	O

TITLE	O
:	O
Fulminant	O
varicella	B-DISO
infection	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
in	O
an	O
immunocompetent	O
young	O
adult	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
on	O
CXCL8	O
(	O
interleukin	O
8	O
)	O
and	O
CXCL10	O
(	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	O
10	O
)	O
in	O
human	O
intestinal	O
epithelial	O
(	O
Caco2	O
)	O
cells	O
.	O

Western	O
blot	O
and	O
indirect	O
fluorescence	O
assay	O
showed	O
that	O
the	O
McAbs	O
reacted	O
specifically	O
with	O
nucleocapsid	O
protein	O
and	O
SARS	B-DISO
-	O
CoV	O
.	O
Among	O
the	O
six	O
McAbs	O
,	O
three	O
recognize	O
the	O
epitopes	O
located	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
protein	O
,	O
whereas	O
the	O
others	O
reacted	O
with	O
those	O
located	O
in	O
the	O
C	O
-	O
terminus	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
levels	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
IgG	O
antibody	O
of	O
SARS	B-DISO
patients	O
,	O
people	O
who	O
closely	O
contacted	O
SARS	B-DISO
patients	O
and	O
normal	O
subjects	O
in	O
Gansu	O
province	O
.	O

RESULTS	O
:	O
SARS	B-DISO
coronavirus	O
IgG	O
antibody	O
was	O
detected	O
positive	O
in	O
6	O
of	O
the	O
9	O
patients	O
,	O
it	O
was	O
still	O
positive	O
in	O
the	O
sera	O
twelve	O
months	O
after	O
recovery	O
;	O
1	O
of	O
the	O
closely	O
contacted	O
persons	O
and	O
3	O
normal	O
subjects	O
were	O
found	O
positive	O
.	O

He	O
was	O
diagnosed	O
as	O
having	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
severe	O
pneumonia	B-DISO
,	O
and	O
was	O
treated	O
with	O
pulse	O
methylprednisolone	O
and	O
sivelestat	O
sodium	O
in	O
combination	O
with	O
intravenous	O
erythromycin	O
and	O
ciprofloxacin	O
.	O

It	O
is	O
suggested	O
that	O
administration	O
of	O
methylprednisolone	O
and	O
sivelestat	O
sodium	O
in	O
combination	O
with	O
intravenous	O
erythromycin	O
and	O
ciprofloxacin	O
in	O
a	O
case	O
of	O
severe	O
Legionella	B-DISO
pneumonia	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
effective	O
,	O
and	O
may	O
be	O
of	O
use	O
in	O
similar	O
cases	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
this	O
mode	O
for	O
disease	B-DISO
transmission	I-DISO
is	O
capable	O
of	O
spreading	O
a	O
fatal	O
disease	O
such	O
as	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
over	O
a	O
wide	O
area	O
.	O

TITLE	O
:	O
Increased	O
sensitivity	O
of	O
SARS	B-DISO
-	O
coronavirus	O
to	O
a	O
combination	O
of	O
human	O
type	O
I	O
and	O
type	O
II	O
interferons	O
.	O

These	O
peptides	O
strongly	O
partitioned	O
into	O
lipid	O
membranes	O
and	O
induced	O
lipid	O
vesicle	B-DISO
permeabilization	O
at	O
peptide	O
/	O
lipid	O
ratios	O
of	O
1	O
:	O
100	O
in	O
two	O
independent	O
leakage	B-DISO
assays	O
.	O

Because	O
a	O
resurgence	O
of	O
the	O
SARS	B-DISO
epidemic	O
is	O
constantly	O
possible	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
understand	O
the	O
involvement	O
of	O
the	O
digestive	O
system	O
in	O
this	O
new	O
disease	O
.	O

Several	O
genes	O
were	O
highly	O
up	O
-	O
regulated	O
in	O
patients	O
with	O
SARS	B-DISO
,	O
such	O
as	O
,	O
the	O
genes	O
coding	O
for	O
Lactoferrin	O
,	O
S100A9	O
and	O
Lipocalin	O
2	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
the	O
SARS	B-DISO
catastrophe	O
on	O
an	O
urban	O
ED	O
.	O

The	O
patients	O
'	O
characteristics	O
in	O
an	O
urban	O
ED	O
were	O
collected	O
from	O
March	O
to	O
May	O
2003	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
.	O

This	O
newly	O
discovered	O
virus	O
may	O
have	O
worldwide	O
distribution	O
and	O
may	O
account	O
for	O
a	O
significant	O
proportion	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
infants	O
and	O
young	O
children	O
.	O

SARS	B-DISO
infection	B-DISO
threatens	O
the	O
physical	O
and	O
emotional	O
health	O
of	O
nurses	O
.	O

Interferon	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	B-DISO
,	O
and	O
remained	O
at	O
a	O
high	O
level	O
until	O
convalescence	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
enzymatic	O
activity	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
and	O
its	O
four	O
site	O
-	O
directed	O
mutants	O
.	O

Until	O
recently	O
,	O
traditional	O
approaches	O
to	O
mechanical	O
ventilatory	O
support	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
have	O
called	O
for	O
adaptation	O
of	O
the	O
patient	O
to	O
the	O
mechanical	O
ventilator	O
using	O
heavy	O
sedation	B-DISO
and	O
administration	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
.	O

Global	O
threats	O
from	O
indoor	O
and	O
outdoor	O
air	O
pollution	O
,	O
urban	O
crowding	B-DISO
,	O
biologic	O
weapons	O
,	O
and	O
worldwide	O
rapid	O
transportation	O
complicate	O
our	O
efforts	O
to	O
reduce	O
the	O
impact	O
of	O
LRI	O
disease	O
in	O
children	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
a	O
year	O
in	O
review	O
.	O

Results	O
revealed	O
fluctuations	B-DISO
in	O
state	B-DISO
anxiety	I-DISO
across	O
time	O
points	O
.	O

ABSTRACT	O
:	O
Pathogens	O
causing	O
bovine	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
Finland	O
were	O
investigated	O
.	O

Eighteen	O
cattle	O
herds	O
with	O
bovine	O
respiratory	B-DISO
disease	I-DISO
were	O
included	O
.	O

According	O
to	O
serological	O
findings	O
,	O
PIV	O
-	O
3	O
,	O
BAV	B-DISO
-	O
7	O
,	O
BAV	B-DISO
-	O
3	O
,	O
BCV	O
and	O
BRSV	O
are	O
common	O
pathogens	O
in	O
Finnish	O
cattle	O
with	O
respiratory	B-DISO
problems	I-DISO
.	O

In	O
view	O
of	O
the	O
low	O
rate	O
of	O
false	O
-	O
positive	O
results	O
(	O
high	O
specificity	O
)	O
the	O
mRNA	O
RT	O
-	O
PCR	O
may	O
be	O
a	O
valuable	O
addition	O
to	O
the	O
diagnostic	O
arsenal	O
for	O
FIP	B-DISO
.	O

Group	O
1	O
(	O
FC	O
)	O
pigs	O
survived	O
9	O
days	O
and	O
showed	O
signs	O
of	O
sepsis	B-DISO
(	O
bacteremia	B-DISO
with	O
polymicrobial	O
organisms	O
),	O
an	O
inflammatory	B-DISO
response	I-DISO
in	O
the	O
form	O
of	O
elevated	O
cytokines	O
,	O
yet	O
no	O
physiologic	O
or	O
histologic	O
evidence	O
of	O
lung	O
injury	O
.	O

Group	O
2	O
(	O
SMA	B-DISO
+	O
FC	O
)	O
pigs	O
demonstrated	O
more	O
severe	B-DISO
sepsis	I-DISO
,	O
a	O
significantly	O
increased	O
cytokine	O
response	O
compared	O
with	O
animals	O
in	O
the	O
FC	O
group	O
,	O
and	O
physiologic	O
signs	O
of	O
progressive	O
pulmonary	O
injury	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
large	O
animal	O
experiment	O
that	O
definitively	O
and	O
consistently	O
causes	O
insidious	O
onset	O
ARDS	B-DISO
in	O
pigs	O
.	O

We	O
hypothesised	O
that	O
the	O
occurrence	O
of	O
alveolar	O
hyperinflation	B-DISO
during	O
the	O
application	O
of	O
PEEP	O
would	O
lead	O
to	O
an	O
increase	O
in	O
PaCO	O
(	O
2	O
)	O
responsible	O
for	O
a	O
rise	O
in	O
intracranial	O
pressure	O
.	O

Pulmonary	B-DISO
involvement	I-DISO
in	O
leptospirosis	B-DISO
was	O
present	O
in	O
urban	O
but	O
not	O
rural	O
areas	O
.	O

ABSTRACT	O
:	O
Findings	O
coming	O
from	O
autopsies	O
and	O
serum	O
of	O
SARS	B-DISO
patients	O
suggest	O
an	O
important	O
immune	O
-	O
inflammatory	O
implication	O
in	O
the	O
evolution	O
to	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
acute	B-DISO
renal	I-DISO
impairment	I-DISO
is	O
likely	O
to	O
be	O
related	O
to	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
rather	O
than	O
the	O
kidney	O
tropism	O
of	O
the	O
virus	O
.	O

The	O
development	O
of	O
acute	B-DISO
renal	I-DISO
impairment	I-DISO
is	O
an	O
important	O
negative	O
prognostic	O
indicator	O
for	O
survival	O
with	O
SARS	B-DISO
.	O

RESULTS	O
:	O
Among	O
these	O
536	O
patients	O
with	O
SARS	B-DISO
,	O
36	O
(	O
6	O
.	O
7	O
%)	O
developed	O
acute	B-DISO
renal	I-DISO
impairment	I-DISO
occurring	O
at	O
a	O
median	O
duration	O
of	O
20	O
days	O
(	O
range	O
5	O
-	O
48	O
days	O
)	O
after	O
the	O
onset	O
of	O
viral	B-DISO
infection	I-DISO
despite	O
a	O
normal	O
plasma	O
creatinine	O
level	O
at	O
first	O
clinical	O
presentation	O
.	O

The	O
initial	O
laboratory	O
tests	O
and	O
immunological	O
evaluation	O
confirmed	O
active	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
complicated	O
by	O
severe	B-DISO
pre	I-DISO
-	I-DISO
eclampsia	I-DISO
.	O

She	O
died	O
from	O
worsening	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
the	O
25th	O
day	O
.	O

Most	O
natural	O
infections	B-DISO
are	O
caused	O
by	O
enterotropic	O
strains	O
.	O

Based	O
on	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	O
subunit	O
,	O
all	O
Korean	O
WD	O
strains	O
clustered	O
with	O
the	O
respiratory	O
strain	O
OK	O
,	O
BCQ3994	O
and	O
the	O
enteric	O
strain	O
LY	O
-	O
138	O
,	O
while	O
the	O
Canadian	O
BCQ	O
calf	O
diarrhea	B-DISO
and	O
WD	O
strains	O
,	O
and	O
the	O
American	O
RBCV	O
LSU	O
,	O
French	O
EBCV	O
F15	O
and	O
avirulent	O
VACC	O
,	O
L9	O
,	O
and	O
Mebus	O
strains	O
clustered	O
on	O
a	O
separate	O
major	O
branch	O
.	O

Regulation	O
of	O
transcription	O
in	O
coronaviruses	O
has	O
been	O
studied	O
by	O
reverse	O
-	O
genetics	O
analysis	O
of	O
the	O
sequences	O
immediately	O
flanking	O
a	O
unique	O
CS	O
in	O
the	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
genome	O
(	O
CS	O
-	O
S2	O
),	O
located	O
inside	O
the	O
S	O
gene	O
,	O
that	O
does	O
not	O
lead	O
to	O
detectable	O
amounts	O
of	O
the	O
corresponding	O
mRNA	O
,	O
in	O
spite	O
of	O
its	O
canonical	O
sequence	O
.	O

To	O
test	O
the	O
susceptibility	O
of	O
civets	O
to	O
experimental	O
infection	B-DISO
by	O
different	O
SARS	B-DISO
-	O
CoV	O
isolates	O
,	O
10	O
civets	O
were	O
inoculated	O
with	O
two	O
human	O
isolates	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
BJ01	O
(	O
with	O
a	O
29	O
-	O
nucleotide	O
deletion	O
)	O
and	O
GZ01	O
(	O
without	O
the	O
29	O
-	O
nucleotide	O
deletion	O
).	O

Cost	O
estimates	O
that	O
consider	O
only	O
excess	O
expenditures	O
may	O
considerably	O
underestimate	O
the	O
true	O
cost	O
of	O
infection	B-DISO
control	O
strategies	O
.	O

TITLE	O
:	O
Critical	O
roles	O
of	O
platelets	O
in	O
lipopolysaccharide	O
-	O
induced	O
lethality	O
:	O
effects	O
of	O
glycyrrhizin	O
and	O
possible	O
strategy	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Within	O
a	O
few	O
minutes	O
of	O
an	O
intravenous	O
injection	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
into	O
mice	O
,	O
platelets	O
accumulate	O
,	O
largely	O
in	O
the	O
lung	O
.	O

At	O
higher	O
doses	O
,	O
LPS	B-DISO
induces	O
rapid	O
shock	O
(	O
within	O
10	O
min	O
),	O
leading	O
to	O
death	O
within	O
1	O
h	O
.	O
This	O
type	O
of	O
shock	O
differs	O
from	O
so	O
-	O
called	O
endotoxin	O
shock	O
,	O
in	O
which	O
shock	O
signs	O
and	O
death	O
occur	O
several	O
hours	O
or	O
more	O
later	O
.	O

We	O
studied	O
changes	O
in	O
haematological	O
parameters	O
in	O
SARS	B-DISO
patients	O
using	O
median	O
values	O
analysed	O
according	O
to	O
the	O
day	O
of	O
symptom	B-DISO
onset	O
.	O

METHODS	O
:	O
Twelve	O
TCM	O
prescriptions	O
of	O
herbal	O
drugs	O
(	O
orally	O
or	O
i	O
.	O
v	O
.)	O
were	O
used	O
to	O
treat	O
16	O
cases	O
of	O
SARS	B-DISO
without	O
using	O
glucocorticoids	O
,	O
anti	O
-	O
viral	O
agents	O
,	O
immune	O
-	O
regulators	O
or	O
antibiotics	O
(	O
in	O
case	O
there	O
was	O
no	O
definite	O
bacterial	B-DISO
infections	I-DISO
).	O

Three	O
unique	O
detection	O
formats	O
were	O
developed	O
for	O
real	O
-	O
time	O
RNA	O
amplification	B-DISO
assays	O
:	O
a	O
post	O
amplification	B-DISO
detection	O
step	O
with	O
a	O
virus	O
-	O
specific	O
internal	O
capture	O
probe	O
based	O
on	O
Taqman	O
(	O
RT	O
-	O
PCR	O
TaqMan	O
assay	O
),	O
hybridization	O
probe	O
(	O
RT	O
-	O
PCR	O
hybridization	O
probe	O
assay	O
)	O
and	O
a	O
real	O
-	O
time	O
assay	O
with	O
virus	O
-	O
specific	O
molecular	O
beacon	O
probes	O
(	O
NASBA	O
-	O
Beacon	O
assay	O
).	O

TITLE	O
:	O
Three	O
-	O
dimensional	O
model	O
of	O
a	O
substrate	O
-	O
bound	O
SARS	B-DISO
chymotrypsin	O
-	O
like	O
cysteine	O
proteinase	O
predicted	O
by	O
multiple	O
molecular	O
dynamics	O
simulations	O
:	O
catalytic	O
efficiency	O
regulated	O
by	O
substrate	O
binding	O
.	O

The	O
protein	O
sequence	O
of	O
the	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinase	O
(	O
CCP	B-DISO
)	O
responsible	O
for	O
SARS	B-DISO
viral	O
replication	O
has	O
been	O
identified	O
as	O
a	O
target	O
for	O
developing	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

Here	O
,	O
I	O
report	O
the	O
ATVRLQ	O
(	O
p1	O
)	O
A	O
(	O
p1	O
')-	O
bound	O
CCP	B-DISO
3D	O
model	O
predicted	O
by	O
420	O
different	O
molecular	O
dynamics	O
simulations	O
(	O
2	O
.	O
0	O
ns	O
for	O
each	O
simulation	O
with	O
a	O
1	O
.	O
0	O
-	O
fs	O
time	O
step	O
).	O

TITLE	O
:	O
Myositis	B-DISO
,	O
lameness	B-DISO
,	O
and	O
recumbency	O
after	O
use	O
of	O
water	O
-	O
in	O
-	O
oil	O
adjuvanted	O
vaccines	O
in	O
near	O
-	O
term	O
beef	O
cattle	O
.	O

Histological	O
examination	O
revealed	O
pyogranulomatous	O
myositis	B-DISO
,	O
fibrosis	B-DISO
,	O
and	O
myonecrosis	B-DISO
.	O

In	O
summary	O
,	O
the	O
COPD	B-DISO
Roundtable	O
Group	O
supports	O
implementation	O
of	O
the	O
GOLD	O
strategy	O
for	O
the	O
diagnosis	O
,	O
management	O
and	O
prevention	O
of	O
COPD	B-DISO
in	O
the	O
Asia	O
-	O
Pacific	O
region	O
,	O
subject	O
to	O
the	O
additions	O
and	O
modifications	O
to	O
the	O
guidelines	O
suggested	O
above	O
.	O

Perceptions	O
of	O
comfort	O
,	O
ease	O
of	O
use	O
,	O
visual	O
,	O
hearing	O
,	O
breathing	O
and	O
speech	B-DISO
impairment	I-DISO
,	O
perceived	O
protection	O
against	O
SARS	B-DISO
and	O
usage	O
preferences	O
were	O
recorded	O
.	O

TITLE	O
:	O
Protective	O
effect	O
of	O
vaccination	O
in	O
chicks	O
with	O
local	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
against	O
field	O
virus	O
challenge	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
protease	O
inhibitors	O
design	O
using	O
virtual	O
screening	O
method	O
from	O
natural	O
products	O
libraries	O
.	O

ABSTRACT	O
:	O
Two	O
natural	O
products	O
databases	O
,	O
the	O
marine	O
natural	O
products	O
database	O
(	O
MNPD	O
)	O
and	O
the	O
traditional	O
Chinese	O
medicines	O
database	O
(	O
TCMD	O
),	O
were	O
used	O
to	O
find	O
novel	O
structures	O
of	O
potent	O
SARS	B-DISO
-	O
CoV	O
protease	O
inhibitors	O
through	O
virtual	O
screening	O
.	O

Annual	O
rates	O
of	O
influenza	B-DISO
in	O
children	O
may	O
be	O
1	O
.	O
5	O
to	O
3	O
times	O
those	O
in	O
the	O
adult	O
population	O
,	O
and	O
infection	B-DISO
rates	O
during	O
a	O
community	O
epidemic	O
may	O
exceed	O
40	O
%	O
in	O
preschool	O
-	O
aged	O
children	O
and	O
30	O
%	O
in	O
school	O
-	O
aged	O
children	O
.	O

Infected	O
children	O
also	O
play	O
a	O
central	O
role	O
in	O
disseminating	O
influenza	B-DISO
,	O
as	O
they	O
are	O
the	O
major	O
point	O
of	O
entry	O
for	O
the	O
virus	O
into	O
the	O
household	O
,	O
from	O
which	O
adults	O
spread	O
disease	O
into	O
the	O
community	O
.	O

Both	O
birds	O
and	O
a	O
super	O
flu	B-DISO
could	O
bring	O
about	O
the	O
end	O
of	O
civilization	O
as	O
we	O
know	O
it	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
demographic	O
characteristics	O
between	O
CLD	B-DISO
with	O
RDS	O
and	O
CLD	B-DISO
without	O
RDS	O
.	O

Although	O
CLD	B-DISO
without	O
RDS	O
was	O
still	O
less	O
common	O
than	O
CLD	B-DISO
with	O
RDS	O
,	O
it	O
comprised	O
over	O
a	O
third	O
of	O
all	O
cases	O
of	O
CLD	B-DISO
in	O
our	O
study	O
.	O

Clinical	O
characteristics	O
and	O
chronic	O
oxygen	O
requirement	O
pattern	O
of	O
CLD	B-DISO
without	O
RDS	O
seems	O
to	O
be	O
less	O
severe	O
than	O
those	O
of	O
CLD	B-DISO
with	O
RDS	O
.	O

Chorioamnionitis	B-DISO
may	O
be	O
one	O
of	O
antecedents	O
of	O
CLD	B-DISO
without	O
RDS	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
RNA	O
in	O
plasma	O
during	O
the	O
course	O
of	O
infection	B-DISO
.	O

Acute	B-DISO
renal	I-DISO
failure	I-DISO
has	O
been	O
reported	O
in	O
patients	O
with	O
SARS	B-DISO
,	O
but	O
whether	O
cytokines	O
can	O
injure	O
renal	O
tubules	O
is	O
unknown	O
.	O

Sixty	O
patients	O
diagnosed	O
with	O
SARS	B-DISO
in	O
Taiwan	O
in	O
April	O
2003	O
were	O
studied	O
.	O

Sixteen	O
patients	O
(	O
26	O
.	O
7	O
%)	O
had	O
hypouricemia	B-DISO
(	O
UA	O
,	O
1	O
.	O
68	O
+/-	O
0	O
.	O
52	O
mg	O
/	O
dL	O
[	O
100	O
+/-	O

RESULTS	O
:	O
Sixteen	O
patients	O
(	O
26	O
.	O
7	O
%)	O
had	O
hypouricemia	B-DISO
(	O
UA	O
,	O
1	O
.	O
68	O
+/-	O
0	O
.	O
52	O
mg	O
/	O
dL	O
[	O
100	O
+/-	O

CONCLUSIONS	O
:	O
One	O
fourth	O
of	O
patients	O
with	O
SARS	B-DISO
developed	O
hypouricemia	B-DISO
,	O
which	O
might	O
result	O
from	O
a	O
defect	O
in	O
renal	O
UA	O
handling	O
and	O
was	O
associated	O
with	O
a	O
high	O
serum	O
IL	O
-	O
8	O
level	O
.	O

The	O
Beck	O
Anxiety	O
Inventory	O
,	O
the	O
Beck	O
Depression	B-DISO
Inventory	O
,	O
and	O
a	O
newly	O
developed	O
measure	O
,	O
the	O
SARS	B-DISO
Impact	O
Scale	O
(	O
SIS	O
),	O
were	O
mailed	O
to	O
453	O
Hong	O
Kong	O
Chinese	O
SARS	B-DISO
survivors	O
discharged	O
from	O
hospital	O
for	O
4	O
weeks	O
or	O
more	O
.	O

METHODS	O
:	O
The	O
Beck	O
Anxiety	O
Inventory	O
,	O
the	O
Beck	O
Depression	B-DISO
Inventory	O
,	O
and	O
a	O
newly	O
developed	O
measure	O
,	O
the	O
SARS	B-DISO
Impact	O
Scale	O
(	O
SIS	O
),	O
were	O
mailed	O
to	O
453	O
Hong	O
Kong	O
Chinese	O
SARS	B-DISO
survivors	O
discharged	O
from	O
hospital	O
for	O
4	O
weeks	O
or	O
more	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
posed	O
an	O
unprecedented	O
threat	O
and	O
a	O
great	O
challenge	O
to	O
health	O
professionals	O
in	O
Hong	O
Kong	O
.	O

The	O
study	O
reported	O
here	O
aimed	O
at	O
investigating	O
the	O
origin	O
of	O
stress	O
and	O
psychological	B-DISO
morbidity	O
among	O
frontline	O
healthcare	O
workers	O
in	O
response	O
to	O
this	O
catastrophe	O
.	O

Forty	O
-	O
two	O
percent	O
of	O
parents	O
feared	O
catching	B-DISO
an	O
infection	B-DISO
from	O
their	O
children	O
,	O
and	O
36	O
.	O
1	O
%	O
of	O
parents	O
feared	O
transmitting	O
HIV	B-DISO
to	O
their	O
children	O
.	O

Thus	O
,	O
the	O
novel	O
N	O
-	O
S	O
fusion	O
antigen	O
-	O
based	O
IFA	O
could	O
be	O
an	O
attractive	O
alternative	O
to	O
present	O
whole	O
-	O
virus	O
-	O
based	O
IFAs	O
for	O
the	O
diagnosis	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Furthermore	O
,	O
scientists	O
were	O
aware	O
of	O
compelling	O
evidence	O
pointing	O
to	O
the	O
emergence	O
of	O
new	O
CoV	O
strains	O
and	O
the	O
mutation	O
of	O
existing	O
strains	O
resulting	O
in	O
new	O
disease	O
syndromes	B-DISO
in	O
animals	O
,	O
but	O
the	O
evolution	O
and	O
disease	O
impact	O
of	O
CoVs	O
was	O
not	O
widely	O
appreciated	O
before	O
SARS	B-DISO
.	O

Risk	O
factors	O
for	O
infection	B-DISO
in	O
HCWs	O
included	O
lack	O
of	O
awareness	O
and	O
preparedness	O
when	O
the	O
disease	O
first	O
struck	B-DISO
,	O
poor	O
institutional	B-DISO
infection	I-DISO
control	O
measures	O
,	O
lack	O
of	O
training	O
in	O
infection	B-DISO
control	O
procedures	O
,	O
poor	O
compliance	O
with	O
the	O
use	O
of	O
personal	O
protection	O
equipment	O
(	O
PPE	O
),	O
exposure	O
to	O
high	O
-	O
risk	O
procedures	O
such	O
as	O
intubation	O
and	O
nebulization	O
,	O
and	O
exposure	O
to	O
unsuspected	O
SARS	B-DISO
patients	O
.	O

This	O
motif	O
is	O
missing	O
from	O
the	O
spike	O
protein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
resulting	O
in	O
high	O
level	O
of	O
surface	O
expression	O
of	O
the	O
spike	O
protein	O
when	O
it	O
is	O
expressed	O
on	O
its	O
own	O
in	O
vitro	O
.	O

Subsequent	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
,	O
using	O
the	O
enzymes	O
Acc	B-DISO
I	O
,	O
Alu	O
I	O
,	O
EcoR	O
I	O
and	O
Mbo	O
I	O
,	O
demonstrated	O
that	O
these	O
strains	O
could	O
be	O
divided	O
into	O
five	O
distinct	O
subgroups	O
and	O
that	O
the	O
same	O
MHV	O
strains	O
were	O
detected	O
from	O
closely	O
related	O
mouse	O
facilities	O
.	O

TITLE	O
:	O
Border	O
screening	O
for	O
SARS	B-DISO
.	O

In	O
spite	O
of	O
intensive	O
screening	O
,	O
no	O
SARS	B-DISO
cases	O
were	O
detected	O
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	B-DISO
-	O
CoV	O
immunoglobulin	O
G	O
in	O
healthcare	O
workers	O
,	O
Guangzhou	O
,	O
China	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
inapparent	B-DISO
infection	I-DISO
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
among	O
healthcare	O
workers	O
,	O
we	O
performed	O
a	O
serosurvey	O
to	O
test	O
for	O
immunoglobulin	O
(	O
Ig	O
)	O
G	O
antibodies	O
to	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
among	O
1	O
,	O
147	O
healthcare	O
workers	O
in	O
3	O
hospitals	O
that	O
admitted	O
SARS	B-DISO
patients	O
in	O
mid	O
-	O
May	O
2003	O
.	O

Low	O
level	O
of	O
immunity	O
among	O
unaffected	O
healthcare	O
workers	O
reinforces	O
the	O
need	O
for	O
adequate	O
personal	O
protection	O
and	O
other	O
infection	B-DISO
control	O
measures	O
in	O
hospitals	O
to	O
prevent	O
future	O
epidemics	O
.	O

ABSTRACT	O
:	O
We	O
report	O
11	O
cases	O
of	O
severe	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
in	O
Bikaner	O
(	O
western	O
India	O
).	O

TITLE	O
:	O
SARS	B-DISO
clinical	O
features	O
,	O
United	O
States	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
We	O
compared	O
the	O
clinical	O
features	O
of	O
8	O
U	O
.	O
S	O
.	O
case	O
-	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
65	O
controls	O
who	O
tested	O
negative	O
for	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

The	O
participants	O
collectively	O
reported	O
:	O
1	O
)	O
the	O
creation	O
of	O
four	O
new	O
HEICS	O
unit	O
leader	O
positions	O
and	O
corresponding	O
units	O
during	O
the	O
outbreak	O
,	O
including	O
the	O
infection	B-DISO
control	O
officer	O
(	O
administrative	O
section	O
)	O
and	O
SARS	B-DISO
assessment	O
,	O
isolation	O
,	O
and	O
critical	O
care	O
unit	O
leaders	O
(	O
operations	O
section	O
);	O
2	O
)	O
the	O
creation	O
of	O
six	O
new	O
HEICS	O
subunits	O
,	O
including	O
functional	O
areas	O
for	O
fever	O
screening	O
,	O
SARS	B-DISO
assessment	O
,	O
and	O
resuscitation	O
outside	O
the	O
hospital	O
,	O
and	O
SARS	B-DISO
patient	O
care	O
,	O
SARS	B-DISO
critical	O
care	O
,	O
and	O
employee	O
isolation	O
inside	O
the	O
hospital	O
;	O
and	O
3	O
)	O
the	O
performance	O
of	O
new	O
job	O
actions	O
related	O
to	O
infection	B-DISO
control	O
by	O
all	O
HEICS	O
unit	O
leaders	O
.	O

Response	O
activities	O
are	O
described	O
for	O
the	O
isolation	O
of	O
patients	O
;	O
contact	O
tracing	O
;	O
quarantine	O
of	O
contact	O
persons	O
;	O
fever	O
screening	O
for	O
inbound	O
and	O
outbound	O
passengers	O
at	O
the	O
airport	O
;	O
and	O
hospital	B-DISO
infection	I-DISO
control	O
as	O
assessed	O
by	O
mobile	O
SARS	B-DISO
containment	O
teams	O
.	O

In	O
this	O
outbreak	O
,	O
an	O
emergency	B-DISO
plan	B-DISO
consisted	O
of	O
patient	O
isolation	O
and	O
strict	O
hospital	B-DISO
infection	I-DISO
control	O
.	O

Since	O
then	O
,	O
much	O
progress	O
has	O
been	O
made	O
in	O
the	O
virological	O
and	O
molecular	O
characterization	O
of	O
the	O
proteins	O
encoded	O
by	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
,	O
which	O
contains	O
14	O
potential	O
open	O
reading	O
frames	O
(	O
ORFs	O
).	O

ABSTRACT	O
:	O
Transfusion	B-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
a	O
rare	O
but	O
potentially	O
severe	O
complication	B-DISO
of	I-DISO
blood	I-DISO
transfusion	I-DISO
,	O
manifested	O
by	O
pulmonary	B-DISO
oedema	I-DISO
,	O
fever	O
and	O
hypotension	O
.	O

Our	O
data	O
suggest	O
that	O
a	O
major	O
mechanism	O
for	O
neutralizing	O
SARS	B-DISO
-	O
CoV	O
likely	O
occurs	O
through	O
blocking	B-DISO
the	O
interaction	O
between	O
virus	O
and	O
the	O
cellular	O
receptor	O
ACE2	O
.	O

Thus	O
,	O
our	O
system	O
represents	O
a	O
versatile	O
and	O
universal	O
tool	O
to	O
study	O
all	O
aspects	O
of	O
MHV	O
molecular	O
biology	O
and	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
showed	O
the	O
association	O
of	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
accessory	O
protein	O
,	O
3a	O
,	O
with	O
plasma	O
membrane	O
and	O
intracellular	O
SCoV	O
particles	O
in	O
infected	O
cells	O
.	O

Current	O
knowledge	O
based	O
on	O
case	O
studies	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
the	O
four	O
cities	O
suggested	O
that	O
the	O
SARS	B-DISO
outbreaks	O
were	O
significantly	O
associated	O
with	O
the	O
temperature	O
and	O
its	O
variations	O
.	O

However	O
,	O
because	O
the	O
fallacy	O
and	O
the	O
uncontrolled	O
confounding	O
effects	O
might	O
have	O
biased	O
the	O
results	O
,	O
the	O
possibility	O
of	O
other	O
meteorological	O
factors	O
having	O
an	O
affect	O
on	O
the	O
SARS	B-DISO
outbreaks	O
deserves	O
further	O
investigation	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
SARS	B-DISO
cases	O
and	O
the	O
environmental	O
temperature	O
seven	O
days	O
before	O
the	O
onset	O
and	O
the	O
seven	O
day	O
time	O
lag	O
corresponds	O
well	O
with	O
the	O
known	O
incubation	O
period	O
for	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNV	B-DISO
)	O
infection	B-DISO
is	O
an	O
ongoing	O
seasonal	O
epidemic	O
.	O

We	O
correlated	O
the	O
MR	O
imaging	O
findings	O
with	O
the	O
clinical	O
presentations	O
and	O
outcomes	O
of	O
WNV	B-DISO
infection	B-DISO
.	O

Histopathology	O
suggests	O
that	O
acid	O
aspiration	B-DISO
induced	O
acute	O
lung	O
injury	O
can	O
be	O
effectively	O
treated	O
by	O
lidocaine	O
and	O
methylprednisolone	O
,	O
if	O
applied	O
early	O
.	O

TITLE	O
:	O
The	O
transmembrane	O
oligomers	O
of	O
coronavirus	O
protein	O
E	O
.	O
ABSTRACT	O
:	O
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
protein	O
E	O
(	O
SCoVE	O
)	O
and	O
its	O
homologs	O
in	O
other	O
coronaviruses	O
associate	O
through	O
their	O
putative	O
transmembrane	O
domain	O
to	O
form	O
homooligomeric	O
alpha	O
-	O
helical	O
bundles	O
in	O
vivo	O
.	O

In	O
support	O
of	O
this	O
,	O
we	O
have	O
observed	O
only	O
dimeric	O
,	O
trimeric	O
,	O
and	O
pentameric	O
aggregates	O
for	O
the	O
synthetic	O
transmembrane	O
domain	O
of	O
SARS	B-DISO
protein	O
E	O
in	O
SDS	B-DISO
.	O

The	O
health	O
department	O
can	O
use	O
these	O
data	O
to	O
track	O
and	O
characterize	O
the	O
temporal	O
and	O
geographic	O
spread	O
of	O
a	O
known	O
outbreak	O
or	O
demonstrate	O
the	O
absence	O
of	O
cases	O
during	O
the	O
same	O
period	O
(	O
e	O
.	O
g	O
.,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
]	O
or	O
anthrax	B-DISO
).	O

HASS	O
was	O
adapted	O
to	O
meet	O
changing	O
surveillance	O
needs	O
(	O
e	O
.	O
g	O
.,	O
surveillance	O
for	O
anthrax	B-DISO
,	O
smallpox	B-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
).	O

HASS	O
was	O
sensitive	O
enough	O
to	O
reflect	O
annual	O
increases	O
in	O
hospital	O
-	O
admission	O
rates	O
for	O
pneumonia	B-DISO
during	O
the	O
influenza	B-DISO
season	O
and	O
to	O
confirm	O
an	O
outbreak	O
of	O
gastrointestinal	O
illness	O
.	O

Follow	O
-	O
up	O
of	O
HASS	O
neurologic	O
-	O
admissions	O
reports	O
has	O
led	O
to	O
diagnosis	O
of	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
encephalitis	B-DISO
cases	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
glycyrrhizic	O
acid	O
derivatives	O
against	O
SARS	B-DISO
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Glycyrrhizin	O
(	O
GL	O
)	O
was	O
shown	O
to	O
inhibit	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
replication	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
In	O
southern	O
Vietnam	O
,	O
a	O
four	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
severe	B-DISO
diarrhea	I-DISO
,	O
followed	O
by	O
seizures	B-DISO
,	O
coma	B-DISO
,	O
and	O
death	O
.	O

The	O
diagnosis	O
of	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
was	O
established	O
by	O
isolation	O
of	O
the	O
virus	O
from	O
cerebrospinal	O
fluid	O
,	O
fecal	O
,	O
throat	O
,	O
and	O
serum	O
specimens	O
.	O

TITLE	O
:	O
Field	O
investigations	O
of	O
emergency	B-DISO
department	O
syndromic	O
surveillance	O
signals	O
--	O
New	O
York	O
City	O
.	O

The	O
New	O
York	O
City	O
(	O
NYC	O
)	O
Department	O
of	O
Health	O
and	O
Mental	O
Hygiene	O
(	O
DOHMH	O
)	O
has	O
operated	O
a	O
syndromic	O
surveillance	O
system	O
based	O
on	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
chief	O
-	O
complaint	O
data	O
since	O
November	O
2001	O
.	O

In	O
those	O
instances	O
,	O
epidemiologic	O
investigation	O
provided	O
reassurance	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
was	O
not	O
present	O
.	O

TITLE	O
:	O
SARS	B-DISO
Surveillance	O
Project	O
--	O
Internet	O
-	O
enabled	O
multiregion	O
surveillance	O
for	O
rapidly	O
emerging	O
disease	O
.	O

Single	O
isolation	O
being	O
not	O
always	O
possible	O
,	O
the	O
patient	O
may	O
have	O
to	O
be	O
isolated	O
with	O
a	O
group	O
of	O
SARS	B-DISO
patients	O
.	O

The	O
treatment	O
of	O
SARS	B-DISO
and	O
tuberculosis	B-DISO
resulted	O
in	O
liver	B-DISO
dysfunction	I-DISO
.	O

tl	O
/	O
CH	O
/	O
LDT3	O
/	O
03	O
had	O
a	O
spike	O
protein	O
gene	O
with	O
95	O
%	O
identity	O
to	O
that	O
of	O
a	O
Chinese	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolate	O
,	O
although	O
more	O
extensive	O
sequencing	O
revealed	O
the	O
possibility	O
that	O
this	O
strain	O
may	O
have	O
undergone	O
recombination	O
.	O

TITLE	O
:	O
Chest	O
radiograph	O
scores	O
as	O
potential	O
prognostic	O
indicators	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
[	O
Clinical	O
investigation	O
of	O
the	O
first	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Beijing	O
in	O
2004	O
].	O

The	O
numbers	O
of	O
peripheral	O
white	O
blood	O
cells	O
and	O
lymphocytes	O
were	O
in	O
the	O
normal	O
range	O
without	O
any	O
specific	O
changes	O
typical	O
of	O
SARS	B-DISO
.	O

ALI	O
is	O
characterized	O
by	O
microvascular	O
protein	O
leakage	B-DISO
,	O
neutrophil	O
influx	O
,	O
and	O
expression	O
of	O
proinflammatory	O
mediators	O
,	O
followed	O
by	O
severe	O
lung	O
damage	O
.	O

Our	O
results	O
show	O
that	O
CD14	O
and	O
TLR4	O
are	O
necessary	O
for	O
low	O
-	O
dose	O
(	O
300	O
-	O
microg	O
/	O
ml	O
)	O
LPS	B-DISO
-	O
induced	O
microvascular	O
leakage	B-DISO
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
neutrophil	O
influx	O
,	O
cytokine	O
and	O
chemokine	O
(	O
KC	O
,	O
macrophage	O
inflammatory	O
protein	O
2	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
,	O
interleukin	O
-	O
6	O
)	O
expression	O
,	O
and	O
subsequent	O
lung	O
damage	O
.	O

We	O
developed	O
an	O
adoptive	O
-	O
transfer	O
model	O
to	O
more	O
clearly	O
elucidate	O
the	O
role	O
of	O
virus	O
-	O
specific	O
CD8	O
+	O
T	O
cells	O
during	O
the	O
acute	O
and	O
chronic	O
phases	O
of	O
infection	B-DISO
with	O
A59	O
that	O
is	O
described	O
as	O
follows	O
.	O

The	O
results	O
suggest	O
that	O
these	O
proteins	O
serve	O
roles	O
in	O
pathogenesis	B-DISO
or	O
virus	O
survival	O
in	O
vivo	O
distinct	O
from	O
functions	O
in	O
virus	O
replication	O
.	O

TITLE	O
:	O
Exogenous	O
ACE2	O
expression	O
allows	O
refractory	O
cell	O
lines	O
to	O
support	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
replication	O
.	O

CaCo	O
-	O
2	O
was	O
the	O
only	O
human	O
cell	O
type	O
of	O
13	O
tested	O
that	O
supported	O
efficient	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

A	O
total	O
of	O
12	O
children	O
developed	O
neutropenic	B-DISO
fever	I-DISO
and	O
3	O
of	O
them	O
had	O
positive	O
blood	O
culture	O
,	O
including	O
staphylococcus	O
epidermal	O
,	O
staphylococcus	O
saprophyte	O
and	O
bacillus	O
subtilis	O
.	O

None	O
of	O
the	O
children	O
died	O
of	O
transplantation	O
-	O
associated	O
complication	B-DISO
.	O

Varying	O
amounts	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
found	O
in	O
the	O
26	O
SARS	B-DISO
-	O
CoV	O
positive	O
specimens	O
and	O
SARS	B-DISO
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
40	O
follow	O
up	O
specimens	O
and	O
controls	O
.	O

We	O
present	O
here	O
a	O
novel	O
application	O
of	O
mass	O
spectrometry	O
(	O
MS	O
)-	O
based	O
technology	O
in	O
characterizing	O
viral	O
sequence	O
variations	O
that	O
overcomes	O
these	O
problems	O
,	O
and	O
we	O
apply	O
it	O
retrospectively	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Singapore	O
.	O

Our	O
direct	O
determination	O
of	O
viral	O
sequence	O
variation	O
from	O
a	O
clinical	O
sample	O
also	O
clarified	O
an	O
unresolved	O
epidemiological	O
link	O
regarding	O
the	O
acquisition	O
of	O
SARS	B-DISO
in	O
a	O
German	O
patient	O
.	O

This	O
study	O
has	O
further	O
demonstrated	O
the	O
importance	O
of	O
improving	O
clinical	O
and	O
epidemiological	O
studies	O
of	O
pathogen	B-DISO
transmission	I-DISO
through	O
the	O
use	O
of	O
genetic	O
analysis	O
and	O
has	O
revealed	O
the	O
MS	O
-	O
based	O
analysis	O
to	O
be	O
a	O
sensitive	O
and	O
accurate	O
method	O
for	O
characterizing	O
SARS	B-DISO
-	O
CoV	O
genetic	O
variations	O
in	O
clinical	O
samples	O
.	O

This	O
paper	O
presents	O
a	O
detailed	O
study	O
of	O
environmental	O
evidence	O
of	O
possible	O
airborne	O
transmission	O
in	O
a	O
hospital	O
ward	O
during	O
the	O
largest	O
nosocomial	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
in	O
March	O
2003	O
.	O

The	O
outbreak	O
in	O
Ward	O
8A	O
,	O
which	O
was	O
in	O
a	O
general	O
hospital	O
and	O
could	O
house	O
nearly	O
40	O
patients	O
,	O
demonstrated	O
the	O
cross	O
-	O
infection	B-DISO
risks	O
of	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
in	O
hospitals	O
if	O
a	O
potential	O
highly	O
infectious	B-DISO
patient	O
was	O
not	O
identified	O
and	O
isolated	O
.	O

TITLE	O
:	O
Identification	O
of	O
single	O
-	O
chain	O
antibody	O
fragments	O
specific	O
against	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
from	O
phage	O
-	O
displayed	O
antibody	O
library	O
.	O

TITLE	O
:	O
Practice	O
of	O
habitual	O
and	O
volitional	O
health	O
behaviors	O
to	O
prevent	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
Chinese	O
adolescents	O
in	O
Hong	O
Kong	O
.	O

Random	O
-	O
digit	O
dialing	O
of	O
the	O
local	O
residential	O
telephone	O
directory	O
was	O
used	O
to	O
select	O
respondents	O
,	O
who	O
were	O
asked	O
to	O
provide	O
information	O
on	O
their	O
practice	O
of	O
SARS	B-DISO
preventive	O
health	O
behaviors	O
and	O
associated	O
factors	O
as	O
specified	O
by	O
the	O
Health	O
Belief	O
Model	O
.	O

ABSTRACT	O
:	O
Taiwan	O
experienced	O
a	O
large	O
number	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
viral	B-DISO
infections	I-DISO
between	O
March	O
and	O
July	O
2003	O
;	O
by	O
September	O
of	O
that	O
year	O
,	O
346	O
SARS	B-DISO
cases	O
were	O
confirmed	O
by	O
RT	O
-	O
PCR	O
or	O
serological	O
tests	O
.	O

TITLE	O
:	O
Quality	O
management	O
case	O
studies	O
in	O
health	O
service	O
emergencies	B-DISO
:	O
SARS	B-DISO
and	O
wildland	O
-	O
urban	O
interface	O
fires	O
.	O

ABSTRACT	O
:	O
The	O
province	O
of	O
British	O
Columbia	O
,	O
Canada	O
,	O
experienced	O
2	O
major	O
health	O
emergency	B-DISO
situations	O
during	O
2003	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
early	O
2003	O
and	O
wildland	O
-	O
urban	O
interface	O
fires	O
during	O
the	O
summer	O
of	O
2003	O
.	O

TITLE	O
:	O
Current	O
status	O
of	O
anti	O
-	O
SARS	B-DISO
agents	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
several	O
synthetic	O
peptides	O
,	O
including	O
those	O
that	O
mimic	O
the	O
S	O
-	O
binding	O
domain	O
,	O
the	O
HR2	O
fusion	O
protein	O
and	O
SARS	B-DISO
proteinase	O
substrates	O
,	O
will	O
be	O
discussed	O
.	O

An	O
apparent	O
cause	O
of	O
fever	O
and	O
positive	O
blood	O
cultures	O
cannot	O
exclude	O
a	O
diagnosis	O
of	O
SARS	B-DISO
.	O

Such	O
immunity	O
is	O
often	O
short	O
-	O
lived	O
,	O
requires	O
frequent	O
boosting	O
and	O
may	O
not	O
prevent	O
re	O
-	O
infection	B-DISO
,	O
all	O
factors	O
complicating	O
CoV	O
vaccine	O
design	O
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
outcomes	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
predictive	O
factors	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
study	O
retrospectively	O
analyzed	O
data	O
for	O
67	O
SARS	B-DISO
patients	O
,	O
who	O
were	O
grouped	O
according	O
to	O
whether	O
or	O
not	O
ARDS	B-DISO
developed	O
during	O
the	O
clinical	O
course	O
of	O
SARS	B-DISO
.	O

The	O
overall	O
mortality	O
rate	O
was	O
31	O
.	O
3	O
%	O
(	O
21	O
/	O
67	O
),	O
whereas	O
the	O
rate	O
for	O
patients	O
who	O
developed	O
ARDS	B-DISO
was	O
63	O
.	O
6	O
%	O
(	O
21	O
/	O
33	O
).	O

Multivariate	O
analyses	O
showed	O
that	O
age	O
greater	O
than	O
65	O
years	O
(	O
odds	O
ratio	O
,	O
OR	O
,	O
10	O
.	O
6	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
2	O
.	O
1	O
-	O
54	O
.	O
1	O
),	O
pre	O
-	O
existing	O
diabetes	B-DISO
mellitus	I-DISO
(	O
OR	O
,	O
13	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
146	O
.	O
9	O
),	O
and	O
elevated	O
levels	O
of	O
LDH	O
(	O
OR	O
,	O
8	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
36	O
.	O
9	O
)	O
at	O
admission	O
,	O
were	O
independent	O
predictors	O
of	O
ARDS	B-DISO
.	O

Importantly	O
,	O
the	O
development	O
of	O
ARDS	B-DISO
was	O
associated	O
with	O
significant	O
mortality	O
,	O
despite	O
aggressive	B-DISO
therapy	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
hospital	O
because	O
of	O
severe	O
foot	B-DISO
pain	I-DISO
following	O
several	O
weeks	O
of	O
skin	B-DISO
ulcerations	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
LJB	O
/	O
03	O
was	O
isolated	O
from	O
the	O
fece	O
of	O
piglets	O
infected	O
with	O
PEDV	O
on	O
a	O
pig	O
farm	O
,	O
Heilongjiang	O
province	O
,	O
China	O
.	O

We	O
have	O
isolated	O
a	O
SARS	B-DISO
-	O
CoV	O
in	O
China	O
and	O
analyzed	O
47	O
SARS	B-DISO
-	O
CoV	O
genomes	O
with	O
the	O
aims	O
to	O
reveal	O
the	O
evolution	O
trends	O
of	O
the	O
virus	O
and	O
provide	O
insights	O
into	O
understanding	O
pathogenesis	B-DISO
and	O
SARS	B-DISO
epidemic	O
.	O

The	O
presence	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
confirmed	O
by	O
electron	O
microscopy	O
.	O

ABSTRACT	O
:	O
The	O
Law	O
Concerning	O
the	O
Prevention	O
of	O
Infectious	B-DISO
Diseases	I-DISO
and	O
Medical	O
Care	O
for	O
Patients	O
of	O
Infections	B-DISO
(	O
the	O
Infectious	B-DISO
Diseases	I-DISO
Control	O
Law	O
)	O
enacted	O
on	O
April	O
1	O
,	O
1999	O
,	O
accompanies	O
an	O
additional	O
rule	O
for	O
reconsideration	O
in	O
five	O
years	O
after	O
putting	O
the	O
law	O
in	O
operation	O
and	O
for	O
taking	O
necessary	O
steps	O
when	O
needed	O
.	O

On	O
November	O
5	O
,	O
2003	O
,	O
partial	O
amendment	O
of	O
the	O
Infectious	B-DISO
Diseases	I-DISO
Control	O
Law	O
and	O
the	O
Quarantine	O
Law	O
was	O
approved	O
and	O
put	O
into	O
operation	O
on	O
.	O

reviewing	O
target	O
diseases	O
of	O
the	O
Infectious	B-DISO
Diseases	I-DISO
Control	O
Law	O
and	O
categories	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Controlling	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
like	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
control	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
like	O
SARS	B-DISO
,	O
it	O
is	O
necessary	O
to	O
resort	O
to	O
basic	O
control	O
measures	O
that	O
limit	O
exposures	O
to	O
infectious	B-DISO
individuals	O
.	O

Viruses	O
with	O
S33G	O
,	O
L79M	O
/	O
T82M	O
or	O
K183G	O
substitutions	O
could	O
only	O
be	O
recovered	O
from	O
cells	O
that	O
over	O
-	O
expressed	O
a	O
mutant	B-DISO
mCEACAM1a	O
.	O

These	O
mAbs	O
could	O
recognize	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
by	O
immunofluorescence	O
analysis	O
(	O
IFA	O
).	O

In	O
particular	O
,	O
inhibitors	O
of	O
viral	O
entry	O
,	O
comprising	O
therapeutic	O
peptides	O
,	O
were	O
based	O
on	O
the	O
recently	O
launched	O
anti	O
-	O
HIV	B-DISO
drug	O
enfuvirtide	O
.	O

TITLE	O
:	O
Protecting	O
healthcare	O
staff	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
filtration	O
capacity	O
of	O
multiple	O
surgical	O
masks	O
.	O

ABSTRACT	O
:	O
Although	O
winter	B-DISO
dysentery	I-DISO
(	O
WD	B-DISO
)	O
has	O
been	O
suspected	O
to	O
occur	O
frequently	O
in	O
Korea	O
,	O
to	O
date	O
the	O
exact	O
epidemiology	O
of	O
WD	B-DISO
has	O
remained	O
unknown	O
.	O

SARS	B-DISO
attack	O
rates	O
and	O
changes	O
in	O
quality	O
of	O
life	O
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
were	O
also	O
examined	O
at	O
three	O
timepoints	O
among	O
herbal	O
supplement	O
users	O
.	O

Improvements	O
in	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
and	O
quality	O
of	O
life	O
measurements	O
were	O
also	O
observed	O
among	O
herbal	O
supplement	O
users	O
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
there	O
is	O
a	O
good	O
potential	O
of	O
using	O
Traditional	O
Chinese	O
Medicine	O
(	O
TCM	O
)	O
supplements	O
to	O
prevent	O
the	O
spread	O
of	O
SARS	B-DISO
.	O

We	O
constructed	O
a	O
decision	O
-	O
analysis	O
model	O
to	O
identify	O
the	O
most	O
efficient	O
strategies	O
for	O
managing	O
undifferentiated	O
FRIs	O
within	O
a	O
hypothetical	O
SARS	B-DISO
outbreak	O
in	O
New	O
York	O
City	O
during	O
the	O
season	O
of	O
respiratory	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Late	O
recognition	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
associated	O
with	O
no	O
known	O
SARS	B-DISO
contact	O
,	O
hospitalization	O
before	O
the	O
nosocomial	O
outbreak	O
was	O
recognized	O
,	O
symptom	B-DISO
onset	O
while	O
hospitalized	O
,	O
wards	O
with	O
SARS	B-DISO
clusters	O
,	O
and	O
postoperative	O
status	O
.	O

TITLE	O
:	O
Growth	O
kinetics	O
of	O
SARS	B-DISO
-	O
coronavirus	O
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
Antibody	O
detection	O
with	O
a	O
recombinant	O
COOH	O
portion	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
N13	O
(	O
amino	O
acids	O
221	O
to	O
422	O
),	O
was	O
demonstrated	O
to	O
be	O
more	O
specific	O
and	O
sensitive	O
than	O
that	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
,	O
and	O
an	O
N13	O
-	O
based	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
providing	O
a	O
convenient	O
and	O
specific	O
test	O
for	O
serodiagnosis	O
and	O
epidemiological	O
study	O
of	O
SARS	B-DISO
was	O
developed	O
.	O

During	O
the	O
past	O
8	O
yrs	O
,	O
there	O
have	O
been	O
increasing	O
numbers	O
of	O
studies	O
describing	O
its	O
use	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Although	O
there	O
are	O
limitations	O
,	O
multiple	O
studies	O
have	O
shown	O
that	O
earlier	O
initiation	O
of	O
HFOV	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
may	O
also	O
be	O
associated	O
with	O
a	O
lower	O
mortality	O
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
has	O
been	O
used	O
successfully	O
in	O
our	O
regional	O
burn	O
center	O
since	O
1999	O
for	O
the	O
management	O
of	O
oxygenation	O
failure	O
secondary	O
to	O
ARDS	B-DISO
and	O
as	O
a	O
method	O
of	O
intraoperative	O
ventilation	O
to	O
allow	O
surgical	O
burn	O
wound	O
excision	O
to	O
proceed	O
,	O
despite	O
the	O
presence	O
of	O
severe	O
ARDS	B-DISO
.	O

HFOV	O
produced	O
significant	O
improvements	O
in	O
oxygenation	O
among	O
burn	O
patients	O
with	O
oxygenation	O
failure	O
secondary	O
to	O
ARDS	B-DISO
.	O

As	O
a	O
result	O
,	O
various	O
salvage	O
therapies	O
aimed	O
at	O
improving	O
oxygenation	O
,	O
including	O
HFOV	O
,	O
iNO	O
,	O
and	O
PP	O
alone	O
or	O
in	O
combination	O
,	O
have	O
been	O
evaluated	O
in	O
patients	O
with	O
refractory	O
ARDS	B-DISO
.	O

There	O
is	O
limited	O
clinical	O
data	O
to	O
recommend	O
the	O
widespread	O
use	O
of	O
combination	O
therapy	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

More	O
rigorous	O
randomized	O
,	O
controlled	O
trials	O
are	O
needed	O
to	O
help	O
delineate	O
the	O
therapeutic	O
role	O
of	O
combination	O
therapy	O
in	O
adults	O
with	O
ARDS	B-DISO
.	O

It	O
is	O
important	O
to	O
recognize	O
that	O
patients	O
evolve	O
from	O
severe	O
ARDS	B-DISO
through	O
phases	O
of	O
recovery	O
to	O
the	O
resolution	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
that	O
ventilatory	O
management	O
,	O
as	O
well	O
as	O
sedative	O
and	O
related	O
medication	O
requirements	O
,	O
will	O
vary	O
markedly	O
over	O
the	O
course	O
of	O
this	O
process	O
.	O

RESULTS	O
:	O
Sedative	O
,	O
analgesic	O
,	O
and	O
NMBA	O
are	O
used	O
with	O
great	O
frequency	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
are	O
undergoing	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

It	O
is	O
important	O
to	O
recognize	O
that	O
patients	O
evolve	O
from	O
severe	O
ARDS	B-DISO
through	O
phases	O
of	O
recovery	O
to	O
the	O
resolution	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
that	O
ventilatory	O
management	O
,	O
as	O
well	O
as	O
sedative	O
and	O
related	O
medication	O
requirements	O
,	O
will	O
vary	O
markedly	O
over	O
the	O
course	O
of	O
this	O
process	O
.	O

This	O
modality	O
has	O
been	O
used	O
to	O
manage	O
severe	O
lung	B-DISO
disease	I-DISO
in	O
the	O
neonatal	O
and	O
pediatric	O
population	O
,	O
treat	O
inhalation	O
injury	O
in	O
pediatric	O
and	O
adult	O
patients	O
,	O
and	O
as	O
salvage	O
therapy	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Combining	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
and	O
recruitment	B-DISO
maneuvers	O
in	O
adults	O
with	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
the	O
Treatment	O
with	O
Oscillation	O
and	O
an	O
Open	O
Lung	O
Strategy	O
(	O
TOOLS	O
)	O
Trial	O
pilot	O
study	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
virus	O
infections	B-DISO
such	O
as	O
SARS	B-DISO
and	O
pandemic	O
influenza	B-DISO
are	O
highly	O
contagious	B-DISO
diseases	I-DISO
that	O
cause	O
global	O
crisis	O
,	O
and	O
inflict	O
severe	O
human	O
mortality	O
and	O
morbidity	O
.	O

Poly	O
ICLC	O
and	O
CpG	O
oligonucleotides	O
are	O
promising	O
gene	O
-	O
based	O
drugs	O
which	O
have	O
been	O
shown	O
in	O
animal	O
studies	O
to	O
protect	O
against	O
acute	O
respiratory	O
virus	O
infections	B-DISO
.	O

To	O
determine	O
whether	O
these	O
DNA	O
vaccines	O
could	O
induce	O
T	O
cell	O
immune	O
responses	O
in	O
humans	O
as	O
well	O
as	O
in	O
mice	O
,	O
SCID	B-DISO
-	O
PBL	O
/	O
hu	O
mice	O
was	O
immunized	O
with	O
these	O
DNA	O
vaccines	O
.	O

As	O
expected	O
,	O
virus	O
-	O
specific	O
CTL	O
responses	O
and	O
T	O
cell	O
proliferation	B-DISO
were	O
induced	O
from	O
human	O
T	O
cells	O
.	O

TITLE	O
:	O
Rabies	B-DISO
control	O
in	O
South	O
and	O
Southeast	O
Asia	O
.	O

The	O
high	O
cost	O
of	O
rabies	B-DISO
immunoglobulin	O
and	O
tissue	O
culture	O
vaccines	O
are	O
remaining	O
barriers	O
,	O
but	O
new	O
manufacturers	O
and	O
the	O
use	O
of	O
intradermal	O
vaccination	O
schedules	O
can	O
reduce	O
costs	O
.	O

ABSTRACT	O
:	O
The	O
four	O
hospitals	O
assessed	O
in	O
this	O
study	O
use	O
active	O
surveillance	O
cultures	O
for	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
and	O
contact	O
precautions	O
for	O
MRSA	B-DISO
-	O
positive	O
patients	O
as	O
part	O
of	O
routine	O
infection	B-DISO
control	O
practices	O
.	O

Increased	O
attention	O
was	O
paid	O
to	O
infection	B-DISO
control	O
education	O
following	O
the	O
outbreak	O
.	O

We	O
demonstrate	O
this	O
principle	O
by	O
using	O
14	O
isolates	O
of	O
9	O
diverse	O
Coronavirus	O
spp	O
.,	O
including	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

We	O
show	O
that	O
this	O
method	O
could	O
identify	O
and	O
distinguish	O
between	O
SARS	B-DISO
and	O
other	O
known	O
CoV	O
,	O
including	O
the	O
human	O
CoV	O
229E	O
and	O
OC43	O
,	O
individually	O
and	O
in	O
a	O
mixture	O
of	O
all	O
3	O
human	O
viruses	O
.	O

TITLE	O
:	O
SARS	B-DISO
risk	O
perceptions	O
in	O
healthcare	O
workers	O
,	O
Japan	O
.	O

The	O
general	O
public	O
in	O
Hong	O
Kong	O
has	O
been	O
very	O
vigilant	O
about	O
SARS	B-DISO
but	O
needs	O
to	O
be	O
more	O
psychologically	O
prepared	O
to	O
face	B-DISO
a	O
resurgence	O
of	O
the	O
epidemic	O
.	O

ABSTRACT	O
:	O
Traditional	O
infection	B-DISO
control	O
policies	O
have	O
focused	O
on	O
engineering	O
controls	O
,	O
specific	O
protocols	O
,	O
and	O
personal	O
protective	O
equipment	O
(	O
PPE	O
).	O

A	O
critical	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
,	O
directed	O
at	O
understanding	O
what	O
organizational	O
and	O
individual	O
factors	O
are	O
important	O
in	O
protecting	O
HCWs	O
from	O
infectious	B-DISO
diseases	I-DISO
at	O
work	O
.	O

RESULTS	O
:	O
Literature	O
searches	O
were	O
conducted	O
in	O
several	O
databases	O
for	O
articles	O
published	O
in	O
the	O
last	O
15	O
years	O
that	O
related	O
to	O
infection	B-DISO
control	O
practices	O
,	O
occupational	O
health	O
and	O
safety	O
issues	O
,	O
environmental	O
factors	O
,	O
and	O
other	O
issues	O
of	O
importance	O
in	O
protecting	O
workers	O
against	O
respiratory	B-DISO
infections	I-DISO
in	O
health	O
care	O
settings	O
.	O

Expressed	O
3a	O
protein	O
was	O
reported	O
to	O
localize	O
to	O
Golgi	O
complex	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
cells	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
at	O
gene	O
sequence	O
level	O
of	O
host	O
-	O
driven	O
selection	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
incidence	O
and	O
severity	O
of	O
organ	O
dysfunction	O
associated	O
with	O
sepsis	B-DISO
.	O

Respiratory	O
and	O
cardiovascular	O
dysfunction	O
and	O
fungal	B-DISO
infection	I-DISO
were	O
strong	O
independent	O
risk	O
factors	O
for	O
death	O
in	O
SS	O
patients	O
,	O
with	O
5	O
.	O
64	O
-	O
fold	O
,	O
4	O
.	O
35	O
-	O
fold	O
,	O
and	O
2	O
.	O
0	O
-	O
fold	O
increased	O
risks	O
,	O
respectively	O
.	O

Only	O
focal	O
pulmonary	B-DISO
edema	I-DISO
or	O
hemorrhage	B-DISO
was	O
seen	O
.	O

The	O
absence	O
of	O
DAD	O
does	O
not	O
rule	O
out	O
the	O
possibility	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
particularly	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

Our	O
findings	O
suggest	O
that	O
polymorphisms	O
of	O
two	O
IFN	O
-	O
inducible	O
genes	O
OAS	B-DISO
-	O
1	O
and	O
MxA	O
might	O
affect	O
susceptibility	O
to	O
the	O
disease	O
and	O
progression	O
of	O
SARS	B-DISO
at	O
each	O
level	O
.	O

TITLE	O
:	O
Treatment	O
and	O
vaccines	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

And	O
the	O
epidemic	O
investigations	O
for	O
the	O
SARS	B-DISO
patients	O
were	O
also	O
carried	O
out	O
.	O

Of	O
these	O
populations	O
,	O
the	O
detective	O
rate	O
of	O
Ab	O
-	O
IgG	O
for	O
the	O
clinic	O
diagnosed	O
SARS	B-DISO
patients	O
,	O
which	O
was	O
53	O
.	O
7	O
%;	O
That	O
for	O
the	O
wild	O
animal	O
salesman	O
and	O
community	O
common	O
people	O
were	O
16	O
.	O
7	O
%	O
and	O
0	O
.	O
9	O
%,	O
respectively	O
.	O

Among	O
the	O
clinic	O
diagnosed	O
SARS	B-DISO
patients	O
,	O
the	O
positive	O
antibody	O
detective	O
rate	O
was	O
90	O
.	O
4	O
%	O
for	O
those	O
which	O
had	O
specific	O
contact	O
history	O
or	O
infectivity	O
,	O
which	O
was	O
higher	O
than	O
that	O
for	O
other	O
population	O
.	O

CONCLUSIONS	O
:	O
As	O
a	O
whole	O
SARS	B-DISO
-	O
CoV	O
Ab	O
-	O
IgG	O
detective	O
rate	O
for	O
the	O
clinic	O
diagnosed	O
SARS	B-DISO
patients	O
was	O
53	O
.	O
7	O
%	O
only	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
relation	O
between	O
psychological	B-DISO
symptoms	I-DISO
and	O
physical	O
parameters	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
at	O
different	O
stages	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Critical	O
deep	B-DISO
venous	I-DISO
thrombosis	I-DISO
and	O
occlusion	B-DISO
constitutes	O
a	O
small	O
percentage	O
of	O
patients	O
with	O
venous	B-DISO
disease	I-DISO
,	O
who	O
exhibit	O
severe	O
symptomatology	O
.	O

Failure	O
of	O
treatment	O
identified	O
as	O
both	O
lack	O
of	O
clinical	O
response	O
and	O
evidence	O
of	O
continued	O
venous	B-DISO
thrombosis	I-DISO
occurred	O
3	O
of	O
25	O
patients	O
(	O
12	O
%).	O

Both	O
patients	O
with	O
SVC	B-DISO
syndrome	I-DISO
experienced	O
resolution	O
of	O
respiratory	O
compromise	O
and	O
facial	B-DISO
edema	I-DISO
.	O

Complications	O
included	O
transfusion	O
requirement	O
(	O
2	O
),	O
hematuria	O
(	O
2	O
),	O
retroperitoneal	O
hematoma	B-DISO
(	O
1	O
),	O
and	O
cellulitis	B-DISO
(	O
1	O
).	O

ABSTRACT	O
:	O
In	O
his	O
second	O
week	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
illness	O
,	O
a	O
patient	O
developed	O
an	O
unusually	O
complicated	O
course	O
of	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

Sex	O
,	O
degree	O
of	O
CSF	O
inflammation	B-DISO
,	O
neuroanatomical	O
location	O
and	O
systemic	O
signs	O
provided	O
little	O
contributory	O
information	O
to	O
the	O
final	O
diagnosis	O
.	O

In	O
a	O
case	O
-	O
control	O
evaluation	O
of	O
573	O
cats	O
in	O
eight	O
shelters	O
in	O
California	O
in	O
2001	O
and	O
2002	O
,	O
the	O
prevalence	O
of	O
feline	O
calicivirus	O
(	O
FCV	O
)	O
was	O
from	O
13	O
to	O
36	O
%,	O
feline	O
herpesvirus	O
(	O
FHV	O
)	O
was	O
from	O
3	O
to	O
38	O
%,	O
and	O
prevalence	O
of	O
Bordetella	O
bronchiseptica	O
,	O
Chlamydophila	O
felis	O
,	O
and	O
Mycoplasma	B-DISO
species	O
was	O
from	O
2	O
to	O
14	O
%.	O

Four	O
out	O
of	O
15	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
with	O
ARDS	B-DISO
maintained	O
a	O
low	O
EVLW	O
and	O
had	O
better	O
28	O
-	O
day	O
survival	O
than	O
did	O
ARDS	B-DISO
patients	O
with	O
high	O
EVLW	O
(	O
100	O
%	O
versus	O
36	O
%;	O
P	O
=	O
0	O
.	O
03	O
).	O

The	O
arterial	O
oxygen	O
tension	B-DISO
/	O
fractional	O
inspired	O
oxygen	O
ratio	O
,	O
lung	O
injury	O
score	O
,	O
and	O
chest	O
radiograph	O
scores	O
correlated	O
with	O
EVLW	O
(	O
r2	O
=	O
0	O
.	O
27	O
,	O
r2	O
=	O
0	O
.	O
18	O
,	O
and	O
r2	O
=	O
0	O
.	O
28	O
,	O
respectively	O
;	O
all	O
P	O
<	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
[	O
A	O
follow	O
-	O
up	O
study	O
of	O
the	O
lung	O
function	O
and	O
the	O
chest	O
CT	O
changes	O
in	O
medical	O
staff	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Beijing	O
].	O

Lung	O
function	O
and	O
lung	O
imaging	O
were	O
abnormal	O
in	O
some	O
patients	O
with	O
SARS	B-DISO
after	O
recovery	O
.	O

Modified	O
levels	O
of	O
several	O
transcripts	O
involved	O
in	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
processes	O
exemplified	O
the	O
balance	O
between	O
opposing	O
forces	O
during	O
SARS	B-DISO
pathogenesis	B-DISO
.	O

It	O
also	O
includes	O
infections	B-DISO
for	O
which	O
the	O
incidence	O
could	O
increase	O
because	O
of	O
favorable	O
conditions	O
.	O

TITLE	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3a	O
is	O
a	O
novel	O
structural	O
protein	O
.	O

ABSTRACT	O
:	O
After	O
four	O
months	O
of	O
silence	B-DISO
before	O
a	O
new	O
incursion	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
SARS	B-DISO
),	O
world	O
wide	O
investigators	O
specially	O
from	O
Asia	O
had	O
have	O
to	O
face	B-DISO
a	O
coronavirus	O
capable	O
of	O
great	O
spreading	O
and	O
inducing	O
high	O
morbidity	O
.	O

TITLE	O
:	O
Th2	O
predominance	O
and	O
CD8	O
+	O
memory	O
T	O
cell	O
depletion	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Immunoglobulins	O
and	O
complement	O
were	O
elevated	O
during	O
the	O
first	O
month	O
of	O
SARS	B-DISO
.	O

Nurses	O
relied	O
more	O
on	O
peer	O
support	O
than	O
doctors	O
,	O
felt	O
less	O
informed	O
and	O
less	O
involved	O
in	O
decision	O
-	O
making	O
than	O
doctors	O
felt	O
,	O
and	O
were	O
more	O
likely	O
to	O
report	O
that	O
infection	B-DISO
control	O
procedures	O
were	O
not	O
strict	O
enough	O
.	O

The	O
between	O
-	O
group	O
differences	O
and	O
the	O
pattern	O
of	O
these	O
differences	O
clearly	O
illustrate	O
the	O
polarizing	O
and	O
stressful	O
impact	O
SARS	B-DISO
had	O
at	O
a	O
hospital	O
with	O
only	O
a	O
small	O
number	O
of	O
probable	O
or	O
suspect	O
cases	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
and	O
specificity	O
of	O
ELISA	O
for	O
detecting	O
IgG	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
100	O
.	O
0	O
%	O
and	O
97	O
.	O
2	O
%	O
and	O
for	O
IgM	O
89	O
.	O
8	O
%	O
and	O
97	O
.	O
6	O
%	O
respectively	O
;	O
the	O
figures	O
using	O
IFA	O
for	O
IgG	O
were	O
100	O
.	O
0	O
%	O
and	O
100	O
.	O
0	O
%	O
and	O
for	O
IgM	O
81	O
.	O
8	O
%	O
and	O
100	O
.	O
0	O
%	O
respectively	O
.	O

We	O
inoculated	O
confluent	O
monolayers	O
of	O
Vero	O
cells	O
with	O
SARS	B-DISO
-	O
CoV	O
at	O
a	O
multiplicity	O
of	O
infection	B-DISO
of	O
0	O
.	O
1	O
TCID50	O
and	O
passaged	O
the	O
remaining	O
cells	O
every	O
4	O
to	O
8	O
days	O
for	O
a	O
total	O
of	O
11	O
passages	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
further	O
the	O
present	O
knowledge	O
of	O
the	O
emerging	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
486	O
different	O
specimens	O
from	O
54	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
were	O
investigated	O
for	O
the	O
presence	O
of	O
viral	O
RNA	O
,	O
and	O
314	O
plasma	O
specimens	O
of	O
73	O
patients	O
were	O
examined	O
for	O
IgM	O
and	O
IgG	O
antibodies	O
specific	O
against	O
SARS	B-DISO
-	O
CoV	O
using	O
an	O
indirect	O
ELISA	O
.	O

Hematological	O
and	O
biochemical	O
abnormalities	O
,	O
particularly	O
lymphopenia	B-DISO
,	O
are	O
common	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

Two	O
-	O
hundred	O
and	O
seventy	O
-	O
six	O
serum	O
samples	O
were	O
collected	O
from	O
health	O
care	O
workers	O
in	O
a	O
hospital	O
in	O
which	O
a	O
nosocomial	O
SARS	B-DISO
outbreak	O
took	O
place	O
and	O
used	O
for	O
evaluation	O
.	O

HIV	B-DISO
-	O
specific	O
memory	O
CD8	O
+	O
T	O
cells	O
were	O
recruited	O
early	O
into	O
the	O
CNS	O
as	O
components	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
,	O
preceding	O
CD8	O
+	O
T	O
cells	O
specific	O
for	O
the	O
dominant	O
coronavirus	O
epitope	O
,	O
designated	O
pN	O
.	O
Although	O
pN	O
-	O
specific	O
T	O
-	O
cell	O
numbers	O
gradually	O
exceeded	O
bystander	O
p18	O
-	O
specific	O
CD8	O
+	O
T	O
-	O
cell	O
numbers	O
,	O
both	O
populations	O
peaked	O
concurrently	O
within	O
the	O
CNS	O
.	O

Immunosuppression	O
increased	O
both	O
MMP	O
-	O
3	O
and	O
MMP	O
-	O
12	O
mRNA	O
levels	O
in	O
CNS	O
resident	O
cells	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
virus	O
rather	O
than	O
inflammation	B-DISO
induced	O
protease	O
up	O
-	O
regulation	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
authors	O
examined	O
fear	O
related	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
among	O
2	O
samples	O
of	O
hospital	O
staff	O
in	O
Hong	O
Kong	O
.	O

Fear	O
related	O
to	O
SARS	B-DISO
was	O
also	O
correlated	O
positively	O
with	O
posttraumatic	O
stress	B-DISO
symptoms	I-DISO
among	O
respondents	O
of	O
Sample	O
2	O
(	O
recovered	O
staff	O
).	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibodies	O
against	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
.	O

Amino	O
acid	O
residues	O
450	O
-	O
650	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
S450	O
-	O
650	O
)	O
contains	O
dominant	O
epitopes	O
for	O
anti	O
-	O
viral	O
antibodies	O
(	O
Abs	O
)	O
in	O
patient	O
sera	O
.	O

Some	O
of	O
them	O
produced	O
anti	O
-	O
S	O
Abs	O
early	O
during	O
their	O
infection	B-DISO
,	O
while	O
others	O
failed	O
to	O
make	O
IgG	O
Abs	O
against	O
the	O
S450	O
-	O
650	O
polypeptide	O
.	O

Specimens	O
from	O
clinically	O
suspected	O
SARS	B-DISO
patients	O
collected	O
during	O
outbreak	O
and	O
post	O
-	O
epidemic	O
periods	O
were	O
tested	O
by	O
an	O
automatic	O
nucleic	O
acid	O
extraction	O
system	O
followed	O
by	O
our	O
first	O
generation	O
conventional	O
RT	O
-	O
PCR	O
and	O
two	O
standardized	O
real	O
-	O
time	O
PCR	O
assays	O
(	O
Artus	O
GmbH	O
,	O
Germany	O
and	O
Roche	O
Diagnostics	O
,	O
Germany	O
).	O

For	O
post	O
-	O
epidemic	O
period	O
,	O
no	O
SARS	B-DISO
CoV	O
was	O
identified	O
among	O
56	O
respiratory	O
specimens	O
by	O
all	O
PCR	O
assays	O
.	O

This	O
study	O
highlights	O
the	O
high	O
throughput	O
and	O
performance	O
of	O
automatic	O
RNA	O
extraction	O
in	O
coordination	O
with	O
standardized	O
real	O
-	O
time	O
PCR	O
assays	O
suitable	O
for	O
large	O
-	O
scale	O
routine	O
diagnosis	O
in	O
case	O
of	O
future	O
SARS	B-DISO
epidemic	O
.	O

We	O
describe	O
the	O
initial	O
clinical	O
characteristics	O
of	O
probable	O
or	O
suspect	O
SARS	B-DISO
patients	O
that	O
presented	O
to	O
the	O
ED	O
.	O

TITLE	O
:	O
Surveillance	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
the	O
post	O
-	O
outbreak	O
period	O
.	O

She	O
required	O
ECMO	O
for	O
20	O
days	O
,	O
during	O
which	O
time	O
sedation	B-DISO
was	O
reduced	O
,	O
and	O
she	O
was	O
able	O
to	O
interact	O
with	O
those	O
around	O
her	O
.	O

TITLE	O
:	O
The	O
immediate	O
effects	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
on	O
childbirth	O
in	O
Taiwan	O
.	O

TITLE	O
:	O
Coping	O
responses	O
of	O
emergency	B-DISO
physicians	O
and	O
nurses	O
to	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
.	O

Childhood	B-DISO
asthma	I-DISO
was	O
observed	O
in	O
40	O
,	O
4	O
%	O
of	O
children	O
without	O
any	O
associated	O
factor	O
wether	O
at	O
birth	O
or	O
in	O
PICU	O
related	O
to	O
such	O
outcome	O
.	O

In	O
addition	O
,	O
several	O
PCR	O
-	O
positive	O
swab	O
samples	O
were	O
recovered	O
from	O
frequently	O
touched	O
surfaces	O
in	O
rooms	O
occupied	O
by	O
patients	O
with	O
SARS	B-DISO
(	O
a	O
bed	B-DISO
table	O
and	O
a	O
television	O
remote	O
control	O
)	O
and	O
in	O
a	O
nurses	O
'	O
station	O
used	O
by	O
staff	O
(	O
a	O
medication	O
refrigerator	O
door	O
).	O

TITLE	O
:	O
Molecular	O
epidemiology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infections	I-DISO
in	O
Taiwan	O
.	O

Subsequently	O
,	O
this	O
new	O
tool	O
was	O
applied	O
to	O
provide	O
a	O
better	O
understanding	O
of	O
the	O
entire	O
complement	O
of	O
Taiwanese	O
SARS	B-DISO
-	O
CoV	O
isolates	O
,	O
including	O
20	O
previously	O
published	O
and	O
19	O
identified	O
in	O
this	O
study	O
.	O

We	O
report	O
the	O
progression	O
and	O
clinical	O
significance	O
of	O
liver	O
derangement	O
in	O
a	O
large	O
cohort	O
of	O
SARS	B-DISO
patient	O
.	O

Chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
was	O
not	O
associated	O
with	O
worse	O
clinical	O
outcomes	O
.	O

We	O
developed	O
a	O
rapid	O
method	O
to	O
amplify	O
and	O
sequence	O
the	O
whole	O
SARS	B-DISO
-	O
CoV	O
genome	O
from	O
clinical	O
specimens	O
.	O

RESULTS	O
:	O
We	O
sequenced	O
the	O
genomes	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
3	O
clinical	O
specimens	O
obtained	O
in	O
Taiwan	O
.	O

WS	O
is	O
commonly	O
associated	O
with	O
poor	O
long	O
-	O
term	O
outcome	O
,	O
especially	O
in	O
symptomatic	O
cases	O
,	O
with	O
development	O
of	O
other	O
seizure	B-DISO
types	O
,	O
impaired	B-DISO
cognitive	O
and	O
psychosocial	O
functioning	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
control	O
of	O
infantile	B-DISO
spasms	I-DISO
using	O
synthetic	O
ACTH	O
or	O
vigabatrin	O
in	O
newly	O
diagnosed	O
cases	O
and	O
to	O
correlate	O
it	O
with	O
the	O
underlyning	O
causes	O
,	O
outcome	O
and	O
adverse	B-DISO
effects	I-DISO
.	O

In	O
22	O
/	O
32	O
spasm	B-DISO
control	O
was	O
achieved	O
within	O
15	O
days	O
.	O

The	O
majority	O
of	O
cases	O
have	O
been	O
reported	O
among	O
healthcare	O
providers	O
and	O
family	O
members	O
of	O
SARS	B-DISO
patients	O
.	O

Most	O
of	O
the	O
mAbs	O
(	O
23	O
of	O
25	O
)	O
that	O
recognized	O
the	O
conformational	O
epitopes	O
possessed	B-DISO
potent	O
neutralizing	O
activities	O
against	O
SARS	B-DISO
pseudovirus	O
with	O
50	O
%	O
neutralizing	O
dose	O
ranging	O
from	O
0	O
.	O
005	O
to	O
6	O
.	O
569	O
microg	O
/	O
ml	O
.	O

Therefore	O
,	O
the	O
RBD	O
of	O
SARS	B-DISO
S	O
protein	O
contains	O
multiple	O
conformational	O
epitopes	O
capable	O
of	O
inducing	O
potent	O
neutralizing	O
Ab	O
responses	O
,	O
and	O
is	O
an	O
important	O
target	O
site	O
for	O
developing	O
vaccines	O
and	O
immunotherapeutics	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
or	O
perimyocarditis	O
?--	O
case	O
report	O
].	O

However	O
,	O
active	O
surveillance	O
programmes	O
taking	O
advantage	O
of	O
new	O
methodologies	O
,	O
including	O
virtual	O
tools	O
and	O
mathematical	O
programs	O
,	O
should	O
be	O
the	O
goal	O
for	O
early	O
detection	O
of	O
unusual	O
patterns	O
of	O
microbial	O
pathogens	O
,	O
outbreaks	O
and	O
healthcare	O
-	O
associated	O
infections	B-DISO
.	O

The	O
need	O
for	O
isolation	O
units	O
became	O
acute	O
when	O
many	O
countries	O
prepared	O
themselves	O
for	O
a	O
possible	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Europe	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
OC43	O
causes	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
in	O
residents	O
and	O
staff	O
of	O
aged	O
-	O
care	O
facilities	O
in	O
Melbourne	O
,	O
Australia	O
.	O

cDNA	O
RDA	B-DISO
has	O
been	O
applied	O
for	O
the	O
subtraction	O
of	O
poly	O
(	O
A	O
)(+)	O
RNAs	O
but	O
not	O
for	O
poly	O
(	O
A	O
)(-)	O
RNAs	O
,	O
such	O
as	O
RNA	O
virus	O
genomes	O
,	O
owing	O
to	O
the	O
vast	O
quantity	O
of	O
ribosomal	O
RNAs	O
.	O

We	O
constructed	O
96	O
hexanucleotides	O
(	O
non	O
-	O
ribosomal	O
hexanucleotides	O
)	O
and	O
used	O
them	O
as	O
mixed	O
primers	O
for	O
reverse	O
transcription	O
of	O
cDNA	O
RDA	B-DISO
.	O

TITLE	O
:	O
Retrospective	O
serological	O
investigation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
antibodies	O
in	O
recruits	O
from	O
mainland	O
China	O
.	O

Clinically	O
relevant	O
paresis	B-DISO
was	O
confirmed	O
in	O
27	O
ARDS	B-DISO
patients	O
(	O
60	O
%),	O
whereas	O
in	O
18	O
patients	O
no	O
paresis	B-DISO
was	O
determined	O
(	O
controls	O
);	O
five	O
patients	O
died	O
before	O
clinical	O
assessment	O
of	O
paresis	B-DISO
was	O
feasible	O
.	O

Patients	O
who	O
developed	O
paresis	B-DISO
had	O
elevated	O
daily	O
peak	O
blood	O
glucose	O
levels	O
during	O
28	O
days	O
of	O
intensive	O
care	O
unit	O
treatment	O
:	O
166	O
(	O
134	O
,	O
200	O
)	O
mg	O
/	O
dL	O
in	O
CIP	O
/	O
CIM	O
patients	O
vs	O
.	O
144	O
(	O
132	O
,	O
161	O
)	O
mg	O
/	O
dL	O
in	O
controls	O
(	O
median	O
,	O
quartiles	O
).	O

An	O
association	O
between	O
hyperglycemia	B-DISO
and	O
CIP	O
/	O
CIM	O
has	O
been	O
found	O
.	O

Improved	O
diagnostic	O
techniques	O
will	O
aid	O
the	O
treatment	O
of	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

Both	O
progressive	O
and	O
nonresolving	O
pneumonia	B-DISO
represent	O
treatment	O
failure	O
as	O
a	O
result	O
of	O
inappropriate	O
initial	O
therapy	O
,	O
a	O
noninfectious	O
cause	O
,	O
or	O
an	O
overwhelming	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
life	O
-	O
threatening	O
and	O
highly	O
contagious	B-DISO
disease	I-DISO
caused	O
by	O
the	O
novel	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

We	O
studied	O
the	O
pathologic	O
specimens	O
from	O
6	O
SARS	B-DISO
patients	O
by	O
immunohistochemical	O
staining	O
using	O
a	O
specific	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
Positive	O
viral	O
staining	O
was	O
only	O
found	O
in	O
the	O
lung	O
tissue	O
taken	O
from	O
the	O
patients	O
who	O
died	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
,	O
usually	O
less	O
than	O
10	O
days	O
after	O
symptom	B-DISO
onset	O
.	O

A	O
photochemical	O
treatment	O
(	O
PCT	B-DISO
)	O
process	O
with	O
amotosalen	O
-	O
HCl	O
and	O
long	O
-	O
wavelength	O
ultraviolet	O
light	O
(	O
UVA	O
),	O
which	O
cross	O
-	O
links	O
nucleic	O
acids	O
,	O
was	O
developed	O
to	O
inactivate	O
viruses	O
and	O
other	O
pathogens	O
in	O
PLT	O
concentrates	O
.	O

After	O
PCT	B-DISO
with	O
150	O
micromol	O
per	O
L	O
amotosalen	O
and	O
3	O
J	O
per	O
cm	O
(	O
2	O
)	O
UVA	O
,	O
residual	O
viral	O
infectivity	O
was	O
assayed	O
by	O
sensitive	O
cell	O
culture	O
or	O
animal	O
systems	O
.	O

Enveloped	O
viruses	O
were	O
uniformly	O
sensitive	O
to	O
inactivation	B-DISO
by	O
PCT	B-DISO
whereas	O
nonenveloped	O
viruses	O
demonstrated	O
variable	O
inactivation	B-DISO
.	O

Moreover	O
,	O
the	O
ACE	O
D	O
allele	O
has	O
been	O
shown	O
to	O
be	O
more	O
prevalent	O
in	O
patients	O
suffering	B-DISO
from	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
a	O
previous	O
study	O
.	O

Thus	O
,	O
we	O
have	O
investigated	O
the	O
association	O
between	O
ACE	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
and	O
the	O
progression	O
to	O
ARDS	B-DISO
or	O
requirement	O
of	O
intensive	O
care	O
in	O
SARS	B-DISO
patients	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
genotypic	O
distributions	O
and	O
the	O
allelic	O
frequencies	O
of	O
the	O
ACE	O
I	O
/	O
D	O
polymorphism	O
between	O
the	O
SARS	B-DISO
patients	O
and	O
the	O
healthy	O
control	O
subjects	O
.	O

This	O
study	O
to	O
identify	O
the	O
possible	O
causes	O
for	O
the	O
tachycardia	O
excluded	O
active	O
disease	O
,	O
thyroid	B-DISO
dysfunction	I-DISO
,	O
haematological	O
,	O
cardiac	O
,	O
autonomic	O
and	O
significant	O
pulmonary	O
defect	O
at	O
2	O
months	O
from	O
onset	O
of	O
disease	O
.	O

They	O
are	O
subject	O
to	O
many	O
infectious	B-DISO
diseases	I-DISO
no	O
longer	O
seen	O
commonly	O
in	O
the	O
United	O
States	O
such	O
as	O
malaria	B-DISO
,	O
tuberculosis	B-DISO
,	O
and	O
HIV	B-DISO
.	O

TITLE	O
:	O
[	O
Recurrent	O
Candida	B-DISO
sepsis	I-DISO
with	O
prolonged	O
respiratory	B-DISO
failure	I-DISO
and	O
severe	O
liver	B-DISO
dysfunction	I-DISO
].	O

ABSTRACT	O
:	O
Systemic	O
mycoses	B-DISO
,	O
especially	O
pulmonary	B-DISO
diseases	I-DISO
and	O
septicemia	B-DISO
are	O
observed	O
increasingly	O
at	O
intensive	O
care	O
units	O
.	O

Later	O
on	O
development	O
of	O
a	O
severe	O
liver	B-DISO
dysfunction	I-DISO
with	O
test	O
results	O
that	O
showed	O
an	O
intrahepatic	B-DISO
cholestasis	I-DISO
.	O

Decrease	O
of	O
high	O
bilirubin	O
levels	O
was	O
accompanied	O
by	O
improvement	O
of	O
clinical	O
condition	B-DISO
of	O
the	O
patient	O
.	O

ABSTRACT	O
:	O
Zygomycosis	B-DISO
caused	O
by	O
Rhizopus	O
species	O
is	O
an	O
aggressive	B-DISO
and	O
rapidly	O
progressive	O
opportunistic	O
fungal	B-DISO
infection	I-DISO
in	O
immunocompromised	O
patients	O
.	O

The	O
histopathologic	O
demonstrable	O
invasion	B-DISO
of	O
blood	O
vessels	O
is	O
remarkable	O
for	O
a	O
fungal	B-DISO
infection	I-DISO
.	O

Patient	O
2	O
,	O
male	O
68	O
years	O
old	O
:	O
transplantation	O
of	O
kidney	O
in	O
past	O
medical	O
history	O
,	O
presenting	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
with	O
quite	O
a	O
few	O
infections	B-DISO
before	O
.	O

It	O
is	O
strongly	O
recommended	O
to	O
settle	B-DISO
germfree	O
urine	O
in	O
the	O
preoperative	O
period	O
.	O

ABSTRACT	O
:	O
The	O
expression	O
of	O
the	O
genomic	O
information	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
)	O
involves	O
synthesis	O
of	O
a	O
nested	O
set	O
of	O
subgenomic	O
RNAs	O
(	O
sgRNAs	O
)	O
by	O
discontinuous	O
transcription	O
.	O

In	O
SARS	B-DISO
CoV	O
-	O
infected	O
cells	O
,	O
10	O
sgRNAs	O
,	O
including	O
2	O
novel	O
ones	O
,	O
were	O
identified	O
,	O
which	O
were	O
predicted	O
to	O
be	O
functional	O
in	O
the	O
expression	O
of	O
12	O
open	O
reading	O
frames	O
located	O
in	O
the	O
3	O
'	O
one	O
-	O
third	O
of	O
the	O
genome	O
.	O

For	O
the	O
two	O
novel	O
sgRNAs	O
,	O
each	O
used	O
a	O
variant	O
of	O
the	O
TRS	B-DISO
that	O
has	O
one	O
nucleotide	O
mismatch	O
in	O
the	O
conserved	O
hexanucleotide	O
core	O
(	O
ACGAAC	O
)	O
in	O
the	O
TRS	B-DISO
.	O

Moreover	O
,	O
one	O
rare	O
species	O
of	O
sgRNA	O
has	O
the	O
junction	O
sequence	O
AAA	B-DISO
,	O
indicating	O
that	O
its	O
transcription	O
could	O
result	O
from	O
a	O
noncanonical	O
transcription	O
signal	O
.	O

SARS	B-DISO
-	O
associated	O
mortality	O
may	O
exceed	O
50	O
%	O
for	O
persons	O
aged	O
60	O
years	O
or	O
older	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
106	O
Eurasian	O
lynx	O
(	O
Lynx	O
lynx	O
)	O
from	O
across	O
Sweden	O
,	O
found	O
dead	O
or	O
shot	O
by	O
hunters	O
in	O
1993	O
-	O
99	O
,	O
were	O
investigated	O
for	O
presence	O
of	O
antibodies	O
to	O
feline	O
parvovirus	B-DISO
(	O
FPV	O
),	O
feline	O
coronavirus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
herpesvirus	O
,	O
feline	O
immunodeficiency	B-DISO
virus	O
,	O
Francisella	O
tularensis	O
,	O
and	O
Anaplasma	O
phagocytophila	O
,	O
and	O
for	O
feline	B-DISO
leukemia	I-DISO
virus	O
antigen	O
.	O

Clinical	O
symptoms	O
that	O
were	O
significantly	O
more	O
common	O
among	O
patients	O
with	O
SARS	B-DISO
were	O
fever	O
,	O
myalgia	B-DISO
,	O
dyspnoea	B-DISO
,	O
and	O
nausea	B-DISO
or	O
vomiting	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
:	O

The	O
article	O
briefly	O
covers	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
followed	O
by	O
a	O
review	O
of	O
current	O
epidemiological	O
and	O
empirical	O
data	O
on	O
this	O
new	O
disease	O
.	O

The	O
SARS	B-DISO
experience	O
provided	O
us	O
a	O
lesson	O
on	O
the	O
importance	O
of	O
promoting	O
hygienic	O
practices	O
among	O
individuals	O
and	O
different	O
working	O
sectors	O
.	O

ABSTRACT	O
:	O
Although	O
optimists	O
once	O
imagined	O
that	O
serious	O
infectious	B-DISO
disease	I-DISO
threats	O
would	O
by	O
now	O
be	O
conquered	O
,	O
newly	O
emerging	O
(	O
e	O
.	O
g	O
.,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
]),	O
reemerging	O
(	O
e	O
.	O
g	O
.,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
),	O
and	O
even	O
deliberately	O
disseminated	O
infectious	B-DISO
diseases	I-DISO
(	O
e	O
.	O
g	O
.,	O
anthrax	B-DISO
bioterrorism	O
)	O
continue	O
to	O
appear	O
throughout	O
the	O
world	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
mobilizing	O
and	O
maintaining	O
a	O
public	O
health	O
emergency	B-DISO
response	O
.	O

ABSTRACT	O
:	O
During	O
the	O
spring	O
and	O
summer	O
of	O
2003	O
,	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
mobilized	O
the	O
resources	O
of	O
the	O
entire	O
agency	O
in	O
a	O
concerted	O
effort	O
to	O
meet	O
the	O
challenges	O
posed	O
by	O
the	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Critical	O
assessment	O
of	O
important	O
regions	O
in	O
the	O
subunit	O
association	O
and	O
catalytic	O
action	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
main	O
protease	O
.	O

To	O
understand	O
the	O
functional	O
roles	O
of	O
the	O
two	O
structural	O
parts	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
,	O
we	O
generated	O
the	O
full	O
-	O
length	O
of	O
this	O
enzyme	O
as	O
well	O
as	O
several	O
terminally	O
truncated	O
forms	O
,	O
different	O
from	O
each	O
other	O
only	O
by	O
the	O
number	O
of	O
amino	O
acid	O
residues	O
at	O
the	O
C	O
-	O
or	O
N	O
-	O
terminal	O
regions	O
.	O

We	O
concluded	O
that	O
both	O
the	O
C	O
-	O
and	O
the	O
N	O
-	O
terminal	O
regions	O
influence	O
the	O
dimerization	O
and	O
enzyme	O
activity	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
.	O

TITLE	O
:	O
Molecular	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
current	O
disease	O
prevention	O
strategies	O
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
is	O
an	O
autoimmune	B-DISO
disease	I-DISO
associated	O
with	O
environmental	O
factors	O
,	O
possibly	O
including	O
several	O
viruses	O
such	O
as	O
the	O
coronaviruses	O
.	O

To	O
confirm	O
that	O
the	O
F	O
and	O
M	O
gene	O
mutations	O
described	O
above	O
are	O
solely	O
responsible	O
for	O
the	O
phenotypic	O
differences	O
seen	O
in	O
wild	O
-	O
type	O
versus	O
F1	O
-	O
R	O
infections	B-DISO
,	O
reverse	O
genetics	O
was	O
used	O
to	O
construct	O
recombinant	O
Sendai	O
viruses	O
with	O
various	O
combinations	O
of	O
the	O
mutations	O
found	O
in	O
the	O
M	O
and	O
F	O
genes	O
of	O
F1	O
-	O
R	O
.	O
Plaque	B-DISO
assays	O
were	O
performed	O
with	O
or	O
without	O
trypsin	O
addition	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
three	O
N	O
fragments	O
(	O
N1	O
,	O
N2	O
,	O
and	O
N3	O
)	O
and	O
the	O
intraviral	O
domain	O
of	O
the	O
membrane	O
protein	O
(	O
M2	O
)	O
were	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
histidine	O
-	O
tagged	O
proteins	O
.	O

Six	O
reference	O
sera	O
from	O
SARS	B-DISO
patients	O
were	O
used	O
to	O
detect	O
virus	O
-	O
specific	O
IgG	O
in	O
an	O
ELISA	O
using	O
each	O
recombinant	O
protein	O
as	O
coating	O
antigen	O
.	O

High	O
-	O
titre	O
positive	O
reactions	O
were	O
detected	O
in	O
all	O
SARS	B-DISO
positive	O
sera	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
67	O
-	O
year	O
-	O
old	O
patient	O
who	O
developed	O
quadriparesis	B-DISO
,	O
ophthalmoplegia	B-DISO
and	O
severe	O
sensory	O
impairment	B-DISO
along	O
with	O
thrombocytopenia	O
.	O

Detailed	O
examinations	O
,	O
including	O
the	O
measurement	O
of	O
anti	O
-	O
ganglioside	O
antibodies	O
and	O
anti	O
-	O
glycoprotein	O
-	O
IIb	O
-	O
IIIa	O
-	O
IgG	O
-	O
producing	O
B	O
-	O
cells	O
,	O
revealed	O
that	O
he	O
developed	O
AIP	B-DISO
and	O
ITP	B-DISO
.	O

By	O
reviewing	O
past	O
similar	O
reports	O
,	O
we	O
noticed	O
that	O
AIP	B-DISO
associated	O
with	O
ITP	B-DISO
tends	O
to	O
manifest	O
severe	O
sensory	O
impairment	B-DISO
and	O
is	O
often	O
preceded	O
by	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
but	O
not	O
by	O
gastrointestinal	B-DISO
infection	I-DISO
.	O

Diarrhea	B-DISO
occurred	O
in	O
20	O
.	O
4	O
%	O
of	O
patients	O
after	O
admission	O
.	O

The	O
initial	O
chest	O
X	O
-	O
ray	O
study	O
was	O
normal	O
in	O
22	O
/	O
53	O
SARS	B-DISO
cases	O
versus	O
5	O
/	O
31	O
non	O
-	O
SARS	B-DISO
cases	O
.	O

ABSTRACT	O
:	O
An	O
inactivated	O
vaccine	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
evaluated	O
in	O
rhesus	O
monkeys	O
.	O

ABSTRACT	O
:	O
We	O
studied	O
the	O
adjuvanticity	O
of	O
recombinant	O
Onchocerca	O
volvulus	B-DISO
activation	O
associated	O
protein	O
-	O
1	O
(	O
rOv	O
-	O
ASP	O
-	O
1	O
)	O
for	O
ovalbumin	O
(	O
OVA	O
)	O
in	O
mice	O
.	O

TRFIA	O
is	O
a	O
new	O
,	O
sensitive	O
and	O
specific	O
immunoassay	O
for	O
detecting	O
SARS	B-DISO
N	O
protein	O
with	O
potential	O
value	O
in	O
clinical	O
applications	O
.	O

TITLE	O
:	O
In	O
vitro	O
analysis	O
of	O
a	O
hammerhead	O
ribozyme	O
targeted	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
nucleocapsid	O
mRNA	O
.	O

This	O
work	O
provides	O
a	O
basis	O
for	O
biochemical	O
and	O
structural	O
studies	O
of	O
SARS	B-DISO
-	O
CoV	O
RdRp	O
and	O
for	O
development	O
of	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

Here	O
,	O
we	O
report	O
the	O
X	O
-	O
ray	O
structure	O
of	O
a	O
previously	O
characterized	O
HR1	O
/	O
HR2	O
complex	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
.	O

It	O
might	O
improve	O
the	O
reliability	O
of	O
test	O
by	O
employing	O
RT	O
-	O
PCR	O
targeted	O
for	O
two	O
or	O
more	O
fragments	O
in	O
SARS	B-DISO
-	O
CoV	O
genome	O
.	O

Ligation	O
of	O
internal	O
iliac	O
arteries	O
was	O
performed	O
in	O
33	O
cases	O
for	O
ceasing	O
massive	B-DISO
bleeding	I-DISO
due	O
to	O
pelvic	O
fracture	O
,	O
and	O
angioembolization	O
in	O
8	O
.	O

The	O
overall	O
mortality	O
rate	O
was	O
9	O
%	O
(	O
7	O
/	O
79	O
);	O
The	O
main	O
causes	O
were	O
hemorrhagic	B-DISO
shock	I-DISO
and	O
associated	O
injury	O
.	O

RESULTS	O
:	O
Ligation	O
of	O
internal	O
iliac	O
arteries	O
was	O
performed	O
in	O
33	O
cases	O
for	O
ceasing	O
massive	B-DISO
bleeding	I-DISO
due	O
to	O
pelvic	O
fracture	O
,	O
and	O
angioembolization	O
in	O
8	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
potential	O
of	O
using	O
non	O
-	O
human	O
coronaviruses	O
for	O
cancer	B-DISO
therapy	O
,	O
we	O
first	O
established	O
their	O
ability	O
to	O
kill	O
human	O
tumor	B-DISO
cells	O
.	O

These	O
antibodies	O
potently	O
neutralize	O
infectious	B-DISO
virus	O
in	O
tissue	O
cultures	O
and	O
animal	O
models	O
,	O
and	O
,	O
alone	O
or	O
in	O
combination	O
with	O
vaccines	O
and	O
other	O
drugs	O
,	O
may	O
have	O
potential	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Transcriptional	O
analysis	O
of	O
avian	O
embryonic	O
tissues	O
following	O
infection	B-DISO
with	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
.	O

Better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
viral	B-DISO
pathogenesis	I-DISO
should	O
contribute	O
significantly	O
towards	O
the	O
development	O
of	O
improved	O
prophylactic	O
,	O
therapeutic	O
and	O
diagnostic	O
reagents	O
to	O
control	O
infections	B-DISO
.	O

TITLE	O
:	O
Epidemic	O
of	O
leptospirosis	B-DISO
:	O
an	O
ICU	O
experience	O
.	O

RESULTS	O
:	O
Out	O
of	O
834	O
total	O
admissions	O
in	O
this	O
period	O
,	O
60	O
(	O
7	O
.	O
2	O
%)	O
patients	O
suffered	B-DISO
from	O
leptospirosis	B-DISO
.	O

This	O
method	O
also	O
detected	O
an	O
additional	O
85	O
viruses	O
and	O
33	O
co	B-DISO
-	I-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
test	O
the	O
survivability	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
dead	O
chicken	O
carcasses	O
during	O
24	O
h	O
of	O
cold	B-DISO
storage	O
,	O
7	O
week	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
were	O
infected	O
with	O
virulent	O
IBV	O
Massachusetts	O
strain	O
M41	O
,	O
and	O
were	O
killed	O
humanely	O
10	O
days	O
later	O
.	O

TITLE	O
:	O
Study	O
on	O
the	O
resistance	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

SARS	B-DISO
-	O
CoV	O
is	O
more	O
susceptible	O
to	O
disinfectants	O
than	O
Escherichia	O
coli	O
and	O
f2	O
phage	O
.	O

Further	O
expression	O
and	O
characterization	O
of	O
wild	O
type	O
N	O
protein	O
and	O
K62A	O
mutant	B-DISO
reveal	O
that	O
sumoylation	O
of	O
the	O
N	O
protein	O
drastically	O
promotes	O
its	O
homo	O
-	O
oligomerization	O
,	O
and	O
plays	O
certain	O
roles	O
in	O
the	O
N	O
protein	O
-	O
mediated	O
interference	O
of	O
host	O
cell	O
division	O
.	O

APHS	O
could	O
also	O
not	O
inhibit	O
the	O
replication	O
of	O
the	O
RNA	O
viruses	O
,	O
respiratory	O
syncytium	O
virus	O
or	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

In	O
contrast	O
,	O
APHS	O
did	O
inhibit	O
the	O
replication	O
of	O
wild	O
-	O
type	O
herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
as	O
well	O
as	O
acyclovir	O
-	O
resistant	O
HSV	O
-	O
1	O
and	O
HSV	O
-	O
2	O
mutant	B-DISO
.	O

These	O
results	O
suggest	O
that	O
APHS	O
is	O
a	O
NNRTI	O
of	O
HIV	B-DISO
-	O
1	O
replication	O
,	O
but	O
not	O
HIV	B-DISO
-	O
2	O
replication	O
,	O
and	O
that	O
APHS	O
is	O
an	O
inhibitor	O
of	O
both	O
HSV	O
-	O
1	O
and	O
HSV	O
-	O
2	O
replication	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
novel	O
infectious	B-DISO
disease	I-DISO
which	O
is	O
characterized	O
by	O
an	O
overaggressive	O
immune	O
response	O
.	O

In	O
previous	O
study	O
,	O
we	O
found	O
that	O
SARS	B-DISO
-	O
CoV	O
has	O
the	O
ability	O
to	O
replicate	O
in	O
mononuclear	O
cells	O
.	O

To	O
determine	O
whether	O
RANTES	O
play	O
an	O
role	O
in	O
the	O
process	O
of	O
SARS	B-DISO
,	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
heat	O
-	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
and	O
ELISA	O
was	O
used	O
to	O
test	O
RANTES	O
levels	O
in	O
the	O
supernatants	O
;	O
Then	O
the	O
effect	O
of	O
dexamethasone	O
on	O
the	O
induced	O
secretion	O
was	O
evaluated	O
.	O

In	O
further	O
research	O
,	O
we	O
will	O
have	O
to	O
take	O
into	O
account	O
the	O
population	O
people	O
vaccinated	O
of	O
for	O
smallpox	B-DISO
,	O
who	O
account	O
for	O
about	O
70	O
%	O
of	O
the	O
total	O
population	O
in	O
Japan	O
.	O

Ten	O
episodes	O
of	O
multiorgan	B-DISO
failure	I-DISO
were	O
identified	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
and	O
defining	O
criteria	O
of	O
organ	B-DISO
failure	I-DISO
of	O
two	O
or	O
more	O
organs	O
that	O
is	O
lung	O
,	O
liver	O
,	O
or	O
renal	O
were	O
established	O
according	O
to	O
Acute	O
Physiological	O
and	O
Chronic	O
Health	O
Evaluation	O
-	O
II	O
(	O
APACHE	O
-	O
II	O
)	O
criteria	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
ORF	O
3a	O
is	O
one	O
such	O
gene	O
.	O

Highly	O
lytic	B-DISO
and	O
productive	O
rates	O
of	O
infections	B-DISO
within	O
48	O
h	O
of	O
inoculation	O
were	O
reproducible	O
with	O
both	O
viruses	O
.	O

TITLE	O
:	O
Immunological	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
by	O
monoclonal	O
antibodies	O
.	O

Hydrogen	O
cyanamide	O
is	O
highly	O
toxic	O
,	O
and	O
adverse	O
health	O
effects	O
from	O
contact	O
include	O
severe	O
irritation	O
and	O
ulceration	B-DISO
of	O
the	O
eyes	O
,	O
skin	O
,	O
and	O
respiratory	O
tract	O
.	O

TITLE	O
:	O
[	O
Hantavirus	B-DISO
infections	I-DISO
].	O

The	O
environmental	O
changes	O
,	O
the	O
geographical	O
distribution	O
depending	O
on	O
the	O
biotope	O
,	O
the	O
dynamics	O
and	O
behaviour	O
of	O
rodents	O
and	O
the	O
viral	O
circulation	O
between	O
them	O
and	O
its	O
transmission	O
to	O
human	O
beings	O
and	O
its	O
risk	O
factors	O
must	O
continue	O
to	O
be	O
studied	O
in	O
order	O
to	O
gain	O
further	O
knowledge	O
on	O
the	O
epidemiology	O
of	O
this	O
anthropozoonosis	B-DISO
.	O

The	O
exercise	O
capacity	O
and	O
health	O
status	O
of	O
SARS	B-DISO
survivors	O
was	O
considerably	O
lower	O
than	O
that	O
of	O
a	O
normal	O
population	O
at	O
6	O
months	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
relationship	O
between	O
ambient	O
air	O
pollution	O
and	O
daily	O
mortality	O
of	O
SARS	B-DISO
in	O
Beijing	O
.	O

The	O
relative	O
risks	O
(	O
RRs	B-DISO
)	O
values	O
depended	O
largely	O
on	O
the	O
selection	O
of	O
lag	O
days	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
has	O
a	O
high	O
binding	O
affinity	O
to	O
the	O
human	O
cellular	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
A1	O
.	O

TITLE	O
:	O
Development	O
of	O
immunoglobulin	O
G	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
serodiagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

We	O
report	O
on	O
serum	O
cytokine	O
levels	O
,	O
viral	O
load	O
and	O
clinical	O
parameters	O
over	O
the	O
course	O
of	O
the	O
disease	O
in	O
a	O
cohort	O
of	O
nine	O
adult	O
SARS	B-DISO
patients	O
treated	O
with	O
steroids	O
and	O
interferon	O
alfacon	O
-	O
1	O
at	O
North	O
York	O
General	O
Hospital	O
in	O
Toronto	O
,	O
Ontario	O
.	O

Considerable	O
variation	O
among	O
SARS	B-DISO
patients	O
with	O
respect	O
to	O
circulating	O
viral	O
load	O
and	O
patterns	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
evoked	O
cytokine	O
responses	O
was	O
recorded	O
.	O

TITLE	O
:	O
Molecular	O
cloning	O
,	O
expression	O
,	O
and	O
purification	O
of	O
SARS	B-DISO
-	O
CoV	O
nsp13	O
.	O

The	O
His	O
-	O
tag	B-DISO
-	O
fused	O
protein	O
was	O
expressed	O
by	O
induction	O
of	O
0	O
.	O
5mM	O
IPTG	O
and	O
purified	O
by	O
a	O
single	O
Ni	O
(	O
2	O
+)	O
affinity	O
chromatography	O
.	O

The	O
result	O
of	O
this	O
study	O
opens	O
the	O
way	O
for	O
the	O
development	O
of	O
an	O
edible	O
vaccine	O
against	O
PEDV	O
infection	B-DISO
in	O
Korea	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
that	O
has	O
led	O
to	O
large	O
hospital	O
and	O
community	O
outbreaks	O
,	O
necessitating	O
stringent	O
infection	B-DISO
control	O
in	O
its	O
management	O
.	O

This	O
may	O
be	O
one	O
of	O
the	O
most	O
important	O
factors	O
that	O
influence	O
the	O
SARS	B-DISO
transmission	O
in	O
air	O
.	O

Since	O
July	O
2003	O
,	O
a	O
number	O
of	O
SARS	B-DISO
cases	O
have	O
occurred	O
in	O
China	O
,	O
raising	O
the	O
possibility	O
of	O
future	O
epidemics	O
.	O

Using	O
rolling	O
circle	O
amplification	B-DISO
(	O
RCA	O
),	O
we	O
were	O
able	O
to	O
achieve	O
sensitive	O
detection	O
levels	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
in	O
both	O
solid	O
and	O
liquid	O
phases	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
fatal	O
,	O
coronavirus	O
(	O
CoV	O
)-	O
induced	O
systemic	B-DISO
disease	I-DISO
in	O
cats	O
,	O
characterized	O
by	O
granulomas	B-DISO
in	O
organs	O
and	O
granulomatous	B-DISO
vasculitis	I-DISO
.	O

Colonoscopic	O
control	O
verified	O
recurrent	B-DISO
disease	I-DISO
in	O
the	O
anastomotic	O
area	O
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
(	O
mAb	O
)	O
to	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
nucleoprotein	O
(	O
N	O
)	O
and	O
membrane	O
protein	O
(	O
M	O
)	O
were	O
prepared	O
and	O
used	O
for	O
the	O
comparative	O
assessment	O
of	O
three	O
blocking	B-DISO
ELISA	O
variants	O
to	O
detect	O
TGEV	O
.	O

TITLE	O
:	O
Precautions	O
in	O
ophthalmic	O
practice	O
in	O
a	O
hospital	O
with	O
a	O
major	O
acute	O
SARS	B-DISO
outbreak	O
:	O
an	O
experience	O
from	O
Hong	O
Kong	O
.	O

Therefore	O
,	O
the	O
availability	O
of	O
effective	O
antiviral	O
drugs	O
against	O
SARS	B-DISO
-	O
CoV	O
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
future	O
SARS	B-DISO
outbreaks	O
.	O

He	O
evolved	O
with	O
findings	O
suggestive	O
of	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
,	O
with	O
electrocardiographic	O
and	O
enzymatic	O
alterations	O
compatible	O
with	O
that	O
diagnosis	O
.	O

On	O
evolution	O
,	O
complete	O
recovery	O
of	O
the	O
electrocardiographic	O
alterations	O
and	O
systolic	O
ventricular	O
function	O
assessed	O
on	O
echocardiography	O
occurred	O
,	O
confirming	O
the	O
syndrome	B-DISO
.	O

In	O
this	O
observational	O
study	O
,	O
we	O
report	O
on	O
the	O
prevalence	O
of	O
GERD	B-DISO
in	O
this	O
population	O
,	O
including	O
all	O
pediatric	O
patients	O
undergoing	O
single	O
(	O
SLTx	O
)	O
or	O
double	O
(	O
DLTx	O
)	O
lung	O
transplantation	O
or	O
heart	O
-	O
lung	O
(	O
HLTx	O
)	O
transplantation	O
from	O
January	O
2003	O
-	O
May	O
2004	O
.	O

One	O
patient	O
had	O
end	O
-	O
stage	O
pulmonary	B-DISO
disease	I-DISO
secondary	O
to	O
chronic	O
aspiration	B-DISO
pneumonia	I-DISO
and	O
postadenovirus	O
lung	O
damage	O
.	O

TITLE	O
:	O
Mutational	O
and	O
inhibitive	O
analysis	O
of	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
-	O
based	O
assays	O
.	O

In	O
this	O
report	O
,	O
a	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)-	O
based	O
method	O
was	O
developed	O
to	O
assess	O
the	O
proteolytic	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

Two	O
internally	O
quenched	O
fluorogenic	O
peptides	O
,	O
1NC	O
and	O
2NC	O
,	O
corresponding	O
to	O
the	O
N	O
-	O
terminal	O
and	O
the	O
C	O
-	O
terminal	O
autocleavage	O
sites	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
),	O
respectively	O
,	O
were	O
used	O
as	O
substrates	O
.	O

Inspection	O
of	O
the	O
overlap	O
regions	O
between	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
revealed	O
that	O
,	O
similar	O
to	O
all	O
coronaviruses	O
,	O
a	O
programmed	O
-	O
1	O
ribosomal	O
frameshift	B-DISO
could	O
be	O
used	O
by	O
the	O
virus	O
to	O
produce	O
a	O
fusion	O
protein	O
.	O

The	O
main	O
outcome	O
measure	O
was	O
daily	O
number	O
of	O
isolation	O
beds	O
occupied	O
by	O
SARS	B-DISO
patients	O
.	O

ARIMA	O
models	O
provide	O
useful	O
tools	O
for	O
administrators	O
and	O
clinicians	O
in	O
planning	O
for	O
real	O
-	O
time	O
bed	B-DISO
capacity	O
during	O
an	O
outbreak	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
such	O
as	O
SARS	B-DISO
.	O

Total	O
number	O
of	O
admissions	O
and	O
probable	O
cases	O
admitted	O
on	O
the	O
previous	O
day	O
were	O
also	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
of	O
bed	B-DISO
occupancy	O
.	O

CONCLUSIONS	O
:	O
ARIMA	O
models	O
provide	O
useful	O
tools	O
for	O
administrators	O
and	O
clinicians	O
in	O
planning	O
for	O
real	O
-	O
time	O
bed	B-DISO
capacity	O
during	O
an	O
outbreak	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
such	O
as	O
SARS	B-DISO
.	O

In	O
2000	O
,	O
the	O
ARDS	B-DISO
Network	O
published	O
reported	O
a	O
reduced	O
mortality	O
(	O
from	O
40	O
%	O
to	O
31	O
%)	O
in	O
a	O
mixed	O
population	O
of	O
patients	O
with	O
ALI	O
and	O
ARDS	B-DISO
ventilated	O
with	O
half	O
the	O
tidal	O
volume	O
of	O
the	O
control	O
group	O
.	O

In	O
the	O
QF	O
-	O
RT	O
-	O
PCR	O
assay	O
,	O
there	O
was	O
a	O
linear	O
amplification	B-DISO
from	O
100	O
copies	O
to	O
10	O
(	O
8	O
)	O
copies	O
of	O
the	O
control	O
RNA	O
per	O
RT	O
-	O
PCR	O
and	O
at	O
least	O
10	O
copies	O
,	O
and	O
sometimes	O
even	O
1	O
copy	O
,	O
of	O
target	O
RNA	O
tested	O
positive	O
in	O
our	O
assay	O
.	O

TITLE	O
:	O
Persistence	O
of	O
lung	B-DISO
inflammation	I-DISO
and	O
lung	O
cytokines	O
with	O
high	O
-	O
resolution	O
CT	O
abnormalities	O
during	O
recovery	O
from	O
SARS	B-DISO
.	O

Viral	O
particles	O
in	O
AM	O
were	O
detected	O
by	O
electron	O
microscopy	O
in	O
7	O
of	O
12	O
SARS	B-DISO
patients	O
with	O
high	O
HRCT	O
score	O
.	O

Resolution	O
of	O
pneumonitis	B-DISO
is	O
delayed	O
in	O
some	O
patients	O
during	O
SARS	B-DISO
recovery	O
and	O
may	O
be	O
associated	O
with	O
delayed	O
clearance	O
of	O
coronavirus	O
,	O
Complete	O
resolution	O
may	O
occur	O
by	O
90	O
days	O
or	O
later	O
.	O

TITLE	O
:	O
A	O
throat	O
lozenge	O
containing	O
amyl	O
meta	O
cresol	O
and	O
dichlorobenzyl	O
alcohol	O
has	O
a	O
direct	O
virucidal	O
effect	O
on	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-DISO
A	O
and	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
A	O
potent	O
virucidal	O
mixture	O
containing	O
amyl	O
metacresol	O
and	O
dichlorobenzyl	O
alcohol	O
at	O
low	O
pH	O
inactivated	O
enveloped	O
respiratory	O
viruses	O
influenza	B-DISO
A	O
,	O
respiratory	O
synctial	O
virus	O
(	O
RSV	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
but	O
not	O
viruses	O
with	O
icosahedral	O
symmetry	O
,	O
such	O
as	O
adenoviruses	O
or	O
rhinoviruses	O
.	O

However	O
,	O
more	O
than	O
half	O
the	O
staff	O
claimed	O
ignorance	O
on	O
the	O
knowledge	O
of	O
infection	B-DISO
isolation	O
ward	O
(	O
56	O
.	O
2	O
%),	O
Infection	B-DISO
Control	O
Nurse	O
(	O
57	O
.	O
9	O
%)	O
and	O
Chairman	O
(	O
65	O
.	O
3	O
%).	O

Our	O
findings	O
demonstrated	O
that	O
SARS	B-DISO
crisis	O
had	O
some	O
positive	O
impact	O
on	O
the	O
infection	B-DISO
control	O
practices	O
and	O
awareness	O
of	O
medical	O
staff	O
especially	O
on	O
those	O
with	O
direct	O
SARS	B-DISO
involvement	O
.	O

In	O
this	O
study	O
,	O
a	O
database	O
containing	O
structural	O
information	O
of	O
more	O
than	O
8	O
,	O
000	O
existing	O
drugs	O
was	O
virtually	O
screened	O
by	O
a	O
docking	O
approach	O
to	O
identify	O
potential	O
binding	O
molecules	O
of	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
.	O

The	O
level	O
of	O
virus	O
RNA	O
and	O
infectious	B-DISO
particles	O
was	O
reduced	O
by	O
up	O
to	O
4	O
log	O
units	O
,	O
with	O
IC50	O
values	O
ranging	O
from	O
19	O
to	O
34	O
microM	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
old	O
drug	O
cinanserin	O
is	O
an	O
inhibitor	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
,	O
acting	O
most	O
likely	O
via	O
inhibition	O
of	O
the	O
3CL	O
proteinase	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
the	O
putative	O
fusion	O
peptide	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
newly	O
identified	O
member	O
of	O
the	O
family	O
Coronaviridae	O
and	O
poses	O
a	O
serious	O
public	O
health	O
threat	O
.	O

S	O
-	O
A5D5	O
reacted	O
specifically	O
react	O
with	O
both	O
recombinant	O
and	O
native	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
CoV	O
.	O
The	O
reactivity	O
of	O
S	O
-	O
A5D5	O
with	O
purified	O
N195	O
protein	O
and	O
utilization	O
of	O
the	O
MAb	O
as	O
a	O
detector	O
antibody	O
to	O
develop	O
an	O
antigen	O
capture	O
ELISA	O
was	O
assessed	O
.	O

The	O
mAb	O
could	O
recognize	O
the	O
spike	O
protein	O
on	O
the	O
MLV	O
/	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
albeit	O
with	O
no	O
neutralizing	O
effect	O
on	O
the	O
infectivity	O
of	O
the	O
pseudotype	O
virus	O
.	O

Although	O
this	O
evidence	O
is	O
still	O
far	O
from	O
being	O
definitive	O
,	O
the	O
results	O
so	O
far	O
obtained	O
suggest	O
that	O
PIs	O
should	O
be	O
seriously	O
taken	O
into	O
consideration	O
for	O
further	O
testing	O
as	O
potential	O
therapeutic	O
agents	O
for	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

In	O
the	O
current	O
study	O
,	O
we	O
established	O
the	O
utility	O
of	O
two	O
additional	O
assays	O
to	O
measure	O
the	O
neutralizing	O
activities	O
against	O
SCV	O
:	O
the	O
plaque	B-DISO
reduction	O
(	O
PR	O
)	O
and	O
the	O
neutral	O
red	O
staining	O
(	O
NRS	O
)	O
assays	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
and	O
contrast	O
the	O
impact	O
of	O
SARS	B-DISO
on	O
family	O
physicians	O
in	O
Hong	O
Kong	O
and	O
Toronto	O
.	O

For	O
public	O
health	O
measures	O
in	O
the	O
control	O
of	O
SARS	B-DISO
,	O
Hong	O
Kong	O
physicians	O
were	O
less	O
likely	O
to	O
quarantined	O
themselves	O
(	O
77	O
.	O
1	O
%	O
versus	O
19	O
.	O
4	O
%,	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
gave	O
quarantine	O
leave	O
to	O
staff	O
(	O
95	O
%	O
versus	O
59	O
.	O
7	O
%,	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
exposure	O
to	O
probable	O
or	O
suspected	O
SARS	B-DISO
.	O

There	O
were	O
noticeable	O
differences	O
in	O
how	O
family	O
physicians	O
deal	O
with	O
SARS	B-DISO
between	O
the	O
two	O
cities	O
.	O

An	O
analysis	O
of	O
receptor	O
engagement	O
revealed	O
that	O
NL63	O
-	O
S	O
binds	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
2	O
,	O
the	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
NL63	O
uses	O
ACE2	O
as	O
a	O
receptor	O
for	O
infection	B-DISO
of	O
target	O
cells	O
.	O

We	O
have	O
explored	O
whether	O
determination	O
of	O
several	O
proinflammatory	O
cytokine	O
or	O
mediator	O
concentrations	O
can	O
complement	O
physiologic	O
scoring	O
systems	O
to	O
identify	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
who	O
will	O
survive	O
or	O
expire	O
within	O
28	O
days	O
.	O

One	O
hundred	O
twenty	O
-	O
four	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
with	O
or	O
without	O
septic	B-DISO
shock	I-DISO
were	O
included	O
in	O
this	O
analysis	O
.	O

The	O
nucleotide	O
sequence	O
and	O
protein	O
sequence	O
of	O
GD	O
nsp2	O
were	O
compared	O
with	O
that	O
of	O
other	O
SARS	B-DISO
-	O
CoV	O
strains	O
by	O
nucleotide	O
-	O
nucleotide	O
basic	O
local	O
alignment	O
search	O
tool	O
(	O
BLASTN	O
)	O
and	O
protein	O
-	O
protein	O
basic	O
local	O
alignment	O
search	O
tool	O
(	O
BLASTP	O
)	O
to	O
investigate	O
its	O
variance	O
trend	O
during	O
the	O
transmission	O
.	O

The	O
result	O
of	O
sequencing	O
and	O
sequence	O
comparison	O
with	O
other	O
SARS	B-DISO
-	O
CoV	O
strains	O
showed	O
that	O
nsp2	O
gene	O
was	O
relatively	O
conservative	O
during	O
the	O
transmission	O
and	O
total	O
five	O
base	O
sites	O
mutated	O
in	O
about	O
100	O
strains	O
investigated	O
,	O
three	O
of	O
which	O
in	O
the	O
early	O
and	O
middle	O
phases	O
caused	O
synonymous	O
mutation	O
,	O
and	O
another	O
two	O
base	O
sites	O
variation	O
in	O
the	O
late	O
phase	O
resulted	O
in	O
the	O
amino	O
acid	O
substitutions	O
and	O
secondary	O
structure	O
changes	O
.	O

The	O
RNA	O
levels	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
were	O
determined	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
morphology	O
of	O
coherently	O
pathologic	O
lung	O
tissue	O
was	O
characterized	O
by	O
the	O
length	O
of	O
the	O
borderline	O
between	O
consolidated	O
,	O
infiltrated	B-DISO
and	O
atelectatic	O
lung	O
tissue	O
and	O
radiologically	O
normal	O
lung	O
tissue	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
demonstrate	O
that	O
the	O
gross	O
morphological	O
distribution	O
of	O
pathological	O
lung	O
tissue	O
influences	O
iNO	O
response	O
in	O
ARDS	B-DISO
.	O

All	O
patients	O
had	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
or	O
CT	O
,	O
some	O
even	O
with	O
multi	O
-	O
infiltrates	B-DISO
.	O

Although	O
hypovolemic	B-DISO
shock	I-DISO
was	O
suspected	O
,	O
the	O
patient	O
did	O
not	O
respond	O
to	O
conventional	O
treatment	O
of	O
volume	O
expansion	O
and	O
inotropic	O
support	O
.	O

Two	O
weeks	O
later	O
,	O
cranial	O
ultrasonography	O
revealed	O
multiple	O
,	O
right	O
-	O
sided	O
,	O
cystic	O
lesions	O
that	O
were	O
subsequently	O
diagnosed	O
as	O
cerebral	B-DISO
infarction	I-DISO
by	O
magnetic	O
resonance	O
imaging	O
.	O

TITLE	O
:	O
A	O
deficient	O
public	O
health	O
system	O
as	O
a	O
contributing	O
cause	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
in	O
mainland	O
China	O
.	O

TITLE	O
:	O
The	O
economic	O
impact	O
of	O
quarantine	O
:	O
SARS	B-DISO
in	O
Toronto	O
as	O
a	O
case	O
study	O
.	O

RESULTS	O
:	O
Our	O
results	O
indicate	O
that	O
quarantine	O
is	O
effective	O
in	O
containing	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
and	O
also	O
cost	O
saving	O
when	O
compared	O
to	O
not	O
implementing	O
a	O
widespread	O
containment	O
mechanism	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
affected	O
over	O
8000	O
people	O
killing	O
774	O
by	O
July	O
2003	O
.	O

TITLE	O
:	O
Longitudinal	O
assessment	O
of	O
community	O
psychobehavioral	O
responses	O
during	O
and	O
after	O
the	O
2003	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Hong	O
Kong	O
.	O

Using	O
random	O
-	O
digit	O
dialing	O
,	O
we	O
sampled	O
4481	O
Hong	O
Kong	O
residents	O
in	O
6	O
population	O
-	O
based	O
surveys	O
that	O
were	O
conducted	O
at	O
different	O
times	O
during	O
and	O
after	O
the	O
2003	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

In	O
this	O
study	O
,	O
cirrhotic	O
patients	O
with	O
ARDS	B-DISO
after	O
MCT	O
were	O
compared	O
with	O
others	O
without	O
ARDS	B-DISO
.	O

It	O
also	O
inhibited	O
giant	B-DISO
cell	O
formation	O
in	O
co	O
-	O
cultures	O
of	O
HIV	B-DISO
-	O
infected	O
cells	O
and	O
uninfected	O
Molt	O
-	O
4	O
cells	O
.	O

Mizoribine	O
inhibited	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
more	O
strongly	O
than	O
ribavirin	O
.	O

SARS	B-DISO
-	O
CoV	O
was	O
not	O
found	O
in	O
peripheral	O
blood	O
or	O
sputum	O
specimens	O
from	O
three	O
patients	O
.	O

In	O
this	O
article	O
,	O
we	O
aim	O
to	O
focus	O
on	O
the	O
management	O
of	O
the	O
subgroup	O
of	O
SARS	B-DISO
patients	O
who	O
are	O
critically	B-DISO
ill	I-DISO
.	O

The	O
management	O
of	O
critically	B-DISO
ill	I-DISO
SARS	B-DISO
patients	O
requires	O
timely	O
institution	O
of	O
pharmacotherapy	O
where	O
applicable	O
and	O
supportive	O
treatment	O
(	O
oxygen	O
therapy	O
,	O
noninvasive	O
and	O
invasive	O
ventilation	O
).	O

TITLE	O
:	O
The	O
pathogenesis	B-DISO
of	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
:	O
its	O
relevance	O
to	O
developing	O
effective	O
strategies	O
for	O
prevention	O
.	O

Strategies	O
to	O
prevent	O
VAP	O
are	O
likely	O
to	O
be	O
successful	O
only	O
if	O
based	O
upon	O
a	O
sound	O
understanding	O
of	O
pathogenesis	B-DISO
and	O
epidemiology	O
.	O

In	O
contrast	O
,	O
epidemic	O
VAP	O
is	O
most	O
often	O
caused	O
by	O
contamination	O
of	O
respiratory	O
therapy	O
equipment	O
,	O
bronchoscopes	O
,	O
medical	O
aerosols	O
,	O
water	O
(	O
eg	O
,	O
Legionella	O
)	O
or	O
air	O
(	O
eg	O
,	O
Aspergillus	O
or	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
).	O

Residents	O
attributed	O
stigma	O
to	O
government	O
mismanagement	O
,	O
contagiousness	O
of	O
the	O
mysterious	O
SARS	B-DISO
virus	O
,	O
and	O
alarmist	O
media	O
reporting	O
.	O

TITLE	O
:	O
Risk	O
of	O
respiratory	B-DISO
infections	I-DISO
in	O
health	O
care	O
workers	O
:	O
lessons	O
on	O
infection	B-DISO
control	O
emerge	O
from	O
the	O
SARS	B-DISO
outbreak	O
.	O

SARS	B-DISO
-	O
CoV	O
diluted	O
to	O
2	O
PFU	O
failed	O
to	O
establish	O
persistence	O
,	O
suggesting	O
that	O
some	O
particular	O
viruses	O
in	O
the	O
seed	O
virus	O
did	O
not	O
induce	O
persistent	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Impacts	O
of	O
SARS	B-DISO
on	O
health	O
-	O
seeking	O
behaviors	O
in	O
general	O
population	O
in	O
Hong	O
Kong	O
.	O

The	O
community	O
in	O
Hong	O
Kong	O
responded	O
to	O
the	O
SARS	B-DISO
epidemic	O
by	O
practicing	O
more	O
favorable	O
health	O
-	O
seeking	O
behaviors	O
.	O

The	O
cause	O
of	O
death	O
was	O
life	O
-	O
threatening	O
organ	B-DISO
failure	I-DISO
,	O
including	O
malignancy	B-DISO
(	O
44	O
%),	O
cerebral	B-DISO
lesion	I-DISO
(	O
10	O
%)	O
and	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
(	O
10	O
%).	O

RESULTS	O
:	O
Among	O
674	O
patients	O
,	O
71	O
%	O
suffered	B-DISO
respiratory	B-DISO
insufficiency	I-DISO
,	O
43	O
%	O
were	O
unconscious	O
and	O
32	O
%	O
had	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
during	O
the	O
24h	O
before	O
death	O
.	O

TITLE	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
catastrophic	O
antiphospholipid	B-DISO
syndrome	I-DISO
:	O
analysis	O
of	O
a	O
series	O
of	O
47	O
patients	O
.	O

It	O
can	O
be	O
precipitated	O
by	O
various	O
serious	O
medical	O
and	O
surgical	O
conditions	O
,	O
including	O
systemic	O
autoimmune	B-DISO
diseases	I-DISO
.	O

So	O
far	O
,	O
no	O
animal	O
model	O
is	O
available	O
to	O
study	O
the	O
pathogenesis	B-DISO
of	O
infection	B-DISO
by	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Cytokine	O
responses	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
infected	O
macrophages	O
in	O
vitro	O
:	O
possible	O
relevance	O
to	O
pathogenesis	B-DISO
.	O

SARS	B-DISO
-	O
CoV	O
initiated	O
viral	O
gene	O
transcription	O
and	O
protein	O
synthesis	O
in	O
macrophages	O
,	O
but	O
replication	O
was	O
abortive	O
and	O
no	O
infectious	B-DISO
virus	O
was	O
produced	O
.	O

In	O
contrast	O
to	O
the	O
case	O
with	O
human	O
coronavirus	O
229E	O
and	O
influenza	B-DISO
A	O
virus	O
,	O
there	O
was	O
little	O
or	O
no	O
induction	O
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
beta	O
)	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
macrophages	O
.	O

TITLE	O
:	O
Coronaviral	O
hypothetical	O
and	O
structural	O
proteins	O
were	O
found	O
in	O
the	O
intestinal	O
surface	O
enterocytes	O
and	O
pneumocytes	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
[	O
Surveillance	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
in	O
animals	O
at	O
a	O
live	O
animal	O
market	O
of	O
Guangzhou	O
in	O
2004	O
].	O

A	O
single	O
step	O
realtime	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
diagnostic	O
kit	O
was	O
performed	O
for	O
screening	O
SARS	B-DISO
-	O
CoV	O
like	O
virus	O
,	O
the	O
manual	O
nested	O
RT	O
-	O
PCR	O
and	O
DNA	O
sequencing	O
were	O
performed	O
for	O
confirmation	O
.	O

This	O
findings	O
revealed	O
that	O
animals	O
being	O
sampled	O
in	O
April	O
,	O
May	O
,	O
June	O
,	O
July	O
,	O
August	O
and	O
November	O
of	O
2004	O
,	O
only	O
one	O
rectal	O
swab	O
from	O
a	O
pig	O
was	O
tested	O
positive	O
as	O
SARS	B-DISO
-	O
CoV	O
like	O
virus	O
,	O
much	O
lower	O
than	O
the	O
results	O
from	O
the	O
previous	O
year	O
,	O
suggesting	O
that	O
the	O
possibility	O
of	O
re	O
-	O
emerging	O
of	O
human	O
infection	B-DISO
from	O
animal	O
origins	O
is	O
low	O
for	O
the	O
winter	O
of	O
2004	O
-	O
2005	O
.	O

CONCLUSIONS	O
:	O
This	O
findings	O
revealed	O
that	O
animals	O
being	O
sampled	O
in	O
April	O
,	O
May	O
,	O
June	O
,	O
July	O
,	O
August	O
and	O
November	O
of	O
2004	O
,	O
only	O
one	O
rectal	O
swab	O
from	O
a	O
pig	O
was	O
tested	O
positive	O
as	O
SARS	B-DISO
-	O
CoV	O
like	O
virus	O
,	O
much	O
lower	O
than	O
the	O
results	O
from	O
the	O
previous	O
year	O
,	O
suggesting	O
that	O
the	O
possibility	O
of	O
re	O
-	O
emerging	O
of	O
human	O
infection	B-DISO
from	O
animal	O
origins	O
is	O
low	O
for	O
the	O
winter	O
of	O
2004	O
-	O
2005	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
various	O
disinfectants	O
against	O
SARS	B-DISO
coronavirus	O
.	O

Withdrawal	B-DISO
of	O
FP	O
resulted	O
in	O
a	O
sustained	O
decrease	O
in	O
FEV1	O
:	O
mean	O
(	O
SE	O
)	O
change	O
from	O
baseline	O
-	O
4	O
.	O
4	O
(	O
0	O
.	O
9	O
)%	O
(	O
S	O
)	O
v	O
-	O
0	O
.	O
1	O
(	O
0	O
.	O
9	O
)%	O
(	O
SFC	O
);	O
adjusted	O
difference	O
4	O
.	O
1	O
(	O
95	O
%	O
CI	O
1	O
.	O
6	O
to	O
6	O
.	O
6	O
)	O
percentage	O
points	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

An	O
immediate	O
and	O
sustained	O
increase	O
in	O
dyspnoea	B-DISO
score	O
(	O
scale	O
0	O
-	O
4	O
;	O
mean	O
difference	O
between	O
groups	O
0	O
.	O
17	O
(	O
0	O
.	O
04	O
),	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
percentage	O
of	O
disturbed	O
nights	O
(	O
6	O
(	O
2	O
)	O
percentage	O
points	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
after	O
withdrawal	B-DISO
of	O
fluticasone	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
reviews	O
the	O
epidemiology	O
and	O
control	O
measures	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
.	O

Hong	O
Kong	O
was	O
ill	B-DISO
-	O
prepared	O
at	O
the	O
early	O
stage	O
of	O
the	O
epidemic	O
.	O

TITLE	O
:	O
Reducing	O
the	O
impact	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
in	O
children	O
.	O

Evolution	O
of	O
new	O
viral	O
pathogens	O
,	O
such	O
as	O
avian	B-DISO
influenza	I-DISO
virus	O
and	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
are	O
discussed	O
.	O

Serum	O
neopterin	O
may	O
allow	O
early	O
assessment	O
of	O
the	O
severity	O
of	O
SARS	B-DISO
.	O

Using	O
general	O
estimating	O
equations	O
(	O
GEE	O
)	O
statistical	O
analysis	O
to	O
control	O
possible	O
for	O
affecting	O
factors	O
,	O
we	O
found	O
that	O
the	O
nursing	O
staff	O
'	O
s	O
anxiety	O
and	O
depression	B-DISO
along	O
with	O
sleep	O
quality	O
started	O
to	O
improve	O
2	O
weeks	O
after	O
the	O
initiation	O
of	O
SARS	B-DISO
prevention	O
controls	O
.	O

Infectious	B-DISO
diseases	I-DISO
that	O
emerge	O
in	O
Africa	O
or	O
Asia	O
may	O
arrive	O
on	O
US	O
shores	O
within	O
days	O
.	O

Calcitonin	O
positive	O
cells	O
were	O
found	O
in	O
the	O
normal	O
thyroid	O
glands	O
and	O
not	O
in	O
the	O
thyroid	O
glands	O
of	O
the	O
SARS	B-DISO
patients	O
.	O

One	O
-	O
step	O
real	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
for	O
plasma	O
SARS	B-DISO
-	O
CoV	O
RNA	O
quantification	O
was	O
useful	O
for	O
early	O
diagnosis	O
and	O
monitoring	O
viremia	B-DISO
.	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
proteinase	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
key	O
target	O
for	O
drug	O
design	O
against	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
disease	O
severity	O
,	O
corticosteroids	O
and	O
social	O
factors	O
on	O
neuropsychiatric	O
complaints	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
,	O
both	O
during	O
acute	O
and	O
convalescent	O
phases	O
.	O

Severity	O
of	O
symptoms	O
,	O
corticosteroids	O
and	O
social	O
factors	O
explained	O
about	O
half	O
of	O
the	O
variances	O
(	O
R	O
(	O
2	O
)	O
=	O
52	O
)	O
in	O
anxiety	O
-	O
depression	B-DISO
at	O
acute	O
phase	O
and	O
33	O
%	O
at	O
convalescent	O
phase	O
.	O

By	O
cloning	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
of	O
the	O
ACE2	O
gene	O
in	O
the	O
lung	O
,	O
where	O
replication	O
occurs	O
on	O
SARS	B-DISO
-	O
CoV	O
,	O
it	O
was	O
shown	O
that	O
there	O
are	O
different	O
splicing	O
sites	O
.	O

In	O
them	O
,	O
ARF	B-DISO
was	O
caused	O
by	O
acute	B-DISO
interstitial	I-DISO
nephritis	I-DISO
in	O
18	O
.	O
8	O
%,	O
by	O
urosepsis	B-DISO
in	O
18	O
.	O
8	O
%,	O
by	O
non	O
-	O
urological	O
sepsis	B-DISO
in	O
19	O
%,	O
by	O
destructive	O
pancreatitis	B-DISO
in	O
18	O
%,	O
in	O
13	O
%	O
rapidly	B-DISO
progressive	I-DISO
glomerulonephritis	I-DISO
was	O
present	O
in	O
systemic	O
vasculitis	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
significance	O
of	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
elevation	O
in	O
the	O
development	O
of	O
oxygenation	O
impairment	B-DISO
and	O
clinical	O
outcome	O
with	O
distal	O
type	O
AAD	O
.	O

The	O
B1	O
recognized	O
SARS	B-DISO
pseudovirus	O
in	O
vivo	O
and	O
competed	O
with	O
SARS	B-DISO
sera	O
for	O
binding	O
to	O
SARS	B-DISO
-	O
CoV	O
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	B-DISO
constant	O
,	O
K	O
(	O
d	O
)	O
=	O
105	O
nM	O
).	O

Wavelet	O
technique	O
was	O
also	O
used	O
to	O
decompose	O
Moran	O
'	O
s	O
I	O
frequency	O
to	O
survey	O
the	O
spatial	O
clustering	O
process	O
of	O
SARS	B-DISO
.	O

The	O
predictable	O
number	O
of	O
SARS	B-DISO
cases	O
evolving	O
with	O
time	O
were	O
also	O
calculated	O
.	O

CONCLUSIONS	O
:	O
Data	O
showed	O
that	O
all	O
the	O
SARS	B-DISO
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	O
antibody	O
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	O
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	O
antibody	O
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
RNA	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
the	O
blood	O
and	O
excretion	O
of	O
convalescent	O
patient	O
with	O
SARS	B-DISO
for	O
prevention	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

A	O
total	O
of	O
276	O
samples	O
,	O
including	O
plasma	O
,	O
urine	O
,	O
feces	O
and	O
sputum	O
,	O
obtained	O
from	O
23	O
convalescent	O
patients	O
with	O
SARS	B-DISO
were	O
studied	O
at	O
3	O
time	O
-	O
points	O
at	O
least	O
21	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

ABSTRACT	O
:	O
To	O
prepare	O
and	O
characterize	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
and	O
polyclonal	O
antibodies	O
against	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
to	O
establish	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
for	O
detecting	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
might	O
apply	O
to	O
early	O
diagnosis	O
of	O
patients	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
purified	O
recombinant	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
for	O
producing	O
mAbs	O
,	O
and	O
New	O
Zealand	O
white	O
rabbits	O
were	O
immunized	O
for	O
producing	O
polyclonal	O
antibodies	O
.	O

Two	O
hours	O
after	O
blunt	O
chest	O
trauma	O
,	O
plasma	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
were	O
markedly	O
increased	O
,	O
as	O
was	O
peripheral	O
blood	O
mononuclear	O
cell	O
cytokine	O
production	O
,	O
lung	O
myeloperoxidase	O
activity	O
,	O
and	O
lung	O
chemokine	O
concentrations	O
.	O

Avidity	O
indices	O
of	O
40	O
%	O
and	O
55	O
%	O
could	O
be	O
considered	O
as	O
cutoff	O
values	O
for	O
determination	O
of	O
recent	O
(<	O
or	O
=	O
50	O
days	O
)	O
and	O
past	O
(>	O
65	O
days	O
)	O
infection	B-DISO
,	O
respectively	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
the	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
:	O
modulation	O
of	O
effector	O
cell	O
function	O
without	O
productive	O
infection	B-DISO
.	O

We	O
found	O
neither	O
cell	O
to	O
be	O
permissive	O
for	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

Also	O
,	O
exposure	O
to	O
infectious	B-DISO
SARS	B-DISO
-	O
CoV	O
led	O
to	O
the	O
phenotypic	O
and	O
functional	O
maturation	O
of	O
DC	O
,	O
with	O
regard	O
to	O
MHC	O
class	O
II	O
and	O
costimulatory	O
molecule	O
expression	O
,	O
T	O
cell	O
-	O
stimulatory	O
capacity	O
,	O
and	O
cytokine	O
production	O
,	O
respectively	O
.	O

Poor	O
awareness	O
of	O
TRALI	B-DISO
outside	O
of	O
the	O
blood	O
transfusion	O
medicine	O
community	O
has	O
led	O
to	O
a	O
serious	O
underestimation	O
of	O
this	O
condition	B-DISO
,	O
currently	O
the	O
most	O
Important	O
severe	O
complication	B-DISO
of	I-DISO
blood	I-DISO
transfusion	I-DISO
.	O

ABSTRACT	O
:	O
To	O
follow	O
-	O
up	O
on	O
the	O
changes	O
in	O
lung	O
function	O
and	O
lung	O
radiographic	O
pictures	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
discharged	O
from	O
Xiaotangshan	O
Hospital	O
in	O
Beijing	O
(	O
by	O
regularly	O
receiving	O
examination	O
),	O
and	O
to	O
analyze	O
retrospectively	O
the	O
treatment	O
strategy	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
7863	O
contacts	O
of	O
SARS	B-DISO
cases	O
were	O
served	O
with	O
an	O
HQO	O
,	O
giving	O
a	O
ratio	O
of	O
38	O
contacts	O
per	O
case	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
laws	O
of	O
the	O
appearance	O
of	O
the	O
specific	O
serum	O
antibodies	O
against	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
evaluate	O
the	O
value	O
of	O
these	O
two	O
proteins	O
to	O
be	O
used	O
as	O
diagnostic	O
makers	O
for	O
SARS	B-DISO
.	O

The	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
positive	O
rate	O
in	O
the	O
healthy	O
persons	O
was	O
1	O
.	O
88	O
%	O
(	O
14	O
.	O
745	O
).	O

Nucleocapsid	O
gene	O
was	O
obtained	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
a	O
SARS	B-DISO
patient	O
and	O
inserted	O
into	O
the	O
vector	O
pFastBacHTa	O
expressing	O
baculovirus	O
.	O

RESULTS	O
:	O
The	O
recombinant	O
SARS	B-DISO
-	O
specific	O
antigen	O
reacted	O
only	O
with	O
SARS	B-DISO
positive	O
sera	O
but	O
not	O
with	O
normal	O
sera	O
.	O

Of	O
a	O
thousand	O
existing	O
drugs	O
examined	O
,	O
hexachlorophene	O
was	O
identified	O
as	O
the	O
most	O
potent	O
in	O
inhibiting	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
.	O

These	O
analogues	O
gave	O
optimal	O
inhibitory	O
activity	O
against	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
7	O
.	O
6	O
to	O
84	O
.	O
5	O
microM	O
.	O
Optimization	O
of	O
hexachlorophene	O
analogues	O
was	O
shown	O
to	O
provide	O
several	O
active	O
3CL	O
protease	O
inhibitors	O
that	O
function	O
as	O
potential	O
anti	O
-	O
SARS	B-DISO
agents	O
.	O

Decision	O
-	O
making	O
in	O
a	O
time	O
of	O
emergency	B-DISO
is	O
associated	O
with	O
a	O
high	O
potential	O
for	O
ethical	O
dilemmas	O
and	O
conflicts	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
3	O
(	O
MHV3	O
)	O
infection	B-DISO
of	O
A	O
/	O
J	O
and	O
BALB	O
/	O
c	O
mice	O
has	O
been	O
used	O
as	O
a	O
model	O
of	O
resistance	O
/	O
susceptibility	O
.	O

A	O
/	O
J	O
mice	O
recover	O
from	O
a	O
mild	O
disease	O
after	O
4	O
-	O
6	O
days	O
of	O
infection	B-DISO
and	O
the	O
BALB	O
/	O
c	O
mice	O
develop	O
an	O
acute	B-DISO
hepatitis	I-DISO
and	O
die	O
after	O
3	O
-	O
4	O
days	O
of	O
infection	B-DISO
.	O

Our	O
experiments	O
contribute	O
to	O
the	O
hypothesis	O
that	O
IFN	O
-	O
gamma	O
activation	O
of	O
macrophages	O
plays	O
an	O
important	O
role	O
against	O
MHV3	O
infection	B-DISO
by	O
downregulating	O
the	O
expression	O
of	O
viral	O
receptors	O
.	O

SARS	B-DISO
patients	O
(	O
N	O
=	O
171	O
)	O
discharged	O
from	O
the	O
hospital	O
.	O

Recent	O
studies	O
indicate	O
that	O
SARS	B-DISO
-	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
and	O
its	O
truncated	O
fragments	O
are	O
considered	O
the	O
best	O
candidates	O
for	O
generation	O
of	O
the	O
recombinant	O
vaccine	O
.	O

We	O
produced	O
a	O
series	O
of	O
recombinant	O
viruses	O
,	O
with	O
an	O
isogenic	O
background	O
,	O
in	O
which	O
complete	O
expression	O
of	O
gene	O
5	O
products	O
was	O
prevented	O
by	O
the	O
inactivation	B-DISO
of	O
gene	O
5	O
following	O
scrambling	O
of	O
the	O
transcription	O
-	O
associated	O
sequence	O
,	O
thereby	O
preventing	O
the	O
expression	O
of	O
IBV	O
subgenomic	O
mRNA	O
5	O
,	O
or	O
scrambling	O
either	O
separately	O
or	O
together	O
of	O
the	O
translation	O
initiation	O
codons	O
for	O
the	O
two	O
gene	O
5	O
products	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occurred	O
in	O
China	O
and	O
the	O
first	O
case	O
emerged	O
in	O
mid	O
-	O
November	O
2002	O
.	O

The	O
aetiological	O
agent	O
of	O
this	O
disease	O
was	O
found	O
to	O
be	O
a	O
previously	O
unknown	O
coronavirus	O
,	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
severity	O
and	O
global	O
spread	O
of	O
the	O
2003	O
outbreak	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
highlighted	O
the	O
risks	O
to	O
human	O
health	O
posed	O
by	O
emerging	O
viral	B-DISO
diseases	I-DISO
and	O
emphasized	O
the	O
need	O
for	O
specific	O
therapeutic	O
agents	O
instead	O
of	O
relying	O
on	O
existing	O
broadly	O
active	O
antiviral	O
compounds	O
.	O

TITLE	O
:	O
Appropriate	O
use	O
of	O
personal	O
protective	O
equipment	O
among	O
healthcare	O
workers	O
in	O
public	O
sector	O
hospitals	O
and	O
primary	O
healthcare	O
polyclinics	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Singapore	O
.	O

Radiographers	O
were	O
easily	O
infected	O
by	O
SARS	B-DISO
because	O
they	O
had	O
close	O
contact	O
with	O
suspected	O
or	O
probable	O
cases	O
while	O
conducting	O
chest	O
X	O
-	O
ray	O
examinations	O
.	O

The	O
ability	O
of	O
residents	O
to	O
cope	O
with	O
the	O
stress	O
of	O
the	O
SARS	B-DISO
outbreak	O
was	O
enhanced	O
by	O
the	O
communication	O
of	O
relevant	O
information	O
and	O
by	O
the	O
leadership	O
of	O
their	O
supervisors	O
and	O
infection	B-DISO
control	O
officers	O
.	O

TITLE	O
:	O
Concentration	O
and	O
detection	O
of	O
SARS	B-DISO
coronavirus	O
in	O
sewage	O
from	O
Xiao	O
Tang	O
Shan	O
Hospital	O
and	O
the	O
309th	O
Hospital	O
.	O

These	O
findings	O
provide	O
strong	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
can	O
be	O
excreted	O
through	O
the	O
stool	O
/	O
urine	O
of	O
patients	O
into	O
sewage	O
system	O
,	O
thus	O
making	O
the	O
sewage	O
system	O
a	O
possible	O
route	O
of	O
transmission	O
.	O

Moreover	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
herds	O
in	O
which	O
no	O
calves	O
had	O
a	O
recorded	O
history	O
of	O
respiratory	B-DISO
disease	I-DISO
(	O
n	O
=	O
15	O
)	O
were	O
classified	O
as	O
negative	O
to	O
all	O
four	O
infections	B-DISO
monitored	O
when	O
compared	O
to	O
herds	O
in	O
which	O
disease	O
was	O
observed	O
(	O
P	O
=	O
0	O
.	O
0002	O
).	O

About	O
a	O
month	O
into	O
the	O
epidemic	O
,	O
a	O
public	O
education	O
campaign	O
was	O
mounted	O
to	O
educate	O
Singaporeans	O
on	O
SARS	B-DISO
and	O
adoption	O
of	O
appropriate	O
behaviours	O
to	O
prevent	O
the	O
spread	O
of	O
the	O
disease	O
.	O

The	O
survey	O
also	O
sought	O
to	O
assess	O
their	O
confidence	O
in	O
the	O
ability	O
of	O
various	O
institutions	O
to	O
deal	O
with	O
SARS	B-DISO
and	O
their	O
opinion	O
on	O
the	O
seemingly	O
tough	O
measures	O
enforced	O
.	O

ABSTRACT	O
:	O
We	O
employed	O
the	O
staggered	B-DISO
extension	O
process	O
(	O
StEP	O
)	O
to	O
shuffle	O
the	O
S1	O
genes	O
from	O
four	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
representing	O
four	O
unique	O
serotypes	O
.	O

TITLE	O
:	O
A	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Extranet	O
:	O
supporting	O
local	O
communication	O
and	O
information	O
dissemination	O
.	O

During	O
July	O
,	O
2003	O
,	O
a	O
web	B-DISO
-	O
based	O
and	O
paper	O
-	O
based	O
survey	O
was	O
conducted	O
with	O
53	O
SARS	B-DISO
Steering	O
Committee	O
members	O
in	O
Hamilton	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
of	O
52	O
years	O
who	O
had	O
direct	O
contact	O
with	O
a	O
probable	O
case	O
of	O
SARS	B-DISO
.	O

In	O
this	O
context	O
the	O
recognition	O
of	O
probably	O
infectious	B-DISO
asymptomatic	O
forms	O
is	O
essential	O
.	O

Firefly	O
luciferase	O
expression	O
of	O
pGL	B-DISO
-	O
R	O
was	O
reduced	O
to	O
13	O
%	O
by	O
esiRNA	O
-	O
R	O
.	O
Expression	O
of	O
pGLS	O
was	O
reduced	O
to	O
11	O
%	O
by	O
esiRNA	O
-	O
S	O
.	O
Expression	O
of	O
pGL	B-DISO
-	O
N	O
was	O
reduced	O
to	O
40	O
%	O
by	O
esiRNA	O
-	O
N	O
.	O
Control	O
esiRNAs	O
didn	O
'	O
t	O
affect	O
luciferase	O
expression	O
;	O
Hybrid	O
mRNAs	O
'	O
abundance	O
was	O
dramatically	O
reduced	O
by	O
corresponding	O
esiRNAs	O
.	O

TITLE	O
:	O
[	O
Over	O
-	O
expression	O
in	O
Escherichia	O
coli	O
and	O
purification	O
of	O
nucleocaspid	O
and	O
membrane	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
].	O

The	O
recombinant	O
N	O
protein	O
was	O
demonstrated	O
highly	O
antigenic	O
and	O
could	O
be	O
employed	O
as	O
antigen	O
to	O
detect	O
SARS	B-DISO
antibodies	O
in	O
ELISA	O
system	O
for	O
SARS	B-DISO
diagnosis	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
changes	O
and	O
pattern	O
of	O
pulmonary	O
function	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
during	O
convalescent	O
period	O
.	O

Both	O
SARS	B-DISO
-	O
IgM	O
and	O
IgG	O
sero	O
-	O
conversion	O
occurred	O
earlier	O
in	O
all	O
the	O
patients	O
with	O
the	O
titer	O
increased	O
more	O
than	O
4	O
-	O
fold	O
shortly	O
.	O

The	O
4	O
sporadic	O
SARS	B-DISO
patients	O
in	O
2004	O
have	O
milder	O
manifestations	O
,	O
shorter	O
course	O
of	O
disease	O
with	O
no	O
complications	O
during	O
an	O
epidemic	O
,	O
compared	O
with	O
patients	O
seen	O
previously	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
is	O
eliminated	O
rapidly	O
.	O

TITLE	O
:	O
Risk	O
perception	O
and	O
impact	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
on	O
work	O
and	O
personal	O
lives	O
of	O
healthcare	O
workers	O
in	O
Singapore	O
:	O
what	O
can	O
we	O
learn	O
?	O

TITLE	O
:	O
Response	O
of	O
memory	O
CD8	O
+	O
T	O
cells	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
in	O
recovered	O
SARS	B-DISO
patients	O
and	O
healthy	O
individuals	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
the	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
humans	O
is	O
still	O
not	O
well	O
understood	O
.	O

Intriguingly	O
,	O
heat	O
-	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
elicited	O
recall	O
-	O
like	O
CTL	O
responses	O
to	O
SSp	O
-	O
1	O
but	O
not	O
to	O
S978	O
,	O
S1202	O
,	O
or	O
dominant	O
epitopes	O
from	O
several	O
other	O
human	O
viruses	O
in	O
5	O
of	O
36	O
(	O
13	O
.	O
8	O
%)	O
HLA	O
-	O
A	O
*	O
0201	O
(+)	O
healthy	O
donors	O
without	O
any	O
contact	O
history	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
expanded	O
from	O
memory	O
T	O
cells	O
of	O
both	O
recovered	O
SARS	B-DISO
patients	O
,	O
and	O
the	O
five	O
exceptional	O
healthy	O
donors	O
shared	O
a	O
differentiated	O
effector	O
CTL	O
phenotype	O
,	O
CD45RA	O
(+)	O
CCR7	O
(-)	O
CD62L	O
(-),	O
and	O
expressed	O
CCR5	O
and	O
CD44	O
.	O

ABSTRACT	O
:	O
A	O
diversified	O
library	O
of	O
peptide	O
anilides	O
was	O
prepared	O
,	O
and	O
their	O
inhibition	O
activities	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
were	O
examined	O
by	O
a	O
fluorogenic	O
tetradecapeptide	O
substrate	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
Key	O
factors	O
in	O
crisis	O
management	O
.	O

There	O
were	O
no	O
negative	O
reports	O
related	O
to	O
the	O
selected	O
hospital	O
despite	O
its	O
being	O
located	O
right	O
in	O
the	O
center	O
of	O
an	O
area	O
struck	B-DISO
by	O
the	O
epidemic	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
key	O
factors	O
enabling	O
the	O
hospital	O
to	O
survive	O
SARS	B-DISO
unscathed	O
.	O

Data	O
were	O
collected	O
from	O
in	O
-	O
depth	O
interviews	O
with	O
the	O
nursing	O
directors	O
and	O
nursing	O
managers	O
of	O
the	O
SARS	B-DISO
units	O
,	O
along	O
with	O
a	O
review	O
of	O
relevant	O
hospital	O
documents	O
.	O

It	O
is	O
important	O
to	O
be	O
aware	O
of	O
cell	O
culture	O
associated	O
mutations	O
when	O
interpreting	O
data	O
on	O
molecular	O
evolution	O
of	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
In	O
a	O
group	O
of	O
N	O
individuals	O
,	O
carrying	O
an	O
infection	B-DISO
with	O
prevalence	O
pi	O
,	O
the	O
exact	O
probability	O
P	O
of	O
failing	O
in	O
detecting	O
the	O
infection	B-DISO
is	O
evaluated	O
when	O
a	O
diagnostic	O
test	O
of	O
sensitivity	O
s	O
and	O
specificity	O
s	O
'	O
is	O
carried	O
out	O
on	O
a	O
sample	O
of	O
n	O
individuals	O
extracted	O
without	O
replacement	O
from	O
the	O
group	O
.	O

ABSTRACT	O
:	O
We	O
recently	O
published	O
experimental	O
results	O
that	O
indicated	O
Aurintricarboxylic	O
Acid	O
(	O
ATA	O
)	O
could	O
selectively	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
replication	O
inside	O
host	O
cells	O
by	O
greater	O
than	O
1000	O
times	O
.	O

ABSTRACT	O
:	O
Because	O
phosphorylation	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
may	O
regulate	O
its	O
multiple	O
roles	O
in	O
viral	O
replication	O
,	O
the	O
dynamics	O
of	O
N	O
phosphorylation	O
were	O
examined	O
.	O

Pulse	O
labeling	O
with	O
32P	O
-	O
orthophosphate	O
indicated	O
that	O
the	O
IBV	O
N	O
protein	O
was	O
phosphorylated	O
in	O
the	O
virion	O
,	O
as	O
well	O
as	O
at	O
all	O
times	O
during	O
infection	B-DISO
in	O
either	O
chicken	O
embryo	O
kidney	O
cells	O
or	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
Dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
is	O
a	O
leading	O
cause	O
of	O
mortality	O
among	O
Indian	O
children	O
.	O

TITLE	O
:	O
Tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
convertase	O
(	O
ADAM17	O
)	O
mediates	O
regulated	O
ectodomain	O
shedding	O
of	O
the	O
severe	O
-	O
acute	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
).	O

This	O
review	O
also	O
highlights	O
the	O
need	O
for	O
continual	O
vigilance	O
for	O
potential	O
zoonotic	O
viruses	O
belonging	O
to	O
the	O
order	O
Nidovirales	O
,	O
such	O
as	O
the	O
SARS	B-DISO
coronavirus	O
.	O

Young	O
pigs	O
that	O
were	O
fed	O
the	O
TGEV	O
corn	B-DISO
orally	O
were	O
protected	O
against	O
challenge	O
with	O
virulent	O
TGEV	O
.	O

Deletion	O
or	O
mutations	O
in	O
SP	O
-	O
B	O
and	O
-	O
C	O
cause	O
acute	O
and	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
in	O
neonates	O
and	O
infants	O
.	O

Mutations	O
in	O
ABCA3	O
cause	O
fatal	O
respiratory	B-DISO
disease	I-DISO
in	O
newborns	O
and	O
severe	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
in	O
infancy	O
.	O

However	O
,	O
as	O
they	O
are	O
more	O
resistant	O
to	O
inactivation	B-DISO
they	O
may	O
have	O
a	O
role	O
in	O
treatment	O
of	O
adult	O
or	O
acute	O
RDS	O
.	O

CONCLUSIONS	O
:	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
and	O
neutrophil	O
activator	O
production	O
by	O
the	O
isolated	O
perfused	O
liver	O
,	O
in	O
response	O
to	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
LPS	B-DISO
,	O
does	O
not	O
appear	O
to	O
be	O
enhanced	O
during	O
AP	O
.	O

TITLE	O
:	O
Emerging	O
viral	B-DISO
infections	I-DISO
in	O
transplant	O
recipients	O
.	O

Of	O
the	O
14	O
trees	O
from	O
p65	O
to	O
nsp10	O
,	O
nine	O
showed	O
that	O
CoV	O
-	O
HKU1	O
was	O
clustered	O
with	O
murine	B-DISO
hepatitis	I-DISO
virus	O
.	O

Recent	O
examples	O
of	O
viruses	O
that	O
have	O
crossed	O
the	O
species	O
barrier	O
from	O
animal	O
reservoirs	O
to	O
humans	O
are	O
hantavirus	O
,	O
haemorrhagic	B-DISO
fever	I-DISO
viruses	O
,	O
arboviruses	O
,	O
Nipah	O
and	O
Hendra	O
viruses	O
,	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AI	O
),	O
monkeypox	B-DISO
virus	O
,	O
and	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
the	O
SARS	B-DISO
virus	O
.	O

He	O
had	O
fetal	O
acute	O
suffering	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
.	O

Surgical	O
biopsy	O
informed	O
of	O
a	O
highly	O
vascularized	O
mesenchymal	B-DISO
tumor	I-DISO
.	O

Microscopically	O
,	O
it	O
was	O
an	O
inflammatory	B-DISO
myofibroblastic	I-DISO
tumor	I-DISO
.	O

ABSTRACT	O
:	O
Pathological	O
characterization	O
of	O
autopsied	O
tissues	O
from	O
patients	O
with	O
SARS	B-DISO
revealed	O
severe	O
damage	O
in	O
restricted	O
tissues	O
,	O
such	O
as	O
lung	O
,	O
with	O
no	O
apparent	O
cell	B-DISO
damage	I-DISO
in	O
other	O
tissues	O
,	O
such	O
as	O
intestine	O
and	O
brain	O
.	O

ABSTRACT	O
:	O
During	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Hong	O
Kong	O
in	O
2003	O
,	O
patients	O
were	O
treated	O
with	O
very	O
high	O
doses	O
of	O
corticosteroid	O
and	O
ribavirin	O
.	O

ABSTRACT	O
:	O
Different	O
forms	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
neutralizing	O
antibody	O
response	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
compared	O
using	O
a	O
mouse	O
model	O
.	O

DNA	O
vaccine	O
control	O
and	O
oral	O
Salmonella	B-DISO
-	O
S	O
-	O
DNA	O
-	O
control	O
showed	O
no	O
neutralizing	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
Sera	O
of	O
the	O
mice	O
immunized	O
with	O
i	O
.	O
m	O
.	O

TITLE	O
:	O
Comparison	O
of	O
9	O
different	O
PCR	O
primers	O
for	O
the	O
rapid	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
using	O
2	O
RNA	O
extraction	O
methods	O
.	O

As	O
exemplified	O
by	O
this	O
study	O
,	O
the	O
continued	O
refinement	O
and	O
evaluation	O
of	O
PCR	O
procedures	O
will	O
greatly	O
benefit	O
the	O
diagnostic	O
laboratory	O
during	O
an	O
outbreak	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Inhibition	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
3CL	O
protease	O
by	O
peptidomimetic	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
esters	O
.	O

ABSTRACT	O
:	O
Although	O
overexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
165	O
in	O
the	O
lung	O
causes	O
pulmonary	B-DISO
oedema	I-DISO
,	O
its	O
role	O
in	O
human	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
unclear	O
.	O

TITLE	O
:	O
Clinical	O
impact	O
of	O
community	O
-	O
acquired	O
respiratory	O
viruses	O
on	O
bronchiolitis	B-DISO
obliterans	I-DISO
after	O
lung	O
transplant	O
.	O

A	O
cohort	O
of	O
100	O
patients	O
was	O
enrolled	O
from	O
2001	O
to	O
2003	O
in	O
which	O
50	O
patients	O
had	O
clinically	O
diagnosed	O
viral	O
RTI	B-DISO
and	O
50	O
were	O
asymptomatic	O
.	O

In	O
the	O
50	O
patients	O
with	O
RTI	B-DISO
,	O
a	O
microbial	O
etiology	O
was	O
identified	O
in	O
33	O
of	O
50	O
(	O
66	O
%)	O
and	O
included	O
rhinovirus	O
(	O
9	O
),	O
coronavirus	O
(	O
8	O
),	O
RSV	O
(	O
6	O
),	O
influenza	B-DISO
A	O
(	O
5	O
),	O
parainfluenza	B-DISO
(	O
4	O
)	O
and	O
human	O
metapneumovirus	O
(	O
1	O
).	O

Patients	O
with	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
left	B-DISO
ventricular	I-DISO
failure	I-DISO
were	O
excluded	O
.	O

PP	O
was	O
effective	O
in	O
treating	O
severe	O
hypoxemia	O
in	O
COPD	B-DISO
patients	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
problems	O
and	O
solutions	O
of	O
setting	O
up	O
the	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
based	O
ELISA	O
for	O
antibody	O
detection	O
.	O

The	O
most	O
prevalent	O
gas	O
exchange	O
abnormality	O
in	O
cirrhosis	B-DISO
was	O
the	O
alteration	O
of	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	B-DISO
gradient	O
,	O
directly	O
correlated	O
with	O
hepatocellur	O
disfunction	O
.	O

HPS	B-DISO
was	O
confirmed	O
in	O
8	O
patients	O
(	O
16	O
%).	O

Inapparent	B-DISO
infection	I-DISO
with	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
is	O
not	O
well	O
characterized	O
.	O

protein	O
-	O
based	O
ELISA	O
is	O
not	O
only	O
safe	O
but	O
also	O
a	O
more	O
specific	O
and	O
more	O
sensitive	O
method	O
to	O
diagnose	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
hence	O
a	O
useful	O
tool	O
for	O
large	O
-	O
scale	O
epidemiological	O
studies	O
.	O

When	O
both	O
the	O
liver	O
and	O
lung	O
were	O
perfused	O
,	O
endotoxin	O
caused	O
marked	O
hypoxemia	O
,	O
large	O
increases	O
in	O
perfusate	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
8	O
-	O
isoprostane	O
concentrations	O
,	O
and	O
severe	O
lung	B-DISO
edema	I-DISO
.	O

Intense	O
activation	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
and	O
oxidative	O
injury	O
that	O
results	O
in	O
pulmonary	B-DISO
edema	I-DISO
and	O
hypoxemia	O
(	O
acute	O
lung	O
injury	O
)	O
requires	O
interaction	O
of	O
the	O
lungs	O
with	O
the	O
liver	O
.	O

Notably	O
,	O
injection	O
of	O
SARS	B-DISO
-	O
CoV	O
Spike	O
into	O
mice	O
worsens	O
acute	O
lung	O
failure	O
in	O
vivo	O
that	O
can	O
be	O
attenuated	O
by	O
blocking	B-DISO
the	O
renin	O
-	O
angiotensin	O
pathway	O
.	O

TITLE	O
:	O
Experience	O
with	O
ARDS	B-DISO
caused	O
by	O
tuberculosis	B-DISO
in	O
a	O
respiratory	O
intensive	O
care	O
unit	O
.	O

Tuberculosis	B-DISO
is	O
an	O
uncommon	O
but	O
definite	O
cause	O
of	O
ARDS	B-DISO
,	O
and	O
in	O
patients	O
with	O
ARDS	B-DISO
of	O
obscure	O
aetiology	O
where	O
the	O
clinical	O
features	O
suggest	O
tuberculosis	B-DISO
as	O
the	O
inciting	O
cause	O
,	O
antitubercular	O
therapy	O
should	O
be	O
started	O
empirically	O
and	O
the	O
diagnosis	O
actively	O
pursued	O
later	O
.	O

TITLE	O
:	O
Epidemiologic	O
evaluation	O
of	O
diarrhea	B-DISO
in	O
dogs	O
in	O
an	O
animal	O
shelter	O
.	O

Fresh	O
fecal	O
specimens	O
were	O
screened	O
for	O
bacteria	O
and	O
bacterial	O
toxins	O
via	O
bacteriologic	O
culture	O
and	O
ELISA	O
,	O
parvovirus	B-DISO
via	O
ELISA	O
,	O
canine	O
coronavirus	O
via	O
nested	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
protozoal	O
cysts	B-DISO
and	O
oocysts	O
via	O
a	O
direct	O
fluorescent	O
antibody	O
technique	O
,	O
and	O
parasite	O
ova	O
and	O
larvae	O
via	O
microscopic	O
examination	O
of	O
direct	O
wet	O
mounts	O
and	O
zinc	O
sulfate	O
centrifugation	O
flotation	O
.	O

This	O
study	O
provided	O
an	O
epidemiologic	O
overview	O
of	O
diarrhea	B-DISO
and	O
interacting	O
diarrhea	B-DISO
-	O
associated	O
pathogens	O
in	O
a	O
densely	O
housed	O
,	O
highly	O
predisposed	O
shelter	O
population	O
of	O
dogs	O
.	O

ABSTRACT	O
:	O
The	O
March	O
2003	O
outbreak	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
resulted	O
in	O
significant	O
morbidity	O
and	O
mortality	O
.	O

To	O
determine	O
the	O
exact	O
nature	O
of	O
the	O
myopathy	B-DISO
associated	O
with	O
SARS	B-DISO
.	O

All	O
4	O
patients	O
treated	O
with	O
a	O
steroid	O
had	O
significant	O
myofiber	O
atrophy	B-DISO
.	O

A	O
questionnaire	O
survey	O
was	O
conducted	O
and	O
serum	O
samples	O
were	O
collected	O
for	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
antibody	O
.	O

Primary	B-DISO
immunodeficiency	I-DISO
disorders	O
of	O
these	O
patients	O
were	O
as	O
follows	O
:	O
cyclic	B-DISO
neutropenia	I-DISO
(	O
8	O
patients	O
),	O
Shwachman	B-DISO
-	I-DISO
Diamond	I-DISO
syndrome	I-DISO
(	O
7	O
patients	O
),	O
Kostmann	B-DISO
syndrome	I-DISO
(	O
6	O
patients	O
),	O
and	O
Chediak	B-DISO
-	I-DISO
Higashi	I-DISO
syndrome	I-DISO
(	O
5	O
patients	O
).	O

The	O
most	O
common	O
infections	B-DISO
,	O
in	O
descending	O
order	O
of	O
frequency	O
,	O
were	O
otitis	B-DISO
media	I-DISO
,	O
abscesses	B-DISO
,	O
pneumonia	B-DISO
,	O
oral	B-DISO
ulcers	I-DISO
,	O
acute	B-DISO
diarrhea	I-DISO
,	O
cutaneous	O
infections	B-DISO
,	O
oral	B-DISO
candidiasis	I-DISO
,	O
and	O
periodontitis	B-DISO
.	O

The	O
infectious	B-DISO
manifestations	O
both	O
at	O
presentation	O
and	O
during	O
follow	O
-	O
up	O
in	O
inherited	O
neutropenia	O
were	O
similar	O
.	O

TITLE	O
:	O
Pneumonia	B-DISO
:	O
classification	O
,	O
diagnosis	O
and	O
nursing	O
management	O
.	O

Vaccinations	O
for	O
influenza	B-DISO
and	O
,	O
more	O
recently	O
,	O
pneumococcal	B-DISO
infections	I-DISO
are	O
becoming	O
widely	O
available	O
for	O
vulnerable	O
groups	O
of	O
people	O
,	O
which	O
will	O
help	O
to	O
reduce	O
the	O
incidence	O
of	O
these	O
diseases	O
.	O

ABSTRACT	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
to	O
examine	O
the	O
relationship	O
between	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
the	O
time	O
-	O
dependent	O
precautionary	O
behaviors	O
taken	O
during	O
an	O
outbreak	O
of	O
SARS	B-DISO
in	O
Hanoi	O
French	O
Hospital	O
(	O
HFH	O
),	O
Vietnam	O
.	O

A	O
full	O
understanding	O
of	O
how	O
SARS	B-DISO
-	O
CoV	O
would	O
interact	O
with	O
lung	O
epithelial	O
cells	O
will	O
be	O
vital	O
for	O
advancing	O
our	O
knowledge	O
of	O
SARS	B-DISO
pathogenesis	B-DISO
.	O

The	O
P	O
-	O
PMO	O
were	O
tested	O
for	O
their	O
capacity	O
to	O
inhibit	O
production	O
of	O
infectious	B-DISO
virus	O
as	O
well	O
as	O
to	O
probe	O
the	O
function	O
of	O
conserved	O
viral	O
RNA	O
motifs	O
and	O
secondary	O
structures	O
.	O

Certain	O
other	O
virus	O
-	O
targeted	O
P	O
-	O
PMO	O
reduced	O
virus	O
-	O
induced	O
cytopathology	O
and	O
cell	O
-	O
to	O
-	O
cell	O
spread	O
as	O
a	O
consequence	O
of	O
decreasing	O
viral	O
amplification	B-DISO
.	O

P	O
-	O
PMO	O
showed	O
low	O
nonspecific	O
inhibitory	O
activity	O
against	O
translation	O
of	O
nontargeted	O
RNA	O
or	O
growth	O
of	O
the	O
arenavirus	O
lymphocytic	B-DISO
choriomeningitis	I-DISO
virus	O
.	O

Those	O
partially	O
resistant	O
viruses	O
grew	O
more	O
slowly	O
and	O
formed	O
smaller	O
plaques	B-DISO
than	O
wild	O
-	O
type	O
SARS	B-DISO
-	O
CoV	O
.	O
These	O
results	O
suggest	O
PMO	O
compounds	O
have	O
powerful	O
therapeutic	O
and	O
investigative	O
potential	O
toward	O
coronavirus	B-DISO
infection	I-DISO
.	O

Elderly	O
participants	O
who	O
perceived	O
greater	O
personal	O
vulnerability	O
to	O
the	O
disease	O
,	O
who	O
possessed	B-DISO
greater	O
self	O
-	O
efficacy	O
,	O
who	O
had	O
greater	O
confidence	O
in	O
local	O
health	O
authorities	O
,	O
and	O
who	O
had	O
lower	O
educational	O
attainment	O
were	O
more	O
likely	O
to	O
adopt	O
the	O
suggested	O
SARS	B-DISO
preventive	O
behaviors	O
.	O

This	O
successful	O
treatment	O
with	O
beneficial	O
neurological	O
outcome	O
suggests	O
that	O
ECMO	O
therapy	O
should	O
not	O
be	O
withheld	O
from	O
severely	O
injured	O
patients	O
with	O
combined	O
brain	O
and	O
thoracic	B-DISO
trauma	O
presenting	O
with	O
life	O
-	O
threatening	O
hypoxemia	O
.	O

Moreover	O
,	O
even	O
craniotomy	O
may	O
be	O
performed	O
during	O
ECMO	O
therapy	O
without	O
major	O
bleeding	B-DISO
and	O
adverse	B-DISO
effects	I-DISO
on	O
neurological	O
function	O
.	O

ABSTRACT	O
:	O
The	O
subjects	O
of	O
the	O
study	O
were	O
149	O
patients	O
with	O
severe	O
pyo	O
-	O
septic	O
complications	O
of	O
abdominal	O
diseases	O
,	O
resulting	O
in	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
syndrome	B-DISO
(	O
MOFS	O
)	O
with	O
clinical	O
and	O
laboratory	O
manifestations	O
.	O

We	O
retrospectively	O
analyzed	O
the	O
response	O
of	O
100	O
emergency	B-DISO
departments	O
regarding	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
and	O
implementation	O
of	O
infection	B-DISO
control	O
measures	O
(	O
ICMs	O
)	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Taiwan	O
.	O

Emergency	B-DISO
department	O
workers	O
in	O
large	O
hospitals	O
were	O
more	O
severely	O
affected	O
by	O
the	O
epidemic	O
.	O

Because	O
ability	O
to	O
prepare	O
for	O
and	O
respond	O
to	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
varies	O
among	O
hospitals	O
,	O
grouping	O
infectious	B-DISO
patients	O
in	O
a	O
centralized	O
location	O
in	O
an	O
early	O
stage	O
of	O
infection	B-DISO
may	O
reduce	O
the	O
extent	O
of	O
epidemics	O
.	O

These	O
results	O
indicate	O
that	O
an	O
adenoviral	O
-	O
based	O
vaccine	O
carrying	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
Spike	O
gene	O
is	O
able	O
to	O
elicit	O
strong	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
humoral	O
immune	O
responses	O
in	O
rats	O
,	O
and	O
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
a	O
protective	O
vaccine	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

RT	O
-	O
PCR	O
detected	O
human	O
metapneumovirus	O
in	O
40	O
/	O
306	O
(	O
13	O
.	O
1	O
%)	O
children	O
positive	O
for	O
respiratory	O
viruses	O
,	O
with	O
an	O
incidence	O
intermediate	O
between	O
that	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
58	O
patients	O
,	O
18	O
.	O
9	O
%)	O
and	O
that	O
of	O
influenzavirus	O
infections	B-DISO
(	O
29	O
patients	O
,	O
9	O
.	O
5	O
%).	O

Clinically	O
,	O
human	O
metapneumovirus	O
was	O
found	O
to	O
be	O
second	O
to	O
human	O
respiratory	O
syncytial	O
virus	O
alone	O
,	O
as	O
a	O
cause	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
while	O
duration	O
of	O
virus	O
excretion	O
appeared	O
to	O
correlate	O
with	O
severity	O
of	O
infection	B-DISO
,	O
and	O
virus	O
load	O
in	O
NPA	O
with	O
the	O
stage	O
of	O
respiratory	B-DISO
infection	I-DISO
.	O

During	O
the	O
first	O
10	O
days	O
after	O
onset	O
,	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
,	O
SARS	B-DISO
-	O
CoV	O
RNA	O
and	O
the	O
N	O
protein	O
were	O
detected	O
in	O
21	O
.	O
4	O
,	O
42	O
.	O
9	O
,	O
and	O
90	O
%	O
of	O
the	O
patients	O
'	O
sera	O
,	O
respectively	O
.	O

TITLE	O
:	O
Variations	O
in	O
the	O
nucleocapsid	O
protein	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

The	O
detection	O
of	O
both	O
antigens	O
and	O
antibodies	O
in	O
SARS	B-DISO
-	O
CoV	O
from	O
human	O
specimens	O
with	O
suspected	O
SARS	B-DISO
plays	O
an	O
important	O
role	O
in	O
preventing	O
infection	B-DISO
.	O

TITLE	O
:	O
Yeast	O
expression	O
and	O
characterization	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
.	O

An	O
extensive	O
diagnostic	O
work	O
-	O
up	O
revealed	O
no	O
evidence	O
of	O
infection	B-DISO
.	O

No	O
antibodies	O
against	O
organs	O
but	O
lung	O
were	O
found	O
in	O
SARS	B-DISO
patients	O
.	O

SARS	B-DISO
-	O
CoV	O
was	O
inactivated	O
completely	O
in	O
beta	O
-	O
propiolactone	O
(	O
1	O
:	O
4000	O
).	O

RESULTS	O
:	O
Vero	O
and	O
Vero	O
-	O
E6	O
cell	O
lines	O
were	O
sensitive	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
cytopathic	O
changes	O
of	O
the	O
cells	O
were	O
75	O
%	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	O
incubator	O
after	O
infection	B-DISO
.	O

The	O
36	O
serum	O
samples	O
and	O
40	O
mouthwash	O
of	O
SARS	B-DISO
patients	O
and	O
80	O
samples	O
of	O
healthy	O
people	O
were	O
tested	O
.	O

TITLE	O
:	O
A	O
case	O
-	O
control	O
study	O
of	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
general	O
practice	O
patients	O
in	O
The	O
Netherlands	O
.	O

TITLE	O
:	O
Chest	O
radiograph	O
screening	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
the	O
ED	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
use	O
of	O
chest	O
radiography	O
for	O
the	O
screening	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
initial	O
chest	O
radiograph	O
has	O
poor	O
sensitivity	O
,	O
and	O
serial	O
radiographs	O
are	O
required	O
to	O
rule	O
out	O
SARS	B-DISO
.	O

It	O
is	O
concluded	O
that	O
some	O
autoantibodies	O
against	O
human	O
epithelial	O
cells	O
and	O
endothelial	O
cells	O
would	O
be	O
developed	O
after	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
this	O
phenomenon	O
may	O
indicate	O
post	O
-	O
infectious	B-DISO
cellular	O
injury	O
and	O
also	O
induce	O
SARS	B-DISO
-	O
induced	O
immunopathology	B-DISO
.	O

The	O
genomic	O
RNA	O
was	O
analysed	O
for	O
putative	O
cis	B-DISO
-	O
acting	O
elements	O
and	O
the	O
pattern	O
of	O
subgenomic	O
mRNA	O
synthesis	O
was	O
analysed	O
by	O
Northern	O
blotting	O
.	O

A	O
SARS	B-DISO
-	O
CoV	O
-	O
S	O
protein	O
-	O
bearing	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
)	O
pseudotype	O
using	O
the	O
VSVDeltaG	O
*	O
system	O
was	O
generated	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
new	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Excretion	O
and	O
detection	O
of	O
SARS	B-DISO
coronavirus	O
and	O
its	O
nucleic	O
acid	O
from	O
digestive	O
system	O
.	O

The	O
main	O
abnormal	O
radiographic	O
appearance	O
of	O
lung	O
in	O
patients	O
with	O
SARS	B-DISO
is	O
exudative	O
changes	O
.	O

No	O
lymphadenopathy	O
,	O
effusion	B-DISO
of	O
pericadiaum	O
and	O
pleura	O
were	O
found	O
on	O
the	O
initial	O
chest	O
radiographs	O
.	O

Results	O
showed	O
that	O
the	O
plasmid	O
-	O
derived	O
siRNAs	O
targeting	O
the	O
non	O
-	O
structural	O
protein	O
1	O
(	O
NSP1	O
)	O
sequence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
could	O
specifically	O
inhibit	O
the	O
expression	O
of	O
the	O
NSP1	O
sequence	O
and	O
effectively	O
suppress	O
the	O
replication	O
and	O
propagation	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
cultured	O
Vero	O
E6	O
cell	O
lines	O
.	O

The	O
expression	O
of	O
the	O
Spike	O
and	O
Nucleoprotein	O
genes	O
of	O
SARS	B-DISO
-	O
CoV	O
at	O
mRNA	O
and	O
protein	O
levels	O
in	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
-	O
expressing	O
cells	O
was	O
significantly	O
less	O
than	O
that	O
in	O
controls	O
when	O
analysed	O
with	O
PCR	O
and	O
Western	O
-	O
blot	O
assays	O
,	O
3	O
days	O
post	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Retinal	B-DISO
degeneration	I-DISO
in	O
experimental	O
coronavirus	O
retinopathy	B-DISO
(	O
ECOR	O
)	O
is	O
associated	O
with	O
increased	O
TNF	O
-	O
alpha	O
,	O
soluble	O
TNFR2	O
and	O
altered	O
TNF	O
-	O
alpha	O
signaling	O
.	O

ABSTRACT	O
:	O
Viral	O
proteases	O
are	O
essential	O
for	O
pathogenesis	B-DISO
and	O
virulence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Little	O
information	O
is	O
available	O
on	O
SARS	B-DISO
-	O
CoV	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
),	O
and	O
development	O
of	O
inhibitors	O
against	O
PLP2	O
is	O
attractive	O
for	O
antiviral	O
therapy	O
.	O

We	O
demonstrate	O
that	O
SARS	B-DISO
-	O
CoV	O
PLP2	O
by	O
itself	O
differentially	O
cleaves	O
between	O
the	O
amino	O
acids	O
Gly180	O
and	O
Ala181	O
,	O
Gly818	O
and	O
Ala819	O
,	O
and	O
Gly2740	O
and	O
Lys2741	O
of	O
the	O
viral	O
polypeptide	O
pp1a	O
,	O
as	O
determined	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
analysis	O
coupled	O
with	O
mass	O
spectrometry	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
protection	O
from	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
conferred	O
by	O
a	O
single	O
immunization	O
with	O
an	O
attenuated	O
VSV	O
-	O
based	O
vaccine	O
.	O

TITLE	O
:	O
Antibody	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
spike	O
protein	O
domain	O
2	O
cross	O
-	O
reacts	O
with	O
lung	O
epithelial	O
cells	O
and	O
causes	O
cytotoxicity	B-DISO
.	O

ABSTRACT	O
:	O
Both	O
viral	O
effect	O
and	O
immune	O
-	O
mediated	O
mechanism	O
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

The	O
medical	O
records	O
of	O
children	O
diagnosed	O
with	O
bacterial	B-DISO
tracheitis	I-DISO
and	O
admitted	O
to	O
our	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
from	O
June	O
1992	O
to	O
May	O
2004	O
(	O
12	O
years	O
)	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
The	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
)	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
encodes	O
a	O
predicted	O
154	O
-	O
amino	O
acid	O
protein	O
,	O
which	O
lacks	O
similarities	O
to	O
any	O
known	O
protein	O
,	O
and	O
is	O
named	O
3b	O
.	O

The	O
causes	O
of	O
DNM	O
were	O
primary	O
peritonsillar	O
or	O
parapharyngeal	B-DISO
abscess	I-DISO
in	O
5	O
patients	O
,	O
post	O
-	O
extraction	O
odontogenic	O
abscess	B-DISO
in	O
3	O
,	O
cervical	B-DISO
abscess	I-DISO
of	O
post	O
-	O
tracheostomy	O
in	O
1	O
,	O
and	O
unknown	O
in	O
1	O
patient	O
.	O

ABSTRACT	O
:	O
At	O
the	O
peak	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
,	O
hospital	O
workers	O
were	O
under	O
high	O
risks	O
of	O
contraction	B-DISO
of	O
the	O
infection	B-DISO
.	O

There	O
were	O
hardly	O
any	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
and	O
the	O
quality	O
of	O
life	O
improved	O
.	O

It	O
was	O
concluded	O
that	O
there	O
might	O
be	O
a	O
good	O
indication	O
for	O
using	O
suitable	O
herbal	O
preparations	O
as	O
a	O
means	O
of	O
preventing	O
influenza	B-DISO
-	O
like	O
infection	B-DISO
.	O

The	O
mode	O
of	O
preventive	O
effect	O
could	O
be	O
treatment	O
of	O
the	O
infection	B-DISO
at	O
its	O
very	O
early	O
stage	O
instead	O
of	O
producing	O
a	O
period	O
of	O
higher	O
immunological	O
ability	O
,	O
as	O
in	O
the	O
case	O
of	O
vaccination	O
.	O

How	O
SARS	B-DISO
highlighted	O
the	O
risk	O
of	O
viral	O
pandemics	O
.	O

ABSTRACT	O
:	O
As	O
recent	O
events	O
involving	O
SARS	B-DISO
and	O
bird	B-DISO
flu	I-DISO
have	O
shown	O
,	O
foreign	O
travel	O
can	O
be	O
a	O
hazardous	O
undertaking	O
.	O

SARS	B-DISO
-	O
CoV	O
(	O
SARS	B-DISO
coronavirus	O
),	O
a	O
novel	O
coronavirus	O
that	O
has	O
been	O
etiologically	O
associated	O
with	O
SARS	B-DISO
cases	O
,	O
is	O
homologous	O
with	O
MHV	O
(	O
murine	B-DISO
hepatitis	I-DISO
coronavirus	O
),	O
and	O
MHV	O
small	O
envelope	O
E	O
protein	O
is	O
capable	O
of	O
inducing	O
apoptosis	O
.	O

However	O
,	O
apoptosis	O
was	O
inhibited	O
by	O
overexpressed	O
antiapoptotic	O
protein	O
Bcl	O
-	O
xL	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
interacted	O
with	O
Bcl	O
-	O
xL	O
in	O
vitro	O
and	O
endogenous	O
Bcl	O
-	O
xL	O
in	O
vivo	O
and	O
that	O
Bcl	O
-	O
xL	O
interaction	O
with	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
was	O
mediated	O
by	O
BH3	O
(	O
Bcl	O
-	O
2	O
homology	O
domain	O
3	O
)	O
of	O
Bcl	O
-	O
xL	O
.	O
Finally	O
,	O
we	O
identified	O
a	O
novel	O
BH3	O
-	O
like	O
region	O
located	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
,	O
which	O
mediates	O
its	O
binding	O
to	O
Bcl	O
-	O
xL	O
.	O
These	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
molecular	O
mechanism	O
of	O
T	O
-	O
cell	O
apoptosis	O
that	O
contributes	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
lymphopenia	B-DISO
observed	O
in	O
most	O
SARS	B-DISO
patients	O
.	O

Although	O
intravenous	O
aciclovir	O
was	O
administered	O
,	O
the	O
widespread	O
cutaneous	O
HSV	B-DISO
infection	I-DISO
was	O
followed	O
by	O
systemic	O
dissemination	O
.	O

It	O
underlines	O
the	O
importance	O
of	O
rapidly	O
recognizing	O
HSV	B-DISO
infection	I-DISO
in	O
Darier	B-DISO
disease	I-DISO
and	O
stresses	O
the	O
risk	O
of	O
lethal	O
outcome	O
.	O

These	O
findings	O
identify	O
the	O
common	O
marmoset	O
as	O
a	O
promising	O
nonhuman	O
primate	O
to	O
study	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
.	O

We	O
present	O
two	O
cases	O
of	O
treating	O
severe	B-DISO
sepsis	I-DISO
utilizing	O
recombinant	O
human	O
activated	O
protein	O
C	O
(	O
rhAPC	O
)	O
in	O
the	O
course	O
of	O
bilateral	B-DISO
pneumonia	I-DISO
in	O
patients	O
with	O
hairy	B-DISO
cell	I-DISO
leukemia	I-DISO
(	O
HCL	O
)	O
and	O
T	B-DISO
-	I-DISO
cell	I-DISO
acute	I-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
(	O
ALL	O
).	O

The	O
WHO	O
case	O
definitions	O
were	O
helpful	O
in	O
evaluating	O
majority	O
of	O
SARS	B-DISO
patients	O
initially	O
.	O

Here	O
,	O
we	O
show	O
that	O
LSECtin	O
enhances	O
infection	B-DISO
driven	O
by	O
filovirus	O
glycoproteins	O
(	O
GP	O
)	O
and	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
,	O
but	O
does	O
not	O
interact	O
with	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
-	O
1	O
and	O
hepatitis	B-DISO
C	I-DISO
virus	O
envelope	O
proteins	O
.	O

TITLE	O
:	O
Pulmonary	O
vasodilator	O
therapy	O
in	O
congenital	B-DISO
diaphragmatic	I-DISO
hernia	I-DISO
:	O
acute	O
,	O
late	O
,	O
and	O
chronic	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

In	O
the	O
most	O
severe	O
cases	O
,	O
the	O
fetal	O
condition	B-DISO
of	O
markedly	O
elevated	O
pulmonary	O
vascular	O
resistance	O
persists	O
after	O
birth	O
and	O
is	O
associated	O
with	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
and	O
severe	O
disturbances	O
in	O
cardiac	O
performance	O
.	O

Different	O
pathophysiological	O
mechanisms	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
have	O
been	O
described	O
.	O

It	O
is	O
possible	O
that	O
the	O
most	O
severe	O
form	O
of	O
any	O
syndrome	B-DISO
,	O
leading	O
to	O
cardio	B-DISO
-	I-DISO
respiratory	I-DISO
arrest	I-DISO
,	O
may	O
cause	O
myocardial	B-DISO
stunning	I-DISO
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
has	O
been	O
to	O
study	O
and	O
describe	O
the	O
possible	O
development	O
of	O
myocardial	B-DISO
dysfunction	I-DISO
in	O
patients	O
resuscitated	O
after	O
cardio	B-DISO
-	I-DISO
respiratory	I-DISO
arrest	I-DISO
,	O
in	O
the	O
absence	O
of	O
acute	O
or	O
previous	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Report	O
of	O
a	O
patient	O
with	O
severe	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
after	O
multiple	O
transfusions	O
,	O
resuscitated	O
with	O
albumin	O
.	O

PATIENT	O
AND	O
HISTORY	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
with	O
GIST	B-DISO
metastatic	O
to	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
treated	O
with	O
tyrosine	O
kinase	O
inhibitors	O
,	O
underwent	O
a	O
right	O
hepatectomy	O
requiring	O
multiple	O
transfusions	O
.	O

Chest	O
radiograph	O
revealed	O
diffuse	O
bilateral	O
infiltrates	B-DISO
.	O

After	O
unsuccessful	O
fluid	O
resuscitation	O
with	O
crystalloid	O
fluid	O
,	O
the	O
patient	O
'	O
s	O
condition	B-DISO
improved	O
rapidly	O
with	O
human	O
albumin	O
boluses	O
.	O

TITLE	O
:	O
Cutaneous	O
lesions	O
associated	O
with	O
coronavirus	O
-	O
induced	O
vasculitis	B-DISO
in	O
a	O
cat	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
and	O
concurrent	O
feline	O
immunodeficiency	B-DISO
virus	B-DISO
infection	I-DISO
.	O

Air	B-DISO
trapping	I-DISO
,	O
ground	O
-	O
glass	O
opacity	B-DISO
,	O
and	O
reticulation	O
were	O
found	O
in	O
37	O
(	O
92	O
%),	O
36	O
(	O
90	O
%),	O
and	O
28	O
(	O
70	O
%)	O
of	O
40	O
patients	O
,	O
respectively	O
,	O
at	O
initial	O
thin	O
-	O
section	O
CT	O
examination	O
and	O
in	O
16	O
(	O
80	O
%),	O
14	O
(	O
70	O
%),	O
and	O
10	O
(	O
50	O
%)	O
of	O
20	O
patients	O
,	O
respectively	O
,	O
at	O
follow	O
-	O
up	O
examination	O
.	O

At	O
the	O
second	O
examination	O
,	O
scores	O
for	O
ground	O
-	O
glass	O
opacity	B-DISO
and	O
interstitial	O
opacity	B-DISO
correlated	O
with	O
peak	O
lactate	O
dehydrogenase	O
level	O
;	O
that	O
for	O
air	B-DISO
trapping	I-DISO
,	O
with	O
age	O
and	O
peak	O
C	O
-	O
reactive	O
protein	O
level	O
.	O

TITLE	O
:	O
An	O
atypical	O
RNA	O
pseudoknot	O
stimulator	O
and	O
an	O
upstream	O
attenuation	O
signal	O
for	O
-	O
1	O
ribosomal	O
frameshifting	O
of	O
SARS	B-DISO
coronavirus	O
.	O

Mutational	O
analysis	O
of	O
the	O
extra	O
stem	O
suggests	O
frameshift	B-DISO
efficiency	O
can	O
be	O
modulated	O
via	O
manipulation	O
of	O
the	O
secondary	O
structure	O
within	O
the	O
loop	O
2	O
of	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
-	O
type	O
pseudoknot	O
.	O

Patients	O
with	O
pre	O
-	O
existing	O
endocrine	B-DISO
disorders	I-DISO
were	O
excluded	O
.	O

Two	O
(	O
3	O
.	O
3	O
%)	O
of	O
the	O
hypocortisolic	O
cohort	O
had	O
transient	O
subclinical	O
thyrotoxicosis	B-DISO
.	O

These	O
preliminary	O
findings	O
highlight	O
a	O
possible	O
aetiologic	O
role	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
causing	O
a	O
reversible	O
hypophysitis	B-DISO
or	O
direct	O
hypothalamic	O
effect	O
,	O
with	O
the	O
HPA	O
axis	O
affected	O
more	O
frequently	O
than	O
the	O
HPT	O
axis	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
(	O
39	O
.	O
3	O
%)	O
patients	O
had	O
evidence	O
of	O
hypocortisolism	B-DISO
.	O

The	O
word	O
""""	O
atypical	O
""""	O
is	O
reserved	O
for	O
unusual	O
presentations	O
of	O
KD	O
such	O
as	O
those	O
with	O
hemophagocytic	B-DISO
syndrome	I-DISO
or	O
nerve	B-DISO
palsy	I-DISO
.	O

Since	O
PLMA	O
provides	O
a	O
higher	O
airway	O
occlusion	B-DISO
pressure	O
compared	O
to	O
the	O
classic	O
laryngeal	O
mask	O
airway	O
(	O
CLMA	O
),	O
the	O
use	O
of	O
this	O
device	O
may	O
be	O
justified	O
for	O
elective	O
laparoscopic	O
surgery	O
.	O

False	O
-	O
negative	O
PCT	B-DISO
was	O
related	O
to	O
lower	O
severity	O
of	O
infection	B-DISO
(	O
lower	O
inflammatory	B-DISO
reaction	I-DISO
and	O
lower	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
)	O
than	O
true	O
-	O
positive	O
PCT	B-DISO
.	O

TITLE	O
:	O
Serine	O
-	O
scanning	O
mutagenesis	O
studies	O
of	O
the	O
C	O
-	O
terminal	O
heptad	O
repeats	O
in	O
the	O
SARS	B-DISO
coronavirus	O
S	O
glycoprotein	O
highlight	O
the	O
important	O
role	O
of	O
the	O
short	O
helical	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
major	O
immunodominant	O
epitopes	O
on	O
the	O
M	O
protein	O
located	O
in	O
the	O
extreme	O
N	O
-	O
terminal	O
region	O
(	O
residues	O
1	O
to	O
31	O
)	O
and	O
the	O
interior	O
C	O
-	O
terminal	O
region	O
(	O
residues	O
132	O
to	O
161	O
),	O
respectively	O
,	O
by	O
Pepscan	O
analyses	O
against	O
convalescent	O
-	O
phase	O
sera	O
from	O
SARS	B-DISO
patients	O
and	O
antisera	O
from	O
virus	O
-	O
immunized	O
mice	O
and	O
rabbits	O
.	O

TITLE	O
:	O
Performance	O
of	O
single	O
-	O
step	O
gel	O
-	O
based	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
equivalent	O
to	O
that	O
of	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
for	O
detection	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

Participating	O
laboratories	O
(	O
9	O
/	O
20	O
)	O
correctly	O
detected	O
anti	O
-	O
SARS	B-DISO
antibodies	O
in	O
serum	O
samples	O
without	O
false	O
positive	O
results	O
in	O
an	O
immunofluorescence	O
assay	O
.	O

Despite	O
ongoing	O
and	O
intensive	O
scientific	O
research	O
in	O
this	O
area	O
,	O
the	O
mechanisms	O
underlying	O
ALI	O
/	O
ARDS	B-DISO
are	O
still	O
not	O
completely	O
understood	O
,	O
and	O
until	O
recently	O
,	O
there	O
were	O
no	O
studies	O
demonstrating	O
any	O
beneficial	O
effect	O
of	O
a	O
single	O
treatment	O
modality	O
in	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
innovative	O
therapies	O
.	O

After	O
reviewing	O
these	O
newer	O
investigations	O
in	O
the	O
context	O
of	O
previously	O
published	O
literature	O
,	O
we	O
have	O
drawn	O
several	O
preliminary	O
conclusions	O
:	O
(	O
1	O
)	O
Long	O
-	O
term	O
survival	O
after	O
hospital	O
discharge	O
is	O
unaffected	O
by	O
ARDS	B-DISO
,	O
but	O
is	O
strongly	O
affected	O
by	O
ARDS	B-DISO
risk	O
factor	O
and	O
comorbidities	O
.	O

TITLE	O
:	O
MR	O
diffusion	O
tensor	O
imaging	O
,	O
fiber	O
tracking	O
,	O
and	O
single	O
-	O
voxel	O
spectroscopy	O
findings	O
in	O
an	O
unusual	O
MELAS	B-DISO
case	O
.	O

ABSTRACT	O
:	O
Histidine	O
-	O
tagged	O
N	O
(	O
rNH	O
)	O
and	O
E	O
(	O
rEH	O
)	O
proteins	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronovirus	O
were	O
expressed	O
in	O
the	O
baculovirus	O
/	O
insect	O
cell	O
system	O
and	O
purified	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
.	O

To	O
determine	O
the	O
diagnostic	O
and	O
prognostic	O
role	O
of	O
PCT	B-DISO
in	O
patients	O
admitted	O
in	O
an	O
intensive	O
care	O
unit	O
for	O
severe	O
CAP	B-DISO
,	O
110	O
patients	O
hospitalized	O
in	O
our	O
unit	O
were	O
prospectively	O
studied	O
.	O

Initially	O
focusing	O
on	O
the	O
diagnostic	O
value	O
of	O
PCT	B-DISO
,	O
20	O
%	O
of	O
the	O
patients	O
had	O
a	O
serum	O
PCT	B-DISO
level	O
<	O
0	O
.	O
5	O
ng	O
/	O
ml	O
,	O
30	O
%	O
between	O
0	O
.	O
5	O
ng	O
/	O
ml	O
and	O
2	O
ng	O
/	O
ml	O
,	O
and	O
50	O
%>/=	O
2	O
ng	O
/	O
ml	O
.	O

Finally	O
,	O
the	O
initial	O
PCT	B-DISO
level	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
died	O
during	O
the	O
ICU	O
stay	O
(	O
5	O
.	O
6	O
ng	O
/	O
ml	O
vs	O
1	O
.	O
5	O
ng	O
/	O
ml	O
;	O
p	O
<	O
0	O
.	O
0001	O
).	O

In	O
ICU	O
patients	O
admitted	O
for	O
severe	O
CAP	B-DISO
,	O
initial	O
PCT	B-DISO
values	O
could	O
be	O
an	O
interesting	O
predictor	O
for	O
complications	O
and	O
mortality	O
.	O

A	O
combination	O
of	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
strongly	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
Vero	O
cells	O
,	O
while	O
the	O
single	O
cytokines	O
were	O
much	O
less	O
effective	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
CD45	O
+,	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+,	O
CD19	O
+	O
and	O
CD16	O
+/	O
56	O
+	O
cell	O
counts	O
over	O
the	O
five	O
weeks	O
of	O
the	O
SARS	B-DISO
illness	O
although	O
CD4	O
+/	O
CD8	O
+	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O

To	O
eliminate	O
these	O
confounding	O
variables	O
,	O
this	O
study	O
evaluates	O
the	O
association	O
between	O
delayed	O
Tx	O
and	O
serious	O
,	O
well	O
-	O
defined	O
respiratory	B-DISO
complications	I-DISO
(	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
[	O
VAP	O
]	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
[	O
ARDS	B-DISO
])	O
and	O
death	O
in	O
a	O
cohort	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admissions	O
with	O
less	O
severe	O
(	O
Injury	O
Severity	O
Score	O
[	O
ISS	B-DISO
]	O
<	O
25	O
)	O
blunt	O
trauma	O
who	O
received	O
no	O
Tx	O
within	O
the	O
initial	O
48	O
hours	O
after	O
admission	O
.	O

VAP	O
required	O
quantitative	O
bronchoalveolar	O
lavage	O
culture	O
(>	O
or	O
=	O
10	O
(	O
5	O
)	O
colonies	O
/	O
mL	O
),	O
and	O
ARDS	B-DISO
required	O
Pao2	O
/	O
Fio2	O
ratio	O
<	O
200	O
mm	O
Hg	O
,	O
***	O
no	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
,	O
diffuse	O
bilateral	O
infiltrates	B-DISO
,	O
and	O
peak	O
airway	O
pressure	O
>	O
50	O
cm	O
H2O	O
for	O
diagnosis	O
.	O

Logistic	O
regression	O
analysis	O
identified	O
age	O
,	O
base	O
excess	O
,	O
chest	O
Abbreviated	O
Injury	O
Scale	O
score	O
,	O
ISS	B-DISO
,	O
and	O
any	O
transfusion	O
as	O
significant	O
predictors	O
for	O
VAP	O
;	O
chest	O
Abbreviated	O
Injury	O
Scale	O
score	O
and	O
transfusion	O
as	O
significant	O
predictors	O
for	O
ARDS	B-DISO
;	O
and	O
age	O
and	O
transfusion	O
as	O
significant	O
predictors	O
for	O
death	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
transfusion	O
is	O
independently	O
associated	O
with	O
VAP	O
,	O
ARDS	B-DISO
,	O
and	O
death	O
in	O
trauma	O
patients	O
regardless	O
of	O
injury	O
severity	O
.	O

The	O
highest	O
temperature	O
in	O
the	O
animals	O
recorded	O
was	O
40	O
.	O
4	O
degrees	O
C	O
.	O
After	O
a	O
recovery	O
phase	O
,	O
the	O
macaques	O
developed	O
a	O
second	O
febrile	O
condition	B-DISO
.	O

The	O
macaques	O
infected	O
with	O
the	O
newly	O
isolated	O
reovirus	O
developed	O
a	O
fever	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
pulmonary	O
interstitial	B-DISO
inflammation	I-DISO
similar	O
to	O
that	O
noted	O
in	O
SARS	B-DISO
patients	O
.	O

These	O
results	O
strongly	O
demonstrated	O
that	O
the	O
pVAX	O
-	O
S1	O
plasmid	O
could	O
induce	O
humoral	O
and	O
cellular	O
immune	O
responses	O
in	O
mice	O
,	O
and	O
may	O
be	O
a	O
potential	O
candidate	O
for	O
a	O
DNA	O
vaccine	O
against	O
the	O
SARS	B-DISO
coronavirus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
recombinant	O
proteins	O
N	O
and	O
S3	O
are	O
potentially	O
useful	O
antigens	O
for	O
a	O
serological	O
diagnosis	O
of	O
SARS	B-DISO
.	O

The	O
selection	O
of	O
25	O
test	O
materials	O
includes	O
eleven	O
trioxa	O
-	O
adamantane	O
-	O
triols	O
(	O
TATs	O
)	O
[	O
BN	O
,	O
IBNCA	O
,	O
ABNCA	O
,	O
VANBA	O
,	O
ethylVANBA	O
,	O
euBN	O
,	O
euVANBA	O
,	O
ansaBN	O
,	O
Ehrlich	O
BN	O
,	O
[	O
6	O
]	O
prismaneBN	O
,	O
nitrodiBN	O
],	O
trivially	O
termed	O
bananins	O
,	O
one	O
trioxa	O
-	O
adamantan	O
-	O
ol	O
(	O
TAO	B-DISO
)	O
THYMOBA	O
,	O
one	O
bis	O
-	O
bananin	O
pi	O
-	O
bananin	O
(	O
piBN	O
),	O
one	O
triazaadamantane	O
delta	O
-	O
bananin	O
(	O
deltaBN	O
),	O
seven	O
potential	O
nucleic	O
acid	O
-	O
binding	O
drugs	O
(	O
XBQC	O
,	O
INDO	O
,	O
PivINDO	O
,	O
AZTRION	O
,	O
AZADO	O
,	O
AZOCYS	O
,	O
AZOGALL	O
),	O
one	O
potential	O
antiviral	O
interferon	O
-	O
inducer	O
and	O
distant	O
nucleoside	O
analog	O
diazon	O
,	O
one	O
potential	O
HIV	B-DISO
protein	O
Vif	O
antagonist	O
AZODIAZON	O
,	O
one	O
folic	O
acid	O
-	O
diazon	O
condensate	O
DIAZONOFOL	O
,	O
and	O
one	O
special	O
nucleoside	O
analog	O
(	O
fructoinosine	O
/	O
fructovir	O
).	O

Four	O
of	O
the	O
eleven	O
bananins	O
(	O
BN	O
,	O
IBNCA	O
,	O
VANBA	O
,	O
euBN	O
)	O
were	O
already	O
demonstrated	O
to	O
constitute	O
effective	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
NSP10	O
/	O
nsp13	O
RNA	O
/	O
DNA	O
helicase	O
/	O
NTPase	O
protein	O
ATPase	O
enzymatic	O
function	O
.	O

In	O
summary	O
,	O
at	O
least	O
one	O
selected	O
compound	O
of	O
the	O
synthesized	O
test	O
materials	O
represents	O
an	O
interesting	O
drug	O
candidate	O
for	O
treatment	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
human	O
disease	O
(	O
SARS	B-DISO
).	O

We	O
used	O
contact	O
network	O
epidemiology	O
to	O
predict	O
the	O
effect	O
of	O
various	O
control	O
policies	O
for	O
a	O
mildly	O
contagious	B-DISO
disease	I-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
and	O
a	O
moderately	O
contagious	B-DISO
disease	I-DISO
,	O
such	O
as	O
smallpox	B-DISO
.	O

TITLE	O
:	O
Posttraumatic	O
stress	O
after	O
SARS	B-DISO
.	O

Risk	O
factors	O
associated	O
with	O
psychological	B-DISO
distress	I-DISO
were	O
identified	O
.	O

B6	O
,	O
129SF2	O
/	O
J	O
mice	O
were	O
subjected	O
to	O
either	O
3	O
hours	O
of	O
unilateral	O
hind	O
limb	O
ischemia	B-DISO
alone	O
(	O
IA	O
)	O
or	O
3	O
hours	O
of	O
ischemia	B-DISO
followed	O
by	O
4	O
or	O
24	O
hours	O
of	O
reperfusion	O
(	O
I	O
/	O
R	O
).	O

IA	O
did	O
not	O
increase	O
KC	O
or	O
MIP	B-DISO
-	O
2	O
mRNA	O
or	O
protein	O
levels	O
.	O

One	O
protein	O
,	O
the	O
product	O
of	O
SARS	B-DISO
-	O
CoV	O
ORF6	O
,	O
converted	O
a	O
sublethal	O
infection	B-DISO
to	O
a	O
uniformly	O
lethal	O
encephalitis	B-DISO
and	O
enhanced	O
virus	O
growth	O
in	O
tissue	O
culture	O
cells	O
,	O
indicating	O
that	O
SARS	B-DISO
-	O
CoV	O
proteins	O
function	O
in	O
the	O
context	O
of	O
a	O
heterologous	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Intracellular	O
localization	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nucleocapsid	O
protein	O
:	O
absence	O
of	O
nucleolar	O
accumulation	O
during	O
infection	B-DISO
and	O
after	O
expression	O
as	O
a	O
recombinant	O
protein	O
in	O
vero	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
relevance	O
of	O
infections	B-DISO
with	O
the	O
novel	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
has	O
not	O
been	O
investigated	O
systematically	O
.	O

TITLE	O
:	O
G0	O
/	O
G1	O
arrest	O
and	O
apoptosis	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
3b	O
protein	O
in	O
transfected	O
cells	O
.	O

Through	O
cell	O
cycle	O
analysis	O
,	O
it	O
was	O
found	O
that	O
over	O
-	O
expression	O
of	O
3b	O
-	O
EGFP	O
protein	O
in	O
Vero	O
,	O
293	O
and	O
COS	O
-	O
7	O
cells	O
could	O
induce	O
cell	O
cycle	O
arrest	O
at	O
G0	O
/	O
G1	O
phase	O
,	O
and	O
that	O
especially	O
in	O
COS	O
-	O
7	O
cells	O
,	O
expression	O
of	O
3b	O
-	O
EGFP	O
was	O
able	O
to	O
induce	O
the	O
increase	O
of	O
sub	O
-	O
G1	O
phase	O
from	O
24	O
h	O
after	O
transfection	O
,	O
which	O
was	O
most	O
obvious	O
at	O
48	O
h	O
.	O
The	O
apoptosis	O
induction	O
of	O
3b	O
fusion	O
protein	O
in	O
COS	O
-	O
7	O
cells	O
was	O
further	O
confirmed	O
by	O
double	O
cell	O
labeling	O
with	O
7	O
-	O
AAD	O
and	O
Annexin	O
V	O
,	O
the	O
function	O
of	O
3b	O
protein	O
inducing	O
cell	O
G0	O
/	O
G1	O
arrest	O
and	O
apoptosis	O
may	O
provide	O
a	O
new	O
insight	O
for	O
further	O
study	O
on	O
the	O
mechanism	O
of	O
SARS	B-DISO
pathogenesis	B-DISO
.	O

The	O
highly	O
infectious	B-DISO
nature	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
compelled	O
our	O
pathologists	O
to	O
consider	O
biosafety	O
issues	O
in	O
the	O
autopsy	O
room	O
and	O
for	O
tissue	O
processing	O
procedures	O
.	O

ABSTRACT	O
:	O
With	O
use	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
a	O
centrifugation	O
-	O
enhanced	O
viral	O
culture	O
method	O
,	O
we	O
characterized	O
the	O
viruses	O
causing	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
adults	O
during	O
an	O
influenza	B-DISO
season	O
.	O

ABSTRACT	O
:	O
To	O
screen	O
small	O
animals	O
susceptible	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
five	O
species	O
of	O
animals	O
,	O
including	O
guinea	O
pig	O
,	O
hamster	O
,	O
albino	B-DISO
hamster	O
,	O
chicken	O
and	O
rat	O
,	O
were	O
experimentally	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
strain	O
BJ	O
-	O
01	O
by	O
different	O
routes	O
.	O

After	O
inoculated	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
all	O
inoculated	O
cynomolgus	O
and	O
rhesus	O
macaques	O
had	O
developed	O
interstitial	B-DISO
pneumonia	I-DISO
of	O
differing	O
severity	O
.	O

MODS	B-DISO
associated	O
with	O
acute	B-DISO
pancreatitis	I-DISO
is	O
the	O
primary	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
this	O
condition	B-DISO
.	O

This	O
review	O
intends	O
to	O
present	O
an	O
overview	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
that	O
takes	O
place	O
following	O
pancreatic	O
acinar	O
cell	B-DISO
injury	I-DISO
.	O

To	O
study	O
seroconversion	O
and	O
the	O
magnitude	O
of	O
IgG	O
responses	O
in	O
a	O
SARS	B-DISO
cohort	O
with	O
different	O
disease	O
severities	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
causes	O
an	O
infectious	B-DISO
disease	I-DISO
through	O
respiratory	O
route	O
.	O

TITLE	O
:	O
Molecular	O
evolution	O
and	O
multilocus	O
sequence	O
typing	O
of	O
145	O
strains	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
have	O
identified	O
876	O
polymorphism	O
sites	O
in	O
145	O
complete	O
or	O
partial	O
genomes	O
of	O
SARS	B-DISO
-	O
CoV	O
available	O
in	O
the	O
NCBI	O
GenBank	O
.	O

One	O
hundred	O
and	O
seventy	O
-	O
four	O
of	O
these	O
sites	O
existed	O
in	O
two	O
or	O
more	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequences	O
.	O

By	O
comparing	O
the	O
death	O
rates	O
of	O
SARS	B-DISO
patients	O
in	O
the	O
different	O
regions	O
,	O
it	O
was	O
found	O
that	O
the	O
death	O
rate	O
caused	O
by	O
the	O
viruses	O
of	O
the	O
genotype	O
C	O
was	O
lower	O
than	O
that	O
of	O
the	O
genotype	O
T	O
.	O
SARS	B-DISO
-	O
CoVs	O
might	O
originate	O
from	O
an	O
unknown	O
ancestor	O
.	O

RESULTS	O
:	O
We	O
report	O
,	O
however	O
,	O
that	O
chloroquine	O
has	O
strong	O
antiviral	O
effects	O
on	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
of	O
primate	O
cells	O
.	O

In	O
this	O
study	O
,	O
Isatis	O
indigotica	O
root	O
extract	O
,	O
five	O
major	O
compounds	O
of	O
I	O
.	O
indigotica	O
root	O
,	O
and	O
seven	O
plant	O
-	O
derived	O
phenolic	O
compounds	O
were	O
tested	O
for	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
effects	O
using	O
cell	O
-	O
free	O
and	O
cell	O
-	O
based	O
cleavage	O
assays	O
.	O

We	O
found	O
that	O
proteases	O
such	O
as	O
trypsin	O
and	O
thermolysin	O
enabled	O
SARS	B-DISO
-	O
CoV	O
adsorbed	O
onto	O
the	O
cell	O
surface	O
to	O
enter	O
cells	O
directly	O
from	O
that	O
site	O
.	O

A	O
rapid	O
diagnostic	O
test	O
for	O
influenza	B-DISO
was	O
performed	O
on	O
131	O
individuals	O
,	O
with	O
52	O
having	O
positive	O
results	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
new	O
virus	O
species	O
is	O
a	O
key	O
issue	O
for	O
the	O
study	O
of	O
infectious	B-DISO
disease	I-DISO
but	O
is	O
technically	O
very	O
difficult	O
.	O

Finally	O
,	O
it	O
considers	O
whether	O
the	O
Hong	O
Kong	O
health	O
system	O
can	O
be	O
reformed	O
to	O
manage	O
any	O
future	O
infectious	B-DISO
disease	I-DISO
epidemic	O
better	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
encoding	O
sequences	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
were	O
analyzed	O
by	O
bioinformatics	O
methods	O
,	O
the	O
structural	O
characteristics	O
and	O
functions	O
were	O
forecasted	O
based	O
on	O
available	O
data	O
.	O

TITLE	O
:	O
A	O
serological	O
survey	O
on	O
neutralizing	O
antibody	O
titer	O
of	O
SARS	B-DISO
convalescent	O
sera	O
.	O

The	O
anti	O
-	O
SARS	B-DISO
antibodies	O
were	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
neutralization	O
assay	O
,	O
and	O
Western	O
blot	O
.	O

Eighty	O
-	O
seven	O
serum	O
samples	O
were	O
confirmed	O
to	O
be	O
positive	O
for	O
SARS	B-DISO
antibodies	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
caused	O
by	O
a	O
newly	O
identified	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2003	O
.	O

The	O
SARS	B-DISO
-	O
S	O
,	O
-	O
M	O
,	O
and	O
-	O
N	O
primer	O
/	O
probe	O
sets	O
described	O
in	O
this	O
paper	O
could	O
detect	O
one	O
to	O
ten	O
copies	O
of	O
in	O
vitro	O
transcribed	O
S	O
,	O
M	O
,	O
and	O
N	O
RNA	O
per	O
test	O
using	O
both	O
the	O
ABI	O
and	O
Roche	O
assay	O
systems	O
.	O

The	O
cell	O
culture	O
-	O
adapted	O
strains	O
of	O
influenza	B-DISO
viruses	O
A	O
and	O
B	O
,	O
parainfluenza	B-DISO
viruses	O
1	O
-	O
4	O
,	O
respiratory	O
syncytial	O
viruses	O
A	O
and	O
B	O
,	O
both	O
strains	O
of	O
the	O
human	O
metapneumoviruses	O
,	O
numerous	O
rhinoviruses	O
,	O
most	O
of	O
the	O
adenoviruses	O
,	O
coronaviruses	O
229E	O
and	O
OC43	O
,	O
and	O
a	O
number	O
of	O
enteroviruses	O
(	O
poliovirus	O
type	O
3	O
,	O
coxsackie	B-DISO
virus	I-DISO
B1	O
,	O
echovirus	O
type	O
30	O
)	O
replicate	O
in	O
HuH7	O
.	O

Predisposing	O
events	O
included	O
sepsis	B-DISO
(	O
3	O
patients	O
),	O
pneumomia	O
(	O
7	O
patients	O
),	O
pancreatitis	B-DISO
(	O
1	O
patient	O
)	O
and	O
two	O
children	O
with	O
other	O
infections	B-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
commonly	O
recognized	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
following	O
a	O
variety	O
of	O
insults	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
inflammatory	O
and	O
anti	O
-	O
viral	O
genes	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

Recent	O
endeavours	O
have	O
focussed	O
on	O
the	O
development	O
of	O
improved	O
antiviral	O
therapies	O
for	O
virus	O
infections	B-DISO
that	O
have	O
already	O
proved	O
amenable	O
to	O
antiviral	O
drug	O
treatment	O
,	O
as	O
well	O
as	O
for	O
virus	O
infections	B-DISO
for	O
which	O
,	O
at	O
present	O
,	O
no	O
antiviral	O
drugs	O
have	O
been	O
formally	O
approved	O
(	O
i	O
.	O
e	O
.	O
human	O
papilloma	B-DISO
viruses	O
,	O
adenoviruses	O
,	O
human	O
herpesvirus	O
type	O
6	O
,	O
poxviruses	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
hemorrhagic	B-DISO
fever	I-DISO
viruses	O
).	O

Mechanism	O
-	O
based	O
irreversible	O
inhibitors	O
were	O
designed	O
,	O
based	O
on	O
this	O
conserved	O
structural	O
region	O
,	O
and	O
a	O
uniform	O
inhibition	O
mechanism	O
was	O
elucidated	O
from	O
the	O
structures	O
of	O
Mpro	O
-	O
inhibitor	O
complexes	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
CoV	O
and	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
impacts	O
of	O
public	O
health	O
interventions	O
on	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
Beijing	O
by	O
analyzing	O
the	O
intervals	O
between	O
symptom	B-DISO
onset	O
,	O
hospital	O
admission	O
and	O
notification	O
of	O
its	O
cases	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
fusion	O
protein	O
system	O
employing	O
the	O
substrate	O
-	O
binding	O
domain	O
(	O
SBD	O
)	O
of	O
poly	O
(	O
hydroxyalkanoate	O
)	O
(	O
PHA	B-DISO
)	O
depolymerase	O
was	O
developed	O
for	O
the	O
specific	O
immobilization	O
of	O
proteins	O
on	O
PHA	B-DISO
microbeads	O
,	O
and	O
was	O
consequently	O
used	O
for	O
immunoassays	O
.	O

A	O
recombinant	O
partial	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
was	O
used	O
as	O
a	O
serodiagnostic	O
antigen	O
in	O
the	O
ELISA	O
.	O

These	O
models	O
can	O
be	O
viewed	O
as	O
age	O
of	O
infection	B-DISO
epidemic	O
models	O
and	O
analyzed	O
using	O
the	O
approach	O
of	O
the	O
full	O
Kermack	O
-	O
McKendrick	O
model	O
.	O

In	O
total	O
,	O
44	O
cases	O
were	O
subsequently	O
confirmed	O
to	O
have	O
SARS	B-DISO
by	O
RT	O
-	O
PCR	O
(	O
68	O
.	O
2	O
%)	O
and	O
serology	O
(	O
100	O
%).	O

All	O
SARS	B-DISO
patients	O
were	O
sedated	O
and	O
received	O
mechanical	O
ventilation	O
in	O
the	O
isolation	O
ICU	O
.	O

TITLE	O
:	O
Clinical	O
review	O
:	O
SARS	B-DISO
-	O
lessons	O
in	O
disaster	O
management	O
.	O

Infectious	B-DISO
diseases	I-DISO
,	O
whether	O
they	O
be	O
natural	O
(	O
e	O
.	O
g	O
.	O
SARS	B-DISO
[	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
]	O
and	O
influenza	B-DISO
)	O
or	O
the	O
result	O
of	O
bioterrorism	O
,	O
have	O
the	O
potential	O
to	O
create	O
a	O
large	O
influx	O
of	O
critically	B-DISO
ill	I-DISO
into	O
our	O
already	O
strained	O
hospital	O
systems	O
.	O

In	O
contrast	O
,	O
one	O
PCR	O
product	O
of	O
356	O
bp	O
corresponding	O
to	O
a	O
fragment	O
of	O
N	O
gene	O
was	O
obtained	O
for	O
IBV	O
strains	O
and	O
one	O
PCR	O
product	O
of	O
568	O
bp	O
corresponding	O
to	O
a	O
fragment	O
of	O
S	O
gene	O
was	O
obtained	O
for	O
BCoV	O
.	O
There	O
were	O
no	O
PCR	O
products	O
with	O
the	O
same	O
primers	O
for	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
Marek	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
virus	O
,	O
turkey	O
pox	O
virus	O
,	O
pigeon	O
pox	O
virus	O
,	O
fowl	B-DISO
pox	I-DISO
virus	O
,	O
reovirus	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
,	O
enterovirus	O
,	O
astrovirus	O
,	O
Salmonella	B-DISO
enterica	O
,	O
Escherichia	O
coli	O
,	O
and	O
Mycoplasma	B-DISO
gallisepticum	O
.	O

ABSTRACT	O
:	O
Viruses	O
in	O
the	O
family	O
Coronaviridae	O
have	O
elicited	O
new	O
interest	O
,	O
with	O
the	O
outbreaks	O
caused	O
by	O
SARS	B-DISO
-	O
HCoV	O
in	O
2003	O
and	O
the	O
recent	O
discovery	O
of	O
a	O
new	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
NL63	O
.	O

TITLE	O
:	O
Survival	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

SARS	B-DISO
-	O
CoV	O
GVU6109	O
can	O
survive	O
for	O
4	O
days	O
in	O
diarrheal	O
stool	O
samples	O
with	O
an	O
alkaline	O
pH	O
,	O
and	O
it	O
can	O
remain	O
infectious	B-DISO
in	O
respiratory	O
specimens	O
for	O
>	O
7	O
days	O
at	O
room	O
temperature	O
.	O

The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
key	O
transcription	O
factor	O
that	O
activates	O
numerous	O
genes	O
involved	O
in	O
cellular	O
immune	O
response	O
and	O
inflammation	B-DISO
.	O

Many	O
studies	O
have	O
shown	O
that	O
NF	O
-	O
kappaB	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
lung	B-DISO
diseases	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
regulatory	O
interaction	O
between	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
NF	O
-	O
kappaB	O
by	O
luciferase	O
activity	O
assay	O
.	O

The	O
majority	O
of	O
outpatients	O
(	O
86	O
%)	O
had	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
,	O
while	O
the	O
majority	O
of	O
inpatients	O
(	O
58	O
%)	O
had	O
bronchiolitis	B-DISO
.	O

TITLE	O
:	O
[	O
Sleep	B-DISO
apnea	I-DISO
syndromes	I-DISO
and	O
cardiovascular	B-DISO
disease	I-DISO
].	O

Obstructive	O
apnea	B-DISO
can	O
also	O
have	O
substantial	O
health	O
consequences	O
.	O

Although	O
the	O
exact	O
mechanism	O
linking	O
sleep	B-DISO
apnea	I-DISO
with	O
cardiovascular	B-DISO
disease	I-DISO
is	O
unknown	O
,	O
there	O
is	O
evidence	O
that	O
obstructive	O
apnea	B-DISO
is	O
associated	O
with	O
a	O
group	O
of	O
proinflammatory	O
and	O
prothrombic	O
factors	O
that	O
are	O
also	O
important	O
in	O
the	O
development	O
of	O
atherosclerosis	B-DISO
.	O

Enhanced	O
platelet	O
activity	O
and	O
aggregation	O
,	O
leukocyte	O
adhesion	B-DISO
and	O
accumulation	O
of	O
endothelial	O
cells	O
are	O
common	O
in	O
both	O
obstructive	O
apnea	B-DISO
and	O
atherosclerosis	B-DISO
.	O

More	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
relationship	O
between	O
sleep	B-DISO
apnea	I-DISO
and	O
cardiovascular	B-DISO
disease	I-DISO
,	O
but	O
clinicians	O
should	O
be	O
aware	O
of	O
this	O
link	O
and	O
should	O
attempt	O
to	O
identify	O
patients	O
with	O
these	O
syndromes	B-DISO
.	O

A	O
third	O
patient	O
died	O
from	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
17	O
months	O
after	O
HSCT	O
with	O
progressive	O
granulocytic	B-DISO
sarcoma	I-DISO
.	O

ABSTRACT	O
:	O
The	O
aetiological	O
agent	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
determined	O
to	O
be	O
a	O
new	O
type	O
of	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
infects	O
a	O
wide	O
range	O
of	O
mammalian	O
hosts	O
.	O

Additionally	O
,	O
we	O
observed	O
that	O
F	O
(	O
ab	O
')	O
2	O
,	O
against	O
BJ	O
-	O
01	O
strain	O
could	O
also	O
protect	O
cells	O
from	O
infection	B-DISO
by	O
the	O
variant	O
GZ	O
-	O
01	O
strain	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
is	O
frequently	O
complicated	O
by	O
respiratory	B-DISO
failure	I-DISO
requiring	O
ventilatory	O
support	O
.	O

Retrospective	O
analysis	O
was	O
conducted	O
on	O
all	O
respiratory	B-DISO
failure	I-DISO
patients	O
identified	O
from	O
the	O
Hong	O
Kong	O
Hospital	O
Authority	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Database	O
.	O

Intubation	O
rate	O
,	O
mortality	O
and	O
secondary	O
outcome	O
of	O
a	O
hospital	O
utilizing	O
non	O
-	O
invasive	O
ventilation	O
under	O
standard	O
infection	B-DISO
control	O
conditions	O
(	O
NIV	O
Hospital	O
)	O
were	O
compared	O
against	O
13	O
hospitals	O
using	O
solely	O
invasive	O
ventilation	O
(	O
IMV	O
Hospitals	O
).	O

Compared	O
to	O
invasive	O
mechanical	O
ventilation	O
,	O
non	O
-	O
invasive	O
ventilation	O
as	O
initial	O
ventilatory	O
support	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
the	O
presence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
appeared	O
to	O
be	O
associated	O
with	O
reduced	O
intubation	O
need	O
and	O
mortality	O
.	O

There	O
were	O
no	O
instances	O
of	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
health	O
care	O
workers	O
due	O
to	O
the	O
use	O
of	O
non	O
-	O
invasive	O
ventilation	O
.	O

Eighty	O
two	O
were	O
classed	O
as	O
normal	O
,	O
seven	O
as	O
having	O
""""	O
impairment	B-DISO
""","	O
and	O
four	O
as	O
having	O
""""	O
severe	O
disability	O
"""."	O

Most	O
newborn	O
infants	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
treated	O
with	O
ECMO	O
will	O
have	O
a	O
normal	O
neurodevelopment	O
screening	O
assessment	O
at	O
11	O
-	O
19	O
months	O
of	O
postnatal	O
age	O
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
severe	O
propylene	O
glycol	O
-	O
induced	O
lactic	B-DISO
acidosis	I-DISO
not	O
attributable	O
to	O
renal	O
dysfunction	O
that	O
was	O
secondary	O
to	O
administration	O
of	O
high	O
-	O
dose	O
intravenous	O
lorazepam	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
female	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
presented	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

To	O
maintain	O
adequate	O
sedation	B-DISO
and	O
ventilation	O
and	O
reduce	O
airway	O
pressure	O
,	O
several	O
relaxation	O
strategies	O
were	O
used	O
including	O
high	O
-	O
dose	O
intravenous	O
lorazepam	O
,	O
fentanyl	O
,	O
and	O
cisatracurium	O
.	O

TITLE	O
:	O
[	O
Rhabdomyolysis	B-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
after	O
severe	O
narcotics	O
intoxication	O
(	O
MDMA	O
,	O
THC	B-DISO
,	O
amphetamine	O
)].	O

TITLE	O
:	O
Detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
the	O
brain	O
:	O
potential	O
role	O
of	O
the	O
chemokine	O
mig	O
in	O
pathogenesis	B-DISO
.	O

A	O
fragment	O
specific	O
for	O
SARS	B-DISO
human	O
coronavirus	O
was	O
amplified	O
from	O
cultures	O
of	O
the	O
brain	O
suspension	O
,	O
and	O
transmission	O
electronic	O
microscopy	O
revealed	O
the	O
presence	O
of	O
an	O
enveloped	O
virus	O
morphologically	O
compatible	O
with	O
a	O
coronavirus	O
isolated	O
in	O
the	O
cultures	O
.	O

Immunostaining	O
demonstrated	O
that	O
monokine	O
induced	O
by	O
interferon	O
-	O
gamma	O
(	O
Mig	O
)	O
was	O
expressed	O
in	O
gliocytes	O
with	O
the	O
infiltration	B-DISO
of	O
CD68	O
+	O
monocytes	O
/	O
macrophages	O
and	O
CD3	O
+	O
T	O
lymphocytes	O
in	O
the	O
brain	O
mesenchyme	O
.	O

Nine	O
patients	O
survived	O
,	O
4	O
died	O
due	O
to	O
respiratory	B-DISO
failure	I-DISO
and	O
2	O
were	O
subjected	O
to	O
euthanasia	O
in	O
a	O
moribund	O
state	O
.	O

The	O
T	O
cell	O
array	O
is	O
an	O
early	O
and	O
sensitive	O
multiplex	O
measure	O
of	O
active	O
infection	B-DISO
,	O
exposure	O
to	O
a	O
pathogen	O
,	O
or	O
effective	O
,	O
recent	O
vaccination	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
resulted	O
in	O
346	O
probable	O
SARS	B-DISO
cases	O
and	O
37	O
deaths	O
in	O
Taiwan	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
female	O
nurses	O
of	O
the	O
SARS	B-DISO
team	O
completed	O
a	O
questionnaire	O
about	O
their	O
experiences	O
serving	O
in	O
the	O
SARS	B-DISO
team	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
like	O
virus	O
in	O
Chinese	O
horseshoe	O
bats	O
.	O

A	O
total	O
of	O
123	O
(	O
36	O
.	O
0	O
%)	O
of	O
352	O
patients	O
with	O
SARS	B-DISO
and	O
100	O
(	O
25	O
.	O
5	O
%)	O
of	O
392	O
control	O
subjects	O
had	O
haplotype	O
pairs	O
associated	O
with	O
medium	O
or	O
low	O
expression	O
of	O
MBL	O
(	O
OR	O
,	O
1	O
.	O
67	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
-	O
2	O
.	O
29	O
];	O
P	O
=.	O
00187	O
).	O

Successful	O
control	O
of	O
the	O
global	O
SARS	B-DISO
epidemic	O
will	O
require	O
rapid	O
and	O
sensitive	O
diagnostic	O
tests	O
to	O
monitor	O
its	O
spread	O
,	O
as	O
well	O
as	O
,	O
the	O
development	O
of	O
vaccines	O
and	O
new	O
antiviral	O
compounds	O
including	O
neutralizing	O
antibodies	O
that	O
effectively	O
prevent	O
or	O
treat	O
this	O
disease	O
.	O

The	O
human	O
synthetic	O
single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
ETH	O
-	O
2	O
phage	O
antibody	O
library	O
was	O
used	O
for	O
the	O
isolation	O
of	O
scFvs	O
against	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
using	O
a	O
bio	O
panning	O
-	O
based	O
strategy	O
.	O

Human	O
scFv	O
antibodies	O
to	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
can	O
be	O
easily	O
isolated	O
by	O
selecting	O
the	O
ETH	O
-	O
2	O
phage	O
library	O
on	O
immunotubes	O
coated	O
with	O
antigen	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
recent	O
epidemic	O
human	O
disease	O
,	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

First	O
reported	O
in	O
Asia	O
,	O
SARS	B-DISO
quickly	O
spread	O
worldwide	O
through	O
international	O
travelling	O
.	O

The	O
rank	O
of	O
SARS	B-DISO
severity	O
was	O
significantly	O
correlated	O
with	O
the	O
recovery	O
period	O
(	O
in	O
days	O
)	O
and	O
with	O
the	O
clinical	O
pulmonary	B-DISO
infection	I-DISO
score	O
.	O

The	O
clinical	O
data	O
of	O
94	O
SARS	B-DISO
cases	O
treated	O
during	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
South	O
China	O
in	O
2003	O
were	O
collected	O
for	O
a	O
retrospective	O
review	O
.	O

Hormone	O
therapy	O
may	O
not	O
produce	O
significant	O
effect	O
in	O
controlling	O
the	O
temperature	O
of	O
SARS	B-DISO
patients	O
.	O

Hormone	O
therapy	O
did	O
not	O
significantly	O
affect	O
the	O
temperature	O
of	O
SARS	B-DISO
patients	O
(	O
P	O
=	O
0	O
.	O
180	O
),	O
who	O
had	O
longer	O
duration	O
of	O
high	O
fever	O
.	O

The	O
recombinant	O
N	O
protein	O
expressed	O
was	O
about	O
6	O
%	O
of	O
the	O
total	O
cell	O
proteins	O
,	O
410	O
mg	O
/	O
L	O
of	O
recombinant	O
N	O
protein	O
and	O
45	O
OD600	O
were	O
achieved	O
in	O
shake	B-DISO
flask	O
.	O

SDS	B-DISO
-	O
PAGE	O
or	O
Western	O
blot	O
analysis	O
of	O
the	O
induced	O
expression	O
products	O
demonstrated	O
that	O
the	O
5	O
recombinant	O
proteins	O
were	O
expressed	O
in	O
the	O
fission	O
yeast	O
respectively	O
.	O

TITLE	O
:	O
Rhabdomyolysis	B-DISO
associated	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Eleven	O
(	O
36	O
.	O
7	O
%)	O
patients	O
had	O
respiratory	B-DISO
failure	I-DISO
and	O
required	O
mechanical	O
ventilation	O
with	O
paralytic	O
therapy	O
;	O
three	O
(	O
10	O
%)	O
patients	O
had	O
rhabdomyolysis	B-DISO
complicated	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
one	O
received	O
haemodialysis	O
;	O
four	O
(	O
13	O
.	O
3	O
%)	O
patients	O
died	O
.	O

Immobilisation	O
under	O
paralytic	O
therapy	O
and	O
steroids	O
may	O
also	O
be	O
important	O
in	O
developing	O
rhabdomyolysis	B-DISO
.	O

Lymphopenia	B-DISO
and	O
thrombocytopenia	O
in	O
SARS	B-DISO
patients	O
may	O
be	O
caused	O
,	O
in	O
part	O
,	O
by	O
enhanced	O
vascular	O
sequestration	O
associated	O
with	O
increased	O
sVCAM	O
-	O
1	O
levels	O
.	O

TITLE	O
:	O
Sirolimus	O
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
renal	O
transplant	O
recipient	O
.	O

We	O
report	O
a	O
new	O
case	O
that	O
was	O
complicated	O
by	O
a	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
which	O
required	O
several	O
days	O
of	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
immunological	O
responses	O
and	O
clinical	O
outcome	O
of	O
coronavirus	O
(	O
SARS	B-DISO
)	O
infected	O
healthcare	O
workers	O
(	O
HCW	O
)	O
who	O
had	O
been	O
administered	O
with	O
convalescent	O
plasma	O
as	O
a	O
treatment	O
.	O

As	O
part	O
of	O
the	O
routine	O
check	O
with	O
donated	O
plasma	O
,	O
the	O
convalescent	O
plasma	O
was	O
confirmed	O
free	O
of	O
residual	O
SARS	B-DISO
-	O
CoV	O
by	O
RT	O
-	O
PCR	O
.	O

These	O
included	O
132	O
patients	O
who	O
had	O
moderate	O
course	O
of	O
SARS	B-DISO
infection	B-DISO
(	O
home	O
subgroup	O
),	O
26	O
patients	O
with	O
a	O
severe	O
course	O
requiring	O
treatment	O
in	O
an	O
intensive	O
care	O
ward	O
(	O
ICU	O
subgroup	O
)	O
and	O
a	O
subgroup	O
of	O
22	O
patients	O
who	O
died	O
from	O
SARS	B-DISO
(	O
deceased	O
subgroup	O
).	O

TITLE	O
:	O
The	O
impact	O
of	O
SARS	B-DISO
on	O
epilepsy	B-DISO
:	O
the	O
experience	O
of	O
drug	B-DISO
withdrawal	I-DISO
in	O
epileptic	B-DISO
patients	O
.	O

Bacterially	O
expressed	O
forms	O
of	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
X	O
domains	O
were	O
shown	O
to	O
dephosphorylate	O
Appr	O
-	O
1	O
"""-"	O
p	O
,	O
a	O
side	O
product	O
of	O
cellular	O
tRNA	O
splicing	O
,	O
to	O
ADP	O
-	O
ribose	O
in	O
a	O
highly	O
specific	O
manner	O
.	O

Characterization	O
of	O
an	O
Appr	O
-	O
1	O
"""-"	O
pase	O
-	O
deficient	O
HCoV	O
-	O
229E	O
mutant	B-DISO
revealed	O
no	O
significant	O
effects	O
on	O
viral	O
RNA	O
synthesis	O
and	O
virus	O
titer	O
,	O
and	O
no	O
reversion	O
to	O
the	O
wild	O
-	O
type	O
sequence	O
was	O
observed	O
when	O
the	O
mutant	B-DISO
virus	O
was	O
passaged	O
in	O
cell	O
culture	O
.	O

ABSTRACT	O
:	O
Here	O
,	O
we	O
report	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nsP7	O
,	O
a	O
component	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
replicase	O
polyprotein	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
in	O
2002	O
as	O
a	O
severe	O
and	O
highly	O
contagious	O
infectious	B-DISO
disease	I-DISO
that	O
rapidly	O
spread	O
to	O
a	O
number	O
of	O
different	O
countries	O
.	O

At	O
weekly	O
intervals	O
up	O
to	O
3	O
weeks	O
post	O
-	O
infection	B-DISO
,	O
excess	O
lachrymation	O
was	O
induced	O
either	O
by	O
placing	O
sodium	O
chloride	O
(	O
salt	O
)	O
crystals	O
on	O
the	O
eyes	O
or	O
by	O
intramuscular	O
injection	O
of	O
carbachol	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
lung	B-DISO
fibrosis	I-DISO
after	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
ortho	O
-	O
phenylphenol	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
important	O
for	O
vaccine	O
development	O
.	O

Using	O
the	O
exon	O
splicing	O
enhancers	O
,	O
including	O
a	O
bidirectional	O
splicing	O
enhancer	O
(	O
BSE	B-DISO
)	O
or	O
an	O
exon	O
splicing	O
enhancer	O
derived	O
from	O
the	O
EDA	B-DISO
alternative	O
exon	O
of	O
the	O
fibronectin	O
gene	O
(	O
EDA	B-DISO
ESE	O
),	O
were	O
also	O
found	O
to	O
increase	O
STR2	O
protein	O
expression	O
in	O
CHO	O
/	O
dhFr	O
-	O
cells	O
by	O
1	O
.	O
7	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
.	O

IP	O
-	O
10	O
was	O
increased	O
in	O
lung	O
tissue	O
from	O
patients	O
who	O
died	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
in	O
2002	O
to	O
2003	O
in	O
southern	O
China	O
.	O

These	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
acute	O
alcohol	O
administration	O
aggravates	O
systemic	O
and	O
local	O
oxidative	B-DISO
stress	I-DISO
leading	O
to	O
acute	O
lung	O
injury	O
,	O
ranging	O
from	O
mild	O
pulmonary	O
dysfunction	O
to	O
severe	O
lung	O
injury	O
.	O

Therefore	O
,	O
precautions	O
against	O
ARDS	B-DISO
may	O
prevent	O
morbidity	O
and	O
mortality	O
in	O
alcohol	O
-	O
induced	O
lung	O
damage	O
in	O
at	O
-	O
risk	O
patients	O
.	O

The	O
recombinant	O
N	O
fusion	O
protein	O
was	O
expressed	O
and	O
purified	O
,	O
and	O
its	O
antigenicity	O
and	O
specificity	O
was	O
analyzed	O
by	O
Western	O
Blot	O
,	O
to	O
establish	O
the	O
recombinant	O
N	O
protein	O
-	O
based	O
ELISA	O
for	O
detection	O
of	O
IgG	O
antibodies	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
,	O
and	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
lysates	O
-	O
based	O
ELISA	O
was	O
compared	O
parallelly	O
.	O

Shiraz	O
University	O
of	O
Medical	O
Sciences	O
has	O
records	O
of	O
7130	O
autopsies	O
performed	O
in	O
the	O
past	O
40	O
years	O
,	O
33	O
of	O
which	O
are	O
anthrax	B-DISO
cases	O
.	O

Novel	O
findings	O
included	O
hyaline	B-DISO
membrane	I-DISO
formation	O
in	O
respiratory	O
system	O
cases	O
that	O
is	O
similar	O
to	O
acute	O
(	O
adult	O
)	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
and	O
evidence	O
of	O
primary	O
gastrointestinal	O
involvement	O
,	O
showing	O
the	O
ability	O
of	O
the	O
organism	O
to	O
pass	O
the	O
gastric	O
barrier	O
.	O

Results	O
from	O
the	O
ESCAPE	O
trial	O
of	O
patients	O
with	O
severe	O
heart	B-DISO
failure	I-DISO
were	O
also	O
included	O
.	O

The	O
neutrality	O
of	O
the	O
PAC	B-DISO
for	O
clinical	O
outcomes	O
may	O
result	O
from	O
the	O
absence	O
of	O
effective	O
evidence	O
-	O
based	O
treatments	O
to	O
use	O
in	O
combination	O
with	O
PAC	B-DISO
information	O
across	O
the	O
spectrum	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

The	O
antibody	O
development	O
in	O
seven	O
cats	O
experimentally	O
infected	O
with	O
FCoV	O
type	O
1	O
revealed	O
that	O
,	O
with	O
progressing	O
duration	O
of	O
infection	B-DISO
,	O
antibodies	O
to	O
FCoV	O
type	O
1	O
significantly	O
increased	O
over	O
those	O
to	O
FCoV	O
type	O
2	O
.	O

We	O
conclude	O
that	O
a	O
vaccine	O
against	O
FCoV	O
should	O
be	O
based	O
on	O
FCoV	O
type	O
1	O
-	O
related	O
antigens	O
and	O
that	O
for	O
serodiagnosis	O
of	O
FCoV	O
infection	B-DISO
TGEV	O
should	O
be	O
used	O
to	O
attain	O
the	O
highest	O
diagnostic	O
efficiency	O
.	O

TITLE	O
:	O
Persevering	O
through	O
a	O
difficult	O
time	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
experience	O
of	O
persevering	O
through	O
a	O
difficult	O
time	O
for	O
patients	O
,	O
family	O
members	O
of	O
patients	O
,	O
nurses	O
,	O
and	O
allied	O
health	O
professionals	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
.	O

Data	O
gathering	O
occurred	O
in	O
early	O
April	O
2003	O
in	O
the	O
midst	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Toronto	O
,	O
Canada	O
.	O

The	O
finding	O
was	O
the	O
structural	O
definition	O
,	O
persevering	O
through	O
a	O
difficult	O
time	O
is	O
dispiriting	O
trepidation	O
arising	O
with	O
witnessing	O
suffering	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
membrane	O
protein	O
and	O
5	O
-	O
lipoxygenase	O
-	O
activating	O
protein	O
(	O
FLAP	O
)	O
are	O
among	O
a	O
large	O
number	O
of	O
membrane	O
proteins	O
that	O
are	O
poorly	O
expressed	O
when	O
traditional	O
expression	O
systems	O
and	O
methods	O
are	O
employed	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
FLAP	O
and	O
SARS	B-DISO
-	O
CoV	O
membrane	O
proteins	O
are	O
greatly	O
enhanced	O
by	O
SUMO	O
fusions	O
in	O
E	O
.	O
coli	O
.	O

ABSTRACT	O
:	O
Concanavalin	O
A	O
-	O
Sandwich	O
ELISA	O
(	O
Con	O
A	O
-	O
S	O
-	O
ELISA	O
)	O
was	O
developed	O
for	O
the	O
detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
or	O
chicken	O
specific	O
anti	O
-	O
viral	O
antibodies	O
.	O

Using	O
a	O
specific	O
monoclonal	O
antibody	O
,	O
we	O
demonstrated	O
that	O
the	O
3a	O
protein	O
displayed	O
a	O
punctate	O
cytoplasmic	O
localization	O
in	O
Drosophila	O
as	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
laboratory	O
diagnosis	O
of	O
dengue	B-DISO
has	O
largely	O
relied	O
on	O
serological	O
assays	O
,	O
although	O
many	O
different	O
RT	O
-	O
PCR	O
protocols	O
have	O
been	O
reported	O
.	O

Our	O
experience	O
indicates	O
that	O
RT	O
-	O
PCR	O
for	O
dengue	B-DISO
can	O
be	O
set	O
up	O
rapidly	O
in	O
a	O
clinical	O
laboratory	O
,	O
with	O
very	O
sensitive	O
and	O
specific	O
results	O
for	O
the	O
diagnosis	O
of	O
dengue	B-DISO
,	O
particularly	O
in	O
the	O
first	O
5	O
days	O
from	O
onset	O
of	O
symptoms	O
.	O

As	O
systemic	B-DISO
infection	I-DISO
is	O
not	O
the	O
key	O
event	O
in	O
the	O
development	O
of	O
FIP	B-DISO
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
a	O
potential	O
difference	O
in	O
viral	O
load	O
might	O
be	O
of	O
importance	O
.	O

In	O
cats	O
that	O
died	O
from	O
FIP	B-DISO
,	O
viral	O
loads	O
were	O
significantly	O
higher	O
,	O
indicating	O
a	O
higher	O
rate	O
of	O
viral	O
replication	O
or	O
a	O
reduced	O
capacity	O
for	O
viral	O
clearance	O
in	O
cats	O
developing	O
and	O
/	O
or	O
suffering	B-DISO
from	O
FIP	B-DISO
.	O

A	O
two	O
step	O
inactivation	B-DISO
procedure	O
involving	O
sequential	O
formaldehyde	O
and	O
U	O
.	O
V	O
.	O
inactivation	B-DISO
was	O
utilised	O
in	O
order	O
to	O
ensure	O
an	O
extremely	O
high	O
safety	O
margin	O
with	O
respect	O
to	O
residual	O
infectivity	O
.	O

Recent	O
research	O
has	O
demonstrated	O
the	O
potential	O
of	O
certain	O
dietary	O
oils	O
(	O
eg	O
,	O
fish	O
oil	O
,	O
borage	O
oil	O
)	O
to	O
modulate	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
thereby	O
improving	O
lung	O
compliance	O
and	O
oxygenation	O
,	O
and	O
reducing	O
time	O
on	O
mechanical	O
ventilation	O
.	O

Influenza	B-DISO
vaccination	O
can	O
reduce	O
the	O
prevalence	O
of	O
respiratory	O
hospitalizations	O
among	O
pregnant	O
women	O
during	O
influenza	B-DISO
season	O
.	O

TITLE	O
:	O
Comparison	O
of	O
prone	O
positioning	O
and	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
physiologic	O
and	O
proinflammatory	O
effects	O
of	O
HFOV	O
,	O
prone	O
positioning	O
,	O
or	O
their	O
combination	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
contrast	O
,	O
supine	O
-	O
HFOV	O
did	O
not	O
improve	O
gas	O
exchange	O
and	O
was	O
associated	O
with	O
enhanced	O
lung	B-DISO
inflammation	I-DISO
.	O

Following	O
induction	O
of	O
acute	O
lung	O
injury	O
,	O
gut	O
epithelial	B-DISO
proliferation	I-DISO
and	O
apoptosis	O
were	O
assessed	O
in	O
a	O
)	O
C3H	O
/	O
HeN	O
wild	O
-	O
type	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
lack	O
functional	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
n	O
=	O
17	O
);	O
b	O
)	O
C57Bl	O
/	O
6	O
mice	O
that	O
received	O
monoclonal	O
anti	O
-	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
or	O
control	O
antibody	O
(	O
n	O
=	O
22	O
);	O
and	O
c	O
)	O
C57Bl	O
/	O
6	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
that	O
overexpress	O
Bcl	O
-	O
2	O
in	O
their	O
gut	O
epithelium	O
(	O
n	O
=	O
21	O
).	O

TITLE	O
:	O
Screening	O
of	O
electrophilic	O
compounds	O
yields	O
an	O
aziridinyl	O
peptide	O
as	O
new	O
active	O
-	O
site	O
directed	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
inhibitor	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
main	O
protease	O
,	O
M	O
(	O
pro	O
),	O
is	O
considered	O
a	O
major	O
target	O
for	O
drugs	O
suitable	O
to	O
combat	O
coronavirus	B-DISO
infections	I-DISO
including	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

What	O
distinguished	O
this	O
illness	O
clinically	O
was	O
the	O
fact	O
that	O
approximately	O
half	O
of	O
the	O
victims	O
were	O
health	O
care	O
workers	O
,	O
infected	O
while	O
caring	O
for	O
recognized	O
or	O
unrecognized	O
patients	O
with	O
SARS	B-DISO
.	O

There	O
are	O
many	O
curiosities	O
and	O
uncertainties	O
surrounding	O
the	O
epidemic	O
of	O
SARS	B-DISO
with	O
lessons	O
that	O
may	O
be	O
useful	O
to	O
the	O
community	O
of	O
infectious	B-DISO
diseases	I-DISO
physicians	O
,	O
especially	O
when	O
looking	O
ahead	O
to	O
the	O
next	O
epidemic	O
.	O

The	O
second	O
part	O
of	O
this	O
review	O
focuses	O
on	O
new	O
challenges	O
for	O
infection	B-DISO
control	O
,	O
such	O
as	O
1	O
)	O
the	O
ever	O
-	O
growing	O
number	O
of	O
immunocompromised	O
patients	O
and	O
basic	O
control	O
measures	O
to	O
avoid	O
opportunistic	B-DISO
infections	I-DISO
;	O
2	O
)	O
the	O
concerns	O
about	O
the	O
capacity	O
of	O
the	O
public	O
health	O
systems	O
to	O
deal	O
with	O
terrorist	O
acts	O
;	O
3	O
)	O
the	O
practice	O
of	O
high	O
-	O
risk	O
procedures	O
in	O
facilities	O
lacking	O
trained	O
personnel	O
,	O
efficient	O
laboratories	O
,	O
and	O
protective	O
items	O
;	O
and	O
4	O
)	O
gene	O
therapy	O
and	O
its	O
potential	O
infectious	B-DISO
complications	O
.	O

Consideration	O
is	O
given	O
to	O
the	O
asymmetric	O
development	O
of	O
infection	B-DISO
control	O
globally	O
.	O

TITLE	O
:	O
SARS	B-DISO
Immunity	O
and	O
Vaccination	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
serious	O
and	O
fatal	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
Cov	O
),	O
a	O
novel	O
human	O
coronavirus	O
.	O

A	O
questionnaire	O
was	O
used	O
to	O
survey	O
Year	O
4	O
medical	O
students	O
at	O
the	O
end	O
of	O
their	O
undergraduate	O
anaesthesia	B-DISO
attachment	O
,	O
during	O
which	O
basic	O
life	O
support	O
(	O
BLS	B-DISO
)	O
skills	O
were	O
taught	O
.	O

They	O
were	O
concerned	O
about	O
disease	B-DISO
transmission	I-DISO
during	O
resuscitation	O
but	O
were	O
less	O
positive	O
regarding	O
whether	O
the	O
risks	O
had	O
increased	O
due	O
to	O
SARS	B-DISO
.	O

In	O
all	O
situations	O
they	O
were	O
significantly	O
more	O
likely	O
to	O
perform	O
mouth	O
-	O
to	O
-	O
mouth	O
ventilation	O
for	O
a	O
family	O
member	O
compared	O
with	O
a	O
stranger	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
to	O
withhold	O
mouth	O
-	O
to	O
-	O
mouth	O
ventilation	O
if	O
either	O
vomit	B-DISO
or	O
blood	O
were	O
present	O
in	O
the	O
victim	O
'	O
s	O
mouth	O
.	O

ABSTRACT	O
:	O
Partial	O
liquid	O
ventilation	O
(	O
PLV	O
)	O
with	O
perfluorochemical	O
(	O
PFC	O
)	O
has	O
been	O
advocated	O
as	O
a	O
new	O
therapy	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
both	O
clinical	O
and	O
animal	O
studies	O
,	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
,	O
and	O
RDS	O
.	O

One	O
survey	O
asked	O
individual	O
general	O
practitioners	O
(	O
GPs	B-DISO
)	O
about	O
how	O
they	O
gathered	O
information	O
about	O
SARS	B-DISO
in	O
2003	O
,	O
how	O
they	O
preferred	O
to	O
receive	O
information	O
,	O
current	O
practices	O
,	O
and	O
how	O
they	O
perceived	O
the	O
threat	O
of	O
SARS	B-DISO
and	O
other	O
infectious	B-DISO
agents	O
.	O

Planning	O
for	O
future	O
infectious	B-DISO
disease	I-DISO
outbreak	O
events	O
in	O
the	O
Australian	O
Capital	O
Territory	O
should	O
incorporate	O
general	O
practitioners	O
so	O
that	O
the	O
plans	O
reflect	O
what	O
is	O
a	O
feasible	O
response	O
in	O
the	O
general	O
practice	O
setting	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
and	O
rapid	O
global	O
spread	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
in	O
2002	O
-	O
2003	O
prompted	O
efforts	O
by	O
modelers	O
to	O
characterize	O
SARS	B-DISO
epidemiology	O
and	O
inform	O
control	O
policies	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
cell	O
types	O
infected	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
lung	O
tissues	O
and	O
explore	O
the	O
mechanism	O
of	O
lung	O
injury	O
in	O
SARS	B-DISO
.	O

Various	O
types	O
of	O
cells	O
damaged	O
by	O
SARS	B-DISO
-	O
CoV	O
and	O
inflammatory	O
mediators	O
released	O
by	O
those	O
cells	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
lung	O
injury	O
in	O
SARS	B-DISO
.	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	O
to	O
protein	O
X4	O
expressed	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Cross	O
-	O
reaction	O
of	O
SARS	B-DISO
-	O
CoV	O
antigen	O
with	O
autoantibodies	O
in	O
autoimmune	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
significance	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
antibody	O
,	O
detected	O
by	O
ELISA	O
and	O
indirect	O
immunofluorescence	O
assays	O
(	O
IFA	O
)	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
Vero	O
E6	O
cell	O
lysates	O
,	O
in	O
non	O
-	O
SARS	B-DISO
subjects	O
,	O
114	O
serum	O
samples	O
from	O
healthy	O
controls	O
and	O
104	O
serum	O
specimens	O
from	O
autoimmune	B-DISO
disease	I-DISO
patients	O
were	O
collected	O
.	O

Recently	O
,	O
we	O
identified	O
a	O
dilysine	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
retrieval	O
signal	O
and	O
a	O
tyrosine	O
-	O
based	O
endocytosis	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
S	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

Our	O
results	O
suggest	O
that	O
the	O
endocytosis	O
signal	O
of	O
IBV	O
S	O
is	O
essential	O
for	O
productive	O
virus	B-DISO
infection	I-DISO
.	O

Transfer	O
of	O
the	O
CCA4	B-DISO
mutation	O
into	O
a	O
partially	O
diploid	O
MHV	O
genome	O
showed	O
that	O
CCA4	B-DISO
was	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
rather	O
than	O
a	O
dominant	B-DISO
-	I-DISO
negative	I-DISO
mutation	I-DISO
.	O

The	O
Deltansp2	O
mutant	B-DISO
viruses	O
lacked	O
expression	O
of	O
both	O
nsp2	O
and	O
an	O
nsp2	O
-	O
nsp3	O
precursor	O
,	O
but	O
cleaved	O
the	O
engineered	O
chimeric	O
nsp1	O
-	O
nsp3	O
cleavage	O
site	O
as	O
efficiently	O
as	O
the	O
native	O
nsp1	O
-	O
nsp2	O
cleavage	O
site	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
fails	O
to	O
activate	O
cytokine	O
-	O
mediated	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
in	O
cultured	O
human	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
.	O

No	O
induction	O
of	O
cytokine	O
genes	O
(	O
alpha	O
interferon	O
[	O
IFN	O
-	O
alpha	O
],	O
IFN	O
-	O
beta	O
,	O
interleukin	O
-	O
28A	O
/	O
B	O
[	O
IL	O
-	O
28A	O
/	O
B	O
],	O
IL	O
-	O
29	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
,	O
CCL5	O
,	O
or	O
CXCL10	O
)	O
or	O
IFN	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
MxA	O
gene	O
was	O
seen	O
in	O
SCV	O
-	O
infected	O
A549	O
cells	O
,	O
macrophages	O
,	O
or	O
DCs	B-DISO
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
major	O
antigen	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

350	O
throat	O
washes	O
of	O
confirmed	O
,	O
suspected	O
and	O
observed	O
SARS	B-DISO
cases	O
were	O
tested	O
by	O
TaqMan	O
and	O
molecular	O
beacon	O
fluorescence	O
RT	O
-	O
PCR	O
methods	O
.	O

RESULTS	O
:	O
10	O
positive	O
were	O
detected	O
from	O
41	O
SARS	B-DISO
clinical	O
confirmed	O
cases	O
(	O
24	O
.	O
39	O
%).	O

CONCLUSIONS	O
:	O
TaqMan	O
and	O
molecular	O
beacon	O
PCR	O
methods	O
both	O
can	O
be	O
used	O
in	O
SARS	B-DISO
detection	O
.	O

TITLE	O
:	O
[	O
Modified	O
molecular	O
beacon	O
-	O
based	O
dual	O
real	O
-	O
time	O
PCR	O
for	O
detection	O
of	O
SARS	B-DISO
virus	O
and	O
its	O
application	O
].	O

We	O
present	O
here	O
a	O
simple	O
and	O
rapid	O
assay	O
for	O
the	O
screening	O
of	O
SARS	B-DISO
-	O
coronavirus	O
genotypes	O
based	O
on	O
the	O
use	O
of	O
fluorogenic	O
oligonucleotide	O
probes	O
for	O
allelic	O
discrimination	O
.	O

Low	O
tide	O
volume	O
lung	O
-	O
protective	O
ventilation	O
strategy	O
and	O
lung	O
recruitment	B-DISO
measures	O
may	O
prove	O
beneficial	O
.	O

ABSTRACT	O
:	O
Kawasaki	B-DISO
disease	I-DISO
(	O
KD	O
)	O
is	O
a	O
self	O
-	O
limited	O
,	O
systemic	O
vasculitis	B-DISO
of	O
children	O
for	O
which	O
an	O
infectious	B-DISO
trigger	O
is	O
suspected	O
.	O

TITLE	O
:	O
[	O
Syndromic	O
surveillance	O
for	O
the	O
detection	O
of	O
outbreaks	O
of	O
unusual	O
infectious	B-DISO
diseases	I-DISO
].	O

Although	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Toronto	O
did	O
not	O
reach	O
such	O
a	O
level	O
,	O
it	O
created	O
a	O
unique	O
opportunity	O
to	O
identify	O
the	O
optimal	O
use	O
of	O
the	O
Internet	O
to	O
promote	O
communication	O
with	O
the	O
public	O
and	O
to	O
preserve	O
health	O
services	O
during	O
an	O
epidemic	O
.	O

We	O
evaluated	O
survivors	O
with	O
confirmed	O
SARS	B-DISO
at	O
the	O
Prince	O
of	O
Wales	O
Hospital	O
,	O
Hong	O
Kong	O
,	O
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
symptom	B-DISO
onset	O
.	O

Exercise	O
capacity	O
and	O
health	O
status	O
of	O
SARS	B-DISO
survivors	O
were	O
remarkably	O
lower	O
than	O
those	O
of	O
a	O
normal	O
population	O
.	O

CONCLUSIONS	O
:	O
Significant	O
impairment	B-DISO
in	O
Dlco	O
was	O
noted	O
in	O
23	O
.	O
7	O
%	O
of	O
survivors	O
1	O
year	O
after	O
illness	O
onset	O
.	O

Our	O
findings	O
indicated	O
that	O
orchitis	B-DISO
is	O
a	O
complication	B-DISO
of	O
SARS	B-DISO
.	O

Data	O
from	O
the	O
Hong	O
Kong	O
SARS	B-DISO
epidemic	O
are	O
used	O
for	O
illustration	O
.	O

We	O
first	O
validate	O
this	O
method	O
on	O
the	O
human	B-DISO
influenza	I-DISO
A	O
viral	O
genomes	O
as	O
well	O
as	O
on	O
the	O
human	O
mitochondrial	O
DNA	O
database	O
.	O

We	O
then	O
apply	O
the	O
method	O
to	O
study	O
the	O
origin	O
of	O
the	O
SARS	B-DISO
coronavirus	O
.	O

This	O
study	O
reports	O
the	O
use	O
of	O
ECMO	O
in	O
a	O
cohort	O
of	O
adults	O
referred	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
following	O
trauma	O
.	O

Twenty	O
of	O
28	O
patients	O
who	O
received	O
ECMO	O
with	O
severe	O
trauma	O
related	O
respiratory	B-DISO
failure	I-DISO
(	O
mean	O
PaO2	O
/	O
FiO2	O
of	O
62	O
mmHg	O
)	O
survived	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
neonates	O
and	O
children	O
.	O

C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
GE	O
-	O
XDP	B-DISO
and	O
D	O
-	O
dimer	O
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
infection	B-DISO
,	O
DIC	B-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
[	O
Construction	O
of	O
recombinant	O
canine	O
adenovirus	B-DISO
type	O
2	O
expressing	O
Canine	O
coronavirus	O
spike	O
glycoprotein	O
and	O
its	O
immunogenicity	O
].	O

The	O
expressed	O
S1	O
protein	O
of	O
CCV	B-DISO
,	O
which	O
was	O
identified	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
can	O
be	O
specifically	O
recognized	O
by	O
polyclonal	O
antibody	O
against	O
CCV	B-DISO
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
our	O
lead	O
inhibitor	O
(	O
4	O
)	O
bound	O
to	O
SARS	B-DISO
-	O
3CLpro	O
provided	O
important	O
drug	O
-	O
design	O
templates	O
for	O
the	O
design	O
of	O
small	O
-	O
molecule	O
inhibitors	O
.	O

TITLE	O
:	O
Assembly	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
RNA	O
packaging	O
signal	O
into	O
virus	O
-	O
like	O
particles	O
is	O
nucleocapsid	O
dependent	O
.	O

TITLE	O
:	O
Modulation	O
of	O
the	O
immune	O
response	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
spike	O
glycoprotein	O
by	O
gene	O
-	O
based	O
and	O
inactivated	O
virus	O
immunization	O
.	O

TITLE	O
:	O
Acquisition	O
of	O
macrophage	O
tropism	O
during	O
the	O
pathogenesis	B-DISO
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
is	O
determined	O
by	O
mutations	O
in	O
the	O
feline	O
coronavirus	O
spike	O
protein	O
.	O

Interestingly	O
,	O
this	O
property	O
mapped	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
protein	O
,	O
implying	O
that	O
the	O
difference	O
in	O
infection	B-DISO
efficiency	O
between	O
the	O
two	O
viruses	O
is	O
not	O
determined	O
at	O
the	O
level	O
of	O
receptor	O
usage	O
,	O
which	O
we	O
confirmed	O
by	O
showing	O
that	O
infection	B-DISO
by	O
both	O
viruses	O
was	O
equally	O
blocked	O
by	O
antibodies	O
directed	O
against	O
the	O
feline	O
aminopeptidase	O
N	O
receptor	O
.	O

A	O
multi	O
-	O
target	O
real	O
-	O
time	O
NASBA	O
application	O
was	O
developed	O
for	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
polymerase	O
(	O
Pol	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
.	O

Similarly	O
,	O
the	O
sera	O
of	O
immunized	O
mice	O
could	O
also	O
react	O
specifically	O
with	O
SARS	B-DISO
-	O
CoV	O
particles	O
.	O

HIV	B-DISO
-	O
NS	O
is	O
suggested	O
to	O
be	O
particularly	O
suitable	O
to	O
enhance	O
antigen	O
delivery	O
to	O
dendritic	O
cells	O
(	O
DCs	B-DISO
).	O

These	O
results	O
suggest	O
that	O
HIV	B-DISO
-	O
NS	O
provides	O
an	O
efficient	O
vaccine	O
delivery	O
system	O
for	O
the	O
induction	O
of	O
a	O
mucosal	O
immune	O
response	O
and	O
the	O
development	O
of	O
a	O
mucosal	O
vaccine	O
.	O

After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	O
were	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
interferon	O
group	O
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

Through	O
pathological	O
examination	O
,	O
the	O
morphology	O
of	O
the	O
lung	O
tissues	O
of	O
two	O
Macaques	O
in	O
the	O
treated	O
group	O
was	O
normal	O
,	O
while	O
the	O
other	O
three	O
displayed	O
the	O
interstitial	B-DISO
pneumonia	I-DISO
with	O
the	O
thickened	O
septum	O
and	O
infiltration	B-DISO
with	O
mononuclear	O
cells	O
.	O

RESULTS	O
:	O
After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	O
were	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
interferon	O
group	O
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
Using	O
recombinant	O
human	O
interferon	O
alpha	O
-	O
2b	O
for	O
nasal	O
spray	O
could	O
lead	O
to	O
some	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
,	O
however	O
,	O
all	O
those	O
symptoms	O
were	O
mild	O
,	O
reversible	O
,	O
and	O
relieved	O
after	O
completion	O
of	O
the	O
use	O
of	O
the	O
trial	O
drug	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
preventive	O
effect	O
of	O
recombinant	O
human	O
interferon	O
alpha	O
-	O
2b	O
for	O
nasal	O
spray	O
against	O
SARS	B-DISO
and	O
other	O
common	O
respiratory	O
viral	B-DISO
infections	I-DISO
by	O
serum	O
-	O
epidemiological	O
method	O
.	O

CONCLUSIONS	O
:	O
The	O
recombinant	O
human	O
interferon	O
alpha	O
-	O
2b	O
for	O
nasal	O
spray	O
could	O
decrease	O
the	O
rates	O
of	O
common	O
respiratory	O
viruses	O
infection	B-DISO
in	O
the	O
selected	O
population	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	O
-	O
2	O
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
so	O
its	O
gene	O
was	O
cloned	O
and	O
eukaryotic	O
expressed	O
for	O
further	O
insight	O
into	O
mechanisms	O
in	O
SARS	B-DISO
-	O
CoV	O
entry	O
and	O
pathogenesis	B-DISO
,	O
as	O
well	O
as	O
development	O
of	O
a	O
safe	O
and	O
reliable	O
neutralization	O
assay	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
Total	O
RNA	O
was	O
extracted	O
from	O
right	O
atrial	O
tissue	O
of	O
a	O
patient	O
with	O
right	B-DISO
heart	I-DISO
failure	I-DISO
resected	O
during	O
a	O
valvular	O
replacement	O
surgery	O
by	O
Trizol	O
one	O
-	O
step	O
method	O
,	O
and	O
the	O
full	O
-	O
length	O
ACE	O
-	O
2	O
encoding	O
gene	O
was	O
acquired	O
by	O
RT	O
-	O
nested	O
-	O
PCR	O
.	O

This	O
cell	O
-	O
cell	O
fusion	O
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	B-DISO
-	O
CoV	O
neutralizing	O
antibody	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
aimed	O
to	O
clone	O
and	O
express	O
three	O
fragments	O
of	O
genomic	O
RNA	O
derived	O
from	O
SARS	B-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
S1	O
domain	O
and	O
to	O
study	O
its	O
immunogenicity	O
.	O

TITLE	O
:	O
Cross	O
-	O
reactivity	O
of	O
antibody	O
against	O
SARS	B-DISO
-	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
IL	O
-	O
11	O
.	O

TITLE	O
:	O
Structural	O
insights	O
into	O
SARS	B-DISO
coronavirus	O
proteins	O
.	O

The	O
availability	O
of	O
structures	O
of	O
SARS	B-DISO
coronavirus	O
macromolecules	O
has	O
enabled	O
the	O
elucidation	O
of	O
their	O
important	O
functions	O
,	O
such	O
as	O
mediating	O
the	O
fusion	O
of	O
viral	O
and	O
host	O
cellular	O
membranes	O
,	O
and	O
in	O
replication	O
and	O
transcription	O
.	O

Diarrhea	B-DISO
can	O
also	O
occur	O
in	O
patients	O
with	O
systemic	O
bacterial	B-DISO
infections	I-DISO
.	O

The	O
time	O
of	O
disappearance	O
of	O
symptoms	O
,	O
the	O
recovery	O
time	O
of	O
acetyl	O
cholinesterase	O
(	O
AChE	B-DISO
),	O
atropinization	O
time	O
,	O
atropine	O
dosage	O
,	O
pralidoxime	O
chloride	O
dosage	O
,	O
naloxone	O
dosage	O
,	O
hospitalization	O
days	O
and	O
other	O
targets	O
were	O
also	O
observed	O
.	O

ABSTRACT	O
:	O
A	O
24	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
4	O
-	O
year	O
history	O
of	O
bronchial	B-DISO
asthma	I-DISO
suffered	B-DISO
from	O
bloody	B-DISO
sputum	I-DISO
,	O
numbness	B-DISO
of	O
the	O
extremities	O
,	O
elevated	O
eosinophil	O
count	O
,	O
and	O
hypoxemia	O
.	O

Prospectively	O
collected	O
(	O
during	O
a	O
12	O
-	O
month	O
period	O
)	O
nasopharyngeal	O
aspirates	O
(	O
NPAs	O
)	O
from	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
from	O
4	O
hospitals	O
were	O
subjected	O
to	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
for	O
detection	O
of	O
CoV	O
-	O
HKU1	O
.	O

RESULTS	O
:	O
NPAs	O
from	O
10	O
(	O
2	O
.	O
4	O
%)	O
of	O
418	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
were	O
found	O
to	O
be	O
positive	O
for	O
CoV	O
-	O
HKU1	O
.	O

In	O
patients	O
with	O
uncomplicated	O
malaria	B-DISO
,	O
Vc	O
was	O
reduced	O
at	O
presentation	O
but	O
improved	O
thereafter	O
.	O

Pulmonary	B-DISO
complications	I-DISO
of	O
leptospirosis	B-DISO
were	O
defined	O
as	O
the	O
occurrence	O
of	O
respiratory	B-DISO
symptoms	I-DISO
and	O
an	O
abnormal	O
CXR	O
.	O

Factors	O
associated	O
with	O
pulmonary	B-DISO
complications	I-DISO
were	O
delayed	O
antibiotic	O
treatment	O
and	O
thrombocytopenia	O
(	O
platelet	O
count	O
<	O
100	O
x	O
10	O
(	O
9	O
)/	O
L	O
).	O

Western	O
blot	O
analysis	O
as	O
well	O
as	O
electron	O
microscopy	O
indicated	O
that	O
the	O
ratios	O
of	O
spike	O
to	O
nucleocapsid	O
protein	O
in	O
clone	O
#	O
21	O
as	O
well	O
as	O
its	O
parental	O
persistently	O
infected	O
cells	O
were	O
lower	O
than	O
that	O
in	O
the	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
infection	B-DISO
.	O

This	O
rapid	O
immunoturbidimetric	O
assay	O
for	O
measurement	O
of	O
feline	O
AGP	O
in	O
serum	O
and	O
peritoneal	O
fluid	O
may	O
be	O
of	O
value	O
in	O
the	O
diagnosis	O
of	O
FIP	B-DISO
and	O
possibly	O
other	O
inflammatory	O
diseases	O
in	O
cats	O
.	O

Rapid	O
and	O
reliable	O
diagnosis	O
of	O
human	O
coronavirus	B-DISO
infections	I-DISO
therefore	O
becomes	O
indispensable	O
in	O
a	O
routine	O
clinical	O
setting	O
.	O

Despite	O
advances	O
in	O
critical	O
care	O
therapies	O
and	O
infection	B-DISO
control	O
practices	O
,	O
severe	B-DISO
sepsis	I-DISO
remains	O
a	O
major	O
health	O
problem	O
,	O
with	O
an	O
estimated	O
mortality	O
rate	O
of	O
30	O
-	O
50	O
%	O
(	O
Ely	O
,	O
Kleinpell	O
,	O
&	O
Goyett	O
,	O
2003	O
).	O

New	O
strategies	O
to	O
improve	O
upon	O
SCT	B-DISO
patient	O
outcome	O
include	O
use	O
of	O
a	O
scoring	O
system	O
to	O
predict	O
mortality	O
,	O
better	O
therapies	O
for	O
MOSF	O
and	O
integration	O
of	O
ICU	O
components	O
and	O
multispecialist	O
involvement	O
earlier	O
in	O
the	O
clinical	O
course	O
to	O
prevent	O
severe	O
complications	O
such	O
as	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
viscosity	O
of	O
total	O
blood	O
and	O
plasma	O
,	O
the	O
hematocrit	O
,	O
and	O
the	O
erythrocyte	O
osmotic	O
fragility	B-DISO
were	O
all	O
increased	O
.	O

The	O
functional	O
damage	O
of	O
blood	O
vessel	O
endothelium	O
,	O
the	O
apoptosis	O
of	O
capillary	O
vessel	O
endothelium	O
,	O
WBC	O
edging	O
-	O
concentration	O
and	O
the	O
increasing	O
of	O
erythrocyte	O
fragility	B-DISO
are	O
the	O
main	O
reasons	O
of	O
ALI	O
.	O

The	O
case	O
fatality	O
rate	O
of	O
SARS	B-DISO
in	O
Beijing	O
was	O
7	O
.	O
66	O
%,	O
and	O
had	O
an	O
ascending	O
trend	O
while	O
the	O
age	O
of	O
cases	O
was	O
getting	O
older	O
,	O
and	O
a	O
descending	O
trend	O
while	O
the	O
epidemic	O
development	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiologic	O
features	O
of	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
urban	O
and	O
suburb	O
areas	O
in	O
Beijing	O
and	O
to	O
explore	O
their	O
differences	O
between	O
these	O
two	O
areas	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
tPA	O
and	O
sTM	O
in	O
patients	O
with	O
SARS	B-DISO
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

ABSTRACT	O
:	O
Between	O
March	O
and	O
July	O
2003	O
,	O
671	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
were	O
diagnosed	O
in	O
Taiwan	O
with	O
a	O
total	O
of	O
84	O
fatalities	O
.	O

TITLE	O
:	O
Serological	O
responses	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
and	O
cross	O
-	O
reactivity	O
with	O
human	O
coronaviruses	O
229E	O
,	O
OC43	O
,	O
and	O
NL63	O
.	O

In	O
contrast	O
,	O
patients	O
who	O
had	O
OC43	O
infections	B-DISO
,	O
and	O
probably	O
also	O
229E	O
infections	B-DISO
,	O
without	O
prior	O
exposure	O
to	O
SARS	B-DISO
CoV	O
had	O
increases	O
of	O
antibodies	O
specific	O
for	O
the	O
infecting	O
virus	O
but	O
not	O
for	O
SARS	B-DISO
CoV	O
.	O
There	O
is	O
a	O
need	O
for	O
awareness	O
of	O
cross	O
-	O
reactive	O
antibody	O
responses	O
between	O
coronaviruses	O
when	O
interpreting	O
IF	O
serology	O
.	O

The	O
PBO	O
derivatives	O
specifically	O
designed	O
to	O
target	O
the	O
highly	O
conserved	O
amino	O
acid	O
residues	O
within	O
the	O
beta12	O
-	O
beta13	O
hairpin	O
,	O
namely	O
primer	O
grip	O
,	O
proved	O
to	O
be	O
very	O
potent	O
against	O
the	O
most	O
common	O
mutant	B-DISO
enzymes	O
,	O
including	O
the	O
highly	O
resistant	O
K103N	O
mutant	B-DISO
strain	O
.	O

When	O
the	O
identical	O
mutations	O
were	O
directly	O
inserted	O
into	O
the	O
MHV	O
genome	O
,	O
most	O
mutant	B-DISO
genomes	O
were	O
viable	O
but	O
formed	O
smaller	O
plaques	B-DISO
than	O
the	O
wild	O
-	O
type	O
parent	O
virus	O
.	O

TITLE	O
:	O
ACE2	O
receptor	O
expression	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
depend	O
on	O
differentiation	O
of	O
human	O
airway	O
epithelia	O
.	O

Undifferentiated	O
cells	O
expressing	O
little	O
ACE2	O
were	O
poorly	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
while	O
well	O
-	O
differentiated	O
cells	O
expressing	O
more	O
ACE2	O
were	O
readily	O
infected	O
.	O

To	O
determine	O
the	O
significance	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
group	O
-	O
specific	O
ORFs	O
in	O
virus	O
replication	O
in	O
vitro	O
and	O
in	O
mice	O
,	O
we	O
systematically	O
deleted	O
five	O
of	O
the	O
eight	O
group	O
-	O
specific	O
ORFs	O
,	O
ORF3a	O
,	O
OF3b	O
,	O
ORF6	O
,	O
ORF7a	O
,	O
and	O
ORF7b	O
,	O
and	O
characterized	O
recombinant	O
virus	O
replication	O
and	O
gene	O
expression	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
insertion	O
of	O
the	O
29	O
-	O
bp	O
deletion	O
fusing	O
ORF8a	O
/	O
b	O
into	O
the	O
single	O
ORF8	O
,	O
noted	O
in	O
early	O
-	O
stage	O
SARS	B-DISO
-	O
CoV	O
human	O
and	O
civet	O
cat	O
isolates	O
,	O
had	O
little	O
if	O
any	O
impact	O
on	O
in	O
vitro	O
growth	O
or	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
human	O
ScFv	O
H12	O
against	O
SARS	B-DISO
-	O
CoV	O
has	O
been	O
selected	O
from	O
a	O
SARS	B-DISO
immune	O
library	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
reported	O
to	O
function	O
in	O
encapsidating	O
the	O
viral	O
genomic	O
RNA	O
into	O
helical	O
nucleocapsid	O
,	O
and	O
its	O
self	O
-	O
association	O
is	O
believed	O
to	O
be	O
vital	O
in	O
coating	O
the	O
viral	O
genomic	O
RNA	O
.	O

In	O
the	O
current	O
work	O
,	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
technique	O
,	O
an	O
unexpected	O
interaction	O
between	O
residues	O
1	O
-	O
210	O
and	O
211	O
-	O
290	O
(	O
central	O
region	O
)	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
was	O
detected	O
,	O
and	O
SPR	O
results	O
further	O
revealed	O
that	O
the	O
SR	O
-	O
rich	O
motif	O
(	O
amino	O
acids	O
183	O
-	O
197	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
is	O
responsible	O
for	O
such	O
an	O
interaction	O
.	O

In	O
addition	O
,	O
the	O
multimeric	O
ability	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
could	O
be	O
weakened	O
by	O
the	O
SR	O
-	O
rich	O
motif	O
interaction	O
with	O
the	O
central	O
region	O
(	O
amino	O
acids	O
211	O
-	O
290	O
).	O

The	O
psychometric	O
properties	O
of	O
a	O
SARS	B-DISO
patient	O
care	O
attrition	B-DISO
prediction	O
tool	O
,	O
based	O
on	O
the	O
Theory	O
of	O
Planned	O
Behavior	O
,	O
were	O
examined	O
in	O
this	O
study	O
.	O

The	O
instrument	O
can	O
be	O
used	O
by	O
nurse	O
administrators	O
and	O
researcher	O
to	O
assess	O
clinical	O
nurses	O
'	O
salient	O
beliefs	O
about	O
caring	O
for	O
SARS	B-DISO
patients	O
,	O
guide	O
tailored	O
intervention	O
strategies	O
to	O
effective	O
caring	O
,	O
and	O
evaluate	O
the	O
effectiveness	O
of	O
interventions	O
.	O

The	O
fingerprint	O
map	O
proposed	O
here	O
has	O
the	O
merits	O
of	O
clear	O
visibility	O
and	O
reliability	O
that	O
can	O
serve	O
as	O
a	O
complementary	O
clinical	O
tool	O
for	O
detecting	O
SARS	B-DISO
-	O
CoV	O
,	O
particularly	O
for	O
the	O
cases	O
where	O
the	O
results	O
obtained	O
by	O
the	O
conventional	O
methods	O
are	O
uncertain	O
or	O
conflicted	O
with	O
each	O
other	O
.	O

As	O
it	O
happens	O
with	O
other	O
viruses	O
peptidic	O
fusion	O
inhibitors	O
,	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
HR2	O
-	O
derived	O
peptides	O
are	O
potential	O
therapeutic	O
drugs	O
against	O
the	O
virus	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
implications	O
for	O
perinatal	O
and	O
neonatal	O
nurses	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
quantify	O
the	O
public	O
health	O
risk	O
associated	O
with	O
inhalation	O
of	O
indoor	O
airborne	O
infection	B-DISO
based	O
on	O
a	O
probabilistic	O
transmission	O
dynamic	O
modeling	O
approach	O
.	O

We	O
also	O
obtained	O
an	O
estimate	O
of	O
the	O
basic	O
reproductive	O
number	O
for	O
influenza	B-DISO
in	O
a	O
commercial	O
airliner	O
:	O
the	O
median	O
value	O
is	O
10	O
.	O
4	O
.	O

TITLE	O
:	O
Preparation	O
and	O
development	O
of	O
equine	O
hyperimmune	O
globulin	O
F	O
(	O
ab	O
')	O
2	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
resurgence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
still	O
a	O
threat	O
because	O
the	O
causative	O
agent	O
remaining	O
in	O
animal	O
reservoirs	O
is	O
not	O
fully	O
understood	O
,	O
and	O
sporadic	O
cases	O
continue	O
to	O
be	O
reported	O
.	O

SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
F69	O
(	O
AY313906	O
)	O
and	O
Z2	O
-	O
Y3	O
(	O
AY394989	O
)	O
were	O
isolated	O
and	O
identified	O
from	O
2	O
different	O
Cantonese	O
onset	O
SARS	B-DISO
patients	O
.	O

The	O
psychological	B-DISO
and	O
psychosocial	O
impact	O
on	O
HCWs	O
during	O
the	O
outbreak	O
are	O
also	O
discussed	O
.	O

For	O
prompt	O
identification	O
of	O
a	O
case	O
and	O
to	O
reduce	O
the	O
time	O
between	O
onset	O
of	O
symptoms	O
and	O
isolation	O
,	O
the	O
Infectious	B-DISO
Diseases	I-DISO
Act	O
was	O
amended	O
.	O

Lessons	O
learned	O
are	O
being	O
incorporated	O
into	O
the	O
HPA	O
'	O
s	O
preparedness	O
to	O
prevent	O
and	O
control	O
future	O
newly	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
threats	O
.	O

TITLE	O
:	O
Differential	O
localization	O
and	O
turnover	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
3b	O
protein	O
in	O
mammalian	O
versus	O
avian	O
cells	O
.	O

IBV	O
3b	O
was	O
virtually	O
undetectable	O
by	O
microscopy	O
in	O
mammalian	O
cells	O
transfected	O
without	O
vaccinia	B-DISO
virus	O
and	O
in	O
IBV	O
-	O
infected	O
mammalian	O
cells	O
because	O
of	O
a	O
greatly	O
reduced	O
half	O
-	O
life	O
in	O
these	O
cells	O
.	O

Four	O
patients	O
died	O
during	O
further	O
treatment	O
due	O
to	O
multiple	O
trauma	O
or	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Antibody	O
responses	O
against	O
SARS	B-DISO
coronavirus	O
are	O
correlated	O
with	O
disease	O
outcome	O
of	O
infected	O
individuals	O
.	O

ABSTRACT	O
:	O
The	O
genome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
contains	O
four	O
structural	O
genes	O
that	O
are	O
homologous	O
to	O
genes	O
found	O
in	O
other	O
coronaviruses	O
,	O
and	O
also	O
contains	O
six	O
subgroup	O
-	O
specific	O
open	O
reading	O
frames	O
(	O
ORFs	O
).	O

After	O
analyzing	O
the	O
cellular	O
proteins	O
involving	O
in	O
regulation	O
of	O
cell	O
cycle	O
progression	O
,	O
we	O
demonstrated	O
that	O
ORF7a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	O
D3	O
level	O
of	O
mRNA	O
transcription	O
and	O
expression	O
,	O
and	O
phosphorylation	O
of	O
retinoblastoma	B-DISO
(	O
Rb	O
)	O
protein	O
at	O
ser795	O
and	O
ser809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	O
D1	O
,	O
D2	O
,	O
cdk4	O
and	O
cdk6	O
in	O
HEK	O
293	O
cells	O
.	O

TITLE	O
:	O
Radiographic	O
-	O
clinical	O
correlation	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
study	O
of	O
1373	O
patients	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
man	O
developed	O
a	O
giant	B-DISO
pseudoaneurysm	B-DISO
of	O
the	O
innominate	O
artery	O
5	O
months	O
after	O
blunt	O
chest	O
trauma	O
,	O
causing	O
severe	O
respiratory	B-DISO
distress	I-DISO
and	O
superior	O
vena	O
cava	O
compression	O
symptoms	O
.	O

But	O
despite	O
considerable	O
progress	O
,	O
infectious	B-DISO
diseases	I-DISO
continue	O
to	O
present	O
significant	O
challenges	O
as	O
new	O
microbial	O
threats	O
emerge	O
and	O
reemerge	O
.	O

ABSTRACT	O
:	O
Group	O
2	O
coronaviruses	O
encode	O
an	O
accessory	O
envelope	O
glycoprotein	O
species	O
,	O
the	O
hemagglutinin	O
esterase	O
(	O
HE	O
),	O
which	O
possesses	B-DISO
sialate	O
-	O
O	O
-	O
acetylesterase	O
activity	O
and	O
which	O
,	O
presumably	O
,	O
promotes	O
virus	O
spread	O
and	O
entry	O
in	O
vivo	O
by	O
facilitating	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

TITLE	O
:	O
Expression	O
of	O
hemagglutinin	O
esterase	O
protein	O
from	O
recombinant	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
enhances	O
neurovirulence	O
.	O

However	O
,	O
in	O
combination	O
with	O
JHM	O
S	O
,	O
the	O
expression	O
of	O
HE	O
,	O
regardless	O
of	O
whether	O
it	O
retained	O
esterase	O
activity	O
or	O
not	O
,	O
resulted	O
in	O
increased	O
viral	O
spread	O
within	O
the	O
central	O
nervous	B-DISO
system	O
and	O
in	O
increased	O
neurovirulence	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
genomic	O
RNA	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
mediated	O
by	O
replicase	O
polyproteins	O
that	O
are	O
processed	O
by	O
two	O
viral	O
proteases	O
,	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

Mutagenesis	O
studies	O
revealed	O
that	O
Asp1826	O
and	O
the	O
four	O
cysteine	O
residues	O
involved	O
in	O
zinc	O
binding	O
are	O
essential	O
for	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
papain	O
-	O
like	O
protease	O
(	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
)	O
is	O
involved	O
in	O
the	O
processing	O
of	O
the	O
viral	O
polyprotein	O
and	O
,	O
thereby	O
,	O
contributes	O
to	O
the	O
biogenesis	O
of	O
the	O
virus	O
replication	O
complex	O
.	O

In	O
addition	O
,	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
was	O
inhibited	O
by	O
the	O
specific	O
deubiquitinating	O
enzyme	O
inhibitor	O
ubiquitin	O
aldehyde	O
,	O
with	O
an	O
inhibition	O
constant	O
of	O
210	O
nM	O
.	O
The	O
purified	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
disassembles	O
branched	O
polyubiquitin	O
chains	O
with	O
lengths	O
of	O
two	O
to	O
seven	O
(	O
Ub2	O
-	O
7	O
)	O
or	O
four	O
(	O
Ub4	O
)	O
units	O
,	O
which	O
involves	O
isopeptide	O
bond	O
cleavage	O
.	O

However	O
,	O
only	O
soR	O
-	O
425	O
was	O
able	O
to	O
target	O
MHV	O
to	O
human	O
EGFR	O
-	O
expressing	O
cancer	B-DISO
cells	O
.	O

Furthermore	O
,	O
the	O
soR	O
-	O
425	O
-	O
mediated	O
infections	B-DISO
were	O
blocked	O
by	O
heptad	O
repeat	O
-	O
mimicking	O
peptides	O
,	O
indicating	O
that	O
virus	O
entry	O
requires	O
the	O
regular	O
S	O
protein	O
fusion	O
process	O
.	O

SARS	B-DISO
-	O
CoV	O
GFP	O
also	O
replicated	O
to	O
a	O
lesser	O
extent	O
in	O
ciliated	O
cell	O
cultures	O
derived	O
from	O
hamster	O
or	O
rhesus	O
monkey	O
airways	O
.	O

There	O
are	O
no	O
specific	O
effective	O
therapies	O
for	O
ARDS	B-DISO
and	O
novel	O
therapeutic	O
approaches	O
are	O
desperately	O
needed	O
.	O

These	O
findings	O
suggest	O
a	O
possible	O
role	O
of	O
S	O
and	O
S2	O
protein	O
in	O
SARS	B-DISO
-	O
CoV	O
induced	O
apoptosis	O
and	O
the	O
molecular	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

There	O
was	O
no	O
live	O
SARS	B-DISO
-	O
CoV	O
detected	O
in	O
the	O
sewage	O
in	O
these	O
assays	O
.	O

An	O
animal	O
model	O
of	O
human	O
coronavirus	O
infectious	B-DISO
disease	I-DISO
has	O
been	O
generated	O
by	O
gene	O
transfer	O
of	O
the	O
human	O
receptor	O
for	O
virus	O
-	O
cell	O
interaction	O
(	O
aminopeptidase	O
N	O
,	O
APN	O
,	O
CD13	O
)	O
into	O
mice	O
.	O

TITLE	O
:	O
Progressive	O
cavitating	O
leukoencephalopathy	B-DISO
:	O
a	O
novel	O
childhood	O
disease	O
.	O

After	O
repeated	O
episodes	O
,	O
areas	O
of	O
tissue	O
loss	O
coalesce	O
with	O
older	O
lesions	O
to	O
become	O
larger	O
cystic	O
regions	O
in	O
brain	O
or	O
spinal	O
cord	B-DISO
.	O

Pathological	O
studies	O
show	O
severe	O
loss	O
of	O
myelin	O
sparing	O
U	O
-	O
fibers	O
,	O
axonal	O
disruption	O
,	O
and	O
cavitary	O
lesions	O
without	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
clinicopathological	O
findings	O
in	O
naturally	O
-	O
occurring	O
,	O
histopathologically	O
confirmed	O
cases	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
client	O
-	O
owned	O
cats	O
in	O
Sydney	O
,	O
Australia	O
,	O
with	O
the	O
purpose	O
of	O
identifying	O
factors	O
assisting	O
in	O
the	O
diagnosis	O
of	O
this	O
complex	O
disease	O
syndrome	B-DISO
and	O
to	O
characterise	O
the	O
disease	O
as	O
it	O
occurs	O
in	O
this	O
region	O
.	O

TITLE	O
:	O
When	O
family	O
-	O
centered	O
care	O
is	O
challenged	O
by	O
infectious	B-DISO
disease	I-DISO
:	O
pediatric	O
health	O
care	O
delivery	O
during	O
the	O
SARS	B-DISO
outbreaks	O
.	O

TITLE	O
:	O
Rapid	O
detection	O
and	O
characterisation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
from	O
New	O
Zealand	O
using	O
RT	O
-	O
PCR	O
and	O
sequence	O
analysis	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
three	O
patients	O
referred	O
from	O
a	O
SARS	B-DISO
Review	O
Clinic	O
solely	O
for	O
physiotherapy	O
were	O
included	O
.	O

It	O
was	O
concluded	O
that	O
the	O
exercise	O
training	O
program	O
was	O
effective	O
in	O
improving	O
both	O
the	O
cardiorespiratory	O
and	O
musculoskeletal	O
fitness	O
in	O
patients	O
recovering	O
from	O
SARS	B-DISO
.	O

TITLE	O
:	O
Immunopathogenesis	O
of	O
coronavirus	B-DISO
infections	I-DISO
:	O
implications	O
for	O
SARS	B-DISO
.	O

SARS	B-DISO
is	O
caused	O
by	O
a	O
novel	O
species	O
of	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
is	O
the	O
most	O
severe	O
coronavirus	O
-	O
mediated	O
human	O
disease	O
that	O
has	O
been	O
described	O
so	O
far	O
.	O

ABSTRACT	O
:	O
A	O
review	O
of	O
250	O
patients	O
with	O
the	O
catastrophic	O
antiphospholipid	O
(	O
Asherson	O
'	O
s	O
)	O
syndrome	B-DISO
(	O
CAPS	B-DISO
)	O
taken	O
from	O
the	O
web	B-DISO
site	O
organized	O
by	O
the	O
Europhospholipid	O
Group	O
(	O
http	O
://	O
www	O
.	O
med	O
.	O
ub	O
.	O
es	O
/	O
MIMMUN	O
/	O
FORUM	O
/	O
CAPS	B-DISO
.	O
HTM	O
)	O
is	O
presented	O
in	O
this	O
paper	O
.	O

the	O
rapid	O
development	O
of	O
multiorgan	B-DISO
failure	I-DISO
following	O
the	O
above	O
-	O
mentioned	O
identifiable	O
precipitating	O
factors	O
,	O
the	O
involvement	O
of	O
unusual	O
organs	O
such	O
as	O
bowel	O
,	O
reproductive	O
organs	O
,	O
and	O
bone	O
marrow	O
,	O
complicating	O
features	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
in	O
20	O
%	O
of	O
cases	O
,	O
the	O
acute	O
(	O
adult	O
)	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
one	O
third	O
of	O
patients	O
,	O
and	O
severe	O
thrombocytopenia	O
;	O
these	O
not	O
being	O
encountered	O
in	O
the	O
simple	O
/	O
classic	O
APS	B-DISO
.	O

Antifungal	O
therapy	O
may	O
also	O
be	O
indicated	O
with	O
prolonged	O
treatment	O
and	O
the	O
use	O
of	O
the	O
monoclonal	O
anti	O
-	O
CD20	O
molecule	O
,	O
Rituximab	O
,	O
has	O
proven	O
useful	O
in	O
those	O
patients	O
where	O
thrombocytopenia	O
poses	O
a	O
major	O
risk	O
of	O
hemorrhage	B-DISO
.	O

ABSTRACT	O
:	O
To	O
document	O
the	O
prevalence	O
of	O
respiratory	O
virus	O
infections	B-DISO
in	O
patients	O
with	O
chronic	O
cardiac	O
or	O
pulmonary	B-DISO
disorders	I-DISO
admitted	O
to	O
a	O
critical	O
care	O
unit	O
for	O
acute	O
cardiorespiratory	B-DISO
failure	I-DISO
.	O

A	O
nasal	O
swab	O
was	O
taken	O
for	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
detection	O
of	O
influenza	B-DISO
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
metapneumovirus	O
,	O
rhinovirus	O
,	O
and	O
coronavirus	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
the	O
X4	O
protein	O
coded	O
by	O
the	O
SARS	B-DISO
related	O
coronavirus	O
reveals	O
an	O
immunoglobulin	O
like	O
fold	O
and	O
suggests	O
a	O
binding	O
activity	O
to	O
integrin	O
I	O
domains	O
.	O

The	O
dimer	O
dissociation	B-DISO
constant	O
of	O
the	O
wild	O
-	O
type	O
protein	O
was	O
determined	O
to	O
be	O
14	O
.	O
0microM	O
by	O
analytical	O
ultracentrifugation	O
method	O
.	O

Because	O
of	O
the	O
context	O
of	O
a	O
winter	O
influenza	B-DISO
outbreak	O
,	O
a	O
nasal	O
swabbing	O
sample	O
was	O
tested	O
for	O
the	O
presence	O
of	O
Influenzavirus	O
nucleocapsid	O
-	O
antigens	O
(	O
Immunochromatographic	O
test	O
;	O
BinaxNow	O
Flu	B-DISO
A	O
&	O
B	O
,	O
Binax	O
,	O
Portland	O
,	O
USA	O
).	O

TITLE	O
:	O
Study	O
on	O
substrate	O
specificity	O
at	O
subsites	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3CL	O
protease	O
.	O

In	O
addition	O
,	O
based	O
on	O
both	O
peptide	O
-	O
based	O
assay	O
and	O
autocleavage	O
assay	O
,	O
Ile	O
at	O
the	O
P1	O
'	O
position	O
could	O
not	O
be	O
hydrolyzed	O
,	O
but	O
the	O
mutant	B-DISO
L27A	O
could	O
hydrolyze	O
the	O
Ile	O
peptide	O
fragment	O
.	O

Our	O
findings	O
suggest	O
that	O
SP	O
-	O
10	O
may	O
be	O
developed	O
as	O
an	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
agent	O
for	O
the	O
treatment	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Furthermore	O
,	O
the	O
authors	O
also	O
explored	O
the	O
influence	O
of	O
various	O
factors	O
on	O
the	O
SARS	B-DISO
incubation	O
period	O
by	O
analysis	O
of	O
variance	O
,	O
linear	O
regression	O
analysis	O
,	O
and	O
analysis	O
of	O
covariance	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
,	O
but	O
not	O
human	O
coronavirus	O
NL63	O
,	O
utilizes	O
cathepsin	O
L	O
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
cellular	O
receptor	O
for	O
two	O
divergent	O
coronaviruses	O
,	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
).	O

Here	O
we	O
show	O
that	O
SARS	B-DISO
-	O
CoV	O
,	O
but	O
not	O
HCoV	O
-	O
NL63	O
,	O
utilizes	O
the	O
enzymatic	O
activity	O
of	O
the	O
cysteine	O
protease	O
cathepsin	O
L	O
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

Inhibitors	O
of	O
cathepsin	O
L	O
blocked	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
and	O
by	O
a	O
retrovirus	O
pseudotyped	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
but	O
not	O
infection	B-DISO
by	O
HCoV	O
-	O
NL63	O
or	O
a	O
retrovirus	O
pseudotyped	O
with	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
.	O

Finally	O
,	O
an	O
inhibitor	O
of	O
endosomal	O
acidification	O
had	O
substantially	O
less	O
effect	O
on	O
infection	B-DISO
mediated	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
than	O
on	O
that	O
mediated	O
by	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
.	O

TITLE	O
:	O
Coronavirus	O
pathogenesis	B-DISO
and	O
the	O
emerging	O
pathogen	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

The	O
data	O
gathered	O
on	O
the	O
animal	O
coronaviruses	O
continue	O
to	O
be	O
helpful	O
in	O
understanding	O
SARS	B-DISO
-	O
CoV	O
.	O

Finally	O
,	O
our	O
analysis	O
of	O
viral	O
RNA	O
synthesis	O
in	O
ts	O
mutant	B-DISO
virus	O
-	O
infected	O
cells	O
allows	O
us	O
to	O
discriminate	O
three	O
phenotypes	O
with	O
regard	O
to	O
the	O
inability	O
of	O
specific	O
mutants	O
to	O
synthesize	O
viral	O
RNA	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
membrane	O
protein	O
is	O
an	O
abundant	O
virion	O
protein	O
,	O
and	O
its	O
interaction	O
with	O
the	O
nucleocapsid	O
protein	O
is	O
crucial	O
for	O
viral	O
assembly	O
and	O
morphogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
electrostatic	O
interactions	O
between	O
the	O
carboxyl	O
termini	O
of	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
and	O
nucleocapsid	O
protein	O
largely	O
mediate	O
the	O
interaction	O
of	O
these	O
two	O
proteins	O
.	O

With	O
the	O
exception	O
of	O
a	O
few	O
well	O
sustained	O
associations	O
-	O
for	O
example	O
hepatitis	B-DISO
B	I-DISO
or	O
C	O
with	O
known	O
vasculitic	O
syndromes	B-DISO
-	O
most	O
of	O
the	O
purported	O
links	O
between	O
microbial	O
agents	O
and	O
primary	O
vasculitides	B-DISO
remain	O
speculative	O
.	O

Based	O
on	O
the	O
work	O
mentioned	O
above	O
,	O
different	O
functional	O
units	O
,	O
such	O
as	O
membrane	O
,	O
monolithic	O
,	O
isotachophoresis	O
(	O
ITP	B-DISO
)	O
etc	O
were	O
set	O
up	O
and	O
integrated	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3a	O
protein	O
is	O
released	O
in	O
membranous	O
structures	O
from	O
3a	O
protein	O
-	O
expressing	O
cells	O
and	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
accessory	O
protein	O
3a	O
is	O
a	O
virus	O
structural	O
protein	O
.	O

Phase	O
1	O
was	O
a	O
curriculum	O
design	O
of	O
a	O
SARS	B-DISO
-	O
specific	O
cardiac	B-DISO
arrest	I-DISO
protocol	O
in	O
three	O
steps	O
:	O
planning	O
the	O
new	O
protocol	O
,	O
repeated	O
simulations	O
of	O
this	O
protocol	O
in	O
a	O
classroom	O
,	O
and	O
a	O
subsequent	O
simulation	O
of	O
a	O
cardiac	B-DISO
arrest	I-DISO
on	O
a	O
hospital	O
ward	O
.	O

Body	O
weight	O
at	O
28	O
d	O
,	O
56	O
d	O
,	O
daily	O
body	O
weight	O
gain	O
,	O
intake	O
of	O
milk	O
replacer	O
,	O
fecal	O
scores	O
,	O
days	O
with	O
diarrhea	B-DISO
,	O
and	O
days	O
treated	O
with	O
antibiotics	O
were	O
increased	O
with	O
feeding	O
variable	O
amount	O
of	O
milk	O
replacer	O
over	O
the	O
56	O
-	O
d	O
study	O
.	O

There	O
is	O
continuing	O
use	O
of	O
EM	O
for	O
the	O
investigation	O
of	O
new	O
and	O
emerging	O
agents	O
,	O
such	O
as	O
SARS	B-DISO
and	O
human	B-DISO
monkeypox	I-DISO
virus	O
.	O

However	O
,	O
it	O
is	O
presently	O
unknown	O
whether	O
the	O
amount	O
of	O
transfused	O
blood	O
is	O
independently	O
associated	O
with	O
development	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
severe	O
trauma	O
.	O

All	O
PCR	O
results	O
were	O
negative	O
for	O
both	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
NH	O
;	O
therefore	O
,	O
we	O
did	O
not	O
find	O
any	O
association	O
between	O
HCoV	O
-	O
NH	O
infection	B-DISO
and	O
KD	O
in	O
Taiwan	O
.	O

A	O
review	O
of	O
variant	B-DISO
Creutzfeldt	I-DISO
-	I-DISO
Jakob	I-DISO
disease	I-DISO
is	O
followed	O
by	O
a	O
discussion	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
section	O
on	O
viral	B-DISO
disease	I-DISO
concludes	O
with	O
an	O
article	O
on	O
morbilliviruses	O
.	O

The	O
intracellular	O
effects	O
of	O
bacteria	O
are	O
addressed	O
in	O
a	O
review	O
of	O
Listeria	B-DISO
infection	I-DISO
and	O
a	O
further	O
review	O
outlines	O
recent	O
advances	O
in	O
our	O
knowledge	O
of	O
syphilis	B-DISO
.	O

Compared	O
with	O
cells	O
heterozygous	O
for	O
L	O
-	O
SIGN	O
,	O
cells	O
homozygous	O
for	O
L	O
-	O
SIGN	O
show	O
higher	O
binding	O
capacity	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
higher	O
proteasome	O
-	O
dependent	O
viral	O
degradation	O
and	O
a	O
lower	O
capacity	O
for	O
trans	O
infection	B-DISO
.	O

The	O
pumpless	O
extracorporeal	O
lung	O
assist	O
device	O
remained	O
in	O
situ	O
for	O
ten	O
days	O
without	O
any	O
adverse	O
side	B-DISO
effect	I-DISO
.	O

Nine	O
(	O
75	O
.	O
0	O
%)	O
of	O
the	O
symptomatic	O
children	O
had	O
mixed	O
viral	B-DISO
infections	I-DISO
.	O

Ventilator	O
management	O
was	O
analyzed	O
to	O
determine	O
the	O
proportion	O
of	O
patients	O
with	O
subarachnoid	B-DISO
hemorrhage	I-DISO
and	O
acute	O
lung	O
injury	O
who	O
a	O
received	O
a	O
low	O
-	O
tidal	O
volume	O
ventilation	O
strategy	O
.	O

ABSTRACT	O
:	O
Cellular	O
localization	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
the	O
lungs	O
of	O
patients	O
with	O
SARS	B-DISO
is	O
important	O
in	O
confirming	O
the	O
etiological	O
association	O
of	O
the	O
virus	O
with	O
disease	O
as	O
well	O
as	O
in	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
the	O
disease	O
.	O

We	O
collected	O
the	O
largest	O
series	O
of	O
fatal	O
cases	O
of	O
SARS	B-DISO
with	O
autopsy	O
material	O
to	O
date	O
by	O
merging	O
the	O
pathological	O
material	O
from	O
two	O
regions	O
involved	O
in	O
the	O
2003	O
worldwide	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
,	O
China	O
,	O
and	O
Toronto	O
,	O
Canada	O
.	O

We	O
developed	O
a	O
monoclonal	O
antibody	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleoprotein	O
and	O
used	O
it	O
together	O
with	O
in	O
situ	O
hybridization	O
(	O
ISH	B-DISO
)	O
to	O
analyze	O
the	O
autopsy	O
lung	O
tissues	O
of	O
32	O
patients	O
with	O
SARS	B-DISO
from	O
Hong	O
Kong	O
and	O
Toronto	O
.	O

The	O
pulmonary	O
alveolar	O
epithelium	O
is	O
the	O
chief	O
target	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
with	O
macrophages	O
infected	O
subsequently	O
.	O

However	O
,	O
the	O
mechanisms	O
evoking	O
respiratory	B-DISO
distress	I-DISO
and	O
a	O
fulminant	O
systemic	O
response	O
remain	O
unclear	O
.	O

The	O
median	O
duration	O
from	O
onset	O
of	O
fever	O
to	O
the	O
nadir	O
level	O
or	O
most	O
severe	O
condition	B-DISO
was	O
9	O
days	O
for	O
hypoxia	B-DISO
,	O
7	O
days	O
for	O
lymphocytopenia	B-DISO
,	O
6	O
.	O
5	O
days	O
for	O
thrombocytopenia	O
,	O
9	O
.	O
5	O
days	O
for	O
maximal	O
pulmonary	B-DISO
infiltrates	I-DISO
;	O
to	O
peak	O
serum	O
levels	O
was	O
9	O
days	O
for	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
10	O
.	O
5	O
days	O
for	O
IL	O
-	O
6	O
,	O
13	O
.	O
5	O
days	O
for	O
IL	O
-	O
8	O
and	O
12	O
days	O
for	O
TNF	O
-	O
alpha	O
;	O
to	O
defervescence	O
was	O
13	O
days	O
.	O

TITLE	O
:	O
[	O
Prospective	O
2	O
-	O
year	O
clinical	O
study	O
of	O
patients	O
with	O
positive	O
IgG	O
-	O
antibodies	O
after	O
recovering	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

ABSTRACT	O
:	O
Enveloped	O
animal	O
viruses	O
such	O
as	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
),	O
hepatitis	B-DISO
B	I-DISO
virus	O
,	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
human	O
papillomavirus	O
,	O
Marburg	O
,	O
and	O
influenza	B-DISO
are	O
major	O
public	O
health	O
concerns	O
around	O
the	O
world	O
.	O

The	O
prohibitive	O
cost	O
of	O
antiretroviral	O
(	O
ARV	O
)	O
drugs	O
for	O
most	O
HIV	B-DISO
-	O
infected	O
patients	O
in	O
sub	O
-	O
Saharan	O
Africa	O
and	O
the	O
serious	O
side	O
effects	O
in	O
those	O
who	O
have	O
access	O
to	O
ARV	O
drugs	O
make	O
a	O
compelling	O
case	O
for	O
the	O
study	O
of	O
complementary	O
and	O
alternative	O
therapies	O
.	O

Using	O
a	O
previously	O
described	O
attenuated	O
vaccinia	B-DISO
virus	O
vGK5	O
,	O
we	O
established	O
the	O
antiviral	O
activity	O
of	O
Secomet	O
-	O
V	O
.	O
Chemical	O
analysis	O
showed	O
that	O
it	O
has	O
an	O
acidic	O
pH	O
,	O
nontoxic	O
traces	O
of	O
iron	O
(<	O
10	O
ppm	O
),	O
and	O
almost	O
undetectable	O
levels	O
of	O
arsenic	O
(<	O
1	O
.	O
0	O
ppm	O
).	O

The	O
color	O
varies	O
from	O
colorless	O
to	O
pale	B-DISO
yellow	O
to	O
dark	O
brown	O
.	O

TITLE	O
:	O
Pyridine	O
N	O
-	O
oxide	O
derivatives	O
are	O
inhibitory	O
to	O
the	O
human	O
SARS	B-DISO
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
coronavirus	O
in	O
cell	O
culture	O
.	O

A	O
wide	O
variety	O
of	O
pyridine	O
N	O
-	O
oxide	O
derivatives	O
have	O
been	O
found	O
to	O
be	O
inhibitory	O
against	O
feline	O
coronavirus	O
(	O
FIPV	O
strain	O
)	O
and	O
human	O
SARS	B-DISO
-	O
CoV	O
(	O
Frankfurt	O
strain	O
-	O
1	O
)	O
in	O
CRFK	O
and	O
simian	O
kidney	O
(	O
Vero	O
)	O
cell	O
cultures	O
,	O
respectively	O
.	O

The	O
purified	O
inactivated	O
SARS	B-DISO
vaccine	O
could	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibody	O
,	O
and	O
protect	O
the	O
monkeys	O
from	O
the	O
challenge	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
SARS	B-DISO
vaccine	O
prepared	O
in	O
the	O
study	O
appeared	O
to	O
be	O
safe	O
in	O
monkeys	O
.	O

Information	O
on	O
related	O
factors	O
of	O
SARS	B-DISO
was	O
collected	O
using	O
a	O
pre	O
-	O
testing	O
questionnaire	O
.	O

CONCLUSIONS	O
:	O
mxA	O
promoter	O
-	O
88G	O
/	O
T	O
SNP	O
might	O
be	O
confered	O
to	O
host	O
genetic	O
susceptibility	O
to	O
SARS	B-DISO
in	O
Chinese	O
Han	O
population	O
.	O

TITLE	O
:	O
Safety	O
of	O
direct	O
administration	O
of	O
AAV2	O
(	O
CU	O
)	O
hCLN2	O
,	O
a	O
candidate	O
treatment	O
for	O
the	O
central	O
nervous	B-DISO
system	O
manifestations	O
of	O
late	B-DISO
infantile	I-DISO
neuronal	I-DISO
ceroid	I-DISO
lipofuscinosis	I-DISO
,	O
to	O
the	O
brain	O
of	O
rats	O
and	O
nonhuman	O
primates	O
.	O

Multiple	O
alignments	O
of	O
nucleotide	O
sequences	O
obtained	O
from	O
SARS	B-DISO
GeneChips	O
and	O
conventional	O
sequencing	O
revealed	O
full	O
concordance	O
.	O

Specific	O
best	O
-	O
fit	B-DISO
mediators	O
or	O
mediator	O
pairs	O
varied	O
with	O
aspirate	O
type	O
,	O
animal	O
type	O
,	O
and	O
time	O
of	O
injury	O
.	O

This	O
review	O
evaluates	O
the	O
physiological	O
and	O
clinical	O
effects	O
of	O
persisting	O
spontaneous	O
breathing	O
during	O
ventilator	O
support	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
improvements	O
in	O
pulmonary	O
gas	O
exchange	O
,	O
systemic	O
blood	O
flow	O
and	O
oxygen	O
supply	O
to	O
the	O
tissue	O
which	O
have	O
been	O
observed	O
when	O
spontaneous	O
breathing	O
has	O
been	O
maintained	O
during	O
mechanical	O
ventilation	O
are	O
reflected	O
in	O
the	O
clinical	O
improvement	O
in	O
the	O
patient	O
'	O
s	O
condition	B-DISO
.	O

Computer	O
tomography	O
observations	O
demonstrated	O
that	O
spontaneous	O
breathing	O
improves	O
gas	O
exchange	O
by	O
redistribution	O
of	O
ventilation	O
and	O
end	O
-	O
expiratory	O
gas	O
to	O
dependent	O
,	O
juxtadiaphragmatic	O
lung	O
regions	O
and	O
thereby	O
promotes	O
alveolar	O
recruitment	B-DISO
.	O

Recent	O
publications	O
have	O
stressed	O
the	O
benefits	O
of	O
appropriate	O
staffing	O
levels	O
,	O
the	O
use	O
of	O
single	O
occupancy	O
rooms	O
,	O
the	O
immunization	O
of	O
healthcare	O
workers	O
against	O
influenza	B-DISO
,	O
and	O
the	O
importance	O
of	O
healthcare	O
workers	O
remaining	O
home	O
when	O
ill	B-DISO
in	O
reducing	O
the	O
morbidity	O
and	O
mortality	O
of	O
respiratory	B-DISO
infection	I-DISO
within	O
the	O
intensive	O
care	O
unit	O
.	O

Despite	O
this	O
,	O
healthcare	O
worker	O
awareness	O
of	O
clinical	O
syndromes	B-DISO
associated	O
with	O
respiratory	O
pathogens	O
that	O
require	O
airborne	O
precautions	O
,	O
combined	O
with	O
the	O
use	O
of	O
standard	O
precautions	O
for	O
all	O
patients	O
,	O
and	O
contact	O
/	O
droplet	O
precautions	O
for	O
patients	O
with	O
undifferentiated	O
febrile	O
respiratory	O
illness	O
should	O
be	O
effective	O
in	O
interrupting	O
the	O
transmission	O
of	O
respiratory	O
pathogens	O
within	O
the	O
intensive	O
care	O
unit	O
.	O

Patients	O
who	O
could	O
benefit	O
from	O
prone	O
position	O
sessions	O
are	O
those	O
with	O
the	O
most	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
those	O
with	O
dorsal	O
lung	O
infiltrates	B-DISO
.	O

This	O
research	O
indicates	O
the	O
need	O
for	O
greater	O
credibility	O
in	O
public	O
health	O
communications	O
to	O
increase	O
compliance	O
with	O
quarantine	O
protocols	O
and	O
to	O
contain	O
outbreaks	O
of	O
new	O
and	O
deadly	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
coronavirus	O
strains	O
isolated	O
in	O
China	O
between	O
1995	O
and	O
2004	O
.	O

TITLE	O
:	O
[	O
Systematic	O
review	O
and	O
meta	O
-	O
analysis	O
on	O
the	O
integrative	O
traditional	O
Chinese	O
and	O
Western	O
medicine	O
in	O
treating	O
SARS	B-DISO
].	O

Anesthetized	O
eNOS	O
-	O
transgenic	O
(	O
Tg	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
C57BL	O
/	O
6	O
mice	O
were	O
ventilated	O
at	O
high	O
or	O
low	O
tidal	O
volume	O
(	O
Vt	O
;	O
20	O
or	O
7	O
ml	O
/	O
kg	O
,	O
respectively	O
)	O
for	O
4	O
h	O
.	O
After	O
MV	O
,	O
lung	O
damage	O
,	O
including	O
neutrophil	O
infiltration	B-DISO
,	O
water	O
leakage	B-DISO
,	O
and	O
cytokine	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
plasma	O
,	O
was	O
evaluated	O
.	O

Under	O
high	O
Vt	O
conditions	O
,	O
neutrophil	O
infiltration	B-DISO
and	O
lung	O
water	O
content	O
were	O
significantly	O
attenuated	O
in	O
eNOS	O
-	O
Tg	O
mice	O
compared	O
with	O
WT	O
animals	O
.	O

Other	O
useful	O
applications	O
of	O
the	O
DriF	O
technique	O
include	O
demarcating	O
culling	O
zone	O
for	O
the	O
containment	O
of	O
bird	B-DISO
flu	I-DISO
infection	B-DISO
and	O
containment	O
of	O
person	O
-	O
to	O
-	O
person	O
transmission	O
should	O
it	O
occur	O
.	O

These	O
observations	O
concern	O
(	O
i	O
)	O
the	O
induction	O
of	O
interferon	O
by	O
synthetic	O
polyanions	O
such	O
as	O
polyacrylic	O
acid	O
and	O
polymethacrylic	O
acid	O
;	O
(	O
ii	O
)	O
the	O
prolonged	O
antiviral	O
activity	O
shown	O
by	O
polyacrylic	O
acid	O
in	O
vivo	O
;	O
(	O
iii	O
)	O
the	O
interferon	O
-	O
inducing	O
ability	O
of	O
double	O
-	O
stranded	O
RNAs	O
such	O
as	O
poly	O
(	O
I	O
)	O
x	O
poly	O
(	O
C	O
)	O
and	O
(	O
iv	O
)	O
mismatched	O
derivatives	O
thereof	O
(	O
i	O
.	O
e	O
.	O
ampligen	O
);	O
(	O
v	O
)	O
the	O
cloning	O
and	O
expression	O
of	O
interferon	O
-	O
beta	O
,	O
and	O
(	O
vi	O
)	O
its	O
usefulness	O
in	O
the	O
treatment	O
of	O
multiple	B-DISO
sclerosis	I-DISO
;	O
(	O
vii	O
)	O
the	O
potential	O
of	O
(	O
pegylated	O
)	O
interferon	O
-	O
alpha	O
in	O
the	O
treatment	O
of	O
hepatitis	B-DISO
C	I-DISO
and	O
(	O
viii	O
)	O
the	O
therapy	O
/	O
prophylaxis	O
of	O
SARS	B-DISO
;	O
(	O
ix	O
)	O
the	O
efficacy	O
of	O
interferon	O
(	O
inducers	O
)	O
in	O
the	O
experimental	O
treatment	O
of	O
flavivirus	O
encephalitis	B-DISO
and	O
enterovirus	O
myocarditis	B-DISO
;	O
and	O
,	O
finally	O
,	O
(	O
x	O
)	O
the	O
role	O
of	O
interferon	O
in	O
the	O
activity	O
shown	O
by	O
S	O
-	O
adenosylhomocysteine	O
inhibitors	O
such	O
as	O
3	O
-	O
deazaneplanocin	O
A	O
against	O
experimental	O
Ebola	O
virus	O
infections	B-DISO
in	O
mice	O
.	O

TITLE	O
:	O
Effect	O
of	O
IBV	O
-	O
H120	O
vaccination	O
in	O
broilers	O
on	O
colibacillosis	B-DISO
susceptibility	O
after	O
infection	B-DISO
with	O
a	O
virulent	O
Massachusetts	O
-	O
type	O
IBV	O
strain	O
.	O

ABSTRACT	O
:	O
Vaccination	O
against	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
is	O
aimed	O
to	O
protect	O
against	O
clinical	O
IB	B-DISO
.	O

Body	O
weight	O
uniformity	O
,	O
severity	O
of	O
E	O
.	O
coli	O
airsacculitis	B-DISO
,	O
and	O
systemic	O
E	B-DISO
.	I-DISO
coli	I-DISO
infection	I-DISO
at	O
7	O
days	O
following	O
E	O
.	O
coli	O
inoculation	O
were	O
used	O
as	O
parameters	O
for	O
colibacillosis	B-DISO
.	O

Eighty	O
-	O
two	O
different	O
variant	O
viruses	O
were	O
identified	O
although	O
only	O
two	O
(	O
GAV	O
and	O
GA98	O
)	O
became	O
persistent	O
and	O
caused	O
widespread	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
vivax	B-DISO
malaria	I-DISO
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

ABSTRACT	O
:	O
Severe	O
pulmonary	B-DISO
involvement	I-DISO
in	O
malaria	B-DISO
has	O
been	O
frequently	O
reported	O
in	O
cases	O
of	O
Plasmodium	B-DISO
falciparum	I-DISO
infection	I-DISO
,	O
but	O
rarely	O
in	O
vivax	B-DISO
malaria	I-DISO
.	O

ABSTRACT	O
:	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
appeared	O
as	O
the	O
first	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
of	O
this	O
century	O
.	O

Despite	O
all	O
the	O
available	O
sophisticated	O
tests	O
,	O
alertness	O
with	O
early	O
recognition	O
by	O
healthcare	O
workers	O
and	O
prompt	O
isolation	O
of	O
suspected	O
cases	O
is	O
still	O
the	O
most	O
important	O
step	O
for	O
containing	O
the	O
spread	O
of	O
the	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
causes	O
a	O
significant	O
fraction	O
of	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

Infection	B-DISO
is	O
usually	O
initiated	O
after	O
inhalation	O
of	O
rodent	O
excreta	O
containing	O
virus	O
particles	O
,	O
but	O
human	O
-	O
to	O
-	O
human	O
transmission	O
has	O
been	O
documented	O
.	O

Our	O
data	O
suggest	O
that	O
hantavirus	B-DISO
infection	I-DISO
of	O
the	O
respiratory	O
epithelium	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
or	O
prodrome	B-DISO
phase	O
of	O
disease	O
as	O
well	O
as	O
serving	O
as	O
a	O
source	O
of	O
virus	O
involved	O
in	O
transmission	O
.	O

Furthermore	O
,	O
inoculation	O
of	O
human	O
target	O
cells	O
with	O
the	O
virus	O
resulted	O
in	O
a	O
His	O
receptor	O
-	O
specific	O
infection	B-DISO
that	O
was	O
multiround	O
.	O

Two	O
different	O
fragments	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
using	O
a	O
pET	O
expression	O
vector	O
,	O
respectively	O
.	O

The	O
S260	O
-	O
600	O
fragment	O
probably	O
contains	O
the	O
important	O
receptor	O
binding	O
domain	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
the	O
development	O
of	O
SARS	B-DISO
vaccine	O
and	O
anti	O
-	O
SARS	B-DISO
therapeutics	O
.	O

The	O
SARS	B-DISO
epidemic	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
completed	B-DISO
suicide	I-DISO
in	O
female	O
elders	O
,	O
but	O
not	O
in	O
male	O
elders	O
or	O
the	O
population	O
under	O
65	O
years	O
of	O
age	O
.	O

Here	O
we	O
present	O
a	O
forty	O
-	O
two	O
-	O
year	O
-	O
old	O
Caucasian	O
female	O
with	O
altered	B-DISO
mental	I-DISO
status	I-DISO
,	O
inability	O
to	O
eat	O
,	O
speak	O
or	O
walk	O
properly	O
,	O
with	O
shaking	B-DISO
and	O
vomiting	B-DISO
for	O
three	O
days	O
.	O

Acute	B-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
and	O
other	O
causes	O
of	O
respiratory	B-DISO
distress	I-DISO
were	O
ruled	O
out	O
;	O
diagnosis	O
of	O
Adult	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
made	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
various	O
viruses	O
including	O
HIV	B-DISO
(	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
)	O
examined	O
in	O
parallel	O
,	O
the	O
functions	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
Spike	O
glycoprotein	O
exhibit	O
a	O
significant	O
and	O
surprising	O
independence	O
of	O
redox	O
state	O
,	O
which	O
may	O
contribute	O
to	O
the	O
wide	O
host	O
range	O
of	O
the	O
virus	O
.	O

One	O
hundred	O
ninety	O
-	O
seven	O
children	O
,	O
aged	O
4	O
to	O
8	O
years	O
,	O
and	O
their	O
parents	O
were	O
recruited	O
from	O
the	O
pediatric	O
emergency	B-DISO
department	O
of	O
a	O
tertiary	O
care	O
center	O
.	O

Parents	O
filled	O
out	O
a	O
questionnaire	O
regarding	O
their	O
experiences	O
in	O
the	O
pediatric	O
emergency	B-DISO
department	O
during	O
the	O
SARS	B-DISO
epidemic	O
.	O

The	O
parents	O
selected	O
the	O
physician	O
in	O
SARS	B-DISO
standard	O
precautions	O
attire	O
as	O
most	O
liked	O
0	O
%	O
of	O
the	O
time	O
and	O
least	O
liked	O
94	O
.	O
8	O
%	O
of	O
the	O
time	O
.	O

During	O
three	O
consecutive	O
winter	O
-	O
spring	O
seasons	O
,	O
49	O
symptomatic	O
lung	O
transplant	O
recipients	O
with	O
suspected	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
,	O
and	O
26	O
asymptomatic	O
patients	O
were	O
investigated	O
for	O
presence	O
of	O
respiratory	O
viruses	O
either	O
in	O
56	O
nasopharyngeal	O
aspirate	O
or	O
72	O
bronchoalveolar	O
lavage	O
samples	O
taken	O
at	O
different	O
times	O
after	O
transplantation	O
.	O

TITLE	O
:	O
Assessing	O
the	O
genetic	O
component	O
of	O
the	O
susceptibility	O
of	O
mice	O
to	O
viral	B-DISO
infections	I-DISO
.	O

Influenza	B-DISO
virus	O
should	O
be	O
considered	O
as	O
a	O
cause	O
of	O
pneumonia	B-DISO
during	O
the	O
winter	O
months	O
,	O
especially	O
during	O
periods	O
of	O
peak	O
activity	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
convalescence	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
protein	O
plays	O
a	O
critical	O
role	O
in	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
,	O
and	O
high	O
-	O
level	O
anti	O
-	O
nucleocapsid	O
antibodies	O
are	O
detected	O
in	O
the	O
patients	O
infected	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
ELISA	O
analysis	O
using	O
the	O
N	O
antigen	O
or	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
particles	O
as	O
capture	O
antigen	O
showed	O
that	O
co	O
-	O
injection	O
of	O
SARS	B-DISO
-	O
M	O
could	O
enhance	O
N	O
-	O
induced	O
antibody	O
production	O
,	O
especially	O
IgG2a	O
subclass	O
.	O

Virus	O
challenge	O
test	O
was	O
conducted	O
in	O
BSL3	O
bio	O
safety	O
laboratory	O
with	O
Brandt	O
'	O
s	O
vole	O
SARS	B-DISO
-	O
CoV	O
model	O
,	O
and	O
the	O
results	O
indicated	O
that	O
co	O
-	O
immunization	O
of	O
M	O
and	O
N	O
antigens	O
could	O
reduce	O
the	O
mortality	O
and	O
pathological	O
changes	O
in	O
lung	O
from	O
the	O
virus	B-DISO
infection	I-DISO
.	O

Two	O
were	O
correlated	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
viral	O
load	O
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
efficacy	O
and	O
findings	O
of	O
a	O
large	O
-	O
scale	O
preventive	O
screening	O
program	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
using	O
amplification	B-DISO
of	O
the	O
virus	O
from	O
a	O
nasopharyngeal	O
swab	O
(	O
NPS	B-DISO
)	O
obtained	O
from	O
the	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
).	O

CONCLUSIONS	O
:	O
With	O
the	O
second	O
RT	O
-	O
PCR	O
assay	O
more	O
sensitive	O
than	O
the	O
first	O
RT	O
-	O
PCR	O
assay	O
,	O
we	O
are	O
able	O
to	O
show	O
that	O
approximately	O
11	O
.	O
5	O
%	O
of	O
well	O
-	O
protected	O
HCWs	O
exposed	O
to	O
SARS	B-DISO
patients	O
or	O
specimens	O
may	O
have	O
colonization	O
without	O
seroconversion	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
impact	O
of	O
the	O
2003	O
SARS	B-DISO
outbreak	O
on	O
Chinese	O
students	O
living	O
in	O
Japan	O
.	O

The	O
results	O
showed	O
approximately	O
60	O
%	O
(	O
96	O
/	O
161	O
)	O
of	O
the	O
respondents	O
felt	O
an	O
impact	O
of	O
SARS	B-DISO
on	O
college	O
life	O
;	O
they	O
had	O
experienced	O
SARS	B-DISO
-	O
related	O
fear	O
,	O
worry	O
,	O
depression	B-DISO
as	O
well	O
as	O
social	O
discrimination	O
and	O
had	O
taken	O
SARS	B-DISO
prevention	O
measures	O
for	O
daily	O
protection	O
in	O
Japan	O
during	O
the	O
epidemic	O
.	O

The	O
N	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
bears	O
signature	O
motifs	O
for	O
binding	O
to	O
cyclin	O
and	O
phosphorylation	O
by	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
and	O
has	O
recently	O
been	O
reported	O
by	O
us	O
to	O
get	O
phosphorylated	O
by	O
the	O
cyclin	O
-	O
CDK	O
complex	O
(	O
Surjit	O
,	O
M	O
.,	O
Kumar	O
,	O
R	O
.,	O
Mishra	O
,	O
R	O
.	O
N	O
.,	O
Reddy	O
,	O
M	O
.	O
K	O
.,	O
Chow	O
,	O
V	O
.	O
T	O
.,	O
and	O
Lal	O
,	O
S	O
.	O
K	O
.	O
(	O
2005	O
)	O
J	O
.	O
Virol	O
.	O
79	O
,	O
11476	O
-	O
11486	O
).	O

Analysis	O
of	O
RXL	O
and	O
CDK	O
phosphorylation	O
mutant	B-DISO
N	O
protein	O
identified	O
the	O
mechanism	O
of	O
inhibition	O
of	O
CDK4	O
and	O
CDK2	O
activity	O
to	O
be	O
different	O
.	O

Down	O
-	O
regulation	O
of	O
E2F1	O
targets	O
was	O
also	O
observed	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
VeroE6	O
cells	O
.	O

Its	O
short	O
N	O
-	O
terminal	O
ectodomain	O
was	O
found	O
to	O
elicit	O
strong	O
humoral	O
responses	O
in	O
half	O
of	O
the	O
patients	O
who	O
had	O
recovered	O
from	O
SARS	B-DISO
.	O

To	O
determine	O
if	O
the	O
patterns	O
of	O
personal	O
protection	O
or	O
concerns	O
changed	O
over	O
time	O
,	O
data	O
were	O
analyzed	O
according	O
to	O
whether	O
the	O
intubation	O
occurred	O
during	O
SARS	B-DISO
1	O
(	O
February	O
23	O
to	O
April	O
21	O
)	O
or	O
SARS	B-DISO
2	O
(	O
April	O
22	O
to	O
July	O
1	O
).	O

Personal	O
protection	O
increased	O
from	O
SARS	B-DISO
1	O
to	O
SARS	B-DISO
2	O
and	O
HCWs	O
'	O
concerns	O
changed	O
over	O
time	O
.	O

During	O
SARS	B-DISO
1	O
,	O
concerns	O
focused	O
on	O
the	O
need	O
for	O
personal	O
protective	O
equipment	O
whereas	O
during	O
SARS	B-DISO
2	O
,	O
concerns	O
focused	O
on	O
the	O
need	O
for	O
strict	O
training	O
and	O
patient	O
care	O
protocols	O
.	O

Protection	O
guidelines	O
failed	O
to	O
completely	O
prevent	O
the	O
transmission	O
of	O
SARS	B-DISO
to	O
HCWs	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
hfgl2	O
expression	O
and	O
the	O
severity	O
of	O
the	O
liver	B-DISO
disease	I-DISO
as	O
indicated	O
by	O
the	O
levels	O
of	O
TBil	O
.	O

PCA	B-DISO
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	B-DISO
B	I-DISO
.	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	B-DISO
hepatitis	I-DISO
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	O
/	O
fibroleukin	O
expression	O
and	O
the	O
coagulation	O
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	B-DISO
.	O

These	O
results	O
provide	O
a	O
novel	O
idea	O
for	O
further	O
studying	O
the	O
pharmacology	O
of	O
TCM	O
and	O
exploring	O
the	O
mechanism	O
of	O
SARS	B-DISO
virus	B-DISO
infection	I-DISO
.	O

Among	O
them	O
,	O
43	O
were	O
classified	O
as	O
probable	O
SARS	B-DISO
cases	O
and	O
a	O
SARS	B-DISO
etiology	O
was	O
excluded	O
in	O
32	O
patients	O
.	O

Common	O
laboratory	O
features	O
included	O
lymphopenia	B-DISO
and	O
elevated	O
aspartate	O
aminotransferase	O
,	O
alanine	O
aminotransferase	O
,	O
lactate	O
dehydrogenase	O
,	O
C	O
-	O
reactive	O
protein	O
and	O
creatine	O
kinase	O
values	O
.	O

The	O
clinical	O
presentation	O
and	O
laboratory	O
features	O
at	O
the	O
early	O
stage	O
do	O
not	O
allow	O
differentiation	O
of	O
patients	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
from	O
other	O
febrile	O
patients	O
.	O

In	O
an	O
amazing	O
pace	O
of	O
research	O
,	O
several	O
potent	O
human	O
mAbs	O
targeting	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
S	O
glycoprotein	O
that	O
can	O
affect	O
infections	B-DISO
in	O
animal	O
models	O
have	O
been	O
developed	O
months	O
after	O
the	O
virus	O
was	O
identified	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2003	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
epidemic	O
,	O
healthcare	O
workers	O
mandatorily	O
wore	O
the	O
protective	O
N95	O
face	B-DISO
-	O
mask	O
.	O

Four	O
(	O
2	O
.	O
1	O
%)	O
took	O
preventive	O
medications	O
for	O
headaches	B-DISO
during	O
this	O
period	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
pre	O
-	O
existing	O
headaches	B-DISO
[	O
P	O
=	O
0	O
.	O
041	O
,	O
OR	O
=	O
1	O
.	O
97	O
(	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
3	O
.	O
77	O
)]	O
and	O
continuous	O
use	O
of	O
the	O
N95	O
face	B-DISO
-	O
mask	O
exceeding	O
4	O
h	O
[	O
P	O
=	O
0	O
.	O
053	O
,	O
OR	O
=	O
1	O
.	O
85	O
(	O
95	O
%	O
CI	O
0	O
.	O
99	O
-	O
3	O
.	O
43	O
)]	O
were	O
associated	O
with	O
development	O
of	O
headaches	B-DISO
.	O

Healthcare	O
providers	O
may	O
develop	O
headaches	B-DISO
following	O
the	O
use	O
of	O
the	O
N95	O
face	B-DISO
-	O
mask	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
pre	O
-	O
existing	O
headaches	B-DISO
[	O
P	O
=	O
0	O
.	O
041	O
,	O
OR	O
=	O
1	O
.	O
97	O
(	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
3	O
.	O
77	O
)]	O
and	O
continuous	O
use	O
of	O
the	O
N95	O
face	B-DISO
-	O
mask	O
exceeding	O
4	O
h	O
[	O
P	O
=	O
0	O
.	O
053	O
,	O
OR	O
=	O
1	O
.	O
85	O
(	O
95	O
%	O
CI	O
0	O
.	O
99	O
-	O
3	O
.	O
43	O
)]	O
were	O
associated	O
with	O
development	O
of	O
headaches	B-DISO
.	O

Using	O
a	O
newly	O
established	O
human	O
monoclonal	O
anti	O
-	O
M	O
antibody	O
we	O
detected	O
glycosylated	O
and	O
nonglycosylated	O
membrane	O
-	O
associated	O
M	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infected	O
cells	O
and	O
in	O
purified	O
virions	O
.	O

Precedents	O
for	O
these	O
also	O
exist	O
in	O
the	O
field	O
of	O
genetics	O
,	O
notably	O
with	O
the	O
patents	O
pertaining	O
to	O
the	O
SARS	B-DISO
genome	O
.	O

Pathogens	O
directly	O
or	O
indirectly	O
transmitted	B-DISO
by	O
aerosolized	O
droplets	O
,	O
such	O
as	O
avian	B-DISO
influenza	I-DISO
and	O
SARS	B-DISO
,	O
pose	O
considerable	O
containment	O
challenges	O
.	O

Our	O
results	O
suggest	O
that	O
HCoV	O
-	O
HKU1	O
could	O
be	O
associated	O
with	O
respiratory	O
and	O
enteric	O
diseases	O
,	O
and	O
its	O
detection	O
can	O
be	O
related	O
to	O
a	O
persistent	O
asymptomatic	B-DISO
infection	I-DISO
in	O
patients	O
with	O
poor	O
underlying	O
conditions	O
.	O

TITLE	O
:	O
Stigmatization	O
of	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
:	O
AIDS	O
and	O
SARS	B-DISO
.	O

Sequence	O
analysis	O
found	O
that	O
ten	O
type	O
II	O
CCVs	O
fragments	O
of	O
M	O
gene	O
shared	O
a	O
high	O
similarity	O
with	O
reference	O
strain	O
CCV	B-DISO
1	O
-	O
71	O
(	O
96	O
.	O
5	O
-	O
99	O
.	O
5	O
%),	O
and	O
four	O
type	O
I	O
CCVs	O
shared	O
a	O
high	O
similarity	O
(	O
96	O
.	O
7	O
%-	O
98	O
.	O
1	O
%)	O
with	O
a	O
reported	O
FCV	O
-	O
like	O
CCV	B-DISO
strain	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
describes	O
the	O
design	O
and	O
synthesis	O
of	O
dipeptidyl	O
N	O
,	O
N	O
-	O
dimethyl	O
glutaminyl	O
fluoromethyl	O
ketones	O
(	O
fmk	O
)	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronovirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
inhibitors	O
.	O

We	O
found	O
a	O
decrease	O
in	O
UIP	B-DISO
from	O
acute	O
to	O
established	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Acute	O
and	O
sustained	O
effects	O
of	O
lucinactant	O
versus	O
poractant	O
-	O
alpha	O
on	O
pulmonary	O
gas	O
exchange	O
and	O
mechanics	O
in	O
premature	O
lambs	O
with	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Interstitial	B-DISO
pneumonia	I-DISO
is	O
a	O
rare	B-DISO
disease	I-DISO
,	O
posing	O
a	O
diagnostic	O
challenge	O
to	O
pneumologists	O
,	O
pediatricians	O
,	O
radiologists	O
and	O
pathologists	O
.	O

Using	O
the	O
ATS	B-DISO
/	O
ERS	B-DISO
classification	O
of	O
interstitial	O
pulmonary	B-DISO
diseases	I-DISO
in	O
premature	O
infants	O
,	O
infants	O
and	O
children	O
is	O
problematic	O
,	O
since	O
UIP	B-DISO
,	O
RB	B-DISO
-	I-DISO
ILD	I-DISO
and	O
AIP	B-DISO
do	O
not	O
occur	O
at	O
this	O
age	O
.	O

Ser380	O
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
autophosphorylation	O
by	O
activation	O
of	O
the	O
C	O
-	O
terminal	O
kinase	O
domain	O
,	O
was	O
phosphorylated	O
in	O
confluent	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
,	O
and	O
this	O
phosphorylation	O
was	O
inhibited	O
by	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	O
).	O

However	O
,	O
a	O
novel	O
hypothesis	O
to	O
explain	O
this	O
observation	O
proposes	O
that	O
it	O
is	O
related	O
to	O
the	O
life	O
-	O
saving	O
ventilatory	O
support	O
used	O
to	O
treat	O
the	O
respiratory	B-DISO
failure	I-DISO
.	O

According	O
to	O
this	O
hypothesis	O
,	O
mechanical	O
ventilation	O
per	O
se	O
,	O
by	O
altering	O
both	O
the	O
magnitude	O
and	O
the	O
pattern	O
of	O
lung	O
stretch	O
,	O
can	O
cause	O
changes	O
in	O
gene	O
expression	O
and	O
/	O
or	O
cellular	O
metabolism	O
that	O
ultimately	O
can	O
lead	O
to	O
the	O
development	O
of	O
an	O
overwhelming	O
inflammatory	B-DISO
response	I-DISO
-	O
even	O
in	O
the	O
absence	O
of	O
overt	O
structural	O
damage	O
.	O

No	O
difference	O
between	O
these	O
two	O
groups	O
was	O
found	O
in	O
the	O
prevalence	O
of	O
post	O
-	O
traumatic	O
stress	B-DISO
symptoms	I-DISO
(	O
33	O
%	O
vs	O
.	O
18	O
.	O
7	O
%),	O
yet	O
,	O
three	O
unit	O
subjects	O
(	O
SARS	B-DISO
ICU	O
,	O
SARS	B-DISO
regular	O
and	O
Neurology	O
)	O
had	O
significantly	O
higher	O
rate	O
than	O
those	O
in	O
CCU	O
(	O
29	O
.	O
7	O
%	O
vs	O
.	O
11	O
.	O
8	O
%,	O
respectively	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
conclusion	O
,	O
the	O
psychological	B-DISO
impact	O
on	O
the	O
caring	O
staffs	O
facing	O
future	O
bio	O
-	O
disaster	O
will	O
be	O
minimized	O
with	O
lowered	O
risk	O
factors	O
and	O
a	O
safer	O
and	O
more	O
structured	O
work	O
environment	O
.	O

121	O
patients	O
(	O
37	O
.	O
5	O
(	O
SD13	O
.	O
2	O
)	O
years	O
,	O
36	O
%	O
male	O
)	O
diagnosed	O
to	O
have	O
SARS	B-DISO
were	O
assessed	O
continuously	O
for	O
blood	O
pressure	O
,	O
pulse	O
,	O
and	O
temperature	O
during	O
their	O
stay	O
in	O
hospital	O
.	O

Bradycardia	B-DISO
only	O
occurred	O
in	O
18	O
(	O
14	O
.	O
9	O
%)	O
patients	O
as	O
a	O
transient	O
event	O
.	O

Reversible	O
cardiomegaly	O
was	O
reported	O
in	O
13	O
(	O
10	O
.	O
7	O
%)	O
patients	O
,	O
but	O
without	O
clinical	O
evidence	O
of	O
heart	B-DISO
failure	I-DISO
.	O

In	O
patients	O
with	O
SARS	B-DISO
,	O
cardiovascular	O
complications	O
including	O
hypotension	O
and	O
tachycardia	O
were	O
common	O
but	O
usually	O
self	O
limiting	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
infectious	B-DISO
disease	I-DISO
which	O
was	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

These	O
results	O
strongly	O
suggest	O
that	O
an	O
unknown	O
group	O
2	O
coronavirus	O
as	O
well	O
as	O
the	O
known	O
enteritis	B-DISO
-	O
causing	O
CCoV	O
(	O
group	O
1	O
coronavirus	O
)	O
is	O
prevalent	O
among	O
domestic	O
dogs	O
in	O
Japan	O
.	O

TITLE	O
:	O
[	O
Toxic	O
-	O
shock	O
-	O
like	O
-	O
syndrome	B-DISO
caused	O
by	O
beta	O
-	O
hemolysing	O
group	O
G	O
streptococci	O
in	O
a	O
multimorbid	O
patient	O
with	O
erysipelas	B-DISO
].	O

Erysipelas	B-DISO
is	O
infrequently	O
associated	O
with	O
GGS	O
but	O
,	O
much	O
more	O
often	O
,	O
with	O
group	O
A	O
streptococci	O
(	O
GAS	O
).	O

The	O
56th	O
nucleotide	O
of	O
SARS	B-DISO
-	O
CoV	O
5	O
'	O
UTR	O
was	O
found	O
to	O
be	O
the	O
initiation	O
site	O
for	O
transcription	O
.	O

B	O
:	O
The	O
cDNA	O
sequence	O
corresponding	O
to	O
SARS	B-DISO
-	O
CoV	O
5	O
'	O
UTR	O
possessed	B-DISO
a	O
promoter	O
activity	O
in	O
eukaryotic	O
cells	O
.	O

C	O
:	O
The	O
promoter	O
domain	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
5	O
'	O
UTR	O
contains	O
both	O
stem	O
-	O
loop	O
I	O
and	O
II	O
.	O

casei	O
together	O
with	O
dextran	O
induced	O
an	O
effective	O
increase	O
in	O
humoral	O
immune	O
response	O
to	O
mixed	O
inactivated	O
vaccines	O
against	O
Newcastle	B-DISO
disease	I-DISO
and	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
,	O
and	O
the	O
treatment	O
may	O
be	O
advantageous	O
in	O
protecting	O
against	O
these	O
infectious	B-DISO
diseases	I-DISO
in	O
chickens	O
in	O
actual	O
application	O
.	O

Seventy	O
-	O
three	O
per	O
cent	O
of	O
the	O
patient	O
population	O
evaluated	O
had	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Glycosylation	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
triple	O
-	O
spanning	O
membrane	O
proteins	O
3a	O
and	O
M	O
.	O
ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
open	O
reading	O
frame	O
3a	O
protein	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
structural	O
protein	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
antiviral	O
effects	O
of	O
interferon	O
-	O
alpha	O
against	O
a	O
SARS	B-DISO
-	O
like	O
coronoavirus	O
infection	B-DISO
in	O
vitro	O
.	O

In	O
this	O
report	O
we	O
examined	O
the	O
contribution	O
of	O
IFN	O
-	O
inducible	O
phosphorylation	O
-	O
activation	O
of	O
specific	O
signaling	O
effectors	O
to	O
protection	O
from	O
infection	B-DISO
by	O
a	O
SARS	B-DISO
-	O
related	O
murine	O
coronavirus	O
,	O
MHV	O
-	O
1	O
.	O

Necropsy	O
revealed	O
a	O
severe	O
ileo	O
-	O
cecal	O
intussusception	B-DISO
and	O
segmental	O
necrotic	B-DISO
enteritis	I-DISO
of	O
the	O
small	O
intestine	O
.	O

Electron	O
microscopy	O
of	O
the	O
intestinal	O
contents	O
was	O
positive	O
for	O
coronavirus	O
and	O
negative	O
for	O
parvovirus	B-DISO
.	O

A	O
whole	O
killed	O
(	O
inactivated	O
by	O
beta	O
-	O
propiolactone	O
)	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
and	O
a	O
combination	O
of	O
two	O
adenovirus	B-DISO
-	O
based	O
vectors	O
,	O
one	O
expressing	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
the	O
other	O
expressing	O
the	O
spike	O
(	O
S	O
)	O
protein	O
(	O
collectively	O
designated	O
Ad	O
S	O
/	O
N	O
),	O
were	O
evaluated	O
for	O
the	O
induction	O
of	O
serum	O
neutralizing	O
antibodies	O
and	O
cellular	O
immune	O
responses	O
and	O
their	O
ability	O
to	O
protect	O
against	O
pulmonary	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

ABSTRACT	O
:	O
In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
the	O
relationships	O
between	O
changes	O
in	O
the	O
elastic	O
behavior	O
of	O
the	O
respiratory	O
system	O
and	O
biological	O
markers	O
of	O
extra	O
-	O
cellular	O
matrix	O
or	O
surfactant	O
turn	O
-	O
over	O
could	O
give	O
some	O
insights	O
into	O
its	O
pathophysiological	O
determinants	O
.	O

In	O
17	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
we	O
assessed	O
the	O
relationship	O
between	O
chord	O
compliance	O
measured	O
on	O
pressure	O
-	O
volume	O
curves	O
obtained	O
at	O
two	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
0	O
and	O
10	O
[	O
Symbol	O
:	O
see	O
text	O
]	O
cm	O
[	O
Symbol	O
:	O
see	O
text	O
]	O
H	O
(	O
2	O
)	O
O	O
)	O
and	O
biological	O
markers	O
of	O
collagen	O
turn	O
-	O
over	O
or	O
surfactant	O
degradation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
obtained	O
simultaneously	O
in	O
the	O
early	O
phase	O
of	O
the	O
disease	O
(	O
first	O
4	O
days	O
).	O

The	O
correlations	O
were	O
stronger	O
when	O
the	O
curve	O
was	O
traced	O
from	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
suggesting	O
that	O
this	O
condition	B-DISO
may	O
improve	O
the	O
assessment	O
of	O
tissue	O
mechanics	O
.	O

A	O
logarithmic	O
relationship	O
best	O
described	O
the	O
correlation	O
between	O
compliance	O
and	O
type	O
III	O
procollagen	O
peptide	O
,	O
in	O
agreement	O
with	O
a	O
collagen	O
-	O
dependent	O
model	O
of	O
maximal	O
distension	B-DISO
.	O

The	O
functional	O
contribution	O
of	O
the	O
CXCL10	O
receptor	O
CXCR3	O
in	O
host	O
defense	O
and	O
disease	O
in	O
response	O
to	O
MHV	O
infection	B-DISO
was	O
evaluated	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
poorly	O
understood	O
and	O
cytokine	O
dysregulation	O
has	O
been	O
suggested	O
as	O
one	O
relevant	O
mechanism	O
to	O
be	O
explored	O
.	O

Toll	O
-	O
like	O
receptors	O
4	O
and	O
9	O
,	O
which	O
correlate	O
with	O
the	O
induction	O
of	O
inflammatory	B-DISO
response	I-DISO
,	O
were	O
upregulated	O
by	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Absence	O
of	O
infection	B-DISO
in	O
asymptomatic	O
contacts	O
of	O
index	O
SARS	B-DISO
case	O
in	O
France	O
.	O

ABSTRACT	O
:	O
The	O
first	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
France	O
was	O
diagnosed	O
in	O
March	O
2003	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
a	O
restaurant	O
from	O
palm	O
civet	O
.	O

ABSTRACT	O
:	O
Epidemiologic	O
investigations	O
showed	O
that	O
2	O
of	O
4	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
identified	O
in	O
the	O
winter	O
of	O
2003	O
-	O
2004	O
were	O
a	O
waitresss	O
at	O
a	O
restaurant	O
in	O
Guangzhou	O
,	O
China	O
,	O
that	O
served	O
palm	O
civets	O
as	O
food	O
and	O
a	O
customer	O
who	O
ate	B-DISO
in	O
the	O
restaurant	O
ashort	O
distance	O
from	O
animal	O
cages	O
.	O

We	O
studied	O
nasopharyngeal	O
viral	O
load	O
of	O
SARS	B-DISO
patients	O
on	O
admission	O
and	O
their	O
geographic	O
distribution	O
.	O

However	O
,	O
treatment	O
with	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
small	O
interfering	O
RNA	O
indicated	O
that	O
the	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
signaling	O
pathway	O
was	O
not	O
related	O
to	O
inhibition	O
of	O
cell	O
proliferation	B-DISO
.	O

ABSTRACT	O
:	O
To	O
identify	O
key	O
nursing	O
issues	O
for	O
paediatric	O
patients	O
suspected	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
relation	O
to	O
the	O
family	O
-	O
centred	O
model	O
of	O
nursing	O
care	O
and	O
to	O
develop	O
a	O
data	O
-	O
based	O
model	O
of	O
paediatric	O
nursing	O
care	O
to	O
be	O
better	O
applied	O
in	O
situations	O
of	O
suspected	O
SARS	B-DISO
or	O
where	O
outbreaks	O
of	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
occur	O
.	O

This	O
is	O
a	O
retrospective	O
descriptive	O
case	O
series	O
,	O
which	O
analysed	O
the	O
medical	O
and	O
nursing	O
records	O
of	O
all	O
highly	O
-	O
suspected	O
/	O
suspected	O
SARS	B-DISO
patients	O
admitted	O
to	O
a	O
major	O
acute	O
hospital	O
in	O
Hong	O
Kong	O
.	O

Both	O
the	O
children	O
and	O
parents	O
experienced	O
fear	O
of	O
SARS	B-DISO
,	O
as	O
well	O
as	O
separation	B-DISO
anxiety	I-DISO
arisen	O
from	O
hospitalization	O
in	O
a	O
strict	O
isolation	O
setting	O
.	O

SARS	B-DISO
also	O
appeared	O
to	O
retreat	O
naturally	O
over	O
time	O
.	O

Four	O
isolates	O
of	O
TCoV	O
were	O
sequenced	O
over	O
the	O
entire	O
3	O
'-	O
end	O
structural	O
protein	O
-	O
encoding	O
region	O
and	O
compared	O
phylogenetically	O
along	O
with	O
the	O
corresponding	O
sequences	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
.	O

Previous	O
influenza	B-DISO
pandemics	O
have	O
arrived	O
with	O
little	O
or	O
no	O
warning	O
,	O
but	O
the	O
current	O
widespread	O
circulation	O
of	O
H5N1	B-DISO
viruses	O
among	O
avian	O
populations	O
and	O
their	O
potential	O
for	O
increased	O
transmission	O
to	O
humans	O
and	O
other	O
mammalian	O
species	O
may	O
afford	O
us	O
an	O
unprecedented	O
opportunity	O
to	O
prepare	O
for	O
the	O
next	O
pandemic	O
threat	O
.	O

The	O
US	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
is	O
coordinating	O
a	O
national	O
strategy	O
to	O
respond	O
to	O
an	O
influenza	B-DISO
pandemic	O
that	O
involves	O
multiple	O
agencies	O
,	O
including	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
the	O
Food	O
and	O
Drug	O
Administration	O
,	O
and	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
NIH	O
).	O

TITLE	O
:	O
Non	O
-	O
pharmaceutical	O
interventions	O
for	O
pandemic	O
influenza	B-DISO
,	O
international	O
measures	O
.	O

ABSTRACT	O
:	O
Since	O
global	O
availability	O
of	O
vaccine	O
and	O
antiviral	O
agents	O
against	O
influenza	B-DISO
caused	O
by	O
novel	O
human	O
subtypes	O
is	O
insufficient	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
recommends	O
non	O
-	O
pharmaceutical	O
public	O
health	O
interventions	O
to	O
contain	O
infection	B-DISO
,	O
delay	O
spread	O
,	O
and	O
reduce	O
the	O
impact	O
of	O
pandemic	O
disease	O
.	O

The	O
principal	O
focus	O
of	O
interventions	O
against	O
pandemic	O
influenza	B-DISO
spread	O
should	O
be	O
at	O
national	O
and	O
community	O
levels	O
rather	O
than	O
international	O
borders	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
replication	O
in	O
cell	O
lines	O
.	O

The	O
study	O
identified	O
10	O
new	O
cell	O
lines	O
capable	O
of	O
supporting	O
the	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
confirmed	O
the	O
susceptibility	O
of	O
4	O
cell	O
lines	O
previously	O
reported	O
.	O

This	O
information	O
is	O
very	O
important	O
for	O
the	O
development	O
SARS	B-DISO
diagnostic	O
kits	O
and	O
a	O
vaccine	O
.	O

ABSTRACT	O
:	O
Side	O
effects	O
of	O
interferon	O
-	O
ribavirin	O
combination	O
therapy	O
limit	O
the	O
sustained	O
viral	O
response	O
achievable	O
in	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
patients	O
.	O

In	O
vivo	O
,	O
untreated	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
all	O
developed	O
clinical	O
and	O
biochemical	O
signs	O
of	O
acute	B-DISO
viral	I-DISO
hepatitis	I-DISO
and	O
died	O
by	O
day	O
4	O
post	O
infection	B-DISO
.	O

212	O
IU	O
/	O
L	O
(	O
HRC	O
203	O
)]	O
and	O
histological	O
evidence	O
of	O
hepatic	B-DISO
necrosis	I-DISO
(<	O
10	O
%	O
in	O
ribavirin	O
/	O
HRC	O
203	O
vs	O
.	O
90	O
%	O
in	O
untreated	O
controls	O
).	O

TITLE	O
:	O
A	O
recombinant	O
baculovirus	O
-	O
expressed	O
S	O
glycoprotein	O
vaccine	O
elicits	O
high	O
titers	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
neutralizing	O
antibodies	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
A	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
vaccine	O
produced	O
in	O
insect	O
cells	O
in	O
a	O
pre	O
-	O
clinical	O
development	O
stage	O
is	O
described	O
.	O

HIV	B-DISO
-	O
1	O
promoted	O
frameshifting	O
was	O
also	O
compared	O
between	O
Escherichia	O
coli	O
and	O
a	O
human	O
T	O
-	O
cell	O
line	O
expression	O
systems	O
.	O

Dyspnoea	B-DISO
,	O
diarrhoea	B-DISO
,	O
travel	O
,	O
close	O
contact	O
,	O
hospital	O
exposure	O
,	O
and	O
household	O
history	O
were	O
identified	O
as	O
predictive	O
indicators	O
in	O
the	O
triage	O
stage	O
.	O

Leukocytosis	B-DISO
,	O
thrombocytopenia	O
,	O
lymphopenia	B-DISO
,	O
and	O
CXR	O
were	O
identified	O
as	O
predictive	O
indicators	O
in	O
the	O
fever	O
screening	O
stage	O
.	O

RESULTS	O
:	O
Of	O
737	O
patients	O
who	O
presented	O
to	O
our	O
ED	O
for	O
possible	O
SARS	B-DISO
from	O
March	O
to	O
June	O
2003	O
,	O
we	O
enrolled	O
484	O
patients	O
with	O
a	O
temperature	O
>	O
38	O
.	O
0	O
degrees	O
C	O
(>	O
100	O
.	O
3	O
degrees	O
F	O
)	O
(	O
age	O
>	O
18	O
years	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
relationship	O
between	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
antibody	O
titres	O
and	O
age	O
,	O
breed	O
,	O
gender	O
and	O
health	O
status	O
of	O
Australian	O
cats	O
Retrospective	O
study	O
Results	O
from	O
two	O
serological	O
tests	O
that	O
measure	O
FCoV	O
antibody	O
levels	O
,	O
the	O
Coronase	O
test	O
and	O
the	O
7B	O
Feline	B-DISO
Infectious	I-DISO
Peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
test	O
,	O
were	O
recorded	O
over	O
a	O
2	O
-	O
year	O
period	O
,	O
with	O
patient	O
signalment	O
,	O
history	O
,	O
presenting	O
complaint	O
and	O
the	O
reason	O
for	O
ordering	O
the	O
test	O
(	O
as	O
available	O
).	O

There	O
was	O
no	O
statistical	O
relationship	O
between	O
the	O
Coronase	O
or	O
7B	O
FIP	B-DISO
antibody	O
titres	O
and	O
age	O
,	O
gender	O
or	O
overall	O
health	O
status	O
,	O
even	O
when	O
considering	O
only	O
those	O
cats	O
in	O
which	O
clinical	O
signs	O
suggestive	O
of	O
FIP	B-DISO
were	O
present	O
.	O

TITLE	O
:	O
Rapid	O
differentiation	O
of	O
current	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccine	O
strains	O
and	O
field	O
isolates	O
in	O
Australia	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
glucocorticoid	O
with	O
traditional	O
Chinese	O
medicine	O
in	O
severe	O
acute	O
aespiratory	O
syndrome	B-DISO
(	O
SARS	B-DISO
)].	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
a	O
novel	O
coronavirus	O
associated	O
with	O
epizootic	O
catarrhal	O
enteritis	B-DISO
(	O
ECE	O
)	O
in	O
ferrets	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
,	O
designated	O
as	O
ferret	O
enteric	O
coronavirus	O
(	O
FECV	O
),	O
was	O
identified	O
in	O
feces	O
of	O
domestic	O
ferrets	O
clinically	O
diagnosed	O
with	O
epizootic	O
catarrhal	O
enteritis	B-DISO
(	O
ECE	O
).	O

TITLE	O
:	O
Identification	O
of	O
Hepta	O
-	O
and	O
Octo	O
-	O
Uridine	O
stretches	B-DISO
as	O
sole	O
signals	O
for	O
programmed	O
+	O
1	O
and	O
-	O
1	O
ribosomal	O
frameshifting	O
during	O
translation	O
of	O
SARS	B-DISO
-	O
CoV	O
ORF	O
3a	O
variants	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
identification	O
of	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	O
stretches	B-DISO
as	O
sole	O
signals	O
for	O
programmed	O
+	O
1	O
and	O
-	O
1	O
ribosomal	O
frameshifting	O
during	O
translation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
ORF	O
3a	O
variants	O
.	O

SARS	B-DISO
-	O
CoV	O
ORF	O
3a	O
encodes	O
a	O
minor	O
structural	O
protein	O
of	O
274	O
amino	O
acids	O
.	O

We	O
also	O
demonstrated	O
that	O
DC	O
-	O
SIGN	O
was	O
inducible	O
in	O
THP	O
-	O
1	O
as	O
well	O
as	O
A549	O
cells	O
after	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
To	O
identify	O
patients	O
with	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
who	O
have	O
only	O
mild	O
symptoms	O
.	O

University	O
hospital	O
intensive	O
care	O
unit	O
,	O
caring	O
solely	O
for	O
patients	O
with	O
SARS	B-DISO
or	O
suspected	O
to	O
have	O
SARS	B-DISO
.	O

Recently	O
,	O
the	O
structure	O
of	O
a	O
post	O
-	O
fusion	O
form	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
,	O
which	O
consists	O
of	O
isolated	O
domains	O
of	O
heptad	O
repeats	O
1	O
and	O
2	O
(	O
HR1	O
and	O
HR2	O
),	O
has	O
been	O
determined	O
by	O
x	O
-	O
ray	O
crystallography	O
.	O

The	O
S2	O
-	O
HR2	O
structure	O
,	O
which	O
is	O
the	O
first	O
example	O
of	O
the	O
prefusion	O
form	O
of	O
coronavirus	O
envelope	O
,	O
supports	O
the	O
current	O
model	O
of	O
viral	O
membrane	O
fusion	O
and	O
gives	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	O
of	O
SARS	B-DISO
.	O

To	O
examine	O
the	O
anti	O
-	O
viral	O
and	O
/	O
or	O
regulatory	O
role	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
signaling	O
in	O
the	O
cell	O
that	O
synthesizes	O
and	O
maintains	O
the	O
myelin	O
sheath	O
,	O
we	O
analyzed	O
JHMV	O
pathogenesis	B-DISO
in	O
transgenic	O
mice	O
expressing	O
a	O
dominant	O
-	O
negative	O
IFN	O
-	O
gamma	O
receptor	O
on	O
oligodendroglia	O
.	O

ABSTRACT	O
:	O
The	O
34	O
kDa	O
main	O
proteinase	O
(	O
Mpro	O
)	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
life	O
cycle	O
through	O
the	O
specific	O
processing	O
of	O
viral	O
polyproteins	O
.	O

As	O
such	O
,	O
SARS	B-DISO
-	O
CoV	O
Mpro	O
is	O
a	O
key	O
target	O
for	O
the	O
identification	O
of	O
specific	O
inhibitors	O
directed	O
against	O
the	O
SARS	B-DISO
virus	O
.	O

TITLE	O
:	O
A	O
human	O
neutralizing	O
antibody	O
against	O
a	O
conformational	O
epitope	O
shared	O
by	O
oligomeric	O
SARS	B-DISO
S1	O
protein	O
.	O

This	O
study	O
should	O
aid	O
in	O
the	O
manufacture	O
of	O
neutralizing	O
antibody	O
,	O
provide	O
a	O
better	O
understanding	O
the	O
immunological	O
characteristics	O
of	O
SARS	B-DISO
protein	O
and	O
facilitate	O
the	O
design	O
of	O
a	O
SARS	B-DISO
vaccine	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
human	O
coronavirus	O
(	O
CoV	O
)	O
has	O
been	O
identified	O
as	O
the	O
etiological	O
agent	O
that	O
caused	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
incidence	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
in	O
Iran	O
.	O

Mechanically	O
ventilated	O
patients	O
had	O
a	O
low	O
GBS	B-DISO
disability	O
score	O
on	O
discharge	O
compared	O
with	O
patients	O
not	O
mechanically	O
ventilated	O
(	O
P	O
=	O
0	O
.	O
05	O
).	O

Mechanically	O
ventilated	O
patients	O
had	O
a	O
low	O
GBS	B-DISO
disability	O
score	O
on	O
discharge	O
compared	O
with	O
patients	O
not	O
mechanically	O
ventilated	O
(	O
P	O
=	O
0	O
.	O
05	O
).	O

Herein	O
,	O
we	O
report	O
a	O
two	O
years	O
old	O
girl	O
that	O
developed	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
due	O
to	O
an	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
that	O
first	O
manifested	O
in	O
humans	O
in	O
November	O
2002	O
.	O

CONCLUSIONS	O
:	O
Direct	O
injury	O
of	O
SARS	B-DISO
-	O
CoV	O
on	O
alveolar	O
epithelium	O
,	O
prominent	O
macrophage	O
infiltration	B-DISO
and	O
distinctive	O
fibroblast	O
/	O
myofibroblast	O
proliferation	B-DISO
may	O
play	O
major	O
roles	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
a	O
serious	O
postoperative	B-DISO
complication	I-DISO
of	O
esophageal	B-DISO
cancer	I-DISO
,	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

Clinical	O
data	O
of	O
1	O
488	O
esophageal	B-DISO
cancer	I-DISO
patients	O
,	O
received	O
esophagectomy	O
from	O
2000	O
to	O
2002	O
in	O
our	O
hospital	O
,	O
were	O
retrospectively	O
reviewed	O
.	O

Early	O
postoperative	O
intensive	O
care	O
significantly	O
decreased	O
the	O
occurrence	O
of	O
ARDS	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
patients	O
with	O
ARDS	B-DISO
and	O
brain	O
imaging	O
had	O
cognitive	B-DISO
impairments	I-DISO
,	O
significant	O
brain	B-DISO
atrophy	I-DISO
,	O
ventricular	O
enlargement	B-DISO
and	O
53	O
%	O
had	O
atrophy	B-DISO
or	O
lesions	O
by	O
radiological	O
report	O
.	O

These	O
microarrays	O
were	O
used	O
to	O
screen	O
approximately	O
400	O
Canadian	O
sera	O
from	O
the	O
SARS	B-DISO
outbreak	O
,	O
including	O
samples	O
from	O
confirmed	O
SARS	B-DISO
-	O
CoV	O
cases	O
,	O
respiratory	O
illness	O
patients	O
,	O
and	O
healthcare	O
professionals	O
.	O

The	O
test	O
assigned	O
patients	O
into	O
two	O
distinct	O
groups	O
:	O
those	O
with	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
and	O
those	O
without	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
roles	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
and	O
HR2	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
virus	O
-	O
cell	O
interactions	O
,	O
the	O
conserved	O
Leu	O
or	O
Ile	O
residues	O
located	O
at	O
positions	O
913	O
,	O
927	O
,	O
941	O
,	O
and	O
955	O
in	O
HR1	O
and	O
1151	O
,	O
1165	O
,	O
and	O
1179	O
in	O
HR2	O
were	O
individually	O
replaced	O
with	O
an	O
alpha	O
-	O
helix	O
-	O
breaker	O
Pro	O
residue	O
.	O

ABSTRACT	O
:	O
The	O
virally	O
encoded	O
integrase	O
protein	O
is	O
an	O
essential	O
enzyme	O
in	O
the	O
life	O
cycle	O
of	O
the	O
HIV	B-DISO
-	O
1	O
virus	O
and	O
represents	O
an	O
attractive	O
and	O
validated	O
target	O
in	O
the	O
development	O
of	O
therapeutics	O
against	O
HIV	B-DISO
infection	I-DISO
.	O

Among	O
the	O
HIV	B-DISO
-	O
1	O
integrase	O
inhibitors	O
,	O
the	O
beta	O
-	O
diketo	O
acids	O
(	O
DKAs	O
)	O
represent	O
a	O
major	O
lead	O
for	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
drug	O
development	O
.	O

Oxygenation	O
continued	O
to	O
improve	O
for	O
24	O
hrs	B-DISO
after	O
implementation	O
(	O
101	O
mm	O
Hg	O
[	O
74	O
-	O
142	O
],	O
p	O
<	O
.	O
05	O
).	O

The	O
incidence	O
of	O
complications	O
was	O
24	O
.	O
4	O
%,	O
mostly	O
due	O
to	O
ischemia	B-DISO
in	O
a	O
lower	O
limb	O
.	O

TITLE	O
:	O
Evolutionary	O
implications	O
of	O
Avian	B-DISO
Infectious	I-DISO
Bronchitis	I-DISO
Virus	O
(	O
AIBV	O
)	O
analysis	O
.	O

In	O
addition	O
,	O
the	O
SARS	B-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
also	O
analyzed	O
in	O
the	O
same	O
way	O
.	O

We	O
speculate	O
that	O
corticosteroid	O
with	O
higher	O
in	O
-	O
vitro	O
inflammatory	O
potency	O
administered	O
at	O
timing	O
and	O
dosages	O
commensurate	O
with	O
disease	O
severity	O
may	O
be	O
conducive	O
to	O
better	O
outcome	O
from	O
SARS	B-DISO
as	O
a	O
consequence	O
of	O
more	O
effective	O
control	O
of	O
immunopathological	O
lung	O
damage	O
.	O

TITLE	O
:	O
SARS	B-DISO
patients	O
-	O
derived	O
human	O
recombinant	O
antibodies	O
to	O
S	O
and	O
M	O
proteins	O
efficiently	O
neutralize	O
SARS	B-DISO
-	O
coronavirus	O
infectivity	O
.	O

The	O
selected	O
Fab	O
antibodies	O
expressed	O
in	O
the	O
periplasma	O
of	O
E	O
.	O
coli	O
were	O
soluble	O
and	O
further	O
purified	O
and	O
tested	O
for	O
their	O
binding	O
properties	O
and	O
antiviral	O
function	O
to	O
SARS	B-DISO
virus	O
.	O

TITLE	O
:	O
Changes	O
in	O
coagulation	O
and	O
fibrinolysis	O
of	O
post	O
-	O
SARS	B-DISO
osteonecrosis	B-DISO
in	O
a	O
Chinese	O
population	O
.	O

Activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
),	O
protein	O
C	O
(	O
PC	O
),	O
antithrombin	O
III	O
(	O
AT	O
-	O
III	O
),	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
),	O
activated	B-DISO
protein	I-DISO
C	I-DISO
resistance	I-DISO
(	O
APC	B-DISO
-	O
R	O
),	O
plasminogen	O
(	O
PLG	O
),	O
von	O
Willebrand	O
'	O
s	O
factor	O
(	O
vWF	O
),	O
D	O
-	O
dimer	O
(	O
D	O
-	O
D	O
),	O
fibrinogen	O
(	O
Fib	O
),	O
and	O
homocysteine	O
(	O
HCY	O
)	O
were	O
examined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

ABSTRACT	O
:	O
RNA	O
viruses	O
are	O
notorious	O
for	O
their	O
genetic	O
plasticity	O
and	O
propensity	O
to	O
exploit	O
new	O
host	O
-	O
range	O
opportunities	O
,	O
which	O
can	O
lead	O
to	O
the	O
emergence	O
of	O
human	O
disease	O
epidemics	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
AIDS	O
,	O
dengue	B-DISO
,	O
and	O
influenza	B-DISO
.	O

Bacterially	O
expressed	O
forms	O
of	O
SARS	B-DISO
-	O
CoV	O
nsp14	O
were	O
shown	O
to	O
act	O
on	O
both	O
ssRNAs	O
and	O
dsRNAs	O
in	O
a	O
3	O
'-->	O
5	O
'	O
direction	O
.	O

TITLE	O
:	O
High	O
expression	O
level	O
of	O
soluble	O
SARS	B-DISO
spike	O
protein	O
mediated	O
by	O
adenovirus	B-DISO
in	O
HEK293	O
cells	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
reports	O
a	O
study	O
which	O
aimed	O
to	O
:	O
(	O
1	O
)	O
investigate	O
the	O
relationship	O
between	O
nurses	O
'	O
commitment	O
to	O
the	O
nursing	O
profession	O
and	O
organization	O
and	O
their	O
intention	O
to	O
leave	O
;	O
(	O
2	O
)	O
investigate	O
nurses	O
'	O
perceptions	O
of	O
the	O
possibility	O
of	O
acquiring	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
infection	B-DISO
and	O
its	O
moderation	O
of	O
their	O
commitment	O
to	O
the	O
nursing	O
profession	O
and	O
the	O
organization	O
and	O
their	O
consequent	O
intentions	O
to	O
leave	O
the	O
profession	O
and	O
the	O
organization	O
following	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
.	O

Nurses	O
in	O
hospitals	O
caring	O
for	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
maintained	O
close	O
contact	O
with	O
the	O
infected	O
patients	O
.	O

Nurses	O
'	O
perceptions	O
of	O
the	O
possibility	O
of	O
acquiring	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
infection	B-DISO
through	O
caring	O
for	O
these	O
patients	O
had	O
a	O
moderating	O
effect	O
on	O
the	O
relationship	O
between	O
commitment	O
and	O
the	O
intention	O
to	O
leave	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
an	O
important	O
issue	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
fluorescence	O
intensity	O
of	O
dihydrorhodamine	O
123	O
staining	O
indicated	O
that	O
cellular	O
reactive	O
oxygen	O
species	O
were	O
markedly	O
increased	O
in	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
-	O
expressing	O
cells	O
.	O

Additional	O
comparative	O
genomic	O
studies	O
,	O
including	O
sequence	O
similarity	O
and	O
protein	O
secondary	O
structure	O
analyses	O
,	O
suggested	O
that	O
SARS	B-DISO
-	O
CoV	O
may	O
bear	O
a	O
closer	O
relationship	O
with	O
group	O
2	O
than	O
with	O
the	O
other	O
coronavirus	O
groups	O
.	O

Flu	B-DISO
A	O
and	O
B	O
Plus	O
test	O
(	O
Meridian	O
Bioscience	O
,	O
Cincinnati	O
,	O
OH	O
)	O
is	O
a	O
new	O
point	O
of	O
care	O
(	O
POC	O
)	O
test	O
utilizing	O
influenza	B-DISO
-	O
specific	O
monoclonal	O
antibodies	O
for	O
rapid	O
diagnosis	O
.	O

The	O
significant	O
relationship	O
between	O
the	O
breed	O
of	O
the	O
cat	O
and	O
the	O
FCoV	O
antibody	O
titre	O
further	O
supports	O
the	O
notion	O
,	O
proposed	O
previously	O
by	O
the	O
authors	O
,	O
that	O
breed	O
related	O
differences	O
exist	O
in	O
the	O
immunological	O
response	O
to	O
FCoV	O
infection	B-DISO
.	O

Naïve	O
peripheral	O
blood	O
leukocytes	O
(	O
PBL	O
)	O
were	O
exposed	O
to	O
longitudinal	O
(	O
days	O
1	O
-	O
10	O
)	O
plasma	O
samples	O
from	O
ARDS	B-DISO
patients	O
divided	O
into	O
three	O
groups	O
based	O
on	O
physiological	O
improvement	O
and	O
clinical	O
outcome	O
by	O
days	O
7	O
-	O
10	O
:	O
improvers	O
,	O
nonimprovers	O
-	O
survivors	O
,	O
and	O
nonimprovers	O
-	O
nonsurvivors	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
in	O
a	O
two	O
-	O
center	O
study	O
that	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
and	O
low	O
tidal	O
volume	O
(	O
LTV	O
)	O
improved	O
outcome	O
in	O
ARDS	B-DISO
.	O

In	O
85	O
-	O
90	O
%	O
of	O
patients	O
,	O
acute	B-DISO
pancreatitis	I-DISO
is	O
self	O
-	O
limiting	O
and	O
subsides	O
spontaneously	O
within	O
4	O
-	O
7	O
days	O
.	O

Urinothorax	O
is	O
a	O
rare	O
entity	O
associated	O
with	O
obstructive	B-DISO
uropathy	I-DISO
.	O

Sleep	B-DISO
disturbances	I-DISO
are	O
extremely	O
common	O
in	O
patients	O
with	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
,	O
with	O
sleep	B-DISO
apnea	I-DISO
occurring	O
in	O
60	O
%	O
or	O
more	O
of	O
such	O
patients	O
.	O

The	O
mass	O
migration	O
during	O
the	O
Hajj	O
is	O
unparalleled	O
in	O
scale	O
,	O
and	O
pilgrims	O
face	B-DISO
numerous	O
health	O
hazards	O
.	O

We	O
review	O
the	O
communicable	O
and	O
non	O
-	O
communicable	O
hazards	O
that	O
pilgrims	O
face	B-DISO
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
structurally	O
based	O
drug	O
design	O
against	O
SARS	B-DISO
.	O

The	O
enzyme	O
activity	O
of	O
the	O
hybrid	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
of	O
the	O
wild	O
-	O
type	O
protein	O
and	O
the	O
inactive	O
mutant	B-DISO
proves	O
that	O
the	O
dimerization	O
is	O
important	O
for	O
enzyme	O
activity	O
and	O
only	O
one	O
active	O
protomer	O
in	O
the	O
dimer	O
is	O
enough	O
for	O
the	O
catalysis	O
.	O

ABSTRACT	O
:	O
Aspiration	B-DISO
of	O
gastric	O
acid	O
commonly	O
injures	O
airway	O
epithelium	O
and	O
,	O
if	O
severe	O
,	O
can	O
lead	O
to	O
respiratory	B-DISO
failure	I-DISO
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
):	O
implications	O
for	O
intensive	O
care	O
.	O

Clinical	O
features	O
of	O
gemcitabine	O
-	O
associated	O
lung	O
injury	O
included	O
dyspnea	B-DISO
,	O
fever	O
,	O
pulmonary	B-DISO
infiltrate	I-DISO
,	O
and	O
cough	B-DISO
with	O
recognition	O
of	O
toxicity	O
occurring	O
after	O
a	O
median	O
duration	O
of	O
48	O
(	O
range	O
,	O
1	O
-	O
529	O
)	O
days	O
after	O
initiation	O
of	O
gemcitabine	O
.	O

Eleven	O
Phase	O
II	O
or	O
Phase	O
III	O
clinical	O
trials	O
with	O
317	O
patients	O
identified	O
gemcitabine	O
-	O
associated	O
lung	O
injury	O
rates	O
of	O
greater	O
than	O
10	O
%,	O
with	O
the	O
highest	O
rates	O
(	O
22	O
%	O
and	O
42	O
%)	O
being	O
observed	O
in	O
Phase	O
III	O
clinical	O
trials	O
where	O
Hodgkin	B-DISO
disease	I-DISO
patients	O
were	O
treated	O
with	O
a	O
regimen	O
that	O
included	O
gemcitabine	O
and	O
bleomycin	O
.	O

ABSTRACT	O
:	O
The	O
Vaccine	O
Research	O
Center	O
has	O
developed	O
a	O
number	O
of	O
vaccine	O
candidates	O
for	O
different	O
diseases	O
/	O
infectious	B-DISO
agents	O
(	O
HIV	B-DISO
-	O
1	O
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
virus	O
,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
and	O
Ebola	O
virus	O
,	O
plus	O
a	O
plasmid	O
cytokine	O
adjuvant	O
-	O
IL	O
-	O
2	O
/	O
Ig	O
)	O
based	O
on	O
a	O
DNA	O
plasmid	O
vaccine	O
platform	O
.	O

TITLE	O
:	O
Biodistribution	O
of	O
DNA	O
plasmid	O
vaccines	O
against	O
HIV	B-DISO
-	O
1	O
,	O
Ebola	O
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
or	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
is	O
similar	O
,	O
without	O
integration	O
,	O
despite	O
differing	O
plasmid	O
backbones	O
or	O
gene	O
inserts	O
.	O

These	O
recommendations	O
cover	O
training	O
,	O
infection	B-DISO
control	O
,	O
staffing	O
,	O
communication	O
and	O
ethical	O
issues	O
.	O

This	O
chapter	O
will	O
highlight	O
recent	O
discoveries	O
that	O
have	O
provided	O
insight	O
into	O
the	O
diverse	O
biologic	O
roles	O
of	O
chemokines	O
and	O
their	O
receptors	O
in	O
coordinating	O
immune	O
responses	O
following	O
viral	B-DISO
infection	I-DISO
of	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

However	O
,	O
synthesis	O
of	O
IP	O
-	O
10	O
and	O
IL	O
-	O
8	O
,	O
which	O
are	O
established	O
markers	O
for	O
acute	O
-	O
stage	O
SARS	B-DISO
,	O
escapes	O
the	O
virus	O
-	O
induced	O
silencing	O
at	O
least	O
in	O
some	O
cell	O
types	O
.	O

An	O
acute	O
motor	O
weaknesses	B-DISO
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
may	O
be	O
caused	O
by	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
or	O
critical	B-DISO
illness	I-DISO
myopathy	I-DISO
.	O

The	O
latter	O
,	O
originally	O
discovered	O
in	O
influenza	B-DISO
C	O
virus	O
,	O
are	O
also	O
found	O
in	O
certain	O
nidoviruses	O
,	O
namely	O
in	O
group	O
2	O
coronaviruses	O
and	O
in	O
toroviruses	O
,	O
as	O
well	O
as	O
in	O
infectious	B-DISO
salmon	O
anemia	B-DISO
virus	O
,	O
an	O
orthomyxovirus	O
of	O
teleosts	O
.	O

Persistent	B-DISO
infection	I-DISO
with	O
FCoV	O
in	O
a	O
cheetah	O
population	O
results	O
in	O
continued	O
virus	O
circulation	O
and	O
may	O
lead	O
to	O
a	O
quasispecies	O
of	O
virus	O
variants	O
.	O

In	O
the	O
lung	O
,	O
ACE2	O
protects	O
against	O
acute	O
lung	O
injury	O
in	O
several	O
animal	O
models	O
of	O
ARDS	B-DISO
.	O

To	O
identify	O
features	O
of	O
the	O
clinical	O
assessment	O
that	O
are	O
useful	O
in	O
SARS	B-DISO
diagnosis	O
,	O
the	O
exposure	O
status	O
and	O
the	O
prevalence	O
and	O
timing	O
of	O
symptoms	O
,	O
signs	O
,	O
laboratory	O
and	O
radiographic	O
findings	O
were	O
determined	O
for	O
all	O
adult	O
patients	O
admitted	O
with	O
suspected	O
SARS	B-DISO
during	O
the	O
Toronto	O
SARS	B-DISO
outbreak	O
.	O

Respiratory	O
findings	O
including	O
cough	B-DISO
,	O
dyspnea	B-DISO
and	O
pulmonary	B-DISO
infiltrates	I-DISO
evolved	O
later	O
and	O
were	O
present	O
in	O
only	O
59	O
,	O
37	O
and	O
68	O
%	O
of	O
patients	O
,	O
respectively	O
,	O
at	O
admission	O
.	O

Fusion	O
inhibitors	O
reminiscent	O
of	O
enfuvirtide	O
in	O
the	O
case	O
of	O
HIV	B-DISO
may	O
also	O
be	O
developed	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
Various	O
peptidomimetic	O
and	O
nonpeptidic	O
inhibitors	O
of	O
3CLpro	O
have	O
been	O
described	O
,	O
the	O
best	O
ones	O
inhibiting	O
SARS	B-DISO
-	O
CoV	O
replication	O
with	O
a	O
selectivity	O
index	O
greater	O
than	O
1000	O
.	O

After	O
a	O
prolonged	O
stay	O
in	O
the	O
Intensive	O
Care	O
Unit	O
during	O
which	O
the	O
patient	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
methicillin	O
resistant	O
Staphylococcus	B-DISO
aureus	I-DISO
pneumonia	I-DISO
and	O
Enterobacter	B-DISO
septicaemia	I-DISO
,	O
the	O
patient	O
was	O
discharged	O
,	O
returning	O
to	O
his	O
pre	O
-	O
admission	O
lifestyle	O
.	O

TITLE	O
:	O
Structure	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
receptor	O
-	O
binding	O
domain	O
complexed	O
with	O
neutralizing	O
antibody	O
.	O

TITLE	O
:	O
Olfactory	O
neuropathy	B-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
report	O
of	O
A	O
case	O
.	O

Olfactory	O
neuropathy	B-DISO
,	O
which	O
rarely	O
occurred	O
in	O
typical	O
peripheral	B-DISO
neuropathy	I-DISO
,	O
could	O
be	O
a	O
special	O
type	O
of	O
neuropathy	B-DISO
induced	O
by	O
corona	B-DISO
virus	I-DISO
infection	I-DISO
in	O
SARS	B-DISO
.	O

In	O
the	O
clinical	O
experiments	O
,	O
the	O
doctors	O
wearing	O
the	O
equipment	O
who	O
performed	O
the	O
tracheotomy	O
for	O
a	O
SARS	B-DISO
patient	O
in	O
a	O
deep	O
coma	B-DISO
were	O
not	O
infected	O
.	O

Each	O
batch	O
of	O
mixed	O
peptide	O
substrates	O
with	O
defined	O
amino	O
acid	O
substitutions	O
at	O
the	O
target	O
amino	O
acid	O
position	O
was	O
synthesized	O
via	O
the	O
""""	O
cartridge	O
replacement	O
""""	O
approach	O
and	O
was	O
subjected	O
to	O
enzymatic	O
cleavage	O
by	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

Seldom	O
,	O
the	O
classical	O
trial	O
of	O
muscle	B-DISO
pain	I-DISO
,	O
weakness	B-DISO
,	O
and	O
dark	B-DISO
urine	I-DISO
is	O
observed	O
.	O

In	O
the	O
previous	O
our	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
spike	O
glycoprotein	O
gene	O
of	O
Korean	O
winter	B-DISO
dysentery	I-DISO
(	O
WD	O
)	O
BCoV	O
had	O
a	O
genetic	O
property	O
of	O
both	O
enteric	O
(	O
EBCV	O
)	O
and	O
respiratory	O
BCoV	O
(	O
RBCV	O
)	O
and	O
were	O
significantly	O
distinct	O
from	O
the	O
ancestral	O
enteric	O
strains	O
.	O

We	O
report	O
the	O
first	O
findings	O
of	O
measurable	O
clinical	O
disease	O
in	O
nonhuman	O
primates	O
(	O
NHPs	O
)	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
In	O
order	O
to	O
characterize	O
clinically	O
relevant	O
parameters	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
NHPs	O
,	O
we	O
infected	O
cynomolgus	O
macaques	O
with	O
SARS	B-DISO
-	O
CoV	O
in	O
three	O
groups	O
:	O
Group	O
I	O
was	O
infected	O
in	O
the	O
nares	O
and	O
bronchus	O
,	O
group	O
II	O
in	O
the	O
nares	O
and	O
conjunctiva	O
,	O
and	O
group	O
III	O
intravenously	O
.	O

SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
of	O
cynomolgus	O
macaques	O
did	O
not	O
reproduce	O
the	O
severe	O
illness	O
seen	O
in	O
the	O
majority	O
of	O
adult	O
human	O
cases	O
of	O
SARS	B-DISO
;	O
however	O
,	O
our	O
results	O
suggest	O
similarities	O
to	O
the	O
milder	O
syndrome	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
characteristically	O
seen	O
in	O
young	O
children	O
.	O

Measurements	O
were	O
repeated	O
at	O
different	O
degrees	O
of	O
pulmonary	O
gas	B-DISO
exchange	I-DISO
impairment	I-DISO
with	O
the	O
pulmonary	O
venous	O
admixture	O
ranging	O
from	O
35	O
.	O
0	O
%	O
to	O
70	O
.	O
6	O
%.	O

RESULTS	O
:	O
Compared	O
with	O
saline	O
and	O
control	O
groups	O
,	O
the	O
albuterol	O
groups	O
had	O
lower	O
pause	O
and	O
peak	O
inspiratory	O
pressures	O
,	O
decreased	O
pulmonary	O
transvascular	O
fluid	O
flux	O
,	O
a	O
significantly	O
higher	O
Pao2	O
/	O
Fio2	O
ratio	O
,	O
and	O
decreased	O
shunt	O
fraction	O
at	O
48	O
hrs	B-DISO
postinjury	O
.	O

Comorbidities	O
of	O
diabetes	B-DISO
and	O
heart	B-DISO
failure	I-DISO
were	O
more	O
common	O
in	O
patients	O
who	O
developed	O
ARF	B-DISO
(	O
38	O
%	O
vs	O
6	O
%,	O
p	O
<	O
0	O
.	O
01	O
and	O
38	O
%	O
vs	O
2	O
%,	O
p	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
the	O
incidence	O
of	O
respiratory	B-DISO
failure	I-DISO
(	O
85	O
%	O
vs	O
26	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mortality	O
(	O
77	O
%	O
vs	O
8	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
were	O
also	O
higher	O
.	O

RESULTS	O
:	O
Patients	O
were	O
assigned	O
to	O
ARF	B-DISO
(	O
n	O
=	O
13	O
;	O
17	O
%)	O
and	O
non	O
-	O
ARF	B-DISO
groups	O
(	O
n	O
=	O
65	O
).	O

TITLE	O
:	O
Characterization	O
and	O
inhibition	O
of	O
SARS	B-DISO
-	O
coronavirus	O
main	O
protease	O
.	O

Thus	O
,	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
peptidomimetics	O
,	O
anilides	O
,	O
metal	O
-	O
conjugated	O
compounds	O
,	O
boronic	O
acids	O
,	O
quinolinecarboxylate	O
derivatives	O
,	O
thiophenecarboxylates	O
,	O
phthalhydrazide	O
-	O
substituted	O
ketoglutamine	O
analogues	O
,	O
isatin	O
and	O
natural	O
products	O
have	O
been	O
identified	O
as	O
potent	O
inhibitors	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
.	O

To	O
determine	O
the	O
importance	O
of	O
these	O
negatively	O
charged	O
residues	O
,	O
a	O
series	O
of	O
alanine	O
and	O
other	O
charged	O
-	O
residue	O
substitutions	O
were	O
introduced	O
in	O
place	O
of	O
those	O
in	O
the	O
N	O
gene	O
within	O
a	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
A59	O
infectious	B-DISO
clone	O
.	O

Drug	O
-	O
or	O
toxin	O
-	O
induced	O
eosinophilic	B-DISO
pneumonia	I-DISO
is	O
indistinguishable	O
from	O
idiopathic	O
acute	O
or	O
chronic	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
by	O
clinical	O
,	O
radiographic	O
,	O
and	O
histopathologic	O
criteria	O
.	O

The	O
condition	B-DISO
usually	O
resolves	O
with	O
removal	O
from	O
the	O
agent	O
and	O
recurs	O
with	O
rechallenge	O
.	O

A	O
recent	O
report	O
has	O
described	O
an	O
outbreak	O
of	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
found	O
in	O
soldiers	O
in	O
Iraq	O
.	O

They	O
reported	O
271	O
suspect	O
or	O
probable	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
cases	O
under	O
investigation	O
(	O
average	O
4	O
.	O
7	O
).	O

95	O
patients	O
(	O
92	O
.	O
2	O
%)	O
with	O
ARDS	B-DISO
had	O
pulmonary	B-DISO
artery	I-DISO
hypertension	I-DISO
,	O
16	O
of	O
them	O
(	O
16	O
.	O
8	O
%)	O
mild	O
,	O
72	O
(	O
75	O
.	O
8	O
%)	O
moderate	O
,	O
and	O
7	O
(	O
7	O
.	O
4	O
%)	O
severe	O
,	O
as	O
assessed	O
by	O
right	O
heart	O
catheterization	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
RBD	O
-	O
Fc	O
bearing	O
R441A	O
mutation	O
could	O
not	O
bind	O
to	O
soluble	O
and	O
cell	O
-	O
associated	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
and	O
failed	O
to	O
block	O
S	O
protein	O
-	O
mediated	O
pseudovirus	O
entry	O
,	O
indicating	O
that	O
this	O
point	O
mutation	O
also	O
disrupted	O
the	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
)	O
in	O
the	O
RBD	O
.	O

TITLE	O
:	O
Psychiatric	O
inpatients	O
'	O
reactions	O
to	O
the	O
SARS	B-DISO
epidemic	O
:	O
an	O
Israeli	O
survey	O
.	O

Patients	O
felt	O
more	O
protected	O
by	O
the	O
authorities	O
and	O
some	O
perceived	O
the	O
epidemic	O
in	O
a	O
psychotic	B-DISO
manner	O
.	O

with	O
SARS	B-DISO
-	O
CoV	O
S	O
DNA	O
vaccine	O
,	O
and	O
three	O
different	O
methods	O
(	O
ELISA	O
,	O
ELISPOT	O
and	O
FACS	O
)	O
were	O
used	O
to	O
evaluate	O
the	O
immune	O
responses	O
when	O
the	O
cells	O
were	O
stimulated	O
in	O
vitro	O
with	O
a	O
pool	O
of	O
peptides	O
overlapping	O
entire	O
SARS	B-DISO
spike	O
protein	O
.	O

To	O
investigate	O
if	O
this	O
newly	O
discovered	O
virus	O
is	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
pediatric	O
patients	O
in	O
Beijing	O
,	O
tests	O
were	O
developed	O
to	O
detect	O
HCoV	O
-	O
NL63	O
gene	O
fragments	O
from	O
throat	O
swab	O
and	O
nasopharyngeal	O
aspirates	O
collected	O
from	O
children	O
in	O
outpatient	O
and	O
inpatient	O
departments	O
with	O
ARI	O
in	O
Beijing	O
from	O
Dec	O
.	O
2003	O
to	O
Mar	B-DISO
.	O
2004	O
.	O

TITLE	O
:	O
[	O
Expression	O
and	O
significance	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)-	O
X4	O
protein	O
in	O
lungs	O
of	O
SARS	B-DISO
patients	O
].	O

ABSTRACT	O
:	O
The	O
early	O
phase	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
impaired	B-DISO
respiratory	O
mechanics	O
,	O
ventilation	O
-	O
perfusion	O
mismatch	O
,	O
and	O
severe	O
hypoxemia	O
.	O

It	O
is	O
interesting	O
to	O
find	O
that	O
position	O
18379	O
which	O
has	O
not	O
been	O
identified	O
to	O
be	O
polymorphic	O
in	O
any	O
of	O
the	O
other	O
115	O
published	O
SARS	B-DISO
-	O
CoV	O
genomes	O
is	O
actually	O
a	O
polymorphic	O
site	O
.	O

Among	O
116	O
SARS	B-DISO
-	O
CoV	O
genomes	O
,	O
18	O
types	O
of	O
deletions	O
and	O
2	O
insertions	O
were	O
identified	O
.	O

Indeed	O
,	O
HCPs	O
-	O
both	O
in	O
clinical	O
care	O
and	O
in	O
public	O
health	O
-	O
were	O
severely	O
tested	O
by	O
SARS	B-DISO
.	O

Many	O
were	O
exposed	O
to	O
serious	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
as	O
evidenced	O
by	O
the	O
World	O
Health	O
Organization	O
figures	O
showing	O
that	O
approximately	O
30	O
%	O
of	O
reported	O
cases	O
were	O
among	O
HCPs	O
,	O
some	O
of	O
whom	O
died	O
from	O
the	O
infection	B-DISO
.	O

We	O
argue	O
that	O
there	O
is	O
a	O
pressing	O
need	O
to	O
clarify	O
the	O
rights	O
and	O
responsibilities	O
of	O
HCPs	O
in	O
the	O
current	O
context	O
of	O
pandemic	O
flu	B-DISO
preparedness	O
,	O
and	O
that	O
these	O
rights	O
and	O
responsibilities	O
ought	O
to	O
be	O
codified	O
in	O
professional	O
codes	O
of	O
ethics	O
.	O

Respondents	O
considering	O
SARS	B-DISO
a	O
high	O
public	O
health	O
threat	O
reported	O
higher	O
compliance	O
with	O
handwashing	O
(	O
4	O
.	O
8	O
v	O
4	O
.	O
4	O
),	O
always	O
wearing	O
a	O
mask	O
(	O
3	O
.	O
9	O
vs	O
3	O
.	O
2	O
)	O
and	O
gloves	O
(	O
3	O
.	O
6	O
v	O
2	O
.	O
9	O
)	O
in	O
the	O
ED	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
not	O
eye	O
protection	O
(	O
3	O
.	O
4	O
v	O
3	O
.	O
0	O
),	O
gown	O
use	O
(	O
4	O
.	O
9	O
v	O
4	O
.	O
7	O
),	O
or	O
wearing	O
a	O
mask	O
when	O
examining	O
patients	O
(	O
5	O
.	O
0	O
v	O
4	O
.	O
8	O
).	O

Concern	O
of	O
SARS	B-DISO
as	O
a	O
public	O
health	O
threat	O
rather	O
than	O
perceived	O
effectiveness	O
of	O
infection	B-DISO
control	O
measures	O
appears	O
to	O
have	O
a	O
greater	O
impact	O
on	O
compliance	O
.	O

This	O
article	O
defines	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
summarizes	O
historical	O
background	O
,	O
and	O
discusses	O
factors	O
that	O
contribute	O
to	O
emergence	O
.	O

This	O
article	O
provides	O
a	O
brief	O
overview	O
of	O
global	O
challenges	O
in	O
infection	B-DISO
control	O
and	O
SARS	B-DISO
.	O

Salmonella	B-DISO
spp	O
.	O

ABSTRACT	O
:	O
Maturation	O
of	O
dendritic	O
cells	O
(	O
DC	O
)	O
is	O
a	O
key	O
immunological	O
process	O
regulating	O
immune	O
responses	O
to	O
pathogens	O
and	O
vaccines	O
,	O
as	O
well	O
as	O
tolerance	B-DISO
and	O
autoimmune	B-DISO
processes	O
.	O

Indeed	O
,	O
MoDC	O
did	O
not	O
respond	O
to	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
whereas	O
NIPC	O
produced	O
high	O
levels	O
of	O
IFN	O
-	O
alpha	O
and	O
TNF	O
-	O
alpha	O
after	O
TGEV	O
stimulation	O
.	O

Moreover	O
,	O
our	O
identified	O
N317	O
-	O
325	O
and	O
S1042	O
-	O
1050	O
CTL	O
epitopes	O
could	O
induce	O
recall	O
responses	O
when	O
IFN	O
-	O
gamma	O
stimulation	O
of	O
blood	O
CD8	O
+	O
T	O
-	O
cells	O
revealed	O
significant	O
difference	O
between	O
normal	O
healthy	O
donors	O
and	O
SARS	B-DISO
-	O
recovered	O
patients	O
after	O
those	O
PBMCs	O
were	O
in	O
vitro	O
vaccinated	O
with	O
their	O
cognate	O
antigen	O
.	O

TITLE	O
:	O
Mapping	O
a	O
neutralizing	O
epitope	O
on	O
the	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
:	O
computational	O
prediction	O
based	O
on	O
affinity	O
-	O
selected	O
peptides	O
.	O

These	O
peptides	O
,	O
which	O
had	O
no	O
apparent	O
homologous	O
motif	O
within	O
or	O
between	O
the	O
peptide	O
pools	O
and	O
spike	O
protein	O
,	O
were	O
deconvoluted	O
into	O
amino	O
acid	O
pairs	O
(	O
AAPs	O
)	O
by	O
Mapitope	O
and	O
the	O
statistically	O
significant	O
pairs	O
(	O
SSPs	B-DISO
)	O
were	O
defined	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
is	O
a	O
prime	O
target	O
for	O
antiviral	O
therapy	O
.	O

Here	O
,	O
a	O
class	O
of	O
stable	O
benzotriazole	O
esters	O
was	O
reported	O
as	O
mechanism	O
-	O
based	O
inactivators	O
of	O
3CL	O
(	O
pro	O
),	O
and	O
the	O
most	O
potent	O
inactivator	O
exhibited	O
a	O
k	O
(	O
inact	O
)	O
of	O
0	O
.	O
0011	O
s	O
(-	O
1	O
)	O
and	O
a	O
K	O
(	O
i	O
)	O
of	O
7	O
.	O
5	O
nM	O
.	O
Mechanistic	O
investigation	O
with	O
kinetic	O
and	O
mass	O
spectrometry	O
analyses	O
indicates	O
that	O
the	O
active	O
site	O
Cys145	O
is	O
acylated	O
,	O
and	O
that	O
no	O
irreversible	O
inactivation	B-DISO
was	O
observed	O
with	O
the	O
use	O
of	O
the	O
C145A	O
mutant	B-DISO
.	O

Moreover	O
,	O
this	O
new	O
class	O
of	O
bioorganometallic	O
compounds	O
exert	O
antiviral	O
effects	O
with	O
some	O
selectivity	O
toward	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

These	O
new	O
drugs	O
may	O
offer	O
an	O
interesting	O
alternative	O
for	O
Asia	O
where	O
SARS	B-DISO
originated	O
and	O
malaria	B-DISO
has	O
remained	O
endemic	O
.	O

TITLE	O
:	O
Receptor	O
-	O
independent	O
infection	B-DISO
of	O
murine	O
coronavirus	O
:	O
analysis	O
by	O
spinoculation	O
.	O

Attachment	O
of	O
S	O
protein	O
on	O
cells	O
without	O
MHVR	O
during	O
the	O
S	O
-	O
protein	O
activation	O
process	O
seems	O
to	O
be	O
a	O
key	O
condition	B-DISO
.	O

In	O
order	O
to	O
make	O
virions	O
attach	O
to	O
the	O
cell	O
surface	O
without	O
MHVR	O
,	O
we	O
have	O
used	O
spinoculation	O
,	O
namely	O
,	O
the	O
centrifugation	O
of	O
cells	O
together	O
with	O
inoculated	O
virus	O
at	O
3	O
,	O
000	O
rpm	O
for	O
2	O
h	O
.	O
This	O
procedure	O
forces	O
viruses	O
to	O
attach	O
to	O
the	O
cell	O
surface	O
,	O
as	O
revealed	O
by	O
quantitative	O
estimation	O
of	O
attached	O
virions	O
by	O
real	O
-	O
time	O
PCR	O
and	O
also	O
facilitated	O
wt	O
JHMV	O
infection	B-DISO
to	O
MHVR	O
-	O
negative	O
cells	O
,	O
but	O
failed	O
to	O
do	O
so	O
for	O
srr7	O
.	O

TITLE	O
:	O
Investigation	O
of	O
avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
)	O
outbreak	O
in	O
humans	O
--	O
Thailand	O
,	O
2004	O
.	O

Leucopenia	B-DISO
and	O
thrombocytopenia	O
were	O
present	O
respectively	O
in	O
nine	O
(	O
100	O
%)	O
and	O
four	O
(	O
44	O
%)	O
persons	O
aged	O
<	O
15	O
years	O
.	O

Avian	B-DISO
influenza	I-DISO
was	O
more	O
severe	O
in	O
children	O
,	O
who	O
should	O
avoid	O
handling	O
dead	O
poultry	O
during	O
epizootics	O
.	O

Enzyme	O
activity	O
from	O
the	O
SARS	B-DISO
CoV	O
main	O
proteinase	O
dimer	O
could	O
readily	O
be	O
detected	O
at	O
low	O
pM	O
concentrations	O
.	O

ABSTRACT	O
:	O
The	O
existence	O
of	O
coronaviruses	O
in	O
bats	O
is	O
unknown	O
until	O
the	O
recent	O
discovery	O
of	O
bat	O
-	O
SARS	B-DISO
-	O
CoV	O
in	O
Chinese	O
horseshoe	O
bats	O
and	O
a	O
novel	O
group	O
1	O
coronavirus	O
in	O
other	O
bat	O
species	O
.	O

Here	O
,	O
we	O
generated	O
coronavirus	O
-	O
like	O
particles	O
carrying	O
in	O
their	O
envelope	O
chimeric	O
HCV	O
glycoproteins	O
composed	O
of	O
the	O
ectodomains	O
of	O
E1	O
and	O
E2	O
,	O
each	O
fused	O
to	O
the	O
transmembrane	O
plus	O
endodomain	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
spike	O
glycoprotein	O
.	O

By	O
comparing	O
the	O
plasma	O
proteins	O
of	O
SARS	B-DISO
patients	O
with	O
those	O
of	O
a	O
normal	O
control	O
group	O
,	O
several	O
proteins	O
with	O
a	O
significant	O
alteration	O
were	O
found	O
.	O

Postal	O
survey	O
comprising	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
HRQoL	O
)	O
questionnaires	O
and	O
anxiety	O
and	O
depression	B-DISO
measures	O
was	O
sent	O
to	O
them	O
at	O
3	O
months	O
'	O
postdischarge	O
.	O

There	O
was	O
a	O
significant	O
impairment	B-DISO
in	O
both	O
the	O
HRQoL	O
and	O
mental	O
functioning	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
has	O
significant	O
impact	O
on	O
HRQoL	O
and	O
psychological	B-DISO
status	O
at	O
3	O
months	O
.	O

TITLE	O
:	O
Nasopharyngeal	O
shedding	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
is	O
associated	O
with	O
genetic	O
polymorphisms	O
.	O

Titers	O
of	O
SARS	B-DISO
-	O
CoV	O
shed	O
in	O
nasopharyngeal	O
specimens	O
varied	O
widely	O
,	O
ranging	O
from	O
nondetectable	O
to	O
10	O
(	O
8	O
)	O
SARS	B-DISO
-	O
CoV	O
RNA	O
copies	O
/	O
mL	O
,	O
and	O
they	O
were	O
correlated	O
positively	O
with	O
a	O
high	O
mortality	O
rate	O
(	O
P	O
<.	O
0001	O
,	O
by	O
trend	O
test	O
)	O
and	O
with	O
early	O
death	O
(	O
i	O
.	O
e	O
.,	O
death	O
occurring	O
within	O
2	O
weeks	O
of	O
the	O
onset	O
of	O
illness	O
)	O
(	O
P	O
=.	O
0015	O
,	O
by	O
trend	O
test	O
).	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronaviruses	O
by	O
antibodies	O
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
spike	O
protein	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
Tor2	O
-	O
RBD	O
induced	O
-	O
Conf	O
I	O
-	O
VI	O
mAbs	O
can	O
potently	O
neutralize	O
both	O
human	O
SARS	B-DISO
-	O
CoV	O
strains	O
,	O
Tor2	O
and	O
GD03	O
.	O

A	O
2	O
,	O
300	O
-	O
bed	B-DISO
medical	O
center	O
in	O
Kaohsiung	O
,	O
Taiwan	O
.	O

A	O
chest	O
physician	O
team	O
reviewed	O
medical	O
charts	O
and	O
chest	O
radiographs	O
and	O
monitored	O
the	O
development	O
of	O
SARS	B-DISO
in	O
patients	O
staying	O
in	O
the	O
ward	O
.	O

Some	O
cases	O
of	O
SARS	B-DISO
were	O
diagnosed	O
after	O
the	O
patients	O
had	O
died	O
.	O

Six	O
HCWs	O
(	O
40	O
%)	O
reused	O
items	O
(	O
eg	O
,	O
stethoscopes	O
,	O
goggles	O
,	O
and	O
cleaning	O
equipment	O
)	O
elsewhere	O
on	O
the	O
ward	O
after	O
initial	O
use	O
in	O
a	O
room	O
in	O
which	O
a	O
patient	O
with	O
SARS	B-DISO
was	O
staying	O
.	O

CONCLUSIONS	O
:	O
Multiple	O
factors	O
were	O
likely	O
responsible	O
for	O
SARS	B-DISO
in	O
these	O
HCWs	O
,	O
including	O
the	O
performance	O
of	O
high	O
-	O
risk	O
patient	O
care	O
procedures	O
,	O
inconsistent	O
use	O
of	O
personal	O
protective	O
equipment	O
,	O
fatigue	B-DISO
,	O
and	O
lack	O
of	O
adequate	O
infection	B-DISO
control	O
training	O
.	O

It	O
has	O
been	O
estimated	O
that	O
upper	O
respiratory	B-DISO
disease	I-DISO
accounts	O
for	O
at	O
least	O
25	O
million	O
absences	O
from	O
work	O
and	O
23	O
million	O
absences	O
of	O
school	O
annually	O
in	O
the	O
United	O
States	O
[	O
Anzueto	O
,	O
A	O
.,	O
Niederman	O
,	O
M	O
.	O
S	O
.,	O
2003	O
.	O

Treatment	O
of	O
picornavirus	B-DISO
infections	I-DISO
.	O

2	O
positive	O
clones	O
that	O
having	O
specific	O
affinity	O
to	O
SARS	B-DISO
sera	O
were	O
obtained	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
effect	O
of	O
corticosteroid	O
treatment	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infection	B-DISO
itself	O
on	O
the	O
marrow	O
conversion	O
in	O
the	O
proximal	O
femoral	O
marrow	O
in	O
the	O
recovered	O
patients	O
of	O
health	O
care	O
workers	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
An	O
epidemic	O
outbreak	O
of	O
respiratory	B-DISO
infection	I-DISO
caused	O
by	O
Chlamydia	O
pneumoniae	O
in	O
medical	O
workers	O
].	O

All	O
patients	O
presented	O
fever	O
,	O
headache	B-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
hoarseness	B-DISO
,	O
muscular	O
ache	B-DISO
,	O
and	O
dry	B-DISO
cough	I-DISO
.	O

Fast	O
peripheral	O
venous	O
blood	O
samples	O
were	O
collected	O
from	O
61	O
post	O
-	O
SARS	B-DISO
patients	O
with	O
osteonecrosis	B-DISO
,	O
25	O
males	O
and	O
36	O
females	O
,	O
aged	O
30	O
.	O
4	O
(	O
20	O
-	O
60	O
),	O
and	O
52	O
sex	O
and	O
age	O
-	O
matched	O
healthy	O
persons	O
as	O
controls	O
.	O

Synthetic	O
controls	O
produced	O
using	O
this	O
approach	O
have	O
been	O
employed	O
in	O
all	O
molecular	O
diagnostic	O
tests	O
performed	O
in	O
our	O
laboratory	O
and	O
are	O
used	O
irrespective	O
of	O
whether	O
we	O
possess	B-DISO
the	O
organism	O
or	O
not	O
.	O

TITLE	O
:	O
A	O
climatologic	O
investigation	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
outbreak	O
in	O
Beijing	O
,	O
China	O
.	O

On	O
January	O
12	O
,	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
&	O
Human	O
Services	O
Secretary	O
Mike	O
Leavitt	O
announced	O
funding	O
to	O
assist	O
in	O
the	O
preparation	O
for	O
a	O
pandemic	O
flu	B-DISO
response	O
.	O

The	O
library	O
seems	O
to	O
be	O
a	O
potent	O
tool	O
for	O
the	O
production	O
of	O
human	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
was	O
relatively	O
mild	O
in	O
children	O
,	O
and	O
the	O
incidence	O
was	O
significantly	O
lower	O
when	O
compared	O
with	O
adults	O
.	O

None	O
of	O
the	O
14	O
children	O
who	O
lived	O
in	O
the	O
high	O
-	O
risk	O
area	O
and	O
had	O
known	O
contacts	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
were	O
seropositive	O
.	O

ABSTRACT	O
:	O
A	O
history	O
of	O
alcohol	B-DISO
abuse	I-DISO
is	O
very	O
common	O
and	O
many	O
times	O
unrecognized	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
adults	O
with	O
septic	B-DISO
shock	I-DISO
,	O
a	O
history	O
of	O
alcohol	B-DISO
abuse	I-DISO
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
the	O
development	O
of	O
more	O
severe	O
organ	O
dysfunction	O
.	O

These	O
data	O
were	O
used	O
in	O
the	O
second	O
phase	O
to	O
construct	O
two	O
sets	O
of	O
clinical	O
vignettes	O
,	O
pertaining	O
to	O
SARS	B-DISO
patient	O
care	O
in	O
both	O
conventional	O
and	O
alternative	O
practice	O
models	O
.	O

Preliminary	O
findings	O
concerning	O
infection	B-DISO
control	O
and	O
nurse	O
satisfaction	O
revealed	O
that	O
the	O
alternative	O
model	O
had	O
an	O
advantage	O
over	O
the	O
conventional	O
.	O

Using	O
a	O
recently	O
constructed	O
integrated	O
severe	B-DISO
sepsis	I-DISO
database	O
,	O
our	O
objectives	O
in	O
this	O
study	O
were	O
to	O
describe	O
the	O
influence	O
of	O
baseline	O
clinical	O
characteristics	O
on	O
timing	O
of	O
DrotAA	O
treatment	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
,	O
to	O
evaluate	O
the	O
efficacy	O
of	O
DrotAA	O
with	O
respect	O
to	O
timing	O
of	O
administration	O
,	O
and	O
to	O
examine	O
the	O
association	O
between	O
early	O
intervention	O
with	O
DrotAA	O
and	O
patient	O
outcomes	O
,	O
using	O
adjustments	O
for	O
imbalances	O
.	O

Using	O
an	O
integrated	O
database	O
of	O
five	O
severe	B-DISO
sepsis	I-DISO
trials	O
and	O
appropriate	O
statistical	O
adjustments	O
to	O
reduce	O
sources	O
of	O
potential	O
bias	O
,	O
earlier	O
treatment	O
with	O
DrotAA	O
seemed	O
to	O
be	O
associated	O
with	O
a	O
lower	O
risk	O
-	O
adjusted	O
mortality	O
than	O
later	O
treatment	O
.	O

TITLE	O
:	O
Biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
mixed	O
membrane	O
topologies	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
envelope	O
protein	O
expressed	O
in	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
secondary	O
to	O
inhalation	O
of	O
chlorine	O
gas	O
in	O
sheep	O
.	O

This	O
process	O
is	O
indispensable	O
in	O
the	O
replication	O
of	O
numerous	O
viral	O
pathogens	O
,	O
including	O
HIV	B-DISO
and	O
the	O
coronavirus	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
and	O
is	O
also	O
exploited	O
in	O
the	O
expression	O
of	O
several	O
cellular	O
genes	O
.	O

A	O
peptide	O
aldehyde	O
library	O
was	O
designed	O
for	O
targeting	O
the	O
SARS	B-DISO
coronavirus	O
main	O
protease	O
,	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)(	O
also	O
known	O
as	O
3CL	O
(	O
pro	O
)),	O
on	O
the	O
basis	O
of	O
three	O
different	O
reported	O
binding	O
modes	O
and	O
supported	O
by	O
virtual	O
screening	O
.	O

An	O
IC	O
(	O
50	O
)	O
of	O
7	O
.	O
5	O
muM	O
was	O
found	O
for	O
AcNSTSQ	O
-	O
H	O
and	O
AcESTLQ	O
-	O
H	O
.	O
Interestingly	O
,	O
the	O
most	O
potent	O
inhibitors	O
seem	O
to	O
bind	O
to	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
in	O
a	O
noncanonical	O
binding	O
mode	O
.	O

This	O
study	O
sheds	O
new	O
light	O
on	O
the	O
immune	O
-	O
evasive	O
nature	O
of	O
FIPV	O
infections	B-DISO
.	O

TITLE	O
:	O
Analysis	O
of	O
ACE2	O
in	O
polarized	O
epithelial	O
cells	O
:	O
surface	O
expression	O
and	O
function	O
as	O
receptor	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

This	O
article	O
reviews	O
the	O
results	O
of	O
the	O
investigations	O
and	O
provides	O
recommendations	O
for	O
maintenance	O
and	O
other	O
measures	O
that	O
building	O
owners	O
can	O
take	O
to	O
help	O
prevent	O
environmental	O
transmission	O
of	O
SARS	B-DISO
and	O
other	O
flulike	O
viruses	O
in	O
their	O
buildings	O
.	O

Uterine	B-DISO
infection	I-DISO
and	O
abortion	O
represent	O
the	O
major	O
complaint	O
in	O
camelid	O
veterinary	O
practice	O
.	O

The	O
major	O
infectious	B-DISO
organisms	O
in	O
endometritis	B-DISO
and	O
metritis	B-DISO
are	O
E	O
.	O
coli	O
and	O
Streptococcus	O
equi	O
subspecies	O
zooepidemicus	O
.	O

Udder	O
infections	B-DISO
are	O
primarily	O
due	O
to	O
Streptococcus	O
agalactiae	O
and	O
Staphylococcus	O
aureus	O
.	O

Neonatal	O
mortality	O
is	O
primarily	O
due	O
to	O
diarrhea	B-DISO
following	O
failure	O
of	O
passive	O
transfer	O
and	O
exposure	O
to	O
E	O
.	O
coli	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
Coccidia	O
and	O
Salmonella	B-DISO
.	O

Our	O
results	O
provide	O
a	O
structural	O
framework	O
for	O
understanding	O
the	O
control	O
of	O
membrane	O
fusion	O
and	O
should	O
guide	O
efforts	O
to	O
intervene	O
in	O
the	O
SARS	B-DISO
coronavirus	O
entry	O
process	O
.	O

For	O
the	O
diagnosis	O
of	O
SARS	B-DISO
virus	B-DISO
infection	I-DISO
,	O
an	O
epidemiological	O
investigation	O
is	O
necessary	O
to	O
know	O
whether	O
the	O
patient	O
has	O
been	O
exposed	O
to	O
a	O
risk	O
in	O
a	O
country	O
where	O
the	O
SARS	B-DISO
virus	O
is	O
circulating	O
or	O
whether	O
the	O
patient	O
had	O
worked	O
in	O
a	O
laboratory	O
handling	O
SARS	B-DISO
virus	O
.	O

TITLE	O
:	O
Coronavirus	O
HKU1	O
infection	B-DISO
in	O
the	O
United	O
States	O
.	O

There	O
have	O
been	O
occasional	O
reports	O
of	O
OP	O
occurring	O
in	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
.	O

Three	O
patients	O
ultimately	O
died	O
from	O
complications	O
of	O
their	O
underlying	O
hematologic	B-DISO
disorder	I-DISO
and	O
1	O
patient	O
died	O
of	O
unknown	O
causes	O
.	O

Antitumor	O
response	O
was	O
seen	O
in	O
5	O
out	O
of	O
15	O
evaluable	B-DISO
patients	O
(	O
one	O
with	O
a	O
complete	O
response	O
,	O
two	O
with	O
partial	O
responses	O
,	O
two	O
with	O
stable	O
disease	O
)	O
at	O
dose	O
levels	O
of	O
>	O
or	O
=	O
100	O
microg	O
.	O

Similar	O
changes	O
have	O
been	O
documented	O
in	O
diabetes	B-DISO
,	O
sepsis	B-DISO
,	O
children	O
with	O
vasculitis	B-DISO
,	O
allograft	O
rejection	O
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
patients	O
with	O
recurrent	O
pregnancy	O
losses	O
,	O
hereditary	B-DISO
angioedema	I-DISO
,	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
.	O

Direct	O
involvement	O
of	O
the	O
KKS	O
in	O
the	O
pathogenesis	B-DISO
of	O
experimental	O
acute	B-DISO
arthritis	I-DISO
and	O
acute	O
and	O
chronic	B-DISO
enterocolitis	I-DISO
has	O
been	O
documented	O
by	O
previous	O
studies	O
from	O
our	O
laboratory	O
using	O
experimental	O
animal	O
models	O
.	O

In	O
summary	O
,	O
these	O
results	O
indicate	O
that	O
the	O
plasma	O
KKS	O
plays	O
a	O
central	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
chronic	O
intestinal	O
inflammation	B-DISO
,	O
arthritis	B-DISO
and	O
angiogenesis	O
.	O

Such	O
systems	O
focus	O
on	O
detecting	O
clusters	O
of	O
syndromes	B-DISO
in	O
excess	O
of	O
baseline	O
levels	O
,	O
which	O
may	O
indicate	O
an	O
outbreak	O
.	O

In	O
addition	O
,	O
CoV	O
infection	B-DISO
may	O
cause	O
inflammation	B-DISO
,	O
alter	O
immune	O
and	O
stress	O
responses	O
,	O
and	O
modify	O
the	O
coagulation	O
pathways	O
.	O

The	O
outcome	O
measures	O
were	O
parental	O
report	O
of	O
child	O
'	O
s	O
awareness	O
of	O
parental	O
HIV	B-DISO
status	O
,	O
how	O
others	O
reacted	O
to	O
child	O
'	O
s	O
parent	O
having	O
HIV	B-DISO
,	O
and	O
reasons	O
for	O
nondisclosure	O
.	O

Parents	O
reported	O
that	O
11	O
%	O
of	O
children	O
worried	O
they	O
could	O
catch	B-DISO
HIV	B-DISO
from	O
their	O
parent	O
.	O

TITLE	O
:	O
Thin	O
-	O
Section	O
CT	O
12	O
Months	O
After	O
the	O
Diagnosis	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
in	O
Pediatric	O
Patients	O
.	O

The	O
objective	O
of	O
our	O
study	O
was	O
to	O
report	O
the	O
thin	O
-	O
section	O
CT	O
findings	O
12	O
months	O
after	O
the	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
pediatric	O
patients	O
who	O
had	O
recovered	O
clinically	O
but	O
had	O
persistent	O
abnormal	O
CT	O
findings	O
6	O
months	O
after	O
the	O
diagnosis	O
.	O

None	O
of	O
our	O
patients	O
showed	O
any	O
evidence	O
of	O
bronchiectasis	B-DISO
or	O
bronchial	B-DISO
wall	I-DISO
thickening	I-DISO
.	O

We	O
found	O
that	O
32	O
%	O
of	O
the	O
children	O
(	O
15	O
/	O
47	O
)	O
affected	O
with	O
SARS	B-DISO
showed	O
thin	O
-	O
section	O
CT	O
abnormalities	O
up	O
to	O
12	O
months	O
after	O
diagnosis	O
despite	O
clinical	O
remission	B-DISO
and	O
unremarkable	O
pulmonary	O
function	O
assessment	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
that	O
32	O
%	O
of	O
the	O
children	O
(	O
15	O
/	O
47	O
)	O
affected	O
with	O
SARS	B-DISO
showed	O
thin	O
-	O
section	O
CT	O
abnormalities	O
up	O
to	O
12	O
months	O
after	O
diagnosis	O
despite	O
clinical	O
remission	B-DISO
and	O
unremarkable	O
pulmonary	O
function	O
assessment	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
vaccine	O
based	O
on	O
a	O
nonhuman	O
primate	O
adenovirus	B-DISO
in	O
the	O
presence	O
of	O
immunity	O
against	O
human	O
adenovirus	B-DISO
.	O

ABSTRACT	O
:	O
Replication	O
-	O
deficient	O
human	O
adenovirus	B-DISO
type	O
5	O
(	O
AdH5	O
)	O
vectors	O
can	O
induce	O
strong	O
transgene	O
product	O
-	O
specific	O
cellular	O
and	O
humoral	O
responses	O
.	O

However	O
,	O
many	O
adult	O
humans	O
have	O
neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
AdH5	O
as	O
a	O
result	O
of	O
natural	O
infection	B-DISO
with	O
this	O
virus	O
.	O

Efficacy	O
was	O
assessed	O
after	O
intramuscular	O
injection	O
of	O
the	O
vector	O
into	O
mice	O
and	O
was	O
measured	O
as	O
the	O
frequency	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
T	O
cells	O
and	O
NAbs	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
Immunogenicity	O
of	O
the	O
AdH5	O
-	O
based	O
vaccine	O
was	O
significantly	O
attenuated	O
or	O
completely	O
abolished	O
when	O
the	O
preexisting	O
anti	O
-	O
AdH5	O
NAb	O
titer	O
was	O
higher	O
than	O
40	O
.	O

TITLE	O
:	O
Genetic	O
variability	O
of	O
human	O
coronavirus	O
OC43	O
-,	O
229E	O
-,	O
and	O
NL63	O
-	O
like	O
strains	O
and	O
their	O
association	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
of	O
hospitalized	O
infants	O
and	O
immunocompromised	O
patients	O
.	O

ABSTRACT	O
:	O
In	O
the	O
winter	O
-	O
spring	O
seasons	O
2003	O
-	O
2004	O
and	O
2004	O
-	O
2005	O
,	O
47	O
(	O
5	O
.	O
7	O
%)	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
associated	O
with	O
human	O
coronavirus	O
(	O
hCoV	O
)	O
229E	O
-,	O
NL63	O
-,	O
and	O
OC43	O
-	O
like	O
strains	O
were	O
identified	O
among	O
823	O
(	O
597	O
immunocompetent	O
and	O
226	O
immunocompromised	O
)	O
patients	O
admitted	O
to	O
hospital	O
with	O
acute	O
respiratory	O
syndromes	B-DISO
.	O

TITLE	O
:	O
Inhibition	O
of	O
human	O
coronavirus	O
NL63	O
infection	B-DISO
at	O
early	O
stages	O
of	O
the	O
replication	O
cycle	O
.	O

Intravenous	O
immunoglobulins	O
,	O
heptad	O
repeat	O
2	O
peptide	O
,	O
small	O
interfering	O
RNA1	O
(	O
siRNA1	O
),	O
siRNA2	O
,	O
beta	O
-	O
D	O
-	O
N	O
(	O
4	O
)-	O
hydroxycytidine	O
,	O
and	O
6	O
-	O
azauridine	O
showed	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
125	O
microg	O
/	O
ml	O
,	O
2	O
microM	O
,	O
5	O
nM	O
,	O
3	O
nM	O
,	O
400	O
nM	O
,	O
and	O
32	O
nM	O
,	O
respectively	O
,	O
and	O
low	O
50	O
%	O
cytotoxicity	B-DISO
concentrations	O
(>	O
10	O
mg	O
/	O
ml	O
,	O
>	O
40	O
microM	O
,	O
>	O
200	O
nM	O
,	O
>	O
200	O
nM	O
,	O
>	O
100	O
microM	O
,	O
and	O
80	O
microM	O
,	O
respectively	O
).	O

These	O
agents	O
may	O
be	O
investigated	O
further	O
for	O
the	O
treatment	O
of	O
coronavirus	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
considered	O
as	O
a	O
major	O
antigen	O
for	O
vaccine	O
design	O
.	O

Here	O
,	O
we	O
further	O
characterized	O
the	O
antigenic	O
structure	O
in	O
the	O
RBD	O
by	O
a	O
panel	O
of	O
novel	O
mAbs	O
isolated	O
from	O
the	O
mice	O
immunized	O
with	O
an	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
.	O

ABSTRACT	O
:	O
Tuberculosis	B-DISO
miliar	O
is	O
a	O
very	O
rare	O
complication	B-DISO
of	O
bacillus	O
Calmette	O
-	O
Guérin	O
(	O
BCG	O
)	O
immunotherapy	O
that	O
is	O
associated	O
to	O
high	O
mortality	O
.	O

A	O
case	O
of	O
a	O
75	O
year	O
old	O
patient	O
with	O
intravesical	O
BCG	O
instillations	O
after	O
a	O
transurethral	O
resection	O
of	O
bladder	B-DISO
cancer	I-DISO
is	O
presented	O
.	O

To	O
achieve	O
a	O
PRV	B-DISO
genome	O
-	O
based	O
virus	O
live	O
vector	O
,	O
aiming	O
at	O
further	O
TGEV	O
/	O
PRV	B-DISO
bivalent	O
vaccine	O
development	O
,	O
a	O
recombinant	O
plasmid	O
pUG	O
was	O
constructed	O
via	O
inserting	O
partial	O
PK	O
and	O
full	O
-	O
length	O
gG	O
genes	O
of	O
PRV	B-DISO
strain	O
Bartha	O
K	O
-	O
61	O
amplified	O
into	O
pUC119	O
vector	O
.	O

In	O
parallel	O
,	O
another	O
recombinant	O
pHS	B-DISO
was	O
generated	O
by	O
introducing	O
a	O
fragment	O
designated	O
S1	O
encoding	O
the	O
major	O
antigen	O
sites	O
of	O
S	O
gene	O
from	O
TGEV	O
strain	O
TH	O
-	O
98	O
into	O
a	O
prokaryotic	O
expression	O
vector	O
pP	O
(	O
RO	O
)	O
EX	O
HTc	O
.	O

These	O
data	O
provide	O
important	O
information	O
for	O
understanding	O
the	O
antigenicity	O
and	O
immunogenicity	O
of	O
S	O
protein	O
and	O
for	O
designing	O
SARS	B-DISO
vaccines	O
.	O

This	O
panel	O
of	O
anti	O
-	O
S	O
MAbs	O
can	O
be	O
used	O
as	O
tools	O
for	O
studying	O
the	O
structure	O
and	O
function	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
.	O

Confocal	O
immunofluorescence	O
microscopy	O
demonstrated	O
the	O
colocalization	O
,	O
throughout	O
infection	B-DISO
,	O
of	O
replicase	O
cleavage	O
products	O
containing	O
different	O
key	O
enzymes	O
for	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

The	O
periphery	O
T	O
lymphocyte	O
subsets	O
in	O
SARS	B-DISO
infection	B-DISO
shows	O
transient	O
decrease	O
and	O
then	O
rapid	O
recovery	O
.	O

The	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
),	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
localizes	O
to	O
the	O
cytoplasm	O
and	O
the	O
nucleolus	O
.	O

TITLE	O
:	O
Complex	O
extra	O
-	O
intestinal	O
complications	O
of	O
ulcerative	B-DISO
colitis	I-DISO
in	O
a	O
patient	O
with	O
alpha1	O
-	O
antitrypsin	O
deficiency	O
.	O

An	O
aetiologic	O
role	O
of	O
alpha1	O
-	O
antitrypsin	O
deficiency	O
in	O
chronic	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
has	O
recently	O
been	O
suggested	O
.	O

On	O
the	O
basis	O
of	O
alpha1	O
-	O
antitrypsin	O
deficiency	O
and	O
UC	O
,	O
the	O
present	O
patient	O
likely	O
developed	O
severe	O
systemic	O
vasculitis	B-DISO
with	O
multi	O
-	O
organ	O
involvement	O
.	O

The	O
US	O
and	O
CT	O
scan	O
showed	O
a	O
dilated	B-DISO
stomach	I-DISO
,	O
extended	O
into	O
the	O
pelvis	O
,	O
dislocating	O
the	O
intestinal	O
organs	O
and	O
compressed	O
the	O
aorta	O
and	O
mesenteric	O
veins	O
.	O

During	O
the	O
operation	O
,	O
the	O
cardio	O
-	O
respiratory	O
status	O
was	O
stabilized	O
,	O
but	O
in	O
the	O
following	O
24	O
hours	O
irreversible	B-DISO
shock	I-DISO
developed	O
,	O
possibly	O
due	O
to	O
the	O
reperfusion	O
of	O
the	O
retroperitoneal	O
organs	O
and	O
the	O
lower	O
extremities	O
.	O

In	O
an	O
uncontrollable	O
state	O
of	O
diffuse	B-DISO
bleeding	I-DISO
,	O
36	O
hours	O
post	O
-	O
operation	O
,	O
the	O
patient	O
died	O
.	O

Acute	O
gastric	B-DISO
dilatation	I-DISO
is	O
very	O
uncommon	O
and	O
is	O
of	O
various	O
etiologies	O
,	O
two	O
of	O
these	O
being	O
anorexia	B-DISO
nervosa	I-DISO
and	O
bulimia	B-DISO
.	O

TITLE	O
:	O
The	O
placentas	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
pathophysiological	O
evaluation	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
massive	O
doses	O
of	O
corticosteroid	O
therapy	O
on	O
bone	O
metabolism	O
using	O
specific	O
biochemical	O
markers	O
of	O
bone	O
metabolism	O
,	O
and	O
the	O
prevalence	O
of	O
osteonecrosis	B-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
at	O
a	O
university	O
teaching	O
hospital	O
in	O
Hong	O
Kong	O
.	O

Seventy	O
-	O
one	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
were	O
studied	O
according	O
to	O
the	O
modified	O
World	O
Health	O
Organization	O
case	O
definition	O
of	O
SARS	B-DISO
who	O
were	O
involved	O
in	O
the	O
SARS	B-DISO
epidemic	O
between	O
10	O
March	O
and	O
20	O
June	O
2003	O
.	O

The	O
Day	O
28	O
-	O
44	O
increase	O
in	O
the	O
serum	O
CTx	B-DISO
coincided	O
with	O
the	O
timing	O
of	O
corticosteroid	O
use	O
.	O

TITLE	O
:	O
Reciprocal	O
antibody	O
and	O
complement	O
responses	O
of	O
two	O
chicken	O
breeds	O
to	O
vaccine	O
strains	O
of	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Serum	O
antibody	O
responses	O
and	O
haemolytic	O
complement	O
activity	O
were	O
evaluated	O
in	O
White	O
Leghorn	O
(	O
WLH	O
)	O
and	O
Rhode	O
Island	O
Red	O
(	O
RIR	O
)	O
chickens	O
that	O
were	O
vaccinated	O
with	O
live	O
-	O
attenuated	O
vaccines	O
of	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
or	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
or	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
by	O
means	O
of	O
ocular	O
challenge	O
at	O
10	O
times	O
the	O
normal	O
vaccination	O
dose	O
.	O

The	O
lentogenic	O
viral	B-DISO
infection	I-DISO
resulted	O
in	O
an	O
immediate	O
stimulation	O
of	O
complement	O
activity	O
,	O
followed	O
by	O
a	O
decrease	O
to	O
initial	O
complement	O
levels	O
within	O
2	O
weeks	O
post	O
vaccination	O
,	O
when	O
the	O
antibody	O
response	O
took	O
over	O
immune	O
defence	O
.	O

TITLE	O
:	O
A	O
patient	O
with	O
asymptomatic	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
antigenemia	O
from	O
the	O
2003	O
-	O
2004	O
community	O
outbreak	O
of	O
SARS	B-DISO
in	O
Guangzhou	O
,	O
China	O
.	O

ABSTRACT	O
:	O
An	O
asymptomatic	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occurred	O
early	O
in	O
2004	O
,	O
during	O
a	O
community	O
outbreak	O
of	O
SARS	B-DISO
in	O
Guangzhou	O
,	O
China	O
.	O

Epidemiological	O
information	O
and	O
laboratory	O
findings	O
suggested	O
that	O
the	O
findings	O
for	O
the	O
patient	O
with	O
asymptomatic	B-DISO
infection	I-DISO
,	O
together	O
with	O
the	O
findings	O
from	O
previously	O
reported	O
serological	O
analyses	O
of	O
handlers	O
of	O
wild	O
animals	O
and	O
the	O
4	O
index	O
case	O
patients	O
from	O
the	O
2004	O
community	O
outbreak	O
,	O
reflected	O
a	O
likely	O
intermediate	O
phase	O
of	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
of	O
infection	B-DISO
,	O
rather	O
than	O
a	O
case	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

We	O
aimed	O
to	O
study	O
the	O
incidence	O
and	O
clinical	O
characteristics	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
due	O
to	O
respiratory	O
viruses	O
in	O
adults	O
adding	O
PCR	O
to	O
routine	O
conventional	O
laboratory	O
tests	O
.	O

PCR	O
revealed	O
that	O
viruses	O
represent	O
a	O
common	O
aetiology	O
of	O
CAP	B-DISO
.	O

CONCLUSIONS	O
:	O
PCR	O
revealed	O
that	O
viruses	O
represent	O
a	O
common	O
aetiology	O
of	O
CAP	B-DISO
.	O

A	O
known	O
history	O
of	O
diabetes	B-DISO
and	O
ambient	O
hyperglycaemia	B-DISO
were	O
independent	O
predictors	O
for	O
death	O
and	O
morbidity	O
in	O
SARS	B-DISO
patients	O
.	O

Survival	O
analysis	O
showed	O
that	O
FPG	O
was	O
independently	O
associated	O
with	O
an	O
increased	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
mortality	O
(	O
HR	O
=	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
,	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
hypoxia	B-DISO
(	O
HR	O
=	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
,	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
after	O
controlling	O
for	O
age	O
and	O
gender	O
.	O

Since	O
then	O
,	O
several	O
animal	O
models	O
have	O
been	O
developed	O
for	O
the	O
study	O
of	O
SARS	B-DISO
and	O
,	O
although	O
no	O
model	O
replicates	O
the	O
human	O
disease	O
in	O
all	O
aspects	O
,	O
the	O
use	O
of	O
animal	O
models	O
for	O
SARS	B-DISO
has	O
led	O
to	O
the	O
establishment	O
of	O
several	O
important	O
principles	O
for	O
vaccine	O
and	O
immunotherapy	O
.	O

In	O
this	O
study	O
,	O
the	O
interaction	O
of	O
SARS	B-DISO
-	O
CoV	O
with	O
dendritic	O
cells	O
(	O
DCs	B-DISO
),	O
the	O
key	O
regulators	O
of	O
immune	O
responses	O
,	O
was	O
analysed	O
.	O

Total	O
RNA	O
was	O
harvested	O
from	O
MHV	O
-	O
or	O
mock	O
-	O
infected	O
L	O
cells	O
at	O
3	O
,	O
5	O
and	O
6	O
h	O
post	O
-	O
infection	B-DISO
and	O
hybridized	O
to	O
Affymetrix	O
microarrays	O
representing	O
approximately	O
12	O
,	O
500	O
murine	O
genes	O
and	O
expressed	O
sequences	O
.	O

Blood	O
samples	O
were	O
tested	O
for	O
total	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
by	O
immunofluorescence	O
antibody	O
test	O
.	O

Subclinical	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
was	O
rare	O
in	O
a	O
residential	O
care	O
home	O
for	O
the	O
elderly	O
with	O
an	O
outbreak	O
of	O
SARS	B-DISO
.	O

Data	O
was	O
collected	O
prospectively	O
through	O
an	O
ongoing	O
emergency	B-DISO
airway	O
registry	O
.	O

The	O
complication	B-DISO
rates	O
were	O
10	O
.	O
5	O
%,	O
9	O
.	O
9	O
%	O
and	O
9	O
.	O
4	O
%	O
in	O
periods	O
1	O
-	O
3	O
,	O
respectively	O
.	O

We	O
surveyed	O
their	O
ED	O
facilities	O
and	O
procedures	O
for	O
managing	O
patients	O
with	O
infectious	B-DISO
diseases	I-DISO
.	O

EDs	B-DISO
in	O
the	O
UK	O
are	O
not	O
prepared	O
for	O
emerging	O
biological	O
threats	O
and	O
bioterrorism	O
.	O

TITLE	O
:	O
Biophysical	O
characterization	O
of	O
HRC	O
peptide	O
analogs	O
interaction	O
with	O
heptad	O
repeat	O
regions	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
Spike	O
fusion	O
protein	O
core	O
.	O

Findings	O
showed	O
that	O
public	O
stigma	O
was	O
the	O
highest	O
towards	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
,	O
followed	O
by	O
TB	O
and	O
SARS	B-DISO
.	O

Clinical	O
diagnosis	O
comprises	O
severe	O
hypoxemia	O
assessed	O
by	O
arterial	O
oxygen	O
tension	B-DISO
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
of	O
less	O
than	O
200	O
and	O
bilateral	O
infiltrate	B-DISO
on	O
a	O
chest	O
radiograph	O
in	O
the	O
absence	O
of	O
left	O
atrial	O
hypertension	B-DISO
.	O

Except	O
for	O
presence	O
of	O
bilateral	O
infiltrate	B-DISO
on	O
chest	O
radiograph	O
and	O
severe	O
hypoxemia	O
on	O
arterial	O
blood	O
gas	O
,	O
most	O
diagnostic	O
studies	O
are	O
used	O
to	O
exclude	O
mimics	O
of	O
ARDS	B-DISO
and	O
potentially	O
modify	O
treatment	O
.	O

Measurements	O
of	O
alveolar	O
dead	O
space	O
ventilation	O
fraction	O
can	O
be	O
helpful	O
in	O
determining	O
the	O
prognosis	O
in	O
individuals	O
with	O
ARDS	B-DISO
.	O

Most	O
common	O
complications	O
of	O
these	O
procedures	O
include	O
transient	O
hypoxemia	O
,	O
respiratory	B-DISO
acidosis	I-DISO
,	O
and	O
pneumothorax	B-DISO
with	O
occasional	O
persistent	B-DISO
air	I-DISO
leak	I-DISO
.	O

Subjects	O
with	O
cognitive	B-DISO
impairment	I-DISO
had	O
no	O
detectable	O
difference	O
in	O
the	O
physical	O
function	O
domains	O
of	O
the	O
Short	O
Form	O
36	O
.	O

When	O
administered	O
to	O
the	O
validation	O
population	O
,	O
telephone	O
tests	O
of	O
memory	O
,	O
attention	O
,	O
reasoning	O
,	O
and	O
executive	O
functions	O
had	O
good	O
intraclass	O
correlation	O
with	O
the	O
in	O
-	O
face	B-DISO
interviews	O
(	O
P	O
<	O
.	O
01	O
).	O

These	O
observations	O
imply	O
the	O
possible	O
involvement	O
of	O
lung	O
stem	O
/	O
progenitor	O
cells	O
,	O
in	O
addition	O
to	O
pneumocytes	O
,	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
,	O
accounting	O
for	O
the	O
continued	O
deterioration	O
of	O
lung	O
tissues	O
and	O
apparent	O
loss	O
of	O
capacity	O
for	O
lung	O
repair	O
.	O

TITLE	O
:	O
Novel	O
mfgl2	O
antisense	O
plasmid	O
inhibits	O
murine	O
fgl2	O
expression	O
and	O
ameliorates	O
murine	B-DISO
hepatitis	I-DISO
virus	O
type	O
3	O
-	O
induced	O
fulminant	B-DISO
hepatitis	I-DISO
in	O
BALB	O
/	O
cJ	O
mice	O
.	O

This	O
hypothesis	O
was	O
also	O
supported	O
by	O
the	O
low	O
levels	O
of	O
IFN	O
-	O
gamma	O
recorded	O
in	O
blood	O
from	O
cats	O
with	O
FIP	B-DISO
.	O

Among	O
the	O
401	O
SARS	B-DISO
patients	O
studied	O
,	O
147	O
of	O
249	O
noncritical	O
patients	O
(	O
59	O
.	O
0	O
%)	O
received	O
corticosteroids	O
(	O
mean	O
daily	O
dose	O
,	O
105	O
.	O
3	O
+/-	O

With	O
the	O
case	O
-	O
control	O
study	O
,	O
a	O
standardized	O
questionnaire	O
was	O
used	O
for	O
data	O
collection	O
in	O
three	O
general	O
hospitals	O
where	O
nosocomial	B-DISO
infection	I-DISO
had	O
occurred	O
.	O

All	O
concerned	O
factors	O
about	O
SARS	B-DISO
infection	B-DISO
were	O
scanned	O
by	O
using	O
Chi	O
-	O
square	O
test	O
and	O
Fisher	O
'	O
s	O
exact	O
test	O
one	O
by	O
one	O
,	O
and	O
determined	O
as	O
to	O
whether	O
they	O
were	O
risk	O
factors	O
or	O
protective	O
factors	O
according	O
to	O
odd	O
ratio	O
(	O
OR	O
)	O
score	O
.	O

In	O
children	O
and	O
adults	O
who	O
closely	O
contacted	O
with	O
these	O
clinically	O
diagnosed	O
SARS	B-DISO
adult	O
patients	O
,	O
the	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
0	O
to	O
9	O
.	O
7	O
%	O
and	O
4	O
.	O
4	O
%	O
to	O
7	O
.	O
1	O
%,	O
respectively	O
.	O

TITLE	O
:	O
Amino	O
acids	O
15	O
-	O
28	O
in	O
the	O
ectodomain	O
of	O
SARS	B-DISO
coronavirus	O
3a	O
protein	O
induces	O
neutralizing	O
antibodies	O
.	O

Thus	O
,	O
our	O
study	O
provides	O
the	O
evidence	O
that	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
humans	O
can	O
induce	O
cellular	O
immune	O
response	O
that	O
is	O
persistent	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
ARDS	B-DISO
dog	O
model	O
was	O
replicated	O
by	O
intratracheal	O
instillation	O
of	O
hydrochloric	O
acid	O
,	O
and	O
mechanical	O
ventilation	O
was	O
carried	O
out	O
according	O
to	O
the	O
following	O
ventilatory	O
protocols	O
.	O

Histopathological	O
changes	O
were	O
observed	O
under	O
light	O
microscope	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
scores	O
was	O
estimated	O
,	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMN	O
)	O
count	O
was	O
done	O
.	O

ABSTRACT	O
:	O
The	O
mortality	O
rate	O
of	O
severe	B-DISO
sepsis	I-DISO
is	O
still	O
high	O
(	O
20	O
to	O
65	O
%)	O
despite	O
the	O
advances	O
in	O
critical	O
care	O
.	O

The	O
current	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
suggests	O
that	O
the	O
degree	O
of	O
inflammatory	B-DISO
response	I-DISO
and	O
its	O
sustained	O
leukocyte	O
activation	O
may	O
determine	O
the	O
clinical	O
evolution	O
of	O
ARDS	B-DISO
.	O

Cardiac	O
output	O
was	O
continuously	O
deteriorating	O
during	O
the	O
recruitment	B-DISO
manoeuvre	O
in	O
both	O
study	O
groups	O
(	O
HFOV	O
:	O
T	O
(	O
Ali	O
):	O
6	O
.	O
1	O
+/-	O

The	O
results	O
demonstrated	O
that	O
(	O
1	O
)	O
a	O
single	O
dose	O
of	O
RBD	O
-	O
rAAV	O
vaccination	O
could	O
induce	O
sufficient	O
neutralizing	O
antibody	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
;	O
(	O
2	O
)	O
two	O
more	O
repeated	O
doses	O
of	O
the	O
vaccination	O
boosted	O
the	O
neutralizing	O
antibody	O
to	O
about	O
5	O
times	O
of	O
the	O
level	O
achieved	O
by	O
a	O
single	O
dose	O
of	O
the	O
immunization	O
and	O
(	O
3	O
)	O
the	O
level	O
of	O
the	O
antibody	O
continued	O
to	O
increase	O
for	O
the	O
entire	O
duration	O
of	O
the	O
experiment	O
of	O
5	O
.	O
5	O
months	O
.	O

TITLE	O
:	O
Generality	O
of	O
the	O
final	O
size	O
formula	O
for	O
an	O
epidemic	O
of	O
a	O
newly	O
invading	O
infectious	B-DISO
disease	I-DISO
.	O

We	O
generated	O
in	O
vitro	O
SARS	B-DISO
-	O
CoV	O
variants	O
escaping	O
neutralization	O
by	O
CR3014	O
,	O
which	O
all	O
had	O
a	O
single	O
P462L	O
mutation	O
in	O
the	O
glycoprotein	O
spike	O
(	O
S	O
)	O
of	O
the	O
escape	O
virus	O
.	O

A	O
novel	O
mAb	O
,	O
CR3022	O
,	O
was	O
identified	O
that	O
neutralized	O
CR3014	O
escape	O
viruses	O
,	O
did	O
not	O
compete	O
with	O
CR3014	O
for	O
binding	O
to	O
recombinant	O
S1	O
fragments	O
,	O
and	O
bound	O
to	O
S1	O
fragments	O
derived	O
from	O
the	O
civet	O
cat	O
SARS	B-DISO
-	O
CoV	O
-	O
like	O
strain	O
SZ3	O
.	O

The	O
mixture	O
of	O
both	O
mAbs	O
showed	O
neutralization	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
a	O
synergistic	O
fashion	O
by	O
recognizing	O
different	O
epitopes	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
.	O

Initial	O
neutrophil	O
count	O
,	O
CRP	O
and	O
LDH	O
levels	O
are	O
important	O
predictors	O
of	O
mortality	O
from	O
SARS	B-DISO
.	O

Despite	O
its	O
highly	O
sensitive	O
and	O
specific	O
algorithm	O
,	O
it	O
did	O
incorrectly	O
deny	O
authorization	O
to	O
a	O
very	O
small	O
number	O
of	O
patients	O
without	O
SARS	B-DISO
.	O

The	O
estimated	O
mean	O
incubation	O
period	O
was	O
5	O
.	O
3	O
days	O
(	O
95	O
%	O
CI	O
4	O
.	O
2	O
-	O
6	O
.	O
8	O
days	O
),	O
mean	O
time	O
to	O
hospitalisation	O
was	O
3	O
.	O
5	O
days	O
(	O
95	O
%	O
CI	O
2	O
.	O
8	O
-	O
3	O
.	O
6	O
days	O
),	O
mean	O
time	O
from	O
symptom	B-DISO
onset	O
to	O
recovery	O
was	O
26	O
days	O
(	O
95	O
%	O
CI	O
25	O
-	O
27	O
days	O
)	O
and	O
mean	O
time	O
from	O
symptom	B-DISO
onset	O
to	O
death	O
was	O
21	O
days	O
(	O
95	O
%	O
CI	O
16	O
-	O
26	O
days	O
).	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
development	O
of	O
diagnostics	O
and	O
antivirals	O
.	O

TITLE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
):	O
paradox	O
or	O
paradigm	O
?	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
remains	O
a	O
devastating	O
condition	B-DISO
with	O
a	O
high	O
mortality	O
.	O

Vascular	O
endothelial	O
cell	O
growth	O
factor	O
(	O
VEGF	O
)	O
was	O
identified	O
by	O
its	O
properties	O
to	O
increase	O
permeability	O
and	O
act	O
as	O
a	O
cellular	O
growth	O
factor	O
,	O
hence	O
its	O
potential	O
for	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
a	O
naval	O
diver	O
.	O

Problems	O
in	O
the	O
late	O
recovery	O
period	O
include	O
increased	O
risk	O
of	O
diving	O
complications	O
(	O
such	O
as	O
pulmonary	O
barotrauma	O
)	O
resulting	O
from	O
fibrosis	B-DISO
and	O
scarring	B-DISO
within	O
the	O
lung	O
parenchyma	O
,	O
which	O
are	O
known	O
complications	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
the	O
establishment	O
of	O
cells	O
with	O
persistent	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
after	O
apoptotic	O
events	O
and	O
showed	O
that	O
both	O
JNK	O
and	O
PI3K	O
/	O
Akt	O
signaling	O
pathways	O
are	O
important	O
for	O
persistence	O
by	O
treatment	O
with	O
inhibitors	O
at	O
the	O
early	O
stages	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Among	O
the	O
signaling	O
pathways	O
in	O
persistently	O
infected	O
cells	O
,	O
Akt	O
and	O
JNK	O
were	O
phosphorylated	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
-	O
expressing	O
Vero	O
E6	O
cells	O
using	O
vaccinia	B-DISO
viral	O
vector	O
(	O
DIs	O
),	O
strongly	O
suggesting	O
that	O
N	O
protein	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
and	O
JNK	O
are	O
necessary	O
to	O
establish	O
persistence	O
.	O

Using	O
another	O
set	O
of	O
isogenic	O
recombinant	O
viruses	O
with	O
JHM	O
background	O
genes	O
expressing	O
either	O
the	O
JHM	O
or	O
A59	O
spike	O
,	O
we	O
have	O
further	O
investigated	O
the	O
roles	O
of	O
viral	O
genes	O
in	O
pathogenesis	B-DISO
.	O

While	O
expression	O
of	O
the	O
JHM	O
spike	O
is	O
sufficient	O
to	O
confer	O
a	O
neurovirulent	O
phenotype	O
,	O
as	O
well	O
as	O
increased	O
macrophage	O
infiltration	B-DISO
,	O
background	O
genes	O
contribute	O
to	O
virulence	O
as	O
well	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
dictating	O
the	O
extent	O
of	O
the	O
T	O
-	O
cell	O
immune	O
response	O
.	O

TITLE	O
:	O
[	O
Establishment	O
of	O
molecular	O
differential	O
diagnostic	O
(	O
MDD	B-DISO
)	O
technology	O
for	O
detection	O
of	O
common	O
respiratory	O
viruses	O
].	O

All	O
the	O
specimens	O
were	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
and	O
reovirus	O
by	O
RT	O
-	O
PCR	O
,	O
but	O
the	O
fecal	O
specimens	O
from	O
4	O
persons	O
were	O
positive	O
for	O
poliovirus	O
.	O

The	O
positive	O
rate	O
of	O
the	O
poliovirus	O
antibody	O
in	O
the	O
serum	O
of	O
SARS	B-DISO
patients	O
2	O
years	O
after	O
recovery	O
was	O
significantly	O
different	O
from	O
that	O
of	O
the	O
normal	O
controls	O
,	O
and	O
the	O
positive	O
rate	O
of	O
poliovirus	O
in	O
the	O
fecal	O
specimens	O
was	O
still	O
very	O
high	O
,	O
and	O
more	O
importantly	O
back	O
mutations	O
have	O
occurred	O
in	O
the	O
attenuating	O
mutation	O
sites	O
at	O
nucleotide	O
position	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
poliomyelitis	B-DISO
.	O

Aggressive	B-DISO
diagnosis	O
and	O
intensive	O
treatment	O
are	O
essential	O
to	O
good	O
outcomes	O
in	O
ARDS	B-DISO
caused	O
by	O
infection	B-DISO
.	O

The	O
prognosis	O
for	O
survival	O
is	O
good	O
,	O
but	O
morbidity	O
after	O
the	O
syndrome	B-DISO
is	O
a	O
major	O
burden	O
.	O

Now	O
that	O
the	O
SARS	B-DISO
epidemic	O
has	O
ended	O
,	O
the	O
primary	O
function	O
of	O
the	O
SARS	B-DISO
Grid	O
project	O
is	O
that	O
of	O
a	O
web	B-DISO
-	O
based	O
informatics	O
tool	O
to	O
increase	O
pubic	O
awareness	O
of	O
SARS	B-DISO
and	O
other	O
epidemic	O
diseases	O
.	O

The	O
associations	O
of	O
AG	O
genotype	O
in	O
OAS1	O
and	O
GT	O
genotype	O
in	O
MxA	O
remained	O
significant	O
in	O
multivariate	O
analyses	O
after	O
adjusting	O
for	O
SARS	B-DISO
protective	O
measures	O
(	O
OR	O
=	O
0	O
.	O
38	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
14	O
-	O
0	O
.	O
98	O
and	O
OR	O
=	O
3	O
.	O
22	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
13	O
-	O
9	O
.	O
18	O
,	O
respectively	O
).	O

Among	O
the	O
control	O
beliefs	O
,	O
""""	O
SARS	B-DISO
-	O
patient	O
caring	O
would	O
be	O
a	O
challenge	O
""""	O
""""	O
SARS	B-DISO
-	O
patient	O
caring	O
is	O
a	O
professional	O
responsibility	O
""","	O
""""	O
tension	B-DISO
during	O
the	O
care	O
of	O
SARS	B-DISO
patients	O
""""	O
and	O
""""	O
support	O
from	O
team	O
members	O
""""	O
were	O
the	O
significant	O
determinants	O
of	O
the	O
intentions	O
.	O

CONCLUSIONS	O
:	O
Advanced	O
age	O
,	O
neutrophilia	O
and	O
high	O
LDH	O
predict	O
poor	O
outcomes	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
Patients	O
infected	O
with	O
the	O
SARS	B-DISO
coronavirus	O
had	O
a	O
wide	O
clinical	O
presentation	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

This	O
study	O
is	O
a	O
retrospective	O
review	O
of	O
chest	O
radiographic	O
findings	O
in	O
children	O
with	O
suspected	O
and	O
probable	O
SARS	B-DISO
during	O
the	O
2003	O
outbreak	O
in	O
Singapore	O
.	O

However	O
,	O
it	O
resulted	O
in	O
nearly	O
8000	O
contacts	O
being	O
put	O
on	O
home	O
quarantine	O
and	O
4300	O
on	O
telephone	O
surveillance	O
,	O
with	O
58	O
individuals	O
eventually	O
being	O
diagnosed	O
with	O
probable	O
SARS	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
and	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
:	O
a	O
challenge	O
to	O
place	O
global	O
solidarity	O
above	O
national	O
sovereignty	O
.	O

Discussion	O
on	O
laboratory	O
containment	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
initiated	O
in	O
Hong	O
Kong	O
in	O
August	O
2003	O
.	O

TITLE	O
:	O
SARS	B-DISO
revisited	O
:	O
managing	O
""""	O
outbreaks	O
""""	O
with	O
""""	O
communications	O
"""."	O

They	O
were	O
perceived	O
to	O
be	O
a	O
potential	O
source	O
of	O
infection	B-DISO
in	O
the	O
community	O
because	O
of	O
their	O
contact	O
with	O
SARS	B-DISO
patients	O
,	O
whom	O
they	O
risked	O
their	O
lives	O
looking	O
after	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
inactivation	B-DISO
expressed	O
as	O
log	O
-	O
reduction	O
were	O
as	O
follows	O
:	O
cell	O
-	O
free	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
-	O
1	O
(	O
HIV	B-DISO
-	O
1	O
),	O
greater	O
than	O
6	O
.	O
8	O
;	O
cell	O
-	O
associated	O
HIV	B-DISO
-	O
1	O
,	O
greater	O
than	O
6	O
.	O
4	O
;	O
human	O
T	O
-	O
lymphotropic	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
),	O
4	O
.	O
5	O
;	O
HTLV	O
-	O
II	O
,	O
greater	O
than	O
5	O
.	O
7	O
;	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
and	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
greater	O
than	O
4	O
.	O
5	O
;	O
duck	O
HBV	B-DISO
,	O
4	O
.	O
4	O
to	O
4	O
.	O
5	O
;	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
,	O
6	O
.	O
0	O
;	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
5	O
.	O
5	O
;	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
6	O
.	O
8	O
;	O
bluetongue	B-DISO
virus	O
,	O
5	O
.	O
1	O
;	O
human	O
adenovirus	B-DISO
5	O
,	O
6	O
.	O
8	O
;	O
Klebsiella	O
pneumoniae	O
,	O
greater	O
than	O
7	O
.	O
4	O
;	O
Staphylococcus	O
epidermidis	O
and	O
Yersinia	B-DISO
enterocolitica	O
,	O
greater	O
than	O
7	O
.	O
3	O
;	O
Treponema	O
pallidum	O
,	O
greater	O
than	O
5	O
.	O
9	O
;	O
Borrelia	B-DISO
burgdorferi	O
,	O
greater	O
than	O
10	O
.	O
6	O
;	O
Plasmodium	O
falciparum	O
,	O
6	O
.	O
9	O
;	O
Trypanosoma	O
cruzi	O
,	O
greater	O
than	O
5	O
.	O
0	O
;	O
and	O
Babesia	O
microti	O
,	O
greater	O
than	O
5	O
.	O
3	O
.	O

In	O
expressing	O
cells	O
,	O
7a	O
protein	O
exhibits	O
a	O
variety	O
of	O
biological	O
activities	O
,	O
including	O
induction	O
of	O
apoptosis	O
,	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
,	O
inhibition	O
of	O
host	O
protein	O
translation	O
,	O
and	O
suppression	B-DISO
of	O
cell	O
growth	O
progression	O
.	O

A	O
variety	O
of	O
infectious	B-DISO
agents	O
,	O
some	O
with	O
a	O
potential	O
for	O
bioterrorism	O
,	O
and	O
liver	O
biopsies	O
serving	O
as	O
an	O
example	O
for	O
routine	O
histopathology	O
samples	O
were	O
studied	O
.	O

RNAi	O
.	O
jp	O
/)	O
is	O
a	O
web	B-DISO
-	O
based	O
online	O
software	O
system	O
that	O
provides	O
efficient	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
design	O
for	O
antiviral	O
RNA	O
interference	O
(	O
RNAi	O
).	O

siVirus	O
will	O
be	O
a	O
useful	O
tool	O
for	O
designing	O
optimal	O
siRNAs	O
targeting	O
highly	O
divergent	O
pathogens	O
,	O
including	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
),	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
),	O
influenza	B-DISO
virus	O
and	O
SARS	B-DISO
coronavirus	O
,	O
all	O
of	O
which	O
pose	O
enormous	O
threats	O
to	O
global	O
human	O
health	O
.	O

ABSTRACT	O
:	O
The	O
basic	O
reproductive	O
ratio	O
,	O
R0	O
,	O
is	O
defined	O
as	O
the	O
expected	O
number	O
of	O
secondary	B-DISO
infections	I-DISO
arising	O
from	O
a	O
single	O
individual	O
during	O
his	O
or	O
her	O
entire	O
infectious	B-DISO
period	O
,	O
in	O
a	O
population	O
of	O
susceptibles	O
.	O

Finally	O
,	O
we	O
survey	O
the	O
recent	O
use	O
of	O
R0	O
in	O
assessing	O
emerging	O
diseases	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
,	O
a	O
number	O
of	O
recent	O
livestock	O
diseases	O
,	O
and	O
vector	O
-	O
borne	O
diseases	O
malaria	B-DISO
,	O
dengue	B-DISO
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
.	O

ABSTRACT	O
:	O
Pneumocystis	B-DISO
pneumonia	I-DISO
(	O
PCP	B-DISO
)	O
is	O
a	O
severe	O
infection	B-DISO
of	O
the	O
immunocompromised	O
host	O
,	O
resulting	O
in	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
life	O
-	O
threatening	O
respiratory	B-DISO
failure	I-DISO
.	O

This	O
study	O
investigated	O
whether	O
an	O
enteral	O
diet	O
enriched	O
with	O
EPA	O
,	O
GLA	O
,	O
and	O
antioxidant	O
vitamins	O
can	O
improve	O
outcomes	O
and	O
reduce	O
28	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

Gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
is	O
an	O
important	O
cytokine	O
produced	O
during	O
the	O
early	O
stages	O
of	O
an	O
infection	B-DISO
by	O
macrophages	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
and	O
other	O
cell	O
types	O
,	O
and	O
it	O
is	O
also	O
a	O
central	O
cytokine	O
mediator	O
for	O
the	O
induction	O
of	O
cellular	O
or	O
Th1	O
immunity	O
.	O

To	O
assess	O
the	O
effectiveness	O
of	O
delivering	O
a	O
telephone	O
health	O
education	O
programme	O
dealing	O
with	O
anxiety	O
levels	O
,	O
and	O
knowledge	O
and	O
practice	O
of	O
measures	O
to	O
prevent	O
transmission	O
of	O
SARS	B-DISO
among	O
a	O
group	O
of	O
older	O
adults	O
with	O
low	B-DISO
SES	I-DISO
.	O

Pathogenicity	O
was	O
assessed	O
by	O
observing	O
the	O
effect	O
on	O
hatchability	O
,	O
and	O
/	O
or	O
the	O
production	O
of	O
nasal	B-DISO
discharge	I-DISO
and	O
/	O
or	O
the	O
effects	O
on	O
ciliary	O
activity	O
in	O
the	O
trachea	B-DISO
at	O
various	O
time	O
points	O
post	O
hatch	O
.	O

This	O
result	O
suggests	O
a	O
mechanism	O
of	O
inactivation	B-DISO
of	O
3C	O
peptidases	O
by	O
methyl	O
ketone	O
inhibitors	O
that	O
is	O
distinct	O
from	O
that	O
occurring	O
in	O
the	O
structurally	O
related	O
serine	O
proteinases	O
or	O
in	O
the	O
papain	O
-	O
like	O
cysteine	O
peptidases	O
.	O

It	O
also	O
provides	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
both	O
the	O
inactivation	B-DISO
of	O
HAV	B-DISO
3C	O
by	O
these	O
inhibitors	O
and	O
on	O
the	O
proteolysis	O
of	O
natural	O
substrates	O
by	O
this	O
viral	O
cysteine	O
peptidase	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
downregulated	O
cell	O
surface	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
.	O

No	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
like	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
3043	O
samples	O
,	O
indicating	O
the	O
current	O
absence	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
like	O
-	O
CoV	O
in	O
the	O
bats	O
captured	O
in	O
Guangzhou	O
and	O
its	O
vicinity	O
.	O

Additional	O
predictors	O
in	O
the	O
full	O
model	O
included	O
haziness	O
or	O
infiltrates	B-DISO
on	O
chest	O
radiography	O
,	O
less	O
than	O
95	O
%	O
oxygen	O
saturation	O
on	O
room	O
air	O
,	O
high	O
lactate	O
dehydrogenase	O
level	O
,	O
and	O
high	O
neutrophil	O
and	O
low	O
platelet	O
counts	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
noted	O
that	O
SARS	B-DISO
transmission	O
is	O
characterised	O
by	O
a	O
few	O
super	O
-	O
spreading	O
events	O
(	O
SSEs	O
)	O
giving	O
rise	O
to	O
a	O
disproportionate	O
number	O
of	O
secondary	O
cases	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
predictors	O
of	O
premenstrual	B-DISO
syndrome	I-DISO
among	O
college	O
-	O
aged	O
women	O
in	O
Saudi	O
Arabia	O
.	O

We	O
recommend	O
that	O
women	O
vulnerable	O
to	O
mental	B-DISO
stress	I-DISO
take	O
advantage	O
of	O
relaxation	O
techniques	O
and	O
psychotropic	O
therapies	O
.	O

Moreover	O
,	O
women	O
with	O
PMS	B-DISO
might	O
eliminate	O
sweet	O
-	O
tasting	O
food	O
and	O
caffeine	B-DISO
-	O
containing	O
beverages	O
,	O
particularly	O
coffee	O
,	O
from	O
their	O
diet	O
.	O

There	O
was	O
no	O
evidence	O
of	O
transmission	O
of	O
infection	B-DISO
before	O
symptom	B-DISO
onset	O
.	O

Physically	O
caring	O
for	O
a	O
symptomatic	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
case	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
for	O
SARS	B-DISO
transmission	O
(	O
OR	O
5	O
.	O
78	O
,	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
24	O
.	O
24	O
).	O

Two	O
-	O
dimensional	O
images	O
of	O
the	O
S	O
,	O
M	O
,	O
and	O
N	O
structural	O
proteins	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
two	O
other	O
coronaviruses	O
were	O
refined	O
to	O
a	O
resolution	O
of	O
approximately	O
4	O
nm	O
.	O

ECMO	O
treatment	O
does	O
not	O
predict	O
mortality	O
in	O
patients	O
with	O
most	O
severe	O
ARDS	B-DISO
.	O

Twelve	O
of	O
them	O
were	O
evaluated	O
for	O
their	O
antiviral	O
potential	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
-	O
induced	O
cytopathicity	O
in	O
Vero	O
E6	O
cell	O
culture	O
.	O

This	O
review	O
summarizes	O
both	O
classical	O
and	O
contemporary	O
discoveries	O
in	O
the	O
study	O
of	O
the	O
molecular	O
biology	O
of	O
these	O
infectious	B-DISO
agents	O
,	O
with	O
particular	O
emphasis	O
on	O
the	O
nature	O
and	O
recognition	O
of	O
viral	O
receptors	O
,	O
viral	O
RNA	O
synthesis	O
,	O
and	O
the	O
molecular	O
interactions	O
governing	O
virion	O
assembly	O
.	O

The	O
optimal	O
cutoff	O
point	O
for	O
predicting	O
mortality	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
was	O
a	O
BNP	O
level	O
of	O
650	O
pg	O
mL	O
on	O
day	O
2	O
,	O
in	O
which	O
sensitivity	O
and	O
specificity	O
were	O
92	O
%	O
and	O
80	O
%,	O
respectively	O
.	O

Because	O
of	O
high	O
maternal	O
mortality	O
and	O
morbidity	O
found	O
among	O
patients	O
with	O
HELLP	B-DISO
syndrome	I-DISO
,	O
standard	O
antenatal	O
follow	O
-	O
up	O
protocols	O
should	O
be	O
applied	O
,	O
so	O
as	O
to	O
obtain	O
early	O
diagnosis	O
and	O
improve	O
the	O
speed	O
of	O
transfer	O
to	O
obstetric	O
departments	O
with	O
expertise	O
in	O
this	O
field	O
.	O

CONCLUSIONS	O
:	O
Because	O
of	O
high	O
maternal	O
mortality	O
and	O
morbidity	O
found	O
among	O
patients	O
with	O
HELLP	B-DISO
syndrome	I-DISO
,	O
standard	O
antenatal	O
follow	O
-	O
up	O
protocols	O
should	O
be	O
applied	O
,	O
so	O
as	O
to	O
obtain	O
early	O
diagnosis	O
and	O
improve	O
the	O
speed	O
of	O
transfer	O
to	O
obstetric	O
departments	O
with	O
expertise	O
in	O
this	O
field	O
.	O

0	O
.	O
7	O
,	O
angina	B-DISO
73	O
%,	O
LVEF	O
58	O
+/-	O

Perceptions	O
of	O
the	O
infectivity	O
and	O
health	O
conditions	O
of	O
recovered	O
SARS	B-DISO
patients	O
and	O
avoidance	O
and	O
discrimination	O
towards	O
them	O
were	O
measured	O
.	O

Of	O
the	O
respondents	O
,	O
75	O
.	O
7	O
%	O
and	O
16	O
.	O
2	O
%,	O
respectively	O
,	O
believed	O
that	O
SARS	B-DISO
could	O
be	O
transmitted	B-DISO
via	O
asymptomatic	O
SARS	B-DISO
patients	O
and	O
those	O
patients	O
who	O
have	O
recovered	O
from	O
SARS	B-DISO
for	O
18	O
months	O
;	O
72	O
.	O
7	O
%	O
of	O
the	O
respondents	O
believed	O
that	O
the	O
health	O
of	O
SARS	B-DISO
patients	O
would	O
severely	O
and	O
permanently	O
be	O
damaged	O
;	O
16	O
.	O
6	O
%	O
showed	O
some	O
tendency	O
of	O
avoiding	O
recovered	O
SARS	B-DISO
patients	O
and	O
35	O
.	O
7	O
%	O
expressed	O
some	O
sort	O
of	O
job	O
-	O
related	O
discriminatory	O
attitudes	O
.	O

The	O
study	O
showed	O
that	O
misconceptions	O
about	O
the	O
infectivity	O
of	O
asymptomatic	O
and	O
recovered	O
SARS	B-DISO
patients	O
were	O
common	O
.	O

Demographic	O
data	O
,	O
SARS	B-DISO
experience	O
,	O
self	O
-	O
perceived	O
health	O
state	O
,	O
neighborhood	O
relationships	O
,	O
and	O
depression	B-DISO
were	O
surveyed	O
by	O
telephone	O
interviewing	O
.	O

In	O
the	O
pediatric	O
study	O
of	O
zanamivir	O
,	O
as	O
in	O
the	O
adult	O
zanamivir	O
study	O
,	O
cough	B-DISO
and	O
fever	O
were	O
the	O
best	O
predictors	O
of	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
;	O
a	O
temperature	O
>	O
or	O
=	O
38	O
.	O
2	O
degrees	O
C	O
plus	O
cough	B-DISO
predicted	O
83	O
%	O
(	O
95	O
%	O
CI	O
,	O
79	O
%-	O
88	O
%)	O
of	O
illnesses	O
that	O
were	O
determined	O
to	O
be	O
influenza	B-DISO
virus	O
positive	O
.	O

The	O
results	O
of	O
these	O
studies	O
suggest	O
that	O
,	O
during	O
the	O
influenza	B-DISO
season	O
,	O
symptomatic	O
predictors	O
of	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
are	O
applicable	O
to	O
identification	O
of	O
cases	O
in	O
children	O
,	O
although	O
confirmation	O
of	O
predictive	O
values	O
in	O
subjects	O
1	O
-	O
4	O
years	O
of	O
age	O
may	O
require	O
further	O
study	O
of	O
additional	O
signs	O
/	O
symptoms	O
.	O

Specifically	O
,	O
that	O
of	O
travelers	O
disguising	O
symptoms	O
of	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
at	O
international	O
airports	O
,	O
in	O
order	O
to	O
board	O
aircraft	O
to	O
return	O
to	O
their	O
home	O
countries	O
-	O
notwithstanding	O
the	O
infection	B-DISO
risks	O
this	O
involves	O
to	O
others	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
-	O
specific	O
CTL	O
epitopes	O
.	O

TITLE	O
:	O
Observations	O
and	O
immunohistochemical	O
detection	O
of	O
Coronavirus	O
,	O
Cryptosporidium	O
parvum	O
and	O
Giardia	B-DISO
intestinalis	O
in	O
neonatal	B-DISO
diarrhoea	I-DISO
in	O
lambs	O
and	O
kids	O
.	O

The	O
mortality	O
in	O
patients	O
with	O
ARDS	B-DISO
is	O
more	O
commonly	O
associated	O
with	O
the	O
sequels	O
of	O
sepsis	B-DISO
and	O
multiple	O
organ	O
dysfunction	O
than	O
with	O
respiratory	B-DISO
failure	I-DISO
although	O
the	O
latest	O
papers	O
on	O
protective	O
ventilation	O
suggest	O
that	O
death	O
in	O
these	O
patients	O
directly	O
results	O
from	O
lung	O
lesion	O
in	O
a	O
number	O
of	O
cases	O
.	O

Using	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
as	O
a	O
model	O
,	O
we	O
engineered	O
a	O
different	O
transcription	O
regulatory	O
circuit	O
and	O
isolated	O
recombinant	O
viruses	O
.	O

Engineering	O
regulatory	O
transcription	O
circuits	O
of	O
intercommunicating	O
alleles	O
successfully	O
introduces	O
genetic	O
traps	B-DISO
into	O
a	O
viral	O
genome	O
that	O
are	O
lethal	O
in	O
RNA	O
recombinant	O
progeny	O
viruses	O
.	O

We	O
conducted	O
a	O
multicenter	O
evaluation	O
of	O
four	O
automated	O
and	O
four	O
manual	O
extraction	O
methods	O
using	O
dilutions	O
of	O
viral	O
lysate	O
in	O
replicate	O
mock	O
stool	O
samples	O
,	O
followed	O
by	O
quantitation	O
of	O
SARS	B-DISO
CoV	O
RNA	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	O
PCR	O
.	O

A	O
questionnaire	O
was	O
distributed	O
to	O
physicians	O
,	O
nurses	O
,	O
and	O
EMRs	O
attending	O
conferences	O
on	O
SARS	B-DISO
in	O
the	O
summer	O
of	O
2003	O
.	O

However	O
,	O
there	O
appears	O
to	O
be	O
a	O
growing	O
use	O
of	O
the	O
Internet	O
,	O
which	O
correlated	O
best	O
with	O
the	O
correct	O
answers	O
on	O
symptoms	O
of	O
SARS	B-DISO
.	O

These	O
findings	O
suggest	O
the	O
need	O
for	O
more	O
effective	O
means	O
of	O
education	O
and	O
training	O
for	O
front	O
-	O
line	O
clinicians	O
,	O
as	O
well	O
as	O
the	O
institution	O
of	O
policies	O
and	O
procedures	O
in	O
medical	O
offices	O
,	O
clinics	O
,	O
and	O
emergency	B-DISO
services	O
in	O
the	O
community	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
our	O
success	O
in	O
developing	O
a	O
novel	O
red	O
-	O
shifted	O
(	O
RS	O
)	O
fluorescence	O
-	O
based	O
assay	O
for	O
3CLpro	O
and	O
its	O
application	O
for	O
identifying	O
small	O
-	O
molecule	O
anti	O
-	O
SARS	B-DISO
agents	O
from	O
marine	O
organisms	O
.	O

In	O
contrast	O
to	O
BS	O
-	O
IQFSs	O
,	O
the	O
RS	O
-	O
IQFS	O
was	O
not	O
susceptible	O
to	O
fluorescence	O
interference	O
from	O
coloured	O
samples	O
and	O
allowed	O
for	O
successful	O
screening	O
of	O
marine	O
natural	O
products	O
and	O
identification	O
of	O
a	O
coumarin	O
derivative	O
,	O
esculetin	O
-	O
4	O
-	O
carboxylic	O
acid	O
ethyl	O
ester	O
,	O
a	O
novel	O
3CLpro	O
inhibitor	O
(	O
IC50	O
=	O
46	O
microM	O
)	O
and	O
anti	O
-	O
SARS	B-DISO
agent	O
(	O
EC50	O
=	O
112	O
microM	O
;	O
median	O
toxic	O
concentration	O
>	O
800	O
microM	O
)	O
from	O
the	O
tropical	O
marine	O
sponge	O
Axinella	O
corrugata	O
.	O

TITLE	O
:	O
Adrenal	B-DISO
insufficiency	I-DISO
in	O
severe	O
West	B-DISO
Nile	I-DISO
Virus	I-DISO
infection	I-DISO
.	O

CONCLUSIONS	O
:	O
Adrenal	B-DISO
insufficiency	I-DISO
is	O
frequent	O
in	O
severe	O
WNV	B-DISO
infection	B-DISO
and	O
carries	O
a	O
poor	O
outcome	O
.	O

The	O
present	O
study	O
assessed	O
the	O
prevalence	O
and	O
severity	O
of	O
five	O
types	O
of	O
aggressive	B-DISO
behaviours	I-DISO
in	O
3165	O
adult	O
men	O
and	O
women	O
with	O
ID	O
receiving	O
services	O
from	O
three	O
rehabilitation	O
agencies	O
in	O
Québec	O
by	O
surveying	O
their	O
carers	O
using	O
the	O
Modified	O
Overt	O
Aggressive	B-DISO
Scale	O
.	O

Excluding	O
job	O
categories	O
with	O
<	O
3	O
workers	O
,	O
the	O
highest	O
SARS	B-DISO
attack	O
rates	O
occurred	O
among	O
nurses	O
who	O
worked	O
in	O
the	O
outpatient	O
and	O
inpatient	O
general	O
wards	O
(	O
57	O
.	O
1	O
,	O
47	O
.	O
4	O
%,	O
respectively	O
).	O

Entering	O
the	O
index	O
patient	O
'	O
s	O
room	O
and	O
having	O
seen	O
(	O
viewed	O
)	O
the	O
patient	O
were	O
the	O
behaviors	O
associated	O
with	O
highest	O
risk	O
for	O
infection	B-DISO
by	O
univariate	O
analysis	O
(	O
odds	O
ratios	O
20	O
.	O
0	O
,	O
14	O
.	O
0	O
;	O
95	O
%	O
confidence	O
intervals	O
4	O
.	O
1	O
-	O
97	O
.	O
1	O
,	O
3	O
.	O
6	O
-	O
55	O
.	O
3	O
,	O
respectively	O
).	O

CONCLUSIONS	O
:	O
This	O
study	O
highlights	O
job	O
categories	O
and	O
activities	O
associated	O
with	O
increased	O
risk	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
demonstrates	O
that	O
a	O
broad	O
diversity	O
of	O
hospital	O
workers	O
may	O
be	O
vulnerable	O
during	O
an	O
outbreak	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
the	O
coagulation	O
cascade	O
in	O
the	O
continuum	O
of	O
sepsis	B-DISO
and	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Severe	B-DISO
sepsis	I-DISO
includes	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
.	O

The	O
organ	O
most	O
often	O
affected	O
is	O
the	O
lung	O
,	O
with	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
which	O
,	O
in	O
its	O
most	O
severe	O
form	O
,	O
is	O
referred	O
to	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

With	O
this	O
clinical	O
success	O
,	O
administration	O
of	O
drotecogin	O
alfa	O
(	O
recombinant	O
activated	O
protein	O
C	O
),	O
the	O
importance	O
of	O
coagulation	O
in	O
the	O
pathogenesis	B-DISO
of	O
human	O
sepsis	B-DISO
is	O
becoming	O
clearer	O
.	O

Then	O
,	O
in	O
2003	O
,	O
a	O
novel	O
member	O
of	O
the	O
coronavirus	O
family	O
was	O
introduced	O
into	O
the	O
human	O
population	O
:	O
SARS	B-DISO
-	O
CoV	O
,	O
causing	O
an	O
aggressive	B-DISO
lung	B-DISO
disease	I-DISO
.	O

As	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
murine	O
ACE2	O
is	O
used	O
less	O
efficiently	O
by	O
NL63	O
-	O
S	O
for	O
entry	O
than	O
human	O
ACE2	O
.	O

To	O
date	O
,	O
sepsis	B-DISO
seems	O
to	O
be	O
the	O
principal	O
link	O
between	O
pneumonia	B-DISO
and	O
ARDS	B-DISO
.	O

To	O
date	O
,	O
based	O
on	O
the	O
publicly	O
released	O
full	O
genomic	O
sequences	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
various	O
molecular	O
detection	O
methods	O
based	O
on	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
been	O
developed	O
.	O

TITLE	O
:	O
Genomic	O
sequencing	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
discuss	O
how	O
we	O
managed	O
to	O
accomplish	O
this	O
task	O
with	O
our	O
optimized	O
protocols	O
on	O
reverse	O
-	O
transcription	O
,	O
nested	O
PCR	O
amplification	B-DISO
,	O
and	O
DNA	O
cycle	O
sequencing	O
.	O

We	O
will	O
also	O
discuss	O
the	O
sequence	O
variations	O
that	O
typified	O
some	O
strains	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
different	O
phases	O
during	O
this	O
epidemic	O
.	O

With	O
other	O
infections	B-DISO
such	O
as	O
tuberculosis	B-DISO
,	O
measles	B-DISO
and	O
chickenpox	B-DISO
,	O
the	O
concept	O
of	O
aerosol	O
transmission	O
is	O
so	O
well	O
accepted	O
that	O
isolation	O
of	O
such	O
patients	O
is	O
the	O
norm	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
review	O
is	O
to	O
describe	O
the	O
factors	O
involved	O
in	O
:	O
(	O
1	O
)	O
the	O
generation	O
of	O
an	O
infectious	B-DISO
aerosol	O
,	O
(	O
2	O
)	O
the	O
transmission	O
of	O
infectious	B-DISO
droplets	O
or	O
droplet	O
nuclei	O
from	O
this	O
aerosol	O
,	O
and	O
(	O
3	O
)	O
the	O
potential	O
for	O
inhalation	O
of	O
such	O
droplets	O
or	O
droplet	O
nuclei	O
by	O
a	O
susceptible	O
host	O
.	O

The	O
successful	O
fusion	O
and	O
inhibition	O
of	O
cell	O
-	O
based	O
binding	O
assay	O
shows	O
that	O
it	O
can	O
be	O
well	O
used	O
for	O
the	O
study	O
of	O
SARS	B-DISO
-	O
CoV	O
entry	O
and	O
inhibition	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
viral	B-DISO
infection	I-DISO
has	O
been	O
reported	O
in	O
many	O
humans	O
since	O
this	O
virus	O
was	O
found	O
to	O
infect	O
humans	O
in	O
Hong	O
Kong	O
in	O
1997	O
,	O
but	O
no	O
studies	O
regarding	O
an	O
animal	O
model	O
of	O
ARDS	B-DISO
with	O
H5N1	B-DISO
viral	B-DISO
infection	I-DISO
have	O
been	O
found	O
in	O
the	O
literature	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
H5N1	B-DISO
viral	B-DISO
infection	I-DISO
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	B-DISO
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	B-DISO
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	O
infiltration	B-DISO
,	O
alveolar	O
and	O
interstitial	B-DISO
edema	I-DISO
,	O
and	O
hemorrhage	B-DISO
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

cDNAs	O
corresponding	O
to	O
MHV	O
/	O
SCoV	O
chimeric	O
genomes	O
were	O
constructed	O
by	O
replacing	O
the	O
complete	O
MHV	O
5	O
'	O
UTR	O
with	O
the	O
corresponding	O
SCoV	O
sequence	O
and	O
by	O
separately	O
replacing	O
MHV	O
5	O
'	O
UTR	O
putative	O
SL1	O
,	O
putative	O
SL2	O
,	O
TRS	B-DISO
,	O
and	O
putative	O
SL4	O
with	O
the	O
corresponding	O
SCoV	O
sequences	O
.	O

Leukocytosis	B-DISO
and	O
slight	O
hypoxemia	O
were	O
observed	O
.	O

The	O
issues	O
are	O
explored	O
in	O
reference	O
to	O
two	O
areas	O
of	O
regulation	O
,	O
isolation	O
and	O
quarantine	O
in	O
the	O
case	O
of	O
SARS	B-DISO
,	O
and	O
the	O
rights	O
of	O
parents	O
to	O
refuse	O
mandatory	O
childhood	O
immunizations	O
.	O

Application	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
of	O
10	O
cmH	B-DISO
(	O
2	O
)	O
O	O
at	O
FIO	O
(	O
2	O
)	O
of	O
0	O
.	O
7	O
worsened	O
oxygenation	O
,	O
and	O
transthoracic	O
echocardiography	O
showed	O
right	O
-	O
to	O
-	O
left	O
shunting	O
of	O
blood	O
through	O
the	O
patent	B-DISO
foramen	I-DISO
ovale	I-DISO
.	O

TITLE	O
:	O
Viral	O
nephropathy	B-DISO
.	O

Hepatitis	B-DISO
C	I-DISO
virus	O
causes	O
various	O
forms	O
of	O
glomerulonephritis	B-DISO
,	O
including	O
cryoglobulinemia	B-DISO
-	O
mediated	O
glomerulonephritis	B-DISO
.	O

Both	O
hantaviruses	O
,	O
and	O
coronaviruses	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
can	O
lead	O
to	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

Of	O
these	O
,	O
six	O
individuals	O
had	O
had	O
SARS	B-DISO
previously	O
.	O

The	O
extremely	O
low	O
rate	O
(	O
0	O
.	O
008	O
%)	O
of	O
asymptomatic	O
SARS	B-DISO
infection	B-DISO
found	O
attests	O
to	O
the	O
high	O
virulence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
virus	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
specifically	O
modulates	O
the	O
UPR	O
to	O
facilitate	O
viral	O
replication	O
.	O

Lung	B-DISO
edema	I-DISO
clearance	O
is	O
largely	O
affected	O
by	O
active	O
sodium	O
transport	O
out	O
of	O
the	O
alveoli	O
rather	O
than	O
by	O
reversal	O
of	O
the	O
Starling	O
forces	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
profile	O
leptospirosis	B-DISO
-	O
induced	O
ARF	B-DISO
and	O
pulmonary	B-DISO
edema	I-DISO
.	O

Leptospirosis	B-DISO
-	O
induced	O
ARF	B-DISO
resulted	O
in	O
natriuresis	O
,	O
lower	O
creatinine	O
clearance	O
,	O
and	O
impaired	B-DISO
urinary	O
concentrating	O
ability	O
.	O

Leptospirosis	B-DISO
-	O
induced	O
lesions	O
,	O
predominantly	O
in	O
the	O
proximal	O
tubule	O
,	O
were	O
responsible	O
for	O
the	O
polyuria	B-DISO
and	O
natriuresis	O
observed	O
.	O

The	O
two	O
most	O
notable	O
infectious	B-DISO
diseases	I-DISO
in	O
recent	O
years	O
are	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

A	O
specific	O
amplification	B-DISO
was	O
also	O
observed	O
with	O
the	O
human	O
coronaviruses	O
(	O
HCoV	O
)	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
229E	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
report	O
the	O
extrarenal	O
computerized	O
tomography	O
(	O
CT	O
)	O
findings	O
in	O
patients	O
with	O
acute	B-DISO
pyelonephritis	I-DISO
(	O
APN	O
).	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
the	O
presence	O
of	O
the	O
L386del	O
variant	O
and	O
SARS	B-DISO
clinical	O
severity	O
as	O
defined	O
either	O
by	O
the	O
need	O
for	O
intensive	O
-	O
care	O
therapy	O
and	O
/	O
or	O
ventilation	O
or	O
by	O
death	O
.	O

After	O
fitting	B-DISO
the	O
patterns	O
of	O
time	O
series	O
and	O
controlling	O
for	O
the	O
calendar	O
effect	O
of	O
the	O
Chinese	O
New	O
Year	O
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
2003	O
,	O
three	O
strategies	O
(	O
generic	O
grouping	O
,	O
delegation	O
of	O
financial	O
responsibility	O
and	O
reduction	O
of	O
the	O
flat	O
payment	O
rate	O
of	O
clinics	O
)	O
were	O
significantly	O
associated	O
with	O
a	O
reduction	O
in	O
PE	O
.	O

Laboratory	O
diagnosis	O
of	O
these	O
viral	B-DISO
infections	I-DISO
based	O
on	O
viral	O
isolation	O
or	O
detection	O
by	O
immune	O
electron	O
microscopy	O
,	O
immunoassay	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
dramatically	O
improved	O
in	O
the	O
recent	O
years	O
,	O
and	O
SARS	B-DISO
represents	O
a	O
good	O
example	O
of	O
a	O
diagnostic	O
approach	O
to	O
emerging	O
viral	B-DISO
infections	I-DISO
.	O

Finally	O
,	O
old	O
and	O
new	O
promising	O
agents	O
are	O
in	O
the	O
pipeline	O
of	O
pharmaceutical	O
companies	O
to	O
treat	O
emerging	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Waste	O
water	O
disinfection	O
during	O
SARS	B-DISO
epidemic	O
for	O
microbiological	O
and	O
toxicological	O
control	O
.	O

Children	O
awaiting	O
international	O
adoption	O
and	O
families	O
traveling	O
to	O
adopt	O
these	O
children	O
can	O
be	O
exposed	O
to	O
a	O
variety	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
a	O
coronavirus	O
from	O
pigeons	O
with	O
pancreatitis	B-DISO
.	O

Furthermore	O
,	O
when	O
the	O
virus	O
was	O
inoculated	O
into	O
SPF	O
chickens	O
,	O
pancreatitis	B-DISO
developed	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
neutralization	O
by	O
a	O
human	O
anti	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
spike	O
protein	O
antibody	O
,	O
80R	O
.	O

Although	O
we	O
previously	O
detected	O
,	O
isolated	O
,	O
and	O
characterized	O
BCoV	O
strains	O
from	O
adult	O
cattle	O
with	O
WD	O
(	O
WD	O
-	O
BCoV	O
strains	O
)	O
during	O
the	O
winter	O
in	O
South	O
Korea	O
,	O
the	O
precise	O
epidemiology	O
,	O
as	O
well	O
as	O
the	O
causative	O
agent	O
of	O
diarrhea	B-DISO
in	O
adult	O
cattle	O
in	O
the	O
warmer	O
seasons	O
,	O
has	O
not	O
been	O
examined	O
.	O

The	O
outcome	O
of	O
scleroderma	B-DISO
patients	O
admitted	O
to	O
the	O
ICU	O
was	O
extremely	O
poor	O
.	O

Infectious	B-DISO
complication	B-DISO
was	O
the	O
most	O
common	O
cause	O
of	O
death	O
in	O
our	O
patients	O
.	O

Specific	O
interventions	O
such	O
as	O
activated	O
protein	O
C	O
for	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
have	O
been	O
shown	O
to	O
provide	O
good	O
value	O
for	O
money	O
.	O

Animal	O
studies	O
showed	O
that	O
pulmonary	B-DISO
failure	I-DISO
and	O
death	O
could	O
be	O
caused	O
by	O
intravenous	O
injection	O
of	O
a	O
killed	O
culture	O
of	O
either	O
Escherichia	O
coli	O
or	O
pneumococcal	O
organisms	O
or	O
by	O
severe	O
muscle	O
contusion	O
.	O

Both	O
ARDS	B-DISO
and	O
death	O
were	O
prevented	O
by	O
administration	O
of	O
a	O
plasminogen	O
activator	O
,	O
and	O
ARDS	B-DISO
in	O
human	O
septic	O
or	O
traumatic	B-DISO
shock	I-DISO
were	O
safely	O
and	O
effectively	O
treated	O
by	O
administration	O
of	O
a	O
plasminogen	O
activator	O
.	O

Despite	O
being	O
extubated	O
successfully	O
,	O
respiratory	B-DISO
failure	I-DISO
reappeared	O
1	O
month	O
later	O
.	O

Approximately	O
40	O
%	O
of	O
all	O
such	O
patients	O
die	O
while	O
the	O
surviving	O
continue	O
to	O
suffer	B-DISO
from	O
these	O
complications	O
because	O
no	O
curative	O
therapy	O
yet	O
exists	O
.	O

Besides	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
results	O
of	O
CPET	O
between	O
subjects	O
recovered	O
from	O
SARS	B-DISO
and	O
those	O
never	O
infected	O
.	O

Minor	O
pulmonary	O
function	O
defects	O
as	O
well	O
as	O
decreased	O
exercise	O
capacity	O
were	O
detected	O
in	O
previously	O
healthy	O
medical	O
staff	O
after	O
recovering	O
from	O
SARS	B-DISO
.	O

Besides	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
results	O
of	O
CPET	O
between	O
subjects	O
recovered	O
from	O
SARS	B-DISO
and	O
those	O
never	O
infected	O
.	O

ABSTRACT	O
:	O
This	O
survey	O
aimed	O
to	O
illustrate	O
factors	O
that	O
contribute	O
to	O
nurses	O
'	O
fear	O
when	O
faced	O
with	O
a	O
possible	O
human	O
-	O
to	O
-	O
human	O
avian	B-DISO
flu	I-DISO
pandemic	O
and	O
their	O
willingness	O
to	O
care	O
for	O
patients	O
with	O
avian	B-DISO
flu	I-DISO
in	O
Taiwan	O
.	O

ABSTRACT	O
:	O
Health	O
-	O
care	O
workers	O
are	O
concerned	O
about	O
the	O
risk	O
of	O
acquiring	O
contagious	B-DISO
diseases	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
after	O
recent	O
outbreaks	O
.	O

A	O
leakage	B-DISO
jet	O
plume	O
was	O
revealed	O
by	O
a	O
laser	O
light	O
sheet	O
and	O
images	O
captured	O
by	O
video	O
.	O

To	O
assess	O
this	O
risk	O
,	O
a	O
human	O
lung	O
model	O
(	O
respiration	O
rate	O
,	O
12	O
breaths	O
/	O
min	O
)	O
was	O
designed	O
to	O
test	O
the	O
potential	O
for	O
a	O
simple	O
oxygen	O
mask	O
at	O
a	O
common	O
setting	O
(	O
4	O
L	O
/	O
min	O
)	O
to	O
disperse	O
potentially	O
infectious	B-DISO
exhaled	O
air	O
into	O
the	O
surrounding	O
area	O
.	O

In	O
response	O
to	O
the	O
WHO	O
request	O
we	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
published	O
literature	O
on	O
ribavirin	O
,	O
corticosteroids	O
,	O
lopinavir	O
and	O
ritonavir	O
(	O
LPV	O
/	O
r	O
),	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
),	O
and	O
SARS	B-DISO
convalescent	O
plasma	O
from	O
both	O
in	O
vitro	O
studies	O
and	O
in	O
SARS	B-DISO
patients	O
.	O

In	O
total	O
,	O
54	O
SARS	B-DISO
treatment	O
studies	O
,	O
15	O
in	O
vitro	O
studies	O
,	O
and	O
three	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
studies	O
met	O
our	O
inclusion	O
criteria	O
.	O

In	O
SARS	B-DISO
-	O
infected	O
patient	O
reports	O
on	O
ribavirin	O
,	O
26	O
studies	O
were	O
classified	O
as	O
inconclusive	O
,	O
and	O
four	O
showed	O
possible	O
harm	O
.	O

To	O
determine	O
whether	O
HECV	O
-	O
4408	O
infects	O
gnotobiotic	O
calves	O
and	O
induces	O
cross	O
-	O
protective	O
immunity	O
against	O
the	O
virulent	O
enteric	O
BCoV	O
DB2	O
strain	O
,	O
gnotobiotic	O
calves	O
(	O
n	O
=	O
4	O
)	O
were	O
orally	O
inoculated	O
with	O
HECV	O
-	O
4408	O
and	O
then	O
challenged	O
with	O
BCoV	O
DB2	O
at	O
postinoculation	O
day	O
(	O
PID	B-DISO
)	O
21	O
.	O

After	O
challenge	O
with	O
bovine	O
coronavirus	O
,	O
no	O
diarrhea	B-DISO
or	O
virus	B-DISO
shedding	I-DISO
was	O
detected	O
in	O
calves	O
inoculated	O
with	O
HECV	O
-	O
4408	O
,	O
but	O
a	O
mock	O
-	O
inoculated	O
calf	O
developed	O
diarrhea	B-DISO
and	O
fecal	O
and	O
nasal	O
shedding	O
.	O

However	O
,	O
although	O
SARS	B-DISO
infected	O
some	O
10	O
,	O
000	O
individuals	O
,	O
killing	O
around	O
1000	O
,	O
it	O
did	O
not	O
lead	O
to	O
the	O
devastating	O
health	O
impact	O
that	O
many	O
feared	O
,	O
but	O
a	O
rather	O
disproportionate	O
economic	O
impact	O
.	O

Thermography	O
is	O
being	O
used	O
with	O
ANN	O
/	O
AI	O
to	O
analyse	O
the	O
data	O
collected	O
from	O
the	O
designated	O
SARS	B-DISO
hospital	O
in	O
Singapore	O
,	O
and	O
conclusive	O
results	O
are	O
drawn	O
.	O

TITLE	O
:	O
A	O
trimerizing	O
GxxxG	O
motif	O
is	O
uniquely	O
inserted	O
in	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
spike	O
protein	O
transmembrane	O
domain	O
.	O

Using	O
molecular	O
modeling	O
,	O
we	O
show	O
that	O
the	O
SCoV	O
spike	O
protein	O
TMD	B-DISO
adopts	O
a	O
distinct	O
and	O
unique	O
structure	O
as	O
opposed	O
to	O
all	O
other	O
coronaviruses	O
.	O

Their	O
impact	O
as	O
a	O
cause	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
adults	O
at	O
risk	O
for	O
complications	O
needs	O
to	O
be	O
established	O
.	O

All	O
patients	O
with	O
respiratory	B-DISO
disease	I-DISO
for	O
whom	O
bronchoalveolar	O
lavage	O
was	O
performed	O
were	O
screened	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
for	O
the	O
presence	O
of	O
all	O
4	O
HCoVs	O
.	O

The	O
most	O
frequent	O
final	O
diagnosis	O
was	O
a	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

Multivariate	O
analysis	O
,	O
controlling	O
for	O
the	O
confounding	O
factors	O
,	O
revealed	O
that	O
marriages	O
between	O
first	O
cousins	O
had	O
no	O
effect	O
on	O
any	O
of	O
our	O
outcome	O
variables	O
including	O
neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Although	O
the	O
risk	O
of	O
SARS	B-DISO
-	O
CoV	O
transmission	O
within	O
aircraft	O
cabins	O
has	O
been	O
addressed	O
by	O
several	O
studies	O
,	O
the	O
magnitude	O
of	O
the	O
risk	O
remains	O
unclear	O
.	O

Consenting	O
participants	O
responded	O
to	O
a	O
questionnaire	O
,	O
and	O
a	O
serum	O
sample	O
was	O
collected	O
at	O
least	O
38	O
days	O
after	O
the	O
flight	O
and	O
tested	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
associated	O
antibodies	O
.	O

Here	O
we	O
review	O
the	O
role	O
of	O
ACE2	O
in	O
disease	O
pathogenesis	B-DISO
,	O
including	O
lung	B-DISO
diseases	I-DISO
and	O
cardiovascular	B-DISO
diseases	I-DISO
.	O

RESULTS	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
developed	O
in	O
6	O
.	O
9	O
%	O
of	O
patients	O
who	O
were	O
more	O
severely	O
ill	B-DISO
with	O
higher	O
APACHE	O
II	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
Injury	O
Severity	O
Score	O
(	O
P	O
=	O
.	O
002	O
)	O
scores	O
vs	O
patients	O
not	O
developing	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
entire	O
S1	O
protein	O
genes	O
of	O
eight	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
vaccine	O
strains	O
used	O
in	O
China	O
were	O
compared	O
with	O
those	O
of	O
the	O
IB	B-DISO
virus	O
isolates	O
present	O
in	O
the	O
field	O
in	O
China	O
.	O

TITLE	O
:	O
Amino	O
acids	O
1	O
to	O
422	O
of	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
associated	O
coronavirus	O
are	O
required	O
for	O
induction	O
of	O
cyclooxygenase	O
-	O
2	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
started	O
in	O
November	O
2002	O
and	O
spread	O
worldwide	O
.	O

ABSTRACT	O
:	O
Recently	O
Simmons	O
et	O
al	O
.	O
reported	O
a	O
new	O
mechanism	O
for	O
SARS	B-DISO
virus	O
entry	O
into	O
target	O
cells	O
,	O
where	O
MDL28170	O
was	O
identified	O
as	O
an	O
efficient	O
inhibitor	O
of	O
CTSL	O
-	O
meditated	O
substrate	O
cleavage	O
with	O
IC	O
(	O
50	O
)	O
of	O
2	O
.	O
5	O
nmol	O
/	O
l	O
.	O

TITLE	O
:	O
Comparison	O
of	O
multiplex	O
PCR	O
assays	O
and	O
conventional	O
techniques	O
for	O
the	O
diagnostic	O
of	O
respiratory	O
virus	O
infections	B-DISO
in	O
children	O
admitted	O
to	O
hospital	O
with	O
an	O
acute	O
respiratory	O
illness	O
.	O

RSV	O
,	O
rhinovirus	O
,	O
and	O
influenza	B-DISO
virus	O
were	O
the	O
most	O
frequent	O
viruses	O
detected	O
in	O
this	O
population	O
,	O
representing	O
43	O
.	O
6	O
%,	O
31	O
.	O
8	O
%,	O
and	O
8	O
.	O
8	O
%	O
of	O
the	O
virus	O
found	O
,	O
respectively	O
,	O
followed	O
by	O
human	O
metapneumovirus	O
(	O
4	O
.	O
4	O
%),	O
coronavirus	O
(	O
3	O
.	O
4	O
%),	O
parainfluenza	B-DISO
virus	O
(	O
3	O
.	O
2	O
%),	O
adenovirus	B-DISO
(	O
2	O
.	O
3	O
%),	O
and	O
enterovirus	O
(	O
2	O
.	O
1	O
%).	O

Computational	O
fluid	O
dynamics	O
can	O
be	O
used	O
to	O
assess	O
airflow	O
in	O
a	O
negative	O
-	O
pressure	O
operating	O
room	O
and	O
model	O
the	O
dispersion	O
of	O
infectious	B-DISO
particles	O
from	O
the	O
patient	O
.	O

Applying	O
this	O
method	O
to	O
SARS	B-DISO
DNA	O
sequence	O
analysis	O
,	O
a	O
characteristic	O
of	O
SARS	B-DISO
-	O
CoV	O
differing	O
from	O
non	O
-	O
SARS	B-DISO
is	O
discovered	O
.	O

Compared	O
with	O
all	O
known	O
coronaviruses	O
'	O
images	O
,	O
It	O
is	O
found	O
that	O
this	O
is	O
a	O
unique	O
characteristic	O
of	O
SARS	B-DISO
virus	O
,	O
and	O
it	O
is	O
helpful	O
to	O
clinical	O
identification	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Combating	O
infectious	B-DISO
disease	I-DISO
using	O
mathematical	O
modelling	O
].	O

This	O
study	O
investigated	O
the	O
frequency	O
of	O
hMPV	O
and	O
HCoV	O
-	O
NL63	O
infections	B-DISO
in	O
Swedish	O
children	O
by	O
screening	O
221	O
nasopharyngeal	O
aspirates	O
,	O
collected	O
between	O
November	O
2003	O
and	O
May	O
2005	O
,	O
from	O
212	O
children	O
attending	O
the	O
paediatric	O
department	O
of	O
a	O
county	O
hospital	O
in	O
Sweden	O
or	O
submitted	O
from	O
local	O
general	O
practitioners	O
.	O

Treated	O
samples	O
were	O
tested	O
for	O
inactivation	B-DISO
in	O
a	O
tissue	O
culture	O
growth	O
assay	O
.	O

RESULTS	O
:	O
Viral	O
inactivation	B-DISO
by	O
heat	O
treatment	O
at	O
60	O
degrees	O
C	O
required	O
15	O
to	O
30	O
minutes	O
to	O
inactivate	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
UVC	O
efficiently	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
in	O
40	O
minutes	O
,	O
whereas	O
UVA	O
required	O
the	O
addition	O
of	O
psoralen	O
to	O
enhance	O
inactivation	B-DISO
of	O
the	O
virus	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
biosensors	O
in	O
the	O
detection	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Global	O
biosecurity	O
threats	O
such	O
as	O
the	O
spread	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
(	O
i	O
.	O
e	O
.,	O
avian	B-DISO
influenza	I-DISO
,	O
SARS	B-DISO
,	O
Hendra	O
,	O
Nipah	O
,	O
etc	O
.)	O
and	O
bioterrorism	O
have	O
generated	O
significant	O
interest	O
in	O
recent	O
years	O
.	O

TITLE	O
:	O
What	O
to	O
think	O
if	O
the	O
results	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
randomized	O
trial	O
of	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
and	O
vancomycin	O
-	O
resistant	O
enterococcus	O
control	O
measures	O
are	O
negative	O
(	O
and	O
other	O
advice	O
to	O
young	O
epidemiologists	O
):	O
a	O
review	O
and	O
an	O
au	O
revoir	O
.	O

Effective	O
measures	O
should	O
be	O
used	O
to	O
minimize	O
the	O
morbidity	O
and	O
mortality	O
attributable	O
to	O
these	O
largely	O
preventable	O
infections	B-DISO
.	O

These	O
include	O
the	O
integration	O
of	O
the	O
emergency	B-DISO
medical	O
services	O
and	O
health	O
-	O
facility	O
medical	O
systems	O
with	O
other	O
response	O
systems	O
;	O
the	O
use	O
of	O
the	O
hospital	O
emergency	B-DISO
incident	O
command	O
system	O
;	O
crisis	O
risk	O
-	O
communications	O
approaches	O
;	O
and	O
the	O
use	O
of	O
practical	O
,	O
hands	O
-	O
on	O
training	O
programs	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
the	O
incidence	O
,	O
characteristics	O
,	O
outcomes	O
,	O
and	O
risk	O
factors	O
of	O
pneumonia	B-DISO
in	O
GBS	B-DISO
patients	O
receiving	O
mechanical	O
ventilation	O
.	O

The	O
study	O
included	O
81	O
patients	O
who	O
required	O
intubation	O
for	O
GBS	B-DISO
.	O

In	O
order	O
to	O
facilitate	O
armored	O
RNA	O
purification	O
,	O
a	O
His6	O
tag	B-DISO
was	O
introduced	O
into	O
the	O
loop	O
region	O
of	O
the	O
MS2	O
coat	O
protein	O
,	O
which	O
allows	O
the	O
exposure	O
of	O
multiple	O
His	O
tags	O
on	O
the	O
surface	O
during	O
armored	O
RNA	O
assembly	O
.	O

To	O
better	O
understand	O
the	O
genomic	O
mechanisms	O
for	O
viral	O
attenuation	O
,	O
we	O
sequenced	O
the	O
complete	O
genomes	O
of	O
two	O
virulent	O
TGEV	O
strains	O
and	O
their	O
attenuated	O
counterparts	O
:	O
virulent	O
TGEV	O
Miller	O
M6	O
and	O
attenuated	O
TGEV	O
Miller	O
M60	O
and	O
virulent	O
TGEV	O
Purdue	O
and	O
attenuated	O
TGEV	O
Purdue	O
P115	O
,	O
together	O
with	O
the	O
ISU	O
-	O
1	O
strain	O
of	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
-	O
ISU	O
-	O
1	O
),	O
a	O
naturally	O
occurring	O
TGEV	O
deletion	O
mutant	B-DISO
with	O
an	O
altered	O
respiratory	O
tropism	O
and	O
reduced	O
virulence	O
.	O

ABSTRACT	O
:	O
In	O
(+)	O
RNA	O
coronaviruses	O
,	O
replication	O
and	O
transcription	O
of	O
the	O
giant	B-DISO
approximately	O
30	O
kb	O
genome	O
to	O
produce	O
genome	O
-	O
and	O
subgenome	O
-	O
size	O
RNAs	O
of	O
both	O
polarities	O
are	O
mediated	O
by	O
a	O
cognate	O
membrane	O
-	O
bound	O
enzymatic	O
complex	O
.	O

Similarly	O
,	O
the	O
important	O
cause	O
of	O
mortality	O
in	O
2001	O
was	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
71	O
.	O
10	O
%)	O
with	O
predominant	O
presentation	O
of	O
jaundice	B-DISO
and	O
renal	B-DISO
failure	I-DISO
,	O
whereas	O
in	O
1994	O
,	O
it	O
was	O
cerebral	B-DISO
malaria	I-DISO
(	O
77	O
.	O
96	O
%).	O

ABSTRACT	O
:	O
The	O
Provincial	O
Transfer	O
Authorization	O
Centre	O
(	O
PTAC	O
)	O
was	O
established	O
as	O
a	O
part	O
of	O
the	O
emergency	B-DISO
response	O
in	O
Ontario	O
,	O
Canada	O
to	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
2003	O
.	O

Although	O
it	O
was	O
created	O
during	O
an	O
emergency	B-DISO
situation	O
and	O
data	O
collection	O
is	O
dependent	O
on	O
front	O
-	O
line	O
medical	O
workers	O
,	O
the	O
PTAC	O
data	O
has	O
achieved	O
a	O
high	O
level	O
of	O
validity	O
,	O
perhaps	O
even	O
higher	O
than	O
many	O
purpose	O
built	O
databases	O
created	O
during	O
non	O
-	O
emergency	B-DISO
settings	O
.	O

TITLE	O
:	O
The	O
cell	O
biology	O
of	O
acute	O
childhood	O
respiratory	B-DISO
disease	I-DISO
:	O
therapeutic	O
implications	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
causes	O
acute	O
,	O
self	O
-	O
limited	O
respiratory	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Expression	O
of	O
elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
ACE2	O
+	O
cells	O
in	O
SARS	B-DISO
patients	O
:	O
relation	O
to	O
the	O
acute	O
lung	O
injury	O
and	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

These	O
results	O
suggest	O
that	O
cells	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
produce	O
elevated	O
levels	O
of	O
PICs	O
which	O
may	O
cause	O
immuno	O
-	O
mediated	O
damage	O
to	O
the	O
lungs	O
and	O
other	O
organs	O
,	O
resulting	O
in	O
ALI	O
and	O
,	O
subsequently	O
,	O
multi	O
-	O
organ	O
dysfunction	O
.	O

Participants	O
were	O
70	O
SARS	B-DISO
recoverers	O
,	O
59	O
family	O
members	O
of	O
SARS	B-DISO
recoverers	O
,	O
and	O
172	O
healthy	O
adults	O
residing	O
in	O
Hong	O
Kong	O
--	O
a	O
SARS	B-DISO
-	O
affected	O
region	O
.	O

During	O
the	O
SARS	B-DISO
outbreak	O
,	O
Hastings	O
'	O
s	O
successor	O
,	O
Sheela	O
Basrur	O
,	O
discovered	O
that	O
nearly	O
a	O
decade	O
of	O
underfunding	O
and	O
new	O
policy	O
foci	O
such	O
as	O
health	O
promotion	O
had	O
left	O
the	O
department	O
vulnerable	O
when	O
faced	O
with	O
a	O
potential	O
epidemic	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
and	O
to	O
what	O
extent	O
ARF	B-DISO
clinically	O
affects	O
pulmonary	O
function	O
,	O
in	O
particular	O
oxygenation	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
epitope	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
specific	O
neutralizing	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
2C5	O
.	O

SCID	B-DISO
-	O
PBL	O
/	O
hu	O
mice	O
thus	O
constructed	O
can	O
be	O
used	O
to	O
analyze	O
the	O
human	O
immune	O
response	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
In	O
February	O
2003	O
,	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
emerged	O
in	O
humans	O
in	O
Guangdong	O
Province	O
,	O
China	O
,	O
and	O
caused	O
an	O
epidemic	O
that	O
had	O
severe	O
impact	O
on	O
public	O
health	O
,	O
travel	O
,	O
and	O
economic	O
trade	O
.	O

These	O
include	O
other	O
acute	O
emerging	O
or	O
re	O
-	O
emerging	O
viral	B-DISO
diseases	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
West	O
-	O
Nile	O
virus	O
,	O
Ebola	O
virus	O
,	O
monkeypox	B-DISO
,	O
as	O
well	O
as	O
the	O
more	O
inapparent	O
insidious	O
slow	O
viral	O
and	O
prion	B-DISO
diseases	I-DISO
.	O

These	O
animals	O
developed	O
a	O
less	O
robust	O
type	O
I	O
interferon	O
response	O
to	O
MHV	O
-	O
1	O
infection	B-DISO
than	O
resistant	O
C57BL	O
/	O
6J	O
mice	O
,	O
and	O
treatment	O
with	O
recombinant	O
beta	O
interferon	O
improved	O
survival	O
.	O

TITLE	O
:	O
Bats	O
as	O
a	O
continuing	O
source	O
of	O
emerging	O
infections	B-DISO
in	O
humans	O
.	O

Cross	O
-	O
infection	B-DISO
between	O
the	O
huge	O
number	O
of	O
bat	O
species	O
may	O
generate	O
new	O
viruses	O
which	O
are	O
able	O
to	O
jump	O
the	O
trans	O
-	O
mammalian	O
species	O
barrier	O
more	O
efficiently	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
crisis	O
led	O
to	O
the	O
construction	O
of	O
a	O
negative	O
pressure	O
operating	O
theatre	O
at	O
a	O
hospital	O
in	O
Hong	O
Kong	O
.	O

Furthermore	O
,	O
experimental	O
evidence	O
showed	O
that	O
the	O
secondary	O
structure	O
and	O
enzymatic	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
were	O
not	O
affected	O
by	O
the	O
Q189A	O
mutation	O
.	O

TITLE	O
:	O
Antibodies	O
against	O
trimeric	O
S	O
glycoprotein	O
protect	O
hamsters	O
against	O
SARS	B-DISO
-	O
CoV	O
challenge	O
despite	O
their	O
capacity	O
to	O
mediate	O
FcgammaRII	O
-	O
dependent	O
entry	O
into	O
B	O
cells	O
in	O
vitro	O
.	O

The	O
serum	O
levels	O
of	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	O
-	O
2	O
and	O
IL	O
-	O
6	O
were	O
significantly	O
elevated	O
during	O
SARS	B-DISO
infection	B-DISO
.	O

Effective	O
respiratory	O
hygiene	O
in	O
the	O
ED	O
is	O
imperative	O
to	O
limit	O
the	O
spread	O
of	O
dangerous	O
respiratory	O
pathogens	O
,	O
including	O
influenza	B-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
bioterrorism	O
agents	O
,	O
particularly	O
given	O
that	O
these	O
agents	O
may	O
not	O
be	O
immediately	O
identifiable	O
.	O

Sustaining	O
effective	O
respiratory	O
control	O
measures	O
is	O
especially	O
challenging	O
in	O
the	O
ED	O
because	O
of	O
patient	O
crowding	B-DISO
,	O
inadequate	O
staffing	O
and	O
resources	O
,	O
and	O
ever	O
-	O
increasing	O
numbers	O
of	O
immunocompromised	O
patients	O
.	O

The	O
patient	O
care	O
section	O
addresses	O
the	O
potentially	O
infected	O
ED	O
patient	O
,	O
including	O
emergency	B-DISO
medical	O
services	O
concerns	O
,	O
triage	O
planning	O
,	O
and	O
patient	O
transport	O
.	O

TITLE	O
:	O
Effectiveness	O
of	O
handwashing	O
in	O
preventing	O
SARS	B-DISO
:	O
a	O
review	O
.	O

ABSTRACT	O
:	O
Antibodies	O
to	O
SARS	B-DISO
-	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)-	O
specific	O
B	O
cell	O
epitopes	O
might	O
recognize	O
the	O
pathogen	O
and	O
interrupt	O
its	O
adherence	O
to	O
and	O
penetration	O
of	O
host	O
cells	O
.	O

This	O
might	O
help	O
us	O
to	O
know	O
greatly	O
more	O
about	O
the	O
consequences	O
of	O
virus	B-DISO
infection	I-DISO
and	O
achieve	O
biotherapy	O
of	O
specifically	O
targeted	O
in	O
future	O
.	O

Model	O
simulations	O
is	O
utilized	O
to	O
show	O
that	O
Level	O
A	O
quarantine	O
prevented	O
approximately	O
461	O
additional	O
SARS	B-DISO
cases	O
and	O
62	O
additional	O
deaths	O
,	O
while	O
the	O
effect	O
of	O
Level	O
B	O
quarantine	O
was	O
comparatively	O
minor	O
,	O
yielding	O
only	O
around	O
5	O
%	O
reduction	O
of	O
cases	O
and	O
deaths	O
.	O

TITLE	O
:	O
A	O
study	O
on	O
antigenicity	O
and	O
receptor	O
-	O
binding	O
ability	O
of	O
fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
.	O

The	O
SARS	B-DISO
agent	O
was	O
found	O
to	O
hybridise	O
with	O
micro	O
-	O
array	O
probes	O
from	O
both	O
coronaviruses	O
and	O
astroviruses	O
,	O
but	O
one	O
of	O
the	O
coronavirus	O
probes	O
and	O
the	O
four	O
astrovirus	O
probes	O
contained	O
redundant	O
sequences	O
,	O
spanning	O
a	O
highly	O
conserved	O
motif	O
,	O
named	O
s2m	O
,	O
found	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genomes	O
of	O
almost	O
all	O
astroviruses	O
,	O
one	O
picornavirus	O
,	O
and	O
the	O
poultry	O
coronaviruses	O
.	O

The	O
three	O
other	O
coronavirus	O
probes	O
,	O
that	O
hybridised	O
with	O
the	O
SARS	B-DISO
agent	O
,	O
were	O
located	O
in	O
the	O
replicase	O
gene	O
,	O
and	O
it	O
could	O
be	O
concluded	O
that	O
the	O
SARS	B-DISO
agent	O
was	O
a	O
novel	O
coronavirus	O
,	O
harbouring	O
s2m	O
.	O

Phylogenetic	O
analyses	O
performed	O
on	O
both	O
replicase	O
gene	O
and	O
nucleocapsid	O
protein	O
could	O
not	O
add	B-DISO
support	O
to	O
a	O
close	O
relationship	O
between	O
avian	O
and	O
SARS	B-DISO
coronaviruses	O
,	O
but	O
all	O
the	O
novel	O
avian	O
coronaviruses	O
were	O
found	O
to	O
harbour	O
s2m	O
.	O

ABSTRACT	O
:	O
In	O
March	O
2003	O
,	O
the	O
Institute	O
of	O
Medicine	O
published	O
an	O
update	O
to	O
its	O
1992	O
landmark	O
report	O
on	O
emerging	O
infections	B-DISO
.	O

Coincident	O
with	O
this	O
publication	O
came	O
increasing	O
reports	O
of	O
severe	O
atypical	B-DISO
pneumonia	I-DISO
of	O
unknown	O
etiology	O
among	O
persons	O
in	O
southeast	O
Asia	O
.	O

Effectively	O
addressing	O
the	O
threat	O
of	O
SARS	B-DISO
will	O
require	O
enhanced	O
global	O
infectious	B-DISO
disease	I-DISO
surveillance	O
,	O
the	O
development	O
of	O
rapid	O
diagnostics	O
,	O
new	O
therapies	O
,	O
and	O
vaccines	O
,	O
implementation	O
of	O
aggressive	B-DISO
evidence	O
-	O
based	O
infection	B-DISO
control	O
strategies	O
,	O
and	O
effective	O
communication	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
novel	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
pseudotype	O
-	O
based	O
assay	O
for	O
detection	O
of	O
neutralizing	O
antibody	O
responses	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
SARS	B-DISO
.	O

3	O
.	O
30	O
years	O
)	O
who	O
attended	O
the	O
Emergency	B-DISO
Department	O
of	O
Milan	O
University	O
'	O
s	O
Institute	O
of	O
Pediatrics	O
because	O
of	O
an	O
acute	B-DISO
disease	I-DISO
excluding	O
trauma	O
during	O
the	O
winter	O
season	O
2003	O
-	O
2004	O
was	O
designed	O
to	O
compare	O
the	O
prevalence	O
and	O
clinical	O
importance	O
of	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
in	O
children	O
.	O

In	O
this	O
context	O
,	O
local	O
and	O
systemic	O
cytokine	O
production	O
plays	O
a	O
major	O
role	O
in	O
inducing	O
the	O
septic	O
cascade	O
,	O
which	O
although	O
meant	O
to	O
be	O
a	O
phlogistic	O
defense	O
reaction	O
,	O
can	O
often	O
become	O
an	O
uncontrolled	O
and	O
dangerous	O
inflammatory	B-DISO
reaction	I-DISO
.	O

TITLE	O
:	O
Cloning	O
and	O
further	O
sequence	O
analysis	O
of	O
the	O
spike	O
gene	O
of	O
attenuated	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
DR13	O
.	O

In	O
deciding	O
how	O
countries	O
should	O
react	O
to	O
this	O
potential	O
pandemic	O
,	O
individually	O
and	O
collectively	O
,	O
a	O
reasonable	O
and	O
practical	O
balance	O
must	O
be	O
struck	B-DISO
between	O
the	O
rights	O
and	O
obligations	O
of	O
individual	O
citizens	O
and	O
protection	O
of	O
the	O
wider	O
community	O
and	O
,	O
indeed	O
,	O
society	O
as	O
a	O
whole	O
.	O

In	O
this	O
communication	O
,	O
ethical	O
issues	O
are	O
discussed	O
in	O
the	O
context	O
of	O
some	O
of	O
the	O
scientific	O
questions	O
relating	O
to	O
a	O
potential	O
influenza	B-DISO
pandemic	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
proposed	O
that	O
immune	O
injury	O
is	O
the	O
central	O
mechanism	O
of	O
pathogenesis	B-DISO
of	O
the	O
infectious	B-DISO
disease	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
routine	O
laboratory	O
variables	O
that	O
might	O
indicate	O
the	O
need	O
for	O
SARS	B-DISO
-	O
CoV	O
testing	O
.	O

A	O
model	O
combining	O
age	O
<	O
65	O
years	O
,	O
a	O
change	O
in	O
ANC	O
of	O
>-	O
3	O
x	O
10	O
(	O
9	O
)/	O
l	O
,	O
and	O
a	O
change	O
in	O
bilirubin	O
of	O
>	O
or	O
=	O
0	O
mmol	O
/	O
l	O
had	O
a	O
sensitivity	O
of	O
43	O
%	O
and	O
a	O
specificity	O
of	O
95	O
%	O
for	O
SARS	B-DISO
(	O
AUC	O
0	O
.	O
90	O
).	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
resulted	O
in	O
substantial	O
morbidity	O
,	O
mortality	O
,	O
and	O
economic	O
losses	O
during	O
the	O
2003	O
epidemic	O
.	O

Of	O
the	O
eight	O
putative	O
accessory	O
proteins	O
encoded	O
by	O
the	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
only	O
two	O
-	O
open	O
reading	O
frame	O
3a	O
(	O
ORF3a	O
)	O
and	O
ORF7a	O
-	O
have	O
been	O
identified	O
in	O
virus	O
-	O
infected	O
cells	O
to	O
date	O
.	O

After	O
adjusting	O
for	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
,	O
oliguria	B-DISO
(	O
odds	O
ratio	O
,	O
30	O
.	O
8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
7	O
.	O
7	O
-	O
123	O
.	O
0	O
)	O
remained	O
as	O
a	O
strong	O
risk	O
factor	O
for	O
mortality	O
.	O

This	O
study	O
shows	O
that	O
renal	O
dysfunction	O
has	O
serious	O
consequences	O
in	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
weaning	O
from	O
mechanical	O
ventilation	O
,	O
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
cancer	B-DISO
patients	O
.	O

Results	O
indicated	O
that	O
the	O
induction	O
of	O
the	O
autoAb	O
is	O
not	O
only	O
related	O
to	O
molecular	O
or	O
structural	O
mimicry	B-DISO
,	O
but	O
rather	O
supports	O
the	O
Danger	O
model	O
,	O
in	O
which	O
any	O
aggression	B-DISO
,	O
in	O
this	O
case	O
the	O
MHV	O
infection	B-DISO
,	O
is	O
susceptible	O
to	O
trigger	O
the	O
production	O
of	O
autoAb	O
.	O

The	O
patients	O
'	O
condition	B-DISO
was	O
improved	O
much	O
as	O
demonstrated	O
by	O
pH	O
7	O
.	O
38	O
+/-	O

The	O
anxiety	O
level	O
of	O
the	O
SARS	B-DISO
cohort	O
was	O
slightly	O
higher	O
than	O
that	O
of	O
the	O
pre	O
-	O
SARS	B-DISO
control	O
.	O

This	O
article	O
reviews	O
the	O
currently	O
used	O
definition	O
of	O
ARDS	B-DISO
and	O
ALI	O
,	O
different	O
studies	O
that	O
have	O
advanced	O
the	O
understanding	O
of	O
the	O
epidemiology	O
and	O
outcomes	O
of	O
these	O
entities	O
,	O
and	O
several	O
diagnostic	O
issues	O
that	O
are	O
important	O
for	O
both	O
clinicians	O
and	O
researchers	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
clinical	O
syndrome	B-DISO
that	O
describes	O
a	O
single	O
common	O
end	O
point	O
:	O
severe	O
injury	O
to	O
the	O
alveolar	O
capillary	O
membrane	O
and	O
the	O
development	O
of	O
proteinaceous	O
edema	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
Hochu	O
-	O
ekki	O
-	O
to	O
(	O
TJ	O
-	O
41	O
),	O
a	O
Japanese	O
herbal	O
medicine	O
,	O
on	O
the	O
development	O
of	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
.	O

ALI	O
was	O
induced	O
in	O
female	O
BALB	O
/	O
c	O
mice	O
by	O
the	O
intranasal	O
administration	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
LPS	B-DISO
.	O

These	O
findings	O
indicated	O
that	O
the	O
preadministration	O
of	O
TJ	O
-	O
41	O
could	O
show	O
an	O
inhibitory	O
effect	O
on	O
ALI	O
in	O
this	O
experimental	O
murine	O
system	O
associated	O
with	O
the	O
suppression	B-DISO
of	O
chemokine	O
production	O
.	O

After	O
admission	O
,	O
he	O
displayed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
severe	O
hypoxemia	O
as	O
dyspnea	B-DISO
gradually	O
progressed	O
.	O

TITLE	O
:	O
Diffuse	O
alveolar	O
lesion	O
in	O
BALB	O
/	O
c	O
mice	O
induced	O
with	O
human	O
reovirus	O
BYD1	O
strain	O
and	O
its	O
potential	O
relation	O
with	O
SARS	B-DISO
.	O

Mice	O
infected	O
firstly	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
followed	O
with	O
ReoV	O
developed	O
a	O
typical	O
diffuse	O
alveolar	O
lesion	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
high	O
volume	O
hemofiltration	O
on	O
respiration	O
,	O
hemodynamics	O
and	O
oxygen	O
metabolism	O
in	O
sepsis	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

The	O
culture	O
of	O
CRCoV	O
will	O
enable	O
analysis	O
of	O
the	O
expression	O
and	O
function	O
of	O
this	O
and	O
other	O
CRCoV	O
proteins	O
as	O
well	O
as	O
allowing	O
the	O
study	O
of	O
the	O
role	O
of	O
CRCoV	O
in	O
the	O
aetiology	O
of	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
elicits	O
highly	O
potent	O
neutralizing	O
antibody	O
responses	O
in	O
the	O
immunized	O
animals	O
.	O

Mice	O
were	O
challenged	O
with	O
the	O
homologous	O
strain	O
of	O
SARS	B-DISO
-	O
CoV	O
5	O
days	O
after	O
the	O
last	O
boost	O
,	O
and	O
sacrificed	O
5	O
days	O
after	O
the	O
challenge	O
.	O

TITLE	O
:	O
A	O
serosurvey	O
of	O
viral	B-DISO
infections	I-DISO
in	O
lions	O
(	O
Panthera	O
leo	O
),	O
from	O
Queen	O
Elizabeth	O
National	O
Park	B-DISO
,	O
Uganda	O
.	O

ABSTRACT	O
:	O
An	O
integrated	O
system	O
has	O
been	O
developed	O
for	O
discovering	O
potent	O
inhibitors	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
(	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
))	O
by	O
virtual	O
screening	O
correlating	O
with	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
and	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technologies	O
-	O
based	O
assays	O
.	O

Based	O
on	O
this	O
integrated	O
assay	O
platform	O
,	O
8	O
new	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitors	O
were	O
discovered	O
.	O

By	O
contrast	O
,	O
the	O
HVR	O
deletion	O
mutant	B-DISO
was	O
highly	O
attenuated	O
in	O
mice	O
,	O
causing	O
no	O
signs	O
of	O
clinical	O
disease	O
and	O
minimal	O
weight	O
loss	O
compared	O
to	O
wild	O
-	O
type	O
virus	O
.	O

TITLE	O
:	O
Alveolar	O
recruitment	B-DISO
versus	O
hyperinflation	B-DISO
:	O
A	O
balancing	O
act	O
.	O

Using	O
the	O
lower	O
inflection	O
point	O
on	O
the	O
static	O
pressure	O
/	O
volume	O
inflation	O
curve	O
plus	O
2	O
cmH2O	O
as	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
setting	O
limits	O
hyperinflation	B-DISO
in	O
acute	O
lung	O
injury	O
,	O
but	O
may	O
not	O
provide	O
enough	O
positive	O
end	O
-	O
expiratory	O
pressure	O
to	O
avoid	O
cyclical	O
recruitment	B-DISO
/	O
derecruitment	O
injury	O
in	O
more	O
severe	O
acute	O
lung	O
injury	O
regions	O
.	O

Partial	O
SARS	B-DISO
-	O
CoV	O
cDNAs	O
and	O
antibiotic	O
resistance	O
/	O
reporter	O
gene	O
DNA	O
were	O
generated	O
and	O
assembled	O
in	O
vitro	O
to	O
produce	O
the	O
replicon	O
transcription	O
template	O
,	O
which	O
was	O
then	O
transcribed	O
in	O
vitro	O
to	O
generate	O
the	O
replicon	O
RNA	O
.	O

The	O
suitability	O
of	O
this	O
replicon	O
cell	O
line	O
in	O
drug	O
screening	O
was	O
demonstrated	O
by	O
testing	O
the	O
inhibitory	O
effect	O
of	O
several	O
existing	O
drugs	O
and	O
the	O
results	O
demonstrate	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
replicon	O
cell	O
lines	O
provide	O
a	O
safe	O
tool	O
for	O
the	O
identification	O
of	O
SARS	B-DISO
-	O
CoV	O
replicase	O
inhibitors	O
.	O

ABSTRACT	O
:	O
In	O
the	O
2003	O
outbreak	O
in	O
Toronto	O
(	O
in	O
Ontario	O
,	O
Canada	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
about	O
20	O
%	O
of	O
cases	O
resulted	O
from	O
household	O
transmission	O
.	O

To	O
adequately	O
diagnose	O
and	O
treat	O
patients	O
at	O
risk	O
of	O
developing	O
PTSD	B-DISO
,	O
close	O
collaboration	O
between	O
physicians	O
of	O
all	O
subspecialties	O
and	O
C	O
-	O
L	O
psychiatrists	O
will	O
be	O
necessary	O
.	O

If	O
enhanced	O
engineering	O
controls	O
could	O
reduce	O
the	O
basic	O
reproductive	O
number	O
(	O
R0	O
)	O
below	O
1	O
.	O
60	O
for	O
chickenpox	B-DISO
and	O
3	O
for	O
measles	B-DISO
,	O
our	O
simulations	O
show	O
that	O
in	O
such	O
a	O
prepared	O
response	O
with	O
public	O
health	O
interventions	O
would	O
have	O
a	O
high	O
probability	O
of	O
containing	O
the	O
indoor	O
airborne	O
infections	B-DISO
.	O

Data	O
could	O
be	O
provided	O
from	O
the	O
field	O
to	O
estimate	O
value	O
of	O
R0	O
,	O
the	O
serial	O
interval	O
between	O
cases	O
,	O
the	O
distributions	O
of	O
the	O
latent	O
,	O
incubation	O
,	O
and	O
infectious	B-DISO
periods	O
,	O
case	O
fatality	O
rates	O
,	O
and	O
secondary	O
spread	O
within	O
important	O
mixing	O
groups	O
.	O

The	O
combination	O
of	O
enhanced	O
engineering	O
control	O
measures	O
and	O
assigned	O
effective	O
public	O
health	O
interventions	O
would	O
have	O
a	O
high	O
probability	O
for	O
containing	O
airborne	O
infection	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
of	O
mice	O
transgenic	O
for	O
the	O
human	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
virus	O
receptor	O
.	O

The	O
severity	O
of	O
the	O
disease	O
that	O
developed	O
in	O
these	O
transgenic	O
mice	O
--	O
AC70	O
in	O
particular	O
--	O
makes	O
these	O
mouse	O
models	O
valuable	O
not	O
only	O
for	O
evaluating	O
the	O
efficacy	O
of	O
antivirals	O
and	O
vaccines	O
,	O
but	O
also	O
for	O
studying	O
SARS	B-DISO
coronavirus	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3b	O
,	O
ORF	O
6	O
,	O
and	O
nucleocapsid	O
proteins	O
function	O
as	O
interferon	O
antagonists	O
.	O

The	O
rJ	O
.	O
6	O
infections	B-DISO
proceeded	O
rapidly	O
,	O
secreting	O
progeny	O
about	O
1	O
.	O
5	O
h	O
earlier	O
than	O
rJ	O
.	O
6	O
-	O
KO	O
infections	B-DISO
did	O
.	O

The	O
SARS	B-DISO
coronavirus	O
encodes	O
a	O
novel	O
membrane	O
protein	O
6	O
that	O
can	O
accelerate	O
replication	O
of	O
a	O
related	O
mouse	O
virus	O
,	O
a	O
property	O
that	O
may	O
explain	O
its	O
ability	O
to	O
increase	O
in	O
vivo	O
virus	O
virulence	O
.	O

ABSTRACT	O
:	O
We	O
reported	O
the	O
analytical	O
interference	O
of	O
anti	O
-	O
Escherichia	O
coli	O
protein	O
(	O
EP	O
)	O
antibodies	O
in	O
human	O
sera	O
and	O
residual	O
EP	O
in	O
a	O
recombinant	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
as	O
a	O
possible	O
source	O
of	O
false	O
positives	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
serodiagnosis	O
.	O

SARS	B-DISO
is	O
related	O
to	O
a	O
high	O
morbidity	O
and	O
mortality	O
and	O
first	O
appeared	O
during	O
an	O
epidemic	O
in	O
2002	O
-	O
2003	O
.	O

TITLE	O
:	O
The	O
STAT4	O
and	O
STAT6	O
pathways	O
in	O
pancreatitis	B-DISO
-	O
associated	O
lung	O
injury	O
.	O

We	O
examined	O
the	O
roles	O
of	O
STAT4	O
and	O
STAT6	O
in	O
lung	O
injury	O
after	O
caerulein	O
-	O
induced	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

We	O
hypothesized	O
that	O
a	O
modified	O
organ	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
that	O
occurs	O
in	O
transgenic	O
mice	O
may	O
affect	O
the	O
systemic	O
response	O
to	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Standard	O
histological	O
staining	O
hematoxylin	O
and	O
eosin	O
was	O
performed	O
and	O
blindly	O
scored	O
by	O
a	O
pathologist	O
for	O
evidence	O
of	O
lung	O
injury	O
(	O
pulmonary	B-DISO
edema	I-DISO
,	O
accumulations	O
of	O
neutrophils	O
and	O
mononuclear	O
cells	O
,	O
thickness	O
of	O
alveolar	O
-	O
capillary	O
membrane	O
,	O
perivascular	O
infiltrate	B-DISO
,	O
and	O
hemorrhage	B-DISO
).	O

These	O
temporal	O
differences	O
may	O
suggest	O
alternative	O
roles	O
in	O
the	O
systemic	O
inflammatory	B-DISO
response	I-DISO
associated	O
with	O
pancreatitis	B-DISO
.	O

He	O
developed	O
subcutaneous	B-DISO
emphysema	I-DISO
and	O
pneumomediastinum	B-DISO
as	O
complications	O
of	O
mechanical	O
ventilation	O
.	O

When	O
Vero	O
E6	O
cells	O
expressing	O
siRNA	O
2	O
,	O
3	O
or	O
7	O
were	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
yield	O
of	O
progeny	O
virus	O
was	O
observed	O
.	O

TITLE	O
:	O
Characterizing	O
56	O
complete	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
gene	O
sequences	O
from	O
Hong	O
Kong	O
.	O

To	O
analyze	O
the	O
risk	O
factors	O
for	O
postoperative	O
severe	O
pneumonia	B-DISO
in	O
OLT	O
patients	O
,	O
we	O
collected	O
data	O
from	O
132	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
OLT	O
between	O
February	O
1999	O
and	O
April	O
2004	O
.	O

According	O
to	O
the	O
American	O
Thoracic	B-DISO
Society	O
consensus	O
statement	O
,	O
episodes	O
of	O
severe	O
pneumonia	B-DISO
were	O
observed	O
in	O
24	O
patients	O
(	O
18	O
.	O
2	O
%).	O

The	O
mortality	O
rate	O
was	O
37	O
.	O
5	O
%	O
(	O
9	O
of	O
24	O
)	O
for	O
patients	O
with	O
severe	O
pneumonia	B-DISO
versus	O
7	O
.	O
4	O
%	O
(	O
8	O
of	O
108	O
,	O
P	O
=	O
.	O
004	O
)	O
for	O
patients	O
without	O
pneumonia	B-DISO
.	O

The	O
number	O
of	O
IBV	O
isolations	O
was	O
consistently	O
higher	O
in	O
broilers	O
aged	O
27	O
to	O
43	O
days	O
,	O
coinciding	O
with	O
lymphocytic	O
depletion	O
of	O
the	O
bursa	O
and	O
/	O
or	O
thymus	O
,	O
providing	O
circumstantial	O
evidence	O
that	O
immunodeficiency	B-DISO
and	O
IBV	O
incidence	O
may	O
be	O
linked	O
.	O

At	O
the	O
same	O
time	O
,	O
IBV	O
RNA	O
concentrations	O
in	O
tracheas	O
and	O
lachrymal	O
fluids	O
were	O
higher	O
and	O
more	O
persistent	O
in	O
immunodeficient	B-DISO
chickens	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
life	O
-	O
threatening	O
complication	B-DISO
of	O
talc	O
pleurodesis	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
the	O
induction	O
of	O
acute	O
lung	O
injury	O
by	O
promoting	O
the	O
synthesis	O
of	O
chemokine	O
/	O
cytokines	O
in	O
human	O
endothelial	O
cells	O
.	O

Chemokines	O
/	O
cytokines	O
in	O
the	O
blood	O
of	O
patients	O
with	O
SARS	B-DISO
were	O
dynamically	O
screened	O
by	O
liquid	O
chip	O
system	O
.	O

(	O
2	O
)	O
The	O
Spike	O
glycoprotein	O
of	O
SARS	B-DISO
-	O
CoV	O
induced	O
a	O
high	O
level	O
of	O
IP	O
-	O
10	O
in	O
endothelial	O
cells	O
,	O
which	O
in	O
turn	O
damaged	O
endothelial	O
cells	O
.	O

Significant	O
difference	O
was	O
found	O
in	O
average	O
daily	O
symptom	B-DISO
scores	O
between	O
H	O
(	O
1	O
)	O
(	O
0	O
.	O
29	O
+/-	O
0	O
.	O
39	O
)	O
and	O
H	O
(	O
2	O
)	O
(	O
0	O
.	O
19	O
+/-	O
0	O
.	O
27	O
)	O
in	O
the	O
active	O
group	O
(	O
Z	O
=	O
2	O
.	O
923	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
no	O
significant	O
difference	O
was	O
found	O
between	O
H	O
(	O
1	O
)	O
(	O
0	O
.	O
45	O
+/-	O
0	O
.	O
62	O
)	O
and	O
H	O
(	O
2	O
)	O
(	O
0	O
.	O
40	O
+/-	O
0	O
.	O
68	O
)	O
in	O
the	O
placebo	O
group	O
(	O
Z	O
=	O
1	O
.	O
885	O
,	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
demographic	O
and	O
clinical	O
characteristics	O
associated	O
with	O
coronavirus	B-DISO
infection	I-DISO
were	O
examined	O
retrospectively	O
.	O

Although	O
4	O
subtypes	O
of	O
coronavirus	O
were	O
detected	O
,	O
the	O
recently	O
discovered	O
coronavirus	O
subtypes	O
NL63	O
and	O
HKU1	O
accounted	O
for	O
the	O
majority	O
of	O
coronaviruses	O
detected	O
in	O
our	O
cohort	O
of	O
mostly	O
hospitalized	O
children	O
with	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Children	O
whose	O
only	O
detectable	O
respiratory	O
virus	O
was	O
a	O
coronavirus	O
were	O
more	O
likely	O
to	O
have	O
underlying	O
chronic	B-DISO
disease	I-DISO
than	O
were	O
children	O
coinfected	O
with	O
another	O
respiratory	O
virus	O
.	O

TITLE	O
:	O
Pathophysiology	O
of	O
pulmonary	B-DISO
complications	I-DISO
of	O
acute	B-DISO
pancreatitis	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
pancreatitis	I-DISO
in	O
its	O
severe	O
form	O
is	O
complicated	O
by	O
multiple	O
organ	O
system	O
dysfunction	O
,	O
most	O
importantly	O
by	O
pulmonary	B-DISO
complications	I-DISO
which	O
include	O
hypoxia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
atelectasis	B-DISO
,	O
and	O
pleural	B-DISO
effusion	I-DISO
.	O

The	O
pathogenesis	B-DISO
of	O
some	O
of	O
the	O
above	O
complications	O
is	O
attributed	O
to	O
the	O
production	O
of	O
noxious	O
cytokines	O
.	O

The	O
role	O
of	O
circulating	O
trypsin	O
,	O
phospholipase	O
A2	O
,	O
platelet	O
activating	O
factor	O
,	O
release	O
of	O
free	O
fatty	O
acids	O
,	O
chemoattractants	O
such	O
as	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
fMet	O
-	O
leu	O
-	O
phe	O
(	O
a	O
bacterial	O
wall	O
product	O
),	O
nitric	O
oxide	O
,	O
substance	O
P	O
,	O
and	O
macrophage	O
inhibitor	O
factor	O
is	O
currently	O
studied	O
.	O

TITLE	O
:	O
Palmitoylation	O
of	O
the	O
cysteine	O
-	O
rich	O
endodomain	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
spike	O
glycoprotein	O
is	O
important	O
for	O
spike	O
-	O
mediated	O
cell	O
fusion	O
.	O

Given	O
the	O
IFN	O
mediated	O
antiviral	O
and	O
immunomodulatory	O
effects	O
,	O
the	O
use	O
of	O
IFN	O
or	O
IFN	O
inducers	O
may	O
prove	O
an	O
efficient	O
strategy	O
for	O
a	O
better	O
control	O
of	O
influenza	B-DISO
virus	O
and	O
coronavirus	B-DISO
infections	I-DISO
in	O
pigs	O
.	O

Although	O
the	O
chickens	O
were	O
not	O
vaccinated	O
against	O
any	O
poultry	B-DISO
diseases	I-DISO
,	O
serum	O
antibodies	O
to	O
Newcastle	O
disease	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
and	O
infectious	B-DISO
bronchitis	B-DISO
were	O
detected	O
.	O

The	O
present	O
study	O
illustrates	O
specific	O
histopathological	O
features	O
that	O
highlight	O
a	O
possible	O
association	O
between	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
,	O
constrictive	B-DISO
bronchiolitis	I-DISO
and	O
eosinophilic	O
micro	O
-	O
abscesses	B-DISO
.	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
gene	O
expression	O
by	O
adenovirus	B-DISO
-	O
delivered	O
small	O
hairpin	O
RNA	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	O
and	O
lethal	O
disease	O
caused	O
by	O
a	O
new	O
type	O
of	O
coronavirus	O
,	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

In	O
this	O
study	O
,	O
we	O
designed	O
several	O
plasmids	O
that	O
express	O
small	O
hairpin	O
RNA	O
molecules	O
(	O
shRNA	O
)	O
specifically	O
targeting	O
to	O
the	O
genes	O
encoding	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
envelope	O
(	O
E	O
)	O
protein	O
,	O
respectively	O
.	O

Effective	O
shRNA	O
molecules	O
to	O
the	O
viral	O
genes	O
were	O
screened	O
and	O
identified	O
,	O
and	O
then	O
constructed	O
into	O
adenovirus	B-DISO
vectors	O
.	O

Since	O
many	O
cell	O
types	O
can	O
be	O
efficiently	O
infected	O
by	O
adenovirus	B-DISO
,	O
recombinant	O
adenoviruses	O
could	O
serve	O
as	O
an	O
alternative	O
powerful	O
tool	O
for	O
shRNA	O
delivery	O
and	O
for	O
gene	O
suppression	B-DISO
,	O
especially	O
when	O
the	O
targeted	O
cells	O
are	O
resistant	O
to	O
transfection	O
by	O
DNA	O
or	O
RNA	O
.	O

In	O
addition	O
,	O
we	O
performed	O
this	O
study	O
in	O
order	O
to	O
delineate	O
the	O
prevalence	O
,	O
the	O
potential	O
clinical	O
impacts	O
and	O
evaluation	O
of	O
the	O
genetic	O
characterization	O
of	O
this	O
pathogen	O
in	O
young	O
children	O
who	O
presented	O
with	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
ALRI	O
).	O

Respiratory	O
specimens	O
from	O
children	O
aged	O
2	O
to	O
17	O
years	O
with	O
asthma	B-DISO
exacerbations	O
(	O
case	O
patients	O
,	O
n	O
=	O
65	O
)	O
and	O
with	O
well	O
-	O
controlled	O
asthma	B-DISO
(	O
control	O
subjects	O
,	O
n	O
=	O
77	O
),	O
frequency	O
matched	O
by	O
age	O
and	O
season	O
of	O
enrollment	O
,	O
were	O
tested	O
for	O
rhinoviruses	O
,	O
enteroviruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
229E	O
and	O
OC43	O
,	O
parainfluenza	B-DISO
viruses	O
1	O
to	O
3	O
,	O
influenza	B-DISO
viruses	O
,	O
adenoviruses	O
,	O
and	O
human	O
bocavirus	O
.	O

is	O
one	O
of	O
eight	O
Bioinformatics	O
Resource	O
Centers	O
(	O
BRCs	O
)	O
funded	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	B-DISO
and	O
Infection	B-DISO
Diseases	O
(	O
NIAID	O
)	O
to	O
create	O
a	O
data	O
and	O
analysis	O
resource	O
for	O
selected	O
NIAID	O
priority	O
pathogens	O
,	O
specifically	O
proteobacteria	O
of	O
the	O
genera	O
Brucella	O
,	O
Rickettsia	O
and	O
Coxiella	O
,	O
and	O
corona	O
-,	O
calici	O
-	O
and	O
lyssaviruses	O
and	O
viruses	O
associated	O
with	O
hepatitis	B-DISO
A	I-DISO
and	O
E	O
.	O
The	O
goal	O
of	O
the	O
project	O
is	O
to	O
provide	O
a	O
comprehensive	O
bioinformatics	O
resource	O
for	O
these	O
pathogens	O
,	O
including	O
consistently	O
annotated	O
genome	O
,	O
proteome	O
and	O
metabolic	O
pathway	O
data	O
to	O
facilitate	O
research	O
into	O
counter	O
-	O
measures	O
,	O
including	O
drugs	O
,	O
vaccines	O
and	O
diagnostics	O
.	O

TITLE	O
:	O
T	O
cell	O
antiviral	O
effector	O
function	O
is	O
not	O
dependent	O
on	O
CXCL10	O
following	O
murine	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
The	O
chemokine	O
CXCL10	O
is	O
expressed	O
within	O
the	O
CNS	O
in	O
response	O
to	O
intracerebral	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

TITLE	O
:	O
[	O
Respiratory	B-DISO
diseases	I-DISO
in	O
confined	O
non	O
-	O
industrial	O
working	O
environments	O
].	O

Respiratory	B-DISO
infections	I-DISO
may	O
have	O
a	O
human	O
source	O
such	O
as	O
tuberculosis	B-DISO
or	O
viral	B-DISO
diseases	I-DISO
or	O
may	O
originate	O
in	O
ventilation	O
systems	O
such	O
as	O
Legionnaire	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
(	O
Legionella	B-DISO
pneumophila	I-DISO
pneumonia	I-DISO
).	O

Analysis	O
of	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
data	O
from	O
a	O
series	O
of	O
measurements	O
at	O
different	O
SARS	B-DISO
CoV	O
main	O
proteinase	O
concentrations	O
yielded	O
KD	O
values	O
of	O
5	O
.	O
8	O
+/-	O

These	O
results	O
strongly	O
indicate	O
that	O
host	O
and	O
virus	O
factors	O
such	O
as	O
advanced	O
age	O
and	O
virus	O
adaptation	O
are	O
critical	O
for	O
the	O
development	O
of	O
SARS	B-DISO
in	O
rats	O
.	O

TITLE	O
:	O
Long	O
-	O
range	O
cooperative	O
interactions	O
modulate	O
dimerization	O
in	O
SARS	B-DISO
3CLpro	O
.	O

ALI	O
/	O
ARDS	B-DISO
may	O
also	O
be	O
related	O
to	O
a	O
coincidental	O
bacterial	B-DISO
sepsis	I-DISO
that	O
may	O
not	O
be	O
clinically	O
obvious	O
.	O

Both	O
treatments	O
blocked	O
virus	B-DISO
infection	I-DISO
and	O
apoptosis	O
,	O
indicating	O
that	O
virus	O
-	O
receptor	O
binding	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
the	O
apoptosis	O
induction	O
.	O

All	O
patients	O
15	O
years	O
or	O
older	O
admitted	O
to	O
our	O
Level	O
I	O
trauma	O
center	O
with	O
an	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
)	O
<	O
16	O
were	O
included	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
different	O
chicken	O
flocks	O
(	O
n	O
=	O
20	O
)	O
that	O
suffered	B-DISO
from	O
respiratory	B-DISO
disease	I-DISO
were	O
tested	O
for	O
IBV	O
antibodies	O
using	O
commercial	O
IBV	O
antibody	O
ELISA	O
at	O
time	O
of	O
the	O
initial	O
signs	O
of	O
the	O
respiratory	B-DISO
disease	I-DISO
and	O
repeated	O
on	O
serum	O
samples	O
from	O
the	O
same	O
flocks	O
10	O
-	O
14	O
days	O
later	O
.	O

ELISA	O
titer	O
for	O
IBV	O
increased	O
in	O
14	O
out	O
of	O
20	O
flocks	O
(	O
70	O
%)	O
after	O
10	O
-	O
14	O
days	O
of	O
the	O
initial	O
signs	O
of	O
the	O
respiratory	B-DISO
disease	I-DISO
and	O
this	O
indicates	O
a	O
recent	O
exposure	O
to	O
IBV	O
.	O

These	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
containing	O
HCoV	O
229E	O
-	O
based	O
vector	O
RNA	O
have	O
the	O
ability	O
to	O
transduce	O
human	O
DCs	B-DISO
and	O
to	O
mediate	O
heterologous	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Finally	O
,	O
coronavirus	B-DISO
infections	I-DISO
are	O
associated	O
with	O
mainly	O
respiratory	O
and	O
enteric	O
diseases	O
,	O
and	O
natural	O
transmission	O
of	O
coronaviruses	O
occurs	O
via	O
mucosal	O
surfaces	O
.	O

HCoV	O
229E	O
infections	B-DISO
are	O
mainly	O
encountered	O
in	O
children	O
and	O
re	O
-	O
infection	B-DISO
occurs	O
frequently	O
in	O
adults	O
.	O

Subsequently	O
,	O
the	O
characterizations	O
including	O
entrapment	O
efficiency	O
,	O
size	O
,	O
span	O
and	O
micrograph	O
of	O
DIP	B-DISO
liposomes	O
were	O
measured	O
.	O

All	O
of	O
the	O
results	O
suggested	O
that	O
DIP	B-DISO
liposomes	O
have	O
the	O
potential	O
efficacy	O
in	O
treating	O
ALI	O
/	O
ARDS	B-DISO
due	O
to	O
their	O
obvious	O
lung	O
targeting	O
.	O

Only	O
one	O
patient	O
required	O
nitric	O
oxide	O
therapy	O
for	O
transient	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

All	O
of	O
the	O
clinical	O
data	O
and	O
survival	O
time	O
during	O
72	O
hours	O
were	O
collected	O
and	O
analyzed	O
,	O
including	O
the	O
collection	O
of	O
bronchioalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
for	O
the	O
determination	O
of	O
total	O
protein	O
(	O
TP	O
),	O
total	O
phospholipids	O
(	O
TPL	O
),	O
disaturated	O
phosphatidyl	O
choline	O
(	O
DSPC	O
),	O
and	O
measurement	O
of	O
alveolar	O
tension	B-DISO
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
TPL	O
,	O
DSPC	O
,	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
of	O
BALF	O
in	O
each	O
group	O
,	O
so	O
were	O
lung	O
surface	O
tension	B-DISO
and	O
W	O
/	O
D	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

Previously	O
,	O
we	O
reported	O
the	O
identification	O
of	O
a	O
dibasic	O
motif	O
(	O
KxHxx	O
)	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
SARS	B-DISO
CoV	O
spike	O
(	O
S	O
)	O
protein	O
that	O
was	O
similar	O
to	O
a	O
canonical	O
dilysine	O
ER	O
retrieval	O
signal	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulator	O
of	O
the	O
renin	O
angiotensin	O
system	O
involved	O
in	O
acute	O
lung	O
failure	O
,	O
cardiovascular	O
functions	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infections	B-DISO
in	O
mammals	O
.	O

Expression	O
of	O
collectrin	O
in	O
Xenopus	O
oocytes	O
and	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	O
enhances	O
amino	O
acid	O
transport	O
by	O
the	O
transporter	O
B	O
(	O
0	O
)	O
AT1	B-DISO
.	O

The	O
concerted	O
and	O
cooperative	O
response	O
for	O
the	O
treatment	O
of	O
the	O
SARS	B-DISO
disease	O
has	O
been	O
proved	O
to	O
be	O
a	O
triumph	O
of	O
global	O
public	O
health	O
and	O
provides	O
a	O
new	O
paradigm	O
for	O
the	O
detection	O
and	O
control	O
of	O
future	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
threats	O
.	O

TITLE	O
:	O
Quaternary	O
structure	O
,	O
substrate	O
selectivity	O
and	O
inhibitor	O
design	O
for	O
SARS	B-DISO
3C	O
-	O
like	O
proteinase	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
proteinase	O
is	O
recognized	O
as	O
a	O
potential	O
drug	O
design	O
target	O
for	O
the	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Theoretical	O
models	O
,	O
either	O
Logistic	O
model	O
or	O
SIR	O
model	O
,	O
were	O
developed	O
to	O
describe	O
the	O
transmission	O
of	O
SARS	B-DISO
.	O

Finally	O
,	O
a	O
brief	O
introduction	O
is	O
given	O
for	O
how	O
to	O
use	O
computer	O
-	O
generated	O
graphs	O
to	O
rapidly	O
diagnose	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Attenuated	O
Salmonella	B-DISO
have	O
been	O
used	O
as	O
vectors	O
to	O
deliver	O
foreign	O
antigens	O
as	O
live	O
vaccines	O
.	O

Of	O
imminent	O
importance	O
to	O
prepare	O
against	O
a	O
resurgence	O
of	O
SARS	B-DISO
,	O
remain	O
,	O
besides	O
an	O
exact	O
knowledge	O
about	O
the	O
viral	O
pathogen	O
and	O
its	O
possible	O
further	O
behavior	O
,	O
constant	O
vigilance	O
,	O
early	O
recognition	O
,	O
and	O
instant	O
isolation	O
of	O
suspected	O
cases	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
,	O
avian	B-DISO
flu	I-DISO
,	O
bioterror	O
:	O
infection	B-DISO
control	O
awareness	O
for	O
the	O
optometrist	O
.	O

The	O
trachea	B-DISO
and	O
kidney	O
of	O
challenged	O
vaccinated	O
hens	O
were	O
protected	O
to	O
a	O
moderate	O
extent	O
,	O
but	O
the	O
oviduct	O
was	O
protected	O
to	O
only	O
a	O
small	O
extent	O
.	O

We	O
used	O
a	O
well	O
-	O
established	O
recombinant	O
vaccinia	B-DISO
virus	O
(	O
VV	O
)-	O
based	O
expression	O
system	O
that	O
lacks	O
the	O
viral	O
IFN	O
antagonist	O
E3L	O
to	O
screen	O
viral	O
genes	O
for	O
their	O
ability	O
to	O
rescue	O
the	O
IFN	O
sensitivity	O
of	O
the	O
mutant	B-DISO
.	O

With	O
these	O
insights	O
we	O
explain	O
why	O
contact	O
tracing	O
was	O
and	O
will	O
be	O
effective	O
for	O
control	O
of	O
smallpox	B-DISO
and	O
SARS	B-DISO
,	O
only	O
partially	O
effective	O
for	O
foot	B-DISO
-	I-DISO
and	I-DISO
-	I-DISO
mouth	I-DISO
disease	I-DISO
,	O
and	O
likely	O
not	O
effective	O
for	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
Rapid	O
response	O
to	O
outbreaks	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
is	O
impeded	O
by	O
uncertain	O
diagnoses	O
and	O
delayed	O
communication	O
.	O

ABSTRACT	O
:	O
Most	O
of	O
the	O
individuals	O
infected	O
with	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spontaneously	O
recovered	O
without	O
clinical	O
intervention	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
a	O
post	O
-	O
hoc	O
analysis	O
on	O
the	O
effect	O
of	O
recombinant	O
factor	O
VIIa	O
(	O
rFVIIa	O
)	O
on	O
coagulopathic	O
patients	O
from	O
two	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	B-DISO
trials	O
of	O
rFVIIa	O
as	O
an	O
adjunctive	O
therapy	O
for	O
bleeding	B-DISO
in	O
patients	O
with	O
severe	O
trauma	O
.	O

While	O
new	O
ventilation	O
strategies	O
have	O
reduced	O
the	O
mortality	O
rate	O
in	O
patients	O
with	O
ARDS	B-DISO
,	O
this	O
mortality	O
rate	O
still	O
remains	O
high	O
.	O

In	O
immunocompetent	O
individuals	O
,	O
the	O
infection	B-DISO
is	O
usually	O
subclinical	O
but	O
it	O
can	O
sometimes	O
be	O
life	O
threatening	O
.	O

He	O
recovered	O
but	O
developed	O
melena	B-DISO
and	O
massive	O
fresh	O
rectal	B-DISO
bleeding	I-DISO
.	O

In	O
cases	O
of	O
this	O
kind	O
,	O
in	O
order	O
to	O
quickly	O
detect	O
the	O
prevalence	O
of	O
such	O
infections	B-DISO
,	O
a	O
surveillance	O
system	O
that	O
includes	O
hospital	O
personnel	O
is	O
essential	O
.	O

Lyssaviruses	O
of	O
different	O
genotypes	O
have	O
emerged	O
from	O
bats	O
in	O
America	O
(	O
Genotype	O
1	O
rabies	B-DISO
virus	O
;	O
RABV	O
),	O
Europe	O
(	O
European	O
bat	O
lyssavirus	O
;	O
EBLV	O
),	O
and	O
Australia	O
(	O
Australian	O
bat	O
lyssavirus	O
;	O
ABLV	O
),	O
whereas	O
Nipah	O
virus	O
is	O
the	O
most	O
important	O
recent	O
zoonosis	B-DISO
of	O
bat	O
origin	O
in	O
Asia	O
.	O

TITLE	O
:	O
Absence	O
of	O
surface	O
expression	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
antigens	O
on	O
infected	O
cells	O
isolated	O
from	O
cats	O
with	O
FIP	B-DISO
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
SARS	B-DISO
-	O
related	O
deaths	O
in	O
2003	O
,	O
Beijing	O
.	O

Old	O
age	O
(	O
over	O
60	O
years	O
)	O
was	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
SARS	B-DISO
-	O
related	O
deaths	O
in	O
the	O
univariate	O
analysis	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
found	O
four	O
risk	O
factors	O
for	O
SARS	B-DISO
-	O
related	O
deaths	O
.	O

Vaccinia	B-DISO
virus	O
replication	O
is	O
significantly	O
abrogated	O
upon	O
ATA	O
treatment	O
,	O
which	O
is	O
associated	O
with	O
the	O
inhibition	O
of	O
early	O
viral	O
gene	O
transcription	O
.	O

VRP	O
-	O
N	O
vaccines	O
not	O
only	O
failed	O
to	O
protect	O
from	O
homologous	O
or	O
heterologous	O
challenge	O
,	O
but	O
resulted	O
in	O
enhanced	O
immunopathology	B-DISO
with	O
eosinophilic	O
infiltrates	B-DISO
within	O
the	O
lungs	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
challenged	O
mice	O
.	O

The	O
alveolar	O
wall	O
ruptures	O
and	O
bronchial	O
dilatation	B-DISO
became	O
severe	O
during	O
this	O
period	O
.	O

We	O
identified	O
6	O
case	O
series	O
reporting	O
135	O
pediatric	O
SARS	B-DISO
patients	O
(	O
80	O
laboratory	O
-	O
confirmed	O
,	O
27	O
probable	O
and	O
28	O
suspect	O
)	O
from	O
Canada	O
,	O
Hong	O
Kong	O
,	O
Taiwan	O
and	O
Singapore	O
.	O

Children	O
and	O
adolescents	O
are	O
susceptible	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
infection	B-DISO
,	O
although	O
the	O
clinical	O
course	O
and	O
outcome	O
are	O
more	O
favorable	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
compared	O
with	O
adolescents	O
and	O
adults	O
.	O

The	O
structural	O
data	O
further	O
suggest	O
that	O
the	O
binding	O
of	O
APE	O
to	O
M	O
(	O
pro	O
)	O
follows	O
an	O
induced	O
-	O
fit	B-DISO
model	O
.	O

The	O
substrate	O
likely	O
also	O
binds	O
in	O
an	O
induced	O
-	O
fit	B-DISO
manner	O
in	O
a	O
process	O
that	O
may	O
help	O
drive	O
the	O
catalytic	O
cycle	O
.	O

ABSTRACT	O
:	O
Four	O
outbreaks	O
of	O
infectious	B-DISO
canine	I-DISO
hepatitis	I-DISO
(	O
ICH	B-DISO
)	O
occurring	O
in	O
Italy	O
between	O
2001	O
and	O
2006	O
are	O
reported	O
.	O

In	O
three	O
outbreaks	O
,	O
other	O
canine	O
viral	O
pathogens	O
were	O
detected	O
,	O
including	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
canine	O
parvovirus	B-DISO
or	O
canine	O
coronavirus	O
.	O

TITLE	O
:	O
[	O
Imported	O
severe	O
malaria	B-DISO
in	O
adults	O
:	O
a	O
retrospective	O
study	O
of	O
ten	O
cases	O
admitted	O
to	O
intensive	O
care	O
units	O
in	O
Casablanca	O
].	O

All	O
patients	O
presented	O
with	O
nosocomial	O
respiratory	B-DISO
infection	I-DISO
related	O
to	O
Gram	O
-	O
negative	O
bacilli	O
,	O
in	O
the	O
evolution	O
.	O

RESULTS	O
:	O
Ten	O
patients	O
were	O
included	O
for	O
severe	O
imported	O
malaria	B-DISO
.	O

TITLE	O
:	O
Development	O
and	O
validation	O
of	O
a	O
high	O
-	O
throughput	O
screen	O
for	O
inhibitors	O
of	O
SARS	B-DISO
CoV	O
and	O
its	O
application	O
in	O
screening	O
of	O
a	O
100	O
,	O
000	O
-	O
compound	O
library	O
.	O

ABSTRACT	O
:	O
The	O
authors	O
have	O
developed	O
a	O
high	O
-	O
throughput	O
screen	O
(	O
HTS	B-DISO
)	O
that	O
allows	O
for	O
the	O
identification	O
of	O
potential	O
inhibitors	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
)	O
from	O
large	O
compound	O
libraries	O
.	O

The	O
luminescent	O
-	O
based	O
assay	O
measures	O
the	O
inhibition	O
of	O
SARS	B-DISO
CoV	O
-	O
induced	O
cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
in	O
Vero	O
E6	O
cells	O
.	O

After	O
induction	O
of	O
general	O
anaesthesia	B-DISO
and	O
controlled	O
ventilation	O
,	O
an	O
arterial	O
line	O
and	O
a	O
pulmonary	O
artery	O
catheter	O
were	O
inserted	O
.	O

These	O
upregulated	O
immune	O
response	O
genes	O
included	O
TLR2	O
,	O
TLR3	O
,	O
interferon	O
-	O
induced	O
antiviral	O
genes	O
(	O
Mx	O
),	O
and	O
genes	O
responsible	O
for	O
cytotoxic	O
T	O
cell	O
killing	O
such	O
as	O
Fas	B-DISO
antigen	O
and	O
granzyme	O
-	O
A	O
.	O
Overall	O
,	O
a	O
diversity	O
of	O
innate	O
immunity	O
and	O
helper	O
T	O
cell	O
type	O
1	O
(	O
Th1	O
)-	O
biased	O
adaptive	O
immunity	O
are	O
activated	O
in	O
the	O
host	O
'	O
s	O
early	O
defense	O
against	O
IBV	O
invasion	B-DISO
,	O
and	O
they	O
are	O
responsible	O
for	O
the	O
rapid	O
clearance	O
of	O
virus	O
from	O
the	O
local	O
infection	B-DISO
.	O

Our	O
newly	O
developed	O
MAC	O
-	O
ELISA	O
system	O
offers	O
a	O
new	O
alternative	O
for	O
the	O
confirmation	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Changes	O
in	O
level	O
of	O
oxygen	O
metabolism	O
might	O
be	O
closely	O
correlated	O
with	O
development	O
of	O
MODS	B-DISO
in	O
trauma	O
patients	O
.	O

Dynamic	O
monitorings	O
of	O
metabolic	O
status	O
of	O
tissue	O
and	O
cell	O
are	O
valuable	O
in	O
predicting	O
the	O
development	O
of	O
MODS	B-DISO
after	O
severe	O
trauma	O
.	O

The	O
treatment	O
of	O
choice	O
for	O
non	O
-	O
falciparum	B-DISO
malaria	I-DISO
is	O
a	O
3	O
-	O
day	O
course	O
of	O
oral	O
chloroquine	O
,	O
to	O
which	O
only	O
a	O
limited	O
proportion	O
of	O
P	O
.	O
vivax	O
strains	O
have	O
gained	O
resistance	O
.	O

This	O
may	O
exacerbate	O
hypoglycaemia	B-DISO
that	O
can	O
occur	O
in	O
malaria	B-DISO
;	O
patients	O
treated	O
with	O
intravenous	O
quinine	O
therefore	O
require	O
careful	O
monitoring	O
.	O

An	O
acute	O
attack	O
of	O
malaria	B-DISO
does	O
not	O
confer	O
protection	O
from	O
future	O
attacks	O
:	O
individuals	O
who	O
have	O
had	O
malaria	B-DISO
should	O
take	O
effective	O
anti	O
-	O
mosquito	O
precautions	O
and	O
chemoprophylaxis	O
during	O
future	O
visits	O
to	O
endemic	O
areas	O
.	O

While	O
the	O
likelihood	O
of	O
such	O
a	O
prospect	O
is	O
uncertain	O
,	O
the	O
inevitability	O
of	O
future	O
pandemics	O
of	O
influenza	B-DISO
is	O
clear	O
.	O

Young	O
inbred	O
mice	O
support	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
replication	O
in	O
the	O
respiratory	O
tract	O
and	O
are	O
available	O
in	O
sufficient	O
numbers	O
for	O
statistical	O
evaluation	O
.	O

Older	O
(	O
12	O
-	O
to	O
14	O
-	O
mo	O
-	O
old	O
)	O
BALB	O
/	O
c	O
mice	O
develop	O
clinical	O
illness	O
and	O
pneumonitis	B-DISO
,	O
but	O
they	O
can	O
be	O
hard	O
to	O
procure	O
,	O
and	O
immune	O
senescence	O
complicates	O
pathogenesis	B-DISO
studies	O
.	O

Abundant	O
viral	O
antigen	O
is	O
extensively	O
distributed	O
in	O
bronchial	O
epithelial	O
cells	O
and	O
alveolar	O
pneumocytes	O
,	O
and	O
necrotic	O
cellular	O
debris	O
is	O
present	O
in	O
airways	O
and	O
alveoli	O
,	O
with	O
only	O
mild	O
and	O
focal	O
pneumonitis	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
respiratory	O
coronavirus	O
(	O
hCoV	O
)	O
HKU1	O
infections	B-DISO
were	O
reported	O
for	O
the	O
first	O
time	O
in	O
2005	O
in	O
Hong	O
Kong	O
.	O

HKU1	O
-	O
specific	O
MAb	O
may	O
contribute	O
to	O
the	O
rapid	O
diagnosis	O
of	O
HKU1	O
infections	B-DISO
currently	O
performed	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
nsps	O
assemble	O
with	O
membranes	O
to	O
generate	O
double	O
membrane	O
vesicles	B-DISO
,	O
which	O
are	O
the	O
sites	O
of	O
viral	O
RNA	O
synthesis	O
.	O

Pulmonary	B-DISO
infection	I-DISO
is	O
the	O
primary	O
manifestation	O
of	O
histoplasmosis	B-DISO
,	O
varying	O
from	O
mild	O
pneumonitis	B-DISO
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Our	O
objectives	O
are	O
to	O
quickly	O
interpret	O
symptoms	O
of	O
emergency	B-DISO
patients	O
to	O
identify	O
likely	O
syndromes	B-DISO
and	O
to	O
improve	O
population	O
-	O
wide	O
disease	O
outbreak	O
detection	O
.	O

59	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
ARDS	B-DISO
caused	O
by	O
SARS	B-DISO
between	O
March	O
and	O
July	O
2003	O
were	O
studied	O
prospectively	O
and	O
followed	O
up	O
for	O
1	O
year	O
.	O

Laboratory	O
data	O
showed	O
a	O
severe	O
anion	O
gap	O
metabolic	B-DISO
acidosis	I-DISO
,	O
with	O
a	O
serum	O
lactate	O
level	O
of	O
185	O
mg	O
/	O
dL	O
.	O
An	O
initial	O
diagnosis	O
of	O
cyanide	O
intoxication	O
was	O
considered	O
and	O
she	O
was	O
given	O
sodium	O
nitrite	O
and	O
sodium	O
thiosulfate	O
i	O
.	O
v	O
.	O

Yam	O
bean	O
seed	O
poisoning	O
can	O
cause	O
acute	O
metabolic	B-DISO
acidosis	I-DISO
and	O
altered	B-DISO
mental	I-DISO
status	I-DISO
,	O
which	O
could	O
be	O
confused	B-DISO
with	O
acute	O
cyanide	O
intoxication	O
from	O
a	O
cyanogenic	O
glycoside	O
-	O
containing	O
plant	O
.	O

We	O
characterized	O
the	O
structures	O
of	O
N	O
-	O
NTD	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
two	O
crystal	O
forms	O
,	O
at	O
1	O
.	O
17	O
A	O
(	O
monoclinic	O
)	O
and	O
at	O
1	O
.	O
85	O
A	O
(	O
cubic	O
),	O
respectively	O
,	O
resolved	O
by	O
molecular	O
replacement	O
using	O
the	O
homologous	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
structure	O
.	O

In	O
39	O
children	O
suffering	B-DISO
from	O
coronavirus	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
or	O
HKU1	O
,	O
the	O
sensitivity	O
was	O
equal	O
to	O
that	O
of	O
individual	O
real	O
-	O
time	O
RT	O
-	O
PCRs	O
.	O

Ninety	O
SARS	B-DISO
-	O
care	O
task	O
force	O
members	O
(	O
SARS	B-DISO
HCWs	O
)	O
and	O
82	O
control	O
subjects	O
.	O

All	O
serum	O
specimens	O
tested	O
negative	O
for	O
SARS	B-DISO
antibody	O
.	O

We	O
discuss	O
and	O
compare	O
different	O
methods	O
of	O
estimating	O
the	O
incubation	O
distribution	O
allowing	O
for	O
interval	O
censoring	O
of	O
exposures	O
,	O
using	O
data	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
in	O
2003	O
as	O
an	O
example	O
.	O

Currently	O
,	O
facility	O
engineers	O
and	O
designers	O
of	O
heating	O
,	O
ventilation	O
,	O
and	O
air	O
-	O
conditioning	O
(	O
HVAC	O
)	O
systems	O
have	O
few	O
analytical	O
tools	O
to	O
estimate	O
a	O
room	O
'	O
s	O
leakage	B-DISO
area	O
and	O
establish	O
an	O
appropriate	O
flow	O
differential	O
(	O
DeltaQ	O
)	O
in	O
hospitals	O
,	O
shelters	O
,	O
and	O
other	O
facilities	O
where	O
communicable	B-DISO
diseases	I-DISO
are	O
present	O
.	O

Statistical	O
analysis	O
of	O
the	O
model	O
and	O
experimental	O
validation	O
showed	O
that	O
the	O
model	O
effectively	O
estimated	O
the	O
actual	O
leakage	B-DISO
area	O
from	O
-	O
39	O
%	O
to	O
+	O
22	O
%	O
with	O
90	O
%	O
confidence	O
.	O

Complete	O
bio	O
-	O
isolation	O
or	O
the	O
use	O
of	O
biohazard	O
suits	O
are	O
not	O
practical	O
solutions	O
for	O
routine	O
day	O
-	O
to	O
-	O
day	O
patient	O
-	O
doctor	O
interactions	O
with	O
highly	O
infectious	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
New	O
respiratory	O
viruses	O
associated	O
with	O
pneumonia	B-DISO
have	O
in	O
the	O
past	O
few	O
years	O
been	O
detected	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
Two	O
factors	O
dominated	O
the	O
epidemiology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
during	O
the	O
2002	O
-	O
2003	O
global	O
outbreak	O
,	O
namely	O
super	O
-	O
spreading	O
events	O
(	O
SSE	O
)	O
and	O
hospital	B-DISO
infections	I-DISO
.	O

The	O
broadest	O
of	O
the	O
supported	O
hypotheses	O
ascribes	O
the	O
initial	O
surge	O
in	O
cases	O
to	O
a	O
single	O
super	O
-	O
spreading	O
individual	O
and	O
suggests	O
that	O
the	O
per	O
capita	O
risk	O
of	O
infection	B-DISO
to	O
patients	O
increased	O
approximately	O
one	O
month	O
after	O
the	O
start	O
of	O
the	O
outbreak	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
performed	O
double	O
labeling	O
combining	O
in	O
situ	O
hybridization	O
with	O
immunohistochemistry	O
and	O
alternating	O
each	O
of	O
these	O
techniques	O
separately	O
in	O
consecutive	O
sections	O
to	O
evaluate	O
the	O
viral	O
distribution	O
on	O
various	O
cell	O
types	O
in	O
the	O
lungs	O
of	O
seven	O
patients	O
affected	O
with	O
SARS	B-DISO
.	O

In	O
addition	O
,	O
our	O
present	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
infection	B-DISO
of	O
endothelial	O
cells	O
and	O
fibroblasts	O
in	O
SARS	B-DISO
.	O

Human	O
metapneumovirus	O
was	O
identified	O
in	O
nasopharyngeal	O
aspirate	O
amplification	B-DISO
of	O
the	O
viral	O
fusion	O
and	O
nucleocapsid	O
genes	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
and	O
phylogenetic	O
analysis	O
.	O

There	O
have	O
been	O
few	O
recent	O
studies	O
demonstrating	O
a	O
definitive	O
association	O
between	O
the	O
transmission	O
of	O
airborne	O
infections	B-DISO
and	O
the	O
ventilation	O
of	O
buildings	O
.	O

Ten	O
of	O
40	O
studies	O
reviewed	O
were	O
considered	O
to	O
be	O
conclusive	O
with	O
regard	O
to	O
the	O
association	O
between	O
building	O
ventilation	O
and	O
the	O
transmission	O
of	O
airborne	O
infection	B-DISO
.	O

TITLE	O
:	O
Association	O
of	O
bovine	O
respiratory	B-DISO
disease	I-DISO
with	O
clinical	O
status	O
and	O
acute	O
phase	O
proteins	O
in	O
calves	O
.	O

ABSTRACT	O
:	O
Eighty	O
-	O
four	O
calves	O
with	O
respiratory	B-DISO
disease	I-DISO
from	O
18	O
herds	O
in	O
different	O
parts	O
of	O
Finland	O
were	O
chosen	O
for	O
a	O
study	O
evaluating	O
the	O
capacity	O
of	O
different	O
respiratory	O
pathogens	O
to	O
cause	O
changes	O
in	O
different	O
acute	O
phase	O
protein	O
concentrations	O
,	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
and	O
clinical	O
signs	O
.	O

The	O
selected	O
acute	O
phase	O
proteins	O
were	O
fibrinogen	O
,	O
haptoglobin	O
,	O
serum	O
amyloid	B-DISO
-	O
A	O
,	O
lipopolysaccharide	O
binding	O
protein	O
and	O
alpha1	O
-	O
acid	O
glycoprotein	O
.	O

TITLE	O
:	O
[	O
Lessons	O
from	O
SARS	B-DISO
].	O

Although	O
the	O
initial	O
SARS	B-DISO
epidemic	O
was	O
contained	O
,	O
sporadic	O
outbreaks	O
of	O
the	O
disease	B-DISO
still	I-DISO
occur	O
,	O
suggesting	O
a	O
continuous	O
need	O
for	O
a	O
vaccine	O
against	O
this	O
virus	O
.	O

After	O
priming	O
with	O
the	O
SARS	B-DISO
-	O
S	O
exosomal	O
vaccine	O
and	O
boosting	O
with	O
the	O
adenoviral	O
vector	O
the	O
neutralizing	O
antibody	O
titers	O
exceeded	O
those	O
observed	O
in	O
the	O
convalescent	O
serum	O
of	O
a	O
SARS	B-DISO
patient	O
.	O

Influenza	B-DISO
and	O
parainfluenza	B-DISO
viruses	O
were	O
most	O
prevalent	O
,	O
at	O
14	O
.	O
2	O
%	O
and	O
15	O
.	O
5	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
the	O
novel	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
,	O
produced	O
a	O
scare	O
when	O
it	O
appeared	O
in	O
2003	O
in	O
China	O
and	O
later	O
quickly	O
spread	O
to	O
other	O
countries	O
around	O
the	O
world	O
.	O

The	O
most	O
promising	O
newly	O
developed	O
technology	O
for	O
intervention	O
in	O
SARS	B-DISO
may	O
be	O
RNA	O
interference	O
,	O
an	O
endogenous	O
cellular	O
process	O
for	O
the	O
inhibition	O
of	O
gene	O
expression	O
mediated	O
by	O
sequence	O
-	O
specific	O
double	O
-	O
stranded	O
RNAs	O
.	O

Because	O
of	O
this	O
,	O
it	O
is	O
speculated	O
that	O
children	O
vaccinated	O
with	O
various	O
childhood	O
vaccines	O
might	O
develop	O
cross	O
immunity	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
Antisera	O
and	O
T	O
cells	O
from	O
mice	O
immunised	O
with	O
various	O
vaccines	O
were	O
used	O
to	O
determine	O
whether	O
they	O
developed	O
cross	O
reactivity	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
results	O
showed	O
no	O
marked	O
cross	O
reactivity	O
against	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
implies	O
that	O
the	O
reduced	O
symptoms	O
among	O
children	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
may	O
be	O
caused	O
by	O
other	O
factors	O
.	O

It	O
makes	O
visible	O
how	O
during	O
SARS	B-DISO
China	O
eventually	O
complied	O
with	O
the	O
spirit	O
of	O
the	O
international	O
sanitation	O
regulations	O
but	O
the	O
lack	O
of	O
commitment	O
to	O
improving	O
access	O
to	O
health	O
care	O
for	O
persons	O
living	O
with	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
reflects	O
a	O
failure	O
by	O
China	O
to	O
guarantee	O
the	O
right	O
to	O
adequate	O
health	O
care	O
.	O

TITLE	O
:	O
Inhibitor	O
design	O
for	O
SARS	B-DISO
coronavirus	O
main	O
protease	O
based	O
on	O
""""	O
distorted	O
key	O
theory	O
"""."	O

Moreover	O
,	O
it	O
was	O
found	O
through	O
the	O
ligand	O
-	O
receptor	O
docking	O
studies	O
that	O
of	O
the	O
11	O
cleavable	O
peptides	O
,	O
NH2	O
-	O
ATLQ	O
/	O
AIAS	O
-	O
COOH	O
and	O
NH2	O
-	O
ATLQ	O
/	O
AENV	O
-	O
COOH	O
had	O
the	O
highest	O
affinity	O
with	O
SARS	B-DISO
CoV	O
M	O
(	O
pro	O
).	O

Our	O
results	O
provide	O
evidence	O
that	O
helps	O
us	O
understand	O
the	O
function	O
of	O
SRAS	O
-	O
CoV	O
spike	O
protein	O
in	O
SARS	B-DISO
pathogenesis	B-DISO
.	O

Furthermore	O
,	O
the	O
most	O
closely	O
related	O
bat	O
and	O
SARS	B-DISO
coronaviruses	O
diverged	O
in	O
1986	O
,	O
an	O
estimated	O
divergence	O
time	O
of	O
17	O
years	O
prior	O
to	O
the	O
outbreak	O
,	O
suggesting	O
that	O
there	O
may	O
have	O
been	O
transmission	O
via	O
an	O
unknown	O
intermediate	O
host	O
.	O

Analysis	O
of	O
lineage	O
-	O
specific	O
selection	O
pressure	O
also	O
indicated	O
that	O
only	O
SARS	B-DISO
coronaviruses	O
in	O
civets	O
and	O
humans	O
were	O
under	O
significant	O
positive	O
selection	O
,	O
also	O
demonstrating	O
a	O
recent	O
interspecies	O
transmission	O
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
a	O
prophylactic	O
/	O
therapeutic	O
HIV	B-DISO
-	O
1	O
vaccine	O
based	O
on	O
recombinant	O
proteins	O
is	O
needed	O
for	O
the	O
control	O
of	O
the	O
worldwide	O
AIDS	O
epidemic	O
.	O

We	O
evaluated	O
the	O
immunization	O
strategies	O
for	O
HIV	B-DISO
-	O
1	O
-	O
capturing	O
core	O
-	O
corona	O
type	O
polystyrene	O
nanospheres	O
that	O
would	O
efficiently	O
induce	O
HIV	B-DISO
-	O
1	O
-	O
specific	O
IgA	O
responses	O
in	O
female	O
mice	O
and	O
the	O
macaque	O
genital	O
tract	O
.	O

We	O
refer	O
to	O
the	O
images	O
captured	O
from	O
IR	O
imaging	O
as	O
thermal	O
texture	O
maps	O
(	O
TTM	B-DISO
).	O

The	O
nosocomial	O
prevalence	O
rate	O
was	O
highest	O
in	O
the	O
Intensive	O
Care	O
Unit	O
,	O
followed	O
by	O
the	O
Pediatric	O
and	O
Neonatal	O
Intensive	O
Care	O
Units	O
,	O
Children	O
'	O
s	O
Cancer	B-DISO
Centre	O
/	O
Bone	O
Marrow	O
Transplant	O
Unit	O
and	O
Orthopaedics	O
with	O
Traumatology	O
.	O

ABSTRACT	O
:	O
The	O
role	O
that	O
bats	O
have	O
played	O
in	O
the	O
emergence	O
of	O
several	O
new	O
infectious	B-DISO
diseases	I-DISO
has	O
been	O
under	O
review	O
.	O

In	O
SAP	O
-	O
S	O
group	O
,	O
rats	O
received	O
the	O
first	O
intraperitoneal	O
injection	O
of	O
isotonic	O
saline	O
2	O
h	O
after	O
induction	O
of	O
acute	B-DISO
pancreatitis	I-DISO
and	O
a	O
repeated	O
injection	O
after	O
12	O
h	O
.	O
In	O
SAP	O
-	O
ICE	O
-	O
I	O
group	O
,	O
the	O
rats	O
were	O
firstly	O
given	O
ICE	O
inhibitors	O
intraperitoneally	O
2	O
h	O
after	O
induction	O
of	O
pancreatitis	B-DISO
.	O

ABSTRACT	O
:	O
To	O
describe	O
Ottawa	O
family	O
physicians	O
'	O
perceptions	O
of	O
their	O
preparedness	O
to	O
respond	O
to	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
or	O
other	O
public	O
health	O
emergencies	B-DISO
and	O
to	O
assess	O
their	O
capacity	O
and	O
willingness	O
to	O
assist	O
in	O
the	O
event	O
of	O
such	O
emergencies	B-DISO
.	O

Association	O
rule	O
mining	O
was	O
applied	O
first	O
but	O
results	O
showed	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
locations	O
of	O
the	O
lesions	O
or	O
infiltrate	B-DISO
.	O

A	O
sample	O
set	O
contains	O
both	O
the	O
pneumonia	B-DISO
and	O
SARS	B-DISO
X	O
-	O
ray	O
images	O
was	O
built	O
in	O
the	O
first	O
place	O
.	O

Final	O
result	O
shows	O
that	O
70	O
.	O
94	O
%	O
SARS	B-DISO
cases	O
can	O
be	O
detected	O
by	O
CART	O
.	O

TITLE	O
:	O
Characterizing	O
Transmission	O
and	O
Control	O
of	O
the	O
SARS	B-DISO
Epidemic	O
:	O
Novel	O
Stochastic	O
Spatio	O
-	O
Temporal	O
Models	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
novel	O
comprehensive	O
stochastic	O
spatio	O
-	O
temporal	O
models	O
from	O
both	O
of	O
the	O
macro	O
aspect	O
and	O
individual	O
aspect	O
for	O
characterizing	O
transmission	O
and	O
control	O
of	O
the	O
SARS	B-DISO
disease	O
.	O

Recent	O
experiences	O
with	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
monkeypox	B-DISO
,	O
and	O
anthrax	B-DISO
,	O
as	O
well	O
as	O
response	O
planning	O
for	O
bioterrorism	O
and	O
pandemic	O
influenza	B-DISO
,	O
illustrate	O
the	O
challenges	O
of	O
making	O
recommendations	O
about	O
treatment	O
and	O
prophylaxis	O
for	O
pregnant	O
women	O
.	O

TITLE	O
:	O
Reflections	O
on	O
critical	O
care	O
emergency	B-DISO
preparedness	O
:	O
the	O
necessity	O
of	O
planned	O
education	O
and	O
leadership	O
training	O
for	O
nurses	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
TGEV	O
infection	B-DISO
,	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
(	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
)	O
targeting	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
gene	O
of	O
TGEV	O
were	O
constructed	O
and	O
transfected	O
into	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
.	O

into	O
IL	O
-	O
2	O
receptor	O
gamma	O
-	O
chain	O
disrupted	O
SCID	B-DISO
mice	O
,	O
and	O
SCID	B-DISO
-	O
PBL	O
/	O
hu	O
mice	O
were	O
constructed	O
.	O

Phylogenetic	O
analysis	O
suggested	O
that	O
there	O
are	O
at	O
least	O
four	O
groups	O
of	O
IBVs	O
circulating	O
in	O
China	O
and	O
the	O
disease	O
outbreaks	O
might	O
have	O
been	O
caused	O
by	O
infection	B-DISO
of	O
multiple	O
strains	O
of	O
IBV	O
.	O

A	O
systematic	O
review	O
(	O
Highwire	O
,	O
Medline	O
,	O
Cochrane	O
Library	O
from	O
1976	O
to	O
2004	O
),	O
using	O
the	O
keywords	O
:	O
prone	O
position	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
allowed	O
us	O
to	O
include	O
the	O
human	O
studies	O
on	O
PP	O
in	O
ARDS	B-DISO
patients	O
,	O
independantly	O
of	O
their	O
objectives	O
or	O
their	O
type	O
of	O
protocol	O
.	O

The	O
highest	O
values	O
of	O
sICAM	O
-	O
1	O
were	O
observed	O
in	O
patients	O
with	O
TBI	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
those	O
of	O
sE	O
-	O
Selectin	O
in	O
patients	O
with	O
sepsis	B-DISO
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

A	O
sustained	O
increase	O
of	O
adhesion	B-DISO
molecules	O
occurs	O
during	O
acute	B-DISO
stress	I-DISO
in	O
children	O
which	O
may	O
contribute	O
to	O
morbidity	O
in	O
patients	O
with	O
sepsis	B-DISO
(	O
sE	O
-	O
Selectin	O
)	O
or	O
traumatic	O
brain	O
injury	O
(	O
sICAM	O
-	O
1	O
).	O

TITLE	O
:	O
Coronavirus	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
.	O

Interestingly	O
breeds	O
of	O
chicken	O
vary	O
with	O
respect	O
to	O
the	O
severity	O
of	O
infection	B-DISO
with	O
IBV	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
The	O
association	O
between	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
outcomes	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
is	O
unclear	O
.	O

To	O
evaluate	O
the	O
epidemics	O
and	O
disease	O
spectrum	O
of	O
HCoV	O
-	O
NL63	O
infection	B-DISO
in	O
children	O
in	O
Taiwan	O
,	O
we	O
prospectively	O
screened	O
children	O
admitted	O
to	O
the	O
hospital	O
with	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
from	O
May	O
2004	O
to	O
April	O
2005	O
.	O

TITLE	O
:	O
The	O
potential	O
of	O
targeted	O
antibody	O
prophylaxis	O
in	O
SARS	B-DISO
outbreak	O
control	O
:	O
a	O
mathematic	O
analysis	O
.	O

TITLE	O
:	O
[	O
Perioperative	O
respiratory	B-DISO
complications	I-DISO
in	O
pediatric	O
patients	O
with	O
mediastinal	O
masses	O
:	O
a	O
report	O
of	O
2	O
cases	O
].	O

He	O
developed	O
negative	B-DISO
pressure	I-DISO
pulmonary	I-DISO
edema	I-DISO
secondary	O
to	O
severe	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
in	O
spontaneous	O
ventilation	O
.	O

The	O
second	O
was	O
a	O
14	O
-	O
year	O
-	O
old	O
boy	O
with	O
Rosai	B-DISO
-	I-DISO
Dorfman	I-DISO
disease	I-DISO
and	O
paratracheal	O
lymph	O
node	O
involvement	O
.	O

Rescued	O
virus	O
-	O
infected	O
cells	O
were	O
detected	O
by	O
indirect	O
fluorescent	O
antibody	O
staining	O
demonstrated	O
that	O
it	O
can	O
specifically	O
reaction	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
By	O
CPE	O
method	O
and	O
plaque	B-DISO
assay	O
,	O
the	O
titers	O
of	O
the	O
rescued	O
virus	O
and	O
wild	O
-	O
type	O
virus	O
were	O
assessed	O
,	O
which	O
demonstrated	O
there	O
are	O
no	O
significant	O
difference	O
between	O
the	O
viruses	O
and	O
they	O
have	O
similar	O
biological	O
characteristics	O
.	O

TITLE	O
:	O
Detection	O
and	O
typing	O
by	O
molecular	O
techniques	O
of	O
respiratory	O
viruses	O
in	O
children	O
hospitalized	O
for	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
Rome	O
,	O
Italy	O
.	O

When	O
N	O
-	O
IgG	O
and	O
S	O
-	O
IgG	O
were	O
tested	O
40	O
days	O
after	O
the	O
onset	O
of	O
the	O
disease	O
at	O
three	O
different	O
times	O
,	O
the	O
positive	O
rate	O
of	O
N	O
-	O
IgG	O
(	O
92	O
.	O
5	O
%,	O
37	O
/	O
40	O
)	O
was	O
higher	O
than	O
that	O
of	O
S	O
-	O
IgG	O
(	O
67	O
.	O
5	O
%,	O
27	O
/	O
40	O
),	O
but	O
the	O
two	O
structure	O
protein	O
antibodies	O
were	O
always	O
lower	O
than	O
the	O
total	O
IgG	O
.	O
In	O
SARS	B-DISO
patients	O
with	O
definite	O
clinical	O
and	O
etiological	O
diagnosis	O
,	O
the	O
highest	O
positive	O
rate	O
of	O
the	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
was	O
found	O
at	O
21	O
-	O
40	O
days	O
after	O
the	O
onset	O
.	O

TITLE	O
:	O
Natural	O
mutations	O
in	O
the	O
receptor	O
binding	O
domain	O
of	O
spike	O
glycoprotein	O
determine	O
the	O
reactivity	O
of	O
cross	O
-	O
neutralization	O
between	O
palm	O
civet	O
coronavirus	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Moreover	O
,	O
pseudoviruses	O
generated	O
in	O
our	O
laboratory	O
with	O
four	O
civet	O
S	O
genes	O
,	O
each	O
with	O
a	O
distinct	O
RBD	O
,	O
infected	O
cells	O
expressing	O
human	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
but	O
with	O
90	O
to	O
95	O
%	O
less	O
efficiency	O
compared	O
to	O
that	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
These	O
four	O
civet	O
S	O
genes	O
were	O
also	O
constructed	O
as	O
DNA	O
vaccines	O
to	O
immunize	O
mice	O
.	O

Infection	B-DISO
of	O
fibroblasts	O
with	O
the	O
murine	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
and	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
did	O
not	O
result	O
in	O
nuclear	O
translocation	B-DISO
of	O
interferon	O
-	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
),	O
a	O
key	O
transcription	O
factor	O
involved	O
in	O
IFN	O
induction	O
,	O
and	O
induction	O
of	O
IFN	O
mRNA	O
transcription	O
.	O

Aspirin	O
non	O
-	O
responsiveness	O
is	O
more	O
frequent	O
in	O
severe	O
infections	B-DISO
,	O
such	O
as	O
pneumonia	B-DISO
.	O

Detection	O
of	O
tuberculosis	B-DISO
had	O
stagnated	O
at	O
around	O
30	O
%	O
of	O
the	O
estimated	O
total	O
of	O
new	O
cases	O
,	O
and	O
multidrug	B-DISO
-	I-DISO
resistant	I-DISO
tuberculosis	I-DISO
was	O
a	O
major	O
problem	O
.	O

These	O
signs	O
of	O
inadequate	O
tuberculosis	B-DISO
control	O
can	O
be	O
linked	O
to	O
a	O
malfunctioning	O
health	O
system	O
.	O

The	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
,	O
brought	O
to	O
light	O
substantial	O
weaknesses	B-DISO
in	O
the	O
country	O
'	O
s	O
public	O
-	O
health	O
system	O
.	O

TITLE	O
:	O
Ultrastructural	O
study	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
in	O
infundibulum	O
and	O
magnum	O
of	O
commercial	O
laying	O
hens	O
.	O

IBV	O
can	O
cause	O
pathology	B-DISO
in	O
parts	O
of	O
the	O
fully	O
functional	O
oviduct	O
which	O
may	O
persist	O
up	O
to	O
the	O
30th	O
day	O
p	O
.	O
i	O
.	O

A	O
27	O
-	O
year	O
-	O
old	O
male	O
,	O
previously	O
treated	O
with	O
bleomycin	O
for	O
a	O
testicular	O
germ	B-DISO
cell	I-DISO
tumour	I-DISO
presented	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
the	O
second	O
postoperative	O
day	O
following	O
an	O
extensive	O
retroperitoneal	O
dissection	O
.	O

Alfacell	O
is	O
conducting	O
a	O
confirmatory	O
phase	O
IIIb	O
registration	O
trial	O
of	O
ranpirnase	O
plus	O
doxorubicin	O
versus	O
doxorubicin	O
alone	O
in	O
more	O
than	O
360	O
patients	O
with	O
unresectable	O
malignant	B-DISO
mesothelioma	I-DISO
,	O
and	O
will	O
assess	O
survival	O
as	O
the	O
primary	O
endpoint	O
.	O

Inhibitors	O
of	O
iNOS	O
may	O
be	O
potential	O
therapeutic	O
agents	O
for	O
clinical	O
application	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Feline	O
aminopeptidase	O
N	O
(	O
fAPN	O
)	O
serves	O
as	O
a	O
functional	O
receptor	O
for	O
most	O
group	O
1	O
coronaviruses	O
including	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
),	O
canine	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

TITLE	O
:	O
Challenges	O
faced	O
by	O
hospital	O
healthcare	O
workers	O
in	O
using	O
a	O
syndrome	B-DISO
-	O
based	O
surveillance	O
system	O
during	O
the	O
2003	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Taiwan	O
.	O

From	O
13	O
to	O
26	O
months	O
after	O
the	O
SARS	B-DISO
outbreak	O
,	O
769	O
HCWs	O
at	O
9	O
Toronto	O
hospitals	O
that	O
treated	O
SARS	B-DISO
patients	O
and	O
4	O
Hamilton	O
hospitals	O
that	O
did	O
not	O
treat	O
SARS	B-DISO
patients	O
completed	O
a	O
survey	O
of	O
several	O
adverse	O
outcomes	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
the	O
first	O
natural	O
disaster	O
that	O
challenged	O
the	O
Chinese	O
people	O
at	O
the	O
beginning	O
of	O
the	O
twenty	O
-	O
first	O
century	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
life	O
-	O
threatening	O
melioidosis	B-DISO
with	O
activated	O
protein	O
C	O
and	O
meropenem	O
.	O

TITLE	O
:	O
A	O
human	O
anti	O
-	O
neuronal	O
autoantibody	O
against	O
GABA	O
B	O
receptor	O
induces	O
experimental	O
autoimmune	B-DISO
agrypnia	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
nucleoside	O
analogues	O
having	O
6	O
-	O
chloropurine	O
as	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
agents	O
.	O

During	O
the	O
SARS	B-DISO
outbreak	O
in	O
2003	O
,	O
ED	O
visits	O
declined	O
by	O
21	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
18	O
%-	O
24	O
%)	O
over	O
the	O
4	O
-	O
week	O
study	O
period	O
.	O

This	O
research	O
may	O
facilitate	O
those	O
healthcare	O
services	O
planning	O
to	O
minimise	O
the	O
impact	O
of	O
infection	B-DISO
control	O
measures	O
on	O
patient	O
care	O
.	O

TITLE	O
:	O
REMOVED	O
:	O
SARS	B-DISO
Epidemiology	O
From	O
descriptive	O
to	O
mechanistic	O
analyses	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
possess	B-DISO
large	O
RNA	O
genomes	O
and	O
exist	O
as	O
quasispecies	O
,	O
which	O
increases	O
the	O
possibility	O
of	O
adaptive	O
mutations	O
and	O
interspecies	O
transmission	O
.	O

CoV	O
particles	O
were	O
detected	O
by	O
immune	O
electron	O
microscopy	O
in	O
fecal	O
samples	O
from	O
three	O
giraffes	O
with	O
mild	O
-	O
to	O
-	O
severe	B-DISO
diarrhea	I-DISO
.	O

However	O
,	O
the	O
strong	O
antiviral	O
effect	O
observed	O
suggests	O
that	O
with	O
further	O
development	O
,	O
P	O
-	O
PMO	O
may	O
provide	O
an	O
effective	O
therapeutic	O
approach	O
against	O
a	O
broad	O
range	O
of	O
coronavirus	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
This	O
article	O
summarizes	O
the	O
significant	O
developments	O
and	O
new	O
discoveries	O
in	O
both	O
the	O
virology	O
and	O
antiviral	O
research	O
associated	O
with	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
)	O
that	O
were	O
reported	O
in	O
2005	O
and	O
2006	O
.	O

Areas	O
reviewed	O
include	O
genomic	O
studies	O
and	O
the	O
identification	O
of	O
bat	O
-	O
SARS	B-DISO
CoV	O
,	O
spike	O
protein	O
and	O
host	O
cell	O
entry	O
,	O
nucleocapsid	O
protein	O
,	O
accessory	O
proteins	O
,	O
non	O
-	O
structural	O
proteins	O
of	O
the	O
replicase	O
complex	O
,	O
viral	O
proteases	O
and	O
their	O
inhibitors	O
,	O
and	O
clinical	O
treatment	O
of	O
SARS	B-DISO
with	O
ribavirin	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
pandemic	O
took	O
774	O
lives	O
around	O
the	O
globe	O
and	O
infected	O
more	O
than	O
8000	O
people	O
in	O
29	O
countries	O
.	O

SARS	B-DISO
-	O
CoV	O
is	O
believed	O
to	O
be	O
of	O
zoonotic	O
origin	O
,	O
transmitted	B-DISO
from	O
its	O
natural	O
reservoir	O
in	O
bats	O
through	O
several	O
animal	O
species	O
(	O
e	O
.	O
g	O
.,	O
civet	O
cats	O
,	O
raccoon	O
dogs	O
sold	O
for	O
human	O
consumption	O
in	O
markets	O
in	O
southern	O
China	O
).	O

HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
were	O
identified	O
shortly	O
after	O
the	O
SARS	B-DISO
-	O
CoV	O
outbreak	O
.	O

ABSTRACT	O
:	O
Fragments	O
within	O
S1	O
genes	O
((	O
poly100	O
)	O
S1	O
)	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
ZJ971	O
,	O
M41	O
and	O
SC021202	O
(	O
SC	O
)	O
were	O
subcloned	O
into	O
a	O
prokaryotic	O
expression	O
vector	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

This	O
concern	O
makes	O
it	O
important	O
to	O
review	O
the	O
most	O
current	O
guidelines	O
for	O
the	O
management	O
of	O
viral	O
respiratory	B-DISO
diseases	I-DISO
in	O
pregnancy	O
.	O

The	O
topics	O
covered	O
are	O
influenza	B-DISO
,	I-DISO
avian	I-DISO
influenza	B-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

There	O
is	O
no	O
commercially	O
available	O
vaccine	O
at	O
this	O
time	O
to	O
prevent	O
infection	B-DISO
.	O

Examples	O
of	O
CBAs	O
include	O
the	O
procaryotic	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
plant	O
lectins	O
such	O
as	O
HHA	B-DISO
,	O
GNA	O
,	O
NPA	O
,	O
CA	O
and	O
UDA	O
,	O
the	O
monoclonal	O
antibody	O
2G12	O
directed	O
against	O
a	O
glycan	O
-	O
containing	O
epitope	O
on	O
HIV	B-DISO
envelope	O
gp120	O
,	O
and	O
the	O
mannose	O
-	O
specific	O
non	O
-	O
peptidic	O
antibiotic	O
Pradimicin	O
A	O
,	O
which	O
inhibits	O
the	O
entry	O
of	O
HIV	B-DISO
-	O
1	O
into	O
its	O
target	O
cells	O
.	O

TITLE	O
:	O
Angiogenesis	O
in	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
.	O

In	O
emphysema	B-DISO
patients	O
,	O
there	O
is	O
a	O
loss	O
of	O
lung	O
microvessels	O
,	O
and	O
in	O
many	O
forms	O
of	O
severe	O
PH	O
there	O
is	O
obliteration	O
of	O
precapillary	O
arterioles	O
by	O
angioproliferation	O
.	O

The	O
mean	O
age	O
was	O
42	O
.	O
9	O
+/-	O
15	O
.	O
9	O
years	O
(	O
range	O
:	O
18	O
-	O
80	O
years	O
)	O
and	O
the	O
etiology	O
of	O
the	O
pancreatitis	B-DISO
was	O
gallstones	B-DISO
in	O
29	O
patients	O
,	O
alcohol	O
in	O
22	O
patients	O
while	O
no	O
cause	O
could	O
be	O
ascertained	O
in	O
9	O
.	O

The	O
patients	O
who	O
were	O
hypoxemic	O
at	O
presentation	O
had	O
a	O
higher	O
incidence	O
of	O
organ	B-DISO
failure	I-DISO
during	O
the	O
course	O
of	O
the	O
disease	O
.	O

Pleural	B-DISO
effusion	I-DISO
at	O
admission	O
was	O
noticed	O
in	O
50	O
%,	O
atelectasis	B-DISO
in	O
25	O
%,	O
and	O
pulmonary	B-DISO
infiltrates	I-DISO
in	O
6	O
.	O
7	O
%.	O

On	O
logistic	O
regression	O
analysis	O
,	O
the	O
development	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
other	O
organ	O
dysfunctions	O
were	O
independent	O
risk	O
factors	O
for	O
mortality	O
.	O

The	O
public	O
in	O
Hong	O
Kong	O
is	O
likely	O
to	O
adopt	O
self	O
-	O
protective	O
behaviors	O
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	B-DISO
mask	O
in	O
public	O
venues	O
(	O
73	O
.	O
8	O
%),	O
increasing	O
the	O
frequency	O
of	O
handwashing	O
(	O
86	O
.	O
7	O
%))	O
and	O
behaviors	O
that	O
protect	O
others	O
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	B-DISO
masks	O
when	O
experiencing	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
,	O
92	O
.	O
4	O
%),	O
immediately	O
seeking	O
medical	O
consultation	O
(	O
94	O
.	O
2	O
%),	O
making	O
declarations	O
when	O
crossing	O
the	O
border	O
with	O
ILI	O
(	O
87	O
.	O
1	O
%),	O
complying	O
to	O
quarantine	O
policies	O
(	O
88	O
.	O
3	O
%)).	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
cyclin	O
D1	O
was	O
reduced	O
post	O
-	O
transcriptionally	O
within	O
infected	O
cells	O
independently	O
of	O
the	O
cell	O
-	O
cycle	O
stage	O
at	O
the	O
time	O
of	O
infection	B-DISO
.	O

Some	O
infectious	B-DISO
pathogens	O
,	O
originated	O
in	O
wild	O
animals	O
and	O
/	O
or	O
maintained	O
in	O
sylvatic	O
environments	O
,	O
have	O
become	O
increasingly	O
important	O
worldwide	O
for	O
their	O
impact	O
on	O
wildlife	O
,	O
human	O
health	O
,	O
livestock	O
and	O
agricultural	O
production	O
systems	O
.	O

TITLE	O
:	O
Unusual	O
etiology	O
of	O
acute	O
lung	O
injury	O
in	O
a	O
patient	O
with	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
.	O

To	O
report	O
a	O
patient	O
with	O
Acute	B-DISO
Myocardial	I-DISO
Infarction	I-DISO
(	O
AMI	B-DISO
)	O
who	O
developed	O
ALI	O
possibly	O
due	O
to	O
multiple	O
defibrillation	O
shocks	B-DISO
.	O

Cardiac	B-DISO
failure	I-DISO
or	O
any	O
known	O
etiology	O
of	O
ALI	O
was	O
ruled	O
out	O
.	O

The	O
patient	O
was	O
discharged	O
alive	O
and	O
in	O
good	O
condition	B-DISO
at	O
the	O
19th	O
day	O
after	O
admission	O
.	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	B-DISO
effect	O
is	O
lost	O
when	O
the	O
immune	O
cells	O
undergo	O
premature	O
apoptosis	O
apparently	O
because	O
their	O
Bcl	O
-	O
2	O
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

TITLE	O
:	O
Anti	O
-	O
viral	O
effector	O
T	O
cell	O
responses	O
and	O
trafficking	O
are	O
not	O
dependent	O
upon	O
DRAK2	O
signaling	O
following	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
.	O

Intracerebral	O
infection	B-DISO
of	O
mice	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
followed	O
by	O
an	O
immune	O
-	O
mediated	O
demyelinating	B-DISO
disease	I-DISO
.	O

Among	O
2197	O
subjects	O
studied	O
,	O
a	O
total	O
of	O
9	O
subjects	O
(	O
0	O
.	O
4	O
%)	O
displayed	O
positive	O
findings	O
for	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
.	O

In	O
conclusion	O
,	O
HCWs	O
from	O
the	O
ER	O
faced	O
a	O
relatively	O
high	O
risk	O
for	O
potential	O
infection	B-DISO
by	O
the	O
SARS	B-DISO
virus	O
when	O
caring	O
for	O
patients	O
who	O
had	O
not	O
been	O
diagnosed	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
Ethics	O
and	O
public	O
health	O
emergencies	B-DISO
:	O
restrictions	O
on	O
liberty	O
.	O

Six	O
risk	O
factors	O
were	O
significant	O
in	O
the	O
final	O
multiple	O
-	O
logistic	O
regression	O
model	O
:	O
minimum	O
distance	O
between	O
beds	O
of	O
<	O
or	O
=	O
1	O
m	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
6	O
.	O
94	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
68	O
-	O
28	O
.	O
75	O
),	O
availability	O
of	O
washing	O
or	O
changing	O
facilities	O
for	O
staff	O
(	O
OR	O
,	O
0	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
02	O
-	O
0	O
.	O
97	O
),	O
whether	O
resuscitation	O
was	O
ever	O
performed	O
in	O
the	O
ward	O
(	O
OR	O
,	O
3	O
.	O
81	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
04	O
-	O
13	O
.	O
87	O
),	O
whether	O
staff	O
members	O
worked	O
while	O
experiencing	O
symptoms	O
(	O
OR	O
,	O
10	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
28	O
-	O
48	O
.	O
87	O
),	O
whether	O
any	O
host	O
patients	O
(	O
index	O
patient	O
or	O
the	O
first	O
patient	O
with	O
SARS	B-DISO
admitted	O
to	O
a	O
ward	O
)	O
required	O
oxygen	O
therapy	O
(	O
OR	O
,	O
4	O
.	O
30	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
00	O
-	O
18	O
.	O
43	O
),	O
and	O
whether	O
any	O
host	O
patients	O
required	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
ventilation	O
(	O
OR	O
,	O
11	O
.	O
82	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
97	O
-	O
70	O
.	O
80	O
).	O

In	O
opioid	O
-	O
dependent	O
patients	O
,	O
naloxone	O
is	O
used	O
in	O
the	O
treatment	O
of	O
opioid	O
-	O
overdose	O
-	O
induced	O
respiratory	B-DISO
depression	I-DISO
,	O
in	O
(	O
ultra	O
)	O
rapid	O
detoxification	O
and	O
in	O
combination	O
with	O
buprenorphine	O
for	O
maintenance	O
therapy	O
(	O
to	O
prevent	O
intravenous	O
abuse	B-DISO
).	O

Since	O
1998	O
,	O
a	O
web	B-DISO
based	O
informatics	O
tool	O
has	O
been	O
developed	O
in	O
order	O
to	O
allow	O
information	O
to	O
be	O
shared	O
between	O
the	O
relevant	O
public	O
health	O
authorities	O
.	O

TITLE	O
:	O
Human	O
immunopathogenesis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
molecular	O
and	O
cellular	O
basis	O
for	O
how	O
SARS	B-DISO
CoV	O
impacts	O
the	O
host	O
immune	O
system	O
resulting	O
in	O
severe	O
SARS	B-DISO
,	O
however	O
,	O
has	O
not	O
been	O
elucidated	O
.	O

We	O
contend	O
that	O
dysregulated	O
type	O
I	O
and	O
II	O
interferon	O
(	O
IFN	O
)	O
responses	O
during	O
SARS	B-DISO
may	O
culminate	O
in	O
a	O
failure	O
of	O
the	O
switch	O
from	O
hyper	O
-	O
innate	O
immunity	O
to	O
protective	O
adaptive	O
immune	O
responses	O
in	O
the	O
human	O
host	O
.	O

ABSTRACT	O
:	O
The	O
sequential	O
determination	O
of	O
crystal	O
structures	O
of	O
the	O
SARS	B-DISO
coronavirus	O
spike	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
cellular	O
receptor	O
or	O
neutralizing	O
antibody	O
opened	O
a	O
door	O
for	O
the	O
design	O
and	O
development	O
of	O
antiviral	O
competitive	O
inhibitors	O
.	O

ABSTRACT	O
:	O
In	O
total	O
,	O
55	O
isolates	O
of	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
were	O
collected	O
from	O
cases	O
of	O
enteric	O
and	O
respiratory	B-DISO
disease	I-DISO
occurring	O
between	O
1999	O
and	O
2006	O
in	O
Japan	O
.	O

Patients	O
were	O
selected	O
from	O
all	O
infants	O
>	O
or	O
=	O
34	O
weeks	O
gestational	O
age	O
who	O
required	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
SLE	B-DISO
2000	O
HFO	O
,	O
SLE	B-DISO
,	O
UK	O
)	O
or	O
conventional	O
mechanical	O
ventilation	O
for	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
PPHN	O
.	O

Inhaled	O
nitric	O
oxide	O
significantly	O
improved	O
oxygenation	O
index	O
,	O
arterial	O
alveolar	O
oxygen	O
tension	B-DISO
ratio	O
(	O
a	O
/	O
A	O
O2	O
),	O
and	O
alveolar	O
arterial	O
oxygen	O
gradient	O
in	O
survivors	O
at	O
one	O
hour	O
after	O
treatment	O
.	O

Inhaled	O
nitric	O
oxide	O
should	O
be	O
used	O
early	O
in	O
severe	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
with	O
persistent	B-DISO
pulmonary	I-DISO
hypertension	I-DISO
of	I-DISO
newborn	I-DISO
and	O
can	O
improve	O
survival	O
rates	O
without	O
any	O
major	O
immediate	O
side	O
effects	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
SARS	B-DISO
coronavirus	O
nucleocapsid	O
protein	O
RNA	O
-	O
binding	O
dimerization	O
domain	O
suggests	O
a	O
mechanism	O
for	O
helical	O
packaging	O
of	O
viral	O
RNA	O
.	O

The	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
highly	O
antigenic	O
and	O
associated	O
with	O
several	O
host	O
-	O
cell	O
interactions	O
.	O

ABSTRACT	O
:	O
Timeliness	O
is	O
a	O
critical	O
issue	O
in	O
preventing	O
the	O
spread	O
of	O
emerging	O
/	O
notifiable	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
avian	B-DISO
influenza	I-DISO
(	O
bird	B-DISO
flu	I-DISO
).	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
65	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
repeated	O
lung	O
injuries	O
after	O
reduced	O
-	O
intensity	O
allogeneic	O
stem	O
cell	O
transplantation	O
(	O
RIST	O
)	O
for	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
.	O

Severe	O
pneumonitis	B-DISO
developed	O
twice	O
at	O
the	O
time	O
of	O
neutrophil	O
recovery	O
and	O
acute	B-DISO
graft	I-DISO
-	I-DISO
versus	I-DISO
-	I-DISO
host	I-DISO
disease	I-DISO
.	O

The	O
use	O
of	O
high	O
-	O
dose	O
ribavirin	O
is	O
appropriate	O
only	O
for	O
the	O
treatment	O
of	O
infectious	B-DISO
diseases	I-DISO
for	O
which	O
ribavirin	O
has	O
proven	O
clinical	O
efficacy	O
,	O
or	O
in	O
the	O
context	O
of	O
a	O
clinical	O
trial	O
.	O

RESULTS	O
:	O
Modulation	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
using	O
a	O
combination	O
of	O
immunomodulatory	O
agents	O
may	O
decrease	O
the	O
incidence	O
of	O
severe	O
pancreatitis	B-DISO
-	O
related	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Mediterranean	B-DISO
spotted	I-DISO
fever	I-DISO
is	O
considered	O
to	O
be	O
a	O
benign	O
disease	O
,	O
however	O
,	O
approximately	O
10	O
%	O
of	O
patients	O
present	O
with	O
a	O
severe	O
systemic	O
manifestation	O
in	O
which	O
neurologic	O
involvement	O
occurs	O
.	O

In	O
the	O
context	O
of	O
an	O
extensive	O
outbreak	O
with	O
major	O
pressure	O
on	O
hospital	O
resources	O
,	O
patient	O
self	O
-	O
collected	O
samples	O
are	O
an	O
alternative	O
to	O
nasopharyngeal	O
aspirates	O
for	O
laboratory	O
confirmation	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
replicase	O
protein	O
nsp10	O
is	O
a	O
critical	O
regulator	O
of	O
viral	O
RNA	O
synthesis	O
.	O

Of	O
the	O
16	O
engineered	O
clones	O
,	O
5	O
viable	O
viruses	O
were	O
rescued	O
,	O
3	O
mutant	B-DISO
viruses	O
generated	O
no	O
cytopathic	B-DISO
effect	I-DISO
but	O
were	O
competent	O
to	O
synthesize	O
viral	O
subgenomic	O
RNAs	O
,	O
and	O
8	O
were	O
not	O
viable	O
.	O

Finally	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
common	O
assay	O
components	O
including	O
DTT	O
,	O
NaCl	O
,	O
EDTA	O
and	O
DMSO	O
on	O
enzymatic	O
activity	O
,	O
and	O
we	O
recommend	O
standardized	O
assay	O
conditions	O
and	O
constructs	O
for	O
routine	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
assays	O
to	O
facilitate	O
direct	O
comparisons	O
between	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
inhibitors	O
under	O
development	O
worldwide	O
.	O

Evidence	O
for	O
change	O
within	O
the	O
ORF1ab	O
coding	O
sequence	O
during	O
the	O
SARS	B-DISO
epidemic	O
,	O
as	O
well	O
as	O
evidence	O
from	O
studies	O
with	O
other	O
coronaviruses	O
,	O
indicates	O
that	O
it	O
is	O
likely	O
that	O
the	O
ORF1ab	O
proteins	O
play	B-DISO
roles	I-DISO
in	O
virus	B-DISO
pathogenesis	I-DISO
distinct	O
from	O
or	O
in	O
addition	O
to	O
functions	O
directly	O
involved	O
in	O
viral	O
replication	O
.	O

These	O
patients	O
often	O
have	O
severely	O
impaired	B-DISO
respiratory	O
mechanics	O
because	O
of	O
acute	O
lung	O
injury	O
and	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
.	O

The	O
prevalence	O
of	O
specific	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
in	O
employees	O
of	O
the	O
animal	O
market	O
were	O
somehow	O
related	O
with	O
the	O
presence	O
or	O
absence	O
of	O
palm	O
civet	O
.	O

The	O
avian	B-DISO
influenza	I-DISO
patient	O
had	O
never	O
left	O
Guangzhou	O
in	O
the	O
month	O
prior	O
to	O
disease	O
onset	O
.	O

A	O
total	O
of	O
56	O
close	O
contacts	O
,	O
including	O
his	O
girl	O
friend	O
,	O
relatives	O
,	O
friends	O
and	O
medical	O
staff	O
who	O
had	O
taken	O
care	O
of	O
him	O
,	O
were	O
brought	O
under	O
medical	O
observation	O
for	O
7	O
days	O
but	O
none	O
of	O
them	O
showed	O
signs	O
of	O
infection	B-DISO
.	O

Acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
are	O
responsible	O
for	O
considerable	O
morbidity	O
and	O
mortality	O
in	O
humans	O
and	O
animals	O
.	O

No	O
pathogens	O
can	O
be	O
detected	O
in	O
a	O
relatively	O
large	O
proportion	O
of	O
patients	O
with	O
respiratory	B-DISO
disease	I-DISO
,	O
partially	O
owing	O
to	O
limitations	O
of	O
current	O
diagnostic	O
assays	O
but	O
also	O
since	O
some	O
infections	B-DISO
are	O
caused	O
by	O
as	O
yet	O
unknown	O
pathogens	O
.	O

The	O
recent	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
CoV	O
and	O
subsequent	O
identification	O
of	O
two	O
additional	O
human	O
coronaviruses	O
(	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
)	O
has	O
drawn	O
attention	O
to	O
this	O
virus	O
family	O
.	O

Stigmatization	O
of	O
and	O
discrimination	O
against	O
the	O
chronically	B-DISO
ill	I-DISO
and	O
the	O
sense	O
of	O
searching	O
coping	O
strategy	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
further	O
motivated	O
their	O
practice	O
.	O

When	O
DT	O
was	O
administrated	O
to	O
the	O
mice	O
they	O
suffered	B-DISO
from	O
acute	O
lung	O
injury	O
and	O
died	O
within	O
4	O
days	O
.	O

She	O
had	O
undergone	O
2	O
surgical	O
resections	O
of	O
liver	B-DISO
hemangiomas	I-DISO
.	O

From	O
the	O
patients	O
'	O
experiences	O
,	O
85	O
.	O
2	O
%	O
and	O
21	O
.	O
7	O
%	O
of	O
the	O
dentists	O
wore	O
face	B-DISO
masks	O
and	O
face	B-DISO
shields	O
,	O
respectively	O
,	O
when	O
delivering	O
dental	O
treatment	O
.	O

RESULTS	O
:	O
Less	O
than	O
one	O
-	O
third	O
(	O
30	O
.	O
0	O
%)	O
of	O
the	O
463	O
respondents	O
said	O
they	O
were	O
not	O
afraid	O
of	O
contracting	O
the	O
SARS	B-DISO
coronavirus	O
from	O
their	O
dentists	O
and	O
did	O
not	O
avoid	O
dental	O
treatment	O
for	O
that	O
reason	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
a	O
monomeric	O
form	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
endonuclease	O
nsp15	O
suggests	O
a	O
role	O
for	O
hexamerization	O
as	O
an	O
allosteric	O
switch	O
.	O

ABSTRACT	O
:	O
Mature	O
nonstructural	O
protein	O
-	O
15	O
(	O
nsp15	O
)	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
contains	O
a	O
novel	O
uridylate	O
-	O
specific	O
Mn2	O
+-	O
dependent	O
endoribonuclease	O
(	O
NendoU	O
).	O

ABSTRACT	O
:	O
This	O
review	O
examines	O
perspectives	O
of	O
human	O
infection	B-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
H5N1	B-DISO
(	O
AI	O
H5N1	B-DISO
),	O
specifically	O
focusing	O
on	O
the	O
presentation	O
,	O
diagnosis	O
,	O
and	O
management	O
of	O
those	O
critically	B-DISO
ill	I-DISO
with	O
AI	O
H5N1	B-DISO
.	O

It	O
has	O
been	O
observed	O
that	O
pulmonary	B-DISO
infection	I-DISO
with	O
Leishmania	O
donovani	O
can	O
occur	O
in	O
immunodeficient	B-DISO
and	O
lung	O
transplant	O
patients	O
.	O

Parenteral	O
ivermectin	O
is	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
disseminated	B-DISO
strongyloidiasis	I-DISO
.	O

For	O
comparison	O
between	O
the	O
cohorts	O
data	O
on	O
patients	O
status	O
(	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
at	O
arrival	O
,	O
Revised	O
Trauma	O
Score	O
,	O
Trauma	O
and	O
Injury	O
Severity	O
Score	O
survival	O
prognosis	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
score	O
),	O
treatment	O
(	O
intubation	O
rate	O
,	O
thoracic	B-DISO
drainage	O
,	O
surgery	O
),	O
and	O
outcomes	O
(	O
duration	O
of	O
intensive	O
care	O
unit	O
stay	O
and	O
ventilation	O
,	O
rate	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
[	O
ARDS	B-DISO
],	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
syndrome	B-DISO
[	O
MOFS	O
],	O
and	O
mortality	O
)	O
were	O
selected	O
from	O
hospital	O
databases	O
.	O

Rates	O
of	O
ARDS	B-DISO
,	O
MOFS	O
,	O
and	O
mortality	O
were	O
not	O
negatively	O
influenced	O
by	O
early	O
unreamed	O
IMN	O
.	O

Informative	O
papers	O
emerged	O
this	O
past	O
year	O
concerning	O
collateral	O
damage	O
to	O
the	O
liver	O
in	O
extrahepatic	O
infections	B-DISO
,	O
diabetic	O
lesions	O
and	O
causes	O
of	O
liver	B-DISO
dysfunction	I-DISO
after	O
transplantation	O
,	O
among	O
other	O
topics	O
.	O

TITLE	O
:	O
Vaccines	O
to	O
prevent	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
induced	O
disease	O
.	O

TITLE	O
:	O
Manipulation	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
genome	O
for	O
vaccine	O
development	O
and	O
analysis	O
of	O
the	O
accessory	O
proteins	O
.	O

Do	O
the	O
NIH	O
ARDS	B-DISO
Clinical	O
Trials	O
Network	O
PEEP	O
/	O
FIO2	O
tables	O
provide	O
the	O
best	O
evidence	O
-	O
based	O
guide	O
to	O
balancing	O
PEEP	O
and	O
FIO2	O
settings	O
in	O
adults	O
?	O

The	O
improved	O
survival	O
found	O
in	O
the	O
National	O
Institutes	O
of	O
Health	O
'	O
s	O
ARDS	B-DISO
Network	O
low	O
-	O
tidal	O
-	O
volume	O
study	O
may	O
suggest	O
that	O
their	O
PEEP	O
/	O
F	O
(	O
IO	O
(	O
2	O
))	O
titration	O
tables	O
represent	O
the	O
best	O
method	O
for	O
adjusting	O
these	O
variables	O
.	O

Based	O
upon	O
an	O
extensive	O
literature	O
review	O
of	O
PEEP	O
and	O
respiratory	O
system	O
mechanics	O
in	O
ARDS	B-DISO
,	O
we	O
conclude	O
that	O
:	O
(	O
1	O
)	O
for	O
most	O
patients	O
the	O
therapeutic	O
range	O
of	O
PEEP	O
is	O
relatively	O
narrow	O
,	O
so	O
the	O
ARDS	B-DISO
Network	O
PEEP	O
/	O
F	O
(	O
IO	O
(	O
2	O
))	O
strategy	O
is	O
reasonable	O
and	O
supported	O
by	O
high	O
-	O
level	O
evidence	O
,	O
(	O
2	O
)	O
how	O
best	O
to	O
adjust	O
PEEP	O
to	O
prevent	O
or	O
ameliorate	O
ventilator	O
-	O
associated	O
lung	O
injury	O
is	O
unknown	O
and	O
still	O
under	O
investigation	O
,	O
and	O
(	O
3	O
)	O
in	O
a	O
small	O
subset	O
of	O
patients	O
with	O
severe	O
lung	O
injury	O
and	O
/	O
or	O
abnormal	O
chest	O
-	O
wall	O
compliance	O
,	O
highly	O
individualized	O
titration	O
of	O
PEEP	O
,	O
based	O
upon	O
the	O
respiratory	O
-	O
system	O
pressure	O
-	O
volume	O
curve	O
,	O
PEEP	O
/	O
tidal	O
-	O
volume	O
titration	O
grids	O
,	O
or	O
a	O
recruitment	B-DISO
maneuver	O
and	O
a	O
PEEP	O
decrement	O
trial	O
is	O
a	O
reasonable	O
alternative	O
.	O

HFOV	O
(	O
8	O
-	O
10	O
Hz	O
)	O
was	O
started	O
using	O
a	O
recruitment	B-DISO
strategy	O
and	O
oxygenation	O
improved	O
within	O
2	O
h	O
.	O
After	O
5	O
days	O
,	O
the	O
patient	O
was	O
switched	O
back	O
to	O
CV	O
uneventfully	O
and	O
av	O
-	O
ECLA	O
was	O
removed	O
after	O
8	O
days	O
.	O

Rejection	O
did	O
not	O
precede	O
any	O
case	O
of	O
post	O
-	O
transplant	O
blastomycosis	B-DISO
.	O

Opportunistic	O
co	B-DISO
-	I-DISO
infections	I-DISO
were	O
common	O
,	O
occurring	O
in	O
36	O
%	O
of	O
patients	O
.	O

Extrapulmonary	O
disease	O
predominantly	O
involved	O
the	O
skin	O
and	O
spared	O
the	O
central	O
nervous	B-DISO
system	O
.	O

After	O
cure	O
,	O
post	O
-	O
transplant	O
blastomycosis	B-DISO
may	O
not	O
require	O
lifelong	O
antifungal	O
suppression	B-DISO
.	O

1	O
:	O
e39	O
,	O
2005	O
),	O
based	O
upon	O
complementation	O
studies	O
of	O
known	O
temperature	O
-	O
sensitive	O
(	O
TS	O
)	O
mutants	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
,	O
proposes	O
that	O
an	O
intermediate	O
comprised	O
of	O
nsp4	O
to	O
nsp10	O
/	O
11	O
(	O
approximately	O
150	O
kDa	O
)	O
is	O
involved	O
in	O
negative	O
-	O
strand	O
synthesis	O
.	O

To	O
characterize	O
the	O
S1	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
from	O
China	O
,	O
five	O
representative	O
nephropathogenic	O
IB	O
viruses	O
isolated	O
from	O
chickens	O
in	O
different	O
provinces	O
were	O
genetically	O
and	O
phylogenetically	O
analyzed	O
.	O

RESULTS	O
:	O
Of	O
821	O
patients	O
,	O
205	O
had	O
confirmed	O
SARS	B-DISO
,	O
35	O
undetermined	O
SARS	B-DISO
and	O
581	O
non	O
-	O
SARS	B-DISO
.	O

Notable	O
innovations	O
include	O
the	O
use	O
of	O
home	O
quarantine	O
orders	O
,	O
mass	O
temperature	O
screening	O
using	O
thermal	O
imaging	O
,	O
modular	O
systems	O
of	O
hospital	O
staffing	O
,	O
""""	O
virtual	O
""""	O
hospital	O
visits	O
,	O
and	O
innovations	O
in	O
emergency	B-DISO
department	O
design	O
.	O

TITLE	O
:	O
Sequence	O
analysis	O
of	O
the	O
partial	O
spike	O
glycoprotein	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

We	O
hypothesized	O
that	O
combined	O
HFO	O
and	O
TGI	O
(	O
HFO	O
-	O
TGI	O
)	O
might	O
result	O
in	O
improved	O
gas	O
exchange	O
relative	O
to	O
both	O
standard	O
HFO	O
and	O
CMV	O
according	O
to	O
the	O
ARDS	B-DISO
Network	O
protocol	O
.	O

A	O
total	O
of	O
14	O
patients	O
with	O
early	O
(<	O
72	O
hrs	B-DISO
in	O
duration	O
),	O
severe	O
(	O
PaO2	O
/	O
FiO2	O
of	O
<	O
150	O
mm	O
Hg	O
and	O
prerecruitment	O
oxygenation	O
index	O
of	O
22	O
.	O
8	O
+/-	O

HFO	O
sessions	O
were	O
repeated	O
in	O
inverse	O
order	O
within	O
24	O
hrs	B-DISO
.	O

Publications	O
before	O
TRICC	O
indicated	O
that	O
clinicians	O
used	O
higher	O
transfusion	O
thresholds	O
in	O
patients	O
with	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
compared	O
with	O
younger	O
,	O
healthier	O
patients	O
(	O
p	O
=	O
.	O
001	O
).	O

He	O
was	O
diagnosed	O
as	O
spontaneous	B-DISO
rupture	I-DISO
of	O
the	O
esophagus	O
.	O

Emergency	B-DISO
T	O
-	O
tube	O
drainage	O
was	O
therefore	O
scheduled	O
.	O

Early	O
detection	O
of	O
increases	O
in	O
plasma	O
levels	O
of	O
soluble	O
E	O
selectin	O
by	O
a	O
rapid	O
assay	O
system	O
,	O
developed	O
by	O
the	O
authors	O
,	O
enables	O
early	O
effective	O
treatment	O
of	O
patients	O
with	O
sepsis	B-DISO
.	O

Diseases	O
with	O
a	O
prominent	O
reduction	O
were	O
respiratory	B-DISO
diseases	I-DISO
,	O
minor	O
problems	O
,	O
and	O
elective	O
procedures	O
.	O

It	O
most	O
commonly	O
presents	O
either	O
as	O
a	O
superficial	B-DISO
ulcer	I-DISO
on	O
the	O
glans	O
or	O
around	O
the	O
corona	O
.	O

This	O
report	O
is	O
noteworthy	O
because	O
it	O
is	O
the	O
first	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
demonstrating	O
the	O
presence	O
of	O
antibody	O
against	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
coronavirus	O
in	O
human	O
milk	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
incidence	O
,	O
causes	O
and	O
mortality	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
in	O
Beijing	O
.	O

Results	O
Of	O
8	O
482	O
patients	O
admitted	O
to	O
ICUs	O
in	O
the	O
same	O
period	O
,	O
there	O
were	O
383	O
patients	O
(	O
4	O
.	O
5	O
%)	O
diagnosed	O
as	O
having	O
ARDS	B-DISO
.	O

ARDS	B-DISO
was	O
frequent	O
in	O
ICU	O
in	O
Beijing	O
,	O
the	O
mortality	O
remains	O
high	O
,	O
and	O
there	O
is	O
no	O
tendency	O
to	O
decline	O
in	O
recent	O
years	O
.	O

CONCLUSIONS	O
:	O
ARDS	B-DISO
was	O
frequent	O
in	O
ICU	O
in	O
Beijing	O
,	O
the	O
mortality	O
remains	O
high	O
,	O
and	O
there	O
is	O
no	O
tendency	O
to	O
decline	O
in	O
recent	O
years	O
.	O

Our	O
findings	O
have	O
promising	O
implications	O
in	O
the	O
investigation	O
of	O
the	O
role	O
of	O
molecular	O
mimicry	B-DISO
between	O
coronaviruses	O
and	O
myelin	O
in	O
MS	O
as	O
a	O
mechanism	O
related	O
to	O
disease	O
initiation	O
or	O
relapses	O
.	O

RESULTS	O
:	O
The	O
ELSO	O
registry	O
currently	O
includes	O
31	O
,	O
340	O
ECMO	O
cases	O
,	O
of	O
which	O
151	O
were	O
post	O
-	O
LTx	O
patients	O
with	O
primary	B-DISO
graft	I-DISO
dysfunction	I-DISO
(	O
PGD	O
).	O

Major	O
complications	O
during	O
ECMO	O
included	O
hemorrhage	B-DISO
(	O
52	O
%),	O
hemodialysis	O
(	O
42	O
%),	O
neurologic	O
(	O
12	O
%),	O
and	O
cardiac	O
(	O
28	O
%)	O
complications	O
,	O
inotropic	O
support	O
(	O
77	O
%),	O
and	O
sepsis	B-DISO
(	O
15	O
%).	O

To	O
assess	O
infectivity	O
in	O
ciliated	O
airway	O
cultures	O
derived	O
from	O
susceptible	O
animal	O
species	O
we	O
generated	O
a	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
by	O
deletion	O
of	O
open	O
reading	O
frame	O
7a	O
/	O
7b	O
(	O
ORF	O
7a	O
/	O
7b	O
)	O
and	O
insertion	O
of	O
the	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
resulting	O
in	O
SARS	B-DISO
-	O
CoV	O
GFP	O
.	O

pCDNA3	O
.	O
1	O
(-)/	O
his	O
-	O
myc	O
vector	O
containing	O
the	O
SARS	B-DISO
coronavirus	O
nucleocapsid	O
gene	O
(	O
N	O
),	O
matric	O
gene	O
(	O
M	O
),	O
spike	O
gene	O
(	O
S	O
)	O
were	O
transfected	O
into	O
COS	O
-	O
1	O
,	O
Huh	O
-	O
7	O
and	O
HepG2	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
26	O
-	O
month	O
-	O
old	O
previously	O
healthy	O
boy	O
of	O
15	O
kg	O
was	O
admitted	O
to	O
our	O
hospital	O
due	O
to	O
cyanosis	B-DISO
following	O
the	O
aspiration	B-DISO
of	O
lamp	O
oil	O
.	O

Mechanical	O
ventilation	O
is	O
considered	O
the	O
hallmark	O
treatment	O
for	O
ALI	O
patients	O
aimed	O
to	O
recruit	O
lung	O
tissue	O
and	O
thereby	O
reverse	O
hypoxemia	O
without	O
causing	O
additional	O
lung	O
injury	O
potentially	O
resulting	O
from	O
overdistention	O
or	O
cycling	O
collapse	B-DISO
during	O
expiration	O
.	O

ABSTRACT	O
:	O
Rhinoviruses	O
and	O
coronaviruses	O
cause	O
the	O
majority	O
of	O
common	B-DISO
colds	I-DISO
and	O
play	O
a	O
part	O
in	O
more	O
serious	O
respiratory	O
illnesses	O
that	O
lead	O
to	O
increased	O
morbidity	O
and	O
mortality	O
.	O

Serum	O
AGP	O
levels	O
from	O
cats	O
with	O
FIP	B-DISO
(	O
group	O
1	O
;	O
n	O
=	O
58	O
)	O
and	O
without	O
FIP	B-DISO
(	O
group	O
2	O
;	O
n	O
=	O
104	O
)	O
were	O
evaluated	O
.	O

Non	O
-	O
FIP	B-DISO
cats	O
were	O
further	O
subgrouped	O
as	O
follows	O
:	O
2a	O
)	O
inflammation	B-DISO
(	O
n	O
=	O
26	O
),	O
2b	O
)	O
asymptomatic	O
FCoV	O
infection	B-DISO
(	O
n	O
=	O
49	O
),	O
2c	O
)	O
injection	O
-	O
site	O
sarcoma	B-DISO
(	O
n	O
=	O
19	O
),	O
2d	O
)	O
postvaccination	O
(	O
n	O
=	O
7	O
),	O
and	O
2e	O
)	O
specific	O
pathogen	O
free	O
(	O
n	O
=	O
3	O
).	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strain	O
Beaudette	O
is	O
an	O
embryo	O
-	O
adapted	O
virus	O
that	O
has	O
extended	O
species	O
tropism	O
in	O
cell	O
culture	O
.	O

Selected	O
molecules	O
having	O
close	O
structural	O
relationship	O
to	O
a	O
2	O
-	O
methyl	O
-	O
2	O
,	O
4	O
-	O
pentanediol	O
may	O
provide	O
candidate	O
lead	O
compounds	O
toward	O
the	O
development	O
of	O
novel	O
allosteric	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
protease	O
inhibitors	O
.	O

The	O
overall	O
downward	O
trend	O
of	O
the	O
infection	B-DISO
curve	O
after	O
early	O
May	O
corresponds	O
well	O
to	O
the	O
date	O
(	O
May	O
10	O
)	O
when	O
changes	O
in	O
the	O
review	O
and	O
classification	O
procedure	O
were	O
implemented	O
by	O
the	O
SARS	B-DISO
Prevention	O
and	O
Extrication	O
Committee	O
.	O

The	O
SARS	B-DISO
case	O
definition	O
must	O
be	O
revised	O
if	O
it	O
is	O
to	O
be	O
used	O
as	O
a	O
screening	O
tool	O
in	O
emergency	B-DISO
departments	O
and	O
primary	O
care	O
settings	O
.	O

103	O
adult	O
patients	O
with	O
ARDS	B-DISO
(	O
white	O
Germans	O
).	O

Antibodies	O
against	O
canine	O
herpesvirus	O
and	O
Brucella	B-DISO
canis	I-DISO
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
samples	O
.	O

Only	O
one	O
of	O
the	O
73	O
red	O
pandas	B-DISO
had	O
a	O
weak	O
positive	O
influenza	B-DISO
A	O
titer	O
.	O

TITLE	O
:	O
The	O
molecular	O
biology	O
of	O
SARS	B-DISO
coronavirus	O
.	O

The	O
population	O
dense	O
regions	O
of	O
Southeast	O
Asia	O
are	O
the	O
epicenter	O
of	O
many	O
emerging	O
diseases	O
,	O
as	O
evidenced	O
by	O
the	O
outbreak	O
of	O
Nipah	O
,	O
SARS	B-DISO
,	O
avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
),	O
Dengue	B-DISO
,	O
and	O
enterovirus	O
71	O
in	O
this	O
region	O
in	O
the	O
past	O
decade	O
.	O

Anti	O
-	O
GBM	B-DISO
antibodies	O
were	O
negative	O
.	O

4	O
weeks	O
later	O
,	O
the	O
patient	O
presented	O
again	O
with	O
a	O
clinical	O
relapse	B-DISO
of	O
severe	O
hemoptysis	B-DISO
and	O
respiratory	B-DISO
insufficiency	I-DISO
after	O
smoke	O
exposition	O
.	O

TITLE	O
:	O
High	O
-	O
level	O
prokaryotic	O
expression	O
of	O
envelope	O
exterior	O
of	O
membrane	O
protein	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

SDS	B-DISO
-	O
PAGE	O
analysis	O
showed	O
recombinant	O
truncated	O
M	O
'	O
protein	O
was	O
highly	O
expressed	O
by	O
pGEX	O
-	O
6p	O
-	O
M	O
'	O
and	O
the	O
product	O
fusion	O
protein	O
GST	O
-	O
M	O
'	O
reached	O
45	O
%	O
in	O
the	O
total	O
bacteria	O
proteins	O
with	O
the	O
analysis	O
of	O
software	O
AlphaImager2200	O
.	O

ABSTRACT	O
:	O
Higher	O
-	O
order	O
cis	B-DISO
-	O
acting	O
RNA	O
replication	O
structures	O
have	O
been	O
identified	O
in	O
the	O
3	O
'-	O
and	O
5	O
'-	O
terminal	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
of	O
a	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
.	O

For	O
Canada	O
,	O
a	O
similar	O
catalyst	O
stemmed	O
from	O
the	O
lessons	O
learned	O
during	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
.	O

Pneumococci	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
any	O
young	O
woman	O
who	O
develops	O
peritonitis	B-DISO
without	O
an	O
obvious	O
cause	O
.	O

Our	O
findings	O
suggest	O
that	O
FCoVs	O
may	O
be	O
present	O
in	O
the	O
blood	O
samples	O
from	O
healthy	O
cats	O
as	O
well	O
as	O
cats	O
with	O
clinical	O
FIP	B-DISO
.	O

Self	O
-	O
reported	O
hand	O
-	O
washing	O
compliance	O
increased	O
in	O
the	O
first	O
phase	O
of	O
the	O
SARS	B-DISO
outbreak	O
and	O
maintained	O
a	O
high	O
level	O
22	O
months	O
after	O
the	O
outbreak	O
.	O

Morbid	B-DISO
obesity	I-DISO
was	O
not	O
associated	O
with	O
increased	O
mortality	O
(	O
OR	O
0	O
.	O
810	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
353	O
to	O
1	O
.	O
856	O
).	O

The	O
final	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
hypoxia	B-DISO
refractory	O
to	O
conventional	O
therapy	O
modalities	O
is	O
the	O
extracorporeal	O
gas	O
exchange	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
presentation	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
represent	O
a	O
full	O
spectrum	O
of	O
a	O
complex	O
and	O
devastating	O
illness	O
,	O
with	O
associated	O
mortality	O
that	O
still	O
hovers	O
around	O
30	O
-	O
40	O
%.	O

M	O
.	O
pneumoniae	O
-	O
associated	O
mucositis	B-DISO
is	O
distinct	O
from	O
the	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
replication	O
induces	O
host	O
translational	O
shutoff	O
and	O
mRNA	O
decay	B-DISO
,	O
with	O
concomitant	O
formation	O
of	O
stress	O
granules	O
and	O
processing	O
bodies	O
.	O

Mixed	B-DISO
infection	I-DISO
of	O
two	O
or	O
more	O
viral	O
agents	O
was	O
seen	O
in	O
23	O
(	O
25	O
%)	O
specimens	O
.	O

The	O
availability	O
of	O
new	O
simian	O
rotaviruses	O
,	O
enteric	O
adenoviruses	O
,	O
enteroviruses	O
,	O
and	O
coronaviruses	O
and	O
the	O
discovery	O
of	O
noroviruses	O
and	O
picobirnaviruses	O
may	O
allow	O
us	O
to	O
develop	O
better	O
diagnostics	O
for	O
these	O
agents	O
and	O
determine	O
which	O
of	O
these	O
agents	O
are	O
clearly	O
associated	O
with	O
gastroenteritis	B-DISO
in	O
monkeys	O
.	O

TITLE	O
:	O
Cell	O
cycle	O
arrest	O
and	O
apoptosis	O
induced	O
by	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
the	O
absence	O
of	O
p53	O
.	O

Index	O
patients	O
who	O
were	O
aged	O
60	O
years	O
or	O
older	O
or	O
whose	O
lactate	O
dehydrogenase	O
level	O
was	O
elevated	O
upon	O
admission	O
to	O
the	O
hospital	O
(	O
indicating	O
higher	O
viral	O
loads	O
)	O
were	O
more	O
likely	O
to	O
transmit	O
SARS	B-DISO
to	O
their	O
contacts	O
.	O

At	O
admission	O
,	O
temperature	O
,	O
heart	O
rate	O
,	O
blood	O
pressure	O
,	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
,	O
base	O
deficit	B-DISO
,	O
hemoglobin	O
,	O
platelets	O
,	O
prothrombin	O
time	O
/	O
International	O
Normalized	O
Ratio	O
,	O
and	O
Injury	O
Severity	O
Score	O
were	O
similar	O
in	O
both	O
groups	O
as	O
were	O
administered	O
units	O
of	O
fresh	O
frozen	O
plasma	O
,	O
fresh	O
whole	O
blood	O
,	O
cryoprecipitate	O
(	O
cryo	O
),	O
and	O
crystalloid	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
was	O
attenuated	O
by	O
serial	O
passage	O
in	O
chicken	O
embryos	O
.	O

At	O
necropsy	O
the	O
prominent	O
lesion	O
was	O
enteritis	B-DISO
.	O

To	O
facilitate	O
the	O
studies	O
on	O
the	O
function	O
and	O
antigenicity	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
,	O
6x	O
histidine	O
-	O
tagged	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
N	O
(	O
rSARS	O
-	O
N	O
)	O
with	O
a	O
molecular	O
mass	O
of	O
46	O
and	O
48kDa	O
was	O
successfully	O
produced	O
using	O
the	O
recombinant	O
baculovirus	O
system	O
in	O
insect	O
cells	O
.	O

Therefore	O
,	O
the	O
BrSARS	O
-	O
N	O
protein	O
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
highly	O
sensitive	O
and	O
specific	O
assays	O
to	O
determine	O
SARS	B-DISO
infection	B-DISO
and	O
for	O
further	O
research	O
of	O
SARS	B-DISO
-	O
N	O
pathology	B-DISO
.	O

Finally	O
,	O
we	O
summarize	O
findings	O
of	O
a	O
variety	O
of	O
vaccine	O
approaches	O
and	O
discuss	O
the	O
available	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
addressing	O
the	O
potential	O
for	O
disease	O
enhancement	O
following	O
re	O
-	O
infection	B-DISO
in	O
animals	O
previously	O
vaccinated	O
against	O
or	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O

One	O
year	O
later	O
,	O
we	O
reassessed	O
these	O
health	O
care	O
workers	O
with	O
the	O
PSS	B-DISO
-	O
10	O
,	O
the	O
21	O
-	O
Item	O
Depression	B-DISO
and	O
Anxiety	O
Scale	O
(	O
DASS	O
-	O
21	O
),	O
and	O
the	O
Impact	O
of	O
Events	O
Scale	O
-	O
Revised	O
(	O
IES	O
-	O
R	O
).	O

ABSTRACT	O
:	O
Sepsis	B-DISO
in	O
different	O
states	O
of	O
severity	O
(	O
sepsis	B-DISO
,	I-DISO
severe	I-DISO
sepsis	B-DISO
,	O
septic	B-DISO
shock	I-DISO
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
))	O
is	O
associated	O
with	O
microcirculatory	O
blood	O
flow	O
abnormalities	O
leading	O
to	O
decreased	O
red	O
blood	O
cell	O
'	O
s	O
(	O
RBC	O
'	O
s	O
)	O
deformability	O
,	O
impaired	B-DISO
oxygen	I-DISO
delivery	I-DISO
to	O
tissues	O
and	O
organs	O
failure	O
.	O

It	O
seems	O
that	O
the	O
RBC	O
'	O
s	O
deformability	O
is	O
a	O
useful	O
mechanical	O
parameter	O
to	O
estimate	O
the	O
prognosis	O
and	O
monitor	O
patients	O
suffering	B-DISO
from	O
different	O
severity	O
levels	O
of	O
sepsis	B-DISO
.	O

TITLE	O
:	O
[	O
Modelling	O
epidemics	O
:	O
the	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Canada	O
].	O

In	O
this	O
review	O
,	O
we	O
will	O
compare	O
the	O
structures	O
,	O
distributions	O
and	O
properties	O
of	O
ACE	O
and	O
its	O
new	O
homologue	O
in	O
the	O
context	O
of	O
cardiovascular	O
function	O
,	O
focusing	O
on	O
the	O
autocrine	O
/	O
paracrine	O
cardiac	O
and	O
brain	O
renin	O
-	O
angiotensin	O
systems	O
and	O
we	O
will	O
present	O
recent	O
data	O
from	O
the	O
literature	O
and	O
our	O
laboratory	O
offering	O
a	O
new	O
perspective	O
on	O
this	O
potential	O
target	O
for	O
the	O
treatment	O
of	O
cardiovascular	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
synthetic	O
vaccine	O
candidates	O
against	O
SARS	B-DISO
CoV	O
infection	B-DISO
.	O

The	O
peptides	O
mixture	O
formulated	O
either	O
with	O
Freund	O
'	O
s	O
adjuvant	O
or	O
synthetic	O
adjuvant	O
Montanide	O
ISA	O
-	O
51	O
/	O
oligodeoxy	O
nucleotide	O
CpG	O
(	O
ISA	O
/	O
CpG	O
)	O
could	O
elicit	O
antisera	O
in	O
immunized	O
animals	O
which	O
were	O
capable	O
of	O
inhibiting	O
SARS	B-DISO
/	O
HIV	B-DISO
pseudovirus	O
entry	O
into	O
HepG2	O
cells	O
.	O

ABSTRACT	O
:	O
During	O
the	O
last	O
few	O
years	O
a	O
number	O
of	O
previously	O
undescribed	O
viruses	O
,	O
including	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
SARS	B-DISO
,	O
NL63	O
and	O
HKU1	O
,	O
and	O
bocavirus	O
,	O
were	O
identified	O
in	O
nasopharyngeal	O
samples	O
from	O
patients	O
with	O
signs	O
of	O
respiratory	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Synthetic	O
reconstruction	O
of	O
zoonotic	O
and	O
early	O
human	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
isolates	O
that	O
produce	O
fatal	O
disease	O
in	O
aged	O
mice	O
.	O

This	O
paper	O
presents	O
a	O
series	O
of	O
cases	O
where	O
HCW	O
'	O
s	O
have	O
been	O
exposed	O
to	O
toxic	O
or	O
infectious	B-DISO
material	O
through	O
the	O
respiratory	O
route	O
,	O
discusses	O
standards	O
of	O
respiratory	O
protection	O
and	O
describes	O
how	O
this	O
risk	O
can	O
be	O
mitigated	O
to	O
protect	O
medical	O
personnel	O
.	O

No	O
laboratory	O
tests	O
for	O
SARS	B-DISO
were	O
available	O
,	O
and	O
no	O
educational	O
material	O
on	O
SARS	B-DISO
was	O
displayed	O
.	O

We	O
previously	O
revealed	O
that	O
UV	O
-	O
inactivated	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
virions	O
(	O
UV	O
-	O
V	O
)	O
elicited	O
high	O
levels	O
of	O
humoral	O
immunity	O
and	O
a	O
weak	O
Th0	O
response	O
in	O
mice	O
immunized	O
subcutaneously	O
.	O

To	O
ensure	O
the	O
safety	O
of	O
such	O
a	O
whole	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
,	O
we	O
additionally	O
treated	O
the	O
UV	O
-	O
V	O
vaccine	O
with	O
formalin	O
,	O
resulting	O
in	O
the	O
UV	O
-	O
F	O
-	O
V	O
vaccine	O
.	O

Moreover	O
,	O
both	O
vaccines	O
induced	O
similar	O
frequencies	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
-	O
producing	O
cells	O
in	O
bone	O
marrow	O
.	O

Interventional	O
,	O
extracorporeal	O
pump	O
-	O
free	O
pulmonary	O
support	O
opens	O
up	O
new	O
possibilities	O
for	O
pulmonary	O
protection	O
due	O
to	O
ease	O
of	O
use	O
,	O
effectiveness	O
,	O
and	O
low	O
costs	O
;	O
however	O
,	O
there	O
is	O
concern	O
of	O
distal	O
limb	O
ischemia	B-DISO
.	O

Furthermore	O
,	O
genetic	B-DISO
disorders	I-DISO
of	O
surfactant	O
metabolism	O
have	O
recently	O
been	O
linked	O
to	O
respiratory	B-DISO
diseases	I-DISO
of	O
formerly	O
unknown	O
origin	O
.	O

Research	O
around	O
surfactant	O
is	O
evolving	O
and	O
recent	O
developments	O
include	O
further	O
evolution	O
of	O
synthetic	O
surfactants	O
,	O
evaluation	O
of	O
surfactant	O
as	O
a	O
therapeutic	O
option	O
in	O
lung	B-DISO
diseases	I-DISO
other	O
than	O
RDS	O
and	O
the	O
discovery	O
of	O
genetic	B-DISO
disorders	I-DISO
of	O
surfactant	O
metabolism	O
.	O

However	O
,	O
it	O
can	O
be	O
expected	O
to	O
be	O
important	O
for	O
the	O
virus	O
-	O
host	O
interplay	O
and	O
for	O
pathogenicity	O
,	O
due	O
to	O
its	O
large	O
number	O
of	O
interactions	O
,	O
by	O
enhancing	O
the	O
global	O
stability	O
of	O
the	O
SARS	B-DISO
proteome	O
network	O
,	O
or	O
play	O
some	O
unrealized	O
role	O
in	O
regulating	O
protein	O
-	O
protein	O
interactions	O
.	O

Shortly	O
after	O
the	O
rabbits	O
were	O
killed	O
at	O
3	O
hour	O
after	O
iv	O
OA	O
injection	O
,	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
colleted	O
,	O
and	O
the	O
concentrations	O
of	O
protein	O
,	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	B-DISO
),	O
intercellular	O
adhesion	B-DISO
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
in	O
BALF	O
were	O
then	O
measured	O
by	O
ELISA	O
.	O

The	O
ratio	O
of	O
wet	O
to	O
dry	O
weight	O
(	O
W	O
/	O
D	O
)	O
of	O
left	O
lung	O
was	O
calculated	O
to	O
assess	O
alveolar	B-DISO
edema	I-DISO
.	O

These	O
results	O
suggest	O
that	O
when	O
SARS	B-DISO
-	O
CoV	O
binds	O
ACE2	O
it	O
is	O
internalized	O
and	O
penetrates	O
early	O
endosomes	O
in	O
a	O
clathrin	O
-	O
dependent	O
manner	O
and	O
that	O
the	O
cytoplasmic	O
tail	O
of	O
ACE2	O
is	O
not	O
required	O
for	O
the	O
penetration	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

Unrelated	O
to	O
the	O
pulmonary	O
arterial	O
pressor	O
response	O
,	O
microvascular	O
leakage	B-DISO
of	O
PLY	O
was	O
diminished	O
in	O
lungs	O
of	O
PAF	B-DISO
receptor	O
-	O
deficient	O
mice	O
as	O
well	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
genome	O
is	O
predicted	O
to	O
contain	O
14	O
functional	O
open	O
reading	O
frames	O
(	O
ORFs	O
).	O

TITLE	O
:	O
Immune	O
response	O
induced	O
by	O
spike	O
protein	O
from	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
expressed	O
in	O
mouse	O
mammary	O
cells	O
.	O

ABSTRACT	O
:	O
Extraordinary	O
infection	B-DISO
control	O
measures	O
limited	O
access	O
to	O
medical	O
care	O
in	O
the	O
Greater	O
Toronto	O
Area	O
during	O
the	O
2003	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
.	O

Efforts	O
to	O
contain	O
future	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
due	O
to	O
influenza	B-DISO
or	O
other	O
agents	O
must	O
consider	O
effects	O
on	O
access	O
to	O
essential	O
health	O
care	O
services	O
.	O

African	O
green	O
monkeys	O
immunized	O
through	O
the	O
respiratory	O
tract	O
with	O
two	O
doses	O
of	O
the	O
vaccine	O
developed	O
a	O
titer	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
neutralizing	O
antibodies	O
comparable	O
with	O
the	O
robust	O
secondary	O
response	O
observed	O
in	O
animals	O
that	O
have	O
been	O
immunized	O
with	O
a	O
different	O
experimental	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
and	O
challenged	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
When	O
animals	O
immunized	O
with	O
NDV	O
expressing	O
S	O
were	O
challenged	O
with	O
a	O
high	O
dose	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
direct	O
viral	O
assay	O
of	O
lung	O
tissues	O
taken	O
by	O
necropsy	O
at	O
the	O
peak	O
of	O
viral	O
replication	O
demonstrated	O
a	O
236	O
-	O
or	O
1	O
,	O
102	O
-	O
fold	O
(	O
depending	O
on	O
the	O
NDV	O
vector	O
construct	O
)	O
mean	O
reduction	O
in	O
pulmonary	O
SARS	B-DISO
-	O
CoV	O
titer	O
compared	O
with	O
control	O
animals	O
.	O

One	O
area	O
of	O
strong	O
controversy	O
is	O
the	O
role	O
of	O
interferon	O
(	O
IFN	O
)	O
responses	O
in	O
the	O
natural	O
history	O
of	O
SARS	B-DISO
.	O

The	O
fact	O
that	O
the	O
majority	O
of	O
SARS	B-DISO
patients	O
recover	O
after	O
relatively	O
moderate	O
illness	O
suggests	O
that	O
the	O
prevailing	O
notion	O
of	O
deficient	O
type	O
I	O
IFN	O
-	O
mediated	O
immunity	O
,	O
with	O
hypercytokinemia	O
driving	O
a	O
poor	O
clinical	O
course	O
,	O
is	O
oversimplified	O
.	O

Individuals	O
with	O
RANTES	O
-	O
28	O
CG	O
and	O
GG	O
genotypes	O
had	O
a	O
3	O
.	O
28	O
-	O
fold	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
32	O
-	O
4	O
.	O
64	O
)	O
and	O
3	O
.	O
06	O
-	O
fold	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
47	O
-	O
6	O
.	O
39	O
)	O
increased	O
risk	O
of	O
developing	O
SARS	B-DISO
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
associated	O
with	O
high	O
mortality	O
rates	O
despite	O
therapeutic	O
advances	O
.	O

TITLE	O
:	O
SARS	B-DISO
and	O
New	O
York	O
'	O
s	O
Chinatown	O
:	O
the	O
politics	O
of	O
risk	O
and	O
blame	O
during	O
an	O
epidemic	O
of	O
fear	O
.	O

TITLE	O
:	O
Pulmonary	O
-	O
renal	O
syndromes	B-DISO
.	O

Treatment	O
of	O
generalized	O
ANCA	B-DISO
-	I-DISO
associated	I-DISO
vasculitis	I-DISO
consists	O
of	O
corticosteroids	O
and	O
immunosuppressive	O
agents	O
such	O
as	O
cyclophosphamide	O
(	O
as	O
induction	O
therapy	O
)	O
or	O
azathioprine	O
(	O
as	O
maintenance	O
therapy	O
once	O
remission	B-DISO
has	O
been	O
achieved	O
).	O

The	O
potential	O
application	O
for	O
early	O
diagnosis	O
was	O
evaluated	O
using	O
N	O
protein	O
capture	O
ELISA	O
in	O
which	O
N18	O
antibody	O
demonstrated	O
high	O
sensitive	O
activity	O
in	O
detecting	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Finally	O
,	O
the	O
potential	O
usefulness	O
of	O
the	O
N18	O
antibody	O
in	O
prophylaxis	O
,	O
vaccine	O
design	O
and	O
therapy	O
of	O
SARS	B-DISO
is	O
discussed	O
.	O

Using	O
immunohistochemistry	O
to	O
examine	O
both	O
banked	O
human	O
lung	O
specimens	O
from	O
patients	O
with	O
ALI	O
and	O
lungs	O
from	O
mice	O
with	O
LPS	B-DISO
-	O
induced	O
pneumonitis	B-DISO
,	O
we	O
found	O
that	O
pulmonary	O
SDF	O
-	O
1	O
expression	O
increases	O
during	O
ALI	O
.	O

These	O
results	O
implicate	O
SDF	O
-	O
1	O
in	O
neutrophil	O
recruitment	B-DISO
to	O
the	O
lung	O
in	O
the	O
later	O
period	O
of	O
acute	O
lung	O
injury	O
and	O
suggest	O
a	O
novel	O
role	O
for	O
this	O
cytokine	O
in	O
coordinating	O
the	O
transition	B-DISO
from	O
the	O
inflammatory	B-DISO
response	I-DISO
to	O
the	O
initiation	O
of	O
tissue	O
repair	O
.	O

This	O
study	O
showed	O
that	O
BoTV	O
is	O
a	O
common	O
virus	O
in	O
fecal	O
specimens	O
of	O
calves	O
with	O
diarrhea	B-DISO
in	O
Japan	O
and	O
may	O
be	O
an	O
important	O
pathogen	O
of	O
cattle	O
,	O
principally	O
in	O
young	O
calves	O
less	O
than	O
2	O
weeks	O
of	O
age	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
check	O
the	O
association	O
between	O
coagulopathy	B-DISO
and	O
mortality	O
.	O

About	O
77	O
%	O
of	O
patients	O
had	O
coagulopathy	B-DISO
,	O
whose	O
occurrence	O
was	O
directly	O
associated	O
with	O
the	O
severity	O
of	O
the	O
trauma	O
,	O
but	O
not	O
with	O
the	O
rise	O
in	O
mortality	O
.	O

ABSTRACT	O
:	O
Sickle	O
hemoglobin	O
(	O
Hb	O
S	O
;	O
betaGlu	O
6	O
Val	O
)	O
is	O
due	O
to	O
an	O
A	O
>	O
T	O
transversion	B-DISO
in	O
codon	O
6	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
is	O
an	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
a	O
highly	O
fatal	O
acute	B-DISO
diarrhea	I-DISO
in	O
newborn	O
pigs	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
hepatitis	B-DISO
C	I-DISO
virus	O
NS3	B-DISO
/	O
4A	O
and	O
secreted	O
alkaline	O
phosphatase	O
to	O
quantitate	O
cell	O
-	O
cell	O
membrane	O
fusion	O
mediated	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
S	O
protein	O
and	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

As	O
we	O
obtained	O
information	O
that	O
a	O
parakeet	O
had	O
recently	O
died	O
at	O
her	O
home	O
,	O
minocycline	O
was	O
administered	O
,	O
resulting	O
in	O
prompt	O
improvement	O
of	O
the	O
symptoms	O
,	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
pulmonary	B-DISO
infiltrates	I-DISO
.	O

Accordingly	O
,	O
we	O
investigated	O
whether	O
AM	O
infusion	O
ameliorates	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

LPS	B-DISO
instillation	O
caused	O
severe	O
acute	O
lung	O
injury	O
,	O
as	O
indicated	O
by	O
the	O
histological	O
findings	O
and	O
the	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
.	O

Angiotensin	O
II	O
is	O
one	O
key	O
effector	O
peptide	O
of	O
the	O
RAS	O
,	O
inducing	O
vasoconstriction	B-DISO
and	O
exerting	O
multiple	O
biological	O
functions	O
.	O

We	O
investigated	O
the	O
pathogenetic	O
mechanisms	O
of	O
ALI	O
caused	O
by	O
leptospirosis	B-DISO
.	O

The	O
study	O
included	O
five	O
cases	O
of	O
leptospirosis	B-DISO
.	O

Finally	O
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
damage	O
ensued	O
.	O

The	O
pathogenesis	B-DISO
of	O
lung	O
and	O
organ	O
injury	O
may	O
involve	O
iNOS	O
and	O
NO	O
production	O
.	O

So	O
far	O
antivirals	O
are	O
hardly	O
available	O
to	O
combat	O
infections	B-DISO
with	O
viruses	O
of	O
this	O
order	O
.	O

In	O
this	O
article	O
the	O
application	O
of	O
the	O
plant	O
lectins	O
Hippeastrum	O
hybrid	O
agglutinin	O
(	O
HHA	B-DISO
),	O
Galanthus	O
nivalis	O
agglutinin	O
(	O
GNA	O
),	O
Cymbidium	O
sp	O
.	O
agglutinin	O
(	O
CA	O
)	O
and	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	O
)	O
as	O
well	O
as	O
non	O
-	O
plant	O
derived	O
pradimicin	O
-	O
A	O
(	O
PRM	O
-	O
A	O
)	O
and	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
)	O
as	O
potential	O
antiviral	O
agents	O
was	O
evaluated	O
.	O

ABSTRACT	O
:	O
The	O
syndrome	B-DISO
of	O
preschool	O
wheeze	B-DISO
commonly	O
regresses	O
completely	O
in	O
the	O
preschool	O
years	O
,	O
but	O
it	O
may	O
lead	O
to	O
prolonged	O
symptoms	O
and	O
established	O
asthma	B-DISO
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
better	O
treatment	O
of	O
preschool	O
wheeze	B-DISO
.	O

In	O
subjects	O
with	O
OSA	B-DISO
plus	O
OHS	B-DISO
,	O
43	O
%	O
continued	O
to	O
spend	O
>	O
20	O
%	O
of	O
TST	O
with	O
SpO2	O
<	O
90	O
%,	O
compared	O
to	O
9	O
%	O
of	O
the	O
OSA	B-DISO
group	O
,	O
despite	O
the	O
adequate	O
relief	O
of	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
.	O

Both	O
SARS	B-DISO
-	O
CoV	O
receptors	O
of	O
ACE2	O
and	O
CD209L	O
were	O
expressed	O
in	O
the	O
8	O
organ	O
/	O
tissue	O
-	O
derived	O
endothelial	O
cells	O
.	O

The	O
organ	O
derived	O
microvascular	O
endothelial	O
cells	O
are	O
the	O
important	O
target	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
pathological	O
injury	O
of	O
lung	O
and	O
lymph	O
system	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
may	O
be	O
mediated	O
respectively	O
by	O
different	O
receptors	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
RESULTS	O
:	O
Both	O
SARS	B-DISO
-	O
CoV	O
receptors	O
of	O
ACE2	O
and	O
CD209L	O
were	O
expressed	O
in	O
the	O
8	O
organ	O
/	O
tissue	O
-	O
derived	O
endothelial	O
cells	O
.	O

Study	O
of	O
the	O
activation	O
of	O
HIV	B-DISO
envelope	O
fusogenicity	O
has	O
revealed	O
new	O
knowledge	O
about	O
how	O
redox	O
changes	O
within	O
a	O
viral	O
envelope	O
trigger	O
fusion	O
.	O

Predisposing	O
factors	O
include	O
young	O
age	O
,	O
severe	O
critical	B-DISO
illness	I-DISO
of	O
central	O
nervous	B-DISO
system	O
or	O
respiratory	O
origin	O
,	O
exogenous	O
catecholamine	O
or	O
glucocorticoid	O
administration	O
,	O
inadequate	O
carbohydrate	O
intake	O
and	O
subclinical	O
mitochondrial	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
areas	O
most	O
affected	O
by	O
SARS	B-DISO
was	O
Beijing	O
with	O
2521	O
reported	O
cases	O
.	O

The	O
viruses	O
identified	O
were	O
influenza	B-DISO
A	O
(	O
7	O
.	O
3	O
%),	O
coronavirus	O
OC43	O
(	O
4	O
.	O
6	O
%),	O
rhinovirus	O
(	O
3	O
.	O
1	O
%),	O
influenza	B-DISO
B	O
(	O
2	O
.	O
7	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
2	O
.	O
3	O
%).	O

TITLE	O
:	O
Bird	B-DISO
flu	I-DISO
:	O
lessons	O
from	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
avian	B-DISO
influenza	I-DISO
are	O
two	O
important	O
newly	O
emerged	O
infections	B-DISO
with	O
pandemic	O
potential	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
EGF	O
on	O
atrophic	B-DISO
enteritis	B-DISO
induced	O
in	O
piglets	O
by	O
experimental	O
infection	B-DISO
with	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
strain	O
Dr13	O
.	O

Comparative	O
analysis	O
between	O
FFA	O
and	O
plaque	B-DISO
assay	O
showed	O
no	O
significant	O
difference	O
in	O
estimating	O
the	O
titer	O
of	O
cell	O
adapted	O
PEDV	O
.	O

During	O
the	O
early	O
and	O
late	O
SARS	B-DISO
restriction	O
periods	O
,	O
the	O
rate	O
of	O
overall	O
and	O
medical	O
admissions	O
decreased	O
by	O
10	O
%-	O
12	O
%	O
in	O
Toronto	O
;	O
there	O
was	O
no	O
change	O
in	O
the	O
comparison	O
regions	O
.	O

ABSTRACT	O
:	O
Acute	O
hypercytokinaemia	O
represents	O
an	O
imbalance	B-DISO
of	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
is	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
in	O
severe	O
cases	O
of	O
avian	O
(	O
H5N1	B-DISO
)	O
influenza	B-DISO
.	O

Adrenal	B-DISO
insufficiency	I-DISO
,	O
as	O
defined	O
in	O
the	O
sepsis	B-DISO
/	O
shock	O
literature	O
,	O
is	O
a	O
plasma	O
cortisol	O
rise	O
of	O
at	O
least	O
9	O
microg	O
dl	O
(-	O
1	O
)	O
following	O
a	O
250	O
microg	O
dose	O
of	O
adrenocorticotropin	O
hormone	O
(	O
ACTH	O
),	O
or	O
reaching	O
a	O
plasma	O
cortisol	O
concentration	O
of	O
>	O
25	O
microg	O
dl	O
(-	O
1	O
)	O
following	O
a	O
1	O
-	O
2	O
microg	O
dose	O
of	O
ACTH	O
.	O

This	O
is	O
a	O
much	O
lower	O
dose	O
than	O
has	O
been	O
typically	O
used	O
to	O
treat	O
avian	B-DISO
influenza	I-DISO
patients	O
.	O

We	O
detected	O
complexes	O
between	O
anti	O
-	O
KC	O
autoantibodies	O
and	O
KC	O
in	O
lung	O
lavages	O
and	O
tissues	O
of	O
mice	O
treated	O
with	O
LPS	B-DISO
.	O

Virus	O
replication	O
was	O
monitored	O
by	O
cytopathic	B-DISO
effect	I-DISO
observation	O
,	O
electron	O
microscopy	O
,	O
indirect	O
immunofluorescence	O
,	O
and	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SCoV	O
)	O
M	O
protein	O
plays	O
a	O
key	O
role	O
in	O
viral	O
assembly	O
and	O
budding	O
.	O

TITLE	O
:	O
Chlorine	O
and	O
its	O
impact	O
on	O
an	O
emergency	B-DISO
department	O
.	O

The	O
hospital	O
hazardous	O
materials	O
(	O
HAZMAT	O
)	O
disaster	O
plan	B-DISO
was	O
activated	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
ORF6	O
antagonizes	O
STAT1	O
function	O
by	O
sequestering	O
nuclear	O
import	O
factors	O
on	O
the	O
rough	O
endoplasmic	O
reticulum	O
/	O
Golgi	O
membrane	O
.	O

We	O
discuss	O
the	O
likely	O
implications	O
of	O
these	O
data	O
on	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
Attenuated	O
Salmonella	B-DISO
enterica	O
serovar	O
Typhi	O
strains	O
have	O
been	O
considered	O
to	O
be	O
attractive	O
as	O
potential	O
live	O
oral	O
delivery	O
vector	O
vaccines	O
because	O
of	O
their	O
ability	O
to	O
elicit	O
the	O
full	O
array	O
of	O
immune	O
responses	O
in	O
humans	O
.	O

Our	O
work	O
provides	O
insights	O
into	O
how	O
the	O
type	O
IVB	O
pilus	O
operon	O
promoter	O
controlling	O
SARS	B-DISO
-	O
CoV	O
N	O
gene	O
expression	O
in	O
Salmonella	B-DISO
might	O
be	O
attractive	O
for	O
a	O
live	O
-	O
vector	O
vaccine	O
against	O
SRAS	O
-	O
CoV	O
infection	B-DISO
,	O
for	O
it	O
could	O
induce	O
mucosal	O
,	O
humoral	O
,	O
and	O
cellular	O
immune	O
responses	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
analyze	O
antibody	O
reactivity	O
to	O
ORF8a	O
in	O
patients	O
with	O
SARS	B-DISO
and	O
to	O
elucidate	O
the	O
function	O
of	O
ORF8a	O
.	O

Viral	O
etiology	O
was	O
identified	O
in	O
231	O
children	O
hospitalized	O
with	O
acute	O
wheezing	B-DISO
,	O
aged	O
from	O
1	O
month	O
to	O
5	O
years	O
.	O

PCR	O
assays	O
for	O
hBoV	O
DNA	O
were	O
performed	O
using	O
the	O
primer	O
sets	O
for	O
noncapsid	O
protein	O
(	O
NP1	O
)	O
and	O
nonstructural	O
protein	O
(	O
NS1	B-DISO
)	O
genes	O
.	O

Critical	B-DISO
illness	I-DISO
-	O
related	O
corticosteroid	O
insufficiency	O
leads	O
to	O
an	O
exaggerated	O
proinflammatory	O
response	O
with	O
increased	O
tissue	O
injury	O
and	O
organ	O
dysfunction	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
main	O
peptidase	O
3CL	O
(	O
pro	O
)	O
is	O
a	O
viral	O
polyprotein	O
processing	O
enzyme	O
essential	O
for	O
the	O
viability	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Distinct	O
regulation	O
of	O
MHC	O
molecule	O
expression	O
on	O
astrocytes	O
and	O
microglia	O
during	O
viral	O
encephalomyelitis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
potential	O
interplay	O
of	O
glial	O
cells	O
with	O
T	O
cells	O
during	O
viral	O
induced	O
inflammation	B-DISO
was	O
assessed	O
by	O
comparing	O
major	O
histocompatibility	O
complex	O
molecule	O
upregulation	O
and	O
retention	O
on	O
astrocytes	O
and	O
microglia	O
.	O

These	O
data	O
demonstrate	O
distinct	O
regulation	O
of	O
both	O
class	O
I	O
and	O
class	O
II	O
expression	O
by	O
microglia	O
and	O
astrocytes	O
in	O
vivo	O
following	O
viral	O
induced	O
inflammation	B-DISO
.	O

In	O
addition	O
,	O
a	O
blood	O
sample	O
was	O
taken	O
from	O
each	O
calf	O
upon	O
enrollment	O
in	O
the	O
study	O
,	O
for	O
assessment	O
of	O
maternal	O
antibody	O
transfer	O
and	O
for	O
polymerase	O
chain	O
reaction	O
testing	O
for	O
persistent	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
.	O

We	O
performed	O
a	O
multicentre	O
study	O
in	O
GBS	B-DISO
diagnosed	O
according	O
to	O
international	O
criteria	O
.	O

The	O
first	O
symptom	B-DISO
was	O
usually	O
a	O
disturbance	O
of	O
gait	O
or	O
neuropathic	B-DISO
pain	I-DISO
.	O

79	O
%	O
complained	O
of	O
neuropathic	B-DISO
pain	I-DISO
,	O
half	O
of	O
them	O
to	O
a	O
severe	O
degree	O
.	O

However	O
,	O
a	O
change	O
to	O
CIDP	B-DISO
and	O
concurrent	O
myelitis	B-DISO
can	O
give	O
rise	O
to	O
a	O
worse	O
prognosis	O
.	O

SARS	B-DISO
-	O
CoV	O
viral	O
load	O
and	O
SARS	B-DISO
-	O
CoV	O
/	O
GAPDH	O
RNA	O
ratio	O
for	O
each	O
organ	O
type	O
were	O
related	O
to	O
four	O
time	O
durations	O
:	O
onset	O
of	O
illness	O
to	O
death	O
,	O
death	O
to	O
post	O
-	O
mortem	O
tissue	O
sampling	O
,	O
and	O
total	O
durations	O
of	O
treatment	O
with	O
ribavirin	O
and	O
hydrocortisone	O
.	O

TITLE	O
:	O
Emerging	O
occupational	O
lung	O
infections	B-DISO
.	O

Expression	O
of	O
virally	O
encoded	O
CXCL10	O
within	O
the	O
brain	O
protected	O
mice	O
from	O
death	O
and	O
correlated	O
with	O
increased	O
infiltration	B-DISO
of	O
T	O
lymphocytes	O
,	O
enhanced	O
IFN	O
-	O
gamma	O
secretion	O
,	O
and	O
accelerated	O
viral	O
clearance	O
when	O
compared	O
with	O
mice	O
infected	O
with	O
an	O
isogenic	O
control	O
virus	O
,	O
MHV	O
.	O

This	O
case	O
represents	O
the	O
first	O
description	O
of	O
morphological	O
lesions	O
associated	O
with	O
a	O
type	O
II	O
pantropic	O
fatal	O
coronavirus	B-DISO
infection	I-DISO
in	O
the	O
dog	O
.	O

The	O
main	O
sites	O
of	O
primary	B-DISO
tumor	I-DISO
were	O
oral	O
cavity	B-DISO
(	O
30	O
%),	O
larynx	B-DISO
(	O
25	O
%),	O
pharynx	O
(	O
14	O
%)	O
and	O
thyroid	O
(	O
9	O
%).	O

The	O
main	O
reasons	O
for	O
ICU	O
admission	O
were	O
sepsis	B-DISO
(	O
37	O
%)	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
20	O
%).	O

A	O
performance	O
status	O
>	O
or	O
=	O
2	O
[	O
odds	O
ratio	O
(	O
OR	O
)=	O
5	O
.	O
17	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
=	O
1	O
.	O
84	O
-	O
14	O
.	O
53	O
)],	O
advanced	B-DISO
cancer	I-DISO
(	O
TNM	O
stage	O
IV	O
)	O
[	O
OR	O
=	O
3	O
.	O
80	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
28	O
-	O
11	O
.	O
28	O
)],	O
and	O
the	O
number	O
of	O
organ	O
failures	O
[	O
OR	O
=	O
2	O
.	O
87	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
83	O
-	O
4	O
.	O
50	O
)]	O
were	O
associated	O
with	O
increased	O
mortality	O
in	O
multivariate	O
analysis	O
.	O

TITLE	O
:	O
Infection	B-DISO
of	O
HeLa	O
cells	O
by	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
is	O
dependent	O
on	O
cell	O
status	O
.	O

TITLE	O
:	O
Potent	O
cross	O
-	O
reactive	O
neutralization	O
of	O
SARS	B-DISO
coronavirus	O
isolates	O
by	O
human	O
monoclonal	O
antibodies	O
.	O

Two	O
putative	O
hot	O
-	O
spot	O
residues	O
in	O
the	O
RBD	O
(	O
Ile	O
-	O
489	O
and	O
Tyr	O
-	O
491	O
)	O
were	O
identified	O
within	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
that	O
likely	O
contribute	O
to	O
most	O
of	O
the	O
m396	O
-	O
binding	O
energy	O
.	O

Was	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
one	O
such	O
circumstance	O
?	O

Guénaël	O
R	O
.	O
M	O
.	O
Rodier	O
thinks	O
WHO	O
'	O
s	O
decision	O
to	O
impose	O
a	O
SARS	B-DISO
-	O
related	O
travel	O
advisory	O
was	O
justifiable	O
,	O
even	O
reasonable	O
,	O
though	O
it	O
caused	O
a	O
loss	O
of	O
over	O
$	O
1	O
.	O
1	O
billion	O
in	O
the	O
Greater	O
Toronto	O
Area	O
.	O

As	O
rates	O
of	O
CA	O
-	O
MRSA	B-DISO
increase	O
worldwide	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
MRSA	B-DISO
to	O
cause	O
life	O
-	O
threatening	O
infections	B-DISO
in	O
patients	O
presenting	O
to	O
Canadian	O
emergency	B-DISO
departments	O
(	O
EDs	B-DISO
).	O

Sequence	O
analysis	O
revealed	O
that	O
KQ6	O
was	O
an	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
a	O
member	O
of	O
coronavirus	O
in	O
group	O
3	O
.	O

We	O
discontinued	O
the	O
infusion	O
and	O
started	O
steroids	O
,	O
which	O
improved	O
her	O
respiratory	O
condition	B-DISO
.	O

However	O
,	O
she	O
developed	O
respiratory	B-DISO
failure	I-DISO
again	O
after	O
resuming	O
infusion	O
of	O
the	O
graft	O
.	O

Although	O
we	O
could	O
not	O
identify	O
the	O
antibody	O
which	O
might	O
have	O
been	O
involved	O
in	O
the	O
respiratory	B-DISO
distress	I-DISO
,	O
the	O
clear	O
temporal	O
relationship	O
between	O
marrow	O
infusion	O
and	O
respiratory	B-DISO
distress	I-DISO
suggested	O
that	O
similar	O
acute	O
lung	O
injury	O
to	O
TRALI	B-DISO
might	O
have	O
occurred	O
following	O
allogenic	O
marrow	O
infusion	O
in	O
the	O
present	O
case	O
.	O

In	O
addition	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
protein	O
receptor	O
-	O
binding	O
domain	O
inhibited	O
entry	O
mediated	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
.	O

TITLE	O
:	O
Cell	O
-	O
penetrating	O
peptide	O
-	O
morpholino	O
conjugates	O
alter	O
pre	O
-	O
mRNA	O
splicing	O
of	O
DMD	B-DISO
(	O
Duchenne	B-DISO
muscular	I-DISO
dystrophy	I-DISO
)	O
and	O
inhibit	O
murine	O
coronavirus	O
replication	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
discuss	O
our	O
recent	O
findings	O
regarding	O
(	O
R	O
-	O
Ahx	B-DISO
-	O
R	O
)(	O
4	O
)	O
AhxB	O
(	O
Ahx	B-DISO
is	O
6	O
-	O
aminohexanoic	O
acid	O
and	O
B	O
is	O
beta	O
-	O
alanine	O
)	O
CPP	O
-	O
PMO	O
conjugates	O
in	O
DMD	B-DISO
(	O
Duchenne	B-DISO
muscular	I-DISO
dystrophy	I-DISO
)	O
and	O
murine	O
coronavirus	O
research	O
.	O

On	O
clinical	O
suspicion	O
of	O
pregnancy	O
-	O
related	O
liver	B-DISO
dysfunction	I-DISO
such	O
as	O
HELLP	B-DISO
syndrome	I-DISO
(	O
hemolysis	B-DISO
,	O
elevated	O
liver	O
enzyme	O
levels	O
,	O
low	O
platelet	O
count	O
)	O
or	O
acute	B-DISO
fatty	I-DISO
liver	I-DISO
of	I-DISO
pregnancy	I-DISO
(	O
AFLP	O
),	O
emergency	B-DISO
caesarean	O
section	O
was	O
performed	O
and	O
a	O
healthy	O
baby	O
was	O
delivered	O
.	O

Postoperatively	O
,	O
the	O
patient	O
was	O
stable	O
,	O
but	O
5	O
days	O
later	O
she	O
developed	O
clouding	O
of	O
consciousness	O
,	O
severe	O
jaundice	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Towards	O
our	O
understanding	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
an	O
emerging	O
and	O
devastating	O
but	O
quickly	O
conquered	O
virus	O
.	O

Using	O
a	O
phage	O
display	O
technology	O
in	O
a	O
chicken	O
system	O
,	O
high	O
-	O
affinity	O
monoclonal	O
antibody	O
fragments	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
were	O
characterized	O
.	O

ABSTRACT	O
:	O
The	O
most	O
striking	O
difference	O
between	O
the	O
subgenomic	O
mRNA8	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
isolated	O
from	O
human	O
and	O
some	O
animal	O
species	O
is	O
the	O
deletion	O
of	O
29	O
nucleotides	O
,	O
resulting	O
in	O
splitting	O
of	O
a	O
single	O
ORF	O
(	O
ORF8	O
)	O
into	O
two	O
ORFs	O
(	O
ORF8a	O
and	O
ORF8b	O
).	O

In	O
the	O
absence	O
of	O
the	O
8a	O
region	O
,	O
protein	O
8b	O
undergoes	O
rapid	O
degradation	O
by	O
proteasomes	O
,	O
and	O
addition	O
of	O
proteasome	O
inhibitors	O
inhibits	O
the	O
degradation	O
of	O
protein	O
8b	O
as	O
well	O
as	O
the	O
protein	O
8b	O
-	O
induced	O
rapid	O
degradation	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
E	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
incidence	O
,	O
etiology	O
,	O
physiological	O
and	O
clinical	O
features	O
,	O
mortality	O
,	O
and	O
predictors	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

On	O
admission	O
,	O
the	O
non	O
-	O
survivors	O
had	O
significantly	O
higher	O
MODS	B-DISO
and	O
lower	O
BE	O
(	O
base	O
excess	O
).	O

The	O
main	O
cause	O
of	O
death	O
was	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

Sepsis	B-DISO
and	O
pneumonia	B-DISO
are	O
the	O
most	O
common	O
risk	O
factors	O
.	O

TITLE	O
:	O
Amino	O
acid	O
substitutions	O
in	O
the	O
s2	O
region	O
enhance	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
infectivity	O
in	O
rat	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
-	O
expressing	O
cells	O
.	O

TITLE	O
:	O
Expression	O
of	O
a	O
synthetic	O
neutralizing	O
epitope	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
fused	O
with	O
synthetic	O
B	O
subunit	O
of	O
Escherichia	O
coli	O
heat	O
labile	O
enterotoxin	O
in	O
rice	O
endosperm	O
.	O

ABSTRACT	O
:	O
Alterations	O
to	O
pulmonary	O
surfactant	O
composition	O
have	O
been	O
encountered	O
in	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
only	O
few	O
data	O
are	O
available	O
regarding	O
the	O
time	O
-	O
course	O
and	O
duration	O
of	O
surfactant	O
changes	O
in	O
ARDS	B-DISO
patients	O
,	O
although	O
this	O
information	O
may	O
largely	O
influence	O
the	O
optimum	O
design	O
of	O
clinical	O
trials	O
addressing	O
surfactant	O
replacement	O
therapy	O
.	O

Over	O
time	O
,	O
significant	O
improvements	O
were	O
encountered	O
especially	O
in	O
view	O
of	O
LA	O
content	O
,	O
DPPC	O
,	O
PG	O
and	O
SP	O
-	O
A	O
,	O
but	O
minimum	O
surface	O
tension	B-DISO
of	O
LA	O
was	O
not	O
fully	O
restored	O
(	O
15	O
mN	O
/	O
m	O
at	O
T2	O
).	O

ABSTRACT	O
:	O
This	O
study	O
examines	O
a	O
cohort	O
of	O
persons	O
quarantined	O
during	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Canada	O
and	O
describes	O
their	O
understanding	O
of	O
,	O
difficulties	O
and	O
compliance	O
with	O
,	O
and	O
the	O
psychological	B-DISO
impact	O
of	O
the	O
quarantine	O
experience	O
.	O

However	O
,	O
at	O
that	O
point	O
in	O
infection	B-DISO
,	O
translation	O
of	O
host	O
mRNA	O
is	O
already	O
severely	O
reduced	O
in	O
infected	O
cells	O
,	O
preventing	O
the	O
synthesis	O
of	O
CXCL2	O
and	O
ER	O
stress	O
proteins	O
despite	O
their	O
increased	O
mRNA	O
concentrations	O
.	O

The	O
presenting	O
symptoms	O
were	O
respiratory	B-DISO
distress	I-DISO
and	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

One	O
patient	O
had	O
pneumothorax	B-DISO
at	O
presentation	O
;	O
however	O
,	O
ten	O
patients	O
had	O
inadvertent	O
intercostal	O
tube	O
insertion	O
before	O
surgical	O
referral	O
.	O

Postoperative	B-DISO
complications	I-DISO
included	O
atelectasis	B-DISO
(	O
2	O
),	O
pneumothorax	B-DISO
(	O
2	O
)	O
and	O
fluid	O
collection	O
(	O
4	O
cases	O
).	O

It	O
has	O
been	O
argued	O
that	O
SARS	B-DISO
should	O
be	O
regarded	O
as	O
contagious	O
infection	B-DISO
,	O
whereas	O
avian	B-DISO
influenza	I-DISO
-	O
as	O
non	O
-	O
contagious	O
.	O

However	O
,	O
valvular	B-DISO
heart	I-DISO
diseases	I-DISO
causing	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
are	O
rare	O
.	O

Apelin	O
mutant	B-DISO
mice	O
are	O
viable	O
and	O
fertile	O
,	O
appear	O
healthy	O
,	O
and	O
exhibit	O
normal	O
body	O
weight	O
,	O
water	O
and	O
food	O
intake	O
,	O
heart	O
rates	O
,	O
and	O
heart	O
morphology	O
.	O

All	O
mechanically	O
ventilated	O
patients	O
without	O
Down	B-DISO
syndrome	I-DISO
from	O
January	O
1998	O
to	O
January	O
2001	O
served	O
as	O
controls	O
.	O

Postoperative	O
patients	O
(	O
cases	O
and	O
controls	O
)	O
and	O
those	O
with	O
a	O
cardiac	O
left	B-DISO
to	I-DISO
right	I-DISO
shunt	I-DISO
were	O
excluded	O
.	O

The	O
cat	O
was	O
diagnosed	O
with	O
an	O
isolated	O
fourth	O
ventricle	O
(	O
IFV	O
)	O
with	O
syringomyelia	B-DISO
.	O

After	O
the	O
cat	O
died	O
,	O
a	O
pathological	O
examination	O
revealed	O
nonsuppurative	O
encephalomyelitis	B-DISO
.	O

In	O
this	O
article	O
,	O
we	O
will	O
review	O
the	O
progress	O
of	O
structural	O
proteomics	O
initiatives	O
targeting	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
the	O
etiological	O
agent	O
of	O
the	O
2003	O
worldwide	O
epidemic	O
that	O
culminated	O
in	O
approximately	O
8	O
,	O
000	O
cases	O
and	O
800	O
deaths	O
.	O

Our	O
findings	O
demonstrate	O
that	O
SARS	B-DISO
CoV	O
VLPs	O
are	O
immunogenic	O
and	O
can	O
elicit	O
strong	O
SARS	B-DISO
CoV	O
-	O
specific	O
humoral	O
and	O
cellular	O
immune	O
responses	O
in	O
mice	O
.	O

TITLE	O
:	O
The	O
feline	O
acute	B-DISO
phase	I-DISO
reaction	I-DISO
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
effect	O
of	O
clinical	O
P	B-DISO
falciparum	I-DISO
isolates	O
on	O
barrier	O
function	O
of	O
primary	O
dermal	O
and	O
lung	O
microvascular	O
endothelium	O
in	O
vitro	O
.	O

Furthermore	O
,	O
even	O
low	O
doses	O
of	O
nsp1	O
mutant	B-DISO
MHV	O
elicited	O
potent	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
protected	O
mice	O
against	O
homologous	O
and	O
heterologous	O
virus	O
challenge	O
.	O

ABSTRACT	O
:	O
Angiosarcoma	B-DISO
is	O
a	O
rare	O
soft	O
-	O
tissue	O
neoplasm	B-DISO
that	O
occurs	O
most	O
often	O
in	O
the	O
skin	O
and	O
the	O
subcutaneous	O
tissues	O
but	O
very	O
rarely	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
pathology	B-DISO
was	O
consistent	O
with	O
angiosarcoma	B-DISO
of	O
the	O
duodenum	O
.	O

Corticotherapy	O
may	O
be	O
beneficial	O
to	O
some	O
patients	O
with	O
sepsis	B-DISO
.	O

TITLE	O
:	O
Prone	O
position	O
to	O
treat	O
bronchopleural	B-DISO
fistula	I-DISO
in	O
post	O
-	O
operative	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
is	O
used	O
to	O
treat	O
patients	O
with	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
because	O
it	O
improves	O
gas	O
exchange	O
and	O
respiratory	O
mechanics	O
.	O

RESULTS	O
:	O
Prone	O
position	O
associated	O
with	O
lung	O
protective	O
strategy	O
was	O
implemented	O
during	O
16	O
-	O
18	O
h	O
daily	O
and	O
after	O
the	O
change	O
of	O
position	O
PaO2	O
/	O
FiO2	O
increased	O
of	O
35	O
%	O
and	O
PaCO2	O
-	O
PetCO2	O
decreased	O
about	O
40	O
%;	O
at	O
4th	O
day	O
under	O
treatment	O
,	O
the	O
subcutaneous	B-DISO
emphysema	I-DISO
and	O
pneumothorax	B-DISO
could	O
not	O
be	O
detected	O
either	O
clinically	O
or	O
radiologically	O
.	O

TITLE	O
:	O
On	O
the	O
role	O
of	O
asymptomatic	B-DISO
infection	I-DISO
in	O
transmission	O
dynamics	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

This	O
dynamic	O
behavior	O
did	O
not	O
arise	O
in	O
a	O
SARS	B-DISO
model	O
without	O
asymptomatic	O
infective	O
class	O
studied	O
by	O
Hsu	O
and	O
Hsieh	O
(	O
SIAM	O
J	O
.	O
Appl	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
asymptomatic	B-DISO
infections	I-DISO
could	O
result	O
in	O
either	O
a	O
positive	O
or	O
negative	O
impact	O
on	O
the	O
outbreak	O
,	O
depending	O
on	O
different	O
sets	O
of	O
conditions	O
on	O
the	O
parameters	O
,	O
as	O
illustrated	O
with	O
numerical	O
simulations	O
.	O

Given	O
the	O
diversity	O
detected	O
here	O
,	O
larger	O
-	O
scale	O
studies	O
will	O
be	O
necessary	O
to	O
determine	O
whether	O
particular	O
substrains	O
of	O
viruses	O
confer	O
an	O
elevated	O
risk	O
of	O
asthma	B-DISO
exacerbation	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
2	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
T	O
and	O
N1	O
/	O
88	O
strains	O
)	O
was	O
studied	O
in	O
the	O
eggshell	O
-	O
forming	O
regions	O
of	O
the	O
oviduct	O
of	O
commercial	O
laying	O
hens	O
.	O

The	O
T	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
was	O
more	O
pathogenic	O
compared	O
with	O
the	O
N1	O
/	O
88	O
strain	O
.	O

Different	O
strains	O
of	O
two	O
coronaviruses	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
,	O
were	O
exposed	O
to	O
CBA	O
:	O
the	O
plant	O
lectins	O
Galanthus	O
nivalis	O
agglutinin	O
,	O
Hippeastrum	O
hybrid	O
agglutinin	O
and	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	O
)	O
and	O
the	O
non	O
-	O
peptidic	O
mannose	O
-	O
binding	O
antibiotic	O
pradimicin	O
A	O
.	O
Our	O
results	O
indicate	O
that	O
CBA	O
target	O
the	O
two	O
glycosylated	O
envelope	O
glycoproteins	O
,	O
the	O
spike	O
(	O
S	O
)	O
and	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infects	O
many	O
organs	O
,	O
such	O
as	O
lung	O
,	O
liver	O
,	O
and	O
immune	O
organs	O
and	O
causes	O
life	O
-	O
threatening	O
atypical	B-DISO
pneumonia	I-DISO
,	O
SARS	B-DISO
causes	O
high	O
morbidity	O
and	O
mortality	O
rates	O
.	O

A	O
review	O
of	O
the	O
publications	O
during	O
and	O
after	O
the	O
SARS	B-DISO
crisis	O
enabled	O
us	O
to	O
get	O
an	O
objective	O
view	O
of	O
the	O
true	O
value	O
of	O
the	O
adjuvant	O
therapy	O
using	O
Chinese	O
medicinal	O
herbs	O
.	O

In	O
present	O
study	O
,	O
mice	O
were	O
immunized	O
with	O
SARS	B-DISO
CoV	O
S	O
DNA	O
vaccine	O
.	O

Importantly	O
,	O
our	O
novel	O
finding	O
is	O
that	O
mice	O
primed	O
with	O
SARS	B-DISO
S	O
DNA	O
vaccine	O
and	O
boosted	O
with	O
T	O
cell	O
epitopes	O
(	O
N50	O
and	O
N60	O
)	O
could	O
promote	O
antigen	O
specific	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cell	O
immune	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
nonpathogenic	O
SIV	B-DISO
infection	B-DISO
of	O
sooty	O
mangabeys	O
(	O
SMs	B-DISO
),	O
a	O
natural	O
host	O
species	O
for	O
SIV	B-DISO
,	O
is	O
also	O
associated	O
with	O
an	O
early	O
,	O
severe	O
,	O
and	O
persistent	O
depletion	O
of	O
memory	O
CD4	O
+	O
T	O
cells	O
from	O
the	O
intestinal	O
and	O
respiratory	O
mucosa	O
.	O

Importantly	O
,	O
the	O
kinetics	O
of	O
the	O
loss	O
of	O
mucosal	O
CD4	O
+	O
T	O
cells	O
in	O
SMs	B-DISO
is	O
similar	O
to	O
that	O
of	O
SIVmac239	O
-	O
infected	O
rhesus	O
macaques	O
.	O

The	O
frequencies	O
of	O
severe	O
deviations	O
from	O
the	O
desired	O
values	O
of	O
the	O
physiological	O
variables	O
for	O
at	O
least	O
one	O
treatment	O
day	O
were	O
:	O
hypotensive	B-DISO
episodes	O
(	O
systolic	O
BP	O
<	O
90	O
mmHg	O
)	O
-	O
20	O
%,	O
anaemia	B-DISO
(	O
hgb	O
<	O
8	O
g	O
/	O
dL	O
)	O
-	O
22	O
%,	O
blood	O
glucose	O
>	O
10	O
mmol	O
/	O
l	O
-	O
26	O
%,	O
serum	O
sodium	O
concentration	O
<	O
130	O
mmol	O
/	O
l	O
-	O
10	O
%,	O
serum	O
albumin	O
<	O
25	O
g	O
/	O
l	O
(-	O
1	O
)-	O
31	O
%	O
and	O
hyperthermia	O
>	O
39	O
degrees	O
C	O
-	O
24	O
%.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
a	O
newly	O
emerged	O
coronavirus	O
(	O
CoV	O
)	O
designated	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
virus	O
utilizes	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
as	O
the	O
primary	O
receptor	O
.	O

Of	O
240	O
patients	O
registered	O
with	O
SCD	B-DISO
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	O
.	O

TITLE	O
:	O
Survey	O
of	O
sedation	B-DISO
practices	O
during	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
to	O
treat	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Of	O
the	O
790	O
of	O
2	O
,	O
985	O
(	O
27	O
%)	O
of	O
physicians	O
who	O
responded	O
,	O
15	O
%,	O
6	O
%,	O
and	O
28	O
%	O
never	O
used	O
sedation	B-DISO
,	O
analgesia	B-DISO
,	O
or	O
hand	O
restraints	O
any	O
of	O
the	O
time	O
for	O
NPPV	O
patients	O
,	O
respectively	O
,	O
and	O
the	O
large	O
majority	O
reported	O
using	O
these	O
interventions	O
in	O
<	O
or	O
=	O
25	O
%	O
of	O
patients	O
.	O

Sedation	B-DISO
was	O
usually	O
administered	O
as	O
an	O
intermittent	O
intravenous	O
bolus	O
,	O
outside	O
of	O
a	O
protocol	O
,	O
and	O
was	O
assessed	O
by	O
nurses	O
using	O
clinical	O
end	O
points	O
rather	O
than	O
a	O
sedation	B-DISO
scale	O
.	O

We	O
review	O
the	O
strong	O
evidence	O
supporting	O
the	O
use	O
of	O
noninvasive	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
to	O
prevent	O
intubation	O
in	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
exacerbations	O
or	O
acute	B-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
and	O
in	O
immunocompromised	O
patients	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
extubation	O
in	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
who	O
require	O
initial	O
intubation	O
.	O

Noninvasive	O
ventilation	O
has	O
assumed	O
an	O
important	O
role	O
in	O
managing	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Among	O
25	O
patients	O
who	O
underwent	O
virus	O
studies	O
,	O
influenza	B-DISO
A	O
(	O
H3N2	O
)	O
(	O
n	O
=	O
7	O
)	O
was	O
the	O
most	O
frequently	O
identified	O
agent	O
.	O

Other	O
viruses	O
included	O
parainfluenza	B-DISO
(	O
4	O
),	O
influenza	B-DISO
B	O
(	O
1	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
3	O
).	O

Contrary	O
to	O
the	O
clinical	O
observations	O
of	O
a	O
clear	O
seasonal	O
variation	O
in	O
the	O
onset	O
of	O
acute	B-DISO
pancreatitis	I-DISO
,	O
we	O
found	O
no	O
correlation	O
between	O
death	O
due	O
to	O
acute	B-DISO
pancreatitis	I-DISO
and	O
a	O
specific	O
month	O
or	O
season	O
.	O

While	O
gallstones	B-DISO
represent	O
the	O
main	O
etiologic	O
factor	O
in	O
most	O
larger	O
clinical	O
series	O
,	O
biliary	O
etiology	O
seems	O
to	O
play	O
only	O
a	O
minor	O
role	O
in	O
outpatient	O
deaths	O
undergoing	O
medicolegal	O
autopsies	O
.	O

These	O
range	O
from	O
mild	O
fever	O
,	O
sweats	O
,	O
fatigue	B-DISO
,	O
and	O
myalgias	B-DISO
to	O
severe	O
multiorgan	B-DISO
failure	I-DISO
,	O
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
death	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
severe	I-DISO
asthma	I-DISO
is	O
the	O
most	O
severe	O
acute	O
complication	B-DISO
of	O
infant	O
asthma	B-DISO
.	O

The	O
acute	B-DISO
severe	I-DISO
asthma	I-DISO
was	O
induced	O
by	O
a	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
in	O
80	O
%	O
of	O
cases	O
.	O

The	O
combination	O
of	O
the	O
surgical	O
approach	O
,	O
pre	O
-	O
existing	O
pulmonary	B-DISO
disorders	I-DISO
,	O
poor	O
nutritional	O
status	O
and	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
may	O
be	O
contributing	O
factors	O
.	O

In	O
severe	B-DISO
sepsis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
positive	O
effects	O
of	O
NAC	O
on	O
morbidity	O
and	O
mortality	O
were	O
discovered	O
.	O

Rather	O
,	O
PLpro	O
interacts	O
with	O
IRF	O
-	O
3	O
and	O
inhibits	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	B-DISO
of	O
IRF	O
-	O
3	O
,	O
thereby	O
disrupting	O
the	O
activation	O
of	O
type	O
I	O
IFN	O
responses	O
through	O
either	O
Toll	O
-	O
like	O
receptor	O
3	O
or	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
/	O
melanoma	B-DISO
differentiation	O
-	O
associated	O
gene	O
5	O
pathways	O
.	O

This	O
suggests	O
that	O
active	O
or	O
passive	O
immunisation	O
might	O
be	O
an	O
effective	O
option	O
in	O
preventing	O
or	O
treating	O
SARS	B-DISO
.	O

Therefore	O
,	O
the	O
development	O
of	O
SARS	B-DISO
vaccination	O
strategies	O
belongs	O
to	O
the	O
most	O
important	O
targets	O
of	O
SARS	B-DISO
research	O
.	O

A	O
number	O
of	O
approaches	O
has	O
been	O
used	O
on	O
the	O
basis	O
of	O
inactivated	O
SARS	B-DISO
coronaviruses	O
,	O
recombinant	O
subunits	O
,	O
recombinant	O
DNA	O
,	O
and	O
viral	O
vectors	O
.	O

ABSTRACT	O
:	O
Human	O
bocavirus	O
(	O
HBoV	O
)	O
is	O
a	O
recently	O
discovered	O
parvovirus	B-DISO
associated	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
.	O

The	O
relationship	O
between	O
breastfeeding	O
and	O
cardiovascular	B-DISO
diseases	I-DISO
was	O
unclear	O
.	O

Fourteen	O
cats	O
had	O
seizure	B-DISO
(	O
s	O
),	O
while	O
41	O
cats	O
had	O
no	O
history	O
of	O
seizure	B-DISO
(	O
s	O
).	O

However	O
,	O
seizures	B-DISO
were	O
significantly	O
more	O
frequent	O
in	O
animals	O
with	O
marked	O
extension	O
of	O
the	O
inflammatory	O
lesions	O
to	O
the	O
forebrain	O
(	O
P	O
=	O
0	O
.	O
038	O
).	O

TITLE	O
:	O
5	O
'-	O
O	O
-	O
masked	O
2	O
'-	O
deoxyadenosine	O
analogues	O
as	O
lead	O
compounds	O
for	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
therapeutic	O
agents	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
our	O
previous	O
study	O
on	O
antiviral	O
agents	O
against	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
,	O
a	O
series	O
of	O
nucleoside	O
analogues	O
whose	O
5	O
'-	O
hydroxyl	O
groups	O
are	O
masked	O
by	O
various	O
protective	O
groups	O
such	O
as	O
carboxylate	O
,	O
sulfonate	O
,	O
and	O
ether	O
were	O
synthesized	O
and	O
evaluated	O
to	O
develop	O
novel	O
anti	O
-	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
agents	O
.	O

In	O
a	O
multivariate	O
model	O
,	O
inbreeding	O
coefficient	O
strongly	O
predicted	O
mortality	O
,	O
with	O
closely	O
inbred	O
mole	B-DISO
-	O
rats	O
(	O
F	O
>	O
or	O
=	O
0	O
.	O
25	O
)	O
over	O
300	O
%	O
more	O
likely	O
to	O
die	O
than	O
their	O
outbred	O
counterparts	O
.	O

The	O
lung	O
diffusion	O
function	O
of	O
the	O
SARS	B-DISO
patients	O
had	O
recovered	O
after	O
they	O
were	O
discharged	O
from	O
hospital	O
within	O
three	O
years	O
,	O
but	O
in	O
20	O
%-	O
30	O
%	O
patients	O
there	O
is	O
still	O
mild	O
or	O
moderate	O
restrictive	O
ventilation	O
function	O
abnormality	O
and	O
small	O
airway	O
function	O
impairment	B-DISO
.	O

These	O
data	O
support	O
a	O
risk	O
factor	O
model	O
in	O
which	O
numerical	O
and	O
functional	O
deficits	O
in	O
PDC	B-DISO
-	O
mediated	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
contribute	O
to	O
an	O
impaired	B-DISO
control	O
of	O
latent	O
herpes	B-DISO
virus	O
infections	B-DISO
and	O
subsequent	O
development	O
of	O
ARN	O
.	O

TITLE	O
:	O
Prevention	O
and	O
control	O
of	O
emerging	O
infections	B-DISO
:	O
a	O
challenge	O
for	O
the	O
3rd	O
millennium	O
.	O

Ecological	O
and	O
genetic	O
changes	O
are	O
important	O
determinants	O
of	O
the	O
emergence	O
of	O
new	O
viral	B-DISO
infections	I-DISO
,	O
driving	O
to	O
an	O
increase	O
of	O
R0	O
(	O
the	O
basic	O
reproductive	O
number	O
)	O
through	O
increasing	O
the	O
probability	O
of	O
transmission	O
.	O

ALI	O
is	O
characterized	O
by	O
disruption	O
of	O
the	O
lung	O
alveolar	O
-	O
capillary	O
membrane	O
barrier	O
and	O
resultant	O
pulmonary	B-DISO
edema	I-DISO
associated	O
with	O
a	O
proteinaceous	O
alveolar	O
exudate	O
.	O

Fluorescently	O
tagged	O
MSCs	O
were	O
detected	O
in	O
the	O
lung	O
tissues	O
by	O
confocal	O
microscopy	O
and	O
flow	O
cytometry	O
in	O
both	O
naïve	O
and	O
LPS	B-DISO
-	O
injured	O
animals	O
up	O
to	O
3	O
d	O
.	O
Treatment	O
with	O
MSCs	O
alone	O
significantly	O
reduced	O
LPS	B-DISO
-	O
induced	O
acute	O
pulmonary	B-DISO
inflammation	I-DISO
in	O
mice	O
,	O
while	O
administration	O
of	O
pANGPT1	O
-	O
transfected	O
MSCs	O
resulted	O
in	O
a	O
further	O
improvement	O
in	O
both	O
alveolar	O
inflammation	B-DISO
and	O
permeability	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
for	O
cell	O
-	O
based	O
ANGPT1	O
gene	O
therapy	O
to	O
treat	O
clinical	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
implications	O
of	O
the	O
proposed	O
pathogenesis	B-DISO
for	O
prevention	O
,	O
diagnosis	O
and	O
therapy	O
of	O
the	O
disease	O
are	O
discussed	O
.	O

The	O
overall	O
hospital	O
mortality	O
of	O
severe	B-DISO
sepsis	I-DISO
was	O
48	O
.	O
7	O
%.	O

A	O
palpable	O
abdominal	O
fluid	O
wave	O
,	O
dehydration	B-DISO
,	O
and	O
a	O
small	O
tear	O
on	O
the	O
left	O
flank	O
were	O
noted	O
during	O
initial	O
examination	O
.	O

Its	O
inclusion	O
as	O
a	O
clinical	O
sign	O
associated	O
with	O
FIP	B-DISO
may	O
facilitate	O
a	O
diagnosis	O
.	O

Early	O
epidemiologic	O
investigations	O
suggested	O
an	O
animal	O
origin	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
Virological	O
and	O
serological	O
studies	O
indicated	O
that	O
masked	O
palm	O
civets	O
(	O
Paguma	O
larvata	O
),	O
together	O
with	O
two	O
other	O
wildlife	O
animals	O
,	O
sampled	O
from	O
a	O
live	O
animal	O
market	O
were	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
or	O
a	O
closely	O
related	O
virus	O
.	O

HBoV	O
causes	O
severe	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
infants	O
and	O
young	O
children	O
.	O

ABSTRACT	O
:	O
Intestinal	B-DISO
ischemia	I-DISO
is	O
reported	O
to	O
be	O
the	O
most	O
common	O
gastrointestinal	B-DISO
complication	I-DISO
of	O
renal	O
transplantation	O
and	O
a	O
potential	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
This	O
article	O
reports	O
on	O
the	O
findings	O
of	O
a	O
qualitative	O
study	O
exploring	O
the	O
impact	O
of	O
SARS	B-DISO
on	O
social	O
work	O
practice	O
in	O
five	O
different	O
hospitals	O
in	O
Singapore	O
.	O

The	O
findings	O
from	O
this	O
study	O
could	O
also	O
inform	O
the	O
development	O
of	O
training	O
programs	O
for	O
social	O
work	O
and	O
other	O
clinical	O
health	O
workers	O
,	O
and	O
emergency	B-DISO
management	O
planning	O
.	O

As	O
a	O
first	O
step	O
to	O
getting	O
more	O
insight	O
into	O
the	O
formation	O
of	O
the	O
coronavirus	O
replication	O
complex	O
,	O
the	O
membrane	O
topology	O
,	O
processing	O
,	O
and	O
subcellular	O
localization	O
of	O
nsp4	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
elucidated	O
in	O
this	O
study	O
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
inherited	O
COQ2	O
mutations	O
cause	O
a	O
primary	O
glomerular	B-DISO
disease	I-DISO
with	O
renal	O
lesions	O
that	O
vary	O
in	O
severity	O
and	O
are	O
not	O
necessarily	O
associated	O
with	O
neurological	O
signs	O
.	O

COQ2	O
nephropathy	B-DISO
should	O
be	O
suspected	O
when	O
electron	O
microscopy	O
shows	O
an	O
increased	O
number	O
of	O
abnormal	O
mitochondria	O
in	O
podocytes	O
and	O
other	O
glomerular	O
cells	O
.	O

Despite	O
engraftment	O
in	O
the	O
4	O
remaining	O
adults	O
,	O
1	O
died	O
of	O
fatal	O
graft	O
-	O
vs	O
.-	O
host	O
disease	O
,	O
1	O
of	O
infectious	B-DISO
complications	O
,	O
1	O
of	O
disease	O
relapse	B-DISO
,	O
and	O
1	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Acute	O
life	O
-	O
threatening	O
thymic	O
bleeding	B-DISO
apparently	O
from	O
ruptured	O
thymic	B-DISO
cysts	I-DISO
into	O
the	O
pleural	O
spaces	O
complicated	O
the	O
clinical	O
situation	O
.	O

Histologic	O
examination	O
revealed	O
normal	O
thymic	O
architecture	O
with	O
cysts	B-DISO
of	O
different	O
sizes	O
and	O
an	O
increased	O
thymic	O
weight	O
of	O
30	O
g	O
.	O
The	O
combination	O
of	O
true	B-DISO
thymic	I-DISO
hyperplasia	I-DISO
and	O
cyst	B-DISO
bleeding	B-DISO
in	O
a	O
newborn	O
has	O
not	O
been	O
previously	O
reported	O
and	O
will	O
be	O
discussed	O
in	O
relation	O
to	O
the	O
available	O
literature	O
on	O
respiratory	B-DISO
distress	I-DISO
due	O
to	O
thymic	O
pathology	B-DISO
in	O
childhood	O
.	O

Ample	O
preparation	O
and	O
appropriate	O
communication	O
among	O
parents	O
,	O
health	O
care	O
workers	O
,	O
and	O
children	O
might	O
minimize	O
fear	O
and	O
anxiety	O
,	O
sustain	O
trust	O
,	O
and	O
facilitate	O
mutual	O
understanding	O
during	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

TITLE	O
:	O
Persistent	O
memory	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
-	O
cell	O
responses	O
in	O
recovered	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
to	O
SARS	B-DISO
coronavirus	O
M	O
antigen	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
memory	O
T	O
cells	O
against	O
M	O
protein	O
were	O
persistent	O
in	O
recovered	O
SARS	B-DISO
patients	O
by	O
detecting	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
production	O
using	O
ELISA	O
and	O
ELISpot	O
assays	O
.	O

ABSTRACT	O
:	O
We	O
recently	O
reported	O
a	O
high	O
success	O
rate	O
using	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
to	O
treat	O
COPD	B-DISO
exacerbations	O
with	O
hypercapnic	B-DISO
encephalopathy	I-DISO
.	O

Low	O
-	O
avidity	O
antibodies	O
of	O
IgA	O
and	O
IgM	O
subclasses	O
were	O
detected	O
in	O
14	O
/	O
14	O
(	O
100	O
%)	O
and	O
3	O
/	O
14	O
(	O
21	O
%)	O
serum	O
samples	O
,	O
respectively	O
,	O
collected	O
in	O
the	O
first	O
month	O
after	O
the	O
onset	O
of	O
infection	B-DISO
.	O

About	O
half	O
of	O
the	O
nurses	O
had	O
frequent	O
involuntary	O
recalls	O
of	O
incidents	O
relating	O
to	O
SARS	B-DISO
,	O
the	O
frequency	O
of	O
which	O
was	O
positively	O
correlated	O
with	O
knowing	O
a	O
person	O
suffering	B-DISO
from	O
long	O
-	O
term	O
complications	O
of	O
SARS	B-DISO
.	O

In	O
vitro	O
studies	O
revealed	O
antiviral	O
activity	O
against	O
HIV	B-DISO
-	O
1	O
,	O
SARS	B-DISO
related	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
arboviruses	O
,	O
vaccinia	B-DISO
virus	O
and	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
.	O

Prior	O
to	O
our	O
study	O
,	O
several	O
cases	O
of	O
neonatal	B-DISO
infection	I-DISO
were	O
observed	O
in	O
infants	O
born	O
at	O
our	O
hospital	O
.	O

Possible	O
vertical	B-DISO
transmission	I-DISO
of	O
HCoV	O
was	O
evidenced	O
in	O
this	O
pilot	O
study	O
and	O
requires	O
further	O
investigation	O
on	O
a	O
larger	O
scale	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
recombinant	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
in	O
vaccinia	B-DISO
virus	O
and	O
analysis	O
of	O
its	O
immunogenicity	O
].	O

HeLa	O
cells	O
infected	O
with	O
rWR	O
-	O
SARS	B-DISO
-	O
S	O
also	O
showed	O
high	O
sensitivity	O
in	O
detecting	O
specific	O
serum	O
antibody	O
by	O
indirect	O
immunofluoresence	O
assay	O
(	O
IFA	O
).	O

The	O
results	O
above	O
indicated	O
that	O
the	O
availability	O
of	O
such	O
a	O
faithful	O
model	O
system	O
offers	O
particular	O
advantages	O
for	O
the	O
study	O
of	O
SARS	B-DISO
in	O
that	O
it	O
reduces	O
the	O
need	O
for	O
direct	O
manipulation	O
of	O
an	O
exotic	O
pathogen	O
.	O

ABSTRACT	O
:	O
Membrane	O
(	O
M	O
)	O
protein	O
genes	O
of	O
20	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
isolated	O
in	O
China	O
between	O
1995	O
and	O
2004	O
were	O
sequenced	O
and	O
analyzed	O
.	O

TITLE	O
:	O
Mathematical	O
modeling	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
nosocomial	O
transmission	O
in	O
Japan	O
:	O
the	O
dynamics	O
of	O
incident	O
cases	O
and	O
prevalent	O
cases	O
.	O

Using	O
mathematical	O
modeling	O
,	O
we	O
simulated	O
the	O
number	O
of	O
new	O
incident	O
and	O
prevalent	O
cases	O
of	O
SARS	B-DISO
after	O
one	O
infected	O
person	O
was	O
admitted	O
to	O
a	O
hospital	O
(	O
index	O
case	O
).	O

There	O
is	O
a	O
possibility	O
that	O
an	O
epidemic	O
will	O
occur	O
with	O
the	O
isolation	O
of	O
the	O
index	O
case	O
even	O
at	O
early	O
days	O
if	O
the	O
infection	B-DISO
is	O
transmitted	B-DISO
outside	O
the	O
hospital	O
.	O

Much	O
is	O
still	O
uncertain	O
concerning	O
the	O
etiology	O
,	O
and	O
BPD	B-DISO
is	O
also	O
seen	O
in	O
infants	O
with	O
no	O
or	O
minimal	O
ventilatory	O
support	O
.	O

Proper	O
treatment	O
,	O
however	O
,	O
depends	O
on	O
correct	O
identification	O
of	O
the	O
pathogen	O
involved	O
as	O
antibiotics	O
provide	O
little	O
or	O
no	O
benefit	O
with	O
viral	B-DISO
infections	I-DISO
.	O

The	O
goal	O
of	O
this	O
project	O
was	O
to	O
better	O
define	O
the	O
relationship	O
between	O
the	O
endoribonuclease	O
activity	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
Nsp15	O
(	O
mNsp15	O
)	O
and	O
its	O
role	O
in	O
virus	B-DISO
infection	I-DISO
.	O

Alanine	O
substitutions	O
at	O
three	O
key	O
residues	O
in	O
the	O
mNsp15	O
catalytic	O
pocket	O
(	O
H262	O
,	O
H277	O
,	O
and	O
G275	O
)	O
and	O
a	O
double	O
-	O
mutant	B-DISO
version	O
(	O
H262P	O
and	O
H277A	O
)	O
generated	O
proteins	O
with	O
greatly	O
reduced	O
but	O
detectable	O
endoribonuclease	O
activities	O
.	O

Furthermore	O
,	O
these	O
mutant	B-DISO
proteins	O
demonstrated	O
lower	O
cleavage	O
specificities	O
for	O
uridylate	O
than	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mNsp15	O
.	O

Plaques	B-DISO
derived	O
from	O
vH262A	O
produced	O
approximately	O
6	O
-	O
to	O
13	O
-	O
fold	O
fewer	O
PFU	O
than	O
those	O
from	O
WT	O
virus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
human	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
coronavirus	O
.	O

According	O
to	O
this	O
study	O
,	O
the	O
overall	O
prevalence	O
rate	O
of	O
lymphopenia	B-DISO
in	O
SARS	B-DISO
is	O
77	O
.	O
2	O
%.	O

TITLE	O
:	O
Cold	B-DISO
antibody	O
autoimmune	B-DISO
hemolytic	I-DISO
anemias	I-DISO
.	O

Additionally	O
,	O
a	O
marked	O
increase	O
of	O
CD4	O
T	O
cell	O
immune	O
responses	O
and	O
high	O
levels	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
humoral	O
responses	O
were	O
also	O
detected	O
in	O
the	O
vAc	O
-	O
N	O
or	O
vAc	O
-	O
S	O
immunized	O
groups	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
serious	O
disorder	O
of	O
intensive	O
care	O
unit	O
patients	O
.	O

This	O
was	O
a	O
prospective	O
observational	O
clinical	O
study	O
conducted	O
in	O
a	O
respiratory	O
intensive	O
care	O
unit	O
of	O
a	O
1200	O
-	O
bed	B-DISO
medical	O
center	O
in	O
central	O
Taiwan	O
.	O

By	O
phylogenetic	O
analysis	O
,	O
SARS	B-DISO
-	O
CoV	O
is	O
distinct	O
from	O
known	O
CoVs	O
and	O
most	O
closely	O
related	O
to	O
group	O
2	O
CoVs	O
.	O

Using	O
Escherichia	O
coli	O
-	O
expressed	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
and	O
fragments	O
,	O
the	O
cross	O
-	O
reactive	O
region	O
was	O
localized	O
between	O
amino	O
acids	O
(	O
aa	O
)	O
120	O
to	O
208	O
.	O

The	O
TGEV	O
and	O
SARS	B-DISO
-	O
CoV	O
N	O
proteins	O
are	O
RNA	O
chaperons	O
with	O
long	O
disordered	O
regions	O
.	O

We	O
speculate	O
that	O
during	O
natural	O
infection	B-DISO
,	O
antibodies	O
target	O
similar	O
short	O
antigenic	O
sites	O
within	O
the	O
N	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
porcine	O
group	O
1	O
CoVs	O
that	O
are	O
exposed	O
to	O
an	O
immune	O
response	O
.	O

These	O
so	O
-	O
called	O
""""	O
CTL	O
escape	O
variant	O
viruses	O
""""	O
are	O
commonly	O
selected	O
during	O
persistent	O
infections	B-DISO
and	O
are	O
associated	O
with	O
rapid	O
disease	B-DISO
progression	I-DISO
and	O
increased	O
disease	O
severity	O
.	O

We	O
found	O
that	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
B	O
-	O
cell	O
-	O
deficient	O
mice	O
did	O
not	O
efficiently	O
clear	O
infectious	B-DISO
virus	O
,	O
uniformly	O
developed	O
clinical	O
disease	O
,	O
and	O
harbored	O
CTL	O
escape	O
variant	O
viruses	O
.	O

The	O
prevalence	O
of	O
the	O
CD14	O
-	O
159CC	O
polymorphism	O
was	O
significantly	O
higher	O
in	O
the	O
patients	O
with	O
severe	O
SARS	B-DISO
than	O
in	O
the	O
those	O
with	O
mild	O
SARS	B-DISO
or	O
controls	O
(	O
31	O
%	O
versus	O
15	O
%	O
[	O
mild	O
SARS	B-DISO
]	O
or	O
20	O
%	O
[	O
controls	O
];	O
mild	O
SARS	B-DISO
:	O
P	O
=	O
0	O
.	O
029	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
15	O
to	O
6	O
.	O
57	O
;	O
controls	O
,	O
P	O
=	O
0	O
.	O
04	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
41	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
05	O
to	O
5	O
.	O
54	O
),	O
and	O
both	O
CD14	O
-	O
159CC	O
and	O
FcgammaRIIA	O
-	O
RR131	O
are	O
risk	O
genotypes	O
for	O
severe	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Virus	O
isolation	O
,	O
hemagglutination	O
and	O
receptor	O
-	O
destroying	O
enzyme	O
activity	O
showed	O
that	O
the	O
buffalo	O
coronavirus	O
(	O
BuCoV	O
)	O
is	O
closely	O
related	O
to	O
BCoV	O
but	O
possesses	B-DISO
some	O
different	O
biological	O
properties	O
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
acute	O
and	O
chronic	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
with	O
variants	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
strain	O
JHM	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
mice	O
with	O
variants	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
strain	O
JHM	O
(	O
MHV	O
-	O
JHM	O
),	O
provide	O
models	O
of	O
acute	O
and	O
chronic	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
).	O

Through	O
targeted	O
recombination	O
and	O
reverse	O
genetic	O
manipulation	O
,	O
studies	O
of	O
infection	B-DISO
with	O
MHV	O
-	O
JHM	O
variants	O
have	O
identified	O
phenotypic	O
differences	O
and	O
examined	O
the	O
effects	O
of	O
these	O
differences	O
on	O
viral	B-DISO
pathogenesis	I-DISO
and	O
anti	O
-	O
viral	O
host	O
immune	O
responses	O
.	O

Demyelinating	B-DISO
disease	I-DISO
during	O
MHV	O
-	O
JHM	O
infection	B-DISO
is	O
immune	O
-	O
mediated	O
,	O
as	O
mice	O
that	O
lack	O
T	O
lymphocytes	O
fail	O
to	O
develop	O
disease	O
despite	O
succumbing	O
to	O
encephalitis	B-DISO
with	O
high	O
levels	O
of	O
infectious	B-DISO
virus	O
in	O
the	O
CNS	O
.	O

These	O
suggest	O
that	O
severe	O
infection	B-DISO
of	O
BCV	O
in	O
the	O
cow	O
without	O
the	O
BCV	O
antibody	O
accompanied	O
by	O
severe	O
hemorrhagic	B-DISO
anemia	I-DISO
resulted	O
in	O
the	O
cow	O
'	O
s	O
death	O
.	O

TITLE	O
:	O
Analysis	O
of	O
high	O
risk	O
factors	O
related	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
following	O
severe	O
thoracoabdominal	O
injuries	O
.	O

The	O
mortality	O
caused	O
by	O
ARDS	B-DISO
was	O
37	O
.	O
8	O
%	O
(	O
34	O
/	O
90	O
).	O

The	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
demonstrated	O
that	O
the	O
clinical	O
conditions	O
such	O
as	O
elder	O
age	O
,	O
shock	O
,	O
dyspnea	B-DISO
,	O
abnormal	O
arterial	O
blood	O
gas	O
,	O
hemopneumothorax	B-DISO
,	O
pulmonary	O
contusion	O
,	O
flail	B-DISO
chest	I-DISO
,	O
coexisting	O
pulmonary	B-DISO
diseases	I-DISO
,	O
multiple	O
abdominal	O
injury	O
and	O
high	O
ISS	B-DISO
score	O
were	O
the	O
independent	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	B-DISO
.	O

The	O
TBI	B-DISO
+	I-DISO
ARDS	I-DISO
group	O
had	O
an	O
overall	O
mean	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
length	O
of	O
stay	O
of	O
15	O
.	O
6	O
days	O
,	O
versus	O
8	O
.	O
4	O
days	O
in	O
the	O
TBI	O
group	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
presence	O
of	O
ARDS	B-DISO
was	O
not	O
associated	O
with	O
higher	O
mortality	O
or	O
worse	O
discharge	O
disability	O
.	O

RESULTS	O
:	O
Among	O
362	O
TBI	O
patients	O
,	O
28	O
(	O
7	O
.	O
7	O
%)	O
developed	O
ARDS	B-DISO
.	O

The	O
TBI	B-DISO
+	I-DISO
ARDS	I-DISO
group	O
had	O
significantly	O
higher	O
hospital	O
charges	O
than	O
the	O
TBI	O
group	O
($	O
210	O
,	O
097	O
versus	O
$	O
115	O
,	O
342	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

Previous	O
vaccine	O
reports	O
have	O
noted	O
robust	O
neutralizing	O
antibody	O
and	O
inflammatory	B-DISO
responses	I-DISO
in	O
ferrets	O
,	O
resulting	O
in	O
enhanced	O
hepatitis	B-DISO
.	O

ABSTRACT	O
:	O
Identification	O
of	O
the	O
nature	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
infected	O
cells	O
is	O
crucial	O
toward	O
understanding	O
the	O
pathogenesis	B-DISO
.	O

Our	O
model	O
was	O
developed	O
based	O
upon	O
the	O
events	O
of	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
,	O
Canada	O
.	O

ABSTRACT	O
:	O
Despite	O
airway	O
pressure	O
limitation	O
,	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
persists	O
in	O
a	O
minority	O
of	O
ARDS	B-DISO
patients	O
.	O

RESULTS	O
:	O
Before	O
PP	O
,	O
21	O
patients	O
(	O
50	O
%)	O
had	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
,	O
defined	O
by	O
RV	O
enlargement	B-DISO
associated	O
with	O
septal	O
dyskinesia	B-DISO
(	O
group	O
1	O
),	O
whereas	O
21	O
patients	O
had	O
a	O
normal	O
RV	O
(	O
group	O
2	O
).	O

A	O
19	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
with	O
fever	O
(	O
400C	O
),	O
lymph	O
node	O
enlargement	B-DISO
,	O
hepatomegaly	B-DISO
,	O
splenomegaly	O
and	O
eosinophilia	B-DISO
(	O
1640	O
/	O
mm3	O
).	O

The	O
diagnosis	O
of	O
DRESS	O
was	O
immediately	O
suspected	O
as	O
the	O
patient	O
had	O
been	O
treated	O
for	O
acne	B-DISO
with	O
minocycline	O
for	O
28	O
days	O
,	O
and	O
IV	O
corticosteroids	O
(	O
2	O
mmg	O
/	O
kg	O
/	O
day	O
)	O
were	O
initiated	O
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
future	O
of	O
the	O
Internet	O
in	O
China	O
as	O
a	O
tool	O
to	O
mitigate	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
through	O
rapid	O
information	O
dissemination	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
exoribonuclease	O
encoded	O
by	O
SARS	B-DISO
coronavirus	O
.	O

This	O
occurred	O
in	O
open	O
reading	O
frame	O
8	O
(	O
ORF8	O
),	O
one	O
of	O
the	O
accessory	O
genes	O
unique	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
function	O
of	O
ORF8	O
and	O
the	O
significance	O
of	O
the	O
deletion	O
are	O
unknown	O
.	O

ORF8b	O
appeared	O
not	O
to	O
be	O
expressed	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
or	O
when	O
expressed	O
from	O
mRNA	O
'	O
s	O
mimicking	O
mRNA8	O
.	O

ABSTRACT	O
:	O
Viral	B-DISO
infections	I-DISO
in	O
chickens	O
pose	O
a	O
major	O
health	O
threat	O
to	O
the	O
poultry	O
industry	O
.	O

Nephropathogenic	O
strains	O
of	O
IBV	O
,	O
such	O
as	O
the	O
Australian	O
T	O
strain	O
,	O
can	O
cause	O
high	O
mortalities	O
due	O
to	O
kidney	B-DISO
failure	I-DISO
characterized	O
by	O
mononuclear	O
cell	O
infiltration	B-DISO
and	O
inflammation	B-DISO
.	O

In	O
addition	O
,	O
S	O
-	O
line	O
birds	O
also	O
showed	O
three	O
times	O
higher	O
serum	O
IL	O
-	O
6	O
levels	O
than	O
HWL	O
birds	O
after	O
IBV	O
infection	B-DISO
.	O

These	O
findings	O
suggest	O
that	O
IL	O
-	O
6	O
may	O
play	O
a	O
role	O
in	O
IBV	O
-	O
induced	O
nephritis	B-DISO
and	O
may	O
open	O
an	O
avenue	O
to	O
develop	O
alternative	O
strategies	O
,	O
such	O
as	O
the	O
use	O
of	O
antiinflammatory	O
cytokines	O
,	O
to	O
overcome	O
the	O
nephropathogenic	O
effects	O
of	O
IBV	O
.	O

TITLE	O
:	O
Molecular	O
docking	O
identifies	O
the	O
binding	O
of	O
3	O
-	O
chloropyridine	O
moieties	O
specifically	O
to	O
the	O
S1	O
pocket	O
of	O
SARS	B-DISO
-	O
CoV	O
Mpro	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
main	O
proteinase	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
),	O
is	O
widely	O
considered	O
to	O
be	O
a	O
major	O
drug	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	B-DISO
treatment	O
.	O

Since	O
avian	B-DISO
influenza	I-DISO
virus	O
A	O
(	O
H5N1	B-DISO
)	O
produces	O
human	O
infections	B-DISO
with	O
high	O
morbidity	O
and	O
mortality	O
rates	O
,	O
the	O
probability	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
and	O
its	O
consequences	O
attract	O
a	O
great	O
deal	O
of	O
attention	O
,	O
recently	O
.	O

The	O
explosive	O
nature	O
of	O
the	O
first	O
SARS	B-DISO
epidemic	O
,	O
the	O
high	O
mortality	O
,	O
its	O
transient	O
reemergence	O
a	O
year	O
later	O
,	O
and	O
economic	O
disruptions	O
led	O
to	O
a	O
rush	O
on	O
research	O
of	O
the	O
epidemiological	O
,	O
clinical	O
,	O
pathological	O
,	O
immunological	O
,	O
virological	O
,	O
and	O
other	O
basic	O
scientific	O
aspects	O
of	O
the	O
virus	O
and	O
the	O
disease	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
protection	O
conferred	O
by	O
commercial	O
vaccines	O
and	O
attenuated	O
heterologous	O
isolates	O
in	O
China	O
against	O
the	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
clinico	O
-	O
epidemiological	O
significance	O
of	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
detected	O
during	O
the	O
SARS	B-DISO
outbreak	O
is	O
unknown	O
.	O

Clinico	O
-	O
epidemiological	O
information	O
was	O
used	O
to	O
analyze	O
the	O
relationship	O
of	O
hMPV	O
co	B-DISO
-	I-DISO
infection	I-DISO
to	O
specific	O
risk	O
factors	O
(	O
demographics	O
/	O
symptoms	O
/	O
outcomes	O
;	O
status	O
as	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
)/	O
patients	O
;	O
history	O
of	O
exposure	O
/	O
contact	O
;	O
ward	O
location	O
).	O

hMPV	O
RNA	O
was	O
detected	O
in	O
31	O
of	O
155	O
(	O
20	O
%)	O
NPAs	O
from	O
SARS	B-DISO
patients	O
.	O

The	O
median	O
and	O
mean	O
amount	O
subjects	O
reported	O
being	O
willing	O
to	O
pay	O
for	O
a	O
SARS	B-DISO
vaccine	O
was	O
US	O
$	O
1762	O
and	O
US	O
$	O
720	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
peptides	O
derived	O
from	O
the	O
heptad	O
repeat	O
(	O
HRP	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
spike	O
protein	O
(	O
sHRPs	O
)	O
are	O
known	O
to	O
inhibit	O
SCoV	O
infection	B-DISO
,	O
yet	O
their	O
efficacies	O
are	O
fairly	O
low	O
.	O

Conventional	O
weaned	O
pigs	O
(	O
n	O
=	O
130	O
)	O
in	O
one	O
of	O
four	O
groups	O
(	O
PRCV	O
/	O
phosphate	O
-	O
buffered	O
saline	O
[	O
PBS	B-DISO
]	O
[	O
n	O
=	O
41	O
],	O
PRCV	O
/	O
DEX	O
[	O
n	O
=	O
41	O
],	O
mock	O
/	O
PBS	B-DISO
[	O
n	O
=	O
23	O
],	O
and	O
mock	O
/	O
DEX	O
[	O
n	O
=	O
25	O
])	O
were	O
inoculated	O
intranasally	O
and	O
intratracheally	O
with	O
the	O
ISU	O
-	O
1	O
strain	O
of	O
PRCV	O
(	O
1	O
x	O
10	O
(	O
7	O
)	O
PFU	O
)	O
or	O
cell	O
culture	O
medium	O
.	O

Our	O
results	O
confirm	O
that	O
DEX	O
treatment	O
alleviates	O
PRCV	O
pneumonia	B-DISO
early	O
(	O
PID	B-DISO
2	O
)	O
in	O
the	O
infection	B-DISO
but	O
continued	O
use	O
through	O
PID	B-DISO
6	O
exacerbates	O
later	O
stages	O
of	O
infection	B-DISO
(	O
PID	B-DISO
4	O
,	O
10	O
,	O
and	O
21	O
),	O
possibly	O
by	O
decreasing	O
cellular	O
immune	O
responses	O
in	O
the	O
lungs	O
(	O
IFN	O
-	O
gamma	O
-	O
secreting	O
T	O
cells	O
),	O
thereby	O
creating	O
an	O
environment	O
for	O
more	O
-	O
extensive	O
viral	O
replication	O
.	O

Patients	O
with	O
trauma	O
-	O
associated	O
lung	O
injury	O
are	O
less	O
acutely	O
and	O
chronically	B-DISO
ill	I-DISO
than	O
other	O
lung	O
injury	O
patients	O
;	O
however	O
,	O
these	O
baseline	O
clinical	O
differences	O
do	O
not	O
adequately	O
explain	O
their	O
improved	O
outcomes	O
.	O

Animals	O
were	O
randomized	O
to	O
an	O
interventional	O
group	O
with	O
a	O
tidal	O
volume	O
of	O
3	O
mL	O
/	O
kg	O
with	O
interventional	O
lung	O
assist	O
(	O
n	O
=	O
7	O
)	O
or	O
to	O
a	O
control	O
group	O
with	O
a	O
tidal	O
volume	O
of	O
6	O
mL	O
/	O
kg	O
without	O
interventional	O
lung	O
assist	O
(	O
n	O
=	O
7	O
)	O
for	O
24	O
hrs	B-DISO
.	O

Obviously	O
,	O
ventilation	O
with	O
tidal	O
volumes	O
of	O
<	O
6	O
mL	O
/	O
kg	O
may	O
cause	O
pulmonary	O
de	O
-	O
recruitment	B-DISO
when	O
positive	O
end	O
-	O
expiratory	O
pressure	O
is	O
not	O
adequately	O
increased	O
.	O

On	O
evidence	O
-	O
based	O
medicine	O
,	O
We	O
undertook	O
some	O
large	O
-	O
sample	O
randomized	O
clinical	O
trials	O
in	O
immunity	O
regulation	O
,	O
anticoagulant	O
therapy	O
,	O
promoting	O
motility	O
of	O
intestinal	O
tract	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
mechanical	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

First	O
,	O
modulation	O
of	O
immunity	O
benefitted	O
MODS	B-DISO
/	O
severe	B-DISO
sepsis	I-DISO
;	O
second	O
,	O
early	O
anticoagulant	O
therapy	O
was	O
essential	O
to	O
MODS	B-DISO
/	O
severe	B-DISO
sepsis	I-DISO
,	O
because	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
occurred	O
in	O
44	O
.	O
1	O
%	O
of	O
MODS	B-DISO
;	O
third	O
,	O
Chinese	O
herb	O
medicines	O
could	O
promote	O
and	O
protect	O
gastrointestinal	O
function	O
in	O
MODS	B-DISO
/	O
severe	B-DISO
sepsis	I-DISO
;	O
fourth	O
,	O
institution	O
of	O
mechanical	O
ventilation	O
with	O
low	O
tidal	O
volume	O
(	O
VT	O
)	O
was	O
effective	O
and	O
safe	O
in	O
ARDS	B-DISO
.	O

After	O
a	O
report	O
describing	O
these	O
cases	O
was	O
posted	O
on	O
CDC	O
'	O
s	O
Epidemic	O
Information	O
Exchange	O
(	O
Epi	B-DISO
-	O
X	O
),	O
health	O
officials	O
in	O
Washington	O
reported	O
a	O
third	O
severe	O
case	O
associated	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
a	O
case	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
in	O
a	O
castrated	O
cat	O
which	O
first	O
presented	O
with	O
the	O
unusual	O
sign	O
of	O
priapism	B-DISO
.	O

At	O
necropsy	O
,	O
histopathological	O
evaluation	O
of	O
organs	O
showed	O
inflammatory	O
granulomatous	B-DISO
lesions	I-DISO
compatible	O
with	O
non	O
-	O
effusive	O
FIP	B-DISO
and	O
coronavirus	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
confirmed	O
the	O
diagnosis	O
.	O

TITLE	O
:	O
Vaccination	O
against	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
affects	O
sperm	O
concentration	O
,	O
sperm	O
quality	O
and	O
blood	O
testosterone	O
concentrations	O
in	O
cockerels	O
.	O

Acute	B-DISO
kidney	I-DISO
failure	I-DISO
,	O
one	O
of	O
the	O
main	O
consequences	O
of	O
rhabdomyolysis	B-DISO
,	O
occurs	O
in	O
4	O
%	O
to	O
33	O
%	O
of	O
cases	O
.	O

TITLE	O
:	O
[	O
The	O
change	O
of	O
health	O
related	O
behavior	O
during	O
and	O
after	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
prevalence	O
].	O

The	O
rate	O
of	O
cellular	O
RNA	O
synthesis	O
in	O
contact	O
-	O
inhibited	O
confluent	O
NIH	O
3T3	O
cells	O
was	O
also	O
lower	O
than	O
in	O
cells	O
permissive	O
to	O
cytopathic	O
MHV	O
infection	B-DISO
.	O

TITLE	O
:	O
Transcriptional	O
profiling	O
of	O
Vero	O
E6	O
cells	O
over	O
-	O
expressing	O
SARS	B-DISO
-	O
CoV	O
S2	O
subunit	O
:	O
insights	O
on	O
viral	O
regulation	O
of	O
apoptosis	O
and	O
proliferation	B-DISO
.	O

This	O
study	O
is	O
expected	O
to	O
extend	O
our	O
understanding	O
on	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
at	O
a	O
molecular	O
level	O
.	O

ABSTRACT	O
:	O
Clostridium	O
difficile	O
was	O
investigated	O
as	O
a	O
possible	O
cause	O
of	O
enteritis	B-DISO
in	O
calves	O
.	O

Prevalence	O
rates	O
for	O
coronavirus	O
and	O
Cryptosporidium	O
sp	O
.	O
were	O
substantially	O
higher	O
in	O
nondiarrheic	O
calves	O
than	O
in	O
diarrheic	O
,	O
but	O
rates	O
of	O
detection	O
of	O
rotavirus	O
and	O
Giardia	B-DISO
sp	O
.	O
were	O
more	O
nearly	O
equal	O
between	O
groups	O
.	O

High	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
exerts	O
beneficial	O
effects	O
on	O
gas	O
exchange	O
in	O
neonates	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

We	O
examined	O
whether	O
continuous	O
negative	O
extrathoracic	O
pressure	O
(	O
CNEP	O
)	O
combined	O
with	O
HFO	O
would	O
be	O
effective	O
for	O
treating	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
an	O
animal	O
model	O
.	O

The	O
values	O
of	O
plasma	O
fibrinogen	O
of	O
the	O
148	O
SARS	B-DISO
patients	O
were	O
analyzed	O
and	O
compared	O
among	O
the	O
different	O
groups	O
.	O

ABSTRACT	O
:	O
A	O
hallmark	O
of	O
acute	O
lung	O
injury	O
is	O
the	O
accumulation	O
of	O
a	O
protein	O
rich	O
edema	B-DISO
which	O
impairs	O
gas	O
exchange	O
and	O
leads	O
to	O
hypoxemia	O
.	O

The	O
resolution	O
of	O
lung	B-DISO
edema	I-DISO
is	O
effected	O
by	O
active	O
sodium	O
transport	O
,	O
mostly	O
contributed	O
by	O
apical	O
Na	O
(+)	O
channels	O
and	O
the	O
basolateral	O
located	O
Na	O
,	O
K	O
-	O
ATPase	O
.	O

TITLE	O
:	O
The	O
""""	O
SARS	B-DISO
-	O
unique	O
domain	O
""""	O
(	O
SUD	O
)	O
of	O
SARS	B-DISO
coronavirus	O
is	O
an	O
oligo	O
(	O
G	O
)-	O
binding	O
protein	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
drug	O
discovery	O
,	O
and	O
its	O
dimerization	O
has	O
been	O
extensively	O
proved	O
to	O
be	O
indispensable	O
for	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
mutation	O
of	O
the	O
dimer	O
-	O
interface	O
residue	O
Gly	O
-	O
11	O
to	O
alanine	O
entirely	O
abolished	O
the	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

As	O
evident	O
during	O
the	O
2003	O
global	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
it	O
is	O
important	O
to	O
provide	O
support	O
for	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
who	O
are	O
vulnerable	O
during	O
infectious	B-DISO
outbreak	O
scenarios	O
.	O

While	O
support	O
mechanisms	O
for	O
HCWs	O
are	O
included	O
in	O
this	O
sample	O
of	O
emergency	B-DISO
plans	O
,	O
content	O
analysis	O
revealed	O
few	O
emotional	O
or	O
social	O
supports	O
planned	O
for	O
critical	O
personnel	O
;	O
particularly	O
for	O
those	O
who	O
will	O
be	O
required	O
to	O
work	O
in	O
extremely	O
stressful	O
conditions	O
under	O
significant	O
personal	O
risk	O
.	O

ELISA	O
analysis	O
indicated	O
the	O
SARS	B-DISO
-	O
CoV	O
antigen	O
prepared	O
from	O
SARS	B-DISO
-	O
CoV	O
lysates	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	O
oxide	O
in	O
the	O
management	O
of	O
preterm	O
infants	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
conclude	O
that	O
iNO	O
therapy	O
leads	O
to	O
an	O
improvement	O
in	O
oxygenation	O
without	O
short	O
-	O
term	O
side	O
effects	O
(	O
such	O
as	O
pulmonary	O
hemorrhage	B-DISO
,	I-DISO
intracranial	I-DISO
hemorrhage	B-DISO
,	O
pneumothorax	B-DISO
or	O
acute	O
deterioration	O
)	O
in	O
premature	O
infants	O
with	O
severe	O
RDS	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
vaccinated	O
chickens	O
of	O
two	O
different	O
major	O
histocompatibility	O
B	O
complex	O
genotypes	O
.	O

ABSTRACT	O
:	O
Twelve	O
Korean	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
were	O
isolated	O
in	O
the	O
field	O
from	O
chickens	O
suspected	O
of	O
being	O
carriers	O
of	O
infectious	B-DISO
bronchitis	B-DISO
between	O
2001	O
and	O
2003	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
safety	O
,	O
immunogenicity	O
and	O
pharmacokinetics	O
of	O
equine	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
F	O
(	O
ab	O
')(	O
2	O
)	O
in	O
macaque	O
.	O

In	O
addition	O
,	O
it	O
can	O
also	O
provide	O
the	O
precious	O
time	O
for	O
the	O
combined	O
use	O
of	O
other	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
agents	O
such	O
as	O
antiviral	O
drug	O
and	O
vaccine	O
.	O

TITLE	O
:	O
Dying	O
and	O
caring	O
on	O
the	O
edge	O
:	O
Taiwan	O
'	O
s	O
surviving	O
nurses	O
'	O
reflections	O
on	O
taking	O
care	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
Taiwan	O
'	O
s	O
nurses	O
were	O
terrified	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
four	O
of	O
them	O
sacrificed	O
their	O
life	O
in	O
the	O
course	O
of	O
their	O
work	O
with	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
The	O
spike	O
glycoprotein	O
of	O
murine	O
coronavirus	O
MHV	O
-	O
JHM	O
mediates	O
receptor	O
-	O
independent	O
infection	B-DISO
and	O
spread	O
in	O
the	O
central	O
nervous	B-DISO
systems	O
of	O
Ceacam1a	O
-/-	O
Mice	O
.	O

This	O
study	O
shows	O
that	O
infection	B-DISO
and	O
spread	O
of	O
MHV	O
-	O
JHM	O
in	O
the	O
brain	O
are	O
dependent	O
upon	O
the	O
viral	O
spike	O
glycoprotein	O
.	O

While	O
mechanical	O
ventilation	O
is	O
integral	O
to	O
the	O
care	O
of	O
these	O
patients	O
,	O
its	O
adverse	O
consequences	O
including	O
ventilator	O
-	O
induced	O
lung	O
injury	O
are	O
determinants	O
of	O
disease	B-DISO
progression	I-DISO
and	O
prognosis	O
.	O

ABSTRACT	O
:	O
Chemokines	O
and	O
their	O
receptors	O
function	O
in	O
the	O
recruitment	B-DISO
and	O
activation	O
of	O
cells	O
of	O
the	O
immune	O
system	O
to	O
sites	O
of	O
inflammation	B-DISO
.	O

The	O
lack	O
of	O
a	O
preferred	O
characterized	O
animal	O
model	O
for	O
SARS	B-DISO
has	O
brought	O
our	O
attention	O
to	O
ferrets	O
,	O
which	O
have	O
been	O
used	O
for	O
years	O
in	O
influenza	B-DISO
studies	O
.	O

TITLE	O
:	O
Safety	O
and	O
immunogenicity	O
from	O
a	O
phase	O
I	O
trial	O
of	O
inactivated	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
vaccine	O
.	O

After	O
SARS	B-DISO
,	O
more	O
respondents	O
were	O
unwilling	O
to	O
perform	O
SCPR	O
on	O
a	O
family	O
member	O
(	O
p	O
=	O
0	O
.	O
039	O
),	O
but	O
there	O
was	O
no	O
difference	O
in	O
the	O
preference	O
to	O
perform	O
CCPR	O
(	O
p	O
=	O
1	O
.	O
000	O
).	O

TITLE	O
:	O
Interaction	O
of	O
a	O
peptide	O
from	O
the	O
pre	O
-	O
transmembrane	O
domain	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
with	O
phospholipid	O
membranes	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
a	O
Class	O
I	O
viral	O
fusion	O
protein	O
,	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
-	O
CoV	O
accessory	O
protein	O
7a	O
is	O
a	O
type	O
I	O
membrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
of	O
81	O
amino	O
acid	O
residues	O
.	O

Hence	O
,	O
differentiated	O
adult	O
human	O
alveolar	O
type	O
II	O
cells	O
were	O
infectible	O
but	O
alveolar	O
type	O
I	O
-	O
like	O
cells	O
and	O
alveolar	O
macrophages	O
did	O
not	O
support	O
productive	O
infection	B-DISO
.	O

The	O
patient	O
'	O
s	O
insulin	B-DISO
resistance	I-DISO
responded	O
to	O
glucocorticoids	O
and	O
plasmapheresis	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
4	O
Chinese	O
herbal	O
polysaccharides	O
on	O
the	O
production	O
of	O
serum	O
antibodies	O
and	O
the	O
proliferation	B-DISO
of	O
peripheral	O
T	O
lymphocytes	O
,	O
including	O
subpopulations	O
in	O
vaccinated	O
chickens	O
.	O

TITLE	O
:	O
SARS	B-DISO
and	O
health	O
worker	O
safety	O
:	O
lessons	O
for	O
influenza	B-DISO
pandemic	O
planning	O
and	O
response	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
provided	O
valuable	O
lessons	O
for	O
protecting	O
health	O
workers	O
during	O
an	O
influenza	B-DISO
pandemic	O
or	O
other	O
public	O
health	O
crisis	O
.	O

As	O
recommended	O
by	O
the	O
SARS	B-DISO
Commission	O
,	O
this	O
principle	O
has	O
now	O
been	O
enshrined	O
in	O
the	O
Health	O
Protection	O
and	O
Promotion	O
Act	O
(	O
2007	O
),	O
Ontario	O
'	O
s	O
public	O
health	O
legislation	O
and	O
in	O
Ontario	O
'	O
s	O
influenza	B-DISO
pandemic	O
plan	B-DISO
.	O

The	O
picture	O
they	O
paint	O
of	O
the	O
possible	O
risk	O
of	O
a	O
global	O
pandemic	O
posed	O
by	O
the	O
avian	B-DISO
influenza	I-DISO
virus	O
H5N1	B-DISO
is	O
indeed	O
a	O
chilling	B-DISO
one	O
,	O
not	O
only	O
for	O
the	O
possible	O
extent	O
of	O
the	O
epidemic	O
itself	O
but	O
also	O
because	O
of	O
the	O
likely	O
burden	O
it	O
could	O
place	O
on	O
an	O
already	O
thinly	O
stretched	O
healthcare	O
workforce	O
.	O

ABSTRACT	O
:	O
A	O
pantropic	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
strain	O
(	O
CB	O
/	O
05	O
)	O
has	O
been	O
recently	O
associated	O
to	O
a	O
fatal	O
outbreak	O
of	O
systemic	B-DISO
disease	I-DISO
in	O
young	O
dogs	O
.	O

The	O
latter	O
finding	O
was	O
strongly	O
supported	O
by	O
phylogenetic	O
evidence	O
and	O
by	O
the	O
construction	O
of	O
a	O
deletion	O
mutant	B-DISO
that	O
reduced	O
the	O
3	O
'	O
UTR	O
to	O
its	O
minimal	O
essential	O
elements	O
.	O

In	O
addition	O
,	O
we	O
will	O
discuss	O
how	O
the	O
formation	O
of	O
these	O
large	O
vesicles	B-DISO
might	O
be	O
induced	O
.	O

Recently	O
,	O
emerging	O
new	O
infections	B-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
or	O
bird	B-DISO
flu	I-DISO
,	O
have	O
placed	O
significant	O
occupational	O
and	O
psychological	B-DISO
stress	I-DISO
on	O
epidemiologists	O
,	O
especially	O
in	O
South	O
-	O
East	O
Asia	O
,	O
resulting	O
in	O
a	O
high	O
intent	O
to	O
change	O
their	O
career	O
.	O

Correlation	O
analysis	O
and	O
hierarchical	O
multiple	O
regression	O
analysis	O
were	O
used	O
to	O
examine	O
relationships	O
among	O
occupational	O
stress	B-DISO
,	I-DISO
psychological	I-DISO
stress	O
,	O
human	O
resources	O
and	O
intent	O
to	O
stay	O
in	O
their	O
career	O
.	O

CONCLUSIONS	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
raised	O
worldwide	O
attention	O
and	O
challenged	O
epidemiologists	O
'	O
intent	O
to	O
stay	O
.	O

The	O
existence	O
of	O
asymptomatic	O
seroconvertors	O
and	O
the	O
detection	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
RNA	O
in	O
plasma	O
during	O
the	O
course	O
of	O
infection	B-DISO
all	O
suggest	O
that	O
SARS	B-DISO
could	O
,	O
as	O
least	O
theoretically	O
,	O
be	O
transmitted	B-DISO
by	O
transfusion	O
.	O

An	O
estimate	O
of	O
the	O
risk	O
of	O
SARS	B-DISO
transmission	O
through	O
blood	O
transfusion	O
will	O
contribute	O
to	O
decisions	O
concerning	O
blood	O
safety	O
monitoring	O
and	O
may	O
be	O
useful	O
in	O
the	O
design	O
of	O
strategies	O
to	O
decrease	O
the	O
risk	O
of	O
transfusion	O
-	O
transmitted	B-DISO
infections	B-DISO
.	O

Although	O
there	O
are	O
currently	O
no	O
confirmed	O
reports	O
of	O
the	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
asymptomatic	O
individuals	O
,	O
recent	O
research	O
data	O
indicate	O
that	O
transfusion	O
-	O
transmitted	B-DISO
SARS	B-DISO
-	O
CoV	O
is	O
at	O
least	O
theoretically	O
possible	O
.	O

Many	O
patients	O
with	O
evidence	O
of	O
PTSD	B-DISO
after	O
critical	B-DISO
illness	I-DISO
have	O
been	O
treated	O
in	O
intensive	O
care	O
units	O
(	O
ICUs	O
).	O

Conversely	O
,	O
the	O
prolonged	O
administration	O
of	O
beta	O
-	O
adrenergic	O
antagonists	O
during	O
the	O
recovery	O
phase	O
after	O
cardiac	O
surgery	O
resulted	O
in	O
a	O
lower	O
number	O
of	O
traumatic	O
memories	O
and	O
a	O
lower	O
incidence	O
of	O
stress	B-DISO
symptoms	I-DISO
at	O
6	O
months	O
after	O
surgery	O
.	O

These	O
augmented	O
innate	O
responses	O
observed	O
correlated	O
with	O
the	O
development	O
of	O
autoimmune	B-DISO
reactivity	O
and	O
retinal	B-DISO
degeneration	I-DISO
and	O
thus	O
may	O
contribute	O
to	O
the	O
pathogenic	O
processes	O
.	O

Six	O
cynomolgus	O
monkeys	O
were	O
inoculated	O
with	O
the	O
HKU39849	O
isolate	O
of	O
SARS	B-DISO
-	O
CoV	O
via	O
four	O
routes	O
.	O

It	O
has	O
been	O
suggested	O
previously	O
that	O
viraemia	B-DISO
may	O
cause	O
intestinal	B-DISO
infections	I-DISO
in	O
SARS	B-DISO
patients	O
.	O

Of	O
these	O
,	O
nine	O
were	O
for	O
viral	B-DISO
diseases	I-DISO
,	O
including	O
four	O
against	O
HIV	B-DISO
,	O
two	O
against	O
hepatitis	B-DISO
C	I-DISO
virus	O
and	O
one	O
each	O
against	O
respiratory	O
syncytial	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
coronavirus	O
)	O
and	O
a	O
variety	O
of	O
viruses	O
.	O

The	O
incremental	O
effect	O
of	O
adding	O
virucidals	O
or	O
antiseptics	O
to	O
normal	O
handwashing	O
to	O
decrease	O
the	O
spread	O
of	O
respiratory	B-DISO
disease	I-DISO
remains	O
uncertain	O
.	O

TITLE	O
:	O
Structural	O
and	O
functional	O
analyses	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
endoribonuclease	O
Nsp15	O
.	O

As	O
acid	O
-	O
fast	O
bacilli	O
were	O
positive	O
in	O
urine	O
(	O
Gaffky	O
8	O
)	O
and	O
sputum	O
(	O
Gaffky	O
1	O
),	O
we	O
diagnosed	O
as	O
miliary	B-DISO
tuberculosis	I-DISO
and	O
pulmonary	B-DISO
tuberculosis	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

A	O
typical	O
clinical	O
feature	O
associated	O
with	O
SARS	B-DISO
is	O
pulmonary	B-DISO
fibrosis	I-DISO
and	O
the	O
associated	O
lung	O
failure	O
.	O

TITLE	O
:	O
Surviving	O
Sepsis	B-DISO
Campaign	O
:	O
international	O
guidelines	O
for	O
management	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
:	O
2008	O
.	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
or	O
acute	B-DISO
hemorrhage	I-DISO
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	B-DISO
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	B-DISO
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	B-DISO
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	B-DISO
/	O
analgesia	B-DISO
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	B-DISO
or	O
continuous	O
infusion	O
sedation	B-DISO
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
)	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
(	O
1A	O
);	O
use	O
of	O
stress	B-DISO
ulcer	I-DISO
prophylaxis	O
to	O
prevent	O
upper	B-DISO
GI	I-DISO
bleeding	I-DISO
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	O
pump	O
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

ACE	O
I	O
/	O
D	O
polymorphism	O
was	O
not	O
associated	O
with	O
severe	B-DISO
sepsis	I-DISO
susceptibility	O
or	O
mortality	O
.	O

This	O
method	O
,	O
which	O
has	O
been	O
successfully	O
applied	O
to	O
isolate	O
broadly	O
neutralizing	O
antibodies	O
against	O
SARS	B-DISO
and	O
H5N1	B-DISO
influenza	I-DISO
viruses	O
,	O
is	O
expected	O
to	O
accelerate	O
the	O
development	O
of	O
therapeutics	O
in	O
the	O
field	O
of	O
infectious	B-DISO
diseases	I-DISO
not	O
only	O
by	O
providing	O
neutralizing	O
antibodies	O
for	O
passive	O
serotherapy	O
,	O
but	O
also	O
by	O
generating	O
relevant	O
information	O
for	O
vaccine	O
design	O
.	O

Except	O
for	O
one	O
case	O
,	O
which	O
required	O
conversion	O
to	O
conventional	O
surgery	O
,	O
stent	O
-	O
graft	O
implantation	O
was	O
successful	O
in	O
all	O
cases	O
,	O
without	O
peri	O
-	O
interventional	O
complications	O
or	O
procedure	O
-	O
induced	O
paraplegia	B-DISO
.	O

Three	O
cases	O
are	O
reported	O
in	O
which	O
patients	O
experienced	O
the	O
acute	O
onset	O
of	O
breathlessness	B-DISO
in	O
association	O
with	O
transfusion	O
of	O
blood	O
components	O
containing	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
antibodies	O
reactive	O
with	O
recipient	O
HLA	O
antigens	O
.	O

TITLE	O
:	O
The	O
GPRLQPY	O
motif	O
located	O
at	O
the	O
carboxy	O
-	O
terminal	O
of	O
the	O
spike	O
protein	O
induces	O
antibodies	O
that	O
neutralize	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

The	O
predicted	O
unknown	O
proteins	O
(	O
PUPs	O
)	O
encoded	O
by	O
the	O
accessory	O
genes	O
,	O
which	O
are	O
considered	O
to	O
be	O
unique	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
,	O
might	O
play	O
important	O
roles	O
in	O
the	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

The	O
severity	O
of	O
abnormalities	O
quantified	O
on	O
chest	O
radiographs	O
in	O
patients	O
with	O
SARS	B-DISO
correlates	O
with	O
the	O
clinical	O
parameters	O
.	O

CONCLUSIONS	O
:	O
The	O
severity	O
of	O
abnormalities	O
quantified	O
on	O
chest	O
radiographs	O
in	O
patients	O
with	O
SARS	B-DISO
correlates	O
with	O
the	O
clinical	O
parameters	O
.	O

Following	O
a	O
suicide	B-DISO
attempt	I-DISO
by	O
intravenous	O
self	O
-	O
injection	O
of	O
10	O
ml	O
of	O
gasoline	O
,	O
a	O
26	O
-	O
year	O
-	O
old	O
medical	O
student	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
hemoptysis	B-DISO
,	O
symptoms	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
chest	B-DISO
pain	I-DISO
,	O
and	O
severe	O
abdominal	B-DISO
cramps	I-DISO
.	O

Early	O
and	O
aggressive	B-DISO
supportive	O
care	O
may	O
be	O
conducive	O
to	O
a	O
favorable	O
outcome	O
with	O
minimal	O
residual	O
pulmonary	O
sequelae	O
.	O

After	O
7	O
days	O
of	O
surgical	O
recovery	O
,	O
sheep	O
were	O
given	O
a	O
cutaneous	O
burn	O
(	O
40	O
%	O
of	O
total	O
body	O
surface	O
,	O
third	O
degree	O
)	O
and	O
insufflated	O
with	O
cotton	O
smoke	O
(	O
48	O
breaths	O
,	O
<	O
40	O
degrees	O
C	O
)	O
under	O
halothane	O
anesthesia	B-DISO
.	O

TITLE	O
:	O
Intratracheal	O
inoculation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
monkeys	O
Macaca	O
rhesus	O
.	O

The	O
monkeys	O
were	O
inoculated	O
into	O
the	O
trachea	B-DISO
with	O
NS	O
-	O
I	O
strain	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
the	O
clinical	O
manifestation	O
of	O
the	O
illness	O
was	O
monitored	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
which	O
uses	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
as	O
its	O
receptor	O
for	O
cell	O
entry	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
that	O
caused	O
almost	O
800	O
victims	O
requires	O
a	O
development	O
of	O
efficient	O
inhibitor	O
against	O
SARS	B-DISO
coronavirus	O
(	O
SCV	O
).	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
in	O
the	O
second	O
trimester	O
of	O
pregnancy	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
associated	O
with	O
miliary	B-DISO
tuberculosis	I-DISO
.	O

Most	O
exposures	O
to	O
superwarfarins	O
are	O
harmless	O
but	O
prolonged	O
bleeding	B-DISO
may	O
occur	O
.	O

Data	O
were	O
compared	O
with	O
viral	O
prevalences	O
that	O
had	O
been	O
determined	O
retrospectively	O
by	O
electron	O
microscopy	O
for	O
936	O
dogs	O
with	O
acute	O
haemorrhagic	B-DISO
diarrhoea	I-DISO
.	O

With	O
a	O
prevalence	O
of	O
17	O
.	O
5	O
per	O
cent	O
,	O
significantly	O
more	O
healthy	O
dogs	O
were	O
shedding	O
coronavirus	O
compared	O
with	O
11	O
.	O
6	O
per	O
cent	O
in	O
dogs	O
with	O
acute	O
haemorrhagic	B-DISO
diarrhoea	I-DISO
(	O
P	O
=	O
0	O
.	O
034	O
).	O

Parvovirus	B-DISO
was	O
only	O
detected	O
in	O
one	O
healthy	O
dog	O
(	O
0	O
.	O
5	O
per	O
cent	O
),	O
thus	O
with	O
a	O
prevalence	O
that	O
was	O
significantly	O
lower	O
than	O
16	O
.	O
0	O
per	O
cent	O
detected	O
in	O
the	O
dogs	O
with	O
acute	O
haemorrhagic	B-DISO
diarrhoea	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Patients	O
with	O
alcoholic	B-DISO
liver	I-DISO
disease	I-DISO
display	O
immune	O
responses	O
consistent	O
with	O
those	O
observed	O
in	O
immunocompromised	O
individuals	O
and	O
alcohol	O
is	O
a	O
potent	O
immunosuppressor	O
.	O

CONCLUSIONS	O
:	O
Chronic	B-DISO
alcoholism	I-DISO
and	O
alcoholic	B-DISO
liver	I-DISO
disease	I-DISO
are	O
both	O
associated	O
with	O
an	O
important	O
degree	O
of	O
immunosuppression	O
.	O

To	O
develop	O
and	O
apply	O
a	O
safe	O
neutralization	O
assay	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
lentiviral	O
SARS	B-DISO
-	O
CoV	O
S	O
pseudotypes	O
had	O
been	O
constructed	O
based	O
on	O
a	O
three	O
plasmid	O
system	O
,	O
which	O
contained	O
pVRC8304	O
(	O
harboring	O
codon	O
optimized	O
full	O
-	O
length	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
),	O
pCMV	O
delta	O
8	O
.	O

2	O
(	O
HIV	B-DISO
-	O
1	O
gag	O
/	O
pol	O
construct	O
)	O
and	O
pHR	O
'	O
CMV	O
EGFP	O
(	O
the	O
green	O
fluorescent	O
protein	O
reporter	O
construct	O
).	O

Enhanced	O
protection	O
in	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
correlated	O
with	O
increased	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
production	O
by	O
infiltrating	B-DISO
natural	O
killer	O
(	O
NK	O
)	O
cells	O
within	O
the	O
brain	O
and	O
reduced	O
liver	O
pathology	B-DISO
.	O

TITLE	O
:	O
Mechanisms	O
of	O
zoonotic	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
host	O
range	O
expansion	O
in	O
human	O
airway	O
epithelium	O
.	O

Zoonotic	O
SARS	B-DISO
-	O
CoV	O
likely	O
evolved	O
to	O
infect	O
humans	O
by	O
a	O
series	O
of	O
transmission	O
events	O
between	O
humans	O
and	O
animals	O
for	O
sale	O
in	O
China	O
.	O

The	O
epidemic	O
,	O
icSZ16	O
-	O
S	O
K479N	O
,	O
and	O
icSZ16	O
-	O
S	O
K479N	O
D22	O
viruses	O
replicate	O
similarly	O
in	O
the	O
BALB	O
/	O
c	O
mouse	O
lung	O
,	O
highlighting	O
the	O
potential	O
use	O
of	O
these	O
zoonotic	O
spike	O
SARS	B-DISO
-	O
CoVs	O
to	O
assess	O
vaccine	O
or	O
serotherapy	O
efficacy	O
in	O
vivo	O
.	O

To	O
look	O
for	O
viruses	O
which	O
are	O
non	O
detectable	O
by	O
antigen	O
detection	O
assays	O
(	O
rhinovirus	O
,	O
coronavirus	O
,	O
bocavirus	O
,	O
polyomavirus	O
...)	O
or	O
in	O
severe	O
or	O
complicated	O
respiratory	O
lower	O
infections	B-DISO
,	O
the	O
use	O
of	O
molecular	O
tools	O
is	O
highly	O
indicated	O
.	O

TITLE	O
:	O
Retrospective	O
study	O
of	O
severe	O
cases	O
of	O
leptospirosis	B-DISO
admitted	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
initial	O
diagnosis	O
of	O
leptospirosis	B-DISO
depends	O
on	O
a	O
high	O
index	O
of	O
clinical	O
suspicion	O
,	O
routinely	O
available	O
diagnostic	O
tests	O
being	O
unreliable	O
in	O
the	O
initial	O
period	O
.	O

Our	O
descriptions	O
of	O
these	O
issues	O
are	O
drawn	O
from	O
our	O
experience	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Taiwan	O
.	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
or	O
acute	B-DISO
hemorrhage	I-DISO
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	B-DISO
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	B-DISO
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	B-DISO
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	B-DISO
/	O
analgesia	B-DISO
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	B-DISO
or	O
continuous	O
infusion	O
sedation	B-DISO
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
),	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
(	O
1A	O
);	O
use	O
of	O
stress	B-DISO
ulcer	I-DISO
prophylaxis	O
to	O
prevent	O
upper	B-DISO
gastrointestinal	I-DISO
bleeding	I-DISO
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	O
pump	O
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

TITLE	O
:	O
Mannan	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
serum	O
concentration	O
in	O
relation	O
to	O
propagation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
The	O
common	O
respiratory	O
viruses	O
,	O
including	O
influenza	B-DISO
A	O
,	O
influenza	B-DISO
B	O
,	O
and	O
newly	O
emerging	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
viruses	O
,	O
may	O
cause	O
similar	O
clinical	O
symptoms	O
.	O

ABSTRACT	O
:	O
We	O
intended	O
to	O
evaluate	O
the	O
diagnostic	O
usefulness	O
of	O
a	O
multiplex	O
reverse	O
transcriptase	O
-	O
PCR	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
kit	O
under	O
dual	O
priming	O
oligonucleotide	O
system	O
(	O
DPO	O
)	O
for	O
the	O
childhood	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Two	O
hundred	O
nasopharyngeal	O
aspirates	O
were	O
taken	O
from	O
children	O
<	O
or	O
=	O
5	O
yr	O
old	O
admitted	O
due	O
to	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
2004	O
.	O

We	O
report	O
a	O
case	O
of	O
gemcitabine	O
-	O
induced	O
ARDS	B-DISO
in	O
a	O
72	O
-	O
year	O
old	O
patient	O
treated	O
with	O
gemcitabine	O
and	O
cisplatin	O
for	O
a	O
bladder	B-DISO
cancer	I-DISO
without	O
lung	B-DISO
metastasis	I-DISO
.	O

SARS	B-DISO
-	O
CoV	O
N	O
and	O
N199	O
(	O
a	O
truncated	O
nucleocapsid	O
gene	O
)	O
genes	O
were	O
cloned	O
,	O
expressed	O
,	O
identified	O
by	O
Western	O
blotting	O
,	O
and	O
applied	O
in	O
screening	O
of	O
human	O
and	O
swine	O
samples	O
.	O

CONCLUSIONS	O
:	O
N199	O
protein	O
is	O
feasible	O
in	O
both	O
clinical	O
diagnosis	O
and	O
SARS	B-DISO
-	O
CoV	O
reservoir	O
screening	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
sudden	O
onset	O
of	O
respiratory	B-DISO
distress	I-DISO
,	O
infiltrates	B-DISO
on	O
radiographs	O
consistent	O
with	O
pulmonary	B-DISO
oedema	I-DISO
,	O
hypoxaemia	O
and	O
increased	O
work	O
in	O
breathing	O
.	O

TITLE	O
:	O
Sequence	O
analysis	O
of	O
the	O
ORF	O
7	O
region	O
of	O
transmissible	O
gastroenteritis	B-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

Cultural	O
beliefs	O
and	O
practices	O
within	O
the	O
Chinese	O
population	O
support	O
the	O
recommendations	O
set	O
by	O
the	O
health	O
department	O
for	O
the	O
protection	O
of	O
individuals	O
and	O
the	O
community	O
during	O
the	O
SARS	B-DISO
pandemic	O
.	O

A	O
basic	O
understanding	O
of	O
the	O
epidemiology	O
,	O
clinical	B-DISO
findings	I-DISO
,	O
diagnosis	O
,	O
and	O
treatment	O
of	O
these	O
agents	O
will	O
provide	O
a	O
foundation	O
for	O
early	O
isolation	O
,	O
evaluation	O
,	O
infection	B-DISO
control	O
,	O
and	O
public	O
health	O
involvement	O
and	O
response	O
in	O
cases	O
of	O
a	O
febrile	O
respiratory	O
illness	O
that	O
causes	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Pulmonary	B-DISO
hypertension	I-DISO
and	O
cor	B-DISO
pulmonale	I-DISO
during	O
severe	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	I-DISO
sickle	I-DISO
cell	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
with	O
cough	B-DISO
in	O
infancy	O
:	O
a	O
community	O
-	O
based	O
birth	O
cohort	O
study	O
.	O

All	O
112	O
infants	O
who	O
had	O
an	O
ARI	O
had	O
cough	B-DISO
,	O
and	O
39	O
(	O
35	O
%)	O
had	O
wheeze	B-DISO
.	O

Although	O
symptom	B-DISO
scores	O
and	O
need	O
for	O
general	O
practitioner	O
(	O
GP	O
)	O
consultations	O
were	O
highest	O
in	O
infants	O
infected	O
with	O
RSV	O
,	O
they	O
were	O
similar	O
in	O
infants	O
infected	O
with	O
other	O
viruses	O
.	O

vaccination	O
against	O
SARS	B-DISO
-	O
CoV	O
challenge	O
in	O
mice	O
;	O
4	O
)	O
higher	O
titers	O
of	O
mucosal	O
IgA	O
and	O
serum	O
-	O
neutralizing	O
Ab	O
were	O
associated	O
with	O
lower	O
viral	O
load	O
and	O
less	O
pulmonary	O
pathological	O
damage	O
,	O
while	O
no	O
Ab	O
-	O
mediated	O
disease	O
enhancement	O
effect	O
was	O
observed	O
;	O
and	O
5	O
)	O
the	O
vaccination	O
could	O
provide	O
long	O
-	O
term	O
protection	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
RBD	O
-	O
rAAV	O
can	O
be	O
further	O
developed	O
into	O
a	O
vaccine	O
candidate	O
for	O
prevention	O
of	O
SARS	B-DISO
and	O
that	O
i	O
.	O
n	O
.	O

Past	O
history	O
of	O
psychiatric	B-DISO
illness	I-DISO
,	O
years	O
of	O
health	O
care	O
experience	O
,	O
and	O
the	O
perception	O
of	O
adequate	O
training	O
and	O
support	O
were	O
tested	O
as	O
predictors	O
of	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
episodes	O
of	O
psychiatric	B-DISO
disorders	I-DISO
after	O
the	O
SARS	B-DISO
outbreak	O
.	O

In	O
this	O
study	O
,	O
we	O
confirmed	O
that	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
A59	O
E	O
protein	O
is	O
palmitoylated	O
.	O

Double	O
-	O
and	O
triple	O
-	O
mutant	B-DISO
E	O
proteins	O
resulted	O
in	O
decreased	O
virus	O
-	O
like	O
particle	O
output	O
when	O
coexpressed	O
with	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
.	O

A	O
comparison	O
of	O
intracellular	O
and	O
extracellular	O
virus	O
yields	O
suggested	O
that	O
release	O
is	O
only	O
slightly	O
impaired	B-DISO
.	O

TITLE	O
:	O
Chimeric	O
coronavirus	O
-	O
like	O
particles	O
carrying	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
S	O
protein	O
protect	O
mice	O
against	O
challenge	O
with	O
SCoV	O
.	O
ABSTRACT	O
:	O
We	O
tested	O
the	O
efficacy	O
of	O
coronavirus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
for	O
protecting	O
mice	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
infection	B-DISO
.	O

Despite	O
some	O
differences	O
in	O
the	O
cellular	O
composition	O
of	O
inflammatory	O
infiltrates	B-DISO
,	O
we	O
did	O
not	O
observe	O
any	O
overt	O
lung	O
pathology	B-DISO
in	O
the	O
chimeric	O
-	O
VLP	O
-	O
treated	O
mice	O
,	O
when	O
compared	O
to	O
the	O
negative	O
control	O
mice	O
.	O

Although	O
there	O
have	O
been	O
many	O
reports	O
of	O
such	O
work	O
done	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
these	O
were	O
mainly	O
focused	O
on	O
the	O
immune	O
responses	O
of	O
humans	O
and	O
mice	O
.	O

Amoxapine	O
was	O
stopped	O
,	O
resulting	O
in	O
complete	O
resolution	O
of	O
the	O
pulmonary	B-DISO
infiltrates	I-DISO
.	O

CONCLUSIONS	O
:	O
A	O
proper	O
ventilation	O
strategy	O
,	O
early	O
pharmacologic	O
therapy	O
including	O
glucocorticoids	O
,	O
and	O
complication	B-DISO
prevention	O
may	O
contribute	O
to	O
good	O
treatment	O
outcomes	O
after	O
white	O
smoke	O
inhalation	O
.	O

These	O
three	O
MAbs	O
(	O
S109	O
.	O
8	O
,	O
S227	O
.	O
14	O
,	O
and	O
S230	O
.	O
15	O
)	O
were	O
tested	O
for	O
use	O
in	O
passive	O
vaccination	O
studies	O
using	O
lethal	O
SARS	B-DISO
-	O
CoV	O
challenge	O
models	O
for	O
young	O
and	O
senescent	O
mice	O
with	O
four	O
different	O
homologous	O
and	O
heterologous	O
SARS	B-DISO
-	O
CoV	O
S	O
variants	O
.	O

We	O
also	O
rescued	O
a	O
two	O
-	O
segmented	O
virus	O
expressing	O
GFP	O
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
spike	O
S	O
protein	O
,	O
which	O
is	O
about	O
200	O
kDa	O
.	O

The	O
aromatic	O
amino	O
acids	O
in	O
the	O
JMD	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
glycoprotein	O
play	O
critical	O
roles	O
in	O
receptor	O
-	O
dependent	O
virus	O
-	O
cell	O
and	O
cell	O
-	O
cell	O
fusion	O
.	O

TITLE	O
:	O
Advances	O
in	O
critical	O
care	O
for	O
the	O
nephrologist	O
:	O
acute	O
lung	O
injury	O
/	O
ARDS	B-DISO
.	O

ALI	O
and	O
ARDS	B-DISO
may	O
occur	O
in	O
association	O
with	O
a	O
number	O
of	O
clinical	O
disorders	O
,	O
including	O
sepsis	B-DISO
,	O
pneumonia	B-DISO
,	I-DISO
aspiration	I-DISO
,	O
trauma	O
including	O
inhalational	O
injury	O
,	O
and	O
blood	O
transfusions	O
.	O

Of	O
these	O
,	O
a	O
low	O
tidal	O
volume	O
,	O
lung	O
protective	O
ventilation	O
strategy	O
is	O
the	O
only	O
strategy	O
that	O
has	O
been	O
demonstrated	O
in	O
a	O
large	O
,	O
multicenter	O
randomized	O
clinical	O
trial	O
to	O
reduce	O
mortality	O
for	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
duration	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
2	O
.	O
7	O
+/-	O

21	O
.	O
0	O
d	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
renal	B-DISO
failure	I-DISO
(	O
1	O
.	O
3	O
+/-	O

The	O
infection	B-DISO
rate	O
(	O
7	O
.	O
9	O
%	O
vs	O
26	O
.	O
3	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
operation	O
rate	O
(	O
13	O
.	O
2	O
%	O
vs	O
34	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
mortality	O
(	O
5	O
.	O
3	O
%	O
vs	O
21	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
early	O
treatment	O
group	O
were	O
lower	O
than	O
in	O
the	O
late	O
treatment	O
group	O
.	O

The	O
overall	O
influenza	B-DISO
vaccination	O
rate	O
for	O
nurses	O
in	O
Hong	O
Kong	O
was	O
about	O
50	O
%.	O

Concern	O
about	O
contracting	O
avian	B-DISO
influenza	I-DISO
was	O
a	O
predictor	O
of	O
the	O
vaccination	O
rate	O
in	O
2006	O
but	O
not	O
in	O
2007	O
(	O
OR	O
,	O
1	O
.	O
47	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
2	O
.	O
09	O
];	O
P	O
<.	O
05	O
),	O
as	O
was	O
the	O
perceived	O
lack	O
of	O
control	O
over	O
avian	B-DISO
influenza	I-DISO
infection	B-DISO
(	O
OR	O
,	O
1	O
.	O
52	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
2	O
.	O
18	O
];	O
P	O
<.	O
05	O
).	O

In	O
particular	O
,	O
the	O
paper	O
illustrates	O
how	O
risk	O
management	O
can	O
be	O
improved	O
by	O
adopting	O
practices	O
and	O
procedures	O
which	O
actively	O
involve	O
the	O
public	O
in	O
dealing	O
with	O
the	O
emergency	B-DISO
,	O
by	O
taking	O
a	O
transparent	O
and	O
accessible	O
approach	O
to	O
communication	O
with	O
the	O
public	O
(	O
including	O
the	O
provision	O
of	O
information	O
about	O
the	O
risks	O
)	O
and	O
by	O
fostering	O
the	O
unrestricted	O
exchange	O
of	O
scientific	O
knowledge	O
among	O
researchers	O
.	O

To	O
model	O
28	O
-	O
day	O
survival	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
compare	O
the	O
utility	O
of	O
Cox	O
and	O
accelerated	O
failure	O
time	O
(	O
AFT	O
)	O
models	O
.	O

Both	O
log	O
-	O
normal	O
(	O
R2	O
=	O
0	O
.	O
451	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
321	O
,	O
0	O
.	O
695	O
)	O
and	O
log	O
-	O
logistic	O
(	O
R2	O
0	O
.	O
470	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
346	O
,	O
0	O
.	O
714	O
)	O
AFT	O
models	O
identified	O
the	O
same	O
predictors	O
as	O
the	O
Cox	O
model	O
,	O
but	O
did	O
not	O
demonstrate	O
convincingly	O
superior	O
overall	O
fit	B-DISO
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
evolution	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
Spain	O
over	O
a	O
fourteen	O
-	O
year	O
period	O
.	O

ABSTRACT	O
:	O
An	O
in	O
-	O
depth	O
molecular	O
study	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBV	O
)	O
with	O
particular	O
interest	O
in	O
evolutionary	O
aspects	O
of	O
IBV	O
in	O
Spain	O
was	O
carried	O
out	O
in	O
the	O
present	O
study	O
based	O
on	O
the	O
S1	O
gene	O
molecular	O
characterization	O
of	O
twenty	O
-	O
six	O
Spanish	O
strains	O
isolated	O
over	O
a	O
fourteen	O
-	O
year	O
period	O
.	O

These	O
patients	O
will	O
be	O
sicker	O
than	O
those	O
typically	O
managed	O
in	O
the	O
operating	O
room	O
and	O
will	O
require	O
more	O
emergency	B-DISO
management	O
of	O
their	O
airways	O
.	O

TITLE	O
:	O
Application	O
of	O
ProteinChip	O
array	O
profiling	O
in	O
serum	O
biomarker	O
discovery	O
for	O
patients	O
suffering	B-DISO
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

By	O
protein	O
chip	O
array	O
profiling	O
technology	O
,	O
a	O
number	O
of	O
serum	O
biomarkers	O
that	O
might	O
be	O
useful	O
in	O
monitoring	O
the	O
clinical	O
course	O
of	O
SARS	B-DISO
patients	O
were	O
identified	O
.	O

The	O
serum	O
profiling	O
spectra	O
in	O
SARS	B-DISO
patients	O
were	O
acquired	O
,	O
baseline	O
subtracted	O
and	O
analyzed	O
in	O
parallel	O
with	O
those	O
from	O
the	O
control	O
subjects	O
by	O
Ciphergen	O
ProteinChip	O
Software	O
3	O
.	O
0	O
.	O
2	O
with	O
their	O
peak	O
intensities	O
compared	O
by	O
a	O
nonparametric	O
two	O
sample	O
Mann	O
-	O
Whitney	O
-	O
U	O
test	O
.	O

More	O
than	O
twelve	O
peaks	O
were	O
differentially	O
expressed	O
in	O
SARS	B-DISO
patients	O
with	O
one	O
at	O
m	O
/	O
z	O
of	O
11	O
,	O
695	O
(	O
later	O
identified	O
to	O
be	O
serum	O
amyloid	B-DISO
A	O
protein	O
),	O
which	O
had	O
increase	O
in	O
peak	O
intensity	O
correlating	O
with	O
the	O
extent	O
of	O
SARS	B-DISO
-	O
coronavirus	O
induced	O
pneumonia	B-DISO
as	O
defined	O
by	O
a	O
serial	O
chest	O
X	O
-	O
ray	O
opacity	B-DISO
score	O
.	O

HCWs	O
in	O
a	O
Toronto	O
hospital	O
who	O
worked	O
in	O
high	O
-	O
risk	O
areas	O
completed	O
a	O
questionnaire	O
regarding	O
their	O
attitude	O
toward	O
the	O
SARS	B-DISO
crisis	O
along	O
with	O
the	O
Impact	O
of	O
Event	O
Scale	O
-	O
Revised	O
,	O
which	O
screens	O
for	O
PTSS	O
.	O

ABSTRACT	O
:	O
Two	O
randomized	O
controlled	O
trials	O
confirmed	O
the	O
existence	O
of	O
so	O
-	O
called	O
ventilator	O
-	O
associated	O
lung	O
injury	O
by	O
showing	O
reduced	O
morbidity	O
and	O
mortality	O
with	O
the	O
use	O
of	O
lower	O
tidal	O
volumes	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
its	O
more	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
entry	O
into	O
host	O
cells	O
through	O
a	O
novel	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
endocytic	O
pathway	O
.	O

Treatment	O
of	O
cells	O
with	O
either	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
or	O
spike	O
-	O
bearing	O
pseudoviruses	O
resulted	O
in	O
the	O
translocation	B-DISO
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
from	O
the	O
cell	O
surface	O
to	O
endosomes	O
.	O

In	O
41	O
cases	O
,	O
15	O
cases	O
were	O
congenital	B-DISO
laryngeal	I-DISO
stridor	I-DISO
,	O
accounting	O
for	O
31	O
.	O
9	O
%,	O
involving	O
6	O
cases	O
accompanied	O
by	O
the	O
gastroesophageal	B-DISO
reflux	I-DISO
.	O

Others	O
were	O
6	O
cases	O
of	O
acute	O
membrane	O
laryngotracheobronchitis	B-DISO
,	O
3	O
cases	O
of	O
congenital	O
main	O
respiratory	O
tract	O
stenosis	B-DISO
,	O
2	O
cases	O
of	O
congenital	O
laryngeal	B-DISO
webs	I-DISO
,	O
2	O
cases	O
of	O
vocal	B-DISO
cord	I-DISO
paralysis	I-DISO
,	O
3	O
cases	O
of	O
Pierre	B-DISO
Robin	I-DISO
syndrome	I-DISO
,	O
2	O
cases	O
of	O
Cri	B-DISO
-	I-DISO
du	I-DISO
-	I-DISO
chat	I-DISO
syndrome	I-DISO
.	O

All	O
individuals	O
had	O
been	O
vaccinated	O
with	O
a	O
Chinese	O
canine	O
vaccine	O
that	O
included	O
modified	O
live	O
CDV	O
,	O
CPV	O
,	O
CAV	O
,	O
CCV	B-DISO
,	O
and	O
CPIV	O
.	O

To	O
investigate	O
the	O
underlying	O
mechanisms	O
,	O
yeast	O
two	O
-	O
hybrid	O
screen	O
was	O
carried	O
out	O
using	O
SARS	B-DISO
-	O
CoV	O
proteins	O
as	O
baits	O
,	O
revealing	O
that	O
a	O
subunit	O
of	O
the	O
eukaryotic	O
initiation	O
factor	O
3	O
(	O
eIF3	O
),	O
eIF3f	O
,	O
may	O
interact	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
.	O

This	O
study	O
reveals	O
a	O
novel	O
mechanism	O
exploited	O
by	O
coronavirus	O
to	O
regulate	O
viral	B-DISO
pathogenesis	I-DISO
.	O

TITLE	O
:	O
Microbiology	O
and	O
management	O
of	O
neonatal	B-DISO
necrotizing	I-DISO
enterocolitis	I-DISO
.	O

The	O
predominant	O
organisms	O
include	O
Enterobacteriaceae	O
(	O
i	O
.	O
e	O
.,	O
Escherichia	O
coli	O
,	O
Klebsiella	O
pneumoniae	O
)	O
,	O
Clostridium	O
spp	O
.,	O
enteric	O
pathogens	O
(	O
salmonellae	O
,	O
Coxsackie	O
B2	O
virus	O
,	O
coronavirus	O
,	O
rotavirus	O
),	O
and	O
potential	O
pathogens	O
(	O
Bacteroides	B-DISO
fragilis	I-DISO
).	O

Diagnosis	O
of	O
ARDS	B-DISO
was	O
based	O
on	O
the	O
following	O
criterias	O
:	O
(	O
1	O
)	O
Gestational	O
age	O
>	O
or	O
=	O
35	O
weeks	O
of	O
gestation	O
;	O
(	O
2	O
)	O
Severe	O
and	O
immediate	O
respiratory	B-DISO
distress	I-DISO
requiring	O
mechanical	O
ventilation	O
with	O
PEEP	O
>	O
or	O
=	O
4	O
cmH2O	O
and	O
FiO2	O
>	O
or	O
=	O
0	O
.	O
5	O
during	O
at	O
least	O
6	O
hours	O
;	O
(	O
3	O
)	O
Dependence	B-DISO
on	I-DISO
oxygen	O
>	O
or	O
=	O
48	O
hours	O
;	O
(	O
4	O
)	O
Diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
in	O
the	O
chest	O
radiograph	O
;	O
(	O
5	O
)	O
PaO2	O
<	O
or	O
=	O
60	O
mmHg	O
under	O
FiO2	O
>	O
or	O
=	O
0	O
.	O
5	O
.	O

TITLE	O
:	O
Steady	O
-	O
state	O
and	O
pre	O
-	O
steady	O
-	O
state	O
kinetic	O
evaluation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
3CLpro	O
cysteine	O
protease	O
:	O
development	O
of	O
an	O
ion	O
-	O
pair	O
model	O
for	O
catalysis	O
.	O

Proton	O
inventory	O
(	O
PI	O
)	O
studies	O
on	O
amide	O
peptide	O
hydrolysis	O
were	O
consistent	O
with	O
two	O
proton	O
-	O
transfer	O
reactions	O
in	O
the	O
transition	B-DISO
state	O
while	O
the	O
ester	O
data	O
was	O
consistent	O
with	O
a	O
single	O
proton	O
-	O
transfer	O
reaction	O
.	O

There	O
are	O
currently	O
no	O
known	O
immune	O
correlates	O
of	O
protection	O
against	O
HIV	B-DISO
.	O

Polymorphisms	O
in	O
cytokine	O
genes	O
,	O
linked	O
to	O
cytokine	O
inducibility	O
,	O
may	O
influence	O
the	O
susceptibility	O
to	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
serve	O
as	O
risk	O
predictors	O
.	O

Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
frequency	O
differed	O
significantly	O
with	O
the	O
IL	O
-	O
10	O
-	O
1082	O
genotype	O
(	O
P	O
=	O
.	O
007	O
;	O
P	O
corrected	O
,	O
.	O
03	O
),	O
whereas	O
there	O
was	O
no	O
significant	O
relation	O
to	O
any	O
other	O
cytokine	O
genotype	O
after	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
.	O

The	O
-	O
1082	O
GG	O
genotype	O
was	O
a	O
marker	O
of	O
decreased	O
risk	O
to	O
develop	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
univariate	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
0	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
;	O
P	O
=	O
.	O
004	O
)	O
and	O
multivariate	O
(	O
OR	O
,	O
0	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
1	O
-	O
0	O
.	O
9	O
;	O
P	O
=	O
.	O
03	O
)	O
logistic	O
regression	O
analysis	O
,	O
with	O
male	O
gender	O
,	O
severe	O
abdominal	O
injury	O
,	O
and	O
an	O
APACHE	O
II	O
score	O
>	O
19	O
being	O
significant	O
risk	O
factors	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
responsible	O
for	O
SARS	B-DISO
infection	B-DISO
.	O

Nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
encapsidates	O
the	O
viral	O
RNA	O
and	O
plays	O
an	O
important	O
role	O
in	O
virus	O
particle	O
assembly	O
and	O
release	O
.	O

Moreover	O
,	O
syncytium	O
formation	O
was	O
observed	O
as	O
the	O
other	O
type	O
of	O
cytopathic	B-DISO
effect	I-DISO
in	O
ECoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
influenza	I-DISO
virus	O
of	O
H9N2	O
subtype	O
is	O
pathotyped	O
as	O
a	O
non	O
-	O
highly	O
pathogenic	O
virus	O
.	O

ABSTRACT	O
:	O
Systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
),	O
severe	O
infection	B-DISO
and	O
sepsis	B-DISO
are	O
the	O
problems	O
of	O
present	O
interest	O
in	O
contemporary	O
medicine	O
.	O

In	O
severe	O
viral	B-DISO
infections	I-DISO
or	O
inflammatory	B-DISO
reaction	I-DISO
of	O
non	O
-	O
infective	O
origin	O
the	O
level	O
of	O
PCT	B-DISO
does	O
not	O
elevate	O
or	O
increases	O
moderately	O
.	O

The	O
levels	O
of	O
PCT	B-DISO
correlate	O
with	O
levels	O
of	O
TNF	O
and	O
IL	O
-	O
6	O
.	O

Samples	O
of	O
testis	O
,	O
trachea	B-DISO
,	O
and	O
lungs	O
from	O
breeder	O
males	O
aged	O
57	O
wk	O
were	O
positive	O
for	O
IBV	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
virus	O
isolation	O
and	O
testis	O
samples	O
were	O
also	O
positive	O
for	O
aMPV	O
by	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
,	O
which	O
is	O
characterized	O
by	O
respiratory	O
,	O
reproductive	O
,	O
and	O
renal	O
signs	O
.	O

Birds	O
were	O
presenting	O
watery	B-DISO
diarrhea	I-DISO
and	O
poor	O
general	O
condition	B-DISO
but	O
were	O
without	O
respiratory	O
,	O
renal	O
,	O
or	O
reproductive	O
signs	O
.	O

This	O
group	O
has	O
the	O
potential	O
to	O
accelerate	O
global	O
spread	O
of	O
infectious	B-DISO
respiratory	B-DISO
diseases	I-DISO
.	O

This	O
international	O
survey	O
provides	O
insight	O
into	O
what	O
might	O
be	O
expected	O
during	O
an	O
influenza	B-DISO
pandemic	O
.	O

ABSTRACT	O
:	O
Traumatic	B-DISO
shock	I-DISO
is	O
a	O
complex	O
phenomenon	O
that	O
represents	O
the	O
culminating	O
element	O
of	O
a	O
series	O
of	O
events	O
.	O

Basically	O
,	O
it	O
is	O
a	O
form	O
of	O
hypovolemic	B-DISO
shock	I-DISO
in	O
which	O
further	O
factors	O
have	O
a	O
role	O
,	O
including	O
the	O
activation	O
of	O
inflammation	B-DISO
mediators	O
.	O

The	O
viral	O
components	O
of	O
the	O
complex	O
are	O
encoded	O
by	O
the	O
giant	B-DISO
replicase	O
gene	O
,	O
which	O
is	O
expressed	O
in	O
the	O
form	O
of	O
two	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
)	O
that	O
are	O
processed	O
into	O
16	O
cleavage	O
products	O
(	O
nonstructural	O
proteins	O
1	O
-	O
16	O
).	O

Using	O
the	O
combination	O
of	O
yeast	O
two	O
-	O
hybrid	O
screening	O
and	O
GST	O
pull	O
-	O
down	O
assays	O
,	O
we	O
have	O
now	O
analyzed	O
all	O
potential	O
interactions	O
between	O
SARS	B-DISO
-	O
Coronavirus	O
nonstructural	O
proteins	O
,	O
which	O
may	O
contribute	O
to	O
the	O
structure	O
and	O
/	O
or	O
function	O
of	O
the	O
viral	O
replication	O
/	O
transcription	O
complex	O
.	O

ABSTRACT	O
:	O
Among	O
176	O
patients	O
who	O
had	O
had	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
SARS	B-DISO
-	O
specific	O
antibodies	O
were	O
maintained	O
for	O
an	O
average	O
of	O
2	O
years	O
,	O
and	O
significant	O
reduction	O
of	O
immunoglobulin	O
G	O
-	O
positive	O
percentage	O
and	O
titers	O
occurred	O
in	O
the	O
third	O
year	O
.	O

TITLE	O
:	O
International	O
Circumpolar	O
Surveillance	O
,	O
an	O
Arctic	O
network	O
for	O
the	O
surveillance	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
presence	O
of	O
anti	O
-	O
HRPO	O
MAb	O
is	O
an	O
acceptable	O
impurity	O
as	O
it	O
will	O
not	O
bind	O
to	O
the	O
target	O
SARS	B-DISO
-	O
CoV	O
NP	O
antigen	O
and	O
will	O
get	O
washed	B-DISO
out	I-DISO
during	O
the	O
ELISA	O
procedure	O
.	O

TITLE	O
:	O
Anti	O
-	O
interleukin	O
-	O
8	O
autoantibody	O
:	O
interleukin	O
-	O
8	O
immune	O
complexes	O
in	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
is	O
a	O
year	O
'	O
s	O
retrospective	O
study	O
of	O
autopsied	O
cases	O
of	O
leptospirosis	B-DISO
,	O
selected	O
on	O
the	O
basis	O
of	O
clinical	O
criteria	O
.	O

The	O
predominant	O
feature	O
on	O
histopathological	O
examination	O
was	O
the	O
presence	O
of	O
interstitial	B-DISO
myocarditis	I-DISO
(	O
100	O
%	O
of	O
cases	O
),	O
with	O
involvement	O
of	O
the	O
epicardium	O
/	O
endocardium	O
(	O
39	O
%),	O
valves	O
(	O
36	O
%),	O
coronary	O
arteries	O
(	O
51	O
%)	O
and	O
aorta	O
(	O
56	O
%).	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
showing	O
selection	O
of	O
a	O
more	O
fit	B-DISO
virus	O
subpopulation	O
as	O
well	O
as	O
mutations	O
associated	O
with	O
replication	O
of	O
modified	O
live	O
IBV	O
vaccine	O
viruses	O
in	O
chickens	O
.	O

Transbronchial	O
biopsies	O
showed	O
grade	O
B0	O
(	O
normal	O
)	O
(	O
n	O
=	O
501	O
),	O
B1	O
(	O
minimal	O
)	O
(	O
n	O
=	O
762	O
),	O
B2	O
(	O
mild	O
)	O
(	O
n	O
=	O
176	O
),	O
B3	O
(	O
moderate	O
)	O
(	O
n	O
=	O
70	O
),	O
B4	O
(	O
severe	O
)	O
(	O
n	O
=	O
4	O
)	O
lymphocytic	O
bronchiolitis	B-DISO
,	O
and	O
Bx	O
(	O
no	O
bronchiolar	O
tissue	O
)	O
(	O
n	O
=	O
75	O
).	O

Cumulative	O
incidence	O
of	O
BOS	B-DISO
and	O
death	O
were	O
dependent	O
on	O
highest	O
B	O
grade	O
(	O
Kaplan	O
-	O
Meier	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
log	O
-	O
rank	O
).	O

Severity	O
of	O
lymphocytic	O
bronchiolitis	B-DISO
is	O
associated	O
with	O
increased	O
risk	O
of	O
BOS	B-DISO
and	O
death	O
after	O
lung	O
transplantation	O
independent	O
of	O
acute	O
vascular	O
rejection	O
.	O

TITLE	O
:	O
Hypophosphatemia	B-DISO
as	O
unusual	O
cause	O
of	O
ARDS	B-DISO
in	O
Cushing	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
secondary	O
to	O
ectopic	O
CRH	O
production	O
.	O

Although	O
our	O
current	O
understanding	O
of	O
these	O
processes	O
is	O
limited	O
by	O
the	O
inability	O
to	O
accurately	O
replicate	O
the	O
complex	O
human	O
physiology	O
in	O
laboratory	O
settings	O
,	O
it	O
has	O
recently	O
become	O
apparent	O
that	O
the	O
process	O
of	O
repair	O
and	O
remodelling	O
begins	O
early	O
in	O
the	O
course	O
of	O
ARDS	B-DISO
/	O
ALI	O
and	O
may	O
be	O
determined	O
by	O
the	O
type	O
of	O
pulmonary	O
injury	O
.	O

Understanding	O
the	O
mechanisms	O
leading	O
to	O
and	O
regulating	O
fibroproliferative	O
changes	O
may	O
contribute	O
to	O
the	O
development	O
of	O
novel	O
early	O
therapeutic	O
interventions	O
in	O
ARDS	B-DISO
/	O
ALI	O
patients	O
.	O

In	O
patients	O
with	O
severe	O
asthma	B-DISO
or	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
,	O
iLA	O
might	O
represent	O
an	O
attractive	O
rescue	O
therapy	O
in	O
the	O
future	O
.	O

Viral	O
gene	O
expression	O
and	O
viral	O
particle	O
production	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)-	O
deficient	O
and	O
G6PD	O
-	O
knockdown	O
cells	O
were	O
much	O
higher	O
than	O
their	O
counterparts	O
when	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
was	O
applied	O
at	O
0	O
.	O
1	O
multiplicity	O
of	O
infection	B-DISO
.	O

Accordingly	O
,	O
ectopic	O
expression	O
of	O
G6PD	O
in	O
G6PD	O
-	O
deficient	O
cells	O
or	O
addition	O
of	O
antioxidant	O
(	O
such	O
as	O
alpha	O
-	O
lipoic	O
acid	O
)	O
to	O
G6PD	O
-	O
knockdown	O
cells	O
attenuated	O
the	O
increased	O
susceptibility	O
to	O
HCoV	O
229E	O
infection	B-DISO
.	O

All	O
experimental	O
data	O
indicated	O
that	O
oxidative	B-DISO
stress	I-DISO
in	O
host	O
cells	O
is	O
an	O
important	O
factor	O
in	O
HCoV	O
229E	O
infectivity	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
crisis	O
exposed	O
serious	O
deficiencies	O
in	O
China	O
'	O
s	O
public	O
health	O
system	O
and	O
willingness	O
to	O
report	O
outbreaks	O
of	O
threats	O
to	O
public	O
health	O
.	O

We	O
postulated	O
that	O
additional	O
factors	O
should	O
regulate	O
transcription	O
of	O
sg	O
mRNA	O
N	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
described	O
a	O
novel	O
transcription	O
regulation	O
mechanism	O
operating	O
in	O
CoV	O
by	O
which	O
a	O
9	O
-	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
located	O
449	O
nt	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	B-DISO
core	O
sequence	O
(	O
CS	O
-	O
N	O
)	O
interacts	O
with	O
a	O
complementary	O
sequence	O
just	O
upstream	O
of	O
CS	O
-	O
N	O
,	O
specifically	O
increasing	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
Alteration	O
of	O
this	O
complementarity	O
in	O
mutant	B-DISO
replicon	O
genomes	O
showed	O
a	O
correlation	O
between	O
the	O
predicted	O
stability	O
of	O
the	O
base	O
pairing	O
between	O
9	O
-	O
nt	O
sequences	O
and	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
This	O
interaction	O
is	O
exclusively	O
conserved	O
in	O
group	O
1a	O
CoVs	O
,	O
the	O
only	O
CoV	O
subgroup	O
in	O
which	O
the	O
N	O
gene	O
is	O
not	O
the	O
most	O
3	O
'	O
gene	O
in	O
the	O
viral	O
genome	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
exerted	O
a	O
massive	O
toll	O
on	O
Hong	O
Kong	O
'	O
s	O
healthcare	O
system	O
in	O
2003	O
.	O

Detailed	O
analysis	O
of	O
the	O
point	O
mutants	O
of	O
these	O
two	O
amino	O
acid	O
residues	O
and	O
their	O
nearby	O
hydrogen	O
bond	O
partner	O
Ser	O
-	O
123	O
and	O
Ser	O
-	O
139	O
revealed	O
a	O
strong	O
correlation	O
between	O
the	O
enzyme	O
activity	O
loss	O
and	O
dimer	O
dissociation	B-DISO
.	O

The	O
overall	O
incidence	O
of	O
OM	O
that	O
complicated	O
URI	O
was	O
61	O
%,	O
including	O
a	O
37	O
%	O
incidence	O
of	O
AOM	B-DISO
and	O
a	O
24	O
%	O
incidence	O
of	O
OME	O
.	O

AOM	B-DISO
occurred	O
in	O
approximately	O
one	O
-	O
half	O
of	O
children	O
with	O
URI	O
due	O
to	O
adenovirus	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
coronavirus	O
and	O
in	O
approximately	O
one	O
-	O
third	O
of	O
those	O
with	O
URI	O
due	O
to	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
enterovirus	O
,	O
or	O
rhinovirus	O
.	O

Young	O
age	O
and	O
specific	O
virus	O
types	O
were	O
predictors	O
of	O
URI	O
complicated	O
by	O
AOM	B-DISO
.	O

RESULTS	O
:	O
We	O
documented	O
1295	O
URI	O
episodes	O
(	O
5	O
.	O
06	O
episodes	O
per	O
child	O
-	O
year	O
)	O
and	O
440	O
AOM	B-DISO
episodes	O
(	O
1	O
.	O
72	O
episodes	O
per	O
child	O
-	O
year	O
).	O

AOM	B-DISO
occurred	O
in	O
approximately	O
one	O
-	O
half	O
of	O
children	O
with	O
URI	O
due	O
to	O
adenovirus	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
coronavirus	O
and	O
in	O
approximately	O
one	O
-	O
third	O
of	O
those	O
with	O
URI	O
due	O
to	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
enterovirus	O
,	O
or	O
rhinovirus	O
.	O

Cerebral	B-DISO
haemorrhage	I-DISO
may	O
result	O
from	O
the	O
use	O
of	O
amphetamines	O
or	O
cocaine	O
.	O

MDMA	O
is	O
a	O
major	O
cause	O
of	O
acute	O
severe	O
hyponatraemia	O
and	O
also	O
has	O
been	O
linked	O
with	O
hepatic	O
syndromes	B-DISO
.	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
corticosteroid	O
in	O
the	O
treatment	O
of	O
severe	O
SARS	B-DISO
in	O
Guangdong	O
province	O
with	O
multi	O
-	O
factor	O
regression	O
analysis	O
].	O

Infectivity	O
assay	O
showed	O
the	O
integrity	O
of	O
lipid	O
rafts	O
was	O
required	O
for	O
productive	O
infection	B-DISO
of	O
pseudotyped	O
SARS	B-DISO
-	O
CoV	O
.	O
Depletion	O
of	O
plasma	O
membrane	O
cholesterol	O
with	O
MbetaCD	O
relocalized	O
raft	O
-	O
resident	O
marker	O
caveolin	O
-	O
1	O
as	O
well	O
as	O
SARS	B-DISO
-	O
CoV	O
receptor	O
ACE2	O
to	O
a	O
nonraft	O
environment	O
,	O
but	O
did	O
not	O
significantly	O
change	O
the	O
surface	O
expression	O
of	O
ACE2	O
.	O

But	O
relapses	O
are	O
frequent	O
after	O
stopping	O
corticosteroid	O
treatment	O
,	O
as	O
well	O
as	O
the	O
occurrence	O
of	O
severe	O
asthma	B-DISO
.	O

Uncircumcised	O
men	O
have	O
an	O
increased	O
risk	O
of	O
HPV	O
infection	B-DISO
,	O
including	O
with	O
oncogenic	O
HPV	O
,	O
specifically	O
localized	O
to	O
the	O
glans	O
/	O
corona	O
,	O
possibly	O
because	O
of	O
its	O
proximity	O
to	O
the	O
foreskin	O
,	O
which	O
may	O
be	O
particularly	O
vulnerable	O
to	O
infection	B-DISO
.	O

We	O
treated	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)-	O
infected	O
conventional	O
pigs	O
with	O
the	O
corticosteroid	O
dexamethasone	O
(	O
DEX	O
)	O
as	O
a	O
model	O
for	O
SARS	B-DISO
.	O

PRCV	O
infection	B-DISO
increased	O
T	O
-	O
cell	O
frequencies	O
in	O
BAL	O
,	O
but	O
DEX	O
treatment	O
of	O
PRCV	O
-	O
infected	O
pigs	O
reduced	O
frequencies	O
of	O
T	O
cells	O
;	O
interestingly	O
B	O
and	O
SWC3a	O
(+)	O
(	O
monocytes	O
/	O
macrophages	O
/	O
granulocytes	O
)	O
cell	O
frequencies	O
were	O
increased	O
.	O

(	O
1	O
%),	O
and	O
Mycoplasma	B-DISO
haemocanis	O
(	O
1	O
%)	O
observed	O
.	O

Since	O
T	O
cell	O
epitopes	O
are	O
highly	O
conserved	O
and	O
boosting	O
with	O
peptides	O
may	O
induce	O
the	O
production	O
of	O
effector	O
memory	O
T	O
cells	O
,	O
which	O
may	O
be	O
effective	O
against	O
viruses	O
with	O
mutations	O
in	O
the	O
neutralizing	O
epitopes	O
,	O
our	O
results	O
suggest	O
that	O
the	O
vaccination	O
protocol	O
used	O
may	O
be	O
ideal	O
for	O
providing	O
effective	O
,	O
broad	O
and	O
long	O
-	O
term	O
protection	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

This	O
is	O
probably	O
the	O
first	O
serological	O
evidence	O
of	O
coronavirus	B-DISO
infection	I-DISO
in	O
mithuns	O
.	O

TITLE	O
:	O
Postoperative	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
following	O
adenotonsillectomy	O
in	O
children	O
with	O
neuropathy	B-DISO
.	O

Comparison	O
of	O
the	O
growth	O
ability	O
in	O
embryos	O
and	O
replication	O
and	O
pathogenicity	O
in	O
chickens	O
with	O
IBV	O
carrying	O
the	O
normal	O
3a	O
gene	O
indicated	O
that	O
this	O
deleted	O
sequence	O
in	O
the	O
3a	O
gene	O
of	O
CK	O
/	O
CH	O
/	O
LSD	O
/	O
03I	O
was	O
not	O
necessary	O
for	O
viral	B-DISO
pathogenesis	I-DISO
and	O
replication	O
either	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O

TITLE	O
:	O
Two	O
-	O
year	O
prospective	O
study	O
of	O
single	O
infections	B-DISO
and	O
co	B-DISO
-	I-DISO
infections	I-DISO
by	O
respiratory	O
syncytial	O
virus	O
and	O
viruses	O
identified	O
recently	O
in	O
infants	O
with	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
.	O

RSV	O
was	O
associated	O
with	O
the	O
presence	O
of	O
complications	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
hypoxia	B-DISO
(	O
P	O
<	O
0	O
.	O
015	O
).	O

TITLE	O
:	O
Coronavirus	B-DISO
infection	I-DISO
modulates	O
the	O
unfolded	O
protein	O
response	O
and	O
mediates	O
sustained	O
translational	O
repression	O
.	O

These	O
data	O
demonstrated	O
that	O
SARS	B-DISO
-	O
CoV	O
nsp1	O
suppressed	O
host	O
innate	O
immune	O
functions	O
,	O
including	O
type	O
I	O
IFN	O
expression	O
,	O
in	O
infected	O
cells	O
and	O
suggested	O
that	O
SARS	B-DISO
-	O
CoV	O
nsp1	O
most	O
probably	O
plays	O
a	O
critical	O
role	O
in	O
SARS	B-DISO
-	O
CoV	O
virulence	O
.	O

His	O
condition	B-DISO
was	O
well	O
controlled	O
before	O
the	O
operation	O
.	O

With	O
regard	O
to	O
Ang	O
(	O
1	O
-	O
7	O
),	O
the	O
identification	O
of	O
ACE2	O
and	O
of	O
Mas	B-DISO
as	O
a	O
receptor	O
implicated	O
in	O
its	O
actions	O
contributed	O
to	O
decisively	O
establish	O
this	O
heptapeptide	O
as	O
a	O
biologically	O
active	O
member	O
of	O
the	O
RAS	O
cascade	O
.	O

Relationships	O
of	O
TNF	O
-	O
alpha	O
gene	O
polymorphisms	O
with	O
interstitial	B-DISO
lung	I-DISO
fibrosis	I-DISO
and	O
femoral	O
head	O
osteonecrosis	B-DISO
were	O
carried	O
out	O
in	O
two	O
case	O
-	O
case	O
studies	O
in	O
discharged	O
SARS	B-DISO
patients	O
.	O

CONCLUSIONS	O
:	O
SNPs	O
of	O
TNF	O
-	O
alpha	O
gene	O
of	O
promoter	O
region	O
may	O
not	O
associate	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Hematological	O
changes	O
in	O
patients	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
are	O
common	O
and	O
frequently	O
include	O
thrombocytopenia	O
.	O

Using	O
a	O
ELISA	O
method	O
,	O
we	O
found	O
an	O
increase	O
in	O
thrombopoietin	O
(	O
TPO	O
)	O
levels	O
in	O
the	O
plasma	O
of	O
convalesced	O
SARS	B-DISO
patients	O
(	O
290	O
+/-	O
53	O
pg	O
/	O
ml	O
)	O
and	O
active	O
SARS	B-DISO
patients	O
(	O
251	O
+/-	O
23	O
pg	O
/	O
ml	O
)	O
comparing	O
to	O
that	O
from	O
normal	O
control	O
patients	O
(	O
228	O
+/-	O
17	O
pg	O
/	O
ml	O
).	O

In	O
addition	O
,	O
the	O
plasma	O
from	O
active	O
SARS	B-DISO
patients	O
had	O
an	O
inhibitory	O
effect	O
on	O
CFU	O
-	O
MK	O
formation	O
,	O
which	O
could	O
be	O
neutralized	O
by	O
anti	O
-	O
TGF	O
-	O
beta	O
antibodies	O
.	O

TITLE	O
:	O
Amiodarone	O
alters	O
late	O
endosomes	O
and	O
inhibits	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
at	O
a	O
post	O
-	O
endosomal	O
level	O
.	O

Exaggerated	O
cytokine	O
release	O
of	O
mononuclear	O
cells	O
was	O
observed	O
in	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
).	O

To	O
investigate	O
endotoxemia	O
,	O
plasma	O
TNFalpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
the	O
liberation	O
capacity	O
of	O
those	O
cytokines	O
from	O
mononuclear	O
cells	O
after	O
LPS	B-DISO
challenge	O
(	O
Delta	O
values	O
),	O
and	O
plasma	O
antibodies	O
to	O
endotoxins	O
and	O
alpha	O
-	O
hemolysin	O
of	O
Staphylococcus	O
aureus	O
in	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
respondents	O
were	O
23	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
.	O

ALI	O
/	O
ARDS	B-DISO
was	O
defined	O
according	O
to	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
on	O
ARDS	B-DISO
.	O

The	O
more	O
severe	O
the	O
disease	O
,	O
the	O
more	O
intense	O
is	O
endotoxemia	O
but	O
the	O
lower	O
is	O
the	O
capacity	O
of	O
mononuclear	O
cells	O
to	O
release	O
cytokines	O
(	O
tolerance	B-DISO
).	O

It	O
is	O
now	O
well	O
established	O
that	O
the	O
causative	O
agent	O
,	O
a	O
newly	O
identified	O
coronavirus	O
termed	O
SARS	B-DISO
-	O
CoV	O
,	O
employs	O
multiple	O
passive	O
and	O
active	O
mechanisms	O
to	O
avoid	O
induction	O
of	O
the	O
antiviral	O
type	O
I	O
interferons	O
in	O
tissue	O
cells	O
.	O

There	O
was	O
an	O
epidemic	O
of	O
diarrhoea	B-DISO
affecting	O
pigs	O
of	O
all	O
ages	O
in	O
Italy	O
between	O
May	O
2005	O
and	O
June	O
2006	O
.	O

Watery	B-DISO
diarrhoea	I-DISO
without	O
mucus	O
and	O
blood	O
was	O
usually	O
associated	O
with	O
a	O
reduction	O
of	O
feed	O
consumption	O
.	O

ABSTRACT	O
:	O
The	O
masked	O
palm	O
civet	O
(	O
Paguma	O
larvata	O
)	O
has	O
been	O
suspected	O
to	O
be	O
the	O
host	O
of	O
a	O
SARS	B-DISO
-	O
like	O
CoV	O
virus	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
humans	O
.	O

Recent	O
animal	O
studies	O
have	O
demonstrated	O
that	O
administration	O
of	O
heparins	O
,	O
activated	O
protein	O
C	O
(	O
APC	B-DISO
),	O
Antithrombin	O
(	O
AT	O
),	O
Tissue	O
factor	O
-	O
Factor	O
VIIa	O
(	O
TF	O
-	O
FVIIa	O
)	O
pathway	O
inhibitors	O
,	O
plasminogen	O
activators	O
(	O
PA	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
)	O
can	O
attenuate	O
pulmonary	O
coagulopathy	B-DISO
and	O
reduce	O
lung	O
injury	O
and	O
/	O
or	O
improve	O
oxygenation	O
.	O

The	O
use	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
3	O
(	O
MHV3	O
)	O
attenuated	O
variants	O
showing	O
selected	O
tropisms	O
for	O
KC	O
or	O
LSEC	O
have	O
allowed	O
determining	O
their	O
roles	O
in	O
the	O
disturbances	O
of	O
immune	B-DISO
tolerance	I-DISO
during	O
viral	B-DISO
hepatitis	I-DISO
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
has	O
many	O
serotypes	O
that	O
do	O
not	O
confer	O
cross	O
protection	O
against	O
each	O
other	O
.	O

Additionally	O
,	O
lungs	O
isolated	O
from	O
alcohol	O
-	O
fed	O
rats	O
developed	O
more	O
edema	B-DISO
than	O
comparably	O
treated	O
lungs	O
from	O
control	O
-	O
fed	O
rats	O
,	O
as	O
reflected	O
by	O
increased	O
lung	O
tissue	O
wet	O
:	O
dry	O
ratios	O
.	O

This	O
provides	O
a	O
potential	O
explanation	O
as	O
to	O
why	O
the	O
otherwise	O
healthy	O
alcoholic	O
does	O
not	O
have	O
evidence	O
of	O
pulmonary	B-DISO
edema	I-DISO
at	O
baseline	O
.	O

ABSTRACT	O
:	O
Although	O
multiple	O
viruses	O
utilize	O
host	O
cell	O
cyclophilins	O
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
-	O
1	O
(	O
HIV	B-DISO
-	O
1	O
),	O
their	O
role	O
in	O
infection	B-DISO
is	O
poorly	O
understood	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
is	O
a	O
highly	O
infectious	B-DISO
upper	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
,	O
a	O
previously	O
unidentified	O
human	O
coronavirus	O
.	O

SARS	B-DISO
-	O
3CL	O
(	O
pro	O
)	O
is	O
a	O
viral	O
cysteine	O
protease	O
critical	O
to	O
the	O
pathogen	O
'	O
s	O
life	O
cycle	O
and	O
hence	O
a	O
therapeutic	O
target	O
of	O
importance	O
.	O

Infected	O
animals	O
become	O
less	O
aggressive	B-DISO
and	O
develop	O
pyrexia	O
,	O
lethargy	B-DISO
and	O
diarrhoea	B-DISO
.	O

The	O
data	O
also	O
demonstrated	O
that	O
the	O
NL63	O
RBD	O
bound	O
to	O
hACE2	O
more	O
efficiently	O
than	O
its	O
full	O
-	O
length	O
counterpart	O
and	O
had	O
a	O
binding	O
efficiency	O
comparable	O
to	O
the	O
S1	O
or	O
RBD	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
A	O
further	O
series	O
of	O
RBD	O
variants	O
was	O
generated	O
using	O
site	O
-	O
directed	O
mutagenesis	O
and	O
random	O
mutant	B-DISO
library	O
screening	O
assays	O
,	O
and	O
identified	O
15	O
residues	O
(	O
C497	O
,	O
Y498	O
,	O
V499	O
,	O
C500	O
,	O
K501	O
,	O
R518	O
,	O
R530	O
,	O
V531	O
,	O
G534	O
,	O
G537	O
,	O
D538	O
,	O
S540	O
,	O
E582	O
,	O
W585	O
and	O
T591	O
)	O
that	O
appeared	O
to	O
be	O
critical	O
for	O
the	O
RBD	O
-	O
hACE2	O
association	O
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
mechanism	O
of	O
antibody	O
-	O
dependent	O
enhancement	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	B-DISO
infection	I-DISO
:	O
aminopeptidase	O
N	O
is	O
not	O
important	O
and	O
a	O
process	O
of	O
acidification	O
of	O
the	O
endosome	O
is	O
necessary	O
.	O

Planning	O
for	O
future	O
outbreaks	O
should	O
take	O
into	O
account	O
the	O
need	O
to	O
(	O
1	O
)	O
develop	O
systems	O
that	O
enable	O
rapid	O
two	O
-	O
way	O
communication	O
between	O
public	O
health	O
officials	O
and	O
homeless	O
service	O
providers	O
,	O
(	O
2	O
)	O
ensure	O
that	O
homeless	O
service	O
providers	O
have	O
access	O
to	O
infection	B-DISO
control	O
supplies	O
and	O
staff	O
training	O
,	O
(	O
3	O
)	O
prepare	O
for	O
possible	O
homeless	O
shelter	O
closures	O
due	O
to	O
staff	O
shortages	O
or	O
high	O
attack	O
rates	O
among	O
clients	O
,	O
and	O
(	O
4	O
)	O
plan	B-DISO
for	O
where	O
and	O
how	O
clinically	O
ill	B-DISO
homeless	O
individuals	O
will	O
be	O
isolated	O
and	O
treated	O
.	O

The	O
Toronto	O
SARS	B-DISO
experience	O
provided	O
insights	O
that	O
are	O
relevant	O
to	O
response	O
planning	O
for	O
future	O
outbreaks	O
in	O
cities	O
with	O
substantial	O
numbers	O
of	O
homeless	O
individuals	O
.	O

Temporal	O
trends	O
in	O
marker	O
concentrations	O
during	O
36	O
hours	O
and	O
the	O
relations	O
between	O
initial	O
concentrations	O
and	O
lowest	O
Pao2	O
/	O
Fio2	O
or	O
ARDS	B-DISO
within	O
72	O
hours	O
were	O
assessed	O
using	O
random	O
coefficients	O
modeling	O
and	O
cross	O
-	O
sectional	O
analysis	O
.	O

Patients	O
were	O
recruited	O
from	O
cases	O
of	O
snakebites	O
admitted	O
to	O
the	O
emergency	B-DISO
care	O
unit	O
of	O
Kottayam	O
Medical	O
College	O
between	O
May	O
2005	O
and	O
December	O
2006	O
.	O

Higher	O
rates	O
of	O
complications	O
were	O
seen	O
in	O
those	O
with	O
severe	O
coagulopathy	B-DISO
(	O
OR	O
=	O
8	O
.	O
0	O
),	O
leucocytosis	B-DISO
(	O
OR	O
=	O
3	O
.	O
7	O
)	O
and	O
those	O
who	O
received	O
SAV	O
late	O
.	O

The	O
presence	O
of	O
a	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunt	O
through	O
a	O
patent	B-DISO
foramen	I-DISO
ovale	I-DISO
was	O
documented	O
by	O
transesophageal	O
echocardiography	O
24	O
h	O
after	O
admission	O
to	O
intensive	O
care	O
.	O

The	O
next	O
day	O
,	O
the	O
patient	O
underwent	O
a	O
percutaneous	O
occlusion	B-DISO
procedure	O
with	O
an	O
Amplatzer	O
device	O
after	O
consultation	O
with	O
surgeons	O
and	O
cardiologists	O
.	O

This	O
system	O
,	O
named	O
rapid	O
determination	O
of	O
viral	O
RNA	O
sequences	O
(	O
RDV	O
),	O
involves	O
whole	O
-	O
genome	O
amplification	B-DISO
and	O
a	O
new	O
direct	O
sequencing	O
technique	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
major	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
high	O
mortality	O
despite	O
lung	O
-	O
protective	O
ventilation	O
.	O

We	O
measured	O
plasma	O
markers	O
of	O
inflammation	B-DISO
,	O
coagulation	O
and	O
fibrinolysis	O
simultaneously	O
to	O
assess	O
whether	O
these	O
markers	O
remain	O
predictive	O
in	O
the	O
era	O
of	O
lung	O
-	O
protective	O
ventilation	O
.	O

Our	O
results	O
suggest	O
that	O
enhanced	O
colibacillosis	B-DISO
after	O
IBV	O
infection	B-DISO
or	O
vaccination	O
is	O
caused	O
at	O
least	O
by	O
altered	O
innate	O
immunity	O
and	O
less	O
by	O
impairment	B-DISO
of	O
phagocytic	O
cell	O
function	O
.	O

A	O
prospective	O
study	O
of	O
consecutive	O
children	O
presenting	O
with	O
acute	O
wheezing	B-DISO
to	O
a	O
pediatric	O
hospital	O
from	O
May	O
2004	O
to	O
November	O
2005	O
was	O
undertaken	O
.	O

TITLE	O
:	O
A	O
series	O
of	O
five	O
adult	O
cases	O
of	O
respiratory	O
syncytial	O
virus	O
-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
hospital	O
,	O
he	O
initially	O
manifested	O
coma	B-DISO
,	O
hypoxemia	O
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
and	O
a	O
carboxyhemoglobin	O
level	O
of	O
45	O
.	O
8	O
%.	O

He	O
was	O
treated	O
with	O
hyperbaric	O
oxygen	O
but	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
day	O
four	O
despite	O
an	O
early	O
improvement	O
.	O

The	O
53	O
-	O
year	O
-	O
old	O
mother	O
felt	O
dizziness	B-DISO
,	O
headache	B-DISO
and	O
had	O
a	O
carboxyhemoglobin	O
level	O
of	O
23	O
.	O
0	O
%.	O

We	O
report	O
a	O
case	O
of	O
diamnionic	O
monochorionic	O
female	O
twins	O
in	O
which	O
the	O
acardiac	B-DISO
twin	I-DISO
demonstrated	O
severe	O
hydrops	B-DISO
fetalis	I-DISO
and	O
bilateral	O
talipes	O
varus	B-DISO
deformity	I-DISO
.	O

ABSTRACT	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
PBL	O
is	O
an	O
effective	O
method	O
for	O
preparing	O
multidisciplinary	O
learner	O
groups	O
at	O
community	O
health	O
centers	O
(	O
CHCs	O
)	O
for	O
pandemics	O
,	O
quantitative	O
and	O
qualitative	O
methods	O
were	O
utilized	O
to	O
evaluate	O
the	O
conduct	O
of	O
a	O
PBL	O
case	O
of	O
a	O
hypothetical	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
at	O
two	O
CHCs	O
in	O
Hawaii	O
,	O
with	O
multidisciplinary	O
health	O
professional	O
and	O
student	O
participants	O
.	O

As	O
few	O
as	O
10	O
arthroconidia	O
are	O
capable	O
of	O
causing	O
an	O
infection	B-DISO
in	O
animal	O
models	O
.	O

Prevention	O
and	O
control	O
programs	O
for	O
animals	O
and	O
humans	O
are	O
improving	O
,	O
with	O
infections	B-DISO
in	O
poultry	O
currently	O
under	O
control	O
and	O
no	O
human	O
cases	O
seen	O
in	O
2007	O
.	O

Public	O
health	O
response	O
to	O
avian	B-DISO
influenza	I-DISO
and	O
pandemic	O
preparedness	O
benefit	O
significantly	O
from	O
the	O
experience	O
of	O
responses	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Proteins	O
packaged	O
during	O
virus	O
assembly	O
may	O
subsequently	O
form	O
the	O
first	O
line	O
of	O
attack	O
and	O
host	O
manipulation	O
upon	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
systemic	B-DISO
disease	I-DISO
characterized	O
by	O
both	O
lung	O
pathology	B-DISO
and	O
widespread	O
extrapulmonary	O
virus	O
dissemination	O
causing	O
multiple	O
organ	O
injuries	O
.	O

In	O
this	O
regard	O
,	O
renal	O
dysfunction	O
is	O
an	O
ominous	O
sign	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

This	O
SARS	B-DISO
-	O
CoV	O
variant	O
acquired	O
a	O
single	O
nonconservative	O
amino	O
acid	O
change	O
from	O
glutamic	O
acid	O
(	O
E	O
)	O
to	O
alanine	O
(	O
A	O
)	O
at	O
position	O
11	O
in	O
the	O
viral	O
membrane	O
(	O
M	O
)	O
protein	O
.	O

TITLE	O
:	O
Application	O
of	O
siRNA	O
against	O
SARS	B-DISO
in	O
the	O
rhesus	O
macaque	O
model	O
.	O

The	O
prophylactic	O
and	O
therapeutic	O
efficacies	O
resulted	O
in	O
relief	O
of	O
animals	O
from	O
SCV	O
infection	B-DISO
-	O
induced	O
fever	O
,	O
diminished	O
SCV	O
in	O
upper	O
airway	O
and	O
lung	O
alveoli	O
,	O
and	O
milder	O
acute	O
diffuse	O
alveoli	O
damage	O
(	O
DAD	O
).	O

Models	O
that	O
strive	O
to	O
predict	O
the	O
dynamics	O
of	O
agents	O
may	O
be	O
useful	O
but	O
can	O
also	O
blind	B-DISO
us	O
to	O
increasing	O
disease	O
risks	O
if	O
it	O
does	O
not	O
match	O
a	O
specific	O
model	O
.	O

TITLE	O
:	O
Feasibility	O
of	O
very	O
high	O
-	O
frequency	O
ventilation	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

To	O
determine	O
the	O
region	O
on	O
the	O
NP	O
molecule	O
where	O
the	O
monoclonal	O
antibodies	O
bind	O
,	O
we	O
generated	O
four	O
truncated	O
recombinant	O
NPs	B-DISO
and	O
analyzed	O
the	O
reactivity	O
between	O
monoclonal	O
antibodies	O
and	O
truncated	O
NPs	B-DISO
.	O

The	O
information	O
about	O
binding	O
sites	O
and	O
epitopes	O
of	O
monoclonal	O
antibodies	O
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
new	O
diagnostic	O
methods	O
for	O
SARS	B-DISO
and	O
for	O
analyzing	O
the	O
function	O
of	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
The	O
European	O
Centre	O
for	O
Disease	O
Prevention	O
and	O
Control	O
was	O
founded	O
in	O
response	O
to	O
newly	O
emerging	O
infections	B-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

After	O
five	O
cycles	O
of	O
screening	O
,	O
a	O
dodecapeptide	O
KKKKYRNIRRPG	O
(	O
DP	O
)	O
was	O
identified	O
to	O
possess	B-DISO
the	O
highest	O
binding	O
affinity	O
to	O
the	O
immobilized	O
sense	O
peptide	O
.	O

TITLE	O
:	O
A	O
novel	B-DISO
mutation	I-DISO
in	O
murine	B-DISO
hepatitis	I-DISO
virus	O
nsp5	O
,	O
the	O
viral	O
3C	O
-	O
like	O
proteinase	O
,	O
causes	O
temperature	O
-	O
sensitive	O
defects	O
in	O
viral	O
growth	O
and	O
protein	O
processing	O
.	O

ABSTRACT	O
:	O
Sequencing	O
and	O
reversion	O
analysis	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
viruses	O
has	O
identified	O
putative	O
ts	O
mutations	O
in	O
the	O
replicase	O
nonstructural	O
proteins	O
(	O
nsp	O
'	O
s	O
)	O
of	O
these	O
coronaviruses	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
induces	O
transcription	O
of	O
hfgl2	O
prothrombinase	O
gene	O
dependent	O
on	O
C	O
/	O
EBP	O
alpha	O
.	O

To	O
investigate	O
whether	O
and	O
which	O
structural	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
induced	O
transcription	O
of	O
hfgl2	O
prothrombinase	O
gene	O
,	O
three	O
eukaryotic	O
expression	O
plasmids	O
expressing	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
membrane	O
protein	O
(	O
M	O
)	O
and	O
spike	O
protein	O
2	O
(	O
S2	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
co	O
-	O
transfected	O
with	O
hfgl2	O
promoter	O
luciferase	O
-	O
reporter	O
plasmids	O
and	O
beta	O
-	O
galactosidase	O
plasmid	O
in	O
CHO	O
cells	O
,	O
respectively	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
and	O
EMSA	O
assay	O
further	O
demonstrated	O
that	O
transcription	O
factor	O
C	O
/	O
EBP	O
alpha	O
band	O
with	O
its	O
cognate	O
cis	B-DISO
-	O
element	O
in	O
hfgl2	O
promoter	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
causes	O
severe	B-DISO
diarrhea	I-DISO
in	O
newborn	O
calves	O
,	O
is	O
associated	O
with	O
winter	B-DISO
dysentery	I-DISO
in	O
adult	O
cattle	O
and	O
respiratory	B-DISO
infections	I-DISO
in	O
calves	O
and	O
feedlot	O
cattle	O
.	O

Some	O
veterinarians	O
prescribe	O
immune	O
modulators	O
to	O
treat	O
cats	O
with	O
FIP	B-DISO
with	O
no	O
documented	O
controlled	O
evidence	O
of	O
efficacy	O
.	O

This	O
report	O
describes	O
an	O
Armored	O
RNA	O
(	O
aRNA	O
)	O
internal	O
control	O
developed	O
originally	O
to	O
be	O
multiplexed	O
in	O
a	O
real	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
detecting	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
Coronavirus	I-DISO
,	O
but	O
can	O
be	O
incorporated	O
into	O
any	O
RT	O
-	O
PCR	O
assay	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
Infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
coronavirus	O
that	O
infects	O
chickens	O
via	O
the	O
respiratory	O
epithelium	O
as	O
primary	O
target	O
cells	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
infiltration	B-DISO
shadows	O
in	O
2	O
-	O
3	O
quadrants	O
,	O
pediatric	O
critical	B-DISO
illness	I-DISO
score	O
(	O
PCIS	O
),	O
and	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO2	O
)	O
at	O
the	O
onset	O
of	O
ARDS	B-DISO
were	O
independently	O
associated	O
with	O
the	O
mortality	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
infiltration	B-DISO
shadows	O
in	O
2	O
-	O
3	O
quadrants	O
,	O
pediatric	O
critical	B-DISO
illness	I-DISO
score	O
(	O
PCIS	O
),	O
and	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO2	O
)	O
at	O
the	O
onset	O
of	O
ARDS	B-DISO
were	O
independently	O
associated	O
with	O
the	O
mortality	O
.	O

TITLE	O
:	O
Impact	O
of	O
extravascular	O
lung	O
water	O
index	O
on	O
outcomes	O
of	O
severe	B-DISO
sepsis	I-DISO
patients	O
in	O
a	O
medical	O
intensive	O
care	O
unit	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
is	O
predicted	O
as	O
a	O
triple	O
-	O
spanning	O
membrane	O
protein	O
lack	O
of	O
a	O
conventional	O
signal	O
peptide	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
novel	O
B	O
cell	O
epitopes	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
S1D	O
(	O
residues	O
636	O
-	O
789	O
)	O
is	O
a	O
neutralizing	O
epitope	O
region	O
on	O
the	O
spike	O
protein	O
(	O
S	O
)	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

To	O
further	O
map	O
epitopes	O
of	O
the	O
MER	O
,	O
seven	O
overlapping	O
mini	O
-	O
fragments	O
covering	O
MER	O
nucleotides	O
were	O
separately	O
synthesized	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
with	O
a	O
GST	O
tag	B-DISO
.	O

Nursing	O
cohorts	O
who	O
worked	O
on	O
the	O
specific	O
ward	O
in	O
which	O
nosocomial	O
transmission	O
occurred	O
had	O
work	O
-	O
shift	O
and	O
patient	O
-	O
assignment	O
records	O
reviewed	O
to	O
determine	O
source	O
of	O
infection	B-DISO
.	O

Five	O
of	O
seven	O
nurses	O
who	O
cared	O
for	O
a	O
specific	O
SARS	B-DISO
patient	O
during	O
this	O
period	O
acquired	O
SARS	B-DISO
.	O

Staff	O
members	O
who	O
worked	O
the	O
evening	O
shift	O
or	O
the	O
morning	O
shift	O
and	O
therefore	O
likely	O
attended	O
a	O
nursing	O
appreciation	O
breakfast	O
were	O
five	O
times	O
more	O
likely	O
to	O
acquire	O
SARS	B-DISO
than	O
those	O
who	O
did	O
not	O
attend	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
and	O
CT	O
severity	O
index	O
scales	O
,	O
the	O
activities	O
of	O
amylase	O
and	O
lipase	O
,	O
the	O
incidence	O
rate	O
of	O
liver	B-DISO
function	I-DISO
failure	I-DISO
,	O
the	O
infection	B-DISO
rate	O
and	O
the	O
operability	O
between	O
the	O
PE	O
group	O
and	O
the	O
non	O
-	O
PE	O
group	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

In	O
this	O
report	O
,	O
interferon	O
alfacon	O
1	O
was	O
examined	O
for	O
inhibitory	O
activities	O
against	O
SARS	B-DISO
-	O
CoV	O
on	O
human	O
lung	B-DISO
carcinoma	I-DISO
epithelial	O
Calu	O
-	O
3	O
cell	O
line	O
and	O
the	O
other	O
three	O
African	O
green	O
monkey	O
kidney	O
epithelial	O
cell	O
lines	O
.	O

TITLE	O
:	O
Interferon	O
-	O
gamma	O
in	O
the	O
serum	O
and	O
effusions	B-DISO
of	O
cats	O
with	O
feline	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
serum	O
concentration	O
of	O
IFN	O
-	O
gamma	O
was	O
not	O
significantly	O
different	O
in	O
cats	O
with	O
FIP	B-DISO
compared	O
with	O
clinically	O
normal	O
FCoV	O
-	O
infected	O
animals	O
living	O
in	O
catteries	O
with	O
a	O
low	O
prevalence	O
of	O
the	O
disease	O
.	O

Epidemics	O
that	O
recently	O
affected	O
the	O
world	O
of	O
work	O
are	O
zoonoses	B-DISO
,	O
such	O
as	O
cases	O
of	O
SARS	B-DISO
in	O
healthcare	O
staff	O
Dutch	O
poultry	O
workers	O
infected	O
with	O
the	O
avian	O
virus	O
A	O
/	O
H7N7	O
in	O
2003	O
,	O
the	O
current	O
threat	O
of	O
avian	B-DISO
flu	I-DISO
A	O
/	O
H5N1	B-DISO
to	O
poultry	O
workers	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
viral	O
cause	O
of	O
laryngeal	O
croup	B-DISO
by	O
use	O
of	O
highly	O
sensitive	O
methods	O
,	O
and	O
including	O
recently	O
recognized	O
viruses	O
in	O
the	O
analysis	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
is	O
a	O
widely	O
used	O
and	O
suitable	O
tool	O
for	O
the	O
amplification	B-DISO
and	O
detection	O
of	O
extraneous	O
nucleic	O
acids	O
.	O

TITLE	O
:	O
Priming	O
of	O
CD8	O
+	O
T	O
cells	O
during	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
with	O
a	O
murine	O
coronavirus	O
is	O
strain	O
dependent	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
are	O
critical	O
for	O
protection	O
against	O
neurotropic	O
coronaviruses	O
;	O
however	O
,	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
infection	B-DISO
with	O
the	O
recombinant	O
JHM	O
(	O
RJHM	O
)	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
elicits	O
a	O
weak	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
brain	O
and	O
causes	O
lethal	O
encephalomyelitis	B-DISO
.	O

However	O
,	O
despite	O
these	O
treatments	O
,	O
he	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
outcome	O
suggests	O
that	O
treatment	O
with	O
corticosteroid	O
and	O
sivelestat	O
,	O
in	O
addition	O
to	O
a	O
combination	O
of	O
appropriate	O
anti	O
-	O
Legionella	O
antibiotics	O
,	O
should	O
be	O
considered	O
for	O
patients	O
with	O
severe	O
Legionella	B-DISO
pneumonia	I-DISO
with	O
ARDS	B-DISO
.	O

23	O
.	O
8	O
,	O
P	O
=	O
0	O
.	O
005	O
)	O
and	O
lower	O
plasma	O
PCT	B-DISO
at	O
baseline	O
(	O
9	O
.	O
83	O
+/-	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remain	O
important	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
,	O
with	O
far	O
-	O
reaching	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
implications	O
for	O
individual	O
patients	O
and	O
for	O
healthcare	O
providers	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
leading	O
cause	O
of	O
death	O
in	O
people	O
infected	O
with	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
virus	O
or	O
the	O
SARS	B-DISO
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Multiple	O
lung	O
pathogens	O
such	O
as	O
chemical	O
agents	O
,	O
H5N1	B-DISO
avian	B-DISO
flu	I-DISO
,	O
or	O
SARS	B-DISO
cause	O
high	O
lethality	O
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Moreover	O
,	O
deletion	O
of	O
ncf1	O
,	O
which	O
controls	O
ROS	O
production	O
,	O
improves	O
the	O
severity	O
of	O
H5N1	B-DISO
-	O
mediated	O
ALI	O
.	O

The	O
power	O
and	O
sensitivity	O
of	O
the	O
UBL	O
-	O
PLA	O
(	O
2	O
)	O
assay	O
are	O
demonstrated	O
by	O
its	O
ability	O
to	O
differentiate	O
the	O
contrasting	O
deISGylase	O
and	O
DUB	O
activities	O
of	O
two	O
coronavirus	O
proteases	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
papain	O
-	O
like	O
protease	O
(	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
)	O
and	O
NL63	O
CoV	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
).	O

This	O
reveals	O
the	O
coexistence	O
of	O
2	O
cohorts	O
of	O
phagocytes	O
whose	O
FIP	B-DISO
viral	O
contents	O
differed	O
by	O
the	O
presence	O
or	O
absence	O
of	O
the	O
FIPV3	O
-	O
70	O
-	O
recognized	O
epitope	O
.	O

ABSTRACT	O
:	O
From	O
2002	O
to	O
2007	O
,	O
23	O
ferrets	O
from	O
Europe	O
and	O
the	O
United	O
States	O
were	O
diagnosed	O
with	O
systemic	O
pyogranulomatous	O
inflammation	B-DISO
resembling	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Frequent	O
hematologic	O
findings	O
were	O
mild	O
anemia	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
hypergammaglobulinemia	B-DISO
.	O

Over	O
the	O
past	O
few	O
years	O
,	O
research	O
work	O
has	O
looked	O
into	O
factors	O
that	O
may	O
lead	O
to	O
super	O
-	O
spreading	O
events	O
,	O
clinical	O
/	O
laboratory	O
parameters	O
that	O
may	O
differentiate	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
from	O
other	O
causes	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
the	O
origin	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
reservoir	O
host	O
distribution	O
and	O
transmission	O
routes	O
.	O

The	O
presence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
like	O
coronaviruses	O
in	O
horseshoe	O
bats	O
raises	O
the	O
possible	O
role	O
of	O
bats	O
in	O
previous	O
and	O
potentially	O
future	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreaks	O
in	O
human	O
.	O

These	O
subjects	O
developed	O
respiratory	B-DISO
distress	I-DISO
shortly	O
after	O
admission	O
,	O
and	O
expired	O
following	O
respiratory	B-DISO
failure	I-DISO
.	O

At	O
autopsy	O
,	O
generalised	B-DISO
lymphadenopathy	I-DISO
was	O
observed	O
.	O

Scrub	B-DISO
typhus	I-DISO
is	O
usually	O
a	O
mild	O
infectious	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
transcriptional	O
repressor	O
(	O
HEPIS	O
)	O
that	O
interacts	O
with	O
nsp	O
-	O
10	O
of	O
SARS	B-DISO
coronavirus	O
.	O

Eligible	O
studies	O
reported	O
data	O
on	O
psychiatric	O
morbidity	O
at	O
least	O
once	O
after	O
intensive	O
care	O
treatment	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
prevalence	O
of	O
psychiatric	O
morbidity	O
in	O
patients	O
surviving	O
ARDS	B-DISO
seems	O
high	O
.	O

ABSTRACT	O
:	O
To	O
perform	O
a	O
retrospective	O
analysis	O
of	O
the	O
macro	O
-	O
economic	O
impact	O
of	O
the	O
2003	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
.	O

National	O
statistics	O
were	O
examined	O
for	O
anomalies	O
that	O
corresponded	O
to	O
the	O
timing	O
of	O
the	O
SARS	B-DISO
outbreak	O
and	O
,	O
where	O
possible	O
,	O
the	O
size	O
of	O
any	O
gain	O
or	O
loss	O
found	O
estimated	O
.	O

Estimates	O
and	O
models	O
produced	O
at	O
the	O
time	O
of	O
the	O
outbreak	O
suggested	O
that	O
SARS	B-DISO
could	O
have	O
a	O
catastrophic	O
effect	O
on	O
the	O
global	O
economy	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
frequent	O
cause	O
of	O
admission	O
in	O
intensive	O
care	O
unit	O
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
of	O
childhood	O
scrub	B-DISO
typhus	I-DISO
in	O
our	O
hospital	O
from	O
January	O
1997	O
to	O
December	O
2006	O
.	O

One	O
patient	O
died	O
of	O
progressive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
pulmonary	B-DISO
hemorrhage	I-DISO
.	O

We	O
conclude	O
that	O
scrub	B-DISO
typhus	I-DISO
should	O
be	O
taken	O
into	O
consideration	O
among	O
patients	O
of	O
acute	O
systemic	O
febrile	B-DISO
illness	I-DISO
,	O
especially	O
those	O
with	O
suspected	O
exposure	O
history	O
and	O
typical	O
skin	B-DISO
lesion	I-DISO
.	O

Although	O
most	O
patients	O
responded	O
well	O
to	O
treatment	O
,	O
severe	O
complications	O
such	O
as	O
meningoencephalitis	B-DISO
,	O
interstitial	B-DISO
pneumonia	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hemophagocytic	B-DISO
syndrome	I-DISO
,	O
and	O
myocarditis	B-DISO
might	O
lead	O
to	O
morbidity	O
and	O
mortality	O
.	O

RESULTS	O
:	O
Postmortem	O
examination	O
of	O
brain	O
revealed	O
a	O
tauopathy	B-DISO
,	O
with	O
deposition	O
of	O
abnormal	O
phosphorylated	O
tau	O
in	O
threads	O
and	O
in	O
coiled	O
-	O
shaped	O
as	O
well	O
as	O
globose	O
tangles	O
in	O
the	O
brainstem	O
,	O
subthalamic	O
nuclei	O
and	O
hippocampus	O
.	O

Ultrastructural	O
analysis	O
of	O
globoid	O
-	O
shaped	O
tangles	O
in	O
the	O
brainstem	O
revealed	O
the	O
presence	O
of	O
straight	O
and	O
paired	O
helicoidal	O
filaments	O
compatible	O
with	O
a	O
PSP	B-DISO
.	O

ABSTRACT	O
:	O
Waste	O
ashes	O
from	O
three	O
types	O
of	O
hospital	O
waste	O
(	O
HW	O
)	O
incinerators	O
,	O
built	O
in	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
)	O
period	O
and	O
currently	O
running	O
in	O
China	O
,	O
were	O
collected	O
and	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAH	B-DISO
)	O
properties	O
in	O
the	O
ashes	O
were	O
investigated	O
.	O

Among	O
the	O
three	O
types	O
of	O
incinerators	O
,	O
two	O
medium	O
-	O
scale	O
incinerators	O
generated	O
relatively	O
high	O
levels	O
of	O
PAHs	O
(	O
mean	O
summation	O
PAH	B-DISO
22	O
.	O
50	O
and	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
))	O
compared	O
to	O
small	O
-	O
scale	O
and	O
large	O
-	O
scale	O
incinerators	O
(	O
mean	O
summation	O
PAH	B-DISO
4	O
.	O
16	O
and	O
16	O
.	O
43	O
mg	O
kg	O
(-	O
1	O
)).	O

Moreover	O
,	O
it	O
was	O
found	O
that	O
PAHs	O
in	O
the	O
ashes	O
correlated	O
highly	O
with	O
some	O
metallic	O
elements	O
either	O
positively	O
(	O
e	O
.	O
g	O
.	O
Fe	O
,	O
Ti	O
,	O
Mg	O
)	O
or	O
negatively	O
(	O
Ca	O
),	O
indicating	O
that	O
these	O
elements	O
might	O
promote	O
or	O
prevent	O
PAH	B-DISO
formation	O
during	O
HW	O
combustion	O
.	O

Although	O
bottom	O
ash	B-DISO
resulted	O
from	O
HW	O
incinerators	O
has	O
not	O
been	O
classified	O
as	O
hazardous	O
material	O
,	O
the	O
results	O
of	O
this	O
study	O
indicated	O
that	O
this	O
type	O
of	O
waste	O
ash	B-DISO
contained	O
high	O
levels	O
of	O
PAHs	O
thus	O
need	O
special	O
treatment	O
before	O
landfill	O
.	O

Patients	O
who	O
have	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
require	O
mechanical	O
ventilation	O
should	O
receive	O
a	O
lung	O
protective	O
,	O
low	O
tidal	O
volume	O
strategy	O
.	O

TITLE	O
:	O
Search	O
for	O
potential	O
target	O
site	O
of	O
nucleocapsid	O
gene	O
for	O
the	O
design	O
of	O
an	O
epitope	O
-	O
based	O
SARS	B-DISO
DNA	O
vaccine	O
.	O

ABSTRACT	O
:	O
It	O
is	O
believed	O
today	O
that	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
is	O
one	O
of	O
the	O
most	O
promising	O
antigen	O
candidates	O
for	O
vaccine	O
design	O
.	O

Results	O
showed	O
that	O
N1	O
and	O
N3	O
fragments	O
of	O
N	O
protein	O
expressed	O
by	O
E	O
.	O
coli	O
were	O
able	O
to	O
react	O
with	O
sera	O
of	O
SARS	B-DISO
patients	O
but	O
N2	O
could	O
not	O
.	O

Acute	O
lung	O
injury	O
was	O
induced	O
successfully	O
by	O
intratracheal	O
administration	O
of	O
LPS	B-DISO
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
in	O
male	O
BALB	O
/	O
c	O
mice	O
.	O

It	O
was	O
found	O
that	O
CoPPIX	O
(	O
5	O
,	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.)	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
total	O
cells	O
and	O
neutrophils	O
in	O
BALF	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
W	O
/	O
D	O
ratio	O
and	O
EBA	O
leakage	B-DISO
at	O
24	O
h	O
after	O
LPS	B-DISO
challenge	O
.	O

Ethyl	O
pyruvate	O
was	O
shown	O
to	O
ameliorate	O
some	O
of	O
the	O
structural	O
and	O
functional	O
changes	O
associated	O
with	O
mesenteric	B-DISO
ischemia	I-DISO
and	O
reperfusion	O
in	O
rats	O
.	O

Ethyl	O
pyruvate	O
has	O
been	O
shown	O
to	O
improve	O
cardiac	O
function	O
after	O
coronary	O
ischemia	B-DISO
and	O
reperfusion	O
.	O

Clinical	O
characteristics	O
of	O
Nipah	B-DISO
virus	I-DISO
infection	I-DISO
in	O
Bangladesh	O
,	O
including	O
a	O
severe	O
respiratory	O
component	O
,	O
appear	O
distinct	O
from	O
clinical	O
characteristics	O
reported	O
during	O
earlier	O
outbreaks	O
in	O
other	O
countries	O
.	O

However	O
,	O
infected	O
animals	O
were	O
capable	O
of	O
producing	O
neutralizing	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
,	O
suggesting	O
the	O
seroconversion	O
did	O
occur	O
.	O

TITLE	O
:	O
Methods	O
of	O
data	O
collection	O
and	O
analysis	O
for	O
the	O
economic	O
evaluation	O
alongside	O
a	O
national	O
,	O
multi	O
-	O
centre	O
trial	O
in	O
the	O
UK	O
:	O
conventional	O
ventilation	O
or	O
ECMO	O
for	O
Severe	O
Adult	O
Respiratory	B-DISO
Failure	I-DISO
(	O
CESAR	O
).	O

Other	O
unit	O
costs	O
are	O
based	O
on	O
published	O
NHS	B-DISO
tariffs	O
.	O

Lymphopenia	B-DISO
can	O
be	O
caused	O
by	O
glucocorticoids	O
,	O
and	O
thus	O
any	O
debilitating	O
condition	B-DISO
has	O
the	O
potential	O
to	O
induce	O
lymphopenia	B-DISO
via	O
stress	O
mechanism	O
involving	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
.	O

Treatment	O
with	O
glucocorticoids	O
complicated	O
the	O
issue	O
regarding	O
lymphopenia	B-DISO
,	O
and	O
certainly	O
calls	O
into	O
question	O
the	O
status	O
of	O
lymphokines	O
and	O
their	O
prognostic	O
implications	O
in	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
SARS	B-DISO
,	O
an	O
emerging	O
disease	O
characterized	O
by	O
atypical	B-DISO
pneumonia	I-DISO
.	O

Proliferation	B-DISO
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
other	O
human	O
cell	O
lines	O
was	O
significantly	O
inhibited	O
by	O
the	O
infection	B-DISO
of	O
recombinant	O
retrovirus	O
expressing	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
.	O

One	O
of	O
these	O
accessory	O
proteins	O
is	O
set	O
apart	O
by	O
its	O
function	O
in	O
the	O
context	O
of	O
a	O
related	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infection	B-DISO
.	O

Interestingly	O
,	O
a	O
novel	O
homologue	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
,	O
termed	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
Angiotensin	O
-	O
converting	O
enzyme	O
and	O
ACE2	O
share	O
homology	O
in	O
their	O
catalytic	O
domain	O
and	O
provide	O
different	O
key	O
functions	O
in	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
,	O
extensively	O
burnt	O
2	O
years	O
previously	O
,	O
admitted	O
to	O
hospital	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
complicating	O
COPD	B-DISO
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
variants	O
lacking	O
the	O
group	O
specific	O
genes	O
6	O
,	O
7a	O
,	O
7b	O
,	O
8a	O
,	O
8b	O
and	O
9b	O
(	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
6	O
-	O
9b	O
]),	O
the	O
structural	O
gene	O
E	O
(	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
),	O
and	O
a	O
combination	O
of	O
both	O
sets	O
of	O
genes	O
(	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
E	O
,	O
6	O
-	O
9b	O
])	O
have	O
been	O
generated	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
risk	O
factors	O
affecting	O
the	O
mortality	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
).	O

TITLE	O
:	O
Appraisal	O
of	O
recommended	O
respiratory	B-DISO
infection	I-DISO
control	O
practices	O
in	O
primary	O
care	O
and	O
emergency	B-DISO
department	O
settings	O
.	O

The	O
survey	O
revealed	O
important	O
shortcomings	O
in	O
overall	O
personal	O
and	O
institutional	O
use	O
of	O
CDC	O
recommended	O
practices	O
,	O
including	O
deficiencies	O
in	O
posted	O
alerts	O
,	O
patient	O
masking	O
and	O
separation	B-DISO
,	O
hand	O
hygiene	O
,	O
personal	O
protective	O
equipment	O
,	O
staff	O
training	O
,	O
and	O
written	O
procedures	O
.	O

Forty	O
-	O
seven	O
(	O
26	O
.	O
4	O
%)	O
of	O
178	O
NPAs	O
were	O
positive	O
:	O
18	O
rhinovirus	O
,	O
15	O
hMPV	O
,	O
4	O
RSV	O
A	O
,	O
3	O
coronavirus	O
OC43	O
,	O
3	O
influenza	B-DISO
virus	O
A	O
,	O
2	O
adenovirus	B-DISO
,	O
1	O
coronavirus	O
NL63	O
,	O
and	O
1	O
RSV	O
B	O
.	O
Based	O
on	O
maximum	O
identity	O
,	O
each	O
of	O
the	O
sequences	O
indicating	O
rhinovirus	O
,	O
hMPV	O
,	O
and	O
coronavirus	O
OC43	O
matched	O
to	O
the	O
corresponding	O
viruses	O
with	O
homology	O
of	O
94	O
-	O
98	O
%,	O
96	O
-	O
99	O
%,	O
and	O
98	O
-	O
100	O
%,	O
respectively	O
.	O

It	O
may	O
improve	O
the	O
diagnostic	O
sensitivity	O
for	O
RSV	O
,	O
influenza	B-DISO
virus	O
,	O
PIV	O
,	O
and	O
adenovirus	B-DISO
.	O

ABSTRACT	O
:	O
The	O
epidemic	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
swept	O
through	O
the	O
globe	O
with	O
more	O
than	O
8000	O
reported	O
probable	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
2003	O
pandemic	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
profiled	O
the	O
ability	O
of	O
modern	O
diagnostic	O
microbiology	O
and	O
molecular	O
biology	O
to	O
identify	O
,	O
isolate	O
and	O
characterize	O
,	O
within	O
weeks	O
,	O
a	O
previously	O
unknown	O
viral	O
infectious	B-DISO
pathogen	O
.	O

The	O
early	O
development	O
of	O
SARS	B-DISO
-	O
CoV	O
diagnostics	O
is	O
now	O
being	O
replaced	O
by	O
refinement	O
and	O
optimization	O
of	O
these	O
assays	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
clinical	O
and	O
laboratory	O
manifestations	O
.	O

Therefore	O
,	O
early	O
recognition	O
of	O
a	O
viral	O
cause	O
of	O
acute	O
FRI	O
leading	O
to	O
ARDS	B-DISO
becomes	O
important	O
for	O
protection	O
of	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
),	O
lessening	O
spread	O
to	O
other	O
patients	O
,	O
and	O
notification	O
of	O
public	O
health	O
officials	O
.	O

Hamsters	O
immunized	O
with	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
developed	O
high	O
serum	O
-	O
neutralizing	O
antibody	O
titers	O
and	O
were	O
protected	O
from	O
replication	O
of	O
homologous	O
(	O
SARS	B-DISO
-	O
CoV	O
Urbani	O
)	O
and	O
heterologous	O
(	O
GD03	O
)	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
.	O

rSARS	O
-	O
CoV	O
-	O
DeltaE	O
-	O
immunized	O
hamsters	O
remained	O
active	O
following	O
wild	O
-	O
type	O
virus	O
challenge	O
,	O
while	O
mock	O
-	O
immunized	O
hamsters	O
displayed	O
decreased	B-DISO
activity	I-DISO
.	O

TITLE	O
:	O
[	O
Traumatic	O
mitral	B-DISO
regurgitation	I-DISO
with	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
].	O

Echocardiography	O
showed	O
severe	O
mitral	B-DISO
regurgitation	I-DISO
due	O
to	O
tendon	O
rupture	O
of	O
posterior	O
leaflet	O
.	O

TITLE	O
:	O
Human	O
LINE1	O
endonuclease	O
domain	O
as	O
a	O
putative	O
target	O
of	O
SARS	B-DISO
-	O
associated	O
autoantibodies	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Anti	O
-	O
EN	O
antibody	O
was	O
positive	O
in	O
the	O
sera	O
of	O
40	O
.	O
9	O
%	O
of	O
SARS	B-DISO
patients	O
.	O

This	O
study	O
describes	O
a	O
method	O
for	O
the	O
detection	O
of	O
SARS	B-DISO
associated	O
coronavirus	O
gene	O
by	O
the	O
combination	O
of	O
functionalized	O
nanoparticles	O
and	O
PCR	O
-	O
based	O
assay	O
.	O

We	O
examined	O
whether	O
polymorphisms	O
of	O
interleukin	O
(	O
IL	O
)-	O
12	O
receptor	O
B1	O
(	O
IL	O
-	O
12RB1	O
)	O
affect	O
the	O
susceptibility	O
to	O
and	O
outcome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
SARS	B-DISO
patients	O
and	O
healthy	O
controls	O
.	O

TITLE	O
:	O
Immunomodulatory	O
and	O
anti	O
-	O
SARS	B-DISO
activities	O
of	O
Houttuynia	O
cordata	O
.	O

(	O
Saururaceae	O
)(	O
HC	O
)	O
was	O
shortlisted	O
by	O
Chinese	O
scientists	O
to	O
tackle	O
SARS	B-DISO
problem	O
as	O
it	O
is	O
conventionally	O
used	O
to	O
treat	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Using	O
a	O
comprehensive	O
set	O
of	O
discovery	O
and	O
optimization	O
tools	O
,	O
antibodies	O
were	O
produced	O
with	O
the	O
ability	O
to	O
neutralize	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
in	O
Vero	O
E6	O
cells	O
and	O
in	O
animal	O
models	O
.	O

The	O
second	O
case	O
was	O
a	O
patient	O
with	O
an	O
operated	O
obstructive	O
SAS	O
in	O
which	O
quetiapine	O
was	O
associated	O
with	O
nocturnal	O
respiratory	B-DISO
dysfunction	I-DISO
and	O
confusion	B-DISO
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
audited	O
the	O
resources	O
available	O
to	O
infection	B-DISO
control	O
(	O
IC	O
)	O
and	O
occupational	O
health	O
(	O
OH	O
)	O
to	O
promote	O
safe	O
work	O
behaviour	O
,	O
whilst	O
comparing	O
audited	O
findings	O
with	O
perceptions	O
by	O
healthcare	O
workers	O
(	O
HCWs	O
).	O

HCWs	O
believed	O
that	O
plans	O
were	O
available	O
to	O
protect	O
against	O
future	O
SARS	B-DISO
-	O
like	O
events	O
but	O
audits	O
revealed	O
that	O
these	O
did	O
not	O
exist	O
in	O
many	O
facilities	O
.	O

Apart	O
from	O
foci	O
of	O
mild	O
residual	O
inflammation	B-DISO
in	O
some	O
postnatal	O
calves	O
,	O
consistent	O
brain	B-DISO
lesions	I-DISO
,	O
per	O
se	O
,	O
have	O
not	O
been	O
reported	O
.	O

The	O
authors	O
provide	O
a	O
number	O
of	O
recommendations	O
for	O
consideration	O
in	O
infectious	B-DISO
disease	I-DISO
pandemic	O
plan	B-DISO
development	O
to	O
better	O
support	O
the	O
healthcare	O
workers	O
in	O
their	O
roles	O
as	O
first	O
responders	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
humans	O
with	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
results	O
in	O
substantial	O
morbidity	O
and	O
mortality	O
,	O
with	O
death	O
resulting	O
primarily	O
from	O
respiratory	B-DISO
failure	I-DISO
.	O

Herein	O
,	O
we	O
use	O
these	O
mice	O
to	O
show	O
that	O
virus	O
enters	O
the	O
brain	O
primarily	O
via	O
the	O
olfactory	O
bulb	O
,	O
and	O
infection	B-DISO
results	O
in	O
rapid	O
,	O
transneuronal	O
spread	O
to	O
connected	O
areas	O
of	O
the	O
brain	O
.	O

Remarkably	O
,	O
the	O
virus	O
induces	O
minimal	O
cellular	O
infiltration	B-DISO
in	O
the	O
brain	O
.	O

Prior	O
studies	O
using	O
single	O
indicator	O
thermodilution	O
have	O
reported	O
that	O
21	O
%	O
to	O
35	O
%	O
of	O
patients	O
with	O
clinical	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
have	O
normal	O
EVLW	O
(<	O
10	O
mL	O
/	O
kg	O
).	O

Thirty	O
patients	O
within	O
72	O
hrs	B-DISO
of	O
meeting	O
American	O
-	O
European	O
Consensus	O
Conference	O
definition	O
of	O
ARDS	B-DISO
and	O
14	O
severe	B-DISO
sepsis	I-DISO
patients	O
without	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
2003	O
had	O
an	O
enormous	O
impact	O
on	O
Hong	O
Kong	O
society	O
and	O
the	O
suicide	O
rate	O
was	O
also	O
at	O
its	O
historical	O
high	O
,	O
18	O
.	O
6	O
per	O
100	O
,	O
000	O
.	O

Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
compare	O
the	O
profile	O
of	O
the	O
older	O
adult	O
suicide	O
cases	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
,	O
peri	O
-	O
SARS	B-DISO
and	O
post	O
-	O
SARS	B-DISO
periods	O
.	O

The	O
SARS	B-DISO
epidemic	O
was	O
associated	O
with	O
an	O
increase	O
in	O
older	O
adults	O
'	O
suicide	O
rate	O
in	O
April	O
2003	O
and	O
some	O
suicide	O
deaths	O
in	O
June	O
2003	O
might	O
have	O
been	O
brought	O
forward	O
.	O

Maintaining	O
and	O
enhancing	O
mental	O
well	O
being	O
of	O
the	O
public	O
over	O
the	O
period	O
of	O
epidemic	O
is	O
as	O
important	O
as	O
curbing	B-DISO
the	O
spread	O
of	O
the	O
epidemic	O
.	O

Based	O
on	O
the	O
Coroners	O
'	O
suicide	O
death	O
records	O
,	O
overall	O
severity	O
of	O
illness	O
,	O
level	O
of	O
dependency	O
and	O
worrying	O
of	O
having	O
sickness	O
among	O
the	O
older	O
adult	O
suicides	O
were	O
found	O
to	O
be	O
significantly	O
different	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
,	O
peri	O
-	O
SARS	B-DISO
and	O
post	O
-	O
SARS	B-DISO
periods	O
.	O

CRCoV	O
has	O
been	O
associated	O
with	O
respiratory	B-DISO
disease	I-DISO
,	O
particularly	O
in	O
kenneled	O
dog	O
populations	O
.	O

In	O
the	O
H5N1	B-DISO
/	O
PR8	O
-	O
5B19	O
virus	O
,	O
the	O
HA	O
cleavage	O
site	O
was	O
modified	O
to	O
resemble	O
that	O
of	O
low	O
-	O
pathogenic	O
avian	O
strains	O
and	O
a	O
portion	O
of	O
the	O
NA	O
stalk	B-DISO
region	O
was	O
replaced	O
by	O
the	O
immunodominant	O
5B19	O
epitope	O
of	O
the	O
S2	O
glycoprotein	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

H5N1	B-DISO
/	O
PR8	O
-	O
5B19	O
is	O
not	O
lethal	O
to	O
embryonated	O
eggs	O
or	O
chickens	O
.	O

This	O
viral	O
super	O
-	O
group	O
,	O
known	O
for	O
decades	O
,	O
has	O
still	O
to	O
face	B-DISO
the	O
full	O
force	O
of	O
a	O
molecular	O
biology	O
onslaught	O
.	O

However	O
,	O
newly	O
identified	O
viruses	O
(	O
NIVs	O
)	O
including	O
human	O
metapneumovirus	O
and	O
bocavirus	O
and	O
emergent	O
viruses	O
including	O
SARS	B-DISO
-	O
CoV	O
have	O
already	O
been	O
exhaustively	O
scrutinized	O
.	O

HRV	O
infections	B-DISO
result	O
in	O
undue	O
antibiotic	O
prescriptions	O
,	O
sizable	O
healthcare	O
-	O
related	O
expenditure	O
and	O
exacerbation	O
of	O
expiratory	B-DISO
wheezing	I-DISO
associated	O
with	O
hospital	O
admission	O
.	O

RESULTS	O
:	O
HRV	O
infections	B-DISO
result	O
in	O
undue	O
antibiotic	O
prescriptions	O
,	O
sizable	O
healthcare	O
-	O
related	O
expenditure	O
and	O
exacerbation	O
of	O
expiratory	B-DISO
wheezing	I-DISO
associated	O
with	O
hospital	O
admission	O
.	O

I	O
also	O
provide	O
new	O
insight	O
on	O
how	O
the	O
SARS	B-DISO
-	O
associated	O
stigma	O
could	O
create	O
problems	O
for	O
public	O
health	O
development	O
in	O
Hong	O
Kong	O
.	O

At	O
12	O
months	O
after	O
successful	O
LT	O
,	O
the	O
patient	O
has	O
good	O
graft	O
function	O
,	O
but	O
findings	O
of	O
YNS	B-DISO
including	O
chronic	B-DISO
cough	I-DISO
,	O
lymphedema	B-DISO
and	I-DISO
yellow	I-DISO
nails	I-DISO
are	O
still	O
present	O
.	O

As	O
there	O
was	O
no	O
evidence	O
for	O
drug	O
-	O
or	O
infection	B-DISO
-	O
related	O
thromboembolic	O
or	O
myocardial	O
causes	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
we	O
conclude	O
that	O
our	O
patient	O
experienced	O
a	O
rare	O
type	O
of	O
non	O
-	O
fatal	O
amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
.	O

Complications	O
occurred	O
in	O
7	O
patients	O
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
3	O
cases	O
,	O
thrombosis	B-DISO
of	O
right	O
common	O
iliac	O
artery	O
in	O
1	O
,	O
subphernic	O
abscess	B-DISO
in	O
2	O
and	O
infection	B-DISO
of	O
deep	O
wound	O
in	O
lower	O
extremity	O
in	O
1	O
.	O

RESULTS	O
:	O
As	O
a	O
first	O
-	O
stage	O
therapy	O
,	O
devascularization	O
of	O
internal	O
iliac	O
arteries	O
was	O
performed	O
in	O
29	O
patients	O
with	O
pelvic	O
fractures	O
combined	O
with	O
massive	B-DISO
bleeding	I-DISO
,	O
including	O
ligation	O
of	O
bilateral	O
internal	O
iliac	O
arteries	O
in	O
21	O
patients	O
and	O
embolization	O
of	O
bilateral	O
internal	O
iliac	O
arteries	O
in	O
8	O
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
of	O
the	O
CNS	O
:	O
a	O
model	O
for	O
defense	O
,	O
disease	O
,	O
and	O
repair	O
.	O

TITLE	O
:	O
[	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
pregnancy	O
].	O

ABSTRACT	O
:	O
SARS	B-DISO
is	O
a	O
highly	O
contagious	O
infection	B-DISO
,	O
caused	O
by	O
new	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
.	O
Immunopathological	O
mechanisms	O
responsible	O
for	O
the	O
reaction	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
have	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O

Infants	O
born	O
to	O
pregnant	O
women	O
with	O
SARS	B-DISO
did	O
not	O
appear	O
to	O
have	O
acquired	O
the	O
infection	B-DISO
through	O
vertical	B-DISO
transmission	I-DISO
.	O

ClustalW	O
analysis	O
revealed	O
88	O
.	O
99	O
%	O
identity	O
and	O
96	O
.	O
99	O
%	O
similarity	O
for	O
pp1ab	O
between	O
TCoV	O
and	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
at	O
the	O
amino	O
acid	O
level	O
.	O

TITLE	O
:	O
Does	O
leflunomide	O
attenuate	O
the	O
sepsis	B-DISO
-	O
induced	O
acute	O
lung	O
injury	O
?	O

Oxygen	O
radicals	O
and	O
active	O
neutrophils	O
in	O
the	O
lung	O
are	O
important	O
sources	O
for	O
severe	O
pulmonary	B-DISO
inflammation	I-DISO
leading	O
to	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
lung	O
MPO	O
,	O
malondialdehyde	O
(	O
MDA	O
),	O
protein	O
carbonyl	O
and	O
NO	O
levels	O
were	O
higher	O
in	O
the	O
sepsis	B-DISO
group	O
when	O
compared	O
to	O
group	O
control	O
,	O
sham	O
,	O
leflunomide	O
and	O
sepsis	B-DISO
+	O
leflunomide	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
MPO	O
,	O
MDA	O
and	O
NO	O
levels	O
were	O
higher	O
in	O
the	O
sepsis	B-DISO
+	O
leflunomide	O
group	O
than	O
in	O
the	O
sham	O
,	O
control	O
and	O
leflunomide	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Because	O
its	O
complications	O
are	O
life	O
threatening	O
,	O
when	O
we	O
see	O
a	O
patient	O
with	O
fever	O
and	O
eruptions	B-DISO
,	O
it	O
is	O
necessary	O
to	O
keep	O
in	O
mind	O
the	O
possibility	O
of	O
Tsutsugamushi	B-DISO
disease	I-DISO
.	O

Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
was	O
significantly	O
associated	O
with	O
more	O
severe	O
organ	O
failures	O
,	O
particularly	O
renal	O
and	O
respiratory	O
,	O
and	O
a	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
.	O

Cats	O
were	O
grouped	O
as	O
having	O
nonneurologic	O
disease	O
(	O
controls	O
;	O
n	O
=	O
37	O
),	O
brain	B-DISO
tumors	I-DISO
(	O
n	O
=	O
8	O
),	O
FIP	B-DISO
involving	O
the	O
CNS	O
(	O
n	O
=	O
12	O
),	O
and	O
extraneural	O
FIP	B-DISO
(	O
n	O
=	O
12	O
).	O

Patients	O
with	O
ARDS	B-DISO
have	O
higher	O
hospital	O
mortality	O
rates	O
and	O
reduced	O
long	O
-	O
term	O
pulmonary	O
function	O
and	O
quality	O
of	O
life	O
.	O

This	O
study	O
evaluated	O
17	O
risk	O
factors	O
potentially	O
associated	O
with	O
the	O
conversion	O
from	O
ALI	O
to	O
ARDS	B-DISO
in	O
severe	O
multiple	O
trauma	O
.	O

The	O
results	O
indicate	O
that	O
the	O
impact	O
of	O
pulmonary	O
contusion	O
,	O
APACHE	O
II	O
score	O
,	O
gastrointestinal	B-DISO
haemorrhage	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
may	O
help	O
to	O
predict	O
conversion	O
from	O
ALI	O
to	O
ARDS	B-DISO
in	O
the	O
early	O
phase	O
after	O
multiple	O
-	O
trauma	O
injury	O
.	O

Four	O
cats	O
,	O
which	O
had	O
ceased	O
shedding	O
,	O
re	O
-	O
manifested	O
a	O
primary	O
type	O
infection	B-DISO
when	O
secondarily	O
infected	O
.	O

Natural	O
kittenhood	O
infections	B-DISO
appeared	O
to	O
be	O
low	O
grade	O
and	O
abortive	O
.	O

ABSTRACT	O
:	O
Viral	B-DISO
upper	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
vURI	O
)	O
may	O
or	O
may	O
not	O
present	O
with	O
a	O
cold	B-DISO
/	O
flu	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
CFLI	O
).	O

About	O
85	O
%	O
of	O
RSV	O
,	O
influenza	B-DISO
A	O
and	O
adenovirus	B-DISO
detections	O
were	O
associated	O
with	O
a	O
CFLI	O
,	O
whereas	O
less	O
than	O
62	O
%	O
of	O
other	O
virus	O
detections	O
were	O
associated	O
with	O
CFLI	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
glycoproteins	O
of	O
the	O
class	O
I	O
family	O
,	O
which	O
include	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
),	O
influenza	B-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
mediate	O
viral	O
entry	O
by	O
first	O
binding	O
to	O
their	O
cellular	O
receptors	O
and	O
subsequently	O
inducing	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

Conversion	O
from	O
the	O
prefusion	O
state	O
to	O
the	O
postfusion	O
state	O
requires	O
passage	O
through	O
the	O
transition	B-DISO
state	O
,	O
a	O
state	O
that	O
may	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
in	O
general	O
.	O

Primary	O
outcome	O
was	O
extubation	O
12	O
hours	O
postoperatively	O
or	O
postpneumonectomy	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
severe	O
postpneumonectomy	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
obtained	O
after	O
9	O
+/-	O

ABSTRACT	O
:	O
It	O
has	O
recently	O
been	O
shown	O
that	O
cell	O
entry	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
2	O
(	O
MHV	O
-	O
2	O
)	O
is	O
mediated	O
through	O
endocytosis	O
(	O
Z	O
.	O
Qiu	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
a	O
dominant	B-DISO
-	I-DISO
negative	I-DISO
mutant	I-DISO
of	O
caveolin	O
1	O
did	O
not	O
have	O
any	O
effect	O
on	O
MHV	O
-	O
2	O
infection	B-DISO
,	O
while	O
it	O
significantly	O
blocked	O
the	O
caveolin	O
-	O
dependent	O
uptake	O
of	O
cholera	B-DISO
toxin	O
subunit	O
B	O
.	O
These	O
results	O
demonstrate	O
that	O
MHV	O
-	O
2	O
utilizes	O
the	O
clathrin	O
-	O
but	O
not	O
caveolin	O
-	O
mediated	O
endocytic	O
pathway	O
for	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	B-DISO
)	O
are	O
a	O
family	O
of	O
viral	O
envelope	O
glycoproteins	O
that	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
(	O
RDEs	O
).	O

ARF1	O
,	O
the	O
cellular	O
effector	O
of	O
GBF1	O
,	O
also	O
appeared	O
to	O
be	O
involved	O
in	O
MHV	O
replication	O
,	O
as	O
siRNAs	O
targeting	O
this	O
small	O
GTPase	O
inhibited	O
MHV	O
infection	B-DISO
significantly	O
.	O

Upon	O
loading	O
the	O
cell	O
samples	O
and	O
lysis	B-DISO
solution	O
into	O
the	O
mixing	O
chamber	O
,	O
the	O
integrated	O
microfluidic	O
device	O
allows	O
efficient	O
cell	O
disruption	O
by	O
rotation	O
of	O
a	O
micromagnetic	O
disk	O
and	O
control	O
of	O
mixing	O
time	O
using	O
the	O
Teflon	O
-	O
coated	O
hydrophobic	O
film	O
as	O
a	O
microvalve	O
.	O

We	O
demonstrated	O
that	O
the	O
RBD	O
spike	O
protein	O
alone	O
could	O
be	O
internalized	O
into	O
SARS	B-DISO
-	O
CoV	O
susceptible	O
cells	O
together	O
with	O
ACE2	O
.	O

Elevated	B-DISO
intracranial	I-DISO
pressure	I-DISO
causes	O
encephalopathy	B-DISO
and	O
the	O
risk	O
of	O
neuronal	O
damage	O
due	O
to	O
the	O
sharp	O
decrease	O
in	O
cerebral	O
perfusion	O
pressure	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
coronavirus	O
in	O
experimental	O
pneumocystic	O
pneumonia	B-DISO
].	O

Alterations	O
in	O
these	O
cytokines	O
were	O
associated	O
with	O
increased	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
number	O
of	O
days	O
under	O
ventilation	O
,	O
increased	O
peak	O
inspiratory	O
pressure	O
,	O
and	O
lower	O
PaO2	O
/	O
FiO2	O
ratio	O
in	O
this	O
patient	O
population	O
.	O

Flexibility	O
with	O
respect	O
to	O
the	O
peptide	O
tag	B-DISO
is	O
essential	O
since	O
no	O
single	O
tag	B-DISO
suites	O
all	O
purposes	O
.	O

To	O
test	O
the	O
efficacy	O
of	O
activated	O
protein	O
C	O
(	O
APC	B-DISO
)	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
ALI	O
.	O

The	O
results	O
of	O
this	O
trial	O
do	O
not	O
support	O
a	O
large	O
clinical	O
trial	O
of	O
APC	B-DISO
for	O
ALI	O
in	O
the	O
absence	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
high	O
disease	O
severity	O
.	O

TITLE	O
:	O
The	O
management	O
of	O
coronavirus	B-DISO
infections	I-DISO
with	O
particular	O
reference	O
to	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
A	O
survey	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
genotypes	O
in	O
poultry	O
flocks	O
in	O
selected	O
countries	O
in	O
Western	O
Europe	O
was	O
carried	O
out	O
between	O
March	O
2002	O
and	O
December	O
2006	O
.	O

TITLE	O
:	O
Prospective	O
community	O
-	O
based	O
cluster	O
census	O
and	O
case	O
-	O
control	O
study	O
of	O
stillbirths	B-DISO
and	O
neonatal	O
deaths	O
in	O
the	O
West	O
Bank	O
and	O
Gaza	O
Strip	O
.	O

The	O
present	O
study	O
identified	O
risk	O
factors	O
for	O
perinatal	O
death	O
and	O
the	O
level	O
and	O
causes	O
of	O
stillbirths	B-DISO
and	O
neonatal	O
deaths	O
in	O
the	O
West	O
Bank	O
and	O
Gaza	O
Strip	O
.	O

Stillbirths	B-DISO
are	O
not	O
officially	O
reportable	O
in	O
the	O
West	O
Bank	O
and	O
Gaza	O
Strip	O
and	O
this	O
is	O
the	O
first	O
time	O
that	O
perinatal	O
mortality	O
has	O
been	O
examined	O
.	O

By	O
conventional	O
amplification	B-DISO
,	O
43	O
rectal	O
,	O
54	O
nasal	O
and	O
34	O
ocular	O
samples	O
tested	O
positive	O
,	O
whereas	O
the	O
TaqMan	O
assay	O
was	O
able	O
to	O
detect	O
the	O
BCoV	O
nucleic	O
acid	O
in	O
49	O
rectal	O
,	O
60	O
nasal	O
and	O
37	O
ocular	O
swabs	O
.	O

To	O
propagate	O
a	O
chimeric	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
bearing	O
an	O
SZ16	O
spike	O
(	O
S	O
)	O
glycoprotein	O
(	O
icSZ16	O
-	O
S	O
),	O
we	O
constructed	O
cell	O
lines	O
expressing	O
the	O
civet	O
ortholog	O
(	O
DBT	O
-	O
cACE2	O
)	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
(	O
hACE2	O
).	O

Furthermore	O
,	O
zoonotic	O
SARS	B-DISO
-	O
CoV	O
was	O
variably	O
neutralized	O
by	O
antibodies	O
that	O
were	O
effective	O
against	O
the	O
epidemic	O
strain	O
,	O
highlighting	O
their	O
utility	O
for	O
evaluating	O
passive	O
immunization	O
efficacy	O
.	O

TITLE	O
:	O
C3d	B-DISO
and	O
C4d	O
deposition	O
early	O
after	O
lung	O
transplantation	O
.	O

Complement	O
staining	O
was	O
increased	O
in	O
LTRs	O
with	O
severe	O
primary	B-DISO
graft	I-DISO
dysfunction	I-DISO
or	O
airway	O
infection	B-DISO
,	O
but	O
was	O
not	O
associated	O
with	O
acute	O
cellular	O
or	O
chronic	O
rejection	O
,	O
or	O
with	O
morphologic	O
features	O
of	O
AMR	O
.	O

TITLE	O
:	O
Mannose	O
-	O
binding	O
lectin	O
and	O
mannose	O
-	O
binding	O
lectin	O
-	O
associated	O
serine	O
protease	O
2	O
in	O
susceptibility	O
,	O
severity	O
,	O
and	O
outcome	O
of	O
pneumonia	B-DISO
in	O
adults	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
significance	O
of	O
MBL	B-DISO
deficiency	I-DISO
(	O
O	O
/	O
O	O
genotypes	O
)	O
and	O
insufficiency	O
(	O
O	O
/	O
O	O
plus	O
XA	O
/	O
O	O
genotypes	O
),	O
as	O
well	O
as	O
MASP	O
-	O
2	O
deficiency	O
(	O
D105G	O
mutation	O
),	O
in	O
the	O
susceptibility	O
to	O
and	O
severity	O
and	O
outcome	O
of	O
CAP	B-DISO
in	O
adults	O
.	O

However	O
,	O
in	O
a	O
multivariate	O
analysis	O
MBL	O
insufficiency	O
was	O
associated	O
with	O
the	O
development	O
of	O
the	O
most	O
severe	O
forms	O
of	O
sepsis	B-DISO
(	O
P	O
=	O
.	O
007	O
),	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
P	O
=	O
.	O
009	O
),	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
(	O
P	O
=	O
.	O
036	O
),	O
intensive	O
care	O
unit	O
admission	O
(	O
P	O
=	O
.	O
020	O
),	O
and	O
death	O
(	O
P	O
=	O
.	O
003	O
).	O

There	O
is	O
growing	O
evidence	O
that	O
infection	B-DISO
control	O
measures	O
were	O
helpful	O
in	O
containment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
as	O
well	O
as	O
avian	B-DISO
influenza	I-DISO
.	O

By	O
using	O
a	O
cell	O
line	O
expressing	O
a	O
SARS	B-DISO
-	O
CoV	O
subgenomic	O
replicon	O
,	O
we	O
developed	O
a	O
high	O
-	O
throughput	O
assay	O
and	O
used	O
it	O
to	O
screen	O
small	O
molecule	O
compounds	O
for	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
the	O
absence	O
of	O
live	O
virus	O
.	O

In	O
a	O
SARS	B-DISO
-	O
CoV	O
plaque	B-DISO
reduction	O
assay	O
,	O
these	O
compounds	O
were	O
confirmed	O
to	O
have	O
antiviral	O
activity	O
.	O

These	O
compounds	O
should	O
be	O
valuable	O
for	O
developing	O
anti	O
-	O
SARS	B-DISO
therapeutic	O
drugs	O
as	O
well	O
as	O
research	O
tools	O
to	O
study	O
the	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

When	O
this	O
occurs	O
,	O
it	O
can	O
be	O
difficult	O
to	O
distinguish	O
GBS	B-DISO
from	O
critical	B-DISO
illness	I-DISO
neuropathy	B-DISO
(	O
CIN	B-DISO
).	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nucleocapsid	O
protein	O
confers	O
ability	O
to	O
efficiently	O
produce	O
virus	O
-	O
like	O
particles	O
when	O
substituted	O
for	O
the	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
nucleocapsid	O
domain	O
.	O

Currently	O
,	O
high	O
quality	O
intensive	O
care	O
,	O
early	O
institution	O
of	O
renal	O
replacement	O
therapy	O
,	O
and	O
avoidance	O
of	O
nephrotoxic	O
drugs	O
are	O
standard	O
practice	O
of	O
the	O
prevention	O
and	O
management	O
of	O
ARF	B-DISO
.	O

ABSTRACT	O
:	O
Lipoid	B-DISO
pneumonia	I-DISO
usually	O
presents	O
after	O
chronic	O
recurrent	O
ingestion	O
of	O
oily	O
substances	O
or	O
accidental	O
aspiration	B-DISO
during	O
""""	O
fire	O
-	O
eating	O
""""	O
demonstrations	O
.	O

A	O
66	O
-	O
year	O
-	O
old	O
woman	O
who	O
nearly	O
drowned	O
in	O
a	O
vat	O
of	O
vegetable	O
oil	O
was	O
admitted	O
as	O
an	O
emergency	B-DISO
case	O
with	O
severe	O
hypoxia	B-DISO
after	O
rescue	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
acute	O
lung	O
injury	O
for	O
a	O
part	O
of	O
a	O
devastating	O
syndrome	B-DISO
characterized	O
by	O
acute	O
onset	O
,	O
hypoxemia	O
and	O
bilateral	O
infiltrates	B-DISO
in	O
the	O
chest	O
x	O
-	O
ray	O
with	O
absence	O
of	O
heart	B-DISO
failure	I-DISO
signs	O
.	O

Acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
are	O
associated	O
with	O
increased	O
procoagulant	O
and	O
reduced	O
fibrinolytic	O
activities	O
mainly	O
in	O
alveoli	O
and	O
interstitial	O
spaces	O
in	O
the	O
lung	O
.	O

Future	O
clinical	O
trials	O
should	O
consider	O
the	O
potential	O
benefit	O
of	O
anticoagulants	O
administrated	O
systemically	O
or	O
locally	O
in	O
the	O
lungs	O
to	O
determine	O
the	O
role	O
of	O
anticoagulants	O
in	O
the	O
treatment	O
of	O
acute	O
pulmonary	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
terminal	B-DISO
disease	I-DISO
of	O
cats	O
caused	O
by	O
systemic	B-DISO
infection	I-DISO
with	O
a	O
feline	O
coronavirus	O
(	O
FCoV	O
).	O

Antigenically	O
similar	O
to	O
their	O
virulent	O
counterparts	O
are	O
FCoV	O
biotypes	O
designated	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
),	O
which	O
usually	O
cause	O
only	O
mild	O
enteritis	B-DISO
and	O
are	O
unable	O
to	O
efficiently	O
infect	O
macrophages	O
and	O
monocytes	O
.	O

The	O
FCoV	O
spike	O
protein	O
mediates	O
viral	O
entry	O
into	O
the	O
host	O
cell	O
and	O
has	O
previously	O
been	O
shown	O
to	O
determine	O
the	O
distinct	O
tropism	O
exhibited	O
by	O
certain	O
isolates	O
of	O
FIPV	O
and	O
FECV	O
,	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
viral	B-DISO
pathogenesis	I-DISO
has	O
yet	O
to	O
be	O
determined	O
.	O

TITLE	O
:	O
A	O
second	O
SARS	B-DISO
-	O
CoV	O
S2	O
glycoprotein	O
internal	O
membrane	O
-	O
active	O
peptide	O
.	O

TITLE	O
:	O
Impact	O
of	O
preexisting	O
organ	O
dysfunction	O
on	O
extracorporeal	O
life	O
support	O
for	O
non	O
-	O
postcardiotomy	O
cardiopulmonary	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
rate	O
in	O
patients	O
with	O
preexisting	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

The	O
indications	O
for	O
ECLS	O
were	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
n	O
=	O
23	O
),	O
acute	B-DISO
myocarditis	I-DISO
(	O
n	O
=	O
10	O
)	O
and	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
(	O
n	O
=	O
12	O
).	O

ABSTRACT	O
:	O
The	O
national	O
strategy	O
against	O
pandemic	O
influenza	B-DISO
essentially	O
consists	O
of	O
3	O
prongs	O
:	O
(	O
i	O
)	O
effective	O
surveillance	O
,	O
(	O
ii	O
)	O
mitigation	O
of	O
the	O
pandemic	O
'	O
s	O
impact	O
,	O
and	O
(	O
iii	O
)	O
render	O
the	O
population	O
immune	O
through	O
vaccination	O
.	O

Early	O
tests	O
for	O
diagnosis	O
were	O
not	O
always	O
conclusive	O
in	O
identifying	O
a	O
SARS	B-DISO
suspected	O
patient	O
.	O

Interstitial	B-DISO
nephritis	I-DISO
is	O
the	O
principal	O
feature	O
of	O
the	O
disease	O
.	O

The	O
ability	O
of	O
the	O
ribosome	O
to	O
change	O
translational	O
reading	O
frames	O
in	O
the	O
-	O
1	O
direction	O
(-	O
1	O
PRF	O
)	O
is	O
employed	O
by	O
many	O
positive	O
strand	O
RNA	O
viruses	O
,	O
including	O
economically	O
important	O
plant	O
viruses	O
and	O
many	O
human	O
pathogens	O
,	O
such	O
as	O
retroviruses	O
,	O
e	O
.	O
g	O
.,	O
HIV	B-DISO
-	O
1	O
,	O
and	O
coronaviruses	O
,	O
e	O
.	O
g	O
.,	O
the	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
in	O
order	O
to	O
properly	O
express	O
their	O
genomes	O
.	O

This	O
study	O
demonstrates	O
a	O
reduction	O
in	O
palliative	O
RT	O
services	O
that	O
is	O
similar	O
in	O
magnitude	O
to	O
decreases	O
observed	O
in	O
other	O
essential	O
cancer	B-DISO
services	O
during	O
the	O
SARS	B-DISO
epidemic	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
remains	O
poorly	O
understood	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
insect	O
cells	O
with	O
these	O
two	O
recombinant	O
baculoviruses	O
led	O
to	O
self	O
-	O
assembly	O
of	O
virus	O
-	O
like	O
particles	O
(	O
BVLPs	O
)	O
as	O
demonstrated	O
by	O
electron	O
microscopy	O
.	O

Finding	O
in	O
this	O
study	O
may	O
provide	O
important	O
information	O
for	O
vaccine	O
development	O
as	O
well	O
as	O
for	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
like	O
CoV	O
.	O

IMS	O
was	O
diagnosed	O
in	O
ten	O
out	O
of	O
78	O
patients	O
using	O
a	O
priori	O
clinical	O
diagnostic	O
criteria	O
,	O
and	O
five	O
of	O
them	O
developed	O
respiratory	B-DISO
failure	I-DISO
.	O

Severe	O
decrement	O
preceded	O
respiratory	B-DISO
failure	I-DISO
in	O
four	O
patients	O
.	O

Scanning	O
alanine	O
mutagenesis	O
identified	O
two	O
regions	O
in	O
the	O
carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
TMD	B-DISO
that	O
eliminated	O
the	O
Golgi	O
complex	O
localization	O
of	O
the	O
chimeric	O
CD4	O
proteins	O
or	O
ORF7b	O
protein	O
.	O

ABSTRACT	O
:	O
Nondepolarizing	O
neuromuscular	O
blocking	B-DISO
agents	O
(	O
NNMBAs	O
)	O
are	O
commonly	O
used	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
mainly	O
to	O
facilitate	O
mechanical	O
ventilation	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
who	O
are	O
not	O
responding	O
to	O
sedatives	O
and	O
analgesics	O
alone	O
.	O

We	O
report	O
three	O
cases	O
of	O
tachyphylaxis	O
to	O
cisatracurium	O
in	O
a	O
surgical	O
intensive	O
care	O
unit	O
(	O
SICU	O
):	O
one	O
in	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
the	O
other	O
two	O
with	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
).	O

During	O
PECLA	O
therapy	O
,	O
48	O
.	O
7	O
%	O
of	O
patients	O
died	O
,	O
mainly	O
as	O
a	O
result	O
of	O
multiorgan	B-DISO
failure	I-DISO
after	O
a	O
mean	O
interval	O
of	O
4	O
.	O
8	O
+/-	O

TITLE	O
:	O
Electron	O
microscopic	O
identification	O
of	O
viruses	O
associated	O
with	O
poult	O
enteritis	B-DISO
in	O
turkeys	O
grown	O
in	O
California	O
1993	O
-	O
2003	O
.	O

ABSTRACT	O
:	O
Twelve	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
obtained	O
from	O
commercial	O
chickens	O
in	O
China	O
between	O
2005	O
and	O
2006	O
were	O
characterized	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
sequencing	O
of	O
the	O
entire	O
S1	O
gene	O
.	O

ABSTRACT	O
:	O
Thirty	O
-	O
three	O
field	O
isolates	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
were	O
recovered	O
from	O
commercial	O
chicken	O
flocks	O
in	O
Korea	O
between	O
2003	O
and	O
2006	O
and	O
were	O
characterized	O
phylogenetically	O
by	O
nucleotide	O
sequence	O
analysis	O
of	O
the	O
IBV	O
S1	O
gene	O
hyper	O
-	O
variable	O
region	O
.	O

TITLE	O
:	O
Sudden	O
oronasal	O
bleeding	B-DISO
in	O
a	O
young	O
child	O
.	O

ABSTRACT	O
:	O
Antiphospholipid	B-DISO
syndrome	I-DISO
(	O
APS	B-DISO
)	O
is	O
a	O
systemic	O
autoimmune	B-DISO
disorder	I-DISO
characterized	O
by	O
a	O
combination	O
of	O
arterial	O
or	O
venous	B-DISO
thrombosis	I-DISO
and	O
recurrent	O
fetal	O
loss	O
,	O
accompanied	O
by	O
elevated	O
titers	O
of	O
antiphospholipid	O
antibodies	O
(	O
aPL	B-DISO
).	O

Clinical	O
and	O
laboratory	O
data	O
of	O
13	O
SoJIA	O
patients	O
with	O
MAS	B-DISO
treated	O
in	O
our	O
hospital	O
from	O
January	O
2003	O
to	O
October	O
2007	O
were	O
analyzed	O
.	O

TITLE	O
:	O
[	O
Global	O
threats	O
from	O
emerging	O
viral	B-DISO
diseases	I-DISO
].	O

TITLE	O
:	O
Murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
is	O
recognized	O
by	O
MDA5	O
and	O
induces	O
type	O
I	O
interferon	O
in	O
brain	O
macrophages	O
/	O
microglia	O
.	O

There	O
is	O
evidence	O
that	O
acute	O
administration	O
of	O
corticosteroids	O
decreases	O
the	O
inflammatory	B-DISO
response	I-DISO
and	O
might	O
decrease	O
mortality	O
in	O
severe	O
pneumonia	B-DISO
.	O

The	O
results	O
showed	O
that	O
mutation	O
of	O
the	O
P1	O
Gln	O
to	O
Pro	O
or	O
deletion	O
of	O
the	O
Gln	O
residue	O
in	O
the	O
nsp10	O
-	O
nsp11	O
/	O
12	O
site	O
completely	O
abolished	O
the	O
3CLpro	O
-	O
mediated	O
processing	O
,	O
but	O
allowed	O
production	O
of	O
infectious	B-DISO
recombinant	O
viruses	O
with	O
variable	O
degrees	O
of	O
growth	O
defect	O
,	O
suggesting	O
that	O
cleavage	O
at	O
the	O
nsp10	O
-	O
nsp11	O
/	O
12	O
site	O
of	O
IBV	O
is	O
dispensable	O
for	O
viral	O
replication	O
in	O
cultured	O
cells	O
.	O

NATs	O
from	O
swabs	O
were	O
tested	O
for	O
influenza	B-DISO
,	I-DISO
human	I-DISO
metapneumovirus	O
(	O
hMPV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
rhinovirus	O
,	O
parainfluenza	B-DISO
virus	O
1	O
-	O
4	O
,	O
coronaviruses	O
(	O
OC43	O
,	O
229E	O
,	O
and	O
NL63	O
),	O
and	O
adenovirus	B-DISO
.	O

Influenza	B-DISO
(	O
n	O
=	O
7	O
),	O
hMPV	O
(	O
n	O
=	O
7	O
),	O
and	O
RSV	O
(	O
n	O
=	O
5	O
)	O
accounted	O
for	O
most	O
viral	B-DISO
infections	I-DISO
;	O
other	O
infections	B-DISO
included	O
rhinovirus	O
(	O
n	O
=	O
4	O
),	O
parainfluenza	B-DISO
(	O
n	O
=	O
3	O
),	O
coronavirus	O
(	O
n	O
=	O
4	O
),	O
and	O
adenovirus	B-DISO
(	O
n	O
=	O
2	O
).	O

Compared	O
with	O
bacterial	B-DISO
infection	I-DISO
,	O
patients	O
with	O
viral	B-DISO
infection	I-DISO
were	O
older	O
(	O
76	O
vs	O
64	O
years	O
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
01	O
),	O
were	O
more	O
likely	O
to	O
have	O
cardiac	B-DISO
disease	I-DISO
(	O
66	O
%	O
vs	O
32	O
%,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
006	O
),	O
and	O
were	O
more	O
frail	O
(	O
eg	O
,	O
48	O
%	O
with	O
limited	O
ambulation	O
vs	O
21	O
%	O
of	O
bacterial	B-DISO
infections	I-DISO
;	O
p	O
=	O
0	O
.	O
02	O
).	O

There	O
were	O
few	O
clinically	O
meaningful	O
differences	O
in	O
presentation	O
and	O
no	O
differences	O
in	O
outcomes	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
viral	B-DISO
infection	I-DISO
.	O

There	O
were	O
few	O
clinically	O
meaningful	O
differences	O
in	O
presentation	O
and	O
no	O
differences	O
in	O
outcomes	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
viral	B-DISO
infection	I-DISO
.	O

We	O
performed	O
a	O
pooled	O
analysis	O
of	O
all	O
five	O
multicenter	O
studies	O
in	O
which	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
various	O
predisposing	O
events	O
were	O
treated	O
with	O
rSP	O
-	O
C	O
surfactant	O
.	O

In	O
the	O
subgroup	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
due	O
to	O
pneumonia	B-DISO
or	O
aspiration	B-DISO
,	O
surfactant	O
treatment	O
was	O
associated	O
with	O
markedly	O
improved	O
oxygenation	O
(	O
p	O
=	O
0	O
.	O
0008	O
)	O
and	O
improved	O
survival	O
(	O
p	O
=	O
0	O
.	O
018	O
).	O

To	O
facilitate	O
future	O
chemical	O
-	O
based	O
drug	O
discovery	O
research	O
on	O
new	O
agent	O
development	O
,	O
this	O
paper	O
reviews	O
present	O
pharmacotherapy	O
for	O
ALI	O
/	O
ARDS	B-DISO
in	O
the	O
context	O
of	O
biological	O
and	O
biochemical	O
drug	O
activities	O
.	O

The	O
complex	O
lung	O
injury	O
pathophysiology	O
of	O
ALI	O
/	O
ARDS	B-DISO
offers	O
an	O
array	O
of	O
possible	O
targets	O
for	O
drug	O
therapy	O
,	O
including	O
inflammation	B-DISO
,	O
cell	O
and	O
tissue	O
injury	O
,	O
vascular	O
dysfunction	O
,	O
surfactant	O
dysfunction	O
,	O
and	O
oxidant	O
injury	O
.	O

A	O
number	O
of	O
pharmacologic	O
agents	O
have	O
been	O
studied	O
individually	O
in	O
ALI	O
/	O
ARDS	B-DISO
,	O
with	O
limited	O
or	O
minimal	O
success	O
in	O
improving	O
survival	O
.	O

Improvement	O
of	O
sensitivity	O
by	O
two	O
orders	O
of	O
magnitude	O
was	O
achieved	O
for	O
both	O
targets	O
,	O
compared	O
with	O
our	O
previously	O
reported	O
system	O
without	O
signal	O
amplification	B-DISO
.	O

The	O
crystal	O
structure	O
of	O
Nsp9	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
reveals	O
a	O
novel	O
disulfide	O
-	O
linked	O
homodimer	O
,	O
which	O
is	O
very	O
different	O
from	O
the	O
previously	O
reported	O
Nsp9	O
dimer	O
of	O
SARS	B-DISO
coronavirus	O
.	O

Seventeen	O
patients	O
were	O
identified	O
who	O
underwent	O
HFOV	O
for	O
ARDS	B-DISO
due	O
primarily	O
to	O
pulmonary	O
contusions	O
.	O

Mean	O
ISS	B-DISO
was	O
36	O
.	O
6	O
,	O
mean	O
APACHE	O
II	O
score	O
was	O
21	O
.	O
7	O
,	O
and	O
the	O
mean	O
time	O
before	O
initiation	O
of	O
HFOV	O
was	O
2	O
.	O
0	O
days	O
.	O

A	O
variable	B-DISO
number	I-DISO
tandem	I-DISO
repeat	I-DISO
(	O
VNTR	O
)	O
polymorphism	O
in	O
its	O
neck	O
region	O
was	O
recently	O
associated	O
with	O
susceptibility	O
to	O
SARS	B-DISO
infection	B-DISO
.	O

23	O
tagSNPs	O
were	O
genotyped	O
in	O
181	O
SARS	B-DISO
patients	O
and	O
172	O
population	O
controls	O
.	O

RESULTS	O
:	O
23	O
tagSNPs	O
were	O
genotyped	O
in	O
181	O
SARS	B-DISO
patients	O
and	O
172	O
population	O
controls	O
.	O

He	O
presented	O
with	O
cyanotic	O
digits	O
,	O
high	O
fever	O
and	O
dyspnea	B-DISO
.	O

This	O
case	O
has	O
been	O
followed	O
but	O
no	O
myositis	B-DISO
or	O
recurrence	B-DISO
of	O
interstitial	B-DISO
pneumonia	I-DISO
has	O
been	O
recognized	O
.	O

Aspiration	B-DISO
of	O
gastric	O
contents	O
could	O
lead	O
to	O
incremental	O
mortality	O
due	O
to	O
severe	O
ventilation	O
associated	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
date	O
,	O
neither	O
an	O
effective	O
antiviral	O
drug	O
nor	O
a	O
vaccine	O
against	O
SARS	B-DISO
is	O
available	O
.	O

To	O
understand	O
the	O
fine	O
details	O
of	O
the	O
molecular	O
interactions	O
between	O
these	O
proteinase	O
inhibitors	O
and	O
the	O
SARS	B-DISO
virus	O
via	O
complexation	O
,	O
molecular	O
dynamics	O
simulations	O
were	O
carried	O
out	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
free	O
enzyme	O
(	O
free	O
SARS	B-DISO
)	O
and	O
its	O
complexes	O
with	O
lopinavir	O
(	O
SARS	B-DISO
-	O
LPV	O
)	O
and	O
ritonavir	O
(	O
SARS	B-DISO
-	O
RTV	O
).	O

In	O
addition	O
,	O
six	O
hydrogen	O
bonds	O
were	O
detected	O
in	O
the	O
SARS	B-DISO
-	O
LPV	O
system	O
,	O
while	O
seven	O
hydrogen	O
bonds	O
were	O
found	O
in	O
SARS	B-DISO
-	O
RTV	O
complex	O
.	O

These	O
results	O
indicate	O
that	O
immunostimulatory	O
BV	O
of	O
ApNPV	O
can	O
stimulate	O
the	O
innate	O
immune	O
activities	O
and	O
enhance	O
the	O
resistance	O
to	O
infectious	B-DISO
virus	O
of	O
neonatal	O
chickens	O
.	O

Human	O
lymphocytes	O
and	O
monocytes	O
are	O
not	O
permissive	O
to	O
productive	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
in	O
vitro	O
.	O

Lymphopaenia	O
in	O
SARS	B-DISO
patients	O
is	O
likely	O
to	O
result	O
from	O
indirect	O
mechanisms	O
secondary	O
to	O
the	O
viral	B-DISO
infection	I-DISO
.	O

A	O
novel	O
HLA	O
-	O
A2	O
.	O
1	O
-	O
specific	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
epitope	O
(	O
N220	O
-	O
N228	O
LALLLLDRL	O
)	O
able	O
to	O
activate	O
cytotoxic	O
T	O
cells	O
in	O
vitro	O
has	O
been	O
identified	O
.	O

A	O
genetic	O
risk	O
-	O
association	O
study	O
involving	O
more	O
than	O
1200	O
subjects	O
showed	O
individuals	O
homozygous	O
for	O
L	O
-	O
SIGN	O
tandem	O
repeats	O
are	O
less	O
susceptible	O
to	O
SARS	B-DISO
infection	B-DISO
.	O

2	O
.	O
Using	O
high	O
throughput	O
screen	O
and	O
chemical	O
synthesis	O
,	O
several	O
lead	O
compounds	O
targeting	O
the	O
SARS	B-DISO
-	O
CoV	O
helicase	O
have	O
been	O
identified	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
inactivated	O
vaccine	O
,	O
RBD	O
-	O
Fc	O
and	O
RBD	O
-	O
rAAV	O
,	O
can	O
be	O
further	O
developed	O
into	O
effective	O
and	O
safe	O
vaccines	O
against	O
SARS	B-DISO
and	O
that	O
intranasal	O
vaccination	O
may	O
be	O
the	O
preferred	O
route	O
of	O
administration	O
.	O

These	O
different	O
case	O
definitions	O
can	O
vary	O
with	O
regard	O
to	O
sensitivity	O
and	O
predictive	O
values	O
for	O
laboratory	O
confirmed	O
influenza	B-DISO
.	O

TITLE	O
:	O
First	O
report	O
on	O
fatal	O
myocarditis	B-DISO
associated	O
with	O
adenovirus	B-DISO
infection	I-DISO
in	O
Cuba	O
.	O

Nested	O
polymerase	O
chain	O
reaction	O
(	O
nPCR	O
)	O
and	O
nested	O
reverse	O
transcription	O
-	O
PCR	O
(	O
nRT	O
-	O
PCR	O
)	O
were	O
carried	O
out	O
on	O
fresh	O
heart	O
muscle	O
and	O
lung	O
tissue	O
to	O
analyze	O
the	O
genomic	O
sequences	O
of	O
adenovirus	B-DISO
,	O
CMV	O
,	O
HHV	O
-	O
6	O
,	O
herpes	B-DISO
simplex	I-DISO
virus	O
,	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
),	O
varizella	O
zoster	B-DISO
virus	O
,	O
influenza	B-DISO
virus	O
A	O
,	O
B	O
,	O
C	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
A	O
and	O
B	O
,	O
parainfluenza	B-DISO
viruses	O
,	O
rhinoviruses	O
,	O
coronavirus	O
,	O
flaviruses	O
and	O
enteroviruses	O
.	O

TITLE	O
:	O
Multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
severe	O
bone	O
marrow	O
dysfunction	O
in	O
two	O
18	O
year	O
-	O
old	O
Caucasian	O
patients	O
:	O
Epstein	O
-	O
Barr	O
virus	O
and	O
the	O
haemophagocytic	B-DISO
syndrome	I-DISO
.	O

Serological	O
tests	O
and	O
bone	O
marrow	O
examination	O
with	O
in	O
-	O
situ	O
hybridisation	O
revealed	O
severe	O
acquired	O
haemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
secondary	O
to	O
acute	O
Epstein	B-DISO
-	I-DISO
Barr	I-DISO
virus	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Certain	O
aspects	O
of	O
pulmonary	B-DISO
pathology	I-DISO
observed	O
in	O
autopsies	O
of	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
patients	O
are	O
still	O
unknown	O
.	O

TITLE	O
:	O
[	O
Clinicopathogenetic	O
features	O
of	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
combined	O
with	O
chronic	O
obstructive	B-DISO
pulmonary	I-DISO
diseases	I-DISO
and	O
efficiency	O
of	O
therapy	O
with	O
trimetazidin	O
].	O

ABSTRACT	O
:	O
To	O
report	O
the	O
immediate	O
use	O
of	O
High	O
-	O
Frequency	O
Oscillatory	O
ventilation	O
in	O
an	O
adult	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
have	O
explored	O
the	O
capacity	O
of	O
these	O
selected	O
membrane	O
-	O
interacting	O
regions	O
of	O
the	O
S2	O
SARS	B-DISO
-	O
CoV	O
fusion	O
protein	O
,	O
alone	O
or	O
in	O
equimolar	O
mixtures	O
,	O
to	O
insert	O
into	O
the	O
membrane	O
as	O
well	O
as	O
to	O
perturb	O
the	O
dipole	O
potential	O
of	O
the	O
bilayer	O
.	O

We	O
show	O
that	O
the	O
three	O
peptides	O
interact	O
with	O
lipid	O
membranes	O
depending	O
on	O
lipid	O
composition	O
and	O
experiments	O
using	O
equimolar	O
mixtures	O
of	O
these	O
peptides	O
show	O
that	O
different	O
segments	O
of	O
the	O
protein	O
may	O
act	O
in	O
a	O
synergistic	O
way	O
suggesting	O
that	O
several	O
membrane	O
-	O
active	O
regions	O
could	O
participate	O
in	O
the	O
fusion	O
process	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O

We	O
assessed	O
whether	O
there	O
were	O
unintended	O
health	O
consequences	O
to	O
seriously	O
ill	B-DISO
hospitalized	O
patients	O
.	O

Short	O
-	O
term	O
mortality	O
,	O
overall	O
readmissions	O
,	O
cardiac	O
readmissions	O
for	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
patients	O
,	O
serious	O
complications	O
for	O
very	O
low	O
birth	O
weight	O
babies	O
,	O
and	O
quality	O
of	O
care	O
measures	O
,	O
comparing	O
adjusted	O
rates	O
across	O
time	O
periods	O
within	O
regions	O
.	O

ABSTRACT	O
:	O
Mouse	O
susceptibility	O
to	O
experimental	O
infections	B-DISO
with	O
flaviviruses	O
is	O
significantly	O
influenced	O
by	O
a	O
cluster	O
of	O
genes	O
on	O
chromosome	O
5	O
encoding	O
a	O
family	O
of	O
proteins	O
with	O
enzymatic	O
properties	O
,	O
the	O
2	O
'-	O
5	O
'	O
oligoadenylate	O
synthetases	O
(	O
OAS	B-DISO
).	O

Positional	O
cloning	O
of	O
the	O
locus	O
in	O
question	O
has	O
revealed	O
that	O
susceptibility	O
of	O
laboratory	O
inbred	O
strains	O
to	O
this	O
class	O
of	O
virus	O
is	O
associated	O
with	O
a	O
nonsense	B-DISO
mutation	I-DISO
in	O
the	O
gene	O
encoding	O
the	O
OAS1B	O
isoform	O
.	O

Finally	O
,	O
convergent	O
observations	O
indicate	O
that	O
the	O
molecules	O
encoded	O
by	O
the	O
2	O
'-	O
5	O
'	O
OAS	B-DISO
cluster	O
might	O
be	O
involved	O
in	O
other	O
fundamental	O
cellular	O
functions	O
such	O
as	O
cell	O
growth	O
and	O
differentiation	O
,	O
gene	O
regulation	O
,	O
and	O
apoptosis	O
.	O

This	O
suggests	O
that	O
the	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
assembly	O
differs	O
from	O
that	O
of	O
other	O
studied	O
coronaviruses	O
,	O
which	O
only	O
require	O
M	O
and	O
E	O
proteins	O
for	O
VLP	O
formation	O
.	O

Both	O
the	O
whole	O
killed	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
(	O
with	O
and	O
without	O
alum	O
)	O
and	O
adenovirus	B-DISO
-	O
based	O
vectors	O
encoding	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
protein	O
induced	O
neutralizing	O
antibody	O
responses	O
and	O
reduced	O
viral	O
replication	O
and	O
shedding	O
in	O
the	O
upper	O
respiratory	O
tract	O
and	O
progression	O
of	O
virus	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
The	O
Emergency	B-DISO
Department	O
experience	O
,	O
for	O
many	O
patients	O
,	O
involves	O
procedures	O
and	O
therapies	O
that	O
can	O
compromise	O
ventilation	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
woman	O
suffered	B-DISO
a	O
mechanical	O
fall	O
,	O
fractured	O
her	O
T6	O
vertebral	O
body	O
and	O
right	O
proximal	O
humerus	O
,	O
and	O
,	O
after	O
spinal	O
immobilization	O
and	O
the	O
administration	O
of	O
routine	O
doses	O
of	O
opioid	O
analgesics	O
,	O
suffered	B-DISO
significant	O
hypoxemia	O
and	O
respiratory	B-DISO
acidosis	I-DISO
.	O

The	O
condition	B-DISO
is	O
easily	O
addressed	O
through	O
non	O
-	O
invasive	O
ventilation	O
.	O

TITLE	O
:	O
Steroid	O
-	O
induced	O
osteonecrosis	B-DISO
:	O
the	O
number	O
of	O
lesions	O
is	O
related	O
to	O
the	O
dosage	O
.	O

TITLE	O
:	O
An	O
immunosuppressed	O
Syrian	O
golden	O
hamster	O
model	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Adaptive	O
modeling	O
of	O
viral	B-DISO
diseases	I-DISO
in	O
bats	O
with	O
a	O
focus	O
on	O
rabies	B-DISO
.	O

ABSTRACT	O
:	O
Many	O
emerging	O
and	O
reemerging	O
viruses	O
,	O
such	O
as	O
rabies	B-DISO
,	O
SARS	B-DISO
,	O
Marburg	O
,	O
and	O
Ebola	O
have	O
bat	O
populations	O
as	O
disease	O
reservoirs	O
.	O

TITLE	O
:	O
Toona	O
sinensis	O
Roem	O
tender	O
leaf	O
extract	O
inhibits	O
SARS	B-DISO
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Purification	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
analysis	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
nsp3	O
ADRP	O
domain	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
encodes	O
15	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
which	O
play	O
crucial	O
roles	O
in	O
RNA	O
transcription	O
and	O
genome	O
replication	O
.	O

TITLE	O
:	O
Practice	O
and	O
perception	O
--	O
a	O
nationwide	O
survey	O
of	O
therapy	O
habits	O
in	O
sepsis	B-DISO
.	O

TITLE	O
:	O
The	O
studies	O
on	O
the	O
aetiology	O
of	O
diarrhoea	B-DISO
in	O
neonatal	O
calves	O
and	O
determination	O
of	O
virulence	O
gene	O
markers	O
of	O
Escherichia	O
coli	O
strains	O
by	O
multiplex	O
PCR	O
.	O

Characterization	O
of	O
the	O
profile	O
of	O
IFN	O
-	O
alpha	O
subtypes	O
genes	O
expression	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
PBMCs	O
demonstrated	O
that	O
the	O
level	O
of	O
IFN	O
-	O
alpha2	O
and	O
-	O
6	O
subtypes	O
were	O
higher	O
compared	O
to	O
other	O
IFN	O
-	O
alpha	O
subtypes	O
namely	O
,	O
IFN	O
-	O
alpha5	O
,	O
-	O
8	O
,	O
-	O
10	O
,	O
-	O
13	O
/	O
1	O
,	O
-	O
17	O
,	O
and	O
-	O
21	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
known	O
to	O
take	O
an	O
endosomal	O
pathway	O
for	O
cell	O
entry	O
;	O
however	O
,	O
it	O
is	O
thought	O
to	O
enter	O
directly	O
from	O
the	O
cell	O
surface	O
when	O
a	O
receptor	O
-	O
bound	O
virion	O
spike	O
(	O
S	O
)	O
protein	O
is	O
affected	O
by	O
trypsin	O
,	O
which	O
induces	O
cleavage	O
of	O
the	O
S	O
protein	O
and	O
activates	O
its	O
fusion	O
potential	O
.	O

The	O
relationship	O
between	O
outbreak	O
exposure	O
and	O
alcohol	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
symptom	B-DISO
count	O
remained	O
significant	O
even	O
when	O
sociodemographic	O
and	O
other	O
factors	O
were	O
controlled	O
for	O
.	O

The	O
findings	O
will	O
help	O
policy	O
makers	O
and	O
health	O
professionals	O
to	O
better	O
prepare	O
for	O
potential	O
outbreaks	O
of	O
diseases	O
such	O
as	O
SARS	B-DISO
or	O
avian	B-DISO
flu	I-DISO
.	O

ABSTRACT	O
:	O
A	O
Chinese	O
isolate	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
designated	O
HH06	O
was	O
isolated	O
from	O
the	O
kidney	O
tissues	O
of	O
a	O
chicken	O
flock	O
experiencing	O
an	O
outbreak	O
of	O
nephritis	B-DISO
.	O

Furthermore	O
,	O
a	O
phylogenetic	O
tree	O
based	O
on	O
these	O
M	O
DNA	O
sequences	O
was	O
generated	O
,	O
and	O
the	O
tree	O
topology	O
suggests	O
that	O
some	O
Chinese	O
IBV	O
strains	O
may	O
have	O
a	O
common	O
ancestor	O
;	O
however	O
,	O
HH06	O
is	O
a	O
new	O
local	O
IBV	O
isolate	O
that	O
is	O
responsible	O
for	O
the	O
field	O
outbreak	O
of	O
nephritis	B-DISO
.	O

TITLE	O
:	O
Interactions	O
between	O
M	O
protein	O
and	O
other	O
structural	O
proteins	O
of	O
severe	O
,	O
acute	O
respiratory	O
syndrome	B-DISO
-	O
associated	O
coronavirus	O
.	O

However	O
,	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
is	O
co	O
-	O
localized	O
almost	O
entirely	O
with	O
S	O
,	O
E	O
,	O
or	O
NC	O
protein	O
when	O
co	O
-	O
expressed	O
in	O
the	O
cells	O
.	O

The	O
training	O
model	O
included	O
nosocomial	B-DISO
infection	I-DISO
control	O
guidelines	O
,	O
a	O
training	O
CD	O
,	O
training	O
program	O
,	O
evaluation	O
form	O
,	O
and	O
descriptive	O
procedures	O
for	O
conducting	O
training	O
and	O
evaluation	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
frequency	O
,	O
etiologic	O
factors	O
,	O
outcome	O
,	O
and	O
the	O
comorbid	O
conditions	O
affecting	O
the	O
morbidity	O
and	O
mortality	O
of	O
pulmonary	B-DISO
complications	I-DISO
in	O
acute	O
childhood	B-DISO
leukemia	I-DISO
.	O

Tachypnea	B-DISO
,	O
shock	O
,	O
oxygen	O
and	O
mechanical	O
ventilation	O
requirement	O
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
involvement	O
of	O
other	O
organs	O
or	O
systems	O
,	O
cytopenias	B-DISO
,	O
requirement	O
of	O
modification	O
in	O
antimicrobial	O
drugs	O
were	O
found	O
to	O
be	O
related	O
with	O
increased	O
mortality	O
risk	O
.	O

The	O
mortality	O
rate	O
of	O
pulmonary	B-DISO
complications	I-DISO
was	O
8	O
.	O
9	O
%.	O

In	O
conclusion	O
,	O
pulmonary	B-DISO
complications	I-DISO
are	O
frequent	O
in	O
children	O
with	O
acute	B-DISO
leukemia	I-DISO
,	O
and	O
early	O
diagnosis	O
and	O
appropriate	O
management	O
are	O
important	O
to	O
avoid	O
mortality	O
owing	O
to	O
pulmonary	B-DISO
complications	I-DISO
,	O
especially	O
in	O
neutropenic	O
patients	O
receiving	O
induction	O
or	O
consolidation	O
phase	O
of	O
chemotherapy	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
serious	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
the	O
SARS	B-DISO
coronavirus	O
.	O

Faecal	O
samples	O
from	O
147	O
untreated	O
calves	O
suffering	B-DISO
from	O
acute	B-DISO
diarrhoea	I-DISO
were	O
analysed	O
by	O
standardised	O
diagnostic	O
methods	O
,	O
and	O
the	O
immunoglobulin	O
status	O
of	O
each	O
calf	O
was	O
evaluated	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
SARS	B-DISO
infection	B-DISO
within	O
hospitals	O
in	O
Hanoi	O
,	O
Vietnam	O
.	O

In	O
malaria	B-DISO
,	O
ARDS	B-DISO
can	O
develop	O
either	O
at	O
initial	O
presentation	O
or	O
after	O
initiation	O
of	O
treatment	O
when	O
the	O
parasitaemia	O
is	O
falling	O
and	O
the	O
patient	O
is	O
improving	O
.	O

ARDS	B-DISO
in	O
malaria	B-DISO
is	O
a	O
disease	O
with	O
a	O
high	O
mortality	O
.	O

ABSTRACT	O
:	O
Postinfectious	O
acute	B-DISO
glomerulonephritis	I-DISO
mostly	O
happens	O
in	O
children	O
aged	O
two	O
to	O
10	O
years	O
old	O
.	O

Fluid	B-DISO
overload	I-DISO
must	O
be	O
urgently	O
treated	O
by	O
loop	O
diuretics	O
or	O
renal	O
replacement	O
therapy	O
in	O
the	O
most	O
severe	O
cases	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
described	O
isolation	O
of	O
a	O
potentially	O
new	O
mammalian	O
reovirus	O
,	O
designated	O
BYD1	O
,	O
which	O
can	O
cause	O
clinical	O
symptoms	O
similar	O
to	O
that	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
guinea	O
pigs	O
and	O
macaques	O
,	O
from	O
throat	O
swabs	O
of	O
one	O
SARS	B-DISO
patient	O
of	O
Beijing	O
,	O
in	O
2003	O
.	O

TITLE	O
:	O
[	O
Decompensated	O
pulmonary	B-DISO
hypertension	I-DISO
].	O

Right	B-DISO
ventricular	I-DISO
failure	I-DISO
in	O
the	O
course	O
of	O
PHT	B-DISO
represents	O
a	O
great	O
challenge	O
in	O
clinical	O
and	O
intensive	O
care	O
practice	O
.	O

Once	O
the	O
vicious	O
circle	O
of	O
right	B-DISO
heart	I-DISO
failure	I-DISO
is	O
reached	O
an	O
optimal	O
balance	O
has	O
to	O
be	O
found	O
between	O
preload	O
and	O
afterload	O
.	O

Lung	O
transplantation	O
or	O
surgical	O
atrioseptostomy	O
may	O
represent	O
possible	O
ultimate	O
therapeutic	O
options	O
for	O
patients	O
with	O
PHT	B-DISO
.	O

TITLE	O
:	O
Importance	O
of	O
cholesterol	O
-	O
rich	O
membrane	O
microdomains	O
in	O
the	O
interaction	O
of	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
with	O
the	O
cellular	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

ABSTRACT	O
:	O
Cholesterol	O
present	O
in	O
the	O
plasma	O
membrane	O
of	O
target	O
cells	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
show	O
that	O
cholesterol	B-DISO
depletion	I-DISO
by	O
treatment	O
with	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
(	O
m	O
beta	O
CD	O
)	O
affects	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
to	O
the	O
same	O
extent	O
as	O
infection	B-DISO
by	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
-	O
based	O
pseudotypes	O
containing	O
the	O
surface	O
glycoprotein	O
S	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
VSV	O
-	O
Delta	O
G	O
-	O
S	O
).	O

This	O
result	O
suggests	O
that	O
optimal	O
infection	B-DISO
requires	O
a	O
multivalent	O
interaction	O
between	O
viral	O
attachment	O
protein	O
and	O
cellular	O
receptors	O
.	O

In	O
addition	O
,	O
we	O
engineered	O
the	O
heterologous	O
green	O
fluorescent	O
protein	O
gene	O
in	O
place	O
of	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
)	O
of	O
the	O
NL63	O
clone	O
,	O
simultaneously	O
creating	O
a	O
unique	O
marker	O
for	O
NL63	O
infection	B-DISO
and	O
demonstrating	O
that	O
the	O
ORF3	O
protein	O
product	O
is	O
nonessential	O
for	O
the	O
replication	O
of	O
NL63	O
in	O
cell	O
culture	O
.	O

Epidemiological	O
analysis	O
of	O
a	O
hospital	O
outbreak	O
in	O
Hong	O
Kong	O
revealed	O
that	O
blood	O
group	O
O	O
was	O
associated	O
with	O
a	O
low	O
risk	O
of	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
viruses	O
are	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
humans	O
worldwide	O
and	O
most	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
are	O
caused	O
by	O
viruses	O
.	O

by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
in	O
patients	O
with	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
.	O

The	O
numbers	O
of	O
NK	O
cells	O
in	O
their	O
livers	O
,	O
spleens	O
,	O
blood	O
and	O
bone	O
marrow	O
and	O
the	O
expression	O
of	O
CD69	O
on	O
liver	O
NK	O
cells	O
at	O
0	O
,	O
24	O
,	O
48	O
and	O
70	O
h	O
after	O
MHV	O
-	O
3	O
infection	B-DISO
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

CONCLUSIONS	O
:	O
After	O
MHV	O
-	O
3	O
infection	B-DISO
,	O
NK	O
cells	O
were	O
recruited	O
to	O
the	O
liver	O
quickly	O
,	O
probably	O
from	O
the	O
spleen	O
and	O
bone	O
marrow	O
.	O

TITLE	O
:	O
Psychological	B-DISO
resilience	O
and	O
dysfunction	O
among	O
hospitalized	O
survivors	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
:	O
a	O
latent	O
class	O
approach	O
.	O

This	O
novel	O
approach	O
might	O
also	O
have	O
utility	O
for	O
other	O
serious	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
,	O
including	O
non	O
-	O
avian	B-DISO
influenza	I-DISO
,	O
SARS	B-DISO
,	O
hantavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
antibiotic	O
-	O
resistant	O
Streptococcus	O
pneumoniae	O
and	O
pneumonia	B-DISO
-	O
causing	O
Staphylococcus	O
aureus	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
cinanserin	O
analogs	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
3CL	O
protease	O
inhibitors	O
.	O

MYLK	O
encodes	O
protein	O
isoforms	O
involved	O
in	O
multiple	O
components	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
,	O
including	O
apoptosis	O
,	O
vascular	O
permeability	O
,	O
and	O
leukocyte	O
diapedesis	O
.	O

The	O
serum	O
cytokine	O
profile	O
during	O
acute	B-DISO
infection	I-DISO
indicated	O
a	O
significant	O
elevation	O
of	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

In	O
the	O
meantime	O
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
and	O
the	O
concern	O
over	O
pandemic	O
influenza	B-DISO
have	O
stimulated	O
considerable	O
government	O
and	O
health	O
care	O
institutional	O
efforts	O
to	O
improve	O
infection	B-DISO
control	O
systems	O
in	O
Canada	O
.	O

Canadian	O
infection	B-DISO
control	O
programs	O
in	O
2005	O
continued	O
to	O
fall	O
short	O
of	O
expert	O
recommendations	O
for	O
human	O
resources	O
and	O
surveillance	O
and	O
control	O
activities	O
.	O

CONCLUSIONS	O
:	O
Canadian	O
infection	B-DISO
control	O
programs	O
in	O
2005	O
continued	O
to	O
fall	O
short	O
of	O
expert	O
recommendations	O
for	O
human	O
resources	O
and	O
surveillance	O
and	O
control	O
activities	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
antibodies	O
to	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
infections	B-DISO
was	O
studied	O
in	O
20	O
conventional	O
and	O
20	O
organic	O
dairy	O
herds	O
.	O

Experience	O
with	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
/	O
acquired	B-DISO
immunodeficiency	I-DISO
syndrome	I-DISO
,	O
the	O
return	O
of	O
cholera	B-DISO
to	O
the	O
Americas	O
in	O
1991	O
,	O
the	O
plague	B-DISO
outbreak	O
in	O
India	O
in	O
1994	O
,	O
and	O
the	O
emergence	O
of	O
Ebola	O
in	O
Zaire	O
in	O
1995	O
created	O
awareness	O
of	O
a	O
new	O
vulnerability	O
to	O
epidemics	O
due	O
to	O
population	O
growth	O
,	O
unplanned	O
urbanization	O
,	O
antimicrobial	O
resistance	O
,	O
poverty	O
,	O
societal	O
change	O
,	O
and	O
rapid	O
mass	O
movement	O
of	O
people	O
.	O

A	O
prospective	O
cohort	O
of	O
children	O
diagnosed	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

In	O
addition	O
,	O
the	O
overexpression	O
of	O
human	O
apoD	O
in	O
the	O
neurons	O
of	O
Thy	O
-	O
1	O
/	O
ApoD	O
transgenic	O
mice	O
results	O
in	O
a	O
threefold	O
increase	O
of	O
the	O
number	O
of	O
mice	O
surviving	O
to	O
HCoV	O
-	O
OC43	O
infection	B-DISO
.	O

While	O
best	O
described	O
in	O
patients	O
with	O
IPF	O
,	O
they	O
have	O
also	O
been	O
reported	O
in	O
patients	O
with	O
other	O
forms	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

All	O
patients	O
had	O
a	O
clinical	O
course	O
similar	O
to	O
that	O
most	O
frequently	O
described	O
in	O
AEs	O
of	O
IPF	O
:	O
respiratory	B-DISO
failure	I-DISO
requiring	O
assisted	O
ventilation	O
,	O
lack	O
of	O
clinical	O
response	O
to	O
high	O
-	O
dose	O
corticosteroid	O
therapy	O
,	O
and	O
a	O
poor	O
prognosis	O
(	O
all	O
cases	O
resulted	O
in	O
death	O
or	O
emergent	O
lung	O
transplantation	O
).	O

The	O
most	O
common	O
potentially	O
lethal	O
complication	B-DISO
of	O
rhabdomyoloysis	O
is	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

In	O
this	O
article	O
we	O
present	O
a	O
case	O
of	O
a	O
patient	O
that	O
developed	O
clinical	O
signs	O
of	O
acute	O
rhabdomyolysis	B-DISO
after	O
consumption	O
of	O
heroin	O
and	O
alcohol	O
.	O

After	O
approximately	O
nine	O
hours	O
of	O
alcohol	O
and	O
heroin	O
induced	O
coma	B-DISO
he	O
had	O
acute	O
compartment	B-DISO
syndrome	I-DISO
of	O
the	O
right	O
arm	O
,	O
and	O
clinical	O
and	O
laboratory	O
signs	O
of	O
acute	O
rhabdomyolysis	B-DISO
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
as	O
a	O
complication	B-DISO
of	O
rhabdomyolysis	B-DISO
.	O

During	O
the	O
period	O
of	O
coma	B-DISO
,	O
due	O
to	O
lying	O
in	O
particular	O
position	O
over	O
a	O
long	O
period	O
of	O
time	O
,	O
pressure	O
upon	O
the	O
certain	O
part	O
of	O
the	O
body	O
caused	O
muscle	O
compression	O
and	O
capillary	O
occlusion	B-DISO
in	O
fascial	O
compartments	O
,	O
which	O
led	O
to	O
ischemia	B-DISO
.	O

TITLE	O
:	O
Evaluation	O
of	O
peptide	O
-	O
aldehyde	O
inhibitors	O
using	O
R188I	O
mutant	B-DISO
of	O
SARS	B-DISO
3CL	O
protease	O
as	O
a	O
proteolysis	O
-	O
resistant	O
mutant	B-DISO
.	O

We	O
found	O
for	O
the	O
first	O
time	O
that	O
the	O
mature	O
SARS	B-DISO
3CL	O
protease	O
is	O
subject	O
to	O
degradation	O
at	O
188Arg	O
/	O
189Gln	O
.	O

The	O
R188I	O
mutant	B-DISO
digested	O
a	O
conserved	O
undecapeptide	O
substrate	O
with	O
a	O
K	O
(	O
m	O
)	O
of	O
33	O
.	O
8	O
microM	O
and	O
k	O
(	O
cat	O
)	O
of	O
4753	O
s	O
(-	O
1	O
).	O

The	O
long	O
-	O
term	O
outcome	O
of	O
patients	O
who	O
have	O
survived	O
ARDS	B-DISO
has	O
been	O
studied	O
extensively	O
and	O
should	O
in	O
the	O
future	O
be	O
taken	O
into	O
account	O
in	O
assessing	O
new	O
treatment	O
modalities	O
.	O

These	O
symptoms	O
are	O
not	O
at	O
all	O
specific	O
to	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
An	O
excessive	O
inflammatory	B-DISO
response	I-DISO
is	O
a	O
clinical	O
problem	O
following	O
major	O
infections	B-DISO
and	O
severe	O
injury	O
that	O
may	O
lead	O
to	O
Sepsis	B-DISO
Syndrome	I-DISO
and	O
Multiple	B-DISO
Organ	I-DISO
Failure	I-DISO
(	O
MOF	B-DISO
),	O
including	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Management	O
of	O
excessive	O
inflammation	B-DISO
may	O
be	O
possible	O
through	O
control	O
of	O
key	O
inflammatory	O
pathways	O
such	O
as	O
those	O
mediated	O
by	O
the	O
important	O
interleukin	O
-	O
1	O
receptor	O
associated	O
kinase	O
-	O
1	O
(	O
IRAK	O
-	O
1	O
).	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
the	O
impact	O
on	O
gene	O
expression	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
stimulation	O
of	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
an	O
antisense	O
oligonucleotide	O
(	O
ASODN	O
)	O
against	O
the	O
IRAK	O
-	O
1	O
gene	O
using	O
cDNA	O
microarrays	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Following	O
LPS	B-DISO
stimulation	O
,	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
ASODN	O
against	O
the	O
IRAK	O
-	O
1	O
gene	O
expression	O
is	O
evidenced	O
by	O
the	O
lower	O
expression	O
of	O
inflammatory	O
chemokines	O
,	O
cytokines	O
and	O
acute	O
-	O
phase	O
proteins	O
compared	O
to	O
control	O
cells	O
.	O

After	O
sensitization	O
,	O
cats	O
(	O
n	O
=	O
20	O
)	O
were	O
anaesthetized	O
and	O
challenged	O
with	O
IV	O
D	O
.	O
immitis	O
Ag	O
in	O
various	O
forms	O
or	O
with	O
IV	O
sterile	B-DISO
0	O
.	O
9	O
%	O
saline	O
(	O
n	O
=	O
3	O
).	O

TITLE	O
:	O
Delayed	O
recognition	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
in	O
a	O
child	O
:	O
a	O
misleading	O
respiratory	B-DISO
distress	I-DISO
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
acute	O
flaccid	B-DISO
paralysis	I-DISO
in	O
childhood	O
.	O

This	O
case	O
report	O
describes	O
a	O
9	O
-	O
year	O
-	O
old	O
girl	O
presenting	O
with	O
respiratory	B-DISO
distress	I-DISO
,	O
weakness	B-DISO
,	O
limb	B-DISO
pain	I-DISO
,	O
and	O
hypertension	B-DISO
.	O

The	O
severe	O
respiratory	O
involvement	O
due	O
to	O
a	O
Mycoplasma	B-DISO
pneumoniae	O
lung	B-DISO
infection	I-DISO
led	O
to	O
a	O
delay	O
in	O
diagnosing	O
GBS	B-DISO
in	O
this	O
child	O
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
liver	O
pathology	B-DISO
is	O
dependent	O
on	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphatase	O
,	O
a	O
viral	O
function	O
conserved	O
in	O
the	O
alpha	O
-	O
like	O
supergroup	O
.	O

By	O
using	O
reverse	O
genetics	O
,	O
we	O
constructed	O
a	O
recombinant	O
murine	O
coronavirus	O
MHV	O
-	O
A59	O
mutant	B-DISO
encoding	O
a	O
single	O
-	O
amino	O
-	O
acid	O
substitution	O
of	O
a	O
strictly	O
conserved	O
residue	O
that	O
is	O
essential	O
for	O
coronaviral	O
ADRP	O
activity	O
.	O

In	O
women	O
with	O
cervical	O
changes	O
,	O
by	O
application	O
of	O
hybridization	O
technique	O
in	O
situ	O
,	O
the	O
most	O
frequently	O
identified	O
virus	O
genotypes	O
are	O
human	O
papilloma	B-DISO
viruses	O
16	O
and	O
18	O
(	O
in	O
21	O
.	O
67	O
%),	O
genotypes	O
6	O
and	O
11	O
in	O
8	O
.	O
33	O
%	O
and	O
genotypes	O
31	O
,	O
33	O
and	O
35	O
in	O
3	O
.	O
33	O
%	O
examined	O
women	O
.	O

Recent	O
knowledge	O
described	O
in	O
SARS	B-DISO
infected	O
patients	O
indicates	O
that	O
induction	O
of	O
the	O
so	O
-	O
called	O
TH2	O
cytokine	O
profile	O
can	O
be	O
responsible	O
for	O
death	O
of	O
infected	O
patients	O
.	O

China	O
is	O
a	O
major	O
contributor	O
to	O
the	O
worldwide	O
infectious	B-DISO
disease	I-DISO
burden	O
because	O
of	O
its	O
population	O
size	O
.	O

Despite	O
the	O
emerging	O
nature	O
of	O
A	O
/	O
H5N1	B-DISO
,	O
there	O
is	O
limited	O
research	O
on	O
public	O
knowledge	O
and	O
perceptions	O
of	O
this	O
disease	O
.	O

ABSTRACT	O
:	O
Although	O
aspiration	B-DISO
pneumonitis	I-DISO
is	O
a	O
severe	O
complication	B-DISO
in	O
patients	O
hospitalized	O
in	O
intensive	O
care	O
units	O
,	O
its	O
pathogenesis	B-DISO
is	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
intensity	O
of	O
lung	O
injury	O
and	O
inflammation	B-DISO
developing	O
after	O
aspiration	B-DISO
during	O
mechanical	O
ventilation	O
differed	O
depending	O
on	O
the	O
inflammatory	O
activity	O
of	O
intensive	O
care	O
unit	O
patients	O
'	O
gastric	O
fluid	O
.	O

Two	O
gastric	O
juices	O
from	O
intensive	O
care	O
unit	O
patients	O
with	O
similar	O
pH	O
but	O
differing	O
for	O
their	O
in	O
vitro	O
proinflammatory	O
activity	O
(	O
high	O
and	O
low	O
)	O
were	O
further	O
instilled	O
into	O
the	O
trachea	B-DISO
of	O
ventilated	O
rabbits	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	O
disease	O
derived	O
from	O
wild	O
animals	O
and	O
is	O
highly	O
pathogenic	O
with	O
a	O
high	O
mortality	O
.	O

Asian	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
differ	O
from	O
their	O
Western	O
counterparts	O
in	O
microbiological	O
aetiology	O
,	O
in	O
particular	O
the	O
prominence	O
of	O
Gram	O
-	O
negative	O
organisms	O
,	O
Mycobacterium	O
tuberculosis	B-DISO
,	O
Burkholderia	O
pseudomallei	O
and	O
Staphylococcus	O
aureus	O
.	O

Pulmonary	B-DISO
eosinophilia	I-DISO
,	O
endemic	O
in	O
parts	O
of	O
Asia	O
,	O
could	O
occur	O
with	O
a	O
wide	O
range	O
of	O
tropical	O
infections	B-DISO
.	O

Tropical	B-DISO
eosinophilia	I-DISO
is	O
believed	O
to	O
be	O
a	O
hyper	O
-	O
sensitivity	O
reaction	O
to	O
degenerating	B-DISO
microfilariae	O
trapped	O
in	O
the	O
lungs	O
.	O

ABSTRACT	O
:	O
Tuberculosis	B-DISO
is	O
the	O
most	O
common	O
infectious	B-DISO
complication	B-DISO
in	O
HIV	B-DISO
infected	O
patients	O
.	O

The	O
patient	O
died	O
sixteen	O
hours	O
later	O
due	O
to	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Association	O
of	O
a	O
history	O
of	O
varicella	B-DISO
virus	B-DISO
infection	I-DISO
with	O
multiple	B-DISO
sclerosis	I-DISO
.	O

An	O
association	O
between	O
varicella	B-DISO
infection	I-DISO
history	O
and	O
MS	O
was	O
found	O
,	O
particularly	O
in	O
the	O
RR	O
subtype	O
.	O

We	O
used	O
the	O
consensus	O
peptide	O
-	O
binding	O
motif	O
for	O
the	O
Major	O
Histocompatibility	O
Complex	O
molecule	O
H	O
-	O
2K	O
(	O
b	O
)	O
to	O
design	O
a	O
heteroclitic	O
version	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
-	O
specific	O
subdominant	O
S598	O
determinant	O
.	O

TITLE	O
:	O
Emerging	O
and	O
zoonotic	O
infections	B-DISO
in	O
women	O
.	O

TITLE	O
:	O
Detection	O
of	O
antibodies	O
against	O
SARS	B-DISO
-	O
Coronavirus	O
using	O
recombinant	O
truncated	O
nucleocapsid	O
proteins	O
by	O
ELISA	O
.	O

The	O
recombinants	O
containing	O
N1	O
and	O
N3	O
reacted	O
with	O
convalescent	O
SARS	B-DISO
serum	O
in	O
Western	O
blotting	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
rapid	O
and	O
economical	O
method	O
for	O
the	O
expression	O
of	O
viral	O
proteins	O
in	O
high	O
yield	O
and	O
purity	O
by	O
Pichia	O
pastoris	O
,	O
the	O
S	O
protein	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
was	O
selected	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
[	O
Descending	O
necrotising	B-DISO
mediastinitis	I-DISO
:	O
report	O
of	O
two	O
cases	O
].	O

It	O
represents	O
a	O
virulent	O
form	O
of	O
mediastinal	B-DISO
infection	I-DISO
,	O
requiring	O
prompt	O
diagnosis	O
and	O
treatment	O
to	O
reduce	O
the	O
high	O
mortality	O
associated	O
.	O

Two	O
patients	O
,	O
males	O
,	O
70	O
and	O
75	O
-	O
years	O
-	O
old	O
with	O
descending	O
necrotising	B-DISO
mediastinitis	I-DISO
were	O
treated	O
in	O
our	O
Institution	O
in	O
April	O
'	O
05	O
.	O

One	O
had	O
an	O
odontogenic	O
abscess	B-DISO
and	O
the	O
other	O
had	O
a	O
retropharyngeal	B-DISO
abscess	I-DISO
.	O

Descending	O
Necrotising	B-DISO
Mediastinitis	I-DISO
cannot	O
be	O
adequately	O
treated	O
without	O
mediastinal	O
and	O
cervical	O
excision	O
of	O
necrotic	O
tissue	O
and	O
drainage	O
including	O
an	O
open	O
thoracic	B-DISO
and	O
cervical	O
approach	O
.	O

The	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
was	O
primarily	O
limited	O
to	O
hospital	O
settings	O
.	O

We	O
found	O
that	O
HeLa	O
cells	O
infected	O
with	O
229E	O
via	O
APN	O
formed	O
syncytia	O
when	O
treated	O
with	O
trypsin	O
or	O
other	O
proteases	O
but	O
not	O
in	O
a	O
low	O
-	O
pH	O
environment	O
,	O
a	O
finding	O
consistent	O
with	O
syncytium	O
formation	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
In	O
this	O
territory	O
-	O
wide	O
molecular	O
epidemiology	O
study	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
in	O
Hong	O
Kong	O
involving	O
1	O
,	O
541	O
dead	O
wild	O
birds	O
,	O
three	O
novel	O
CoVs	O
were	O
identified	O
in	O
three	O
different	O
bird	O
families	O
(	O
bulbul	O
CoV	O
HKU11	O
[	O
BuCoV	O
HKU11	O
],	O
thrush	B-DISO
CoV	O
HKU12	O
[	O
ThCoV	O
HKU12	O
],	O
and	O
munia	O
CoV	O
HKU13	O
[	O
MuCoV	O
HKU13	O
]).	O

Further	O
studies	O
would	O
be	O
important	O
to	O
delineate	O
whether	O
the	O
Asian	O
leopard	O
cat	O
CoV	O
was	O
a	O
result	O
of	O
interspecies	O
jumping	O
from	O
birds	O
,	O
a	O
situation	O
analogous	O
to	O
that	O
of	O
bat	O
and	O
civet	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoVs	O
.	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
a	O
leadership	O
training	O
program	O
for	O
public	O
health	O
emergency	B-DISO
response	O
:	O
results	O
from	O
a	O
Chinese	O
study	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
,	O
deliver	O
,	O
and	O
evaluate	O
a	O
participatory	O
leadership	O
training	O
program	O
for	O
emergency	B-DISO
response	O
.	O

Forty	O
-	O
one	O
public	O
health	O
leaders	O
(	O
N	O
=	O
41	O
)	O
from	O
five	O
provinces	O
completed	O
the	O
entire	O
emergency	B-DISO
preparedness	O
training	O
program	O
in	O
China	O
.	O

This	O
suggests	O
that	O
the	O
leadership	O
training	O
model	O
was	O
effective	O
and	O
feasible	O
in	O
improving	O
the	O
emergency	B-DISO
preparedness	O
capability	O
.	O

CONCLUSIONS	O
:	O
The	O
emergency	B-DISO
preparedness	O
training	O
program	O
met	O
its	O
aims	O
and	O
objectives	O
satisfactorily	O
,	O
and	O
improved	O
the	O
emergency	B-DISO
capability	O
of	O
public	O
health	O
leaders	O
.	O

TITLE	O
:	O
Insertion	O
of	O
the	O
CXC	O
chemokine	O
ligand	O
9	O
(	O
CXCL9	O
)	O
into	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
genome	O
results	O
in	O
protection	O
from	O
viral	O
-	O
induced	O
encephalitis	B-DISO
and	O
hepatitis	B-DISO
.	O

In	O
trachea	B-DISO
,	O
lungs	O
and	O
airsacs	O
the	O
CD4	O
+	O
and	O
CD8	O
+	O
populations	O
were	O
significantly	O
larger	O
than	O
in	O
the	O
E	O
.	O
coli	O
and	O
PBS	B-DISO
groups	O
.	O

TITLE	O
:	O
Quantification	O
of	O
mRNA	O
encoding	O
cytokines	O
and	O
chemokines	O
and	O
assessment	O
of	O
ciliary	O
function	O
in	O
canine	O
tracheal	O
epithelium	O
during	O
infection	B-DISO
with	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
).	O

ABSTRACT	O
:	O
To	O
document	O
perinatal	O
events	O
,	O
brain	O
imaging	O
,	O
neurophysiology	O
and	O
clinical	O
outcome	O
in	O
term	O
infants	O
with	O
early	O
postnatal	O
collapse	B-DISO
(	O
PNC	O
).	O

Seven	O
infants	O
became	O
severely	O
encephalopathic	O
,	O
with	O
severely	O
abnormal	O
EEG	O
/	O
aEEG	O
recorded	O
within	O
12	O
h	O
.	O
MRI	O
showed	O
acute	O
severe	O
hypoxic	B-DISO
-	O
ischaemic	O
injury	O
.	O

One	O
infant	O
showed	O
rapid	O
recovery	O
,	O
had	O
mild	O
encephalopathy	B-DISO
,	O
and	O
good	O
outcome	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
a	O
minimal	O
HR2	O
peptide	O
,	O
P6	O
of	O
23	O
-	O
mer	O
,	O
can	O
block	O
the	O
fusion	O
of	O
SARS	B-DISO
-	O
CoV	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
1	O
.	O
04	O
+/-	O
0	O
.	O
22	O
microM	O
.	O
This	O
finding	O
supports	O
the	O
structural	O
prediction	O
of	O
the	O
deep	O
groove	O
of	O
HR1	O
trimer	O
as	O
a	O
target	O
for	O
fusion	O
inhibitors	O
,	O
and	O
suggests	O
P6	O
as	O
a	O
potential	O
lead	O
peptide	O
for	O
future	O
drug	O
development	O
.	O

A	O
human	O
-	O
mouse	O
chimeric	O
antibody	O
,	O
based	O
upon	O
the	O
original	O
murine	O
mAb	O
,	O
was	O
also	O
constructed	O
and	O
shown	O
to	O
possess	B-DISO
good	O
neutralizing	O
activity	O
and	O
high	O
affinity	O
.	O

TITLE	O
:	O
Identification	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
C	O
molecule	O
as	O
an	O
attachment	O
factor	O
that	O
facilitates	O
coronavirus	O
HKU1	O
spike	O
-	O
mediated	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
HKU1	O
(	O
HCoV	O
-	O
HKU1	O
)	O
is	O
a	O
recently	O
discovered	O
human	O
coronavirus	O
associated	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
worldwide	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
C	O
molecule	O
(	O
HLA	O
-	O
C	O
)	O
as	O
an	O
attachment	O
factor	O
in	O
facilitating	O
HCoV	O
-	O
HKU1	O
spike	O
(	O
S	O
)-	O
mediated	O
infection	B-DISO
.	O

Together	O
with	O
data	O
from	O
a	O
previous	O
analysis	O
of	O
the	O
ADRP	O
domain	O
from	O
the	O
group	O
II	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
from	O
other	O
related	O
functional	O
studies	O
of	O
ADRP	O
domains	O
,	O
a	O
systematic	O
structural	O
analysis	O
of	O
the	O
coronavirus	O
ADRP	O
domains	O
was	O
realized	O
for	O
the	O
first	O
time	O
to	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
function	O
of	O
this	O
domain	O
in	O
the	O
coronavirus	O
replication	O
process	O
.	O

Recently	O
,	O
a	O
more	O
conserved	O
group	O
-	O
specific	O
open	O
reading	O
frame	O
(	O
ORF	O
),	O
the	O
3a	O
gene	O
,	O
was	O
found	O
in	O
both	O
SARS	B-DISO
-	O
CoV	O
and	O
SL	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
studied	O
the	O
immunogenicity	O
of	O
human	O
SARS	B-DISO
-	O
CoV	O
3a	O
and	O
bat	O
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccines	O
in	O
mice	O
through	O
electroporation	O
immunization	O
followed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
,	O
enzyme	O
-	O
linked	O
immunospot	O
,	O
and	O
flow	O
cytometry	O
assays	O
.	O

TITLE	O
:	O
Simple	O
tests	O
for	O
rapid	O
detection	O
of	O
canine	O
parvovirus	B-DISO
antigen	O
and	O
canine	O
parvovirus	B-DISO
-	O
specific	O
antibodies	O
.	O

ABSTRACT	O
:	O
Canine	O
parvovirus	B-DISO
(	O
CPV	O
)	O
is	O
the	O
number	O
one	O
viral	O
cause	O
of	O
enteritis	B-DISO
,	O
morbidity	O
,	O
and	O
mortality	O
in	O
8	O
-	O
week	O
-	O
old	O
young	O
puppies	O
.	O

ABSTRACT	O
:	O
Incineration	O
has	O
become	O
the	O
main	O
mechanism	O
for	O
hospital	O
waste	O
(	O
HW	O
)	O
disposal	O
in	O
China	O
after	O
the	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
Emerging	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
,	O
and	O
their	O
determinants	O
,	O
have	O
recently	O
attracted	O
substantial	O
scientific	O
and	O
popular	O
attention	O
.	O

Q7R	O
did	O
not	O
directly	O
interact	O
with	O
or	O
inactivate	O
PEDV	O
particles	O
and	O
affect	O
the	O
initial	O
stage	O
of	O
PEDV	O
infection	B-DISO
by	O
interfering	O
of	O
PEDV	O
replication	O
.	O

Moreover	O
,	O
a	O
preceding	O
infection	B-DISO
with	O
vaccine	O
or	O
virulent	O
IBV	O
does	O
not	O
seem	O
to	O
impair	O
the	O
clearance	O
of	O
E	O
.	O
coli	O
in	O
the	O
respiratory	O
tract	O
of	O
broilers	O
,	O
but	O
rather	O
induces	O
an	O
exaggerated	O
inflammatory	B-DISO
response	I-DISO
in	O
the	O
airsacs	O
only	O
,	O
which	O
seems	O
to	O
be	O
the	O
mechanism	O
behind	O
the	O
pattern	O
of	O
airsacculitis	B-DISO
in	O
commercial	O
poultry	O
in	O
the	O
field	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
which	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
is	O
a	O
highly	O
communicable	B-DISO
disease	I-DISO
with	O
the	O
lungs	O
as	O
the	O
major	O
pathological	O
target	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
insights	O
into	O
the	O
molecular	O
and	O
cellular	O
bases	O
of	O
the	O
host	O
antiviral	O
innate	O
immunity	O
within	O
the	O
lungs	O
that	O
eventually	O
lead	O
to	O
an	O
exacerbated	O
inflammatory	O
cascades	O
and	O
severe	O
tissue	O
damage	O
in	O
SARS	B-DISO
patients	O
.	O

The	O
OPHL	O
plan	B-DISO
includes	O
:	O
(	O
1	O
)	O
an	O
aggressive	B-DISO
restructuring	O
of	O
the	O
overall	O
molecular	O
microbiology	O
testing	O
capacity	O
of	O
the	O
OPHL	O
;	O
(	O
2	O
)	O
the	O
ability	O
to	O
shift	O
influenza	B-DISO
testing	O
of	O
samples	O
between	O
designated	O
OPHL	O
laboratories	O
;	O
and	O
(	O
3	O
)	O
the	O
development	O
of	O
screening	O
tools	O
for	O
pandemic	O
influenza	B-DISO
diagnostic	O
tests	O
.	O

Despite	O
limited	O
contribution	O
to	O
oxygen	O
transfer	O
it	O
may	O
allow	O
a	O
more	O
protective	O
ventilation	O
in	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

Currently	O
,	O
the	O
H5N1	B-DISO
avian	B-DISO
flu	I-DISO
virus	I-DISO
is	O
limited	O
to	O
outbreaks	O
among	O
poultry	O
and	O
persons	O
in	O
direct	O
contact	O
to	O
infected	O
poultry	O
,	O
but	O
the	O
mortality	O
rate	O
among	O
infected	O
humans	O
is	O
high	O
.	O

TITLE	O
:	O
[	O
Inhaled	O
nitric	O
oxide	O
for	O
rescue	O
treatment	O
of	O
refractory	O
hypoxemia	O
in	O
ARDS	B-DISO
patients	O
].	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
a	O
maldistribution	O
of	O
pulmonary	O
blood	O
flow	O
towards	O
non	O
-	O
ventilated	O
atelectatic	O
lung	O
areas	O
being	O
the	O
main	O
reason	O
for	O
intrapulmonary	O
right	O
-	O
to	O
-	O
left	O
shunt	O
with	O
the	O
consequence	O
of	O
severe	O
arterial	O
hypoxemia	O
.	O

Although	O
randomized	O
controlled	O
trials	O
demonstrated	O
no	O
survival	O
benefit	O
in	O
patient	O
populations	O
covering	O
the	O
entire	O
severity	O
range	O
of	O
acute	O
lung	O
injury	O
,	O
iNO	O
represents	O
a	O
feasible	O
rescue	O
treatment	O
for	O
ARDS	B-DISO
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
and	O
is	O
,	O
therefore	O
,	O
an	O
important	O
option	O
for	O
ARDS	B-DISO
therapy	O
in	O
specialized	O
centers	O
.	O

Vaccine	O
development	O
for	O
lentivirus	B-DISO
infections	I-DISO
in	O
general	O
,	O
and	O
for	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
in	O
particular	O
,	O
has	O
been	O
little	O
successful	O
.	O

Certain	O
experimental	O
lentiviral	O
vaccines	O
even	O
proved	O
to	O
be	O
counterproductive	O
:	O
they	O
rendered	O
vaccinated	O
subjects	O
more	O
susceptible	O
to	O
infection	B-DISO
rather	O
than	O
protecting	O
them	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
currently	O
known	O
mechanisms	O
of	O
vaccine	O
-	O
induced	O
enhancement	O
of	O
susceptibility	O
to	O
virus	B-DISO
infection	I-DISO
or	O
of	O
aberrant	O
viral	B-DISO
pathogenesis	I-DISO
.	O

Introduction	O
of	O
the	O
mutation	O
into	O
the	O
IBV	O
infectious	B-DISO
clone	O
system	O
showed	O
recovery	O
of	O
a	O
mutant	B-DISO
virus	O
with	O
severe	O
growth	O
defects	O
,	O
supporting	O
that	O
dimerization	O
is	O
critical	O
for	O
the	O
function	O
of	O
this	O
replicase	O
protein	O
.	O

The	O
living	O
districts	O
,	O
characterized	O
by	O
varying	O
extents	O
of	O
infection	B-DISO
,	O
had	O
stronger	O
associations	O
with	O
SWB	O
than	O
participants	O
'	O
age	O
.	O

ABSTRACT	O
:	O
Bioline	O
-	O
coated	O
polymethylpentene	O
(	O
PMP	O
)	O
membrane	O
oxygenators	O
(	O
MO	O
)	O
are	O
used	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
improve	O
gas	O
exchange	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

This	O
article	O
reviews	O
some	O
of	O
the	O
emerging	O
and	O
reemerging	O
viral	O
pathogens	O
infecting	O
solid	O
organ	O
and	O
hematopoietic	O
stem	O
-	O
cell	O
recipients	O
,	O
including	O
adenovirus	B-DISO
,	O
bocavirus	O
,	O
coronavirus	O
,	O
human	O
herpesvirus	O
-	O
6	O
,	O
lymphocytic	B-DISO
choriomeningitis	I-DISO
virus	O
,	O
measles	B-DISO
,	O
mumps	B-DISO
,	O
metapneumovirus	O
,	O
parainfluenza	B-DISO
,	O
rotavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
.	O

TITLE	O
:	O
Mortality	O
and	O
life	O
-	O
threatening	O
events	O
after	O
vertical	O
expandable	O
prosthetic	O
titanium	O
rib	O
surgery	O
in	O
children	O
with	O
hypoplastic	O
chest	O
wall	O
deformity	B-DISO
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
report	O
the	O
mortality	O
and	O
life	O
-	O
threatening	O
adverse	O
events	O
in	O
a	O
cohort	O
of	O
subjects	O
with	O
severe	O
hypoplastic	O
chest	O
wall	O
deformity	B-DISO
,	O
specifically	O
with	O
Jeune	B-DISO
syndrome	I-DISO
and	O
Jarcho	B-DISO
-	I-DISO
Levin	I-DISO
syndrome	I-DISO
,	O
after	O
treatment	O
with	O
the	O
VEPTR	O
device	O
.	O

A	O
cohort	O
of	O
43	O
patients	O
with	O
either	O
Jeune	B-DISO
syndrome	I-DISO
or	O
Jarcho	B-DISO
-	I-DISO
Levin	I-DISO
syndrome	I-DISO
was	O
extracted	O
from	O
a	O
multicenter	O
Investigational	O
Device	O
Exemption	O
study	O
of	O
214	O
patients	O
who	O
had	O
surgery	O
with	O
the	O
VEPTR	O
device	O
.	O

Of	O
the	O
43	O
patients	O
,	O
19	O
had	O
Jeune	B-DISO
syndrome	I-DISO
and	O
24	O
had	O
Jarcho	B-DISO
-	I-DISO
Levin	I-DISO
syndrome	I-DISO
.	O

Two	O
(	O
50	O
%)	O
patients	O
were	O
diagnosed	O
with	O
Jeune	B-DISO
syndrome	I-DISO
and	O
the	O
remaining	O
2	O
(	O
50	O
%)	O
with	O
Jarcho	B-DISO
-	I-DISO
Levin	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
seek	O
differentially	O
expressed	O
serum	O
proteins	O
in	O
recovered	O
SARS	B-DISO
patients	O
complicating	O
avascular	B-DISO
necrosis	I-DISO
of	I-DISO
femoral	I-DISO
head	I-DISO
(	O
AVNFH	O
).	O

2	O
-	O
DE	O
and	O
MALDI	O
-	O
TOF	B-DISO
MS	O
were	O
used	O
to	O
study	O
the	O
comparative	O
serum	O
proteomics	O
among	O
female	O
SARS	B-DISO
AVNFH	O
group	O
,	O
female	O
SARS	B-DISO
non	O
-	O
AVNFH	O
group	O
and	O
female	O
healthy	O
group	O
.	O

The	O
CCoV	O
-	O
II	O
strains	O
were	O
strictly	O
related	O
to	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
spike	O
protein	O
,	O
whereas	O
in	O
the	O
other	O
parts	O
of	O
the	O
genome	O
,	O
a	O
higher	O
genetic	O
relatedness	O
to	O
recent	O
CCoV	O
-	O
II	O
isolates	O
was	O
observed	O
.	O

Bat	O
-	O
SRBD	O
was	O
infectious	B-DISO
in	O
cell	O
culture	O
and	O
in	O
mice	O
and	O
was	O
efficiently	O
neutralized	O
by	O
antibodies	O
specific	O
for	O
both	O
bat	O
and	O
human	O
CoV	O
Spike	O
proteins	O
.	O

TITLE	O
:	O
The	O
expression	O
and	O
antigenicity	O
of	O
a	O
truncated	O
spike	O
-	O
nucleocapsid	O
fusion	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

The	O
fusion	O
protein	O
was	O
analyzed	O
for	O
reactivity	O
with	O
SARS	B-DISO
patients	O
'	O
sera	O
and	O
with	O
anti	O
-	O
sera	O
against	O
the	O
two	O
human	O
coronaviruses	O
HCoV	O
229E	O
and	O
HCoV	O
OC43	O
by	O
ELISA	O
,	O
IFA	O
and	O
immunoblot	O
assays	O
.	O

These	O
recombinant	O
fragments	O
were	O
designed	O
as	O
parts	O
of	O
two	O
different	O
structural	O
proteins	O
from	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
B	O
-	O
cell	O
activation	O
in	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
by	O
FIP	B-DISO
-	O
virus	O
-	O
induced	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
.	O

ABSTRACT	O
:	O
Bat	O
coronaviruses	O
(	O
Bt	O
-	O
CoVs	O
)	O
are	O
thought	O
to	O
be	O
the	O
precursors	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

A	O
38	O
-	O
year	O
-	O
old	O
male	O
who	O
presented	O
progressive	O
symptoms	O
of	O
dysphagia	B-DISO
,	O
dysphonia	O
and	O
weakness	B-DISO
hindering	O
movement	O
of	O
the	O
upper	O
limbs	O
.	O

Two	O
weeks	O
earlier	O
,	O
the	O
patient	O
had	O
presented	O
acute	O
self	O
-	O
limiting	O
diarrhoea	B-DISO
.	O

The	O
effects	O
of	O
the	O
compounds	O
were	O
specific	O
to	O
NS1	B-DISO
,	O
because	O
they	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
papainlike	O
protease	O
protein	O
to	O
block	O
beta	O
interferon	O
promoter	O
activation	O
.	O

TITLE	O
:	O
Characteristic	O
features	O
and	O
outcomes	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
found	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
intensive	O
care	O
unit	O
patients	O
.	O

This	O
retrospective	O
study	O
enrolled	O
all	O
patients	O
admitted	O
to	O
a	O
12	O
-	O
bed	B-DISO
SARS	B-DISO
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
in	O
a	O
tertiary	O
care	O
medical	O
center	O
in	O
Taipei	O
between	O
May	O
15	O
and	O
July	O
17	O
,	O
2003	O
.	O

TITLE	O
:	O
The	O
pediatric	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
.	O

Critically	B-DISO
ill	I-DISO
children	O
may	O
frequently	O
develop	O
multisystemic	O
manifestations	O
during	O
the	O
course	O
of	O
severe	O
infections	B-DISO
,	O
multiple	O
trauma	O
,	O
surgery	O
for	O
congenital	B-DISO
heart	I-DISO
defects	I-DISO
,	O
or	O
transplantations	O
.	O

Descriptive	O
scores	O
to	O
estimate	O
the	O
severity	O
of	O
pediatric	O
MODS	B-DISO
have	O
been	O
validated	O
.	O

As	O
the	O
method	O
is	O
based	O
on	O
the	O
common	O
presence	O
of	O
restriction	O
sites	O
,	O
it	O
results	O
in	O
the	O
generation	O
of	O
reproducible	O
,	O
species	O
-	O
specific	O
amplification	B-DISO
patterns	O
.	O

TITLE	O
:	O
Detection	O
of	O
SARS	B-DISO
coronavirus	O
in	O
humans	O
and	O
animals	O
by	O
conventional	O
and	O
quantitative	O
(	O
real	O
time	O
)	O
reverse	O
transcription	O
polymerase	O
chain	O
reactions	O
.	O

Neutralization	O
assay	O
with	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
antibody	O
revealed	O
that	O
VSV	O
-	O
SARS	B-DISO
-	O
St19	O
/	O
GFP	O
pseudotype	O
infection	B-DISO
is	O
mediated	O
by	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
.	O

Thus	O
,	O
VSV	O
pseudotyped	O
with	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
is	O
useful	O
for	O
developing	O
a	O
rapid	O
detection	O
system	O
for	O
neutralizing	O
antibody	O
specific	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
as	O
well	O
as	O
studying	O
the	O
S	O
-	O
mediated	O
cell	O
entry	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
reverse	O
genetic	O
systems	O
have	O
become	O
valuable	O
tools	O
for	O
studying	O
the	O
molecular	O
biology	O
of	O
coronavirus	B-DISO
infections	I-DISO
.	O

Additional	O
mutations	O
created	O
in	O
the	O
donor	O
RNA	O
can	O
be	O
co	O
-	O
incorporated	O
into	O
the	O
recombinant	O
virus	O
in	O
order	O
to	O
generate	O
mutant	B-DISO
viruses	O
.	O

Here	O
we	O
describe	O
detailed	O
methods	O
for	O
establishing	O
monoclonal	O
antibodies	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
hybridomas	O
produce	O
monoclonal	O
antibodies	O
that	O
recognize	O
viral	O
component	O
molecules	O
,	O
including	O
the	O
spike	O
protein	O
(	O
S	O
)	O
and	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
enabling	O
the	O
immunological	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
by	O
immunofluorescence	O
staining	O
,	O
immunoblot	O
,	O
or	O
an	O
antigen	O
-	O
capture	O
ELISA	O
system	O
.	O

These	O
proteins	O
are	O
dispensable	O
for	O
replication	O
in	O
cell	O
culture	O
,	O
but	O
are	O
thought	O
to	O
be	O
important	O
for	O
infection	B-DISO
of	O
the	O
natural	O
host	O
.	O

ABSTRACT	O
:	O
In	O
general	O
,	O
a	O
whole	O
virion	O
serves	O
as	O
a	O
simple	O
vaccine	O
antigen	O
and	O
often	O
essential	O
material	O
for	O
the	O
analysis	O
of	O
immune	O
responses	O
against	O
virus	B-DISO
infection	I-DISO
.	O

All	O
human	O
coronaviruses	O
characterized	O
at	O
present	O
are	O
associated	O
with	O
respiratory	O
illnesses	O
,	O
ranging	O
from	O
mild	O
common	B-DISO
colds	I-DISO
to	O
more	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
an	O
invariably	O
fatal	O
disease	O
of	O
cats	O
caused	O
by	O
systemic	B-DISO
infection	I-DISO
with	O
a	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
termed	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
).	O

Here	O
we	O
show	O
that	O
infection	B-DISO
of	O
primary	O
blood	O
-	O
derived	O
feline	O
mononuclear	O
cells	O
by	O
FIPV	O
WSU	O
79	O
-	O
1146	O
and	O
FIPV	O
-	O
DF2	O
leads	O
to	O
rapid	O
activation	O
of	O
the	O
p38	O
MAPK	O
pathway	O
and	O
that	O
this	O
activation	O
regulates	O
production	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
).	O

Several	O
ATCs	B-DISO
were	O
active	O
at	O
micromolar	O
concentrations	O
against	O
HIV	B-DISO
-	O
1	O
strains	O
carrying	O
the	O
RT	O
Y181C	O
mutation	O
and	O
one	O
of	O
them	O
was	O
also	O
moderately	O
active	O
against	O
the	O
K103R	O
variant	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
critical	O
syndrome	B-DISO
associated	O
with	O
respiratory	B-DISO
dysfunction	I-DISO
,	O
and	O
neutrophils	O
are	O
considered	O
to	O
be	O
central	O
to	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
glutamine	O
(	O
Gln	O
)	O
on	O
neutrophil	O
recruitment	B-DISO
in	O
a	O
model	O
of	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
ALI	O
.	O

Mice	O
were	O
killed	O
at	O
0	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
after	O
LPS	B-DISO
administration	O
(	O
n	O
=	O
10	O
/	O
group	O
).	O

Histopathological	O
findings	O
showed	O
that	O
the	O
thickening	O
of	O
alveolar	O
septal	O
space	O
was	O
extensive	O
in	O
the	O
Gln	O
group	O
24	O
h	O
and	O
2	O
wk	O
after	O
LPS	B-DISO
.	O

Severe	O
hypercapnia	B-DISO
tended	O
to	O
be	O
more	O
frequent	O
during	O
HFOV	O
among	O
patients	O
with	O
smoke	O
inhalation	O
.	O

These	O
findings	O
,	O
combined	O
with	O
the	O
difficulties	O
in	O
delivery	O
of	O
nebulized	O
medications	O
during	O
HFOV	O
suggest	O
that	O
HFOV	O
may	O
not	O
be	O
the	O
optimal	O
""""	O
rescue	O
""""	O
ventilation	O
modality	O
in	O
cases	O
of	O
ARDS	B-DISO
if	O
there	O
has	O
been	O
an	O
inhalation	O
injury	O
.	O

A	O
60	O
-	O
y	O
-	O
old	O
obese	B-DISO
man	O
,	O
with	O
a	O
diagnosis	O
of	O
esophageal	B-DISO
carcinoma	I-DISO
with	O
local	O
metastases	B-DISO
,	O
underwent	O
feeding	O
jejunostomy	O
tube	O
insertion	O
.	O

Using	O
viral	O
culture	O
,	O
57	O
specimens	O
(	O
56	O
.	O
4	O
%)	O
were	O
positive	O
without	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

The	O
overall	O
malnutrition	B-DISO
-	O
attributable	O
fraction	O
for	O
in	O
-	O
hospital	O
deaths	O
was	O
51	O
%	O
(	O
95	O
%	O
CI	O
:	O
42	O
%,	O
61	O
%)	O
with	O
midupper	O
arm	O
circumference	O
.	O

Similar	O
malnutrition	B-DISO
-	O
attributable	O
fractions	O
were	O
seen	O
for	O
the	O
major	O
causes	O
of	O
severe	O
disease	O
(	O
severe	O
malaria	B-DISO
,	O
gastroenteritis	B-DISO
,	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
HIV	B-DISO
,	O
and	O
invasive	O
bacterial	B-DISO
disease	I-DISO
).	O

ABSTRACT	O
:	O
Numerous	O
studies	O
have	O
evaluated	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
DNA	O
load	O
in	O
women	O
,	O
especially	O
HPV	O
-	O
16	O
viral	O
load	O
,	O
and	O
its	O
role	O
in	O
cervical	O
carcinogenicity	B-DISO
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
was	O
a	O
public	O
health	O
crisis	O
.	O

Classical	O
plaque	B-DISO
assays	O
cannot	O
be	O
used	O
for	O
viruses	O
that	O
do	O
not	O
cause	O
significant	O
cytopathic	B-DISO
effects	I-DISO
,	O
which	O
is	O
the	O
case	O
for	O
prototype	O
strains	O
229E	O
and	O
OC43	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
).	O
Therefore	O
,	O
an	O
alternative	O
indirect	O
immunoperoxidase	O
assay	O
(	O
IPA	O
)	O
was	O
developed	O
for	O
the	O
detection	O
and	O
titration	O
of	O
these	O
viruses	O
and	O
is	O
described	O
herein	O
.	O

TITLE	O
:	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
induces	O
acute	O
interferon	O
-	O
gamma	O
production	O
through	O
polyclonal	O
stimulation	O
of	O
chicken	O
leukocytes	O
.	O

Recently	O
,	O
our	O
laboratory	O
and	O
others	O
developed	O
a	O
recombinant	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoV	O
(	O
rMA15	O
)	O
that	O
was	O
lethal	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

This	O
risk	O
can	O
be	O
amplified	O
by	O
ecological	O
factors	O
which	O
effect	O
the	O
spread	O
of	O
these	O
pathogens	O
once	O
they	O
are	O
transferred	O
to	O
a	O
naïve	O
ecosystem	O
,	O
as	O
happened	O
with	O
West	B-DISO
Nile	I-DISO
Virus	I-DISO
(	O
WNV	B-DISO
)	O
in	O
North	O
America	O
.	O

Before	O
infection	B-DISO
with	O
MHV	O
-	O
3	O
,	O
susceptible	O
BALB	O
/	O
cJ	O
mice	O
had	O
increased	O
numbers	O
of	O
Tregs	O
and	O
expression	O
of	O
fgl2	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
and	O
FGL2	O
protein	O
compared	O
with	O
resistant	O
A	O
/	O
J	O
mice	O
.	O

In	O
an	O
earlier	O
study	O
using	O
sentinel	O
chickens	O
we	O
determined	O
the	O
incidence	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
Ontario	O
commercial	O
layer	O
flocks	O
.	O

Men	O
were	O
eligible	O
if	O
they	O
reported	O
sex	O
with	O
a	O
woman	O
within	O
the	O
past	O
year	O
,	O
no	O
history	O
of	O
genital	B-DISO
warts	I-DISO
or	O
penile	O
or	O
anal	B-DISO
cancer	I-DISO
,	O
and	O
no	O
current	O
diagnosis	O
of	O
a	O
sexually	B-DISO
transmitted	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Comprehensive	O
detection	O
of	O
causative	O
pathogens	O
using	O
real	O
-	O
time	O
PCR	O
to	O
diagnose	O
pediatric	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

A	O
57	O
-	O
year	O
-	O
old	O
female	O
patient	O
was	O
admitted	O
to	O
hospital	O
due	O
to	O
increasing	O
dyspnea	B-DISO
.	O

A	O
20	O
-	O
year	O
-	O
old	O
male	O
patient	O
presented	O
with	O
most	O
intense	O
headache	B-DISO
and	O
psychomotor	O
deceleration	O
.	O

A	O
82	O
-	O
year	O
-	O
old	O
female	O
patient	O
used	O
moxifloxacin	O
(	O
400	O
mg	O
/	O
d	O
)	O
for	O
febrile	O
bronchopulmonary	B-DISO
infection	I-DISO
for	O
one	O
week	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infections	B-DISO
in	O
poultry	O
cause	O
great	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

In	O
addition	O
,	O
it	O
was	O
shown	O
that	O
FMECs	O
are	O
susceptible	O
to	O
infection	B-DISO
with	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
feline	O
herpesvirus	O
(	O
FHV	O
-	O
1	O
),	O
feline	O
coronavirus	O
(	O
FeCoV	O
),	O
and	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
(	O
FPV	O
).	O

However	O
,	O
virus	O
replication	O
was	O
not	O
impaired	B-DISO
by	O
these	O
events	O
,	O
suggesting	O
that	O
SARS	B-DISO
-	O
CoV	O
possesses	B-DISO
a	O
mechanism	O
to	O
overcome	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF2alpha	O
on	O
viral	O
mRNA	O
translation	O
.	O

While	O
the	O
analysis	O
of	O
the	O
literature	O
,	O
through	O
limited	O
experiences	O
on	O
the	O
use	O
of	O
ECMO	O
in	O
children	O
with	O
severe	O
pertussis	B-DISO
does	O
not	O
allow	O
concluding	O
definitively	O
on	O
the	O
utility	O
of	O
ECMO	O
in	O
this	O
situation	O
,	O
the	O
contribution	O
of	O
ECMO	O
in	O
the	O
favourable	O
outcome	O
for	O
our	O
patient	O
was	O
considerable	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
proteins	O
decrease	O
levels	O
and	O
activity	O
of	O
human	O
ENaC	O
via	O
activation	O
of	O
distinct	O
PKC	B-DISO
isoforms	O
.	O

No	O
direct	O
interactions	O
among	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
with	O
either	O
alpha	O
-	O
or	O
gamma	O
-	O
ENaC	O
were	O
indentified	O
.	O

Instead	O
,	O
the	O
downregulation	O
of	O
ENaC	O
activity	O
by	O
SARS	B-DISO
proteins	O
was	O
partially	O
or	O
completely	O
restored	O
by	O
administration	O
of	O
inhibitors	O
of	O
PKCalpha	O
/	O
beta1	O
and	O
PKCzeta	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
severity	O
assessment	O
tool	O
to	O
predict	O
mortality	O
in	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
patients	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
comparing	O
its	O
performance	O
with	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
II	O
score	O
and	O
American	O
Thoracic	B-DISO
Society	O
/	O
Infectious	B-DISO
Disease	I-DISO
Society	O
of	O
America	O
(	O
ATS	B-DISO
/	O
IDSA	O
)	O
criteria	O
as	O
a	O
prognostic	O
index	O
in	O
CAP	B-DISO
patients	O
requiring	O
ICU	O
admission	O
.	O

Accordingly	O
,	O
a	O
preliminary	O
report	O
of	O
our	O
experience	O
of	O
suspected	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infections	I-DISO
in	O
children	O
was	O
published	O
without	O
microbiological	O
findings	O
.	O

Serology	O
results	O
,	O
from	O
a	O
neutralizing	O
antibody	O
assay	O
,	O
were	O
considered	O
positive	O
if	O
the	O
sera	O
inhibited	O
the	O
development	O
of	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
-	O
specific	O
cytopathic	B-DISO
effect	I-DISO
at	O
a	O
dilution	O
of	O
>	O
or	O
=	O
1	O
:	O
8	O
.	O

Neutralizing	O
antibody	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
was	O
demonstrated	O
in	O
8	O
of	O
25	O
children	O
admitted	O
with	O
suspect	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infection	I-DISO
.	O

All	O
8	O
had	O
documented	O
exposure	O
to	O
>	O
or	O
=	O
1	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
-	O
infected	O
adults	O
residing	O
in	O
the	O
same	O
household	O
.	O

This	O
study	O
identifies	O
type	O
I	O
IFN	O
-	O
mediated	O
cross	O
-	O
talk	O
between	O
plasmacytoid	O
dendritic	O
cells	O
on	O
one	O
side	O
and	O
macrophages	O
and	O
conventional	O
dendritic	O
cells	O
on	O
the	O
other	O
,	O
as	O
an	O
essential	O
cellular	O
pathway	O
for	O
the	O
control	O
of	O
fatal	O
cytopathic	O
virus	B-DISO
infection	I-DISO
.	O

Our	O
study	O
focused	O
primarily	O
on	O
the	O
coronavirus	O
prototype	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

Transmissible	O
gastroenteritis	B-DISO
coronavirion	O
tomograms	O
confirm	O
all	O
the	O
general	O
features	O
and	O
global	O
architecture	O
observed	O
for	O
MHV	O
.	O

The	O
questionnaire	O
focused	O
on	O
perceived	O
threat	O
,	O
vulnerability	O
,	O
severity	O
,	O
response	O
efficacy	O
,	O
and	O
self	O
-	O
efficacy	O
related	O
to	O
SARS	B-DISO
and	O
eight	O
other	O
diseases	O
.	O

The	O
McNemar	O
and	O
Chi	O
-	O
squared	O
test	O
,	O
standard	O
Pearson	O
correlation	O
,	O
ANOVA	O
,	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	B-DISO
),	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
ROC	O
)	O
analysis	O
were	O
used	O
to	O
calculate	O
the	O
alarm	O
temperature	O
for	O
each	O
imager	O
.	O

One	O
patient	O
with	O
coma	B-DISO
died	O
due	O
to	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
mortality	O
=	O
2	O
.	O
3	O
%).	O

ABSTRACT	O
:	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
strain	O
JHM	O
(	O
JHMV	O
)	O
develop	O
a	O
rapidly	O
fatal	O
acute	O
encephalitis	B-DISO
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
clinical	O
disease	O
in	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	B-DISO
results	O
from	O
a	O
balance	O
between	O
factors	O
critical	O
for	O
virus	O
clearance	O
,	O
such	O
as	O
virus	O
-	O
specific	O
effector	O
T	O
cells	O
and	O
anti	O
-	O
inflammatory	O
elements	O
,	O
such	O
as	O
Tregs	O
.	O

ABSTRACT	O
:	O
Gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
protection	O
against	O
lethal	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
A59	O
.	O

Extracorporeal	O
removal	O
of	O
carbon	O
dioxide	O
by	O
interventional	O
lung	O
assist	O
may	O
be	O
a	O
useful	O
tool	O
to	O
enable	O
'	O
ultraprotective	O
'	O
ventilation	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
also	O
exists	O
in	O
human	O
coronaviruses	O
(	O
CoV	O
)	O
such	O
as	O
229E	O
and	O
the	O
one	O
causing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
We	O
describe	O
an	O
evidence	O
-	O
based	O
approach	O
to	O
enhancing	O
the	O
resilience	O
of	O
healthcare	O
workers	O
in	O
preparation	O
for	O
an	O
influenza	B-DISO
pandemic	O
,	O
based	O
on	O
evidence	O
about	O
the	O
stress	O
associated	O
with	O
working	O
in	O
healthcare	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

Here	O
,	O
we	O
have	O
designed	O
and	O
produced	O
a	O
prototypic	O
SARS	B-DISO
vaccine	O
:	O
a	O
self	O
-	O
assembling	O
polypeptide	O
nanoparticle	O
that	O
repetitively	O
displays	O
a	O
SARS	B-DISO
B	O
-	O
cell	O
epitope	O
from	O
the	O
C	O
-	O
terminal	O
heptad	O
repeat	O
of	O
the	O
virus	O
'	O
spike	O
protein	O
.	O

We	O
conclude	O
that	O
these	O
peptide	O
nanoparticles	O
represent	O
a	O
promising	O
platform	O
for	O
vaccine	O
design	O
,	O
in	O
particular	O
for	O
diseases	O
that	O
are	O
characterized	O
by	O
neutralizing	O
epitopes	O
with	O
coiled	O
-	O
coil	O
conformation	O
such	O
as	O
SARS	B-DISO
-	O
CoV	O
or	O
other	O
enveloped	O
viruses	O
.	O

TITLE	O
:	O
Rate	O
of	O
concurrent	O
otitis	B-DISO
media	I-DISO
in	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
with	O
specific	O
viruses	O
.	O

ABSTRACT	O
:	O
To	O
estimate	O
the	O
coincidence	O
of	O
new	O
otitis	B-DISO
media	I-DISO
(	O
OM	O
)	O
for	O
first	O
nasopharyngeal	O
detections	O
of	O
the	O
more	O
common	O
viruses	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

New	O
OM	O
episodes	O
are	O
usually	O
coincident	O
with	O
a	O
viral	B-DISO
upper	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
vURTI	O
),	O
but	O
there	O
are	O
conflicting	O
data	O
regarding	O
the	O
association	O
between	O
specific	O
viruses	O
and	O
OM	O
.	O

In	O
addition	O
,	O
the	O
SARS	B-DISO
outbreak	O
of	O
2002	O
-	O
2003	O
focused	O
global	O
attention	O
on	O
China	O
'	O
s	O
public	O
health	O
.	O

Its	O
interactions	O
with	O
United	O
Nations	O
agencies	O
have	O
triggered	O
a	O
learning	O
process	O
for	O
China	O
to	O
securitize	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
as	O
a	O
security	O
threat	O
.	O

ABSTRACT	O
:	O
With	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
of	O
2003	O
and	O
renewed	O
attention	O
on	O
avian	B-DISO
influenza	I-DISO
viral	O
pandemics	O
,	O
new	O
surveillance	O
systems	O
are	O
needed	O
for	O
the	O
earlier	O
detection	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
nasopharyngeal	O
samples	O
,	O
although	O
whole	O
genome	O
analysis	O
was	O
not	O
available	O
because	O
the	O
majority	O
(>	O
90	O
%)	O
of	O
reads	O
were	O
host	O
genome	O
-	O
derived	O
,	O
20	O
-	O
460	O
Flu	B-DISO
-	O
reads	O
were	O
detected	O
,	O
which	O
was	O
sufficient	O
for	O
subtype	O
identification	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
major	O
pathogen	O
in	O
commercial	O
poultry	O
flocks	O
.	O

Here	O
,	O
we	O
report	O
our	O
findings	O
of	O
a	O
head	O
-	O
to	O
-	O
head	O
comparison	O
of	O
two	O
viral	O
vectors	O
modified	O
vaccinia	B-DISO
Ankara	O
(	O
MVA	O
)	O
and	O
a	O
novel	O
replication	O
-	O
competent	O
modified	O
vaccinia	B-DISO
Tian	O
Tan	O
(	O
MVTT	O
)	O
for	O
inducing	O
neutralizing	O
antibodies	O
(	O
Nabs	O
)	O
via	O
intramuscular	O
and	O
mucosal	O
vaccinations	O
in	O
mice	O
.	O

The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
used	O
as	O
the	O
test	O
antigen	O
after	O
the	O
S	O
gene	O
was	O
constructed	O
in	O
the	O
identical	O
genomic	O
location	O
of	O
two	O
vectors	O
to	O
generate	O
vaccine	O
candidates	O
MVTT	O
-	O
S	O
and	O
MVA	O
-	O
S	O
.	O
Using	O
identical	O
doses	O
,	O
MVTT	O
-	O
S	O
induced	O
lower	O
levels	O
(	O
approximately	O
2	O
-	O
3	O
-	O
fold	O
)	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
neutralizing	O
antibodies	O
(	O
Nabs	O
)	O
than	O
MVA	O
-	O
S	O
through	O
intramuscular	O
inoculation	O
.	O

Moreover	O
,	O
pre	O
-	O
exposure	O
to	O
the	O
wild	O
-	O
type	O
VTT	O
via	O
intranasal	O
or	O
intraoral	O
route	O
impaired	B-DISO
the	O
Nab	O
response	O
via	O
the	O
same	O
routes	O
of	O
MVTT	O
-	O
S	O
vaccination	O
probably	O
due	O
to	O
the	O
pre	O
-	O
existing	O
anti	O
-	O
VTT	O
Nab	O
response	O
.	O

Seven	O
samples	O
were	O
positive	O
for	O
CCoV	O
while	O
all	O
samples	O
were	O
negative	O
for	O
CRCoV	O
.	O
Sequence	O
analysis	O
of	O
five	O
CCoV	O
strains	O
showed	O
a	O
high	O
similarity	O
with	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
spike	O
protein	O
.	O

The	O
prevalence	O
of	O
elderly	O
Chinese	O
people	O
undergoing	O
influenza	B-DISO
vaccination	O
remains	O
suboptimal	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
contribute	O
to	O
the	O
morbidity	O
and	O
mortality	O
of	O
intensive	O
care	O
patients	O
worldwide	O
,	O
and	O
have	O
large	O
associated	O
human	O
and	O
financial	O
costs	O
.	O

Severe	O
respiratory	B-DISO
symptoms	I-DISO
were	O
observed	O
in	O
4	O
-	O
day	O
-	O
old	O
specific	O
pathogen	O
free	O
chicks	O
inoculated	O
with	O
a	O
4	O
/	O
91	O
genotype	O
isolate	O
,	O
either	O
JP	O
/	O
Wakayama	O
/	O
2003	O
or	O
JP	O
/	O
Iwate	O
/	O
2005	O
;	O
body	O
weights	O
3	O
wk	O
after	O
inoculation	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
chicks	O
inoculated	O
with	O
a	O
4	O
/	O
91	O
vaccine	O
strain	O
.	O

Using	O
a	O
cross	O
-	O
sectional	O
survey	O
,	O
EMTs	O
in	O
Toronto	O
,	O
Ont	O
.,	O
were	O
surveyed	O
1	O
year	O
after	O
the	O
SARS	B-DISO
outbreak	O
during	O
mandatory	O
training	O
on	O
the	O
use	O
of	O
personal	O
protective	O
equipment	O
in	O
airway	O
management	O
during	O
the	O
outbreak	O
and	O
just	O
before	O
taking	O
the	O
survey	O
.	O

ABSTRACT	O
:	O
In	O
Australia	O
,	O
currently	O
,	O
all	O
pullets	O
reared	O
for	O
egg	O
production	O
are	O
vaccinated	O
with	O
live	O
attenuated	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

However	O
,	O
there	O
was	O
visual	B-DISO
loss	I-DISO
of	O
shell	O
colour	O
in	O
the	O
unvaccinated	O
hens	O
challenged	O
with	O
the	O
Vic	O
S	O
strain	O
.	O

Infiltrating	B-DISO
neutrophils	O
are	O
considered	O
to	O
be	O
central	O
mediators	O
of	O
lung	O
injuries	O
after	O
blunt	O
trauma	O
.	O

This	O
increase	O
corresponded	O
with	O
activation	O
of	O
integrin	O
CD11b	O
mRNA	O
and	O
lung	O
inflammatory	O
chemokine	O
mRNA	O
expression	O
;	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
(	O
MIP	B-DISO
-	O
1	O
),	O
monocyte	O
chemotactic	O
peptide	O
-	O
1	O
(	O
MCP	O
-	O
1	O
),	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
(	O
CINC	O
-	O
1	O
).	O

ABSTRACT	O
:	O
The	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
ns2	B-DISO
protein	O
is	O
a	O
30	O
-	O
kDa	O
nonstructural	O
protein	O
that	O
is	O
expressed	O
from	O
a	O
subgenomic	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
virus	O
-	O
infected	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
vaccination	O
of	O
pregnant	O
heifers	O
at	O
as	O
early	O
as	O
3	O
months	O
of	O
gestation	O
(	O
6	O
months	O
before	O
calving	O
)	O
provides	O
passive	O
protection	O
in	O
neonatal	O
calves	O
against	O
colibacillosis	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
recent	O
advances	O
and	O
achievements	O
on	O
the	O
use	O
of	O
extracorporeal	O
gas	O
exchange	O
for	O
long	O
-	O
term	O
application	O
in	O
the	O
therapy	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
various	O
forms	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
most	O
important	O
results	O
regarding	O
the	O
use	O
of	O
extracorporeal	O
gas	O
exchange	O
are	O
expected	O
from	O
the	O
Conventional	O
Ventilatory	O
Support	O
vs	O
.	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
Severe	O
Adult	O
Respiratory	B-DISO
Failure	I-DISO
(	O
CESAR	O
)	O
study	O
,	O
a	O
randomized	O
clinical	O
trial	O
assessing	O
the	O
effectiveness	O
of	O
extracorporeal	O
lung	O
assist	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

Results	O
of	O
recent	O
clinical	O
trials	O
,	O
widespread	O
use	O
of	O
clinical	O
applications	O
,	O
and	O
technical	O
progress	O
are	O
leading	O
to	O
reevaluation	O
and	O
extension	O
of	O
extracorporeal	O
gas	O
exchange	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
of	O
various	O
forms	O
.	O

Preexisting	O
histological	O
patterns	O
included	O
three	O
usual	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
(	O
UIP	B-DISO
)	O
and	O
two	O
non	O
-	O
specific	O
interstitial	B-DISO
pneumonia	I-DISO
(	O
NSIP	O
).	O

ABSTRACT	O
:	O
The	O
fibroproliferative	O
phase	O
of	O
late	O
ALI	O
/	O
ARDS	B-DISO
as	O
described	O
by	O
Hudson	O
and	O
Hough	O
(	O
Clin	O
Chest	O
Med	O
27	O
:	O
671	O
-	O
677	O
,	O
2006	O
)	O
is	O
associated	O
with	O
pronounced	O
reductions	O
in	O
pulmonary	O
compliance	O
and	O
an	O
accompanying	O
hypercapnia	B-DISO
complicating	O
low	O
tidal	O
volume	O
mechanical	O
ventilation	O
.	O

Normalization	O
of	O
pCO	B-DISO
(	O
2	O
)	O
levels	O
permitted	O
significant	O
reduction	O
in	O
the	O
dosages	O
of	O
analgesics	O
and	O
sedatives	O
.	O

Elimination	O
of	O
CO	O
(	O
2	O
)	O
by	O
p	O
-	O
ECLA	O
therapy	O
allowed	O
reduction	O
of	O
ventilator	O
-	O
induced	O
shear	O
stress	O
through	O
ventilation	O
with	O
tidal	O
volumes	O
below	O
4	O
ml	O
/	O
kg	O
predicted	O
body	O
weight	O
in	O
pneumonia	B-DISO
patients	O
with	O
severely	O
impaired	B-DISO
pulmonary	O
compliance	O
during	O
late	O
-	O
phase	O
ARDS	B-DISO
.	O

p	O
-	O
ECLA	O
treatment	O
supported	O
control	O
of	O
breathing	O
pattern	O
while	O
sedation	B-DISO
requirements	O
were	O
reduced	O
and	O
facilitated	O
the	O
implementation	O
of	O
assisted	O
spontaneous	O
breathing	O
.	O

They	O
had	O
higher	O
self	O
-	O
efficacy	O
beliefs	O
regarding	O
SARS	B-DISO
and	O
avian	B-DISO
flu	I-DISO
.	O

CONCLUSIONS	O
:	O
In	O
case	O
of	O
new	O
outbreaks	O
of	O
SARS	B-DISO
/	O
avian	B-DISO
flu	I-DISO
in	O
China	O
,	O
local	O
authorities	O
in	O
the	O
UK	O
and	O
The	O
Netherlands	O
can	O
best	O
reach	O
Chinese	O
people	O
through	O
informal	O
networks	O
and	O
British	O
/	O
Dutch	O
TV	O
,	O
while	O
trying	O
to	O
improve	O
confidence	O
in	O
information	O
from	O
the	O
government	O
.	O

The	O
study	O
shed	O
light	O
on	O
how	O
two	O
European	O
populations	O
differed	O
substantially	O
regarding	O
lay	O
responses	O
to	O
SARS	B-DISO
.	O

RESULTS	O
:	O
Adjusted	O
for	O
age	O
,	O
education	O
,	O
and	O
income	O
,	O
Finns	O
were	O
more	O
likely	O
to	O
be	O
knowledgeable	O
and	O
worried	O
about	O
SARS	B-DISO
as	O
well	O
as	O
to	O
have	O
low	O
perceived	O
comparative	O
SARS	B-DISO
risk	O
and	O
poor	O
personal	O
efficacy	O
beliefs	O
about	O
preventing	O
SARS	B-DISO
.	O

The	O
names	O
of	O
avian	O
paramyxovirus	O
(	O
APMV	O
)	O
and	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
)	O
isolates	O
have	O
long	O
since	O
contained	O
this	O
information	O
;	O
I	O
suggest	O
that	O
we	O
adopt	O
a	O
similar	O
convention	O
for	O
isolates	O
of	O
avian	O
coronaviruses	O
.	O

In	O
this	O
review	O
,	O
I	O
highlight	O
some	O
recent	O
developments	O
with	O
many	O
avian	O
viruses	O
:	O
Newcastle	B-DISO
disease	I-DISO
virus	O
;	O
circoviruses	O
in	O
canary	O
and	O
pigeon	O
;	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
Gumboro	B-DISO
disease	I-DISO
virus	O
);	O
avian	O
adenoviruses	O
,	O
including	O
Angara	O
disease	O
/	O
infectious	B-DISO
hydropericardium	B-DISO
virus	O
,	O
haemorrhagic	B-DISO
enteritis	I-DISO
virus	O
of	O
turkeys	O
,	O
and	O
egg	B-DISO
drop	I-DISO
syndrome	I-DISO
virus	O
;	O
avian	O
herpesviruses	O
,	O
including	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
,	O
duck	B-DISO
plague	I-DISO
virus	O
,	O
psittacine	O
herpesvirus	O
(	O
Pacheco	O
'	O
s	O
parrot	O
disease	O
virus	O
),	O
Marek	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
virus	O
and	O
herpesvirus	O
of	O
turkeys	O
;	O
avian	B-DISO
leukosis	I-DISO
virus	O
(	O
associated	O
with	O
lymphoid	O
leukosis	O
or	O
myeloid	O
leukosis	O
,	O
and	O
egg	O
transmission	O
);	O
avian	O
pneumoviruses	O
(	O
turkey	B-DISO
rhinotracheitis	I-DISO
virus	O
);	O
avian	O
coronaviruses	O
,	O
including	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
turkey	O
coronavirus	O
and	O
pheasant	O
coronavirus	O
;	O
astrovirus	O
,	O
in	O
the	O
context	O
of	O
poult	O
enteritis	B-DISO
and	O
mortality	O
syndrome	B-DISO
,	O
and	O
avian	O
nephritis	B-DISO
virus	O
;	O
and	O
avian	B-DISO
encephalomyelitis	I-DISO
virus	O
,	O
a	O
picornavirus	O
related	O
to	O
hepatitis	B-DISO
A	I-DISO
virus	O
.	O

The	O
90	O
samples	O
were	O
cultivated	O
and	O
investigated	O
by	O
PCR	O
tests	O
targeting	O
the	O
species	O
Histophilus	O
somni	O
,	O
Mannheimia	O
haemolytica	O
,	O
Pasteurella	O
multocida	O
,	O
Mycoplasma	B-DISO
bovis	O
,	O
Mycoplasma	B-DISO
dispar	O
,	O
and	O
Mycoplasma	B-DISO
bovirhinis	O
.	O

This	O
review	O
analyzes	O
the	O
effects	O
of	O
NMBAs	O
on	O
thoracopulmonary	O
mechanics	O
,	O
gas	O
exchange	O
,	O
patient	O
outcome	O
and	O
their	O
potential	O
adverse	B-DISO
effects	I-DISO
.	O

NMBAs	O
are	O
used	O
in	O
25	O
-	O
45	O
%	O
of	O
acute	O
lung	O
injury	O
/	O
ARDS	B-DISO
patients	O
for	O
a	O
mean	O
period	O
of	O
12	O
days	O
,	O
especially	O
in	O
severe	O
ARDS	B-DISO
.	O

The	O
use	O
of	O
NMBAs	O
in	O
acute	O
lung	O
injury	O
/	O
ARDS	B-DISO
patients	O
is	O
not	O
marginal	O
.	O

Several	O
studies	O
have	O
implicated	O
that	O
APC	B-DISO
may	O
be	O
protective	O
in	O
ALI	O
.	O

Bovine	O
APC	B-DISO
(	O
25	O
microg	O
x	O
kg	O
(-	O
1	O
)	O
x	O
h	O
(-	O
1	O
))	O
was	O
intravenously	O
administered	O
.	O

In	O
addition	O
,	O
APC	B-DISO
limited	O
the	O
increase	O
in	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
both	O
in	O
plasma	O
(	O
control	O
group	O
was	O
(	O
0	O
.	O
68	O
+/-	O
0	O
.	O
12	O
)	O
ng	O
/	O
ml	O
at	O
1	O
hour	O
,	O
(	O
0	O
.	O
84	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
at	O
2	O
hours	O
,	O
(	O
0	O
.	O
87	O
+/-	O
0	O
.	O
08	O
)	O
ng	O
/	O
ml	O
at	O
4	O
hours	O
and	O
(	O
0	O
.	O
91	O
+/-	O
0	O
.	O
05	O
)	O
ng	O
/	O
ml	O
at	O
6	O
hours	O
,	O
vs	O
APC	B-DISO
group	O
(	O
0	O
.	O
42	O
+/-	O
0	O
.	O
16	O
)	O
ng	O
/	O
ml	O
at	O
1	O
hour	O
,	O
(	O
0	O
.	O
43	O
+/-	O
0	O
.	O
04	O
)	O
ng	O
/	O
ml	O
at	O
2	O
hours	O
,	O
(	O
0	O
.	O
45	O
+/-	O
0	O
.	O
09	O
)	O
ng	O
/	O
ml	O
at	O
4	O
hours	O
and	O
(	O
0	O
.	O
45	O
+/-	O
0	O
.	O
14	O
)	O
ng	O
/	O
ml	O
at	O
6	O
hours	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
at	O
6	O
hours	O
:	O
sham	O
,	O
(	O
1	O
.	O
05	O
+/-	O
0	O
.	O
05	O
)	O
ng	O
/	O
ml	O
;	O
control	O
,	O
(	O
1	O
.	O
13	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
;	O
APC	B-DISO
,	O
(	O
1	O
.	O
06	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

0	O
.	O
6	O
in	O
APC	B-DISO
group	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Of	O
1	O
,	O
091	O
patients	O
with	O
malaria	B-DISO
,	O
635	O
had	O
P	O
.	O
falciparum	B-DISO
malaria	I-DISO
and	O
456	O
had	O
P	O
.	O
vivax	B-DISO
malaria	I-DISO
.	O

TITLE	O
:	O
Establishing	O
a	O
surveillance	O
network	O
for	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
Korean	O
infants	O
and	O
young	O
children	O
.	O

ABSTRACT	O
:	O
To	O
reduce	O
morbidity	O
and	O
mortality	O
through	O
integrated	O
case	O
management	O
,	O
a	O
pilot	O
study	O
to	O
detect	O
respiratory	O
viruses	O
in	O
patients	O
with	O
acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
(	O
ALRIs	O
)	O
was	O
designed	O
as	O
part	O
of	O
a	O
nationwide	O
surveillance	O
for	O
this	O
disease	O
in	O
Korea	O
.	O

The	O
study	O
population	O
consisted	O
of	O
hospitalized	O
patients	O
under	O
the	O
age	O
of	O
5	O
years	O
with	O
bronchiolitis	B-DISO
,	O
pneumonia	B-DISO
,	O
croup	B-DISO
,	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Using	O
our	O
methods	O
to	O
detect	O
viral	O
causes	O
seemed	O
to	O
be	O
acceptable	O
for	O
the	O
national	O
surveillance	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
infants	O
and	O
children	O
.	O

TITLE	O
:	O
The	O
impact	O
of	O
social	O
amplification	B-DISO
and	O
attenuation	O
of	O
risk	O
and	O
the	O
public	O
reaction	O
to	O
mad	B-DISO
cow	I-DISO
disease	I-DISO
in	O
Canada	O
.	O

Overall	O
hospital	O
mortality	O
was	O
49	O
.	O
7	O
%	O
and	O
comorbidities	O
were	O
found	O
in	O
40	O
.	O
3	O
%	O
of	O
patients	O
,	O
the	O
most	O
common	O
of	O
which	O
was	O
haematological	B-DISO
malignancy	I-DISO
.	O

Patients	O
with	O
risk	O
factors	O
for	O
increased	O
mortality	O
should	O
be	O
carefully	O
monitored	O
and	O
aggressive	B-DISO
treatment	O
administered	O
.	O

The	O
general	O
condition	B-DISO
,	O
serum	O
total	O
bilirubin	O
,	O
albumin	O
,	O
creatinine	O
,	O
and	O
prothrombin	O
activity	O
,	O
Child	O
-	O
Turcotte	O
-	O
Pugh	O
(	O
CTP	O
)	O
score	O
,	O
and	O
model	O
for	O
end	O
-	O
stage	O
liver	B-DISO
disease	I-DISO
(	O
MELD	O
)	O
score	O
48	O
h	O
before	O
operation	O
were	O
recorded	O
.	O

The	O
operation	O
time	O
,	O
cold	B-DISO
ischemia	I-DISO
time	O
of	O
donor	O
'	O
s	O
liver	O
,	O
time	O
of	O
anhepatic	O
phase	O
,	O
ascitic	O
fluid	O
,	O
blood	B-DISO
loss	I-DISO
,	O
RBC	O
infusion	O
amount	O
,	O
crystal	O
infusion	O
,	O
and	O
total	O
infusion	O
during	O
operation	O
were	O
recorded	O
too	O
.	O

The	O
widespread	O
incorporation	O
of	O
molecular	O
methods	O
into	O
clinical	O
microbiology	O
laboratories	O
has	O
not	O
only	O
led	O
to	O
notable	O
advances	O
in	O
the	O
etiological	O
diagnosis	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
but	O
has	O
also	O
increased	O
insight	O
into	O
the	O
pathology	B-DISO
and	O
epidemiological	O
profiles	O
of	O
the	O
causative	O
viruses	O
.	O

The	O
sensitivity	O
of	O
IHC	O
in	O
detecting	O
IBV	O
antigens	O
in	O
the	O
CAM	B-DISO
of	O
inoculated	O
eggs	O
matched	O
the	O
virus	O
reisolation	O
and	O
detection	O
in	O
CEK	O
.	O

IHC	O
can	O
be	O
an	O
additional	O
useful	O
tool	O
for	O
diagnosis	O
of	O
IBV	O
infection	B-DISO
in	O
chickens	O
and	O
allows	O
further	O
studies	O
to	O
foster	O
a	O
deeper	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
infections	B-DISO
with	O
IBV	O
strains	O
of	O
different	O
virulence	O
.	O

Moreover	O
,	O
these	O
results	O
underline	O
that	O
embryonic	O
tissues	O
in	O
addition	O
to	O
CAM	B-DISO
could	O
be	O
also	O
used	O
as	O
possible	O
source	O
to	O
generate	O
IBV	O
antigens	O
for	O
diagnostic	O
purposes	O
.	O

TITLE	O
:	O
The	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
--	O
a	O
target	O
for	O
vaccine	O
and	O
therapeutic	O
development	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
composed	O
of	O
two	O
subunits	O
;	O
the	O
S1	O
subunit	O
contains	O
a	O
receptor	O
-	O
binding	O
domain	O
that	O
engages	O
with	O
the	O
host	O
cell	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
and	O
the	O
S2	O
subunit	O
mediates	O
fusion	O
between	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

A	O
case	O
of	O
nosocomial	O
acquisition	O
of	O
MRSA	B-DISO
colonization	O
or	O
infection	B-DISO
represented	O
a	O
patient	O
first	O
identified	O
as	O
colonized	O
or	O
infected	O
more	O
than	O
72	O
hours	O
after	O
admission	O
or	O
at	O
admission	O
after	O
a	O
previous	O
hospitalization	O
.	O

The	O
rate	O
of	O
nosocomial	O
acquisition	O
of	O
MRSA	B-DISO
colonization	O
or	O
infection	B-DISO
was	O
8	O
.	O
8	O
cases	O
per	O
100	O
admission	O
MRSA	B-DISO
exposure	O
-	O
days	O
for	O
the	O
period	O
before	O
SARS	B-DISO
,	O
3	O
.	O
8	O
cases	O
per	O
100	O
admission	O
MRSA	B-DISO
exposure	O
-	O
days	O
for	O
the	O
period	O
after	O
SARS	B-DISO
(	O
P	O
<.	O
001	O
for	O
before	O
SARS	B-DISO
vs	O
after	O
SARS	B-DISO
),	O
and	O
1	O
.	O
9	O
cases	O
per	O
100	O
admission	O
MRSA	B-DISO
exposure	O
-	O
days	O
for	O
the	O
period	O
after	O
education	O
(	O
P	O
=.	O
02	O
for	O
after	O
education	O
vs	O
before	O
education	O
).	O

TITLE	O
:	O
Enteral	O
omega	O
-	O
3	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
ARDS	B-DISO
,	O
an	O
overwhelming	O
inflammatory	B-DISO
response	I-DISO
damages	O
the	O
endothelial	O
-	O
alveolar	O
units	O
,	O
reducing	O
oxygen	O
diffusion	O
and	O
increasing	O
pulmonary	O
workload	O
.	O

Contemporary	O
modeling	O
tools	O
can	O
run	O
on	O
standard	O
PCs	B-DISO
,	O
with	O
short	O
processing	O
time	O
and	O
with	O
easy	O
-	O
to	O
-	O
use	O
interfaces	O
.	O

This	O
enables	O
health	O
professionals	O
without	O
modeling	O
experience	O
to	O
assess	O
consequences	O
of	O
dispersion	O
incidents	O
,	O
for	O
example	O
,	O
from	O
accidental	O
releases	O
from	O
industries	O
,	O
shedding	O
of	O
pathogens	O
from	O
infectious	B-DISO
animals	O
or	O
humans	O
,	O
as	O
well	O
as	O
intentional	O
releases	O
caused	O
by	O
terrorist	O
activity	O
.	O

The	O
genetically	O
engineered	O
attenuated	O
form	O
of	O
the	O
virus	O
or	O
viral	O
vector	O
vaccine	O
encoding	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
glycoprotein	O
has	O
been	O
shown	O
to	O
elicit	O
protective	O
immunity	O
in	O
vaccinated	O
animals	O
.	O

Within	O
20	O
h	O
,	O
she	O
deteriorated	O
and	O
progressed	O
to	O
severe	O
type	B-DISO
2	I-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Surviving	O
a	O
life	O
-	O
threatening	O
crisis	O
:	O
Taiwan	O
'	O
s	O
nurse	O
leaders	O
'	O
reflections	O
and	O
difficulties	O
fighting	O
the	O
SARS	B-DISO
epidemic	O
.	O

Data	O
were	O
then	O
analysed	O
using	O
Hobfall	O
'	O
s	O
concepts	O
of	O
conservation	O
of	O
resources	O
to	O
further	O
discuss	O
participants	O
'	O
reactions	O
and	O
actions	O
in	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
crisis	O
.	O

Five	O
stages	O
arose	O
in	O
the	O
participants	O
'	O
involvement	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
over	O
12	O
weeks	O
:	O
facing	O
shock	O
and	O
chaos	O
;	O
searching	O
for	O
reliable	O
sources	O
to	O
clarify	O
myths	O
;	O
developing	O
and	O
adjusting	O
nursing	O
care	O
;	O
supporting	O
nurses	O
and	O
their	O
clients	O
;	O
and	O
rewarding	O
nurses	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
(	O
SARS	B-DISO
CoVMpro	O
)	O
is	O
an	O
important	O
enzyme	O
for	O
the	O
replication	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
virus	O
.	O

The	O
one	O
turn	O
alpha	O
-	O
helix	O
chain	O
(	O
residues	O
47	O
-	O
54	O
)	O
of	O
the	O
SARS	B-DISO
CoVMpro	O
was	O
directly	O
involved	O
in	O
the	O
induced	O
-	O
fit	B-DISO
model	O
of	O
the	O
enzyme	O
-	O
substrate	O
complex	O
.	O

TITLE	O
:	O
Functional	O
screen	O
reveals	O
SARS	B-DISO
coronavirus	O
nonstructural	O
protein	O
nsp14	O
as	O
a	O
novel	O
cap	B-DISO
N7	O
methyltransferase	O
.	O

A	O
survey	O
using	O
a	O
self	O
-	O
administered	O
questionnaire	O
was	O
conducted	O
on	O
300	O
printing	O
company	O
workers	O
in	O
Beijing	O
,	O
China	O
,	O
which	O
was	O
under	O
mass	O
isolation	O
following	O
the	O
2003	O
SARS	B-DISO
outbreak	O
,	O
in	O
the	O
7	O
-	O
8	O
months	O
after	O
the	O
isolation	O
was	O
lifted	O
.	O

Other	O
items	O
obtained	O
were	O
gender	O
,	O
range	O
of	O
activities	O
,	O
eating	O
restrictions	O
,	O
restrictions	O
in	O
going	O
out	O
,	O
disinfection	O
of	O
clothing	O
,	O
and	O
infection	B-DISO
control	O
,	O
with	O
odds	O
ratios	O
of	O
3	O
.	O
2	O
,	O
5	O
.	O
5	O
,	O
3	O
.	O
9	O
,	O
3	O
.	O
2	O
,	O
0	O
.	O
2	O
,	O
and	O
0	O
.	O
1	O
,	O
respectively	O
,	O
and	O
the	O
contribution	O
ratio	O
was	O
87	O
.	O
7	O
%.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
major	O
target	O
in	O
the	O
development	O
of	O
diagnostic	O
assays	O
and	O
vaccines	O
,	O
but	O
its	O
antigenic	O
and	O
immunogenic	O
properties	O
remain	O
unclear	O
.	O

Seven	O
SARS	B-DISO
-	O
CoV	O
spike	O
proteins	O
(	O
S	O
,	O
SQ	O
,	O
S1	O
,	O
RBD	O
,	O
S2	O
,	O
S2Q	O
,	O
and	O
CX	O
)	O
were	O
generated	O
using	O
the	O
modified	O
vaccinia	B-DISO
virus	O
(	O
Tiantan	O
strain	O
)	O
as	O
a	O
vector	O
,	O
and	O
their	O
antigenicity	O
and	O
immunogenicity	O
were	O
evaluated	O
.	O

Here	O
we	O
investigated	O
immunocompromised	O
adults	O
with	O
suspected	O
Pneumocystis	B-DISO
jirovecii	O
pneumonia	B-DISO
(	O
PCP	B-DISO
)	O
for	O
new	O
respiratory	O
viruses	O
.	O

P	O
.	O
jirovecii	O
was	O
detected	O
in	O
26	O
/	O
128	O
,	O
bacteria	O
in	O
10	O
,	O
fungi	O
in	O
four	O
,	O
Influenza	B-DISO
A	O
in	O
two	O
patients	O
.	O

However	O
,	O
the	O
task	O
force	O
recommended	O
treatment	O
with	O
stress	O
-	O
dose	O
corticosteroids	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
who	O
respond	O
poorly	O
to	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
and	O
in	O
patients	O
with	O
early	O
ARDS	B-DISO
(<	O
14	O
days	O
after	O
onset	O
).	O

The	O
therapeutic	O
use	O
of	O
corticosteroids	O
in	O
stress	O
doses	O
reduces	O
the	O
incidence	O
of	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
)	O
after	O
intensive	O
care	O
treatment	O
.	O

Upon	O
intranasal	O
inoculation	O
,	O
virus	O
replication	O
could	O
initially	O
be	O
observed	O
in	O
the	O
nasal	O
cavity	B-DISO
and	O
the	O
cervical	O
lymph	O
nodes	O
,	O
after	O
which	O
the	O
infection	B-DISO
spread	O
to	O
the	O
brain	O
and	O
frequently	O
to	O
the	O
eyes	O
.	O

ABSTRACT	O
:	O
Several	O
countries	O
plan	B-DISO
to	O
introduce	O
non	O
-	O
contact	O
infrared	O
thermometers	O
(	O
NCIT	O
)	O
at	O
international	O
airports	O
in	O
order	O
to	O
detect	O
febrile	O
passengers	O
,	O
thus	O
to	O
delay	O
the	O
introduction	O
of	O
a	O
novel	O
influenza	B-DISO
strain	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
well	O
established	O
that	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
the	O
more	O
severe	O
presentation	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
constitute	O
complex	O
traits	O
characterized	O
by	O
a	O
multigenic	O
and	O
multifactorial	O
etiology	O
.	O

TITLE	O
:	O
Identification	O
of	O
sequence	O
changes	O
responsible	O
for	O
the	O
attenuation	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
strain	O
Arkansas	O
DPI	O
.	O

ABSTRACT	O
:	O
Use	O
of	O
inhaled	O
nitric	O
oxide	O
in	O
humans	O
with	O
traumatic	O
brain	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
twice	O
previously	O
been	O
reported	O
to	O
be	O
beneficial	O
.	O

The	O
majority	O
of	O
patients	O
had	O
residual	O
lung	O
parenchymal	O
changes	O
on	O
HRCT	O
suggestive	O
of	O
fibrosis	B-DISO
,	O
but	O
the	O
extension	O
of	O
morphologic	O
abnormalities	O
was	O
limited	O
and	O
without	O
the	O
typical	O
anterior	O
localization	O
presumed	O
to	O
indicate	O
ventilator	O
-	O
associated	O
lung	O
injury	O
.	O

CONCLUSIONS	O
:	O
The	O
majority	O
of	O
ECMO	O
-	O
treated	O
ARDS	B-DISO
patients	O
have	O
good	O
physical	O
and	O
social	O
functioning	O
.	O

The	O
presenting	O
symptoms	O
in	O
the	O
majority	O
of	O
both	O
groups	O
consisted	O
of	O
fever	O
and	O
headache	B-DISO
.	O

ABSTRACT	O
:	O
As	O
anti	O
-	O
HCV	O
aryl	O
diketoacids	O
(	O
ADK	O
)	O
are	O
good	O
metal	O
chelators	O
,	O
we	O
anticipated	O
that	O
ADKs	O
might	O
serve	O
as	O
potential	O
inhibitors	O
of	O
SARS	B-DISO
CoV	O
(	O
SCV	O
)	O
NTPase	O
/	O
helicase	O
(	O
Hel	O
)	O
by	O
mimicking	O
the	O
binding	O
modes	O
of	O
the	O
bismuth	O
complexes	O
which	O
effectively	O
competes	O
for	O
the	O
Zn	O
(	O
2	O
+)	O
ion	O
binding	O
sites	O
in	O
SCV	O
Hel	O
thereby	O
disrupting	O
and	O
inhibiting	O
both	O
the	O
NTPase	O
and	O
helicase	O
activities	O
.	O

However	O
,	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
in	O
relation	O
to	O
different	O
characteristics	O
relevant	O
to	O
age	O
remains	O
unclear	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
cytokines	O
in	O
the	O
immunopathological	O
processes	O
of	O
SARS	B-DISO
,	O
weanling	O
(	O
4	O
weeks	O
old	O
),	O
young	O
(	O
6	O
weeks	O
old	O
)	O
and	O
adult	O
(	O
10	O
weeks	O
old	O
)	O
male	O
BALB	O
/	O
C	O
mice	O
were	O
inoculated	O
intranasally	O
with	O
N	O
-	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
this	O
study	O
.	O

RESULTS	O
:	O
Histopathological	O
analysis	O
of	O
adult	O
male	O
BALB	O
/	O
C	O
mice	O
after	O
N	O
-	O
protein	O
infection	B-DISO
showed	O
progressive	O
inflammatory	O
reactions	O
,	O
especially	O
pulmonary	B-DISO
edema	I-DISO
,	O
in	O
accordance	O
with	O
a	O
moderately	O
(	O
approximately	O
13	O
%)	O
elevated	O
level	O
of	O
W	O
/	O
D	O
ratio	O
at	O
24	O
h	O
.	O
Although	O
adult	O
groups	O
underwent	O
a	O
progressive	O
lung	B-DISO
inflammation	I-DISO
in	O
the	O
acute	O
phase	O
accompanied	O
by	O
raised	O
levels	O
of	O
TNF	O
-	O
alpha	O
in	O
serum	O
,	O
no	O
significant	O
changes	O
in	O
lung	O
TNF	O
-	O
alpha	O
level	O
were	O
reported	O
simultaneously	O
.	O

HCoV	O
illnesses	O
were	O
compared	O
with	O
other	O
acute	O
respiratory	O
illnesses	O
identified	O
by	O
active	O
surveillance	O
,	O
during	O
the	O
1998	O
-	O
99	O
winter	O
respiratory	O
-	O
virus	O
season	O
,	O
of	O
2215	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
who	O
were	O
>	O
or	O
=	O
50	O
years	O
old	O
and	O
who	O
received	O
influenza	B-DISO
vaccines	O
.	O

CONCLUSIONS	O
:	O
Cocktail	O
therapy	O
seems	O
promising	O
in	O
delaying	O
the	O
disease	B-DISO
progression	I-DISO
of	O
SARS	B-DISO
-	O
associated	O
femoral	O
head	O
necrosis	O
in	O
the	O
short	O
-	O
term	O
.	O

This	O
catastrophic	O
example	O
of	O
a	O
lethal	O
outcome	O
secondary	O
to	O
failure	O
of	O
anterior	O
column	O
fixation	O
for	O
pyogenic	O
thoracic	B-DISO
spondylodiscitis	B-DISO
underlines	O
the	O
notion	O
that	O
surgical	O
strategies	O
for	O
the	O
infected	O
spine	O
must	O
be	O
aimed	O
at	O
achieving	O
absolute	O
stability	O
by	O
a	O
360	O
degrees	O
fusion	O
.	O

The	O
participants	O
were	O
127	O
healthcare	O
workers	O
who	O
had	O
taken	O
care	O
of	O
suspected	O
SARS	B-DISO
patients	O
.	O

All	O
participants	O
completed	O
the	O
Chinese	O
Health	O
Questionnaire	O
(	O
CHQ	O
),	O
Eysenck	O
Personality	B-DISO
Questionnaire	O
,	O
and	O
Parental	O
Bonding	O
Instrument	O
at	O
the	O
first	O
stage	O
and	O
the	O
CHQ	O
again	O
a	O
year	O
later	O
.	O

Additionally	O
,	O
individual	O
'	O
s	O
early	O
maternal	O
attachment	O
and	O
neuroticism	B-DISO
were	O
found	O
to	O
have	O
greater	O
effect	O
on	O
mental	O
health	O
of	O
life	O
-	O
threatening	O
stress	O
.	O

ABSTRACT	O
:	O
Interest	O
in	O
the	O
potential	O
of	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
to	O
serve	O
as	O
therapeutic	O
agents	O
has	O
surged	O
in	O
the	O
past	O
decade	O
with	O
a	O
major	O
emphasis	O
on	O
human	O
viral	B-DISO
diseases	I-DISO
.	O

There	O
has	O
been	O
much	O
attention	O
in	O
this	O
area	O
directed	O
towards	O
the	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
-	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
and	O
promising	O
research	O
developments	O
have	O
emerged	O
on	O
the	O
inhibition	O
of	O
HIV	B-DISO
-	I-DISO
1	I-DISO
infection	I-DISO
by	O
mAbs	O
and	O
the	O
identification	O
of	O
several	O
highly	O
conserved	O
neutralizing	O
epitopes	O
.	O

More	O
recently	O
,	O
potent	O
fully	O
-	O
human	O
neutralizing	O
mAbs	O
have	O
been	O
developed	O
against	O
a	O
variety	O
of	O
important	O
human	O
viral	B-DISO
disease	I-DISO
agents	O
including	O
the	O
paramyxoviruses	O
Hendra	O
virus	O
and	O
Nipah	O
virus	O
,	O
and	O
human	O
or	O
humanized	O
mAbs	O
have	O
been	O
developed	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
),	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
among	O
others	O
.	O

RESULTS	O
:	O
The	O
PPS	B-DISO
aerosol	O
particles	O
were	O
less	O
than	O
2	O
.	O
0	O
mum	O
in	O
size	O
as	O
determined	O
by	O
a	O
laser	O
aerosol	O
particle	O
counter	O
.	O

Long	O
-	O
term	O
MHV	O
-	O
infected	O
mice	O
represented	O
a	O
good	O
model	O
of	O
non	O
-	O
pathogenic	O
autoimmune	B-DISO
response	I-DISO
since	O
the	O
animals	O
were	O
apparently	O
healthy	O
in	O
spite	O
of	O
the	O
presence	O
of	O
autoAb	O
.	O

TITLE	O
:	O
Mouse	O
studies	O
of	O
SARS	B-DISO
coronavirus	O
-	O
specific	O
immune	O
responses	O
to	O
recombinant	O
replication	O
-	O
defective	O
adenovirus	B-DISO
expressing	O
SARS	B-DISO
coronavirus	O
N	O
protein	O
.	O

The	O
protease	O
inhibitor	O
Ben	B-DISO
-	O
HCl	O
effectively	O
suppresses	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
by	O
blocking	B-DISO
virus	O
entry	O
.	O

Two	O
new	O
aspects	O
of	O
the	O
interaction	O
between	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
and	O
the	O
cell	O
have	O
been	O
defined	O
.	O

The	O
RANTES	O
-	O
28	O
G	O
allele	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Early	O
induction	O
of	O
PMX	O
-	O
DHP	O
improves	O
oxygenation	O
in	O
severe	B-DISO
sepsis	I-DISO
patients	O
with	O
acute	O
lung	O
injury	O
.	O

We	O
analyzed	O
the	O
modified	O
APACHE	O
-	O
II	O
score	O
,	O
the	O
sepsis	B-DISO
-	O
related	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
mean	O
blood	O
pressure	O
(	O
mBP	O
),	O
catecholamine	O
index	O
(	O
CAI	O
),	O
P	O
/	O
F	O
ratio	O
,	O
and	O
28	O
days	O
mortality	O
before	O
and	O
after	O
PMX	O
-	O
DHP	O
treatment	O
.	O

CONCLUSIONS	O
:	O
This	O
extensive	O
evolutionary	O
analysis	O
revealed	O
the	O
stepwise	O
evolution	O
of	O
different	O
functional	O
proteins	O
of	O
SARS	B-DISO
-	O
CoVs	O
at	O
different	O
epidemic	O
stages	O
and	O
different	O
hosts	O
.	O

Higher	O
infectivity	O
values	O
were	O
obtained	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
than	O
with	O
the	O
TGEV	O
S	O
protein	O
.	O

For	O
the	O
TGEV	O
S	O
protein	O
,	O
the	O
inactivation	B-DISO
of	O
an	O
intracellular	O
retention	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
was	O
required	O
.	O

Exchange	O
of	O
the	O
membrane	O
anchor	O
of	O
the	O
S	O
proteins	O
led	O
to	O
a	O
low	O
infection	B-DISO
efficiency	O
.	O

The	O
results	O
of	O
our	O
studies	O
suggested	O
a	O
conserved	O
function	O
among	O
nsp1	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
group	O
2	O
bat	O
CoVs	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
effects	O
of	O
hemodialysis	O
on	O
the	O
injured	O
brain	O
,	O
however	O
;	O
concern	O
exists	O
over	O
the	O
use	O
of	O
intermittent	O
hemodialysis	O
in	O
patients	O
with	O
acute	O
brain	O
injury	O
(	O
ABI	O
)	O
due	O
to	O
its	O
hemodynamic	O
effects	O
and	O
increased	B-DISO
intracranial	I-DISO
pressure	I-DISO
(	O
ICP	B-DISO
)	O
associated	O
with	O
therapy	O
.	O

Furthermore	O
,	O
exacerbations	O
of	O
cerebral	B-DISO
edema	I-DISO
have	O
been	O
reported	O
.	O

CRRT	O
is	O
an	O
option	O
for	O
the	O
treatment	O
of	O
hypervolemia	B-DISO
and	O
in	O
theory	O
may	O
improve	O
intracranial	O
compliance	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
poly	O
-	O
trauma	O
patient	O
with	O
severe	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
in	O
which	O
CRRT	O
was	O
implemented	O
solely	O
for	O
refractory	O
intracranial	B-DISO
hypertension	I-DISO
.	O

TITLE	O
:	O
A	O
child	O
with	O
benign	O
acute	O
childhood	O
myositis	B-DISO
after	O
influenza	B-DISO
.	O

Little	O
is	O
written	O
in	O
the	O
Emergency	B-DISO
Medicine	O
literature	O
regarding	O
this	O
clinical	O
entity	O
.	O

Although	O
quite	O
alarming	O
and	O
potentially	O
puzzling	O
to	O
the	O
physician	O
who	O
is	O
not	O
familiar	O
with	O
BACM	O
,	O
this	O
syndrome	B-DISO
is	O
self	O
limited	O
and	O
spontaneously	O
resolves	O
with	O
no	O
specific	O
intervention	O
.	O

These	O
actions	O
may	O
have	O
contributed	O
to	O
the	O
adverse	O
impacts	O
of	O
SARS	B-DISO
on	O
the	O
communities	O
.	O

The	O
average	O
duration	O
of	O
symptoms	O
pre	O
-	O
hospitalisation	O
was	O
23	O
.	O
0	O
(+/-	O
50	O
.	O
2	O
)	O
days	O
,	O
with	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
the	O
initial	O
syndrome	B-DISO
in	O
36	O
patients	O
.	O

Dental	B-DISO
disease	I-DISO
and	O
immunodeficiency	B-DISO
were	O
the	O
main	O
risk	O
factors	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
reported	O
the	O
clinical	O
manifestation	O
and	O
pathological	O
findings	O
in	O
patients	O
with	O
hypercalcemia	B-DISO
and	O
metastatic	B-DISO
calcification	I-DISO
.	O

They	O
displayed	O
hypercalcemia	B-DISO
and	O
metastatic	B-DISO
calcification	I-DISO
in	O
the	O
kidney	O
and	O
stomach	O
.	O

One	O
case	O
with	O
transitional	B-DISO
cell	I-DISO
carcinoma	I-DISO
of	I-DISO
the	I-DISO
urinary	I-DISO
bladder	I-DISO
developed	O
acute	O
episode	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

One	O
patient	O
with	O
esophageal	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
experienced	O
an	O
acute	O
hypercalcemia	B-DISO
(	O
plasma	O
calcium	O
4	O
.	O
8	O
-	O
5	O
.	O
1	O
mM	O
)	O
accompanied	O
by	O
ARDS	B-DISO
.	O

TITLE	O
:	O
The	O
current	O
infectious	B-DISO
risks	O
of	O
transfusions	O
.	O

Currently	O
the	O
blood	O
supply	O
is	O
much	O
safer	O
because	O
of	O
very	O
sensitive	O
testing	O
for	O
HIV	B-DISO
as	O
well	O
as	O
hepatitis	B-DISO
C	I-DISO
.	O
However	O
,	O
new	O
infectious	B-DISO
agents	O
emerge	O
constantly	O
and	O
pose	O
a	O
threat	O
to	O
our	O
blood	O
supply	O
.	O

Prions	O
also	O
have	O
been	O
transmitted	B-DISO
by	O
a	O
blood	O
transfusion	O
.	O

TITLE	O
:	O
Which	O
preventive	O
measures	O
might	O
protect	O
health	O
care	O
workers	O
from	O
SARS	B-DISO
?	O

TITLE	O
:	O
Interaction	O
of	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
membrane	O
protein	O
with	O
beta	O
-	O
actin	O
and	O
its	O
implication	O
in	O
virion	O
assembly	O
and	O
budding	O
.	O

With	O
biological	O
parameters	O
for	O
SARS	B-DISO
estimated	O
from	O
the	O
initial	O
case	O
series	O
in	O
Hong	O
Kong	O
and	O
infection	B-DISO
rates	O
from	O
hospitalizations	O
in	O
Singapore	O
,	O
we	O
determined	O
Re	O
'	O
s	O
sensitivity	O
to	O
control	O
parameters	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
spike	O
is	O
highly	O
effective	O
for	O
the	O
protection	O
of	O
mice	O
in	O
the	O
murine	O
SARS	B-DISO
model	O
.	O

We	O
observed	O
a	O
strong	O
humoral	O
and	O
cell	O
-	O
mediated	O
response	O
against	O
AAV1	O
-	O
hrGFP	O
in	O
transduced	O
monkeys	O
irrespective	O
of	O
the	O
anatomic	O
location	O
of	O
the	O
infusion	O
,	O
as	O
evidenced	O
by	O
induction	O
of	O
circulating	O
anti	O
-	O
AAV1	O
and	O
anti	O
-	O
hrGFP	O
antibodies	O
,	O
as	O
well	O
as	O
infiltration	B-DISO
of	O
CD4	O
(+)	O
lymphocytes	O
and	O
upregulation	O
of	O
MHC	O
-	O
II	O
in	O
regions	O
infused	O
with	O
vector	O
.	O

ABSTRACT	O
:	O
A	O
26	O
-	O
year	O
-	O
old	O
man	O
developed	O
acute	B-DISO
disseminated	I-DISO
encephalomyelitis	I-DISO
(	O
ADEM	O
)	O
after	O
Mycoplasma	B-DISO
pneumoniae	O
infection	B-DISO
,	O
and	O
was	O
admitted	O
after	O
developing	O
disturbed	O
consciousness	O
.	O

Magnetic	O
resonance	O
images	O
revealed	O
lesions	O
in	O
the	O
midbrain	O
,	O
bilateral	O
internal	O
capsules	O
,	O
left	O
corona	O
radiata	O
,	O
white	O
matter	O
of	O
the	O
left	O
occipital	O
lobe	O
,	O
and	O
thoracic	B-DISO
spinal	O
cord	B-DISO
.	O

The	O
kinetics	O
of	O
virus	O
replication	O
and	O
the	O
inflammatory	B-DISO
responses	I-DISO
within	O
the	O
lungs	O
and	O
brains	O
,	O
as	O
well	O
as	O
the	O
clinical	O
and	O
pathological	O
outcomes	O
,	O
were	O
assessed	O
in	O
each	O
lineage	O
.	O

Consistently	O
,	O
recombinant	O
full	O
-	O
length	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
or	O
its	O
receptor	O
-	O
binding	O
domain	O
in	O
the	O
presence	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
could	O
effectively	O
induce	O
a	O
mixed	O
but	O
Th1	O
-	O
skewed	O
immune	O
response	O
in	O
immunized	O
mice	O
.	O

It	O
appears	O
that	O
rOv	O
-	O
ASP	O
-	O
1	O
primarily	O
bound	O
to	O
the	O
APCs	B-DISO
among	O
human	O
PBMCs	O
and	O
triggered	O
Th1	O
-	O
biased	O
proinflammatory	O
cytokine	O
production	O
probably	O
via	O
the	O
activation	O
of	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
and	O
the	O
TLR	O
,	O
TLR2	O
,	O
and	O
TLR4	O
,	O
thus	O
suggesting	O
that	O
rOv	O
-	O
ASP	O
-	O
1	O
is	O
a	O
novel	O
potent	O
innate	O
adjuvant	O
.	O

One	O
study	O
reported	O
higher	O
rates	O
of	O
sepsis	B-DISO
and	O
single	O
/	O
multiorgan	B-DISO
failure	I-DISO
(	O
MOF	B-DISO
),	O
and	O
another	O
study	O
revealed	O
a	O
higher	O
risk	O
of	O
nosocomial	B-DISO
infections	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
the	O
high	O
FFP	O
:	O
PRBC	O
ratio	O
group	O
.	O

TITLE	O
:	O
[	O
Prokaryotic	O
expression	O
of	O
S2	O
extracellular	O
domain	O
of	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
and	O
its	O
fusion	O
with	O
Hela	O
cell	O
membrane	O
].	O

The	O
patient	O
was	O
diagnosed	O
with	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
,	O
and	O
an	O
alternative	O
treatment	O
regimen	O
with	O
prolonged	O
administration	O
of	O
ampicillin	O
,	O
clindamycin	O
,	O
and	O
metronidazole	O
resulted	O
in	O
improvement	O
of	O
the	O
patient	O
'	O
s	O
respiratory	O
function	O
and	O
general	O
condition	B-DISO
.	O

TITLE	O
:	O
Pandemic	O
threats	O
and	O
the	O
need	O
for	O
new	O
emergency	B-DISO
public	O
health	O
legislation	O
in	O
Canada	O
.	O

Surfactant	O
inactivation	B-DISO
and	O
dysfunction	O
is	O
also	O
a	O
hallmark	O
in	O
newborns	O
with	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
),	O
for	O
which	O
a	O
beneficial	O
effect	O
of	O
exogenous	O
surfactant	O
replacement	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
is	O
predicted	O
to	O
be	O
a	O
double	O
-	O
spanning	O
membrane	O
protein	O
lacking	O
a	O
conventional	O
signal	O
peptide	O
.	O

Within	O
S	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
mediates	O
the	O
interaction	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	B-DISO
-	O
CoV	O
host	O
cell	O
receptor	O
.	O

2	O
-	O
h	O
adherent	O
BMMSCs	O
were	O
smaller	O
,	O
less	O
granular	O
,	O
possessed	B-DISO
higher	O
proliferative	B-DISO
capacity	O
and	O
expressed	O
higher	O
levels	O
of	O
several	O
stem	O
cell	O
markers	O
and	O
chemokine	O
receptors	O
than	O
9	O
-	O
day	O
cultured	O
BMMSCs	O
,	O
but	O
lower	O
type	O
I	O
procollagen	O
,	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
,	O
tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
beta	O
and	O
oncogenic	O
transcription	O
factor	O
c	O
-	O
Myc	O
,	O
suggesting	O
that	O
they	O
may	O
be	O
advantageous	O
for	O
cell	O
-	O
based	O
therapy	O
compared	O
with	O
9	O
-	O
day	O
cultured	O
BMMSCs	O
.	O

The	O
localization	O
of	O
ACE2	O
expression	O
in	O
the	O
endocrine	O
part	O
of	O
the	O
pancreas	O
suggests	O
that	O
SARS	B-DISO
coronavirus	O
enters	O
islets	O
using	O
ACE2	O
as	O
its	O
receptor	O
and	O
damages	O
islets	O
causing	O
acute	O
diabetes	B-DISO
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
Jordanian	O
chickens	O
:	O
seroprevalence	O
and	O
detection	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
frequent	O
and	O
severe	O
complication	B-DISO
after	O
trauma	O
,	O
caused	O
by	O
an	O
excessive	O
inflammatory	B-DISO
response	I-DISO
mediated	O
by	O
polymorphonuclear	O
granulocytes	O
(	O
PMNs	O
).	O

ABSTRACT	O
:	O
The	O
relative	O
contributions	O
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
and	O
IL	O
-	O
23	O
to	O
viral	B-DISO
pathogenesis	I-DISO
have	O
not	O
been	O
extensively	O
studied	O
.	O

Reduced	O
morbidity	O
in	O
infected	O
IL	O
-	O
12	O
deficient	O
mice	O
was	O
also	O
not	O
associated	O
with	O
altered	O
recruitment	B-DISO
or	O
composition	O
of	O
inflammatory	O
cells	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VA	O
-	O
ECMO	O
)	O
is	O
a	O
cardio	O
-	O
pulmonary	O
bypass	O
technique	O
to	O
provide	O
life	O
support	O
in	O
acute	O
reversible	O
cardio	B-DISO
-	I-DISO
respiratory	I-DISO
failure	I-DISO
when	O
conventional	O
management	O
is	O
not	O
successful	O
.	O

Type	O
II	O
was	O
only	O
detected	O
in	O
3	O
.	O
5	O
%	O
in	O
animals	O
with	O
Feline	B-DISO
Infectious	I-DISO
Peritonitis	I-DISO
.	O

TITLE	O
:	O
Examination	O
of	O
seroprevalence	O
of	O
coronavirus	O
HKU1	O
infection	B-DISO
with	O
S	O
protein	O
-	O
based	O
ELISA	O
and	O
neutralization	O
assay	O
against	O
viral	O
spike	O
pseudotyped	O
virus	O
.	O

These	O
observations	O
suggest	O
that	O
sustained	O
production	O
of	O
neutrophil	O
survival	O
factors	O
by	O
macrophages	O
during	O
FCoV	O
infection	B-DISO
is	O
sufficient	O
for	O
neutrophil	O
survival	O
and	O
contributes	O
to	O
development	O
of	O
granulomatous	B-DISO
lesions	I-DISO
.	O

Like	O
HIV	B-DISO
-	O
1	O
NC	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
or	O
HCoV	O
-	O
229E	O
N	O
-	O
associated	O
with	O
hA3G	O
depends	O
on	O
the	O
presence	O
of	O
RNA	O
,	O
with	O
the	O
first	O
linker	O
region	O
essential	O
for	O
hA3G	O
packaging	O
into	O
both	O
HIV	B-DISO
-	O
1	O
and	O
SARS	B-DISO
-	O
CoV	O
VLPs	O
.	O

Preliminary	O
results	O
from	O
recent	O
studies	O
suggest	O
these	O
drugs	O
up	O
-	O
regulate	O
the	O
production	O
of	O
interferons	O
(-	O
alpha	O
,	O
-	O
beta	O
,	O
and	O
-	O
gamma	O
),	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
-	O
alpha	O
)	O
but	O
downregulate	O
some	O
proinflammatory	O
cytokines	O
including	O
IL	O
-	O
2	O
and	O
IL	O
-	O
4	O
.	O

Since	O
a	O
similar	O
nsp1	O
coding	O
region	O
appears	O
in	O
all	O
characterized	O
groups	O
1	O
and	O
2	O
coronavirus	O
DI	O
RNAs	O
and	O
must	O
be	O
translated	O
in	O
cis	B-DISO
for	O
BCoV	O
DI	O
RNA	O
replication	O
,	O
we	O
hypothesized	O
that	O
nsp1	O
might	O
regulate	O
ORF	O
1	O
expression	O
by	O
binding	O
this	O
intra	O
-	O
nsp1	O
cistronic	O
element	O
.	O

ABSTRACT	O
:	O
Critical	O
Care	O
Air	O
Transport	O
Teams	O
(	O
CCATTs	O
)	O
are	O
an	O
integral	O
component	O
of	O
modern	O
casualty	O
care	O
,	O
allowing	O
early	O
transport	O
of	O
critically	B-DISO
ill	I-DISO
and	O
injured	O
patients	O
.	O

Aeromedical	O
evacuation	O
of	O
patients	O
with	O
significant	O
pulmonary	O
impairment	B-DISO
is	O
sometimes	O
beyond	O
the	O
scope	O
of	O
CCATT	O
because	O
of	O
limitations	O
of	O
the	O
transport	O
ventilator	O
and	O
potential	O
for	O
further	O
respiratory	O
deterioration	O
in	O
flight	O
.	O

Patients	O
with	O
even	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
can	O
be	O
successfully	O
transported	O
by	O
experienced	O
,	O
equipped	O
specialty	O
teams	O
.	O

Three	O
types	O
of	O
SB	O
are	O
distinguished	O
:	O
the	O
first	O
is	O
acute	O
and	O
develops	O
after	O
an	O
infectious	B-DISO
disease	I-DISO
,	O
the	O
second	O
is	O
of	O
insidious	O
evolution	O
and	O
is	O
associated	O
with	O
monoclonal	B-DISO
gammopathy	I-DISO
,	O
and	O
the	O
third	O
is	O
associated	O
with	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
.	O

Intravenous	O
immunoglobulins	O
were	O
thus	O
initiated	O
with	O
excellent	O
response	O
as	O
of	O
the	O
first	O
cycle	O
regarding	O
trunk	O
mobility	O
and	O
dysphagia	B-DISO
.	O

The	O
expression	O
of	O
this	O
genomic	O
information	O
of	O
SARS	B-DISO
-	O
CoV	O
involves	O
synthesis	O
of	O
a	O
nested	O
set	O
of	O
subgenomic	O
RNAs	O
(	O
sgRNAs	O
).	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
intimately	O
engages	O
and	O
regulates	O
the	O
host	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
during	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
neonatal	B-DISO
calf	I-DISO
diarrhoea	I-DISO
.	O

TITLE	O
:	O
[	O
A	O
discussion	O
about	O
the	O
tactics	O
of	O
mechanical	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
occurring	O
in	O
the	O
first	O
case	O
of	O
influenza	B-DISO
A	O
(	O
H5N1	B-DISO
)	O
in	O
Guizhou	O
Province	O
].	O

The	O
initial	O
symptom	B-DISO
was	O
unremitting	O
high	O
fever	O
,	O
and	O
then	O
the	O
clinical	O
situation	O
deteriorated	O
progressively	O
with	O
occurrence	O
of	O
dyspnea	B-DISO
.	O

Plant	O
-	O
derived	O
oral	O
vaccines	O
are	O
potentially	O
useful	O
in	O
combating	O
viral	B-DISO
infections	I-DISO
involving	O
mucosal	O
immunity	O
.	O

The	O
GFP	O
tag	B-DISO
enables	O
a	O
relatively	O
quick	O
confirmation	O
of	O
antigen	O
expression	O
in	O
plant	O
cells	O
by	O
fluorescent	O
microscopy	O
.	O

A	O
GBL	O
withdrawal	B-DISO
syndrome	I-DISO
was	O
diagnosed	O
.	O

TITLE	O
:	O
The	O
cat	O
with	O
neurological	O
manifestations	O
of	O
systemic	B-DISO
disease	I-DISO
.	O

When	O
using	O
the	O
incubation	O
period	O
,	O
it	O
is	O
important	O
to	O
consider	O
its	O
full	O
distribution	O
:	O
the	O
right	O
tail	O
for	O
quarantine	O
policy	O
,	O
the	O
central	O
regions	O
for	O
likely	O
times	O
and	O
sources	O
of	O
infection	B-DISO
,	O
and	O
the	O
full	O
distribution	O
for	O
models	O
used	O
in	O
pandemic	O
planning	O
.	O

TITLE	O
:	O
Viral	O
nanoparticles	O
associate	O
with	O
regions	O
of	O
inflammation	B-DISO
and	O
blood	O
brain	O
barrier	O
disruption	O
during	O
CNS	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Targeted	O
treatment	O
of	O
inflammatory	B-DISO
diseases	I-DISO
of	I-DISO
the	I-DISO
central	I-DISO
nervous	I-DISO
system	I-DISO
(	O
CNS	O
)	O
remains	O
problematic	O
due	O
to	O
the	O
complex	O
pathogenesis	B-DISO
of	O
these	O
disorders	O
and	O
difficulty	O
in	O
drug	O
delivery	O
.	O

We	O
describe	O
a	O
female	O
patient	O
with	O
secondary	O
steroid	B-DISO
-	I-DISO
resistant	I-DISO
nephrotic	I-DISO
syndrome	I-DISO
who	O
no	O
longer	O
responded	O
to	O
conventional	O
treatment	O
.	O

The	O
positive	O
rate	O
in	O
the	O
SARS	B-DISO
high	O
-	O
risk	O
population	O
was	O
0	O
.	O
61	O
%	O
tested	O
by	O
ELISA	O
and	O
0	O
.	O
21	O
%	O
by	O
IFA	O
.	O

IgG	O
antibody	O
in	O
convalescent	O
serum	O
of	O
patients	O
with	O
SARS	B-DISO
revealed	O
an	O
increasing	O
trend	O
,	O
peaking	O
at	O
the	O
22nd	O
week	O
after	O
onset	O
of	O
illness	O
followed	O
by	O
a	O
slow	O
decline	O
.	O

Surfactant	O
inactivation	B-DISO
--	O
and	O
dysfunction	O
--	O
is	O
also	O
a	O
hallmark	O
in	O
newborns	O
with	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
),	O
pneumonia	B-DISO
and	O
other	O
disorders	O
affecting	O
the	O
pulmonary	O
function	O
.	O

Newborns	O
with	O
MAS	B-DISO
will	O
definitely	O
benefit	O
from	O
a	O
reduced	O
need	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Vaccines	O
,	O
such	O
as	O
those	O
developed	O
for	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
,	O
have	O
the	O
potential	O
to	O
stimulate	O
both	O
mucosal	O
and	O
systemic	O
,	O
as	O
well	O
as	O
,	O
lactogenic	O
immunity	O
as	O
has	O
already	O
been	O
seen	O
in	O
target	O
animal	O
trials	O
.	O

SARS	B-DISO
-	O
CoV	O
encodes	O
a	O
unique	O
accessory	O
gene	O
called	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3b	O
that	O
,	O
like	O
other	O
unique	O
accessory	O
genes	O
in	O
SARS	B-DISO
-	O
CoV	O
,	O
likely	O
contributes	O
to	O
viral	O
pathogenicity	O
.	O

Tag	B-DISO
single	O
nucleotide	O
polymorphisms	O
(	O
tagSNPs	O
)	O
were	O
chosen	O
using	O
pairwise	O
tagging	O
algorithms	O
.	O

ABSTRACT	O
:	O
Injury	O
to	O
the	O
lung	O
parenchyma	O
results	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
which	O
is	O
a	O
common	O
and	O
life	O
-	O
threatening	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
mortality	O
that	O
develops	O
after	O
a	O
variety	O
of	O
insults	O
,	O
including	O
sepsis	B-DISO
,	O
multiple	O
trauma	O
,	O
pneumonia	B-DISO
,	I-DISO
aspiration	I-DISO
of	O
gastric	O
contents	O
and	O
severe	O
burns	O
.	O

We	O
performed	O
a	O
retrospective	O
cohort	O
study	O
comparing	O
a	O
population	O
of	O
patients	O
managed	O
with	O
early	O
and	O
aggressive	B-DISO
CVVH	O
compared	O
with	O
historical	O
controls	O
managed	O
conservatively	O
before	O
the	O
availability	O
of	O
CVVH	O
.	O

By	O
using	O
an	O
infectious	B-DISO
cloning	O
system	O
developed	O
recently	O
for	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
gene	O
,	O
the	O
firefly	O
luciferase	O
gene	O
and	O
several	O
host	O
and	O
viral	O
genes	O
(	O
eIF3f	O
,	O
SARS	B-DISO
ORF6	O
,	O
Dengue	B-DISO
virus	O
1	O
core	O
protein	O
gene	O
)	O
were	O
inserted	O
into	O
various	O
positions	O
of	O
the	O
IBV	O
genome	O
,	O
and	O
the	O
effects	O
on	O
gene	O
expression	O
,	O
virus	O
recovery	O
,	O
and	O
stability	O
in	O
cell	O
culture	O
were	O
studied	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
))	O
is	O
vital	O
for	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
is	O
a	O
promising	O
drug	O
target	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
terminal	O
carboxypeptidase	O
and	O
the	O
receptor	O
for	O
the	O
SARS	B-DISO
and	O
NL63	O
coronaviruses	O
(	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	O
.	O

These	O
data	O
would	O
support	O
its	O
role	O
in	O
SARS	B-DISO
-	O
CoV	O
mediated	O
membrane	O
fusion	O
and	O
suggest	O
that	O
the	O
region	O
where	O
this	O
peptide	O
resides	O
could	O
be	O
involved	O
in	O
the	O
merging	O
of	O
the	O
viral	O
and	O
target	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
Turkey	O
coronavirus	O
(	O
TCoV	O
)	O
causes	O
diarrhoea	B-DISO
in	O
young	O
turkey	O
poults	O
but	O
little	O
is	O
known	O
about	O
its	O
prevalence	O
in	O
the	O
field	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
evaluate	O
the	O
risk	O
factors	O
associated	O
with	O
both	O
infections	B-DISO
.	O

The	O
results	O
of	O
the	O
present	O
study	O
indicate	O
the	O
importance	O
of	O
PCR	O
as	O
rapid	O
,	O
effective	O
and	O
reliable	O
tool	O
for	O
screening	O
of	O
ETEC	O
and	O
Salmonella	B-DISO
spp	O
.	O

The	O
other	O
is	O
domain	O
N1b	O
,	O
which	O
corresponds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
that	O
has	O
been	O
structurally	O
characterized	O
in	O
detail	O
for	O
two	O
other	O
coronaviruses	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Infection	B-DISO
of	O
aged	O
,	O
but	O
not	O
young	O
,	O
mice	O
with	O
recombinant	O
viruses	O
bearing	O
spike	O
glycoproteins	O
derived	O
from	O
early	O
human	O
or	O
palm	O
civet	O
isolates	O
resulted	O
in	O
death	O
accompanied	O
by	O
pathological	O
changes	O
associated	O
with	O
ARDS	B-DISO
.	O

In	O
1994	O
,	O
the	O
definition	O
was	O
recommended	O
by	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
Committee	O
,	O
which	O
facilitated	O
easy	O
nomination	O
of	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
for	O
a	O
randomized	O
,	O
clinical	O
trial	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	O
SARS	B-DISO
virus	O
.	O

The	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	O
SARS	B-DISO
-	O
CoV	O
significantly	O
inhibited	O
multiplication	O
of	O
MHV	O
in	O
DBT	O
cells	O
by	O
about	O
60	O
%.	O

These	O
findings	O
indicate	O
that	O
the	O
synthetic	O
chimeric	O
DNA	O
-	O
RNA	O
ribozyme	O
could	O
provide	O
a	O
feasible	O
treatment	O
for	O
SARS	B-DISO
.	O

Effects	O
of	O
the	O
chimeric	O
ribozyme	O
on	O
expression	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
evaluated	O
in	O
cultured	O
3T3	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
contains	O
multiple	O
conformation	O
-	O
dependent	O
epitopes	O
that	O
induce	O
neutralizing	O
antibody	O
responses	O
.	O

TITLE	O
:	O
Procyanidins	O
and	O
butanol	O
extract	O
of	O
Cinnamomi	O
Cortex	O
inhibit	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
severe	B-DISO
diarrhea	I-DISO
which	O
leads	O
to	O
death	O
in	O
piglets	O
.	O

TITLE	O
:	O
Coronaviruses	O
post	O
-	O
SARS	B-DISO
:	O
update	O
on	O
replication	O
and	O
pathogenesis	B-DISO
.	O

A	O
vaccination	O
-	O
challenge	O
study	O
in	O
three	O
-	O
week	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
leghorn	O
chickens	O
demonstrated	O
that	O
a	O
commercial	O
live	O
attenuated	O
IBV	O
vaccine	O
containing	O
the	O
Massachusetts	O
strain	O
conferred	O
protection	O
against	O
challenge	O
with	O
DMV	O
/	O
5642	O
/	O
06	O
based	O
on	O
virus	O
reisolation	O
attempts	O
and	O
microscopic	O
pathology	B-DISO
.	O

179	O
.	O
0	O
mg	O
/	O
L	O
)	O
cats	O
were	O
detectable	O
,	O
suggesting	O
that	O
the	O
simple	O
infection	B-DISO
by	O
FCoVs	O
does	O
not	O
influence	O
TSA	O
levels	O
.	O

However	O
,	O
within	O
the	O
large	O
Nsp3	O
(	O
1922	O
amino	O
-	O
acid	O
residues	O
),	O
the	O
structure	O
and	O
function	O
of	O
the	O
so	O
-	O
called	O
SARS	B-DISO
-	O
unique	O
domain	O
(	O
SUD	O
)	O
have	O
remained	O
elusive	O
.	O

Sixteen	O
patients	O
with	O
SARS	B-DISO
,	O
19	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
(	O
Streptococcus	O
pneumonia	B-DISO
)	O
and	O
16	O
healthy	O
control	O
subjects	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

However	O
,	O
some	O
adverse	B-DISO
effects	I-DISO
were	O
seen	O
in	O
normal	O
mouse	O
brain	O
tissues	O
that	O
were	O
likely	O
caused	O
by	O
the	O
natural	O
murine	O
tropism	O
of	O
MHV	O
.	O

It	O
suggests	O
that	O
nonhuman	O
coronaviruses	O
may	O
be	O
attractive	O
new	O
therapeutic	O
agents	O
against	O
human	O
tumors	B-DISO
.	O

Mutagenesis	O
studies	O
of	O
these	O
residues	O
in	O
SARS	B-DISO
-	O
CoV	O
S	O
,	O
followed	O
by	O
cell	O
-	O
cell	O
fusion	O
and	O
pseudotyped	O
virion	O
infectivity	O
assays	O
,	O
showed	O
a	O
critical	O
role	O
for	O
residues	O
L803	O
,	O
L804	O
,	O
and	O
F805	O
in	O
membrane	O
fusion	O
.	O

Throughout	O
the	O
years	O
,	O
clinicians	O
have	O
considered	O
respiratory	O
syncytial	O
virus	O
followed	O
by	O
influenza	B-DISO
as	O
the	O
most	O
common	O
pathogens	O
responsible	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
28	O
-	O
year	O
-	O
old	O
primigravida	O
female	O
with	O
ARDS	B-DISO
due	O
to	O
community	O
-	O
acquired	O
severe	O
pneumonia	B-DISO
in	O
whom	O
non	O
-	O
invasive	O
ventilation	O
was	O
instituted	O
in	O
an	O
attempt	O
to	O
improve	O
oxygenation	O
and	O
avoid	O
intubation	O
.	O

ABSTRACT	O
:	O
Arbidol	O
is	O
an	O
antiviral	O
drug	O
indicated	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
all	O
types	O
of	O
influenza	B-DISO
infection	B-DISO
and	O
some	O
other	O
kinds	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
,	O
specifically	O
against	O
influenza	B-DISO
groups	O
A	O
and	O
B	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

It	O
is	O
used	O
to	O
help	O
prevent	O
influenza	B-DISO
infection	B-DISO
as	O
long	O
as	O
necessary	O
with	O
little	O
risk	O
for	O
influenza	B-DISO
mutation	O
rendering	O
it	O
less	O
effective	O
.	O

The	O
90	O
%	O
CIs	B-DISO
for	O
the	O
log	O
-	O
transformed	O
ratios	O
of	O
C	O
(	O
max	O
),	O
AUC	O
(	O
0	O
-	O
t	O
),	O
and	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
were	O
91	O
.	O
7	O
%	O
to	O
109	O
.	O
7	O
%,	O
91	O
.	O
0	O
%	O
to	O
112	O
.	O
8	O
%,	O
and	O
92	O
.	O
0	O
%	O
to	O
116	O
.	O
3	O
%,	O
respectively	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
which	O
were	O
within	O
the	O
predetermined	O
range	O
for	O
bioequivalence	O
.	O

TITLE	O
:	O
[	O
Histoplasmosis	B-DISO
].	O

People	O
acquired	O
the	O
infection	B-DISO
through	O
the	O
inhalation	O
of	O
conidial	O
forms	O
present	O
in	O
the	O
environmental	O
,	O
such	O
as	O
caves	O
dwelling	O
bats	O
and	O
soils	O
inhabited	O
by	O
chickens	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
a	O
novel	O
respiratory	O
virus	O
which	O
is	O
associated	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
.	O

Standard	O
shell	O
vial	O
culture	O
and	O
immunofluoresence	O
was	O
used	O
to	O
detect	O
the	O
common	O
respiratory	O
viruses	O
including	O
RSV	O
,	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
,	O
parainfluenza	B-DISO
viruses	O
1	O
,	O
2	O
,	O
3	O
,	O
adenovirus	B-DISO
and	O
CMV	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
HCoV	O
-	O
NL63	O
infections	B-DISO
in	O
hospitalised	O
children	O
in	O
Africa	O
.	O

ABSTRACT	O
:	O
Development	O
of	O
cancer	B-DISO
after	O
transplantation	O
has	O
rapidly	O
became	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
in	O
kidney	O
transplant	O
recipients	O
with	O
functioning	O
grafts	O
.	O

These	O
preliminary	O
data	O
demonstrated	O
a	O
high	O
incidence	O
of	O
HPV	O
infection	B-DISO
in	O
renal	O
transplant	O
recipients	O
.	O

Symptoms	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
were	O
recorded	O
and	O
nasopharyngeal	O
and	O
oropharyngeal	O
swabs	O
were	O
obtained	O
.	O

Thirty	O
-	O
four	O
CARV	O
were	O
detected	O
in	O
30	O
patients	O
(	O
7	O
.	O
7	O
%):	O
12	O
parainfluenza	B-DISO
,	O
7	O
respiratory	O
syncytial	O
virus	O
,	O
6	O
metapneumovirus	O
,	O
5	O
coronavirus	O
,	O
3	O
rhinovirus	O
,	O
and	O
1	O
influenza	B-DISO
virus	O
.	O

After	O
paramyxovirus	O
infection	B-DISO
,	O
8	O
of	O
24	O
patients	O
developed	O
new	O
-	O
onset	O
BOS	B-DISO
,	O
whereas	O
no	O
case	O
was	O
recorded	O
after	O
rhinovirus	O
and	O
coronavirus	B-DISO
infection	I-DISO
.	O

Failing	O
to	O
account	O
for	O
dynamic	O
molecular	O
evolution	O
can	O
affect	O
greatly	O
estimating	O
index	O
case	O
dates	O
,	O
resulting	O
in	O
an	O
overestimated	O
age	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
human	O
infection	B-DISO
,	O
for	O
instance	O
.	O

Infection	B-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
can	O
cause	O
disease	O
and	O
mortality	O
in	O
cats	O
and	O
is	O
mostly	O
subclinical	O
in	O
dogs	O
.	O

Lung	B-DISO
metastases	I-DISO
and	O
tuberculosis	B-DISO
were	O
excluded	O
and	O
fungal	B-DISO
infection	I-DISO
suspected	O
.	O

Fungal	B-DISO
infection	I-DISO
should	O
always	O
be	O
considered	O
in	O
immunocompromised	O
patients	O
with	O
clinical	O
signs	O
of	O
systemic	B-DISO
infection	I-DISO
.	O

Inflammatory	O
damage	O
and	O
fibrosis	B-DISO
were	O
evaluated	O
,	O
and	O
the	O
molecular	O
mechanism	O
was	O
analyzed	O
according	O
to	O
Th1	O
/	O
Th2	O
balance	O
,	O
Sma	B-DISO
-	O
and	O
MAD	O
-	O
related	O
proteins	O
(	O
Smads	O
)	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcriptions	O
(	O
STATs	O
)	O
expression	O
.	O

The	O
investigation	O
was	O
not	O
only	O
performed	O
to	O
establish	O
a	O
new	O
rapid	O
pulmonary	B-DISO
fibrosis	I-DISO
model	O
,	O
but	O
also	O
to	O
provide	O
the	O
elicitation	O
for	O
mechanism	O
of	O
ALI	O
changed	O
into	O
the	O
rapid	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

Nevertheless	O
,	O
patient	O
became	O
comatose	B-DISO
with	O
severe	O
muscle	B-DISO
stiffness	I-DISO
,	O
persistent	O
shock	O
,	O
coagulation	O
problems	O
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
hyperkalemia	O
and	O
died	O
less	O
than	O
24	O
hours	O
later	O
.	O

These	O
findings	O
illustrate	O
the	O
complexities	O
of	O
OPC	O
transplantation	O
into	O
areas	O
of	O
robust	O
immune	O
-	O
mediated	O
pathology	B-DISO
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	B-DISO
infection	I-DISO
is	O
ubiquitous	O
in	O
domestic	O
cats	O
,	O
and	O
is	O
particularly	O
common	O
where	O
conditions	O
are	O
crowded	O
.	O

The	O
'	O
wet	O
'	O
or	O
effusive	O
form	O
,	O
characterised	O
by	O
polyserositis	B-DISO
(	O
abdominal	O
and	O
/	O
or	O
thoracic	B-DISO
effusion	B-DISO
)	O
and	O
vasculitis	B-DISO
,	O
and	O
the	O
'	O
dry	O
'	O
or	O
non	O
-	O
effusive	O
form	O
(	O
pyogranulomatous	O
lesions	O
in	O
organs	O
)	O
reflect	O
clinical	O
extremes	O
of	O
a	O
continuum	O
.	O

TITLE	O
:	O
Effect	O
of	O
Polyprenyl	O
Immunostimulant	O
on	O
the	O
survival	O
times	O
of	O
three	O
cats	O
with	O
the	O
dry	O
form	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
considered	O
a	O
fatal	O
disease	O
.	O

Three	O
cats	O
with	O
dry	O
form	O
FIP	B-DISO
were	O
treated	O
with	O
Polyprenyl	O
Immunostimulant	O
.	O

TITLE	O
:	O
Emerging	O
infections	B-DISO
:	O
a	O
tribute	O
to	O
the	O
one	O
medicine	O
,	O
one	O
health	O
concept	O
.	O

ABSTRACT	O
:	O
The	O
number	O
of	O
scarlet	B-DISO
fever	I-DISO
occurrences	O
reported	O
between	O
2000	O
and	O
2006	O
fluctuated	O
considerably	O
in	O
central	O
Taiwan	O
and	O
throughout	O
the	O
nation	O
.	O

CONCLUSIONS	O
:	O
The	O
occurrences	O
of	O
scarlet	B-DISO
fever	I-DISO
in	O
central	O
Taiwan	O
in	O
2000	O
-	O
2006	O
were	O
primarily	O
caused	O
by	O
five	O
emm	O
types	O
,	O
which	O
accounted	O
for	O
96	O
.	O
8	O
%	O
of	O
the	O
isolates	O
collected	O
.	O

TITLE	O
:	O
[	O
Analysis	O
of	O
treatments	O
and	O
deceased	O
cases	O
of	O
severe	O
adverse	O
drug	O
reactions	O
--	O
analysis	O
of	O
46	O
cases	O
of	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
and	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
].	O

TITLE	O
:	O
Sivelestat	O
(	O
selective	O
neutrophil	O
elastase	O
inhibitor	O
)	O
improves	O
the	O
mortality	O
rate	O
of	O
sepsis	B-DISO
associated	O
with	O
both	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
patients	O
.	O

TITLE	O
:	O
Synthetic	O
peptides	O
coupled	O
to	O
the	O
surface	O
of	O
liposomes	O
effectively	O
induce	O
SARS	B-DISO
coronavirus	O
-	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
and	O
viral	O
clearance	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
mice	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
whether	O
the	O
surface	O
-	O
linked	O
liposomal	O
peptide	O
was	O
applicable	O
to	O
a	O
vaccine	O
based	O
on	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Coronavirus	O
immunoreactivity	O
in	O
individuals	O
with	O
a	O
recent	O
onset	O
of	O
psychotic	B-DISO
symptoms	I-DISO
.	O

Doxycycline	O
reduced	O
PMN	O
migration	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
therefore	O
might	O
represent	O
a	O
novel	O
strategy	O
for	O
the	O
prevention	O
of	O
secondary	O
pulmonary	B-DISO
complications	I-DISO
in	O
acute	B-DISO
pancreatitis	I-DISO
.	O

TITLE	O
:	O
Recombinant	O
S	O
-	O
layer	O
proteins	O
of	O
Lactobacillus	O
brevis	O
mediating	O
antibody	O
adhesion	B-DISO
to	O
calf	O
intestine	O
alleviated	O
neonatal	B-DISO
diarrhea	I-DISO
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
This	O
document	O
summarizes	O
the	O
limited	O
experience	O
of	O
SARS	B-DISO
in	O
pregnancy	O
and	O
suggests	O
guidelines	O
for	O
management	O
.	O

Upon	O
arrival	O
in	O
the	O
labour	O
triage	O
unit	O
,	O
pregnant	O
patients	O
with	O
suspected	O
and	O
probable	O
SARS	B-DISO
should	O
be	O
placed	O
in	O
a	O
negative	O
pressure	O
isolation	O
room	O
with	O
at	O
least	O
6	O
air	O
exchanges	O
per	O
hour	O
.	O

All	O
labour	O
and	O
delivery	O
units	O
caring	O
for	O
suspected	O
and	O
probable	O
SARS	B-DISO
should	O
have	O
available	O
at	O
least	O
one	O
room	O
in	O
which	O
patients	O
can	O
safely	O
labour	O
and	O
deliver	O
while	O
in	O
need	O
of	O
airborne	O
isolation	O
.	O

If	O
possible	O
,	O
labour	O
and	O
delivery	O
(	O
including	O
operative	O
delivery	O
or	O
Caesarean	O
section	O
)	O
should	O
be	O
managed	O
in	O
a	O
designated	O
negative	O
pressure	O
isolation	O
room	O
,	O
by	O
designated	O
personnel	O
with	O
specialized	O
infection	B-DISO
control	O
preparation	O
and	O
protective	O
gear	O
.	O

Staff	O
caring	O
for	O
pregnant	O
SARS	B-DISO
patients	O
should	O
be	O
actively	O
monitored	O
for	O
fever	O
and	O
other	O
symptoms	O
of	O
SARS	B-DISO
.	O

Therefore	O
,	O
massive	O
hemoptysis	B-DISO
should	O
be	O
considered	O
as	O
a	O
possible	O
presenting	O
symptom	B-DISO
of	O
pheochromocytoma	B-DISO
,	O
especially	O
in	O
patients	O
with	O
severe	O
paroxysmal	B-DISO
hypertension	I-DISO
.	O

A	O
double	O
antibody	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
DAS	O
-	O
ELISA	O
)	O
based	O
on	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
was	O
developed	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
).	O

The	O
complications	O
in	O
P	O
.	O
vivax	O
were	O
thrombocytopenia	O
,	O
biochemical	O
evidence	O
of	O
hepatic	B-DISO
dysfunction	I-DISO
,	O
renal	O
damage	O
,	O
positive	O
DCT	O
and	O
death	O
due	O
to	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Until	O
recently	O
,	O
human	O
coronaviruses	O
(	O
HCoVs	O
),	O
such	O
as	O
HCoV	O
strain	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
),	O
were	O
mainly	O
known	O
to	O
cause	O
15	O
to	O
30	O
%	O
of	O
mild	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

Our	O
results	O
show	O
that	O
chloroquine	O
can	O
be	O
highly	O
effective	O
against	O
HCoV	O
-	O
OC43	O
infection	B-DISO
in	O
newborn	O
mice	O
and	O
may	O
be	O
considered	O
as	O
a	O
future	O
drug	O
against	O
HCoVs	O
.	O

ABSTRACT	O
:	O
To	O
give	O
an	O
overview	O
of	O
the	O
recent	O
history	O
of	O
publications	O
on	O
mathematical	O
modelling	O
of	O
infectious	B-DISO
diseases	I-DISO
in	O
the	O
Chinese	O
literature	O
,	O
and	O
a	O
more	O
detailed	O
review	O
of	O
the	O
models	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

This	O
increase	O
not	O
only	O
included	O
papers	O
on	O
SARS	B-DISO
,	O
but	O
also	O
on	O
various	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
indicating	O
a	O
substantial	O
expansion	O
of	O
modelling	O
experience	O
in	O
China	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
spatiotemporal	O
diffusion	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
in	O
mainland	O
China	O
,	O
and	O
to	O
analyse	O
the	O
spatial	O
pattern	O
of	O
SARS	B-DISO
transmission	O
from	O
the	O
Beijing	O
epicentre	O
to	O
its	O
neighbouring	O
areas	O
.	O

TITLE	O
:	O
Duration	O
of	O
symptom	B-DISO
onset	O
to	O
hospital	O
admission	O
and	O
admission	O
to	O
discharge	O
or	O
death	O
in	O
SARS	B-DISO
in	O
mainland	O
China	O
:	O
a	O
descriptive	O
study	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
relationship	O
between	O
avascular	O
osteonecrosis	B-DISO
(	O
AVN	O
)	O
and	O
corticosteroid	O
treatment	O
given	O
to	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Because	O
of	O
their	O
deteriorated	O
health	O
status	O
and	O
apparent	O
complications	O
,	O
SARS	B-DISO
patients	O
aged	O
>	O
60	O
years	O
had	O
a	O
much	O
higher	O
risk	O
of	O
dying	O
than	O
younger	O
patients	O
.	O

The	O
significance	O
of	O
timely	O
information	O
was	O
perhaps	O
the	O
main	O
lesson	O
which	O
the	O
SARS	B-DISO
epidemic	O
taught	O
.	O

The	O
resulting	O
database	O
contains	O
a	O
total	O
of	O
5327	O
probable	O
SARS	B-DISO
cases	O
,	O
of	O
whom	O
343	O
died	O
,	O
giving	O
a	O
case	O
fatality	O
ratio	O
(	O
CFR	O
)	O
of	O
6	O
.	O
4	O
%.	O

When	O
compared	O
with	O
Hong	O
Kong	O
Special	O
Administrative	O
Region	O
of	O
China	O
,	O
China	O
Taiwan	O
,	O
and	O
Singapore	O
,	O
the	O
SARS	B-DISO
epidemic	O
in	O
mainland	O
China	O
resulted	O
in	O
a	O
considerably	O
lower	O
CFR	O
,	O
involved	O
relatively	O
younger	O
cases	O
and	O
included	O
fewer	O
health	O
care	O
workers	O
.	O

When	O
compared	O
with	O
Hong	O
Kong	O
Special	O
Administrative	O
Region	O
of	O
China	O
,	O
China	O
Taiwan	O
,	O
and	O
Singapore	O
,	O
the	O
SARS	B-DISO
epidemic	O
in	O
mainland	O
China	O
resulted	O
in	O
a	O
considerably	O
lower	O
CFR	O
,	O
involved	O
relatively	O
younger	O
cases	O
and	O
included	O
fewer	O
health	O
care	O
workers	O
.	O

Diagnostic	O
assays	O
are	O
required	O
to	O
detect	O
novel	O
influenza	B-DISO
strains	O
with	O
pandemic	O
potential	O
.	O

TITLE	O
:	O
Altered	O
pathogenicity	O
,	O
immunogenicity	O
,	O
tissue	O
tropism	O
and	O
3	O
'-	O
7kb	O
region	O
sequence	O
of	O
an	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
coronavirus	O
strain	O
after	O
serial	O
passage	O
in	O
embryos	O
.	O

Our	O
results	O
demonstrated	O
that	O
low	O
levels	O
of	O
specific	O
memory	O
T	O
cell	O
responses	O
to	O
SARS	B-DISO
-	O
CoV	O
S	O
,	O
M	O
,	O
E	O
and	O
N	O
peptides	O
were	O
detected	O
in	O
a	O
proportion	O
of	O
SARS	B-DISO
-	O
recovered	O
patients	O
,	O
and	O
IFN	O
-	O
gamma	O
was	O
the	O
predominant	O
cytokine	O
produced	O
by	O
T	O
cells	O
after	O
stimulation	O
with	O
peptides	O
.	O

TITLE	O
:	O
[	O
Prevention	O
and	O
control	O
of	O
infectious	B-DISO
diseases	I-DISO
with	O
pandemic	O
potential	O
:	O
the	O
EU	O
-	O
project	O
SARSControl	O
].	O

""""	O
SARSControl	O
""""	O
is	O
a	O
three	O
-	O
year	O
project	O
funded	O
by	O
the	O
European	O
Commission	O
with	O
the	O
objective	O
to	O
aid	O
European	O
member	O
states	O
in	O
the	O
public	O
health	O
management	O
of	O
new	O
emerging	O
infections	B-DISO
.	O

A	O
lack	O
of	O
knowledge	O
and	O
delayed	O
international	O
communication	O
resulted	O
in	O
the	O
rapid	O
spread	O
of	O
SARS	B-DISO
,	O
highlighting	O
the	O
importance	O
of	O
a	O
global	O
system	O
for	O
rapid	O
and	O
transparent	O
information	O
transfer	O
.	O

TITLE	O
:	O
Management	O
of	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
children	O
.	O

Among	O
the	O
examined	O
series	O
,	O
the	O
most	O
cytotoxic	O
derivatives	O
(	O
11	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
18	O
,	O
19	O
,	O
20	O
,	O
21	O
,	O
23	O
,	O
25	O
-	O
30	O
)	O
against	O
mock	O
-	O
infected	O
MT	O
-	O
4	O
cells	O
(	O
CC50	O
<	O
8	O
.	O
0	O
microM	O
)	O
were	O
evaluated	O
against	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
derived	O
from	O
haematological	O
and	O
solid	O
tumours	B-DISO
,	O
using	O
6	O
-	O
mercaptopurine	O
(	O
6	O
-	O
MP	O
)	O
and	O
etoposide	O
as	O
reference	O
drugs	O
.	O

The	O
membrane	O
topology	O
of	O
SARS	B-DISO
-	O
CoV	O
M	O
and	O
the	O
functional	O
significance	O
of	O
its	O
N	O
-	O
glycosylation	O
are	O
not	O
completely	O
understood	O
as	O
is	O
its	O
interaction	O
with	O
the	O
surface	O
glycoprotein	O
S	O
.	O
Using	O
biochemical	O
and	O
immunofluorescence	O
analyses	O
we	O
found	O
that	O
M	O
consists	O
of	O
a	O
short	O
glycosylated	O
N	O
-	O
terminal	O
ectodomain	O
,	O
three	O
transmembrane	O
segments	O
and	O
a	O
long	O
,	O
immunogenic	O
C	O
-	O
terminal	O
endodomain	O
.	O

TITLE	O
:	O
SARS	B-DISO
vaccines	O
:	O
where	O
are	O
we	O
?	O

The	O
estimated	O
incidence	O
of	O
MRSA	B-DISO
CAP	B-DISO
is	O
0	O
.	O
51	O
-	O
0	O
.	O
64	O
cases	O
per	O
100	O
,	O
000	O
.	O

TITLE	O
:	O
[	O
Effect	O
on	O
mRNA	O
and	O
secretion	O
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
DC	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
N	O
gene	O
recombinant	O
adenovirus	B-DISO
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
exact	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
at	O
the	O
protein	O
level	O
.	O

After	O
the	O
SARS	B-DISO
epidemic	O
,	O
up	O
to	O
December	O
2008	O
,	O
there	O
was	O
an	O
addition	O
of	O
16	O
coronaviruses	O
with	O
complete	O
genomes	O
sequenced	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
remain	O
leading	O
factors	O
for	O
morbidity	O
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Childhood	B-DISO
asthma	I-DISO
in	O
the	O
Caribbean	O
is	O
advancing	O
in	O
prevalence	O
and	O
morbidity	O
.	O

Though	O
viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
are	O
reported	O
triggers	O
for	O
exacerbations	O
,	O
information	O
on	O
these	O
infections	B-DISO
with	O
asthma	B-DISO
is	O
sparse	O
in	O
Caribbean	O
territories	O
.	O

RESULTS	O
:	O
Wheezing	B-DISO
children	O
had	O
a	O
higher	O
[	O
chi	O
(	O
2	O
)=	O
5	O
.	O
561	O
,	O
p	O
=	O
0	O
.	O
018	O
]	O
prevalence	O
of	O
respiratory	O
viruses	O
compared	O
with	O
stabilized	O
asthmatics	B-DISO
(	O
34	O
.	O
3	O
%	O
(	O
24	O
)	O
versus	O
(	O
vs	O
.)	O
17	O
.	O
5	O
%	O
(	O
14	O
)).	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
field	O
simulation	O
that	O
was	O
conducted	O
using	O
volunteers	O
to	O
assess	O
the	O
ability	O
of	O
3	O
hospitals	O
in	O
a	O
network	O
to	O
manage	O
a	O
large	O
influx	O
of	O
patients	O
with	O
a	O
potentially	O
communicable	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Long	O
-	O
term	O
psychiatric	O
morbidities	O
among	O
SARS	B-DISO
survivors	O
.	O

Psychiatric	O
morbidities	O
were	O
assessed	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	O
-	O
IV	O
,	O
the	O
Impact	O
of	O
Events	O
Scale	O
-	O
Revised	O
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	B-DISO
Scale	O
.	O

Post	O
-	O
SARS	B-DISO
cumulative	O
incidence	O
of	O
DSM	O
-	O
IV	O
psychiatric	B-DISO
disorders	I-DISO
was	O
58	O
.	O
9	O
%.	O

Our	O
results	O
highlight	O
the	O
need	O
to	O
enhance	O
preparedness	O
and	O
competence	O
of	O
health	O
care	O
professionals	O
in	O
detecting	O
and	O
managing	O
the	O
psychological	B-DISO
sequelae	O
of	O
future	O
comparable	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

We	O
describe	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
brought	O
to	O
the	O
emergency	B-DISO
department	O
with	O
a	O
new	O
-	O
onset	O
seizure	B-DISO
and	O
clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
consistent	O
with	O
advanced	O
delirium	B-DISO
tremens	I-DISO
.	O

Although	O
the	O
cornerstone	O
of	O
treatment	O
for	O
AWS	B-DISO
remains	O
benzodiazepines	O
,	O
this	O
case	O
highlights	O
the	O
potential	O
utility	O
of	O
phenobarbital	O
in	O
patients	O
with	O
resistant	O
AWS	B-DISO
.	O

Ninety	O
-	O
six	O
percent	O
of	O
the	O
nurses	O
preferred	O
nebulizer	O
over	O
MDI	B-DISO
with	O
spacer	O
.	O

TITLE	O
:	O
A	O
self	O
-	O
assembled	O
fusion	O
protein	O
-	O
based	O
surface	O
plasmon	O
resonance	O
biosensor	O
for	O
rapid	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
single	O
-	O
stranded	O
RNA	O
viruses	O
which	O
contain	O
the	O
largest	O
RNA	O
genomes	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
a	O
newly	O
found	O
group	O
2	O
CoV	O
,	O
emerged	O
as	O
infectious	B-DISO
disease	I-DISO
with	O
high	O
mortality	O
rate	O
.	O

We	O
describe	O
the	O
clinical	O
and	O
epidemiologic	O
characteristics	O
of	O
persons	O
hospitalized	O
for	O
pneumonia	B-DISO
at	O
the	O
national	O
tertiary	O
hospital	O
for	O
respiratory	O
illnesses	O
in	O
Mexico	O
City	O
who	O
had	O
laboratory	O
-	O
confirmed	O
S	O
-	O
OIV	O
infection	B-DISO
,	O
also	O
known	O
as	O
swine	B-DISO
flu	I-DISO
.	O

S	O
-	O
OIV	O
infection	B-DISO
was	O
confirmed	O
in	O
specimens	O
with	O
the	O
use	O
of	O
a	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assay	O
.	O

ABSTRACT	O
:	O
One	O
week	O
after	O
a	O
flu	B-DISO
-	O
like	O
prodrome	B-DISO
,	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
developed	O
acute	O
severe	O
,	O
symmetrical	O
,	O
painless	O
weakness	B-DISO
and	O
wasting	B-DISO
of	O
the	O
shoulder	O
girdle	O
and	O
upper	O
limbs	O
,	O
drooling	B-DISO
,	O
dysphagia	B-DISO
,	O
dysarthria	B-DISO
,	O
atrophy	B-DISO
and	O
fasciculations	B-DISO
of	O
the	O
tongue	O
.	O

Electrodiagnostic	O
findings	O
suggested	O
demyelinating	O
motor	B-DISO
neuropathy	I-DISO
sparing	O
the	O
legs	O
.	O

Furthermore	O
,	O
cell	O
fractionation	O
experiments	O
revealed	O
that	O
significantly	O
more	O
genomic	O
RNAs	O
for	O
the	O
nonfusogenic	O
MHVs	O
were	O
detected	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
within	O
the	O
first	O
2	O
h	O
after	O
infection	B-DISO
than	O
for	O
the	O
fusogenic	O
MHVs	O
.	O

ABSTRACT	O
:	O
Intranasal	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
1	O
(	O
MHV	O
-	O
1	O
)	O
infection	B-DISO
of	O
mice	O
induces	O
lung	O
pathology	B-DISO
similar	O
to	O
that	O
observed	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

TITLE	O
:	O
Intragastric	O
administration	O
of	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
harbouring	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
DNA	O
vaccine	O
induced	O
specific	O
antibody	O
production	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
DNA	O
vaccine	O
and	O
the	O
immunoregulatory	O
activity	O
of	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
were	O
investigated	O
.	O

ABSTRACT	O
:	O
To	O
monitor	O
and	O
study	O
the	O
molecular	O
epidemiology	O
,	O
evolution	O
and	O
pathogenicity	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
in	O
China	O
in	O
recent	O
years	O
and	O
further	O
our	O
knowledge	O
of	O
the	O
evolution	O
of	O
IBVs	O
.	O

The	O
incidence	O
of	O
ARDS	B-DISO
was	O
compared	O
between	O
the	O
two	O
groups	O
by	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

Single	O
-	O
dose	O
etomidate	O
for	O
RSI	B-DISO
in	O
severely	O
injured	O
trauma	O
patients	O
is	O
associated	O
with	O
increased	O
ARDS	B-DISO
and	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
,	O
in	O
part	O
,	O
because	O
of	O
an	O
effect	O
of	O
etomidate	O
on	O
the	O
inflammatory	B-DISO
response	I-DISO
.	O

RESULTS	O
:	O
Over	O
a	O
2	O
-	O
year	O
period	O
,	O
94	O
study	O
patients	O
underwent	O
RSI	B-DISO
,	O
of	O
which	O
35	O
received	O
etomidate	O
(	O
37	O
%).	O

Patients	O
were	O
categorized	O
into	O
nonobese	O
(	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
<	O
or	O
=	O
29	O
kg	O
/	O
m	O
),	O
obese	B-DISO
(	O
BMI	O
30	O
-	O
39	O
kg	O
/	O
m	O
),	O
and	O
severely	O
obese	B-DISO
(	O
BMI	O
>	O
or	O
=	O
40	O
kg	O
/	O
m	O
)	O
groups	O
.	O

Of	O
these	O
,	O
104	O
(	O
5	O
.	O
7	O
%)	O
were	O
treated	O
with	O
DCL	O
:	O
nonobese	O
,	O
n	O
=	O
51	O
(	O
49	O
%);	O
obese	B-DISO
,	O
n	O
=	O
38	O
(	O
37	O
%);	O
and	O
severely	O
obese	B-DISO
,	O
n	O
=	O
15	O
(	O
14	O
%).	O

TITLE	O
:	O
Risk	O
parameters	O
of	O
fulminant	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
)	O
infection	B-DISO
in	O
Vietnamese	O
children	O
.	O

Serum	O
and	O
BAL	O
fluid	O
levels	O
of	O
the	O
studied	O
cytokines	O
on	O
admission	O
may	O
provide	O
valuable	O
prognostic	O
information	O
for	O
patients	O
with	O
severe	O
CAP	B-DISO
.	O

We	O
have	O
previously	O
shown	O
for	O
the	O
coronavirus	O
species	O
responsible	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
the	O
transmembrane	O
domain	O
of	O
E	O
protein	O
(	O
ETM	O
)	O
forms	O
pentameric	O
alpha	O
-	O
helical	O
bundles	O
that	O
are	O
likely	O
responsible	O
for	O
the	O
observed	O
channel	O
activity	O
.	O

ABSTRACT	O
:	O
Activation	O
of	O
the	O
innate	O
immune	O
system	O
results	O
from	O
severe	O
trauma	O
and	O
the	O
resultant	O
systemic	O
inflammatory	B-DISO
response	I-DISO
is	O
thought	O
to	O
mediate	O
remote	O
organ	O
injury	O
.	O

Conclusions	O
Hemorrhagic	O
necrotizing	O
adrenalitis	B-DISO
should	O
be	O
considered	O
as	O
one	O
of	O
the	O
important	O
pathological	O
changes	O
in	O
fatal	O
MOF	B-DISO
resulting	O
from	O
severe	O
infection	B-DISO
and	O
trauma	O
etc	O
.	O

For	O
generalisability	O
,	O
all	O
admissions	O
for	O
severe	O
acute	O
malnutrition	B-DISO
treatment	O
were	O
eligible	O
for	O
recruitment	B-DISO
.	O

Secondary	O
outcomes	O
included	O
death	O
,	O
weight	O
gain	O
,	O
time	O
to	O
cure	O
,	O
and	O
prevalence	O
of	O
clinical	O
symptoms	O
(	O
diarrhoea	B-DISO
,	O
fever	O
,	O
and	O
respiratory	B-DISO
problems	I-DISO
).	O

Empirical	O
treatment	O
may	O
have	O
to	O
be	O
started	O
based	O
on	O
epidemiological	O
probability	O
of	O
infection	B-DISO
whilst	O
waiting	O
for	O
results	O
to	O
return	O
.	O

The	O
evidence	O
base	O
for	O
much	O
of	O
the	O
management	O
of	O
tropical	O
infections	B-DISO
is	O
limited	O
.	O

In	O
this	O
study	O
,	O
the	O
immunogenicity	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
protein	O
(	O
S	O
(	O
SL	O
))	O
was	O
studied	O
and	O
compared	O
with	O
that	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
S	O
(	O
SARS	B-DISO
)).	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
crush	B-DISO
syndrome	I-DISO
complicated	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
using	O
hybrid	O
continuous	O
renal	O
replacement	O
therapy	O
.	O

Infections	B-DISO
and	O
crush	B-DISO
syndrome	I-DISO
caused	O
sepsis	B-DISO
,	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
renal	B-DISO
failure	I-DISO
,	O
heart	B-DISO
failure	I-DISO
,	O
liver	B-DISO
dysfunction	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
in	O
a	O
short	O
time	O
.	O

ABSTRACT	O
:	O
Historically	O
,	O
ships	O
brought	O
infectious	B-DISO
diseases	I-DISO
to	O
the	O
continents	O
of	O
the	O
world	O
,	O
but	O
in	O
this	O
modern	O
era	O
,	O
infectious	B-DISO
diseases	I-DISO
and	O
pandemics	O
are	O
primarily	O
spread	O
through	O
aviation	O
as	O
a	O
mode	O
of	O
travel	O
.	O

This	O
is	O
a	O
significant	O
issue	O
in	O
the	O
realm	O
of	O
infection	B-DISO
control	O
because	O
of	O
the	O
increased	O
potential	O
for	O
the	O
rapid	O
worldwide	O
transmission	O
and	O
spread	O
of	O
disease	O
.	O

In	O
addition	O
,	O
he	O
developed	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
the	O
6th	O
hospital	O
day	O
,	O
therefore	O
siveletat	O
sodium	O
was	O
given	O
.	O

As	O
of	O
July	O
6	O
,	O
a	O
total	O
of	O
122	O
countries	O
had	O
reported	O
94	O
,	O
512	O
cases	O
of	O
novel	O
influenza	B-DISO
A	I-DISO
(	I-DISO
H1N1	I-DISO
)	I-DISO
virus	I-DISO
infection	I-DISO
,	O
429	O
of	O
which	O
were	O
fatal	O
;	O
in	O
the	O
United	O
States	O
,	O
a	O
total	O
of	O
33	O
,	O
902	O
cases	O
were	O
reported	O
,	O
170	O
of	O
which	O
were	O
fatal	O
.	O

Fires	O
in	O
tall	O
buildings	O
(	O
61	O
.	O
6	O
%),	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
(	O
61	O
%)	O
and	O
stampedes	O
caused	O
by	O
overcrowding	O
(	O
48	O
.	O
8	O
%)	O
were	O
rated	O
as	O
the	O
events	O
most	O
likely	O
to	O
happen	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Experimental	O
infection	B-DISO
of	O
Mongolian	O
gerbils	O
by	O
a	O
genotype	O
4	O
strain	O
of	O
swine	O
hepatitis	B-DISO
E	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
a	O
costly	O
respiratory	O
viral	B-DISO
disease	I-DISO
of	O
chickens	O
.	O

ABSTRACT	O
:	O
Aryl	O
diketoacids	O
have	O
been	O
identified	O
as	O
the	O
first	O
SARS	B-DISO
-	O
CoV	O
NTPase	O
/	O
helicase	O
inhibitors	O
with	O
a	O
distinct	O
pharmacophore	O
featuring	O
an	O
arylmethyl	O
group	O
attached	O
to	O
a	O
diketoacid	O
.	O

Based	O
on	O
SAR	O
study	O
,	O
an	O
extended	O
feature	O
of	O
the	O
pharmacophore	O
model	O
of	O
SARS	B-DISO
-	O
CoV	O
NTPase	O
/	O
helicase	O
was	O
proposed	O
which	O
is	O
constituted	O
of	O
a	O
diketoacid	O
core	O
,	O
a	O
hydrophobic	O
arylmethyl	O
substituent	O
,	O
and	O
a	O
free	O
catechol	O
unit	O
.	O

These	O
findings	O
emphasize	O
the	O
importance	O
of	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	O
in	O
amplifying	O
demyelination	B-DISO
in	O
JHMV	O
-	O
infected	O
mice	O
.	O

An	O
approximately	O
70	O
kDa	O
fragment	O
of	O
the	O
N	O
-	O
terminal	O
globular	O
domain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
(	O
SN	O
protein	O
)	O
from	O
the	O
coronavirus	O
TGEV	O
was	O
used	O
as	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
antigen	O
model	O
.	O

Expression	O
and	O
localization	O
of	O
the	O
transcribed	O
SN	O
protein	O
from	O
the	O
recombinant	O
LNZ9000	O
-	O
rTGEV	O
-	O
SN	O
were	O
detected	O
via	O
SDS	B-DISO
-	O
PAGE	O
,	O
Western	O
blot	O
,	O
and	O
immunofluorescence	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
field	O
vaccination	O
coverage	O
and	O
persistence	O
of	O
Arkansas	O
-	O
type	O
viruses	O
in	O
commercial	O
broilers	O
.	O

Moreover	O
,	O
the	O
infection	B-DISO
was	O
blocked	O
by	O
antibodies	O
against	O
pAPN	O
,	O
implying	O
the	O
critical	O
role	O
of	O
pAPN	O
during	O
virus	O
entry	O
.	O

We	O
performed	O
real	O
-	O
time	O
quantitative	O
PCR	O
analysis	O
of	O
107	O
genes	O
with	O
functional	O
roles	O
in	O
inflammation	B-DISO
,	O
coagulation	O
,	O
fibrosis	B-DISO
and	O
apoptosis	O
;	O
some	O
key	O
genes	O
were	O
confirmed	O
at	O
a	O
protein	O
expression	O
level	O
by	O
immunohistochemistry	O
and	O
correlated	O
to	O
the	O
degree	O
of	O
morphological	O
severity	O
present	O
in	O
the	O
individual	O
samples	O
analyzed	O
.	O

Clinical	O
Respiratory	O
Score	O
(	O
CRS	B-DISO
)	O
was	O
assigned	O
retrospectively	O
to	O
assess	O
respiratory	B-DISO
distress	I-DISO
(	O
0	O
=	O
no	O
distress	O
,	O
>	O
6	O
=	O
severe	O
).	O

Six	O
deaths	O
occurred	O
(	O
mortality	O
rate	O
9	O
.	O
2	O
%),	O
4	O
of	O
which	O
were	O
due	O
to	O
septic	B-DISO
shock	I-DISO
/	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
(	O
2	O
patients	O
)	O
or	O
interstitial	B-DISO
pneumonia	I-DISO
/	O
pulmonary	B-DISO
fibrosis	I-DISO
after	O
Legionella	B-DISO
pneumonia	I-DISO
(	O
2	O
patients	O
),	O
whereas	O
the	O
other	O
2	O
deaths	O
were	O
due	O
to	O
causes	O
unrelated	O
to	O
Legionella	B-DISO
pneumonia	I-DISO
.	O

In	O
the	O
present	O
case	O
,	O
soluble	O
interleukin	O
-	O
2	O
receptor	O
(	O
sIL	B-DISO
-	O
2R	O
)	O
proved	O
useful	O
for	O
assessing	O
symptoms	O
.	O

Although	O
several	O
nsp	O
'	O
s	O
exhibit	O
catalytic	O
activities	O
that	O
are	O
important	O
for	O
viral	O
replication	O
and	O
transcription	O
,	O
other	O
nsp	O
'	O
s	O
have	O
less	O
clearly	O
defined	O
roles	O
during	O
an	O
infection	B-DISO
.	O

These	O
data	O
,	O
together	O
with	O
high	O
-	O
field	O
relaxation	O
and	O
heteronuclear	O
NOE	O
,	O
provide	O
evidence	O
for	O
correlated	O
rigid	B-DISO
-	O
body	O
motions	O
of	O
the	O
entire	O
beta	O
-	O
hairpin	O
,	O
and	O
corresponding	O
motions	O
of	O
adjacent	O
loops	O
with	O
a	O
time	O
constant	O
of	O
0	O
.	O
8	O
ns	O
(	O
mesodynamics	O
).	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
novel	O
and	O
reversible	O
inhibitors	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

TITLE	O
:	O
Two	O
forms	O
of	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
in	O
the	O
lungs	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
type	O
I	O
IFNs	O
in	O
protecting	O
against	O
coronavirus	O
(	O
CoV	O
)	O
infections	B-DISO
is	O
not	O
fully	O
understood	O
.	O

In	O
BALB	O
/	O
c	O
mice	O
,	O
which	O
display	O
high	O
viral	O
loads	O
but	O
are	O
able	O
to	O
control	O
the	O
infection	B-DISO
,	O
57	O
and	O
121	O
genes	O
were	O
significantly	O
differentially	O
expressed	O
(>	O
or	O
=	O
1	O
.	O
5	O
fold	O
change	O
)	O
upon	O
infection	B-DISO
at	O
2	O
and	O
5	O
days	O
post	O
infection	B-DISO
,	O
respectively	O
.	O

Overall	O
,	O
this	O
study	O
broadens	O
our	O
present	O
knowledge	O
of	O
the	O
type	O
I	O
and	O
II	O
IFN	O
-	O
mediated	O
effector	O
responses	O
during	O
CoV	O
infection	B-DISO
in	O
vivo	O
.	O

We	O
speculate	O
that	O
the	O
additional	O
type	O
I	O
IFN	O
-	O
dependent	O
genes	O
that	O
we	O
discovered	O
may	O
also	O
be	O
important	O
for	O
protection	O
against	O
MHV	O
infection	B-DISO
.	O

The	O
impact	O
of	O
'	O
other	O
'	O
viruses	O
(	O
RSV	O
,	O
influenza	B-DISO
,	O
adenovirus	B-DISO
,	O
parainfluenza	B-DISO
,	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
[	O
hMPV	O
],	O
coronavirus	O
,	O
boca	B-DISO
-	O
virus	O
,	O
enterovirus	O
,	O
paraechovirus	O
)	O
has	O
been	O
investigated	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
prototype	O
of	O
the	O
group	O
III	O
coronaviruses	O
and	O
encodes	O
15	O
nonstructural	O
proteins	O
which	O
make	O
up	O
the	O
transcription	O
/	O
replication	O
machinery	O
.	O

TITLE	O
:	O
Serological	O
studies	O
of	O
infectious	B-DISO
bronchitis	B-DISO
vaccines	O
against	O
Japanese	O
field	O
isolates	O
of	O
homologous	O
and	O
heterologous	O
genotypes	O
.	O

This	O
distress	O
can	O
be	O
amplified	O
in	O
the	O
face	B-DISO
of	O
unclear	O
information	O
and	O
communication	O
that	O
is	O
common	O
in	O
the	O
initial	O
period	O
of	O
disease	O
outbreaks	O
.	O

ABSTRACT	O
:	O
Zoonotic	O
infections	B-DISO
constitute	O
a	O
major	O
public	O
health	O
concern	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
hypothesized	O
that	O
the	O
hemorrhagic	B-DISO
enteritis	I-DISO
virus	O
(	O
HEV	O
),	O
an	O
avian	O
adenovirus	B-DISO
that	O
causes	O
illness	O
among	O
turkeys	O
,	O
might	O
infect	O
humans	O
.	O

Therefore	O
,	O
the	O
LSPCF	O
fiber	O
-	O
optic	O
biosensor	O
shows	O
an	O
ability	O
to	O
detect	O
very	O
low	O
concentration	O
(	O
approximately	O
1	O
pg	O
/	O
mL	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
in	O
serum	O
.	O

The	O
biosensor	O
should	O
help	O
with	O
the	O
early	O
diagnosis	O
of	O
SARS	B-DISO
infection	B-DISO
.	O

This	O
review	O
is	O
focused	O
on	O
members	O
of	O
the	O
GBF	O
/	O
Gea	O
and	O
BIG	O
/	O
Sec7	O
subfamilies	O
of	O
Arf	B-DISO
GEFs	O
,	O
all	O
of	O
which	O
use	O
the	O
class	O
I	O
Arf	B-DISO
proteins	O
(	O
Arf1	O
-	O
3	O
)	O
as	O
substrates	O
,	O
and	O
play	O
a	O
fundamental	O
role	O
in	O
trafficking	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
and	O
endosomal	O
membrane	O
systems	O
.	O

TITLE	O
:	O
Multiply	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
due	O
to	O
tramadol	O
intoxication	O
alone	O
.	O

We	O
present	O
a	O
case	O
of	O
19	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
had	O
multiply	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
due	O
to	O
oral	O
tramadol	O
alone	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
one	O
of	O
the	O
most	O
abundant	O
structural	O
proteins	O
and	O
serves	O
as	O
a	O
diagnostic	O
marker	O
for	O
accurate	O
and	O
sensitive	O
detection	O
of	O
the	O
virus	O
.	O

In	O
addition	O
,	O
osteonecrosis	B-DISO
and	O
bone	O
abnormalities	O
with	O
reduced	O
bone	O
density	O
have	O
been	O
observed	O
in	O
patients	O
following	O
recovery	O
from	O
SARS	B-DISO
,	O
which	O
were	O
partly	O
but	O
not	O
entirely	O
explained	O
by	O
the	O
short	O
-	O
term	O
use	O
of	O
steroids	O
.	O

Case	O
1	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
bacteremia	B-DISO
of	O
Escherichia	O
coli	O
and	O
Klebsiella	O
pneumoniae	O
soon	O
after	O
admission	O
,	O
and	O
died	O
even	O
after	O
receiving	O
albendazole	O
and	O
antibiotic	O
treatment	O
.	O

Not	O
only	O
the	O
viruses	O
,	O
but	O
bacteria	O
can	O
also	O
expand	O
their	O
host	O
range	O
:	O
a	O
new	O
disease	O
,	O
streptococcal	B-DISO
toxic	I-DISO
shock	I-DISO
syndrome	I-DISO
,	O
caused	O
by	O
human	O
Streptococcus	O
suis	O
serotype	O
2	O
infection	B-DISO
,	O
has	O
been	O
observed	O
in	O
China	O
with	O
52	O
human	O
fatalities	O
in	O
two	O
separate	O
outbreaks	O
(	O
1998	O
and	O
2005	O
,	O
respectively	O
).	O

A	O
new	O
highly	O
pathogenic	O
variant	O
of	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
has	O
been	O
isolated	O
in	O
both	O
China	O
and	O
Vietnam	O
recently	O
;	O
although	O
PRRSV	O
is	O
not	O
a	O
zoonotic	O
human	O
pathogen	O
,	O
its	O
severe	O
outbreaks	O
have	O
implications	O
for	O
food	O
safety	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
an	O
inflammatory	B-DISO
disorder	I-DISO
associated	O
with	O
reduced	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
,	O
increased	O
pulmonary	O
vascular	O
permeability	O
,	O
and	O
infiltration	B-DISO
of	O
leukocytes	O
into	O
the	O
alveolar	O
space	O
.	O

Our	O
data	O
show	O
that	O
axonal	O
loss	O
and	O
demyelination	B-DISO
can	O
be	O
independent	O
direct	O
viral	O
cytopathic	O
events	O
,	O
and	O
suggest	O
that	O
similar	O
direct	O
axonal	O
damage	O
may	O
occur	O
in	O
MS	O
.	O

These	O
results	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
neuroprotective	O
strategies	O
for	O
CNS	B-DISO
demyelinating	I-DISO
disease	I-DISO
,	O
and	O
our	O
model	O
identifies	O
the	O
spike	O
protein	O
as	O
a	O
therapeutic	O
target	O
to	O
prevent	O
axonal	O
transport	O
of	O
neurotropic	O
viruses	O
.	O

TITLE	O
:	O
Fulminant	O
,	O
undetected	O
Candida	B-DISO
sepsis	I-DISO
after	O
an	O
apparently	O
survivable	O
burn	O
injury	O
.	O

He	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
and	O
severe	O
inflammatory	B-DISO
response	I-DISO
syndrome	B-DISO
.	O

Occult	O
aggressive	B-DISO
fungal	B-DISO
sepsis	I-DISO
resulting	O
in	O
early	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
should	O
be	O
kept	O
in	O
mind	O
.	O

TITLE	O
:	O
Temporal	O
variability	O
and	O
social	O
heterogeneity	O
in	O
disease	B-DISO
transmission	I-DISO
:	O
the	O
case	O
of	O
SARS	B-DISO
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Assessing	O
the	O
quality	O
of	O
a	O
web	B-DISO
-	O
based	O
learning	O
system	O
for	O
nurses	O
.	O

The	O
research	O
results	O
show	O
that	O
all	O
indicators	O
of	O
the	O
instrument	O
provide	O
a	O
fit	B-DISO
to	O
the	O
quality	O
measurement	O
of	O
a	O
web	B-DISO
-	O
based	O
learning	O
system	O
and	O
have	O
high	O
reliability	O
and	O
validity	O
.	O

Despite	O
antibiotic	O
administration	O
,	O
infiltration	B-DISO
progressed	O
to	O
the	O
entire	O
right	O
lung	O
and	O
upper	O
left	O
lung	O
after	O
12	O
hours	O
,	O
and	O
he	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

Microscopically	O
,	O
the	O
lung	O
specimen	O
showed	O
prominent	O
cellular	O
alveolar	O
exudate	O
and	O
partial	O
hyaline	B-DISO
membrane	I-DISO
with	O
suppurative	B-DISO
pneumonia	B-DISO
.	O

Although	O
A	O
.	O
baumannii	O
is	O
considered	O
the	O
causative	O
agent	O
in	O
nosocomical	O
pneumonia	B-DISO
,	O
community	O
-	O
acquired	O
pneumonia	B-DISO
due	O
to	O
A	O
.	O
baumannii	O
is	O
very	O
rare	O
.	O

Given	O
the	O
apparent	O
progress	O
of	O
global	O
warming	O
,	O
physicians	O
in	O
Japan	O
would	O
do	O
well	O
to	O
familiarize	O
themselves	O
with	O
subtropical	O
disease	O
causes	O
such	O
A	O
.	O
baumannii	O
when	O
managing	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Reverse	O
genetic	O
characterization	O
of	O
the	O
natural	O
genomic	O
deletion	O
in	O
SARS	B-DISO
-	O
Coronavirus	O
strain	O
Frankfurt	O
-	O
1	O
open	O
reading	O
frame	O
7b	O
reveals	O
an	O
attenuating	O
function	O
of	O
the	O
7b	O
protein	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
.	O

This	O
difference	O
could	O
explain	O
earlier	O
observations	O
of	O
enhanced	O
virulence	O
of	O
Frankfurt	O
-	O
1	O
in	O
Hamsters	O
as	O
compared	O
to	O
other	O
SARS	B-DISO
-	O
Coronavirus	O
reference	O
strains	O
and	O
identifies	O
the	O
SARS	B-DISO
-	O
CoV	O
7b	O
protein	O
as	O
an	O
attenuating	O
factor	O
with	O
the	O
SARS	B-DISO
-	O
Coronavirus	O
genome	O
.	O

Interestingly	O
,	O
consecutive	O
treatment	O
with	O
CPL	B-DISO
and	O
then	O
chlorpromazine	O
enabled	O
a	O
portion	O
of	O
the	O
virus	O
to	O
enter	O
from	O
cell	O
surface	O
.	O

TITLE	O
:	O
ARDS	B-DISO
as	O
presenting	O
symptom	B-DISO
in	O
an	O
infant	O
with	O
CD40L	O
deficiency	O
(	O
Hyper	B-DISO
-	I-DISO
IgM	I-DISO
syndrome	I-DISO
Type	O
1	O
).	O

TITLE	O
:	O
Severe	O
necrotizing	O
stomatitis	B-DISO
and	O
osteomyelitis	B-DISO
after	O
chemotherapy	O
for	O
acute	B-DISO
leukaemia	I-DISO
.	O

ABSTRACT	O
:	O
Leukaemia	B-DISO
is	O
a	O
malignant	B-DISO
neoplasm	I-DISO
characterized	O
by	O
clonal	O
proliferation	B-DISO
of	O
white	O
blood	O
cells	O
within	O
the	O
bone	O
marrow	O
.	O

This	O
case	O
report	O
describes	O
severe	O
maxillary	O
and	O
mandibular	O
necrotizing	O
stomatitis	B-DISO
and	O
osteomyelitis	B-DISO
in	O
a	O
young	O
female	O
patient	O
after	O
chemotherapy	O
for	O
acute	B-DISO
leukaemia	I-DISO
.	O

However	O
,	O
severe	O
alveolar	O
bone	B-DISO
destruction	I-DISO
remained	O
evident	O
.	O

RESULTS	O
:	O
During	O
the	O
course	O
of	O
management	O
the	O
patient	O
'	O
s	O
oral	O
condition	B-DISO
improved	O
with	O
some	O
re	O
-	O
epithelialization	B-DISO
being	O
noted	O
.	O

TITLE	O
:	O
Severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
at	O
the	O
Hajj	O
:	O
etiologies	O
and	O
outcomes	O
.	O

Acute	B-DISO
renal	I-DISO
failure	I-DISO
is	O
common	O
among	O
pilgrims	O
who	O
presented	O
with	O
septic	B-DISO
shock	I-DISO
,	O
and	O
carries	O
high	O
mortality	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
coronavirus	O
spike	O
S2	O
domain	O
flanked	O
by	O
cysteine	O
residues	O
C822	O
and	O
C833	O
is	O
important	O
for	O
activation	O
of	O
membrane	O
fusion	O
.	O

In	O
addition	O
to	O
a	O
well	O
-	O
recognized	O
cleavage	O
site	O
at	O
the	O
S1	O
-	O
S2	O
boundary	O
,	O
a	O
second	O
proteolytic	O
cleavage	O
site	O
has	O
been	O
identified	O
in	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
S2	O
domain	O
(	O
R797	O
).	O

TITLE	O
:	O
Serum	O
lipopolysaccharide	O
binding	O
protein	O
levels	O
predict	O
severity	O
of	O
lung	O
injury	O
and	O
mortality	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

At	O
48	O
hours	O
,	O
LBP	B-DISO
levels	O
were	O
significantly	O
higher	O
in	O
ARDS	B-DISO
patients	O
than	O
in	O
ALI	O
patients	O
(	O
112	O
.	O
5	O
+/-	O
71	O
.	O
8	O
microg	O
/	O
ml	O
vs	O
.	O
76	O
.	O
6	O
+/-	O
55	O
.	O
9	O
microg	O
/	O
ml	O
,	O
P	O
=	O
0	O
.	O
0001	O
).	O

Such	O
a	O
potential	O
is	O
already	O
known	O
for	O
rabies	B-DISO
encephalitis	B-DISO
since	O
seven	O
out	O
of	O
the	O
eight	O
genotypes	O
of	O
Lyssavirus	O
are	O
transmitted	B-DISO
by	O
bats	O
.	O

On	O
the	O
other	O
hand	O
,	O
rabies	B-DISO
control	O
in	O
bat	O
still	O
remains	O
non	O
realistic	O
,	O
particularly	O
as	O
the	O
pathogenicity	O
of	O
bat	O
Lyssavirus	O
for	O
bats	O
is	O
still	O
under	O
debate	O
,	O
suggesting	O
that	O
a	O
""""	O
diplomatic	O
relationship	O
""""	O
between	O
partners	O
would	O
have	O
arisen	O
from	O
a	O
long	O
term	O
cohabitation	O
.	O

Surprisingly	O
,	O
no	O
lysis	B-DISO
was	O
observed	O
in	O
the	O
CrFK	O
cells	O
and	O
the	O
monocytes	O
that	O
do	O
show	O
surface	O
-	O
expressed	O
viral	O
proteins	O
,	O
while	O
controls	O
showed	O
that	O
the	O
ADCML	O
assay	O
was	O
functional	O
.	O

This	O
new	O
evasion	O
strategy	O
is	O
not	O
attributed	O
to	O
the	O
group	O
-	O
specific	O
proteins	O
since	O
lysis	B-DISO
of	O
cells	O
infected	O
with	O
FIPV	O
Delta	O
3abc	O
/	O
Delta	O
7ab	O
was	O
not	O
detected	O
.	O

ABSTRACT	O
:	O
Corticosteroids	O
are	O
widely	O
used	O
to	O
treat	O
a	O
diversity	O
of	O
pathological	O
conditions	O
including	O
allergic	O
,	O
autoimmune	B-DISO
and	O
some	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
[	O
CD4	O
(+)	O
T	O
lymphocyte	O
detection	O
in	O
renal	O
transplant	O
recipients	O
and	O
its	O
clinical	O
value	O
for	O
cytomegalovirus	B-DISO
pneumonia	I-DISO
treatment	O
].	O

Of	O
the	O
133	O
recipients	O
,	O
12	O
(	O
9	O
.	O
0	O
%,	O
12	O
/	O
133	O
)	O
had	O
severe	O
pneumonia	B-DISO
,	O
during	O
58	O
-	O
118	O
days	O
after	O
operation	O
,	O
including	O
7	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
4	O
patients	O
(	O
33	O
.	O
3	O
%,	O
4	O
/	O
12	O
)	O
died	O
and	O
8	O
(	O
66	O
.	O
7	O
%,	O
8	O
/	O
12	O
)	O
were	O
cured	O
.	O

During	O
the	O
withdrawal	B-DISO
of	O
immunosuppressive	O
agents	O
,	O
34	O
patients	O
had	O
normal	O
kidney	O
function	O
(	O
serum	O
creatinine	O
71	O
-	O
126	O
micromol	O
/	O
L	O
),	O
except	O
2	O
cases	O
underwent	O
mild	O
acute	O
rejection	O
.	O

ABSTRACT	O
:	O
In	O
our	O
previous	O
study	O
by	O
Gupta	O
et	O
al	O
,	O
dominant	O
T	O
-	O
cell	O
epitopes	O
of	O
SARS	B-DISO
CoV	O
-	O
N	O
(	O
N	O
)	O
protein	O
were	O
predicted	O
by	O
software	O
.	O

TITLE	O
:	O
A	O
real	O
-	O
time	O
TaqMan	O
RT	O
-	O
PCR	O
assay	O
with	O
an	O
internal	O
amplification	B-DISO
control	O
for	O
rapid	O
detection	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
swine	O
fecal	O
samples	O
.	O

RESULTS	O
:	O
The	O
interaction	O
between	O
SARS	B-DISO
-	O
CoV	O
N	O
and	O
MAP19	O
was	O
already	O
demonstrated	O
by	O
immuno	O
-	O
coprecipitation	O
.	O

These	O
results	O
suggest	O
that	O
TLR2	O
and	O
heparan	O
sulphate	O
receptors	O
can	O
act	O
as	O
new	O
viral	O
PPRs	O
involved	O
in	O
inflammatory	B-DISO
responses	I-DISO
.	O

Intratracheal	O
instillation	O
of	O
rats	O
with	O
SDAV	O
coronavirus	O
caused	O
an	O
acute	O
,	O
self	O
-	O
limited	O
infection	B-DISO
that	O
is	O
a	O
useful	O
model	O
for	O
studying	O
the	O
early	O
events	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
respiratory	O
coronavirus	B-DISO
infections	I-DISO
in	O
lungs	O
of	O
the	O
natural	O
virus	O
host	O
.	O

Mainland	O
China	O
had	O
three	O
outbreaks	O
of	O
SARS	B-DISO
between	O
November	O
2002	O
-	O
May	O
2004	O
and	O
suffered	B-DISO
the	O
greatest	O
impact	O
on	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

Chinese	O
nurses	O
faced	O
personal	O
challenge	O
,	O
focused	O
on	O
the	O
essence	O
of	O
care	O
and	O
experienced	O
self	O
-	O
growth	O
while	O
caring	O
for	O
SARS	B-DISO
patients	O
.	O

We	O
previously	O
generated	O
human	O
mAbs	O
specific	O
to	O
the	O
S1	O
region	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
.	O

Other	O
factors	O
found	O
to	O
increase	O
the	O
risk	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
calves	O
were	O
shared	O
housing	O
with	O
cows	O
during	O
the	O
first	O
week	O
of	O
life	O
compared	O
with	O
separate	O
housing	O
(	O
HR	O
=	O
16	O
.	O
7	O
),	O
a	O
larger	O
herd	O
size	O
(>	O
50	O
cow	O
years	O
)	O
compared	O
with	O
smaller	O
herds	O
(	O
HR	O
=	O
8	O
.	O
2	O
),	O
more	O
than	O
an	O
8	O
-	O
wk	O
age	O
difference	O
between	O
calves	O
housed	O
together	O
in	O
the	O
same	O
group	O
pen	O
compared	O
with	O
having	O
pen	O
mates	O
of	O
a	O
more	O
similar	O
age	O
(	O
HR	O
=	O
3	O
.	O
9	O
),	O
previous	O
recordings	O
of	O
diarrhea	B-DISO
compared	O
with	O
no	O
recorded	O
diarrhea	B-DISO
(	O
HR	O
=	O
3	O
.	O
9	O
),	O
and	O
leaving	O
calves	O
with	O
dams	O
for	O
>	O
24	O
h	O
after	O
birth	O
compared	O
with	O
earlier	O
separation	B-DISO
(	O
HR	O
=	O
3	O
.	O
5	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Survival	O
among	O
this	O
cohort	O
of	O
adults	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
supported	O
with	O
ECMO	O
was	O
50	O
%.	O

TITLE	O
:	O
[	O
The	O
cloning	O
,	O
expression	O
and	O
structural	O
analysis	O
of	O
putative	O
unknown	O
protein	O
Orf	O
9b	O
in	O
SARS	B-DISO
-	O
CoV	O
].	O

TITLE	O
:	O
[	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
epidemic	O
in	O
Argentina	O
.	O

ABSTRACT	O
:	O
The	O
preparation	O
and	O
medical	O
care	O
during	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
outbreak	O
(	O
June	O
2009	O
)	O
in	O
a	O
high	O
complexity	O
level	O
,	O
public	O
,	O
general	O
hospital	O
with	O
laboratory	O
diagnosis	O
,	O
general	O
and	O
intensive	O
care	O
(	O
ICU	O
)	O
hospitalization	O
is	O
described	O
.	O

Evidence	O
that	O
the	O
more	O
uncomfortable	O
and	O
expensive	O
N95	O
masks	O
were	O
superior	O
to	O
simple	O
surgical	O
masks	O
was	O
limited	O
,	O
but	O
they	O
caused	O
skin	B-DISO
irritation	I-DISO
.	O

More	O
resources	O
should	O
be	O
invested	O
into	O
studying	O
which	O
physical	O
interventions	O
are	O
the	O
most	O
effective	O
,	O
flexible	O
,	O
and	O
cost	O
effective	O
means	O
of	O
minimising	O
the	O
impact	O
of	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
A	O
56	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
man	O
was	O
admitted	O
to	O
our	O
hospital	O
with	O
a	O
severe	O
chest	B-DISO
pain	I-DISO
that	O
started	O
shortly	O
after	O
being	O
stung	O
by	O
a	O
honeybee	O
.	O

ABSTRACT	O
:	O
Destruction	O
of	O
the	O
architectural	O
and	O
subsequently	O
the	O
functional	O
integrity	O
of	O
the	O
lung	O
following	O
pulmonary	O
viral	B-DISO
infections	I-DISO
is	O
attributable	O
to	O
both	O
the	O
extent	O
of	O
pathogen	O
replication	O
and	O
to	O
the	O
host	O
-	O
generated	O
inflammation	B-DISO
associated	O
with	O
the	O
recruitment	B-DISO
of	O
immune	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
cell	O
death	O
processes	O
during	O
infection	B-DISO
and	O
the	O
underlying	O
mechanisms	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
the	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
encode	O
a	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
that	O
harbors	O
two	O
independent	O
RNA	O
binding	O
domains	O
of	O
known	O
structure	O
,	O
but	O
poorly	O
characterized	O
RNA	O
binding	O
properties	O
.	O

It	O
is	O
not	O
known	O
whether	O
these	O
cells	O
are	O
maintained	O
by	O
proliferation	B-DISO
of	O
T	O
cells	O
that	O
entered	O
the	O
CNS	O
during	O
acute	B-DISO
infection	I-DISO
or	O
are	O
newly	O
recruited	O
from	O
Ag	O
-	O
experienced	O
or	O
naive	O
T	O
cell	O
pools	O
.	O

The	O
mortality	O
rate	O
was	O
lower	O
in	O
the	O
PCD	B-DISO
group	O
than	O
in	O
the	O
surgery	O
group	O
(	O
P	O
=	O
0	O
.	O
048	O
).	O

TITLE	O
:	O
Distant	O
relatives	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
close	O
relatives	O
of	O
human	O
coronavirus	O
229E	O
in	O
bats	O
,	O
Ghana	O
.	O

TITLE	O
:	O
Genetics	O
and	O
pathogenesis	B-DISO
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
IFN	O
-	O
alpha	O
/	O
beta	O
plays	O
a	O
critical	O
role	O
in	O
limiting	O
viral	O
spread	O
,	O
restricting	O
viral	O
tropism	O
and	O
protecting	O
mice	O
from	O
neurotropic	O
coronavirus	B-DISO
infection	I-DISO
.	O

Extensive	O
multiple	O
lobular	O
infiltrates	B-DISO
developed	O
quickly	O
,	O
followed	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
multi	O
-	O
organ	O
dysfunction	O
.	O

A	O
/	O
H5N1	B-DISO
vaccinated	O
plasma	O
may	O
be	O
useful	O
for	O
improving	O
the	O
prognosis	O
.	O

Then	O
,	O
bronchopleural	B-DISO
fistula	I-DISO
on	O
the	O
surface	O
of	O
visceral	O
pleura	O
was	O
successfully	O
blocked	O
by	O
biogel	O
and	O
OB	O
gel	O
through	O
pleural	O
cavity	B-DISO
by	O
fibrobronchoscopy	O
.	O

Bronchopleural	B-DISO
fistula	I-DISO
was	O
an	O
intractable	O
complication	B-DISO
for	O
patient	O
with	O
A	O
/	O
H5N1	B-DISO
infection	B-DISO
.	O

The	O
prognosis	O
for	O
HPS	B-DISO
is	O
ominous	O
and	O
misdiagnoses	O
may	O
increase	O
mortality	O
.	O

High	O
awareness	O
of	O
HPS	B-DISO
allowed	O
successful	O
management	O
of	O
the	O
patient	O
,	O
even	O
before	O
establishing	O
the	O
diagnosis	O
,	O
by	O
serological	O
tests	O
at	O
the	O
reference	O
laboratory	O
of	O
the	O
Ministry	O
of	O
Health	O
.	O

Clinical	O
suspicion	O
favored	O
warning	O
local	O
health	O
authorities	O
about	O
a	O
new	O
case	O
of	O
HPS	B-DISO
.	O

While	O
CIV	O
appears	O
not	O
to	O
be	O
currently	O
present	O
in	O
New	O
Zealand	O
,	O
veterinarians	O
should	O
consider	O
infection	B-DISO
with	O
this	O
virus	O
as	O
a	O
differential	O
diagnosis	O
in	O
dogs	O
presenting	O
with	O
respiratory	O
signs	O
.	O

Herein	O
we	O
report	O
a	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
caused	O
by	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
due	O
to	O
an	O
adult	O
A	O
.	O
lumbricoides	O
nematodes	O
after	O
cardiac	O
surgery	O
.	O

Social	O
and	O
organizational	O
supports	O
are	O
critical	O
to	O
help	O
buffer	O
the	O
effects	O
of	O
stress	O
for	O
nurses	O
and	O
assist	O
them	O
in	O
managing	O
difficult	O
role	O
conflicts	O
during	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

TITLE	O
:	O
Pandemic	O
flu	B-DISO
:	O
lessons	O
from	O
the	O
Toronto	O
SARS	B-DISO
outbreak	O
.	O

ABSTRACT	O
:	O
In	O
some	O
cases	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hypoxemia	O
occurs	O
despite	O
optimized	O
conservative	O
therapy	O
;	O
however	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
assure	O
sufficient	O
gas	O
exchange	O
.	O

The	O
autoAb	O
recognized	O
conformational	O
as	O
well	O
as	O
linear	O
antigenic	O
determinants	O
in	O
the	O
enzyme	O
,	O
and	O
the	O
autoimmune	B-DISO
response	I-DISO
was	O
not	O
entirely	O
restricted	O
to	O
molecular	O
mimicry	B-DISO
and	O
/	O
or	O
epitope	O
spreading	O
.	O

Such	O
hypothetical	O
B	O
-	O
cell	O
epitopes	O
could	O
be	O
present	O
in	O
any	O
viral	O
protein	O
,	O
originating	O
a	O
cross	O
-	O
reaction	O
leading	O
to	O
the	O
autoimmune	B-DISO
response	I-DISO
induced	O
by	O
MHV	O
.	O

The	O
working	O
definition	O
of	O
probable	O
SARS	B-DISO
used	O
during	O
the	O
epidemic	O
appeared	O
to	O
have	O
been	O
fairly	O
accurate	O
.	O

RESULTS	O
:	O
The	O
SARS	B-DISO
outbreak	O
started	O
with	O
a	O
patient	O
from	O
Beijing	O
on	O
15	O
April	O
2003	O
,	O
and	O
spread	O
quickly	O
among	O
the	O
healthcare	O
workers	O
and	O
in	O
-	O
patients	O
in	O
the	O
hospital	O
.	O

ABSTRACT	O
:	O
To	O
quantify	O
the	O
transmissibility	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
hospitals	O
in	O
mainland	O
China	O
and	O
to	O
assess	O
the	O
effectiveness	O
of	O
control	O
measures	O
.	O

ABSTRACT	O
:	O
Three	O
out	O
of	O
109	O
mixed	O
lung	O
and	O
tracheal	O
tissue	O
extracts	O
originating	O
from	O
Korean	O
dogs	O
tested	O
positive	O
for	O
infection	B-DISO
with	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
of	O
Coronaviridae	O
group	O
2	O
.	O

Infants	O
with	O
RV	O
infection	B-DISO
had	O
higher	O
blood	O
eosinophil	O
counts	O
than	O
infants	O
with	O
bronchiolitis	B-DISO
from	O
RSV	O
and	O
hBoV	O
(	O
307	O
+/-	O
436	O
vs	O
138	O
+/-	O
168	O
vs	O
89	O
+/-	O
19	O
n	O
/	O
mm	O
(	O
3	O
);	O
p	O
<	O
0	O
.	O
05	O
).	O

Few	O
patients	O
had	O
comorbid	O
respiratory	B-DISO
disorders	I-DISO
,	O
but	O
21	O
(	O
36	O
%)	O
were	O
obese	B-DISO
.	O

CONCLUSIONS	O
:	O
Critical	B-DISO
illness	I-DISO
from	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
Mexico	O
occurred	O
in	O
young	O
individuals	O
,	O
was	O
associated	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
,	O
and	O
had	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

RESULTS	O
:	O
Critical	B-DISO
illness	I-DISO
occurred	O
in	O
215	O
patients	O
with	O
confirmed	O
(	O
n	O
=	O
162	O
),	O
probable	O
(	O
n	O
=	O
6	O
),	O
or	O
suspected	O
(	O
n	O
=	O
47	O
)	O
community	O
-	O
acquired	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

CONCLUSIONS	O
:	O
Critical	B-DISO
illness	I-DISO
due	O
to	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
Canada	O
occurred	O
rapidly	O
after	O
hospital	O
admission	O
,	O
often	O
in	O
young	O
adults	O
,	O
and	O
was	O
associated	O
with	O
severe	O
hypoxemia	O
,	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
,	O
a	O
requirement	O
for	O
prolonged	O
mechanical	O
ventilation	O
,	O
and	O
the	O
frequent	O
use	O
of	O
rescue	O
therapies	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
affected	O
Australia	O
and	O
New	O
Zealand	O
during	O
the	O
2009	O
southern	O
hemisphere	O
winter	O
.	O

Before	O
ECMO	O
,	O
patients	O
had	O
severe	O
respiratory	B-DISO
failure	I-DISO
despite	O
advanced	O
mechanical	O
ventilatory	O
support	O
with	O
a	O
median	O
(	O
IQR	O
)	O
Pao	O
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
ratio	O
of	O
56	O
(	O
48	O
-	O
63	O
),	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
18	O
(	O
15	O
-	O
20	O
)	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
and	O
an	O
acute	O
lung	O
injury	O
score	O
of	O
3	O
.	O
8	O
(	O
3	O
.	O
5	O
-	O
4	O
.	O
0	O
).	O

During	O
June	O
to	O
August	O
2009	O
in	O
Australia	O
and	O
New	O
Zealand	O
,	O
the	O
ICUs	O
at	O
regional	O
referral	O
centers	O
provided	O
mechanical	O
ventilation	O
for	O
many	O
patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)-	O
associated	O
respiratory	B-DISO
failure	I-DISO
,	O
one	O
-	O
third	O
of	O
whom	O
received	O
ECMO	O
.	O

TITLE	O
:	O
Enhanced	O
viral	O
etiological	O
diagnosis	O
of	O
respiratory	O
system	O
infection	B-DISO
outbreaks	O
by	O
use	O
of	O
a	O
multitarget	O
nucleic	O
acid	O
amplification	B-DISO
assay	O
.	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
presenting	O
with	O
serious	O
hyperthermia	O
treated	O
with	O
a	O
non	O
-	O
invasive	O
cooling	O
device	O
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
A	O
rare	O
side	B-DISO
effect	I-DISO
of	O
antipsychotic	O
medication	O
is	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
,	O
mainly	O
characterized	O
by	O
hyperthermia	O
,	O
altered	O
mental	O
state	O
,	O
haemodynamic	O
dysregulation	O
,	O
elevated	O
serum	O
creatine	O
kinase	O
and	O
rigor	B-DISO
.	O

The	O
prevalence	O
of	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
is	O
between	O
0	O
.	O
02	O
%	O
and	O
2	O
.	O
44	O
%	O
for	O
patients	O
taking	O
neuroleptics	O
and	O
it	O
is	O
not	O
necessary	O
to	O
fulfil	O
all	O
cardinal	O
features	O
characterizing	O
the	O
syndrome	B-DISO
to	O
be	O
diagnosed	O
with	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
.	O

Because	O
of	O
other	O
different	O
life	O
-	O
threatening	O
diseases	O
matching	O
the	O
various	O
clinical	B-DISO
findings	I-DISO
,	O
the	O
correct	O
diagnosis	O
can	O
sometimes	O
be	O
hard	O
to	O
make	O
.	O

A	O
22	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
was	O
admitted	O
unconscious	O
with	O
a	O
body	O
temperature	O
of	O
42	O
degrees	O
C	O
,	O
elevated	O
serum	O
creatine	O
phosphokinase	O
,	O
tachycardia	O
and	O
hypotonic	B-DISO
blood	O
pressure	O
.	O

After	O
successful	O
treatment	O
it	O
became	O
possible	O
to	O
obtain	O
information	O
from	O
the	O
patient	O
about	O
his	O
recent	O
ambulant	O
treatment	O
with	O
Olanzapin	O
(	O
Zyprexa	O
(	O
R	O
))	O
for	O
schizophrenia	B-DISO
.	O

Numerous	O
case	O
reports	O
have	O
been	O
published	O
about	O
patients	O
who	O
developed	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
due	O
to	O
Olanzapin	O
(	O
Zyprexa	O
(	O
R	O
))	O
medication	O
.	O

The	O
prolonged	O
immunosuppression	O
following	O
specific	O
treatment	O
may	O
be	O
associated	O
with	O
a	O
high	O
risk	O
of	O
developing	O
severe	O
infections	B-DISO
.	O

One	O
month	O
after	O
the	O
last	O
dose	O
of	O
rrituximab	O
,	O
she	O
presented	O
with	O
recurrence	B-DISO
of	O
severe	O
hemolysis	B-DISO
and	O
received	O
two	O
more	O
doses	O
of	O
rrituximab	O
.	O

It	O
is	O
characterized	O
by	O
acute	O
-	O
onset	O
difficulty	O
in	O
walking	O
as	O
a	O
result	O
of	O
severe	O
bilateral	O
calf	B-DISO
pain	I-DISO
and	O
by	O
elevated	O
muscle	O
enzymes	O
including	O
creatinine	O
kinase	O
.	O

ABSTRACT	O
:	O
One	O
in	O
every	O
7	O
pregnancies	O
ends	O
with	O
meconium	O
-	O
stained	O
amniotic	O
fluid	O
and	O
approximately	O
5	O
%	O
of	O
these	O
infants	O
develop	O
the	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
).	O

The	O
pathophysiology	O
of	O
MAS	B-DISO
is	O
multifactorial	O
and	O
complex	O
.	O

The	O
detection	O
limits	O
for	O
the	O
IBV	O
RT	O
-	O
LAMP	O
assay	O
were	O
10	O
(	O
1	O
)	O
50	O
%	O
egg	O
infection	B-DISO
dose	O
(	O
EID	O
(	O
50	O
))	O
per	O
50	O
microl	O
of	O
titrated	O
viruses	O
and	O
no	O
cross	O
-	O
reaction	O
of	O
IBV	O
RT	O
-	O
LAMP	O
was	O
found	O
when	O
tested	O
with	O
other	O
viruses	O
including	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
avian	O
reovirus	O
(	O
ARV	O
),	O
and	O
infectious	B-DISO
laryngotrachietis	O
virus	O
(	O
ILTV	O
)	O
due	O
to	O
their	O
mismatch	O
with	O
IBV	O
RT	O
-	O
LAMP	O
primers	O
.	O

Our	O
findings	O
indicate	O
that	O
even	O
with	O
early	O
and	O
aggressive	B-DISO
weaning	O
from	O
a	O
respirator	O
with	O
extensive	O
lung	O
contusions	O
an	O
adequate	O
therapy	O
of	O
thorax	O
trauma	O
is	O
possible	O
without	O
having	O
a	O
higher	O
incidence	O
of	O
complications	O
.	O

As	O
this	O
mutant	B-DISO
virus	O
is	O
more	O
neurovirulent	O
in	O
mice	O
,	O
our	O
results	O
also	O
suggest	O
that	O
two	O
mutations	O
in	O
the	O
S	O
glycoprotein	O
could	O
eventually	O
modulate	O
viral	O
neuropathogenesis	B-DISO
.	O

Molecular	O
characterization	O
of	O
the	O
viruses	O
was	O
done	O
through	O
amplification	B-DISO
of	O
genes	O
3	O
and	O
5	O
and	O
showed	O
evidence	O
of	O
genetic	O
similarity	O
between	O
them	O
,	O
although	O
they	O
differed	O
from	O
sequences	O
of	O
other	O
TCoVs	O
described	O
in	O
the	O
literature	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
nucleotide	O
sequencing	O
,	O
and	O
GenBank	O
BLAST	O
database	O
analyses	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
virus	O
spike	O
gene	O
showed	O
that	O
the	O
three	O
isolates	O
,	O
designated	O
TN20	O
/	O
00	O
,	O
TN200	O
/	O
01	O
,	O
and	O
TN335	O
/	O
01	O
,	O
share	O
from	O
64	O
%	O
to	O
82	O
%	O
homologies	O
between	O
each	O
other	O
but	O
are	O
very	O
different	O
from	O
the	O
H120	O
strain	O
,	O
the	O
only	O
infectious	B-DISO
bronchitis	B-DISO
vaccine	O
used	O
in	O
Tunisia	O
.	O

Systemic	O
and	O
pulmonary	O
hemodynamics	O
,	O
blood	O
gas	O
exchange	O
parameters	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
,	O
and	O
angiotensin	O
II	O
levels	O
were	O
examined	O
before	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
induction	O
and	O
at	O
various	O
time	O
points	O
after	O
administering	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
or	O
saline	O
.	O

Furthermore	O
,	O
angiotensin	O
II	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
levels	O
,	O
both	O
of	O
which	O
were	O
substantially	O
increased	O
,	O
returned	O
to	O
basal	O
values	O
.	O

Inhibitory	O
AMs	B-DISO
are	O
believed	O
to	O
prevent	O
the	O
development	O
of	O
immune	O
responses	O
to	O
environmental	O
antigens	O
and	O
allergic	O
responses	O
by	O
interacting	O
with	O
lung	O
dendritic	O
cells	O
and	O
T	O
cells	O
.	O

Strain	O
v2163	O
provided	O
a	O
valuable	O
model	O
for	O
anti	O
-	O
SARS	B-DISO
research	O
.	O

One	O
of	O
the	O
169	O
peptides	O
screened	O
,	O
peptide	O
9626	O
(	O
S	O
residues	O
217	O
-	O
234	O
),	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
mediated	O
entry	O
of	O
the	O
pseudotyped	O
virions	O
in	O
293T	O
cells	O
expressing	O
a	O
functional	O
SARS	B-DISO
-	O
CoV	O
receptor	O
(	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
approximately	O
11	O
microM	O
).	O

Infection	B-DISO
by	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
can	O
cause	O
severe	O
respiratory	O
illness	O
,	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
secondary	B-DISO
infections	I-DISO
among	O
healthcare	O
workers	O
.	O

Thus	O
,	O
young	O
piglets	O
,	O
growing	O
16	O
-	O
20	O
-	O
week	O
-	O
old	O
finisher	O
pigs	O
,	O
and	O
mature	O
third	O
parity	O
sows	O
were	O
infected	O
with	O
virulent	O
or	O
attenuated	O
PRRSV	O
,	O
and	O
the	O
dynamics	O
of	O
viral	B-DISO
infection	I-DISO
,	O
disease	O
,	O
and	O
immune	O
response	O
were	O
monitored	O
over	O
time	O
.	O

Interferon	O
gamma	O
(	O
IFN	O
gamma	O
)	O
secreting	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
more	O
abundant	O
in	O
sows	O
but	O
not	O
specifically	O
increased	O
by	O
PRRSV	O
infection	B-DISO
in	O
any	O
age	O
group	O
,	O
and	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)	O
levels	O
in	O
blood	O
were	O
not	O
correlated	O
with	O
PRRSV	O
infection	B-DISO
status	O
.	O

Equivalent	O
antibody	O
responses	O
were	O
elicited	O
in	O
response	O
to	O
virulent	O
and	O
attenuated	O
viruses	O
,	O
indicating	O
that	O
the	O
antigenic	O
mass	O
necessary	O
for	O
an	O
immune	O
response	O
is	O
produced	O
at	O
a	O
low	O
level	O
of	O
infection	B-DISO
,	O
and	O
is	O
not	O
predicted	O
by	O
viremic	O
status	O
.	O

RESULTS	O
:	O
Virulent	O
PRRSV	O
infection	B-DISO
and	O
disease	O
were	O
markedly	O
more	O
severe	O
and	O
prolonged	O
in	O
young	O
piglets	O
than	O
in	O
finishers	O
or	O
sows	O
.	O

Using	O
a	O
simple	O
model	O
of	O
the	O
epidemiological	O
and	O
evolutionary	O
dynamics	O
of	O
emerging	O
pathogens	O
,	O
along	O
with	O
rough	O
estimates	O
of	O
parameters	O
for	O
pathogens	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
and	O
myxomatosis	O
,	O
we	O
estimated	O
the	O
potential	O
magnitude	O
and	O
timing	O
of	O
such	O
transient	O
virulence	O
peaks	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
this	O
investigation	O
is	O
to	O
review	O
existing	O
research	O
pertaining	O
to	O
cognitive	B-DISO
impairment	I-DISO
and	O
decline	O
following	O
critical	B-DISO
illness	I-DISO
and	O
describe	O
a	O
case	O
involving	O
a	O
49	O
-	O
year	O
-	O
old	O
female	O
with	O
sepsis	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
no	O
prior	O
neurologic	O
history	O
who	O
,	O
compared	O
to	O
baseline	O
neuropsychological	O
test	O
data	O
,	O
experienced	O
dramatic	O
cognitive	B-DISO
decline	I-DISO
and	O
brain	B-DISO
atrophy	I-DISO
following	O
treatment	O
in	O
the	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
at	O
Vanderbilt	O
University	O
Medical	O
Center	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
effects	O
of	O
critical	B-DISO
illness	I-DISO
in	O
the	O
daily	O
lives	O
and	O
functioning	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
survivors	O
.	O

However	O
,	O
the	O
experiences	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
survivors	O
have	O
not	O
been	O
reported	O
.	O

Transcripts	O
were	O
analyzed	O
,	O
using	O
Colaizzi	O
'	O
s	O
qualitative	O
methodology	O
,	O
to	O
identify	O
significant	O
ways	O
in	O
which	O
survivors	O
'	O
critical	B-DISO
illness	I-DISO
experience	O
impacted	B-DISO
their	O
lives	O
.	O

The	O
diverse	O
and	O
unique	O
experiences	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
survivors	O
reflect	O
the	O
global	O
impact	O
of	O
severe	O
critical	B-DISO
illness	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
current	O
demographic	O
,	O
clinical	O
and	O
prognostic	O
characteristics	O
of	O
acute	B-DISO
post	I-DISO
-	I-DISO
streptococcal	I-DISO
glomerulonephritis	I-DISO
(	O
APSGN	O
)	O
in	O
French	O
Polynesia	O
and	O
to	O
compare	O
these	O
features	O
with	O
those	O
of	O
other	O
populations	O
.	O

Signs	O
of	O
previous	O
respiratory	B-DISO
infections	I-DISO
were	O
clearly	O
evident	O
in	O
40	O
%	O
of	O
the	O
children	O
.	O

Acute	B-DISO
post	I-DISO
-	I-DISO
streptococcal	I-DISO
glomerulonephritis	I-DISO
is	O
endemic	O
among	O
French	O
Polynesians	O
,	O
and	O
they	O
can	O
be	O
considered	O
to	O
be	O
a	O
high	O
-	O
risk	O
population	O
.	O

ABSTRACT	O
:	O
Disruption	O
of	O
fibrinolytic	O
homeostasis	O
participates	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	O
lung	B-DISO
diseases	I-DISO
like	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
)	O
and	O
plastic	B-DISO
bronchitis	I-DISO
.	O

Male	O
and	O
female	O
B6C3F1	O
mice	O
received	O
one	O
of	O
two	O
intratracheal	O
(	O
IT	O
)	O
doses	O
of	O
either	O
nebulized	O
pf	O
-	O
mtPA	O
or	O
sterile	B-DISO
saline	O
twice	O
daily	O
for	O
28	O
days	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
male	O
living	O
in	O
a	O
malaria	B-DISO
-	O
endemic	O
area	O
who	O
presented	O
with	O
ARDS	B-DISO
and	O
was	O
diagnosed	O
as	O
having	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
.	O

The	O
use	O
of	O
NIPPV	O
in	O
vivax	O
-	O
malaria	B-DISO
related	O
ARDS	B-DISO
was	O
associated	O
with	O
a	O
good	O
outcome	O
.	O

TITLE	O
:	O
Otitis	B-DISO
media	I-DISO
:	O
viruses	O
,	O
bacteria	O
,	O
biofilms	O
and	O
vaccines	O
.	O

These	O
include	O
respiratory	O
syncytial	O
virus	O
,	O
rhinovirus	O
,	O
adenovirus	B-DISO
,	O
parainfluenza	B-DISO
and	O
coronavirus	O
.	O

However	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
interferons	O
are	O
produced	O
during	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
humans	O
and	O
macaques	O
.	O

These	O
treatments	O
include	O
recombinant	O
human	O
activated	O
C	O
protein	O
and	O
protective	O
-	O
ventilation	O
strategy	O
for	O
respiratory	B-DISO
failure	I-DISO
.	O

This	O
was	O
shown	O
by	O
the	O
occurrence	O
of	O
faecal	O
shedding	O
,	O
and	O
dogs	O
displaying	O
moderate	O
clinical	O
signs	O
,	O
mainly	O
vomiting	B-DISO
and	O
diarrhoea	B-DISO
.	O

TITLE	O
:	O
The	O
open	O
reading	O
frame	O
3a	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
promotes	O
membrane	O
rearrangement	O
and	O
cell	O
death	O
.	O

In	O
addition	O
,	O
we	O
report	O
that	O
ORF	O
3a	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
Golgi	O
fragmentation	B-DISO
and	O
that	O
the	O
3a	O
protein	O
accumulates	O
and	O
localizes	O
to	O
vesicles	B-DISO
containing	O
markers	O
for	O
late	O
endosomes	O
.	O

TITLE	O
:	O
Integrity	O
of	O
the	O
early	O
secretory	O
pathway	O
promotes	O
,	O
but	O
is	O
not	O
required	O
for	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
RNA	O
synthesis	O
and	O
virus	O
-	O
induced	O
remodeling	O
of	O
endoplasmic	O
reticulum	O
membranes	O
.	O

ABSTRACT	O
:	O
To	O
accommodate	O
its	O
RNA	O
synthesis	O
in	O
the	O
infected	O
cell	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
induces	O
a	O
cytoplasmic	O
reticulovesicular	O
network	O
(	O
RVN	O
)	O
that	O
is	O
derived	O
from	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membranes	O
.	O

Confocal	O
microscopy	O
studies	O
showed	O
that	O
early	O
secretory	O
pathway	O
components	O
are	O
not	O
associated	O
with	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
replication	O
sites	O
,	O
although	O
our	O
studies	O
revealed	O
that	O
infection	B-DISO
induces	O
a	O
remarkable	O
redistribution	O
of	O
the	O
translocon	O
subunit	O
Sec61alpha	O
.	O

Whilst	O
intact	O
in	O
all	O
FECVs	O
,	O
the	O
3c	O
gene	O
was	O
mutated	O
in	O
the	O
majority	O
(	O
71	O
.	O
4	O
%)	O
of	O
FIPVs	O
,	O
but	O
not	O
in	O
all	O
,	O
implying	O
that	O
mutation	O
in	O
3c	O
is	O
not	O
the	O
(	O
single	O
)	O
cause	O
of	O
FIP	B-DISO
.	O

Most	O
cats	O
with	O
FIP	B-DISO
had	O
no	O
detectable	O
intestinal	O
feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
and	O
had	O
seemingly	O
cleared	O
the	O
primary	O
FECV	O
infection	B-DISO
.	O

Apparently	O
,	O
3c	O
-	O
inactivated	O
viruses	O
replicate	O
not	O
at	O
all	O
--	O
or	O
only	O
poorly	O
--	O
in	O
the	O
gut	O
,	O
explaining	O
the	O
rare	O
incidence	O
of	O
FIP	B-DISO
outbreaks	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
examine	O
the	O
relationship	O
between	O
ERI	O
and	O
compliance	O
with	O
infection	B-DISO
control	O
,	O
as	O
well	O
as	O
the	O
impact	O
of	O
nurses	O
'	O
experience	O
in	O
caring	O
for	O
SARS	B-DISO
patients	O
on	O
their	O
compliance	O
behaviour	O
with	O
infection	B-DISO
control	O
.	O

Past	O
medical	O
history	O
includes	O
retained	O
dentition	O
of	O
six	O
primary	O
teeth	O
,	O
two	O
episodes	O
of	O
childhood	B-DISO
pneumonia	I-DISO
that	O
required	O
hospitalization	O
,	O
and	O
three	O
wrist	O
and	O
ankle	O
fractures	O
.	O

ABSTRACT	O
:	O
To	O
measure	O
the	O
incidence	O
and	O
impact	O
of	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
)	O
in	O
a	O
cohort	O
of	O
70	O
subjects	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
In	O
marked	O
contrast	O
to	O
their	O
historical	O
classification	O
as	O
relatively	O
harmless	O
,	O
common	B-DISO
cold	I-DISO
-	O
causing	O
,	O
respiratory	O
pathogens	O
,	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
associated	O
with	O
more	O
severe	O
clinical	O
complications	O
,	O
as	O
emphasized	O
by	O
the	O
discovery	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
CoV	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2003	O
.	O

We	O
present	O
a	O
case	O
of	O
confirmed	O
CA	O
-	O
MRSA	B-DISO
necrotizing	B-DISO
pneumonia	I-DISO
with	O
post	O
-	O
hospital	O
discharge	O
follow	O
-	O
up	O
involving	O
radiologic	O
imaging	O
and	O
pulmonary	O
function	O
testing	O
.	O

ABSTRACT	O
:	O
The	O
functional	O
role	O
of	O
ELR	O
-	O
positive	O
CXC	O
chemokines	O
in	O
host	O
defense	O
during	O
acute	O
viral	O
-	O
induced	O
encephalomyelitis	B-DISO
was	O
determined	O
.	O

Correspondingly	O
,	O
CXCR2	O
neutralization	O
resulted	O
in	O
diminished	O
infiltration	B-DISO
of	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
an	O
inability	O
to	O
control	O
viral	O
replication	O
within	O
the	O
brain	O
,	O
and	O
100	O
%	O
mortality	O
.	O

Both	O
affinity	O
-	O
purified	O
anti	O
-	O
CD134	O
and	O
anti	O
-	O
SU	O
antibodies	O
blocked	O
FIV	O
infection	B-DISO
ex	O
vivo	O
.	O

ABSTRACT	O
:	O
Post	O
hoc	O
analysis	O
of	O
a	O
previous	O
trial	O
has	O
suggested	O
that	O
prone	O
positioning	O
may	O
improve	O
survival	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
and	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Data	O
from	O
this	O
study	O
indicate	O
that	O
prone	O
positioning	O
does	O
not	O
provide	O
significant	O
survival	O
benefit	O
in	O
patients	O
with	O
ARDS	B-DISO
or	O
in	O
subgroups	O
of	O
patients	O
with	O
moderate	O
and	O
severe	O
hypoxemia	O
.	O

Enhanced	O
production	O
of	O
cytokines	O
(	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
and	O
interleukin	O
-	O
6	O
[	O
IL	O
-	O
6	O
])	O
and	O
chemokines	O
(	O
CXCL10	O
,	O
CCL2	O
,	O
CCL3	O
,	O
and	O
CCL5	O
)	O
correlated	O
with	O
migration	O
of	O
NK	O
cells	O
,	O
macrophages	O
,	O
and	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	B-DISO
)	O
into	O
the	O
lungs	O
.	O

Depletion	O
of	O
CD8	O
(+)	O
T	O
cells	O
at	O
the	O
time	O
of	O
infection	B-DISO
did	O
not	O
affect	O
viral	O
replication	O
or	O
clearance	O
.	O

However	O
,	O
depletion	O
of	O
CD4	O
(+)	O
T	O
cells	O
resulted	O
in	O
an	O
enhanced	O
immune	O
-	O
mediated	O
interstitial	B-DISO
pneumonitis	I-DISO
and	O
delayed	O
clearance	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
the	O
lungs	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
neutralizing	O
antibody	O
and	O
cytokine	O
production	O
and	O
reduced	O
pulmonary	O
recruitment	B-DISO
of	O
lymphocytes	O
.	O

Innate	O
defense	O
mechanisms	O
are	O
able	O
to	O
control	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
the	O
absence	O
of	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
and	O
antibodies	O
.	O

Most	O
notable	O
is	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
of	O
humans	O
that	O
was	O
first	O
reported	O
in	O
late	O
2002	O
in	O
Guangdong	O
Province	O
,	O
China	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
molecular	O
mechanisms	O
that	O
govern	O
coronavirus	O
cross	O
-	O
species	O
transmission	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
using	O
the	O
emergence	O
of	O
SARS	B-DISO
-	O
CoV	O
as	O
a	O
model	O
.	O

H5N1	B-DISO
-	O
inoculated	O
mice	O
presented	O
two	O
stages	O
of	O
pulmonary	B-DISO
disease	I-DISO
over	O
a	O
30	O
-	O
d	O
period	O
after	O
infection	B-DISO
.	O

Our	O
findings	O
show	O
that	O
H5N1	B-DISO
-	O
infected	O
mice	O
develop	O
the	O
typical	O
PF	O
during	O
restoration	O
period	O
,	O
which	O
will	O
contribute	O
to	O
the	O
investigation	O
of	O
fibrogenesis	O
and	O
potential	O
therapeutic	O
intervention	O
in	O
human	O
H5N1	B-DISO
disease	O
.	O

Canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
and	O
canine	O
parainfluenza	B-DISO
virus	O
(	O
CPIV	O
)	O
titers	O
were	O
not	O
detected	O
in	O
all	O
serum	O
samples	O
.	O

TITLE	O
:	O
MicroRNome	O
analysis	O
unravels	O
the	O
molecular	O
basis	O
of	O
SARS	B-DISO
infection	B-DISO
in	O
bronchoalveolar	O
stem	O
cells	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
the	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
,	O
is	O
an	O
acute	B-DISO
infectious	I-DISO
disease	I-DISO
with	O
significant	O
mortality	O
.	O

Our	O
observation	O
reveals	O
the	O
BASCs	O
(	O
Sca	O
-	O
1	O
+	O
CD34	O
+	O
CD45	O
-	O
Pecam	O
-),	O
a	O
subset	O
of	O
Oct	O
-	O
4	O
+	O
ACE2	O
+	O
epithelial	O
colony	O
cells	O
at	O
the	O
broncho	O
-	O
alveolar	O
duct	O
junction	O
,	O
to	O
be	O
the	O
prime	O
target	O
cells	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
To	O
survey	O
the	O
dose	O
of	O
glucocorticosteroids	O
administered	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
assess	O
the	O
effect	O
of	O
glucocorticosteroid	O
doses	O
in	O
improving	O
the	O
patients	O
'	O
lung	O
function	O
.	O

Glococoticostecoids	O
were	O
used	O
in	O
59	O
.	O
56	O
%	O
of	O
the	O
SARS	B-DISO
cases	O
.	O

We	O
prospectively	O
evaluated	O
the	O
response	O
to	O
oseltamivir	O
and	O
prolonged	O
corticosteroid	O
treatment	O
in	O
patients	O
with	O
ALI	O
-	O
ARDS	B-DISO
and	O
suspected	O
H1N1	B-DISO
influenza	I-DISO
.	O

RESULTS	O
:	O
Patients	O
with	O
and	O
without	O
confirmed	O
H1N1	B-DISO
influenza	I-DISO
had	O
similar	O
disease	O
severity	O
at	O
presentation	O
and	O
a	O
comparable	O
response	O
to	O
treatment	O
.	O

TITLE	O
:	O
[	O
Fulminant	O
,	O
life	O
-	O
threatening	O
influenza	B-DISO
A	O
/	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
].	O

The	O
patient	O
was	O
in	O
poor	O
general	O
condition	B-DISO
.	O

TITLE	O
:	O
Severe	O
late	O
-	O
onset	O
nosocomial	B-DISO
pneumonia	I-DISO
caused	O
by	O
Chlamydophila	O
pneumoniae	O
.	O

Intravenous	O
azithromycin	O
treatment	O
was	O
used	O
to	O
cure	O
pneumonia	B-DISO
in	O
both	O
of	O
our	O
patients	O
.	O

TITLE	O
:	O
Caring	O
for	O
HIV	B-DISO
-	O
infected	O
patients	O
in	O
the	O
ICU	O
in	O
the	O
highly	O
active	O
antiretroviral	O
therapy	O
era	O
.	O

ABSTRACT	O
:	O
Beta	O
-	O
defensins	O
are	O
cationic	O
peptides	O
which	O
form	O
part	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
of	O
the	O
respiratory	O
epithelium	O
.	O

Using	O
molecular	O
assays	O
for	O
virus	O
detection	O
and	O
characterisation	O
,	O
CPV	O
and	O
CCoV	O
were	O
found	O
to	O
be	O
widespread	O
in	O
European	O
dog	O
populations	O
,	O
either	O
alone	O
or	O
in	O
mixed	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
During	O
the	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
,	O
some	O
patients	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
severe	O
cardiopulmonary	B-DISO
failure	I-DISO
despite	O
the	O
use	O
of	O
conventional	O
management	O
.	O

He	O
was	O
intubated	O
2	O
days	O
later	O
due	O
to	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
and	O
persistent	O
shock	O
refractory	O
to	O
conventional	O
management	O
.	O

Severe	O
ARDS	B-DISO
with	O
multiorgan	O
dysfunction	O
in	O
the	O
absence	O
of	O
bacterial	B-DISO
infection	I-DISO
was	O
a	O
common	O
clinical	O
presentation	O
.	O

Specific	O
pathogen	O
free	O
1	O
-	O
week	O
-	O
old	O
chickens	O
exhibited	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
(	O
dyspnea	B-DISO
)	O
and	O
nephropathogenic	O
lesions	O
(	O
swollen	O
kidneys	O
with	O
nephritis	B-DISO
and	O
urate	O
deposits	O
)	O
following	O
challenge	O
with	O
the	O
recent	O
IBV	O
field	O
strain	O
.	O

However	O
,	O
acute	O
lung	O
injury	O
with	O
its	O
attendant	O
hypoxemia	O
,	O
hypercapnia	B-DISO
and	O
mechanical	O
ventilation	O
worsens	O
renal	O
hemodynamics	O
and	O
function	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
kidney	O
and	O
lung	O
interact	O
(	O
crosstalk	O
)	O
during	O
severe	O
insults	O
,	O
such	O
as	O
shock	O
,	O
trauma	O
,	O
and	O
sepsis	B-DISO
,	O
due	O
to	O
a	O
loss	O
of	O
the	O
normal	O
balance	O
of	O
immune	O
,	O
inflammatory	O
and	O
soluble	O
mediators	O
.	O

TITLE	O
:	O
Infection	B-DISO
with	O
a	O
pathogenic	O
turkey	O
coronavirus	O
isolate	O
negatively	O
affects	O
growth	O
performance	O
and	O
intestinal	O
morphology	O
of	O
young	O
turkey	O
poults	O
in	O
Canada	O
.	O

Diarrhoea	B-DISO
was	O
consistently	O
seen	O
in	O
infected	O
poults	O
at	O
2	O
to	O
3	O
days	O
post	O
infection	B-DISO
(	O
d	O
.	O
p	O
.	O
i	O
.)	O
with	O
a	O
duration	O
of	O
about	O
3	O
to	O
5	O
days	O
.	O

Severe	O
kidney	O
damage	O
and	O
dilatation	B-DISO
of	O
the	O
oviduct	O
were	O
the	O
prominent	O
lesions	O
that	O
could	O
be	O
related	O
to	O
the	O
QX	O
-	O
like	O
IBV	O
strains	O
,	O
although	O
neither	O
marked	O
virus	O
replication	O
nor	O
histopathological	O
lesions	O
were	O
detected	O
in	O
the	O
oviduct	O
.	O

This	O
atypical	O
response	O
of	O
pDCs	O
to	O
PRRSV	O
may	O
contribute	O
to	O
its	O
pathogenesis	B-DISO
,	O
which	O
unlike	O
that	O
associated	O
with	O
PrV	B-DISO
,	O
SIV	B-DISO
or	O
TGEV	O
includes	O
persistent	B-DISO
infection	I-DISO
and	O
limited	O
development	O
of	O
protective	O
immunity	O
.	O

ABSTRACT	O
:	O
Treatment	O
strategies	O
for	O
critically	O
-	O
ill	B-DISO
patients	O
can	O
and	O
should	O
never	O
be	O
excluded	O
from	O
grading	O
processes	O
that	O
classify	O
the	O
evidence	O
and	O
provide	O
decision	O
support	O
for	O
health	O
care	O
workers	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

TITLE	O
:	O
Lung	O
parenchyma	O
remodeling	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
the	O
most	O
severe	O
manifestation	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
is	O
described	O
as	O
a	O
stereotyped	B-DISO
response	I-DISO
to	O
lung	O
injury	O
with	O
a	O
transition	B-DISO
from	O
alveolar	O
capillary	O
damage	O
to	O
a	O
fibroproliferative	O
phase	O
.	O

In	O
this	O
line	O
,	O
mechanical	O
ventilation	O
may	O
affect	O
the	O
macromolecules	O
that	O
constitute	O
the	O
extracellular	O
matrix	O
(	O
collagen	O
,	O
elastin	O
,	O
fibronectin	O
,	O
laminin	O
,	O
proteoglycan	O
and	O
glycosaminoglycans	O
),	O
suffer	B-DISO
changes	O
and	O
impact	O
the	O
biomechanical	O
behavior	O
of	O
lung	O
parenchyma	O
.	O

H9N2	O
-	O
infected	O
mice	O
exhibited	O
severe	O
respiratory	O
syndrome	B-DISO
,	O
with	O
a	O
mortality	O
rate	O
of	O
60	O
%.	O

Gross	O
observations	O
showed	O
that	O
infected	O
lungs	O
were	O
highly	O
edematous	B-DISO
.	O

The	O
features	O
described	O
above	O
satisfy	O
the	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Despite	O
extensive	O
evaluation	O
neither	O
infectious	B-DISO
,	O
autoimmune	B-DISO
,	O
hematological	O
nor	O
oncological	O
disorders	O
were	O
revealed	O
.	O

Rather	O
,	O
the	O
diagnosis	O
is	O
based	O
on	O
the	O
clinical	O
criteria	O
and	O
requires	O
the	O
exclusion	O
of	O
infectious	B-DISO
,	O
neoplastic	O
,	O
and	O
other	O
autoimmune	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complications	I-DISO
following	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
are	O
relatively	O
common	O
,	O
with	O
up	O
to	O
12	O
%	O
of	O
patients	O
experiencing	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

The	O
treatment	O
for	O
ALI	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
primarily	O
supportive	O
with	O
specific	O
modes	O
of	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
[	O
Pulmonary	O
manifestations	O
of	O
leptospirosis	B-DISO
].	O

134	O
patients	O
(	O
36	O
.	O
7	O
+	O
or	O
-	O
14	O
years	O
of	O
age	O
)	O
had	O
pulmonary	B-DISO
involvement	I-DISO
.	O

Haemoptysis	B-DISO
was	O
associated	O
with	O
survival	O
(	O
OR	O
0	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
02	O
).	O

Haemoptysis	B-DISO
was	O
associated	O
with	O
survival	O
(	O
OR	O
0	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
02	O
).	O

TITLE	O
:	O
The	O
treatment	O
of	O
bleeding	B-DISO
is	O
to	O
stop	O
the	O
bleeding	B-DISO
!	O

This	O
can	O
be	O
done	O
by	O
reducing	O
the	O
volume	O
of	O
blood	B-DISO
loss	I-DISO
.	O

Analysis	O
of	O
data	O
for	O
the	O
117	O
blunt	O
trauma	O
patients	O
who	O
survived	O
at	O
least	O
48	O
hours	O
after	O
receiving	O
study	O
treatment	O
shows	O
that	O
,	O
in	O
addition	O
to	O
reducing	O
RBC	O
requirement	O
,	O
rFVIIa	O
significantly	O
reduced	O
the	O
need	O
for	O
massive	O
transfusion	O
over	O
48	O
hours	O
(>	O
20	O
RBC	O
units	O
)	O
(	O
relative	O
risk	O
reduction	O
of	O
56	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
:	O
9	O
%-	O
79	O
%];	O
p	O
=	O
0	O
.	O
03	O
),	O
and	O
the	O
fresh	O
-	O
frozen	O
plasma	O
(	O
p	O
=	O
0	O
.	O
036	O
),	O
platelet	O
(	O
p	O
=	O
0	O
.	O
023	O
),	O
and	O
cryoprecipitate	O
(	O
p	O
=	O
0	O
.	O
053	O
)	O
requirements	O
within	O
48	O
hours	O
,	O
and	O
was	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
the	O
30	O
-	O
day	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
/	O
or	O
ARDS	B-DISO
(	O
p	O
=	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
[	O
Analysis	O
of	O
clinical	O
risk	O
factors	O
in	O
progression	O
from	O
acute	O
lung	O
injury	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
severe	O
trauma	O
patients	O
].	O

The	O
7	O
-	O
day	O
and	O
28	O
-	O
day	O
mortality	O
,	O
the	O
days	O
in	O
ICU	O
and	O
the	O
length	O
of	O
stay	O
,	O
the	O
changes	O
of	O
oxygenation	O
index	O
,	O
the	O
days	O
of	O
mechanical	O
ventilation	O
and	O
the	O
rates	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
were	O
observed	O
.	O

ABSTRACT	O
:	O
Despite	O
consensus	O
criteria	O
,	O
diagnosing	O
acute	O
lung	O
injury	O
,	O
or	O
its	O
more	O
severe	O
form	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
remains	O
challenging	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
and	O
compare	O
the	O
diagnostic	O
accuracy	O
of	O
biological	O
markers	O
for	O
ALI	O
/	O
ARDS	B-DISO
with	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
VAP	O
).	O

The	O
adjusted	O
excess	O
case	O
fatality	O
ratios	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
receiving	O
the	O
combined	O
therapy	O
of	O
ribavirin	O
and	O
corticosteroids	O
within	O
2	O
days	O
of	O
admission	O
,	O
compared	O
with	O
those	O
receiving	O
neither	O
treatment	O
within	O
2	O
days	O
of	O
admission	O
,	O
were	O
3	O
.	O
8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
1	O
.	O
5	O
to	O
9	O
.	O
2	O
)	O
in	O
Hong	O
Kong	O
and	O
2	O
.	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
44	O
.	O
3	O
to	O
48	O
.	O
5	O
)	O
in	O
Toronto	O
.	O

RESULTS	O
:	O
The	O
adjusted	O
excess	O
case	O
fatality	O
ratios	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
receiving	O
the	O
combined	O
therapy	O
of	O
ribavirin	O
and	O
corticosteroids	O
within	O
2	O
days	O
of	O
admission	O
,	O
compared	O
with	O
those	O
receiving	O
neither	O
treatment	O
within	O
2	O
days	O
of	O
admission	O
,	O
were	O
3	O
.	O
8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
1	O
.	O
5	O
to	O
9	O
.	O
2	O
)	O
in	O
Hong	O
Kong	O
and	O
2	O
.	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
44	O
.	O
3	O
to	O
48	O
.	O
5	O
)	O
in	O
Toronto	O
.	O

RESULTS	O
:	O
The	O
majority	O
of	O
physicians	O
agreed	O
that	O
home	O
quarantine	O
of	O
contacts	O
of	O
patients	O
with	O
probable	O
SARS	B-DISO
was	O
warranted	O
(	O
95	O
%),	O
government	O
'	O
s	O
public	O
education	O
effort	O
was	O
effective	O
(	O
83	O
%),	O
and	O
the	O
overall	O
Singapore	O
'	O
s	O
response	O
was	O
commendable	O
(	O
82	O
%).	O

TITLE	O
:	O
Cost	O
-	O
effectiveness	O
analysis	O
of	O
hospital	B-DISO
infection	I-DISO
control	O
response	O
to	O
an	O
epidemic	O
respiratory	O
virus	O
threat	O
.	O

We	O
studied	O
actual	O
direct	O
costs	O
and	O
cost	O
-	O
effectiveness	O
of	O
different	O
response	O
measures	O
from	O
a	O
hospital	O
perspective	O
in	O
tertiary	O
hospitals	O
in	O
Singapore	O
by	O
simulating	O
outbreaks	O
of	O
SARS	B-DISO
,	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
,	O
and	O
1918	O
Spanish	O
influenza	B-DISO
.	O

The	O
regulatory	O
network	O
can	O
extract	O
unique	O
features	O
of	O
each	O
disease	O
condition	B-DISO
,	O
thus	O
one	O
immediate	O
application	O
of	O
regulatory	O
network	O
is	O
to	O
classifying	O
different	O
diseases	O
.	O

Influenza	B-DISO
,	O
plague	B-DISO
,	O
and	O
trypanosomiasis	B-DISO
are	O
classic	O
examples	O
of	O
zoonotic	O
infections	B-DISO
that	O
transmit	O
from	O
animals	O
to	O
humans	O
.	O

Meanwhile	O
,	O
vector	O
-	O
transmitted	B-DISO
,	O
chronic	O
,	O
and	O
protozoan	B-DISO
infections	I-DISO
have	O
been	O
neglected	O
,	O
as	O
have	O
crucial	O
processes	O
such	O
as	O
cross	O
-	O
species	O
transmission	O
.	O

Since	O
the	O
downregulation	O
of	O
ACE2	O
by	O
SARS	B-DISO
-	O
S	O
protein	O
was	O
proposed	O
as	O
an	O
etiological	O
event	O
in	O
the	O
severe	O
clinical	O
manifestations	O
,	O
our	O
data	O
suggest	O
that	O
TACE	O
antagonists	O
block	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
also	O
attenuate	O
its	O
severe	O
clinical	O
outcome	O
.	O

Body	O
weight	O
was	O
measured	O
,	O
and	O
fecal	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
the	O
dogs	O
during	O
the	O
experiment	O
for	O
the	O
measurement	O
of	O
hematology	O
,	O
fecal	O
immunoglobulin	O
(	O
Ig	O
)	O
A	O
and	O
IgG	O
,	O
circulating	O
IgA	O
and	O
IgG	O
,	O
and	O
canine	O
corona	O
virus	O
(	O
CCV	B-DISO
)-	O
specific	O
IgG	O
.	O
There	O
were	O
no	O
differences	O
in	O
body	O
weights	O
among	O
the	O
groups	O
,	O
but	O
monocyte	O
counts	O
in	O
hematology	O
and	O
serum	O
IgA	O
were	O
higher	O
in	O
the	O
group	O
receiving	O
L	O
.	O
casei	O
expressing	O
cGMCSF	O
than	O
in	O
the	O
other	O
two	O
groups	O
.	O

Most	O
of	O
them	O
confirm	O
previous	O
results	O
and	O
few	O
add	B-DISO
new	O
information	O
.	O

It	O
has	O
been	O
definitely	O
confirmed	O
that	O
opening	O
pressures	O
are	O
different	O
throughout	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
lung	O
parenchyma	O
,	O
ranging	O
from	O
5	O
-	O
10	O
up	O
to	O
30	O
-	O
40	O
cmH2O	O
.	O

However	O
,	O
in	O
the	O
most	O
severe	O
patients	O
,	O
recruitment	B-DISO
maneuver	O
has	O
to	O
be	O
considered	O
and	O
higher	O
PEEP	O
applied	O
.	O

Methods	O
of	O
detection	O
and	O
the	O
role	O
for	O
cattle	O
persistently	O
infected	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
(	O
BVDV	O
)	O
were	O
identified	O
;	O
viral	O
subunits	O
,	O
cellular	O
components	O
and	O
bacterial	O
products	O
have	O
been	O
characterized	O
.	O

TITLE	O
:	O
Fact	O
-	O
finding	O
survey	O
of	O
nosocomial	B-DISO
infection	I-DISO
control	O
in	O
hospitals	O
in	O
Vietnam	O
and	O
application	O
to	O
training	O
programs	O
.	O

ABSTRACT	O
:	O
Nosocomial	B-DISO
infection	I-DISO
control	O
is	O
crucial	O
for	O
improving	O
the	O
quality	O
of	O
medical	O
care	O
.	O

ABSTRACT	O
:	O
Young	O
infants	O
with	O
measles	B-DISO
requiring	O
respiratory	O
support	O
have	O
a	O
significant	O
risk	O
for	O
death	O
and	O
long	O
-	O
term	O
complications	O
.	O

Furthermore	O
,	O
an	O
increased	O
surface	O
expression	O
and	O
raft	O
-	O
structure	O
distribution	O
of	O
annexin	O
A2	O
was	O
present	O
in	O
A549	O
cells	O
after	O
stimulation	O
with	O
SARS	B-DISO
-	O
induced	O
cytokines	O
interleukin	O
-	O
6	O
and	O
interferon	O
-	O
gamma	O
.	O

TITLE	O
:	O
Intraspecies	O
diversity	O
of	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
in	O
Rhinolophus	O
sinicus	O
and	O
its	O
implications	O
for	O
the	O
origin	O
of	O
SARS	B-DISO
coronaviruses	O
in	O
humans	O
.	O

A	O
steady	O
number	O
of	O
cases	O
of	O
imported	O
malaria	B-DISO
are	O
also	O
seen	O
in	O
many	O
countries	O
of	O
the	O
developed	O
world	O
.	O

Effective	O
management	O
of	O
severe	O
malaria	B-DISO
includes	O
early	O
suspicion	O
,	O
prompt	O
diagnosis	O
,	O
early	O
institution	O
of	O
appropriate	O
antimalarial	O
chemotherapy	O
,	O
and	O
supportive	O
care	O
,	O
preferably	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
Coronavirus	O
3a	O
protein	O
causes	O
endoplasmic	O
reticulum	O
stress	O
and	O
induces	O
ligand	O
-	O
independent	O
downregulation	O
of	O
the	O
type	O
1	O
interferon	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
reported	O
to	O
cause	O
apoptosis	O
of	O
infected	O
cells	O
and	O
several	O
of	O
its	O
proteins	O
including	O
the	O
3a	O
accessory	O
protein	O
,	O
are	O
pro	O
-	O
apoptotic	O
.	O

ABSTRACT	O
:	O
There	O
is	O
inconclusive	O
data	O
on	O
whether	O
critically	B-DISO
ill	I-DISO
individuals	O
with	O
severe	O
secondary	B-DISO
peritonitis	I-DISO
requiring	O
multiple	O
staged	O
laparotomies	O
may	O
became	O
eligible	O
candidates	O
for	O
deferred	O
primary	O
anastomoses	B-DISO
(	O
DPA	O
).	O

EOVAP	O
was	O
also	O
significantly	O
associated	O
with	O
a	O
longer	O
duration	O
of	O
mechanical	O
ventilation	O
(	O
14	O
.	O
0	O
vs	O
.	O
11	O
.	O
0	O
d	O
,	O
P	O
=	O
0	O
.	O
024	O
),	O
and	O
a	O
longer	O
sedation	B-DISO
duration	O
(	O
8	O
.	O
3	O
vs	O
.	O
5	O
.	O
8	O
d	O
P	O
=	O
0	O
.	O
005	O
).	O

Although	O
only	O
a	O
minority	O
of	O
hospitalizations	O
for	O
cardiomyopathy	B-DISO
are	O
consistent	O
with	O
peripartum	B-DISO
cardiomyopathy	I-DISO
,	O
cardiomyopathy	B-DISO
and	O
other	O
myocardial	O
disorders	O
are	O
important	O
contributors	O
to	O
severe	O
obstetric	O
complications	O
.	O

Vitamin	O
K3	O
also	O
suppressed	O
the	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
nuclear	O
translocation	B-DISO
of	O
NF	O
-	O
kappaB	O
and	O
production	O
of	O
TNF	O
-	O
alpha	O
in	O
mouse	O
macrophage	O
RAW264	O
.	O
7	O
cells	O
.	O

Despite	O
marked	O
efforts	O
,	O
little	O
therapeutic	O
progress	O
has	O
been	O
made	O
,	O
and	O
the	O
mortality	O
rate	O
of	O
ARDS	B-DISO
remains	O
high	O
.	O

The	O
highest	O
and	O
lowest	O
rates	O
of	O
prevalence	O
for	O
CCoV	O
-	O
II	O
infection	B-DISO
were	O
found	O
in	O
samples	O
from	O
Hungary	O
and	O
Greece	O
(	O
96	O
.	O
87	O
%	O
and	O
3	O
.	O
45	O
%,	O
respectively	O
).	O

Specifically	O
,	O
two	O
to	O
five	O
infections	B-DISO
could	O
occur	O
during	O
a	O
5	O
hour	O
flight	O
,	O
5	O
-	O
10	O
during	O
an	O
11	O
hour	O
flight	O
and	O
7	O
-	O
17	O
during	O
a	O
17	O
hour	O
flight	O
.	O

Case	O
-	O
study	O
reports	O
on	O
2002	O
-	O
2004	O
SARS	B-DISO
outbreaks	O
have	O
discussed	O
the	O
role	O
of	O
quarantine	O
in	O
the	O
community	O
in	O
transmission	O
.	O

The	O
inverse	O
of	O
this	O
statistic	O
is	O
proposed	O
as	O
the	O
number	O
needed	O
to	O
quarantine	O
(	O
NNQ	O
)	O
to	O
prevent	O
one	O
additional	O
secondary	B-DISO
transmission	I-DISO
.	O

This	O
review	O
focuses	O
on	O
nonventilatory	O
strategies	O
in	O
the	O
advanced	O
treatment	O
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
refractory	O
hypoxemia	O
such	O
as	O
that	O
seen	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
attributable	O
to	O
2009	O
H1N1	B-DISO
influenza	I-DISO
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
is	O
a	O
progressive	O
inflammatory	O
and	O
/	O
or	O
demyelinating	B-DISO
disease	I-DISO
of	O
the	O
human	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
).	O

In	O
untreated	O
animals	O
,	O
neurological	B-DISO
symptoms	I-DISO
developed	O
quickly	O
:	O
90	O
%	O
of	O
infected	O
mice	O
died	O
10	O
days	O
after	O
virus	O
inoculation	O
and	O
the	O
few	O
survivors	O
presented	O
neurological	O
deficits	O
.	O

There	O
was	O
a	O
high	O
incidence	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
,	O
but	O
a	O
lung	O
-	O
protective	O
strategy	O
was	O
not	O
fully	O
implemented	O
.	O

ABSTRACT	O
:	O
Neurotropic	O
coronavirus	O
induces	O
acute	O
encephalomyelitis	B-DISO
and	O
demyelination	B-DISO
in	O
mice	O
.	O

We	O
performed	O
surveillance	O
for	O
1	O
year	O
and	O
describe	O
the	O
natural	O
history	O
of	O
these	O
infections	B-DISO
during	O
the	O
first	O
100	O
days	O
after	O
allogeneic	O
HCT	O
,	O
when	O
symptom	B-DISO
surveys	O
and	O
upper	O
respiratory	O
samples	O
were	O
collected	O
weekly	O
.	O

HRV	O
infection	B-DISO
was	O
associated	O
with	O
rhinorrhea	B-DISO
,	O
congestion	B-DISO
,	O
postnasal	B-DISO
drip	I-DISO
,	O
sputum	O
,	O
and	O
cough	B-DISO
;	O
HCoV	O
infection	B-DISO
was	O
not	O
associated	O
with	O
respiratory	B-DISO
symptoms	I-DISO
or	O
hepatic	B-DISO
dysfunction	I-DISO
.	O

HRV	O
and	O
HCoV	O
infections	B-DISO
are	O
common	O
in	O
the	O
first	O
100	O
days	O
after	O
HCT	O
,	O
viral	B-DISO
shedding	I-DISO
lasts	O
more	O
than	O
3	O
weeks	O
in	O
half	O
,	O
and	O
lower	B-DISO
respiratory	I-DISO
infection	I-DISO
is	O
rare	O
.	O

In	O
this	O
regards	O
,	O
we	O
have	O
created	O
a	O
mutant	B-DISO
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
mTNF	O
-	O
K90R	O
,	O
that	O
exhibits	O
high	O
bioactivity	O
and	O
resistance	O
to	O
proteases	O
.	O

In	O
order	O
to	O
decide	O
on	O
whether	O
to	O
make	O
changes	O
to	O
the	O
screening	O
levels	O
,	O
a	O
review	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
scoliosis	B-DISO
among	O
the	O
10	O
-	O
year	O
-	O
old	O
girls	O
(	O
in	O
Primary	O
5	O
)	O
and	O
12	O
-	O
year	O
-	O
old	O
girls	O
(	O
in	O
Secondary	O
1	O
).	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
prevalence	O
rates	O
of	O
adolescent	B-DISO
idiopathic	I-DISO
scoliosis	I-DISO
(	O
AIS	B-DISO
)	O
in	O
the	O
10	O
-	O
to	O
11	O
-	O
year	O
-	O
old	O
females	O
compared	O
to	O
the	O
9	O
-	O
year	O
-	O
old	O
females	O
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
2	O
.	O
4	O
;	O
P	O
=	O
0	O
.	O
010	O
).	O

The	O
study	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
prevalence	O
rates	O
of	O
scoliosis	B-DISO
in	O
the	O
10	O
-	O
to	O
11	O
-	O
year	O
-	O
old	O
female	O
students	O
and	O
again	O
a	O
significant	O
increase	O
in	O
the	O
prevalence	O
rates	O
in	O
the	O
12	O
-	O
to	O
13	O
-	O
year	O
-	O
old	O
female	O
students	O
.	O

CONCLUSIONS	O
:	O
We	O
believe	O
that	O
cyclosporine	O
is	O
a	O
cornerstone	O
for	O
the	O
treatment	O
of	O
Still	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
secondary	O
to	O
severe	O
compression	O
of	O
the	O
left	O
main	O
bronchus	O
by	O
the	O
ductus	O
arteriosus	O
.	O

A	O
diagnosis	O
of	O
retained	O
fetal	O
fluid	O
secondary	O
to	O
vascular	B-DISO
compression	I-DISO
of	O
the	O
left	O
bronchus	O
by	O
the	O
ductus	O
arteriosus	O
was	O
made	O
by	O
combining	O
various	O
imaging	O
methods	O
including	O
chest	O
radiograph	O
,	O
computed	O
tomography	O
(	O
CT	O
),	O
and	O
echocardiography	O
.	O

More	O
than	O
half	O
of	O
patients	O
had	O
patchy	O
alveolar	O
infiltrates	B-DISO
on	O
chest	O
X	O
ray	O
.	O

Moreover	O
,	O
the	O
only	O
APN	O
inhibitor	O
blocking	B-DISO
the	O
protease	O
activity	O
site	O
had	O
no	O
obvious	O
negative	O
effect	O
on	O
viral	B-DISO
infection	I-DISO
,	O
indicating	O
that	O
the	O
enzymatic	O
role	O
of	O
APN	O
is	O
dispensable	O
for	O
the	O
process	O
of	O
virus	O
replication	O
.	O

The	O
following	O
were	O
used	O
to	O
determine	O
patient	O
characteristics	O
:	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
,	O
14	O
;	O
simplified	O
acute	O
physiology	O
score	O
II	O
,	O
41	O
;	O
and	O
Murray	O
score	O
,	O
4	O
.	O

Of	O
81	O
positive	O
samples	O
,	O
the	O
viruses	O
isolated	O
included	O
rhinovirus	O
(	O
n	O
=	O
46	O
),	O
parainfluenza	B-DISO
1	O
to	O
4	O
(	O
n	O
=	O
17	O
),	O
coronavirus	O
(	O
n	O
=	O
11	O
),	O
influenza	B-DISO
(	O
n	O
=	O
4	O
),	O
metapneumovirus	O
(	O
n	O
=	O
4	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
n	O
=	O
2	O
).	O

Here	O
we	O
present	O
two	O
cases	O
:	O
in	O
the	O
first	O
one	O
,	O
a	O
23	O
years	O
old	O
woman	O
,	O
with	O
15	O
.	O
5	O
weeks	O
of	O
gestation	O
has	O
a	O
cuadriplegia	O
associated	O
to	O
blood	O
potassium	O
level	O
of	O
1	O
.	O
4	O
meq	O
/	O
L	O
,	O
diagnosed	O
with	O
distal	O
tubular	O
acidosis	B-DISO
;	O
she	O
required	O
mechanical	O
ventilation	O
for	O
respiratory	O
paralysis	O
.	O

The	O
medical	O
profile	O
remits	O
with	O
potassium	O
intravenous	O
replacement	O
and	O
the	O
pregnancy	O
ends	O
with	O
a	O
spontaneous	B-DISO
abortion	I-DISO
.	O

Enhanced	O
macrophage	O
tropism	O
and	O
the	O
resulting	O
induction	O
of	O
pyogranulomatous	O
lesions	O
are	O
shared	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
infection	B-DISO
in	O
cats	O
,	O
but	O
are	O
not	O
features	O
of	O
ferret	O
enteric	O
coronavirus	O
(	O
FRECV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Inhibition	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
replication	O
in	O
mini	O
-	O
pigs	O
by	O
shRNA	O
.	O

The	O
specificity	O
of	O
these	O
pandemic	O
strains	O
to	O
infect	O
lower	O
respiratory	O
tract	O
is	O
of	O
immunological	O
origin	O
:	O
only	O
patients	O
with	O
little	O
or	O
no	O
immunity	O
to	O
the	O
virus	O
can	O
develop	O
viral	B-DISO
pneumonia	I-DISO
and	O
ARDS	B-DISO
.	O

During	O
winter	O
2009	O
-	O
2010	O
,	O
an	O
inflow	O
of	O
flu	B-DISO
-	O
related	O
ARDS	B-DISO
cases	O
is	O
expected	O
in	O
French	O
ICUs	O
.	O

We	O
have	O
evaluated	O
a	O
multiplex	O
real	O
-	O
time	O
PCR	O
method	O
for	O
the	O
detection	O
of	O
13	O
respiratory	O
viruses	O
and	O
2	O
bacteria	O
(	O
Mycoplasma	B-DISO
and	O
Chlamydophila	O
)	O
in	O
a	O
clinical	O
setting	O
.	O

No	O
associations	O
were	O
observed	O
between	O
the	O
myosin	O
light	O
chain	O
kinase	O
gene	O
single	O
nucleotide	O
polymorphisms	O
genotyped	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
and	O
increased	O
severity	O
of	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
From	O
March	O
to	O
July	O
2009	O
,	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
(	O
H1N1	O
-	O
2009	O
)	O
virus	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
that	O
required	O
mechanical	O
ventilation	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
characteristics	O
,	O
treatment	O
,	O
and	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
in	O
Canada	O
who	O
had	O
H1N1	O
-	O
2009	O
infection	B-DISO
and	O
were	O
treated	O
with	O
extracorporeal	O
lung	O
support	O
(	O
ECLS	O
).	O

Internal	O
struggle	O
consisted	O
of	O
3	O
themes	O
:	O
(	O
1	O
)	O
struggle	O
with	O
being	O
quarantined	O
,	O
(	O
2	O
)	O
struggle	O
with	O
emotional	O
turmoil	O
,	O
and	O
(	O
3	O
)	O
struggle	O
with	O
possible	O
SARS	B-DISO
diagnosis	O
.	O

These	O
immune	O
complexes	O
associate	O
with	O
FcgammaRIIa	O
(	O
Fcgamma	O
IIa	O
receptor	O
)	O
in	O
lungs	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
We	O
describe	O
an	O
autopsy	O
case	O
of	O
a	O
patient	O
with	O
pandemic	O
influenza	B-DISO
(	O
A	O
/	O
H1N1pdm	O
)	O
virus	B-DISO
infection	I-DISO
in	O
Japan	O
,	O
who	O
developed	O
rapidly	O
progressive	O
viral	B-DISO
pneumonia	I-DISO
exhibiting	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

Immunohistochemically	O
,	O
influenza	B-DISO
A	O
viral	O
protein	O
was	O
confirmed	O
in	O
the	O
damaged	O
type	O
II	O
pneumocytes	O
and	O
also	O
in	O
the	O
infiltrated	B-DISO
macrophages	O
.	O

ABSTRACT	O
:	O
H1N1	B-DISO
influenza	I-DISO
is	O
an	O
emerging	O
threat	O
that	O
is	O
life	O
threatening	O
to	O
pregnant	O
women	O
in	O
the	O
third	O
trimester	O
.	O

Treatment	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
with	O
QR448	O
(	O
a	O
)	O
reduced	O
the	O
virus	O
titer	O
as	O
measured	O
in	O
two	O
laboratory	O
host	O
systems	O
,	O
Vero	O
E6	O
cells	O
and	O
embryonating	O
eggs	O
.	O

Most	O
recently	O
,	O
efforts	O
to	O
connect	O
theoretical	O
work	O
to	O
data	O
have	O
exploded	O
as	O
attempts	O
to	O
deal	O
with	O
the	O
threat	O
of	O
emergent	O
and	O
re	O
-	O
emergent	O
diseases	O
including	O
the	O
most	O
recent	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
,	O
have	O
marched	O
to	O
the	O
forefront	O
of	O
our	O
global	O
priorities	O
.	O

TITLE	O
:	O
Are	O
inhaled	O
vasodilators	O
useful	O
in	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
?	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
inhaled	O
vasodilator	O
can	O
result	O
in	O
important	O
physiologic	O
benefits	O
(	O
eg	O
,	O
improved	O
hypoxemia	O
,	O
lower	O
pulmonary	O
arterial	O
pressure	O
,	O
and	O
improved	O
right	O
-	O
ventricular	O
function	O
and	O
cardiac	O
output	O
)	O
without	O
systemic	O
hemodynamic	O
effects	O
.	O

ABSTRACT	O
:	O
Between	O
August	O
and	O
September	O
2009	O
,	O
on	O
Reunion	O
Island	O
,	O
our	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
treated	O
several	O
severe	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
S	O
-	O
OIV	O
cases	O
.	O

Expression	O
of	O
p6	O
,	O
or	O
of	O
its	O
N	O
-	O
terminal	O
41	O
-	O
amino	O
-	O
acid	O
region	O
,	O
in	O
the	O
absence	O
of	O
other	O
viral	O
proteins	O
,	O
induced	O
the	O
formation	O
of	O
membranous	O
structures	O
,	O
some	O
of	O
which	O
were	O
similar	O
to	O
double	O
membrane	O
vesicles	B-DISO
involved	O
in	O
virus	O
replication	O
.	O

Today	O
,	O
ticks	O
transmit	O
the	O
most	O
common	O
arthropod	B-DISO
-	I-DISO
borne	I-DISO
infectious	I-DISO
disease	I-DISO
in	O
the	O
United	O
States	O
(	O
US	O
),	O
Lyme	B-DISO
disease	I-DISO
(	O
LD	O
);	O
and	O
the	O
most	O
lethal	O
arthropod	B-DISO
-	I-DISO
borne	I-DISO
infectious	I-DISO
disease	I-DISO
in	O
the	O
US	O
,	O
Rocky	B-DISO
Mountain	I-DISO
spotted	I-DISO
fever	I-DISO
(	O
RMSF	O
).	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
caused	O
substantial	O
morbidity	O
and	O
mortality	O
in	O
2002	O
-	O
2003	O
.	O

All	O
but	O
one	O
had	O
fever	O
,	O
cough	B-DISO
,	O
dyspnea	B-DISO
and	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
x	O
-	O
ray	O
and	O
developed	O
any	O
organ	O
failures	O
(	O
mean	O
SOFA	O
score	O
7	O
).	O

Key	O
words	O
:	O
influenza	B-DISO
A	O
,	O
pneumonia	B-DISO
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
death	O
rate	O
,	O
intensive	O
care	O
,	O
ventilator	O
therapy	O
,	O
ECMO	O
.	O

Progressive	O
azotemia	B-DISO
and	O
oliguria	B-DISO
then	O
developed	O
,	O
and	O
he	O
required	O
temporary	O
hemodialysis	O
.	O

TITLE	O
:	O
Efficacy	O
and	O
safety	O
of	O
quinine	O
-	O
artesunate	O
in	O
an	O
HIV	B-DISO
-	O
positive	O
patient	O
with	O
severe	O
falciparum	B-DISO
malaria	I-DISO
.	O

This	O
article	O
describes	O
the	O
case	O
of	O
an	O
HIV	B-DISO
-	O
positive	O
patient	O
,	O
who	O
returned	O
from	O
Africa	O
and	O
presented	O
with	O
10	O
%	O
parasitemia	B-DISO
and	O
clinical	O
signs	O
of	O
severe	O
falciparum	B-DISO
malaria	I-DISO
;	O
this	O
individual	O
was	O
successfully	O
treated	O
with	O
a	O
combination	O
of	O
artesunate	O
and	O
quinine	O
.	O

TITLE	O
:	O
Delayed	O
clearance	O
of	O
viral	O
load	O
and	O
marked	O
cytokine	O
activation	O
in	O
severe	O
cases	O
of	O
pandemic	O
H1N1	O
2009	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
.	O

SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
causes	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
that	O
may	O
develop	O
into	O
life	O
-	O
threatening	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
advanced	O
age	O
correlating	O
positively	O
with	O
adverse	O
disease	O
outcome	O
.	O

We	O
conclude	O
that	O
RS	O
cells	O
irrespective	O
of	O
LMP1	O
expression	O
are	O
end	O
-	O
stage	O
tumor	B-DISO
cells	O
in	O
which	O
the	O
extent	O
of	O
their	O
inability	O
to	O
divide	O
further	O
is	O
proportional	O
to	O
the	O
increase	O
of	O
very	O
short	O
telomeres	O
,	O
telomere	O
loss	O
,	O
aggregate	O
formation	O
and	O
the	O
generation	O
of	O
'	O
ghost	O
'	O
nuclei	O
.	O

Our	O
results	O
provide	O
the	O
first	O
proof	O
-	O
of	O
-	O
principle	O
that	O
hexokinase	O
II	O
protects	O
against	O
dopaminergic	O
neurodegeneration	B-DISO
in	O
vivo	O
,	O
emphasizing	O
the	O
role	O
of	O
this	O
enzyme	O
in	O
promoting	O
neuronal	O
survival	O
.	O

During	O
the	O
current	O
pandemic	O
of	O
H1N1	B-DISO
influenza	I-DISO
,	O
few	O
cases	O
of	O
H1N1	O
have	O
been	O
reported	O
in	O
pregnancy	O
.	O

We	O
report	O
two	O
cases	O
of	O
H1N1	B-DISO
influenza	I-DISO
which	O
occurred	O
in	O
single	O
institution	O
in	O
the	O
course	O
of	O
one	O
month	O
.	O

Further	O
research	O
is	O
warranted	O
to	O
determine	O
whether	O
T	O
(	O
4	O
)	O
supplementation	O
would	O
be	O
beneficial	O
in	O
term	O
and	O
late	O
preterm	O
infants	O
with	O
respiratory	B-DISO
distress	I-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
novel	O
live	O
attenuated	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccine	O
candidate	O
derived	O
from	O
a	O
Korean	O
nephropathogenic	O
strain	O
.	O

Here	O
we	O
demonstrate	O
the	O
self	O
-	O
assembly	O
and	O
release	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
M	O
protein	O
in	O
medium	O
in	O
the	O
form	O
of	O
membrane	O
-	O
enveloped	O
vesicles	B-DISO
with	O
densities	O
lower	O
than	O
those	O
of	O
VLPs	O
formed	O
by	O
M	O
plus	O
N	O
.	O
Although	O
efficient	O
N	O
-	O
N	O
interactions	O
require	O
the	O
presence	O
of	O
RNA	O
,	O
we	O
found	O
that	O
M	O
-	O
M	O
interactions	O
were	O
RNA	O
-	O
independent	O
.	O

GBS	B-DISO
affected	O
predominantly	O
young	O
adult	O
males	O
living	O
in	O
rural	O
areas	O
.	O

TITLE	O
:	O
Mathematical	O
modeling	O
of	O
the	O
effectiveness	O
of	O
facemasks	O
in	O
reducing	O
the	O
spread	O
of	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
).	O

TITLE	O
:	O
Developing	O
policy	O
options	O
for	O
SARS	B-DISO
and	O
SARS	B-DISO
-	O
like	O
diseases	O
-	O
a	O
Delphi	O
study	O
.	O

The	O
genomic	O
organizations	O
of	O
many	O
other	O
frameshifting	O
viruses	O
,	O
including	O
the	O
coronaviruses	O
,	O
are	O
very	O
different	O
,	O
in	O
that	O
their	O
upstream	O
open	O
reading	O
frames	O
encode	O
nonstructural	O
proteins	O
,	O
the	O
frameshift	B-DISO
-	O
dependent	O
downstream	O
open	O
reading	O
frames	O
encode	O
enzymes	O
involved	O
in	O
transcription	O
and	O
replication	O
,	O
and	O
their	O
structural	O
proteins	O
are	O
encoded	O
by	O
subgenomic	O
mRNAs	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
describing	O
amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
in	O
which	O
CT	O
revealed	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
like	O
shadow	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
and	O
porcine	O
group	O
A	O
rotavirus	O
(	O
PRV	B-DISO
-	O
A	O
)	O
are	O
major	O
viruses	O
causing	O
enteric	O
diseases	O
of	O
piglets	O
.	O

A	O
total	O
of	O
175	O
field	O
samples	O
were	O
collected	O
from	O
swine	O
with	O
diarrhea	B-DISO
from	O
January	O
2005	O
until	O
July	O
2007	O
.	O

ABSTRACT	O
:	O
This	O
article	O
reviews	O
the	O
virology	O
,	O
history	O
,	O
pathology	B-DISO
,	O
epidemiology	O
,	O
clinical	O
presentations	O
,	O
complications	O
,	O
radiology	O
,	O
laboratory	O
testing	O
,	O
diagnosis	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
severe	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
with	O
reference	O
to	O
documented	O
outbreaks	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
main	O
cause	O
of	O
death	O
in	O
lung	O
transplantation	O
patients	O
is	O
chronic	O
rejection	O
,	O
known	O
as	O
bronchiolitis	B-DISO
obliterans	I-DISO
syndrome	B-DISO
(	O
BOS	B-DISO
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
factors	O
associated	O
with	O
BOS	B-DISO
and	O
its	O
impact	O
on	O
survival	O
among	O
lung	O
transplantation	O
patients	O
.	O

We	O
retrospectively	O
analyzed	O
charts	O
of	O
lung	O
transplant	O
patients	O
from	O
1999	O
to	O
2009	O
,	O
evaluating	O
survival	O
,	O
BOS	B-DISO
,	O
and	O
associated	O
factors	O
.	O

Among	O
the	O
factors	O
analyzed	O
,	O
13	O
patients	O
(	O
72	O
%)	O
displayed	O
acute	O
cellular	O
rejection	O
and	O
nine	O
(	O
50	O
%)	O
gastroesophageal	B-DISO
reflux	I-DISO
disease	I-DISO
(	O
GERD	B-DISO
)	O
diagnosed	O
by	O
pHmetry	O
,	O
both	O
of	O
which	O
were	O
significantly	O
associated	O
with	O
BOS	B-DISO
(	O
P	O
=	O
.	O
005	O
).	O

Among	O
seven	O
lung	O
transplantation	O
patients	O
with	O
invasive	O
cytomegalovirus	O
disease	O
,	O
the	O
four	O
who	O
developed	O
BOS	B-DISO
(	O
P	O
=	O
.	O
04	O
)	O
showed	O
the	O
worst	O
survival	O
(	O
P	O
=	O
.	O
05	O
).	O

BOS	B-DISO
was	O
associated	O
with	O
worse	O
survival	O
.	O

Twenty	O
-	O
one	O
(	O
n	O
=	O
21	O
)	O
child	O
and	O
adolescent	O
participants	O
were	O
interviewed	O
from	O
a	O
variety	O
of	O
medical	O
areas	O
including	O
cardiac	O
(	O
n	O
=	O
2	O
),	O
critical	O
care	O
(	O
n	O
=	O
2	O
),	O
organ	O
transplant	O
(	O
n	O
=	O
4	O
),	O
respiratory	O
medicine	O
(	O
n	O
=	O
8	O
)	O
and	O
infectious	B-DISO
diseases	I-DISO
(	O
patients	O
diagnosed	O
with	O
suspected	O
or	O
probable	O
SARS	B-DISO
;	O
n	O
=	O
5	O
).	O

In	O
order	O
to	O
elucidate	O
the	O
multifactorial	O
aetiology	O
of	O
porcine	O
respiratory	B-DISO
disease	I-DISO
complex	O
(	O
PRDC	O
)	O
in	O
Denmark	O
,	O
lungs	O
from	O
148	O
finishing	O
pigs	O
with	O
cranioventral	O
bronchopneumonia	B-DISO
(	O
case	O
group	O
)	O
and	O
60	O
pigs	O
without	O
lung	O
lesions	O
(	O
control	O
group	O
)	O
were	O
collected	O
from	O
abattoirs	O
.	O

There	O
was	O
a	O
broad	O
range	O
of	O
microscopical	O
lesions	O
and	O
the	O
cases	O
were	O
characterized	O
as	O
acute	O
(	O
n	O
=	O
10	O
),	O
subacute	O
(	O
n	O
=	O
24	O
)	O
or	O
chronic	O
(	O
n	O
=	O
114	O
)	O
bronchopneumonia	B-DISO
.	O

Based	O
on	O
our	O
work	O
,	O
we	O
suggest	O
that	O
sampling	O
chickens	O
in	O
poultry	O
slaughterhouses	O
is	O
an	O
effective	O
and	O
valuable	O
means	O
of	O
compiling	O
viral	O
prevalence	O
data	O
,	O
particularly	O
in	O
situations	O
where	O
there	O
is	O
subclinical	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Swine	O
intestine	O
antimicrobial	O
peptides	O
inhibit	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
infectivity	O
in	O
chick	O
embryos	O
.	O

TITLE	O
:	O
Delayed	O
onset	O
of	O
severe	O
neonatal	O
toxoplasmosis	B-DISO
.	O

Clinicians	O
facing	O
an	O
unexplained	O
life	O
-	O
threatening	O
condition	B-DISO
in	O
the	O
first	O
week	O
of	O
life	O
should	O
take	O
into	O
consideration	O
the	O
possibility	O
of	O
neonatal	O
toxoplasmosis	B-DISO
.	O

TITLE	O
:	O
Inhaled	O
aerosolized	O
insulin	O
:	O
a	O
""""	O
topical	O
""""	O
anti	O
-	O
inflammatory	O
treatment	O
for	O
acute	O
lung	O
injury	O
and	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
?	O

The	O
model	O
achieved	O
a	O
satisfactory	O
fit	B-DISO
,	O
CFI	O
=	O
0	O
.	O
98	O
,	O
NNFI	O
=	O
0	O
.	O
98	O
,	O
RMSEA	O
=	O
0	O
.	O
06	O
,	O
and	O
explained	O
75	O
.	O
2	O
%	O
of	O
the	O
variance	O
in	O
mental	O
health	O
status	O
.	O

The	O
study	O
is	O
the	O
first	O
attempt	O
in	O
understanding	O
long	O
-	O
term	O
psychological	B-DISO
adjustment	O
of	O
SARS	B-DISO
survivors	O
.	O

Findings	O
may	O
be	O
applicable	O
to	O
other	B-DISO
infectious	I-DISO
disease	I-DISO
outbreaks	O
in	O
informing	O
psychosocial	O
factors	O
that	O
are	O
important	O
to	O
long	O
-	O
term	O
recovery	O
.	O

Excessive	O
inflammatory	B-DISO
response	I-DISO
to	O
necrotic	O
debris	O
might	O
contribute	O
to	O
the	O
development	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Genomic	O
characterization	O
of	O
a	O
proventriculitis	O
-	O
associated	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
.	O

Although	O
the	O
morbidity	O
and	O
mortality	O
is	O
acceptable	O
,	O
surgeons	O
should	O
be	O
more	O
attentive	O
to	O
lethal	O
postoperative	B-DISO
complications	I-DISO
such	O
as	O
ARDS	B-DISO
induced	O
by	O
lung	B-DISO
ischemia	I-DISO
-	O
reperfusion	O
injury	O
.	O

RESULTS	O
:	O
In	O
our	O
series	O
,	O
PA	O
reconstruction	O
with	O
end	O
-	O
to	O
-	O
end	O
anastomosis	B-DISO
was	O
performed	O
in	O
18	O
patients	O
(	O
52	O
.	O
9	O
%).	O

Examples	O
include	O
established	O
viruses	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
the	O
leading	O
cause	O
of	O
respiratory	B-DISO
infection	I-DISO
in	O
infants	O
and	O
young	O
children	O
,	O
and	O
emerging	O
viruses	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
which	O
reached	O
near	O
pandemic	O
levels	O
in	O
2003	O
,	O
or	O
H1N1	O
(	O
swine	O
)	O
influenza	B-DISO
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
gene	O
3	O
region	O
sequences	O
of	O
Chinese	O
field	O
strains	O
of	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Thyroid	O
transcription	O
factor	O
-	O
1	O
(	O
TTF	O
-	O
1	O
)	O
deficiency	O
syndrome	B-DISO
is	O
characterized	O
by	O
neurologic	O
,	O
thyroidal	O
,	O
and	O
pulmonary	O
dysfunction	O
.	O

Patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
requiring	O
mechanical	O
ventilation	O
were	O
mostly	O
middle	O
-	O
aged	O
adults	O
,	O
often	O
with	O
comorbidities	O
,	O
and	O
frequently	O
developed	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiorgan	B-DISO
failure	I-DISO
requiring	O
advanced	O
organ	O
support	O
.	O

Cow	B-DISO
'	I-DISO
s	I-DISO
milk	I-DISO
allergy	I-DISO
should	O
be	O
suspected	O
in	O
children	O
who	O
have	O
immediate	O
symptoms	O
such	O
as	O
acute	B-DISO
urticaria	I-DISO
/	O
angioedema	B-DISO
,	O
wheezing	B-DISO
,	O
rhinitis	B-DISO
,	O
dry	B-DISO
cough	I-DISO
,	O
vomiting	B-DISO
,	O
laryngeal	B-DISO
edema	I-DISO
,	O
acute	B-DISO
asthma	I-DISO
with	O
severe	O
respiratory	B-DISO
distress	I-DISO
,	O
anaphylaxis	B-DISO
.	O

In	O
both	O
instances	O
,	O
transfer	O
of	O
Tregs	O
decreased	O
weight	O
loss	O
,	O
clinical	O
scores	O
,	O
and	O
demyelination	B-DISO
.	O

TITLE	O
:	O
An	O
sveir	O
model	O
for	O
assessing	O
potential	O
impact	O
of	O
an	O
imperfect	O
anti	O
-	O
sars	B-DISO
vaccine	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
qingyi	O
decoction	O
in	O
treating	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
and	O
its	O
impacts	O
on	O
blood	O
level	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
,	O
interleukin	O
-	O
6	O
and	O
inteleukin	O
-	O
8	O
].	O

The	O
incidences	O
of	O
the	O
two	O
severe	O
complications	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
intestinal	B-DISO
paralysis	I-DISO
,	O
in	O
the	O
treated	O
group	O
was	O
3	O
.	O
6	O
%	O
and	O
5	O
.	O
4	O
%	O
respectively	O
,	O
while	O
in	O
the	O
control	O
group	O
,	O
12	O
.	O
7	O
%	O
and	O
18	O
.	O
2	O
%,	O
showing	O
statistical	O
significance	O
between	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Prevalence	O
of	O
antibodies	O
against	O
transmissible	O
gastroenteritis	B-DISO
virus	O
and	O
porcine	O
respiratory	O
coronavirus	O
among	O
pigs	O
in	O
six	O
regions	O
in	O
Japan	O
.	O

TITLE	O
:	O
Trypsin	O
-	O
induced	O
hemagglutination	O
activity	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

TITLE	O
:	O
Identification	O
of	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
in	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
hipposideros	O
)	O
in	O
Slovenia	O
.	O

The	O
most	O
closely	O
related	O
virus	O
sequence	O
in	O
GenBank	O
was	O
SARS	B-DISO
bat	O
isolate	O
Rp3	B-DISO
/	O
2004	O
(	O
DQ071615	O
)	O
within	O
the	O
SARS	B-DISO
-	O
like	O
CoV	O
cluster	O
,	O
sharing	O
85	O
%	O
nucleotide	O
identity	O
and	O
95	O
.	O
6	O
%	O
amino	O
acid	O
identity	O
.	O

ABSTRACT	O
:	O
Mathematical	O
modeling	O
can	O
be	O
used	O
for	O
the	O
development	O
and	O
implementation	O
of	O
infection	B-DISO
control	O
policy	O
to	O
combat	O
outbreaks	O
and	O
epidemics	O
of	O
communicable	O
viral	B-DISO
diseases	I-DISO
.	O

This	O
study	O
was	O
designed	O
to	O
explore	O
the	O
efficacy	O
of	O
dual	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
interference	O
with	O
fgl2	O
and	O
TNFR1	O
in	O
the	O
treatment	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
fulminant	B-DISO
hepatitis	I-DISO
in	O
mice	O
.	O

However	O
,	O
the	O
vaccines	O
which	O
can	O
be	O
delivered	O
safely	O
by	O
this	O
method	O
are	O
limited	O
and	O
there	O
is	O
no	O
currently	O
licensed	O
embryo	O
-	O
safe	O
vaccine	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
affected	O
South	O
Africa	O
late	O
during	O
the	O
2009	O
Southern	O
hemisphere	O
winter	O
and	O
placed	O
an	O
extra	O
burden	O
on	O
a	O
health	O
care	O
system	O
already	O
dealing	O
with	O
a	O
high	O
prevalence	O
of	O
chronic	O
lung	B-DISO
diseases	I-DISO
and	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
)	O
infection	B-DISO
.	O

We	O
included	O
all	O
adult	O
patients	O
with	O
confirmed	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
that	O
were	O
referred	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
of	O
a	O
large	O
academic	O
hospital	O
in	O
Cape	O
Town	O
for	O
ventilatory	O
support	O
in	O
this	O
prospective	O
observational	O
study	O
.	O

Of	O
these	O
,	O
15	O
were	O
female	O
and	O
16	O
had	O
identifiable	O
risk	O
factors	O
for	O
severe	O
disease	O
,	O
including	O
pregnancy	O
(	O
n	O
=	O
6	O
),	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
(	O
n	O
=	O
6	O
),	O
obesity	B-DISO
(	O
n	O
=	O
4	O
),	O
HIV	B-DISO
infection	I-DISO
(	O
n	O
=	O
3	O
),	O
immunosuppressive	O
therapy	O
(	O
n	O
=	O
3	O
)	O
and	O
active	O
pulmonary	B-DISO
tuberculosis	I-DISO
(	O
n	O
=	O
2	O
).	O

However	O
,	O
in	O
primary	O
cell	O
types	O
such	O
as	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	B-DISO
)	O
and	O
macrophages	O
,	O
IFN	O
is	O
induced	O
by	O
MHV	O
infection	B-DISO
and	O
an	O
antiviral	O
state	O
is	O
established	O
.	O

We	O
propose	O
a	O
simple	O
method	O
to	O
measure	O
the	O
severity	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

CONCLUSIONS	O
:	O
The	O
method	O
is	O
practical	O
for	O
rating	O
the	O
severity	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
,	O
though	O
it	O
should	O
be	O
optimized	O
.	O

ABSTRACT	O
:	O
Assessment	O
of	O
the	O
risks	O
posed	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
on	O
surfaces	O
requires	O
data	O
on	O
survival	O
of	O
this	O
virus	O
on	O
environmental	O
surfaces	O
and	O
on	O
how	O
survival	O
is	O
affected	O
by	O
environmental	O
variables	O
,	O
such	O
as	O
air	O
temperature	O
(	O
AT	O
)	O
and	O
relative	O
humidity	O
(	O
RH	O
).	O

Two	O
potential	O
surrogates	O
were	O
evaluated	O
in	O
this	O
study	O
;	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
were	O
used	O
to	O
determine	O
effects	O
of	O
AT	O
and	O
RH	O
on	O
the	O
survival	O
of	O
coronaviruses	O
on	O
stainless	O
steel	O
.	O

Both	O
viruses	O
were	O
inactivated	O
more	O
rapidly	O
at	O
40	O
degrees	O
C	O
than	O
at	O
20	O
degrees	O
C	O
.	O
The	O
relationship	O
between	O
inactivation	B-DISO
and	O
RH	O
was	O
not	O
monotonic	O
,	O
and	O
there	O
was	O
greater	O
survival	O
or	O
a	O
greater	O
protective	O
effect	O
at	O
low	O
RH	O
(	O
20	O
%)	O
and	O
high	O
RH	O
(	O
80	O
%)	O
than	O
at	O
moderate	O
RH	O
(	O
50	O
%).	O

The	O
results	O
show	O
that	O
when	O
high	O
numbers	O
of	O
viruses	O
are	O
deposited	O
,	O
TGEV	O
and	O
MHV	O
may	O
survive	O
for	O
days	O
on	O
surfaces	O
at	O
ATs	B-DISO
and	O
RHs	B-DISO
typical	O
of	O
indoor	O
environments	O
.	O

Data	O
from	O
the	O
SARS	B-DISO
outbreak	O
illustrated	O
that	O
if	O
hospitals	O
are	O
seen	O
as	O
sources	O
of	O
contagion	O
,	O
many	O
patients	O
with	O
non	O
-	O
bioterrorism	O
-	O
related	O
healthcare	O
needs	O
may	O
delay	O
seeking	O
help	O
.	O

TITLE	O
:	O
Induction	O
of	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	O
10	O
by	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
interferon	O
alfacon	O
1	O
and	O
interferon	O
inducer	O
in	O
human	O
bronchial	O
epithelial	O
Calu	O
-	O
3	O
cells	O
and	O
BALB	O
/	O
c	O
mice	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
first	O
evaluated	O
the	O
efficacy	O
of	O
IFN	O
-	O
alfacon	O
1	O
in	O
Calu	O
-	O
3	O
cells	O
during	O
the	O
first	O
7	O
days	O
of	O
virus	B-DISO
infection	I-DISO
.	O

A	O
potent	O
,	O
prolonged	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
Calu	O
-	O
3	O
cells	O
with	O
IFN	O
-	O
alfacon	O
1	O
was	O
observed	O
.	O

IP	O
-	O
10	O
expression	O
was	O
detected	O
in	O
the	O
lungs	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
BALB	O
/	O
c	O
mice	O
.	O

To	O
find	O
out	O
if	O
HCoVs	O
can	O
be	O
found	O
in	O
stools	O
of	O
children	O
with	O
acute	B-DISO
gastroenteritis	I-DISO
and	O
to	O
assess	O
the	O
significance	O
of	O
HCoVs	O
in	O
the	O
etiology	O
of	O
acute	B-DISO
gastroenteritis	I-DISO
in	O
children	O
.	O

Persistently	O
infected	O
,	O
healthy	O
carriers	O
are	O
believed	O
to	O
be	O
important	O
in	O
the	O
epidemiology	O
of	O
FIP	B-DISO
,	O
as	O
they	O
represent	O
a	O
constant	O
source	O
of	O
FCoV	O
,	O
shed	O
either	O
persistently	O
or	O
intermittently	O
in	O
faeces	O
.	O

ABSTRACT	O
:	O
The	O
threat	O
of	O
mass	O
casualties	O
caused	O
by	O
an	O
unconventional	O
terrorist	O
attack	O
is	O
a	O
challenge	O
for	O
the	O
public	O
health	O
system	O
,	O
with	O
special	O
implications	O
for	O
emergency	B-DISO
medicine	O
,	O
anesthesia	B-DISO
,	O
and	O
intensive	O
care	O
.	O

ABSTRACT	O
:	O
We	O
need	O
to	O
apply	O
lessons	O
learned	O
from	O
previous	O
influenza	B-DISO
pandemics	O
to	O
continuously	O
update	O
preparedness	O
and	O
response	O
plans	O
.	O

Noninvasive	O
ventilation	O
constitutes	O
an	O
alternative	O
treatment	O
for	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Children	O
(	O
age	O
range	O
,	O
1	O
month	O
-	O
16	O
yrs	O
)	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
who	O
received	O
noninvasive	O
ventilation	O
during	O
a	O
4	O
-	O
year	O
period	O
.	O

TITLE	O
:	O
[	O
New	O
influenza	B-DISO
virus	O
(	O
H1N1	O
)	O
related	O
pneumonia	B-DISO
with	O
fatal	O
outcome	O
].	O

In	O
this	O
paper	O
,	O
a	O
case	O
with	O
a	O
complicated	O
,	O
partially	O
organized	O
hemorrhagic	B-DISO
pneumonia	I-DISO
and	O
DAD	O
is	O
presented	O
in	O
a	O
patient	O
with	O
H1N1	O
virus	O
positivity	O
,	O
which	O
can	O
be	O
referred	O
as	O
a	O
classical	O
pulmonary	O
change	O
.	O

RESULTS	O
:	O
Two	O
early	O
postoperative	O
death	O
occurred	O
in	O
this	O
group	O
due	O
to	O
severe	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
,	O
with	O
the	O
mortality	O
rate	O
of	O
1	O
.	O
57	O
%.	O

Interestingly	O
,	O
we	O
found	O
that	O
SARS	B-DISO
coronavirus	O
was	O
present	O
in	O
feces	O
from	O
infected	O
mice	O
lacking	O
receptors	O
for	O
both	O
type	O
I	O
and	O
type	O
III	O
IFN	O
but	O
not	O
in	O
those	O
from	O
mice	O
lacking	O
single	O
receptors	O
,	O
supporting	O
the	O
view	O
that	O
IFN	O
-	O
lambda	O
contributes	O
to	O
the	O
control	O
of	O
viral	B-DISO
infections	I-DISO
in	O
epithelial	O
cells	O
of	O
both	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
.	O

injection	O
of	O
MVTT	O
-	O
S	O
primarily	O
targeted	O
draining	O
inguinal	O
lymph	O
nodes	O
,	O
whereas	O
mucosal	O
inoculation	O
had	O
broader	O
range	O
of	O
tissue	O
infections	B-DISO
.	O

Critically	O
,	O
the	O
infection	B-DISO
did	O
not	O
cause	O
severe	O
pathogenic	O
consequences	O
in	O
infected	O
tissues	O
,	O
which	O
was	O
consistent	O
to	O
the	O
attenuated	O
phenotype	O
of	O
MVTT	O
-	O
S	O
.	O
Our	O
findings	O
have	O
implications	O
for	O
the	O
optimization	O
of	O
vaccination	O
route	O
and	O
for	O
studies	O
on	O
the	O
correlation	O
between	O
the	O
magnitude	O
of	O
immune	O
responses	O
and	O
the	O
extent	O
of	O
tissue	O
involvement	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
infectivity	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
during	O
its	O
incubation	O
period	O
by	O
investigating	O
chains	O
of	O
transmission	O
and	O
individuals	O
isolated	O
for	O
medical	O
observation	O
with	O
a	O
view	O
to	O
providing	O
scientific	O
evidence	O
for	O
updating	O
protocols	O
of	O
medical	O
isolation	O
.	O

Of	O
them	O
,	O
669	O
had	O
a	O
history	O
of	O
close	O
contact	O
with	O
symptomatic	O
SARS	B-DISO
patients	O
,	O
101	O
developed	O
symptoms	O
with	O
a	O
rate	O
of	O
15	O
.	O
1	O
%,	O
363	O
had	O
a	O
history	O
of	O
close	O
contact	O
with	O
patients	O
in	O
their	O
incubation	O
period	O
,	O
none	O
of	O
whom	O
developed	O
symptoms	O
(	O
0	O
%).	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
antibody	O
.	O

Recruitment	B-DISO
of	O
atelectatic	O
lung	O
areas	O
may	O
improve	O
responsiveness	O
and	O
preservation	O
of	O
spontaneous	O
breathing	O
(	O
SB	O
)	O
may	O
cause	O
recruitment	B-DISO
.	O

Thus	O
combined	O
iNO	O
and	O
unassisted	O
SB	O
is	O
possibly	O
most	O
effective	O
to	O
improve	O
gas	O
exchange	O
in	O
severe	O
hypoxemic	O
ARDS	B-DISO
.	O

This	O
2	O
-	O
year	O
study	O
of	O
a	O
selected	O
population	O
of	O
SARS	B-DISO
survivors	O
,	O
showed	O
significant	O
impairment	B-DISO
of	O
DL	O
(	O
CO	O
),	O
exercise	O
capacity	O
and	O
health	O
status	O
persisted	O
,	O
with	O
a	O
more	O
marked	O
adverse	O
impact	O
among	O
HCW	O
.	O

Combining	O
these	O
data	O
with	O
those	O
of	O
other	O
studies	O
in	O
Western	O
Europe	O
revealed	O
that	O
HCoV	O
-	O
NL63	O
infections	B-DISO
follow	O
a	O
2	O
-	O
year	O
inter	O
-	O
epidemic	O
period	O
with	O
peaks	O
of	O
infection	B-DISO
in	O
the	O
winters	O
of	O
2000	O
/	O
2001	O
,	O
2002	O
/	O
2003	O
and	O
2004	O
/	O
2005	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

CONCLUSIONS	O
:	O
Quantitative	O
polymerase	O
chain	O
reaction	O
detects	O
high	O
viral	O
loads	O
in	O
BAL	O
samples	O
from	O
HCT	O
recipients	O
with	O
respiratory	O
virus	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Secretory	O
phospholipase	O
A₂	O
pathway	O
during	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
preliminary	O
study	O
.	O

All	O
infants	O
<	O
6	O
months	O
old	O
hospitalized	O
for	O
severe	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
bronchiolitis	I-DISO
,	O
who	O
developed	O
ARDS	B-DISO
(	O
respiratory	O
syncytial	O
virus	O
-	O
ARDS	B-DISO
group	O
);	O
all	O
infants	O
<	O
6	O
months	O
old	O
diagnosed	O
with	O
ARDS	B-DISO
secondary	O
to	O
other	O
causes	O
(	O
ARDS	B-DISO
group	O
);	O
and	O
infants	O
<	O
6	O
months	O
old	O
who	O
needed	O
ventilation	O
for	O
reasons	O
other	O
than	O
any	O
lung	B-DISO
disease	I-DISO
(	O
control	O
group	O
).	O

Bronchiolitis	B-DISO
(	O
6	O
.	O
7	O
%),	O
pneumonia	B-DISO
(	O
6	O
.	O
7	O
%),	O
and	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
(	O
5	O
.	O
3	O
%)	O
were	O
the	O
most	O
frequent	O
causes	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
and	O
altered	B-DISO
mental	I-DISO
status	I-DISO
(	O
9	O
.	O
2	O
%)	O
was	O
the	O
most	O
frequent	O
reason	O
for	O
MV	O
.	O

Liver	B-DISO
damage	I-DISO
was	O
confirmed	O
by	O
deterioration	O
in	O
pH	O
(	O
7	O
.	O
23	O
+/-	O
0	O
.	O
05	O
vs	O
7	O
.	O
45	O
+/-	O

Replication	O
of	O
other	O
RNA	O
viruses	O
,	O
including	O
Theiler	O
'	O
s	O
murine	O
encephalitis	B-DISO
virus	O
(	O
TMEV	O
),	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
),	O
Sindbis	O
virus	O
,	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
and	O
Sendai	O
virus	O
(	O
SeV	O
),	O
was	O
significantly	O
inhibited	O
in	O
L2	O
cells	O
treated	O
with	O
IFN	O
-	O
alpha	O
/	O
beta	O
,	O
and	O
MHV	O
had	O
the	O
ability	O
to	O
rescue	O
only	O
SeV	O
replication	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
the	O
most	O
devastating	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
pulmonary	B-DISO
edema	I-DISO
(	O
PE	O
).	O

Corn	B-DISO
oil	O
was	O
mixed	O
with	O
distilled	O
water	O
to	O
form	O
fatty	O
micelles	O
.	O

CD209	O
facilitates	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
spike	O
protein	O
-	O
bearing	O
pseudotype	O
driven	O
infection	B-DISO
of	O
permissive	O
cells	O
in	O
vitro	O
.	O

Genetic	O
association	O
analysis	O
of	O
this	O
SNP	O
with	O
clinico	O
-	O
pathologic	O
outcomes	O
in	O
824	O
serologic	O
confirmed	O
SARS	B-DISO
patients	O
showed	O
that	O
the	O
-	O
336AG	O
/	O
GG	O
genotype	O
SARS	B-DISO
patients	O
was	O
associated	O
with	O
lower	O
standardized	O
lactate	O
-	O
dehydrogenase	O
(	O
LDH	O
)	O
levels	O
compared	O
with	O
the	O
-	O
336AA	O
patients	O
(	O
p	O
=	O
0	O
.	O
014	O
,	O
odds	O
ratio	O
=	O
0	O
.	O
40	O
).	O

This	O
association	O
is	O
in	O
keeping	O
with	O
the	O
role	O
of	O
CD209	O
in	O
modulating	O
immune	O
response	O
to	O
viral	B-DISO
infection	I-DISO
.	O

Metabolic	B-DISO
acidosis	I-DISO
(	O
odds	O
ratio	O
[	O
OR	O
]	O
6	O
.	O
1	O
),	O
ARDS	B-DISO
(	O
OR	O
3	O
.	O
6	O
),	O
altered	O
sensorium	O
(	O
OR	O
3	O
.	O
6	O
)	O
and	O
shock	O
(	O
OR	O
3	O
.	O
1	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
develop	O
a	O
visual	O
protein	O
chip	O
that	O
can	O
differentiate	O
the	O
antibodies	O
induced	O
by	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
,	O
simultaneously	O
.	O

A	O
diagnostic	O
protein	O
chip	O
was	O
constructed	O
to	O
differentiate	O
antibodies	O
of	O
four	O
poultry	B-DISO
diseases	I-DISO
This	O
protein	O
chip	O
showed	O
good	O
sensitivity	O
compared	O
with	O
traditional	O
methods	O
,	O
and	O
it	O
was	O
more	O
than	O
400	O
times	O
as	O
sensitive	O
as	O
the	O
agar	O
gel	O
precipitin	O
methods	O
used	O
to	O
detect	O
avian	B-DISO
influenza	I-DISO
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
article	O
I	O
demonstrate	O
the	O
knowledge	O
perceptions	O
of	O
and	O
the	O
preventive	O
health	O
behaviors	O
toward	O
the	O
influenza	B-DISO
A	O
H1N1	O
pandemic	O
,	O
or	O
""""	O
human	O
swine	B-DISO
flu	I-DISO
","""	O
among	O
the	O
chronic	B-DISO
renal	I-DISO
disease	I-DISO
patients	O
in	O
Hong	O
Kong	O
.	O

However	O
,	O
application	O
of	O
many	O
of	O
these	O
advanced	O
phylogenetic	O
methods	O
are	O
currently	O
limited	O
to	O
specialized	O
phylogeneticists	O
and	O
statisticians	O
,	O
mainly	O
because	O
of	O
their	O
mathematical	O
basis	O
and	O
their	O
dependence	B-DISO
on	I-DISO
the	O
use	O
of	O
a	O
large	O
number	O
of	O
computer	O
programs	O
.	O

Three	O
were	O
obese	B-DISO
with	O
body	O
mass	O
index	O
over	O
30	O
kg	O
/	O
m	O
(	O
2	O
).	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
75	O
patients	O
with	O
severe	O
influenza	B-DISO
A	O
H1N1	O
in	O
Qinghai	O
Province	O
].	O

ABSTRACT	O
:	O
To	O
observe	O
clinical	O
features	O
of	O
severe	O
influenza	B-DISO
A	O
H1N1	O
in	O
Qinghai	O
Province	O
.	O

The	O
clinical	O
data	O
of	O
75	O
severe	O
influenza	B-DISO
A	O
H1N1	O
patients	O
were	O
analyzed	O
retrospectively	O
in	O
regard	O
to	O
common	O
features	O
,	O
clinical	O
symptoms	O
,	O
signs	O
,	O
laboratory	O
data	O
and	O
treatments	O
hospitalized	O
in	O
Qinghai	O
Hospital	O
for	O
Infectious	B-DISO
Diseases	I-DISO
during	O
September	O
4	O
,	O
2009	O
to	O
December	O
31	O
,	O
2009	O
.	O

On	O
the	O
strength	O
of	O
history	O
,	O
clinical	O
and	O
laboratory	O
investigation	O
the	O
diagnosis	O
of	O
D	O
-	O
positive	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
was	O
established	O
.	O

This	O
case	O
suggests	O
that	O
patients	O
with	O
severe	O
Guillain	O
-	O
Barrd	O
syndrome	B-DISO
may	O
benefit	O
from	O
plasma	O
exchange	O
after	O
immunoglobulin	O
treatment	O
in	O
refractory	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
maturation	O
of	O
SARS	B-DISO
coronavirus	O
involves	O
the	O
autocleavage	O
of	O
polyproteins	O
1a	O
and	O
1ab	O
by	O
the	O
main	O
protease	O
(	O
Mpro	O
)	O
and	O
a	O
papain	O
-	O
like	O
protease	O
;	O
these	O
represent	O
attractive	O
targets	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

TITLE	O
:	O
A	O
novel	O
B	O
-	O
cell	O
epitope	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
N	O
protein	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
,	O
especially	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
plays	O
important	O
roles	O
in	O
the	O
prevention	O
of	O
SARS	B-DISO
infection	B-DISO
,	O
and	O
is	O
thus	O
an	O
important	O
component	O
in	O
SARS	B-DISO
vaccine	O
development	O
.	O

TITLE	O
:	O
Occupational	O
respiratory	B-DISO
infections	I-DISO
.	O

Ultraviolet	O
germicidal	O
irradiation	O
is	O
underused	O
at	O
present	O
,	O
despite	O
good	O
evidence	O
of	O
safety	O
and	O
efficacy	O
in	O
elimination	O
of	O
airborne	O
respiratory	O
infectious	B-DISO
agents	O
including	O
TB	O
.	O

Damage	O
control	O
orthopedics	O
(	O
DCO	B-DISO
)	O
is	O
defined	O
as	O
the	O
minimally	O
-	O
traumatic	O
interventions	O
intended	O
to	O
provide	O
quick	O
stabilization	O
of	O
orthopedic	O
injuries	O
to	O
minimize	O
the	O
systemic	O
inflammatory	B-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
spread	O
during	O
the	O
winter	O
of	O
2003	O
,	O
and	O
attempts	O
have	O
been	O
made	O
to	O
develop	O
vaccines	O
against	O
SARS	B-DISO
corona	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
present	O
report	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
on	O
a	O
heart	O
transplant	O
patient	O
who	O
developed	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
and	O
had	O
a	O
favorable	O
outcome	O
,	O
thus	O
generating	O
discussion	O
on	O
the	O
real	O
role	O
of	O
immunosuppressive	O
therapy	O
as	O
a	O
risk	O
factor	O
for	O
the	O
severe	O
form	O
of	O
the	O
disease	O
.	O

Although	O
there	O
are	O
a	O
variety	O
of	O
methods	O
to	O
address	O
hypoxia	B-DISO
,	O
it	O
is	O
not	O
well	O
documented	O
what	O
strategies	O
are	O
used	O
by	O
anesthesiologists	O
when	O
faced	O
with	O
a	O
hypoxic	B-DISO
patient	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
is	O
regulated	O
by	O
a	O
STAT1	O
dependent	O
but	O
a	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	O
receptor	O
independent	O
mechanism	O
.	O

This	O
suggests	O
that	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	O
signaling	O
play	O
minor	O
roles	O
in	O
regulating	O
SARS	B-DISO
pathogenesis	B-DISO
in	O
mouse	O
models	O
.	O

The	O
main	O
clinical	O
manifestations	O
were	O
noted	O
as	O
:	O
headache	B-DISO
(	O
in	O
70	O
.	O
9	O
%),	O
sore	B-DISO
throat	I-DISO
(	O
69	O
%),	O
chills	B-DISO
(	O
68	O
%),	O
cough	B-DISO
(	O
33	O
%),	O
sputum	O
(	O
21	O
.	O
3	O
%),	O
rhinorrhea	B-DISO
(	O
21	O
.	O
4	O
%),	O
nasal	O
obstruction	B-DISO
(	O
16	O
.	O
5	O
%),	O
and	O
a	O
few	O
of	O
patients	O
were	O
visible	O
as	O
vomiting	B-DISO
(	O
6	O
.	O
8	O
%),	O
dyspnea	B-DISO
(	O
3	O
.	O
9	O
%),	O
diarrhea	B-DISO
(	O
in	O
1	O
.	O
9	O
%).	O

Despite	O
antituberculosis	O
chemotherapy	O
with	O
isoniazid	O
,	O
rifampicin	O
and	O
ethambutol	O
,	O
his	O
general	O
condition	B-DISO
worsened	O
.	O

We	O
diagnosed	O
pulmonary	B-DISO
tuberculosis	I-DISO
complicated	O
with	O
septic	B-DISO
shock	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
based	O
on	O
his	O
clinical	O
course	O
and	O
laboratory	O
data	O
.	O

TITLE	O
:	O
[	O
Perceived	O
stress	O
in	O
general	O
public	O
during	O
prevalence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
its	O
impact	O
on	O
health	O
behavior	O
].	O

ABSTRACT	O
:	O
Recently	O
,	O
the	O
causal	O
relationship	O
between	O
eggshell	O
apex	O
abnormalities	O
(	O
EAA	O
)	O
and	O
Mycoplasma	B-DISO
synoviae	O
was	O
described	O
.	O

TITLE	O
:	O
Viral	O
respiratory	B-DISO
diseases	I-DISO
(	O
ILT	O
,	O
aMPV	O
infections	B-DISO
,	O
IB	O
):	O
are	O
they	O
ever	O
under	O
control	O
?	O

The	O
use	O
of	O
vaccines	O
is	O
the	O
main	O
approach	O
to	O
control	O
of	O
the	O
economically	O
important	O
poultry	O
viral	O
respiratory	B-DISO
diseases	I-DISO
infectious	B-DISO
laryngotracheitis	B-DISO
(	O
ILT	O
),	O
avian	O
metapneumovirus	O
(	O
aMPV	O
)	O
infections	B-DISO
and	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
).	O

Geographic	O
information	O
system	O
(	O
GIS	O
)	O
can	O
be	O
applied	O
during	O
an	O
acute	B-DISO
infectious	I-DISO
disease	I-DISO
outbreak	O
to	O
reveal	O
new	O
geospatial	O
information	O
in	O
addition	O
to	O
standard	O
field	O
epidemiological	O
analyses	O
.	O

When	O
applied	O
in	O
real	O
time	O
during	O
the	O
onset	O
and	O
evolution	O
of	O
an	O
epidemic	O
,	O
GIS	O
can	O
monitor	O
and	O
enhance	O
understanding	O
of	O
the	O
transmission	O
dynamics	O
of	O
an	O
infectious	B-DISO
agent	O
,	O
thereby	O
facilitating	O
the	O
design	O
,	O
implementation	O
and	O
evaluation	O
of	O
potential	O
intervention	O
strategies	O
.	O

The	O
promotion	O
of	O
personal	O
protective	O
health	O
practices	O
must	O
take	O
into	O
account	O
background	O
perceptions	O
of	O
risk	O
and	O
psychological	B-DISO
responses	O
in	O
the	O
community	O
-	O
at	O
-	O
large	O
.	O

The	O
parturient	O
had	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
of	O
respiratory	B-DISO
distress	I-DISO
due	O
to	O
high	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
the	O
pregnancy	O
was	O
complicated	O
by	O
preeclampsia	B-DISO
.	O

ABSTRACT	O
:	O
Public	O
health	O
concerns	O
such	O
as	O
multi	O
-	O
and	O
extensive	O
drug	B-DISO
-	I-DISO
resistant	I-DISO
tuberculosis	I-DISO
,	O
bioterrorism	O
,	O
pandemic	O
influenza	B-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
have	O
intensified	O
efforts	O
to	O
prevent	O
transmission	O
of	O
infections	B-DISO
that	O
are	O
completely	O
or	O
partially	O
airborne	O
using	O
environmental	O
controls	O
.	O

Despite	O
manpower	O
and	O
equipment	O
reinforcements	O
,	O
staff	O
infection	B-DISO
occurred	O
as	O
a	O
result	O
of	O
bodily	O
exhaustion	B-DISO
,	O
working	O
in	O
an	O
unfamiliar	O
environment	O
and	O
lapses	O
in	O
infection	B-DISO
control	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
experimentally	O
-	O
induced	O
respiratory	B-DISO
disease	I-DISO
was	O
not	O
mediated	O
by	O
cytokine	O
over	O
-	O
production	O
,	O
but	O
rather	O
reflected	O
the	O
concerted	O
action	O
of	O
particular	O
cytokine	O
interactions	O
and	O
/	O
or	O
as	O
yet	O
unidentified	O
mediators	O
.	O

TITLE	O
:	O
Role	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
receptor	O
murine	O
CEACAM1	O
in	O
the	O
resistance	O
of	O
mice	O
to	O
MHV	O
infection	B-DISO
:	O
studies	O
of	O
mice	O
with	O
chimeric	O
mCEACAM1a	O
and	O
mCEACAM1b	O
.	O

Thus	O
,	O
cB61ba	O
mice	O
are	O
apparently	O
completely	O
resistant	O
to	O
MHV	O
-	O
A59	O
infection	B-DISO
,	O
while	O
SJL	O
mice	O
permit	O
low	O
levels	O
of	O
MHV	O
-	O
A59	O
virus	O
replication	O
during	O
self	O
-	O
limited	O
,	O
asymptomatic	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
The	O
relationship	O
between	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
and	O
canine	O
influenza	B-DISO
virus	O
(	O
CIV	O
)	O
seropositivity	O
in	O
dogs	O
in	O
Korea	O
was	O
examined	O
.	O

ABSTRACT	O
:	O
A	O
strain	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
designated	O
H16	O
,	O
was	O
isolated	O
in	O
PK	O
-	O
15	O
cells	O
and	O
passaged	O
serially	O
to	O
level	O
165	O
.	O

Vaccines	O
based	O
on	O
passages	O
155	O
-	O
165	O
in	O
cell	O
cultures	O
are	O
available	O
commercially	O
as	O
vaccines	O
for	O
the	O
prevention	O
and	O
control	O
of	O
infections	B-DISO
with	O
TGEV	O
in	O
China	O
.	O

The	O
WMP	O
of	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
in	O
AECOPD	O
was	O
34	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
:	O
23	O
.	O
9	O
-	O
44	O
.	O
4	O
).	O

TITLE	O
:	O
The	O
impact	O
of	O
epidemic	O
outbreak	O
:	O
the	O
case	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
suicide	O
among	O
older	O
adults	O
in	O
Hong	O
Kong	O
.	O

The	O
peak	O
coincided	O
with	O
the	O
majority	O
of	O
SARS	B-DISO
cases	O
being	O
reported	O
in	O
April	O
2003	O
.	O

SARS	B-DISO
-	O
related	O
older	O
adult	O
suicide	O
victims	O
were	O
more	O
likely	O
to	O
be	O
afraid	O
of	O
contracting	O
the	O
disease	O
and	O
had	O
fears	O
of	O
disconnection	O
.	O

We	O
recommend	O
that	O
the	O
mental	O
and	O
psychological	B-DISO
well	O
-	O
being	O
of	O
the	O
community	O
,	O
in	O
particular	O
older	O
adults	O
,	O
be	O
taken	O
into	O
careful	O
account	O
when	O
developing	O
epidemic	O
control	O
measures	O
to	O
combat	O
the	O
future	O
outbreak	O
of	O
diseases	O
in	O
the	O
community	O
.	O

From	O
24	O
April	O
through	O
1	O
July	O
2009	O
,	O
47	O
confirmed	O
fatal	O
cases	O
of	O
2009	O
H1N1	B-DISO
influenza	I-DISO
were	O
reported	O
to	O
the	O
New	O
York	O
City	O
Department	O
of	O
Health	O
and	O
Mental	O
Hygiene	O
.	O

We	O
repeatedly	O
measured	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
)	O
in	O
a	O
29	O
-	O
year	O
-	O
old	O
man	O
with	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
over	O
the	O
course	O
of	O
activated	O
protein	O
C	O
therapy	O
.	O

Here	O
,	O
we	O
have	O
reconstituted	O
complete	O
SARS	B-DISO
-	O
CoV	O
mRNA	O
cap	B-DISO
methylation	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
direct	O
anterior	O
sternal	O
split	O
expansion	O
as	O
a	O
surgical	O
option	O
for	O
a	O
case	O
of	O
severe	O
Thoracic	B-DISO
Insufficiency	O
Syndrome	B-DISO
(	O
TIS	O
)	O
in	O
an	O
arthrogryposis	B-DISO
-	O
like	O
patient	O
.	O

Adam	O
Robert	O
Wright	O
Syndrome	B-DISO
.	O

We	O
show	O
that	O
direct	O
anterior	O
sternal	O
split	O
expansion	O
is	O
a	O
surgical	O
treatment	O
option	O
in	O
some	O
patients	O
with	O
thoracic	B-DISO
insufficiency	O
syndrome	B-DISO
.	O

This	O
induction	O
is	O
completely	O
dependent	O
on	O
virus	O
replication	O
,	O
since	O
infection	B-DISO
with	O
UV	O
light	O
-	O
inactivated	O
virus	O
could	O
no	O
longer	O
induce	O
IFN	O
-	O
alpha	O
/	O
beta	O
.	O

However	O
,	O
knockdown	O
of	O
RIG	O
-	O
I	O
only	O
partially	O
blocked	O
NF	O
-	O
kappaB	O
activity	O
induced	O
by	O
MHV	O
infection	B-DISO
and	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
a	O
decoy	O
peptide	O
inhibitor	O
had	O
little	O
effect	O
on	O
IFN	O
-	O
alpha	O
/	O
beta	O
production	O
.	O

ABSTRACT	O
:	O
The	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO	O
(	O
2	O
)	O
R	O
)	O
concept	O
,	O
used	O
as	O
an	O
integrated	O
tool	O
with	O
conventional	O
ventilation	O
,	O
plays	O
a	O
role	O
in	O
adjusting	O
respiratory	B-DISO
acidosis	I-DISO
consequent	O
to	O
tidal	O
volume	O
(	O
Vt	O
)	O
reduction	O
in	O
a	O
protective	O
ventilation	O
setting	O
.	O

Among	O
those	O
admitted	O
to	O
ICUs	O
,	O
the	O
pandemic	O
was	O
associated	O
with	O
a	O
mortality	O
of	O
approximately	O
16	O
%,	O
a	O
high	O
incidence	O
of	O
acute	O
lung	O
injury	O
and	O
,	O
in	O
some	O
cases	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
severe	O
enough	O
to	O
require	O
support	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Severe	O
falciparum	B-DISO
malaria	I-DISO
is	O
an	O
important	O
cause	O
of	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
in	O
Indian	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
.	O

The	O
clinical	O
spectrum	O
of	O
severe	O
falciparum	B-DISO
malaria	I-DISO
in	O
a	O
tertiary	O
care	O
level	O
III	O
ICU	O
was	O
analysed	O
from	O
December	O
1998	O
to	O
June	O
2008	O
.	O

CONCLUSIONS	O
:	O
Severe	O
falciparum	B-DISO
malaria	I-DISO
is	O
a	O
common	O
cause	O
of	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
in	O
the	O
ICUs	O
in	O
eastern	O
India	O
.	O

Patient	O
with	O
AMAN	O
variant	O
of	O
GBS	B-DISO
after	O
severe	O
bilateral	B-DISO
pneumonia	I-DISO
and	O
ARDS	B-DISO
due	O
to	O
the	O
novel	O
pandemic	O
H1N1	B-DISO
influenza	I-DISO
A	O
virus	O
is	O
presented	O
.	O

An	O
underlying	O
condition	B-DISO
was	O
present	O
in	O
83	O
%	O
of	O
the	O
patients	O
.	O

Twenty	O
-	O
nine	O
patients	O
required	O
mechanical	O
ventilation	O
(	O
96	O
.	O
6	O
%);	O
only	O
one	O
required	O
extracorporeal	O
membrane	O
oxygenation	O
;	O
and	O
19	O
(	O
63	O
%)	O
had	O
respiratory	B-DISO
complications	I-DISO
.	O

When	O
both	O
groups	O
were	O
compared	O
,	O
patients	O
with	O
influenza	B-DISO
A	O
pH1N1	O
infection	B-DISO
were	O
older	O
;	O
pneumonia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
shock	O
were	O
more	O
frequently	O
seen	O
at	O
the	O
time	O
of	O
PICU	O
admission	O
,	O
although	O
length	O
of	O
stay	O
and	O
mortality	O
were	O
similar	O
.	O

TITLE	O
:	O
A	O
multiplex	O
reverse	O
transcription	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
for	O
detection	O
and	O
differentiation	O
of	O
wild	O
-	O
type	O
and	O
vaccine	O
strains	O
of	O
canine	B-DISO
distemper	I-DISO
virus	O
.	O

The	O
RT	O
-	O
nPCR	O
method	O
was	O
used	O
to	O
detect	O
30	O
field	O
samples	O
suspected	O
of	O
canine	B-DISO
distemper	I-DISO
from	O
Heilongjiang	O
and	O
Jilin	O
Provinces	O
,	O
and	O
51	O
samples	O
in	O
Shandong	O
province	O
.	O

TITLE	O
:	O
Upper	O
-	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
,	O
biomarkers	O
,	O
and	O
COPD	B-DISO
exacerbations	O
.	O

Prevalence	O
of	O
upper	O
-	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
,	O
as	O
detected	O
from	O
nasopharyngeal	O
swab	O
by	O
RT	O
-	O
PCR	O
,	O
is	O
high	O
in	O
AECOPD	O
and	O
low	O
after	O
clinical	O
recovery	O
,	O
suggesting	O
that	O
AECOPD	O
frequently	O
are	O
triggered	O
by	O
viral	B-DISO
infections	I-DISO
initiated	O
in	O
the	O
upper	O
-	O
respiratory	O
tract	O
.	O

Following	O
challenge	O
with	O
IBV	O
,	O
chickens	O
inoculated	O
with	O
SNH	O
showed	O
fewer	O
and	O
less	O
severe	O
clinical	O
signs	O
,	O
lower	O
death	O
rate	O
and	O
less	O
kidney	O
pathology	B-DISO
,	O
as	O
compared	O
to	O
those	O
of	O
the	O
control	O
groups	O
.	O

Three	O
children	O
,	O
aged	O
8	O
,	O
11	O
,	O
and	O
17	O
yrs	O
,	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
hemodynamic	O
compromise	O
related	O
to	O
the	O
2009	O
pH1N1	O
influenza	B-DISO
A	O
virus	O
documented	O
by	O
polymerase	O
chair	O
reaction	O
.	O

Using	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
as	O
an	O
example	O
,	O
we	O
conducted	O
a	O
comprehensive	O
time	O
-	O
stratified	O
review	O
of	O
the	O
published	O
literature	O
to	O
describe	O
the	O
different	O
types	O
of	O
epidemiological	O
outputs	O
.	O

The	O
submission	O
-	O
to	O
-	O
acceptance	O
and	O
acceptance	O
-	O
to	O
-	O
publication	O
intervals	O
of	O
the	O
SARS	B-DISO
articles	O
submitted	O
during	O
the	O
epidemic	O
period	O
were	O
significantly	O
shorter	O
than	O
the	O
corresponding	O
intervals	O
of	O
matched	O
-	O
control	O
non	O
-	O
SARS	B-DISO
articles	O
published	O
in	O
the	O
same	O
journal	O
issues	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
,	O
respectively	O
).	O

This	O
condition	B-DISO
is	O
often	O
lethal	O
,	O
usually	O
requiring	O
mechanical	O
ventilation	O
and	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

Pleural	B-DISO
effusion	I-DISO
was	O
present	O
in	O
three	O
of	O
four	O
patients	O
undergoing	O
ECMO	O
therapy	O
.	O

CONCLUSIONS	O
:	O
Patients	O
requiring	O
treatment	O
in	O
an	O
intensive	O
care	O
unit	O
for	O
severe	O
H1N1	O
pneumonia	B-DISO
are	O
at	O
high	O
risk	O
for	O
developing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
frequently	O
require	O
ECMO	O
therapy	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
viruses	O
(	O
IBVs	O
)	O
isolated	O
from	O
commercial	O
layer	O
flocks	O
kept	O
in	O
Ibaraki	O
Prefecture	O
in	O
2009	O
were	O
genetically	O
and	O
serologically	O
characterized	O
.	O

The	O
prevailing	O
sociocultural	O
practices	O
and	O
weak	O
public	O
health	O
infrastructure	O
further	O
enhances	O
the	O
vulnerability	O
of	O
Asia	O
as	O
the	O
epicenter	O
of	O
outbreaks	O
due	O
to	O
zoonotic	O
infections	B-DISO
.	O

However	O
,	O
the	O
vast	O
majority	O
of	O
infected	O
persons	O
are	O
asymptomatic	O
or	O
have	O
mild	O
respiratory	B-DISO
symptoms	I-DISO
that	O
are	O
not	O
diagnosed	O
as	O
being	O
caused	O
by	O
a	O
fungal	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Survey	O
of	O
infectious	B-DISO
and	I-DISO
parasitic	I-DISO
diseases	I-DISO
in	O
stray	O
cats	O
at	O
the	O
Lisbon	O
Metropolitan	O
Area	O
,	O
Portugal	O
.	O

TITLE	O
:	O
A	O
small	O
-	O
molecule	O
oxocarbazate	O
inhibitor	O
of	O
human	O
cathepsin	O
L	O
blocks	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
ebola	O
pseudotype	O
virus	B-DISO
infection	I-DISO
into	O
human	O
embryonic	O
kidney	O
293T	O
cells	O
.	O

The	O
compound	O
also	O
displayed	O
cathepsin	O
L	O
/	O
B	O
selectivity	O
of	O
>	O
700	O
-	O
fold	O
and	O
was	O
nontoxic	O
to	O
human	O
aortic	O
endothelial	O
cells	O
at	O
100	O
muM	O
.	O
The	O
oxocarbazate	O
and	O
a	O
related	O
thiocarbazate	O
(	O
PubChem	O
CID	O
16725315	O
)	O
were	O
tested	O
in	O
a	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
and	O
Ebola	O
virus	O
-	O
pseudotype	O
infection	B-DISO
assay	O
with	O
the	O
oxocarbazate	O
but	O
not	O
the	O
thiocarbazate	O
,	O
demonstrating	O
activity	O
in	O
blocking	B-DISO
both	O
SARS	B-DISO
-	O
CoV	O
(	O
IC	O
(	O
50	O
)	O
=	O
273	O
+/-	O

TITLE	O
:	O
Quantitative	O
proteomics	O
using	O
stable	O
isotope	O
labeling	O
with	O
amino	O
acids	O
in	O
cell	O
culture	O
reveals	O
changes	O
in	O
the	O
cytoplasmic	O
,	O
nuclear	O
,	O
and	O
nucleolar	O
proteomes	O
in	O
Vero	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

TITLE	O
:	O
[	O
An	O
overwhelming	B-DISO
post	I-DISO
-	I-DISO
splenectomy	I-DISO
infection	I-DISO
with	O
toxic	B-DISO
shock	I-DISO
syndrome	I-DISO
by	O
group	B-DISO
B	I-DISO
Streptococcus	O
].	O

Here	O
we	O
report	O
a	O
rare	O
case	O
of	O
toxic	B-DISO
shock	I-DISO
syndrome	I-DISO
(	O
TSS	B-DISO
)	O
evoked	O
by	O
group	B-DISO
B	I-DISO
streptococcus	O
(	O
GBS	B-DISO
)	O
in	O
an	O
asplenic	O
young	O
woman	O
,	O
which	O
we	O
considered	O
a	O
case	O
of	O
OPSI	O
.	O

However	O
,	O
the	O
next	O
morning	O
,	O
she	O
was	O
transferred	O
to	O
the	O
hospital	O
complicated	O
by	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
severe	O
liver	B-DISO
damage	I-DISO
,	O
respiratory	B-DISO
insufficiency	I-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
and	O
hypotension	O
.	O

Duration	O
of	O
mechanical	O
ventilation	O
,	O
alternatively	O
,	O
was	O
not	O
associated	O
with	O
long	O
-	O
term	O
cognitive	B-DISO
impairment	I-DISO
(	O
p	O
=.	O
20	O
and	O
.	O
58	O
).	O

The	O
available	O
randomized	O
clinical	O
trials	O
,	O
however	O
,	O
have	O
failed	O
to	O
demonstrate	O
that	O
prone	O
positioning	O
improves	O
the	O
outcomes	O
of	O
patients	O
with	O
ARDS	B-DISO
overall	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
data	O
suggest	O
that	O
long	O
-	O
term	O
prone	O
positioning	O
may	O
expose	O
patients	O
with	O
less	O
severe	O
ARDS	B-DISO
to	O
unnecessary	O
complications	O
.	O

The	O
most	O
common	O
risk	O
factors	O
among	O
hospitalised	O
adult	O
cases	O
were	O
asthma	B-DISO
and	O
diabetes	B-DISO
.	O

In	O
addition	O
,	O
one	O
-	O
fifth	O
of	O
cases	O
with	O
severe	O
illness	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Alcohol	B-DISO
abuse	I-DISO
and	O
acute	O
lung	O
injury	O
:	O
can	O
we	O
target	O
therapy	O
?	O

Alcohol	B-DISO
abuse	I-DISO
independently	O
increases	O
the	O
risk	O
approximately	O
two	O
-	O
to	O
fourfold	O
and	O
,	O
therefore	O
,	O
causes	O
tens	O
of	O
thousands	O
of	O
excess	O
deaths	O
annually	O
.	O

Furthermore	O
,	O
these	O
therapies	O
are	O
already	O
used	O
clinically	O
for	O
other	O
conditions	O
and	O
could	O
readily	O
be	O
tested	O
in	O
clinical	O
studies	O
of	O
alcoholics	O
at	O
high	O
risk	O
for	O
ARDS	B-DISO
and	O
/	O
or	O
with	O
severe	O
lung	O
infections	B-DISO
.	O

Using	O
surface	O
plasmon	O
resonance	O
biomolecular	O
interaction	O
analysis	O
(	O
SPR	O
/	O
BIA	O
)	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
of	O
flight	O
(	O
MALDI	O
-	O
TOF	B-DISO
)	O
mass	O
spectrometry	O
,	O
we	O
found	O
that	O
only	O
the	O
proteasome	O
subunit	O
p42	O
from	O
human	O
fetal	O
lung	O
diploid	O
fibroblast	O
(	O
2BS	O
)	O
cells	O
bound	O
to	O
SARS	B-DISO
-	O
CoV	O
NP	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	B-DISO
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	O
subunit	O
p42	O
within	O
host	O
cells	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	B-DISO
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	O
subunit	O
p42	O
within	O
host	O
cells	O
.	O

Phylogenetic	O
analysis	O
revealed	O
close	O
correlations	O
between	O
one	O
of	O
the	O
positive	O
samples	O
and	O
SARS	B-DISO
-	O
related	O
CoV	O
belonging	O
to	O
the	O
genus	O
Betacoronavirus	O
.	O

However	O
,	O
NIV	O
failed	O
to	O
significantly	O
reduce	O
the	O
number	O
of	O
patients	O
remaining	O
hypoxemic	O
at	O
day	O
3	O
,	O
and	O
was	O
associated	O
with	O
greater	O
patient	O
discomfort	B-DISO
.	O

ABSTRACT	O
:	O
Various	O
extraintestinal	O
manifestations	O
including	O
pulmonary	O
abnormalities	O
have	O
been	O
reported	O
in	O
patients	O
with	O
ulcerative	B-DISO
colitis	I-DISO
.	O

We	O
have	O
experienced	O
a	O
67	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
ARDS	B-DISO
associated	O
with	O
a	O
severe	O
type	O
of	O
ulcerative	B-DISO
colitis	I-DISO
(	O
UC	O
).	O

We	O
believe	O
that	O
severe	O
colonic	O
inflammation	B-DISO
from	O
UC	O
was	O
closely	O
associated	O
with	O
the	O
onset	O
of	O
ARDS	B-DISO
of	O
the	O
patient	O
.	O

Results	O
from	O
oligonucleotide	O
-	O
based	O
microarray	O
,	O
real	O
-	O
time	O
PCR	O
,	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
indicated	O
an	O
upregulation	O
of	O
the	O
fibrosis	B-DISO
-	O
associated	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	O
2	O
(	O
CCL2	O
)	O
by	O
the	O
viral	O
spike	O
protein	O
and	O
the	O
virus	O
-	O
like	O
particles	O
.	O

The	O
upregulation	O
of	O
CCL2	O
by	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
was	O
mainly	O
mediated	O
by	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
and	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
AP	O
-	O
1	O
but	O
not	O
the	O
IkappaBalpha	O
-	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
role	O
of	O
the	O
UPS	O
in	O
different	O
steps	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
cycle	O
.	O

TITLE	O
:	O
Feline	O
lectin	O
activity	O
is	O
critical	O
for	O
the	O
cellular	O
entry	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

Rather	O
,	O
inhibition	O
of	O
the	O
proteasome	O
caused	O
enhanced	O
infection	B-DISO
with	O
lethal	O
outcome	O
,	O
calling	O
for	O
caution	O
when	O
using	O
this	O
type	O
of	O
drug	O
during	O
infection	B-DISO
.	O

TITLE	O
:	O
Ultrastructural	O
and	O
biochemical	O
analyses	O
of	O
hepatitis	B-DISO
C	I-DISO
virus	O
-	O
associated	O
host	O
cell	O
membranes	O
.	O

They	O
were	O
found	O
to	O
contain	O
the	O
non	O
-	O
structural	O
NS3	B-DISO
and	O
NS5A	O
HCV	O
proteins	O
,	O
HCV	O
RNA	O
and	O
LC3	O
-	O
II	O
,	O
a	O
specific	O
marker	O
of	O
autophagic	O
membranes	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
novel	O
alpha	O
-	O
amino	O
cyclic	O
boronates	O
as	O
inhibitors	O
of	O
HCV	O
NS3	B-DISO
protease	O
.	O

Among	O
109	O
individuals	O
with	O
swine	B-DISO
flu	I-DISO
influenza	B-DISO
,	O
67	O
%	O
have	O
not	O
complicated	O
clinical	O
manifestation	O
and	O
they	O
recovered	O
during	O
3	O
-	O
4	O
days	O
.	O

The	O
recent	O
cases	O
have	O
been	O
much	O
more	O
severe	O
,	O
and	O
many	O
patients	O
have	O
presented	O
pneumonia	B-DISO
,	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

There	O
were	O
109	O
patients	O
(	O
age	O
:	O
17	O
-	O
71y	O
),	O
with	O
A	O
/	O
H1N1	O
infection	B-DISO
confirmed	O
by	O
PCR	O
.	O

We	O
observed	O
bacterial	O
superinfections	B-DISO
associated	O
with	O
swine	B-DISO
flu	I-DISO
,	O
ARDS	B-DISO
and	O
shock	B-DISO
syndrome	I-DISO
,	O
secondary	B-DISO
bacterial	I-DISO
pneumonia	I-DISO
and	O
neurological	O
complications	O
.	O

Two	O
woman	O
with	O
clinically	O
-	O
relevant	O
obesity	B-DISO
have	O
developed	O
rapid	O
progression	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
were	O
still	O
on	O
mechanical	O
ventilation	O
.	O

Influenza	B-DISO
A	O
/	O
H1N1	O
were	O
observed	O
in	O
10	O
pregnant	O
women	O
,	O
without	O
co	O
-	O
morbidities	O
.	O

Participants	O
were	O
children	O
aged	O
1	O
day	O
to	O
12	O
years	O
,	O
residing	O
in	O
a	O
systematically	O
enumerated	O
catchment	O
area	O
,	O
and	O
who	O
either	O
were	O
admitted	O
to	O
Kilifi	O
District	O
Hospital	O
meeting	O
World	O
Health	O
Organization	O
clinical	O
criteria	O
for	O
severe	O
pneumonia	B-DISO
or	O
very	O
severe	O
pneumonia	B-DISO
;	O
(	O
2	O
)	O
presented	O
with	O
mild	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
but	O
were	O
not	O
admitted	O
;	O
or	O
(	O
3	O
)	O
were	O
well	O
infants	O
and	O
children	O
attending	O
for	O
immunization	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
was	O
detected	O
in	O
260	O
participants	O
(	O
34	O
%	O
[	O
95	O
%	O
CI	O
,	O
31	O
%-	O
38	O
%])	O
and	O
other	O
respiratory	O
viruses	O
were	O
detected	O
in	O
219	O
participants	O
(	O
29	O
%;	O
95	O
%	O
CI	O
,	O
26	O
%-	O
32	O
%),	O
the	O
most	O
common	O
being	O
Human	O
coronavirus	O
229E	O
(	O
n	O
=	O
51	O
[	O
6	O
.	O
7	O
%]),	O
influenza	B-DISO
type	O
A	O
(	O
n	O
=	O
44	O
[	O
5	O
.	O
8	O
%]),	O
Parainfluenza	B-DISO
type	O
3	O
(	O
n	O
=	O
29	O
[	O
3	O
.	O
8	O
%]),	O
Human	O
adenovirus	B-DISO
(	O
n	O
=	O
29	O
[	O
3	O
.	O
8	O
%]),	O
and	O
Human	O
metapneumovirus	O
(	O
n	O
=	O
23	O
[	O
3	O
.	O
0	O
%]).	O

In	O
a	O
sample	O
of	O
Kenyan	O
infants	O
and	O
children	O
admitted	O
with	O
severe	O
pneumonia	B-DISO
to	O
a	O
rural	O
hospital	O
,	O
RSV	O
was	O
the	O
predominant	O
viral	O
pathogen	O
.	O

CONCLUSIONS	O
:	O
Close	O
contact	O
with	O
the	O
airway	O
of	O
severely	O
ill	B-DISO
patients	O
and	O
failure	O
of	O
infection	B-DISO
control	O
practices	O
to	O
prevent	O
exposure	O
to	O
respiratory	O
secretions	O
were	O
associated	O
with	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Rates	O
of	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
varied	O
widely	O
among	O
patients	O
.	O

Up	O
to	O
60	O
%	O
of	O
the	O
mice	O
showed	O
dyspnea	B-DISO
,	O
airway	B-DISO
obstruction	I-DISO
and	O
hypoxemia	O
and	O
died	O
between	O
days	O
7	O
and	O
12	O
post	O
-	O
infection	B-DISO
.	O

The	O
most	O
common	O
pathological	O
findings	O
were	O
pleural	B-DISO
effusion	I-DISO
,	O
pulmonary	B-DISO
hemorrhage	I-DISO
and	O
edema	B-DISO
,	O
consistent	O
with	O
increased	O
lung	O
vessel	O
permeability	O
,	O
while	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
intact	O
.	O

TITLE	O
:	O
Case	O
report	O
:	O
Sanjad	O
--	O
Sakati	B-DISO
syndrome	I-DISO
:	O
dental	O
findings	O
and	O
treatment	O
.	O

Plaque	B-DISO
removal	O
,	O
restorations	O
and	O
extractions	O
of	O
infected	O
teeth	O
were	O
performed	O
.	O

Half	O
a	O
month	O
later	O
,	O
she	O
had	O
a	O
high	O
fever	O
and	O
abdominal	O
distension	B-DISO
.	O

Four	O
patients	O
had	O
bacterial	O
bronchopneumonia	B-DISO
.	O

Thirteen	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Using	O
Bayesian	O
meta	O
-	O
analytic	O
methods	O
from	O
three	O
randomised	O
controlled	O
trials	O
(	O
RCTs	O
)	O
of	O
ECMO	O
in	O
ARDS	B-DISO
,	O
we	O
estimate	O
the	O
mortality	O
odds	O
ratio	O
to	O
be	O
0	O
.	O
78	O
(	O
95	O
%	O
credible	O
interval	O
,	O
0	O
.	O
25	O
-	O
3	O
.	O
04	O
),	O
P	O
(	O
OR	O
>	O
1	O
)	O
=	O
30	O
%.	O

ABSTRACT	O
:	O
Influenza	B-DISO
infection	B-DISO
can	O
affect	O
cardiac	O
function	O
.	O

These	O
patients	O
have	O
less	O
left	B-DISO
heart	I-DISO
failure	I-DISO
than	O
expected	O
on	O
the	O
basis	O
of	O
prior	O
descriptions	O
of	O
influenza	B-DISO
myopericarditis	B-DISO
or	O
of	O
general	O
populations	O
of	O
septic	O
patients	O
.	O

TITLE	O
:	O
Remembering	O
a	O
critical	O
triad	O
in	O
severe	O
deceleration	O
injuries	O
to	O
the	O
chest	O
:	O
report	O
of	O
a	O
traumatic	O
aortic	B-DISO
rupture	I-DISO
case	O
.	O

For	O
educational	O
purposes	O
,	O
the	O
classic	O
signs	O
of	O
a	O
widened	O
mediastinum	O
,	O
right	O
tracheal	B-DISO
deviation	I-DISO
,	O
and	O
left	O
-	O
sided	O
hemothorax	B-DISO
(	O
in	O
a	O
context	O
of	O
significant	O
deceleration	O
injury	O
)	O
are	O
incorporated	O
into	O
an	O
acute	O
care	O
triad	O
for	O
traumatic	O
aortic	B-DISO
rupture	I-DISO
.	O

A	O
higher	O
proportion	O
amongst	O
the	O
BCV	O
negative	O
herds	O
used	O
external	O
technicians	O
for	O
AI	O
instead	O
of	O
farm	O
personnel	O
,	O
indicating	O
that	O
it	O
is	O
possible	O
to	O
avoid	O
infection	B-DISO
although	O
having	O
regular	O
visits	O
.	O

Subsequently	O
,	O
we	O
carried	O
out	O
lead	O
optimization	O
and	O
structure	O
-	O
activity	O
studies	O
to	O
provide	O
a	O
series	O
of	O
improved	O
inhibitors	O
that	O
show	O
potent	O
PLpro	O
inhibition	O
and	O
antiviral	O
activity	O
against	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

Population	O
-	O
based	O
rates	O
of	O
hospital	O
admissions	O
,	O
emergency	B-DISO
department	O
and	O
outpatient	O
visits	O
,	O
inter	O
-	O
hospital	O
transfers	O
,	O
diagnostic	O
testing	O
and	O
essential	O
drug	O
prescribing	O
,	O
adjusted	O
for	O
age	O
and	O
sex	O
.	O

We	O
will	O
document	O
the	O
extent	O
to	O
which	O
utilization	O
of	O
healthcare	O
services	O
decreased	O
during	O
the	O
SARS	B-DISO
epidemic	O
and	O
identify	O
clinical	O
problem	O
areas	O
where	O
SARS	B-DISO
-	O
related	O
restrictions	O
had	O
adverse	O
consequences	O
on	O
health	O
.	O

Moreover	O
,	O
small	O
molecule	O
-	O
mediated	O
antagonism	O
of	O
CXCR4	O
,	O
but	O
not	O
CXCR7	O
,	O
impaired	B-DISO
migration	O
and	O
proliferation	B-DISO
,	O
to	O
an	O
extent	O
similar	O
to	O
that	O
with	O
anti	O
-	O
CXCL12	O
treatment	O
.	O

We	O
also	O
counted	O
the	O
annual	O
number	O
of	O
stories	O
,	O
published	O
in	O
a	O
12	O
-	O
year	O
period	O
,	O
containing	O
following	O
terms	O
:	O
'	B-DISO
cancer	I-DISO
,'	O
'	B-DISO
diabetes	I-DISO
,'	O
'	B-DISO
hypertension	I-DISO
,'	O
'	B-DISO
pneumonia	I-DISO
,'	O
and	O
'	B-DISO
tuberculosis	I-DISO
.'	O

The	O
news	O
media	O
reduced	O
the	O
relative	O
level	O
of	O
attention	O
given	O
to	O
pneumonia	B-DISO
and	O
tuberculosis	B-DISO
.	O

TITLE	O
:	O
Differential	O
sensitivity	O
of	O
well	O
-	O
differentiated	O
avian	O
respiratory	O
epithelial	O
cells	O
to	O
infection	B-DISO
by	O
different	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

PCLSs	O
should	O
also	O
be	O
a	O
valuable	O
tool	O
for	O
investigation	O
of	O
other	O
respiratory	O
pathogens	O
,	O
such	O
as	O
avian	B-DISO
influenza	I-DISO
viruses	O
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
China	O
.	O

TITLE	O
:	O
Swine	B-DISO
flu	I-DISO
,	O
doctors	O
and	O
pandemics	O
:	O
is	O
there	O
a	O
duty	O
to	O
treat	O
during	O
a	O
pandemic	O
?	O

Pulmonary	B-DISO
involvement	I-DISO
falls	O
into	O
two	O
categories	O
of	O
different	O
grades	O
of	O
clinical	O
significance	O
:	O
(	O
i	O
)	O
the	O
ubiquitous	O
'	B-DISO
lipoid	I-DISO
pneumonia	I-DISO
',	O
the	O
so	O
-	O
called	O
'	O
amiodarone	O
effect	O
',	O
which	O
is	O
usually	O
asymptomatic	O
;	O
and	O
(	O
ii	O
)	O
the	O
more	O
appropriately	O
named	O
'	O
amiodarone	O
toxicity	O
',	O
which	O
includes	O
several	O
distinct	O
clinical	O
entities	O
related	O
to	O
the	O
differing	O
patterns	O
of	O
lung	O
inflammatory	B-DISO
reaction	I-DISO
,	O
such	O
as	O
eosinophilic	B-DISO
pneumonia	I-DISO
,	O
chronic	O
organizing	B-DISO
pneumonia	I-DISO
,	O
acute	B-DISO
fibrinous	I-DISO
organizing	I-DISO
pneumonia	I-DISO
,	O
nodules	B-DISO
or	O
mass	O
-	O
like	O
lesions	O
,	O
nonspecific	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
-	O
like	O
and	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
-	O
like	O
interstitial	B-DISO
pneumonia	I-DISO
,	O
desquamative	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
,	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
diffuse	O
alveolar	O
haemorrhage	B-DISO
.	O

ABSTRACT	O
:	O
Four	O
human	O
coronaviruses	O
(	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
HKU1	O
,	O
HCoV	O
-	O
NL63	O
,	O
and	O
HCoV	O
-	O
OC43	O
)	O
are	O
associated	O
with	O
a	O
range	O
of	O
respiratory	O
outcomes	O
,	O
including	O
bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
T	O
cell	O
epitope	O
specificity	O
and	O
pathogenesis	B-DISO
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
-	O
1	O
-	O
induced	O
disease	O
in	O
susceptible	O
and	O
resistant	O
hosts	O
.	O

The	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
remains	O
poorly	O
understood	O
,	O
although	O
increasing	O
evidence	O
suggests	O
that	O
immunopathology	B-DISO
could	O
play	O
an	O
important	O
role	O
.	O

We	O
previously	O
reported	O
that	O
the	O
adaptive	O
immune	O
response	O
plays	O
an	O
important	O
protective	O
role	O
in	O
MHV	O
-	O
1	O
-	O
infected	O
resistant	O
B6	O
mice	O
and	O
that	O
both	O
CD4	O
and	O
CD8	O
T	O
cells	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
morbidity	O
and	O
lung	O
pathology	B-DISO
following	O
intranasal	O
MHV	O
-	O
1	O
infection	B-DISO
of	O
susceptible	O
C3H	O
/	O
HeJ	O
and	O
A	O
/	O
J	O
mice	O
.	O

The	O
detection	O
rates	O
of	O
CCoV	O
and	O
CPV	O
-	O
2	O
for	O
dogs	O
aged	O
less	O
than	O
1	O
year	O
were	O
66	O
.	O
3	O
%	O
and	O
43	O
.	O
8	O
%,	O
while	O
those	O
for	O
dogs	O
aged	O
1	O
year	O
or	O
older	O
were	O
6	O
.	O
9	O
%	O
and	O
10	O
.	O
3	O
%,	O
respectively	O
,	O
which	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
0001	O
and	O
p	O
=	O
0	O
.	O
0003	O
,	O
respectively	O
),	O
indicating	O
not	O
CPV	O
-	O
2	O
but	O
CCoV	O
is	O
an	O
important	O
diarrhoea	B-DISO
-	O
causing	O
organism	O
in	O
juvenile	O
dogs	O
.	O

TITLE	O
:	O
[	O
Bronchiolitis	B-DISO
viruses	O
].	O

hRSV	O
acute	B-DISO
bronchiolitis	I-DISO
increased	O
from	O
261	O
cases	O
in	O
epidemics	O
from	O
1999	O
-	O
2003	O
to	O
341	O
cases	O
from	O
2004	O
-	O
2009	O
.	O

TITLE	O
:	O
Prolonged	O
depletion	O
of	O
circulating	O
CD4	O
+	O
T	O
lymphocytes	O
and	O
acute	O
monocytosis	B-DISO
after	O
pantropic	O
canine	O
coronavirus	B-DISO
infection	I-DISO
in	O
dogs	O
.	O

The	O
medical	O
records	O
of	O
nine	O
severe	O
crush	B-DISO
syndrome	I-DISO
patients	O
were	O
retrospectively	O
reviewed	O
.	O

Multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
sepsis	B-DISO
developed	O
in	O
eight	O
patients	O
,	O
but	O
no	O
patients	O
died	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
SF2	O
/	O
ASF	B-DISO
regulates	O
the	O
function	O
of	O
CD200	O
by	O
controlling	O
CD200	O
alternative	O
splicing	O
,	O
through	O
direct	O
binding	O
to	O
an	O
ESE	O
located	O
in	O
exon	O
2	O
of	O
CD200	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
possess	B-DISO
the	O
largest	O
known	O
RNA	O
genome	O
,	O
a	O
27	O
-	O
to	O
32	O
-	O
kb	O
(+)-	O
strand	O
molecule	O
that	O
replicates	O
in	O
the	O
cytoplasm	O
.	O

An	O
unanswered	O
question	O
is	O
whether	O
the	O
sgmRNAs	O
,	O
which	O
appear	O
rapidly	O
and	O
abundantly	O
,	O
undergo	O
posttranscriptional	O
amplification	B-DISO
.	O

We	O
searched	O
the	O
PubMed	O
database	O
for	O
clinical	O
trials	O
that	O
examined	O
the	O
use	O
of	O
the	O
following	O
therapies	O
in	O
severe	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
recruitment	B-DISO
maneuvers	O
,	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
prone	O
position	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
glucocorticoids	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
buffer	O
therapy	O
,	O
and	O
extracorporeal	O
life	O
support	O
.	O

By	O
August	O
2003	O
,	O
there	O
were	O
8422	O
SARS	B-DISO
cases	O
and	O
916	O
deaths	O
reported	O
from	O
29	O
countries	O
.	O

METHODS	O
:	O
A	O
quasi	O
-	O
experimental	O
design	O
was	O
used	O
and	O
a	O
16	O
-	O
hour	O
,	O
purpose	O
-	O
designed	O
infection	B-DISO
control	O
education	O
programme	O
was	O
implemented	O
for	O
preservice	O
nursing	O
students	O
in	O
southern	O
Taiwan	O
.	O

Following	O
the	O
education	O
programme	O
,	O
students	O
in	O
the	O
intervention	O
group	O
showed	O
a	O
statistically	O
significant	O
improvement	O
across	O
time	O
in	O
their	O
knowledge	O
of	O
these	O
precautions	O
[	O
F	O
(	O
2	O
,	O
180	O
)	O
=	O
13	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
001	O
]	O
and	O
confidence	O
in	O
resolving	O
infection	B-DISO
-	O
related	O
issues	O
[	O
F	O
(	O
1	O
.	O
79	O
,	O
168	O
.	O
95	O
)	O
=	O
3	O
.	O
24	O
]	O
when	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
To	O
improve	O
nursing	O
students	O
'	O
capacity	O
in	O
responding	O
to	O
infectious	B-DISO
epidemics	O
,	O
an	O
educational	O
programme	O
that	O
integrates	O
the	O
theme	O
of	O
infection	B-DISO
precautions	O
,	O
learning	O
theory	O
and	O
teaching	O
strategies	O
is	O
recommended	O
for	O
all	O
nursing	O
institutes	O
.	O

There	O
was	O
an	O
increased	O
eosinophilia	B-DISO
in	O
both	O
blood	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
experimentally	O
the	O
pathogenicity	O
and	O
tissue	O
distribution	O
of	O
the	O
recently	O
emerged	O
QX	O
-	O
like	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
with	O
the	O
widespread	O
M41	O
and	O
793	O
/	O
B	O
serotypes	O
of	O
the	O
virus	O
.	O

Replication	O
of	O
the	O
isolates	O
in	O
the	O
alimentary	O
tract	O
was	O
detected	O
,	O
but	O
the	O
infection	B-DISO
did	O
not	O
cause	O
significant	O
gut	O
lesions	O
.	O

Taking	O
the	O
context	O
of	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
as	O
an	O
example	O
,	O
we	O
use	O
a	O
simple	O
cost	O
function	O
to	O
compare	O
the	O
total	O
cost	O
of	O
each	O
mixed	O
(	O
quarantine	O
and	O
isolation	O
)	O
control	O
strategy	O
from	O
a	O
public	O
health	O
resource	O
allocation	O
perspective	O
.	O

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
S	O
protein	O
for	O
interaction	O
with	O
M	O
protein	O
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

The	O
SARS	B-DISO
experience	O
and	O
unconfirmed	O
beliefs	O
about	O
the	O
transmission	O
modes	O
were	O
associated	O
with	O
variables	O
on	O
anticipated	O
preventive	O
behaviors	O
and	O
emotional	B-DISO
distress	I-DISO
.	O

SIRS	B-DISO
score	O
and	O
serum	O
IL	O
-	O
6	O
concentration	O
were	O
measured	O
in	O
first	O
hour	O
after	O
admission	O
.	O

The	O
higher	O
rate	O
of	O
hepatitis	B-DISO
B	I-DISO
e	O
antigen	O
(	O
HBeAg	O
)	O
seroconversion	O
during	O
telbivudine	O
treatment	O
than	O
other	O
potent	O
anti	O
-	O
HBV	B-DISO
agents	O
suggests	O
a	O
potential	O
immunomodulatory	O
effect	O
.	O

Further	O
analysis	O
revealed	O
that	O
vaccine	O
-	O
matched	O
circulating	O
influenza	B-DISO
A	O
viruses	O
were	O
significantly	O
associated	O
with	O
lower	O
excess	O
P	O
&	O
I	O
mortality	O
during	O
post	O
-	O
SARS	B-DISO
winters	O
(	O
i	O
.	O
e	O
.,	O
2005	O
-	O
2007	O
)	O
than	O
during	O
pre	O
-	O
SARS	B-DISO
winters	O
[	O
0	O
.	O
03	O
+/-	O
0	O
.	O
06	O
vs	O
.	O
1	O
.	O
57	O
+/-	O
1	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
01	O
].	O

TITLE	O
:	O
CXCR2	O
signaling	O
protects	O
oligodendrocytes	O
and	O
restricts	O
demyelination	B-DISO
in	O
a	O
mouse	O
model	O
of	O
viral	O
-	O
induced	O
demyelination	B-DISO
.	O

Rather	O
,	O
blocking	B-DISO
CXCR2	O
was	O
associated	O
with	O
increased	O
numbers	O
of	O
apoptotic	O
cells	O
primarily	O
within	O
white	O
matter	O
tracts	O
,	O
suggesting	O
that	O
oligodendrocytes	O
were	O
affected	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
HB	O
-	O
EGF	O
to	O
protect	O
the	O
lungs	O
from	O
remote	O
organ	O
injury	O
after	O
intestinal	B-DISO
ischemia	I-DISO
/	O
reperfusion	O
(	O
I	O
/	O
R	O
).	O

Special	O
attention	O
has	O
been	O
provided	O
to	O
the	O
use	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
as	O
vector	O
for	O
the	O
expression	O
of	O
PRRSV	O
antigens	O
.	O

TITLE	O
:	O
New	O
mothers	O
'	O
experiences	O
of	O
social	O
disruption	O
and	O
isolation	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Hong	O
Kong	O
.	O

In	O
searching	O
for	O
agents	O
that	O
may	O
prove	O
clinically	O
effective	O
against	O
FCoV	O
infection	B-DISO
,	O
16	O
compounds	O
were	O
screened	O
for	O
their	O
antiviral	O
activity	O
against	O
a	O
local	O
FCoV	O
strain	O
in	O
Felis	O
catus	O
whole	O
fetus	O
-	O
4	O
cells	O
.	O

In	O
-	O
depth	O
interviews	O
were	O
performed	O
(	O
n	O
=	O
26	O
)	O
to	O
develop	O
a	O
questionnaire	O
for	O
a	O
cross	O
-	O
sectional	O
survey	O
of	O
microbiologists	O
(	O
100	O
%	O
response	O
),	O
infection	B-DISO
preventionists	O
(	O
74	O
%	O
response	O
),	O
public	O
health	O
physicians	O
(	O
96	O
%	O
response	O
),	O
and	O
public	O
health	O
nurses	O
(	O
82	O
%	O
response	O
).	O

The	O
groups	O
were	O
asked	O
to	O
appraise	O
barriers	O
encountered	O
during	O
4	O
outbreaks	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
],	O
Clostridium	O
difficile	O
ribotype	O
027	O
,	O
rubella	B-DISO
,	O
and	O
avian	B-DISO
influenza	I-DISO
)	O
according	O
to	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
.	O

However	O
,	O
we	O
recently	O
showed	O
that	O
inefficient	O
immune	O
activation	O
and	O
a	O
poor	O
virus	O
-	O
specific	O
T	O
cell	O
response	O
underlie	O
severe	O
disease	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
mice	O
.	O

They	O
also	O
provide	O
a	O
new	O
approach	O
to	O
SARS	B-DISO
vaccine	O
design	O
.	O

No	O
consistent	O
antigenic	O
or	O
genetic	O
markers	O
have	O
been	O
identified	O
to	O
discriminate	O
BCoVs	O
from	O
the	O
different	O
clinical	O
syndromes	B-DISO
.	O

Patient	O
demographics	O
and	O
the	O
situational	O
and	O
clinical	B-DISO
findings	I-DISO
at	O
the	O
initial	O
drowning	O
scene	O
were	O
reviewed	O
.	O

Survivor	O
long	O
-	O
term	O
morbidity	O
was	O
often	O
related	O
to	O
the	O
sequelae	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
hypoxic	B-DISO
encephalopathy	I-DISO
.	O

Finally	O
,	O
the	O
RNA	O
suppression	B-DISO
property	O
and	O
the	O
enhancement	O
of	O
heterologous	O
replicon	O
activity	O
by	O
the	O
7a	O
protein	O
were	O
confirmed	O
for	O
animal	O
cell	O
lines	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strain	O
N1	O
/	O
88	O
from	O
the	O
oviduct	O
and	O
feces	O
of	O
experimentally	O
infected	O
vaccinated	O
and	O
unvaccinated	O
hens	O
.	O

Pomegranates	O
have	O
high	O
levels	O
of	O
polyphenols	O
(	O
PPs	B-DISO
)	O
and	O
may	O
be	O
a	O
rich	O
source	O
of	O
compounds	O
with	O
antiviral	O
activity	O
.	O

We	O
evaluated	O
the	O
direct	O
anti	O
-	O
influenza	B-DISO
activity	O
of	O
three	O
commercially	O
available	O
pomegranate	O
extracts	O
:	O
pomegranate	O
juice	O
(	O
PJ	O
),	O
a	O
concentrated	O
liquid	O
extract	O
(	O
POMxl	O
),	O
and	O
a	O
93	O
%	O
PP	O
powder	O
extract	O
(	O
POMxp	O
).	O

Our	O
findings	O
demonstrate	O
that	O
the	O
direct	O
anti	O
-	O
influenza	B-DISO
activity	O
of	O
pomegranate	O
PPs	B-DISO
is	O
substantially	O
modulated	O
by	O
small	O
changes	O
in	O
envelope	O
glycoproteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
induced	O
indirect	O
lung	O
injury	O
by	O
intraperitoneal	O
injection	O
of	O
LPS	B-DISO
and	O
direct	O
lung	O
injury	O
by	O
intratracheal	O
injection	O
of	O
LPS	B-DISO
in	O
wild	O
-	O
type	O
and	O
Sftpd	O
(-/-)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
SP	O
-	O
D	O
during	O
ALI	O
/	O
ARDS	B-DISO
.	O

In	O
the	O
field	O
,	O
19	O
persons	O
were	O
found	O
in	O
coma	B-DISO
Glasgow	O
Coma	B-DISO
Scale	O
(	O
GCS	O
<	O
8	O
)	O
and	O
respiratory	B-DISO
depression	I-DISO
and	O
were	O
treated	O
with	O
naloxone	O
.	O

1	O
days	O
,	O
while	O
two	O
patients	O
succumbed	O
because	O
of	O
anoxemic	O
encephalopathy	B-DISO
and	O
brain	B-DISO
death	I-DISO
.	O

The	O
complications	O
observed	O
were	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
eight	O
patients	O
,	O
severe	B-DISO
sepsis	I-DISO
in	O
four	O
,	O
catheter	O
-	O
related	O
bacteremia	B-DISO
in	O
one	O
,	O
iatrogenic	B-DISO
pneumothorax	I-DISO
in	O
one	O
,	O
and	O
rhabdomyolysis	B-DISO
in	O
two	O
,	O
while	O
four	O
among	O
them	O
died	O
due	O
to	O
severe	B-DISO
sepsis	I-DISO
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
spike	O
glycoprotein	O
of	O
human	O
coronavirus	O
OC43	O
modulate	O
disease	O
in	O
BALB	O
/	O
c	O
mice	O
from	O
encephalitis	B-DISO
to	O
flaccid	B-DISO
paralysis	I-DISO
and	O
demyelination	B-DISO
.	O

The	O
proteins	O
showed	O
discrepant	O
binding	O
activity	O
to	O
either	O
pAPN	O
antibody	O
or	O
TGE	B-DISO
virions	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
developmental	O
assessment	O
and	O
its	O
outcome	O
in	O
two	O
groups	O
of	O
NNFU	O
clinic	O
patients	O
,	O
SARS	B-DISO
versus	O
non	O
-	O
SARS	B-DISO
,	O
over	O
three	O
standard	O
clinic	O
appointments	O
.	O

We	O
compared	O
the	O
diagnostic	O
accuracy	O
(	O
identification	O
of	O
developmental	B-DISO
delay	I-DISO
),	O
and	O
patient	O
management	O
(	O
referral	O
for	O
therapy	O
or	O
communication	O
of	O
a	O
new	O
diagnosis	O
)	O
of	O
the	O
strategies	O
used	O
during	O
SARS	B-DISO
,	O
April	O
/	O
May	O
2003	O
,	O
to	O
the	O
standard	O
assessment	O
methods	O
used	O
for	O
patients	O
seen	O
in	O
April	O
/	O
May	O
2005	O
(	O
non	O
-	O
SARS	B-DISO
).	O

There	O
were	O
95	O
patients	O
in	O
the	O
SARS	B-DISO
group	O
and	O
99	O
non	O
-	O
SARS	B-DISO
patients	O
.	O

Of	O
those	O
who	O
responded	O
to	O
the	O
mailed	O
questionnaire	O
,	O
referrals	O
for	O
therapy	O
rates	O
were	O
similar	O
to	O
non	O
-	O
SARS	B-DISO
group	O
.	O

About	O
9	O
.	O
2	O
%	O
of	O
the	O
participants	O
reported	O
that	O
their	O
perceptions	O
of	O
life	O
became	O
more	O
pessimistic	O
following	O
the	O
SARS	B-DISO
crisis	O
.	O

The	O
most	O
common	O
DAMNITV	O
classification	O
associated	O
with	O
SPE	O
abnormalities	O
was	O
infectious	B-DISO
/	O
inflammatory	B-DISO
disease	I-DISO
(	O
80	O
/	O
136	O
;	O
58	O
.	O
8	O
%),	O
including	O
39	O
cats	O
diagnosed	O
with	O
FIP	B-DISO
.	O

Enteritis	B-DISO
first	O
appeared	O
in	O
one	O
shed	O
of	O
post	O
-	O
parturient	O
cows	O
;	O
it	O
spread	O
for	O
6	O
weeks	O
,	O
until	O
at	O
least	O
30	O
%	O
of	O
the	O
lactating	O
stock	O
contracted	O
enteritis	B-DISO
or	O
dysentery	B-DISO
.	O

Twelve	O
(	O
50	O
.	O
0	O
%)	O
were	O
defined	O
as	O
having	O
severe	O
CAP	B-DISO
and	O
9	O
(	O
37	O
.	O
5	O
%)	O
were	O
diagnosed	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Pros	O
and	O
cons	O
of	O
recruitment	B-DISO
maneuvers	O
in	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
a	O
protective	O
mechanical	O
ventilation	O
strategy	O
characterized	O
by	O
low	O
tidal	O
volumes	O
has	O
been	O
associated	O
with	O
reduced	O
mortality	O
.	O

Thus	O
,	O
recruitment	B-DISO
maneuvers	O
(	O
RMs	O
)	O
have	O
been	O
used	O
to	O
open	O
up	O
collapsed	B-DISO
lungs	I-DISO
,	O
while	O
adequate	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
levels	O
may	O
counteract	O
alveolar	O
derecruitment	O
during	O
low	O
tidal	O
volume	O
ventilation	O
,	O
improving	O
respiratory	O
function	O
and	O
minimizing	O
ventilator	O
-	O
associated	O
lung	O
injury	O
.	O

To	O
learn	O
about	O
the	O
functions	O
of	O
N	O
protein	O
domains	O
in	O
the	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
we	O
replaced	O
the	O
MHV	O
N	O
gene	O
with	O
its	O
counterpart	O
from	O
the	O
closely	O
related	O
bovine	O
coronavirus	O
(	O
BCoV	O
).	O

The	O
resulting	O
viral	O
mutant	B-DISO
was	O
severely	O
defective	O
,	O
even	O
though	O
individual	O
domains	O
of	O
the	O
N	O
protein	O
responsible	O
for	O
N	O
-	O
RNA	O
,	O
N	O
-	O
M	O
,	O
or	O
N	O
-	O
N	O
interactions	O
were	O
completely	O
interchangeable	O
between	O
BCoV	O
and	O
MHV	O
.	O

A	O
similarly	O
defective	O
MHV	O
N	O
mutant	B-DISO
bearing	O
an	O
insertion	O
of	O
the	O
SR	O
region	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
N	O
protein	O
was	O
rescued	O
by	O
the	O
same	O
two	O
classes	O
of	O
reverting	O
mutations	O
.	O

TITLE	O
:	O
Detection	O
of	O
a	O
respiratory	O
coronavirus	O
from	O
tissues	O
archived	O
during	O
a	O
pneumonia	B-DISO
epizootic	O
in	O
free	O
-	O
ranging	O
Pacific	O
harbor	O
seals	O
Phoca	O
vitulina	O
richardsii	O
.	O

Histopathological	O
changes	O
in	O
lungs	O
from	O
2	O
of	O
these	O
seals	O
included	O
a	O
necrotizing	O
lymphocytic	O
and	O
histocytic	O
lobar	B-DISO
pneumonia	I-DISO
with	O
intra	O
-	O
lesional	O
bacteria	O
.	O

ABSTRACT	O
:	O
Chlamydiae	O
induce	O
persistent	O
infections	B-DISO
,	O
which	O
have	O
been	O
associated	O
with	O
a	O
wide	O
range	O
of	O
chronic	B-DISO
diseases	I-DISO
in	O
humans	O
and	O
animals	O
.	O

By	O
IF	O
,	O
Chlamydia	O
-	O
infected	O
cells	O
showed	O
normal	O
inclusions	O
after	O
39	O
hpi	B-DISO
.	O

Here	O
,	O
the	O
factors	O
that	O
affected	O
hand	O
washing	O
behavior	O
were	O
similar	O
to	O
those	O
identified	O
at	O
the	O
beginning	O
of	O
the	O
H1N1	O
or	O
SARS	B-DISO
pandemics	O
,	O
suggesting	O
that	O
public	O
education	O
campaigns	O
regarding	O
hand	O
hygiene	O
are	O
effective	O
in	O
altering	O
individual	O
hand	O
hygiene	O
habits	O
during	O
the	O
peak	O
periods	O
of	O
influenza	B-DISO
transmission	O
.	O

ABSTRACT	O
:	O
Feline	O
coronaviruses	O
(	O
FCoV	O
)	O
comprise	O
two	O
biotypes	O
:	O
feline	O
enteric	O
coronaviruses	O
(	O
FECV	O
)	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
viruses	O
(	O
FIPV	O
).	O

It	O
seems	O
that	O
adaptation	O
of	O
the	O
virus	O
within	O
the	O
host	O
animal	O
and	O
the	O
subsequent	O
abnormal	O
immune	O
responses	O
may	O
be	O
key	O
factors	O
in	O
the	O
pathogenesis	B-DISO
of	O
this	O
new	O
and	O
fatal	O
respiratory	B-DISO
disease	I-DISO
.	O

This	O
conclusion	O
was	O
confirmed	O
using	O
a	O
vaccinia	B-DISO
virus	O
-	O
based	O
reverse	O
genetics	O
system	O
to	O
produce	O
a	O
recombinant	O
virus	O
,	O
Bristol	O
tsc31	O
(	O
MHV	O
-	O
Brtsc31	O
),	O
which	O
has	O
the	O
same	O
RNA	O
-	O
negative	O
ts	O
phenotype	O
and	O
complementation	O
profile	O
as	O
those	O
of	O
MHV	O
-	O
Brts31	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
serum	O
DNA	O
concentrations	O
were	O
elevated	O
in	O
patients	O
with	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
-	O
hypopnea	B-DISO
syndrome	I-DISO
(	O
OSAHS	B-DISO
).	O

Appearing	O
in	O
1997	O
and	O
becoming	O
epidemic	O
in	O
2003	O
,	O
influenza	B-DISO
A	I-DISO
/	I-DISO
H5N1	I-DISO
provoked	O
many	O
deadly	O
enzootics	O
in	O
poultry	O
batteries	O
(	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
of	O
HPAI	O
).	O

It	O
was	O
feared	O
that	O
this	O
deadly	O
virus	O
could	O
become	O
easily	O
transmitted	B-DISO
between	O
humans	O
,	O
leading	O
to	O
a	O
new	O
pandemic	O
.	O

Intercontinental	O
health	O
disparities	O
create	O
a	O
risk	O
of	O
pandemics	O
such	O
as	O
SARS	B-DISO
and	O
so	O
-	O
called	O
bird	B-DISO
flu	I-DISO
.	O

Other	O
problems	O
include	O
relative	O
hypoxia	B-DISO
,	O
gas	O
expansion	O
,	O
air	O
dryness	O
,	O
ozone	O
,	O
cosmic	O
rays	O
,	O
airsickness	B-DISO
,	O
jet	B-DISO
lag	I-DISO
,	O
the	O
effects	O
of	O
alcohol	O
and	O
tobacco	O
,	O
and	O
,	O
more	O
recently	O
,	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
(	O
DVT	B-DISO
)	O
and	O
pulmonary	B-DISO
embolism	I-DISO
(	O
PE	O
),	O
collectively	O
known	O
as	O
""""	O
coach	O
class	O
syndrome	B-DISO
"""."	O

In	O
addition	O
,	O
enhanced	O
DNA	O
unwinding	O
was	O
observed	O
for	O
gapped	O
DNA	O
substrates	O
that	O
had	O
a	O
5	O
'-	O
overhang	O
,	O
indicating	O
that	O
the	O
translocated	O
nsP13	O
molecules	O
pile	B-DISO
up	O
and	O
the	O
preceding	O
helicase	O
facilitate	O
DNA	O
unwinding	O
.	O

Respiratory	B-DISO
failure	I-DISO
is	O
the	O
major	O
complication	B-DISO
,	O
and	O
patients	O
may	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

There	O
is	O
currently	O
no	O
proven	O
effective	O
treatment	O
of	O
SARS	B-DISO
,	O
so	O
early	O
recognition	O
,	O
isolation	O
,	O
and	O
stringent	O
infection	B-DISO
control	O
are	O
the	O
key	O
to	O
controlling	O
this	O
highly	O
contagious	B-DISO
disease	I-DISO
.	O

The	O
lessons	O
from	O
these	O
3	O
are	O
relevant	O
for	O
all	O
nosocomial	O
pulmonary	O
infectious	B-DISO
diseases	I-DISO
.	O

Among	O
compounds	O
tested	O
,	O
the	O
fluorene	O
compound	O
4b	O
was	O
found	O
to	O
possess	B-DISO
the	O
most	O
potent	O
activity	O
(	O
EC	O
(	O
50	O
)=	O
0	O
.	O
3	O
microM	O
),	O
lower	O
cytotoxicity	B-DISO
(	O
CC	O
(	O
50	O
)>	O
50	O
microM	O
),	O
and	O
significantly	O
better	O
pharmacokinetic	O
properties	O
compared	O
to	O
its	O
corresponding	O
fluorenone	O
compound	O
4c	O
.	O

After	O
virus	O
replication	O
in	O
the	O
bats	O
was	O
confirmed	O
,	O
an	O
additional	O
passage	O
of	O
the	O
virus	O
was	O
made	O
in	O
Leschenault	O
rousette	O
bats	O
,	O
and	O
bat	O
pathogenesis	B-DISO
was	O
investigated	O
.	O

This	O
coronavirus	O
caused	O
an	O
enteric	O
disease	O
called	O
epizootic	O
catarrhal	O
enteritis	B-DISO
(	O
ECE	O
).	O

A	O
SARS	B-DISO
-	O
related	O
virus	O
(	O
BtCoV	O
/	O
BM48	O
-	O
31	O
/	O
Bulgaria	O
/	O
2008	O
)	O
from	O
a	O
Rhinolophus	O
blasii	O
(	O
Rhi	O
bla	O
)	O
bat	O
was	O
fully	O
sequenced	O
.	O

Because	O
of	O
its	O
sensitivity	O
,	O
specificity	O
,	O
and	O
simplicity	O
,	O
the	O
LAMP	O
assay	O
could	O
be	O
a	O
useful	O
method	O
for	O
early	O
and	O
rapid	O
differentiation	O
of	O
swine	O
vaccinated	O
with	O
PRV	B-DISO
gE	O
-	O
deleted	O
vaccine	O
from	O
swine	O
infected	O
with	O
wild	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
successful	O
reversal	O
of	O
intractable	O
hypoxemia	O
after	O
exogenous	O
surfactant	O
(	O
calfactant	O
)	O
administration	O
,	O
facilitating	O
neurological	O
recovery	O
in	O
a	O
toddler	O
cold	B-DISO
-	O
water	O
drowning	O
victim	O
with	O
significant	O
circulatory	B-DISO
arrest	I-DISO
time	O
.	O

ABSTRACT	O
:	O
Sensitivity	O
and	O
specificity	O
of	O
respiratory	O
change	O
in	O
pulse	O
pressure	O
(	O
DeltaPP	O
)	O
to	O
predict	O
preload	O
dependency	O
has	O
been	O
questioned	O
at	O
small	O
tidal	O
volumes	O
(	O
VT	O
)	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
suffering	B-DISO
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
After	O
bleeding	B-DISO
,	O
in	O
the	O
control	O
group	O
ventilated	O
with	O
a	O
VT	O
of	O
10	O
ml	O
/	O
kg	O
,	O
DeltaPP	O
increased	O
from	O
8	O
.	O
5	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
7	O
.	O
1	O
to	O
9	O
.	O
9	O
%)	O
to	O
18	O
.	O
5	O
%	O
(	O
CI	O
,	O
15	O
.	O
3	O
to	O
21	O
.	O
7	O
%;	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Information	O
about	O
the	O
electrophoretic	O
distribution	O
of	O
CK	O
-	O
MM	O
,	O
CK	O
-	O
MB	O
,	O
and	O
CK	O
-	O
BB	O
,	O
serum	O
creatine	O
kinase	O
(	O
CK	O
)	O
isoenzymes	O
that	O
are	O
indicators	O
of	O
skeletal	O
muscle	O
,	O
cardiac	O
muscle	O
,	O
and	O
brain	B-DISO
lesions	I-DISO
,	O
respectively	O
,	O
and	O
CK	O
macroenzymes	O
(	O
macro	O
-	O
CK1	O
and	O
macro	O
-	O
CK2	O
)	O
in	O
dogs	O
and	O
cats	O
with	O
and	O
without	O
central	O
neurologic	O
disease	O
is	O
scant	O
and	O
equivocal	O
.	O

This	O
study	O
identified	O
the	O
electophoretic	O
distribution	O
of	O
CK	O
isoenzymes	O
and	O
macroenzymes	O
of	O
dogs	O
and	O
cats	O
and	O
provided	O
encouraging	O
data	O
about	O
the	O
possible	O
use	O
of	O
CK	O
-	O
BB	O
as	O
a	O
biomarker	O
for	O
canine	O
neurologic	B-DISO
disorders	I-DISO
,	O
but	O
not	O
for	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Even	O
though	O
coronavirus	B-DISO
infection	I-DISO
of	O
humans	O
is	O
not	O
normally	O
associated	O
with	O
severe	O
diseases	O
,	O
the	O
identification	O
of	O
the	O
coronavirus	O
responsible	O
for	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
showed	O
that	O
highly	O
pathogenic	O
coronaviruses	O
can	O
enter	O
the	O
human	O
population	O
.	O

Using	O
high	O
-	O
throughput	O
mRNA	O
profiling	O
,	O
we	O
examined	O
the	O
transcriptional	O
response	O
of	O
wild	O
-	O
type	O
(	O
WT	O
),	O
type	O
I	O
interferon	O
receptor	O
knockout	O
(	O
IFNAR1	O
-/-),	O
and	O
STAT1	O
knockout	O
(	O
STAT1	O
-/-)	O
mice	O
infected	O
with	O
a	O
recombinant	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoV	O
(	O
rMA15	O
)	O
to	O
better	O
understand	O
the	O
contribution	O
of	O
specific	O
gene	O
expression	O
changes	O
to	O
disease	B-DISO
progression	I-DISO
.	O

TITLE	O
:	O
ORF8a	O
of	O
SARS	B-DISO
-	O
CoV	O
forms	O
an	O
ion	O
channel	O
:	O
experiments	O
and	O
molecular	O
dynamics	O
simulations	O
.	O

TITLE	O
:	O
CD8	O
+	O
T	O
cell	O
response	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
mice	O
is	O
elicited	O
by	O
epitopes	O
from	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
NMR	O
structure	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
7	O
in	O
aqueous	O
solution	O
at	O
pH	O
6	O
.	O
5	O
was	O
determined	O
and	O
compared	O
with	O
the	O
results	O
of	O
previous	O
structure	O
determinations	O
of	O
nsp7	O
in	O
solution	O
at	O
pH	O
7	O
.	O
5	O
and	O
in	O
the	O
crystals	O
of	O
a	O
hexadecameric	O
nsp7	O
/	O
nsp8	O
complex	O
obtained	O
from	O
a	O
solution	O
at	O
pH	O
7	O
.	O
5	O
.	O

Little	O
information	O
is	O
available	O
on	O
the	O
management	O
of	O
patients	O
with	O
Panton	O
-	O
Valentine	O
leukocidin	O
expressing	O
S	O
.	O
aureus	O
pneumonia	B-DISO
with	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
.	O

As	O
a	O
large	O
extracorporeal	O
membrane	O
oxygenation	O
center	O
,	O
we	O
reviewed	O
our	O
experience	O
and	O
outcomes	O
with	O
Panton	O
-	O
Valentine	O
Leukocidin	O
expressing	O
S	O
.	O
aureus	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
showed	O
that	O
intraperitoneal	O
infection	B-DISO
with	O
murine	O
coronavirus	O
strain	O
JHM	O
(	O
JHMV	O
)	O
established	O
a	O
persistent	B-DISO
infection	I-DISO
with	O
subacute	O
granulomatous	O
serositis	B-DISO
in	O
interferon	O
-	O
gamma	O
-	O
deficient	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
.	O

Mastadenovirus	O
,	O
bovine	O
coronavirus	O
,	O
influenza	B-DISO
A	O
virus	O
or	O
Chlamydiaceae	O
were	O
not	O
detected	O
.	O

RESULTS	O
:	O
At	O
the	O
time	O
of	O
surgical	O
decompression	O
,	O
the	O
median	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
among	O
patients	O
was	O
12	O
(	O
interquartile	O
range	O
,	O
10	O
-	O
15	O
),	O
and	O
the	O
median	O
intra	O
-	O
abdominal	O
pressure	O
was	O
31	O
.	O
5	O
(	O
interquartile	O
range	O
,	O
27	O
-	O
35	O
)	O
mm	O
Hg	O
.	O

Diarrhoea	B-DISO
was	O
more	O
common	O
in	O
case	O
herd	O
calves	O
.	O

We	O
propose	O
that	O
the	O
HAE	O
model	O
provides	O
a	O
ready	O
platform	O
for	O
molecular	O
studies	O
and	O
characterization	O
of	O
HCoV	O
-	O
HKU1	O
and	O
in	O
general	O
serves	O
as	O
a	O
robust	O
technology	O
for	O
the	O
recovery	O
,	O
amplification	B-DISO
,	O
adaptation	O
,	O
and	O
characterization	O
of	O
novel	O
coronaviruses	O
and	O
other	O
respiratory	O
viruses	O
from	O
clinical	O
material	O
.	O

The	O
3	O
most	O
commonly	O
detected	O
viruses	O
were	O
parainfluenza	B-DISO
virus	O
type	O
1	O
(	O
PIV1	O
)	O
in	O
44	O
(	O
24	O
.	O
2	O
%)	O
patients	O
,	O
HCoV	O
-	O
NL63	O
in	O
30	O
(	O
16	O
.	O
5	O
%)	O
patients	O
,	O
and	O
influenza	B-DISO
A	O
virus	O
in	O
25	O
(	O
13	O
.	O
7	O
%)	O
patients	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
prospective	O
observational	O
comparative	O
study	O
.	O

Results	O
demonstrated	O
that	O
this	O
multiplex	O
semi	O
-	O
nested	O
RT	O
-	O
PCR	O
was	O
effective	O
in	O
the	O
detection	O
of	O
BCoV	O
and	O
rotavirus	O
,	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
simultaneous	O
detection	O
of	O
both	O
viruses	O
at	O
a	O
lower	O
cost	O
,	O
providing	O
an	O
important	O
tool	O
for	O
studies	O
on	O
the	O
etiology	O
of	O
diarrhea	B-DISO
in	O
cattle	O
.	O

TITLE	O
:	O
Intra	O
-	O
abdominal	O
vacuum	O
-	O
assisted	O
closure	O
(	O
VAC	O
)	O
after	O
necrosectomy	O
for	O
acute	B-DISO
necrotising	I-DISO
pancreatitis	I-DISO
:	O
preliminary	O
experience	O
.	O

Two	O
patients	O
admitted	O
to	O
ICU	O
for	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
a	O
diagnosis	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
developed	O
pancreatic	B-DISO
necrosis	I-DISO
and	O
were	O
treated	O
by	O
necrosectomy	O
,	O
lesser	O
sac	O
marsupialisation	O
and	O
posterior	O
lumbotomic	O
opening	O
.	O

TITLE	O
:	O
Identification	O
of	O
phenanthroindolizines	O
and	O
phenanthroquinolizidines	O
as	O
novel	O
potent	O
anti	O
-	O
coronaviral	O
agents	O
for	O
porcine	O
enteropathogenic	O
coronavirus	O
transmissible	O
gastroenteritis	B-DISO
virus	O
and	O
human	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Here	O
,	O
we	O
identified	O
tylophorine	O
compounds	O
,	O
including	O
naturally	O
occurring	O
and	O
synthetic	O
phenanthroindolizidines	O
and	O
phenanthroquinolizidines	O
,	O
as	O
potent	O
in	O
vitro	O
inhibitors	O
of	O
enteropathogenic	O
coronavirus	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
).	O

This	O
study	O
shows	O
that	O
the	O
protective	O
effects	O
of	O
ANP	O
against	O
LPS	B-DISO
-	O
induced	O
vascular	O
leak	O
are	O
mediated	O
at	O
least	O
in	O
part	O
by	O
PAK1	O
-	O
dependent	O
signaling	O
leading	O
to	O
EC	O
barrier	O
enhancement	O
.	O

The	O
reaction	O
is	O
performed	O
in	O
one	O
step	O
in	O
a	O
single	O
tube	O
at	O
65	O
°	O
C	O
for	O
45	O
min	O
,	O
with	O
hydroxynaphthol	O
blue	O
(	O
HNB	O
)	O
dye	O
added	O
prior	O
to	O
amplification	B-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
mononucleosis	I-DISO
usually	O
runs	O
a	O
mild	O
self	O
-	O
limiting	O
course	O
.	O

We	O
sought	O
to	O
review	O
the	O
usage	O
of	O
antivirals	O
for	O
severe	O
EBV	B-DISO
infection	I-DISO
in	O
apparently	O
immunocompetent	O
patients	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
receptors	O
are	O
differentially	O
expressed	O
in	O
the	O
central	O
nervous	B-DISO
system	O
and	O
play	O
virus	O
strain	O
-	O
dependent	O
roles	O
in	O
neuronal	O
spread	O
.	O

TITLE	O
:	O
Rhabdomyolysis	B-DISO
following	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

We	O
present	O
a	O
17	O
-	O
year	O
-	O
old	O
patient	O
who	O
developed	O
rhabdomyalysis	O
following	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
/	O
09	O
)	O
infection	B-DISO
.	O

Haematological	O
and	O
biochemical	O
abnormalities	O
in	O
FIP	B-DISO
cases	O
are	O
also	O
non	O
-	O
specific	O
.	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
has	O
been	O
used	O
to	O
detect	O
FCoV	O
and	O
is	O
rapid	O
and	O
sensitive	O
,	O
but	O
results	O
must	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
clinical	B-DISO
findings	I-DISO
.	O

This	O
paper	O
describes	O
and	O
compares	O
diagnostic	O
methods	O
for	O
FCoVs	O
and	O
includes	O
a	O
brief	O
account	O
of	O
the	O
virus	O
biology	O
,	O
epidemiology	O
,	O
and	O
pathogenesis	B-DISO
.	O

This	O
conference	O
report	O
highlights	O
selected	O
presentations	O
on	O
human	O
norovirus	O
(	O
HuNoV	O
),	O
SARS	B-DISO
coronavirus	O
and	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
virus	O
vaccine	O
technologies	O
;	O
programmed	O
cell	O
death	O
-	O
1	O
(	O
PD1	O
)	O
blockade	O
and	O
HyperAcute	O
alpha	O
-	O
Gal	O
platform	O
technology	O
methods	O
;	O
aerosol	O
vaccination	O
delivery	O
;	O
novel	O
technologies	O
to	O
produce	O
influenza	B-DISO
virus	O
-	O
like	O
particles	O
(	O
VLP	O
)	O
in	O
mammalian	O
cell	O
lines	O
;	O
and	O
investigational	O
human	O
rotavirus	O
vaccines	O
.	O

It	O
also	O
helped	O
reduce	O
the	O
amount	O
of	O
sclerosant	O
,	O
an	O
issue	O
that	O
is	O
associated	O
with	O
severe	O
complications	O
,	O
such	O
as	O
hemolysis	B-DISO
,	O
allergy	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
others	O
.	O

ABSTRACT	O
:	O
Clostridium	O
difficile	O
is	O
the	O
most	O
common	O
cause	O
of	O
nosocomial	O
infectious	B-DISO
diarrhea	I-DISO
in	O
adults	O
,	O
with	O
recent	O
reports	O
of	O
increased	O
severity	O
and	O
case	O
fatality	O
.	O

ABSTRACT	O
:	O
Certain	O
emerging	O
infections	B-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
,	O
represent	O
a	O
great	O
risk	O
to	O
healthcare	O
workers	O
(	O
HCWs	O
).	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
intratracheally	O
instilled	O
with	O
LPS	B-DISO
(	O
2	O
mg	O
/	O
kg	O
)	O
to	O
induce	O
ALI	O
.	O

These	O
results	O
confirm	O
that	O
the	O
IRES	O
-	O
driven	O
dhfr	O
promoter	O
generates	O
greater	O
gene	B-DISO
amplification	I-DISO
,	O
which	O
in	O
turn	O
enhances	O
S	O
(	O
TR2	O
)	O
expression	O
.	O

TITLE	O
:	O
Pandemic	O
influenza	B-DISO
control	O
in	O
Europe	O
and	O
the	O
constraints	O
resulting	O
from	O
incoherent	O
public	O
health	O
laws	O
.	O

ICU	O
onset	O
bacteraemic	O
MRSA	B-DISO
infection	I-DISO
was	O
significantly	O
reduced	O
from	O
1	O
.	O
94	O
(	O
phase	O
1	O
)	O
to	O
0	O
.	O
9	O
(	O
phase	O
2	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
0	O
.	O
28	O
(	O
phase	O
3	O
,	O
p	O
=	O
0	O
.	O
021	O
)	O
per	O
1000	O
-	O
patient	O
-	O
days	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
extent	O
of	O
elimination	O
of	O
trimethoprim	O
(	O
TMP	O
)	O
and	O
sulfamethoxazole	O
(	O
SMX	O
)	O
via	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
in	O
2	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
renal	B-DISO
failure	I-DISO
.	O

Both	O
patients	O
developed	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
necessitating	O
CVVHDF	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
the	O
major	O
causative	O
agent	O
of	O
fatal	O
diarrhea	B-DISO
in	O
piglets	O
.	O

ABSTRACT	O
:	O
As	O
a	O
consequence	O
of	O
the	O
novel	O
therapeutic	O
option	O
of	O
mechanical	O
ventilation	O
in	O
early	O
intensive	O
care	O
medicine	O
,	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
defined	O
as	O
a	O
disease	O
entity	O
of	O
its	O
own	O
representing	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

The	O
large	O
ARDS	B-DISO
Network	O
clinical	O
trial	O
on	O
the	O
magnitude	O
of	O
tidal	O
volume	O
impressively	O
demonstrated	O
the	O
feasibility	O
of	O
targeted	O
clinical	O
trials	O
in	O
patients	O
with	O
ARDS	B-DISO
that	O
provide	O
robust	O
evidence	O
in	O
this	O
field	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infections	I-DISO
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
worldwide	O
.	O

Influenza	B-DISO
A	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
4	O
and	O
SARS	B-DISO
-	O
coronavirus	O
were	O
not	O
detected	O
during	O
the	O
study	O
period	O
.	O

TITLE	O
:	O
The	O
membrane	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
acts	O
as	O
a	O
dominant	O
immunogen	O
revealed	O
by	O
a	O
clustering	O
region	O
of	O
novel	O
functionally	O
and	O
structurally	O
defined	O
cytotoxic	O
T	O
-	O
lymphocyte	O
epitopes	O
.	O

This	O
,	O
together	O
with	O
previous	O
reports	O
of	O
a	O
strong	O
humoral	O
response	O
against	O
the	O
M	O
protein	O
,	O
may	O
help	O
to	O
further	O
explain	O
the	O
immunogenicity	O
of	O
SARS	B-DISO
and	O
serves	O
as	O
potential	O
targets	O
for	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
design	O
.	O

We	O
checked	O
and	O
analyzed	O
the	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
(	O
Ab	O
)	O
for	O
five	O
consecutive	O
years	O
using	O
the	O
commercial	O
ELISA	O
test	O
kit	O
.	O

These	O
data	O
provide	O
a	O
useful	O
reference	O
for	O
diagnosis	O
and	O
control	O
of	O
SARS	B-DISO
infection	B-DISO
,	O
the	O
evaluation	O
of	O
immune	O
response	O
and	O
vaccine	O
efficacy	O
.	O

Phrenic	B-DISO
nerve	I-DISO
palsy	I-DISO
should	O
be	O
considered	O
in	O
patients	O
presenting	O
with	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
without	O
any	O
underlying	O
respiratory	O
or	O
cardiovascular	O
illness	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
undergoing	O
mechanical	O
ventilation	O
for	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
neuromuscular	O
blocking	B-DISO
agents	O
may	O
improve	O
oxygenation	O
and	O
decrease	O
ventilator	O
-	O
induced	O
lung	O
injury	O
but	O
may	O
also	O
cause	O
muscle	B-DISO
weakness	I-DISO
.	O

In	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
early	O
administration	O
of	O
a	O
neuromuscular	O
blocking	B-DISO
agent	O
improved	O
the	O
adjusted	O
90	O
-	O
day	O
survival	O
and	O
increased	O
the	O
time	O
off	O
the	O
ventilator	O
without	O
increasing	O
muscle	B-DISO
weakness	I-DISO
.	O

TITLE	O
:	O
Molecular	O
analysis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
in	O
Slovenia	O
between	O
1990	O
and	O
2005	O
:	O
a	O
retrospective	O
study	O
.	O

TITLE	O
:	O
Protective	O
immune	O
responses	O
induced	O
by	O
in	O
ovo	O
immunization	O
with	O
recombinant	O
adenoviruses	O
expressing	O
spike	O
(	O
S1	O
)	O
glycoprotein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
fused	O
/	O
co	O
-	O
administered	O
with	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
tremendous	O
economic	O
losses	O
associated	O
with	O
production	O
inefficiencies	O
and	O
mortality	O
in	O
poultry	O
industry	O
worldwide	O
.	O

There	O
is	O
limited	O
information	O
on	O
the	O
prevalence	O
of	O
precipitating	O
factors	O
of	O
heart	B-DISO
failure	I-DISO
decompensation	O
in	O
this	O
population	O
.	O

The	O
variables	O
independently	O
associated	O
with	O
hospital	O
mortality	O
were	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
severe	O
hypoalbuminemia	O
,	O
systolic	O
blood	O
pressure	O
<	O
110mmHg	O
,	O
white	O
blood	O
cell	O
count	O
>	O
10	O
.	O
000	O
per	O
mm³	O
and	O
valvular	B-DISO
heart	I-DISO
disease	I-DISO
.	O

In	O
the	O
case	O
of	O
the	O
Coronaviridae	O
this	O
family	O
is	O
now	O
recognized	O
as	O
including	O
potent	O
human	O
pathogens	O
causing	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
as	O
well	O
as	O
nosocomial	O
ones	O
.	O

TITLE	O
:	O
Proteasome	O
inhibition	O
in	O
vivo	O
promotes	O
survival	O
in	O
a	O
lethal	O
murine	O
model	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Here	O
we	O
report	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
E	O
small	O
envelope	O
protein	O
(	O
E	O
)	O
binds	O
to	O
human	O
PALS1	O
.	O

ABSTRACT	O
:	O
Severe	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
VAP	O
)	O
caused	O
by	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
developed	O
in	O
a	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

During	O
vancomycin	O
(	O
VCM	O
)	O
therapy	O
for	O
MRSA	B-DISO
VAP	O
,	O
MRSA	B-DISO
bacteremia	B-DISO
occurred	O
even	O
though	O
the	O
trough	O
value	O
of	O
VCM	O
was	O
sufficiently	O
high	O
.	O

Our	O
experiments	O
show	O
that	O
the	O
GPU	O
-	O
accelerated	O
Amber	O
scoring	O
achieves	O
a	O
6	O
.	O
5	O
×	O
speedup	O
with	O
respect	O
to	O
the	O
original	O
version	O
running	O
on	O
AMD	B-DISO
dual	O
-	O
core	O
CPU	O
for	O
the	O
same	O
problem	O
size	O
.	O

Enteric	B-DISO
fever	I-DISO
was	O
associated	O
with	O
loose	B-DISO
stools	I-DISO
,	O
normal	O
to	O
low	O
leukocyte	O
counts	O
and	O
normal	O
platelet	O
counts	O
.	O

ABSTRACT	O
:	O
The	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
is	O
central	O
to	O
the	O
international	O
community	O
'	O
s	O
efforts	O
to	O
control	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
T	O
cell	O
inhibitory	O
ligand	O
B7	O
-	O
H1	O
hinders	O
T	O
cell	O
-	O
mediated	O
virus	O
control	O
,	O
but	O
also	O
ameliorates	O
clinical	O
disease	O
during	O
autoimmune	B-DISO
and	O
virus	O
-	O
induced	O
CNS	B-DISO
disease	I-DISO
.	O

We	O
analyzed	O
,	O
in	O
ALI	O
/	O
ARDS	B-DISO
patients	O
,	O
plasma	O
and	O
alveolar	O
levels	O
of	O
sRAGE	O
over	O
time	O
and	O
the	O
association	O
with	O
severity	O
of	O
lung	O
injury	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
lung	B-DISO
infection	I-DISO
yielded	O
higher	O
alveolar	O
sRAGE	O
levels	O
.	O

TITLE	O
:	O
Avian	B-DISO
influenza	I-DISO
:	O
update	O
.	O

Avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
)	O
infections	B-DISO
may	O
be	O
asymptomatic	O
or	O
present	O
as	O
mild	O
conjunctivitis	B-DISO
in	O
humans	O
;	O
however	O
,	O
H5N1	B-DISO
infections	B-DISO
may	O
present	O
as	O
severe	O
pneumonia	B-DISO
progressing	O
to	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
syndrome	B-DISO
,	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
and	O
death	O
.	O

18	O
influenza	B-DISO
(	O
influenza	B-DISO
A	O
=	O
13	O
and	O
influenza	B-DISO
B	O
=	O
5	O
)	O
and	O
17	O
parainfluenza	B-DISO
admissions	O
were	O
identified	O
over	O
the	O
7	O
-	O
year	O
period	O
.	O

Admissions	O
associated	O
with	O
proven	O
influenza	B-DISO
and	O
parainfluenza	B-DISO
infections	B-DISO
accounted	O
for	O
2	O
%	O
of	O
PICU	O
annual	O
admissions	O
.	O

Bacterial	O
co	B-DISO
-	I-DISO
infections	I-DISO
were	O
identified	O
in	O
25	O
%	O
of	O
these	O
patients	O
.	O

The	O
results	O
of	O
our	O
study	O
clarify	O
how	O
each	O
virus	O
modulates	O
the	O
host	O
innate	O
and	O
adaptive	O
immune	O
responses	O
,	O
leading	O
to	O
inflammatory	O
reactions	O
and	O
lung	O
pathology	B-DISO
.	O

Adjuvant	O
Systems	O
AS01	O
(	O
B	O
)	O
and	O
AS03	O
(	O
A	O
)	O
were	O
selected	O
and	O
tested	O
for	O
their	O
capacity	O
to	O
elicit	O
high	O
humoral	O
and	O
cellular	O
immune	O
responses	O
to	O
WI	O
-	O
SARS	B-DISO
vaccine	O
.	O

TITLE	O
:	O
Household	O
transmission	O
of	O
the	O
2009	O
pandemic	O
A	O
/	O
H1N1	B-DISO
influenza	I-DISO
virus	O
:	O
elevated	O
laboratory	O
‐	O
confirmed	O
secondary	O
attack	O
rates	O
and	O
evidence	O
of	O
asymptomatic	B-DISO
infections	I-DISO
.	O

We	O
identified	O
53	O
laboratory	O
-	O
confirmed	O
secondary	O
case	O
patients	O
with	O
pH1N1	O
virus	B-DISO
infection	I-DISO
,	O
for	O
an	O
SAR	O
of	O
45	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
35	O
.	O
6	O
%-	O
53	O
.	O
5	O
%).	O

Young	O
children	O
(<	O
7	O
years	O
of	O
age	O
)	O
were	O
at	O
highest	O
risk	O
of	O
developing	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

Further	O
,	O
this	O
study	O
showed	O
that	O
hypertonic	O
saline	O
resuscitation	O
and	O
suppression	B-DISO
of	O
iNOS	O
might	O
improve	O
immunosuppressive	O
reaction	O
after	O
hemorrhagic	B-DISO
shock	I-DISO
.	O

TITLE	O
:	O
Anti	O
-	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
activity	O
of	O
1	O
,	O
8	O
-	O
cineole	O
:	O
effect	O
on	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

This	O
review	O
aims	O
to	O
summarize	O
current	O
respiratory	O
health	O
issues	O
in	O
the	O
region	O
including	O
smoking	O
-	O
related	O
diseases	O
especially	O
COPD	B-DISO
,	O
lung	B-DISO
cancer	I-DISO
and	O
infectious	B-DISO
problems	O
such	O
as	O
pandemic	O
influenza	B-DISO
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
bacterial	B-DISO
pneumonia	I-DISO
and	O
tuberculosis	B-DISO
,	O
as	O
well	O
as	O
the	O
contribution	O
of	O
air	O
pollution	O
to	O
respiratory	B-DISO
disease	I-DISO
.	O

Published	O
data	O
on	O
trends	O
in	O
the	O
epidemiology	O
and	O
management	O
of	O
respiratory	B-DISO
diseases	I-DISO
and	O
are	O
summarized	O
;	O
finally	O
,	O
the	O
limitations	O
of	O
available	O
data	O
and	O
projections	O
for	O
the	O
future	O
of	O
respiratory	O
health	O
in	O
the	O
region	O
are	O
discussed	O
.	O

Bilateral	O
interstitial	O
opacities	B-DISO
were	O
observed	O
in	O
chest	O
radiography	O
in	O
20	O
cases	O
;	O
5	O
had	O
unilateral	O
lobar	O
consolidation	O
.	O

Mechanical	O
ventilation	O
was	O
required	O
in	O
23	O
patients	O
and	O
18	O
developed	O
ARDS	B-DISO
.	O

Six	O
patients	O
died	O
(	O
19	O
%);	O
they	O
were	O
all	O
over	O
75	O
years	O
old	O
,	O
had	O
cancer	B-DISO
or	O
immune	O
-	O
suppression	B-DISO
.	O

TITLE	O
:	O
U	O
.	O
S	O
.	O
attitudes	O
and	O
perceived	O
practice	O
for	O
noninvasive	O
ventilation	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Respondents	O
included	O
U	O
.	O
S	O
.	O
physicians	O
practicing	O
pediatric	O
critical	O
care	O
(	O
90	O
%),	O
pediatric	O
anesthesia	B-DISO
critical	O
care	O
(	O
4	O
%),	O
pediatric	O
pulmonary	O
critical	O
care	O
(	O
4	O
%),	O
and	O
other	O
disciplines	O
(	O
2	O
%).	O

Droplet	O
counts	O
in	O
mean	O
diameter	O
size	O
ranges	O
from	O
0	O
.	O
3	O
to	O
>	O
10	O
µm	O
were	O
measured	O
with	O
an	O
counter	O
placed	O
adjacent	O
to	O
the	O
face	B-DISO
and	O
at	O
a	O
1	O
-	O
m	O
distance	O
from	O
the	O
subject	O
/	O
patient	O
,	O
at	O
the	O
height	O
of	O
the	O
nose	O
/	O
mouth	O
of	O
an	O
average	O
health	O
-	O
care	O
worker	O
.	O

These	O
results	O
may	O
have	O
infection	B-DISO
control	O
implications	O
for	O
other	O
airborne	O
infections	B-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
tuberculosis	B-DISO
,	O
as	O
well	O
as	O
for	O
pandemic	O
influenza	B-DISO
infection	B-DISO
.	O

Empirical	O
evidence	O
is	O
drawn	O
from	O
a	O
number	O
of	O
cases	O
,	O
including	O
Chernobyl	O
;	O
Goiania	O
,	O
Brazil	O
;	O
the	O
sarin	O
gas	O
attack	O
in	O
Tokyo	O
;	O
the	O
anthrax	B-DISO
attacks	O
in	O
the	O
USA	O
;	O
Three	O
Mile	O
Island	O
;	O
and	O
by	O
features	O
of	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
pandemic	O
.	O

Reconstruction	O
of	O
one	O
variant	O
M	O
gene	O
in	O
a	O
ΔE	O
background	O
showed	O
that	O
expression	O
of	O
the	O
M	O
*	O
protein	O
markedly	O
enhanced	O
the	O
growth	O
of	O
the	O
ΔE	O
mutant	B-DISO
and	O
that	O
the	O
M	O
*	O
protein	O
was	O
incorporated	O
into	O
assembled	O
virions	O
.	O

In	O
Vero	O
cells	O
expressing	O
TMPRSS2	O
,	O
large	O
syncytia	O
were	O
induced	O
by	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Effective	O
prediction	O
of	O
future	O
viral	O
zoonoses	B-DISO
requires	O
an	O
in	O
-	O
depth	O
understanding	O
of	O
the	O
heterologous	O
viral	O
population	O
in	O
key	O
animal	O
species	O
that	O
will	O
likely	O
serve	O
as	O
reservoir	O
hosts	O
or	O
intermediates	O
during	O
the	O
next	O
viral	O
epidemic	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
respiratory	O
status	O
and	O
the	O
prognosis	O
of	O
patients	O
,	O
including	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
ECMO	O
)	O
to	O
maintain	O
respiratory	O
status	O
.	O

ECMO	O
could	O
be	O
removed	O
from	O
six	O
patients	O
(	O
55	O
%,	O
group	O
A	O
),	O
but	O
in	O
five	O
(	O
45	O
%,	O
group	B-DISO
B	I-DISO
)	O
could	O
not	O
.	O

We	O
report	O
three	O
cases	O
of	O
ARDS	B-DISO
,	O
which	O
occurred	O
as	O
a	O
complication	B-DISO
of	O
vivax	B-DISO
malaria	I-DISO
,	O
from	O
the	O
city	O
of	O
Kolkata	O
.	O

All	O
cases	O
typically	O
had	O
dramatic	O
onset	O
of	O
ARDS	B-DISO
,	O
and	O
required	O
immediate	O
(	O
within	O
hour	O
of	O
onset	O
of	O
dyspnea	B-DISO
)	O
institution	O
of	O
mechanical	O
ventilation	O
with	O
high	O
positive	O
end	O
expiratory	O
pressure	O
.	O

Secondary	O
causes	O
of	O
hypokalaemic	O
paralysis	O
were	O
present	O
in	O
13	O
patients	O
and	O
included	O
thyrotoxic	O
paralysis	O
in	O
five	O
and	O
renal	B-DISO
tubular	I-DISO
acidosis	I-DISO
(	O
RTA	B-DISO
)	O
and	O
Gitelman	B-DISO
syndrome	I-DISO
in	O
four	O
each	O
.	O

ARDS	B-DISO
is	O
caused	O
by	O
protein	O
-	O
rich	O
pulmonary	B-DISO
edema	I-DISO
that	O
causes	O
severe	O
hypoxemia	O
and	O
impaired	B-DISO
carbon	O
dioxide	O
excretion	O
.	O

However	O
,	O
there	O
is	O
no	O
effective	O
pharmacologic	O
therapy	O
,	O
although	O
cell	O
-	O
based	O
therapy	O
and	O
other	O
therapies	O
currently	O
being	O
tested	O
in	O
clinical	O
trials	O
may	O
provide	O
novel	O
treatments	O
for	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Extracorporeal	O
lung	O
assist	O
in	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
ARDS	B-DISO
.	O

Many	O
strategies	O
and	O
treatments	O
for	O
this	O
syndrome	B-DISO
have	O
been	O
investigated	O
over	O
the	O
last	O
few	O
year	O
.	O

Severe	O
respiratory	B-DISO
insufficiency	I-DISO
developed	O
and	O
she	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

By	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
we	O
measured	O
anti	O
-	O
HCoV	O
IgG	O
antibodies	O
in	O
serum	O
and	O
IgA	O
antibodies	O
in	O
nasal	O
wash	O
specimens	O
collected	O
at	O
seven	O
U	O
.	O
S	O
.	O
sites	O
from	O
105	O
adults	O
aged	O
50	O
years	O
and	O
older	O
(	O
mean	O
age	O
,	O
67	O
±	O
9	O
years	O
)	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
.	O

Patients	O
likely	O
had	O
experienced	O
infections	B-DISO
with	O
more	O
than	O
one	O
HCoV	O
strain	O
,	O
and	O
IgG	O
antibodies	O
to	O
these	O
HCoV	O
strains	O
in	O
serum	O
were	O
more	O
likely	O
to	O
be	O
detected	O
than	O
IgA	O
antibodies	O
to	O
these	O
HCoV	O
strains	O
in	O
nasal	O
wash	O
specimens	O
.	O

We	O
have	O
previously	O
identified	O
the	O
putative	O
causal	O
mutation	O
of	O
MHV	O
-	O
Wüts18	O
as	O
a	O
C	O
to	O
U	O
transition	B-DISO
at	O
codon	O
2446	O
in	O
ORF1b	O
,	O
which	O
results	O
in	O
a	O
substitution	O
of	O
proline	O
12	O
with	O
serine	O
in	O
non	O
-	O
structural	O
protein	O
16	O
.	O

The	O
rapid	O
induction	O
of	O
autoantibodies	O
in	O
ARDS	B-DISO
and	O
severe	B-DISO
sepsis	I-DISO
suggests	O
that	O
ongoing	O
systemic	O
inflammation	B-DISO
and	O
associated	O
tissue	O
destruction	O
mediate	O
the	O
break	O
in	O
tolerance	B-DISO
against	O
these	O
self	O
proteins	O
.	O

RESULTS	O
:	O
From	O
screening	O
patient	O
plasma	O
,	O
57	O
%	O
of	O
ARDS	B-DISO
and	O
46	O
%	O
of	O
septic	O
patients	O
without	O
ARDS	B-DISO
demonstrated	O
at	O
least	O
one	O
statistically	O
significant	O
elevated	O
autoantibody	O
compared	O
to	O
the	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
rapid	O
induction	O
of	O
autoantibodies	O
in	O
ARDS	B-DISO
and	O
severe	B-DISO
sepsis	I-DISO
suggests	O
that	O
ongoing	O
systemic	O
inflammation	B-DISO
and	O
associated	O
tissue	O
destruction	O
mediate	O
the	O
break	O
in	O
tolerance	B-DISO
against	O
these	O
self	O
proteins	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
pyrazolone	O
compounds	O
as	O
possible	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
inhibitors	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
by	O
in	O
vitro	O
protease	O
assay	O
using	O
fluorogenic	O
substrate	O
peptide	O
in	O
which	O
several	O
showed	O
potent	O
inhibition	O
against	O
the	O
3CL	O
protease	O
.	O

ABSTRACT	O
:	O
Smallpox	B-DISO
is	O
an	O
acute	B-DISO
disease	I-DISO
caused	O
by	O
infection	B-DISO
with	O
variola	B-DISO
virus	O
that	O
has	O
had	O
historic	O
effects	O
on	O
the	O
human	O
population	O
due	O
to	O
its	O
virulence	O
and	O
infectivity	O
.	O

The	O
membrane	O
(	O
M	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
highly	O
abundant	O
during	O
viral	B-DISO
infections	I-DISO
and	O
is	O
a	O
critical	O
element	O
for	O
viral	O
assembly	O
.	O

This	O
study	O
was	O
designed	O
to	O
explore	O
the	O
opportunity	O
of	O
RNA	O
interference	O
technique	O
in	O
inhibiting	O
TNFR1	O
expression	O
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
variety	O
of	O
diseases	O
including	O
fulminant	O
viral	B-DISO
hepatitis	I-DISO
and	O
severe	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
.	O

Although	O
analysis	O
of	O
the	O
cases	O
of	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
gives	O
credence	O
to	O
criticisms	O
of	O
this	O
approach	O
,	O
securitization	O
theory	O
proves	O
useful	O
in	O
outlining	O
the	O
different	O
stages	O
in	O
China	O
'	O
s	O
reaction	O
to	O
epidemics	O
involving	O
reactive	O
mobilization	O
and	O
subsequent	O
efforts	O
to	O
return	O
to	O
politics	O
as	O
usual	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
radiographic	O
findings	O
of	O
pediatric	O
patients	O
with	O
severe	O
Influenza	B-DISO
-	O
A	O
(	O
H1N1	O
)	O
disease	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
first	O
documented	O
case	O
of	O
morbillivirus	B-DISO
infection	I-DISO
in	O
a	O
wild	O
,	O
free	O
-	O
ranging	O
Siberian	O
tiger	O
(	O
Panthera	O
tigris	O
altaica	O
).	O

Histologic	O
lesions	O
included	O
vacuolated	O
to	O
malacic	O
white	O
matter	O
in	O
the	O
brain	O
stem	O
,	O
cerebellum	O
,	O
and	O
thalamus	O
,	O
with	O
associated	O
lymphocytic	B-DISO
meningoencephalitis	I-DISO
.	O

ABSTRACT	O
:	O
46year	O
old	O
female	O
presented	O
with	O
a	O
one	O
week	O
history	O
of	O
high	O
grade	O
fever	O
,	O
chills	B-DISO
,	O
cough	B-DISO
,	O
and	O
severe	O
nausea	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
could	O
inhibit	O
IFN	O
-	O
beta	O
(	O
IFN	O
-	O
β	O
)	O
induced	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
Sendai	O
virus	O
.	O

These	O
results	O
indicate	O
that	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
targets	O
the	O
initial	O
step	O
,	O
probably	O
the	O
cellular	O
PRRs	B-DISO
(	O
pattern	O
recognition	O
receptors	O
)-	O
RNAs	O
-	O
recognition	O
step	O
in	O
the	O
innate	O
immune	O
pathways	O
,	O
to	O
suppress	O
IFN	O
expression	O
responses	O
.	O

However	O
,	O
IFN	O
is	O
produced	O
in	O
infected	O
macrophages	O
,	O
microglia	O
,	O
and	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	B-DISO
).	O

(	O
i	O
)	O
Most	O
were	O
similarly	O
regulated	O
in	O
response	O
to	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
.	O

All	O
16	O
patients	O
had	O
radiologically	O
confirmed	O
pneumonia	B-DISO
with	O
bilateral	O
patchy	O
alveolar	O
opacities	B-DISO
,	O
affecting	O
3	O
or	O
4	O
lung	O
quadrants	O
.	O

Findings	O
on	O
chest	O
radiographs	O
were	O
consistent	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
all	O
patients	O
requiring	O
mechanical	O
ventilation	O
.	O

Respiratory	B-DISO
distress	I-DISO
requiring	O
intubation	O
and	O
mechanical	O
ventilation	O
developed	O
in	O
9	O
pregnant	O
patients	O
within	O
the	O
first	O
24	O
hours	O
after	O
admission	O
,	O
and	O
2	O
of	O
them	O
in	O
the	O
third	O
trimester	O
died	O
,	O
while	O
7	O
patients	O
for	O
whom	O
pregnancy	O
was	O
timely	O
terminated	O
recovered	O
.	O

Respiratory	B-DISO
distress	I-DISO
requiring	O
intubation	O
and	O
mechanical	O
ventilation	O
developed	O
in	O
9	O
pregnant	O
patients	O
within	O
the	O
first	O
24	O
hours	O
after	O
admission	O
,	O
and	O
2	O
of	O
them	O
in	O
the	O
third	O
trimester	O
died	O
,	O
while	O
7	O
patients	O
for	O
whom	O
pregnancy	O
was	O
timely	O
terminated	O
recovered	O
.	O

TITLE	O
:	O
[	O
The	O
changes	O
of	O
chest	O
imaging	O
and	O
clinical	O
features	O
in	O
patients	O
with	O
severe	O
infection	B-DISO
of	O
new	O
influenza	B-DISO
A	O
(	O
H1N1	O
)].	O

The	O
pulmonary	O
imaging	O
changes	O
were	O
varied	O
,	O
including	O
ground	O
-	O
glass	O
opacity	B-DISO
,	O
consolidation	O
,	O
atelectasis	B-DISO
,	O
fluid	O
pneumothorax	B-DISO
and	O
pleural	B-DISO
effusion	I-DISO
,	O
and	O
manifestations	O
of	O
acute	B-DISO
pneumonia	I-DISO
and	O
interstitial	B-DISO
pneumonia	I-DISO
simultaneously	O
.	O

Extensive	O
pulmonary	B-DISO
infiltration	I-DISO
developed	O
quickly	O
,	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
occurred	O
in	O
5	O
patients	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
3	O
cases	O
.	O

Aged	O
animals	O
receiving	O
VRP	O
(	O
3000	O
)-	O
based	O
vaccines	O
were	O
protected	O
from	O
SARS	B-DISO
-	O
CoV	O
disease	O
,	O
while	O
animals	O
receiving	O
the	O
VRP	O
(	O
3014	O
)-	O
based	O
vaccines	O
were	O
not	O
.	O

The	O
severity	O
of	O
the	O
respiratory	B-DISO
failure	I-DISO
contrasted	O
with	O
the	O
absence	O
of	O
significant	O
liver	O
or	O
renal	O
dysfunction	O
.	O

Bedside	O
open	O
lung	O
biopsy	O
was	O
only	O
consistent	O
with	O
a	O
postinfectious	O
BOOP	B-DISO
.	O

Finally	O
,	O
we	O
used	O
the	O
density	O
-	O
optimized	O
nanotube	O
biosensors	O
to	O
detect	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
the	O
SARS	B-DISO
virus	O
and	O
demonstrated	O
improved	O
detection	O
limits	O
under	O
physiological	O
conditions	O
.	O

(	O
5	O
)	O
Four	O
patients	O
died	O
,	O
the	O
mortality	O
was	O
therefore	O
3	O
.	O
2	O
%	O
with	O
the	O
main	O
cause	O
of	O
septicemia	B-DISO
complicating	O
of	O
MOSF	O
,	O
but	O
their	O
prognosis	O
was	O
improved	O
while	O
comprehensive	O
treatment	O
measures	O
including	O
early	O
mechanical	O
ventilation	O
and	O
broad	O
spectrum	O
antibiotics	O
were	O
taken	O
into	O
account	O
.	O

TITLE	O
:	O
Early	O
gene	O
expression	O
events	O
in	O
ferrets	O
in	O
response	O
to	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
versus	O
direct	O
interferon	O
-	O
alpha2b	O
stimulation	O
.	O

Among	O
46	O
documented	O
EV	O
-	O
71	O
infections	B-DISO
,	O
39	O
were	O
self	O
-	O
limited	O
.	O

A	O
time	O
-	O
course	O
study	O
revealed	O
that	O
8b	O
was	O
expressed	O
at	O
late	O
-	O
stages	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ISG20	O
inhibited	O
infections	B-DISO
by	O
cell	O
culture	O
-	O
derived	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
and	O
a	O
pestivirus	O
,	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
and	O
a	O
picornavirus	O
,	O
hepatitis	B-DISO
A	I-DISO
virus	O
.	O

Therefore	O
,	O
antiviral	O
effects	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
exerted	O
by	O
EPs	O
®	O
7630	O
in	O
acute	B-DISO
bronchitis	I-DISO
patients	O
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
children	O
hospitalized	O
with	O
malaria	B-DISO
--	O
a	O
study	O
from	O
Bikaner	O
,	O
northwest	O
India	O
.	O

Despite	O
the	O
equivocal	O
evidence	O
for	O
the	O
efficacy	O
of	O
surgical	O
and	O
N95	O
masks	O
and	O
the	O
provision	O
of	O
algorithms	O
appropriate	O
for	O
the	O
level	O
of	O
risk	O
according	O
to	O
clinical	O
care	O
during	O
a	O
pandemic	O
,	O
clinicians	O
still	O
demanded	O
N95	O
masks	O
plus	O
face	B-DISO
shields	O
in	O
combination	O
with	O
prophylaxis	O
and	O
novel	O
vaccination	O
.	O

Since	O
immunohistochemistry	O
(	O
IHC	O
)	O
includes	O
most	O
of	O
these	O
features	O
,	O
its	O
sensitivity	O
,	O
specificity	O
,	O
predictive	O
positive	O
value	O
(	O
PPV	O
)	O
and	O
predictive	O
negative	O
value	O
(	O
PNV	O
)	O
for	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNv	B-DISO
)	O
screening	O
were	O
compared	O
to	O
those	O
of	O
the	O
gold	O
standard	O
,	O
RT	O
-	O
PCR	O
testing	O
of	O
kidney	O
tissue	O
in	O
dead	O
birds	O
.	O

Hence	O
,	O
activation	O
and	O
recruitment	B-DISO
of	O
neutrophils	O
are	O
regarded	O
to	O
play	O
a	O
key	O
role	O
in	O
progression	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
not	O
only	O
mediates	O
receptor	O
-	O
binding	O
but	O
also	O
induces	O
neutralizing	O
antibodies	O
.	O

CONCLUSIONS	O
:	O
The	O
RBD	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
highly	O
immunogenic	O
in	O
humans	O
and	O
mediates	O
protective	O
responses	O
and	O
RBD	O
-	O
based	O
vaccines	O
and	O
diagnostic	O
approaches	O
can	O
be	O
further	O
developed	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
are	O
group	O
III	O
coronaviruses	O
that	O
infect	O
poultry	O
worldwide	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
commercial	O
ResPlex	O
II	O
v2	O
.	O
0	O
,	O
MultiCode	O
-	O
PLx	O
,	O
and	O
xTAG	O
respiratory	O
viral	O
panels	O
for	O
the	O
diagnosis	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
adults	O
.	O

ResPlex	O
II	O
Panel	O
v2	O
.	O
0	O
(	O
Qiagen	O
),	O
MultiCode	O
-	O
PLx	O
(	O
EraGen	O
Biosciences	O
),	O
and	O
xTAG	O
(	O
Luminex	O
)	O
PRV	B-DISO
'	O
s	O
were	O
studied	O
.	O

Fungi	O
were	O
found	O
in	O
2	O
of	O
20	O
sputum	O
cultures	O
in	O
2	O
patients	O
and	O
these	O
2	O
patients	O
had	O
been	O
considered	O
as	O
having	O
fungal	B-DISO
pneumonias	I-DISO
.	O

The	O
pneumonia	B-DISO
may	O
be	O
misdiagnosed	O
as	O
fungal	B-DISO
infection	I-DISO
.	O

METHODS	O
:	O
The	O
clinical	O
manifestations	O
,	O
radiologic	O
features	O
,	O
reasons	O
of	O
misdiagnosis	O
,	O
experiences	O
in	O
treatment	O
and	O
prognosis	O
of	O
4	O
children	O
with	O
lymphoma	B-DISO
complicated	O
with	O
pneumonia	B-DISO
due	O
to	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
during	O
chemotherapy	O
were	O
analyzed	O
retrospectively	O
.	O

A	O
positive	O
correlation	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
IL	O
-	O
15	O
levels	O
with	O
C	O
-	O
reactive	O
protein	O
and	O
with	O
>	O
5	O
-	O
day	O
interval	O
between	O
symptom	B-DISO
onset	O
and	O
admission	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	O
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
were	O
found	O
in	O
nvA	O
(	O
H1N1	O
)	O
groups	O
.	O

When	O
comparing	O
viral	O
ARDS	B-DISO
with	O
bacterial	O
ARDS	B-DISO
,	O
the	O
level	O
of	O
IL	O
-	O
8	O
,	O
IL	O
-	O
17	O
and	O
TNFα	O
was	O
significantly	O
higher	O
in	O
bacterial	O
ARDS	B-DISO
and	O
IL	O
-	O
12	O
was	O
increased	O
only	O
in	O
viral	O
ARDS	B-DISO
.	O

Perceived	O
sufficiency	O
of	O
information	O
about	O
several	O
aspects	O
of	O
the	O
A	O
/	O
H1N1	B-DISO
influenza	I-DISO
was	O
moderately	O
high	O
,	O
and	O
the	O
overall	O
information	O
about	O
the	O
A	O
/	O
H1N1	B-DISO
influenza	I-DISO
was	O
considered	O
clear	O
(	O
median	O
7	O
.	O
4	O
/	O
9	O
).	O

This	O
possibility	O
has	O
focused	O
continuous	O
action	O
on	O
SARS	B-DISO
vaccine	O
research	O
.	O

TITLE	O
:	O
Role	O
of	O
two	O
-	O
way	O
airflow	O
owing	O
to	O
temperature	O
difference	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
transmission	O
:	O
revisiting	O
the	O
largest	O
nosocomial	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Hong	O
Kong	O
.	O

The	O
primary	O
receptor	O
for	O
the	O
human	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
(	O
SARS	B-DISO
)	O
CoV	O
is	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

The	O
present	O
article	O
reviews	O
recent	O
advances	O
that	O
have	O
elucidated	O
biological	O
and	O
biochemical	O
activities	O
of	O
EPO	O
that	O
may	O
be	O
potentially	O
applicable	O
for	O
ALI	O
/	O
ARDS	B-DISO
management	O
.	O

LPS	B-DISO
instillation	O
induced	O
ALI	O
in	O
both	O
PTX3	O
-	O
KO	O
and	O
WT	O
mice	O
.	O

The	O
severe	O
lung	O
injury	O
was	O
accompanied	O
by	O
elevated	O
neutrophil	O
infiltration	B-DISO
,	O
cell	O
death	O
,	O
and	O
fibrin	B-DISO
deposition	I-DISO
in	O
the	O
lung	O
.	O

PTX3	O
deficiency	O
also	O
enhanced	O
LPS	B-DISO
-	O
induced	O
tissue	O
factor	O
expression	O
/	O
activation	O
in	O
the	O
lung	O
and	O
increased	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
the	O
plasma	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
endogenously	O
expressed	O
PTX3	O
plays	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
and	O
that	O
a	O
lack	O
of	O
PTX3	O
may	O
enhance	O
neutrophil	O
recruitment	B-DISO
,	O
cell	O
death	O
,	O
activation	O
of	O
coagulation	O
cascades	O
,	O
and	O
inflammatory	B-DISO
responses	I-DISO
in	O
the	O
lung	O
.	O

TITLE	O
:	O
Nucleic	O
acid	O
amplification	B-DISO
-	O
based	O
diagnosis	O
of	O
respiratory	O
virus	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Recovery	O
from	O
ambulatory	O
surgical	O
procedures	O
can	O
be	O
limited	O
by	O
postoperative	B-DISO
pain	I-DISO
.	O

ABSTRACT	O
:	O
Increasing	O
the	O
intracellular	O
Zn	O
(	O
2	O
+)	O
concentration	O
with	O
zinc	O
-	O
ionophores	O
like	O
pyrithione	O
(	O
PT	O
)	O
can	O
efficiently	O
impair	O
the	O
replication	O
of	O
a	O
variety	O
of	O
RNA	O
viruses	O
,	O
including	O
poliovirus	O
and	O
influenza	B-DISO
virus	O
.	O

We	O
hypothesized	O
that	O
SA	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
perioperative	O
pulmonary	B-DISO
complications	I-DISO
,	O
thus	O
providing	O
a	O
basis	O
for	O
an	O
increase	O
in	O
the	O
utilization	O
of	O
resources	O
,	O
including	O
intensive	O
monitoring	O
and	O
development	O
of	O
strategies	O
to	O
prevent	O
and	O
treat	O
these	O
events	O
.	O

Usually	O
,	O
immediate	O
diagnosis	O
of	O
such	O
a	O
condition	B-DISO
with	O
MRI	O
is	O
not	O
possible	O
in	O
hospitals	O
in	O
the	O
Coastal	O
border	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
peptidase	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
strictly	O
required	O
for	O
viral	O
replication	O
,	O
thus	O
being	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
agents	O
.	O

In	O
this	O
study	O
,	O
the	O
increase	O
of	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
peptidase	O
activity	O
in	O
presence	O
of	O
kosmotropic	O
salts	O
and	O
crowding	B-DISO
agents	O
is	O
described	O
.	O

The	O
viral	O
peptidase	O
activation	O
described	O
here	O
could	O
be	O
related	O
to	O
the	O
crowded	O
intracellular	O
environment	O
and	O
indicates	O
a	O
further	O
fine	O
-	O
tuning	O
mechanism	O
for	O
biological	O
control	O
,	O
particularly	O
in	O
the	O
microenvironment	O
of	O
the	O
vesicles	B-DISO
that	O
are	O
induced	O
in	O
host	O
cells	O
during	O
positive	O
strand	O
RNA	B-DISO
virus	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
polyclonal	O
antibody	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
spike	O
protein	O
.	O

Polyclonal	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
S1	O
protein	O
was	O
generated	O
in	O
a	O
rabbit	O
immunized	O
with	O
the	O
purified	O
S1	O
protein	O
.	O

In	O
addition	O
,	O
low	O
doses	O
of	O
mDEF201	O
protected	O
lungs	O
in	O
a	O
dose	O
dependent	O
manner	O
as	O
measured	O
by	O
a	O
reduction	O
in	O
gross	O
pathology	B-DISO
.	O

She	O
was	O
admitted	O
to	O
our	O
hospital	O
for	O
respiratory	B-DISO
failure	I-DISO
with	O
fever	O
and	O
her	O
clinical	O
course	O
deteriorated	O
,	O
progressing	O
to	O
hemiconvulsion	O
hemiplegia	B-DISO
epilepsy	B-DISO
syndrome	B-DISO
.	O

When	O
status	O
epileptics	B-DISO
or	O
prolonged	O
coma	B-DISO
manifests	O
even	O
in	O
patients	O
with	O
severe	O
brain	B-DISO
disorders	I-DISO
,	O
we	O
must	O
consider	O
encephalopathy	B-DISO
in	O
the	O
differential	O
diagnosis	O
.	O

ALI	O
and	O
its	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
are	O
responsible	O
for	O
significant	O
morbidity	O
and	O
mortality	O
in	O
intensive	O
care	O
units	O
,	O
despite	O
improvement	O
in	O
ventilation	O
strategies	O
.	O

In	O
addition	O
,	O
the	O
meta	O
-	O
analyses	O
on	O
the	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
sepsis	B-DISO
combine	O
trials	O
with	O
discordant	O
results	O
.	O

Although	O
the	O
evidence	O
for	O
the	O
efficacy	O
of	O
activated	O
protein	O
C	O
is	O
not	O
conclusive	O
,	O
it	O
should	O
be	O
considered	O
in	O
patients	O
that	O
are	O
at	O
a	O
high	O
risk	O
for	O
death	O
without	O
any	O
contraindications	O
related	O
to	O
bleeding	B-DISO
risk	O
.	O

During	O
initial	O
examinations	O
of	O
patients	O
,	O
physicians	O
must	O
rule	O
out	O
other	O
neurologic	B-DISO
disorders	I-DISO
or	O
conditions	O
that	O
resemble	O
Fisher	B-DISO
syndrome	I-DISO
,	O
such	O
as	O
vitamin	B-DISO
B1	I-DISO
deficiency	I-DISO
(	O
Wernicke	B-DISO
'	I-DISO
s	I-DISO
encephalopathy	I-DISO
),	O
vascular	B-DISO
disease	I-DISO
,	O
multiple	B-DISO
sclerosis	I-DISO
,	O
collagen	B-DISO
disease	I-DISO
,	O
Behçet	O
disease	O
,	O
sarcoidosis	B-DISO
,	O
neoplasm	B-DISO
of	I-DISO
the	I-DISO
brainstem	I-DISO
,	O
and	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
diphtheria	B-DISO
,	O
botulism	O
,	O
and	O
viral	B-DISO
infections	I-DISO
(	O
eg	O
,	O
herpes	B-DISO
encephalitis	I-DISO
).	O

The	O
acute	O
phase	O
of	O
Fisher	B-DISO
syndrome	I-DISO
should	O
be	O
carefully	O
observed	O
to	O
see	O
if	O
it	O
occurs	O
concomitantly	O
with	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
or	O
if	O
there	O
is	O
development	O
to	O
Bickerstaff	B-DISO
brainstem	I-DISO
encephalitis	I-DISO
,	O
as	O
these	O
require	O
specific	O
immune	O
treatments	O
.	O

Typically	O
,	O
Fisher	B-DISO
syndrome	I-DISO
has	O
a	O
fairly	O
good	O
natural	O
course	O
.	O

There	O
have	O
been	O
no	O
prospective	O
,	O
controlled	O
studies	O
(	O
randomized	O
or	O
nonrandomized	O
)	O
of	O
the	O
use	O
of	O
immunotherapy	O
to	O
treat	O
Fisher	B-DISO
syndrome	I-DISO
.	O

When	O
only	O
patients	O
developing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
were	O
analyzed	O
,	O
similar	O
results	O
were	O
observed	O
.	O

When	O
only	O
patients	O
developing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
were	O
analyzed	O
,	O
similar	O
results	O
were	O
observed	O
.	O

After	O
amplification	B-DISO
,	O
the	O
products	O
are	O
captured	O
and	O
concentrated	O
in	O
a	O
cross	O
-	O
linked	O
acrylamide	O
gel	O
capture	O
matrix	O
copolymerized	O
with	O
acrydite	O
-	O
functionalized	O
streptavidin	O
-	O
capture	O
agents	O
.	O

Thermal	O
dehybridization	O
releases	O
the	O
fluorescently	O
labeled	O
DNA	O
strand	O
for	O
capillary	O
electrophoresis	O
injection	O
,	O
separation	B-DISO
,	O
and	O
detection	O
.	O

When	O
a	O
two	O
-	O
step	O
reverse	O
transcription	O
PCR	O
amplification	B-DISO
is	O
employed	O
,	O
the	O
device	O
can	O
detect	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
analogues	O
of	O
all	O
four	O
viral	O
targets	O
with	O
detection	O
limits	O
in	O
the	O
range	O
of	O
25	O
-	O
100	O
copies	O
/	O
reactor	O
.	O

Similarly	O
,	O
the	O
NEP	O
activity	O
in	O
plasma	O
and	O
lung	O
tissue	O
was	O
markedly	O
lower	O
,	O
and	O
lung	O
injuries	O
more	O
severe	O
in	O
LPS	B-DISO
-	O
than	O
in	O
HCl	O
-	O
treated	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
activity	O
of	O
NEP	O
in	O
the	O
BALF	O
of	O
LPS	B-DISO
-	O
treated	O
mice	O
was	O
increased	O
.	O

In	O
this	O
experimental	O
and	O
clinical	O
study	O
of	O
ALI	O
/	O
ARDS	B-DISO
,	O
the	O
activity	O
of	O
NEP	O
was	O
significantly	O
decreased	O
in	O
plasma	O
and	O
increased	O
in	O
the	O
alveolar	O
air	O
space	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
its	O
subsequent	O
worldwide	O
spread	O
challenged	O
the	O
global	O
public	O
health	O
community	O
to	O
confront	O
a	O
novel	O
infectious	B-DISO
disease	I-DISO
.	O

Although	O
this	O
pathogen	O
was	O
eradicated	O
in	O
humans	O
,	O
SARS	B-DISO
or	O
SARS	B-DISO
-	O
like	O
viruses	O
might	O
reemerge	O
from	O
animals	O
or	O
from	O
laboratory	O
incidents	O
.	O

TITLE	O
:	O
Bedside	O
lung	O
mechanics	O
predict	O
survival	O
in	O
hypoplastic	O
lung	B-DISO
disease	I-DISO
.	O

We	O
sought	O
to	O
determine	O
whether	O
the	O
degree	O
of	O
pulmonary	B-DISO
hypoplasia	I-DISO
could	O
be	O
measured	O
using	O
bedside	O
pulmonary	O
graphics	O
and	O
whether	O
survival	O
could	O
be	O
predicted	O
in	O
potential	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
candidates	O
.	O

TITLE	O
:	O
Comparison	O
of	O
two	O
oral	O
symptom	B-DISO
-	O
triggered	O
pharmacological	O
inpatient	O
treatments	O
of	O
acute	O
alcohol	B-DISO
withdrawal	I-DISO
:	O
clomethiazole	O
vs	O
.	O
clonazepam	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
two	O
inpatient	O
symptom	B-DISO
-	O
triggered	O
pharmacological	O
treatments	O
of	O
acute	O
alcohol	B-DISO
withdrawal	I-DISO
(	O
AWS	B-DISO
)	O
(	O
clomethiazole	O
vs	O
.	O
clonazepam	O
).	O

Effectiveness	O
was	O
measured	O
by	O
Clinical	O
Global	O
Impression	O
Scale	O
,	O
Revised	O
Clinical	O
Institute	O
Withdrawal	B-DISO
Assessment	O
for	O
Alcohol	O
Scale	O
,	O
Mainz	O
Alcohol	B-DISO
Withdrawal	I-DISO
Scale	O
,	O
Essen	O
Self	O
-	O
Assessment	O
-	O
Alcohol	B-DISO
Withdrawal	I-DISO
and	O
attrition	B-DISO
rate	O
.	O

No	O
withdrawal	B-DISO
seizure	I-DISO
or	O
delirium	B-DISO
occurred	O
.	O

Subanalysis	O
of	O
the	O
prone	O
cases	O
showed	O
no	O
significant	O
changes	O
in	O
the	O
PaO₂	O
/	O
FiO₂	O
ratio	O
or	O
oxygenation	O
index	O
but	O
again	O
showed	O
a	O
significant	O
but	O
temporary	O
increase	O
in	O
intraoperative	O
PaCO₂	O
.	O
HFOV	O
was	O
aborted	O
for	O
conventional	O
mechanical	O
ventilation	O
in	O
three	O
cases	O
due	O
to	O
respiratory	O
deterioration	O
(	O
2	O
cases	O
)	O
and	O
hemodynamic	B-DISO
instability	I-DISO
(	O
1	O
case	O
).	O

Active	O
compression	O
-	O
decompression	O
(	O
ACD	B-DISO
-	O
CPR	O
)	O
and	O
inspiratory	O
threshold	O
valve	O
(	O
ITV	O
-	O
CPR	O
)	O
are	O
not	O
superior	O
to	O
good	O
standard	O
CPR	O
.	O

4000	O
IU	O
),	O
enoxaparin	O
,	O
bivalirudin	O
or	O
fondaparinux	O
depending	O
on	O
the	O
diagnosis	O
(	O
STEMI	B-DISO
or	O
non	O
-	O
STEMI	B-DISO
-	O
ACS	O
)	O
and	O
the	O
planned	O
therapeutic	O
strategy	O
.	O

For	O
successful	O
CPR	O
of	O
trauma	O
patients	O
a	O
minimal	O
intravascular	O
volume	O
status	O
and	O
management	O
of	O
hypoxia	B-DISO
are	O
essential	O
.	O

Since	O
dermatomyositis	B-DISO
(	O
DM	B-DISO
)-	O
specific	O
skin	O
alterations	O
were	O
not	O
found	O
,	O
none	O
of	O
the	O
patients	O
in	O
this	O
study	O
fulfilled	O
Bohan	O
and	O
Peter	O
'	O
s	O
criteria	O
for	O
DM	B-DISO
;	O
however	O
,	O
anti	O
-	O
PL	O
-	O
7	O
antibody	O
was	O
detected	O
in	O
case	O
number	O
1	O
.	O

The	O
other	O
2	O
cases	O
also	O
required	O
glucocorticoids	O
to	O
achieve	O
remission	B-DISO
.	O

A	O
recent	O
surge	O
in	O
the	O
number	O
of	O
patients	O
with	O
leptospirosis	B-DISO
has	O
been	O
noted	O
in	O
the	O
Sub	O
-	O
Himalayan	O
region	O
of	O
North	O
India	O
which	O
was	O
uncommon	O
.	O

We	O
present	O
here	O
a	O
case	O
series	O
of	O
13	O
patients	O
who	O
were	O
positive	O
for	O
leptospirosis	B-DISO
either	O
by	O
IgM	O
Elisa	O
or	O
PCR	O
method	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
,	O
and	O
sensitive	O
detection	O
methods	O
are	O
required	O
for	O
preventing	O
the	O
disease	O
.	O

The	O
optimal	O
reaction	O
condition	B-DISO
was	O
achieved	O
at	O
60	O
°	O
C	O
for	O
30	O
min	O
.	O

Rates	O
of	O
mortality	O
,	O
severe	O
neurological	O
injury	O
,	O
severe	O
retinopathy	B-DISO
of	I-DISO
prematurity	I-DISO
,	O
and	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
were	O
compared	O
.	O

Takotsubo	B-DISO
cardiomyopathy	I-DISO
is	O
a	O
rare	O
clinical	O
syndrome	B-DISO
defined	O
as	O
a	O
profound	O
but	O
reversible	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
in	O
the	O
absence	O
of	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
.	O

On	O
admission	O
,	O
she	O
presented	O
with	O
severe	O
mid	O
-	O
sternal	O
chest	B-DISO
pain	I-DISO
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
shortly	O
after	O
a	O
personally	O
significant	O
stressful	O
life	O
event	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
Emergency	B-DISO
Department	O
for	O
abdominal	B-DISO
pain	I-DISO
,	O
nausea	B-DISO
,	O
vomiting	B-DISO
,	O
multiple	O
daily	O
diarrheas	B-DISO
,	O
hypoglycaemia	B-DISO
(	O
0	O
.	O
2g	O
/	O
L	O
)	O
and	O
severe	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
with	O
glomerular	O
filtration	O
rate	O
estimated	O
at	O
21	O
ml	O
/	O
min	O
.	O

The	O
autopsy	O
revealed	O
widespread	O
asphyxia	B-DISO
syndrome	B-DISO
and	O
erosive	B-DISO
gastritis	I-DISO
.	O

Future	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
efficacy	O
of	O
these	O
therapies	O
on	O
outcomes	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
and	O
refractory	O
hypoxemia	O
.	O

It	O
proved	O
that	O
this	O
method	O
is	O
sensitive	O
for	O
clinical	O
fecal	O
samples	O
and	O
is	O
worth	O
applying	O
to	O
laboratory	O
diagnosis	O
for	O
BCoV	O
and	O
group	O
A	O
BRV	B-DISO
.	O

ABSTRACT	O
:	O
Although	O
coronavirus	O
tropism	O
is	O
most	O
often	O
ascribed	O
to	O
receptor	O
availability	O
,	O
increasing	O
evidence	O
suggests	O
that	O
for	O
the	O
neurotropic	O
strains	O
of	O
the	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
spike	O
-	O
receptor	O
interactions	O
cannot	O
fully	O
explain	O
neurovirulence	O
.	O

The	O
most	O
common	O
symptoms	O
of	O
influenza	B-DISO
A	O
/	O
H1N1v	O
were	O
:	O
high	O
fever	O
(>	O
39	O
°	O
C	O
)	O
-	O
96	O
%	O
of	O
patients	O
,	O
dry	B-DISO
cough	I-DISO
-	O
86	O
%	O
of	O
patients	O
,	O
malaise	B-DISO
-	O
78	O
%	O
of	O
patients	O
,	O
headache	B-DISO
-	O
66	O
%	O
of	O
patients	O
,	O
and	O
diarrhea	B-DISO
or	O
vomiting	B-DISO
-	O
28	O
%	O
of	O
patients	O
.	O

Two	O
children	O
received	O
treatment	O
with	O
oseltamivir	O
(	O
one	O
boy	O
with	O
congenital	B-DISO
heart	I-DISO
defect	I-DISO
and	O
Down	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
and	O
another	O
with	O
severe	O
bronchial	B-DISO
asthma	I-DISO
).	O

No	O
patients	O
required	O
hospitalization	O
either	O
due	O
to	O
primary	O
influenza	B-DISO
infection	B-DISO
or	O
secondary	O
complications	O
.	O

This	O
plant	O
expression	O
vector	O
was	O
transformed	O
into	O
lettuce	O
(	O
Lactuca	O
sativa	O
L	O
.)	O
using	O
the	O
Agrobacterium	O
-	O
mediated	O
transformation	B-DISO
method	O
.	O

H1N1	O
2009	O
was	O
first	O
recognized	O
as	O
a	O
pathogen	O
in	O
March	O
of	O
2009	O
,	O
when	O
there	O
was	O
a	O
spike	O
in	O
the	O
number	O
of	O
cases	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
leading	O
to	O
severe	O
and	O
at	O
times	O
fatal	O
pneumonia	B-DISO
.	O

The	O
etiological	O
diagnosis	O
of	O
S	O
-	O
OIV	O
infection	B-DISO
was	O
performed	O
by	O
use	O
of	O
a	O
real	O
time	O
RT	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assay	O
allowing	O
the	O
detection	O
of	O
all	O
the	O
known	O
human	B-DISO
influenza	I-DISO
A	O
viruses	O
(	O
rRT	O
-	O
PCR	O
targeting	O
the	O
influenza	B-DISO
gene	O
M	O
)	O
and	O
of	O
the	O
new	O
influenza	B-DISO
A	O
/	O
H1N1	O
pandemic	O
strain	O
.	O

Special	O
antibody	O
titer	O
to	O
SARS	B-DISO
-	O
CoV	O
of	O
14	O
patients	O
from	O
5	O
different	O
families	O
and	O
their	O
10	O
kinfolks	O
continuously	O
tested	O
by	O
IFA	O
and	O
antigen	O
-	O
capturing	O
ELISA	O
methods	O
.	O

All	O
cats	O
had	O
severe	O
hyperproteinemia	B-DISO
due	O
to	O
hyperglobulinemia	O
.	O

Clinical	O
baseline	O
characteristics	O
and	O
scores	O
on	O
the	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
and	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
were	O
similar	O
in	O
the	O
corticosteroid	O
and	O
noncorticosteroid	O
groups	O
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
as	O
a	O
prominent	O
cause	O
of	O
childhood	O
acute	O
flaccid	B-DISO
paralysis	I-DISO
in	O
post	O
polio	B-DISO
eradication	O
era	O
in	O
Egypt	O
.	O

Based	O
on	O
this	O
finding	O
,	O
a	O
liposome	O
vaccine	O
that	O
is	O
capable	O
of	O
inducing	O
CTL	O
response	O
against	O
internal	O
antigens	O
of	O
influenza	B-DISO
viruses	O
and	O
removing	O
virus	O
-	O
infected	O
cells	O
in	O
the	O
host	O
has	O
been	O
developed	O
.	O

TITLE	O
:	O
[	O
Molecular	O
epidemiological	O
and	O
clinical	O
features	O
of	O
coronavirus	O
HKU1	O
in	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
Lanzhou	O
].	O

3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assays	O
confirmed	O
the	O
protective	O
effect	O
of	O
the	O
peptides	O
on	O
cell	O
infection	B-DISO
by	O
TGEV	O
.	O

TITLE	O
:	O
Interferon	O
interplay	O
helps	O
tissue	O
cells	O
to	O
cope	O
with	O
SARS	B-DISO
-	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Hospitalized	O
children	O
with	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
):	O
comparison	O
to	O
seasonal	O
influenza	B-DISO
and	O
risk	O
factors	O
for	O
admission	O
to	O
the	O
ICU	O
.	O

HCoV	O
infections	B-DISO
,	O
especially	O
those	O
caused	O
by	O
the	O
two	O
HCoVs	O
identified	O
most	O
recently	O
,	O
NL63	O
and	O
HKU	O
-	O
1	O
,	O
have	O
not	O
been	O
characterized	O
fully	O
.	O

The	O
demographic	O
and	O
clinical	O
data	O
present	O
in	O
this	O
study	O
of	O
HCoV	O
infections	B-DISO
in	O
adults	O
with	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
should	O
improve	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
HCoVs	O
.	O

We	O
hypothesized	O
that	O
proteins	O
,	O
of	O
which	O
the	O
abundance	O
or	O
distribution	O
is	O
affected	O
by	O
infection	B-DISO
,	O
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

TITLE	O
:	O
Molecular	O
study	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
after	O
serial	O
animal	O
passages	O
revealed	O
point	O
mutations	O
in	O
S	O
protein	O
.	O

A	O
typical	O
experimental	O
infection	B-DISO
,	O
molecular	O
characterization	O
,	O
and	O
serological	O
analysis	O
were	O
also	O
carried	O
out	O
to	O
further	O
characterize	O
and	O
to	O
evaluate	O
any	O
significant	O
difference	O
between	O
strains	O
.	O

Suppression	B-DISO
occurred	O
independently	O
of	O
virus	O
viability	O
and	O
acidification	O
of	O
pDC	B-DISO
early	O
endosomes	O
but	O
correlated	O
with	O
diminished	O
levels	O
of	O
IFN	O
-	O
α	O
mRNA	O
.	O

Thus	O
,	O
as	O
supported	O
by	O
a	O
demonstrated	O
resilience	O
of	O
pDC	B-DISO
to	O
PRRSV	O
infection	B-DISO
,	O
this	O
pathogen	O
may	O
interact	O
with	O
a	O
cell	O
surface	O
protein	O
(	O
s	O
)	O
to	O
selectively	O
impede	O
the	O
completion	O
of	O
cascades	O
involved	O
in	O
cytokine	O
production	O
by	O
stimulated	O
pDC	B-DISO
.	O

This	O
report	O
characterizes	O
expression	O
kinetics	O
of	O
factors	O
associated	O
with	O
ASC	O
homing	O
,	O
differentiation	O
,	O
and	O
survival	O
in	O
the	O
spinal	O
cord	B-DISO
,	O
the	O
prominent	O
site	O
of	O
coronavirus	O
persistence	O
.	O

However	O
,	O
the	O
cytopathic	B-DISO
effect	I-DISO
of	O
the	O
recombinants	O
with	O
the	O
partial	O
S	O
deletion	O
was	O
reduced	O
significantly	O
in	O
these	O
cells	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
has	O
been	O
a	O
major	O
threat	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

Fluorescein	O
-	O
KCl	O
solution	O
was	O
sprayed	B-DISO
onto	O
the	O
faces	O
of	O
participants	O
wearing	O
the	O
facemasks	O
and	O
performing	O
intermittent	O
exercises	O
on	O
a	O
treadmill	O
in	O
a	O
climatic	O
chamber	O
.	O

Separating	O
the	O
breathing	O
pathway	O
from	O
the	O
virus	O
-	O
contaminated	O
area	O
in	O
facemasks	O
can	O
provide	O
more	O
effective	O
protection	O
against	O
communicable	O
respiratory	B-DISO
infections	I-DISO
such	O
as	O
influenza	B-DISO
and	O
SARS	B-DISO
.	O

TITLE	O
:	O
Transesophageal	O
echocardiography	O
in	O
prone	O
position	O
during	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
often	O
require	O
prolonged	O
sessions	O
of	O
prone	O
position	O
(	O
PP	O
)	O
because	O
of	O
refractory	O
hypoxemia	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
34	O
patients	O
with	O
ARDS	B-DISO
underwent	O
TEE	O
in	O
PP	O
.	O

In	O
conclusion	O
,	O
an	O
auto	O
-	O
release	O
model	O
of	O
M	O
(	O
pro	O
)	O
from	O
the	O
polyproteins	O
is	O
proposed	O
,	O
which	O
will	O
help	O
understand	O
the	O
auto	O
-	O
processing	O
mechanism	O
and	O
the	O
difference	O
between	O
the	O
autocleavage	O
and	O
trans	O
-	O
cleavage	O
proteolytic	O
activities	O
of	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
caused	O
enteric	O
disease	O
with	O
devastating	O
impact	O
since	O
the	O
first	O
identification	O
of	O
PEDV	O
in	O
1992	O
in	O
Korea	O
.	O

However	O
,	O
which	O
clinical	O
parameters	O
and	O
inflammatory	O
biomarkers	O
including	O
sRAGE	O
are	O
associated	O
with	O
death	O
in	O
ARDS	B-DISO
patients	O
remain	O
unknown	O
.	O

This	O
study	O
demonstrated	O
that	O
sRAGE	O
was	O
independently	O
associated	O
with	O
death	O
in	O
ARDS	B-DISO
patients	O
.	O

TITLE	O
:	O
Mutation	O
of	O
neutralizing	O
/	O
antibody	O
-	O
dependent	O
enhancing	O
epitope	O
on	O
spike	O
protein	O
and	O
7b	O
gene	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
:	O
influences	O
of	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
and	O
virulence	O
in	O
cats	O
.	O

The	O
analysis	O
of	O
the	O
pattern	O
of	O
nucleotide	O
substitutions	O
disclosed	O
""""	O
hot	B-DISO
spots	I-DISO
""""	O
sites	O
which	O
may	O
represent	O
immunological	O
domains	O
.	O

In	O
serial	O
blood	O
examinations	O
of	O
the	O
effusive	O
group	O
,	O
anaemia	B-DISO
and	O
increases	O
in	O
bilirubin	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
were	O
observed	O
from	O
2	O
weeks	O
to	O
0	O
-	O
3	O
days	O
before	O
death	O
.	O

TITLE	O
:	O
Sudden	B-DISO
death	I-DISO
of	O
an	O
immunocompetent	O
young	O
adult	O
caused	O
by	O
novel	O
(	O
swine	O
origin	O
)	O
influenza	B-DISO
A	O
/	O
H1N1	O
-	O
associated	O
myocarditis	B-DISO
.	O

Autopsy	O
revealed	O
a	O
predominantly	O
lymphocytic	B-DISO
myocarditis	I-DISO
in	O
the	O
absence	O
of	O
a	O
significant	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

Unselected	O
patients	O
were	O
recruited	O
sequentially	O
from	O
the	O
Hull	O
Cough	B-DISO
Clinic	O
.	O

This	O
case	O
series	O
summarizes	O
the	O
disease	O
course	O
of	O
four	O
patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
who	O
were	O
treated	O
at	O
our	O
institution	O
from	O
November	O
2009	O
until	O
September	O
2010	O
.	O

Nasal	O
LTB4	O
induces	O
a	O
selective	O
recruitment	B-DISO
/	O
activation	O
of	O
neutrophils	O
.	O

CONCLUSIONS	O
:	O
Nasal	O
LTB4	O
induces	O
a	O
selective	O
recruitment	B-DISO
/	O
activation	O
of	O
neutrophils	O
.	O

Here	O
we	O
show	O
that	O
IFITM	O
proteins	O
restricted	O
infection	B-DISO
mediated	O
by	O
the	O
entry	O
glycoproteins	O
(	O
GP	O
(	O
1	O
,	O
2	O
))	O
of	O
Marburg	O
and	O
Ebola	O
filoviruses	O
(	O
MARV	O
,	O
EBOV	O
).	O

TITLE	O
:	O
An	O
emerging	O
recombinant	O
cluster	O
of	O
nephropathogenic	O
strains	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
Korea	O
.	O

LM	O
and	O
HM	O
herds	O
were	O
compared	O
using	O
five	O
logistic	O
regression	O
models	O
,	O
covering	O
potential	O
risk	O
factors	O
within	O
different	O
areas	O
:	O
""""	O
Disease	O
susceptibility	O
""","	O
""""	O
Factors	O
affecting	O
the	O
gastrointestinal	O
tract	O
""","	O
""""	O
Factors	O
related	O
to	O
transmission	B-DISO
of	I-DISO
infectious	I-DISO
disease	I-DISO
""","	O
""""	O
Hygiene	O
""""	O
and	O
""""	O
Labour	O
management	O
"""."	O

The	O
mortality	O
rate	O
for	O
children	O
with	O
pandemic	O
influenza	B-DISO
2009	O
was	O
30	O
.	O
1	O
%	O
compared	O
to	O
an	O
overall	O
mortality	O
rate	O
of	O
13	O
.	O
7	O
%	O
(	O
p	O
=	O
.	O
0016	O
)	O
among	O
pediatric	O
intensive	O
care	O
unit	O
patients	O
without	O
pandemic	O
influenza	B-DISO
during	O
the	O
study	O
period	O
.	O

Death	O
attributable	O
to	O
pandemic	O
influenza	B-DISO
occurred	O
in	O
all	O
age	O
groups	O
of	O
children	O
with	O
or	O
without	O
underlying	O
illness	O
.	O

In	O
conclusion	O
,	O
simultaneous	O
blockade	O
of	O
inducible	O
and	O
neuronal	O
NO	O
synthase	O
exerts	O
beneficial	O
pulmonary	O
effects	O
in	O
an	O
ovine	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
secondary	O
to	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

Emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
have	O
exacted	O
heavy	O
public	O
health	O
and	O
economic	O
tolls	O
.	O

Influenza	B-DISO
A	O
H5N1	B-DISO
has	O
had	O
a	O
profound	O
effect	O
on	O
the	O
poultry	O
industry	O
.	O

The	O
reasons	O
why	O
southeast	O
Asia	O
is	O
at	O
risk	O
from	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
are	O
complex	O
.	O

PLpro	O
antagonized	O
IFN	O
-	O
α	O
-	O
induced	O
responses	O
such	O
as	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
and	O
AP	O
-	O
1	O
-	O
driven	O
promoter	O
activation	O
,	O
protein	O
kinase	O
R	O
,	O
2	O
'-	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	B-DISO
),	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
8	O
expression	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
1	O
(	O
Tyr701	O
),	O
STAT1	O
(	O
Ser727	O
)	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
.	O

TITLE	O
:	O
[	O
Current	O
approaches	O
to	O
the	O
treatment	O
of	O
severe	O
hypoxic	B-DISO
respiratory	B-DISO
insufficiency	I-DISO
(	O
acute	O
lung	O
injury	O
;	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
)].	O

Virus	O
diversity	O
included	O
environmentally	O
transmitted	B-DISO
agents	O
such	O
as	O
parechovirus	O
,	O
coronavirus	O
,	O
adenovirus	B-DISO
and	O
aichi	O
virus	O
,	O
as	O
well	O
as	O
viruses	O
associated	O
with	O
chronic	O
human	O
infections	B-DISO
such	O
as	O
human	O
herpes	B-DISO
and	O
hepatitis	B-DISO
C	I-DISO
viruses	O
.	O

Very	O
premature	O
infants	O
have	O
more	O
severe	O
diseases	O
and	O
also	O
'	O
late	O
preterm	O
infants	O
'	O
may	O
be	O
more	O
susceptible	O
to	O
the	O
infection	B-DISO
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
oxidative	B-DISO
stress	I-DISO
,	O
alveolar	O
antioxidant	O
status	O
and	O
multiple	O
organ	O
injury	O
in	O
ARDS	B-DISO
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
in	O
rats	O
.	O

African	O
American	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
n	O
=	O
395	O
)	O
either	O
evaluated	O
in	O
the	O
emergency	B-DISO
department	O
or	O
admitted	O
to	O
the	O
hospital	O
.	O

Three	O
hundred	O
ninety	O
-	O
five	O
African	O
American	O
children	O
(	O
14	O
days	O
to	O
18	O
yrs	O
of	O
age	O
)	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
were	O
enrolled	O
.	O

Univariate	O
analysis	O
demonstrated	O
two	O
linkage	O
disequilibrium	B-DISO
-	O
tag	B-DISO
single	O
nucleotide	O
polymorphisms	O
,	O
rs1130866	O
(	O
also	O
known	O
as	O
SP	O
-	O
B	O
+	O
1580	O
C	O
/	O
T	O
)	O
and	O
rs3024793	O
,	O
were	O
associated	O
with	O
the	O
need	O
for	O
mechanical	O
ventilation	O
in	O
African	O
American	O
children	O
(	O
p	O
=	O
.	O
016	O
and	O
p	O
=	O
.	O
030	O
,	O
respectively	O
).	O

Influenza	B-DISO
surveillance	O
was	O
performed	O
by	O
weekly	O
telephone	O
calls	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
6	O
months	O
.	O

Nasal	O
washes	O
were	O
taken	O
from	O
subjects	O
with	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Viral	O
agents	O
were	O
identified	O
in	O
39	O
/	O
60	O
(	O
65	O
%)	O
episodes	O
of	O
respiratory	B-DISO
infections	I-DISO
from	O
the	O
HIV	B-DISO
-	O
infected	O
group	O
and	O
in	O
17	O
/	O
32	O
episodes	O
(	O
53	O
.	O
1	O
%)	O
from	O
the	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
273	O
).	O

ABSTRACT	O
:	O
The	O
shedding	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
into	O
saliva	O
droplets	O
plays	O
a	O
critical	O
role	O
in	O
viral	O
transmission	O
.	O

Here	O
we	O
investigate	O
the	O
early	O
target	O
cells	O
of	O
infection	B-DISO
in	O
the	O
entire	O
array	O
of	O
respiratory	O
tissues	O
in	O
Chinese	O
macaques	O
after	O
intranasal	O
inoculations	O
with	O
a	O
single	O
-	O
cycle	O
pseudotyped	O
virus	O
and	O
a	O
pathogenic	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
found	O
that	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
-	O
positive	O
(	O
ACE2	O
(+))	O
cells	O
were	O
widely	O
distributed	O
in	O
the	O
upper	O
respiratory	O
tract	O
,	O
and	O
ACE2	O
(+)	O
epithelial	O
cells	O
lining	O
salivary	O
gland	O
ducts	O
were	O
the	O
early	O
target	O
cells	O
productively	O
infected	O
.	O

In	O
the	O
case	O
of	O
massive	B-DISO
blood	I-DISO
loss	I-DISO
a	O
combination	O
of	O
coagulation	B-DISO
defects	I-DISO
,	O
acidosis	B-DISO
and	O
hypothermia	O
arise	O
,	O
which	O
are	O
accompanied	O
by	O
high	O
morbidity	O
and	O
mortality	O
rates	O
unless	O
properly	O
corrected	O
.	O

We	O
discuss	O
the	O
role	O
of	O
computational	O
chemistry	O
in	O
the	O
development	O
of	O
small	O
molecules	O
as	O
agents	O
against	O
HIV	B-DISO
integrase	O
,	O
HIV	B-DISO
-	O
1	O
protease	O
,	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
,	O
the	O
influenza	B-DISO
virus	O
M2	O
channel	O
protein	O
,	O
influenza	B-DISO
virus	O
neuraminidase	O
,	O
the	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
and	O
spike	O
protein	O
,	O
thymidine	O
kinases	O
of	O
herpes	B-DISO
viruses	O
,	O
hepatitis	B-DISO
c	I-DISO
virus	O
proteins	O
and	O
other	O
flaviviruses	O
as	O
well	O
as	O
human	O
rhinovirus	O
coat	O
protein	O
and	O
proteases	O
,	O
and	O
other	O
picornaviridae	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
as	O
rescue	O
-	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
All	O
patients	O
presented	O
with	O
a	O
mixture	O
of	O
bilateral	O
patchy	O
consolidations	O
and	O
ground	O
glass	O
opacities	B-DISO
.	O

Protection	O
was	O
evaluated	O
at	O
5	O
and	O
7	O
days	O
postchallenge	O
by	O
scoring	O
clinical	O
signs	O
and	O
quantifying	O
the	O
challenge	O
virus	O
load	O
in	O
the	O
trachea	B-DISO
using	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
).	O

However	O
,	O
the	O
NDV	O
(	O
BI	O
)	O
and	O
the	O
multivalent	O
(	O
B1	O
/	O
MASS	O
/	O
ARK	O
)	O
vaccines	O
interfered	O
with	O
the	O
protection	O
induced	O
by	O
the	O
TCO	B-DISO
vaccine	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Males	O
of	O
Mecp2	O
-	O
deficient	O
mice	O
(	O
Mecp2	O
(-/	O
y	O
))	O
normally	O
breathe	O
at	O
birth	O
but	O
develop	O
first	O
altered	O
breathing	O
regulations	O
,	O
thereafter	O
erratic	O
breathing	O
with	O
severe	O
apnoeas	B-DISO
,	O
aggravating	O
until	O
respiratory	B-DISO
distress	I-DISO
and	O
premature	O
death	O
.	O

Furthermore	O
,	O
IL	O
-	O
10	O
produced	O
by	O
CD8	O
T	O
cells	O
diminished	O
disease	O
severity	O
in	O
mice	O
with	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	B-DISO
,	O
suggesting	O
a	O
self	O
-	O
regulatory	O
mechanism	O
that	O
minimizes	O
immunopathological	O
changes	O
.	O

Gas	O
exchange	O
,	O
hemodynamics	O
,	O
hemolysis	B-DISO
,	O
and	O
coagulation	O
activation	O
were	O
examined	O
.	O

FCGR2A	O
-	O
H131R	O
polymorphism	O
was	O
determined	O
in	O
1	O
,	O
262	O
patients	O
with	O
CAP	B-DISO
and	O
in	O
1	O
,	O
224	O
in	O
the	O
subject	O
control	O
group	O
.	O

No	O
significant	O
differences	O
in	O
genotype	O
or	O
allele	O
frequencies	O
were	O
seen	O
among	O
patients	O
with	O
CAP	B-DISO
or	O
pneumococcal	O
CAP	B-DISO
(	O
PCAP	B-DISO
)	O
and	O
controls	O
.	O

ABSTRACT	O
:	O
Recently	O
emerged	O
viral	O
infectious	B-DISO
diseases	I-DISO
(	O
VIDs	O
)	O
include	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
,	O
influenzas	B-DISO
H5N1	B-DISO
and	O
2009	O
H1N1	O
,	O
SARS	B-DISO
,	O
and	O
Ebola	O
hemorrhagic	B-DISO
fevers	I-DISO
.	O

Anxiety	O
was	O
induced	O
by	O
showing	O
a	O
video	O
of	O
interviews	O
with	O
frontline	O
nurses	O
and	O
doctors	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
Hong	O
Kong	O
,	O
China	O
;	O
calmness	O
was	O
induced	O
by	O
a	O
video	O
of	O
a	O
nursing	O
student	O
'	O
s	O
pleasant	O
orientation	O
to	O
a	O
clinical	O
placement	O
site	O
.	O

To	O
obtain	O
further	O
insight	O
into	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
-	O
associated	O
ALI	O
,	O
we	O
compared	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
in	O
two	O
different	O
nonhuman	O
primate	O
species	O
,	O
cynomolgus	O
macaques	O
and	O
African	O
green	O
monkeys	O
.	O

Induction	O
of	O
distinct	O
proinflammatory	O
genes	O
after	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
different	O
nonhuman	O
primate	O
species	O
needs	O
to	O
be	O
taken	O
into	O
account	O
when	O
analyzing	O
outcomes	O
of	O
intervention	O
strategies	O
in	O
these	O
species	O
.	O

trans	O
-	O
cleavage	O
activated	O
SARS	B-DISO
S	O
on	O
effector	O
cells	O
for	O
fusion	O
with	O
target	O
cells	O
and	O
allowed	O
efficient	O
SARS	B-DISO
S	O
-	O
driven	O
viral	O
entry	O
into	O
targets	O
treated	O
with	O
a	O
lysosomotropic	O
agent	O
or	O
a	O
cathepsin	O
inhibitor	O
.	O

TITLE	O
:	O
Benefits	O
of	O
random	O
-	O
priming	O
:	O
exhaustive	O
survey	O
of	O
a	O
cDNA	O
library	O
from	O
lung	O
tissue	O
of	O
a	O
SARS	B-DISO
patient	O
.	O

The	O
EST	O
data	O
could	O
be	O
a	O
useful	O
supplemental	O
source	O
for	O
SARS	B-DISO
pathology	B-DISO
researches	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
generally	O
associated	O
with	O
respiratory	O
and	O
enteric	O
infections	B-DISO
and	O
have	O
long	O
been	O
recognized	O
as	O
important	O
pathogens	O
of	O
livestock	O
and	O
companion	O
animals	O
.	O

The	O
single	O
amino	O
acid	O
mutation	O
at	O
Nsp16	O
position	O
76	O
or	O
position	O
130	O
could	O
also	O
revert	O
the	O
ts	O
mutant	B-DISO
Wu	O
"""-"	O
ts18	O
(	O
cd	O
)	O
to	O
non	O
-	O
ts	O
phenotype	O
,	O
an	O
additional	O
independent	O
mutation	O
in	O
Nsp13	O
position	O
115	O
played	O
an	O
important	O
role	O
on	O
plaque	B-DISO
size	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
coronaviruses	O
newly	O
isolated	O
in	O
China	O
,	O
and	O
pathogenicity	O
and	O
evaluation	O
of	O
protection	O
induced	O
by	O
Massachusetts	O
serotype	O
H120	O
vaccine	O
against	O
QX	O
-	O
like	O
strains	O
.	O

ABSTRACT	O
:	O
The	O
attenuation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
QX	O
-	O
like	O
virus	O
strain	O
L1148	O
is	O
described	O
.	O

Historically	O
,	O
the	O
term	O
""""	O
disuse	B-DISO
atrophy	I-DISO
""""	O
has	O
described	O
a	O
situation	O
wherein	O
sustained	O
inactivity	O
of	O
the	O
respiratory	O
muscles	O
(	O
ie	O
,	O
passive	O
ventilation	O
)	O
results	O
in	O
deconditioning	O
and	O
weakness	B-DISO
.	O

However	O
,	O
promotion	O
of	O
unassisted	O
spontaneous	O
breathing	O
in	O
the	O
acute	O
phase	O
of	O
critical	B-DISO
illness	I-DISO
also	O
may	O
carry	O
a	O
substantial	O
risk	O
of	O
respiratory	O
muscle	O
injury	O
and	O
weakness	B-DISO
.	O

Studies	O
on	O
sedation	B-DISO
use	O
have	O
serious	O
methodological	O
limitations	O
.	O

To	O
evaluate	O
the	O
importance	O
of	O
cellular	O
immunity	O
for	O
FIPV	O
infection	B-DISO
,	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
feline	O
interferon	O
(	O
fIFN	O
)-	O
γ	O
were	O
first	O
created	O
to	O
establish	O
fIFN	O
-	O
γ	O
detection	O
systems	O
using	O
the	O
MAbs	O
.	O

In	O
contrast	O
,	O
fIFN	O
-	O
γ	O
production	O
from	O
PBMCs	O
isolated	O
from	O
cats	O
that	O
had	O
developed	O
FIP	B-DISO
and	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
cats	O
was	O
not	O
increased	O
by	O
heat	O
-	O
inactivated	O
FIPV	O
stimulation	O
.	O

Intensive	O
care	O
units	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Clinical	O
Trials	O
Network	O
centers	O
across	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Prehospital	O
statin	O
and	O
aspirin	O
use	O
and	O
the	O
prevalence	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
SLE	B-DISO
)	O
is	O
a	O
chronic	B-DISO
inflammatory	I-DISO
disease	I-DISO
that	O
can	O
lead	O
to	O
damage	O
to	O
several	O
vital	O
organs	O
.	O

The	O
spontaneous	O
hemorrhage	B-DISO
of	O
left	O
fourth	O
intercostal	O
artery	O
(	O
ICA	O
)	O
and	O
left	O
axillary	O
artery	O
occured	O
at	O
the	O
same	O
time	O
without	O
vasculitis	B-DISO
or	O
severe	O
trauma	O
.	O

Syndromes	B-DISO
associated	O
with	O
granulocyte	O
dysfunctions	O
can	O
cause	O
severe	O
clinical	O
conditions	O
(	O
1	O
,	O
2	O
).	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
performances	O
of	O
tests	O
carried	O
out	O
in	O
vivo	O
or	O
at	O
postmortem	O
examination	O
in	O
challenging	O
cases	O
in	O
which	O
FIP	B-DISO
was	O
confirmed	O
or	O
excluded	O
based	O
on	O
IHC	O
or	O
on	O
adequate	O
follow	O
-	O
up	O
.	O

Twelve	O
cases	O
(	O
four	O
without	O
FIP	B-DISO
,	O
eight	O
with	O
FIP	B-DISO
)	O
were	O
retrospectively	O
studied	O
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
when	O
histopathology	O
is	O
controversial	O
,	O
elevated	O
AGP	O
concentrations	O
may	O
support	O
the	O
diagnosis	O
of	O
FIP	B-DISO
.	O

We	O
analyzed	O
the	O
data	O
collected	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
GBS	B-DISO
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
our	O
university	O
hospital	O
between	O
1996	O
and	O
2009	O
.	O

Treatment	O
with	O
UDA	O
at	O
5	O
mg	O
/	O
kg	O
significantly	O
protected	O
the	O
mice	O
against	O
a	O
lethal	O
infection	B-DISO
with	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoV	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
but	O
did	O
not	O
significantly	O
reduce	O
virus	O
lung	O
titers	O
.	O

TITLE	O
:	O
[	O
Isolation	O
and	O
characteristics	O
of	O
virus	O
culture	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
LJB	O
/	O
03	O
].	O

The	O
molecular	O
data	O
presented	O
in	O
this	O
study	O
provide	O
the	O
first	O
genetic	O
evidence	O
for	O
a	O
new	O
coronavirus	O
associated	O
with	O
epizootic	O
catarrhal	O
gastroenteritis	B-DISO
outbreaks	O
in	O
mink	O
and	O
demonstrate	O
that	O
MCoVs	O
possess	B-DISO
high	O
genomic	O
variability	O
and	O
relatively	O
low	O
overall	O
nucleotide	O
sequence	O
identities	O
(	O
91	O
.	O
7	O
%)	O
between	O
contemporary	O
strains	O
.	O

The	O
NIH	O
estimates	O
that	O
more	O
than	O
4	O
.	O
5	O
million	O
people	O
suffer	B-DISO
from	O
ALI	O
/	O
ARDS	B-DISO
per	O
year	O
.	O

TITLE	O
:	O
Alizarine	O
derivatives	O
as	O
new	O
dual	O
inhibitors	O
of	O
the	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
-	O
associated	O
DNA	O
polymerase	O
and	O
RNase	O
H	O
activities	O
effective	O
also	O
on	O
the	O
RNase	O
H	O
activity	O
of	O
non	O
-	O
nucleoside	O
resistant	O
reverse	O
transcriptases	O
.	O

To	O
improve	O
the	O
functionality	O
of	O
the	O
vaccine	O
and	O
investigate	O
its	O
potential	O
as	O
a	O
delivery	O
vector	O
for	O
foreign	O
antigens	O
and	O
immunomodulatory	O
proteins	O
,	O
we	O
developed	O
a	O
derivative	O
of	O
ts	O
-	O
11	O
expressing	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
-	O
S1	O
glycoprotein	O
(	O
IBV	O
-	O
S1	O
)	O
and	O
releasing	O
chicken	O
interleukin	O
-	O
6	O
into	O
the	O
extracellular	O
milieu	O
(	O
MG	O
ts	O
-	O
11	O
C3	O
(+	O
CS	O
))	O
using	O
a	O
transposon	O
-	O
based	O
delivery	O
vector	O
.	O

ABSTRACT	O
:	O
The	O
open	O
-	O
reading	O
-	O
frame	O
3a	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
had	O
been	O
demonstrated	O
previously	O
to	O
form	O
a	O
cation	O
-	O
selective	O
channel	O
that	O
may	O
become	O
expressed	O
in	O
the	O
infected	O
cell	O
and	O
is	O
then	O
involved	O
in	O
virus	O
release	O
.	O

Toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
is	O
the	O
most	O
severe	O
form	O
of	O
drug	O
-	O
induced	O
skin	O
reaction	O
and	O
includes	O
denudation	O
of	O
>	O
30	O
%	O
of	O
total	O
body	O
surface	O
area	O
.	O

These	O
results	O
suggest	O
that	O
PLP2	O
not	O
only	O
inactivates	O
TBK1	O
,	O
but	O
also	O
prevents	O
IRF3	O
nuclear	O
translocation	B-DISO
hence	O
inhibits	O
IFN	O
transcription	O
activation	O
.	O

TITLE	O
:	O
Longitudinal	O
profiles	O
of	O
immunoglobulin	O
G	O
antibodies	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
components	O
and	O
neutralizing	O
activities	O
in	O
recovered	O
patients	O
.	O

Currently	O
,	O
the	O
longitudinal	O
profiles	O
of	O
antibody	O
responses	O
in	O
recovered	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

TITLE	O
:	O
Virus	O
-	O
associated	O
hemophagocytic	B-DISO
syndrome	I-DISO
as	O
a	O
major	O
contributor	O
to	O
death	O
in	O
patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

RESULTS	O
:	O
VAHS	O
developed	O
in	O
9	O
(	O
36	O
%)	O
of	O
25	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
confirmed	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
,	O
and	O
8	O
(	O
89	O
%)	O
of	O
them	O
died	O
.	O

TITLE	O
:	O
Views	O
of	O
GPs	B-DISO
and	O
practice	O
nurses	O
on	O
support	O
needed	O
to	O
respond	O
to	O
pandemic	O
influenza	B-DISO
:	O
a	O
qualitative	O
study	O
.	O

TITLE	O
:	O
In	O
vitro	O
inhibition	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
replication	O
with	O
siRNAs	O
targeting	O
the	O
spike	O
glycoprotein	O
and	O
replicase	O
polyprotein	O
genes	O
.	O

Transfection	O
with	O
siRNAs	O
also	O
suppressed	O
the	O
production	O
of	O
infectious	B-DISO
virus	O
by	O
up	O
to	O
18	O
-	O
to	O
32	O
-	O
fold	O
as	O
assessed	O
by	O
a	O
HA	O
test	O
and	O
93	O
-	O
to	O
494	O
-	O
fold	O
as	O
assessed	O
by	O
TCID	O
(	O
50	O
)	O
assay	O
.	O

These	O
results	O
suggested	O
that	O
the	O
four	O
species	O
of	O
siRNAs	O
can	O
efficiently	O
inhibit	O
PHE	O
-	O
CoV	O
genome	O
replication	O
and	O
infectious	B-DISO
virus	O
production	O
.	O

The	O
patient	O
had	O
an	O
acute	O
unilateral	O
hydrops	B-DISO
,	O
with	O
a	O
monolateral	O
keratoconus	B-DISO
.	O

To	O
this	O
aim	O
,	O
we	O
designed	O
,	O
through	O
a	O
bioinformatic	O
approach	O
,	O
8	O
potentially	O
immunogenic	O
peptides	O
from	O
the	O
protein	O
N	O
corresponding	O
to	O
sequences	O
of	O
residues	O
14	O
,	O
182	O
,	O
198	O
detected	O
only	O
in	O
FCoVs	O
from	O
FIP	B-DISO
cats	O
(	O
virulent	O
strains	O
),	O
only	O
in	O
FCoVs	O
from	O
healthy	O
cats	O
(	O
avirulent	O
strains	O
)	O
and	O
both	O
in	O
FIP	B-DISO
and	O
in	O
healthy	O
cats	O
(	O
mixed	O
strains	O
).	O

Within	O
the	O
first	O
30	O
days	O
,	O
a	O
fatal	O
outcome	O
caused	O
by	O
therapy	O
-	O
resistant	O
progressive	O
RF	O
was	O
observed	O
in	O
33	O
%	O
of	O
the	O
patients	O
with	O
pandemic	O
influenza	B-DISO
treated	O
at	O
the	O
intensive	O
care	O
unit	O
.	O

Diagnoses	O
of	O
viral	B-DISO
infections	I-DISO
were	O
established	O
according	O
to	O
positive	O
results	O
in	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
influenza	B-DISO
rapid	O
diagnostic	O
testing	O
,	O
and	O
based	O
on	O
a	O
fourfold	O
increase	O
in	O
antibody	O
titer	O
of	O
influenza	B-DISO
virus	O
antibody	O
in	O
paired	O
sera	O
.	O

Information	O
remains	O
limited	O
about	O
the	O
comparative	O
protein	O
expression	O
profiles	O
of	O
chicken	O
embryonic	O
tissues	O
in	O
response	O
to	O
IBV	O
infection	B-DISO
in	O
ovo	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
we	O
have	O
performed	O
the	O
first	O
analysis	O
of	O
the	O
proteomic	O
changes	O
in	O
chicken	O
embryonic	O
trachea	B-DISO
and	O
kidney	O
tissues	O
during	O
IBV	O
infection	B-DISO
in	O
ovo	O
.	O

It	O
has	O
been	O
previously	O
proposed	O
that	O
TRS	B-DISO
-	O
Bs	O
act	O
as	O
attenuation	O
or	O
stop	O
signals	O
during	O
the	O
synthesis	O
of	O
minus	O
-	O
sense	O
RNAs	O
.	O

The	O
nascent	O
minus	O
-	O
stranded	O
RNA	O
would	O
then	O
be	O
transferred	O
by	O
a	O
template	O
switch	O
process	O
to	O
the	O
TRS	B-DISO
-	O
L	O
,	O
which	O
acts	O
as	O
the	O
acceptor	O
RNA	O
.	O

The	O
results	O
indicated	O
that	O
a	O
36	O
-	O
nucleotide	O
oligomer	O
encompassing	O
the	O
wild	O
-	O
type	O
TRS	B-DISO
-	O
L	O
forms	O
a	O
structured	O
hairpin	O
closed	O
by	O
an	O
apical	O
AACUAAA	O
heptaloop	O
.	O

ABSTRACT	O
:	O
Conditions	O
characterized	O
by	O
immunosuppression	O
have	O
been	O
recently	O
reported	O
as	O
risk	O
factors	O
for	O
severe	O
novel	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
infection	B-DISO
during	O
the	O
current	O
2009	O
pandemic	O
.	O

Here	O
,	O
we	O
studied	O
N214A	O
,	O
another	O
mutant	B-DISO
with	O
only	O
a	O
doubled	O
dissociation	B-DISO
constant	O
but	O
significantly	O
abolished	O
activity	O
.	O

The	O
present	O
MD	O
simulations	O
represent	O
the	O
longest	O
reported	O
so	O
far	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
,	O
unveiling	O
that	O
its	O
catalysis	O
is	O
critically	O
dependent	O
on	O
the	O
dynamics	O
,	O
which	O
can	O
be	O
amazingly	O
modulated	O
by	O
the	O
extra	O
domain	O
.	O

Nsp16	O
is	O
an	O
RNA	O
-	O
cap	B-DISO
AdoMet	O
-	O
dependent	O
(	O
nucleoside	O
-	O
2	O
'-	O
O	O
-)-	O
methyltransferase	O
that	O
is	O
only	O
active	O
in	O
the	O
presence	O
of	O
nsp10	O
.	O

Another	O
1300	O
questionnaires	O
were	O
distributed	O
between	O
10	O
March	O
and	O
10	O
May	O
2004	O
,	O
after	O
the	O
SARS	B-DISO
epidemic	O
.	O

ABSTRACT	O
:	O
Infections	B-DISO
caused	O
by	O
human	O
rhinoviruses	O
(	O
HRVs	O
)	O
are	O
important	O
triggers	O
of	O
wheezing	B-DISO
in	O
young	O
children	O
.	O

Two	O
hundred	O
and	O
twenty	O
children	O
presenting	O
consecutively	O
at	O
a	O
tertiary	O
children	O
'	O
s	O
hospital	O
with	O
a	O
wheezing	B-DISO
illness	O
from	O
May	O
2004	O
to	O
November	O
2005	O
were	O
prospectively	O
enrolled	O
.	O

Exchange	O
transfusion	O
may	O
be	O
indicated	O
in	O
severe	O
forms	O
of	O
ACS	O
,	O
characterized	O
by	O
a	O
right	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Patients	O
usually	O
present	O
with	O
chronic	O
recurrent	O
rhinosinusitis	B-DISO
,	O
otitis	B-DISO
media	I-DISO
,	O
pneumonia	B-DISO
,	O
and	O
bronchiectasis	B-DISO
caused	O
by	O
pseudomonal	O
infection	B-DISO
.	O

She	O
was	O
diagnosed	O
with	O
Kartagener	B-DISO
syndrome	I-DISO
based	O
on	O
her	O
clinical	O
presentation	O
and	O
genetic	O
studies	O
.	O

We	O
recently	O
determined	O
the	O
crystal	O
structures	O
of	O
NL63	O
coronavirus	O
(	O
NL63	O
-	O
CoV	O
)	O
and	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
receptor	O
-	O
binding	O
domains	O
(	O
RBDs	O
),	O
each	O
complexed	O
with	O
their	O
common	O
receptor	O
,	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
and	O
proposed	O
the	O
existence	O
of	O
a	O
virus	O
-	O
binding	O
hot	B-DISO
spot	I-DISO
on	O
hACE2	O
.	O

TITLE	O
:	O
Spongiform	O
degeneration	B-DISO
induced	O
by	O
neuropathogenic	O
murine	O
coronavirus	B-DISO
infection	I-DISO
.	O

Thus	O
,	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
mainly	O
causes	O
damage	O
to	O
the	O
nervous	B-DISO
system	O
but	O
also	O
impacts	O
other	O
organs	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
),	O
including	O
the	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
)	O
and	O
the	O
more	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
are	O
common	O
and	O
complex	O
inflammatory	O
lung	B-DISO
diseases	I-DISO
potentially	O
affected	O
by	O
various	O
genetic	O
and	O
nongenetic	O
factors	O
.	O

TITLE	O
:	O
Inhaled	O
ribavirin	O
therapy	O
in	O
adult	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Influenza	B-DISO
,	O
for	O
example	O
,	O
recurs	O
annually	O
and	O
has	O
been	O
modeled	O
more	O
thoroughly	O
than	O
any	O
other	B-DISO
infectious	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Histopathological	O
and	O
immunohistochemical	O
study	O
of	O
air	O
sac	O
lesions	O
induced	O
by	O
two	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Although	O
mortality	O
is	O
low	O
,	O
infection	B-DISO
with	O
IBV	O
results	O
in	O
substantial	O
losses	O
for	O
the	O
egg	O
and	O
meat	O
chicken	O
industries	O
.	O

ABSTRACT	O
:	O
The	O
worldwide	O
outbreak	O
of	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	B-DISO
influenza	I-DISO
)	O
infection	B-DISO
in	O
2009	O
caused	O
numerous	O
hospitalizations	O
and	O
deaths	O
resulting	O
from	O
severe	O
complications	O
such	O
as	O
pneumonia	B-DISO
,	O
sepsis	B-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Fulminant	O
myocarditis	B-DISO
caused	O
by	O
H1N1	O
infection	B-DISO
has	O
been	O
reported	O
in	O
children	O
but	O
rarely	O
in	O
adults	O
.	O

We	O
present	O
an	O
adult	O
who	O
contracted	O
H1N1	O
infection	B-DISO
followed	O
by	O
fulminant	O
myocarditis	B-DISO
.	O

Early	O
implementation	O
of	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
support	O
in	O
conjunction	O
with	O
a	O
specific	O
anti	O
-	O
influenza	B-DISO
viral	O
medication	O
(	O
Oseltamivir	O
)	O
led	O
to	O
the	O
patient	O
'	O
s	O
complete	O
recovery	O
from	O
cardiogenic	B-DISO
shock	I-DISO
in	O
2	O
weeks	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
may	O
be	O
lifesaving	O
in	O
multiple	O
injured	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
due	O
to	O
chest	O
trauma	O
.	O

TITLE	O
:	O
Resilience	O
training	O
for	O
hospital	O
workers	O
in	O
anticipation	O
of	O
an	O
influenza	B-DISO
pandemic	O
.	O

The	O
intervention	O
we	O
describe	O
emerged	O
from	O
the	O
recognition	O
that	O
an	O
expected	O
influenza	B-DISO
pandemic	O
indicated	O
a	O
need	O
to	O
build	O
resilience	O
to	O
maintain	O
the	O
health	O
of	O
individuals	O
within	O
the	O
organization	O
and	O
to	O
protect	O
the	O
capacity	O
of	O
the	O
organization	O
to	O
respond	O
to	O
extraordinary	O
demands	O
.	O

TITLE	O
:	O
Comparative	O
evaluation	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
patients	O
with	O
and	O
without	O
H1N1	O
infection	B-DISO
at	O
a	O
tertiary	O
care	O
referral	O
center	O
.	O

The	O
outbreaks	O
of	O
SARS	B-DISO
and	O
AH1N1	O
Flu	B-DISO
were	O
considered	O
like	O
represented	O
by	O
a	O
reduction	O
of	O
previously	O
existing	O
contact	O
networks	O
via	O
the	O
control	O
measures	O
executed	O
by	O
health	O
authorities	O
.	O

WHO	O
responded	O
quickly	O
to	O
this	O
multi	O
-	O
country	O
outbreak	O
and	O
on	O
12	O
March	O
released	O
a	O
""""	O
global	O
alert	O
""""	O
about	O
SARS	B-DISO
.	O

Hospitals	O
were	O
dedicated	O
to	O
the	O
screening	O
and	O
treatment	O
of	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
long	O
term	O
adverse	B-DISO
effects	I-DISO
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
viral	B-DISO
disease	I-DISO
,	O
are	O
poorly	O
understood	O
.	O

Chronic	O
post	O
-	O
SARS	B-DISO
is	O
characterized	O
by	O
persistent	O
fatigue	B-DISO
,	O
diffuse	O
myalgia	B-DISO
,	O
weakness	B-DISO
,	O
depression	B-DISO
,	O
and	O
nonrestorative	O
sleep	O
with	O
associated	O
REM	O
-	O
related	O
apneas	B-DISO
/	O
hypopneas	O
,	O
an	O
elevated	O
sleep	O
EEG	O
cyclical	O
alternating	O
pattern	O
,	O
and	O
alpha	O
EEG	O
sleep	O
anomaly	O
.	O

Post	O
-	O
SARS	B-DISO
patients	O
had	O
symptoms	O
of	O
pre	O
and	O
post	O
-	O
sleep	O
fatigue	B-DISO
and	O
post	O
sleep	O
sleepiness	O
that	O
were	O
similar	O
to	O
the	O
symptoms	O
of	O
patients	O
with	O
FMS	B-DISO
,	O
and	O
similar	O
to	O
symptoms	O
of	O
patients	O
with	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
.	O

The	O
post	O
-	O
SARS	B-DISO
group	O
had	O
a	O
lower	O
rating	O
of	O
the	O
alpha	O
EEG	O
sleep	O
anomaly	O
as	O
compared	O
to	O
the	O
FMS	B-DISO
patients	O
.	O

The	O
clinical	O
and	O
sleep	O
features	O
of	O
chronic	O
post	O
-	O
SARS	B-DISO
form	O
a	O
syndrome	B-DISO
of	O
chronic	O
fatigue	B-DISO
,	O
pain	O
,	O
weakness	B-DISO
,	O
depression	B-DISO
and	O
sleep	B-DISO
disturbance	I-DISO
,	O
which	O
overlaps	O
with	O
the	O
clinical	O
and	O
sleep	O
features	O
of	O
FMS	B-DISO
and	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
.	O

Equid	O
herpesvirus	O
1	O
and	O
equine	O
rhinitis	B-DISO
A	O
virus	O
were	O
prevalent	O
,	O
and	O
equine	O
arteritis	B-DISO
virus	O
and	O
equid	O
herpesvirus	O
3	O
were	O
detected	O
over	O
a	O
wide	O
area	O
though	O
their	O
rates	O
of	O
antibody	O
-	O
positivity	O
were	O
not	O
high	O
.	O

Equine	B-DISO
infectious	I-DISO
anemia	I-DISO
was	O
distributed	O
locally	O
.	O

We	O
conclude	O
that	O
not	O
all	O
viral	B-DISO
infections	I-DISO
in	O
children	O
with	O
asthma	B-DISO
lead	O
to	O
an	O
asthma	B-DISO
exacerbation	O
and	O
the	O
attributing	O
effect	O
of	O
different	O
triggers	O
of	O
asthma	B-DISO
exacerbations	O
in	O
children	O
vary	O
across	O
different	O
time	O
periods	O
and	O
across	O
different	O
localities	O
.	O

TITLE	O
:	O
[	O
Acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
--	O
what	O
should	O
we	O
know	O
?].	O

ABSTRACT	O
:	O
Acutelunginjury	O
(	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
syndromes	B-DISO
with	O
a	O
spectrum	O
of	O
increasing	O
severity	O
of	O
lung	O
injury	O
defined	O
by	O
physiologic	O
and	O
radiographic	O
criteria	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Golgi	O
complex	O
-	O
targeting	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
envelope	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
2003	O
global	O
outbreak	O
of	O
progressive	O
respiratory	B-DISO
failure	I-DISO
was	O
caused	O
by	O
a	O
newly	O
emerged	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

To	O
dissect	O
the	O
targeting	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
to	O
the	O
Golgi	O
region	O
,	O
we	O
exogenously	O
expressed	O
the	O
protein	O
and	O
various	O
mutants	O
from	O
cDNA	O
and	O
determined	O
their	O
localization	O
using	O
immunofluorescence	O
microscopy	O
and	O
biochemical	O
assays	O
.	O

We	O
determined	O
that	O
antiviral	O
activity	O
was	O
dependent	O
on	O
both	O
the	O
Tat	O
sequence	O
and	O
the	O
native	O
EboV	O
CHR	B-DISO
sequence	O
.	O

CONCLUSIONS	O
:	O
Similar	O
to	O
other	O
parts	O
in	O
the	O
world	O
,	O
RSV	O
and	O
influenza	B-DISO
were	O
the	O
predominant	O
viral	O
pathogens	O
detected	O
in	O
Vietnamese	O
hospitalized	O
children	O
.	O

ABSTRACT	O
:	O
The	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
may	O
be	O
severe	O
in	O
non	O
-	O
immune	O
people	O
.	O

Steroid	O
therapy	O
is	O
part	O
of	O
the	O
management	O
of	O
severe	O
vasculitis	B-DISO
.	O

No	O
dogs	O
showed	O
evidence	O
of	O
exposure	O
to	O
Ehrlichia	O
canis	O
,	O
Anaplasma	O
phagocytophilum	O
,	O
Borrelia	B-DISO
burgdorferi	O
,	O
Dirofilaria	O
immitis	O
,	O
or	O
Cryptococcus	O
gattii	O
.	O

Lactic	B-DISO
acidosis	I-DISO
is	O
also	O
associated	O
with	O
conditions	O
such	O
as	O
diabetes	B-DISO
mellitus	I-DISO
,	O
significant	O
tissue	O
hypoperfusion	O
,	O
and	O
hypoxemia	O
caused	O
by	O
lactic	O
acid	O
overproduction	O
or	O
underutilization	O
.	O

The	O
estimated	O
incidence	O
of	O
this	O
syndrome	B-DISO
is	O
2	O
-	O
9	O
cases	O
per	O
100	O
000	O
patients	O
.	O

Concerns	O
have	O
been	O
raised	O
for	O
the	O
use	O
of	O
metformin	O
in	O
patients	O
with	O
cardiovascular	O
,	O
renal	O
,	O
hepatic	O
,	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Virtual	O
screening	O
identification	O
of	O
novel	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
3C	O
-	O
like	O
protease	O
inhibitors	O
and	O
in	O
vitro	O
confirmation	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
vital	O
for	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
is	O
a	O
promising	O
drug	O
target	O
.	O

This	O
finding	O
has	O
important	O
implications	O
both	O
for	O
public	O
health	O
and	O
for	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
.	O

Bronchoalveolar	O
lavage	O
and	O
serum	O
from	O
patients	O
with	O
acute	O
exacerbation	B-DISO
of	I-DISO
idiopathic	I-DISO
pulmonary	I-DISO
fibrosis	I-DISO
,	O
stable	O
disease	O
,	O
and	O
acute	O
lung	O
injury	O
were	O
tested	O
for	O
viral	O
nucleic	O
acid	O
using	O
multiplex	O
polymerase	O
chain	O
reaction	O
,	O
pan	O
-	O
viral	O
microarray	O
,	O
and	O
high	O
-	O
throughput	O
cDNA	O
sequencing	O
.	O

Viral	B-DISO
infection	I-DISO
was	O
not	O
detected	O
in	O
most	O
cases	O
of	O
acute	O
exacerbation	B-DISO
of	I-DISO
idiopathic	I-DISO
pulmonary	I-DISO
fibrosis	I-DISO
.	O

Shock	O
wave	O
pressure	O
less	O
than	O
1	O
210	O
.	O
5	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
,	O
group	O
A	O
,	O
B	O
)	O
resulted	O
in	O
limited	O
injury	O
to	O
the	O
lung	O
within	O
grade	O
2	O
as	O
assessed	O
with	O
the	O
abbreviated	O
injury	O
scale	O
(	O
AIS	B-DISO
).	O

Shock	O
wave	O
pressure	O
at	O
1	O
917	O
.	O
3	O
mm	O
Hg	O
(	O
group	O
C	O
)	O
produced	O
extensive	O
contusion	O
from	O
grade	O
4	O
to	O
grade	O
5	O
as	O
assessed	O
with	O
AIS	B-DISO
.	O

RESULTS	O
:	O
Shock	O
wave	O
pressure	O
less	O
than	O
1	O
210	O
.	O
5	O
mm	O
Hg	O
(	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
,	O
group	O
A	O
,	O
B	O
)	O
resulted	O
in	O
limited	O
injury	O
to	O
the	O
lung	O
within	O
grade	O
2	O
as	O
assessed	O
with	O
the	O
abbreviated	O
injury	O
scale	O
(	O
AIS	B-DISO
).	O

TITLE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
),	O
produced	O
by	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
virus	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
,	O
induces	O
vascular	O
permeability	O
and	O
effusion	B-DISO
in	O
cats	O
with	O
FIP	B-DISO
.	O

The	O
first	O
test	O
employs	O
a	O
one	O
-	O
step	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
in	O
which	O
the	O
amplification	B-DISO
is	O
monitored	O
in	O
real	O
time	O
using	O
a	O
TaqMan	O
(®)	O
probe	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
an	O
acute	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
due	O
to	O
non	B-DISO
-	I-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
with	O
diverse	O
etiologies	O
and	O
high	O
mortality	O
.	O

In	O
2006	O
,	O
randomly	O
selected	O
employees	O
(	O
N	O
=	O
549	O
)	O
of	O
a	O
hospital	O
in	O
Beijing	O
were	O
surveyed	O
concerning	O
their	O
exposures	O
to	O
the	O
city	O
'	O
s	O
2003	O
SARS	B-DISO
outbreak	O
and	O
the	O
ways	O
in	O
which	O
the	O
outbreak	O
had	O
affected	O
their	O
mental	O
health	O
.	O

ABSTRACT	O
:	O
Neuralgic	B-DISO
amyotrophy	I-DISO
(	O
brachial	O
plexus	O
neuropathy	B-DISO
,	I-DISO
brachial	I-DISO
plexus	I-DISO
neuritis	B-DISO
,	O
or	O
Parsonage	B-DISO
-	I-DISO
Turner	I-DISO
syndrome	I-DISO
)	O
is	O
an	O
uncommon	O
inflammatory	O
condition	B-DISO
typically	O
characterized	O
by	O
acute	O
and	O
severe	O
shoulder	B-DISO
pain	I-DISO
followed	O
by	O
paresis	B-DISO
with	O
muscle	B-DISO
weakness	I-DISO
and	O
atrophy	B-DISO
of	O
the	O
upper	O
limb	O
or	O
shoulder	O
girdle	O
.	O

Clinical	O
examination	O
at	O
admission	O
and	O
at	O
the	O
2	O
-	O
month	O
follow	O
-	O
up	O
did	O
not	O
show	O
upper	O
limb	B-DISO
weakness	I-DISO
or	O
atrophy	B-DISO
,	O
except	O
for	O
a	O
mild	O
atrophy	B-DISO
of	O
the	O
right	O
supraspinatus	O
muscle	O
.	O

CONCLUSIONS	O
:	O
Shoulder	B-DISO
pain	I-DISO
followed	O
by	O
diaphragmatic	O
paralysis	O
with	O
dyspnea	B-DISO
and	O
hoarseness	B-DISO
may	O
be	O
a	O
manifestation	O
of	O
neuralgic	B-DISO
amyotrophy	I-DISO
even	O
if	O
upper	O
limb	O
or	O
shoulder	O
girdle	O
palsies	O
are	O
absent	O
.	O

The	O
pandemic	O
influenza	B-DISO
outbreak	O
in	O
the	O
province	O
started	O
in	O
October	O
2009	O
(	O
week	O
44	O
)	O
in	O
students	O
who	O
had	O
returned	O
from	O
a	O
school	O
-	O
organized	O
trip	O
to	O
Prague	O
,	O
Bratislava	O
,	O
and	O
Vienna	O
.	O

Sentinel	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
and	O
SARI	O
surveillance	O
,	O
both	O
followed	O
with	O
virological	O
surveillance	O
,	O
seem	O
to	O
be	O
the	O
optimal	O
method	O
to	O
monitor	O
the	O
full	O
scope	O
of	O
the	O
influenza	B-DISO
pandemic	O
(	O
from	O
mild	O
to	O
severe	O
influenza	B-DISO
)	O
in	O
Vojvodina	O
.	O

TITLE	O
:	O
Circulation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strains	O
from	O
Italy	O
02	O
and	O
QX	O
genotypes	O
in	O
Slovenia	O
between	O
2007	O
and	O
2009	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
may	O
persist	O
in	O
the	O
airways	O
of	O
asthmatics	B-DISO
between	O
episodes	O
of	O
clinical	O
worsening	O
.	O

Rapid	O
identification	O
of	O
Panton	O
-	O
Valentine	O
leukocidin	O
in	O
methicillin	O
-	O
sensitive	O
S	O
.	O
aureus	O
isolates	O
causing	O
severe	O
infections	B-DISO
is	O
necessary	O
so	O
as	O
not	O
to	O
miss	O
their	O
potentially	O
devastating	O
consequences	O
.	O

TITLE	O
:	O
[	O
Clinical	O
characteristics	O
of	O
human	O
bocavirus	O
infection	B-DISO
in	O
90	O
children	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
characteristics	O
of	O
human	O
bocavirus	O
(	O
HBoV	O
)	O
infection	B-DISO
in	O
children	O
.	O

The	O
common	O
clinical	O
manifestations	O
of	O
HBoV	O
-	O
infected	O
patients	O
included	O
frequent	O
coughing	B-DISO
,	O
wheezing	B-DISO
and	O
fever	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
of	O
HBoV	O
with	O
other	O
respiratory	O
track	O
viruses	O
can	O
be	O
present	O
in	O
some	O
patients	O
.	O

In	O
Spain	O
,	O
75	O
%	O
of	O
the	O
crises	O
identified	O
by	O
senior	O
public	O
health	O
experts	O
from	O
the	O
Autonomous	O
Regions	O
involved	O
infectious	B-DISO
diseases	I-DISO
.	O

But	O
despite	O
improvement	O
in	O
our	O
understanding	O
of	O
the	O
therapy	O
and	O
supportive	O
care	O
for	O
patients	O
with	O
ARDS	B-DISO
,	O
mortality	O
remains	O
high	O
.	O

Bovine	O
parainfluenza	B-DISO
virus	O
type	O
3	O
,	O
feline	O
coronavirus	O
,	O
and	O
feline	O
calicivirus	O
were	O
used	O
as	O
models	O
for	O
other	O
important	O
avian	O
pathogens	O
,	O
such	O
as	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
and	O
avian	O
hepatitis	B-DISO
E	I-DISO
virus	O
.	O

The	O
average	O
time	O
from	O
the	O
beginning	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
to	O
the	O
admission	O
in	O
hospital	O
was	O
3	O
days	O
(	O
0	O
-	O
16	O
days	O
)	O
and	O
from	O
the	O
moment	O
of	O
hospitalization	O
to	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
admission	O
was	O
2	O
days	O
(	O
0	O
-	O
5	O
days	O
).	O

A	O
small	O
number	O
of	O
the	O
patients	O
develop	O
severe	O
illness	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
death	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
hospitalized	O
young	O
children	O
in	O
Northern	O
Taiwan	O
.	O

The	O
hMPV	O
group	O
had	O
higher	O
mixed	B-DISO
infection	I-DISO
rate	O
than	O
RSV	O
group	O
.	O

E	O
protein	O
was	O
mainly	O
found	O
in	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
)	O
of	O
cells	O
transfected	O
with	O
a	O
plasmid	O
encoding	O
E	O
protein	O
or	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
No	O
evidence	O
of	O
E	O
protein	O
presence	O
in	O
the	O
plasma	O
membrane	O
was	O
found	O
by	O
using	O
immunofluorescence	O
,	O
immunoelectron	O
microscopy	O
and	O
cell	O
surface	O
protein	O
labeling	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
associated	O
with	O
novel	O
H1N1	O
treated	O
with	O
intravenous	O
immunoglobulin	O
G	O
.	O
ABSTRACT	O
:	O
Influenza	B-DISO
A	O
""""	O
novel	O
H1N1	O
""""	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
serious	O
illness	O
that	O
poses	O
a	O
challenge	O
to	O
clinicians	O
managing	O
such	O
cases	O
.	O

This	O
case	O
report	O
reveals	O
a	O
patient	O
with	O
ARDS	B-DISO
secondary	O
to	O
influenza	B-DISO
A	O
with	O
deteriorating	O
clinical	O
status	O
,	O
who	O
improved	O
tremendously	O
after	O
intravenous	O
immunoglobulin	O
G	O
(	O
IV	O
IgG	O
).	O

TITLE	O
:	O
The	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
monophosphatase	O
domains	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
human	O
coronavirus	O
229E	O
mediate	O
resistance	O
to	O
antiviral	O
interferon	O
responses	O
.	O

Here	O
,	O
we	O
report	O
that	O
genetically	O
engineered	O
mutants	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
expressing	O
ADRP	O
-	O
deficient	O
macrodomains	O
displayed	O
an	O
increased	O
sensitivity	O
to	O
the	O
antiviral	O
effect	O
of	O
alpha	O
interferon	O
compared	O
with	O
their	O
wild	O
-	O
type	O
counterparts	O
.	O

The	O
data	O
suggest	O
that	O
macrodomain	O
-	O
associated	O
ADRP	O
activities	O
may	O
have	O
a	O
role	O
in	O
viral	O
escape	O
from	O
the	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
of	O
the	O
host	O
.	O

Intensive	O
therapy	O
of	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
A	O
H1N1	B-DISO
influenza	I-DISO
virus	O
requires	O
MV	O
which	O
should	O
be	O
carried	O
out	O
according	O
to	O
guidelines	O
of	O
international	O
expert	O
forums	O
.	O

Unexpectedly	O
,	O
we	O
found	O
a	O
positive	O
correlation	O
between	O
duration	O
of	O
MV	O
and	O
survival	O
although	O
two	O
patients	O
,	O
who	O
were	O
on	O
MV	O
for	O
the	O
longest	O
period	O
of	O
time	O
(	O
43	O
and	O
39	O
days	O
,	O
respectively	O
),	O
developed	O
,	O
as	O
a	O
complication	B-DISO
,	O
secondary	B-DISO
bacterial	I-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Differentiation	O
of	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
N	O
protein	O
using	O
a	O
virus	O
-	O
based	O
ELISA	O
.	O

TITLE	O
:	O
Inflammation	B-DISO
induced	O
by	O
infection	B-DISO
potentiates	O
tau	O
pathological	O
features	O
in	O
transgenic	O
mice	O
.	O

Researchers	O
have	O
recently	O
demonstrated	O
that	O
triggering	O
inflammation	B-DISO
in	O
the	O
brain	O
exacerbates	O
tau	O
pathological	O
characteristics	O
in	O
animal	O
models	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
value	O
of	O
adding	O
baseline	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
Fio₂	O
to	O
PaO₂	O
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
enrolled	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Network	O
clinical	O
trials	O
.	O

At	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Network	O
hospitals	O
,	O
the	O
addition	O
of	O
baseline	O
positive	O
end	O
-	O
expiratory	O
pressure	O
would	O
not	O
have	O
increased	O
the	O
value	O
of	O
PaO₂	O
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

TITLE	O
:	O
Comparative	O
pathogenesis	B-DISO
of	O
three	O
human	O
and	O
zoonotic	O
SARS	B-DISO
-	O
CoV	O
strains	O
in	O
cynomolgus	O
macaques	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
was	O
characterized	O
by	O
increased	O
pathogenicity	O
in	O
the	O
elderly	O
due	O
to	O
an	O
early	O
exacerbated	O
innate	O
host	O
response	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
patient	O
who	O
had	O
received	O
a	O
liver	O
transplant	O
.	O

Although	O
HFOV	O
has	O
failed	O
to	O
show	O
a	O
mortality	O
benefit	O
in	O
ARDS	B-DISO
patients	O
,	O
the	O
unique	O
lung	O
recruitment	B-DISO
by	O
HFOV	O
can	O
be	O
a	O
useful	O
therapeutic	O
option	O
for	O
severe	O
ARDS	B-DISO
patients	O
in	O
combination	O
with	O
sufficient	O
lung	O
rest	O
produced	O
by	O
ECMO	O
.	O

ABSTRACT	O
:	O
The	O
focus	O
of	O
this	O
protocol	O
is	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
with	O
occasional	O
references	O
to	O
other	O
coronaviruses	O
.	O

The	O
results	O
suggest	O
that	O
bundles	O
are	O
likely	O
with	O
the	O
second	O
TMD	B-DISO
facing	O
the	O
putative	O
pore	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
are	O
complex	O
illnesses	O
involving	O
the	O
interplay	O
of	O
both	O
environmental	O
(	O
such	O
as	O
mechanical	O
ventilation	O
)	O
and	O
genetic	O
factors	O
.	O

TITLE	O
:	O
[	O
Management	O
of	O
acute	O
and	O
severe	O
complications	O
in	O
adults	O
with	O
cystic	B-DISO
fibrosis	I-DISO
].	O

Nutritional	O
support	O
,	O
including	O
hypercaloric	O
diet	O
,	O
control	O
of	O
hyperglycemia	B-DISO
and	O
pancreatic	O
enzyme	O
supplementation	O
is	O
warranted	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
severe	O
posttraumatic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
complicated	O
by	O
bronchopleural	O
fistulae	O
(	O
BPF	O
).	O

The	O
stiff	O
ARDS	B-DISO
lung	O
and	O
huge	O
air	O
leaks	O
from	O
BPF	O
resulted	O
in	O
the	O
failure	O
of	O
different	O
protective	O
mechanical	O
ventilation	O
strategies	O
to	O
provide	O
viable	O
gas	O
exchange	O
.	O

Eight	O
accessory	O
proteins	O
of	O
SARS	B-DISO
coronavirus	O
were	O
the	O
suspected	O
players	O
in	O
the	O
pathogenesis	B-DISO
of	O
the	O
virus	O
.	O

We	O
have	O
previously	O
reported	O
that	O
ADAM17	O
is	O
able	O
to	O
mediate	O
the	O
cleavage	O
secretion	O
of	O
the	O
ectodomain	O
of	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
functional	O
receptor	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

TITLE	O
:	O
An	O
NFKB1	O
promoter	O
insertion	O
/	O
deletion	O
polymorphism	O
influences	O
risk	O
and	O
outcome	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
among	O
Caucasians	O
.	O

ABSTRACT	O
:	O
Nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
)	O
is	O
required	O
for	O
transcription	O
of	O
many	O
pro	O
-	O
inflammatory	O
genes	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
multivariate	O
analysis	O
,	O
patients	O
with	O
ARDS	B-DISO
and	O
the	O
del	O
/	O
del	O
genotype	O
also	O
had	O
increased	O
60	O
day	O
mortality	O
(	O
HR	O
1	O
.	O
54	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
36	O
)	O
and	O
more	O
severe	O
daily	O
organ	O
dysfunction	O
(	O
P	O
<.	O
001	O
)	O
when	O
compared	O
to	O
ARDS	B-DISO
patients	O
with	O
other	O
genotypes	O
.	O

TITLE	O
:	O
Action	O
mechanisms	O
of	O
lithium	O
chloride	O
on	O
cell	O
infection	B-DISO
by	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
a	O
porcine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Protocols	O
using	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
combination	O
with	O
low	O
tidal	O
volumes	O
have	O
been	O
shown	O
to	O
reduce	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Memory	O
T	O
cell	O
responses	O
to	O
a	O
pool	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
peptides	O
were	O
identified	O
in	O
14	O
of	O
23	O
(	O
60	O
.	O
9	O
%)	O
recovered	O
SARS	B-DISO
patients	O
,	O
whereas	O
there	O
was	O
no	O
such	O
specific	O
response	O
in	O
either	O
close	O
contacts	O
or	O
healthy	O
controls	O
.	O

In	O
contrast	O
,	O
specific	O
T	O
cell	O
anamnestic	O
responses	O
can	O
be	O
maintained	O
for	O
at	O
least	O
6	O
y	O
.	O
These	O
findings	O
have	O
applications	O
in	O
preparation	O
for	O
the	O
possible	O
reemergence	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
During	O
the	O
pandemy	O
caused	O
by	O
novel	O
influenza	B-DISO
A	O
virus	O
(	O
subgroup	O
H1N1	O
),	O
a	O
significant	O
number	O
of	O
patients	O
became	O
critically	B-DISO
ill	I-DISO
from	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
RBD	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
plays	O
important	O
roles	O
in	O
receptor	O
binding	O
and	O
induction	O
of	O
specific	O
neutralizing	O
antibodies	O
against	O
virus	B-DISO
infection	I-DISO
.	O

The	O
protocol	O
described	O
here	O
can	O
also	O
be	O
used	O
to	O
design	O
and	O
study	O
recombinant	O
subunit	O
vaccines	O
against	O
other	O
viruses	O
with	O
class	O
I	O
fusion	O
proteins	O
,	O
for	O
example	O
,	O
HIV	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
Ebola	O
virus	O
,	O
influenza	B-DISO
virus	O
,	O
as	O
well	O
as	O
Nipah	O
and	O
Handra	O
viruses	O
.	O

After	O
virtual	O
screening	O
of	O
about	O
80	O
,	O
000	O
compounds	O
against	O
the	O
SARS	B-DISO
-	O
pseudoknot	O
structure	O
,	O
high	O
-	O
ranked	O
compounds	O
were	O
selected	O
and	O
their	O
activities	O
were	O
examined	O
by	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
-	O
1	O
RF	O
assay	O
.	O

TITLE	O
:	O
The	O
rumouring	O
of	O
SARS	B-DISO
during	O
the	O
2003	O
epidemic	O
in	O
China	O
.	O

5H10	O
has	O
potential	O
for	O
use	O
in	O
prevention	O
and	O
treatment	O
of	O
SARS	B-DISO
if	O
it	O
reemerges	O
.	O

TITLE	O
:	O
Clinical	O
course	O
of	O
ICU	O
patients	O
with	O
severe	O
pandemic	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pneumonia	B-DISO
:	O
single	O
center	O
experience	O
with	O
proning	O
and	O
pressure	O
release	O
ventilation	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
different	O
modalities	O
have	O
been	O
employed	O
in	O
addition	O
to	O
conventional	O
ventilation	O
to	O
improve	O
oxygenation	O
in	O
patients	O
with	O
severe	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Ultrastructure	O
of	O
Felis	O
catus	O
whole	O
fetus	O
(	O
Fcwf	O
-	O
4	O
)	O
cell	O
culture	O
following	O
infection	B-DISO
with	O
feline	O
coronavirus	O
.	O

TITLE	O
:	O
Virally	O
expressed	O
interleukin	O
-	O
10	O
ameliorates	O
acute	O
encephalomyelitis	B-DISO
and	O
chronic	O
demyelination	B-DISO
in	O
coronavirus	O
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
absence	O
of	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
),	O
a	O
potent	O
anti	O
-	O
inflammatory	O
cytokine	O
results	O
in	O
increased	O
immune	O
-	O
mediated	O
demyelination	B-DISO
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
(	O
recombinant	O
J2	O
.	O
2	O
-	O
V	O
-	O
1	O
[	O
rJ2	O
.	O
2	O
]).	O

Additionally	O
,	O
IL	O
-	O
10	O
increased	O
both	O
the	O
frequency	O
and	O
number	O
of	O
Foxp3	O
(+)	O
regulatory	O
CD4	O
T	O
cells	O
in	O
the	O
infected	O
central	O
nervous	B-DISO
system	O
.	O

The	O
CoVs	O
,	O
including	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
encode	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
activity	O
(	O
ExoN	O
)	O
in	O
nsp14	O
.	O

The	O
results	O
of	O
a	O
virus	O
neutralization	O
assay	O
indicated	O
that	O
the	O
carboxyl	O
terminal	O
region	O
of	O
the	O
S1	O
protein	O
(	O
Mod4F	O
/	O
Epi4R	O
)	O
or	O
the	O
combined	O
carboxyl	O
terminal	O
S1	O
and	O
amino	O
terminal	O
S2	O
protein	O
(	O
4F	O
/	O
4R	O
)	O
possesses	B-DISO
the	O
neutralizing	O
epitopes	O
,	O
while	O
the	O
S2	O
fragment	O
(	O
6F	O
/	O
6R	O
)	O
contains	O
antigenic	O
epitopes	O
but	O
not	O
neutralizing	O
epitopes	O
.	O

The	O
role	O
of	O
fAPN	O
in	O
infection	B-DISO
of	O
in	O
vivo	O
target	O
cells	O
,	O
monocytes	O
,	O
is	O
not	O
yet	O
confirmed	O
.	O

Blocking	B-DISO
fAPN	O
reduced	O
FIPV	O
II	O
binding	O
by	O
53	O
%	O
and	O
infection	B-DISO
by	O
80	O
%.	O

These	O
results	O
suggest	O
the	O
possibility	O
of	O
designing	O
a	O
relatively	O
broad	O
-	O
spectrum	O
class	O
of	O
antiviral	O
peptides	O
that	O
can	O
reduce	O
the	O
effects	O
of	O
mixed	O
-	O
infections	B-DISO
.	O

Cytological	O
examination	O
of	O
pleural	O
exudates	O
revealed	O
severe	O
purulent	B-DISO
inflammation	I-DISO
with	O
abundant	O
clusters	O
of	O
rod	O
-	O
shaped	O
microorganisms	O
with	O
a	O
clear	O
surrounding	O
halo	O
.	O

Two	O
ferrets	O
were	O
subjected	O
to	O
necropsy	O
examination	O
,	O
which	O
revealed	O
pyothorax	B-DISO
,	O
mediastinal	B-DISO
lymphadenopathy	I-DISO
and	O
multiple	O
white	O
nodules	B-DISO
(	O
1	O
-	O
2mm	O
)	O
in	O
the	O
lungs	O
.	O

Microscopical	O
examination	O
showed	O
multifocal	O
necrotizing	O
-	O
pyogranulomatous	O
pleuropneumonia	B-DISO
and	O
lymphadenitis	B-DISO
with	O
aggregates	O
of	O
encapsulated	O
microorganisms	O
,	O
some	O
of	O
which	O
were	O
positively	O
stained	O
by	O
periodic	O
acid	O
-	O
Schiff	O
and	O
alcian	O
blue	O
.	O

TITLE	O
:	O
Inhibitors	O
of	O
SARS	B-DISO
-	O
3CLpro	O
:	O
virtual	O
screening	O
,	O
biological	O
evaluation	O
,	O
and	O
molecular	O
dynamics	O
simulation	O
studies	O
.	O

Complication	B-DISO
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
by	O
pneumonia	B-DISO
makes	O
patients	O
very	O
ill	B-DISO
due	O
to	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

Biomarkers	O
that	O
can	O
discriminate	O
the	O
presence	O
of	O
complicating	O
ALI	O
/	O
ARDS	B-DISO
are	O
required	O
for	O
early	O
detection	O
.	O

Among	O
these	O
patients	O
,	O
six	O
had	O
ALI	O
or	O
a	O
condition	B-DISO
that	O
was	O
clinically	O
comparable	O
to	O
ALI	O
(	O
cALI	O
).	O

RESULTS	O
:	O
Circulating	O
sES	O
levels	O
were	O
elevated	O
in	O
pneumonia	B-DISO
patients	O
with	O
ALI	O
/	O
cALI	O
,	O
and	O
sES	O
levels	O
decreased	O
following	O
treatment	O
of	O
their	O
pneumonia	B-DISO
.	O

However	O
,	O
the	O
potential	O
role	O
of	O
proteases	O
in	O
the	O
infection	B-DISO
process	O
remains	O
unclear	O
.	O

Radiographs	O
were	O
evaluated	O
for	O
consolidation	O
,	O
ground	O
-	O
glass	O
opacities	B-DISO
,	O
interstitial	O
patterns	O
,	O
distribution	O
,	O
and	O
extent	O
of	O
findings	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
kidney	O
transplantation	O
from	O
HBcAb	O
-	O
positive	O
donors	O
is	O
safe	O
with	O
a	O
low	O
rate	O
of	O
HBV	B-DISO
transmission	O
.	O

TITLE	O
:	O
Acute	O
physiologic	O
effects	O
of	O
a	O
stepwise	O
recruitment	B-DISO
maneuver	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Approximately	O
7	O
hours	O
after	O
aspiration	B-DISO
,	O
she	O
required	O
mechanical	O
ventilation	O
and	O
had	O
an	O
oxygenation	O
index	O
(	O
OI	O
)	O
of	O
13	O
.	O
2	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
amplify	O
and	O
diversify	O
the	O
autoimmune	B-DISO
response	I-DISO
restricted	O
to	O
FAH	O
through	O
the	O
use	O
of	O
the	O
exogenous	O
adjuvant	O
called	O
PADRE	O
.	O

9b	O
is	O
known	O
to	O
localize	O
in	O
the	O
extra	O
-	O
nuclear	O
region	O
and	O
has	O
been	O
postulated	O
to	O
possess	B-DISO
a	O
nuclear	O
export	O
signal	O
(	O
NES	O
),	O
however	O
the	O
role	O
of	O
NES	O
in	O
9b	O
functioning	O
is	O
not	O
well	O
understood	O
.	O

We	O
found	O
that	O
an	O
export	O
signal	O
deficient	O
SARS	B-DISO
-	O
CoV	O
9b	O
protein	O
induces	O
apoptosis	O
in	O
transiently	O
transfected	O
cells	O
and	O
showed	O
elevated	O
caspase	O
-	O
3	O
activity	O
.	O

Here	O
,	O
we	O
showed	O
that	O
nuclear	O
shuttling	O
of	O
9b	O
and	O
its	O
interaction	O
with	O
Crm1	O
are	O
essential	O
for	O
the	O
proper	O
degradation	O
of	O
9b	O
and	O
blocking	B-DISO
the	O
nuclear	O
export	O
of	O
this	O
protein	O
induces	O
apoptosis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
lesions	O
in	O
the	O
respiratory	O
tract	O
and	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
of	O
ferrets	O
(	O
n	O
=	O
8	O
)	O
inoculated	O
intranasally	O
with	O
influenza	B-DISO
virus	O
A	O
/	O
Indonesia	O
/	O
5	O
/	O
2005	O
(	O
H5N1	B-DISO
).	O

As	O
such	O
,	O
rabies	B-DISO
in	O
bats	O
has	O
been	O
largely	O
neglected	O
until	O
recently	O
.	O

Patients	O
with	O
cardiopulmonary	O
comorbidities	O
and	O
acute	O
GBS	B-DISO
-	O
like	O
onset	O
of	O
CIDP	B-DISO
may	O
be	O
at	O
higher	O
risk	O
of	O
ventilatory	B-DISO
failure	I-DISO
which	O
typically	O
responds	O
to	O
'	O
standard	O
'	O
treatments	O
of	O
CIDP	B-DISO
.	O

M	O
.	O
catarrhalis	O
(	O
96	O
%),	O
H	O
.	O
influenzae	O
(	O
91	O
%),	O
S	O
.	O
pneumoniae	O
(	O
89	O
%)	O
and	O
respiratory	O
viruses	O
(	O
59	O
%)	O
were	O
common	O
;	O
including	O
rhinovirus	O
(	O
HRV	O
)	O
(	O
38	O
%),	O
polyomavirus	O
(	O
HPyV	O
)	O
(	O
14	O
%),	O
adenovirus	B-DISO
(	O
HAdV	O
)	O
(	O
13	O
%),	O
bocavirus	O
(	O
HBoV	O
)	O
(	O
8	O
%)	O
and	O
coronavirus	O
(	O
HCoV	O
)	O
(	O
4	O
%).	O

RESULTS	O
:	O
M	O
.	O
catarrhalis	O
(	O
96	O
%),	O
H	O
.	O
influenzae	O
(	O
91	O
%),	O
S	O
.	O
pneumoniae	O
(	O
89	O
%)	O
and	O
respiratory	O
viruses	O
(	O
59	O
%)	O
were	O
common	O
;	O
including	O
rhinovirus	O
(	O
HRV	O
)	O
(	O
38	O
%),	O
polyomavirus	O
(	O
HPyV	O
)	O
(	O
14	O
%),	O
adenovirus	B-DISO
(	O
HAdV	O
)	O
(	O
13	O
%),	O
bocavirus	O
(	O
HBoV	O
)	O
(	O
8	O
%)	O
and	O
coronavirus	O
(	O
HCoV	O
)	O
(	O
4	O
%).	O

In	O
our	O
experience	O
,	O
respiratory	B-DISO
dysfunction	I-DISO
can	O
remain	O
isolated	O
but	O
may	O
also	O
be	O
associated	O
with	O
other	O
dysfunctions	O
or	O
complications	O
,	O
such	O
as	O
,	O
septic	B-DISO
shock	I-DISO
,	O
seizures	B-DISO
,	O
myasthenia	B-DISO
gravis	I-DISO
exacerbation	O
,	O
Guillan	O
-	O
Barre	O
syndrome	B-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
nosocomial	B-DISO
infections	I-DISO
and	O
biological	O
disturbances	O
.	O

However	O
,	O
the	O
epidemiological	O
data	O
regarding	O
the	O
MS	O
occurrence	O
rate	O
following	O
herpes	B-DISO
zoster	I-DISO
are	O
still	O
scanty	O
.	O

We	O
present	O
a	O
new	O
ultrasound	O
-	O
guided	O
technique	O
for	O
the	O
placement	O
of	O
a	O
dual	O
-	O
lumen	O
VV	O
-	O
ECMO	O
cannula	O
in	O
a	O
patient	O
with	O
ARDS	B-DISO
and	O
extreme	O
obesity	B-DISO
.	O

The	O
NIPPV	O
may	O
be	O
of	O
great	O
use	O
in	O
treating	O
patients	O
with	O
H1N1	O
-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
resource	O
poor	O
setting	O
or	O
when	O
invasive	O
ventilator	O
is	O
unavailable	O
.	O

Secondary	O
outcomes	O
included	O
the	O
development	O
of	O
individual	O
organ	B-DISO
failure	I-DISO
,	O
increased	O
ICU	O
and	O
hospital	O
length	O
of	O
stay	O
,	O
need	O
for	O
mechanical	O
ventilation	O
and	O
28	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
.	O

Among	O
the	O
synthesized	O
carbanucleosides	O
,	O
D	O
-	O
thymine	O
nucleoside	O
,	O
D	O
-	O
2	O
and	O
L	O
-	O
thymine	O
nucleoside	O
,	O
L	O
-	O
2	O
exhibited	O
excellent	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
and	O
-	O
2	O
activities	O
,	O
in	O
MT	O
-	O
4	O
cells	O
,	O
which	O
were	O
higher	O
than	O
those	O
of	O
ddI	O
,	O
an	O
anti	O
-	O
AIDS	O
drug	O
.	O

L	O
-	O
2	O
also	O
showed	O
weak	O
anti	O
-	O
HSV	O
-	O
2	O
activity	O
without	O
cytotoxicity	B-DISO
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
refractory	O
,	O
life	O
-	O
threatening	O
,	O
and	O
herpes	B-DISO
simplex	I-DISO
virus	O
1	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Near	O
-	O
normal	O
lung	O
structures	O
and	O
functions	O
were	O
documented	O
on	O
a	O
chest	O
x	O
-	O
ray	O
/	O
computed	O
tomography	O
,	O
thoracic	B-DISO
ultrasonography	O
,	O
and	O
pulmonary	O
functional	O
tests	O
at	O
hospital	O
discharge	O
and	O
at	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

Simple	O
pericardiocentesis	O
is	O
usually	O
sufficient	O
in	O
patients	O
with	O
acute	O
idiopathic	O
or	O
viral	B-DISO
pericarditis	I-DISO
.	O

Massive	O
chronic	O
idiopathic	O
pericardial	B-DISO
effusions	I-DISO
do	O
not	O
respond	O
to	O
medical	O
treatment	O
and	O
tend	O
to	O
recur	O
after	O
pericardiocentesis	O
,	O
so	O
wide	O
anterior	O
pericardiectomy	O
is	O
finally	O
necessary	O
in	O
many	O
cases	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
in	O
Vero	O
cells	O
is	O
facilitated	O
by	O
trypsin	O
through	O
an	O
undefined	O
mechanism	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
heart	I-DISO
failure	I-DISO
syndromes	B-DISO
(	O
AHFS	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
commonly	O
encountered	O
and	O
difficult	O
to	O
manage	O
clinical	O
syndromes	B-DISO
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

Respiratory	B-DISO
alkalosis	I-DISO
in	O
high	O
altitude	O
studies	O
cause	O
impairment	B-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
,	O
presumably	O
by	O
cerebral	B-DISO
vasoconstriction	I-DISO
.	O

The	O
authors	O
proposed	O
that	O
altitude	O
changes	O
from	O
travelling	O
to	O
the	O
moderately	O
high	O
altitude	O
and	O
cold	B-DISO
windy	O
winter	O
weather	O
were	O
the	O
predisposing	O
factors	O
for	O
the	O
attack	O
of	O
RCVS	O
.	O

To	O
address	O
this	O
,	O
children	O
less	O
than	O
5	O
years	O
of	O
age	O
with	O
respiratory	B-DISO
infections	I-DISO
from	O
3	O
public	O
sector	O
hospitals	O
,	O
Pretoria	O
South	O
Africa	O
were	O
screened	O
for	O
14	O
respiratory	O
viruses	O
,	O
by	O
PCR	O
over	O
2	O
years	O
.	O

Her	O
dyspnoea	B-DISO
improved	O
gradually	O
after	O
oxygen	O
use	O
.	O

ABSTRACT	O
:	O
Antiviral	O
antisepsis	O
and	O
disinfection	O
are	O
crucial	O
for	O
preventing	O
the	O
environmental	O
spread	O
of	O
viral	B-DISO
infections	I-DISO
.	O

This	O
unit	O
describes	O
a	O
global	O
methodology	O
for	O
evaluating	O
chemical	O
ATS	B-DISO
-	O
D	O
antiviral	O
activity	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
genome	O
contains	O
three	O
accessory	O
genes	O
:	O
3a	O
,	O
3b	O
and	O
7	O
.	O

Moreover	O
,	O
the	O
interaction	O
between	O
protein	O
7	O
and	O
PP1	O
was	O
required	O
,	O
during	O
the	O
infection	B-DISO
,	O
for	O
eIF2α	O
dephosphorylation	O
and	O
inhibition	O
of	O
cell	O
RNA	O
degradation	O
.	O

Inoculation	O
of	O
newborn	O
piglets	O
with	O
rTGEV	O
-	O
Δ7	O
and	O
rTGEV	O
-	O
wt	O
viruses	O
showed	O
that	O
rTGEV	O
-	O
Δ7	O
virus	O
presented	O
accelerated	O
growth	O
kinetics	O
and	O
pathology	B-DISO
compared	O
with	O
the	O
parental	O
virus	O
.	O

ABSTRACT	O
:	O
Drug	O
-	O
and	O
device	O
-	O
associated	O
hypersensitivity	B-DISO
reactions	I-DISO
are	O
serious	O
toxicities	O
that	O
can	O
result	O
in	O
respiratory	B-DISO
failure	I-DISO
or	O
acute	O
cardiac	O
ischemic	O
events	O
,	O
or	O
even	O
severe	O
hypersensitivity	B-DISO
syndromes	B-DISO
such	O
as	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
.	O

In	O
contrast	O
to	O
prior	O
studies	O
showing	O
no	O
activity	O
with	O
bacterially	O
produced	O
S	O
protein	O
,	O
results	O
indicated	O
that	O
polyclonal	O
serum	O
recognized	O
TGEV	O
-	O
infected	O
cells	O
and	O
reduced	O
infection	B-DISO
by	O
100	O
%.	O

As	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
developed	O
(	O
PaO2	O
/	O
Fio2	O
ratio	O
<	O
200	O
),	O
plateau	O
pressures	O
were	O
limited	O
to	O
<	O
35	O
cm	O
H2O	O
.	O

Furthermore	O
,	O
during	O
states	O
of	O
severe	O
gas	O
exchange	O
disturbance	O
or	O
impaired	B-DISO
neurological	O
conditions	O
with	O
the	O
threat	O
of	O
aspiration	B-DISO
or	O
cardiovascular	O
instability	O
,	O
it	O
is	O
a	O
life	O
-	O
saving	O
intervention	O
on	O
every	O
ICU	O
.	O

Even	O
the	O
induction	O
of	O
anaesthesia	B-DISO
disturbs	O
the	O
physiological	O
lung	O
function	O
,	O
due	O
to	O
changes	O
in	O
chest	O
wall	O
mechanics	O
and	O
diaphragm	O
relaxation	O
,	O
generating	O
atelectases	B-DISO
,	O
gas	O
exchange	O
disturbance	O
and	O
ventilation	O
-	O
perfusion	O
mismatch	O
.	O

Although	O
these	O
pathophysiological	O
changes	O
may	O
be	O
of	O
minor	O
importance	O
for	O
the	O
majority	O
of	O
ventilated	O
patients	O
in	O
the	O
operating	O
room	O
,	O
these	O
mechanisms	O
may	O
harm	O
patients	O
during	O
surgical	O
interventions	O
with	O
the	O
need	O
for	O
one	O
-	O
lung	O
ventilation	O
or	O
with	O
underlying	O
co	O
-	O
morbidities	O
such	O
as	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
future	O
research	O
should	O
focus	O
on	O
the	O
intracellular	O
signaling	O
pathways	O
that	O
mediate	O
ALI	O
development	O
,	O
potentially	O
focusing	O
on	O
the	O
role	O
of	O
reactive	O
biological	O
species	O
in	O
ALI	O
pathogenesis	B-DISO
.	O

Future	O
research	O
can	O
also	O
elucidate	O
how	O
such	O
pathways	O
may	O
be	O
targeted	O
by	O
hypercapnia	B-DISO
and	O
hypercapnic	B-DISO
acidosis	I-DISO
to	O
attenuate	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
usually	O
considered	O
not	O
indicated	O
for	O
treatment	O
of	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
because	O
of	O
the	O
theoretical	O
risk	O
of	O
air	B-DISO
trapping	I-DISO
and	O
hyperinflation	B-DISO
.	O

Viruses	O
carrying	O
the	O
(	O
131	O
)	O
ACA	O
(	O
133	O
)	O
deletion	O
were	O
heterogeneous	O
in	O
plaque	B-DISO
size	O
.	O

We	O
isolated	O
three	O
viruses	O
with	O
second	O
-	O
site	O
mutations	O
in	O
the	O
5	O
'	O
UTR	O
which	O
compensated	O
for	O
decreased	O
plaque	B-DISO
sizes	O
,	O
delayed	B-DISO
growth	I-DISO
kinetics	O
,	O
and	O
lower	O
titers	O
associated	O
with	O
the	O
(	O
131	O
)	O
ACA	O
(	O
133	O
)	O
deletion	O
.	O

These	O
results	O
suggest	O
that	O
the	O
proposed	O
SL4	O
in	O
the	O
MHV	O
5	O
'	O
UTR	O
functions	O
in	O
part	O
as	O
a	O
spacer	O
element	O
that	O
orients	O
SL1	O
,	O
SL2	O
,	O
and	O
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-DISO
),	O
and	O
this	O
spacer	O
function	O
may	O
play	O
an	O
important	O
role	O
in	O
directing	O
subgenomic	O
RNA	O
synthesis	O
.	O

The	O
existence	O
of	O
""""	O
distinct	O
circulating	O
avirulent	O
and	O
virulent	O
strains	O
""""	O
is	O
an	O
alternative	O
hypothesis	O
of	O
viral	B-DISO
pathogenesis	I-DISO
.	O

However	O
,	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
),	O
which	O
was	O
previously	O
absent	O
from	O
HiP	O
,	O
appears	O
to	O
have	O
been	O
introduced	O
into	O
the	O
lion	O
population	O
through	O
translocation	B-DISO
.	O

TITLE	O
:	O
Sweet	B-DISO
syndrome	I-DISO
,	O
cutis	B-DISO
laxa	I-DISO
,	O
and	O
fatal	O
cardiac	O
manifestations	O
in	O
a	O
2	O
-	O
year	O
-	O
old	O
girl	O
.	O

Inspection	O
on	O
autopsy	O
revealed	O
a	O
markedly	O
enlarged	O
heart	O
and	O
2	O
large	O
aneurysms	B-DISO
of	O
the	O
sinus	B-DISO
of	O
Valsalva	O
.	O

Histologic	O
analysis	O
disclosed	O
acute	B-DISO
necrosis	I-DISO
in	O
the	O
cardiac	O
apex	O
and	O
interventricular	O
septum	O
,	O
and	O
focal	O
chronic	O
inflammatory	O
and	O
granulation	O
tissue	O
in	O
the	O
aortic	O
wall	O
.	O

Because	O
cardiac	O
lesions	O
may	O
remain	O
clinically	O
silent	O
,	O
we	O
recommend	O
that	O
children	O
with	O
Sweet	B-DISO
syndrome	I-DISO
and	O
cutis	B-DISO
laxa	I-DISO
undergo	O
complete	O
cardiac	O
evaluation	O
,	O
including	O
2	O
-	O
dimensional	O
Doppler	O
echocardiography	O
,	O
by	O
a	O
pediatric	O
cardiologist	O
.	O

The	O
ensemble	O
of	O
succinylated	O
interferon	O
-	O
γ	O
with	O
two	O
modified	O
lysines	O
may	O
hold	O
promise	O
for	O
the	O
treatment	O
of	O
severe	O
viral	B-DISO
infections	I-DISO
with	O
fast	O
courses	O
,	O
such	O
as	O
influenza	B-DISO
and	O
the	O
diseases	O
caused	O
by	O
the	O
Ebola	O
,	O
Marburg	O
,	O
SARS	B-DISO
,	O
and	O
other	O
viruses	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
human	O
immune	O
system	O
could	O
tolerate	O
invasion	B-DISO
with	O
a	O
plant	O
virus	O
.	O

This	O
was	O
a	O
retrospective	O
case	O
series	O
of	O
13	O
consecutive	O
patients	O
with	O
established	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ICU	O
patients	O
with	O
ARDS	B-DISO
or	O
ALI	O
)	O
at	O
a	O
university	O
hospital	O
.	O

In	O
ARDS	B-DISO
,	O
the	O
primary	O
objective	O
of	O
PEEP	O
is	O
to	O
increase	O
the	O
amount	O
of	O
non	O
-	O
aerated	O
lung	O
at	O
the	O
end	O
of	O
expiration	O
.	O

TITLE	O
:	O
The	O
Italian	O
ECMO	O
network	O
experience	O
during	O
the	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
:	O
preparation	O
for	O
severe	O
respiratory	O
emergency	B-DISO
outbreaks	O
.	O

Between	O
August	O
2009	O
and	O
March	O
2010	O
,	O
153	O
critically	B-DISO
ill	I-DISO
patients	O
(	O
53	O
%	O
referred	O
from	O
other	O
hospitals	O
)	O
were	O
admitted	O
to	O
the	O
ECMOnet	O
ICU	O
with	O
suspected	O
H1N1	O
.	O

She	O
was	O
referred	O
for	O
generalized	B-DISO
weakness	I-DISO
,	O
found	O
in	O
hemodynamic	O
compromise	O
,	O
and	O
had	O
laboratory	O
data	O
significant	O
for	O
a	O
lithium	O
level	O
of	O
3	O
.	O
3	O
mmole	O
/	O
L	O
,	O
needing	O
emergent	O
hemodialysis	O
.	O

Subsequently	O
,	O
she	O
developed	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
requiring	O
intubation	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
that	O
lithium	O
is	O
a	O
likely	O
culprit	O
in	O
the	O
initiation	O
of	O
ARDS	B-DISO
and	O
propose	O
the	O
addition	O
of	O
ARDS	B-DISO
to	O
the	O
family	O
of	O
clinical	O
manifestations	O
of	O
severe	O
lithium	O
toxicity	O
.	O

TITLE	O
:	O
Super	O
-	O
spreaders	O
in	O
infectious	B-DISO
diseases	I-DISO
.	O

Predicting	O
and	O
identifying	O
super	O
-	O
spreaders	O
open	O
significant	O
medical	O
and	O
public	O
health	O
challenges	O
,	O
and	O
represent	O
important	O
facets	O
of	O
infectious	B-DISO
disease	I-DISO
management	O
and	O
pandemic	O
preparedness	O
plans	O
.	O

In	O
addition	O
to	O
retroviruses	O
,	O
many	O
structural	O
proteins	O
of	O
unrelated	O
viruses	O
,	O
including	O
influenza	B-DISO
M1	O
,	O
NEP	O
and	O
NP	O
proteins	O
,	O
38	O
Borna	B-DISO
disease	I-DISO
virus	O
N	O
and	O
P	O
proteins28	O
,	O
56	O
and	O
coronavirus	O
N	O
protein	O
,	O
23	O
,	O
57	O
undergo	O
nuclear	O
localization	O
and	O
bind	O
viral	O
RNAs	O
to	O
form	O
viral	O
ribonuclear	O
protein	O
(	O
RNP	O
)	O
complexes	O
that	O
are	O
exported	O
from	O
the	O
nucleus	O
for	O
packaging	O
into	O
virus	O
particles	O
.	O

HCWs	O
perceived	O
risk	O
factors	O
for	O
occupationally	O
acquired	O
infectious	B-DISO
diseases	I-DISO
to	O
be	O
1	O
.)	O
exposure	O
to	O
patients	O
with	O
undiagnosed	O
infections	B-DISO
2	O
.)	O

TITLE	O
:	O
Post	O
-	O
infection	B-DISO
immunocomplex	O
glomerulonephritis	B-DISO
and	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
in	O
a	O
patient	O
with	O
adult	B-DISO
Still	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
during	O
treatment	O
with	O
interleukin	O
1	O
receptor	O
antagonist	O
anakinra	O
:	O
a	O
case	O
report	O
.	O

A	O
27	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
with	O
known	O
adult	B-DISO
Still	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
was	O
admitted	O
to	O
our	O
hospital	O
for	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
due	O
to	O
Legionella	B-DISO
infection	I-DISO
,	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

Under	O
this	O
treatment	O
regimen	O
,	O
her	O
severe	B-DISO
edema	I-DISO
and	O
proteinuria	O
disappeared	O
.	O

The	O
median	O
time	O
from	O
symptom	B-DISO
onset	O
to	O
hospital	O
admission	O
was	O
6	O
days	O
(	O
interquartile	O
-	O
range	O
3	O
-	O
14	O
days	O
)	O
and	O
23	O
critically	B-DISO
ill	I-DISO
patients	O
were	O
admitted	O
to	O
Intensive	O
Care	O
Unit	O
after	O
admission	O
.	O

This	O
is	O
the	O
first	O
case	O
of	O
novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
Evans	B-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
prone	O
position	O
has	O
been	O
used	O
to	O
improve	O
oxygenation	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
since	O
1974	O
.	O

All	O
studies	O
with	O
the	O
prone	O
position	O
document	O
an	O
improvement	O
in	O
systemic	O
oxygenation	O
in	O
70	O
%	O
to	O
80	O
%	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
with	O
maximal	O
improvement	O
seen	O
in	O
the	O
most	O
hypoxemic	O
patients	O
.	O

Also	O
described	O
is	O
a	O
simple	O
,	O
safe	O
,	O
quick	O
,	O
and	O
inexpensive	O
procedure	O
used	O
to	O
prone	O
patients	O
with	O
severe	O
ARDS	B-DISO
on	O
a	O
standard	O
bed	B-DISO
in	O
the	O
intensive	O
care	O
unit	O
at	O
the	O
University	O
of	O
Michigan	O
.	O

Referral	O
to	O
a	O
specialized	O
center	O
with	O
ECMO	O
experience	O
should	O
be	O
considered	O
early	O
after	O
the	O
initiation	O
of	O
high	O
-	O
level	O
ventilator	O
support	O
in	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
:	O
diagnostic	O
approach	O
and	O
management	O
].	O

TITLE	O
:	O
Recombinational	O
histories	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
and	O
turkey	O
coronavirus	O
.	O

Our	O
results	O
showed	O
that	O
antigen	O
specific	O
CD8	O
(+)	O
T	O
cells	O
were	O
elicited	O
by	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
SARS	B-DISO
-	O
CoV	O
S	O
epitopes	O
.	O

An	O
H1N1	O
-	O
infection	B-DISO
was	O
confirmed	O
by	O
PCR	O
on	O
the	O
sixth	O
day	O
.	O

She	O
was	O
treated	O
for	O
influenza	B-DISO
,	O
which	O
was	O
isolated	O
repeatedly	O
from	O
oropharynx	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
later	O
empirically	O
for	O
lupus	B-DISO
pneumonitis	I-DISO
,	O
but	O
died	O
6	O
months	O
after	O
transplant	O
.	O

TITLE	O
:	O
Programmed	O
death	O
(	O
PD	O
)-	O
1	O
-	O
deficient	O
mice	O
are	O
extremely	O
sensitive	O
to	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
)	O
infection	B-DISO
.	O

In	O
addition	O
,	O
ns2	B-DISO
mutants	O
are	O
more	O
sensitive	O
than	O
wt	O
virus	O
to	O
pretreatment	O
of	O
BMM	O
,	O
but	O
not	O
L2	O
fibroblasts	O
or	O
primary	O
astrocytes	O
,	O
with	O
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
).	O

The	O
ns2	B-DISO
mutants	O
induced	O
similar	O
levels	O
of	O
IFN	O
-	O
α	O
/	O
β	O
in	O
wt	O
and	O
IFNAR	O
(-/-)	O
BMM	O
,	O
indicating	O
that	O
ns2	B-DISO
expression	O
has	O
no	O
effect	O
on	O
the	O
induction	O
of	O
IFN	O
but	O
rather	O
that	O
it	O
antagonizes	O
a	O
later	O
step	O
in	O
IFN	O
signaling	O
.	O

EC	O
-	O
SOD	O
attenuated	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
decreased	O
bronchoalveolar	O
lavage	O
neutrophil	O
counts	O
,	O
and	O
reduced	O
interleukin	O
-	O
6	O
and	O
CINC	O
-	O
1	O
concentrations	O
.	O

The	O
new	O
viruses	O
cause	O
respiratory	B-DISO
symptoms	I-DISO
like	O
the	O
common	B-DISO
cold	I-DISO
,	O
cough	B-DISO
,	O
bronchitis	B-DISO
,	O
bronchiolitis	B-DISO
,	O
exacerbations	O
of	O
asthma	B-DISO
and	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
pneumonia	B-DISO
.	O

Twenty	O
-	O
two	O
(	O
39	O
%)	O
had	O
severe	O
malaria	B-DISO
;	O
of	O
these	O
,	O
6	O
(	O
27	O
%)	O
died	O
.	O

These	O
chimeric	O
SARS	B-DISO
VLPs	O
have	O
a	O
similar	O
size	O
and	O
morphology	O
to	O
the	O
wild	O
type	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
tested	O
the	O
immunogenicity	O
and	O
protective	O
efficacy	O
of	O
purified	O
chimeric	O
SARS	B-DISO
VLPs	O
and	O
full	O
length	O
SARS	B-DISO
S	O
protein	O
vaccines	O
in	O
a	O
mouse	O
lethal	O
challenge	O
model	O
.	O

Likewise	O
,	O
the	O
SARS	B-DISO
VLP	O
vaccine	O
,	O
containing	O
4	O
μg	O
of	O
S	O
protein	O
without	O
adjuvant	O
,	O
reduced	O
lung	O
virus	O
titer	O
to	O
below	O
detectable	O
level	O
,	O
protected	O
mice	O
from	O
weight	O
loss	O
,	O
and	O
elicited	O
a	O
high	O
level	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
Sf9	O
cell	O
-	O
produced	O
full	O
length	O
purified	O
SARS	B-DISO
S	O
protein	O
was	O
also	O
an	O
effective	O
vaccine	O
against	O
SARS	B-DISO
-	O
CoV	O
but	O
only	O
when	O
co	O
-	O
administered	O
IM	O
with	O
aluminum	O
hydroxide	O
.	O

The	O
syndrome	B-DISO
rapidly	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
upon	O
reception	O
of	O
corticosteroids	O
in	O
low	O
doses	O
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
great	O
challenges	O
in	O
the	O
ecology	O
of	O
infectious	B-DISO
diseases	I-DISO
is	O
to	O
understand	O
what	O
drives	O
the	O
emergence	O
of	O
new	O
pathogens	O
including	O
the	O
relationship	O
between	O
viruses	O
and	O
their	O
hosts	O
.	O

In	O
the	O
case	O
of	O
the	O
emergence	O
of	O
SevereAcute	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
several	O
studies	O
have	O
shown	O
coronavirus	O
diversity	O
in	O
bats	O
as	O
well	O
as	O
the	O
existence	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
apparently	O
healthy	O
bats	O
,	O
suggesting	O
that	O
bats	O
may	O
be	O
a	O
crucial	O
host	O
in	O
the	O
genesis	O
of	O
this	O
disease	O
.	O

Reasons	O
for	O
stopping	O
high	O
-	O
frequency	O
oscillation	O
included	O
death	O
or	O
withdrawal	B-DISO
of	O
life	O
support	O
(	O
39	O
.	O
1	O
%),	O
significant	O
improvement	O
in	O
respiratory	B-DISO
failure	I-DISO
(	O
37	O
.	O
6	O
%),	O
and	O
inadequate	O
improvement	O
(	O
23	O
.	O
3	O
%).	O

Most	O
patients	O
treated	O
with	O
high	O
-	O
frequency	O
oscillation	O
have	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
severe	O
hypoxemia	O
that	O
modestly	O
improves	O
2	O
hrs	B-DISO
after	O
high	O
-	O
frequency	O
oscillation	O
application	O
.	O

ABSTRACT	O
:	O
Bat	O
coronaviruses	O
(	O
CoV	O
)	O
are	O
putative	O
precursors	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
CoV	O
and	O
other	O
CoV	O
that	O
crossed	O
the	O
species	O
barrier	O
from	O
zoonotic	O
reservoirs	O
into	O
the	O
human	O
population	O
.	O

ABSTRACT	O
:	O
Despite	O
advances	O
in	O
critical	O
care	O
facilities	O
and	O
ventilation	O
therapies	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
associated	O
with	O
high	O
mortality	O
rates	O
.	O

We	O
describe	O
here	O
the	O
introduction	O
and	O
advances	O
of	O
both	O
ECMO	O
and	O
PECLA	O
in	O
the	O
management	O
of	O
ARDS	B-DISO
.	O

This	O
paper	O
develops	O
such	O
a	O
model	O
of	O
behavioural	O
response	O
,	O
presenting	O
a	O
mathematical	O
interpretation	O
of	O
a	O
well	O
-	O
known	O
psychological	B-DISO
model	O
of	O
individual	O
decision	O
making	O
,	O
the	O
health	O
belief	O
model	O
,	O
suitable	O
for	O
incorporation	O
within	O
an	O
agent	O
-	O
based	O
disease	O
-	O
transmission	O
model	O
.	O

Antibody	O
-	O
mediated	O
infection	B-DISO
was	O
dependent	O
on	O
Fcγ	O
receptor	O
II	O
but	O
did	O
not	O
use	O
the	O
endosomal	O
/	O
lysosomal	O
pathway	O
utilized	O
by	O
angiotensin	O
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
accepted	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
This	O
suggests	O
that	O
ADE	O
of	O
SARS	B-DISO
-	O
CoV	O
utilizes	O
a	O
novel	O
cell	O
entry	O
mechanism	O
into	O
immune	O
cells	O
.	O

Cell	O
replacement	O
therapies	O
for	O
the	O
treatment	O
of	O
chronic	O
neurologic	B-DISO
diseases	I-DISO
are	O
now	O
a	O
reality	O
and	O
in	O
vivo	O
models	O
are	O
vital	O
in	O
understanding	O
the	O
interactions	O
between	O
the	O
engrafted	O
cells	O
and	O
host	O
tissue	O
microenvironment	O
.	O

Of	O
the	O
51	O
universities	O
evaluated	O
,	O
only	O
9	O
(	O
17	O
.	O
6	O
%)	O
either	O
had	O
no	O
influenza	B-DISO
Web	B-DISO
site	O
or	O
had	O
a	O
university	O
influenza	B-DISO
preparedness	O
plan	B-DISO
with	O
no	O
dedicated	O
Web	B-DISO
site	O
.	O

TITLE	O
:	O
Novel	O
interventional	O
approaches	O
for	O
ALI	O
/	O
ARDS	B-DISO
:	O
cell	O
-	O
based	O
gene	O
therapy	O
.	O

This	O
property	O
was	O
shared	O
with	O
nsp6	O
of	O
mammalian	O
coronaviruses	O
Mouse	B-DISO
Hepatitis	I-DISO
Virus	O
,	O
and	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Virus	O
,	O
and	O
the	O
equivalent	O
nsp5	O
-	O
7	O
of	O
the	O
arterivirus	O
Porcine	B-DISO
Reproductive	I-DISO
and	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Virus	O
.	O

The	O
vesicles	B-DISO
recruited	O
double	O
FYVE	O
-	O
domain	O
containing	O
protein	O
(	O
DFCP	O
)	O
indicating	O
localised	O
concentration	O
of	O
phosphatidylinositol	O
3	O
phosphate	O
,	O
and	O
therefore	O
shared	O
many	O
features	O
with	O
omegasomes	O
formed	O
from	O
the	O
ER	O
in	O
response	O
to	O
starvation	O
.	O

Furthermore	O
,	O
myeloid	O
cell	O
depletion	O
implicated	O
MMP9	O
in	O
facilitating	O
leukocyte	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
infiltration	B-DISO
via	O
loss	O
of	O
BBB	O
integrity	O
.	O

Although	O
MMP9	O
deficiency	O
did	O
not	O
expand	O
the	O
overall	O
limited	O
pattern	O
of	O
MMP	O
expression	O
during	O
JHMV	O
infection	B-DISO
,	O
it	O
coincided	O
with	O
MMP3	O
upregulation	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
are	O
one	O
of	O
the	O
main	O
causes	O
of	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
humans	O
.	O

Notably	O
,	O
XendoU	O
family	O
members	O
have	O
been	O
implicated	O
in	O
human	O
pathologies	O
such	O
as	O
cancer	B-DISO
and	O
respiratory	B-DISO
diseases	I-DISO
:	O
PP11	O
is	O
aberrantly	O
expressed	O
in	O
various	O
tumors	B-DISO
,	O
while	O
NendoU	O
activity	O
has	O
been	O
associated	O
with	O
respiratory	B-DISO
infections	I-DISO
by	O
pathogenic	O
coronaviruses	O
.	O

The	O
subjects	O
of	O
this	O
study	O
were	O
31	O
pediatric	O
patients	O
who	O
needed	O
mechanical	O
ventilation	O
due	O
to	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
influenza	B-DISO
(	O
H1N1	O
)	O
2009	O
as	O
reported	O
to	O
the	O
Emergency	B-DISO
Medical	O
Information	O
Center	O
of	O
the	O
Japan	O
Pediatric	O
Society	O
in	O
Kanagawa	O
Prefecture	O
in	O
Japan	O
from	O
August	O
1	O
to	O
December	O
31	O
,	O
2009	O
.	O

The	O
diagnosis	O
of	O
influenza	B-DISO
(	O
H1N1	O
)	O
2009	O
infection	B-DISO
was	O
based	O
on	O
positive	O
results	O
of	O
a	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
of	O
asthma	B-DISO
in	I-DISO
children	I-DISO
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
(	O
SCD	B-DISO
)	O
were	O
based	O
on	O
reports	O
of	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-DISO
with	O
limited	O
description	O
of	O
asthma	B-DISO
features	O
.	O

Doctor	O
-	O
diagnoses	O
of	O
asthma	B-DISO
may	O
represent	O
asthma	B-DISO
or	O
wheezing	B-DISO
unrelated	O
to	O
asthma	B-DISO
.	O

A	O
dominant	O
memory	O
CD8	O
+	O
T	O
cell	O
response	O
against	O
SARS	B-DISO
-	O
CoV	O
nucleocaspid	O
protein	O
(	O
NP	O
;	O
amino	O
acids	O
216	O
to	O
225	O
)	O
was	O
then	O
defined	O
in	O
SARS	B-DISO
-	O
recovered	O
individuals	O
carrying	O
HLA	O
-	O
B	O
*	O
40	O
:	O
01	O
,	O
a	O
HLA	O
-	O
B	O
molecule	O
present	O
in	O
approximately	O
one	O
-	O
quarter	O
of	O
subjects	O
of	O
Asian	O
ethnicities	O
.	O

With	O
several	O
prognostic	O
indicators	O
(	O
including	O
status	O
myoclonus	B-DISO
)	O
having	O
been	O
validated	O
in	O
the	O
pre	O
-	O
hypothermia	O
era	O
,	O
their	O
current	O
relevance	O
is	O
debatable	O
.	O

Although	O
FE	O
has	O
been	O
described	O
in	O
other	O
animal	O
models	O
,	O
this	O
study	O
represents	O
the	O
first	O
reported	O
cases	O
of	O
FE	O
and	O
bone	O
marrow	B-DISO
embolism	I-DISO
in	O
nonhuman	O
primates	O
.	O

TITLE	O
:	O
17β	O
-	O
Estradiol	O
administration	O
attenuates	O
seawater	O
aspiration	B-DISO
-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

The	O
seawater	O
aspiration	B-DISO
group	O
also	O
presented	O
with	O
severe	O
pulmonary	B-DISO
edema	I-DISO
which	O
was	O
paralleled	O
with	O
over	O
expressed	O
AQP1	O
and	O
AQP5	O
.	O

ABSTRACT	O
:	O
Deep	O
neck	O
infections	B-DISO
(	O
DNI	O
)	O
are	O
potentially	O
lethal	O
processes	O
and	O
are	O
susceptible	O
to	O
severe	O
complications	O
.	O

The	O
mayor	O
complications	O
were	O
mediastinitis	B-DISO
,	O
septic	B-DISO
shock	I-DISO
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
syndrome	B-DISO
,	O
necrotising	B-DISO
fasciitis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

A	O
lower	O
cranial	B-DISO
nerve	I-DISO
palsy	I-DISO
that	O
develops	O
into	O
dysphagia	B-DISO
and	O
leukoencephalopathy	B-DISO
are	O
the	O
most	O
frequent	O
sequela	O
.	O

A	O
Cesarean	O
delivery	O
was	O
performed	O
under	O
deep	O
general	O
anesthesia	B-DISO
with	O
high	O
-	O
dose	O
opioid	O
administration	O
to	O
avoid	O
tachycardia	O
and	O
hypertension	B-DISO
during	O
tracheal	O
intubation	O
and	O
obstetric	O
surgery	O
.	O

Deep	O
general	O
anesthesia	B-DISO
for	O
emergency	B-DISO
Cesarean	O
delivery	O
while	O
accepting	O
the	O
risk	O
of	O
respiratory	B-DISO
depression	I-DISO
in	O
the	O
newborn	O
is	O
a	O
viable	O
option	O
for	O
the	O
anesthetic	O
management	O
of	O
life	O
-	O
threatening	O
events	O
such	O
as	O
Stanford	O
type	O
A	O
dissection	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
liver	I-DISO
failure	I-DISO
is	O
a	O
very	O
complex	O
type	O
of	O
disease	O
with	O
a	O
mortality	O
of	O
up	O
to	O
90	O
%,	O
leading	O
to	O
numerous	O
severe	O
disturbances	O
of	O
the	O
whole	O
organism	O
.	O

TITLE	O
:	O
Pulmonary	B-DISO
complications	I-DISO
in	O
pregnancy	O
:	O
considerations	O
for	O
care	O
.	O

We	O
also	O
compared	O
respiratory	O
deterioration	O
rates	O
,	O
need	O
for	O
ventilation	O
and	O
nosocomial	B-DISO
infections	I-DISO
.	O

Clinical	O
applications	O
of	O
NMBAs	O
in	O
intensive	O
care	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
immobilizing	O
patients	O
for	O
procedural	O
interventions	O
,	O
decreasing	O
oxygen	O
consumption	O
,	O
facilitating	O
mechanical	O
ventilation	O
,	O
reducing	O
intracranial	O
pressure	O
,	O
preventing	O
shivering	O
,	O
and	O
management	O
of	O
tetanus	B-DISO
.	O

New	O
data	O
are	O
available	O
regarding	O
the	O
use	O
of	O
these	O
agents	O
for	O
treatment	O
of	O
ALI	O
/	O
ARDS	B-DISO
and	O
status	B-DISO
asthmaticus	I-DISO
,	O
management	O
of	O
elevated	O
ICP	B-DISO
,	O
and	O
provision	O
of	O
therapeutic	O
hypothermia	O
after	O
cardiac	B-DISO
arrest	I-DISO
.	O

The	O
study	O
of	O
infectious	B-DISO
disease	I-DISO
has	O
depended	O
on	O
strategies	O
for	O
integrating	O
patterns	O
of	O
observed	O
disease	O
incidence	O
with	O
mechanistic	O
process	O
models	O
since	O
John	O
Snow	O
first	O
mapped	O
cholera	B-DISO
cases	O
around	O
a	O
London	O
water	O
pump	O
in	O
1854	O
.	O

We	O
use	O
four	O
case	O
studies	O
to	O
demonstrate	O
that	O
advances	O
in	O
disease	O
forecasting	O
require	O
better	O
understanding	O
of	O
zoonotic	O
host	O
and	O
vector	O
populations	O
,	O
as	O
well	O
of	O
the	O
dynamics	O
that	O
facilitate	O
pathogen	O
amplification	B-DISO
and	O
disease	O
spillover	O
into	O
humans	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
pathogenesis	B-DISO
of	O
infection	B-DISO
caused	O
by	O
this	O
infectious	B-DISO
bronchitis	B-DISO
variant	O
and	O
to	O
be	O
able	O
to	O
support	O
the	O
poultry	O
industry	O
with	O
substantiated	O
advice	O
to	O
prevent	O
or	O
decrease	O
the	O
damage	O
caused	O
by	O
the	O
D388	O
strain	O
,	O
several	O
vaccination	O
and	O
challenge	O
experiments	O
were	O
performed	O
in	O
young	O
specific	O
pathogen	O
free	O
layers	O
,	O
young	O
layers	O
with	O
maternally	O
derived	O
antibodies	O
against	O
the	O
D388	O
strain	O
and	O
young	O
commercial	O
broiler	O
breeders	O
.	O

Together	O
,	O
these	O
observations	O
provide	O
new	O
insight	O
into	O
the	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
entry	O
and	O
suggest	O
that	O
HR2	O
may	O
be	O
an	O
attractive	O
target	O
for	O
therapeutic	O
intervention	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
),	O
herein	O
we	O
report	O
the	O
design	O
and	O
microwave	O
-	O
assisted	O
synthesis	O
of	O
a	O
novel	O
series	O
of	O
1	O
-	O
H	O
-	O
benzylindole	O
derivatives	O
.	O

ABSTRACT	O
:	O
Viruses	O
are	O
the	O
major	O
cause	O
of	O
pediatric	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
and	O
yet	O
many	O
suspected	O
cases	O
of	O
illness	O
remain	O
uncharacterized	O
.	O

Antileukocyte	O
antibodies	O
in	O
blood	O
donors	O
plasma	O
,	O
caused	O
TRALI	B-DISO
in	O
89	O
%	O
of	O
cases	O
;	O
also	O
it	O
has	O
been	O
found	O
antigen	O
specificity	O
against	O
leukocyte	O
blood	O
receptor	O
in	O
59	O
%.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
the	O
S1	O
glycoprotein	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
in	O
China	O
during	O
2009	O
-	O
2010	O
.	O

TITLE	O
:	O
Massive	O
systemic	O
air	O
embolism	B-DISO
during	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
of	O
a	O
neonate	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
cardiac	O
surgery	O
.	O

Here	O
we	O
describe	O
the	O
evolution	O
of	O
the	O
respiratory	O
compromise	O
,	O
ventilatory	O
management	O
and	O
laboratory	O
variables	O
of	O
patients	O
with	O
diffuse	O
viral	B-DISO
pneumonitis	I-DISO
caused	O
by	O
pandemic	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
admitted	O
to	O
the	O
ICU	O
.	O

This	O
was	O
a	O
multicenter	O
,	O
prospective	O
inception	O
cohort	O
study	O
including	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
admitted	O
to	O
20	O
ICUs	O
in	O
Argentina	O
between	O
June	O
and	O
September	O
of	O
2009	O
during	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
.	O

At	O
all	O
time	O
points	O
,	O
pH	O
,	O
platelet	O
count	O
,	O
lactate	O
dehydrogenase	O
assay	O
(	O
LDH	O
)	O
and	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
differed	O
significantly	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
.	O

Persistence	O
of	O
thrombocytopenia	O
,	O
acidosis	B-DISO
and	O
leukocytosis	B-DISO
,	O
and	O
high	O
LDH	O
levels	O
found	O
in	O
non	O
-	O
survivors	O
during	O
the	O
course	O
of	O
the	O
disease	O
might	O
be	O
novel	O
prognostic	O
findings	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
(	O
RVIs	O
)	O
are	O
common	O
causes	O
of	O
mild	O
illness	O
in	O
immunocompetent	O
children	O
and	O
adults	O
with	O
rare	O
occurrences	O
of	O
significant	O
morbidity	O
or	O
mortality	O
.	O

TITLE	O
:	O
[	O
Respiratory	B-DISO
disorders	I-DISO
in	O
preterm	O
and	O
term	O
neonates	O
:	O
an	O
update	O
on	O
diagnostics	O
and	O
therapy	O
].	O

Further	O
disorders	O
in	O
term	O
neonates	O
include	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
and	O
congenital	B-DISO
diaphragmatic	I-DISO
hernia	I-DISO
leading	O
to	O
impaired	B-DISO
gas	I-DISO
exchange	I-DISO
and	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

ABSTRACT	O
:	O
Sustained	O
high	O
-	O
efficiency	O
daily	O
diafiltration	O
using	O
a	O
mediator	O
-	O
adsorbing	O
membrane	O
(	O
SHEDD	O
-	O
fA	O
)	O
is	O
an	O
effective	O
,	O
intensive	O
modality	O
for	O
sepsis	B-DISO
treatment	O
.	O

55	O
consecutive	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
were	O
studied	O
.	O

We	O
demonstrate	O
that	O
SHEDD	O
-	O
fA	O
may	O
be	O
an	O
effective	O
,	O
intensive	O
modality	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
is	O
a	O
possible	O
modality	O
for	O
cytokine	O
modulation	O
therapy	O
.	O

ABSTRACT	O
:	O
The	O
effect	O
of	O
sialodacryoadenitis	O
virus	O
(	O
SDAV	O
)	O
infection	B-DISO
on	O
axonal	O
regeneration	O
and	O
functional	B-DISO
recovery	I-DISO
was	O
investigated	O
in	O
male	O
Lewis	O
rats	O
.	O

After	O
separation	B-DISO
of	O
the	O
nanoparticle	O
-	O
protein	O
complex	O
from	O
plasma	O
,	O
the	O
protein	O
mixture	O
was	O
digested	O
,	O
and	O
peptides	O
were	O
analyzed	O
by	O
nanoliquid	O
chromatography	O
-	O
Orbitrap	O
LTQ	O
-	O
XL	O
mass	O
spectrometry	O
.	O

ABSTRACT	O
:	O
Caspase	O
-	O
8	O
(	O
casp8	O
)	O
is	O
required	O
for	O
extrinsic	O
apoptosis	O
,	O
and	O
mice	O
deficient	O
in	O
casp8	O
fail	O
to	O
develop	O
and	O
die	O
in	O
utero	O
while	O
ultimately	O
failing	O
to	O
maintain	O
the	O
proliferation	B-DISO
of	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
a	O
host	O
of	O
other	O
cell	O
types	O
.	O

Paradoxically	O
,	O
these	O
failures	O
are	O
not	O
caused	O
by	O
a	O
defect	O
in	O
apoptosis	O
,	O
but	O
by	O
a	O
presumed	O
proliferative	B-DISO
function	O
of	O
this	O
protease	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
caspase	O
-	O
mediated	O
cleavage	O
of	O
RIPK1	O
-	O
containing	O
necrosis	O
inducing	O
complexes	O
(	O
necrosomes	O
)	O
is	O
sufficient	O
to	O
prevent	O
necroptosis	B-DISO
in	O
the	O
face	B-DISO
of	O
death	O
receptor	O
signaling	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
use	O
of	O
urine	O
dopamine	O
and	O
catecholamine	O
concentrations	O
as	O
diagnostic	O
aids	O
in	O
a	O
patient	O
with	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
(	O
NMS	B-DISO
)	O
in	O
the	O
emergency	B-DISO
department	O
setting	O
.	O

This	O
develops	O
as	O
a	O
complication	B-DISO
due	O
to	O
viral	B-DISO
infections	I-DISO
,	O
and	O
drug	B-DISO
abuse	I-DISO
.	O

We	O
enrolled	O
125	O
(	O
first	O
period	O
,	O
n	O
=	O
54	O
)	O
patients	O
with	O
arterial	O
oxygen	O
tension	B-DISO
(	O
P	O
(	O
a	O
,	O
O	O
(	O
2	O
)))/	O
inspiratory	O
oxygen	O
fraction	O
(	O
F	O
(	O
I	O
,	O
O	O
(	O
2	O
)))	O
of	O
<	O
150	O
mmHg	O
for	O
>	O
12	O
consecutive	O
hours	O
at	O
an	O
end	O
-	O
expiratory	O
pressure	O
of	O
≥	O
8	O
cmH	B-DISO
(	O
2	O
)	O
O	O
.	O
Patients	O
were	O
randomly	O
assigned	O
to	O
an	O
HFO	O
-	O
TGI	O
group	O
(	O
receiving	O
HFO	O
-	O
TGI	O
sessions	O
with	O
RMs	O
,	O
interspersed	O
with	O
lung	O
-	O
protective	O
CMV	O
;	O
n	O
=	O
61	O
)	O
or	O
CMV	O
group	O
(	O
receiving	O
lung	O
-	O
protective	O
CMV	O
and	O
RMs	O
;	O
n	O
=	O
64	O
).	O

However	O
,	O
the	O
most	O
lung	O
protective	O
tidal	O
volume	O
in	O
association	O
with	O
hypercapnia	B-DISO
is	O
unknown	O
.	O

Occupational	O
health	O
and	O
safety	O
issues	O
anticipated	O
by	O
Canadian	O
nurses	O
for	O
future	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
outbreaks	O
were	O
grouped	O
into	O
four	O
major	O
themes	O
:	O
(	O
1	O
)	O
apprehension	O
about	O
occupational	O
risks	O
to	O
pregnant	O
nurses	O
;	O
(	O
2	O
)	O
unknown	O
pregnancy	O
risks	O
of	O
anti	O
-	O
infective	O
therapy	O
/	O
prophylaxis	O
;	O
(	O
3	O
)	O
occupational	O
risk	O
communication	O
for	O
pregnant	O
nurses	O
;	O
and	O
(	O
4	O
)	O
human	O
resource	O
strategies	O
required	O
for	O
pregnant	O
nurses	O
during	O
outbreaks	O
.	O

Reproductive	O
risk	O
assessments	O
should	O
be	O
performed	O
for	O
each	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
outbreak	O
to	O
provide	O
female	O
healthcare	O
workers	O
and	O
in	O
particular	O
pregnant	O
women	O
with	O
guidelines	O
regarding	O
infection	B-DISO
control	O
and	O
use	O
of	O
anti	O
-	O
infective	O
therapy	O
and	O
prophylaxis	O
.	O

In	O
our	O
prospective	O
non	O
-	O
controlled	O
trial	O
,	O
we	O
enrolled	O
patients	O
with	O
severe	O
neurological	B-DISO
symptoms	I-DISO
and	O
confirmed	O
recent	O
E	O
coli	O
O104	O
:	O
H4	O
infection	B-DISO
without	O
other	O
acute	O
bacterial	B-DISO
infection	I-DISO
or	O
raised	O
procalcitonin	O
concentrations	O
.	O

In	O
non	O
-	O
intubated	O
patients	O
,	O
improvement	O
was	O
apparent	O
during	O
immunoadsorption	O
(	O
eg	O
,	O
disappearance	O
of	O
aphasia	B-DISO
).	O

Antibodies	O
are	O
probably	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	O
neurological	B-DISO
symptoms	I-DISO
in	O
patients	O
with	O
E	O
coli	O
O104	O
:	O
H4	O
-	O
induced	O
haemolytic	B-DISO
uraemic	I-DISO
syndrome	I-DISO
.	O

Conversely	O
,	O
a	O
down	O
regulation	O
of	O
ChPLA2	O
-	O
IB	O
,	O
-	O
IIA	O
and	O
-	O
X	O
was	O
observed	O
in	O
lungs	O
and	O
spleen	O
in	O
case	O
of	O
infectious	B-DISO
bronchitis	B-DISO
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
objectively	O
the	O
impact	O
of	O
wearing	O
N95	O
face	B-DISO
masks	O
on	O
breathing	O
resistance	O
.	O

A	O
total	O
of	O
ten	O
tag	B-DISO
SNPs	O
were	O
selected	O
and	O
genotyped	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
only	O
rs2248690	O
(	O
AOR	O
,	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
-	O
2	O
.	O
04	O
)	O
was	O
found	O
to	O
be	O
associated	O
with	O
SARS	B-DISO
susceptibility	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
led	O
to	O
a	O
rapid	O
response	O
not	O
only	O
to	O
contain	O
the	O
outbreak	O
but	O
also	O
to	O
identify	O
possible	O
therapeutic	O
interventions	O
,	O
including	O
the	O
generation	O
of	O
human	O
monoclonal	O
antibodies	O
(	O
hmAbs	O
).	O

According	O
to	O
recent	O
systematic	O
reviews	O
,	O
evidence	O
is	O
sufficient	O
for	O
cognitive	B-DISO
impairments	I-DISO
caused	O
by	O
low	O
lead	O
exposure	O
levels	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
exposure	O
of	O
captive	O
wild	O
felids	O
to	O
various	O
infectious	B-DISO
pathogens	O
using	O
serological	O
and	O
molecular	O
methods	O
.	O

ABSTRACT	O
:	O
Human	O
metapneumovirus	O
(	O
hMPV	O
)	O
and	O
the	O
Netherlands	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
NL63	O
)	O
have	O
been	O
isolated	O
from	O
children	O
with	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

All	O
children	O
infected	O
with	O
HCoV	O
-	O
NL63	O
had	O
underlying	O
conditions	O
;	O
1	O
of	O
the	O
4	O
patients	O
developed	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
frequency	O
and	O
clinical	O
significance	O
of	O
polymicrobial	O
aetiology	O
in	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
patients	O
admitted	O
to	O
the	O
ICU	O
have	O
been	O
poorly	O
studied	O
.	O

Chronic	B-DISO
respiratory	I-DISO
disease	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
criteria	O
were	O
independent	O
predictors	O
of	O
polymicrobial	O
aetiology	O
.	O

The	O
predefined	O
composite	O
endpoint	O
was	O
the	O
occurrence	O
of	O
any	O
of	O
the	O
following	O
:	O
death	O
(	O
any	O
cause	O
),	O
cardiac	O
dysfunction	O
(	O
myocardial	B-DISO
infarction	I-DISO
or	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
),	O
cerebral	B-DISO
dysfunction	I-DISO
(	O
stroke	B-DISO
or	O
encephalopathy	B-DISO
),	O
renal	O
dysfunction	O
(	O
dysfunction	O
or	O
failure	O
),	O
or	O
pulmonary	O
dysfunction	O
(	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
).	O

An	O
ATR	O
-	O
dependent	O
cellular	O
DNA	B-DISO
damage	I-DISO
response	O
was	O
shown	O
to	O
be	O
activated	O
by	O
IBV	O
infection	B-DISO
.	O

RESULTS	O
:	O
From	O
26	O
April	O
2009	O
to	O
11	O
January	O
2010	O
,	O
confirmed	O
cases	O
of	O
pandemic	O
2009	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
reached	O
806	O
.	O

In	O
some	O
conditions	O
,	O
such	O
as	O
bronchiolitis	B-DISO
,	O
cystic	B-DISO
fibrosis	I-DISO
,	O
and	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
,	O
their	O
use	O
is	O
controversial	O
and	O
is	O
not	O
recommended	O
routinely	O
.	O

ABSTRACT	O
:	O
In	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
the	O
envelope	O
heptad	O
repeat	O
2	O
(	O
HR2	O
)	O
plays	O
a	O
critical	O
role	O
in	O
viral	O
entry	O
.	O

TITLE	O
:	O
[	O
Causes	O
,	O
complications	O
and	O
risk	O
factors	O
of	O
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
)].	O

Performances	O
of	O
four	O
different	O
types	O
of	O
facemask	O
fits	B-DISO
,	O
varying	O
from	O
ideal	O
to	O
normal	O
wearing	O
practice	O
,	O
were	O
also	O
investigated	O
.	O

In	O
young	O
and	O
1	O
-	O
year	O
-	O
old	O
animals	O
,	O
we	O
demonstrate	O
that	O
adjuvanted	O
DIV	O
vaccine	O
provides	O
protection	O
against	O
lethal	O
disease	O
in	O
young	O
animals	O
following	O
homologous	O
and	O
heterologous	O
challenge	O
,	O
although	O
enhanced	O
immune	O
pathology	B-DISO
and	O
eosinophilia	B-DISO
are	O
evident	O
following	O
heterologous	O
challenge	O
.	O

TITLE	O
:	O
Clinical	O
features	O
in	O
a	O
series	O
of	O
fast	O
channel	O
congenital	B-DISO
myasthenia	I-DISO
syndrome	B-DISO
.	O

The	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
increased	O
by	O
grade	O
of	O
injury	O
:	O
0	O
,	O
22	O
,	O
57	O
,	O
and	O
80	O
%,	O
respectively	O
,	O
at	O
24	O
hours	O
(	O
P	O
<	O
.	O
01	O
),	O
and	O
remained	O
statistically	O
different	O
at	O
48	O
and	O
72	O
hours	O
.	O

These	O
acids	O
have	O
a	O
double	O
effect	O
on	O
the	O
lungs	O
:	O
a	O
direct	O
toxicity	O
with	O
severe	O
inflammation	B-DISO
of	O
the	O
mucosa	O
leading	O
to	O
alveolar	O
haemorrhage	B-DISO
and	O
subsequently	O
the	O
acid	O
anhydrides	O
may	O
lead	O
to	O
the	O
syndrome	B-DISO
of	O
intra	B-DISO
-	I-DISO
alveolar	I-DISO
haemorrhage	I-DISO
and	O
anaemia	B-DISO
described	O
in	O
occupational	O
lung	B-DISO
diseases	I-DISO
by	O
Herbert	O
in	O
Oxford	O
in	O
1979	O
.	O

ABSTRACT	O
:	O
Guillain	B-DISO
-	I-DISO
Barre	I-DISO
Syndrome	I-DISO
(	O
GBS	B-DISO
)	O
is	O
an	O
acute	O
polyradidulonevritis	O
which	O
is	O
primitive	O
inflammatory	O
and	O
demyelinisant	O
.	O

Acute	O
Respiratory	B-DISO
disorder	I-DISO
is	O
the	O
most	O
severe	O
complication	B-DISO
this	O
syndrome	B-DISO
can	O
lead	O
to	O
in	O
5	O
%	O
of	O
cases	O
.	O

The	O
course	O
of	O
the	O
disease	O
is	O
often	O
mild	O
and	O
severe	O
scars	B-DISO
are	O
only	O
encountered	O
in	O
5	O
to	O
10	O
%	O
of	O
cases	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
Korean	O
cats	O
with	O
natural	O
feline	O
coronavirus	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
is	O
comprised	O
of	O
two	O
pathogenic	O
biotypes	O
consisting	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
and	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
),	O
which	O
are	O
both	O
divided	O
into	O
two	O
serotypes	O
.	O

ABSTRACT	O
:	O
We	O
aimed	O
at	O
synchronously	O
examining	O
the	O
early	O
time	O
course	O
of	O
4	O
proinflammatory	O
cytokines	O
as	O
predictive	O
factors	O
for	O
development	O
of	O
organ	B-DISO
failure	I-DISO
in	O
patients	O
with	O
acute	B-DISO
pancreatitis	I-DISO
(	O
AP	O
).	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoV	O
)	O
are	O
recognized	O
respiratory	O
pathogens	O
,	O
and	O
some	O
strains	O
,	O
including	O
HCoV	O
-	O
OC43	O
,	O
can	O
infect	O
human	O
neuronal	O
and	O
glial	O
cells	O
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
and	O
activate	O
neuroinflammatory	O
mechanisms	O
.	O

ABSTRACT	O
:	O
Induction	O
of	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
is	O
a	O
crucial	O
cellular	O
process	O
that	O
detects	O
and	O
controls	O
the	O
invading	O
viruses	O
at	O
early	O
stages	O
of	O
the	O
infection	B-DISO
.	O

Several	O
countries	O
are	O
expanding	O
access	O
to	O
voluntary	O
medical	O
male	O
circumcision	O
to	O
reduce	O
HIV	B-DISO
prevalence	O
.	O

The	O
study	O
enrolled	O
all	O
patients	O
who	O
were	O
diagnosed	O
with	O
PC	O
on	O
admission	O
by	O
CT	O
and	O
had	O
a	O
chest	O
Abbreviated	O
Injury	O
Score	O
(	O
AIS	B-DISO
)	O
exceeding	O
2	O
between	O
January	O
1	O
,	O
2010	O
,	O
and	O
October	O
31	O
,	O
2010	O
.	O

The	O
admission	O
partial	O
pressure	O
of	O
oxygen	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
PC	O
volume	O
percentage	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
were	O
independent	O
predictive	O
factors	O
of	O
ARDS	B-DISO
development	O
.	O

The	O
partial	O
pressure	O
of	O
oxygen	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
,	O
the	O
needed	O
maximal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
level	O
,	O
and	O
ARDS	B-DISO
incidence	O
between	O
the	O
severe	O
group	O
and	O
the	O
general	O
group	O
was	O
significantly	O
different	O
(	O
p	O
<.	O
05	O
).	O

APE1	O
is	O
able	O
to	O
cleave	O
CD44	O
mRNA	O
,	O
microRNAs	O
(	O
miR	O
-	O
21	O
,	O
miR	O
-	O
10b	O
),	O
and	O
three	O
RNA	O
components	O
of	O
SARS	B-DISO
-	O
corona	O
virus	O
(	O
orf1b	O
,	O
orf3	O
,	O
spike	O
)	O
suggesting	O
that	O
,	O
when	O
challenged	O
,	O
it	O
can	O
cleave	O
any	O
RNAs	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Pre	B-DISO
-	I-DISO
eclampsia	I-DISO
/	O
Eclampsia	B-DISO
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
maternal	O
and	O
perinatal	B-DISO
morbidity	I-DISO
and	O
mortality	O
in	O
sub	O
-	O
Saharan	O
Africa	O
including	O
Nigeria	O
.	O

Activation	O
of	O
viral	O
glycoprotein	O
(	O
GP	O
)	O
by	O
protease	O
also	O
has	O
been	O
reported	O
for	O
influenza	B-DISO
virus	O
.	O

TITLE	O
:	O
Referral	O
to	O
an	O
extracorporeal	O
membrane	O
oxygenation	O
center	O
and	O
mortality	O
among	O
patients	O
with	O
severe	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
).	O

The	O
ECMO	O
-	O
referred	O
patients	O
and	O
the	O
non	O
-	O
ECMO	O
-	O
referred	O
patients	O
were	O
matched	O
using	O
data	O
from	O
a	O
concurrent	O
,	O
longitudinal	O
cohort	O
study	O
(	O
Swine	B-DISO
Flu	I-DISO
Triage	O
study	O
)	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
suspected	O
or	O
confirmed	O
H1N1	O
.	O

During	O
9	O
days	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
,	O
the	O
patient	O
had	O
diabetes	B-DISO
decompensation	O
,	O
haemorrhagic	B-DISO
pneumonia	I-DISO
,	O
rhabdomyolysis	B-DISO
,	O
respiratory	O
and	O
renal	B-DISO
failure	I-DISO
,	O
pericarditis	B-DISO
,	O
and	O
brain	B-DISO
edema	I-DISO
and	O
died	O
.	O

Ocular	O
sequelae	O
may	O
appear	O
after	O
the	O
acute	O
period	O
and	O
they	O
can	O
be	O
extremely	O
disabling	O
,	O
even	O
causing	O
almost	O
complete	O
loss	B-DISO
of	I-DISO
vision	I-DISO
.	O

Evidence	O
from	O
several	O
studies	O
indicates	O
that	O
a	O
complex	O
network	O
of	O
inflammatory	O
cytokines	O
and	O
mediators	O
play	O
a	O
key	O
role	O
in	O
mediation	O
,	O
amplification	B-DISO
,	O
and	O
perpetuation	O
of	O
the	O
process	O
of	O
lung	O
injury	O
and	O
that	O
the	O
thoracotomy	O
itself	O
is	O
a	O
risk	O
factor	O
for	O
developing	O
ALI	O
or	O
ARDS	B-DISO
.	O

HAT	O
cleaved	O
SARS	B-DISO
-	O
S	O
at	O
R667	O
,	O
as	O
determined	O
by	O
mutagenesis	O
and	O
mass	O
spectrometry	O
,	O
and	O
activated	O
SARS	B-DISO
-	O
S	O
for	O
cell	O
-	O
cell	O
fusion	O
in	O
cis	B-DISO
and	O
trans	O
,	O
while	O
the	O
related	O
pulmonary	O
protease	O
TMPRSS2	O
cleaved	O
SARS	B-DISO
-	O
S	O
at	O
multiple	O
sites	O
and	O
activated	O
SARS	B-DISO
-	O
S	O
only	O
in	O
trans	O
.	O

Similar	O
to	O
other	O
human	O
coronaviruses	O
,	O
HCoV	O
-	O
HKU1	O
infections	B-DISO
have	O
been	O
reported	O
globally	O
,	O
with	O
a	O
median	O
(	O
range	O
)	O
incidence	O
of	O
0	O
.	O
9	O
(	O
0	O
-	O
4	O
.	O
4	O
)	O
%.	O

Although	O
3c	O
gene	O
mutants	O
in	O
this	O
study	O
were	O
not	O
horizontally	O
transmitted	B-DISO
,	O
the	O
parental	O
fecal	O
virus	O
was	O
readily	O
transmitted	B-DISO
by	O
contact	O
from	O
a	O
cat	O
that	O
died	O
of	O
FIP	B-DISO
to	O
its	O
housemate	O
.	O

Molecular	O
clock	O
analysis	O
using	O
various	O
gene	O
loci	O
revealed	O
that	O
the	O
time	O
of	O
most	O
recent	O
common	O
ancestor	O
of	O
human	O
/	O
civet	O
SARS	B-DISO
related	O
coronavirus	O
to	O
be	O
1999	O
-	O
2002	O
,	O
with	O
estimated	O
substitution	O
rate	O
of	O
4	O
×	O
10	O
(-	O
4	O
)	O
to	O
2	O
×	O
10	O
(-	O
2	O
)	O
substitutions	O
per	O
site	O
per	O
year	O
.	O

In	O
this	O
study	O
,	O
the	O
full	O
-	O
length	O
genomes	O
of	O
eight	O
avian	O
gamma	O
-	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
were	O
sequenced	O
and	O
along	O
with	O
other	O
full	O
-	O
length	O
IBV	O
genomes	O
available	O
from	O
GenBank	O
were	O
analyzed	O
for	O
recombination	O
.	O

In	O
a	O
suburban	O
US	O
community	O
with	O
high	O
access	O
to	O
critical	O
care	O
services	O
,	O
cumulative	O
incidences	O
of	O
critical	O
care	O
syndromes	B-DISO
and	O
life	O
-	O
support	O
interventions	O
were	O
higher	O
than	O
previously	O
reported	O
.	O

Among	O
viruses	O
detectable	O
by	O
both	O
commercial	O
assays	O
(	O
adenovirus	B-DISO
,	O
human	O
metapneumovirus	O
,	O
influenza	B-DISO
A	O
virus	O
,	O
influenza	B-DISO
B	O
virus	O
,	O
parainfluenza	B-DISO
viruses	O
1	O
to	O
3	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
),	O
the	O
FilmArray	O
and	O
Prodesse	O
assays	O
showed	O
good	O
overall	O
agreement	O
(	O
181	O
/	O
192	O
[	O
94	O
.	O
3	O
%];	O
kappa	O
=	O
0	O
.	O
87	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
79	O
to	O
0	O
.	O
94	O
).	O

In	O
this	O
population	O
of	O
young	O
children	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
RV	O
/	O
EV	O
accounted	O
for	O
the	O
majority	O
of	O
the	O
additional	O
pathogens	O
detected	O
by	O
FilmArray	O
RP	O
.	O

TITLE	O
:	O
Surfactant	O
therapy	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
in	O
severe	O
pediatric	O
burn	O
injury	O
:	O
a	O
case	O
series	O
.	O

Its	O
role	O
in	O
susceptibility	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
not	O
been	O
well	O
defined	O
.	O

Plasma	O
angiotensin	O
-	O
II	O
levels	O
were	O
associated	O
with	O
genotype	O
in	O
the	O
ARDS	B-DISO
group	O
,	O
but	O
not	O
controls	O
,	O
being	O
higher	O
in	O
D	O
allele	O
carriers	O
(	O
p	O
=	O
0	O
.	O
016	O
).	O

We	O
review	O
several	O
approaches	O
referred	O
to	O
as	O
""""	O
rescue	O
""""	O
therapies	O
for	O
severe	O
hypoxemia	O
,	O
including	O
lung	O
-	O
recruitment	B-DISO
maneuvers	O
,	O
ventilation	O
modes	O
,	O
prone	O
positioning	O
,	O
inhaled	O
vasodilator	O
therapy	O
,	O
and	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

The	O
outcomes	O
of	O
these	O
patients	O
,	O
for	O
whom	O
endotracheal	O
intubation	O
is	O
not	O
mandatory	O
,	O
depend	O
on	O
the	O
degree	O
of	O
hypoxia	B-DISO
,	O
the	O
presence	O
of	O
comorbidities	O
and	O
complications	O
,	O
and	O
their	O
illness	O
severity	O
.	O

TITLE	O
:	O
Crosstalk	O
between	O
innate	O
and	O
adaptive	O
immune	O
responses	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
after	O
vaccination	O
and	O
challenge	O
of	O
chickens	O
varying	O
in	O
serum	O
mannose	O
-	O
binding	O
lectin	O
concentrations	O
.	O

The	O
primary	O
IBV	O
infection	B-DISO
induced	I-DISO
changes	O
in	O
circulating	O
T	O
-	O
cell	O
populations	O
and	O
in	O
the	O
specific	O
antibody	O
responses	O
.	O

ABSTRACT	O
:	O
The	O
influenza	B-DISO
pandemic	O
of	O
2009	O
was	O
reported	O
to	O
be	O
frequently	O
associated	O
with	O
pulmonary	B-DISO
complications	I-DISO
,	O
including	O
ARDS	B-DISO
.	O

On	O
admission	O
,	O
she	O
was	O
deeply	O
unconscious	O
(	O
GCS	O
5	O
),	O
hypotonic	B-DISO
and	O
anuric	O
.	O

During	O
the	O
2009	O
pandemic	O
,	O
a	O
high	O
number	O
of	O
pulmonary	B-DISO
complications	I-DISO
were	O
observed	O
all	O
over	O
the	O
world	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
proapoptotic	O
proteins	O
BAX	O
,	O
cytochrome	O
c	O
(	O
CytC	O
),	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
were	O
relocalized	O
toward	O
the	O
mitochondria	O
,	O
cytosol	O
,	O
and	O
nucleus	O
,	O
respectively	O
,	O
after	O
infection	B-DISO
by	O
both	O
virus	O
variants	O
.	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
low	O
molecular	O
weight	O
peptide	O
-	O
based	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
)	O
protease	O
inhibitors	O
are	O
described	O
.	O

Structural	O
optimization	O
was	O
carried	O
out	O
based	O
on	O
X	O
-	O
ray	O
crystallographic	O
analyses	O
of	O
the	O
R188I	O
SARS	B-DISO
3CL	O
protease	O
in	O
a	O
complex	O
with	O
each	O
inhibitor	O
to	O
provide	O
a	O
tetrapeptide	O
aldehyde	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
98	O
nM	O
.	O
The	O
resulting	O
compound	O
carried	O
no	O
substrate	O
sequence	O
,	O
except	O
for	O
a	O
P	O
(	O
3	O
)	O
site	O
directed	O
toward	O
the	O
outside	O
of	O
the	O
protease	O
.	O

One	O
of	O
these	O
children	O
had	O
diagnosis	O
criteria	O
for	O
acute	O
lung	O
injury	O
,	O
another	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
one	O
child	O
,	O
NAVA	O
facilitated	O
the	O
management	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
extensive	O
subcutaneous	B-DISO
emphysema	I-DISO
.	O

Moderate	O
levels	O
of	O
haemolysis	B-DISO
had	O
a	O
similar	O
,	O
but	O
less	O
consistent	O
,	O
effect	O
to	O
that	O
of	O
severe	O
haemolysis	B-DISO
,	O
producing	O
results	O
that	O
were	O
significantly	O
different	O
from	O
the	O
reference	O
standard	O
only	O
for	O
the	O
IBV	O
(	O
less	O
positive	O
)	O
and	O
AEV	O
(	O
more	O
positive	O
)	O
ELISAs	O
.	O

Twenty	O
adult	O
patients	O
(	O
nine	O
women	O
and	O
11	O
men	O
;	O
mean	O
age	O
43	O
.	O
5	O
±	O
16	O
.	O
4	O
years	O
)	O
with	O
a	O
diagnosis	O
of	O
H1N1	O
infection	B-DISO
confirmed	O
by	O
pharyngeal	O
swab	O
came	O
to	O
our	O
attention	O
from	O
September	O
to	O
November	O
2009	O
and	O
were	O
followed	O
up	O
until	O
September	O
2010	O
.	O

In	O
patients	O
with	O
H1N1	O
pneumonia	B-DISO
,	O
post	O
-	O
ARDS	B-DISO
pulmonary	B-DISO
fibrosis	I-DISO
is	O
not	O
a	O
rare	O
complication	B-DISO
.	O

Our	O
study	O
demonstrated	O
that	O
in	O
these	O
patients	O
,	O
fibrosis	B-DISO
could	O
present	O
a	O
different	O
spatial	O
distribution	O
and	O
a	O
different	O
temporal	O
trend	O
,	O
with	O
delayed	O
late	O
onset	O
;	O
moreover	O
,	O
in	O
one	O
case	O
,	O
the	O
signs	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
partially	O
regressed	O
over	O
time	O
.	O

A	O
unique	O
feature	O
for	O
SARS	B-DISO
-	O
CoV	O
is	O
that	O
nsp16	O
requires	O
non	O
-	O
structural	O
protein	O
nsp10	O
as	O
a	O
stimulatory	O
factor	O
to	O
execute	O
its	O
MTase	O
activity	O
.	O

After	O
severe	O
trauma	O
,	O
an	O
enteral	O
immuno	O
-	O
enhancing	O
diet	O
,	O
enriched	O
with	O
arginine	O
,	O
omega	O
-	O
3	O
fatty	O
acids	O
,	O
and	O
nucleotides	O
,	O
decreases	O
infectious	B-DISO
complications	O
.	O

ABSTRACT	O
:	O
Hospitalists	O
often	O
treat	O
patients	O
with	O
severe	O
acute	O
hypertension	B-DISO
(	O
AH	O
)	O
presenting	O
to	O
the	O
hospital	O
.	O

This	O
review	O
summarizes	O
interdisciplinary	O
current	O
knowledge	O
in	O
regard	O
to	O
virology	O
,	O
immunology	O
,	O
pathology	B-DISO
,	O
diagnostics	O
,	O
and	O
treatment	O
options	O
in	O
the	O
context	O
of	O
multicat	O
environments	O
.	O

It	O
was	O
also	O
associated	O
with	O
decreased	O
morbidity	O
,	O
which	O
included	O
increased	O
ventilator	O
-	O
free	O
days	O
,	O
increased	O
ICU	O
-	O
free	O
days	O
,	O
and	O
increased	O
organ	B-DISO
failure	I-DISO
-	O
free	O
days	O
.	O

These	O
benefits	O
occurred	O
without	O
increasing	O
the	O
incidence	O
of	O
ICU	O
-	O
acquired	O
weakness	B-DISO
.	O

Most	O
patients	O
coming	O
for	O
care	O
had	O
typical	O
,	O
influenza	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
with	O
fever	O
(	O
98	O
.	O
8	O
%),	O
cough	B-DISO
(	O
92	O
.	O
6	O
%)	O
and	O
rhinorrhea	B-DISO
(	O
74	O
.	O
1	O
%).	O

Early	O
therapy	O
with	O
oseltamivir	O
in	O
severely	O
ill	B-DISO
patients	O
,	O
without	O
waiting	O
for	O
laboratory	O
confirmation	O
for	O
diagnosis	O
,	O
will	O
save	O
patients	O
from	O
severe	O
complications	O
.	O

However	O
,	O
in	O
some	O
instances	O
,	O
especially	O
if	O
syringomyelia	B-DISO
is	O
associated	O
,	O
an	O
abrupt	O
clinical	O
onset	O
is	O
reported	O
and	O
is	O
accompanied	O
by	O
an	O
acknowledged	O
risk	O
of	O
potentially	O
severe	O
clinical	O
signs	O
or	O
even	O
sudden	B-DISO
death	I-DISO
.	O

The	O
authors	O
describe	O
3	O
challenging	O
cases	O
of	O
the	O
abrupt	O
onset	O
of	O
CM	O
-	O
I	O
/	O
syringomyelia	B-DISO
to	O
reveal	O
more	O
information	O
on	O
the	O
clinical	O
presentation	O
and	O
pathogenetic	O
mechanisms	O
of	O
this	O
sudden	O
and	O
potentially	O
severe	O
clinical	O
phenomenon	O
:	O
a	O
38	O
-	O
year	O
-	O
old	O
man	O
experienced	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
intubation	O
following	O
acute	O
decompensation	O
of	O
hydrocephalus	B-DISO
associated	O
with	O
Noonan	B-DISO
syndrome	I-DISO
,	O
a	O
1	O
-	O
year	O
-	O
old	O
boy	O
had	O
sudden	O
hemiparesis	B-DISO
and	O
Horner	B-DISO
syndrome	I-DISO
after	O
a	O
minor	O
head	O
/	O
neck	O
injury	O
,	O
and	O
a	O
2	O
.	O
5	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
quickly	O
progressing	O
tetraplegia	B-DISO
and	O
dyspnea	B-DISO
after	O
a	O
mild	O
flexion	O
and	O
extension	O
neck	O
injury	O
a	O
few	O
hours	O
before	O
.	O

The	O
levels	O
of	O
oxidative	O
biomarker	O
8	O
-	O
oxo	O
-	O
dG	O
in	O
the	O
lung	O
and	O
liver	O
were	O
significantly	O
decreased	O
on	O
day	O
2	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
but	O
the	O
marker	O
in	O
the	O
liver	O
increased	O
abruptly	O
after	O
day	O
3	O
of	O
hyperoxia	B-DISO
when	O
the	O
mortality	O
increased	O
.	O

Preclinical	O
studies	O
suggest	O
that	O
cellular	O
therapies	O
may	O
offer	O
unique	O
and	O
effective	O
alternatives	O
for	O
respiratory	B-DISO
diseases	I-DISO
that	O
currently	O
have	O
limited	O
(	O
or	O
no	O
)	O
treatment	O
options	O
.	O

A	O
retrospective	O
chart	O
review	O
was	O
conducted	O
on	O
the	O
medical	O
records	O
of	O
400	O
intensive	O
care	O
patients	O
who	O
were	O
admitted	O
to	O
the	O
ICU	O
three	O
months	O
before	O
and	O
during	O
the	O
2003	O
SARS	B-DISO
outbreak	O
.	O

The	O
rate	O
of	O
HAIs	O
was	O
higher	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
period	O
than	O
the	O
SARS	B-DISO
period	O
.	O

ABSTRACT	O
:	O
Clonally	O
expanded	O
CD8	O
(+)	O
T	O
lymphocytes	O
are	O
present	O
in	O
multiple	B-DISO
sclerosis	I-DISO
lesions	O
,	O
as	O
well	O
as	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
patients	O
with	O
multiple	B-DISO
sclerosis	I-DISO
.	O

Finally	O
,	O
we	O
show	O
that	O
in	O
vitro	O
migration	O
of	O
CD8	O
(+)	O
T	O
lymphocytes	O
across	O
blood	O
-	O
brain	O
barrier	O
-	O
endothelial	O
cells	O
is	O
dependent	O
on	O
α4	O
integrin	O
,	O
but	O
independent	O
of	O
intercellular	O
adhesion	B-DISO
molecule	O
-	O
1	O
/	O
leucocyte	O
function	O
-	O
associated	O
antigen	O
-	O
1	O
,	O
activated	O
leucocyte	O
cell	O
adhesion	B-DISO
molecule	O
/	O
CD6	O
and	O
the	O
chemokine	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
/	O
CCL2	O
.	O

Among	O
the	O
related	O
salicyloylanilides	O
,	O
the	O
m	O
-	O
fluorophenyl	O
analogue	O
was	O
most	O
promising	O
;	O
niclosamide	O
and	O
close	O
analogues	O
suffered	B-DISO
from	O
very	O
low	O
solubility	O
and	O
bioavailability	O
.	O

Conditions	O
such	O
as	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
and	O
toxoplasmosis	B-DISO
are	O
of	O
global	O
significance	O
.	O

Acknowledging	O
that	O
the	O
critical	O
care	O
needs	O
of	O
children	O
during	O
disasters	O
were	O
unaddressed	O
by	O
this	O
effort	O
,	O
a	O
17	O
-	O
member	O
Steering	O
Committee	O
,	O
assembled	O
by	O
the	O
Oak	B-DISO
Ridge	O
Institute	O
for	O
Science	O
and	O
Education	O
with	O
guidance	O
from	O
members	O
of	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
,	O
convened	O
in	O
April	O
2009	O
to	O
determine	O
priority	O
topic	O
areas	O
for	O
pediatric	O
emergency	B-DISO
mass	O
critical	O
care	O
recommendations	O
.	O

Since	O
young	O
and	O
aged	O
(	O
1	O
-	O
year	O
-	O
old	O
)	O
mice	O
do	O
not	O
develop	O
severe	O
clinical	O
disease	O
following	O
infection	B-DISO
with	O
wild	O
-	O
type	O
SARS	B-DISO
-	O
CoV	O
,	O
a	O
mouse	O
-	O
adapted	O
strain	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
called	O
MA15	O
)	O
was	O
developed	O
and	O
was	O
shown	O
to	O
cause	O
lethal	O
infection	B-DISO
in	O
these	O
animals	O
.	O

ABSTRACT	O
:	O
The	O
new	O
strain	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
,	O
often	O
referred	O
to	O
colloquially	O
as	O
""""	O
swine	B-DISO
flu	I-DISO
""","	O
which	O
was	O
first	O
detected	O
in	O
April	O
2009	O
,	O
raised	O
to	O
a	O
pandemic	O
of	O
which	O
the	O
impact	O
was	O
not	O
completely	O
predictable	O
.	O

The	O
adipose	O
COPD	B-DISO
-	O
patient	O
died	O
due	O
to	O
septic	B-DISO
shock	I-DISO
with	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
without	O
possibility	O
for	O
ECMO	O
support	O
.	O

Osteonecrosis	B-DISO
risk	O
was	O
<	O
1	O
%	O
in	O
patients	O
receiving	O
<	O
3	O
g	O
and	O
13	O
%	O
in	O
patients	O
receiving	O
>	O
3	O
g	O
cumulative	O
prednisolone	O
-	O
equivalent	O
dose	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
severe	O
form	O
of	O
respiratory	B-DISO
failure	I-DISO
characterized	O
by	O
acute	O
onset	O
of	O
significant	O
hypoxaemia	O
(	O
PaO2	O
:	O
FiO2	O
<	O
200mmHg	O
)	O
with	O
diffuse	O
bilateral	O
pulmonary	O
air	O
-	O
space	O
shadowing	O
on	O
chest	O
X	O
-	O
ray	O
,	O
without	O
clinical	O
signs	O
of	O
heart	B-DISO
failure	I-DISO
(	O
Bernard	O
et	O
al	O
,	O
1994	O
).	O

Here	O
,	O
we	O
expanded	O
the	O
study	O
through	O
small	O
RNA	O
transcriptome	O
sequencing	O
analysis	O
of	O
the	O
host	O
response	O
to	O
both	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
influenza	B-DISO
virus	O
infections	B-DISO
across	O
four	O
founder	B-DISO
mouse	O
strains	O
of	O
the	O
Collaborative	O
Cross	O
,	O
a	O
recombinant	O
inbred	O
mouse	O
resource	O
for	O
mapping	O
complex	O
traits	O
.	O

We	O
observed	O
differential	O
expression	O
of	O
over	O
200	O
small	O
RNAs	O
of	O
diverse	O
classes	O
during	O
infection	B-DISO
.	O

These	O
findings	O
represent	O
the	O
first	O
integrated	O
sequencing	O
analysis	O
of	O
the	O
response	O
of	O
host	O
small	O
RNAs	O
to	O
virus	B-DISO
infection	I-DISO
and	O
show	O
that	O
small	O
RNAs	O
are	O
an	O
integrated	O
component	O
of	O
complex	O
networks	O
involved	O
in	O
regulating	O
the	O
host	O
response	O
to	O
infection	B-DISO
.	O

Most	O
studies	O
examining	O
the	O
host	O
transcriptional	O
response	O
to	O
infection	B-DISO
focus	O
only	O
on	O
protein	O
-	O
coding	O
genes	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
gastrointestinal	O
surgery	O
.	O

Four	O
patients	O
died	O
3	O
-	O
45	O
days	O
after	O
onset	O
of	O
ARDS	B-DISO
(	O
mortality	O
rate	O
,	O
26	O
.	O
6	O
%).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
ARDS	B-DISO
in	O
adults	O
.	O

ABSTRACT	O
:	O
This	O
experimental	O
animal	O
study	O
investigates	O
the	O
effects	O
of	O
combined	O
recombinant	O
human	O
activated	O
protein	O
C	O
(	O
rhAPC	O
)	O
and	O
ceftazidime	O
on	O
cardiopulmonary	O
function	O
in	O
acute	O
lung	O
injury	O
and	O
severe	B-DISO
sepsis	I-DISO
.	O

Recombinant	O
human	O
APC	B-DISO
(	O
continuous	O
infusion	O
24	O
μg	O
/	O
kg	O
per	O
hour	O
)	O
and	O
ceftazidime	O
(	O
3	O
-	O
g	O
bolus	O
at	O
1	O
and	O
13	O
h	O
)	O
were	O
intravenously	O
administered	O
.	O

The	O
increase	O
in	O
pulmonary	O
microvascular	O
shunt	O
fraction	O
and	O
airway	B-DISO
obstruction	I-DISO
in	O
bronchi	O
and	O
bronchiole	O
,	O
as	O
well	O
as	O
lung	O
3	O
-	O
nitrotyrosine	O
,	O
lung	O
myeloperoxidase	O
,	O
cardiac	O
3	O
-	O
nitrotyrosine	O
,	O
and	O
cardiac	O
malondialdehyde	O
levels	O
,	O
was	O
significantly	O
reduced	O
as	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
each	O
).	O

In	O
contrast	O
,	O
there	O
was	O
a	O
modest	O
reduction	O
in	O
infection	B-DISO
in	O
AMs	B-DISO
by	O
SP	O
-	O
A	O
,	O
but	O
not	O
by	O
SP	O
-	O
D	O
.	O
In	O
summary	O
,	O
AMs	B-DISO
are	O
an	O
important	O
target	O
for	O
HCoV	O
-	O
229E	O
,	O
and	O
they	O
can	O
mount	O
a	O
pro	O
-	O
inflammatory	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
infection	B-DISO
.	O

This	O
study	O
did	O
not	O
detect	O
an	O
effect	O
of	O
PPF	O
on	O
the	O
survival	O
time	O
,	O
the	O
quality	O
of	O
life	O
,	O
or	O
any	O
clinical	O
or	O
laboratory	O
parameter	O
in	O
cats	O
with	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
healthcare	O
workers	O
'	O
perceptions	O
of	O
risk	O
from	O
exposure	O
to	O
emerging	O
acute	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
and	O
the	O
perceived	O
effectiveness	O
of	O
strategies	O
used	O
to	O
facilitate	O
healthy	O
coping	O
in	O
acute	O
hospital	O
and	O
community	O
healthcare	O
settings	O
.	O

It	O
appears	O
that	O
healthcare	O
workers	O
'	O
risk	O
perceptions	O
can	O
influence	O
their	O
behaviour	O
towards	O
patients	O
with	O
emerging	O
acute	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
as	O
well	O
as	O
their	O
use	O
of	O
risk	O
-	O
mitigating	O
strategies	O
.	O

Future	O
research	O
needs	O
to	O
examine	O
how	O
perception	O
of	O
risk	O
related	O
to	O
acute	O
emerging	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
,	O
epidemic	O
or	O
pandemic	O
,	O
and	O
the	O
factors	O
that	O
would	O
influence	O
healthcare	O
workers	O
':	O
decisions	O
to	O
stay	O
within	O
the	O
workforce	O
and	O
provide	O
care	O
or	O
resign	O
from	O
the	O
workforce	O
and	O
compliance	O
with	O
institutional	O
and	O
government	O
policies	O
and	O
procedures	O
,	O
as	O
well	O
as	O
compliance	O
to	O
use	O
of	O
personal	O
protective	O
equipment	O
.	O

TITLE	O
:	O
Virus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
epidemiology	O
,	O
management	O
and	O
outcome	O
.	O

Notably	O
,	O
a	O
novel	O
coronavirus	O
was	O
responsible	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
2003	O
.	O

Among	O
Herpesviridae	O
,	O
herpes	B-DISO
simplex	I-DISO
virus	O
(	O
HSV	O
)	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
the	O
two	O
viruses	O
causing	O
nosocomial	O
viral	B-DISO
pneumonia	I-DISO
that	O
can	O
evolve	O
into	O
ARDS	B-DISO
.	O

To	O
compare	O
the	O
prevalence	O
of	O
HCoV	O
species	O
among	O
children	O
hospitalized	O
for	O
acute	O
respiratory	O
illness	O
and	O
/	O
or	O
fever	O
(	O
ARI	O
/	O
fever	O
)	O
with	O
that	O
among	O
asymptomatic	O
controls	O
and	O
to	O
assess	O
the	O
severity	O
of	O
outcomes	O
among	O
hospitalized	O
children	O
with	O
HCoV	O
infection	B-DISO
compared	O
with	O
other	O
respiratory	O
viruses	O
.	O

To	O
determine	O
whether	O
germline	O
library	O
represented	O
the	O
endogenous	O
immune	O
status	O
,	O
specific	O
scFv	O
clones	O
for	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SCoV	O
)	O
were	O
obtained	O
both	O
from	O
naïve	O
and	O
immunized	O
germline	O
scFv	O
libraries	O
.	O

TITLE	O
:	O
Varicella	B-DISO
zoster	I-DISO
virus	O
and	O
relapsing	B-DISO
remitting	I-DISO
multiple	I-DISO
sclerosis	I-DISO
.	O

The	O
patient	O
who	O
had	O
the	O
longest	O
ECMO	O
support	O
for	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
lung	O
surgery	O
was	O
successfully	O
weaned	O
from	O
ECMO	O
because	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
improved	O
respiratory	O
function	O
.	O

TITLE	O
:	O
Acute	O
phase	O
proteins	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
wasting	B-DISO
diseases	I-DISO
in	O
growing	O
pigs	O
.	O

ABSTRACT	O
:	O
The	O
concentrations	O
of	O
haptoglobin	O
(	O
Hp	O
),	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
serum	O
amyloid	B-DISO
A	O
(	O
SAA	O
)	O
were	O
measured	O
in	O
wasted	B-DISO
pigs	O
,	O
first	O
to	O
evaluate	O
their	O
usefulness	O
in	O
the	O
diagnosis	O
of	O
infectious	B-DISO
,	O
wasting	B-DISO
diseases	I-DISO
in	O
pigs	O
,	O
and	O
second	O
,	O
to	O
evaluate	O
whether	O
their	O
concentrations	O
can	O
distinguish	O
the	O
lymphoid	O
depletion	O
score	O
in	O
the	O
lymph	O
tissues	O
of	O
wasted	B-DISO
affected	O
pigs	O
.	O

Fifty	O
-	O
three	O
wasted	B-DISO
pigs	O
and	O
seven	O
specific	O
pathogen	O
free	O
(	O
SPF	O
)	O
pigs	O
were	O
postmortem	O
examined	O
.	O

ABSTRACT	O
:	O
The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
is	O
felt	O
most	O
keenly	O
among	O
the	O
elderly	O
.	O

However	O
,	O
the	O
development	O
of	O
robust	O
T	O
cell	O
responses	O
in	O
the	O
lung	O
also	O
requires	O
respiratory	O
DCs	B-DISO
(	O
rDCs	O
),	O
which	O
must	O
process	O
antigen	O
and	O
migrate	O
to	O
draining	O
LNs	B-DISO
(	O
DLNs	O
),	O
and	O
little	O
is	O
known	O
about	O
age	O
-	O
related	O
defects	O
in	O
these	O
T	O
cell	O
-	O
extrinsic	O
functions	O
.	O

Here	O
,	O
we	O
show	O
that	O
increases	O
in	O
prostaglandin	O
D	O
(	O
2	O
)	O
(	O
PGD	O
(	O
2	O
))	O
expression	O
in	O
mouse	O
lungs	O
upon	O
aging	O
correlate	O
with	O
a	O
progressive	O
impairment	B-DISO
in	O
rDC	B-DISO
migration	O
to	O
DLNs	O
.	O

Blocking	B-DISO
PGD	O
(	O
2	O
)	O
function	O
with	O
small	O
-	O
molecule	O
antagonists	O
enhanced	O
rDC	B-DISO
migration	O
,	O
T	O
cell	O
responses	O
,	O
and	O
survival	O
.	O

They	O
show	O
that	O
migration	O
of	O
respiratory	O
DCs	B-DISO
from	O
the	O
site	O
of	O
virus	O
replication	O
to	O
the	O
draining	O
lymph	O
nodes	O
in	O
response	O
to	O
infection	B-DISO
with	O
several	O
different	O
respiratory	O
viruses	O
is	O
markedly	O
diminished	O
with	O
increasing	O
age	O
.	O

ABSTRACT	O
:	O
After	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
experience	O
in	O
2003	O
,	O
ethics	O
has	O
found	O
a	O
place	O
in	O
discourses	O
on	O
pandemic	O
planning	O
and	O
public	O
health	O
.	O

India	O
'	O
s	O
pandemic	O
plan	B-DISO
suffers	B-DISO
from	O
a	O
glaring	O
omission	O
in	O
this	O
aspect	O
.	O

It	O
ends	O
with	O
the	O
suggestion	O
that	O
the	O
Indian	O
health	O
authorities	O
should	O
add	B-DISO
an	O
ethical	O
dimension	O
to	O
the	O
national	O
pandemic	O
plan	B-DISO
,	O
as	O
has	O
been	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
and	O
by	O
post	O
-	O
SARS	B-DISO
studies	O
.	O

This	O
paper	O
emphasizes	O
the	O
need	O
to	O
suspect	O
influenza	B-DISO
B	I-DISO
virus	I-DISO
infection	I-DISO
in	O
critically	B-DISO
ill	I-DISO
immunocompromised	O
patients	O
with	O
progressive	O
deterioration	O
of	O
cardiopulmonary	O
function	O
despite	O
treatment	O
with	O
antibiotics	O
.	O

ABSTRACT	O
:	O
Differentiation	O
syndrome	B-DISO
(	O
DS	O
)	O
represents	O
a	O
life	O
-	O
threatening	O
complication	B-DISO
in	O
patients	O
with	O
acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
(	O
APL	B-DISO
)	O
undergoing	O
induction	O
therapy	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
or	O
arsenic	O
trioxide	O
(	O
ATO	O
).	O

DS	O
pathogenesis	B-DISO
is	O
not	O
completely	O
understood	O
,	O
but	O
it	O
is	O
believed	O
that	O
an	O
excessive	O
inflammatory	B-DISO
response	I-DISO
is	O
the	O
main	O
phenomenon	O
involved	O
,	O
which	O
results	O
in	O
increased	O
production	O
of	O
chemokines	O
and	O
expression	O
of	O
adhesion	B-DISO
molecules	O
on	O
APL	B-DISO
cells	O
.	O

TITLE	O
:	O
Low	O
usage	O
of	O
government	O
healthcare	O
facilities	O
for	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
guatemala	O
:	O
implications	O
for	O
influenza	B-DISO
surveillance	O
.	O

ABSTRACT	O
:	O
Sentinel	O
surveillance	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
hospitals	O
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
in	O
ambulatory	O
clinics	O
is	O
recommended	O
to	O
assist	O
in	O
global	O
pandemic	O
influenza	B-DISO
preparedness	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
measure	O
healthcare	O
utilization	O
patterns	O
in	O
Guatemala	O
to	O
inform	O
the	O
establishment	O
of	O
a	O
sentinel	O
surveillance	O
system	O
for	O
influenza	B-DISO
and	O
other	O
respiratory	B-DISO
infections	I-DISO
,	O
and	O
allow	O
estimation	O
of	O
disease	O
burden	O
.	O

TITLE	O
:	O
Potential	O
clinical	O
application	O
of	O
KGF	O
-	O
2	O
(	O
FGF	O
-	O
10	O
)	O
for	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
combination	O
of	O
sport	O
practice	O
and	O
infection	B-DISO
was	O
noted	O
in	O
11	O
patients	O
(	O
group	O
IV	O
).	O

To	O
investigate	O
outcomes	O
of	O
srr7	O
infection	B-DISO
,	O
we	O
re	O
-	O
cloned	O
srr7	O
(	O
H2	O
)	O
from	O
the	O
viral	O
stock	O
srr7	O
(	O
Mix	O
).	O

TITLE	O
:	O
Hyperoxygenated	O
solutions	O
in	O
clinical	O
practice	O
:	O
preventing	O
or	O
reducing	O
hypoxic	B-DISO
injury	O
.	O

Mechanical	O
ventilation	O
including	O
high	O
-	O
frequency	O
oscillation	O
could	O
not	O
stabilise	O
the	O
course	O
,	O
and	O
the	O
child	O
developed	O
pneumothorax	B-DISO
and	O
emphysema	B-DISO
.	O

TITLE	O
:	O
Isolation	O
of	O
influenza	B-DISO
viruses	O
in	O
MDCK	O
33016PF	O
cells	O
and	O
clearance	O
of	O
contaminating	O
respiratory	O
viruses	O
.	O

Double	O
infections	B-DISO
of	O
influenza	B-DISO
virus	O
together	O
with	O
another	O
virus	O
were	O
found	O
for	O
adenovirus	B-DISO
B	O
and	O
E	O
,	O
bocavirus	O
,	O
coronavirus	O
,	O
enterovirus	O
and	O
for	O
rhinovirus	O
.	O

EC	O
(	O
50	O
)	O
values	O
were	O
determined	O
to	O
be	O
54μM	O
for	O
HBeAg	O
,	O
61μM	O
for	O
HBsAg	O
and	O
2	O
.	O
66μM	O
for	O
supernatant	O
HBV	B-DISO
DNA	O
,	O
as	O
compared	O
to	O
1671	O
,	O
1570	O
,	O
169μM	O
,	O
respectively	O
,	O
for	O
the	O
commercially	O
-	O
available	O
hepatitis	B-DISO
B	I-DISO
drug	O
adefovir	O
dipivoxil	O
(	O
ADV	O
).	O

TITLE	O
:	O
Applications	O
of	O
PCR	O
(	O
real	O
-	O
time	O
and	O
MassTag	O
)	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
in	O
diagnosis	O
of	O
respiratory	B-DISO
infections	I-DISO
and	O
diarrheal	O
illness	O
among	O
deployed	O
U	O
.	O
S	O
.	O
military	O
personnel	O
during	O
exercise	O
Balikatan	O
2009	O
,	O
Philippines	O
.	O

Acute	B-DISO
chest	I-DISO
syndrome	I-DISO
is	O
a	O
severe	O
respiratory	B-DISO
complication	I-DISO
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

All	O
of	O
the	O
patients	O
received	O
a	O
single	O
dose	O
of	O
the	O
MF59	O
-	O
adjuvanted	O
seasonal	O
influenza	B-DISO
vaccine	O
(	O
Fluad	O
,	O
Siena	O
,	O
Italy	O
).	O

TITLE	O
:	O
Contemporary	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
adult	O
respiratory	B-DISO
failure	I-DISO
:	O
life	O
support	O
in	O
the	O
new	O
era	O
.	O

TITLE	O
:	O
[	O
A	O
protocol	O
for	O
the	O
cessation	O
of	O
sedation	B-DISO
in	O
brain	O
-	O
injured	O
patients	O
].	O

This	O
is	O
the	O
first	O
case	O
report	O
from	O
Saudi	O
Arabia	O
with	O
H1N1	O
-	O
induced	O
secondary	O
hemophagocytosis	B-DISO
.	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
increasingly	O
used	O
in	O
adults	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
who	O
remain	O
hypoxemic	O
during	O
conventional	O
mechanical	O
ventilation	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
summarize	O
the	O
trials	O
evaluating	O
HFOV	O
in	O
adults	O
with	O
ARDS	B-DISO
and	O
discuss	O
issues	O
relevant	O
to	O
the	O
clinician	O
regarding	O
the	O
use	O
of	O
HFOV	O
.	O

The	O
animal	O
reservoirs	O
for	O
SARS	B-DISO
-	O
CoV	O
precursors	O
still	O
exist	O
and	O
the	O
likelihood	O
of	O
future	O
outbreaks	O
in	O
the	O
human	O
population	O
is	O
high	O
.	O

Furthermore	O
the	O
data	O
with	O
NSC158362	O
suggest	O
a	O
novel	O
mechanism	O
for	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
that	O
may	O
involve	O
an	O
unknown	O
activity	O
of	O
PLP	O
,	O
or	O
alternatively	O
a	O
direct	O
effect	O
on	O
a	O
cellular	O
target	O
that	O
modifies	O
or	O
bypasses	O
PLP	O
function	O
in	O
yeast	O
and	O
mammalian	O
cells	O
.	O

Furthermore	O
,	O
we	O
isolated	O
a	O
BToV	O
strain	O
,	O
designated	O
Niigata	O
(	O
TC	O
),	O
from	O
a	O
fecal	O
sample	O
using	O
a	O
human	O
rectal	B-DISO
tumor	I-DISO
cell	O
line	O
.	O

Two	O
approaches	O
were	O
chosen	O
:	O
(	O
i	O
)	O
laboratories	O
testing	O
samples	O
using	O
their	O
in	O
-	O
house	O
procedures	O
for	O
extraction	O
and	O
amplification	B-DISO
and	O
(	O
ii	O
)	O
laboratories	O
using	O
their	O
in	O
-	O
house	O
amplification	B-DISO
procedures	O
on	O
centrally	O
extracted	O
samples	O
.	O

However	O
,	O
large	O
differences	O
in	O
amplification	B-DISO
efficacy	O
were	O
found	O
between	O
the	O
commercially	O
available	O
tests	O
;	O
acceptable	O
results	O
were	O
obtained	O
by	O
using	O
the	O
PathoFinder	O
assays	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
a	O
worldwide	O
disease	O
affecting	O
chickens	O
of	O
all	O
ages	O
and	O
causing	O
important	O
economic	O
losses	O
in	O
poultry	O
industry	O
.	O

The	O
use	O
of	O
ISH	B-DISO
technique	O
demonstrated	O
the	O
presence	O
of	O
viral	O
RNA	O
in	O
nasal	O
turbinates	O
prior	O
to	O
trachea	B-DISO
,	O
but	O
more	O
consistent	O
and	O
longer	O
replication	O
periods	O
in	O
enterocytes	O
of	O
lower	O
gastrointestinal	O
tract	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
nsp1	O
protein	O
induces	O
template	O
-	O
dependent	O
endonucleolytic	O
cleavage	O
of	O
mRNAs	O
:	O
viral	O
mRNAs	O
are	O
resistant	O
to	O
nsp1	O
-	O
induced	O
RNA	O
cleavage	O
.	O

Remarkably	O
,	O
SCoV	O
mRNAs	O
,	O
which	O
have	O
a	O
5	O
'	O
cap	B-DISO
structure	O
and	O
3	O
'	O
poly	O
A	O
tail	O
like	O
those	O
of	O
typical	O
host	O
mRNAs	O
,	O
were	O
not	O
susceptible	O
to	O
nsp1	O
-	O
mediated	O
RNA	O
cleavage	O
and	O
importantly	O
,	O
the	O
presence	O
of	O
the	O
5	O
'-	O
end	O
leader	O
sequence	O
protected	O
the	O
SCoV	O
mRNAs	O
from	O
nsp1	O
-	O
induced	O
endonucleolytic	O
RNA	O
cleavage	O
.	O

MPV	O
,	O
RSV	O
and	O
HRV	O
were	O
the	O
main	O
pathogens	O
caused	O
infection	B-DISO
among	O
children	O
under	O
4	O
years	O
old	O
,	O
accounting	O
for	O
9	O
.	O
7	O
%	O
(	O
49	O
/	O
503	O
),	O
21	O
.	O
7	O
%	O
(	O
109	O
/	O
503	O
)	O
and	O
18	O
.	O
9	O
%	O
(	O
95	O
/	O
503	O
).	O

Co	B-DISO
-	I-DISO
infections	I-DISO
of	O
other	O
respiratory	O
virus	O
were	O
also	O
detected	O
in	O
parts	O
of	O
ARI	O
patients	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
an	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
of	O
domestic	O
fowl	O
that	O
affects	O
poultry	O
of	O
all	O
ages	O
causing	O
economic	O
problems	O
for	O
the	O
poultry	O
industry	O
worldwide	O
.	O

SARS	B-DISO
-	O
CoV	O
infected	O
approximately	O
8000	O
people	O
worldwide	O
before	O
public	O
health	O
measures	O
halted	O
the	O
epidemic	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
interhospital	O
transfer	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
:	O
5	O
-	O
year	O
experience	O
.	O

NATs	O
not	O
only	O
provide	O
fast	O
,	O
accurate	O
and	O
sensitive	O
detection	O
of	O
respiratory	O
viruses	O
in	O
clinical	O
specimens	O
but	O
also	O
have	O
increased	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
both	O
new	O
emerging	O
viruses	O
such	O
as	O
the	O
pandemic	O
H1N1	B-DISO
influenza	I-DISO
virus	O
of	O
2009	O
,	O
and	O
conventional	O
viruses	O
such	O
as	O
the	O
common	B-DISO
cold	I-DISO
viruses	O
,	O
including	O
rhinovirus	O
and	O
coronavirus	O
.	O

TITLE	O
:	O
﻿	O
Fighting	O
against	O
infectious	B-DISO
diseases	I-DISO
in	O
China	O
.	O

Although	O
recent	O
studies	O
suggested	O
that	O
veno	O
-	O
venous	O
ECMO	O
might	O
improve	O
the	O
outcomes	O
of	O
patients	O
with	O
ARDS	B-DISO
,	O
indications	O
for	O
ECMO	O
use	O
remain	O
uncertain	O
.	O

The	O
frequencies	O
of	O
severe	O
HCoVs	O
infection	B-DISO
was	O
determined	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
among	O
1471	O
hospitalized	O
infants	O
(<	O
2	O
-	O
years	O
old	O
)	O
with	O
acute	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
.	O

HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
may	O
elicit	O
immunity	O
that	O
protects	O
from	O
subsequent	O
HCoV	O
-	O
HKU1	O
and	O
HCoV	O
-	O
229E	O
infection	B-DISO
,	O
respectively	O
,	O
which	O
would	O
explain	O
why	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
are	O
the	O
most	O
frequently	O
infecting	O
HCoVs	O
.	O

The	O
replicase	O
proteins	O
of	O
arteriviruses	O
are	O
associated	O
with	O
double	O
-	O
membrane	O
vesicles	B-DISO
(	O
DMVs	O
),	O
which	O
were	O
previously	O
proposed	O
to	O
derive	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
).	O

Since	O
no	O
specific	O
pharmacologic	O
intervention	O
exists	O
for	O
ARDS	B-DISO
,	O
our	O
objective	O
was	O
to	O
determine	O
the	O
effect	O
of	O
treatment	O
with	O
ergothioneine	O
-	O
a	O
safe	O
agent	O
with	O
multiple	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
on	O
the	O
development	O
of	O
lung	O
injury	O
and	O
inflammation	B-DISO
in	O
rats	O
insufflated	O
with	O
cytokines	O
found	O
in	O
lung	O
lavages	O
of	O
ARDS	B-DISO
patients	O
.	O

Ergothioneine	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
generally	O
decreased	O
lung	O
injury	O
and	O
lung	B-DISO
inflammation	I-DISO
in	O
cytokine	O
insufflated	O
rats	O
.	O

ABSTRACT	O
:	O
This	O
review	O
highlights	O
the	O
advantages	O
and	O
current	O
status	O
of	O
plant	O
-	O
derived	O
vaccine	O
development	O
with	O
special	O
reference	O
to	O
the	O
dengue	B-DISO
virus	O
.	O

This	O
indicates	O
the	O
feasibility	O
of	O
using	O
plant	O
-	O
derived	O
vaccine	O
antigens	O
as	O
a	O
low	O
-	O
cost	O
method	O
to	O
combat	O
dengue	B-DISO
and	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

The	O
application	O
of	O
new	O
methods	O
and	O
strategies	O
such	O
as	O
dendritic	O
cell	O
targeting	O
in	O
cancer	B-DISO
therapy	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
tuberculosis	B-DISO
,	O
human	O
immune	B-DISO
deficiency	I-DISO
virus	O
,	O
and	O
malaria	B-DISO
might	O
play	O
an	O
important	O
role	O
.	O

TITLE	O
:	O
CD4	O
T	O
cells	O
promote	O
CD8	O
T	O
cell	O
immunity	O
at	O
the	O
priming	O
and	O
effector	O
site	O
during	O
viral	B-DISO
encephalitis	I-DISO
.	O

Encephalitis	B-DISO
induced	O
by	O
the	O
sublethal	O
coronavirus	O
JHMV	O
was	O
used	O
to	O
identify	O
when	O
CD4	O
T	O
cells	O
regulate	O
CD8	O
T	O
cell	O
responses	O
following	O
CNS	B-DISO
infection	I-DISO
.	O

Respirable	O
pathogen	O
-	O
carrying	O
droplets	O
provide	O
a	O
vector	O
for	O
the	O
spatial	O
spread	O
of	O
infection	B-DISO
with	O
droplet	O
transport	O
determined	O
by	O
diffusive	O
and	O
convective	O
processes	O
.	O

It	O
is	O
found	O
that	O
small	O
droplets	O
(∼	O
0	O
.	O
4μm	O
)	O
generate	O
a	O
negligible	O
infectious	B-DISO
force	O
due	O
to	O
the	O
small	O
viral	O
load	O
and	O
the	O
associated	O
duration	O
they	O
require	O
to	O
transmit	O
infection	B-DISO
.	O

For	O
the	O
5	O
years	O
following	O
the	O
initial	O
treatment	O
for	O
SLE	B-DISO
,	O
the	O
patient	O
experienced	O
a	O
number	O
of	O
infections	B-DISO
and	O
had	O
a	O
low	O
serum	O
total	O
IgG	O
level	O
;	O
she	O
was	O
eventually	O
diagnosed	O
with	O
CVID	B-DISO
.	O

The	O
administration	O
of	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
was	O
required	O
to	O
prevent	O
subsequent	O
infections	B-DISO
,	O
and	O
no	O
relapse	B-DISO
of	O
SLE	B-DISO
was	O
observed	O
.	O

The	O
reports	O
were	O
combined	O
with	O
data	O
regarding	O
the	O
presence	O
/	O
absence	O
of	O
several	O
pathogens	O
in	O
the	O
herd	O
and	O
potential	O
farm	O
-	O
level	O
risk	O
factors	O
for	O
respiratory	B-DISO
disease	I-DISO
.	O

Enzootic	O
pneumonia	B-DISO
score	O
,	O
severe	O
pleurisy	B-DISO
and	O
acute	O
pleuropneumonia	B-DISO
had	O
the	O
highest	O
loadings	O
for	O
the	O
principal	O
component	O
which	O
explained	O
the	O
largest	O
percentage	O
of	O
the	O
total	O
variance	O
(	O
35	O
%)	O
(	O
BPHS	O
component	O
1	O
),	O
it	O
was	O
thought	O
that	O
this	O
component	O
identifies	O
farms	O
with	O
acute	B-DISO
disease	I-DISO
.	O

In	O
addition	O
,	O
farms	O
positive	O
for	O
H1N2	O
and	O
porcine	O
reproductive	O
and	O
respiratory	B-DISO
disease	I-DISO
virus	O
(	O
PRRSV	O
)	O
were	O
more	O
likely	O
to	O
have	O
higher	O
levels	O
of	O
severe	O
and	O
mild	O
pleurisy	B-DISO
reported	O
by	O
the	O
BPHS	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
interferon	O
(	O
IFN	O
)-	O
α	O
,	O
plenty	O
of	O
keratinocyte	O
-	O
derived	O
chemokines	O
(	O
KC	O
),	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
MIP	B-DISO
-	O
2	O
),	O
regulated	O
on	O
activation	O
normal	O
T	O
-	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
),	O
and	O
monocyte	O
chemotactic	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
)	O
were	O
significantly	O
released	O
into	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
the	O
model	O
.	O

The	O
present	O
study	O
suggests	O
that	O
MPO	O
-	O
mediated	O
OCl	O
(-)	O
generation	O
affects	O
claudin	O
molecules	O
and	O
leads	O
to	O
protein	O
leakage	B-DISO
and	O
viral	O
spread	O
as	O
a	O
damage	O
factor	O
in	O
influenza	B-DISO
-	O
induced	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Clinical	O
cases	O
of	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
)	O
can	O
be	O
challenging	O
to	O
differentiate	O
from	O
other	O
acute	O
respiratory	B-DISO
diseases	I-DISO
,	O
which	O
can	O
lead	O
to	O
delays	O
in	O
diagnosis	O
,	O
treatment	O
,	O
and	O
disease	O
reporting	O
.	O

Test	O
results	O
of	O
blood	O
samples	O
from	O
U	O
.	O
S	O
.	O
patients	O
suspected	O
of	O
having	O
HPS	B-DISO
submitted	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
from	O
1998	O
-	O
2010	O
were	O
reviewed	O
.	O

Of	O
567	O
patients	O
included	O
,	O
36	O
%	O
were	O
HPS	B-DISO
-	O
confirmed	O
.	O

TITLE	O
:	O
Immune	O
responses	O
to	O
mucosal	O
vaccination	O
by	O
the	O
recombinant	O
A1	O
and	O
N	O
proteins	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

TITLE	O
:	O
How	O
large	O
is	O
the	O
lung	O
recruitability	O
in	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
prospective	O
case	O
series	O
of	O
patients	O
monitored	O
by	O
computed	O
tomography	O
.	O

ABSTRACT	O
:	O
The	O
benefits	O
of	O
higher	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
have	O
been	O
modest	O
,	O
but	O
few	O
studies	O
have	O
fully	O
tested	O
the	O
""""	O
open	O
-	O
lung	O
hypothesis	O
"""."	O

To	O
further	O
validate	O
the	O
hypothesis	O
and	O
understand	O
initial	O
immune	O
responses	O
to	O
different	O
viruses	O
,	O
two	O
phage	O
-	O
displayed	O
human	O
cord	B-DISO
blood	O
-	O
derived	O
IgM	O
libraries	O
were	O
constructed	O
which	O
contained	O
mostly	O
germline	O
antibodies	O
or	O
antibodies	O
with	O
very	O
low	O
level	O
of	O
somatic	O
hypermutations	O
.	O

These	O
results	O
further	O
support	O
and	O
expand	O
our	O
initial	O
hypothesis	O
for	O
fundamental	O
differences	O
in	O
immune	O
responses	O
leading	O
to	O
elicitation	O
of	O
bnAbs	O
against	O
HIV	B-DISO
-	O
1	O
compared	O
to	O
SARS	B-DISO
CoV	O
and	O
Hendra	O
virus	O
.	O

TITLE	O
:	O
Understanding	O
the	O
clinical	O
spectrum	O
of	O
complicated	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
:	O
a	O
systematic	O
review	O
on	O
the	O
contributions	O
of	O
the	O
Brazilian	O
literature	O
.	O

In	O
the	O
Brazilian	O
Amazon	O
(	O
considered	O
to	O
be	O
a	O
low	O
to	O
moderate	O
intensity	O
area	O
of	O
transmission	O
),	O
clinical	O
data	O
are	O
in	O
accordance	O
with	O
the	O
recent	O
findings	O
of	O
severity	O
described	O
in	O
diverse	O
P	O
.	O
vivax	O
endemic	O
areas	O
(	O
especially	O
anaemia	B-DISO
in	O
Southeast	O
Asia	O
),	O
however	O
in	O
this	O
region	O
both	O
children	O
and	O
adults	O
are	O
affected	O
.	O

Mice	O
were	O
inoculated	O
with	O
A	O
/	O
swine	O
/	O
Shandong	O
/	O
731	O
/	O
2009	O
(	O
SD	O
/	O
09	O
),	O
which	O
was	O
a	O
2009	O
H1N1	B-DISO
influenza	I-DISO
variant	O
with	O
a	O
G222D	O
mutation	O
in	O
the	O
hemagglutinin	O
.	O

TITLE	O
:	O
Two	O
palmitylated	O
cysteine	O
residues	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
are	O
critical	O
for	O
S	O
incorporation	O
into	O
virus	O
-	O
like	O
particles	O
,	O
but	O
not	O
for	O
M	O
-	O
S	O
co	O
-	O
localization	O
.	O

However	O
,	O
pathogen	B-DISO
transmission	I-DISO
within	O
threatened	O
host	O
populations	O
may	O
also	O
be	O
important	O
,	O
and	O
may	O
not	O
be	O
controllable	O
by	O
managing	O
another	O
host	O
species	O
.	O

We	O
reviewed	O
all	O
patients	O
with	O
osteolysis	B-DISO
of	O
lymphatic	O
origin	O
and	O
treated	O
in	O
our	O
department	O
who	O
had	O
died	O
in	O
the	O
last	O
15	O
years	O
,	O
and	O
we	O
reviewed	O
all	O
published	O
cases	O
of	O
death	O
with	O
this	O
disease	O
since	O
the	O
1950	O
'	O
s	O
.	O

Patients	O
with	O
severe	O
osteolysis	B-DISO
of	O
lymphatic	O
origin	O
suffer	B-DISO
three	O
main	O
disorders	O
with	O
overlapping	O
comorbidity	O
:	O
the	O
lymphatic	B-DISO
malformation	I-DISO
of	O
soft	O
tissue	O
,	O
the	O
bone	O
resorption	O
and	O
the	O
chylothorax	B-DISO
.	O

Unlike	O
respiratory	B-DISO
failure	I-DISO
,	O
which	O
is	O
difficult	O
to	O
control	O
after	O
the	O
failure	O
of	O
medical	O
and	O
surgical	O
treatment	O
,	O
morbidity	O
from	O
infections	B-DISO
can	O
be	O
reduced	O
through	O
careful	O
nutritional	O
support	O
,	O
rational	O
antibiotic	O
prophylaxis	O
and	O
a	O
reduction	O
to	O
a	O
minimum	O
in	O
the	O
use	O
of	O
central	O
catheters	O
and	O
total	O
parenteral	O
nutrition	O
.	O

TITLE	O
:	O
[	O
Recommendations	O
of	O
the	O
Infectious	B-DISO
Diseases	I-DISO
Work	O
Group	O
(	O
GTEI	O
)	O
of	O
the	O
Spanish	O
Society	O
of	O
Intensive	O
and	O
Critical	O
Care	O
Medicine	O
and	O
Coronary	O
Units	O
(	O
SEMICYUC	O
)	O
and	O
the	O
Infections	B-DISO
in	O
Critically	B-DISO
Ill	I-DISO
Patients	O
Study	O
Group	O
(	O
GEIPC	O
)	O
of	O
the	O
Spanish	O
Society	O
of	O
Infectious	B-DISO
Diseases	I-DISO
and	O
Clinical	O
Microbiology	O
(	O
SEIMC	O
)	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
influenza	B-DISO
A	O
/	O
H1N1	O
in	O
seriously	O
ill	B-DISO
adults	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
].	O

A	O
diagnostic	O
test	O
should	O
be	O
performed	O
in	O
all	O
patients	O
with	O
fever	O
and	O
flu	B-DISO
symptoms	I-DISO
that	O
require	O
hospitalization	O
.	O

Immunochromatographic	O
methods	O
have	O
low	O
sensitivity	O
;	O
a	O
negative	O
result	O
therefore	O
does	O
not	O
rule	O
out	O
active	O
infection	B-DISO
.	O

Early	O
antiviral	O
administration	O
is	O
associated	O
to	O
improved	O
survival	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
patients	O
with	O
influenza	B-DISO
A	O
/	O
H1N1	O
pneumonia	B-DISO
,	O
empirical	O
antibiotic	O
therapy	O
should	O
be	O
provided	O
due	O
to	O
the	O
possibility	O
of	O
bacterial	O
coinfection	B-DISO
.	O

Such	O
problems	O
may	O
appear	O
due	O
to	O
the	O
deterioration	O
of	O
pre	O
-	O
existing	O
cardiomyopathy	B-DISO
,	O
myocarditis	B-DISO
,	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
and	O
right	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
are	O
characterized	O
by	O
protein	O
rich	O
alveolar	B-DISO
edema	I-DISO
,	O
reduced	O
lung	O
compliance	O
,	O
and	O
acute	O
severe	O
hypoxemia	O
.	O

Female	O
BLM	B-DISO
WT	O
mice	O
had	O
mild	O
fibrosis	B-DISO
and	O
displayed	O
a	O
possible	O
compensatory	O
upregulation	O
of	O
the	O
AT2	O
receptor	O
.	O

We	O
conclude	O
that	O
ACE2	O
gene	B-DISO
deletion	I-DISO
worsens	O
BLM	B-DISO
-	O
induced	O
lung	O
injury	O
and	O
more	O
so	O
in	O
males	O
than	O
females	O
.	O

He	O
had	O
experienced	O
high	O
fever	O
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
for	O
5	O
days	O
before	O
coming	O
to	O
the	O
hospital	O
.	O

Antibodies	O
to	O
all	O
of	O
the	O
infectious	B-DISO
pathogens	O
except	O
SVDV	O
were	O
detected	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
our	O
early	O
experience	O
with	O
the	O
Cardiohelp	O
,	O
a	O
new	O
portable	O
miniaturized	O
ECMO	O
system	O
,	O
in	O
22	O
consecutive	O
patients	O
with	O
ARDS	B-DISO
.	O

Additionally	O
,	O
mRNA	O
levels	O
of	O
MIP	B-DISO
-	O
1α	O
,	O
a	O
RUNX1b	O
target	O
gene	O
upregulated	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
,	O
were	O
found	O
to	O
be	O
elevated	O
in	O
3b	O
expressing	O
U937	O
monocyte	O
cells	O
.	O

TITLE	O
:	O
Up	O
-	O
regulation	O
of	O
Mcl	B-DISO
-	O
1	O
and	O
Bak	O
by	O
coronavirus	B-DISO
infection	I-DISO
of	O
human	O
,	O
avian	O
and	O
animal	O
cells	O
modulates	O
apoptosis	O
and	O
viral	O
replication	O
.	O

In	O
this	O
study	O
,	O
the	O
global	O
gene	O
expression	O
profiles	O
are	O
first	O
determined	O
in	O
IBV	O
-	O
infected	O
Vero	O
cells	O
at	O
24	O
hours	O
post	O
-	O
infection	B-DISO
by	O
Affymetrix	O
array	O
,	O
using	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
as	O
a	O
model	O
system	O
.	O

Snoring	B-DISO
is	O
a	O
symptom	B-DISO
which	O
may	O
indicate	O
the	O
presence	O
of	O
OSAS	B-DISO
;	O
thus	O
investigation	O
of	O
snoring	B-DISO
sounds	O
,	O
which	O
can	O
be	O
recorded	O
in	O
the	O
patient	O
'	O
s	O
own	O
sleeping	O
environment	O
,	O
has	O
become	O
popular	O
in	O
recent	O
years	O
to	O
diagnose	O
OSAS	B-DISO
.	O

It	O
improved	O
all	O
histological	O
lesions	O
of	O
ARDS	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
placebo	O
).	O

We	O
see	O
this	O
clearly	O
in	O
the	O
first	O
two	O
pandemics	O
of	O
the	O
21st	O
century	O
:	O
SARS	B-DISO
and	O
influenza	B-DISO
H1N1	O
-	O
2009	O
.	O

To	O
date	O
,	O
avian	B-DISO
influenza	I-DISO
has	O
low	O
human	O
-	O
to	O
-	O
human	O
transmission	O
;	O
infection	B-DISO
typically	O
requires	O
close	O
contact	O
with	O
poultry	O
,	O
but	O
presents	O
with	O
severe	O
disease	O
and	O
a	O
high	O
fatality	O
rate	O
.	O

ABSTRACT	O
:	O
Alcohol	O
intake	O
increases	O
the	O
risk	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
is	O
associated	O
with	O
poor	O
outcomes	O
in	O
patients	O
who	O
develop	O
these	O
syndromes	B-DISO
.	O

We	O
have	O
recently	O
shown	O
increased	O
levels	O
of	O
lung	O
adenosine	O
inhibit	O
alveolar	O
fluid	O
clearance	O
,	O
an	O
important	O
predictor	O
of	O
outcome	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

Physical	O
examination	O
showed	O
fine	O
bilateral	O
basal	O
crackles	B-DISO
.	O

On	O
the	O
fifth	O
day	O
of	O
admission	O
,	O
he	O
deteriorated	O
and	O
developed	O
severe	O
respiratory	B-DISO
distress	I-DISO
.	O

In	O
contrast	O
,	O
fecal	O
isolates	O
from	O
healthy	O
cats	O
were	O
infectious	B-DISO
following	O
oronasal	O
infection	B-DISO
and	O
shed	O
at	O
high	O
levels	O
in	O
feces	O
without	O
causing	O
disease	O
,	O
as	O
expected	O
for	O
FECVs	O
.	O

infection	B-DISO
,	O
indicating	O
that	O
FECVs	O
can	O
replicate	O
systemically	O
,	O
but	O
with	O
difficulty	O
.	O

Clinically	O
,	O
ARDS	B-DISO
can	O
be	O
divided	O
into	O
ARDS	B-DISO
due	O
to	O
direct	O
causes	O
such	O
as	O
pneumonia	B-DISO
,	I-DISO
aspiration	I-DISO
or	O
injurious	O
ventilation	O
,	O
and	O
due	O
to	O
extrapulmonary	O
indirect	O
causes	O
such	O
as	O
sepsis	B-DISO
,	I-DISO
severe	I-DISO
burns	O
or	O
pancreatitis	B-DISO
.	O

The	O
underlying	O
mechanisms	O
that	O
involve	O
canonical	O
inflammatory	O
pathways	O
such	O
as	O
MAP	O
kinases	O
,	O
CXCR2	O
chemokines	O
,	O
PAF	B-DISO
,	O
leukotrienes	O
,	O
adhesions	B-DISO
molecules	O
(	O
CD18	O
,	O
ICAM	O
-	O
1	O
)	O
and	O
elastase	O
have	O
been	O
defined	O
relatively	O
well	O
.	O

However	O
,	O
only	O
few	O
studies	O
have	O
linked	O
these	O
pathways	O
to	O
hypoxemia	O
,	O
the	O
most	O
important	O
clinical	O
aspect	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Mini	O
bronchoalveolar	O
lavage	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
].	O

TITLE	O
:	O
Mechanisms	O
of	O
host	O
receptor	O
adaptation	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
impact	O
of	O
these	O
mutations	O
on	O
receptor	O
recognition	O
,	O
an	O
important	O
determinant	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
pathogenesis	B-DISO
.	O

Metabolic	B-DISO
acidosis	I-DISO
and	O
low	O
oxygen	O
saturation	O
was	O
observed	O
in	O
7	O
%	O
patients	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
anti	O
-	O
murine	O
colon	B-DISO
cancer	I-DISO
immunity	O
by	O
fusion	O
of	O
a	O
SARS	B-DISO
fragment	O
to	O
a	O
low	O
-	O
immunogenic	O
carcinoembryonic	O
antigen	O
.	O

Oral	O
vaccination	O
of	O
an	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
strain	O
transformed	O
with	O
plasmids	O
encoding	O
CEA	O
-	O
SARS	B-DISO
-	O
CoV	O
fusion	O
gene	O
into	O
BALB	O
/	O
c	O
mice	O
elicited	O
significant	O
increases	O
in	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
10	O
in	O
the	O
serum	O
.	O

He	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
requiring	O
high	O
frequency	O
percussive	O
ventilation	O
.	O

Such	O
exposures	O
can	O
evolve	O
to	O
severe	O
ARDS	B-DISO
and	O
benefit	O
from	O
high	O
frequency	O
percussive	O
ventilation	O
.	O

ABSTRACT	O
:	O
High	O
-	O
throughput	O
screening	O
(	O
HTS	B-DISO
)	O
of	O
large	O
compound	O
libraries	O
has	O
become	O
a	O
commonly	O
used	O
method	O
for	O
the	O
identification	O
of	O
drug	O
leads	O
,	O
and	O
nonphysiological	O
reducing	O
agents	O
have	O
been	O
widely	O
used	O
for	O
HTS	B-DISO
.	O

However	O
,	O
a	O
comparison	O
of	O
the	O
difference	O
in	O
the	O
HTS	B-DISO
results	O
based	O
on	O
the	O
choice	O
of	O
reducing	O
agent	O
used	O
and	O
potency	O
comparisons	O
of	O
selected	O
inhibitors	O
has	O
not	O
been	O
done	O
with	O
the	O
physiological	O
reducing	O
agent	O
reduced	O
glutathione	O
(	O
GSH	B-DISO
).	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
is	O
useful	O
for	O
the	O
rapid	O
diagnosis	O
of	O
coronavirus	B-DISO
infections	I-DISO
.	O

Complete	O
genome	O
sequencing	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
bat	O
-	O
SARS	B-DISO
-	O
CoV	O
formed	O
a	O
distinct	O
cluster	O
with	O
SARS	B-DISO
-	O
CoV	O
as	O
group	O
2b	O
coronaviruses	O
,	O
distantly	O
related	O
to	O
known	O
group	O
2	O
coronaviruses	O
.	O

Notably	O
,	O
HCoV	O
-	O
NL63	O
infections	B-DISO
were	O
significantly	O
more	O
common	O
among	O
children	O
hospitalised	O
in	O
2006	O
/	O
2007	O
(	O
1	O
.	O
2	O
%)	O
than	O
in	O
2005	O
/	O
2006	O
(	O
0	O
.	O
3	O
%).	O
3	O
.	O

These	O
data	O
suggest	O
that	O
CXC	O
chemokines	O
produced	O
by	O
RCoV	O
-	O
infected	O
AT1	B-DISO
-	O
like	O
cells	O
inhibit	O
PMN	O
apoptosis	O
during	O
infection	B-DISO
.	O

TITLE	O
:	O
The	O
paradox	O
of	O
feline	O
coronavirus	O
pathogenesis	B-DISO
:	O
a	O
review	O
.	O

FCoV	O
is	O
also	O
associated	O
with	O
a	O
lethal	O
,	O
systemic	B-DISO
disease	I-DISO
known	O
as	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Feline	O
and	O
canine	O
coronaviruses	O
are	O
widespread	O
among	O
dog	O
and	O
cat	O
populations	O
,	O
sometimes	O
leading	O
to	O
the	O
fatal	O
diseases	O
known	O
as	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
and	O
pantropic	O
canine	O
coronavirus	B-DISO
infection	I-DISO
in	O
cats	O
and	O
dogs	O
,	O
respectively	O
.	O

It	O
may	O
also	O
explain	O
why	O
some	O
Asian	O
countries	O
in	O
tropical	O
area	O
(	O
such	O
as	O
Malaysia	O
,	O
Indonesia	O
or	O
Thailand	O
)	O
with	O
high	O
temperature	O
and	O
high	O
relative	O
humidity	O
environment	O
did	O
not	O
have	O
major	O
community	O
outbreaks	O
of	O
SARS	B-DISO
.	O

STING	O
dimerization	O
was	O
also	O
substantially	O
reduced	O
in	O
cells	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
level	O
of	O
ubiquitinated	O
forms	O
of	O
STING	O
,	O
RIG	O
-	O
I	O
,	O
TBK1	O
and	O
IRF	O
-	O
3	O
are	O
reduced	O
in	O
cells	O
expressing	O
wild	O
type	O
or	O
catalytic	O
mutants	O
of	O
PLP2	O
-	O
TM	O
,	O
likely	O
contributing	O
to	O
disruption	O
of	O
signaling	O
required	O
for	O
IFN	O
induction	O
.	O

Deterministic	O
and	O
probabilistic	O
approaches	O
were	O
used	O
to	O
quantify	O
the	O
risks	O
based	O
on	O
the	O
amount	O
of	O
inhaled	O
influenza	B-DISO
virus	O
RNA	O
particles	O
and	O
quanta	O
,	O
respectively	O
.	O

TITLE	O
:	O
Quarantine	O
protects	O
Falkland	O
Islands	O
(	O
Malvinas	O
)	O
cats	O
from	O
feline	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
FCoV	O
/	O
FIP	B-DISO
-	O
free	O
status	O
of	O
the	O
Falkland	O
Islands	O
cats	O
should	O
be	O
maintained	O
by	O
FCoV	O
testing	O
incoming	O
cats	O
.	O

We	O
used	O
conditional	O
targeting	O
of	O
pDC	B-DISO
-	O
specific	O
transcription	O
factor	O
E2	O
-	O
2	O
to	O
generate	O
mice	O
that	O
constitutively	O
lack	O
pDCs	O
in	O
peripheral	O
lymphoid	O
organs	O
and	O
tissues	O
.	O

Despite	O
clinical	O
improvement	O
of	O
the	O
paralysis	O
over	O
subsequent	O
3	O
days	O
and	O
successful	O
weaning	O
off	O
the	O
ventilator	O
,	O
the	O
dog	O
decompensated	O
and	O
succumbed	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
[	O
The	O
application	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
critically	B-DISO
ill	I-DISO
patient	O
].	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
supportive	O
effects	O
on	O
cardiopulmonary	B-DISO
failure	I-DISO
in	O
critically	B-DISO
ill	I-DISO
patients	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Acute	B-DISO
renal	I-DISO
insufficiency	I-DISO
occurred	O
in	O
5	O
patients	O
,	O
hyperbilirubinemia	B-DISO
in	O
6	O
patients	O
,	O
and	O
catheter	O
related	O
blood	O
stream	O
infection	B-DISO
in	O
4	O
patients	O
.	O

Remarkably	O
,	O
the	O
same	O
protein	O
harboring	O
the	O
sequence	O
GPLG	O
instead	O
of	O
the	O
His	O
(	O
6	O
)	O
tag	B-DISO
at	O
its	O
N	O
terminus	O
exhibits	O
a	O
substantially	O
increased	O
,	O
primer	O
-	O
independent	O
RNA	O
polymerase	O
activity	O
.	O

We	O
assessed	O
the	O
characteristics	O
and	O
predictors	O
of	O
outcome	O
of	O
patients	O
with	O
CAP	B-DISO
and	O
severe	O
ARF	B-DISO
treated	O
with	O
NIV	O
.	O

Worsening	O
radiologic	O
infiltrate	B-DISO
24	O
h	O
after	O
admission	O
,	O
maximum	O
Sepsis	B-DISO
-	O
Related	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
,	O
after	O
1	O
h	O
of	O
NIV	O
,	O
higher	O
heart	O
rate	O
and	O
lower	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
bicarbonate	O
independently	O
predicted	O
NIV	O
failure	O
.	O

These	O
patients	O
were	O
hospitalized	O
patients	O
in	O
department	O
of	O
internal	O
medicine	O
or	O
outpatients	O
in	O
emergency	B-DISO
department	O
in	O
Beijing	O
Children	O
'	O
s	O
Hospital	O
.	O

Different	O
viral	B-DISO
infections	I-DISO
had	O
different	O
seasonal	O
features	O
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
PCR	O
methods	O
were	O
applied	O
to	O
detect	O
common	O
respiratory	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
influenza	B-DISO
virus	O
type	O
A	O
,	O
B	O
and	O
C	O
(	O
IFA	O
,	O
IFB	O
,	O
IFC	O
),	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
type	O
1	O
-	O
4	O
,	O
adenovirus	B-DISO
(	O
ADV	O
),	O
enterovirus	O
(	O
EV	O
),	O
human	O
coronavirus	O
(	O
HCOV	O
),	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
and	O
human	O
bocavirus	O
(	O
HBOV	O
).	O

Fecal	O
samples	O
from	O
935	O
dogs	O
with	O
acute	O
hemorrhagic	B-DISO
diarrhea	I-DISO
were	O
examined	O
by	O
electron	O
microscopy	O
.	O

Virus	O
was	O
detected	O
in	O
44	O
.	O
2	O
%	O
of	O
the	O
dogs	O
presented	O
with	O
acute	O
bloody	B-DISO
diarrhea	I-DISO
.	O

Among	O
virus	O
-	O
positive	O
dogs	O
,	O
dogs	O
with	O
parvovirus	B-DISO
infection	I-DISO
were	O
significantly	O
younger	O
when	O
compared	O
to	O
dogs	O
infected	O
with	O
other	O
enteric	O
viruses	O
.	O

Parvovirus	B-DISO
-	O
infected	O
patients	O
also	O
showed	O
significantly	O
lower	O
leukocyte	O
and	O
erythrocyte	O
counts	O
as	O
well	O
as	O
hematocrit	O
,	O
total	O
protein	O
,	O
and	O
albumin	O
levels	O
compared	O
to	O
all	O
other	O
groups	O
.	O

As	O
an	O
effective	O
measure	O
of	O
respiratory	O
supports	O
,	O
ECMO	O
may	O
provide	O
pulmonary	O
rest	O
and	O
improve	O
gas	O
exchanges	O
in	O
severe	O
ARDS	B-DISO
induced	O
by	O
novel	B-DISO
H1N1	I-DISO
Influenza	I-DISO
.	O

Fourteen	O
out	O
of	O
3	O
,	O
525	O
(	O
0	O
.	O
4	O
%)	O
patients	O
with	O
respiratory	O
syndrome	B-DISO
and	O
five	O
out	O
of	O
five	O
patients	O
with	O
sepsis	B-DISO
-	O
like	O
illness	O
were	O
positive	O
for	O
HPeV	O
.	O
In	O
3	O
/	O
5	O
patients	O
with	O
sepsis	B-DISO
-	O
like	O
illness	O
multiple	O
samples	O
(	O
e	O
.	O
g	O
.,	O
stool	O
,	O
plasma	O
,	O
CSF	O
,	O
or	O
respiratory	O
samples	O
)	O
were	O
available	O
,	O
and	O
HPeV	O
was	O
found	O
in	O
all	O
specimens	O
.	O

Although	O
not	O
circulating	O
at	O
high	O
frequency	O
and	O
unlikely	O
to	O
cause	O
respiratory	O
syndrome	B-DISO
,	O
HPeV	O
was	O
associated	O
with	O
severe	O
clinical	O
syndromes	B-DISO
in	O
a	O
minority	O
of	O
newborns	O
.	O

A	O
good	O
ALI	O
model	O
will	O
help	O
us	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
real	O
pathophysiological	O
picture	O
and	O
to	O
evaluate	O
novel	O
treatment	O
approaches	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
more	O
accurately	O
and	O
liberally	O
.	O

The	O
lung	O
histology	O
showed	O
severe	O
inflammation	B-DISO
,	O
hyaline	B-DISO
membranes	I-DISO
,	O
intra	O
-	O
alveolar	O
and	O
interstitial	O
hemorrhage	B-DISO
.	O

We	O
show	O
that	O
by	O
introducing	O
human	O
DC	O
-	O
SIGN	O
/	O
L	O
-	O
SIGN	O
into	O
non	O
-	O
permissive	O
cells	O
,	O
infection	B-DISO
by	O
the	O
IBV	O
is	O
dramatically	O
increased	O
.	O

Enhancement	O
of	O
IBV	O
infection	B-DISO
also	O
occurred	O
for	O
different	O
serotypes	O
of	O
IBV	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
swine	O
testis	O
(	O
ST	O
)	O
cells	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	B-DISO
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	B-DISO
of	O
Bax	O
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	O
c	O
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

Moreover	O
,	O
TGEV	O
infection	B-DISO
did	O
not	O
induce	O
significant	O
DNA	O
fragmentation	B-DISO
in	O
ammonium	O
chloride	O
(	O
NH	O
(	O
4	O
)	O
Cl	O
)	O
pretreated	O
PK	O
-	O
15	O
cells	O
or	O
cells	O
infected	O
with	O
UV	O
-	O
inactivated	O
TGEV	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
refractory	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
questionnaire	O
was	O
designed	O
de	O
novo	O
following	O
discussions	O
with	O
colleagues	O
at	O
Imperial	O
College	O
and	O
with	O
reference	O
to	O
the	O
literature	O
on	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
.	O

The	O
angle	O
of	O
the	O
exhaled	O
air	O
from	O
coughing	B-DISO
was	O
around	O
38	O
°	O
for	O
the	O
males	O
and	O
32	O
°	O
for	O
the	O
females	O
,	O
while	O
that	O
of	O
the	O
exhaled	O
air	O
from	O
speaking	O
was	O
around	O
49	O
°	O
and	O
78	O
°	O
respectively	O
.	O

Both	O
D2	O
-	O
tsS133A	O
and	O
D3	O
-	O
tsF219L	O
were	O
impaired	B-DISO
for	O
viral	O
replication	O
and	O
nsp5	O
-	O
mediated	O
polyprotein	O
processing	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Passage	O
of	O
tsS133A	O
and	O
tsF219L	O
at	O
the	O
nonpermissive	O
temperature	O
resulted	O
in	O
emergence	O
of	O
multiple	O
second	O
-	O
site	O
suppressor	B-DISO
mutations	I-DISO
,	O
singly	O
and	O
in	O
combinations	O
.	O

However	O
,	O
incidence	O
and	O
severity	O
of	O
lung	B-DISO
inflammation	I-DISO
was	O
not	O
reduced	O
despite	O
the	O
limited	O
viral	O
replication	O
upon	O
rechallenge	O
.	O

Most	O
of	O
the	O
contigs	O
had	O
low	O
identities	O
to	O
known	O
viral	O
genomic	O
or	O
protein	O
sequences	O
,	O
suggesting	O
that	O
a	O
large	O
number	O
of	O
novel	O
and	O
genetically	O
diverse	O
insect	O
viruses	O
as	O
well	O
as	O
putative	O
mammalian	O
viruses	O
are	O
transmitted	B-DISO
by	O
bats	O
in	O
China	O
.	O

ABSTRACT	O
:	O
θ	O
-	O
Defensins	O
are	O
cyclic	O
octadecapeptides	O
found	O
in	O
nonhuman	O
primates	O
whose	O
broad	O
antiviral	O
spectrum	O
includes	O
HIV	B-DISO
-	O
1	O
,	O
HSV	O
-	O
1	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
).	O

Development	O
of	O
modified	O
θ	O
-	O
defensin	O
analogs	O
provides	O
an	O
approach	O
for	O
creating	O
novel	O
antiviral	O
agents	O
for	O
IAV	O
infections	B-DISO
.	O

Male	O
preponderance	O
and	O
motor	O
weakness	B-DISO
was	O
the	O
most	O
common	O
presenting	O
illness	O
and	O
a	O
majority	O
achieved	O
full	O
recovery	O
in	O
our	O
series	O
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
secondary	O
to	O
acute	O
fibrinous	O
and	O
organizing	B-DISO
pneumonia	I-DISO
requiring	O
mechanical	O
ventilation	O
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

Seven	O
critically	B-DISO
ill	I-DISO
patients	O
on	O
venovenous	O
ECMO	O
for	O
severe	O
pandemic	O
(	O
H1N1	O
)	O
influenza	B-DISO
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
treated	O
with	O
various	O
doses	O
of	O
oseltamivir	O
(	O
75	O
or	O
150	O
mg	O
twice	O
daily	O
).	O

However	O
,	O
the	O
drug	O
accumulated	O
in	O
the	O
plasma	O
of	O
patients	O
on	O
ECMO	O
who	O
also	O
received	O
CVVHDF	O
for	O
renal	B-DISO
failure	I-DISO
.	O

The	O
disease	O
is	O
characterized	O
by	O
vomiting	B-DISO
,	O
severe	B-DISO
diarrhea	I-DISO
,	O
and	O
a	O
high	O
mortality	O
rate	O
(	O
82	O
.	O
3	O
%)	O
in	O
newborn	O
piglets	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
new	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
genotypes	O
or	O
serotypes	O
along	O
with	O
the	O
poor	O
cross	O
-	O
protection	O
observed	O
among	O
IBV	O
serotypes	O
have	O
complicated	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
control	O
programs	O
in	O
different	O
geographic	O
regions	O
.	O

Strong	O
government	O
commitment	O
to	O
public	O
health	O
responses	O
and	O
improvements	O
in	O
quality	O
of	O
life	O
has	O
led	O
to	O
the	O
eradication	O
or	O
containment	O
of	O
a	O
wide	O
range	O
of	O
infectious	B-DISO
diseases	I-DISO
in	O
China	O
.	O

TITLE	O
:	O
New	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

Rarely	O
,	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
may	O
occur	O
.	O

ABSTRACT	O
:	O
In	O
this	O
review	O
,	O
we	O
report	O
that	O
the	O
receptor	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	B-DISO
molecule	O
1	O
(	O
CEACAM1	O
),	O
is	O
an	O
important	O
determinant	O
of	O
mouse	O
susceptibility	O
to	O
MHV	O
infection	B-DISO
.	O

TITLE	O
:	O
Mycoplasma	B-DISO
pneumoniae	I-DISO
pneumonia	I-DISO
in	O
children	O
.	O

ABSTRACT	O
:	O
Mycoplasma	B-DISO
pneumoniae	O
(	O
MP	O
),	O
the	O
smallest	O
self	O
-	O
replicating	O
biological	O
system	O
,	O
is	O
a	O
common	O
cause	O
of	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
,	O
leading	O
to	O
a	O
wide	O
range	O
of	O
pulmonary	O
and	O
extra	O
-	O
pulmonary	O
manifestations	O
.	O

MP	O
infection	B-DISO
is	O
endemic	O
in	O
larger	O
communities	O
of	O
the	O
world	O
with	O
cyclic	O
epidemics	O
every	O
3	O
to	O
7	O
years	O
.	O

Within	O
28	O
d	O
after	O
HSCT	O
,	O
nine	O
patients	O
were	O
infected	O
with	O
RVs	O
;	O
the	O
incidence	O
of	O
a	O
first	O
episode	O
of	O
RV	O
infection	B-DISO
within	O
28	O
d	O
after	O
HSCT	O
was	O
5	O
.	O
1	O
%.	O

TITLE	O
:	O
Etiology	O
and	O
clinical	O
characterization	O
of	O
respiratory	O
virus	O
infections	B-DISO
in	O
adult	O
patients	O
attending	O
an	O
emergency	B-DISO
department	O
in	O
Beijing	O
.	O

RbCoV	O
HKU14	O
was	O
able	O
to	O
replicate	O
in	O
HRT	O
-	O
18G	O
and	O
RK13	O
cells	O
with	O
cytopathic	B-DISO
effects	I-DISO
.	O

Therefore	O
,	O
an	O
experiment	O
with	O
1	O
-	O
d	O
-	O
old	O
male	O
broilers	O
(	O
Ross	O
308	O
)	O
was	O
carried	O
out	O
to	O
examine	O
the	O
effects	O
of	O
feeding	O
DON	O
-	O
contaminated	O
low	O
-	O
protein	O
grower	O
diets	O
on	O
performance	O
,	O
serum	O
biochemical	O
parameters	O
,	O
lymphoid	O
organ	O
weight	O
,	O
and	O
antibody	O
titers	O
to	O
infectious	B-DISO
bronchitis	B-DISO
vaccination	O
in	O
serum	O
and	O
to	O
evaluate	O
the	O
effects	O
of	O
Mycofix	O
select	O
dietary	O
supplementation	O
in	O
either	O
the	O
presence	O
or	O
absence	O
of	O
DON	O
in	O
broilers	O
.	O

Moreover	O
,	O
contamination	O
of	O
the	O
broiler	O
diet	O
with	O
DON	O
increased	O
the	O
heteropil	O
:	O
lymphocyte	O
ratio	O
(	O
stress	O
index	O
),	O
suggesting	O
that	O
DON	O
elevated	O
the	O
physiological	B-DISO
stress	I-DISO
responses	O
of	O
broilers	O
.	O

When	O
left	O
untreated	O
,	O
the	O
mortality	O
rate	O
for	O
scrub	B-DISO
typhus	I-DISO
will	O
be	O
increased	O
.	O

ABSTRACT	O
:	O
In	O
2009	O
,	O
during	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
epidemic	O
,	O
there	O
were	O
many	O
reported	O
cases	O
of	O
pulmonary	B-DISO
infection	I-DISO
with	O
severe	O
hypoxemia	O
that	O
was	O
refractory	O
to	O
the	O
ventilatory	O
strategies	O
and	O
rescue	O
therapies	O
commonly	O
used	O
to	O
treat	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Barth	B-DISO
syndrome	I-DISO
in	O
a	O
female	O
patient	O
.	O

This	O
girl	O
experienced	O
severe	O
heart	B-DISO
failure	I-DISO
at	O
1	O
-	O
month	O
of	O
age	O
.	O

Echocardiography	O
diagnosed	O
dilated	O
-	O
hypokinetic	B-DISO
and	O
hypertrophic	B-DISO
cardiomyopathy	I-DISO
with	O
noncompaction	O
of	O
the	O
left	O
ventricle	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
find	O
new	O
molecules	O
for	O
antiviral	O
drug	O
design	O
,	O
we	O
screened	O
102	O
ethyl	O
acetate	O
extracts	O
from	O
New	O
-	O
Caledonian	O
flora	O
for	O
antiviral	O
activity	O
against	O
the	O
dengue	B-DISO
2	O
virus	O
RNA	O
-	O
dependant	O
RNA	O
polymerase	O
(	O
DV	O
-	O
NS5	B-DISO
RdRp	O
).	O

Biflavonoids	O
appeared	O
to	O
be	O
potent	O
inhibitors	O
of	O
DV	O
-	O
NS5	B-DISO
RdRp	O
with	O
IC	O
(	O
50	O
)	O
s	O
between	O
0	O
.	O
26	O
and	O
3	O
.	O
12	O
µM	O
.	O
Inhibitory	O
activity	O
evaluations	O
against	O
the	O
RNA	O
polymerase	O
from	O
other	O
Flaviviridae	O
viruses	O
allowed	O
us	O
to	O
conclude	O
that	O
these	O
compounds	O
are	O
specific	O
inhibitors	O
of	O
the	O
DV	O
RNA	O
polymerase	O
.	O

Transfection	O
of	O
the	O
RNA	O
transcripts	O
into	O
permissive	O
cells	O
led	O
to	O
the	O
recovery	O
of	O
infectious	B-DISO
virus	O
(	O
recSARS	O
-	O
CoV	O
).	O

The	O
patient	O
was	O
diagnosed	O
with	O
hepatopulmonary	B-DISO
syndrome	I-DISO
,	O
since	O
liver	B-DISO
disease	I-DISO
of	O
alcoholic	O
origin	O
was	O
present	O
,	O
markedly	O
increased	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
existed	O
,	O
and	O
intrapulmonary	O
vascular	O
dilations	O
were	O
demonstrated	O
.	O

The	O
incidence	O
of	O
DAH	O
(	O
in	O
the	O
US	O
and	O
Europe	O
is	O
100	O
,	O
000	O
-	O
150	O
,	O
000	O
,	O
and	O
50	O
,	O
000	O
patients	O
annually	O
are	O
at	O
risk	O
of	O
developing	O
DAH	O
following	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
HSCT	O
)	O
and	O
autoimmune	B-DISO
diseases	I-DISO
.	O

We	O
have	O
provided	O
evidence	O
for	O
the	O
involvement	O
of	O
recruited	O
neutrophils	O
,	O
their	O
toxic	O
enzymes	O
such	O
as	O
myeloperoxidase	O
and	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
and	O
neutrophil	O
extracellular	O
traps	B-DISO
in	O
aggravating	O
alveolar	O
-	O
capillary	O
damage	O
.	O

Our	O
results	O
demonstrate	O
significantly	O
decreased	O
inflammation	B-DISO
and	O
protein	O
leakage	B-DISO
in	O
the	O
lungs	O
after	O
DOX	O
treatment	O
.	O

ABSTRACT	O
:	O
This	O
retrospective	O
study	O
was	O
conducted	O
in	O
order	O
to	O
determine	O
the	O
incidence	O
of	O
various	O
complications	O
of	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
based	O
on	O
a	O
review	O
of	O
case	O
records	O
in	O
a	O
tertiary	O
care	O
hospital	O
in	O
New	O
Delhi	O
,	O
India	O
.	O

The	O
complications	O
seen	O
in	O
the	O
P	O
.	O
vivax	O
cases	O
were	O
:	O
thrombocytopenia	O
;	O
hepatic	B-DISO
dysfunction	I-DISO
;	O
renal	O
damage	O
;	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

There	O
were	O
three	O
deaths	O
as	O
a	O
result	O
of	O
ARDS	B-DISO
.	O

Given	O
the	O
genetic	O
diversity	O
of	O
respiratory	O
viruses	O
and	O
the	O
emergence	O
of	O
drug	O
resistant	O
strains	O
,	O
the	O
targeted	O
disruption	O
of	O
human	O
host	O
-	O
virus	O
interactions	O
is	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
treating	O
multi	O
-	O
viral	B-DISO
infections	I-DISO
.	O

75	O
C3H	O
/	O
HeJ	O
female	O
mice	O
were	O
done	O
into	O
two	O
groups	O
,	O
39	O
for	O
model	O
group	O
of	O
chronic	B-DISO
hepatitis	I-DISO
induced	O
by	O
MHV3	O
,	O
36	O
for	O
control	O
.	O

Similar	O
to	O
previous	O
studies	O
,	O
nurses	O
working	O
at	O
the	O
'	O
front	O
line	O
'	O
believed	O
that	O
infection	B-DISO
from	O
these	O
diseases	O
was	O
an	O
unavoidable	O
occupational	O
hazard	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
used	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
describe	O
two	O
patients	O
,	O
both	O
with	O
H1N1	O
pneumonia	B-DISO
complicated	O
by	O
invasive	B-DISO
Aspergillosis	I-DISO
,	O
who	O
required	O
ECMO	O
support	O
significantly	O
longer	O
at	O
45	O
and	O
52	O
days	O
,	O
but	O
eventually	O
made	O
a	O
full	O
recovery	O
.	O

Early	O
in	O
infection	B-DISO
,	O
nascent	O
viral	O
RNA	O
and	O
nsp	O
'	O
s	O
colocalized	O
with	O
or	O
occurred	O
adjacent	O
to	O
dsRNA	O
foci	O
.	O

TITLE	O
:	O
Evidence	O
for	O
ACE2	O
-	O
utilizing	O
coronaviruses	O
(	O
CoVs	O
)	O
related	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
in	O
bats	O
.	O

We	O
have	O
previously	O
shown	O
that	O
transplantation	O
of	O
neural	O
progenitor	O
cells	O
(	O
NPCs	O
)	O
into	O
mice	O
persistently	O
infected	O
with	O
the	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
results	O
in	O
enhanced	O
differentiation	O
into	O
oligodendrocyte	O
progenitor	O
cells	O
(	O
OPCs	O
)	O
that	O
is	O
associated	O
with	O
remyelination	O
and	O
axonal	O
sparing	O
.	O

The	O
current	O
study	O
examines	O
the	O
contributions	O
of	O
the	O
transcription	O
factor	O
Olig1	O
on	O
NPC	B-DISO
differentiation	O
and	O
remyelination	O
.	O

Transplantation	O
of	O
Olig1	O
-/-	O
and	O
Olig1	O
+/+	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
mice	O
resulted	O
in	O
similar	O
cell	O
survival	O
,	O
proliferation	B-DISO
,	O
and	O
selective	O
migration	O
to	O
areas	O
of	O
demyelination	B-DISO
.	O

TITLE	O
:	O
Trends	O
in	O
and	O
perspectives	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
adult	O
respiratory	B-DISO
failure	I-DISO
.	O

RNS	B-DISO
was	O
done	O
on	O
right	O
and	O
left	O
median	O
and	O
ulnar	O
nerves	O
at	O
1	O
,	O
3	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
and	O
30	O
Hz	O
.	O

The	O
authors	O
propose	O
that	O
increasing	O
the	O
concentration	O
of	O
the	O
inoculum	O
without	O
changing	O
the	O
bacterial	O
dose	O
will	O
lead	O
to	O
severe	B-DISO
sepsis	I-DISO
with	O
pronounced	O
pulmonary	O
lesions	O
.	O

Although	O
Heme	O
/	O
HO	O
-	O
1	O
and	O
CXCL10	O
/	O
CXCR3	O
interactions	O
are	O
directly	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
CM	O
and	O
fatal	O
disease	O
,	O
the	O
mechanism	O
dictating	O
how	O
Heme	O
/	O
HO	O
-	O
1	O
and	O
CXCL10	O
/	O
CXCR3	O
are	O
expressed	O
and	O
regulated	O
under	O
these	O
conditions	O
is	O
still	O
unknown	O
.	O

The	O
results	O
demonstrate	O
that	O
(	O
1	O
)	O
STAT3	O
is	O
activated	O
by	O
P	O
.	O
berghei	O
ANKA	O
(	O
PBA	O
)	O
infection	B-DISO
in	O
vivo	O
and	O
Heme	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
these	O
factors	O
are	O
mutually	O
regulated	O
and	O
provide	O
new	O
opportunities	O
to	O
develop	O
potential	O
novel	O
therapeutic	O
targets	O
that	O
could	O
be	O
used	O
to	O
supplement	O
traditional	O
prophylactics	O
and	O
treatments	O
for	O
malaria	B-DISO
and	O
improve	O
clinical	O
outcomes	O
while	O
reducing	O
malaria	B-DISO
mortality	O
.	O

Our	O
ultimate	O
goal	O
is	O
to	O
develop	O
novel	O
therapies	O
targeting	O
Heme	O
or	O
CXCL10	O
-	O
related	O
biological	O
signaling	O
molecules	O
associated	O
with	O
development	O
of	O
fatal	O
malaria	B-DISO
.	O

To	O
investigate	O
single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
repertoire	O
against	O
pAPN	O
,	O
the	O
genes	O
encoding	O
the	O
immunoglobulin	O
light	O
chain	O
variable	O
region	O
(	O
VL	O
)	O
and	O
heavy	O
chain	O
variable	O
region	O
(	O
VH	O
)	O
were	O
amplified	O
by	O
reverse	O
transcript	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
series	O
of	O
degenerate	B-DISO
primers	O
from	O
the	O
spleen	O
of	O
BABL	O
/	O
c	O
mice	O
immunized	O
with	O
native	O
pAPN	O
.	O

TITLE	O
:	O
Immunopathological	O
effects	O
of	O
experimental	O
T	O
-	O
2	O
mycotoxocosis	O
in	O
broiler	O
chicken	O
co	O
-	O
infected	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

The	O
mean	O
HI	O
titres	O
to	O
ND	O
vaccine	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lower	O
in	O
the	O
toxin	O
groups	O
at	O
all	O
the	O
intervals	O
,	O
and	O
the	O
antibody	O
titres	O
in	O
IBV	O
infected	O
group	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
than	O
that	O
of	O
T	O
-	O
2	O
toxin	O
fed	O
and	O
co	O
-	O
infected	O
with	O
IBV	O
group	O
but	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lower	O
than	O
the	O
control	O
at	O
21	O
(	O
3	O
)	O
and	O
28	O
(	O
10	O
)	O
days	O
of	O
toxin	O
feeding	O
(	O
DTF	O
)	O
(	O
days	O
post	O
infection	B-DISO
(	O
DPI	O
)).	O

The	O
patient	O
decompensated	O
,	O
developing	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
with	O
renal	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Lung	O
injury	O
in	O
acute	B-DISO
pancreatitis	I-DISO
:	O
mechanisms	O
underlying	O
augmented	O
secondary	O
injury	O
.	O

Following	O
secondary	O
pulmonary	B-DISO
infection	I-DISO
there	O
can	O
be	O
an	O
exacerbation	O
of	O
AP	O
-	O
associated	O
lung	O
injury	O
,	O
greater	O
than	O
the	O
sum	O
of	O
the	O
individual	O
injuries	O
alone	O
.	O

TITLE	O
:	O
A	O
reverse	O
genetics	O
approach	O
to	O
study	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
The	O
world	O
had	O
been	O
anticipating	O
another	O
influenza	B-DISO
pandemic	O
since	O
the	O
last	O
one	O
in	O
1968	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
ECMO	O
)	O
support	O
was	O
applied	O
in	O
cases	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
not	O
responsive	O
to	O
conventional	O
treatments	O
.	O

Eleven	O
patients	O
received	O
VA	O
ECMO	O
support	O
due	O
to	O
cardiac	B-DISO
failure	I-DISO
(	O
2	O
post	O
-	O
resuscitation	O
).	O

ABSTRACT	O
:	O
HELLP	B-DISO
syndrome	I-DISO
(	O
hemolysis	B-DISO
,	O
elevated	O
liver	O
enzymes	O
,	O
low	O
platelets	O
)	O
is	O
a	O
severe	O
microcirculatory	O
disturbance	O
during	O
pregnancy	O
,	O
associated	O
with	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
,	O
but	O
it	O
may	O
occur	O
also	O
without	O
it	O
.	O

Typical	O
complications	O
include	O
coagulation	B-DISO
disorder	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
infections	B-DISO
,	I-DISO
central	I-DISO
nervous	I-DISO
system	I-DISO
symptoms	O
,	O
hepatic	B-DISO
failure	I-DISO
and	O
bleeding	B-DISO
,	O
and	O
premature	O
ablation	O
of	O
the	O
placenta	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
vivax	O
is	O
causing	O
increasingly	O
more	O
cases	O
of	O
severe	O
malaria	B-DISO
worldwide	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
in	O
farmed	O
European	O
wild	O
boars	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
associated	O
with	O
a	O
range	O
of	O
common	O
porcine	O
viral	O
and	O
bacterial	B-DISO
infections	I-DISO
,	O
namely	O
,	O
porcine	O
parvovirus	B-DISO
(	O
PPV	O
),	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
swine	B-DISO
influenza	I-DISO
virus	O
(	O
SIV	B-DISO
),	O
Aujeszky	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
virus	O
(	O
ADV	O
),	O
classical	B-DISO
swine	I-DISO
fever	I-DISO
virus	O
(	O
CSFV	O
),	O
swine	B-DISO
vesicular	I-DISO
disease	I-DISO
virus	O
(	O
SVDV	O
),	O
coronavirus	O
causing	O
transmissible	O
gastroenteritis	B-DISO
(	O
TGEV	O
),	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
),	O
Mycoplasma	B-DISO
hyopneumoniae	O
,	O
Lawsonia	O
intracellularis	O
,	O
Brucella	O
spp	O
.,	O
and	O
Leptospira	O
spp	O
.	O

ABSTRACT	O
:	O
Fifty	O
-	O
seven	O
derivatives	O
of	O
glycyrrhetinic	O
acid	O
(	O
GA	O
)	O
were	O
synthesized	O
,	O
and	O
their	O
anti	O
-	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
activity	O
was	O
evaluated	O
in	O
HepG	O
2	O
.	O
2	O
.	O
15	O
cells	O
.	O

ABSTRACT	O
:	O
Treatment	O
of	O
patients	O
suffering	B-DISO
from	O
acute	O
lung	O
injury	O
is	O
a	O
challenge	O
for	O
the	O
treating	O
physician	O
.	O

This	O
easy	O
-	O
to	O
-	O
score	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
virus	B-DISO
infection	I-DISO
risk	O
index	O
accurately	O
stratifies	O
patients	O
hospitalized	O
for	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
into	O
low	O
-,	O
intermediate	O
-,	O
and	O
high	O
-	O
risk	O
groups	O
for	O
SIHC	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
and	O
phylogenetic	O
analysis	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
field	O
strains	O
in	O
south	O
China	O
.	O

ABSTRACT	O
:	O
A	O
virulent	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
strain	O
,	O
DR13	O
,	O
was	O
obtained	O
from	O
suckling	O
pigs	O
suspected	O
of	O
having	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
in	O
1999	O
in	O
Korea	O
,	O
and	O
its	O
attenuated	O
counterpart	O
was	O
derived	O
from	O
virulent	O
strain	O
DR13	O
by	O
serial	O
propagation	O
in	O
Vero	O
cells	O
.	O

These	O
results	O
demonstrated	O
that	O
peptide	O
Kn2	O
-	O
7	O
could	O
inhibit	O
HIV	B-DISO
-	O
1	O
by	O
direct	O
interaction	O
with	O
viral	O
particle	O
and	O
may	O
become	O
a	O
promising	O
candidate	O
compound	O
for	O
further	O
development	O
of	O
microbicide	O
against	O
HIV	B-DISO
-	O
1	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
in	O
China	O
in	O
2002	O
and	O
spread	O
to	O
other	O
countries	O
before	O
brought	O
under	O
control	O
.	O

Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
have	O
been	O
functionally	O
linked	O
with	O
septic	O
and	O
endotoxin	O
shock	O
,	O
with	O
cytokine	O
release	O
syndromes	B-DISO
and	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Participants	O
were	O
invited	O
to	O
discuss	O
their	O
perceptions	O
of	O
influenza	B-DISO
(	O
seasonal	O
vs	O
.	O
pandemic	O
)	O
in	O
terms	O
of	O
perceived	O
severity	O
and	O
impact	O
,	O
and	O
attitudes	O
towards	O
infection	B-DISO
control	O
measures	O
including	O
hand	O
-	O
washing	O
and	O
the	O
use	O
of	O
social	O
distancing	O
,	O
isolation	O
or	O
cough	B-DISO
etiquette	O
.	O

While	O
participants	O
were	O
generally	O
knowledgeable	O
about	O
influenza	B-DISO
transmission	O
,	O
they	O
were	O
unable	O
to	O
accurately	O
define	O
what	O
'	O
pandemic	O
influenza	B-DISO
'	O
meant	O
.	O

Given	O
the	O
high	O
levels	O
of	O
interaction	O
that	O
occurs	O
in	O
a	O
university	O
setting	O
,	O
it	O
is	O
really	O
important	O
that	O
students	O
are	O
informed	O
about	O
disease	B-DISO
transmission	I-DISO
and	O
about	O
risk	O
of	O
infection	B-DISO
.	O

Of	O
those	O
animals	O
sampled	O
on	O
two	O
or	O
more	O
occasions	O
,	O
none	O
tested	O
positive	O
on	O
arrival	O
,	O
and	O
54	O
.	O
5	O
%	O
later	O
shed	O
CECoV	O
,	O
suggesting	O
that	O
infection	B-DISO
may	O
have	O
been	O
acquired	O
within	O
the	O
kennel	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
61	O
-	O
year	O
-	O
old	O
woman	O
with	O
no	O
significant	O
pulmonary	O
or	O
cardiac	B-DISO
disease	I-DISO
who	O
presented	O
with	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
in	O
the	O
setting	O
of	O
opioid	O
overdose	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
vitro	O
infection	B-DISO
by	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
induces	O
massive	O
cytopathic	B-DISO
effects	I-DISO
in	O
DCs	B-DISO
,	O
including	O
the	O
formation	O
of	O
large	O
syncytia	O
and	O
cell	O
death	O
within	O
only	O
few	O
hours	O
.	O

In	O
sum	O
,	O
our	O
results	O
show	O
that	O
TMPRSS2	O
and	O
HAT	O
are	O
expressed	O
by	O
important	O
influenza	B-DISO
and	O
SARS	B-DISO
-	O
coronavirus	O
target	O
cells	O
and	O
could	O
thus	O
support	O
viral	O
spread	O
in	O
the	O
human	O
host	O
.	O

Therefore	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
novel	O
vaccines	O
that	O
prevent	O
QX	O
-	O
like	O
IBV	O
infection	B-DISO
.	O

We	O
identified	O
5	O
case	O
-	O
control	O
and	O
5	O
retrospective	O
cohort	O
studies	O
which	O
evaluated	O
transmission	O
of	O
SARS	B-DISO
to	O
HCWs	O
.	O

Other	O
intubation	O
associated	O
procedures	O
,	O
endotracheal	O
aspiration	B-DISO
,	O
suction	O
of	O
body	O
fluids	O
,	O
bronchoscopy	O
,	O
nebulizer	O
treatment	O
,	O
administration	O
of	O
O2	O
,	O
high	O
flow	O
O2	O
,	O
manipulation	O
of	O
O2	O
mask	O
or	O
BiPAP	O
mask	O
,	O
defibrillation	O
,	O
chest	O
compressions	O
,	O
insertion	O
of	O
nasogastric	O
tube	O
,	O
and	O
collection	O
of	O
sputum	O
were	O
not	O
significant	O
.	O

The	O
samples	O
from	O
various	O
tissues	O
were	O
collected	O
at1	B-DISO
,	O
2	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
13	O
,	O
15	O
,	O
and	O
20	O
days	O
postinoculation	O
.	O

ABSTRACT	O
:	O
Colonic	B-DISO
obstruction	I-DISO
due	O
to	O
sigmoid	B-DISO
colon	I-DISO
volvulus	I-DISO
during	O
pregnancy	O
is	O
a	O
rare	O
but	O
complication	B-DISO
with	O
significant	O
maternal	O
and	O
fetal	O
mortality	O
.	O

ARDS	B-DISO
was	O
successfully	O
treated	O
using	O
emergency	B-DISO
extracorporeal	O
membrane	O
oxygenation	O
within	O
3	O
h	O
after	O
the	O
incident	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
pathogenesis	B-DISO
:	O
host	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
and	O
viral	O
antagonism	O
of	O
interferon	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
-	O
CoV	O
is	O
a	O
pathogenic	O
coronavirus	O
that	O
emerged	O
from	O
a	O
zoonotic	O
reservoir	O
,	O
leading	O
to	O
global	O
dissemination	O
of	O
the	O
virus	O
.	O

The	O
association	O
SARS	B-DISO
-	O
CoV	O
with	O
aberrant	O
cytokine	O
,	O
chemokine	O
,	O
and	O
Interferon	O
Stimulated	O
Gene	O
(	O
ISG	O
)	O
responses	O
in	O
patients	O
provided	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
is	O
at	O
least	O
partially	O
controlled	O
by	O
innate	O
immune	O
signaling	O
.	O

Following	O
infection	B-DISO
of	O
Vero118	O
cells	O
,	O
virus	O
-	O
induced	O
CPE	O
was	O
too	O
low	O
to	O
allow	O
readout	O
based	O
on	O
classical	O
colorimetric	O
methods	O
(	O
such	O
as	O
the	O
MTS	B-DISO
assay	O
),	O
even	O
following	O
prolonged	O
incubation	O
times	O
(>	O
7	O
days	O
).	O

While	O
none	O
of	O
the	O
compounds	O
,	O
examined	O
in	O
our	O
study	O
inhibited	O
the	O
DNA	O
unwinding	O
activity	O
or	O
ATPase	O
activity	O
of	O
human	O
HCV	O
helicase	O
protein	O
,	O
we	O
found	O
that	O
myricetin	O
and	O
scutellarein	O
potently	O
inhibit	O
the	O
SARS	B-DISO
-	O
CoV	O
helicase	O
protein	O
in	O
vitro	O
by	O
affecting	O
the	O
ATPase	O
activity	O
,	O
but	O
not	O
the	O
unwinding	O
activity	O
,	O
nsP13	O
.	O

It	O
is	O
not	O
surprising	O
that	O
change	O
in	O
NOXs	O
'	O
expression	O
and	O
function	O
is	O
involved	O
in	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Inoculation	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
into	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
of	O
susceptible	O
strains	O
of	O
mice	O
results	O
in	O
wide	O
-	O
spread	O
replication	O
within	O
glial	O
cells	O
accompanied	O
by	O
infiltration	B-DISO
of	O
virus	O
-	O
specific	O
T	O
lymphocytes	O
that	O
control	O
virus	O
through	O
cytokine	O
secretion	O
and	O
cytolytic	O
activity	O
.	O

Virus	O
persists	O
within	O
white	O
matter	O
tracts	O
of	O
surviving	O
mice	O
resulting	O
in	O
demyelination	B-DISO
that	O
is	O
amplified	O
by	O
inflammatory	O
T	O
cells	O
and	O
macrophages	O
.	O

During	O
chronic	B-DISO
disease	I-DISO
,	O
CXCR2	O
signaling	O
on	O
oligodendroglia	O
protects	O
these	O
cells	O
from	O
apoptosis	O
and	O
restricts	O
the	O
severity	O
of	O
demyelination	B-DISO
.	O

ILI	O
could	O
not	O
distinguish	O
A	O
/	O
H1N1p	O
infection	B-DISO
from	O
that	O
due	O
to	O
other	O
respiratory	O
viruses	O
.	O

On	O
the	O
3rd	O
day	O
,	O
the	O
patient	O
showed	O
progressive	O
amelioration	O
of	O
his	O
dyspnoea	B-DISO
,	O
oxygen	O
needs	O
and	O
chest	O
infiltrates	B-DISO
.	O

TITLE	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
secondary	O
to	O
chronic	B-DISO
constipation	I-DISO
.	O

ABSTRACT	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
is	O
defined	O
as	O
an	O
elevated	O
intraabdominal	O
pressure	O
with	O
evidence	O
of	O
organ	O
dysfunction	O
.	O

We	O
describe	O
the	O
unusual	O
presentation	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
with	O
a	O
long	O
history	O
of	O
chronic	B-DISO
constipation	I-DISO
who	O
developed	O
acute	O
ACS	O
requiring	O
resuscitative	O
measures	O
and	O
emergent	O
disimpaction	O
.	O

To	O
determine	O
the	O
detection	O
frequency	O
of	O
HPeV	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
samples	O
collected	O
from	O
children	O
aged	O
<	O
5	O
years	O
hospitalized	O
between	O
2008	O
and	O
2010	O
in	O
the	O
University	O
Hospital	O
of	O
Lyon	O
and	O
to	O
describe	O
the	O
clinical	O
,	O
virological	O
and	O
biological	O
characteristics	O
associated	O
with	O
HPeV	O
infection	B-DISO
.	O

Some	O
of	O
them	O
developed	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
or	O
severe	O
dyspnea	B-DISO
on	O
6	O
days	O
after	O
disease	O
onset	O
.	O

Malignancy	B-DISO
may	O
be	O
considered	O
to	O
be	O
a	O
relative	O
contraindication	O
to	O
ECMO	O
support	O
.	O

The	O
reason	O
for	O
death	O
in	O
all	O
these	O
patients	O
was	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
with	O
subsequent	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
.	O

In	O
influenza	B-DISO
A	I-DISO
virus	I-DISO
infection	I-DISO
we	O
show	O
that	O
viral	O
clearance	O
is	O
determined	O
by	O
sex	O
but	O
not	O
by	O
CD200R	O
signaling	O
.	O

This	O
effect	O
is	O
specific	O
for	O
SARS	B-DISO
-	O
CoV	O
nsp12	O
,	O
as	O
no	O
change	O
in	O
nsp13	O
activity	O
was	O
observed	O
when	O
foot	O
-	O
and	O
-	O
mouth	O
-	O
disease	O
virus	O
RdRp	O
was	O
used	O
in	O
place	O
of	O
nsp12	O
.	O

TITLE	O
:	O
The	O
adjuvanticity	O
of	O
an	O
O	O
.	O
volvulus	B-DISO
-	O
derived	O
rOv	O
-	O
ASP	O
-	O
1	O
protein	O
in	O
mice	O
using	O
sequential	O
vaccinations	O
and	O
in	O
non	O
-	O
human	O
primates	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
biochemical	O
and	O
biological	O
properties	O
of	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
15	O
among	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
virus	O
-	O
infected	O
and	O
ectopically	O
expressed	O
cells	O
.	O

Among	O
the	O
polyphenolic	O
compounds	O
examined	O
,	O
(-)-	O
catechin	O
gallate	O
and	O
(-)-	O
gallocatechin	O
gallate	O
demonstrated	O
a	O
remarkable	O
inhibition	O
activity	O
on	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
.	O

It	O
could	O
not	O
be	O
verified	O
whether	O
being	O
overweight	B-DISO
was	O
a	O
factor	O
of	O
higher	O
mortality	O
due	O
to	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
amongst	O
pregnant	O
women	O
in	O
the	O
state	O
of	O
Mexico	O
.	O

The	O
B	O
and	O
T	O
lymphocyte	O
attenuator	O
(	O
BTLA	O
)	O
is	O
an	O
immunoglobulin	O
-	O
domain	O
-	O
containing	O
protein	O
that	O
has	O
the	O
capacity	O
to	O
maintain	O
peripheral	O
tolerance	B-DISO
and	O
limit	O
immunopathological	O
damage	O
during	O
immune	O
responses	O
.	O

The	O
early	O
loss	O
of	O
macrophages	O
resulted	O
in	O
reduced	O
pathogenic	O
tumour	B-DISO
necrosis	I-DISO
factor	O
α	O
(	O
TNFα	O
)	O
and	O
FGL2	O
levels	O
and	O
lower	O
viral	O
titres	O
.	O

The	O
importance	O
of	O
TNFα	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
pathology	B-DISO
was	O
demonstrated	O
by	O
increased	O
mortality	O
in	O
TNFα	O
-	O
treated	O
MHV	O
-	O
3	O
-	O
infected	O
BTLA	O
-/-	O
mice	O
,	O
whereas	O
TNFα	O
-/-	O
mice	O
were	O
resistant	O
to	O
the	O
infection	B-DISO
.	O

TITLE	O
:	O
IFN	O
-	O
γ	O
protects	O
from	O
lethal	O
IL	O
-	O
17	O
mediated	O
viral	O
encephalomyelitis	B-DISO
independent	O
of	O
neutrophils	O
.	O

Transfer	O
of	O
GKO	O
memory	O
CD4	O
+	O
T	O
cells	O
into	O
infected	O
SCID	B-DISO
mice	O
induced	O
rapid	O
mortality	O
compared	O
to	O
recipients	O
of	O
WT	O
memory	O
CD4	O
+	O
T	O
cells	O
,	O
despite	O
similar	O
virus	O
control	O
and	O
demyelination	B-DISO
.	O

Recipients	O
of	O
WT	O
CD4	O
+	O
T	O
cells	O
depleted	O
of	O
IFN	O
-	O
γ	O
did	O
not	O
express	O
IL	O
-	O
17	O
and	O
were	O
spared	O
from	O
mortality	O
despite	O
abundant	O
CNS	O
neutrophil	O
infiltration	B-DISO
,	O
indicating	O
that	O
mortality	O
was	O
not	O
mediated	O
by	O
excessive	O
CNS	O
neutrophil	O
accumulation	O
.	O

Animals	O
were	O
examined	O
for	O
T	O
lymphocyte	O
proliferation	B-DISO
,	O
anti	O
-	O
PEDV	O
antibodies	O
,	O
IFN	O
-	O
γ	O
and	O
IL	O
-	O
4	O
protein	O
levels	O
,	O
and	O
cytotoxic	O
T	O
cell	O
function	O
in	O
mouse	O
peripheral	O
blood	O
and	O
spleen	O
.	O

TITLE	O
:	O
Drug	O
-	O
induced	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
:	O
mechanisms	O
and	O
best	O
diagnostic	O
approaches	O
.	O

On	O
physical	O
exam	O
the	O
patient	O
showed	O
tachycardia	O
,	O
dyspnoea	B-DISO
and	O
progressive	O
somnolence	O
.	O

The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	B-DISO
following	O
the	O
administration	O
of	O
MCP	O
is	O
described	O
in	O
this	O
case	O
report	O
.	O

(	O
2	O
)	O
Open	O
thoracic	B-DISO
surgery	O
is	O
needed	O
for	O
acute	O
cardiac	B-DISO
tamponade	I-DISO
,	O
intrapulmonary	O
vascular	O
injuries	O
,	O
progressive	O
intrathoracic	O
bleeding	B-DISO
,	O
lung	O
laceration	O
,	O
tracheal	O
breakage	O
,	O
and	O
diaphragmatic	O
injury	O
.	O

ABSTRACT	O
:	O
Cryptococcus	B-DISO
neoformans	I-DISO
is	O
associated	O
with	O
a	O
spectrum	O
of	O
diseases	O
including	O
meningoencephalitis	B-DISO
,	O
pneumonia	B-DISO
and	O
soft	B-DISO
tissue	I-DISO
infections	I-DISO
.	O

This	O
phenomenon	O
resulted	O
in	O
many	O
more	O
wounds	O
after	O
operations	O
,	O
increasing	O
the	O
risk	O
of	O
wound	B-DISO
infection	I-DISO
.	O

Compared	O
with	O
patients	O
who	O
received	O
treatment	O
≥	O
6	O
days	O
after	O
illness	O
onset	O
,	O
patients	O
treated	O
≤	O
2	O
days	O
after	O
illness	O
onset	O
were	O
less	O
likely	O
to	O
develop	O
ARDS	B-DISO
(	O
17	O
%	O
versus	O
37	O
%,	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
die	O
(	O
7	O
%	O
versus	O
35	O
%,	O
P	O
<	O
0	O
.	O
01	O
).	O

This	O
retrospective	O
study	O
included	O
13	O
patients	O
with	O
confirmed	O
S	O
-	O
OIV	O
infection	B-DISO
suffering	B-DISO
from	O
an	O
underlying	O
immunodeficiency	B-DISO
or	O
who	O
were	O
receiving	O
immunosuppressive	O
therapy	O
.	O

Six	O
(	O
50	O
%)	O
patients	O
showed	O
an	O
adverse	O
outcome	O
with	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
4	O
of	O
these	O
died	O
.	O

We	O
found	O
previously	O
that	O
the	O
de	O
novo	O
pyrimidine	O
synthesis	O
inhibitor	O
A77	O
-	O
1726	O
reversed	O
the	O
influenza	B-DISO
-	O
induced	O
impairment	B-DISO
of	O
alveolar	O
fluid	O
clearance	O
.	O

Patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
intact	O
alveolar	O
fluid	O
clearance	O
demonstrate	O
lower	O
mortality	O
than	O
those	O
with	O
compromised	O
fluid	O
clearance	O
.	O

ABSTRACT	O
:	O
Prone	O
positioning	O
(	O
PP	O
)	O
improves	O
oxygenation	O
and	O
may	O
provide	O
a	O
benefit	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
Influenza	B-DISO
is	O
easily	O
overlooked	O
in	O
intensive	O
care	O
units	O
(	O
ICUs	O
),	O
particularly	O
in	O
patients	O
with	O
alternative	O
causes	O
of	O
respiratory	B-DISO
failure	I-DISO
or	O
in	O
those	O
who	O
acquire	O
influenza	B-DISO
during	O
their	O
ICU	O
stay	O
.	O

We	O
defined	O
influenza	B-DISO
as	O
unsuspected	O
if	O
testing	O
was	O
not	O
requested	O
and	O
the	O
patient	O
was	O
not	O
receiving	O
empirical	O
antiviral	O
therapy	O
after	O
sample	O
collection	O
.	O

Multivariate	O
analysis	O
showed	O
admission	O
to	O
the	O
surgical	O
ICU	O
(	O
odds	O
ratio	O
(	O
OR	O
),	O
37	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
2	O
.	O
1	O
to	O
666	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
localized	O
infiltrate	B-DISO
on	O
chest	O
radiograph	O
(	O
OR	O
,	O
27	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
to	O
584	O
.	O
1	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
to	O
be	O
independent	O
risk	O
factors	O
for	O
unsuspected	O
influenza	B-DISO
.	O

CONCLUSIONS	O
:	O
During	O
the	O
influenza	B-DISO
season	O
,	O
almost	O
one	O
third	O
of	O
critical	O
patients	O
with	O
suspected	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
had	O
influenza	B-DISO
,	O
and	O
in	O
48	O
.	O
4	O
%,	O
the	O
influenza	B-DISO
was	O
unsuspected	O
.	O

ABSTRACT	O
:	O
Swine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
HEV	O
)	O
has	O
been	O
shown	O
to	O
have	O
a	O
capability	O
to	O
propagate	O
via	O
neural	O
circuits	O
to	O
the	O
central	O
nervous	B-DISO
system	O
after	O
peripheral	O
inoculation	O
,	O
resulting	O
in	O
acute	O
deadly	O
encephalomyelitis	B-DISO
in	O
natural	O
host	O
piglets	O
as	O
well	O
as	O
in	O
experimental	O
younger	O
rodents	O
.	O

TITLE	O
:	O
The	O
long	O
view	O
:	O
40	O
years	O
of	O
infectious	B-DISO
bronchitis	B-DISO
research	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
is	O
a	O
significant	O
pathogen	O
in	O
the	O
domestic	O
chicken	O
,	O
affecting	O
the	O
respiratory	O
and	O
renal	O
systems	O
as	O
well	O
as	O
the	O
female	O
reproductive	O
tract	O
.	O

We	O
are	O
showing	O
here	O
that	O
viruses	O
are	O
characterized	O
by	O
the	O
widest	O
spread	O
of	O
the	O
proteome	O
disorder	O
content	O
(	O
the	O
percentage	O
of	O
disordered	O
residues	O
ranges	O
from	O
7	O
.	O
3	O
%	O
in	O
human	O
coronavirus	O
NL63	O
to	O
77	O
.	O
3	O
%	O
in	O
Avian	O
carcinoma	B-DISO
virus	O
).	O

TITLE	O
:	O
Antagonism	O
of	O
the	O
interferon	O
-	O
induced	O
OAS	B-DISO
-	O
RNase	O
L	O
pathway	O
by	O
murine	O
coronavirus	O
ns2	B-DISO
protein	O
is	O
required	O
for	O
virus	O
replication	O
and	O
liver	O
pathology	B-DISO
.	O

The	O
murine	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
causes	O
acute	B-DISO
hepatitis	I-DISO
in	O
its	O
natural	O
host	O
and	O
provides	O
a	O
useful	O
model	O
for	O
understanding	O
virus	O
interaction	O
with	O
liver	O
cells	O
.	O

An	O
ns2	B-DISO
mutant	B-DISO
virus	O
was	O
unable	O
to	O
replicate	O
in	O
the	O
liver	O
or	O
induce	O
hepatitis	B-DISO
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
was	O
highly	O
pathogenic	O
in	O
RNase	O
L	O
deficient	O
mice	O
.	O

The	O
degree	O
to	O
which	O
achieving	O
IHR	O
compliance	O
will	O
result	O
in	O
global	O
health	O
security	O
is	O
not	O
clear	O
,	O
but	O
what	O
is	O
clear	O
is	O
that	O
progress	O
against	O
the	O
threat	O
of	O
epidemic	B-DISO
disease	I-DISO
requires	O
a	O
focused	O
approach	O
that	O
can	O
be	O
monitored	O
and	O
measured	O
efficiently	O
.	O

The	O
results	O
of	O
the	O
survey	O
showed	O
that	O
encephalopathy	B-DISO
was	O
reported	O
predominantly	O
in	O
males	O
.	O

In	O
conclusion	O
,	O
pdm	O
H1N1	O
2009	O
infection	B-DISO
-	O
associated	O
encephalopathy	B-DISO
was	O
a	O
critical	O
disease	O
in	O
children	O
,	O
with	O
rapidly	O
progressive	O
characteristics	O
similar	O
to	O
those	O
of	O
seasonal	O
influenza	B-DISO
-	O
associated	O
encephalopathy	B-DISO
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
with	O
a	O
large	O
deletion	O
in	O
the	O
5	O
'-	O
terminal	O
region	O
of	O
the	O
spike	O
gene	O
retains	O
its	O
virulence	O
for	O
cats	O
.	O

Resistant	O
cells	O
encode	O
distinct	O
mutations	O
in	O
the	O
NPC1	B-DISO
gene	O
,	O
resulting	O
in	O
loss	O
of	O
protein	O
expression	O
.	O

These	O
studies	O
reinforce	O
the	O
importance	O
of	O
NPC1	B-DISO
for	O
ebolavirus	O
entry	O
.	O

A	O
rapidly	O
growing	O
number	O
of	O
studies	O
have	O
reported	O
the	O
appearance	O
of	O
distinct	O
populations	O
of	O
microparticles	O
(	O
MPs	O
)	O
in	O
both	O
the	O
vascular	O
and	O
alveolar	O
compartments	O
in	O
animal	O
models	O
of	O
ALI	O
/	O
ARDS	B-DISO
or	O
respective	O
patient	O
populations	O
,	O
where	O
they	O
may	O
serve	O
as	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
long	O
pentraxin	O
PTX3	O
on	O
lung	O
injury	O
in	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
model	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
reinforces	O
the	O
potential	O
of	O
lethal	O
pandemics	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

Cytokine	O
expression	O
,	O
severity	O
of	O
lung	O
injury	O
,	O
leukocyte	O
infiltration	B-DISO
and	O
inflammatory	B-DISO
responses	I-DISO
were	O
examined	O
in	O
vivo	O
.	O

This	O
compound	O
also	O
has	O
inhibitory	O
activity	O
(	O
50	O
%	O
effective	O
concentration	O
[	O
EC	O
(	O
50	O
)]	O
=	O
8	O
.	O
95	O
μM	O
)	O
in	O
a	O
SARS	B-DISO
-	O
CoV	O
replicon	O
assay	O
,	O
with	O
low	O
cytotoxicity	B-DISO
(	O
50	O
%	O
cytotoxic	O
concentration	O
[	O
CC	O
(	O
50	O
)]	O
=	O
>	O
250	O
μM	O
),	O
suggesting	O
that	O
the	O
helicase	O
plays	O
a	O
still	O
unidentified	O
critical	O
role	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
life	O
cycle	O
.	O

SSYA10	O
-	O
001	O
did	O
not	O
inhibit	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
other	O
bacterial	O
and	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
,	O
or	O
reverse	O
transcriptase	O
.	O

Hence	O
,	O
it	O
is	O
possible	O
that	O
SSYA10	O
-	O
001	O
inhibits	O
unwinding	O
by	O
nsp13	O
by	O
affecting	O
conformational	O
changes	O
during	O
the	O
course	O
of	O
the	O
reaction	O
or	O
translocation	B-DISO
on	O
the	O
nucleic	O
acid	O
.	O

SSYA10	O
-	O
001	O
will	O
be	O
a	O
valuable	O
tool	O
for	O
studying	O
the	O
specific	O
role	O
of	O
nsp13	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
life	O
cycle	O
,	O
which	O
could	O
be	O
a	O
model	O
for	O
other	O
nidoviruses	O
and	O
also	O
a	O
candidate	O
for	O
further	O
development	O
as	O
a	O
SARS	B-DISO
antiviral	O
target	O
.	O

ABSTRACT	O
:	O
Balloon	O
-	O
occluded	B-DISO
retrograde	O
transvenous	O
obliteration	O
has	O
been	O
traditionally	O
based	O
on	O
liquid	O
sclerotherapy	O
.	O

No	O
serious	O
complication	B-DISO
occurred	O
.	O

CONCLUSIONS	O
:	O
Balloon	O
-	O
occluded	B-DISO
retrograde	O
transvenous	O
obliteration	O
with	O
polidocanol	O
foam	O
under	O
C	O
-	O
arm	O
CT	O
guidance	O
allowed	O
significant	O
reduction	O
of	O
sclerosant	O
dose	O
and	O
resulted	O
in	O
a	O
low	O
complication	B-DISO
rate	O
while	O
a	O
high	O
technical	O
success	O
rate	O
and	O
efficacy	O
were	O
maintained	O
.	O

His	O
rapid	O
course	O
was	O
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
status	B-DISO
epilepticus	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
).	O

Overall	O
,	O
these	O
data	O
reveal	O
that	O
oligodendroglia	O
from	O
the	O
adult	O
CNS	O
are	O
poor	O
sensors	O
of	O
viral	B-DISO
infection	I-DISO
and	O
suggest	O
they	O
require	O
exogenous	O
IFNα	O
/	O
β	O
to	O
establish	O
an	O
antiviral	O
state	O
.	O

Computational	O
fluid	O
dynamics	O
(	O
CFD	B-DISO
)	O
was	O
used	O
to	O
assess	O
by	O
simulation	O
whether	O
the	O
approach	O
adopted	O
meets	O
US	O
Centers	O
for	O
Disease	O
and	O
Control	O
and	O
Prevention	O
requirements	O
for	O
properly	O
constructed	O
isolation	O
wards	O
.	O

CFD	B-DISO
simulation	O
revealed	O
that	O
this	O
makeshift	O
approach	O
could	O
match	O
the	O
ventilation	O
standards	O
of	O
isolation	O
rooms	O
.	O

TITLE	O
:	O
Anicteric	B-DISO
leptospirosis	I-DISO
-	O
associated	O
severe	O
pulmonary	O
hemorrhagic	O
syndrome	B-DISO
:	O
a	O
case	O
series	O
study	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
reveals	O
platelet	O
factor	O
4	O
and	O
beta	O
-	O
thromboglobulin	O
as	O
prognostic	O
markers	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
prognostic	O
values	O
of	O
the	O
SARS	B-DISO
-	O
associated	O
proteomic	O
features	O
by	O
biostatistical	O
analysis	O
,	O
and	O
deciphered	O
the	O
identities	O
of	O
those	O
with	O
prognostic	O
values	O
.	O

TITLE	O
:	O
Liver	O
TCRγδ	O
(+)	O
CD3	O
(+)	O
CD4	O
(-)	O
CD8	O
(-)	O
T	O
cells	O
contribute	O
to	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
3	O
-	O
induced	O
hepatic	O
injury	O
through	O
a	O
TNF	O
-	O
α	O
-	O
dependent	O
pathway	O
.	O

The	O
proportion	O
of	O
TCRγδ	O
(+)	O
DN	O
T	O
cells	O
in	O
liver	O
CD3	O
(+)	O
T	O
cells	O
was	O
markedly	O
increased	O
after	O
MHV	O
-	O
3	O
infection	B-DISO
.	O

nTregs	O
develop	O
in	O
the	O
thymus	O
and	O
function	O
in	O
maintaining	O
peripheral	O
immune	B-DISO
tolerance	I-DISO
.	O

Coronaviruses	O
(	O
CoVs	O
)	O
are	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	O
RNA	O
viruses	O
that	O
cause	O
acute	O
and	O
chronic	B-DISO
infections	I-DISO
and	O
can	O
productively	O
infect	O
macrophages	O
.	O

In	O
contrast	O
,	O
pre	O
-	O
stimulation	O
of	O
TLR3	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
I	O
:	O
C	O
)	O
hindered	O
MHV	O
infection	B-DISO
through	O
induction	O
of	O
IFN	O
-	O
β	O
in	O
macrophages	O
.	O

Tracheal	O
aspirates	O
for	O
Pneumocystis	B-DISO
jiroveci	O
detection	O
,	O
bacterial	O
culture	O
,	O
tuberculosis	B-DISO
culture	O
,	O
and	O
viral	O
identification	O
were	O
performed	O
.	O

Sixty	O
-	O
three	O
patients	O
met	O
the	O
recruitment	B-DISO
criteria	O
.	O

A	O
case	O
fatality	O
rate	O
of	O
30	O
%	O
is	O
achievable	O
if	O
severe	O
pneumonia	B-DISO
with	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
managed	O
with	O
a	O
combination	O
of	O
antibiotics	O
and	O
ventilation	O
strategies	O
.	O

TITLE	O
:	O
[	O
Effectiveness	O
analysis	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
pediatrics	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
a	O
tertiary	O
hospital	O
].	O

No	O
nosocomial	B-DISO
pneumonia	I-DISO
occurred	O
during	O
HFNC	O
O	O
(	O
2	O
)	O
therapy	O
.	O

TITLE	O
:	O
Food	O
Safety	O
:	O
at	O
the	O
center	O
of	O
a	O
One	O
Health	O
approach	O
for	O
combating	O
zoonoses	B-DISO
.	O

Some	O
diseases	O
have	O
global	O
epidemic	O
-	O
or	O
pandemic	O
-	O
potential	O
,	O
resulting	O
in	O
dramatic	O
action	O
from	O
international	O
organizations	O
and	O
national	O
agricultural	O
-	O
and	O
health	O
authorities	O
in	O
most	O
countries	O
,	O
for	O
instance	O
as	O
was	O
the	O
case	O
with	O
avian	B-DISO
influenza	I-DISO
.	O

The	O
intervals	O
between	O
the	O
initiation	O
of	O
appropriate	O
therapy	O
to	O
defervescence	O
were	O
longer	O
in	O
patients	O
with	O
hyperbilirubinemia	B-DISO
than	O
those	O
without	O
hyperbilirubinemia	B-DISO
(	O
6	O
.	O
1	O
versus	O
4	O
.	O
1	O
days	O
;	O
P	O
=	O
0	O
.	O
015	O
).	O

Only	O
one	O
died	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

By	O
modification	O
of	O
the	O
infectious	B-DISO
cDNA	O
of	O
the	O
genome	O
of	O
coronaviruse	O
,	O
it	O
has	O
led	O
to	O
an	O
efficient	O
(>	O
50	O
microg	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
stable	O
(>	O
30	O
passages	O
)	O
expression	O
of	O
the	O
foreign	O
gene	O
.	O

The	O
high	O
mortality	O
could	O
be	O
due	O
to	O
the	O
pre	O
-	O
existing	O
clinical	O
severity	O
of	O
cases	O
prior	O
to	O
request	O
for	O
peramivir	O
,	O
but	O
also	O
raises	O
questions	O
about	O
peramivir	O
safety	O
and	O
effectiveness	O
in	O
hospitalized	O
and	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Upon	O
arrival	O
of	O
the	O
emergency	B-DISO
physician	O
at	O
the	O
scene	O
the	O
patient	O
was	O
unconscious	O
and	O
cyanotic	O
.	O

TITLE	O
:	O
Pleural	B-DISO
effusion	I-DISO
following	O
ovarian	B-DISO
hyperstimulation	I-DISO
.	O

Since	O
replication	O
of	O
the	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
is	O
impaired	B-DISO
upon	O
proteasomal	O
inhibition	O
,	O
the	O
relevance	O
of	O
the	O
UPS	O
for	O
the	O
replication	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
investigated	O
in	O
this	O
study	O
.	O

Additional	O
m	O
-	O
calpain	O
knockdown	O
experiments	O
confirmed	O
the	O
dependence	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
on	O
the	O
activity	O
of	O
the	O
cysteine	O
protease	O
m	O
-	O
calpain	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
biochemical	O
properties	O
of	O
a	O
full	O
-	O
length	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
nsp12	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

TITLE	O
:	O
Protective	O
roles	O
of	O
Cordyceps	O
on	O
lung	B-DISO
fibrosis	I-DISO
in	O
cellular	O
and	O
rat	O
models	O
.	O

Idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
is	O
a	O
chronic	O
,	O
irreversible	O
and	O
debilitating	O
lung	B-DISO
disease	I-DISO
showing	O
fibroblast	O
/	O
myofibroblast	O
expansion	O
and	O
excessive	O
deposition	O
of	O
extracellular	O
matrix	O
in	O
the	O
interstitium	O
leading	O
to	O
breathing	B-DISO
difficulty	I-DISO
.	O

The	O
findings	O
provide	O
an	O
insight	O
into	O
the	O
preventive	O
and	O
therapeutic	O
potentials	O
of	O
Cordyceps	O
for	O
the	O
treatment	O
of	O
lung	B-DISO
fibrosis	I-DISO
.	O

In	O
totally	O
147	O
cases	O
of	O
ALI	O
/	O
ARDS	B-DISO
,	O
89	O
cases	O
(	O
60	O
.	O
5	O
%)	O
were	O
male	O
and	O
58	O
(	O
39	O
.	O
5	O
%)	O
were	O
female	O
,	O
mean	O
age	O
was	O
(	O
43	O
.	O
4	O
±	O
36	O
.	O
7	O
)	O
months	O
.	O

The	O
cause	O
of	O
ALI	O
/	O
ARDS	B-DISO
was	O
mainly	O
severe	O
pneumonia	B-DISO
,	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
leukemia	B-DISO
or	O
tumor	B-DISO
diseases	O
.	O

CBP	O
adjuvant	O
treatment	O
for	O
ALI	O
/	O
ARDS	B-DISO
could	O
reduce	O
pulmonary	B-DISO
edema	I-DISO
,	O
improve	O
PaO2	O
/	O
FiO2	O
and	O
Cdyn	O
,	O
and	O
improve	O
mechanical	O
ventilation	O
parameters	O
.	O

Twenty	O
-	O
three	O
infants	O
with	O
ventricular	B-DISO
septal	I-DISO
defect	I-DISO
(	O
VSD	B-DISO
)	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
infants	O
with	O
ventricular	B-DISO
septal	I-DISO
defect	I-DISO
(	O
VSD	B-DISO
)	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Improved	O
outcome	O
from	O
using	O
ECMO	O
for	O
respiratory	B-DISO
failure	I-DISO
has	O
been	O
reported	O
worldwide	O
,	O
ranging	O
from	O
15	O
%	O
to	O
over	O
50	O
%	O
in	O
recent	O
reviews	O
.(	O
1	O
,	O
2	O
)	O
The	O
rationale	O
of	O
this	O
therapy	O
is	O
to	O
allow	O
time	O
for	O
the	O
lungs	O
to	O
heal	O
,	O
minimizing	O
further	O
lung	O
injury	O
from	O
positive	O
pressure	O
ventilation	O
.(	O
3	O
,	O
4	O
)	O
We	O
describe	O
a	O
case	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
extensive	O
barotrauma	O
supported	O
by	O
VV	O
-	O
ECMO	O
for	O
96	O
days	O
in	O
a	O
resource	O
-	O
limited	O
center	O
.	O

Using	O
routinely	O
available	O
clinical	O
data	O
,	O
our	O
prediction	O
model	O
identifies	O
patients	O
at	O
high	O
risk	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
early	O
after	O
severe	O
traumatic	O
injury	O
.	O

This	O
retrospective	O
study	O
found	O
that	O
the	O
positive	O
predictive	O
value	O
of	O
an	O
albumin	O
:	O
globulin	O
(	O
A	O
:	O
G	O
)	O
ratio	O
of	O
<	O
0	O
.	O
8	O
and	O
<	O
0	O
.	O
6	O
was	O
only	O
12	O
.	O
5	O
%	O
and	O
25	O
%,	O
respectively	O
,	O
in	O
a	O
group	O
of	O
100	O
cats	O
with	O
one	O
or	O
more	O
clinical	O
signs	O
consistent	O
with	O
FIP	B-DISO
.	O

H1N1	O
infection	B-DISO
can	O
lead	O
to	O
severe	O
illness	O
.	O

In	O
a	O
retrospective	O
review	O
of	O
cases	O
from	O
1997	O
to	O
2007	O
,	O
we	O
identified	O
111	O
patients	O
with	O
acute	B-DISO
leukemia	I-DISO
or	O
MDS	B-DISO
/	O
MPN	O
who	O
underwent	O
pleural	O
procedures	O
.	O

A	O
total	O
of	O
270	O
pleural	O
procedures	O
were	O
performed	O
in	O
111	O
patients	O
(	O
69	O
AML	B-DISO
,	O
27	O
ALL	O
,	O
15	O
MDS	B-DISO
/	O
MPN	O
).	O

TITLE	O
:	O
Enteropathogens	O
identified	O
in	O
cats	O
entering	O
a	O
Florida	O
animal	O
shelter	O
with	O
normal	O
feces	O
or	O
diarrhea	B-DISO
.	O

Fecal	O
samples	O
collected	O
within	O
24	O
hours	O
after	O
admission	O
from	O
50	O
cats	O
with	O
normal	O
feces	O
and	O
50	O
cats	O
with	O
diarrhea	B-DISO
were	O
tested	O
by	O
fecal	O
flotation	O
,	O
antigen	O
testing	O
,	O
PCR	O
assay	O
,	O
and	O
electron	O
microscopy	O
for	O
selected	O
enteropathogens	O
.	O

Fecal	O
samples	O
were	O
collected	O
within	O
24	O
hours	O
after	O
admission	O
from	O
50	O
dogs	O
with	O
normal	O
feces	O
and	O
50	O
dogs	O
with	O
diarrhea	B-DISO
.	O

Dogs	O
with	O
diarrhea	B-DISO
were	O
significantly	O
more	O
likely	O
to	O
be	O
infected	O
with	O
≥	O
1	O
enteropathogens	O
(	O
96	O
%)	O
than	O
were	O
dogs	O
with	O
normal	O
feces	O
(	O
78	O
%).	O

Only	O
Clostridium	O
perfringens	O
enterotoxin	O
A	O
gene	O
was	O
significantly	O
more	O
common	O
in	O
dogs	O
with	O
diarrhea	B-DISO
(	O
64	O
%)	O
than	O
in	O
dogs	O
with	O
normal	O
feces	O
(	O
40	O
%).	O

Most	O
infections	B-DISO
were	O
not	O
associated	O
with	O
diarrhea	B-DISO
or	O
any	O
specific	O
dog	O
characteristics	O
,	O
making	O
it	O
difficult	O
to	O
predict	O
the	O
risk	O
of	O
infection	B-DISO
for	O
individual	O
animals	O
.	O

ABSTRACT	O
:	O
Animal	O
coronaviruses	O
,	O
such	O
as	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
and	O
arteriviruses	O
,	O
such	O
as	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
),	O
are	O
able	O
to	O
manifest	O
highly	O
contagious	O
infections	B-DISO
in	O
their	O
specific	O
native	O
hosts	O
,	O
thereby	O
arising	O
in	O
critical	O
economic	O
damage	O
to	O
animal	O
industries	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
zinc	O
salts	O
against	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
vitro	O
.	O

We	O
sought	O
to	O
investigate	O
whether	O
this	O
experience	O
has	O
altered	O
our	O
knowledge	O
and	O
our	O
current	O
and	O
future	O
practice	O
on	O
the	O
management	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
SARI	O
)	O
and	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

To	O
further	O
analyze	O
this	O
functions	O
,	O
the	O
interaction	O
of	O
SARS	B-DISO
-	O
CoV	O
protein	O
6	O
with	O
other	O
viral	O
and	O
/	O
or	O
cellular	O
factors	O
has	O
been	O
analyzed	O
during	O
SARS	B-DISO
-	O
CoV	O
infective	O
cycle	O
.	O

There	O
were	O
91	O
(	O
58	O
.	O
3	O
%)	O
patients	O
with	O
severe	O
malaria	B-DISO
:	O
P	O
.	O
vivax	O
mono	B-DISO
-	O
infection	B-DISO
46	O
(	O
50	O
.	O
5	O
%),	O
P	O
.	O
falciparum	O
mono	B-DISO
-	O
infection	B-DISO
35	O
(	O
38	O
.	O
5	O
%)	O
and	O
mixed	O
10	O
(	O
11	O
%).	O

Risk	O
of	O
mortality	O
in	O
vivax	B-DISO
malaria	I-DISO
was	O
highest	O
in	O
patients	O
with	O
ARDS	B-DISO
followed	O
by	O
MODS	B-DISO
and	O
shock	O
.	O

Flow	O
cytometry	O
(	O
using	O
an	O
anti	O
-	O
feline	O
AGP	O
antibody	O
),	O
serum	O
protein	O
electrophoresis	O
,	O
routine	O
haematology	O
and	O
measurement	O
of	O
the	O
serum	O
AGP	O
concentration	O
were	O
performed	O
using	O
blood	O
samples	O
from	O
32	O
healthy	O
cats	O
(	O
19	O
FCoV	O
-	O
seropositive	O
),	O
13	O
cats	O
with	O
FIP	B-DISO
and	O
12	O
with	O
other	O
diseases	O
(	O
6	O
FCoV	O
-	O
seropositive	O
).	O

Compared	O
with	O
controls	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
positive	O
granulocytes	O
and	O
monocytes	O
was	O
higher	O
among	O
sick	O
cats	O
(	O
especially	O
cats	O
with	O
diseases	O
other	O
than	O
FIP	B-DISO
)	O
and	O
cats	O
with	O
high	O
serum	O
AGP	O
concentration	O
,	O
but	O
not	O
in	O
cats	O
with	O
leucocytosis	B-DISO
or	O
that	O
were	O
FCoV	O
-	O
seropositive	O
.	O

Conversely	O
,	O
no	O
association	O
between	O
AGP	O
-	O
positive	O
leucocytes	O
and	O
FIP	B-DISO
was	O
found	O
.	O

Fewer	O
infections	B-DISO
were	O
found	O
in	O
summer	O
(	O
RespiFinder	O
-	O
19	O
:	O
20	O
%;	O
RVP	O
:	O
6	O
%).	O

APRV	O
may	O
safely	O
be	O
applied	O
to	O
neurocritically	O
ill	B-DISO
patients	O
,	O
and	O
that	O
this	O
mode	O
of	O
ventilation	O
may	O
increase	O
cerebral	O
blood	O
flow	O
without	O
increasing	O
intracranial	O
pressure	O
.	O

In	O
the	O
first	O
decade	O
of	O
the	O
21st	O
century	O
,	O
several	O
events	O
further	O
highlighted	O
global	O
shared	O
interests	O
in	O
and	O
vulnerability	O
to	O
infectious	B-DISO
diseases	I-DISO
.	O

Obtained	O
data	O
shows	O
early	O
emergence	O
of	O
lung	B-DISO
disorders	I-DISO
that	O
precede	O
changes	O
in	O
hepatic	O
tissue	O
.	O

To	O
understand	O
the	O
kinetics	O
and	O
relationships	O
between	O
the	O
humoral	O
(	O
Ab	O
)	O
and	O
antigen	O
specific	O
T	O
cell	O
immunity	O
as	O
well	O
as	O
pathological	O
changes	O
during	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
and	O
immunization	O
,	O
one	O
-	O
week	O
-	O
old	O
SPF	O
chickens	O
were	O
vaccinated	O
with	O
live	O
IBV	O
H52	O
strain	O
and	O
challenged	O
with	O
IBV	O
M41	O
15	O
days	O
post	O
primary	B-DISO
infection	I-DISO
.	O

However	O
,	O
in	O
a	O
substantial	O
number	O
of	O
patients	O
with	O
a	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
,	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
various	O
viral	O
pathogens	O
has	O
been	O
confirmed	O
.	O

Gestational	O
age	O
,	O
sepsis	B-DISO
,	O
oxygen	O
therapy	O
,	O
and	O
frequency	O
of	O
blood	O
transfusions	O
remained	O
significant	O
variables	O
after	O
logistic	O
regression	O
analysis	O
.	O

Gestational	O
age	O
,	O
sepsis	B-DISO
,	O
oxygen	O
therapy	O
,	O
and	O
frequency	O
of	O
blood	O
transfusions	O
remained	O
significant	O
variables	O
after	O
logistic	O
regression	O
analysis	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
ROP	B-DISO
in	O
this	O
study	O
was	O
19	O
.	O
2	O
%;	O
low	O
gestational	O
age	O
,	O
sepsis	B-DISO
,	O
oxygen	O
therapy	O
,	O
and	O
frequent	O
blood	O
transfusions	O
were	O
significant	O
risk	O
factors	O
for	O
ROP	B-DISO
.	O

ABSTRACT	O
:	O
In	O
2011	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
rates	O
rose	O
substantially	O
in	O
vaccinated	O
swine	O
herds	O
.	O

Pressure	O
-	O
volume	O
curves	O
(	O
P	O
(	O
el	O
)/	O
V	O
),	O
blood	O
gases	O
,	O
and	O
haemodynamics	O
were	O
studied	O
at	O
0	O
,	O
4	O
,	O
8	O
,	O
16	O
,	O
and	O
24	O
h	O
after	O
the	O
induction	O
of	O
ARDS	B-DISO
and	O
lung	O
histology	O
was	O
evaluated	O
.	O

This	O
overview	O
gives	O
a	O
general	O
idea	O
on	O
some	O
topics	O
that	O
are	O
currently	O
significant	O
and	O
specific	O
to	O
paediatric	O
infectious	B-DISO
diseases	I-DISO
.	O

Physiologically	O
,	O
ARDS	B-DISO
is	O
characterized	O
by	O
increased	O
permeability	O
pulmonary	B-DISO
edema	I-DISO
,	O
severe	O
arterial	O
hypoxemia	O
,	O
and	O
impaired	B-DISO
carbon	O
dioxide	O
excretion	O
.	O

Underlying	O
chronic	B-DISO
disease	I-DISO
was	O
reported	O
in	O
cases	O
and	O
one	O
diabetic	O
adult	O
died	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nsp1	O
facilitates	O
efficient	O
propagation	O
in	O
cells	O
through	O
a	O
specific	O
translational	O
shutoff	O
of	O
host	O
mRNA	O
.	O

However	O
,	O
effects	O
of	O
H1N1	B-DISO
influenza	I-DISO
infection	B-DISO
on	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratios	O
and	O
related	O
pathophysiologic	O
readouts	O
of	O
lung	O
function	O
have	O
not	O
been	O
reported	O
in	O
mice	O
.	O

At	O
day	O
2	O
following	O
infection	B-DISO
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratios	O
indicated	O
the	O
onset	O
of	O
acute	O
lung	O
injury	O
.	O

A	O
false	O
notion	O
of	O
hypogalactia	B-DISO
is	O
the	O
major	O
factor	O
for	O
early	O
termination	O
,	O
which	O
is	O
allied	O
to	O
the	O
technical	O
difficulties	O
of	O
the	O
feeding	O
.	O

We	O
also	O
found	O
long	O
-	O
term	O
benefits	O
,	O
such	O
as	O
for	O
obesity	B-DISO
(	O
7	O
-	O
24	O
%)	O
and	O
other	O
cardiovascular	O
risk	O
factors	O
in	O
adulthood	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
the	O
more	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
represent	O
a	O
spectrum	O
of	O
lung	B-DISO
disease	I-DISO
characterized	O
by	O
the	O
sudden	O
onset	O
of	O
inflammatory	O
pulmonary	O
edema	B-DISO
secondary	I-DISO
to	O
myriad	O
local	O
or	O
systemic	O
insults	O
.	O

Our	O
results	O
demonstrate	O
that	O
frequent	O
enteric	O
infections	B-DISO
with	O
diverse	O
viruses	O
occur	O
during	O
early	O
childhood	O
in	O
the	O
absence	O
of	O
severe	O
clinical	O
symptoms	O
.	O

Here	O
we	O
describe	O
the	O
crystal	O
structures	O
of	O
the	O
receptor	O
-	O
binding	O
domains	O
(	O
RBDs	O
)	O
of	O
two	O
closely	O
related	O
CoV	O
strains	O
,	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
respiratory	O
CoV	O
(	O
PRCV	O
),	O
in	O
complex	O
with	O
their	O
receptor	O
,	O
porcine	O
APN	O
(	O
pAPN	O
),	O
or	O
with	O
a	O
neutralizing	O
antibody	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
infected	O
DC	O
-	O
SIGN	O
-	O
transfected	O
monocytes	O
(	O
THP	O
-	O
1	O
-	O
DC	O
-	O
SIGN	O
)	O
at	O
6	O
and	O
24	O
h	O
after	O
infection	B-DISO
,	O
and	O
the	O
gene	O
expression	O
was	O
profiled	O
in	O
oligonucleotide	O
-	O
based	O
microarrays	O
.	O

ABSTRACT	O
:	O
Pseudomembranous	B-DISO
colitis	I-DISO
and	O
toxic	B-DISO
megacolon	I-DISO
(	O
TM	O
)	O
are	O
well	O
-	O
known	O
complications	O
of	O
Clostridium	B-DISO
difficile	I-DISO
infections	I-DISO
.	O

Systemic	O
antibiotic	O
is	O
considered	O
as	O
the	O
major	O
risk	O
factor	O
for	O
the	O
development	O
of	O
C	B-DISO
difficile	I-DISO
colitis	I-DISO
.	O

We	O
here	O
report	O
the	O
first	O
complete	O
genome	O
sequence	O
of	O
HCoV	O
-	O
NL63	O
strain	O
CBJ	O
037	O
isolated	O
in	O
2008	O
from	O
a	O
patient	O
with	O
bronchitis	B-DISO
in	O
Beijing	O
,	O
China	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
a	O
highly	O
prevalent	O
isolate	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
South	O
China	O
.	O

TITLE	O
:	O
Laninamivir	O
octanoate	O
and	O
artificial	O
surfactant	O
combination	O
therapy	O
significantly	O
increases	O
survival	O
of	O
mice	O
infected	O
with	O
lethal	O
influenza	B-DISO
H1N1	O
Virus	O
.	O

Combination	O
therapy	O
of	O
laninamivir	O
octanoate	O
with	O
artificial	O
surfactant	O
reduces	O
lethality	O
in	O
mice	O
infected	O
with	O
influenza	B-DISO
virus	O
,	O
and	O
eventually	O
suppresses	O
DAD	O
formation	O
and	O
preserves	O
lung	O
function	O
.	O

This	O
combination	O
could	O
be	O
effective	O
for	O
prevention	O
of	O
severe	O
pneumonia	B-DISO
secondary	O
to	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
in	O
humans	O
,	O
which	O
is	O
not	O
improved	O
by	O
NAI	O
monotherapy	O
.	O

Recent	O
large	O
-	O
scale	O
accidents	O
,	O
including	O
terrorist	O
attacks	O
and	O
biological	O
warfare	O
as	O
the	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2002	O
/	O
2003	O
and	O
pandemic	O
influenza	B-DISO
have	O
demonstrated	O
the	O
need	O
for	O
an	O
adequate	O
response	O
from	O
Intensive	O
Care	O
Medicine	O
in	O
those	O
contexts	O
.	O

These	O
findings	O
provide	O
potential	O
inhibitors	O
for	O
SARS	B-DISO
-	O
CoV	O
viral	B-DISO
infection	I-DISO
and	O
replication	O
.	O

IL	O
-	O
17	O
mRNA	O
levels	O
in	O
liver	O
tissue	O
were	O
quantified	O
by	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cytokine	O
IL	O
-	O
17	O
levels	O
in	O
liver	O
tissue	O
and	O
serum	O
were	O
determined	O
by	O
using	O
ELISA	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
murine	O
fulminant	B-DISO
hepatitis	I-DISO
model	O
.	O

Moreover	O
,	O
a	O
time	O
course	O
study	O
showed	O
that	O
the	O
percentage	O
of	O
both	O
IL	O
-	O
17	O
-	O
producing	O
CD4	O
(+)	O
T	O
cells	O
and	O
IL	O
-	O
17	O
-	O
producing	O
CD8	O
(+)	O
T	O
cells	O
was	O
increased	O
remarkably	O
in	O
the	O
liver	O
starting	O
from	O
48	O
h	O
and	O
peaked	O
at	O
72	O
h	O
post	O
-	O
infection	B-DISO
.	O

TITLE	O
:	O
Richards	O
model	O
revisited	O
:	O
validation	O
by	O
and	O
application	O
to	O
infection	B-DISO
dynamics	O
.	O

The	O
observed	O
elevation	O
in	O
serum	O
CC16	O
declined	O
to	O
control	O
values	O
within	O
12	O
to	O
24	O
hours	O
after	O
trauma	O
unless	O
patients	O
secondarily	O
developed	O
pneumonia	B-DISO
.	O

Among	O
predisposing	O
factors	O
occurring	O
on	O
farms	O
,	O
feed	O
protein	O
content	O
increased	O
by	O
20	O
%	O
(	O
26	O
.	O
3	O
%	O
crude	O
protein	O
,	O
provided	O
by	O
48	O
%	O
soybean	O
meal	O
)	O
seemed	O
to	O
enhance	O
EPEC	O
colonisation	O
and	O
resulted	O
in	O
the	O
mobilisation	O
of	O
spontaneous	O
latent	O
EPEC	O
/	O
ETEC	O
infection	B-DISO
.	O

TITLE	O
:	O
[	O
Lung	O
protective	O
ventilation	O
in	O
ARDS	B-DISO
].	O

TITLE	O
:	O
Prevalence	O
of	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
in	O
breath	O
-	O
hold	O
divers	O
.	O

TITLE	O
:	O
Diagnostic	O
accuracy	O
of	O
the	O
Rivalta	O
test	O
for	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

These	O
values	O
increased	O
when	O
cats	O
with	O
lymphoma	B-DISO
or	O
bacterial	B-DISO
infections	I-DISO
were	O
excluded	O
,	O
or	O
when	O
only	O
cats	O
≤	O
2	O
years	O
were	O
considered	O
.	O

Increased	O
effusion	B-DISO
cholesterol	O
concentration	O
and	O
specific	O
gravity	O
as	O
well	O
as	O
decreased	O
serum	O
albumin	O
:	O
globulin	O
ratio	O
and	O
hyperbilirubinemia	B-DISO
were	O
positively	O
correlated	O
with	O
positive	O
Rivalta	O
test	O
results	O
.	O

Texas	O
Veterinary	O
Medical	O
Diagnostic	O
Laboratory	O
current	O
methods	O
for	O
calf	O
diarrhea	B-DISO
pathogen	O
identification	O
include	O
electron	O
microscopy	O
(	O
EM	O
)	O
for	O
BCV	O
and	O
BRV	B-DISO
and	O
a	O
direct	O
fluorescent	O
antibody	O
test	O
(	O
DFAT	O
)	O
for	O
organism	O
detection	O
of	O
Cryptosporidium	O
spp	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
S	O
protein	O
maturation	O
in	O
the	O
endoplasmic	O
reticulum	O
by	O
calnexin	O
is	O
important	O
for	O
the	O
infectivity	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

To	O
address	O
this	O
age	O
-	O
related	O
susceptibility	O
to	O
SARS	B-DISO
-	O
CoV	O
and	O
IAV	O
,	O
we	O
infected	O
C57BL	O
/	O
6	O
(	O
B6	O
)	O
mice	O
with	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoV	O
(	O
MA15	O
)	O
or	O
IAV	O
(	O
PR8	O
),	O
both	O
of	O
which	O
cause	O
severe	O
disease	O
in	O
aged	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
intranasal	O
poly	O
(	O
I	O
·	O
C	O
)	O
should	O
be	O
evaluated	O
as	O
a	O
prophylactic	O
agent	O
in	O
aged	O
individuals	O
at	O
high	O
risk	O
for	O
contracting	O
SARS	B-DISO
-	O
CoV	O
or	O
IAV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
often	O
the	O
last	O
resort	O
for	O
serious	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
when	O
all	O
non	O
-	O
invasive	O
treatment	O
options	O
have	O
failed	O
to	O
improve	O
the	O
patient	O
'	O
s	O
pulmonary	O
condition	B-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
antigen	O
characteristics	O
of	O
different	O
fragments	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
expressed	O
in	O
E	O
.	O
Coli	O
and	O
their	O
application	O
in	O
the	O
serological	O
diagnosis	O
.	O

TITLE	O
:	O
No	O
serologic	O
evidence	O
for	O
zoonotic	O
canine	O
respiratory	O
coronavirus	B-DISO
infections	I-DISO
among	O
immunocompetent	O
adults	O
.	O

ABSTRACT	O
:	O
Viruses	O
are	O
detected	O
in	O
most	O
hospitalized	O
children	O
admitted	O
for	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
.	O

A	O
3	O
-	O
year	O
prospective	O
descriptive	O
study	O
was	O
conducted	O
among	O
Cambodian	O
children	O
admitted	O
to	O
2	O
provincial	O
hospitals	O
for	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

CONCLUSIONS	O
:	O
Similar	O
to	O
other	O
tropical	O
countries	O
,	O
rhinovirus	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
the	O
principal	O
viral	O
pathogens	O
detected	O
among	O
children	O
hospitalized	O
for	O
lower	O
tract	O
respiratory	B-DISO
infection	I-DISO
in	O
Cambodia	O
.	O

Patients	O
may	O
have	O
ARDS	B-DISO
if	O
the	O
onset	O
is	O
within	O
1	O
week	O
of	O
a	O
known	O
clinical	O
insult	O
or	O
new	O
/	O
worsening	O
respiratory	B-DISO
symptoms	I-DISO
.	O

The	O
pulmonary	O
artery	O
wedge	O
pressure	O
criterion	O
for	O
hydrostatic	O
edema	B-DISO
was	O
removed	O
,	O
and	O
illustrative	O
vignettes	O
were	O
created	O
to	O
guide	O
judgments	O
about	O
the	O
primary	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Observation	O
of	O
the	O
cytopathic	B-DISO
effect	I-DISO
and	O
apoptosis	O
,	O
as	O
well	O
as	O
a	O
cell	O
proliferation	B-DISO
assay	O
demonstrated	O
that	O
the	O
three	O
shRNAs	O
were	O
capable	O
of	O
protecting	O
ST	O
cells	O
against	O
TGEV	O
destruction	O
,	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

These	O
findings	O
provide	O
evidence	O
that	O
the	O
shRNAs	O
have	O
potential	O
therapeutic	O
application	O
for	O
treatment	O
of	O
TGE	B-DISO
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
characterize	O
the	O
management	O
and	O
prognosis	O
of	O
severe	O
Pneumocystis	B-DISO
jirovecii	O
pneumonia	B-DISO
(	O
PJP	O
)	O
in	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
)-	O
negative	O
patients	O
.	O

In	O
-	O
ICU	O
mortality	O
was	O
52	O
.	O
9	O
%	O
overall	O
,	O
reaching	O
80	O
.	O
9	O
%	O
and	O
86	O
.	O
8	O
%,	O
respectively	O
,	O
for	O
patients	O
who	O
required	O
ETI	O
and	O
for	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
review	O
of	O
simulation	O
modelling	O
approaches	O
used	O
for	O
the	O
spread	O
of	O
zoonotic	O
influenza	B-DISO
viruses	O
in	O
animal	O
and	O
human	O
populations	O
.	O

ABSTRACT	O
:	O
Neuromuscular	O
blocking	B-DISO
agents	O
(	O
NMBAs	O
)	O
are	O
part	O
of	O
the	O
pharmaceutical	O
arsenal	O
employed	O
to	O
treat	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

NMBAs	O
have	O
been	O
shown	O
to	O
improve	O
oxygenation	O
during	O
severe	O
ARDS	B-DISO
in	O
three	O
randomized	O
controlled	O
trials	O
.	O

TITLE	O
:	O
Emerging	O
zoonoses	B-DISO
:	O
the	O
""""	O
one	O
health	O
approach	O
"""."	O

ABSTRACT	O
:	O
This	O
paper	O
,	O
based	O
on	O
relevant	O
literature	O
articles	O
and	O
the	O
authors	O
'	O
clinical	O
experience	O
,	O
presents	O
a	O
goal	O
-	O
oriented	O
respiratory	O
management	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
that	O
can	O
help	O
improve	O
clinicians	O
'	O
ability	O
to	O
care	O
for	O
these	O
patients	O
.	O

TITLE	O
:	O
Rituximab	O
treatment	O
in	O
a	O
case	O
of	O
antisynthetase	B-DISO
syndrome	I-DISO
with	O
severe	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Intranasal	O
MHV	O
-	O
1	O
infection	B-DISO
produces	O
a	O
respiratory	B-DISO
infection	I-DISO
in	O
mice	O
.	O

The	O
most	O
common	O
DAI	O
type	O
was	O
catheter	O
-	O
associated	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
(	O
3	O
.	O
76	O
per	O
1000	O
urinary	O
catheter	O
-	O
days	O
).	O

The	O
decrease	O
in	O
the	O
rate	O
of	O
DAI	O
and	O
infection	B-DISO
by	O
resistant	O
bacteria	O
on	O
the	O
impact	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
can	O
be	O
attributed	O
to	O
active	O
infection	B-DISO
control	O
and	O
improved	O
adherence	O
after	O
2003	O
.	O

Y367	O
and	O
L374	O
were	O
predicated	O
to	O
possess	B-DISO
the	O
most	O
important	O
role	O
in	O
peptide	O
binding	O
.	O

Our	O
patient	O
was	O
temporarily	O
provided	O
with	O
portable	O
noninvasive	O
positive	O
pressure	O
ventilation	O
at	O
night	O
-	O
time	O
following	O
an	O
improvement	O
in	O
his	O
condition	B-DISO
,	O
but	O
his	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
again	O
worsened	O
due	O
to	O
the	O
recurrence	B-DISO
of	O
a	O
respiratory	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
epidemiological	O
and	O
clinical	O
profile	O
of	O
children	O
with	O
Henoch	B-DISO
-	I-DISO
Schonlein	I-DISO
purpura	I-DISO
(	O
HSP	B-DISO
)	O
in	O
eastern	O
Saudi	O
Arabia	O
during	O
a	O
15	O
-	O
year	O
period	O
.	O

Differences	O
between	O
GX	O
-	O
YL5	O
and	O
GX	O
-	O
YL9	O
were	O
found	O
mainly	O
in	O
stem	O
-	O
loop	O
structure	O
I	O
in	O
the	O
predicted	O
RNA	O
secondary	O
structure	O
of	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
and	O
the	O
S	O
protein	O
gene	B-DISO
fusion	I-DISO
region	O
,	O
which	O
will	O
help	O
us	O
understand	O
the	O
molecular	O
evolutionary	O
mechanism	O
of	O
IBV	O
and	O
the	O
disconcordance	O
between	O
the	O
genotypes	O
and	O
serotypes	O
of	O
coronavirus	O
.	O

ABSTRACT	O
:	O
A	O
diarrhea	B-DISO
outbreak	O
caused	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
been	O
observed	O
in	O
China	O
since	O
December	O
2010	O
.	O

The	O
causative	O
agent	O
of	O
the	O
diarrhea	B-DISO
was	O
ultimately	O
identified	O
as	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
PEDV	O
strain	O
designated	O
CHGD	O
-	O
01	O
from	O
piglet	O
intestines	O
using	O
Vero	O
cell	O
cultures	O
,	O
and	O
its	O
specific	O
cytopathic	B-DISO
effects	I-DISO
were	O
confirmed	O
in	O
susceptible	O
cells	O
by	O
direct	O
immunofluorescence	O
testing	O
and	O
electron	O
microscopy	O
.	O

TITLE	O
:	O
MHC	O
mismatch	O
results	O
in	O
neural	O
progenitor	O
cell	O
rejection	O
following	O
spinal	O
cord	B-DISO
transplantation	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
demyelination	B-DISO
.	O

Transplantation	O
of	O
MHC	O
-	O
mismatched	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
mice	O
resulted	O
in	O
increased	O
transcripts	O
encoding	O
the	O
T	O
-	O
cell	O
chemoattractant	O
chemokines	O
CXCL9	O
and	O
CXCL10	O
that	O
correlated	O
with	O
increased	O
T	O
-	O
cell	O
infiltration	B-DISO
that	O
was	O
associated	O
with	O
NPC	B-DISO
rejection	O
.	O

Despite	O
decades	O
of	O
research	O
,	O
few	O
therapeutic	O
strategies	O
for	O
clinical	O
ARDS	B-DISO
have	O
emerged	O
.	O

Identified	O
viruses	O
included	O
37	O
of	O
human	O
rhinovirus	O
(	O
22	O
.	O
6	O
%	O
of	O
cases	O
),	O
32	O
of	O
influenza	B-DISO
A	O
virus	O
(	O
19	O
.	O
5	O
%),	O
30	O
of	O
parainfluenzavirus	O
-	O
2	O
(	O
18	O
.	O
3	O
%),	O
23	O
of	O
parainfluenzavirus	O
-	O
3	O
(	O
14	O
.	O
0	O
%),	O
15	O
of	O
human	O
enterovirus	O
(	O
9	O
.	O
1	O
%),	O
14	O
each	O
of	O
parainfluenzavirus	O
-	O
1	O
,	O
respiratory	O
syncytial	O
virus	O
B	O
and	O
adenovirus	B-DISO
(	O
8	O
.	O
5	O
%),	O
8	O
of	O
coronavirus	O
229E	O
/	O
NL63	O
(	O
4	O
.	O
9	O
%),	O
6	O
of	O
human	O
bocavirus	O
(	O
3	O
.	O
7	O
%),	O
5	O
each	O
of	O
influenza	B-DISO
B	O
virus	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
3	O
.	O
0	O
%),	O
3	O
of	O
parainfluenzavirus	O
-	O
4	O
(	O
1	O
.	O
8	O
%),	O
2	O
of	O
coronavirus	O
OC43	O
/	O
HKU1	O
(	O
1	O
.	O
2	O
%),	O
and	O
1	O
human	O
metapneumovirus	O
(	O
0	O
.	O
6	O
%).	O

Thus	O
,	O
there	O
is	O
a	O
need	O
for	O
multidisciplinary	O
cooperation	O
to	O
ensure	O
the	O
early	O
identification	O
and	O
prevention	O
of	O
child	B-DISO
abuse	I-DISO
.	O

The	O
ELISA	O
assay	O
yielded	O
no	O
positive	O
results	O
of	O
the	O
total	O
61	O
HIV	B-DISO
-	O
1	O
negative	O
IDU	O
samples	O
(	O
100	O
%	O
specificity	O
)	O
and	O
two	O
positive	O
results	O
of	O
the	O
total	O
68	O
HIV	B-DISO
-	O
1	O
positive	O
IDU	O
samples	O
(	O
97	O
.	O
06	O
%	O
specificity	O
).	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
various	O
viral	B-DISO
infections	I-DISO
was	O
examined	O
in	O
primary	O
accession	O
cases	O
of	O
feline	B-DISO
lower	I-DISO
urinary	I-DISO
tract	I-DISO
disease	I-DISO
(	O
FLUTD	O
)	O
and	O
healthy	O
control	O
cats	O
in	O
Norway	O
.	O

Disaster	O
medicine	O
topics	O
provided	O
at	O
the	O
highest	O
frequency	O
included	O
pandemic	O
influenza	B-DISO
/	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
,	O
27	O
.	O
5	O
%),	O
and	O
principles	O
of	O
triage	O
(	O
10	O
.	O
3	O
%).	O

Using	O
optical	O
tweezers	O
to	O
apply	O
tension	B-DISO
across	O
the	O
RNA	O
,	O
we	O
measured	O
the	O
distribution	O
of	O
forces	O
required	O
to	O
unfold	O
each	O
pseudoknot	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
infections	I-DISO
caused	O
by	O
respiratory	O
viruses	O
are	O
common	O
in	O
paediatric	O
cystic	B-DISO
fibrosis	I-DISO
(	O
CF	O
)	O
patients	O
and	O
are	O
associated	O
with	O
increased	O
morbidity	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
Gammacoronavirus	O
of	O
the	O
family	O
Coronaviridae	O
and	O
is	O
a	O
causative	O
agent	O
of	O
an	O
economically	O
important	O
disease	O
in	O
poultry	O
.	O

The	O
leucine	O
-	O
rich	O
repeat	O
regions	O
in	O
Massachusetts	O
strains	O
consisted	O
of	O
stretches	B-DISO
of	O
63	O
to	O
69	O
amino	O
acids	O
,	O
while	O
in	O
the	O
QX	O
-	O
like	O
strains	O
they	O
contained	O
59	O
amino	O
acids	O
in	O
length	O
.	O

TITLE	O
:	O
Sublingual	O
immunization	O
with	O
recombinant	O
adenovirus	B-DISO
encoding	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
induces	O
systemic	O
and	O
mucosal	O
immunity	O
without	O
redirection	O
of	O
the	O
virus	O
to	O
the	O
brain	O
.	O

TITLE	O
:	O
[	O
Peculiarities	O
of	O
present	O
-	O
day	O
morbidity	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
swl	O
)].	O

We	O
consider	O
the	O
epidemiological	O
situation	O
as	O
regards	O
respiratory	O
viral	B-DISO
diseases	I-DISO
during	O
recent	O
years	O
with	O
special	O
reference	O
to	O
influenza	B-DISO
A	O
(	O
H1N1	O
swl	O
).	O

Because	O
of	O
the	O
expanding	O
size	O
and	O
density	O
of	O
its	O
population	O
and	O
the	O
frequent	O
interaction	O
of	O
people	O
with	O
animals	O
,	O
China	O
is	O
a	O
hotspot	O
for	O
the	O
emergence	O
and	O
spread	O
of	O
new	O
microbial	O
threats	O
and	O
is	O
a	O
major	O
contributor	O
to	O
the	O
worldwide	O
infectious	B-DISO
disease	I-DISO
burden	O
.	O

In	O
recent	O
years	O
,	O
the	O
emergence	O
and	O
rapid	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
generated	O
considerable	O
interest	O
in	O
the	O
Chinese	O
healthcare	O
system	O
and	O
its	O
infection	B-DISO
control	O
and	O
prevention	O
measures	O
.	O

TITLE	O
:	O
[	O
Prevalence	O
and	O
clinical	O
characteristics	O
of	O
coronavirus	O
NL63	O
infection	B-DISO
in	O
children	O
hospitalized	O
for	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
Changsha	O
].	O

There	O
is	O
significant	O
difference	O
in	O
the	O
infection	B-DISO
rate	O
between	O
the	O
boys	O
and	O
the	O
girls	O
:	O
the	O
boys	O
had	O
higher	O
rate	O
than	O
the	O
girls	O
.	O

Histopathological	O
examination	O
revealed	O
multifocal	O
non	O
-	O
suppurative	B-DISO
bronchointerstitial	O
pneumonia	B-DISO
with	O
formation	O
of	O
epithelial	O
syncytial	O
cells	O
,	O
sometimes	O
associated	O
with	O
suppurative	B-DISO
bronchopneumonia	B-DISO
.	O

This	O
is	O
believed	O
to	O
be	O
the	O
first	O
report	O
of	O
BCoV	O
in	O
association	O
with	O
bovine	B-DISO
respiratory	I-DISO
disease	I-DISO
complex	I-DISO
in	O
Australia	O
.	O

ABSTRACT	O
:	O
We	O
here	O
report	O
a	O
33	O
-	O
year	O
old	O
male	O
with	O
diabetes	B-DISO
,	O
hypertension	B-DISO
and	O
history	O
of	O
orthotopic	O
heart	O
transplantation	O
treated	O
by	O
plasma	O
exchange	O
for	O
severe	O
HTG	O
(	O
hypertriglyceridemia	O
)	O
induced	O
pancreatitis	B-DISO
.	O

Two	O
patients	O
also	O
received	O
corticosteroids	O
as	O
treatment	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Bone	O
marrow	O
chimera	B-DISO
experiments	O
demonstrated	O
that	O
hematopoietic	O
cells	O
are	O
responsible	O
for	O
the	O
pathogenesis	B-DISO
in	O
STAT1	O
(-/-)	O
mice	O
,	O
and	O
because	O
of	O
an	O
induction	O
of	O
alternatively	O
activated	O
(	O
AA	O
)	O
macrophages	O
after	O
infection	B-DISO
,	O
we	O
hypothesized	O
that	O
the	O
AA	O
macrophages	O
were	O
critical	O
for	O
disease	O
severity	O
.	O

A	O
retrospective	O
analysis	O
of	O
the	O
clinical	O
data	O
of	O
180	O
patients	O
with	O
severe	O
AOPP	O
admitted	O
to	O
the	O
Emergency	B-DISO
Center	O
of	O
Wuwei	O
City	O
People	O
'	O
s	O
Hospital	O
from	O
January	O
2007	O
to	O
August	O
2011	O
was	O
conducted	O
.	O

However	O
,	O
tracheal	O
mucosal	O
thicknesses	O
of	O
intratracheally	O
challenged	O
pullets	O
were	O
not	O
statistically	O
different	O
from	O
those	O
of	O
the	O
eye	O
drop	O
challenged	O
or	O
control	O
pullets	O
at	O
two	O
and	O
three	O
weeks	O
post	O
infection	B-DISO
.	O

TITLE	O
:	O
Factors	O
associated	O
with	O
the	O
willingness	O
of	O
health	O
care	O
personnel	O
to	O
work	O
during	O
an	O
influenza	B-DISO
public	O
health	O
emergency	B-DISO
:	O
an	O
integrative	O
review	O
.	O

Interventions	O
that	O
resulted	O
in	O
the	O
greatest	O
increase	O
in	O
the	O
HCP	B-DISO
'	O
s	O
willingness	O
to	O
work	O
were	O
preferential	O
access	O
to	O
Tamiflu	O
for	O
the	O
HCP	B-DISO
and	O
his	O
/	O
her	O
family	O
,	O
and	O
the	O
provision	O
of	O
a	O
vaccine	O
for	O
the	O
individual	O
and	O
his	O
/	O
her	O
family	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
represent	O
a	O
continuum	O
of	O
a	O
clinical	O
syndrome	B-DISO
of	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
refractory	O
hypoxia	B-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
differentiated	O
from	O
ALI	O
by	O
a	O
greater	O
degree	O
of	O
hypoxemia	O
and	O
is	O
associated	O
with	O
higher	O
morbidity	O
and	O
mortality	O
.	O

Three	O
pharmacologic	O
treatment	O
strategies	O
are	O
reviewed	O
in	O
detail	O
:	O
corticosteroids	O
,	O
fluid	O
management	O
,	O
and	O
neuromuscular	O
blocking	B-DISO
agents	O
.	O

CONCLUSIONS	O
:	O
RSV	O
was	O
the	O
most	O
common	O
etiologic	O
agent	O
for	O
children	O
with	O
bronchiolitis	B-DISO
in	O
Taiwan	O
.	O

In	O
ovo	O
vaccination	O
with	O
a	O
low	O
dose	O
of	O
AdArkIBV	O
.	O
S1	O
(	O
ck	O
)	O
resulted	O
in	O
a	O
mild	O
increase	O
of	O
systemic	O
antibody	O
and	O
reduced	O
viral	B-DISO
shedding	I-DISO
but	O
no	O
protection	O
against	O
IBV	O
signs	O
and	O
lesions	O
.	O

This	O
virus	O
has	O
been	O
identified	O
in	O
two	O
patients	O
,	O
both	O
previously	O
healthy	O
adults	O
who	O
suffered	B-DISO
severe	O
respiratory	O
illness	O
.	O

The	O
present	O
report	O
describes	O
the	O
use	O
of	O
a	O
new	O
set	O
of	O
degenerate	B-DISO
primers	O
that	O
amplify	O
a	O
636	O
-	O
bp	O
fragment	O
within	O
the	O
S1	O
gene	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
to	O
detect	O
the	O
occurrence	O
of	O
IBV	O
-	O
QX	O
infection	B-DISO
in	O
Switzerland	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
1800	O
nasopharyngeal	O
samples	O
from	O
adult	O
outpatients	O
with	O
respiratory	B-DISO
disease	I-DISO
symptoms	O
and	O
healthy	O
individuals	O
.	O

Morbidities	O
included	O
a	O
pyothorax	B-DISO
and	O
a	O
persistent	B-DISO
air	I-DISO
leak	I-DISO
;	O
both	O
made	O
a	O
recovery	O
.	O

Most	O
often	O
the	O
viruses	O
isolated	O
include	O
rhinovirus	O
(	O
RV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
adenovirus	B-DISO
,	O
coronavirus	O
,	O
and	O
picornavirus	O
.	O

TITLE	O
:	O
Frequency	O
of	O
common	O
viruses	O
in	O
etiology	O
of	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
frequency	O
rate	O
of	O
C	O
.	O
pneumoniae	O
,	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-DISO
virus	O
,	O
metapneumovirus	O
,	O
adenovirus	B-DISO
',	O
parainfluenza	B-DISO
virus	O
and	O
coronavirus	O
in	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
.	O

Specificity	O
of	O
the	O
PCR	O
and	O
DFA	O
methods	O
for	O
RSV	B-DISO
infections	I-DISO
were	O
detected	O
as	O
97	O
%	O
and	O
100	O
%	O
respectively	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
between	O
COPD	B-DISO
smokers	O
and	O
healthy	O
non	O
-	O
COPD	B-DISO
smokers	O
(	O
P	O
=	O
0	O
.	O
010	O
).	O

The	O
same	O
could	O
be	O
observed	O
comparing	O
the	O
group	O
of	O
patients	O
with	O
acute	O
inflammation	B-DISO
and	O
non	O
-	O
COPD	B-DISO
healthy	O
smokers	O
(	O
P	O
=	O
0	O
.	O
007	O
).	O

αB	O
-	O
crystallin	O
is	O
increased	O
in	O
patients	O
with	O
inflammatory	O
lung	B-DISO
diseases	I-DISO
.	O

We	O
found	O
high	O
prevalences	O
of	O
antibody	O
to	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
CDV	O
;	O
13	O
/	O
14	O
),	O
canine	O
parvovirus	B-DISO
(	O
CPV	O
;	O
4	O
/	O
14	O
),	O
canine	O
adenovirus	B-DISO
type	O
2	O
(	O
13	O
/	O
14	O
),	O
canine	O
coronavirus	O
(	O
5	O
/	O
11	O
),	O
canine	O
parainfluenza	B-DISO
virus	O
(	O
5	O
/	O
5	O
),	O
and	O
Toxoplasma	O
gondii	O
(	O
6	O
/	O
8	O
),	O
along	O
with	O
Ancylostomidae	O
eggs	O
in	O
all	O
feces	O
samples	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
exposure	O
to	O
canine	O
parainfluenza	B-DISO
virus	O
in	O
Neotropical	O
free	O
-	O
ranging	O
wild	O
canids	O
.	O

Ultimately	O
,	O
we	O
conclude	O
that	O
NMBAs	O
should	O
be	O
considered	O
a	O
lung	O
protective	O
adjuvant	O
in	O
early	O
ARDS	B-DISO
and	O
that	O
clinicians	O
should	O
consider	O
using	O
an	O
alternative	O
NMBA	O
to	O
the	O
aminosteroids	O
in	O
septic	B-DISO
shock	I-DISO
with	O
less	O
severe	O
lung	O
injury	O
pending	O
further	O
studies	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
inhaled	O
nitric	O
oxide	O
and	O
prone	O
position	O
in	O
an	O
ARDS	B-DISO
patient	O
with	O
severe	O
traumatic	O
brain	O
injury	O
during	O
spine	O
stabilization	O
.	O

The	O
active	O
site	O
and	O
peptide	O
-	O
binding	O
channel	O
of	O
APN	O
reside	O
in	O
cavities	B-DISO
with	O
wide	O
openings	O
,	O
allowing	O
easy	O
access	O
to	O
peptides	O
.	O

TITLE	O
:	O
Is	O
the	O
discovery	O
of	O
the	O
novel	O
human	O
betacoronavirus	O
2c	O
EMC	B-DISO
/	O
2012	O
(	O
HCoV	O
-	O
EMC	B-DISO
)	O
the	O
beginning	O
of	O
another	O
SARS	B-DISO
-	O
like	O
pandemic	O
?	O

As	O
a	O
bridge	O
to	O
LTx	O
-	O
for	O
patients	O
with	O
irreversible	O
end	O
stage	O
lung	B-DISO
disease	I-DISO
requiring	O
LTx	O
.	O

ABSTRACT	O
:	O
This	O
health	O
technology	O
policy	O
assessment	O
will	O
answer	O
the	O
following	O
questions	O
:	O
When	O
should	O
in	O
-	O
room	O
air	O
cleaners	O
be	O
used	O
?	O
How	O
effective	O
are	O
in	O
-	O
room	O
air	O
cleaners	O
?	O
Are	O
in	O
-	O
room	O
air	O
cleaners	O
that	O
use	O
combined	O
HEPA	O
and	O
UVGI	O
air	O
cleaning	O
technology	O
more	O
effective	O
than	O
those	O
that	O
use	O
HEPA	O
filtration	O
alone	O
?	O
What	O
is	O
the	O
Plasmacluster	O
ion	O
air	O
purifier	O
in	O
the	O
pandemic	O
influenza	B-DISO
preparation	O
plan	B-DISO
?	O
The	O
experience	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
locally	O
,	O
nationally	O
,	O
and	O
internationally	O
underscored	O
the	O
importance	O
of	O
administrative	O
,	O
environmental	O
,	O
and	O
personal	O
protective	O
infection	B-DISO
control	O
measures	O
in	O
health	O
care	O
facilities	O
.	O

ABSTRACT	O
:	O
A	O
previously	O
unknown	O
coronavirus	O
was	O
isolated	O
from	O
the	O
sputum	O
of	O
a	O
60	O
-	O
year	O
-	O
old	O
man	O
who	O
presented	O
with	O
acute	B-DISO
pneumonia	I-DISO
and	O
subsequent	O
renal	B-DISO
failure	I-DISO
with	O
a	O
fatal	O
outcome	O
in	O
Saudi	O
Arabia	O
.	O

Liver	B-DISO
dysfunction	I-DISO
was	O
present	O
in	O
cases	O
with	O
increased	O
morbidity	O
as	O
a	O
late	O
finding	O
and	O
was	O
the	O
least	O
frequent	O
organ	O
injury	O
.	O

We	O
found	O
increasing	O
rates	O
of	O
blood	O
transfusion	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
shock	O
,	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
,	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
aneurysms	B-DISO
,	O
and	O
cardiac	O
surgery	O
during	O
delivery	O
hospitalizations	O
.	O

Viruses	O
were	O
commonly	O
detected	O
in	O
children	O
with	O
severe	O
pneumonia	B-DISO
in	O
the	O
Philippines	O
.	O

Age	O
,	O
GCS	O
score	O
,	O
pupil	B-DISO
dilation	I-DISO
,	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
),	O
ICP	B-DISO
>	O
25	O
mmHg	O
,	O
hyperglycaemia	B-DISO
and	O
pneumonia	B-DISO
predicted	O
a	O
worse	O
outcome	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
and	O
clinical	O
characteristics	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
at	O
San	O
Felipe	O
,	O
Valparaiso	O
Region	O
,	O
Chile	O
:	O
June	O
-	O
August	O
2009	O
].	O

ABSTRACT	O
:	O
The	O
perioperative	O
inflammatory	B-DISO
response	I-DISO
as	O
measured	O
by	O
elevated	O
levels	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
has	O
been	O
linked	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
postoperative	B-DISO
confusion	I-DISO
,	O
and	O
fever	O
.	O

It	O
is	O
worth	O
including	O
the	O
incubation	O
period	O
in	O
the	O
case	O
definition	O
of	O
novel	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
two	O
new	O
influenza	B-DISO
A	O
subtypes	O
and	O
they	O
have	O
become	O
a	O
cause	O
of	O
concern	O
for	O
the	O
global	O
community	O
.	O

However	O
,	O
in	O
the	O
recent	O
two	O
years	O
,	O
there	O
was	O
no	O
significant	O
progress	O
in	O
the	O
development	O
of	O
a	O
new	O
drug	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
January	O
2011	O
,	O
it	O
was	O
announced	O
that	O
the	O
worldwide	O
phase	O
3	O
randomized	O
trial	O
of	O
a	O
novel	O
anti	O
-	O
Toll	O
-	O
like	O
receptor	O
-	O
4	O
compound	O
,	O
eritoran	O
tetrasodium	O
,	O
had	O
failed	O
to	O
demonstrate	O
an	O
improvement	O
in	O
the	O
mortality	O
of	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

A	O
study	O
was	O
published	O
showing	O
that	O
sepsis	B-DISO
can	O
be	O
associated	O
to	O
a	O
state	O
of	O
immunosuppression	O
and	O
loss	O
of	O
immune	O
function	O
in	O
human	O
.	O

Studies	O
that	O
test	O
the	O
complete	O
screening	O
chain	O
on	O
sufficiently	O
large	O
groups	O
of	O
pregnant	O
women	O
would	O
provide	O
the	O
best	O
basis	O
for	O
answering	O
the	O
question	O
of	O
whether	O
screening	O
for	O
gestational	B-DISO
diabetes	I-DISO
has	O
a	O
benefit	O
.	O

The	O
most	O
common	O
pathogens	O
found	O
in	O
diarrheic	O
calves	O
are	O
cryptosporidium	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
Salmonella	B-DISO
,	O
attaching	O
and	O
effacing	O
E	O
coli	O
and	O
F5	O
(	O
K99	O
)	O
Escherichia	O
coli	O
.	O

However	O
,	O
in	O
the	O
last	O
ten	O
years	O
thanks	O
to	O
progress	O
in	O
molecular	O
technologies	O
,	O
newly	O
discovered	O
viruses	O
have	O
been	O
identified	O
including	O
human	O
Metapneumovirus	O
(	O
hMPV	O
),	O
coronaviruses	O
NL63	O
(	O
HcoV	O
-	O
NL63	O
)	O
and	O
HKU1	O
(	O
HcoV	O
-	O
HKU1	O
),	O
human	O
Bocavirus	O
(	O
HBoV	O
),	O
new	O
enterovirus	O
(	O
HEV	O
),	O
parechovirus	O
(	O
HpeV	O
)	O
and	O
rhinovirus	O
(	O
HRV	O
)	O
strains	O
,	O
polyomaviruses	O
WU	O
(	O
WUPyV	O
)	O
and	O
KI	O
(	O
KIPyV	O
)	O
and	O
the	O
pandemic	O
H1N1v	O
influenza	B-DISO
A	O
virus	O
.	O

This	O
review	O
will	O
present	O
an	O
overview	O
of	O
newly	O
recognized	O
as	O
well	O
as	O
the	O
main	O
emerging	O
respiratory	O
viruses	O
and	O
seek	O
to	O
focus	O
on	O
the	O
their	O
contribution	O
to	O
infection	B-DISO
and	O
co	B-DISO
-	I-DISO
infection	I-DISO
in	O
LRTIs	O
in	O
childhood	O
.	O

ABSTRACT	O
:	O
This	O
article	O
describes	O
the	O
clinical	O
presentation	O
of	O
pneumonia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
lung	B-DISO
abscess	I-DISO
,	O
and	O
empyema	B-DISO
:	O
life	O
-	O
threatening	O
infections	B-DISO
of	O
the	O
pulmonary	O
system	O
.	O

On	O
22	O
September	O
2012	O
,	O
the	O
Ministry	O
of	O
Health	O
(	O
MOH	O
)	O
in	O
Saudi	O
Arabia	O
announced	O
the	O
detection	O
of	O
what	O
was	O
described	O
as	O
a	O
""""	O
rare	O
pattern	O
""""	O
of	O
coronavirus	O
respiratory	B-DISO
infection	I-DISO
in	O
three	O
individuals	O
,	O
two	O
Saudi	O
citizens	O
and	O
one	O
person	O
from	O
the	O
Gulf	O
Region	O
.	O

Neither	O
Saudi	O
citizen	O
survived	O
the	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
A	O
31	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
presented	O
with	O
refractory	O
severe	O
hypercalcemia	B-DISO
due	O
to	O
an	O
advanced	O
neuroendocrine	B-DISO
tumor	I-DISO
masquerading	O
as	O
hyperemesis	B-DISO
gravidarum	I-DISO
.	O

Octreotide	O
therapy	O
and	O
extensive	O
tumor	B-DISO
debulking	O
surgery	O
resulted	O
in	O
symptom	B-DISO
control	O
.	O

Neuroendocrine	B-DISO
tumors	I-DISO
are	O
a	O
rare	O
complication	B-DISO
of	I-DISO
pregnancy	I-DISO
and	O
a	O
seldom	O
cause	O
of	O
refractory	O
hypercalcemia	B-DISO
.	O

We	O
found	O
that	O
polyclonal	O
antibodies	O
derived	O
from	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
HR2	O
and	O
upstream	O
region	O
were	O
cross	O
-	O
reactive	O
with	O
the	O
S	O
proteins	O
of	O
the	O
same	O
serogroup	O
in	O
western	O
blotting	O
.	O

Using	O
the	O
natural	O
routes	O
of	O
infection	B-DISO
,	O
we	O
observed	O
that	O
co	B-DISO
-	I-DISO
infection	I-DISO
exacerbated	O
chronic	B-DISO
tuberculosis	I-DISO
while	O
rendering	O
mice	O
less	O
refractory	O
to	O
Plasmodium	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
2003	O
alerted	O
the	O
Ontario	O
government	O
to	O
the	O
issue	O
of	O
part	O
-	O
time	O
and	O
casual	O
nursing	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
caused	O
a	O
similar	O
burden	O
of	O
disease	O
in	O
Argentina	O
as	O
in	O
other	O
countries	O
.	O

TITLE	O
:	O
Fine	O
level	O
epitope	O
mapping	O
and	O
conservation	O
analysis	O
of	O
two	O
novel	O
linear	O
B	O
-	O
cell	O
epitopes	O
of	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
coronavirus	O
nucleocapsid	O
protein	O
.	O

To	O
deeply	O
reveal	O
the	O
interaction	O
of	O
host	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
based	O
on	O
the	O
basic	O
structural	O
feature	O
of	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
,	O
we	O
created	O
a	O
new	O
bioinformatics	O
method	O
for	O
searching	O
potential	O
pathogenic	O
molecules	O
and	O
identified	O
a	O
set	O
of	O
SARS	B-DISO
-	O
CoV	O
specific	O
GU	O
-	O
rich	O
ssRNA	O
fragments	O
with	O
a	O
high	O
-	O
density	O
distribution	O
in	O
the	O
genome	O
.	O

Easy	O
accessibility	O
to	O
FA	O
in	O
this	O
region	O
makes	O
it	O
available	O
to	O
be	O
used	O
for	O
deliberate	B-DISO
self	I-DISO
-	I-DISO
harm	I-DISO
.	O

The	O
prevalence	O
of	O
esophageal	B-DISO
stricture	I-DISO
(	O
n	O
=	O
98	O
)	O
was	O
50	O
.	O
2	O
%	O
among	O
survivors	O
and	O
was	O
the	O
most	O
common	O
long	O
-	O
term	O
sequela	O
among	O
the	O
survivors	O
.	O

TITLE	O
:	O
New	O
anthraquinone	O
derivatives	O
as	O
inhibitors	O
of	O
the	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
-	O
associated	O
ribonuclease	O
H	O
function	O
.	O

TITLE	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
caused	O
by	O
tension	B-DISO
pneumoperitoneum	B-DISO
in	O
a	O
scuba	O
diver	O
.	O

Tension	B-DISO
pneumoperitoneum	B-DISO
(	O
TP	O
)	O
is	O
a	O
rare	O
cause	O
of	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
most	O
often	O
seen	O
after	O
gastrointestinal	O
endoscopy	O
with	O
perforation	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
fit	B-DISO
52	O
-	O
year	O
-	O
old	O
experienced	O
female	O
diver	O
who	O
developed	O
TP	O
and	O
shock	O
following	O
a	O
routine	O
training	O
dive	O
to	O
27m	O
.	O

Clinical	O
and	O
radiological	O
examination	O
revealed	O
a	O
shocked	B-DISO
patient	O
with	O
dramatic	O
free	O
intra	O
-	O
abdominal	O
gas	O
and	O
signs	O
of	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
,	O
which	O
was	O
treated	O
with	O
needle	O
decompression	O
.	O

The	O
third	O
patient	O
,	O
initially	O
manifested	O
as	O
acute	O
encephalitic	O
syndrome	B-DISO
.	O

Respiratory	B-DISO
failure	I-DISO
,	O
pneumonia	B-DISO
,	O
acute	O
lung	O
injury	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
),	O
pulmonary	O
edema	B-DISO
,	I-DISO
pulmonary	I-DISO
contusions	O
and	O
pneumo	O
/	O
hemothorax	B-DISO
,	O
and	O
pulmonary	B-DISO
embolism	I-DISO
are	O
frequently	O
encountered	O
in	O
the	O
setting	O
of	O
severe	O
brain	O
injury	O
.	O

Bortezomib	O
is	O
a	O
proteasome	O
inhibitor	O
indicated	O
for	O
the	O
treatment	O
of	O
multiple	B-DISO
myeloma	I-DISO
patients	O
.	O

Systemic	O
corticotherapy	O
led	O
to	O
a	O
rapid	O
improvement	O
in	O
the	O
patient	O
'	O
s	O
condition	B-DISO
.	O

Laboratory	O
markers	O
,	O
interventions	O
,	O
medications	O
,	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
and	O
sepsis	B-DISO
criteria	O
,	O
length	O
of	O
stay	O
,	O
and	O
hospital	O
mortality	O
as	O
well	O
as	O
expected	O
mortality	O
,	O
based	O
on	O
the	O
SAPSII	O
-	O
expanded	O
score	O
,	O
were	O
assessed	O
retrospectively	O
.	O

TITLE	O
:	O
Biogenesis	O
of	O
the	O
vaccinia	B-DISO
virus	O
membrane	O
:	O
genetic	O
and	O
ultrastructural	O
analysis	O
of	O
the	O
contributions	O
of	O
the	O
A14	O
and	O
A17	O
proteins	O
.	O

When	O
N	O
-	O
terminal	O
processing	O
was	O
abrogated	O
,	O
virions	O
attempted	O
to	O
undergo	O
the	O
IV	O
-	O
to	O
-	O
MV	O
transition	B-DISO
without	O
removing	O
the	O
D13	O
scaffold	O
and	O
were	O
therefore	O
noninfectious	O
and	O
structurally	O
aberrant	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	O
(	O
nsp	O
)	O
3	O
is	O
the	O
largest	O
of	O
16	O
nsps	O
translated	O
from	O
the	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
genome	O
.	O

62	O
patients	O
undergoing	O
either	O
scheduled	O
or	O
emergency	B-DISO
upper	O
-	O
limb	O
surgery	O
received	O
brachial	O
plexus	O
block	O
of	O
modified	O
interscalene	O
or	O
axillary	O
brachial	O
and	O
then	O
postoperative	O
patient	O
-	O
controlled	O
analgesia	B-DISO
(	O
PCA	B-DISO
)	O
with	O
local	O
analgesics	O
using	O
a	O
specially	O
designed	O
non	O
-	O
stimulation	O
needle	O
with	O
an	O
external	O
indwelling	O
cannula	O
.	O

The	O
success	O
rate	O
of	O
anesthesia	B-DISO
was	O
96	O
.	O
8	O
%.	O

CXCL10	O
may	O
not	O
be	O
a	O
bystander	O
to	O
the	O
severe	O
virus	B-DISO
infection	I-DISO
but	O
may	O
directly	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
neutrophil	O
-	O
mediated	O
,	O
excessive	O
pulmonary	B-DISO
inflammation	I-DISO
.	O

We	O
induced	O
nonviral	O
ARDS	B-DISO
by	O
acid	O
aspiration	B-DISO
and	O
viral	O
ARDS	B-DISO
by	O
intratracheal	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
in	O
wild	O
-	O
type	O
mice	O
and	O
mice	O
deficient	O
in	O
CXCL10	O
,	O
CXCR3	O
,	O
IFNAR1	O
(	O
IFN	O
-	O
α	O
/	O
β	O
receptor	O
1	O
),	O
or	O
TIR	O
domain	O
-	O
containing	O
adaptor	O
inducing	O
IFN	O
-	O
β	O
(	O
TRIF	O
).	O

CXCL10	O
-	O
CXCR3	O
signaling	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
for	O
the	O
exacerbation	O
of	O
the	O
pathology	B-DISO
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Construction	O
of	O
recombinant	O
lactobacilli	O
expressing	O
the	O
core	O
neutralizing	O
epitope	O
(	O
COE	O
)	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
a	O
fusion	O
protein	O
consisting	O
of	O
COE	O
and	O
Escherichia	O
coli	O
heat	O
-	O
labile	O
enterotoxin	O
B	O
,	O
and	O
comparison	O
of	O
the	O
immune	O
responses	O
by	O
orogastric	O
immunization	O
.	O

ABSTRACT	O
:	O
Disseminated	O
phaeohyphomycoses	B-DISO
are	O
rare	O
infections	B-DISO
caused	O
by	O
dematiaceous	O
fungi	O
.	O

We	O
report	O
herein	O
an	O
O	O
gallopavum	O
phaeohyphomycosis	B-DISO
with	O
involvement	O
of	O
skin	O
in	O
a	O
transplant	O
recipient	O
.	O

Chest	O
X	O
-	O
ray	O
showed	O
no	O
evidence	O
of	O
pneumonia	B-DISO
.	O

Excision	O
biopsy	O
was	O
performed	O
because	O
of	O
a	O
suspected	O
pigmented	B-DISO
basal	I-DISO
cell	I-DISO
carcinoma	I-DISO
.	O

Organ	O
complications	O
,	O
infection	B-DISO
,	O
operation	O
rate	O
,	O
mortality	O
and	O
hospital	O
stay	O
were	O
also	O
compared	O
.	O

ABSTRACT	O
:	O
A	O
/	O
H1N1	O
/	O
09	O
influenza	B-DISO
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
complications	O
in	O
patients	O
with	O
chronic	B-DISO
diseases	I-DISO
,	O
but	O
data	O
on	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
cirrhosis	B-DISO
are	O
limited	O
.	O

A	O
/	O
H1N1	O
/	O
09	O
infection	B-DISO
rate	O
did	O
not	O
differ	O
in	O
patients	O
with	O
and	O
without	O
cirrhosis	B-DISO
(	O
4	O
/	O
21	O
,	O
19	O
%;	O
4	O
/	O
27	O
,	O
15	O
%),	O
but	O
three	O
patients	O
with	O
cirrhosis	B-DISO
died	O
of	O
pneumonia	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
with	O
fungal	O
or	O
bacterial	O
superinfection	B-DISO
in	O
two	O
cases	O
,	O
despite	O
antiviral	O
treatment	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
is	O
caused	O
by	O
a	O
coronavirus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

Infectious	B-DISO
bronchitis	B-DISO
is	O
an	O
acute	O
and	O
highly	O
contagious	B-DISO
disease	I-DISO
of	O
economic	O
importance	O
due	O
to	O
the	O
reduction	O
in	O
weight	O
gain	O
observed	O
with	O
infected	O
broilers	O
and	O
the	O
drop	O
in	O
egg	O
quality	O
and	O
production	O
associated	O
with	O
infected	O
laying	O
hens	O
.	O

Upon	O
microscopic	O
examination	O
,	O
the	O
muscle	O
samples	O
from	O
the	O
case	O
group	O
presented	O
extensive	O
necrosis	O
,	O
intense	O
mononuclear	O
inflammatory	B-DISO
infiltration	I-DISO
,	O
muscle	O
fiber	O
fragmentation	B-DISO
,	O
and	O
fibrotic	O
tissue	O
,	O
confirming	O
myopathy	B-DISO
,	O
whereas	O
muscles	O
from	O
the	O
control	O
group	O
showed	O
no	O
alterations	O
.	O

TITLE	O
:	O
Heroin	B-DISO
addict	I-DISO
with	O
gangrene	B-DISO
of	O
the	O
extremities	O
,	O
rhabdomyolysis	B-DISO
and	O
severe	O
hyperkalemia	O
.	O

It	O
is	O
also	O
connected	O
to	O
damages	O
of	O
different	O
organic	O
systems	O
and	O
it	O
often	O
leads	O
to	O
appearance	O
of	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

Rhabdomyolysis	B-DISO
is	O
characterized	O
by	O
injury	O
of	O
skeletal	O
muscle	O
with	O
subsequent	O
release	O
of	O
intracellular	O
contents	O
,	O
such	O
as	O
myoglobin	O
,	O
potassium	O
and	O
creatine	O
phosphokinase	O
.	O

Therefore	O
we	O
introduced	O
V	O
-	O
V	O
ECMO	O
for	O
the	O
treatment	O
of	O
severe	O
hypoxia	B-DISO
and	O
could	O
anesthetize	O
him	O
safely	O
during	O
surgical	O
operation	O
.	O

TITLE	O
:	O
[	O
Emergency	B-DISO
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
pediatric	O
critically	B-DISO
ill	I-DISO
patients	O
].	O

ECMO	O
is	O
a	O
justifiable	O
alternative	O
treatment	O
for	O
reversible	O
severe	O
cardiopulmonary	B-DISO
failure	I-DISO
in	O
critically	B-DISO
ill	I-DISO
children	O
.	O

Laboratory	O
and	O
radiologic	O
investigations	O
confirmed	O
the	O
clinical	O
diagnosis	O
of	O
teratoma	B-DISO
on	O
the	O
basis	O
of	O
elevated	O
AFP	O
values	O
and	O
imaging	O
findings	O
.	O

Two	O
years	O
after	O
the	O
first	O
exeresis	O
at	O
birth	O
,	O
relapse	B-DISO
was	O
observed	O
in	O
case	O
N	O
°	O
3	O
,	O
with	O
a	O
malignant	O
component	O
,	O
YST	O
,	O
anticipated	O
by	O
elevated	O
AFP	O
values	O
but	O
negative	O
physical	O
signs	O
and	O
a	O
benign	O
cystic	O
imaging	O
pattern	O
.	O

Forty	O
patients	O
after	O
the	O
resuscitation	O
phase	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
who	O
were	O
mechanically	O
ventilated	O
with	O
6	O
ml	O
kg	O
(-	O
1	O
)	O
were	O
included	O
.	O

The	O
ΔPP	O
performance	O
[	O
ROC	O
curve	O
area	O
:	O
0	O
.	O
91	O
(	O
0	O
.	O
82	O
-	O
1	O
.	O
0	O
)]	O
was	O
better	O
than	O
that	O
of	O
the	O
RAP	O
[	O
ROC	O
curve	O
area	O
:	O
0	O
.	O
73	O
(	O
0	O
.	O
59	O
-	O
0	O
.	O
90	O
)]	O
and	O
pulmonary	O
artery	B-DISO
occlusion	I-DISO
pressure	O
[	O
ROC	O
curve	O
area	O
:	O
0	O
.	O
58	O
(	O
0	O
.	O
40	O
-	O
0	O
.	O
76	O
)].	O

RESULTS	O
:	O
Thirty	O
-	O
four	O
patients	O
had	O
characteristics	O
consistent	O
with	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
were	O
ventilated	O
with	O
high	O
levels	O
of	O
PEEP	O
[	O
median	O
(	O
inter	O
-	O
quartile	O
range	O
)	O
10	O
.	O
0	O
(	O
10	O
.	O
0	O
-	O
13	O
.	O
5	O
)].	O

ABSTRACT	O
:	O
Recently	O
,	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
outbreaks	O
have	O
occurred	O
in	O
commercial	O
broiler	O
flocks	O
and	O
have	O
been	O
associated	O
with	O
a	O
high	O
incidence	O
and	O
morbidity	O
in	O
China	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
novel	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
GD	O
-	O
1	O
in	O
China	O
.	O

We	O
report	O
here	O
the	O
complete	O
genome	O
sequence	O
of	O
SD	O
-	O
M	O
.	O
This	O
sequence	O
will	O
promote	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	B-DISO
of	O
PEDV	O
.	O

We	O
used	O
data	O
from	O
a	O
new	O
sentinel	O
surveillance	O
system	O
to	O
investigate	O
the	O
seasonality	O
and	O
characteristics	O
of	O
influenza	B-DISO
,	O
including	O
pandemic	O
(	O
pdm	O
)	O
influenza	B-DISO
A	O
H1N1	O
,	O
in	O
Zambia	O
.	O

Among	O
all	O
influenza	B-DISO
cases	O
,	O
54	O
(	O
95	O
%)	O
were	O
influenza	B-DISO
A	O
and	O
3	O
(	O
5	O
%)	O
were	O
influenza	B-DISO
B	O
.	O
Of	O
the	O
influenza	B-DISO
A	O
viruses	O
,	O
16	O
(	O
30	O
%)	O
were	O
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
29	O
(	O
54	O
%)	O
were	O
seasonal	O
A	O
(	O
H1N1	O
),	O
6	O
(	O
11	O
%)	O
were	O
A	O
(	O
H3N2	O
),	O
and	O
4	O
(	O
7	O
%)	O
were	O
unsubtyped	O
.	O

While	O
influenza	B-DISO
virus	O
,	O
enterovirus	O
,	O
RSV	O
,	O
and	O
HMPV	O
had	O
a	O
defined	O
period	O
of	O
circulation	O
,	O
the	O
other	O
viruses	O
were	O
detected	O
throughout	O
the	O
year	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
replicase	O
gene	O
of	O
coronaviruses	O
with	O
completely	O
sequenced	O
genomes	O
showed	O
that	O
HCoV	O
-	O
EMC	B-DISO
/	O
2012	O
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	O
bat	O
coronavirus	O
HKU4	O
(	O
BtCoV	O
-	O
HKU4	O
)	O
and	O
Pipistrellus	O
bat	O
coronavirus	O
HKU5	O
(	O
BtCoV	O
-	O
HKU5	O
),	O
which	O
prototype	O
two	O
species	O
in	O
lineage	O
C	O
of	O
the	O
genus	O
Betacoronavirus	O
.	O

Most	O
infections	B-DISO
caused	O
by	O
human	O
coronaviruses	O
are	O
relatively	O
mild	O
.	O

By	O
establishing	O
its	O
complete	O
genome	O
sequence	O
,	O
HCoV	O
-	O
EMC	B-DISO
/	O
2012	O
was	O
characterized	O
as	O
a	O
new	O
genotype	O
which	O
is	O
closely	O
related	O
to	O
bat	O
coronaviruses	O
that	O
are	O
distant	O
from	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
expect	O
that	O
this	O
information	O
will	O
be	O
vital	O
to	O
rapid	O
advancement	O
of	O
both	O
clinical	O
and	O
vital	O
research	O
on	O
this	O
emerging	O
pathogen	O
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
malaria	B-DISO
in	O
tissues	O
and	O
blood	O
.	O

In	O
primigravidae	O
from	O
endemic	O
areas	O
,	O
life	O
threatening	O
placental	O
malaria	B-DISO
may	O
also	O
be	O
present	O
.	O

TITLE	O
:	O
Clinical	O
review	O
:	O
Exogenous	O
surfactant	O
therapy	O
for	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
--	O
where	O
do	O
we	O
go	O
from	O
here	O
?	O

Exploring	O
the	O
clinical	O
benefit	O
of	O
such	O
an	O
approach	O
should	O
be	O
a	O
priority	O
for	O
future	O
ARDS	B-DISO
research	O
.	O

Transfusion	O
is	O
a	O
lifesaving	O
medical	O
intervention	O
among	O
patients	O
with	O
bleeding	B-DISO
disorders	I-DISO
.	O

We	O
report	O
a	O
14	O
years	O
old	O
white	O
girl	O
,	O
with	O
a	O
history	O
of	O
type	B-DISO
1	I-DISO
von	I-DISO
Willebrand	I-DISO
disease	I-DISO
(	O
vWd	O
),	O
recipient	O
of	O
2	O
units	O
'	O
fresh	O
-	O
frozen	O
plasma	O
(	O
FFP	O
)	O
and	O
1	O
unit	O
whole	O
blood	O
transfusion	O
who	O
developed	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
with	O
severe	O
hypoxemia	O
and	O
bilateral	O
pulmonary	B-DISO
infiltrate	I-DISO
on	O
chest	O
X	O
-	O
ray	O
within	O
3	O
hours	O
of	O
the	O
whole	O
blood	O
transfusion	O
,	O
completely	O
reversible	O
after	O
mechanical	O
ventilation	O
.	O

Strong	O
reactivity	O
to	O
the	O
NPs	B-DISO
of	O
HCoV	O
-	O
OC43	O
was	O
observed	O
in	O
96	O
%,	O
82	O
%,	O
and	O
93	O
%	O
of	O
the	O
serum	O
samples	O
from	O
the	O
young	O
adults	O
,	O
respiratory	O
patients	O
,	O
and	O
cord	B-DISO
blood	O
samples	O
,	O
respectively	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
offer	O
insight	O
into	O
the	O
design	O
of	O
diagnostic	O
tools	O
for	O
HCoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
four	O
Massachusetts	O
type	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
genomes	O
reveals	O
a	O
novel	O
Massachusetts	O
type	O
strain	O
and	O
evidence	O
of	O
natural	O
recombination	O
in	O
the	O
genome	O
.	O

Following	O
M41	O
strain	O
infection	B-DISO
,	O
birds	O
with	O
B2	O
/	O
B2	O
and	O
B8	O
/	O
B8	O
haplotypes	O
were	O
again	O
more	O
resistant	O
to	O
clinical	O
illness	O
than	O
B19	O
/	O
B19	O
birds	O
.	O

TITLE	O
:	O
Nasal	O
cytokine	O
responses	O
to	O
natural	O
colds	B-DISO
in	O
asthmatic	B-DISO
children	O
.	O

ABSTRACT	O
:	O
The	O
mechanisms	O
by	O
which	O
viruses	O
induce	O
asthma	B-DISO
exacerbations	O
are	O
not	O
well	O
understood	O
.	O

Sixteen	O
children	O
underwent	O
home	O
collections	O
of	O
nasal	O
aspirates	O
when	O
they	O
were	O
without	O
cold	B-DISO
symptoms	I-DISO
and	O
again	O
during	O
self	O
-	O
reported	O
respiratory	O
illnesses	O
.	O

While	O
many	O
aspirates	O
were	O
dilute	O
and	O
showed	O
no	O
mRNA	O
signal	O
,	O
viral	B-DISO
infection	I-DISO
significantly	O
increased	O
the	O
number	O
of	O
samples	O
that	O
were	O
positive	O
for	O
IFN	O
-	O
λ1	O
,	O
IFN	O
-	O
λ2	O
/	O
3	O
,	O
TLR3	O
,	O
RIG	O
-	O
I	O
,	O
and	O
IRF7	O
mRNA	O
.	O

We	O
conclude	O
that	O
in	O
children	O
with	O
asthma	B-DISO
,	O
naturally	O
occurring	O
viral	B-DISO
infections	I-DISO
apparently	O
induce	O
a	O
robust	O
innate	B-DISO
immune	I-DISO
response	I-DISO
including	O
expression	O
of	O
specific	O
chemokines	O
,	O
IFNs	O
,	O
and	O
IFN	O
-	O
responsive	O
genes	O
.	O

While	O
many	O
aspirates	O
were	O
dilute	O
and	O
showed	O
no	O
mRNA	O
signal	O
,	O
viral	B-DISO
infection	I-DISO
significantly	O
increased	O
the	O
number	O
of	O
samples	O
that	O
were	O
positive	O
for	O
IFN	O
-	O
λ1	O
,	O
IFN	O
-	O
λ2	O
/	O
3	O
,	O
TLR3	O
,	O
RIG	O
-	O
I	O
,	O
and	O
IRF7	O
mRNA	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
to	O
productively	O
infect	O
monocytes	O
/	O
macrophages	O
is	O
the	O
most	O
important	O
difference	O
between	O
the	O
low	O
virulent	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
and	O
the	O
lethal	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
).	O

ABSTRACT	O
:	O
Entry	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
its	O
envelope	O
fusion	O
with	O
host	O
cell	O
membrane	O
are	O
controlled	O
by	O
a	O
series	O
of	O
complex	O
molecular	O
mechanisms	O
,	O
largely	O
dependent	O
on	O
the	O
viral	O
envelope	O
glycoprotein	O
Spike	O
(	O
S	O
).	O

Ezrin	O
interacts	O
with	O
SARS	B-DISO
-	O
CoV	O
S	O
endodomain	O
and	O
limits	O
virus	O
entry	O
and	O
fusion	O
.	O

ABSTRACT	O
:	O
The	O
enteropathogenic	O
coronavirus	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
causes	O
severe	O
disease	O
in	O
young	O
piglets	O
.	O

Two	O
(	O
0	O
.	O
7	O
%)	O
patients	O
succumbed	O
to	O
LRTI	B-DISO
from	O
parainfluenza	B-DISO
virus	O
-	O
3	O
and	O
respiratory	O
syncytial	O
virus	O
/	O
human	O
rhinovirus	B-DISO
infection	I-DISO
,	O
respectively	O
.	O

EAdi	O
allows	O
accurate	O
analysis	O
of	O
asynchrony	O
patterns	O
and	O
magnitude	O
in	O
ARDS	B-DISO
patients	O
with	O
very	O
low	O
Cst	O
(	O
rs	O
)	O
undergoing	O
ECMO	O
.	O

CDC	O
relied	O
on	O
vertical	O
programs	O
,	O
some	O
of	O
them	O
successful	O
(	O
such	O
as	O
elimination	O
of	O
lymphatic	B-DISO
filariasis	I-DISO
and	O
child	O
immunisation	O
),	O
but	O
others	O
(	O
such	O
as	O
control	O
of	O
schistosomiasis	B-DISO
and	O
tuberculosis	B-DISO
)	O
demonstrating	O
only	O
intermittent	O
progress	O
due	O
to	O
failed	O
strategies	O
or	O
reliance	O
on	O
support	O
by	O
the	O
poorest	O
governments	O
and	O
health	O
workers	O
,	O
who	O
could	O
not	O
or	O
would	O
not	O
collaborate	O
.	O

Patients	O
had	O
direct	O
contact	O
with	O
dead	O
/	O
sick	O
poultry	O
infected	O
with	O
H5N1	B-DISO
virus	O
or	O
lived	O
in	O
areas	O
where	O
H5N1	B-DISO
poultry	O
outbreaks	O
had	O
been	O
reported	O
at	O
the	O
same	O
time	O
as	O
their	O
illness	O
.	O

An	O
SNU8067	O
infection	B-DISO
inhibited	O
formation	O
of	O
hierarchal	O
ovarian	O
follicles	O
(	O
80	O
%)	O
and	O
oviduct	O
maturation	O
(	O
50	O
%)	O
in	O
the	O
control	O
group	O
,	O
whereas	O
70	O
%	O
of	O
vaccinated	O
chickens	O
were	O
protected	O
from	O
lesions	O
.	O

Mixed	B-DISO
infection	I-DISO
with	O
hMPV	O
was	O
most	O
commonly	O
found	O
in	O
infants	O
less	O
than	O
6	O
months	O
old	O
and	O
ERV	O
was	O
most	O
commonly	O
found	O
in	O
mixed	B-DISO
infection	I-DISO
with	O
hMPV	O
(	O
230	O
/	O
373	O
,	O
56	O
%)	O
across	O
all	O
age	O
groups	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
accessory	O
proteins	O
in	O
virus	B-DISO
pathogenesis	I-DISO
.	O

They	O
have	O
also	O
been	O
involved	O
in	O
nosocomial	O
viral	B-DISO
infections	I-DISO
.	O

Records	O
returned	O
from	O
these	O
queries	O
can	O
then	O
be	O
subjected	O
to	O
web	B-DISO
-	O
based	O
analyses	O
including	O
:	O
multiple	O
sequence	O
alignment	O
,	O
phylogenetic	O
inference	O
,	O
sequence	O
variation	O
determination	O
,	O
BLAST	O
comparison	O
,	O
and	O
metadata	O
-	O
driven	O
comparative	O
genomics	O
statistical	O
analysis	O
.	O

In	O
addition	O
,	O
coronavirus	B-DISO
infection	I-DISO
has	O
been	O
demonstrated	O
to	O
induce	O
autophagy	O
.	O

ABSTRACT	O
:	O
The	O
S2	O
glycoprotein	O
and	O
membrane	O
(	O
M	O
)	O
protein	O
genes	O
and	O
S1	O
glycoprotein	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
of	O
11	O
Korean	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
,	O
cloned	O
,	O
and	O
sequenced	O
.	O

ABSTRACT	O
:	O
Acute	O
fibrinous	O
and	O
organizing	B-DISO
pneumonia	I-DISO
(	O
AFOP	O
)	O
is	O
a	O
newly	O
recognized	O
form	O
of	O
diffuse	O
lung	O
injury	O
.	O

Critically	B-DISO
ill	I-DISO
patients	O
with	O
severe	O
2009	O
H1N1	O
infection	B-DISO
in	O
this	O
limited	O
resource	O
country	O
had	O
a	O
much	O
higher	O
mortality	O
rate	O
than	O
the	O
predicted	O
APACHE	O
II	O
mortality	O
rate	O
or	O
when	O
compared	O
with	O
the	O
reported	O
mortality	O
rates	O
for	O
severe	O
cases	O
in	O
other	O
countries	O
during	O
2009	O
H1N1	O
pandemic	O
.	O

We	O
report	O
our	O
experience	O
in	O
17	O
patients	O
under	O
VV	O
-	O
ECMO	O
for	O
severe	O
ARDS	B-DISO
.	O

This	O
report	O
describes	O
coronavirus	O
genetic	O
diversity	O
,	O
species	O
specificity	O
and	O
infection	B-DISO
prevalence	O
in	O
three	O
wild	O
African	O
carnivores	O
.	O

TITLE	O
:	O
[	O
Protocol	O
of	O
the	O
management	O
of	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
].	O

TITLE	O
:	O
Identification	O
of	O
a	O
noncanonically	O
transcribed	O
subgenomic	O
mRNA	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
other	O
gammacoronaviruses	O
.	O

We	O
confirmed	O
previous	O
reports	O
that	O
coronaviruses	O
can	O
produce	O
sgmRNAs	O
from	O
noncanonical	O
TRS	B-DISO
-	O
Bs	O
,	O
which	O
may	O
expand	O
their	O
repertoire	O
of	O
proteins	O
.	O

To	O
study	O
the	O
differences	O
of	O
dynamic	O
distribution	O
between	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
such	O
as	O
SAIBK	O
and	O
other	O
strains	O
(	O
the	O
M41	O
and	O
H120	O
strains	O
),	O
relative	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
was	O
developed	O
by	O
housekeeping	O
gene	O
selection	O
.	O

TITLE	O
:	O
Aerophagia	B-DISO
in	O
a	O
toddler	O
with	O
gastric	O
pull	O
-	O
up	O
:	O
an	O
unusual	O
combination	O
precipitating	O
severe	O
respiratory	B-DISO
distress	I-DISO
.	O

We	O
hereby	O
report	O
case	O
of	O
a	O
child	O
who	O
had	O
successfully	O
undergone	O
gastric	O
pull	O
-	O
up	O
approximately	O
18	O
months	O
before	O
and	O
presented	O
with	O
gradually	O
progressing	O
dyspnea	B-DISO
due	O
to	O
aerophagia	B-DISO
from	O
excessive	O
crying	O
.	O

Adult	O
patients	O
admitted	O
to	O
participating	O
ICUs	O
during	O
the	O
study	O
period	O
with	O
an	O
ICU	O
length	O
of	O
stay	O
>	O
24	O
hrs	B-DISO
.	O

Seven	O
hundred	O
sixty	O
-	O
five	O
patients	O
(	O
59	O
.	O
0	O
%)	O
developed	O
infections	B-DISO
,	O
followed	O
by	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
(	O
484	O
,	O
37	O
.	O
3	O
%),	O
acute	O
kidney	O
injury	O
(	O
398	O
,	O
30	O
.	O
7	O
%),	O
and	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
351	O
,	O
27	O
.	O
1	O
%).	O

Between	O
December	O
2009	O
and	O
March	O
2011	O
,	O
18	O
patients	O
underwent	O
ECMO	O
therapy	O
for	O
severe	O
H1N1	O
-	O
related	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Patent	B-DISO
foramen	I-DISO
ovale	I-DISO
(	O
PFO	O
),	O
although	O
frequently	O
observed	O
in	O
adults	O
,	O
rarely	O
causes	O
adverse	O
clinical	O
consequences	O
.	O

ABSTRACT	O
:	O
A	O
new	O
human	O
coronavirus	O
(	O
hCoV	O
-	O
EMC	B-DISO
)	O
has	O
emerged	O
very	O
recently	O
in	O
the	O
Middle	O
East	O
.	O

Here	O
we	O
investigated	O
whether	O
it	O
might	O
utilize	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
.	O

TTS	O
must	O
be	O
considered	O
within	O
the	O
extra	O
-	O
neurological	O
complications	O
arising	O
from	O
myasthenic	B-DISO
crisis	I-DISO
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
were	O
the	O
most	O
common	O
additional	O
respiratory	O
viruses	O
,	O
Lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
were	O
the	O
most	O
frequent	O
diagnoses	O
made	O
in	O
the	O
hospital	O
,	O
in	O
which	O
there	O
were	O
52	O
pneumonia	B-DISO
(	O
30	O
.	O
4	O
%)	O
cases	O
.	O

TITLE	O
:	O
Acute	B-DISO
asthma	I-DISO
exacerbations	O
in	O
childhood	O
:	O
risk	O
factors	O
,	O
prevention	O
and	O
treatment	O
.	O

In	O
this	O
review	O
,	O
the	O
authors	O
focus	O
on	O
such	O
sudden	O
-	O
onset	O
events	O
,	O
emphasizing	O
on	O
their	O
diversity	O
on	O
the	O
basis	O
of	O
the	O
numerous	O
asthma	B-DISO
phenotypes	O
.	O

ABSTRACT	O
:	O
In	O
2007	O
,	O
a	O
novel	O
coronavirus	O
associated	O
with	O
an	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
alpacas	O
(	O
Alpaca	O
Coronavirus	O
,	O
ACoV	O
)	O
was	O
isolated	O
.	O

In	O
case	O
of	O
the	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
),	O
a	O
member	O
of	O
the	O
family	O
Flaviviridae	O
,	O
infected	O
cells	O
contain	O
accumulations	O
of	O
vesicles	B-DISO
forming	O
a	O
membranous	O
web	B-DISO
(	O
MW	O
)	O
that	O
is	O
thought	O
to	O
be	O
the	O
site	O
of	O
viral	O
RNA	O
replication	O
.	O

We	O
found	O
that	O
the	O
MW	O
is	O
derived	O
primarily	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
contains	O
markers	O
of	O
rough	O
ER	O
as	O
well	O
as	O
markers	O
of	O
early	O
and	O
late	O
endosomes	O
,	O
COP	O
vesicles	B-DISO
,	O
mitochondria	O
and	O
lipid	O
droplets	O
(	O
LDs	O
).	O

Means	O
and	O
SDs	B-DISO
were	O
compared	O
for	O
those	O
treated	O
with	O
early	O
(	O
0	O
-	O
48	O
hours	O
)	O
institution	O
of	O
HFOV	O
with	O
those	O
who	O
received	O
it	O
late	O
(	O
48	O
-	O
72	O
hours	O
).	O

hMPV	O
was	O
detected	O
in	O
14	O
.	O
2	O
%	O
(	O
41	O
/	O
288	O
)	O
of	O
all	O
samples	O
:	O
17	O
%	O
(	O
28	O
/	O
165	O
)	O
of	O
immunocompetent	O
patients	O
with	O
suspected	O
H1N1	O
infection	B-DISO
and	O
10	O
.	O
6	O
%	O
(	O
13	O
/	O
123	O
)	O
among	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
.	O

In	O
the	O
early	O
phase	O
of	O
infection	B-DISO
,	O
neurons	O
,	O
astrocytes	O
and	O
neural	O
progenitor	O
cells	O
were	O
infected	O
by	O
MK	O
-	O
p10	O
,	O
whereas	O
neural	O
progenitor	O
cells	O
were	O
the	O
only	O
target	O
cells	O
infected	O
by	O
MK	O
.	O

On	O
days	O
4	O
-	O
5	O
post	O
-	O
inoculation	O
,	O
MK	O
-	O
p10	O
antigens	O
were	O
distributed	O
in	O
a	O
number	O
of	O
neurons	O
in	O
a	O
wide	O
area	O
of	O
the	O
brain	O
;	O
however	O
,	O
antigens	O
were	O
restricted	O
in	O
MK	O
infection	B-DISO
.	O

The	O
wide	O
spectrum	O
of	O
initial	O
target	O
cells	O
following	O
MK	O
-	O
p10	O
infection	B-DISO
,	O
as	O
well	O
as	O
its	O
faster	O
spread	O
in	O
the	O
brain	O
,	O
may	O
be	O
evidence	O
of	O
enhanced	O
virulence	O
in	O
suckling	O
mice	O
.	O

However	O
,	O
viruses	O
have	O
also	O
been	O
associated	O
with	O
petechial	B-DISO
rash	I-DISO
.	O

A	O
roadmap	O
for	O
the	O
product	O
development	O
of	O
the	O
RBD	O
-	O
S	O
SARS	B-DISO
vaccine	O
is	O
outlined	O
with	O
a	O
goal	O
to	O
manufacture	O
the	O
vaccine	O
for	O
clinical	O
testing	O
within	O
the	O
next	O
5	O
years	O
.	O

We	O
therefore	O
assessed	O
the	O
effects	O
on	O
gas	O
exchange	O
and	O
lung	O
mechanics	O
and	O
the	O
possible	O
detrimental	O
effects	O
of	O
a	O
sequential	O
lung	O
RMs	O
and	O
decremental	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
titration	O
in	O
pediatric	O
ARDS	B-DISO
patients	O
.	O

We	O
included	O
25	O
patients	O
,	O
of	O
median	O
age	O
5	O
(	O
1	O
-	O
16	O
)	O
months	O
,	O
median	O
weight	O
7	O
.	O
0	O
(	O
4	O
.	O
1	O
-	O
9	O
.	O
2	O
)	O
kg	O
,	O
median	O
PaO2	O
/	O
FIO2	O
117	O
(	O
96	O
-	O
139	O
),	O
and	O
median	O
Cdyn	O
0	O
.	O
48	O
(	O
0	O
.	O
41	O
-	O
0	O
.	O
68	O
)	O
ml	O
/	O
cmH2	B-DISO
O	O
/	O
kg	O
at	O
baseline	O
.	O

Sequential	O
RMs	O
were	O
safe	O
and	O
well	O
tolerated	O
in	O
hemodynamically	O
stable	O
children	O
with	O
ARDS	B-DISO
.	O

In	O
the	O
presence	O
of	O
alveolar	O
capillary	O
damage	O
,	O
which	O
occurs	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
promotes	O
lung	O
injury	O
as	O
well	O
as	O
edema	B-DISO
,	O
impedes	O
the	O
pulmonary	O
lymphatic	O
drainage	O
,	O
and	O
increases	O
intra	O
-	O
thoracic	B-DISO
pressures	O
,	O
leading	O
to	O
atelectasis	B-DISO
,	O
airway	O
closure	O
,	O
and	O
deterioration	O
of	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
.	O

ABSTRACT	O
:	O
Secondary	B-DISO
sclerosing	I-DISO
cholangitis	I-DISO
is	O
a	O
severe	O
disease	O
of	O
the	O
biliary	O
tract	O
.	O

Reports	O
in	O
the	O
literature	O
so	O
far	O
are	O
characterized	O
by	O
a	O
wide	O
variety	O
of	O
underlying	O
causes	O
of	O
critical	B-DISO
illness	I-DISO
,	O
thereby	O
hindering	O
a	O
risk	O
-	O
factor	O
analysis	O
.	O

Both	O
patient	O
groups	O
showed	O
severe	O
pulmonary	O
impairment	B-DISO
.	O

Our	O
results	O
suggest	O
that	O
obesity	B-DISO
,	O
intraperitoneal	O
fat	O
volume	O
,	O
and	O
a	O
longer	O
cumulative	O
duration	O
spent	O
in	O
the	O
prone	O
position	O
may	O
put	O
patients	O
with	O
ARDS	B-DISO
at	O
risk	O
of	O
developing	O
SC	O
-	O
CIP	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
obesity	B-DISO
,	O
intraperitoneal	O
fat	O
volume	O
,	O
and	O
a	O
longer	O
cumulative	O
duration	O
spent	O
in	O
the	O
prone	O
position	O
may	O
put	O
patients	O
with	O
ARDS	B-DISO
at	O
risk	O
of	O
developing	O
SC	O
-	O
CIP	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
recommended	O
the	O
multiplex	O
nested	O
PCR	O
as	O
an	O
effective	O
tool	O
for	O
detecting	O
and	O
studying	O
the	O
molecular	O
epidemiology	O
of	O
various	O
mixed	B-DISO
infections	I-DISO
of	O
one	O
or	O
more	O
of	O
these	O
viruses	O
in	O
poultry	O
.	O

The	O
delicate	O
balance	O
of	O
multiple	O
effects	O
of	O
DN	O
T	O
cells	O
may	O
lead	O
to	O
viral	O
persistence	O
in	O
MHV	O
-	O
3	O
induced	O
hepatitis	B-DISO
.	O

We	O
propose	O
two	O
novel	O
related	O
strategies	O
for	O
the	O
management	O
of	O
hypoxemia	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

TITLE	O
:	O
Genetic	O
variation	O
analysis	O
of	O
reemerging	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
prevailing	O
in	O
central	O
China	O
from	O
2010	O
to	O
2011	O
.	O

To	O
investigate	O
and	O
analyze	O
the	O
reason	O
of	O
this	O
outbreak	O
,	O
the	O
M	O
and	O
ORF3	O
genes	O
of	O
15	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
(	O
PEDV	O
),	O
which	O
were	O
collected	O
from	O
different	O
areas	O
of	O
central	O
China	O
during	O
October	O
2010	O
and	O
December	O
2011	O
,	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
sequenced	O
,	O
and	O
analyzed	O
.	O

It	O
displays	O
a	O
six	O
-	O
stranded	O
β	O
-	O
barrel	O
fold	O
with	O
a	O
long	O
alpha	O
helix	O
on	O
the	O
rim	O
of	O
the	O
barrel	O
,	O
a	O
fold	O
shared	O
with	O
SARS	B-DISO
-	O
CoV	O
nsp1	O
(	O
13	O
-	O
128	O
).	O

High	O
concentrations	O
of	O
inspired	O
oxygen	O
may	O
play	O
a	O
role	O
in	O
such	O
injury	O
,	O
but	O
aggressive	B-DISO
measures	O
to	O
reduce	O
them	O
in	O
order	O
to	O
avoid	O
oxygen	O
toxicity	O
-	O
which	O
dominated	O
ventilator	O
management	O
in	O
previous	O
decades	O
-	O
have	O
been	O
tempered	O
in	O
the	O
present	O
era	O
of	O
lung	O
-	O
protective	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
non	O
—	O
structural	O
protein	O
13	O
(	O
nsp13	O
)	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	O
—	O
CoV	O
)	O
is	O
a	O
helicase	O
that	O
separates	O
double	O
—	O
stranded	O
RNA	O
or	O
DNA	O
with	O
a	O
5	O
'—	O
3	O
'	O
polarity	O
,	O
using	O
the	O
energy	O
of	O
nucleotide	O
hydrolysis	O
.	O

Here	O
we	O
present	O
new	O
information	O
describing	O
structure	O
and	O
function	O
of	O
the	O
third	O
stem	O
of	O
the	O
SARS	B-DISO
pseudoknot	O
.	O

Furthermore	O
,	O
the	O
inability	O
to	O
dimerize	O
caused	O
by	O
the	O
silent	O
codon	O
change	O
in	O
Stem	O
3	O
of	O
SARS	B-DISO
-	O
CoV	O
changed	O
the	O
viral	O
growth	O
kinetics	O
and	O
affected	O
the	O
levels	O
of	O
genomic	O
and	O
subgenomic	O
RNA	O
in	O
infected	O
cells	O
.	O

Smoking	O
prevention	O
and	O
standardized	O
management	O
programs	O
for	O
asthma	B-DISO
and	O
COPD	B-DISO
are	O
now	O
available	O
but	O
prompt	O
actions	O
are	O
needed	O
to	O
make	O
them	O
more	O
effective	O
in	O
this	O
region	O
and	O
thus	O
avoid	O
an	O
adverse	O
impact	O
on	O
national	O
economic	O
development	O
.	O

ABSTRACT	O
:	O
Most	O
betacoronaviruses	O
possess	B-DISO
an	O
hemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
protein	O
,	O
which	O
appears	O
to	O
play	O
a	O
role	O
in	O
binding	O
to	O
or	O
release	O
from	O
the	O
target	O
cell	O
.	O

Complementation	O
experiments	O
,	O
using	O
BHK	O
-	O
21	O
cells	O
expressing	O
wild	O
-	O
type	O
HE	O
,	O
either	O
transiently	O
or	O
in	O
a	O
stable	O
ectopic	O
expression	O
,	O
demonstrate	O
that	O
this	O
protein	O
plays	O
a	O
very	O
significant	O
role	O
in	O
the	O
production	O
of	O
infectious	B-DISO
recombinant	O
coronaviral	O
particles	O
that	O
can	O
subsequently	O
more	O
efficiently	O
infect	O
susceptible	O
epithelial	O
and	O
neuronal	O
cells	O
.	O

The	O
clinical	O
data	O
of	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
supported	O
with	O
ECMO	O
in	O
respiratory	O
intensive	O
care	O
unit	O
of	O
Beijing	O
Chaoyang	O
Hospital	O
from	O
November	O
2009	O
to	O
December	O
2011	O
were	O
prospectively	O
collected	O
and	O
analyzed	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
value	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
adult	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
[	O
A	O
clinical	O
study	O
of	O
early	O
continuous	O
high	O
-	O
volume	O
-	O
hemofiltration	O
in	O
the	O
treatment	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
].	O

The	O
most	O
common	O
symptoms	O
were	O
oropharyngeal	O
ulceration	B-DISO
(	O
5	O
/	O
10	O
),	O
nausea	B-DISO
and	I-DISO
vomiting	I-DISO
(	O
3	O
/	O
10	O
).	O

The	O
main	O
altered	O
biological	O
parameters	O
were	O
high	O
lactate	O
(	O
3	O
/	O
10	O
)	O
and	O
acidosis	B-DISO
(	O
7	O
/	O
10	O
).	O

Inhalation	O
of	O
many	O
CWAs	O
and	O
biological	O
toxins	O
can	O
induce	O
severe	O
pulmonary	B-DISO
toxicity	I-DISO
leading	O
to	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
as	O
well	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

These	O
results	O
suggest	O
that	O
CXCL10	O
is	O
critical	O
for	O
two	O
phases	O
:	O
recruitment	B-DISO
of	O
ASC	O
to	O
the	O
CNS	O
vasculature	O
and	O
ASC	O
entry	O
into	O
the	O
CNS	O
parenchyma	O
.	O

With	O
early	O
intervention	O
,	O
most	O
intrathoracic	B-DISO
goiters	I-DISO
can	O
be	O
removed	O
through	O
a	O
cervical	O
approach	O
,	O
while	O
tracheomalacia	B-DISO
is	O
avoided	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
characterized	O
by	O
damage	O
to	O
the	O
lung	O
caused	O
by	O
various	O
insults	O
,	O
including	O
ventilation	O
itself	O
,	O
and	O
tidal	O
hyperinflation	B-DISO
can	O
lead	O
to	O
ventilator	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

ABSTRACT	O
:	O
By	O
using	O
a	O
fragment	O
-	O
assembly	O
strategy	O
and	O
bioisosteric	O
-	O
replacement	O
principle	O
,	O
a	O
series	O
of	O
novel	O
piperazine	O
derivatives	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
cellular	O
target	O
-	O
effector	O
fusion	O
activities	O
and	O
in	O
vitro	O
antiviral	O
activities	O
against	O
HIV	B-DISO
-	O
1	O
.	O

Preliminary	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
of	O
target	O
compounds	O
were	O
concluded	O
in	O
this	O
study	O
,	O
and	O
five	O
compounds	O
were	O
found	O
to	O
exhibited	O
medium	O
to	O
potent	O
CCR5	O
fusion	O
activities	O
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
low	O
micromolar	O
level	O
.	O

TITLE	O
:	O
Occurrence	O
of	O
refeeding	B-DISO
syndrome	I-DISO
in	O
adults	O
started	O
on	O
artificial	O
nutrition	O
support	O
:	O
prospective	O
cohort	O
study	O
.	O

Tertiary	O
outcome	O
:	O
mortality	O
due	O
to	O
refeeding	B-DISO
syndrome	I-DISO
and	O
all	O
-	O
cause	O
mortality	O
.	O

Baseline	O
low	O
-	O
serum	O
magnesium	O
was	O
an	O
independent	O
predictor	O
of	O
the	O
refeeding	B-DISO
syndrome	I-DISO
(	O
p	O
=	O
0	O
.	O
021	O
).	O

Death	O
of	O
these	O
participants	O
was	O
due	O
to	O
cerebrovascular	B-DISO
accident	I-DISO
,	O
traumatic	O
injury	O
,	O
respiratory	B-DISO
failure	I-DISO
,	O
organ	B-DISO
failure	I-DISO
or	O
end	O
-	O
of	O
-	O
life	O
causes	O
.	O

ABSTRACT	O
:	O
Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
is	O
the	O
main	O
cause	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
SARI	O
)	O
in	O
infants	O
and	O
young	O
children	O
.	O

The	O
presence	O
of	O
cyanosis	B-DISO
(	O
P	O
=	O
0	O
.	O
000	O
;	O
OR	O
,	O
351	O
.	O
7	O
)	O
and	O
lung	B-DISO
consolidation	I-DISO
(	O
P	O
=	O
0	O
.	O
006	O
,	O
OR	O
,	O
9	O
.	O
3	O
)	O
were	O
independent	O
risk	O
factors	O
associated	O
with	O
ICU	O
admission	O
.	O

We	O
report	O
a	O
case	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
occurring	O
in	O
a	O
patient	O
with	O
Down	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
.	O

We	O
investigated	O
HBP	B-DISO
in	O
plasma	O
samples	O
within	O
36	O
h	O
from	O
trauma	O
in	O
47	O
patients	O
admitted	O
to	O
a	O
level	O
one	O
trauma	O
centre	O
with	O
a	O
mean	O
injury	O
severity	O
score	O
(	O
ISS	B-DISO
)	O
of	O
26	O
(	O
21	O
-	O
34	O
).	O

We	O
found	O
no	O
correlation	O
between	O
individual	O
maximal	O
plasma	O
HBP	B-DISO
levels	O
at	O
admission	O
and	O
ISS	B-DISO
,	O
admission	O
SOFA	O
or	O
APACHE	O
II	O
.	O

While	O
only	O
a	O
few	O
infected	O
patients	O
have	O
been	O
identified	O
,	O
the	O
mortality	O
of	O
the	O
infection	B-DISO
is	O
greater	O
than	O
50	O
%.	O

These	O
results	O
provide	O
a	O
strong	O
incentive	O
for	O
identifying	O
the	O
host	O
cell	O
receptor	O
used	O
by	O
HCoV	O
-	O
EMC	B-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
clinical	O
syndrome	B-DISO
characterized	O
by	O
hypoxia	B-DISO
,	O
which	O
is	O
caused	O
by	O
the	O
breakdown	B-DISO
of	O
the	O
alveolar	O
capillary	O
barrier	O
.	O

TITLE	O
:	O
Adenovirus	B-DISO
serotype	O
3	O
and	O
7	O
infection	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
children	O
in	O
Taiwan	O
,	O
2010	O
-	O
2011	O
.	O

We	O
collected	O
cases	O
of	O
severe	O
adenovirus	B-DISO
infection	I-DISO
between	O
November	O
2010	O
and	O
June	O
2011	O
to	O
analyze	O
their	O
clinical	O
characteristics	O
in	O
two	O
medical	O
centers	O
in	O
northern	O
Taiwan	O
.	O

Severe	O
adenovirus	B-DISO
infection	I-DISO
was	O
defined	O
as	O
laboratory	O
-	O
confirmed	O
adenovirus	B-DISO
cases	O
with	O
required	O
intensive	O
care	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
in	O
the	O
pathophysiology	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
not	O
well	O
understood	O
.	O

TITLE	O
:	O
Visualizing	O
the	O
autophagy	O
pathway	O
in	O
avian	O
cells	O
and	O
its	O
application	O
to	O
studying	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
avian	O
LC3	O
paralogs	O
A	O
,	O
B	O
and	O
C	O
from	O
the	O
domestic	O
chicken	O
,	O
Gallus	O
gallus	O
domesticus	O
,	O
and	O
the	O
production	O
of	O
replication	O
-	O
deficient	O
,	O
recombinant	O
adenovirus	B-DISO
vectors	O
expressing	O
these	O
avian	O
LC3s	O
tagged	O
with	O
EGFP	O
and	O
FLAG	O
-	O
mCherry	O
.	O

We	O
have	O
used	O
them	O
to	O
study	O
autophagy	O
during	O
replication	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
an	O
important	O
pathogen	O
in	O
swine	O
and	O
is	O
responsible	O
for	O
substantial	O
economic	O
losses	O
.	O

Employing	O
human	O
prostate	B-DISO
cancer	I-DISO
and	O
melanoma	B-DISO
cell	O
models	O
,	O
we	O
found	O
that	O
the	O
intensity	O
and	O
duration	O
of	O
STAT1	O
phosphorylation	O
as	O
well	O
as	O
the	O
downstream	O
activation	O
of	O
pathobiologically	O
relevant	O
genes	O
were	O
dose	O
and	O
particle	O
dependent	O
.	O

We	O
sought	O
to	O
determine	O
the	O
epidemiology	O
,	O
clinical	O
characteristics	O
,	O
outcomes	O
and	O
severity	O
of	O
illness	O
associated	O
with	O
HCoV	O
-	O
OC43	O
infections	B-DISO
in	O
a	O
pediatric	O
population	O
.	O

In	O
a	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
conducted	O
at	O
39	O
intensive	O
care	O
units	O
in	O
five	O
countries	O
,	O
we	O
randomly	O
assigned	O
adults	O
with	O
new	O
-	O
onset	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
to	O
HFOV	O
targeting	O
lung	O
recruitment	B-DISO
or	O
to	O
a	O
control	O
ventilation	O
strategy	O
targeting	O
lung	O
recruitment	B-DISO
with	O
the	O
use	O
of	O
low	O
tidal	O
volumes	O
and	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
.	O

Laboratory	O
analyses	O
showed	O
elevated	O
infection	B-DISO
parameters	O
,	O
azotemia	B-DISO
,	O
proteinuria	O
and	O
thrombopenia	O
.	O

Due	O
to	O
the	O
parallel	O
HIV	B-DISO
-	O
and	O
Hepatits	O
B	O
infection	B-DISO
an	O
antiretroviral	O
therapy	O
was	O
initiated	O
.	O

CONCLUSIONS	O
:	O
In	O
summary	O
the	O
Puumala	O
infection	B-DISO
bears	O
the	O
potential	O
for	O
a	O
severe	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
,	O
which	O
is	O
not	O
typical	O
for	O
this	O
usually	O
benign	O
infection	B-DISO
.	O

TITLE	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
after	O
hematopoietic	O
stem	O
cell	O
transplantation	O
in	O
children	O
.	O

TITLE	O
:	O
Adjuvant	O
activity	O
of	O
Sargassum	O
pallidum	O
polysaccharides	O
against	O
combined	O
Newcastle	O
disease	B-DISO
,	I-DISO
infectious	I-DISO
bronchitis	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
inactivated	O
vaccines	O
.	O

During	O
the	O
2003	O
pandemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
the	O
use	O
of	O
quarantine	O
,	O
border	O
controls	O
,	O
contact	O
tracing	O
,	O
and	O
surveillance	O
proved	O
effective	O
in	O
containing	O
the	O
global	O
threat	O
in	O
just	O
over	O
3	O
months	O
.	O

Across	O
intracellular	O
and	O
extracellular	O
GSH	B-DISO
pools	O
in	O
alveolar	O
type	O
II	O
cells	O
and	O
alveolar	O
macrophages	O
,	O
chronic	O
alcohol	O
ingestion	O
consistently	O
induced	O
a	O
40	O
-	O
60	O
mV	O
oxidation	O
of	O
GSH	B-DISO
/	O
GSSG	O
suggesting	O
that	O
the	O
redox	O
potentials	O
of	O
different	O
alveolar	O
GSH	B-DISO
pools	O
are	O
in	O
equilibrium	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
.	O

The	O
potential	O
effects	O
of	O
supplemental	O
oxygen	O
may	O
include	O
augmentation	O
of	O
lung	B-DISO
inflammation	I-DISO
by	O
inhibiting	O
anti	O
-	O
inflammatory	O
pathways	O
in	O
alveolar	O
macrophages	O
.	O

Chimera	B-DISO
experiments	O
demonstrated	O
that	O
the	O
transfer	O
of	O
WT	O
but	O
not	O
ADORA2A	O
(-/-)	O
bone	O
marrow	O
cells	O
into	O
irradiated	O
ADORA2A	O
(-/-)	O
mice	O
reduced	O
lung	O
injury	O
after	O
LPS	B-DISO
plus	O
oxygen	O
,	O
demonstrating	O
myeloid	O
ADORA2A	O
protection	O
.	O

Oxygen	O
after	O
LPS	B-DISO
increases	O
macrophage	O
activation	O
to	O
augment	O
lung	O
injury	O
by	O
inhibiting	O
the	O
ADORA2A	O
pathway	O
.	O

It	O
is	O
generally	O
thought	O
that	O
prognosis	O
of	O
miliary	B-DISO
tuberculosis	I-DISO
complicated	O
by	O
DIC	B-DISO
and	O
ARDS	B-DISO
is	O
very	O
poor	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
miliary	B-DISO
tuberculosis	I-DISO
complicated	O
by	O
DIC	B-DISO
and	O
ARDS	B-DISO
successfully	O
treated	O
with	O
rTM	O
.	O

Patients	O
with	O
pulmonary	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
were	O
included	O
in	O
a	O
crossover	O
study	O
with	O
two	O
Vt	O
levels	O
:	O
6	O
and	O
4	O
ml	O
/	O
kg	O
.	O

Decreasing	O
Vt	O
from	O
6	O
to	O
4	O
ml	O
/	O
kg	O
consistently	O
decreased	O
cyclic	O
recruitment	B-DISO
-	O
derecruitment	O
from	O
3	O
.	O
6	O
(	O
2	O
.	O
5	O
to	O
5	O
.	O
7	O
)	O
%	O
to	O
2	O
.	O
9	O
(	O
0	O
.	O
9	O
to	O
4	O
.	O
7	O
)	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
end	O
-	O
inspiratory	O
hyperinflation	B-DISO
from	O
0	O
.	O
7	O
(	O
0	O
.	O
3	O
to	O
2	O
.	O
2	O
)	O
to	O
0	O
.	O
6	O
(	O
0	O
.	O
2	O
to	O
1	O
.	O
7	O
)	O
%	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

Microarray	O
analysis	O
revealed	O
significant	O
changes	O
in	O
differential	O
gene	O
expression	O
,	O
with	O
approximately	O
twice	O
as	O
many	O
upregulated	O
genes	O
in	O
the	O
mutant	B-DISO
virus	O
samples	O
by	O
48	O
h	O
postinfection	O
,	O
despite	O
identical	O
viral	O
titers	O
.	O

Among	O
473	O
cases	O
,	O
29	O
%	O
had	O
asthma	B-DISO
.	O

The	O
majority	O
of	O
persons	O
with	O
asthma	B-DISO
had	O
an	O
uncomplicated	O
course	O
;	O
however	O
,	O
severe	O
disease	O
,	O
including	O
ICU	O
admission	O
and	O
death	O
,	O
occurred	O
in	O
asthma	B-DISO
patients	O
who	O
presented	O
with	O
pneumonia	B-DISO
.	O

Our	O
method	O
for	O
assessing	O
PaO2	O
/	O
FiO2	O
greatly	O
improved	O
risk	O
stratification	O
of	O
ARDS	B-DISO
and	O
could	O
be	O
used	O
for	O
enrolling	O
appropriate	O
ARDS	B-DISO
patients	O
into	O
therapeutic	O
clinical	O
trials	O
.	O

To	O
evaluate	O
the	O
accuracy	O
of	O
these	O
clinical	O
criteria	O
using	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
at	O
autopsy	O
as	O
the	O
reference	O
standard	O
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
has	O
a	O
significant	O
impact	O
on	O
public	O
health	O
in	O
terms	O
of	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
morbidity	O
and	O
mortality	O
.	O

There	O
is	O
consistent	O
evidence	O
that	O
downregulation	O
of	O
systemic	O
inflammation	B-DISO
with	O
prolonged	O
low	O
-	O
dose	O
glucocorticoid	O
treatment	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
improves	O
cardiovascular	O
and	O
pulmonary	O
organ	O
physiology	O
.	O

The	O
American	O
Academy	O
of	O
Pediatrics	O
,	O
Elk	O
Grove	O
Village	O
,	O
Ill	B-DISO
.,	O
recommends	O
that	O
breastfeeding	O
should	O
be	O
exclusive	O
for	O
about	O
the	O
first	O
six	O
months	O
of	O
life	O
and	O
should	O
continue	O
,	O
with	O
the	O
introduction	O
of	O
appropriate	O
complementary	O
foods	O
,	O
to	O
at	O
least	O
age	O
12	O
months	O
or	O
beyond	O
,	O
as	O
desired	O
by	O
mother	O
and	O
child	O
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
health	O
outcomes	O
among	O
formula	O
-	O
fed	O
children	O
,	O
the	O
health	O
advantages	O
associated	O
with	O
breastfeeding	O
include	O
a	O
lower	O
risk	O
of	O
acute	B-DISO
otitis	I-DISO
media	I-DISO
,	O
gastroenteritis	B-DISO
and	O
diarrhea	B-DISO
,	O
severe	O
lower	O
respiratory	B-DISO
infections	I-DISO
,	O
asthma	B-DISO
,	O
sudden	B-DISO
infant	I-DISO
death	I-DISO
syndrome	I-DISO
,	O
obesity	B-DISO
and	O
other	O
childhood	O
diseases	O
and	O
conditions	O
.	O

TITLE	O
:	O
Detection	O
of	O
human	O
coronaviruses	O
in	O
simultaneously	O
collected	O
stool	O
samples	O
and	O
nasopharyngeal	O
swabs	O
from	O
hospitalized	O
children	O
with	O
acute	B-DISO
gastroenteritis	I-DISO
.	O

Stool	O
samples	O
and	O
nasopharyngeal	O
(	O
NP	O
)	O
swabs	O
collected	O
from	O
260	O
children	O
hospitalized	O
for	O
AGE	O
(	O
160	O
also	O
had	O
respiratory	B-DISO
symptoms	I-DISO
)	O
and	O
157	O
otherwise	O
healthy	O
control	O
children	O
admitted	O
for	O
elective	O
surgery	O
were	O
tested	O
for	O
the	O
presence	O
of	O
four	O
HCoVs	O
using	O
real	O
time	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Genetic	O
variation	O
of	O
nucleocapsid	O
genes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
field	O
strains	O
in	O
China	O
.	O

ABSTRACT	O
:	O
Corticosteroids	O
have	O
been	O
widely	O
administered	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
for	O
various	O
indications	O
.	O

In	O
this	O
study	O
,	O
the	O
N	O
genes	O
of	O
15	O
PEDV	O
strains	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
the	O
pMT	B-DISO
-	O
19T	O
vector	O
,	O
sequenced	O
,	O
and	O
compared	O
to	O
each	O
other	O
as	O
well	O
as	O
to	O
PEDV	O
reference	O
strains	O
.	O

This	O
study	O
suggests	O
a	O
scientific	O
and	O
potential	O
clinical	O
therapeutic	O
importance	O
of	O
epithelial	O
-	O
endothelial	O
cross	O
talk	O
in	O
maintaining	O
alveolar	O
integrity	O
in	O
ALI	O
/	O
ARDS	B-DISO
.	O

They	O
are	O
caused	O
by	O
adenoviruses	O
,	O
rhinoviruses	O
,	O
influenza	B-DISO
and	O
parainfluenza	B-DISO
viruses	O
,	O
metapneumoviruses	O
,	O
syncytial	O
-	O
respiratory	O
viruses	O
and	O
coronaviruses	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
angiogenic	O
factors	O
and	O
their	O
soluble	O
receptors	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
associated	O
with	O
critical	B-DISO
illness	I-DISO
.	O

Moreover	O
,	O
Ang2	O
and	O
sVEGFR2	O
also	O
independently	O
predicted	O
the	O
mortality	O
in	O
ALI	O
/	O
ARDS	B-DISO
patients	O
.	O

TITLE	O
:	O
Plasma	O
kallistatin	O
levels	O
in	O
patients	O
with	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
correlations	O
of	O
kallistatin	O
with	O
other	O
biomarkers	O
and	O
to	O
determine	O
whether	O
kallistatin	O
levels	O
have	O
a	O
prognostic	O
value	O
in	O
severe	O
CAP	B-DISO
.	O

ABSTRACT	O
:	O
Protein	O
ubiquitination	O
regulates	O
important	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

Compared	O
with	O
WT	O
virus	B-DISO
infection	I-DISO
,	O
IFN	O
-	O
β	O
mRNA	O
levels	O
in	O
equine	O
cells	O
infected	O
with	O
PLP2	O
mutants	O
were	O
increased	O
by	O
nearly	O
an	O
order	O
of	O
magnitude	O
.	O

The	O
patient	O
was	O
otherwise	O
stable	O
until	O
he	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
from	O
an	O
acute	O
upper	B-DISO
gastrointestinal	I-DISO
bleed	I-DISO
and	O
died	O
four	O
days	O
into	O
his	O
hospital	O
course	O
.	O

CONCLUSIONS	O
:	O
We	O
present	O
a	O
rare	O
case	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	B-DISO
as	O
sequelae	O
of	O
severe	O
pulmonary	O
parenchymal	O
tuberculosis	B-DISO
infection	I-DISO
along	O
with	O
a	O
review	O
of	O
literature	O
,	O
in	O
the	O
hopes	O
of	O
aiding	O
clinicians	O
to	O
include	O
the	O
differential	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	B-DISO
in	O
patients	O
presenting	O
with	O
worsening	O
dyspnea	B-DISO
without	O
a	O
history	O
of	O
surgical	O
lung	O
resection	O
.	O

ABSTRACT	O
:	O
Exotic	O
and	O
emerging	O
viral	O
pathogens	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
in	O
humans	O
are	O
being	O
identified	O
annually	O
with	O
recent	O
examples	O
including	O
Lujo	O
virus	O
in	O
southern	O
Africa	O
,	O
Severe	O
Fever	O
with	O
Thrombocytopenia	O
Syndrome	B-DISO
virus	O
in	O
China	O
and	O
a	O
SARS	B-DISO
-	O
like	O
coronavirus	O
in	O
the	O
Middle	O
East	O
.	O

For	O
these	O
reasons	O
it	O
is	O
imperative	O
that	O
animal	O
models	O
of	O
disease	O
recapitulate	O
the	O
human	O
condition	B-DISO
as	O
closely	O
as	O
possible	O
in	O
order	O
to	O
provide	O
the	O
best	O
predictive	O
data	O
with	O
respect	O
to	O
the	O
potential	O
efficacy	O
in	O
humans	O
.	O

Bacterial	O
translocation	B-DISO
has	O
been	O
described	O
in	O
patients	O
with	O
ACS	O
,	O
and	O
this	O
may	O
apply	O
to	O
patients	O
with	O
SAP	O
.	O

TITLE	O
:	O
Predicting	O
postoperative	O
pulmonary	B-DISO
complications	I-DISO
in	O
high	O
-	O
risk	O
populations	O
.	O

When	O
OSA	B-DISO
is	O
diagnosed	O
preoperatively	O
,	O
the	O
rate	O
of	O
postoperative	O
pulmonary	B-DISO
complications	I-DISO
is	O
low	O
and	O
not	O
associated	O
with	O
OSA	B-DISO
severity	O
.	O

Strategies	O
based	O
on	O
preoperative	O
and	O
immediate	O
postoperative	O
clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
can	O
help	O
identify	O
patients	O
with	O
a	O
high	O
likelihood	O
of	O
OSA	B-DISO
,	O
postoperative	O
desaturations	O
,	O
and	O
pulmonary	B-DISO
complications	I-DISO
.	O

TITLE	O
:	O
Low	O
-	O
dose	O
interferon	O
-	O
α	O
treatment	O
improves	O
survival	O
and	O
inflammatory	B-DISO
responses	I-DISO
in	O
a	O
mouse	O
model	O
of	O
fulminant	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Therefore	O
,	O
we	O
investigated	O
how	O
this	O
cytokine	O
affected	O
ARDS	B-DISO
in	O
a	O
mouse	O
model	O
.	O

The	O
infection	B-DISO
rates	O
were	O
15	O
.	O
8	O
%	O
for	O
human	O
rhinovirus	O
,	O
14	O
.	O
4	O
&	O
percnt	O
;	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
A	O
,	O
9	O
.	O
7	O
%	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
B	O
,	O
10	O
.	O
1	O
%	O
for	O
human	O
adenovirus	B-DISO
,	O
5	O
.	O
4	O
%	O
for	O
influenza	B-DISO
A	O
virus	O
,	O
1	O
.	O
7	O
%	O
for	O
influenza	B-DISO
B	O
virus	O
,	O
4	O
.	O
7	O
%	O
for	O
human	O
metapneumovirus	O
,	O
2	O
.	O
3	O
%	O
for	O
human	O
coronavirus	O
OC43	O
,	O
1	O
.	O
9	O
%	O
for	O
human	O
coronavirus	O
229E	O
/	O
NL63	O
,	O
3	O
.	O
7	O
%	O
for	O
human	O
parainfluenza	B-DISO
virus	O
(	O
HPIV	O
)-	O
1	O
,	O
1	O
.	O
1	O
%	O
for	O
HPIV	O
-	O
2	O
,	O
and	O
5	O
.	O
3	O
%	O
for	O
HPIV	O
-	O
3	O
.	O

Human	O
respiratory	O
syncytial	O
virus	O
was	O
the	O
most	O
common	O
virus	O
in	O
children	O
under	O
5	O
years	O
of	O
age	O
,	O
and	O
the	O
influenza	B-DISO
A	O
virus	O
was	O
the	O
most	O
prevalent	O
virus	O
in	O
children	O
over	O
5	O
years	O
of	O
age	O
.	O

The	O
total	O
dose	O
of	O
steroid	O
,	O
gender	O
,	O
age	O
,	O
stage	O
,	O
lesion	O
location	O
,	O
volume	O
of	O
necrosis	O
,	O
viable	O
lateral	O
column	O
and	O
bone	B-DISO
marrow	I-DISO
edema	I-DISO
were	O
analyzed	O
and	O
correlated	O
with	O
progression	O
.	O

Most	O
of	O
the	O
title	O
compounds	O
displayed	O
excellent	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
activity	O
at	O
submicromolar	O
concentrations	O
ranging	O
from	O
34	O
nM	O
to	O
5	O
.	O
08	O
μM	O
.	O
The	O
most	O
promising	O
compound	O
8g	O
inhibited	O
HIV	B-DISO
-	O
1	O
IIIB	O
in	O
MT	O
-	O
4	O
cells	O
at	O
a	O
low	O
EC50	O
value	O
(	O
0	O
.	O
034	O
μM	O
),	O
which	O
was	O
lower	O
than	O
the	O
reference	O
drug	O
nevirapine	O
and	O
delavirdine	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
and	O
outcomes	O
of	O
influenza	B-DISO
and	O
other	O
influenza	B-DISO
-	O
like	O
illnesses	O
in	O
Mexico	O
City	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
-	O
like	O
illnesses	O
(	O
ILI	O
)	O
are	O
estimated	O
to	O
cause	O
millions	O
of	O
deaths	O
annually	O
.	O

Swabs	O
were	O
tested	O
by	O
multiplex	O
PCR	O
for	O
15	O
viral	O
pathogens	O
and	O
real	O
-	O
time	O
PCR	O
for	O
influenza	B-DISO
.	O

One	O
or	O
more	O
pathogens	O
were	O
detected	O
by	O
PCR	O
in	O
64	O
%	O
of	O
subjects	O
,	O
most	O
commonly	O
rhinovirus	O
(	O
25	O
%	O
of	O
all	O
isolates	O
)	O
and	O
influenza	B-DISO
(	O
24	O
%	O
of	O
isolates	O
).	O

TITLE	O
:	O
Innate	B-DISO
immune	I-DISO
response	I-DISO
of	O
human	O
alveolar	O
type	O
II	O
cells	O
infected	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
.	O

However	O
,	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
of	O
primary	O
human	O
alveolar	O
epithelial	O
cells	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
has	O
not	O
been	O
defined	O
.	O

In	O
conclusion	O
,	O
the	O
cultivation	O
of	O
alveolar	O
type	O
II	O
cells	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
provides	O
primary	O
cultures	O
in	O
which	O
to	O
study	O
the	O
pulmonary	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
to	O
infection	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
to	O
explore	O
possible	O
therapeutic	O
approaches	O
to	O
modulating	O
these	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

These	O
new	O
findings	O
demonstrate	O
that	O
trans	O
-	O
3	O
-	O
aryl	O
acrylic	O
acids	O
and	O
their	O
derivatives	O
represent	O
a	O
new	O
template	O
for	O
antiviral	O
studies	O
and	O
could	O
be	O
considered	O
for	O
novel	O
therapy	O
against	O
plant	O
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
consists	O
of	O
a	O
group	O
of	O
neuropathic	O
conditions	O
characterized	O
by	O
progressive	O
weakness	B-DISO
and	O
diminished	O
or	O
absent	O
myotatic	O
reflexes	O
.	O

Guillain	O
-	O
Barré	O
syndrome	B-DISO
is	O
believed	O
to	O
result	O
from	O
an	O
aberrant	O
immune	O
response	O
that	O
attacks	O
nerve	O
tissue	O
.	O

Importantly	O
,	O
however	O
,	O
we	O
demonstrate	O
that	O
both	O
type	O
I	O
and	O
type	O
III	O
IFN	O
can	O
efficiently	O
reduce	O
HCoV	O
-	O
EMC	B-DISO
replication	O
in	O
HAE	O
cultures	O
,	O
providing	O
a	O
possible	O
treatment	O
option	O
in	O
cases	O
of	O
suspected	O
HCoV	O
-	O
EMC	B-DISO
infection	B-DISO
.	O

Since	O
the	O
animal	O
reservoir	O
and	O
circumstances	O
of	O
zoonotic	O
transmission	O
are	O
yet	O
elusive	O
,	O
it	O
is	O
critically	O
important	O
to	O
assess	O
potential	O
species	O
barriers	O
of	O
HCoV	O
-	O
EMC	B-DISO
infection	B-DISO
.	O

During	O
2010	O
-	O
2011	O
,	O
195	O
patients	O
with	O
vivax	B-DISO
malaria	I-DISO
diagnosed	O
by	O
positive	O
peripheral	O
blood	O
film	O
and	O
rapid	O
malaria	B-DISO
test	O
were	O
studied	O
for	O
AKI	O
using	O
RIFLE	O
criteria	O
.	O

Poor	O
prognostic	O
factors	O
were	O
delayed	O
diagnosis	O
,	O
anaemia	B-DISO
,	O
severe	O
AKI	O
,	O
shock	O
,	O
ARDS	B-DISO
,	O
need	O
for	O
ventilatory	O
support	O
,	O
raised	O
serum	O
transaminases	O
and	O
metabolic	B-DISO
acidosis	I-DISO
.	O

TITLE	O
:	O
Bronchiolitis	B-DISO
obliterans	I-DISO
syndrome	B-DISO
and	O
restrictive	O
allograft	O
syndrome	B-DISO
:	O
do	O
risk	O
factors	O
differ	O
?	O

BAL	O
neutrophilia	O
in	O
BOS	B-DISO
and	O
RAS	O
were	O
elevated	O
at	O
days	O
360	O
,	O
540	O
,	O
and	O
720	O
versus	O
control	O
.	O

Nowadays	O
,	O
four	O
HCoVs	O
,	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
HKU1	O
,	O
and	O
HCoV	O
-	O
NL63	O
,	O
are	O
known	O
to	O
be	O
circulating	O
worldwide	O
,	O
causing	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
nonhospitalized	O
and	O
hospitalized	O
children	O
.	O

To	O
expand	O
the	O
knowledge	O
on	O
fundamental	O
virus	O
-	O
host	O
interactions	O
for	O
all	O
four	O
HCoVs	O
at	O
the	O
site	O
of	O
primary	B-DISO
infection	I-DISO
,	O
we	O
used	O
pseudostratified	O
HAE	O
cell	O
cultures	O
to	O
isolate	O
and	O
characterize	O
representative	O
clinical	O
HCoV	O
strains	O
directly	O
from	O
nasopharyngeal	O
material	O
.	O

Surprisingly	O
,	O
by	O
visualizing	O
HCoV	O
infection	B-DISO
by	O
confocal	O
microscopy	O
,	O
we	O
observed	O
that	O
HCoV	O
-	O
229E	O
employs	O
a	O
target	O
cell	O
tropism	O
for	O
nonciliated	O
cells	O
,	O
whereas	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
HKU1	O
,	O
and	O
HCoV	O
-	O
NL63	O
all	O
infect	O
ciliated	O
cells	O
.	O

After	O
infectious	B-DISO
challenge	O
by	O
TCoV	O
,	O
clinical	O
signs	O
and	O
TCoV	O
detected	O
by	O
immunofluorescence	O
antibody	O
(	O
IFA	O
)	O
assay	O
were	O
observed	O
in	O
less	O
number	O
of	O
turkeys	O
in	O
vaccination	O
groups	O
than	O
that	O
in	O
challenge	O
control	O
groups	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
children	O
after	O
open	O
heart	O
surgery	O
,	O
although	O
uncommon	O
,	O
can	O
be	O
a	O
significant	O
source	O
of	O
morbidity	O
.	O

From	O
October	O
2008	O
to	O
August	O
2012	O
,	O
64	O
of	O
10	O
,	O
843	O
patients	O
with	O
refractory	O
ARDS	B-DISO
who	O
underwent	O
corrective	O
surgery	O
at	O
our	O
institution	O
were	O
ventilated	O
with	O
HFOV	O
.	O

TITLE	O
:	O
Suppression	B-DISO
of	O
NK	O
cells	O
and	O
regulatory	O
T	O
lymphocytes	O
in	O
cats	O
naturally	O
infected	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

In	O
conclusion	O
,	O
light	O
-	O
induced	O
antigen	O
decay	B-DISO
(	O
tissue	O
section	O
aging	O
)	O
is	O
antigen	O
dependent	O
and	O
could	O
explain	O
unexpectedly	O
weak	O
or	O
negative	O
immunohistochemical	O
reactions	O
in	O
stored	O
paraffin	O
sections	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
pneumothorax	B-DISO
caused	O
by	O
a	O
bronchial	O
perforation	O
during	O
a	O
reintubation	O
using	O
an	O
airway	O
exchange	O
catheter	O
(	O
AEC	O
)	O
in	O
a	O
patient	O
with	O
a	O
head	B-DISO
and	I-DISO
neck	I-DISO
cancer	I-DISO
.	O

A	O
CXR	O
performed	O
a	O
day	O
after	O
chest	O
tube	O
removal	O
revealed	O
a	O
small	O
right	O
upper	O
pneumothorax	B-DISO
,	O
but	O
the	O
patient	O
remained	O
asymptomatic	O
.	O

Heterogeneity	O
in	O
the	O
number	O
of	O
secondary	O
cases	O
caused	O
per	O
infectious	B-DISO
individual	O
is	O
a	O
plausible	O
explanation	O
for	O
the	O
observed	O
skewness	O
in	O
genotypic	O
cluster	O
size	O
distribution	O
of	O
TB	O
.	O

In	O
the	O
following	O
days	O
the	O
lesions	O
extended	O
and	O
became	O
confluent	O
with	O
blisters	B-DISO
and	O
epidermal	B-DISO
necrosis	I-DISO
.	O

He	O
denied	O
allergies	B-DISO
to	O
any	O
medications	O
and	O
had	O
no	O
history	O
of	O
tranexamic	O
acid	O
exposure	O
.	O

A	O
chest	O
computed	O
tomography	O
revealed	O
bilateral	O
nonsegmental	O
ground	O
-	O
glass	O
opacities	B-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
are	O
syndromes	B-DISO
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
included	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
which	O
compared	O
partial	O
liquid	O
ventilation	O
with	O
other	O
forms	O
of	O
ventilation	O
in	O
children	O
(	O
aged	O
28	O
days	O
to	O
18	O
years	O
)	O
with	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
septic	B-DISO
syndrome	I-DISO
,	O
which	O
is	O
the	O
most	O
prevalent	O
and	O
lethal	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
remains	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
of	O
admission	O
and	O
death	O
in	O
intensive	O
care	O
units	O
(	O
ICU	O
).	O

Our	O
data	O
provide	O
a	O
novel	O
insight	O
into	O
the	O
epidemiology	O
and	O
clinical	O
knowledge	O
of	O
HCoVs	O
among	O
different	O
subsets	O
of	O
patients	O
,	O
revealing	O
that	O
these	O
viruses	O
may	O
cause	O
more	O
than	O
mild	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
phylogenetic	O
analysis	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
field	O
isolates	O
in	O
Korea	O
.	O

The	O
immune	O
reaction	O
of	O
granuloma	B-DISO
formation	O
evolved	O
in	O
order	O
to	O
combat	O
mycobacteria	O
with	O
the	O
aim	O
of	O
localizing	O
mycobacteria	O
and	O
to	O
avoid	O
spreading	O
of	O
mycobacteria	O
throughout	O
the	O
body	O
.	O

The	O
spectrum	O
of	O
granulomatous	O
lung	B-DISO
diseases	I-DISO
is	O
broad	O
.	O

Samples	O
from	O
flocks	O
exhibiting	O
clinical	O
signs	O
of	O
intestinal	B-DISO
disease	I-DISO
showed	O
a	O
higher	O
rate	O
of	O
positivity	O
,	O
and	O
TAstV	O
-	O
1	O
,	O
TAstV	O
-	O
2	O
,	O
and	O
TCoV	O
were	O
the	O
most	O
frequently	O
occurring	O
viruses	O
in	O
this	O
cohort	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
findings	O
of	O
a	O
recent	O
study	O
suggesting	O
a	O
decreased	O
cold	B-DISO
-	O
induced	O
ascites	O
incidence	O
in	O
broiler	O
progeny	O
from	O
hyperthyroid	B-DISO
(	O
HYPER	O
)	O
breeder	O
hens	O
,	O
and	O
a	O
controversy	O
on	O
the	O
effects	O
of	O
hyperthyroidism	B-DISO
on	O
immunocompetence	O
,	O
the	O
present	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
probable	O
adverse	B-DISO
effect	I-DISO
of	O
induced	O
maternal	O
hyperthyroidism	B-DISO
on	O
immune	O
function	O
in	O
progeny	O
chicks	O
.	O

Independent	O
of	O
T4	O
treatment	O
,	O
cold	B-DISO
exposure	O
was	O
generally	O
associated	O
with	O
decreased	O
immune	O
functions	O
at	O
early	O
stages	O
.	O

We	O
have	O
developed	O
a	O
simple	O
approach	O
with	O
limited	O
data	O
requirements	O
that	O
enables	O
robust	O
assessment	O
of	O
the	O
risks	O
posed	O
by	O
emerging	O
zoonoses	B-DISO
.	O

TITLE	O
:	O
Serological	O
evidence	O
of	O
Toxoplasma	B-DISO
gondii	I-DISO
infection	I-DISO
in	O
five	O
species	O
of	O
bats	O
in	O
China	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
seroprevalence	O
of	O
T	O
.	O
gondii	O
infection	B-DISO
in	O
bats	O
in	O
China	O
.	O

METHODS	O
:	O
100	O
consecutive	O
adult	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
were	O
evaluated	O
in	O
this	O
retrospective	O
study	O
.	O

Leptospirosis	B-DISO
-	O
induced	O
AKI	O
is	O
typically	O
nonoliguric	O
with	O
a	O
high	O
frequency	O
of	O
hypokalemia	O
.	O

Pooled	O
milk	O
samples	O
of	O
'	O
home	O
-	O
bred	O
'	O
primiparous	O
animals	O
were	O
found	O
to	O
be	O
most	O
useful	O
in	O
terms	O
of	O
monitoring	O
herd	O
status	O
but	O
could	O
gradually	O
be	O
replaced	O
by	O
bulk	O
-	O
tank	O
sampling	O
once	O
freedom	O
from	O
infection	B-DISO
was	O
established	O
.	O

The	O
electrocardiogram	O
showed	O
a	O
sinus	B-DISO
tachycardia	I-DISO
with	O
unspecific	O
T	O
-	O
wave	O
-	O
inversions	O
,	O
the	O
echocardiogram	O
revealed	O
a	O
dilated	B-DISO
left	I-DISO
ventricle	I-DISO
and	O
severely	O
reduced	O
systolic	O
LV	O
-	O
function	O
.	O

In	O
case	O
of	O
recovery	O
continuous	O
care	O
in	O
a	O
specialized	O
Heart	B-DISO
Failure	I-DISO
Clinic	O
can	O
help	O
to	O
maintain	O
the	O
clinical	O
status	O
and	O
offer	O
frequent	O
reevaluation	O
of	O
cardiac	O
status	O
and	O
therapeutic	O
concepts	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
severe	O
Cushing	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
developing	O
into	O
life	O
-	O
threatening	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
cryptococcus	O
and	O
cytomegalovirus	O
co	B-DISO
-	I-DISO
infection	I-DISO
soon	O
after	O
hypercortisolism	B-DISO
treatment	O
using	O
metyrapone	O
,	O
an	O
11	O
-	O
beta	O
-	O
hydroxylase	O
inhibitor	O
.	O

ABSTRACT	O
:	O
Most	O
human	O
coronaviruses	O
cause	O
mild	O
upper	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
but	O
may	O
be	O
associated	O
with	O
more	O
severe	O
pulmonary	B-DISO
disease	I-DISO
in	O
immunocompromised	O
individuals	O
.	O

Antibodies	O
directed	O
against	O
DPP4	O
inhibited	O
hCoV	O
-	O
EMC	B-DISO
infection	B-DISO
of	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
and	O
Huh	O
-	O
7	O
cells	O
.	O

Expression	O
of	O
human	O
and	O
bat	O
(	O
Pipistrellus	O
pipistrellus	O
)	O
DPP4	O
in	O
non	O
-	O
susceptible	O
COS	O
-	O
7	O
cells	O
enabled	O
infection	B-DISO
by	O
hCoV	O
-	O
EMC	B-DISO
.	O

ABSTRACT	O
:	O
CDC	O
continues	O
to	O
work	O
closely	O
with	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
other	O
partners	O
to	O
better	O
understand	O
the	O
public	O
health	O
risk	O
posed	O
by	O
a	O
novel	O
coronavirus	O
that	O
was	O
first	O
reported	O
to	O
cause	O
human	O
infection	B-DISO
in	O
September	O
2012	O
.	O

Onset	O
of	O
symptoms	O
is	O
usually	O
within	O
72	O
h	O
of	O
the	O
inciting	O
event	O
and	O
complicates	O
a	O
wide	O
variety	O
of	O
clinical	O
disorders	O
,	O
ranging	O
from	O
infection	B-DISO
to	O
trauma	O
.	O

Eight	O
patients	O
were	O
co	O
-	O
infected	O
with	O
HIV	B-DISO
,	O
five	O
of	O
whom	O
were	O
newly	O
diagnosed	O
.	O

TITLE	O
:	O
Physiological	O
predictors	O
of	O
survival	O
during	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Multivariate	O
analysis	O
showed	O
that	O
HFOV	O
was	O
more	O
effective	O
in	O
younger	O
patients	O
,	O
when	O
instituted	O
early	O
,	O
and	O
in	O
patients	O
with	O
milder	O
respiratory	B-DISO
acidosis	I-DISO
.	O

Our	O
findings	O
point	O
to	O
the	O
need	O
for	O
risk	O
assessment	O
and	O
continued	O
surveillance	O
of	O
coronavirus	B-DISO
infections	I-DISO
of	O
bats	O
in	O
Brazil	O
.	O

ABSTRACT	O
:	O
Complicated	O
falciparum	B-DISO
malaria	I-DISO
remains	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
study	O
clinical	O
presentation	O
and	O
complications	O
of	O
patients	O
with	O
complicated	O
P	O
.	O
falciparum	B-DISO
malaria	I-DISO
and	O
its	O
outcome	O
.	O

Total	O
6	O
(	O
12	O
.	O
76	O
%)	O
had	O
cerebral	B-DISO
malaria	I-DISO
,	O
6	O
(	O
12	O
.	O
76	O
%)	O
had	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
),	O
5	O
(	O
10	O
.	O
63	O
%)	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
1	O
(	O
2	O
.	O
12	O
%)	O
had	O
thrombocytopenia	O
.	O

No	O
plague	B-DISO
cases	O
occurred	O
among	O
family	O
and	O
village	O
contacts	O
and	O
health	O
care	O
workers	O
.	O

TITLE	O
:	O
Initial	O
ventilator	O
settings	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
strategy	O
has	O
been	O
standard	O
practice	O
for	O
management	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
for	O
more	O
than	O
a	O
decade	O
.	O

Observational	O
data	O
,	O
small	O
randomized	O
studies	O
and	O
two	O
recent	O
systematic	O
reviews	O
suggest	O
that	O
lung	O
protective	O
ventilation	O
is	O
both	O
safe	O
and	O
potentially	O
beneficial	O
in	O
patients	O
who	O
do	O
not	O
have	O
ARDS	B-DISO
at	O
the	O
onset	O
of	O
mechanical	O
ventilation	O
.	O

We	O
therefore	O
asked	O
whether	O
(	O
1	O
)	O
any	O
preoperative	O
indicators	O
predict	O
major	O
complications	O
after	O
major	O
extremity	O
surgery	O
;	O
(	O
2	O
)	O
perioperative	O
routine	O
parameters	O
other	O
than	O
those	O
indicative	O
of	O
hemorrhagic	B-DISO
shock	I-DISO
predict	O
postoperative	B-DISO
complications	I-DISO
;	O
and	O
(	O
3	O
)	O
any	O
postoperative	O
clinical	B-DISO
findings	I-DISO
can	O
predict	O
major	O
complications	O
in	O
the	O
further	O
course	O
of	O
the	O
patient	O
.	O

We	O
prospectively	O
followed	O
patients	O
with	O
femoral	O
midshaft	O
fracture	O
,	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
)	O
>	O
16	O
points	O
,	O
or	O
three	O
fractures	O
and	O
Abbreviated	O
Injury	O
Scale	O
(	O
AIS	B-DISO
)	O
≥	O
2	O
points	O
and	O
another	O
injury	O
(	O
AIS	B-DISO
≥	O
2	O
points	O
),	O
and	O
age	O
18	O
to	O
65	O
years	O
.	O

This	O
paper	O
reports	O
the	O
first	O
case	O
occurred	O
in	O
Mexico	O
:	O
a	O
39	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
diabetes	B-DISO
mellitus	I-DISO
type	I-DISO
2	I-DISO
and	O
obesity	B-DISO
grade	O
II	O
,	O
which	O
suffered	B-DISO
atypical	O
and	O
aggressive	B-DISO
pneumonia	B-DISO
positive	O
to	O
coronavirus	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
somatostatin	O
,	O
ulinastatin	O
and	O
Salvia	O
miltiorrhiza	O
on	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
treatment	O
.	O

Tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
and	O
IL	O
-	O
6	O
levels	O
on	O
the	O
fourth	O
and	O
seventh	O
days	O
,	O
and	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
on	O
the	O
seventh	O
day	O
after	O
treatment	O
showed	O
significant	O
decrease	O
in	O
the	O
somatostatin	O
,	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

The	O
incidences	O
of	O
pancreatic	O
sepsis	B-DISO
,	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
and	O
mortality	O
were	O
lower	O
in	O
the	O
somatostatin	O
,	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

TITLE	O
:	O
Impact	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
on	O
clinical	O
outcome	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiopulmonary	B-DISO
failure	I-DISO
:	O
a	O
single	O
-	O
center	O
experience	O
.	O

In	O
a	O
small	O
percentage	O
of	O
cats	O
,	O
FCoV	O
infection	B-DISO
is	O
associated	O
with	O
the	O
fatal	O
disease	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

This	O
prospective	O
outbreak	O
investigation	O
was	O
initiated	O
during	O
an	O
outbreak	O
of	O
FIP	B-DISO
in	O
cats	O
within	O
or	O
rehomed	O
from	O
a	O
rescue	O
/	O
rehoming	O
center	O
.	O

The	O
performance	O
of	O
the	O
test	O
based	O
on	O
virus	O
isolates	O
in	O
tissue	O
culture	O
and	O
in	O
clinical	O
samples	O
was	O
judged	O
good	O
for	O
the	O
virological	O
diagnosis	O
of	O
transmissible	O
gastroenteritis	B-DISO
of	O
pigs	O
.	O

ABSTRACT	O
:	O
The	O
sudden	B-DISO
death	I-DISO
of	O
three	O
calves	O
,	O
one	O
diarrheic	O
calf	O
,	O
and	O
one	O
aborted	O
fetus	O
from	O
four	O
farms	O
in	O
southern	O
Brazil	O
was	O
investigated	O
.	O

The	O
most	O
potent	O
derivative	O
of	O
this	O
series	O
inhibits	O
TMPRSS2	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
0	O
.	O
9	O
nM	O
and	O
showed	O
an	O
efficient	O
blockage	O
of	O
influenza	B-DISO
virus	O
propagation	O
in	O
human	O
airway	O
epithelial	O
cells	O
.	O

In	O
the	O
end	O
,	O
2	O
patients	O
(	O
33	O
.	O
3	O
%)	O
died	O
from	O
multiple	O
-	O
organ	B-DISO
failure	I-DISO
,	O
despite	O
intensive	O
resuscitation	O
.	O

Hypercapnia	B-DISO
and	O
hypercapnic	B-DISO
acidosis	I-DISO
is	O
often	O
noted	O
with	O
lung	O
protective	O
ventilation	O
.	O

To	O
the	O
contrary	O
,	O
some	O
clinicians	O
do	O
not	O
tolerate	O
hypercapnic	B-DISO
acidosis	I-DISO
and	O
use	O
various	O
techniques	O
including	O
extracorporeal	O
carbon	O
dioxide	O
elimination	O
to	O
treat	O
hypercapnia	B-DISO
and	O
acidosis	B-DISO
.	O

Clinical	O
and	O
laboratory	O
characteristics	O
of	O
hospitalized	O
children	O
with	O
viral	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
were	O
analyzed	O
.	O

Monocytosis	B-DISO
was	O
the	O
most	O
remarkable	O
finding	O
in	O
the	O
patients	O
(	O
n	O
=	O
48	O
,	O
53	O
.	O
3	O
%),	O
especially	O
in	O
patients	O
with	O
adenovirus	B-DISO
(	O
p	O
<	O
0	O
.	O
05	O
).	O

There	O
was	O
a	O
U	O
-	O
shaped	O
association	O
between	O
validated	O
Alcohol	B-DISO
Use	I-DISO
Disorders	I-DISO
Identification	O
Test	O
zones	O
and	O
death	O
or	O
persistent	O
hospitalization	O
at	O
90	O
days	O
(	O
34	O
%	O
in	O
zone	O
1	O
,	O
26	O
%	O
in	O
zone	O
2	O
,	O
27	O
%	O
in	O
zone	O
3	O
,	O
36	O
%	O
in	O
zone	O
4	O
;	O
p	O
<	O
0	O
.	O
05	O
for	O
comparison	O
of	O
zone	O
1	O
to	O
zone	O
2	O
and	O
zone	O
4	O
to	O
zone	O
2	O
).	O

Approximately	O
40	O
%	O
(	O
n	O
=	O
32	O
)	O
of	O
the	O
patients	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

HFOV	O
enabled	O
an	O
improvement	O
in	O
hypercapnia	B-DISO
and	O
oxygenation	O
.	O

The	O
patient	O
was	O
weaned	O
from	O
mechanical	O
ventilation	O
and	O
has	O
done	O
well	O
without	O
recurrence	B-DISO
.	O

To	O
our	O
knowledge	O
,	O
only	O
case	O
reports	O
of	O
AAC	O
related	O
to	O
12	O
malaria	B-DISO
adult	O
patients	O
have	O
been	O
published	O
.	O

In	O
this	O
series	O
,	O
seven	O
cases	O
of	O
AAC	O
from	O
a	O
cohort	O
of	O
42	O
adult	O
patients	O
with	O
severe	O
imported	O
falciparum	B-DISO
malaria	I-DISO
[	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
]	O
are	O
presented	O
.	O

Each	O
patient	O
presented	O
five	O
to	O
nine	O
WHO	O
severe	O
malaria	B-DISO
criteria	O
:	O
all	O
had	O
hyperparasitaemia	O
and	O
hyperbilirubinaemia	B-DISO
.	O

While	O
SARS	B-DISO
-	O
CoV	O
productively	O
replicated	O
in	O
lung	O
tissue	O
,	O
replication	O
in	O
human	O
bronchial	O
tissue	O
was	O
limited	O
.	O

HCoV	O
-	O
EMC	B-DISO
failed	O
to	O
elicit	O
strong	O
type	O
I	O
or	O
III	O
interferon	O
(	O
IFN	O
)	O
or	O
proinflammatory	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
in	O
ex	O
vivo	O
respiratory	O
tissue	O
cultures	O
.	O

TITLE	O
:	O
TIM	O
-	O
family	O
proteins	O
promote	O
infection	B-DISO
of	O
multiple	O
enveloped	O
viruses	O
through	O
virion	O
-	O
associated	O
phosphatidylserine	O
.	O

Here	O
we	O
show	O
that	O
TIM1	O
promotes	O
infection	B-DISO
of	O
retroviruses	O
and	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
pseudotyped	O
with	O
a	O
range	O
of	O
viral	O
entry	O
proteins	O
,	O
in	O
particular	O
those	O
from	O
the	O
filovirus	O
,	O
flavivirus	O
,	O
New	O
World	O
arenavirus	O
and	O
alphavirus	O
families	O
.	O

TIM1	O
also	O
robustly	O
enhanced	O
the	O
infection	B-DISO
of	O
replication	O
-	O
competent	O
viruses	O
from	O
the	O
same	O
families	O
,	O
including	O
dengue	B-DISO
,	O
Tacaribe	O
,	O
Sindbis	O
and	O
Ross	O
River	O
viruses	O
.	O

The	O
predictors	O
of	O
NIV	O
failure	O
were	O
the	O
severity	O
of	O
associated	O
organ	O
dysfunctions	O
(	O
OR	O
,	O
1	O
.	O
20	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
to	O
1	O
.	O
34	O
),	O
ARDS	B-DISO
(	O
OR	O
,	O
2	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
to	O
4	O
.	O
82	O
)	O
and	O
positive	O
fluid	O
balance	O
(	O
OR	O
,	O
2	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
to	O
4	O
.	O
30	O
).	O

ABSTRACT	O
:	O
Progress	O
in	O
intensive	O
care	O
(	O
ICU	O
)	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
over	O
the	O
last	O
20	O
years	O
includes	O
the	O
introduction	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
CO2	O
removal	O
and	O
the	O
widespread	O
use	O
of	O
evidence	O
-	O
based	O
lung	O
-	O
protective	O
ventilatory	O
strategies	O
.	O

Data	O
on	O
long	O
-	O
term	O
outcome	O
were	O
collected	O
in	O
a	O
subcohort	O
(	O
n	O
=	O
125	O
)	O
of	O
patients	O
who	O
responded	O
to	O
mailed	O
questionnaires	O
and	O
included	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
,	O
SF	O
-	O
36	O
questionnaire	O
),	O
symptoms	O
of	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
),	O
traumatic	O
memories	O
from	O
ICU	O
treatment	O
(	O
PTSS	O
-	O
10	O
instrument	O
)	O
and	O
current	O
state	O
of	O
employment	O
.	O

The	O
average	O
total	O
MCC	B-DISO
per	O
high	O
-	O
power	O
field	O
in	O
ECA	O
(	O
40	O
.	O
8	O
±	O
2	O
.	O
2	O
)	O
and	O
IBD	B-DISO
(	O
24	O
.	O
7	O
±	O
2	O
.	O
1	O
)	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
.	O
05	O
)	O
than	O
in	O
the	O
control	O
(	O
3	O
.	O
4	O
±	O
0	O
.	O
6	O
).	O

TITLE	O
:	O
Diffusion	O
tensor	O
MRI	O
evaluation	O
of	O
the	O
corona	O
radiata	O
,	O
cingulate	O
gyri	O
,	O
and	O
corpus	O
callosum	O
in	O
HIV	B-DISO
patients	O
.	O

CONCLUSIONS	O
:	O
Since	O
the	O
DTI	O
can	O
detect	O
abnormalities	O
in	O
the	O
normal	O
-	O
appearing	O
white	O
matter	O
,	O
this	O
technique	O
may	O
play	O
a	O
role	O
as	O
an	O
early	O
marker	O
of	O
HIV	B-DISO
disease	I-DISO
progression	I-DISO
,	O
including	O
clinical	O
manifestations	O
such	O
as	O
cognitive	B-DISO
impairment	I-DISO
.	O

When	O
the	O
lung	O
is	O
the	O
single	O
failing	O
organ	O
,	O
quick	O
resolution	O
of	O
ARDS	B-DISO
should	O
skip	O
some	O
complications	O
arising	O
from	O
a	O
prolonged	O
stay	O
in	O
the	O
critical	O
care	O
unit	O
.	O

Gross	O
necropsy	O
and	O
histopathologic	O
examination	O
revealed	O
necrotizing	O
,	O
multifocal	O
myocarditis	B-DISO
;	O
necrotizing	O
,	O
neutrophilic	O
,	O
and	O
histiocytic	O
myositis	B-DISO
and	O
vasculitis	B-DISO
of	O
the	O
tunica	O
muscularis	O
layer	O
of	O
the	O
small	O
and	O
large	O
intestines	O
;	O
and	O
embolic	O
,	O
multifocal	O
,	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

A	O
PCR	O
for	O
coronavirus	O
performed	O
on	O
kidney	O
tissue	O
was	O
positive	O
,	O
confirming	O
a	O
diagnosis	O
of	O
FIP	B-DISO
.	O

Although	O
coronavirus	B-DISO
infection	I-DISO
has	O
been	O
documented	O
in	O
mountain	O
lions	O
by	O
serology	O
,	O
this	O
is	O
the	O
first	O
confirmed	O
report	O
of	O
FIP	B-DISO
.	O

In	O
premature	O
infants	O
,	O
CMV	B-DISO
infection	I-DISO
is	O
often	O
protracted	O
and	O
causes	O
a	O
diffuse	O
interstitial	B-DISO
pneumonitis	I-DISO
leading	O
to	O
fibrosis	B-DISO
and	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
(	O
BPD	B-DISO
).	O

TITLE	O
:	O
Unusual	O
presentation	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
following	O
traumatic	O
bone	O
injuries	O
:	O
report	O
of	O
two	O
cases	O
.	O

The	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
GBS	B-DISO
.	O

He	O
then	O
developed	O
ascending	O
areflexic	O
weakness	B-DISO
of	O
all	O
four	O
limbs	O
and	O
bifacial	O
weakness	B-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
protection	O
efficacy	O
of	O
monomeric	O
and	O
trimeric	O
recombinant	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
subunit	O
vaccine	O
candidates	O
.	O

ABSTRACT	O
:	O
More	O
than	O
40	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
have	O
been	O
approved	O
for	O
a	O
number	O
of	O
disease	O
indications	O
with	O
only	O
one	O
of	O
these	O
(	O
Synagis	O
)	O
-	O
for	O
a	O
viral	B-DISO
disease	I-DISO
,	O
and	O
not	O
for	O
therapy	O
but	O
for	O
prevention	O
.	O

TITLE	O
:	O
Complete	O
protection	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
mediated	O
lethal	O
respiratory	B-DISO
disease	I-DISO
in	O
aged	O
mice	O
by	O
immunization	O
with	O
a	O
mouse	O
-	O
adapted	O
virus	O
lacking	O
E	O
protein	O
.	O

A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
was	O
isolated	O
from	O
respiratory	O
specimens	O
obtained	O
from	O
all	O
three	O
patients	O
and	O
was	O
identified	O
as	O
H7N9	O
.	O

A	O
deletion	O
of	O
five	O
amino	O
acids	O
in	O
the	O
neuraminidase	O
(	O
NA	O
)	O
stalk	B-DISO
region	O
was	O
found	O
in	O
all	O
three	O
viruses	O
.	O

The	O
clinical	O
signs	O
in	O
the	O
affected	O
birds	O
included	O
swelling	B-DISO
of	O
the	O
face	B-DISO
and	O
eyes	O
,	O
loss	O
of	O
condition	B-DISO
,	O
gasping	B-DISO
respirations	O
and	O
coughing	B-DISO
.	O

TITLE	O
:	O
Cross	O
-	O
reactive	O
antibodies	O
in	O
convalescent	O
SARS	B-DISO
patients	O
'	O
sera	O
against	O
the	O
emerging	O
novel	O
human	O
coronavirus	O
EMC	B-DISO
(	O
2012	O
)	O
by	O
both	O
immunofluorescent	O
and	O
neutralizing	O
antibody	O
tests	O
.	O

HCoV	O
-	O
EMC	B-DISO
is	O
phylogenetically	O
closely	O
related	O
to	O
Tylonycteris	O
-	O
bat	O
-	O
coronavirus	O
-	O
HKU4	O
and	O
Pipistrellus	O
-	O
bat	O
-	O
coronavirus	O
-	O
HKU5	O
in	O
Hong	O
Kong	O
.	O

We	O
conducted	O
a	O
seroprevalence	O
study	O
on	O
archived	O
sera	O
from	O
94	O
game	O
-	O
food	O
animal	O
handlers	O
at	O
a	O
wild	O
life	O
market	O
,	O
28	O
SARS	B-DISO
patients	O
,	O
and	O
152	O
healthy	O
blood	O
donors	O
in	O
Southern	O
China	O
to	O
assess	O
the	O
zoonotic	O
potential	O
and	O
evidence	O
for	O
intrusion	O
of	O
HCoV	O
-	O
EMC	B-DISO
and	O
related	O
viruses	O
into	O
humans	O
.	O

Convalescent	O
SARS	B-DISO
sera	O
may	O
contain	O
cross	O
-	O
reactive	O
antibodies	O
against	O
other	O
betacoronaviruses	O
and	O
confound	O
seroprevalence	O
study	O
for	O
HCoV	O
-	O
EMC	B-DISO
.	O

This	O
translates	O
to	O
tens	O
of	O
thousands	O
of	O
excess	O
deaths	O
in	O
the	O
United	O
States	O
each	O
year	O
from	O
alcohol	O
-	O
mediated	O
lung	O
injury	O
,	O
which	O
is	O
comparable	O
to	O
scarring	B-DISO
of	O
the	O
liver	O
(	O
i	O
.	O
e	O
.,	O
cirrhosis	B-DISO
)	O
in	O
terms	O
of	O
alcohol	O
-	O
related	O
mortality	O
.	O

In	O
parallel	O
,	O
efforts	O
to	O
study	O
complex	O
diseases	O
such	O
as	O
acute	O
lung	O
injury	O
and	O
pneumonia	B-DISO
using	O
a	O
genomics	O
and	O
/	O
or	O
proteomics	O
approach	O
,	O
which	O
involves	O
the	O
study	O
of	O
an	O
organism	O
'	O
s	O
genes	O
and	O
/	O
or	O
proteins	O
,	O
still	O
are	O
in	O
their	O
infancy	O
.	O

TITLE	O
:	O
[	O
Diffuse	B-DISO
infiltrative	I-DISO
lung	I-DISO
disease	I-DISO
in	O
scleroderma	B-DISO
.	O

The	O
pulmonary	O
function	O
objectified	O
a	O
severe	O
restrictive	O
ventilatory	B-DISO
defect	I-DISO
in	O
all	O
cases	O
.	O

DILD	O
in	O
scleroderma	B-DISO
is	O
rare	O
and	O
seldom	O
reveals	O
the	O
disease	O
,	O
it	O
affects	O
the	O
patient	O
'	O
s	O
prognosis	O
especially	O
when	O
associated	O
with	O
arterial	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

An	O
emergency	B-DISO
procedure	O
to	O
implant	O
a	O
stent	O
graft	O
was	O
successful	O
in	O
repairing	O
the	O
IVC	O
injury	O
.	O

CONCLUSIONS	O
:	O
Plasminogen	O
activator	O
inhibitor	O
-	O
1	O
is	O
sensitive	O
blood	O
symbol	O
for	O
screening	O
high	O
-	O
risk	O
susceptible	O
population	O
;	O
4G	O
/	O
4G	O
PAI	O
-	O
1	O
genotype	O
may	O
be	O
an	O
etiological	O
factor	O
in	O
osteonecrosis	B-DISO
.	O

Of	O
the	O
cats	O
without	O
FIP	B-DISO
that	O
harboured	O
FECoV	O
,	O
the	O
amino	O
acid	O
sequence	O
identities	O
for	O
the	O
M	O
gene	O
were	O
100	O
%	O
among	O
cats	O
(	O
Cats	O
1	O
-	O
3	O
)	O
from	O
the	O
same	O
cattery	O
,	O
and	O
the	O
overall	O
sequence	O
identity	O
for	O
the	O
M	O
gene	O
was	O
≥	O
91	O
%.	O

ABSTRACT	O
:	O
The	O
investigators	O
present	O
a	O
series	O
of	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
who	O
were	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
at	O
a	O
regional	O
referral	O
center	O
.	O

Patients	O
with	O
refractory	O
hypoxic	B-DISO
ARDS	B-DISO
received	O
ECMO	O
until	O
they	O
recovered	O
lung	O
function	O
or	O
demonstrated	O
futility	O
.	O

The	O
investigators	O
present	O
a	O
series	O
of	O
36	O
adults	O
with	O
refractory	O
hypoxemic	O
ARDS	B-DISO
(	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
<	O
50	O
)	O
from	O
17	O
different	O
facilities	O
who	O
,	O
treated	O
with	O
ECMO	O
at	O
a	O
single	O
referral	O
center	O
,	O
had	O
a	O
60	O
%	O
survival	O
rate	O
.	O

Three	O
infected	O
index	O
patients	O
developed	O
severe	O
viral	B-DISO
pneumonia	I-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
resulted	O
in	O
fatal	O
outcome	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
by	O
deletion	O
of	O
the	O
LLRKxGxKG	O
region	O
of	O
Nsp1	O
.	O

hCoV	O
-	O
EMC	B-DISO
/	O
2012	O
was	O
sensitive	O
to	O
both	O
interferon	O
-	O
α2b	O
and	O
ribavirin	O
alone	O
in	O
Vero	O
and	O
LLC	O
-	O
MK2	O
cells	O
,	O
but	O
only	O
at	O
relatively	O
high	O
concentrations	O
;	O
however	O
,	O
when	O
combined	O
,	O
lower	O
concentrations	O
of	O
interferon	O
-	O
α2b	O
and	O
ribavirin	O
achieved	O
comparable	O
endpoints	O
.	O

TITLE	O
:	O
The	O
papain	O
-	O
like	O
protease	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
negatively	O
regulates	O
type	O
I	O
interferon	O
pathway	O
by	O
acting	O
as	O
a	O
viral	O
deubiquitinase	O
.	O

TITLE	O
:	O
Bayesian	O
inference	O
of	O
the	O
lung	O
alveolar	O
spatial	O
model	O
for	O
the	O
identification	O
of	O
alveolar	O
mechanics	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
alobar	B-DISO
holoprosencephaly	I-DISO
(	O
HPE	O
)	O
and	O
cebocephaly	B-DISO
associated	O
with	O
uncontrolled	O
maternal	O
type	O
1	O
(	O
insulin	O
-	O
dependent	O
)	O
diabetes	B-DISO
mellitus	I-DISO
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
case	O
represents	O
the	O
longest	O
reported	O
survival	O
of	O
an	O
infant	O
with	O
alobar	O
HPE	O
and	O
cebocephaly	B-DISO
.	O

ABSTRACT	O
:	O
To	O
compare	O
effects	O
of	O
different	O
resuscitation	O
fluid	O
on	O
microcirculation	O
,	O
inflammation	B-DISO
,	O
intestinal	O
barrier	O
and	O
clinical	O
results	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
).	O

Additionally	O
,	O
although	O
the	O
type	O
of	O
MAb	O
1H4	O
was	O
IgM	O
,	O
it	O
could	O
reduce	O
cell	O
infection	B-DISO
by	O
TGEV	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
new	O
transmission	O
tracking	O
analysis	O
technique	O
during	O
incubation	O
period	O
of	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
,	O
and	O
to	O
discuss	O
its	O
practical	O
value	O
in	O
the	O
field	O
survey	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

Eight	O
serious	O
sever	O
acute	O
respiratory	O
syndrome	B-DISO
(	O
SARS	B-DISO
)	O
cases	O
in	O
Shanghai	O
in	O
year	O
2003	O
were	O
then	O
chose	O
as	O
prototype	O
to	O
set	O
up	O
the	O
test	O
cases	O
A	O
-	O
H	O
.	O
The	O
electronic	O
map	O
and	O
population	O
density	O
data	O
were	O
separately	O
collected	O
from	O
Institute	O
of	O
Surveying	O
and	O
Mapping	O
in	O
Shanghai	O
and	O
Shanghai	O
statistical	O
yearbook	O
2003	O
,	O
to	O
calculate	O
and	O
explore	O
the	O
parameters	O
as	O
length	O
of	O
transmission	O
path	O
,	O
area	O
of	O
buffer	O
zone	O
and	O
key	O
departments	O
by	O
single	O
and	O
multi	O
case	O
analysis	O
module	O
.	O

Intensivists	O
in	O
academic	O
hospitals	O
with	O
clinical	O
trial	O
expertise	O
in	O
critical	B-DISO
illness	I-DISO
.	O

We	O
administered	O
the	O
survey	O
to	O
experienced	O
intensivists	O
practicing	O
in	O
selected	O
North	O
American	O
centres	O
actively	O
enrolling	O
patients	O
in	O
the	O
multicentre	O
Oscillation	O
for	O
ARDS	B-DISO
Treated	O
Early	O
(	O
OSCILLATE	O
)	O
Trial	O
(	O
ISRCTN87124254	O
).	O

Near	O
-	O
absolute	O
indications	O
selected	O
by	O
most	O
respondents	O
included	O
known	O
adrenal	B-DISO
insufficiency	I-DISO
(	O
99	O
%)	O
and	O
suspicion	O
of	O
cryptogenic	B-DISO
organizing	I-DISO
pneumonia	I-DISO
(	O
89	O
%),	O
connective	B-DISO
tissue	I-DISO
disease	I-DISO
(	O
85	O
%),	O
or	O
other	O
potentially	O
corticosteroid	O
-	O
responsive	O
illnesses	O
(	O
85	O
%).	O

HMGB1	O
levels	O
in	O
the	O
lungs	O
increased	O
to	O
a	O
higher	O
level	O
in	O
ARDS	B-DISO
mice	O
compared	O
to	O
those	O
in	O
mice	O
treated	O
with	O
LPS	B-DISO
alone	O
.	O

This	O
case	O
report	O
describes	O
the	O
antemortem	O
diagnosis	O
of	O
FIP	B-DISO
in	O
a	O
2	O
-	O
year	O
-	O
old	O
spayed	O
female	O
Sphinx	O
cat	O
that	O
presented	O
with	O
a	O
bilateral	O
panuveitis	B-DISO
and	O
multiple	O
papular	O
cutaneous	O
lesions	O
.	O

Logistic	O
regression	O
modeling	O
demonstrates	O
that	O
the	O
presence	O
of	O
an	O
operative	O
fracture	O
increased	O
the	O
odds	O
of	O
developing	O
at	O
least	O
one	O
complication	B-DISO
approximately	O
three	O
times	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
88	O
,	O
p	O
=	O
0	O
.	O
006	O
),	O
after	O
controlling	O
for	O
presence	O
of	O
chest	O
injury	O
and	O
type	O
of	O
injured	O
abdominal	O
organ	O
.	O

ABSTRACT	O
:	O
Factor	O
V	O
Leiden	O
is	O
a	O
procoagulant	O
mutation	O
associated	O
with	O
venous	O
and	O
arterial	B-DISO
thrombosis	I-DISO
and	O
pregnancy	B-DISO
complications	I-DISO
.	O

ABSTRACT	O
:	O
A	O
nine	O
-	O
month	O
old	O
boy	O
was	O
initially	O
admitted	O
at	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Infection	I-DISO
Unit	O
of	O
Dhaka	O
Hospital	O
of	O
icddr	O
,	O
b	O
and	O
soon	O
after	O
transferred	O
to	O
the	O
Intensive	O
Care	O
Unit	O
of	O
the	O
same	O
hospital	O
.	O

In	O
2012	O
,	O
a	O
novel	O
CoV	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
;	O
MERS	O
-	O
CoV	O
)	O
emerged	O
,	O
causing	O
49	O
human	O
cases	O
thus	O
far	O
,	O
of	O
which	O
23	O
had	O
a	O
fatal	O
outcome	O
.	O

Viruses	O
related	O
to	O
the	O
novel	O
human	O
betacoronavirus	O
EMC	B-DISO
/	O
2012	O
were	O
detected	O
in	O
46	O
(	O
24	O
.	O
9	O
%)	O
of	O
185	O
Nycteris	O
bats	O
and	O
40	O
(	O
14	O
.	O
7	O
%)	O
of	O
272	O
Pipistrellus	O
bats	O
.	O

Their	O
genetic	O
relatedness	O
indicated	O
EMC	B-DISO
/	O
2012	O
originated	O
from	O
bats	O
.	O

Conditional	O
ablation	O
of	O
lymphotoxin	O
-	O
β	O
receptor	O
(	O
LTβR	O
)	O
expression	O
in	O
LN	O
FRCs	O
and	O
their	O
mesenchymal	O
progenitors	O
in	O
developing	O
LNs	B-DISO
revealed	O
that	O
LTβR	O
-	O
signaling	O
in	O
these	O
cells	O
was	O
not	O
essential	O
for	O
the	O
formation	O
of	O
LNs	B-DISO
.	O

CV	O
was	O
found	O
in	O
10	O
.	O
6	O
%	O
of	O
virus	O
-	O
positive	O
pneumonia	B-DISO
patients	O
in	O
one	O
study	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
HCoV	O
-	O
EMC	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
induce	O
similar	O
or	O
distinct	O
host	O
responses	O
after	O
infection	B-DISO
of	O
a	O
human	O
lung	O
epithelial	O
cell	O
line	O
.	O

The	O
most	O
common	O
causes	O
of	O
ARDS	B-DISO
are	O
pneumonia	B-DISO
and	O
sepsis	B-DISO
.	O

Intermittent	O
prone	O
positioning	O
can	O
reduce	O
mortality	O
in	O
severe	O
cases	O
of	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
cleaves	O
two	O
virion	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
);	O
this	O
essential	O
process	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

The	O
potential	O
interactome	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
N	O
protein	O
was	O
mapped	O
using	O
stable	O
isotope	O
labeling	O
with	O
amino	O
acids	O
in	O
cell	O
culture	O
(	O
SILAC	O
)	O
coupled	O
to	O
a	O
green	O
fluorescent	O
protein	O
-	O
nanotrap	O
pulldown	O
methodology	O
and	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
.	O

Primary	O
cultures	O
of	O
murine	O
alveolar	O
epithelial	O
cells	O
provide	O
a	O
robust	O
in	O
vitro	O
model	O
to	O
perform	O
mechanistic	O
studies	O
that	O
can	O
be	O
correlated	O
with	O
in	O
vivo	O
studies	O
to	O
identify	O
cell	O
type	O
-	O
specific	O
factors	O
that	O
contribute	O
to	O
pathology	B-DISO
within	O
the	O
alveoli	O
of	O
the	O
lung	O
during	O
viral	B-DISO
infection	I-DISO
.	O

Both	O
cell	O
types	O
had	O
increased	O
expression	O
of	O
IL	O
-	O
1β	O
mRNA	O
upon	O
viral	B-DISO
infection	I-DISO
,	O
though	O
at	O
different	O
levels	O
.	O

Furthermore	O
,	O
dieckol	O
(	O
8	O
)	O
exhibited	O
a	O
high	O
association	O
rate	O
in	O
the	O
SPR	O
sensorgram	O
and	O
formed	O
extremely	O
strong	O
hydrogen	O
bonds	O
to	O
the	O
catalytic	O
dyad	O
(	O
Cys145	O
and	O
His41	O
)	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

In	O
vivo	O
study	O
using	O
cats	O
with	O
experimentally	O
induced	O
FIP	B-DISO
,	O
the	O
clinical	O
score	O
of	O
chloroquine	O
-	O
treatment	O
groups	O
were	O
better	O
than	O
in	O
chloroquine	O
-	O
untreated	O
group	O
.	O

No	O
evidence	O
of	O
sustained	O
human	O
-	O
to	O
-	O
human	O
transmission	O
has	O
been	O
found	O
,	O
and	O
no	O
human	O
cases	O
of	O
H7N9	O
virus	B-DISO
infection	I-DISO
have	O
been	O
detected	O
outside	O
China	O
,	O
including	O
the	O
United	O
States	O
.	O

ABSTRACT	O
:	O
An	O
epidemic	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
led	O
to	O
the	O
identification	O
of	O
an	O
associated	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
This	O
virus	O
evades	O
the	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
in	O
part	O
through	O
the	O
expression	O
of	O
its	O
non	O
-	O
structural	O
protein	O
(	O
nsp	O
)	O
1	O
,	O
which	O
inhibits	O
both	O
host	O
gene	O
expression	O
and	O
virus	O
-	O
and	O
interferon	O
(	O
IFN	O
)-	O
dependent	O
signaling	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
nsp1	O
mode	O
of	O
action	O
,	O
we	O
generated	O
and	O
analyzed	O
38	O
mutants	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
nsp1	O
,	O
targeting	O
62	O
solvent	O
exposed	O
residues	O
out	O
of	O
the	O
180	O
amino	O
acid	O
protein	O
.	O

Malaysia	O
experienced	O
a	O
large	O
dengue	B-DISO
outbreak	O
in	O
2006	O
to	O
2007	O
,	O
involving	O
mostly	O
adults	O
,	O
with	O
a	O
high	O
number	O
of	O
deaths	O
.	O

We	O
undertook	O
a	O
retrospective	O
study	O
to	O
examine	O
dengue	B-DISO
death	O
cases	O
in	O
our	O
hospital	O
from	O
June	O
2006	O
to	O
October	O
2007	O
with	O
a	O
view	O
to	O
determine	O
if	O
there	O
have	O
been	O
changes	O
in	O
the	O
presentation	O
of	O
severe	O
to	O
fatal	O
dengue	B-DISO
.	O

Seven	O
patients	O
presented	O
with	O
thrombocytopenia	O
and	O
hypoalbuminemia	O
,	O
five	O
of	O
which	O
had	O
hemoconcentration	O
and	O
increased	O
ALT	O
and	O
AST	O
indicative	O
of	O
liver	B-DISO
damage	I-DISO
.	O

Co	O
-	O
morbidities	O
particularly	O
diabetes	B-DISO
mellitus	I-DISO
was	O
common	O
in	O
our	O
cohort	O
.	O

Underlying	O
co	O
-	O
morbidities	O
may	O
contribute	O
to	O
the	O
rapid	O
clinical	O
deterioration	O
in	O
severe	O
dengue	B-DISO
.	O

The	O
uncommon	O
presentations	O
of	O
dengue	B-DISO
are	O
likely	O
a	O
reflection	O
of	O
the	O
changing	O
demographics	O
where	O
adults	O
are	O
now	O
more	O
likely	O
to	O
contract	O
dengue	B-DISO
in	O
dengue	B-DISO
endemic	O
regions	O
.	O

ABSTRACT	O
:	O
To	O
ascertain	O
the	O
metabolic	O
changes	O
in	O
patients	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
SARS	B-DISO
-	O
related	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
)	O
and	O
elucidate	O
the	O
relationship	O
between	O
PTSD	B-DISO
,	O
SARS	B-DISO
and	O
brain	O
metabolism	O
.	O

And	O
the	O
correlations	O
between	O
MRS	B-DISO
findings	O
and	O
the	O
scores	O
of	O
SAS	O
,	O
SDS	B-DISO
and	O
IES	O
were	O
evaluated	O
.	O

SARS	B-DISO
may	O
also	O
lead	O
to	O
the	O
changes	O
of	O
brain	O
metabolism	O
.	O

RESULTS	O
:	O
In	O
comparisons	O
with	O
the	O
control	O
subjects	O
(	O
n	O
=	O
18	O
)	O
and	O
convalescent	O
SARS	B-DISO
patients	O
without	O
PTSD	B-DISO
(	O
n	O
=	O
26	O
),	O
the	O
SARS	B-DISO
-	O
related	O
PTSD	B-DISO
group	O
(	O
n	O
=	O
18	O
)	O
had	O
significantly	O
lower	O
N	O
-	O
acetylaspartate	O
/	O
creatine	O
(	O
NAA	O
/	O
Cr	O
)	O
in	O
4	O
regions	O
of	O
interest	O
while	O
the	O
NAA	O
/	O
Cr	O
of	O
the	O
convalescent	O
SARS	B-DISO
patients	O
was	O
significantly	O
lower	O
than	O
controls	O
in	O
3	O
regions	O
of	O
interest	O
(	O
ACG	O
,	O
PCG	O
and	O
LAPWM	O
).	O

During	O
the	O
hospitalization	O
,	O
she	O
required	O
emergency	B-DISO
transfer	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
because	O
of	O
progressive	O
deterioration	O
of	O
respiratory	O
muscle	O
function	O
,	O
severe	O
respiratory	B-DISO
acidosis	I-DISO
,	O
obtundation	O
and	O
hypotension	O
.	O

Despite	O
aggressive	B-DISO
potassium	O
supplementation	O
,	O
hypokalemia	O
continued	O
to	O
worsen	O
over	O
the	O
next	O
several	O
hours	O
(	O
K	O
(+)	O
of	O
1	O
.	O
7	O
mEq	O
/	O
L	O
).	O

TITLE	O
:	O
Predictive	O
factors	O
of	O
mortality	O
in	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
:	O
a	O
model	O
with	O
data	O
on	O
the	O
first	O
24h	O
of	O
ICU	O
admission	O
.	O

Bivariate	O
analysis	O
showed	O
high	O
mortality	O
to	O
be	O
more	O
frequent	O
in	O
elderly	O
patients	O
,	O
as	O
well	O
as	O
in	O
patients	O
with	O
high	O
SAPS	O
II	O
scores	O
,	O
neoplastic	B-DISO
disease	I-DISO
or	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
investigated	O
the	O
clinical	O
relevance	O
of	O
early	O
general	O
chest	O
ultrasonography	O
(	O
ie	O
,	O
heart	O
and	O
lung	O
recordings	O
)	O
in	O
patients	O
in	O
the	O
ICU	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
).	O

Inclusion	O
criteria	O
were	O
age	O
≥	O
18	O
years	O
and	O
the	O
presence	O
of	O
severe	O
ARF	B-DISO
criteria	O
to	O
justify	O
ICU	O
admission	O
.	O

Therefore	O
,	O
although	O
the	O
diagnosis	O
remains	O
difficult	O
before	O
the	O
onset	O
of	O
renal	O
involvement	O
,	O
the	O
occurrence	O
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
mimicking	O
community	O
-	O
acquired	O
pneumonia	B-DISO
must	O
alert	O
the	O
clinician	O
for	O
possible	O
HPS	B-DISO
,	O
especially	O
in	O
endemic	O
areas	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
potentially	O
devastating	O
form	O
of	O
acute	O
inflammatory	O
lung	O
injury	O
with	O
a	O
high	O
short	O
-	O
term	O
mortality	O
rate	O
and	O
significant	O
long	O
-	O
term	O
consequences	O
among	O
survivors	O
.	O

Cor	B-DISO
pulmonale	I-DISO
was	O
detected	O
in	O
49	O
patients	O
(	O
prevalence	O
of	O
22	O
%;	O
95	O
%	O
confidence	O
interval	O
,	O
16	O
-	O
27	O
%).	O

Multivariate	O
logistic	O
regression	O
identified	O
infectious	B-DISO
causes	O
of	O
lung	O
injury	O
and	O
higher	O
driving	O
pressures	O
as	O
independent	O
factors	O
associated	O
with	O
cor	B-DISO
pulmonale	I-DISO
.	O

Patients	O
with	O
cor	B-DISO
pulmonale	I-DISO
exhibited	O
a	O
higher	O
incidence	O
of	O
shock	O
(	O
need	O
for	O
vasoactive	O
drug	O
)	O
at	O
the	O
time	O
of	O
TEE	O
and	O
were	O
more	O
often	O
managed	O
with	O
prone	O
positioning	O
and	O
/	O
or	O
nitric	O
oxide	O
as	O
adjunctive	O
therapy	O
for	O
severe	O
hypoxemia	O
during	O
ARDS	B-DISO
course	O
.	O

However	O
,	O
all	O
specimens	O
still	O
were	O
positive	O
for	O
SARS	B-DISO
-	O
CoV	O
IgG	O
in	O
the	O
48th	O
month	O
.	O

RESULTS	O
:	O
90	O
%	O
of	O
257	O
patient	O
serum	O
specimens	O
after	O
20	O
days	O
of	O
disease	O
onset	O
showed	O
positive	O
SARS	B-DISO
-	O
CoV	O
IgG	O
either	O
using	O
ELISA	O
or	O
IFA	O
.	O

TGEV	O
infection	B-DISO
induced	I-DISO
the	O
transient	O
activation	O
of	O
p38	O
MAPK	O
in	O
the	O
early	O
phase	O
of	O
inoculation	O
and	O
constant	O
activation	O
in	O
the	O
later	O
phase	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Cytokine	B-DISO
release	I-DISO
syndrome	I-DISO
after	O
blinatumomab	O
treatment	O
related	O
to	O
abnormal	O
macrophage	O
activation	O
and	O
ameliorated	O
with	O
cytokine	O
-	O
directed	O
therapy	O
.	O

He	O
became	O
ill	B-DISO
36	O
hours	O
into	O
the	O
infusion	O
with	O
fever	O
,	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
circulatory	B-DISO
collapse	I-DISO
.	O

Studies	O
on	O
their	O
mechanisms	O
of	O
action	O
revealed	O
that	O
the	O
compounds	O
act	O
by	O
three	O
distinct	O
mechanisms	O
:	O
(	O
i	O
)	O
SSAA09E2	O
{	O
N	O
-[[	O
4	O
-(	O
4	O
-	O
methylpiperazin	O
-	O
1	O
-	O
yl	O
)	O
phenyl	O
]	O
methyl	O
]-	O
1	O
,	O
2	O
-	O
oxazole	O
-	O
5	O
-	O
carboxamide	O
}	O
acts	O
through	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
by	O
blocking	B-DISO
early	O
interactions	O
of	O
SARS	B-DISO
-	O
S	O
with	O
the	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
);	O
(	O
ii	O
)	O
SSAA09E1	O
{[(	O
Z	O
)-	O
1	O
-	O
thiophen	O
-	O
2	O
-	O
ylethylideneamino	O
]	O
thiourea	O
}	O
acts	O
later	O
,	O
by	O
blocking	B-DISO
cathepsin	O
L	O
,	O
a	O
host	O
protease	O
required	O
for	O
processing	O
of	O
SARS	B-DISO
-	O
S	O
during	O
viral	O
entry	O
;	O
and	O
(	O
iii	O
)	O
SSAA09E3	O
[	O
N	O
-(	O
9	O
,	O
10	O
-	O
dioxo	O
-	O
9	O
,	O
10	O
-	O
dihydroanthracen	O
-	O
2	O
-	O
yl	O
)	O
benzamide	O
]	O
also	O
acts	O
later	O
and	O
does	O
not	O
affect	O
interactions	O
of	O
SARS	B-DISO
-	O
S	O
with	O
ACE2	O
or	O
the	O
enzymatic	O
functions	O
of	O
cathepsin	O
L	O
but	O
prevents	O
fusion	O
of	O
the	O
viral	O
membrane	O
with	O
the	O
host	O
cellular	O
membrane	O
.	O

Mass	O
+	O
Ark	O
vaccinations	O
,	O
applied	O
under	O
commercial	O
conditions	O
in	O
the	O
hatchery	O
(	O
spray	O
)	O
and	O
on	O
-	O
farm	O
(	O
spray	O
),	O
did	O
not	O
protect	O
the	O
trachea	B-DISO
or	O
kidney	O
from	O
DMV	O
/	O
1639	O
/	O
11	O
challenge	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
enteric	O
viruses	O
of	O
fecal	O
origin	O
,	O
emerging	O
zoonotic	O
viruses	O
such	O
as	O
respiratory	O
coronaviruses	O
and	O
influenza	B-DISO
viruses	O
may	O
potentially	O
be	O
transmitted	B-DISO
via	O
contaminated	O
foods	O
.	O

Biochemistry	O
revealed	O
markedly	O
elevated	O
creatinine	O
kinase	O
and	O
aspartate	O
aminotransferase	O
which	O
indicated	O
a	O
myopathy	B-DISO
.	O

TITLE	O
:	O
Prone	O
positioning	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
evaluated	O
the	O
effect	O
of	O
early	O
application	O
of	O
prone	O
positioning	O
on	O
outcomes	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Influenza	B-DISO
A	O
(	O
Flu	B-DISO
A	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
and	O
human	O
bocavirus	O
(	O
BoCA	B-DISO
)	O
were	O
found	O
4	O
.	O
4	O
%,	O
3	O
.	O
7	O
%	O
and	O
2	O
.	O
2	O
%,	O
respectively	O
.	O

High	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
exerts	O
innate	O
protective	O
effects	O
in	O
systemic	O
inflammation	B-DISO
.	O

Based	O
on	O
the	O
evaluation	O
of	O
the	O
patients	O
in	O
this	O
analysis	O
,	O
ECMO	O
seems	O
to	O
be	O
a	O
safe	O
therapeutic	O
approach	O
in	O
lung	O
transplant	O
recipients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
directly	O
after	O
transplantation	O
.	O

TITLE	O
:	O
Treatment	O
of	O
cerebral	B-DISO
malaria	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
parenteral	O
artesunate	O
.	O

This	O
prospective	O
cohort	O
enrolled	O
previously	O
healthy	O
term	O
infants	O
during	O
inpatient	O
or	O
outpatient	O
visits	O
for	O
acute	B-DISO
URI	I-DISO
or	O
bronchiolitis	B-DISO
during	O
September	O
to	O
May	O
2004	O
to	O
2008	O
.	O

Illness	O
severity	O
was	O
determined	O
using	O
an	O
ordinal	O
bronchiolitis	B-DISO
severity	O
score	O
.	O

There	O
are	O
no	O
randomised	O
trials	O
of	O
ECMO	O
in	O
poisoned	O
patients	O
with	O
refractory	B-DISO
shock	I-DISO
or	O
who	O
have	O
ARDS	B-DISO
caused	O
by	O
an	O
intoxication	O
.	O

In	O
patients	O
with	O
life	O
-	O
threatening	O
haemodynamic	B-DISO
instability	I-DISO
,	O
VA	O
-	O
ECMO	O
can	O
be	O
considered	O
when	O
shock	O
persists	O
despite	O
volume	O
administration	O
,	O
inotropes	O
and	O
vasoconstrictors	O
,	O
and	O
(	O
sometimes	O
)	O
intra	O
-	O
aortic	O
balloon	O
counterpulsation	O
.	O

On	O
admission	O
,	O
108	O
patients	O
(	O
97	O
.	O
3	O
%)	O
had	O
findings	O
consistent	O
with	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
nonstructural	O
protein	O
2	O
(	O
ns2	B-DISO
)	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	O
that	O
inhibits	O
activation	O
of	O
the	O
interferon	O
-	O
induced	O
oligoadenylate	O
synthetase	O
(	O
OAS	B-DISO
)-	O
RNase	O
L	O
pathway	O
.	O

Enzymatically	O
active	O
ns2	B-DISO
is	O
required	O
for	O
efficient	O
MHV	O
replication	O
in	O
macrophages	O
,	O
as	O
well	O
as	O
for	O
the	O
induction	O
of	O
hepatitis	B-DISO
in	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
replication	O
of	O
wild	O
-	O
type	O
MHV	O
strain	O
A59	O
(	O
A59	O
)	O
and	O
a	O
mutant	B-DISO
with	O
an	O
inactive	O
phosphodiesterase	O
(	O
ns2	B-DISO
-	O
H126R	O
)	O
was	O
assessed	O
in	O
primary	O
hepatocytes	O
and	O
primary	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
cell	O
types	O
-	O
neurons	O
,	O
astrocytes	O
,	O
and	O
oligodendrocytes	O
.	O

Pretreatment	O
of	O
nonmyeloid	O
cells	O
with	O
interferon	O
restricted	O
A59	O
and	O
ns2	B-DISO
-	O
H126R	O
to	O
the	O
same	O
extent	O
and	O
failed	O
to	O
activate	O
RNase	O
L	O
following	O
infection	B-DISO
,	O
despite	O
induction	O
of	O
OAS	B-DISO
expression	O
.	O

Thus	O
,	O
RNase	O
L	O
activation	O
during	O
MHV	O
infection	B-DISO
is	O
cell	O
type	O
specific	O
and	O
correlates	O
with	O
relatively	O
high	O
levels	O
of	O
expression	O
of	O
OAS	B-DISO
genes	O
,	O
which	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
induction	O
of	O
an	O
effective	O
RNase	O
L	O
antiviral	O
response	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
infect	O
a	O
variety	O
of	O
mammalian	O
and	O
avian	O
species	O
and	O
cause	O
serious	O
diseases	O
in	O
humans	O
,	O
cats	O
,	O
mice	O
,	O
and	O
birds	O
in	O
the	O
form	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
mouse	B-DISO
hepatitis	I-DISO
,	O
and	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
,	O
respectively	O
.	O

Also	O
,	O
many	O
viruses	O
require	O
cyclophilins	O
for	O
replication	O
;	O
these	O
include	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
,	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
,	O
and	O
hepatitis	B-DISO
C	I-DISO
virus	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
GTP	O
,	O
dGTP	O
as	O
well	O
as	O
cap	B-DISO
analogs	O
GpppG	O
,	O
GpppA	O
and	O
m7GpppG	O
could	O
be	O
methylated	O
by	O
SARS	B-DISO
-	O
CoV	O
nsp14	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	O
D	O
(	O
ApoD	O
)	O
gene	O
expression	O
is	O
increased	O
in	O
several	O
neurological	B-DISO
disorders	I-DISO
such	O
as	O
Alzheimer	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
(	O
AD	O
)	O
and	O
multiple	B-DISO
sclerosis	I-DISO
.	O

We	O
previously	O
showed	O
that	O
transgenic	O
mice	O
that	O
overexpress	O
human	O
ApoD	O
show	O
a	O
better	O
resistance	O
against	O
paraquat	O
or	O
OC43	O
coronavirus	O
-	O
induced	O
neurodegeneration	B-DISO
.	O

The	O
co	O
-	O
incidence	O
case	O
was	O
identified	O
more	O
frequently	O
in	O
patients	O
with	O
hematologic	B-DISO
malignancy	I-DISO
or	O
organ	O
transplantation	O
recipients	O
,	O
however	O
it	O
was	O
not	O
related	O
to	O
clinical	O
outcomes	O
.	O

The	O
co	O
-	O
incidence	O
case	O
was	O
identified	O
more	O
frequently	O
in	O
patients	O
with	O
hematologic	B-DISO
malignancy	I-DISO
or	O
organ	O
transplantation	O
recipients	O
,	O
however	O
it	O
was	O
not	O
related	O
to	O
clinical	O
outcomes	O
.	O

TITLE	O
:	O
Transient	O
oligomerization	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
--	O
implication	O
for	O
virus	O
ribonucleoprotein	O
packaging	O
.	O

Immunohistochemical	O
staining	O
for	O
corona	O
virus	O
on	O
the	O
same	O
tissues	O
was	O
negative	O
,	O
ruling	O
out	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Besides	O
the	O
success	O
in	O
protective	O
ventilation	O
strategies	O
,	O
no	O
efficient	O
pharmacological	O
approaches	O
exist	O
to	O
treat	O
this	O
devastating	O
condition	B-DISO
.	O

The	O
flow	O
cytometric	O
method	O
provided	O
repeatable	O
results	O
for	O
neutrophils	O
(	O
coefficients	O
of	O
variations	O
,	O
CVs	B-DISO
<	O
15	O
%)	O
but	O
not	O
for	O
monocytes	O
(	O
CVs	B-DISO
>	O
20	O
%)	O
which	O
had	O
also	O
a	O
high	O
individual	O
variability	O
.	O

ABSTRACT	O
:	O
Ten	O
years	O
have	O
elapsed	O
since	O
the	O
World	O
Health	O
Organization	O
issued	O
its	O
first	O
global	O
alert	O
for	O
an	O
unexplained	O
illness	O
named	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
2002	O
-	O
2003	O
exacted	O
considerable	O
human	O
and	O
economic	O
costs	O
from	O
countries	O
involved	O
.	O

TITLE	O
:	O
Novel	O
SARS	B-DISO
-	O
like	O
betacoronaviruses	O
in	O
bats	O
,	O
China	O
,	O
2011	O
.	O

We	O
identified	O
complete	O
genomes	O
of	O
2	O
novel	O
betacoronaviruses	O
in	O
Rhinolophus	O
pusillus	O
and	O
Chaerephon	O
plicata	O
bats	O
,	O
which	O
showed	O
close	O
genetic	O
relationships	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronaviruses	O
.	O

We	O
retrospectively	O
analyzed	O
253	O
consecutive	O
patients	O
hospitalized	O
for	O
acute	B-DISO
pancreatitis	I-DISO
in	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
A	O
4	O
-	O
month	O
-	O
old	O
female	O
entire	O
domestic	O
shorthair	O
cat	O
presented	O
with	O
an	O
acute	O
onset	O
of	O
blindness	B-DISO
,	O
tetraparesis	B-DISO
and	O
subsequent	O
generalised	B-DISO
seizure	I-DISO
activity	O
.	O

The	O
cat	O
was	O
subsequently	O
euthanased	O
,	O
and	O
both	O
histopathology	O
and	O
immunohistochemistry	O
were	O
consistent	O
with	O
a	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Severe	O
forms	O
of	O
the	O
disease	O
with	O
affection	O
of	O
the	O
throat	O
and	O
respiratory	O
muscles	O
can	O
vitally	O
endan	O
-	O
ger	B-DISO
patients	O
.	O

Pathognomonic	O
cutaneous	O
manifestations	O
of	O
dermatomyositis	B-DISO
are	O
Gottron	O
'	O
s	O
papules	O
and	O
heliotrope	O
erythema	B-DISO
.	O

A	O
prompt	O
treatment	O
of	O
infections	B-DISO
and	O
heart	B-DISO
failure	I-DISO
is	O
sometimes	O
life	O
-	O
saving	O
in	O
patients	O
with	O
myositis	B-DISO
.	O

Docking	O
studies	O
were	O
performed	O
to	O
model	O
the	O
binding	O
interaction	O
of	O
the	O
compound	O
26m	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
22	O
-	O
year	O
-	O
old	O
male	O
with	O
severe	O
autism	B-DISO
and	O
intellectual	O
disorder	O
who	O
developed	O
respiratory	B-DISO
failure	I-DISO
and	O
required	O
a	O
prolonged	O
ICU	O
course	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
an	O
extreme	O
presentation	O
of	O
the	O
chylomicronemia	B-DISO
syndrome	I-DISO
resulting	O
in	O
multiorgan	O
system	O
dysfunction	O
.	O

His	O
diabetes	B-DISO
and	O
hypertriglyceridemia	O
were	O
newly	O
diagnosed	O
and	O
drug	O
therapy	O
was	O
instituted	O
with	O
home	O
discharge	O
on	O
day	O
14	O
.	O

Recombinant	O
human	O
activated	O
protein	O
C	O
(	O
APC	B-DISO
)	O
reportedly	O
improves	O
circulation	O
and	O
respiration	O
in	O
severe	B-DISO
sepsis	I-DISO
,	O
but	O
is	O
contraindicated	O
after	O
head	O
injury	O
because	O
of	O
increased	O
risk	O
of	O
intracranial	B-DISO
bleeding	I-DISO
.	O

A	O
21	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
head	O
injury	O
after	O
a	O
car	B-DISO
accident	O
was	O
endotracheally	O
intubated	O
,	O
mechanically	O
ventilated	O
,	O
and	O
hemodynamically	O
stabilized	O
before	O
transfer	O
to	O
our	O
university	O
hospital	O
.	O

TITLE	O
:	O
Update	O
:	O
Severe	O
respiratory	O
illness	O
associated	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)--	O
worldwide	O
,	O
2012	O
-	O
2013	O
.	O

Nosocomial	O
outbreaks	O
with	O
transmission	O
to	O
health	O
-	O
care	O
personnel	O
highlight	O
the	O
importance	O
of	O
infection	B-DISO
control	O
procedures	O
.	O

Our	O
results	O
support	O
a	O
model	O
in	O
which	O
the	O
N	O
-	O
nsp3	O
interaction	O
serves	O
to	O
tether	O
the	O
genome	O
to	O
the	O
newly	O
translated	O
replicase	O
-	O
transcriptase	O
complex	O
at	O
a	O
very	O
early	O
stage	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
[	O
Nutrition	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
].	O

In	O
this	O
review	O
,	O
basic	O
features	O
of	O
nutrition	O
in	O
intensive	O
care	O
medicine	O
and	O
ARDS	B-DISO
-	O
specific	O
aspects	O
(	O
e	O
.	O
g	O
.,	O
immunonutrition	O
)	O
are	O
presented	O
and	O
discussed	O
.	O

Abdominal	O
processes	O
often	O
present	O
a	O
difficult	O
diagnostic	O
dilemma	O
in	O
the	O
truly	O
critically	B-DISO
ill	I-DISO
patient	O
who	O
,	O
due	O
to	O
hemodynamic	B-DISO
instability	I-DISO
or	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
requiring	O
high	O
-	O
level	O
ventilatory	O
support	O
,	O
is	O
at	O
significant	O
risk	O
during	O
transport	O
to	O
radiology	O
department	O
.	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
was	O
23	O
.	O
5	O
%.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
screening	O
tool	O
were	O
75	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
61	O
.	O
3	O
%	O
to	O
85	O
.	O
8	O
%)	O
and	O
46	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
38	O
.	O
2	O
%	O
to	O
54	O
.	O
7	O
%),	O
respectively	O
.	O

We	O
document	O
a	O
functionally	O
relevant	O
S1	O
/	O
S2	O
mutation	O
that	O
arises	O
when	O
FIP	B-DISO
develops	O
in	O
a	O
cat	O
.	O

These	O
insights	O
into	O
FIP	B-DISO
pathogenesis	B-DISO
may	O
be	O
useful	O
in	O
development	O
of	O
diagnostic	O
,	O
prevention	O
,	O
and	O
treatment	O
measures	O
against	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
is	O
an	O
acute	O
,	O
highly	O
contagious	B-DISO
disease	I-DISO
in	O
piglets	O
that	O
is	O
caused	O
by	O
the	O
porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
).	O

However	O
,	O
the	O
pathogenesis	B-DISO
of	O
PHEV	O
and	O
the	O
relationship	O
between	O
PHEV	O
and	O
the	O
host	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

In	O
addition	O
,	O
PHEV	O
caused	O
DNA	O
fragmentation	B-DISO
detectable	O
by	O
agarose	O
gel	O
electrophoresis	O
48h	O
post	O
-	O
infection	B-DISO
,	O
increasing	O
with	O
the	O
incubation	O
time	O
.	O

The	O
percentage	O
of	O
apoptotic	O
cells	O
increased	O
with	O
the	O
incubation	O
time	O
and	O
reached	O
a	O
maximum	O
at	O
96h	O
post	O
-	O
infection	B-DISO
,	O
as	O
determined	O
using	O
flow	O
cytometry	O
and	O
fluorescence	O
microscopy	O
of	O
cells	O
that	O
were	O
stained	O
with	O
annexin	O
V	O
-	O
FITC	O
and	O
propidium	O
iodide	O
(	O
PI	O
).	O

The	O
overall	O
prevalence	O
for	O
any	O
infectious	B-DISO
agent	O
was	O
63	O
.	O
2	O
%	O
in	O
the	O
GI	O
-	O
diseased	O
group	O
and	O
43	O
.	O
2	O
%	O
in	O
the	O
healthy	O
group	O
.	O

TITLE	O
:	O
Inhibitory	O
effect	O
of	O
resveratrol	O
against	O
duck	O
enteritis	B-DISO
virus	O
in	O
vitro	O
.	O

In	O
this	O
paper	O
,	O
resveratrol	O
was	O
found	O
to	O
inhibit	O
duck	O
enteritis	B-DISO
virus	O
(	O
DEV	O
)	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
50	O
%	O
inhibition	O
concentration	O
of	O
3	O
.	O
85	O
μg	O
/	O
mL	O
.	O
The	O
inhibition	O
in	O
virus	O
multiplication	O
in	O
the	O
presence	O
of	O
resveratrol	O
was	O
not	O
attributed	O
to	O
direct	O
inactivation	B-DISO
or	O
inhibition	O
of	O
virus	O
attachment	O
to	O
the	O
host	O
cells	O
,	O
but	O
to	O
the	O
inhibition	O
of	O
viral	O
multiplication	O
in	O
host	O
cells	O
.	O

ABSTRACT	O
:	O
Although	O
minimization	O
of	O
crystalloids	O
is	O
a	O
widely	O
adopted	O
practice	O
in	O
the	O
resuscitation	O
of	O
patients	O
with	O
severe	O
hemorrhage	B-DISO
,	O
its	O
direct	O
impact	O
on	O
high	O
-	O
ratio	O
resuscitation	O
(	O
HRR	O
)	O
outcomes	O
has	O
not	O
been	O
analyzed	O
.	O

During	O
late	O
resuscitation	O
,	O
age	O
(	O
OR	O
,	O
1	O
.	O
02	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
00	O
-	O
1	O
.	O
04	O
),	O
chest	O
AIS	B-DISO
score	O
(	O
OR	O
,	O
1	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
-	O
1	O
.	O
59	O
),	O
and	O
crystalloids	O
given	O
during	O
this	O
period	O
(	O
OR	O
,	O
1	O
.	O
05	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
10	O
)	O
were	O
also	O
predictive	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
hypoxemia	O
.	O

We	O
describe	O
a	O
cluster	O
of	O
health	O
care	O
-	O
acquired	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
virological	O
analysis	O
of	O
a	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

We	O
have	O
provided	O
the	O
first	O
complete	O
viral	O
load	O
profile	O
in	O
a	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

To	O
our	O
surprise	O
,	O
no	O
relationship	O
was	O
observed	O
between	O
clinical	O
severity	O
and	O
sole	O
or	O
coinfections	B-DISO
.	O

TITLE	O
:	O
The	O
clinical	O
course	O
of	O
late	O
diagnosed	O
fatal	O
cases	O
of	O
A	O
(	O
H1N1	O
)	O
influenza	B-DISO
in	O
Poland	O
.	O

During	O
the	O
influenza	B-DISO
epidemic	I-DISO
,	O
patients	O
presenting	O
typical	O
symptoms	O
should	O
always	O
be	O
suspected	O
of	O
having	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
Previous	O
reports	O
suggest	O
that	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
underdiagnosed	O
in	O
both	O
adult	O
and	O
pediatric	O
clinical	O
practice	O
.	O

Underrecognition	O
of	O
this	O
condition	B-DISO
may	O
be	O
a	O
barrier	O
to	O
instituting	O
a	O
low	O
tidal	O
volume	O
ventilation	O
strategy	O
.	O

Two	O
independent	O
reviewers	O
assigned	O
each	O
patient	O
to	O
those	O
with	O
ALI	O
/	O
ARDS	B-DISO
or	O
no	O
ALI	O
.	O

Those	O
with	O
histologic	O
evidence	O
of	O
ALI	O
/	O
ARDS	B-DISO
(	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
)	O
and	O
with	O
a	O
more	O
severe	O
chest	O
x	O
-	O
ray	O
pattern	O
or	O
who	O
satisfied	O
the	O
criteria	O
for	O
a	O
number	O
of	O
consecutive	O
days	O
were	O
no	O
more	O
likely	O
to	O
have	O
a	O
clinical	O
diagnosis	O
of	O
ALI	O
/	O
ARDS	B-DISO
recorded	O
.	O

Among	O
the	O
tested	O
compounds	O
,	O
the	O
derivatives	O
4d	O
and	O
4f	O
were	O
found	O
to	O
be	O
the	O
most	O
active	O
,	O
which	O
demonstrated	O
certain	O
sensitivity	O
profile	O
toward	O
the	O
leukemia	B-DISO
subpanel	O
cell	O
lines	O
with	O
GI₅₀	O
value	O
ranges	O
of	O
2	O
.	O
12	O
-	O
4	O
.	O
58	O
μM	O
(	O
4d	O
)	O
and	O
1	O
.	O
64	O
-	O
3	O
.	O
20	O
μM	O
(	O
4f	O
).	O

Lethargy	B-DISO
,	O
severe	B-DISO
anemia	I-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
splenomegaly	O
,	O
hepatomegaly	B-DISO
,	O
digestive	B-DISO
disorders	I-DISO
,	O
and	O
prostration	B-DISO
were	O
common	O
in	O
children	O
under	O
5	O
years	O
,	O
with	O
significant	O
difference	O
(	O
P	O
,	O
0	O
.	O
05	O
)	O
to	O
the	O
older	O
children	O
.	O

Transfusion	O
because	O
of	O
to	O
severe	B-DISO
anemia	I-DISO
was	O
found	O
necessary	O
in	O
54	O
.	O
4	O
%	O
of	O
cases	O
.	O

This	O
prospective	O
observational	O
study	O
was	O
performed	O
among	O
children	O
admitted	O
with	O
severe	O
malaria	B-DISO
at	O
a	O
tertiary	O
care	O
referral	O
hospital	O
of	O
northern	O
India	O
from	O
January	O
2012	O
to	O
December	O
2012	O
.	O

Two	O
children	O
[	O
2	O
/	O
18	O
(	O
11	O
·	O
1	O
%)]	O
infected	O
with	O
P	O
.	O
vivax	O
had	O
died	O
of	O
cerebral	B-DISO
malaria	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
shock	O
,	O
and	O
metabolic	B-DISO
acidosis	I-DISO
.	O

RESULTS	O
:	O
Thirty	O
-	O
five	O
children	O
with	O
a	O
diagnosis	O
of	O
severe	O
malaria	B-DISO
were	O
enrolled	O
[	O
18	O
(	O
51	O
·	O
4	O
%)	O
P	O
.	O
vivax	O
,	O
nine	O
(	O
25	O
·	O
7	O
%)	O
mixed	B-DISO
infection	I-DISO
,	O
eight	O
(	O
22	O
·	O
8	O
%)	O
P	O
.	O
falciparum	O
].	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
sputum	O
polymerase	O
chain	O
reaction	O
findings	O
,	O
and	O
the	O
four	O
-	O
fold	O
elevation	O
of	O
paired	O
antibodies	O
,	O
the	O
patient	O
was	O
diagnosed	O
as	O
having	O
Legionella	B-DISO
pneumonia	I-DISO
accompanied	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
considered	O
administering	O
fluoroquinolone	O
antibiotics	O
,	O
that	O
are	O
recommended	O
for	O
severe	O
Legionella	B-DISO
pneumonia	I-DISO
,	O
although	O
quinolones	O
have	O
a	O
potential	O
risk	O
for	O
causing	O
convulsions	B-DISO
.	O

We	O
also	O
administered	O
a	O
corticosteroid	O
for	O
severe	O
pneumonia	B-DISO
with	O
the	O
expectation	O
of	O
clinical	O
improvement	O
and	O
to	O
avoid	O
intubation	O
.	O

Cause	O
of	O
death	O
was	O
classified	O
as	O
acute	O
hemorrhagic	B-DISO
shock	I-DISO
;	O
severe	O
traumatic	O
brain	O
injury	O
or	O
high	O
spinal	O
cord	B-DISO
injury	O
;	O
complications	O
of	O
preexisting	O
medical	O
condition	B-DISO
only	O
(	O
PM	O
);	O
survivable	O
trauma	O
combined	O
with	O
complications	O
of	O
preexisting	O
medical	O
condition	B-DISO
(	O
TCoM	O
);	O
multiple	O
-	O
organ	B-DISO
failure	I-DISO
,	O
sepsis	B-DISO
,	O
or	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
MOF	B-DISO
/	O
S	O
/	O
ARDS	B-DISO
),	O
or	O
trauma	O
not	O
otherwise	O
categorized	O
(	O
e	O
.	O
g	O
.,	O
asphyxiation	B-DISO
).	O

Causes	O
of	O
death	O
were	O
severe	O
traumatic	O
brain	O
injury	O
or	O
high	O
spinal	O
cord	B-DISO
injury	O
at	O
44	O
%,	O
acute	O
hemorrhagic	B-DISO
shock	I-DISO
at	O
28	O
%,	O
PM	O
at	O
11	O
%,	O
TCoM	O
at	O
10	O
%,	O
MOF	B-DISO
/	O
S	O
/	O
ARDS	B-DISO
at	O
2	O
%,	O
and	O
trauma	O
not	O
otherwise	O
categorized	O
at	O
5	O
%.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
deaths	O
because	O
of	O
TCoM	O
(	O
3	O
.	O
3	O
-	O
20	O
.	O
9	O
%)	O
and	O
PM	O
(	O
6	O
.	O
7	O
-	O
16	O
.	O
4	O
%),	O
while	O
deaths	O
caused	O
by	O
MOF	B-DISO
/	O
S	O
/	O
ARDS	B-DISO
decreased	O
from	O
5	O
%	O
to	O
0	O
%	O
by	O
2007	O
.	O

TITLE	O
:	O
Biological	O
features	O
of	O
novel	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	O
.	O

ABSTRACT	O
:	O
Human	O
infection	B-DISO
associated	O
with	O
a	O
novel	O
reassortant	O
avian	B-DISO
influenza	I-DISO
H7N9	O
virus	O
has	O
recently	O
been	O
identified	O
in	O
China	O
.	O

TITLE	O
:	O
Rapid	O
Generation	O
of	O
Human	O
-	O
Like	O
Neutralizing	O
Monoclonal	O
Antibodies	O
in	O
Urgent	O
Preparedness	O
for	O
Influenza	B-DISO
Pandemics	O
and	O
Virulent	O
Infectious	B-DISO
Diseases	I-DISO
.	O

Neutralizing	O
antibodies	O
from	O
individuals	O
who	O
have	O
recovered	O
from	O
an	O
infection	B-DISO
confer	O
therapeutic	O
protection	O
to	O
others	O
infected	O
with	O
the	O
same	O
pathogen	O
.	O

Using	O
the	O
H5N1	B-DISO
influenza	I-DISO
virus	O
as	O
a	O
model	O
,	O
we	O
first	O
immunized	O
rhesus	O
macaques	O
with	O
recombinant	O
adenoviruses	O
carrying	O
a	O
synthetic	O
gene	O
encoding	O
hemagglutinin	O
(	O
HA	O
).	O

ABSTRACT	O
:	O
Innate	B-DISO
immune	I-DISO
response	I-DISO
is	O
the	O
first	O
line	O
of	O
antiviral	O
defense	O
resulting	O
,	O
in	O
most	O
cases	O
,	O
in	O
pathogen	O
clearance	O
with	O
minimal	O
clinical	O
consequences	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
in	O
the	O
S	O
protein	O
of	O
the	O
novel	O
human	O
coronavirus	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
as	O
an	O
essential	O
target	O
for	O
vaccine	O
development	O
.	O

From	O
these	O
experiments	O
,	O
it	O
is	O
clear	O
that	O
double	O
-	O
hinged	O
doors	O
pose	O
the	O
greatest	O
risk	O
of	O
leakage	B-DISO
into	O
or	O
out	O
of	O
the	O
room	O
,	O
followed	O
by	O
(	O
in	O
order	O
of	O
decreasing	O
risk	O
)	O
single	O
-	O
hinged	O
,	O
double	O
-	O
sliding	O
and	O
single	O
-	O
sliding	O
doors	O
.	O

ABSTRACT	O
:	O
Poulvac	O
IB	O
®	O
Primer	O
is	O
a	O
lyophilized	O
vaccine	O
containing	O
two	O
attenuated	O
infectious	B-DISO
bronchitis	B-DISO
strains	O
in	O
one	O
vial	O
,	O
IB	O
H120	O
and	O
IB	O
D274	O
.	O

This	O
study	O
assessed	O
the	O
economic	O
impact	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
)	O
on	O
families	O
with	O
children	O
attending	O
childcare	O
using	O
a	O
societal	O
perspective	O
.	O

Economic	O
impacts	O
of	O
ILI	O
(	O
temperature	O
≥	O
37	O
·	O
8	O
°	O
C	O
or	O
parental	O
report	O
of	O
fever	O
,	O
plus	O
≥	O
1	O
respiratory	B-DISO
symptoms	I-DISO
)	O
were	O
collected	O
at	O
2	O
and	O
4	O
weeks	O
after	O
ILI	O
onset	O
by	O
telephone	O
interview	O
.	O

Furthermore	O
,	O
binding	O
between	O
the	O
RBD	O
and	O
CD26	O
is	O
measured	O
using	O
real	O
-	O
time	O
surface	O
plasmon	O
resonance	O
with	O
a	O
dissociation	B-DISO
constant	O
of	O
16	O
.	O
7	O
nM	O
.	O
The	O
viral	O
RBD	O
is	O
composed	O
of	O
a	O
core	O
subdomain	O
homologous	O
to	O
that	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
,	O
and	O
a	O
unique	O
strand	O
-	O
dominated	O
external	O
receptor	O
binding	O
motif	O
that	O
recognizes	O
blades	O
IV	O
and	O
V	O
of	O
the	O
CD26	O
β	O
-	O
propeller	O
.	O

Sequence	O
alignment	O
indicates	O
,	O
among	O
betacoronaviruses	O
,	O
a	O
possible	O
structural	O
conservation	O
for	O
the	O
region	O
homologous	O
to	O
the	O
MERS	O
-	O
CoV	O
RBD	O
core	O
,	O
but	O
a	O
high	O
variation	O
in	O
the	O
external	O
receptor	O
binding	O
motif	O
region	O
for	O
virus	O
-	O
specific	O
pathogenesis	B-DISO
such	O
as	O
receptor	O
recognition	O
.	O

From	O
2006	O
to	O
2009	O
,	O
at	O
least	O
21	O
%	O
of	O
117	O
patients	O
diagnosed	O
with	O
HV	O
infection	B-DISO
had	O
HV	O
Fever	O
(	O
HF	O
)	O
with	O
no	O
evidence	O
of	O
pulmonary	B-DISO
edema	I-DISO
(	O
no	O
respiratory	B-DISO
distress	I-DISO
or	O
radiographic	O
lung	O
infiltrates	B-DISO
),	O
and	O
44	O
%	O
of	O
patients	O
had	O
very	O
mild	O
HPS	B-DISO
(	O
radiographic	O
pulmonary	B-DISO
edema	I-DISO
but	O
no	O
respiratory	B-DISO
insufficiency	I-DISO
).	O

TITLE	O
:	O
Acute	B-DISO
pancreatitis	I-DISO
:	O
a	O
prospective	O
study	O
on	O
incidence	O
,	O
etiology	O
,	O
and	O
outcome	O
.	O

Alcohol	O
was	O
more	O
often	O
the	O
cause	O
in	O
men	O
(	O
25	O
vs	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
the	O
incidence	O
of	O
gallstone	B-DISO
-	O
induced	O
pancreatitis	B-DISO
was	O
similar	O
in	O
men	O
and	O
women	O
(	O
26	O
vs	O
.	O
27	O
).	O

The	O
H7N9	O
viruses	O
were	O
readily	O
transmitted	B-DISO
to	O
naive	O
ferrets	O
through	O
direct	O
contact	O
but	O
,	O
unlike	O
the	O
seasonal	O
H3N2	O
virus	O
,	O
did	O
not	O
transmit	O
readily	O
by	O
respiratory	O
droplets	O
.	O

ABSTRACT	O
:	O
The	O
Berlin	O
definition	O
divides	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
into	O
three	O
severity	O
categories	O
.	O

The	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWi	O
)	O
and	O
pulmonary	O
vascular	O
permeability	O
index	O
(	O
PVPI	O
)	O
were	O
measured	O
using	O
a	O
transpulmonary	O
thermodilution	O
method	O
for	O
three	O
consecutive	O
days	O
in	O
195	O
patients	O
with	O
an	O
EVLWi	O
of	O
≥	O
10	O
mL	O
/	O
kg	O
and	O
who	O
fulfilled	O
the	O
Berlin	O
definition	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
experience	O
of	O
a	O
pediatric	O
intensive	O
care	O
unit	O
.	O

CONCLUSIONS	O
:	O
HFOV	O
improves	O
oxygenation	O
in	O
pediatric	O
patients	O
with	O
ARDS	B-DISO
and	O
severe	O
hypoxemia	O
refractory	O
to	O
conventional	O
ventilatory	O
support	O
.	O

ABSTRACT	O
:	O
The	O
most	O
severe	O
complication	B-DISO
of	O
ischemia	B-DISO
-	O
reperfusion	O
injury	O
following	O
lower	O
limb	O
arterial	O
surgery	O
is	O
reperfusion	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
are	O
the	O
leading	O
cause	O
of	O
acute	B-DISO
infections	I-DISO
in	O
humans	O
.	O

TITLE	O
:	O
Systemic	O
involvement	O
of	O
acute	B-DISO
generalized	I-DISO
exanthematous	I-DISO
pustulosis	I-DISO
:	O
a	O
retrospective	O
study	O
on	O
58	O
patients	O
.	O

Among	O
the	O
58	O
patients	O
enrolled	O
,	O
10	O
had	O
at	O
least	O
one	O
systemic	O
involvement	O
:	O
hepatic	O
function	O
test	O
results	O
were	O
abnormal	O
for	O
seven	O
;	O
six	O
had	O
renal	B-DISO
insufficiency	I-DISO
;	O
two	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
with	O
one	O
patient	O
'	O
s	O
bronchoalveolar	O
lavage	O
fluid	O
containing	O
many	O
neutrophils	O
but	O
no	O
microorganisms	O
;	O
one	O
was	O
agranulocytotic	O
.	O

The	O
neutrophil	O
count	O
-	O
systemic	O
involvement	O
association	O
may	O
suggest	O
a	O
role	O
for	O
neutrophils	O
in	O
AGEP	B-DISO
systemic	O
involvement	O
.	O

Information	O
remains	O
limited	O
about	O
the	O
comparative	O
protein	O
expression	O
of	O
host	O
cells	O
in	O
response	O
to	O
TGEV	O
infection	B-DISO
.	O

RESULTS	O
:	O
33	O
differentially	O
expressed	O
protein	O
spots	B-DISO
,	O
of	O
which	O
23	O
were	O
up	O
-	O
regulated	O
and	O
10	O
were	O
down	O
-	O
regulated	O
were	O
identified	O
.	O

Western	O
blot	O
analysis	O
was	O
used	O
to	O
validate	O
the	O
changes	O
of	O
alpha	O
tubulin	O
,	O
keratin	O
19	O
,	O
and	O
prohibitin	O
during	O
TGEV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Breathing	O
occurs	O
in	O
single	O
breaths	O
and	O
in	O
patterns	O
which	O
are	O
altered	O
by	O
the	O
onset	O
,	O
progression	O
and	O
resolution	O
of	O
respiratory	B-DISO
diseases	I-DISO
.	O

The	O
result	O
of	O
severe	O
lung	O
injury	O
,	O
ARDS	B-DISO
is	O
characterized	O
by	O
lung	O
infiltrates	B-DISO
,	O
rapidly	O
progressive	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
possible	O
progression	O
to	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

We	O
included	O
78	O
patients	O
seen	O
in	O
a	O
tertiary	O
trauma	O
centre	O
between	O
July	O
2009	O
and	O
October	O
2011	O
who	O
had	O
hypotension	O
and	O
bleeding	B-DISO
and	O
were	O
expected	O
to	O
need	O
massive	O
transfusion	O
(≥	O
10	O
RBC	O
units	O
in	O
24	O
h	O
).	O

The	O
28	O
-	O
day	O
mortality	O
and	O
number	O
of	O
days	O
free	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
statistically	O
similar	O
between	O
the	O
groups	O
.	O

The	O
28	O
-	O
day	O
mortality	O
and	O
number	O
of	O
days	O
free	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
statistically	O
similar	O
between	O
the	O
groups	O
.	O

ABSTRACT	O
:	O
Legionella	O
is	O
a	O
common	O
cause	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
and	O
is	O
second	O
only	O
to	O
Pneumococcal	B-DISO
pneumonia	I-DISO
as	O
a	O
cause	O
of	O
severe	O
CAP	B-DISO
that	O
requires	O
treatment	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

Two	O
(	O
13	O
%)	O
died	O
of	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
,	O
one	O
patient	O
(	O
8	O
%)	O
died	O
from	O
global	O
hypoxic	B-DISO
encephalopathy	I-DISO
and	O
one	O
(	O
8	O
%)	O
was	O
weaned	O
from	O
ECLS	O
,	O
but	O
ultimately	O
died	O
of	O
liver	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Microglia	O
are	O
the	O
resident	O
macrophage	O
-	O
like	O
populations	O
in	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
).	O

TITLE	O
:	O
An	O
outbreak	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
a	O
Taiwanese	O
shelter	O
:	O
epidemiologic	O
and	O
molecular	O
evidence	O
for	O
horizontal	O
transmission	O
of	O
a	O
novel	O
type	O
II	O
feline	O
coronavirus	O
.	O

After	O
24	O
hours	O
,	O
the	O
number	O
of	O
endothelial	O
progenitor	O
cells	O
in	O
peripheral	O
blood	O
increased	O
in	O
the	O
acute	O
lung	O
injury	O
group	O
but	O
was	O
not	O
altered	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
sorghum	O
XILP	O
is	O
thermostable	O
and	O
pH	O
stable	O
and	O
exhibits	O
potent	O
antifungal	O
,	O
antiproliferative	O
,	O
and	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
inhibitory	O
activities	O
.	O

Their	O
trachea	B-DISO
,	O
lungs	O
,	O
and	O
cecal	O
tonsil	O
were	O
collected	O
for	O
virus	O
detection	O
and	O
quantitation	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
PCR	O
assay	O
.	O

The	O
results	O
show	O
that	O
transportation	O
among	O
regions	O
will	O
change	O
the	O
disease	O
dynamics	O
and	O
break	O
infection	B-DISO
out	O
even	O
if	O
infectious	B-DISO
diseases	I-DISO
will	O
go	O
to	O
extinction	O
in	O
each	O
isolated	O
region	O
without	O
transport	O
-	O
related	O
infection	B-DISO
.	O

The	O
results	O
show	O
that	O
the	O
transport	O
-	O
related	O
infection	B-DISO
is	O
effected	O
to	O
the	O
number	O
of	O
infected	O
individuals	O
and	O
the	O
duration	O
of	O
outbreak	O
in	O
such	O
the	O
way	O
that	O
the	O
disease	O
becomes	O
more	O
endemic	O
due	O
to	O
the	O
movement	O
between	O
two	O
cities	O
.	O

ABSTRACT	O
:	O
The	O
integrated	O
US	O
Public	O
Health	O
Emergency	B-DISO
Medical	O
Countermeasures	O
Enterprise	O
(	O
PHEMCE	O
)	O
has	O
made	O
great	O
strides	O
in	O
strategic	O
preparedness	O
and	O
response	O
capabilities	O
.	O

Thus	O
,	O
VP3	O
-	O
CTD	O
is	O
a	O
2	O
',	O
5	O
'-	O
PDE	B-DISO
able	O
to	O
functionally	O
substitute	O
for	O
ns2	B-DISO
in	O
MHV	O
infection	B-DISO
.	O

The	O
peak	O
months	O
were	O
September	O
and	O
May	O
for	O
Rhino	O
/	O
Entero	O
infections	B-DISO
,	O
January	O
for	O
RSV	O
and	O
February	O
for	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
syndromes	B-DISO
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
that	O
are	O
associated	O
with	O
substantial	O
mortality	O
and	O
morbidity	O
.	O

The	O
primary	O
objective	O
of	O
this	O
review	O
was	O
to	O
assess	O
whether	O
PLV	O
reduced	O
mortality	O
(	O
at	O
28	O
d	O
,	O
at	O
discharge	O
from	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
at	O
discharge	O
from	O
hospital	O
and	O
at	O
one	O
,	O
two	O
and	O
five	O
years	O
)	O
in	O
adults	O
with	O
ALI	O
or	O
ARDS	B-DISO
when	O
compared	O
with	O
conventional	O
ventilatory	O
support	O
.	O

Considering	O
these	O
data	O
,	O
we	O
diagnosed	O
eosinophilic	B-DISO
pneumonia	I-DISO
induced	O
by	O
gemcitabine	O
.	O

TITLE	O
:	O
The	O
emerging	O
novel	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
the	O
""""	O
knowns	O
""""	O
and	O
""""	O
unknowns	O
"""."	O

TITLE	O
:	O
Potential	O
for	O
the	O
international	O
spread	O
of	O
middle	O
East	O
respiratory	O
syndrome	B-DISO
in	O
association	O
with	O
mass	O
gatherings	O
in	O
saudi	O
arabia	O
.	O

A	O
variety	O
of	O
infectious	B-DISO
agents	O
are	O
implicated	O
in	O
calf	O
diarrhea	B-DISO
and	O
co	B-DISO
-	I-DISO
infection	I-DISO
of	O
multiple	O
pathogens	O
is	O
not	O
uncommon	O
in	O
diarrheic	O
calves	O
.	O

TITLE	O
:	O
A	O
2	O
-	O
year	O
-	O
old	O
girl	O
with	O
co	O
-	O
inherited	O
cystic	B-DISO
fibrosis	I-DISO
and	O
sickle	O
cell	O
-	O
β	O
+	O
thalassemia	B-DISO
presenting	O
with	O
recurrent	O
vaso	O
-	O
occlusive	O
events	O
during	O
cystic	O
fibrosis	B-DISO
pulmonary	I-DISO
exacerbations	O
:	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
Epidemiological	O
,	O
demographic	O
,	O
and	O
clinical	O
characteristics	O
of	O
47	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
disease	O
from	O
Saudi	O
Arabia	O
:	O
a	O
descriptive	O
study	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
a	O
new	O
human	O
disease	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
).	O

We	O
abstracted	O
and	O
analysed	O
epidemiological	O
,	O
demographic	O
,	O
clinical	O
,	O
and	O
laboratory	O
data	O
from	O
confirmed	O
cases	O
of	O
sporadic	O
,	O
household	O
,	O
community	O
,	O
and	O
health	O
-	O
care	O
-	O
associated	O
MERS	O
-	O
CoV	O
infections	B-DISO
reported	O
from	O
Saudi	O
Arabia	O
between	O
Sept	O
1	O
,	O
2012	O
,	O
and	O
June	O
15	O
,	O
2013	O
.	O

Common	O
symptoms	O
at	O
presentation	O
were	O
fever	O
(	O
46	O
[	O
98	O
%]),	O
fever	B-DISO
with	I-DISO
chills	I-DISO
or	O
rigors	B-DISO
(	O
41	O
[	O
87	O
%]),	O
cough	B-DISO
(	O
39	O
[	O
83	O
%]),	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
34	O
[	O
72	O
%]),	O
and	O
myalgia	B-DISO
(	O
15	O
[	O
32	O
%]).	O

ABSTRACT	O
:	O
Hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
(	O
HLH	B-DISO
)	O
is	O
a	O
severe	O
immunological	O
disorder	O
that	O
leads	O
to	O
a	O
massive	O
inflammatory	B-DISO
reaction	I-DISO
that	O
may	O
prove	O
rapidly	O
fatal	O
.	O

A	O
case	O
series	O
of	O
four	O
children	O
with	O
acute	O
surgical	O
presentation	O
and	O
prolonged	O
unexplained	O
postoperative	O
sepsis	B-DISO
,	O
who	O
were	O
diagnosed	O
with	O
HLH	B-DISO
.	O

In	O
the	O
absence	O
of	O
explanation	O
for	O
their	O
symptoms	O
and	O
deteriorating	O
clinical	O
condition	B-DISO
,	O
a	O
total	O
of	O
six	O
'	O
negative	O
'	O
exploratory	O
laparotomies	O
were	O
performed	O
.	O

HLH	B-DISO
may	O
rarely	O
present	O
with	O
symptoms	B-DISO
and	I-DISO
signs	I-DISO
of	O
surgical	O
disease	O
or	O
complicate	O
post	O
-	O
operative	O
recovery	O
.	O

Only	O
four	O
primary	O
research	O
articles	O
investigated	O
social	O
media	O
in	O
the	O
context	O
of	O
foodborne	O
disease	O
or	O
gastroenteritis	B-DISO
.	O

Binding	O
tests	O
with	O
soluble	O
spike	O
proteins	O
carrying	O
an	O
IgG	O
Fc	O
-	O
tag	B-DISO
revealed	O
pronounced	O
differences	O
between	O
these	O
two	O
viral	O
proteins	O
.	O

TITLE	O
:	O
A	O
patient	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
novel	O
human	O
coronavirus	O
.	O

TITLE	O
:	O
Application	O
of	O
a	O
new	O
bivalent	O
Marek	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
vaccine	O
does	O
not	O
interfere	O
with	O
infectious	B-DISO
bronchitis	B-DISO
or	O
Newcastle	B-DISO
disease	I-DISO
vaccinations	O
and	O
proves	O
efficacious	O
.	O

In	O
conclusion	O
,	O
no	O
signs	O
of	O
interference	O
or	O
adverse	B-DISO
effects	I-DISO
were	O
detected	O
.	O

ABSTRACT	O
:	O
The	O
aims	O
of	O
this	O
study	O
are	O
(	O
1	O
)	O
to	O
investigate	O
the	O
occurrence	O
rate	O
of	O
postoperative	B-DISO
complications	I-DISO
in	O
patients	O
≥	O
80	O
years	O
old	O
after	O
cardiac	O
surgery	O
and	O
(	O
2	O
)	O
to	O
elucidate	O
the	O
impact	O
of	O
the	O
most	O
common	O
postoperative	B-DISO
complications	I-DISO
on	O
mortality	O
.	O

A	O
multivariate	O
analysis	O
revealed	O
that	O
advanced	O
age	O
(	O
OR	O
1	O
.	O
130	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
017	O
-	O
1	O
.	O
256	O
,	O
p	O
=	O
0	O
.	O
023	O
),	O
low	O
output	O
syndrome	B-DISO
(	O
OR	O
5	O
.	O
094	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
1635	O
-	O
15	O
.	O
871	O
,	O
p	O
=	O
0	O
.	O
005	O
),	O
renal	B-DISO
failure	I-DISO
(	O
OR	O
8	O
.	O
128	O
,	O
95	O
%	O
CI	O
;	O
3	O
.	O
347	O
-	O
19	O
.	O
742	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
sepsis	B-DISO
(	O
OR	O
4	O
.	O
975	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
420	O
-	O
17	O
.	O
426	O
,	O
p	O
=	O
0	O
.	O
012	O
)	O
as	O
independent	O
risk	O
factors	O
.	O

TITLE	O
:	O
The	O
epidemiology	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
patients	O
presenting	O
to	O
the	O
emergency	B-DISO
department	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
defined	O
using	O
the	O
Berlin	O
definition	O
.	O

Independent	O
risk	O
factors	O
associated	O
with	O
increased	O
risk	O
of	O
ARDS	B-DISO
development	O
included	O
intermediate	O
(	O
2	O
-	O
3	O
.	O
9	O
mmol	O
/	O
L	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
high	O
(≥	O
4	O
)	O
serum	O
lactate	O
levels	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
Lung	O
Injury	O
Prediction	O
score	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
microbiologically	O
proven	O
infection	B-DISO
(	O
P	O
=	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
The	O
role	O
of	O
hepatic	O
CD69	O
+	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
in	O
virus	O
-	O
induced	O
severe	O
liver	O
injury	O
and	O
subsequent	O
hepatic	B-DISO
failure	I-DISO
is	O
not	O
well	O
defined	O
.	O

The	O
expression	O
of	O
CD107a	O
and	O
NKG2D	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
TNF	O
-	O
α	O
,	O
IFN	O
-	O
γ	O
and	O
IL	O
-	O
9	O
in	O
hepatic	O
CD69	O
+	O
NK	O
cells	O
was	O
all	O
significantly	O
up	O
-	O
regulated	O
during	O
48	O
-	O
72	O
h	O
post	O
-	O
infection	B-DISO
.	O

First	O
,	O
the	O
full	O
-	O
length	O
gene	O
of	O
SARS	B-DISO
-	O
S	O
protein	O
was	O
PCR	O
amplified	O
,	O
purified	O
and	O
then	O
digested	O
with	O
DNase	O
I	O
to	O
obtain	O
DNA	O
fragments	O
in	O
the	O
size	O
range	O
of	O
50	O
-	O
500	O
bp	O
.	O

Therefore	O
,	O
the	O
S	O
protein	O
-	O
specific	O
phage	O
displayed	O
antigen	O
library	O
provides	O
a	O
crucial	O
platform	O
for	O
the	O
epitope	O
characterization	O
of	O
anti	O
-	O
S	O
antibodies	O
and	O
it	O
is	O
highly	O
valuable	O
for	O
development	O
of	O
SARS	B-DISO
vaccines	O
and	O
diagnostics	O
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	B-DISO
coronavirus	O
agents	O
:	O
a	O
patent	O
review	O
(	O
2008	O
-	O
present	O
).	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
unlike	O
previous	O
typical	O
human	O
coronaviruses	O
(	O
HCoVs	O
),	O
was	O
identified	O
as	O
causative	O
agent	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

SARS	B-DISO
first	O
surfaced	O
as	O
a	O
pandemic	O
in	O
late	O
2002	O
and	O
originated	O
in	O
southern	O
China	O
.	O

The	O
therapeutic	O
interventions	O
or	O
prophylaxis	O
discussed	O
in	O
this	O
review	O
seems	O
to	O
offer	O
promising	O
solutions	O
to	O
tackle	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designed	O
to	O
identify	O
factors	O
associated	O
with	O
death	O
by	O
6	O
months	O
post	O
-	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
discharge	O
and	O
to	O
develop	O
a	O
practical	O
mortality	O
risk	O
score	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)-	O
treated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
.	O

We	O
also	O
assessed	O
long	O
-	O
term	O
survivors	O
'	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
),	O
respiratory	B-DISO
symptoms	I-DISO
,	O
and	O
anxiety	O
,	O
depression	B-DISO
and	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
)	O
frequencies	O
.	O

Main	O
ARDS	B-DISO
etiologies	O
were	O
bacterial	O
(	O
45	O
%),	O
influenza	B-DISO
A	O
[	O
H₁N₁	O
]	O
(	O
26	O
%)	O
and	O
post	O
-	O
operative	O
(	O
17	O
%)	O
pneumonias	B-DISO
.	O

HRQL	O
evaluation	O
in	O
80	O
%	O
of	O
the	O
6	O
-	O
month	O
survivors	O
revealed	O
satisfactory	O
mental	O
health	O
but	O
persistent	O
physical	O
and	O
emotional	O
-	O
related	O
difficulties	O
,	O
with	O
anxiety	O
,	O
depression	B-DISO
or	O
PTSD	B-DISO
symptoms	O
reported	O
,	O
by	O
34	O
,	O
25	O
or	O
16	O
%,	O
respectively	O
.	O

The	O
PRESERVE	O
score	O
might	O
help	O
ICU	O
physicians	O
select	O
appropriate	O
candidates	O
for	O
ECMO	O
among	O
severe	O
ARDS	B-DISO
patients	O
.	O

The	O
most	O
common	O
were	O
influenza	B-DISO
A	O
strains	O
(	O
17	O
.	O
9	O
%),	O
with	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
and	O
seasonal	O
H3N2	O
strain	O
accounting	O
for	O
52	O
%	O
and	O
43	O
%	O
of	O
these	O
,	O
respectively	O
.	O

Other	O
virus	O
detections	O
included	O
:	O
rhinovirus	O
(	O
12	O
.	O
4	O
%),	O
enterovirus	O
(	O
8	O
.	O
9	O
%),	O
influenza	B-DISO
B	O
(	O
8	O
.	O
3	O
%),	O
adenovirus	B-DISO
(	O
5	O
.	O
3	O
%),	O
parainfluenza	B-DISO
(	O
4	O
.	O
7	O
%),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
(	O
3	O
.	O
9	O
%),	O
human	O
coronavirus	O
(	O
3	O
.	O
0	O
%)	O
and	O
human	O
metapneumovirus	O
(	O
0	O
.	O
3	O
%).	O

The	O
outbreak	O
in	O
2009	O
of	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
strain	O
provided	O
a	O
practical	O
test	O
of	O
the	O
laboratory	O
'	O
s	O
pandemic	O
plan	B-DISO
.	O

TITLE	O
:	O
Diagnostic	O
utility	O
of	O
aqueocentesis	O
and	O
aqueous	B-DISO
humor	I-DISO
analysis	O
in	O
dogs	O
and	O
cats	O
with	O
anterior	B-DISO
uveitis	I-DISO
.	O

Microbial	O
nucleic	O
acids	O
,	O
antigens	O
,	O
or	O
antibodies	O
against	O
them	O
were	O
seldom	O
found	O
in	O
blood	O
/	O
serum	O
;	O
however	O
,	O
serum	O
feline	O
coronavirus	O
titers	O
≥	O
1	O
:	O
6400	O
were	O
detected	O
only	O
in	O
cats	O
with	O
FIP	B-DISO
.	O

TITLE	O
:	O
Altered	O
expression	O
of	O
adhesion	B-DISO
molecules	O
on	O
peripheral	O
blood	O
leukocytes	O
in	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

T	O
-	O
and	O
B	O
-	O
lymphocytes	O
from	O
FIP	B-DISO
patients	O
exhibit	O
higher	O
expression	O
of	O
both	O
subunits	O
(	O
CD11a	O
and	O
CD18	O
)	O
composing	O
the	O
β2	O
integrin	O
lymphocyte	O
function	O
-	O
associated	O
antigen	O
(	O
LFA	O
)-	O
1	O
.	O

Granulocytes	O
of	O
FIP	B-DISO
cats	O
displayed	O
an	O
increased	O
expression	O
of	O
the	O
α	O
chain	O
of	O
Mac	O
-	O
1	O
(	O
CD11b	O
).	O

We	O
present	O
the	O
clinical	O
,	O
laboratory	O
and	O
epidemiological	O
details	O
of	O
3	O
patients	O
from	O
a	O
family	O
cluster	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
in	O
the	O
latter	O
2	O
patients	O
was	O
confirmed	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
testing	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
on	O
recruitment	B-DISO
,	O
cyclic	O
recruitment	B-DISO
and	O
derecruitment	O
and	O
strain	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
using	O
lung	O
computed	O
tomography	O
.	O

While	O
strain	O
is	O
an	O
adverse	B-DISO
effect	I-DISO
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
the	O
decision	O
use	O
positive	O
end	O
-	O
expiratory	O
pressure	O
with	O
any	O
patient	O
should	O
be	O
balanced	O
against	O
the	O
potential	O
benefits	O
of	O
recruitment	B-DISO
.	O

Some	O
of	O
these	O
viruses	O
have	O
the	O
potential	O
for	O
rapid	O
and	O
global	O
spread	O
with	O
high	O
morbidity	O
and	O
mortality	O
,	O
such	O
as	O
the	O
SARS	B-DISO
coronavirus	O
outbreak	O
.	O

We	O
validated	O
the	O
importance	O
of	O
the	O
urokinase	O
pathway	O
for	O
SARS	B-DISO
-	O
CoV	O
disease	O
severity	O
using	O
genetically	O
defined	O
knockout	O
mice	O
,	O
proteomic	O
correlates	O
of	O
pathway	O
activation	O
,	O
and	O
pathological	O
disease	O
severity	O
.	O

The	O
incidence	O
of	O
infections	B-DISO
with	O
each	O
strain	O
was	O
similar	O
,	O
although	O
asymptomatic	B-DISO
infection	I-DISO
and	O
viral	O
coinfection	B-DISO
was	O
significantly	O
more	O
common	O
with	O
229E	O
than	O
OC43	O
infection	B-DISO
.	O

CoV	O
infections	B-DISO
in	O
the	O
elderly	O
are	O
frequent	O
,	O
likely	O
causing	O
substantial	O
medical	O
disease	O
burden	O
.	O

Bleeding	B-DISO
is	O
the	O
most	O
frequent	O
complication	B-DISO
during	O
ECMO	O
support	O
.	O

Eleven	O
ICU	O
patients	O
died	O
(	O
42	O
%),	O
three	O
of	O
them	O
carrying	O
the	O
D222G	O
variant	O
,	O
which	O
was	O
associated	O
with	O
RBS	B-DISO
mutation	O
S183P	O
in	O
two	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
ARI	O
)	O
are	O
the	O
leading	O
cause	O
of	O
pediatric	O
morbidity	O
and	O
mortality	O
worldwide	O
,	O
particularly	O
in	O
developing	O
countries	O
.	O

Further	O
studies	O
are	O
required	O
to	O
better	O
understand	O
the	O
impact	O
of	O
coinfections	B-DISO
in	O
children	O
with	O
ARI	O
.	O

Both	O
titres	O
and	O
seroprevalences	O
in	O
sera	O
from	O
different	O
locations	O
in	O
Oman	O
suggest	O
widespread	O
infection	B-DISO
.	O

TITLE	O
:	O
Inhaled	O
epoprostenol	O
to	O
support	O
the	O
severely	O
hypoxemic	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
This	O
article	O
presents	O
a	O
case	O
study	O
demonstrating	O
various	O
rescue	O
therapies	O
considered	O
in	O
the	O
care	O
of	O
a	O
patient	O
with	O
severe	O
,	O
refractory	O
hypoxemia	O
secondary	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Research	O
comparing	O
the	O
2	O
inhaled	O
vasodilators	O
suggests	O
that	O
epoprostenol	O
is	O
equally	O
efficacious	O
,	O
easier	O
to	O
administer	O
,	O
less	O
costly	O
,	O
and	O
has	O
fewer	O
adverse	B-DISO
effects	I-DISO
.	O

TITLE	O
:	O
Viral	O
pathogens	O
and	O
acute	O
lung	O
injury	O
:	O
investigations	O
inspired	O
by	O
the	O
SARS	B-DISO
epidemic	O
and	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

There	O
are	O
pathogen	O
-	O
specific	O
pathways	O
underlying	O
virally	O
mediated	O
ALI	O
that	O
converge	O
onto	O
a	O
common	O
end	O
pathway	O
resulting	O
in	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nonstructural	O
proteins	O
3	O
,	O
4	O
,	O
and	O
6	O
induce	O
double	O
-	O
membrane	O
vesicles	B-DISO
.	O

nsp3	O
has	O
membrane	O
disordering	O
and	O
proliferation	B-DISO
ability	O
,	O
both	O
in	O
its	O
full	O
-	O
length	O
form	O
and	O
in	O
a	O
C	O
-	O
terminal	O
-	O
truncated	O
form	O
.	O

nsp6	O
has	O
membrane	O
proliferation	B-DISO
ability	O
as	O
well	O
,	O
inducing	O
perinuclear	O
vesicles	B-DISO
localized	O
around	O
the	O
microtubule	O
organizing	O
center	O
.	O

A	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
complicating	O
a	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
secondary	O
of	O
a	O
major	O
hypertriglyceridemia	O
was	O
mentioned	O
.	O

TITLE	O
:	O
Scrub	B-DISO
typhus	I-DISO
associated	O
acute	O
kidney	O
injury	O
--	O
a	O
study	O
from	O
a	O
tertiary	O
care	O
hospital	O
from	O
western	O
Himalayan	O
State	O
of	O
India	O
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
clinical	O
profile	O
of	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
associated	O
with	O
scrub	B-DISO
typhus	I-DISO
.	O

The	O
complications	O
of	O
hypotension	O
(	O
5	O
.	O
7	O
%),	O
septic	B-DISO
shock	I-DISO
(	O
3	O
.	O
4	O
%),	O
pneumonia	B-DISO
(	O
10	O
.	O
9	O
%),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
11	O
.	O
5	O
%),	O
meningoencephalitis	B-DISO
(	O
6	O
.	O
9	O
%),	O
encephalopathy	B-DISO
(	O
5	O
.	O
2	O
%),	O
gastrointestinal	B-DISO
bleed	I-DISO
(	O
1	O
.	O
3	O
%),	O
myocarditis	B-DISO
(	O
3	O
.	O
4	O
%),	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
2	O
.	O
9	O
%)	O
and	O
multi	B-DISO
organ	I-DISO
failure	I-DISO
(	O
MOF	B-DISO
)	O
(	O
10	O
.	O
3	O
%)	O
developed	O
during	O
course	O
of	O
hospitalization	O
in	O
these	O
patients	O
.	O

We	O
envision	O
the	O
application	O
of	O
ECMO	O
in	O
many	O
other	O
forms	O
of	O
respiratory	B-DISO
failure	I-DISO
in	O
the	O
coming	O
years	O
.	O

Histology	O
revealed	O
severe	O
atrophy	B-DISO
of	O
villi	O
in	O
all	O
segments	O
of	O
the	O
small	O
intestines	O
with	O
occasional	O
villus	O
-	O
epithelial	O
syncytial	O
cells	O
,	O
but	O
testing	O
for	O
rotaviruses	O
and	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
Alphacoronavirus	O
1	O
)	O
were	O
negative	O
.	O

TITLE	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
--	O
how	O
worried	O
should	O
we	O
be	O
?	O

The	O
cultures	O
were	O
susceptible	O
to	O
infection	B-DISO
with	O
different	O
serotype	O
I	O
enteric	O
strains	O
and	O
two	O
of	O
these	O
strains	O
were	O
further	O
propagated	O
.	O

Additionally	O
,	O
the	O
resistance	O
of	O
SARS	B-DISO
-	O
CoV	O
to	O
ribavirin	O
(	O
RBV	O
)	O
demonstrates	O
the	O
need	O
to	O
define	O
new	O
targets	O
for	O
inhibition	O
of	O
CoV	O
replication	O
.	O

Our	O
studies	O
illuminate	O
the	O
viral	O
diversity	O
found	O
in	O
ferrets	O
and	O
provide	O
tools	O
to	O
prescreen	O
for	O
newly	O
identified	O
viruses	O
that	O
potentially	O
could	O
influence	O
disease	O
outcome	O
of	O
experimental	O
virus	O
infections	B-DISO
in	O
ferrets	O
.	O

Early	O
diagnosis	O
of	O
infected	O
patients	O
and	O
appropriate	O
infection	B-DISO
control	O
measures	O
will	O
limit	O
the	O
spread	O
in	O
hospitals	O
,	O
while	O
social	O
distancing	O
strategies	O
may	O
be	O
necessary	O
to	O
control	O
the	O
outbreak	O
in	O
communities	O
if	O
it	O
remained	O
uncontrolled	O
as	O
in	O
the	O
SARS	B-DISO
epidemic	O
.	O

Procedures	O
reported	O
to	O
present	O
an	O
increased	O
risk	O
of	O
SARS	B-DISO
transmission	O
include	O
tracheal	O
intubation	O
,	O
non	O
-	O
invasive	O
ventilation	O
,	O
tracheotomy	O
and	O
manual	O
ventilation	O
before	O
intubation	O
whereas	O
oxygen	O
therapy	O
and	O
bed	B-DISO
distance	O
<	O
1	O
m	O
were	O
also	O
implicated	O
.	O

TITLE	O
:	O
A	O
safe	O
and	O
convenient	O
pseudovirus	O
-	O
based	O
inhibition	O
assay	O
to	O
detect	O
neutralizing	O
antibodies	O
and	O
screen	O
for	O
viral	O
entry	O
inhibitors	O
against	O
the	O
novel	O
human	O
coronavirus	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Evidence	O
points	O
to	O
the	O
emergence	O
of	O
a	O
novel	O
human	O
coronavirus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
causes	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
like	O
disease	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
generated	O
MERS	O
-	O
CoV	O
pseudovirus	O
allows	O
for	O
single	O
-	O
cycle	O
infection	B-DISO
of	O
a	O
variety	O
of	O
cells	O
expressing	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
the	O
confirmed	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Consistent	O
with	O
the	O
results	O
from	O
a	O
live	O
MERS	O
-	O
CoV	O
-	O
based	O
inhibition	O
assay	O
,	O
the	O
antisera	O
of	O
mice	O
vaccinated	O
with	O
a	O
recombinant	O
protein	O
containing	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
,	O
residues	O
377	O
-	O
662	O
)	O
of	O
MERS	O
-	O
CoV	O
S	O
fused	O
with	O
Fc	O
of	O
human	O
IgG	O
exhibited	O
neutralizing	O
antibody	O
response	O
against	O
infection	B-DISO
of	O
MERS	O
-	O
CoV	O
pseudovirus	O
.	O

Furthermore	O
,	O
one	O
small	O
molecule	O
HIV	B-DISO
entry	O
inhibitor	O
targeting	O
gp41	O
(	O
ADS	O
-	O
J1	O
)	O
and	O
the	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
-	O
modified	O
human	O
serum	O
albumin	O
(	O
HP	O
-	O
HSA	B-DISO
)	O
could	O
significantly	O
inhibit	O
MERS	O
-	O
CoV	O
pseudovirus	O
infection	B-DISO
.	O

Emerging	O
evidence	O
for	O
the	O
pathogenic	O
role	O
of	O
microglia	O
and	O
the	O
activation	O
of	O
inflammatory	O
pathways	O
in	O
these	O
cells	O
in	O
MHV	O
infection	B-DISO
supports	O
the	O
concept	O
that	O
microglia	O
induced	O
neuroinflammation	O
is	O
an	O
amplifier	O
of	O
virus	O
-	O
induced	O
neuropathology	B-DISO
.	O

ABSTRACT	O
:	O
Mechanical	O
circulatory	O
support	O
(	O
MCS	B-DISO
)	O
is	O
a	O
rescue	O
therapy	O
for	O
infants	O
and	O
children	O
suffering	B-DISO
from	O
severe	O
cardiorespiratory	B-DISO
failure	I-DISO
with	O
specific	O
system	O
-	O
related	O
complications	O
like	O
bleeding	B-DISO
,	O
thromboembolism	B-DISO
and	O
device	O
failure	O
.	O

Novel	O
circuit	O
components	O
for	O
temporary	O
MCS	B-DISO
with	O
improved	O
haemodynamic	O
properties	O
may	O
improve	O
patients	O
'	O
outcome	O
and	O
reduce	O
system	O
-	O
related	O
morbidities	O
.	O

In	O
this	O
commentary	O
,	O
the	O
authors	O
discuss	O
the	O
rationale	O
,	O
based	O
on	O
the	O
physiologic	O
principle	O
of	O
targeting	O
both	O
vital	O
organs	O
,	O
of	O
applying	O
high	O
-	O
frequency	O
oscillation	O
and	O
tracheal	O
gas	O
insufflation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
with	O
traumatic	O
brain	O
injury	O
.	O

A	O
pharmacoepidemiologic	O
cohort	O
study	O
of	O
patients	O
with	O
sepsis	B-DISO
and	O
a	O
respiratory	B-DISO
infection	I-DISO
who	O
had	O
been	O
admitted	O
to	O
intensive	O
care	O
and	O
placed	O
on	O
mechanical	O
ventilation	O
within	O
the	O
first	O
2	O
days	O
of	O
hospitalization	O
.	O

Venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
vvECMO	O
)	O
is	O
a	O
rescue	O
strategy	O
that	O
may	O
ensure	O
sufficient	O
gas	O
exchange	O
in	O
ARDS	B-DISO
patients	O
failing	O
conventional	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
case	O
series	O
was	O
to	O
describe	O
the	O
feasibility	O
and	O
pitfalls	O
of	O
combining	O
positioning	O
therapy	O
and	O
vvECMO	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
spike	O
protein	O
delivered	O
by	O
modified	O
vaccinia	B-DISO
virus	O
Ankara	O
efficiently	O
induces	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

Despite	O
improvement	O
in	O
current	O
therapies	O
,	O
the	O
clinical	O
course	O
of	O
infants	O
with	O
BPD	B-DISO
is	O
often	O
characterized	O
by	O
marked	O
hypoxemia	O
that	O
can	O
become	O
refractory	O
to	O
therapy	O
.	O

Preacinar	O
anatomic	O
and	O
functional	O
communications	O
between	O
systemic	O
and	O
pulmonary	O
vascular	O
systems	O
has	O
been	O
established	O
in	O
fetal	O
lungs	O
,	O
but	O
whether	O
increased	O
intrapulmonary	O
anastomotic	O
vessels	O
or	O
their	O
failure	O
to	O
regress	O
after	O
birth	O
contributes	O
to	O
hypoxemia	O
in	O
preterm	O
infants	O
with	O
BPD	B-DISO
is	O
unknown	O
.	O

TITLE	O
:	O
Risperidone	O
-	O
induced	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
.	O

Medical	O
ICU	O
and	O
dermatology	O
department	O
of	O
a	O
tertiary	O
care	O
hospital	O
,	O
which	O
hosts	O
the	O
French	O
national	O
referral	O
center	O
for	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
.	O

This	O
study	O
defines	O
the	O
contribution	O
of	O
interleukin	O
(	O
IL	O
)-	O
21	O
,	O
a	O
regulator	O
of	O
T	O
and	O
B	O
cell	O
function	O
,	O
to	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
immunity	O
.	O

Viral	O
control	O
was	O
already	O
lost	O
prior	O
to	O
humoral	O
CNS	O
responses	O
,	O
but	O
demyelination	B-DISO
remained	O
comparable	O
.	O

Fecal	O
samples	O
from	O
each	O
puppy	O
were	O
examined	O
for	O
6	O
gastrointestinal	O
pathogens	O
:	O
parvovirus	B-DISO
type	O
2	O
(	O
CPV2	O
),	O
coronavirus	O
,	O
Toxocara	O
canis	O
,	O
Cystoisospora	O
ohioensis	O
-	O
complex	O
,	O
Cystoisospora	O
canis	O
,	O
and	O
Giardia	B-DISO
intestinalis	O
.	O

The	O
prevalence	O
of	O
trichomonad	O
infection	B-DISO
was	O
15	O
.	O
8	O
%	O
(	O
34	O
/	O
215	O
)	O
among	O
puppies	O
and	O
20	O
%	O
(	O
5	O
/	O
25	O
)	O
among	O
breeding	O
kennels	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
been	O
detected	O
in	O
a	O
number	O
of	O
countries	O
in	O
the	O
Middle	O
East	O
and	O
Europe	O
with	O
an	O
apparently	O
high	O
mortality	O
rate	O
.	O

TITLE	O
:	O
Adenovirus	B-DISO
respiratory	B-DISO
infection	I-DISO
in	O
hospitalized	O
children	O
in	O
Hong	O
Kong	O
:	O
serotype	O
-	O
clinical	O
syndrome	B-DISO
association	O
and	O
risk	O
factors	O
for	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

Children	O
aged	O
1	O
to	O
2	O
years	O
old	O
were	O
the	O
at	O
-	O
risk	O
group	O
for	O
adenovirus	B-DISO
LRTI	B-DISO
,	O
but	O
respiratory	B-DISO
morbidity	I-DISO
was	O
relatively	O
mild	O
in	O
our	O
locality	O
.	O

TITLE	O
:	O
[	O
Evaluating	O
efficiency	O
of	O
influenza	B-DISO
vaccinal	O
prevention	O
among	O
oil	O
and	O
gas	O
industry	O
workers	O
].	O

ABSTRACT	O
:	O
Plasmodium	O
vivax	O
(	O
p	O
.	O
vivax	O
)	O
malaria	B-DISO
was	O
traditionally	O
considered	O
as	O
benign	B-DISO
tertian	I-DISO
malaria	I-DISO
,	O
however	O
,	O
recent	O
studies	O
have	O
pointed	O
out	O
that	O
p	O
.	O
vivax	O
have	O
potential	O
to	O
cause	O
all	O
severe	O
complications	O
previously	O
attributed	O
to	O
p	O
.	O
falciparum	O
infection	B-DISO
only	O
.	O

Severe	O
malaria	B-DISO
was	O
defined	O
as	O
per	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
.	O

TITLE	O
:	O
Lung	O
ventilation	O
strategies	O
and	O
regional	O
lung	B-DISO
inflammation	I-DISO
.	O

ABSTRACT	O
:	O
This	O
article	O
introduces	O
a	O
series	O
of	O
invited	O
papers	O
in	O
Antiviral	O
Research	O
marking	O
the	O
10th	O
anniversary	O
of	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
emerged	O
in	O
southern	O
China	O
in	O
late	O
2002	O
.	O

Our	O
results	O
identify	O
high	O
-	O
molecular	O
weight	O
γ	O
-	O
PGA	B-DISO
as	O
a	O
TLR4	O
ligand	O
and	O
demonstrate	O
that	O
γ	O
-	O
PGA	B-DISO
requires	O
both	O
CD14	O
and	O
MD2	O
for	O
the	O
activation	O
of	O
type	O
I	O
IFN	O
responses	O
.	O

EVLWI	O
increases	O
when	O
H7N9	O
avian	B-DISO
influenza	I-DISO
patients	O
are	O
complicated	O
with	O
severe	O
ARDS	B-DISO
.	O

There	O
is	O
relevance	O
between	O
the	O
motive	O
changes	O
in	O
EVLWI	O
and	O
severity	O
of	O
ARDS	B-DISO
and	O
pulmonary	O
oxygenation	O
.	O

None	O
of	O
the	O
cells	O
were	O
sensitive	O
to	O
infection	B-DISO
by	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
porcine	O
coronavirus	O
,	O
or	O
to	O
infection	B-DISO
mediated	O
by	O
the	O
Spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
incorporated	O
into	O
pseudotypes	O
based	O
on	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
).	O

These	O
results	O
indicate	O
that	O
bat	O
cells	O
are	O
more	O
resistant	O
to	O
infection	B-DISO
by	O
coronaviruses	O
than	O
to	O
infection	B-DISO
by	O
paramyxoviruses	O
,	O
filoviruses	O
and	O
influenza	B-DISO
viruses	O
.	O

TITLE	O
:	O
Incidence	O
and	O
outcomes	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
lung	O
transplant	O
recipients	O
:	O
a	O
prospective	O
study	O
.	O

Patients	O
were	O
seen	O
in	O
three	O
contexts	O
:	O
study	O
-	O
specific	O
screenings	O
covering	O
all	O
seasons	O
;	O
routine	O
post	O
-	O
transplantation	O
follow	O
-	O
up	O
;	O
and	O
emergency	B-DISO
visits	O
.	O

The	O
viral	B-DISO
infection	I-DISO
rates	O
upon	O
screening	O
,	O
routine	O
and	O
emergency	B-DISO
visits	O
were	O
14	O
%,	O
15	O
%	O
and	O
34	O
%,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
in	O
supine	O
position	O
,	O
there	O
is	O
a	O
decrease	O
of	O
inflation	O
along	O
the	O
sternum	O
vertebral	O
axis	O
,	O
up	O
to	O
lung	B-DISO
collapse	I-DISO
.	O

This	O
is	O
associated	O
with	O
oxygenation	O
improvement	O
as	O
the	O
dorsal	O
recruitment	B-DISO
,	O
for	O
anatomical	O
reasons	O
,	O
prevails	O
on	O
the	O
ventral	O
de	O
-	O
recruitment	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
with	O
as	O
yet	O
unclear	O
epidemiology	O
.	O

To	O
test	O
for	O
conservation	O
of	O
nsp5	O
structure	O
-	O
function	O
determinants	O
,	O
we	O
engineered	O
chimeric	O
betacoronavirus	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
genomes	O
encoding	O
nsp5	O
proteases	O
of	O
human	O
and	O
bat	O
alphacoronaviruses	O
and	O
betacoronaviruses	O
.	O

ABSTRACT	O
:	O
In	O
lung	O
transplant	O
recipients	O
(	O
LTRs	O
),	O
severe	O
clinical	O
complications	O
,	O
such	O
as	O
microbial	O
infections	B-DISO
of	O
the	O
lung	O
or	O
transplant	O
rejection	O
,	O
may	O
occur	O
.	O

Plasma	O
SP	O
-	O
D	O
levels	O
are	O
usually	O
low	O
,	O
but	O
may	O
increase	O
when	O
the	O
lung	O
-	O
blood	O
barrier	O
is	O
impaired	B-DISO
.	O

An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
used	O
to	O
measure	O
SP	O
-	O
D	O
levels	O
in	O
plasma	O
samples	O
from	O
58	O
LTRs	O
during	O
intervals	O
without	O
pathologic	O
respiratory	O
findings	O
and	O
during	O
episodes	O
of	O
acute	O
cellular	O
rejection	O
(	O
ACR	O
),	O
microbial	B-DISO
colonization	I-DISO
,	O
and	O
microbial	O
pneumonia	B-DISO
.	O

salbutamol	O
early	O
in	O
the	O
course	O
of	O
ARDS	B-DISO
was	O
poorly	O
tolerated	O
,	O
is	O
unlikely	O
to	O
be	O
beneficial	O
and	O
could	O
worsen	O
outcomes	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
rescue	O
therapy	O
in	O
a	O
case	O
of	O
portopulmonary	B-DISO
hypertension	I-DISO
during	O
liver	O
transplantation	O
:	O
a	O
case	O
report	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
scheduled	O
for	O
OLT	O
due	O
to	O
alcoholic	B-DISO
cirrhosis	I-DISO
with	O
hemosiderosis	B-DISO
.	O

At	O
the	O
beginning	O
of	O
the	O
OLT	O
the	O
hemodynamic	O
profile	O
showed	O
mean	O
pulmonary	O
artery	O
pressure	O
(	O
mPAP	O
)	O
38	O
mm	O
Hg	O
,	O
wedge	O
pressure	O
(	O
WP	O
)	O
19	O
mm	O
Hg	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
9	O
.	O
1	O
L	O
/	O
min	O
,	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	B-DISO
)	O
166	O
dyne	O
s	O
/	O
cm	O
(	O
5	O
),	O
transpulmonary	O
gradient	O
(	O
TPG	O
)	O
19	O
mm	O
Hg	O
,	O
which	O
lead	O
us	O
to	O
promptly	O
initiate	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
and	O
intravenous	O
epoprostenol	O
2	O
to	O
5	O
ng	O
/	O
kg	O
/	O
min	O
.	O

TITLE	O
:	O
Vaccination	O
of	O
healthcare	O
workers	O
to	O
protect	O
patients	O
at	O
increased	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
:	O
summary	O
of	O
a	O
systematic	O
review	O
.	O

Further	O
mechanistic	O
analyses	O
reveal	O
that	O
knockdown	O
of	O
LIMK1	O
or	O
SSH	O
-	O
1L	O
each	O
attenuates	O
nuclear	O
translocation	B-DISO
and	O
thereby	O
DNA	O
binding	O
of	O
RelA	O
/	O
p65	O
.	O

TITLE	O
:	O
Detection	O
and	O
differentiation	O
of	O
Newcastle	B-DISO
disease	I-DISO
virus	O
and	O
influenza	B-DISO
virus	O
by	O
using	O
duplex	O
real	O
-	O
time	O
PCR	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
non	O
-	O
SARS	B-DISO
)-	O
related	O
human	O
coronaviruses	O
(	O
HCoVs	O
),	O
including	O
HCoV	O
-	O
229E	O
,	O
-	O
HKU1	O
,	O
-	O
NL63	O
,	O
and	O
-	O
OC43	O
,	O
have	O
been	O
detected	O
in	O
respiratory	O
tract	O
samples	O
from	O
children	O
and	O
adults	O
.	O

To	O
measure	O
antibodies	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
four	O
common	O
non	O
-	O
SARS	B-DISO
HCoVs	O
,	O
recombinant	O
S	O
proteins	O
of	O
the	O
four	O
HCoVs	O
were	O
expressed	O
and	O
characterised	O
in	O
293	O
T	O
cell	O
.	O

Large	O
proportions	O
of	O
children	O
and	O
adults	O
in	O
Beijing	O
have	O
evidence	O
of	O
anti	O
-	O
S	O
IgG	O
against	O
four	O
the	O
HCoVs	O
,	O
and	O
first	O
infections	B-DISO
by	O
all	O
four	O
non	O
-	O
SARS	B-DISO
HCoVs	O
takes	O
place	O
during	O
childhood	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
is	O
the	O
major	O
viral	O
attachment	O
protein	O
of	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
ultimately	O
determines	O
viral	O
tropism	O
.	O

TITLE	O
:	O
Risks	O
and	O
benefits	O
of	O
late	O
onset	O
hypogonadism	B-DISO
treatment	O
:	O
an	O
expert	O
opinion	O
.	O

In	O
addition	O
,	O
TRT	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
bone	O
mineral	O
density	O
in	O
men	O
with	O
osteoporosis	B-DISO
,	O
with	O
an	O
improvement	O
in	O
lean	O
body	O
mass	O
in	O
subjects	O
with	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
infection	I-DISO
or	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
,	O
as	O
well	O
as	O
with	O
peripheral	O
oxygenation	O
in	O
patients	O
with	O
chronic	B-DISO
kidney	I-DISO
diseases	I-DISO
.	O

The	O
following	O
characteristics	O
(	O
or	O
predictors	O
)	O
were	O
compared	O
between	O
the	O
groups	O
:	O
age	O
,	O
sex	O
,	O
calculated	O
amount	O
of	O
glufosinate	O
(	O
volume	O
of	O
ingested	O
poison	O
(	O
glufosinate	O
-	O
containing	O
herbicide	O
)	O
×	O
glufosinate	O
concentration	O
of	O
the	O
product	O
),	O
time	O
duration	O
from	O
poison	O
ingestion	O
to	O
arrival	O
at	O
our	O
hospital	O
,	O
use	O
of	O
gastric	O
lavage	O
,	O
use	O
of	O
whole	O
bowel	O
irrigation	O
,	O
Glasgow	O
Coma	B-DISO
Scale	O
,	O
laboratory	O
parameters	O
,	O
PaO₂	O
/	O
FiO₂	O
ratio	O
(	O
P	O
/	O
F	O
ratio	O
),	O
shock	O
index	O
,	O
and	O
presence	O
or	O
absence	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
on	O
arrival	O
.	O

Deletion	O
of	O
the	O
3c	O
gene	O
could	O
therefore	O
cause	O
more	O
efficient	O
viral	O
replication	O
,	O
which	O
leads	O
to	O
a	O
fatal	O
infection	B-DISO
.	O

It	O
is	O
apparent	O
from	O
the	O
recent	O
experiences	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
influenza	B-DISO
that	O
healthcare	O
workers	O
may	O
have	O
difficulty	O
in	O
choosing	O
the	O
correct	O
type	O
of	O
facial	O
and	O
respiratory	O
protection	O
in	O
any	O
given	O
clinical	O
situation	O
.	O

ABSTRACT	O
:	O
Since	O
June	O
,	O
2012	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
,	O
worldwide	O
,	O
caused	O
104	O
infections	B-DISO
in	O
people	O
including	O
49	O
deaths	O
,	O
with	O
82	O
cases	O
and	O
41	O
deaths	O
reported	O
from	O
Saudi	O
Arabia	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
ability	O
of	O
NetMHCpan	O
to	O
predict	O
antiviral	O
CD8	O
(+)	O
T	O
cell	O
epitopes	O
that	O
we	O
identified	O
with	O
a	O
traditional	O
approach	O
in	O
patients	O
of	O
Asian	O
ethnicity	O
infected	O
with	O
Dengue	B-DISO
virus	O
,	O
hepatitis	B-DISO
B	I-DISO
virus	O
,	O
or	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

In	O
conclusion	O
,	O
the	O
alarmin	O
cytokine	O
IL	O
-	O
33	O
was	O
over	O
-	O
expressed	O
during	O
fulminant	B-DISO
hepatitis	I-DISO
in	O
mice	O
with	O
LSEC	O
,	O
VEC	O
and	O
hepatocytes	O
as	O
potential	O
sources	O
of	O
IL	O
-	O
33	O
.	O

Interestingly	O
,	O
increased	O
expression	O
of	O
genes	O
involved	O
in	O
lipid	O
transport	O
,	O
processing	O
,	O
and	O
catabolism	O
,	O
including	O
some	O
with	O
known	O
roles	O
in	O
neurodegenerative	B-DISO
diseases	I-DISO
,	O
coincided	O
with	O
demyelination	B-DISO
.	O

The	O
availability	O
of	O
an	O
animal	B-DISO
disease	I-DISO
model	O
is	O
essential	O
for	O
understanding	O
pathogenesis	B-DISO
and	O
developing	O
effective	O
countermeasures	O
.	O

MERS	O
-	O
CoV	O
caused	O
a	O
multifocal	O
,	O
mild	O
to	O
marked	O
interstitial	B-DISO
pneumonia	I-DISO
,	O
with	O
virus	O
replication	O
occurring	O
mainly	O
in	O
alveolar	O
pneumocytes	O
.	O

The	O
aberrant	O
induction	O
of	O
inflammatory	O
cytokines	O
/	O
chemokines	O
could	O
be	O
important	O
in	O
the	O
disease	O
pathogenesis	B-DISO
.	O

Clinical	O
signs	O
of	O
depression	B-DISO
,	O
huddling	O
,	O
and	O
lack	O
of	O
uniform	O
size	O
were	O
observed	O
in	O
the	O
challenged	O
group	O
but	O
not	O
in	O
the	O
control	O
group	O
.	O

It	O
is	O
known	O
that	O
the	O
surface	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
coronaviruses	O
mediate	O
receptor	O
recognition	O
and	O
membrane	O
fusion	O
,	O
thereby	O
playing	O
an	O
indispensable	O
role	O
in	O
initiating	O
infection	B-DISO
.	O

This	O
study	O
reveals	O
for	O
the	O
first	O
time	O
that	O
the	O
mortality	O
of	O
H1N1	O
infection	B-DISO
in	O
Germany	O
is	O
comparable	O
to	O
that	O
in	O
other	O
countries	O
.	O

Incidences	O
of	O
pneumonia	B-DISO
,	O
atelectasis	B-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
were	O
assessed	O
.	O

Incidence	O
of	O
infections	B-DISO
,	O
sepsis	B-DISO
,	O
and	O
respiratory	O
parameters	O
were	O
recorded	O
.	O

Furthermore	O
,	O
incidence	O
of	O
infection	B-DISO
and	O
sepsis	B-DISO
were	O
significantly	O
higher	O
in	O
the	O
high	O
group	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

Effusion	B-DISO
specimens	O
were	O
collected	O
antemortem	O
from	O
17	O
cats	O
and	O
tested	O
by	O
DIF	O
,	O
followed	O
by	O
postmortem	O
examination	O
.	O

In	O
the	O
seven	O
cats	O
where	O
FIP	B-DISO
was	O
ruled	O
out	O
at	O
postmortem	O
examination	O
,	O
DIF	O
was	O
negative	O
in	O
five	O
cases	O
and	O
positive	O
in	O
the	O
remaining	O
two	O
cases	O
.	O

Duplicate	O
effusion	B-DISO
specimens	O
from	O
eight	O
cats	O
that	O
were	O
initially	O
DIF	O
positive	O
were	O
stored	O
refrigerated	O
(	O
4	O
°	O
C	O
)	O
or	O
at	O
room	O
temperature	O
(	O
22	O
-	O
25	O
°	O
C	O
)	O
and	O
subjected	O
to	O
serial	O
DIF	O
testing	O
to	O
determine	O
the	O
duration	O
of	O
positive	O
results	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
novel	O
spike	O
pseudoparticle	O
neutralisation	O
assay	O
(	O
ppNT	O
)	O
for	O
seroepidemiological	O
studies	O
on	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERSCoV	O
)	O
and	O
apply	O
this	O
assay	O
together	O
with	O
conventional	O
microneutralisation	O
(	O
MN	O
)	O
tests	O
to	O
investigate	O
1	O
,	O
343	O
human	O
and	O
625	O
animal	O
sera	O
.	O

It	O
is	O
possible	O
that	O
both	O
autoimmune	B-DISO
and	O
nonimmune	O
mechanisms	O
such	O
as	O
direct	O
viral	O
toxicity	O
may	O
induce	O
MS	O
.	O

Inflammation	B-DISO
was	O
restricted	O
mainly	O
to	O
white	O
matter	O
at	O
all	O
times	O
in	O
EAE	O
,	O
whereas	O
inflammation	B-DISO
initially	O
largely	O
involved	O
gray	O
matter	O
in	O
acute	O
MHV	O
-	O
induced	O
disease	O
and	O
then	O
is	O
subsequently	O
localized	O
only	O
in	O
white	O
matter	O
in	O
the	O
chronic	B-DISO
disease	I-DISO
phase	O
.	O

Despite	O
clear	O
demonstration	O
of	O
its	O
selective	O
and	O
potent	O
pulmonary	O
vasodilator	O
properties	O
,	O
inhaled	O
NO	O
therapy	O
has	O
only	O
been	O
formally	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicine	O
Evaluation	O
Agency	O
for	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
term	O
and	O
near	O
-	O
term	O
infants	O
with	O
severe	O
persistent	B-DISO
pulmonary	I-DISO
hypertension	I-DISO
of	I-DISO
the	I-DISO
newborn	I-DISO
(	O
PPHN	O
)	O
with	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Other	O
viral	B-DISO
pneumonias	I-DISO
:	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	B-DISO
,	O
hantavirus	O
.	O

ABSTRACT	O
:	O
Viruses	O
are	O
a	O
common	O
and	O
important	O
cause	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
and	O
may	O
lead	O
to	O
severe	O
respiratory	B-DISO
disease	I-DISO
and	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

Our	O
previous	O
studies	O
have	O
demonstrated	O
that	O
TGEV	O
infection	B-DISO
induces	O
the	O
activation	O
of	O
p53	O
signaling	O
pathway	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
infection	B-DISO
induced	I-DISO
cell	O
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
in	O
both	O
asynchronous	O
and	O
synchronized	O
PK	O
-	O
15	O
and	O
ST	O
cells	O
,	O
while	O
UV	O
-	O
inactivated	O
TGEV	O
lost	O
the	O
ability	O
of	O
induction	O
of	O
cell	O
cycle	O
arrest	O
.	O

Influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
syndrome	B-DISO
(	O
ILI	O
)	O
was	O
significantly	O
associated	O
with	O
a	O
VRTI	O
if	O
compared	O
to	O
other	O
presentations	O
(	O
42	O
%),	O
while	O
the	O
European	O
Centre	O
for	O
Disease	O
Prevention	O
and	O
Control	O
definition	O
was	O
not	O
(	O
30	O
%).	O

Influenza	B-DISO
and	O
RSV	O
peak	O
periods	O
were	O
contemporary	O
.	O

Angiography	O
uncovered	O
a	O
saccular	B-DISO
aneurysm	I-DISO
of	O
3	O
mm	O
at	O
the	O
end	O
of	O
branch	O
artery	O
of	O
right	O
anterior	O
cerebral	O
artery	O
,	O
Heubner	O
artery	O
,	O
28	O
days	O
after	O
the	O
admission	O
.	O

ABSTRACT	O
:	O
Chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
is	O
characterized	O
by	O
chronic	O
airway	O
inflammation	B-DISO
and	O
/	O
or	O
airflow	O
limitation	O
due	O
to	O
pulmonary	B-DISO
emphysema	I-DISO
.	O

Similar	O
pathogens	O
,	O
including	O
human	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
and	O
coronavirus	O
,	O
are	O
also	O
frequently	O
detected	O
during	O
exacerbation	O
of	O
asthma	B-DISO
and	O
/	O
or	O
COPD	B-DISO
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
biology	O
of	O
the	O
emerging	O
human	O
group	O
c	O
betacoronavirus	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
as	O
an	O
avian	O
coronavirus	O
is	O
still	O
posing	O
a	O
persistent	O
and	O
imminent	O
threat	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
the	O
Berlin	O
definition	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
during	O
infancy	O
and	O
early	O
childhood	O
:	O
multicenter	O
evaluation	O
and	O
expert	O
consensus	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
influenza	B-DISO
-	O
like	O
illnesses	O
during	O
the	O
influenza	B-DISO
season	O
between	O
December	O
2011	O
and	O
April	O
2012	O
.	O

Patients	O
with	O
RSV	O
were	O
significantly	O
younger	O
whereas	O
children	O
infected	O
with	O
the	O
influenza	B-DISO
viruses	O
were	O
significantly	O
older	O
.	O

TITLE	O
:	O
Acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
occurring	O
in	O
a	O
dedicator	O
of	O
cytokinesis	O
8	O
(	O
DOCK8	O
)	O
deficient	O
patient	O
.	O

Investigation	O
of	O
genomic	O
DNA	O
by	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	B-DISO
(	O
MLPA	O
)	O
revealed	O
a	O
heterozygous	O
large	O
deletion	O
of	O
77	O
kb	O
spanning	O
from	O
intron	O
5	O
to	O
exon	O
22	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
that	O
first	O
appeared	O
in	O
Saudi	O
Arabia	O
during	O
the	O
summer	O
of	O
2012	O
has	O
to	O
date	O
(	O
20th	O
September	O
2013	O
)	O
caused	O
58	O
human	O
deaths	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
infection	B-DISO
screening	O
system	O
for	O
entry	O
inspection	O
at	O
airport	O
quarantine	O
stations	O
using	O
ear	O
temperature	O
,	O
heart	O
and	O
respiration	O
rates	O
.	O

In	O
order	O
to	O
implement	O
more	O
strict	O
entry	O
screening	O
in	O
the	O
epidemic	O
seasons	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
we	O
developed	O
an	O
infection	B-DISO
screening	O
system	O
for	O
airport	O
quarantines	O
using	O
multi	O
-	O
parameter	O
vital	O
signs	O
.	O

The	O
sensitivity	O
of	O
the	O
infection	B-DISO
screening	O
system	O
in	O
detecting	O
influenza	B-DISO
were	O
92	O
.	O
3	O
%,	O
which	O
was	O
higher	O
than	O
the	O
sensitivity	O
reported	O
in	O
our	O
previous	O
paper	O
(	O
88	O
.	O
0	O
%)	O
with	O
average	O
facial	O
skin	O
temperature	O
.	O

After	O
five	O
rounds	O
of	O
biopanning	O
,	O
five	O
phage	O
clones	O
showed	O
specific	O
binding	O
affinities	O
to	O
rpAPN	O
-	O
C	O
.	O
In	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assays	O
,	O
the	O
phage	O
clone	O
PM1	O
,	O
which	O
contained	O
the	O
HDAISWTHYHPW	O
peptide	O
sequence	O
,	O
had	O
a	O
protective	O
effect	O
against	O
TGEV	O
infection	B-DISO
in	O
swine	O
testis	O
cells	O
.	O

TITLE	O
:	O
An	O
attempt	O
to	O
validate	O
the	O
modification	O
of	O
the	O
American	O
-	O
European	O
consensus	O
definition	O
of	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
by	O
the	O
Berlin	O
definition	O
in	O
a	O
university	O
hospital	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
(	O
1	O
)	O
the	O
prevalence	O
and	O
incidence	O
of	O
ARDS	B-DISO
with	O
both	O
definitions	O
,	O
and	O
(	O
2	O
)	O
the	O
initial	O
characteristics	O
of	O
patients	O
with	O
ARDS	B-DISO
and	O
28	O
-	O
day	O
mortality	O
with	O
the	O
Berlin	O
definition	O
.	O

Patients	O
under	O
invasive	O
or	O
noninvasive	O
mechanical	O
ventilation	O
,	O
with	O
PaO2	O
/	O
FiO2	O
<	O
300	O
mmHg	O
regardless	O
of	O
the	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
level	O
,	O
and	O
acute	O
onset	O
of	O
new	O
or	O
increased	O
bilateral	O
infiltrates	B-DISO
or	O
opacities	B-DISO
on	O
chest	O
X	O
-	O
ray	O
were	O
screened	O
from	O
ICU	O
admission	O
up	O
to	O
discharge	O
.	O

TITLE	O
:	O
Children	O
with	O
multiple	O
viral	O
respiratory	B-DISO
infections	I-DISO
are	O
older	O
than	O
those	O
with	O
single	O
viruses	O
.	O

Routine	O
laboratory	O
examinations	O
have	O
not	O
detected	O
any	O
pathogen	O
related	O
to	O
this	O
syndrome	B-DISO
.	O

Furthermore	O
,	O
we	O
wanted	O
to	O
evaluate	O
macroscopic	O
and	O
microscopic	O
findings	O
associated	O
with	O
these	O
outbreaks	O
and	O
if	O
possible	O
propose	O
a	O
preliminary	O
piglet	O
-	O
level	O
case	O
-	O
definition	O
on	O
syndrome	B-DISO
New	O
Neonatal	O
Porcine	O
Diarrhoea	B-DISO
syndrome	B-DISO
(	O
NNPDS	O
).	O

Based	O
on	O
the	O
findings	O
in	O
the	O
four	O
herds	O
the	O
following	O
case	O
-	O
definition	O
of	O
NNPDS	O
was	O
suggested	O
:	O
Non	O
-	O
haemorrhagic	B-DISO
diarrhoea	I-DISO
during	O
the	O
first	O
week	O
of	O
life	O
,	O
without	O
detection	O
of	O
known	O
infectious	B-DISO
pathogens	O
,	O
characterized	O
by	O
milk	O
-	O
filled	O
stomachs	O
and	O
flaccid	O
intestines	O
at	O
necropsy	O
.	O

Spokespersons	O
of	O
health	O
and	O
medical	O
institutions	O
play	O
an	O
important	O
role	O
in	O
media	O
relations	O
during	O
the	O
crisis	O
of	O
a	O
newly	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
.	O

We	O
report	O
the	O
case	O
of	O
a	O
20	O
-	O
year	O
-	O
old	O
man	O
with	O
mandibuloacral	B-DISO
dysplasia	I-DISO
,	O
an	O
extremely	O
rare	O
premature	B-DISO
ageing	I-DISO
syndrome	I-DISO
,	O
and	O
severe	O
symptomatic	B-DISO
aortic	I-DISO
stenosis	I-DISO
,	O
referred	O
to	O
our	O
center	O
for	O
TAVI	O
after	O
being	O
considered	O
unsuitable	O
for	O
surgical	O
aortic	O
valve	O
replacement	O
.	O

Severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
that	O
did	O
not	O
respond	O
to	O
optimal	O
conventional	O
treatment	O
led	O
us	O
to	O
employ	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
spike	O
protein	O
:	O
cutting	O
enzymes	O
at	O
the	O
cutting	O
edge	O
of	O
antiviral	O
research	O
.	O

The	O
activity	O
of	O
host	O
cell	O
proteases	O
,	O
which	O
cleave	O
and	O
activate	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
is	O
essential	O
for	O
viral	O
infectivity	O
and	O
constitutes	O
a	O
target	O
for	O
intervention	O
.	O

TITLE	O
:	O
Prospective	O
evaluation	O
for	O
respiratory	O
pathogens	O
in	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
and	O
acute	O
respiratory	O
illness	O
.	O

ABSTRACT	O
:	O
A	O
class	O
of	O
tripeptidyl	O
transition	B-DISO
state	O
inhibitors	O
containing	O
a	O
P1	O
glutamine	O
surrogate	O
,	O
a	O
P2	O
leucine	O
,	O
and	O
a	O
P3	O
arylalanines	O
,	O
was	O
found	O
to	O
potently	O
inhibit	O
Norwalk	O
virus	O
replication	O
in	O
enzyme	O
and	O
cell	O
based	O
assays	O
.	O

Two	O
patients	O
survived	O
to	O
hospital	O
-	O
discharge	O
(	O
duration	O
of	O
ECMO	O
support	O
:	O
8	O
.	O
5	O
days	O
)	O
and	O
one	O
patient	O
died	O
from	O
nosocomial	O
sepsis	B-DISO
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
after	O
40	O
days	O
of	O
ECMO	O
support	O
.	O

Two	O
patients	O
survived	O
to	O
hospital	O
-	O
discharge	O
(	O
duration	O
of	O
ECMO	O
support	O
:	O
8	O
.	O
5	O
days	O
)	O
and	O
one	O
patient	O
died	O
from	O
nosocomial	O
sepsis	B-DISO
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
after	O
40	O
days	O
of	O
ECMO	O
support	O
.	O

Even	O
in	O
prepubescent	O
children	O
,	O
the	O
presentation	O
of	O
acute	B-DISO
pneumonia	I-DISO
or	O
chronic	B-DISO
diseases	I-DISO
mimics	O
the	O
adult	O
pattern	O
.	O

The	O
similarities	O
observed	O
between	O
males	O
and	O
Turner	B-DISO
syndrome	I-DISO
patients	O
using	O
an	O
endotoxin	O
stimulation	O
model	O
support	O
the	O
difference	O
in	O
gene	O
expression	O
between	O
monosomy	B-DISO
and	O
disomy	O
for	O
the	O
X	O
chromosome	O
.	O

Considering	O
the	O
enhanced	O
inflammation	B-DISO
in	O
females	O
,	O
cytokine	O
production	O
may	O
be	O
assumed	O
to	O
be	O
higher	O
in	O
females	O
than	O
males	O
.	O

There	O
were	O
209	O
samples	O
(	O
59	O
.	O
9	O
%)	O
of	O
the	O
349	O
NPA	O
specimens	O
were	O
positive	O
for	O
viruses	O
,	O
which	O
included	O
117	O
cases	O
positive	O
for	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
60	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
20	O
for	O
influenza	B-DISO
virus	O
A	O
(	O
Inf	O
A	O
),	O
10	O
for	O
adenovirus	B-DISO
(	O
ADV	O
),	O
6	O
for	O
parainfluenza	B-DISO
virus	O
type	O
3	O
(	O
PIV	O
-	O
3	O
),	O
6	O
for	O
human	O
Boca	B-DISO
virus	O
(	O
HBoV	O
),	O
5	O
for	O
influenza	B-DISO
virus	O
C	O
(	O
Inf	O
C	O
),	O
4	O
for	O
parainfluenza	B-DISO
virus	O
type	O
4	O
(	O
PIV	O
-	O
4	O
),	O
4	O
for	O
human	O
coronavirus	O
-	O
HKU1	O
/	O
OC43	O
,	O
3	O
for	O
influenza	B-DISO
virus	O
B	O
(	O
Inf	O
B	O
),	O
3	O
for	O
WU	O
Polyomavirus	O
(	O
WUPyV	O
),	O
2	O
parainfluenza	B-DISO
virus	O
type	O
1	O
(	O
PIV	O
-	O
1	O
),	O
2	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
and	O
1	O
human	O
coronavirus	O
-	O
NL63	O
/	O
229E	O
.	O

Among	O
the	O
130	O
CSF	O
specimens	O
,	O
in	O
58	O
cases	O
the	O
diagnosis	O
was	O
viral	B-DISO
encephalitis	I-DISO
.	O

There	O
were	O
22	O
samples	O
(	O
37	O
.	O
9	O
%)	O
among	O
the	O
58	O
CSF	O
specimens	O
positive	O
for	O
viruses	O
,	O
which	O
included	O
14	O
enterovirus	O
(	O
EV	O
),	O
3	O
human	O
cytomegalovirus	O
(	O
HCMV	O
),	O
2	O
mumps	B-DISO
virus	O
,	O
1	O
coxsackie	B-DISO
virus	I-DISO
A16	O
(	O
Cox	O
-	O
A16	O
),	O
1	B-DISO
herpes	I-DISO
simplex	I-DISO
virus	O
(	O
HSV	O
)	O
and	O
1	O
human	O
rhinovirus	O
(	O
HRV	O
).	O

Our	O
objective	O
was	O
to	O
determine	O
whether	O
nitric	O
oxide	O
reduces	O
hospital	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PaO2	O
/	O
FIO2	O
≤	O
100	O
mm	O
Hg	O
)	O
but	O
not	O
in	O
patients	O
with	O
mild	O
-	O
moderate	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
100	O
<	O
PaO2	O
/	O
FIO2	O
≤	O
300	O
mm	O
Hg	O
)	O
at	O
the	O
time	O
of	O
randomization	O
.	O

ABSTRACT	O
:	O
In	O
the	O
prone	O
position	O
,	O
computed	O
tomography	O
scan	O
densities	O
redistribute	O
from	O
dorsal	O
to	O
ventral	O
as	O
the	O
dorsal	O
region	O
tends	O
to	O
reexpand	O
while	O
the	O
ventral	O
zone	O
tends	O
to	O
collapse	B-DISO
.	O

ABSTRACT	O
:	O
In	O
neonatal	O
rodents	O
,	O
a	O
loss	O
of	O
brain	O
stem	O
serotonin	O
[	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
)]	O
in	O
utero	O
or	O
at	O
birth	O
compromises	O
anoxia	B-DISO
-	O
induced	O
gasping	B-DISO
and	O
the	O
recovery	O
of	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
breathing	O
with	O
reoxygenation	O
(	O
i	O
.	O
e	O
.,	O
autoresuscitation	O
).	O

TITLE	O
:	O
Calcium	O
signaling	O
-	O
related	O
proteins	O
are	O
associated	O
with	O
broncho	O
-	O
pulmonary	O
dysplasia	B-DISO
progression	O
.	O

To	O
build	O
up	O
new	O
therapeutic	O
strategies	O
for	O
BPD	B-DISO
babies	O
,	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
pathogenic	O
mechanisms	O
,	O
which	O
are	O
complicated	O
by	O
environmental	O
risk	O
factors	O
and	O
genetic	O
predisposition	O
.	O

We	O
confirmed	O
that	O
gestational	O
age	O
is	O
relevant	O
for	O
BPD	B-DISO
progression	O
,	O
but	O
we	O
also	O
detected	O
few	O
de	O
-	O
regulated	O
proteins	O
in	O
the	O
younger	O
babies	O
;	O
we	O
discovered	O
less	O
abundant	O
calcium	O
signaling	O
-	O
related	O
proteins	O
,	O
consistent	O
with	O
BPD	B-DISO
severity	O
,	O
comparing	O
severe	O
to	O
mild	O
BPD	B-DISO
babies	O
with	O
matched	O
gestational	O
age	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
suggests	O
a	O
subset	O
of	O
proteins	O
to	O
be	O
investigated	O
to	O
better	O
treat	O
BPD	B-DISO
babies	O
and	O
facilitate	O
the	O
definition	O
of	O
potential	O
drug	O
targets	O
for	O
novel	O
therapies	O
.	O

Using	O
a	O
proteomic	O
-	O
based	O
approach	O
we	O
compared	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
protein	O
profile	O
from	O
preterm	O
neonates	O
at	O
different	O
postmenstrual	O
ages	O
,	O
to	O
have	O
a	O
molecular	O
description	O
of	O
broncho	O
-	O
pulmonary	O
dysplasia	B-DISO
(	O
BPD	B-DISO
)	O
progression	O
.	O

BALF	O
provided	O
a	O
snapshot	O
of	O
local	O
molecular	O
changes	O
,	O
which	O
are	O
relevant	O
for	O
early	O
diagnosis	O
,	O
assessment	O
and	O
characterization	O
of	O
lung	B-DISO
disorders	I-DISO
.	O

We	O
showed	O
that	O
even	O
if	O
the	O
studied	O
patients	O
had	O
similar	O
clinical	O
phenotype	O
(	O
they	O
all	O
developed	O
severe	O
BPD	B-DISO
and	O
they	O
were	O
all	O
cured	O
in	O
the	O
same	O
way	O
in	O
terms	O
of	O
mechanical	O
ventilation	O
,	O
surfactant	O
administration	O
,	O
antenatal	O
steroid	O
treatment	O
and	O
ibuprofen	O
treatment	O
for	O
patent	B-DISO
ductus	I-DISO
arteriosus	I-DISO
),	O
however	O
their	O
BALF	O
protein	O
profiling	O
displayed	O
significant	O
differences	O
in	O
a	O
subset	O
of	O
proteins	O
,	O
which	O
could	O
be	O
exploited	O
to	O
facilitate	O
the	O
development	O
of	O
novel	O
effective	O
therapies	O
,	O
distinct	O
for	O
age	O
and	O
severity	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Although	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
(	O
IAH	O
)	O
and	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
are	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
among	O
critically	B-DISO
ill	I-DISO
adults	O
,	O
it	O
remains	O
unknown	O
if	O
prevention	O
or	O
treatment	O
of	O
these	O
conditions	O
improves	O
patient	O
outcomes	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
-	O
alga	O
-	O
derived	O
lectin	O
that	O
binds	O
the	O
terminal	O
mannose	O
residues	O
of	O
N	O
-	O
linked	O
glycans	O
found	O
on	O
the	O
surface	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
),	O
HIV	B-DISO
-	O
2	O
,	O
and	O
other	O
enveloped	O
viruses	O
,	O
including	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
Ebola	O
virus	O
.	O

We	O
also	O
discuss	O
drivers	O
and	O
forces	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
emergence	O
and	O
describe	O
various	O
existing	O
and	O
potential	O
approaches	O
for	O
control	O
and	O
prevention	O
of	O
such	O
infections	B-DISO
at	O
individual	O
,	O
populational	O
,	O
and	O
societal	O
levels	O
.	O

In	O
all	O
cell	O
types	O
,	O
structures	O
novel	O
to	O
IBV	O
infection	B-DISO
were	O
identified	O
that	O
we	O
have	O
termed	O
zippered	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
spherules	O
.	O

TITLE	O
:	O
The	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
coincides	O
with	O
changes	O
in	O
the	O
epidemiology	O
of	O
other	O
viral	O
pathogens	O
causing	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
.	O

The	O
RSV	O
and	O
hMPV	O
epidemics	O
of	O
2009	O
/	O
2010	O
erupted	O
several	O
weeks	O
later	O
than	O
expected	O
based	O
on	O
data	O
collected	O
in	O
the	O
PID	B-DISO
-	O
ARI	O
-	O
Network	O
during	O
the	O
past	O
10	O
years	O
,	O
whereas	O
in	O
the	O
2010	O
/	O
2011	O
influenza	B-DISO
season	O
they	O
occurred	O
as	O
expected	O
.	O

Patients	O
were	O
categorized	O
according	O
to	O
the	O
Berlin	O
definition	O
as	O
:	O
no	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PaO2	O
/	O
FIO2	O
<	O
300	O
mm	O
Hg	O
),	O
and	O
subdivisions	O
of	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
200	O
-	O
300	O
mm	O
Hg	O
,	O
100	O
-	O
200	O
mm	O
Hg	O
,	O
and	O
<	O
100	O
mm	O
Hg	O
,	O
respectively	O
).	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
required	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
7	O
vs	O
6	O
vs	O
10	O
vs	O
15	O
cm	O
H2O	O
for	O
no	O
,	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
p	O
=	O
0	O
.	O
014	O
),	O
had	O
reduced	O
respiratory	O
system	O
compliance	O
(	O
34	O
vs	O
29	O
vs	O
30	O
vs	O
23	O
L	O
/	O
cm	O
H2O	O
,	O
p	O
=	O
0	O
.	O
028	O
),	O
and	O
an	O
increased	O
number	O
of	O
ventilator	O
days	O
(	O
no	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
10	O
d	O
;	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
acute	O
lung	O
injury	O
,	O
12	O
d	O
;	O
moderate	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
23	O
d	O
;	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
22	O
d	O
;	O
p	O
=	O
0	O
.	O
097	O
).	O

TITLE	O
:	O
Detection	O
and	O
molecular	O
diversity	O
of	O
spike	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
China	O
.	O

Lymphopenia	B-DISO
was	O
the	O
only	O
parameter	O
related	O
to	O
CCoV	O
infection	B-DISO
that	O
was	O
statistically	O
significant	O
;	O
vomiting	B-DISO
,	O
anorexia	B-DISO
,	O
lethargy	B-DISO
,	O
hemorrhagic	O
fluid	O
diarrhea	B-DISO
,	O
leukopenia	B-DISO
,	O
lymphopenia	B-DISO
,	O
thrombocytopenia	O
,	O
hypoglycemia	B-DISO
,	O
and	O
hypoproteinemia	B-DISO
were	O
correlated	O
with	O
CPV	O
infection	B-DISO
.	O

TITLE	O
:	O
MMP	O
-	O
independent	O
role	O
of	O
TIMP	O
-	O
1	O
at	O
the	O
blood	O
brain	O
barrier	O
during	O
viral	O
encephalomyelitis	B-DISO
.	O

A	O
backward	O
elimination	O
model	O
building	O
strategy	O
on	O
1	O
,	O
000	O
bootstrapped	O
data	O
was	O
used	O
to	O
select	O
the	O
best	O
performing	O
biomarkers	O
for	O
further	O
consideration	O
in	O
a	O
logistic	O
regression	O
model	O
for	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

Altered	O
levels	O
of	O
plasma	O
biomarkers	O
may	O
be	O
useful	O
biologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
sepsis	B-DISO
,	O
and	O
also	O
potentially	O
for	O
selecting	O
patients	O
for	O
clinical	O
trials	O
that	O
are	O
designed	O
to	O
reduce	O
lung	O
epithelial	O
injury	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
BNP	O
and	O
RVEDVI	O
are	O
clinically	O
valuable	O
parameters	O
that	O
can	O
distinguish	O
among	O
hypovolemia	O
,	O
euvolemia	O
,	O
and	O
hypervolemia	B-DISO
,	O
as	O
measured	O
by	O
blood	O
volume	O
(	O
BV	O
)	O
analysis	O
in	O
critically	B-DISO
ill	I-DISO
surgical	O
subjects	O
.	O

In	O
a	O
majority	O
of	O
patients	O
with	O
PUUV	O
-	O
infection	B-DISO
,	O
both	O
cardiac	O
and	O
pulmonary	B-DISO
involvement	I-DISO
was	O
demonstrated	O
with	O
implications	O
on	O
patients	O
'	O
recovery	O
.	O

RESULTS	O
:	O
Two	O
-	O
thirds	O
of	O
the	O
patients	O
experienced	O
respiratory	B-DISO
symptoms	I-DISO
as	O
dry	B-DISO
cough	I-DISO
or	O
dyspnoea	B-DISO
.	O

TITLE	O
:	O
Bronchoscopy	O
with	O
N	O
-	O
acetylcysteine	O
lavage	O
in	O
severe	O
respiratory	B-DISO
failure	I-DISO
from	O
pertussis	B-DISO
infection	B-DISO
.	O

Although	O
pulmonary	B-DISO
hypertension	I-DISO
is	O
a	O
key	O
factor	O
in	O
most	O
cases	O
of	O
fatal	O
pertussis	B-DISO
,	O
the	O
adverse	B-DISO
effects	I-DISO
of	O
hyperinflation	B-DISO
and	O
air	O
leaks	O
were	O
more	O
important	O
in	O
this	O
patient	O
'	O
s	O
clinical	O
course	O
.	O

RESULTS	O
:	O
IBV	O
infection	B-DISO
contributed	O
to	O
differential	O
expression	O
of	O
1777	O
genes	O
,	O
of	O
which	O
876	O
were	O
up	O
-	O
regulated	O
and	O
901	O
down	O
-	O
regulated	O
in	O
the	O
kidney	O
compared	O
to	O
those	O
of	O
control	O
chickens	O
and	O
103	O
associated	O
with	O
immune	O
and	O
inflammatory	B-DISO
responses	I-DISO
may	O
play	O
important	O
roles	O
in	O
the	O
host	O
defense	O
response	O
during	O
IBV	O
infection	B-DISO
.	O

Based	O
on	O
a	O
multivariate	O
logistic	O
regression	O
,	O
a	O
score	O
including	O
age	O
,	O
SOFA	O
score	O
,	O
and	O
a	O
diagnosis	O
of	O
influenza	B-DISO
pneumonia	I-DISO
was	O
constructed	O
.	O

Patients	O
with	O
an	O
influenza	B-DISO
pneumonia	I-DISO
diagnosis	O
and	O
a	O
SOFA	O
score	O
before	O
ECMO	O
of	O
less	O
than	O
12	O
had	O
a	O
mortality	O
rate	O
of	O
22	O
%.	O

TITLE	O
:	O
Prolonged	O
duration	O
ECMO	O
for	O
ARDS	B-DISO
:	O
futility	O
,	O
native	O
lung	O
recovery	O
,	O
or	O
transplantation	O
?	O

Upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
were	O
the	O
most	O
frequently	O
identified	O
trigger	O
(	O
151	O
subjects	O
,	O
44	O
.	O
5	O
%).	O

The	O
patient	O
'	O
s	O
response	O
to	O
recommended	O
pharmacotherapy	O
is	O
highly	O
variable	O
which	O
risks	O
poor	O
asthma	B-DISO
control	O
leading	O
to	O
frequent	O
exacerbations	O
that	O
can	O
deteriorate	O
into	O
CAS	B-DISO
.	O

TITLE	O
:	O
The	O
unusual	O
presentation	O
of	O
a	O
usual	O
organism	O
-	O
the	O
changing	O
spectrum	O
of	O
the	O
clinical	O
manifestations	O
of	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
in	O
children	O
:	O
a	O
retrospective	O
study	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
from	O
Plasmodium	B-DISO
ovale	I-DISO
infection	I-DISO
with	O
fatal	O
outcome	O
.	O

Although	O
parasites	O
were	O
cleared	O
off	O
the	O
circulation	O
,	O
the	O
patient	O
'	O
s	O
condition	B-DISO
worsened	O
.	O

Sequencing	O
of	O
the	O
malaria	B-DISO
parasite	O
DNA	O
from	O
both	O
cases	O
,	O
followed	O
by	O
multiple	O
sequence	O
alignment	O
and	O
phylogenetic	O
tree	O
construction	O
suggested	O
that	O
the	O
causative	O
agent	O
for	O
both	O
malaria	B-DISO
cases	O
was	O
P	O
.	O
ovale	O
curtisi	O
.	O

TITLE	O
:	O
Aquaporin	O
-	O
4	O
antibodies	O
,	O
CNS	O
acidosis	B-DISO
and	O
neuromyelitis	B-DISO
optica	I-DISO
:	O
a	O
potential	O
link	O
.	O

As	O
a	O
strongly	O
dissociated	O
anion	O
(	O
pK	O
'=	O
3	O
.	O
7	O
)	O
directly	O
changing	O
the	O
strong	O
ion	O
difference	O
,	O
lactate	O
causes	O
a	O
reduction	O
in	O
the	O
dependent	O
anion	O
[	O
HCO3	O
-]	O
and	O
a	O
rise	O
in	O
[	O
H	O
+],	O
resulting	O
in	O
""""	O
metabolic	O
""""	O
acidosis	B-DISO
in	O
the	O
CSF	O
.	O

CSF	O
acidosis	B-DISO
also	O
develops	O
during	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
brainstem	O
or	O
high	O
cervical	O
spinal	O
cord	B-DISO
lesions	O
,	O
the	O
most	O
common	O
cause	O
of	O
death	O
in	O
NMO	O
.	O

Therefore	O
,	O
we	O
hypothesize	O
that	O
CSF	O
acidosis	B-DISO
might	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
AQP4	O
-	O
Ab	O
-	O
positive	O
NMO	O
and	O
that	O
alterations	O
in	O
CSF	O
pH	O
might	O
possibly	O
influence	O
the	O
outcome	O
of	O
acute	O
attacks	O
in	O
this	O
condition	B-DISO
.	O

ABSTRACT	O
:	O
Should	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
outbreak	O
or	O
an	O
environmental	O
disaster	O
occur	O
,	O
the	O
collection	O
of	O
epidemiological	O
data	O
must	O
start	O
as	O
soon	O
as	O
possible	O
after	O
the	O
event	O
'	O
s	O
onset	O
.	O

Many	O
diseases	O
and	O
emerging	O
infections	B-DISO
of	O
pathogenic	O
bacteria	O
cannot	O
be	O
controlled	O
by	O
conventional	O
pharmaceutics	O
.	O

This	O
synthetically	O
over	O
expressed	O
IFN	O
-	O
λ	O
can	O
be	O
tested	O
as	O
a	O
targeted	O
treatment	O
option	O
for	O
viral	B-DISO
hepatitis	I-DISO
after	O
purification	O
.	O

Bedside	O
positive	O
end	O
-	O
expiratory	O
pressure	O
selection	O
methods	O
based	O
on	O
lung	O
mechanics	O
or	O
absolute	O
esophageal	O
pressures	O
provide	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
unrelated	O
to	O
lung	O
recruitability	O
and	O
similar	O
in	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
whereas	O
the	O
oxygenation	O
-	O
based	O
method	O
provided	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
related	O
with	O
lung	O
recruitability	O
progressively	O
increasing	O
from	O
mild	O
to	O
moderate	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Transcriptional	O
profiling	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
CRFK	O
cells	O
and	O
in	O
PBMCs	O
from	O
FIP	B-DISO
diagnosed	O
cats	O
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
was	O
developed	O
for	O
further	O
transcriptional	O
profiling	O
of	O
three	O
genes	O
(	O
PD	O
-	O
1	O
,	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
in	O
infected	O
CRFK	O
cells	O
and	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	O
(	O
PBMCs	O
)	O
from	O
healthy	O
and	O
FIP	B-DISO
-	O
diseased	O
cats	O
.	O

In	O
this	O
vein	O
,	O
we	O
propose	O
the	O
term	O
""""	O
critical	O
asthma	B-DISO
syndrome	B-DISO
""""	O
(	O
CAS	B-DISO
)	O
to	O
describe	O
any	O
child	O
or	O
adult	O
who	O
is	O
at	O
high	O
risk	O
for	O
fatal	O
asthma	B-DISO
.	O

CAS	B-DISO
is	O
not	O
severe	B-DISO
persistent	I-DISO
asthma	I-DISO
where	O
control	O
of	O
symptoms	O
and	O
prevention	O
of	O
exacerbations	O
are	O
targets	O
of	O
chronic	B-DISO
disease	I-DISO
management	O
in	O
the	O
outpatient	O
setting	O
.	O

Knowledge	O
gaps	O
include	O
a	O
lack	O
of	O
understanding	O
of	O
how	O
to	O
recognize	O
CAS	B-DISO
,	O
how	O
to	O
coordinate	O
and	O
integrate	O
hospital	O
and	O
outpatient	O
resources	O
,	O
when	O
to	O
further	O
phenotype	O
patients	O
with	O
critical	O
asthma	B-DISO
in	O
order	O
to	O
facilitate	O
effective	O
treatment	O
,	O
and	O
how	O
to	O
prevent	O
future	O
acute	O
exacerbations	O
.	O

Lastly	O
,	O
CAS	B-DISO
is	O
complicated	O
by	O
the	O
fact	O
that	O
asthma	B-DISO
care	O
in	O
diverse	O
healthcare	O
settings	O
is	O
haphazard	O
.	O

TITLE	O
:	O
Adjunctive	O
therapies	O
and	O
immunomodulating	O
agents	O
for	O
severe	O
influenza	B-DISO
.	O

RESULTS	O
:	O
Among	O
113	O
patients	O
receiving	O
NIV	O
for	O
AHRF	O
,	O
82	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
31	O
had	O
non	O
-	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Investigation	O
of	O
anti	O
-	O
middle	O
East	O
respiratory	O
syndrome	B-DISO
antibodies	O
in	O
blood	O
donors	O
and	O
slaughterhouse	O
workers	O
in	O
Jeddah	O
and	O
Makkah	O
,	O
Saudi	O
Arabia	O
,	O
fall	O
2012	O
.	O

TITLE	O
:	O
Acute	O
effects	O
of	O
estradiol	O
on	O
lung	B-DISO
inflammation	I-DISO
due	O
to	O
intestinal	O
ischemic	O
insult	O
in	O
male	O
rats	O
.	O

ABSTRACT	O
:	O
Blastomycosis	B-DISO
is	O
an	O
endemic	O
fungal	B-DISO
infection	I-DISO
in	O
North	O
America	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
only	O
four	O
reported	O
cases	O
of	O
cardiac	O
blastomycosis	B-DISO
in	O
the	O
literature	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
cardiac	O
blastomycosis	B-DISO
who	O
initially	O
presented	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
While	O
gammacoronaviruses	O
mainly	O
comprise	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
its	O
closely	O
related	O
bird	O
coronaviruses	O
(	O
CoVs	O
),	O
the	O
only	O
mammalian	O
gammacoronavirus	O
was	O
discovered	O
from	O
a	O
white	O
beluga	O
whale	O
(	O
beluga	O
whale	O
CoV	O
[	O
BWCoV	O
]	O
SW1	O
)	O
in	O
2008	O
.	O

Moreover	O
,	O
we	O
have	O
shown	O
that	O
HCoV	O
-	O
OC43	O
is	O
neurovirulent	O
in	O
susceptible	O
mice	O
,	O
causing	O
encephalitis	B-DISO
,	O
and	O
that	O
a	O
viral	O
mutant	B-DISO
with	O
a	O
single	O
point	O
mutation	O
in	O
the	O
viral	O
surface	O
spike	O
(	O
S	O
)	O
protein	O
induces	O
a	O
paralytic	O
disease	O
that	O
involves	O
glutamate	O
excitotoxicity	O
in	O
susceptible	O
mice	O
.	O

This	O
novel	O
action	O
of	O
memantine	O
on	O
viral	O
replication	O
strongly	O
suggests	O
that	O
it	O
could	O
be	O
used	O
as	O
an	O
antiviral	O
agent	O
to	O
directly	O
limit	O
viral	O
replication	O
while	O
improving	O
neurological	B-DISO
symptoms	I-DISO
in	O
various	O
neurological	O
diseases	O
with	O
a	O
viral	O
involvement	O
.	O

We	O
now	O
show	O
that	O
memantine	O
,	O
a	O
drug	O
that	O
is	O
used	O
for	O
alleviating	O
symptoms	O
associated	O
with	O
neuropathology	B-DISO
,	O
such	O
as	O
Alzheimer	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
,	O
can	O
partially	O
restore	O
the	O
physiological	O
state	O
of	O
infected	O
mice	O
by	O
limiting	O
both	O
neurodegeneration	B-DISO
and	O
viral	O
replication	O
.	O

This	O
study	O
was	O
conducted	O
to	O
elucidate	O
two	O
questions	O
:	O
first	O
,	O
whether	O
the	O
activation	O
of	O
PARP	O
and	O
NF	O
-	O
κB	O
mediates	O
the	O
renal	O
inflammation	B-DISO
secondary	O
to	O
the	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
acute	O
lung	B-DISO
inflammation	I-DISO
;	O
second	O
,	O
whether	O
a	O
PARP	O
inhibitor	O
,	O
3	O
-	O
aminobenzamide	O
(	O
3	O
-	O
AB	O
),	O
attenuates	O
lung	O
and	O
kidney	B-DISO
inflammation	I-DISO
by	O
inhibiting	O
NF	O
-	O
κB	O
-	O
dependent	O
proinflammatory	O
cytokines	O
.	O

TITLE	O
:	O
New	O
and	O
emerging	O
pathogens	O
in	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

Etiology	O
,	O
clinical	O
disease	O
,	O
pathogenesis	B-DISO
,	O
and	O
epidemiology	O
are	O
described	O
for	O
each	O
pathogen	O
,	O
with	O
an	O
emphasis	O
on	O
recent	O
discoveries	O
or	O
novel	O
findings	O
.	O

ABSTRACT	O
:	O
The	O
biosynthesis	O
of	O
fusion	O
-	O
competent	O
envelope	O
glycoproteins	O
(	O
GPs	B-DISO
)	O
is	O
a	O
crucial	O
step	O
in	O
productive	O
viral	B-DISO
infection	I-DISO
.	O

Analysis	O
of	O
human	O
clusters	O
indicated	O
that	O
chains	O
of	O
transmission	O
were	O
not	O
self	O
-	O
sustaining	O
when	O
infection	B-DISO
control	O
was	O
implemented	O
,	O
but	O
that	O
R	O
in	O
the	O
absence	O
of	O
controls	O
was	O
in	O
the	O
range	O
0	O
·	O
8	O
-	O
1	O
·	O
3	O
.	O

In	O
addition	O
,	O
only	O
32	O
.	O
8	O
%	O
of	O
PCPs	O
adopted	O
an	O
adequate	O
business	O
continuity	O
plan	B-DISO
(	O
BCP	O
).	O

Our	O
findings	O
were	O
validated	O
using	O
a	O
convalescent	O
-	O
phase	O
serum	O
specimen	O
from	O
a	O
patient	O
infected	O
with	O
MERS	O
-	O
CoV	O
(	O
NA	O
01	O
)	O
and	O
human	O
antiserum	O
against	O
SARS	B-DISO
-	O
CoV	O
,	O
human	O
CoV	O
NL63	O
,	O
and	O
human	O
CoV	O
OC43	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
an	O
effective	O
rescue	O
therapy	O
for	O
improving	O
oxygenation	O
in	O
selected	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

During	O
a	O
two	O
-	O
year	O
period	O
,	O
15	O
patients	O
with	O
severe	O
ARDS	B-DISO
were	O
turned	O
into	O
PP	O
during	O
VV	O
-	O
ECMO	O
therapy	O
for	O
at	O
least	O
one	O
of	O
the	O
three	O
following	O
conditions	O
:	O
severe	O
hypoxemia	O
(	O
PaO2	O
/	O
FiO2	O
ratio	O
below	O
70	O
)	O
despite	O
maximal	O
oxygenation	O
,	O
injurious	O
ventilation	O
parameters	O
with	O
plateau	O
pressure	O
exceeding	O
32	O
cmH2O	O
or	O
failure	O
of	O
attempt	O
to	O
wean	O
ECMO	O
after	O
at	O
least	O
10	O
days	O
on	O
ECMO	O
support	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
replicates	O
in	O
cells	O
of	O
different	O
species	O
using	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
as	O
a	O
functional	O
receptor	O
.	O

ABSTRACT	O
:	O
This	O
study	O
describes	O
the	O
development	O
of	O
a	O
spatio	O
-	O
temporal	O
disease	O
model	O
based	O
on	O
the	O
episodes	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
that	O
took	O
place	O
in	O
Hong	O
Kong	O
in	O
2003	O
.	O

He	O
was	O
hospitalized	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
a	O
bronchopulmonary	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Lung	O
function	O
in	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

For	O
many	O
years	O
the	O
traditional	O
teaching	O
has	O
been	O
that	O
SCD	B-DISO
is	O
associated	O
with	O
the	O
development	O
of	O
a	O
restrictive	O
lung	O
defect	O
.	O

There	O
were	O
11	O
.	O
8	O
/	O
10	O
,	O
000	O
(	O
95	O
%	O
CI	O
7	O
.	O
9	O
-	O
18	O
.	O
4	O
)	O
influenza	B-DISO
-	O
associated	O
hospitalizations	O
(	O
7	O
%	O
of	O
hospitalizations	O
).	O

80	O
.	O
9	O
%	O
vs	O
.	O
67	O
.	O
2	O
%	O
of	O
index	O
/	O
sporadic	O
and	O
secondary	O
cases	O
,	O
respectively	O
,	O
reported	O
≥	O
1	O
underlying	O
condition	B-DISO
.	O

To	O
investigate	O
the	O
role	O
of	O
macrophage	O
activation	O
in	O
aseptic	O
lung	O
injury	O
and	O
identify	O
molecular	O
mediators	O
with	O
therapeutic	O
potential	O
,	O
lung	O
injury	O
was	O
induced	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
Akt2	O
(-/-)	O
mice	O
by	O
hydrochloric	O
acid	O
aspiration	B-DISO
.	O

In	O
vivo	O
modulation	O
of	O
macrophage	O
phenotype	O
through	O
Akt2	O
or	O
miR	O
-	O
146a	O
could	O
provide	O
a	O
potential	O
therapeutic	O
approach	O
for	O
aseptic	O
ARDS	B-DISO
;	O
however	O
,	O
it	O
may	O
be	O
deleterious	O
in	O
septic	O
ARDS	B-DISO
because	O
of	O
impaired	B-DISO
bacterial	O
clearance	O
.	O

We	O
conclude	O
that	O
the	O
effects	O
on	O
respiratory	O
function	O
and	O
pulmonary	O
radiological	O
appearance	O
are	O
similar	O
to	O
those	O
observed	O
following	O
conventional	O
treatment	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
[	O
ARDS	B-DISO
].	O

This	O
drop	O
in	O
egg	O
production	O
most	O
likely	O
occurred	O
as	O
consequence	O
of	O
the	O
severe	O
enteritis	B-DISO
produced	O
by	O
the	O
TCoV	O
.	O
However	O
,	O
the	O
potential	O
replication	O
of	O
TCoV	O
in	O
the	O
oviduct	O
and	O
its	O
effect	O
on	O
pathogenesis	B-DISO
should	O
be	O
considered	O
and	O
further	O
investigated	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
severe	O
inflammatory	O
condition	B-DISO
whose	O
pathogenesis	B-DISO
is	O
irrevocably	O
linked	O
to	O
neutrophil	O
emigration	O
to	O
the	O
lung	O
.	O

In	O
both	O
models	O
,	O
results	O
demonstrated	O
two	O
phases	O
of	O
neutrophil	O
chemotactic	O
factor	O
expression	O
;	O
first	O
,	O
an	O
early	O
phase	O
characterized	O
by	O
high	O
levels	O
of	O
CXCL1	O
/	O
keratinocyte	O
-	O
derived	O
chemokine	O
,	O
CXCL2	O
/	O
monocyte	O
-	O
inhibitory	O
protein	O
-	O
2	O
,	O
and	O
CXCL5	O
/	O
LPS	B-DISO
-	O
induced	O
chemokine	O
expression	O
,	O
and	O
second	O
,	O
a	O
late	O
phase	O
distinguished	O
by	O
increases	O
in	O
extracellular	O
ATP	O
.	O

These	O
combined	O
results	O
indicate	O
that	O
signaling	O
through	O
TNFR1	O
plays	O
an	O
essential	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
FH	O
caused	O
by	O
MHV	O
-	O
3	O
infection	B-DISO
,	O
and	O
interruption	O
of	O
this	O
signaling	O
pathway	O
could	O
be	O
useful	O
for	O
clinical	O
therapy	O
.	O

TITLE	O
:	O
Aptamer	O
-	O
based	O
therapeutics	O
:	O
new	O
approaches	O
to	O
combat	O
human	O
viral	B-DISO
diseases	I-DISO
.	O

Many	O
life	O
-	O
threatening	O
diseases	O
,	O
such	O
as	O
AIDS	O
,	O
SARS	B-DISO
,	O
hepatitis	B-DISO
and	O
some	O
cancers	B-DISO
,	O
are	O
caused	O
by	O
viruses	O
.	O

TITLE	O
:	O
Development	O
and	O
characterization	O
of	O
a	O
recombinant	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
expressing	O
the	O
ectodomain	O
region	O
of	O
S1	O
gene	O
of	O
H120	O
strain	O
.	O

TITLE	O
:	O
High	O
or	O
conventional	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Respiratory	O
syncytial	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
and	O
pertussis	B-DISO
are	O
other	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
with	O
special	O
problems	O
of	O
their	O
own	O
,	O
from	O
vaccine	O
development	O
to	O
vaccine	O
coverage	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
pathogens	O
of	O
viral	O
(	O
Rotavirus	O
,	O
Coronavirus	O
),	O
parasitic	O
(	O
Toxocara	O
spp	O
.)	O
and	O
bacterial	O
(	O
Escherichia	O
coli	O
,	O
Salmonella	B-DISO
spp	O
.,	O
Rhodococcus	O
equi	O
)	O
origin	O
shed	O
in	O
feces	O
,	O
and	O
the	O
virulence	O
profile	O
of	O
R	O
.	O
equi	O
and	O
E	O
.	O
coli	O
isolates	O
were	O
investigated	O
in	O
200	O
samples	O
of	O
sand	O
obtained	O
from	O
40	O
parks	O
,	O
located	O
in	O
central	O
region	O
of	O
state	O
of	O
Sao	O
Paulo	O
,	O
Brazil	O
,	O
using	O
different	O
diagnostic	O
methods	O
.	O

The	O
Surviving	O
Sepsis	B-DISO
Campaign	O
(	O
SSC	O
)	O
guidelines	O
released	O
in	O
2012	O
emphasize	O
early	O
recognition	O
and	O
treatment	O
of	O
sepsis	B-DISO
,	O
in	O
an	O
effort	O
to	O
reduce	O
the	O
burden	O
of	O
sepsis	B-DISO
worldwide	O
.	O

Management	O
of	O
ARDS	B-DISO
is	O
mainly	O
supportive	O
with	O
specific	O
mechanical	O
ventilation	O
strategies	O
and	O
goal	O
-	O
directed	O
therapies	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
2006	O
Pandemic	O
Influenza	B-DISO
Preparedness	O
and	O
Response	O
Plan	B-DISO
according	O
to	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
recommendation	O
,	O
the	O
Republic	O
of	O
Korea	O
has	O
prepared	O
and	O
periodically	O
evaluated	O
the	O
plan	B-DISO
to	O
respond	O
to	O
various	O
public	O
health	O
crises	O
including	O
pandemic	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
Severe	O
lung	O
injury	O
with	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
serious	O
complication	B-DISO
of	O
cardiac	O
surgery	O
.	O

The	O
durations	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
5	O
.	O
4	O
±	O
2	O
.	O
4	O
vs	O
.	O
2	O
.	O
9	O
±	O
1	O
.	O
3	O
),	O
acute	B-DISO
hepatitis	I-DISO
(	O
4	O
.	O
6	O
±	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
9	O
±	O
0	O
.	O
6	O
)	O
and	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
(	O
3	O
.	O
9	O
±	O
1	O
.	O
6	O
vs	O
.	O
1	O
.	O
3	O
±	O
0	O
.	O
6	O
,	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
control	O
group	O
were	O
longer	O
than	O
those	O
in	O
the	O
treatment	O
group	O
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
three	O
avian	B-DISO
influenza	I-DISO
H7N9	O
virus	O
-	O
infected	O
patients	O
in	O
Shanghai	O
.	O

ABSTRACT	O
:	O
Efficacy	O
of	O
antitumor	O
vaccination	O
depends	O
to	O
a	O
large	O
extent	O
on	O
antigen	O
targeting	O
to	O
dendritic	O
cells	O
(	O
DCs	B-DISO
).	O

TITLE	O
:	O
Peptides	O
corresponding	O
to	O
the	O
predicted	O
heptad	O
repeat	O
2	O
domain	O
of	O
the	O
feline	O
coronavirus	O
spike	O
protein	O
are	O
potent	O
inhibitors	O
of	O
viral	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Mapping	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
and	O
amino	O
acids	O
critical	O
for	O
attachment	O
in	O
the	O
spike	O
protein	O
of	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
highly	O
pathogenic	O
respiratory	O
virus	O
with	O
pathogenic	O
mechanisms	O
that	O
may	O
be	O
driven	O
by	O
innate	O
immune	O
pathways	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
presents	O
a	O
novel	O
emerging	O
threat	O
to	O
public	O
health	O
worldwide	O
.	O

ABSTRACT	O
:	O
Complicated	B-DISO
malaria	I-DISO
is	O
mainly	O
caused	O
by	O
Plasmodium	O
falciparum	O
,	O
but	O
,	O
increasingly	O
,	O
Plasmodium	O
vivax	O
is	O
also	O
being	O
reported	O
as	O
a	O
cause	O
.	O

Since	O
the	O
reemergence	O
of	O
indigenous	O
vivax	B-DISO
malaria	I-DISO
in	O
1993	O
,	O
cases	O
of	O
severe	O
malaria	B-DISO
have	O
been	O
steadily	O
reported	O
in	O
Korea	O
.	O

On	O
admission	O
,	O
the	O
patient	O
had	O
impaired	B-DISO
consciousness	I-DISO
,	O
shock	O
,	O
hypoxia	B-DISO
and	O
haziness	O
in	O
both	O
lungs	O
,	O
jaundice	B-DISO
,	O
thrombocytopenia	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
and	O
acute	O
kidney	O
injury	O
.	O

We	O
hypothesize	O
that	O
genetic	O
variation	O
of	O
IFN	O
-	O
λ	O
could	O
potentially	O
influence	O
the	O
course	O
of	O
disease	O
during	O
infection	B-DISO
with	O
many	O
viruses	O
that	O
infect	O
epithelial	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
employed	O
a	O
new	O
dataset	O
of	O
1725	O
viral	O
siRNAs	O
with	O
experimentally	O
verified	O
quantitative	O
efficacies	O
tested	O
under	O
heterogeneous	O
experimental	O
conditions	O
and	O
targeting	O
as	O
many	O
as	O
37	O
important	O
human	O
viruses	O
including	O
HIV	B-DISO
,	O
Influenza	B-DISO
,	O
HCV	O
,	O
HBV	B-DISO
,	O
SARS	B-DISO
etc	O
.	O

The	O
web	B-DISO
server	O
is	O
freely	O
available	O
at	O
http	O
://	O
crdd	O
.	O
osdd	O
.	O
net	O
/	O
servers	O
/	O
virsirnapred	O
/.	O
RESULTS	O
:	O
During	O
10	O
-	O
fold	O
cross	O
validation	O
on	O
T1380	O
using	O
hybrid	O
approach	O
,	O
we	O
achieved	O
a	O
maximum	O
Pearson	O
Correlation	O
Coefficient	O
(	O
PCC	B-DISO
)	O
of	O
0	O
.	O
55	O
between	O
predicted	O
and	O
actual	O
efficacy	O
of	O
viral	O
siRNAs	O
.	O

This	O
study	O
suggested	O
that	O
the	O
chicken	O
genome	O
has	O
several	O
important	O
loci	O
affecting	O
the	O
immune	O
response	O
against	O
IBV	O
,	O
and	O
increases	O
our	O
knowledge	O
of	O
how	O
to	O
control	O
outbreaks	O
of	O
infectious	B-DISO
bronchitis	B-DISO
.	O

The	O
type	O
of	O
organism	O
causing	O
severe	B-DISO
sepsis	I-DISO
is	O
an	O
important	O
determinant	O
of	O
outcome	O
,	O
and	O
gram	O
-	O
positive	O
organisms	O
as	O
a	O
cause	O
of	O
sepsis	B-DISO
have	O
increased	O
in	O
frequency	O
over	O
time	O
and	O
are	O
now	O
more	O
common	O
than	O
gram	O
-	O
negative	O
infections	B-DISO
.	O

Clinical	O
and	O
experimental	O
studies	O
show	O
that	O
controlled	O
mechanical	O
ventilation	O
with	O
muscle	O
paralysis	O
in	O
the	O
early	O
phase	O
of	O
severe	O
ARDS	B-DISO
reduces	O
lung	O
injury	O
and	O
even	O
mortality	O
.	O

Two	O
PrPs	O
had	O
to	O
be	O
interrupted	O
(	O
endotracheal	O
tube	O
obstruction	B-DISO
,	O
acute	O
pulmonary	B-DISO
embolism	I-DISO
).	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
associated	O
with	O
production	O
inefficiencies	O
in	O
domestic	O
fowl	O
,	O
and	O
causes	O
massive	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

TITLE	O
:	O
How	O
the	O
double	O
spherules	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
impact	O
our	O
understanding	O
of	O
RNA	O
virus	O
replicative	O
organelles	O
.	O

Recently	O
,	O
however	O
,	O
it	O
has	O
been	O
shown	O
in	O
adults	O
with	O
ARDS	B-DISO
that	O
FiO	O
(	O
2	O
),	O
independently	O
of	O
the	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
predicts	O
mortality	O
.	O

However	O
,	O
a	O
higher	O
frequency	O
of	O
pressure	B-DISO
ulcers	I-DISO
has	O
been	O
reported	O
in	O
patients	O
in	O
the	O
prone	O
position	O
.	O

At	O
randomisation	O
,	O
of	O
the	O
229	O
patients	O
allocated	O
to	O
the	O
supine	O
position	O
and	O
the	O
237	O
patients	O
allocated	O
to	O
the	O
prone	O
position	O
,	O
the	O
number	O
of	O
patients	O
with	O
pressure	B-DISO
ulcers	I-DISO
was	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

There	O
are	O
risk	O
groups	O
for	O
the	O
development	O
of	O
pressure	B-DISO
ulcers	I-DISO
in	O
severe	O
ARDS	B-DISO
,	O
and	O
these	O
patients	O
need	O
surveillance	O
and	O
active	O
prevention	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
suggested	O
improved	O
oxygenation	O
and	O
reduced	O
mortality	O
in	O
adults	O
and	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
but	O
the	O
use	O
of	O
outdated	O
control	O
strategies	O
and	O
small	O
numbers	O
of	O
patients	O
in	O
many	O
of	O
the	O
studies	O
rendered	O
these	O
findings	O
hypothesis	O
-	O
generating	O
only	O
.	O

During	O
2013	O
,	O
two	O
large	O
randomized	O
controlled	O
trials	O
comparing	O
HFOV	O
with	O
a	O
conventional	O
lung	O
-	O
protective	O
ventilation	O
were	O
published	O
-	O
the	O
Oscillation	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Treated	O
Early	O
(	O
OSCILLATE	O
)	O
and	O
the	O
Oscillation	O
in	O
ARDS	B-DISO
(	O
OSCAR	O
)	O
trials	O
.	O

The	O
OSCILLATE	O
and	O
OSCAR	O
trials	O
showed	O
that	O
the	O
early	O
application	O
of	O
HFOV	O
in	O
moderate	O
-	O
to	O
-	O
severe	O
adult	O
ARDS	B-DISO
does	O
not	O
reduce	O
mortality	O
compared	O
with	O
conventional	O
ventilation	O
strategies	O
.	O

TITLE	O
:	O
Persistent	O
organ	O
dysfunction	O
after	O
severe	B-DISO
sepsis	I-DISO
:	O
a	O
systematic	O
review	O
.	O

Survivors	O
of	O
sepsis	B-DISO
often	O
suffer	B-DISO
significant	O
resultant	O
morbidity	O
,	O
including	O
organ	O
dysfunction	O
.	O

Two	O
studies	O
contributed	O
the	O
majority	O
of	O
patients	O
and	O
had	O
consistent	O
rates	O
of	O
1	O
month	O
organ	O
dysfunction	O
for	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
8	O
%-	O
9	O
%),	O
renal	O
(	O
7	O
%-	O
8	O
%),	O
hepatic	O
(	O
3	O
%-	O
7	O
%),	O
and	O
central	O
nervous	B-DISO
system	O
(	O
2	O
%-	O
5	O
%).	O

TITLE	O
:	O
Glucocorticosteroid	O
in	O
treatment	O
of	O
severe	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
ARDS	B-DISO
is	O
defined	O
as	O
an	O
acute	O
inflammatory	O
syndrome	B-DISO
characterized	O
with	O
bilateral	O
parenchymal	O
lung	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
and	O
PaO2	O
/	O
FiO2	O
ratio	O
<	O
200	O
resulting	O
from	O
causes	O
other	O
than	O
acute	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
.	O

In	O
particular	O
,	O
ARF	B-DISO
in	O
MERS	O
patients	O
occurred	O
considerably	O
earlier	O
after	O
a	O
median	O
time	O
to	O
onset	O
of	O
11	O
days	O
(	O
SD	O
±	O
2	O
,	O
0	O
days	O
)	O
as	O
opposed	O
to	O
20	O
days	O
for	O
SARS	B-DISO
,	O
according	O
to	O
the	O
literature	O
.	O

Adverse	B-DISO
effects	I-DISO
of	O
HES	B-DISO
on	O
survival	O
and	O
organ	O
function	O
have	O
been	O
reported	O
.	O

There	O
was	O
no	O
evidence	O
that	O
early	O
fluid	O
resuscitation	O
with	O
balanced	O
HES	B-DISO
130	O
/	O
0	O
.	O
4	O
(	O
6	O
%)	O
in	O
addition	O
to	O
lactated	O
Ringer	O
'	O
s	O
solution	O
would	O
lead	O
to	O
a	O
volume	O
-	O
sparing	O
effect	O
in	O
severe	O
burn	O
injury	O
.	O

Together	O
with	O
the	O
findings	O
that	O
early	O
renal	O
function	O
,	O
incidence	O
of	O
ARDS	B-DISO
,	O
length	O
of	O
stay	O
,	O
and	O
mortality	O
were	O
not	O
negatively	O
influenced	O
by	O
HES	B-DISO
in	O
this	O
setting	O
,	O
balanced	O
HES	B-DISO
130	O
/	O
0	O
.	O
4	O
(	O
6	O
%)	O
plus	O
lactated	O
Ringer	O
'	O
s	O
solution	O
could	O
not	O
be	O
considered	O
superior	O
to	O
lactated	O
Ringer	O
'	O
s	O
solution	O
alone	O
.	O

Twenty	O
-	O
eight	O
-	O
day	O
mortality	O
was	O
4	O
patients	O
in	O
each	O
group	O
(	O
risk	O
ratio	O
0	O
.	O
96	O
;	O
95	O
%	O
CI	O
0	O
.	O
27	O
to	O
4	O
.	O
45	O
;	O
P	O
=	O
0	O
.	O
95	O
),	O
and	O
in	O
-	O
hospital	O
mortality	O
was	O
8	O
in	O
the	O
HES	B-DISO
group	O
vs	O
.	O
5	O
patients	O
in	O
the	O
lactated	O
Ringer	O
'	O
s	O
group	O
(	O
hazard	O
ratio	O
1	O
.	O
86	O
;	O
95	O
%	O
CI	O
0	O
.	O
56	O
to	O
6	O
.	O
19	O
;	O
P	O
=	O
0	O
.	O
31	O
).	O

ABSTRACT	O
:	O
A	O
unique	O
avian	O
-	O
origin	O
A	O
/	O
H7N9	O
influenza	B-DISO
virus	O
has	O
so	O
far	O
caused	O
134	O
cases	O
with	O
44	O
deaths	O
.	O

TITLE	O
:	O
The	O
efficacy	O
and	O
safety	O
of	O
prone	O
positional	O
ventilation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
updated	O
study	O
-	O
level	O
meta	O
-	O
analysis	O
of	O
11	O
randomized	O
controlled	O
trials	O
.	O

Prone	O
ventilation	O
was	O
also	O
significantly	O
associated	O
with	O
pressure	B-DISO
ulcers	I-DISO
and	O
major	O
airway	O
problems	O
.	O

This	O
experience	O
showed	O
that	O
ECMO	O
can	O
be	O
lifesaving	O
for	O
severe	O
H1N1	O
infection	B-DISO
also	O
in	O
patients	O
with	O
atypical	O
clinical	O
presentation	O
of	O
influenza	B-DISO
.	O

TITLE	O
:	O
A	O
life	O
-	O
threatening	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
:	O
a	O
previously	O
healthy	O
infant	O
with	O
bilateral	O
spontaneous	B-DISO
pneumothorax	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
conclude	O
that	O
RSV	B-DISO
infections	I-DISO
can	O
be	O
severe	O
,	O
and	O
some	O
patients	O
may	O
require	O
mechanical	O
ventilation	O
.	O

Laboratory	O
tests	O
demonstrated	O
severe	O
hemolytic	O
anemia	B-DISO
,	I-DISO
profound	I-DISO
thrombocytopenia	O
,	O
markedly	O
elevated	O
fibrin	O
degradation	O
products	O
,	O
and	O
renal	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Ventilation	O
therapy	O
for	O
patients	O
suffering	B-DISO
from	O
obstructive	B-DISO
lung	I-DISO
diseases	I-DISO
.	O

The	O
non	O
-	O
invasive	O
ventilation	O
is	O
very	O
efficient	O
in	O
treating	O
acute	O
or	O
chronic	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
COPD	B-DISO
patients	O
and	O
is	O
capable	O
of	O
shortening	O
the	O
duration	O
of	O
hospitalization	O
.	O

TITLE	O
:	O
Aerobic	O
and	O
strength	O
training	O
in	O
concomitant	O
metabolic	B-DISO
syndrome	I-DISO
and	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
.	O

AER	O
and	O
AER	O
+	O
RES	O
training	O
significantly	O
improved	O
metabolic	B-DISO
syndrome	I-DISO
scores	O
and	O
prevalence	O
in	O
patients	O
with	O
T2D	B-DISO
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
metabolic	B-DISO
syndrome	I-DISO
scores	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
003	O
)	O
for	O
AER	O
(-	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
-	O
0	O
.	O
21	O
)	O
and	O
AER	O
+	O
RES	O
(-	O
0	O
.	O
79	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
40	O
to	O
-	O
0	O
.	O
35	O
),	O
both	O
being	O
significant	O
(	O
P	O
≤	O
0	O
.	O
02	O
)	O
versus	O
control	O
(	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
58	O
to	O
0	O
.	O
40	O
)	O
and	O
RES	O
(-	O
0	O
.	O
13	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
0	O
.	O
24	O
).	O

High	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	B-DISO
necrosis	I-DISO
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

Secretion	O
of	O
large	O
amounts	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
decreased	O
level	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
during	O
the	O
acute	O
phase	O
of	O
trauma	O
may	O
lead	O
to	O
the	O
development	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
in	O
unstable	O
polytraumatized	O
patients	O
.	O

TITLE	O
:	O
Anaphylactic	B-DISO
Shock	I-DISO
:	O

ABSTRACT	O
:	O
Experiments	O
have	O
shown	O
that	O
anaphylaxis	B-DISO
decreases	O
cardiac	O
output	O
;	O
increases	O
left	O
ventricular	O
end	O
diastolic	O
pressure	O
;	O
induces	O
severe	O
early	O
acute	O
increase	O
in	O
respiratory	O
resistance	O
with	O
pulmonary	O
interstitial	B-DISO
edema	I-DISO
;	O
and	O
decreases	O
splanchnic	O
,	O
cerebral	O
,	O
and	O
myocardial	O
blood	O
flow	O
more	O
than	O
what	O
would	O
be	O
expected	O
from	O
severe	O
arterial	O
dilation	B-DISO
and	O
hypotension	O
.	O

Combined	O
tissue	O
suppression	B-DISO
from	O
arterial	O
involvement	O
and	O
peripheral	B-DISO
vasodilatation	I-DISO
,	O
perhaps	O
,	O
occur	O
simultaneously	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
has	O
spread	O
worldwide	O
since	O
2012	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
therapeutic	O
efficacy	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
following	O
esophagectomy	O
for	O
esophageal	B-DISO
cancer	I-DISO
.	O

Salivary	O
IL	O
-	O
6	O
and	O
IL	O
-	O
33	O
concentrations	O
were	O
similar	O
in	O
the	O
two	O
OSAS	B-DISO
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
),	O
which	O
were	O
statistically	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
the	O
UPR	O
-	O
activating	O
domain	O
in	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
remains	O
to	O
be	O
identified	O
.	O

Transmembrane	O
serine	O
protease	O
TMPRSS2	O
catalyzed	O
the	O
cleavage	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
,	O
but	O
not	O
the	O
counterpart	O
in	O
HCoV	O
-	O
HKU1	O
.	O

We	O
studied	O
enteropathogen	O
co	B-DISO
-	I-DISO
infection	I-DISO
in	O
diarrhoeic	O
UK	O
cats	O
using	O
results	O
of	O
a	O
real	O
time	O
PCR	O
assay	O
for	O
8	O
enteropathogenic	O
species	O
;	O
feline	O
coronavirus	O
(	O
Co	O
),	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
(	O
Pa	O
),	O
Clostridium	O
perfringens	O
(	O
Cl	O
),	O
Salmonella	B-DISO
enterica	O
(	O
Sa	O
),	O
Giardia	B-DISO
spp	O
.	O

TITLE	O
:	O
Resolution	O
of	O
obstructive	B-DISO
atelectasis	I-DISO
with	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
How	O
safe	O
is	O
the	O
prone	O
position	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
at	O
late	B-DISO
pregnancy	I-DISO
?	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
phosphoprotein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
)	O
packages	O
the	O
viral	O
genome	O
into	O
a	O
helical	O
ribonucleocapsid	O
(	O
RNP	O
)	O
and	O
plays	O
a	O
fundamental	O
role	O
during	O
viral	O
self	O
-	O
assembly	O
.	O

ABSTRACT	O
:	O
Bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
is	O
one	O
of	O
the	O
major	O
pathogens	O
involved	O
in	O
the	O
bovine	O
respiratory	B-DISO
disease	I-DISO
(	O
BRD	O
)	O
complex	O
.	O

ABSTRACT	O
:	O
Emerging	O
and	O
reemerging	O
viral	B-DISO
diseases	I-DISO
of	O
livestock	O
and	O
human	O
beings	O
are	O
in	O
sharp	O
rise	O
in	O
recent	O
years	O
.	O

TITLE	O
:	O
Choice	O
of	O
optimal	O
time	O
and	O
type	O
of	O
orthopedic	O
surgery	O
in	O
multiple	O
injured	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
depending	O
on	O
age	O
:	O
retrospective	O
study	O
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
of	O
the	O
surgical	O
management	O
tactic	O
of	O
145	O
patients	O
with	O
multiple	O
trauma	O
complicated	O
by	O
ARDS	B-DISO
.	O

Although	O
many	O
pathogens	O
have	O
been	O
individually	O
detected	O
with	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
),	O
a	O
comprehensive	O
panel	O
of	O
agents	O
that	O
cause	O
diarrhea	B-DISO
in	O
privately	O
owned	O
dogs	O
has	O
not	O
yet	O
been	O
established	O
.	O

Overall	O
,	O
71	O
/	O
104	O
(	O
68	O
.	O
3	O
%)	O
dogs	O
with	O
diarrhea	B-DISO
were	O
positive	O
for	O
at	O
least	O
one	O
pathogen	O
:	O
a	O
single	O
infection	B-DISO
in	O
39	O
/	O
71	O
dogs	O
(	O
54	O
.	O
9	O
%)	O
and	O
co	B-DISO
-	I-DISO
infections	I-DISO
in	O
32	O
/	O
71	O
dogs	O
(	O
45	O
.	O
1	O
%),	O
including	O
21	O
/	O
32	O
dogs	O
(	O
65	O
.	O
6	O
%)	O
with	O
dual	O
,	O
5	O
/	O
32	O
(	O
15	O
.	O
6	O
%)	O
with	O
triple	O
,	O
and	O
6	O
/	O
32	O
(	O
18	O
.	O
8	O
%)	O
with	O
quadruple	O
infections	B-DISO
.	O

The	O
most	O
prevalent	O
pathogens	O
in	O
the	O
diarrheic	O
dogs	O
were	O
CPA	O
(	O
40	O
/	O
104	O
dogs	O
,	O
38	O
.	O
5	O
%),	O
CPV	O
-	O
2	O
(	O
36	O
/	O
104	O
dogs	O
,	O
34	O
.	O
6	O
%),	O
and	O
Giardia	B-DISO
spp	O
.	O

Diarrheic	O
dogs	O
showed	O
a	O
higher	O
prevalence	O
of	O
pathogen	O
infections	B-DISO
than	O
the	O
controls	O
.	O

Dose	O
-	O
response	O
cytotoxicity	B-DISO
curves	O
on	O
Vero	O
cells	O
using	O
trypan	O
blue	O
staining	O
determined	O
the	O
highest	O
non	O
-	O
cytotoxic	O
concentrations	O
of	O
each	O
plant	O
extract	O
.	O

Further	O
translation	O
of	O
peritoneal	O
oxygenation	O
with	O
OMBs	O
may	O
provide	O
therapy	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
arising	O
from	O
trauma	O
,	O
sepsis	B-DISO
,	O
pneumonia	B-DISO
,	I-DISO
aspiration	I-DISO
,	O
burns	O
and	O
other	O
pulmonary	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
in	O
adult	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

We	O
report	O
the	O
first	O
series	O
of	O
adult	O
patients	O
with	O
ARF	B-DISO
and	O
HMs	B-DISO
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Three	O
patients	O
received	O
venoarterial	O
ECMO	O
because	O
of	O
acute	B-DISO
circulatory	I-DISO
failure	I-DISO
in	O
addition	O
to	O
ARF	B-DISO
;	O
all	O
other	O
patients	O
received	O
venovenous	O
ECMO	O
.	O

All	O
survivors	O
were	O
alive	O
at	O
follow	O
-	O
up	O
(	O
36	O
(	O
10	O
to	O
58	O
)	O
months	O
);	O
five	O
patients	O
were	O
in	O
complete	O
remission	B-DISO
,	O
one	O
in	O
partial	O
remission	B-DISO
,	O
and	O
one	O
had	O
relapsed	O
.	O

We	O
report	O
on	O
the	O
use	O
of	O
an	O
intra	O
-	O
aortic	O
balloon	O
pump	O
(	O
IABP	O
)	O
in	O
a	O
24	O
-	O
year	O
-	O
old	O
woman	O
brought	O
to	O
our	O
hospital	O
after	O
an	O
intentional	O
ingestion	O
of	O
a	O
tablet	O
of	O
AlP	O
(	O
3	O
g	O
),	O
which	O
caused	O
refractory	O
AlP	O
-	O
induced	O
cardiogenic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Multivariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
underlying	O
disease	O
scores	O
[	O
odds	O
ratio	O
(	O
OR	O
)=	O
1	O
.	O
874	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
1	O
.	O
138	O
-	O
3	O
.	O
084	O
,	O
P	O
=	O
0	O
.	O
014	O
],	O
whether	O
patients	O
occurrence	O
of	O
severe	B-DISO
sepsis	I-DISO
/	O
septic	B-DISO
shock	I-DISO
(	O
OR	O
=	O
0	O
.	O
167	O
,	O
95	O
%	O
CI	O
0	O
.	O
064	O
-	O
0	O
.	O
435	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
and	O
SOFA	O
scores	O
(	O
OR	O
=	O
1	O
.	O
498	O
,	O
95	O
%	O
CI	O
1	O
.	O
283	O
-	O
1	O
.	O
750	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
were	O
independent	O
factors	O
for	O
predicting	O
28	O
-	O
day	O
mortality	O
.	O

AUC	O
for	O
PIRO	O
model	O
based	O
on	O
underlying	O
disease	O
scores	O
,	O
severe	B-DISO
sepsis	I-DISO
/	O
septic	B-DISO
shock	I-DISO
,	O
SOFA	O
scores	O
was	O
0	O
.	O
871	O
(	O
0	O
.	O
814	O
-	O
0	O
.	O
928	O
),	O
P	O
=	O
0	O
.	O
000	O
.	O

The	O
neuropathology	B-DISO
after	O
Mu	O
-	O
3	O
infection	B-DISO
exhibited	O
a	O
mixed	O
pattern	O
comparable	O
to	O
that	O
induced	O
by	O
srr7	O
and	O
cl	O
-	O
2	O
infections	B-DISO
.	O

These	O
data	O
indicated	O
that	O
apoptosis	O
observed	O
in	O
Mu	O
-	O
3	O
infection	B-DISO
could	O
be	O
induced	O
by	O
the	O
indirect	O
effects	O
of	O
infection	B-DISO
in	O
addition	O
to	O
direct	O
effects	O
of	O
the	O
infected	O
cells	O
occurring	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
.	O

Therefore	O
,	O
interactions	O
of	O
MERS	O
-	O
CoV	O
at	O
the	O
human	O
-	O
animal	O
interface	O
may	O
have	O
been	O
ongoing	O
for	O
several	O
,	O
perhaps	O
many	O
,	O
years	O
and	O
by	O
inference	O
,	O
a	O
widespread	O
pandemic	O
may	O
be	O
less	O
likely	O
unless	O
significant	O
evolution	O
of	O
the	O
virus	O
allow	O
accelerated	O
infection	B-DISO
and	O
spread	O
potential	O
in	O
the	O
human	O
population	O
.	O

Outcomes	O
included	O
the	O
number	O
of	O
days	O
on	O
mechanical	O
ventilation	O
,	O
days	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
days	O
in	O
the	O
hospital	O
,	O
and	O
rates	O
of	O
pneumonia	B-DISO
,	O
sepsis	B-DISO
,	O
tracheostomy	O
,	O
chest	O
tube	O
placement	O
,	O
and	O
death	O
.	O

Patients	O
who	O
have	O
sustained	O
a	O
flail	B-DISO
chest	I-DISO
have	O
significant	O
morbidity	O
and	O
mortality	O
.	O

We	O
reviewed	O
the	O
evidence	O
regarding	O
the	O
pathogenesis	B-DISO
of	O
BPH	B-DISO
/	O
LUTS	O
with	O
particular	O
attention	O
to	O
metabolic	O
influence	O
.	O

The	O
combined	O
action	O
of	O
all	O
three	O
hits	O
,	O
or	O
even	O
two	O
of	O
them	O
,	O
may	O
result	O
in	O
overexpression	O
of	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
),	O
transformation	B-DISO
of	O
prostatic	O
cells	O
into	O
antigen	O
-	O
presenting	O
cells	O
and	O
activation	O
of	O
resident	O
human	O
prostate	O
-	O
associated	O
lymphoid	O
tissue	O
ending	O
in	O
overproduction	O
of	O
growth	O
factors	O
which	O
,	O
in	O
turn	O
,	O
will	O
induce	O
prostate	O
remodeling	O
and	O
further	O
prostate	O
enlargement	B-DISO
.	O

The	O
mechanical	O
obstruction	B-DISO
,	O
along	O
with	O
the	O
direct	O
action	O
of	O
the	O
unfavorable	O
metabolic	O
and	O
hormonal	O
milieu	O
on	O
the	O
bladder	O
neck	O
,	O
helps	O
in	O
generating	O
LUTS	O
.	O

The	O
mechanical	O
obstruction	B-DISO
,	O
along	O
with	O
the	O
direct	O
action	O
of	O
the	O
unfavorable	O
metabolic	O
and	O
hormonal	O
milieu	O
on	O
the	O
bladder	O
neck	O
,	O
helps	O
in	O
generating	O
LUTS	O
.	O

TITLE	O
:	O
Opioid	O
overdose	O
with	O
gluteal	O
compartment	B-DISO
syndrome	I-DISO
and	O
acute	O
peripheral	B-DISO
neuropathy	I-DISO
.	O

However	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
G	O
-	O
CSF	O
-	O
producing	O
lung	B-DISO
cancer	I-DISO
is	O
extremely	O
rare	O
.	O

Five	O
thousand	O
and	O
65	O
individuals	O
were	O
screened	O
for	O
MER	O
-	O
CoV	O
:	O
hospitalized	O
patients	O
with	O
suspected	O
MERS	O
-	O
CoV	O
infection	B-DISO
(	O
n	O
=	O
2908	O
,	O
57	O
.	O
4	O
%),	O
healthcare	O
worker	O
(	O
HCW	O
)	O
contacts	O
(	O
n	O
=	O
1695	O
;	O
33	O
.	O
5	O
%),	O
and	O
family	O
contacts	O
of	O
laboratory	O
-	O
confirmed	O
MERS	O
cases	O
(	O
n	O
=	O
462	O
;	O
9	O
.	O
1	O
%).	O

Ocular	O
disease	O
associated	O
with	O
viral	O
pathogens	O
is	O
not	O
unusual	O
,	O
particularly	O
with	O
viruses	O
causing	O
upper	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
cats	O
,	O
such	O
as	O
feline	O
herpesvirus	O
type	O
1	O
and	O
feline	O
calicivirus	O
.	O

We	O
report	O
the	O
successful	O
rehabilitation	O
of	O
an	O
8	O
-	O
year	O
-	O
old	O
boy	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Using	O
a	O
novel	O
visual	O
analogue	O
scale	O
(	O
VAS	O
),	O
we	O
sought	O
to	O
undertake	O
a	O
systematic	O
exploration	O
of	O
the	O
symptomatology	O
of	O
AMS	B-DISO
using	O
an	O
unbiased	O
,	O
data	O
-	O
driven	O
approach	O
originally	O
designed	O
for	O
analysis	O
of	O
gene	O
expression	O
.	O

The	O
commonest	O
pattern	O
of	O
symptoms	O
was	O
sleep	B-DISO
disturbance	I-DISO
and	O
fatigue	B-DISO
,	O
with	O
little	O
or	O
no	O
headache	B-DISO
.	O

Sleep	B-DISO
disturbance	I-DISO
correlates	O
poorly	O
with	O
other	O
symptoms	O
of	O
AMS	B-DISO
(	O
Mean	O
Spearman	O
correlation	O
0	O
.	O
25	O
).	O

This	O
is	O
the	O
first	O
report	O
on	O
a	O
patient	O
with	O
acute	O
dermatomyositis	B-DISO
and	O
fulminant	O
systemic	B-DISO
capillary	I-DISO
leak	I-DISO
syndrome	I-DISO
.	O

During	O
volume	O
loading	O
,	O
anasarca	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
rapidly	O
developed	O
.	O

This	O
case	O
report	O
indicates	O
that	O
acute	O
exacerbation	O
of	O
chronic	O
dermatomyositis	B-DISO
can	O
result	O
in	O
a	O
fulminant	O
systemic	B-DISO
capillary	I-DISO
leak	I-DISO
syndrome	I-DISO
with	O
intense	O
hemoconcentration	O
,	O
hypovolemic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Validation	O
of	O
respiratory	O
inductive	O
plethysmography	O
(	O
LifeShirt	O
)	O
in	O
obesity	B-DISO
hypoventilation	I-DISO
syndrome	I-DISO
.	O

The	O
SARS	B-DISO
epidemic	O
provided	O
valuable	O
information	O
and	O
lessons	O
relevant	O
in	O
controlling	O
outbreaks	O
of	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
and	O
has	O
led	O
to	O
fundamental	O
reforms	O
of	O
the	O
Chinese	O
health	O
system	O
.	O

These	O
associated	O
pathological	O
changes	O
of	O
lung	O
are	O
in	O
part	O
responsible	O
for	O
the	O
additional	O
morbidity	O
and	O
mortality	O
observed	O
in	O
HP	O
-	O
PRRSV	O
infection	B-DISO
.	O

Extensive	O
laboratory	O
investigations	O
failed	O
to	O
detect	O
an	O
infectious	B-DISO
cause	O
.	O

Presenting	O
symptoms	O
,	O
comorbid	O
conditions	O
,	O
pulmonary	O
and	O
extrapulmonary	O
manifestations	O
,	O
measures	O
of	O
severity	O
of	O
illness	O
and	O
organ	B-DISO
failure	I-DISO
,	O
ICU	O
course	O
,	O
and	O
outcome	O
are	O
described	O
,	O
as	O
are	O
the	O
results	O
of	O
surveillance	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
and	O
patients	O
with	O
potential	O
exposure	O
.	O

This	O
is	O
the	O
first	O
occurrence	O
of	O
stillbirth	B-DISO
during	O
an	O
infection	B-DISO
with	O
MERS	O
-	O
CoV	O
and	O
may	O
have	O
bearing	O
upon	O
the	O
surveillance	O
and	O
management	O
of	O
pregnant	O
women	O
in	O
settings	O
of	O
unexplained	O
respiratory	O
illness	O
potentially	O
due	O
to	O
MERS	O
-	O
CoV	O
.	O
Future	O
prospective	O
investigations	O
of	O
MERS	O
-	O
CoV	O
should	O
ascertain	O
pregnancy	O
status	O
and	O
obtain	O
further	O
pregnancy	O
-	O
related	O
data	O
,	O
including	O
biological	O
specimens	O
for	O
confirmatory	O
testing	O
.	O

Work	O
focused	O
on	O
enhancements	O
to	O
three	O
interrelated	O
priority	O
areas	O
and	O
included	O
achievements	O
in	O
1	O
)	O
establishing	O
an	O
emergency	B-DISO
operations	O
center	O
(	O
EOC	O
)	O
at	O
the	O
General	O
Department	O
of	O
Preventive	O
Medicine	O
with	O
training	O
of	O
personnel	O
for	O
public	O
health	O
emergency	B-DISO
management	O
;	O
2	O
)	O
improving	O
the	O
nationwide	O
laboratory	O
system	O
,	O
including	O
enhanced	O
testing	O
capability	O
for	O
several	O
priority	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
those	O
in	O
Vietnam	O
most	O
likely	O
to	O
contribute	O
to	O
public	O
health	O
emergencies	B-DISO
of	O
international	O
concern	O
);	O
and	O
3	O
)	O
creating	O
an	O
emergency	B-DISO
response	O
information	O
systems	O
platform	O
,	O
including	O
a	O
demonstration	O
of	O
real	O
-	O
time	O
reporting	O
capability	O
.	O

TITLE	O
:	O
Attenuation	O
and	O
restoration	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
mutant	B-DISO
lacking	O
2	O
'-	O
o	O
-	O
methyltransferase	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
sudden	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
and	O
,	O
more	O
recently	O
,	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
underscores	O
the	O
importance	O
of	O
understanding	O
critical	O
aspects	O
of	O
CoV	O
infection	B-DISO
and	O
pathogenesis	B-DISO
.	O

Preventing	O
recognition	O
by	O
the	O
host	O
immune	O
response	O
represents	O
a	O
critical	O
aspect	O
necessary	O
for	O
successful	O
viral	B-DISO
infection	I-DISO
.	O

Generalized	O
hypotonia	B-DISO
,	O
lactic	B-DISO
acidosis	I-DISO
,	O
hyperammonemia	B-DISO
and	O
3	O
-	O
MGA	O
were	O
present	O
in	O
all	O
since	O
birth	O
.	O

Five	O
patients	O
presented	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
at	O
birth	O
requiring	O
intubation	O
and	O
ventilatory	O
support	O
.	O

Other	O
viruses	O
have	O
developed	O
'	B-DISO
cap	I-DISO
-	O
mimicking	O
'	O
mechanisms	O
by	O
attaching	O
a	O
peptide	O
to	O
the	O
5	O
'	O
end	O
of	O
viral	O
RNA	O
(	O
e	O
.	O
g	O
.	O
picornavirus	O
and	O
calicivirus	O
)	O
or	O
by	O
having	O
a	O
complex	O
5	O
'	O
RNA	O
structure	O
(	O
internal	O
ribosome	O
entry	O
site	O
)	O
for	O
translation	O
initiation	O
(	O
e	O
.	O
g	O
.	O
picornavirus	O
,	O
pestivirus	O
and	O
hepacivirus	O
).	O

Functionally	O
,	O
capping	O
is	O
essential	O
for	O
prevention	O
of	O
triphosphate	O
-	O
triggered	O
innate	O
immune	O
activation	O
;	O
N	O
-	O
7	O
methylation	O
is	O
critical	O
for	O
enhancement	O
of	O
viral	O
translation	O
;	O
and	O
2	O
'-	O
O	O
methylation	O
is	O
important	O
for	O
subversion	O
of	O
innate	B-DISO
immune	I-DISO
response	I-DISO
during	O
viral	B-DISO
infection	I-DISO
.	O

Thus	O
,	O
our	O
study	O
provides	O
a	O
theoretical	O
foundation	O
for	O
using	O
intravenous	O
infusion	O
of	O
PFC	O
to	O
prevent	O
and	O
treat	O
ALI	O
/	O
ARDS	B-DISO
in	O
clinical	O
practice	O
.	O

Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
can	O
no	O
longer	O
be	O
considered	O
a	O
benign	O
condition	B-DISO
.	O

Out	O
of	O
the	O
164	O
recorded	O
pain	O
scores	O
(	O
2	O
.	O
9	O
pain	O
assessment	O
/	O
day	O
/	O
infant	O
),	O
14	O
.	O
6	O
%	O
confirmed	O
acute	B-DISO
pain	I-DISO
.	O

This	O
study	O
highlighted	O
the	O
difficulty	O
in	O
managing	O
pain	O
in	O
neonates	O
who	O
are	O
exposed	O
to	O
numerous	O
painful	B-DISO
procedures	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
highlighted	O
the	O
difficulty	O
in	O
managing	O
pain	O
in	O
neonates	O
who	O
are	O
exposed	O
to	O
numerous	O
painful	B-DISO
procedures	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
characteristics	O
of	O
human	O
bocavirus	O
(	O
hBoV	O
),	O
human	O
rhinovirus	O
(	O
hRV	O
),	O
polyomavirus	O
-	O
WU	O
(	O
WUPyV	O
)	O
and	O
-	O
KI	O
(	O
KIPyV	O
)	O
and	O
human	O
coronaviruses	O
(	O
CoV	O
)-	O
OC43	O
,	O
-	O
NL63	O
,	O
-	O
HKU1	O
and	O
-	O
229E	O
among	O
children	O
hospitalized	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
LRTI	B-DISO
).	O

We	O
established	O
that	O
combined	O
with	O
previously	O
-	O
investigated	O
viruses	O
,	O
at	O
least	O
one	O
respiratory	O
virus	O
was	O
identified	O
in	O
the	O
majority	O
of	O
HIV	B-DISO
-	O
infected	O
and	O
HIV	B-DISO
-	O
uninfected	O
children	O
hospitalized	O
for	O
LRTI	B-DISO
.	O

Although	O
one	O
half	O
of	O
the	O
patients	O
reported	O
respiratory	B-DISO
symptoms	I-DISO
,	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
was	O
within	O
the	O
range	O
of	O
that	O
previously	O
described	O
in	O
adult	O
asymptomatic	O
patients	O
outside	O
the	O
homeless	O
community	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
broad	O
-	O
spectrum	O
antiviral	O
small	O
molecule	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
by	O
using	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
are	O
members	O
of	O
different	O
viral	O
families	O
and	O
are	O
known	O
causative	O
agents	O
of	O
fatal	O
viral	B-DISO
diseases	I-DISO
.	O

The	O
small	O
molecule	O
inhibited	O
the	O
entry	O
of	O
all	O
pseudotyped	O
viruses	O
in	O
vitro	O
and	O
the	O
cleavage	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
glycoprotein	O
in	O
an	O
in	O
vitro	O
cleavage	O
assay	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
replicates	O
in	O
the	O
epithelial	O
cells	O
of	O
trachea	B-DISO
and	O
lungs	O
of	O
chicken	O
,	O
however	O
the	O
mechanism	O
of	O
generation	O
of	O
innate	B-DISO
immune	I-DISO
response	I-DISO
against	O
IBV	O
infection	B-DISO
in	O
these	O
tissues	O
has	O
not	O
been	O
fully	O
characterized	O
.	O

ECLS	O
might	O
,	O
therefore	O
,	O
represent	O
an	O
important	O
step	O
towards	O
improved	O
management	O
and	O
outcomes	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
compare	O
H1N1	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
ARDS	B-DISO
due	O
to	O
other	O
causes	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
focusing	O
on	O
pulmonary	O
function	O
.	O

Our	O
data	O
highlight	O
the	O
diverse	O
immune	O
responses	O
between	O
SPF	O
and	O
conventional	O
cats	O
and	O
suggest	O
a	O
decisive	O
role	O
of	O
previous	O
infection	B-DISO
by	O
heterologous	O
causative	O
agents	O
in	O
the	O
outcome	O
of	O
the	O
vaccination	O
against	O
FIP	B-DISO
.	O

The	O
implementation	O
of	O
nosocomial	B-DISO
pneumonia	I-DISO
prevention	O
bundles	O
,	O
or	O
early	O
extubation	O
in	O
a	O
fast	O
-	O
track	O
program	O
,	O
has	O
proven	O
to	O
be	O
effective	O
in	O
reducing	O
the	O
complication	B-DISO
rate	O
.	O

Postoperative	O
pulmonary	B-DISO
complications	I-DISO
are	O
common	O
,	O
but	O
severe	O
complications	O
are	O
infrequent	O
.	O

TITLE	O
:	O
Use	O
of	O
recombinant	O
nucleocapsid	O
proteins	O
for	O
serological	O
diagnosis	O
of	O
feline	O
coronavirus	B-DISO
infection	I-DISO
by	O
three	O
immunochromatographic	O
tests	O
.	O

TITLE	O
:	O
Myosins	O
1	O
and	O
6	O
,	O
myosin	O
light	O
chain	O
kinase	O
,	O
actin	O
and	O
microtubules	O
cooperate	O
during	O
antibody	O
-	O
mediated	O
internalisation	O
and	O
trafficking	O
of	O
membrane	O
-	O
expressed	O
viral	O
antigens	O
in	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
infected	O
monocytes	O
.	O

Subsequently	O
,	O
she	O
started	O
showing	O
signs	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
severe	O
tracheobronchial	O
involvement	O
,	O
and	O
gastric	O
and	O
abdominal	O
distension	B-DISO
.	O

We	O
have	O
discussed	O
the	O
role	O
of	O
key	O
residues	O
in	O
the	O
design	O
of	O
fusion	O
inhibitors	O
and	O
the	O
potential	O
of	O
the	O
substructure	O
as	O
a	O
general	O
target	O
for	O
the	O
development	O
of	O
novel	O
therapeutics	O
against	O
CoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
that	O
developed	O
nephrotic	B-DISO
syndrome	I-DISO
during	O
hospitalization	O
for	O
severe	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
without	O
history	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

The	O
antiviral	O
roles	O
of	O
triterpenoids	O
in	O
licorice	O
against	O
herpes	B-DISO
virus	O
,	O
HIV	B-DISO
,	O
hepatitis	B-DISO
virus	O
,	O
SARS	B-DISO
coronavirus	O
and	O
influenza	B-DISO
virus	O
were	O
briefly	O
summarized	O
.	O

MERS	O
-	O
CoV	O
4a	O
protein	O
interacted	O
with	O
PACT	B-DISO
in	O
an	O
RNA	O
-	O
dependent	O
manner	O
but	O
not	O
with	O
RIG	O
-	O
I	O
or	O
MDA5	O
.	O

Of	O
54	O
patients	O
,	O
there	O
were	O
18	O
ARDS	B-DISO
patients	O
in	O
mild	O
group	O
,	O
22	O
in	O
moderate	O
group	O
and	O
14	O
in	O
severe	O
group	O
.	O

Dynamic	O
observation	O
of	O
EVLWI	O
can	O
be	O
one	O
of	O
prognostic	O
factors	O
in	O
the	O
patients	O
with	O
ARDS	B-DISO
.	O

The	O
development	O
of	O
an	O
FIP	B-DISO
-	O
preventive	O
vaccine	O
requires	O
an	O
antigen	O
that	O
does	O
not	O
induce	O
antibody	O
-	O
dependent	O
enhancement	O
,	O
and	O
T	O
helper	O
(	O
Th	O
)	O
1	O
activity	O
plays	O
an	O
important	O
role	O
in	O
protect	O
against	O
FIPV	O
infection	B-DISO
.	O

As	O
the	O
new	O
disease	O
was	O
very	O
similar	O
to	O
the	O
deadly	O
SARS	B-DISO
(	O
2002	O
-	O
2003	O
)	O
and	O
since	O
it	O
was	O
provoked	O
by	O
a	O
Betacoronavirus	O
,	O
chiroptera	O
were	O
first	O
suspected	O
to	O
be	O
at	O
the	O
origin	O
of	O
this	O
infection	B-DISO
.	O

TITLE	O
:	O
Spread	O
,	O
circulation	O
,	O
and	O
evolution	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

The	O
size	O
of	O
the	O
population	O
infected	O
with	O
MERS	O
-	O
CoV	O
showed	O
a	O
gradual	O
increase	O
to	O
June	O
2013	O
,	O
followed	O
by	O
a	O
decline	O
,	O
possibly	O
due	O
to	O
increased	O
surveillance	O
and	O
infection	B-DISO
control	O
measures	O
combined	O
with	O
a	O
basic	O
reproduction	O
number	O
(	O
R0	O
)	O
for	O
the	O
virus	O
that	O
is	O
less	O
than	O
1	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
wartime	O
military	O
burns	O
:	O
application	O
of	O
the	O
Berlin	O
criteria	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
prevalence	O
and	O
related	O
outcomes	O
in	O
burned	O
military	O
casualties	O
from	O
Iraq	O
and	O
Afghanistan	O
have	O
not	O
been	O
described	O
previously	O
.	O

Multivariate	O
logistic	O
regression	O
identified	O
independent	O
risk	O
factors	O
for	O
developing	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
.	O

In	O
this	O
cohort	O
of	O
military	O
casualties	O
with	O
thermal	O
injuries	O
,	O
nearly	O
a	O
third	O
required	O
mechanical	O
ventilation	O
;	O
of	O
those	O
,	O
nearly	O
one	O
third	O
developed	O
ARDS	B-DISO
,	O
and	O
nearly	O
one	O
third	O
of	O
patients	O
with	O
ARDS	B-DISO
did	O
not	O
survive	O
.	O

Moderate	O
and	O
severe	O
ARDS	B-DISO
increased	O
the	O
odds	O
of	O
death	O
by	O
more	O
than	O
fourfold	O
and	O
ninefold	O
,	O
respectively	O
.	O

We	O
also	O
describe	O
other	O
inbound	O
migration	O
categories	O
such	O
as	O
tourists	O
and	O
resident	O
visa	B-DISO
holders	O
relevant	O
to	O
the	O
context	O
of	O
preparedness	O
and	O
planning	O
.	O

Oral	O
valganciclovir	O
treatment	O
reduces	O
the	O
risk	O
of	O
hearing	B-DISO
loss	I-DISO
in	O
congenital	B-DISO
CMV	I-DISO
infection	I-DISO
.	O

Cases	O
consisted	O
of	O
patients	O
with	O
either	O
sepsis	B-DISO
or	O
trauma	O
and	O
ALI	O
/	O
ARDS	B-DISO
;	O
controls	O
consisted	O
of	O
equivalent	O
numbers	O
of	O
matched	O
patients	O
with	O
either	O
sepsis	B-DISO
or	O
trauma	O
alone	O
.	O

We	O
measured	O
serum	O
25	O
-	O
OHD	B-DISO
levels	O
the	O
morning	O
after	O
ICU	O
admission	O
and	O
used	O
multivariable	O
regression	O
to	O
assess	O
the	O
relationship	O
between	O
25	O
-	O
OHD	B-DISO
and	O
diagnosis	O
of	O
ALI	O
/	O
ARDS	B-DISO
during	O
the	O
first	O
four	O
ICU	O
days	O
,	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
diabetes	B-DISO
,	O
smoking	O
status	O
and	O
season	O
.	O

In	O
the	O
current	O
paper	O
,	O
we	O
present	O
two	O
diabetic	O
patients	O
with	O
cystic	B-DISO
fibrosis	I-DISO
,	O
who	O
are	O
treated	O
with	O
automated	O
peritoneal	O
dialysis	O
and	O
suffered	B-DISO
from	O
episodic	O
lower	O
limb	O
infarction	B-DISO
.	O

Metapneumovirus	O
,	O
parainfluenza	B-DISO
viruses	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
highly	O
overrepresented	O
in	O
case	O
patients	O
.	O

Selectivity	O
and	O
cytotoxicity	B-DISO
studies	O
established	O
a	O
more	O
than	O
100	O
-	O
fold	O
preference	O
for	O
the	O
coronaviral	O
enzyme	O
over	O
homologous	O
human	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
),	O
and	O
no	O
significant	O
cytotoxicity	B-DISO
in	O
Vero	O
E6	O
and	O
HEK293	O
cell	O
lines	O
is	O
observed	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
one	O
of	O
the	O
most	O
important	O
fatal	O
infectious	B-DISO
diseases	I-DISO
of	O
cats	O
,	O
the	O
pathogenesis	B-DISO
of	O
which	O
has	O
not	O
yet	O
been	O
fully	O
revealed	O
.	O

Thus	O
,	O
key	O
events	O
in	O
the	O
pathogenesis	B-DISO
of	O
FIP	B-DISO
are	O
systemic	B-DISO
infection	I-DISO
with	O
FIPV	O
,	O
effective	O
and	O
sustainable	O
viral	O
replication	O
in	O
monocytes	O
,	O
and	O
activation	O
of	O
infected	O
monocytes	O
.	O

It	O
is	O
the	O
activation	O
of	O
monocytes	O
and	O
macrophages	O
that	O
directly	O
leads	O
to	O
the	O
pathologic	O
features	O
of	O
FIP	B-DISO
,	O
including	O
vasculitis	B-DISO
,	O
body	O
cavity	B-DISO
effusions	B-DISO
,	O
and	O
fibrinous	O
and	O
granulomatous	O
inflammatory	O
lesions	O
.	O

Indications	O
included	O
post	O
-	O
cardiotomy	O
cardiogenic	B-DISO
shock	I-DISO
,	O
post	O
-	O
cardiotomy	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
emergency	B-DISO
cardiac	O
resuscitation	O
,	O
and	O
post	O
-	O
percutaneous	O
coronary	O
intervention	O
cardiogenic	B-DISO
shock	I-DISO
.	O

We	O
present	O
the	O
first	O
and	O
an	O
unusual	O
case	O
of	O
East	O
African	B-DISO
trypanosomiasis	I-DISO
imported	O
to	O
Poland	O
by	O
a	O
patient	O
returning	O
from	O
a	O
tourist	O
trip	O
to	O
Uganda	O
and	O
Rwanda	O
,	O
which	O
was	O
successfully	O
treated	O
with	O
pentamidine	O
.	O

He	O
experienced	O
a	O
single	O
tsetse	O
fly	O
bite	O
during	O
a	O
safari	O
trip	O
to	O
the	O
Queen	O
Elizabeth	O
National	O
Park	B-DISO
in	O
Uganda	O
.	O

There	O
was	O
a	O
typical	O
non	O
-	O
painful	B-DISO
trypanosomal	B-DISO
chancre	I-DISO
with	O
central	O
necrosis	O
and	O
peripheral	O
erythema	B-DISO
on	O
his	O
left	O
arm	O
.	O

Sleeping	B-DISO
sickness	I-DISO
should	O
always	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
fever	O
in	O
people	O
returning	O
from	O
safari	O
trips	O
to	O
the	O
national	O
parks	O
or	O
nature	O
reserves	O
of	O
sub	O
-	O
Saharan	O
Africa	O
.	O

ABSTRACT	O
:	O
The	O
aim	O
of	O
this	O
research	O
was	O
to	O
investigate	O
the	O
blood	O
coagulation	O
function	O
in	O
the	O
patients	O
with	O
avascular	B-DISO
necrosis	I-DISO
of	I-DISO
the	I-DISO
femoral	I-DISO
head	I-DISO
(	O
ANFH	B-DISO
)	O
after	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Fifty	O
-	O
six	O
patients	O
were	O
included	O
,	O
of	O
whom	O
34	O
had	O
OSA	B-DISO
(	O
age	O
(	O
years	O
±	O
S	O
.	O
D	O
),	O
4	O
.	O
22	O
±	O
1	O
.	O
14	O
)	O
and	O
22	O
with	O
RI	O
(	O
4	O
.	O
35	O
±	O
1	O
.	O
36	O
).	O

Early	O
life	O
viral	B-DISO
infections	I-DISO
may	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
pediatric	O
OSA	B-DISO
.	O

RESULTS	O
:	O
Fifty	O
-	O
six	O
patients	O
were	O
included	O
,	O
of	O
whom	O
34	O
had	O
OSA	B-DISO
(	O
age	O
(	O
years	O
±	O
S	O
.	O
D	O
),	O
4	O
.	O
22	O
±	O
1	O
.	O
14	O
)	O
and	O
22	O
with	O
RI	O
(	O
4	O
.	O
35	O
±	O
1	O
.	O
36	O
).	O

TITLE	O
:	O
High	O
-	O
frequency	O
percussive	O
ventilation	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
A	O
single	O
center	O
experience	O
.	O

Central	O
nervous	B-DISO
system	O
involvement	O
in	O
leptospirosis	B-DISO
most	O
commonly	O
occurs	O
as	O
aseptic	B-DISO
meningitis	I-DISO
,	O
often	O
asymptomatic	O
,	O
only	O
with	O
abnormal	O
cerebrospinal	O
fluid	O
findings	O
.	O

TITLE	O
:	O
Unique	O
reassortant	O
of	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
associated	O
with	O
severe	O
disease	O
emerging	O
in	O
Hong	O
Kong	O
.	O

We	O
analyzed	O
demographic	O
and	O
clinical	O
data	O
from	O
all	O
patients	O
<	O
5	O
years	O
of	O
age	O
with	O
solo	O
detection	O
of	O
HCoV	O
-	O
OC43	O
(	O
n	O
=	O
52	O
)	O
and	O
HCoV	O
-	O
NL63	O
(	O
n	O
=	O
44	O
)	O
and	O
for	O
comparison	O
,	O
samples	O
of	O
children	O
with	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
and	O
picornaviruses	O
.	O

There	O
is	O
a	O
lack	O
of	O
proven	O
effective	O
medications	O
for	O
therapy	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
current	O
knowledge	O
of	O
therapeutic	O
options	O
for	O
MERS	O
-	O
CoV	O
is	O
based	O
on	O
the	O
experience	O
from	O
SARS	B-DISO
-	O
CoV	O
and	O
from	O
in	O
vitro	O
studies	O
.	O

The	O
aim	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
combination	O
of	O
NIV	O
with	O
administration	O
of	O
a	O
neutrophil	O
elastase	O
inhibitor	O
could	O
improve	O
outcome	O
and	O
respiratory	O
conditions	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)-	O
patients	O
,	O
according	O
to	O
the	O
Berlin	O
definition	O
.	O

This	O
virus	O
,	O
named	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
,	O
is	O
phylogenetically	O
related	O
to	O
bat	O
CoVs	O
,	O
but	O
other	O
animal	O
species	O
like	O
dromedary	O
camels	O
may	O
potentially	O
act	O
as	O
intermediate	O
hosts	O
by	O
spreading	O
the	O
virus	O
to	O
humans	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
the	O
exposure	O
to	O
Avian	O
metapneumovirus	O
(	O
aMPV	O
)	O
and	O
/	O
or	O
to	O
Turkey	B-DISO
hemorrhagic	I-DISO
enteritis	I-DISO
virus	O
(	O
THEV	O
)	O
was	O
significant	O
for	O
the	O
induction	O
of	O
episodes	O
of	O
colibacillosis	B-DISO
in	O
aMPV	O
and	O
THEV	O
vaccinated	O
turkeys	O
.	O

Vaccination	O
with	O
a	O
single	O
dose	O
of	O
the	O
THEV	O
commercial	O
inactivated	O
vaccine	O
available	O
in	O
Italy	O
seems	O
does	O
not	O
protect	O
the	O
birds	O
from	O
the	O
infection	B-DISO
.	O

We	O
examined	O
three	O
CAP	B-DISO
cohorts	O
and	O
two	O
control	O
populations	O
:	O
241	O
adult	O
Memphis	O
African	O
American	O
CAP	B-DISO
patients	O
,	O
443	O
pediatric	O
African	O
American	O
CAP	B-DISO
patients	O
,	O
90	O
adult	O
South	O
African	O
CAP	B-DISO
patients	O
,	O
120	O
Memphis	O
healthy	O
adult	O
African	O
American	O
controls	O
and	O
405	O
adult	O
Chicago	O
African	O
American	O
controls	O
.	O

A	O
26	O
-	O
day	O
-	O
old	O
boy	O
was	O
brought	O
to	O
the	O
emergency	B-DISO
department	O
because	O
of	O
severe	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
baby	O
was	O
considered	O
to	O
have	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
case	O
report	O
describes	O
a	O
rapid	O
and	O
persistent	O
improvement	O
after	O
2	O
doses	O
of	O
surfactant	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
severe	O
oxygenation	O
failure	O
caused	O
by	O
near	O
drowning	O
in	O
a	O
newborn	O
.	O

4	O
.	O
2	O
%	O
of	O
patients	O
in	O
Group	O
A	O
died	O
,	O
9	O
.	O
3	O
%	O
in	O
Group	B-DISO
B	I-DISO
and	O
26	O
%	O
in	O
Group	O
C	O
,	O
p	O
<	O
0	O
.	O
001	O
.	O

Mice	O
developed	O
a	O
pneumonia	B-DISO
characterized	O
by	O
extensive	O
inflammatory	O
-	O
cell	O
infiltration	B-DISO
with	O
virus	O
clearance	O
occurring	O
6	O
-	O
8	O
d	O
after	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
reaffirmed	O
the	O
importance	O
of	O
understanding	O
how	O
coronaviruses	O
emerge	O
,	O
infect	O
,	O
and	O
cause	O
disease	O
.	O

By	O
comparing	O
what	O
is	O
known	O
about	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
to	O
what	O
has	O
recently	O
been	O
found	O
for	O
MERS	O
-	O
CoV	O
,	O
researchers	O
are	O
discovering	O
similarities	O
and	O
differences	O
that	O
may	O
be	O
important	O
for	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
Proteolytic	O
cleavage	O
of	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
protein	O
is	O
essential	O
for	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
to	O
acquire	O
infectivity	O
.	O

Consequently	O
,	O
the	O
present	O
paper	O
could	O
have	O
a	O
large	O
impact	O
on	O
the	O
battle	O
against	O
respiratory	O
virus	O
infections	B-DISO
and	O
contribute	O
greatly	O
to	O
human	O
health	O
.	O

TITLE	O
:	O
Autopsy	O
findings	O
in	O
fatal	O
dengue	B-DISO
haemorrhagic	I-DISO
fever	I-DISO
-	O
06	O
Cases	O
.	O

ABSTRACT	O
:	O
Neuroleptic	B-DISO
malignant	I-DISO
-	O
like	O
syndrome	B-DISO
(	O
NMLS	O
)	O
is	O
a	O
rare	O
but	O
catastrophic	O
complication	B-DISO
of	O
drug	O
treatment	O
for	O
Parkinson	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
(	O
PD	O
).	O

Just	O
as	O
its	O
name	O
suggests	O
,	O
the	O
clinical	O
features	O
of	O
NMLS	O
are	O
similar	O
to	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
,	O
which	O
is	O
a	O
dangerous	O
adverse	O
response	O
to	O
antipsychotic	O
drugs	O
.	O

The	O
scar	B-DISO
above	O
the	O
suprasternal	O
notch	O
was	O
visibly	O
sunken	O
and	O
retracted	O
with	O
respiration	O
.	O

In	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
,	O
low	O
VT	O
,	O
higher	O
levels	O
of	O
positive	O
end	O
expiratory	O
pressure	O
,	O
long	O
duration	O
prone	O
position	O
and	O
neuromuscular	B-DISO
blockade	I-DISO
within	O
the	O
first	O
48	O
hours	O
are	O
associated	O
to	O
a	O
better	O
outcome	O
.	O

Community	O
-	O
acquired	O
bacterial	O
co	B-DISO
-	I-DISO
infection	I-DISO
was	O
seen	O
in	O
8	O
%;	O
2	O
%	O
had	O
gram	B-DISO
-	I-DISO
negative	I-DISO
bacteraemia	I-DISO
at	O
admission	O
.	O

Preliminary	O
biological	O
evaluation	O
indicated	O
that	O
most	O
of	O
the	O
compounds	O
exhibited	O
marked	O
inhibitory	O
activity	O
against	O
wild	O
-	O
type	O
HIV	B-DISO
-	O
1	O
IIIB	O
.	O

ABSTRACT	O
:	O
Viral	O
fulminant	B-DISO
hepatitis	I-DISO
(	O
FH	O
)	O
remains	O
a	O
serious	O
clinical	O
problem	O
with	O
very	O
high	O
mortality	O
.	O

Furthermore	O
,	O
inhibiting	O
ERK1	O
/	O
2	O
and	O
p38	O
efficiently	O
blocks	O
C5a	O
-	O
mediated	O
Fgl2	O
production	O
during	O
viral	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Rett	B-DISO
syndrome	I-DISO
(	O
RS	O
)	O
causes	O
severe	O
cognitive	B-DISO
impairment	I-DISO
,	O
loss	O
of	O
speech	O
,	O
epilepsy	B-DISO
,	O
and	O
breathing	O
disturbances	O
with	O
intermittent	O
hypoxia	B-DISO
.	O

An	O
important	O
role	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
influenza	B-DISO
and	O
ARVI	O
occupy	O
modern	O
nanotechnological	O
products	O
of	O
natural	O
origin	O
such	O
as	O
anaferon	O
,	O
aflubin	O
,	O
oscillococcinum	O
having	O
antiviral	O
,	O
immunomodulatory	O
,	O
anti	O
-	O
inflammatory	O
,	O
disintoxicational	O
and	O
antipyretic	O
activity	O
.	O

TITLE	O
:	O
Protection	O
from	O
SARS	B-DISO
coronavirus	O
conferred	O
by	O
live	O
measles	B-DISO
vaccine	O
expressing	O
the	O
spike	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
cause	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
that	O
can	O
range	O
from	O
mild	O
to	O
severe	O
.	O

ABSTRACT	O
:	O
The	O
mucosa	O
that	O
lines	O
the	O
respiratory	O
and	O
gastrointestinal	O
(	O
GI	O
)	O
tracts	O
is	O
an	O
important	O
portal	O
of	O
entry	O
for	O
pathogens	O
and	O
provides	O
the	O
first	O
line	O
of	O
innate	O
immune	O
defense	O
against	O
infections	B-DISO
.	O

Although	O
an	O
abundance	O
of	O
memory	O
CD4	O
(+)	O
T	O
cells	O
at	O
mucosal	O
sites	O
render	O
them	O
highly	O
susceptible	O
to	O
HIV	B-DISO
infection	I-DISO
,	O
the	O
gut	O
and	O
not	O
the	O
lung	O
experiences	O
severe	O
and	O
sustained	O
CD4	O
(+)	O
T	O
cell	O
depletion	O
and	O
tissue	O
disruption	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
STAT	O
/	O
NF	O
-	O
κB	O
inhibitor	O
and	O
free	O
radical	O
scavenger	O
,	O
was	O
administered	O
systemically	O
to	O
a	O
subset	O
of	O
mice	O
to	O
determine	O
whether	O
this	O
altered	O
the	O
muscle	O
contraction	B-DISO
response	O
.	O

LoFS	O
induced	O
phosphorylated	O
-	O
S6	O
in	O
BL	O
-	O
6	O
mice	O
,	O
but	O
this	O
induction	O
was	O
blocked	O
by	O
cachexia	B-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
(	O
IBV	O
),	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
and	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
)	O
H9	O
subtype	O
are	O
major	O
pathogens	O
of	O
chickens	O
causing	O
serious	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
and	O
heavy	O
economic	O
losses	O
.	O

TITLE	O
:	O
Effects	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
antigen	O
on	O
eggshell	O
formation	O
and	O
immunoreaction	O
in	O
hen	O
oviduct	O
.	O

TITLE	O
:	O
Organophosphate	O
poisoning	O
presenting	O
with	O
muscular	B-DISO
weakness	I-DISO
and	O
abdominal	B-DISO
pain	I-DISO
--	O
a	O
case	O
report	O
.	O

ALI	O
and	O
ARDS	B-DISO
are	O
induced	O
by	O
a	O
plethora	O
of	O
local	O
or	O
systemic	O
insults	O
,	O
leading	O
to	O
the	O
activation	O
of	O
multiple	O
pathways	O
responsible	O
for	O
injury	O
,	O
resolution	O
,	O
and	O
repair	O
or	O
scarring	B-DISO
of	O
the	O
lungs	O
.	O

However	O
,	O
robust	O
cluster	O
-	O
based	O
estimates	O
for	O
low	O
R0	O
values	O
are	O
still	O
desirable	O
so	O
as	O
to	O
help	O
prioritise	O
scarce	O
resources	O
between	O
different	O
emerging	O
infections	B-DISO
and	O
to	O
detect	O
significant	O
changes	O
between	O
clusters	O
and	O
over	O
time	O
.	O

However	O
,	O
in	O
more	O
vulnerable	O
populations	O
,	O
such	O
as	O
newborns	O
,	O
infants	O
,	O
the	O
elderly	O
,	O
and	O
immune	O
-	O
compromised	O
individuals	O
,	O
they	O
can	O
also	O
affect	O
the	O
lower	O
respiratory	O
tract	O
,	O
leading	O
to	O
pneumonia	B-DISO
,	O
exacerbations	O
of	O
asthma	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
or	O
even	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Macrophages	O
in	O
chronic	O
lesions	O
of	O
antibody	O
-	O
mediated	O
demyelinating	O
encephalomyelitis	B-DISO
showed	O
lysosomal	O
activity	O
but	O
very	O
little	O
p22phox	O
or	O
iNOS	O
expressions	O
.	O

Our	O
study	O
shows	O
that	O
oxidative	O
injury	O
and	O
its	O
triggering	O
mechanisms	O
diverge	O
in	O
different	O
models	O
of	O
rodent	O
central	B-DISO
nervous	I-DISO
system	I-DISO
inflammation	I-DISO
.	O

ABSTRACT	O
:	O
The	O
replication	O
of	O
coronaviruses	O
occurs	O
in	O
association	O
with	O
multiple	O
virus	O
-	O
induced	O
membrane	O
structures	O
that	O
evolve	O
during	O
the	O
course	O
of	O
infection	B-DISO
;	O
however	O
,	O
the	O
dynamics	O
of	O
this	O
process	O
remain	O
poorly	O
understood	O
.	O

Current	O
use	O
of	O
ECMO	O
extends	O
beyond	O
its	O
most	O
familiar	O
role	O
in	O
the	O
support	O
of	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
to	O
treat	O
patients	O
with	O
various	O
forms	O
of	O
severe	O
hypoxemic	O
or	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
ranging	O
from	O
bridging	O
patients	O
to	O
lung	O
transplantation	O
to	O
managing	O
pulmonary	O
hypertensive	O
crises	O
.	O

Bats	O
are	O
the	O
natural	O
reservoirs	O
of	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
(	O
CoVs	O
)	O
and	O
are	O
likely	O
the	O
reservoir	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Takotsubo	B-DISO
cardiomyopathy	I-DISO
which	O
is	O
characterised	O
by	O
a	O
transient	O
left	O
ventricular	O
wall	O
motion	O
abnormality	O
was	O
first	O
described	O
in	O
1990	O
.	O

Therefore	O
,	O
experimental	O
studies	O
are	O
needed	O
to	O
investigate	O
the	O
role	O
of	O
hypoxia	B-DISO
in	O
takotsubo	B-DISO
cardiomyopathy	I-DISO
.	O

However	O
,	O
in	O
recent	O
years	O
,	O
the	O
pig	O
industry	O
has	O
experienced	O
an	O
increased	O
number	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
cases	O
in	O
which	O
the	O
above	O
mentioned	O
pathogens	O
are	O
no	O
longer	O
detected	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
E	O
.	O
coli	O
,	O
Enterococcus	O
spp	O
.,	O
C	O
.	O
perfringens	O
and	O
C	O
.	O
difficile	O
in	O
the	O
pathogenesis	B-DISO
of	O
neonatal	O
porcine	O
diarrhea	B-DISO
with	O
no	O
established	O
casual	O
agents	O
.	O

TITLE	O
:	O
Molecular	O
characterizations	O
of	O
subcellular	O
localization	O
signals	O
in	O
the	O
nucleocapsid	O
protein	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

The	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
plays	O
important	O
roles	O
in	O
the	O
process	O
of	O
virus	O
replication	O
and	O
cellular	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	O
has	O
jumped	O
species	O
barrier	O
and	O
caused	O
severe	O
human	O
infections	B-DISO
.	O

Here	O
,	O
we	O
present	O
the	O
virological	O
features	O
relevant	O
to	O
clinical	O
practice	O
,	O
and	O
summarize	O
the	O
epidemiology	O
,	O
clinical	B-DISO
findings	I-DISO
,	O
diagnosis	O
,	O
treatment	O
,	O
and	O
preventive	O
strategies	O
of	O
A	O
(	O
H7N9	O
)	O
infection	B-DISO
.	O

Most	O
patients	O
acquired	O
the	O
infection	B-DISO
from	O
direct	O
contact	O
with	O
poultry	O
or	O
from	O
a	O
contaminated	O
environment	O
,	O
although	O
person	O
-	O
to	O
-	O
person	O
transmission	O
has	O
likely	O
occurred	O
.	O

ABSTRACT	O
:	O
The	O
outbreaks	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
in	O
2003	O
resulted	O
in	O
unprecedented	O
impacts	O
on	O
people	O
'	O
s	O
daily	O
life	O
.	O

We	O
found	O
that	O
for	O
each	O
reported	O
new	O
SARS	B-DISO
case	O
there	O
is	O
an	O
immediate	O
loss	O
of	O
about	O
1200	O
underground	O
ridership	O
(	O
the	O
fresh	O
fear	O
).	O

About	O
50	O
%	O
of	O
daily	O
ridership	O
was	O
lost	O
during	O
the	O
peak	O
of	O
the	O
2003	O
SARS	B-DISO
period	O
,	O
compared	O
with	O
the	O
loss	O
of	O
80	O
%	O
daily	O
ridership	O
during	O
the	O
closure	O
of	O
the	O
underground	O
system	O
after	O
Typhoon	O
Nari	O
,	O
the	O
loss	O
of	O
50	O
-	O
70	O
%	O
ridership	O
due	O
to	O
the	O
closure	O
of	O
the	O
governmental	O
offices	O
and	O
schools	O
during	O
typhoon	O
periods	O
,	O
and	O
the	O
loss	O
of	O
60	O
%	O
daily	O
ridership	O
during	O
Chinese	O
New	O
Year	O
holidays	O
.	O

TITLE	O
:	O
Protein	O
interferon	O
-	O
stimulated	O
gene	O
15	O
conjugation	O
delays	O
but	O
does	O
not	O
overcome	O
coronavirus	O
proliferation	B-DISO
in	O
a	O
model	O
of	O
fulminant	B-DISO
hepatitis	I-DISO
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
increasing	O
MHV	O
-	O
3	O
titers	O
were	O
coincident	O
with	O
increased	O
PLP2	O
mRNA	O
and	O
decreased	O
ISGylation	O
over	O
the	O
course	O
of	O
infection	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
an	O
important	O
host	O
viral	O
defense	O
-	O
the	O
ISG15	O
pathway	O
-	O
is	O
only	O
partially	O
effective	O
in	O
controlling	O
severe	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Human	O
metapneumovirus	O
(	O
hMPV	O
)	O
causes	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
in	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

Infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
suspected	O
on	O
March	O
21	O
and	O
confirmed	O
on	O
March	O
23	O
;	O
the	O
patient	O
,	O
who	O
had	O
contact	O
with	O
an	O
ill	B-DISO
camel	O
shortly	O
before	O
symptom	B-DISO
onset	O
,	O
died	O
on	O
March	O
26	O
.	O

Nucleic	O
acids	O
collected	O
using	O
FTA	O
Cards	O
without	O
the	O
need	O
for	O
a	O
cold	B-DISO
-	O
chain	O
or	O
special	O
liquid	O
media	O
handling	O
provided	O
realtime	O
PCR	O
results	O
consistent	O
(	O
96	O
.	O
8	O
%	O
agreement	O
,	O
kappa	O
0	O
.	O
923	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
89	O
-	O
0	O
.	O
96	O
])	O
with	O
the	O
same	O
specimens	O
collected	O
using	O
traditional	O
viral	O
transport	O
media	O
and	O
shipped	O
on	O
ice	O
using	O
the	O
U	O
.	O
S	O
.	O
Department	O
of	O
Transportation	O
mandated	O
liquid	O
handling	O
requirements	O
.	O

We	O
previously	O
demonstrated	O
that	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
co	O
-	O
infection	B-DISO
induced	I-DISO
Chlamydia	O
pecorum	O
persistence	O
/	O
stress	O
in	O
culture	O
.	O

TITLE	O
:	O
Multi	O
-	O
organ	O
lesions	O
in	O
suckling	O
mice	O
infected	O
with	O
SARS	B-DISO
-	O
associated	O
mammalian	O
reovirus	O
linked	O
with	O
apoptosis	O
induced	O
by	O
viral	O
proteins	O
μ1	O
and	O
σ1	O
.	O

Notably	O
,	O
ectopically	O
expressed	O
μ1	O
and	O
σ1	O
induced	O
similar	O
pathological	O
apoptosis	O
,	O
independent	O
of	O
BYD1	O
infection	B-DISO
,	O
in	O
host	O
cells	O
in	O
which	O
they	O
were	O
expressed	O
,	O
which	O
suggests	O
that	O
μ1	O
and	O
σ1	O
are	O
both	O
apoptotic	O
virulence	O
factors	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
can	O
result	O
from	O
both	O
direct	O
and	O
indirect	O
pulmonary	O
damage	O
caused	O
by	O
trauma	O
and	O
shock	O
.	O

Moreover	O
,	O
patients	O
with	O
low	O
OCT	O
results	O
at	O
T24	O
exhibited	O
more	O
severe	O
respiratory	B-DISO
failure	I-DISO
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Passage	O
of	O
BtCoV	O
HKU5	O
-	O
SE	O
in	O
young	O
mice	O
resulted	O
in	O
enhanced	O
virulence	O
,	O
causing	O
20	O
%	O
weight	O
loss	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
and	O
hyaline	B-DISO
membrane	I-DISO
formation	O
in	O
aged	O
mice	O
.	O

We	O
included	O
RCTs	O
in	O
ARDS	B-DISO
published	O
in	O
English	O
.	O

A	O
diagnosis	O
of	O
acute	O
pulmonary	B-DISO
thromboembolism	I-DISO
was	O
suggested	O
by	O
initial	O
evaluation	O
.	O

ABSTRACT	O
:	O
More	O
than	O
a	O
decade	O
after	O
the	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
/	O
2003	O
the	O
occurrence	O
of	O
a	O
novel	O
CoV	O
termed	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
CoV	O
challenges	O
researchers	O
and	O
public	O
health	O
authorities	O
.	O

Furthermore	O
,	O
pigs	O
receiving	O
high	O
Zn	O
diet	O
showed	O
a	O
down	O
-	O
regulation	O
of	O
interferon	O
(	O
IFN	O
)-	O
α	O
,	O
oligoadenylate	O
synthetase	O
(	O
OAS	B-DISO
),	O
Zn	O
transporter	O
SLC39A4	O
(	O
ZIP4	O
),	O
but	O
up	O
-	O
regulation	O
of	O
metallothionein	O
-	O
1	O
(	O
MT1	O
),	O
as	O
well	O
as	O
the	O
Zn	O
transporters	O
SLC30A1	O
(	O
ZnT1	O
)	O
and	O
SLC30A5	O
(	O
ZnT5	O
).	O

TITLE	O
:	O
Anxiety	O
,	O
worry	O
and	O
cognitive	O
risk	O
estimate	O
in	O
relation	O
to	O
protective	O
behaviors	O
during	O
the	O
2009	O
influenza	B-DISO
A	O
/	O
H1N1	O
pandemic	O
in	O
Hong	O
Kong	O
:	O
ten	O
cross	O
-	O
sectional	O
surveys	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
4	O
-(	O
naphthalen	O
-	O
1	O
-	O
yl	O
)-	O
1	O
,	O
2	O
,	O
5	O
-	O
thiadiazol	O
-	O
3	O
-	O
hydroxyl	O
derivatives	O
(	O
Ia	O
-	O
Im	O
and	O
IIa	O
-	O
IIe	O
)	O
designed	O
as	O
novel	O
HIV	B-DISO
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NNRTIs	O
)	O
was	O
synthesized	O
via	O
an	O
expeditious	O
route	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	B-DISO
activities	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

Molecular	O
docking	O
of	O
compound	O
Ih	O
with	O
wt	O
HIV	B-DISO
-	O
1	O
RT	O
was	O
performed	O
to	O
understand	O
the	O
binding	O
mode	O
between	O
these	O
inhibitors	O
and	O
the	O
wt	O
HIV	B-DISO
-	O
1	O
RT	O
and	O
to	O
rationalize	O
some	O
SARs	B-DISO
.	O

ABSTRACT	O
:	O
The	O
year	O
2013	O
marks	O
the	O
10th	O
anniversary	O
of	O
the	O
outbreak	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
possibility	O
that	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
variants	O
isolated	O
from	O
broilers	O
with	O
enteric	O
and	O
respiratory	B-DISO
problems	I-DISO
have	O
a	O
different	O
tropism	O
and	O
pathological	O
outcome	O
from	O
those	O
IBV	O
strains	O
causing	O
classical	O
respiratory	B-DISO
disease	I-DISO
was	O
investigated	O
.	O

IBV	O
variants	O
were	O
isolated	O
from	O
broiler	O
flocks	O
with	O
enteric	O
and	O
respiratory	B-DISO
problems	I-DISO
in	O
two	O
regions	O
of	O
Brazil	O
.	O

Broilers	O
were	O
more	O
susceptible	O
to	O
infection	B-DISO
than	O
SPF	O
chickens	O
,	O
and	O
seroconversion	O
was	O
detected	O
in	O
all	O
of	O
the	O
chicks	O
.	O

Fifty	O
percentage	O
of	O
subjects	O
reported	O
allergy	B-DISO
,	O
59	O
%	O
had	O
≥	O
1	O
nasopharyngeal	O
viruses	O
,	O
and	O
24	O
%	O
had	O
≥	O
1	O
intratonsillar	O
viruses	O
.	O

Tonsillar	O
cytokine	O
expression	O
is	O
closely	O
related	O
to	O
existing	O
viral	B-DISO
infections	I-DISO
,	O
age	O
,	O
and	O
allergic	O
illnesses	O
and	O
shows	O
distinct	O
clusters	O
between	O
antiviral	O
and	O
immune	O
regulatory	O
genes	O
.	O

Peripheral	O
blood	O
smear	O
and	O
bone	O
marrow	O
aspirate	O
examinations	O
revealed	O
abnormal	O
large	O
intracytoplasmic	O
granules	O
,	O
which	O
was	O
diagnostic	O
of	O
CHS	B-DISO
.	O

TITLE	O
:	O
Spectrum	O
of	O
viral	B-DISO
infections	I-DISO
in	O
patients	O
with	O
cystic	B-DISO
fibrosis	I-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
the	O
agent	O
of	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
that	O
affects	O
domestic	O
fowl	O
(	O
Gallus	O
gallus	O
).	O

Clinical	O
heterogeneity	O
makes	O
JMML	B-DISO
diagnosis	O
difficult	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	B-DISO
infections	I-DISO
in	O
cats	O
in	O
southwestern	O
Poland	O
in	O
the	O
years	O
2006	O
to	O
2010	O
.	O

Examinations	O
were	O
performed	O
to	O
diagnose	O
the	O
following	O
infections	B-DISO
:	O
feline	B-DISO
leukemia	I-DISO
virus	O
(	O
FeLV	O
),	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
),	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
and	O
feline	O
herpesvirus	O
(	O
FHV	O
).	O

To	O
create	O
a	O
model	O
for	O
predicting	O
hospital	O
survival	O
at	O
initiation	O
of	O
ECMO	O
for	O
respiratory	B-DISO
failure	I-DISO
.	O

Adult	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
treated	O
by	O
ECMO	O
from	O
2000	O
to	O
2012	O
were	O
extracted	O
from	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
)	O
international	O
registry	O
.	O

The	O
RESP	O
score	O
is	O
a	O
relevant	O
and	O
validated	O
tool	O
to	O
predict	O
survival	O
for	O
patients	O
receiving	O
ECMO	O
for	O
respiratory	B-DISO
failure	I-DISO
.	O

Acute	B-DISO
heart	I-DISO
failure	I-DISO
and	O
multiorgan	B-DISO
failure	I-DISO
,	O
have	O
been	O
successfully	O
cured	O
with	O
the	O
concomitant	O
use	O
of	O
ECMO	O
,	O
hemodiafiltration	O
and	O
oscillatory	O
ventilation	O
.	O

Two	O
liquid	O
chip	O
assay	O
panels	O
,	O
developed	O
based	O
on	O
xMAP	O
technology	O
,	O
can	O
detect	O
5	O
types	O
/	O
subtypes	O
of	O
influenza	B-DISO
viruses	O
and	O
14	O
respiratory	O
viruses	O
simultaneously	O
in	O
one	O
reaction	O
in	O
6	O
hours	O
.	O

They	O
are	O
potentially	O
rapid	O
,	O
sensitive	O
,	O
specific	O
,	O
and	O
high	O
throughput	O
diagnostic	O
tools	O
for	O
major	O
viral	O
pathogens	O
associated	O
with	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

To	O
test	O
plans	O
that	O
were	O
developed	O
for	O
mass	O
prophylaxis	O
scenarios	O
,	O
in	O
April	O
2013	O
the	O
Cook	O
Country	O
Department	O
of	O
Public	O
Health	O
(	O
CCDPH	O
)	O
and	O
the	O
Triple	O
Community	O
(	O
TripCom	O
)	O
Medical	O
Reserve	O
Corps	O
(	O
MRC	O
)	O
executed	O
a	O
full	O
-	O
scale	O
mass	O
prophylaxis	O
exercise	O
in	O
response	O
to	O
a	O
simulated	O
anthrax	B-DISO
bioterrorism	O
attack	O
.	O

His	O
post	O
-	O
operative	O
recovery	O
was	O
complicated	O
by	O
myocardial	B-DISO
infarction	I-DISO
and	O
stroke	B-DISO
but	O
he	O
made	O
a	O
full	O
recovery	O
.	O

In	O
the	O
diagnosis	O
and	O
treatment	O
of	O
bacterial	B-DISO
infections	I-DISO
,	O
three	O
aspects	O
must	O
be	O
considered	O
:	O
the	O
appropriateness	O
of	O
antibacterial	O
therapy	O
,	O
the	O
initiation	O
and	O
evaluation	O
of	O
an	O
effective	O
initial	O
therapy	O
,	O
and	O
termination	O
of	O
the	O
antimicrobial	O
treatment	O
.	O

Furthermore	O
,	O
it	O
is	O
important	O
to	O
realize	O
that	O
besides	O
bacterial	B-DISO
infection	I-DISO
,	O
other	O
disease	O
states	O
can	O
elevate	O
PCT	B-DISO
levels	O
.	O

TITLE	O
:	O
Early	O
response	O
to	O
the	O
emergence	O
of	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
in	O
humans	O
in	O
China	O
:	O
the	O
central	O
role	O
of	O
prompt	O
information	O
sharing	O
and	O
public	O
communication	O
.	O

Demographics	O
,	O
comorbidities	O
,	O
clinical	B-DISO
findings	I-DISO
,	O
radiologic	O
appearance	O
and	O
scores	O
of	O
the	O
affected	O
lung	O
parenchyma	O
were	O
compared	O
between	O
survivor	O
group	O
(	O
n	O
=	O
15	O
)	O
and	O
mortality	O
group	O
(	O
n	O
=	O
7	O
).	O

All	O
the	O
patients	O
in	O
mortality	O
group	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
required	O
mechanical	O
ventilation	O
,	O
while	O
in	O
the	O
survival	O
group	O
33	O
%	O
(	O
5	O
/	O
15	O
)	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
27	O
%	O
(	O
4	O
/	O
15	O
)	O
required	O
mechanical	O
ventilation	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
High	O
initial	O
radiologic	O
score	O
is	O
associated	O
with	O
mortality	O
in	O
patients	O
with	O
avian	B-DISO
influenza	I-DISO
H7N9	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
This	O
review	O
focuses	O
on	O
current	O
knowledge	O
of	O
traditional	O
Chinese	O
herbs	O
on	O
prevention	O
and	O
treatment	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
,	O
especially	O
caused	O
by	O
Severe	O
Acute	O
Respiratory	O
Syndromes	B-DISO
(	O
SARS	B-DISO
)	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
influenza	B-DISO
viruses	O
.	O

Terms	O
of	O
Chinese	O
herbs	O
and	O
infections	B-DISO
of	O
respiratory	O
tract	O
were	O
used	O
in	O
the	O
search	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
severe	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
non	O
-	O
surgical	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
postoperative	B-DISO
complications	I-DISO
was	O
higher	O
in	O
older	O
compared	O
to	O
younger	O
patients	O
.	O

Notably	O
,	O
lumbar	O
puncture	O
and	O
MRI	O
scan	O
were	O
relatively	O
contraindicated	O
,	O
hence	O
a	O
CNS	B-DISO
infection	I-DISO
was	O
not	O
completely	O
ruled	O
out	O
.	O

However	O
,	O
not	O
long	O
after	O
,	O
she	O
returned	O
to	O
the	O
emergency	B-DISO
department	O
complaining	O
of	O
a	O
red	O
,	O
painful	B-DISO
,	O
swollen	O
right	O
knee	O
.	O

TITLE	O
:	O
A	O
conformation	O
-	O
dependent	O
neutralizing	O
monoclonal	O
antibody	O
specifically	O
targeting	O
receptor	O
-	O
binding	O
domain	O
in	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
spike	O
protein	O
.	O

Notably	O
,	O
it	O
showed	O
the	O
highest	O
sequence	O
identity	O
with	O
the	O
S	O
gene	O
of	O
SARS	B-DISO
CoVs	O
and	O
Rs3367	O
,	O
especially	O
in	O
the	O
RBD	O
region	O
.	O

Confusing	O
case	O
definitions	O
such	O
as	O
MERS	O
(	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
)	O
and	O
SARI	O
(	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
)	O
were	O
coined	O
.	O

In	O
early	O
2013	O
,	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
presented	O
with	O
sars	B-DISO
,	O
ARDS	B-DISO
(	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
),	O
right	O
-	O
sided	O
pneumonia	B-DISO
and	O
pleural	B-DISO
effusion	I-DISO
.	O

Experimental	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
the	O
pathogenesis	B-DISO
of	O
lung	O
injuries	O
in	O
MP	O
infection	B-DISO
is	O
associated	O
with	O
a	O
cell	B-DISO
-	I-DISO
mediated	I-DISO
immune	I-DISO
reaction	I-DISO
,	O
and	O
high	O
responsiveness	O
to	O
corticosteroid	O
therapy	O
has	O
been	O
reported	O
especially	O
for	O
severe	O
disease	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
a	O
case	O
-	O
control	O
study	O
of	O
hospitalized	O
patients	O
.	O

Admission	O
chest	O
radiography	O
with	O
interstitial	O
infiltrates	B-DISO
was	O
more	O
frequent	O
in	O
case	O
patients	O
than	O
in	O
controls	O
(	O
67	O
%	O
vs	O
20	O
%;	O
OR	O
,	O
8	O
.	O
13	O
;	O
P	O
=	O
.	O
001	O
).	O

Few	O
clinical	O
predictors	O
could	O
enhance	O
the	O
ability	O
to	O
predict	O
which	O
patients	O
with	O
pneumonia	B-DISO
would	O
have	O
MERS	O
-	O
CoV	O
.	O
However	O
,	O
further	O
prospective	O
analysis	O
and	O
matched	O
case	O
-	O
control	O
studies	O
may	O
shed	O
light	O
on	O
other	O
predictors	O
of	O
infection	B-DISO
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
severe	O
pneumonia	B-DISO
and	O
ARDS	B-DISO
requiring	O
mechanical	O
ventilation	O
experience	O
high	O
rates	O
of	O
ICU	O
mortality	O
or	O
disability	O
,	O
even	O
if	O
they	O
were	O
quite	O
healthy	O
before	O
.	O

The	O
testing	O
for	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
turned	O
negative	O
on	O
day	O
16	O
since	O
the	O
antivirus	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
the	O
availability	O
of	O
existing	O
nucleic	O
acid	O
amplification	B-DISO
-	O
based	O
diagnostic	O
methods	O
for	O
MERS	O
-	O
CoV	O
infections	B-DISO
by	O
providing	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
kit	O
,	O
including	O
an	O
internal	O
control	O
and	O
two	O
target	O
regions	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

CONCLUSIONS	O
:	O
Concomitance	O
of	O
bacterial	O
and	O
viral	O
agents	O
is	O
frequent	O
and	O
resemble	O
with	O
bacterial	B-DISO
infections	I-DISO
alone	O
.	O

Their	O
morbidities	O
and	O
mortalities	O
are	O
often	O
a	O
direct	O
result	O
of	O
cytokine	B-DISO
storm	I-DISO
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
used	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
can	O
damage	O
pulmonary	O
epithelial	O
cells	O
through	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
oxygen	O
radicals	O
,	O
and	O
neutrophil	O
infiltration	B-DISO
,	O
termed	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Understanding	O
the	O
protective	O
effects	O
of	O
neutrophil	O
elastase	O
inhibitor	O
associated	O
with	O
the	O
reduction	O
of	O
MIP	B-DISO
-	O
2	O
allow	O
clarification	O
of	O
the	O
pathophysiological	O
mechanisms	O
regulating	O
severe	O
lung	B-DISO
inflammation	I-DISO
and	O
development	O
of	O
possible	O
therapeutic	O
strategies	O
involved	O
in	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
novel	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
emerged	O
as	O
a	O
result	O
of	O
spike	O
gene	O
recombination	O
between	O
two	O
highly	O
diverged	O
parent	O
strains	O
.	O

TITLE	O
:	O
Mechanical	O
ventilation	O
drives	O
pneumococcal	B-DISO
pneumonia	I-DISO
into	O
lung	O
injury	O
and	O
sepsis	B-DISO
in	O
mice	O
:	O
protection	O
by	O
adrenomedullin	O
.	O

We	O
analyzed	O
in	O
mice	O
the	O
impact	O
of	O
MV	O
in	O
established	O
pneumonia	B-DISO
on	O
lung	O
injury	O
,	O
inflammation	B-DISO
,	O
bacterial	O
burden	O
,	O
hemodynamics	O
and	O
extrapulmonary	O
organ	O
injury	O
,	O
and	O
assessed	O
the	O
therapeutic	O
potential	O
of	O
AM	O
by	O
starting	O
treatment	O
at	O
intubation	O
.	O

Lung	O
and	O
blood	O
bacterial	O
burden	O
was	O
not	O
affected	O
by	O
MV	O
pneumonia	B-DISO
and	O
MV	O
increased	O
lung	O
AM	O
expression	O
,	O
whereas	O
receptor	O
activity	O
modifying	O
protein	O
(	O
RAMP	O
)	O
1	O
-	O
3	O
expression	O
was	O
increased	O
in	O
pneumonia	B-DISO
and	O
reduced	O
by	O
MV	O
.	O

Consequently	O
,	O
48	O
derivatives	O
of	O
dehydroandrographolide	O
and	O
andrographolide	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HBV	B-DISO
properties	O
to	O
yield	O
a	O
series	O
of	O
active	O
derivatives	O
with	O
lower	O
cytotoxicity	B-DISO
,	O
including	O
14	O
derivatives	O
against	O
HBsAg	O
secretion	O
,	O
19	O
derivatives	O
against	O
HBeAg	O
secretion	O
and	O
38	O
derivatives	O
against	O
HBV	B-DISO
DNA	O
replication	O
.	O

TITLE	O
:	O
Mechanical	O
ventilation	O
in	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
:	O
a	O
review	O
of	O
new	O
strategies	O
for	O
the	O
practicing	O
hospitalist	O
.	O

This	O
review	O
focuses	O
on	O
emerging	O
evidence	O
regarding	O
strategies	O
for	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
including	O
:	O
low	O
tidal	O
volume	O
ventilation	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
novel	O
ventilator	O
modes	O
as	O
alternatives	O
to	O
low	O
tidal	O
volume	O
ventilation	O
,	O
adjunctive	O
strategies	O
that	O
may	O
enhance	O
recovery	O
in	O
ARDS	B-DISO
,	O
the	O
use	O
of	O
lung	O
-	O
protective	O
strategies	O
in	O
patients	O
without	O
ARDS	B-DISO
,	O
rescue	O
therapies	O
in	O
refractory	O
hypoxemia	O
,	O
and	O
an	O
evidence	O
-	O
based	O
approach	O
to	O
weaning	O
from	O
mechanical	O
ventilation	O
.	O

Adjunctive	O
therapies	O
in	O
ARDS	B-DISO
include	O
a	O
conservative	O
fluid	O
management	O
strategy	O
,	O
as	O
well	O
as	O
neuromuscular	B-DISO
blockade	I-DISO
and	O
prone	O
positioning	O
in	O
moderate	O
-	O
to	O
-	O
severe	O
disease	O
.	O

Methods	O
:	O
Thirty	O
patients	O
with	O
nasal	B-DISO
polyps	I-DISO
and	O
a	O
group	O
of	O
20	O
healthy	O
patients	O
(	O
control	O
group	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

None	O
of	O
these	O
strategies	O
has	O
progressed	O
to	O
an	O
approved	O
human	O
coronavirus	O
vaccine	O
in	O
the	O
ten	O
years	O
since	O
SARS	B-DISO
-	O
CoV	O
emerged	O
.	O

Dendritic	O
cells	O
(	O
DCs	B-DISO
),	O
through	O
uptake	O
and	O
presentation	O
of	O
antigens	O
to	O
T	O
cells	O
,	O
initiate	O
distinct	O
immune	O
responses	O
to	O
different	O
infections	B-DISO
.	O

TITLE	O
:	O
Spinal	O
cord	B-DISO
injury	O
,	O
immunodepression	O
,	O
and	O
antigenic	O
challenge	O
.	O

ECLS	O
patients	O
received	O
more	O
blood	O
transfusions	O
and	O
had	O
more	O
bleeding	B-DISO
complications	O
,	O
while	O
the	O
CONV	O
patients	O
had	O
more	O
pulmonary	B-DISO
complications	I-DISO
.	O

TITLE	O
:	O
Role	O
of	O
transportation	O
in	O
spread	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
,	O
United	O
States	O
.	O

Based	O
on	O
the	O
field	O
situation	O
,	O
the	O
effectiveness	O
of	O
current	O
vaccination	O
practices	O
mostly	O
based	O
on	O
Massachusetts	O
and	O
Connecticut	O
-	O
type	O
vaccines	O
appeared	O
generally	O
satisfactory	O
for	O
minimizing	O
the	O
damage	O
due	O
to	O
infection	B-DISO
with	O
Canadian	O
variant	O
and	O
US	O
variant	O
-	O
like	O
viruses	O
.	O

Piglets	O
originating	O
from	O
severely	O
affected	O
litters	O
were	O
estimated	O
to	O
have	O
a	O
reduced	O
ADG	O
of	O
38	O
g	O
.	O
The	O
study	O
did	O
not	O
show	O
an	O
overall	O
effect	O
of	O
diarrhoea	B-DISO
on	O
mortality	O
,	O
but	O
herd	O
of	O
origin	O
,	O
sow	O
parity	O
,	O
birth	O
weight	O
,	O
and	O
gender	O
were	O
significantly	O
associated	O
with	O
mortality	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
prevalence	O
of	O
these	O
conditions	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

We	O
report	O
the	O
clinical	O
presentation	O
and	O
outcome	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
11	O
pediatric	O
patients	O
.	O

The	O
sources	O
of	O
the	O
infections	B-DISO
are	O
not	O
known	O
,	O
but	O
strains	O
D274	O
and	O
4	O
/	O
91	O
are	O
widely	O
used	O
in	O
vaccines	O
elsewhere	O
.	O

The	O
independence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
E	O
enhancement	O
effect	O
on	O
VLP	O
production	O
from	O
its	O
viral	O
packaging	O
capacity	O
suggests	O
a	O
distinct	O
SARS	B-DISO
-	O
CoV	O
E	O
role	O
in	O
virus	O
assembly	O
.	O

RESULTS	O
:	O
SARS	B-DISO
-	O
CoV	O
N	O
is	O
released	O
from	O
cells	O
through	O
an	O
association	O
with	O
E	O
protein	O
-	O
containing	O
vesicles	B-DISO
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
common	O
,	O
devastating	O
complication	B-DISO
of	O
critical	B-DISO
illness	I-DISO
that	O
is	O
characterized	O
by	O
pulmonary	O
injury	O
and	O
inflammation	B-DISO
.	O

In	O
the	O
training	O
cohort	O
(	O
40	O
patients	O
with	O
ARDS	B-DISO
versus	O
66	O
controls	O
)	O
the	O
diagnostic	O
model	O
for	O
ARDS	B-DISO
showed	O
a	O
moderate	O
discrimination	O
,	O
with	O
an	O
area	O
under	O
the	O
receiver	O
-	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
-	O
ROC	O
)	O
of	O
0	O
.	O
72	O
(	O
95	O
%-	O
confidence	O
interval	O
(	O
CI	O
):	O
0	O
.	O
63	O
-	O
0	O
.	O
82	O
).	O

The	O
exhaled	O
breath	O
profile	O
from	O
patients	O
with	O
cardiopulmonary	O
edema	B-DISO
and	O
pneumonia	B-DISO
was	O
different	O
from	O
that	O
of	O
patients	O
with	O
moderate	O
/	O
severe	O
ARDS	B-DISO
.	O

However	O
,	O
their	O
fatal	B-DISO
outcomes	I-DISO
and	O
critically	O
severe	O
illness	O
were	O
significantly	O
associated	O
with	O
high	O
serum	O
levels	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
α	O
.	O

Recently	O
,	O
there	O
were	O
reports	O
supposed	O
to	O
be	O
cases	O
of	O
human	O
to	O
human	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
pathophysiology	O
of	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
)	O
remains	O
unclear	O
because	O
of	O
a	O
lack	O
of	O
surrogate	O
disease	O
models	O
with	O
which	O
to	O
perform	O
pathogenesis	B-DISO
studies	O
.	O

Here	O
we	O
show	O
that	O
rhesus	O
macaques	O
infected	O
with	O
Sin	O
Nombre	O
virus	O
(	O
SNV	O
),	O
the	O
primary	O
etiological	O
agent	O
of	O
HPS	B-DISO
in	O
North	O
America	O
,	O
propagated	O
in	O
deer	O
mice	O
develop	O
HPS	B-DISO
,	O
which	O
is	O
characterized	O
by	O
thrombocytopenia	O
,	O
leukocytosis	B-DISO
,	O
and	O
rapid	O
onset	O
of	O
respiratory	B-DISO
distress	I-DISO
caused	O
by	O
severe	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

The	O
ferret	O
is	O
also	O
used	O
to	O
study	O
cystic	B-DISO
fibrosis	I-DISO
and	O
various	O
cancers	B-DISO
,	O
as	O
well	O
as	O
reproductive	O
biology	O
and	O
physiology	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
foamy	O
virus	O
reverse	O
transcriptase	O
by	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
RNase	O
H	O
inhibitors	O
.	O

Structural	O
overlays	O
were	O
performed	O
with	O
HIV	B-DISO
-	O
1	O
and	O
PFV	O
RNase	O
H	O
to	O
propose	O
the	O
RDS1643	O
binding	O
site	O
in	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
.	O
Our	O
results	O
suggest	O
that	O
this	O
approach	O
can	O
be	O
used	O
to	O
establish	O
PFV	O
RNase	O
H	O
as	O
a	O
model	O
system	O
for	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
in	O
order	O
to	O
identify	O
putative	O
inhibitor	O
binding	O
sites	O
in	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
.	O

TITLE	O
:	O
T	O
-	O
tube	O
drainage	O
and	O
intercostals	O
muscle	O
flap	O
reinforcement	O
for	O
the	O
management	O
of	O
intrathoracic	O
esophago	O
-	O
gastric	O
anastomotic	B-DISO
leakage	I-DISO
with	O
pyothorax	B-DISO
:	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
coronavirus	O
spike	O
fusion	O
protein	O
by	O
trypsin	O
in	O
cell	O
culture	O
.	O

Understanding	O
the	O
biology	O
of	O
PEDV	O
is	O
critical	O
for	O
combatting	O
the	O
infection	B-DISO
.	O

35	O
patients	O
with	O
ARDS	B-DISO
were	O
included	O
.	O

Early	O
lactate	O
clearance	O
rate	O
could	O
be	O
used	O
as	O
an	O
important	O
variable	O
for	O
evaluating	O
the	O
prognosis	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
patients	O
on	O
ECMO	O
.	O

TITLE	O
:	O
Characteristics	O
and	O
outcomes	O
of	O
patients	O
hospitalized	O
following	O
pulmonary	B-DISO
aspiration	I-DISO
.	O

The	O
patient	O
was	O
managed	O
by	O
intravenous	O
quinine	O
and	O
norepinephrine	O
infusion	O
due	O
to	O
refractory	B-DISO
shock	I-DISO
.	O

The	O
patient	O
developed	O
as	O
an	O
early	B-DISO
complication	I-DISO
ischemic	O
lesions	O
of	O
both	O
arms	B-DISO
and	O
feet	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
rates	O
,	O
trends	O
,	O
predictive	O
risk	O
factors	O
,	O
and	O
outcomes	O
associated	O
with	O
pneumothorax	B-DISO
in	O
neonates	O
.	O

Pneumothorax	B-DISO
rates	O
were	O
higher	O
among	O
term	O
and	O
early	O
preterm	O
neonates	O
admitted	O
to	O
the	O
NICU	O
.	O

The	O
cat	O
was	O
referred	O
to	O
veterinary	O
hospital	O
with	O
clinical	O
signs	O
related	O
to	O
diffuse	O
gastro	O
-	O
intestinal	O
inflammation	B-DISO
,	O
it	O
had	O
developed	O
a	O
severe	O
pneumopathy	B-DISO
with	O
fibrinous	O
exudation	O
in	O
all	O
body	O
cavities	B-DISO
and	O
died	O
8	O
days	O
after	O
initial	O
presentation	O
.	O

TITLE	O
:	O
Determinants	O
of	O
noninvasive	O
ventilation	O
success	O
or	O
failure	O
in	O
morbidly	O
obese	B-DISO
patients	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

We	O
prospectively	O
included	O
76	O
consecutive	O
patients	O
with	O
BMI	O
>	O
40	O
kg	O
/	O
m2	O
diagnosed	O
with	O
OHS	B-DISO
and	O
treated	O
by	O
NIV	O
for	O
ARF	B-DISO
in	O
a	O
15	O
-	O
bed	B-DISO
ICU	O
of	O
a	O
tertiary	O
hospital	O
.	O

RESULTS	O
:	O
NIV	O
failed	O
to	O
reverse	O
ARF	B-DISO
in	O
only	O
13	O
patients	O
.	O

Time	O
-	O
sequenced	O
cohort	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
role	O
of	O
viral	O
-	O
bacterial	O
interactions	O
in	O
exacerbations	O
of	O
bronchiectasis	B-DISO
.	O

We	O
describe	O
the	O
surgical	O
procedure	O
and	O
the	O
management	O
of	O
a	O
later	O
complication	B-DISO
consisting	O
in	O
the	O
collapse	B-DISO
of	O
the	O
osteoporotic	O
vertebra	O
below	O
the	O
instrumentation	O
that	O
required	O
a	O
surgical	O
revision	O
.	O

ABSTRACT	O
:	O
Since	O
mid	O
-	O
March	O
2014	O
,	O
the	O
frequency	O
with	O
which	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
have	O
been	O
reported	O
has	O
increased	O
,	O
with	O
the	O
majority	O
of	O
recent	O
cases	O
reported	O
from	O
Saudi	O
Arabia	O
and	O
United	O
Arab	O
Emirates	O
(	O
UAE	O
).	O

Importance	O
:	O
Influenza	B-DISO
A	O
viruses	O
are	O
respiratory	O
pathogens	O
that	O
may	O
cause	O
pneumonia	B-DISO
in	O
humans	O
.	O

TITLE	O
:	O
Ribavirin	O
and	O
interferon	O
-	O
α2b	O
as	O
primary	O
and	O
preventive	O
treatment	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
a	O
preliminary	O
report	O
of	O
two	O
cases	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
recognized	O
transmissible	O
viral	B-DISO
infection	I-DISO
with	O
high	O
virulence	O
and	O
case	O
fatality	O
rates	O
for	O
which	O
there	O
is	O
no	O
currently	O
defined	O
primary	O
treatment	O
or	O
prophylaxis	O
.	O

The	O
follow	O
-	O
up	O
of	O
199	O
close	O
contacts	O
identified	O
through	O
contact	O
tracing	O
and	O
vigilant	O
surveillance	O
did	O
not	O
result	O
in	O
detecting	O
any	O
other	O
confirmed	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
syndrome	B-DISO
(	O
TEN	O
)	O
is	O
a	O
rare	O
severe	O
cutaneous	O
adverse	O
drug	O
reaction	O
that	O
involves	O
skin	O
and	O
mucous	O
membranes	O
.	O

Although	O
allopurinol	O
is	O
a	O
known	O
triggering	O
agent	O
,	O
TEN	O
presenting	O
with	O
rhabdomyolysis	B-DISO
and	O
acute	O
kidney	O
injury	O
is	O
rare	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
SSYA10	O
-	O
001	O
as	O
a	O
replication	O
inhibitor	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
mouse	B-DISO
hepatitis	I-DISO
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronaviruses	O
.	O

Registered	O
therapeutics	O
for	O
the	O
treatment	O
of	O
coronavirus	B-DISO
infections	I-DISO
are	O
not	O
available	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
comprise	O
a	O
large	O
group	O
of	O
emergent	O
human	O
and	O
animal	O
pathogens	O
,	O
including	O
the	O
highly	O
pathogenic	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
strains	O
that	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
infected	O
individuals	O
,	O
especially	O
the	O
elderly	O
.	O

A	O
strong	O
neutralizing	O
antibody	O
response	O
generated	O
against	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
completely	O
protective	O
in	O
the	O
susceptible	O
host	O
.	O

However	O
,	O
neutralizing	O
antibody	O
titers	O
and	O
the	O
memory	O
B	O
cell	O
response	O
are	O
short	O
lived	O
in	O
SARS	B-DISO
-	O
recovered	O
patients	O
and	O
the	O
antibody	O
will	O
target	O
primary	O
homologous	O
strain	O
.	O

Surprisingly	O
,	O
only	O
a	O
limited	O
number	O
of	O
studies	O
have	O
explored	O
the	O
role	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
adaptive	O
immune	O
response	O
in	O
respiratory	O
coronavirus	O
pathogenesis	B-DISO
.	O

The	O
ARDS	B-DISO
severity	O
(	O
mild	O
[	O
200	O
<	O
PaO2	O
/	O
FiO2	O
≤	O
300	O
],	O
moderate	O
[	O
100	O
<	O
PaO2	O
/	O
FiO2	O
≤	O
200	O
]	O
and	O
severe	O
[	O
PaO2	O
/	O
FiO2	O
≤	O
100	O
])	O
must	O
be	O
immediately	O
assessed	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
related	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
an	O
emerging	O
pathogen	O
that	O
causes	O
severe	O
respiratory	O
illness	O
.	O

These	O
findings	O
suggest	O
that	O
vaccine	O
-	O
induced	O
eosinophil	O
immunopathology	B-DISO
in	O
the	O
lungs	O
upon	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
could	O
be	O
avoided	O
by	O
the	O
TLR	O
agonist	O
adjuvants	O
.	O

Inactivated	O
whole	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
related	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
vaccines	O
induce	O
neutralizing	O
antibodies	O
in	O
mouse	O
models	O
;	O
however	O
,	O
they	O
also	O
cause	O
increased	O
eosinophilic	O
immunopathology	B-DISO
in	O
the	O
lungs	O
upon	O
SARS	B-DISO
-	O
CoV	O
challenge	O
.	O

Since	O
PLUS	O
is	O
readily	O
available	O
,	O
easily	O
affordable	O
,	O
and	O
biologically	O
non	O
-	O
invasive	O
,	O
it	O
is	O
especially	O
suitable	O
for	O
bedside	O
clinical	O
care	O
in	O
critically	B-DISO
ill	I-DISO
and	O
unstable	O
adult	O
patients	O
.	O

There	O
is	O
no	O
'	O
one	O
size	O
fits	B-DISO
all	O
'	O
approach	O
to	O
achieving	O
the	O
intersectoral	O
collaboration	O
,	O
significant	O
resource	O
mobilisation	O
and	O
political	O
co	O
-	O
operation	O
required	O
to	O
realise	O
a	O
One	O
Health	O
approach	O
.	O

The	O
major	O
findings	O
are	O
as	O
follows	O
:	O
(	O
i	O
)	O
nts	O
from	O
-	O
5	O
to	O
-	O
39	O
within	O
the	O
3	O
'-	O
terminal	O
55	O
nts	O
are	O
the	O
cis	B-DISO
-	O
acting	O
elements	O
responsible	O
for	O
(-)-	O
strand	O
BCoV	O
DI	O
RNA	O
synthesis	O
,	O
(	O
ii	O
)	O
nts	O
from	O
-	O
3	O
to	O
-	O
34	O
within	O
the	O
3	O
'-	O
terminal	O
55	O
nts	O
are	O
cis	B-DISO
-	O
acting	O
elements	O
required	O
for	O
(+)-	O
strand	O
BCoV	O
DI	O
RNA	O
synthesis	O
,	O
and	O
(	O
iii	O
)	O
the	O
nucleotide	O
species	O
at	O
the	O
3	O
'-	O
most	O
position	O
(-	O
1	O
)	O
is	O
important	O
,	O
but	O
not	O
critical	O
,	O
for	O
both	O
(-)-	O
and	O
(+)-	O
strand	O
BCoV	O
DI	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
Influenza	B-DISO
and	O
other	O
respiratory	O
virus	O
infections	B-DISO
in	O
outpatients	O
with	O
medically	O
attended	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
during	O
the	O
2011	O
-	O
12	O
influenza	B-DISO
season	O
.	O

Using	O
MRT	O
-	O
PCR	O
,	O
a	O
viral	O
etiology	O
was	O
found	O
in	O
three	O
-	O
fifths	O
of	O
patients	O
with	O
medically	O
attended	O
outpatient	O
visits	O
for	O
acute	O
respiratory	O
illness	O
during	O
the	O
influenza	B-DISO
season	O
;	O
co	O
-	O
detected	O
viruses	O
were	O
infrequent	O
.	O

RESULTS	O
:	O
Among	O
662	O
participants	O
(	O
6	O
months	O
-	O
82	O
years	O
),	O
detection	O
of	O
influenza	B-DISO
was	O
similar	O
between	O
the	O
MRT	O
-	O
PCR	O
and	O
SRT	O
-	O
PCR	O
(	O
κ	O
=	O
0	O
.	O
83	O
).	O

In	O
regression	O
analyses	O
,	O
compared	O
with	O
non	O
-	O
viral	O
illnesses	O
,	O
RSV	O
and	O
hMPV	O
were	O
significantly	O
more	O
frequent	O
in	O
children	O
and	O
less	O
frequent	O
in	O
18	O
-	O
to	O
49	O
-	O
year	O
-	O
olds	O
than	O
in	O
those	O
≥	O
50	O
years	O
(	O
P	O
=	O
0	O
.	O
01	O
),	O
fever	O
was	O
more	O
common	O
in	O
hMPV	O
and	O
influenza	B-DISO
infections	B-DISO
(	O
P	O
=	O
0	O
.	O
008	O
),	O
nasal	B-DISO
congestion	I-DISO
was	O
more	O
frequent	O
in	O
CoV	O
,	O
HRV	O
,	O
hMPV	O
,	O
influenza	B-DISO
and	O
RSV	B-DISO
infections	I-DISO
(	O
P	O
=	O
0	O
.	O
001	O
),	O
and	O
body	O
mass	O
index	O
was	O
higher	O
among	O
those	O
with	O
influenza	B-DISO
(	O
P	O
=	O
0	O
.	O
036	O
).	O

In	O
both	O
cohorts	O
,	O
we	O
identified	O
a	O
hyperinflammatory	O
subphenotype	O
(	O
phenotype	O
2	O
)	O
that	O
was	O
characterised	O
by	O
higher	O
plasma	O
concentrations	O
of	O
inflammatory	O
biomarkers	O
,	O
a	O
higher	O
prevalence	O
of	O
vasopressor	O
use	O
,	O
lower	O
serum	O
bicarbonate	O
concentrations	O
,	O
and	O
a	O
higher	O
prevalence	O
of	O
sepsis	B-DISO
than	O
phenotype	O
1	O
.	O

We	O
have	O
identified	O
two	O
subphenotypes	O
within	O
ARDS	B-DISO
,	O
one	O
of	O
which	O
is	O
categorised	O
by	O
more	O
severe	O
inflammation	B-DISO
,	O
shock	O
,	O
and	O
metabolic	B-DISO
acidosis	I-DISO
and	O
by	O
worse	O
clinical	O
outcomes	O
.	O

This	O
identification	O
of	O
key	O
and	O
unique	O
sites	O
in	O
PLpro	O
required	O
for	O
recognition	O
and	O
processing	O
of	O
diubiquitin	O
and	O
ISG15	O
versus	O
mono	B-DISO
-	O
ubiquitin	O
and	O
protease	O
activity	O
provides	O
new	O
insight	O
into	O
ubiquitin	O
-	O
chain	O
and	O
ISG15	O
recognition	O
and	O
highlights	O
a	O
role	O
for	O
PLpro	O
DUB	O
and	O
deISGylase	O
activity	O
in	O
antagonism	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
This	O
review	O
is	O
concerned	O
with	O
what	O
has	O
been	O
learned	O
about	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
diagnostics	O
and	O
therapeutics	O
since	O
the	O
publication	O
of	O
an	O
extensive	O
overview	O
of	O
literature	O
covering	O
the	O
period	O
1963	O
-	O
2009	O
.	O

Although	O
progress	O
has	O
been	O
made	O
in	O
both	O
areas	O
,	O
obtaining	O
a	O
definitive	O
diagnosis	O
of	O
FIP	B-DISO
remains	O
a	O
problem	O
for	O
those	O
veterinarians	O
and	O
/	O
or	O
cat	O
owners	O
who	O
require	O
absolute	O
certainty	O
.	O

There	O
is	O
still	O
no	O
effective	O
treatment	O
for	O
FIP	B-DISO
,	O
although	O
there	O
are	O
both	O
claims	O
that	O
such	O
therapies	O
exist	O
and	O
glimmers	O
of	O
hope	O
coming	O
from	O
new	O
therapies	O
that	O
are	O
under	O
research	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
a	O
case	O
of	O
human	O
infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
after	O
exposure	O
to	O
infected	O
camels	O
.	O

ABSTRACT	O
:	O
We	O
performed	O
revascularization	O
by	O
an	O
anti	O
-	O
anatomical	O
bypass	O
in	O
a	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
extended	O
ischemia	B-DISO
of	O
both	O
legs	O
beyond	O
12	O
hr	O
after	O
onset	O
because	O
of	O
traumatic	O
aortic	B-DISO
dissection	I-DISO
.	O

This	O
patient	O
developed	O
myonephropathic	O
metabolic	B-DISO
syndrome	I-DISO
,	O
including	O
renal	O
and	O
circulatory	B-DISO
failure	I-DISO
accompanied	O
by	O
a	O
creatine	O
phosphokinase	O
level	O
above	O
200	O
,	O
000	O
IU	O
/	O
L	O
.	O
Nevertheless	O
,	O
his	O
bilateral	O
affected	O
limbs	O
were	O
salvaged	O
by	O
intensive	O
care	O
based	O
on	O
aggressive	B-DISO
hemocatharsis	O
with	O
continuous	O
hemodiafiltration	O
with	O
treatment	O
for	O
poor	O
hemodynamics	O
and	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
Chinese	O
government	O
has	O
devised	O
new	O
strategies	O
and	O
has	O
taken	O
measures	O
to	O
deal	O
with	O
the	O
challenges	O
of	O
these	O
diseases	O
,	O
including	O
the	O
issuing	O
of	O
laws	O
and	O
regulations	O
,	O
establishment	O
of	O
disease	O
reporting	O
systems	O
,	O
implementation	O
of	O
special	O
projects	O
for	O
major	O
infectious	B-DISO
diseases	I-DISO
,	O
interdisciplinary	O
and	O
international	O
cooperation	O
,	O
exotic	O
disease	O
surveillance	O
,	O
and	O
health	O
education	O
.	O

Using	O
a	O
glia	O
-	O
tropic	O
coronavirus	B-DISO
infection	I-DISO
,	O
which	O
is	O
initiated	O
in	O
the	O
brain	O
but	O
rapidly	O
spreads	O
to	O
and	O
predominantly	O
persists	O
in	O
the	O
spinal	O
cord	B-DISO
,	O
this	O
study	O
characterizes	O
longitudinal	O
changes	O
in	O
B	O
cell	O
subsets	O
at	O
both	O
infected	O
anatomical	O
sites	O
.	O

A	O
more	O
rapid	O
transition	B-DISO
to	O
B	O
(	O
mem	O
)	O
and	O
ASC	O
in	O
spinal	O
cord	B-DISO
than	O
in	O
brain	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
persisting	O
viral	O
RNA	O
and	O
transcripts	O
encoding	O
factors	O
promoting	O
B	O
cell	O
migration	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

ABSTRACT	O
:	O
Genomes	O
of	O
positive	O
(+)-	O
strand	O
RNA	O
viruses	O
use	O
cis	B-DISO
-	O
acting	O
signals	O
to	O
direct	O
both	O
translation	O
and	O
replication	O
.	O

cis	B-DISO
-	O
Acting	O
RNA	O
and	O
protein	O
structures	O
that	O
regulate	O
(+)-	O
strand	O
RNA	O
virus	O
genome	O
synthesis	O
are	O
potential	O
sites	O
for	O
blocking	B-DISO
virus	O
replication	O
.	O

TITLE	O
:	O
Targeting	O
membrane	O
-	O
bound	O
viral	O
RNA	O
synthesis	O
reveals	O
potent	O
inhibition	O
of	O
diverse	O
coronaviruses	O
including	O
the	O
middle	O
East	O
respiratory	O
syndrome	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
a	O
highly	O
lethal	O
pneumonia	B-DISO
.	O

The	O
genome	O
exhibits	O
noteworthy	O
stability	O
,	O
which	O
may	O
inform	O
the	O
development	O
of	O
vaccines	O
and	O
therapeutics	O
used	O
to	O
treat	O
infection	B-DISO
with	O
this	O
virus	O
.	O

Treatment	O
of	O
cells	O
with	O
neuraminidase	O
(	O
NA	O
)	O
enhanced	O
infection	B-DISO
efficiency	O
,	O
showing	O
that	O
terminal	O
sialic	O
acid	O
residues	O
on	O
the	O
cell	O
surface	O
were	O
not	O
receptor	O
determinants	O
and	O
even	O
hampered	O
efficient	O
virus	O
-	O
receptor	O
engagement	O
.	O

Median	O
daytime	O
SpO2	O
was	O
97	O
%	O
(	O
range	O
,	O
89	O
%-	O
100	O
%),	O
and	O
36	O
%	O
of	O
patients	O
had	O
daytime	O
hypoxia	B-DISO
defined	O
as	O
SpO2	O
<	O
96	O
%.	O

Among	O
patients	O
with	O
normal	O
daytime	O
SpO2	O
,	O
35	O
%	O
had	O
nocturnal	O
and	O
42	O
%	O
postexercise	O
hypoxia	B-DISO
.	O

TITLE	O
:	O
Prone	O
ventilation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Meta	O
-	O
analyses	O
have	O
suggested	O
better	O
survival	O
in	O
patients	O
with	O
an	O
arterial	O
oxygen	O
tension	B-DISO
(	O
PaO2	O
)/	O
inspiratory	O
oxygen	O
fraction	O
(	O
FIO2	O
)	O
ratio	O
<	O
100	O
mmHg	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
30	O
years	O
,	O
we	O
have	O
learned	O
much	O
about	O
the	O
molecular	O
,	O
cellular	O
,	O
and	O
physiological	O
mechanisms	O
that	O
regulate	O
the	O
resolution	O
of	O
pulmonary	B-DISO
edema	I-DISO
in	O
both	O
the	O
normal	O
and	O
the	O
injured	O
lung	O
.	O

ABSTRACT	O
:	O
Activin	O
A	O
and	O
its	O
binding	O
protein	O
follistatin	O
(	O
FS	O
)	O
are	O
increased	O
in	O
inflammatory	O
disorders	O
and	O
sepsis	B-DISO
.	O

We	O
have	O
used	O
primary	O
human	O
immune	O
cells	O
to	O
evaluate	O
their	O
susceptibility	O
to	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
presence	O
of	O
anti	O
-	O
Spike	O
antibodies	O
.	O

These	O
results	O
demonstrate	O
that	O
human	O
macrophages	O
can	O
be	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
as	O
a	O
result	O
of	O
IgG	O
-	O
mediated	O
ADE	O
and	O
indicate	O
that	O
this	O
infection	B-DISO
route	O
requires	O
signaling	O
pathways	O
activated	O
downstream	O
of	O
binding	O
to	O
FcγRII	O
receptors	O
.	O

Since	O
cellular	O
immunity	O
is	O
thought	O
to	O
be	O
critical	O
in	O
preventing	O
FIP	B-DISO
and	O
because	O
diseased	O
cats	O
often	O
show	O
a	O
significant	O
decrease	O
in	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
production	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
the	O
feline	O
IFN	O
-	O
γ	O
gene	O
(	O
fIFNG	O
)	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
infection	B-DISO
.	O

This	O
meta	O
-	O
analysis	O
revealed	O
that	O
,	O
compared	O
with	O
supine	O
positioning	O
,	O
PP	O
decreased	O
the	O
28	O
-	O
to	O
30	O
-	O
day	O
mortality	O
of	O
ARDS	B-DISO
patients	O
with	O
a	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
≤	O
100	O
mmHg	O
(	O
n	O
=	O
508	O
,	O
risk	O
ratio	O
(	O
RR	O
)	O
=	O
0	O
.	O
71	O
,	O
95	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
57	O
to	O
0	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
003	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
humans	O
is	O
caused	O
by	O
an	O
unchecked	O
proinflammatory	O
response	O
that	O
results	O
in	O
diffuse	O
and	O
severe	O
lung	O
injury	O
,	O
and	O
it	O
is	O
associated	O
with	O
a	O
mortality	O
rate	O
of	O
35	O
to	O
45	O
%.	O

TITLE	O
:	O
IL	O
-	O
27	O
limits	O
central	O
nervous	B-DISO
system	O
viral	O
clearance	O
by	O
promoting	O
IL	O
-	O
10	O
and	O
enhances	O
demyelination	B-DISO
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
in	O
contrast	O
to	O
viral	B-DISO
infections	I-DISO
at	O
other	O
sites	O
,	O
IL	O
-	O
27	O
does	O
not	O
play	O
a	O
proinflammatory	O
role	O
during	O
JHMV	O
-	O
induced	O
encephalomyelitis	B-DISO
.	O

We	O
hypothesised	O
that	O
clinical	O
grade	O
hMSCs	O
would	O
reduce	O
the	O
severity	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
would	O
be	O
safe	O
in	O
a	O
sheep	O
model	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
different	O
avian	O
physiological	O
systems	O
-	O
a	O
field	O
study	O
in	O
Brazilian	O
poultry	O
flocks	O
.	O

The	O
disease	O
presents	O
multi	O
-	O
systemic	O
clinical	O
signs	O
(	O
respiratory	O
,	O
renal	O
,	O
enteric	O
,	O
and	O
reproductive	O
)	O
and	O
is	O
caused	O
by	O
one	O
coronavirus	O
(	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
IBV	O
).	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
was	O
detected	O
by	O
reverse	O
-	O
transcription	O
,	O
real	O
-	O
time	O
PCR	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
.	O

These	O
data	O
suggest	O
that	O
this	O
fatal	O
case	O
of	O
human	O
MERS	O
-	O
CoV	O
infection	B-DISO
was	O
transmitted	B-DISO
through	O
close	O
contact	O
with	O
an	O
infected	O
camel	O
.	O

In	O
cancer	B-DISO
patients	O
,	O
90	O
%	O
of	O
ARDS	B-DISO
cases	O
are	O
infection	B-DISO
-	O
related	O
,	O
including	O
one	O
-	O
third	O
due	O
to	O
invasive	O
fungal	B-DISO
infections	I-DISO
.	O

Risk	O
factors	O
for	O
higher	O
mortality	O
were	O
allogeneic	O
bone	O
-	O
marrow	O
transplantation	O
,	O
modified	O
SOFA	O
,	O
NIV	O
failure	O
,	O
severe	O
ARDS	B-DISO
,	O
and	O
invasive	O
fungal	B-DISO
infection	I-DISO
.	O

Our	O
results	O
reveal	O
the	O
complexity	O
of	O
the	O
transcriptional	O
response	O
to	O
viral	B-DISO
infection	I-DISO
,	O
previously	O
undocumented	O
genomic	O
elements	O
,	O
and	O
extensive	O
diversity	O
in	O
the	O
response	O
across	O
mouse	O
strains	O
.	O

These	O
data	O
suggest	O
the	O
therapeutic	O
potential	O
of	O
GAPDH	O
for	O
sepsis	B-DISO
-	O
related	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
monomer	O
-	O
dimer	O
nanoswitch	O
that	O
mimics	O
the	O
working	O
principle	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
enzyme	O
controls	O
copper	O
-	O
catalysed	O
cyclopropanation	O
.	O

Recently	O
,	O
the	O
occurrence	O
of	O
Guillain	O
-	O
Barré	O
Syndrome	B-DISO
after	O
major	O
and	O
minor	O
surgical	O
operations	O
has	O
been	O
increasingly	O
debated	O
.	O

Cerebrospinal	O
fluid	O
examination	O
showed	O
320	O
mg	O
/	O
dL	O
protein	O
,	O
and	O
acute	O
motor	O
-	O
sensorial	O
axonal	B-DISO
neuropathy	I-DISO
was	O
identified	O
by	O
electromyelography	O
.	O

In	O
this	O
work	O
we	O
undertook	O
a	O
mutational	O
analysis	O
to	O
attempt	O
to	O
identify	O
specific	O
amino	O
acid	O
sequences	O
within	O
the	O
spike	O
glycoprotein	O
crucial	O
for	O
molecular	O
mimicry	B-DISO
of	O
FcγRII	O
.	O

Evaluation	O
of	O
a	O
diagnostic	O
approach	O
including	O
multiplex	O
PCR	O
assays	O
for	O
revisiting	O
the	O
epidemiology	O
and	O
etiology	O
of	O
CAP	B-DISO
in	O
children	O
at	O
hospital	O
.	O

Coinfection	B-DISO
by	O
at	O
least	O
two	O
viruses	O
was	O
observed	O
in	O
37	O
cases	O
(	O
43	O
.	O
5	O
%).	O

One	O
of	O
them	O
had	O
severe	O
respiratory	B-DISO
distress	I-DISO
right	O
after	O
birth	O
(	O
PIII	O
).	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
chest	O
CT	O
findings	O
in	O
seven	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

Furthermore	O
,	O
a	O
clear	O
source	O
of	O
infection	B-DISO
to	O
humans	O
remains	O
unknown	O
.	O

ABSTRACT	O
:	O
The	O
outcome	O
of	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
is	O
determined	O
by	O
a	O
complex	O
interplay	O
of	O
viral	O
and	O
host	O
factors	O
.	O

Here	O
we	O
systematically	O
inferred	O
the	O
regulatory	O
functions	O
of	O
host	O
lncRNAs	O
in	O
response	O
to	O
influenza	B-DISO
A	O
virus	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
based	O
on	O
their	O
similarity	O
in	O
expression	O
with	O
genes	O
of	O
known	O
function	O
.	O

Each	O
lncRNA	O
was	O
further	O
individually	O
annotated	O
using	O
a	O
rank	O
-	O
based	O
method	O
,	O
enabling	O
us	O
to	O
associate	O
5	O
,	O
295	O
lncRNAs	O
to	O
at	O
least	O
one	O
gene	O
set	O
and	O
to	O
predict	O
their	O
potential	O
cis	B-DISO
effects	O
.	O

During	O
ICU	O
stay	O
,	O
7	O
patients	O
(	O
38	O
.	O
9	O
%)	O
suffered	B-DISO
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Human	O
coronavirus	O
and	O
human	O
bocavirus	O
were	O
the	O
most	O
common	O
pathogens	O
,	O
tending	O
to	O
occur	O
in	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
other	O
respiratory	O
viruses	O
.	O

This	O
work	O
adds	O
to	O
our	O
knowledge	O
of	O
the	O
epidemiology	O
characteristics	O
of	O
these	O
seven	O
common	O
respiratory	O
viruses	O
among	O
patients	O
with	O
RTI	B-DISO
in	O
southern	O
China	O
.	O

The	O
molecular	O
assays	O
detected	O
53	O
and	O
31	O
CPV	O
-	O
and	O
CCoV	O
-	O
positive	O
specimens	O
,	O
respectively	O
,	O
with	O
mixed	O
CPV	O
-	O
CCoV	O
infections	B-DISO
diagnosed	O
in	O
28	O
dogs	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
infect	O
humans	O
and	O
many	O
animal	O
species	O
,	O
and	O
are	O
associated	O
with	O
respiratory	O
,	O
enteric	O
,	O
hepatic	O
,	O
and	O
central	B-DISO
nervous	I-DISO
system	I-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Extra	O
Corporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
)	O
in	O
three	O
HIV	B-DISO
-	O
positive	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
life	O
-	O
saving	O
bridging	O
procedure	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
the	O
care	O
of	O
patients	O
with	O
HIV	B-DISO
infection	I-DISO
has	O
advanced	O
since	O
the	O
introduction	O
of	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
),	O
with	O
increased	O
life	O
expectancy	O
and	O
decreased	O
mortality	O
.	O

Three	O
HIV	B-DISO
-	O
infected	O
patients	O
with	O
AIDS	O
were	O
admitted	O
to	O
ICU	O
and	O
were	O
treated	O
with	O
ECMO	O
:	O
a	O
21	O
years	O
old	O
Caucasian	O
female	O
with	O
congenital	B-DISO
HIV	I-DISO
infection	I-DISO
presented	O
with	O
Pneumocystis	B-DISO
jirovecii	O
pneumonia	B-DISO
(	O
PJP	B-DISO
);	O
a	O
38	O
years	O
old	O
Caucasian	O
female	O
with	O
HIV	B-DISO
-	O
HCV	O
infection	B-DISO
and	O
L	O
.	O
pneumophila	O
pneumonia	B-DISO
;	O
a	O
24	O
years	O
old	O
Caucasian	O
male	O
with	O
fever	O
,	O
cough	B-DISO
weight	O
loss	O
and	O
PJP	B-DISO
pneumonia	B-DISO
.	O

A	O
multidisciplinary	O
critical	O
team	O
is	O
needed	O
to	O
individualize	O
the	O
use	O
of	O
ECMO	O
in	O
immunocompromised	O
patients	O
,	O
including	O
those	O
with	O
HIV	B-DISO
infection	I-DISO
.	O

CONCLUSIONS	O
:	O
ECMO	O
was	O
effective	O
in	O
three	O
HIV	B-DISO
-	O
positive	O
patients	O
with	O
an	O
otherwise	O
fatal	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Infectious	B-DISO
diseases	I-DISO
in	O
large	O
-	O
scale	O
cat	O
hoarding	O
investigations	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
infectious	B-DISO
diseases	I-DISO
carried	O
by	O
clinically	O
affected	O
cats	O
and	O
to	O
determine	O
the	O
prevalence	O
of	O
retroviral	O
infections	B-DISO
among	O
cats	O
in	O
large	O
-	O
scale	O
cat	O
hoarding	O
investigations	O
.	O

Mycoplasma	B-DISO
felis	O
(	O
78	O
%),	O
calicivirus	O
(	O
78	O
%),	O
and	O
Streptococcus	O
equi	O
subspecies	O
zooepidemicus	O
(	O
55	O
%)	O
were	O
the	O
most	O
common	O
respiratory	B-DISO
infections	I-DISO
.	O

Meta	O
-	O
analyses	O
showed	O
reduced	O
28	O
-	O
day	O
mortality	O
with	O
a	O
48	O
-	O
hour	O
infusion	O
of	O
cis	B-DISO
-	O
atracurium	O
in	O
early	O
ARDS	B-DISO
(	O
relative	O
risk	O
0	O
.	O
66	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
50	O
to	O
0	O
.	O
87	O
;	O
431	O
patients	O
,	O
138	O
deaths	O
).	O

Cis	B-DISO
-	O
atracurium	O
is	O
a	O
promising	O
treatment	O
for	O
early	O
moderate	O
-	O
severe	O
ARDS	B-DISO
(	O
using	O
Berlin	O
definition	O
nomenclature	O
)	O
and	O
merits	O
further	O
investigation	O
in	O
a	O
large	O
RCT	O
.	O

CONCLUSIONS	O
:	O
Effective	O
pharmacotherapy	O
for	O
ARDS	B-DISO
remains	O
extremely	O
limited	O
.	O

TITLE	O
:	O
SOCS3	O
expression	O
correlates	O
with	O
severity	O
of	O
inflammation	B-DISO
in	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
3	O
-	O
induced	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
and	O
HBV	B-DISO
-	O
ACLF	O
.	O

PCP	B-DISO
was	O
detected	O
in	O
23	O
(	O
7	O
.	O
9	O
%)	O
patients	O
.	O

HIV	B-DISO
-	O
infected	O
patients	O
were	O
more	O
often	O
positive	O
(	O
56	O
.	O
6	O
%,	O
95	O
%	O
CI	O
=	O
37	O
.	O
3	O
-	O
72	O
.	O
4	O
)	O
compared	O
to	O
other	O
groups	O
(	O
patients	O
with	O
malignant	B-DISO
disease	I-DISO
7	O
.	O
7	O
%,	O
95	O
%	O
CI	O
=	O
2	O
.	O
6	O
-	O
20	O
.	O
3	O
;	O
transplant	O
patients	O
7	O
.	O
7	O
%,	O
95	O
%	O
CI	O
=	O
2	O
.	O
2	O
-	O
24	O
.	O
1	O
;	O
patients	O
with	O
other	O
diagnosis	O
1	O
.	O
5	O
%,	O
95	O
%	O
CI	O
=	O
0	O
.	O
5	O
-	O
4	O
.	O
4	O
).	O

Inoculation	O
of	O
FBAHV1	O
into	O
laboratory	O
mice	O
caused	O
a	O
lethal	O
infection	B-DISO
.	O

Genome	O
sequence	O
analysis	O
suggested	O
that	O
the	O
virus	O
is	O
a	O
member	O
of	O
the	O
genus	O
Simplexvirus	O
within	O
the	O
subfamily	O
Alphaherpesvirinae	O
,	O
which	O
also	O
includes	O
common	O
human	O
viruses	O
,	O
such	O
as	O
herpes	B-DISO
simplex	I-DISO
virus	O
1	O
and	O
herpes	B-DISO
simplex	I-DISO
virus	O
2	O
.	O

TITLE	O
:	O
Heart	O
and	O
lung	O
,	O
a	O
dangerous	O
liaison	O
-	O
Tako	B-DISO
-	I-DISO
tsubo	I-DISO
cardiomyopathy	I-DISO
and	O
respiratory	B-DISO
diseases	I-DISO
:	O
A	O
systematic	O
review	O
.	O

An	O
association	O
between	O
respiratory	B-DISO
diseases	I-DISO
and	O
TTC	O
is	O
likely	O
to	O
exist	O
.	O

IN	O
BOTH	O
PATIENTS	O
,	O
CHARACTERISTIC	O
LUNG	O
ULTRASOUND	O
FINDINGS	O
HAVE	O
BEEN	O
OBSERVED	O
AS	O
PREVIOUSLY	O
DESCRIBED	O
IN	O
VIRAL	O
PULMONARY	B-DISO
INFECTIONS	I-DISO
:	O
subpleural	O
consolidations	O
associated	O
or	O
not	O
with	O
local	O
pleural	B-DISO
effusion	I-DISO
.	O

In	O
addition	O
,	O
numerous	O
,	O
confluent	O
,	O
or	O
coalescing	O
B	O
-	O
lines	O
leading	O
to	O
'	O
white	O
lung	O
'	O
with	O
corresponding	O
pleural	O
line	O
thickening	O
are	O
associated	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Programmed	O
-	O
1	O
frameshifting	O
by	O
kinetic	O
partitioning	O
during	O
impeded	O
translocation	B-DISO
.	O

We	O
studied	O
the	O
role	O
of	O
polymorphic	O
variants	O
at	O
the	O
genes	O
of	O
MBL	O
(	O
MBL2	O
),	O
SP	O
-	O
A1	O
(	O
SFTPA1	O
),	O
SP	O
-	O
A2	O
(	O
SFTPA2	O
),	O
and	O
SP	O
-	O
D	O
(	O
SFTPD	O
)	O
in	O
93	O
patients	O
with	O
H1N1	O
pandemic	O
2009	O
(	O
H1N1pdm	O
)	O
infection	B-DISO
.	O

RESULTS	O
:	O
Multivariate	O
analysis	O
showed	O
that	O
two	O
frequent	O
SFTPA2	O
missense	O
alleles	O
(	O
rs1965708	O
-	O
C	O
and	O
rs1059046	O
-	O
A	O
)	O
and	O
the	O
SFTPA2	O
haplotype	O
1A	O
(	O
0	O
)	O
were	O
associated	O
with	O
a	O
need	O
for	O
mechanical	O
ventilation	O
,	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
disease	O
that	O
spread	O
widely	O
in	O
the	O
world	O
during	O
late	O
2002	O
to	O
2004	O
,	O
severely	O
threatened	O
public	O
health	O
.	O

No	O
symptom	B-DISO
was	O
found	O
in	O
his	O
135	O
close	O
contacts	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
a	O
member	O
of	O
the	O
Coronaviridae	O
family	O
,	O
is	O
an	O
enveloped	O
,	O
positive	O
-	O
sense	O
,	O
single	O
-	O
stranded	O
RNA	O
virus	O
,	O
which	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
dehydration	B-DISO
in	O
suckling	O
pigs	O
.	O

In	O
2007	O
,	O
the	O
Kenyan	O
Ministry	O
of	O
Health	O
with	O
technical	O
support	O
from	O
the	O
CDC	O
-	O
Kenya	O
established	O
a	O
national	O
sentinel	O
surveillance	O
system	O
for	O
influenza	B-DISO
.	O

At	O
one	O
location	O
,	O
evidence	O
for	O
active	O
virus	B-DISO
shedding	I-DISO
in	O
nasal	O
secretions	O
and	O
/	O
or	O
faeces	O
was	O
observed	O
for	O
7	O
/	O
12	O
camels	O
;	O
viral	O
RNA	O
was	O
detected	O
in	O
milk	O
of	O
five	O
of	O
these	O
seven	O
camels	O
.	O

TITLE	O
:	O
Assessment	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
epidemic	O
in	O
the	O
Middle	O
East	O
and	O
risk	O
of	O
international	O
spread	O
using	O
a	O
novel	O
maximum	O
likelihood	O
analysis	O
approach	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infection	I-DISO
is	O
a	O
very	O
common	O
condition	B-DISO
in	O
the	O
general	O
population	O
.	O

Preexisting	O
neutralizing	O
antibody	O
did	O
not	O
appear	O
to	O
protect	O
against	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Emergence	O
of	O
viruses	O
belonging	O
to	O
the	O
coronavirus	O
family	O
has	O
been	O
widespread	O
in	O
the	O
past	O
,	O
causing	O
respiratory	B-DISO
infections	I-DISO
in	O
humans	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Since	O
2012	O
,	O
the	O
Saudi	O
Ministry	O
of	O
Health	O
(	O
MoH	O
)	O
has	O
required	O
screening	O
for	O
MERS	O
-	O
CoV	O
for	O
all	O
cases	O
of	O
severe	O
pneumonia	B-DISO
requiring	O
hospitalization	O
.	O

We	O
aimed	O
to	O
screen	O
Hajj	O
pilgrims	O
admitted	O
to	O
healthcare	O
facilities	O
in	O
2013	O
with	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
for	O
MERS	O
-	O
CoV	O
and	O
to	O
determine	O
other	O
etiologies	O
.	O

Sputum	O
samples	O
were	O
collected	O
from	O
all	O
pilgrims	O
admitted	O
to	O
15	O
healthcare	O
facilities	O
in	O
the	O
cities	O
of	O
Makkah	O
and	O
Medina	O
,	O
Saudi	O
Arabia	O
,	O
who	O
were	O
diagnosed	O
with	O
severe	O
CAP	B-DISO
on	O
admission	O
,	O
presenting	O
with	O
bilateral	B-DISO
pneumonia	I-DISO
.	O

MERS	O
-	O
CoV	O
was	O
not	O
the	O
cause	O
of	O
severe	O
CAP	B-DISO
in	O
any	O
of	O
the	O
hospitalized	O
pilgrims	O
investigated	O
.	O

The	O
results	O
of	O
the	O
microarray	O
analysis	O
showed	O
that	O
365	O
genes	O
on	O
day	O
3	O
post	O
-	O
infection	B-DISO
(	O
p	O
.	O
i	O
.)	O
and	O
781	O
genes	O
on	O
day	O
5	O
p	O
.	O
i	O
.	O
were	O
differentially	O
expressed	O
in	O
response	O
to	O
PHEV	O
infection	B-DISO
in	O
the	O
cerebral	O
cortex	O
.	O

Knockdown	O
of	O
EF1A	O
impairs	O
N	O
protein	O
proliferation	B-DISO
and	O
TGEV	O
replication	O
in	O
host	O
cell	O
.	O

TITLE	O
:	O
Fluids	O
in	O
ARDS	B-DISO
:	O
from	O
onset	O
through	O
recovery	O
.	O

No	O
specific	O
studies	O
are	O
available	O
to	O
recommend	O
a	O
given	O
fluid	O
composition	O
in	O
ARDS	B-DISO
.	O

We	O
report	O
herein	O
a	O
patient	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
who	O
developed	O
fever	O
with	O
worsening	O
of	O
respiratory	B-DISO
symptoms	I-DISO
and	O
severe	O
hypoxemia	O
requiring	O
ventilatory	O
support	O
shortly	O
after	O
influenza	B-DISO
vaccination	O
.	O

Early	O
treatment	O
with	O
ceftriaxone	O
and	O
azithromycin	O
,	O
along	O
with	O
oseltamivir	O
in	O
winter	O
months	O
,	O
should	O
be	O
initiated	O
with	O
all	O
cases	O
of	O
severe	O
exacerbations	O
where	O
infection	B-DISO
is	O
suspected	O
,	O
and	O
definitely	O
in	O
critical	O
asthma	B-DISO
syndrome	B-DISO
until	O
infection	B-DISO
is	O
excluded	O
by	O
appropriate	O
diagnostic	O
testing	O
.	O

Samples	O
with	O
infection	B-DISO
of	O
other	O
respiratory	O
viruses	O
preserved	O
in	O
our	O
lab	O
were	O
used	O
to	O
evaluate	O
specificity	O
of	O
this	O
assay	O
.	O

ns2	B-DISO
confers	O
virulence	O
by	O
cleaving	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	O
L	O
in	O
macrophages	O
.	O

We	O
speculate	O
that	O
AKAP7	O
is	O
the	O
ancestral	O
precursor	O
of	O
viral	O
proteins	O
,	O
such	O
as	O
ns2	B-DISO
and	O
VP3	O
,	O
that	O
degrade	O
2	O
-	O
5A	O
to	O
evade	O
the	O
antiviral	O
activity	O
of	O
RNase	O
L	O
.	O

The	O
epidemiological	O
profiles	O
of	O
the	O
patients	O
with	O
HCoV	O
-	O
OC43	O
infection	B-DISO
were	O
described	O
.	O

This	O
may	O
favor	O
coronavirus	B-DISO
infection	I-DISO
by	O
compromising	O
the	O
ability	O
of	O
autophagosomes	O
to	O
deliver	O
viral	O
components	O
to	O
lysosomes	O
for	O
degradation	O
.	O

The	O
overall	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
is	O
similar	O
to	O
that	O
of	O
the	O
corresponding	O
SARS	B-DISO
-	O
CoV	O
enzyme	O
,	O
but	O
the	O
architecture	O
of	O
the	O
oxyanion	O
hole	O
and	O
of	O
the	O
S3	O
as	O
well	O
as	O
the	O
S5	O
specificity	O
sites	O
differ	O
from	O
the	O
latter	O
.	O

TITLE	O
:	O
Accessory	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
other	O
coronaviruses	O
.	O

However	O
,	O
docetaxel	O
-	O
associated	O
adverse	O
events	O
(	O
AEs	O
)	O
such	O
as	O
febrile	B-DISO
neutropenia	I-DISO
(	O
FN	O
)	O
can	O
impair	O
quality	O
of	O
life	O
and	O
may	O
become	O
life	O
-	O
threatening	O
.	O

Pre	O
-	O
and	O
post	O
-	O
treatment	O
lymphopenia	B-DISO
and	O
pre	O
-	O
treatment	O
serum	O
albumin	O
should	O
be	O
considered	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
FN	O
when	O
selecting	O
patients	O
with	O
prostate	B-DISO
cancer	I-DISO
for	O
docetaxel	O
therapy	O
,	O
and	O
when	O
considering	O
dose	O
modifications	O
,	O
and	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

RESULTS	O
:	O
Hematological	O
AEs	O
of	O
≥	O
grade	O
3	O
included	O
neutrocytopenia	O
in	O
36	O
patients	O
(	O
97	O
.	O
3	O
%),	O
leukopenia	B-DISO
in	O
24	O
patients	O
(	O
64	O
.	O
9	O
%),	O
lymphopenia	B-DISO
in	O
10	O
patients	O
(	O
27	O
.	O
0	O
%),	O
and	O
FN	O
in	O
4	O
patients	O
(	O
10	O
.	O
8	O
%).	O

The	O
patient	O
survived	O
after	O
early	O
empiric	O
treatment	O
with	O
antibiotics	O
and	O
intensive	O
supportive	O
care	O
,	O
including	O
ventilation	O
support	O
,	O
a	O
high	O
dose	O
of	O
noradrenalin	O
,	O
and	O
continuous	O
venovenous	O
hemodialysis	O
applied	O
prior	O
to	O
the	O
definitive	O
diagnosis	O
of	O
Capnocytophaga	O
canimorsus	O
sepsis	B-DISO
.	O

Severe	O
Capnocytophaga	O
canimorsus	O
sepsis	B-DISO
may	O
be	O
complicated	O
by	O
life	O
-	O
threatening	O
nosocomial	B-DISO
infection	I-DISO
in	O
immunocompromized	O
patients	O
.	O

ABSTRACT	O
:	O
Occupational	O
and	O
environmental	O
health	O
nurses	O
must	O
monitor	O
credible	O
sources	O
for	O
accurate	O
information	O
,	O
provide	O
timely	O
education	O
to	O
workers	O
,	O
and	O
ensure	O
adequate	O
workplace	O
policies	O
to	O
protect	O
their	O
workforce	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
).	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
a	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
humans	O
,	O
is	O
a	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Of	O
interest	O
,	O
serum	O
miR	O
-	O
125b	O
expression	O
was	O
also	O
decreased	O
and	O
inversely	O
correlated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
in	O
a	O
silversmith	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
whether	O
mice	O
with	O
coronavirus	O
-	O
induced	O
encephalomyelitis	B-DISO
(	O
CIE	B-DISO
)	O
develop	O
neurogenic	O
bladder	B-DISO
dysfunction	I-DISO
that	O
is	O
comparable	O
with	O
the	O
neurogenic	O
detrusor	O
overactivity	O
observed	O
in	O
patients	O
with	O
multiple	B-DISO
sclerosis	I-DISO
.	O

Adult	O
mice	O
(	O
C57BL	O
/	O
6J	O
,	O
8	O
wk	O
of	O
age	O
,	O
n	O
=	O
146	O
)	O
were	O
inoculated	O
with	O
a	O
neurotropic	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
A59	O
strain	O
)	O
and	O
followed	O
for	O
4	O
wk	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
sought	O
to	O
investigate	O
whether	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
induces	O
apoptosis	O
and	O
to	O
elucidate	O
the	O
mechanisms	O
associated	O
with	O
apoptotic	O
cell	O
death	O
after	O
PEDV	O
infection	B-DISO
.	O

Our	O
data	O
showed	O
significant	O
differential	O
up	O
-	O
regulation	O
of	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
8	O
(	O
CXCLi2	O
)	O
and	O
MIP	B-DISO
-	O
1β	O
genes	O
and	O
suppression	B-DISO
of	O
IL	O
-	O
6	O
gene	O
expression	O
being	O
associated	O
with	O
inhibition	O
of	O
IBV	O
replication	O
in	O
lungs	O
tissue	O
retrieved	O
from	O
embryos	O
pre	O
-	O
treated	O
with	O
CpG	O
ODN	O
.	O

ABSTRACT	O
:	O
Since	O
2009	O
pandemic	O
,	O
international	O
health	O
authorities	O
recommended	O
monitoring	O
severe	O
and	O
complicated	O
cases	O
of	O
respiratory	B-DISO
disease	I-DISO
,	O
that	O
is	O
,	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
SARI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
evaluated	O
the	O
proportion	O
of	O
SARI	O
/	O
ARDS	B-DISO
cases	O
and	O
deaths	O
due	O
to	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	B-DISO
and	O
the	O
impact	O
of	O
other	O
respiratory	O
viruses	O
during	O
pandemic	O
and	O
postpandemic	O
period	O
(	O
2009	O
-	O
2011	O
)	O
in	O
northern	O
Italy	O
;	O
additionally	O
we	O
searched	O
for	O
unknown	O
viruses	O
in	O
those	O
cases	O
for	O
which	O
diagnosis	O
remained	O
negative	O
.	O

206	O
respiratory	O
samples	O
were	O
collected	O
from	O
SARI	O
/	O
ARDS	B-DISO
cases	O
and	O
analyzed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
/	O
PCR	O
to	O
investigate	O
influenza	B-DISO
viruses	O
and	O
other	O
common	O
respiratory	O
pathogens	O
;	O
also	O
,	O
a	O
virus	O
discovery	O
technique	O
(	O
VIDISCA	O
-	O
454	O
)	O
was	O
applied	O
on	O
those	O
samples	O
tested	O
negative	O
to	O
all	O
pathogens	O
.	O

VIDISCA	O
-	O
454	O
enabled	O
the	O
identification	O
of	O
one	O
previously	O
undiagnosed	O
measles	B-DISO
infection	B-DISO
.	O

Different	O
kinds	O
of	O
DNA	O
vaccines	O
are	O
investigated	O
to	O
provide	O
protection	O
against	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
including	O
tuberculosis	B-DISO
,	O
coronavirus	O
,	O
influenza	B-DISO
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
etc	O
.	O

TITLE	O
:	O
Microorganisms	O
in	O
respiratory	O
tract	O
of	O
patients	O
diagnosed	O
with	O
atypical	B-DISO
pneumonia	I-DISO
:	O
results	O
of	O
a	O
research	O
based	O
on	O
the	O
use	O
of	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
DNA	O
microarray	O
method	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
most	O
active	O
drugs	O
against	O
SARS	B-DISO
/	O
MERS	O
CoV	O
at	O
clinically	O
achievable	O
serum	O
levels	O
were	O
type	O
I	O
interferons	O
and	O
a	O
TLR3	O
agonist	O
,	O
interferon	O
inducer	O
/	O
activator	O
.	O

In	O
patients	O
with	O
acute	B-DISO
disease	I-DISO
,	O
the	O
most	O
common	O
findings	O
are	O
lobar	O
or	O
segmental	O
consolidation	O
,	O
multifocal	O
consolidation	O
,	O
and	O
nodules	B-DISO
.	O

Adenopathy	O
and	O
pleural	B-DISO
effusions	I-DISO
are	O
also	O
seen	O
,	O
usually	O
in	O
association	O
with	O
parenchymal	O
disease	O
.	O

Pulmonary	O
findings	O
are	O
miliary	O
nodules	B-DISO
and	O
confluent	O
parenchymal	O
opacities	B-DISO
.	O

By	O
generating	O
mutant	B-DISO
SARS	B-DISO
-	O
CoV	O
that	O
escapes	O
the	O
neutralization	O
by	O
mAb	O
1A9	O
,	O
the	O
residue	O
D1128	O
in	O
S	O
was	O
found	O
to	O
be	O
crucial	O
for	O
its	O
interaction	O
with	O
mAb	O
1A9	O
.	O

Large	O
-	O
scale	O
prospective	O
surveillance	O
studies	O
are	O
required	O
to	O
provide	O
more	O
accurate	O
information	O
about	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
etiology	O
,	O
which	O
could	O
favorably	O
influence	O
clinical	O
outcomes	O
.	O

Among	O
296	O
patients	O
hospitalized	O
for	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
,	O
75	O
(	O
25	O
.	O
3	O
%)	O
developed	O
ARDS	B-DISO
.	O

Narrative	O
analyses	O
revealed	O
consistent	O
evidence	O
for	O
a	O
reduction	O
in	O
mortality	O
,	O
especially	O
when	O
convalescent	O
plasma	O
is	O
administered	O
early	O
after	O
symptom	B-DISO
onset	O
.	O

This	O
therapy	O
should	O
be	O
studied	O
within	O
the	O
context	O
of	O
a	O
well	O
-	O
designed	O
clinical	O
trial	O
or	O
other	O
formal	O
evaluation	O
,	O
including	O
for	O
treatment	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
lethal	O
respiratory	B-DISO
infections	I-DISO
mainly	O
on	O
the	O
Arabian	O
Peninsula	O
.	O

TITLE	O
:	O
Extracorporeal	O
carbon	O
dioxide	O
removal	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
secondary	O
to	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
systematic	O
review	O
.	O

Complication	B-DISO
rates	O
varied	O
greatly	O
across	O
the	O
included	O
studies	O
,	O
representing	O
technological	O
advances	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
demonstrated	O
that	O
the	O
length	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
in	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
which	O
belongs	O
to	O
genus	O
betacoronaviruses	O
,	O
is	O
regulated	O
throughout	O
infection	B-DISO
in	O
human	O
rectal	B-DISO
tumor	I-DISO
-	O
18	O
(	O
HRT	O
-	O
18	O
)	O
cells	O
,	O
and	O
the	O
length	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
is	O
associated	O
with	O
the	O
efficiency	O
of	O
virus	O
translation	O
.	O

The	O
results	O
suggest	O
that	O
the	O
regulation	O
of	O
coronaviral	O
poly	O
(	O
A	O
)	O
tail	O
length	O
during	O
infection	B-DISO
may	O
be	O
a	O
common	O
feature	O
among	O
coronaviruses	O
and	O
can	O
occur	O
in	O
a	O
noncancerous	O
cell	O
line	O
(	O
BHK	O
-	O
21	O
cells	O
),	O
primary	O
cell	O
culture	O
(	O
CEK	O
cells	O
),	O
and	O
living	O
system	O
(	O
chickens	O
),	O
further	O
reinforcing	O
the	O
biological	O
significance	O
of	O
this	O
regulation	O
during	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
infections	B-DISO
caused	O
by	O
influenza	B-DISO
viruses	O
,	O
human	O
parainfluenza	B-DISO
virus	O
(	O
hPIV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
coronaviruses	O
are	O
an	O
eminent	O
threat	O
for	O
public	O
health	O
.	O

Modified	O
Vaccinia	B-DISO
Virus	O
Ankara	O
(	O
MVA	O
)	O
is	O
a	O
replication	O
-	O
deficient	O
viral	O
vector	O
that	O
holds	O
great	O
promise	O
as	O
a	O
vaccine	O
platform	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
promising	O
novel	O
influenza	B-DISO
virus	O
vaccine	O
targets	O
and	O
the	O
use	O
of	O
MVA	O
for	O
vaccine	O
development	O
against	O
various	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Dynamically	O
-	O
driven	O
enhancement	O
of	O
the	O
catalytic	O
machinery	O
of	O
the	O
SARS	B-DISO
3C	O
-	O
like	O
protease	O
by	O
the	O
S284	O
-	O
T285	O
-	O
I286	O
/	O
A	O
mutations	O
on	O
the	O
extra	O
domain	O
.	O

ABSTRACT	O
:	O
A	O
retrospective	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
prevalence	O
and	O
seasonality	O
of	O
bovine	O
viral	O
diarrhoea	O
virus	O
(	O
BVDV	O
),	O
bovine	O
coronavirus	O
(	O
BoCV	O
),	O
bovine	O
herpesvirus	O
-	O
1	O
(	O
BoHV	O
-	O
1	O
),	O
bovine	O
respiratory	O
syncytical	O
virus	O
(	O
BRSV	O
)	O
and	O
parainfluenza	B-DISO
virus	O
-	O
3	O
(	O
PI3V	O
)	O
in	O
calves	O
(	O
aged	O
three	O
months	O
and	O
below	O
)	O
in	O
Ireland	O
.	O

Results	O
from	O
real	O
-	O
time	O
PCR	O
testing	O
,	O
including	O
cycle	O
threshold	O
values	O
,	O
conducted	O
on	O
nasal	O
swabs	O
(	O
single	O
or	O
pooled	O
)	O
submitted	O
from	O
1364	O
respiratory	B-DISO
disease	I-DISO
outbreaks	O
between	O
January	O
1	O
,	O
2008	O
and	O
December	O
31	O
,	O
2012	O
were	O
included	O
in	O
this	O
study	O
.	O

From	O
2002	O
to	O
2011	O
,	O
surveillance	O
of	O
enteric	O
pathogens	O
was	O
performed	O
in	O
cows	O
of	O
various	O
breed	O
and	O
age	O
from	O
302	O
farms	O
in	O
which	O
diarrhea	B-DISO
had	O
occurred	O
in	O
Yamagata	O
Prefecture	O
,	O
Japan	O
.	O

Aspects	O
dealt	O
with	O
in	O
this	O
review	O
include	O
the	O
emergence	O
of	O
the	O
SARS	B-DISO
coronavirus	O
in	O
2002	O
-	O
2003	O
and	O
of	O
the	O
MERS	O
coronavirus	O
10	O
years	O
later	O
and	O
the	O
origins	O
of	O
these	O
viruses	O
.	O

The	O
observed	O
epidemiology	O
is	O
different	O
to	O
SARS	B-DISO
,	O
which	O
showed	O
a	O
classic	O
epidemic	O
curve	O
and	O
was	O
over	O
in	O
eight	O
months	O
.	O

Efforts	O
to	O
minimize	O
bloodstream	O
infections	B-DISO
during	O
the	O
resuscitation	O
must	O
be	O
increased	O
.	O

Apgar	O
score	O
<	O
4	O
,	O
male	O
gender	O
,	O
Score	O
for	O
Neonatal	O
Acute	O
Physiology	O
Perinatal	O
Extension	O
(	O
SNAPPE	O
II	O
),	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
),	O
late	O
sepsis	B-DISO
(	O
LS	O
),	O
mechanical	O
ventilation	O
(	O
MV	O
),	O
surfactant	O
(<	O
2	O
h	O
of	O
life	O
),	O
and	O
time	O
of	O
MV	O
.	O

Theoretical	O
advantages	O
of	O
ECLS	O
for	O
respiratory	B-DISO
failure	I-DISO
include	O
the	O
ability	O
to	O
rest	O
the	O
lungs	O
by	O
avoiding	O
injurious	O
mechanical	O
ventilator	O
settings	O
and	O
the	O
potential	O
to	O
facilitate	O
early	O
mobilization	O
,	O
which	O
may	O
be	O
advantageous	O
for	O
bridging	O
to	O
recovery	O
or	O
to	O
lung	O
transplantation	O
.	O

The	O
use	O
of	O
venoarterial	O
ECMO	O
has	O
been	O
expanded	O
and	O
applied	O
to	O
critically	B-DISO
ill	I-DISO
adults	O
with	O
hemodynamic	O
compromise	O
from	O
a	O
variety	O
of	O
etiologies	O
,	O
beyond	O
postcardiotomy	O
failure	O
.	O

TITLE	O
:	O
Travel	O
implications	O
of	O
emerging	O
coronaviruses	O
:	O
SARS	B-DISO
and	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
of	O
the	O
Middle	O
East	B-DISO
Syndrome	I-DISO
Cornavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
caused	O
widespread	O
fear	O
and	O
concern	O
for	O
their	O
potential	O
threat	O
to	O
global	O
health	O
security	O
.	O

Deep	O
sedation	B-DISO
was	O
observed	O
in	O
113	O
patients	O
(	O
35	O
.	O
1	O
%).	O

While	O
bats	O
were	O
suggested	O
to	O
be	O
involved	O
in	O
human	O
MERS	O
-	O
CoV	O
infections	B-DISO
,	O
a	O
direct	O
link	O
between	O
bats	O
and	O
MERS	O
-	O
CoV	O
is	O
uncertain	O
.	O

TITLE	O
:	O
Characterization	O
of	O
oleic	O
acid	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
model	O
in	O
rat	O
.	O

Pulmonary	B-DISO
edema	I-DISO
was	O
induced	O
at	O
all	O
doses	O
.	O

ABSTRACT	O
:	O
Infiltration	B-DISO
and	O
runoff	O
from	O
manured	O
agricultural	O
fields	O
can	O
result	O
in	O
livestock	O
pathogens	O
reaching	O
groundwater	O
and	O
surface	O
waters	O
.	O

Glass	O
wool	O
filtration	O
is	O
a	O
cost	O
-	O
effective	O
method	O
for	O
concentrating	O
several	O
waterborne	O
pathogens	O
of	O
bovine	O
origin	O
simultaneously	O
,	O
although	O
recovery	O
may	O
be	O
low	O
for	O
some	O
specific	O
taxa	O
such	O
as	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
1	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
provide	O
physicians	O
,	O
ECMO	O
center	O
directors	O
and	O
coordinators	O
,	O
hospital	O
directors	O
,	O
health	O
-	O
care	O
organizations	O
,	O
and	O
regional	O
,	O
national	O
,	O
and	O
international	O
policy	O
makers	O
a	O
description	O
of	O
the	O
optimal	O
approach	O
to	O
organizing	O
ECMO	O
programs	O
for	O
ARF	B-DISO
in	O
adult	O
patients	O
.	O

TITLE	O
:	O
Immunogenicity	O
,	O
safety	O
and	O
tolerability	O
of	O
a	O
bivalent	O
human	O
papillomavirus	O
vaccine	O
in	O
adolescents	O
with	O
juvenile	B-DISO
idiopathic	I-DISO
arthritis	I-DISO
.	O

TITLE	O
:	O
The	O
relevance	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
the	O
exacerbations	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	O
—	O
a	O
systematic	O
review	O
.	O

Venovenous	O
ECMO	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
a	O
preferred	O
modality	O
of	O
support	O
for	O
patients	O
with	O
refractory	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

We	O
also	O
generated	O
monoclonal	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
spike	O
proteins	O
and	O
observed	O
that	O
most	O
of	O
them	O
promoted	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Budd	O
-	O
Chiari	O
-	O
like	O
syndrome	B-DISO
is	O
a	O
rare	O
phenomenon	O
in	O
veterinary	O
medicine	O
,	O
and	O
congenital	B-DISO
malformations	I-DISO
should	O
be	O
considered	O
in	O
young	O
feline	O
patients	O
with	O
ascites	O
.	O

All	O
inpatients	O
with	O
suspected	O
respiratory	B-DISO
infections	I-DISO
who	O
were	O
admitted	O
overnight	O
to	O
the	O
study	O
hospitals	O
were	O
screened	O
daily	O
.	O

TITLE	O
:	O
Israeli	O
acute	O
paralysis	O
virus	O
:	O
epidemiology	O
,	O
pathogenesis	B-DISO
and	O
implications	O
for	O
honey	O
bee	O
health	O
.	O

The	O
expression	O
of	O
genes	O
involved	O
in	O
immune	O
pathways	O
in	O
adult	O
bees	O
indicates	O
that	O
IAPV	O
infection	B-DISO
triggers	O
active	O
immune	O
responses	O
.	O

HCoVs	O
could	O
play	O
significant	O
role	O
in	O
causing	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
among	O
adults	O
and	O
older	O
children	O
in	O
rural	O
areas	O
of	O
Ghana	O
.	O

Chikungunya	B-DISO
virus	O
represents	O
a	O
new	O
threat	O
.	O

In	O
particular	O
,	O
human	O
bocavirus	O
and	O
enterovirus	O
have	O
significant	O
correlations	O
with	O
monthly	O
patterns	O
of	O
KD	O
occurrence	O
(	O
p	O
=	O
0	O
.	O
032	O
and	O
p	O
=	O
0	O
.	O
007	O
,	O
respectively	O
)	O
and	O
influenza	B-DISO
virus	O
correlated	O
with	O
KD	O
occurrence	O
with	O
borderline	O
significance	O
(	O
p	O
=	O
0	O
.	O
063	O
).	O

In	O
particular	O
,	O
human	O
bocavirus	O
and	O
enterovirus	O
have	O
significant	O
correlations	O
with	O
monthly	O
patterns	O
of	O
KD	O
occurrence	O
(	O
p	O
=	O
0	O
.	O
032	O
and	O
p	O
=	O
0	O
.	O
007	O
,	O
respectively	O
)	O
and	O
influenza	B-DISO
virus	O
correlated	O
with	O
KD	O
occurrence	O
with	O
borderline	O
significance	O
(	O
p	O
=	O
0	O
.	O
063	O
).	O

CONCLUSIONS	O
:	O
The	O
temporal	O
association	O
between	O
monthly	O
occurrence	O
of	O
KD	O
and	O
viral	O
detection	O
suggests	O
the	O
etiologic	O
importance	O
of	O
precedent	O
infection	B-DISO
in	O
the	O
development	O
of	O
KD	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
):	O
a	O
new	O
zoonotic	O
viral	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Axonal	O
pathology	B-DISO
and	O
demyelination	B-DISO
in	O
viral	O
models	O
of	O
multiple	B-DISO
sclerosis	I-DISO
.	O

TITLE	O
:	O
Safety	O
of	O
research	O
bronchoscopy	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Biochemical	O
analysis	O
verified	O
double	O
-	O
mutant	B-DISO
3CLpro	O
enzyme	O
as	O
impaired	B-DISO
for	O
protease	O
activity	O
and	O
exhibiting	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	O
and	O
revealed	O
a	O
delayed	O
kinetics	O
of	O
inhibitor	O
hydrolysis	O
and	O
activity	O
restoration	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
chimeric	O
-	O
virus	O
system	O
can	O
be	O
adapted	O
to	O
study	O
the	O
proteases	O
of	O
emerging	O
human	O
pathogens	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

These	O
cells	O
are	O
more	O
suppressive	O
than	O
bulk	O
Tregs	O
and	O
provide	O
a	O
targeted	O
approach	O
to	O
ameliorating	O
immunopathological	O
disease	O
in	O
infectious	B-DISO
settings	O
.	O

In	O
conclusion	O
,	O
an	O
early	O
upregulation	O
of	O
expression	O
of	O
proinflammatory	O
cytokines	O
such	O
as	O
IL6	O
,	O
IL1β	O
,	O
and	O
IFNγ	O
induced	O
by	O
the	O
M41	O
strain	O
of	O
IBV	O
may	O
be	O
partially	O
implicated	O
in	O
the	O
viral	O
pathogenicity	O
on	O
trachea	B-DISO
tissues	O
of	O
nonimmune	O
challenged	O
chickens	O
,	O
in	O
addition	O
to	O
a	O
late	O
induction	O
of	O
a	O
putative	O
protective	O
immune	O
responses	O
by	O
this	O
virus	O
through	O
upregulation	O
of	O
CD8αα	O
and	O
Granzyme	O
homolog	O
A	O
genes	O
in	O
this	O
organ	O
.	O

Severe	O
malaria	B-DISO
was	O
defined	O
as	O
per	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
guidelines	O
.	O

Of	O
922	O
malaria	B-DISO
cases	O
included	O
in	O
the	O
study	O
,	O
P	O
.	O
vivax	O
was	O
the	O
largest	O
(	O
63	O
.	O
4	O
%,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
60	O
.	O
3	O
-	O
66	O
.	O
5	O
%)	O
infecting	O
species	O
,	O
followed	O
by	O
P	O
.	O
falciparum	O
(	O
34	O
.	O
4	O
%,	O
95	O
%	O
CI	O
31	O
.	O
3	O
-	O
37	O
.	O
5	O
%)	O
and	O
their	O
mixed	B-DISO
infection	I-DISO
(	O
2	O
.	O
2	O
%,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
3	O
.	O
2	O
%).	O

Except	O
hyperparasitaemia	O
and	O
shock	O
,	O
other	O
complications	O
were	O
associated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
mortality	O
in	O
falciparum	B-DISO
malaria	I-DISO
.	O

Retrospective	O
design	O
of	O
this	O
study	O
possesses	B-DISO
inherent	O
limitations	O
.	O

Retrospective	O
design	O
of	O
this	O
study	O
possesses	B-DISO
inherent	O
limitations	O
.	O

A	O
new	O
dosage	O
formulation	O
of	O
nitazoxanide	O
is	O
presently	O
undergoing	O
global	O
Phase	O
3	O
clinical	O
development	O
for	O
the	O
treatment	O
of	O
influenza	B-DISO
.	O

Nitazoxanide	O
inhibits	O
a	O
broad	O
range	O
of	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
including	O
influenza	B-DISO
A	O
(	O
pH1N1	O
)	O
and	O
the	O
avian	O
A	O
(	O
H7N9	O
)	O
as	O
well	O
as	O
viruses	O
that	O
are	O
resistant	O
to	O
neuraminidase	O
inhibitors	O
.	O

EGDT	O
and	O
the	O
Surviving	O
Sepsis	B-DISO
Campaign	O
Guidelines	O
recommend	O
targeting	O
a	O
central	O
venous	O
pressure	O
(	O
CVP	O
)	O
>	O
8	O
mmHg	O
.	O

This	O
paper	O
reviews	O
the	O
adverse	B-DISO
effects	I-DISO
of	O
large	O
volume	O
resuscitation	O
,	O
a	O
high	O
CVP	O
and	O
the	O
excessive	O
use	O
of	O
normal	O
saline	O
.	O

Conversely	O
,	O
the	O
interaction	O
of	O
S	O
with	O
the	O
M	O
protein	O
,	O
essential	O
for	O
VLP	O
incorporation	O
of	O
S	O
,	O
was	O
not	O
impaired	B-DISO
by	O
lack	O
of	O
palmitoylation	O
.	O

Thus	O
,	O
MERS	O
-	O
CoV	O
,	O
but	O
not	O
HKU4	O
,	O
has	O
adapted	O
to	O
use	O
human	O
DPP4	O
and	O
human	O
cellular	O
proteases	O
for	O
efficient	O
human	O
cell	O
entry	O
,	O
contributing	O
to	O
the	O
enhanced	O
pathogenesis	B-DISO
of	O
MERS	O
-	O
CoV	O
in	O
humans	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

Clinically	O
,	O
heliox	O
can	O
decrease	O
airway	O
resistance	O
in	O
acute	B-DISO
asthma	I-DISO
in	O
adults	O
and	O
children	O
and	O
in	O
COPD	B-DISO
.	O

Risk	O
factors	O
for	O
mortality	O
included	O
having	O
an	O
underlying	O
comorbidity	O
,	O
multiorgan	O
dysfunction	O
,	O
a	O
low	O
PF	O
ratio	O
,	O
and	O
high	O
OI	O
at	O
24	O
h	O
of	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
fatal	O
disease	O
caused	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
).	O

Infection	B-DISO
of	O
the	O
type	O
I	O
FCoV	O
was	O
dominant	O
,	O
with	O
a	O
seropositive	O
rate	O
of	O
70	O
.	O
4	O
%,	O
whereas	O
3	O
.	O
5	O
%	O
of	O
cats	O
were	O
infected	O
with	O
the	O
type	O
II	O
FCoV	O
.	O
In	O
most	O
cases	O
,	O
results	O
derived	O
from	O
serotyping	O
and	O
genotyping	O
were	O
highly	O
agreeable	O
.	O

Results	O
derived	O
from	O
serotyping	O
and	O
genotyping	O
support	O
our	O
current	O
understanding	O
of	O
evolution	O
of	O
disease	O
-	O
related	O
FCoV	O
and	O
transmission	O
of	O
FIP	B-DISO
.	O

The	O
model	O
of	O
left	O
lung	O
ARDS	B-DISO
was	O
reproduced	O
,	O
and	O
the	O
respective	O
RM	O
was	O
implemented	O
according	O
to	O
respective	O
method	O
of	O
the	O
two	O
groups	O
.	O

For	O
severe	O
ARDS	B-DISO
caused	O
by	O
single	O
lung	O
injury	O
,	O
implementation	O
of	O
independent	O
lung	O
RM	O
on	O
the	O
basis	O
of	O
independent	O
lung	O
mechanical	O
ventilation	O
for	O
individual	O
lung	O
was	O
significantly	O
superior	O
to	O
the	O
traditional	O
lung	O
RM	O
for	O
the	O
improvement	O
of	O
hemodynamic	O
parameters	O
and	O
VD	O
/	O
VT	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
the	O
most	O
frequent	O
lethal	O
infectious	B-DISO
disease	I-DISO
in	O
cats	O
.	O

Here	O
,	O
we	O
investigated	O
282	O
tissue	O
specimens	O
from	O
28	O
cats	O
that	O
succumbed	O
to	O
FIP	B-DISO
.	O

In	O
three	O
of	O
the	O
FIP	B-DISO
cats	O
,	O
coronavirus	O
isolates	O
with	O
both	O
intact	O
3c	O
genes	O
as	O
well	O
as	O
7b	O
genes	O
of	O
full	O
length	O
could	O
also	O
be	O
detected	O
.	O

The	O
goal	O
of	O
ECMO	O
is	O
to	O
maintain	O
a	O
safe	O
level	O
of	O
oxygenation	O
and	O
controlled	O
respiratory	B-DISO
acidosis	I-DISO
under	O
protective	O
ventilation	O
.	O

Before	O
widespread	O
diffusion	O
of	O
ECMO	O
,	O
new	O
trials	O
should	O
test	O
the	O
efficacy	O
of	O
early	O
initiation	O
or	O
CO2	O
removal	O
in	O
addition	O
to	O
,	O
or	O
even	O
as	O
an	O
alternative	O
to	O
mechanical	O
ventilation	O
for	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Detection	O
and	O
molecular	O
characterization	O
of	O
infectious	B-DISO
bronchitis	B-DISO
-	O
like	O
viruses	O
in	O
wild	O
bird	O
populations	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
protein	O
encoded	O
by	O
SARS	B-DISO
-	O
CoV	O
designated	O
as	O
open	O
reading	O
frame	O
-	O
9b	O
(	O
ORF	O
-	O
9b	O
)	O
localizes	O
to	O
mitochondria	O
and	O
causes	O
mitochondrial	O
elongation	O
by	O
triggering	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
dynamin	O
-	O
like	O
protein	O
1	O
,	O
a	O
host	O
protein	O
involved	O
in	O
mitochondrial	O
fission	O
.	O

These	O
results	O
indicate	O
that	O
SARS	B-DISO
-	O
CoV	O
ORF	O
-	O
9b	O
manipulates	O
host	O
cell	O
mitochondria	O
and	O
mitochondrial	O
function	O
to	O
help	O
evade	O
host	O
innate	O
immunity	O
.	O

These	O
results	O
support	O
a	O
brain	O
-	O
lung	O
crosstalk	O
during	O
sepsis	B-DISO
and	O
sepsis	B-DISO
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Mice	O
were	O
infected	O
intracranially	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

Treatment	O
with	O
FTY720	O
did	O
not	O
affect	O
virus	O
-	O
specific	O
T	O
cell	O
proliferation	B-DISO
,	O
expression	O
of	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
or	O
cytolytic	O
activity	O
.	O

Both	O
symptomatic	O
horses	O
developed	O
viremia	B-DISO
,	O
while	O
the	O
asymptomatic	O
horse	O
did	O
not	O
.	O

Manipulations	O
of	O
the	O
coronavirus	O
-	O
induced	O
UPR	O
may	O
provide	O
novel	O
therapeutic	O
targets	O
for	O
the	O
control	O
of	O
coronavirus	B-DISO
infection	I-DISO
and	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
availability	O
of	O
a	O
robust	O
disease	O
model	O
is	O
essential	O
for	O
the	O
development	O
of	O
countermeasures	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Most	O
of	O
the	O
marmosets	O
developed	O
a	O
progressive	O
severe	O
pneumonia	B-DISO
leading	O
to	O
euthanasia	O
of	O
some	O
animals	O
.	O

TITLE	O
:	O
[	O
The	O
effects	O
of	O
prone	O
position	O
ventilation	O
combined	O
with	O
recruitment	B-DISO
maneuvers	O
on	O
outcomes	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
prone	O
position	O
ventilation	O
combined	O
with	O
recruitment	B-DISO
maneuvers	O
(	O
RM	O
)	O
on	O
clinical	O
outcomes	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
this	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
,	O
we	O
randomly	O
assigned	O
116	O
sequential	O
patients	O
with	O
severe	O
ARDS	B-DISO
to	O
the	O
intervention	O
group	O
(	O
which	O
undergo	O
prone	O
-	O
positioning	O
with	O
RM	O
sessions	O
of	O
at	O
least	O
10	O
hours	O
)	O
or	O
to	O
the	O
control	O
group	O
(	O
which	O
be	O
left	O
in	O
the	O
supine	O
position	O
).	O

No	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
was	O
shown	O
in	O
the	O
incidence	O
of	O
complications	O
,	O
except	O
for	O
the	O
grade	O
1	O
pressure	B-DISO
sore	I-DISO
,	O
which	O
was	O
higher	O
in	O
the	O
intervention	O
group	O
.	O

No	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
was	O
shown	O
in	O
the	O
incidence	O
of	O
complications	O
,	O
except	O
for	O
the	O
grade	O
1	O
pressure	B-DISO
sore	I-DISO
,	O
which	O
was	O
higher	O
in	O
the	O
intervention	O
group	O
.	O

ABSTRACT	O
:	O
Reduced	O
levels	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
Rett	B-DISO
syndrome	I-DISO
(	O
RTT	B-DISO
),	O
a	O
severe	O
neurodevelopmental	B-DISO
disorder	I-DISO
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
gene	O
encoding	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
(	O
MeCP2	O
).	O

In	O
Mecp2	O
mutant	B-DISO
mice	O
,	O
BDNF	O
deficits	O
have	O
been	O
associated	O
with	O
breathing	B-DISO
abnormalities	I-DISO
,	O
a	O
core	O
feature	O
of	O
RTT	B-DISO
,	O
as	O
well	O
as	O
with	O
synaptic	O
hyperexcitability	O
within	O
the	O
brainstem	O
respiratory	O
network	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
pyrimidinylthioacetanilides	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
biological	O
activity	O
as	O
potent	O
HIV	B-DISO
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NNRTIs	O
).	O

Sequence	O
comparisons	O
revealed	O
that	O
3c	O
genes	O
of	O
animals	O
with	O
FIP	B-DISO
were	O
heavily	O
affected	O
by	O
nucleotide	O
deletions	O
and	O
point	O
mutations	O
compared	O
to	O
animals	O
infected	O
with	O
FECV	O
;	O
these	O
alterations	O
resulted	O
either	O
in	O
early	O
termination	O
or	O
destruction	O
of	O
the	O
translation	O
initiation	O
codon	O
.	O

The	O
RRP	O
tested	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-DISO
A	O
and	O
B	O
,	O
parainfluenza	B-DISO
1	O
through	O
4	O
,	O
human	O
metapneumovirus	O
,	O
adenovirus	B-DISO
,	O
rhinovirus	O
/	O
enterovirus	O
,	O
and	O
coronavirus	O
NL62	O
.	O

Consequently	O
,	O
CCoV	O
is	O
now	O
considered	O
to	O
be	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
of	O
dogs	O
.	O

Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
common	O
rescue	O
therapy	O
for	O
severe	O
ARDS	B-DISO
which	O
can	O
be	O
easily	O
tracked	O
in	O
the	O
EMR	O
,	O
and	O
some	O
patients	O
started	O
on	O
iNO	O
may	O
have	O
indications	O
for	O
initiating	O
ECMO	O
.	O

Probable	O
cases	O
of	O
secondary	B-DISO
transmission	I-DISO
occurred	O
in	O
6	O
of	O
26	O
clusters	O
(	O
23	O
%).	O

The	O
rate	O
of	O
secondary	B-DISO
transmission	I-DISO
among	O
household	O
contacts	O
of	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
has	O
been	O
approximately	O
5	O
%.	O

TITLE	O
:	O
Lung	O
postmortem	O
autopsy	O
revealing	O
extramedullary	O
involvement	O
in	O
multiple	B-DISO
myeloma	I-DISO
causing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Computed	O
tomography	O
showed	O
severe	O
bullous	B-DISO
emphysema	I-DISO
and	O
diffuse	O
,	O
patchy	O
,	O
multifocal	O
infiltrations	O
bilaterally	O
with	O
nodular	O
character	O
,	O
small	O
bilateral	O
pleural	B-DISO
effusions	I-DISO
,	O
mediastinal	B-DISO
lymphadenopathy	I-DISO
,	O
and	O
a	O
known	O
lytic	B-DISO
lesion	O
of	O
the	O
12th	O
vertebra	O
.	O

Anesthesia	B-DISO
,	O
postoperative	B-DISO
pain	I-DISO
and	O
surgery	O
will	O
induce	O
respiratory	O
modifications	O
:	O
hypoxemia	O
,	O
pulmonary	O
volumes	O
decrease	O
and	O
atelectasis	B-DISO
associated	O
to	O
a	O
restrictif	O
syndrome	B-DISO
and	O
a	O
diaphragm	O
dysfunction	O
.	O

Therefore	O
,	O
major	O
objectives	O
for	O
anesthesiologists	O
and	O
surgeons	O
are	O
first	O
to	O
prevent	O
the	O
occurrence	O
of	O
postoperative	B-DISO
complications	I-DISO
and	O
second	O
if	O
ARF	B-DISO
occurs	O
is	O
to	O
ensure	O
oxygen	O
administration	O
and	O
carbon	O
dioxide	O
CO2	O
removal	O
while	O
avoiding	O
intubation	O
.	O

Postoperative	O
NIV	O
improves	O
gas	O
exchange	O
,	O
decreases	O
work	O
of	O
breathing	O
and	O
reduces	O
atelectasis	B-DISO
.	O

ABSTRACT	O
:	O
Viral	B-DISO
infection	I-DISO
converts	O
the	O
normal	O
constitution	O
of	O
a	O
cell	O
to	O
optimise	O
viral	O
entry	O
,	O
replication	O
,	O
and	O
virion	O
production	O
.	O

Finally	O
,	O
the	O
PEDV	O
and	O
TGEV	O
infection	B-DISO
affected	O
the	O
MAPK	O
pathway	O
,	O
and	O
inhibition	O
of	O
MAPK	O
pathway	O
regulated	O
the	O
changes	O
of	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
cells	O
.	O

TITLE	O
:	O
Extracorporeal	O
support	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
positive	O
results	O
from	O
the	O
CESAR	O
(	O
Conventional	O
ventilation	O
or	O
ECMO	O
for	O
Severe	O
Adult	O
Respiratory	B-DISO
failure	I-DISO
)	O
study	O
and	O
excellent	O
outcomes	O
in	O
patients	O
who	O
suffered	B-DISO
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
/	O
09	O
)	O
infection	B-DISO
have	O
established	O
ECMO	O
in	O
the	O
care	O
of	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Swab	O
samples	O
were	O
tested	O
by	O
cell	O
culture	O
and	O
/	O
or	O
nucleic	O
amplification	B-DISO
tests	O
.	O

Viral	O
etiology	O
was	O
established	O
in	O
fifty	O
-	O
two	O
(	O
34	O
.	O
9	O
%)	O
of	O
149	O
CAP	B-DISO
patients	O
,	O
twenty	O
-	O
two	O
(	O
81	O
.	O
5	O
%)	O
of	O
27	O
influenza	B-DISO
like	I-DISO
illness	I-DISO
patients	O
,	O
and	O
none	O
of	O
75	O
volunteer	O
controls	O
.	O

Multivariable	O
logistic	O
regression	O
demonstrated	O
that	O
higher	O
BMI	O
was	O
associated	O
with	O
progression	O
to	O
ARDS	B-DISO
(	O
adjusted	O
OR	O
11	O
.	O
84	O
,	O
95	O
%	O
CI	O
1	O
.	O
24	O
to	O
113	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
02	O
).	O

Multivariable	O
logistic	O
regression	O
demonstrated	O
that	O
higher	O
BMI	O
was	O
associated	O
with	O
progression	O
to	O
ARDS	B-DISO
(	O
adjusted	O
OR	O
11	O
.	O
84	O
,	O
95	O
%	O
CI	O
1	O
.	O
24	O
to	O
113	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
02	O
).	O

The	O
present	O
study	O
demonstrates	O
that	O
the	O
both	O
BCoV	O
and	O
GARV	O
are	O
involved	O
in	O
the	O
neonatal	O
calves	O
'	O
diarrhea	B-DISO
,	O
where	O
the	O
frequency	O
of	O
BCoV	O
is	O
clearly	O
higher	O
than	O
that	O
of	O
GARV	O
.	O

This	O
study	O
examined	O
how	O
CD4	O
T	O
cells	O
affect	O
primary	O
and	O
secondary	O
anti	O
-	O
viral	O
CD8	O
T	O
-	O
cell	O
responses	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
during	O
encephalomyelitis	B-DISO
induced	O
by	O
sublethal	O
gliatropic	O
coronavirus	O
.	O

Nevertheless	O
,	O
impaired	B-DISO
virus	O
control	O
in	O
the	O
absence	O
of	O
CD4	O
T	O
cells	O
was	O
associated	O
with	O
gradually	O
diminished	O
CNS	O
CD8	O
T	O
-	O
cell	O
interferon	O
-	O
γ	O
production	O
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
actively	O
causes	O
disease	O
in	O
environments	O
with	O
low	O
relative	O
humidity	O
(<	O
20	O
%)	O
and	O
high	O
temperature	O
(	O
15	O
°	O
C	O
-	O
35	O
°	O
C	O
).	O

Patients	O
included	O
adults	O
receiving	O
a	O
non	O
-	O
cardiac	O
,	O
non	O
-	O
thoracic	B-DISO
,	O
non	O
-	O
transplant	O
,	O
non	O
-	O
trauma	O
,	O
general	O
anesthetic	O
between	O
2	O
/	O
1	O
/	O
05	O
,	O
and	O
3	O
/	O
31	O
/	O
09	O
at	O
the	O
University	O
of	O
Michigan	O
.	O

The	O
pathogenesis	B-DISO
and	O
mode	O
of	O
transmission	O
of	O
MERS	O
-	O
CoV	O
and	O
H7N9	O
influenza	B-DISO
A	O
virus	O
are	O
poorly	O
understood	O
,	O
making	O
it	O
more	O
difficult	O
to	O
implement	O
intervention	O
and	O
preventive	O
measures	O
.	O

A	O
united	O
and	O
coordinated	O
global	O
response	O
is	O
needed	O
to	O
tackle	O
emerging	O
viruses	O
that	O
can	O
cause	O
fatal	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
and	O
to	O
fill	O
major	O
gaps	O
in	O
the	O
understanding	O
of	O
the	O
epidemiology	O
and	O
transmission	O
dynamics	O
of	O
these	O
viruses	O
.	O

Successful	O
treatment	O
outcomes	O
for	O
patients	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
across	O
all	O
health	O
-	O
care	O
settings	O
will	O
necessitate	O
rapid	O
,	O
precise	O
diagnosis	O
and	O
more	O
effective	O
and	O
pathogen	O
-	O
specific	O
therapies	O
.	O

We	O
examined	O
the	O
case	O
of	O
a	O
woman	O
who	O
presented	O
to	O
our	O
Emergency	B-DISO
Department	O
with	O
septic	B-DISO
shock	I-DISO
due	O
to	O
PVL	O
-	O
expressing	O
S	O
.	O
aureus	O
-	O
associated	O
pneumonia	B-DISO
.	O

She	O
had	O
a	O
medical	O
history	O
of	O
osteosarcoma	B-DISO
of	O
the	O
leg	O
and	O
hyperthyroidism	B-DISO
.	O

This	O
case	O
demonstrates	O
that	O
early	O
induction	O
of	O
ECMO	O
support	O
can	O
be	O
a	O
reasonable	O
therapeutic	O
option	O
for	O
PVL	O
-	O
S	O
.	O
aureus	O
-	O
associated	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
as	O
a	O
rare	O
complication	B-DISO
of	O
celiac	O
plexus	O
block	O
in	O
a	O
patient	O
with	O
adenocarcinoma	B-DISO
of	O
the	O
ampulla	O
of	O
vater	O
.	O

However	O
,	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
(	O
EID	O
)	O
and	O
more	O
well	O
-	O
established	O
tropical	B-DISO
disease	I-DISO
pathogens	O
present	O
complex	O
challenges	O
to	O
vaccine	O
developers	O
;	O
in	O
particular	O
,	O
neglected	O
tropical	B-DISO
diseases	I-DISO
,	O
which	O
are	O
most	O
prevalent	O
among	O
the	O
world	O
'	O
s	O
poorest	O
,	O
include	O
many	O
pathogens	O
with	O
large	O
sizes	O
,	O
multistage	O
life	O
cycles	O
and	O
a	O
variety	O
of	O
nonhuman	O
vectors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
conduct	O
an	O
epidemiological	O
and	O
laboratory	O
surveillance	O
of	O
Influenza	B-DISO
-	O
Like	O
Illnesses	O
(	O
ILI	O
)	O
in	O
Polish	O
Armed	O
Forces	O
,	O
civilian	O
military	O
personnel	O
and	O
their	O
families	O
in	O
2011	O
/	O
2012	O
epidemic	O
season	O
,	O
under	O
the	O
United	O
States	O
Department	O
of	O
Defense	O
-	O
Global	O
Emerging	O
Infections	B-DISO
Surveillance	O
and	O
Response	O
System	O
(	O
DoD	O
-	O
GEIS	O
).	O

Transmissible	B-DISO
spongiform	I-DISO
encephalopathy	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
and	O
Ebola	O
fever	O
were	O
ranked	O
first	O
,	O
second	O
,	O
and	O
third	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
report	O
that	O
SARS	B-DISO
-	O
CoV	O
nsp7	O
and	O
nsp8	O
activate	O
and	O
confer	O
processivity	O
to	O
the	O
RNA	O
-	O
synthesizing	O
activity	O
of	O
nsp12	O
.	O

TITLE	O
:	O
Critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
and	O
myopathy	B-DISO
:	O
a	O
systematic	O
review	O
.	O

Many	O
patients	O
continue	O
to	O
suffer	B-DISO
from	O
decreased	O
exercise	O
capacity	O
and	O
compromised	O
quality	O
of	O
life	O
for	O
months	O
to	O
years	O
after	O
the	O
acute	O
event	O
.	O

However	O
spontaneous	B-DISO
pneumothorax	I-DISO
was	O
developed	O
one	O
week	O
after	O
she	O
weaned	O
off	O
the	O
ventilator	O
.	O

However	O
she	O
re	O
-	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
a	O
recurrent	O
pneumothorax	B-DISO
one	O
week	O
later	O
.	O

She	O
was	O
discharged	O
in	O
good	O
health	O
after	O
being	O
treated	O
with	O
negative	O
continuous	O
pleural	O
aspiration	B-DISO
for	O
10	O
days	O
.	O

ABSTRACT	O
:	O
Varicella	B-DISO
-	I-DISO
zoster	I-DISO
virus	I-DISO
infection	I-DISO
can	O
lead	O
to	O
severe	O
illness	O
in	O
immunocompromised	O
patients	O
.	O

TITLE	O
:	O
[	O
High	O
-	O
efficiency	O
expression	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
in	O
tobacco	O
chloroplasts	O
].	O

TITLE	O
:	O
Message	O
in	O
a	O
bottle	O
:	O
lessons	O
learned	O
from	O
antagonism	O
of	O
STING	O
signalling	O
during	O
RNA	B-DISO
virus	I-DISO
infection	I-DISO
.	O

Compared	O
with	O
patients	O
receiving	O
WM	O
treatment	O
alone	O
,	O
patients	O
receiving	O
integrative	O
treatment	O
were	O
more	O
likely	O
to	O
have	O
complete	O
or	O
partial	O
resolution	O
of	O
pulmonary	B-DISO
infiltrate	I-DISO
(	O
RD	O
=	O
0	O
.	O
18	O
,	O
95	O
%	O
CI	O
;	O
0	O
.	O
07	O
to	O
0	O
.	O
30	O
),	O
lower	O
average	O
daily	O
dosage	O
(	O
mg	O
)	O
of	O
corticosteroid	O
(	O
WMD	O
=-	O
60	O
.	O
27	O
,	O
95	O
%	O
CI	O
;	O
-	O
70	O
.	O
58	O
to	O
-	O
49	O
.	O
96	O
),	O
higher	O
CD4	O
+	O
counts	O
(	O
cells	O
/	O
uL	O
)	O
(	O
WMD	O
=	O
167	O
.	O
96	O
,	O
95	O
%	O
CI	O
;	O
109	O
.	O
68	O
to	O
226	O
.	O
24	O
),	O
and	O
shorter	O
time	O
to	O
defervescence	O
(	O
days	O
)	O
(	O
WMD	O
=	O
-	O
1	O
.	O
06	O
,	O
95	O
%	O
CI	O
;-	O
1	O
.	O
60	O
to	O
-	O
0	O
.	O
53	O
).	O

ABSTRACT	O
:	O
High	O
-	O
volume	O
hemofiltration	O
(	O
HVHF	O
)	O
is	O
technically	O
possible	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
)	O
patients	O
complicated	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
explore	O
the	O
effects	O
of	O
fluid	O
resuscitation	O
and	O
HVHF	O
on	O
alveolar	O
-	O
arterial	O
oxygen	O
exchange	O
,	O
the	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
in	O
patients	O
with	O
refractory	O
septic	B-DISO
shock	I-DISO
.	O

A	O
total	O
of	O
89	O
refractory	O
septic	B-DISO
shock	I-DISO
patients	O
,	O
who	O
were	O
admitted	O
to	O
ICU	O
,	O
the	O
Provincial	O
Hospital	O
affiliated	O
to	O
Shandong	O
University	O
from	O
August	O
2006	O
to	O
December	O
2009	O
,	O
were	O
enrolled	O
in	O
this	O
retrospective	O
study	O
.	O

The	O
levels	O
of	O
CcvO2	O
,	O
CaO2	O
on	O
day	O
7	O
in	O
group	O
A	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
group	B-DISO
B	I-DISO
(	O
CcvO2	O
:	O
0	O
.	O
60	O
±	O
0	O
.	O
24	O
vs	O
.	O
0	O
.	O
72	O
±	O
0	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
CaO2	O
:	O
0	O
.	O
84	O
±	O
0	O
.	O
43	O
vs	O
.	O
0	O
.	O
94	O
±	O
0	O
.	O
46	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
APACHE	O
II	O
score	O
in	O
the	O
two	O
groups	O
reduced	O
gradually	O
after	O
7	O
-	O
day	O
treatment	O
,	O
and	O
the	O
APACHE	O
II	O
score	O
on	O
the	O
7th	O
day	O
in	O
group	B-DISO
B	I-DISO
was	O
significantly	O
lower	O
than	O
that	O
in	O
group	O
A	O
(	O
8	O
.	O
2	O
±	O
3	O
.	O
8	O
vs	O
.	O
17	O
.	O
2	O
±	O
6	O
.	O
8	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

HVHF	O
combined	O
with	O
fluid	O
resuscitation	O
can	O
improve	O
alveolar	O
-	O
arterial	O
-	O
oxygen	O
exchange	O
,	O
decrease	O
the	O
APACHE	O
II	O
score	O
in	O
patients	O
with	O
refractory	O
septic	B-DISO
shock	I-DISO
,	O
and	O
thus	O
it	O
increases	O
the	O
survival	O
rate	O
of	O
patients	O
.	O

The	O
APACHE	O
II	O
score	O
in	O
the	O
two	O
groups	O
reduced	O
gradually	O
after	O
7	O
-	O
day	O
treatment	O
,	O
and	O
the	O
APACHE	O
II	O
score	O
on	O
the	O
7th	O
day	O
in	O
group	B-DISO
B	I-DISO
was	O
significantly	O
lower	O
than	O
that	O
in	O
group	O
A	O
(	O
8	O
.	O
2	O
±	O
3	O
.	O
8	O
vs	O
.	O
17	O
.	O
2	O
±	O
6	O
.	O
8	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Health	O
concerns	O
and	O
social	O
experiences	O
motivated	O
the	O
participants	O
to	O
practise	O
tai	O
chi	O
in	O
post	O
-	O
SARS	B-DISO
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
observed	O
that	O
all	O
known	O
potent	O
broadly	O
neutralizing	O
antibodies	O
(	O
bnAbs	O
)	O
against	O
HIV	B-DISO
-	O
1	O
are	O
highly	O
divergent	O
from	O
their	O
putative	O
germline	O
predecessors	O
in	O
contrast	O
to	O
bnAbs	O
against	O
viruses	O
causing	O
acute	B-DISO
infections	I-DISO
such	O
as	O
henipaviruses	O
and	O
SARS	B-DISO
CoV	O
,	O
which	O
are	O
much	O
less	O
divergent	O
from	O
their	O
germline	O
counterparts	O
.	O

The	O
specificity	O
of	O
the	O
ARMS	B-DISO
RT	O
-	O
PCR	O
and	O
the	O
ARMS	B-DISO
qRT	O
-	O
PCR	O
was	O
verified	O
using	O
unrelated	O
avian	O
viruses	O
.	O

In	O
addition	O
to	O
being	O
able	O
to	O
detect	O
the	O
presence	O
of	O
IBV	O
vaccine	O
and	O
wild	O
-	O
type	O
strains	O
by	O
ARMS	B-DISO
RT	O
-	O
PCR	O
,	O
the	O
IBV	O
Mass	O
,	O
IBV	O
H120	O
,	O
IBV	O
TW	O
-	O
I	O
,	O
and	O
IBV	O
TW	O
-	O
II	O
strains	O
were	O
distinguished	O
using	O
ARMS	B-DISO
qRT	O
-	O
PCR	O
by	O
their	O
melting	O
temperatures	O
and	O
by	O
HRMA	O
.	O

ABSTRACT	O
:	O
Apoptosis	O
of	O
alveolar	O
macrophages	O
(	O
AMs	B-DISO
)	O
plays	O
a	O
pathogenic	O
role	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
type	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
conclude	O
that	O
using	O
either	O
single	O
nAbs	O
or	O
dual	O
nAb	O
combinations	O
to	O
target	O
a	O
SARS	B-DISO
-	O
CoV	O
RBD	O
epitope	O
that	O
shows	O
plasticity	O
may	O
have	O
limitations	O
for	O
preventing	O
neutralization	O
escape	O
during	O
in	O
vivo	O
immunotherapy	O
.	O

Limitations	O
on	O
routine	O
clinical	O
applicability	O
of	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
(	O
WHO	O
)	O
guidelines	O
for	O
determination	O
of	O
severity	O
in	O
malaria	B-DISO
does	O
result	O
in	O
underestimation	O
of	O
the	O
true	O
burden	O
of	O
clinicians	O
'	O
perceived	O
severity	O
in	O
malaria	B-DISO
.	O

More	O
than	O
three	O
days	O
of	O
history	O
of	O
fever	O
,	O
cerebral	B-DISO
malaria	I-DISO
,	O
PE	O
/	O
ARDS	B-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
hyperparasitaemia	O
,	O
leucocytosis	B-DISO
and	O
severe	O
thrombocytopaenia	O
were	O
independently	O
associated	O
factors	O
with	O
intensive	O
care	O
requirement	O
.	O

At	O
the	O
calf	O
level	O
,	O
the	O
odds	O
of	O
C	O
.	O
parvum	O
shedding	O
and	O
of	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
any	O
combination	O
of	O
pathogens	O
were	O
greater	O
in	O
calves	O
that	O
were	O
9	O
-	O
21	O
than	O
1	O
-	O
5	O
days	O
-	O
old	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
11	O
years	O
later	O
--	O
a	O
radiology	O
perspective	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
coronavirus	O
,	O
identified	O
in	O
patients	O
with	O
respiratory	B-DISO
symptoms	I-DISO
in	O
the	O
Middle	O
East	O
.	O

Although	O
dromedary	O
camels	O
appear	O
to	O
be	O
the	O
most	O
important	O
source	O
in	O
primary	O
cases	O
,	O
nosocomial	O
transmission	O
has	O
proved	O
to	O
be	O
a	O
major	O
cause	O
of	O
secondary	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
The	O
role	O
of	O
myeloid	O
cell	O
activation	O
and	O
arginine	O
metabolism	O
in	O
the	O
pathogenesis	B-DISO
of	O
virus	O
-	O
induced	O
diseases	O
.	O

In	O
the	O
context	O
of	O
viral	B-DISO
infections	I-DISO
,	O
expression	O
of	O
these	O
enzymes	O
can	O
result	O
in	O
a	O
variety	O
of	O
outcomes	O
for	O
the	O
host	O
.	O

In	O
this	O
prospective	O
observational	O
study	O
,	O
we	O
wanted	O
to	O
shed	O
light	O
on	O
the	O
kinetic	O
of	O
plasmatic	O
RAGE	O
and	O
cytokeratin	O
18	O
isoforms	O
after	O
severe	O
trauma	O
,	O
thereby	O
also	O
addressing	O
the	O
association	O
of	O
these	O
markers	O
with	O
inflammation	B-DISO
and	O
their	O
potential	O
use	O
as	O
biomarkers	O
.	O

ABSTRACT	O
:	O
Sepsis	B-DISO
is	O
a	O
frequent	O
cause	O
of	O
admission	O
,	O
but	O
incidence	O
rates	O
based	O
on	O
administrative	O
data	O
have	O
previously	O
produced	O
large	O
differences	O
in	O
estimates	O
.	O

Vital	O
signs	O
and	O
laboratory	O
values	O
were	O
collected	O
to	O
define	O
the	O
presence	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
and	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
A	O
review	O
of	O
genetic	O
methods	O
and	O
models	O
for	O
analysis	O
of	O
coronavirus	O
-	O
induced	O
severe	O
pneumonitis	B-DISO
.	O

Through	O
the	O
review	O
and	O
analysis	O
of	O
the	O
available	O
disease	O
models	O
,	O
investigators	O
can	O
employ	O
the	O
most	O
appropriate	O
available	O
model	O
to	O
study	O
various	O
aspects	O
of	O
CoV	O
pathogenesis	B-DISO
and	O
evaluate	O
possible	O
antiviral	O
treatments	O
that	O
may	O
potentially	O
be	O
successful	O
in	O
future	O
treatment	O
and	O
prevention	O
of	O
severe	O
CoV	O
respiratory	B-DISO
infections	I-DISO
.	O

The	O
validation	O
of	O
the	O
results	O
of	O
swabs	O
taken	O
from	O
the	O
nose	O
and	O
throat	O
were	O
carried	O
out	O
in	O
the	O
Department	O
of	O
Influenza	B-DISO
Research	O
,	O
National	O
Influenza	B-DISO
Center	O
in	O
Warsaw	O
.	O

TITLE	O
:	O
Genotypic	O
characterization	O
of	O
canine	O
coronaviruses	O
associated	O
with	O
fatal	O
canine	O
neonatal	O
enteritis	B-DISO
in	O
the	O
United	O
States	O
.	O

Concurrent	O
infections	B-DISO
with	O
either	O
parvovirus	B-DISO
(	O
n	O
=	O
1	O
),	O
attaching	O
-	O
effacing	O
Escherichia	O
coli	O
(	O
n	O
=	O
4	O
),	O
or	O
protozoan	O
parasites	O
(	O
n	O
=	O
3	O
)	O
were	O
found	O
in	O
the	O
other	O
six	O
puppies	O
.	O

CCoV	O
is	O
an	O
important	O
differential	O
diagnosis	O
in	O
outbreaks	O
of	O
severe	O
enterocolitis	B-DISO
among	O
puppies	O
between	O
4	O
days	O
and	O
21	O
weeks	O
of	O
age	O
that	O
are	O
housed	O
at	O
high	O
population	O
density	O
.	O

These	O
findings	O
will	O
assist	O
with	O
the	O
rapid	O
laboratory	O
diagnosis	O
of	O
enteritis	B-DISO
in	O
puppies	O
and	O
highlight	O
the	O
need	O
for	O
continued	O
surveillance	O
for	O
CCoV	O
variants	O
and	O
intestinal	O
viral	B-DISO
diseases	I-DISO
of	O
global	O
significance	O
.	O

Hypotonic	B-DISO
stress	O
,	O
which	O
causes	O
plasma	O
membrane	O
stretching	O
,	O
also	O
transiently	O
increased	O
the	O
[	O
Ca	O
(	O
2	O
+)]	O
i	O
.	O

TITLE	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
in	O
Children	O
:	O
Croup	B-DISO
and	O
Acute	B-DISO
Asthma	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
is	O
one	O
of	O
the	O
most	O
common	O
reason	O
for	O
emergency	B-DISO
visits	O
in	O
children	O
under	O
5	O
y	O
of	O
age	O
.	O

Specific	O
treatment	O
depends	O
on	O
the	O
exact	O
cause	O
,	O
however	O
croup	B-DISO
and	O
acute	B-DISO
severe	I-DISO
asthma	I-DISO
have	O
been	O
discussed	O
in	O
this	O
article	O
.	O

TITLE	O
:	O
Computer	O
aided	O
prediction	O
and	O
identification	O
of	O
potential	O
epitopes	O
in	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
belongs	O
to	O
the	O
coronaviridae	O
family	O
.	O

In	O
the	O
current	O
study	O
,	O
in	O
a	O
lipopolysaccharide	O
-	O
based	O
mouse	O
model	O
of	O
ALI	O
,	O
we	O
found	O
that	O
insulin	O
alleviated	O
pulmonary	B-DISO
edema	I-DISO
by	O
promoting	O
ENaC	O
-	O
mediated	O
alveolar	O
fluid	O
clearance	O
through	O
serum	O
and	O
glucocorticoid	O
induced	O
kinase	O
-	O
1	O
(	O
SGK1	O
).	O

TITLE	O
:	O
The	O
influence	O
of	O
age	O
and	O
genetics	O
on	O
natural	O
resistance	O
to	O
experimentally	O
induced	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
Naturally	O
occurring	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
usually	O
fatal	O
,	O
giving	O
the	O
impression	O
that	O
immunity	O
to	O
the	O
FIP	B-DISO
virus	O
(	O
FIPV	O
)	O
is	O
extremely	O
poor	O
.	O

Six	O
of	O
these	O
40	O
survivors	O
succumbed	O
to	O
FIP	B-DISO
to	O
a	O
second	O
or	O
third	O
challenge	O
exposure	O
,	O
suggesting	O
that	O
immunity	O
was	O
not	O
always	O
sustained	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
of	O
human	O
infection	B-DISO
with	O
a	O
novel	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H10N8	O
)	O
virus	O
.	O

Three	O
cases	O
of	O
human	O
infection	B-DISO
with	O
a	O
new	O
reassortment	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H10N8	O
)	O
virus	O
were	O
described	O
,	O
of	O
which	O
two	O
were	O
fatal	O
cases	O
,	O
and	O
one	O
was	O
severe	O
case	O
.	O

CONCLUSIONS	O
:	O
This	O
novel	O
reassortment	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H10N8	O
)	O
virus	O
in	O
China	O
resulted	O
in	O
fatal	O
human	O
infections	B-DISO
,	O
and	O
should	O
be	O
added	O
to	O
concerns	O
in	O
clinical	O
practice	O
.	O

Fifty	O
four	O
randomly	O
selected	O
patients	O
with	O
confirmed	O
SAP	O
complicated	O
by	O
ARDS	B-DISO
after	O
being	O
admitted	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
within	O
72	O
hr	O
of	O
onset	O
were	O
included	O
in	O
the	O
study	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
respiratory	O
viruses	O
in	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
in	O
Shijiazhuang	O
,	O
China	O
in	O
2011	O
].	O

Throat	O
swab	O
specimens	O
were	O
collected	O
from	O
483	O
cases	O
of	O
ILI	O
who	O
were	O
outpatients	O
in	O
the	O
influenza	B-DISO
surveillance	O
sentinel	O
hospitals	O
in	O
Shijiazhuang	O
between	O
January	O
and	O
December	O
2011	O
.	O

All	O
cases	O
of	O
RSV	O
were	O
identified	O
to	O
be	O
subtype	O
A	O
.	O
PIV	O
infection	B-DISO
was	O
mainly	O
caused	O
by	O
PIV	O
-	O
3	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
Sprouty	O
-	O
related	O
EVH1	O
-	O
domain	O
-	O
containing	O
protein	O
(	O
Spred	O
)-	O
2	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)-	O
MAPK	O
pathway	O
,	O
in	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
acute	O
lung	B-DISO
inflammation	I-DISO
.	O

Spred	O
-	O
2	O
controls	O
the	O
development	O
of	O
LPS	B-DISO
-	O
induced	O
lung	B-DISO
inflammation	I-DISO
by	O
negatively	O
regulating	O
the	O
ERK	O
-	O
MAPK	O
pathway	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
if	O
immune	O
phenotypes	O
associated	O
with	O
immunosenescence	B-DISO
predict	O
risk	O
of	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
in	O
elderly	O
nursing	O
home	O
residents	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
we	O
included	O
adults	O
(	O
aged	O
≥	O
16	O
years	O
)	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
pneumonia	B-DISO
needing	O
ventilation	O
support	O
,	O
diagnosed	O
between	O
Oct	O
23	O
,	O
2012	O
,	O
and	O
May	O
1	O
,	O
2014	O
,	O
at	O
the	O
Prince	O
Sultan	O
Military	O
Medical	O
City	O
(	O
Riyadh	O
,	O
Saudi	O
Arabia	O
).	O

Average	O
daily	O
gain	O
was	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
for	O
one	O
week	O
post	O
-	O
infection	B-DISO
in	O
challenged	O
pigs	O
.	O

Microscopic	O
lesions	O
included	O
severe	O
diffuse	O
atrophic	B-DISO
enteritis	B-DISO
with	O
significantly	O
reduced	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
villous	O
length	O
observed	O
on	O
dpi	O
3	O
,	O
4	O
,	O
and	O
7	O
.	O

The	O
biological	O
role	O
that	O
alcohol	O
plays	O
in	O
genital	O
HPV	O
infection	B-DISO
remains	O
understudied	O
and	O
limited	O
epidemiological	O
data	O
exist	O
,	O
especially	O
among	O
men	O
.	O

TITLE	O
:	O
The	O
spray	O
-	O
drying	O
process	O
is	O
sufficient	O
to	O
inactivate	O
infectious	B-DISO
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
plasma	O
.	O

Recently	O
it	O
has	O
been	O
suggested	O
that	O
PEDV	O
could	O
be	O
transmitted	B-DISO
to	O
naïve	O
pig	O
populations	O
through	O
inclusion	O
of	O
spray	O
-	O
dried	O
porcine	O
plasma	O
(	O
SDPP	O
)	O
into	O
the	O
nursery	O
diet	O
which	O
led	O
to	O
a	O
ban	O
of	O
SDPP	O
in	O
several	O
areas	O
in	O
North	O
America	O
and	O
Europe	O
.	O

TITLE	O
:	O
Innate	O
receptors	O
and	O
cellular	O
defense	O
against	O
pulmonary	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Among	O
the	O
various	O
respiratory	O
viruses	O
infecting	O
human	O
beings	O
,	O
coronaviruses	O
are	O
important	O
pathogens	O
,	O
which	O
usually	O
infect	O
the	O
upper	O
respiratory	O
tract	O
,	O
where	O
they	O
are	O
mainly	O
associated	O
with	O
common	B-DISO
colds	I-DISO
.	O

Neuroinvasive	O
coronaviruses	O
could	O
damage	O
the	O
CNS	O
as	O
a	O
result	O
of	O
misdirected	O
host	O
immune	O
responses	O
that	O
could	O
be	O
associated	O
with	O
autoimmunity	B-DISO
in	O
susceptible	O
individuals	O
(	O
virus	O
-	O
induced	O
neuroimmunopathology	O
)	O
and	O
/	O
or	O
viral	O
replication	O
,	O
which	O
directly	O
induces	O
damage	O
to	O
CNS	O
cells	O
(	O
virus	O
-	O
induced	O
neuropathology	B-DISO
).	O

TITLE	O
:	O
[	O
Quick	O
simultaneous	O
analyses	O
are	O
important	O
when	O
MERS	O
-	O
coronavirus	B-DISO
infection	I-DISO
is	O
suspected	O
].	O

It	O
was	O
named	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
.	O
Here	O
,	O
a	O
small	O
series	O
of	O
case	O
stories	O
illustrates	O
how	O
simultaneous	O
analyses	O
for	O
MERS	O
-	O
CoV	O
and	O
other	O
agents	O
of	O
infections	B-DISO
at	O
the	O
loca	O
l	O
laboratory	O
resulted	O
in	O
rapid	O
rejection	O
of	O
suspicion	O
of	O
MERS	O
and	O
establishment	O
of	O
the	O
true	O
cause	O
of	O
disease	O
.	O

TITLE	O
:	O
Serial	O
intervals	O
of	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
:	O
a	O
systematic	O
review	O
and	O
analysis	O
.	O

A	O
good	O
evidence	O
base	O
for	O
such	O
values	O
is	O
essential	O
,	O
because	O
they	O
allow	O
investigators	O
to	O
identify	O
epidemiologic	O
links	O
between	O
cases	O
and	O
serve	O
as	O
an	O
important	O
parameter	O
in	O
epidemic	O
transmission	O
models	O
used	O
to	O
design	O
infection	B-DISO
control	O
strategies	O
.	O

For	O
varicella	B-DISO
,	O
we	O
found	O
an	O
evidence	O
-	O
based	O
value	O
that	O
deviates	O
substantially	O
from	O
the	O
21	O
days	O
commonly	O
used	O
in	O
transmission	O
models	O
.	O

N	O
phosphorylation	O
allows	O
recruitment	B-DISO
of	O
the	O
RNA	O
helicase	O
DDX1	O
to	O
the	O
phosphorylated	O
-	O
N	O
-	O
containing	O
complex	O
,	O
which	O
facilitates	O
template	O
readthrough	O
and	O
enables	O
longer	O
sgmRNA	O
synthesis	O
.	O

One	O
hundred	O
and	O
seventy	O
six	O
children	O
in	O
the	O
age	O
group	O
of	O
one	O
month	O
to	O
12	O
years	O
,	O
presented	O
with	O
fever	O
≤	O
2wks	O
duration	O
and	O
altered	B-DISO
mental	I-DISO
status	I-DISO
lasting	O
for	O
more	O
than	O
4h	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Anemia	B-DISO
was	O
observed	O
in	O
78	O
%	O
of	O
the	O
sample	O
.	O

TITLE	O
:	O
Clinical	O
aspects	O
and	O
outcomes	O
of	O
70	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
:	O
a	O
single	O
-	O
center	O
experience	O
in	O
Saudi	O
Arabia	O
.	O

Patients	O
were	O
mostly	O
of	O
older	O
age	O
(	O
median	O
62	O
years	O
),	O
male	O
(	O
46	O
,	O
65	O
.	O
7	O
%),	O
and	O
had	O
healthcare	O
acquisition	O
of	O
infection	B-DISO
(	O
39	O
,	O
55	O
.	O
7	O
%).	O

UPR	O
is	O
closely	O
associated	O
with	O
a	O
number	O
of	O
major	O
signaling	O
pathways	O
,	O
including	O
autophagy	O
,	O
apoptosis	O
,	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
pathways	O
,	O
innate	O
immunity	O
and	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
.	O

Three	O
out	O
of	O
four	O
hypoxic	B-DISO
patients	O
with	O
elevated	O
EVLWI	O
tolerated	O
the	O
NFB	O
protocol	O
.	O

Noninvasive	O
mechanical	O
ventilation	O
can	O
reduce	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
,	O
improve	O
gas	O
exchange	O
,	O
alleviate	O
symptoms	O
as	O
dyspnea	B-DISO
caused	O
by	O
fatigue	B-DISO
of	O
the	O
respiratory	O
muscles	O
,	O
reduce	O
duration	O
of	O
hospitalization	O
,	O
decrease	O
need	O
for	O
invasive	O
mechanical	O
ventilation	O
,	O
reduce	O
number	O
of	O
complications	O
and	O
also	O
lessen	O
hospital	O
mortality	O
.	O

The	O
main	O
complications	O
found	O
were	O
:	O
facial	O
skin	B-DISO
erythema	I-DISO
,	O
claustrophobia	B-DISO
,	O
nasal	B-DISO
congestion	I-DISO
,	O
face	O
pain	B-DISO
,	I-DISO
eye	I-DISO
irritation	O
,	O
aspiration	B-DISO
pneumonia	I-DISO
,	O
hypotension	O
,	O
pneumothorax	B-DISO
,	O
aerophagia	B-DISO
,	O
hypercapnia	B-DISO
,	O
gastric	O
insufflation	O
,	O
vomit	B-DISO
,	O
bronchoaspiration	O
,	O
morning	O
headaches	B-DISO
,	O
face	B-DISO
injuries	O
,	O
air	O
embolism	B-DISO
and	O
,	O
last	O
but	O
not	O
least	O
,	O
discomfort	B-DISO
of	O
the	O
patient	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
a	O
virulent	O
TGEV	O
SHXB	O
strain	O
could	O
infect	O
porcine	O
immature	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
(	O
Mo	O
-	O
DCs	B-DISO
),	O
and	O
down	O
-	O
regulate	O
cell	O
surface	O
markers	O
(	O
SLA	O
-	O
II	O
-	O
DR	O
,	O
CD1a	O
and	O
CD80	O
/	O
86	O
).	O

Association	O
studies	O
reproducible	O
in	O
large	O
populations	O
will	O
definitely	O
allow	O
genomics	O
to	O
be	O
included	O
into	O
the	O
diagnostic	O
and	O
therapeutic	O
armamentarium	O
for	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Cats	O
that	O
live	O
in	O
areas	O
where	O
canine	O
and	O
human	O
leishmaniosis	B-DISO
due	O
to	O
Leishmania	O
infantum	O
is	O
endemic	O
may	O
become	O
infected	O
and	O
may	O
develop	O
anti	O
-	O
Leishmania	O
antibodies	O
.	O

The	O
survey	O
questionnaire	O
was	O
developed	O
and	O
internally	O
piloted	O
at	O
University	O
Hospital	O
Southampton	O
NHS	B-DISO
Foundation	O
Trust	O
.	O

There	O
was	O
a	O
perceived	O
decline	O
in	O
both	O
incidence	O
and	O
mortality	O
in	O
ARDS	B-DISO
.	O

There	O
is	O
substantial	O
variation	O
in	O
the	O
diagnostic	O
and	O
management	O
strategies	O
employed	O
for	O
patients	O
with	O
ARDS	B-DISO
across	O
the	O
UK	O
.	O

It	O
causes	O
two	O
syndromes	B-DISO
:	O
hemorrhagic	B-DISO
fever	I-DISO
with	I-DISO
renal	I-DISO
syndrome	I-DISO
(	O
HFRS	B-DISO
),	O
endemic	O
in	O
Asia	O
and	O
Europe	O
and	O
the	O
Hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
),	O
found	O
in	O
the	O
American	O
continent	O
,	O
including	O
Brazil	O
,	O
with	O
high	O
mortality	O
rates	O
.	O

Diffuse	O
interstitial	O
alveolar	O
infiltrates	B-DISO
were	O
seen	O
in	O
the	O
chest	O
X	O
-	O
Ray	O
.	O

Extensive	O
review	O
of	O
the	O
adrenal	O
physiology	O
and	O
its	O
pathophysiological	O
derangements	O
and	O
clinical	O
implications	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

These	O
studies	O
were	O
designed	O
to	O
examine	O
the	O
changes	O
in	O
the	O
function	O
of	O
the	O
bladder	O
that	O
may	O
underlie	O
neurogenic	O
bladder	B-DISO
dysfunction	I-DISO
using	O
a	O
mouse	O
model	O
of	O
demyelination	B-DISO
in	O
the	O
CNS	O
.	O

RESULTS	O
:	O
The	O
maximum	O
effect	O
of	O
EFS	O
was	O
not	O
significantly	O
different	O
between	O
CIE	B-DISO
and	O
control	O
bladders	O
.	O

TITLE	O
:	O
[	O
Inhaled	O
nitric	O
oxide	O
for	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

Further	O
studies	O
should	O
be	O
concentrated	O
on	O
early	O
treatment	O
,	O
when	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
potentially	O
reversible	O
.	O

The	O
authors	O
describe	O
a	O
newborn	O
who	O
suffered	B-DISO
from	O
sepsis	B-DISO
,	O
shock	O
and	O
multiple	O
organ	O
dysfunction	O
syndromes	B-DISO
(	O
MODS	B-DISO
)	O
that	O
recovered	O
after	O
the	O
administration	O
of	O
activated	O
C	O
protein	O
.	O

The	O
newborn	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
due	O
to	O
intrauterine	B-DISO
pneumonia	I-DISO
and	O
was	O
taken	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
.	O

The	O
activated	O
C	O
protein	O
can	O
'	O
t	O
be	O
recommended	O
as	O
a	O
routine	O
in	O
the	O
treatment	O
of	O
newborns	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

Varicella	B-DISO
pneumonia	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
very	O
rare	O
in	O
adults	O
and	O
is	O
associated	O
with	O
high	O
morbimortality	O
.	O

TITLE	O
:	O
[	O
Severe	O
imported	O
malaria	B-DISO
:	O
case	O
report	O
].	O

During	O
his	O
stay	O
at	O
the	O
hospital	O
,	O
P	O
.	O
Falciparum	B-DISO
Malaria	I-DISO
was	O
diagnosed	O
through	O
the	O
thick	O
drop	O
test	O
.	O

And	O
,	O
even	O
with	O
the	O
adequate	O
anti	O
-	O
malaria	B-DISO
therapy	O
,	O
the	O
patient	O
	O
s	O
condition	B-DISO
evolved	O
to	O
an	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
requiring	O
hemodialis	O
;	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
septic	B-DISO
shock	I-DISO
,	O
and	O
hematological	B-DISO
disorders	I-DISO
,	O
forming	O
a	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

TITLE	O
:	O
Longitudinal	O
study	O
of	O
Salmonella	B-DISO
spp	O
.,	O
diarrheagenic	O
Escherichia	O
coli	O
,	O
Rotavirus	O
,	O
and	O
Coronavirus	O
isolated	O
from	O
healthy	O
and	O
diarrheic	O
calves	O
in	O
a	O
Brazilian	O
dairy	O
herd	O
.	O

ABSTRACT	O
:	O
This	O
prospective	O
longitudinal	O
study	O
investigated	O
the	O
epidemiology	O
of	O
enteric	O
disease	O
associated	O
with	O
infections	B-DISO
in	O
calves	O
aging	O
up	O
to	O
70	O
days	O
.	O

It	O
is	O
relatively	O
contraindicated	O
in	O
patients	O
with	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
due	O
to	O
bleeding	B-DISO
complications	O
and	O
use	O
of	O
anticoagulation	O
.	O

Clinical	O
signs	O
,	O
pathological	O
changes	O
,	O
virus	O
titration	O
in	O
tissues	O
of	O
mice	O
,	O
arterial	O
blood	O
gas	O
,	O
and	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
serum	O
were	O
observed	O
at	O
different	O
time	O
points	O
after	O
AIV	O
infection	B-DISO
.	O

In	O
addition	O
,	O
H9N2	O
viral	B-DISO
infection	I-DISO
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	B-DISO
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	O
.	O

TITLE	O
:	O
Golden	O
tracheal	O
secretions	O
and	O
bronchoalveolar	O
fluid	O
during	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	I-DISO
sickle	I-DISO
cell	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
chest	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
is	O
the	O
leading	O
cause	O
of	O
ICU	O
admission	O
in	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
and	O
is	O
characterized	O
by	O
golden	O
sputum	O
,	O
which	O
is	O
commonly	O
attributed	O
to	O
the	O
presence	O
of	O
bilirubin	O
.	O

Through	O
IIF	O
,	O
33	O
(	O
20	O
.	O
4	O
%)	O
specimens	O
with	O
respiratory	O
virus	O
were	O
recognised	O
,	O
with	O
influenza	B-DISO
virus	O
representing	O
over	O
half	O
of	O
the	O
positive	O
samples	O
.	O

These	O
activities	O
have	O
been	O
suggested	O
to	O
suppress	O
host	O
antiviral	O
responses	O
during	O
infection	B-DISO
.	O

The	O
ability	O
to	O
decouple	O
the	O
DUB	O
activity	O
of	O
PL	O
(	O
pro	O
)	O
from	O
its	O
role	O
in	O
viral	O
polyprotein	O
processing	O
now	O
provides	O
an	O
approach	O
to	O
further	O
dissect	O
the	O
role	O
(	O
s	O
)	O
of	O
PL	O
(	O
pro	O
)	O
as	O
a	O
viral	O
DUB	O
during	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Virus	B-DISO
shedding	I-DISO
and	O
virus	O
functions	O
did	O
not	O
change	O
significantly	O
during	O
the	O
outbreak	O
in	O
Jeddah	O
.	O

ABSTRACT	O
:	O
Toxic	O
epidermal	B-DISO
necrosis	I-DISO
is	O
a	O
severe	O
mucocutaneous	O
disease	O
with	O
a	O
high	O
mortality	O
rate	O
.	O

TITLE	O
:	O
Challenging	O
rescue	O
of	O
a	O
4	O
years	O
old	O
boy	O
with	O
H1N1	O
infection	B-DISO
by	O
extracorporeal	O
membrane	O
oxygenator	O
:	O
A	O
case	O
report	O
.	O

ABSTRACT	O
:	O
World	O
Health	O
Organization	O
announced	O
on	O
April	O
2009	O
a	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
caused	O
by	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
.	O

Second	O
,	O
it	O
highlights	O
the	O
importance	O
of	O
a	O
closely	O
monitoring	O
of	O
clotting	O
parameters	O
during	O
ECMO	O
therapy	O
and	O
third	O
,	O
if	O
severe	O
respiratory	B-DISO
failure	I-DISO
is	O
complicated	O
by	O
cardiogenic	B-DISO
shock	I-DISO
,	O
veno	O
-	O
atrial	O
ECMO	O
support	O
via	O
median	O
sternotomy	O
should	O
be	O
considered	O
as	O
a	O
viable	O
treatment	O
option	O
without	O
further	O
delay	O
.	O

Exposure	O
to	O
MERS	O
-	O
CoV	O
during	O
a	O
hospital	O
visit	O
is	O
considered	O
a	O
likely	O
source	O
of	O
infection	B-DISO
for	O
Case	O
1	O
but	O
not	O
for	O
Case	O
2	O
.	O

TITLE	O
:	O
Red	O
blood	O
cells	O
induce	O
necroptosis	B-DISO
of	O
lung	O
endothelial	O
cells	O
and	O
increase	O
susceptibility	O
to	O
lung	B-DISO
inflammation	I-DISO
.	O

To	O
determine	O
the	O
mechanisms	O
of	O
lung	O
endothelial	O
cell	O
(	O
EC	O
)	O
High	O
Mobility	O
Group	O
Box	O
1	O
(	O
HMGB1	O
)	O
release	O
following	O
exposure	O
to	O
RBCs	O
and	O
to	O
determine	O
whether	O
RBC	O
transfusion	O
increases	O
susceptibility	O
to	O
lung	B-DISO
inflammation	I-DISO
in	O
vivo	O
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

RBC	O
transfusion	O
sensitized	O
mice	O
to	O
LPS	B-DISO
-	O
induced	O
lung	B-DISO
inflammation	I-DISO
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

TITLE	O
:	O
Swift	O
recovery	O
of	O
severe	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
under	O
non	O
-	O
invasive	O
ventilation	O
.	O

The	O
swift	O
resolution	O
over	O
10	O
h	O
of	O
a	O
severe	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
P	O
/	O
F	O
=	O
57	O
)	O
caused	O
by	O
aspiration	B-DISO
following	O
heroin	O
overdose	O
,	O
using	O
non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)-	O
high	O
PEEP	O
(	O
15	O
-	O
20	O
cm	O
H2O	O
)-	O
low	O
pressure	O
support	O
(	O
8	O
cm	O
H20	O
)	O
is	O
reported	O
.	O

The	O
success	O
in	O
treating	O
non	O
-	O
invasively	O
severe	O
hypoxia	B-DISO
was	O
presumably	O
linked	O
to	O
a	O
highly	O
restricted	O
subset	O
:	O
healthy	O
young	O
patient	O
,	O
minimal	O
alteration	B-DISO
of	I-DISO
consciousness	I-DISO
,	O
non	O
-	O
combativeness	O
,	O
absence	O
of	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
,	O
quick	O
resolution	O
of	O
supraventricular	B-DISO
arrhythmia	I-DISO
,	O
one	O
-	O
to	O
-	O
one	O
supervision	O
by	O
the	O
intensivist	O
in	O
the	O
critical	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
cardiovascular	B-DISO
symptoms	I-DISO
are	O
mainly	O
diagnosed	O
in	O
cardiological	O
wards	O
.	O

The	O
most	O
dangerous	O
for	O
patients	O
is	O
involvement	O
of	O
the	O
nervous	B-DISO
and	O
cardiovascular	O
systems	O
.	O

None	O
of	O
the	O
participants	O
were	O
positive	O
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

Indeed	O
,	O
we	O
demonstrate	O
here	O
that	O
iminosugar	O
treatment	O
altered	O
the	O
N	O
-	O
linked	O
glycan	O
structure	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
did	O
not	O
affect	O
its	O
expression	O
on	O
the	O
cell	O
surface	O
or	O
its	O
binding	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
glycoprotein	O
.	O

However	O
,	O
alteration	O
of	O
N	O
-	O
linked	O
glycans	O
of	O
ACE2	O
impaired	B-DISO
its	O
ability	O
to	O
support	O
the	O
transduction	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
spike	O
glycoprotein	O
-	O
pseudotyped	O
lentiviral	O
particles	O
by	O
disruption	O
of	O
the	O
viral	O
envelope	O
protein	O
-	O
triggered	O
membrane	O
fusion	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
proposed	O
that	O
the	O
analysis	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)-	O
induced	O
volume	O
changes	O
can	O
quantify	O
alveolar	O
recruitment	B-DISO
.	O

The	O
potential	O
of	O
a	O
lung	O
to	O
be	O
recruited	O
is	O
expected	O
to	O
be	O
high	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
where	O
collapsed	B-DISO
lung	I-DISO
tissue	O
is	O
very	O
common	O
.	O

Maximum	O
plateau	O
pressure	O
was	O
reached	O
with	O
fewer	O
PEEP	O
steps	O
in	O
ARDS	B-DISO
compared	O
with	O
LH	O
patients	O
(	O
11	O
vs	O
.	O
14	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Here	O
,	O
we	O
identify	O
epidemiological	O
traits	O
of	O
self	O
-	O
limited	O
infections	B-DISO
(	O
i	O
.	O
e	O
.	O
infections	B-DISO
with	O
an	O
effective	O
reproduction	O
number	O
satisfying	O
[	O
0	O
<	O
R	O
eff	O
<	O
1	O
)	O
that	O
correlate	O
with	O
transmissibility	O
.	O

Our	O
approach	O
provides	O
insight	O
into	O
a	O
variety	O
of	O
scenarios	O
,	O
including	O
the	O
transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
the	O
Arabian	O
peninsula	O
,	O
measles	B-DISO
in	O
North	O
America	O
,	O
pre	O
-	O
eradication	O
smallpox	B-DISO
in	O
Europe	O
,	O
and	O
human	B-DISO
monkeypox	I-DISO
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

TITLE	O
:	O
Quantitative	O
proteomic	O
analysis	O
reveals	O
that	O
transmissible	O
gastroenteritis	B-DISO
virus	O
activates	O
the	O
JAK	O
-	O
STAT1	O
signaling	O
pathway	O
.	O

The	O
cases	O
in	O
the	O
current	O
report	O
document	O
lesions	O
observed	O
in	O
association	O
with	O
CaHV	O
-	O
1	O
in	O
4	O
cases	O
of	O
fatal	O
canine	O
herpesvirus	O
pneumonia	B-DISO
in	O
adult	O
dogs	O
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
upregulates	O
genes	O
involved	O
in	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

RSA59	O
induced	O
neuropathology	B-DISO
is	O
partially	O
caused	O
by	O
activation	O
of	O
CNS	O
resident	O
microglia	O
,	O
as	O
demonstrated	O
by	O
changes	O
in	O
cellular	O
morphology	O
and	O
increased	O
expression	O
of	O
a	O
microglia	O
/	O
macrophage	O
specific	O
calcium	O
ion	O
binding	O
factor	O
,	O
Iba1	O
.	O

Protein	O
analysis	O
of	O
spinal	O
cord	B-DISO
extracts	O
taken	O
from	O
mice	O
6	O
days	O
post	O
-	O
inoculation	O
,	O
the	O
time	O
of	O
peak	O
inflammation	B-DISO
,	O
reveals	O
robust	O
expression	O
of	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
12	O
and	O
mKC	O
.	O

In	O
this	O
case	O
,	O
lung	O
recruitment	B-DISO
maneuver	O
(	O
RM	O
)	O
with	O
positive	O
end	O
-	O
expiratory	O
pressure	O
under	O
computed	O
tomography	O
guidance	O
is	O
the	O
procedure	O
of	O
choice	O
,	O
but	O
cumulative	O
ionizing	O
radiation	O
exposure	O
is	O
a	O
major	O
radiologic	O
concern	O
,	O
especially	O
in	O
infants	O
.	O

Based	O
on	O
multiple	O
logistic	O
regression	O
analysis	O
,	O
septic	B-DISO
shock	I-DISO
associated	O
with	O
severe	O
hypoxemia	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
for	O
mortality	O
.	O

Articles	O
on	O
emerging	O
diseases	O
caused	O
by	O
Ebola	O
virus	O
,	O
Marburg	O
virus	O
,	O
coronaviruses	O
such	O
as	O
SARS	B-DISO
and	O
MERS	O
,	O
Nipah	O
virus	O
and	O
noroviruses	O
are	O
followed	O
by	O
reviews	O
of	O
enteroviruses	O
,	O
HIV	B-DISO
infection	I-DISO
,	O
measles	B-DISO
,	O
mumps	B-DISO
,	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-DISO
,	O
cytomegalovirus	O
(	O
CMV	O
)	O
and	O
varicella	B-DISO
zoster	I-DISO
virus	O
(	O
VZV	O
).	O

TITLE	O
:	O
Effects	O
of	O
ultraprotective	O
ventilation	O
,	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
,	O
and	O
spontaneous	O
breathing	O
on	O
lung	O
morphofunction	O
and	O
inflammation	B-DISO
in	O
experimental	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
induced	O
by	O
saline	O
lung	O
lavage	O
and	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
with	O
higher	O
tidal	O
volume	O
(	O
VT	O
)	O
in	O
28	O
anesthetized	O
pigs	O
(	O
32	O
.	O
8	O
to	O
52	O
.	O
5	O
kg	O
).	O

In	O
this	O
model	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
MV	O
with	O
VT	O
≈	O
3	O
ml	O
/	O
kg	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
without	O
SB	O
slightly	O
reduced	O
lung	O
histologic	O
damage	O
,	O
but	O
not	O
inflammation	B-DISO
,	O
as	O
compared	O
to	O
MV	O
with	O
VT	O
=	O
4	O
to	O
6	O
ml	O
/	O
kg	O
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
bilateral	O
branch	O
retinal	B-DISO
artery	I-DISO
occlusions	I-DISO
associated	O
with	O
vancomycin	O
infusion	O
in	O
an	O
African	O
American	O
patient	O
in	O
acute	O
sickle	O
crisis	O
.	O

TITLE	O
:	O
Coronavirus	O
cell	O
entry	O
occurs	O
through	O
the	O
endo	B-DISO
-/	O
lysosomal	O
pathway	O
in	O
a	O
proteolysis	O
-	O
dependent	O
manner	O
.	O

Using	O
siRNA	O
gene	O
silencing	O
,	O
we	O
found	O
that	O
proteins	O
known	O
to	O
be	O
important	O
for	O
late	O
endosomal	O
maturation	O
and	O
endosome	O
-	O
lysosome	O
fusion	O
profoundly	O
promote	O
infection	B-DISO
of	O
cells	O
with	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
).	O

Cholesterol	B-DISO
depletion	I-DISO
from	O
the	O
cell	O
membrane	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
reduction	O
,	O
but	O
not	O
abolishment	O
,	O
of	O
virus	O
infectivity	O
,	O
and	O
at	O
a	O
concentration	O
of	O
15	O
mM	O
,	O
the	O
reduction	O
in	O
the	O
infection	B-DISO
rate	O
was	O
about	O
68	O
%.	O

TITLE	O
:	O
Influenza	B-DISO
A	O
/	O
H1N1	O
Severe	O
Pneumonia	B-DISO
:	O
Novel	O
Morphocytological	O
Findings	O
in	O
Bronchoalveolar	O
Lavage	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
results	O
of	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
performed	O
in	O
three	O
patients	O
with	O
severe	O
influenza	B-DISO
A	O
/	O
H1N1	O
pneumonia	B-DISO
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
Tapentadol	O
(	O
Nucynta	O
)	O
is	O
a	O
centrally	O
acting	O
opioid	O
analgesic	O
prescribed	O
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
acute	B-DISO
pain	I-DISO
.	O

Possible	O
mechanisms	O
of	O
death	O
include	O
respiratory	B-DISO
depression	I-DISO
,	O
central	B-DISO
nervous	I-DISO
system	I-DISO
depression	I-DISO
,	O
and	O
serotonin	B-DISO
syndrome	I-DISO
.	O

Among	O
423	O
participants	O
hospitalized	O
with	O
febrile	B-DISO
illness	I-DISO
,	O
there	O
were	O
25	O
septic	B-DISO
shock	I-DISO
,	O
37	O
severe	O
respiratory	B-DISO
distress	I-DISO
without	O
shock	O
,	O
and	O
109	O
severe	O
pneumonia	B-DISO
cases	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
SP3	O
peptide	O
,	O
corresponding	O
to	O
amino	O
-	O
acid	O
residues	O
736	O
-	O
761	O
of	O
the	O
S	O
protein	O
,	O
elicited	O
robust	O
neutralizing	O
activities	O
by	O
blocking	B-DISO
viral	O
entry	O
at	O
the	O
postbinding	O
and	O
membrane	O
fusion	O
steps	O
.	O

TITLE	O
:	O
Septic	O
thrombosis	B-DISO
of	O
the	O
internal	O
jugular	O
vein	O
:	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
revisited	O
.	O

Therapy	O
included	O
broad	O
-	O
spectrum	O
antibiotics	O
,	O
surgery	O
of	O
the	O
primary	O
infectious	B-DISO
lesion	O
,	O
and	O
postoperative	O
anticoagulation	O
.	O

Anticoagulation	O
,	O
intensive	O
antibiotic	O
therapy	O
assisted	O
by	O
surgery	O
of	O
the	O
primary	B-DISO
infection	I-DISO
site	O
,	O
and	O
intensive	O
supportive	O
care	O
can	O
reach	O
remission	B-DISO
rates	O
of	O
100	O
%.	O

Potential	O
of	O
mean	O
force	O
(	O
PMF	O
)	O
profiles	O
for	O
mono	B-DISO
(	O
Na	O
(+)	O
,	O
K	O
(+)	O
,	O
Cl	O
(-)	O
)	O
and	O
divalent	O
(	O
Ca	O
(	O
2	O
+)	O
)	O
ions	O
along	O
the	O
pore	O
are	O
calculated	O
.	O

ABSTRACT	O
:	O
An	O
elevated	O
physiological	O
dead	O
space	O
,	O
calculated	O
from	O
measurements	O
of	O
arterial	O
CO2	O
and	O
mixed	O
expired	O
CO2	O
,	O
has	O
proven	O
to	O
be	O
a	O
useful	O
clinical	O
marker	O
of	O
prognosis	O
both	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
for	O
patients	O
with	O
severe	O
heart	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
epidemiology	O
and	O
disease	O
control	O
measures	O
.	O

The	O
conference	O
covered	O
emerging	O
and	O
potentially	O
pandemic	O
influenza	B-DISO
viruses	O
and	O
discussed	O
novel	O
/	O
pre	O
-	O
licensure	O
therapeutics	O
and	O
currently	O
approved	O
antivirals	O
and	O
vaccines	O
for	O
the	O
control	O
of	O
influenza	B-DISO
.	O

Kaplan	O
-	O
Meier	O
showed	O
that	O
the	O
survival	O
patients	O
in	O
ARDS	B-DISO
group	O
was	O
significantly	O
lower	O
than	O
those	O
in	O
severe	O
control	O
group	O
(	O
χ²	O
=	O
7	O
.	O
032	O
,	O
P	O
=	O
0	O
.	O
008	O
).	O

Respiratory	O
rate	O
>	O
30	O
beats	O
/	O
min	O
and	O
heart	O
rate	O
>	O
100	O
beats	O
/	O
min	O
could	O
predict	O
the	O
occurrence	O
of	O
ARDS	B-DISO
in	O
critical	O
patients	O
.	O

TITLE	O
:	O
[	O
Comparison	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
and	O
mechanical	O
ventilation	O
for	O
inter	O
-	O
hospital	O
transport	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
].	O

ABSTRACT	O
:	O
To	O
compare	O
inter	O
-	O
hospital	O
transport	O
and	O
clinical	O
outcome	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
whom	O
were	O
transported	O
either	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
or	O
on	O
conventional	O
ventilation	O
,	O
and	O
to	O
investigate	O
the	O
optimal	O
means	O
of	O
inter	O
-	O
hospital	O
transport	O
.	O

TITLE	O
:	O
[	O
The	O
levels	O
of	O
angiopoietin	O
-	O
2	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
its	O
value	O
on	O
prognosis	O
].	O

ABSTRACT	O
:	O
To	O
approach	O
the	O
correlation	O
between	O
angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
levels	O
and	O
degree	O
of	O
lung	O
injury	O
and	O
prognosis	O
and	O
its	O
clinical	O
significance	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
Compared	O
with	O
non	O
-	O
ARDS	B-DISO
group	O
,	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
LIS	O
score	O
,	O
mortality	O
were	O
significantly	O
increased	O
,	O
PaO2	O
/	O
FiO2	O
was	O
significantly	O
decreased	O
,	O
and	O
plasma	O
Ang	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
CRP	O
were	O
significantly	O
elevated	O
[	O
APACHEII	O
score	O
:	O
20	O
.	O
7	O
±	O
5	O
.	O
0	O
vs	O
.	O
14	O
.	O
1	O
±	O
5	O
.	O
3	O
,	O
SOFA	O
score	O
:	O
7	O
.	O
7	O
±	O
3	O
.	O
5	O
vs	O
.	O
3	O
.	O
5	O
±	O
2	O
.	O
1	O
,	O
LIS	O
score	O
:	O
1	O
.	O
69	O
±	O
0	O
.	O
71	O
vs	O
.	O
0	O
.	O
28	O
±	O
0	O
.	O
27	O
,	O
PaO₂	O
/	O
FiO₂	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
159	O
.	O
5	O
±	O
61	O
.	O
3	O
vs	O
.	O
394	O
.	O
0	O
±	O
3	O
.	O
2	O
,	O
mortality	O
:	O
45	O
.	O
3	O
%	O
(	O
24	O
/	O
53	O
)	O
vs	O
.	O
20	O
.	O
0	O
%	O
(	O
4	O
/	O
20	O
),	O
Ang	O
-	O
2	O
(	O
μg	O
/	O
L	O
):	O
4	O
.	O
73	O
(	O
2	O
.	O
59	O
,	O
6	O
.	O
99	O
)	O
vs	O
.	O

ATF3	O
overexpression	O
abrogated	O
LPS	B-DISO
induced	O
membrane	O
permeability	O
.	O

For	O
this	O
report	O
,	O
medical	O
masks	O
(	O
also	O
known	O
as	O
surgical	O
masks	O
or	O
surgical	O
face	B-DISO
masks	O
)	O
are	O
defined	O
as	O
unfitted	O
devices	O
worn	O
by	O
the	O
healthcare	O
worker	O
(	O
HCW	O
)	O
“	O
to	O
reduce	O
transfer	O
of	O
potentially	O
infectious	B-DISO
bodily	O
fluids	O
between	O
individuals	O
”.	O

It	O
must	O
be	O
noted	O
that	O
masks	O
are	O
not	O
designed	O
to	O
filter	O
small	O
airborne	O
infectious	B-DISO
particles	O
.	O

The	O
study	O
cohort	O
of	O
119	O
adults	O
with	O
bronchiectasis	B-DISO
was	O
followed	O
up	O
prospectively	O
for	O
12	O
months	O
.	O

TITLE	O
:	O
Viral	O
respiratory	B-DISO
infections	I-DISO
among	O
Hajj	O
pilgrims	O
in	O
2013	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
emerged	O
in	O
the	O
Arabian	O
Gulf	O
region	O
,	O
with	O
its	O
epicentre	O
in	O
Saudi	O
Arabia	O
,	O
the	O
host	O
of	O
the	O
'	O
Hajj	O
'	O
which	O
is	O
the	O
world	O
'	O
s	O
the	O
largest	O
mass	O
gathering	O
.	O

We	O
detected	O
infectious	B-DISO
virus	O
in	O
nasal	O
secretions	O
through	O
7	O
days	O
postinoculation	O
,	O
and	O
viral	O
RNA	O
up	O
to	O
35	O
days	O
postinoculation	O
.	O

TITLE	O
:	O
Experience	O
and	O
results	O
with	O
VV	O
-	O
ECMO	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
:	O
weaning	O
versus	O
nonweaning	O
.	O

Further	O
investigation	O
into	O
lung	O
donors	O
with	O
heavy	B-DISO
alcohol	I-DISO
use	I-DISO
histories	O
is	O
necessary	O
to	O
determine	O
those	O
at	O
highest	O
risk	O
for	O
PGD	O
following	O
transplant	O
.	O

The	O
odds	O
of	O
developing	O
severe	O
primary	B-DISO
graft	I-DISO
dysfunction	I-DISO
(	O
PGD	B-DISO
)	O
in	O
the	O
Heavy	B-DISO
Alcohol	I-DISO
Use	I-DISO
group	O
versus	O
the	O
No	O
Alcohol	O
Use	O
group	O
were	O
8	O
.	O
7	O
times	O
greater	O
(	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
427	O
to	O
53	O
.	O
404	O
,	O
p	O
=	O
0	O
.	O
019	O
)	O
after	O
controlling	O
for	O
factors	O
known	O
to	O
be	O
associated	O
with	O
PGD	B-DISO
.	O

ABSTRACT	O
:	O
The	O
usual	O
duration	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
7	O
-	O
10	O
days	O
.	O

Novel	O
hantaviruses	O
emerged	O
in	O
the	O
Americas	O
in	O
the	O
mid	O
-	O
1990s	O
as	O
the	O
cause	O
of	O
severe	O
respiratory	B-DISO
infections	I-DISO
,	O
designated	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
,	O
with	O
case	O
fatality	O
rates	O
of	O
around	O
40	O
%.	O

TITLE	O
:	O
Novel	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
variant	O
with	O
large	O
genomic	O
deletion	O
,	O
South	O
Korea	O
.	O

We	O
conducted	O
a	O
large	O
-	O
scale	O
investigation	O
of	O
the	O
incidence	O
of	O
PEDV	O
in	O
pigs	O
with	O
diarrhea	B-DISO
in	O
South	O
Korea	O
and	O
consequently	O
identified	O
and	O
characterized	O
a	O
novel	O
PEDV	O
variant	O
with	O
a	O
large	O
genomic	O
deletion	O
.	O

ABSTRACT	O
:	O
Acute	O
Aspergillus	B-DISO
fumigatus	I-DISO
infection	I-DISO
in	O
immunocompetent	O
patients	O
is	O
rare	O
.	O

An	O
immunocompetent	O
54	O
-	O
year	O
-	O
old	O
woman	O
was	O
exposed	O
to	O
plant	O
mulch	O
during	O
gardening	O
and	O
subsequently	O
developed	O
pulmonary	B-DISO
failure	I-DISO
that	O
progressed	O
to	O
sepsis	B-DISO
with	O
multiorgan	B-DISO
failure	I-DISO
.	O

The	O
current	O
report	O
presents	O
information	O
on	O
BoCV	O
infections	B-DISO
associated	O
with	O
enteric	O
disease	O
of	O
postweaned	O
beef	O
cattle	O
in	O
Oklahoma	O
.	O

Detection	O
of	O
BoCV	O
clade	O
2	O
in	O
beef	O
cattle	O
in	O
Oklahoma	O
is	O
consistent	O
with	O
recovery	O
of	O
BoCV	O
clade	O
2	O
from	O
the	O
respiratory	O
tract	O
of	O
postweaned	O
beef	O
calves	O
that	O
had	O
respiratory	B-DISO
disease	I-DISO
signs	O
or	O
were	O
healthy	O
.	O

However	O
,	O
the	O
adaptive	O
immune	O
system	O
was	O
required	O
for	O
protection	O
since	O
N1347A	O
virus	O
was	O
able	O
to	O
cause	O
lethal	O
encephalitis	B-DISO
in	O
RAG1	O
(-/-)	O
(	O
recombination	O
activation	O
gene	O
1	O
knockout	O
)	O
mice	O
although	O
disease	O
onset	O
was	O
modestly	O
delayed	O
.	O

Before	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
24	O
h	O
after	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
and	O
at	O
the	O
end	O
of	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
variables	O
of	O
blood	O
gas	O
analysis	O
(	O
pH	O
,	O
PaO2	O
,	O
and	O
PaCO2	O
)	O
were	O
obtained	O
by	O
blood	O
gas	O
analyzer	O
,	O
and	O
the	O
OI	O
values	O
were	O
calculated	O
;	O
hemodynamic	O
parameters	O
including	O
heart	O
rate	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
),	O
central	O
venous	O
pressure	O
(	O
CVP	O
)	O
of	O
all	O
patients	O
and	O
the	O
cardiac	O
output	O
(	O
CO	O
),	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
of	O
4	O
patients	O
who	O
received	O
pulse	O
contour	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
monitoring	O
were	O
monitored	O
.	O

TITLE	O
:	O
Clinical	O
outcomes	O
of	O
children	O
with	O
acute	B-DISO
asthma	I-DISO
and	O
pneumonia	B-DISO
in	O
Mulago	O
hospital	O
,	O
Uganda	O
:	O
a	O
prospective	O
study	O
.	O

ABSTRACT	O
:	O
Little	O
attention	O
has	O
been	O
paid	O
to	O
asthma	B-DISO
in	O
'	O
under	O
-	O
fives	O
'	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
.	O

Bacterial	B-DISO
pneumonia	I-DISO
is	O
still	O
associated	O
with	O
high	O
case	O
fatality	O
.	O

This	O
complex	O
disease	O
can	O
be	O
triggered	O
by	O
both	O
infectious	B-DISO
and	O
non	O
-	O
infectious	B-DISO
causes	O
.	O

This	O
review	O
deals	O
with	O
prevention	O
and	O
treatment	O
of	O
neonatal	O
dairy	O
calf	O
diarrhoea	B-DISO
focusing	O
on	O
the	O
importance	O
of	O
a	O
good	O
colostrum	O
management	O
and	O
a	O
correct	O
fluid	O
therapy	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
two	O
highly	O
pathogenic	O
human	O
coronaviruses	O
(	O
CoVs	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
CoV	O
,	O
has	O
ignited	O
a	O
strong	O
interest	O
in	O
the	O
identification	O
of	O
viral	O
factors	O
that	O
determine	O
the	O
virulence	O
and	O
pathogenesis	B-DISO
of	O
CoVs	O
.	O

TITLE	O
:	O
Anaphylaxis	B-DISO
:	O
Unique	O
aspects	O
of	O
clinical	O
diagnosis	O
and	O
management	O
in	O
infants	O
(	O
birth	O
to	O
age	O
2	O
years	O
).	O

ABSTRACT	O
:	O
In	O
this	O
rostrum	O
we	O
aim	O
to	O
increase	O
awareness	O
of	O
anaphylaxis	B-DISO
in	O
infancy	O
in	O
order	O
to	O
improve	O
clinical	O
diagnosis	O
,	O
management	O
,	O
and	O
prevention	O
of	O
recurrences	B-DISO
.	O

Anaphylaxis	B-DISO
is	O
increasingly	O
reported	O
in	O
this	O
age	O
group	O
.	O

The	O
records	O
of	O
65	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
received	O
venovenous	O
ECMO	O
were	O
analyzed	O
.	O

Severe	O
ARDS	B-DISO
patients	O
who	O
are	O
younger	O
,	O
have	O
shorter	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
lower	O
organ	O
dysfunction	O
scores	O
before	O
ECMO	O
initiation	O
have	O
more	O
favorable	O
survival	O
outcome	O
.	O

RESULTS	O
:	O
The	O
records	O
of	O
65	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
received	O
venovenous	O
ECMO	O
were	O
analyzed	O
.	O

Protein	O
-	O
rich	O
alveolar	B-DISO
edema	I-DISO
,	O
which	O
is	O
the	O
abnormality	O
that	O
leads	O
to	O
ARDS	B-DISO
,	O
may	O
occur	O
from	O
multiple	O
causes	O
,	O
including	O
inhalation	O
injury	O
.	O

Whereas	O
binding	O
to	O
the	O
host	O
cell	O
receptor	O
is	O
an	O
essential	O
first	O
step	O
in	O
establishing	O
infection	B-DISO
,	O
the	O
proteolytic	O
activation	O
step	O
is	O
often	O
critical	O
for	O
the	O
fusion	O
function	O
of	O
spike	O
,	O
as	O
it	O
allows	O
for	O
controlled	O
release	O
of	O
the	O
fusion	O
peptide	O
into	O
target	O
cellular	O
membranes	O
.	O

TITLE	O
:	O
Noninvasive	O
mechanical	O
ventilation	O
in	O
high	O
-	O
risk	O
pulmonary	B-DISO
infections	I-DISO
:	O
a	O
clinical	O
review	O
.	O

ABSTRACT	O
:	O
Avian	O
coronaviruses	O
of	O
the	O
genus	O
Gammacoronavirus	O
are	O
represented	O
by	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
the	O
coronavirus	O
of	O
chicken	O
.	O

Receptor	O
-	O
binding	O
domains	O
(	O
RBD	O
)	O
have	O
been	O
identified	O
in	O
the	O
S	O
of	O
diverse	O
CoV	O
;	O
they	O
usually	O
contain	O
antigenic	O
determinants	O
targeted	O
by	O
antibodies	O
that	O
neutralize	O
CoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
has	O
led	O
to	O
more	O
than	O
800	O
laboratory	O
-	O
confirmed	O
MERS	B-DISO
cases	O
with	O
a	O
high	O
case	O
fatality	O
rate	O
(∼	O
35	O
%),	O
posing	O
a	O
serious	O
threat	O
to	O
global	O
public	O
health	O
and	O
calling	O
for	O
the	O
development	O
of	O
effective	O
and	O
safe	O
therapeutic	O
and	O
prophylactic	O
strategies	O
to	O
treat	O
and	O
prevent	O
MERS	B-DISO
-	O
CoV	O
infection	B-DISO
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
revealed	O
a	O
unique	O
course	O
of	O
infection	B-DISO
for	O
the	O
SCID	B-DISO
group	O
.	O

Etiology	O
of	O
EA	O
COPD	B-DISO
are	O
mainly	O
infectious	B-DISO
,	O
viral	O
(	O
rhinovirus	O
,	O
influenzae	O
or	O
parainfluenzae	O
virus	O
,	O
coronavirus	O
,	O
adenovirus	B-DISO
and	O
respiratory	O
syncytial	O
virus	O
)	O
or	O
bacterial	O
(	O
Haemophilus	O
influenzae	O
,	O
Streptococcus	O
pneumoniae	O
,	O
or	O
Moraxella	O
catarrhalis	O
).	O

Although	O
no	O
method	O
for	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
titration	O
has	O
proven	O
most	O
advantageous	O
,	O
experimental	O
and	O
clinical	O
data	O
support	O
the	O
use	O
of	O
higher	O
PEEP	O
in	O
patients	O
with	O
moderate	O
/	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
complicating	O
an	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
:	O
potential	O
benefit	O
of	O
early	O
combination	O
of	O
exchange	O
transfusion	O
and	O
prone	O
positioning	O
].	O

We	O
discuss	O
the	O
various	O
treatments	O
available	O
for	O
the	O
management	O
of	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
and	O
their	O
actual	O
relevance	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
the	O
absence	O
of	O
strong	O
evidence	O
-	O
based	O
guidelines	O
in	O
pediatric	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infects	O
host	O
cells	O
through	O
binding	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
its	O
spike	O
glycoprotein	O
to	O
human	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
).	O

ABSTRACT	O
:	O
SHAPE	O
technology	O
was	O
used	O
to	O
analyze	O
RNA	O
secondary	O
structure	O
of	O
the	O
5	O
'	O
most	O
474	O
nts	O
of	O
the	O
MHV	O
-	O
A59	O
genome	O
encompassing	O
the	O
minimal	O
5	O
'	O
cis	B-DISO
-	O
acting	O
region	O
required	O
for	O
defective	O
interfering	O
RNA	O
replication	O
.	O

The	O
initial	O
study	O
sample	O
was	O
positive	O
in	O
15	O
patients	O
with	O
the	O
following	O
respiratory	O
viruses	O
:	O
rhinovirus	O
(	O
6	O
),	O
metapneumovirus	O
(	O
1	O
),	O
coronavirus	O
(	O
2	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
2	O
),	O
parainfluenza	B-DISO
virus	O
(	O
2	O
),	O
and	O
influenza	B-DISO
A	O
virus	O
(	O
2	O
).	O

Over	O
the	O
years	O
,	O
it	O
has	O
been	O
proposed	O
that	O
HCoVs	O
play	O
a	O
possible	O
role	O
in	O
gastrointestinal	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
coronavirus	O
that	O
causes	O
a	O
severe	O
respiratory	B-DISO
disease	I-DISO
with	O
high	O
case	O
fatality	O
rate	O
.	O

Results	O
indicated	O
liquid	O
samples	O
contained	O
infective	O
virus	O
,	O
but	O
none	O
of	O
the	O
spray	O
dried	O
samples	O
were	O
infectious	B-DISO
.	O

Unlike	O
in	O
surgical	O
patients	O
,	O
the	O
effects	O
of	O
fish	O
oil	O
on	O
infection	B-DISO
rates	O
were	O
not	O
found	O
to	O
be	O
statistically	O
significant	O
in	O
ICU	O
patients	O
,	O
and	O
dose	O
-	O
effect	O
relationships	O
were	O
not	O
established	O
for	O
any	O
cohort	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
A	O
viruses	O
,	O
human	O
coronaviruses	O
(	O
hCoV	O
)	O
and	O
human	O
bocavirus	O
(	O
hBoV	O
)	O
are	O
emerging	O
respiratory	O
viruses	O
.	O

More	O
and	O
larger	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
role	O
of	O
hCoV	O
,	O
hBoV	O
in	O
causing	O
severe	O
disease	O
when	O
they	O
co	O
-	O
infect	O
with	O
influenza	B-DISO
A	O
viruses	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
poses	O
a	O
serious	O
public	O
health	O
hazard	O
.	O

Neonatal	O
calves	O
are	O
particularly	O
sensitive	O
to	O
infections	B-DISO
with	O
enteropathogens	O
.	O

Two	O
hours	O
after	O
PiCCO	O
monitoring	O
,	O
the	O
oxygenation	O
index	O
decreased	O
to	O
140	O
mmHg	O
,	O
GEDVI	O
481	O
ml	O
/	O
m²	O
,	O
EVLWI	O
9	O
ml	O
/	O
kg	O
,	O
thus	O
the	O
dehydration	B-DISO
speed	O
of	O
CVVHDF	O
was	O
increased	O
(	O
up	O
to	O
100	O
ml	O
/	O
h	O
).	O

TITLE	O
:	O
Open	O
lung	O
biopsy	O
in	O
nonresolving	O
ARDS	B-DISO
frequently	O
identifies	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
regardless	O
of	O
the	O
severity	O
stage	O
and	O
may	O
have	O
implications	O
for	O
patient	O
management	O
.	O

A	O
single	O
-	O
center	O
retrospective	O
study	O
of	O
patients	O
meeting	O
the	O
Berlin	O
definition	O
criteria	O
for	O
ARDS	B-DISO
who	O
had	O
undergone	O
OLB	O
for	O
nonresolving	O
ARDS	B-DISO
.	O

Patients	O
were	O
classified	O
into	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
categories	O
and	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
DAD	O
on	O
the	O
OLB	O
.	O

From	O
January	O
1998	O
to	O
August	O
2013	O
,	O
113	O
patients	O
underwent	O
OLB	O
for	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
83	O
of	O
whom	O
met	O
the	O
inclusion	O
criteria	O
for	O
ARDS	B-DISO
.	O

At	O
the	O
time	O
the	O
OLB	O
was	O
performed	O
,	O
11	O
of	O
these	O
patients	O
had	O
mild	O
,	O
56	O
moderate	O
,	O
and	O
16	O
severe	O
ARDS	B-DISO
,	O
respectively	O
.	O

The	O
median	O
(	O
1st	O
-	O
3rd	O
quartiles	O
)	O
time	O
to	O
OLB	O
was	O
13	O
(	O
10	O
-	O
18	O
)	O
and	O
9	O
(	O
6	O
-	O
14	O
)	O
days	O
from	O
the	O
onset	O
of	O
respiratory	B-DISO
symptoms	I-DISO
and	O
from	O
ARDS	B-DISO
onset	O
,	O
respectively	O
,	O
with	O
no	O
statistical	O
difference	O
between	O
the	O
three	O
ARDS	B-DISO
groups	O
.	O

Since	O
there	O
is	O
documented	O
resistance	O
to	O
the	O
current	O
drugs	O
used	O
against	O
herpesviruses	O
and	O
there	O
is	O
no	O
treatment	O
for	O
equine	B-DISO
viral	I-DISO
arteritis	I-DISO
,	O
it	O
is	O
advisable	O
to	O
search	O
for	O
new	O
antiviral	O
compounds	O
to	O
overcome	O
these	O
infections	B-DISO
.	O

However	O
,	O
inhibition	O
of	O
PLpro	O
'	O
s	O
DUB	O
activity	O
by	O
mutagenesis	O
blocked	O
the	O
IRF3	O
inhibition	O
activity	O
of	O
PLpro	O
,	O
suggesting	O
a	O
role	O
for	O
IRF3	O
ubiquitination	O
in	O
induction	O
of	O
a	O
type	O
I	O
IFN	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

In	O
oocyst	O
calculations	O
for	O
C	O
.	O
parvum	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
single	O
-	O
infection	B-DISO
cases	O
and	O
the	O
mixed	O
-	O
infection	B-DISO
cases	O
with	O
rotavirus	O
.	O

TITLE	O
:	O
Immune	O
responses	O
and	O
interactions	O
following	O
simultaneous	O
application	O
of	O
live	O
Newcastle	O
disease	B-DISO
,	I-DISO
infectious	I-DISO
bronchitis	B-DISO
and	O
avian	O
metapneumovirus	O
vaccines	O
in	O
specific	O
-	O
pathogen	O
-	O
free	O
chicks	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
etiology	O
of	O
reported	O
sporadic	O
suspected	O
mumps	B-DISO
cases	O
with	O
a	O
negative	O
RT	O
-	O
PCR	O
result	O
for	O
the	O
mumps	B-DISO
virus	O
in	O
the	O
Barcelona	O
-	O
South	O
region	O
in	O
2007	O
-	O
2011	O
.	O

Samples	O
from	O
mumps	B-DISO
virus	O
-	O
negative	O
patients	O
presenting	O
unilateral	O
or	O
bilateral	B-DISO
parotitis	I-DISO
or	O
other	O
salivary	O
gland	O
swelling	B-DISO
were	O
tested	O
for	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
by	O
real	O
-	O
time	O
PCR	O
and	O
for	O
respiratory	O
viruses	O
by	O
two	O
multiplex	O
-	O
PCR	O
-	O
based	O
assays	O
to	O
detect	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
1	O
-	O
4	O
,	O
influenza	B-DISO
virus	O
(	O
InV	O
)	O
A	O
,	O
B	O
and	O
C	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
enterovirus	O
,	O
coronavirus	O
229E	O
,	O
coronavirus	O
OC43	O
,	O
and	O
rhinovirus	O
.	O

Oral	O
samples	O
were	O
collected	O
on	O
the	O
first	O
day	O
of	O
glandular	O
swelling	B-DISO
in	O
53	O
patients	O
(	O
52	O
.	O
5	O
%),	O
and	O
on	O
the	O
first	O
two	O
days	O
in	O
74	O
patients	O
(	O
73	O
.	O
3	O
%).	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
main	O
protease	O
in	O
complex	O
with	O
an	O
inhibitor	O
.	O

Interestingly	O
,	O
a	O
functional	O
mutant	B-DISO
(	O
N60K	O
)	O
of	O
nsp9	O
was	O
identified	O
to	O
compensate	O
for	O
a	O
6	O
nt	O
insertion	O
mutation	O
of	O
the	O
3	O
'-	O
untranslated	O
region	O
(	O
UTR	O
),	O
which	O
is	O
critical	O
for	O
viral	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
Antiviral	O
potential	O
of	O
ERK	O
/	O
MAPK	O
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
signaling	O
modulation	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
as	O
identified	O
by	O
temporal	O
kinome	O
analysis	O
.	O

TITLE	O
:	O
Damage	O
-	O
control	O
thoracic	B-DISO
surgery	O
:	O
Management	O
and	O
outcomes	O
.	O

Forty	O
-	O
two	O
patients	O
(	O
95	O
%)	O
had	O
thoracic	B-DISO
packing	O
with	O
vacuum	O
-	O
assisted	O
closure	O
.	O

Predictors	O
included	O
higher	O
ISS	B-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
continuous	O
renal	O
replacement	O
therapy	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
reservoir	O
hosts	O
of	O
several	O
high	O
-	O
impact	O
viruses	O
that	O
cause	O
significant	O
human	O
diseases	O
,	O
including	O
Nipah	O
virus	O
,	O
Marburg	O
virus	O
and	O
rabies	B-DISO
virus	O
.	O

They	O
also	O
harbor	O
many	O
other	O
viruses	O
that	O
are	O
thought	O
to	O
have	O
caused	O
disease	O
in	O
humans	O
after	O
spillover	O
into	O
intermediate	O
hosts	O
,	O
including	O
SARS	B-DISO
and	O
MERS	O
coronaviruses	O
.	O

Blood	O
transfusions	O
are	O
known	O
to	O
increase	O
morbidity	O
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
which	O
may	O
extend	O
to	O
patients	O
receiving	O
ECMO	O
.	O

Bleeding	B-DISO
occurred	O
in	O
10	O
patients	O
(	O
26	O
.	O
3	O
%);	O
severe	O
bleeding	B-DISO
occurred	O
in	O
2	O
patients	O
(	O
5	O
.	O
3	O
%).	O

This	O
review	O
will	O
present	O
data	O
from	O
recent	O
studies	O
relating	O
to	O
hypercapnia	B-DISO
,	O
focusing	O
on	O
issues	O
that	O
are	O
of	O
importance	O
to	O
anesthesiologists	O
caring	O
for	O
the	O
surgical	O
and	O
/	O
or	O
critically	B-DISO
ill	I-DISO
patient	O
.	O

We	O
calculated	O
Systemic	B-DISO
Inflammatory	I-DISO
Response	I-DISO
Syndrome	I-DISO
criteria	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
,	O
and	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
scores	O
.	O

ABSTRACT	O
:	O
To	O
characterize	O
the	O
2013	O
-	O
2014	O
epidemic	O
season	O
from	O
the	O
results	O
of	O
detection	O
of	O
influenza	B-DISO
infection	B-DISO
in	O
patients	O
;	O
to	O
provide	O
the	O
molecular	O
genetic	O
characteristics	O
of	O
the	O
strains	O
isolated	O
from	O
deceased	O
patients	O
.	O

There	O
is	O
evidence	O
that	O
there	O
are	O
mutant	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
viruses	O
that	O
have	O
high	O
pneumotropicity	O
.	O

The	O
high	O
risk	O
of	O
their	O
circulation	O
in	O
the	O
population	O
and	O
the	O
risk	O
of	O
severe	O
influenza	B-DISO
forms	O
involving	O
the	O
lower	O
respiratory	O
tract	O
remain	O
.	O

RESULTS	O
:	O
Out	O
of	O
the	O
1203	O
examinees	O
,	O
284	O
(	O
23	O
.	O
6	O
%)	O
were	O
influenza	B-DISO
-	O
positive	O
:	O
221	O
(	O
77	O
.	O
8	O
%),	O
24	O
(	O
8	O
.	O
5	O
%),	O
and	O
39	O
(	O
13	O
.	O
7	O
%)	O
patients	O
had	O
influenza	B-DISO
A	O
(	O
H3N2	O
),	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
and	O
influenza	B-DISO
B	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
evidence	O
that	O
there	O
are	O
mutant	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
viruses	O
that	O
have	O
high	O
pneumotropicity	O
.	O

One	O
hundred	O
forty	O
-	O
eight	O
patients	O
with	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
according	O
to	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
criteria	O
.	O

At	O
5	O
cm	O
H2O	O
,	O
54	O
%	O
of	O
patients	O
with	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
at	O
clinical	O
positive	O
end	O
-	O
expiratory	O
pressure	O
were	O
reclassified	O
to	O
either	O
moderate	O
or	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
provide	O
a	O
summary	O
of	O
the	O
recent	O
literature	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
focusing	O
on	O
advances	O
in	O
equipment	O
,	O
current	O
conventional	O
and	O
unconventional	O
indications	O
,	O
complications	O
,	O
and	O
future	O
applications	O
.	O

TITLE	O
:	O
Association	O
of	O
host	O
tropism	O
of	O
Middle	O
East	B-DISO
syndrome	I-DISO
coronavirus	O
with	O
the	O
amino	O
acid	O
structure	O
of	O
host	O
cell	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
.	O

Whereas	O
unadjuvanted	O
or	O
alum	O
-	O
formulated	O
vaccines	O
were	O
associated	O
with	O
significantly	O
increased	O
lung	O
eosinophilic	O
immunopathology	B-DISO
on	O
day	O
6	O
postchallenge	O
,	O
this	O
was	O
not	O
seen	O
in	O
mice	O
immunized	O
with	O
vaccines	O
formulated	O
with	O
delta	O
inulin	O
adjuvant	O
.	O

Coronaviruses	O
such	O
as	O
SARS	B-DISO
-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
associated	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
cause	O
high	O
case	O
fatality	O
rates	O
and	O
remain	O
major	O
human	O
public	O
health	O
threats	O
,	O
creating	O
a	O
need	O
for	O
effective	O
vaccines	O
.	O

TITLE	O
:	O
Successful	O
use	O
of	O
daily	O
intravenous	O
infusion	O
of	O
C1	O
esterase	O
inhibitor	O
concentrate	O
in	O
the	O
treatment	O
of	O
a	O
hereditary	B-DISO
angioedema	I-DISO
patient	O
with	O
ascites	O
,	O
hypovolemic	B-DISO
shock	I-DISO
,	O
sepsis	B-DISO
,	O
renal	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Mass	O
Thermography	O
Screening	O
for	O
Infection	B-DISO
and	O
Prevention	O
:	O
A	O
Review	O
of	O
the	O
Clinical	O
Effectiveness	O
ABSTRACT	O
:	O
Thermography	O
involves	O
the	O
quantification	O
of	O
emitted	O
radiation	O
to	O
measure	O
temperature	O
,	O
and	O
provides	O
a	O
quick	O
non	O
-	O
invasive	O
means	O
to	O
measure	O
body	O
temperature	O
.	O

Infrared	O
thermography	O
(	O
IRT	O
)	O
can	O
be	O
implemented	O
at	O
international	O
airports	O
in	O
order	O
to	O
detect	O
febrile	O
passengers	O
and	O
prevent	O
the	O
introduction	O
and	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
to	O
other	O
countries	O
.	O

IRT	O
has	O
also	O
been	O
used	O
as	O
a	O
measure	O
to	O
detect	O
and	O
prevent	O
influenza	B-DISO
outbreaks	O
and	O
transmission	O
of	O
dengue	B-DISO
fever	I-DISO
across	O
borders	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
the	O
Scandinavian	O
Society	O
of	O
Anaesthesiology	O
and	O
Intensive	O
Care	O
Medicine	O
(	O
SSAI	O
)	O
task	O
force	O
on	O
mechanical	O
ventilation	O
in	O
adults	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
to	O
formulate	O
treatment	O
recommendations	O
based	O
on	O
available	O
evidence	O
from	O
systematic	O
reviews	O
and	O
randomised	O
trials	O
.	O

We	O
found	O
evidence	O
of	O
moderately	O
high	O
quality	O
to	O
support	O
a	O
strong	O
recommendation	O
for	O
pressure	O
limitation	O
and	O
small	O
tidal	O
volumes	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

A	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
assay	O
was	O
used	O
to	O
detect	O
nucleic	O
acids	O
from	O
the	O
following	O
viruses	O
and	O
bacteria	O
in	O
nasal	O
swab	O
samples	O
:	O
Bovine	O
coronavirus	O
(	O
BoCV	O
;	O
Betacoronavirus	O
1	O
),	O
Bovine	O
herpesvirus	O
1	O
(	O
BoHV	O
-	O
1	O
),	O
Bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
1	O
(	O
BVDV	O
-	O
1	O
),	O
Bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
Bovine	O
parainfluenza	B-DISO
virus	O
3	O
(	O
BPIV	O
-	O
3	O
),	O
Histophilus	O
somni	O
,	O
Mycoplasma	B-DISO
bovis	O
,	O
Mannheimia	O
haemolytica	O
,	O
and	O
Pasteurella	O
multocida	O
.	O

ABSTRACT	O
:	O
The	O
state	O
of	O
homeostasis	O
links	O
in	O
the	O
children	O
with	O
intestinal	B-DISO
colic	I-DISO
is	O
represented	O
by	O
the	O
following	O
parameters	O
and	O
clinical	O
characteristics	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
OC43	O
is	O
the	O
most	O
prevalent	O
HCoV	O
in	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Levels	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
in	O
blood	O
,	O
effusions	B-DISO
,	O
and	O
various	O
tissues	O
and	O
the	O
role	O
of	O
lymphopenia	B-DISO
in	O
disease	O
outcome	O
following	O
experimental	O
infection	B-DISO
.	O

Furthermore	O
,	O
the	O
function	O
of	O
vimentin	O
cytoskeleton	O
in	O
ST	O
cells	O
during	O
TGEV	O
infection	B-DISO
was	O
examined	O
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
of	O
patients	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
severe	O
pneumonia	B-DISO
with	O
levels	O
of	O
cTnI	O
obtained	O
within	O
24	O
hours	O
of	O
admittance	O
.	O

A	O
retrospective	O
investigation	O
of	O
the	O
clinical	O
manifestation	O
,	O
laboratory	O
test	O
,	O
imagelogy	O
,	O
clinical	O
course	O
and	O
outcome	O
of	O
3	O
cases	O
with	O
MP	O
-	O
HLH	B-DISO
seen	O
between	O
June	O
2013	O
and	O
July	O
2013	O
in	O
Shenzhen	O
Children	O
'	O
s	O
Hospital	O
,	O
and	O
review	O
of	O
relevant	O
literature	O
were	O
conducted	O
.	O

Diagnosis	O
of	O
refractory	O
Mycoplasma	B-DISO
pneumoniae	I-DISO
pneumonia	I-DISO
was	O
made	O
,	O
which	O
was	O
accompanied	O
by	O
decreased	O
neutrophils	O
[(	O
0	O
.	O
08	O
-	O
0	O
.	O
68	O
)×	O
10	O
(	O
9	O
)/	O
L	O
],	O
hemoglobin	O
[(	O
79	O
-	O
103	O
)	O
g	O
/	O
L	O
],	O
platelet	O
[(	O
64	O
-	O
157	O
)×	O
10	O
(	O
9	O
)/	O
L	O
],	O
plasma	O
fibrinogen	O
[(	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
)	O
g	O
/	O
L	O
],	O
lactate	O
dehydrogenase	O
[(	O
1	O
,	O
170	O
-	O
1	O
,	O
285	O
)	O
U	O
/	O
L	O
]	O
and	O
increased	O
serum	O
ferritin	O
[(	O
936	O
.	O
7	O
-	O
39	O
789	O
.	O
0	O
)	O
µg	O
/	O
L	O
]	O
in	O
the	O
third	O
week	O
of	O
course	O
.	O

We	O
introduced	O
smartphone	O
data	O
collection	O
to	O
replace	O
paper	O
-	O
based	O
data	O
collection	O
for	O
an	O
influenza	B-DISO
sentinel	O
surveillance	O
system	O
in	O
four	O
hospitals	O
in	O
Kenya	O
.	O

A	O
cut	O
-	O
off	O
level	O
of	O
175	O
μg	O
/	O
L	O
had	O
92	O
%	O
sensitivity	O
and	O
77	O
%	O
specificity	O
for	O
a	O
symptomatic	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
.	O

Here	O
,	O
we	O
report	O
the	O
discovery	O
that	O
two	O
SARS	B-DISO
-	O
CoV	O
PL	O
(	O
pro	O
)	O
inhibitors	O
,	O
6	O
-	O
mercaptopurine	O
(	O
6MP	O
)	O
and	O
6	O
-	O
thioguanine	O
(	O
6TG	O
),	O
as	O
well	O
as	O
the	O
immunosuppressive	O
drug	O
mycophenolic	O
acid	O
,	O
are	O
able	O
to	O
inhibit	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
cases	O
without	O
documented	O
contact	O
with	O
another	O
human	O
MERS	O
-	O
CoV	O
case	O
make	O
up	O
61	O
%	O
(	O
517	O
/	O
853	O
)	O
of	O
all	O
reported	O
cases	O
.	O

Other	O
possible	O
sources	O
and	O
vehicles	O
of	O
infection	B-DISO
include	O
food	O
-	O
borne	O
transmission	O
through	O
consumption	O
of	O
unpasteurized	O
camel	O
milk	O
and	O
raw	O
meat	O
,	O
medicinal	O
use	O
of	O
camel	O
urine	O
and	O
zoonotic	O
transmission	O
from	O
other	O
species	O
.	O

ABSTRACT	O
:	O
Supplemental	O
oxygen	O
inhalation	O
is	O
frequently	O
used	O
to	O
treat	O
severe	O
respiratory	B-DISO
failure	I-DISO
;	O
however	O
,	O
prolonged	O
exposure	O
to	O
hyperoxia	B-DISO
causes	O
hyperoxic	O
acute	O
lung	O
injury	O
(	O
HALI	O
),	O
which	O
induces	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
leads	O
to	O
high	O
mortality	O
rates	O
.	O

ABSTRACT	O
:	O
Inhaled	O
nitric	O
oxide	O
(	O
INO	O
)	O
improves	O
ventilation	O
-	O
perfusion	O
matching	O
and	O
alleviates	O
pulmonary	B-DISO
hypertension	I-DISO
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
INO	O
acts	O
may	O
guide	O
in	O
improving	O
treatment	O
with	O
INO	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
conclude	O
that	O
INO	O
in	O
short	O
-	O
term	O
experiments	O
,	O
in	O
addition	O
to	O
causing	O
selective	O
pulmonary	O
vasodilation	B-DISO
in	O
ventilated	O
lung	O
regions	O
,	O
increases	O
the	O
ET	O
-	O
A	O
/	O
ET	O
-	O
B	O
mRNA	O
expression	O
ratio	O
in	O
lung	O
tissue	O
.	O

Patients	O
reported	O
a	O
sensation	O
of	O
""""	O
electric	O
shocks	B-DISO
""""	O
which	O
could	O
last	O
hours	O
.	O

Two	O
patients	O
had	O
evidence	O
of	O
intense	O
rhabdomyolysis	B-DISO
and	O
acute	O
kidney	O
injury	O
.	O

(	O
3	O
)	O
External	O
flow	O
and	O
its	O
three	O
typical	O
kinds	O
showed	O
obvious	O
spatial	O
heterogeneity	O
,	O
such	O
as	O
self	O
-	O
spreading	O
flow	O
(	O
spatial	O
displacement	O
of	O
SARS	B-DISO
cases	O
only	O
within	O
the	O
province	O
or	O
municipality	O
of	O
onset	O
and	O
medical	O
locations	O
);	O
hospitalized	O
flow	O
(	O
spatial	O
displacement	O
of	O
SARS	B-DISO
cases	O
that	O
had	O
been	O
seen	O
by	O
a	O
hospital	O
doctor	O
);	O
and	O
migrant	O
flow	O
(	O
spatial	O
displacement	O
of	O
SARS	B-DISO
cases	O
among	O
migrant	O
workers	O
).	O

These	O
findings	O
constitute	O
valuable	O
input	O
to	O
prevent	O
and	O
control	O
future	O
serious	O
infectious	B-DISO
diseases	I-DISO
like	O
SARS	B-DISO
.	O

We	O
found	O
that	O
while	O
macropinocytotic	O
uptake	O
of	O
filamentous	O
EBOV	O
viruslike	O
particles	O
(	O
VLPs	O
)	O
expressing	O
the	O
EBOV	O
glycoprotein	O
(	O
GP	O
)	O
occurs	O
relatively	O
quickly	O
,	O
VLPs	O
only	O
begin	O
to	O
enter	O
the	O
cytoplasm	O
after	O
a	O
30	O
-	O
min	O
lag	O
,	O
considerably	O
later	O
than	O
particles	O
bearing	O
the	O
influenza	B-DISO
hemagglutinin	O
or	O
GP	O
from	O
lymphocytic	B-DISO
choriomeningitis	I-DISO
virus	O
,	O
which	O
enter	O
through	O
late	O
endosomes	O
(	O
LE	O
).	O

For	O
EBOV	O
,	O
the	O
long	O
lag	O
is	O
not	O
due	O
to	O
the	O
large	O
size	O
or	O
unusual	O
shape	O
of	O
EBOV	O
filaments	O
,	O
the	O
need	O
to	O
prime	O
EBOV	O
GP	O
to	O
the	O
19	O
-	O
kDa	O
receptor	O
-	O
binding	O
species	O
,	O
or	O
a	O
need	O
for	O
unusually	O
low	O
endosomal	O
pH	O
.	O
In	O
contrast	O
,	O
since	O
we	O
observed	O
that	O
EBOV	O
entry	O
occurs	O
upon	O
arrival	O
in	O
Niemann	O
-	O
Pick	O
C1	O
(	O
NPC1	B-DISO
)-	O
positive	O
endolysosomes	O
(	O
LE	O
/	O
Lys	O
),	O
we	O
propose	O
that	O
trafficking	O
to	O
LE	O
/	O
Lys	O
is	O
a	O
key	O
rate	O
-	O
defining	O
step	O
.	O

Additional	O
experiments	O
revealed	O
,	O
unexpectedly	O
,	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
S	O
-	O
mediated	O
entry	O
also	O
begins	O
only	O
after	O
a	O
30	O
-	O
min	O
lag	O
.	O

A	O
devastating	O
outbreak	O
of	O
EBOV	O
occurred	O
in	O
West	O
Africa	O
in	O
2014	O
,	O
and	O
there	O
was	O
a	O
significant	O
outbreak	O
of	O
SARS	B-DISO
in	O
2003	O
.	O

ChRCoV	O
HKU24	O
possessed	B-DISO
genome	O
features	O
that	O
resemble	O
those	O
of	O
both	O
Betacoronavirus	O
1	O
and	O
murine	O
coronavirus	O
,	O
being	O
closer	O
to	O
Betacoronavirus	O
1	O
in	O
most	O
predicted	O
proteins	O
but	O
closer	O
to	O
murine	O
coronavirus	O
by	O
G	O
+	O
C	O
content	O
,	O
the	O
presence	O
of	O
a	O
single	O
nonstructural	O
protein	O
(	O
NS4	B-DISO
),	O
and	O
an	O
absent	O
transcription	O
regulatory	O
sequence	O
for	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
-	O
coronavirus	O
papain	O
-	O
like	O
protease	O
:	O
structure	O
,	O
function	O
and	O
inhibition	O
by	O
designed	O
antiviral	O
compounds	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
pandemic	O
infected	O
over	O
8500	O
individuals	O
,	O
claimed	O
over	O
800	O
lives	O
and	O
cost	O
billions	O
of	O
dollars	O
in	O
economic	O
loss	O
worldwide	O
,	O
there	O
still	O
are	O
no	O
clinically	O
approved	O
antiviral	O
drugs	O
,	O
vaccines	O
or	O
monoclonal	O
antibody	O
therapies	O
to	O
treat	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
.	O

CONCLUSIONS	O
:	O
Lung	O
HRCT	O
of	O
severe	O
ARDS	B-DISO
survivors	O
after	O
ECMO	O
treatment	O
showed	O
various	O
degrees	O
of	O
morphological	O
changes	O
in	O
the	O
lung	O
parenchyma	O
.	O

TITLE	O
:	O
Mechanical	O
ventilation	O
for	O
ARDS	B-DISO
patients	O
--	O
for	O
a	O
better	O
understanding	O
of	O
the	O
2012	O
Surviving	O
Sepsis	B-DISO
Campaign	O
Guidelines	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
laboratory	O
course	O
of	O
HELLP	B-DISO
syndrome	I-DISO
between	O
patients	O
who	O
recover	O
and	O
those	O
who	O
progress	O
to	O
postpartum	O
thrombotic	O
microangiopathic	O
syndrome	B-DISO
(	O
PTMS	B-DISO
)	O
and	O
require	O
postpartum	O
plasma	O
exchange	O
(	O
PPEX	O
)	O
and	O
to	O
describe	O
maternal	O
characteristics	O
and	O
morbidity	O
in	O
women	O
with	O
PTMS	B-DISO
.	O

Bioinformatics	O
,	O
GO	O
annotation	O
and	O
pathway	O
analysis	O
indicated	O
that	O
five	O
of	O
these	O
genes	O
(	O
Plexin	O
B1	O
,	O
TRIM27	O
,	O
PDGFC	O
,	O
SETBP1	O
and	O
USP7	O
)	O
may	O
be	O
important	O
for	O
the	O
generation	O
of	O
protective	O
antibodies	O
against	O
NDV	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

Among	O
them	O
,	O
compounds	O
Ib	O
and	O
If	O
possessed	B-DISO
antiviral	O
activities	O
against	O
influenza	B-DISO
A	O
virus	O
(	O
A	O
/	O
Jinan	O
/	O
15	O
/	O
90	O
)	O
with	O
IC50	O
values	O
of	O
4	O
.	O
12	O
and	O
12	O
.	O
35	O
μg	O
/	O
mL	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
are	O
economically	O
important	O
swine	O
enteropathogenic	O
coronaviruses	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
virus	O
-	O
host	O
interaction	O
that	O
regulates	O
coronavirus	O
pathogenesis	B-DISO
.	O

A	O
mouse	O
lung	B-DISO
infection	I-DISO
model	O
was	O
described	O
where	O
a	O
mouse	O
adenovirus	B-DISO
was	O
used	O
to	O
transfect	O
lung	O
cells	O
for	O
receptor	O
expression	O
.	O

It	O
seems	O
many	O
clinical	O
and	O
radiological	O
aspects	O
of	O
sarcoidosis	B-DISO
in	O
our	O
patients	O
are	O
similar	O
to	O
other	O
series	O
.	O

However	O
,	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
interstitial	B-DISO
pneumonia	I-DISO
,	O
and	O
acute	O
exacerbation	B-DISO
of	I-DISO
idiopathic	I-DISO
pulmonary	I-DISO
fibrosis	I-DISO
,	O
which	O
,	O
unlike	O
AEP	O
are	O
mostly	O
life	O
-	O
threatening	O
diseases	O
,	O
also	O
exhibit	O
DAD	O
.	O

AEP	O
also	O
presents	O
with	O
severe	O
hypoxia	B-DISO
but	O
rapidly	O
improves	O
on	O
treatment	O
with	O
corticosteroids	O
alone	O
,	O
without	O
subsequent	O
fibrosis	B-DISO
.	O

Because	O
AEP	O
does	O
not	O
exhibit	O
lung	B-DISO
fibrosis	I-DISO
histopathologically	O
,	O
it	O
should	O
not	O
to	O
be	O
included	O
in	O
DAD	O
which	O
is	O
associated	O
with	O
lung	B-DISO
fibrosis	I-DISO
.	O

Lessons	O
learned	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
.	O

In	O
this	O
article	O
,	O
we	O
briefly	O
review	O
the	O
definition	O
,	O
epidemiology	O
,	O
and	O
pathophysiology	O
of	O
ARDS	B-DISO
and	O
present	O
emerging	O
aspects	O
of	O
ARDS	B-DISO
pathophysiology	O
that	O
encompass	O
modulators	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
,	O
damage	O
signals	O
,	O
and	O
aberrant	O
proteolysis	O
that	O
may	O
serve	O
as	O
a	O
foundation	O
for	O
future	O
therapeutic	O
targets	O
.	O

Prone	O
position	O
ventilation	O
is	O
a	O
safe	O
strategy	O
and	O
reduces	O
mortality	O
in	O
patients	O
with	O
severely	O
impaired	B-DISO
oxygenation	O
.	O

Adverse	B-DISO
effects	I-DISO
associated	O
with	O
pronation	O
were	O
the	O
development	O
of	O
pressure	B-DISO
ulcers	I-DISO
and	O
endotracheal	O
tube	O
obstruction	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
identification	O
of	O
the	O
first	O
case	O
of	O
infection	B-DISO
with	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
corona	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
in	O
June	O
2012	O
,	O
the	O
number	O
of	O
laboratory	O
-	O
confirmed	O
cases	O
has	O
exceeded	O
941	O
cases	O
globally	O
,	O
of	O
which	O
347	O
died	O
.	O

TITLE	O
:	O
Varicella	B-DISO
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
an	O
adult	O
patient	O
:	O
an	O
example	O
for	O
extracorporeal	O
respiratory	O
support	O
in	O
Brazilian	O
endemic	B-DISO
diseases	I-DISO
.	O

The	O
high	O
virulence	O
and	O
mortality	O
rate	O
prompted	O
us	O
to	O
analyze	O
aspects	O
of	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
,	O
especially	O
its	O
interaction	O
with	O
innate	O
immune	O
cells	O
such	O
as	O
antigen	O
-	O
presenting	O
cells	O
(	O
APCs	B-DISO
).	O

In	O
parallel	O
,	O
human	O
pDCs	O
are	O
potent	O
IFN	O
-	O
producing	O
cells	O
upon	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
causes	O
a	O
respiratory	B-DISO
disease	I-DISO
with	O
a	O
mortality	O
rate	O
of	O
10	O
%.	O

To	O
analyze	O
the	O
host	O
responses	O
leading	O
to	O
rSARS	O
-	O
CoV	O
-	O
MA15	O
-	O
E	O
*	O
attenuation	O
,	O
differences	O
in	O
gene	O
expression	O
elicited	O
by	O
the	O
native	O
and	O
mutant	B-DISO
viruses	O
in	O
the	O
lungs	O
of	O
infected	O
mice	O
were	O
determined	O
.	O

Approximately	O
35	O
%	O
of	O
weaners	O
(	O
1	O
-	O
3	O
weeks	O
after	O
weaning	O
)	O
presented	O
clinical	O
symptoms	O
similar	O
to	O
Post	B-DISO
-	I-DISO
weaning	I-DISO
Multisystemic	I-DISO
Wasting	I-DISO
Syndrome	I-DISO
(	O
PMWS	O
).	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
a	O
novel	O
decahydroisoquinolin	O
scaffold	O
as	O
an	O
inhibitor	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
are	O
described	O
.	O

ABSTRACT	O
:	O
The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
retrospectively	O
analyze	O
chest	O
CT	O
findings	O
for	O
15	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
and	O
to	O
identify	O
features	O
associated	O
with	O
survival	O
.	O

Two	O
reviewers	O
scored	O
chest	O
radiographs	O
and	O
CT	O
examinations	O
for	O
segmental	O
involvement	O
,	O
ground	O
-	O
glass	O
opacities	B-DISO
,	O
consolidation	O
,	O
and	O
interstitial	O
thickening	O
.	O

Pleural	B-DISO
effusion	I-DISO
and	O
higher	O
CT	O
lung	O
and	O
chest	O
radiographic	O
scores	O
correlate	O
with	O
poor	O
prognosis	O
and	O
short	O
-	O
term	O
mortality	O
.	O

All	O
nine	O
group	O
1	O
patients	O
and	O
three	O
of	O
six	O
group	O
2	O
patients	O
had	O
pleural	B-DISO
effusion	I-DISO
(	O
p	O
=	O
0	O
.	O
52	O
).	O

All	O
five	O
neonates	O
underwent	O
ExT	B-DISO
at	O
a	O
median	O
age	O
of	O
2	O
days	O
(	O
range	O
,	O
0	O
-	O
5	O
days	O
)	O
before	O
initiation	O
of	O
other	O
cytoreductive	O
therapy	O
with	O
cytarabine	O
,	O
which	O
was	O
carried	O
out	O
in	O
two	O
patients	O
.	O

CONCLUSIONS	O
:	O
ExT	B-DISO
was	O
very	O
effective	O
in	O
improving	O
hyperleukocytosis	O
and	O
may	O
have	O
had	O
favorable	O
effects	O
on	O
respiration	O
.	O

From	O
HIV	B-DISO
to	O
hepatotropic	O
viruses	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
,	O
humanized	O
mice	O
have	O
led	O
to	O
the	O
identification	O
of	O
factors	O
crucial	O
to	O
the	O
viral	O
life	O
cycle	O
,	O
served	O
as	O
an	O
outlet	O
for	O
testing	O
candidate	O
therapies	O
,	O
and	O
improved	O
our	O
abilities	O
to	O
analyze	O
human	O
immune	O
responses	O
to	O
infection	B-DISO
.	O

To	O
identify	O
the	O
main	O
respiratory	O
pathogens	O
isolated	O
from	O
calves	O
in	O
Québec	O
dairy	O
herds	O
with	O
a	O
high	O
incidence	O
of	O
BRD	O
,	O
and	O
to	O
determine	O
if	O
there	O
is	O
an	O
association	O
between	O
the	O
presence	O
of	O
these	O
pathogens	O
and	O
clinical	O
signs	O
of	O
pneumonia	B-DISO
,	O
lung	B-DISO
consolidation	I-DISO
,	O
or	O
average	O
daily	O
gain	O
.	O

Twenty	O
-	O
two	O
calves	O
had	O
clinical	O
BRD	O
and	O
49	O
had	O
ultrasonographic	O
evidence	O
of	O
lung	B-DISO
consolidation	I-DISO
.	O

TITLE	O
:	O
Entry	O
screening	O
for	O
infectious	B-DISO
diseases	I-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
During	O
January	O
2013	O
-	O
August	O
2014	O
,	O
a	O
total	O
of	O
1	O
,	O
800	O
patients	O
in	O
Iran	O
who	O
had	O
respiratory	O
illness	O
were	O
tested	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
We	O
report	O
an	O
extremely	O
rare	O
case	O
of	O
pulmonary	O
lipiodol	O
embolism	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
after	O
transcatheter	O
arterial	O
chemoembolization	O
(	O
TACE	O
)	O
for	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O
HCC	B-DISO
).	O

A	O
subsequent	O
autopsy	O
revealed	O
that	O
the	O
cause	O
of	O
death	O
was	O
ARDS	B-DISO
due	O
to	O
pulmonary	O
lipiodol	O
embolism	B-DISO
.	O

Since	O
the	O
publication	O
of	O
the	O
PROSEVA	O
study	O
in	O
2013	O
,	O
early	O
prone	O
positioning	O
for	O
mechanical	O
ventilation	O
should	O
be	O
recommended	O
to	O
improve	O
survival	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

These	O
changes	O
were	O
interpreted	O
as	O
the	O
transition	B-DISO
from	O
an	O
acute	B-DISO
disease	I-DISO
with	O
a	O
primary	O
respiratory	O
manifestation	O
into	O
a	O
chronic	O
condition	B-DISO
where	O
renal	B-DISO
amyloidosis	I-DISO
led	O
to	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
and	O
death	O
.	O

ABSTRACT	O
:	O
CDC	O
continues	O
to	O
work	O
with	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
other	O
partners	O
to	O
closely	O
monitor	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
globally	O
and	O
to	O
better	O
understand	O
the	O
risks	O
to	O
public	O
health	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
provide	O
a	O
brief	O
update	O
on	O
MERS	O
-	O
CoV	O
epidemiology	O
and	O
to	O
notify	O
health	O
care	O
providers	O
,	O
public	O
health	O
officials	O
,	O
and	O
others	O
to	O
maintain	O
awareness	O
of	O
the	O
need	O
to	O
consider	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
persons	O
who	O
have	O
recently	O
traveled	O
from	O
countries	O
in	O
or	O
near	O
the	O
Arabian	O
Peninsula	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
attenuated	O
a	O
Chinese	O
QX	O
-	O
like	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strain	O
,	O
YX10	O
,	O
by	O
passaging	O
through	O
fertilized	O
chicken	O
eggs	O
.	O

In	O
conclusion	O
,	O
the	O
attenuated	O
YX10p90	O
strain	O
exhibited	O
a	O
fine	O
balance	O
between	O
attenuation	O
and	O
immunogenicity	O
,	O
and	O
should	O
be	O
considered	O
as	O
a	O
candidate	O
vaccine	O
to	O
prevent	O
infection	B-DISO
of	O
Chinese	O
QX	O
-	O
like	O
nephropathogenic	O
IBV	O
.	O

The	O
addition	O
of	O
MF59	O
significantly	O
augmented	O
the	O
immunogenicity	O
of	O
S377	O
-	O
588	O
-	O
Fc	O
to	O
induce	O
strong	O
IgG	O
and	O
neutralizing	O
antibody	O
responses	O
as	O
well	O
as	O
protection	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
mice	O
,	O
suggesting	O
that	O
MF59	O
is	O
an	O
optimal	O
adjuvant	O
for	O
MERS	O
-	O
CoV	O
RBD	O
-	O
based	O
subunit	O
vaccines	O
.	O

ABSTRACT	O
:	O
Classical	B-DISO
swine	I-DISO
fever	I-DISO
(	O
CSF	O
)	O
is	O
an	O
OIE	O
-	O
listed	O
disease	O
that	O
can	O
have	O
a	O
severe	O
impact	O
on	O
the	O
swine	O
industry	O
.	O

ABSTRACT	O
:	O
Severely	O
injured	O
patients	O
experiencing	O
hemorrhagic	B-DISO
shock	I-DISO
often	O
require	O
massive	O
transfusion	O
.	O

The	O
other	O
horse	O
(	O
case	O
No	O
.	O
2	O
)	O
had	O
hyperammonemic	O
encephalopathy	B-DISO
with	O
Alzheimer	O
type	O
II	O
astrocytosis	B-DISO
throughout	O
the	O
cerebral	O
cortex	O
.	O

Vaccinating	O
cows	O
against	O
calf	O
enteropathogens	O
(	O
OR	O
=	O
0	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
1	O
-	O
0	O
.	O
9	O
;	O
P	O
=	O
0	O
.	O
03	O
),	O
administering	O
waste	O
milk	O
(	O
from	O
mastitis	B-DISO
and	O
/	O
or	O
containing	O
antibiotics	O
;	O
OR	O
=	O
0	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
01	O
),	O
the	O
sex	O
of	O
calves	O
(	O
females	O
compared	O
to	O
males	O
OR	O
=	O
0	O
.	O
2	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
07	O
-	O
0	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
use	O
of	O
straw	O
for	O
bedding	O
(	O
OR	O
=	O
0	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
03	O
-	O
0	O
.	O
9	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
decreased	O
the	O
odds	O
of	O
liquid	O
faeces	O
.	O

The	O
antiviral	O
effect	O
of	O
ouabain	O
could	O
be	O
relieved	O
by	O
the	O
addition	O
of	O
different	O
Src	O
kinase	O
inhibitors	O
,	O
indicating	O
that	O
Src	O
signaling	O
mediated	O
via	O
ATP1A1	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
inhibition	O
of	O
CoV	O
and	O
VSV	O
infections	B-DISO
.	O

Antiviral	O
drugs	O
targeting	O
CoV	O
infections	B-DISO
are	O
lacking	O
.	O

Incidence	O
of	O
convulsion	B-DISO
is	O
significantly	O
higher	O
in	O
females	O
.	O

TITLE	O
:	O
Epidemiology	O
and	O
outcomes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
children	O
according	O
to	O
the	O
Berlin	O
definition	O
:	O
a	O
multicenter	O
prospective	O
study	O
.	O

TITLE	O
:	O
Antiviral	O
effect	O
of	O
lithium	O
chloride	O
on	O
infection	B-DISO
of	O
cells	O
by	O
porcine	O
parvovirus	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
parvovirus	B-DISO
(	O
PPV	O
)	O
causes	O
reproductive	O
failure	O
in	O
pigs	O
,	O
which	O
leads	O
to	O
economic	O
losses	O
to	O
the	O
industry	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
plasma	O
levels	O
of	O
sRAGE	O
were	O
elevated	O
in	O
ARDS	B-DISO
patients	O
compared	O
with	O
appropriate	O
controls	O
.	O

The	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
score	O
was	O
applied	O
to	O
assess	O
illness	O
severity	O
.	O

TITLE	O
:	O
Genetic	O
characterization	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
Korea	O
from	O
1998	O
to	O
2013	O
.	O

In	O
addition	O
,	O
SARS	B-DISO
-	O
and	O
MERS	O
-	O
coronavirus	O
can	O
use	O
serine	O
proteases	O
localized	O
at	O
the	O
cell	O
surface	O
,	O
for	O
their	O
activation	O
.	O

Employing	O
a	O
pathogenic	O
animal	O
model	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
we	O
demonstrated	O
that	O
viral	O
spread	O
and	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
is	O
driven	O
by	O
serine	O
rather	O
than	O
cysteine	O
proteases	O
and	O
can	O
be	O
effectively	O
prevented	O
by	O
camostat	O
.	O

Our	O
results	O
support	O
previous	O
studies	O
that	O
implicate	O
S	O
protein	O
mutations	O
in	O
the	O
pathogenesis	B-DISO
of	O
FIP	B-DISO
.	O

TITLE	O
:	O
Tryptophan	O
-	O
dependent	O
membrane	O
interaction	O
and	O
heteromerization	O
with	O
the	O
internal	O
fusion	O
peptide	O
by	O
the	O
membrane	O
proximal	O
external	O
region	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

This	O
was	O
a	O
single	O
-	O
center	O
,	O
prospective	O
,	O
randomized	O
,	O
comparative	O
,	O
double	O
-	O
blind	B-DISO
,	O
controlled	O
study	O
of	O
patients	O
with	O
severe	O
trauma	O
requiring	O
mechanical	O
ventilation	O
.	O

New	O
studies	O
have	O
suggested	O
strategies	O
to	O
identify	O
patients	O
at	O
risk	O
for	O
resistant	O
pathogen	O
infection	B-DISO
and	O
therapies	O
that	O
optimize	O
efficacy	O
,	O
without	O
the	O
overuse	O
of	O
broad	O
-	O
spectrum	O
therapy	O
in	O
patients	O
with	O
healthcare	O
-	O
associated	O
pneumonia	B-DISO
.	O

Then	O
,	O
we	O
treated	O
different	O
bat	O
cells	O
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	O
)	O
and	O
splenocytes	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
polyI	O
:	O
C	O
)	O
and	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
)	O
to	O
assess	O
and	O
compare	O
antiviral	O
immune	O
responses	O
between	O
bats	O
and	O
mice	O
.	O

These	O
findings	O
have	O
provided	O
new	O
insight	O
into	O
the	O
potential	O
characteristics	O
of	O
the	O
bat	O
innate	O
immune	O
system	O
against	O
viral	B-DISO
infection	I-DISO
.	O

Collectively	O
,	O
our	O
data	O
demonstrate	O
that	O
pAPN	O
,	O
the	O
cellular	O
receptor	O
for	O
PEDV	O
,	O
mediates	O
polarized	O
PEDV	O
infection	B-DISO
.	O

Of	O
the	O
isolated	O
alkylated	O
chalcones	O
,	O
chalcone	O
6	O
,	O
containing	O
the	O
perhydroxyl	O
group	O
,	O
exhibited	O
the	O
most	O
potent	O
3CL	O
(	O
pro	O
)	O
and	O
PL	O
(	O
pro	O
)	O
inhibitory	O
activity	O
with	O
IC50	O
values	O
of	O
11	O
.	O
4	O
and	O
1	O
.	O
2	O
µM	O
.	O
Our	O
detailed	O
protein	O
-	O
inhibitor	O
mechanistic	O
analysis	O
of	O
these	O
species	O
indicated	O
that	O
the	O
chalcones	O
exhibited	O
competitive	O
inhibition	O
characteristics	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
),	O
whereas	O
noncompetitive	O
inhibition	O
was	O
observed	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
PL	O
(	O
pro	O
).	O

R0	O
was	O
estimated	O
using	O
the	O
incidence	O
decay	B-DISO
with	O
exponential	O
adjustment	O
"("""	O
IDEA	O
""")"	O
method	O
,	O
while	O
period	O
-	O
specific	O
case	O
fatality	O
rates	O
that	O
incorporated	O
non	O
-	O
attributed	O
death	O
data	O
were	O
estimated	O
using	O
Monte	O
Carlo	O
simulation	O
.	O

TITLE	O
:	O
Methylene	O
blue	O
for	O
burn	O
-	O
induced	O
vasoplegia	B-DISO
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

Many	O
current	O
studies	O
have	O
reported	O
possible	O
application	O
of	O
aptamers	O
as	O
a	O
treatment	O
or	O
diagnostic	O
tool	O
in	O
viral	B-DISO
infections	I-DISO
,	O
e	O
.	O
g	O
.,	O
HIV	B-DISO
(	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
),	O
HBV	B-DISO
(	O
Hepatitis	B-DISO
B	I-DISO
Virus	O
),	O
HCV	O
(	O
Hepatitis	B-DISO
C	I-DISO
Virus	O
),	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
),	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
and	O
recently	O
spread	O
Ebola	O
.	O

CONCLUSIONS	O
:	O
Bilateral	O
infarctions	B-DISO
of	O
the	O
paramedian	O
thalamus	O
may	O
result	O
in	O
severe	O
illness	O
and	O
impairment	B-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
and	O
virulent	O
,	O
systemic	O
calicivirus	B-DISO
infection	I-DISO
are	O
caused	O
by	O
certain	O
types	O
of	O
feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
and	O
feline	O
caliciviruses	O
(	O
FCVs	O
),	O
respectively	O
,	O
and	O
are	O
important	O
infectious	B-DISO
diseases	I-DISO
with	O
high	O
fatality	O
rates	O
in	O
members	O
of	O
the	O
Felidae	O
family	O
.	O

While	O
FCoV	O
and	O
FCV	O
belong	O
to	O
two	O
distinct	O
virus	O
families	O
,	O
the	O
Coronaviridae	O
and	O
the	O
Caliciviridae	O
,	O
respectively	O
,	O
they	O
share	O
a	O
dependence	B-DISO
on	I-DISO
viral	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
for	O
their	O
replication	O
.	O

Here	O
,	O
we	O
tested	O
the	O
effect	O
of	O
altering	O
the	O
Ubl	O
adjacent	O
to	O
PLP2	O
of	O
MHV	O
on	O
enzyme	O
activity	O
,	O
viral	O
replication	O
,	O
and	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Managing	O
hypercapnia	B-DISO
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
and	O
low	O
respiratory	O
system	O
compliance	O
:	O
the	O
role	O
of	O
esophageal	O
pressure	O
monitoring	O
--	O
a	O
case	O
cohort	O
study	O
.	O

The	O
use	O
of	O
esophageal	O
balloon	O
as	O
a	O
guide	O
to	O
mechanical	O
ventilation	O
was	O
able	O
to	O
treat	O
severe	O
hypercapnia	B-DISO
in	O
ARDS	B-DISO
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
use	O
of	O
esophageal	O
balloon	O
as	O
a	O
guide	O
to	O
mechanical	O
ventilation	O
was	O
able	O
to	O
treat	O
severe	O
hypercapnia	B-DISO
in	O
ARDS	B-DISO
patients	O
.	O

Over	O
37	O
,	O
000	O
patients	O
die	O
from	O
pneumonia	B-DISO
each	O
year	O
in	O
Russia	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
NL63	O
was	O
first	O
described	O
in	O
2004	O
and	O
is	O
associated	O
with	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
of	O
varying	O
severity	O
.	O

Crowding	B-DISO
conditions	O
lead	O
to	O
high	O
rates	O
of	O
respiratory	B-DISO
infections	I-DISO
among	O
the	O
pilgrims	O
,	O
representing	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
a	O
major	O
cause	O
of	O
hospitalization	O
.	O

The	O
E	O
protein	O
possesses	B-DISO
ion	O
channel	O
activity	O
.	O

ABSTRACT	O
:	O
Although	O
much	O
recent	O
focus	O
has	O
been	O
on	O
the	O
recognition	O
of	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
among	O
travelers	O
from	O
West	O
Africa	O
,	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
including	O
travel	O
-	O
associated	O
cases	O
,	O
continue	O
to	O
be	O
reported	O
.	O

Infection	B-DISO
control	O
is	O
especially	O
critical	O
,	O
given	O
that	O
most	O
cases	O
have	O
been	O
healthcare	O
-	O
associated	O
.	O

TITLE	O
:	O
Viruses	O
detected	O
by	O
systematic	O
multiplex	O
polymerase	O
chain	O
reaction	O
in	O
adults	O
with	O
suspected	O
community	O
-	O
acquired	O
pneumonia	B-DISO
attending	O
emergency	B-DISO
departments	O
in	O
France	O
.	O

Their	O
imputability	O
and	O
impact	O
in	O
early	O
management	O
of	O
CAP	B-DISO
deserve	O
further	O
studies	O
.	O

The	O
patient	O
was	O
subjected	O
to	O
induced	B-DISO
hypothermia	I-DISO
.	O

In	O
the	O
early	O
phase	O
of	O
severe	B-DISO
sepsis	I-DISO
in	O
mechanically	O
ventilated	O
patients	O
,	O
there	O
was	O
no	O
constant	O
relationship	O
between	O
GEDI	O
and	O
fluid	O
reserve	O
responsiveness	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
SIMD	O
.	O

Case	O
4	O
:	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
with	O
CKD	O
was	O
admitted	O
to	O
the	O
ICU	O
to	O
control	O
gastrointestinal	B-DISO
bleeding	I-DISO
.	O

PSP	B-DISO
in	O
kidney	B-DISO
dysfunction	I-DISO
patients	O
will	O
be	O
high	O
despite	O
non	O
-	O
infectious	B-DISO
conditions	O
.	O

Therefore	O
,	O
evaluation	O
of	O
PSP	B-DISO
in	O
kidney	B-DISO
dysfunction	I-DISO
patients	O
will	O
be	O
difficult	O
.	O

We	O
related	O
structures	O
of	O
influenza	B-DISO
A	O
N10	O
and	O
N11	O
proteins	O
that	O
have	O
no	O
established	O
function	O
to	O
structures	O
of	O
proteins	O
with	O
known	O
function	O
by	O
identifying	O
spatially	O
conserved	O
atoms	O
.	O

The	O
clinical	O
presentation	O
ranges	O
from	O
asymptomatic	B-DISO
infection	I-DISO
to	O
severe	O
pneumonia	B-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

This	O
is	O
a	O
rare	O
report	O
of	O
MERS	O
CoV	O
infection	B-DISO
in	O
renal	O
transplant	O
recipients	O
.	O

ABSTRACT	O
:	O
The	O
risk	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
spreading	O
globally	O
is	O
worrying	O
,	O
given	O
the	O
annual	O
mass	O
gathering	O
of	O
the	O
Hajj	O
and	O
the	O
year	O
-	O
long	O
influx	O
of	O
pilgrims	O
undertaking	O
the	O
Umrah	O
.	O

Here	O
we	O
describe	O
the	O
engineering	O
of	O
CoV	O
full	O
-	O
length	O
cDNA	O
clones	O
as	O
bacterial	O
artificial	O
chromosomes	O
(	O
BACs	O
),	O
using	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
a	O
model	O
.	O

Our	O
assay	O
is	O
particularly	O
convenient	O
to	O
elucidate	O
critical	O
virus	O
-	O
host	O
interactions	O
for	O
viruses	O
for	O
which	O
infection	B-DISO
models	O
are	O
limited	O
.	O

This	O
protocol	O
has	O
been	O
used	O
to	O
screen	O
most	O
non	O
-	O
structural	O
proteins	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
member	O
of	O
betacoronavirus	O
genus	O
,	O
against	O
a	O
mouse	O
brain	O
cDNA	O
library	O
.	O

TITLE	O
:	O
Transcriptome	O
analysis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
generate	O
specialized	O
membrane	O
compartments	O
,	O
which	O
consist	O
of	O
double	O
membrane	O
vesicles	B-DISO
connected	O
to	O
convoluted	O
membranes	O
,	O
the	O
so	O
-	O
called	O
replicative	O
structures	O
,	O
where	O
viral	O
RNA	O
synthesis	O
takes	O
place	O
.	O

There	O
were	O
6	O
mortalities	O
(	O
3	O
pneumonia	B-DISO
,	O
2	O
coagulopathy	B-DISO
,	O
and	O
1	O
cardiac	B-DISO
rupture	I-DISO
with	O
cardiac	B-DISO
tamponade	I-DISO
).	O

The	O
use	O
of	O
ECMO	O
may	O
offer	O
an	O
additional	O
treatment	O
modality	O
in	O
severe	O
traumatic	B-DISO
lung	I-DISO
injury	O
with	O
respiratory	B-DISO
failure	I-DISO
that	O
is	O
unresponsive	O
to	O
optimal	O
conventional	O
ventilator	O
support	O
.	O

RESULTS	O
:	O
Over	O
60	O
months	O
,	O
a	O
total	O
of	O
19	O
patients	O
with	O
severe	O
traumatic	B-DISO
lung	I-DISO
injury	O
who	O
received	O
ECMO	O
management	O
were	O
retrospectively	O
reviewed	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
in	O
chickens	O
caused	O
by	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

These	O
two	O
MAbs	O
react	O
specifically	O
with	O
IBV	O
but	O
not	O
with	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
or	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
)	O
subtype	O
H9	O
or	O
H5	O
,	O
and	O
could	O
cross	O
-	O
react	O
with	O
other	O
10	O
IBV	O
strains	O
in	O
five	O
different	O
genotypes	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	O
to	O
N	O
protein	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
viral	B-DISO
infection	I-DISO
is	O
one	O
of	O
the	O
most	O
common	O
and	O
important	O
diseases	O
in	O
children	O
.	O

On	O
each	O
sampling	O
day	O
,	O
we	O
asked	O
the	O
parents	O
about	O
their	O
children	O
'	O
s	O
health	O
condition	B-DISO
.	O

In	O
samples	O
from	O
symptomatic	O
children	O
,	O
parainfluenza	B-DISO
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
coronavirus	O
OC43	O
were	O
detected	O
in	O
addition	O
to	O
those	O
mentioned	O
above	O
.	O

Camels	O
are	O
the	O
likely	O
animal	O
source	O
for	O
zoonotic	B-DISO
infection	I-DISO
,	O
although	O
exact	O
transmission	O
modes	O
remain	O
to	O
be	O
determined	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aim	O
was	O
to	O
investigate	O
an	O
outbreak	O
of	O
human	O
cases	O
of	O
unexplained	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
and	O
fatal	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
ARI	O
),	O
with	O
simultaneous	O
poultry	O
illness	O
and	O
high	O
mortality	O
raising	O
concerns	O
of	O
possible	O
influenza	B-DISO
A	O
(	O
H5N1	B-DISO
),	O
virus	O
in	O
Cote	O
d	O
'	O
Ivoire	O
in	O
February	O
and	O
March	O
2007	O
.	O

Incidence	O
cases	O
were	O
retrieved	O
from	O
national	O
surveillance	O
systems	O
,	O
except	O
for	O
NEC	O
and	O
SIDS	B-DISO
,	O
which	O
were	O
estimated	O
from	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
Recent	O
reports	O
of	O
Plasmodium	O
vivax	O
associated	O
with	O
severe	O
syndromes	B-DISO
and	O
mortality	O
from	O
malaria	B-DISO
endemic	O
areas	O
questions	O
the	O
""""	O
benign	O
""""	O
course	O
of	O
non	O
-	O
falciparum	O
malarias	B-DISO
.	O

Compared	O
with	O
P	O
.	O
vivax	O
(	O
n	O
=	O
163	O
),	O
the	O
odds	O
of	O
P	O
.	O
falciparum	O
cases	O
classified	O
as	O
severely	O
ill	B-DISO
(	O
n	O
=	O
1416	O
)	O
were	O
1	O
.	O
9	O
(	O
P	O
=	O
.	O
0006	O
),	O
.	O
5	O
(	O
P	O
=	O
.	O
001	O
),	O
and	O
1	O
.	O
3	O
times	O
(	O
P	O
=	O
.	O
1	O
)	O
as	O
likely	O
to	O
present	O
as	O
cerebral	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
and	O
renal	O
syndromes	B-DISO
,	O
respectively	O
.	O

In	O
addition	O
,	O
this	O
method	O
identified	O
multiple	O
coinfections	B-DISO
(	O
39	O
%)	O
with	O
2	O
,	O
3	O
,	O
4	O
and	O
up	O
to	O
5	O
different	O
viruses	O
.	O

However	O
,	O
the	O
coming	O
incorporation	O
of	O
molecular	O
methods	O
in	O
routine	O
procedures	O
will	O
significantly	O
increase	O
the	O
diagnostic	O
yield	O
of	O
these	O
infections	B-DISO
.	O

The	O
underlying	O
conditions	O
were	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
n	O
=	O
3	O
),	O
end	O
-	O
stage	O
pulmonary	B-DISO
fibrosis	I-DISO
(	O
n	O
=	O
5	O
)	O
and	O
respiratory	B-DISO
failure	I-DISO
after	O
major	O
thoracic	B-DISO
surgery	O
(	O
n	O
=	O
1	O
)	O
and	O
Caesarean	O
section	O
(	O
n	O
=	O
1	O
).	O

TITLE	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
CO2	O
removal	O
improves	O
pulmonary	O
hemodynamics	O
in	O
a	O
porcine	O
ARDS	B-DISO
model	O
.	O

The	O
morning	O
after	O
the	O
beginning	O
of	O
BEP	O
,	O
the	O
patient	O
developed	O
hemorrhagic	B-DISO
shock	I-DISO
,	O
in	O
addition	O
to	O
acute	O
pulmonary	O
and	O
renal	B-DISO
failure	I-DISO
,	O
because	O
of	O
TLS	O
and	O
massive	B-DISO
hemorrhage	I-DISO
at	O
bilateral	O
lung	B-DISO
metastases	I-DISO
.	O

In	O
addition	O
,	O
Schisandrin	O
B	O
was	O
also	O
able	O
to	O
impair	O
HIV	B-DISO
-	O
1	O
RT	O
drug	O
resistant	O
mutants	O
and	O
the	O
early	O
phases	O
of	O
viral	O
replication	O
.	O

TITLE	O
:	O
Pediatric	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
:	O
Indicators	O
for	O
a	O
severe	O
course	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
retrospectively	O
evaluate	O
pediatric	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
cases	O
in	O
a	O
tertiary	O
center	O
in	O
Istanbul	O
,	O
Turkey	O
.	O

Patient	O
was	O
successfully	O
treated	O
with	O
antiretroviral	O
therapy	O
(	O
ART	O
),	O
anti	O
-	O
infective	O
agents	O
and	O
58	O
days	O
of	O
veno	O
-	O
venous	O
ECMO	O
support	O
,	O
with	O
complete	O
resolution	O
of	O
the	O
respiratory	B-DISO
symptoms	I-DISO
.	O

HIV	B-DISO
infected	O
patients	O
with	O
ARDS	B-DISO
and	O
MDR	O
bacterial	O
VAP	O
whose	O
HIV	B-DISO
replication	O
is	O
controlled	O
by	O
ART	O
could	O
be	O
successfully	O
managed	O
with	O
ECMO	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	O
ventilation	O
and	O
respiratory	B-DISO
failure	I-DISO
during	O
pregnancy	O
.	O

Airway	O
pressure	O
release	O
ventilation	O
may	O
be	O
an	O
important	O
option	O
as	O
a	O
ventilatory	O
mode	O
for	O
management	O
of	O
maternal	O
respiratory	B-DISO
failure	I-DISO
during	O
pregnancy	O
.	O

The	O
established	O
ELISA	O
was	O
also	O
examined	O
with	O
serum	O
samples	O
obtained	O
from	O
turkeys	O
experimentally	O
infected	O
with	O
TCoV	O
.	O
Those	O
serum	O
samples	O
were	O
collected	O
at	O
various	O
time	O
intervals	O
from	O
1	O
to	O
63	O
days	O
post	O
-	O
infection	B-DISO
.	O

Four	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
lead	O
inhibitors	O
were	O
tested	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
none	O
of	O
which	O
were	O
effective	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
.	O

Ten	O
piglets	O
submitted	O
to	O
an	O
experimental	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

For	O
the	O
entire	O
cohort	O
,	O
despite	O
more	O
severe	O
injury	O
burden	O
,	O
military	O
patients	O
had	O
a	O
significantly	O
lower	O
overall	O
mortality	O
(	O
17	O
%	O
vs	O
.	O
28	O
%;	O
p	O
=	O
0	O
.	O
0002	O
)	O
as	O
well	O
as	O
ARDS	B-DISO
mortality	O
(	O
33	O
vs	O
.	O
48	O
%,	O
p	O
=	O
0	O
.	O
02	O
)	O
when	O
compared	O
to	O
civilians	O
.	O

CONCLUSIONS	O
:	O
Pediatricians	O
should	O
keep	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
scrub	B-DISO
typhus	I-DISO
in	O
any	O
febrile	O
child	O
having	O
a	O
maculopapular	O
rash	B-DISO
,	O
hepatosplenomegaly	B-DISO
,	O
tender	O
lymphadenopathy	O
,	O
thrombocytopenia	O
and	O
features	O
suggestive	O
of	O
capillary	O
leak	O
.	O

TITLE	O
:	O
Urogynecologic	O
conditions	O
:	O
chronic	B-DISO
pelvic	I-DISO
pain	I-DISO
.	O

Clinical	O
signs	O
were	O
associated	O
with	O
epithelial	O
necrosis	O
in	O
the	O
gastric	O
pits	O
and	O
small	O
intestine	O
,	O
the	O
latter	O
resulting	O
in	O
severe	O
villous	O
atrophy	B-DISO
.	O

Mild	O
interstitial	B-DISO
pneumonia	I-DISO
was	O
identified	O
in	O
the	O
lungs	O
of	O
PdCV	O
-	O
infected	O
piglets	O
.	O

This	O
RNA	O
motif	O
presented	O
high	O
homology	O
with	O
the	O
GAIT	O
element	O
,	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
.	O

After	O
delivery	O
,	O
the	O
illness	O
was	O
exacerbated	O
and	O
the	O
patient	O
presented	O
with	O
clinical	O
signs	O
of	O
vital	O
organ	O
dysfunctions	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
cerebral	B-DISO
edema	I-DISO
and	O
hypoxemia	O
that	O
needed	O
mechanical	O
ventilation	O
.	O

We	O
also	O
demonstrate	O
herein	O
in	O
vivo	O
efficacy	O
of	O
an	O
inhibitor	O
using	O
the	O
murine	O
model	O
of	O
norovirus	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
An	O
ideal	O
vaccine	O
against	O
mucosal	O
pathogens	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
should	O
confer	O
sustained	O
,	O
protective	O
immunity	O
at	O
both	O
systemic	O
and	O
mucosal	O
levels	O
.	O

To	O
consider	O
primary	O
prevention	O
of	O
this	O
pathology	B-DISO
,	O
which	O
can	O
have	O
extremely	O
severe	O
consequences	O
.	O

Infection	B-DISO
is	O
characterized	O
by	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
a	O
high	O
fatality	O
rate	O
and	O
the	O
ability	O
to	O
spread	O
from	O
person	O
to	O
person	O
;	O
health	O
care	O
-	O
associated	O
outbreaks	O
have	O
been	O
described	O
.	O

TITLE	O
:	O
Emerging	O
respiratory	O
tract	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
hCoV	O
papain	O
-	O
like	O
protease	O
is	O
a	O
unique	O
Lys48	O
linkage	O
-	O
specific	O
di	O
-	O
distributive	O
deubiquitinating	O
enzyme	O
.	O

TITLE	O
:	O
Successful	O
cardiopulmonary	O
cerebral	O
resuscitation	O
in	O
patient	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
)	O
is	O
a	O
critical	B-DISO
illness	I-DISO
in	O
clinical	O
practice	O
,	O
which	O
is	O
characterized	O
by	O
intensive	O
inflammatory	B-DISO
response	I-DISO
in	O
the	O
early	O
phase	O
and	O
infected	B-DISO
pancreatic	I-DISO
necrosis	I-DISO
in	O
the	O
later	O
phase	O
.	O

Thus	O
,	O
the	O
incidence	O
of	O
unpredictive	O
cardiopulmonary	B-DISO
arrest	I-DISO
is	O
high	O
.	O

TITLE	O
:	O
Establishment	O
of	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
for	O
rapid	O
detection	O
and	O
differentiation	O
of	O
canine	B-DISO
distemper	I-DISO
virus	O
infected	O
and	O
vaccinated	O
animals	O
.	O

TITLE	O
:	O
Hepatitis	B-DISO
E	I-DISO
:	O
A	O
disease	O
of	O
reemerging	O
importance	O
.	O

BALB	O
/	O
C	O
mice	O
were	O
intraperitoneally	O
injected	O
with	O
eucalyptol	O
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
/	O
kg	O
)	O
or	O
dexamethasone	O
(	O
1	O
mg	O
/	O
kg	O
)	O
1	O
h	O
before	O
intratracheal	O
challenge	O
with	O
lipopolysaccharide	O
(	O
LPS	B-DISO
;	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
sacrificed	O
after	O
4	O
h	O
.	O
The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
eucalyptol	O
were	O
assessed	O
by	O
determining	O
cell	O
counts	O
,	O
measuring	O
cytokine	O
and	O
nitric	O
oxide	O
production	O
and	O
performing	O
Western	O
blotting	O
and	O
histological	O
analyses	O
.	O

Owing	O
to	O
genomic	O
and	O
somatic	O
diversities	O
among	O
viral	O
species	O
,	O
identifying	O
protein	O
targets	O
for	O
broad	O
-	O
spectrum	O
virus	O
neutralization	O
is	O
highly	O
challenging	O
even	O
for	O
the	O
same	O
virus	O
,	O
such	O
as	O
HIV	B-DISO
-	O
1	O
.	O

Virulence	O
--	O
the	O
harm	O
a	O
pathogen	O
does	O
to	O
its	O
host	O
-	O
can	O
be	O
extremely	O
high	O
following	O
a	O
host	O
shift	O
(	O
for	O
example	O
Ebola	O
,	O
HIV	B-DISO
,	O
and	O
SARs	B-DISO
),	O
while	O
other	O
host	O
shifts	O
may	O
go	O
undetected	O
as	O
they	O
cause	O
few	O
symptoms	O
in	O
the	O
new	O
host	O
.	O

However	O
,	O
new	O
evidence	O
shows	O
that	O
(	O
at	O
least	O
in	O
Europe	O
)	O
pneumonia	B-DISO
caused	O
by	O
MDRO	O
remains	O
uncommon	O
even	O
in	O
HCAP	O
category	O
patients	O
.	O

Within	O
months	O
after	O
its	O
emergence	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
was	O
reported	O
in	O
several	O
countries	O
worldwide	O
in	O
people	O
who	O
had	O
traveled	O
from	O
the	O
Middle	O
East	O
.	O

Pulmonary	O
air	O
leaks	O
,	O
defined	O
as	O
gross	O
air	O
leaks	O
or	O
pulmonary	B-DISO
interstitial	I-DISO
emphysema	I-DISO
,	O
occurred	O
more	O
frequently	O
in	O
the	O
HFOV	O
group	O
,	O
whereas	O
the	O
risk	O
of	O
severe	O
retinopathy	B-DISO
of	I-DISO
prematurity	I-DISO
was	O
significantly	O
reduced	O
.	O

Most	O
trials	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
long	O
-	O
term	O
neurodevelopmental	O
outcome	O
,	O
although	O
one	O
recent	O
trial	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
risk	O
of	O
cerebral	B-DISO
palsy	I-DISO
and	O
poor	O
mental	O
development	O
.	O

TK9	O
,	O
which	O
forms	O
a	O
beta	O
-	O
sheet	O
rich	O
fibril	O
,	O
contains	O
a	O
key	O
sequence	O
motif	O
that	O
may	O
be	O
critical	O
for	O
beta	O
-	O
sheet	O
formation	O
,	O
thus	O
making	O
it	O
an	O
interesting	O
system	O
to	O
study	O
amyloid	B-DISO
fibrillation	B-DISO
.	O

Unlike	O
SARS	B-DISO
-	O
CoV	O
that	O
resolved	O
within	O
a	O
year	O
,	O
continued	O
introductions	O
of	O
MERS	O
-	O
CoV	O
present	O
an	O
on	O
-	O
going	O
public	O
health	O
threat	O
.	O

The	O
results	O
for	O
the	O
R₀	O
and	O
the	O
SI	O
from	O
the	O
influenza	B-DISO
outbreak	O
in	O
South	O
Africa	O
were	O
similar	O
regardless	O
of	O
the	O
prior	O
information	O
(	O
R0	O
=	O
1	O
.	O
36	O
-	O
1	O
.	O
46	O
,	O
μ	O
=	O
2	O
.	O
0	O
-	O
2	O
.	O
7	O
,	O
μ	O
=	O
mean	O
of	O
the	O
SI	O
).	O

The	O
impact	O
of	O
the	O
contact	O
tracing	O
data	O
was	O
likely	O
due	O
to	O
the	O
small	O
number	O
of	O
SARS	B-DISO
cases	O
relative	O
to	O
the	O
size	O
of	O
the	O
contact	O
tracing	O
sample	O
.	O

Finally	O
,	O
we	O
provide	O
a	O
quarantine	O
and	O
isolation	O
decision	O
tree	O
to	O
assist	O
policy	O
makers	O
and	O
public	O
health	O
officials	O
in	O
applying	O
medically	O
defensible	O
,	O
outcomes	O
-	O
based	O
data	O
and	O
legal	O
authorities	O
to	O
optimize	O
management	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
A	O
lesson	O
learned	O
from	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
caused	O
by	O
novel	O
Corona	O
virus	O
hit	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
)	O
and	O
resulted	O
in	O
hundreds	O
of	O
mortality	O
and	O
morbidity	O
,	O
fears	O
and	O
psychosocial	O
stress	O
among	O
population	O
,	O
economic	O
loss	O
and	O
major	O
political	O
change	O
at	O
Ministry	O
of	O
Health	O
(	O
MoH	O
).	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
from	O
the	O
Middle	O
East	O
and	O
the	O
discovery	O
of	O
the	O
virus	O
from	O
dromedary	O
camels	O
have	O
boosted	O
interest	O
in	O
the	O
search	O
for	O
novel	O
viruses	O
in	O
dromedaries	O
.	O

Similar	O
to	O
other	O
members	O
of	O
the	O
genus	O
Enterovirus	O
,	O
the	O
5	O
'	O
UTR	O
of	O
DcEV	O
possessed	B-DISO
a	O
putative	O
type	O
I	O
internal	O
ribosome	O
entry	O
site	O
.	O

TITLE	O
:	O
Asymptomatic	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
rabbits	O
.	O

Lung	O
involvement	O
can	O
vary	O
from	O
subtle	O
clinical	O
features	O
to	O
deadly	O
pulmonary	B-DISO
hemorrhage	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
the	O
current	O
hot	B-DISO
spots	I-DISO
for	O
MERS	O
CoV	O
a	O
sizeable	O
portion	O
of	O
the	O
population	O
is	O
from	O
other	O
countries	O
,	O
but	O
many	O
of	O
these	O
countries	O
have	O
yet	O
to	O
detect	O
any	O
importation	O
of	O
MERS	O
CoV	O
.	O
To	O
assess	O
the	O
disease	B-DISO
transmission	I-DISO
in	O
these	O
countries	O
,	O
supplemental	O
surveillance	O
strategies	O
are	O
urgently	O
needed	O
beyond	O
the	O
currently	O
recommended	O
measures	O
.	O

A	O
few	O
strategies	O
to	O
address	O
the	O
situation	O
are	O
:	O
(	O
i	O
)	O
improving	O
preparedness	O
with	O
enhanced	O
surveillance	O
in	O
particular	O
regions	O
;	O
(	O
ii	O
)	O
targeting	O
certain	O
sentinel	O
groups	O
for	O
surveillance	O
in	O
hot	B-DISO
spots	I-DISO
;	O
and	O
(	O
iii	O
)	O
limited	O
use	O
of	O
serosurveillance	O
.	O

Influenza	B-DISO
virus	O
B	O
,	O
enterovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
coronavirus	O
and	O
parainfluenza	B-DISO
virus	O
4	O
were	O
rarely	O
detected	O
(<	O
1	O
%).	O

IFV	O
A	O
pneumonia	B-DISO
are	O
usually	O
found	O
in	O
patients	O
older	O
than	O
45	O
years	O
,	O
while	O
,	O
adenovirus	B-DISO
pneumonia	B-DISO
are	O
common	O
in	O
adolescents	O
and	O
young	O
adults	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
coronavirus	O
that	O
induces	O
persistent	O
diarrhoea	B-DISO
in	O
swine	O
,	O
resulting	O
in	O
severe	O
economic	O
losses	O
in	O
swine	O
-	O
producing	O
countries	O
.	O

They	O
were	O
more	O
likely	O
to	O
have	O
complications	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
liver	O
and	O
renal	O
dysfunctions	O
,	O
and	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
death	O
.	O

Aerosol	O
transmission	O
is	O
biologically	O
plausible	O
when	O
infectious	B-DISO
aerosols	O
are	O
generated	O
by	O
or	O
from	O
an	O
infectious	B-DISO
person	O
,	O
the	O
pathogen	O
remains	O
viable	O
in	O
the	O
environment	O
for	O
some	O
period	O
of	O
time	O
,	O
and	O
the	O
target	O
tissues	O
in	O
which	O
the	O
pathogen	O
initiates	O
infection	B-DISO
are	O
accessible	O
to	O
the	O
aerosol	O
.	O

Biological	O
plausibility	O
of	O
aerosol	O
transmission	O
is	O
evaluated	O
for	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
and	O
norovirus	O
and	O
discussed	O
for	O
Mycobacterium	O
tuberculosis	B-DISO
,	O
influenza	B-DISO
,	O
and	O
Ebola	O
virus	O
.	O

ABSTRACT	O
:	O
Bacterial	B-DISO
pneumonia	I-DISO
(	O
BP	O
)	O
is	O
an	O
inflammation	B-DISO
of	O
the	O
lower	O
airways	O
and	O
lung	O
parenchyma	O
secondary	O
to	O
bacterial	B-DISO
infection	I-DISO
.	O

Twenty	O
household	O
dogs	O
with	O
BP	O
caused	O
by	O
opportunistic	O
bacteria	O
and	O
13	O
dogs	O
with	O
chronic	O
(>	O
30	O
days	O
)	O
tracheobronchitis	B-DISO
caused	O
by	O
Bordetella	O
bronchiseptica	O
(	O
BBTB	O
).	O

We	O
examined	O
physiological	O
and	O
ventilator	O
parameters	O
in	O
association	O
with	O
the	O
PaO₂	O
/	O
FiO₂	O
at	O
ARDS	B-DISO
onset	O
,	O
after	O
24	O
h	O
of	O
usual	O
care	O
and	O
at	O
24	O
h	O
under	O
a	O
SVS	O
.	O

The	O
CCL2	O
G	O
-	O
2518A	O
and	O
MBL	O
codon	O
54	O
variant	O
have	O
a	O
significantly	O
cumulative	O
effect	O
on	O
increased	O
risk	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
How	O
to	O
monitor	O
a	O
recruitment	B-DISO
maneuver	O
at	O
the	O
bedside	O
.	O

ABSTRACT	O
:	O
To	O
provide	O
an	O
overview	O
on	O
most	O
recent	O
knowledge	O
on	O
methods	O
currently	O
available	O
for	O
monitoring	O
of	O
recruitment	B-DISO
maneuvers	O
at	O
the	O
bedside	O
.	O

Despite	O
being	O
part	O
of	O
a	O
multifaceted	O
approach	O
of	O
protective	O
ventilation	O
,	O
recruitment	B-DISO
maneuvers	O
are	O
supposed	O
to	O
decrease	O
mortality	O
and	O
improve	O
postoperative	O
outcomes	O
.	O

In	O
addition	O
,	O
although	O
recruitment	B-DISO
maneuvers	O
are	O
being	O
increasingly	O
used	O
,	O
there	O
remains	O
a	O
great	O
deal	O
of	O
uncertainty	O
regarding	O
the	O
precise	O
way	O
to	O
evaluate	O
the	O
effect	O
of	O
recruitment	B-DISO
.	O

An	O
effective	O
recruitment	B-DISO
maneuver	O
is	O
expected	O
to	O
reinflate	O
nonaerated	O
lung	O
units	O
.	O

Fifty	O
-	O
four	O
close	O
contacts	O
of	O
these	O
patients	O
were	O
screened	O
for	O
MERS	O
CoV	O
.	O
Six	O
patients	O
with	O
MERS	O
CoV	O
infection	B-DISO
were	O
included	O
in	O
this	O
study	O
.	O

Results	O
Ten	O
trials	O
of	O
FOB	O
-	O
BAL	O
using	O
an	O
LMA	O
and	O
CPAP	O
were	O
performed	O
in	O
nine	O
patients	O
with	O
severe	O
acute	O
hypoxaemia	O
associated	O
with	O
diffuse	O
lung	O
infiltrates	B-DISO
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
:	O
Etiology	O
,	O
epidemiology	O
,	O
pathogenesis	B-DISO
and	O
immunoprophylaxis	O
.	O

TITLE	O
:	O
Serotype	O
shift	O
of	O
a	O
793	O
/	O
B	O
genotype	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
by	O
natural	O
recombination	O
.	O

ABSTRACT	O
:	O
The	O
ΔWBC	O
(	O
the	O
ratio	O
between	O
DIFF	O
and	O
BASO	O
counts	O
of	O
the	O
Sysmex	O
XT	O
-	O
2000iV	O
),	O
hereafter	O
defined	O
as	O
ΔTNC	O
(	O
total	O
nucleated	O
cells	O
),	O
is	O
high	O
in	O
effusions	B-DISO
due	O
to	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
as	O
cells	O
are	O
entrapped	O
in	O
fibrin	O
clots	B-DISO
formed	O
in	O
the	O
BASO	O
reagent	O
.	O

The	O
ΔTNC	O
was	O
higher	O
(	O
P	O
<	O
.	O
001	O
),	O
and	O
BASO	O
and	O
DIFF	O
counts	O
were	O
lower	O
(	O
P	O
<	O
.	O
001	O
and	O
P	O
<	O
.	O
05	O
)	O
in	O
FIP	B-DISO
than	O
in	O
non	O
-	O
FIP	B-DISO
cats	O
.	O

TITLE	O
:	O
An	O
isolated	O
outbreak	O
of	O
influenza	B-DISO
A	O
H1N1	O
in	O
a	O
haematological	O
department	O
during	O
post	O
-	O
pandemic	O
period	O
.	O

For	O
the	O
systemic	O
response	O
,	O
we	O
obtained	O
plasma	O
levels	O
of	O
Tumor	B-DISO
Necrosis	I-DISO
Factor	O
-	O
α	O
,	O
Interleukin	O
-	O
6	O
and	O
Matrix	O
-	O
Metalloprotease	O
-	O
9	O
by	O
ELISA	O
.	O

This	O
report	O
describes	O
the	O
clinical	O
course	O
of	O
four	O
consecutive	O
patients	O
with	O
blastomycosis	B-DISO
-	O
related	O
ARDS	B-DISO
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
during	O
2009	O
-	O
2014	O
.	O

This	O
report	O
describes	O
the	O
successful	O
application	O
of	O
ECMO	O
as	O
rescue	O
therapy	O
in	O
aid	O
of	O
four	O
patients	O
with	O
refractory	O
blastomycosis	B-DISO
-	O
associated	O
ARDS	B-DISO
.	O

In	O
light	O
of	O
the	O
recent	O
surge	O
in	O
reported	O
infections	B-DISO
we	O
have	O
developed	O
asymmetric	O
five	O
-	O
primer	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
RT	O
-	O
LAMP	O
)	O
assays	O
for	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
Isothermal	O
amplification	B-DISO
assays	O
will	O
facilitate	O
the	O
development	O
of	O
portable	O
point	O
-	O
of	O
-	O
care	O
diagnostics	O
that	O
are	O
crucial	O
for	O
management	O
of	O
emerging	O
infections	B-DISO
.	O

The	O
resulting	O
assays	O
could	O
detect	O
0	O
.	O
02	O
to	O
0	O
.	O
2	O
plaque	B-DISO
forming	O
units	O
(	O
PFU	O
)	O
(	O
5	O
to	O
50	O
PFU	O
/	O
ml	O
)	O
of	O
MERS	O
-	O
CoV	O
in	O
infected	O
cell	O
culture	O
supernatants	O
within	O
30	O
to	O
50	O
min	O
and	O
did	O
not	O
cross	O
-	O
react	O
with	O
common	O
human	O
respiratory	O
pathogens	O
.	O

A	O
comparison	O
was	O
made	O
between	O
those	O
patients	O
that	O
met	O
urine	O
SIADH	B-DISO
criteria	O
and	O
those	O
who	O
did	O
not	O
.	O

Patients	O
in	O
this	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
pneumonia	B-DISO
and	O
/	O
or	O
atelectasis	B-DISO
on	O
chest	O
X	O
-	O
Ray	O
(	O
21	O
.	O
7	O
%	O
vs	O
.	O
1	O
.	O
9	O
%,	O
P	O
=.	O
002	O
),	O
worse	O
response	O
to	O
bronchodilator	O
treatment	O
with	O
nebulized	O
adrenaline	O
(	O
69	O
,	O
5	O
%	O
vs	O
.	O
28	O
,	O
1	O
%,	O
P	O
=.	O
016	O
),	O
more	O
need	O
for	O
respiratory	O
assistance	O
(	O
high	O
flow	O
oxygen	O
therapy	O
(	O
17	O
.	O
4	O
%	O
vs	O
.	O
7	O
.	O
7	O
%,	O
p	O
=.	O
016	O
),	O
or	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
(	O
13	O
%	O
vs	O
.	O
5	O
.	O
8	O
%,	O
P	O
=.	O
034	O
),	O
and	O
more	O
admissions	O
to	O
the	O
PICU	O
(	O
26	O
.	O
1	O
%	O
vs	O
.	O
6	O
.	O
8	O
%,	O
P	O
=.	O
007	O
).	O

Patients	O
in	O
this	O
group	O
had	O
a	O
higher	O
incidence	O
of	O
pneumonia	B-DISO
and	O
/	O
or	O
atelectasis	B-DISO
on	O
chest	O
X	O
-	O
Ray	O
(	O
21	O
.	O
7	O
%	O
vs	O
.	O
1	O
.	O
9	O
%,	O
P	O
=.	O
002	O
),	O
worse	O
response	O
to	O
bronchodilator	O
treatment	O
with	O
nebulized	O
adrenaline	O
(	O
69	O
,	O
5	O
%	O
vs	O
.	O
28	O
,	O
1	O
%,	O
P	O
=.	O
016	O
),	O
more	O
need	O
for	O
respiratory	O
assistance	O
(	O
high	O
flow	O
oxygen	O
therapy	O
(	O
17	O
.	O
4	O
%	O
vs	O
.	O
7	O
.	O
7	O
%,	O
p	O
=.	O
016	O
),	O
or	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
(	O
13	O
%	O
vs	O
.	O
5	O
.	O
8	O
%,	O
P	O
=.	O
034	O
),	O
and	O
more	O
admissions	O
to	O
the	O
PICU	O
(	O
26	O
.	O
1	O
%	O
vs	O
.	O
6	O
.	O
8	O
%,	O
P	O
=.	O
007	O
).	O

Two	O
hundred	O
and	O
sixteen	O
consecutive	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
underwent	O
transesophageal	O
echocardiography	O
with	O
modified	O
gelatine	O
contrast	O
.	O

Hypertension	B-DISO
and	O
cardiogenic	B-DISO
shock	I-DISO
were	O
associated	O
with	O
the	O
emergence	O
of	O
moderate	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
postoperatively	O
(	O
P	O
=	O
0	O
.	O
02	O
and	O
P	O
=	O
0	O
.	O
019	O
,	O
respectively	O
)	O
and	O
were	O
risk	O
factors	O
for	O
this	O
dysfunction	O
(	O
P	O
=	O
0	O
.	O
0023	O
and	O
P	O
=	O
0	O
.	O
0017	O
,	O
respectively	O
).	O

The	O
approach	O
we	O
describe	O
can	O
therefore	O
provide	O
crucial	O
information	O
about	O
novel	O
infections	B-DISO
before	O
serological	O
surveys	O
and	O
other	O
detailed	O
analyses	O
are	O
available	O
.	O

RESULTS	O
:	O
Eight	O
patients	O
were	O
admitted	O
to	O
the	O
ICU	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
characteristics	O
of	O
the	O
serious	O
complications	O
of	O
17	O
cases	O
with	O
measles	B-DISO
in	O
ICU	O
.	O

TITLE	O
:	O
Scrub	B-DISO
typhus	I-DISO
:	O
Clinical	O
spectrum	O
and	O
outcome	O
.	O

Scrub	B-DISO
typhus	I-DISO
is	O
an	O
important	O
differential	O
diagnosis	O
in	O
a	O
patients	O
having	O
fever	O
with	O
thrombocytopenia	O
.	O

ABSTRACT	O
:	O
Guillain	B-DISO
-	I-DISO
Barre	I-DISO
syndrome	I-DISO
(	O
GBS	B-DISO
)	O
is	O
a	O
common	O
cause	O
of	O
acute	O
flaccid	B-DISO
paralysis	I-DISO
in	O
children	O
.	O

GBS	B-DISO
was	O
suspected	O
.	O

The	O
difficulties	O
with	O
the	O
diagnosis	O
and	O
management	O
of	O
this	O
severe	O
and	O
life	O
-	O
threatening	O
condition	B-DISO
are	O
discussed	O
.	O

Axonal	O
variants	O
of	O
GBS	B-DISO
although	O
rare	O
cause	O
significant	O
morbidity	O
in	O
children	O
.	O

Patients	O
often	O
suffer	B-DISO
from	O
opportunistic	O
respiratory	B-DISO
infections	I-DISO
;	O
chronic	O
pulmonary	O
changes	O
have	O
been	O
found	O
in	O
advanced	O
disease	O
.	O

No	O
other	O
infectious	B-DISO
agents	O
were	O
found	O
.	O

A	O
total	O
of	O
968	O
serum	O
samples	O
were	O
tested	O
including	O
samples	O
with	O
confirmed	O
infection	B-DISO
with	O
PDCoV	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
or	O
porcine	O
respiratory	O
coronavirus	O
.	O

After	O
an	O
epidemiologic	O
investigation	O
,	O
an	O
outsourced	O
,	O
pelleted	O
piglet	O
diet	O
was	O
identified	O
for	O
assessment	O
,	O
and	O
a	O
bioassay	O
,	O
where	O
naïve	O
piglets	O
were	O
fed	O
the	O
suspected	O
feed	O
pellets	O
,	O
was	O
initiated	O
to	O
test	O
the	O
pellets	O
for	O
infectious	B-DISO
PEDV	O
.	O

RESULTS	O
:	O
PEDV	O
was	O
isolated	O
from	O
a	O
pig	O
with	O
diarrhea	B-DISO
and	O
complete	O
genome	O
sequencing	O
found	O
>	O
99	O
%	O
nucleotide	O
identity	O
to	O
other	O
U	O
.	O
S	O
.	O
PEDV	O
.	O

In	O
this	O
32	O
-	O
month	O
prospective	O
multicenter	O
study	O
,	O
195	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
were	O
assessed	O
using	O
echocardiography	O
during	O
the	O
first	O
48	O
h	O
of	O
admission	O
(	O
age	O
:	O
56	O
(	O
SD	O
:	O
15	O
)	O
years	O
;	O
Simplified	O
Acute	O
Physiology	O
Score	O
:	O
46	O
(	O
17	O
);	O
PaO2	O
/	O
FiO2	O
:	O
115	O
(	O
39	O
);	O
VT	O
:	O
6	O
.	O
5	O
(	O
1	O
.	O
7	O
)	O
mL	O
/	O
kg	O
;	O
PEEP	O
:	O
11	O
(	O
3	O
)	O
cmH2O	O
;	O
driving	O
pressure	O
:	O
15	O
(	O
5	O
)	O
cmH2O	O
).	O

RESULTS	O
:	O
Within	O
24	O
hours	O
after	O
the	O
onset	O
of	O
ARDS	B-DISO
,	O
the	O
changes	O
of	O
peripheral	O
circulating	O
Th17	O
and	O
Treg	O
cell	O
frequencies	O
gradually	O
increased	O
from	O
mild	O
to	O
severe	O
ARDS	B-DISO
.	O

Low	O
albumin	O
levels	O
had	O
monitoring	O
value	O
for	O
ARDS	B-DISO
severity	O
on	O
all	O
study	O
days	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
,	O
AUROC	O
,	O
0	O
.	O
62	O
-	O
0	O
.	O
82	O
,	O
P	O
<	O
0	O
.	O
001	O
-	O
0	O
.	O
03	O
),	O
whereas	O
supranormal	O
CRP	O
levels	O
performed	O
less	O
.	O

The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
detect	O
and	O
identify	O
CoVs	O
from	O
frugivorous	O
bats	O
in	O
Madagascar	O
to	O
evaluate	O
the	O
risk	O
of	O
human	O
infection	B-DISO
from	O
infected	O
bats	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
decades	O
,	O
Porcine	O
circovirus	O
2	O
(	O
PCV2	O
)	O
infection	B-DISO
has	O
been	O
recognized	O
as	O
the	O
causative	O
agent	O
of	O
postweaning	O
multisystemic	O
wasting	B-DISO
syndrome	I-DISO
,	O
and	O
has	O
become	O
a	O
threat	O
to	O
the	O
swine	O
industry	O
.	O

PCR	O
was	O
used	O
to	O
identify	O
the	O
pathogen	O
and	O
we	O
tested	O
for	O
eight	O
viruses	O
(	O
HEV	O
,	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
,	O
PCV2	O
,	O
Classical	B-DISO
swine	I-DISO
fever	I-DISO
virus	O
,	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
,	O
Transmissible	O
gastroenteritis	B-DISO
coronavirus	O
,	O
Porcine	O
parvovirus	B-DISO
and	O
Pseudorabies	B-DISO
virus	O
)	O
that	O
are	O
prevalent	O
in	O
Chinese	O
pig	O
farms	O
.	O

In	O
vivo	O
,	O
SD	O
rats	O
were	O
pretreatment	O
with	O
c26	O
for	O
seven	O
days	O
and	O
then	O
intratracheally	O
injected	O
with	O
LPS	B-DISO
to	O
induce	O
ALI	O
.	O

This	O
study	O
aims	O
to	O
reveal	O
the	O
etiological	O
role	O
of	O
TGEV	O
in	O
piglet	O
diarrhea	B-DISO
via	O
molecular	O
characterization	O
and	O
phylogenetic	O
analysis	O
.	O

All	O
respiratory	O
viruses	O
were	O
detected	O
in	O
the	O
transition	B-DISO
month	O
between	O
the	O
rainy	O
and	O
dry	O
seasons	O
.	O

ABSTRACT	O
:	O
Alveolar	O
hemorrhage	B-DISO
occurs	O
relatively	O
rarely	O
and	O
is	O
a	O
therapeutic	O
emergency	B-DISO
because	O
it	O
can	O
quickly	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
which	O
can	O
be	O
fatal	O
.	O

In	O
patients	O
with	O
an	O
immune	B-DISO
disease	I-DISO
that	O
can	O
lead	O
to	O
an	O
alveolar	O
hemorrhage	B-DISO
,	O
removing	O
any	O
source	O
of	O
infection	B-DISO
is	O
the	O
first	O
priority	O
.	O

The	O
primary	O
goal	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
incidence	O
and	O
extent	O
of	O
hypoxemia	O
in	O
intubated	O
trauma	O
patients	O
who	O
develop	O
early	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
VAP	O
)	O
secondary	O
to	O
HSB	O
.	O

We	O
next	O
demonstrated	O
that	O
enzymatic	O
removal	O
of	O
the	O
highly	O
sulfated	O
domain	O
of	O
heparan	O
sulfate	O
by	O
heparinase	O
I	O
treatment	O
inhibited	O
PEDV	O
infection	B-DISO
.	O

Age	O
>	O
50	O
years	O
and	O
diabetes	B-DISO
mellitus	I-DISO
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
mortality	O
(	O
OR	O
=	O
26	O
.	O
1	O
;	O
95	O
%	O
CI	O
3	O
.	O
58	O
-	O
190	O
.	O
76	O
;	O
P	O
=	O
0	O
.	O
001	O
and	O
OR	O
=	O
15	O
.	O
74	O
;	O
95	O
%	O
CI	O
2	O
.	O
46	O
-	O
100	O
.	O
67	O
;	O
P	O
=	O
0	O
.	O
004	O
,	O
respectively	O
).	O

In	O
a	O
murine	O
model	O
of	O
intratracheal	O
lipopolysaccharide	O
challenge	O
,	O
dietary	O
-	O
induced	O
vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
resulted	O
in	O
exaggerated	O
alveolar	O
inflammation	B-DISO
,	O
epithelial	O
damage	O
and	O
hypoxia	B-DISO
.	O

ABSTRACT	O
:	O
New	O
variants	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
),	O
which	O
emerged	O
in	O
Taiwan	O
in	O
late	O
2013	O
,	O
have	O
caused	O
a	O
high	O
morbidity	O
and	O
mortality	O
in	O
neonatal	O
piglets	O
.	O

The	O
development	O
of	O
a	O
novel	O
vaccine	O
based	O
on	O
the	O
Taiwan	O
or	O
the	O
global	O
non	O
-	O
S	O
INDEL	O
strains	O
may	O
be	O
contributive	O
to	O
the	O
control	O
of	O
the	O
current	O
global	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
outbreaks	O
.	O

TITLE	O
:	O
Acquired	O
factor	O
V	O
inhibitor	O
in	O
a	O
patient	O
receiving	O
venous	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
Legionella	B-DISO
pneumonia	I-DISO
.	O

A	O
response	O
was	O
required	O
to	O
reduce	O
possible	O
disease	B-DISO
transmission	I-DISO
between	O
the	O
hospital	O
and	O
university	O
.	O

This	O
study	O
revealed	O
a	O
new	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
P6	O
in	O
limiting	O
the	O
IFN	O
signaling	O
to	O
promote	O
SARS	B-DISO
-	O
CoV	O
survival	O
in	O
host	O
cells	O
.	O

Further	O
synthesis	O
of	O
various	O
triazole	O
bioisosteres	O
demonstrated	O
clear	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
in	O
which	O
the	O
antiviral	O
activity	O
against	O
WNV	B-DISO
and	O
DENV	O
hinges	O
largely	O
on	O
both	O
the	O
5	O
'-	O
silyl	O
group	O
and	O
the	O
substituent	O
of	O
3	O
'-	O
triazole	O
or	O
its	O
bioisosteres	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
an	O
endemic	B-DISO
disease	I-DISO
of	O
chickens	O
and	O
a	O
major	O
contributor	O
to	O
economic	O
losses	O
for	O
the	O
poultry	O
industry	O
despite	O
vaccination	O
.	O

TITLE	O
:	O
Tuberculous	B-DISO
lymphadenitis	I-DISO
and	O
syndrome	B-DISO
of	I-DISO
inappropriate	I-DISO
antidiuresis	I-DISO
,	O
improbable	O
partners	O
.	O

The	O
hyponatraemia	O
study	O
was	O
compatible	O
with	O
syndrome	B-DISO
of	I-DISO
inappropriate	I-DISO
antidiuresis	I-DISO
(	O
SIAD	O
)	O
and	O
an	O
association	O
with	O
the	O
respiratory	O
problem	O
was	O
initially	O
assumed	O
.	O

Here	O
,	O
we	O
report	O
the	O
discovery	O
and	O
genetic	O
characterization	O
of	O
a	O
novel	O
virus	O
present	O
in	O
cattle	O
with	O
respiratory	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Tumor	B-DISO
lysis	I-DISO
syndrome	I-DISO
is	O
a	O
serious	O
and	O
dangerous	O
complication	B-DISO
usually	O
associated	O
with	O
antiblastic	O
treatment	O
in	O
some	O
malignancies	B-DISO
characterized	O
by	O
high	O
cell	O
turn	O
-	O
over	O
.	O

Renal	O
damage	O
can	O
be	O
followed	O
by	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
weight	O
gain	O
,	O
progressive	O
liver	O
impairment	B-DISO
,	O
overproduction	O
of	O
cytokines	O
,	O
and	O
subsequent	O
maintenance	O
of	O
multi	O
-	O
organ	O
damage	O
.	O

In	O
addition	O
,	O
the	O
ferret	O
was	O
quiet	O
,	O
in	O
poor	O
body	O
condition	B-DISO
,	O
and	O
dehydrated	B-DISO
.	O

Whole	O
body	O
radiographs	O
showed	O
multifocal	O
thoracic	B-DISO
nodular	O
disease	O
,	O
splenomegaly	O
,	O
and	O
renomegaly	O
.	O

In	O
addition	O
,	O
results	O
indicate	O
the	O
existence	O
of	O
age	O
-	O
dependent	O
changes	O
in	O
key	O
components	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
involved	O
in	O
the	O
inflammatory	B-DISO
response	I-DISO
.	O

Pulmonary	B-DISO
inflammation	I-DISO
seems	O
relatively	O
suppressed	O
in	O
infants	O
/	O
juveniles	O
,	O
whereas	O
in	O
the	O
middle	O
aged	O
/	O
elderly	O
,	O
the	O
inflammatory	B-DISO
response	I-DISO
seems	O
delayed	O
but	O
aggravated	O
.	O

The	O
impact	O
of	O
modern	O
iLA	O
and	O
ECMO	O
systems	O
on	O
coagulation	O
allows	O
comparatively	O
safe	O
long	O
-	O
term	O
treatment	O
of	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Hospitals	O
have	O
implemented	O
measures	O
related	O
to	O
healthcare	O
-	O
associated	O
infections	B-DISO
.	O

Of	O
which	O
,	O
the	O
syndrome	B-DISO
of	O
delayed	O
post	O
hypoxic	B-DISO
encephalopathy	I-DISO
(	O
DPHL	O
)	O
that	O
follows	O
an	O
acute	O
drug	O
overdose	O
,	O
in	O
addition	O
to	O
""""	O
chasing	O
the	O
dragon	O
""""	O
toxicity	O
which	O
results	O
from	O
chronic	O
heroin	O
vapor	O
inhalation	O
remain	O
the	O
most	O
commonly	O
described	O
syndromes	B-DISO
of	O
toxic	O
leukoencephalopathy	B-DISO
.	O

The	O
patient	O
remained	O
in	O
a	O
comatose	B-DISO
state	O
with	O
no	O
signs	O
of	O
neurologic	O
recovery	O
until	O
he	O
died	O
few	O
weeks	O
later	O
following	O
an	O
increase	O
in	O
the	O
brain	B-DISO
edema	I-DISO
and	O
herniation	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)-	O
NL63	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
human	O
bocavirus	O
(	O
Boca	B-DISO
),	O
human	O
polyomavirus	O
KI	O
(	O
KIV	O
)	O
and	O
human	O
polyomavirus	O
WU	O
(	O
WUV	O
)	O
in	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
RTI	B-DISO
)	O
in	O
Kuwait	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
binding	O
of	O
the	O
S1	O
domain	O
of	O
hCoV	O
-	O
HKU1	O
spike	O
to	O
a	O
panel	O
of	O
cells	O
and	O
found	O
that	O
the	O
S1	O
could	O
specifically	O
bind	O
on	O
the	O
cell	O
surface	O
of	O
a	O
human	O
rhabdomyosarcoma	B-DISO
cell	O
line	O
,	O
RD	O
.	O

When	O
compared	O
to	O
influenza	B-DISO
A	O
virus	O
NS1	B-DISO
protein	O
,	O
EBOV	O
VP35	O
showed	O
improved	O
inhibition	O
of	O
viral	O
dsRNA	O
-	O
based	O
IFN	O
-	O
β	O
induction	O
.	O

A	O
previous	O
study	O
identified	O
the	O
compound	O
ML188	O
,	O
also	O
termed	O
16R	O
,	O
as	O
an	O
inhibitor	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
3CL	O
(	O
pro	O
).	O

At	O
present	O
it	O
is	O
unknown	O
whether	O
the	O
risk	O
for	O
respiratory	B-DISO
disease	I-DISO
(	O
BRD	O
)	O
or	O
neonatal	B-DISO
calf	I-DISO
diarrhea	I-DISO
(	O
NCD	O
)	O
in	O
the	O
veal	O
herd	O
is	O
associated	O
with	O
total	O
immunoglobulin	O
(	O
Ig	O
)	O
and	O
/	O
or	O
on	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

ABSTRACT	O
:	O
Our	O
study	O
demonstrated	O
potential	O
mechanisms	O
by	O
which	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
induces	O
greater	O
disease	O
severity	O
of	O
nursing	O
vs	O
.	O
weaned	O
conventional	O
pigs	O
.	O

Severe	O
watery	B-DISO
diarrhea	I-DISO
and	O
atrophic	B-DISO
enteritis	B-DISO
with	O
moderate	O
to	O
high	O
PEDV	O
RNA	O
titers	O
in	O
feces	O
(	O
7	O
.	O
5	O
-	O
12	O
.	O
2	O
log10	O
GE	O
/	O
ml	O
)	O
and	O
low	O
viral	O
RNA	O
titers	O
in	O
serum	O
(	O
5	O
.	O
6	O
-	O
8	O
.	O
6	O
log10	O
GE	O
/	O
ml	O
)	O
were	O
observed	O
in	O
all	O
inoculated	O
nursing	O
piglets	O
at	O
PIDs	O
1	O
-	O
5	O
.	O

Biologic	O
mediators	O
that	O
promote	O
crypt	O
stem	O
cell	O
regeneration	O
would	O
be	O
targets	O
to	O
improve	O
the	O
intestinal	O
epithelium	O
renewal	O
during	O
PEDV	O
infection	B-DISO
.	O

Under	O
VCV	O
mode	O
,	O
compared	O
with	O
the	O
initial	O
level	O
,	O
38	O
.	O
6	O
%	O
and	O
37	O
.	O
5	O
%	O
increase	O
in	O
peak	O
airway	O
pressure	O
(	O
PAP	B-DISO
)	O
were	O
found	O
at	O
1	O
min	O
and	O
10	O
min	O
,	O
respectively	O
.	O

We	O
used	O
a	O
mouse	O
model	O
of	O
ALI	O
induced	O
by	O
intratracheal	O
administration	O
of	O
sterile	B-DISO
bacterial	O
wall	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
to	O
investigate	O
the	O
changes	O
in	O
innate	O
lung	O
microbiota	O
and	O
study	O
microbial	O
community	O
reaction	O
to	O
lung	B-DISO
inflammation	I-DISO
and	O
barrier	O
dysfunction	O
induced	O
by	O
endotoxin	O
insult	O
.	O

To	O
evaluate	O
the	O
effectiveness	O
of	O
HFOV	O
in	O
patients	O
with	O
early	O
phase	O
of	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

The	O
authors	O
compared	O
HFOV	O
with	O
LPSV	O
in	O
adult	O
patients	O
with	O
the	O
early	O
phase	O
of	O
ARDS	B-DISO
who	O
received	O
mechanical	O
ventilation	O
less	O
than	O
72	O
hours	O
and	O
had	O
moderate	O
to	O
severe	O
hypoxemia	O
(	O
PaO	O
/	O
FiO2	O
ratio	O
less	O
than	O
or	O
equal	O
150	O
).	O

Between	O
June	O
2010	O
and	O
February	O
2014	O
,	O
49	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
were	O
included	O
.	O

The	O
presence	O
of	O
hemodynamic	B-DISO
instability	I-DISO
was	O
not	O
different	O
in	O
both	O
groups	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
the	O
most	O
severe	O
lung	O
inflammatory	O
manifestation	O
and	O
has	O
no	O
effective	O
therapy	O
nowadays	O
.	O

TITLE	O
:	O
Psychological	B-DISO
autopsy	O
and	O
necropsy	O
of	O
an	O
unusual	O
case	O
of	O
suicide	O
by	O
intravenous	O
toluene	O
.	O

ABSTRACT	O
:	O
Toluene	O
(	O
methylbenzene	O
;	O
volatile	O
hydrocarbon	O
)	O
is	O
an	O
industrial	O
solvent	O
that	O
causes	O
major	O
injury	O
to	O
the	O
lungs	O
;	O
the	O
organ	O
being	O
the	O
first	O
capillary	O
bed	B-DISO
encountered	O
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
suicide	O
by	O
a	O
24	O
-	O
year	O
-	O
old	O
male	O
,	O
paramedical	O
professional	O
,	O
with	O
fatal	O
outcome	O
within	O
16	O
h	O
of	O
intentional	O
,	O
intravenous	O
self	O
-	O
administration	O
of	O
toluene	O
,	O
with	O
clinical	O
presentation	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Relevant	O
literature	O
of	O
toluene	O
poisoning	O
was	O
identified	O
via	O
PubMed	O
,	O
PubChem	O
,	O
ToxNet	O
,	O
Hazardous	O
Substances	O
Data	O
Bank	O
(	O
HSDB	B-DISO
),	O
Embase	O
,	O
and	O
PsycINFO	O
.	O

TITLE	O
:	O
Polytetrafluoroethylene	O
fume	O
-	O
induced	O
pulmonary	B-DISO
edema	I-DISO
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Overheated	O
polytetrafluoroethylene	O
can	O
generate	O
toxic	O
fumes	O
,	O
inducing	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
in	O
some	O
cases	O
.	O

However	O
,	O
neither	O
the	O
etiology	O
nor	O
the	O
radiological	O
features	O
of	O
this	O
condition	B-DISO
have	O
been	O
determined	O
.	O

A	O
chest	O
computed	O
tomographic	O
scan	O
showed	O
massive	O
bilateral	O
patchy	O
consolidations	O
with	O
ground	O
-	O
glass	O
opacities	B-DISO
and	O
peripheral	O
area	O
sparing	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
enteric	O
disease	O
characterized	O
by	O
severe	O
enteritis	B-DISO
,	O
vomiting	B-DISO
and	O
watery	B-DISO
diarrhea	I-DISO
in	O
swine	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
develop	O
a	O
rapid	O
,	O
sensitive	O
,	O
and	O
real	O
-	O
time	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
RT	O
-	O
LAMP	O
)	O
method	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
less	O
equipped	O
laboratories	O
.	O

RESULTS	O
:	O
The	O
optimal	O
reaction	O
condition	B-DISO
of	O
the	O
current	O
real	O
-	O
time	O
RT	O
-	O
LAMP	O
for	O
PEDV	O
was	O
62	O
°	O
C	O
for	O
45	O
min	O
.	O

As	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
is	O
critical	O
for	O
controlling	O
viruses	O
,	O
the	O
nature	O
of	O
this	O
response	O
in	O
bats	O
and	O
how	O
it	O
may	O
differ	O
from	O
that	O
in	O
other	O
mammals	O
are	O
of	O
great	O
interest	O
.	O

ABSTRACT	O
:	O
Arteriviruses	O
are	O
a	O
family	O
of	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
that	O
includes	O
the	O
prototypic	O
equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
and	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
).	O

Owing	O
to	O
the	O
already	O
high	O
level	O
of	O
protection	O
provided	O
by	O
the	O
parental	O
virus	O
,	O
a	O
possible	O
improvement	O
due	O
to	O
inactivation	B-DISO
of	O
PLP2	O
DUB	O
activity	O
could	O
not	O
be	O
detected	O
under	O
these	O
experimental	O
conditions	O
.	O

TITLE	O
:	O
A	O
comprehensive	O
collection	O
of	O
systems	O
biology	O
data	O
characterizing	O
the	O
host	O
response	O
to	O
viral	B-DISO
infection	I-DISO
.	O

DAD	O
is	O
characterized	O
by	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
lung	B-DISO
edema	I-DISO
,	O
inflammation	B-DISO
,	O
hemorrhage	B-DISO
and	O
alveolar	O
epithelial	O
cell	B-DISO
injury	I-DISO
.	O

Clinical	O
data	O
including	O
baseline	O
characteristics	O
,	O
severity	O
of	O
ARDS	B-DISO
,	O
clinical	O
and	O
pathological	O
diagnoses	O
,	O
and	O
survival	O
outcomes	O
were	O
analyzed	O
.	O

Of	O
these	O
101	O
patients	O
,	O
the	O
severity	O
of	O
ARDS	B-DISO
on	O
diagnosis	O
was	O
mild	O
of	O
16	O
.	O
8	O
%,	O
moderate	O
of	O
56	O
.	O
5	O
%	O
and	O
severe	O
of	O
26	O
.	O
7	O
%.	O

The	O
proportion	O
of	O
DAD	O
were	O
76	O
.	O
5	O
%	O
(	O
13	O
/	O
17	O
)	O
in	O
mild	O
,	O
56	O
.	O
1	O
%	O
(	O
32	O
/	O
57	O
)	O
in	O
moderate	O
and	O
44	O
.	O
4	O
%	O
(	O
12	O
/	O
27	O
)	O
in	O
severe	O
ARDS	B-DISO
and	O
there	O
is	O
no	O
significant	O
difference	O
between	O
the	O
three	O
groups	O
(	O
p	O
=	O
0	O
.	O
113	O
).	O

ABSTRACT	O
:	O
The	O
new	O
variants	O
of	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
produce	O
a	O
range	O
of	O
symptoms	O
and	O
cause	O
global	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
.	O

Serology	O
revealed	O
antibodies	O
against	O
canine	O
adenovirus	B-DISO
(	O
71	O
%),	O
canine	O
coronavirus	O
(	O
32	O
%),	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
17	O
%),	O
canine	O
parvovirus	B-DISO
(	O
96	O
%),	O
and	O
Leptospira	O
spp	O
.	O

We	O
did	O
not	O
detect	O
antibodies	O
against	O
Brucella	B-DISO
abortus	I-DISO
/	O
suis	O
or	O
Brucella	B-DISO
canis	I-DISO
.	O

West	O
Nile	O
disease	O
,	O
measles	B-DISO
,	O
pertussis	B-DISO
and	O
tuberculosis	B-DISO
infect	O
South	O
Dakota	O
patients	O
on	O
a	O
yearly	O
basis	O
.	O

Ultrasound	O
has	O
a	O
very	O
high	O
specificity	O
for	O
pneumothorax	B-DISO
.	O

ABSTRACT	O
:	O
Camels	O
carry	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
but	O
little	O
is	O
known	O
about	O
infection	B-DISO
age	O
or	O
prevalence	O
.	O

ABSTRACT	O
:	O
Humans	O
constantly	O
encounter	O
threats	O
from	O
many	O
infectious	B-DISO
,	O
zoonotic	O
,	O
and	O
devastating	O
pathogens	O
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
inflammatory	I-DISO
demyelinating	I-DISO
polyradiculoneuropathy	I-DISO
with	O
persistent	O
weakness	B-DISO
associated	O
with	O
tumor	B-DISO
-	O
like	O
nerve	O
root	O
enlargement	B-DISO
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
tests	O
of	O
sputum	O
and	O
pleural	B-DISO
effusion	I-DISO
samples	O
confirmed	O
adenovirus	B-DISO
serotype	O
7	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
severe	O
infectious	B-DISO
diseases	I-DISO
have	O
been	O
constantly	O
emerging	O
,	O
causing	O
panic	O
in	O
the	O
world	O
.	O

In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
the	O
detrimental	O
effects	O
of	O
C5a	O
in	O
this	O
model	O
are	O
partly	O
mediated	O
through	O
CCR5	O
activation	O
downstream	O
of	O
C5aR1	O
,	O
which	O
may	O
be	O
evaluated	O
for	O
potential	O
therapeutic	O
exploitation	O
in	O
ALI	O
/	O
ARDS	B-DISO
.	O

Poorly	O
controlled	O
thoracotomy	O
pain	O
in	O
the	O
acute	O
phase	O
may	O
also	O
lead	O
to	O
the	O
development	O
of	O
a	O
chronic	B-DISO
pain	I-DISO
syndrome	I-DISO
.	O

Due	O
to	O
hypotension	O
and	O
fluid	O
losses	O
following	O
surgery	O
,	O
he	O
was	O
maintained	O
on	O
intravenous	O
sedato	O
-	O
analgesia	B-DISO
during	O
postoperative	O
mechanical	O
ventilation	O
.	O

However	O
,	O
during	O
weaning	O
from	O
ventilation	O
and	O
sedation	B-DISO
,	O
he	O
indicated	O
severe	B-DISO
pain	I-DISO
in	O
the	O
thoracotomy	O
incision	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
TLR3	O
(-/-),	O
TLR4	O
(-/-),	O
and	O
TRAM	O
(-/-)	O
mice	O
are	O
more	O
susceptible	O
to	O
SARS	B-DISO
-	O
CoV	O
than	O
wild	O
-	O
type	O
mice	O
but	O
experience	O
only	O
transient	O
weight	O
loss	O
with	O
no	O
mortality	O
in	O
response	O
to	O
infection	B-DISO
.	O

In	O
contrast	O
,	O
mice	O
deficient	O
in	O
the	O
TLR3	O
/	O
TLR4	O
adaptor	O
TRIF	O
are	O
highly	O
susceptible	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
showing	O
increased	O
weight	O
loss	O
,	O
mortality	O
,	O
reduced	O
lung	O
function	O
,	O
increased	O
lung	O
pathology	B-DISO
,	O
and	O
higher	O
viral	O
titers	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
TLR	O
adaptor	O
signaling	O
in	O
generating	O
a	O
balanced	O
protective	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
highly	O
pathogenic	O
coronavirus	B-DISO
infections	I-DISO
.	O

Our	O
findings	O
indicate	O
that	O
a	O
balanced	O
immune	O
response	O
operating	O
through	O
both	O
TRIF	O
-	O
driven	O
and	O
MyD88	O
-	O
driven	O
pathways	O
likely	O
provides	O
the	O
most	O
effective	O
host	O
cell	O
intrinsic	O
antiviral	O
defense	O
responses	O
to	O
severe	O
SARS	B-DISO
-	O
CoV	O
disease	O
,	O
while	O
removal	O
of	O
either	O
branch	O
of	O
TLR	O
signaling	O
causes	O
lethal	O
SARS	B-DISO
-	O
CoV	O
disease	O
in	O
our	O
mouse	O
model	O
.	O

RESULTS	O
:	O
Of	O
94	O
stroke	B-DISO
patients	O
with	O
NC	O
,	O
46	O
(	O
49	O
%)	O
had	O
NC	O
with	O
SE	O
and	O
48	O
(	O
51	O
%)	O
had	O
NC	O
without	O
SE	O
.	O

ABSTRACT	O
:	O
Study	O
the	O
circulation	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
during	O
the	O
period	O
from	O
October	O
2012	O
to	O
May	O
2013	O
.	O

Antibodies	O
against	O
influenza	B-DISO
viruses	O
A	O
/	O
H1N1	O
/	O
pdm09	O
California	O
/	O
07	O
/	O
09	O
,	O
epidemic	O
reference	O
strains	O
of	O
influenza	B-DISO
viruses	O
A	O
/	O
H1N1	O
/	O
Brisbane	O
/	O
59	O
/	O
07	O
,	O
A	O
/	O
H3N2	O
/	O
Victoria	O
/	O
361	O
/	O
201	O
1	O
,	O
B	O
/	O
Wisconsin	O
/	O
1	O
/	O
10	O
,	O
against	O
PI	O
viruses	O
type	O
1	O
,	O
2	O
,	O
3	O
were	O
determined	O
in	O
paired	O
sera	O
by	O
HAI	O
.	O

Bocavirus	O
infection	B-DISO
in	O
50	O
%	O
of	O
cases	O
progresses	O
with	O
laryngo	O
-	O
tracheitis	B-DISO
and	O
bronchiolitis	B-DISO
.	O

Etiology	O
of	O
viral	B-DISO
infection	I-DISO
at	O
the	O
debut	O
of	O
CAP	B-DISO
could	O
only	O
be	O
proven	O
using	O
specialized	O
laboratory	O
studies	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
.	O

We	O
tested	O
a	O
recombinant	O
modified	O
vaccinia	B-DISO
virus	O
Ankara	O
(	O
MVA	O
)	O
vaccine	O
expressing	O
full	O
-	O
length	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
by	O
immunizing	O
BALB	O
/	O
c	O
mice	O
with	O
either	O
intramuscular	O
or	O
subcutaneous	O
regimens	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
findings	O
in	O
small	O
RNA	O
-	O
sequencing	O
(	O
Seq	O
)	O
data	O
analysis	O
,	O
we	O
developed	O
highly	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
assays	O
with	O
locked	O
nucleic	O
acid	O
probes	O
targeting	O
the	O
abundantly	O
expressed	O
leader	O
sequences	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
other	O
human	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Tissue	O
factor	O
(	O
TF	O
)	O
and	O
tissue	O
factor	O
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
play	O
a	O
central	O
role	O
in	O
the	O
endothelial	O
permeability	O
regulation	O
and	O
dysfunction	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
sepsis	B-DISO
and	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
).	O

The	O
AUC	O
of	O
TF	O
for	O
the	O
diagnosis	O
of	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
was	O
0	O
.	O
749	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
675	O
-	O
0	O
.	O
822	O
).	O

RESULTS	O
:	O
Patients	O
with	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
showed	O
significantly	O
higher	O
median	O
levels	O
of	O
TF	O
compared	O
with	O
patients	O
without	O
ARDS	B-DISO
(	O
1425	O
.	O
5	O
(	O
1019	O
.	O
9	O
to	O
2595	O
.	O
2	O
)	O
pg	O
/	O
ml	O
vs	O
916	O
.	O
2	O
(	O
724	O
.	O
1	O
to	O
1618	O
.	O
2	O
)	O
pg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
compared	O
with	O
sepsis	B-DISO
patients	O
(	O
943	O
.	O
5	O
(	O
786	O
.	O
4	O
to	O
992	O
.	O
4	O
)	O
pg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
on	O
the	O
day	O
of	O
admission	O
.	O

TITLE	O
:	O
The	O
Serum	O
Profile	O
of	O
Hypercytokinemia	O
Factors	O
Identified	O
in	O
H7N9	O
-	O
Infected	O
Patients	O
can	O
Predict	O
Fatal	B-DISO
Outcomes	I-DISO
.	O

Importantly	O
,	O
SHED	O
-	O
CM	O
attenuated	O
the	O
BLM	B-DISO
-	O
induced	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
and	O
generated	O
an	O
anti	O
-	O
inflammatory	O
/	O
tissue	O
-	O
regenerating	O
environment	O
,	O
accompanied	O
by	O
the	O
induction	O
of	O
anti	O
-	O
inflammatory	O
M2	O
-	O
like	O
lung	O
macrophages	O
.	O

TITLE	O
:	O
Impact	O
of	O
statin	O
therapy	O
on	O
mortality	O
in	O
patients	O
with	O
sepsis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
depends	O
on	O
ARDS	B-DISO
severity	O
:	O
a	O
prospective	O
observational	O
cohort	O
study	O
.	O

Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
scores	O
and	O
the	O
requirements	O
for	O
organ	O
support	O
were	O
evaluated	O
throughout	O
the	O
observational	O
period	O
to	O
assess	O
organ	B-DISO
failure	I-DISO
.	O

Statin	O
therapy	O
improved	O
28	O
-	O
day	O
survival	O
exclusively	O
in	O
the	O
patients	O
with	O
severe	O
ARDS	B-DISO
compared	O
with	O
patients	O
without	O
statin	O
therapy	O
(	O
88	O
.	O
5	O
%	O
and	O
62	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0193	O
).	O

Hepatocyte	O
growth	O
factor	O
(	O
HGF	B-DISO
)/	O
c	O
-	O
Met	O
and	O
transforming	O
growth	O
factor	O
-	O
α	O
(	O
TGF	O
-	O
α	O
)/	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
are	O
well	O
known	O
to	O
regulate	O
repair	O
of	O
damaged	O
alveolar	O
epithelium	O
by	O
stimulating	O
cell	O
migration	O
and	O
proliferation	B-DISO
.	O

The	O
emergence	O
of	O
new	O
infectious	B-DISO
diseases	I-DISO
requires	O
constant	O
monitoring	O
of	O
interventions	O
to	O
reduce	O
the	O
impact	O
of	O
epidemics	O
on	O
population	O
health	O
and	O
health	O
services	O
.	O

Noninvasive	O
positive	O
pressure	O
ventilation	O
can	O
be	O
beneficial	O
in	O
children	O
with	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
particularly	O
in	O
those	O
with	O
milder	O
disease	O
.	O

TITLE	O
:	O
Ventilatory	O
support	O
in	O
children	O
with	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
proceedings	O
from	O
the	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
.	O

The	O
concept	O
of	O
exploring	O
the	O
effects	O
of	O
careful	O
recruitment	B-DISO
maneuvers	O
during	O
conventional	O
ventilation	O
met	O
an	O
agreement	O
level	O
of	O
88	O
%,	O
whereas	O
the	O
use	O
of	O
recruitment	B-DISO
maneuvers	O
during	O
rescue	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
is	O
highly	O
recommended	O
(	O
strong	O
agreement	O
).	O

The	O
concept	O
of	O
exploring	O
the	O
effects	O
of	O
careful	O
recruitment	B-DISO
maneuvers	O
during	O
conventional	O
ventilation	O
met	O
an	O
agreement	O
level	O
of	O
88	O
%,	O
whereas	O
the	O
use	O
of	O
recruitment	B-DISO
maneuvers	O
during	O
rescue	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
is	O
highly	O
recommended	O
(	O
strong	O
agreement	O
).	O

ABSTRACT	O
:	O
To	O
provide	O
an	O
overview	O
of	O
the	O
current	O
literature	O
on	O
pulmonary	O
-	O
specific	O
therapeutic	O
approaches	O
to	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
to	O
determine	O
recommendations	O
for	O
clinical	O
practice	O
and	O
/	O
or	O
future	O
research	O
.	O

TITLE	O
:	O
Emergence	O
of	O
Avian	B-DISO
Infectious	I-DISO
Bronchitis	I-DISO
Virus	O
and	O
its	O
variants	O
need	O
better	O
diagnosis	O
,	O
prevention	O
and	O
control	O
strategies	O
:	O
a	O
global	O
perspective	O
.	O

TITLE	O
:	O
Clonidine	O
withdrawal	B-DISO
induced	O
sympathetic	O
surge	O
.	O

Clonidine	O
withdrawal	B-DISO
as	O
a	O
cause	O
of	O
such	O
response	O
was	O
proposed	O
.	O

Phylogenetically	O
,	O
HCoV	O
-	O
EMC	B-DISO
is	O
clustered	O
with	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
with	O
high	O
bootstrap	O
supports	O
,	O
indicating	O
that	O
HCoV	O
-	O
EMC	B-DISO
is	O
a	O
group	O
C	O
betaCoV	O
.	O
The	O
major	O
difference	O
between	O
HCoV	O
-	O
EMC	B-DISO
and	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
is	O
in	O
the	O
region	O
between	O
S	O
and	O
E	O
,	O
where	O
HCoV	O
-	O
EMC	B-DISO
possesses	B-DISO
five	O
ORFs	O
(	O
NS3a	O
-	O
NS3e	O
)	O
instead	O
of	O
four	O
,	O
with	O
low	O
(	O
31	O
%-	O
62	O
%)	O
amino	O
acid	O
identities	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
key	O
target	O
for	O
the	O
development	O
of	O
SARS	B-DISO
vaccines	O
.	O

Pathway	O
analysis	O
grouped	O
subsets	O
of	O
these	O
factors	O
in	O
specific	O
cellular	O
processes	O
,	O
including	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
and	O
the	O
metabolism	O
of	O
complex	O
lipids	O
,	O
which	O
appear	O
to	O
play	O
a	O
role	O
in	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

The	O
inventory	O
of	O
pro	O
-	O
and	O
antiviral	O
host	O
factors	O
and	O
pathways	O
described	O
here	O
substantiates	O
and	O
expands	O
our	O
understanding	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
may	O
contribute	O
to	O
the	O
identification	O
of	O
novel	O
targets	O
for	O
antiviral	O
therapy	O
.	O

TITLE	O
:	O
Coronavirus	O
nsp10	O
/	O
nsp16	O
Methyltransferase	O
Can	O
Be	O
Targeted	O
by	O
nsp10	O
-	O
Derived	O
Peptide	O
In	O
Vitro	O
and	O
In	O
Vivo	O
To	O
Reduce	O
Replication	O
and	O
Pathogenesis	B-DISO
.	O

As	O
with	O
coronavirus	O
transcripts	O
,	O
arterivirus	O
mRNAs	O
are	O
assumed	O
to	O
possess	B-DISO
a	O
5	O
'	O
cap	B-DISO
although	O
no	O
candidate	O
MTases	O
have	O
been	O
identified	O
thus	O
far	O
.	O

However	O
,	O
no	O
statistically	O
significant	O
similarity	O
was	O
found	O
between	O
nsp12	O
and	O
the	O
twofold	O
larger	O
coronavirus	O
nsp16	O
,	O
nor	O
could	O
we	O
detect	O
MTase	O
activity	O
in	O
biochemical	O
assays	O
using	O
recombinant	O
equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
nsp12	O
.	O

ABSTRACT	O
:	O
Trimodality	O
therapy	O
for	O
resectable	O
esophageal	O
and	O
gastroesophageal	O
junction	O
cancers	B-DISO
utilizing	O
preoperative	O
radiotherapy	O
with	O
concurrent	O
carboplatin	O
and	O
paclitaxel	O
-	O
based	O
chemotherapy	O
is	O
being	O
increasingly	O
utilized	O
secondary	O
to	O
the	O
results	O
of	O
the	O
phase	O
III	O
CROSS	O
trial	O
.	O

Three	O
early	O
postoperative	O
deaths	O
were	O
seen	O
,	O
due	O
in	O
part	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
all	O
three	O
patients	O
received	O
50	O
-	O
50	O
.	O
4	O
Gy	O
.	O

No	O
specific	O
drug	O
treatment	O
exists	O
for	O
MERS	O
and	O
infection	B-DISO
prevention	O
and	O
control	O
measures	O
are	O
crucial	O
to	O
prevent	O
spread	O
in	O
health	O
-	O
care	O
facilities	O
.	O

The	O
most	O
prevalent	O
bacteria	O
were	O
MRSA	B-DISO
and	O
Klebsiella	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Ligand	O
-	O
induced	O
Dimerization	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
Coronavirus	O
nsp5	O
Protease	O
(	O
3CLpro	O
):	O
IMPLICATIONS	O
FOR	O
nsp5	O
REGULATION	O
AND	O
THE	O
DEVELOPMENT	O
OF	O
ANTIVIRALS	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
,	O
including	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
from	O
the	O
β	O
-	O
CoV	O
subgroup	O
,	O
require	O
the	O
proteolytic	O
activity	O
of	O
the	O
nsp5	O
protease	O
(	O
also	O
known	O
as	O
3C	O
-	O
like	O
protease	O
,	O
3CL	O
(	O
pro	O
))	O
during	O
virus	O
replication	O
,	O
making	O
it	O
a	O
high	O
value	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
coronavirus	O
therapeutics	O
.	O

The	O
revised	O
Plan	B-DISO
refines	O
the	O
descriptions	O
in	O
case	O
-	O
finding	O
and	O
establishment	O
of	O
case	O
-	O
monitoring	O
systems	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
how	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
transmitted	B-DISO
from	O
bats	O
to	O
humans	O

These	O
results	O
suggest	O
that	O
CV777	O
stimulates	O
the	O
ability	O
of	O
Mo	O
-	O
DCs	B-DISO
to	O
sample	O
and	O
present	O
antigen	O
.	O

ABSTRACT	O
:	O
Anthrax	B-DISO
is	O
associated	O
with	O
severe	O
vascular	O
leak	O
,	O
which	O
is	O
caused	O
by	O
the	O
bacterial	O
lethal	O
toxin	O
(	O
LeTx	O
).	O

Such	O
a	O
model	O
could	O
be	O
utilized	O
in	O
evaluating	O
and	O
developing	O
better	O
treatment	O
for	O
ALI	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
as	O
other	O
available	O
rodent	O
models	O
do	O
not	O
consistently	O
produce	O
the	O
endothelial	O
permeability	O
that	O
is	O
a	O
major	O
component	O
of	O
ARDS	B-DISO
.	O

Administration	O
of	O
MVs	O
derived	O
from	O
human	O
MSCs	O
improved	O
survival	O
in	O
part	O
through	O
keratinocyte	O
growth	O
factor	O
secretion	O
and	O
decreased	O
the	O
influx	O
of	O
inflammatory	O
cells	O
,	O
cytokines	O
,	O
protein	O
,	O
and	O
bacteria	O
in	O
mice	O
injured	O
with	O
bacterial	B-DISO
pneumonia	I-DISO
.	O

Possible	O
and	O
proven	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
was	O
less	O
common	O
compared	O
to	O
other	O
respiratory	O
viruses	O
except	O
RhV	O
/	O
EnV	O
.	O
CoV	O
is	O
frequently	O
detected	O
in	O
HSCT	O
and	O
hematologic	B-DISO
malignancy	I-DISO
patients	O
in	O
whom	O
suspicion	O
for	O
a	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
exists	O
,	O
but	O
is	O
less	O
likely	O
to	O
progress	O
to	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
than	O
most	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Endothelin	O
-	O
1	O
induces	O
VCAM	O
-	O
1	O
expression	O
-	O
mediated	O
inflammation	B-DISO
via	O
receptor	O
tyrosine	O
kinases	O
and	O
Elk	O
/	O
p300	O
in	O
human	O
tracheal	O
smooth	O
muscle	O
cells	O
.	O

ET	O
-	O
1	O
may	O
affect	O
vessel	O
tone	O
together	O
with	O
lung	O
physiology	O
and	O
pathology	B-DISO
.	O

TITLE	O
:	O
Effects	O
of	O
disinfection	O
on	O
the	O
molecular	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Routine	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
currently	O
limited	O
to	O
RT	O
-	O
PCR	O
but	O
this	O
test	O
cannot	O
distinguish	O
between	O
viable	O
and	O
inactivated	O
virus	O
.	O

We	O
found	O
there	O
to	O
be	O
a	O
definite	O
gap	O
in	O
the	O
recognition	O
of	O
avian	B-DISO
influenza	I-DISO
between	O
the	O
two	O
subject	O
groups	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
there	O
to	O
be	O
a	O
definite	O
gap	O
in	O
the	O
recognition	O
of	O
avian	B-DISO
influenza	I-DISO
between	O
the	O
two	O
subject	O
groups	O
.	O

Integrating	O
""""	O
big	O
data	O
""""	O
approaches	O
into	O
treatment	O
decisions	O
and	O
trial	O
designs	O
offers	O
a	O
potential	O
means	O
of	O
individualizing	O
care	O
to	O
enhance	O
outcomes	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

RESULTS	O
:	O
After	O
multiple	O
testing	O
adjustments	O
,	O
our	O
analysis	O
revealed	O
10	O
non	O
-	O
coding	O
SNPs	O
in	O
tight	O
linkage	O
disequilibrium	B-DISO
(	O
0	O
.	O
75	O
≤	O
r	O
(	O
2	O
)	O
≤	O
1	O
)	O
that	O
were	O
associated	O
with	O
ARDS	B-DISO
susceptibility	O
as	O
a	O
single	O
association	O
signal	O
.	O

The	O
impact	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
Canada	O
alone	O
is	O
significant	O
,	O
affecting	O
one	O
in	O
five	O
and	O
leading	O
any	O
other	O
cause	O
of	O
repeat	O
hospitalization	O
in	O
all	O
age	O
groups	O
.	O

Several	O
key	O
historical	O
events	O
have	O
shaped	O
this	O
understanding	O
in	O
the	O
Canadian	O
context	O
including	O
the	O
Lalonde	O
and	O
Epp	B-DISO
reports	O
,	O
and	O
public	O
health	O
emergencies	B-DISO
such	O
as	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
2003	O
.	O

These	O
viral	O
agents	O
may	O
lead	O
to	O
severe	O
respiratory	B-DISO
diseases	I-DISO
especially	O
in	O
young	O
children	O
and	O
in	O
the	O
elderly	O
.	O

CONCLUSIONS	O
:	O
Although	O
only	O
supportive	O
therapies	O
are	O
administered	O
generally	O
in	O
viral	O
infections	B-DISO
,	I-DISO
viral	I-DISO
investigations	O
are	O
important	O
in	O
terms	O
of	O
determining	O
the	O
measures	O
to	O
be	O
taken	O
by	O
determining	O
the	O
causes	O
as	O
well	O
as	O
in	O
terms	O
of	O
establishing	O
a	O
general	O
database	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
recently	O
attracted	O
interest	O
as	O
a	O
treatment	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

CONCLUSIONS	O
:	O
Although	O
the	O
overall	O
survival	O
rate	O
of	O
patients	O
treated	O
with	O
ECMO	O
for	O
postoperative	O
ARDS	B-DISO
was	O
unfavorable	O
,	O
ECMO	O
offered	O
an	O
invaluable	O
opportunity	O
for	O
survival	O
to	O
patients	O
who	O
would	O
not	O
have	O
been	O
expected	O
to	O
survive	O
using	O
conventional	O
therapy	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
temporal	O
dynamics	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
dromedary	O
camels	O
,	O
specimens	O
were	O
collected	O
at	O
1	O
-	O
2	O
month	O
intervals	O
from	O
2	O
independent	O
groups	O
of	O
animals	O
during	O
April	O
2013	O
-	O
May	O
2014	O
in	O
Al	O
-	O
Ahsa	O
Province	O
,	O
Saudi	O
Arabia	O
,	O
and	O
tested	O
for	O
MERS	O
-	O
CoV	O
RNA	O
by	O
reverse	O
transcription	O
PCR	O
.	O

Stroke	B-DISO
,	I-DISO
acute	I-DISO
ocular	O
conditions	O
,	O
leg	B-DISO
ulcers	I-DISO
,	O
priapism	B-DISO
,	O
and	O
anemia	B-DISO
are	O
common	O
complications	O
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Nurses	O
at	O
the	O
Seoul	O
Medical	O
Center	O
in	O
South	O
Korea	O
are	O
testing	O
patients	O
to	O
see	O
whether	O
they	O
have	O
contracted	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

More	O
recently	O
,	O
it	O
has	O
been	O
recognized	O
that	O
wildlife	O
constitutes	O
a	O
particularly	O
important	O
source	O
of	O
novel	O
zoonoses	B-DISO
.	O

The	O
zoonotic	O
origin	O
of	O
many	O
human	O
and	O
livestock	O
infections	B-DISO
argues	O
strongly	O
for	O
the	O
synergistic	O
value	O
of	O
a	O
One	O
Health	O
approach	O
,	O
which	O
provides	O
the	O
capability	O
to	O
identify	O
pathogens	O
crossing	O
into	O
new	O
species	O
and	O
could	O
provide	O
earlier	O
warning	O
of	O
potential	O
epidemics	O
.	O

ABSTRACT	O
:	O
This	O
comprehensive	O
review	O
outlines	O
the	O
impact	O
of	O
military	O
-	O
relevant	O
respiratory	B-DISO
infections	I-DISO
,	O
with	O
special	O
attention	O
to	O
recruit	O
training	O
environments	O
,	O
influenza	B-DISO
pandemics	O
in	O
1918	O
to	O
1919	O
and	O
2009	O
to	O
2010	O
,	O
and	O
peacetime	O
operations	O
and	O
conflicts	O
in	O
the	O
past	O
25	O
years	O
.	O

We	O
also	O
outline	O
military	O
-	O
specific	O
initiatives	O
in	O
(	O
i	O
)	O
surveillance	O
,	O
(	O
ii	O
)	O
vaccine	O
development	O
and	O
policy	O
,	O
(	O
iii	O
)	O
novel	O
influenza	B-DISO
and	O
coronavirus	O
diagnostic	O
test	O
development	O
and	O
surveillance	O
methods	O
,	O
(	O
iv	O
)	O
influenza	B-DISO
virus	O
transmission	O
and	O
severity	O
prediction	O
modeling	O
efforts	O
,	O
and	O
(	O
v	O
)	O
evaluation	O
and	O
implementation	O
of	O
nonvaccine	O
,	O
nonpharmacologic	O
interventions	O
.	O

Virus	O
co	B-DISO
-	I-DISO
infections	I-DISO
occurred	O
in	O
10	O
illnesses	O
.	O

Respiratory	O
illnesses	O
were	O
commonly	O
associated	O
with	O
coronaviruses	O
and	O
enteroviruses	O
/	O
rhinoviruses	O
affecting	O
chronically	B-DISO
ill	I-DISO
,	O
older	O
patients	O
more	O
than	O
healthy	O
,	O
young	O
adults	O
.	O

Coronavirus	O
-	O
associated	O
illnesses	O
(	O
percent	O
of	O
illnesses	O
,	O
group	O
1	O
vs	O
group	O
2	O
)	O
were	O
characterized	O
by	O
myalgias	B-DISO
(	O
21	O
%	O
vs	O
68	O
%,	O
P	O
<	O
.	O
01	O
),	O
chills	B-DISO
(	O
50	O
%	O
vs	O
52	O
%),	O
dyspnea	B-DISO
(	O
71	O
%	O
vs	O
24	O
%,	O
P	O
<	O
.	O
01	O
),	O
headache	B-DISO
(	O
64	O
%	O
vs	O
72	O
%),	O
malaise	B-DISO
(	O
64	O
%	O
vs	O
84	O
%),	O
cough	B-DISO
(	O
86	O
%	O
vs	O
68	O
%),	O
sputum	O
production	O
(	O
86	O
%	O
vs	O
60	O
%),	O
sore	B-DISO
throat	I-DISO
(	O
64	O
%	O
vs	O
80	O
%),	O
and	O
nasal	B-DISO
congestion	I-DISO
(	O
93	O
%	O
vs	O
96	O
%).	O

TITLE	O
:	O
Mild	O
to	O
Moderate	O
,	O
but	O
Not	O
Minimal	O
or	O
Severe	O
,	O
Acute	O
Histologic	O
Chorioamnionitis	B-DISO
or	O
Intra	O
-	O
Amniotic	O
Inflammation	B-DISO
Is	O
Associated	O
with	O
a	O
Decrease	O
in	O
Respiratory	B-DISO
Distress	I-DISO
Syndrome	I-DISO
of	O
Preterm	O
Newborns	O
without	O
Fetal	B-DISO
Growth	I-DISO
Restriction	I-DISO
.	O

Activation	O
of	O
p38	O
MAPK	O
by	O
either	O
PDGF	O
or	O
TGFβ1	O
induced	O
α	O
-	O
SMA	B-DISO
but	O
not	O
collagen	O
I	O
in	O
HLF	O
cells	O
,	O
while	O
activation	O
of	O
p42	O
/	O
p44	O
MAPK	O
by	O
PDGF	O
induced	O
collagen	O
I	O
but	O
not	O
α	O
-	O
SMA	B-DISO
in	O
HLF	O
cells	O
.	O

The	O
patient	O
fulfilled	O
the	O
criteria	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Despite	O
multimodal	O
therapy	O
,	O
including	O
noninvasive	O
positive	O
pressure	O
ventilation	O
,	O
polymyxin	O
B	O
-	O
immobilized	O
fiber	O
column	O
hemoperfusion	O
,	O
and	O
methylprednisolone	O
infusion	O
,	O
his	O
general	O
condition	B-DISO
gradually	O
deteriorated	O
.	O

TITLE	O
:	O
Neutralization	O
Analysis	O
of	O
a	O
Chicken	O
Single	O
-	O
Chain	O
Variable	O
Fragment	O
Derived	O
from	O
an	O
Immune	O
Antibody	O
Library	O
Against	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
.	O

Significantly	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
higher	O
median	O
levels	O
of	O
suPAR	O
were	O
found	O
with	O
increasing	O
severity	O
of	O
ARDS	B-DISO
:	O
5	O
.	O
9	O
ng	O
/	O
ml	O
[	O
IQR	O
3	O
.	O
1	O
-	O
12	O
.	O
8	O
]	O
in	O
mild	O
ARDS	B-DISO
(	O
n	O
=	O
82	O
),	O
8	O
.	O
4	O
ng	O
/	O
ml	O
[	O
IQR	O
4	O
.	O
1	O
-	O
15	O
.	O
0	O
]	O
in	O
moderate	O
ARDS	B-DISO
(	O
n	O
=	O
333	O
),	O
and	O
9	O
.	O
0	O
ng	O
/	O
ml	O
[	O
IQR	O
4	O
.	O
5	O
-	O
16	O
.	O
0	O
]	O
in	O
severe	O
ARDS	B-DISO
(	O
n	O
=	O
217	O
).	O

The	O
results	O
showed	O
that	O
oral	O
administration	O
of	O
anti	O
-	O
PEDV	O
S1	O
IgY	O
efficiently	O
protects	O
neonatal	O
piglets	O
against	O
PEDV	O
,	O
suggesting	O
its	O
potential	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
against	O
acute	O
PEDV	O
infection	B-DISO
.	O

In	O
preclinical	O
models	O
,	O
p38	O
inhibitors	O
reduce	O
lung	O
injury	O
following	O
pancreatitis	B-DISO
and	O
burn	O
injury	O
.	O

Although	O
adverse	O
events	O
were	O
common	O
in	O
this	O
critically	B-DISO
ill	I-DISO
population	O
,	O
dilmapimod	O
was	O
well	O
tolerated	O
,	O
with	O
no	O
clinically	O
relevant	O
safety	O
findings	O
.	O

TITLE	O
:	O
Acute	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
:	O
Temporal	O
Lung	O
Changes	O
Observed	O
on	O
the	O
Chest	O
Radiographs	O
of	O
55	O
Patients	O
.	O

Ground	O
-	O
glass	O
opacity	B-DISO
in	O
a	O
peripheral	O
location	O
was	O
the	O
most	O
common	O
abnormality	O
noted	O
on	O
chest	O
radiographs	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
healthcare	O
settings	O
.	O

ABSTRACT	O
:	O
Attracting	O
global	O
attention	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
cause	O
sporadic	O
cases	O
and	O
a	O
potential	O
risk	O
of	O
healthcare	O
-	O
associated	O
infections	B-DISO
.	O

TITLE	O
:	O
Evaluation	O
of	O
Four	O
Commercial	O
Multiplex	O
Molecular	O
Tests	O
for	O
the	O
Diagnosis	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Infections	I-DISO
.	O

Identification	O
of	O
well	O
-	O
characterized	O
small	O
molecules	O
that	O
modulate	O
viral	B-DISO
infection	I-DISO
can	O
accelerate	O
development	O
of	O
antiviral	O
therapeutics	O
while	O
also	O
providing	O
new	O
tools	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
cellular	O
processes	O
that	O
underlie	O
virus	O
-	O
mediated	O
cell	B-DISO
injury	I-DISO
.	O

ABSTRACT	O
:	O
At	O
the	O
end	O
of	O
May	O
2015	O
,	O
an	O
imported	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
was	O
confirmed	O
in	O
China	O
.	O

TITLE	O
:	O
Human	O
rhinovirus	O
infections	B-DISO
in	O
hospitalized	O
children	O
:	O
clinical	O
,	O
epidemiological	O
and	O
virological	O
features	O
.	O

HRV	O
was	O
the	O
most	O
commonly	O
detected	O
virus	O
(	O
30	O
%),	O
in	O
which	O
70	O
%	O
were	O
diagnosed	O
as	O
either	O
pneumonia	B-DISO
or	O
bronchiolitis	B-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Isolate	O
US	O
/	O
Iowa	O
/	O
18984	O
/	O
2013	O
Infection	B-DISO
in	O
1	O
-	O
Day	O
-	O
Old	O
Cesarean	O
-	O
Derived	O
Colostrum	O
-	O
Deprived	O
Piglets	O
.	O

Rectal	O
swabs	O
were	O
collected	O
from	O
all	O
piglets	O
prior	O
to	O
inoculation	O
and	O
every	O
12	O
hours	O
postinoculation	O
(	O
hpi	B-DISO
)	O
thereafter	O
,	O
with	O
4	O
control	O
and	O
5	O
challenged	O
piglets	O
euthanized	O
at	O
12	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hpi	B-DISO
.	O

Clinical	O
disease	O
was	O
severe	O
and	O
developed	O
rapidly	O
following	O
infection	B-DISO
with	O
an	O
original	O
North	O
American	O
PEDV	O
isolate	O
,	O
with	O
lesions	O
,	O
viremia	B-DISO
,	O
and	O
antigen	O
detection	O
possible	O
by	O
12	O
hpi	B-DISO
.	O

These	O
findings	O
indicate	O
that	O
the	O
ERK	O
signaling	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
the	O
PEDV	O
life	O
cycle	O
and	O
beneficially	O
contributes	O
to	O
viral	B-DISO
infection	I-DISO
.	O

These	O
cases	O
illustrate	O
that	O
M	O
.	O
pneumoniae	O
infection	B-DISO
in	O
children	O
can	O
be	O
followed	O
by	O
severe	O
and	O
complicated	O
forms	O
of	O
GBS	B-DISO
.	O

Non	O
-	O
specific	O
clinical	O
features	O
of	O
GBS	B-DISO
in	O
such	O
patients	O
may	O
predispose	O
a	O
potentially	O
life	O
-	O
threatening	O
delay	O
in	O
diagnosis	O
.	O

Together	O
,	O
the	O
work	O
highlights	O
the	O
utility	O
of	O
examining	O
respiratory	O
function	O
following	O
infection	B-DISO
in	O
order	O
to	O
fully	O
understand	O
viral	B-DISO
pathogenesis	I-DISO
.	O

TITLE	O
:	O
Elevated	O
level	O
of	O
renal	O
xanthine	O
oxidase	O
mRNA	O
transcription	O
after	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
in	O
growing	O
layers	O
.	O

ABSTRACT	O
:	O
Babesiosis	B-DISO
,	O
an	O
infection	B-DISO
caused	O
by	O
the	O
protozoan	O
Babesia	O
microti	O
and	O
transmitted	B-DISO
by	O
the	O
Ixodes	O
scapularis	O
tick	O
,	O
is	O
commonly	O
described	O
in	O
the	O
literature	O
with	O
an	O
approximate	O
incidence	O
of	O
1000	O
cases	O
per	O
year	O
(	O
Herwaldt	O
et	O
al	O
.,	O
2012	O
).	O

Splenic	O
rupture	O
has	O
been	O
generally	O
described	O
as	O
a	O
complication	B-DISO
of	O
severe	O
illness	O
secondary	O
to	O
babesiosis	B-DISO
.	O

We	O
present	O
two	O
cases	O
of	O
patients	O
with	O
clinical	O
symptoms	O
of	O
brain	B-DISO
death	I-DISO
,	O
with	O
lung	O
pathology	B-DISO
(	O
acute	O
lung	O
injury	O
,	O
ARDS	B-DISO
,	O
lung	B-DISO
embolism	I-DISO
and	O
lung	B-DISO
infection	I-DISO
),	O
in	O
whom	O
apneic	B-DISO
tests	O
for	O
recognizing	O
brain	B-DISO
death	I-DISO
were	O
difficult	O
to	O
perform	O
.	O

The	O
major	O
causes	O
of	O
MERS	O
included	O
infection	B-DISO
,	O
antiepileptic	O
drug	B-DISO
withdrawal	I-DISO
,	O
high	O
-	O
altitude	O
cerebral	B-DISO
edema	I-DISO
,	O
and	O
cesarean	O
section	O
(	O
C	O
-	O
section	O
).	O

We	O
present	O
an	O
adult	O
SCD	B-DISO
patient	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
AChS	B-DISO
,	O
successfully	O
treated	O
with	O
VV	O
-	O
ECMO	O
.	O

TITLE	O
:	O
Noninvasive	O
Positive	O
-	O
Pressure	O
Ventilation	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
in	O
Patients	O
With	O
Acute	B-DISO
Pancreatitis	I-DISO
:	O

For	O
severe	O
ARDS	B-DISO
,	O
airway	O
pressure	O
release	O
ventilation	O
and	O
neuromuscular	B-DISO
blockade	I-DISO
were	O
the	O
most	O
popular	O
.	O

In	O
this	O
case	O
report	O
,	O
we	O
present	O
epidemic	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
in	O
three	O
farms	O
in	O
South	O
-	O
Western	O
Germany	O
.	O

In	O
the	O
fattening	O
farm	O
yellowish	O
,	O
watery	B-DISO
diarrhea	I-DISO
without	O
evidence	O
of	O
mucus	O
or	O
blood	O
was	O
associated	O
with	O
a	O
massive	O
reduction	O
of	O
feed	O
consumption	O
.	O

However	O
,	O
the	O
precise	O
functions	O
of	O
the	O
CoV	O
E	O
protein	O
during	O
infection	B-DISO
are	O
still	O
enigmatic	O
.	O

TITLE	O
:	O
Myd88	O
Initiates	O
Early	O
Innate	B-DISO
Immune	I-DISO
Responses	I-DISO
and	O
Promotes	O
CD4	O
T	O
Cells	O
during	O
Coronavirus	O
Encephalomyelitis	B-DISO
.	O

In	O
the	O
absence	O
of	O
these	O
responses	O
,	O
functional	O
CD8	O
T	O
cells	O
are	O
insufficient	O
to	O
control	O
viral	O
spread	O
within	O
the	O
CNS	O
,	O
resulting	O
in	O
severe	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
value	O
of	O
lung	O
ultrasound	O
score	O
(	O
LUS	O
)	O
on	O
assessing	O
the	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
to	O
investigate	O
its	O
correlation	O
with	O
oxygenation	O
index	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluationII	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
and	O
clinical	O
pulmonary	B-DISO
infection	I-DISO
score	O
(	O
CPIS	O
),	O
and	O
other	O
traditional	O
parameters	O
.	O

A	O
prospective	O
double	O
-	O
blind	B-DISO
cohort	O
study	O
was	O
conducted	O
.	O

Receiver	O
operator	O
characteristic	O
curve	O
(	O
ROC	O
)	O
was	O
plotted	O
,	O
and	O
the	O
predictive	O
value	O
,	O
sensitivity	O
and	O
specificity	O
of	O
mild	O
ARDS	B-DISO
,	O
moderate	O
ARDS	B-DISO
,	O
severe	O
ARDS	B-DISO
and	O
mortality	O
by	O
LUS	O
were	O
calculated	O
.	O

LUS	O
in	O
the	O
pulmonary	O
ARDS	B-DISO
group	O
had	O
a	O
positive	O
correlation	O
with	O
CPIS	O
(	O
r	O
=	O
0	O
.	O
399	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
a	O
positive	O
correlation	O
was	O
found	O
in	O
non	O
-	O
pulmonary	O
ARDS	B-DISO
group	O
(	O
r	O
=	O
0	O
.	O
350	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
which	O
indicated	O
that	O
the	O
correlation	O
in	O
pulmonary	O
ARDS	B-DISO
was	O
more	O
satisfactory	O
than	O
that	O
in	O
non	O
-	O
pulmonary	O
ARDS	B-DISO
.	O

Pseudotyped	O
viruses	O
are	O
useful	O
for	O
measuring	O
neutralization	O
titers	O
against	O
highly	O
infectious	B-DISO
viruses	O
as	O
well	O
as	O
for	O
studying	O
their	O
mechanism	O
of	O
entry	O
.	O

ABSTRACT	O
:	O
Outcomes	O
and	O
risk	O
factors	O
associated	O
with	O
new	O
-	O
onset	O
atrial	B-DISO
fibrillation	I-DISO
(	O
AF	O
)	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
unclear	O
.	O

CONCLUSIONS	O
:	O
New	O
-	O
onset	O
AF	O
during	O
ARDS	B-DISO
is	O
associated	O
with	O
increased	O
mortality	O
;	O
however	O
,	O
its	O
mechanisms	O
require	O
further	O
study	O
.	O

The	O
result	O
suggested	O
that	O
compared	O
with	O
the	O
P110	O
strain	O
,	O
the	O
P3	O
strain	O
induced	O
a	O
more	O
pronounced	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H5N6	O
)	O
virus	O
was	O
isolated	O
from	O
the	O
throat	O
swab	O
or	O
trachea	B-DISO
aspirate	O
of	O
the	O
patient	O
.	O

Moreover	O
,	O
our	O
data	O
demonstrated	O
that	O
CQ	O
increased	O
lysosome	O
-	O
associated	O
membrane	O
protein	O
-	O
1	O
,	O
lysosome	O
-	O
associated	O
membrane	O
protein	O
-	O
2	O
and	O
light	O
chain	O
-	O
3	O
expressions	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
CQ	O
rescues	O
PQ	O
-	O
induced	O
cytotoxicity	B-DISO
may	O
be	O
through	O
protection	O
of	O
the	O
lysosomal	O
membrane	O
or	O
up	O
-	O
regulation	O
of	O
autophagy	O
.	O

We	O
applied	O
rates	O
of	O
hospitalized	O
and	O
non	O
-	O
hospitalized	O
influenza	B-DISO
-	O
associated	O
SARI	O
to	O
census	O
data	O
to	O
calculate	O
the	O
national	O
number	O
of	O
cases	O
.	O

TITLE	O
:	O
Cytomegalovirus	B-DISO
pneumonia	I-DISO
as	O
the	O
first	O
manifestation	O
of	O
severe	B-DISO
combined	I-DISO
immunodeficiency	I-DISO
.	O

While	O
heterogeneity	O
of	O
the	O
genetic	O
background	O
in	O
SCID	B-DISO
leads	O
to	O
the	O
variability	O
of	O
immune	O
phenotypes	O
,	O
most	O
of	O
affected	O
newborns	O
appear	O
healthy	O
but	O
within	O
the	O
first	O
few	O
months	O
they	O
develop	O
life	O
-	O
threatening	O
opportunistic	O
respiratory	O
or	O
gastrointestinal	O
tract	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
From	O
October	O
2013	O
to	O
date	O
,	O
approximately	O
1	O
,	O
000	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
have	O
occurred	O
in	O
Japan	O
.	O

The	O
comparison	O
between	O
the	O
plaque	B-DISO
assay	O
data	O
and	O
the	O
Virus	O
Counter	O
results	O
revealed	O
a	O
linear	O
relationship	O
(	O
slope	O
=	O
1	O
.	O
155	O
±	O
0	O
.	O
46	O
,	O
R	O
(	O
2	O
)=	O
0	O
.	O
9665	O
)	O
with	O
a	O
significant	O
Pearson	O
correlation	O
(	O
r	O
=	O
0	O
.	O
9809	O
,	O
p	O
<	O
0	O
.	O
0001	O
).	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
sedation	B-DISO
for	O
agitated	B-DISO
patients	O
undergoing	O
NIV	O
in	O
clinical	O
practice	O
in	O
a	O
single	O
hospital	O
.	O

Sedation	B-DISO
was	O
performed	O
only	O
intermittently	O
in	O
72	O
(	O
60	O
%)	O
patients	O
,	O
was	O
switched	O
to	O
continuously	O
in	O
37	O
(	O
31	O
%)	O
and	O
was	O
applied	O
only	O
continuously	O
in	O
11	O
(	O
9	O
%).	O

However	O
,	O
with	O
continuous	O
use	O
,	O
we	O
must	O
be	O
aware	O
of	O
an	O
increased	O
hypercapnic	B-DISO
state	O
and	O
the	O
possibility	O
of	O
increased	O
mortality	O
.	O

Larger	O
controlled	O
studies	O
are	O
needed	O
to	O
better	O
clarify	O
the	O
role	O
of	O
sedation	B-DISO
in	O
improving	O
NIV	O
outcomes	O
in	O
intolerant	O
patients	O
.	O

HR2P	O
-	O
M2	O
was	O
highly	O
effective	O
in	O
inhibiting	O
MERS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
and	O
infection	B-DISO
by	O
pseudoviruses	O
expressing	O
MERS	O
-	O
CoV	O
S	O
protein	O
with	O
or	O
without	O
mutation	O
in	O
the	O
HR1	O
region	O
.	O

Comparisons	O
of	O
EVLWI	O
,	O
PVPI	O
and	O
OI	O
were	O
made	O
for	O
three	O
groups	O
at	O
different	O
timepoints	O
:	O
As	O
the	O
severity	O
of	O
ARDS	B-DISO
aggravated	O
,	O
EVLWI	O
and	O
PVPI	O
of	O
three	O
groups	O
increased	O
significantly	O
at	O
any	O
timepoint	O
while	O
OI	O
decreased	O
sharply	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
ulinastatin	O
plus	O
octreotide	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
).	O

And	O
the	O
incidences	O
of	O
such	O
complications	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
shock	O
of	O
observation	O
group	O
(	O
10	O
.	O
0	O
%,	O
5	O
.	O
0	O
%,	O
13	O
.	O
3	O
%)	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
group	O
(	O
36	O
.	O
7	O
%,	O
21	O
.	O
7	O
%,	O
33	O
.	O
3	O
%)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Most	O
viral	B-DISO
infections	I-DISO
encountered	O
in	O
resource	O
-	O
rich	O
countries	O
are	O
relatively	O
trivial	O
and	O
transient	O
with	O
perhaps	O
fever	O
,	O
malaise	B-DISO
,	O
myalgia	B-DISO
,	O
rash	B-DISO
(	O
exanthema	B-DISO
)	O
and	O
sometimes	O
mucosal	O
manifestations	O
(	O
enanthema	B-DISO
),	O
including	O
oral	O
in	O
some	O
.	O

Infections	B-DISO
are	O
transmitted	B-DISO
from	O
various	O
human	O
or	O
animal	O
vectors	O
,	O
especially	O
by	O
close	O
proximity	O
,	O
and	O
the	O
increasing	O
movements	O
of	O
peoples	O
across	O
the	O
globe	O
,	O
mean	O
that	O
infections	B-DISO
hitherto	O
confined	O
largely	O
to	O
the	O
tropics	O
now	O
appear	O
worldwide	O
.	O

Thus	O
recent	O
decades	O
have	O
seen	O
a	O
most	O
dramatic	O
change	O
with	O
the	O
emergence	O
globally	O
also	O
of	O
new	O
viral	B-DISO
infections	I-DISO
-	O
notably	O
human	O
immunodeficiency	B-DISO
viruses	O
(	O
HIV	B-DISO
)	O
-	O
and	O
the	O
appearance	O
of	O
some	O
other	O
dangerous	O
and	O
sometimes	O
lethal	O
infections	B-DISO
formerly	O
seen	O
mainly	O
in	O
,	O
and	O
reported	O
from	O
,	O
resource	O
-	O
poor	O
areas	O
especially	O
in	O
parts	O
of	O
Asia	O
,	O
Latin	O
America	O
and	O
Africa	O
.	O

Mortality	O
was	O
65	O
.	O
7	O
%,	O
55	O
.	O
7	O
%,	O
and	O
33	O
.	O
3	O
%	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
,	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
sepsis	B-DISO
,	O
respectively	O
.	O

The	O
presence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
renal	O
dysfunction	O
were	O
associated	O
with	O
higher	O
mortality	O
(	O
75	O
%	O
and	O
70	O
.	O
2	O
%,	O
respectively	O
).	O

Several	O
demographic	O
and	O
laboratory	O
parameters	O
as	O
well	O
as	O
composite	O
critical	B-DISO
illness	I-DISO
scoring	O
systems	O
are	O
reliable	O
early	O
predictors	O
of	O
mortality	O
in	O
sepsis	B-DISO
.	O

ABSTRACT	O
:	O
Two	O
of	O
the	O
earliest	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
cases	O
were	O
men	O
who	O
had	O
visited	O
the	O
Doha	O
central	O
animal	O
market	O
and	O
adjoining	O
slaughterhouse	O
in	O
Qatar	O
.	O

In	O
this	O
review	O
,	O
we	O
present	O
factors	O
to	O
consider	O
in	O
establishing	O
an	O
animal	O
model	O
for	O
the	O
study	O
of	O
novel	O
coronaviruses	O
and	O
compare	O
the	O
different	O
animal	O
models	O
that	O
have	O
been	O
employed	O
to	O
study	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
review	O
signalment	O
,	O
clinical	O
signs	O
and	O
laboratory	O
features	O
in	O
a	O
large	O
number	O
of	O
naturally	O
occurring	O
cases	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
and	O
to	O
evaluate	O
potential	O
changes	O
in	O
diagnostic	O
criteria	O
for	O
FIP	B-DISO
and	O
compare	O
findings	O
in	O
cats	O
with	O
and	O
without	O
effusion	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
graft	I-DISO
-	I-DISO
versus	I-DISO
-	I-DISO
host	I-DISO
disease	I-DISO
and	O
bronchiolitis	B-DISO
obliterans	I-DISO
after	O
autologous	O
stem	O
cell	O
transplantation	O
in	O
a	O
patient	O
with	O
multiple	B-DISO
myeloma	I-DISO
.	O

Pulmonary	B-DISO
mucormycosis	I-DISO
has	O
a	O
high	O
mortality	O
rate	O
.	O

Consistent	O
with	O
Benjamin	O
Franklin	O
'	O
s	O
dictum	O
'	O
an	O
ounce	O
of	O
prevention	O
is	O
worth	O
a	O
pound	O
of	O
cure	O
',	O
sepsis	B-DISO
can	O
be	O
prevented	O
by	O
vaccinations	O
against	O
pneumococci	O
and	O
meningococci	O
.	O

Microbial	O
genome	O
products	O
trigger	O
'	O
genome	O
wars	O
'	O
in	O
sepsis	B-DISO
that	O
reprogram	O
the	O
human	O
genome	O
and	O
culminate	O
in	O
a	O
'	O
genomic	O
storm	O
'	O
in	O
blood	O
and	O
vascular	O
cells	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
recently	O
emerged	O
virus	O
that	O
has	O
caused	O
a	O
number	O
of	O
human	O
infections	B-DISO
and	O
deaths	O
,	O
primarily	O
in	O
the	O
Middle	O
East	O
.	O

ABSTRACT	O
:	O
Since	O
1996	O
a	O
new	O
Infectious	B-DISO
Bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
genotype	O
,	O
referred	O
to	O
as	O
Q1	O
,	O
circulated	O
in	O
China	O
and	O
was	O
reported	O
for	O
the	O
first	O
time	O
in	O
Italy	O
in	O
2011	O
,	O
associated	O
with	O
an	O
increase	O
of	O
mortality	O
,	O
kidney	O
lesions	O
and	O
proventriculitis	O
.	O

RESULTS	O
:	O
Five	O
cases	O
were	O
died	O
after	O
4	O
to	O
15	O
hours	O
into	O
hospital	O
(	O
3	O
cases	O
died	O
for	O
severe	O
trauma	O
-	O
hemorrhagic	B-DISO
shock	I-DISO
and	O
2	O
cases	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
).	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
a	O
Korean	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
KNU	O
-	O
141112	O
.	O

Ten	O
piglets	O
with	O
severe	O
lavage	O
-	O
induced	O
lung	O
injury	O
were	O
mechanically	O
ventilated	O
in	O
a	O
decremental	O
PEEP	O
trial	O
after	O
full	O
lung	O
recruitment	B-DISO
in	O
the	O
prone	O
position	O
.	O

To	O
facilitate	O
lung	O
conditioning	O
,	O
we	O
tested	O
liposomal	O
and	O
porous	O
silicon	O
(	O
pSi	O
)	O
delivery	O
systems	O
for	O
their	O
ability	O
to	O
selectively	O
silence	B-DISO
TNFR1	O
using	O
siRNA	O
technology	O
.	O

Outline	O
of	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
revealed	O
that	O
compound	O
BH6870	O
(	O
36	O
)	O
showed	O
high	O
anti	O
-	O
HCV	O
potency	O
([	O
Formula	O
:	O
see	O
text	O
])	O
and	O
a	O
good	O
cell	O
safety	O
index	O
(	O
SI	O
[	O
Formula	O
:	O
see	O
text	O
]).	O

In	O
addition	O
,	O
the	O
S	O
protein	O
needs	O
to	O
be	O
cleaved	O
by	O
host	O
proteases	O
before	O
executing	O
fusion	O
,	O
making	O
these	O
proteases	O
a	O
second	O
determinant	O
of	O
coronavirus	O
interspecies	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
After	O
more	O
than	O
30	O
years	O
of	O
development	O
,	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
has	O
become	O
one	O
of	O
the	O
main	O
treatments	O
of	O
sleep	B-DISO
-	I-DISO
disordered	I-DISO
breathing	I-DISO
(	O
SDB	O
)	O
in	O
the	O
world	O
.	O

ABSTRACT	O
:	O
The	O
distinct	O
characteristic	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
in	O
South	O
Korea	O
is	O
that	O
it	O
not	O
only	O
involves	O
intra	O
-	O
hospital	O
transmission	O
,	O
but	O
it	O
also	O
involves	O
hospital	O
-	O
to	O
-	O
hospital	O
transmission	O
.	O

Taking	O
this	O
as	O
an	O
opportunity	O
,	O
the	O
Korean	O
government	O
should	O
carefully	O
assess	O
the	O
fundamental	O
problems	O
of	O
the	O
vulnerability	O
to	O
hospital	B-DISO
infection	I-DISO
and	O
make	O
short	O
-	O
as	O
well	O
as	O
long	O
-	O
term	O
plans	O
for	O
countermeasures	O
.	O

We	O
herein	O
attempted	O
to	O
identify	O
a	O
microbiota	O
shift	O
that	O
may	O
be	O
affected	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
).	O

Most	O
commensal	O
bacteria	O
(	O
i	O
.	O
e	O
.	O
Psychrobacter	O
,	O
Prevotella	O
,	O
and	O
Faecalibacterium	O
)	O
in	O
the	O
healthy	O
gastrointestinal	O
tract	O
were	O
decreased	O
due	O
to	O
dysbiosis	O
induced	O
by	O
PEDV	O
infection	B-DISO
.	O

Lung	O
recruitment	B-DISO
was	O
low	O
(	O
3	O
±	O
2	O
%)	O
and	O
was	O
not	O
correlated	O
to	O
increases	O
in	O
functional	O
residual	O
capacity	O
(	O
R	O
(	O
2	O
)	O
0	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
19	O
).	O

TITLE	O
:	O
Probable	O
transmission	O
chains	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
and	O
the	O
multiple	O
generations	O
of	O
secondary	B-DISO
infection	I-DISO
in	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
In	O
May	O
2015	O
,	O
South	O
Korea	O
reported	O
its	O
first	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
a	O
68	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
travel	O
in	O
the	O
Middle	O
East	O
.	O

Fomite	O
transmission	O
may	O
explain	O
a	O
significant	O
proportion	O
of	O
the	O
infections	B-DISO
occurring	O
in	O
the	O
absence	O
of	O
direct	O
contact	O
with	O
infected	O
cases	O
.	O

The	O
antibody	O
,	O
named	O
LCA60	O
,	O
binds	O
to	O
a	O
novel	O
site	O
on	O
the	O
spike	O
protein	O
and	O
potently	O
neutralizes	O
infection	B-DISO
of	O
multiple	O
MERS	O
-	O
CoV	O
isolates	O
by	O
interfering	O
with	O
the	O
binding	O
to	O
the	O
cellular	O
receptor	O
CD26	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
candidate	O
vaccine	O
approaches	O
for	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
a	O
cause	O
of	O
severe	O
respiratory	B-DISO
disease	I-DISO
highlights	O
the	O
need	O
for	O
effective	O
approaches	O
to	O
CoV	O
vaccine	O
development	O
.	O

ABSTRACT	O
:	O
A	O
natural	O
recombinant	O
nephropathogenic	O
K40	O
/	O
09	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
heat	O
-	O
adapted	O
for	O
possible	O
future	O
use	O
as	O
live	O
attenuated	O
vaccine	O
.	O

MEDLINE	O
,	O
EMBASE	O
,	O
and	O
PubMed	O
Central	O
(	O
1972	O
to	O
June	O
1	O
,	O
2015	O
)	O
were	O
queried	O
with	O
the	O
following	O
search	O
term	O
combinations	O
:	O
""""	O
Oral	O
""""	O
AND	O
""""	O
ribavirin	O
""""	O
AND	O
"("""	O
respiratory	O
syncytial	O
virus	O
""""	O
OR	O
""""	O
metapneumovirus	O
""""	O
OR	O
""""	O
parainfluenza	B-DISO
""""	O
OR	O
""""	O
coronavirus	O
""""	O
OR	O
""""	O
rhinovirus	O
""""	O
OR	O
""""	O
enterovirus	O
""""	O
OR	O
""""	O
adenovirus	B-DISO
""")."	O

All	O
studies	O
except	O
for	O
2	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
studies	O
were	O
in	O
immunocompromised	O
patients	O
(	O
9	O
malignancy	B-DISO
/	O
stem	O
cell	O
transplant	O
,	O
4	O
lung	O
transplant	O
).	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
multiple	O
improved	O
serological	O
assays	O
for	O
PEDV	O
,	O
including	O
an	O
indirect	O
ELISA	O
(	O
iELISA	O
);	O
a	O
highly	O
specific	O
monoclonal	O
antibody	O
-	O
based	O
blocking	B-DISO
ELISA	O
(	O
bELISA	O
);	O
fluorescent	O
microsphere	O
immunoassays	O
(	O
FMIA	O
)	O
that	O
can	O
be	O
multiplexed	O
to	O
monitor	O
exposure	O
to	O
multiple	O
antigens	O
and	O
pathogens	O
simultaneously	O
;	O
and	O
a	O
fluorescent	O
focus	O
neutralization	O
assay	O
(	O
FFN	O
)	O
to	O
measure	O
functional	O
virus	O
neutralizing	O
antibodies	O
.	O

Genetic	O
variations	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
and	O
copy	O
-	O
number	O
variations	O
are	O
likely	O
associated	O
with	O
susceptibility	O
to	O
ARDS	B-DISO
in	O
children	O
with	O
primary	O
lung	O
injury	O
.	O

Indications	O
for	O
surgery	O
include	O
refractory	O
hypotension	O
not	O
responding	O
to	O
resuscitation	O
due	O
to	O
uncontrolled	O
hemorrhage	B-DISO
from	O
liver	O
trauma	O
;	O
massive	O
hemoperitonem	O
on	O
Focused	O
assessment	O
by	O
ultrasound	O
for	O
trauma	O
(	O
FAST	O
)	O
and	O
/	O
or	O
Diagnostic	O
peritoneal	O
lavage	O
(	O
DPL	O
)	O
as	O
well	O
as	O
Multislice	O
Computed	O
Tomography	O
(	O
MSCT	O
)	O
findings	O
of	O
the	O
severe	O
liver	O
injury	O
and	O
major	O
vascular	O
injuries	O
with	O
active	O
bleeding	B-DISO
.	O

Regarding	O
complications	O
non	O
-	O
survivors	O
had	O
significantly	O
prolonged	O
bleeding	B-DISO
and	O
higher	O
rate	O
of	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
p	O
=	O
0	O
.	O
0001	O
;	O
p	O
=	O
0	O
.	O
0001	O
),	O
while	O
survivors	O
had	O
significantly	O
higher	O
rate	O
of	O
pleural	B-DISO
effusion	I-DISO
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

All	O
efforts	O
in	O
the	O
treatment	O
of	O
severe	O
liver	O
injuries	O
should	O
be	O
directed	O
to	O
the	O
rapid	O
and	O
effective	O
control	O
of	O
bleeding	B-DISO
,	O
because	O
uncontrollable	O
hemorrhage	B-DISO
is	O
the	O
cause	O
of	O
early	O
death	O
and	O
it	O
requires	O
massive	O
blood	O
transfusion	O
,	O
all	O
of	O
which	O
contributes	O
to	O
the	O
late	O
fatal	O
complication	B-DISO
.	O

RESULTS	O
:	O
Non	O
-	O
survivors	O
have	O
significantly	O
higher	O
AAST	O
grade	O
of	O
liver	O
injury	O
and	O
higher	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
)	O
(	O
p	O
=	O
0	O
.	O
000	O
;	O
p	O
=	O
0	O
.	O
0001	O
).	O

CONCLUSIONS	O
:	O
All	O
efforts	O
in	O
the	O
treatment	O
of	O
severe	O
liver	O
injuries	O
should	O
be	O
directed	O
to	O
the	O
rapid	O
and	O
effective	O
control	O
of	O
bleeding	B-DISO
,	O
because	O
uncontrollable	O
hemorrhage	B-DISO
is	O
the	O
cause	O
of	O
early	O
death	O
and	O
it	O
requires	O
massive	O
blood	O
transfusion	O
,	O
all	O
of	O
which	O
contributes	O
to	O
the	O
late	O
fatal	O
complication	B-DISO
.	O

Minocycline	O
is	O
commonly	O
used	O
for	O
pneumonia	B-DISO
,	O
acute	B-DISO
bronchitis	I-DISO
,	O
urinary	B-DISO
tract	I-DISO
infections	I-DISO
,	O
and	O
acne	B-DISO
and	O
is	O
likely	O
the	O
cause	O
of	O
AEP	O
in	O
our	O
patient	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
prevention	O
and	O
control	O
measures	O
are	O
critical	O
to	O
prevent	O
the	O
possible	O
spread	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
healthcare	O
facilities	O
.	O

CONCLUSIONS	O
:	O
Our	O
sequencing	O
results	O
demonstrate	O
a	O
co	O
-	O
circulation	O
of	O
wild	O
-	O
type	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
in	O
broiler	O
chickens	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
nucleocapsid	O
protein	O
from	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
NP	O
-	O
NTD	O
)	O
contains	O
many	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
to	O
be	O
responsible	O
for	O
RNA	O
binding	O
during	O
ribonucleocapsid	O
formation	O
by	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
and	O
characterize	O
aetiologic	O
agent	O
(	O
s	O
)	O
associated	O
with	O
an	O
outbreak	O
of	O
a	O
severe	B-DISO
diarrhoea	I-DISO
in	O
piglets	O
in	O
Jiangxi	O
,	O
China	O
,	O
in	O
March	O
2015	O
,	O
a	O
nested	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
was	O
developed	O
.	O

A	O
survey	O
based	O
on	O
the	O
nested	O
RT	O
-	O
PCR	O
established	O
indicated	O
that	O
the	O
monoinfection	O
of	O
PDCoV	O
(	O
33	O
.	O
71	O
%)	O
and	O
coinfection	B-DISO
of	O
PDCoV	O
(	O
19	O
.	O
66	O
%)	O
with	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
were	O
common	O
in	O
diarrhoeal	O
pigs	O
in	O
Jiangxi	O
,	O
China	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
dramatic	O
increase	O
in	O
reported	O
cases	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
in	O
pig	O
farms	O
is	O
a	O
potential	O
threat	O
to	O
the	O
global	O
swine	O
industry	O
.	O

(	O
1	O
)	O
A	O
43	O
years	O
old	O
male	O
of	O
South	O
Korean	O
nationality	O
was	O
admitted	O
with	O
the	O
complaint	O
of	O
back	B-DISO
ache	I-DISO
for	O
7	O
days	O
and	O
fever	O
2	O
days	O
with	O
the	O
following	O
characteristics	O
:	O
back	B-DISO
ache	I-DISO
7	O
days	O
ago	O
,	O
without	O
fever	O
or	O
cough	B-DISO
or	O
expectoration	O
.	O

Indeed	O
,	O
a	O
truncated	O
NS2B	O
(	O
48	O
-	O
100	O
;	O
Δ77	O
-	O
84	O
)	O
with	O
the	O
flexible	O
loop	O
deleted	O
is	O
able	O
to	O
trap	O
the	O
NS2B	O
-	O
NS3pro	O
complex	O
in	O
a	O
highly	O
dynamic	O
and	O
catalytically	O
-	O
impotent	B-DISO
state	O
.	O

The	O
polymer	O
compound	O
,	O
based	O
on	O
the	O
results	O
of	O
the	O
studies	O
,	O
is	O
a	O
perspective	O
antiseptic	O
and	O
etiotropic	O
means	O
for	O
control	O
of	O
infectious	B-DISO
disease	I-DISO
causative	O
agents	O
.	O

CONCLUSIONS	O
:	O
The	O
polymer	O
compound	O
,	O
based	O
on	O
the	O
results	O
of	O
the	O
studies	O
,	O
is	O
a	O
perspective	O
antiseptic	O
and	O
etiotropic	O
means	O
for	O
control	O
of	O
infectious	B-DISO
disease	I-DISO
causative	O
agents	O
.	O

ABSTRACT	O
:	O
Total	O
ginsenosides	O
synergize	O
with	O
ulinastatin	O
(	O
UTI	B-DISO
)	O
against	O
septic	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

It	O
revealed	O
that	O
prone	O
positioning	O
,	O
when	O
used	O
with	O
low	O
tidal	O
volume	O
ventilation	O
over	O
an	O
extended	O
period	O
,	O
may	O
reduce	O
mortality	O
rates	O
in	O
selected	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Further	O
research	O
is	O
required	O
on	O
the	O
use	O
of	O
prone	O
positioning	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
to	O
support	O
or	O
disclaim	O
the	O
therapy	O
'	O
s	O
use	O
in	O
practice	O
,	O
and	O
to	O
compare	O
confounding	O
variables	O
such	O
as	O
ideal	O
prone	O
duration	O
and	O
mechanical	O
versus	O
manual	O
pronation	O
.	O

Earlier	O
Plasmodium	O
vivax	O
was	O
considered	O
as	O
a	O
benign	O
infection	B-DISO
,	O
but	O
now	O
it	O
is	O
recognized	O
as	O
a	O
cause	O
of	O
severe	O
malarial	O
disease	O
.	O

It	O
causes	O
severe	O
malarial	O
disease	O
similar	O
to	O
those	O
as	O
Plasmodium	O
falciparum	O
including	O
cerebral	B-DISO
malaria	I-DISO
,	O
severe	O
anaemia	B-DISO
,	O
severe	O
thrombocytopenia	O
,	O
hepatic	B-DISO
dysfunction	I-DISO
,	O
shock	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
and	O
pulmonary	B-DISO
oedema	I-DISO
.	O

However	O
,	O
retinal	B-DISO
hemorrhages	I-DISO
are	O
very	O
rare	O
in	O
Plasmodium	O
vivax	O
infestation	B-DISO
.	O

TITLE	O
:	O
Tracheobronchial	O
Stenoses	B-DISO
in	O
Granulomatosis	B-DISO
With	O
Polyangiitis	O
(	O
Wegener	O
'	O
s	O
):	O
A	O
Report	O
on	O
26	O
Cases	O
.	O

However	O
,	O
cyclophosphamide	O
seemed	O
to	O
effectively	O
treat	O
BSs	B-DISO
,	O
but	O
not	O
SGS	B-DISO
,	O
and	O
rituximab	O
may	O
be	O
of	O
interest	O
for	O
SGS	B-DISO
management	O
.	O

ABSTRACT	O
:	O
Despite	O
the	O
identification	O
of	O
horseshoe	O
bats	O
as	O
the	O
reservoir	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoVs	O
),	O
the	O
origin	O
of	O
SARS	B-DISO
-	O
CoV	O
ORF8	O
,	O
which	O
contains	O
the	O
29	O
-	O
nucleotide	O
signature	O
deletion	O
among	O
human	O
strains	O
,	O
remains	O
obscure	O
.	O

To	O
elucidate	O
the	O
origin	O
of	O
SARS	B-DISO
-	O
CoV	O
ORF8	O
,	O
we	O
sampled	O
348	O
bats	O
of	O
various	O
species	O
in	O
Yunnan	O
,	O
among	O
which	O
diverse	O
alphacoronaviruses	O
and	O
betacoronaviruses	O
,	O
including	O
potentially	O
novel	O
CoVs	O
,	O
were	O
identified	O
,	O
with	O
some	O
showing	O
potential	O
interspecies	O
transmission	O
.	O

The	O
high	O
Ka	O
/	O
Ks	O
ratio	O
among	O
human	O
SARS	B-DISO
-	O
CoVs	O
compared	O
to	O
that	O
among	O
SARSr	O
-	O
BatCoVs	O
supported	O
that	O
ORF8	O
is	O
under	O
strong	O
positive	O
selection	O
during	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
.	O

Most	O
human	O
SARS	B-DISO
-	O
CoV	O
epidemic	O
strains	O
contain	O
a	O
signature	O
29	O
-	O
nucleotide	O
deletion	O
in	O
ORF8	O
,	O
compared	O
to	O
civet	O
SARSr	O
-	O
CoVs	O
,	O
suggesting	O
that	O
ORF8	O
may	O
be	O
important	O
for	O
interspecies	O
transmission	O
.	O

In	O
addition	O
,	O
class	O
1	O
had	O
multiplex	O
PCR	O
performed	O
along	O
with	O
the	O
analysis	O
of	O
bed	B-DISO
locations	O
within	O
the	O
barracks	O
.	O

Bed	B-DISO
locations	O
of	O
URI	O
/	O
ILI	O
cases	O
in	O
class	O
1	O
tended	O
to	O
be	O
in	O
closer	O
proximity	O
to	O
each	O
other	O
.	O

Subsequently	O
,	O
the	O
patient	O
became	O
hemodynamically	O
unstable	O
and	O
the	O
identification	O
of	O
a	O
localized	O
tamponade	O
due	O
to	O
compressive	O
left	O
atrial	O
hematoma	B-DISO
prompted	O
reoperation	O
.	O

ABSTRACT	O
:	O
The	O
full	O
genome	O
sequence	O
of	O
a	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
identified	O
from	O
cultured	O
and	O
isolated	O
in	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Safety	O
and	O
efficacy	O
of	O
an	O
attenuated	O
Chinese	O
QX	O
-	O
like	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strain	O
as	O
a	O
candidate	O
vaccine	O
.	O

TITLE	O
:	O
Middle	O
-	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O

We	O
previously	O
reported	O
two	O
human	O
monoclonal	O
antibodies	O
that	O
target	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
and	O
exhibit	O
strong	O
neutralization	O
activity	O
against	O
live	O
and	O
pesudotyped	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

These	O
results	O
shed	O
light	O
on	O
the	O
molecular	O
basis	O
of	O
MERS	O
-	O
27	O
neutralization	O
and	O
will	O
assist	O
in	O
the	O
optimization	O
of	O
MERS	O
-	O
27	O
as	O
a	O
tool	O
to	O
combat	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
inhibits	O
dsRNA	O
-	O
induced	O
interferon	O
-	O
β	O
production	O
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
by	O
blockade	O
of	O
the	O
RIG	O
-	O
I	O
-	O
mediated	O
pathway	O
.	O

In	O
the	O
upstream	O
of	O
IRF	O
-	O
3	O
,	O
TANK	O
-	O
binding	O
kinase	O
1	O
(	O
TBK1	O
)-	O
or	O
inhibitor	O
of	O
κB	O
kinase	O
-	O
ε	O
(	O
IKKε	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	O
-	O
I	O
-	O
and	O
its	O
adapter	O
molecule	O
IFN	O
-	O
β	O
promoter	O
stimulator	O
1	O
(	O
IPS	B-DISO
-	O
1	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	B-DISO
.	O

We	O
performed	O
a	O
detailed	O
analysis	O
of	O
the	O
immunomodulatory	O
properties	O
and	O
proteomic	O
profile	O
of	O
MSCs	O
systemically	O
administered	O
to	O
two	O
patients	O
with	O
severe	O
refractory	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
on	O
a	O
compassionate	O
use	O
basis	O
and	O
attempted	O
to	O
correlate	O
these	O
with	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
actions	O
.	O

Infectious	B-DISO
status	O
was	O
demonstrated	O
for	O
the	O
3	O
viruses	O
,	O
and	O
in	O
the	O
case	O
of	O
IAV	O
and	O
PRRSV	O
,	O
viruses	O
were	O
isolated	O
from	O
particles	O
larger	O
than	O
2	O
.	O
1	O
μm	O
.	O

The	O
median	O
naloxone	O
dose	O
of	O
0	O
.	O
08	O
mg	O
(	O
range	O
,	O
0	O
.	O
04	O
to	O
0	O
.	O
12	O
mg	O
)	O
reversed	O
opioid	O
-	O
induced	O
ventilatory	O
and	O
CNS	B-DISO
depression	I-DISO
.	O

Two	O
patients	O
experienced	O
acute	O
opioid	B-DISO
withdrawal	I-DISO
after	O
receiving	O
0	O
.	O
08	O
mg	O
.	O

Vaccinated	O
macaques	O
were	O
protected	O
and	O
failed	O
to	O
demonstrate	O
any	O
clinical	O
or	O
radiographic	O
signs	O
of	O
pneumonia	B-DISO
.	O

After	O
SARS	B-DISO
,	O
the	O
Taiwan	O
Centers	O
for	O
Disease	O
Control	O
accelerated	O
and	O
strengthened	O
domestic	O
research	O
on	O
influenza	B-DISO
and	O
expanded	O
the	O
exchange	O
of	O
information	O
with	O
international	O
counterparts	O
.	O

ABSTRACT	O
:	O
The	O
population	O
structure	O
of	O
an	O
embryo	O
-	O
attenuated	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
Arkansas	O
(	O
Ark	O
)	O
Delmarva	O
Poultry	O
Industry	O
(	O
DPI	O
)-	O
derived	O
vaccine	O
was	O
characterized	O
during	O
serial	O
passages	O
in	O
chicken	O
embryo	O
kidney	O
(	O
CEK	O
)	O
cells	O
and	O
after	O
back	O
-	O
passage	O
in	O
embryonated	O
chicken	O
eggs	O
(	O
ECE	O
)	O
and	O
in	O
chickens	O
.	O

This	O
study	O
explored	O
respiratory	O
viral	B-DISO
infections	I-DISO
with	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
human	O
bocavirus	O
,	O
coronavirus	O
,	O
and	O
other	O
early	O
diagnostic	O
substances	O
as	O
confirmed	O
by	O
literature	O
resources	O
.	O

Polidocanol	O
foam	O
can	O
achieve	O
obliteration	O
of	O
gastric	B-DISO
varices	I-DISO
comparable	O
to	O
that	O
of	O
ethanolamine	O
oleate	O
but	O
with	O
a	O
significantly	O
lower	O
sclerosant	O
dose	O
and	O
reduced	O
risk	O
of	O
hemolysis	B-DISO
-	O
induced	O
complications	O
and	O
harmful	O
reactions	O
,	O
including	O
pain	O
and	O
fever	O
.	O

CONCLUSIONS	O
:	O
Polidocanol	O
foam	O
can	O
achieve	O
obliteration	O
of	O
gastric	B-DISO
varices	I-DISO
comparable	O
to	O
that	O
of	O
ethanolamine	O
oleate	O
but	O
with	O
a	O
significantly	O
lower	O
sclerosant	O
dose	O
and	O
reduced	O
risk	O
of	O
hemolysis	B-DISO
-	O
induced	O
complications	O
and	O
harmful	O
reactions	O
,	O
including	O
pain	O
and	O
fever	O
.	O

However	O
,	O
until	O
recently	O
no	O
consensus	O
was	O
available	O
regarding	O
the	O
criteria	O
of	O
ARDS	B-DISO
that	O
should	O
be	O
evident	O
in	O
an	O
experimental	O
animal	O
model	O
.	O

TITLE	O
:	O
X	O
-	O
ray	O
Structural	O
and	O
Functional	O
Studies	O
of	O
the	O
Three	O
Tandemly	O
Linked	O
Domains	O
of	O
Non	O
-	O
structural	O
Protein	O
3	O
(	O
nsp3	O
)	O
from	O
Murine	B-DISO
Hepatitis	I-DISO
Virus	O
Reveal	O
Conserved	O
Functions	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
chicken	O
viral	B-DISO
disease	I-DISO
,	O
causing	O
severe	O
economic	O
losses	O
to	O
poultry	O
producers	O
worldwide	O
.	O

However	O
,	O
upregulation	O
of	O
proteins	O
was	O
found	O
,	O
usually	O
incoherent	O
of	O
exerting	O
effects	O
in	O
blunt	O
thoracic	B-DISO
trauma	O
(	O
pendrin	O
,	O
resistin	O
,	O
metallothionein	O
and	O
glucocorticoid	O
-	O
induced	O
leucine	O
zipper	O
).	O

The	O
role	O
of	O
respiratory	O
viruses	O
in	O
the	O
pathogenesis	B-DISO
of	O
KD	O
is	O
not	O
fully	O
understood	O
.	O

A	O
positive	O
respiratory	O
viral	O
PCR	O
or	O
presence	O
of	O
respiratory	B-DISO
symptoms	I-DISO
at	O
the	O
time	O
of	O
presentation	O
should	O
not	O
be	O
used	O
to	O
exclude	O
a	O
diagnosis	O
of	O
KD	O
.	O

High	O
positive	O
end	O
-	O
expiratory	O
pressure	O
levels	O
can	O
be	O
used	O
in	O
severe	O
traumatic	O
brain	O
injury	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
as	O
a	O
safe	O
alternative	O
to	O
improve	O
brain	O
oxygenation	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
indirect	O
ELISA	O
based	O
on	O
a	O
truncated	O
S	O
protein	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

Coronaviruses	O
are	O
RNA	O
viruses	O
representing	O
a	O
real	O
threat	O
for	O
public	O
health	O
,	O
as	O
evidenced	O
by	O
SARS	B-DISO
and	O
the	O
emerging	O
MERS	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
represent	O
highly	O
pathogenic	O
human	O
CoVs	O
that	O
share	O
a	O
property	O
to	O
inhibit	O
host	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
.	O

Until	O
recently	O
five	O
types	O
of	O
human	O
coronaviruses	O
(	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
HKU1	O
,	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
229E	O
,	O
SARS	B-DISO
-	O
CoV	O
)	O
have	O
been	O
known	O
,	O
however	O
a	O
novel	O
CoV	O
has	O
been	O
identified	O
in	O
2012	O
in	O
Saudi	O
Arabia	O
.	O

This	O
virus	O
,	O
namely	O
MERS	O
-	O
CoV	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
),	O
was	O
classified	O
within	O
Coronaviridae	O
family	O
,	O
Coronavirinae	O
sub	O
-	O
family	O
,	O
Betacoronavirus	O
genus	O
,	O
clade	O
C	O
.	O
It	O
causes	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
humans	O
and	O
transmits	O
via	O
respiratory	O
route	O
and	O
close	O
contact	O
between	O
humans	O
.	O

For	O
the	O
amplification	B-DISO
of	O
nucleocapsid	O
(	O
N	O
)	O
and	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
genes	O
,	O
hemi	O
-	O
nested	O
PCR	O
(	O
Invitrogen	O
,	O
ABD	O
)	O
was	O
conducted	O
,	O
followed	O
by	O
sequence	O
analysis	O
of	O
204	O
nucleotide	O
part	O
of	O
N	O
gene	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
transmission	O
,	O
virology	O
and	O
therapeutic	O
targeting	O
to	O
aid	O
in	O
outbreak	O
control	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
high	O
fever	O
,	O
cough	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
and	O
multiorgan	O
dysfunction	O
that	O
may	O
eventually	O
lead	O
to	O
the	O
death	O
of	O
the	O
infected	O
individuals	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
pathogenicity	O
,	O
the	O
immune	O
antibody	O
production	O
,	O
serotype	O
and	O
the	O
tissue	O
tropism	O
.	O

In	O
contrast	O
,	O
regional	O
analgesia	B-DISO
confers	O
excellent	O
site	O
-	O
specific	O
pain	O
relief	O
that	O
is	O
free	O
from	O
major	O
side	O
effects	O
,	O
reduces	O
opioid	O
requirement	O
in	O
trauma	O
patients	O
,	O
and	O
is	O
safe	O
and	O
easy	O
to	O
perform	O
.	O

Six	O
of	O
20	O
critically	B-DISO
ill	I-DISO
patients	O
in	O
the	O
ICU	O
received	O
PPV	O
.	O

Although	O
there	O
was	O
no	O
difference	O
between	O
groups	O
regarding	O
the	O
primary	O
outcome	O
,	O
a	O
restrictive	O
transfusion	O
strategy	O
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
cardiogenic	B-DISO
shock	I-DISO
in	O
elderly	O
patients	O
undergoing	O
cardiac	O
surgery	O
compared	O
with	O
a	O
more	O
liberal	O
strategy	O
.	O

Thirty	O
-	O
day	O
mortality	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
acute	O
renal	O
injury	O
were	O
similar	O
in	O
the	O
restrictive	O
and	O
liberal	O
transfusion	O
groups	O
in	O
both	O
age	O
groups	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
been	O
recognized	O
as	O
a	O
swine	O
pathogen	O
for	O
40	O
years	O
,	O
but	O
until	O
2013	O
had	O
not	O
been	O
detected	O
in	O
the	O
Western	O
Hemisphere	O
.	O

In	O
this	O
study	O
,	O
aided	O
by	O
metagenome	O
sequencing	O
technology	O
,	O
gut	O
microbiota	O
profiles	O
in	O
feces	O
of	O
viral	B-DISO
diarrhea	I-DISO
(	O
VD	O
)	O
and	O
viral	O
control	O
(	O
VC	O
)	O
piglets	O
were	O
investigated	O
.	O

Ten	O
of	O
11	O
human	O
coronavirus	B-DISO
infections	I-DISO
were	O
identified	O
in	O
the	O
fall	O
-	O
winter	O
season	O
.	O

The	O
aim	O
of	O
this	O
mini	O
-	O
review	O
is	O
to	O
give	O
a	O
short	O
overview	O
of	O
some	O
,	O
but	O
not	O
all	O
,	O
adjuvant	O
therapeutic	O
strategies	O
for	O
pneumonia	B-DISO
and	O
its	O
most	O
important	O
complications	O
,	O
sepsis	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
briefly	O
discuss	O
future	O
perspectives	O
.	O

For	O
moderate	O
-	O
severe	O
ARDS	B-DISO
criteria	O
(	O
PaO2	O
/	O
FiO2	O
≤	O
200	O
),	O
sensitivity	O
was	O
64	O
%	O
(	O
95	O
%	O
CI	O
31	O
-	O
89	O
)	O
and	O
specificity	O
was	O
86	O
%	O
(	O
95	O
%	O
CI	O
65	O
-	O
97	O
).	O

Pulse	O
oximetry	O
and	O
pulmonary	O
ultrasound	O
may	O
be	O
useful	O
tools	O
to	O
screen	O
for	O
,	O
or	O
rule	O
out	O
,	O
impaired	B-DISO
oxygenation	O
or	O
lung	O
abnormalities	O
consistent	O
with	O
ARDS	B-DISO
in	O
under	O
-	O
resourced	O
settings	O
where	O
arterial	O
blood	O
gas	O
testing	O
and	O
chest	O
radiography	O
are	O
not	O
readily	O
available	O
.	O

RESULTS	O
:	O
One	O
hundred	O
and	O
twenty	O
three	O
ultrasound	O
assessments	O
were	O
performed	O
on	O
77	O
consecutively	O
enrolled	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

This	O
is	O
the	O
case	O
,	O
for	O
instance	O
,	O
of	O
rabies	B-DISO
virus	O
and	O
other	O
Lyssavirus	O
(	O
Family	O
Rhabdoviridae	O
),	O
Nipah	O
and	O
Hendra	O
viruses	O
(	O
Paramyxoviridae	O
),	O
Ebola	O
and	O
Marburg	O
viruses	O
(	O
Filoviridae	O
),	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
(	O
Coronaviridae	O
).	O

The	O
most	O
frequently	O
observed	O
co	B-DISO
-	I-DISO
infection	I-DISO
patterns	O
were	O
RSV	O
-	O
Rhinovirus	O
(	O
23	O
patients	O
,	O
11	O
.	O
3	O
%,	O
GENDRES	O
cohort	O
)	O
and	O
RSV	O
-	O
bocavirus	O
/	O
bocavirus	O
-	O
influenza	B-DISO
(	O
5	O
patients	O
,	O
5	O
.	O
2	O
%,	O
UK	O
cohort	O
).	O

These	O
receptors	O
are	O
important	O
negative	O
regulators	O
of	O
acute	O
inflammatory	B-DISO
responses	I-DISO
and	O
are	O
potential	O
targets	O
for	O
the	O
treatment	O
of	O
sepsis	B-DISO
and	O
ARDS	B-DISO
.	O

For	O
parainfluenza	B-DISO
virus	O
2	O
only	O
it	O
was	O
10	O
(	O
5	O
)	O
copies	O
/	O
ml	O
.	O

Here	O
we	O
provide	O
a	O
head	O
-	O
to	O
-	O
head	O
comparison	O
of	O
exposure	O
patterns	O
and	O
transmission	O
dynamics	O
of	O
large	O
hospital	O
clusters	O
of	O
MERS	O
and	O
SARS	B-DISO
,	O
including	O
the	O
most	O
recent	O
South	O
Korean	O
outbreak	O
of	O
MERS	O
in	O
2015	O
.	O

We	O
carried	O
out	O
simulations	O
of	O
nosocomial	O
outbreaks	O
of	O
MERS	O
and	O
SARS	B-DISO
using	O
branching	O
process	O
models	O
rooted	O
in	O
transmission	O
tree	O
data	O
,	O
and	O
inferred	O
the	O
probability	O
and	O
characteristics	O
of	O
large	O
outbreaks	O
.	O

Both	O
MERS	O
and	O
SARS	B-DISO
nosocomial	O
outbreaks	O
are	O
characterized	O
by	O
early	O
nosocomial	O
super	O
-	O
spreading	O
events	O
,	O
with	O
the	O
reproduction	O
number	O
dropping	O
below	O
1	O
within	O
three	O
to	O
five	O
disease	O
generations	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
pulmonary	O
ward	O
of	O
the	O
Alfred	O
Sokołowski	O
Regional	O
Pulmonary	O
Hospital	O
in	O
Szczecin	O
-	O
Zdunowo	O
with	O
suspected	O
pneumonia	B-DISO
of	O
unknown	O
etiology	O
.	O

TITLE	O
:	O
[	O
A	O
Case	O
of	O
Nasopharyngeal	B-DISO
Cancer	I-DISO
with	O
Febrile	B-DISO
Neutropenia	I-DISO
Followed	O
by	O
Death	O
during	O
Adjuvant	O
Chemotherapy	O
].	O

ABSTRACT	O
:	O
Chemotherapy	O
-	O
related	O
death	O
can	O
occur	O
,	O
but	O
is	O
rarely	O
experienced	O
in	O
the	O
case	O
of	O
head	B-DISO
and	I-DISO
neck	I-DISO
cancer	I-DISO
.	O

The	O
autopsy	O
findings	O
suggested	O
that	O
the	O
main	O
cause	O
of	O
death	O
was	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
but	O
cytomegalovirus	O
(	O
CMV	O
)	O
infection	B-DISO
was	O
also	O
noted	O
in	O
multiple	O
organs	O
.	O
.	O

Baboons	O
challenged	O
with	O
10	O
(	O
9	O
)	O
cfu	O
/	O
kg	O
(	O
LD50	O
)	O
live	O
E	O
.	O
coli	O
by	O
intravenous	O
infusion	O
were	O
treated	O
or	O
not	O
with	O
compstatin	O
at	O
the	O
time	O
of	O
challenge	O
or	O
5	O
hrs	B-DISO
thereafter	O
.	O

Our	O
data	O
demonstrate	O
that	O
complement	O
inhibition	O
effectively	O
attenuates	O
collagen	O
deposition	O
and	O
fibrotic	O
responses	O
in	O
the	O
lung	O
after	O
severe	B-DISO
sepsis	I-DISO
.	O

This	O
gene	O
locus	O
in	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
encodes	O
the	O
ns12	O
.	O
9	O
accessory	O
protein	O
;	O
however	O
,	O
its	O
function	O
during	O
viral	B-DISO
infection	I-DISO
remains	O
unknown	O
.	O

HCoV	O
-	O
OC43	O
was	O
isolated	O
in	O
the	O
1960s	O
and	O
is	O
a	O
major	O
agent	O
of	O
the	O
common	B-DISO
cold	I-DISO
.	O

We	O
identified	O
the	O
important	O
functions	O
of	O
the	O
ns12	O
.	O
9	O
viroporin	O
in	O
virion	O
morphogenesis	O
during	O
HCoV	O
-	O
OC43	O
infection	B-DISO
.	O

TITLE	O
:	O
Intratracheal	O
exposure	O
of	O
common	O
marmosets	O
to	O
MERS	O
-	O
CoV	O
Jordan	O
-	O
n3	O
/	O
2012	O
or	O
MERS	O
-	O
CoV	O
EMC	B-DISO
/	O
2012	O
isolates	O
does	O
not	O
result	O
in	O
lethal	O
disease	O
.	O

Based	O
on	O
these	O
data	O
we	O
sought	O
to	O
compare	O
two	O
isolates	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
followed	O
disease	B-DISO
progression	I-DISO
in	O
common	O
marmosets	O
after	O
intratracheal	O
exposure	O
with	O
:	O
MERS	O
-	O
CoV	O
-	O
EMC	B-DISO
/	O
2012	O
,	O
MERS	O
-	O
CoV	O
-	O
Jordan	O
-	O
n3	O
/	O
2012	O
,	O
media	O
,	O
or	O
inactivated	O
virus	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
the	O
South	O
of	O
Portugal	O
in	O
January	O
2015	O
and	O
the	O
spread	O
of	O
PEDV	O
northwards	O
in	O
the	O
territory	O
are	O
described	O
.	O

TITLE	O
:	O
Suppression	B-DISO
subtractive	O
hybridization	O
method	O
for	O
the	O
identification	O
of	O
a	O
new	O
strain	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
from	O
xenografted	O
SCID	B-DISO
mice	O
.	O

The	O
pretravel	O
medical	O
consultation	O
includes	O
immunizations	O
,	O
malaria	B-DISO
chemoprophylaxis	O
,	O
self	O
-	O
treatment	O
for	O
traveler	B-DISO
'	I-DISO
s	I-DISO
diarrhea	I-DISO
,	O
and	O
advice	O
on	O
the	O
prevention	O
of	O
a	O
myriad	O
of	O
other	O
infectious	B-DISO
causes	O
including	O
dengue	B-DISO
,	O
chikungunya	B-DISO
,	O
rickettsiosis	B-DISO
,	O
leptospirosis	B-DISO
,	O
schistosomiasis	B-DISO
,	O
and	O
strongyloidiasis	B-DISO
.	O

Travel	O
to	O
locations	O
experiencing	O
outbreaks	O
such	O
as	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
chikungunya	B-DISO
call	O
for	O
specific	O
alerts	O
on	O
preventive	O
strategies	O
.	O

TITLE	O
:	O
Origin	O
and	O
Possible	O
Genetic	O
Recombination	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
from	O
the	O
First	O
Imported	O
Case	O
in	O
China	O
:	O
Phylogenetics	O
and	O
Coalescence	O
Analysis	O
.	O

The	O
replication	O
of	O
MVvac2	O
-	O
CoV	O
-	O
S	O
in	O
Vero	O
cells	O
turned	O
out	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
control	O
virus	O
MVvac2	O
-	O
GFP	O
(	O
encoding	O
green	O
fluorescent	O
protein	O
),	O
while	O
titers	O
of	O
MVvac2	O
-	O
CoV	O
-	O
solS	O
were	O
impaired	B-DISO
approximately	O
3	O
-	O
fold	O
.	O

The	O
potential	O
for	O
this	O
pathogen	O
to	O
infect	O
non	O
-	O
cystic	B-DISO
fibrosis	I-DISO
patients	O
is	O
limited	O
and	O
its	O
epidemiology	O
is	O
poorly	O
understood	O
.	O

Previously	O
reported	O
cases	O
of	O
severe	O
Burkholderia	O
cepacia	O
complex	O
lung	B-DISO
infection	I-DISO
in	O
immunocompetent	O
hosts	O
include	O
pneumonia	B-DISO
,	O
bronchiectasis	B-DISO
,	O
pyopneumothorax	B-DISO
,	O
and	O
cavitary	O
lesions	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curves	O
for	O
the	O
TTS	O
score	O
in	O
predicting	O
ARDS	B-DISO
was	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
0	O
.	O
78	O
-	O
0	O
.	O
86	O
)	O
in	O
the	O
overall	O
population	O
.	O

A	O
TTS	O
score	O
of	O
13	O
-	O
25	O
was	O
found	O
to	O
be	O
independent	O
risk	O
factors	O
of	O
ARDS	B-DISO
(	O
OR	O
25	O
.	O
8	O
[	O
95	O
%	O
CI	O
6	O
.	O
7	O
-	O
99	O
.	O
6	O
]	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
value	O
of	O
B	O
-	O
type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
in	O
the	O
assessment	O
of	O
severity	O
and	O
prognosis	O
in	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
A	O
total	O
of	O
59	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
and	O
14	O
patients	O
without	O
ALI	O
/	O
ARDS	B-DISO
were	O
included	O
in	O
the	O
study	O
.	O

Biochemical	O
studies	O
showed	O
that	O
kuwanon	O
-	O
L	O
is	O
able	O
to	O
inhibit	O
the	O
HIV	B-DISO
-	O
1	O
IN	O
catalytic	O
activity	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
LEDGF	O
/	O
p75	O
protein	O
,	O
the	O
IN	O
dimerization	O
,	O
and	O
the	O
IN	O
/	O
LEDGF	O
binding	O
.	O

ABSTRACT	O
:	O
The	O
re	O
-	O
emerging	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
variant	O
related	O
diarrhea	B-DISO
has	O
been	O
documented	O
in	O
China	O
since	O
late	O
2010	O
and	O
now	O
with	O
global	O
distribution	O
.	O

TITLE	O
:	O
Sepsis	B-DISO
-	O
associated	O
pulmonary	B-DISO
complications	I-DISO
in	O
emergency	B-DISO
department	O
patients	O
monitored	O
with	O
serial	O
lactate	O
:	O
An	O
observational	O
cohort	O
study	O
.	O

Serial	O
lactate	O
monitoring	O
is	O
a	O
useful	O
tool	O
to	O
gauge	O
global	O
tissue	O
hypoxia	B-DISO
in	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
patients	O
with	O
sepsis	B-DISO
.	O

The	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
pulmonary	B-DISO
complications	I-DISO
:	O
(	O
1	O
)	O
ARDS	B-DISO
development	O
and	O
(	O
2	O
)	O
respiratory	B-DISO
failure	I-DISO
.	O

In	O
the	O
a	O
priori	O
subgroup	O
of	O
patients	O
mechanically	O
ventilated	O
in	O
the	O
ED	O
(	O
n	O
=	O
97	O
),	O
those	O
who	O
developed	O
ARDS	B-DISO
received	O
higher	O
tidal	O
volumes	O
compared	O
to	O
patients	O
who	O
did	O
not	O
develop	O
ARDS	B-DISO
(	O
8	O
.	O
7	O
mL	O
/	O
kg	O
predicted	O
body	O
weight	O
[	O
interquartile	O
range	O
,	O
7	O
.	O
6	O
-	O
9	O
.	O
5	O
]	O
vs	O
7	O
.	O
6	O
[	O
interquartile	O
range	O
,	O
6	O
.	O
8	O
-	O
9	O
.	O
0	O
];	O
P	O
<.	O
01	O
).	O

TITLE	O
:	O
Real	O
-	O
time	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
.	O

A	O
range	O
of	O
HDTs	O
are	O
available	O
,	O
including	O
commonly	O
used	O
drugs	O
with	O
good	O
safety	O
profiles	O
,	O
which	O
could	O
augment	O
host	O
innate	O
and	O
adaptive	O
immune	O
mechanisms	O
to	O
MERS	O
-	O
CoV	O
,	O
modulate	O
excessive	O
inflammation	B-DISO
and	O
reduce	O
lung	O
tissue	O
destruction	O
.	O

The	O
recurrent	O
outbreaks	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
at	O
hospitals	O
in	O
the	O
Middle	O
East	O
present	O
unique	O
opportunities	O
to	O
conduct	O
randomized	O
clinical	O
trials	O
.	O

Previous	O
studies	O
reported	O
secondary	O
attack	O
rates	O
(	O
SAR	O
)	O
of	O
4	O
-	O
10	O
%	O
for	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
in	O
the	O
household	O
.	O

Household	O
contacts	O
of	O
index	O
cases	O
with	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
were	O
followed	O
for	O
12	O
days	O
.	O

TITLE	O
:	O
The	O
NLRP3	O
Inflammasome	O
and	O
IL	O
-	O
1β	O
Accelerate	O
Immunologically	O
Mediated	O
Pathology	B-DISO
in	O
Experimental	O
Viral	O
Fulminant	B-DISO
Hepatitis	I-DISO
.	O

When	O
influenza	B-DISO
A	O
epidemics	O
occured	O
early	O
,	O
timing	O
of	O
the	O
epidemics	O
of	O
several	O
respiratory	O
winter	O
viruses	O
usually	O
occurring	O
close	O
in	O
time	O
to	O
influenza	B-DISO
A	O
was	O
affected	O
,	O
while	O
trends	O
in	O
rhinoviruses	O
(	O
occurring	O
in	O
autumn	O
)	O
and	O
trends	O
in	O
enteral	O
viruses	O
were	O
not	O
.	O

TITLE	O
:	O
Infectious	B-DISO
Diseases	I-DISO
,	O
Urbanization	O
and	O
Climate	O
Change	O
:	O
Challenges	O
in	O
Future	O
China	O
.	O

Due	O
to	O
substantial	O
investments	O
from	O
all	O
levels	O
of	O
government	O
,	O
the	O
public	O
health	O
system	O
in	O
China	O
has	O
been	O
improved	O
since	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
.	O

It	O
also	O
explores	O
how	O
the	O
growing	O
migrant	O
population	O
,	O
dramatic	O
changes	O
in	O
the	O
natural	O
landscape	O
following	O
rapid	O
urbanization	O
,	O
and	O
changing	O
climatic	O
conditions	O
can	O
contribute	O
to	O
the	O
emergence	O
and	O
re	O
-	O
emergence	O
of	O
infectious	B-DISO
disease	I-DISO
.	O

Fortunately	O
,	O
the	O
condition	B-DISO
of	O
this	O
woman	O
was	O
stabilized	O
and	O
she	O
achieved	O
complete	O
physical	O
recovery	O
,	O
despite	O
minor	O
neurological	O
deficit	B-DISO
in	O
the	O
fingers	O
of	O
her	O
right	O
hand	O
.	O

TITLE	O
:	O
Clinical	O
and	O
laboratory	O
characteristics	O
of	O
viral	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
preschool	O
children	O
.	O

Pneumonia	B-DISO
was	O
present	O
in	O
71	O
.	O
4	O
%	O
of	O
all	O
coronavirus	B-DISO
infections	I-DISO
,	O
35	O
.	O
1	O
%	O
of	O
all	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infections	I-DISO
,	O
and	O
13	O
.	O
0	O
%	O
of	O
all	O
rhinovirus	O
infections	B-DISO
.	O

As	O
the	O
function	O
of	O
ORF7a	O
in	O
SARS	B-DISO
-	O
CoV	O
replication	O
was	O
previously	O
unknown	O
,	O
we	O
focused	O
our	O
study	O
on	O
ORF7a	O
.	O

Identifying	O
host	O
factors	O
that	O
regulate	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
is	O
critical	O
to	O
understanding	O
how	O
this	O
lethal	O
virus	O
causes	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
reveal	O
infection	B-DISO
dynamics	O
of	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
bovine	O
parainfluenza	B-DISO
virus	O
type	O
3	O
(	O
PI	O
-	O
3	O
),	O
bovine	O
herpesvirus	O
1	O
(	O
BHV	O
-	O
1	O
),	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
(	O
BVDV	O
),	O
bovine	O
adenovirus	B-DISO
type	O
3	O
(	O
BAV	B-DISO
-	O
3	O
)	O
and	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
which	O
are	O
important	O
viral	O
pathogens	O
of	O
respiratory	B-DISO
disease	I-DISO
complex	O
in	O
ruminants	O
.	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
does	O
not	O
improve	O
the	O
prognosis	O
of	O
ARDS	B-DISO
patients	O
despite	O
an	O
improvement	O
in	O
oxygenation	O
.	O

CONCLUSIONS	O
:	O
The	O
RVEDA	O
/	O
LVEDA	O
ratio	O
measured	O
just	O
before	O
HFOV	O
predicts	O
the	O
hemodynamic	O
intolerance	O
of	O
this	O
technique	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Rapid	O
and	O
accurate	O
detection	O
of	O
first	O
cases	O
with	O
certainty	O
will	O
contribute	O
significantly	O
in	O
preventing	O
disease	B-DISO
transmission	I-DISO
and	O
escalation	O
to	O
pandemic	O
levels	O
.	O

The	O
staircase	O
recruitment	B-DISO
maneuver	O
is	O
a	O
step	O
-	O
by	O
-	O
step	O
increase	O
in	O
PEEP	O
followed	O
by	O
a	O
decremental	O
PEEP	O
trial	O
.	O

In	O
early	O
ARDS	B-DISO
,	O
most	O
of	O
the	O
ΔEELV	O
occurs	O
within	O
the	O
first	O
minute	O
,	O
and	O
change	O
is	O
completed	O
within	O
2	O
minutes	O
,	O
following	O
an	O
increase	O
or	O
decrease	O
in	O
PEEP	O
.	O

TITLE	O
:	O
Clinical	O
Effects	O
of	O
a	O
Longer	O
Duration	O
of	O
Polymyxin	O
B	O
-	O
Immobilized	O
Fiber	O
Column	O
Direct	O
Hemoperfusion	O
Therapy	O
for	O
Severe	B-DISO
Sepsis	I-DISO
and	O
Septic	B-DISO
Shock	I-DISO
.	O

In	O
addition	O
,	O
the	O
P	O
/	O
F	O
ratio	O
improved	O
significantly	O
in	O
the	O
group	O
of	O
surviving	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
the	O
period	O
between	O
the	O
start	O
and	O
24	O
h	O
after	O
the	O
end	O
of	O
PMX	O
-	O
DHP	O
therapy	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
between	O
2	O
h	O
after	O
the	O
start	O
of	O
and	O
the	O
end	O
of	O
this	O
therapy	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Then	O
,	O
next	O
generation	O
sequencing	O
was	O
performed	O
on	O
9	O
hpi	B-DISO
and	O
control	O
uninfected	O
cells	O
by	O
Illumina	O
analyzer	O
.	O

RESULTS	O
:	O
The	O
signs	O
of	O
leukostases	B-DISO
were	O
detected	O
in	O
more	O
than	O
half	O
of	O
the	O
18	O
patients	O
with	O
higher	O
white	O
blood	O
cell	O
counts	O
:	O
13	O
(	O
72	O
%)	O
with	O
lung	O
injury	O
,	O
including	O
5	O
of	O
them	O
with	O
signs	O
of	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
6	O
(	O
27	O
.	O
8	O
%)	O
with	O
neurological	O
symptomatology	O
,	O
7	O
(	O
38	O
.	O
9	O
%)	O
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
syndrome	B-DISO
,	O
including	O
1	O
with	O
intracranial	B-DISO
hemorrhage	I-DISO
.	O

Thus	O
,	O
physicians	O
should	O
be	O
familiar	O
with	O
viral	B-DISO
hemorrhagic	I-DISO
fevers	I-DISO
:	O
filoviruses	O
cause	O
Ebola	O
and	O
Marburg	O
fever	O
,	O
arenaviruses	O
cause	O
Lassa	B-DISO
fever	I-DISO
and	O
South	O
American	O
hemorrhagic	B-DISO
fevers	I-DISO
,	O
and	O
the	O
bunyaviruses	O
cause	O
among	O
others	O
Crimean	B-DISO
-	I-DISO
Congo	I-DISO
hemorrhagic	I-DISO
fever	I-DISO
.	O

ABSTRACT	O
:	O
The	O
newly	O
-	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
can	O
cause	O
severe	O
and	O
fatal	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
humans	O
.	O

ECoV	O
is	O
not	O
prevalent	O
and	O
was	O
not	O
related	O
to	O
diarrhea	B-DISO
in	O
thoroughbred	O
foals	O
in	O
the	O
Hidaka	O
district	O
of	O
Hokkaido	O
between	O
2012	O
and	O
2014	O
.	O

CONCLUSIONS	O
:	O
ECoV	O
is	O
not	O
prevalent	O
and	O
was	O
not	O
related	O
to	O
diarrhea	B-DISO
in	O
thoroughbred	O
foals	O
in	O
the	O
Hidaka	O
district	O
of	O
Hokkaido	O
between	O
2012	O
and	O
2014	O
.	O

ABSTRACT	O
:	O
Since	O
SARS	B-DISO
epidemic	O
in	O
2003	O
,	O
Hong	O
Kong	O
has	O
experienced	O
several	O
major	O
epidemic	O
risks	O
,	O
but	O
how	O
general	O
community	O
might	O
react	O
to	O
the	O
repeated	O
infectious	B-DISO
diseases	I-DISO
health	O
risks	O
have	O
not	O
been	O
studied	O
.	O

Educational	O
campaigns	O
and	O
framing	O
the	O
issue	O
to	O
increase	O
public	O
and	O
media	O
awareness	O
are	O
crucial	O
in	O
preventing	O
the	O
current	O
public	O
fatigue	B-DISO
towards	O
outbreaks	O
.	O

Common	O
pathogens	O
such	O
as	O
calicivirus	O
and	O
Influenza	B-DISO
virus	O
as	O
well	O
as	O
blood	O
-	O
borne	O
pathogens	O
such	O
as	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
,	O
hepatitis	B-DISO
B	I-DISO
and	O
C	O
virus	O
,	O
gastro	O
-	O
intestinal	B-DISO
infections	I-DISO
such	O
as	O
Campylobacter	O
and	O
Salmonella	B-DISO
and	O
vector	O
-	O
borne	O
pathogens	O
such	O
as	O
Borrelia	B-DISO
were	O
all	O
in	O
the	O
highest	O
priority	O
group	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
resistant	O
to	O
IFN	O
treatment	O
and	O
identify	O
a	O
role	O
for	O
accessory	O
protein	O
3a	O
in	O
the	O
resistance	O
against	O
the	O
type	O
I	O
IFN	O
response	O
.	O

This	O
is	O
achieved	O
by	O
considering	O
a	O
multi	O
-	O
stage	O
infection	B-DISO
model	O
on	O
networks	O
.	O

To	O
determine	O
the	O
epidemiological	O
and	O
clinical	O
characteristics	O
of	O
18	O
respiratory	O
pathogens	O
,	O
we	O
analyzed	O
12	O
,	O
502	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
ARIs	O
)	O
by	O
performing	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
on	O
patient	O
pharyngeal	O
swabs	O
.	O

Although	O
clinically	O
distinguishing	O
specific	O
pathogens	O
responsible	O
for	O
RTIs	O
is	O
difficult	O
,	O
the	O
epidemiological	O
and	O
clinical	O
characteristics	O
of	O
the	O
various	O
RTI	B-DISO
-	O
causing	O
agents	O
could	O
provide	O
clues	O
for	O
clinicians	O
,	O
thereby	O
informing	O
decisions	O
regarding	O
prevention	O
and	O
medication	O
and	O
guiding	O
appropriate	O
public	O
health	O
strategies	O
.	O

The	O
median	O
pig	O
diarrhea	B-DISO
dose	O
(	O
PDD50	O
)	O
of	O
the	O
virus	O
pool	O
was	O
determined	O
as	O
7	O
.	O
35	O
log10	O
PDD50	O
/	O
mL	O
,	O
similar	O
to	O
the	O
cell	O
culture	O
infectious	B-DISO
titer	O
,	O
7	O
.	O
75	O
log10	O
plaque	B-DISO
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
.	O
100	O
PDD50	O
caused	O
watery	B-DISO
diarrhea	I-DISO
in	O
all	O
conventional	O
suckling	O
piglets	O
(	O
n	O
=	O
12	O
)	O
derived	O
from	O
a	O
PEDV	O
-	O
naive	O
sow	O
,	O
whereas	O
1000	O
and	O
10	O
000	O
PDD50	O
did	O
not	O
cause	O
diarrhea	B-DISO
in	O
piglets	O
derived	O
from	O
two	O
PEDV	O
-	O
field	O
exposed	O
-	O
recovered	O
sows	O
.	O

A	O
pregnant	O
woman	O
was	O
admitted	O
with	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
H1N1	B-DISO
influenza	I-DISO
.	O

TITLE	O
:	O
Rapid	O
and	O
Effective	O
Virucidal	O
Activity	O
of	O
Povidone	O
-	O
Iodine	O
Products	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
Modified	O
Vaccinia	B-DISO
Virus	O
Ankara	O
(	O
MVA	O
).	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
),	O
comprising	O
185	O
cases	O
linked	O
to	O
healthcare	O
facilities	O
,	O
occurred	O
in	O
the	O
Republic	O
of	O
Korea	O
from	O
May	O
to	O
July	O
2015	O
.	O

Etiology	O
of	O
GBS	B-DISO
is	O
incompletely	O
understood	O
,	O
prognosis	O
is	O
usually	O
good	O
with	O
early	O
detection	O
and	O
prompt	O
treatment	O
.	O

Poor	O
control	O
of	O
diabetes	B-DISO
with	O
mean	O
HbA1c	O
of	O
8	O
.	O
1	O
±	O
2	O
.	O
11	O
is	O
found	O
on	O
analysis	O
.	O

Mice	O
deficient	O
in	O
MDA5	O
expression	O
(	O
MDA5	O
(-/-)	O
mice	O
)	O
experienced	O
more	O
severe	O
disease	O
following	O
MHV	O
infection	B-DISO
,	O
with	O
reduced	O
survival	O
,	O
increased	O
spread	O
of	O
virus	O
to	O
additional	O
sites	O
of	O
infection	B-DISO
,	O
and	O
more	O
extensive	O
liver	B-DISO
damage	I-DISO
than	O
did	O
wild	O
-	O
type	O
mice	O
.	O

Optimal	O
strategies	O
for	O
mechanical	O
ventilation	O
also	O
differ	O
between	O
these	O
two	O
conditions	O
;	O
while	O
myasthenic	B-DISO
crisis	I-DISO
is	O
ideally	O
managed	O
with	O
noninvasive	O
bilevel	O
positive	O
airway	O
pressure	O
(	O
BiPAP	O
)	O
ventilation	O
,	O
GBS	B-DISO
demands	O
early	O
intubation	O
.	O

Prompt	O
recognition	O
of	O
neuromuscular	O
respiratory	B-DISO
failure	I-DISO
can	O
be	O
lifesaving	O
,	O
and	O
identification	O
of	O
its	O
cause	O
has	O
substantial	O
prognostic	O
implications	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
aimed	O
to	O
identify	O
the	O
differentially	O
expressed	O
proteins	O
(	O
DEPs	O
)	O
in	O
Calu	O
-	O
3	O
cells	O
infected	O
by	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
subtype	O
H5N1	B-DISO
.	O

Infection	B-DISO
with	O
this	O
virus	O
often	O
caused	O
severe	O
pneumonia	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
resulting	O
in	O
a	O
case	O
fatality	O
rate	O
>	O
35	O
%.	O

Here	O
,	O
we	O
describe	O
the	O
rapid	O
(	O
19	O
days	O
)	O
development	O
of	O
a	O
plant	O
-	O
derived	O
VLP	O
vaccine	O
based	O
on	O
the	O
hemagglutinin	O
sequence	O
of	O
influenza	B-DISO
H7N9	O
A	O
/	O
Hangzhou	O
/	O
1	O
/	O
2013	O
.	O

Two	O
doses	O
of	O
unadjuvanted	O
vaccine	O
significantly	O
increased	O
humoral	O
response	O
and	O
resulted	O
in	O
100	O
%	O
protection	O
with	O
significant	O
reduction	O
of	O
clinical	O
signs	O
leading	O
to	O
nearly	O
asymptomatic	B-DISO
infections	I-DISO
.	O

PEDV	O
infected	O
suckling	O
pigs	O
had	O
significantly	O
higher	O
diarrhea	B-DISO
scores	O
,	O
earlier	O
fecal	O
PEDV	O
RNA	O
shedding	O
and	O
significantly	O
higher	O
viremia	B-DISO
(	O
viral	O
RNA	O
in	O
serum	O
)	O
compared	O
to	O
weaned	O
pigs	O
.	O

TITLE	O
:	O
Isolation	O
and	O
molecular	O
characterization	O
of	O
nephropathic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolates	O
of	O
Gujarat	O
state	O
,	O
India	O
.	O

In	O
a	O
second	O
phase	O
of	O
the	O
study	O
,	O
the	O
rs113350588	O
and	O
rs1048479	O
polymorphisms	O
identified	O
in	O
this	O
sample	O
were	O
genotyped	O
in	O
a	O
sample	O
of	O
356	O
subjects	O
from	O
the	O
northern	O
and	O
northeastern	O
regions	O
of	O
Brazil	O
with	O
a	O
diagnosis	O
of	O
pandemic	O
influenza	B-DISO
.	O

This	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
the	O
association	O
of	O
ST3GAL1	O
gene	O
haplotypes	O
on	O
the	O
risk	O
of	O
more	O
severe	O
disease	O
and	O
death	O
in	O
patients	O
infected	O
with	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
.	O

Given	O
the	O
efficacy	O
of	O
eculizumab	O
in	O
the	O
treatment	O
of	O
the	O
acute	O
thrombotic	O
phase	O
of	O
Degos	B-DISO
disease	I-DISO
/	O
MAP	O
,	O
the	O
patient	O
received	O
this	O
drug	O
,	O
resulting	O
in	O
rapid	O
resolution	O
of	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
associated	O
with	O
her	O
multiorgan	B-DISO
failure	I-DISO
.	O

Multivariate	O
analysis	O
associated	O
hospital	O
mortality	O
with	O
age	O
and	O
Pao	O
The	O
overall	O
hospital	O
mortality	O
(	O
38	O
%)	O
was	O
similar	O
to	O
that	O
of	O
other	O
studies	O
and	O
according	O
to	O
the	O
presence	O
of	O
ARDS	B-DISO
(	O
Pao	O
RESULTS	O
:	O
In	O
the	O
93	O
patients	O
comprising	O
the	O
study	O
,	O
hospital	O
mortality	O
was	O
38	O
%.	O

TITLE	O
:	O
Effect	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Infectious	B-DISO
Doses	O
on	O
Infection	B-DISO
Outcomes	O
in	O
Naïve	O
Conventional	O
Neonatal	O
and	O
Weaned	O
Pigs	O
.	O

These	O
data	O
reveal	O
that	O
PEDV	O
infectious	B-DISO
dose	O
is	O
age	O
-	O
dependent	O
with	O
a	O
significantly	O
lower	O
MID	O
for	O
neonatal	O
pigs	O
compared	O
to	O
weaned	O
pigs	O
.	O

We	O
further	O
characterized	O
this	O
model	O
by	O
determining	O
both	O
the	O
ID50	O
and	O
the	O
LD50	O
of	O
MERS	O
-	O
CoV	O
in	O
order	O
to	O
establish	O
both	O
an	O
infection	B-DISO
model	O
and	O
a	O
lethal	O
model	O
for	O
MERS	O
and	O
followed	O
this	O
by	O
investigating	O
the	O
antibody	O
responses	O
and	O
immunity	O
of	O
the	O
mice	O
that	O
survived	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Prone	O
positioning	O
was	O
beneficial	O
for	O
unloading	O
the	O
right	O
ventricle	O
for	O
treatment	O
of	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
.	O

TITLE	O
:	O
Genetic	O
Predisposition	O
to	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
Syndrome	I-DISO
With	O
Severe	O
Ocular	O
Surface	O
Complications	O
.	O

Moreover	O
,	O
HLA	O
-	O
A	O
*	O
02	O
:	O
06	O
with	O
TLR3	O
polymorphisms	O
and	O
HLA	O
-	O
A	O
*	O
02	O
:	O
06	O
with	O
EP3	O
polymorphisms	O
exerted	O
additive	O
effects	O
in	O
SJS	B-DISO
/	O
TEN	O
with	O
SOCs	O
.	O

EP3	O
is	O
strongly	O
downregulated	O
in	O
the	O
conjunctival	O
epithelium	O
of	O
SJS	B-DISO
/	O
TEN	O
.	O

These	O
data	O
establish	O
the	O
Collaborative	O
Cross	O
platform	O
as	O
a	O
powerful	O
genetic	O
resource	O
for	O
uncovering	O
genetic	O
contributions	O
of	O
complex	O
traits	O
in	O
microbial	B-DISO
disease	I-DISO
severity	O
,	O
inflammation	B-DISO
and	O
virus	O
replication	O
in	O
models	O
of	O
outbred	O
populations	O
.	O

The	O
virus	O
is	O
difficult	O
to	O
control	O
by	O
vaccination	O
,	O
so	O
new	O
methods	O
to	O
curb	B-DISO
the	O
impact	O
of	O
the	O
disease	O
need	O
to	O
be	O
sought	O
.	O

Clinical	O
illness	O
associated	O
with	O
MERS	O
-	O
CoV	O
ranges	O
from	O
mild	O
upper	O
respiratory	B-DISO
symptoms	I-DISO
to	O
rapidly	O
progressive	O
pneumonia	B-DISO
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
.	O

Twenty	O
-	O
nine	O
patients	O
had	O
HAdV	O
pneumonia	B-DISO
.	O

HAdV	O
B7	O
is	O
strongly	O
related	O
to	O
severe	O
infections	B-DISO
and	O
pneumonia	B-DISO
.	O

The	O
frequency	O
of	O
detection	O
of	O
various	O
pathogens	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
may	O
vary	O
greatly	O
depending	O
on	O
the	O
region	O
,	O
season	O
and	O
clinical	O
profile	O
of	O
patients	O
,	O
availability	O
of	O
relevant	O
risk	O
factors	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
superimposed	O
fungal	B-DISO
infections	I-DISO
in	O
patients	O
who	O
are	O
critically	B-DISO
ill	I-DISO
and	O
immunocompromised	O
.	O

Even	O
more	O
recently	O
,	O
convalescent	O
plasma	O
has	O
been	O
used	O
for	O
treatment	O
of	O
individuals	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Assembly	O
and	O
immunogenicity	O
of	O
baculovirus	O
-	O
derived	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
-	O
like	O
particles	O
carrying	O
membrane	O
,	O
envelope	O
and	O
the	O
recombinant	O
spike	O
proteins	O
.	O

TITLE	O
:	O
Complications	O
of	O
Prone	O
Positioning	O
During	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
Respiratory	B-DISO
Failure	I-DISO
:	O
A	O
Systematic	O
Review	O
.	O

More	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
clinical	O
efficacy	O
of	O
the	O
addition	O
of	O
prone	O
positioning	O
therapy	O
to	O
ECMO	O
for	O
patients	O
in	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

Enteric	O
virus	O
infections	B-DISO
are	O
well	O
characterized	O
in	O
poults	O
,	O
but	O
limited	O
studies	O
have	O
been	O
conducted	O
in	O
older	O
birds	O
.	O

The	O
susceptibility	O
of	O
2	O
-,	O
7	O
-,	O
12	O
-,	O
30	O
-,	O
and	O
52	O
-	O
wk	O
-	O
old	O
turkeys	O
to	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
and	O
turkey	O
astrovirus	O
(	O
TAstV	O
)	O
was	O
evaluated	O
,	O
as	O
well	O
as	O
the	O
effect	O
of	O
combined	O
infection	B-DISO
of	O
TAstV	O
and	O
TCoV	O
in	O
2	O
-	O
wk	O
-	O
old	O
poults	O
and	O
turkey	O
hens	O
.	O

The	O
underlying	O
mechanism	O
regarding	O
the	O
age	O
-	O
related	O
TAstV	O
susceptibility	O
and	O
the	O
pathogenesis	B-DISO
of	O
the	O
TAstV	O
and	O
TCoV	O
coinfection	B-DISO
in	O
layer	O
hens	O
needs	O
to	O
be	O
further	O
elucidated	O
.	O

Results	O
Seventeen	O
(	O
85	O
%)	O
of	O
the	O
effusion	B-DISO
samples	O
from	O
20	O
cats	O
with	O
FIP	B-DISO
were	O
positive	O
for	O
FCoV	O
RNA	O
,	O
whereas	O
none	O
of	O
the	O
23	O
cats	O
with	O
other	O
diseases	O
were	O
positive	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
pig	O
epidemic	B-DISO
diarrhoea	I-DISO
viruses	O
isolated	O
in	O
Japan	O
from	O
2013	O
to	O
2014	O
.	O

TITLE	O
:	O
Evaluating	O
Protection	O
Against	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
by	O
Clinical	O
Signs	O
,	O
Ciliostasis	O
,	O
Challenge	O
Virus	O
Detection	O
,	O
and	O
Histopathology	O
.	O

TITLE	O
:	O
A	O
disparate	O
subset	O
of	O
double	O
-	O
negative	O
T	O
cells	O
contributes	O
to	O
the	O
outcome	O
of	O
murine	O
fulminant	O
viral	B-DISO
hepatitis	I-DISO
via	O
effector	O
molecule	O
fibrinogen	O
-	O
like	O
protein	O
2	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
vascular	O
dysfunction	O
has	O
been	O
described	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
We	O
investigated	O
an	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
at	O
King	O
Fahad	O
Medical	O
City	O
(	O
KFMC	O
),	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
during	O
March	O
29	O
-	O
May	O
21	O
,	O
2014	O
.	O

IL28B	O
SNPs	O
were	O
genotyped	O
in	O
269	O
patients	O
,	O
181	O
mono	B-DISO
-	O
and	O
88	O
co	O
-	O
infected	O
,	O
treated	O
with	O
pegylated	O
interferon	O
and	O
ribavirin	O
.	O

ABSTRACT	O
:	O
Recent	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
have	O
resulted	O
in	O
renewed	O
recognition	O
of	O
the	O
importance	O
of	O
risk	O
communication	O
planning	O
and	O
execution	O
to	O
public	O
health	O
control	O
strategies	O
.	O

Although	O
use	O
of	O
the	O
Internet	O
increased	O
from	O
25	O
%	O
during	O
SARS	B-DISO
to	O
56	O
%	O
during	O
H1N1	O
,	O
overall	O
use	O
of	O
social	O
media	O
was	O
not	O
as	O
high	O
as	O
anticipated	O
.	O

The	O
use	O
of	O
five	O
or	O
more	O
information	O
sources	O
increased	O
by	O
almost	O
60	O
%	O
between	O
the	O
SARS	B-DISO
and	O
H1N1	O
surveys	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
life	O
-	O
threatening	O
disease	O
.	O

High	O
virus	O
titers	O
were	O
present	O
in	O
lung	O
and	O
brain	O
tissues	O
2	O
and	O
6	O
days	O
after	O
infection	B-DISO
,	O
respectively	O
.	O

ABSTRACT	O
:	O
As	O
of	O
July	O
15	O
,	O
2015	O
,	O
the	O
South	O
Korean	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
had	O
reported	O
186	O
case	O
-	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
in	O
South	O
Korea	O
.	O

This	O
review	O
discussed	O
the	O
weaknesses	B-DISO
of	O
current	O
hand	O
sanitizers	O
,	O
gathered	O
published	O
results	O
from	O
many	O
studies	O
on	O
the	O
antiviral	O
activities	O
of	O
EGCG	O
and	O
its	O
lipophilic	O
derivatives	O
,	O
and	O
the	O
potential	O
use	O
of	O
these	O
compounds	O
as	O
a	O
novel	O
strategy	O
for	O
disease	O
prevention	O
,	O
especially	O
against	O
pathogenic	O
viruses	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
report	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
in	O
2012	O
in	O
Saudi	O
Arabia	O
,	O
no	O
standard	O
treatment	O
guideline	O
has	O
been	O
set	O
despite	O
the	O
virulence	O
of	O
MERS	B-DISO
-	O
coronavirus	O
(	O
CoV	O
)	O
and	O
the	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

Combining	O
adjunctive	O
therapies	O
(	O
high	O
PEEP	O
,	O
recruitment	B-DISO
maneuvers	O
,	O
and	O
inhaled	O
vasodilators	O
)	O
with	O
PP	O
has	O
an	O
additive	O
effect	O
in	O
improving	O
oxygenation	O
and	O
may	O
be	O
particularly	O
helpful	O
in	O
stabilizing	O
gas	O
exchange	O
in	O
very	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Strengthening	O
epidemiologic	O
investigation	O
of	O
infectious	B-DISO
diseases	I-DISO
in	O
Korea	O
:	O
lessons	O
from	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
outbreak	O
.	O

We	O
evaluated	O
the	O
Korean	O
epidemiologic	O
investigation	O
system	O
and	O
the	O
public	O
preventive	O
measures	O
against	O
infectious	B-DISO
diseases	I-DISO
in	O
light	O
of	O
the	O
recent	O
MERS	O
outbreak	O
.	O

TITLE	O
:	O
Lung	O
inhomogeneities	O
,	O
inflation	O
and	O
[	O
18F	O
]	O
2	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
uptake	O
rate	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
total	O
,	O
20	O
ARDS	B-DISO
patients	O
underwent	O
5	O
and	O
45	O
cmH2O	O
computed	O
tomography	O
(	O
CT	O
)	O
scans	O
to	O
measure	O
lung	O
recruitability	O
.	O

TITLE	O
:	O
Lung	O
ultrasonography	O
for	O
the	O
diagnosis	O
of	O
11	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
bird	B-DISO
flu	I-DISO
H7N9	O
infection	B-DISO
.	O

Among	O
all	O
11	O
patients	O
studied	O
,	O
6	O
patients	O
had	O
thoracic	B-DISO
puncture	O
and	O
drainage	O
of	O
pleural	B-DISO
effusion	I-DISO
and	O
2	O
patients	O
had	O
pneumothorax	B-DISO
puncture	O
drainage	O
.	O

Overall	O
,	O
149	O
subjects	O
with	O
ACS	O
(	O
namely	O
,	O
acute	O
myocardial	B-DISO
infarct	I-DISO
with	O
or	O
without	O
ST	O
-	O
segment	O
elevation	O
or	O
unstable	B-DISO
angina	I-DISO
),	O
with	O
no	O
previous	O
history	O
of	O
CHD	O
,	O
admitted	O
to	O
three	O
cardiac	O
intensive	O
care	O
units	O
were	O
included	O
and	O
evaluated	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
Complicated	O
Grief	O
(	O
SCI	O
-	O
CG	O
),	O
Hamilton	O
Depression	B-DISO
Rating	O
Scale	O
,	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
,	O
and	O
the	O
36	O
-	O
item	O
Short	O
-	O
Form	O
Health	O
Survey	O
(	O
MOS	B-DISO
-	O
SF	O
-	O
36	O
).	O

Among	O
these	O
,	O
subjects	O
who	O
lost	O
a	O
partner	O
,	O
child	O
,	O
or	O
sibling	O
were	O
older	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
less	O
likely	O
to	O
be	O
working	O
(	O
P	O
=	O
0	O
.	O
032	O
),	O
and	O
more	O
likely	O
to	O
be	O
suffering	B-DISO
from	O
hypertension	B-DISO
(	O
P	O
=	O
0	O
.	O
021	O
),	O
returned	O
higher	O
scores	O
on	O
the	O
SCI	O
-	O
CG	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
developed	O
the	O
index	O
ACS	O
more	O
frequently	O
between	O
12	O
and	O
48	O
months	O
after	O
the	O
death	O
than	O
those	O
who	O
lost	O
a	O
parent	O
or	O
another	O
relative	O
(	O
P	O
≤	O
0	O
.	O
0001	O
).	O

The	O
SCI	O
-	O
CG	O
scores	O
significantly	O
predicted	O
lower	O
scores	O
on	O
the	O
""""	O
general	O
health	O
""""	O
domain	O
of	O
MOS	B-DISO
-	O
SF	O
-	O
36	O
(	O
P	O
=	O
0	O
.	O
030	O
),	O
as	O
well	O
as	O
lower	O
scores	O
on	O
""""	O
emotional	O
well	O
-	O
being	O
""""	O
domain	O
(	O
P	O
=	O
0	O
.	O
010	O
).	O

ABSTRACT	O
:	O
The	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
(	O
OHSS	B-DISO
)	O
is	O
a	O
serious	O
but	O
rarely	O
fatal	O
complication	B-DISO
of	O
medical	O
interventions	O
that	O
seek	O
to	O
induce	O
fertility	B-DISO
;	O
it	O
is	O
typically	O
encountered	O
in	O
women	O
who	O
undergo	O
controlled	O
ovarian	B-DISO
hyperstimulation	I-DISO
,	O
but	O
there	O
are	O
very	O
rare	O
patients	O
who	O
have	O
genetic	O
defects	O
who	O
present	O
with	O
OHSS	B-DISO
.	O

In	O
recent	O
years	O
,	O
its	O
pathogenesis	B-DISO
has	O
been	O
elucidated	O
;	O
this	O
knowledge	O
will	O
decrease	O
the	O
frequency	O
of	O
this	O
syndrome	B-DISO
.	O

Due	O
to	O
the	O
increased	O
use	O
of	O
therapeutic	O
strategies	O
for	O
infertility	B-DISO
(	O
particularly	O
those	O
using	O
human	O
chorionic	O
gonadotropin	O
),	O
the	O
systemic	O
,	O
particularly	O
the	O
pulmonary	O
,	O
complications	O
of	O
this	O
syndrome	B-DISO
must	O
be	O
identified	O
early	O
to	O
allow	O
appropriate	O
diagnosis	O
and	O
management	O
.	O

TITLE	O
:	O
A	O
Case	O
of	O
Acute	O
Fulminant	B-DISO
Fat	I-DISO
Embolism	I-DISO
Syndrome	I-DISO
after	O
Liposuction	O
Surgery	O
.	O

ABSTRACT	O
:	O
Fat	B-DISO
embolism	I-DISO
syndrome	I-DISO
(	O
FES	O
)	O
is	O
a	O
clinical	O
manifestation	O
that	O
consists	O
of	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
fat	B-DISO
emboli	I-DISO
.	O

Although	O
the	O
overall	O
incidence	O
was	O
lower	O
than	O
has	O
been	O
reported	O
in	O
a	O
prospective	O
US	O
study	O
,	O
this	O
may	O
reflect	O
underdiagnosis	O
by	O
International	O
Classification	O
of	O
Diseases	O
,	O
9th	O
edition	O
code	O
and	O
identification	O
of	O
only	O
patients	O
with	O
more	O
severe	O
ARDS	B-DISO
in	O
this	O
analysis	O
.	O

Except	O
for	O
Influenza	B-DISO
virus	O
and	O
Respiratory	O
Syncytial	O
virus	O
,	O
mostly	O
viral	O
aetiology	O
of	O
AVRI	O
remains	O
undiagnosed	O
.	O

The	O
samples	O
were	O
also	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
results	O
of	O
this	O
study	O
documents	O
low	O
prevalence	O
of	O
human	O
coronaviruses	O
in	O
SARI	O
cases	O
in	O
south	O
western	O
India	O
and	O
the	O
absence	O
of	O
highly	O
pathogenic	O
human	O
coronaviruses	O
.	O

TITLE	O
:	O
Differential	O
effect	O
of	O
cholesterol	O
on	O
type	O
I	O
and	O
II	O
feline	O
coronavirus	B-DISO
infection	I-DISO
.	O

Since	O
type	O
I	O
FCoV	O
infection	B-DISO
is	O
dominant	O
in	O
the	O
field	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
antiviral	O
agents	O
and	O
vaccines	O
against	O
type	O
I	O
FCoV	O
infection	B-DISO
.	O

A	O
total	O
of	O
7	O
infants	O
developed	O
a	O
secondary	O
bacterial	B-DISO
infection	I-DISO
,	O
and	O
12	O
infants	O
received	O
mechanical	O
ventilation	O
(	O
5	O
with	O
high	O
-	O
frequency	O
mechanical	O
ventilation	O
and	O
3	O
with	O
mechanical	O
ventilation	O
and	O
NO	O
inhalation	O
);	O
the	O
average	O
duration	O
of	O
mechanical	O
ventilation	O
was	O
10	O
.	O
08	O
days	O
,	O
and	O
3	O
infants	O
expired	O
.	O

Children	O
with	O
measles	B-DISO
pneumonia	I-DISO
may	O
experience	O
multiple	O
serious	O
complications	O
,	O
among	O
which	O
ARDS	B-DISO
and	O
pneumothorax	B-DISO
are	O
particularly	O
serious	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
surfactant	O
-	O
depleted	O
model	O
,	O
maintaining	O
PL	O
-	O
exp	O
just	O
greater	O
than	O
0	O
using	O
Pes	O
was	O
unable	O
to	O
maintain	O
lung	O
recruitment	B-DISO
;	O
this	O
was	O
partly	O
caused	O
by	O
a	O
lack	O
of	O
compensation	O
for	O
the	O
increased	O
SP	O
between	O
the	O
esophageal	O
plane	O
and	O
the	O
dorsal	O
level	O
.	O

TITLE	O
:	O
Extracorporeal	O
decarboxylation	O
in	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
and	O
ARDS	B-DISO
enables	O
effective	O
control	O
of	O
intracranial	O
pressure	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
concomitant	O
impairment	B-DISO
of	O
oxygenation	O
and	O
decarboxylation	O
represents	O
a	O
complex	O
problem	O
in	O
patients	O
with	O
increased	B-DISO
intracranial	I-DISO
pressure	I-DISO
(	O
ICP	B-DISO
).	O

Permissive	O
hypercapnia	B-DISO
is	O
not	O
an	O
option	O
to	O
obtain	O
and	O
maintain	O
lung	O
-	O
protective	O
ventilation	O
in	O
the	O
presence	O
of	O
elevated	O
ICP	B-DISO
.	O

The	O
volume	O
of	O
daily	O
CSF	O
drainage	O
needed	O
to	O
maintain	O
ICP	B-DISO
at	O
20	O
mmHg	O
decreased	O
significantly	O
from	O
141	O
.	O
5	O
±	O
103	O
.	O
5	O
ml	O
to	O
62	O
.	O
2	O
±	O
68	O
.	O
1	O
ml	O
(	O
p	O
=	O
0	O
.	O
037	O
).	O

During	O
the	O
study	O
period	O
,	O
88	O
ESKAPE	O
pathogens	O
obtained	O
from	O
respiratory	O
tract	O
specimens	O
of	O
54	O
ARDS	B-DISO
renal	O
recipients	O
were	O
documented	O
including	O
33	O
A	O
.	O
baumannii	O
,	O
24	O
P	O
.	O
aeruginosa	O
,	O
17	O
S	O
.	O
aureus	O
,	O
6	O
K	O
.	O
pneumoniae	O
,	O
8	O
Enterobacter	O
species	O
,	O
and	O
0	O
E	O
.	O
Faecium	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
in	O
infants	O
with	O
acute	B-DISO
leukemia	I-DISO
:	O
a	O
retrospective	O
survey	O
of	O
the	O
Japanese	O
Pediatric	O
Leukemia	B-DISO
/	O
Lymphoma	B-DISO
Study	O
Group	O
.	O

We	O
performed	O
a	O
retrospective	O
nationwide	O
survey	O
to	O
clarify	O
the	O
current	O
status	O
of	O
RSV	O
disease	O
among	O
infants	O
with	O
hematological	B-DISO
malignancies	I-DISO
.	O

In	O
our	O
survey	O
,	O
the	O
prognosis	O
of	O
RSV	O
disease	O
in	O
pediatric	O
hematological	B-DISO
malignancies	I-DISO
was	O
poor	O
,	O
and	O
progression	O
of	O
LRTI	B-DISO
in	O
particular	O
was	O
associated	O
with	O
high	O
mortality	O
.	O

This	O
altered	O
interaction	O
with	O
microbes	O
is	O
believed	O
to	O
be	O
the	O
major	O
driving	O
force	O
behind	O
the	O
increased	O
rate	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
from	O
animals	O
.	O

ABSTRACT	O
:	O
Host	O
genetic	O
factors	O
have	O
frequently	O
been	O
implicated	O
in	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
,	O
often	O
with	O
inconsistent	O
results	O
in	O
replication	O
studies	O
.	O

We	O
also	O
detected	O
an	O
association	O
of	O
TLR2	O
gene	O
with	O
tuberculosis	B-DISO
(	O
rs5743708	O
;	O
3	O
.	O
19	O
[	O
2	O
.	O
03	O
-	O
5	O
.	O
02	O
]).	O

Similar	O
behavior	O
was	O
observed	O
in	O
tracer	O
gas	O
,	O
particle	O
experiments	O
,	O
and	O
flight	O
infection	B-DISO
data	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Critical	O
characteristics	O
of	O
ALI	O
are	O
alveolar	B-DISO
edema	I-DISO
,	O
infiltration	B-DISO
of	O
leukocytes	O
(	O
neutrophils	O
and	O
monocytes	O
),	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
into	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
activation	O
of	O
integrin	O
receptors	O
.	O

Influenza	B-DISO
virus	O
was	O
the	O
most	O
frequently	O
isolated	O
virus	O
,	O
followed	O
by	O
enterovirus	O
/	O
rhinovirus	O
,	O
coronavirus	O
,	O
bocavirus	O
,	O
metapneumovirus	O
,	O
parainfluenza	B-DISO
virus	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

CONCLUSIONS	O
:	O
Respiratory	B-DISO
infection	I-DISO
is	O
a	O
common	O
causative	O
agent	O
of	O
exacerbations	O
in	O
COPD	B-DISO
.	O

Community	O
-	O
acquired	O
ARDS	B-DISO
,	O
hospital	O
-	O
acquired	O
ARDS	B-DISO
and	O
intensive	O
care	O
unit	O
(	O
ICU	O
)-	O
acquired	O
ARDS	B-DISO
were	O
defined	O
as	O
ARDS	B-DISO
occurring	O
within	O
48	O
hours	O
of	O
hospital	O
or	O
ICU	O
admission	O
,	O
more	O
than	O
48	O
hours	O
after	O
hospital	O
admission	O
and	O
ICU	O
admission	O
.	O

The	O
overall	O
ICU	O
mortality	O
rate	O
was	O
not	O
significantly	O
different	O
in	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
(	O
50	O
%,	O
50	O
%	O
and	O
56	O
%,	O
p	O
=	O
0	O
.	O
25	O
).	O

For	O
community	O
-	O
acquired	O
,	O
hospital	O
-	O
acquired	O
and	O
ICU	O
-	O
acquired	O
ARDS	B-DISO
,	O
ICU	O
mortality	O
rates	O
were	O
37	O
%	O
61	O
%	O
and	O
52	O
%;	O
hospital	O
mortality	O
rates	O
were	O
49	O
%,	O
74	O
%	O
and	O
68	O
%.	O

Of	O
the	O
381	O
respondents	O
aged	O
between	O
17	O
and	O
85	O
years	O
,	O
55	O
%	O
had	O
never	O
heard	O
of	O
MERS	O
,	O
while	O
only	O
one	O
in	O
three	O
knew	O
that	O
it	O
is	O
a	O
respiratory	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Plaque	B-DISO
reduction	O
neutralisation	O
tests	O
(	O
PRNT	O
),	O
microneutralisation	O
(	O
MN	O
),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)-	O
spike	O
pseudoparticle	O
neutralisation	O
(	O
ppNT	O
)	O
and	O
MERS	B-DISO
S1	O
-	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibody	O
titres	O
were	O
compared	O
using	O
95	O
sera	O
from	O
17	O
patients	O
with	O
MERS	B-DISO
,	O
collected	O
two	O
to	O
46	O
days	O
after	O
symptom	B-DISO
onset	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Superspreading	O
Event	O
Involving	O
81	O
Persons	O
,	O
Korea	O
2015	O
.	O

TITLE	O
:	O
Ruptured	B-DISO
spinal	I-DISO
arteriovenous	I-DISO
malformation	I-DISO
:	O
Presenting	O
as	O
stunned	B-DISO
myocardium	I-DISO
and	O
neurogenic	B-DISO
shock	I-DISO
.	O

But	O
NPE	O
is	O
rare	O
to	O
occur	O
,	O
and	O
stunned	B-DISO
myocardium	I-DISO
(	O
SM	O
)	O
is	O
not	O
reported	O
in	O
spinal	B-DISO
arteriovenous	I-DISO
malformation	I-DISO
(	O
AVM	B-DISO
)	O
rupture	O
.	O

A	O
32	O
-	O
year	O
-	O
old	O
male	O
who	O
presented	O
with	O
sudden	O
onset	O
of	O
pain	O
and	O
weakness	B-DISO
in	O
upper	O
limbs	O
.	O

Early	O
recognition	O
of	O
AVM	B-DISO
rupture	O
and	O
prompt	O
surgical	O
intervention	O
,	O
as	O
well	O
as	O
aggressive	B-DISO
treatment	O
of	O
shock	O
,	O
may	O
enhance	O
recovery	O
and	O
decrease	O
the	O
long	O
-	O
term	O
morbidity	O
.	O

After	O
magnetic	O
separation	B-DISO
,	O
DNA	O
barcodes	O
specific	O
for	O
PCV2	O
and	O
TGEV	O
were	O
eluted	O
using	O
DTT	O
and	O
characterized	O
by	O
specific	O
PCR	O
assay	O
for	O
specific	O
DNA	O
barcodes	O
subsequently	O
.	O

In	O
an	O
attempt	O
to	O
study	O
the	O
role	O
of	O
this	O
protein	O
in	O
virus	O
spread	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
and	O
neurovirulence	O
,	O
as	O
well	O
as	O
to	O
identify	O
amino	O
acid	O
residues	O
important	O
for	O
such	O
functions	O
,	O
we	O
compared	O
the	O
sequence	O
of	O
the	O
S	O
gene	O
found	O
in	O
the	O
laboratory	O
reference	O
strain	O
HCoV	O
-	O
OC43	O
ATCC	O
VR	O
-	O
759	O
to	O
S	O
sequences	O
of	O
viruses	O
detected	O
in	O
clinical	O
isolates	O
from	O
the	O
human	O
respiratory	O
tract	O
.	O

Inefficient	O
human	O
-	O
to	O
-	O
human	O
transmission	O
of	O
zoonotic	O
strains	O
may	O
initially	O
limit	O
the	O
spread	O
of	O
transmission	O
,	O
but	O
an	O
infection	B-DISO
may	O
be	O
contracted	O
by	O
touching	O
contaminated	O
surfaces	O
.	O

Respiratory	O
viruses	O
are	O
responsible	O
for	O
more	O
deaths	O
globally	O
than	O
any	O
other	O
infectious	B-DISO
agent	O
.	O

Incorporation	O
of	O
copper	O
alloy	O
surfaces	O
in	O
conjunction	O
with	O
effective	O
cleaning	O
regimens	O
and	O
good	O
clinical	O
practice	O
could	O
help	O
to	O
control	O
transmission	O
of	O
respiratory	O
coronaviruses	O
,	O
including	O
MERS	O
and	O
SARS	B-DISO
.	O

Within	O
the	O
TTM	B-DISO
group	O
eight	O
patients	O
were	O
treated	O
with	O
normothermia	O
after	O
TBI	O
and	O
35	O
patients	O
were	O
treated	O
with	O
hypothermia	O
.	O

These	O
findings	O
support	O
more	O
attention	O
to	O
these	O
complications	O
in	O
studies	O
of	O
TTM	B-DISO
in	O
TBI	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
causes	O
of	O
endogenous	O
uveitis	B-DISO
in	O
cats	O
presenting	O
to	O
referral	O
ophthalmology	O
clinics	O
in	O
North	O
Carolina	O
.	O

Using	O
a	O
non	O
-	O
fatal	O
viral	O
mouse	O
model	O
of	O
encephalomyelitis	B-DISO
associated	O
with	O
demyelination	B-DISO
and	O
disability	O
,	O
yet	O
ultimate	O
clinical	O
improvement	O
,	O
this	O
study	O
set	O
out	O
to	O
monitor	O
uptake	O
and	O
presentation	O
of	O
endogenous	O
myelin	O
antigens	O
,	O
as	O
well	O
as	O
induction	O
and	O
fate	O
of	O
SR	O
T	O
cells	O
.	O

The	O
objectives	O
of	O
this	O
review	O
are	O
(	O
1	O
)	O
to	O
ascertain	O
whether	O
prone	O
ventilation	O
offers	O
a	O
mortality	O
advantage	O
when	O
compared	O
with	O
traditional	O
supine	O
or	O
semi	O
recumbent	O
ventilation	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
conventional	O
invasive	O
artificial	O
ventilation	O
,	O
and	O
(	O
2	O
)	O
to	O
supplement	O
previous	O
systematic	O
reviews	O
on	O
prone	O
ventilation	O
for	O
hypoxaemic	O
respiratory	B-DISO
failure	I-DISO
in	O
an	O
adult	O
population	O
.	O

Long	O
-	O
term	O
mortality	O
data	O
(	O
12	O
months	O
and	O
beyond	O
),	O
as	O
well	O
as	O
functional	O
,	O
neuro	O
-	O
psychological	B-DISO
and	O
quality	O
of	O
life	O
data	O
,	O
are	O
required	O
if	O
future	O
studies	O
are	O
to	O
better	O
inform	O
the	O
role	O
of	O
PP	O
in	O
the	O
management	O
of	O
hypoxaemic	O
respiratory	B-DISO
failure	I-DISO
in	O
the	O
ICU	O
.	O

This	O
review	O
,	O
prepared	O
by	O
a	O
multidisciplinary	O
group	O
of	O
researchers	O
,	O
focuses	O
on	O
summarizing	O
the	O
strengths	O
and	O
limitations	O
of	O
epidemiologic	O
studies	O
that	O
specifically	O
addressed	O
the	O
association	O
of	O
at	O
least	O
one	O
heating	O
,	O
ventilating	O
and	O
/	O
or	O
air	O
-	O
conditioning	O
(	O
HVAC	O
)	O
system	O
-	O
related	O
parameter	O
with	O
airborne	O
disease	B-DISO
transmission	I-DISO
in	O
buildings	O
.	O

TITLE	O
:	O
Viral	B-DISO
Shedding	I-DISO
and	O
Antibody	O
Response	O
in	O
37	O
Patients	O
With	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
recruitment	B-DISO
in	O
strain	O
measurements	O
.	O

A	O
79	O
-	O
year	O
-	O
old	O
women	O
was	O
hospitalized	O
complaining	O
of	O
right	O
eyelid	B-DISO
swelling	I-DISO
,	O
severe	O
hyperemia	B-DISO
and	O
purulent	O
conjunctival	B-DISO
discharge	I-DISO
in	O
the	O
right	O
eye	O
.	O

Because	O
diffusion	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
findings	O
demonstrated	O
right	O
optic	B-DISO
neuritis	I-DISO
and	O
ventriculitis	B-DISO
,	O
enucleation	O
of	O
her	O
right	O
eye	O
was	O
performed	O
based	O
on	O
the	O
diagnosis	O
of	O
pyogenic	O
ventriculitis	B-DISO
via	O
the	O
optic	O
nerve	O
.	O

In	O
this	O
report	O
,	O
we	O
reveal	O
two	O
crystal	O
structures	O
of	O
SARS	B-DISO
3CL	O
(	O
pro	O
)	O
complexed	O
with	O
two	O
new	O
inhibitors	O
based	O
on	O
our	O
previous	O
work	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
pancreatitis	I-DISO
is	O
associated	O
with	O
sever	O
multiorgan	B-DISO
failure	I-DISO
from	O
15	O
to	O
50	O
%,	O
depending	O
on	O
the	O
series	O
.	O

Monitoring	O
intraabdominal	O
pressure	O
is	O
a	O
valuable	O
adjunct	O
to	O
decision	O
making	O
while	O
caring	O
for	O
these	O
high	O
-	O
risk	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

RESULTS	O
:	O
Three	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
requiring	O
ECMO	O
suffered	B-DISO
from	O
increased	O
intra	O
abdominal	O
pressure	O
during	O
their	O
ICU	O
stay	O
.	O

ABSTRACT	O
:	O
Adenine	O
derivatives	O
,	O
in	O
particular	O
the	O
scaffold	O
bearing	O
the	O
acyclic	O
nucleoside	O
phosphonates	O
(	O
ANPS	O
),	O
possess	B-DISO
significant	O
antiviral	O
and	O
cytostatic	O
activity	O
.	O

Till	O
now	O
,	O
several	O
effective	O
adenine	O
derivatives	O
have	O
been	O
marketed	O
for	O
the	O
treatment	O
of	O
HIV	B-DISO
,	O
HBV	B-DISO
,	O
CMV	O
and	O
other	O
virus	O
-	O
infected	O
diseases	O
.	O

Here	O
,	O
we	O
systematically	O
summarized	O
the	O
SARs	B-DISO
of	O
the	O
adenine	O
derivatives	O
,	O
and	O
gave	O
important	O
information	O
for	O
further	O
optimizing	O
this	O
template	O
.	O

TITLE	O
:	O
Rapid	O
genome	O
sequencing	O
and	O
characterization	O
of	O
novel	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
H7N9	O
virus	O
directly	O
from	O
clinical	O
sample	O
by	O
semiconductor	O
sequencing	O
.	O

TITLE	O
:	O
Glial	O
response	O
in	O
the	O
central	O
nervous	B-DISO
system	O
of	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Brain	O
and	O
cerebellum	O
were	O
evaluated	O
by	O
light	O
microscopy	O
and	O
immunohistochemistry	O
for	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
vimentin	O
to	O
assess	O
astrocytic	O
morphology	O
,	O
and	O
lectin	O
histochemistry	O
for	O
Ricinus	O
communis	O
agglutinin	O
-	O
I	O
(	O
RCA	O
-	O
I	O
)	O
to	O
detect	O
microglia	O
was	O
performed	O
to	O
evaluate	O
the	O
glial	O
response	O
in	O
the	O
CNS	O
of	O
cats	O
with	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
kinetics	O
of	O
serologic	O
responses	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
by	O
using	O
virus	O
neutralization	O
and	O
MERS	O
-	O
CoV	O
S1	O
IgG	O
ELISA	O
tests	O
.	O

ABSTRACT	O
:	O
A	O
low	O
or	O
moderate	O
expired	O
tidal	O
volume	O
can	O
be	O
difficult	O
to	O
achieve	O
during	O
noninvasive	O
ventilation	O
for	O
de	O
novo	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
i	O
.	O
e	O
.,	O
not	O
due	O
to	O
exacerbation	O
of	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
or	O
cardiac	B-DISO
failure	I-DISO
).	O

Twenty	O
-	O
four	O
bed	B-DISO
university	O
medical	O
ICU	O
.	O

A	O
low	O
expired	O
tidal	O
volume	O
is	O
almost	O
impossible	O
to	O
achieve	O
in	O
the	O
majority	O
of	O
patients	O
receiving	O
noninvasive	O
ventilation	O
for	O
de	O
novo	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
a	O
high	O
expired	O
tidal	O
volume	O
is	O
independently	O
associated	O
with	O
noninvasive	O
ventilation	O
failure	O
.	O

Reanalysis	O
of	O
deidentified	O
data	O
from	O
the	O
phase	O
III	O
randomized	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
trial	O
in	O
severe	B-DISO
sepsis	I-DISO
.	O

Sepsis	B-DISO
patients	O
with	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
and	O
/	O
or	O
shock	O
(	O
original	O
study	O
)	O
were	O
regrouped	O
based	O
on	O
the	O
presence	O
or	O
the	O
absence	O
of	O
concurrent	O
hepatobiliary	O
dysfunction	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
as	O
features	O
of	O
macrophage	B-DISO
activation	I-DISO
syndrome	I-DISO
.	O

Treatment	O
with	O
anakinra	O
was	O
associated	O
with	O
significant	O
improvement	O
in	O
the	O
28	O
-	O
day	O
survival	O
rate	O
in	O
hepatobiliary	O
dysfunction	O
/	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
patients	O
(	O
65	O
.	O
4	O
%	O
anakinra	O
vs	O
35	O
.	O
3	O
%	O
placebo	O
),	O
with	O
hazard	O
ratio	O
for	O
death	O
0	O
.	O
28	O
(	O
0	O
.	O
11	O
-	O
0	O
.	O
71	O
;	O
p	O
=	O
0	O
.	O
0071	O
)	O
for	O
the	O
treatment	O
group	O
in	O
Cox	O
regression	O
.	O

ABSTRACT	O
:	O
In	O
May	O
2015	O
in	O
United	O
Arab	O
Emirates	O
,	O
asymptomatic	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
was	O
identified	O
through	O
active	O
case	O
finding	O
in	O
2	O
men	O
with	O
exposure	O
to	O
infected	O
dromedaries	O
.	O

TITLE	O
:	O
Inhibitors	O
of	O
HIV	B-DISO
-	O
1	O
attachment	O
:	O
The	O
discovery	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
tetrahydroisoquinolines	O
as	O
replacements	O
for	O
the	O
piperazine	O
benzamide	O
in	O
the	O
3	O
-	O
glyoxylyl	O
6	O
-	O
azaindole	O
pharmacophore	O
.	O

Of	O
309	O
cases	O
tested	O
,	O
49	O
(	O
16	O
%)	O
were	O
positive	O
for	O
influenza	B-DISO
viruses	O
,	O
25	O
(	O
8	O
·	O
1	O
%)	O
for	O
human	O
metapneumovirus	O
,	O
20	O
(	O
6	O
·	O
5	O
%)	O
for	O
parainfluenza	B-DISO
viruses	O
,	O
16	O
(	O
5	O
·	O
2	O
%)	O
for	O
coronavirus	O
,	O
11	O
(	O
3	O
·	O
6	O
%)	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
10	O
(	O
3	O
·	O
2	O
%)	O
for	O
rhinovirus	O
,	O
4	O
(	O
1	O
·	O
3	O
%)	O
for	O
rhinovirus	O
/	O
enterovirus	O
,	O
3	O
(	O
1	O
·	O
0	O
%)	O
for	O
enteroviruses	O
,	O
and	O
3	O
(	O
1	O
·	O
0	O
%)	O
for	O
adenovirus	B-DISO
.	O

TITLE	O
:	O
Influenza	B-DISO
virus	O
emitted	O
by	O
naturally	O
-	O
infected	O
hosts	O
in	O
a	O
healthcare	O
setting	O
.	O

TITLE	O
:	O
Rapid	O
Optical	O
Cavity	B-DISO
PCR	O
.	O

Currently	O
,	O
there	O
are	O
no	O
treatments	O
or	O
vaccines	O
available	O
for	O
the	O
treatment	O
of	O
FIP	B-DISO
even	O
though	O
it	O
kills	O
approximately	O
5	O
%	O
of	O
cats	O
in	O
multi	O
-	O
cat	O
households	O
per	O
year	O
.	O

In	O
an	O
effort	O
to	O
develop	O
small	O
molecule	O
drugs	O
targeting	O
FIP	B-DISO
for	O
the	O
treatment	O
of	O
cats	O
,	O
we	O
screened	O
a	O
small	O
set	O
of	O
designed	O
peptidomimetic	O
inhibitors	O
for	O
inhibition	O
of	O
FIPV	O
-	O
3CL	O
(	O
pro	O
),	O
identifying	O
two	O
compounds	O
with	O
low	O
to	O
sub	O
-	O
micromolar	O
inhibition	O
,	O
compound	O
6	O
(	O
IC50	O
=	O
0	O
.	O
59	O
±	O
0	O
.	O
06	O
μM	O
)	O
and	O
compound	O
7	O
(	O
IC50	O
=	O
1	O
.	O
3	O
±	O
0	O
.	O
1	O
μM	O
).	O

High	O
-	O
grade	O
and	O
low	O
-	O
grade	O
INH	O
subjects	O
did	O
not	O
differ	O
significantly	O
in	O
the	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
mortality	O
.	O

The	O
individual	O
grades	O
of	O
the	O
0	O
to	O
4	O
AIS	B-DISO
INH	O
severity	O
grading	O
scale	O
were	O
not	O
particularly	O
robust	O
in	O
the	O
prediction	O
of	O
various	O
outcomes	O
among	O
a	O
population	O
of	O
adult	O
burn	O
patients	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
are	O
a	O
principal	O
cause	O
of	O
illness	O
and	O
mortality	O
in	O
children	O
worldwide	O
and	O
mostly	O
caused	O
by	O
viruses	O
.	O

The	O
children	O
all	O
fit	B-DISO
the	O
defined	O
clinical	O
criteria	O
for	O
febrile	B-DISO
infection	I-DISO
-	O
related	O
epilepsy	B-DISO
syndrome	B-DISO
;	O
all	O
had	O
a	O
history	O
of	O
normal	O
psychomotor	O
development	O
who	O
presented	O
with	O
acute	O
-	O
onset	O
catastrophic	O
partial	O
status	B-DISO
epilepticus	I-DISO
associated	O
with	O
a	O
febrile	B-DISO
illness	I-DISO
or	O
unspecific	O
infectious	B-DISO
process	I-DISO
.	O

Infection	B-DISO
prevention	O
and	O
control	O
implications	O
include	O
the	O
need	O
for	O
hand	O
hygiene	O
and	O
personal	O
protective	O
equipment	O
to	O
minimize	O
self	O
-	O
contamination	O
and	O
to	O
protect	O
against	O
inoculation	O
of	O
mucosal	O
surfaces	O
and	O
the	O
respiratory	O
tract	O
,	O
and	O
enhanced	O
surface	O
cleaning	O
and	O
disinfection	O
in	O
healthcare	O
settings	O
.	O

ABSTRACT	O
:	O
Dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
,	O
CD26	O
),	O
a	O
type	O
II	O
transmembrane	O
ectopeptidase	O
,	O
is	O
the	O
receptor	O
for	O
the	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Patients	O
with	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
,	O
such	O
as	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
cystic	B-DISO
fibrosis	I-DISO
,	O
exhibited	O
increased	O
DPP4	O
immunostaining	O
in	O
alveolar	O
epithelia	O
(	O
type	O
I	O
and	O
II	O
cells	O
)	O
and	O
alveolar	O
macrophages	O
with	O
similar	O
trends	O
in	O
reactive	O
mesothelia	O
.	O

We	O
speculate	O
that	O
the	O
preferential	O
spatial	O
localization	O
of	O
DPP4	O
in	O
alveolar	O
regions	O
may	O
explain	O
why	O
MERS	O
is	O
characterized	O
by	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
following	O
cardiovascular	O
surgery	O
:	O
current	O
concepts	O
and	O
novel	O
therapeutic	O
approaches	O
.	O

Owing	O
to	O
the	O
so	O
far	O
limited	O
treatment	O
options	O
,	O
it	O
is	O
of	O
great	O
importance	O
to	O
determine	O
patients	O
at	O
risk	O
for	O
developing	O
ARDS	B-DISO
already	O
perioperatively	O
.	O

ABSTRACT	O
:	O
Emergence	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
resulted	O
in	O
massive	O
neonatal	O
mortality	O
in	O
the	O
North	O
-	O
American	O
and	O
Asian	O
pork	O
industry	O
.	O

Today	O
,	O
incontrovertible	O
evidence	O
shows	O
that	O
ambient	O
temperature	O
dips	O
and	O
host	O
chilling	B-DISO
increase	O
the	O
incidence	O
and	O
severity	O
of	O
vARIs	O
.	O

Due	O
to	O
their	O
cytotoxic	O
and	O
proinflammatory	O
effects	O
,	O
extracellular	O
histones	O
can	O
lead	O
to	O
excessive	O
and	O
overwhelming	O
cell	B-DISO
damage	I-DISO
and	O
death	O
,	O
thus	O
contributing	O
to	O
the	O
pathogenesis	B-DISO
of	O
both	O
sepsis	B-DISO
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
information	O
types	O
and	O
sources	O
by	O
the	O
public	O
for	O
promoting	O
awareness	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
Saudi	O
Arabia	O
.	O

However	O
,	O
accessing	O
particular	O
-	O
1	O
PRF	O
stimulator	O
information	O
represents	O
a	O
bottle	O
-	O
neck	O
in	O
combating	O
the	O
emerging	O
epidemic	O
viral	O
pathogens	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Recently	O
,	O
an	O
RNA	O
hairpin	O
upstream	O
of	O
frameshifting	O
site	O
was	O
shown	O
to	O
act	O
as	O
a	O
cis	B-DISO
-	O
element	O
to	O
attenuate	O
-	O
1	O
PRF	O
with	O
mechanism	O
unknown	O
.	O

CONCLUSIONS	O
Pulmonary	B-DISO
edema	I-DISO
that	O
occurs	O
in	O
the	O
early	O
and	O
delayed	O
phases	O
after	O
SAH	O
is	O
caused	O
by	O
cardiac	B-DISO
failure	I-DISO
and	O
inflammatory	O
(	O
i	O
.	O
e	O
.,	O
noncardiogenic	O
)	O
conditions	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
defined	O
by	O
acute	O
diffuse	O
inflammatory	O
lung	O
injury	O
invoked	O
by	O
a	O
variety	O
of	O
systemic	O
or	O
pulmonary	O
insults	O
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
has	O
rarely	O
been	O
described	O
in	O
patients	O
with	O
heroin	O
intoxication	O
.	O

At	O
present	O
there	O
is	O
no	O
effective	O
specific	O
therapy	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
use	O
of	O
convalescent	O
plasma	O
(	O
CP	O
)	O
has	O
been	O
suggested	O
as	O
a	O
potential	O
therapy	O
based	O
on	O
existing	O
evidence	O
from	O
other	O
viral	B-DISO
infections	I-DISO
.	O

In	O
the	O
CP	O
therapy	O
phase	O
,	O
20	O
consecutive	O
critically	B-DISO
ill	I-DISO
patients	O
admitted	O
to	O
intensive	O
care	O
unit	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
will	O
be	O
enrolled	O
and	O
each	O
will	O
receive	O
2	O
units	O
of	O
CP	O
.	O

Lipopolysaccharide	O
(	O
LPS	B-DISO
),	O
a	O
component	O
of	O
Gram	O
-	O
negative	O
bacterial	O
cell	O
walls	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

Imatinib	O
had	O
no	O
effect	O
of	O
LPS	B-DISO
-	O
induced	O
XOR	O
activity	O
.	O

These	O
results	O
support	O
the	O
testing	O
of	O
imatinib	O
as	O
a	O
novel	O
pharmacologic	O
agent	O
in	O
the	O
treatment	O
of	O
Gram	O
-	O
negative	O
sepsis	B-DISO
and	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
.	O

C57BL	O
/	O
6J	O
mice	O
were	O
infected	O
with	O
Plasmodium	O
berghei	O
NK65	O
to	O
induce	O
lethal	O
MA	O
-	O
ARDS	B-DISO
,	O
or	O
with	O
Plasmodium	O
chabaudi	O
AS	O
,	O
a	O
parasite	O
strain	O
that	O
does	O
not	O
induce	O
lung	O
pathology	B-DISO
.	O

TITLE	O
:	O
Loss	O
of	O
CARD9	O
-	O
mediated	O
innate	O
activation	O
attenuates	O
severe	O
influenza	B-DISO
pneumonia	I-DISO
without	O
compromising	O
host	O
viral	O
immunity	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
CARD9	O
,	O
a	O
signaling	O
adaptor	O
known	O
to	O
regulate	O
innate	O
immune	O
activation	O
through	O
multiple	O
innate	O
sensor	O
proteins	O
,	O
and	O
investigated	O
its	O
role	O
in	O
anti	O
-	O
IFV	O
defense	O
and	O
lung	O
pathogenesis	B-DISO
in	O
a	O
mouse	O
model	O
recapitulating	O
severe	O
influenza	B-DISO
pneumonia	I-DISO
with	O
ARDS	B-DISO
.	O

We	O
found	O
that	O
influenza	B-DISO
pneumonia	I-DISO
was	O
dramatically	O
attenuated	O
in	O
Card9	O
-	O
deficient	O
mice	O
,	O
which	O
showed	O
improved	O
mortality	O
with	O
reduced	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
the	O
infected	O
lungs	O
.	O

Besides	O
,	O
rRBD	O
vaccination	O
alleviated	O
pneumonia	B-DISO
with	O
evidence	O
of	O
reduced	O
tissue	O
impairment	B-DISO
and	O
clinical	O
manifestation	O
in	O
monkeys	O
.	O

TITLE	O
:	O
Cross	O
-	O
Protection	O
by	O
Infectious	B-DISO
Bronchitis	B-DISO
Viruses	O
Under	O
Controlled	O
Experimental	O
Conditions	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
emerged	O
in	O
the	O
Arabian	O
Peninsula	O
in	O
2012	O
,	O
and	O
subsequently	O
spread	O
to	O
other	O
countries	O
in	O
Europe	O
and	O
Asia	O
,	O
and	O
to	O
the	O
United	O
States	O
.	O

Emerging	O
Microbes	O
&	O
Infections	B-DISO
(	O
2015	O
)	O
4	O
,	O
e74	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
emi	O
.	O
2015	O
.	O
74	O
;	O
published	O
online	O
2	O
December	O
2015	O
.	O

ARDS	B-DISO
-	O
induced	O
respiratory	B-DISO
acidosis	I-DISO
was	O
controlled	O
promptly	O
with	O
a	O
pH	O
of	O
7	O
.	O
2	O
±	O
0	O
.	O
1	O
at	O
baseline	O
increasing	O
to	O
7	O
.	O
4	O
±	O
0	O
.	O
1	O
in	O
both	O
study	O
groups	O
after	O
60	O
min	O
of	O
ECMO	O
support	O
.	O

These	O
findings	O
warrant	O
further	O
investigation	O
into	O
the	O
role	O
of	O
the	O
viral	O
microbiome	O
in	O
CRS	B-DISO
.	O

TITLE	O
:	O
Structural	O
Factors	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Outbreak	O
as	O
a	O
Public	O
Health	O
Crisis	O
in	O
Korea	O
and	O
Future	O
Response	O
Strategies	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
has	O
originated	O
from	O
a	O
failure	O
in	O
the	O
national	O
quarantine	O
system	O
in	O
the	O
Republic	O
of	O
Korea	O
as	O
most	O
basic	O
role	O
of	O
protecting	O
the	O
safety	O
and	O
lives	O
of	O
its	O
citizens	O
.	O

Furthermore	O
,	O
a	O
number	O
of	O
the	O
Korean	O
healthcare	O
system	O
'	O
s	O
weaknesses	B-DISO
seem	O
to	O
have	O
been	O
completely	O
exposed	O
.	O

TITLE	O
:	O
Implementation	O
of	O
Quaternary	O
Prevention	O
in	O
the	O
Korean	O
Healthcare	O
System	O
:	O
Lessons	O
From	O
the	O
2015	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
which	O
first	O
emerged	O
in	O
the	O
United	O
States	O
in	O
2013	O
,	O
spread	O
throughout	O
the	O
U	O
.	O
S	O
.	O
hog	O
population	O
.	O

Noninvasive	O
ventilation	O
maybe	O
useful	O
in	O
selected	O
patients	O
with	O
mild	O
ARDS	B-DISO
but	O
should	O
be	O
used	O
with	O
great	O
caution	O
in	O
moderate	O
and	O
severe	O
ARDS	B-DISO
,	O
as	O
failure	O
risk	O
is	O
high	O
.	O

TITLE	O
:	O
Effect	O
of	O
extracorporeal	O
CO2	O
removal	O
on	O
right	O
ventricular	O
and	O
hemodynamic	O
parameters	O
in	O
a	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Current	O
incidence	O
and	O
outcome	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
This	O
article	O
discusses	O
recently	O
published	O
articles	O
reporting	O
the	O
incidence	O
and	O
outcome	O
of	O
patients	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Nucleoside	O
Inhibitors	O
of	O
Hepatitis	B-DISO
C	I-DISO
Virus	O
NS5B	O
Polymerase	O
:	O
A	O
Systematic	O
Review	O
.	O

TITLE	O
:	O
Acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
during	O
protective	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
prevalence	O
,	O
predictors	O
,	O
and	O
clinical	O
impact	O
.	O

ABSTRACT	O
:	O
Increased	O
right	O
ventricle	O
(	O
RV	O
)	O
afterload	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
may	O
induce	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
(	O
ACP	B-DISO
).	O

Hospital	O
mortality	O
did	O
not	O
differ	O
between	O
patients	O
with	O
or	O
without	O
ACP	B-DISO
,	O
but	O
it	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
severe	O
ACP	B-DISO
than	O
in	O
the	O
other	O
patients	O
[	O
31	O
/	O
54	O
(	O
57	O
%)	O
vs	O
.	O
291	O
/	O
698	O
(	O
42	O
%);	O
p	O
=	O
0	O
.	O
03	O
].	O

In	O
contrast	O
,	O
M41	O
infection	B-DISO
caused	O
greater	O
expression	O
of	O
these	O
genes	O
than	O
885	O
or	O
QX	O
in	O
TOCs	O
.	O

No	O
approved	O
specific	O
drugs	O
or	O
vaccinations	O
are	O
available	O
to	O
treat	O
their	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
A	O
highly	O
pathogenic	O
human	O
coronavirus	O
(	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
has	O
emerged	O
in	O
Jeddah	O
and	O
other	O
places	O
in	O
Saudi	O
Arabia	O
,	O
and	O
has	O
quickly	O
spread	O
to	O
European	O
and	O
Asian	O
countries	O
since	O
September	O
2012	O
.	O

ABSTRACT	O
:	O
A	O
recent	O
prospective	O
trial	O
using	O
porcine	O
models	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
indicated	O
that	O
positive	O
-	O
pressure	O
ventilation	O
delivered	O
by	O
a	O
conventional	O
intensive	O
care	O
ventilator	O
at	O
a	O
moderately	O
high	O
frequency	O
allows	O
safe	O
reduction	O
of	O
tidal	O
volume	O
below	O
6	O
ml	O
/	O
kg	O
,	O
leading	O
to	O
more	O
protective	O
ventilation	O
.	O

Here	O
,	O
the	O
authors	O
present	O
a	O
child	O
with	O
DKA	O
who	O
developed	O
both	O
cerebral	B-DISO
edema	I-DISO
and	O
ARDS	B-DISO
during	O
the	O
course	O
of	O
her	O
management	O
.	O

PEDV	O
specific	O
B	O
cell	O
response	O
in	O
the	O
intestine	O
and	O
spleen	O
of	O
infected	O
sows	O
decline	O
by	O
6	O
months	O
,	O
and	O
this	O
associates	O
with	O
specific	O
antibody	O
levels	O
in	O
the	O
plasma	O
and	O
oral	O
fluid	O
samples	O
;	O
but	O
the	O
virus	O
neutralization	O
titers	O
in	O
plasma	O
remains	O
high	O
beyond	O
6	O
months	O
post	O
-	O
infection	B-DISO
.	O

In	O
conclusion	O
,	O
in	O
sows	O
infected	O
with	O
PEDV	O
the	O
presence	O
of	O
effector	O
/	O
memory	O
B	O
cell	O
response	O
and	O
strong	O
virus	O
neutralization	O
titers	O
in	O
plasma	O
up	O
to	O
6	O
months	O
post	O
-	O
infection	B-DISO
,	O
suggests	O
their	O
potential	O
to	O
protect	O
sows	O
from	O
reinfection	O
and	O
provide	O
maternal	O
immunity	O
to	O
neonates	O
,	O
but	O
challenge	O
studies	O
are	O
required	O
to	O
confirm	O
such	O
responses	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
an	O
illness	O
caused	O
by	O
a	O
coronavirus	O
in	O
which	O
infected	O
persons	O
develop	O
severe	O
acute	O
respiratory	O
illness	O
.	O

At	O
12	O
-	O
36	O
hours	O
after	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
onset	O
,	O
patients	O
were	O
assessed	O
under	O
standardized	O
ventilator	O
settings	O
(	O
FIO2	O
≥	O
0	O
.	O
5	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
≥	O
10	O
cm	O
H2O	O
).	O

Previously	O
,	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
cyclosporin	O
(	O
CsA	B-DISO
)	O
and	O
FK506	O
inhibit	O
virus	O
replication	O
in	O
diverse	O
coronaviruses	O
.	O

Mutations	O
of	O
gap	O
junction	O
proteins	O
,	O
connexins	O
(	O
Cxs	O
),	O
cause	O
dysmyelination	O
and	O
leukoencephalopathy	B-DISO
.	O

After	O
infection	B-DISO
,	O
Cx43	O
did	O
not	O
traffic	O
normally	O
to	O
the	O
membrane	O
to	O
form	O
gap	O
junction	O
plaques	B-DISO
,	O
and	O
that	O
could	O
be	O
the	O
basis	O
of	O
reduced	O
functional	O
gap	O
junction	O
coupling	O
between	O
astrocytes	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
reported	O
systemic	O
coronaviral	O
disease	O
in	O
ferrets	O
(	O
Mustela	O
putorius	O
furo	O
),	O
which	O
resembles	O
the	O
dry	O
form	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
,	O
has	O
been	O
increasing	O
in	O
the	O
literature	O
since	O
its	O
initial	O
diagnosis	O
and	O
characterization	O
approximately	O
10	O
y	O
ago	O
.	O

This	O
case	O
report	O
illustrates	O
the	O
importance	O
of	O
considering	O
FRSCV	O
infection	B-DISO
as	O
a	O
differential	O
diagnosis	O
in	O
young	O
,	O
debilitated	O
ferrets	O
with	O
abdominal	O
masses	O
and	O
other	O
supporting	O
clinical	O
signs	O
.	O

Camels	O
therefore	O
serve	O
as	O
an	O
important	O
reservoir	O
for	O
the	O
maintenance	O
and	O
diversification	O
of	O
the	O
MERS	O
-	O
CoVs	O
and	O
are	O
the	O
source	O
of	O
human	O
infections	B-DISO
with	O
this	O
virus	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
have	O
led	O
to	O
an	O
ongoing	O
outbreak	O
in	O
humans	O
,	O
which	O
was	O
fueled	O
by	O
multiple	O
zoonotic	O
MERS	O
-	O
CoV	O
introductions	O
from	O
dromedary	O
camels	O
.	O

Our	O
results	O
showed	O
that	O
(+)-	O
catechin	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
TGEV	O
proliferation	B-DISO
in	O
vitro	O
and	O
is	O
involved	O
its	O
antioxidation	O
.	O

ABSTRACT	O
:	O
In	O
2013	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
was	O
reported	O
in	O
Japan	O
for	O
the	O
first	O
time	O
in	O
7years	O
and	O
caused	O
significant	O
economic	O
losses	O
.	O

ABSTRACT	O
:	O
Successful	O
gene	O
therapy	O
of	O
neurological	B-DISO
disorders	I-DISO
is	O
predicated	O
on	O
achieving	O
widespread	O
and	O
uniform	O
transgene	O
expression	O
throughout	O
the	O
affected	O
disease	O
area	O
in	O
the	O
brain	O
.	O

Moreover	O
,	O
details	O
of	O
the	O
transmission	O
cycle	O
of	O
the	O
virus	O
remain	O
unclear	O
,	O
particularly	O
regarding	O
the	O
role	O
of	O
camels	O
as	O
a	O
reservoir	O
host	O
for	O
human	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
No	O
major	O
trial	O
evaluating	O
prone	O
positioning	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
incorporated	O
a	O
high	O
-	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
high	O
-	O
PEEP	O
)	O
strategy	O
despite	O
complementary	O
physiological	O
rationales	O
.	O

This	O
paper	O
highlights	O
the	O
current	O
knowledge	O
of	O
molecular	O
epidemiology	O
,	O
diagnosis	O
,	O
and	O
pathogenesis	B-DISO
of	O
PEDV	O
,	O
as	O
well	O
as	O
prevention	O
and	O
control	O
measures	O
against	O
PEDV	O
infection	B-DISO
.	O

It	O
is	O
hoped	O
that	O
this	O
review	O
will	O
stimulate	O
further	O
basic	O
and	O
applied	O
studies	O
and	O
encourage	O
collaboration	O
among	O
producers	O
,	O
researchers	O
,	O
and	O
swine	O
veterinarians	O
to	O
provide	O
answers	O
that	O
improve	O
our	O
understanding	O
of	O
PEDV	O
and	O
PED	O
in	O
an	O
effort	O
to	O
eliminate	O
this	O
economically	O
significant	O
viral	B-DISO
disease	I-DISO
,	O
which	O
emerged	O
or	O
re	O
-	O
emerged	O
worldwide	O
.	O

Various	O
species	O
of	O
horseshoe	O
bats	O
in	O
China	O
have	O
been	O
found	O
to	O
harbor	O
genetically	O
diverse	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
.	O

Some	O
strains	O
are	O
highly	O
similar	O
to	O
SARS	B-DISO
-	O
CoV	O
even	O
in	O
the	O
spike	O
protein	O
and	O
are	O
able	O
to	O
use	O
the	O
same	O
receptor	O
as	O
SARS	B-DISO
-	O
CoV	O
for	O
cell	O
entry	O
.	O

ABSTRACT	O
:	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
identified	O
to	O
cause	O
severe	O
respiratory	B-DISO
infection	I-DISO
in	O
humans	O
since	O
2012	O
.	O

TITLE	O
:	O
Modeling	O
the	O
Transmission	O
of	O
Middle	O
East	O
Respirator	O
Syndrome	B-DISO
Corona	O
Virus	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
nosocomial	B-DISO
infections	I-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
occurred	O
in	O
South	O
Korea	O
in	O
May	O
2015	O
.	O

Conversely	O
,	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
liver	O
injury	O
(	O
LI	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
significantly	O
more	O
common	O
during	O
hospitalization	O
in	O
the	O
O	O
-	O
group	O
,	O
although	O
no	O
significant	O
differences	O
in	O
the	O
duration	O
of	O
hospital	O
stay	O
(	O
p	O
=	O
0	O
.	O
92	O
)	O
or	O
outcomes	O
(	O
p	O
=	O
0	O
.	O
95	O
)	O
were	O
observed	O
between	O
the	O
two	O
groups	O
.	O

Clinical	O
and	O
public	O
health	O
records	O
showed	O
that	O
13	O
patients	O
were	O
healthcare	O
personnel	O
(	O
HCP	B-DISO
).	O

Fifteen	O
patients	O
,	O
including	O
4	O
HCP	B-DISO
,	O
were	O
associated	O
with	O
1	O
dialysis	O
unit	O
.	O

The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
less	O
than	O
10	O
years	O
later	O
demonstrates	O
the	O
potential	O
of	O
coronaviruses	O
to	O
cross	O
species	O
boundaries	O
and	O
further	O
highlights	O
the	O
importance	O
of	O
identifying	O
novel	O
lead	O
compounds	O
with	O
broad	O
spectrum	O
activity	O
.	O

MERS	O
-	O
CoV	O
is	O
enzootic	O
in	O
DC	O
across	O
the	O
Arabian	O
Peninsula	O
and	O
in	O
parts	O
of	O
Africa	O
,	O
causing	O
mild	O
upper	O
respiratory	O
tract	O
illness	O
in	O
its	O
camel	O
reservoir	O
and	O
sporadic	O
,	O
but	O
relatively	O
rare	O
human	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
In	O
April	O
2013	O
,	O
a	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
epidemic	O
began	O
in	O
the	O
United	O
States	O
.	O

ABSTRACT	O
:	O
Data	O
on	O
the	O
management	O
,	O
clinical	O
course	O
,	O
and	O
outcome	O
of	O
critical	O
patients	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
are	O
scarce	O
.	O

Predominant	O
symptoms	O
were	O
fever	O
,	O
cough	B-DISO
,	O
and	O
dyspnea	B-DISO
.	O

All	O
subjects	O
received	O
lung	O
-	O
protective	O
ventilation	O
and	O
1	O
mg	O
/	O
kg	O
/	O
d	O
methylprednisolone	O
infusion	O
for	O
ARDS	B-DISO
.	O

Five	O
subjects	O
,	O
including	O
3	O
health	O
-	O
care	O
workers	O
,	O
were	O
discharged	O
from	O
hospital	O
and	O
were	O
alive	O
after	O
1	O
y	O
.	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
pneumonia	B-DISO
with	O
ARDS	B-DISO
has	O
high	O
mortality	O
in	O
subjects	O
with	O
comorbidities	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
evaluate	O
the	O
usefulness	O
of	O
the	O
sequencing	O
step	O
including	O
FCoV	O
-	O
RNA	O
-	O
positive	O
cats	O
with	O
and	O
without	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
lung	O
function	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
10	O
years	O
after	O
recovery	O
and	O
the	O
influencing	O
factors	O
.	O

Induction	O
of	O
ALI	O
was	O
impaired	B-DISO
in	O
IL	O
-	O
17	O
-	O
deficient	O
mice	O
.	O

Finally	O
,	O
we	O
confirmed	O
the	O
clinical	O
relevance	O
and	O
found	O
that	O
IL	O
-	O
17	O
expression	O
was	O
elevated	O
and	O
associated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
It	O
is	O
crucial	O
to	O
understand	O
the	O
current	O
status	O
of	O
clinical	O
laboratory	O
practices	O
for	O
the	O
largest	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
in	O
the	O
Republic	O
of	O
Korea	O
to	O
be	O
well	O
prepared	O
for	O
future	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
contrast	O
,	O
by	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
of	O
the	O
TUNEL	O
-	O
positive	O
signals	O
(	O
apoptotic	O
nuclear	O
fragmentation	B-DISO
)	O
were	O
found	O
in	O
PDCoV	O
antigen	O
-	O
positive	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
that	O
also	O
showed	O
cytopathic	B-DISO
effects	I-DISO
,	O
such	O
as	O
cell	O
rounding	O
,	O
detachment	B-DISO
and	O
clumping	O
in	O
clusters	O
.	O

For	O
a	O
scenario	O
to	O
be	O
plausible	O
,	O
it	O
had	O
to	O
explain	O
:	O
contamination	O
of	O
a	O
person	O
or	O
product	O
in	O
the	O
source	O
country	O
,	O
its	O
transit	O
and	O
entry	O
to	O
the	O
United	O
States	O
,	O
rapid	O
dispersal	O
across	O
a	O
wide	O
geographic	O
area	O
,	O
and	O
exposure	O
/	O
infection	B-DISO
of	O
pigs	O
.	O

This	O
study	O
describes	O
the	O
molecular	O
detection	O
of	O
BCoV	O
in	O
a	O
diarrhea	B-DISO
outbreak	O
in	O
beef	O
cattle	O
steers	O
(	O
Nellore	O
)	O
raised	O
on	O
pasture	O
in	O
Parana	O
,	O
southern	O
Brazil	O
.	O

The	O
disease	O
,	O
as	O
well	O
as	O
the	O
causative	O
Alphacoronavirus	O
,	O
the	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
was	O
first	O
described	O
in	O
Europe	O
in	O
the	O
1970s	O
and	O
since	O
then	O
has	O
spread	O
over	O
many	O
Asian	O
and	O
American	O
countries	O
,	O
where	O
it	O
recently	O
led	O
to	O
devastating	O
effects	O
on	O
swine	O
health	O
and	O
pork	O
industry	O
.	O

The	O
virus	O
was	O
probably	O
introduced	O
by	O
purchasing	O
piglets	O
from	O
a	O
German	O
source	O
,	O
which	O
underlines	O
the	O
significance	O
of	O
trans	O
-	O
boundary	O
animal	O
trade	O
for	O
the	O
distribution	O
of	O
highly	O
contagious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
PED	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
epidemiological	O
characteristics	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
in	O
2015	O
and	O
provide	O
related	O
information	O
for	O
the	O
public	O
health	O
professionals	O
in	O
China	O
.	O

These	O
analytical	O
methods	O
were	O
limited	O
in	O
the	O
detection	O
of	O
sequences	O
with	O
limited	O
homology	O
to	O
previous	O
annotations	O
within	O
NCBI	O
databases	O
,	O
such	O
as	O
parvovirus	B-DISO
.	O

ABSTRACT	O
:	O
To	O
investigate	O
both	O
the	O
gray	O
matter	O
(	O
GM	O
)	O
and	O
whiter	O
matter	O
(	O
WM	O
)	O
alterations	O
in	O
a	O
homogeneous	O
cohort	O
of	O
early	O
HIV	B-DISO
-	O
infected	O
patients	O
by	O
combining	O
voxel	O
-	O
based	O
morphometry	O
(	O
VBM	O
)	O
and	O
tract	O
-	O
based	O
spatial	O
statistics	O
(	O
TBSS	O
).	O

Our	O
results	O
indicate	O
that	O
structural	O
brain	O
alterations	O
occurred	O
early	O
in	O
HIV	B-DISO
-	O
infected	O
patients	O
.	O

The	O
children	O
and	O
/	O
or	O
their	O
parents	O
completed	O
the	O
ISAAC	O
(	O
International	O
Study	O
of	O
Asthma	B-DISO
and	O
Allergies	B-DISO
in	O
Children	O
)	O
questionnaire	O
.	O

In	O
children	O
with	O
SCD	B-DISO
,	O
there	O
is	O
a	O
high	O
prevalence	O
of	O
AHR	O
that	O
is	O
not	O
associated	O
with	O
asthma	B-DISO
-	O
like	O
symptoms	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
bat	O
coronavirus	O
which	O
is	O
much	O
closer	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
genomic	O
sequence	O
than	O
others	O
previously	O
reported	O
,	O
particularly	O
in	O
its	O
S	O
gene	O
.	O

Type	O
2	O
POPE	O
should	O
be	O
considered	O
in	O
a	O
patient	O
presenting	O
with	O
respiratory	B-DISO
distress	I-DISO
and	O
a	O
history	O
of	O
sleep	B-DISO
apnea	I-DISO
.	O

RESULTS	O
:	O
Of	O
the	O
396	O
,	O
449	O
older	O
patients	O
at	O
293	O
trauma	O
centres	O
that	O
met	O
inclusion	O
criteria	O
,	O
30	O
,	O
761	O
(	O
8	O
%)	O
suffered	B-DISO
a	O
MC	O
.	O

ABSTRACT	O
:	O
This	O
commentary	O
highlights	O
the	O
article	O
by	O
Ng	O
et	O
al	O
,	O
emphasizing	O
the	O
need	O
for	O
autopsies	O
to	O
better	O
model	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

The	O
best	O
method	O
of	O
preventing	O
future	O
outbreaks	O
is	O
to	O
overcome	O
the	O
vulnerabilities	O
observed	O
in	O
this	O
outbreak	O
,	O
such	O
as	O
ward	O
crowding	B-DISO
,	O
patient	O
migration	O
without	O
appropriate	O
data	O
sharing	O
,	O
and	O
the	O
lack	O
of	O
an	O
initial	O
broad	O
quarantine	O
.	O

The	O
patient	O
visited	O
4	O
medical	O
facilities	O
and	O
contacted	O
742	O
people	O
between	O
May	O
11	O
,	O
2015	O
,	O
at	O
symptom	B-DISO
onset	O
,	O
and	O
May	O
20	O
,	O
at	O
admission	O
to	O
the	O
National	O
Medical	O
Center	O
;	O
28	O
people	O
were	O
infected	O
and	O
diagnosed	O
with	O
MERS	O
thereafter	O
.	O

All	O
children	O
(	O
0	O
-	O
12	O
y	O
of	O
age	O
)	O
diagnosed	O
and	O
confirmed	O
as	O
dengue	B-DISO
fever	I-DISO
at	O
a	O
tertiary	O
care	O
hospital	O
at	O
Puducherry	O
,	O
between	O
the	O
1st	O
of	O
August	O
2012	O
and	O
January	O
31st	O
2015	O
were	O
reviewed	O
retrospectively	O
from	O
hospital	O
case	O
records	O
as	O
per	O
the	O
revised	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
guidelines	O
2011	O
for	O
dengue	B-DISO
fever	I-DISO
.	O

Clinicians	O
should	O
have	O
a	O
high	O
index	O
of	O
suspicion	O
and	O
vigilance	O
for	O
atypical	O
manifestations	O
of	O
dengue	B-DISO
fever	I-DISO
as	O
lack	O
of	O
timely	O
detection	O
and	O
management	O
could	O
be	O
fatal	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
recent	O
studies	O
which	O
highlighted	O
the	O
role	O
of	O
the	O
pulmonary	O
endothelium	O
as	O
the	O
center	O
of	O
innate	O
immune	O
cells	O
recruitment	B-DISO
and	O
excessive	O
pro	O
-	O
inflammatory	O
cytokines	O
production	O
.	O

icPEDV	O
-	O
ΔORF3	O
-	O
RFP	O
replicated	O
efficiently	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
was	O
efficiently	O
transmitted	B-DISO
among	O
pigs	O
,	O
and	O
produced	O
lethal	O
disease	O
outcomes	O
.	O

Here	O
,	O
we	O
present	O
a	O
DNA	O
-	O
based	O
infectious	B-DISO
-	O
clone	O
system	O
that	O
replicates	O
the	O
pathogenesis	B-DISO
of	O
circulating	O
U	O
.	O
S	O
.	O
strain	O
PC22A	O
both	O
in	O
vitro	O
and	O
in	O
piglets	O
.	O

This	O
infectious	B-DISO
clone	O
can	O
be	O
used	O
both	O
to	O
study	O
the	O
genetics	O
,	O
virulence	O
,	O
and	O
transmission	O
of	O
PEDV	O
coronavirus	O
and	O
to	O
inform	O
the	O
creation	O
of	O
a	O
live	O
attenuated	O
PEDV	O
vaccine	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
contributions	O
of	O
Oas	B-DISO
gene	O
expression	O
,	O
basal	O
IFN	O
signaling	O
,	O
and	O
virus	O
-	O
induced	O
IFN	O
to	O
RNase	O
L	O
activation	O
.	O

However	O
,	O
ns2	B-DISO
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	O
L	O
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	O
-	O
blocking	B-DISO
antibody	O
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	B-DISO
genes	O
.	O

A	O
smoking	O
habit	O
,	O
the	O
intense	O
physical	O
training	O
and	O
the	O
use	O
of	O
PED	O
'	O
s	O
may	O
have	O
exacerbated	O
the	O
course	O
of	O
the	O
viral	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Macro	O
Domain	O
from	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Is	O
an	O
Efficient	O
ADP	O
-	O
ribose	O
Binding	O
Module	O
:	O
CRYSTAL	O
STRUCTURE	O
AND	O
BIOCHEMICAL	O
STUDIES	O
.	O

Influenza	B-DISO
virus	O
(	O
AF	O
:	O
86	O
.	O
3	O
%;	O
95	O
%	O
CI	O
:	O
77	O
.	O
7	O
-	O
91	O
.	O
6	O
%),	O
hMPV	O
(	O
AF	O
:	O
85	O
.	O
6	O
%;	O
95	O
%	O
CI	O
:	O
72	O
.	O
0	O
-	O
92	O
.	O
6	O
%),	O
and	O
RSV	O
(	O
AF	O
:	O
83	O
.	O
7	O
%;	O
95	O
%	O
CI	O
:	O
77	O
.	O
5	O
-	O
88	O
.	O
2	O
%)	O
infections	B-DISO
were	O
associated	O
with	O
severe	O
disease	O
.,	O
while	O
rhinovirus	O
(	O
AF	O
:	O
46	O
.	O
9	O
%;	O
95	O
%	O
CI	O
:	O
37	O
.	O
6	O
-	O
56	O
.	O
5	O
%)	O
and	O
adenovirus	B-DISO
(	O
AF	O
:	O
36	O
.	O
4	O
%;	O
95	O
%	O
CI	O
:	O
20	O
.	O
6	O
-	O
49	O
.	O
0	O
%)	O
were	O
only	O
moderately	O
associated	O
.	O

Five	O
patients	O
with	O
suspected	O
MERS	O
-	O
CoA	B-DISO
infection	B-DISO
were	O
admitted	O
to	O
our	O
hospital	O
during	O
this	O
outbreak	O
.	O

One	O
patient	O
had	O
no	O
major	O
symptoms	O
upon	O
admission	O
,	O
but	O
pneumonia	B-DISO
was	O
identified	O
upon	O
chest	O
radiography	O
.	O

One	O
patient	O
required	O
extracorporeal	O
membrane	O
oxygenation	O
to	O
treat	O
refractory	O
hypoxemia	O
,	O
and	O
one	O
patient	O
died	O
of	O
shock	O
with	O
multiorgan	B-DISO
failure	I-DISO
.	O

The	O
pneumonia	B-DISO
usually	O
affected	O
the	O
lower	O
lobes	O
.	O

TITLE	O
:	O
Time	O
-	O
and	O
dose	O
-	O
dependent	O
severity	O
of	O
lung	O
injury	O
in	O
a	O
rat	O
model	O
of	O
sepsis	B-DISO
.	O

We	O
did	O
a	O
restrospective	O
analysis	O
of	O
hospital	O
and	O
6	O
month	O
mortality	O
of	O
patients	O
with	O
ARDS	B-DISO
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
of	O
a	O
Univeristy	O
Hospital	O
in	O
Buenos	O
Aires	O
,	O
between	O
January	O
2008	O
and	O
June	O
2011	O
.	O

After	O
logistic	O
regression	O
analysis	O
,	O
only	O
age	O
,	O
the	O
presence	O
of	O
septic	B-DISO
shock	I-DISO
at	O
admission	O
,	O
Ppl	O
>	O
30	O
cmH2O	O
,	O
and	O
major	O
co	O
-	O
morbidities	O
were	O
independently	O
associated	O
with	O
hospital	O
outcome	O
.	O

TITLE	O
:	O
Epidemiology	O
of	O
human	O
coronavirus	O
NL63	O
infection	B-DISO
among	O
hospitalized	O
patients	O
with	O
pneumonia	B-DISO
in	O
Taiwan	O
.	O

Seasonal	O
prevalence	O
of	O
HCoV	O
-	O
NL63	O
infection	B-DISO
was	O
late	O
winter	O
,	O
overlapping	O
the	O
highest	O
peak	O
of	O
the	O
influenza	B-DISO
A	O
/	O
H1N1	O
epidemic	O
during	O
December	O
2010	O
to	O
March	O
2011	O
in	O
Taiwan	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
HCoV	O
-	O
NL63	O
and	O
influenza	B-DISO
A	O
/	O
H1N1	O
was	O
detected	O
in	O
three	O
hospitalized	O
patients	O
.	O

RESULTS	O
:	O
HCoV	O
-	O
NL63	O
infection	B-DISO
was	O
identified	O
in	O
8	O
.	O
4	O
%	O
(	O
9	O
/	O
107	O
)	O
of	O
hospitalized	O
patients	O
with	O
pneumonia	B-DISO
,	O
but	O
not	O
found	O
in	O
outpatients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

The	O
pathophysiological	O
causes	O
are	O
:	O
the	O
change	O
in	O
the	O
pressure	O
gradients	O
in	O
the	O
pulmonary	O
capillaries	O
,	O
the	O
impaired	B-DISO
membrane	O
permeability	O
of	O
the	O
alveolocapillary	O
in	O
the	O
lungs	O
,	O
and	O
impaired	B-DISO
lymphatic	O
drainage	O
.	O

The	O
basic	O
steps	O
of	O
treatment	O
are	O
:	O
the	O
use	O
of	O
different	O
types	O
of	O
ventilatory	O
support	O
in	O
order	O
to	O
achieve	O
adequate	O
oxygenation	O
,	O
dealing	O
with	O
possible	O
hemodynamic	B-DISO
instability	I-DISO
,	O
and	O
,	O
when	O
needed	O
,	O
other	O
specific	O
procedures	O
.	O

It	O
is	O
always	O
important	O
to	O
keep	O
in	O
mind	O
that	O
this	O
is	O
a	O
very	O
serious	O
condition	B-DISO
with	O
a	O
high	O
mortality	O
rate	O
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
remains	O
the	O
cornerstone	O
in	O
the	O
management	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Critically	B-DISO
ill	I-DISO
children	O
aged	O
from	O
2	O
months	O
to	O
18	O
years	O
were	O
included	O
.	O

TITLE	O
:	O
Case	O
-	O
control	O
study	O
of	O
pathogens	O
involved	O
in	O
piglet	O
diarrhea	B-DISO
.	O

RESULTS	O
:	O
All	O
bacterial	O
,	O
viral	O
,	O
protozoan	O
,	O
and	O
parasitic	O
agents	O
here	O
investigated	O
,	O
with	O
the	O
exception	O
of	O
Salmonella	B-DISO
spp	O
.	O

TITLE	O
:	O
A	O
new	O
vinyl	O
selenone	O
-	O
based	O
domino	O
approach	O
to	O
spirocyclopropyl	O
oxindoles	O
endowed	O
with	O
anti	O
-	O
HIV	B-DISO
RT	O
activity	O
.	O

TITLE	O
:	O
The	O
leukocyte	O
-	O
stiffening	O
property	O
of	O
plasma	O
in	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
revealed	O
by	O
a	O
microfluidic	O
single	O
-	O
cell	O
study	O
:	O
the	O
role	O
of	O
cytokines	O
and	O
protection	O
with	O
antibodies	O
.	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	O
expression	O
(	O
CD11b	O
,	O
CD11a	O
,	O
CD18	O
,	O
CD49d	O
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	B-DISO
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	O
of	O
patients	O
with	O
ARDS	B-DISO
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	B-DISO
in	O
early	O
ARDS	B-DISO
.	O

(	O
1	O
)	O
Totally	O
2	O
895	O
cases	O
were	O
positive	O
for	O
at	O
least	O
one	O
virus	O
in	O
this	O
study	O
in	O
4	O
371	O
ALRTI	O
patients	O
(	O
positive	O
rate	O
66	O
.	O
23	O
%),	O
in	O
which	O
147	O
cases	O
were	O
positive	O
for	O
HCoVs	O
infection	B-DISO
(	O
positive	O
rate	O
3	O
.	O
36	O
%).	O

The	O
clinical	O
manifestations	O
and	O
severity	O
of	O
ALRTI	O
caused	O
by	O
single	O
HCoVs	O
was	O
comparable	O
to	O
that	O
of	O
ALRTI	O
with	O
single	O
RSV	B-DISO
infection	I-DISO
in	O
children	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
we	O
compared	O
the	O
characteristics	O
of	O
the	O
children	O
who	O
were	O
admitted	O
into	O
the	O
University	O
of	O
Malaya	O
Medical	O
Centre	O
,	O
Malaysia	O
,	O
for	O
H1N1	B-DISO
influenza	I-DISO
during	O
the	O
pandemic	O
with	O
those	O
who	O
were	O
admitted	O
for	O
seasonal	O
influenza	B-DISO
in	O
2002	O
-	O
2007	O
.	O

The	O
three	O
patients	O
who	O
died	O
had	O
a	O
comorbid	O
medical	O
condition	B-DISO
.	O

Mice	O
in	O
which	O
expression	O
of	O
CXCL1	O
is	O
under	O
the	O
control	O
of	O
a	O
tetracycline	O
-	O
inducible	O
promoter	O
active	O
within	O
glial	O
fibrillary	O
acidic	O
protein	O
-	O
positive	O
cells	O
were	O
generated	O
and	O
this	O
allowed	O
for	O
selectively	O
increasing	O
CNS	O
expression	O
of	O
CXCL1	O
in	O
response	O
to	O
JHMV	O
infection	B-DISO
and	O
evaluating	O
the	O
effects	O
on	O
neuroinflammation	O
,	O
control	O
of	O
viral	O
replication	O
,	O
and	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
Natural	O
products	O
,	O
especially	O
derived	O
from	O
TCMH	O
,	O
have	O
been	O
found	O
to	O
exert	O
antiviral	O
effects	O
against	O
influenza	B-DISO
virus	O
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
virus	O
carriage	O
potentially	O
responsible	O
for	O
RTI	B-DISO
among	O
pilgrims	O
before	O
and	O
after	O
participating	O
in	O
the	O
Hajj	O
.	O

The	O
viruses	O
most	O
commonly	O
isolated	O
from	O
symptomatic	O
patients	O
during	O
the	O
Hajj	O
by	O
PCR	O
were	O
rhinovirus	O
(	O
5	O
.	O
9	O
-	O
48	O
.	O
8	O
%	O
prevalence	O
),	O
followed	O
by	O
influenza	B-DISO
virus	O
(	O
4	O
.	O
5	O
-	O
13	O
.	O
9	O
%)	O
and	O
non	O
-	O
MERS	O
coronaviruses	O
(	O
2	O
.	O
7	O
-	O
13	O
.	O
2	O
%)	O
with	O
most	O
infections	B-DISO
due	O
to	O
coronavirus	O
229E	O
;	O
other	O
viruses	O
were	O
less	O
frequently	O
isolated	O
.	O

ABSTRACT	O
:	O
Previously	O
unidentified	O
viruses	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
continue	O
to	O
emerge	O
and	O
threaten	O
populations	O
,	O
while	O
powerful	O
new	O
techniques	O
have	O
identified	O
many	O
new	O
human	O
and	O
animal	O
viruses	O
.	O

In	O
this	O
review	O
we	O
will	O
introduce	O
various	O
pseudotyping	O
systems	O
for	O
emerging	O
viruses	O
,	O
including	O
chikungunya	B-DISO
virus	O
,	O
Ebola	O
virus	O
,	O
SARS	B-DISO
and	O
MERS	O
coronaviruses	O
and	O
Nipah	O
virus	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
diverse	O
studies	O
including	O
drug	O
screening	O
and	O
antibody	O
neutralization	O
.	O

The	O
main	O
diagnosis	O
was	O
COPD	B-DISO
exacerbation	I-DISO
(	O
45	O
%).	O

However	O
,	O
we	O
should	O
consider	O
that	O
P	O
(	O
tcCO2	O
)	O
underestimates	O
P	O
(	O
aCO2	O
)	O
levels	O
,	O
and	O
its	O
accuracy	O
depends	O
on	O
the	O
level	O
of	O
hypercapnia	B-DISO
,	O
so	O
this	O
method	O
would	O
not	O
be	O
suitable	O
for	O
acute	O
patients	O
with	O
severe	O
hypercapnia	B-DISO
.	O

With	O
a	O
better	O
understanding	O
of	O
the	O
dynamic	O
interaction	O
between	O
host	O
and	O
coronaviruses	O
,	O
it	O
is	O
hoped	O
that	O
insights	O
on	O
the	O
pathogenesis	B-DISO
of	O
newly	O
-	O
identified	O
highly	O
pathogenic	O
human	O
coronaviruses	O
and	O
new	O
strategies	O
in	O
antiviral	O
development	O
can	O
be	O
derived	O
.	O

ABSTRACT	O
:	O
Objectives	O
Diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
remains	O
challenging	O
,	O
especially	O
in	O
cats	O
without	O
effusions	B-DISO
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
performed	O
on	O
PBMCs	O
of	O
37	O
cats	O
(	O
21	O
cats	O
with	O
FIP	B-DISO
,	O
16	O
controls	O
),	O
on	O
serum	O
of	O
51	O
cats	O
(	O
26	O
cats	O
with	O
FIP	B-DISO
,	O
25	O
controls	O
)	O
and	O
on	O
cell	O
-	O
free	O
body	O
cavity	B-DISO
effusion	B-DISO
of	O
69	O
cats	O
(	O
36	O
cats	O
with	O
FIP	B-DISO
,	O
33	O
controls	O
).	O

The	O
use	O
of	O
monoclonal	O
antibodies	O
targeting	O
the	O
stem	O
of	O
the	O
influenza	B-DISO
virus	O
surface	O
hemagglutinin	O
(	O
HA	O
)	O
is	O
a	O
rapidly	O
developing	O
strategy	O
for	O
the	O
control	O
of	O
viruses	O
of	O
multiple	O
HA	O
subtypes	O
.	O

ABSTRACT	O
:	O
Viral	B-DISO
shedding	I-DISO
lasted	O
31	O
and	O
19	O
days	O
from	O
symptom	B-DISO
onset	O
in	O
two	O
patients	O
with	O
east	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
pneumonia	B-DISO
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
human	O
pathogen	O
related	O
to	O
SARS	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
was	O
first	O
identified	O
in	O
2012	O
and	O
has	O
since	O
then	O
remained	O
uncontrolled	O
.	O

In	O
addition	O
,	O
we	O
summarized	O
the	O
virological	O
aspects	O
of	O
the	O
infection	B-DISO
and	O
reviewed	O
the	O
animal	O
models	O
used	O
as	O
well	O
as	O
vaccination	O
and	O
antiviral	O
tested	O
against	O
it	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
related	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spreads	O
to	O
humans	O
via	O
zoonotic	O
transmission	O
from	O
camels	O
.	O

In	O
SAP	O
patients	O
by	O
new	O
criteria	O
,	O
the	O
discharge	O
rate	O
in	O
critical	O
condition	B-DISO
and	O
mortality	O
were	O
not	O
only	O
higher	O
than	O
those	O
in	O
MSAP	O
patients	O
(	O
17	O
.	O
0	O
%	O
vs	O
4	O
.	O
1	O
%,	O
4	O
.	O
1	O
%	O
vs	O
1	O
.	O
5	O
%,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
),	O
but	O
also	O
higher	O
than	O
those	O
in	O
SAP	O
patients	O
by	O
the	O
old	O
classification	O
(	O
17	O
.	O
0	O
%	O
vs	O
7	O
.	O
2	O
%,	O
4	O
.	O
1	O
%	O
vs	O
2	O
.	O
1	O
%,	O
all	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
report	O
a	O
30	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
fever	O
,	O
abdominal	B-DISO
pain	I-DISO
,	O
and	O
diarrhea	B-DISO
,	O
who	O
was	O
diagnosed	O
with	O
MERS	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
the	O
spike	O
and	O
ORF3	O
genes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
the	O
Philippines	O
.	O

A	O
host	O
intracellular	O
filamentous	O
cytoskeletal	O
protein	O
vimentin	O
was	O
identified	O
by	O
immunoprecipitation	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
following	O
chemical	O
cross	O
-	O
linking	O
on	O
Vero	O
E6	O
cells	O
that	O
were	O
pre	O
-	O
incubated	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

RESULTS	O
:	O
A	O
host	O
intracellular	O
filamentous	O
cytoskeletal	O
protein	O
vimentin	O
was	O
identified	O
by	O
immunoprecipitation	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
following	O
chemical	O
cross	O
-	O
linking	O
on	O
Vero	O
E6	O
cells	O
that	O
were	O
pre	O
-	O
incubated	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

82	O
.	O
1	O
%	O
had	O
an	O
infectious	B-DISO
complication	B-DISO
,	O
mainly	O
non	O
-	O
pancreatic	B-DISO
infection	I-DISO
(	O
66	O
.	O
7	O
%	O
on	O
moderately	O
severe	O
AP	O
vs	O
.	O
79	O
.	O
5	O
%	O
on	O
severe	O
,	O
p	O
=	O
0	O
.	O
0443	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
value	O
of	O
serum	O
cholinesterase	O
(	O
S	O
-	O
ChE	O
)	O
levels	O
in	O
judgment	O
of	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

Best	O
truncation	B-DISO
point	O
analysis	O
was	O
used	O
to	O
compare	O
their	O
estimated	O
value	O
for	O
prognosis	O
of	O
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

Eighty	O
-	O
six	O
patients	O
with	O
severe	O
pneumonia	B-DISO
were	O
studied	O
.	O

At	O
the	O
best	O
truncation	B-DISO
points	O
of	O
S	O
-	O
ChE	O
levels	O
,	O
APACHE	O
II	O
score	O
and	O
MODS	B-DISO
score	O
were	O
3	O
.	O
372	O
kU	O
/	O
L	O
,	O
19	O
.	O
5	O
score	O
,	O
and	O
6	O
.	O
5	O
score	O
respectively	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
and	O
negative	O
predictive	O
value	O
in	O
predicting	O
death	O
risk	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
were	O
(	O
80	O
.	O
0	O
%,	O
78	O
.	O
0	O
%,	O
76	O
.	O
19	O
%	O
and	O
81	O
.	O
82	O
%),	O
(	O
95	O
.	O
0	O
%,	O
70	O
.	O
0	O
%,	O
73	O
.	O
08	O
%	O
and	O
94	O
.	O
12	O
%)	O
and	O
(	O
70	O
.	O
0	O
%,	O
91	O
.	O
0	O
%,	O
87	O
.	O
50	O
%,	O
77	O
.	O
78	O
%),	O
respectively	O
.	O

If	O
S	O
-	O
ChE	O
levels	O
was	O
combined	O
with	O
APACHE	O
II	O
score	O
or	O
combined	O
with	O
MODS	B-DISO
score	O
,	O
the	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
and	O
negative	O
predictive	O
value	O
[	O
S	O
-	O
ChE	O
levels	O
combined	O
APACHE	O
II	O
score	O
:	O
100	O
%,	O
92	O
.	O
0	O
%,	O
93	O
.	O
75	O
%	O
and	O
100	O
%;	O
S	O
-	O
ChE	O
levels	O
combined	O
MODS	B-DISO
score	O
:	O
all	O
100	O
%]	O
were	O
higher	O
than	O
single	O
power	O
of	O
S	O
-	O
ChE	O
levels	O
,	O
APACHE	O
II	O
score	O
or	O
MODS	B-DISO
score	O
.	O

S	O
-	O
ChE	O
levels	O
can	O
be	O
considered	O
as	O
an	O
effective	O
and	O
practical	O
index	O
to	O
estimate	O
the	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

Median	O
time	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
development	O
was	O
55	O
.	O
4	O
days	O
(	O
interquartile	O
range	O
,	O
15	O
.	O
1	O
-	O
139	O
d	O
)	O
in	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
and	O
14	O
.	O
2	O
days	O
(	O
interquartile	O
range	O
,	O
10	O
.	O
5	O
-	O
124	O
d	O
)	O
in	O
autologous	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

At	O
12	O
months	O
following	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
89	O
patients	O
(	O
66	O
.	O
9	O
%)	O
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
had	O
died	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
frequent	O
complication	B-DISO
following	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
dramatically	O
influencing	O
patient	O
-	O
important	O
outcomes	O
.	O

These	O
findings	O
highlight	O
the	O
need	O
to	O
better	O
understand	O
the	O
risk	O
factors	O
underlying	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
this	O
population	O
,	O
thereby	O
facilitating	O
the	O
development	O
of	O
effective	O
prevention	O
strategies	O
.	O

TITLE	O
:	O
Genomic	O
Motifs	O
as	O
a	O
Novel	O
Indicator	O
of	O
the	O
Relationship	O
between	O
Strains	O
Isolated	O
from	O
the	O
Epidemic	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
in	O
2013	O
-	O
2014	O
.	O

Besides	O
,	O
OI	O
was	O
a	O
predictive	O
protection	O
factor	O
of	O
ARDS	B-DISO
,	O
whereas	O
lactic	O
acid	O
,	O
EVLWI	O
and	O
PVPI	O
were	O
risk	O
factors	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
transpulmonary	O
pressure	O
-	O
directed	O
mechanical	O
ventilation	O
on	O
respiration	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
patient	O
with	O
intraabdominal	B-DISO
hypertension	I-DISO
].	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effect	O
of	O
mehanical	O
ventilation	O
(	O
MV	O
)	O
guided	O
by	O
transpulmonary	O
pressure	O
(	O
Ptp	B-DISO
)	O
on	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
patient	O
with	O
intraabdominal	B-DISO
hypertension	I-DISO
.	O

Twelve	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
patient	O
with	O
intraabdominal	B-DISO
hypertension	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
underwent	O
mechanical	O
ventilation	O
were	O
involved	O
from	O
Jan	O
to	O
Dec	O
2013	O
.	O

In	O
a	O
severe	O
course	O
of	O
bronchial	B-DISO
asthma	I-DISO
GERD	B-DISO
was	O
detected	O
3	O
,	O
4	O
times	O
more	O
frequently	O
in	O
the	O
boys	O
,	O
while	O
in	O
a	O
lengthy	O
course	O
of	O
pneumonia	B-DISO
with	O
BOS	B-DISO
--	O
1	O
,	O
9	O
times	O
more	O
frequently	O
in	O
the	O
girls	O
.	O

Peculiarities	O
of	O
pre	O
-	O
morbid	O
background	O
of	O
BA	O
and	O
GERD	B-DISO
associative	O
course	O
were	O
exhibited	O
by	O
gestosis	B-DISO
,	O
threat	O
of	O
abortion	O
,	O
intrauterine	B-DISO
hypoxia	I-DISO
of	O
the	O
fetus	O
,	O
social	O
troubles	O
of	O
the	O
family	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
an	O
Automated	O
Multiple	O
Emitter	O
Whole	O
-	O
Room	O
Ultraviolet	O
-	O
C	O
Disinfection	O
System	O
Against	O
Coronaviruses	O
MHV	O
and	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Efficient	O
and	O
automated	O
methods	O
of	O
disinfecting	O
surfaces	O
contaminated	O
with	O
the	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
may	O
prevent	O
the	O
spread	O
of	O
the	O
virus	O
.	O

Here	O
we	O
report	O
the	O
efficacy	O
and	O
use	O
of	O
an	O
automated	O
triple	O
-	O
emitter	O
whole	O
room	O
UV	O
-	O
C	O
disinfection	O
system	O
to	O
inactivate	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
and	O
MERS	O
-	O
CoV	O
viruses	O
on	O
surfaces	O
with	O
a	O
>	O
5	O
log10	O
reduction	O
.	O

It	O
is	O
not	O
rare	O
that	O
ICU	O
patients	O
receive	O
concomitantly	O
neuromuscular	O
blocking	B-DISO
drugs	O
and	O
corticosteroids	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
results	O
from	O
mutations	O
in	O
the	O
viral	O
genome	O
during	O
a	O
common	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
infection	B-DISO
.	O

This	O
article	O
presents	O
the	O
structuring	O
of	O
influenza	B-DISO
surveillance	O
in	O
Brazil	O
and	O
highlights	O
virological	O
surveillance	O
and	O
the	O
role	O
of	O
diagnostic	O
laboratories	O
as	O
well	O
as	O
the	O
expansion	O
of	O
actions	O
to	O
improve	O
detection	O
and	O
expedite	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
delineate	O
the	O
ameliorative	O
effect	O
of	O
dihydro	O
-	O
resveratrol	O
,	O
a	O
prominent	O
analog	O
of	O
trans	O
-	O
resveratrol	O
,	O
against	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
and	O
the	O
underlying	O
molecular	O
actions	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
oral	O
administration	O
of	O
dihydro	O
-	O
resveratrol	O
ameliorated	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
via	O
an	O
inhibitory	O
modulation	O
of	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
,	O
which	O
was	O
associated	O
with	O
a	O
suppression	B-DISO
of	O
the	O
NF	O
-	O
κB	O
signaling	O
pathway	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
M	O
gene	O
delivered	O
by	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
in	O
mice	O
.	O

Moreover	O
,	O
the	O
control	O
groups	O
(	O
pVAX	O
group	O
,	O
PBS	B-DISO
group	O
)	O
maintained	O
at	O
a	O
normal	O
level	O
during	O
week	O
4	O
-	O
8	O
post	O
-	O
immunization	O
.	O

We	O
measured	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
biomarkers	O
of	O
inflammation	B-DISO
and	O
lung	O
injury	O
in	O
smokers	O
and	O
non	O
-	O
smokers	O
in	O
two	O
distinct	O
cohorts	O
of	O
healthy	O
volunteers	O
,	O
one	O
unstimulated	O
(	O
n	O
=	O
20	O
)	O
and	O
one	O
undergoing	O
50	O
μg	O
LPS	B-DISO
inhalation	O
(	O
n	O
=	O
30	O
).	O

Cytopathic	B-DISO
effects	I-DISO
showing	O
detachment	B-DISO
and	O
rounding	O
of	O
cells	O
were	O
observed	O
in	O
Vero	O
cell	O
cultures	O
3	O
days	O
after	O
inoculation	O
of	O
the	O
sample	O
.	O

This	O
paper	O
discusses	O
the	O
interpretive	O
and	O
legislative	O
concerns	O
regarding	O
the	O
Infectious	B-DISO
Disease	I-DISO
Prevention	O
and	O
Control	O
Act	O
,	O
its	O
ordinance	O
and	O
enforcement	O
regulations	O
,	O
as	O
well	O
as	O
public	O
statements	O
from	O
the	O
relevant	O
administrative	O
agency	O
.	O

ABSTRACT	O
:	O
Ethical	O
considerations	O
are	O
essential	O
in	O
planning	O
for	O
and	O
responding	O
to	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

Although	O
there	O
is	O
no	O
consensus	O
about	O
the	O
veno	O
-	O
veno	O
-	O
arterial	O
mode	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
this	O
combined	O
mode	O
can	O
be	O
helpful	O
in	O
patients	O
with	O
acute	O
refractory	O
respiratory	O
and	O
cardiac	B-DISO
failure	I-DISO
,	O
as	O
shown	O
in	O
the	O
present	O
case	O
.	O

Among	O
the	O
50	O
positive	O
specimens	O
,	O
thirteen	O
gave	O
rise	O
to	O
CoV	O
full	O
-	O
length	O
RdRP	O
gene	B-DISO
amplification	I-DISO
for	O
further	O
sequence	O
comparison	O
,	O
of	O
which	O
three	O
divergent	O
sequences	O
(	O
two	O
from	O
a	O
unreported	O
province	O
)	O
were	O
subjected	O
to	O
full	O
genome	O
sequencing	O
.	O

Here	O
,	O
we	O
review	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
adopted	O
by	O
coronaviruses	O
to	O
produce	O
the	O
5	O
'-	O
cap	B-DISO
structure	O
and	O
methylation	O
modification	O
of	O
viral	O
genomic	O
RNAs	O
.	O

Coinjection	O
of	O
a	O
herpesviral	O
vector	O
encoding	O
for	O
BDNF	O
efficiently	O
prevents	O
both	O
the	O
development	O
of	O
cerebellar	O
neuropathology	B-DISO
and	O
the	O
ataxic	B-DISO
phenotype	O
.	O

At	O
stepwise	O
regression	O
analysis	O
the	O
following	O
variables	O
were	O
an	O
independent	O
predictor	O
for	O
in	O
-	O
ICU	O
mortality	O
:	O
Pco2	O
(	O
OR	O
1	O
.	O
08	O
,	O
95	O
%	O
CI	O
1	O
.	O
011	O
-	O
1	O
.	O
161	O
,	O
P	O
=	O
.	O
023	O
),	O
systolic	O
pulmonary	B-DISO
arterial	I-DISO
hypertension	I-DISO
(	O
OR	O
0	O
.	O
83	O
,	O
95	O
%	O
CI	O
0	O
.	O
701	O
-	O
0	O
.	O
977	O
,	O
P	O
=	O
.	O
002	O
),	O
log	O
peak	O
Tn	O
I	O
(	O
OR	O
3	O
.	O
56	O
,	O
95	O
%	O
CI	O
1	O
.	O
045	O
-	O
12	O
.	O
132	O
,	O
P	O
=	O
.	O
042	O
).	O

In	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
,	O
serial	O
troponin	O
I	O
assessment	O
together	O
with	O
echocardiography	O
evaluation	O
helped	O
to	O
identify	O
a	O
subgroup	O
at	O
higher	O
risk	O
for	O
in	O
-	O
ICU	O
death	O
.	O

TITLE	O
:	O
Estimating	O
the	O
Severity	O
and	O
Subclinical	O
Burden	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

The	O
compounds	O
in	O
H	O
.	O
cordata	O
contribute	O
to	O
the	O
superior	O
antiviral	O
efficacy	O
of	O
the	O
EA	O
fraction	O
which	O
lacked	O
cytotoxicity	B-DISO
in	O
vitro	O
and	O
acute	O
toxicity	O
in	O
vivo	O
.	O

The	O
impact	O
of	O
the	O
VNP	O
protein	O
corona	O
on	O
molecular	O
recognition	O
and	O
cell	O
targeting	O
in	O
the	O
context	O
of	O
cancer	B-DISO
and	O
thrombosis	B-DISO
is	O
investigated	O
.	O

Overall	O
,	O
the	O
scientific	O
quality	O
of	O
SARS	B-DISO
and	O
H1N1	O
news	O
media	O
coverage	O
had	O
potentially	O
important	O
shortcomings	O
,	O
but	O
coverage	O
was	O
not	O
too	O
sensationalizing	O
.	O

The	O
patient	O
deteriorated	O
rapidly	O
with	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
ARDS	B-DISO
.	O

This	O
report	O
emphasizes	O
the	O
fatal	O
consequences	O
of	O
common	O
respiratory	O
virus	O
infections	B-DISO
in	O
immunocompromised	O
patients	O
.	O

Thus	O
,	O
the	O
results	O
indicate	O
for	O
the	O
first	O
time	O
that	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
may	O
function	O
as	O
a	O
cytosolic	O
PAMP	O
to	O
stimulate	O
IFN	O
-	O
β	O
production	O
by	O
activating	O
a	O
TLR	O
-	O
related	O
TRAF3	O
-	O
independent	O
signaling	O
cascade	O
.	O

ABSTRACT	O
:	O
Although	O
HIV	B-DISO
antibody	O
tests	O
have	O
been	O
widely	O
accepted	O
in	O
clinical	O
diagnosis	O
of	O
HIV	B-DISO
infection	I-DISO
,	O
they	O
may	O
not	O
be	O
sufficient	O
to	O
diagnose	O
all	O
subjects	O
with	O
HIV	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
and	O
IFN	O
:	O
Too	O
Little	O
,	O
Too	O
Late	O
.	O

This	O
delayed	O
IFN	O
-	O
I	O
signaling	O
promotes	O
the	O
accumulation	O
of	O
pathogenic	O
inflammatory	O
monocyte	O
-	O
macrophages	O
(	O
IMMs	O
),	O
resulting	O
in	O
elevated	O
lung	O
cytokine	O
/	O
chemokine	O
levels	O
,	O
vascular	O
leakage	B-DISO
,	O
and	O
impaired	B-DISO
virus	O
-	O
specific	O
T	O
cell	O
responses	O
.	O

ABSTRACT	O
:	O
Pneumonia	B-DISO
is	O
a	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
infants	O
and	O
young	O
children	O
.	O

Preterm	O
infants	O
had	O
a	O
significantly	O
higher	O
rate	O
of	O
RSV	B-DISO
infection	I-DISO
than	O
other	O
respiratory	O
viruses	O
(	O
8	O
of	O
21	O
;	O
38	O
%	O
vs	O
3	O
of	O
27	O
;	O
11	O
.	O
1	O
%)	O
(	O
p	O
=	O
0	O
.	O
02	O
).	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
current	O
state	O
of	O
knowledge	O
on	O
human	O
MERS	O
-	O
CoV	O
infections	B-DISO
,	O
the	O
probable	O
origin	O
of	O
MERS	O
-	O
CoV	O
,	O
and	O
the	O
available	O
animal	O
models	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
the	O
case	O
of	O
HIV	B-DISO
,	O
it	O
has	O
been	O
shown	O
that	O
CBAs	O
select	O
for	O
mutant	B-DISO
viruses	O
with	O
N	O
-	O
glycosylation	O
site	O
deletions	O
which	O
are	O
more	O
sensitive	O
to	O
neutralizing	O
antibodies	O
.	O

Even	O
if	O
the	O
isolate	O
was	O
not	O
secreting	O
toxin	O
in	O
vitro	O
,	O
it	O
possesses	B-DISO
the	O
tox	O
gene	O
which	O
motivated	O
the	O
use	O
of	O
specific	O
antitoxin	O
serum	O
.	O

The	O
coil	O
-	O
3	O
(	O
10	O
)-	O
helix	O
conformational	O
transition	B-DISO
of	O
the	O
Ser139	O
-	O
Leu141	O
loop	O
serves	O
as	O
an	O
enzyme	O
activity	O
switch	O
.	O

ABSTRACT	O
:	O
Synthesis	O
of	O
serine	O
derivatives	O
having	O
the	O
essential	O
functional	O
groups	O
for	O
the	O
inhibitor	O
of	O
SARS	B-DISO
3CL	O
protease	O
and	O
evaluation	O
of	O
their	O
inhibitory	O
activities	O
using	O
SARS	B-DISO
3CL	O
R188I	O
mutant	B-DISO
protease	O
are	O
described	O
.	O

The	O
treatment	O
of	O
choice	O
for	O
severe	O
or	O
complicated	B-DISO
malaria	I-DISO
in	O
adults	O
and	O
children	O
is	O
intravenous	O
artesunate	O
(	O
Grade	O
1A	O
).	O

Children	O
with	O
severe	O
malaria	B-DISO
should	O
also	O
be	O
treated	O
with	O
empirical	O
broad	O
spectrum	O
antibiotics	O
until	O
bacterial	B-DISO
infection	I-DISO
can	O
be	O
excluded	O
(	O
Grade	O
1B	O
).	O

Either	O
an	O
oral	O
ACT	O
or	O
chloroquine	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
non	O
-	O
falciparum	B-DISO
malaria	I-DISO
.	O

ABSTRACT	O
:	O
Atypical	B-DISO
hemolytic	I-DISO
uremic	I-DISO
syndrome	I-DISO
(	O
aHUS	O
)	O
is	O
caused	O
by	O
alternative	O
complement	O
pathway	O
dysregulation	O
,	O
leading	O
to	O
systemic	O
thrombotic	B-DISO
microangiopathy	I-DISO
(	O
TMA	O
)	O
and	O
severe	O
end	O
-	O
organ	O
damage	O
.	O

However	O
,	O
the	O
incidence	O
and	O
associated	O
causes	O
of	O
ARDS	B-DISO
in	O
isolated	O
TBI	O
have	O
not	O
been	O
well	O
studied	O
.	O

ARDS	B-DISO
within	O
the	O
first	O
8	O
days	O
of	O
admission	O
was	O
rigorously	O
adjudicated	O
using	O
Berlin	O
criteria	O
.	O

Early	O
transfusion	O
of	O
platelets	O
after	O
severe	O
TBI	O
may	O
be	O
a	O
modifiable	O
risk	O
factor	O
for	O
ARDS	B-DISO
,	O
and	O
these	O
findings	O
invite	O
further	O
investigation	O
into	O
causal	O
mechanisms	O
driving	O
this	O
observed	O
association	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
era	O
of	O
balanced	O
hemostatic	O
resuscitation	O
practices	O
,	O
severity	O
of	O
head	O
injury	O
,	O
male	O
sex	O
,	O
early	O
crystalloids	O
,	O
and	O
early	O
transfusion	O
of	O
platelets	O
are	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
ARDS	B-DISO
after	O
severe	O
isolated	O
TBI	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
epidemiological	O
and	O
clinical	O
features	O
of	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
.	O

Influenza	B-DISO
viruses	O
were	O
detected	O
in	O
55	O
.	O
9	O
%	O
of	O
118	O
patients	O
who	O
were	O
found	O
to	O
be	O
compatible	O
with	O
the	O
definition	O
of	O
""""	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
""""	O
specified	O
in	O
the	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
guidelines	O
and	O
other	O
viral	O
agenst	O
were	O
detected	O
in	O
44	O
%.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
most	O
critical	O
pathogens	O
in	O
the	O
poultry	O
industry	O
,	O
causing	O
serious	O
economic	O
losses	O
in	O
all	O
countries	O
including	O
Iraq	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
clinically	O
severe	O
respiratory	B-DISO
disorders	I-DISO
,	O
and	O
there	O
are	O
currently	O
no	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drug	O
therapies	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
Terminal	O
Tail	O
of	O
TRIM56	O
Dictates	O
Antiviral	O
Restriction	O
of	O
Influenza	B-DISO
A	O
and	O
B	O
Viruses	O
by	O
Impeding	O
Viral	O
RNA	O
Synthesis	O
.	O

Extracorporeal	O
membrane	O
oxygenation	O
is	O
used	O
as	O
life	O
support	O
for	O
lung	O
impairment	B-DISO
resulting	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
analyzed	O
data	O
for	O
170	O
patients	O
in	O
South	O
Korea	O
who	O
had	O
laboratory	O
-	O
confirmed	O
infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
during	O
Pregnancy	O
,	O
Abu	O
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
,	O
2013	O
.	O

TITLE	O
:	O
Severe	O
non	O
-	O
infective	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
,	O
shock	O
,	O
and	O
end	O
-	O
organ	O
dysfunction	O
after	O
zoledronic	O
acid	O
administration	O
in	O
a	O
child	O
.	O

We	O
describe	O
an	O
acute	O
,	O
severe	O
,	O
life	O
-	O
threatening	O
,	O
inflammatory	B-DISO
reaction	I-DISO
in	O
a	O
child	O
.	O

TITLE	O
:	O
[	O
Pulmonary	B-DISO
complications	I-DISO
of	O
malaria	B-DISO
:	O
An	O
update	O
].	O

Conclusions	O
and	O
relevance	O
Once	O
the	O
clinical	O
disease	O
of	O
FIP	B-DISO
develops	O
in	O
a	O
cat	O
,	O
it	O
always	O
leads	O
to	O
death	O
,	O
and	O
most	O
of	O
the	O
cats	O
are	O
euthanased	O
within	O
a	O
few	O
days	O
or	O
weeks	O
.	O

We	O
investigated	O
Le	O
(	O
x	O
)	O
expression	O
using	O
CD11b	O
-	O
positive	O
peritoneal	O
exudate	O
cells	O
(	O
PECs	O
)	O
and	O
found	O
that	O
Le	O
(	O
x	O
)	O
is	O
inducible	O
in	O
Mo	O
/	O
Mas	B-DISO
after	O
infection	B-DISO
with	O
srr7	O
,	O
especially	O
in	O
the	O
syncytial	O
cells	O
during	O
the	O
late	O
phase	O
of	O
infection	B-DISO
.	O

Particulate	O
substances	O
in	O
smoke	O
,	O
toxic	O
and	O
harmful	O
gas	O
,	O
and	O
chemical	O
substances	O
act	O
together	O
would	O
rapidly	O
induce	O
the	O
occurrence	O
of	O
dramatic	O
pathophysiologic	O
reaction	O
in	O
the	O
respiratory	O
tract	O
,	O
resulting	O
in	O
acute	O
injury	O
to	O
the	O
respiratory	O
tract	O
,	O
thus	O
inducing	O
serious	O
injury	O
to	O
it	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
leading	O
to	O
death	O
of	O
the	O
victims	O
.	O

Ventilation	O
must	O
be	O
adapted	O
to	O
the	O
pathophysiological	O
situation	O
in	O
patients	O
with	O
OHS	B-DISO
or	O
overlap	B-DISO
syndrome	I-DISO
.	O

Hospital	O
mortality	O
was	O
34	O
.	O
9	O
%	O
(	O
95	O
%	O
CI	O
,	O
31	O
.	O
4	O
%-	O
38	O
.	O
5	O
%)	O
for	O
those	O
with	O
mild	O
,	O
40	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
,	O
37	O
.	O
4	O
%-	O
43	O
.	O
3	O
%)	O
for	O
those	O
with	O
moderate	O
,	O
and	O
46	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
,	O
41	O
.	O
9	O
%-	O
50	O
.	O
4	O
%)	O
for	O
those	O
with	O
severe	O
ARDS	B-DISO
.	O

Awake	O
ECMO	O
was	O
a	O
useful	O
weaning	O
strategy	O
after	O
severe	O
postoperative	O
ARDS	B-DISO
,	O
as	O
it	O
avoids	O
long	O
-	O
duration	O
use	O
of	O
mechanical	O
ventilation	O
.	O

For	O
example	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
lung	O
microvessel	O
endothelia	O
lose	O
their	O
junctional	O
integrity	O
resulting	O
in	O
leakiness	O
of	O
the	O
endothelial	O
barrier	O
and	O
accumulation	O
of	O
protein	O
rich	O
edema	B-DISO
.	O

Most	O
people	O
who	O
arrive	O
in	O
Sweden	O
with	O
suspicious	O
symptoms	O
will	O
likely	O
have	O
other	O
diseases	O
than	O
Ebola	O
/	O
MERS	O
,	O
for	O
example	O
malaria	B-DISO
or	O
pneumococci	O
,	O
but	O
we	O
still	O
need	O
to	O
take	O
care	O
of	O
these	O
patients	O
and	O
be	O
able	O
to	O
provide	O
optimal	O
treatment	O
of	O
electrolyte	O
disturbances	O
,	O
kidney	B-DISO
failure	I-DISO
,	O
bleedings	O
etc	O
.	O

ABSTRACT	O
:	O
Opioid	O
-	O
based	O
analgesics	O
provide	O
the	O
mainstay	O
for	O
attenuating	O
burn	B-DISO
pain	I-DISO
,	O
but	O
they	O
have	O
a	O
myriad	O
of	O
side	O
effects	O
including	O
respiratory	B-DISO
depression	I-DISO
,	O
nausea	B-DISO
,	O
impaired	B-DISO
gastrointestinal	O
motility	O
,	O
sedation	B-DISO
,	O
dependence	B-DISO
,	O
physiologic	O
tolerance	B-DISO
,	O
and	O
opioid	O
-	O
induced	O
hyperalgesia	B-DISO
.	O

Our	O
results	O
indicated	O
that	O
S	O
proteins	O
from	O
different	O
coronaviruses	O
displayed	O
varied	O
abilities	O
to	O
mediate	O
pseudotyped	O
virus	B-DISO
infection	I-DISO
.	O

Both	O
live	O
and	O
pseudoviruses	O
could	O
infected	O
Vero	O
-	O
CCL	B-DISO
-	O
81	O
(	O
monkey	O
kidney	O
),	O
Huh	O
-	O
7	O
(	O
human	O
liver	O
),	O
and	O
PK	O
-	O
15	O
(	O
pig	O
kidney	O
)	O
cells	O
efficiently	O
.	O

The	O
BAL	O
neutrophil	O
content	O
was	O
also	O
higher	O
in	O
the	O
LPS	B-DISO
-	O
supine	O
group	O
compared	O
to	O
the	O
LPS	B-DISO
-	O
prone	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
A	O
Dimerization	O
-	O
Dependent	O
Mechanism	O
Drives	O
the	O
Endoribonuclease	O
Function	O
of	O
Porcine	B-DISO
Reproductive	I-DISO
and	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Virus	O
nsp11	O
.	O

ABSTRACT	O
:	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
RNA	O
endoribonuclease	O
nsp11	O
belongs	O
to	O
the	O
XendoU	O
superfamily	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
arterivirus	O
replication	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
safety	O
and	O
effectiveness	O
of	O
a	O
novel	O
therapeutic	O
regimen	O
for	O
bronchiolitis	B-DISO
obliterans	I-DISO
sydrome	O
(	O
BOS	B-DISO
)	O
affter	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
).	O

Seven	O
patients	O
who	O
had	O
received	O
HSCT	O
and	O
had	O
been	O
diagnosed	O
as	O
BOS	B-DISO
were	O
enrolled	O
in	O
this	O
study	O
.	O

Methylprednisolone	O
was	O
given	O
at	O
a	O
dose	O
of	O
1	O
mg	O
/(	O
kg	O
·	O
d	O
)	O
for	O
2	O
weeks	O
when	O
respiratory	B-DISO
failure	I-DISO
occured	O
.	O

ABSTRACT	O
:	O
The	O
largest	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
outside	O
Middle	O
East	O
Asia	O
in	O
2015	O
has	O
necessitated	O
the	O
rapid	O
expansion	O
of	O
laboratories	O
that	O
conduct	O
MERS	O
-	O
CoV	O
molecular	O
testing	O
in	O
Korea	O
,	O
together	O
with	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
to	O
evaluate	O
the	O
assays	O
used	O
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
evolutionary	O
histories	O
of	O
human	O
coronavirus	O
OC43	O
and	O
HKU1	O
among	O
patients	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
Kuala	O
Lumpur	O
,	O
Malaysia	O
.	O

Correlation	O
of	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
HKU1	O
with	O
the	O
severity	O
of	O
respiratory	B-DISO
symptoms	I-DISO
was	O
not	O
observed	O
.	O

The	O
present	O
study	O
reported	O
the	O
molecular	O
complexity	O
and	O
evolutionary	O
dynamics	O
of	O
human	O
betacoronaviruses	O
among	O
adults	O
with	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
in	O
a	O
tropical	O
country	O
.	O

TITLE	O
:	O
Age	O
-	O
related	O
presence	O
of	O
selected	O
viral	O
and	O
bacterial	O
pathogens	O
in	O
paraffin	O
-	O
embedded	O
lung	O
samples	O
of	O
dogs	O
with	O
pneumonia	B-DISO
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
detect	O
selected	O
pathogens	O
in	O
pneumonic	O
lung	O
tissue	O
of	O
dogs	O
of	O
different	O
age	O
groups	O
by	O
immunohistochemistry	O
(	O
IHC	O
),	O
in	O
situ	O
hybridisation	O
(	O
ISH	B-DISO
)	O
or	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
order	O
to	O
get	O
information	O
about	O
their	O
involvement	O
in	O
pneumonia	B-DISO
formation	O
.	O

Positive	O
end	O
-	O
expiratory	O
pressure	O
with	O
lung	O
recruitment	B-DISO
maneuvers	O
has	O
also	O
been	O
found	O
to	O
be	O
helpful	O
.	O

Other	O
therapies	O
that	O
include	O
vasodilators	O
and	O
neuromuscular	O
agents	O
are	O
still	O
being	O
explored	O
and	O
need	O
further	O
studies	O
to	O
define	O
their	O
role	O
in	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
six	O
-	O
year	O
descriptive	O
epidemiological	O
study	O
of	O
human	O
coronavirus	B-DISO
infections	I-DISO
in	O
hospitalized	O
patients	O
in	O
Hong	O
Kong	O
.	O

The	O
expression	O
of	O
mRNAs	O
encoding	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
3	O
and	O
TLR7	O
were	O
upregulated	O
at	O
3	O
-	O
8	O
dpi	O
,	O
and	O
that	O
of	O
TIR	O
-	O
domain	O
-	O
containing	O
adapter	O
-	O
inducing	O
interferon	O
(	O
IFN	O
)	O
β	O
(	O
TRIF	O
)	O
was	O
upregulated	O
at	O
21	O
dpi	O
in	O
the	O
trachea	B-DISO
and	O
kidney	O
.	O

Tumor	B-DISO
necrosis	I-DISO
factor	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
3	O
and	O
TRAF6	O
were	O
upregulated	O
expression	O
in	O
both	O
tissues	O
.	O

Additionally	O
,	O
consistent	O
responses	O
to	O
IBV	O
infection	B-DISO
were	O
observed	O
during	O
early	O
infection	B-DISO
,	O
with	O
differential	O
and	O
complicated	O
responses	O
in	O
the	O
kidney	O
.	O

this	O
was	O
the	O
first	O
case	O
that	O
demonstrated	O
that	O
MeRS	O
-	O
CoV	O
may	O
cause	O
acute	B-DISO
myocarditis	I-DISO
and	O
acute	O
-	O
onset	O
heart	B-DISO
failure	I-DISO
.	O

The	O
study	O
included	O
767	O
patients	O
with	O
moderate	O
or	O
severe	O
ARDS	B-DISO
who	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
between	O
January	O
1	O
,	O
2005	O
,	O
and	O
December	O
31	O
,	O
2010	O
.	O

The	O
expert	O
opinion	O
-	O
based	O
prediction	O
score	O
(	O
including	O
oxygenation	O
index	O
,	O
change	O
of	O
Pao2	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
,	O
obesity	B-DISO
,	O
aspiration	B-DISO
,	O
and	O
immunocompromised	O
state	O
)	O
yielded	O
a	O
c	O
-	O
statistic	O
of	O
0	O
.	O
61	O
in	O
the	O
validation	O
cohort	O
.	O

No	O
center	O
treated	O
non	O
-	O
lung	O
solid	O
organ	O
transplant	O
(	O
SOT	O
)	O
recipients	O
with	O
URTI	B-DISO
;	O
7	O
/	O
11	O
would	O
use	O
oral	O
or	O
inhaled	O
RBV	O
in	O
the	O
same	O
group	O
with	O
LRTI	B-DISO
.	O

Because	O
these	O
emerging	O
virus	O
infections	B-DISO
are	O
caused	O
by	O
the	O
zoonotic	O
pathogens	O
,	O
the	O
eradiation	O
and	O
the	O
elimination	O
of	O
these	O
infectious	B-DISO
diseases	I-DISO
are	O
impossible	O
.	O

We	O
need	O
to	O
develop	O
the	O
diagnostics	O
,	O
therapeutics	O
,	O
and	O
preventive	O
measures	O
based	O
on	O
the	O
studies	O
of	O
the	O
highly	O
pathogenic	O
pathogens	O
more	O
in	O
detail	O
using	O
the	O
infectious	B-DISO
microbes	O
.	O

The	O
direct	O
effects	O
accounted	O
for	O
78	O
%	O
of	O
the	O
SARS	B-DISO
input	O
-	O
output	O
flows	O
,	O
which	O
was	O
3	O
.	O
56	O
-	O
fold	O
greater	O
than	O
the	O
indirect	O
effects	O
.	O

Railway	O
capacity	O
,	O
per	O
person	O
gross	O
domestic	O
product	O
(	O
PGDP	O
),	O
urban	O
rate	O
and	O
the	O
law	O
of	O
distance	O
decay	B-DISO
also	O
affected	O
the	O
input	O
-	O
output	O
flows	O
.	O

The	O
clinical	O
spectrum	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
humans	O
ranges	O
from	O
an	O
asymptomatic	O
or	O
mild	O
respiratory	O
illness	O
to	O
severe	O
pneumonia	B-DISO
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
;	O
overall	O
mortality	O
is	O
around	O
35	O
.	O
7	O
%.	O

ABSTRACT	O
:	O
The	O
human	O
alphacoronaviruses	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
are	O
commonly	O
associated	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
URTI	B-DISO
).	O

ABSTRACT	O
:	O
Understanding	O
healthcare	O
-	O
seeking	O
patterns	O
for	O
respiratory	O
illness	O
can	O
help	O
improve	O
estimations	O
of	O
disease	O
burden	O
and	O
inform	O
public	O
health	O
interventions	O
to	O
control	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
Indonesia	O
.	O

In	O
particular	O
,	O
our	O
study	O
shows	O
that	O
(	O
i	O
)	O
human	O
coronavirus	B-DISO
infections	I-DISO
are	O
more	O
common	O
during	O
influenza	B-DISO
seasons	O
and	O
in	O
co	B-DISO
-	I-DISO
infections	I-DISO
than	O
previously	O
recognized	O
,	O
(	O
ii	O
)	O
factors	O
associated	O
with	O
co	B-DISO
-	I-DISO
infection	I-DISO
differ	O
from	O
those	O
associated	O
with	O
viral	B-DISO
infection	I-DISO
overall	O
,	O
(	O
iii	O
)	O
virus	O
prevalence	O
has	O
increased	O
over	O
time	O
especially	O
in	O
infants	O
aged	O
<	O
1	O
year	O
,	O
and	O
(	O
iv	O
)	O
viral	B-DISO
infection	I-DISO
risk	O
is	O
greater	O
in	O
the	O
post	O
-	O
2009	O
pandemic	O
era	O
,	O
likely	O
reflecting	O
a	O
widespread	O
change	O
in	O
the	O
viral	O
population	O
that	O
warrants	O
further	O
investigation	O
.	O

TITLE	O
:	O
Spread	O
of	O
Mutant	B-DISO
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
with	O
Reduced	O
Affinity	O
to	O
Human	O
CD26	O
during	O
the	O
South	O
Korean	O
Outbreak	O
.	O

Here	O
,	O
we	O
show	O
the	O
rapid	O
emergence	O
and	O
spread	O
of	O
a	O
mutant	B-DISO
MERS	O
-	O
CoV	O
with	O
reduced	O
affinity	O
to	O
the	O
human	O
CD26	O
receptor	O
during	O
the	O
South	O
Korean	O
outbreak	O
.	O

ABSTRACT	O
:	O
Sarcoidosis	B-DISO
is	O
a	O
common	O
disease	O
that	O
involve	O
almost	O
constantly	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
viral	O
respiratory	B-DISO
disease	I-DISO
.	O

We	O
report	O
the	O
clinical	O
course	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
a	O
pregnant	O
woman	O
who	O
acquired	O
the	O
infection	B-DISO
during	O
the	O
last	O
trimester	O
.	O

She	O
was	O
32	O
weeks	O
pregnant	O
when	O
she	O
presented	O
with	O
respiratory	B-DISO
symptoms	I-DISO
after	O
direct	O
contact	O
with	O
a	O
MERS	O
-	O
COV	O
patient	O
.	O

ABSTRACT	O
:	O
Despite	O
a	O
therapeutic	O
option	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
the	O
survival	O
benefit	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
still	O
controversial	O
in	O
adults	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
found	O
in	O
a	O
wide	O
variety	O
of	O
wild	O
and	O
domestic	O
animals	O
,	O
and	O
constitute	O
a	O
risk	O
for	O
zoonotic	O
and	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
.	O

Coronavirus	B-DISO
infection	I-DISO
in	O
cows	O
.	O

ABSTRACT	O
:	O
To	O
design	O
an	O
alternative	O
vaccine	O
for	O
control	O
of	O
infectious	B-DISO
bronchitis	B-DISO
in	O
chickens	O
,	O
three	O
recombinant	O
duck	O
enteritis	B-DISO
viruses	O
(	O
rDEVs	O
)	O
expressing	O
the	O
N	O
,	O
S	O
,	O
or	O
S1	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
were	O
constructed	O
using	O
conventional	O
homologous	O
recombination	O
methods	O
,	O
and	O
were	O
designated	O
as	O
rDEV	O
-	O
N	O
,	O
rDEV	O
-	O
S	O
,	O
and	O
rDEV	O
-	O
S1	O
,	O
respectively	O
.	O

Based	O
on	O
the	O
clinical	O
signs	O
,	O
viral	B-DISO
shedding	I-DISO
,	O
and	O
mortality	O
rates	O
,	O
rDEV	O
-	O
N	O
&	O
rDEV	O
-	O
S1	O
covalent	O
vaccination	O
conferred	O
better	O
protection	O
than	O
use	O
of	O
any	O
of	O
the	O
single	O
rDEVs	O
.	O

Virological	O
investigations	O
included	O
RT	O
-	O
PCR	O
for	O
Zika	O
virus	O
,	O
and	O
both	O
microsphere	O
immunofluorescent	O
and	O
seroneutralisation	O
assays	O
for	O
Zika	O
virus	O
and	O
dengue	B-DISO
virus	O
.	O

TITLE	O
:	O
A	O
Real	O
-	O
Time	O
Reverse	O
-	O
Transcription	O
Polymerase	O
Chain	O
Reaction	O
for	O
Differentiation	O
of	O
Massachusetts	O
Vaccine	O
and	O
Brazilian	O
Field	O
Genotypes	O
of	O
Avian	B-DISO
Infectious	I-DISO
Bronchitis	I-DISO
Virus	O
.	O

ABSTRACT	O
:	O
The	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
is	O
classified	O
into	O
serotypes	O
or	O
genotypes	O
(	O
or	O
both	O
)	O
in	O
different	O
poultry	O
-	O
producing	O
countries	O
of	O
the	O
world	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	O
infectious	B-DISO
disease	I-DISO
which	O
first	O
emerged	O
in	O
late	O
2002	O
,	O
caused	O
by	O
a	O
then	O
novel	O
human	O
coronavirus	O
,	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Prone	O
position	O
and	O
pressure	O
control	O
inverse	O
ratio	O
ventilation	O
in	O
H1N1	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Early	O
prone	O
combined	O
with	O
ACPC	O
-	O
IRV	O
in	O
H1N1	O
patients	O
having	O
severe	O
ARDS	B-DISO
can	O
be	O
used	O
as	O
a	O
rescue	O
therapy	O
and	O
it	O
should	O
be	O
confirmed	O
by	O
large	O
observational	O
studies	O
.	O

Despite	O
low	O
vaccine	O
effectiveness	O
of	O
solely	O
one	O
component	O
,	O
A	O
/	O
H3N2	O
/,	O
the	O
vaccine	O
could	O
mitigate	O
or	O
shorten	O
the	O
length	O
of	O
influenza	B-DISO
infection	B-DISO
and	O
reduce	O
the	O
number	O
of	O
severe	O
outcomes	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
A	O
large	O
number	O
of	O
viruses	O
,	O
including	O
many	O
human	O
pathogens	O
,	O
bind	O
cell	O
-	O
surface	O
glycans	O
during	O
the	O
initial	O
steps	O
of	O
infection	B-DISO
.	O

In	O
addition	O
to	O
many	O
viral	O
nonstructural	O
proteins	O
,	O
the	O
presence	O
of	O
cell	O
nuclear	O
proteins	O
and	O
the	O
viral	O
nucleocapsid	O
protein	O
increases	O
virus	O
amplification	B-DISO
efficacy	O
.	O

The	O
aim	O
was	O
to	O
assess	O
differences	O
in	O
30	O
-	O
day	O
mortality	O
among	O
patients	O
hospitalized	O
with	O
community	O
-	O
acquired	O
severe	O
infection	B-DISO
presenting	O
with	O
hypothermia	O
,	O
normothermia	O
or	O
fever	O
.	O

Cerebrospinal	O
fluid	O
study	O
revealed	O
albuminocytological	O
dissociation	B-DISO
.	O

ABSTRACT	O
:	O
Severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
caused	O
by	O
human	O
adenovirus	B-DISO
(	O
HAdV	B-DISO
),	O
especially	O
HAdV	B-DISO
type	O
55	O
(	O
HAdV	B-DISO
-	O
55	O
)	O
in	O
immunocompetent	O
adults	O
has	O
raised	O
increasing	O
concerns	O
.	O

The	O
rapid	O
development	O
of	O
bilateral	O
consolidations	O
within	O
10	O
days	O
after	O
illness	O
onset	O
were	O
the	O
most	O
common	O
radiographic	O
finding	O
,	O
usually	O
accompanied	O
by	O
adjacent	O
ground	O
glass	O
opacities	B-DISO
and	O
pleural	B-DISO
effusions	I-DISO
.	O

HAdV	O
and	O
the	O
HAdV	O
-	O
55	O
sub	O
-	O
type	O
play	O
an	O
important	O
role	O
among	O
viral	B-DISO
pneumonia	I-DISO
pathogens	O
in	O
hospitalized	O
immunocompetent	O
adults	O
in	O
Northern	O
China	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
compare	O
outcomes	O
in	O
patients	O
who	O
had	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
Pao2	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
<	O
100	O
)	O
who	O
received	O
early	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
an	O
adjunct	O
to	O
mechanical	O
ventilation	O
,	O
to	O
those	O
in	O
patients	O
who	O
received	O
conventional	O
mechanical	O
ventilation	O
alone	O
.	O

A	O
total	O
of	O
2440	O
patients	O
who	O
had	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
various	O
etiologies	O
were	O
included	O
,	O
46	O
who	O
received	O
early	O
veno	O
-	O
venous	O
ECMO	O
and	O
2394	O
unmatched	O
and	O
398	O
matched	O
controls	O
who	O
received	O
conventional	O
ventilation	O
alone	O
.	O

Importantly	O
,	O
available	O
SARS	B-DISO
monoclonal	O
antibodies	O
offered	O
success	O
in	O
limiting	O
viral	B-DISO
infection	I-DISO
absent	O
from	O
available	O
vaccine	O
approaches	O
.	O

Mixed	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IBV	O
)	O
and	O
avian	B-DISO
influenza	I-DISO
(	O
AI	O
)-	O
H9N2	O
viruses	O
were	O
the	O
most	O
common	O
infection	B-DISO
(	O
41	O
.	O
7	O
%).	O

Interestingly	O
,	O
co	B-DISO
-	I-DISO
infection	I-DISO
of	O
AI	O
-	O
H9N2	O
with	O
either	O
AIV	O
-	O
H5N1	B-DISO
or	O
vNDV	O
rarely	O
resulted	O
in	O
high	O
mortality	O
.	O

Further	O
investigations	O
of	O
the	O
role	O
of	O
AI	O
,	O
IBV	O
,	O
and	O
ND	O
viruses	O
'	O
co	B-DISO
-	I-DISO
infections	I-DISO
and	O
interference	O
in	O
terms	O
of	O
altering	O
the	O
severity	O
of	O
clinical	O
signs	O
and	O
lesions	O
and	O
/	O
or	O
generating	O
novel	O
reassortants	O
within	O
each	O
virus	O
are	O
needed	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
,	O
a	O
series	O
of	O
phenylpropanoid	O
derivatives	O
were	O
synthesized	O
,	O
and	O
their	O
anti	O
-	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
activity	O
was	O
evaluated	O
.	O

Humoral	O
immune	O
responses	O
,	O
as	O
reflected	O
by	O
virus	O
neutralizing	O
antibodies	O
and	O
specific	O
IgG	O
and	O
sIgA	O
,	O
and	O
cellular	O
immune	O
responses	O
,	O
as	O
reflected	O
by	O
IFN	O
-	O
γ	O
,	O
IL	O
-	O
4	O
,	O
and	O
lymphocyte	O
proliferation	B-DISO
,	O
were	O
evaluated	O
.	O

Epidemiologic	O
and	O
genetic	O
sequencing	O
findings	O
suggest	O
that	O
3	O
healthcare	O
clusters	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
occurred	O
,	O
including	O
1	O
that	O
resulted	O
in	O
20	O
infected	O
persons	O
in	O
1	O
hospital	O
.	O

We	O
have	O
conducted	O
an	O
epidemiology	O
study	O
to	O
determine	O
the	O
frequency	O
of	O
infection	B-DISO
and	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
these	O
viruses	O
in	O
China	O
,	O
and	O
characterized	O
the	O
genetic	O
variation	O
of	O
the	O
isolated	O
PEDV	O
and	O
PKV	O
strains	O
.	O

The	O
urgency	O
and	O
panic	O
induced	O
by	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
explain	O
the	O
heightened	O
interest	O
.	O

The	O
main	O
challenges	O
laid	O
out	O
by	O
participants	O
in	O
the	O
workshop	O
were	O
the	O
development	O
of	O
an	O
appropriate	O
PH	O
curriculum	O
,	O
appropriate	O
training	O
spots	B-DISO
for	O
practical	O
placement	O
,	O
the	O
development	O
of	O
research	O
priorities	O
for	O
PH	O
to	O
satisfy	O
the	O
needs	O
of	O
PH	O
programs	O
and	O
agencies	O
,	O
attracting	O
the	O
most	O
qualified	O
academic	O
staff	O
,	O
the	O
enrolment	O
of	O
highly	O
motivated	O
students	O
and	O
finally	O
,	O
the	O
establishment	O
of	O
a	O
quality	O
assurance	O
program	O
to	O
ensure	O
the	O
quality	O
of	O
PH	O
education	O
programs	O
.	O

ABSTRACT	O
:	O
This	O
article	O
is	O
one	O
of	O
ten	O
reviews	O
selected	O
from	O
the	O
Annual	O
Update	O
in	O
Intensive	O
Care	O
and	O
Emergency	B-DISO
medicine	O
2016	O
.	O

Explain	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Risk	O
:	O
a	O
Prospective	O
Cohort	O
Study	O
of	O
Patients	O
with	O
Severe	B-DISO
Sepsis	I-DISO
.	O

The	O
adjusted	O
odds	O
ratio	O
for	O
ARDS	B-DISO
associated	O
with	O
each	O
5	O
mcg	O
increase	O
in	O
adiponectin	O
was	O
1	O
.	O
12	O
(	O
95	O
%	O
CI	O
1	O
.	O
01	O
,	O
1	O
.	O
25	O
),	O
p	O
-	O
value	O
0	O
.	O
025	O
).	O

This	O
review	O
explains	O
immune	O
responses	O
resulting	O
from	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
describes	O
MERS	O
vaccine	O
criteria	O
,	O
and	O
presents	O
available	O
small	O
animal	O
models	O
to	O
evaluate	O
the	O
efficacy	O
of	O
MERS	O
vaccines	O
.	O

Although	O
CMV	O
was	O
superior	O
to	O
HFJV	O
at	O
1	O
h	O
of	O
ventilation	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
differences	O
in	O
lung	O
function	O
or	O
edema	B-DISO
formation	O
between	O
CMV	O
and	O
LAV	O
in	O
both	O
models	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
at	O
4	O
h	O
of	O
ventilation	O
.	O

We	O
discuss	O
the	O
implications	O
for	O
the	O
channel	O
function	O
in	O
the	O
bacterial	O
porins	O
PorA	O
(	O
N	O
.	O
meningitidis	O
)	O
and	O
OmpF	O
(	O
E	O
.	O
coli	O
)	O
and	O
the	O
viroporin	O
SARS	B-DISO
-	O
CoV	O
E	O
.	O

ABSTRACT	O
:	O
Antimicrobial	O
-	O
resistant	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
AMR	O
-	O
RTIs	O
)	O
are	O
increasing	O
,	O
presenting	O
important	O
management	O
challenges	O
worldwide	O
.	O

Overt	O
lung	B-DISO
inflammation	I-DISO
,	O
parenchymal	O
damage	O
,	O
and	O
ineffective	O
immune	O
activation	O
perpetrate	O
increased	O
patient	O
morbidity	O
and	O
mortality	O
.	O

Cellular	O
therapy	O
by	O
reinfusing	O
autologous	O
bone	O
marrow	O
-	O
derived	O
MSCs	O
into	O
MDR	O
/	O
XDR	B-DISO
-	I-DISO
TB	I-DISO
patients	O
shows	O
promise	O
,	O
whereas	O
adjunctive	O
T	O
cell	O
-	O
based	O
therapies	O
are	O
considered	O
.	O

Palivizumab	O
,	O
an	O
anti	O
-	O
RSV	O
monoclonal	O
antibody	O
,	O
effectively	O
prevents	O
RSV	B-DISO
infection	I-DISO
in	O
high	O
-	O
risk	O
paediatric	O
populations	O
.	O

ABSTRACT	O
:	O
To	O
alleviate	O
the	O
shortage	O
of	O
human	O
donor	O
organs	O
or	O
tissues	O
for	O
the	O
treatment	O
of	O
organ	O
and	O
tissue	O
failure	O
including	O
diabetes	B-DISO
,	O
pigs	O
are	O
considered	O
suitable	O
donor	O
animals	O
.	O

TITLE	O
:	O
NMR	O
assignments	O
of	O
the	O
macro	O
domain	O
from	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

The	O
most	O
common	O
side	O
effects	O
are	O
neurological	O
and	O
gastrointestinal	O
,	O
while	O
severe	O
pulmonary	B-DISO
complications	I-DISO
are	O
rarely	O
described	O
.	O

The	O
overarching	O
goal	O
of	O
this	O
article	O
is	O
to	O
provide	O
radiologists	O
with	O
the	O
most	O
up	O
-	O
to	O
-	O
date	O
information	O
regarding	O
the	O
underlying	O
epidemiology	O
,	O
pathophysiology	O
,	O
clinical	O
features	O
,	O
and	O
imaging	O
findings	O
related	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
potentially	O
deadly	O
new	O
infection	B-DISO
.	O

CONCLUSIONS	O
:	O
An	O
increased	O
awareness	O
of	O
MERS	O
-	O
CoV	O
and	O
an	O
understanding	O
of	O
the	O
radiologic	O
features	O
of	O
MERS	O
-	O
CoV	O
can	O
improve	O
the	O
early	O
assessment	O
and	O
monitoring	O
of	O
this	O
new	O
infection	B-DISO
.	O

This	O
reduction	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
expression	O
decreases	O
alveolar	O
fluid	O
clearance	O
,	O
which	O
in	O
turn	O
leads	O
to	O
pulmonary	B-DISO
edema	I-DISO
.	O

The	O
authors	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
crossover	O
study	O
on	O
eight	O
spontaneously	O
breathing	O
ARDS	B-DISO
patients	O
undergoing	O
venovenous	O
ECMO	O
since	O
28	O
±	O
20	O
days	O
.	O

The	O
effects	O
of	O
carbon	O
dioxide	O
removal	O
on	O
spontaneous	O
breathing	O
during	O
the	O
earlier	O
acute	O
phases	O
of	O
ARDS	B-DISO
remain	O
to	O
be	O
elucidated	O
.	O

Systemic	O
inflammation	B-DISO
may	O
be	O
responsible	O
for	O
the	O
rise	O
in	O
endocan	O
levels	O
following	O
CPB	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
examined	O
the	O
susceptibility	O
of	O
rats	O
to	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
determined	O
whether	O
this	O
animal	O
is	O
a	O
suitable	O
model	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Plasma	O
and	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
serum	O
amyloid	B-DISO
P	O
contents	O
were	O
determined	O
by	O
western	O
blot	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Serum	O
amyloid	B-DISO
P	O
concentration	O
was	O
decreased	O
in	O
plasma	O
and	O
dramatically	O
increased	O
in	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

High	O
intensity	O
sedation	B-DISO
with	O
adjunctive	O
drugs	O
led	O
to	O
few	O
cardiovascular	O
adverse	O
events	O
and	O
may	O
have	O
facilitated	O
management	O
,	O
but	O
did	O
not	O
alter	O
intensive	O
care	O
unit	O
course	O
of	O
severe	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
.	O

Serious	O
adverse	O
events	O
were	O
defined	O
as	O
dislocation	O
or	O
obstruction	B-DISO
of	O
endotracheal	O
tube	O
or	O
tracheal	O
cannula	O
,	O
ECMO	O
cannulas	O
and	O
cardiac	B-DISO
arrest	I-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
26	O
patients	O
were	O
treated	O
with	O
vvECMO	O
as	O
bridge	O
to	O
recovery	O
due	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
caused	O
by	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
that	O
affects	O
poultry	O
production	O
worldwide	O
.	O

TITLE	O
:	O
Wildlife	O
Trade	O
and	O
Human	O
Health	O
in	O
Lao	O
PDR	B-DISO
:	O
An	O
Assessment	O
of	O
the	O
Zoonotic	O
Disease	O
Risk	O
in	O
Markets	O
.	O

Wildlife	O
trade	O
can	O
facilitate	O
zoonotic	O
disease	B-DISO
transmission	I-DISO
and	O
represents	O
a	O
threat	O
to	O
human	O
health	O
and	O
economies	O
in	O
Asia	O
,	O
highlighted	O
by	O
the	O
2003	O
SARS	B-DISO
coronavirus	O
outbreak	O
,	O
where	O
a	O
Chinese	O
wildlife	O
market	O
facilitated	O
pathogen	B-DISO
transmission	I-DISO
.	O

To	O
examine	O
the	O
potential	O
conservation	O
impact	O
of	O
trade	O
in	O
markets	O
,	O
we	O
assessed	O
the	O
status	O
of	O
33	O
,	O
752	O
animals	O
observed	O
during	O
375	O
visits	O
to	O
93	O
markets	O
,	O
under	O
the	O
Lao	O
PDR	B-DISO
Wildlife	O
and	O
Aquatic	O
Law	O
.	O

The	O
expression	O
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
β	O
),	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
),	O
and	O
interferon	O
-	O
stimulated	O
genes	O
in	O
cells	O
infected	O
with	O
mutant	B-DISO
rTGEV	O
-	O
ZF	O
-	O
C	O
was	O
reduced	O
compared	O
to	O
the	O
levels	O
seen	O
with	O
the	O
parental	O
virus	O
.	O

Overall	O
,	O
our	O
data	O
revealed	O
a	O
potential	O
role	O
for	O
CoV	O
nsp14	O
in	O
modulation	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
gastric	B-DISO
dilation	I-DISO
resulting	O
in	O
death	O
was	O
identified	O
in	O
two	O
adult	O
black	O
-	O
footed	O
ferrets	O
(	O
Mustela	O
nigripes	O
)	O
housed	O
at	O
the	O
Smithsonian	O
Conservation	O
Biology	O
Institute	O
in	O
Front	O
Royal	O
,	O
Virginia	O
.	O

SAE	O
is	O
considered	O
to	O
include	O
all	O
types	O
of	O
brain	B-DISO
dysfunction	I-DISO
,	O
including	O
delirium	B-DISO
,	O
coma	B-DISO
,	O
seizure	B-DISO
,	O
and	O
focal	O
neurological	O
signs	O
.	O

The	O
duration	O
of	O
delirium	B-DISO
in	O
intensive	O
care	O
patients	O
is	O
associated	O
with	O
long	O
-	O
term	O
functional	O
disability	O
and	O
cognitive	B-DISO
impairment	I-DISO
,	O
although	O
this	O
syndrome	B-DISO
usually	O
reverses	O
after	O
the	O
successful	O
treatment	O
of	O
sepsis	B-DISO
.	O

We	O
expect	O
to	O
see	O
further	O
pathophysiological	O
data	O
and	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
SAD	B-DISO
now	O
that	O
reliable	O
and	O
consistent	O
definitions	O
of	O
SAD	B-DISO
have	O
been	O
established	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
UpToDate	O
searches	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
could	O
be	O
used	O
to	O
detect	O
and	O
monitor	O
MERS	B-DISO
outbreaks	O
in	O
Saudi	O
Arabia	O
.	O

L	B-DISO
.	I-DISO
infantum	I-DISO
-	O
infected	O
stray	O
cats	O
in	O
Milan	O
have	O
a	O
high	O
seropositivity	O
rate	O
,	O
comparable	O
to	O
that	O
of	O
cats	O
in	O
areas	O
endemic	O
for	O
leishmaniosis	B-DISO
.	O

TITLE	O
:	O
Two	O
-	O
way	O
antigenic	O
cross	O
-	O
reactivity	O
between	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
porcine	O
deltacoronavirus	O
.	O

ABSTRACT	O
:	O
This	O
prospective	O
study	O
assessed	O
the	O
incidence	O
,	O
clinical	O
profile	O
and	O
outcome	O
of	O
malarial	O
hepatopathy	B-DISO
and	O
its	O
association	O
with	O
other	O
complications	O
in	O
patients	O
with	O
malaria	B-DISO
,	O
proved	O
by	O
peripheral	O
blood	O
smear	O
examination	O
and	O
rapid	O
malaria	B-DISO
test	O
.	O

Of	O
134	O
(	O
falciparum	O
-	O
81	O
,	O
vivax	O
-	O
48	O
and	O
mixed	O
falciparum	O
and	O
vivax	O
-	O
5	O
)	O
malaria	B-DISO
cases	O
,	O
hyperbilirubinemia	B-DISO
occurred	O
in	O
41	O
.	O
04	O
%.	O

However	O
,	O
during	O
TGEV	O
infection	B-DISO
,	O
the	O
systemic	O
and	O
local	O
immune	O
responses	O
switched	O
from	O
Th1	O
to	O
Th2	O
-	O
based	O
immune	O
responses	O
.	O

This	O
retrospective	O
observational	O
study	O
was	O
performed	O
in	O
a	O
23	O
-	O
bed	B-DISO
adult	O
intensive	O
care	O
unit	O
in	O
a	O
tertiary	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
referral	O
centre	O
.	O

RESULTS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
with	O
bronchiolitis	B-DISO
were	O
evaluated	O
.	O

TITLE	O
:	O
Reversal	O
of	O
the	O
Progression	O
of	O
Fatal	O
Coronavirus	B-DISO
Infection	I-DISO
in	O
Cats	O
by	O
a	O
Broad	O
-	O
Spectrum	O
Coronavirus	O
Protease	O
Inhibitor	O
.	O

The	O
role	O
of	O
mitophagy	O
in	O
the	O
pathological	O
changes	O
caused	O
by	O
TGEV	O
infection	B-DISO
is	O
unclear	O
.	O

Among	O
624	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
,	O
251	O
(	O
40	O
.	O
2	O
%)	O
fulfilled	O
the	O
definition	O
of	O
American	O
-	O
European	O
Consensus	O
Conference	O
definition	O
of	O
ALI	O
.	O

Among	O
the	O
other	B-DISO
sepsis	I-DISO
sites	O
,	O
urinary	O
tract	O
,	O
central	O
nervous	B-DISO
system	O
,	O
catheter	O
-	O
related	O
and	O
undetermined	O
foci	O
of	O
infection	B-DISO
had	O
worse	O
outcomes	O
when	O
associated	O
with	O
ALI	O
.	O

The	O
infection	B-DISO
site	I-DISO
was	O
predictive	O
of	O
outcome	O
in	O
patients	O
with	O
ALI	O
but	O
not	O
in	O
those	O
without	O
ALI	O
.	O

TITLE	O
:	O
Kinetic	O
,	O
Mutational	O
,	O
and	O
Structural	O
Studies	O
of	O
the	O
Venezuelan	B-DISO
Equine	I-DISO
Encephalitis	I-DISO
Virus	O
Nonstructural	O
Protein	O
2	O
Cysteine	O
Protease	O
.	O

ABSTRACT	O
:	O
The	O
Venezuelan	B-DISO
equine	I-DISO
encephalitis	I-DISO
virus	O
(	O
VEEV	O
)	O
nonstructural	O
protein	O
2	O
(	O
nsP2	O
)	O
cysteine	O
protease	O
(	O
EC	O
3	O
.	O
4	O
.	O
22	O
.-)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
is	O
involved	O
in	O
the	O
cytopathic	B-DISO
effects	I-DISO
(	O
CPE	O
)	O
of	O
the	O
virus	O
.	O

The	O
disease	O
rapidly	O
progressed	O
to	O
severe	O
pneumonia	B-DISO
,	O
multiple	O
organ	O
dysfunctions	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
the	O
patient	O
died	O
on	O
6	O
February	O
.	O

These	O
data	O
show	O
that	O
multiple	O
pathogens	O
circulate	O
among	O
young	O
alpaca	O
crias	O
and	O
could	O
be	O
associated	O
with	O
diarrheal	B-DISO
disease	I-DISO
in	O
these	O
animals	O
.	O

The	O
study	O
population	O
was	O
limited	O
to	O
trauma	O
patients	O
diagnosed	O
with	O
severe	O
ARDS	B-DISO
using	O
the	O
Berlin	O
definition	O
(	O
PaO2	O
/	O
FIO2	O
ratio	O
<	O
100	O
).	O

Fifteen	O
ECMO	O
patients	O
managed	O
from	O
March	O
2013	O
to	O
November	O
2014	O
were	O
identified	O
,	O
as	O
were	O
14	O
CONV	O
patients	O
managed	O
from	O
March	O
2012	O
to	O
February	O
2013	O
who	O
met	O
the	O
Berlin	O
definition	O
of	O
severe	O
ARDS	B-DISO
.	O

Data	O
related	O
to	O
age	O
,	O
Injury	O
Severity	O
Scores	O
(	O
ISSs	O
),	O
admission	O
lactic	O
acid	O
levels	O
,	O
base	O
deficit	B-DISO
,	O
the	O
number	O
of	O
transfused	O
red	O
blood	O
cell	O
units	O
within	O
the	O
first	O
24	O
hours	O
,	O
and	O
presence	O
of	O
severe	O
traumatic	O
brain	O
injury	O
were	O
collected	O
and	O
were	O
not	O
statistically	O
different	O
between	O
the	O
groups	O
.	O

Timing	O
from	O
the	O
onset	O
of	O
severe	O
ARDS	B-DISO
to	O
ECMO	O
intervention	O
occurred	O
at	O
a	O
mean	O
1	O
.	O
9	O
±	O
1	O
.	O
4	O
days	O
.	O

ECMO	O
should	O
be	O
considered	O
at	O
the	O
early	O
onset	O
of	O
severe	O
ARDS	B-DISO
to	O
improve	O
survival	O
.	O

RESULTS	O
:	O
Fifteen	O
ECMO	O
patients	O
managed	O
from	O
March	O
2013	O
to	O
November	O
2014	O
were	O
identified	O
,	O
as	O
were	O
14	O
CONV	O
patients	O
managed	O
from	O
March	O
2012	O
to	O
February	O
2013	O
who	O
met	O
the	O
Berlin	O
definition	O
of	O
severe	O
ARDS	B-DISO
.	O

Timing	O
from	O
the	O
onset	O
of	O
severe	O
ARDS	B-DISO
to	O
ECMO	O
intervention	O
occurred	O
at	O
a	O
mean	O
1	O
.	O
9	O
±	O
1	O
.	O
4	O
days	O
.	O

On	O
initial	O
evaluation	O
,	O
he	O
complained	O
of	O
dyspnea	B-DISO
and	O
was	O
afebrile	O
with	O
a	O
pulse	O
rate	O
,	O
blood	O
pressure	O
,	O
and	O
respiratory	O
rate	O
of	O
105	O
beats	O
/	O
min	O
,	O
112	O
/	O
98mmHg	O
,	O
and	O
28	O
breath	O
/	O
min	O
,	O
respectively	O
.	O

Secondary	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
(	O
HLH	B-DISO
)	O
due	O
to	O
IAV	O
was	O
diagnosed	O
and	O
together	O
with	O
corticosteroid	O
therapy	O
,	O
intravenous	O
gamma	O
globulin	O
was	O
administered	O
from	O
the	O
3rd	O
clinical	O
day	O
.	O

Viral	O
-	O
induced	O
HLH	B-DISO
,	O
formerly	O
known	O
as	O
virus	O
-	O
associated	O
hemophagocytic	B-DISO
syndrome	I-DISO
(	O
VAHS	O
),	O
leads	O
to	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
due	O
to	O
a	O
cytokine	B-DISO
storm	I-DISO
scattered	O
by	O
viral	O
-	O
infected	O
pathogenic	O
inflammatory	O
cells	O
.	O

With	O
an	O
early	O
diagnosis	O
and	O
minimum	O
immunotherapy	O
,	O
we	O
report	O
herein	O
on	O
a	O
case	O
of	O
IAV	O
(	O
H3N2	O
)-	O
related	O
HLH	B-DISO
which	O
was	O
treated	O
successfully	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
an	O
outcome	O
score	O
that	O
clinicians	O
could	O
easily	O
calculate	O
at	O
the	O
bedside	O
to	O
predict	O
the	O
risk	O
of	O
death	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
24	O
hours	O
after	O
diagnosis	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
diarrhea	B-DISO
,	O
body	O
weight	O
and	O
virus	B-DISO
shedding	I-DISO
.	O

Recently	O
,	O
the	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
)	O
has	O
attracted	O
attention	O
in	O
the	O
lung	O
inflammatory	B-DISO
response	I-DISO
.	O

However	O
,	O
the	O
function	O
of	O
soluble	O
form	O
of	O
RAGE	O
(	O
sRAGE	O
),	O
which	O
is	O
composed	O
of	O
an	O
extracellular	O
domain	O
of	O
RAGE	O
,	O
in	O
ARDS	B-DISO
remains	O
elusive	O
.	O

For	O
the	O
management	O
of	O
severe	O
ARDS	B-DISO
ventilator	O
settings	O
,	O
positioning	O
therapy	O
,	O
infection	B-DISO
control	O
,	O
and	O
supportive	O
measures	O
are	O
essential	O
to	O
improve	O
survival	O
.	O

Thirty	O
minutes	O
after	O
the	O
start	O
of	O
the	O
transfusion	O
,	O
bradycardia	B-DISO
and	O
dyspnea	B-DISO
appeared	O
,	O
quickly	O
followed	O
by	O
chills	B-DISO
,	O
nausea	B-DISO
,	O
vomiting	B-DISO
,	O
headache	B-DISO
,	O
and	O
hyperthermia	O
.	O

We	O
manually	O
searched	O
reference	O
lists	O
from	O
included	O
studies	O
and	O
review	O
articles	O
;	O
searched	O
conference	O
proceedings	O
of	O
the	O
American	O
Thoracic	B-DISO
Society	O
(	O
1994	O
to	O
2015	O
),	O
Society	O
of	O
Critical	O
Care	O
Medicine	O
(	O
1994	O
to	O
2015	O
),	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	O
(	O
1994	O
to	O
2015	O
),	O
and	O
American	O
College	O
of	O
Chest	O
Physicians	O
(	O
1994	O
to	O
2015	O
);	O
contacted	O
clinical	O
experts	O
in	O
the	O
field	O
;	O
and	O
searched	O
for	O
unpublished	O
and	O
ongoing	O
trials	O
in	O
clinicaltrials	O
.	O
gov	O
and	O
controlled	O
-	O
trials	O
.	O
com	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
contraindications	O
to	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
among	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
assess	O
the	O
impact	O
of	O
contraindications	O
on	O
the	O
number	O
of	O
patients	O
receiving	O
ECMO	O
(	O
case	O
volume	O
).	O

ABSTRACT	O
:	O
The	O
application	O
of	O
extracorporeal	O
lung	O
support	O
(	O
ECLS	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
well	O
-	O
established	O
concept	O
.	O

The	O
molecular	O
diversity	O
and	O
phylogenetic	O
relationships	O
between	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
(	O
PEDV	O
)	O
prevalent	O
in	O
Gansu	O
were	O
probed	O
,	O
and	O
the	O
resultant	O
proteins	O
were	O
characterized	O
.	O

TITLE	O
:	O
Acute	O
ischemic	B-DISO
optic	I-DISO
neuropathy	I-DISO
with	O
extended	O
prone	O
position	O
ventilation	O
in	O
a	O
lung	O
transplant	O
recipient	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
ventilation	O
(	O
PPV	O
)	O
improves	O
mortality	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
but	O
outcomes	O
following	O
its	O
use	O
in	O
lung	O
transplant	O
recipients	O
are	O
not	O
known	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
presented	O
with	O
severe	O
ARDS	B-DISO
from	O
Bordetella	O
pertussis	B-DISO
,	O
5	O
years	O
after	O
bilateral	O
sequential	O
lung	O
transplant	O
for	O
cystic	B-DISO
fibrosis	I-DISO
.	O

He	O
was	O
managed	O
with	O
PPV	O
for	O
22	O
days	O
and	O
had	O
a	O
prolonged	O
ICU	O
stay	O
complicated	O
by	O
hypoxic	B-DISO
ischemic	B-DISO
optic	I-DISO
neuropathy	I-DISO
leading	O
to	O
blindness	B-DISO
.	O

ABSTRACT	O
:	O
The	O
right	O
ventricle	O
(	O
RV	O
)	O
plays	O
a	O
pivotal	O
role	O
during	O
respiratory	B-DISO
failure	I-DISO
because	O
of	O
its	O
high	O
sensitivity	O
to	O
small	O
loading	O
changes	O
during	O
inspiration	O
.	O

TITLE	O
:	O
The	O
Ratio	O
of	O
Partial	O
Pressure	O
Arterial	O
Oxygen	O
and	O
Fraction	O
of	O
Inspired	O
Oxygen	O
1	O
Day	O
After	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Onset	O
Can	O
Predict	O
the	O
Outcomes	O
of	O
Involving	O
Patients	O
.	O

We	O
describe	O
the	O
prevalence	O
,	O
clinical	O
characteristics	O
,	O
outcomes	O
,	O
and	O
risk	O
factors	O
associated	O
with	O
CAP	B-DISO
resulting	O
from	O
multidrug	O
-	O
resistant	O
(	O
MDR	O
)	O
and	O
non	O
-	O
MDR	O
P	O
aeruginosa	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
age	O
≥	O
65	O
years	O
,	O
CAP	B-DISO
resulting	O
from	O
P	O
aeruginosa	O
,	O
chronic	B-DISO
liver	I-DISO
disease	I-DISO
,	O
neurologic	O
disease	O
,	O
nursing	O
home	O
,	O
criteria	O
of	O
ARDS	B-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
ICU	O
admission	O
,	O
and	O
inappropriate	O
empiric	O
treatment	O
were	O
the	O
factors	O
associated	O
with	O
30	O
-	O
day	O
mortality	O
.	O

ABSTRACT	O
:	O
Essentials	O
Role	O
of	O
platelets	O
in	O
immunological	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
debated	O
.	O

Background	O
Transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
a	O
serious	O
transfusion	O
-	O
related	O
complication	B-DISO
.	O

The	O
pathologic	O
responses	O
occurring	O
within	O
the	O
first	O
10	O
min	O
following	O
the	O
injection	O
of	O
the	O
anti	O
-	O
MHC	O
I	O
mAb	O
,	O
i	O
.	O
e	O
.	O
the	O
severity	O
of	O
lung	B-DISO
edema	I-DISO
and	O
the	O
drop	O
in	O
aortic	O
blood	O
oxygenation	O
,	O
were	O
similar	O
in	O
severely	O
thrombocytopenic	O
DT	O
-	O
iDTR	O
and	O
control	O
mice	O
.	O

Infection	B-DISO
with	O
PRRS	B-DISO
virus	O
was	O
confirmed	O
by	O
quantitative	O
PCR	O
and	O
seroconversion	O
.	O

Fecal	O
quantitative	O
PCR	O
was	O
used	O
to	O
confirm	O
PED	O
virus	B-DISO
infection	I-DISO
.	O

Ex	O
vivo	O
transepithelial	O
electrical	O
resistance	O
(	O
TER	O
)	O
did	O
not	O
differ	O
between	O
CON	O
and	O
PRRS	B-DISO
pigs	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
was	O
reduced	O
by	O
40	O
%	O
in	O
PED	O
alone	O
(	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
used	O
for	O
the	O
management	O
of	O
acute	O
severe	O
cardiac	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Infection	B-DISO
,	O
Replication	O
,	O
and	O
Transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
in	O
Alpacas	O
.	O

The	O
trial	O
indicates	O
that	O
alpacas	O
may	O
be	O
suitable	O
models	O
for	O
infection	B-DISO
and	O
shedding	O
dynamics	O
of	O
this	O
virus	O
.	O

Using	O
the	O
equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
model	O
system	O
and	O
electron	O
tomography	O
,	O
we	O
present	O
new	O
data	O
regarding	O
the	O
biogenesis	O
of	O
arterivirus	O
-	O
induced	O
DMVs	O
and	O
uncover	O
numerous	O
putative	O
intermediates	O
in	O
DMV	O
formation	O
.	O

CONCLUSIONS	O
:	O
The	O
transport	O
of	O
mechanically	O
ventilated	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
in	O
the	O
prone	O
position	O
is	O
feasible	O
and	O
safe	O
,	O
with	O
minimal	O
complications	O
identified	O
in	O
this	O
case	O
series	O
.	O

ABSTRACT	O
:	O
Given	O
periodic	O
outbreaks	O
of	O
fatal	O
human	O
infections	B-DISO
caused	O
by	O
coronaviruses	O
,	O
development	O
of	O
an	O
optimal	O
coronavirus	O
vaccine	O
platform	O
capable	O
of	O
rapid	O
production	O
is	O
an	O
ongoing	O
priority	O
.	O

TITLE	O
:	O
A	O
comparison	O
of	O
clinical	O
efficacy	O
between	O
high	O
frequency	O
oscillatory	O
ventilation	O
and	O
conventional	O
ventilation	O
with	O
lung	O
volume	O
recruitment	B-DISO
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

RESULTS	O
:	O
Eighteen	O
children	O
with	O
severe	O
ARDS	B-DISO
were	O
enrolled	O
in	O
our	O
study	O
.	O

TITLE	O
:	O
Lung	O
Transplant	O
Outcomes	O
in	O
Systemic	B-DISO
Sclerosis	I-DISO
with	O
Significant	O
Esophageal	B-DISO
Dysfunction	I-DISO
.	O

We	O
retrospectively	O
reviewed	O
all	O
lung	O
transplants	O
at	O
our	O
center	O
from	O
January	O
1	O
,	O
2000	O
through	O
August	O
31	O
,	O
2012	O
(	O
n	O
=	O
562	O
),	O
comparing	O
the	O
SSc	O
group	O
(	O
n	O
=	O
35	O
)	O
to	O
the	O
following	O
lung	O
transplant	O
diagnostic	O
subsets	O
:	O
all	O
non	O
-	O
SSc	O
(	O
n	O
=	O
527	O
),	O
non	O
-	O
SSc	O
diffuse	O
fibrotic	O
lung	B-DISO
disease	I-DISO
(	O
n	O
=	O
264	O
),	O
and	O
a	O
non	O
-	O
SSc	O
matched	O
group	O
(	O
n	O
=	O
109	O
).	O

Esophageal	B-DISO
dysfunction	I-DISO
rarely	O
precluded	O
active	O
listing	O
for	O
lung	O
transplantation	O
.	O

ABSTRACT	O
:	O
The	O
digestive	O
tract	O
is	O
the	O
entry	O
site	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
).	O

Nevertheless	O
,	O
the	O
mechanism	O
through	O
which	O
ACE2	O
plays	O
a	O
role	O
in	O
inflammatory	O
lung	B-DISO
disease	I-DISO
has	O
not	O
been	O
clearly	O
identified	O
.	O

In	O
an	O
attempt	O
to	O
summarize	O
current	O
literature	O
findings	O
and	O
progress	O
made	O
in	O
uncovering	O
the	O
role	O
of	O
ACE2	O
in	O
inflammatory	O
lung	B-DISO
disease	I-DISO
,	O
this	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
examining	O
pulmonary	O
ACE2	O
biology	O
,	O
its	O
roles	O
in	O
inflammatory	O
lung	B-DISO
disease	I-DISO
pathogenesis	B-DISO
and	O
possible	O
underlying	O
mechanisms	O
.	O

At	O
present	O
,	O
differential	O
diagnosis	O
of	O
PDCoV	O
,	O
PEDV	O
,	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
essential	O
to	O
control	O
viral	O
diarrheas	B-DISO
in	O
US	O
swine	O
.	O

Detection	O
of	O
amplification	B-DISO
products	O
based	O
on	O
labeled	O
probe	O
primers	O
was	O
conducted	O
with	O
strip	O
binding	O
antibody	O
of	O
labeled	O
markers	O
.	O

None	O
of	O
the	O
studies	O
were	O
conducted	O
with	O
HCWs	O
exposed	O
to	O
EVD	O
but	O
in	O
one	O
study	O
participants	O
were	O
exposed	O
to	O
SARS	B-DISO
.	O

TITLE	O
:	O
Disease	O
-	O
specific	O
dynamic	O
biomarkers	O
selected	O
by	O
integrating	O
inflammatory	O
mediators	O
with	O
clinical	O
informatics	O
in	O
ARDS	B-DISO
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

About	O
15	O
or	O
52	O
cytokines	O
showed	O
significant	O
difference	O
between	O
SP	O
and	O
SP	O
-	O
ARDS	B-DISO
patients	O
with	O
controls	O
or	O
13	O
between	O
SP	O
-	O
ARDS	B-DISO
with	O
SP	O
alone	O
and	O
controls	O
,	O
including	O
bone	O
morphogenetic	O
protein	O
-	O
15	O
(	O
BMP	O
-	O
15	O
),	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	O
16	O
(	O
CXCL16	O
),	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
3	O
(	O
CXCR3	O
),	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
protein	O
NOV	O
homolog	O
(	O
NOV	O
/	O
CCN3	O
),	O
glypican	O
3	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
binding	O
protein	O
4	O
(	O
IGFBP	O
-	O
4	O
),	O
IL	O
-	O
5	O
,	O
IL	O
-	O
5	O
R	O
alpha	O
,	O
IL	O
-	O
22	O
BP	O
,	O
leptin	O
,	O
MIP	B-DISO
-	O
1d	O
,	O
and	O
orexin	O
B	O
with	O
a	O
significant	O
correlation	O
with	O
Digital	O
Evaluation	O
Score	O
System	O
(	O
DESS	O
)	O
scores	O
.	O

TITLE	O
:	O
BCX4430	O
-	O
A	O
broad	O
-	O
spectrum	O
antiviral	O
adenosine	O
nucleoside	O
analog	O
under	O
development	O
for	O
the	O
treatment	O
of	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Nitazoxanide	O
,	O
a	O
new	O
drug	O
candidate	O
for	O
the	O
treatment	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

Nitazoxanide	O
exhibits	O
in	O
vitro	O
activity	O
against	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
other	O
coronaviruses	O
,	O
inhibiting	O
expression	O
of	O
the	O
viral	O
N	O
protein	O
.	O

Sensitivity	O
,	O
specificity	O
,	O
positive	O
(	O
PPV	O
)	O
and	O
negative	O
predictive	O
values	O
(	O
NPV	O
)	O
of	O
CSF	O
ICC	B-DISO
were	O
calculated	O
.	O

These	O
findings	O
further	O
support	O
a	O
role	O
of	O
Mmp3	O
as	O
an	O
attractive	O
therapeutic	O
target	O
for	O
drug	O
development	O
in	O
the	O
setting	O
of	O
ARDS	B-DISO
.	O

G6PD	O
-	O
deficient	O
cells	O
experience	O
a	O
high	O
level	O
of	O
oxidative	B-DISO
stress	I-DISO
and	O
an	O
increased	O
susceptibility	O
to	O
viral	B-DISO
infections	I-DISO
.	O

Survival	O
was	O
reduced	O
in	O
the	O
presence	O
of	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
hypotension	O
,	O
hypoxemia	O
,	O
CXR	O
(	O
chest	O
X	O
-	O
ray	O
)	O
abnormalities	O
,	O
leukocytosis	B-DISO
,	O
creatinine	O
>	O
1	O
·	O
5	O
mg	O
/	O
dL	O
,	O
thrombocytopenia	O
,	O
anemia	B-DISO
,	O
and	O
renal	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Rapid	O
generation	O
of	O
a	O
human	O
monoclonal	O
antibody	O
to	O
combat	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

The	O
diarrhea	B-DISO
symptoms	I-DISO
of	O
piglets	O
after	O
challenge	O
were	O
also	O
observed	O
.	O

TITLE	O
:	O
Guidelines	O
for	O
the	O
Laboratory	O
Diagnosis	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
in	O
Korea	O
.	O

The	O
assay	O
exhibited	O
high	O
specificity	O
for	O
IBV	O
infection	B-DISO
.	O

All	O
negative	O
controls	O
,	O
such	O
as	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
,	O
and	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
were	O
not	O
detected	O
.	O

The	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
described	O
herein	O
can	O
be	O
used	O
to	O
rapidly	O
distinguish	O
IBV	O
from	O
other	O
respiratory	O
pathogens	O
,	O
which	O
is	O
important	O
for	O
diagnosis	O
and	O
control	O
of	O
infectious	B-DISO
bronchitis	B-DISO
outbreaks	O
in	O
Morocco	O
.	O

CONCLUSIONS	O
:	O
The	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
described	O
herein	O
can	O
be	O
used	O
to	O
rapidly	O
distinguish	O
IBV	O
from	O
other	O
respiratory	O
pathogens	O
,	O
which	O
is	O
important	O
for	O
diagnosis	O
and	O
control	O
of	O
infectious	B-DISO
bronchitis	B-DISO
outbreaks	O
in	O
Morocco	O
.	O

This	O
study	O
reveals	O
the	O
important	O
role	O
of	O
macrophages	O
in	O
the	O
inflammatory	B-DISO
response	I-DISO
of	O
ferrets	O
against	O
the	O
virus	O
and	O
the	O
variable	O
proportions	O
of	O
leukocytes	O
among	O
different	O
types	O
of	O
lesions	O
,	O
indicating	O
their	O
variable	O
age	O
.	O

TITLE	O
:	O
Correction	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Intra	O
-	O
Host	O
Populations	O
Are	O
Characterized	O
by	O
Numerous	O
High	O
Frequency	O
Variants	O
.	O

3	O
.	O
5	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)),	O
respiratory	O
system	O
compliance	O
(	O
Crs	B-DISO
)	O
increased	O
(+	O
5	O
.	O
1	O
+/-	O

However	O
,	O
the	O
translation	O
of	O
this	O
physiological	O
model	O
in	O
a	O
clinical	O
perspective	O
is	O
not	O
straightforward	O
because	O
our	O
model	O
of	O
acute	O
and	O
severe	O
hemorrhage	B-DISO
is	O
not	O
strictly	O
equivalent	O
to	O
a	O
progressive	O
hypovolemia	O
,	O
as	O
could	O
be	O
obtained	O
in	O
ICU	O
by	O
diuretic	O
.	O

The	O
clinical	O
data	O
of	O
58	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
which	O
met	O
the	O
criteria	O
for	O
ECMO	O
and	O
treated	O
in	O
comprehensive	O
intensive	O
care	O
unit	O
of	O
the	O
Second	O
Affiliated	O
Hospital	O
of	O
Zhengzhou	O
University	O
from	O
August	O
2012	O
to	O
June	O
2015	O
,	O
were	O
retrospectively	O
collected	O
and	O
analyzed	O
.	O

Our	O
experience	O
suggests	O
that	O
VV	O
-	O
ECMO	O
may	O
be	O
an	O
effective	O
life	O
support	O
treatment	O
for	O
severe	O
ARDS	B-DISO
and	O
should	O
be	O
used	O
as	O
early	O
as	O
possible	O
when	O
the	O
ECMO	O
criteria	O
are	O
met	O
.	O

In	O
the	O
meninges	O
,	O
ERfibs	O
together	O
with	O
collagen	O
fibers	O
,	O
lining	O
in	O
a	O
striped	O
pattern	O
,	O
made	O
up	O
a	O
pile	B-DISO
of	O
thin	O
sheets	O
.	O

This	O
protein	O
was	O
expressed	O
by	O
induction	O
of	O
IPTG	O
at	O
concentration	O
of	O
1mM	O
and	O
it	O
was	O
confirmed	O
by	O
Ni	O
-	O
NTA	O
column	O
,	O
dot	O
-	O
blotting	O
analysis	O
and	O
SDS	B-DISO
-	O
PAGE	O
electrophoresis	O
.	O

Creating	O
a	O
functional	O
doctor	O
-	O
patient	O
-	O
psychologist	O
team	O
is	O
key	O
throughout	O
the	O
HIV	B-DISO
-	O
positive	O
patient	O
'	O
s	O
existence	O
,	O
for	O
supporting	O
long	O
term	O
adherence	O
to	O
therapy	O
and	O
acceptance	O
of	O
the	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
pose	O
significant	O
public	O
health	O
threats	O
.	O

Seventy	O
-	O
two	O
percent	O
stated	O
that	O
their	O
institutions	O
lacked	O
a	O
protocol	O
for	O
identification	O
and	O
management	O
of	O
severe	O
or	O
refractory	O
hypoxemia	O
in	O
the	O
setting	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

During	O
caesarean	O
delivery	O
under	O
spinal	O
anaesthesia	B-DISO
a	O
previously	O
healthy	O
woman	O
became	O
hypotensive	B-DISO
,	O
requiring	O
ephedrine	O
to	O
maintain	O
her	O
blood	O
pressure	O
.	O

Three	O
hours	O
after	O
delivery	O
the	O
patient	O
presented	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
and	O
pulmonary	B-DISO
oedema	I-DISO
.	O

Although	O
the	O
application	O
of	O
ECMO	O
during	O
severe	O
ARDS	B-DISO
resulted	O
in	O
a	O
period	O
of	O
maximum	O
sedation	B-DISO
exposure	O
that	O
was	O
both	O
greater	O
and	O
took	O
longer	O
to	O
reach	O
,	O
factors	O
other	O
than	O
ECMO	O
,	O
particularly	O
high	O
-	O
dose	O
opioid	O
administration	O
,	O
appeared	O
more	O
likely	O
to	O
account	O
for	O
this	O
maximum	O
sedation	B-DISO
use	O
.	O

All	O
healthcare	O
facilities	O
need	O
to	O
have	O
policies	O
and	O
plans	O
in	O
place	O
for	O
early	O
identification	O
of	O
patients	O
with	O
a	O
highly	O
communicable	B-DISO
diseases	I-DISO
which	O
are	O
highly	O
virulent	O
,	O
ability	O
to	O
immediately	O
isolate	O
such	O
patients	O
,	O
and	O
provide	O
proper	O
management	O
(	O
e	O
.	O
g	O
.,	O
training	O
and	O
availability	O
of	O
personal	O
protective	O
equipment	O
)	O
to	O
prevent	O
transmission	O
to	O
healthcare	O
personnel	O
,	O
other	O
patients	O
and	O
visitors	O
to	O
the	O
healthcare	O
facility	O
.	O

PPV	O
can	O
improve	O
oxygenation	O
in	O
severe	O
ARDS	B-DISO
.	O

Moreover	O
pleural	B-DISO
effusion	I-DISO
gradually	O
increased	O
as	O
shown	O
by	O
X	O
-	O
ray	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
the	O
early	O
goal	O
-	O
directed	O
therapy	O
(	O
EGDT	O
)	O
on	O
mortality	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
,	O
and	O
to	O
analyze	O
the	O
risk	O
factors	O
of	O
mortality	O
.	O

Complete	O
clinical	O
data	O
of	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
admitted	O
to	O
emergency	B-DISO
intensive	O
care	O
unit	O
(	O
EICU	O
)	O
of	O
Sichuan	O
Provincial	O
People	O
'	O
s	O
Hospital	O
from	O
May	O
1994	O
to	O
December	O
2014	O
were	O
recorded	O
and	O
analyzed	O
.	O

According	O
to	O
the	O
International	O
Guidelines	O
for	O
Management	O
of	O
Severe	B-DISO
Sepsis	I-DISO
and	O
Septic	B-DISO
Shock	I-DISO
(	O
SSC	O
)	O
with	O
the	O
time	O
of	O
promulgation	O
as	O
dividing	O
point	O
,	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
as	O
before	O
and	O
after	O
the	O
publication	O
of	O
the	O
guideline	O
,	O
i	O
.	O
e	O
.	O
early	O
group	O
(	O
from	O
May	O
1994	O
to	O
April	O
2004	O
)	O
and	O
late	O
group	O
(	O
from	O
May	O
2004	O
to	O
December	O
2014	O
).	O

Patients	O
with	O
severe	O
hypoxaemia	O
can	O
be	O
managed	O
with	O
early	O
short	O
-	O
term	O
use	O
of	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
prone	O
position	O
ventilation	O
,	O
or	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Depending	O
on	O
their	O
destinations	O
and	O
activities	O
,	O
international	O
travellers	O
are	O
at	O
a	O
significant	O
risk	O
of	O
contracting	O
both	O
communicable	O
and	O
non	O
-	O
communicable	B-DISO
diseases	I-DISO
.	O

ARDS	B-DISO
and	O
pneumonia	B-DISO
are	O
closely	O
related	O
to	O
critically	B-DISO
ill	I-DISO
patients	O
;	O
however	O
,	O
the	O
etiologic	O
agent	O
is	O
not	O
always	O
identified	O
.	O

The	O
presence	O
of	O
this	O
group	O
of	O
herpesviruses	O
,	O
in	O
addition	O
to	O
the	O
research	O
of	O
influenza	B-DISO
viruses	O
and	O
other	O
common	O
respiratory	O
viruses	O
,	O
was	O
investigated	O
in	O
respiratory	O
samples	O
from	O
54	O
patients	O
hospitalized	O
in	O
ICU	O
,	O
without	O
a	O
known	O
microbiological	O
causative	O
agent	O
.	O

The	O
tasks	O
of	O
the	O
National	O
IHR	O
Fo	O
-	O
cal	O
Point	O
in	O
Poland	O
which	O
was	O
appointed	O
by	O
the	O
Minister	O
of	O
Health	O
and	O
runs	O
in	O
the	O
Department	O
of	O
Epidemiology	O
,	O
National	O
Institute	O
of	O
Public	O
Health	O
--	O
National	O
Institute	O
of	O
Hygiene	O
from	O
1	O
September	O
2007	O
are	O
the	O
notification	O
of	O
events	O
that	O
may	O
constitute	O
a	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
occurring	O
in	O
Poland	O
or	O
abroad	O
and	O
the	O
dissemination	O
of	O
this	O
information	O
to	O
the	O
WHO	O
,	O
other	O
National	O
IHR	O
Focal	O
Points	O
or	O
competent	O
authorities	O
responsible	O
for	O
public	O
health	O
.	O

TITLE	O
:	O
The	O
world	O
first	O
two	O
cases	O
of	O
severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	B-DISO
:	O
An	O
epidemiological	O
study	O
in	O
Nagasaki	O
,	O
Japan	O
.	O

Our	O
data	O
indicates	O
that	O
the	O
risk	O
for	O
SFTSV	O
infection	B-DISO
is	O
not	O
high	O
in	O
Nagasaki	O
prefecture	O
.	O

Nanotrap	O
particles	O
with	O
reactive	O
red	O
baits	O
concentrated	O
numerous	O
respiratory	O
viruses	O
including	O
various	O
strains	O
and	O
subtypes	O
of	O
Influenza	B-DISO
virus	O
,	O
Coronavirus	O
,	O
and	O
Respiratory	O
Syncytial	O
Virus	O
from	O
saliva	O
,	O
nasal	O
fluid	O
swab	O
specimens	O
,	O
and	O
nasal	O
aspirates	O
.	O

However	O
,	O
I	O
argue	O
that	O
people	O
wear	O
a	O
facemask	O
not	O
merely	O
for	O
infection	B-DISO
prevention	O
,	O
and	O
various	O
sociocultural	O
reasons	O
have	O
been	O
motivating	O
people	O
to	O
wear	O
(	O
and	O
not	O
wear	O
)	O
a	O
facemask	O
.	O

The	O
sociocultural	O
meanings	O
of	O
the	O
facemask	O
have	O
been	O
undergoing	O
constant	O
change	O
,	O
from	O
positive	O
to	O
negative	O
,	O
which	O
resulted	O
in	O
the	O
participants	O
displaying	O
hesitation	O
in	O
using	O
a	O
facemask	O
in	O
the	O
post	O
-	O
SARS	B-DISO
era	O
.	O

The	O
changes	O
in	O
meaning	O
not	O
only	O
influenced	O
the	O
participants	O
'	O
perceptions	O
of	O
the	O
facemask	O
but	O
also	O
influenced	O
their	O
perceptions	O
of	O
people	O
who	O
use	O
facemasks	O
,	O
which	O
ultimately	O
influenced	O
their	O
health	O
behavior	O
,	O
preventing	O
them	O
from	O
using	O
facemasks	O
in	O
the	O
post	O
-	O
SARS	B-DISO
era	O
.	O

Because	O
it	O
represents	O
a	O
violation	O
of	O
societal	O
ideologies	O
and	O
traditional	O
Chinese	O
cultural	O
beliefs	O
,	O
the	O
meanings	O
of	O
the	O
facemask	O
that	O
had	O
developed	O
during	O
the	O
SARS	B-DISO
outbreak	O
failed	O
to	O
be	O
sustained	O
in	O
the	O
post	O
-	O
SARS	B-DISO
era	O
.	O

We	O
analyzed	O
clinical	O
data	O
and	O
specimens	O
from	O
fourteen	O
MERS	O
patients	O
treated	O
in	O
a	O
hospital	O
who	O
collectively	O
represent	O
a	O
wide	O
spectrum	O
of	O
disease	O
severity	O
,	O
ranging	O
from	O
mild	O
febrile	B-DISO
illness	I-DISO
to	O
fatal	O
pneumonia	B-DISO
,	O
and	O
classified	O
the	O
patients	O
into	O
four	O
groups	O
based	O
on	O
severity	O
and	O
mortality	O
.	O

No	O
predictive	O
signs	O
or	O
symptoms	O
exist	O
to	O
differentiate	O
MERS	O
-	O
CoV	O
from	O
community	O
-	O
acquired	O
pneumonia	B-DISO
in	O
hospitalized	O
patients	O
.	O

TITLE	O
:	O
Development	O
of	O
Monoclonal	O
Antibody	O
and	O
Diagnostic	O
Test	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Using	O
Cell	O
-	O
Free	O
Synthesized	O
Nucleocapsid	O
Antigen	O
.	O

Bootstrap	O
studies	O
indicated	O
that	O
almost	O
500	O
patients	O
would	O
be	O
needed	O
to	O
confirm	O
a	O
significant	O
reduction	O
in	O
mortality	O
from	O
corticosteroids	O
(	O
type	O
I	O
error	O
=	O
0	O
.	O
05	O
,	O
power	O
=	O
80	O
%).	O
Blastomycosis	B-DISO
is	O
an	O
uncommon	O
,	O
albeit	O
important	O
,	O
cause	O
of	O
ARDS	B-DISO
in	O
this	O
geographic	O
area	O
.	O

Thirteen	O
fecal	O
samples	O
were	O
obtained	O
from	O
calves	O
with	O
a	O
single	O
episode	O
of	O
neonate	O
calf	O
diarrhea	B-DISO
at	O
three	O
different	O
dairies	O
and	O
two	O
samples	O
were	O
collected	O
from	O
field	O
during	O
a	O
severe	O
NCD	O
outbreak	O
.	O

TITLE	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
Africa	O
:	O
a	O
review	O
.	O

It	O
was	O
first	O
described	O
40	O
years	O
ago	O
and	O
it	O
proves	O
to	O
be	O
in	O
alignment	O
with	O
two	O
major	O
ARDS	B-DISO
pathophysiological	O
lung	O
models	O
;	O
the	O
""""	O
sponge	O
lung	O
""""	O
-	O
and	O
the	O
""""	O
shape	O
matching	O
""""	O
-	O
model	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
PDCoV	O
infection	B-DISO
suppresses	O
RIG	O
-	O
I	O
-	O
mediated	O
IFN	O
signaling	O
pathway	O
,	O
providing	O
a	O
better	O
understanding	O
of	O
the	O
PDCoV	O
immune	O
evasion	O
strategy	O
.	O

During	O
the	O
observation	O
period	O
,	O
31	O
patients	O
were	O
admitted	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
(	O
mean	O
age	O
59	O
±	O
20	O
years	O
,	O
22	O
[	O
71	O
%]	O
males	O
).	O

TITLE	O
:	O
Metagenomic	O
characterization	O
of	O
the	O
virome	O
associated	O
with	O
bovine	O
respiratory	B-DISO
disease	I-DISO
in	O
feedlot	O
cattle	O
identified	O
novel	O
viruses	O
and	O
suggests	O
an	O
etiologic	O
role	O
for	O
influenza	B-DISO
D	O
virus	O
.	O

Both	O
infection	B-DISO
prevention	O
compliance	O
and	O
maintenance	O
of	O
patient	O
flow	O
are	O
critical	O
in	O
preventing	O
healthcare	O
-	O
associated	O
transmission	O
of	O
many	O
of	O
these	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
including	O
MERS	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
,	O
we	O
present	O
and	O
discuss	O
a	O
comprehensive	O
set	O
of	O
both	O
newly	O
and	O
previously	O
synthesized	O
compounds	O
belonging	O
to	O
5	O
distinct	O
molecular	O
classes	O
of	O
linear	O
aromatic	O
N	O
-	O
polycyclic	O
systems	O
that	O
efficiently	O
inhibits	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
(	O
BVDV	O
)	O
infection	B-DISO
.	O

Three	O
RdRp	O
(	O
K263	O
,	O
R295	O
and	O
Y674	O
)	O
residues	O
critical	O
for	O
drug	O
binding	O
were	O
selected	O
and	O
mutagenized	O
,	O
both	O
in	O
silico	O
and	O
in	O
vitro	O
,	O
into	O
alanine	O
,	O
and	O
the	O
affinity	O
of	O
a	O
set	O
of	O
selected	O
compounds	O
towards	O
the	O
mutant	B-DISO
RdRp	O
isoforms	O
was	O
determined	O
accordingly	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
(	O
PED	O
)	O
were	O
reported	O
across	O
Europe	O
during	O
the	O
1980s	O
and	O
1990s	O
,	O
but	O
only	O
sporadic	O
outbreaks	O
occurred	O
in	O
recent	O
years	O
.	O

Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
was	O
reported	O
in	O
47	O
.	O
5	O
%	O
of	O
cases	O
,	O
and	O
the	O
fatality	O
rate	O
was	O
40	O
%.	O

TITLE	O
:	O
SARS	B-DISO
Coronavirus	O
Papain	O
-	O
Like	O
Protease	O
Inhibits	O
the	O
TLR7	O
Signaling	O
Pathway	O
through	O
Removing	O
Lys63	O
-	O
Linked	O
Polyubiquitination	O
of	O
TRAF3	O
and	O
TRAF6	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLPro	O
)	O
reportedly	O
inhibits	O
the	O
production	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
Toll	O
-	O
like	O
receptor	O
3	O
(	O
TLR3	O
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
1	O
(	O
RIG	O
-	O
I	O
)	O
pathways	O
.	O

In	O
this	O
study	O
,	O
DcCoV	O
UAE	O
-	O
HKU23	O
was	O
successfully	O
isolated	O
in	O
two	O
of	O
the	O
14	O
dromedary	O
fecal	O
samples	O
using	O
HRT	O
-	O
18G	O
cells	O
,	O
with	O
cytopathic	B-DISO
effects	I-DISO
observed	O
five	O
days	O
after	O
inoculation	O
.	O

TITLE	O
:	O
Isolation	O
of	O
a	O
novel	O
serotype	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
ZZ2004	O
from	O
ducks	O
in	O
China	O
.	O

There	O
was	O
progressive	O
worsening	O
of	O
the	O
lactic	B-DISO
acidosis	I-DISO
.	O

ABSTRACT	O
:	O
In	O
April	O
2014	O
,	O
a	O
surge	O
in	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
was	O
seen	O
in	O
Jeddah	O
,	O
Saudi	O
Arabia	O
.	O

Hence	O
,	O
blocking	B-DISO
the	O
process	O
of	O
six	O
-	O
helix	O
bundle	O
formation	O
can	O
effectively	O
inhibit	O
MERS	O
-	O
CoV	O
entry	O
into	O
the	O
target	O
cells	O
.	O

Measurement	O
using	O
the	O
modified	O
nitrogen	O
multiple	O
breath	O
washout	O
technique	O
may	O
help	O
titrating	O
PEEP	O
during	O
ARDS	B-DISO
and	O
allow	O
determining	O
dynamic	O
lung	O
strain	O
(	O
tidal	O
volume	O
over	O
EELV	O
)	O
in	O
patients	O
ventilated	O
with	O
PEEP	O
.	O

From	O
1	O
April	O
to	O
30	O
June	O
2014	O
(	O
PED	O
epidemic	O
),	O
any	O
herds	O
with	O
clinical	O
signs	O
of	O
PED	O
and	O
feces	O
positive	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
/	O
or	O
immunohistochemical	O
staining	O
were	O
defined	O
as	O
PED	O
-	O
positive	O
(	O
n	O
=	O
38	O
).	O

Like	O
the	O
coronavirus	O
2	O
'-	O
O	O
-	O
MTase	O
,	O
the	O
roniviral	O
2	O
'-	O
O	O
-	O
MTase	O
harbors	O
a	O
catalytic	O
K	O
-	O
D	O
-	O
K	O
-	O
E	O
tetrad	O
that	O
is	O
conserved	O
among	O
2	O
'-	O
O	O
-	O
MTases	O
and	O
can	O
target	O
only	O
the	O
N7	O
-	O
methylated	O
cap	B-DISO
structure	O
of	O
adenylate	O
-	O
primed	O
RNA	O
substrates	O
.	O

They	O
include	O
six	O
types	O
of	O
organ	B-DISO
failure	I-DISO
:	O
liver	O
,	O
renal	O
,	O
coagulation	O
,	O
cerebral	O
,	O
respiratory	O
,	O
and	O
circulatory	O
.	O

Acute	O
-	O
on	O
-	O
chronic	B-DISO
liver	I-DISO
failure	I-DISO
frequently	O
occurs	O
in	O
a	O
closed	O
relationship	O
to	O
a	O
precipitating	O
event	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
papain	O
-	O
like	O
protease	O
induces	O
Egr	O
-	O
1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
β1	O
via	O
ROS	O
/	O
p38	O
MAPK	O
/	O
STAT3	O
pathway	O
.	O

Dual	O
luciferase	O
reporter	O
assays	O
with	O
TGF	O
-	O
β1	O
promoter	O
plasmids	O
indicated	O
that	O
TGF	O
-	O
β1	O
promoter	O
region	O
between	O
-	O
175	O
to	O
-	O
60	O
,	O
the	O
Egr	O
-	O
1	O
binding	O
site	O
,	O
was	O
responsible	O
for	O
TGF	O
-	O
β1	O
promoter	O
activation	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
.	O

Subcellular	O
localization	O
analysis	O
of	O
transcription	O
factors	O
showed	O
PLpro	O
triggering	O
nuclear	O
translocation	B-DISO
of	O
Egr	O
-	O
1	O
,	O
but	O
not	O
NF	O
-	O
κB	O
and	O
Sp	O
-	O
1	O
.	O

The	O
results	O
revealed	O
that	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
significantly	O
triggered	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
β1	O
promoter	O
via	O
ROS	O
/	O
p38	O
MAPK	O
/	O
STAT3	O
pathway	O
,	O
correlating	O
with	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
fibrotic	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

SAA	O
and	O
Hp	O
levels	O
in	O
group	B-DISO
B	I-DISO
were	O
not	O
significantly	O
higher	O
than	O
the	O
group	O
P	O
.	O
The	O
levels	O
of	O
IgG	O
and	O
IgA	O
were	O
found	O
to	O
be	O
lower	O
in	O
groups	O
B	O
and	O
V	O
compared	O
to	O
other	O
groups	O
.	O

Serum	O
SAA	O
,	O
Hp	O
,	O
IgA	O
and	O
IgG	O
levels	O
could	O
be	O
useful	O
for	O
the	O
diagnosis	O
and	O
differential	O
diagnosis	O
of	O
diarrhea	B-DISO
caused	O
by	O
rotavirus	O
,	O
coronavirus	O
,	O
E	O
.	O
coli	O
F5	O
and	O
Eimeria	O
species	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
andrographolide	O
sulfonate	O
,	O
a	O
water	O
-	O
soluble	O
form	O
of	O
andrographolide	O
(	O
trade	O
name	O
:	O
Xi	O
-	O
Yan	O
-	O
Ping	O
Injection	O
),	O
on	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
ALI	O
and	O
inflammation	B-DISO
.	O

The	O
results	O
showed	O
that	O
pretreatment	O
with	O
QF	O
significantly	O
inhibits	O
the	O
release	O
of	O
cytokines	O
(	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
)	O
and	O
chemokines	O
(	O
IL	O
-	O
8	O
and	O
RANTES	O
),	O
reduces	O
leukocytes	O
recruitment	B-DISO
into	O
inflamed	O
tissues	O
and	O
ameliorates	O
pulmonary	B-DISO
edema	I-DISO
and	O
necrosis	O
.	O

P	B-DISO
.	I-DISO
falciparum	I-DISO
may	O
cause	O
severe	O
malaria	B-DISO
with	O
the	O
involvement	O
of	O
central	O
nervous	B-DISO
system	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
severe	B-DISO
anemia	I-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Arthemeter	O
plus	O
lumefantrine	O
therapy	O
was	O
started	O
,	O
however	O
,	O
he	O
developed	O
severe	O
thrombocytopenia	O
and	O
jaundice	B-DISO
under	O
treatment	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
with	O
a	O
mortality	O
rate	O
as	O
high	O
as	O
40	O
‑	O
46	O
%	O
and	O
without	O
any	O
effective	O
pharmacological	O
treatment	O
available	O
.	O

TITLE	O
:	O
Detection	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
-	O
Related	O
Coronavirus	O
and	O
Alphacoronavirus	O
in	O
the	O
Bat	O
Population	O
of	O
Taiwan	O
.	O

This	O
study	O
has	O
important	O
implication	O
for	O
understanding	O
the	O
infectious	B-DISO
,	O
genetic	O
,	O
and	O
evolutionary	O
aspects	O
of	O
PEDV	O
strains	O
in	O
Chinese	O
mainland	O
.	O

ABSTRACT	O
:	O
The	O
peer	O
-	O
reviewed	O
journal	O
Infectious	B-DISO
Diseases	I-DISO
of	O
Poverty	O
provides	O
a	O
new	O
platform	O
to	O
engage	O
with	O
,	O
and	O
disseminate	O
in	O
an	O
open	O
-	O
access	O
format	O
,	O
science	O
outside	O
traditional	O
disciplinary	O
boundaries	O
.	O

Possible	O
explanations	O
include	O
the	O
fact	O
that	O
the	O
2012	O
and	O
2014	O
international	O
conferences	O
pertaining	O
to	O
surveillance	O
-	O
response	O
mechanisms	O
were	O
both	O
hosted	O
by	O
the	O
National	O
Institute	O
of	O
Parasitic	B-DISO
Diseases	I-DISO
(	O
NIPD	O
)	O
in	O
Shanghai	O
,	O
coupled	O
with	O
P	O
.	O
R	O
.	O
China	O
'	O
s	O
growing	O
importance	O
with	O
regard	O
to	O
the	O
control	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Bats	O
are	O
a	O
major	O
reservoir	O
of	O
emerging	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
like	O
coronaviruses	O
,	O
henipaviruses	O
,	O
and	O
Ebola	O
virus	O
.	O

This	O
paper	O
explores	O
policy	O
implementation	O
in	O
two	O
exemplar	O
public	O
health	O
programs	O
-	O
chronic	B-DISO
disease	I-DISO
prevention	O
and	O
sexually	O
-	O
transmitted	B-DISO
infection	B-DISO
prevention	O
-	O
in	O
Ontario	O
,	O
Canada	O
.	O

TITLE	O
:	O
Different	O
pattern	O
of	O
viral	B-DISO
infections	I-DISO
and	O
clinical	O
outcomes	O
in	O
patient	O
with	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
with	O
pneumonia	B-DISO
.	O

However	O
,	O
the	O
differences	O
in	O
a	O
viral	B-DISO
infection	I-DISO
pattern	O
and	O
clinical	O
impacts	O
of	O
respiratory	O
viruses	O
between	O
the	O
two	O
groups	O
have	O
not	O
been	O
well	O
investigated	O
.	O

After	O
excluding	O
88	O
patients	O
(	O
40	O
with	O
AE	O
-	O
COPD	B-DISO
and	O
48	O
with	O
CP	O
-	O
COPD	B-DISO
)	O
who	O
did	O
not	O
undergo	O
a	O
multiplex	O
RT	O
-	O
PCR	O
test	O
for	O
respiratory	O
viruses	O
,	O
the	O
demographic	O
characteristics	O
,	O
identified	O
viruses	O
,	O
and	O
clinical	O
outcomes	O
of	O
the	O
AE	O
-	O
COPD	B-DISO
and	O
CP	O
-	O
COPD	B-DISO
groups	O
were	O
compared	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
:	O
An	O
overview	O
of	O
current	O
virological	O
and	O
serological	O
diagnostic	O
methods	O
.	O

TITLE	O
:	O
Association	O
between	O
Hyperglycaemia	B-DISO
with	O
Neurological	O
Outcomes	O
Following	O
Severe	O
Head	O
Trauma	O
.	O

The	O
mortality	O
rate	O
,	O
length	O
of	O
ICU	O
stay	O
,	O
hospital	O
stay	O
,	O
ISS	B-DISO
and	O
VAP	O
&	O
ARDS	B-DISO
in	O
patients	O
with	O
RBS	B-DISO
levels	O
≥	O
200	O
mg	O
was	O
significantly	O
higher	O
than	O
patients	O
with	O
RBS	B-DISO
levels	O
below	O
≤	O
200mg	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
RBS	B-DISO
with	O
GCS	O
arrival	O
,	O
length	O
of	O
ICU	O
stay	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
ISS	B-DISO
,	O
mechanical	O
ventilation	O
and	O
VAP	O
&	O
ARDS	B-DISO
(	O
p	O
<	O
0	O
.	O
05	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
About	O
34	O
(	O
40	O
%)	O
of	O
patients	O
were	O
admitted	O
with	O
hyperglycaemia	B-DISO
(	O
RBS	B-DISO
≥	O
200	O
mg	O
/	O
dl	O
)	O
over	O
the	O
study	O
period	O
.	O

After	O
MERS	O
-	O
CoV	O
infections	B-DISO
occurred	O
in	O
an	O
extended	O
family	O
in	O
Saudi	O
Arabia	O
in	O
2014	O
,	O
relatives	O
were	O
tested	O
by	O
using	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
and	O
serologic	O
methods	O
.	O

ABSTRACT	O
:	O
Necrosis	O
amplifies	O
inflammation	B-DISO
and	O
plays	O
important	O
roles	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
PREVALENCE	O
OF	O
ANTIBODIES	O
FOR	O
SELECTED	O
CANINE	O
PATHOGENS	O
AMONG	O
WOLVES	O
(	O
CANIS	O
LUPUS	B-DISO
)	O
FROM	O
THE	O
ALASKA	O
PENINSULA	O
,	O
USA	O
.	O

The	O
following	O
day	O
,	O
the	O
patient	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
was	O
put	O
on	O
a	O
respirator	O
.	O

Japanese	B-DISO
spotted	I-DISO
fever	I-DISO
is	O
noted	O
to	O
occur	O
in	O
any	O
place	O
other	O
than	O
Kobe	O
City	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
a	O
DUB	O
that	O
cleaves	O
ISG15	O
,	O
a	O
two	O
-	O
domain	O
Ub	O
-	O
like	O
protein	O
,	O
and	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
,	O
releasing	O
diUb	O
(	O
Lys48	O
)	O
products	O
.	O

ABSTRACT	O
:	O
In	O
this	O
Series	O
paper	O
,	O
we	O
review	O
the	O
current	O
evidence	O
for	O
the	O
use	O
of	O
high	O
-	O
flow	O
oxygen	O
therapy	O
,	O
inhaled	O
gases	O
,	O
and	O
aerosols	O
in	O
the	O
care	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

TITLE	O
:	O
Pulmonary	O
Vascular	O
Dysfunction	O
and	O
Cor	B-DISO
Pulmonale	I-DISO
During	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
in	O
Sicklers	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
chest	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
death	O
among	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
(	O
SCD	B-DISO
)	O
adult	O
patients	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	O
and	O
prognosis	O
of	O
PVD	B-DISO
and	O
ACP	B-DISO
during	O
ACS	O
-	O
ARDS	B-DISO
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
reverse	O
genetics	O
approaches	O
that	O
have	O
been	O
successfully	O
used	O
to	O
engineer	O
infectious	B-DISO
clones	O
of	O
PEDV	O
as	O
well	O
as	O
other	O
potential	O
and	O
complementary	O
methods	O
that	O
have	O
yet	O
to	O
be	O
applied	O
to	O
PEDV	O
.	O

TITLE	O
:	O
Lactogenic	O
immunity	O
and	O
vaccines	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
):	O
Historical	O
and	O
current	O
concepts	O
.	O

Previous	O
advances	O
in	O
the	O
development	O
of	O
live	O
and	O
attenuated	O
vaccines	O
for	O
another	O
devastating	O
diarrheal	O
virus	O
of	O
pigs	O
,	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
provide	O
insights	O
into	O
the	O
mechanisms	O
of	O
maternal	O
immunity	O
and	O
piglet	O
protection	O
.	O

Diverse	O
coronaviruses	O
were	O
first	O
detected	O
in	O
Korean	O
bat	O
faeces	O
,	O
including	O
alphacoronaviruses	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
like	O
and	O
MERS	O
-	O
CoV	O
-	O
like	O
betacoronaviruses	O
.	O

Treatment	O
of	O
cells	O
with	O
selective	O
p38	O
or	O
JNK	O
inhibitors	O
markedly	O
impaired	B-DISO
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
these	O
antiviral	O
effects	O
were	O
found	O
to	O
be	O
maximal	O
during	O
the	O
early	O
times	O
of	O
the	O
infection	B-DISO
.	O

Although	O
qPCR	O
is	O
used	O
to	O
detect	O
antigen	O
during	O
the	O
acute	B-DISO
disease	I-DISO
phase	O
,	O
there	O
is	O
no	O
equine	O
-	O
specific	O
antibody	O
test	O
available	O
to	O
study	O
EqCoV	O
seroprevalence	O
in	O
various	O
horse	O
populations	O
.	O

The	O
greatest	O
seroconversion	O
rate	O
was	O
observed	O
in	O
horses	O
with	O
clinical	O
signs	O
compatible	O
with	O
EqCoV	O
infection	B-DISO
and	O
EqCoV	O
qPCR	O
detection	O
in	O
feces	O
.	O

All	O
contacts	O
reported	O
100	O
%	O
compliance	O
with	O
hand	O
hygiene	O
,	O
using	O
N95	O
respirator	O
,	O
performing	O
respirator	O
fit	B-DISO
test	O
,	O
wearing	O
gown	O
,	O
gloves	O
,	O
eye	O
protection	O
,	O
and	O
cap	B-DISO
during	O
their	O
entire	O
working	O
period	O
.	O

Strict	O
infection	B-DISO
control	O
precautions	O
can	O
protect	O
HCWs	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
),	O
which	O
is	O
threatening	O
the	O
swine	O
industry	O
all	O
over	O
the	O
world	O
.	O

TITLE	O
:	O
Pig	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
S	O
gene	O
variant	O
with	O
a	O
large	O
deletion	O
non	O
-	O
lethal	O
to	O
colostrum	O
-	O
deprived	O
newborn	O
piglets	O
.	O

To	O
investigate	O
the	O
pathogenicity	O
of	O
this	O
variant	O
,	O
TTR	O
-	O
2	O
/	O
JPN	O
/	O
2014	O
,	O
we	O
performed	O
experimental	O
infection	B-DISO
using	O
colostrum	O
-	O
deprived	O
piglets	O
and	O
compared	O
the	O
results	O
with	O
those	O
from	O
the	O
North	O
American	O
type	O
PEDV	O
,	O
OKN	O
-	O
1	O
/	O
JPN	O
/	O
2013	O
.	O

Although	O
all	O
PEDV	O
-	O
inoculated	O
piglets	O
showed	O
acute	O
watery	B-DISO
diarrhoea	I-DISO
,	O
lethality	O
clearly	O
differed	O
between	O
both	O
PEDV	O
-	O
inoculated	O
groups	O
.	O

Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
ENT	O
infections	B-DISO
,	O
influenza	B-DISO
,	O
pyogenic	O
pneumonia	B-DISO
,	O
whooping	B-DISO
cough	I-DISO
,	O
and	O
tuberculosis	B-DISO
are	O
most	O
frequently	O
observed	O
during	O
the	O
Hajj	O
.	O

Pyoderma	B-DISO
and	O
furuncles	B-DISO
are	O
also	O
frequently	O
observed	O
.	O

CONCLUSIONS	O
:	O
Prevention	O
is	O
based	O
on	O
compulsory	O
meningococcal	O
vaccination	O
,	O
vaccination	O
against	O
seasonal	O
influenza	B-DISO
and	O
pneumococcal	B-DISO
infections	I-DISO
for	O
pilgrims	O
at	O
high	O
risk	O
of	O
contracting	O
the	O
infection	B-DISO
,	O
and	O
on	O
vaccination	O
against	O
hepatitis	O
A	O
.	O
Updating	O
immunization	O
for	O
diphtheria	B-DISO
/	O
tetanus	B-DISO
/	O
poliomyelitis	B-DISO
/	O
pertussis	B-DISO
and	O
measles	B-DISO
/	O
mumps	B-DISO
is	O
also	O
crucial	O
and	O
pilgrims	O
must	O
comply	O
with	O
hygiene	O
precautions	O
.	O

Demographic	O
and	O
epidemiologic	O
data	O
were	O
obtained	O
from	O
enrolled	O
patients	O
after	O
which	O
nasopharyngeal	O
and	O
oropharyngeal	O
swabs	O
were	O
collected	O
,	O
and	O
processed	O
by	O
molecular	O
methods	O
for	O
the	O
presence	O
of	O
influenza	B-DISO
viruses	O
.	O

Both	O
SARI	O
and	O
AFI	O
surveillance	O
yielded	O
influenza	B-DISO
A	O
(	O
H3N2	O
)	O
(	O
3	O
%	O
versus	O
1	O
%),	O
A	O
(	O
H1N1	O
)	O
pdm09	O
(	O
2	O
%	O
versus	O
1	O
%),	O
and	O
influenza	B-DISO
B	O
(	O
3	O
%	O
versus	O
4	O
%)	O
in	O
similar	O
proportions	O
.	O

RESULTS	O
:	O
Of	O
730	O
SARI	O
patients	O
,	O
59	O
(	O
8	O
%)	O
were	O
influenza	B-DISO
positive	O
;	O
of	O
543	O
AFI	O
patients	O
,	O
34	O
(	O
6	O
%)	O
were	O
positive	O
for	O
influenza	B-DISO
.	O

Based	O
on	O
a	O
scaffold	O
we	O
reported	O
for	O
inhibiting	O
neuraminidase	O
(	O
NA	O
),	O
we	O
synthesized	O
the	O
analogues	O
and	O
identified	O
compounds	O
with	O
low	O
micromolar	O
inhibitory	O
activity	O
against	O
3CL	O
(	O
pro	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Docking	O
studies	O
show	O
that	O
a	O
carboxylate	O
present	O
at	O
either	O
R	O
(	O
1	O
)	O
or	O
R	O
(	O
4	O
)	O
destabilizes	O
the	O
oxyanion	O
hole	O
in	O
the	O
3CL	O
(	O
pro	O
).	O

TITLE	O
:	O
Can	O
fiberoptic	O
bronchoscopy	O
be	O
applied	O
to	O
critically	B-DISO
ill	I-DISO
patients	O
treated	O
with	O
noninvasive	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
?	O

There	O
was	O
no	O
impairment	B-DISO
in	O
arterial	O
blood	O
gas	O
and	O
cardiopulmonary	O
parameters	O
after	O
FOB	O
.	O

FOB	O
under	O
NIV	O
could	O
be	O
considered	O
as	O
a	O
feasible	O
tool	O
for	O
diagnosis	O
and	O
guide	O
for	O
treatment	O
of	O
patients	O
with	O
ARDS	B-DISO
treated	O
via	O
NIV	O
in	O
intensive	O
care	O
units	O
.	O

Furthermore	O
,	O
further	O
controlled	O
studies	O
involving	O
a	O
larger	O
series	O
of	O
homogeneous	O
ARDS	B-DISO
patients	O
undergoing	O
FOB	O
under	O
NIV	O
are	O
needed	O
to	O
confirm	O
these	O
preliminary	O
findings	O
.	O

ABSTRACT	O
:	O
The	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
of	O
Middle	O
-	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
proteolytic	O
,	O
deubiquitinating	O
,	O
and	O
deISGylating	O
activities	O
.	O

TITLE	O
:	O
Validity	O
of	O
Outcome	O
Prediction	O
Scoring	O
Systems	O
in	O
Korean	O
Patients	O
with	O
Severe	O
Adult	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Receiving	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Therapy	O
.	O

In	O
addition	O
,	O
replication	O
of	O
nsp14	O
G332A	O
virus	O
was	O
diminished	O
following	O
treatment	O
of	O
cells	O
with	O
IFN	O
-	O
β	O
,	O
and	O
nsp14	O
G332A	O
genomes	O
were	O
translated	O
less	O
efficiently	O
both	O
in	O
vitro	O
and	O
during	O
viral	B-DISO
infection	I-DISO
.	O

Human	O
coronaviruses	O
,	O
most	O
notably	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
,	O
cause	O
severe	O
and	O
lethal	O
human	O
disease	O
.	O

Here	O
,	O
we	O
show	O
that	O
substitution	O
of	O
alanine	O
at	O
G332	O
in	O
the	O
N7	O
-	O
MTase	O
domain	O
of	O
nsp14	O
impairs	O
viral	O
replication	O
,	O
enhances	O
sensitivity	O
to	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
,	O
and	O
reduces	O
viral	O
RNA	O
translation	O
efficiency	O
.	O

TITLE	O
:	O
Echocardiographic	O
parameters	O
of	O
right	O
ventricular	O
function	O
predict	O
mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
pilot	O
study	O
.	O

We	O
then	O
compared	O
a	O
panel	O
of	O
pathogenic	O
,	O
mild	O
and	O
attenuated	O
IBV	O
strains	O
in	O
ex	O
vivo	O
tracheal	O
organ	O
culture	O
(	O
TOC	B-DISO
).	O

Severe	O
ARDS	B-DISO
patients	O
should	O
receive	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	O
support	O
aimed	O
to	O
ensure	O
adequate	O
gas	O
exchange	O
while	O
minimizing	O
the	O
risk	O
of	O
VILI	O
,	O
by	O
promoting	O
lung	O
recruitment	B-DISO
and	O
setting	O
protective	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
a	O
contagious	O
intestinal	B-DISO
disease	I-DISO
caused	O
by	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
that	O
characterized	O
by	O
vomiting	B-DISO
,	O
diarrhea	B-DISO
,	O
and	O
dehydration	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
virus	O
that	O
causes	O
severe	O
viral	B-DISO
pneumonia	I-DISO
in	O
humans	O
,	O
known	O
to	O
have	O
a	O
high	O
mortality	O
rate	O
and	O
a	O
similarity	O
in	O
clinical	O
symptoms	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

PDCoV	O
has	O
been	O
experimentally	O
confirmed	O
to	O
cause	O
diarrhea	B-DISO
in	O
inoculated	O
pigs	O
and	O
need	O
to	O
be	O
differentially	O
diagnosed	O
from	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
the	O
field	O
.	O

This	O
review	O
discusses	O
PDCoV	O
infection	B-DISO
dynamics	O
and	O
appropriate	O
sample	O
collection	O
for	O
diagnostic	O
testing	O
,	O
the	O
commonly	O
used	O
virological	O
and	O
serological	O
methods	O
for	O
PDCoV	O
diagnosis	O
,	O
prevalence	O
and	O
genetic	O
evolution	O
of	O
PDCoVs	O
.	O

ABSTRACT	O
:	O
Helicopter	O
emergency	B-DISO
medical	O
services	O
(	O
HEMS	O
)	O
extend	O
the	O
reach	O
of	O
a	O
tertiary	O
care	O
center	O
significantly	O
.	O

HEMS	O
transport	O
is	O
associated	O
with	O
faster	O
transport	O
time	O
,	O
carries	O
sicker	O
patients	O
,	O
and	O
is	O
associated	O
with	O
higher	O
hospital	O
mortality	O
compared	O
with	O
ground	O
ambulance	O
services	O
for	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
.	O

TITLE	O
:	O
Control	O
of	O
an	O
Outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
a	O
Tertiary	O
Hospital	O
in	O
Korea	O
.	O

All	O
in	O
-	O
hospital	O
transmissions	O
originated	O
from	O
3	O
patients	O
with	O
MERS	O
who	O
also	O
had	O
pneumonia	B-DISO
and	O
productive	B-DISO
cough	I-DISO
.	O

Nursing	O
students	O
who	O
engage	O
in	O
clinical	O
practice	O
at	O
hospitals	O
may	O
have	O
been	O
exposed	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
infection	B-DISO
during	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
outbreak	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
new	O
aggravating	O
inflammatory	O
role	O
for	O
TLR2	O
in	O
MHV3	O
-	O
induced	O
acute	B-DISO
fulminant	I-DISO
hepatitis	I-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
viral	B-DISO
diseases	I-DISO
of	O
poultry	O
,	O
affecting	O
chickens	O
of	O
all	O
ages	O
and	O
causing	O
major	O
economic	O
losses	O
in	O
poultry	O
flocks	O
.	O

Tracheal	O
lesions	O
developed	O
in	O
all	O
infected	O
birds	O
,	O
confirm	O
the	O
ability	O
of	O
the	O
three	O
tested	O
strains	O
to	O
induce	O
respiratory	B-DISO
disease	I-DISO
.	O

Canine	O
parvovirus	B-DISO
and	O
coronavirus	O
were	O
detected	O
in	O
feces	O
by	O
qPCR	O
and	O
qRT	O
-	O
PCR	O
respectively	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Gammacoronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
does	O
induce	O
host	O
shutoff	O
,	O
and	O
we	O
find	O
that	O
its	O
accessory	O
protein	O
5b	O
is	O
indispensable	O
for	O
this	O
function	O
.	O

Adult	O
ECMO	O
may	O
now	O
be	O
rapidly	O
deployed	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
cardiogenic	B-DISO
shock	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
a	O
severe	O
clinical	O
enteric	O
disease	O
in	O
suckling	O
neonates	O
with	O
up	O
to	O
100	O
%	O
mortality	O
,	O
resulting	O
in	O
devastating	O
economic	O
losses	O
to	O
the	O
pork	O
industry	O
in	O
recent	O
years	O
.	O

TITLE	O
:	O
Evolution	O
,	O
antigenicity	O
and	O
pathogenicity	O
of	O
global	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strains	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
these	O
samples	O
for	O
PKV	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
and	O
sapovirus	O
and	O
analyzed	O
the	O
amplified	O
2C	O
gene	O
fragments	O
of	O
PKV	O
.	O

Global	O
health	O
sector	O
has	O
learnt	O
many	O
lessons	O
through	O
the	O
recent	O
outbreak	O
of	O
MERS	O
and	O
SARS	B-DISO
,	O
but	O
the	O
need	O
for	O
identifying	O
new	O
antiviral	O
treatment	O
was	O
not	O
learned	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
severe	B-DISO
sepsis	I-DISO
remains	O
a	O
major	O
challenge	O
in	O
intensive	O
care	O
medicine	O
.	O

LPS	B-DISO
-	O
induced	O
lung	O
injury	O
and	O
inflammatory	B-DISO
response	I-DISO
were	O
significantly	O
prevented	O
by	O
ACE2	O
overexpression	O
and	O
deteriorated	O
by	O
Ace2	O
shRNA	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	B-DISO
-	O
induced	O
ARDS	B-DISO
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	B-DISO
pathway	O
by	O
inhibiting	O
ERK	O
/	O
NF	O
-	O
κB	O
activation	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
is	O
an	O
emerging	O
virus	O
respiratory	B-DISO
infection	I-DISO
.	O

Initial	O
presentation	O
was	O
fever	O
in	O
22	O
(	O
75	O
%)	O
cases	O
,	O
cough	B-DISO
in	O
20	O
(	O
69	O
%)	O
cases	O
,	O
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
in	O
20	O
(	O
69	O
%)	O
cases	O
.	O

TITLE	O
:	O
A	O
Coronavirus	O
Associated	O
with	O
Runting	O
Stunting	O
Syndrome	B-DISO
in	O
Broiler	O
Chickens	O
.	O

The	O
frequency	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
this	O
group	O
of	O
patients	O
suggests	O
an	O
etiologic	O
role	O
in	O
febrile	B-DISO
neutropenia	I-DISO
.	O

Here	O
,	O
we	O
generated	O
a	O
humanized	O
monoclonal	O
antibody	O
(	O
mAb	O
),	O
designated	O
hMS	B-DISO
-	O
1	O
,	O
which	O
targeted	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
with	O
high	O
affinity	O
.	O

TITLE	O
:	O
Obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
might	O
trigger	O
acute	O
pulmonary	B-DISO
embolism	I-DISO
:	O
results	O
from	O
a	O
cohort	O
study	O
.	O

Currently	O
,	O
there	O
are	O
no	O
effective	O
treatments	O
for	O
ALI	O
/	O
ARDS	B-DISO
,	O
and	O
ironically	O
,	O
therapies	O
intended	O
to	O
aid	O
patients	O
(	O
specifically	O
mechanical	O
ventilation	O
,	O
MV	O
)	O
may	O
aggravate	O
the	O
symptoms	O
.	O

This	O
report	O
highlights	O
the	O
potential	O
for	O
virus	B-DISO
shedding	I-DISO
by	O
mildly	O
ill	B-DISO
and	O
asymptomatic	O
case	O
-	O
patients	O
.	O

ABSTRACT	O
:	O
Aluminum	O
phosphide	O
(	O
AlP	O
)	O
poisoning	O
has	O
a	O
high	O
mortality	O
rate	O
despite	O
intensive	O
care	O
management	O
,	O
primarily	O
because	O
it	O
causes	O
severe	O
myocardial	B-DISO
depression	I-DISO
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
the	O
novel	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
),	O
a	O
modified	O
""""	O
heart	O
-	O
lung	O
""""	O
machine	O
,	O
in	O
a	O
specific	O
subset	O
of	O
AlP	O
poisoning	O
patients	O
who	O
had	O
profound	O
myocardial	B-DISO
dysfunction	I-DISO
along	O
with	O
either	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
and	O
/	O
or	O
refractory	O
cardiogenic	B-DISO
shock	I-DISO
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
pulmonary	O
dead	O
-	O
space	O
fraction	O
derived	O
from	O
ventilator	O
volumetric	O
capnography	O
and	O
a	O
validated	O
equation	O
in	O
the	O
survival	O
prediction	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Consecutive	O
VD	O
/	O
VT	O
measurements	O
were	O
obtained	O
based	O
upon	O
a	O
prediction	O
equation	O
validated	O
by	O
Frankenfield	O
et	O
al	O
for	O
dead	O
-	O
space	O
ventilation	O
fraction	O
:	O
VD	O
/	O
VT	O
=	O
0	O
.	O
320	O
+	O
0	O
.	O
0106	O
(	O
PaCO₂	O
-	O
ETCO₂	O
)⁺	O
0	O
.	O
003	O
(	O
RR	O
)⁺	O
0	O
.	O
0015	O
(	O
age	O
)	O
in	O
adult	O
patients	O
who	O
had	O
infection	B-DISO
-	O
related	O
severe	O
pneumonia	B-DISO
and	O
were	O
confirmed	O
as	O
having	O
ARDS	B-DISO
.	O

Overall	O
,	O
46	O
patients	O
with	O
ARDS	B-DISO
met	O
the	O
inclusion	O
criteria	O
and	O
24	O
of	O
them	O
died	O
.	O

TITLE	O
:	O
Lung	O
ultrasonography	O
for	O
assessment	O
of	O
oxygenation	O
response	O
to	O
prone	O
position	O
ventilation	O
in	O
ARDS	B-DISO
.	O

Linezolid	O
clearance	O
was	O
increased	O
in	O
ARDS	B-DISO
patients	O
(	O
by	O
82	O
%)	O
and	O
in	O
patients	O
with	O
elevated	O
fibrinogen	O
or	O
decreased	O
lactate	O
concentrations	O
.	O

CONCLUSIONS	O
:	O
Analysis	O
of	O
state	O
responses	O
to	O
infectious	B-DISO
disease	I-DISO
using	O
international	O
relations	O
theories	O
must	O
consider	O
domestic	O
political	O
factors	O
.	O

A	O
13	O
-	O
year	O
-	O
old	O
male	O
with	O
no	O
past	O
medical	O
history	O
and	O
weighing	O
30kg	O
,	O
presented	O
to	O
hospital	O
with	O
severe	O
urosepsis	B-DISO
complicated	O
by	O
acute	O
kidney	O
injury	O
(	O
Creatinine	O
1422mmol	O
/	O
L	O
;	O
Urea	O
74	O
.	O
2mmol	O
/	O
L	O
,	O
Potassium	O
6	O
.	O
3mmol	O
/	O
L	O
,	O
Sodium	O
137mmol	O
/	O
L	O
)	O
and	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
(	O
pH	O
6	O
.	O
99	O
,	O
HC03	O
1	O
.	O
7mmol	O
/	O
L	O
).	O

Elective	O
intubation	O
was	O
done	O
for	O
respiratory	B-DISO
distress	I-DISO
.	O

Patients	O
were	O
evaluated	O
in	O
terms	O
of	O
maternal	O
complication	B-DISO
,	O
as	O
well	O
as	O
the	O
types	O
of	O
delivery	O
.	O

Secondly	O
,	O
the	O
nine	O
Italian	O
recombinants	O
,	O
which	O
are	O
characterized	O
by	O
three	O
different	O
recombination	O
patterns	O
,	O
probably	O
represent	O
less	O
fitted	B-DISO
strains	O
,	O
because	O
they	O
were	O
less	O
viable	O
with	O
respect	O
to	O
their	O
recombinant	O
parents	O
.	O

Zika	O
virus	O
is	O
a	O
vector	B-DISO
-	I-DISO
borne	I-DISO
disease	I-DISO
transmitted	B-DISO
primarily	O
by	O
the	O
Aedes	O
aegypti	O
mosquito	O
.	O

If	O
after	O
a	O
rapid	O
evaluation	O
,	O
Zika	O
or	O
other	B-DISO
arthropod	I-DISO
-	I-DISO
borne	I-DISO
diseases	I-DISO
are	O
the	O
only	O
concern	O
,	O
isolation	O
(	O
contact	O
,	O
droplet	O
,	O
airborne	O
)	O
is	O
unnecessary	O
.	O

TITLE	O
:	O
Successful	O
weaning	O
from	O
65	O
-	O
day	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
in	O
influenza	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
on	O
inanimate	O
surfaces	O
:	O
A	O
risk	O
for	O
health	O
care	O
transmission	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
life	O
-	O
saving	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
pregnant	O
woman	O
with	O
status	B-DISO
asthmaticus	I-DISO
.	O

Severe	O
respiratory	B-DISO
failure	I-DISO
during	O
pregnancy	O
can	O
worsen	O
maternal	O
and	O
fetal	O
outcomes	O
.	O

Despite	O
rescue	O
therapies	O
such	O
as	O
pressure	O
control	O
ventilation	O
with	O
high	O
inspiratory	O
pressures	O
,	O
inhaled	O
beta2	O
agonists	O
and	O
antimuscarinic	O
drugs	O
,	O
intravenous	O
salbutamol	O
,	O
methylprednisolone	O
and	O
magnesium	O
sulfate	O
,	O
her	O
condition	B-DISO
gradually	O
deteriorated	O
.	O

Veno	O
-	O
venous	O
ECMO	O
was	O
initiated	O
for	O
respiratory	O
support	O
and	O
the	O
patient	O
'	O
s	O
clinical	O
condition	B-DISO
as	O
well	O
as	O
the	O
gas	O
exchange	O
improved	O
within	O
the	O
next	O
few	O
days	O
.	O

In	O
patients	O
with	O
severe	O
pneumonia	B-DISO
resulting	O
in	O
ARDS	B-DISO
(	O
ARDSNet	O
-	O
ALVEOLI	O
),	O
plasma	O
leptin	O
levels	O
were	O
found	O
to	O
correlate	O
positively	O
with	O
subsequent	O
mortality	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
association	O
between	O
obesity	B-DISO
and	O
elevated	O
risk	O
of	O
pulmonary	B-DISO
infection	I-DISO
may	O
be	O
driven	O
by	O
hyperleptinemia	O
.	O

ABSTRACT	O
:	O
During	O
the	O
co	O
-	O
evolution	O
of	O
viruses	O
and	O
their	O
hosts	O
,	O
the	O
viruses	O
have	O
evolved	O
numerous	O
strategies	O
to	O
counter	O
and	O
evade	O
host	O
antiviral	O
immune	O
responses	O
in	O
order	O
to	O
establish	O
a	O
successful	O
infection	B-DISO
,	O
replicate	O
and	O
persist	O
in	O
the	O
host	O
.	O

Recently	O
,	O
based	O
on	O
our	O
model	O
of	O
immune	O
signaling	O
,	O
the	O
Signaling	O
Chain	O
HOmoOLigomerization	O
(	O
SCHOOL	O
)	O
model	O
,	O
we	O
suggested	O
specific	O
molecular	O
mechanisms	O
used	O
by	O
different	O
viruses	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
to	O
modulate	O
the	O
host	O
immune	O
response	O
mediated	O
by	O
members	O
of	O
the	O
family	O
of	O
multichain	O
immune	O
recognition	O
receptors	O
(	O
MIRRs	O
).	O

Using	O
the	O
SCHOOL	O
approach	O
and	O
the	O
SARS	B-DISO
-	O
CoV	O
fusion	O
peptide	O
sequence	O
,	O
we	O
rationally	O
designed	O
a	O
novel	O
immunomodulatory	O
peptide	O
that	O
targets	O
TCR	O
.	O

TITLE	O
:	O
Phylogenetic	O
tracking	O
of	O
current	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
strains	O
in	O
the	O
Philippines	O
.	O

Implications	O
for	O
social	O
work	O
practice	O
in	O
an	O
epidemic	O
emergency	B-DISO
are	O
presented	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
continued	O
to	O
cause	O
sporadic	O
outbreaks	O
in	O
Thailand	O
since	O
2007	O
and	O
a	O
pandemic	O
variant	O
containing	O
an	O
insertion	O
and	O
deletion	O
in	O
the	O
spike	O
gene	O
was	O
responsible	O
for	O
outbreaks	O
.	O

TITLE	O
:	O
Transduction	O
of	O
hematopoietic	O
stem	O
cells	O
to	O
stimulate	O
RNA	O
interference	O
against	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

The	O
maximum	O
duration	O
of	O
viral	B-DISO
shedding	I-DISO
from	O
infected	O
camels	O
was	O
2	O
weeks	O
after	O
the	O
first	O
positive	O
test	O
result	O
as	O
detected	O
in	O
nasal	O
swabs	O
and	O
in	O
rectal	O
swabs	O
obtained	O
from	O
infected	O
calves	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
confirm	O
and	O
identify	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
samples	O
from	O
piglets	O
with	O
suggestive	O
clinical	O
signs	O
using	O
virological	O
,	O
histological	O
,	O
and	O
molecular	O
techniques	O
.	O

TITLE	O
:	O
Exportations	O
of	O
Symptomatic	O
Cases	O
of	O
MERS	O
-	O
CoV	O
Infection	B-DISO
to	O
Countries	O
outside	O
the	O
Middle	O
East	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
an	O
outbreak	O
of	O
infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
was	O
detected	O
in	O
the	O
Arabian	O
Peninsula	O
.	O

Incidence	O
of	O
reoperation	O
for	O
bleeding	B-DISO
was	O
2	O
.	O
5	O
%	O
in	O
OPCAB	O
and	O
6	O
%	O
in	O
CABG	O
In	O
the	O
CABG	O
group	O
2	O
%	O
patients	O
developed	O
severe	O
bleeding	B-DISO
complications	O
,	O
3	O
%	O
required	O
ventilation	O
for	O
more	O
than	O
24	O
hour	O
,	O
1	O
%	O
required	O
renal	O
replacement	O
therapy	O
,	O
1	O
%	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
3	O
.	O
5	O
%	O
had	O
neuro	O
-	O
psychiatric	O
manifestations	O
.	O

Aluminum	O
phosphide	O
poisoning	O
causes	O
metabolic	B-DISO
acidosis	I-DISO
,	O
arrhythmia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
,	O
and	O
there	O
is	O
no	O
specific	O
antidote	O
.	O

ABSTRACT	O
:	O
Real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
of	O
sputum	O
samples	O
is	O
commonly	O
used	O
to	O
diagnose	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

IRV	O
significantly	O
improved	O
the	O
PaO2	O
/	O
FiO2	O
from	O
76	O
±	O
27	O
to	O
208	O
±	O
91	O
mmHg	O
without	O
circulatory	O
impairment	B-DISO
.	O

CPV	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
coccidium	O
(	O
10	O
.	O
00	O
%),	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
4	O
.	O
79	O
%),	O
hookworm	O
(	O
2	O
.	O
40	O
%),	O
canine	O
coronavirus	O
(	O
1	O
.	O
11	O
%),	O
roundworm	B-DISO
(	O
1	O
.	O
03	O
%),	O
tapeworm	B-DISO
(	O
0	O
.	O
17	O
%)	O
and	O
Babesia	O
spp	O
.	O

TITLE	O
:	O
The	O
Role	O
of	O
ACTH	O
and	O
Corticosteroids	O
for	O
Sepsis	B-DISO
and	O
Septic	B-DISO
Shock	I-DISO
:	O
An	O
Update	O
.	O

TITLE	O
:	O
A	O
Three	O
-	O
phase	O
Approach	O
for	O
the	O
Early	O
Identification	O
of	O
Acute	O
Lung	O
Injury	O
Induced	O
by	O
Severe	B-DISO
Sepsis	I-DISO
.	O

The	O
final	O
phase	O
is	O
organ	O
dysfunction	O
,	O
caused	O
by	O
pulmonary	B-DISO
veno	I-DISO
-	I-DISO
occlusive	I-DISO
disease	I-DISO
(	O
VOD	O
),	O
fibrosis	B-DISO
,	O
and	O
immunoparalysis	O
induced	O
by	O
EPA	O
.	O

In	O
order	O
to	O
prevent	O
ALI	O
/	O
ARDS	B-DISO
in	O
patients	O
with	O
sepsis	B-DISO
,	O
countermeasures	O
for	O
NET	O
and	O
platelet	O
aggregation	O
should	O
be	O
pre	O
-	O
emptively	O
employed	O
and	O
confirmed	O
by	O
several	O
trials	O
.	O

Severe	O
sleep	B-DISO
disturbance	I-DISO
is	O
a	O
common	O
problem	O
among	O
patients	O
in	O
cardiac	O
care	O
units	O
(	O
CCUs	O
).	O

The	O
involvement	O
of	O
coronavirus	O
-	O
induced	O
stress	O
responses	O
and	O
translational	O
control	O
in	O
viral	B-DISO
pathogenesis	I-DISO
will	O
also	O
be	O
briefly	O
discussed	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	B-DISO
Infection	I-DISO
Inhibits	O
Interferon	O
Signaling	O
by	O
Targeted	O
Degradation	O
of	O
STAT1	O
.	O

On	O
day	O
25	O
,	O
he	O
developed	O
fever	O
and	O
respiratory	B-DISO
distress	I-DISO
with	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
,	O
suggesting	O
differentiation	O
syndrome	B-DISO
(	O
DS	O
)	O
caused	O
by	O
ATRA	O
.	O

No	O
leukemic	O
cell	O
infiltration	B-DISO
was	O
observed	O
.	O

He	O
was	O
diagnosed	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
was	O
treated	O
with	O
antibiosis	O
,	O
oxygen	O
therapy	O
,	O
and	O
required	O
non	O
-	O
invasive	O
ventilation	O
.	O

ABSTRACT	O
:	O
Severe	O
acidosis	B-DISO
can	O
cause	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
failure	O
in	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
patients	O
with	O
acute	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
AHRF	O
).	O

The	O
baseline	O
rates	O
of	O
severe	O
acidosis	B-DISO
were	O
similar	O
among	O
the	O
groups	O
(	O
45	O
%	O
in	O
the	O
ACPE	O
group	O
,	O
41	O
%	O
in	O
the	O
COPD	B-DISO
group	O
,	O
and	O
38	O
%	O
in	O
the	O
OHS	B-DISO
group	O
).	O

The	O
NIV	O
failure	O
rates	O
were	O
similar	O
between	O
the	O
patients	O
with	O
severe	O
and	O
non	O
-	O
severe	O
acidosis	B-DISO
in	O
the	O
three	O
disease	O
groups	O
(	O
ACPE	O
,	O
16	O
%	O
vs	O
.	O
12	O
%;	O
COPD	B-DISO
,	O
7	O
%	O
vs	O
.	O
7	O
%;	O
and	O
OHS	B-DISO
,	O
11	O
%	O
vs	O
.	O
4	O
%).	O

This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
Presepsin	O
in	O
ICU	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
SS	O
),	O
septic	B-DISO
shock	I-DISO
(	O
SSh	O
)	O
and	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
sCAP	O
).	O

Plasma	O
levels	O
of	O
Presepsin	O
and	O
PCT	B-DISO
were	O
significantly	O
higher	O
in	O
septic	O
than	O
in	O
non	O
-	O
septic	O
patients	O
and	O
in	O
SSh	O
as	O
compared	O
to	O
others	O
.	O

In	O
the	O
72	O
/	O
144	O
patients	O
admitted	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
the	O
capability	O
of	O
Presepsin	O
to	O
diagnose	O
sCAP	O
was	O
significantly	O
better	O
than	O
PCT	B-DISO
.	O

Presepsin	O
levels	O
were	O
also	O
predictive	O
of	O
ICU	O
mortality	O
in	O
sepsis	B-DISO
and	O
in	O
sCAP	O
patients	O
.	O

Two	O
did	O
not	O
receive	O
pressure	B-DISO
ulcer	I-DISO
preventive	O
measures	O
and	O
subsequently	O
developed	O
multiple	O
necrotic	O
facial	O
pressure	B-DISO
ulcers	I-DISO
related	O
to	O
prone	O
positioning	O
for	O
treatment	O
of	O
ARDS	B-DISO
.	O

This	O
study	O
uses	O
Affymetrix	O
microarray	O
analysis	O
to	O
compare	O
differential	O
spinal	O
cord	B-DISO
mRNA	O
levels	O
between	O
mice	O
infected	O
with	O
demyelinating	O
and	O
non	O
-	O
demyelinating	O
strains	O
of	O
MHV	O
to	O
identify	O
host	O
immune	O
genes	O
expressed	O
in	O
this	O
demyelinating	B-DISO
disease	I-DISO
model	O
.	O

Similarly	O
,	O
the	O
identity	O
of	O
viral	O
proteins	O
involved	O
in	O
the	O
modulation	O
of	O
host	O
cell	O
pathways	O
influencing	O
CoV	O
pathogenesis	B-DISO
should	O
be	O
analyzed	O
.	O

Pneumothorax	B-DISO
,	O
pneumatocele	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
pulmonary	B-DISO
abscess	I-DISO
,	O
bronchopleural	B-DISO
fistula	I-DISO
,	O
bilateral	O
hemorrhagic	B-DISO
pleural	I-DISO
effusion	I-DISO
and	O
pyopneumothorax	B-DISO
were	O
previously	O
reported	O
.	O

Hereby	O
we	O
report	O
a	O
patient	O
hospitalized	O
due	O
to	O
aspiration	B-DISO
pneumonia	I-DISO
who	O
developed	O
pleurisy	B-DISO
and	O
pneumothorax	B-DISO
after	O
drinking	O
paint	O
thinner	O
.	O

We	O
documented	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
confirmed	O
by	O
real	O
-	O
time	O
PCR	O
testing	O
of	O
sputum	O
samples	O
.	O

Our	O
results	O
showed	O
increased	O
transmission	O
potential	O
of	O
MERS	O
-	O
CoV	O
from	O
a	O
single	O
patient	O
in	O
an	O
overcrowded	O
emergency	B-DISO
room	O
and	O
provide	O
compelling	O
evidence	O
that	O
health	O
-	O
care	O
facilities	O
worldwide	O
need	O
to	O
be	O
prepared	O
for	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Bedside	O
goal	O
-	O
directed	O
ultrasound	O
is	O
a	O
powerful	O
tool	O
for	O
rapid	O
differential	O
diagnosis	O
and	O
monitoring	O
of	O
cardiopulmonary	B-DISO
disease	I-DISO
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
population	O
.	O

The	O
questionnaire	O
was	O
modified	O
for	O
this	O
study	O
to	O
include	O
26	O
items	O
that	O
were	O
divided	O
into	O
three	O
main	O
domains	O
of	O
interest	O
:	O
(	O
1	O
)	O
the	O
ability	O
to	O
care	O
for	O
critically	B-DISO
ill	I-DISO
MERS	O
-	O
CoV	O
patients	O
;	O
(	O
2	O
)	O
laboratory	O
capacity	O
to	O
diagnose	O
MERS	O
-	O
CoV	O
and	O
blood	O
bank	O
ability	O
to	O
prepare	O
convalescent	O
plasma	O
;	O
and	O
(	O
3	O
),	O
research	O
capacity	O
to	O
conduct	O
randomized	O
controlled	O
trials	O
.	O

Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
still	O
has	O
a	O
high	O
-	O
mortality	O
rate	O
,	O
but	O
ECMO	O
may	O
be	O
able	O
to	O
improve	O
the	O
outcome	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
severe	O
pulmonary	B-DISO
tuberculosis	I-DISO
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
A	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

He	O
was	O
also	O
administered	O
anti	O
-	O
tuberculosis	B-DISO
drugs	O
and	O
received	O
systemic	O
corticosteroid	O
therapy	O
.	O

The	O
PRESERVE	O
(	O
Predicting	O
death	O
for	O
severe	O
ARDS	B-DISO
on	O
VV	O
-	O
ECMO	O
),	O
ECMOnet	O
,	O
Respiratory	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Survival	O
Prediction	O
(	O
RESP	O
)	O
score	O
,	O
a	O
center	O
-	O
specific	O
model	O
developed	O
for	O
inter	O
-	O
hospital	O
transfers	O
receiving	O
ECMO	O
,	O
and	O
the	O
classical	O
risk	O
-	O
prediction	O
scores	O
of	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
II	O
and	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
were	O
calculated	O
.	O

TITLE	O
:	O
Productive	O
replication	O
of	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
peripheral	O
blood	O
monocytic	O
cells	O
,	O
a	O
strategy	O
for	O
viral	O
dissemination	O
and	O
kidney	B-DISO
infection	I-DISO
in	O
chickens	O
.	O

Retrospective	O
analysis	O
of	O
disease	O
spectrum	O
,	O
EN	O
approach	O
,	O
preparation	O
,	O
speed	O
and	O
time	O
as	O
well	O
as	O
adverse	O
reactions	O
and	O
outcomes	O
in	O
47	O
pediatric	O
patients	O
with	O
gastrointestinal	B-DISO
disease	I-DISO
underwent	O
EN	O
therapy	O
during	O
July	O
2014	O
to	O
March	O
2015	O
.	O

ABSTRACT	O
:	O
Population	O
-	O
based	O
serologic	O
studies	O
are	O
a	O
vital	O
tool	O
for	O
understanding	O
the	O
epidemiology	O
of	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
,	O
including	O
the	O
early	O
assessment	O
of	O
the	O
transmissibility	O
and	O
severity	O
of	O
the	O
2009	O
influenza	B-DISO
pandemic	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

An	O
evolutive	O
haematological	O
disease	O
(	O
HR	O
1	O
.	O
71	O
;	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
2	O
.	O
58	O
),	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
HR	O
1	O
.	O
81	O
;	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
2	O
.	O
69	O
)	O
and	O
need	O
for	O
renal	O
replacement	O
therapy	O
(	O
HR	O
2	O
.	O
24	O
;	O
95	O
%	O
CI	O
1	O
.	O
52	O
-	O
3	O
.	O
31	O
)	O
were	O
associated	O
with	O
long	O
-	O
term	O
mortality	O
.	O

TITLE	O
:	O
High	O
-	O
resolution	O
CT	O
findings	O
of	O
idiopathic	B-DISO
pneumonia	I-DISO
syndrome	I-DISO
after	O
haematopoietic	O
stem	O
cell	O
transplantation	O
:	O
based	O
on	O
the	O
updated	O
concept	O
of	O
idiopathic	B-DISO
pneumonia	I-DISO
syndrome	I-DISO
by	O
the	O
American	O
Thoracic	B-DISO
Society	O
in	O
2011	O
.	O

Recently	O
,	O
the	O
American	O
Thoracic	B-DISO
Society	O
(	O
ATS	B-DISO
)	O
updated	O
the	O
concept	O
of	O
IPS	B-DISO
and	O
extended	O
the	O
concept	O
to	O
a	O
wider	O
range	O
;	O
it	O
defined	O
IPS	B-DISO
as	O
""""	O
an	O
idiopathic	O
syndrome	B-DISO
of	O
pneumopathy	B-DISO
after	O
HSCT	O
,	O
with	O
evidence	O
of	O
widespread	O
alveolar	O
injury	O
and	O
in	O
which	O
infectious	B-DISO
aetiologies	O
and	O
cardiac	O
dysfunction	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
or	O
iatrogenic	O
fluid	B-DISO
overload	I-DISO
have	O
been	O
excluded	O
.	O

No	O
vaccine	O
is	O
available	O
against	O
MERS	O
-	O
CoV	O
and	O
therapeutic	O
options	O
for	O
MERS	O
-	O
CoV	O
infections	B-DISO
are	O
limited	O
to	O
palliative	O
and	O
supportive	O
care	O
.	O

Although	O
TRPV4	O
knockout	O
mice	O
show	O
relatively	O
mild	O
phenotypes	O
,	O
some	O
mutations	O
in	O
TRPV4	O
cause	O
severe	O
developmental	O
abnormalities	O
,	O
such	O
as	O
the	O
skeletal	O
dyplasia	O
and	O
arthropathy	B-DISO
.	O

Regulated	O
TRPV4	O
function	O
is	O
also	O
essential	O
for	O
healthy	O
cardiovascular	O
system	O
function	O
as	O
a	O
potent	O
agonist	O
compromises	O
endothelial	O
cell	O
function	O
,	O
leading	O
to	O
vascular	B-DISO
collapse	I-DISO
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
surgical	O
situation	O
,	O
length	O
of	O
ICU	O
stay	O
,	O
and	O
occurrence	O
of	O
major	O
complications	O
including	O
infection	B-DISO
,	O
ARDS	B-DISO
,	O
and	O
MODS	B-DISO
/	O
MOF	B-DISO
in	O
patients	O
among	O
these	O
three	O
years	O
(	O
with	O
χ	O
(	O
2	O
)	O
values	O
from	O
0	O
.	O
48	O
to	O
2	O
.	O
43	O
,	O
W	O
=	O
2	O
.	O
100	O
,	O
P	O
values	O
above	O
0	O
.	O
05	O
).	O

Death	O
-	O
associated	O
exposure	O
factors	O
were	O
age	O
,	O
ISS	B-DISO
,	O
APACHE	O
Ⅱ	O
score	O
,	O
urea	O
volume	O
on	O
the	O
first	O
day	O
,	O
platelet	O
count	O
,	O
albumin	O
,	O
and	O
blood	O
sodium	O
.	O

Early	O
recognition	O
of	O
cases	O
and	O
rapid	O
implementation	O
of	O
infection	B-DISO
control	O
measures	O
are	O
necessary	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
with	O
autoimmune	B-DISO
SPS	B-DISO
diagnosed	O
during	O
an	O
episode	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
secondary	O
to	O
repetitive	O
episodes	O
of	O
apnea	B-DISO
,	O
requiring	O
intensive	O
care	O
.	O

Patients	O
were	O
followed	O
for	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
acute	O
kidney	O
injury	O
(	O
AKI	O
),	O
and	O
mortality	O
.	O

Neutropenia	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
AKI	O
(	O
RR	O
1	O
.	O
28	O
;	O
95	O
%	O
CI	O
1	O
.	O
04	O
,	O
1	O
.	O
57	O
;	O
p	O
=	O
0	O
.	O
03	O
),	O
but	O
not	O
ARDS	B-DISO
(	O
RR	O
0	O
.	O
90	O
;	O
95	O
%	O
CI	O
0	O
.	O
70	O
,	O
1	O
.	O
17	O
;	O
p	O
=	O
0	O
.	O
42	O
)	O
or	O
30	O
-	O
day	O
mortality	O
(	O
RR	O
1	O
.	O
05	O
;	O
95	O
%	O
CI	O
0	O
.	O
85	O
,	O
1	O
.	O
31	O
;	O
p	O
=	O
0	O
.	O
65	O
).	O

ABSTRACT	O
:	O
Objectives	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
measurement	O
of	O
acute	O
phase	O
proteins	O
(	O
APPs	O
)	O
as	O
a	O
diagnostic	O
tool	O
to	O
differentiate	O
between	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
and	O
other	O
diseases	O
in	O
cats	O
with	O
body	O
cavity	B-DISO
effusions	B-DISO
.	O

Cats	O
without	O
FIP	B-DISO
were	O
further	O
subdivided	O
into	O
three	O
subgroups	O
:	O
cardiac	B-DISO
disease	I-DISO
,	O
neoplasia	B-DISO
and	O
other	O
diseases	O
.	O

TITLE	O
:	O
Maternal	O
antibody	O
decay	B-DISO
and	O
antibody	O
-	O
mediated	O
immune	O
responses	O
in	O
chicken	O
pullets	O
fed	O
prebiotics	O
and	O
synbiotics	O
.	O

TITLE	O
:	O
Korean	O
Asthma	B-DISO
Guideline	O
2014	O
:	O
Summary	O
of	O
Major	O
Updates	O
to	O
the	O
Korean	O
Asthma	B-DISO
Guideline	O
2014	O
.	O

ADM	O
may	O
be	O
associated	O
with	O
rapidly	O
progressive	O
course	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ADM	O
-	O
ILD	O
)	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
.	O

TITLE	O
:	O
Collaborative	O
Intervention	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
:	O
Rapid	O
Response	O
Team	O
.	O

The	O
Rapid	O
Response	O
Team	O
(	O
RRT	O
)	O
was	O
organized	O
after	O
the	O
Korean	O
government	O
'	O
s	O
calling	O
for	O
specialists	O
that	O
were	O
composed	O
of	O
15	O
Infectious	B-DISO
disease	I-DISO
Doctors	O
and	O
2	O
Infection	B-DISO
Control	O
professionals	O
on	O
the	O
8th	O
of	O
June	O
2015	O
.	O

ABSTRACT	O
:	O
A	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
South	O
Korea	O
in	O
2015	O
started	O
by	O
a	O
single	O
imported	O
case	O
and	O
was	O
amplified	O
by	O
intra	O
-	O
and	O
inter	O
-	O
hospital	O
transmission	O
.	O

We	O
describe	O
two	O
hospital	O
outbreaks	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
Daejeon	O
caused	O
by	O
a	O
single	O
patient	O
who	O
was	O
infected	O
by	O
the	O
first	O
Korean	O
case	O
of	O
MERS	O
.	O

RESULTS	O
:	O
In	O
Daejeon	O
,	O
a	O
MERS	O
patient	O
(	O
the	O
index	O
case	O
)	O
was	O
hospitalized	O
at	O
Hospital	O
A	O
in	O
the	O
first	O
week	O
of	O
illness	O
and	O
was	O
transferred	O
to	O
Hospital	O
B	O
because	O
of	O
pneumonia	B-DISO
progression	O
in	O
the	O
second	O
week	O
of	O
illness	O
,	O
where	O
he	O
received	O
a	O
bronchoscopic	O
examination	O
and	O
nebulizer	O
therapy	O
.	O

TITLE	O
:	O
Epidemiologic	O
Parameters	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Outbreak	O
in	O
Korea	O
,	O
2015	O
.	O

ABSTRACT	O
:	O
Epidemiologic	O
parameters	O
are	O
important	O
in	O
planning	O
infection	B-DISO
control	O
policies	O
during	O
the	O
outbreak	O
of	O
emerging	O
infections	B-DISO
.	O

At	O
admission	O
,	O
leukopenia	B-DISO
(	O
42	O
.	O
6	O
%),	O
thrombocytopenia	O
(	O
46	O
.	O
6	O
%),	O
and	O
elevation	O
of	O
aspartate	O
aminotransferase	O
(	O
42	O
.	O
7	O
%)	O
were	O
observed	O
.	O

Pneumonia	B-DISO
was	O
detected	O
in	O
68	O
.	O
3	O
%	O
of	O
patients	O
at	O
admission	O
and	O
developed	O
in	O
80	O
.	O
8	O
%	O
during	O
the	O
disease	O
course	O
.	O

Most	O
of	O
the	O
patients	O
(	O
80	O
.	O
72	O
%)	O
were	O
aware	O
of	O
the	O
infection	B-DISO
control	O
measures	O
to	O
be	O
followed	O
by	O
dentist	O
and	O
138	O
patients	O
claimed	O
they	O
took	O
some	O
precaution	O
when	O
present	O
inside	O
the	O
dental	O
college	O
.	O

In	O
septic	O
patients	O
with	O
ARDS	B-DISO
complement	O
activation	O
products	O
were	O
found	O
to	O
be	O
elevated	O
in	O
the	O
plasma	O
.	O

The	O
presence	O
of	O
the	O
HEV	O
helicase	O
in	O
cis	B-DISO
dramatically	O
increases	O
the	O
binding	O
of	O
the	O
macro	O
domain	O
to	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
stimulates	O
the	O
de	O
-	O
PARylation	O
activity	O
.	O

Here	O
,	O
we	O
show	O
that	O
viral	O
macro	O
domains	O
reverse	O
cellular	O
ADP	O
-	O
ribosylation	O
,	O
potentially	O
cutting	O
the	O
signal	O
of	O
a	O
viral	B-DISO
infection	I-DISO
in	O
the	O
cell	O
.	O

Eligible	O
patients	O
will	O
be	O
randomly	O
allocated	O
to	O
two	O
arms	B-DISO
:	O
(	O
i	O
)	O
conventional	O
treatment	O
without	O
dexamethasone	O
,	O
(	O
ii	O
)	O
conventional	O
treatment	O
plus	O
dexamethasone	O
.	O

Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Infection	B-DISO
in	O
the	O
United	O
States	O
,	O
2014	O
.	O

RESULTS	O
:	O
Applying	O
the	O
same	O
process	O
used	O
to	O
trace	O
and	O
notify	O
travelers	O
during	O
routine	O
investigations	O
,	O
such	O
as	O
those	O
for	O
tuberculosis	B-DISO
or	O
measles	B-DISO
,	O
CDC	O
was	O
able	O
to	O
notify	O
most	O
travelers	O
of	O
their	O
potential	O
exposure	O
to	O
MERS	O
-	O
CoV	O
during	O
the	O
first	O
few	O
days	O
of	O
each	O
investigation	O
.	O

The	O
outcome	O
suggests	O
that	O
the	O
use	O
of	O
ECMO	O
should	O
be	O
considered	O
for	O
patients	O
with	O
ARDS	B-DISO
induced	O
from	O
scrub	B-DISO
typhus	I-DISO
.	O

TITLE	O
:	O
Rapid	O
one	O
-	O
step	O
construction	O
of	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
-	O
CoV	O
)	O
infectious	B-DISO
clone	O
system	O
by	O
homologous	O
recombination	O
.	O

Since	O
the	O
development	O
of	O
the	O
first	O
viral	O
infectious	B-DISO
clone	O
system	O
for	O
the	O
poliovirus	O
,	O
novel	O
strategies	O
of	O
viral	O
genome	O
construction	O
have	O
allowed	O
for	O
the	O
assembly	O
of	O
viral	O
genomes	O
across	O
the	O
identified	O
viral	O
families	O
.	O

RESULTS	O
:	O
This	O
work	O
examines	O
the	O
available	O
strategies	O
for	O
overcoming	O
the	O
obstacles	O
of	O
assembling	O
the	O
long	O
and	O
complex	O
RNA	O
genomes	O
of	O
coronaviruses	O
and	O
reports	O
one	O
-	O
step	O
construction	O
of	O
an	O
infectious	B-DISO
clone	O
system	O
for	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
by	O
homologous	O
recombination	O
in	O
S	O
.	O
cerevisiae	O
.	O

Abelson	O
Kinase	O
Inhibitors	O
Are	O
Potent	O
Inhibitors	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Fusion	O
.	O

TITLE	O
:	O
Parenchymal	O
lung	O
involvement	O
in	O
adult	B-DISO
-	I-DISO
onset	I-DISO
Still	I-DISO
disease	I-DISO
:	O
A	O
STROBE	O
-	O
compliant	O
case	O
series	O
and	O
literature	O
review	O
.	O

In	O
the	O
latter	O
,	O
a	O
nonspecific	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
computed	O
tomography	O
pattern	O
prevailed	O
in	O
the	O
lower	O
lobes	O
,	O
pulmonary	O
function	O
tests	O
showed	O
a	O
restrictive	O
lung	O
function	O
,	O
the	O
alveolar	O
differential	O
cell	O
count	O
was	O
neutrophilic	O
in	O
half	O
of	O
the	O
cases	O
,	O
and	O
the	O
histological	O
findings	O
were	O
consistent	O
with	O
bronchiolitis	B-DISO
and	O
nonspecific	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
.	O

Most	O
PLIs	O
occurred	O
during	O
the	O
systemic	O
onset	O
of	O
AOSD	O
.	O
PLI	O
may	O
occur	O
in	O
5	O
%	O
of	O
AOSDs	O
,	O
of	O
which	O
ARDS	B-DISO
is	O
the	O
most	O
severe	O
.	O

Participants	O
,	O
on	O
average	O
,	O
suffered	B-DISO
0	O
.	O
49	O
ILI	O
,	O
and	O
0	O
.	O
29	O
virus	O
-	O
positive	O
ILI	O
episodes	O
,	O
with	O
no	O
significant	O
effects	O
of	O
gender	O
,	O
age	O
,	O
or	O
household	O
size	O
.	O

In	O
this	O
study	O
we	O
demonstrated	O
that	O
the	O
last	O
39	O
amino	O
acid	O
stretches	B-DISO
of	O
Alphacoronavirus	O
spike	O
cytoplasmic	O
domains	O
of	O
the	O
human	O
coronavirus	O
229E	O
,	O
NL63	O
,	O
and	O
the	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
TGEV	O
interact	O
with	O
tubulin	O
alpha	O
and	O
beta	O
chains	O
.	O

Logistic	O
regression	O
revealed	O
that	O
patients	O
with	O
ILI	O
/	O
ARI	O
and	O
CRP	O
≥	O
5	O
mg	O
/	O
L	O
were	O
60	O
times	O
more	O
likely	O
to	O
have	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
than	O
other	O
viral	O
agents	O
(	O
OR	O
=	O
60	O
.	O
0	O
,	O
95	O
%	O
CI	O
=	O
2	O
.	O
65	O
to	O
1	O
,	O
358	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
010	O
).	O

Severe	O
disease	O
and	O
fatal	O
pneumonia	B-DISO
may	O
occur	O
in	O
elderly	O
and	O
immunocompromised	O
adults	O
.	O

Though	O
sensitive	O
molecular	O
diagnostics	O
are	O
available	O
to	O
rapidly	O
diagnose	O
HPIV	O
infection	B-DISO
,	O
effective	O
antiviral	O
therapies	O
are	O
not	O
available	O
.	O

The	O
high	O
mortality	O
rates	O
in	O
family	O
-	O
based	O
and	O
hospital	O
-	O
based	O
outbreaks	O
were	O
reported	O
among	O
patients	O
with	O
comorbidities	O
such	O
as	O
diabetes	B-DISO
and	O
renal	B-DISO
failure	I-DISO
.	O

The	O
major	O
complications	O
reported	O
in	O
fatal	O
cases	O
are	O
hyperkalemia	O
with	O
associated	O
ventricular	B-DISO
tachycardia	I-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
pericarditis	B-DISO
,	O
and	O
multiorgan	B-DISO
failure	I-DISO
.	O

Recent	O
examples	O
of	O
newly	O
emerged	O
threats	O
include	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

Its	O
most	O
severe	O
form	O
is	O
a	O
classic	O
model	O
of	O
sepsis	B-DISO
,	O
provoking	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
acute	O
kidney	O
injury	O
(	O
AKI	O
),	O
with	O
associated	O
mortality	O
that	O
remains	O
unacceptably	O
high	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
preservation	O
of	O
the	O
immunotolerant	O
properties	O
of	O
LSECs	O
during	O
acute	B-DISO
viral	I-DISO
hepatitis	I-DISO
is	O
imperative	O
in	O
order	O
to	O
limit	O
hepatic	O
inflammation	B-DISO
and	O
damage	O
.	O

Viral	B-DISO
hepatitis	I-DISO
B	I-DISO
and	O
C	O
infections	B-DISO
are	O
serious	O
health	O
problems	O
affecting	O
over	O
350	O
million	O
and	O
170	O
million	O
people	O
worldwide	O
,	O
respectively	O
.	O

These	O
results	O
highlight	O
a	O
new	O
virus	O
-	O
promoted	O
mechanism	O
of	O
exacerbation	O
of	O
liver	O
inflammatory	B-DISO
response	I-DISO
during	O
acute	B-DISO
hepatitis	I-DISO
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
our	O
study	O
identified	O
CEACAM5	O
as	O
a	O
novel	O
cell	O
surface	O
binding	O
target	O
of	O
MERS	O
-	O
CoV	O
that	O
facilitates	O
MERS	O
-	O
CoV	O
infection	B-DISO
by	O
augmenting	O
the	O
attachment	O
of	O
the	O
virus	O
to	O
the	O
host	O
cell	O
surface	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
Sleep	B-DISO
-	I-DISO
Disordered	I-DISO
Breathing	I-DISO
and	O
Patient	O
Characteristics	O
in	O
a	O
Coronary	B-DISO
Artery	I-DISO
Disease	I-DISO
Cohort	O
Undergoing	O
Cardiovascular	O
Rehabilitation	O
.	O

SDB	O
is	O
a	O
highly	O
prevalent	O
comorbidity	O
in	O
patients	O
with	O
CAD	B-DISO
,	O
particularly	O
those	O
who	O
have	O
undergone	O
CABG	O
.	O

Early	O
diagnosis	O
and	O
intervention	O
has	O
the	O
potential	O
to	O
have	O
a	O
beneficial	O
effect	O
on	O
CAD	B-DISO
prognosis	O
.	O

Furthermore	O
,	O
neutrophils	O
isolated	O
from	O
the	O
blood	O
or	O
BAL	O
fluid	O
differentially	O
regulated	O
the	O
cell	O
surface	O
expression	O
of	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
1	O
and	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
2	O
during	O
ARDS	B-DISO
.	O

This	O
study	O
highlights	O
important	O
inflammatory	O
chemokines	O
involved	O
in	O
regulating	O
neutrophil	B-DISO
migration	I-DISO
,	O
which	O
may	O
have	O
potential	O
value	O
as	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
protective	O
efficacy	O
of	O
recombinant	O
fusion	O
proteins	O
containing	O
spike	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
hemagglutinin	O
of	O
H3N2	O
influenza	B-DISO
virus	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Surgical	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
an	O
extremely	O
critical	O
condition	B-DISO
which	O
may	O
occur	O
after	O
major	O
lung	O
resection	O
.	O

Lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
was	O
administered	O
at	O
2	O
hours	O
after	O
surgery	O
.	O

LPS	B-DISO
administration	O
after	O
left	O
pneumonectomy	O
could	O
induce	O
the	O
severe	O
lung	O
injury	O
.	O

Compared	O
with	O
children	O
with	O
other	O
enteroviruses	O
and	O
rhinoviruses	O
,	O
children	O
with	O
enterovirus	O
D68	O
were	O
more	O
likely	O
to	O
have	O
a	O
history	O
of	O
asthma	B-DISO
(	O
64	O
%	O
vs	O
45	O
%)	O
or	O
multiple	O
prior	O
wheezing	B-DISO
episodes	O
(	O
54	O
%	O
vs	O
34	O
%;	O
p	O
<	O
0	O
.	O
01	O
for	O
both	O
).	O

Leptospirosis	B-DISO
presenting	O
as	O
Weil	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
is	O
a	O
common	O
cause	O
of	O
renal	O
and	O
hyperbilirubinemia	B-DISO
in	O
endemic	O
areas	O
.	O

Nonetheless	O
,	O
the	O
risk	O
of	O
a	O
serious	O
public	O
health	O
impact	O
to	O
Singapore	O
in	O
the	O
event	O
of	O
an	O
imported	O
case	O
of	O
MERS	O
would	O
be	O
mitigated	O
by	O
its	O
strong	O
health	O
-	O
care	O
system	O
and	O
established	O
infection	B-DISO
control	O
practices	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
CD14	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
),	O
and	O
the	O
activity	O
of	O
SMS	B-DISO
and	O
expression	O
of	O
SMS2	O
were	O
significantly	O
upregulated	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
)	O
in	O
the	O
model	O
group	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
degree	O
of	O
lung	O
injury	O
was	O
reduced	O
during	O
the	O
acute	O
inflammatory	B-DISO
reaction	I-DISO
when	O
NF	O
‑	O
κB	O
was	O
inhibited	O
,	O
and	O
that	O
the	O
expression	O
of	O
SMS2	O
may	O
affect	O
the	O
induction	O
of	O
the	O
NF	O
‑	O
κB	O
pathway	O
by	O
LPS	B-DISO
through	O
CD14	O
.	O

TITLE	O
:	O
Inferior	B-DISO
vena	I-DISO
cava	I-DISO
thrombosis	I-DISO
as	O
a	O
cause	O
of	O
haemolysis	B-DISO
in	O
a	O
patient	O
on	O
ECMO	O
.	O

ABSTRACT	O
:	O
Haemolysis	B-DISO
,	O
thrombosis	B-DISO
and	O
haemorrhage	B-DISO
are	O
well	O
-	O
documented	O
complications	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Eosinophilic	B-DISO
Lung	I-DISO
Diseases	O
.	O

The	O
transfer	O
of	O
total	O
IgG	O
with	O
the	O
colostrum	O
and	O
the	O
humoral	O
immunity	O
of	O
the	O
calf	O
could	O
not	O
prevent	O
any	O
infection	B-DISO
with	O
Cryptosporidium	O
,	O
but	O
the	O
severity	O
of	O
the	O
diarrhea	B-DISO
symptoms	I-DISO
decreased	O
with	O
increasing	O
total	O
IgG	O
concentrations	O
.	O

Halofuginone	O
(	O
Halocur	O
®)	O
is	O
approved	O
for	O
prophylaxis	O
against	O
cryptosporidiosis	B-DISO
,	O
but	O
it	O
showed	O
no	O
effect	O
on	O
the	O
excretion	O
of	O
Cryptosporidium	O
oocysts	O
in	O
the	O
present	O
study	O
.	O

Patients	O
lacking	O
the	O
predictive	O
factors	O
did	O
not	O
progress	O
to	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
Berlin	O
definition	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
been	O
applied	O
to	O
military	O
burns	O
resulting	O
from	O
combat	O
-	O
related	O
trauma	O
,	O
but	O
has	O
not	O
been	O
widely	O
studied	O
among	O
civilian	O
burns	O
.	O

Patients	O
with	O
ARDS	B-DISO
had	O
larger	O
%	O
TBSA	O
burns	O
[	O
30	O
.	O
5	O
(	O
23	O
.	O
1	O
-	O
47	O
.	O
0	O
)	O
vs	O
.	O
24	O
.	O
8	O
(	O
17	O
.	O
1	O
-	O
35	O
),	O
p	O
=	O
0	O
.	O
007	O
],	O
larger	O
FT	O
burns	O
[	O
20	O
.	O
5	O
(	O
5	O
.	O
4	O
-	O
35	O
.	O
5	O
)	O
vs	O
.	O
7	O
(	O
0	O
-	O
22	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
001	O
],	O
but	O
had	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
inhalation	O
injury	O
(	O
p	O
=	O
0	O
.	O
216	O
),	O
compared	O
to	O
those	O
without	O
ARDS	B-DISO
.	O

Worsening	O
severity	O
of	O
ARDS	B-DISO
was	O
associated	O
with	O
increased	O
days	O
of	O
mechanical	O
ventilation	O
in	O
survivors	O
(	O
p	O
=	O
0	O
.	O
001	O
),	O
a	O
reduction	O
in	O
ventilator	O
-	O
free	O
days	O
/	O
1st	O
30	O
days	O
in	O
all	O
subjects	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
and	O
a	O
strong	O
indication	O
of	O
increased	O
mortality	O
(	O
0	O
%	O
in	O
mild	O
ARDS	B-DISO
vs	O
.	O
50	O
%	O
in	O
severe	O
ARDS	B-DISO
,	O
unadjusted	O
p	O
=	O
0	O
.	O
02	O
).	O

ARDS	B-DISO
is	O
common	O
among	O
mechanically	O
ventilated	O
civilian	O
burn	O
patients	O
,	O
and	O
develops	O
early	O
after	O
burn	O
.	O

The	O
extent	O
of	O
full	O
thickness	O
burn	O
predicted	O
development	O
of	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

Neither	O
moderate	O
ARDS	B-DISO
nor	O
severe	O
ARDS	B-DISO
were	O
significant	O
predictors	O
of	O
death	O
.	O

Our	O
model	O
was	O
able	O
to	O
provide	O
a	O
good	O
fit	B-DISO
to	O
the	O
trajectory	O
of	O
the	O
outbreak	O
and	O
was	O
useful	O
to	O
analyze	O
the	O
role	O
of	O
hypothetical	O
control	O
scenarios	O
.	O

In	O
addition	O
,	O
CCE	O
precisely	O
depicts	O
the	O
consequences	O
of	O
pulmonary	O
vascular	B-DISO
lesions	I-DISO
on	O
right	O
ventricular	O
function	O
and	O
helps	O
in	O
adjusting	O
the	O
ventilator	O
settings	O
in	O
patients	O
sustaining	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
all	O
these	O
clinical	O
settings	O
,	O
CCE	O
provides	O
unparalleled	O
information	O
on	O
both	O
the	O
efficacy	O
and	O
tolerance	B-DISO
of	O
therapeutic	O
changes	O
.	O

Some	O
classical	O
CIRD	O
agents	O
,	O
such	O
as	O
canine	O
adenoviruses	O
,	O
canine	B-DISO
distemper	I-DISO
virus	O
and	O
canid	O
herpesvirus	O
1	O
,	O
were	O
not	O
detected	O
at	O
all	O
,	O
as	O
were	O
not	O
other	O
emerging	O
respiratory	O
viruses	O
(	O
canine	O
influenza	B-DISO
virus	O
,	O
canine	O
hepacivirus	O
)	O
and	O
bacteria	O
(	O
Streptococcus	O
equi	O
subsp	O
.	O

The	O
viruses	O
used	O
the	O
human	O
entry	O
receptor	O
aminopeptidase	O
N	O
and	O
replicated	O
in	O
human	O
hepatoma	B-DISO
cells	O
,	O
suggesting	O
a	O
principal	O
ability	O
to	O
cause	O
human	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
In	O
pathological	O
situations	O
such	O
as	O
ischemia	B-DISO
-	O
reperfusion	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
produced	O
by	O
different	O
systems	O
which	O
are	O
involved	O
in	O
endothelial	O
cells	O
injury	O
,	O
ultimately	O
leading	O
to	O
severe	O
organ	O
dysfunctions	O
.	O

This	O
study	O
shows	O
that	O
ROS	O
could	O
have	O
both	O
stimulatory	O
and	O
inhibitory	O
effects	O
on	O
HUVEC	O
adhesion	B-DISO
and	O
FAK	O
phosphorylation	O
and	O
suggests	O
that	O
PI3	O
-	O
kinase	O
and	O
tyrosine	O
phosphatase	O
control	O
these	O
effects	O
.	O

However	O
,	O
prolonged	O
low	O
-	O
to	O
-	O
moderate	O
dose	O
glucocorticoid	O
treatment	O
of	O
sepsis	B-DISO
and	O
ARDS	B-DISO
is	O
associated	O
with	O
a	O
reduction	O
in	O
NF	O
-	O
κB	O
DNA	O
-	O
binding	O
,	O
decreased	O
transcription	O
of	O
inflammatory	O
cytokines	O
,	O
enhanced	O
resolution	O
of	O
systemic	O
and	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
leading	O
to	O
fewer	O
days	O
of	O
mechanical	O
ventilation	O
,	O
and	O
lower	O
mortality	O
.	O

Importantly	O
,	O
meta	O
-	O
analyses	O
of	O
a	O
large	O
number	O
of	O
randomized	O
controlled	O
trials	O
investigating	O
low	O
-	O
to	O
-	O
moderate	O
glucocorticoid	O
treatment	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
ARDS	B-DISO
found	O
no	O
increase	O
in	O
ICUAW	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
there	O
have	O
been	O
several	O
systematic	O
reviews	O
with	O
meta	O
-	O
analysis	O
that	O
have	O
shown	O
no	O
reduction	O
in	O
mortality	O
with	O
the	O
use	O
of	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Recently	O
,	O
Bronicki	O
et	O
al	O
.	O
published	O
a	O
prospective	O
randomized	O
control	O
trial	O
investigating	O
the	O
impact	O
of	O
iNO	O
on	O
the	O
pediatric	O
patient	O
population	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Passive	O
Transfer	O
of	O
A	O
Germline	O
-	O
like	O
Neutralizing	O
Human	O
Monoclonal	O
Antibody	O
Protects	O
Transgenic	O
Mice	O
Against	O
Lethal	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
.	O

Immunofluorescence	O
analysis	O
revealed	O
that	O
the	O
endothelial	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
E	O
-	O
selectin	O
,	O
intercellular	O
adhesion	B-DISO
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
vascular	O
cell	O
adhesion	B-DISO
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
was	O
elevated	O
in	O
veins	O
close	O
to	O
granulomatous	O
infiltrates	B-DISO
in	O
the	O
renal	O
cortex	O
of	O
FIP	B-DISO
patients	O
compared	O
to	O
non	O
-	O
infiltrated	B-DISO
regions	O
and	O
specimens	O
from	O
healthy	O
cats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
perioperative	O
metastatic	O
spinal	B-DISO
tumor	I-DISO
frailty	O
index	O
(	O
MSTFI	O
)	O
that	O
could	O
predict	O
morbidity	O
,	O
mortality	O
,	O
and	O
length	O
of	O
stay	O
.	O

A	O
large	O
inpatient	O
hospitalization	O
database	O
was	O
searched	O
from	O
2002	O
to	O
2011	O
to	O
identify	O
4583	O
patients	O
with	O
spinal	O
metastasis	B-DISO
from	O
breast	O
(	O
21	O
.	O
1	O
%),	O
lung	O
(	O
34	O
.	O
1	O
%),	O
thyroid	O
(	O
3	O
.	O
8	O
%),	O
renal	O
(	O
19	O
.	O
9	O
%),	O
and	O
prostate	O
(	O
21	O
.	O
1	O
%)	O
cancer	B-DISO
who	O
underwent	O
surgery	O
.	O

TITLE	O
:	O
Status	O
of	O
vaccines	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
the	O
United	O
States	O
and	O
Canada	O
.	O

Syndecan	O
-	O
1	O
is	O
elevated	O
in	O
emergency	B-DISO
department	O
sepsis	B-DISO
nonsurvivors	O
.	O

TITLE	O
:	O
Synthetic	O
virus	O
-	O
like	O
particles	O
prepared	O
via	O
protein	O
corona	O
formation	O
enable	O
effective	O
vaccination	O
in	O
an	O
avian	O
model	O
of	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Frequency	O
of	O
electrophoretic	O
changes	O
consistent	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
two	O
different	O
time	O
periods	O
(	O
2004	O
-	O
2009	O
vs	O
2013	O
-	O
2014	O
).	O

Methods	O
Agarose	O
gel	O
electrophoresis	O
(	O
AGE	O
)	O
and	O
capillary	O
zone	O
electrophoresis	O
(	O
CZE	O
)	O
from	O
cats	O
with	O
FIP	B-DISO
and	O
healthy	O
cats	O
recorded	O
in	O
the	O
periods	O
2004	O
-	O
2009	O
and	O
2013	O
-	O
2014	O
were	O
retrospectively	O
analysed	O
.	O

TITLE	O
:	O
TGEV	O
infection	B-DISO
up	O
-	O
regulates	O
FcRn	O
expression	O
via	O
activation	O
of	O
NF	O
-	O
κB	O
signaling	O
.	O

Transmissible	O
gastroenteritis	B-DISO
is	O
an	O
acute	O
enteric	O
disease	O
of	O
swine	O
that	O
is	O
caused	O
by	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
).	O

In	O
addition	O
,	O
the	O
NF	O
-	O
κB	O
signaling	O
pathway	O
was	O
activated	O
in	O
IPEC	O
-	O
J2	O
cells	O
by	O
TGEV	O
infection	B-DISO
.	O

Vaccination	O
is	O
the	O
only	O
effective	O
way	O
to	O
prevent	O
and	O
control	O
IBV	O
infection	B-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
recombinant	O
parapoxvirus	O
expressing	O
the	O
spike	O
protein	O
of	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

Many	O
intracellular	O
signaling	O
pathways	O
,	O
including	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
pathway	O
,	O
are	O
activated	O
by	O
viral	B-DISO
infection	I-DISO
.	O

A	O
number	O
of	O
factors	O
could	O
have	O
contributed	O
to	O
transmitting	O
influenza	B-DISO
in	O
NHs	B-DISO
including	O
,	O
the	O
absence	O
of	O
administration	O
of	O
antiviral	O
treatment	O
for	O
prophylaxis	O
of	O
all	O
residents	O
/	O
staff	O
regardless	O
of	O
immunization	O
status	O
because	O
of	O
the	O
poor	O
vaccine	O
match	O
during	O
each	O
outbreak	O
,	O
the	O
intensive	O
contacts	O
with	O
incompletely	O
protected	O
residents	O
and	O
HCWs	O
,	O
and	O
the	O
low	O
adherence	O
of	O
NHs	B-DISO
to	O
notification	O
of	O
ILI	O
outbreaks	O
to	O
the	O
health	O
authorities	O
.	O

TITLE	O
:	O
Trend	O
and	O
manifestations	O
of	O
falciparum	B-DISO
malaria	I-DISO
in	O
a	O
tertiary	O
care	O
hospital	O
of	O
India	O
.	O

Complications	O
and	O
mortality	O
are	O
also	O
more	O
due	O
to	O
falciparum	B-DISO
malaria	I-DISO
.	O

We	O
identified	O
338	O
proteins	O
dysregulated	O
in	O
ARDS	B-DISO
through	O
iTRAQ	O
,	O
18	O
of	O
which	O
showed	O
significant	O
differences	O
with	O
at	O
least	O
1	O
.	O
5	O
-	O
fold	O
differential	O
expression	O
in	O
patients	O
with	O
mild	O
or	O
severe	O
ARDS	B-DISO
.	O

Our	O
results	O
indicate	O
that	O
DMBT1	O
can	O
potentially	O
serve	O
as	O
a	O
biomarker	O
for	O
early	O
ARDS	B-DISO
diagnosis	O
and	O
disease	O
severity	O
assessment	O
.	O

TITLE	O
:	O
Full	O
-	O
length	O
genome	O
sequencing	O
analysis	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
isolate	O
associated	O
with	O
nephropathogenic	O
infection	B-DISO
.	O

Whether	O
MERS	O
-	O
CoV	O
infects	O
the	O
kidney	O
and	O
how	O
it	O
triggers	O
renal	B-DISO
failure	I-DISO
are	O
not	O
understood	O
(	O
5	O
,	O
6	O
).	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
has	O
not	O
been	O
shown	O
to	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
Ten	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
were	O
included	O
.	O

Mild	O
to	O
severe	O
atrophic	B-DISO
enteritis	B-DISO
with	O
PDCoV	O
antigen	O
staining	O
was	O
observed	O
in	O
the	O
small	O
intestine	O
of	O
affected	O
piglets	O
from	O
2	O
to	O
8	O
dpi	O
.	O

There	O
was	O
a	O
difference	O
in	O
the	O
worry	O
and	O
fear	O
scale	O
of	O
contracting	O
the	O
MERS	O
-	O
CoV	O
infection	B-DISO
between	O
participants	O
who	O
worked	O
in	O
areas	O
likely	O
to	O
admit	O
and	O
have	O
MERS	O
-	O
CoV	O
suspected	O
or	O
positive	O
cases	O
.	O

The	O
etiology	O
is	O
unknown	O
and	O
its	O
pathogenesis	B-DISO
appears	O
to	O
be	O
multifactorial	O
.	O

Biopsy	O
of	O
the	O
left	O
sural	O
nerve	O
showed	O
moderate	O
reductions	O
of	O
large	O
and	O
small	O
myelinated	O
fibers	O
with	O
no	O
inflammation	B-DISO
,	O
no	O
depositions	O
of	O
amyloid	B-DISO
,	O
IgG	O
,	O
IgA	O
,	O
or	O
IgM	O
,	O
and	O
teased	O
fiber	O
findings	O
revealed	O
neither	O
myelin	O
ovoids	O
nor	O
segmental	B-DISO
demyelination	I-DISO
.	O

Twelve	O
months	O
after	O
admission	O
,	O
her	O
neurological	B-DISO
symptoms	I-DISO
gradually	O
improved	O
and	O
she	O
was	O
weaned	O
off	O
of	O
mechanical	O
ventilation	O
.	O

Lactobacillus	O
plantarum	O
-	O
Biocenol	O
(	O
TM	O
)	O
LP96	O
(	O
CCM	B-DISO
7512	O
),	O
Lactobacillus	O
fermentum	O
-	O
Biocenol	O
(	O
TM	O
)	O
LF99	O
(	O
CCM	B-DISO
7514	O
)	O
and	O
flaxseed	O
(	O
rich	O
in	O
n	O
-	O
3	O
polyunsaturated	O
fatty	O
acids	O
)	O
were	O
administered	O
to	O
36	O
conventional	O
piglets	O
from	O
a	O
problematic	O
breed	O
with	O
confirmed	O
presence	O
of	O
enterotoxigenic	O
Escherichia	O
coli	O
and	O
Coronavirus	O
.	O

Probiotics	O
and	O
flaxseed	O
applied	O
together	O
seem	O
to	O
be	O
a	O
good	O
source	O
of	O
nutrients	O
to	O
improve	O
the	O
immune	O
status	O
and	O
the	O
integrity	O
of	O
jejunum	O
mucosa	O
during	O
infection	B-DISO
.	O

Inadequate	O
antenatal	O
care	O
,	O
delayed	O
referral	O
practices	O
,	O
pregnancy	B-DISO
-	I-DISO
induced	I-DISO
hypertension	I-DISO
,	O
obstetric	O
haemorrhage	B-DISO
and	O
sepsis	B-DISO
remain	O
the	O
major	O
causes	O
of	O
complications	O
in	O
obstetric	O
patients	O
from	O
rural	O
areas	O
.	O

TITLE	O
:	O
Human	O
Respiratory	O
Coronaviruses	O
Detected	O
In	O
Patients	O
with	O
Influenza	B-DISO
-	I-DISO
Like	I-DISO
Illness	I-DISO
in	O
Arkansas	O
,	O
USA	O
.	O

These	O
droplets	O
or	O
droplet	O
nuclei	O
are	O
transported	O
by	O
expired	O
airflows	O
,	O
which	O
are	O
sometimes	O
affected	O
by	O
the	O
human	O
body	O
plume	O
and	O
use	O
of	O
a	O
face	B-DISO
mask	O
,	O
as	O
well	O
as	O
room	O
airflow	O
.	O

We	O
propose	O
that	O
the	O
short	O
-	O
range	O
airborne	O
route	O
may	O
be	O
important	O
in	O
close	O
contact	O
,	O
and	O
its	O
control	O
may	O
be	O
achieved	O
by	O
face	B-DISO
masks	O
for	O
the	O
source	O
patients	O
and	O
use	O
of	O
personalized	O
ventilation	O
.	O

The	O
occurrence	O
rate	O
of	O
hyperamylasemia	B-DISO
or	O
high	O
lipase	O
levels	O
in	O
critically	B-DISO
ill	I-DISO
children	O
were	O
lower	O
than	O
adults	O
,	O
elevated	O
pancreatic	O
enzymes	O
was	O
accompanied	O
by	O
the	O
progression	O
of	O
critical	B-DISO
illness	I-DISO
,	O
pancreatic	O
enzymes	O
elevated	O
probably	O
due	O
to	O
pancreatic	O
damage	O
,	O
which	O
positively	O
correlated	O
with	O
severity	O
of	O
the	O
disease	O
and	O
the	O
prognosis	O
.	O

CONCLUSIONS	O
:	O
The	O
occurrence	O
rate	O
of	O
hyperamylasemia	B-DISO
or	O
high	O
lipase	O
levels	O
in	O
critically	B-DISO
ill	I-DISO
children	O
were	O
lower	O
than	O
adults	O
,	O
elevated	O
pancreatic	O
enzymes	O
was	O
accompanied	O
by	O
the	O
progression	O
of	O
critical	B-DISO
illness	I-DISO
,	O
pancreatic	O
enzymes	O
elevated	O
probably	O
due	O
to	O
pancreatic	O
damage	O
,	O
which	O
positively	O
correlated	O
with	O
severity	O
of	O
the	O
disease	O
and	O
the	O
prognosis	O
.	O

The	O
BME	O
reveals	O
that	O
SARS	B-DISO
outbreaks	O
show	O
autocorrelation	O
within	O
certain	O
spatial	O
and	O
temporal	O
distances	O
.	O

Using	O
the	O
covariance	O
model	O
,	O
SARS	B-DISO
dynamics	O
were	O
estimated	O
and	O
simulated	O
under	O
the	O
most	O
probable	O
conditions	O
.	O

The	O
damaging	O
effects	O
of	O
the	O
virus	O
on	O
the	O
reproductive	O
organs	O
were	O
evaluated	O
with	O
clinical	O
observations	O
,	O
gross	O
autopsy	O
and	O
histopathological	O
examinations	O
during	O
the	O
100	O
-	O
day	O
monitoring	O
period	O
post	O
infection	B-DISO
.	O

The	O
critical	O
scoring	O
systems	O
proved	O
to	O
have	O
good	O
prognostic	O
ability	O
in	O
predicting	O
hospital	O
mortality	O
for	O
severe	O
ARF	B-DISO
patients	O
supported	O
by	O
VV	O
-	O
ECMO	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
emerged	O
from	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
)	O
in	O
2012	O
and	O
has	O
since	O
spread	O
to	O
26	O
countries	O
.	O

TITLE	O
:	O
Cross	O
-	O
sectional	O
survey	O
and	O
surveillance	O
for	O
influenza	B-DISO
viruses	O
and	O
MERS	O
-	O
CoV	O
among	O
Egyptian	O
pilgrims	O
returning	O
from	O
Hajj	O
during	O
2012	O
-	O
2015	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
estimate	O
influenza	B-DISO
virus	O
and	O
MERS	O
-	O
CoV	O
prevalence	O
among	O
Egyptian	O
pilgrims	O
returning	O
from	O
Hajj	O
.	O

An	O
evaluation	O
of	O
the	O
Ministry	O
of	O
Health	O
and	O
Population	O
'	O
s	O
current	O
risk	O
communication	O
campaigns	O
to	O
increase	O
influenza	B-DISO
vaccine	O
use	O
among	O
pilgrims	O
may	O
help	O
identify	O
strategies	O
to	O
improve	O
vaccine	O
coverage	O
.	O

TITLE	O
:	O
Infectious	B-DISO
diseases	I-DISO
epidemic	O
threats	O
and	O
mass	O
gatherings	O
:	O
refocusing	O
global	O
attention	O
on	O
the	O
continuing	O
spread	O
of	O
the	O
Middle	O
East	O
Respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

The	O
highly	O
lethal	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
remains	O
in	O
the	O
WHO	O
list	O
of	O
top	O
emerging	O
diseases	O
likely	O
to	O
cause	O
major	O
epidemics	O
.	O

The	O
2015	O
MERS	O
-	O
CoV	O
outbreak	O
in	O
South	O
Korea	O
,	O
in	O
which	O
184	O
MERS	O
cases	O
including	O
33	O
deaths	O
occurred	O
in	O
2	O
months	O
,	O
that	O
was	O
imported	O
from	O
the	O
Middle	O
East	O
by	O
a	O
South	O
Korean	O
businessman	O
was	O
a	O
wake	O
-	O
up	O
call	O
for	O
the	O
global	O
community	O
to	O
refocus	O
attention	O
on	O
MERS	O
-	O
CoV	O
and	O
other	O
emerging	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
with	O
epidemic	O
potential	O
.	O

The	O
international	O
donor	O
community	O
and	O
Middle	O
Eastern	O
countries	O
should	O
make	O
available	O
resources	O
for	O
,	O
and	O
make	O
a	O
serious	O
commitment	O
to	O
,	O
taking	O
forward	O
a	O
""""	O
One	O
Health	O
""""	O
global	O
network	O
for	O
proactive	O
surveillance	O
,	O
rapid	O
detection	O
,	O
and	O
prevention	O
of	O
MERS	O
-	O
CoV	O
and	O
other	O
epidemic	O
infectious	B-DISO
diseases	I-DISO
threats	O
.	O

Both	O
IFN	O
-	O
γ	O
secretion	O
and	O
trafficking	O
were	O
impaired	B-DISO
in	O
miR	O
-	O
155	O
(-/-)	O
,	O
virus	O
-	O
specific	O
CD4	O
(+)	O
T	O
cells	O
;	O
however	O
,	O
expression	O
of	O
the	O
chemokine	O
homing	O
receptors	O
analyzed	O
on	O
CD4	O
(+)	O
cells	O
was	O
not	O
affected	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
pathogen	O
,	O
first	O
recognized	O
in	O
2012	O
,	O
with	O
a	O
high	O
case	O
fatality	O
risk	O
,	O
no	O
vaccine	O
,	O
and	O
no	O
treatment	O
beyond	O
supportive	O
care	O
.	O

Pathologic	O
lesions	O
,	O
hemorrhages	B-DISO
,	O
and	O
mononuclear	O
infiltrations	O
were	O
predominantly	O
observed	O
in	O
tracheas	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
lungs	O
and	O
a	O
few	O
in	O
kidneys	O
.	O

Pools	O
of	O
trachea	B-DISO
,	O
lungs	O
,	O
reproductive	O
tract	O
,	O
kidneys	O
,	O
and	O
enteric	O
contents	O
from	O
quail	O
and	O
laying	O
hens	O
kept	O
in	O
the	O
same	O
farms	O
and	O
from	O
quail	O
-	O
only	O
farms	O
as	O
well	O
as	O
from	O
both	O
healthy	O
birds	O
and	O
those	O
showing	O
infectious	B-DISO
bronchitis	B-DISO
-	O
like	O
symptoms	O
were	O
sampled	O
in	O
this	O
study	O
.	O

Additional	O
investigations	O
,	O
including	O
a	O
cell	O
-	O
free	O
haemoglobin	O
of	O
10	O
.	O
2	O
×	O
10	O
(	O
5	O
)	O
ng	O
/	O
mL	O
and	O
an	O
undetectable	O
haptoglobin	O
,	O
confirmed	O
intravascular	B-DISO
haemolysis	I-DISO
.	O

ABSTRACT	O
:	O
The	O
current	O
outbreaks	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
and	O
Ebolavirus	O
(	O
EboV	O
)	O
have	O
revealed	O
a	O
gap	O
in	O
the	O
development	O
and	O
availability	O
of	O
drugs	O
to	O
treat	O
these	O
infections	B-DISO
.	O

All	O
inoculated	O
pigs	O
developed	O
watery	B-DISO
diarrhea	I-DISO
and	O
/	O
or	O
vomiting	B-DISO
at	O
PID	B-DISO
1	O
-	O
2	O
and	O
shed	O
the	O
highest	O
amount	O
of	O
viral	O
RNA	O
in	O
feces	O
at	O
PID	B-DISO
3	O
-	O
5	O
,	O
accompanied	O
by	O
severe	O
atrophic	B-DISO
enteritis	B-DISO
.	O

ABSTRACT	O
:	O
During	O
the	O
years	O
2014	O
and	O
2015	O
,	O
the	O
Region	O
of	O
the	O
Americas	O
underwent	O
a	O
devastating	O
epidemic	O
of	O
chikungunya	B-DISO
virus	O
(	O
CHIKV	O
)	O
of	O
the	O
Asian	O
genotype	O
,	O
resulting	O
in	O
millions	O
of	O
affected	O
individuals	O
.	O

Epidemiological	O
and	O
clinical	O
data	O
on	O
maternal	O
and	O
neonatal	O
infections	B-DISO
were	O
collected	O
prospectively	O
and	O
analyzed	O
.	O

Leukocytosis	B-DISO
with	O
neutrophilia	O
and	O
normal	O
or	O
increased	B-DISO
platelets	I-DISO
was	O
a	O
common	O
finding	O
,	O
and	O
in	O
those	O
with	O
signs	O
of	O
meningeal	O
involvement	O
,	O
moderate	O
lymphocytic	O
pleocytosis	O
with	O
normal	O
glucose	O
and	O
protein	O
levels	O
was	O
typical	O
.	O

TITLE	O
:	O
Polymorphisms	O
in	O
the	O
S1	O
spike	O
glycoprotein	O
of	O
Arkansas	O
-	O
type	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
show	O
differential	O
binding	O
to	O
host	O
tissues	O
and	O
altered	O
antigenicity	O
.	O

ABSTRACT	O
:	O
Sequencing	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
spike	O
genes	O
re	O
-	O
isolated	O
from	O
vaccinated	O
chicks	O
revealed	O
that	O
many	O
sequence	O
changes	O
are	O
found	O
on	O
the	O
S1	O
spike	O
gene	O
.	O

The	O
common	O
early	O
warning	O
signs	O
at	O
the	O
time	O
of	O
admission	O
were	O
persistent	B-DISO
vomiting	I-DISO
(	O
75	O
.	O
1	O
%),	O
liver	B-DISO
enlargement	I-DISO
(	O
59	O
.	O
8	O
%),	O
cold	B-DISO
and	O
clammy	B-DISO
extremities	O
(	O
45	O
.	O
2	O
%),	O
pain	O
abdomen	O
(	O
31	O
.	O
0	O
%),	O
hypotension	O
(	O
29	O
.	O
5	O
%),	O
restlessness	B-DISO
(	O
26	O
.	O
4	O
%),	O
giddiness	B-DISO
(	O
23	O
.	O
0	O
%),	O
bleeding	B-DISO
(	O
19	O
.	O
9	O
%),	O
and	O
oliguria	B-DISO
(	O
18	O
.	O
4	O
%).	O

Clinical	O
vigilance	O
and	O
awareness	O
regarding	O
the	O
changing	O
epidemic	O
pattern	O
and	O
timely	O
detection	O
of	O
cases	O
are	O
vital	O
to	O
reduce	O
mortality	O
and	O
morbidity	O
due	O
to	O
severe	O
dengue	B-DISO
infection	B-DISO
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
evidence	O
to	O
date	O
to	O
suggest	O
that	O
these	O
diseases	O
would	O
have	O
been	O
transmitted	B-DISO
between	O
commercial	O
and	O
non	O
-	O
commercial	O
flocks	O
.	O

To	O
determine	O
the	O
prevalence	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infection	B-DISO
among	O
patients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
,	O
5833	O
clinical	O
samples	O
from	O
nasopharyngeal	O
swabs	O
and	O
aspirates	O
collected	O
between	O
January	O
2012	O
and	O
December	O
2013	O
were	O
examined	O
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
the	O
development	O
of	O
biologically	O
active	O
spirooxindoles	O
for	O
their	O
antiviral	O
potential	O
,	O
primarily	O
focusing	O
on	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
and	O
modes	O
of	O
action	O
,	O
as	O
well	O
as	O
future	O
directions	O
to	O
achieve	O
more	O
potent	O
analogues	O
toward	O
a	O
viable	O
antiviral	O
therapy	O
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
multiplex	O
PCR	O
assays	O
for	O
detection	O
of	O
virus	O
-	O
induced	O
respiratory	B-DISO
disease	I-DISO
complex	O
in	O
dogs	O
.	O

All	O
six	O
viruses	O
were	O
detected	O
in	O
either	O
individual	O
or	O
multiple	O
infections	B-DISO
.	O

The	O
literature	O
on	O
the	O
association	O
between	O
plasma	O
inflammatory	O
cytokines	O
and	O
ARDS	B-DISO
in	O
patients	O
with	O
TBI	O
is	O
sparse	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
helicase	O
is	O
a	O
superfamily	O
1	O
helicase	O
containing	O
seven	O
conserved	O
motifs	O
.	O

We	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
a	O
Strep	B-DISO
-	O
fused	O
recombinant	O
MERS	O
-	O
CoV	O
nonstructural	O
protein	O
13	O
(	O
M	O
-	O
nsp13	O
)	O
helicase	O
.	O

Characterization	O
of	O
its	O
biochemical	O
properties	O
showed	O
that	O
it	O
unwound	O
DNA	O
and	O
RNA	O
similarly	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
nsp13	O
(	O
S	O
-	O
nsp13	O
)	O
helicase	O
.	O

Helicases	O
are	O
motor	O
proteins	O
that	O
catalyze	O
the	O
processive	O
separation	B-DISO
of	O
double	O
-	O
stranded	O
nucleic	O
acids	O
into	O
two	O
single	O
-	O
stranded	O
nucleic	O
acids	O
by	O
utilizing	O
the	O
energy	O
derived	O
from	O
ATP	O
hydrolysis	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
timing	O
,	O
severity	O
,	O
and	O
intensive	O
care	O
management	O
of	O
cytokine	B-DISO
release	I-DISO
syndrome	I-DISO
after	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cell	O
therapy	O
.	O

Eighteen	O
subjects	O
(	O
46	O
%)	O
developed	O
grade	O
3	O
-	O
4	O
cytokine	B-DISO
release	I-DISO
syndrome	I-DISO
,	O
with	O
prolonged	O
fever	O
(	O
median	O
,	O
6	O
.	O
5	O
d	O
),	O
hyperferritinemia	O
(	O
median	O
peak	O
ferritin	O
,	O
60	O
,	O
214	O
ng	O
/	O
mL	O
),	O
and	O
organ	O
dysfunction	O
.	O

Six	O
(	O
15	O
%)	O
developed	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
treated	O
with	O
invasive	O
mechanical	O
ventilation	O
a	O
median	O
of	O
6	O
days	O
after	O
T	O
cell	O
therapy	O
;	O
five	O
met	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

They	O
also	O
appear	O
to	O
be	O
the	O
natural	O
reservoir	O
for	O
the	O
ancestral	O
viruses	O
that	O
generated	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
outbreaks	O
.	O

ABSTRACT	O
:	O
A	O
recently	O
developed	O
prediction	O
score	O
based	O
on	O
age	O
,	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
ratio	O
(	O
PaO2	O
/	O
FiO2	O
)	O
and	O
plateau	O
pressure	O
(	O
abbreviated	O
as	O
'	O
APPS	O
')	O
was	O
shown	O
to	O
accurately	O
predict	O
mortality	O
in	O
patients	O
diagnosed	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
total	O
,	O
439	O
patients	O
with	O
moderate	O
or	O
severe	O
ARDS	B-DISO
were	O
analyzed	O
.	O

TITLE	O
:	O
Building	O
predictive	O
models	O
for	O
MERS	O
-	O
CoV	O
infections	B-DISO
using	O
data	O
mining	O
techniques	O
.	O

As	O
future	O
work	O
,	O
we	O
plan	B-DISO
to	O
directly	O
contact	O
hospitals	O
in	O
Riyadh	O
in	O
order	O
to	O
collect	O
more	O
information	O
related	O
to	O
patients	O
with	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

A	O
new	O
attribute	O
was	O
created	O
to	O
indicate	O
the	O
record	O
type	O
,	O
such	O
that	O
the	O
dataset	O
can	O
be	O
used	O
to	O
predict	O
the	O
recovery	O
from	O
MERS	O
-	O
CoV	O
.	O
The	O
second	O
group	O
contained	O
the	O
new	O
case	O
records	O
to	O
be	O
used	O
to	O
predict	O
the	O
stability	O
of	O
the	O
infection	B-DISO
based	O
on	O
the	O
current	O
status	O
attribute	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
48	O
year	O
-	O
old	O
patient	O
with	O
rhabdomyolysis	B-DISO
complicated	O
by	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
following	O
Legionella	B-DISO
pneumophila	I-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Polio	B-DISO
Eradication	O
Initiative	O
(	O
PEI	O
)	O
contribution	O
in	O
strengthening	O
public	O
health	O
laboratories	O
systems	O
in	O
the	O
African	O
region	O
.	O

The	O
Polio	B-DISO
Eradication	O
Initiative	O
(	O
PEI	O
)	O
is	O
a	O
good	O
example	O
of	O
contribution	O
in	O
strengthening	O
public	O
health	O
laboratories	O
systems	O
in	O
the	O
African	O
region	O
.	O

This	O
could	O
serve	O
as	O
lesson	O
and	O
good	O
example	O
of	O
laboratory	O
based	O
surveillance	O
to	O
improving	O
diseases	O
prevention	O
,	O
detection	O
and	O
control	O
in	O
our	O
middle	O
and	O
low	O
income	O
countries	O
as	O
WHO	O
and	O
partners	O
are	O
heading	O
to	O
polio	B-DISO
eradication	O
in	O
the	O
world	O
.	O

Bipolar	B-DISO
disorder	I-DISO
patients	O
show	O
an	O
increase	O
of	O
blood	O
anti	O
gliadin	O
deamidated	O
antibodies	O
(	O
IgG	O
).	O

Abnormalities	O
of	O
host	O
-	O
microbiota	O
interactions	O
or	O
of	O
gut	O
-	O
microbiota	O
composition	O
have	O
been	O
associated	O
with	O
central	B-DISO
nervous	I-DISO
system	I-DISO
disorders	I-DISO
,	O
such	O
as	O
autism	B-DISO
,	O
anxiety	O
,	O
depression	B-DISO
and	O
the	O
integrity	O
of	O
intestinal	O
microbiota	O
may	O
be	O
considered	O
a	O
potential	O
therapeutic	O
goal	O
to	O
treat	O
these	O
conditions	O
.	O

A	O
severe	O
respiratory	B-DISO
acidosis	I-DISO
was	O
induced	O
in	O
seven	O
anesthetized	O
pigs	O
.	O

The	O
most	O
common	O
finding	O
in	O
CT	O
was	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)-	O
like	O
radiologic	O
manifestations	O
(	O
17	O
.	O
1	O
%),	O
followed	O
by	O
parenchymal	O
nodular	O
infiltration	B-DISO
(	O
13	O
.	O
6	O
%)	O
and	O
cavitation	B-DISO
(	O
10	O
.	O
9	O
%),	O
consolidation	O
(	O
10	O
.	O
2	O
%),	O
interstitial	O
involvement	O
(	O
9	O
.	O
5	O
%),	O
calcified	O
parenchymal	O
mass	O
(	O
8	O
.	O
3	O
%),	O
ground	O
-	O
glass	O
opacities	B-DISO
(	O
7	O
.	O
5	O
%),	O
and	O
pleural	B-DISO
effusion	I-DISO
or	O
thickening	O
(	O
6	O
.	O
9	O
%).	O

Miliary	B-DISO
TB	I-DISO
was	O
observed	O
in	O
2	O
.	O
3	O
%	O
of	O
patients	O
,	O
mostly	O
in	O
those	O
older	O
than	O
60years	O
of	O
age	O
.	O

We	O
set	O
up	O
a	O
retrospective	O
study	O
using	O
nasal	O
swabs	O
collected	O
by	O
sentinel	O
GPs	B-DISO
from	O
ILI	O
patients	O
in	O
2011	O
and	O
2012	O
.	O

We	O
detected	O
respiratory	O
viruses	O
in	O
169	O
/	O
222	O
(	O
76	O
.	O
1	O
%)	O
samples	O
,	O
mostly	O
rhinovirus	O
(	O
23	O
.	O
4	O
%),	O
influenza	B-DISO
A	O
virus	O
(	O
21	O
.	O
2	O
%),	O
influenza	B-DISO
B	O
virus	O
(	O
12	O
.	O
6	O
%),	O
coronavirus	O
(	O
4	O
.	O
9	O
%)	O
and	O
Human	O
metapneumovirus	O
(	O
3	O
.	O
6	O
%).	O

Dexmedetomidine	O
as	O
a	O
primary	O
sedative	O
patients	O
(	O
n	O
=	O
138	O
;	O
11	O
%)	O
were	O
less	O
critically	B-DISO
ill	I-DISO
(	O
Pediatric	O
Risk	O
of	O
Mortality	O
III	O
-	O
12	O
score	O
median	O
,	O
6	O
[	O
interquartile	O
range	O
,	O
3	O
-	O
11	O
])	O
and	O
when	O
compared	O
with	O
all	O
other	O
cohorts	O
,	O
experienced	O
more	O
episodic	O
agitation	B-DISO
.	O

In	O
the	O
intervention	O
group	O
,	O
time	O
in	O
sedation	B-DISO
target	O
improved	O
from	O
28	O
%	O
to	O
50	O
%	O
within	O
1	O
day	O
of	O
initiating	O
dexmedetomidine	O
as	O
a	O
primary	O
sedative	O
.	O

TITLE	O
:	O
New	O
insights	O
into	O
the	O
interaction	O
between	O
pyrrolyl	O
diketoacids	O
and	O
HIV	B-DISO
-	O
1	O
integrase	O
active	O
site	O
and	O
comparison	O
with	O
RNase	O
H	O
.	O
ABSTRACT	O
:	O
HIV	B-DISO
-	O
1	O
integrase	O
(	O
IN	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
recent	O
innovations	O
in	O
the	O
treatment	O
of	O
HIV	B-DISO
infection	I-DISO
.	O

The	O
selection	O
of	O
drug	O
resistance	O
viral	O
strains	O
is	O
however	O
a	O
still	O
open	O
issue	O
requiring	O
constant	O
efforts	O
to	O
identify	O
new	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
drugs	O
.	O

ABSTRACT	O
:	O
Certain	O
bat	O
species	O
serve	O
as	O
natural	O
reservoirs	O
for	O
pathogens	O
in	O
several	O
key	O
viral	O
families	O
including	O
henipa	O
-,	O
lyssa	B-DISO
-,	O
corona	O
-,	O
and	O
filoviruses	O
,	O
which	O
may	O
pose	O
serious	O
threats	O
to	O
human	O
health	O
.	O

Previous	O
studies	O
have	O
investigated	O
rabies	B-DISO
dynamics	O
in	O
D	O
.	O
rotundus	O
,	O
yet	O
the	O
diversity	O
of	O
other	O
viruses	O
,	O
bacteria	O
,	O
and	O
other	O
microbes	O
that	O
these	O
bats	O
may	O
carry	O
remains	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
identified	O
the	O
leader	O
-	O
body	O
junction	O
sites	O
of	O
NS6	B-DISO
subgenomic	O
RNA	O
(	O
sgRNA	O
)	O
and	O
found	O
that	O
the	O
actual	O
transcription	O
regulatory	O
sequence	O
(	O
TRS	B-DISO
)	O
utilized	O
by	O
NS6	B-DISO
is	O
non	O
-	O
canonical	O
and	O
is	O
located	O
upstream	O
of	O
the	O
predicted	O
TRS	B-DISO
.	O

We	O
also	O
found	O
that	O
receptors	O
for	O
the	O
proinflammatory	O
cytokine	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
(	O
TNFα	O
)	O
promote	O
pathogenesis	B-DISO
,	O
presumably	O
through	O
excessive	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
We	O
quantify	O
outbreak	O
risk	O
after	O
importations	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
outside	O
the	O
Arabian	O
Peninsula	O
.	O

TITLE	O
:	O
Fatality	O
risks	O
for	O
nosocomial	O
outbreaks	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
Middle	O
East	O
and	O
South	O
Korea	O
.	O

The	O
median	O
number	O
of	O
days	O
from	O
onset	O
to	O
confirmation	O
of	O
infection	B-DISO
in	O
the	O
fatal	O
cases	O
was	O
longer	O
than	O
that	O
for	O
survivors	O
from	O
the	O
Middle	O
East	O
(	O
8	O
days	O
[	O
1	O
-	O
47	O
]	O
vs	O
.	O
4	O
days	O
[	O
0	O
-	O
14	O
],	O
p	O
=	O
0	O
.	O
009	O
).	O

The	O
percentage	O
of	O
children	O
missing	O
school	O
or	O
daycare	O
ranged	O
from	O
21	O
.	O
4	O
%	O
(	O
HBov	O
)	O
to	O
52	O
.	O
1	O
%	O
(	O
influenza	B-DISO
).	O

The	O
percentage	O
of	O
children	O
missing	O
school	O
or	O
daycare	O
ranged	O
from	O
21	O
.	O
4	O
%	O
(	O
HBov	O
)	O
to	O
52	O
.	O
1	O
%	O
(	O
influenza	B-DISO
).	O

One	O
lion	O
had	O
antibodies	O
to	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
,	O
two	O
had	O
antibodies	O
to	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
and	O
two	O
had	O
feline	O
calicivirus	O
antibodies	O
.	O

The	O
137	O
patients	O
who	O
met	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
but	O
not	O
Berlin	O
criteria	O
had	O
an	O
overall	O
mortality	O
rate	O
of	O
13	O
.	O
1	O
%,	O
but	O
29	O
had	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
31	O
.	O
0	O
%	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
has	O
generated	O
enormous	O
interest	O
in	O
the	O
biodiversity	O
,	O
genomics	O
and	O
cross	O
-	O
species	O
transmission	O
potential	O
of	O
coronaviruses	O
,	O
especially	O
those	O
from	O
bats	O
,	O
the	O
second	O
most	O
speciose	O
order	O
of	O
mammals	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
existence	O
of	O
enteric	O
viruses	O
in	O
two	O
Egyptian	O
farms	O
with	O
a	O
history	O
of	O
recurrent	O
diarrhea	B-DISO
.	O

Severe	B-DISO
edema	I-DISO
results	O
from	O
leakage	B-DISO
of	O
fluid	O
and	O
proteins	O
into	O
tissue	O
.	O

ABSTRACT	O
:	O
We	O
compared	O
the	O
rates	O
of	O
fever	O
in	O
adult	O
subjects	O
with	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
and	O
examined	O
the	O
factors	O
that	O
predict	O
fever	O
in	O
adults	O
.	O

Symptom	B-DISO
data	O
on	O
158	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
with	O
a	O
laboratory	O
-	O
confirmed	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
were	O
collected	O
using	O
standardized	O
data	O
collection	O
forms	O
from	O
three	O
separate	O
studies	O
.	O

TITLE	O
:	O
Morphogenesis	O
and	O
proliferative	B-DISO
rule	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
morphogenesis	O
and	O
proliferative	B-DISO
rule	O
of	O
TGEV	O
in	O
porcine	O
IECs	O
were	O
investigated	O
using	O
transmission	O
electron	O
microscopy	O
,	O
indirect	O
immunofluorescence	O
assays	O
and	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
.	O

The	O
syndrome	B-DISO
is	O
often	O
associated	O
with	O
an	O
infection	B-DISO
with	O

ABSTRACT	O
:	O
The	O
majority	O
of	O
children	O
with	O
febrile	B-DISO
seizures	I-DISO
have	O
viral	B-DISO
infections	I-DISO
and	O
viruses	O
were	O
detected	O
in	O
22	O
%	O
to	O
63	O
%	O
of	O
children	O
in	O
published	O
studies	O
.	O

The	O
viruses	O
most	O
strongly	O
associated	O
with	O
febrile	B-DISO
seizures	I-DISO
were	O
influenza	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	B-DISO
,	O
human	O
coronavirus	O
,	O
and	O
rotavirus	O
.	O

The	O
detected	O
virus	O
did	O
not	O
influence	O
clinical	O
features	O
of	O
febrile	B-DISO
seizure	I-DISO
.	O

TITLE	O
:	O
Awareness	O
of	O
droplet	O
and	O
airborne	O
isolation	O
precautions	O
among	O
dental	O
health	O
professionals	O
during	O
the	O
outbreak	O
of	O
corona	B-DISO
virus	I-DISO
infection	I-DISO
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
.	O

Histopathological	O
grading	O
of	O
lung	O
injury	O
indicated	O
that	O
edema	B-DISO
and	O
congestion	B-DISO
was	O
significantly	O
less	O
severe	O
in	O
the	O
PFC	O
post	O
-	O
OA	O
compared	O
to	O
control	O
(	O
p	O
=	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Constitutively	O
Expressed	O
IFITM3	O
Protein	O
in	O
Human	O
Endothelial	O
Cells	O
Poses	O
an	O
Early	O
Infection	B-DISO
Block	O
to	O
Human	B-DISO
Influenza	I-DISO
Viruses	O
.	O

We	O
also	O
review	O
the	O
current	O
classification	O
of	O
FCoVs	O
into	O
distinct	O
serotypes	O
and	O
biotypes	O
,	O
cellular	O
receptors	O
of	O
FCoVs	O
and	O
their	O
presumed	O
role	O
in	O
viral	O
virulence	O
,	O
and	O
discuss	O
other	O
aspects	O
of	O
FIPV	O
-	O
induced	O
pathogenesis	B-DISO
.	O

The	O
development	O
of	O
attenuated	O
virus	O
vaccines	O
to	O
combat	O
infections	B-DISO
caused	O
by	O
highly	O
pathogenic	O
CoVs	O
was	O
largely	O
based	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
viral	O
virulence	O
proteins	O
that	O
,	O
for	O
example	O
,	O
interfere	O
with	O
the	O
innate	O
and	O
adaptive	O
immune	O
response	O
or	O
are	O
involved	O
in	O
interactions	O
with	O
specific	O
cell	O
types	O
,	O
such	O
as	O
macrophages	O
,	O
dendritic	O
and	O
epithelial	O
cells	O
,	O
and	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
antiviral	O
host	O
responses	O
and	O
viral	B-DISO
pathogenesis	I-DISO
and	O
potentially	O
resulting	O
in	O
deleterious	O
side	O
effects	O
following	O
vaccination	O
.	O

This	O
is	O
particularly	O
illustrated	O
over	O
the	O
last	O
15	O
years	O
by	O
the	O
emergence	O
of	O
two	O
zoonotic	O
CoVs	O
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
.	O
Due	O
to	O
their	O
inherent	O
genetic	O
variability	O
,	O
it	O
is	O
inevitable	O
that	O
new	O
cross	O
-	O
species	O
transmission	O
events	O
of	O
these	O
enveloped	O
,	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
will	O
occur	O
.	O

ABSTRACT	O
:	O
There	O
are	O
gaps	O
in	O
the	O
knowledge	O
about	O
the	O
burden	O
of	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
the	O
Eastern	O
Mediterranean	O
Region	O
(	O
EMR	O
).	O

Laboratory	O
-	O
confirmed	O
influenza	B-DISO
was	O
found	O
in	O
13	O
%	O
of	O
cases	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	B-DISO
)	O
and	O
18	O
%	O
of	O
cases	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
SARI	B-DISO
);	O
positivity	O
for	O
influenza	B-DISO
was	O
similar	O
in	O
cases	O
of	O
ILI	B-DISO
and	O
SARI	B-DISO
in	O
patients	O
up	O
to	O
15	O
years	O
of	O
age	O
but	O
increased	O
for	O
SARI	B-DISO
and	O
decreased	O
for	O
ILI	B-DISO
in	O
people	O
aged	O
≥	O
15	O
years	O
.	O

ABSTRACT	O
:	O
A	O
literature	O
review	O
of	O
publically	O
available	O
information	O
was	O
undertaken	O
to	O
summarize	O
current	O
understanding	O
and	O
gaps	O
in	O
knowledge	O
about	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
including	O
its	O
origin	O
,	O
transmission	O
,	O
effective	O
control	O
measures	O
and	O
management	O
.	O

The	O
use	O
of	O
corticosteroids	O
in	O
patients	O
with	O
severe	O
CAP	B-DISO
and	O
a	O
strong	O
inflammatory	B-DISO
reaction	I-DISO
can	O
reduce	O
the	O
time	O
to	O
clinical	O
stability	O
,	O
the	O
risk	O
of	O
treatment	O
failure	O
,	O
and	O
the	O
risk	O
of	O
progression	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Local	O
dependence	B-DISO
and	O
the	O
contribution	O
of	O
risk	O
factors	O
to	O
this	O
effect	O
were	O
assessed	O
using	O
the	O
residuals	O
from	O
two	O
logistic	O
regression	O
models	O
for	O
each	O
virus	O
.	O

ABSTRACT	O
:	O
Triage	O
nurses	O
have	O
been	O
urged	O
to	O
ask	O
A	O
&	O
E	O
attenders	O
extra	O
questions	O
to	O
help	O
stop	O
the	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Furthermore	O
,	O
we	O
tried	O
to	O
examine	O
if	O
COPD	B-DISO
exacerbations	O
caused	O
by	O
viral	B-DISO
infections	I-DISO
have	O
more	O
severe	O
clinical	O
outcomes	O
in	O
comparison	O
with	O
those	O
with	O
non	O
-	O
viral	O
causes	O
.	O

ABSTRACT	O
:	O
Airway	B-DISO
obstruction	I-DISO
due	O
to	O
enlargement	B-DISO
of	I-DISO
tonsils	I-DISO
and	I-DISO
adenoids	I-DISO
is	O
a	O
common	O
pediatric	O
problem	O
resulting	O
in	O
sleep	B-DISO
disordered	I-DISO
breathing	I-DISO
.	O

Molecular	O
techniques	O
were	O
used	O
to	O
detect	O
9	O
respiratory	O
viruses	O
while	O
Brodsky	O
scores	O
and	O
measurements	O
of	O
percentages	O
airway	B-DISO
obstruction	I-DISO
were	O
used	O
to	O
estimate	O
the	O
degree	O
of	O
airway	O
compromise	O
due	O
to	O
the	O
tonsil	O
and	O
adenoid	O
,	O
respectively	O
.	O

Higher	O
Brodsky	O
scores	O
were	O
only	O
associated	O
with	O
EBV	O
in	O
tonsils	O
,	O
p	O
=	O
0	O
.	O
03	O
,	O
while	O
greater	O
percentages	O
of	O
airway	B-DISO
obstruction	I-DISO
in	O
the	O
adenoids	O
were	O
associated	O
with	O
adenovirus	B-DISO
,	O
EBV	O
,	O
corona	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
and	O
rhinovirus	O
,	O
p	O
≤	O
0	O
.	O
005	O
.	O

TITLE	O
:	O
Cell	O
Entry	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Coronavirus	O
Is	O
Activated	O
by	O
Lysosomal	O
Proteases	O
.	O

ABSTRACT	O
:	O
A	O
&	O
E	O
sister	O
Vicky	O
Hamer	O
was	O
among	O
emergency	B-DISO
staff	O
at	O
Hope	O
Hospital	O
,	O
Salford	O
,	O
who	O
featured	O
in	O
a	O
BBC	O
One	O
fly	O
-	O
onthe	O
-	O
wall	O
documentary	O
series	O
,	O
Trauma	O
,	O
this	O
summer	O
.	O

Microproteinuria	B-DISO
has	O
been	O
associated	O
with	O
the	O
presence	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
as	O
well	O
as	O
trauma	O
,	O
although	O
its	O
association	O
with	O
AP	O
is	O
not	O
well	O
understood	O
.	O

The	O
α1	O
-	O
microglobulin	O
/	O
creatinine	O
ratio	O
upon	O
admission	O
predicted	O
organ	B-DISO
failure	I-DISO
[	O
adjusted	O
odds	O
ratio	O
1	O
.	O
286	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
024	O
-	O
1	O
.	O
614	O
]	O
with	O
similar	O
accuracy	O
(	O
AUROC	O
0	O
.	O
81	O
,	O
95	O
%	O
CI	O
0	O
.	O
69	O
-	O
0	O
.	O
94	O
)	O
as	O
the	O
more	O
complex	O
APACHE	O
II	O
score	O
(	O
AUROC	O
0	O
.	O
86	O
,	O
95	O
%	O
CI	O
0	O
.	O
70	O
-	O
1	O
.	O
00	O
).	O

The	O
α1	O
-	O
microglobulin	O
/	O
creatinine	O
ratio	O
upon	O
admission	O
predicted	O
organ	B-DISO
failure	I-DISO
[	O
adjusted	O
odds	O
ratio	O
1	O
.	O
286	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
024	O
-	O
1	O
.	O
614	O
]	O
with	O
similar	O
accuracy	O
(	O
AUROC	O
0	O
.	O
81	O
,	O
95	O
%	O
CI	O
0	O
.	O
69	O
-	O
0	O
.	O
94	O
)	O
as	O
the	O
more	O
complex	O
APACHE	O
II	O
score	O
(	O
AUROC	O
0	O
.	O
86	O
,	O
95	O
%	O
CI	O
0	O
.	O
70	O
-	O
1	O
.	O
00	O
).	O

RESULTS	O
:	O
Approximately	O
1	O
of	O
50	O
children	O
born	O
each	O
year	O
in	O
developed	O
nations	O
is	O
hospitalized	O
for	O
acute	B-DISO
gastroenteritis	I-DISO
sometime	O
during	O
childhood	O
.	O

TITLE	O
:	O
Hydrocortisone	O
treatment	O
in	O
early	O
sepsis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
Authors	O
of	O
recent	O
meta	O
-	O
analyses	O
have	O
reported	O
that	O
prolonged	O
glucocorticoid	O
treatment	O
is	O
associated	O
with	O
significant	O
improvements	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
of	O
multifactorial	O
etiology	O
.	O

With	O
the	O
exception	O
of	O
hyperglycemia	B-DISO
(	O
80	O
.	O
6	O
%	O
vs	O
.	O
67	O
.	O
7	O
%;	O
p	O
=	O
0	O
.	O
04	O
),	O
the	O
rate	O
of	O
adverse	O
events	O
was	O
similar	O
.	O

Additional	O
factors	O
are	O
also	O
knowingly	O
associated	O
with	O
worse	O
outcomes	O
:	O
higher	O
values	O
of	O
ICU	O
severity	O
score	O
,	O
presence	O
of	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
lower	O
ratio	O
of	O
arterial	O
oxygen	O
tension	B-DISO
to	O
fraction	O
of	O
inspired	O
oxygen	O
.	O

There	O
is	O
therefore	O
an	O
ongoing	O
debate	O
as	O
to	O
whether	O
and	O
which	O
ARDS	B-DISO
patients	O
are	O
good	O
candidates	O
to	O
an	O
NIV	O
trial	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
was	O
first	O
identified	O
in	O
2012	O
,	O
and	O
it	O
continues	O
to	O
threaten	O
human	O
health	O
worldwide	O
.	O

TITLE	O
:	O
Discovery	O
of	O
novel	O
piperidine	O
-	O
substituted	O
indolylarylsulfones	O
as	O
potent	O
HIV	B-DISO
NNRTIs	O
via	O
structure	O
-	O
guided	O
scaffold	O
morphing	O
and	O
fragment	O
rearrangement	O
.	O

This	O
substudy	O
examines	O
the	O
current	O
practice	O
of	O
NIV	O
use	O
in	O
ARDS	B-DISO
,	O
the	O
utility	O
of	O
the	O
Pa	O
Of	O
2	O
,	O
813	O
patients	O
with	O
ARDS	B-DISO
,	O
436	O
(	O
15	O
.	O
5	O
%)	O
were	O
managed	O
with	O
NIV	O
on	O
Days	O
1	O
and	O
2	O
following	O
fulfillment	O
of	O
diagnostic	O
criteria	O
.	O

Of	O
these	O
,	O
samples	O
were	O
processed	O
in	O
395	O
episodes	O
(	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
:	O
377	O
;	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
:	O
18	O
).	O

In	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
,	O
viral	B-DISO
infections	I-DISO
were	O
detected	O
in	O
12	O
(	O
66	O
.	O
7	O
%)	O
episodes	O
,	O
bacterial	B-DISO
infections	I-DISO
in	O
17	O
(	O
94	O
.	O
4	O
%)	O
episodes	O
and	O
mixed	O
bacterial	O
-	O
viral	B-DISO
infections	I-DISO
in	O
8	O
(	O
44	O
.	O
4	O
%)	O
episodes	O
.	O

ABSTRACT	O
:	O
To	O
improve	O
the	O
outcome	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
one	O
needs	O
to	O
identify	O
potentially	O
modifiable	O
factors	O
associated	O
with	O
mortality	O
.	O

Common	O
presenting	O
complaints	O
included	O
fever	O
(	O
100	O
%),	O
generalized	O
myalgia	B-DISO
(	O
83	O
%),	O
headache	B-DISO
(	O
65	O
%),	O
dyspnea	B-DISO
(	O
54	O
%),	O
cough	B-DISO
(	O
24	O
.	O
3	O
%),	O
and	O
altered	O
sensorium	O
(	O
14	O
%).	O

Samples	O
were	O
tested	O
for	O
antibodies	O
against	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
CDV	O
),	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
,	O
enteric	O
coronavirus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
herpesvirus	O
(	O
FHV	O
-	O
1	O
),	O
and	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
).	O

However	O
,	O
among	O
the	O
individual	O
cancer	B-DISO
-	O
related	O
complications	O
,	O
VCS	O
[	O
OR	O
=	O
3	O
.	O
79	O
(	O
1	O
.	O
11	O
-	O
12	O
.	O
92	O
),	O
P	O
=	O
0	O
.	O
033	O
],	O
gastrointestinal	O
involvement	O
[	O
OR	O
=	O
3	O
.	O
05	O
(	O
1	O
.	O
57	O
-	O
5	O
.	O
91	O
),	O
P	O
=	O
<	O
0	O
.	O
001	O
]	O
and	O
respiratory	B-DISO
failure	I-DISO
[	O
OR	O
=	O
1	O
.	O
96	O
(	O
1	O
.	O
04	O
-	O
3	O
.	O
71	O
),	O
P	O
=	O
0	O
.	O
038	O
]	O
were	O
independently	O
associated	O
with	O
in	O
-	O
hospital	O
mortality	O
.	O

Although	O
some	O
complications	O
were	O
associated	O
with	O
worse	O
outcomes	O
,	O
the	O
presence	O
of	O
an	O
acute	O
cancer	B-DISO
-	O
related	O
complication	B-DISO
per	O
se	O
should	O
not	O
guide	O
decisions	O
to	O
admit	O
a	O
patient	O
to	O
ICU	O
.	O

Nuclear	O
orphan	O
receptor	O
Nur77	O
has	O
emerged	O
as	O
a	O
regulator	O
of	O
gene	O
expression	O
in	O
inflammation	B-DISO
,	O
and	O
its	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
is	O
not	O
clear	O
.	O

We	O
demonstrate	O
that	O
LPS	B-DISO
induced	O
Nur77	O
expression	O
and	O
nuclear	O
export	O
in	O
A549	O
cells	O
.	O

Patients	O
with	O
pneumococcal	O
HUS	O
usually	O
have	O
a	O
severe	O
clinical	O
picture	O
with	O
microangiopathic	B-DISO
hemolytic	I-DISO
anemia	I-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
neurological	O
involvement	O
.	O

The	O
atypical	O
HUS	O
,	O
in	O
contrast	O
to	O
STEC	O
-	O
HUS	O
which	O
tends	O
to	O
occur	O
as	O
a	O
single	O
event	O
,	O
is	O
a	O
chronic	O
condition	B-DISO
and	O
involves	O
a	O
poorer	O
prognosis	O
.	O

Typical	O
management	O
of	O
STEC	O
-	O
HUS	O
patients	O
relies	O
on	O
supportive	O
care	O
of	O
electrolyte	O
and	O
water	O
imbalance	B-DISO
,	O
anemia	B-DISO
,	O
hypertension	B-DISO
and	O
renal	B-DISO
failure	I-DISO
.	O

This	O
drug	O
has	O
shown	O
an	O
improvement	O
in	O
platelet	O
count	O
,	O
cessation	O
of	O
hemolysis	B-DISO
,	O
improvement	O
of	O
renal	O
function	O
within	O
a	O
few	O
days	O
after	O
the	O
treatment	O
.	O

We	O
conclude	O
that	O
routine	O
screening	O
for	O
CPV	O
,	O
CCoV	O
and	O
hEC	O
is	O
recommended	O
in	O
puppies	O
with	O
acute	B-DISO
diarrhoea	I-DISO
,	O
especially	O
if	O
they	O
are	O
under	O
3	O
months	O
of	O
age	O
and	O
originate	O
from	O
high	O
-	O
volume	O
dog	O
breeders	O
.	O

One	O
of	O
the	O
more	O
serious	O
adverse	B-DISO
effects	I-DISO
includes	O
amiodarone	O
pulmonary	B-DISO
toxicity	I-DISO
(	O
APT	O
).	O

Key	O
features	O
support	O
a	O
clinical	O
diagnosis	O
:	O
(	O
1	O
)	O
new	O
dyspnea	B-DISO
,	O
(	O
2	O
)	O
exclusion	O
of	O
lung	B-DISO
infection	I-DISO
,	O
(	O
3	O
)	O
exclusion	O
of	O
heart	B-DISO
failure	I-DISO
,	O
(	O
4	O
)	O
new	O
radiographic	O
features	O
,	O
(	O
5	O
)	O
improvement	O
with	O
withdrawal	B-DISO
of	O
amiodarone	O
.	O

Thus	O
,	O
an	O
early	O
evaluation	O
of	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
can	O
mitigate	O
unforeseen	O
outcomes	O
within	O
a	O
series	O
of	O
multiple	O
compounds	O
,	O
although	O
there	O
have	O
been	O
very	O
few	O
examples	O
to	O
follow	O
such	O
a	O
policy	O
.	O

Further	O
work	O
is	O
needed	O
to	O
explore	O
potential	O
pathogen	O
interactions	O
and	O
their	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
PTB	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
159	O
patients	O
with	O
ARDS	B-DISO
were	O
evaluated	O
,	O
but	O
just	O
70	O
patients	O
were	O
included	O
.	O

During	O
the	O
outbreak	O
,	O
27	O
.	O
0	O
%	O
of	O
nurses	O
and	O
18	O
.	O
4	O
%	O
of	O
physicians	O
working	O
in	O
the	O
MERS	O
-	O
designated	O
ICUs	O
reported	O
upper	O
respiratory	B-DISO
symptoms	I-DISO
,	O
and	O
were	O
tested	O
for	O
MERS	O
-	O
CoV	O
.	O
Only	O
2	O
/	O
196	O
(	O
1	O
.	O
0	O
%)	O
ICU	O
nurses	O
and	O
1	O
/	O
80	O
(	O
1	O
.	O
3	O
%)	O
physician	O
tested	O
positive	O
,	O
had	O
mild	O
disease	O
and	O
recovered	O
fully	O
.	O

The	O
need	O
for	O
systemic	O
anticoagulation	O
is	O
a	O
relative	O
contraindication	O
for	O
patients	O
with	O
bleeding	B-DISO
risks	O
,	O
especially	O
in	O
multitraumatic	O
injury	O
.	O

Of	O
these	O
,	O
62	O
(	O
27	O
%)	O
tested	O
positive	O
for	O
seasonal	O
influenza	B-DISO
.	O

None	O
of	O
the	O
patients	O
with	O
positive	O
influenza	B-DISO
results	O
had	O
been	O
vaccinated	O
in	O
the	O
year	O
prior	O
to	O
hospital	O
admission	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
respiratory	B-DISO
infections	I-DISO
that	O
can	O
be	O
life	O
-	O
threatening	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
first	O
emerged	O
in	O
the	O
United	O
States	O
in	O
2013	O
causing	O
high	O
mortality	O
and	O
morbidity	O
in	O
neonatal	O
piglets	O
with	O
immense	O
economic	O
losses	O
to	O
the	O
swine	O
industry	O
.	O

The	O
PEDV	O
S	O
antigen	O
was	O
delivered	O
to	O
the	O
dendritic	O
cells	O
through	O
a	O
single	O
-	O
chain	O
antibody	O
specific	O
to	O
Langerin	O
and	O
the	O
targeted	O
cells	O
were	O
stimulated	O
with	O
cholera	B-DISO
toxin	O
adjuvant	O
.	O

TITLE	O
:	O
Microorganisms	O
Causing	O
Community	O
-	O
Acquired	O
Acute	B-DISO
Bronchitis	I-DISO
:	O
The	O
Role	O
of	O
Bacterial	B-DISO
Infection	I-DISO
.	O

ABSTRACT	O
:	O
Although	O
acute	B-DISO
bronchitis	I-DISO
is	O
quite	O
common	O
,	O
there	O
is	O
relatively	O
limited	O
information	O
regarding	O
the	O
microorganisms	O
that	O
are	O
involved	O
in	O
this	O
illness	O
.	O

Thus	O
,	O
by	O
sensitizing	O
viruses	O
to	O
receptor	O
-	O
induced	O
conformational	O
changes	O
,	O
the	O
first	O
S	O
cleavages	O
expand	O
virus	O
tropism	O
to	O
cell	O
types	O
that	O
are	O
relevant	O
to	O
lung	B-DISO
infection	I-DISO
,	O
and	O
therefore	O
may	O
be	O
significant	O
determinants	O
of	O
MERS	O
-	O
CoV	O
virulence	O
.	O

Two	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBV	O
)	O
were	O
isolated	O
from	O
chickens	O
with	O
respiratory	B-DISO
disease	I-DISO
in	O
Sudan	O
.	O

Here	O
,	O
we	O
report	O
three	O
crystal	O
structures	O
of	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
and	O
equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
nsp11	O
mutants	O
.	O

Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
and	O
equine	O
arteritis	B-DISO
virus	O
are	O
two	O
major	O
members	O
of	O
the	O
arterivirus	O
family	O
.	O

This	O
new	O
approach	O
of	O
identifying	O
a	O
potential	O
binding	O
pocket	O
outside	O
the	O
traditional	O
target	O
and	O
creating	O
an	O
artificial	O
tail	O
anchor	O
can	O
be	O
widely	O
applied	O
to	O
design	O
novel	O
fusion	O
inhibitors	O
against	O
other	O
class	O
I	O
enveloped	O
viruses	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Like	O
the	O
RBD	O
of	O
prototype	O
EMC2012	O
(	O
EMC	B-DISO
-	O
RBD	O
),	O
all	O
five	O
RBDs	O
maintained	O
good	O
antigenicity	O
and	O
functionality	O
,	O
the	O
ability	O
to	O
bind	O
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
and	O
the	O
DPP4	O
receptor	O
,	O
and	O
high	O
immunogenicity	O
,	O
able	O
to	O
elicit	O
S	O
-	O
specific	O
antibodies	O
.	O

This	O
study	O
provides	O
impetus	O
for	O
further	O
development	O
of	O
a	O
safe	O
,	O
highly	O
effective	O
,	O
and	O
broad	O
-	O
spectrum	O
RBD	O
-	O
based	O
subunit	O
vaccine	O
to	O
prevent	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

All	O
samples	O
were	O
seronegative	O
for	O
avian	B-DISO
influenza	I-DISO
virus	O
subtypes	O
H5	O
and	O
H7	O
and	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
.	O

For	O
patients	O
that	O
survive	O
the	O
disease	O
,	O
these	O
are	O
the	O
critical	O
processes	O
that	O
require	O
repair	O
and	O
remodeling	O
to	O
allow	O
for	O
the	O
recovery	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
cleaves	O
its	O
C	O
-	O
terminal	O
autoprocessing	O
site	O
by	O
novel	O
subsite	O
cooperativity	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
high	O
mortality	O
rates	O
in	O
newborn	O
piglets	O
,	O
leading	O
to	O
massive	O
losses	O
to	O
the	O
swine	O
industry	O
worldwide	O
during	O
recent	O
epidemics	O
.	O

Next	O
,	O
we	O
challenged	O
both	O
vaccinated	O
mice	O
and	O
control	O
mice	O
with	O
MERS	O
-	O
CoV	O
after	O
adenovirus	B-DISO
transduction	O
of	O
the	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
receptor	O
and	O
then	O
analyzed	O
the	O
ability	O
of	O
mice	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Neutrophil	O
expression	O
of	O
glucocorticoid	O
-	O
induced	O
leucine	O
zipper	O
(	O
GILZ	O
)	O
anti	O
-	O
inflammatory	O
protein	O
is	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
severity	O
.	O

ABSTRACT	O
:	O
Glucocorticoid	O
-	O
induced	O
leucine	O
zipper	O
(	O
GILZ	O
)	O
is	O
a	O
potent	O
anti	O
-	O
inflammatory	O
protein	O
involved	O
in	O
neutrophil	O
apoptosis	O
and	O
the	O
resolution	O
of	O
inflammation	B-DISO
.	O

Given	O
the	O
numerous	O
pathophysiologic	O
roles	O
of	O
neutrophils	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
we	O
postulated	O
that	O
neutrophil	O
GILZ	O
expression	O
might	O
be	O
induced	O
during	O
ARDS	B-DISO
,	O
to	O
modulate	O
the	O
inflammatory	O
process	O
and	O
participate	O
in	O
lung	O
repair	O
.	O

ABSTRACT	O
:	O
Ebolavirus	O
,	O
MERS	O
coronavirus	O
and	O
influenza	B-DISO
virus	O
are	O
zoonotic	O
RNA	O
viruses	O
,	O
which	O
mutate	O
very	O
rapidly	O
.	O

TITLE	O
:	O
A	O
Comparative	O
Study	O
of	O
Clinical	O
Presentation	O
and	O
Risk	O
Factors	O
for	O
Adverse	O
Outcome	O
in	O
Patients	O
Hospitalised	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Disease	I-DISO
Due	O
to	O
MERS	O
Coronavirus	O
or	O
Other	O
Causes	O
.	O

Patient	O
with	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
were	O
not	O
clinically	O
distinguishable	O
from	O
those	O
with	O
negative	O
MERS	O
-	O
CoV	O
RT	O
-	O
PCR	O
results	O
although	O
diarrhoea	B-DISO
was	O
commoner	O
in	O
MERS	O
patients	O
.	O

TITLE	O
:	O
Health	O
Care	O
-	O
Acquired	O
Viral	O
Respiratory	B-DISO
Diseases	I-DISO
.	O

Influenza	B-DISO
vaccination	O
of	O
health	O
care	O
personnel	O
has	O
been	O
shown	O
to	O
further	O
decrease	O
rates	O
of	O
transmission	O
,	O
thus	O
mandatory	O
vaccination	O
is	O
becoming	O
more	O
common	O
.	O

Future	O
research	O
need	O
to	O
examine	O
the	O
:	O
differences	O
between	O
HCWs	O
'	O
intentions	O
to	O
care	O
during	O
SARS	B-DISO
and	O
influenza	B-DISO
outbreaks	O
;	O
relationship	O
between	O
intentions	O
to	O
care	O
and	O
actual	O
care	O
provided	O
;	O
difference	O
between	O
their	O
intentions	O
to	O
care	O
/	O
resign	O
and	O
acceptance	O
of	O
risks	O
;	O
factors	O
influencing	O
their	O
intentions	O
to	O
care	O
;	O
and	O
factors	O
influencing	O
compliance	O
to	O
infection	B-DISO
control	O
measures	O
.	O

For	O
this	O
reason	O
,	O
cDNAs	O
and	O
/	O
or	O
their	O
derivatives	O
must	O
be	O
tested	O
to	O
ensure	O
the	O
absence	O
of	O
infectious	B-DISO
virus	O
and	O
/	O
or	O
viral	O
RNA	O
before	O
transfer	O
out	O
of	O
the	O
BSL	O
-	O
3	O
/	O
4	O
and	O
/	O
or	O
SA	O
laboratory	O
.	O

RESULTS	O
:	O
The	O
study	O
enrolled	O
40	O
patients	O
,	O
20	O
of	O
whom	O
had	O
H1N1	O
-	O
induced	O
ARDS	B-DISO
.	O

Variables	O
associated	O
with	O
mortality	O
included	O
immunosuppression	O
,	O
shock	O
at	O
time	O
of	O
admission	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
occurrence	O
of	O
heparin	B-DISO
-	I-DISO
induced	I-DISO
thrombocytopenia	I-DISO
antibodies	O
,	O
nosocomial	O
sepsis	B-DISO
and	O
duration	O
of	O
ECMO	O
.	O

Viral	O
infection	B-DISO
induced	I-DISO
translocation	B-DISO
of	O
GLTSCR2	O
from	O
nucleus	O
to	O
cytoplasm	O
that	O
enabled	O
GLTSCR2	O
to	O
attenuate	O
type	O
I	O
interferon	O
IFN	O
-	O
β	O
and	O
support	O
viral	O
replication	O
.	O

GLTSCR2	O
-	O
mediated	O
attenuation	O
of	O
RIG	O
-	O
I	O
and	O
IFN	O
-	O
β	O
led	O
to	O
alleviation	O
of	O
host	O
cell	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
viral	B-DISO
infection	I-DISO
.	O

A	O
longitudinal	O
profile	O
of	O
the	O
infection	B-DISO
showed	O
that	O
seroconversion	O
detected	O
by	O
ELISAs	O
based	O
on	O
the	O
recombinant	O
extracellular	O
domain	O
,	O
S	O
,	O
S1	O
and	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
antigens	O
occurred	O
as	O
early	O
as	O
neutralizing	O
antibodies	O
were	O
detected	O
by	O
the	O
ppNT	O
and	O
earlier	O
than	O
antibodies	O
were	O
detected	O
by	O
the	O
inactivated	O
MERS	O
-	O
CoV	O
and	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
ELISAs	O
.	O

We	O
are	O
the	O
first	O
to	O
characterize	O
the	O
swim	O
bladder	O
of	O
the	O
zebrafish	O
larva	O
,	O
which	O
is	O
similar	O
to	O
the	O
mammalian	O
lung	O
,	O
as	O
a	O
real	O
-	O
time	O
in	O
vivo	O
model	O
for	O
examining	O
pulmonary	O
neutrophil	O
infiltration	B-DISO
during	O
ALI	O
.	O

Inhibitor	O
screening	O
assays	O
with	O
this	O
model	O
showed	O
a	O
reduction	O
in	O
neutrophil	B-DISO
migration	I-DISO
into	O
the	O
LPS	B-DISO
-	O
injected	O
swim	O
bladder	O
in	O
response	O
to	O
Shp2	O
inhibition	O
.	O

Additionally	O
,	O
we	O
used	O
this	O
model	O
to	O
assess	O
pneumonia	B-DISO
-	O
induced	O
neutrophil	O
recruitment	B-DISO
by	O
microinjecting	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
patients	O
into	O
swim	O
bladders	O
;	O
this	O
injection	O
enhanced	O
neutrophil	O
aggregation	O
relative	O
to	O
the	O
control	O
.	O

We	O
performed	O
a	O
retrospective	O
observational	O
study	O
of	O
adults	O
hospitalized	O
during	O
the	O
2014	O
season	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
or	O
A	O
(	O
H3N2	O
).	O

sPD	O
-	O
1	O
levels	O
in	O
murine	O
blood	O
(	O
AUC	O
=	O
1	O
(	O
1	O
-	O
1	O
),	O
p	O
=	O
0	O
.	O
006	O
),	O
murine	O
BAL	O
fluid	O
(	O
AUC	O
=	O
0	O
.	O
905	O
(	O
0	O
.	O
717	O
-	O
1	O
.	O
093	O
),	O
p	O
=	O
0	O
.	O
015	O
),	O
and	O
human	O
BAL	O
(	O
AUC	O
=	O
1	O
(	O
1	O
-	O
1	O
),	O
p	O
=	O
0	O
.	O
001	O
)	O
fluid	O
predicted	O
ARDS	B-DISO
.	O

sPD	O
-	O
1	O
could	O
be	O
used	O
to	O
not	O
only	O
diagnose	O
ARDS	B-DISO
,	O
but	O
may	O
be	O
a	O
potential	O
therapy	O
.	O

The	O
spreadsheet	O
model	O
of	O
a	O
farrow	O
-	O
finish	O
hog	O
farm	O
developed	O
in	O
this	O
study	O
can	O
be	O
used	O
to	O
examine	O
changes	O
to	O
the	O
production	O
parameters	O
or	O
to	O
consider	O
other	O
swine	B-DISO
disease	I-DISO
outbreaks	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
)	O
for	O
Lung	O
Injury	O
in	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
):	O
Review	O
of	O
the	O
Literature	O
.	O

ABSTRACT	O
:	O
Despite	O
advances	O
in	O
mechanical	O
ventilation	O
,	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
rates	O
ranging	O
from	O
26	O
%	O
to	O
58	O
%.	O

TITLE	O
:	O
T	O
-	O
cell	O
immunity	O
of	O
SARS	B-DISO
-	O
CoV	O
:	O
Implications	O
for	O
vaccine	O
development	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Over	O
12	O
years	O
have	O
elapsed	O
since	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
triggered	O
the	O
first	O
global	O
alert	O
for	O
coronavirus	B-DISO
infections	I-DISO
.	O

However	O
,	O
other	O
coronaviruses	O
still	O
pose	O
a	O
continuous	O
threat	O
to	O
human	O
health	O
,	O
as	O
exemplified	O
by	O
the	O
recent	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
humans	O
.	O

Interestingly	O
,	O
the	O
plaque	B-DISO
-	O
purified	O
virus	O
had	O
a	O
large	O
deletion	O
in	O
ORF3abc	O
and	O
E	O
genes	O
(	O
1	O
,	O
165	O
nt	O
),	O
and	O
a	O
short	O
deletion	O
in	O
ORF7b	O
gene	O
(	O
60	O
nt	O
),	O
suggesting	O
that	O
these	O
regions	O
are	O
not	O
necessary	O
for	O
in	O
vitro	O
replication	O
of	O
CCoV	O
.	O
Next	O
,	O
the	O
antigenicity	O
between	O
the	O
isolated	O
CCoV	O
-	O
IIb	O
and	O
the	O
other	O
CCoV	O
-	O
IIa	O
was	O
compared	O
by	O
VN	O
test	O
,	O
revealing	O
that	O
antigenicty	O
of	O
the	O
isolated	O
CCoV	O
is	O
equal	O
or	O
higher	O
than	O
that	O
of	O
the	O
other	O
CCoV	O
.	O
In	O
summary	O
,	O
two	O
subgenotypes	O
of	O
CCoV	O
-	O
II	O
are	O
spreading	O
among	O
Vietnamese	O
dogs	O
.	O

Although	O
20	O
%-	O
25	O
%	O
of	O
HCP	B-DISO
experienced	O
MERS	O
-	O
like	O
symptoms	O
,	O
none	O
of	O
them	O
showed	O
seroconversion	O
by	O
plaque	B-DISO
reduction	O
neutralization	O
test	O
(	O
PRNT	O
).	O

GP	O
IIb	O
/	O
IIIa	O
inhibitors	O
improve	O
outcome	O
in	O
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
for	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

Our	O
results	O
suggest	O
that	O
higher	O
cumulative	O
doses	O
and	O
longer	O
treatment	O
durations	O
of	O
steroids	O
are	O
more	O
likely	O
to	O
lead	O
to	O
the	O
development	O
of	O
osteonecrosis	B-DISO
in	O
SARS	B-DISO
patients	O
.	O

The	O
summary	O
RR	O
of	O
osteonecrosis	B-DISO
was	O
1	O
.	O
57	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
30	O
-	O
1	O
.	O
89	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
per	O
5	O
.	O
0	O
g	O
increase	O
in	O
the	O
cumulative	O
dose	O
of	O
steroids	O
and	O
was	O
1	O
.	O
29	O
(	O
95	O
%	O
CI	O
1	O
.	O
09	O
-	O
1	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
for	O
each	O
10	O
-	O
day	O
increment	O
of	O
increase	O
in	O
treatment	O
duration	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
porcine	O
kidney	O
cells	O
using	O
short	O
hairpin	O
RNAs	O
targeting	O
the	O
membrane	O
gene	O
.	O

Demographic	O
,	O
hemodynamic	O
,	O
physiologic	O
,	O
and	O
ventilator	O
data	O
at	O
the	O
time	O
of	O
the	O
paired	O
PEEP	O
and	O
ICP	B-DISO
observations	O
were	O
recorded	O
.	O

There	O
are	O
concerns	O
that	O
the	O
use	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
patients	O
with	O
brain	O
injury	O
may	O
potentially	O
elevate	O
intracranial	O
pressure	O
(	O
ICP	B-DISO
).	O

TITLE	O
:	O
An	O
investigation	O
into	O
respiratory	O
tract	O
viruses	O
in	O
children	O
with	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
or	O
wheezing	B-DISO
.	O

Statistically	O
significant	O
differences	O
in	O
the	O
detection	O
of	O
influenza	B-DISO
virus	O
A	O
(	O
P	O
=	O
0	O
.	O
000	O
),	O
the	O
total	O
detection	O
of	O
parainfluenza	B-DISO
viruses	O
(	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
coinfection	B-DISO
(	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
observed	O
between	O
the	O
patient	O
and	O
control	O
groups	O
.	O

The	O
advantage	O
of	O
our	O
study	O
compared	O
with	O
other	O
studies	O
is	O
the	O
inclusion	O
of	O
not	O
only	O
wheezing	B-DISO
patients	O
but	O
also	O
children	O
with	O
asthma	B-DISO
without	O
symptom	B-DISO
.	O

RESULTS	O
:	O
The	O
viruses	O
detected	O
in	O
the	O
patient	O
and	O
control	O
groups	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
were	O
as	O
follows	O
,	O
respectively	O
:	O
rhinoviruses	O
A	O
,	O
B	O
,	O
C	O
(	O
25	O
.	O
6	O
%	O
and	O
36	O
.	O
7	O
%),	O
influenza	B-DISO
virus	O
A	O
(	O
21	O
.	O
1	O
%	O
and	O
0	O
.	O
0	O
%),	O
parainfluenza	B-DISO
virus	O
type	O
1	O
(	O
7	O
.	O
8	O
%	O
and	O
1	O
.	O
7	O
%),	O
parainfluenza	B-DISO
virus	O
type	O
4	O
(	O
5	O
.	O
6	O
%	O
and	O
0	O
.	O
0	O
%),	O
adenoviruses	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
,	O
E	O
(	O
4	O
.	O
4	O
%	O
and	O
1	O
.	O
7	O
%),	O
parainfluenza	B-DISO
virus	O
type	O
3	O
(	O
4	O
.	O
4	O
%	O
and	O
1	O
.	O
7	O
%),	O
coronaviruses	O
229E	O
and	O
NL63	O
(	O
4	O
.	O
4	O
%	O
and	O
1	O
.	O
7	O
%),	O
coronavirus	O
OC43	O
(	O
3	O
.	O
3	O
%	O
and	O
0	O
.	O
0	O
%),	O
respiratory	O
syncytial	O
virus	O
A	O
(	O
3	O
.	O
3	O
%	O
and	O
0	O
.	O
0	O
%),	O
parainfluenza	B-DISO
virus	O
type	O
2	O
(	O
2	O
.	O
2	O
%	O
and	O
0	O
.	O
0	O
%),	O
influenza	B-DISO
virus	O
B	O
(	O
2	O
.	O
2	O
%	O
and	O
0	O
.	O
0	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
B	O
(	O
1	O
.	O
1	O
%	O
and	O
1	O
.	O
7	O
%).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
patients	O
with	O
severe	O
biventricular	B-DISO
heart	I-DISO
failure	I-DISO
who	O
underwent	O
Berlin	O
Heart	O
Excor	O
implantation	O
with	O
(	O
cardiogenic	B-DISO
shock	I-DISO
[	O
CS	O
]	O
status	O
)	O
or	O
without	O
the	O
need	O
for	O
preoperative	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
as	O
a	O
bridge	O
to	O
long	O
-	O
term	O
device	O
.	O

Of	O
1207	O
monthly	O
samples	O
taken	O
from	O
random	O
animals	O
over	O
a	O
2	O
-	O
year	O
period	O
,	O
only	O
a	O
single	O
positive	O
result	O
for	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
was	O
observed	O
,	O
demonstrating	O
the	O
high	O
level	O
of	O
biosecurity	O
maintained	O
in	O
the	O
source	O
herd	O
.	O

Given	O
the	O
lack	O
of	O
clinical	O
signs	O
,	O
positive	O
antibody	O
titers	O
for	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
,	O
Porcine	O
parvovirus	B-DISO
,	O
and	O
Influenza	B-DISO
A	O
confirm	O
the	O
efficacy	O
of	O
the	O
herd	O
vaccination	O
program	O
.	O

RESULTS	O
:	O
Of	O
1207	O
monthly	O
samples	O
taken	O
from	O
random	O
animals	O
over	O
a	O
2	O
-	O
year	O
period	O
,	O
only	O
a	O
single	O
positive	O
result	O
for	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
was	O
observed	O
,	O
demonstrating	O
the	O
high	O
level	O
of	O
biosecurity	O
maintained	O
in	O
the	O
source	O
herd	O
.	O

TITLE	O
:	O
Quantitative	O
structure	O
-	O
activity	O
relationship	O
and	O
molecular	O
docking	O
revealed	O
a	O
potency	O
of	O
anti	O
-	O
hepatitis	B-DISO
C	I-DISO
virus	O
drugs	O
against	O
human	O
corona	O
viruses	O
.	O

Some	O
outbreaks	O
of	O
which	O
(	O
eg	O
,	O
SARS	B-DISO
and	O
MERS	O
CoVs	O
)	O
caused	O
the	O
mortality	O
of	O
hundreds	O
of	O
people	O
worldwide	O
.	O

ABSTRACT	O
:	O
The	O
reported	O
survival	O
rates	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
human	O
adenovirus	B-DISO
(	O
HAdV	O
)	O
pneumonia	B-DISO
are	O
poor	O
.	O

Second	O
,	O
we	O
implemented	O
conservative	O
fluid	O
management	O
as	O
recommended	O
by	O
the	O
ARDS	B-DISO
network	O
using	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
).	O

this	O
is	O
a	O
descriptive	O
study	O
of	O
5	O
,	O
158	O
patients	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
;	O
a	O
comparison	O
was	O
made	O
between	O
the	O
characteristics	O
of	O
confirmed	O
cases	O
and	O
those	O
of	O
discarded	O
cases	O
or	O
cases	O
without	O
swab	O
samples	O
.	O

Finally	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
acute	B-DISO
pancreatitis	I-DISO
complicated	O
with	O
diabetic	B-DISO
ketoacidosis	I-DISO
unrelated	O
to	O
hypertriglyceridemia	O
.	O

The	O
most	O
common	O
source	O
of	O
infection	B-DISO
was	O
household	O
contact	O
(	O
10	O
of	O
15	O
with	O
reported	O
source	O
)	O
and	O
5	O
patients	O
acquired	O
infection	B-DISO
within	O
a	O
health	O
care	O
facility	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
the	O
epidemiology	O
,	O
clinical	O
characteristics	O
,	O
outcomes	O
,	O
and	O
severity	O
of	O
illnesses	O
associated	O
with	O
HCoV	O
infections	B-DISO
at	O
a	O
single	O
center	O
in	O
Korea	O
.	O

However	O
,	O
compared	O
with	O
that	O
of	O
RSV	B-DISO
infection	I-DISO
,	O
the	O
disease	O
course	O
HCoV	O
was	O
short	O
.	O

A	O
6	O
-	O
month	O
-	O
old	O
girl	O
with	O
right	O
lung	B-DISO
agenesis	I-DISO
,	O
congenital	B-DISO
heart	I-DISO
defects	I-DISO
,	O
and	O
ear	B-DISO
anomalies	I-DISO
developed	O
repeated	O
and	O
serious	O
respiratory	B-DISO
infection	I-DISO
for	O
a	O
short	O
period	O
.	O

He	O
died	O
within	O
24	O
hours	O
of	O
presentation	O
from	O
a	O
combination	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
.	O

It	O
is	O
widely	O
recognized	O
that	O
chronic	O
intermittent	O
hypoxia	B-DISO
(	O
CIH	O
),	O
a	O
cardinal	O
feature	O
of	O
OSAS	B-DISO
due	O
to	O
recurrent	B-DISO
apnoea	I-DISO
,	O
drives	O
many	O
of	O
the	O
morbid	O
consequences	O
characteristic	O
of	O
the	O
disorder	O
.	O

Sex	O
differences	O
in	O
upper	O
airway	O
muscle	O
physiology	O
may	O
have	O
relevance	O
to	O
human	O
OSAS	B-DISO
.	O

Among	O
1027	O
children	O
,	O
2295	O
days	O
of	O
school	O
were	O
missed	O
due	O
to	O
medically	O
attended	O
ARIs	O
;	O
influenza	B-DISO
accounted	O
for	O
39	O
%	O
of	O
illness	O
episodes	O
and	O
47	O
%	O
of	O
days	O
missed	O
.	O

Mean	O
days	O
absent	O
were	O
highest	O
for	O
influenza	B-DISO
(	O
0	O
.	O
96	O
-	O
1	O
.	O
19	O
)	O
and	O
lowest	O
for	O
coronavirus	O
(	O
0	O
.	O
62	O
).	O

Among	O
children	O
with	O
influenza	B-DISO
,	O
vaccination	O
status	O
was	O
not	O
associated	O
with	O
prolonged	O
absence	O
.	O

ABSTRACT	O
:	O
Obesity	B-DISO
worsens	O
asthma	B-DISO
control	O
partly	O
through	O
enhanced	O
airway	O
neutrophilia	O
,	O
altered	O
lung	O
mechanics	O
and	O
comorbidities	O
,	O
including	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
,	O
gastroesophageal	B-DISO
reflux	I-DISO
disease	I-DISO
and	O
depression	B-DISO
.	O

TITLE	O
:	O
A	O
mouse	O
model	O
for	O
MERS	O
coronavirus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
virus	O
that	O
emerged	O
in	O
2012	O
,	O
causing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
severe	O
pneumonia	B-DISO
-	O
like	O
symptoms	O
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
,	O
with	O
a	O
case	O
fatality	O
rate	O
of	O
∼	O
36	O
%.	O

Models	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
severe	O
respiratory	B-DISO
disease	I-DISO
have	O
been	O
difficult	O
to	O
achieve	O
,	O
and	O
small	O
-	O
animal	O
models	O
traditionally	O
used	O
to	O
investigate	O
viral	B-DISO
pathogenesis	I-DISO
(	O
mouse	O
,	O
hamster	O
,	O
guinea	O
-	O
pig	O
and	O
ferret	O
)	O
are	O
naturally	O
resistant	O
to	O
MERS	O
-	O
CoV	O
.	O
Therefore	O
,	O
we	O
used	O
CRISPR	O
-	O
Cas9	O
gene	O
editing	O
to	O
modify	O
the	O
mouse	O
genome	O
to	O
encode	O
two	O
amino	O
acids	O
(	O
positions	O
288	O
and	O
330	O
)	O
that	O
match	O
the	O
human	O
sequence	O
in	O
the	O
dipeptidyl	O
peptidase	O
4	O
receptor	O
,	O
making	O
mice	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
replication	O
.	O

Although	O
myriads	O
of	O
diagnostic	O
methods	O
based	O
on	O
RNA	O
amplification	B-DISO
have	O
been	O
developed	O
in	O
the	O
last	O
decades	O
,	O
they	O
continue	O
to	O
lack	O
speed	O
,	O
sensitivity	O
,	O
and	O
specificity	O
for	O
clinical	O
use	O
.	O

Here	O
,	O
we	O
report	O
an	O
isothermal	O
,	O
label	O
-	O
free	O
,	O
one	O
-	O
step	O
RNA	O
amplification	B-DISO
and	O
detection	O
system	O
,	O
termed	O
as	O
iROAD	O
,	O
for	O
the	O
diagnosis	O
of	O
respiratory	B-DISO
diseases	I-DISO
.	O

We	O
envision	O
that	O
the	O
iROAD	O
assay	O
will	O
be	O
useful	O
and	O
potentially	O
adaptable	O
for	O
better	O
diagnosis	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
including	O
respiratory	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Non	B-DISO
-	I-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
rhabdomyolysis	B-DISO
and	O
myocardial	O
injury	O
following	O
heroin	O
inhalation	O
:	O
a	O
case	O
report	O
.	O

On	O
the	O
second	O
day	O
of	O
hospitalization	O
the	O
pulmonary	B-DISO
infiltrates	I-DISO
were	O
not	O
present	O
in	O
his	O
chest	O
X	O
-	O
ray	O
while	O
on	O
the	O
eighth	O
day	O
,	O
troponin	O
-	O
I	O
and	O
CK	O
levels	O
were	O
normalized	O
without	O
dynamic	O
ECG	O
changes	O
and	O
the	O
patient	O
was	O
discharged	O
uneventfully	O
.	O

CONCLUSIONS	O
:	O
Heroin	O
inhalation	O
may	O
cause	O
severe	O
complications	O
,	O
such	O
as	O
non	B-DISO
-	I-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
rhabdomyolysis	B-DISO
or	O
myocardial	O
injury	O
.	O

PubMed	O
and	O
Web	B-DISO
of	O
Science	O
databases	O
were	O
searched	O
for	O
clinical	O
and	O
epidemiological	O
studies	O
on	O
confirmed	O
cases	O
of	O
MERS	O
.	O

According	O
to	O
the	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
P	O
/	O
F	O
ratio	O
)	O
at	O
7	O
days	O
,	O
patients	O
were	O
classified	O
into	O
PPP	B-DISO
-	O
positive	O
(	O
P	O
/	O
F	O
ratio	O
>	O
300	O
)	O
and	O
PPP	B-DISO
-	O
negative	O
groups	O
;	O
also	O
,	O
the	O
patients	O
were	O
classified	O
into	O
survival	O
and	O
nonsurvival	O
groups	O
according	O
to	O
28	O
-	O
day	O
mortality	O
.	O

As	O
an	O
alternative	O
to	O
chicks	O
,	O
this	O
study	O
used	O
an	O
in	O
vitro	O
infection	B-DISO
model	O
to	O
identify	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
the	O
part	O
-	O
S1	O
gene	O
of	O
two	O
live	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccine	O
strains	O
(	O
793B	O
and	O
Massachusetts	O
)	O
following	O
single	O
or	O
dual	O
inoculation	O
onto	O
tracheal	O
organ	O
cultures	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	O
oxide	O
and	O
the	O
risk	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
rescue	O
therapy	O
for	O
severe	O
hypoxemia	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
used	O
primary	O
data	O
to	O
evaluate	O
the	O
risk	O
of	O
iNO	O
-	O
associated	O
renal	O
dysfunction	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Adenovirus	B-DISO
infections	I-DISO
are	O
associated	O
with	O
respiratory	O
(	O
especially	O
upper	O
respiratory	O
)	O
infection	B-DISO
and	O
gastrointestinal	B-DISO
disease	I-DISO
and	O
occur	O
primarily	O
in	O
infants	O
and	O
children	O
.	O

Leaves	O
and	O
roots	O
were	O
the	O
most	O
common	O
parts	O
used	O
in	O
ethnomedicines	O
against	O
bronchitis	B-DISO
.	O

TITLE	O
:	O
Legionella	B-DISO
pneumonia	I-DISO
in	O
the	O
Niagara	O
Region	O
,	O
Ontario	O
,	O
Canada	O
:	O
a	O
case	O
series	O
.	O

RESULTS	O
:	O
From	O
June	O
to	O
December	O
2013	O
,	O
there	O
were	O
14	O
hospitalized	O
cases	O
of	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
in	O
the	O
Niagara	O
Region	O
.	O

Noninvasive	O
ventilation	O
can	O
be	O
attempted	O
prior	O
to	O
intubation	O
and	O
mechanical	O
ventilation	O
in	O
the	O
setting	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Prompt	O
recognition	O
and	O
initiation	O
of	O
immunotherapy	O
including	O
intravenous	O
immunoglobulin	O
or	O
plasmapheresis	O
,	O
together	O
with	O
supportive	O
care	O
including	O
treatment	O
of	O
underlying	O
infections	B-DISO
and	O
physical	O
therapy	O
,	O
can	O
improve	O
outcomes	O
in	O
both	O
myasthenic	B-DISO
crisis	I-DISO
and	O
GBS	B-DISO
.	O

TITLE	O
:	O
Impact	O
and	O
seasonality	O
of	O
human	O
rhinovirus	B-DISO
infection	I-DISO
in	O
hospitalized	O
patients	O
for	O
two	O
consecutive	O
years	O
.	O

ABSTRACT	O
:	O
To	O
report	O
epidemiological	O
features	O
,	O
clinical	O
characteristics	O
,	O
and	O
outcomes	O
of	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
infections	B-DISO
in	O
comparison	O
with	O
other	O
community	O
acquired	O
respiratory	O
virus	O
(	O
CRV	B-DISO
)	O
infections	B-DISO
in	O
patients	O
hospitalized	O
for	O
two	O
consecutive	O
years	O
.	O

Detection	O
of	O
HRV	O
was	O
more	O
prevalent	O
during	O
autumn	O
and	O
winter	O
,	O
with	O
a	O
moderately	O
negative	O
correlation	O
between	O
viral	B-DISO
infection	I-DISO
frequency	O
and	O
temperature	O
(	O
r	O
=-	O
0	O
.	O
636	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
but	O
no	O
correlation	O
with	O
rainfall	O
(	O
r	O
=-	O
0	O
.	O
036	O
,	O
p	O
=	O
0	O
.	O
866	O
).	O

To	O
better	O
understand	O
the	O
pathogenesis	B-DISO
mechanism	O
and	O
the	O
virus	O
-	O
host	O
interaction	O
during	O
infection	B-DISO
with	O
both	O
PEDV	O
YN13	O
and	O
YN144	O
strains	O
,	O
a	O
comparative	O
proteomic	O
analysis	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
proteomic	O
changes	O
produced	O
in	O
the	O
primary	O
target	O
organ	O
,	O
using	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantitation	O
(	O
iTRAQ	O
)	O
labeling	O
,	O
followed	O
by	O
liquid	O
chromatography	O
tandem	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
).	O

Emerging	O
zoonotic	O
pathogens	O
,	O
for	O
example	O
,	O
MERS	O
coronavirus	O
,	O
avian	B-DISO
influenza	I-DISO
viruses	O
,	O
Coxiella	O
,	O
and	O
Francisella	O
,	O
would	O
have	O
pandemic	O
potential	O
were	O
they	O
to	O
acquire	O
efficient	O
human	O
-	O
to	O
-	O
human	O
transmissibility	O
.	O

Here	O
,	O
we	O
synthesize	O
insights	O
from	O
microbiological	O
,	O
medical	O
,	O
social	O
,	O
and	O
economic	O
sciences	O
to	O
provide	O
known	O
mechanisms	O
of	O
aerosolized	O
transmissibility	O
and	O
identify	O
knowledge	O
gaps	O
that	O
limit	O
emergency	B-DISO
preparedness	O
plans	O
.	O

TITLE	O
:	O
Outcomes	O
and	O
survival	O
prediction	O
models	O
for	O
severe	O
adult	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
known	O
a	O
growing	O
interest	O
over	O
the	O
last	O
decades	O
with	O
promising	O
results	O
during	O
the	O
2009	O
A	O
(	O
H1N1	O
)	O
influenza	B-DISO
epidemic	I-DISO
.	O

Prehospital	O
professionals	O
face	B-DISO
the	O
risk	O
of	O
infection	B-DISO
as	O
they	O
work	O
to	O
save	O
lives	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
in	O
Dengue	B-DISO
,	O
Malaria	B-DISO
,	O
and	O
Acute	O
Chagas	B-DISO
Disease	I-DISO
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
widely	O
used	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
myocarditis	B-DISO
.	O

For	O
the	O
first	O
time	O
in	O
Ethiopia	O
,	O
we	O
report	O
the	O
detection	O
of	O
variant	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
793B	O
genotype	O
),	O
avian	O
metapneumovirus	O
subtype	O
B	O
and	O
Mycoplasma	B-DISO
synoviae	O
in	O
poultry	O
.	O

Various	O
randomized	O
clinical	O
studies	O
have	O
demonstrated	O
the	O
effect	O
of	O
prone	O
decubitus	O
on	O
the	O
oxygenation	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
measured	O
in	O
terms	O
of	O
the	O
PaO2	O
/	O
FiO2	O
ratio	O
,	O
including	O
its	O
effects	O
on	O
increasing	O
patient	O
survival	O
.	O

Mice	O
developing	O
ALI	O
/	O
ARDS	B-DISO
showed	O
greater	O
neutrophil	O
accumulation	O
in	O
the	O
lungs	O
compared	O
with	O
mice	O
that	O
did	O
not	O
develop	O
pulmonary	B-DISO
complications	I-DISO
.	O

Diagnosis	O
is	O
suggested	O
by	O
a	O
history	O
of	O
cough	B-DISO
,	O
dyspnea	B-DISO
,	O
pleuritic	B-DISO
pain	I-DISO
,	O
or	O
acute	O
functional	O
or	O
cognitive	B-DISO
decline	I-DISO
,	O
with	O
abnormal	O
vital	O
signs	O
(	O
e	O
.	O
g	O
.,	O
fever	O
,	O
tachycardia	O
)	O
and	O
lung	O
examination	O
findings	O
.	O

Using	O
PubMed	O
and	O
Google	O
,	O
a	O
comprehensive	O
search	O
of	O
articles	O
connected	O
to	O
the	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
,	O
SARS	B-DISO
,	O
H1N1	O
and	O
Ebola	O
responses	O
was	O
conducted	O
.	O

The	O
data	O
suggest	O
that	O
the	O
world	O
remains	O
ill	B-DISO
prepared	O
to	O
handle	O
sustained	O
responses	O
and	O
global	O
pandemics	O
.	O

TITLE	O
:	O
Recovery	O
After	O
Critical	B-DISO
Illness	I-DISO
Polyneuropathy	I-DISO
in	O
a	O
Patient	O
With	O
Orthotopic	O
Liver	O
Transplantation	O
:	O
A	O
Case	O
Report	O
.	O

TITLE	O
:	O
Influenza	B-DISO
not	O
MERS	O
CoV	O
among	O
returning	O
Hajj	O
and	O
Umrah	O
pilgrims	O
with	O
respiratory	O
illness	O
,	O
Kashmir	O
,	O
north	O
India	O
,	O
2014	O
-	O
15	O
.	O

ABSTRACT	O
:	O
The	O
increasing	O
reports	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
)	O
caused	O
by	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
from	O
many	O
countries	O
emphasize	O
its	O
importance	O
for	O
international	O
travel	O
.	O

TITLE	O
:	O
Integration	O
of	O
Global	O
Analyses	O
of	O
Host	O
Molecular	O
Responses	O
with	O
Clinical	O
Data	O
To	O
Evaluate	O
Pathogenesis	B-DISO
and	O
Advance	O
Therapies	O
for	O
Emerging	O
and	O
Re	O
-	O
emerging	O
Viral	B-DISO
Infections	I-DISO
.	O

The	O
patient	O
'	O
s	O
condition	B-DISO
deteriorated	O
rapidly	O
and	O
required	O
life	O
support	O
through	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

In	O
a	O
word	O
,	O
this	O
study	O
provided	O
a	O
RNA	O
extraction	O
and	O
transcription	O
free	O
,	O
rapid	O
and	O
economical	O
method	O
for	O
preclinical	O
PEDV	O
infection	B-DISO
,	O
which	O
showed	O
higher	O
sensitivity	O
,	O
specificity	O
and	O
reproducibility	O
,	O
and	O
exhibited	O
application	O
potency	O
for	O
evaluating	O
viral	O
loads	O
of	O
preclinical	O
samples	O
.	O

The	O
results	O
from	O
individual	O
animals	O
,	O
especially	O
when	O
the	O
infection	B-DISO
has	O
occurred	O
within	O
an	O
experimental	O
situation	O
,	O
show	O
more	O
variation	O
.	O

ABSTRACT	O
:	O
Transmission	O
heterogeneity	O
was	O
observed	O
during	O
the	O
2015	O
South	O
Korean	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Genomic	O
investigation	O
of	O
piglet	O
resilience	O
following	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
outbreaks	O
.	O

Although	O
the	O
infection	B-DISO
in	O
adults	O
is	O
not	O
fatal	O
,	O
in	O
naïve	O
suckling	O
piglets	O
mortality	O
is	O
close	O
to	O
100	O
%.	O

Progression	O
to	O
the	O
most	O
severe	O
forms	O
of	O
the	O
syndrome	B-DISO
confers	O
a	O
mortality	O
rate	O
greater	O
than	O
40	O
%	O
and	O
is	O
associated	O
with	O
often	O
severe	O
functional	O
disability	O
and	O
psychological	B-DISO
sequelae	O
in	O
survivors	O
.	O

While	O
there	O
are	O
no	O
disease	O
-	O
modifying	O
pharmacotherapies	O
for	O
the	O
syndrome	B-DISO
,	O
this	O
progression	O
may	O
be	O
prevented	O
through	O
the	O
institution	O
of	O
quality	O
improvement	O
measures	O
that	O
minimise	O
iatrogenic	O
injury	O
associated	O
with	O
acute	O
severe	O
illness	O
.	O

ABSTRACT	O
:	O
A	O
body	O
of	O
evidence	O
supports	O
the	O
use	O
of	O
low	O
tidal	O
volumes	O
in	O
ventilated	O
patients	O
without	O
lung	O
pathology	B-DISO
to	O
slow	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
due	O
to	O
ventilator	O
associated	O
lung	O
injury	O
.	O

TITLE	O
:	O
Vaccines	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
other	O
swine	O
coronaviruses	O
.	O

While	O
vaccines	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
have	O
been	O
available	O
to	O
producers	O
around	O
the	O
world	O
for	O
a	O
long	O
time	O
,	O
effective	O
vaccines	O
for	O
PEDV	O
and	O
deltacoronaviruses	O
were	O
only	O
recently	O
developed	O
or	O
are	O
still	O
in	O
development	O
.	O

However	O
,	O
its	O
function	O
during	O
infection	B-DISO
remains	O
unknown	O
.	O

Understanding	O
the	O
mechanism	O
used	O
by	O
this	O
enzyme	O
to	O
promote	O
disease	O
will	O
open	O
up	O
novel	O
avenues	O
for	O
coronavirus	O
therapies	O
and	O
give	O
further	O
insight	O
into	O
the	O
role	O
of	O
macrodomains	O
in	O
viral	B-DISO
pathogenesis	I-DISO
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
relationships	O
between	O
ARDS	B-DISO
diagnosis	O
and	O
plasma	O
concentrations	O
of	O
tissue	O
factor	O
(	O
TF	O
),	O
tissue	O
plasminogen	O
activator	O
(	O
t	O
-	O
PA	O
),	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
in	O
mechanically	O
ventilated	O
patients	O
at	O
increased	O
risk	O
of	O
developing	O
ARDS	B-DISO
.	O

The	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
have	O
held	O
nine	O
meetings	O
of	O
the	O
Emergency	B-DISO
Committee	O
(	O
EC	O
)	O
convened	O
by	O
the	O
Director	O
-	O
General	O
under	O
the	O
International	O
Health	O
Regulations	O
(	O
IHR	O
2005	O
)	O
regarding	O
MERS	O
-	O
CoV	O
(	O
WHO	O
2015c	O
).	O

There	O
is	O
wishful	O
anticipation	O
in	O
the	O
political	O
and	O
scientific	O
communities	O
that	O
MERS	O
-	O
CoV	O
like	O
SARS	B-DISO
-	O
CoV	O
will	O
disappear	O
with	O
time	O
.	O

RESULTS	O
:	O
After	O
5	O
days	O
of	O
treatment	O
,	O
the	O
low	O
-	O
and	O
high	O
-	O
dose	O
groups	O
had	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
reductions	O
of	O
these	O
markers	O
between	O
the	O
two	O
groups	O
.	O

There	O
were	O
also	O
no	O
significant	O
differences	O
in	O
the	O
incidence	O
rates	O
of	O
pyrexia	O
,	O
headache	B-DISO
,	O
nausea	B-DISO
,	O
and	O
palpitation	O
between	O
the	O
two	O
groups	O
.	O

In	O
the	O
malignant	O
group	O
,	O
the	O
patient	O
-	O
related	O
independent	O
clinical	O
risk	O
factor	O
for	O
the	O
early	B-DISO
complication	I-DISO
rate	O
was	O
current	O
smoking	O
status	O
(	O
B	O
=	O
2	O
.	O
953	O
,	O
P	O
=	O
0	O
.	O
006	O
,	O
OR	O
=	O
19	O
.	O
161	O
,	O
95	O
%	O
CI	O
2	O
.	O
360	O
-	O
155	O
.	O
572	O
).	O

In	O
the	O
benign	O
group	O
,	O
the	O
patient	O
-	O
related	O
independent	O
clinical	O
risk	O
factor	O
for	O
the	O
early	B-DISO
complication	I-DISO
rate	O
was	O
only	O
coronary	O
atherosclerotic	B-DISO
heart	I-DISO
disease	I-DISO
(	O
B	O
=	O
1	O
.	O
976	O
,	O
P	O
=	O
0	O
.	O
022	O
,	O
OR	O
=	O
7	O
.	O
214	O
,	O
95	O
%	O
CI	O
1	O
.	O
324	O
-	O
39	O
.	O
298	O
).	O

In	O
the	O
benign	O
group	O
,	O
the	O
patient	O
-	O
related	O
independent	O
clinical	O
risk	O
factor	O
for	O
the	O
early	B-DISO
complication	I-DISO
rate	O
was	O
only	O
coronary	O
atherosclerotic	B-DISO
heart	I-DISO
disease	I-DISO
(	O
B	O
=	O
1	O
.	O
976	O
,	O
P	O
=	O
0	O
.	O
022	O
,	O
OR	O
=	O
7	O
.	O
214	O
,	O
95	O
%	O
CI	O
1	O
.	O
324	O
-	O
39	O
.	O
298	O
).	O

TITLE	O
:	O
The	O
Identification	O
and	O
Characterization	O
of	O
Two	O
Novel	O
Epitopes	O
on	O
the	O
Nucleocapsid	O
Protein	O
of	O
the	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
.	O

Some	O
of	O
them	O
have	O
been	O
used	O
since	O
ancient	O
times	O
against	O
viral	B-DISO
infections	I-DISO
.	O

1	O
h	O
after	O
the	O
first	O
administration	O
of	O
G	O
-	O
CSF	O
,	O
the	O
donor	O
suddenly	O
presented	O
with	O
dry	B-DISO
cough	I-DISO
and	O
dyspnea	B-DISO
.	O

CONCLUSIONS	O
:	O
These	O
respiratory	B-DISO
symptoms	I-DISO
might	O
be	O
related	O
to	O
anaphylactoid	O
or	O
hypersensitivity	B-DISO
reaction	I-DISO
.	O

Bioinformatics	O
predicts	O
that	O
PDCoV	O
encodes	O
two	O
accessory	O
proteins	O
(	O
NS6	B-DISO
and	O
NS7	B-DISO
),	O
the	O
species	O
-	O
specific	O
proteins	O
for	O
coronavirus	O
.	O

The	O
syndrome	B-DISO
is	O
most	O
commonly	O
a	O
manifestation	O
of	O
sepsis	B-DISO
-	O
induced	O
organ	O
dysfunction	O
,	O
characterized	O
by	O
disruption	O
of	O
endothelial	O
barrier	O
integrity	O
and	O
diffuse	O
lung	O
damage	O
.	O

TITLE	O
:	O
[	O
Risk	O
factors	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
following	O
surgeries	O
for	O
pediatric	O
critical	O
and	O
complex	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
].	O

In	O
the	O
80	O
patients	O
who	O
developed	O
ARDS	B-DISO
postoperatively	O
in	O
group	O
II	O
,	O
27	O
had	O
mild	O
ARDS	B-DISO
,	O
25	O
had	O
moderate	O
ARDS	B-DISO
,	O
and	O
28	O
had	O
severe	O
ARDS	B-DISO
;	O
death	O
occurred	O
in	O
17	O
(	O
21	O
%)	O
cases	O
.	O

Univariate	O
analyses	O
showed	O
that	O
23	O
parameters	O
were	O
significantly	O
different	O
between	O
groups	O
I	O
and	O
II	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
including	O
weight	O
;	O
preoperative	O
PCO2	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
,	O
pulmonary	O
artery	O
pressure	O
,	O
pulmonary	B-DISO
infection	I-DISO
,	O
and	O
coagulation	O
abnormalities	O
;	O
early	O
postoperative	O
serum	O
globulin	O
;	O
intraoperative	O
aortic	O
cross	O
clamp	O
(	O
ACC	B-DISO
)	O
time	O
;	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
time	O
;	O
operation	O
time	O
;	O
blood	B-DISO
loss	I-DISO
and	O
blood	O
transfusion	O
amount	O
intraoperatively	O
and	O
during	O
the	O
first	O
8	O
h	O
after	O
operation	O
;	O
lactic	O
acid	O
level	O
immediately	O
after	O
the	O
operation	O
and	O
its	O
maximum	O
increasing	O
rate	O
within	O
24	O
h	O
postoperatively	O
;	O
postoperative	O
serum	O
levels	O
of	O
albumin	O
and	O
creatinine	O
;	O
serum	O
levels	O
of	O
B	O
-	O
type	O
natriuretic	O
peptide	O
,	O
procalcitonin	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
prealbumin	O
24	O
h	O
after	O
operation	O
;	O
and	O
age	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
how	O
aptamers	O
working	O
against	O
viral	O
proteins	O
are	O
discovered	O
,	O
with	O
a	O
focus	O
on	O
recent	O
advances	O
that	O
improve	O
the	O
aptamers	O
'	O
properties	O
as	O
a	O
real	O
tool	O
for	O
viral	B-DISO
infection	I-DISO
detection	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
alga	O
-	O
derived	O
lectin	O
with	O
demonstrated	O
broad	O
spectrum	O
antiviral	O
activity	O
against	O
enveloped	O
viruses	O
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Japanese	B-DISO
encephalitis	I-DISO
virus	O
(	O
JEV	O
),	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
),	O
and	O
herpes	B-DISO
simplex	I-DISO
virus	O
-	O
2	O
(	O
HSV	O
-	O
2	O
).	O

These	O
findings	O
support	O
further	O
evaluation	O
of	O
GRFT	O
for	O
pre	O
-	O
exposure	O
prophylaxis	O
against	O
emerging	O
epidemics	O
for	O
which	O
specific	O
therapeutics	O
are	O
not	O
available	O
,	O
including	O
systemic	O
and	O
enteric	O
infections	B-DISO
caused	O
by	O
susceptible	O
enveloped	O
viruses	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
circulate	O
in	O
both	O
humans	O
and	O
camels	O
,	O
and	O
the	O
origin	O
and	O
evolution	O
of	O
the	O
virus	O
remain	O
unclear	O
.	O

TITLE	O
:	O
Human	O
lung	O
ex	O
vivo	O
infection	B-DISO
models	O
.	O

The	O
present	O
review	O
gives	O
an	O
overview	O
of	O
common	O
bacterial	O
lung	O
infections	B-DISO
,	O
such	O
as	O
pneumococcal	B-DISO
infection	I-DISO
and	O
of	O
widely	O
neglected	O
pathogens	O
modeled	O
in	O
ex	O
vivo	O
infected	O
lung	O
tissue	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
,	O
PaO₂	O
/	O
FiO₂	O
<	O
100	O
on	O
PEEP	O
≥	O
5	O
cm	O
H₂O	O
)	O
is	O
treated	O
using	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
),	O
recently	O
combined	O
with	O
muscle	B-DISO
relaxation	I-DISO
for	O
48	O
h	O
and	O
prone	O
positioning	O
.	O

ABSTRACT	O
:	O
The	O
second	O
part	O
of	O
this	O
overview	O
on	O
early	O
severe	O
ARDS	B-DISO
delineates	O
the	O
pros	O
and	O
cons	O
of	O
the	O
following	O
:	O
a	O
)	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
:	O
lowered	O
oxygen	O
consumption	O
and	O
perfect	O
patient	O
-	O
to	O
-	O
ventilator	O
synchrony	O
),	O
to	O
be	O
used	O
during	O
acute	O
cardio	O
-	O
ventilatory	O
distress	O
in	O
order	O
to	O
""""	O
buy	O
time	O
""""	O
and	O
correct	O
circulatory	O
insufficiency	O
and	O
metabolic	O
defects	O
(	O
acidosis	B-DISO
,	O
etc	O
.);	O
b	O
)	O
spontaneous	O
ventilation	O
(	O
SV	O
:	O
improved	O
venous	O
return	O
,	O
lowered	O
intrathoracic	O
pressure	O
,	O
absence	B-DISO
of	I-DISO
muscle	I-DISO
atrophy	B-DISO
).	O

Given	O
a	O
stabilized	O
early	O
severe	O
ARDS	B-DISO
,	O
as	O
soon	O
as	O
the	O
overall	O
clinical	O
situation	O
improves	O
,	O
spontaneous	O
ventilation	O
will	O
be	O
used	O
with	O
the	O
following	O
stringent	O
conditionalities	O
:	O
upfront	O
circulatory	O
optimization	O
,	O
upright	O
positioning	O
,	O
lowered	O
VO2	O
,	O
lowered	O
acidotic	O
and	O
hypercapnic	B-DISO
drives	O
,	O
sedation	B-DISO
without	O
ventilatory	B-DISO
depression	I-DISO
and	O
without	O
lowered	O
muscular	O
tone	O
,	O
as	O
well	O
as	O
high	O
PEEP	O
(	O
titrated	O
on	O
transpulmonary	O
pressure	O
,	O
or	O
as	O
a	O
second	O
best	O
:	O
""""	O
trial	O
"""-"	O
PEEP	O
)	O
with	O
spontaneous	O
ventilation	O
+	O
pressure	O
support	O
(	O
or	O
newer	O
modes	O
of	O
ventilation	O
).	O

In	O
this	O
context	O
,	O
a	O
deeper	O
understanding	O
of	O
how	O
the	O
immune	O
system	O
in	O
the	O
elderly	O
functions	O
in	O
relation	O
to	O
ZIKV	O
infection	B-DISO
is	O
necessary	O
,	O
as	O
well	O
as	O
an	O
understanding	O
of	O
what	O
kind	O
of	O
alterations	O
of	O
the	O
nervous	B-DISO
system	O
such	O
an	O
infection	B-DISO
triggers	O
in	O
the	O
elderly	O
,	O
beyond	O
GBS	B-DISO
.	O

ABSTRACT	O
:	O
Health	O
threats	O
due	O
to	O
infectious	B-DISO
diseases	I-DISO
used	O
to	O
be	O
a	O
major	O
public	O
health	O
concerns	O
around	O
the	O
globe	O
till	O
mid	O
of	O
twentieth	O
century	O
when	O
effective	O
public	O
health	O
interventions	O
helped	O
in	O
eradicating	O
a	O
number	O
of	O
infectious	B-DISO
diseases	I-DISO
around	O
the	O
world	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
severe	O
medical	O
condition	B-DISO
occurring	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
and	O
with	O
mortality	O
of	O
33	O
-	O
52	O
%	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

To	O
better	O
understand	O
pathophysiology	O
of	O
ARDS	B-DISO
and	O
to	O
verify	O
novel	O
therapeutical	O
approaches	O
a	O
reliable	O
animal	O
model	O
is	O
needed	O
.	O

However	O
,	O
the	O
association	O
between	O
OSA	B-DISO
and	O
the	O
exacerbation	O
of	O
severe	O
asthma	B-DISO
remains	O
unclear	O
.	O

The	O
patients	O
with	O
asthma	B-DISO
were	O
prospectively	O
studied	O
for	O
one	O
year	O
,	O
and	O
exacerbation	O
episodes	O
were	O
identified	O
based	O
on	O
the	O
patients	O
'	O
medical	O
histories	O
.	O

Here	O
we	O
report	O
the	O
ectodomain	O
structures	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
surface	O
spike	O
trimer	O
in	O
different	O
conformational	O
states	O
determined	O
by	O
single	O
-	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
.	O

ABSTRACT	O
:	O
After	O
a	O
planned	O
extubation	O
,	O
the	O
re	O
-	O
occurrence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
needing	O
the	O
restoration	O
of	O
invasive	O
mechanical	O
support	O
is	O
a	O
severe	O
phenomenon	O
associated	O
with	O
several	O
important	O
consequences	O
,	O
including	O
increased	O
morbidity	O
,	O
Intensive	O
Care	O
Unit	O
mortality	O
,	O
and	O
an	O
enormous	O
financial	O
burden	O
.	O

ABSTRACT	O
:	O
Prevalence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
determined	O
in	O
45	O
dromedary	O
camels	O
from	O
two	O
geographically	O
separated	O
herds	O
in	O
Jordan	O
.	O

TITLE	O
:	O
Four	O
cases	O
with	O
Kawasaki	B-DISO
disease	I-DISO
and	O
viral	B-DISO
infection	I-DISO
:	O
aetiology	O
or	O
association	O
.	O

In	O
addition	O
,	O
these	O
viruses	O
may	O
also	O
be	O
detected	O
in	O
Kawasaki	B-DISO
disease	I-DISO
as	O
a	O
coinfection	B-DISO
.	O

Perceptions	O
about	O
the	O
efficacy	O
and	O
safety	O
of	O
NMBAs	O
varied	O
among	O
prescribers	O
,	O
and	O
inconsistencies	O
existed	O
in	O
the	O
prioritization	O
of	O
management	O
strategies	O
for	O
ARDS	B-DISO
.	O

Severe	O
ARDS	B-DISO
patients	O
did	O
not	O
undergo	O
randomisation	O
and	O
all	O
received	O
cisatracurium	O
besylate	O
per	O
protocol	O
.	O

NMBA	O
infusion	O
was	O
associated	O
with	O
an	O
improvement	O
in	O
oxygenation	O
in	O
both	O
moderate	O
and	O
severe	O
ARDS	B-DISO
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
plateau	O
pressure	O
and	O
total	O
positive	O
end	O
-	O
expiratory	O
pressure	O
.	O

No	O
scientific	O
papers	O
investigated	O
the	O
usage	O
or	O
non	O
-	O
usage	O
of	O
CS	O
in	O
patients	O
with	O
STBI	O
followed	O
by	O
severe	B-DISO
sepsis	I-DISO
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Does	O
permissive	O
hypoxaemia	O
during	O
extracorporeal	O
membrane	O
oxygenation	O
cause	O
long	O
-	O
term	O
neurological	O
impairment	B-DISO
?:	O
A	O
study	O
in	O
patients	O
with	O
H1N1	O
-	O
induced	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

MRI	O
showed	O
no	O
changes	O
related	O
to	O
cerebral	B-DISO
hypoxia	I-DISO
.	O

MRI	O
showed	O
no	O
changes	O
related	O
to	O
cerebral	B-DISO
hypoxia	I-DISO
.	O

Patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
(	O
N	O
=	O
876	O
)	O
were	O
randomly	O
assigned	O
into	O
derivation	O
(	O
N	O
=	O
520	O
)	O
and	O
validation	O
(	O
N	O
=	O
356	O
)	O
datasets	O
.	O

TITLE	O
:	O
Current	O
Concepts	O
of	O
ARDS	B-DISO
:	O

Factors	O
associated	O
with	O
hospital	O
mortality	O
were	O
NIV	O
failure	O
(	O
OR	O
,	O
2	O
.	O
52	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
56	O
-	O
4	O
.	O
07	O
),	O
severe	O
ARDS	B-DISO
as	O
compared	O
with	O
mild	O
ARDS	B-DISO
(	O
OR	O
,	O
1	O
.	O
89	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
-	O
1	O
.	O
19	O
),	O
and	O
modified	O
SOFA	O
score	O
(	O
OR	O
,	O
1	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
-	O
1	O
.	O
19	O
).	O

TITLE	O
:	O
Use	O
of	O
noninvasive	O
and	O
invasive	O
mechanical	O
ventilation	O
in	O
cardiogenic	B-DISO
shock	I-DISO
:	O
A	O
prospective	O
multicenter	O
study	O
.	O

A	O
59	O
-	O
year	O
old	O
man	O
staying	O
near	O
the	O
Belum	O
-	O
Temengor	O
rainforest	O
at	O
the	O
Malaysia	O
-	O
Thailand	O
border	O
was	O
admitted	O
with	O
fever	O
for	O
6	O
days	O
,	O
with	O
respiratory	B-DISO
distress	I-DISO
.	O

He	O
was	O
treated	O
for	O
severe	O
dengue	B-DISO
with	O
compensated	O
shock	O
.	O

Despite	O
aggressive	B-DISO
supportive	O
treatment	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
),	O
the	O
patient	O
had	O
unresolved	O
acidosis	B-DISO
as	O
well	O
as	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
involving	O
respiratory	O
,	O
renal	O
,	O
liver	O
,	O
and	O
haematological	O
systems	O
.	O

The	O
Chinese	O
government	O
and	O
military	O
forces	O
have	O
paid	O
a	O
great	O
deal	O
of	O
attention	O
to	O
infectious	B-DISO
disease	I-DISO
prevention	O
and	O
control	O
,	O
and	O
using	O
military	O
-	O
civilian	O
cooperation	O
,	O
they	O
have	O
successfully	O
prevented	O
numerous	O
severe	O
epidemic	O
situations	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
influenza	B-DISO
A	O
(	O
H1N1	O
),	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
and	O
H7N9	O
,	O
and	O
Ebola	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
,	O
while	O
actively	O
maintained	O
public	O
health	O
,	O
economic	O
development	O
,	O
and	O
national	O
construction	O
.	O

Another	O
useful	O
and	O
portable	O
tool	O
is	O
thoracic	B-DISO
ultrasound	O
directly	O
on	O
the	O
patient	O
,	O
which	O
can	O
be	O
used	O
to	O
further	O
define	O
the	O
underlying	O
disease	O
or	O
as	O
guidance	O
during	O
procedures	O
.	O

It	O
is	O
difficult	O
to	O
distinguish	O
clinically	O
apical	B-DISO
ballooning	I-DISO
syndrome	I-DISO
from	O
the	O
acute	O
airway	O
exacerbation	O
itself	O
.	O

Both	O
asthma	B-DISO
and	O
takotsubo	B-DISO
cardiomyopathy	I-DISO
share	O
the	O
same	O
clinical	O
presentation	O
with	O
dyspnea	B-DISO
and	O
chest	B-DISO
tightness	I-DISO
.	O

Clinicians	O
should	O
re	O
-	O
evaluate	O
asthma	B-DISO
management	O
and	O
be	O
aware	O
of	O
the	O
complications	O
associated	O
with	O
asthma	B-DISO
attacks	I-DISO
such	O
as	O
stress	O
-	O
induced	O
cardiomyopathy	B-DISO
.	O

Risk	O
factors	O
for	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
in	O
humans	O
are	O
incompletely	O
understood	O
.	O

RESULTS	O
:	O
We	O
estimated	O
the	O
best	O
-	O
fit	B-DISO
R	O

Recent	O
advances	O
include	O
promising	O
results	O
from	O
the	O
clinical	O
testing	O
of	O
recombinant	O
MVA	O
-	O
producing	O
antigens	O
of	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
virus	O
H5N1	B-DISO
or	O
Ebola	O
virus	O
.	O

This	O
review	O
summarizes	O
our	O
current	O
knowledge	O
about	O
MVA	O
as	O
a	O
unique	O
strain	O
of	O
vaccinia	B-DISO
virus	O
,	O
and	O
discusses	O
the	O
prospects	O
of	O
exploiting	O
this	O
virus	O
as	O
research	O
tool	O
in	O
poxvirus	O
biology	O
or	O
as	O
safe	O
viral	O
vector	O
vaccine	O
to	O
challenge	O
existing	O
and	O
future	O
bottlenecks	O
in	O
vaccinology	O
.	O

Conventional	O
intratracheal	O
inoculation	O
of	O
a	O
liquid	O
suspension	O
of	O
H5N1	B-DISO
influenza	I-DISO
virus	O
in	O
nonhuman	O
primates	O
likely	O
results	O
in	O
efficient	O
clearance	O
of	O
virus	O
within	O
the	O
upper	O
respiratory	O
tract	O
and	O
rarely	O
produces	O
severe	O
disease	O
.	O

Molecular	O
imaging	O
revealed	O
intense	O
lung	B-DISO
inflammation	I-DISO
coincident	O
with	O
massive	O
increases	O
in	O
proinflammatory	O
proteins	O
and	O
IFN	O
-	O
α	O
in	O
distal	O
airways	O
.	O

Some	O
of	O
these	O
viruses	O
preferentially	O
infect	O
oligodendrocytes	O
in	O
the	O
white	O
matter	O
,	O
causing	O
either	O
direct	O
lysis	B-DISO
of	O
infected	O
cells	O
,	O
or	O
more	O
commonly	O
myelin	O
damage	O
as	O
a	O
consequence	O
of	O
the	O
host	O
immune	O
response	O
to	O
the	O
virus	O
.	O

Also	O
,	O
these	O
infections	B-DISO
may	O
be	O
more	O
severe	O
in	O
immunocompromised	O
patients	O
than	O
in	O
the	O
general	O
population	O
.	O

This	O
article	O
outlines	O
current	O
understanding	O
of	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

To	O
date	O
,	O
in	O
-	O
depth	O
study	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
following	O
pulmonary	O
exposure	O
to	O
toxins	O
is	O
hampered	O
by	O
the	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O

Histological	O
studies	O
revealed	O
lung	O
tissue	O
insults	O
that	O
accumulated	O
over	O
time	O
and	O
led	O
to	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

In	O
fact	O
,	O
as	O
per	O
WHO	O
report	O
,	O
Kuwait	O
has	O
the	O
second	O
highest	O
obesity	B-DISO
prevalence	O
followed	O
closely	O
by	O
other	O
Middle	O
East	O
(	O
ME	O
)	O
countries	O
,	O
namely	O
,	O
Qatar	O
,	O
Saudi	O
Arabia	O
,	O
and	O
United	O
Arab	O
Emirates	O
(	O
UAE	O
).	O

ABSTRACT	O
:	O
As	O
of	O
1	O
November	O
2015	O
,	O
the	O
Saudi	O
Ministry	O
of	O
Health	O
had	O
reported	O
1273	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
);	O
among	O
these	O
cases	O
,	O
which	O
included	O
9	O
outbreaks	O
at	O
several	O
hospitals	O
,	O
717	O
(	O
56	O
%)	O
patients	O
recovered	O
,	O
14	O
(	O
1	O
%)	O
remain	O
hospitalised	O
and	O
543	O
(	O
43	O
%)	O
died	O
.	O

To	O
date	O
,	O
nosocomial	B-DISO
infections	I-DISO
have	O
fuelled	O
MERS	O
outbreaks	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
conduct	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
published	O
reports	O
documenting	O
the	O
prevalence	O
of	O
diabetes	B-DISO
in	O
H1N1	O
and	O
MERS	O
-	O
CoV	O
and	O
compare	O
its	O
frequency	O
in	O
the	O
two	O
viral	O
conditions	O
.	O

ABSTRACT	O
:	O
Disinfectant	O
is	O
commonly	O
employed	O
to	O
eliminate	O
infectious	B-DISO
agents	O
and	O
prevent	O
its	O
transmission	O
.	O

ABSTRACT	O
:	O
Current	O
prevention	O
options	O
for	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
URIs	O
)	O
are	O
not	O
optimal	O
.	O

ARMS	B-DISO
-	O
I	O
is	O
patented	O
novel	O
formulation	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
influenza	B-DISO
,	O
comprising	O
a	O
broad	O
-	O
spectrum	O
antimicrobial	O
agent	O
(	O
cetylpyridinium	O
chloride	O
,	O
CPC	O
)	O
and	O
components	O
(	O
glycerin	O
and	O
xanthan	O
gum	O
)	O
that	O
form	O
a	O
barrier	O
on	O
the	O
host	O
mucosa	O
,	O
thus	O
preventing	O
viral	O
contact	O
and	O
invasion	B-DISO
.	O

Healthy	O
adults	O
(	O
18	O
-	O
45	O
years	O
of	O
age	O
)	O
were	O
randomized	O
into	O
ARMS	B-DISO
-	O
I	O
or	O
placebo	O
group	O
(	O
50	O
subjects	O
each	O
).	O

This	O
randomized	O
proof	O
-	O
of	O
-	O
concept	O
clinical	O
trial	O
demonstrated	O
that	O
ARMS	B-DISO
-	O
I	O
tended	O
to	O
provide	O
protection	O
against	O
URIs	O
in	O
the	O
enrolled	O
study	O
participants	O
,	O
while	O
reducing	O
severity	O
and	O
duration	O
of	O
cough	B-DISO
and	O
sore	B-DISO
throat	I-DISO
.	O

Electronic	O
medical	O
records	O
and	O
EMG	O
reports	O
of	O
patients	O
with	O
ICUAW	O
and	O
a	O
diagnosis	O
of	O
either	O
sepsis	B-DISO
,	O
septicaemia	B-DISO
,	O
severe	B-DISO
sepsis	I-DISO
,	O
or	O
septic	B-DISO
shock	I-DISO
,	O
concurrent	O
with	O
a	O
diagnosis	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
),	O
were	O
retrospectively	O
analyzed	O
in	O
a	O
single	O
center	O
university	O
hospital	O
.	O

TITLE	O
:	O
MPLEx	O
:	O
a	O
method	O
for	O
simultaneous	O
pathogen	O
inactivation	B-DISO
and	O
extraction	O
of	O
samples	O
for	O
multi	O
-	O
omics	O
profiling	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
relationship	O
between	O
community	O
residents	O
'	O
infection	B-DISO
sensitivity	O
and	O
their	O
levels	O
of	O
preventive	O
behaviors	O
during	O
the	O
2015	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
in	O
Korea	O
.	O

ABSTRACT	O
:	O
Since	O
late	O
2013	O
,	O
after	O
an	O
absence	O
of	O
seven	O
years	O
,	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
have	O
reemerged	O
and	O
swept	O
rapidly	O
across	O
Japan	O
,	O
resulting	O
in	O
significant	O
economic	O
losses	O
.	O

His	O
serum	O
adenovirus	B-DISO
load	O
was	O
markedly	O
elevated	O
.	O

RESULTS	O
:	O
VEGF	O
was	O
not	O
associated	O
with	O
ISS	B-DISO
(	O
p	O
>	O
0	O
.	O
05	O
);	O
sVEGFR1	O
was	O
positively	O
associated	O
with	O
ISS	B-DISO
(	O
r	O
=	O
0	O
.	O
459	O
,	O
p	O
<	O
0	O
.	O
0001	O
);	O
however	O
,	O
sVEGFR2	O
was	O
negatively	O
associated	O
with	O
ISS	B-DISO
(	O
r	O
=	O
0	O
.	O
510	O
,	O
p	O
<	O
0	O
.	O
0001	O
).	O

CONCLUSIONS	O
:	O
In	O
conclusion	O
,	O
the	O
increasing	O
of	O
sVEGFR1	O
and	O
the	O
decreasing	O
of	O
sVEGFR2	O
in	O
early	O
trauma	O
might	O
be	O
closely	O
related	O
to	O
the	O
occurrence	O
of	O
late	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Elimination	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
in	O
an	O
Animal	O
Feed	O
Manufacturing	O
Facility	O
.	O

CASE	O
REPORT	O
A	O
47	O
-	O
year	O
-	O
old	O
nonsmoking	O
Hispanic	O
man	O
with	O
advanced	O
HIV	B-DISO
infection	I-DISO
presented	O
with	O
severe	O
acute	O
necrotizing	B-DISO
pneumonia	I-DISO
secondary	O
to	O
R	O
.	O
equi	O
.	O

ABSTRACT	O
:	O
Optimal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
is	O
unknown	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
receiving	O
mechanical	O
ventilation	O
with	O
very	O
low	O
tidal	O
volume	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
Infections	I-DISO
in	O
the	O
Central	O
Nervous	B-DISO
System	O
and	O
Respiratory	O
Tract	O
Show	O
Distinct	O
Features	O
in	O
Hospitalized	O
Children	O
.	O

We	O
aimed	O
to	O
explore	O
the	O
cytokine	O
expression	O
profiles	O
in	O
hospitalized	O
children	O
with	O
CoV	O
-	O
CNS	O
and	O
CoV	O
-	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

CONCLUSIONS	O
:	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
showing	O
a	O
high	O
incidence	O
of	O
CoV	O
infection	B-DISO
in	O
hospitalized	O
children	O
,	O
especially	O
with	O
CNS	O
illness	O
.	O

TITLE	O
:	O
Clinical	O
validation	O
of	O
3	O
commercial	O
real	O
-	O
time	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
the	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
from	O
upper	O
respiratory	O
tract	O
specimens	O
.	O

A	O
new	O
concept	O
is	O
introduced	O
that	O
SR	O
T	O
cells	O
can	O
be	O
dampened	O
by	O
distinct	O
regulatory	O
mechanisms	O
in	O
the	O
periphery	O
and	O
the	O
CNS	O
,	O
thereby	O
preventing	O
autoimmune	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
relationship	O
between	O
hypercapnia	B-DISO
developing	O
within	O
the	O
first	O
48	O
h	O
after	O
the	O
start	O
of	O
mechanical	O
ventilation	O
and	O
outcome	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
IFN	O
-	O
lambda	O
preferably	O
inhibits	O
PEDV	O
infection	B-DISO
of	O
porcine	O
intestinal	O
epithelial	O
cells	O
compared	O
with	O
IFN	O
-	O
alpha	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
activation	O
of	O
IFN	O
responses	O
induced	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
could	O
inhibit	O
viral	O
replication	O
in	O
the	O
early	O
infection	B-DISO
stage	O
,	O
but	O
failed	O
in	O
the	O
late	O
infection	B-DISO
stage	O
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

In	O
the	O
three	O
FmoPV	O
RNA	O
-	O
positive	O
sick	O
cats	O
,	O
respiratory	O
,	O
urinary	O
and	O
digestive	O
system	O
signs	O
were	O
observed	O
as	O
well	O
as	O
weight	O
loss	O
,	O
fever	O
and	O
depression	B-DISO
in	O
some	O
cats	O
.	O

Widespread	O
lymphoid	O
cell	O
infiltrates	B-DISO
were	O
detected	O
in	O
the	O
renal	O
cortex	O
and	O
medullary	O
regions	O
of	O
the	O
kidneys	O
.	O

We	O
reviewed	O
the	O
postmortem	O
cases	O
of	O
cecal	O
infarction	B-DISO
in	O
dairy	O
calves	O
≤	O
30	O
d	O
of	O
age	O
that	O
had	O
been	O
submitted	O
over	O
the	O
course	O
of	O
5	O
y	O
to	O
the	O
Tulare	O
branch	O
of	O
the	O
California	O
Animal	O
Health	O
and	O
Food	O
Safety	O
Laboratory	O
System	O
.	O

The	O
area	O
of	O
cecal	O
infarction	B-DISO
and	O
the	O
associated	O
lesion	O
margins	O
were	O
examined	O
histologically	O
.	O

Cecal	O
infarction	B-DISO
cases	O
were	O
then	O
compared	O
to	O
controls	O
using	O
a	O
retrospective	O
matched	O
case	O
-	O
control	O
study	O
design	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
emerged	O
as	O
a	O
new	O
pathogen	O
,	O
causing	O
severe	O
complications	O
and	O
a	O
high	O
case	O
fatality	O
rate	O
.	O

TITLE	O
:	O
Dynamic	O
driving	O
pressure	O
associated	O
mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
influences	O
of	O
clinical	O
variables	O
and	O
mechanical	O
ventilation	O
settings	O
on	O
the	O
outcomes	O
for	O
severe	O
ARDS	B-DISO
patients	O
receiving	O
ECMO	O
.	O

No	O
patient	O
had	O
air	O
leak	O
syndrome	B-DISO
or	O
died	O
.	O

A	O
controversial	O
question	O
has	O
been	O
whether	O
DC	O
-	O
SIGN	O
functions	O
as	O
a	O
complete	O
receptor	O
for	O
both	O
binding	O
and	O
internalization	O
of	O
dengue	B-DISO
virus	O
(	O
DENV	O
)	O
or	O
whether	O
it	O
is	O
solely	O
a	O
cell	O
surface	O
attachment	O
factor	O
,	O
requiring	O
either	O
hand	O
-	O
off	O
to	O
another	O
receptor	O
or	O
a	O
co	O
-	O
receptor	O
for	O
internalization	O
.	O

ABSTRACT	O
:	O
The	O
prevailing	O
morbidity	O
and	O
mortality	O
in	O
sepsis	B-DISO
are	O
largely	O
due	O
to	O
multiple	O
organ	O
dysfunction	O
(	O
MOD	O
),	O
most	O
commonly	O
lung	O
injury	O
,	O
as	O
well	O
as	O
renal	O
and	O
cardiac	O
dysfunction	O
.	O

Evidence	O
from	O
both	O
human	O
and	O
animal	O
studies	O
has	O
demonstrated	O
the	O
key	O
role	O
of	O
microvascular	O
leakage	B-DISO
in	O
determining	O
the	O
outcome	O
of	O
sepsis	B-DISO
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
thrombosis	B-DISO
-	O
dependent	O
mechanisms	O
that	O
regulate	O
pulmonary	O
endothelial	O
injury	O
and	O
repair	O
following	O
sepsis	B-DISO
,	O
including	O
activation	O
of	O
the	O
coagulation	O
cascade	O
by	O
tissue	O
factor	O
and	O
stimulation	O
of	O
vascular	O
repair	O
by	O
hypoxia	B-DISO
-	O
inducible	O
factors	O
.	O

TITLE	O
:	O
The	O
diagnosis	O
and	O
management	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
cystic	B-DISO
fibrosis	I-DISO
.	O

TITLE	O
:	O
Spontaneous	O
intracranial	B-DISO
hemorrhage	I-DISO
in	O
a	O
patient	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
corona	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
corona	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
positive	O
sense	O
singlestranded	O
ribonucleic	O
acid	O
virus	O
of	O
the	O
genus	O
Beta	O
corona	O
virus	O
.	O

Computed	O
angiogram	O
of	O
the	O
brain	O
did	O
not	O
reveal	O
any	O
aneurysm	B-DISO
or	O
structural	O
defects	O
.	O

Research	O
in	O
this	O
area	O
is	O
predominantly	O
focused	O
on	O
compliance	O
in	O
the	O
use	O
of	O
protective	O
equipment	O
,	O
attitudes	O
and	O
perceptions	O
of	O
paramedics	O
,	O
infectious	B-DISO
disease	I-DISO
policy	O
,	O
and	O
exposure	O
rates	O
to	O
blood	O
and	O
body	O
fluids	O
.	O

ABSTRACT	O
:	O
Noninvasive	O
ventilation	O
(	O
NIV	O
)	O
is	O
commonly	O
used	O
as	O
first	O
-	O
line	O
therapy	O
for	O
immunocompromised	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Seventy	O
-	O
nine	O
patients	O
(	O
mean	O
age	O
56	O
±	O
14	O
years	O
,	O
mean	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
27	O
±	O
5	O
)	O
with	O
HM	O
were	O
treated	O
with	O
NIV	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Despite	O
structural	O
and	O
biochemical	O
data	O
demonstrating	O
that	O
the	O
coronavirus	O
nsp15	O
protein	O
contains	O
an	O
endoribonuclease	O
domain	O
,	O
its	O
precise	O
function	O
during	O
coronavirus	B-DISO
infection	I-DISO
remains	O
unknown	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
nsp15	O
interacted	O
with	O
the	O
putative	O
viral	O
primase	O
nsp8	O
and	O
polymerase	O
nsp12	O
during	O
CoV	O
infection	B-DISO
.	O

These	O
data	O
and	O
tools	O
developed	O
in	O
this	O
study	O
help	O
elucidate	O
the	O
function	O
of	O
nsp15	O
during	O
infection	B-DISO
and	O
may	O
be	O
used	O
to	O
uncover	O
other	O
novel	O
viral	O
protein	O
interactions	O
.	O

TITLE	O
:	O
Short	O
-	O
term	O
Survival	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Patients	O
at	O
a	O
Single	O
Tertiary	O
Referral	O
Centre	O
in	O
Indonesia	O
.	O

RESULTS	O
:	O
there	O
were	O
101	O
ARDS	B-DISO
subjects	O
during	O
10	O
months	O
of	O
study	O
.	O

Bronchoalveolar	O
lavage	O
and	O
serological	O
test	O
were	O
positive	O
for	O
mycoplasma	B-DISO
pneumonia	I-DISO
.	O

As	O
the	O
patient	O
did	O
not	O
improve	O
after	O
3	O
days	O
of	O
antibiotics	O
and	O
donor	O
-	O
specific	O
HLA	O
antibodies	O
had	O
been	O
detected	O
,	O
an	O
acute	O
antibody	B-DISO
-	I-DISO
mediated	I-DISO
graft	I-DISO
rejection	I-DISO
was	O
treated	O
with	O
high	O
-	O
dose	O
corticosteroids	O
,	O
plasma	O
exchange	O
,	O
intravenous	O
immunoglobulin	O
,	O
and	O
rituximab	O
.	O

However	O
,	O
TMPRSS2	O
overexpression	O
decreased	O
MHV	O
structural	O
protein	O
expression	O
,	O
release	O
of	O
infectious	B-DISO
particles	O
,	O
and	O
syncytium	O
formation	O
,	O
and	O
endogenous	O
serine	O
protease	O
activity	O
did	O
not	O
contribute	O
greatly	O
to	O
infection	B-DISO
.	O

The	O
nucleocapsid	O
protein	O
(	O
N	O
protein	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
plays	O
an	O
important	O
role	O
in	O
inhibition	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
via	O
an	O
unknown	O
mechanism	O
.	O

In	O
this	O
study	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
was	O
found	O
to	O
bind	O
to	O
the	O
SPRY	O
domain	O
of	O
the	O
tripartite	O
motif	O
protein	O
25	O
(	O
TRIM25	O
)	O
E3	O
ubiquitin	O
ligase	O
,	O
thereby	O
interfering	O
with	O
the	O
association	O
between	O
TRIM25	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
inhibiting	O
TRIM25	O
-	O
mediated	O
RIG	O
-	O
I	O
ubiquitination	O
and	O
activation	O
.	O

These	O
findings	O
provide	O
an	O
insightful	O
interpretation	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
mediated	O
host	O
innate	O
immune	B-DISO
suppression	I-DISO
caused	O
by	O
the	O
N	O
protein	O
.	O

TITLE	O
:	O
Evidence	O
of	O
human	O
coroanvirus	O
(	O
229E	O
),	O
in	O
patients	O
with	O
respiratory	B-DISO
infection	I-DISO
,	O
Iran	O
,	O
2015	O
:	O
the	O
first	O
report	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
one	O
of	O
the	O
main	O
causes	O
of	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
South	O
Korea	O
was	O
reported	O
on	O
20	O
Data	O
were	O
obtained	O
through	O
the	O
MERS	O
portal	O
by	O
the	O
Ministry	O
for	O
Health	O
and	O
Welfare	O
(	O
MOHW	O
)	O
and	O
Korea	O
Centres	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
press	O
releases	O
by	O
MOHW	O
,	O
and	O
reports	O
by	O
the	O
MERS	O
Policy	O
Committee	O
of	O
the	O
Korean	O
Medical	O
Association	O
.	O

Cases	O
were	O
analysed	O
for	O
general	O
characteristics	O
,	O
exposure	O
source	O
,	O
timeline	O
and	O
infection	B-DISO
generation	O
.	O

The	O
main	O
contributors	O
to	O
the	O
outbreak	O
were	O
late	O
diagnosis	O
,	O
quarantine	O
failure	O
of	O
'	O
super	O
spreaders	O
',	O
familial	O
care	O
-	O
giving	O
and	O
visiting	O
,	O
non	O
-	O
disclosure	O
by	O
patients	O
,	O
poor	O
communication	O
by	O
the	O
South	O
Korean	O
Government	O
,	O
inadequate	O
hospital	B-DISO
infection	I-DISO
management	O
,	O
and	O
'	O
doctor	O
shopping	O
'.	O

The	O
evaluation	O
of	O
the	O
effect	O
of	O
sesquiterpenoids	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
replication	O
showed	O
that	O
compounds	O
1	O
-	O
5	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
17	O
,	O
19	O
,	O
and	O
21	O
increased	O
cell	O
viability	O
against	O
cell	O
death	O
in	O
PEDV	O
-	O
injected	O
cells	O
.	O

Replication	O
of	O
EndoU	O
-	O
deficient	O
coronaviruses	O
is	O
greatly	O
attenuated	O
in	O
vivo	O
and	O
severely	O
restricted	O
in	O
primary	O
cells	O
even	O
during	O
the	O
early	O
phase	O
of	O
the	O
infection	B-DISO
.	O

TITLE	O
:	O
Viral	B-DISO
Pneumonia	I-DISO
and	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

TITLE	O
:	O
Epidemic	O
and	O
Emerging	O
Coronaviruses	O
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
).	O

TITLE	O
:	O
The	O
Prognostic	O
Value	O
of	O
Plasma	O
MicroRNA	O
-	O
155	O
and	O
MicroRNA	O
-	O
146a	O
Level	O
in	O
Severe	B-DISO
Sepsis	I-DISO
and	O
Sepsis	B-DISO
-	O
Induced	O
Acute	O
Lung	O
Injury	O
Patients	O
.	O

ABSTRACT	O
:	O
Severe	O
gastrointestinal	B-DISO
bleeding	I-DISO
in	O
newborn	O
period	O
is	O
a	O
serious	O
but	O
uncommon	O
phenomenon	O
that	O
has	O
a	O
broad	O
differential	O
diagnosis	O
.	O

Resuscitation	O
with	O
multiple	O
blood	O
transfusion	O
and	O
parenteral	O
use	O
of	O
ranitidine	O
controlled	O
the	O
bleeding	B-DISO
.	O

In	O
summary	O
,	O
our	O
studies	O
provide	O
a	O
molecular	O
basis	O
for	O
developing	O
novel	O
therapeutic	O
methods	O
to	O
control	O
PEDV	O
infection	B-DISO
,	O
based	O
on	O
glycyrrhizin	O
and	O
its	O
derivatives	O
.	O

ABSTRACT	O
:	O
Immunodeficiency	B-DISO
is	O
both	O
a	O
preexisting	O
condition	B-DISO
and	O
a	O
risk	O
factor	O
for	O
mortality	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Clinical	O
trials	O
have	O
,	O
so	O
far	O
,	O
failed	O
to	O
establish	O
clear	O
beneficial	O
outcomes	O
of	O
recruitment	B-DISO
maneuvers	O
(	O
RMs	O
)	O
on	O
patient	O
mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
the	O
effects	O
of	O
RMs	O
on	O
the	O
cardiovascular	O
system	O
remain	O
poorly	O
understood	O
.	O

China	O
ranked	O
first	O
on	O
SARS	B-DISO
,	O
Turkey	O
ranked	O
first	O
on	O
Crimean	O
-	O
Congo	B-DISO
fever	I-DISO
,	O
while	O
the	O
United	O
States	O
of	O
America	O
ranked	O
first	O
on	O
the	O
remaining	O
six	O
diseases	O
.	O

Eight	O
patients	O
who	O
had	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
showed	O
recovery	O
of	O
heart	O
and	O
lung	O
function	O
after	O
ECMO	O
therapy	O
.	O

This	O
research	O
reports	O
evidence	O
that	O
pathogens	O
can	O
be	O
aerosolised	O
and	O
transported	O
on	O
airstreams	O
within	O
sanitary	O
plumbing	O
systems	O
and	O
enter	O
buildings	O
via	O
empty	O
U	O
-	O
traps	B-DISO
.	O

,	O
Shandong	O
Province	O
suffered	B-DISO
frequent	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
on	O
pig	O
farms	O
from	O
January	O
2012	O
to	O
July	O
2015	O
,	O
resulting	O
in	O
significant	O
economic	O
losses	O
.	O

The	O
analytical	O
sensitivity	O
of	O
TaqMan	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
10	O
copies	O
/	O
μl	O
of	O
target	O
gene	O
and	O
no	O
cross	O
amplification	B-DISO
with	O
other	O
viruses	O
tested	O
was	O
observed	O
.	O

Although	O
MERS	O
has	O
been	O
associated	O
with	O
30	O
%	O
case	O
fatality	O
in	O
human	O
beings	O
,	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
dromedaries	O
is	O
usually	O
asymptomatic	O
.	O

The	O
Extracorporeal	O
Life	O
Support	O
Organization	O
Registry	O
was	O
reviewed	O
for	O
all	O
cases	O
of	O
adult	O
ARDS	B-DISO
in	O
patients	O
that	O
required	O
inotropic	O
agents	O
or	O
vasopressors	O
or	O
both	O
before	O
ECMO	O
initiation	O
(	O
2009	O
to	O
2013	O
).	O

It	O
seems	O
that	O
the	O
scrotal	B-DISO
abscess	I-DISO
is	O
a	O
very	O
rare	O
complication	B-DISO
of	O
necrotizing	B-DISO
pancreatitis	I-DISO
.	O

TITLE	O
:	O
Effective	O
inhibition	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
by	O
resveratrol	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
viral	O
pathogen	O
that	O
causes	O
severe	O
morbidity	O
and	O
mortality	O
.	O

RESULTS	O
:	O
Resveratrol	O
significantly	O
inhibited	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
prolonged	O
cellular	O
survival	O
after	O
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Isolation	O
due	O
to	O
the	O
management	O
of	O
infectious	B-DISO
diseases	I-DISO
is	O
thought	O
to	O
affect	O
mental	O
health	O
,	O
but	O
the	O
effects	O
are	O
still	O
unknown	O
.	O

Anxiety	O
symptoms	O
were	O
evaluated	O
with	O
the	O
Generalized	B-DISO
Anxiety	I-DISO
Disorder	I-DISO
7	O
-	O
item	O
scale	O
and	O
anger	O
was	O
assessed	O
with	O
the	O
State	O
-	O
Trait	O
Anger	O
Expression	O
Inventory	O
at	O
four	O
to	O
six	O
months	O
after	O
release	O
from	O
isolation	O
for	O
MERS	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
performed	O
as	O
an	O
acceptable	O
life	O
-	O
saving	O
bridging	O
procedure	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O
To	O
patients	O
with	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)-	O
associated	O
ARDS	B-DISO
,	O
ECMO	O
could	O
be	O
adopted	O
as	O
a	O
feasible	O
therapeutic	O
solution	O
.	O

We	O
present	O
our	O
successful	O
experience	O
with	O
ECMO	O
utilized	O
in	O
a	O
respiratory	B-DISO
failure	I-DISO
patient	O
with	O
H7N9	O
infection	B-DISO
.	O

Early	O
detection	O
and	O
rapid	O
response	O
are	O
essential	O
to	O
these	O
serious	O
ECMO	O
-	O
associated	O
complications	O
such	O
as	O
hemorrhage	B-DISO
,	O
thrombosis	B-DISO
and	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
primarily	O
replicates	O
in	O
epithelial	O
cells	O
of	O
the	O
upper	O
respiratory	O
tract	O
of	O
chickens	O
,	O
inducing	O
both	O
morphological	O
and	O
immune	O
modulatory	O
changes	O
.	O

The	O
univariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
patients	O
with	O
hemoglobin	O
<	O
90	O
g	O
/	O
L	O
,	O
plasma	O
albumin	O
<	O
30	O
g	O
/	O
L	O
,	O
C	O
-	O
reactive	O
protein	O
>	O
30	O
mg	O
/	O
L	O
,	O
procalcitonin	O
>	O
10	O
ng	O
/	O
mL	O
,	O
alanine	O
aminotransferase	O
>	O
100	O
U	O
/	O
L	O
,	O
or	O
aspartate	O
aminotransferase	O
>	O
100	O
U	O
/	O
L	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
that	O
those	O
with	O
congenital	B-DISO
dysplasia	I-DISO
of	O
the	O
airway	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
circulatory	O
complications	O
,	O
electrolyte	O
and	O
acid	O
-	O
base	O
disturbance	O
,	O
or	O
more	O
than	O
three	O
complications	O
also	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Reactivity	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Structural	O
Proteins	O
to	O
Antibodies	O
against	O
Porcine	O
Enteric	O
Coronaviruses	O
:	O
Diagnostic	O
Implications	O
.	O

ABSTRACT	O
:	O
The	O
delta	O
total	O
nucleated	O
cells	O
(	O
ΔTNC	O
)	O
measurement	O
with	O
the	O
Sysmex	O
XT	O
-	O
2000iV	O
(	O
Sysmex	O
Europe	O
,	O
Norderstedt	O
,	O
Germany	O
)	O
has	O
high	O
diagnostic	O
accuracy	O
on	O
effusions	B-DISO
in	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
cases	O
,	O
but	O
the	O
test	O
can	O
be	O
performed	O
only	O
on	O
fresh	O
samples	O
.	O

We	O
evaluated	O
whether	O
supernatants	O
from	O
effusions	B-DISO
retain	O
the	O
ability	O
to	O
induce	O
cell	O
clumping	O
and	O
assessed	O
the	O
diagnostic	O
accuracy	O
of	O
this	O
modified	O
ΔTNC	O
method	O
.	O

ABSTRACT	O
:	O
Inborn	O
errors	O
of	O
cobalamin	O
(	O
Cbl	O
)	O
metabolism	O
form	O
a	O
large	O
group	O
of	O
rare	B-DISO
diseases	I-DISO
.	O

However	O
,	O
there	O
has	O
only	O
been	O
a	O
single	O
published	O
case	O
of	O
TMA	O
associated	O
to	O
Cbl	O
deficiency	O
type	O
G	O
(	O
CblG	O
),	O
also	O
known	O
as	O
methionine	B-DISO
synthase	I-DISO
deficiency	I-DISO
(	O
MSD	B-DISO
).	O

A	O
21	O
-	O
month	O
-	O
old	O
boy	O
presented	O
with	O
pallor	B-DISO
and	O
oral	B-DISO
ulcers	I-DISO
during	O
episodes	O
of	O
upper	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
URI	O
).	O

The	O
presumed	O
diagnosis	O
was	O
atypical	B-DISO
hemolytic	I-DISO
uremic	I-DISO
syndrome	I-DISO
,	O
and	O
the	O
patient	O
was	O
started	O
on	O
eculizumab	O
,	O
but	O
his	O
response	O
was	O
poor	O
,	O
even	O
when	O
the	O
dosage	O
was	O
increased	O
.	O

Subsequent	O
treatment	O
consisted	O
of	O
elevating	O
the	O
patient	O
'	O
s	O
serum	O
homocysteine	O
level	O
and	O
starting	O
him	O
on	O
hydroxicobalamin	O
,	O
with	O
normalization	O
of	O
all	O
hematologic	O
parameters	O
although	O
the	O
microalbuminuria	B-DISO
remained	O
.	O

Risk	O
factors	O
for	O
concurrent	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
included	O
older	O
age	O
,	O
illness	O
severity	O
,	O
sepsis	B-DISO
,	O
cancer	B-DISO
,	O
and	O
moderate	O
/	O
severe	O
lung	O
injury	O
.	O

Risk	O
factors	O
for	O
new	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
were	O
moderate	O
/	O
severe	O
lung	O
injury	O
and	O
neuromuscular	B-DISO
blockade	I-DISO
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
):	O
A	O
6	O
-	O
year	O
experience	O
and	O
case	O
-	O
control	O
study	O
.	O

TITLE	O
:	O
""""	O
Your	O
Health	O
Essential	O
for	O
Your	O
Hajj	O
""":"	O
Muslim	O
pilgrims	O
'	O
knowledge	O
,	O
attitudes	O
and	O
practices	O
regarding	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
during	O
Hajj	O
season	O
.	O

Clinical	O
trial	O
design	O
for	O
diseases	O
with	O
high	O
mortality	O
rates	O
and	O
/	O
or	O
high	O
morbidity	O
in	O
the	O
face	B-DISO
of	O
a	O
global	O
perception	O
of	O
immediate	O
need	O
and	O
the	O
factors	O
that	O
drive	O
design	O
in	O
the	O
face	B-DISO
of	O
a	O
changing	O
epidemiology	O
are	O
presented	O
.	O

Community	O
-	O
ARI	O
and	O
inpatient	O
-	O
ARI	O
was	O
also	O
combined	O
with	O
mild	O
and	O
severe	O
cases	O
of	O
influenza	B-DISO
from	O
a	O
historical	O
prospective	O
study	O
as	O
mild	O
-	O
ARI	O
and	O
severe	O
-	O
ARI	O
respectively	O
to	O
evaluate	O
the	O
performance	O
of	O
clinical	O
case	O
definitions	O
.	O

ABSTRACT	O
:	O
Since	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
coronaviruses	O
(	O
CoVs	O
)	O
share	O
similar	O
characteristics	O
with	O
respect	O
to	O
clinical	O
signs	O
,	O
etiology	O
,	O
and	O
transmission	O
,	O
methods	O
for	O
a	O
rapid	O
and	O
accurate	O
differential	O
diagnosis	O
are	O
important	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
epidemiological	O
and	O
clinical	O
factors	O
predictive	O
of	O
the	O
case	O
fatality	O
rate	O
(	O
CFR	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
an	O
outbreak	O
in	O
Daejeon	O
,	O
the	O
Republic	O
of	O
Korea	O
.	O

From	O
very	O
significant	O
preclinical	O
research	O
performed	O
at	O
Virginia	O
Commonwealth	O
University	O
with	O
vitamin	O
C	O
and	O
with	O
the	O
very	O
positive	O
results	O
of	O
a	O
previously	O
performed	O
phase	O
I	O
safety	O
trial	O
infusing	O
high	O
dose	O
vitamin	O
C	O
intravenously	O
into	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
,	O
we	O
reasoned	O
that	O
infusing	O
identical	O
dosing	O
to	O
a	O
patient	O
with	O
ARDS	B-DISO
from	O
viral	B-DISO
infection	I-DISO
would	O
be	O
therapeutic	O
.	O

Of	O
note	O
,	O
it	O
was	O
better	O
able	O
to	O
subtype	O
the	O
influenza	B-DISO
A	O
/	O
H3N2	O
viruses	O
compared	O
with	O
the	O
xTAG	O
RVP	O
FAST	O
v2	O
.	O

Although	O
total	O
virus	O
detection	O
was	O
not	O
statistically	O
different	O
from	O
controls	O
at	O
the	O
middle	O
ear	O
washes	O
(	O
p	O
=	O
0	O
.	O
065	O
),	O
adenovirus	B-DISO
was	O
detected	O
in	O
higher	O
proportions	O
in	O
adenoid	O
samples	O
of	O
OME	O
patients	O
than	O
controls	O
(	O
p	O
=	O
0	O
.	O
019	O
).	O

We	O
describe	O
the	O
histopathological	O
,	O
immunohistochemical	O
,	O
and	O
ultrastructural	O
findings	O
from	O
rhesus	O
macaque	O
and	O
common	O
marmoset	O
animal	O
models	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Evolutionary	O
and	O
epidemiological	O
analyses	O
based	O
on	O
spike	O
genes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
circulating	O
in	O
Thailand	O
in	O
2008	O
-	O
2015	O
.	O

Uncertainties	O
remain	O
as	O
to	O
whether	O
or	O
not	O
ARDS	B-DISO
patients	O
in	O
the	O
postoperative	O
period	O
of	O
abdominal	O
surgery	O
should	O
be	O
turned	O
prone	O
because	O
of	O
the	O
risk	O
of	O
abdominal	O
complications	O
.	O

However	O
,	O
the	O
characteristics	O
of	O
influenza	B-DISO
in	O
Southeast	O
of	O
China	O
haven	O
'	O
t	O
been	O
fully	O
studied	O
.	O

The	O
respiratory	O
specimens	O
have	O
statistically	O
significantly	O
higher	O
positive	O
rate	O
for	O
influenza	B-DISO
among	O
ILI	O
patients	O
than	O
that	O
among	O
SARI	O
patients	O
(	O

Patients	O
with	O
AHEI	O
present	O
with	O
large	O
,	O
target	O
-	O
like	O
purpuric	O
plaques	B-DISO
affecting	O
the	O
face	B-DISO
,	O
ear	O
lobes	O
,	O
and	O
extremities	O
.	O

Coronavirus	O
was	O
implicated	O
as	O
the	O
likely	O
triggering	O
pathogen	O
,	O
and	O
the	O
patient	O
suffered	B-DISO
a	O
recurrence	B-DISO
of	O
purpuric	B-DISO
rash	I-DISO
and	O
swelling	B-DISO
several	O
weeks	O
after	O
her	O
initial	O
presentation	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
different	O
testing	O
modalities	O
available	O
for	O
the	O
ongoing	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
epidemic	O
including	O
cell	O
culture	O
,	O
nucleic	O
acid	O
amplification	B-DISO
,	O
antigen	O
detection	O
,	O
and	O
antibody	O
detection	O
assays	O
.	O

Using	O
the	O
MERS	O
epidemic	O
as	O
an	O
example	O
,	O
we	O
illustrate	O
the	O
various	O
challenges	O
faced	O
by	O
laboratories	O
in	O
test	O
development	O
and	O
implementation	O
in	O
the	O
setting	O
of	O
a	O
rapidly	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Concern	O
regarding	O
functioning	O
and	O
effectiveness	O
of	O
joint	O
health	O
and	O
safety	O
committees	O
(	O
JHSCs	O
)	O
in	O
Ontario	O
hospitals	O
was	O
raised	O
following	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
outbreak	O
in	O
2003	O
.	O

A	O
multiple	O
logistic	O
regression	O
model	O
incorporating	O
oxygenation	O
index	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
R2	O
was	O
superior	O
to	O
a	O
model	O
of	O
oxygenation	O
index	O
alone	O
in	O
predicting	O
the	O
composite	O
outcome	O
of	O
mortality	O
or	O
severe	O
morbidity	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
,	O
0	O
.	O
77	O
[	O
0	O
.	O
70	O
-	O
0	O
.	O
83	O
]	O
vs	O
0	O
.	O
70	O
[	O
0	O
.	O
62	O
-	O
0	O
.	O
77	O
];	O
p	O
=	O
0	O
.	O
042	O
).	O

An	O
interesting	O
feature	O
is	O
the	O
dynamic	O
change	O
in	O
Ubl	O
,	O
which	O
shows	O
a	O
rigid	B-DISO
conformation	O
in	O
the	O
free	O
form	O
of	O
Plpro	O
but	O
is	O
fully	O
flexible	O
upon	O
the	O
binding	O
of	O
ubiquitin	O
.	O

We	O
derived	O
our	O
model	O
using	O
individual	O
data	O
from	O
478	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
and	O
assessed	O
its	O
replicability	O
in	O
a	O
separate	O
cohort	O
of	O
300	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

RESULTS	O
:	O
The	O
built	O
database	O
of	O
patients	O
with	O
influenza	B-DISO
-	O
like	O
syndrome	B-DISO
contained	O
data	O
from	O
the	O
histories	O
of	O
2072	O
men	O
and	O
2537	O
women	O
,	O
of	O
whom	O
there	O
were	O
317	O
(	O
12	O
.	O
49	O
%)	O
pregnant	O
women	O
;	O
gender	O
evidence	O
was	O
not	O
given	O
in	O
the	O
medical	O
records	O
for	O
678	O
patients	O
.	O

Information	O
on	O
laboratory	O
tests	O
was	O
available	O
in	O
1691	O
(	O
31	O
.	O
98	O
%)	O
patients	O
;	O
of	O
these	O
,	O
1291	O
(	O
76	O
.	O
4	O
%)	O
were	O
detected	O
to	O
have	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
.	O

Influenza	B-DISO
B	O
viruses	O
were	O
found	O
in	O
314	O
(	O
18	O
.	O
6	O
%)	O
examinees	O
.	O

All	O
pre	O
-	O
BD	O
quantitative	O
sagittal	O
features	O
measuring	O
diaphragm	O
flattening	O
and	O
hyperinflation	B-DISO
were	O
not	O
significantly	O
different	O
between	O
patients	O
with	O
COPD	B-DISO
and	O
patients	O
with	O
ACOS	O
(	O
P	O
values	O
all	O
>	O
0	O
.	O
05	O
).	O

In	O
RSV	O
-	O
Rhinovirus	O
(	O
RV	O
)	O
multiple	O
infections	B-DISO
,	O
a	O
low	O
viral	O
load	O
of	O
RV	O
was	O
correlated	O
with	O
a	O
high	O
length	O
of	O
hospital	O
stay	O
and	O
a	O
high	O
duration	O
of	O
extra	O
oxygen	O
use	O
.	O

The	O
mean	O
CT	O
value	O
for	O
RV	O
,	O
HCoV	O
and	O
Parainfluenza	B-DISO
virus	O
was	O
significantly	O
lower	O
in	O
single	O
-	O
versus	O
multiple	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Purpose	O
Health	O
systems	O
are	O
periodically	O
confronted	O
by	O
crises	O
-	O
think	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
H1N1	O
,	O
and	O
Ebola	O
-	O
during	O
which	O
they	O
are	O
called	O
upon	O
to	O
manage	O
exceptional	O
situations	O
without	O
interrupting	O
essential	O
services	O
to	O
the	O
population	O
.	O

ABSTRACT	O
:	O
PTA	B-DISO
is	O
a	O
collection	O
of	O
pus	O
located	O
between	O
the	O
tonsillar	O
capsule	O
and	O
the	O
pharyngeal	O
constrictor	O
muscle	O
.	O

It	O
is	O
considered	O
a	O
complication	B-DISO
of	O
acute	B-DISO
tonsillitis	I-DISO
and	O
is	O
the	O
most	O
prevalent	O
deep	O
neck	O
infection	B-DISO
(	O
approximately	O
2000	O
cases	O
annually	O
in	O
Denmark	O
)	O
and	O
cause	O
of	O
acute	O
admission	O
to	O
Danish	O
ENT	O
departments	O
.	O

Furthermore	O
,	O
smoking	O
may	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
peritonsillar	B-DISO
abscess	I-DISO
(	O
PTA	B-DISO
)	O
development	O
,	O
although	O
the	O
magnitude	O
of	O
the	O
association	O
has	O
not	O
been	O
estimated	O
.	O

Culturing	O
of	O
PTA	B-DISO
pus	O
aspirates	O
often	O
yields	O
a	O
polymicrobial	O
mixture	O
of	O
aerobes	O
and	O
anaerobes	O
.	O

In	O
addition	O
,	O
when	O
studying	O
PTA	B-DISO
microbiology	O
,	O
one	O
must	O
consider	O
diagnostic	O
precision	O
,	O
collection	O
,	O
handling	O
,	O
and	O
transportation	O
of	O
appropriate	O
specimens	O
,	O
choice	O
of	O
methodology	O
for	O
detection	O
and	O
quantification	O
of	O
microorganisms	O
,	O
current	O
or	O
recent	O
antibiotic	O
treatment	O
of	O
patients	O
,	O
potential	O
shift	O
in	O
significant	O
pathogens	O
during	O
the	O
course	O
of	O
infection	B-DISO
,	O
and	O
factors	O
associated	O
with	O
increased	O
risk	O
of	O
PTA	B-DISO
development	O
.	O

To	O
explore	O
the	O
microbiology	O
of	O
PTA	B-DISO
with	O
a	O
special	O
attention	O
to	O
Fusobacterium	O
necrophorum	O
(	O
FN	O
).	O

Furthermore	O
,	O
FN	O
was	O
detected	O
significantly	O
more	O
frequently	O
in	O
the	O
tonsillar	O
cores	O
of	O
PTA	B-DISO
patients	O
(	O
56	O
%)	O
compared	O
to	O
the	O
tonsillar	O
cores	O
of	O
the	O
controls	O
(	O
24	O
%)	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Using	O
PCR	O
analysis	O
for	O
the	O
presence	O
of	O
herpes	B-DISO
simplex	I-DISO
1	I-DISO
and	O
2	O
,	O
adenovirus	B-DISO
,	O
influenza	B-DISO
A	O
and	O
B	O
,	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
we	O
explored	O
a	O
possible	O
role	O
of	O
viruses	O
in	O
PTA	B-DISO
.	O

In	O
addition	O
to	O
the	O
involvement	O
of	O
GAS	O
,	O
the	O
following	O
findings	O
suggest	O
a	O
pathogenic	O
role	O
for	O
FN	O
in	O
PTA	B-DISO
:	O
1	O
.	O

This	O
association	O
between	O
PPA	B-DISO
and	O
PTA	B-DISO
was	O
much	O
higher	O
than	O
previously	O
documented	O
.	O

Until	O
further	O
studies	O
are	O
undertaken	O
,	O
we	O
recommend	O
clinicians	O
to	O
have	O
increased	O
focus	O
on	O
acute	B-DISO
tonsillitis	I-DISO
patients	O
aged	O
15	O
-	O
24	O
years	O
with	O
regards	O
to	O
symptoms	O
and	O
findings	O
suggestive	O
of	O
incipient	O
peritonsillar	O
involvement	O
.	O

Bacteremia	B-DISO
during	O
abscess	B-DISO
tonsillectomy	O
is	O
no	O
more	O
prevalent	O
than	O
during	O
elective	O
tonsillectomy	O
.	O

The	O
relationship	O
between	O
bronchiolitis	B-DISO
and	O
asthma	B-DISO
is	O
now	O
better	O
understood	O
thanks	O
to	O
prospective	O
follow	O
up	O
of	O
birth	O
cohorts	O
.	O

Since	O
the	O
previous	O
meeting	O
,	O
significant	O
progress	O
has	O
been	O
made	O
with	O
regulatory	O
approvals	O
of	O
the	O
first	O
malaria	B-DISO
and	O
dengue	B-DISO
vaccines	O
,	O
and	O
the	O
first	O
phase	O
III	O
trials	O
of	O
a	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
vaccine	O
candidate	O
has	O
started	O
in	O
the	O
elderly	O
and	O
pregnant	O
women	O
.	O

Frozen	O
brain	O
was	O
submitted	O
to	O
PCR	O
amplification	B-DISO
and	O
220	O
bp	O
multiple	O
sequence	O
alignment	O
was	O
analysed	O
by	O
Bayesian	O
phylogenetic	O
analysis	O
.	O

ABSTRACT	O
:	O
Severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	B-DISO
(	O
SFTS	O
)	O
is	O
an	O
emerging	O
febrile	B-DISO
illness	I-DISO
.	O

Tight	O
Junction	O
Protein	O
Occludin	O
Is	O
a	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Entry	O
Factor	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
the	O
causative	O
agent	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
,	O
has	O
caused	O
huge	O
economic	O
losses	O
in	O
pig	O
-	O
producing	O
countries	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PEDV	O
infection	B-DISO
of	O
epithelial	O
cells	O
results	O
in	O
disruption	O
of	O
the	O
tight	O
junctional	O
distribution	O
of	O
occludin	O
to	O
its	O
intracellular	O
location	O
.	O

We	O
conclude	O
that	O
occludin	O
plays	O
an	O
essential	O
role	O
in	O
PEDV	O
infection	B-DISO
at	O
the	O
postbinding	O
stages	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
MERS	O
-	O
CoV	O
with	O
optimal	O
immunogen	O
dosage	O
and	O
immunization	O
interval	O
protects	O
human	O
transgenic	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
optimized	O
these	O
criteria	O
using	O
a	O
recombinant	O
MERS	O
-	O
CoV	O
RBD	O
protein	O
fused	O
with	O
Fc	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
and	O
utilized	O
the	O
optimal	O
immunization	O
schedule	O
to	O
evaluate	O
the	O
protective	O
efficacy	O
of	O
RBD	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
human	O
dipeptidyl	O
peptidase	O
4	O
transgenic	O
(	O
hDPP4	O
-	O
Tg	O
)	O
mice	O
.	O

CASE	O
REPORT	O
A	O
76	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
acute	O
onset	O
of	O
diaphoresis	B-DISO
and	O
altered	B-DISO
mental	I-DISO
status	I-DISO
.	O

Thirty	O
-	O
three	O
ARDS	B-DISO
patients	O
(	O
5	O
mild	O
,	O
10	O
moderate	O
,	O
9	O
severe	O
without	O
extracorporeal	O
support	O
,	O
ECMO	O
,	O
and	O
9	O
severe	O
with	O
it	O
)	O
underwent	O
two	O
low	O
-	O
dose	O
end	O
-	O
expiratory	O
CT	O
scans	O
at	O
PEEP	O
5	O
and	O
15	O
cmH	B-DISO
The	O
lung	O
tissue	O
which	O
is	O
opened	O
between	O
30	O
and	O
45	O
cmH	B-DISO
Data	O
show	O
that	O
the	O
prerequisites	O
of	O
the	O
open	O
lung	O
strategy	O
are	O
not	O
satisfied	O
using	O
PEEP	O
up	O
to	O
15	O
cmH	B-DISO
Clinicaltrials	O
.	O
gov	O
identifier	O
:	O
NCT01670747	O
(	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
).	O

ABSTRACT	O
:	O
Viral	B-DISO
infections	I-DISO
are	O
leading	O
causes	O
of	O
both	O
upper	O
and	O
lower	O
airway	O
acute	O
illness	O
in	O
all	O
age	O
groups	O
of	O
healthy	O
persons	O
,	O
and	O
have	O
also	O
been	O
implicated	O
in	O
the	O
acute	O
exacerbations	O
of	O
chronic	O
respiratory	B-DISO
disorders	I-DISO
like	O
asthma	B-DISO
and	O
COPD	B-DISO
.	O

TITLE	O
:	O
Putative	O
vaccine	O
breakthrough	O
event	O
associated	O
with	O
heterotypic	O
rotavirus	B-DISO
infection	I-DISO
in	O
newborn	O
calves	O
,	O
Turkey	O
,	O
2015	O
.	O

Between	O
-	O
group	O
comparison	O
of	O
estimated	O
marginal	O
means	O
(	O
CI	O
95	O
%)	O
during	O
MV	O
were	O
,	O
respectively	O
:	O
PaCO	O
Among	O
patients	O
with	O
MA	O
and	O
COPD	B-DISO
or	O
OHS	B-DISO
,	O
early	O
treatment	O
with	O
ACTZ	O
did	O
not	O
shorten	O
significantly	O
the	O
duration	O
of	O
MV	O
compared	O
with	O
placebo	O
.	O

TITLE	O
:	O
Michael	O
Acceptor	O
-	O
Based	O
Peptidomimetic	O
Inhibitor	O
of	O
Main	O
Protease	O
from	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
.	O

Surgical	O
resection	O
and	O
closure	O
of	O
the	O
GE	O
mucosa	O
resolved	O
this	O
patient	O
'	O
s	O
dyspnea	B-DISO
and	O
is	O
recommended	O
in	O
airway	B-DISO
obstruction	I-DISO
.	O

All	O
patients	O
with	O
severe	O
malaria	B-DISO
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
during	O
the	O
period	O
between	O
1	O
November	O
2009	O
and	O
31	O
December	O
2015	O
were	O
enrolled	O
in	O
our	O
study	O
.	O

To	O
evaluate	O
agreement	O
among	O
TTW	O
and	O
NS	O
,	O
NPS	B-DISO
,	O
or	O
BAL	O
for	O
identification	O
of	O
viral	O
and	O
bacterial	O
pathogens	O
in	O
dairy	O
calves	O
with	O
BRD	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
virus	I-DISO
infection	I-DISO
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplant	O
in	O
a	O
tropical	O
center	O
:	O
Predictive	O
value	O
of	O
the	O
immunodeficiency	B-DISO
scoring	O
index	O
.	O

Receiver	O
operating	O
characteristic	O
analysis	O
showed	O
that	O
an	O
ISI	O
of	O
≥	O
8	O
predicted	O
pneumonia	B-DISO
with	O
a	O
positive	O
predictive	O
value	O
of	O
>	O
80	O
%	O
for	O
RVI	O
caused	O
by	O
RSV	O
,	O
influenza	B-DISO
,	O
adenovirus	B-DISO
,	O
and	O
parainfluenza	B-DISO
,	O
while	O
it	O
was	O
not	O
predictive	O
for	O
coronavirus	O
and	O
rhinovirus	O
.	O

ABSTRACT	O
:	O
The	O
Arkansas	O
Delmarva	O
Poultry	O
Industry	O
(	O
ArkDPI	O
)	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccine	O
is	O
effective	O
when	O
administered	O
by	O
eye	O
drop	O
,	O
where	O
the	O
vaccine	O
virus	O
is	O
able	O
to	O
infect	O
and	O
replicate	O
well	O
in	O
birds	O
and	O
is	O
able	O
to	O
induce	O
protection	O
against	O
homologous	O
challenge	O
.	O

We	O
observed	O
that	O
the	O
level	O
of	O
infection	B-DISO
and	O
replication	O
with	O
spray	O
vaccination	O
matches	O
with	O
that	O
of	O
eye	O
drop	O
vaccination	O
when	O
chicks	O
received	O
100	O
times	O
the	O
standard	O
dose	O
for	O
the	O
commercial	O
ArkDPI	O
vaccine	O
.	O

ABSTRACT	O
:	O
During	O
the	O
early	O
phase	O
of	O
infection	B-DISO
with	O
an	O
extremely	O
neurovirulent	O
murine	O
coronavirus	O
,	O
cl	O
-	O
2	O
,	O
the	O
ER	O
-	O
TR7	O
antigen	O
(	O
ERag	O
)-	O
positive	O
fibers	O
(	O
ERfibs	O
)	O
associated	O
with	O
laminin	O
and	O
collagen	O
III	O
show	O
a	O
rapid	O
increase	O
in	O
expression	O
levels	O
in	O
the	O
meninges	O
,	O
followed	O
by	O
an	O
appearance	O
of	O
the	O
antigens	O
in	O
the	O
ventricle	O
and	O
brain	O
parenchyma	O
.	O

TITLE	O
:	O
Surveillance	O
and	O
Testing	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
,	O
Saudi	O
Arabia	O
,	O
April	O
2015	O
-	O
February	O
2016	O
.	O

Saudi	O
Arabia	O
has	O
reported	O
>	O
80	O
%	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
cases	O
worldwide	O
.	O

Together	O
,	O
mpIL	O
-	O
22	O
inhibited	O
the	O
infection	B-DISO
of	O
PoRV	O
and	O
enteric	O
coronaviruses	O
,	O
and	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
antimicrobial	O
genes	O
in	O
IPEC	O
-	O
J2	O
,	O
which	O
were	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
STAT3	O
signal	O
pathway	O
.	O

TITLE	O
:	O
Rationale	O
,	O
study	O
design	O
and	O
analysis	O
plan	B-DISO
of	O
the	O
lung	O
imaging	O
morphology	O
for	O
ventilator	O
settings	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
study	O
(	O
LIVE	O
study	O
):	O
Study	O
protocol	O
for	O
a	O
randomised	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
The	O
mortality	O
rate	O
for	O
respiratory	B-DISO
failure	I-DISO
resulting	O
from	O
obesity	B-DISO
hypoventilation	I-DISO
syndrome	I-DISO
is	O
high	O
if	O
it	O
requires	O
ventilator	O
management	O
.	O

ABSTRACT	O
:	O
The	O
possible	O
role	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
in	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
(	O
LRTD	O
)	O
in	O
hematopoietic	O
cell	O
transplant	O
(	O
HCT	O
)	O
recipients	O
and	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
(	O
HM	O
)	O
has	O
not	O
been	O
well	O
studied	O
.	O

TITLE	O
:	O
Outcome	O
and	O
Management	O
of	O
Refractory	O
Respiratory	B-DISO
Failure	I-DISO
With	O
Timely	O
Extracorporeal	O
Membrane	O
Oxygenation	O
:	O
Single	O
-	O
Center	O
Experience	O
With	O
Legionella	B-DISO
Pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
management	O
and	O
outcome	O
of	O
patients	O
with	O
refractory	O
respiratory	B-DISO
failure	I-DISO
complicating	O
severe	O
Legionella	B-DISO
pneumonia	I-DISO
rescued	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
our	O
Center	O
.	O

TITLE	O
:	O
Cross	O
-	O
sectional	O
surveillance	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
dromedary	O
camels	O
and	O
other	O
mammals	O
in	O
Egypt	O
,	O
August	O
2015	O
to	O
January	O
2016	O
.	O

TITLE	O
:	O
Building	O
the	O
road	O
to	O
a	O
regional	O
zoonoses	B-DISO
strategy	O
:	O
A	O
survey	O
of	O
zoonoses	B-DISO
programmes	O
in	O
the	O
Americas	O
.	O

Diagnosis	O
for	O
rabies	B-DISO
and	O
leptospirosis	B-DISO
were	O
cited	O
as	O
the	O
capacities	O
most	O
in	O
need	O
of	O
development	O
.	O

The	O
three	O
priority	O
emerging	O
zoonoses	B-DISO
for	O
the	O
MOHs	O
were	O
Ebola	O
viral	O
disease	O
,	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
Chikungunya	B-DISO
while	O
for	O
the	O
MAgs	O
were	O
avian	B-DISO
influenza	I-DISO
,	O
bovine	B-DISO
spongiform	I-DISO
encephalopathy	I-DISO
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
disease	O
.	O

This	O
study	O
investigated	O
serum	O
concentrations	O
of	O
IP	O
-	O
10	O
in	O
healthy	O
individuals	O
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
ARI	O
).	O

Influenza	B-DISO
infections	B-DISO
had	O
higher	O
IP	O
-	O
10	O
concentrations	O
than	O
coronavirus	O
,	O
enterovirus	O
or	O
rhinovirus	O
,	O
and	O
paramyxovirus	O
.	O

Despite	O
extensive	O
research	O
on	O
the	O
relationship	O
between	O
autophagy	O
and	O
virus	B-DISO
infection	I-DISO
,	O
the	O
concrete	O
role	O
of	O
autophagy	O
in	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
has	O
not	O
been	O
reported	O
.	O

This	O
work	O
is	O
the	O
first	O
attempt	O
to	O
explore	O
the	O
complex	O
interplay	O
between	O
autophagy	O
and	O
PEDV	O
infection	B-DISO
.	O

We	O
performed	O
a	O
retrospective	O
investigation	O
of	O
the	O
presence	O
of	O
PDCoV	O
in	O
intestinal	O
samples	O
collected	O
from	O
piglets	O
with	O
diarrhea	B-DISO
in	O
Thailand	O
from	O
2008	O
to	O
2015	O
using	O
RT	O
-	O
PCR	O
.	O

We	O
did	O
a	O
review	O
of	O
the	O
literature	O
summarizing	O
38	O
patients	O
in	O
10	O
publications	O
where	O
TH	O
was	O
successfully	O
utilized	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

We	O
found	O
a	O
prevalence	O
of	O
PDCoV	O
(	O
21	O
.	O
8	O
%),	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
65	O
.	O
5	O
%),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
0	O
%),	O
rotavirus	O
group	O
A	O
(	O
25	O
.	O
0	O
%)	O
and	O
porcine	O
kobuvirus	O
(	O
68	O
.	O
7	O
%).	O

This	O
study	O
also	O
highlights	O
the	O
importance	O
and	O
contribution	O
of	O
enhanced	O
surveillance	O
systems	O
for	O
better	O
infection	B-DISO
control	O
.	O

Existing	O
healthcare	O
systems	O
tragically	O
contributed	O
to	O
186	O
MERS	O
outbreak	O
cases	O
,	O
starting	O
from	O
single	O
""""	O
index	O
patient	O
""""	O
into	O
three	O
generations	O
of	O
secondary	B-DISO
infections	I-DISO
.	O

Phylogenetic	O
and	O
recombination	O
analyses	O
of	O
F46	O
provided	O
evidence	O
of	O
natural	O
recombination	O
between	O
bat	O
SARS	B-DISO
-	O
like	O
CoVs	O
(	O
Rs3367	O
and	O
LYRa11	O
)	O
or	O
SARS	B-DISO
-	O
CoV	O
(	O
BJ01	O
),	O
suggesting	O
that	O
F46	O
could	O
be	O
a	O
new	O
recombinant	O
virus	O
from	O
SARS	B-DISO
-	O
like	O
CoVs	O
or	O
SARS	B-DISO
-	O
CoVs	O
.	O

In	O
multiple	O
regression	O
analyses	O
,	O
younger	O
age	O
,	O
female	O
sex	O
,	O
higher	O
severity	O
of	O
illness	O
,	O
fewer	O
steroid	O
treatment	O
days	O
,	O
and	O
GM	O
-	O
CSF	O
treatment	O
were	O
all	O
independently	O
associated	O
with	O
more	O
severe	O
psychiatric	B-DISO
symptoms	I-DISO
on	O
at	O
least	O
one	O
scale	O
.	O

VILI	O
is	O
characterized	O
by	O
damage	O
to	O
the	O
epithelial	O
barrier	O
with	O
subsequent	O
pulmonary	B-DISO
edema	I-DISO
and	O
profound	O
hypoxia	B-DISO
.	O

ABSTRACT	O
:	O
Swine	O
and	O
poultry	O
viruses	O
,	O
such	O
as	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
),	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
and	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
HPAIV	O
),	O
are	O
economically	O
important	O
pathogens	O
that	O
can	O
spread	O
via	O
aerosols	O
.	O

Extended	O
(	O
intra	O
-	O
pericardial	O
)	O
left	O
pneumonectomy	O
was	O
successfully	O
performed	O
,	O
but	O
the	O
patient	O
died	O
a	O
few	O
weeks	O
later	O
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
SARI	O
)	O
are	O
leading	O
causes	O
of	O
hospitalization	O
,	O
morbidity	O
,	O
and	O
mortality	O
in	O
children	O
worldwide	O
.	O

TITLE	O
:	O
Development	O
of	O
Surface	O
-	O
Variable	O
Polymeric	O
Nanoparticles	O
for	O
Drug	O
Delivery	O
to	O
Tumors	B-DISO
.	O

Our	O
results	O
showed	O
that	O
male	O
mice	O
were	O
more	O
susceptible	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
compared	O
with	O
age	O
-	O
matched	O
females	O
.	O

Furthermore	O
,	O
ovariectomy	O
or	O
treating	O
female	O
mice	O
with	O
an	O
estrogen	O
receptor	O
antagonist	O
increased	O
mortality	O
,	O
indicating	O
a	O
protective	O
effect	O
for	O
estrogen	O
receptor	O
signaling	O
in	O
mice	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
sex	O
differences	O
in	O
the	O
susceptibility	O
to	O
SARS	B-DISO
-	O
CoV	O
in	O
mice	O
parallel	O
those	O
observed	O
in	O
patients	O
and	O
also	O
identify	O
estrogen	O
receptor	O
signaling	O
as	O
critical	O
for	O
protection	O
in	O
females	O
.	O

ABSTRACT	O
:	O
Fecal	O
virus	B-DISO
shedding	I-DISO
,	O
seroconversion	O
and	O
histopathology	O
were	O
evaluated	O
in	O
3	O
-	O
7	O
-	O
year	O
-	O
old	O
gnotobiotic	O
calves	O
orally	O
inoculated	O
with	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
(	O
9	O
.	O
0	O
-	O
9	O
.	O
6	O
log	O

This	O
intercultural	O
dialogue	O
described	O
the	O
contextual	O
realities	O
on	O
different	O
continents	O
regarding	O
the	O
perceptions	O
of	O
health	O
care	O
professionals	O
about	O
risks	O
and	O
infections	B-DISO
.	O

Body	O
temperature	O
of	O
≥	O
38	O
.	O
5	O
°	O
C	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
],	O
5	O
.	O
54	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
38	O
-	O
22	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
016	O
),	O
pulmonary	B-DISO
infiltration	I-DISO
of	O
≥	O
3	O
lung	O
zones	O
(	O
aOR	O
,	O
7	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
93	O
-	O
27	O
.	O
79	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
a	O
more	O
nonisolated	O
in	O
-	O
hospital	O
days	O
(	O
aOR	O
,	O
1	O
.	O
32	O
per	O
1	O
day	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
1	O
.	O
60	O
;	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
significant	O
risk	O
factors	O
in	O
the	O
spreader	O
group	O
.	O

This	O
study	O
tested	O
the	O
performance	O
of	O
these	O
criteria	O
in	O
a	O
contemporary	O
vasculitis	B-DISO
cohort	O
.	O

The	O
Diagnosis	O
and	O
Classification	O
in	O
Vasculitis	B-DISO
Study	O
provided	O
detailed	O
clinical	O
,	O
serological	O
,	O
pathological	O
and	O
radiological	O
data	O
from	O
patients	O
with	O
primary	B-DISO
systemic	I-DISO
vasculitis	I-DISO
and	O
clinical	O
context	O
-	O
specific	O
comparator	O
conditions	O
.	O

With	O
regard	O
to	O
ARDS	B-DISO
,	O
initial	O
levels	O
of	O
cytokeratin	O
fragment	O
21	O
-	O
1	O
,	O
the	O
soluble	O
fragment	O
of	O
cytokeratin	O
19	O
(	O
CYFRA21	O
-	O
1	O
)	O
and	O
of	O
the	O
club	O
cell	O
protein	O
16	O
(	O
CC16	O
)	O
provided	O
significant	O
results	O
in	O
each	O
statistical	O
analysis	O
.	O

With	O
regard	O
to	O
pneumonia	B-DISO
,	O
each	O
statistical	O
analysis	O
supplied	O
significant	O
results	O
for	O
both	O
initial	O
and	O
day	O
-	O
2	O
levels	O
of	O
CYFRA21	O
-	O
1	O
and	O
CC16	O
.	O

In	O
addition	O
,	O
at	O
1	O
dpm	O
,	O
2	O
hair	O
/	O
face	B-DISO
swabs	O
from	O
MB	O
personnel	O
were	O
positive	O
;	O
however	O
,	O
transmission	O
of	O
virus	O
was	O
not	O
detected	O
.	O

Current	O
vaccination	O
approaches	O
against	O
this	O
emerging	O
coronavirus	O
are	O
only	O
partially	O
effective	O
,	O
though	O
natural	O
infection	B-DISO
protects	O
pigs	O
against	O
reinfection	O
and	O
provides	O
lactogenic	O
immunity	O
to	O
suckling	O
piglets	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
risk	O
perception	O
among	O
students	O
at	O
a	O
university	O
in	O
South	O
Korea	O
,	O
2015	O
.	O

TITLE	O
:	O
Risk	O
Factors	O
for	O
Primary	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
in	O
Camel	O
Workers	O
in	O
Qatar	O
During	O
2013	O
-	O
2014	O
:	O
A	O
Case	O
-	O
Control	O
Study	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
is	O
a	O
pathogen	O
related	O
to	O
enteric	O
and	O
respiratory	B-DISO
diseases	I-DISO
in	O
cattle	O
worldwide	O
.	O

Higher	O
viral	O
load	O
was	O
also	O
detected	O
in	O
the	O
supernatant	O
of	O
peritoneal	O
effusions	B-DISO
compared	O
to	O
in	O
the	O
plasma	O
of	O
FCoV	O
-	O
positive	O
cats	O
.	O

As	O
expected	O
,	O
the	O
secretion	O
of	O
IL1β	O
,	O
IL6	O
and	O
TNFα	O
was	O
readily	O
detected	O
in	O
the	O
supernatant	O
of	O
peritoneal	O
effusions	B-DISO
of	O
the	O
FCoV	O
-	O
positive	O
cats	O
.	O

APN	O
participates	O
in	O
tumor	B-DISO
cell	O
expansion	O
and	O
motility	O
,	O
and	O
is	O
a	O
target	O
for	O
cancer	B-DISO
therapies	O
.	O

Blocking	B-DISO
APN	O
dynamics	O
can	O
thus	O
be	O
a	O
valuable	O
approach	O
to	O
development	O
of	O
drugs	O
that	O
target	O
this	O
ectoenzyme	O
.	O

In	O
general	O
,	O
ARDS	B-DISO
was	O
diagnosed	O
prior	O
to	O
pneumonia	B-DISO
and	O
was	O
therefore	O
identified	O
as	O
its	O
risk	O
factor	O
(	O
OR	O
=	O
11	O
.	O
033	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
812	O
-	O
25	O
.	O
299	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Thoracic	B-DISO
trauma	O
was	O
identified	O
as	O
major	O
risk	O
factor	O
for	O
ARDS	B-DISO
occurrence	O
and	O
earlier	O
onset	O
in	O
polytrauma	O
victims	O
.	O

Using	O
mouse	O
models	O
of	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
,	O
we	O
have	O
identified	O
that	O
the	O
wound	O
repair	O
pathway	O
,	O
controlled	O
by	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
),	O
is	O
critical	O
to	O
recovery	O
from	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
tissue	O
damage	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
:	O
new	O
insights	O
into	O
an	O
old	O
disease	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
an	O
enteric	O
disease	O
in	O
swine	O
caused	O
by	O
an	O
alphacoronavirus	O
.	O

Gas	O
Exchange	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

Prospective	O
hypothermia	O
treatment	O
in	O
eight	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
with	O
PaO2	O
/	O
FIO2	O
less	O
than	O
150	O
receiving	O
neuromuscular	B-DISO
blockade	I-DISO
.	O

Development	O
of	O
features	O
of	O
macrophage	B-DISO
activation	I-DISO
syndrome	I-DISO
and	O
death	O
were	O
more	O
common	O
among	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
cases	O
with	O
any	O
of	O
the	O
phenotypes	O
(	O
macrophage	B-DISO
activation	I-DISO
syndrome	I-DISO
:	O
10	O
/	O
37	O
,	O
27	O
%;	O
death	O
:	O
8	O
/	O
37	O
,	O
22	O
%)	O
compared	O
to	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
cases	O
without	O
any	O
phenotype	O
(	O
macrophage	B-DISO
activation	I-DISO
syndrome	I-DISO
:	O
1	O
/	O
38	O
,	O
3	O
%;	O
p	O
=	O
0	O
.	O
003	O
and	O
death	O
:	O
0	O
/	O
38	O
,	O
0	O
%;	O
p	O
=	O
0	O
.	O
002	O
).	O

Apart	O
from	O
such	O
microbiological	O
agents	O
associated	O
with	O
enteritis	B-DISO
as	O
bacteria	O
and	O
parasites	O
,	O
a	O
lot	O
of	O
research	O
has	O
been	O
recently	O
conducted	O
on	O
viral	O
origin	O
of	O
enteric	O
diseases	O
.	O

The	O
respiratory	O
ECMO	O
survival	O
prediction	O
(	O
RESP	O
)	O
score	O
and	O
the	O
predicting	O
death	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
VV	O
-	O
ECMO	O
(	O
PRESERVE	O
)	O
score	O
were	O
created	O
to	O
predict	O
survival	O
at	O
the	O
time	O
of	O
initiation	O
of	O
ECMO	O
.	O

Average	O
yearly	O
incidence	O
rose	O
from	O
300	O
·	O
54	O
per	O
100	O
000	O
in	O
2004	O
to	O
483	O
·	O
63	O
per	O
100	O
000	O
in	O
2013	O
(	O
annual	O
percentage	O
change	O
5	O
·	O
9	O
%);	O
hydatid	B-DISO
disease	I-DISO
(	O
echinococcosis	B-DISO
),	O
hepatitis	B-DISO
C	I-DISO
,	O
and	O
syphilis	B-DISO
showed	O
the	O
fastest	O
growth	O
.	O

The	O
overall	O
increasing	O
trend	O
changed	O
after	O
2009	O
,	O
and	O
the	O
annual	O
percentage	O
change	O
in	O
incidence	O
of	O
infectious	B-DISO
disease	I-DISO
in	O
2009	O
-	O
13	O
(	O
2	O
·	O
3	O
%)	O
was	O
significantly	O
lower	O
than	O
in	O
2004	O
-	O
08	O
(	O
6	O
·	O
2	O
%).	O

Effective	O
prevention	O
and	O
control	O
strategies	O
are	O
needed	O
for	O
diseases	O
with	O
the	O
highest	O
incidence	O
-	O
including	O
hand	B-DISO
,	I-DISO
foot	I-DISO
,	I-DISO
and	I-DISO
mouth	I-DISO
disease	I-DISO
,	O
hepatitis	B-DISO
B	I-DISO
,	O
and	O
tuberculosis	B-DISO
-	O
and	O
those	O
with	O
the	O
fastest	O
rates	O
of	O
increase	O
(	O
including	O
hydatid	B-DISO
disease	I-DISO
,	O
hepatitis	B-DISO
C	I-DISO
,	O
and	O
syphilis	B-DISO
).	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
vaccines	O
:	O
current	O
status	O
and	O
novel	O
approaches	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
reportedly	O
induced	O
the	O
production	O
of	O
TGF	O
-	O
β1	O
through	O
p38	O
MAPK	O
/	O
STAT3	O
-	O
meidated	O
Egr	O
-	O
1	O
-	O
dependent	O
activation	O
(	O
Sci	O
.	O

Nosocomial	B-DISO
infections	I-DISO
and	O
acute	O
kidney	O
injury	O
are	O
also	O
frequent	O
complications	O
of	O
ECMO	O
.	O

TITLE	O
:	O
Persistence	O
in	O
Temporary	O
Lung	O
Niches	O
:	O
A	O
Survival	O
Strategy	O
of	O
Lung	O
-	O
Resident	O
Memory	O
CD8	O
ABSTRACT	O
:	O
Respiratory	O
virus	O
infections	B-DISO
,	O
such	O
as	O
those	O
mediated	O
by	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
rhinovirus	O
,	O
and	O
adenovirus	B-DISO
,	O
are	O
responsible	O
for	O
substantial	O
morbidity	O
and	O
mortality	O
,	O
especially	O
in	O
children	O
and	O
older	O
adults	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
DE	O
as	O
adjuvant	O
in	O
an	O
Ark	O
-	O
DPI	O
live	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccine	O
after	O
ocular	O
or	O
spray	O
application	O
.	O

ABSTRACT	O
:	O
An	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
was	O
a	O
cause	O
for	O
concern	O
in	O
China	O
in	O
the	O
spring	O
of	O
2013	O
.	O

The	O
patient	O
was	O
44	O
years	O
old	O
and	O
had	O
symptoms	O
including	O
high	O
fever	O
,	O
dry	B-DISO
cough	I-DISO
with	O
a	O
little	O
phlegm	O
,	O
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
,	O
which	O
are	O
roughly	O
consistent	O
with	O
those	O
associated	O
with	O
MERS	O
,	O
and	O
had	O
had	O
close	O
contact	O
with	O
individuals	O
with	O
confirmed	O
cases	O
of	O
MERS	O
.	O
After	O
one	O
month	O
of	O
therapy	O
with	O
antiviral	O
,	O
anti	O
-	O
infection	B-DISO
,	O
and	O
immune	O
-	O
enhancing	O
agents	O
,	O
the	O
patient	O
recovered	O
in	O
the	O
hospital	O
and	O
was	O
discharged	O
.	O

ABSTRACT	O
:	O
Kaposi	B-DISO
sarcoma	I-DISO
inflammatory	O
cytokine	O
syndrome	B-DISO
(	O
KICS	O
)	O
is	O
a	O
newly	O
-	O
described	O
condition	B-DISO
affecting	O
individuals	O
who	O
are	O
HIV	B-DISO
-	O
positive	O
and	O
are	O
infected	O
with	O
human	O
herpesvirus	O
8	O
(	O
HHV	O
-	O
8	O
).	O

However	O
,	O
unlike	O
severe	B-DISO
sepsis	I-DISO
,	O
antibiotics	O
provide	O
no	O
benefit	O
.	O

It	O
is	O
crucial	O
for	O
oncologists	O
to	O
be	O
able	O
to	O
recognize	O
this	O
syndrome	B-DISO
and	O
to	O
institute	O
the	O
appropriate	O
therapy	O
.	O

Furthermore	O
,	O
clinical	O
manifestations	O
of	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
(	O
RVI	O
)	O
may	O
be	O
more	O
severe	O
and	O
unusual	O
in	O
solid	O
organ	O
transplant	O
recipients	O
(	O
SOTRs	O
)	O
compared	O
with	O
the	O
non	O
-	O
immunocompromised	O
population	O
.	O

The	O
extracorporeal	O
membrane	O
oxygenation	O
applied	O
in	O
the	O
experienced	O
centers	O
seems	O
to	O
improve	O
the	O
survival	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Lastly	O
,	O
prevention	O
of	O
aspiration	B-DISO
,	O
stress	B-DISO
ulcers	I-DISO
,	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
,	O
catheter	B-DISO
-	I-DISO
related	I-DISO
infection	I-DISO
,	O
overhydration	B-DISO
,	O
and	O
heavy	O
sedation	B-DISO
is	O
essential	O
to	O
achieve	O
better	O
outcomes	O
in	O
ARDS	B-DISO
.	O

At	O
1	O
:	O
16	O
,	O
CFS	B-DISO
dilution	O
(	O
pH	O
6	O
.	O
3	O
-	O
6	O
.	O
8	O
)	O
showed	O
no	O
cytotoxicity	B-DISO
in	O
Vero	O
cells	O
and	O
was	O
therefore	O
used	O
as	O
the	O
dilution	O
for	O
antiviral	O
assays	O
.	O

ABSTRACT	O
:	O
Severe	O
leptospirosis	B-DISO
can	O
be	O
a	O
rare	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
multiorgan	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
anti	O
-	O
viral	O
activity	O
of	O
the	O
cardenolides	O
,	O
Na	O
ABSTRACT	O
:	O
A	O
series	O
of	O
naturally	O
occurring	O
cardenolides	O
that	O
exhibit	O
potent	O
anti	O
-	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
activity	O
in	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
has	O
been	O
identified	O
.	O

In	O
an	O
immunofluorescence	O
assay	O
,	O
these	O
cardenolides	O
were	O
found	O
to	O
diminish	O
the	O
expressions	O
of	O
TGEV	O
nucleocapsid	O
and	O
spike	O
protein	O
,	O
which	O
was	O
used	O
as	O
an	O
indication	O
for	O
viral	O
replication	O
;	O
block	O
TGEV	O
infection	B-DISO
induced	I-DISO
apoptosis	O
and	O
cytopathic	B-DISO
effects	I-DISO
;	O
and	O
impart	O
the	O
same	O
trend	O
of	O
inhibitory	O
activity	O
against	O
Na	O

These	O
children	O
were	O
divided	O
into	O
3	O
groups	O
as	O
Influenza	B-DISO
A	O
/	O
H1N1	O
(	O
n	O
=	O
42	O
),	O
Influenza	B-DISO
A	O
/	O
H3N2	O
(	O
n	O
=	O
23	O
),	O
and	O
Influenza	B-DISO
B	O
(	O
n	O
=	O
35	O
).	O

He	O
developed	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Clinically	O
,	O
hypoxemia	O
,	O
bilateral	O
opacities	B-DISO
in	O
lung	O
images	O
,	O
and	O
decreased	O
pulmonary	O
compliance	O
are	O
observed	O
.	O

TITLE	O
:	O
Hematologic	O
,	O
hepatic	O
,	O
and	O
renal	O
function	O
changes	O
in	O
hospitalized	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

Transient	O
leukopenia	B-DISO
developed	O
in	O
6	O
%	O
(	O
1	O
/	O
16	O
)	O
of	O
the	O
patients	O
on	O
day	O
1	O
and	O
in	O
13	O
%	O
(	O
1	O
/	O
8	O
)	O
on	O
day	O
8	O
.	O

Patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
showed	O
variable	O
hematologic	O
parameters	O
over	O
time	O
.	O

Our	O
results	O
highlight	O
differences	O
in	O
the	O
distribution	O
of	O
DPP4	O
expression	O
among	O
MERS	O
-	O
CoV	O
susceptible	O
species	O
,	O
which	O
might	O
influence	O
variability	O
in	O
virus	O
tropism	O
,	O
pathogenesis	B-DISO
and	O
transmission	O
route	O
.	O

RESULTS	O
:	O
Median	O
age	O
of	O
ARDS	B-DISO
patients	O
was	O
58	O
years	O
,	O
69	O
%	O
were	O
male	O
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
of	O
aerosolized	O
tobramycin	O
for	O
P	O
.	O
aeruginosa	O
VAP	O
in	O
ARDS	B-DISO
patients	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
phenylisoserine	O
derivatives	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
inhibitor	O
.	O

ABSTRACT	O
:	O
From	O
2002	O
to	O
2003	O
,	O
a	O
global	O
pandemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
spread	O
to	O
5	O
continents	O
and	O
caused	O
8000	O
respiratory	B-DISO
infections	I-DISO
and	O
800	O
deaths	O
.	O

ABSTRACT	O
:	O
This	O
document	O
provides	O
evidence	O
-	O
based	O
clinical	O
practice	O
guidelines	O
on	O
the	O
use	O
of	O
mechanical	O
ventilation	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Clinicians	O
managing	O
patients	O
with	O
ARDS	B-DISO
should	O
personalize	O
decisions	O
for	O
their	O
patients	O
,	O
particularly	O
regarding	O
the	O
conditional	O
recommendations	O
in	O
this	O
guideline	O
.	O

Infection	B-DISO
and	O
trauma	O
were	O
the	O
most	O
common	O
etiology	O
of	O
ARDS	B-DISO
(	O
55	O
.	O
1	O
%	O
and	O
34	O
.	O
8	O
%,	O
respectively	O
).	O

Spearman	O
rank	O
correlation	O
analysis	O
showed	O
that	O
both	O
serum	O
PCT	B-DISO
and	O
CRP	O
in	O
patients	O
with	O
ARDS	B-DISO
was	O
correlated	O
well	O
with	O
APACHE	O
II	O
score	O
(	O
r	O
values	O
were	O
0	O
.	O
669	O
and	O
0	O
.	O
601	O
,	O
respectively	O
,	O
both	O
P	O
<	O
0	O
.	O
001	O
),	O
while	O
PCT	B-DISO
was	O
weakly	O
but	O
positively	O
correlated	O
with	O
Murray	O
score	O
(	O
r	O
=	O
0	O
.	O
294	O
,	O
P	O
=	O
0	O
.	O
005	O
),	O
but	O
not	O
the	O
case	O
of	O
CRP	O
(	O
r	O
=	O
0	O
.	O
203	O
,	O
P	O
=	O
0	O
.	O
052	O
).	O

Using	O
a	O
PCT	B-DISO
cut	O
-	O
off	O
value	O
of	O
>	O
4	O
.	O
35	O
μg	O
/	O
L	O
for	O
predicting	O
28	O
-	O
day	O
mortality	O
,	O
the	O
sensitivity	O
and	O
specificity	O
was	O
92	O
.	O
2	O
%	O
and	O
63	O
.	O
2	O
%,	O
respectively	O
,	O
and	O
the	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
were	O
2	O
.	O
50	O
and	O
0	O
.	O
12	O
respectively	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curve	O
analysis	O
indicated	O
that	O
the	O
patients	O
whose	O
PCT	B-DISO
more	O
than	O
4	O
.	O
35	O
μg	O
/	O
L	O
,	O
had	O
lower	O
28	O
-	O
day	O
cummulative	O
survival	O
rate	O
as	O
compared	O
with	O
those	O
with	O
PCT	B-DISO
≤	O
4	O
.	O
35	O
μg	O
/	O
L	O
(	O
log	O
-	O
rank	O
test	O
:	O
χ	O

In	O
vivo	O
,	O
rat	O
model	O
with	O
ALI	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
LPS	B-DISO
was	O
treated	O
by	O
oral	O
administration	O
of	O
AG1478	O
and	O
451	O
.	O

TITLE	O
:	O
Anticoagulation	O
and	O
Transfusions	O
Management	O
in	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
Assessment	O
of	O
Factors	O
Associated	O
With	O
Transfusion	O
Requirements	O
and	O
Mortality	O
.	O

Here	O
we	O
review	O
the	O
current	O
understanding	O
of	O
how	O
a	O
dysregulated	O
immune	O
response	O
may	O
cause	O
lung	O
immunopathology	B-DISO
leading	O
to	O
deleterious	O
clinical	O
manifestations	O
after	O
pathogenic	O
hCoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
a	O
causative	O
agent	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
,	O
causes	O
economic	O
loss	O
in	O
the	O
global	O
swine	O
industry	O
.	O

TITLE	O
:	O
Different	O
evolutionary	O
trajectories	O
of	O
vaccine	O
-	O
controlled	O
and	O
non	O
-	O
controlled	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
viruses	O
in	O
commercial	O
poultry	O
.	O

Strict	O
infection	B-DISO
control	O
precautions	O
and	O
a	O
well	O
-	O
prepared	O
hospital	O
system	O
may	O
have	O
contributed	O
to	O
no	O
nosocomial	O
transmission	O
occurring	O
during	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
imported	O
to	O
Thailand	O
.	O

TITLE	O
:	O
Serological	O
evidence	O
of	O
coronavirus	B-DISO
infections	I-DISO
in	O
native	O
hamadryas	O
baboons	O
(	O
Papio	O
hamadryas	O
hamadryas	O
)	O
of	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

There	O
are	O
no	O
peer	O
-	O
reviewed	O
publications	O
on	O
viral	B-DISO
infections	I-DISO
of	O
the	O
baboons	O
of	O
KSA	O
.	O

ABSTRACT	O
:	O
Hyperventilation	O
caused	O
by	O
physical	O
and	O
/	O
or	O
psychological	B-DISO
stress	I-DISO
may	O
lead	O
to	O
significant	O
respiratory	B-DISO
alkalosis	I-DISO
and	O
an	O
elevated	O
systemic	O
pH	O
.	O
The	O
alkalotic	O
pH	O
may	O
in	O
turn	O
suppress	O
the	O
normal	O
renal	O
release	O
of	O
phosphate	O
into	O
the	O
urine	O
,	O
thereby	O
interrupting	O
the	O
endogenous	O
production	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
(	O
calcitriol	O
).	O

TITLE	O
:	O
ROS	O
feedback	O
regulates	O
the	O
microRNA	O
-	O
19	O
-	O
targeted	O
inhibition	O
of	O
the	O
p47phox	O
-	O
mediated	O
LPS	B-DISO
-	O
induced	O
inflammatory	B-DISO
response	I-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
miR	O
-	O
19	O
inhibited	O
the	O
expression	O
of	O
p47phox	O
in	O
macrophages	O
,	O
resulting	O
in	O
the	O
alleviation	O
of	O
the	O
lipopolysaccharides	O
(	O
LPS	B-DISO
)-	O
induced	O
inflammatory	B-DISO
response	I-DISO
.	O

When	O
siRNA	O
was	O
used	O
to	O
interfere	O
with	O
p47phox	O
expression	O
following	O
stimulation	O
with	O
LPS	B-DISO
,	O
a	O
lower	O
level	O
of	O
ROS	O
-	O
mediated	O
inflammatory	O
cytokines	O
were	O
released	O
.	O

These	O
physiologic	O
alterations	O
are	O
generally	O
more	O
pronounced	O
in	O
obesity	B-DISO
complicated	O
by	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
or	O
obesity	B-DISO
hypoventilation	I-DISO
syndrome	I-DISO
.	O

Respiratory	B-DISO
failure	I-DISO
developed	O
,	O
requiring	O
intubation	O
and	O
mechanical	O
ventilation	O
.	O

Changes	O
on	O
diffusion	O
-	O
weighted	O
MRI	O
of	O
the	O
brain	O
showed	O
the	O
characteristic	O
heart	O
-	O
shaped	O
BMP	O
infarction	B-DISO
,	O
indicating	O
occlusion	B-DISO
of	O
a	O
unilateral	O
ASA	O
.	O

Severe	O
ARDS	B-DISO
survivors	O
admitted	O
to	O
two	O
ICUs	O
in	O
China	O
between	O
January	O
2012	O
and	O
January	O
2014	O
were	O
enrolled	O
.	O

RESULTS	O
:	O
Blood	O
cultures	O
from	O
6	O
of	O
9	O
animals	O
in	O
the	O
SS	O
group	O
were	O
positive	O
for	O
MRSA	B-DISO
.	O

Blood	O
G	O
tests	O
presented	O
the	O
better	O
predicting	O
value	O
for	O
anastomotic	B-DISO
leak	I-DISO
.	O

Within	O
7	O
days	O
postinoculation	O
,	O
TC	O
-	O
PC177	O
caused	O
mild	O
diarrhea	B-DISO
and	O
lower	O
fecal	O
viral	O
RNA	O
shedding	O
,	O
with	O
no	O
mortality	O
,	O
whereas	O
PC21A	O
caused	O
severe	O
clinical	O
signs	O
and	O
55	O
%	O
mortality	O
.	O

ABSTRACT	O
:	O
This	O
work	O
describes	O
the	O
diagnosis	O
and	O
successful	O
treatment	O
of	O
a	O
2	O
-	O
year	O
-	O
old	O
domestic	O
cat	O
infected	O
with	O
Considering	O
the	O
increasing	O
number	O
of	O
feline	O
leishmaniosis	B-DISO
cases	O
and	O
the	O
inconsistent	O
results	O
of	O
most	O
therapeutic	O
protocols	O
described	O
in	O
the	O
literature	O
,	O
the	O
use	O
of	O
new	O
approaches	O
,	O
especially	O
in	O
refractory	O
cases	O
,	O
is	O
essential	O
.	O

Therefore	O
,	O
it	O
is	O
considered	O
that	O
the	O
apoptotic	O
lesions	O
occur	O
through	O
the	O
indirect	O
effects	O
of	O
infection	B-DISO
,	O
and	O
not	O
as	O
a	O
result	O
of	O
direct	O
infection	B-DISO
with	O
Mu	O
-	O
3	O
,	O
similar	O
to	O
the	O
reported	O
neuronal	O
apoptosis	O
in	O
the	O
hippocampus	O
after	O
other	O
types	O
of	O
infection	B-DISO
.	O

All	O
aqueous	B-DISO
humor	I-DISO
samples	O
were	O
collected	O
postmortem	O
by	O
paracentesis	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequences	O
of	O
two	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
viruses	O
isolated	O
in	O
Egypt	O
:	O
Evidence	O
for	O
genetic	O
drift	O
and	O
genetic	O
recombination	O
in	O
the	O
circulating	O
viruses	O
.	O

The	O
optimal	O
mechanical	O
ventilator	O
management	O
and	O
lung	O
recruitment	B-DISO
strategy	O
of	O
a	O
pediatric	O
patient	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	O
is	O
not	O
known	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
treatment	O
strategy	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
the	O
low	O
tidal	O
volume	O
era	O
:	O
A	O
systematic	O
review	O
.	O

Electronic	O
databases	O
were	O
searched	O
for	O
studies	O
of	O
at	O
least	O
10	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
comparing	O
the	O
use	O
of	O
ECMO	O
with	O
low	O
tidal	O
volume	O
ventilation	O
to	O
mechanical	O
ventilation	O
with	O
a	O
low	O
tidal	O
volume	O
alone	O
.	O

Future	O
studies	O
on	O
the	O
use	O
of	O
ECMO	O
for	O
severe	O
ARDS	B-DISO
are	O
needed	O
to	O
clarify	O
the	O
role	O
of	O
ECMO	O
in	O
this	O
disease	O
.	O

Using	O
the	O
PRISMA	O
guidelines	O
for	O
systematic	O
reviews	O
and	O
meta	O
-	O
analysis	O
,	O
MEDLINE	O
and	O
EMBASE	O
were	O
systematically	O
searched	O
for	O
studies	O
reporting	O
complications	O
and	O
hospital	O
mortality	O
of	O
adult	O
patients	O
receiving	O
veno	O
-	O
venous	O
ECMO	O
for	O
severe	O
and	O
refractory	O
ARDS	B-DISO
.	O

The	O
authors	O
present	O
the	O
case	O
of	O
a	O
7	O
-	O
year	O
-	O
old	O
boy	O
with	O
an	O
atypical	O
and	O
severe	O
axonal	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
associated	O
with	O

An	O
iTRAQ	O
-	O
based	O
comparative	O
quantitative	O
proteomic	O
study	O
of	O
IPEC	O
-	O
J2	O
cells	O
infected	O
with	O
YC2014	O
and	O
a	O
classical	O
CV777	O
strain	O
(	O
CV777	O
)	O
was	O
performed	O
to	O
determine	O
the	O
differences	O
between	O
pandemic	O
and	O
classical	O
PEDV	O
strain	O
infection	B-DISO
.	O

Infection	B-DISO
with	O
YC2014	O
could	O
activate	O
the	O
JAK	O
-	O
STAT	O
signaling	O
pathway	O
and	O
the	O
NF	O
-	O
κB	O
pathway	O
more	O
intensively	O
than	O
CV777	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
with	O
normal	O
saline	O
and	O
surfactant	O
allows	O
the	O
removal	O
of	O
inhaled	O
material	O
,	O
the	O
recruitment	B-DISO
of	O
non	O
-	O
ventilating	O
areas	O
and	O
the	O
maintenance	O
of	O
the	O
surfactant	O
pool	O
size	O
.	O

TITLE	O
:	O
miR	O
-	O
142	O
-	O
5p	O
Disrupts	O
Neuronal	O
Morphogenesis	O
Underlying	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	B-DISO
Virus	B-DISO
Infection	I-DISO
by	O
Targeting	O
Ulk1	O
.	O

Relieving	O
Ulk1	O
mRNA	O
repression	O
in	O
primary	O
cortical	O
neurons	O
by	O
miR	O
-	O
142	O
-	O
5p	O
antagomirs	O
or	O
replication	O
-	O
deficient	O
adenoviruses	O
encoding	O
Ulk1	O
(	O
Ad5	B-DISO
-	O
Ulk1	O
),	O
which	O
improved	O
rescue	O
of	O
nerve	O
injury	O
,	O
restricted	O
viral	O
replication	O
,	O
and	O
increased	O
survival	O
rate	O
in	O
mice	O
underlying	O
PHEV	O
infection	B-DISO
.	O

Nasopharyngeal	O
findings	O
of	O
Streptococcus	O
pneumoniae	O
and	O
Haemophilus	O
influenzae	O
by	O
culture	O
correlated	O
to	O
pneumonia	B-DISO
diagnosis	O
,	O
and	O
in	O
those	O
patients	O
laboratory	O
signs	O
of	O
viral	O
co	B-DISO
-	I-DISO
infections	I-DISO
were	O
common	O
but	O
rarely	O
suspected	O
by	O
clinicians	O
.	O

Diagnosing	O
viral	B-DISO
infections	I-DISO
may	O
promote	O
reduction	O
of	O
unnecessary	O
antibiotic	O
use	O
.	O

ABSTRACT	O
:	O
From	O
May	O
through	O
July	O
2015	O
,	O
a	O
total	O
of	O
26	O
cases	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
were	O
reported	O
from	O
2	O
hospitals	O
in	O
Daejeon	O
,	O
South	O
Korea	O
,	O
including	O
1	O
index	O
case	O
and	O
25	O
new	O
cases	O
.	O

Reciprocal	O
bone	O
marrow	O
chimera	B-DISO
studies	O
demonstrated	O
that	O
LIF	O
deficiency	O
in	O
the	O
nonhematopoietic	O
compartment	O
,	O
but	O
not	O
LIF	O
deficiency	O
in	O
hematopoietic	O
cells	O
,	O
eliminated	O
LIF	O
induction	O
during	O
pneumonia	B-DISO
.	O

Although	O
NF	O
-	O
κB	O
RelA	O
(	O
p65	O
)	O
is	O
essential	O
for	O
the	O
expression	O
of	O
many	O
cytokines	O
during	O
pneumonia	B-DISO
,	O
its	O
targeted	O
mutation	O
in	O
the	O
lung	O
epithelium	O
was	O
inconsequential	O
for	O
pneumonia	B-DISO
-	O
driven	O
LIF	O
induction	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
by	O
computer	O
-	O
generated	O
randomisation	O
schedule	O
with	O
variable	O
block	O
size	O
stratified	O
by	O
site	O
and	O
presence	O
of	O
severe	B-DISO
sepsis	I-DISO
requiring	O
vasopressors	O
to	O
receive	O
either	O
recombinant	O
human	O
KGF	O
(	O
palifermin	O
60	O
μg	O
/	O
kg	O
)	O
or	O
placebo	O
(	O
0	O
·	O
9	O
%	O
sodium	O
chloride	O
solution	O
)	O
daily	O
for	O
a	O
maximum	O
of	O
6	O
days	O
.	O

Both	O
groups	O
exhibited	O
high	O
incidences	O
of	O
neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Neonatal	O
complications	O
resulting	O
from	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
)	O
and	O
sepsis	B-DISO
were	O
more	O
common	O
in	O
the	O
non	O
-	O
obstetric	O
causes	O
group	O
;	O
however	O
,	O
neurological	O
development	O
impairment	B-DISO
was	O
more	O
common	O
in	O
the	O
obstetric	O
causes	O
group	O
.	O

Neonatal	O
complications	O
resulting	O
from	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
)	O
and	O
sepsis	B-DISO
were	O
more	O
common	O
in	O
the	O
non	O
-	O
obstetric	O
causes	O
group	O
;	O
however	O
,	O
neurological	O
development	O
impairment	B-DISO
was	O
more	O
common	O
in	O
the	O
obstetric	O
causes	O
group	O
.	O

Then	O
,	O
we	O
developed	O
epidemic	O
models	O
to	O
estimate	O
the	O
effect	O
of	O
persistently	O
infectious	B-DISO
individuals	O
(	O
which	O
shed	O
viruses	O
for	O
extensive	O
periods	O
)	O
on	O
the	O
probability	O
of	O
viral	O
maintenance	O
within	O
the	O
study	O
population	O
.	O

Different	O
from	O
the	O
clinical	O
cases	O
,	O
where	O
co	B-DISO
-	I-DISO
infections	I-DISO
were	O
frequently	O
observed	O
,	O
all	O
positive	O
samples	O
from	O
the	O
control	O
group	O
contained	O
single	O
infections	B-DISO
.	O

Compared	O
to	O
PEDVPT	O
-	O
P5	O
,	O
PEDVPT	O
-	O
P96	O
inoculation	O
induced	O
none	O
-	O
to	O
-	O
mild	O
diarrhea	B-DISO
and	O
lower	O
,	O
delayed	O
fecal	O
viral	B-DISO
shedding	I-DISO
.	O

In	O
addition	O
to	O
mAbs	O
with	O
neutralizing	O
epitopes	O
located	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
one	O
mAb	O
,	O
5F9	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
,	O
showed	O
efficient	O
neutralizing	O
activity	O
against	O
the	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
strain	O
EMC	B-DISO
/	O
2012	O
,	O
with	O
a	O
half	O
maximal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
μg	O
/	O
mL	O
.	O
We	O
concluded	O
that	O
a	O
novel	O
neutralizing	O
epitope	O
for	O
MERS	O
-	O
CoV	O
also	O
resides	O
on	O
the	O
NTD	O
of	O
the	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
NTD	O
might	O
be	O
important	O
during	O
the	O
viral	B-DISO
infection	I-DISO
process	O
.	O

The	O
objective	O
of	O
our	O
study	O
was	O
to	O
characterize	O
inactivation	B-DISO
of	O
PEDV	O
,	O
PDCoV	O
,	O
and	O
TGEV	O
in	O
various	O
feed	O
ingredient	O
matrices	O
.	O

Samples	O
of	O
complete	O
feed	O
,	O
spray	O
dried	O
porcine	O
plasma	O
,	O
meat	O
meal	O
,	O
meat	O
and	O
bone	O
meal	O
,	O
blood	O
meal	O
,	O
corn	B-DISO
,	O
soybean	O
meal	O
,	O
and	O
corn	B-DISO
dried	O
distillers	O
grains	O
with	O
solubles	O
were	O
weighed	O
(	O
5	O
g	O
/	O
sample	O
)	O
into	O
scintillation	O
vials	O
and	O
inoculated	O
with	O
1	O
mL	O
of	O
PEDV	O
,	O
PDCoV	O
,	O
or	O
TGEV	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
plasma	O
concentration	O
of	O
kallistatin	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
and	O
to	O
determine	O
their	O
potential	O
correlation	O
with	O
disease	O
severity	O
and	O
outcomes	O
.	O

They	O
bind	O
and	O
remove	O
ubiquitin	O
(	O
Ub	O
)	O
and	O
interferon	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
from	O
cellular	O
proteins	O
to	O
suppress	O
host	O
antiviral	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

The	O
majority	O
of	O
the	O
deaths	O
had	O
occurred	O
in	O
the	O
first	O
12	O
to	O
24	O
h	O
and	O
the	O
main	O
causes	O
identified	O
are	O
refractory	O
hypotension	O
and	O
arrhythmias	B-DISO
.	O

TITLE	O
:	O
Atypical	O
presentations	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
immunocompromised	O
hosts	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2015	O
Korean	O
MERS	O
outbreak	O
,	O
we	O
experienced	O
atypical	O
presentations	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
in	O
three	O
immunocompromised	O
hosts	O
that	O
warranted	O
exceptional	O
management	O
.	O

TITLE	O
:	O
Diagnostic	O
and	O
prognostic	O
values	O
of	O
Club	O
cell	O
protein	O
16	O
(	O
CC16	O
)	O
in	O
critical	O
care	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
critical	O
condition	B-DISO
characterized	O
by	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
and	O
severe	O
hypoxemia	O
.	O

Furthermore	O
,	O
during	O
the	O
H1N1	O
epidemic	O
in	O
2009	O
-	O
10	O
,	O
a	O
number	O
of	O
observational	O
studies	O
reported	O
good	O
results	O
with	O
the	O
use	O
of	O
ECMO	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
.	O

Influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
infection	B-DISO
is	O
the	O
cause	O
of	O
a	O
respiratory	B-DISO
disease	I-DISO
that	O
poses	O
a	O
significant	O
global	O
public	O
health	O
concern	O
.	O

Herein	O
,	O
we	O
review	O
the	O
contribution	O
of	O
neutrophils	O
to	O
IAV	O
disease	O
pathogenesis	B-DISO
and	O
to	O
other	O
respiratory	O
virus	O
infections	B-DISO
.	O

Patients	O
from	O
four	O
prospective	O
COPD	B-DISO
cohorts	O
in	O
South	O
Korea	O
who	O
underwent	O
follow	O
-	O
up	O
for	O
at	O
least	O
1	O
year	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
The	O
prone	O
posture	O
is	O
known	O
to	O
have	O
numerous	O
effects	O
on	O
gas	O
exchange	O
,	O
both	O
under	O
normal	O
conditions	O
and	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

The	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
is	O
known	O
to	O
infiltrate	B-DISO
the	O
brain	O
,	O
yet	O
findings	O
from	O
studies	O
on	O
associated	O
neurocognitive	O
and	O
neuropathological	O
changes	O
are	O
mixed	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
29	O
-	O
year	O
-	O
old	O
primigravida	O
asian	O
woman	O
with	O
severe	O
peripartal	O
HELLP	O
-	O
syndrome	B-DISO
.	O

HELLP	B-DISO
syndrome	I-DISO
,	O
complicated	O
by	O
severe	O
intracerebral	B-DISO
hemorrhage	I-DISO
was	O
detected	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
septic	B-DISO
shock	I-DISO
in	O
a	O
cat	O
with	O
disseminated	B-DISO
toxoplasmosis	I-DISO
.	O

At	O
the	O
time	O
of	O
presentation	O
it	O
had	O
been	O
receiving	O
cyclosporine	O
for	O
treatment	O
of	O
eosinophilic	B-DISO
dermatitis	I-DISO
.	O

Thoracic	B-DISO
radiographs	O
revealed	O
severe	O
mixed	O
nodular	O
interstitial	O
and	O
alveolar	O
patterns	O
.	O

This	O
is	O
the	O
first	O
detailed	O
report	O
of	O
ARDS	B-DISO
in	O
a	O
cat	O
.	O

ABSTRACT	O
:	O
Intracellular	O
trafficking	O
and	O
localization	O
studies	O
of	O
spike	O
protein	O
from	O
SARS	B-DISO
and	O
OC43	O
showed	O
that	O
SARS	B-DISO
spike	O
protein	O
is	O
localized	O
in	O
the	O
ER	O
or	O
ERGIC	O
compartment	O
and	O
OC43	O
spike	O
protein	O
is	O
predominantly	O
localized	O
in	O
the	O
lysosome	O
.	O

Seventeen	O
patients	O
had	O
abbreviated	O
injury	O
score	O
(	O
AIS	B-DISO
)	O
0	O
,	O
81	O
patients	O
had	O
low	O
-	O
grade	O
injury	O
(	O
AIS	B-DISO
1	O
and	O
2	O
),	O
and	O
63	O
patients	O
had	O
high	O
-	O
grade	O
injury	O
(	O
AIS	B-DISO
3	O
and	O
4	O
).	O

Finally	O
,	O
the	O
results	O
of	O
our	O
analysis	O
suggest	O
that	O
serum	O
cytokines	O
profiles	O
of	O
HPS	B-DISO
and	O
HFRS	B-DISO
cases	O
are	O
consistent	O
with	O
the	O
presence	O
of	O
extracellular	O
matrix	O
degradation	O
,	O
increased	O
mononuclear	O
leukocyte	O
proliferation	B-DISO
,	O
and	O
transendothelial	O
migration	O
.	O

ABSTRACT	O
:	O
The	O
severity	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
is	O
partially	O
determined	O
by	O
the	O
cellular	O
response	O
mounted	O
by	O
infected	O
lung	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
acute	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
,	O
dehydration	B-DISO
,	O
weight	O
loss	O
,	O
and	O
high	O
mortality	O
rate	O
in	O
neonatal	O
piglets	O
.	O

ABSTRACT	O
:	O
Despite	O
the	O
fact	O
that	O
there	O
had	O
been	O
multiple	O
small	O
outbreaks	O
of	O
Ebola	B-DISO
Virus	I-DISO
Disease	I-DISO
,	O
when	O
a	O
large	O
outbreak	O
occurred	O
in	O
2014	O
there	O
were	O
no	O
vaccines	O
or	O
drugs	O
available	O
for	O
use	O
.	O

We	O
here	O
describe	O
two	O
sisters	O
,	O
born	O
to	O
non	O
-	O
consanguineous	O
Portuguese	O
parents	O
,	O
who	O
had	O
short	B-DISO
stature	I-DISO
and	O
presented	O
with	O
recurrent	O
episodes	O
of	O
severe	O
ELT	O
triggered	O
by	O
febrile	O
respiratory	O
viral	B-DISO
infections	I-DISO
since	O
early	O
childhood	O
.	O

This	O
structure	O
provides	O
strong	O
experimental	O
support	O
for	O
the	O
recent	O
proposal	O
advanced	O
by	O
us	O
and	O
others	O
that	O
the	O
""""	O
SARS	B-DISO
-	O
unique	O
""""	O
region	O
is	O
not	O
unique	O
to	O
the	O
human	O
SARS	B-DISO
virus	O
,	O
but	O
is	O
conserved	O
among	O
several	O
different	O
phylogenetic	O
groups	O
of	O
coronaviruses	O
and	O
provides	O
essential	O
functions	O
.	O

TITLE	O
:	O
Comparative	O
epidemiology	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
and	O
South	O
Korea	O
.	O

Therefore	O
,	O
surveillance	O
of	O
zoonotic	O
viruses	O
is	O
necessary	O
for	O
the	O
early	O
warning	O
of	O
potential	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

While	O
,	O
none	O
was	O
positive	O
for	O
hepatitis	B-DISO
A	I-DISO
virus	O
,	O
hepatitis	B-DISO
E	I-DISO
virus	O
or	O
hantavirus	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
proteins	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
share	O
the	O
same	O
IFN	O
-	O
β	O
antagonizing	O
mechanism	O
:	O
attenuation	O
of	O
PACT	B-DISO
-	O
mediated	O
RIG	O
-	O
I	O
/	O
MDA5	O
activation	O
.	O

TITLE	O
:	O
Severe	O
varicella	B-DISO
-	O
zoster	B-DISO
virus	O
pneumonia	B-DISO
:	O
a	O
multicenter	O
cohort	O
study	O
.	O

Steroid	O
therapy	O
did	O
not	O
influence	O
mortality	O
,	O
but	O
increased	O
the	O
risk	O
of	O
superinfection	B-DISO
.	O

We	O
identified	O
a	O
quantitative	O
trait	O
locus	O
of	O
major	O
effect	O
on	O
chromosome	O
18	O
(	O
27	O
.	O
1	O
-	O
58	O
.	O
6	O
Mb	O
)	O
which	O
affected	O
weight	O
loss	O
,	O
viral	O
titer	O
and	O
hemorrhage	B-DISO
.	O

ABSTRACT	O
:	O
Emerging	O
viruses	O
such	O
as	O
HIV	B-DISO
,	O
dengue	B-DISO
,	O
influenza	B-DISO
A	O
,	O
SARS	B-DISO
coronavirus	O
,	O
Ebola	O
,	O
and	O
other	O
viruses	O
pose	O
a	O
significant	O
threat	O
to	O
human	O
health	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
can	O
cause	O
a	O
severe	O
enteric	O
disease	O
affecting	O
pigs	O
of	O
all	O
ages	O
.	O

The	O
present	O
report	O
describes	O
the	O
first	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
outbreak	O
in	O
Hungary	O
after	O
many	O
years	O
and	O
gives	O
an	O
insight	O
into	O
the	O
genetics	O
of	O
the	O
Hungarian	O
PEDV	O
.	O

TITLE	O
:	O
A	O
reverse	O
genetics	O
system	O
for	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
based	O
on	O
targeted	O
RNA	O
recombination	O
.	O

Overall	O
,	O
low	O
-	O
quality	O
evidence	O
indicates	O
that	O
blood	O
purification	O
with	O
CVVH	O
might	O
be	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
mortality	O
when	O
performed	O
in	O
patients	O
with	O
sepsis	B-DISO
or	O
ARDS	B-DISO
.	O

As	O
a	O
result	O
of	O
the	O
outbreak	O
in	O
South	O
Korea	O
,	O
186	O
infections	B-DISO
were	O
reported	O
,	O
and	O
36	O
patients	O
died	O
.	O

The	O
basic	O
reproduction	O
number	O
of	O
an	O
epidemic	O
is	O
defined	O
as	O
the	O
average	O
number	O
of	O
secondary	O
cases	O
that	O
an	O
infected	O
subject	O
produces	O
over	O
its	O
infectious	B-DISO
period	O
in	O
a	O
susceptible	O
and	O
uninfected	O
population	O
.	O

An	O
evaluation	O
of	O
basic	O
reproduction	O
number	O
using	O
epidemic	O
data	O
could	O
be	O
problematic	O
if	O
there	O
are	O
stochastic	O
fluctuations	B-DISO
in	O
the	O
early	O
phase	O
of	O
the	O
outbreak	O
,	O
or	O
if	O
the	O
report	O
is	O
not	O
accurate	O
and	O
there	O
is	O
bias	O
in	O
the	O
data	O
.	O

Though	O
typically	O
self	O
-	O
limited	O
,	O
more	O
severe	O
exposure	O
may	O
lead	O
to	O
respiratory	B-DISO
failure	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
even	O
death	O
.	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
life	O
-	O
threatening	O
condition	B-DISO
of	O
seriously	O
ill	B-DISO
patients	O
,	O
characterized	O
by	O
poor	O
oxygenation	O
,	O
pulmonary	B-DISO
infiltrates	I-DISO
,	O
and	O
acuity	O
of	O
onset	O
.	O

TITLE	O
:	O
Sedation	B-DISO
Management	O
in	O
Children	O
Supported	O
on	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
.	O

Secondary	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
a	O
multicenter	O
randomized	O
trial	O
of	O
sedation	B-DISO
(	O
Randomized	O
Evaluation	O
of	O
Sedation	B-DISO
Titration	O
for	O
Respiratory	B-DISO
Failure	I-DISO
).	O

Thus	O
,	O
in	O
contrast	O
to	O
the	O
current	O
S3	O
guidelines	O
,	O
moxifloxacin	O
may	O
also	O
be	O
safe	O
and	O
effective	O
even	O
in	O
patients	O
with	O
severe	O
CAP	B-DISO
evoked	O
ARDS	B-DISO
while	O
providing	O
coverage	O
of	O
an	O
extended	O
spectrum	O
of	O
severe	O
CAP	B-DISO
evoking	O
bacteria	O
.	O

TITLE	O
:	O
Human	O
Coronavirus	O
-	O
HKU1	O
Infection	B-DISO
Among	O
Adults	O
in	O
Cleveland	O
,	O
Ohio	O
.	O

All	O
of	O
whom	O
had	O
1	O
or	O
more	O
respiratory	B-DISO
symptoms	I-DISO
,	O
and	O
5	O
(	O
38	O
%)	O
also	O
reported	O
1	O
or	O
more	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
H9N2	O
subtype	O
avian	B-DISO
influenza	I-DISO
virus	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
decreases	O
SP	O
-	O
A	O
expression	O
level	O
in	O
chickens	O
.	O

Virus	B-DISO
infection	I-DISO
experiments	O
showed	O
that	O
SD	O
caused	O
high	O
mortality	O
with	O
strong	O
respiratory	O
and	O
renal	O
pathogenicity	O
in	O
chickens	O
,	O
whereas	O
SZ	O
caused	O
milder	O
lesions	O
by	O
comparison	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
rare	O
case	O
of	O
pernicious	B-DISO
anemia	I-DISO
presented	O
as	O
multi	O
-	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
,	O
later	O
found	O
to	O
have	O
pseudo	O
-	O
thrombotic	B-DISO
thrombocytopenic	I-DISO
purpura	I-DISO
.	O

She	O
was	O
admitted	O
to	O
intensive	O
care	O
unit	O
for	O
altered	B-DISO
mental	I-DISO
status	I-DISO
,	O
multi	O
-	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
with	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
in	O
setting	O
of	O
hemolysis	B-DISO
.	O

Hemolysis	B-DISO
and	O
pseudo	O
-	O
thrombotic	B-DISO
thrombocytopenic	I-DISO
purpura	I-DISO
may	O
present	O
as	O
multi	O
-	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
which	O
has	O
dramatic	O
response	O
to	O
appropriate	O
therapy	O
.	O

The	O
unadjusted	O
incidence	O
of	O
ARDS	B-DISO
was	O
4	O
.	O
5	O
cases	O
per	O
100	O
,	O
000	O
population	O
,	O
accounting	O
for	O
1	O
.	O
25	O
%	O
of	O
all	O
ICU	O
patients	O
.	O

Most	O
patients	O
were	O
male	O
(	O
75	O
%),	O
Chinese	O
(	O
62	O
%),	O
had	O
pneumonia	B-DISO
(	O
73	O
%),	O
and	O
were	O
admitted	O
to	O
a	O
Medical	O
ICU	O
(	O
56	O
%).	O

The	O
incidence	O
of	O
ARDS	B-DISO
in	O
a	O
developed	O
S	O
.	O
E	O
Asia	O
country	O
is	O
comparable	O
to	O
reported	O
rates	O
in	O
European	O
studies	O
.	O

TITLE	O
:	O
Infection	B-DISO
of	O
porcine	O
precision	O
cut	O
intestinal	O
slices	O
by	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
demonstrates	O
the	O
importance	O
of	O
the	O
spike	O
protein	O
for	O
enterotropism	O
of	O
different	O
virus	O
strains	O
.	O

PC10	O
neutralized	O
PEDV	O
infection	B-DISO
through	O
interfering	O
with	O
the	O
viral	O
life	O
stages	O
after	O
cellular	O
attachment	O
instead	O
of	O
blocking	B-DISO
the	O
attachment	O
of	O
PEDV	O
to	O
cells	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrom	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
bats	O
are	O
important	O
reservoirs	O
of	O
CoVs	O
.	O

TITLE	O
:	O
Etiologies	O
,	O
diagnostic	O
work	O
-	O
up	O
and	O
outcomes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
no	O
common	O
risk	O
factor	O
:	O
a	O
prospective	O
multicenter	O
study	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
outcomes	O
of	O
a	O
cohort	O
of	O
immunocompromised	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
ventilated	O
with	O
a	O
strategy	O
of	O
stepwise	O
increasing	O
PCO2	O
targets	O
up	O
to	O
140	O
mm	O
Hg	O
.	O

No	O
severe	O
side	O
effects	O
associated	O
with	O
hypercapnia	B-DISO
were	O
observed	O
.	O

Children	O
between	O
the	O
ages	O
of	O
1	O
and	O
6	O
years	O
hospitalised	O
due	O
to	O
viral	B-DISO
pneumonia	I-DISO
between	O
the	O
years	O
of	O
2013	O
and	O
2016	O
were	O
included	O
to	O
this	O
multicentre	O
study	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
29	O
.	O
7	O
%),	O
Influenza	B-DISO
A	O
(	O
20	O
.	O
5	O
%),	O
rhinovirus	O
(	O
18	O
.	O
9	O
%),	O
adenovirus	B-DISO
(	O
10	O
%),	O
human	O
metapneumovirus	O
(	O
8	O
%),	O
parainfluenza	B-DISO
(	O
5	O
.	O
2	O
%),	O
coronavirus	O
(	O
6	O
%),	O
and	O
bocavirus	O
(	O
1	O
.	O
6	O
%)	O
were	O
isolated	O
from	O
respiratory	O
samples	O
.	O

ABSTRACT	O
:	O
Uncertain	O
prediction	O
of	O
outcome	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
impedes	O
individual	O
patient	O
management	O
and	O
clinical	O
trial	O
design	O
.	O

In	O
nine	O
patients	O
with	O
ARDS	B-DISO
,	O
paired	O
inspiratory	O
and	O
expiratory	O
CT	O
scans	O
from	O
the	O
first	O
intensive	O
care	O
unit	O
week	O
were	O
analysed	O
.	O

In	O
patients	O
with	O
ARDS	B-DISO
,	O
a	O
threshold	O
fraction	O
of	O
tissue	O
with	O
unstable	O
inflation	O
was	O
apparent	O
:	O
>	O
28	O
%	O
in	O
all	O
patients	O
who	O
died	O
and	O
≤	O
28	O
%	O
in	O
all	O
who	O
survived	O
,	O
whereas	O
segregation	O
of	O
survivors	O
versus	O
non	O
-	O
survivors	O
was	O
not	O
possible	O
based	O
on	O
oxygenation	O
or	O
lung	O
mechanics	O
.	O

ABSTRACT	O
:	O
Clinical	O
judgement	O
and	O
suspicion	O
of	O
influenza	B-DISO
based	O
on	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
and	O
severe	O
acute	O
respiratory	O
illness	O
are	O
critical	O
for	O
better	O
patient	O
outcome	O
.	O

ABSTRACT	O
:	O
The	O
majority	O
of	O
human	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
are	O
zoonotic	O
,	O
with	O
viruses	O
that	O
originate	O
in	O
wild	O
mammals	O
of	O
particular	O
concern	O
(	O
for	O
example	O
,	O
HIV	B-DISO
,	O
Ebola	O
and	O
SARS	B-DISO
).	O

Here	O
,	O
we	O
investigated	O
which	O
determinants	O
in	O
SARS	B-DISO
S	O
control	O
cleavage	O
and	O
activation	O
by	O
TMPRSS2	O
.	O

Among	O
them	O
,	O
there	O
are	O
the	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
function	O
and	O
the	O
cellular	O
α	O
-	O
glucosidase	O
,	O
involved	O
in	O
the	O
control	O
mechanisms	O
of	O
N	O
-	O
linked	O
glycoproteins	O
formation	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
)	O
has	O
become	O
well	O
established	O
technique	O
of	O
the	O
treatment	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
Veno	O
-	O
Venous	O
ECMO	O
)	O
or	O
circulatory	B-DISO
failure	I-DISO
(	O
Veno	O
-	O
Arterial	O
ECMO	O
)	O
which	O
enables	O
effective	O
blood	O
oxygenation	O
and	O
carbon	O
dioxide	O
removal	O
for	O
several	O
weeks	O
.	O

Here	O
we	O
report	O
the	O
effect	O
of	O
Rapamycin	O
alone	O
or	O
in	O
combination	O
with	O
Oseltamivir	O
for	O
severe	O
influenza	B-DISO
in	O
BALB	O
/	O
c	O
mice	O
.	O

TITLE	O
:	O
The	O
S2	O
glycoprotein	O
subunit	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
contains	O
immunodominant	O
neutralizing	O
epitopes	O
.	O

It	O
is	O
defined	O
as	O
a	O
pauci	O
-	O
immune	O
necrotizing	O
small	O
vessel	O
vasculitis	B-DISO
,	O
which	O
usually	O
affects	O
the	O
kidneys	O
,	O
followed	O
by	O
the	O
lungs	O
.	O

Dromedary	O
camels	O
are	O
the	O
main	O
reservoir	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
but	O
other	O
livestock	O
species	O
(	O
i	O
.	O
e	O
.,	O
alpacas	O
,	O
llamas	O
,	O
and	O
pigs	O
)	O
are	O
also	O
susceptible	O
to	O
infection	B-DISO
with	O
MERS	O
-	O
CoV	O
.	O
Animal	O
-	O
to	O
-	O
animal	O
transmission	O
in	O
alpacas	O
was	O
reported	O
,	O
but	O
evidence	O
for	O
transmission	O
in	O
other	O
species	O
has	O
not	O
been	O
proved	O
.	O

Virus	O
was	O
present	O
in	O
nasal	O
swabs	O
of	O
infected	O
animals	O
,	O
and	O
limited	O
amounts	O
of	O
viral	O
RNA	O
,	O
but	O
no	O
infectious	B-DISO
virus	O
were	O
detected	O
in	O
the	O
direct	O
contact	O
pigs	O
.	O

The	O
incidence	O
of	O
this	O
condition	B-DISO
is	O
estimated	O
at	O
1	O
/	O
1000	O
per	O
year	O
.	O

Broad	O
-	O
spectrum	O
therapies	O
capable	O
of	O
inhibiting	O
CoV	O
infections	B-DISO
would	O
address	O
an	O
immediate	O
unmet	O
medical	O
need	O
and	O
could	O
be	O
invaluable	O
in	O
the	O
treatment	O
of	O
emerging	O
and	O
endemic	O
CoV	O
infections	B-DISO
.	O

These	O
losses	O
were	O
associated	O
with	O
respiratory	B-DISO
problems	I-DISO
,	O
increase	O
of	O
condemnations	O
,	O
drops	O
in	O
egg	O
production	O
and	O
nephritis	B-DISO
in	O
breeders	O
,	O
laying	O
hens	O
and	O
broilers	O
due	O
to	O
infections	B-DISO
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
Fat	B-DISO
embolism	I-DISO
syndrome	I-DISO
(	O
FES	O
)	O
has	O
been	O
described	O
in	O
the	O
literature	O
as	O
a	O
rare	O
complication	B-DISO
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
(	O
SCD	B-DISO
).	O

A	O
total	O
of	O
284	O
nasal	O
swabs	O
were	O
collected	O
during	O
symptomatic	O
(	O
196	O
specimens	O
)	O
and	O
asymptomatic	O
(	O
88	O
specimens	O
)	O
periods	O
of	O
respiratory	B-DISO
symptoms	I-DISO
from	O
a	O
young	O
female	O
child	O
(	O
from	O
4	O
months	O
to	O
31	O
months	O
of	O
age	O
,	O
who	O
was	O
admitted	O
to	O
a	O
nursery	O
school	O
at	O
9	O
months	O
).	O

We	O
report	O
the	O
first	O
case	O
of	O
CHS	B-DISO
as	O
a	O
complication	B-DISO
of	O
lateral	O
medullary	O
infarction	B-DISO
after	O
endovascular	O
treatment	O
.	O

Computed	O
tomography	O
revealed	O
subarachnoid	B-DISO
hemorrhage	I-DISO
and	O
cerebral	O
angiography	O
showed	O
a	O
right	O
vertebral	O
dissecting	B-DISO
aneurysm	I-DISO
involving	O
the	O
posterior	O
inferior	O
cerebellar	O
artery	O
.	O

The	O
SCD	B-DISO
comprised	O
2	O
.	O
2	O
times	O
patients	O
as	O
the	O
BCD	B-DISO
,	O
and	O
3	O
.	O
6	O
times	O
as	O
many	O
as	O
the	O
TCD	B-DISO
.	O

Time	O
course	O
of	O
SARI	O
cases	O
corresponded	O
well	O
to	O
results	O
from	O
primary	O
care	O
surveillance	O
and	O
influenza	B-DISO
virus	O
circulation	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
associated	O
with	O
a	O
high	O
mortality	O
rate	O
.	O

ABSTRACT	O
:	O
Two	O
highly	O
pathogenic	O
human	O
coronaviruses	O
associated	O
with	O
severe	O
respiratory	O
syndromes	B-DISO
emerged	O
since	O
the	O
beginning	O
of	O
the	O
century	O
.	O

Patients	O
with	O
ACO	O
had	O
a	O
better	O
quality	O
of	O
life	O
(	O
St	O
.	O
George	O
'	O
s	O
Respiratory	O
Questionnaire	O
for	O
COPD	B-DISO
score	O
=	O
31	O
.	O
0	O
±	O
18	O
.	O
0	O
[	O
mean	O
±	O
standard	O
deviation	O
])	O
than	O
those	O
with	O
pure	O
COPD	B-DISO
(	O
35	O
.	O
3	O
±	O
19	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
).	O

Although	O
the	O
prevalence	O
of	O
acute	O
exacerbation	O
was	O
not	O
different	O
between	O
the	O
2	O
groups	O
,	O
patients	O
with	O
severe	O
exacerbation	O
required	O
hospital	O
admission	O
significantly	O
more	O
frequently	O
in	O
the	O
pure	O
COPD	B-DISO
group	O
than	O
in	O
the	O
ACO	O
group	O
.	O

RESULTS	O
:	O
Among	O
1	O
,	O
504	O
patients	O
with	O
COPD	B-DISO
,	O
223	O
(	O
14	O
.	O
8	O
%)	O
were	O
diagnosed	O
with	O
ACO	O
.	O

The	O
FIV	O
nucleotide	O
sequence	O
detected	O
in	O
the	O
free	O
-	O
ranging	O
puma	O
,	O
based	O
on	O
comparison	O
of	O
444	O
nucleotides	O
of	O
the	O
pol	O
gene	O
,	O
grouped	O
with	O
other	O
lentiviruses	O
described	O
in	O
pumas	O
,	O
and	O
had	O
82	O
.	O
4	O
%	O
identity	O
with	O
a	O
free	O
-	O
ranging	O
puma	O
from	O
Yellowstone	O
Park	B-DISO
and	O
79	O
.	O
5	O
%	O
with	O
a	O
captive	O
puma	O
from	O
Brazil	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
constitutes	O
a	O
significant	O
disease	O
burden	O
with	O
regard	O
to	O
both	O
morbidity	O
and	O
mortality	O
.	O

It	O
is	O
likely	O
that	O
both	O
patients	O
had	O
pulmonary	B-DISO
TB	I-DISO
initially	O
as	O
they	O
had	O
prolonged	O
symptoms	O
and	O
they	O
subsequently	O
developed	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
α	O
-	O
bisabolol	O
-	O
loaded	O
lipid	O
-	O
core	O
nanocapsules	O
reduce	O
lipopolysaccharide	O
-	O
induced	O
pulmonary	B-DISO
inflammation	I-DISO
in	O
mice	O
.	O

The	O
793	O
/	O
B	O
IB	O
virus	O
is	O
an	O
important	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
genotype	O
currently	O
circulating	O
in	O
several	O
countries	O
,	O
including	O
Iran	O
.	O

AIV	O
-	O
H9N2	O
challenge	O
caused	O
tracheal	O
petechial	B-DISO
hemorrhage	I-DISO
that	O
progressed	O
to	O
tracheal	O
congestion	B-DISO
and	O
caseation	O
.	O

In	O
mixed	O
AIV	O
-	O
H9N2	O
/	O
variant	O
IBV	O
challenge	O
severe	O
congestion	B-DISO
of	O
the	O
tracheal	O
mucosa	O
and	O
excessive	O
exudates	O
with	O
a	O
tendency	O
to	O
form	O
tubular	O
casts	O
were	O
observed	O
.	O

ABSTRACT	O
:	O
To	O
provide	O
optimal	O
cut	O
-	O
off	O
values	O
of	O
anti	O
-	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
serologic	O
tests	O
,	O
we	O
evaluated	O
performance	O
of	O
ELISA	O
IgG	O
,	O
ELISA	O
IgA	O
,	O
IFA	O
IgM	O
,	O
and	O
IFA	O
IgG	O
using	O
138	O
serum	O
samples	O
of	O
49	O
MERS	O
-	O
CoV	O
-	O
infected	O
patients	O
and	O
219	O
serum	O
samples	O
of	O
219	O
rRT	O
-	O
PCR	O
-	O
negative	O
MERS	O
-	O
CoV	O
-	O
exposed	O
healthcare	O
personnel	O
and	O
patients	O
.	O

Traveling	O
plays	O
an	O
important	O
role	O
in	O
transmitting	O
infections	B-DISO
such	O
as	O
Zika	O
virus	B-DISO
infection	I-DISO
,	O
Ebola	O
,	O
avian	B-DISO
flu	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
Chikungunya	B-DISO
,	O
and	O
dengue	B-DISO
fever	I-DISO
and	O
is	O
the	O
principal	O
reason	O
for	O
the	O
epidemics	O
of	O
these	O
types	O
of	O
infections	B-DISO
on	O
a	O
global	O
scale	O
.	O

28	O
/	O
53	O
infants	O
had	O
B	O
.	O
pertussis	B-DISO
alone	O
and	O
25	O
viral	O
coinfection	B-DISO
:	O
10	O
human	O
rhinovirus	O
(	O
9	O
alone	O
and	O
1	O
in	O
coinfection	B-DISO
with	O
parainfluenza	B-DISO
virus	O
),	O
3	O
human	O
coronavirus	O
,	O
2	O
respiratory	O
syncytial	O
virus	O
.	O

Multiple	O
virus	O
infections	B-DISO
,	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
bacteria	O
/	O
fungus	O
,	O
and	O
bacteremia	B-DISO
/	O
fungemia	B-DISO
were	O
observed	O
in	O
60	O
%,	O
49	O
%,	O
and	O
32	O
%	O
of	O
children	O
,	O
respectively	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
non	O
-	O
survivors	O
and	O
survivors	O
regarding	O
the	O
types	O
of	O
pathogen	O
,	O
incidence	O
of	O
multiple	O
virus	B-DISO
infection	I-DISO
,	O
gender	O
,	O
age	O
,	O
clinical	O
features	O
,	O
and	O
treatment	O
.	O

The	O
Middle	O
Eastern	O
Respiratory	O
Syndrome	B-DISO
CoronaVirus	O
(	O
MERS	O
-	O
CoV	O
)	O
2015	O
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
(	O
ROK	O
)	O
provides	O
one	O
such	O
opportunity	O
.	O

In	O
50	O
(	O
96	O
%)	O
cases	O
,	O
SGA	O
was	O
isolated	O
in	O
at	O
least	O
one	O
sterile	B-DISO
sample	O
.	O

TITLE	O
:	O
[	O
Update	O
:	O
acute	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
].	O

Noninvasive	O
ventilation	O
(	O
NIV	O
)	O
is	O
the	O
therapy	O
of	O
choice	O
in	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
AECOPD	O
,	O
enabling	O
stabilization	O
in	O
the	O
majority	O
of	O
cases	O
and	O
generally	O
improving	O
prognosis	O
.	O

A	O
68	O
-	O
year	O
-	O
old	O
man	O
developed	O
fever	O
and	O
myalgia	B-DISO
7	O
days	O
after	O
returning	O
to	O
Korea	O
,	O
following	O
a	O
10	O
-	O
day	O
trip	O
to	O
the	O
Middle	O
East	O
.	O

Crossbred	O
Large	O
White	O
×	O
Landrace	O
gilts	O
(	O
n	O
=	O
641	O
)	O
were	O
fed	O
corn	B-DISO
-	O
soybean	O
diets	O
differing	O
in	O
SID	B-DISO
lysine	O
concentration	O
(%,	O
g	O
SID	B-DISO
lysine	O
:	O
Mcal	O
ME	O
);	O
diets	O
were	O
not	O
isocaloric	O
.	O

Results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
growth	O
rate	O
and	O
age	O
at	O
puberty	O
can	O
be	O
altered	O
by	O
ad	O
libitum	O
fed	O
diets	O
that	O
differ	O
in	O
SID	B-DISO
lysine	O
concentration	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Corona	O
Virus	O
Alert	O
Verification	O
In	O
Mirpur	O
,	O
Azad	O
Kashmir	O
.	O

His	O
son	O
having	O
underlying	O
condition	B-DISO
,	O
confirmed	O
as	O
MERS	O
-	O
CoV	O
on	O
13th	O
February	O
,	O
and	O
expired	O
on	O
17th	O
February	O
.	O

Daughter	O
developed	O
mild	O
respiratory	B-DISO
symptoms	I-DISO
,	O
confirmed	O
as	O
MERS	O
-	O
CoV	O
on	O
16th	O
Feb	O
and	O
recovered	O
.	O

During	O
his	O
stay	O
in	O
Pakistan	O
,	O
he	O
didn	O
'	O
t	O
meet	O
any	O
suspected	O
/	O
ill	B-DISO
person	O
.	O

The	O
four	O
downregulated	O
rno	O
‑	O
let	O
‑	O
7	O
miRNAs	O
may	O
be	O
involved	O
in	O
the	O
inflammatory	O
process	O
in	O
the	O
pathogenesis	B-DISO
and	O
progression	O
of	O
ARDS	B-DISO
,	O
via	O
the	O
synergistic	O
regulation	O
of	O
their	O
target	O
genes	O
,	O
such	O
as	O
IL	O
‑	O
6	O
.	O

No	O
samples	O
were	O
found	O
to	O
be	O
seropositive	O
for	O
canine	O
parainfluenza	B-DISO
virus	O
.	O

Mutational	O
studies	O
demonstrated	O
the	O
essential	O
requirements	O
of	O
the	O
conserved	O
residues	O
of	O
nsp1	O
for	O
NF	O
-	O
κB	O
suppression	B-DISO
.	O

We	O
assessed	O
whether	O
persons	O
exposed	O
to	O
seropositive	O
camels	O
at	O
household	O
level	O
had	O
serological	O
evidence	O
of	O
infection	B-DISO
.	O

Asthma	B-DISO
is	O
characterized	O
by	O
variable	O
airway	O
obstruction	B-DISO
,	I-DISO
airway	I-DISO
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
is	O
involved	O
mainly	O
in	O
enteric	O
infections	B-DISO
in	O
cattle	O
.	O

The	O
current	O
platform	O
has	O
been	O
optimized	O
to	O
include	O
a	O
novel	O
double	O
inactivation	B-DISO
procedure	O
in	O
order	O
to	O
ensure	O
a	O
highly	O
robust	O
inactivation	B-DISO
procedure	O
for	O
novel	O
emerging	O
viruses	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
clinical	O
characteristics	O
,	O
cytokine	O
/	O
chemokine	O
concentrations	O
,	O
viral	B-DISO
shedding	I-DISO
and	O
antibody	O
kinetics	O
in	O
30	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
),	O
including	O
6	O
non	O
-	O
survivors	O
admitted	O
to	O
3	O
MERS	B-DISO
-	O
designated	O
hospitals	O
.	O

Studies	O
on	O
the	O
modes	O
of	O
transmission	O
of	O
SARS	B-DISO
are	O
limited	O
though	O
a	O
number	O
of	O
outbreak	O
studies	O
have	O
revealed	O
the	O
possible	O
airborne	O
route	O
.	O

Our	O
results	O
reveal	O
that	O
under	O
the	O
assumed	O
conditions	O
,	O
the	O
SARS	B-DISO
coronavirus	O
was	O
most	O
possible	O
to	O
have	O
spread	O
via	O
the	O
combined	O
long	O
-	O
range	O
airborne	O
and	O
fomite	O
routes	O
,	O
and	O
that	O
the	O
fomite	O
route	O
played	O
a	O
non	O
-	O
negligible	O
role	O
in	O
the	O
transmission	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
literature	O
indicates	O
that	O
patient	O
delays	O
in	O
seeking	O
medical	O
support	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
are	O
associated	O
with	O
poor	O
clinical	O
outcomes	O
,	O
delays	O
in	O
the	O
diagnosis	O
itself	O
remain	O
poorly	O
understood	O
in	O
these	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
the	O
protein	O
C	O
system	O
,	O
endothelial	O
protein	O
C	O
receptor	O
(	O
EPCR	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
)	O
in	O
the	O
pathogenesis	B-DISO
of	O
malaria	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
relation	O
to	O
hemozoin	O
and	O
proinflammatory	O
cytokines	O
-	O
induced	O
type	O
II	O
pneumocyte	O
injury	O
and	O
-	O
aggravated	O
pulmonary	O
resolution	O
.	O

A	O
total	O
of	O
29	O
left	O
-	O
over	O
lung	O
specimens	O
that	O
were	O
obtained	O
from	O
patients	O
who	O
died	O
from	O
severe	O
falciparum	B-DISO
malaria	I-DISO
were	O
examined	O
.	O

We	O
reviewed	O
and	O
analyzed	O
our	O
experiences	O
with	O
the	O
use	O
of	O
ECMO	O
as	O
a	O
BTT	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
coronavirus	O
rearranges	O
the	O
host	O
cell	O
membrane	O
to	O
assemble	O
a	O
replication	O
/	O
transcription	O
complex	O
in	O
which	O
replication	O
of	O
the	O
viral	O
genome	O
and	O
transcription	O
of	O
viral	O
mRNA	O
occur	O
.	O

Previous	O
work	O
revealed	O
that	O
glycosylation	O
of	O
mouse	O
DPP4	O
plays	O
a	O
role	O
in	O
blocking	B-DISO
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

The	O
potential	O
diagnoses	O
in	O
these	O
four	O
cases	O
included	O
Bickerstaff	O
'	O
s	O
encephalitis	B-DISO
overlapping	O
with	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
intensive	O
-	O
care	O
-	O
unit	O
-	O
acquired	O
weakness	B-DISO
,	O
or	O
other	O
toxic	O
or	O
infectious	B-DISO
neuropathies	B-DISO
.	O

TITLE	O
:	O
Prone	O
position	O
ventilation	O
support	O
for	O
acute	O
exacerbation	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
?	O

TITLE	O
:	O
Risk	O
Stratification	O
in	O
Pediatric	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
A	O
Multicenter	O
Observational	O
Study	O
.	O

Besides	O
the	O
biological	O
interest	O
behind	O
the	O
SARS	B-DISO
coronavirus	O
non	O
-	O
structural	O
protein	O
1	O
(	O
nsp1	O
,	O
117	O
amino	O
acids	O
),	O
this	O
study	O
model	O
has	O
two	O
structural	O
features	O
that	O
motivated	O
its	O
use	O
in	O
this	O
work	O
:	O
1	O
-	O
its	O
recombinant	O
production	O
is	O
dependent	O
on	O
the	O
temperature	O
,	O
with	O
greater	O
solubility	O
when	O
expressed	O
at	O
low	O
temperatures	O
.	O

CASE	O
REPORT	O
A	O
57	O
-	O
year	O
-	O
old	O
man	O
patient	O
presented	O
with	O
acute	O
-	O
on	O
-	O
chronic	B-DISO
hepatic	I-DISO
failure	I-DISO
.	O

Infectious	B-DISO
etiology	O
was	O
excluded	O
as	O
evidenced	O
from	O
negative	O
sputum	O
and	O
blood	O
culture	O
,	O
which	O
were	O
repeated	O
after	O
48	O
h	O
.	O
LDLT	O
was	O
performed	O
and	O
ECMO	O
support	O
was	O
instituted	O
in	O
the	O
immediate	O
postoperative	O
period	O
due	O
to	O
worsening	O
of	O
the	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
electroacupuncture	O
at	O
the	O
Lieque	O
,	O
Chize	O
,	O
and	O
Zusanli	O
points	O
in	O
patients	O
with	O
lung	O
injury	O
caused	O
by	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

ABSTRACT	O
:	O
Scytovirin	O
is	O
a	O
lectin	O
isolated	O
from	O
the	O
cyanobacterium	O
Scytonema	O
varium	O
that	O
has	O
shown	O
activity	O
against	O
HIV	B-DISO
,	O
SARS	B-DISO
coronavirus	O
and	O
Zaire	O
Ebola	O
virus	O
.	O

Current	O
literature	O
has	O
supported	O
the	O
use	O
of	O
ECMO	O
in	O
critically	O
-	O
ill	B-DISO
,	O
pediatric	O
burn	O
patients	O
.	O

TITLE	O
:	O
Appearance	O
of	O
US	O
-	O
like	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
strains	O
before	O
US	O
outbreaks	O
and	O
genetic	O
heterogeneity	O
of	O
PEDVs	O
collected	O
in	O
Northern	O
Vietnam	O
during	O
2012	O
-	O
2015	O
.	O

The	O
data	O
show	O
that	O
(	O
i	O
)	O
7b	O
localizes	O
to	O
and	O
is	O
retained	O
in	O
the	O
medial	O
-	O
and	O
/	O
or	O
trans	O
-	O
Golgi	O
compartment	O
,	O
(	O
ii	O
)	O
the	O
C	O
-	O
terminal	O
KTEL	O
sequence	O
acts	O
as	O
a	O
Golgi	O
[	O
rather	O
than	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)]	O
retention	O
signal	O
,	O
(	O
iii	O
)	O
minor	O
changes	O
in	O
the	O
KTEL	O
motif	O
(	O
such	O
as	O
KTE	O
,	O
KTEV	O
,	O
or	O
the	O
addition	O
of	O
a	O
C	O
-	O
terminal	O
tag	B-DISO
)	O
abolish	O
Golgi	O
retention	O
,	O
resulting	O
in	O
relocalization	O
and	O
secretion	O
of	O
7b	O
,	O
and	O
(	O
iv	O
)	O
a	O
KTEL	O
-	O
to	O
-	O
KDEL	O
replacement	O
causes	O
retention	O
of	O
7b	O
in	O
the	O
ER	O
of	O
rFIPV	O
-	O
infected	O
feline	O
cells	O
.	O

This	O
CD9	O
-	O
facilitated	O
condensation	B-DISO
of	O
receptors	O
and	O
proteases	O
allowed	O
MERS	O
-	O
CoV	O
pseudoviruses	O
to	O
enter	O
cells	O
rapidly	O
and	O
efficiently	O
.	O

When	O
the	O
rAd5	O
-	O
hDPP4	O
vectors	O
co	O
-	O
expressed	O
small	O
RNAs	O
silencing	O
Cd9	O
or	O
Tmprss2	O
,	O
the	O
animals	O
were	O
significantly	O
less	O
susceptible	O
,	O
indicating	O
that	O
CD9	O
and	O
TMPRSS2	O
facilitated	O
robust	O
in	O
vivo	O
MERS	O
-	O
CoV	O
infection	B-DISO
of	O
mouse	O
lungs	O
.	O

Fifty	O
years	O
ago	O
,	O
distinguished	O
critical	O
care	O
colleagues	O
identified	O
a	O
syndrome	B-DISO
of	O
severe	O
lung	O
injury	O
that	O
united	O
a	O
group	O
of	O
patients	O
with	O
disparate	O
admitting	O
diagnoses	O
.	O

TITLE	O
:	O
Sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
detecting	O
feline	O
coronavirus	O
mutations	O
in	O
effusion	B-DISO
and	O
serum	O
/	O
plasma	O
of	O
cats	O
to	O
diagnose	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

A	O
mixed	O
population	O
of	O
FIPV	O
/	O
FECV	O
was	O
detected	O
in	O
the	O
effusion	B-DISO
of	O
2	O
/	O
59	O
cats	O
;	O
all	O
of	O
them	O
had	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
CoV	O
)	O
is	O
a	O
new	O
emerging	O
viral	B-DISO
disease	I-DISO
characterized	O
by	O
high	O
fatality	O
rate	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examines	O
recently	O
revised	O
Korean	O
government	O
legislation	O
addressing	O
global	O
infectious	B-DISO
disease	I-DISO
control	O
for	O
public	O
health	O
emergency	B-DISO
situations	O
,	O
with	O
the	O
aim	O
of	O
proposing	O
more	O
rational	O
,	O
effective	O
and	O
realistic	O
interpretations	O
and	O
applications	O
for	O
improvement	O
of	O
law	O
.	O

ABSTRACT	O
:	O
Diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
),	O
which	O
is	O
the	O
histological	O
surrogate	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
has	O
a	O
multifactorial	O
aetiology	O
.	O

20	O
/	O
51	O
(	O
39	O
.	O
2	O
%)	O
of	O
patients	O
suffered	B-DISO
from	O
mucositis	B-DISO
at	O
the	O
time	O
of	O
diagnosis	O
(	O
10	O
patients	O
had	O
oral	B-DISO
mucositis	I-DISO
,	O
2	O
patients	O
had	O
bowel	O
mucositis	B-DISO
,	O
and	O
8	O
patients	O
both	O
).	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
a	O
highly	O
lethal	O
pneumonia	B-DISO
.	O

Univariable	O
analysis	O
showed	O
that	O
thoracoscopy	O
(	O
shown	O
above	O
)	O
and	O
less	O
blood	B-DISO
loss	I-DISO
(<	O
350	O
mL	O
16	O
.	O
3	O
%,	O
≥	O
350	O
mL	O
30	O
.	O
2	O
%;	O
p	O
=	O
0	O
.	O
022	O
)	O
were	O
associated	O
with	O
PPC	O
prevention	O
,	O
whereas	O
laparoscopy	O
showed	O
a	O
borderline	O
significant	O
association	O
(	O
laparoscopy	O
15	O
.	O
4	O
%,	O
laparotomy	O
26	O
.	O
9	O
%;	O
p	O
=	O
0	O
.	O
079	O
).	O

Multivariable	O
analysis	O
also	O
showed	O
that	O
thoracoscopy	O
and	O
less	O
blood	B-DISO
loss	I-DISO
were	O
associated	O
with	O
PPC	O
prevention	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
PCLS	O
reduced	O
virulence	O
of	O
both	O
virus	O
species	O
compared	O
to	O
mono	B-DISO
-	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
acute	B-DISO
diarrhea	I-DISO
,	O
dehydration	B-DISO
in	O
pigs	O
,	O
and	O
high	O
mortality	O
rates	O
in	O
piglets	O
<	O
3	O
weeks	O
of	O
age	O
.	O

rotavirus	O
and	O
coronavirus	O
,	O
Salmonella	B-DISO
spp	O
.,	O
Escherichia	O
coli	O
,	O
Clostridium	O
perfringens	O
and	O
Eimeria	O
spp	O
.	O

We	O
applied	O
methylprednisolone	O
pulse	O
therapy	O
(	O
10mg	O
/	O
kg	O
/	O
d	O
)	O
for	O
three	O
days	O
and	O
other	O
supportive	O
therapies	O
,	O
the	O
girl	O
survived	O
through	O
complicated	O
with	O
oxygen	O
dependence	B-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
causing	O
major	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
.	O

ABSTRACT	O
:	O
Amiodarone	O
-	O
induced	O
pulmonary	B-DISO
toxicity	I-DISO
(	O
APT	O
)	O
is	O
a	O
severe	O
side	B-DISO
effect	I-DISO
that	O
can	O
lead	O
to	O
lung	B-DISO
fibrosis	I-DISO
or	O
fatal	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
present	O
the	O
case	O
of	O
a	O
58	O
year	O
old	O
woman	O
who	O
underwent	O
thoracic	B-DISO
surgery	O
with	O
lobe	O
resection	O
.	O

We	O
initiated	O
amiodarone	O
therapy	O
and	O
four	O
days	O
later	O
she	O
developed	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
pulmonary	O
function	O
further	O
deteriorated	O
showing	O
signs	O
of	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
the	O
tracheal	O
secretion	O
we	O
only	O
harvested	O
foam	O
cells	O
,	O
but	O
got	O
no	O
evidence	O
for	O
pathogens	O
causing	O
pneumonia	B-DISO
.	O

Owing	O
to	O
the	O
predominance	O
of	O
outbreaks	O
in	O
the	O
Middle	O
Eastern	O
countries	O
,	O
the	O
virus	O
was	O
renamed	O
a	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
corona	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
by	O
the	O
Corona	O
virus	O
Study	O
Group	O
.	O

We	O
discussed	O
the	O
presentation	O
and	O
the	O
clinical	O
workup	O
and	O
examinations	O
of	O
the	O
myositic	O
syndrome	B-DISO
.	O

Rhinoviruses	O
(	O
RVs	O
),	O
respiratory	O
enteroviruses	O
(	O
EVs	O
),	O
influenza	B-DISO
virus	O
,	O
respiratory	O
syncytial	O
viruses	O
(	O
RSVs	O
),	O
and	O
coronaviruses	O
are	O
highly	O
prevalent	O
respiratory	O
pathogens	O
,	O
but	O
because	O
of	O
the	O
lack	O
of	O
reliable	O
animal	O
models	O
,	O
their	O
differential	O
pathogenesis	B-DISO
remains	O
poorly	O
characterized	O
.	O

Persistent	B-DISO
infection	I-DISO
was	O
observed	O
in	O
all	O
cases	O
.	O

Our	O
results	O
highlight	O
the	O
differential	O
in	O
vitro	O
pathogenesis	B-DISO
of	O
respiratory	O
viruses	O
during	O
the	O
acute	B-DISO
infection	I-DISO
phase	O
and	O
their	O
ability	O
to	O
persist	O
under	O
immune	B-DISO
tolerance	I-DISO
.	O

Hence	O
,	O
the	O
requirement	O
for	O
respiratory	O
assistance	O
should	O
also	O
be	O
intensively	O
and	O
promptly	O
investigated	O
in	O
all	O
patients	O
with	O
neuromuscular	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
can	O
cause	O
life	O
-	O
threatening	O
respiratory	B-DISO
diseases	I-DISO
.	O

The	O
present	O
information	O
of	O
PPR	B-DISO
in	O
Chowsingha	O
is	O
the	O
first	O
report	O
of	O
PPRV	O
lineage	O
IV	O
causing	O
cross	O
-	O
species	O
fatal	O
disease	O
in	O
subfamily	O
bovinae	O
and	O
family	O
Bovidae	O
.	O

TITLE	O
:	O
Clinical	O
phenotype	O
of	O
South	O
-	O
East	O
Asian	O
temporomandibular	B-DISO
disorder	I-DISO
patients	O
with	O
upper	B-DISO
airway	I-DISO
resistance	I-DISO
syndrome	I-DISO
.	O

This	O
article	O
discusses	O
in	O
detail	O
the	O
planning	O
,	O
execution	O
,	O
and	O
outcomes	O
of	O
a	O
full	O
-	O
scale	O
exercise	O
involving	O
10	O
simulated	O
patients	O
with	O
a	O
highly	O
infectious	B-DISO
pathogen	O
transmitted	B-DISO
by	O
the	O
airborne	O
route	O
.	O

As	O
in	O
other	O
coronaviruses	O
,	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
mediates	O
receptor	O
recognition	O
and	O
membrane	O
fusion	O
and	O
is	O
the	O
primary	O
target	O
of	O
the	O
humoral	O
immune	O
response	O
during	O
infection	B-DISO
.	O

The	O
assay	O
could	O
detect	O
CDV	O
,	O
but	O
did	O
not	O
show	O
cross	O
-	O
detection	O
of	O
canine	O
parvovirus	B-DISO
-	O
2	O
(	O
CPV	O
-	O
2	O
),	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
canine	O
parainfluenza	B-DISO
virus	O
(	O
CPIV	O
),	O
pseudorabies	B-DISO
virus	O
(	O
PRV	B-DISO
)	O
or	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
demonstrating	O
high	O
specificity	O
.	O

ABSTRACT	O
:	O
From	O
May	O
to	O
July	O
2015	O
,	O
there	O
was	O
a	O
nation	O
-	O
wide	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Korea	O
.	O

TITLE	O
:	O
Enhanced	O
inflammation	B-DISO
in	O
New	O
Zealand	O
white	O
rabbits	O
when	O
MERS	O
-	O
CoV	O
reinfection	O
occurs	O
in	O
the	O
absence	O
of	O
neutralizing	O
antibody	O
.	O

New	O
Zealand	O
white	O
rabbits	O
are	O
a	O
possible	O
model	O
for	O
asymptomatic	B-DISO
infection	I-DISO
with	O
MERS	O
-	O
CoV	O
.	O
In	O
order	O
to	O
discover	O
more	O
about	O
non	O
-	O
lethal	O
infections	B-DISO
and	O
to	O
learn	O
whether	O
a	O
single	O
infection	B-DISO
with	O
MERS	O
-	O
CoV	O
would	O
protect	O
against	O
reinfection	O
,	O
we	O
inoculated	O
rabbits	O
with	O
MERS	O
-	O
CoV	O
and	O
monitored	O
the	O
antibody	O
and	O
inflammatory	B-DISO
response	I-DISO
.	O

Given	O
that	O
the	O
mechanisms	O
of	O
these	O
impairments	O
cannot	O
be	O
addressed	O
adequately	O
in	O
clinical	O
studies	O
,	O
we	O
characterized	O
cardiorespiratory	O
pathophysiology	O
from	O
birth	O
to	O
maturity	O
in	O
the	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
SAD	B-DISO
mouse	O
model	O
.	O

All	O
adult	O
SAD	B-DISO
mice	O
demonstrated	O
impairments	O
in	O
exercise	O
capacity	O
and	O
response	O
to	O
hypoxia	B-DISO
,	O
with	O
a	O
more	O
severe	O
phenotype	O
in	O
the	O
tachypneic	B-DISO
mice	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
adults	O
:	O
an	O
analysis	O
of	O
differences	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
decade	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
become	O
a	O
promising	O
option	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Neural	O
precursor	O
cells	O
derived	O
from	O
induced	O
pluripotent	O
stem	O
cells	O
exhibit	O
reduced	O
susceptibility	O
to	O
infection	B-DISO
with	O
a	O
neurotropic	O
coronavirus	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
five	O
years	O
later	O
.	O

Rigorous	O
application	O
of	O
nationally	O
defined	O
infection	B-DISO
prevention	O
and	O
control	O
measures	O
has	O
reduced	O
the	O
levels	O
of	O
healthcare	O
facility	O
-	O
associated	O
outbreaks	O
.	O

In	O
this	O
study	O
,	O
APS	B-DISO
were	O
employed	O
as	O
an	O
adjuvant	O
for	O
an	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
vaccine	O
,	O
and	O
its	O
effects	O
on	O
the	O
cellular	O
immune	O
and	O
humoral	O
immune	O
responses	O
to	O
vaccination	O
in	O
chicken	O
were	O
investigated	O
.	O

Three	O
of	O
the	O
four	O
vaccinated	O
groups	O
were	O
administered	O
different	O
doses	O
of	O
APS	B-DISO
(	O
APSL	O
,	O
10	O
mg	O
/	O
kg	O
;	O
APSM	O
,	O
50	O
mg	O
/	O
kg	O
;	O
and	O
APSH	O
,	O
100	O
mg	O
/	O
kg	O
)	O
after	O
the	O
first	O
vaccination	O
,	O
and	O
the	O
remaining	O
vaccinated	O
group	O
served	O
as	O
a	O
control	O
,	O
without	O
any	O
additional	O
treatment	O
.	O

These	O
data	O
suggest	O
that	O
APS	B-DISO
could	O
be	O
used	O
as	O
an	O
adjuvant	O
for	O
IBV	O
vaccination	O
to	O
provide	O
better	O
protection	O
against	O
IBV	O
infection	B-DISO
.	O

At	O
the	O
end	O
,	O
significant	O
improvement	O
in	O
survival	O
has	O
been	O
demonstrated	O
in	O
the	O
most	O
severe	O
ARDS	B-DISO
patients	O
,	O
at	O
a	O
threshold	O
of	O
100	O
-	O
150	O
mmHg	O
PaO	O

In	O
the	O
acute	O
phase	O
of	O
bronchiolitis	B-DISO
(≤	O
14	O
days	O
),	O
antibiotics	O
are	O
not	O
routinely	O
prescribed	O
unless	O
the	O
illness	O
is	O
severe	O
or	O
a	O
secondary	O
bacterial	B-DISO
infection	I-DISO
is	O
suspected	O
.	O

Both	O
studies	O
contributed	O
to	O
our	O
primary	O
and	O
secondary	O
outcomes	O
,	O
but	O
we	O
assessed	O
the	O
quality	O
of	O
evidence	O
for	O
our	O
three	O
primary	O
outcomes	O
as	O
low	O
,	O
owing	O
to	O
the	O
small	O
numbers	O
of	O
studies	O
and	O
participants	O
;	O
and	O
high	O
attrition	B-DISO
in	O
one	O
of	O
the	O
studies	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
SARS	B-DISO
-	O
like	O
coronavirus	O
are	O
a	O
potential	O
threat	O
to	O
global	O
health	O
.	O

Three	O
distinct	O
clinical	O
syndromes	B-DISO
were	O
identified	O
:	O
T3	O
-	O
L3	O
myelopathy	B-DISO
(	O
3	O
),	O
central	O
vestibular	O
syndrome	B-DISO
(	O
7	O
),	O
and	O
multifocal	O
CNS	B-DISO
disease	I-DISO
(	O
14	O
).	O

Magnetic	O
resonance	O
imaging	O
abnormalities	O
were	O
detected	O
in	O
all	O
cases	O
,	O
including	O
meningeal	O
contrast	O
enhancement	O
(	O
22	O
),	O
ependymal	O
contrast	O
enhancement	O
(	O
20	O
),	O
ventriculomegaly	O
(	O
20	O
),	O
syringomyelia	B-DISO
(	O
17	O
),	O
and	O
foramen	O
magnum	O
herniation	B-DISO
(	O
14	O
).	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
the	O
rJHM	O
strain	O
(	O
rJ	O
)	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
neurotropic	O
coronavirus	O
that	O
causes	O
acute	O
encephalitis	B-DISO
in	O
susceptible	O
strains	O
of	O
mice	O
.	O

The	O
results	O
showed	O
that	O
some	O
cells	O
were	O
able	O
to	O
survive	O
the	O
infection	B-DISO
,	O
as	O
demonstrated	O
by	O
continued	O
tdTomato	O
expression	O
after	O
virus	O
antigen	O
could	O
no	O
longer	O
be	O
detected	O
.	O

TITLE	O
:	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
,	O
necrotizing	B-DISO
pneumonia	I-DISO
and	O
staphylococcal	O
septic	B-DISO
shock	I-DISO
treated	O
with	O
extracorporeal	O
life	O
support	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
effect	O
of	O
serum	O
antibody	O
abundance	O
against	O
bovine	O
coronavirus	O
on	O
bovine	O
coronavirus	O
shedding	O
and	O
risk	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
beef	O
calves	O
from	O
birth	O
through	O
the	O
first	O
five	O
weeks	O
in	O
a	O
feedlot	O
.	O

ABSTRACT	O
:	O
Recent	O
data	O
suggest	O
that	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
pneumonia	B-DISO
is	O
associated	O
with	O
significant	O
mortality	O
in	O
hematopoietic	O
cell	O
transplant	O
(	O
HCT	O
)	O
recipients	O
.	O

Based	O
on	O
Italian	O
,	O
European	O
and	O
American	O
GLs	O
,	O
specific	O
TTI	O
,	O
including	O
haemoplasmas	O
,	O
feline	O
leukaemia	B-DISO
virus	O
(	O
FeLV	O
),	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
),	O
Anaplasma	O
phagocytophilum	O
,	O
Ehrlichia	O
species	O
,	O
Bartonella	O
species	O
,	O
Babesia	O
species	O
,	O
Theileria	O
species	O
,	O
Cytauxzoon	O
species	O
,	O
Leishmania	O
donovani	O
sensu	O
lato	O
and	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
were	O
screened	O
.	O

Results	O
for	O
FIV	O
and	O
FeLV	O
infections	B-DISO
were	O
negative	O
using	O
rapid	O
tests	O
,	O
whereas	O
five	O
(	O
16	O
.	O
1	O
%)	O
cats	O
were	O
positive	O
for	O
FCoV	O
antibodies	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
the	O
virus	O
was	O
not	O
accompanied	O
by	O
overt	O
inflammation	B-DISO
.	O

TITLE	O
:	O
Increased	O
serum	O
IL	O
-	O
17A	O
and	O
Th2	O
cytokine	O
levels	O
in	O
patients	O
with	O
severe	O
uncontrolled	O
asthma	B-DISO
.	O

ABSTRACT	O
:	O
Although	O
canine	O
parvovirus	B-DISO
(	O
CPV	O
)	O
and	O
canine	O
enteric	O
coronavirus	O
(	O
CCoV	O
)	O
are	O
important	O
enteric	O
pathogens	O
of	O
dogs	O
and	O
have	O
been	O
studied	O
extensively	O
in	O
different	O
parts	O
of	O
the	O
world	O
,	O
there	O
are	O
no	O
reports	O
on	O
these	O
viruses	O
from	O
the	O
Caribbean	O
region	O
.	O

TITLE	O
:	O
Establishment	O
and	O
Application	O
of	O
a	O
Universal	O
Coronavirus	O
Screening	O
Method	O
Using	O
MALDI	O
-	O
TOF	B-DISO
Mass	O
Spectrometry	O
.	O

ABSTRACT	O
:	O
Aichivirus	O
B	O
has	O
been	O
reported	O
worldwide	O
in	O
calves	O
and	O
adult	O
cattle	O
with	O
and	O
without	O
diarrhea	B-DISO
.	O

TITLE	O
:	O
Etiology	O
of	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
fattening	O
pigs	O
in	O
Finland	O
.	O

A	O
total	O
of	O
20	O
case	O
herds	O
having	O
finishing	O
pigs	O
showing	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
and	O
eight	O
control	O
herds	O
showing	O
no	O
clinical	O
signs	O
suggesting	O
of	O
respiratory	B-DISO
problems	I-DISO
were	O
enrolled	O
in	O
the	O
study	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
disease	O
,	O
including	O
Ebola	O
,	O
Zika	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
,	O
have	O
shown	O
the	O
need	O
for	O
a	O
collaborative	O
and	O
co	O
-	O
ordinated	O
response	O
to	O
global	O
health	O
issues	O
.	O

Otherwise	O
,	O
a	O
novel	O
variation	O
(	O
16	O
-	O
20	O
aa	O
deletion	O
and	O
an	O
L25P	O
mutation	O
)	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
E	O
protein	O
affected	O
multiple	O
infection	B-DISO
processes	O
,	O
including	O
up	O
-	O
regulation	O
of	O
the	O
production	O
of	O
the	O
ER	O
stress	O
indicator	O
GRP78	O
,	O
improving	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
and	O
promoting	O
apoptosis	O
.	O

TITLE	O
:	O
A	O
review	O
of	O
candidate	O
therapies	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
from	O
a	O
molecular	O
perspective	O
.	O

ABSTRACT	O
:	O
In	O
the	O
continuous	O
effort	O
to	O
identify	O
new	O
HIV	B-DISO
-	O
1	O
inhibitors	O
endowed	O
with	O
innovative	O
mechanisms	O
,	O
the	O
dual	O
inhibition	O
of	O
different	O
viral	O
functions	O
would	O
provide	O
a	O
significant	O
advantage	O
against	O
drug	O
-	O
resistant	O
variants	O
.	O

The	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
is	O
the	O
only	O
viral	O
-	O
encoded	O
enzymatic	O
activity	O
that	O
still	O
lacks	O
an	O
efficient	O
inhibitor	O
.	O

Moreover	O
,	O
A15	O
retained	O
good	O
inhibition	O
potency	O
against	O
three	O
non	O
-	O
nucleoside	O
RT	O
inhibitor	O
(	O
NNRTI	O
)-	O
resistant	O
enzymes	O
,	O
confirming	O
a	O
mode	O
of	O
action	O
unrelated	O
to	O
NNRTIs	O
and	O
suggesting	O
its	O
potential	O
as	O
a	O
lead	O
compound	O
for	O
development	O
of	O
new	O
HIV	B-DISO
-	O
1	O
RT	O
dual	O
inhibitors	O
active	O
against	O
drug	O
-	O
resistant	O
viruses	O
.	O

Following	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
initiation	O
,	O
97	O
%	O
respondents	O
administer	O
sedative	O
/	O
analgesic	O
infusions	O
,	O
and	O
the	O
sedation	B-DISO
target	O
was	O
""""	O
sedated	O
""""	O
or	O
""""	O
very	O
sedated	O
""""	O
for	O
59	O
%,	O
""""	O
calm	O
and	O
cooperative	O
""""	O
for	O
25	O
%,	O
and	O
""""	O
unarousable	O
""""	O
for	O
16	O
%.	O

TITLE	O
:	O
Current	O
treatment	O
options	O
and	O
the	O
role	O
of	O
peptides	O
as	O
potential	O
therapeutic	O
components	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
):	O
A	O
review	O
.	O

ABSTRACT	O
:	O
Sickle	B-DISO
-	I-DISO
cell	I-DISO
disease	I-DISO
(	O
SCD	B-DISO
)	O
affects	O
millions	O
worldwide	O
.	O

These	O
patients	O
do	O
not	O
typically	O
have	O
the	O
traditional	O
risk	O
factors	O
for	O
the	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

Donning	O
and	O
doffing	O
PPE	O
and	O
N95	O
mask	O
fit	B-DISO
testing	O
has	O
become	O
an	O
annual	O
mandatory	O
competency	O
requirement	O
for	O
staff	O
in	O
nursing	O
and	O
clinical	O
services	O
.	O

CONCLUSIONS	O
:	O
The	O
application	O
of	O
specified	O
protocols	O
minimizes	O
the	O
risks	O
of	O
cross	B-DISO
infection	I-DISO
,	O
placing	O
emphasis	O
on	O
patient	O
and	O
staff	O
safety	O
as	O
well	O
as	O
expediting	O
the	O
patient	O
to	O
definitive	O
treatment	O
.	O

Further	O
diagnostic	O
testing	O
confirmed	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O

Area	O
covered	O
:	O
This	O
review	O
summarizes	O
the	O
current	O
understanding	O
of	O
the	O
structural	O
and	O
functional	O
properties	O
of	O
type	O
II	O
transmembrane	O
serine	O
proteases	O
(	O
TTSPs	O
)	O
as	O
a	O
proteolytic	O
activator	O
of	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
and	O
discusses	O
their	O
potential	O
as	O
antiviral	O
targets	O
.	O

The	O
review	O
also	O
provides	O
an	O
overview	O
of	O
the	O
properties	O
of	O
small	O
molecules	O
,	O
proteins	O
,	O
and	O
peptides	O
that	O
efficiently	O
inhibit	O
the	O
proteolytic	O
activation	O
of	O
the	O
influenza	B-DISO
virus	O
.	O

Expert	O
opinion	O
:	O
TTSPs	O
activate	O
a	O
wide	O
range	O
of	O
influenza	B-DISO
virus	O
subtypes	O
including	O
avian	B-DISO
influenza	I-DISO
viruses	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
via	O
proteolytic	O
cleavage	O
of	O
influenza	B-DISO
hemagglutinin	O
(	O
HA	O
)	O
into	O
infection	B-DISO
-	O
competent	O
fusogenic	O
conformation	O
.	O

Other	O
viruses	O
such	O
as	O
SARS	B-DISO
-,	O
MERS	O
-	O
coronaviruses	O
and	O
human	O
metapneumoviruses	O
may	O
use	O
the	O
same	O
host	O
cell	O
proteases	O
for	O
activation	O
,	O
implying	O
that	O
TTSP	O
inhibition	O
might	O
be	O
a	O
novel	O
strategy	O
for	O
developing	O
broad	O
-	O
spectrum	O
antiviral	O
agents	O
for	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

No	O
cross	O
-	O
reactivity	O
to	O
influenza	B-DISO
A	O
or	O
B	O
was	O
detected	O
.	O

Subsequently	O
,	O
all	O
piglets	O
were	O
inoculated	O
with	O
the	O
corresponding	O
PEDV	O
strains	O
at	O
an	O
age	O
of	O
3	O
to	O
6	O
days	O
,	O
and	O
virus	B-DISO
shedding	I-DISO
,	O
clinical	O
signs	O
and	O
occurrence	O
of	O
specific	O
antibodies	O
were	O
assessed	O
.	O

Piglets	O
without	O
MDA	O
showed	O
a	O
morbidity	O
of	O
100	O
%	O
and	O
low	O
lethality	O
,	O
while	O
almost	O
all	O
MDA	O
-	O
positive	O
piglets	O
stayed	O
clinically	O
healthy	O
and	O
showed	O
considerably	O
lower	O
virus	B-DISO
shedding	I-DISO
.	O

TITLE	O
:	O
Cellular	O
cholesterol	O
is	O
required	O
for	O
porcine	O
nidovirus	O
infection	B-DISO
.	O

Although	O
cholesterol	O
is	O
known	O
to	O
affect	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
in	O
vitro	O
,	O
its	O
significance	O
and	O
role	O
in	O
porcine	O
nidovirus	O
infection	B-DISO
remains	O
to	O
be	O
elucidated	O
.	O

Conversely	O
,	O
cholesterol	B-DISO
depletion	I-DISO
from	O
the	O
viral	O
envelope	O
had	O
no	O
inhibitory	O
effect	O
on	O
porcine	O
nidovirus	O
production	O
.	O

Relying	O
on	O
the	O
available	O
literature	O
and	O
our	O
experience	O
in	O
the	O
recent	O
South	O
Korean	O
MERS	O
-	O
CoV	O
outbreak	O
,	O
we	O
hope	O
to	O
highlight	O
key	O
physiologic	O
and	O
clinical	O
points	O
in	O
VV	O
ECLS	O
for	O
adult	O
respiratory	B-DISO
failure	I-DISO
in	O
this	O
review	O
.	O

2	O
.	O
3	O
%	O
of	O
the	O
3911	O
children	O
examined	O
had	O
HPeV	O
infection	B-DISO
,	O
with	O
most	O
(	O
87	O
.	O
5	O
%)	O
concentrated	O
in	O
September	O
-	O
January	O
(	O
autumn	O
-	O
winter	O
).	O

RESULTS	O
:	O
2	O
.	O
3	O
%	O
of	O
the	O
3911	O
children	O
examined	O
had	O
HPeV	O
infection	B-DISO
,	O
with	O
most	O
(	O
87	O
.	O
5	O
%)	O
concentrated	O
in	O
September	O
-	O
January	O
(	O
autumn	O
-	O
winter	O
).	O

Most	O
rash	B-DISO
illnesses	O
exhibited	O
a	O
generalized	O
maculopapular	O
pattern	O
involving	O
the	O
trunk	O
and	O
limbs	O
,	O
and	O
were	O
more	O
likely	O
associated	O
with	O
HPeV4	O
compared	O
to	O
other	O
syndrome	B-DISO
groups	O
(	O
36	O
.	O
4	O
%	O
vs	O
.	O
3	O
.	O
1	O
%,	O
p	O
=	O
0	O
.	O
011	O
).	O

Transfemoral	O
TAVI	O
without	O
general	O
anesthesia	B-DISO
(	O
28	O
patients	O
)	O
was	O
associated	O
with	O
the	O
lowest	O
rate	O
of	O
respiratory	B-DISO
complications	I-DISO
(	O
3	O
.	O
6	O
%).	O

TITLE	O
:	O
Management	O
Strategies	O
for	O
Severe	O
Respiratory	B-DISO
Failure	I-DISO
:	O

This	O
article	O
provides	O
a	O
basic	O
understanding	O
of	O
the	O
evolution	O
of	O
ARDS	B-DISO
to	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
,	O
recognizing	O
benefits	O
and	O
limits	O
of	O
rescue	O
therapies	O
,	O
indications	O
and	O
contraindications	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
and	O
coordination	O
of	O
care	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

In	O
addition	O
,	O
PEDV	O
did	O
not	O
compromise	O
cell	O
viability	O
at	O
48	O
,	O
72	O
,	O
and	O
96h	O
after	O
infection	B-DISO
at	O
either	O
a	O
MOI	O
of	O
2	O
.	O
5	O
or	O
5	O
.	O

It	O
is	O
known	O
,	O
that	O
ALI	O
and	O
ARDS	B-DISO
differ	O
clinically	O
and	O
pathobiologically	O
from	O
ALI	O
/	O
ARDS	B-DISO
caused	O
by	O
other	O
reasons	O
,	O
but	O
the	O
exact	O
pathology	B-DISO
remains	O
elusive	O
.	O

TITLE	O
:	O
Cytomegalovirus	O
associated	O
severe	O
pneumonia	B-DISO
,	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
Ganciclovir	O
associated	O
arrhythmia	B-DISO
in	O
immunocompetent	O
child	O
.	O

Hereby	O
,	O
we	O
report	O
a	O
twelve	O
-	O
year	O
-	O
old	O
boy	O
who	O
presented	O
with	O
tachycardia	O
,	O
tachypnea	B-DISO
,	O
fever	O
and	O
leukocytosis	B-DISO
,	O
which	O
progressed	O
to	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Cytomegalovirus	B-DISO
infection	I-DISO
was	O
diagnosed	O
by	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
)	O
in	O
blood	O
and	O
histopathological	O
examination	O
of	O
lung	O
biopsy	O
.	O

However	O
,	O
our	O
patient	O
developed	O
transient	O
heart	B-DISO
block	I-DISO
as	O
a	O
rare	O
complication	B-DISO
for	O
Ganciclovir	O
therapy	O
throughout	O
his	O
course	O
.	O

TITLE	O
:	O
Ocular	O
abnormalities	O
associated	O
with	O
hypovitaminosis	B-DISO
A	I-DISO
in	O
Hanwoo	O
calves	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Acute	B-DISO
Glomerulonephritis	I-DISO
(	O
AGN	O
)	O
is	O
uncommon	O
with	O
simultaneous	O
severe	O
throat	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
The	O
mortality	O
rate	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
patients	O
is	O
a	O
major	O
challenge	O
in	O
all	O
healthcare	O
systems	O
worldwide	O
.	O

Cox	O
-	O
proportional	O
hazard	O
(	O
CPH	B-DISO
)	O
models	O
were	O
applied	O
to	O
estimate	O
the	O
hazard	O
ratios	O
for	O
the	O
predictors	O
of	O
3	O
-	O
and	O
30	O
-	O
day	O
mortality	O
.	O

Several	O
factors	O
were	O
identified	O
that	O
could	O
influence	O
mortality	O
outcomes	O
at	O
3	O
days	O
and	O
30	O
days	O
,	O
including	O
age	O
(	O
elderly	O
),	O
non	O
-	O
healthcare	O
workers	O
,	O
severity	O
of	O
illness	O
,	O
and	O
hospital	O
-	O
acquired	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
The	O
inflammasome	O
,	O
a	O
cytosolic	O
protein	O
complex	O
that	O
mediates	O
the	O
processing	O
and	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
is	O
one	O
of	O
the	O
first	O
responders	O
during	O
viral	B-DISO
infection	I-DISO
.	O

The	O
results	O
reveal	O
that	O
the	O
three	O
IBV	O
isolates	O
mainly	O
exhibited	O
mutations	O
in	O
the	O
hypervariable	O
regions	O
(	O
HVRs	O
)	O
of	O
the	O
S1	O
gene	O
and	O
protein	O
,	O
but	O
were	O
phylogenetically	O
and	O
serologically	O
closely	O
related	O
,	O
belonging	O
to	O
lineage	O
11	O
of	O
the	O
GI	O
genotype	O
,	O
the	O
former	O
BR	O
genotype	O
I	O
.	O
All	O
three	O
isolates	O
caused	O
persistent	B-DISO
infection	I-DISO
in	O
broiler	O
breeders	O
reared	O
in	O
the	O
field	O
,	O
despite	O
high	O
systemic	O
anti	O
-	O
IBV	O
antibody	O
titres	O
,	O
and	O
exhibited	O
tropism	O
and	O
pathogenicity	O
for	O
the	O
trachea	B-DISO
and	O
kidney	O
after	O
experimental	O
infection	B-DISO
in	O
SPF	O
chickens	O
and	O
contact	O
birds	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
evolved	O
to	O
navigate	O
through	O
the	O
sophisticated	O
network	O
of	O
a	O
host	O
'	O
s	O
immune	O
system	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
at	O
least	O
two	O
recently	O
identified	O
camel	O
coronaviruses	O
was	O
detected	O
in	O
92	O
.	O
6	O
%	O
of	O
the	O
camels	O
in	O
the	O
study	O
.	O

ABSTRACT	O
:	O
The	O
epidemiology	O
and	O
outcomes	O
of	O
tumor	B-DISO
lysis	I-DISO
syndrome	I-DISO
(	O
TLS	O
)	O
are	O
understudied	O
.	O

Predictors	O
of	O
mortality	O
were	O
derived	O
from	O
a	O
multivariable	O
logistic	O
regression	O
and	O
included	O
age	O
,	O
Elixhauser	O
comorbidity	O
score	O
,	O
insurance	O
status	O
,	O
teaching	O
versus	O
nonteaching	O
hospital	O
,	O
and	O
cancer	B-DISO
type	O
.	O

Mycoplasma	B-DISO
pneumoniae	O
was	O
the	O
most	O
frequent	O
bacterium	O
in	O
patients	O
aged	O
<	O
16	O
years	O
,	O
regardless	O
of	O
the	O
preceding	O
virus	O
type	O
(	O
p	O
=	O
0	O
.	O
630	O
).	O

The	O
major	O
results	O
were	O
as	O
follows	O
(	O
p	O
<	O
0	O
.	O
001	O
):	O
pneumonia	B-DISO
in	O
patients	O
with	O
influenza	B-DISO
virus	O
(	O
type	O
A	O
/	O
B	O
),	O
rhinovirus	O
,	O
and	O
human	O
metapneumovirus	O
infections	B-DISO
was	O
caused	O
by	O
similar	O
bacteria	O
,	O
and	O
the	O
findings	O
indicated	O
that	O
Staphylococcus	B-DISO
aureus	I-DISO
pneumonia	I-DISO
was	O
very	O
common	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
251	O
clinically	O
significant	O
bacteria	O
were	O
identified	O
in	O
233	O
patients	O
with	O
post	O
-	O
viral	O
bacterial	B-DISO
pneumonia	I-DISO
.	O

CONCLUSIONS	O
:	O
The	O
pathogens	O
causing	O
post	O
-	O
viral	O
bacterial	B-DISO
pneumonia	I-DISO
vary	O
according	O
to	O
the	O
type	O
of	O
preceding	O
respiratory	O
virus	O
.	O

Mean	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
was	O
10	O
.	O
5	O
(	O
3	O
.	O
7	O
)	O
cm	O
H	O
Patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
receive	O
treatment	O
adjuncts	O
frequently	O
,	O
especially	O
with	O
refractory	O
hypoxemia	O
.	O

RESULTS	O
:	O
We	O
enrolled	O
664	O
patients	O
:	O
222	O
(	O
33	O
%)	O
with	O
moderate	O
and	O
442	O
(	O
67	O
%)	O
with	O
severe	O
ARDS	B-DISO
.	O

Assessment	O
of	O
Hospital	O
Emergency	B-DISO
Department	O
Response	O
to	O
Potentially	O
Infectious	B-DISO
Diseases	I-DISO
Using	O
Unannounced	O
Mystery	O
Patient	O
Drills	O
-	O
New	O
York	O
City	O
,	O
2016	O
.	O

Drill	O
findings	O
were	O
used	O
to	O
inform	O
hospital	O
improvement	O
planning	O
to	O
more	O
rapidly	O
and	O
consistently	O
identify	O
and	O
isolate	O
patients	O
with	O
a	O
potentially	O
highly	O
infectious	B-DISO
disease	I-DISO
.	O

In	O
this	O
study	O
,	O
a	O
mouse	O
model	O
of	O
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	B-DISO
was	O
established	O
.	O

TITLE	O
:	O
Clinical	O
,	O
immunologic	O
,	O
and	O
genetic	O
spectrum	O
of	O
696	O
patients	O
with	O
combined	B-DISO
immunodeficiency	I-DISO
.	O

Serology	O
testing	O
for	O
the	O
presence	O
of	O
virus	O
-	O
elicited	O
antibodies	O
in	O
blood	O
is	O
one	O
of	O
the	O
methods	O
used	O
commonly	O
for	O
clinical	O
diagnosis	O
of	O
viral	B-DISO
infections	I-DISO
.	O

However	O
,	O
standard	O
serology	O
-	O
based	O
tests	O
have	O
a	O
significant	O
limitation	O
:	O
they	O
cannot	O
easily	O
distinguish	O
active	O
from	O
past	O
,	O
historical	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Interstitial	B-DISO
pneumonia	I-DISO
with	O
autoimmune	B-DISO
features	O
(	O
IPAF	O
)	O
identifies	O
a	O
recently	O
recognized	O
autoimmune	B-DISO
syndrome	B-DISO
characterized	O
by	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
and	O
autoantibodies	O
positivity	O
,	O
but	O
absence	O
of	O
a	O
specific	O
connective	B-DISO
tissue	I-DISO
disease	I-DISO
diagnosis	O
or	O
alternative	O
etiology	O
.	O

Transcriptional	O
regulatory	O
sequences	O
(	O
TRS	B-DISO
)	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
Mouse	B-DISO
Hepatitis	I-DISO
Virus	O
(	O
MHV	O
)	O
sgmRNAs	O
contain	O
a	O
species	O
specific	O
core	O
element	O
(	O
CE	O
).	O

The	O
study	O
of	O
HCoV	O
-	O
host	O
interactions	O
has	O
contributed	O
extensively	O
to	O
our	O
understanding	O
of	O
HCoV	O
pathogenesis	B-DISO
.	O

Previous	O
studies	O
have	O
reported	O
that	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
can	O
produce	O
cytopathic	B-DISO
effects	I-DISO
(	O
CPE	O
)	O
and	O
apoptosis	O
in	O
some	O
mammalian	O
cells	O
and	O
primary	O
cells	O
.	O

In	O
contrast	O
,	O
maternal	O
mortality	O
from	O
postpartum	O
obstetric	O
hemorrhage	B-DISO
has	O
decreased	O
since	O
the	O
late	O
1980s	O
and	O
accounted	O
for	O
slightly	O
more	O
than	O
10	O
%	O
of	O
maternal	O
mortalities	O
(	O
approximately	O
1	O
.	O
7	O
deaths	O
per	O
100	O
,	O
000	O
live	O
births	O
)	O
in	O
2009	O
(	O
2	O
,	O
4	O
).	O

This	O
observed	O
decrease	O
in	O
mortality	O
is	O
associated	O
with	O
increasing	O
rates	O
of	O
transfusion	O
and	O
peripartum	O
hysterectomy	O
(	O
2	O
-	O
4	O
).	O
The	O
purpose	O
of	O
this	O
Practice	O
Bulletin	O
is	O
to	O
discuss	O
the	O
risk	O
factors	O
for	O
postpartum	B-DISO
hemorrhage	I-DISO
as	O
well	O
as	O
its	O
evaluation	O
,	O
prevention	O
,	O
and	O
management	O
.	O

TITLE	O
:	O
Practice	O
Bulletin	O
No	O
.	O
183	O
:	O
Postpartum	B-DISO
Hemorrhage	I-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
variants	O
constantly	O
emerge	O
and	O
pose	O
economic	O
threats	O
to	O
poultry	O
farms	O
worldwide	O
.	O

Varicella	B-DISO
zoster	I-DISO
infection	I-DISO
was	O
confirmed	O
via	O
skin	O
biopsy	O
,	O
bronchial	O
viral	O
PCR	O
and	O
serology	O
for	O
varicella	B-DISO
antibodies	O
.	O

This	O
work	O
performs	O
selection	O
of	O
synthetic	O
polymers	O
as	O
novel	O
broadly	O
active	O
agents	O
and	O
demonstrates	O
activity	O
of	O
these	O
polymers	O
against	O
Zika	O
,	O
Ebola	O
,	O
Lassa	O
,	O
Lyssa	B-DISO
,	O
Rabies	B-DISO
,	O
Marburg	O
,	O
Ebola	O
,	O
influenza	B-DISO
,	O
herpes	B-DISO
simplex	I-DISO
,	O
and	O
human	O
immunodeficiency	B-DISO
viruses	O
.	O

TITLE	O
:	O
First	O
Confirmed	O
Case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
in	O
the	O
Kingdom	O
of	O
Bahrain	O
:	O

We	O
present	O
a	O
case	O
of	O
the	O
successful	O
use	O
of	O
ECMO	O
to	O
treat	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
secondary	O
to	O
staphylococcal	B-DISO
sepsis	I-DISO
in	O
an	O
adolescent	O
CF	O
patient	O
with	O
previously	O
normal	O
lung	O
function	O
.	O

Intriguingly	O
,	O
PHEV	O
invasion	B-DISO
leads	O
to	O
rapid	O
actin	O
rearrangement	O
,	O
suggesting	O
that	O
the	O
intactness	O
and	O
dynamics	O
of	O
the	O
actin	O
cytoskeleton	O
are	O
positively	O
correlated	O
with	O
viral	O
endocytosis	O
.	O

Our	O
findings	O
demonstrate	O
that	O
PHEV	O
hijacks	O
the	O
CME	O
and	O
endosomal	O
system	O
of	O
the	O
host	O
to	O
enter	O
and	O
traffic	O
within	O
neural	O
cells	O
,	O
providing	O
new	O
insights	O
into	O
PHEV	O
pathogenesis	B-DISO
and	O
guidance	O
for	O
antiviral	O
drug	O
design	O
.	O

Protection	O
(	O
reduction	O
of	O
clinical	O
signs	O
and	O
viral	O
loads	O
)	O
assessed	O
5	O
days	O
postchallenge	O
showed	O
nonsignificant	O
differences	O
between	O
chickens	O
primed	O
with	O
Mass	O
vaccine	O
and	O
boosted	O
with	O
rLS	B-DISO
/	O
IBV	O
.	O
S2	O
-	O
4	O
/	O
91	O
and	O
chickens	O
vaccinated	O
with	O
Mass	O
only	O
.	O

We	O
describe	O
the	O
occurrence	O
of	O
an	O
outbreak	O
among	O
HCWs	O
and	O
attempt	O
to	O
characterize	O
at	O
-	O
risk	O
exposures	O
to	O
improve	O
future	O
infection	B-DISO
control	O
interventions	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
in	O
2015	O
,	O
the	O
index	O
case	O
was	O
a	O
30	O
-	O
year	O
-	O
old	O
Filipino	O
nurse	O
who	O
had	O
a	O
history	O
of	O
unprotected	O
exposure	O
to	O
a	O
MERS	O
-	O
CoV	O
-	O
positive	O
case	O
on	O
May	O
15	O
,	O
2015	O
,	O
and	O
had	O
multiple	O
negative	O
tests	O
for	O
MERS	O
-	O
CoV	O
.	O
Weeks	O
later	O
,	O
she	O
was	O
diagnosed	O
with	O
pulmonary	B-DISO
tuberculosis	I-DISO
and	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
High	O
reproduction	O
number	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
nosocomial	O
outbreaks	O
:	O
mathematical	O
modelling	O
in	O
Saudi	O
Arabia	O
and	O
South	O
Korea	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
lnc	O
-	O
IL7R	O
as	O
a	O
potential	O
biomarker	O
in	O
ARDS	B-DISO
was	O
examined	O
.	O

Role	O
of	O
lnc	O
-	O
IL7R	O
as	O
potential	O
biomarker	O
in	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
85	O
ARDS	B-DISO
patients	O
and	O
49	O
healthy	O
controls	O
were	O
included	O
.	O

Sixty	O
-	O
eight	O
patients	O
with	O
severe	O
chest	O
trauma	O
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
that	O
were	O
treated	O
at	O
our	O
Tianjin	O
Hospital	O
from	O
September	O
2013	O
to	O
July	O
2016	O
were	O
recruited	O
.	O

A	O
12	O
-	O
bed	B-DISO
oncological	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
from	O
January	O
2014	O
to	O
December	O
2015	O
.	O

Future	O
studies	O
should	O
investigate	O
means	O
for	O
preventing	O
SARF	O
-	O
MV	O
in	O
critically	B-DISO
ill	I-DISO
cancer	B-DISO
patients	O
,	O
which	O
may	O
have	O
an	O
impact	O
upon	O
outcomes	O
.	O

Moreover	O
,	O
the	O
association	O
between	O
driving	O
airway	O
pressure	O
and	O
mortality	O
in	O
ARDS	B-DISO
patients	O
potentially	O
underlines	O
the	O
importance	O
of	O
sizing	O
tidal	O
volume	O
on	O
respiratory	O
system	O
compliance	O
rather	O
than	O
on	O
predicted	O
body	O
weight	O
.	O

The	O
present	O
review	O
article	O
aims	O
to	O
describe	O
the	O
main	O
alterations	O
of	O
respiratory	O
mechanics	O
in	O
ARDS	B-DISO
as	O
a	O
potent	O
bedside	O
tool	O
to	O
understand	O
severity	O
and	O
guide	O
mechanical	O
ventilation	O
settings	O
,	O
thus	O
representing	O
a	O
readily	O
available	O
clinical	O
resource	O
for	O
ICU	O
physicians	O
.	O

Although	O
the	O
host	O
-	O
feeding	O
patterns	O
for	O
many	O
of	O
these	O
Culex	O
species	O
are	O
well	O
studied	O
,	O
the	O
host	O
-	O
feeding	O
patterns	O
of	O
Culex	O
stigmatosoma	O
Dyar	O
are	O
relatively	O
poorly	O
studied	O
,	O
even	O
though	O
this	O
species	O
is	O
suspected	O
to	O
be	O
an	O
important	O
maintenance	O
vector	O
for	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
and	O
other	O
arboviruses	O
.	O

TITLE	O
:	O
Lianqinjiedu	O
decoction	O
attenuates	O
LPS	B-DISO
-	O
induced	O
inflammation	B-DISO
and	O
acute	O
lung	O
injury	O
in	O
rats	O
via	O
TLR4	O
/	O
NF	O
-	O
κB	O
pathway	O
.	O

The	O
recruitment	B-DISO
of	O
body	O
temperature	O
and	O
the	O
histopathology	O
of	O
lung	O
tissue	O
from	O
all	O
groups	O
were	O
evaluated	O
to	O
grade	O
the	O
severity	O
of	O
the	O
inflammation	B-DISO
.	O

This	O
study	O
demonstrates	O
that	O
LQJD	O
has	O
a	O
protective	O
effect	O
on	O
LPS	B-DISO
-	O
induced	O
inflammatory	O
rats	O
through	O
the	O
signaling	O
pathway	O
of	O
TLR4	O
and	O
NF	O
-	O
κBp65	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
and	O
dysfunction	O
of	O
at	O
least	O
1	O
organ	O
system	O
of	O
the	O
renal	O
,	O
respiratory	O
,	O
cardiovascular	O
,	O
coagulation	O
,	O
and	O
neurologic	O
systems	O
by	O
day	O
7	O
after	O
surgery	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
experimental	O
group	O
strategy	O
increased	O
6	O
-	O
month	O
mortality	O
(	O
65	O
.	O
3	O
%	O
vs	O
59	O
.	O
9	O
%;	O
HR	O
,	O
1	O
.	O
18	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
to	O
1	O
.	O
38	O
;	O
P	O
=	O
.	O
04	O
),	O
decreased	O
the	O
number	O
of	O
mean	O
ventilator	O
-	O
free	O
days	O
(	O
5	O
.	O
3	O
vs	O
6	O
.	O
4	O
;	O
difference	O
,	O
-	O
1	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
-	O
2	O
.	O
1	O
to	O
-	O
0	O
.	O
1	O
;	O
P	O
=	O
.	O
03	O
),	O
increased	O
the	O
risk	O
of	O
pneumothorax	B-DISO
requiring	O
drainage	O
(	O
3	O
.	O
2	O
%	O
vs	O
1	O
.	O
2	O
%;	O
difference	O
,	O
2	O
.	O
0	O
%;	O
95	O
%	O
CI	O
,	O
0	O
.	O
0	O
%	O
to	O
4	O
.	O
0	O
%;	O
P	O
=	O
.	O
03	O
),	O
and	O
the	O
risk	O
of	O
barotrauma	O
(	O
5	O
.	O
6	O
%	O
vs	O
1	O
.	O
6	O
%;	O
difference	O
,	O
4	O
.	O
0	O
%;	O
95	O
%	O
CI	O
,	O
1	O
.	O
5	O
%	O
to	O
6	O
.	O
5	O
%;	O
P	O
=	O
.	O
001	O
).	O

TITLE	O
:	O
A	O
Comparison	O
of	O
China	O
'	O
s	O
Risk	O
Communication	O
in	O
Response	O
to	O
SARS	B-DISO
and	O
H7N9	O
Using	O
Principles	O
Drawn	O
From	O
International	O
Practice	O
.	O

ABSTRACT	O
:	O
China	O
'	O
s	O
emergency	B-DISO
management	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
heavily	O
criticized	O
,	O
whereas	O
the	O
H7N9	O
response	O
was	O
praised	O
by	O
the	O
international	O
community	O
.	O

A	O
qualitative	O
comparative	O
case	O
study	O
approach	O
was	O
employed	O
in	O
the	O
present	O
study	O
,	O
using	O
a	O
set	O
of	O
8	O
risk	O
communication	O
principles	O
selected	O
from	O
international	O
literature	O
to	O
suit	O
the	O
Chinese	O
context	O
for	O
the	O
comparative	O
analysis	O
of	O
emergency	B-DISO
responses	O
of	O
SARS	B-DISO
and	O
H7N9	O
.	O

Twelve	O
pigs	O
(	O
German	O
Landrace	O
)	O
underwent	O
femur	O
fracture	O
,	O
liver	O
laceration	O
,	O
blunt	O
chest	O
trauma	O
,	O
and	O
haemorrhagic	B-DISO
shock	I-DISO
under	O
standard	O
anaesthesia	B-DISO
and	O
intensive	O
care	O
monitoring	O
.	O

Minor	O
bleeding	B-DISO
complications	O
occurred	O
in	O
6	O
of	O
10	O
patients	O
.	O

TITLE	O
:	O
Limitations	O
of	O
using	O
feline	O
coronavirus	O
spike	O
protein	O
gene	O
mutations	O
to	O
diagnose	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

TITLE	O
:	O
Endothelial	O
glycocalyx	O
degradation	O
is	O
more	O
severe	O
in	O
patients	O
with	O
non	O
-	O
pulmonary	B-DISO
sepsis	I-DISO
compared	O
to	O
pulmonary	B-DISO
sepsis	I-DISO
and	O
associates	O
with	O
risk	O
of	O
ARDS	B-DISO
and	O
other	O
organ	O
dysfunction	O
.	O

In	O
patients	O
with	O
non	O
-	O
pulmonary	B-DISO
sepsis	I-DISO
,	O
syndecan	O
-	O
1	O
levels	O
were	O
associated	O
with	O
ARDS	B-DISO
(	O
p	O
=	O
0	O
.	O
05	O
).	O

The	O
extent	O
of	O
endothelial	O
glycocalyx	O
degradation	O
is	O
associated	O
with	O
non	O
-	O
pulmonary	O
organ	O
dysfunction	O
in	O
subjects	O
with	O
sepsis	B-DISO
and	O
is	O
associated	O
with	O
ARDS	B-DISO
but	O
only	O
in	O
the	O
subgroup	O
with	O
non	O
-	O
pulmonary	B-DISO
sepsis	I-DISO
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
locations	O
and	O
architecture	O
of	O
the	O
glycan	O
-	O
and	O
antibody	O
-	O
binding	O
sites	O
in	O
four	O
different	O
viruses	O
with	O
stalk	B-DISO
-	O
like	O
attachment	O
proteins	O
(	O
reovirus	O
,	O
influenza	B-DISO
virus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
)	O
and	O
investigate	O
the	O
mechanisms	O
by	O
which	O
antibodies	O
block	O
glycan	O
recognition	O
.	O

ABSTRACT	O
:	O
Since	O
discovering	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
a	O
causative	O
agent	O
of	O
severe	O
respiratory	O
illness	O
in	O
the	O
Middle	O
East	O
in	O
2012	O
,	O
serological	O
testing	O
has	O
been	O
conducted	O
to	O
assess	O
antibody	O
responses	O
in	O
patients	O
and	O
to	O
investigate	O
the	O
zoonotic	O
reservoir	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Development	O
of	O
rapid	O
immunochromatographic	O
strip	O
test	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
acute	O
and	O
severe	O
watery	B-DISO
diarrhoea	I-DISO
and	O
dehydration	B-DISO
,	O
as	O
well	O
as	O
50	O
-	O
100	O
per	O
cent	O
mortality	O
in	O
piglets	O
.	O

While	O
studies	O
have	O
reported	O
cases	O
of	O
influenza	B-DISO
infections	B-DISO
acquired	O
during	O
travel	O
,	O
here	O
we	O
examine	O
two	O
cases	O
of	O
severe	O
influenza	B-DISO
infection	B-DISO
contracted	O
in	O
the	O
country	O
of	O
origin	O
that	O
led	O
to	O
diagnosis	O
and	O
therapeutic	O
problems	O
in	O
the	O
destination	O
country	O
.	O

No	O
international	O
recommendation	O
exists	O
concerning	O
influenza	B-DISO
vaccination	O
before	O
travel	O
,	O
and	O
few	O
countries	O
recommend	O
it	O
for	O
all	O
travelers	O
.	O

A	O
number	O
of	O
studies	O
have	O
focused	O
on	O
influenza	B-DISO
infection	B-DISO
in	O
travelers	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
a	O
retrospective	O
study	O
to	O
compare	O
clinical	O
and	O
laboratory	O
findings	O
between	O
1	O
)	O
severe	O
influenza	B-DISO
A	O
and	O
mild	O
influenza	B-DISO
A	O
and	O
2	O
)	O
pandemic	O
2009	O
H1N1	O
(	O
pdm09	O
A	O
/	O
H1	O
)	O
and	O
seasonal	O
H3N2	O
(	O
A	O
/	O
H3	O
)	O
from	O
2009	O
to	O
2010	O
.	O

We	O
hypothesized	O
that	O
children	O
and	O
adolescents	O
would	O
experience	O
SIRS	B-DISO
physiology	O
,	O
but	O
would	O
not	O
experience	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
or	O
""""	O
second	O
hit	O
""""	O
related	O
death	O
to	O
the	O
extent	O
seen	O
in	O
the	O
adult	O
populations	O
.	O

TITLE	O
:	O
A	O
rapid	O
bio	O
-	O
optical	O
sensor	O
for	O
diagnosing	O
Q	B-DISO
fever	I-DISO
in	O
clinical	O
specimens	O
.	O

We	O
here	O
describe	O
a	O
rapid	O
bio	O
-	O
optical	O
sensor	O
for	O
the	O
accurate	O
detection	O
of	O
Q	B-DISO
fever	I-DISO
and	O
validate	O
its	O
clinical	O
utility	O
.	O

This	O
study	O
highlights	O
the	O
therapeutic	O
potential	O
of	O
diphyllin	O
and	O
its	O
nanoformulation	O
for	O
the	O
treatment	O
of	O
FIP	B-DISO
.	O

TITLE	O
:	O
Quaternized	O
chitosan	O
nanoparticles	O
loaded	O
with	O
the	O
combined	O
attenuated	O
live	O
vaccine	O
against	O
Newcastle	B-DISO
disease	I-DISO
and	O
infectious	B-DISO
bronchitis	B-DISO
elicit	O
immune	O
response	O
in	O
chicken	O
after	O
intranasal	O
administration	O
.	O

ABSTRACT	O
:	O
Newcastle	B-DISO
disease	I-DISO
(	O
ND	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
are	O
important	O
diseases	O
,	O
which	O
cause	O
respiratory	B-DISO
diseases	I-DISO
in	O
chickens	O
,	O
resulting	O
in	O
severely	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
.	O

In	O
vivo	O
immunization	O
of	O
chickens	O
showed	O
that	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
/	O
IBV	O
NPs	B-DISO
or	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
-	O
IBV	O
NPs	B-DISO
intranasally	O
induced	O
higher	O
titers	O
of	O
IgG	O
and	O
IgA	O
antibodies	O
,	O
significantly	O
promoted	O
proliferation	B-DISO
of	O
lymphocytes	O
and	O
induced	O
higher	O
levels	O
of	O
interleukine	O
-	O
2	O
(	O
IL	O
-	O
2	O
),	O
IL	O
-	O
4	O
and	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
than	O
the	O
commercially	O
combined	O
attenuated	O
live	O
vaccine	O
did	O
.	O

All	O
admitted	O
patients	O
with	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
from	O
2012	O
to	O
2016	O
were	O
tested	O
for	O
MERS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
testing	O
for	O
influenza	B-DISO
viruses	O
was	O
carried	O
out	O
starting	O
April	O
2015	O
.	O

From	O
January	O
2015	O
to	O
December	O
2016	O
,	O
a	O
total	O
of	O
1644	O
patients	O
were	O
tested	O
for	O
both	O
MERS	O
-	O
CoV	O
and	O
influenza	B-DISO
.	O

TITLE	O
:	O
Pathogenic	O
CD8	O
ABSTRACT	O
:	O
Malaria	B-DISO
is	O
a	O
severe	O
disease	O
and	O
kills	O
over	O
400	O
,	O
000	O
people	O
each	O
year	O
.	O

CONCLUSIONS	O
:	O
The	O
mandatory	O
vaccines	O
remain	O
the	O
same	O
with	O
continued	O
vigilance	O
for	O
the	O
development	O
of	O
any	O
new	O
or	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Structural	O
insights	O
of	O
a	O
self	O
-	O
assembling	O
9	O
-	O
residue	O
peptide	O
from	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
the	O
SARS	B-DISO
corona	O
virus	O
E	O
-	O
protein	O
in	O
DPC	O
and	O
SDS	B-DISO
micelles	O
:	O
A	O
combined	O
high	O
and	O
low	O
resolution	O
spectroscopic	O
study	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
several	O
studies	O
based	O
on	O
the	O
interaction	O
of	O
self	O
-	O
assembling	O
short	O
peptides	O
derived	O
from	O
viroporins	O
with	O
model	O
membranes	O
,	O
have	O
improved	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
corona	O
virus	O
(	O
CoV	O
)	O
infection	B-DISO
under	O
physiological	O
conditions	O
.	O

There	O
were	O
24	O
(	O
14	O
.	O
0	O
%)	O
mixed	B-DISO
infections	I-DISO
.	O

There	O
were	O
24	O
(	O
14	O
.	O
0	O
%)	O
mixed	B-DISO
infections	I-DISO
.	O

It	O
remains	O
unclear	O
whether	O
certain	O
types	O
of	O
cases	O
were	O
more	O
likely	O
to	O
cause	O
secondary	B-DISO
infections	I-DISO
than	O
others	O
,	O
and	O
if	O
so	O
,	O
why	O
.	O

Further	O
research	O
to	O
generate	O
robust	O
evidence	O
and	O
repeated	O
HCP	B-DISO
trainings	O
are	O
necessary	O
to	O
ensure	O
HCP	B-DISO
and	O
patient	O
safety	O
in	O
future	O
outbreaks	O
.	O

This	O
analysis	O
was	O
part	O
of	O
the	O
Community	O
-	O
Acquired	O
Pneumonia	B-DISO
immunization	O
Trial	O
in	O
Adults	O
(	O
CAPiTA	O
);	O
a	O
double	O
blind	B-DISO
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
84	O
496	O
immunocompetent	O
individuals	O
aged	O
≥	O
65	O
years	O
.	O

Presence	O
of	O
influenza	B-DISO
A	O
and	O
B	O
,	O
parainfluenza	B-DISO
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
adeno	O
-,	O
boca	B-DISO
-,	O
corona	O
-,	O
metapneumo	O
-,	O
rhino	O
-	O
and	O
respiratory	O
syncytial	O
viruses	O
was	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Annual	O
influenza	B-DISO
vaccination	O
was	O
received	O
by	O
672	O
(	O
87	O
.	O
2	O
%)	O
in	O
the	O
PCV13	O
group	O
and	O
719	O
(	O
87	O
.	O
7	O
%)	O
in	O
the	O
placebo	O
group	O
of	O
the	O
confirmed	O
CAP	B-DISO
cases	O
.	O

DAD	O
was	O
assessed	O
by	O
two	O
pathologists	O
,	O
and	O
ARDS	B-DISO
criteria	O
were	O
evaluated	O
by	O
two	O
intensivists	O
.	O

After	O
multivariable	O
analysis	O
,	O
high	O
PEEP	O
levels	O
,	O
physiological	O
variables	O
,	O
and	O
opacities	B-DISO
involving	O
only	O
three	O
quadrants	O
on	O
chest	O
radiographs	O
were	O
not	O
associated	O
with	O
DAD	O
.	O

DAD	O
was	O
found	O
in	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
a	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
≤	O
100	O
mmHg	O
and	O
opacities	B-DISO
involving	O
the	O
four	O
quadrants	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
-	O
CoV	O
Fusion	O
Peptide	O
Forms	O
an	O
Extended	O
Bipartite	O
Fusion	O
Platform	O
that	O
Perturbs	O
Membrane	O
Order	O
in	O
a	O
Calcium	O
-	O
Dependent	O
Manner	O
.	O

Moreover	O
,	O
MERS	O
-	O
CoV	O
infection	B-DISO
was	O
highlighted	O
in	O
western	O
(	O
40	O
.	O
8	O
%)	O
and	O
central	O
(	O
31	O
.	O
9	O
%)	O
regions	O
,	O
followed	O
by	O
eastern	O
region	O
(	O
20	O
%).	O

Neither	O
an	O
immunodiagnostic	O
nor	O
a	O
vaccine	O
is	O
available	O
for	O
the	O
detection	O
and	O
prevention	O
of	O
RVD	O
infection	B-DISO
.	O

TITLE	O
:	O
Mutation	O
of	O
Asn	O
-	O
475	O
in	O
the	O
Venezuelan	B-DISO
Equine	I-DISO
Encephalitis	I-DISO
Virus	O
nsP2	O
Cysteine	O
Protease	O
Leads	O
to	O
a	O
Self	O
-	O
Inhibited	O
State	O
.	O

Glial	O
fibrillary	O
acidic	O
protein	O
expression	O
was	O
increased	O
in	O
the	O
retina	O
in	O
cases	O
of	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
A	O
new	O
type	O
of	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
H7N9	O
,	O
has	O
been	O
a	O
great	O
threat	O
to	O
public	O
health	O
since	O
its	O
2013	O
outbreak	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
respiratory	O
viruses	O
in	O
Iranian	O
patients	O
with	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
.	O

In	O
this	O
study	O
,	O
in	O
order	O
to	O
explore	O
an	O
efficient	O
oral	O
vaccine	O
against	O
PEDV	O
infection	B-DISO
,	O
a	O
mucosal	O
DC	O
-	O
targeting	O
oral	O
vaccine	O
was	O
developed	O
using	O

The	O
etiology	O
of	O
the	O
disease	O
remains	O
unknown	O
,	O
though	O
recent	O
reports	O
suggest	O
an	O
antecedent	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
or	O
systemic	O
antibiotic	O
administration	O
may	O
trigger	O
the	O
clinical	O
syndrome	B-DISO
.	O

Visual	O
acuity	O
was	O
20	O
/	O
40	O
with	O
an	O
intraocular	B-DISO
pressure	I-DISO
(	O
IOP	O
)	O
of	O
30	O
mmHg	O
in	O
the	O
affected	O
eye	O
despite	O
maximal	O
tolerated	O
medical	O
therapy	O
.	O

Epidemic	O
infectious	B-DISO
disease	I-DISO
agents	O
(	O
e	O
.	O
g	O
.,	O
Ebola	O
virus	O
,	O
Coronavirus	O
,	O
Zika	O
virus	O
)	O
could	O
be	O
controlled	O
more	O
easily	O
by	O
testing	O
travelers	O
on	O
-	O
site	O
at	O
the	O
country	O
borders	O
to	O
prevent	O
outbreaks	O
from	O
spreading	O
.	O

Other	O
noninfluenza	O
respiratory	O
viral	O
pathogens	O
include	O
human	O
metapneumovirus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
adenovirus	B-DISO
.	O

Work	O
is	O
already	O
underway	O
to	O
develop	O
vaccines	O
against	O
a	O
number	O
of	O
other	O
outbreak	O
pathogens	O
and	O
we	O
will	O
also	O
review	O
progress	O
on	O
these	O
approaches	O
here	O
,	O
particularly	O
for	O
Lassa	B-DISO
fever	I-DISO
,	O
Nipah	O
and	O
MERS	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
the	O
effect	O
of	O
hemoadsorption	O
therapy	O
to	O
reduce	O
cytokines	O
in	O
septic	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

A	O
prospective	O
observational	O
study	O
of	O
all	O
consecutive	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
had	O
VV	O
ECMO	O
at	O
a	O
tertiary	O
German	O
ECMO	O
centre	O
from	O
2009	O
to	O
2015	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
long	O
-	O
term	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
alendronate	O
,	O
extracorporeal	O
shock	O
and	O
hyperbaric	O
oxygen	O
for	O
osteonecrosis	B-DISO
of	O
the	O
femoral	O
head	O
(	O
ONFH	O
)	O
of	O
post	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

In	O
order	O
to	O
evaluate	O
piglet	O
diarrhea	B-DISO
caused	O
TGEV	O
and	O
ETEC	O
K88	O
,	O
the	O
authors	O
examin	O
the	O
effects	O
of	O
coinfection	B-DISO
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
analyze	O
piglet	O
diarrhea	B-DISO
caused	O
by	O
TGEV	O
-	O
ETEC	O
K88	O
coinfection	B-DISO
using	O
high	O
-	O
throughput	O
quantitative	O
proteomics	O
.	O

TITLE	O
:	O
Oxalate	B-DISO
nephropathy	I-DISO
following	O
vitamin	O
C	O
intake	O
within	O
intensive	O
care	O
unit	O
.	O

This	O
case	O
highlights	O
an	O
under	O
-	O
recognized	O
secondary	O
adverse	O
event	O
from	O
vitamin	O
C	O
given	O
to	O
critically	O
-	O
ill	B-DISO
patients	O
.	O

CONCLUSIONS	O
:	O
Compelling	O
evidence	O
obtained	O
from	O
in	O
-	O
vitro	O
and	O
animal	O
studies	O
suggest	O
that	O
vitamin	O
C	O
,	O
a	O
circulating	O
antioxidant	O
,	O
may	O
be	O
a	O
valuable	O
adjunctive	O
therapy	O
in	O
critically	O
-	O
ill	B-DISO
patients	O
.	O

Many	O
risk	O
factors	O
contribute	O
in	O
the	O
emergence	O
and	O
rapid	O
spread	O
of	O
epidemic	O
diseases	O
in	O
the	O
Region	O
including	O
acute	O
and	O
protracted	O
humanitarian	O
emergencies	B-DISO
,	O
resulting	O
in	O
fragile	O
health	O
systems	O
,	O
increased	O
population	O
mobility	O
,	O
rapid	O
urbanization	O
,	O
climate	O
change	O
,	O
weak	O
surveillance	O
and	O
limited	O
laboratory	O
diagnostic	O
capacity	O
,	O
and	O
increased	O
human	O
-	O
animal	O
interaction	O
.	O

Dengue	B-DISO
fever	I-DISO
remains	O
an	O
important	O
public	O
health	O
concern	O
,	O
with	O
at	O
least	O
eight	O
countries	O
in	O
the	O
region	O
being	O
endemic	O
for	O
the	O
disease	O
.	O

Virus	B-DISO
shedding	I-DISO
,	O
acute	O
phase	O
protein	O
responses	O
and	O
serological	O
responses	O
were	O
comparable	O
to	O
those	O
seen	O
after	O
experimental	O
challenge	O
with	O
a	O
Danish	O
PRRSV	O
-	O
2	O
reference	O
strain	O
isolated	O
in	O
1997	O
.	O

Overall	O
,	O
the	O
results	O
indicate	O
that	O
the	O
severe	O
disease	O
observed	O
in	O
the	O
field	O
was	O
contributed	O
by	O
additional	O
factors	O
in	O
combination	O
with	O
the	O
PRRS	B-DISO
virus	B-DISO
infection	I-DISO
.	O

There	O
was	O
no	O
cross	O
-	O
amplification	B-DISO
between	O
the	O
two	O
probes	O
when	O
using	O
standard	O
recombinant	O
plasmids	O
,	O
and	O
the	O
specificity	O
was	O
further	O
confirmed	O
by	O
using	O
other	O
seven	O
non	O
-	O
PEDV	O
swine	O
pathogens	O
.	O

TITLE	O
:	O
Raising	O
awareness	O
of	O
health	O
care	O
providers	O
about	O
MERSCoV	O
infection	B-DISO
in	O
public	O
hospitals	O
in	O
Mecca	O
,	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
Molecular	O
survey	O
of	O
infectious	B-DISO
agents	O
associated	O
with	O
bovine	O
respiratory	B-DISO
disease	I-DISO
in	O
a	O
beef	O
cattle	O
feedlot	O
in	O
southern	O
Brazil	O
.	O

Single	O
and	O
concomitant	O
associations	O
of	O
infectious	B-DISO
agents	O
of	O
BRD	O
were	O
identified	O
.	O

TITLE	O
:	O
Clinical	O
signs	O
of	O
hypoxaemia	O
in	O
children	O
aged	O
2	O
months	O
to	O
5	O
years	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
in	O
Switzerland	O
and	O
Senegal	O
.	O

This	O
observational	O
study	O
was	O
conducted	O
in	O
four	O
emergency	B-DISO
units	O
,	O
two	O
in	O
Switzerland	O
and	O
two	O
in	O
Senegal	O
.	O

Patients	O
aged	O
2	O
months	O
to	O
5	O
years	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
were	O
eligible	O
for	O
inclusion	O
.	O

TITLE	O
:	O
Discrepancies	O
between	O
feline	O
coronavirus	O
antibody	O
and	O
nucleic	O
acid	O
detection	O
in	O
effusions	B-DISO
of	O
cats	O
with	O
suspected	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
Intra	O
-	O
vitam	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
challenge	O
for	O
veterinary	O
diagnosticians	O
,	O
since	O
there	O
are	O
no	O
highly	O
specific	O
and	O
sensitive	O
assays	O
currently	O
available	O
.	O

Three	O
samples	O
with	O
high	O
antibody	O
levels	O
tested	O
negative	O
by	O
qRT	O
-	O
PCR	O
,	O
whereas	O
18	O
qRT	O
-	O
PCR	O
positive	O
effusions	B-DISO
contained	O
no	O
or	O
low	O
-	O
titre	O
antibodies	O
.	O

ABSTRACT	O
:	O
The	O
current	O
study	O
was	O
intended	O
to	O
evaluate	O
the	O
knowledge	O
and	O
awareness	O
toward	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
of	O
pilgrims	O
from	O
Saudi	O
Arabia	O
and	O
from	O
different	O
Arabian	O
countries	O
.	O

Using	O
peripheral	O
blood	O
obtained	O
from	O
mature	O
infants	O
with	O
and	O
without	O
NRDS	O
,	O
in	O
tandem	O
with	O
mRNA	O
sequencing	O
(	O
mRNA	O
‑	O
seq	O
)	O
analysis	O
,	O
the	O
present	O
study	O
identified	O
that	O
,	O
while	O
cell	O
cycle	O
regulation	O
and	O
alveolar	O
surfactants	O
serve	O
a	O
role	O
in	O
deterring	O
the	O
further	O
onset	O
of	O
NRDS	O
,	O
innate	O
and	O
pathogen	O
‑	O
induced	O
responses	O
of	O
the	O
immune	O
system	O
are	O
among	O
the	O
most	O
important	O
factors	O
in	O
the	O
pathology	B-DISO
.	O

Four	O
well	O
-	O
managed	O
herds	O
experiencing	O
neonatal	B-DISO
diarrhoea	I-DISO
and	O
suspected	O
to	O
be	O
affected	O
by	O
NNPDS	O
were	O
included	O
in	O
a	O
case	O
-	O
control	O
set	O
up	O
.	O

When	O
MERS	O
-	O
CoV	O
was	O
first	O
identified	O
,	O
the	O
closest	O
related	O
virus	O
was	O
in	O
bats	O
;	O
however	O
,	O
it	O
has	O
since	O
been	O
recognized	O
that	O
dromedary	O
camels	O
serve	O
as	O
a	O
virus	O
reservoir	O
and	O
potential	O
source	O
for	O
human	O
infections	B-DISO
.	O

Our	O
findings	O
indicate	O
that	O
CSF	O
titer	O
of	O
1	O
:	O
640	O
or	O
higher	O
may	O
be	O
served	O
as	O
a	O
candidate	O
for	O
the	O
index	O
for	O
diagnosing	O
FIP	B-DISO
.	O

By	O
using	O
this	O
technology	O
,	O
effective	O
and	O
potential	O
siRNAs	O
can	O
be	O
designed	O
,	O
delivered	O
and	O
their	O
efficacy	O
with	O
toxic	O
effects	O
and	O
immunogenic	O
responses	O
can	O
be	O
tested	O
against	O
MERS	O
-	O
CoV	O
.	O
CONCLUSIONS	O
:	O
The	O
efficacy	O
of	O
siRNA	O
-	O
based	O
therapeutics	O
has	O
been	O
used	O
not	O
only	O
against	O
many	O
viral	B-DISO
diseases	I-DISO
but	O
also	O
against	O
non	O
-	O
viral	B-DISO
diseases	I-DISO
,	O
cancer	B-DISO
,	O
dominant	O
genetic	B-DISO
disorders	I-DISO
,	O
and	O
autoimmune	B-DISO
disease	I-DISO
.	O

In	O
the	O
drug	O
-	O
associated	O
ARDS	B-DISO
group	O
,	O
although	O
high	O
-	O
resolution	O
CT	O
scores	O
indicative	O
of	O
the	O
extent	O
of	O
fibroproliferation	O
(	O
301	O
.	O
6	O
(	O
244	O
.	O
1	O
-	O
339	O
.	O
8	O
)	O
vs	O
208	O
.	O
3	O
(	O
183	O
.	O
4	O
-	O
271	O
.	O
6	O
),	O
p	O
<	O
0	O
.	O
001	O
),	O
serum	O
lactate	O
dehydrogenase	O
levels	O
(	O
477	O
(	O
365	O
-	O
585	O
)	O
vs	O
322	O
(	O
246	O
-	O
434	O
),	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
the	O
McCabe	O
scores	O
(	O
score	O
1	O
/	O
2	O
/	O
3	O
,	O
n	O
(%):	O
20	O
(	O
74	O
)/	O
4	O
(	O
15	O
)/	O
3	O
(	O
11	O
)	O
vs154	O
(	O
91	O
)/	O
7	O
(	O
4	O
)/	O
9	O
(	O
5	O
),	O
p	O
=	O
0	O
.	O
04	O
)	O
were	O
significantly	O
higher	O
,	O
ventilator	O
weaning	O
was	O
earlier	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
28	O
-	O
day	O
mortality	O
was	O
better	O
(	O
p	O
=	O
0	O
.	O
043	O
).	O

The	O
patient	O
also	O
developed	O
circulatory	B-DISO
collapse	I-DISO
after	O
resuscitation	O
for	O
sudden	B-DISO
cardiac	I-DISO
arrest	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
believed	O
to	O
be	O
secondary	O
to	O
aspiration	B-DISO
.	O

With	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
a	O
massive	O
infusion	O
of	O
propofol	O
successfully	O
suppressed	O
status	B-DISO
epilepticus	I-DISO
,	O
and	O
both	O
the	O
circulatory	B-DISO
collapse	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
gradually	O
improved	O
;	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
and	O
propofol	O
treatments	O
were	O
then	O
terminated	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
without	O
further	O
disabilities	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
rates	O
of	O
positive	O
and	O
negative	O
influenza	B-DISO
virus	O
tests	O
between	O
Hajj	O
pilgrims	O
with	O
symptoms	O
and	O
those	O
without	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
infectious	B-DISO
agents	O
in	O
chickens	O
,	O
and	O
in	O
chicken	O
cells	O
,	O
it	O
can	O
be	O
recognized	O
by	O
MDA5	O
to	O
activate	O
interferon	O
production	O
.	O

We	O
also	O
found	O
that	O
IBV	O
can	O
cleave	O
MAVS	O
,	O
an	O
adaptor	O
protein	O
downstream	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
that	O
acts	O
as	O
a	O
platform	O
for	O
antiviral	O
innate	O
immunity	O
at	O
an	O
early	O
stage	O
of	O
infection	B-DISO
.	O

Although	O
chicken	O
MDA5	O
(	O
chMDA5	O
)	O
is	O
functionally	O
active	O
during	O
IBV	O
infection	B-DISO
,	O
the	O
absence	O
of	O
RIG	O
-	O
I	O
may	O
increase	O
the	O
susceptibility	O
of	O
chickens	O
to	O
IBV	O
infection	B-DISO
,	O
and	O
IBV	O
may	O
disrupt	O
the	O
activation	O
of	O
the	O
host	O
antiviral	O
response	O
through	O
the	O
cleavage	O
of	O
MAVS	O
.	O

In	O
a	O
phase	O
I	O
/	O
II	O
,	O
open	O
-	O
label	O
study	O
in	O
37	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
ARDS	B-DISO
,	O
recombinant	O
human	O
IFN	O
beta	O
-	O
1a	O
was	O
well	O
tolerated	O
and	O
mortality	O
rates	O
were	O
significantly	O
lower	O
in	O
treated	O
than	O
in	O
control	O
patients	O
.	O

The	O
results	O
from	O
this	O
study	O
will	O
provide	O
evidence	O
regarding	O
the	O
efficacy	O
of	O
a	O
potential	O
new	O
therapeutic	O
agent	O
,	O
FP	O
-	O
1201	O
-	O
lyo	O
,	O
in	O
improving	O
the	O
clinical	O
course	O
and	O
outcome	O
for	O
patients	O
with	O
moderate	O
/	O
severe	O
ARDS	B-DISO
.	O

In	O
other	O
regions	O
,	O
adults	O
may	O
also	O
develop	O
cerebral	B-DISO
malaria	I-DISO
but	O
neurological	O
sequelae	O
in	O
survivors	O
are	O
rare	O
.	O

Common	O
concurrent	O
injuries	O
included	O
fractures	O
to	O
the	O
rib	O
/	O
sternum	O
/	O
larynx	B-DISO
/	O
trachea	B-DISO
(	O
19	O
.	O
6	O
%).	O

One	O
Health	O
is	O
advocated	O
through	O
an	O
intersectoral	O
coordination	O
to	O
combat	O
zoonoses	B-DISO
,	O
and	O
the	O
term	O
has	O
evolved	O
over	O
centuries	O
.	O

Meta	O
-	O
analysis	O
of	O
observational	O
studies	O
provided	O
evidence	O
of	O
a	O
protective	O
effect	O
of	O
masks	O
(	O
OR	O
=	O
0	O
.	O
13	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
03	O
-	O
0	O
.	O
62	O
)	O
and	O
respirators	O
(	O
OR	O
=	O
0	O
.	O
12	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
06	O
-	O
0	O
.	O
26	O
)	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
risk	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
increased	O
in	O
passive	O
and	O
active	O
smokers	O
after	O
blunt	O
trauma	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	O
aggregation	O
and	O
ARDS	B-DISO
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	B-DISO
platelet	O
activation	O
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	B-DISO
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	O
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
At	O
both	O
0	O
hour	O
and	O
24	O
hours	O
,	O
impaired	B-DISO
platelet	O
aggregation	O
was	O
associated	O
with	O
increased	O
odds	O
of	O
developing	O
ARDS	B-DISO
.	O

TITLE	O
:	O
ECMO	O
used	O
successfully	O
in	O
a	O
near	O
fatal	O
case	O
of	O
opioid	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
29year	O
old	O
male	O
arrived	O
with	O
Emergency	B-DISO
Medical	O
Services	O
(	O
EMS	O
)	O
status	O
post	O
presumed	O
heroin	O
overdose	O
.	O

The	O
patient	O
arrived	O
in	O
severe	O
respiratory	B-DISO
distress	I-DISO
with	O
a	O
pulse	O
oximetry	O
level	O
of	O
50	O
%	O
and	O
was	O
immediately	O
intubated	O
.	O

The	O
patient	O
'	O
s	O
pulse	O
oximetry	O
level	O
remained	O
in	O
the	O
seventies	O
despite	O
intubation	O
and	O
aggressive	B-DISO
ventilator	O
management	O
.	O

The	O
Intensive	O
Care	O
Unit	O
team	O
in	O
conjunction	O
with	O
cardiothoracic	O
surgery	O
initiated	O
venovenous	O
ECMO	O
therapy	O
in	O
the	O
emergency	B-DISO
department	O
itself	O
.	O

Primary	O
outcome	O
measure	O
was	O
composite	O
of	O
all	O
-	O
cause	O
death	O
,	O
myocardial	B-DISO
infarction	I-DISO
and	O
stroke	B-DISO
at	O
5	O
-	O
year	O
follow	O
-	O
up	O
.	O

The	O
most	O
frequent	O
detected	O
viruses	O
were	O
rhinovirus	O
(	O
55	O
.	O
64	O
%),	O
respiratory	O
syncytial	O
virus	O
A	O
/	O
B	O
(	O
33	O
.	O
06	O
%),	O
adenovirus	B-DISO
(	O
25	O
.	O
00	O
%),	O
coronavirus	O
NL63	O
,	O
HKU1	O
,	O
OC43	O
,	O
and	O
229E	O
(	O
21	O
.	O
50	O
%),	O
and	O
metapneumovirus	O
A	O
/	O
B	O
(	O
16	O
.	O
12	O
%).	O

Parainfluenza	B-DISO
virus	O
1	O
-	O
4	O
and	O
parechovirus	O
were	O
found	O
to	O
increase	O
the	O
risk	O
of	O
death	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Rhinovirus	B-DISO
infection	I-DISO
increases	O
the	O
duration	O
of	O
oxygen	O
support	O
(	O
p	O
=	O
0	O
.	O
042	O
).	O

This	O
study	O
confirms	O
the	O
high	O
incidence	O
of	O
respiratory	O
viruses	O
in	O
children	O
hospitalized	O
for	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
the	O
Sousse	O
area	O
,	O
Tunisia	O
.	O

Prior	O
to	O
the	O
widespread	O
use	O
of	O
venovenous	O
ECMO	O
for	O
severe	O
ARDS	B-DISO
,	O
new	O
trials	O
are	O
needed	O
to	O
test	O
the	O
efficacy	O
of	O
early	O
initiation	O
of	O
the	O
technique	O
with	O
tight	O
control	O
of	O
mechanical	O
ventilation	O
in	O
the	O
control	O
group	O
,	O
initiation	O
of	O
ECMO	O
prior	O
to	O
transportation	O
to	O
ECMO	O
centers	O
,	O
and	O
the	O
use	O
of	O
ECMO	O
in	O
all	O
patients	O
randomly	O
assigned	O
to	O
receive	O
this	O
treatment	O
.	O

TITLE	O
:	O
Anaphylactic	B-DISO
shock	I-DISO
with	O
methylprednisolone	O
sodium	O
succinate	O
in	O
a	O
child	O
with	O
short	B-DISO
bowel	I-DISO
syndrome	I-DISO
and	O
cow	B-DISO
'	I-DISO
s	I-DISO
milk	I-DISO
allergy	I-DISO
.	O

ABSTRACT	O
:	O
Medications	O
with	O
methyl	O
-	O
prednisolone	O
sodium	O
succinate	O
containing	O
lactose	O
,	O
which	O
potentially	O
contains	O
traces	O
of	O
cow	O
'	O
s	O
milk	O
proteins	O
(	O
CMP	O
),	O
could	O
cause	O
allergic	B-DISO
reactions	I-DISO
or	O
compromise	O
treatment	O
of	O
acute	O
allergic	B-DISO
reactions	I-DISO
in	O
sensitized	O
patients	O
.	O

TITLE	O
:	O
[	O
Efficacy	O
of	O
noninvasive	O
ventilation	O
on	O
treatment	O
of	O
ARDS	B-DISO
caused	O
by	O
severe	O
pneumonia	B-DISO
after	O
kidney	O
transplantation	O
].	O

The	O
APACHE	O
II	O
score	O
,	O
serum	O
levels	O
of	O
procalcitonin	O
(	O
PCT	B-DISO
)	O
and	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
daily	O
tacrolimus	O
dose	O
,	O
and	O
NIV	O
support	O
condition	B-DISO
in	O
NIV	O
failure	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
NIV	O
success	O
group	O
[	O
APACHE	O
II	O
score	O
:	O
16	O
.	O
7	O
±	O
5	O
.	O
7	O
vs	O
.	O
10	O
.	O
3	O
±	O
2	O
.	O
1	O
,	O
PCT	B-DISO
(	O
μg	O
/	O
L	O
):	O
32	O
.	O
8	O
(	O
1	O
.	O
2	O
,	O
187	O
.	O
7	O
)	O
vs	O
.	O
0	O
.	O
3	O
(	O
0	O
.	O
1	O
,	O
2	O
.	O
9	O
),	O
BNP	O
(	O
ng	O
/	O
L	O
):	O
832	O
.	O
4	O
(	O
263	O
.	O
7	O
,	O
1	O
180	O
.	O
2	O
)	O
vs	O
.	O
157	O
.	O
0	O
(	O
33	O
.	O
9	O
,	O
218	O
.	O
5	O
),	O
SCr	O
(	O
μmol	O
/	O
L	O
):	O
284	O
.	O
8	O
(	O
90	O
.	O
5	O
,	O
474	O
.	O
2	O
)	O
vs	O
.	O
186	O
.	O
6	O
(	O
76	O
.	O
7	O
,	O
206	O
.	O
3	O
),	O
daily	O
tacrolimus	O
dose	O
(	O
mg	O
):	O
3	O
.	O
6	O
(	O
3	O
.	O
1	O
,	O
4	O
.	O
0	O
)	O
vs	O
.	O
2	O
.	O
6	O
(	O
2	O
.	O
0	O
,	O
3	O
.	O
5	O
),	O
inspiratory	O
positive	O
airway	O
pressure	O
(	O
IPAP	O
,	O
cmH	B-DISO
NIV	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
caused	O
by	O
severe	O
pneumonia	B-DISO
after	O
kidney	O
transplantation	O
has	O
a	O
certain	O
value	O
.	O

The	O
APACHE	O
II	O
score	O
,	O
serum	O
levels	O
of	O
procalcitonin	O
(	O
PCT	B-DISO
)	O
and	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
daily	O
tacrolimus	O
dose	O
,	O
and	O
NIV	O
support	O
condition	B-DISO
in	O
NIV	O
failure	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
NIV	O
success	O
group	O
[	O
APACHE	O
II	O
score	O
:	O
16	O
.	O
7	O
±	O
5	O
.	O
7	O
vs	O
.	O
10	O
.	O
3	O
±	O
2	O
.	O
1	O
,	O
PCT	B-DISO
(	O
μg	O
/	O
L	O
):	O
32	O
.	O
8	O
(	O
1	O
.	O
2	O
,	O
187	O
.	O
7	O
)	O
vs	O
.	O
0	O
.	O
3	O
(	O
0	O
.	O
1	O
,	O
2	O
.	O
9	O
),	O
BNP	O
(	O
ng	O
/	O
L	O
):	O
832	O
.	O
4	O
(	O
263	O
.	O
7	O
,	O
1	O
180	O
.	O
2	O
)	O
vs	O
.	O
157	O
.	O
0	O
(	O
33	O
.	O
9	O
,	O
218	O
.	O
5	O
),	O
SCr	O
(	O
μmol	O
/	O
L	O
):	O
284	O
.	O
8	O
(	O
90	O
.	O
5	O
,	O
474	O
.	O
2	O
)	O
vs	O
.	O
186	O
.	O
6	O
(	O
76	O
.	O
7	O
,	O
206	O
.	O
3	O
),	O
daily	O
tacrolimus	O
dose	O
(	O
mg	O
):	O
3	O
.	O
6	O
(	O
3	O
.	O
1	O
,	O
4	O
.	O
0	O
)	O
vs	O
.	O
2	O
.	O
6	O
(	O
2	O
.	O
0	O
,	O
3	O
.	O
5	O
),	O
inspiratory	O
positive	O
airway	O
pressure	O
(	O
IPAP	O
,	O
cmH	B-DISO

However	O
,	O
the	O
use	O
of	O
MSCs	O
,	O
their	O
specific	O
methods	O
and	O
risks	O
,	O
especially	O
on	O
the	O
risk	O
of	O
iatrogenic	O
tumor	B-DISO
formation	O
remains	O
unresolved	O
.	O

TITLE	O
:	O
Human	O
intestinal	O
tract	O
serves	O
as	O
an	O
alternative	O
infection	B-DISO
route	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

We	O
also	O
identified	O
the	O
evidence	O
of	O
enteric	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
the	O
stool	O
specimen	O
of	O
a	O
clinical	O
patient	O
.	O

Notably	O
,	O
direct	O
intragastric	O
inoculation	O
of	O
MERS	O
-	O
CoV	O
caused	O
a	O
lethal	O
infection	B-DISO
in	O
human	O
DPP4	O
transgenic	O
mice	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Nonstructural	O
Protein	O
16	O
Is	O
Necessary	O
for	O
Interferon	O
Resistance	O
and	O
Viral	B-DISO
Pathogenesis	I-DISO
.	O

TITLE	O
:	O
Does	O
a	O
Mobile	O
ECLS	O
Program	O
Reduce	O
Mortality	O
for	O
Patients	O
Transported	O
for	O
ECLS	O
Therapy	O
for	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
?	O

TITLE	O
:	O
Clinical	O
profiles	O
and	O
prognosis	O
of	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
in	O
adult	O
patients	O
with	O
dystrophinopathies	O
on	O
home	O
mechanical	O
ventilation	O
.	O

All	O
the	O
11	O
DMD	B-DISO
patients	O
carried	O
out	O
-	O
of	O
-	O
frame	O
DMD	B-DISO
gene	O
mutations	O
.	O

In	O
patients	O
with	O
cardiogenic	B-DISO
shock	I-DISO
,	O
intra	O
-	O
hospital	O
mortality	O
rate	O
was	O
66	O
.	O
6	O
%,	O
reaching	O
83	O
.	O
3	O
%	O
after	O
1	O
year	O
.	O

We	O
conducted	O
a	O
prospective	O
longitudinal	O
study	O
on	O
respiratory	O
viral	B-DISO
infections	I-DISO
(	O
RVIs	O
)	O
in	O
allo	O
-	O
HSCT	O
recipients	O
with	O
respiratory	B-DISO
symptoms	I-DISO
from	O
December	O
2013	O
until	O
June	O
2016	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
male	O
with	O
undiagnosed	O
leptospirosis	B-DISO
,	O
presenting	O
with	O
fever	O
and	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
returning	O
from	O
a	O
Costa	O
Rican	O
holiday	O
.	O

There	O
was	O
no	O
other	O
organ	B-DISO
failure	I-DISO
.	O

His	O
condition	B-DISO
improved	O
after	O
ampicillin	O
and	O
penicillin	O
G	O
were	O
added	O
empirically	O
.	O

Monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
have	O
been	O
successfully	O
used	O
to	O
treat	O
various	O
diseases	O
,	O
particularly	O
cancer	B-DISO
and	O
immunological	O
disorders	O
.	O

ABSTRACT	O
:	O
Corticosteroid	O
therapy	O
is	O
commonly	O
used	O
among	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
),	O
but	O
its	O
impact	O
on	O
outcomes	O
is	O
uncertain	O
.	O

The	O
aim	O
of	O
this	O
conference	O
summary	O
is	O
to	O
provide	O
information	O
for	O
not	O
only	O
conference	O
participants	O
,	O
but	O
a	O
detailed	O
referenced	O
review	O
of	O
the	O
current	O
status	O
of	O
clinical	O
trials	O
,	O
and	O
pre	O
-	O
clinical	O
development	O
of	O
therapeutics	O
and	O
vaccines	O
for	O
influenza	B-DISO
and	O
other	O
respiratory	B-DISO
diseases	I-DISO
for	O
a	O
broader	O
audience	O
.	O

ABSTRACT	O
:	O
Betacoronaviruses	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
are	O
important	O
pathogens	O
causing	O
potentially	O
lethal	O
infections	B-DISO
in	O
humans	O
and	O
animals	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
rapid	O
molecular	O
assays	O
for	O
differentiating	O
vaccine	O
strains	O
Ma5	O
and	O
4	O
/	O
91	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
More	O
than	O
a	O
decade	O
after	O
the	O
outbreak	O
of	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
SARS	B-DISO
in	O
Guangdong	O
province	O
and	O
Hong	O
Kong	O
SAR	O
of	O
China	O
in	O
2002	O
,	O
there	O
is	O
still	O
no	O
reoccurrence	O
,	O
but	O
the	O
evolution	O
and	O
recombination	O
of	O
the	O
coronaviruses	O
in	O
this	O
region	O
are	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
a	O
73	O
-	O
year	O
-	O
old	O
man	O
presenting	O
with	O
progressive	O
muscular	B-DISO
weakness	I-DISO
of	O
the	O
lower	O
limbs	O
,	O
ascending	O
to	O
the	O
upper	O
limbs	O
,	O
accompanied	O
by	O
distal	O
sensory	O
disturbances	O
.	O

Four	O
weeks	O
later	O
,	O
the	O
patient	O
presented	O
with	O
flaccid	O
tetraparesis	B-DISO
,	O
areflexia	O
,	O
and	O
reduction	O
of	O
position	O
sense	O
,	O
tingling	B-DISO
paresthesias	B-DISO
,	O
and	O
initial	O
respiratory	B-DISO
distress	I-DISO
.	O

Very	O
proximal	O
axonal	O
conduction	O
failure	O
with	O
late	O
distal	O
axonal	O
degeneration	B-DISO
should	O
be	O
taken	O
into	O
consideration	O
,	O
and	O
electrodiagnostic	O
follow	O
-	O
up	O
examinations	O
,	O
even	O
employing	O
unusual	O
techniques	O
,	O
are	O
recommended	O
over	O
several	O
weeks	O
after	O
disease	O
onset	O
.	O

As	O
reported	O
,	O
astragalus	O
polysaccharides	O
(	O
APS	B-DISO
)	O
have	O
potential	O
antiviral	O
effects	O
against	O
several	O
viruses	O
;	O
however	O
,	O
the	O
antiviral	O
effect	O
of	O
APS	B-DISO
against	O
IBV	O
remains	O
unclear	O
.	O

TITLE	O
:	O
Immune	O
responses	O
in	O
influenza	B-DISO
A	O
virus	O
and	O
human	O
coronavirus	B-DISO
infections	I-DISO
:	O
an	O
ongoing	O
battle	O
between	O
the	O
virus	O
and	O
host	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
apparent	O
septic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
requiring	O
life	O
-	O
sustaining	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
).	O

Upon	O
further	O
review	O
of	O
the	O
literature	O
and	O
the	O
chronology	O
of	O
the	O
patient	O
'	O
s	O
presentation	O
,	O
her	O
condition	B-DISO
was	O
most	O
likely	O
due	O
to	O
an	O
immune	O
-	O
mediated	O
reaction	O
to	O
hydrochlorothiazide	O
.	O

TITLE	O
:	O
European	O
surveillance	O
of	O
emerging	O
pathogens	O
associated	O
with	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
(	O
CIRD	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
dogs	O
worldwide	O
,	O
and	O
is	O
associated	O
with	O
a	O
number	O
of	O
new	O
and	O
emerging	O
pathogens	O
.	O

Involvement	O
of	O
M	O
.	O
cynos	O
and	O
influenza	B-DISO
A	O
in	O
CIRD	O
was	O
less	O
apparent	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
that	O
causes	O
respiratory	O
and	O
nephritic	O
diseases	O
in	O
chicken	O
is	O
a	O
major	O
poultry	O
pathogen	O
leading	O
to	O
serious	O
economic	O
loss	O
worldwide	O
.	O

TITLE	O
:	O
Re	O
-	O
examining	O
Permissive	O
Hypercapnia	B-DISO
in	O
ARDS	B-DISO
:	O
A	O
Narrative	O
Review	O
.	O

Gene	O
expression	O
analysis	O
from	O
animal	O
models	O
or	O
from	O
patients	O
with	O
ARDS	B-DISO
,	O
sepsis	B-DISO
or	O
trauma	O
show	O
an	O
enormous	O
number	O
of	O
differentially	O
expressed	O
genes	O
with	O
highly	O
significant	O
overlaps	O
between	O
the	O
various	O
conditions	O
.	O

We	O
suggest	O
to	O
consider	O
inflammation	B-DISO
in	O
ARDS	B-DISO
as	O
a	O
system	O
controlled	O
by	O
scale	O
-	O
free	O
networks	O
of	O
genome	O
-	O
wide	O
molecular	O
interaction	O
with	O
hubs	O
(	O
e	O
.	O
g	O
.	O
NFκB	O
,	O
C	O
/	O
EBPβ	O
,	O
ATF3	O
),	O
exhibiting	O
nonlinear	O
emergence	O
and	O
the	O
ability	O
to	O
adapt	O
,	O
meaning	O
for	O
instance	O
that	O
mild	O
and	O
life	O
-	O
threatening	O
inflammation	B-DISO
in	O
ARDS	B-DISO
are	O
distinct	O
processes	O
.	O

The	O
system	O
is	O
based	O
on	O
mixing	O
condensation	B-DISO
growth	O
method	O
and	O
has	O
high	O
viral	O
preservation	O
at	O
a	O
higher	O
flow	O
rate	O
(	O
12	O
.	O
5	O
LPM	O
).	O

TITLE	O
:	O
Oral	O
immunization	O
with	O
a	O
Lactobacillus	O
casei	O
-	O
based	O
anti	O
-	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
vaccine	O
expressing	O
microfold	O
cell	O
-	O
targeting	O
peptide	O
Co1	O
fused	O
with	O
the	O
COE	O
antigen	O
of	O
PEDV	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
develop	O
an	O
effective	O
M	O
cell	O
-	O
targeting	O
oral	O
vaccine	O
,	O
involving	O
Lactobacillus	O
casei	O
to	O
deliver	O
the	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
core	O
neutralizing	O
epitope	O
(	O
COE	O
)	O
antigen	O
conjugated	O
with	O
M	O
cell	O
-	O
targeting	O
peptide	O
Co1	O
as	O
an	O
adjuvant	O
,	O
against	O
PEDV	O
infection	B-DISO
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
the	O
Co1	O
ligand	O
elicited	O
a	O
splenocyte	O
proliferative	B-DISO
response	O
more	O
effectively	O
in	O
comparison	O
with	O
the	O
COE	O
antigen	O
alone	O
and	O
supported	O
a	O
skewed	O
T	O
helper	O
2	O
type	O
of	O
immune	O
response	O
against	O
PEDV	O
.	O

Lag	O
correlation	O
analyses	O
demonstrated	O
that	O
search	O
engine	O
data	O
/	O
Twitter	O
have	O
a	O
significant	O
temporal	O
relationship	O
with	O
influenza	B-DISO
and	O
MERS	O
data	O
.	O

ABSTRACT	O
:	O
The	O
Livestock	O
Emergency	B-DISO
Response	O
Plan	B-DISO
(	O
LERP	O
)	O
was	O
published	O
in	O
2014	O
as	O
a	O
toolkit	O
to	O
assist	O
state	O
agricultural	O
emergency	B-DISO
planners	O
in	O
writing	O
or	O
modifying	O
state	O
foreign	O
animal	B-DISO
disease	I-DISO
/	O
high	O
-	O
consequence	O
disease	O
(	O
FAD	O
/	O
HCD	B-DISO
)	O
plans	O
.	O

As	O
awareness	O
of	O
the	O
LERP	O
toolkit	O
grows	O
,	O
the	O
authors	O
hope	O
its	O
use	O
as	O
a	O
template	O
by	O
the	O
states	O
will	O
expand	O
accordingly	O
,	O
thereby	O
increasing	O
consistency	O
between	O
plans	O
and	O
more	O
thoroughly	O
addressing	O
challenges	O
in	O
an	O
FAD	O
/	O
HCD	B-DISO
outbreak	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
a	O
routinely	O
used	O
commercial	O
poultry	O
vaccine	O
on	O
the	O
acute	B-DISO
phase	I-DISO
response	I-DISO
(	O
APR	B-DISO
)	O
and	O
H	O
/	O
L	O
ratios	O
in	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
layer	O
chicks	O
was	O
examined	O
to	O
determine	O
if	O
post	O
vaccination	O
(	O
PV	O
)	O
stress	O
and	O
an	O
APR	B-DISO
occur	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
hepatitis	B-DISO
and	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
),	O
a	O
fact	O
closely	O
related	O
to	O
the	O
release	O
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
/	O
or	O
high	O
-	O
mobility	O
group	O
box	O
protein	O
1	O
(	O
HMGB1	O
).	O

ABSTRACT	O
:	O
Type	O
III	O
interferons	O
(	O
IFNs	O
)	O
play	O
a	O
vital	O
role	O
in	O
maintaining	O
the	O
antiviral	O
state	O
of	O
the	O
mucosal	O
epithelial	O
surface	O
in	O
the	O
gut	O
,	O
and	O
in	O
turn	O
,	O
enteric	O
viruses	O
may	O
have	O
evolved	O
to	O
evade	O
the	O
type	O
III	O
IFN	O
responses	O
during	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Lung	O
transplantation	O
(	O
LTPL	O
)	O
is	O
considered	O
as	O
a	O
salvage	O
therapeutic	O
option	O
in	O
patients	O
with	O
end	O
-	O
stage	O
lung	B-DISO
disease	I-DISO
.	O

Although	O
there	O
are	O
few	O
case	O
reports	O
on	O
lung	O
transplant	O
for	O
ARDS	B-DISO
,	O
no	O
case	O
series	O
exists	O
up	O
to	O
date	O
.	O

Patients	O
who	O
had	O
severe	O
ARDS	B-DISO
(	O
PaO2	O
/	O
FiO2	O
ratio	O
≤	O
100	O
mm	O
Hg	O
with	O
positive	O
end	O
-	O
expiratory	O
pressure	O
≥	O
5	O
cm	O
H2O	O
)	O
and	O
were	O
listed	O
for	O
LTPL	O
with	O
no	O
underlying	O
end	O
-	O
stage	O
lung	B-DISO
disease	I-DISO
were	O
included	O
in	O
this	O
single	O
-	O
center	O
retrospective	O
study	O
.	O

We	O
hypothesize	O
that	O
the	O
direct	O
progenitor	O
of	O
SARS	B-DISO
-	O
CoV	O
may	O
have	O
originated	O
after	O
sequential	O
recombination	O
events	O
between	O
the	O
precursors	O
of	O
these	O
SARSr	O
-	O
CoVs	O
.	O

TITLE	O
:	O
The	O
global	O
spread	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
:	O
an	O
analysis	O
fusing	O
traditional	O
epidemiological	O
tracing	O
and	O
molecular	O
phylodynamics	O
.	O

We	O
performed	O
a	O
qualitative	O
meta	O
-	O
analysis	O
of	O
all	O
laboratory	O
confirmed	O
cases	O
worldwide	O
to	O
date	O
based	O
on	O
literature	O
,	O
with	O
emphasis	O
on	O
international	O
transmission	O
and	O
healthcare	O
associated	O
infections	B-DISO
.	O

Together	O
,	O
these	O
analyses	O
can	O
help	O
us	O
identify	O
factors	O
associated	O
with	O
viral	O
evolution	O
and	O
spread	O
as	O
well	O
as	O
establish	O
efficacy	O
of	O
infection	B-DISO
control	O
measures	O
.	O

The	O
seasonality	O
of	O
influenza	B-DISO
and	O
the	O
predominant	O
influenza	B-DISO
type	O
or	O
subtype	O
varied	O
by	O
country	O
and	O
year	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
continued	O
to	O
circulate	O
in	O
West	O
Africa	O
along	O
with	O
influenza	B-DISO
A	O
(	O
H3N2	O
)	O
and	O
influenza	B-DISO
B	O
during	O
2010	O
-	O
2012	O
.	O

In	O
2012	O
,	O
another	O
novel	O
severely	O
human	O
pathogenic	O
CoV	O
-	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
-	O
was	O
identified	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
;	O
80	O
%	O
of	O
over	O
2000	O
human	O
cases	O
have	O
been	O
recorded	O
over	O
five	O
years	O
.	O

TITLE	O
:	O
Experimental	O
Adaptive	O
Evolution	O
of	O
Simian	O
Immunodeficiency	B-DISO
Virus	O
SIVcpz	O
to	O
Pandemic	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
Type	O
1	O
by	O
Using	O
a	O
Humanized	O
Mouse	O
Model	O
.	O

These	O
were	O
tested	O
for	O
four	O
strains	O
of	O
HCoV	O
infection	B-DISO
using	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

Patients	O
infected	O
with	O
a	O
single	O
strain	O
of	O
HCoV	O
infection	B-DISO
were	O
less	O
likely	O
to	O
present	O
fever	O
(≥	O
38	O
°	O
C	O
)	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
and	O
more	O
likely	O
to	O
present	O
pulmonary	O
rales	B-DISO
(	O
p	O
=	O
0	O
.	O
043	O
)	O
than	O
those	O
co	O
-	O
infected	O
with	O
more	O
than	O
one	O
HCoV	O
strain	O
or	O
other	O
respiratory	O
pathogens	O
.	O

There	O
were	O
also	O
significant	O
differences	O
in	O
the	O
prevalence	O
of	O
certain	O
symptoms	O
,	O
including	O
coughing	B-DISO
(	O
p	O
=	O
0	O
.	O
032	O
),	O
pneumonia	B-DISO
(	O
p	O
=	O
0	O
.	O
026	O
),	O
and	O
abnormal	O
pulmonary	O
rales	B-DISO
(	O
p	O
=	O
0	O
.	O
002	O
)	O
according	O
to	O
the	O
strain	O
of	O
HCoV	O
detected	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
TGEV	O
infection	B-DISO
could	O
lead	O
to	O
mitochondrial	B-DISO
damage	I-DISO
and	O
upregulate	O
miR	O
-	O
4331	O
level	O
.	O

The	O
rate	O
of	O
PP	O
use	O
was	O
5	O
.	O
9	O
%	O
(	O
11	O
/	O
187	O
),	O
10	O
.	O
3	O
%	O
(	O
41	O
/	O
399	O
)	O
and	O
32	O
.	O
9	O
%	O
(	O
49	O
/	O
149	O
)	O
in	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
The	O
impacts	O
of	O
baseline	O
ventilator	O
parameters	O
on	O
hospital	O
mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
a	O
retrospective	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Aicardi	O
-	O
Goutières	O
syndrome	B-DISO
(	O
AGS	B-DISO
)	O
is	O
a	O
hereditary	O
inflammatory	O
encephalopathy	B-DISO
resulting	O
in	O
severe	O
neurological	O
damage	O
in	O
the	O
majority	O
of	O
cases	O
.	O

The	O
first	O
sibling	O
presented	O
at	O
12	O
months	O
of	O
age	O
with	O
a	O
subacute	O
encephalopathy	B-DISO
following	O
a	O
mild	O
respiratory	B-DISO
infection	I-DISO
.	O

In	O
multivariable	O
models	O
,	O
a	O
combination	O
of	O
Stimulation	O
-	O
2	O
(	O
ST2	O
;	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
8	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
IL	O
-	O
6	O
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
P	O
=	O
.	O
025	O
)	O
was	O
the	O
best	O
panel	O
for	O
distinguishing	O
IPS	B-DISO
at	O
diagnosis	O
from	O
unaffected	O
controls	O
,	O
whereas	O
tumor	B-DISO
necrosis	I-DISO
factor	O
receptor	O
1	O
(	O
TNFR1	O
;	O
OR	O
,	O
2	O
.	O
9	O
;	O
P	O
=	O
.	O
002	O
)	O
was	O
the	O
best	O
marker	O
when	O
comparing	O
patients	O
with	O
IPS	B-DISO
and	O
viral	B-DISO
pneumonia	I-DISO
.	O

Using	O
estimated	O
sensitivity	O
and	O
specificity	O
values	O
from	O
cutoffs	O
determined	O
with	O
the	O
ROC	O
analysis	O
(	O
cutoff	O
level	O
:	O
ST2	O
,	O
21	O
ng	O
/	O
mL	O
;	O
IL	O
-	O
6	O
,	O
61	O
pg	O
/	O
mL	O
;	O
TNFR1	O
,	O
3421	O
pg	O
/	O
mL	O
),	O
we	O
calculated	O
positive	O
predictive	O
values	O
(	O
PPV	O
)	O
for	O
a	O
range	O
of	O
estimated	O
population	O
prevalence	O
values	O
of	O
IPS	B-DISO
.	O

ABSTRACT	O
:	O
A	O
one	O
-	O
step	O
multiplex	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
simultaneous	O
detection	O
and	O
quantification	O
of	O
four	O
avian	O
respiratory	O
viruses	O
:	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
),	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
and	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
(	O
ILTV	O
).	O

The	O
patients	O
who	O
suffered	B-DISO
from	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
and	O
septic	B-DISO
shock	I-DISO
had	O
a	O
lower	O
platelet	O
concentration	O
than	O
non	O
-	O
sufferers	O
on	O
day	O
3	O
and	O
day	O
5	O
.	O

TITLE	O
:	O
Age	O
is	O
a	O
predictor	O
of	O
a	O
small	O
decrease	O
in	O
lung	O
function	O
in	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
anemia	I-DISO
.	O

ABSTRACT	O
:	O
We	O
utilized	O
one	O
-	O
step	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Luminex	O
xMAP	O
technology	O
to	O
develop	O
a	O
respiratory	O
multiplex	O
liquid	O
-	O
chip	O
assay	O
(	O
rMLA	O
)	O
for	O
simultaneous	O
detection	O
of	O
6	O
common	O
respiratory	O
viruses	O
,	O
including	O
influenza	B-DISO
virus	O
type	O
A	O
(	O
FluA	O
)	O
and	O
type	O
B	O
(	O
FluB	O
),	O
para	B-DISO
-	I-DISO
influenza	I-DISO
virus	O
type	O
3	O
(	O
PIV	O
-	O
3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
(	O
MPV	O
)	O
and	O
a	O
threatening	O
virus	O
to	O
China	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
characterized	O
by	O
excess	O
production	O
of	O
inflammatory	O
factors	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
microbiological	O
diagnosis	O
in	O
14	O
patients	O
with	O
epidemiological	O
and	O
clinical	O
suspicion	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
attended	O
in	O
a	O
non	O
-	O
endemic	O
area	O
between	O
June	O
2015	O
and	O
January	O
2017	O
.	O

TITLE	O
:	O
The	O
Experience	O
of	O
Korean	O
Nurses	O
During	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Outbreak	O
.	O

Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
genomes	O
from	O
six	O
virus	O
-	O
positive	O
animals	O
were	O
sequenced	O
,	O
and	O
these	O
genomes	O
were	O
nearly	O
identical	O
to	O
those	O
found	O
in	O
human	O
patients	O
from	O
corresponding	O
regions	O
.	O

In	O
this	O
study	O
,	O
we	O
proposed	O
a	O
comparative	O
analysis	O
approach	O
and	O
built	O
a	O
model	O
to	O
simulate	O
outbreaks	O
of	O
3	O
different	O
in	O
-	O
flight	O
infections	B-DISO
in	O
a	O
similar	O
cabin	O
environment	O
,	O
that	O
is	O
,	O
influenza	B-DISO
A	O
H1N1	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
),	O
and	O
norovirus	O
.	O

Similar	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
belongs	O
to	O
the	O
coronavirus	O
family	O
and	O
can	O
induce	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
in	O
humans	O
,	O
with	O
an	O
average	O
case	O
fatality	O
rate	O
of	O
35	O
%	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
.	O

PEDV	O
pathogenesis	B-DISO
is	O
strain	O
-	O
specific	O
,	O
and	O
studies	O
in	O
neonatal	O
pigs	O
have	O
demonstrated	O
that	O
the	O
PEDV	O
non	O
-	O
S	O
-	O
INDEL	O
strains	O
are	O
more	O
pathogenic	O
than	O
the	O
PEDV	O
S	O
-	O
INDEL	O
strains	O
.	O

RNA	O
viruses	O
,	O
including	O
PEDV	O
,	O
can	O
interact	O
with	O
a	O
large	O
number	O
of	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	B-DISO
)	O
in	O
the	O
intestinal	O
mucosa	O
,	O
including	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
).	O

This	O
study	O
reveals	O
that	O
the	O
replication	O
of	O
nidoviruses	O
can	O
differ	O
strikingly	O
in	O
its	O
dependence	B-DISO
on	I-DISO
cellular	O
CypA	O
.	O

To	O
minimize	O
the	O
psychological	B-DISO
impact	O
of	O
future	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
healthcare	O
workers	O
should	O
be	O
prepared	O
for	O
the	O
potential	O
psychological	B-DISO
impact	O
;	O
employers	O
should	O
encourage	O
a	O
supportive	O
environment	O
in	O
the	O
workplace	O
and	O
ensure	O
that	O
support	O
is	O
in	O
place	O
for	O
those	O
most	O
at	O
risk	O
,	O
for	O
example	O
,	O
those	O
with	O
the	O
most	O
patient	O
contact	O
.	O

Using	O
the	O
Crisis	O
and	O
Emergency	B-DISO
Risk	O
Communication	O
(	O
CERC	O
)	O
theoretical	O
framework	O
,	O
the	O
study	O
analyzes	O
how	O
the	O
performed	O
ERC	O
strategies	O
during	O
the	O
first	O
days	O
of	O
the	O
outbreak	O
might	O
have	O
contributed	O
to	O
the	O
outbreak	O
management	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
belongs	O
to	O
beta	O
group	O
of	O
coronavirus	O
,	O
can	O
infect	O
multiple	O
host	O
species	O
and	O
causes	O
severe	O
diseases	O
in	O
humans	O
.	O

TITLE	O
:	O
Possible	O
therapeutic	O
effect	O
of	O
orally	O
administered	O
ribavirin	O
for	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
an	O
immunocompetent	O
patient	O
:	O
a	O
case	O
report	O
.	O

We	O
report	O
a	O
case	O
of	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurring	O
in	O
a	O
previously	O
healthy	O
man	O
successfully	O
treated	O
with	O
orally	O
administered	O
ribavirin	O
.	O

We	O
found	O
that	O
silvestrol	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cap	B-DISO
-	O
dependent	O
viral	O
mRNA	O
translation	O
in	O
CoV	O
-	O
infected	O
human	O
embryonic	O
lung	O
fibroblast	O
(	O
MRC	O
-	O
5	O
)	O
cells	O
.	O

TITLE	O
:	O
Frequency	O
and	O
prognostic	O
impact	O
of	O
basic	O
critical	O
care	O
echocardiography	O
abnormalities	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Hospital	O
mortality	O
for	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
was	O
17	O
.	O
0	O
,	O
27	O
.	O
9	O
and	O
50	O
.	O
0	O
%,	O
respectively	O
(	O
without	O
severe	O
ACP	B-DISO
),	O
and	O
was	O
29	O
.	O
2	O
,	O
48	O
.	O
3	O
and	O
53	O
.	O
8	O
%,	O
respectively	O
(	O
with	O
severe	O
ACP	B-DISO
).	O

TITLE	O
:	O
Oxygen	O
Exposure	O
Resulting	O
in	O
Arterial	O
Oxygen	O
Tensions	B-DISO
Above	O
the	O
Protocol	O
Goal	O

Was	O
Associated	O
With	O
Worse	O
Clinical	O
Outcomes	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

We	O
sought	O
to	O
determine	O
if	O
oxygen	O
exposure	O
that	O
resulted	O
in	O
a	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
above	O
goal	O
(>	O
80	O
mm	O
Hg	O
)	O
was	O
associated	O
with	O
worse	O
outcomes	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Loss	O
of	O
ABCA3	O
caused	O
alveolar	O
cell	B-DISO
injury	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

M2	O
-	O
like	O
macrophages	O
were	O
recruited	O
to	O
sites	O
of	O
AT2	O
cell	O
proliferation	B-DISO
during	O
the	O
regenerative	O
process	O
and	O
were	O
present	O
in	O
lung	O
tissue	O
from	O
patients	O
with	O
severe	O
lung	B-DISO
disease	I-DISO
caused	O
by	O
mutations	O
in	O
ABCA3	O
.	O

TITLE	O
:	O
Protective	O
efficacy	O
of	O
a	O
novel	O
simian	O
adenovirus	B-DISO
vaccine	O
against	O
lethal	O
MERS	O
-	O
CoV	O
challenge	O
in	O
a	O
transgenic	O
human	O
DPP4	O
mouse	O
model	O
.	O

Early	O
recognition	O
of	O
risks	O
for	O
ARDS	B-DISO
from	O
severe	O
pneumonia	B-DISO
is	O
of	O
great	O
clinical	O
value	O
.	O

We	O
compared	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
at	O
admission	O
between	O
severe	O
pneumonia	B-DISO
patients	O
with	O
and	O
without	O
ARDS	B-DISO
development	O
,	O
followed	O
by	O
analysis	O
of	O
potential	O
predictors	O
for	O
ARDS	B-DISO
development	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
female	O
presented	O
with	O
confusion	B-DISO
,	O
generalized	B-DISO
tonic	I-DISO
-	I-DISO
clonic	I-DISO
seizures	I-DISO
,	O
and	O
severe	O
hyponatremia	O
after	O
ingesting	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	O
).	O

Hyponatremia	O
was	O
corrected	O
and	O
the	O
encephalopathy	B-DISO
resolved	O
.	O

Genomic	O
surveillance	O
of	O
pathogenic	O
agents	O
will	O
serve	O
as	O
a	O
key	O
epidemiological	O
and	O
research	O
tool	O
in	O
the	O
modern	O
era	O
of	O
precision	O
infectious	B-DISO
diseases	I-DISO
and	O
in	O
the	O
future	O
studies	O
of	O
virosphere	O
.	O

The	O
results	O
demonstrated	O
a	O
link	O
between	O
mortality	O
and	O
geography	O
,	O
disease	O
and	O
patient	O
factors	O
such	O
as	O
regions	O
,	O
symptoms	O
,	O
source	O
of	O
infections	B-DISO
,	O
underlying	O
medical	O
conditions	O
,	O
modes	O
of	O
transmission	O
,	O
non	O
-	O
healthcare	O
workers	O
and	O
those	O
of	O
older	O
age	O
.	O

MBL	O
was	O
assayed	O
from	O
blood	O
drawn	O
at	O
influenza	B-DISO
diagnosis	O
within	O
24	O
-	O
48	O
h	O
following	O
the	O
ICU	O
admission	O
.	O

We	O
measured	O
the	O
EAdi	O
as	O
an	O
indicator	O
of	O
breathing	O
workload	O
in	O
a	O
40	O
-	O
year	O
-	O
old	O
man	O
suffering	B-DISO
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
secondary	O
to	O
influenza	B-DISO
pneumonia	I-DISO
in	O
the	O
process	O
of	O
weaning	O
from	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Turning	O
off	O
the	O
sweep	O
gas	O
flow	O
immediately	O
led	O
to	O
EAdi	O
elevation	O
,	O
followed	O
by	O
hypoxia	B-DISO
.	O

This	O
is	O
the	O
first	O
case	O
report	O
to	O
suggest	O
that	O
EAdi	O
monitoring	O
might	O
be	O
useful	O
for	O
ARDS	B-DISO
patients	O
during	O
ECMO	O
weaning	O
.	O

ExoN	O
excises	O
nucleotide	O
mismatches	O
at	O
the	O
RNA	O
3	O
'-	O
end	O
in	O
vitro	O
,	O
and	O
its	O
inactivation	B-DISO
in	O
vivo	O
jeopardizes	O
viral	O
genetic	O
stability	O
.	O

Moreover	O
,	O
coinfection	B-DISO
was	O
found	O
to	O
modulate	O
several	O
host	O
proteins	O
that	O
could	O
bolster	O
pathogen	O
persistence	O
.	O

We	O
described	O
a	O
case	O
of	O
a	O
39	O
year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
vancomycin	O
for	O
osteomyelitis	B-DISO
of	O
the	O
foot	O
.	O

These	O
symptoms	O
were	O
improved	O
by	O
withdrawal	B-DISO
of	O
vancomycin	O
and	O
a	O
pulsed	O
corticosteroid	O
regimen	O
.	O

This	O
is	O
the	O
first	O
case	O
to	O
report	O
pulmonary	O
manifestation	O
as	O
the	O
initial	O
symptom	B-DISO
in	O
vancomycin	O
induced	O
DRESS	B-DISO
syndrome	I-DISO
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
case	O
to	O
report	O
pulmonary	O
manifestation	O
as	O
the	O
initial	O
symptom	B-DISO
in	O
vancomycin	O
induced	O
DRESS	B-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Nasal	O
high	O
flow	O
therapy	O
in	O
very	O
low	O
birth	O
weight	O
infants	O
with	O
mild	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
single	O
center	O
experience	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
disorders	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
represent	O
one	O
of	O
the	O
most	O
common	O
morbidities	O
of	O
preterm	O
newborns	O
admitted	O
to	O
neonatal	O
intensive	O
care	O
units	O
(	O
NICUs	O
).	O

We	O
performed	O
a	O
retrospective	O
study	O
to	O
evaluate	O
safety	O
and	O
effectiveness	O
of	O
nHFT	O
as	O
primary	O
support	O
for	O
infants	O
born	O
<	O
29	O
weeks	O
of	O
gestation	O
and	O
/	O
or	O
VLBW	O
presenting	O
with	O
mild	O
Respiratory	B-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
RDS	O
).	O

LOS	O
,	O
IVH	O
,	O
ROP	B-DISO
,	O
NEC	O
and	O
PDA	B-DISO
occurred	O
respectively	O
in	O
16	O
.	O
1	O
%,	O
0	O
%,	O
7	O
.	O
8	O
%,	O
and	O
1	O
.	O
6	O
%	O
of	O
newborns	O
.	O

TITLE	O
:	O
Hemodynamic	O
profile	O
of	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
PH	O
)	O
in	O
ARDS	B-DISO
.	O

We	O
conducted	O
a	O
year	O
-	O
long	O
exploratory	O
study	O
of	O
fever	O
syndrome	B-DISO
among	O
patients	O
≥	O
1	O
year	O
if	O
age	O
,	O
presenting	O
to	O
clinical	O
settings	O
with	O
an	O
axillary	O
temperature	O
of	O
≥	O
37	O
.	O
5	O
°	O
C	O
and	O
symptomatic	O
onset	O
of	O
≤	O
5	O
days	O
.	O

TITLE	O
:	O
Construction	O
and	O
immunogenicity	O
analysis	O
of	O
Lactobacillus	O
plantarum	O
expressing	O
a	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
S	O
gene	O
fused	O
to	O
a	O
DC	O
-	O
targeting	O
peptide	O
.	O

TITLE	O
:	O
Rhabdomyolysis	B-DISO
-	O
Associated	O
Acute	O
Kidney	O
Injury	O
With	O
Normal	O
Creatine	O
Phosphokinase	O
.	O

TITLE	O
:	O
Disulfiram	O
can	O
inhibit	O
MERS	O
and	O
SARS	B-DISO
coronavirus	O
papain	O
-	O
like	O
proteases	O
via	O
different	O
modes	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
emerged	O
in	O
southern	O
China	O
in	O
late	O
2002	O
and	O
caused	O
a	O
global	O
outbreak	O
with	O
a	O
fatality	O
rate	O
around	O
10	O
%	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
a	O
highly	O
contagious	O
enteric	O
disease	O
in	O
swine	O
that	O
can	O
cause	O
devastating	O
economic	O
damage	O
to	O
pig	O
producers	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
is	O
a	O
highly	O
contagious	O
,	O
acute	O
viral	O
respiratory	B-DISO
disease	I-DISO
of	O
chickens	O
,	O
caused	O
by	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
Outcomes	O
of	O
Acute	O
Kidney	O
Injury	O
in	O
Patients	O
With	O
Severe	O
ARDS	B-DISO
Due	O
to	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
Virus	O
.	O

ABSTRACT	O
:	O
Memory	O
CD8	O
T	O
cells	O
can	O
provide	O
protection	O
from	O
re	O
-	O
infection	B-DISO
by	O
respiratory	O
viruses	O
such	O
as	O
influenza	B-DISO
and	O
SARS	B-DISO
.	O

Recent	O
outbreaks	O
of	O
avian	B-DISO
influenza	I-DISO
viruses	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronaviruses	O
,	O
Zika	O
virus	O
and	O
Ebola	O
virus	O
present	O
great	O
threats	O
to	O
global	O
health	O
.	O

In	O
severe	O
ARDS	B-DISO
,	O
the	O
ventilatable	O
parenchyma	O
is	O
strongly	O
reduced	O
in	O
size	O
('	O
baby	O
lung	O
');	O
its	O
resting	O
volume	O
could	O
be	O
as	O
low	O
as	O
300	O
mL	O
,	O
and	O
the	O
total	O
inspiratory	O
capacity	O
could	O
be	O
reached	O
with	O
a	O
tidal	O
volume	O
of	O
750	O
-	O
900	O
mL	O
,	O
thus	O
generating	O
lethal	O
stress	O
and	O
strain	O
in	O
the	O
lung	O
.	O

Immunocompromised	O
patients	O
,	O
defined	O
as	O
having	O
hematological	B-DISO
malignancies	I-DISO
,	O
active	O
solid	B-DISO
tumor	I-DISO
,	O
solid	O
-	O
organ	O
transplant	O
,	O
acquired	B-DISO
immunodeficiency	I-DISO
syndrome	I-DISO
,	O
or	O
long	O
-	O
term	O
or	O
high	O
-	O
dose	O
corticosteroid	O
or	O
immunosuppressant	O
use	O
,	O
and	O
severe	O
ECMO	O
-	O
treated	O
ARDS	B-DISO
from	O
2008	O
to	O
2015	O
were	O
included	O
Measurements	O
and	O
Main	O
Results	O
:	O
We	O
collected	O
demographics	O
,	O
clinical	O
,	O
ECMO	O
-	O
related	O
complications	O
,	O
ICU	O
-	O
and	O
6	O
-	O
month	O
-	O
outcome	O
data	O
for	O
203	O
patients	O
(	O
median	O
APACHE	O
II	O
28	O
[	O
25th	O
;	O
75th	O
percentile	O
,	O
20	O
;	O
33	O
];	O
age	O
51	O
[	O
38	O
;	O
59	O
]	O
years	O
,	O
PaO2	O
/	O
FiO2	O
60	O
[	O
50	O
;	O
82	O
]	O
mmHg	O
before	O
ECMO	O
)	O
who	O
fulfilled	O
our	O
inclusion	O
criteria	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
first	O
broken	O
out	O
in	O
Jeddah	O
in	O
2012	O
,	O
causes	O
a	O
severe	O
acute	O
respiratory	O
illness	O
with	O
a	O
high	O
mortality	O
rate	O
.	O

Coronaviruses	O
are	O
one	O
of	O
the	O
most	O
common	O
viruses	O
discovered	O
in	O
bats	O
,	O
which	O
were	O
considered	O
as	O
the	O
natural	O
source	O
of	O
recent	O
human	O
-	O
susceptible	O
coronaviruses	O
,	O
i	O
.	O
e	O
.	O
SARS	B-DISO
-	O
COV	O
and	O
MERS	O
-	O
CoV	O
.	O
Our	O
previous	O
study	O
reported	O
the	O
discovery	O
of	O
a	O
bat	O
-	O
derived	O
putative	O
cross	O
-	O
family	O
recombinant	O
coronavirus	O
with	O
a	O
reovirus	O
gene	O
p10	O
,	O
named	O
as	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
.	O

MACCE	O
and	O
NACE	O
were	O
not	O
significantly	O
different	O
between	O
men	O
and	O
women	O
after	O
adjustment	O
,	O
but	O
women	O
had	O
higher	O
risk	O
of	O
access	O
site	O
bleeding	B-DISO
(	O
male	O
vs	O
.	O
female	O
rate	O
ratio	O
[	O
RR	O
]:	O
0	O
.	O
64	O
;	O
p	O
=	O
0	O
.	O
0016	O
),	O
severe	O
bleeding	B-DISO
(	O
RR	O
:	O
0	O
.	O
17	O
;	O
p	O
=	O
0	O
.	O
0012	O
),	O
and	O
transfusion	O
(	O
RR	O
:	O
0	O
.	O
56	O
;	O
p	O
=	O
0	O
.	O
0089	O
).	O

TITLE	O
:	O
Mitochondrial	O
bioenergy	O
alterations	O
in	O
avian	O
HD11	O
macrophages	O
infected	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Fifteen	O
patients	O
with	O
severe	O
human	O
infection	B-DISO
by	O
avian	B-DISO
influenza	I-DISO
H7N9	O
in	O
Guizhou	O
Province	O
from	O
December	O
29th	O
,	O
2016	O
to	O
June	O
7th	O
,	O
2017	O
were	O
enrolled	O
.	O

We	O
analyzed	O
severely	O
injured	O
patients	O
(	O
ISS	B-DISO
≥	O
16	O
)	O
including	O
a	O
moderate	O
-	O
to	O
-	O
severe	O
traumatic	O
brain	O
injury	O
(	O
AIS	B-DISO
We	O
analyzed	O
278	O
patients	O
(	O
M	O
age	O
=	O
43	O
years	O
,	O
SD	O
19	O
;	O
M	O
ISS	B-DISO
=	O
32	O
.	O
8	O
,	O
SD	O
10	O
.	O
7	O
).	O

In	O
the	O
present	O
report	O
,	O
three	O
cases	O
of	O
AIP	B-DISO
complicated	O
by	O
refractory	O
respiratory	B-DISO
failure	I-DISO
supported	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
are	O
presented	O
.	O

Respiratory	O
drive	O
was	O
evaluated	O
in	O
11	O
patients	O
with	O
ARDS	B-DISO
.	O

Clinical	O
and	O
prognostic	O
analysis	O
revealed	O
the	O
higher	O
injury	O
degree	O
and	O
death	O
rates	O
in	O
ALI	O
/	O
ARDS	B-DISO
group	O
than	O
those	O
in	O
control	O
group	O
,	O
and	O
identified	O
a	O
greater	O
severity	O
and	O
mortality	O
for	O
patients	O
with	O
ARDS	B-DISO
than	O
those	O
with	O
ALI	O
.	O

ABSTRACT	O
:	O
Harmful	O
effects	O
of	O
spontaneous	O
breathing	O
have	O
been	O
shown	O
in	O
experimental	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

To	O
date	O
,	O
no	O
study	O
has	O
compared	O
the	O
effects	O
of	O
spontaneous	O
assisted	O
breathing	O
with	O
those	O
of	O
fully	O
controlled	O
mechanical	O
ventilation	O
at	O
different	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
on	O
lung	O
injury	O
in	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
remain	O
the	O
leading	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
intensive	O
care	O
units	O
.	O

Human	O
lung	O
epithelial	O
(	O
BEAS	O
-	O
2B	O
)	O
cells	O
were	O
incubated	O
with	O
LPS	B-DISO
in	O
the	O
presence	O
or	O
absence	O
of	O
UTI	B-DISO
.	O

UTI	B-DISO
significantly	O
protected	O
animals	O
from	O
LPS	B-DISO
-	O
induced	O
ALI	O
,	O
decreasing	O
the	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
ALI	O
score	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
myeloperoxidase	O
activity	O
,	O
and	O
malondialdehyde	O
content	O
,	O
factors	O
associated	O
with	O
lung	O
histological	O
damage	O
.	O

UTI	B-DISO
treatment	O
also	O
markedly	O
attenuated	O
levels	O
of	O
TLR4	O
and	O
other	O
proinflammatory	O
cytokines	O
.	O

Neutrophil	O
extracellular	O
traps	B-DISO
(	O
NETs	O
)	O
can	O
be	O
induced	O
by	O
pathogens	O
and	O
are	O
responsible	O
for	O
immune	O
tissue	O
damage	O
.	O

TITLE	O
:	O
Loss	O
of	O
Cx43	O
-	O
Mediated	O
Functional	O
Gap	O
Junction	O
Communication	O
in	O
Meningeal	O
Fibroblasts	O
Following	O
Mouse	B-DISO
Hepatitis	I-DISO
Virus	B-DISO
Infection	I-DISO
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infection	B-DISO
causes	O
meningoencephalitis	B-DISO
by	O
disrupting	O
the	O
neuro	O
-	O
glial	O
and	O
glial	O
-	O
pial	O
homeostasis	O
.	O

The	O
primary	O
focus	O
was	O
on	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
,	O
including	O
AdV	O
(	O
adenovirus	B-DISO
),	O
BoV	O
(	O
bocavirus	O
),	O
CoV	O
(	O
coronavirus	O
),	O
CMV	O
(	O
cytomegalovirus	O
),	O
EnV	O
(	O
enterovirus	O
),	O
HSV	O
(	O
herpes	B-DISO
simplex	I-DISO
virus	O
),	O
IfV	O
(	O
influenza	B-DISO
virus	O
),	O
MpV	O
(	O
metapneumovirus	O
),	O
PiV	O
(	O
parainfluenzavirus	O
),	O
RV	O
(	O
rhinovirus	O
)	O
and	O
RSV	O
(	O
respiratory	O
syncytial	O
virus	O
)	O
during	O
asthma	B-DISO
exacerbations	O
.	O

Our	O
findings	O
indicate	O
the	O
need	O
to	O
develop	O
prophylactic	O
polyvalent	O
or	O
polyvirus	O
(	O
including	O
RV	O
,	O
EnV	O
,	O
IfV	O
and	O
RSV	O
)	O
vaccines	O
that	O
produce	O
herd	O
immunity	O
and	O
reduce	O
the	O
healthcare	O
burden	O
associated	O
with	O
virus	O
-	O
induced	O
asthma	B-DISO
exacerbations	O
.	O

In	O
this	O
review	O
,	O
we	O
address	O
important	O
aspects	O
in	O
FCoV	O
genetics	O
,	O
replication	O
and	O
pathogenesis	B-DISO
,	O
focusing	O
on	O
the	O
role	O
of	O
S	O
.	O
To	O
better	O
understand	O
this	O
,	O
FCoV	O
S	O
protein	O
models	O
were	O
constructed	O
,	O
based	O
on	O
the	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
S	O
structure	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
two	O
influenza	B-DISO
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methods	O
.	O

A	O
total	O
of	O
749	O
suspected	O
MERS	O
-	O
CoV	O
patients	O
presenting	O
at	O
Johns	O
Hopkins	O
Aramco	O
Healthcare	O
,	O
Saudi	O
Arabia	O
,	O
each	O
submitted	O
a	O
clinical	O
sample	O
for	O
influenza	B-DISO
A	O
reflex	O
testing	O
using	O
the	O
on	O
-	O
site	O
Cepheid	O
®	O
Xpert	O
Flu	B-DISO
assay	O
and	O
at	O
the	O
Ministry	O
of	O
Health	O
laboratory	O
by	O
the	O
Roche	O
PCR	O
assay	O
.	O

Specificity	O
of	O
the	O
Cepheid	O
®	O
Xpert	O
Flu	B-DISO
was	O
95	O
.	O
8	O
%	O
for	O
H1N1	O
and	O
94	O
.	O
4	O
%	O
for	O
total	O
influenza	B-DISO
A	O
.	O
Cepheid	O
®	O
Xpert	O
Flu	B-DISO
sensitivity	O
for	O
influenza	B-DISO
A	O
was	O
100	O
%	O
for	O
younger	O
patients	O
(	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
)	O
but	O
significantly	O
lower	O
both	O
for	O
older	O
patients	O
(	O
68	O
.	O
2	O
%	O
for	O
60	O
-	O
79	O
-	O
year	O
and	O
50	O
%	O
for	O
≥	O
80	O
-	O
year	O
age	O
groups	O
)	O
and	O
overall	O
for	O
males	O
compared	O
to	O
females	O
(	O
72	O
.	O
6	O
%	O
and	O
94	O
.	O
0	O
%,	O
respectively	O
).	O

TITLE	O
:	O
Induction	O
of	O
innate	B-DISO
immune	I-DISO
response	I-DISO
following	O
introduction	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
the	O
trachea	B-DISO
and	O
renal	O
tissues	O
of	O
chickens	O
.	O

Above	O
all	O
,	O
we	O
found	O
that	O
IFN	O
-	O
λ	O
also	O
have	O
an	O
effect	O
on	O
IBV	O
infection	B-DISO
in	O
trachea	B-DISO
besides	O
many	O
other	O
respiratory	O
virus	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
reverse	O
transcription	O
recombinase	O
polymerase	O
amplification	B-DISO
assay	O
for	O
rapid	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

TITLE	O
:	O
Quality	O
of	O
inter	O
-	O
hospital	O
transportation	O
in	O
431	O
transport	O
survivor	O
patients	O
suffering	B-DISO
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
referred	O
to	O
specialist	O
centers	O
.	O

The	O
qualification	O
of	O
emergency	B-DISO
staff	O
,	O
the	O
organizational	O
aspects	O
and	O
the	O
occurrence	O
of	O
critical	O
events	O
during	O
transport	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
This	O
single	O
-	O
center	O
case	O
series	O
investigated	O
the	O
effect	O
of	O
almitrine	O
infusion	O
on	O
PaO2	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FIO2	O
)	O
in	O
25	O
patients	O
on	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Viral	O
etiology	O
detected	O
in	O
29	O
.	O
6	O
%	O
of	O
the	O
cases	O
was	O
predominantly	O
influenza	B-DISO
A	O
(	O
H1N1	O
and	O
H3N2	O
),	O
and	O
influenza	B-DISO
B	O
infection	B-DISO
(	O
22	O
%).	O

Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
travelers	O
/	O
pilgrims	O
returning	O
to	O
Bangladesh	O
from	O
the	O
Middle	O
East	O
are	O
mainly	O
due	O
to	O
influenza	B-DISO
A	O
and	O
influenza	B-DISO
B	O
.	O
Though	O
MERS	O
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
81	O
patients	O
tested	O
,	O
continuous	O
screening	O
and	O
surveillance	O
are	O
essential	O
for	O
early	O
detection	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
other	O
respiratory	O
pathogens	O
to	O
prevent	O
transmissions	O
in	O
hospital	O
settings	O
and	O
within	O
communities	O
.	O

RESULTS	O
:	O
Eighty	O
one	O
suspected	O
cases	O
tested	O
by	O
real	O
time	O
PCR	O
resulted	O
in	O
zero	O
detection	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

We	O
here	O
report	O
the	O
synthesis	O
of	O
new	O
14	O
quinoxaline	O
derivatives	O
and	O
the	O
evaluation	O
of	O
their	O
cytotoxicity	B-DISO
and	O
antiviral	O
activity	O
against	O
representatives	O
of	O
ssRNA	O
,	O
dsRNA	O
and	O
dsDNA	O
viruses	O
.	O

Utilizing	O
a	O
systems	O
-	O
based	O
approach	O
,	O
we	O
examined	O
differential	O
regulation	O
of	O
IFN	O
-	O
γ	O
-	O
dependent	O
genes	O
following	O
infection	B-DISO
with	O
robust	O
respiratory	O
viruses	O
including	O
influenza	B-DISO
viruses	O
[	O
A	O
/	O
influenza	B-DISO
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
(	O
H5N1	B-DISO
-	O
VN1203	O
)	O
and	O
A	O
/	O
influenza	B-DISO
/	O
California	O
/	O
04	O
/	O
2009	O
(	O
H1N1	O
-	O
CA04	O
)]	O
and	O
coronaviruses	O
[	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
)].	O

The	O
main	O
complications	O
included	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
encephalopathy	B-DISO
in	O
four	O
(	O
11	O
.	O
4	O
%)	O
patients	O
each	O
;	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O
hypertension	B-DISO
and	O
panniculitis	B-DISO
in	O
two	O
(	O
5	O
.	O
7	O
%)	O
patients	O
each	O
and	O
one	O
(	O
2	O
.	O
9	O
%)	O
patient	O
each	O
developed	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
bleeding	I-DISO
,	O
stroke	B-DISO
and	O
polyserositis	B-DISO
.	O

Data	O
on	O
the	O
treatment	O
of	O
and	O
the	O
outcomes	O
of	O
ARDS	B-DISO
were	O
collected	O
to	O
determine	O
the	O
clinical	O
characteristics	O
associated	O
with	O
ICU	O
mortality	O
.	O

In	O
contrast	O
to	O
SPC	O
-	O
TK	O
mice	O
,	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
treated	O
with	O
GCV	O
exhibited	O
more	O
severe	O
inflammation	B-DISO
,	O
resulting	O
in	O
over	O
90	O
%	O
mortality	O
;	O
there	O
was	O
only	O
8	O
%	O
mortality	O
of	O
SPC	O
-	O
TK	O
animals	O
.	O

The	O
patients	O
treated	O
with	O
ECMO	O
belonged	O
to	O
the	O
severe	O
ARDS	B-DISO
group	O
,	O
and	O
almost	O
90	O
%	O
of	O
them	O
belonged	O
to	O
the	O
higher	O
Fi	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
is	O
a	O
known	O
cause	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
).	O

TITLE	O
:	O
Effects	O
of	O
Timely	O
Control	O
Intervention	O
on	O
the	O
Spread	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
.	O

Notably	O
,	O
however	O
,	O
an	O
analysis	O
of	O
the	O
CoV	O
RNA	O
polymerase	O
phylogeny	O
suggested	O
that	O
many	O
such	O
host	O
-	O
jumps	O
likely	O
resulted	O
in	O
short	O
-	O
term	O
spill	O
-	O
over	O
infections	B-DISO
,	O
with	O
little	O
evidence	O
for	O
sustained	O
onward	O
transmission	O
in	O
new	O
co	O
-	O
roosting	O
host	O
species	O
.	O

Compared	O
with	O
mice	O
receiving	O
vehicle	O
control	O
,	O
mice	O
treated	O
with	O
GBT1118	O
had	O
significantly	O
lower	O
mortality	O
after	O
LPS	B-DISO
+	O
5	O
%	O
hypoxia	B-DISO
(	O
47	O
%	O
with	O
vehicle	O
vs	O
.	O
22	O
%	O
with	O
low	O
-	O
dose	O
GBT1118	O
,	O
13	O
%	O
with	O
high	O
-	O
dose	O
GBT1118	O
,	O
P	O
=	O
0	O
.	O
032	O
by	O
log	O
rank	O
)	O
and	O
had	O
reduced	O
severity	O
of	O
illness	O
.	O

During	O
two	O
animal	O
infection	B-DISO
experiments	O
,	O
swabs	O
were	O
collected	O
from	O
personnel	O
(	O
nasal	O
mucosa	O
)	O
and	O
their	O
clothes	O
,	O
boots	O
and	O
equipment	O
after	O
contact	O
with	O
calves	O
shedding	O
either	O
virus	O
.	O

TITLE	O
:	O
Does	O
acute	O
kidney	O
injury	O
affect	O
survival	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
extracorporeal	O
membrane	O
oxygenation	O
?	O

Survival	O
outcomes	O
remain	O
unclear	O
in	O
those	O
who	O
develop	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
requiring	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
during	O
VV	O
ECMO	O
for	O
isolated	O
severe	O
respiratory	B-DISO
failure	I-DISO
in	O
adult	O
populations	O
.	O

AKI	O
was	O
defined	O
by	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
receiving	O
CRRT	O
and	O
the	O
outcomes	O
of	O
patients	O
on	O
VV	O
ECMO	O
were	O
compared	O
between	O
the	O
AKI	O
and	O
non	O
-	O
AKI	O
groups	O
.	O

We	O
identified	O
54	O
ARDS	B-DISO
patients	O
supported	O
by	O
VV	O
ECMO	O
(	O
mean	O
ECMO	O
days	O
12	O
±	O
6	O
.	O
7	O
)	O
with	O
16	O
(	O
30	O
%)	O
in	O
the	O
AKI	O
group	O
and	O
38	O
(	O
70	O
%)	O
in	O
the	O
non	O
-	O
AKI	O
group	O
.	O

TITLE	O
:	O
Multiple	O
Organ	O
Dysfunction	O
:	O
The	O
Defining	O
Syndrome	B-DISO
of	O
Sepsis	B-DISO
.	O

We	O
describe	O
the	O
common	O
clinical	O
manifestations	O
of	O
the	O
six	O
prototypic	O
organ	O
system	O
dysfunction	O
syndromes	B-DISO
of	O
severe	B-DISO
sepsis	I-DISO
and	O
review	O
the	O
associated	O
epidemiology	O
and	O
suspected	O
pathophysiology	O
.	O

TITLE	O
:	O
Galectin	O
-	O
3	O
Enhances	O
Avian	O
H5N1	B-DISO
Influenza	I-DISO
A	O
Virus	O
-	O
Induced	O
Pulmonary	B-DISO
Inflammation	I-DISO
by	O
Promoting	O
NLRP3	O
Inflammasome	O
Activation	O
.	O

Virus	O
-	O
induced	O
excessive	O
inflammatory	B-DISO
response	I-DISO
contributes	O
to	O
severe	O
disease	O
and	O
high	O
mortality	O
rates	O
.	O

Co	O
-	O
immunoprecipitation	O
data	O
indicated	O
galectin	O
-	O
3	O
and	O
NLRP3	O
interaction	O
in	O
BMMs	O
infected	O
with	O
H5N1	B-DISO
.	O

TITLE	O
:	O
Recombinant	O
live	O
attenuated	O
avian	O
coronavirus	O
vaccines	O
with	O
deletions	O
in	O
the	O
accessory	O
genes	O
3ab	O
and	O
/	O
or	O
5ab	O
protect	O
against	O
infectious	B-DISO
bronchitis	B-DISO
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
respiratory	O
pathogen	O
of	O
chickens	O
,	O
causing	O
severe	O
economic	O
losses	O
in	O
poultry	O
industry	O
worldwide	O
.	O

The	O
primary	O
goal	O
of	O
this	O
review	O
was	O
to	O
examine	O
all	O
the	O
case	O
reports	O
published	O
since	O
the	O
syndrome	B-DISO
was	O
defined	O
in	O
1990	O
.	O

For	O
each	O
case	O
,	O
data	O
were	O
extracted	O
pertaining	O
to	O
age	O
,	O
sex	O
,	O
type	O
of	O
medication	O
associated	O
with	O
the	O
disease	O
,	O
time	O
from	O
the	O
onset	O
of	O
symptoms	O
to	O
diagnosis	O
,	O
eosinophil	O
counts	O
in	O
the	O
blood	O
,	O
eosinophil	O
fractions	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
,	O
initial	O
chest	O
radiograph	O
and	O
computed	O
tomography	O
results	O
,	O
use	O
of	O
mechanical	O
ventilation	O
,	O
and	O
use	O
of	O
steroid	O
treatment	O
and	O
recurrence	B-DISO
.	O

A	O
significant	O
portion	O
of	O
AEP	O
patients	O
(	O
20	O
%)	O
presented	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
4b	O
protein	O
interferes	O
with	O
the	O
NF	O
-	O
κB	O
-	O
dependent	O
innate	B-DISO
immune	I-DISO
response	I-DISO
during	O
infection	B-DISO
.	O

The	O
present	O
study	O
suggests	O
the	O
possibility	O
of	O
establishing	O
dedicated	O
training	O
facilities	O
,	O
revising	O
the	O
guidelines	O
on	O
training	O
and	O
improvement	O
of	O
the	O
competency	O
of	O
public	O
health	O
experts	O
,	O
while	O
not	O
limiting	O
the	O
scope	O
of	O
application	O
to	O
communicable	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
exacerbation	O
(	O
s	O
)	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
AECOPD	O
)	O
tend	O
to	O
be	O
critical	O
and	O
debilitating	O
events	O
leading	O
to	O
poorer	O
outcomes	O
in	O
relation	O
to	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
treatment	O
modalities	O
,	O
and	O
contribute	O
to	O
a	O
higher	O
and	O
earlier	O
mortality	O
rate	O
in	O
COPD	B-DISO
patients	O
.	O

Recently	O
,	O
a	O
few	O
adjunctive	O
modalities	O
,	O
including	O
NIV	O
with	O
helmet	O
and	O
helium	O
-	O
oxygen	O
mixture	O
,	O
have	O
been	O
tried	O
in	O
cases	O
of	O
AECOPD	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

High	O
-	O
flow	O
nasal	O
cannula	O
oxygen	O
therapy	O
is	O
another	O
supportive	O
strategy	O
which	O
serves	O
to	O
improve	O
the	O
symptoms	O
of	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
.	O

To	O
compare	O
the	O
mortality	O
and	O
functional	O
status	O
of	O
children	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
supported	O
with	O
and	O
without	O
ECMO	O
.	O

This	O
cohort	O
study	O
compared	O
ECMO	O
-	O
supported	O
children	O
to	O
pair	O
-	O
matched	O
non	O
-	O
ECMO	O
-	O
supported	O
control	O
subjects	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Of	O
2	O
,	O
449	O
children	O
in	O
the	O
RESTORE	O
trial	O
,	O
879	O
(	O
35	O
.	O
9	O
%)	O
non	O
-	O
ECMO	O
-	O
supported	O
patients	O
with	O
severe	O
ARDS	B-DISO
were	O
eligible	O
to	O
match	O
to	O
61	O
(	O
2	O
.	O
5	O
%)	O
ECMO	O
-	O
supported	O
children	O
.	O

Studies	O
on	O
the	O
true	O
burden	O
of	O
the	O
disease	O
,	O
specific	O
risk	O
factors	O
and	O
sources	O
of	O
autochthonous	O
infections	B-DISO
as	O
well	O
as	O
targeted	O
prevention	O
measures	O
are	O
urgently	O
needed	O
.	O

TITLE	O
:	O
Epidemiology	O
characteristics	O
of	O
human	O
coronaviruses	O
in	O
patients	O
with	O
respiratory	B-DISO
infection	I-DISO
symptoms	O
and	O
phylogenetic	O
analysis	O
of	O
HCoV	O
-	O
OC43	O
during	O
2010	O
-	O
2015	O
in	O
Guangzhou	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
throughout	O
the	O
world	O
.	O

Overall	O
,	O
PEDV	O
-	O
inoculated	O
pigs	O
did	O
recover	O
the	O
absorptive	O
capacity	O
that	O
was	O
reduced	O
during	O
PEDV	O
infection	B-DISO
by	O
increasing	O
proliferation	B-DISO
of	O
intestinal	O
stem	O
cells	O
.	O

RESULTS	O
:	O
Although	O
all	O
nasopharyngeal	O
samples	O
were	O
negative	O
,	O
MERS	O
CoV	O
infection	B-DISO
was	O
confirmed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
of	O
the	O
E	O
gene	O
(	O
UpE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF1b	O
)	O
on	O
sputum	O
samples	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
-	O
Induced	O
Epidermal	O
Growth	O
Factor	O
Receptor	O
Activation	O
Impairs	O
the	O
Antiviral	O
Activity	O
of	O
Type	O
I	O
Interferon	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
PEDV	O
infection	B-DISO
stimulated	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
activation	O
,	O
which	O
has	O
been	O
linked	O
to	O
not	O
only	O
anticancer	O
therapeutics	O
,	O
but	O
also	O
antiviral	O
signaling	O
.	O

After	O
clinical	O
picture	O
worsened	O
with	O
a	O
profound	O
respiratory	B-DISO
insufficiency	I-DISO
,	O
the	O
patient	O
was	O
intubated	O
and	O
transferred	O
to	O
our	O
ICU	O
.	O

PCR	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
for	O
influenza	B-DISO
A	O
/	O
B	O
,	O
human	O
parainfluenza	B-DISO
virus	O
1	O
-	O
4	O
,	O
adenovirus	B-DISO
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
rhinovirus	O
,	O
enterovirus	O
,	O
human	O
coronavirus	O
and	O
human	O
Bocavirus	O
(	O
HBoV	O
).	O

In	O
total	O
,	O
188	O
episodes	O
of	O
ARI	O
were	O
reported	O
,	O
being	O
rhinovirus	O
the	O
most	O
frequently	O
detected	O
(	O
n	O
=	O
53	O
),	O
followed	O
by	O
influenza	B-DISO
A	O
(	O
H3	O
)	O
(	O
n	O
=	O
19	O
)	O
and	O
HBoV	O
(	O
n	O
=	O
14	O
).	O

Severe	O
infections	B-DISO
were	O
reported	O
in	O
19	O
patients	O
,	O
11	O
of	O
which	O
were	O
fatal	O
,	O
Legionela	O
pneumophila	O
,	O
rhinovirus	O
,	O
HMPV	O
and	O
RSV	O
associated	O
with	O
these	O
fatalities	O
.	O

TITLE	O
:	O
Swine	O
enteric	O
coronavirus	O
disease	O
:	O
A	O
review	O
of	O
4	O
years	O
with	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
and	O
porcine	O
deltacoronavirus	O
in	O
the	O
United	O
States	O
and	O
Canada	O
.	O

However	O
,	O
unique	O
properties	O
of	O
SECD	O
,	O
such	O
as	O
ineffective	O
immunity	O
through	O
parenteral	O
vaccination	O
and	O
a	O
low	O
oral	O
infectious	B-DISO
dose	O
,	O
play	O
a	O
major	O
role	O
in	O
management	O
of	O
SECD	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
genogroup	O
1	O
based	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
live	O
vaccine	O
against	O
genogroup	O
2	O
field	O
strain	O
in	O
Japan	O
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
rates	O
among	O
camels	O
in	O
livestock	O
markets	O
and	O
slaughterhouses	O
were	O
investigated	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
Pancreatitis	B-DISO
is	O
a	O
condition	B-DISO
characterized	O
by	O
parenchymal	O
inflammation	B-DISO
of	O
the	O
pancreas	O
,	O
which	O
is	O
often	O
associated	O
with	O
lung	O
injury	O
due	O
to	O
low	O
level	O
of	O
oxygen	O
and	O
the	O
condition	B-DISO
is	O
termed	O
as	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
(	O
APALI	O
).	O

TITLE	O
:	O
Simvastatin	O
to	O
reduce	O
pulmonary	O
dysfunction	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
the	O
HARP	O
-	O
2	O
RCT	O
ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
is	O
a	O
common	O
devastating	O
clinical	O
syndrome	B-DISO
characterised	O
by	O
life	O
-	O
threatening	O
respiratory	B-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
and	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

The	O
potential	O
role	O
of	O
simvastatin	O
in	O
the	O
prevention	O
of	O
ARDS	B-DISO
in	O
patients	O
at	O
a	O
high	O
risk	O
of	O
developing	O
ARDS	B-DISO
has	O
not	O
yet	O
been	O
evaluated	O
.	O

Several	O
familiar	O
biothreat	O
diseases	O
such	O
as	O
anthrax	B-DISO
and	O
tularemia	B-DISO
were	O
judged	O
,	O
by	O
our	O
experts	O
,	O
to	O
be	O
less	O
threatening	O
than	O
many	O
others	O
owing	O
to	O
a	O
number	O
of	O
factors	O
including	O
ease	O
of	O
detection	O
,	O
lack	O
of	O
communicability	O
,	O
and	O
the	O
ready	O
availability	O
of	O
countermeasures	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
there	O
have	O
been	O
increasing	O
numbers	O
of	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
that	O
spread	O
rapidly	O
to	O
population	O
centers	O
resulting	O
from	O
global	O
travel	O
,	O
population	O
vulnerabilities	O
,	O
environmental	O
factors	O
,	O
and	O
ecological	O
disasters	O
such	O
as	O
floods	O
and	O
earthquakes	O
.	O

One	O
patient	O
died	O
from	O
Haemophilus	O
influenzae	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

Nocturnal	O
ventilatory	O
polygraphy	O
(	O
PV	O
)	O
or	O
polysomnography	O
(	O
PSG	O
)	O
were	O
performed	O
in	O
patients	O
having	O
symptoms	O
evocative	O
of	O
the	O
SAS	O
syndrome	B-DISO
and	O
an	O
index	O
of	O
respiratory	O
events	O
(	O
IER	O
)>	O
10	O
/	O
h	O
or	O
>	O
25	O
in	O
one	O
hour	O
,	O
measured	O
by	O
RU	O
Sleeping	O
.	O

The	O
mean	O
age	O
of	O
the	O
study	O
population	O
was	O
44	O
±	O
12	O
years	O
with	O
a	O
mean	O
body	O
mass	O
index	O
of	O
21	O
.	O
6	O
±	O
5	O
.	O
2kg	O
/	O
m	O
CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
OSAS	B-DISO
is	O
quite	O
high	O
in	O
the	O
Vietnamese	O
population	O
and	O
comparable	O
with	O
current	O
literature	O
data	O
.	O

TITLE	O
:	O
Factors	O
associated	O
with	O
farm	O
-	O
level	O
infection	B-DISO
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
during	O
the	O
early	O
phase	O
of	O
the	O
epidemic	O
in	O
Japan	O
in	O
2013	O
and	O
2014	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
IBV	O
,	O
and	O
to	O
determine	O
whether	O
prostaglandin	O
(	O
PG	O
)	O
E2	O
,	O
which	O
is	O
synthesized	O
during	O
inflammation	B-DISO
,	O
is	O
involved	O
in	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
in	O
the	O
uterine	O
mucosa	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
peroxygen	O
-	O
based	O
disinfectant	O
for	O
inactivation	B-DISO
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
at	O
low	O
temperatures	O
on	O
metal	O
surfaces	O
.	O

In	O
this	O
study	O
,	O
a	O
transcriptomic	O
shotgun	O
sequencing	O
(	O
RNA	O
-	O
Seq	O
)	O
procedure	O
was	O
used	O
to	O
study	O
gene	O
responses	O
against	O
PEDV	O
infection	B-DISO
.	O

Many	O
of	O
these	O
deadly	O
infectious	B-DISO
diseases	I-DISO
that	O
have	O
epidemic	O
potential	O
can	O
become	O
global	O
health	O
emergencies	B-DISO
in	O
the	O
absence	O
of	O
effective	O
vaccines	O
.	O

Histologically	O
,	O
3	O
main	O
distinct	O
distributions	O
of	O
neuropathologic	O
changes	O
were	O
observed	O
,	O
namely	O
periventricular	O
encephalitis	B-DISO
(	O
12	O
cases	O
),	O
rhombencephalitis	O
(	O
8	O
cases	O
),	O
and	O
diffuse	O
leptomeningitis	B-DISO
with	O
superficial	O
encephalitis	B-DISO
(	O
6	O
cases	O
).	O

TITLE	O
:	O
ACUTE	O
RESPIRATORY	B-DISO
DISEASES	I-DISO
IN	O
BRAZILIAN	O
CHILDREN	O
:	O
ARE	O
CAREGIVERS	O
ABLE	O
TO	O
DETECT	O
EARLY	O
WARNING	O
SIGNS	O
?	O

Fever	O
(	O
34	O
.	O
1	O
%)	O
and	O
cough	B-DISO
(	O
15	O
.	O
8	O
%)	O
were	O
major	O
reasons	O
for	O
referral	O
to	O
hospital	O
.	O

A	O
prominent	O
pro	O
-	O
inflammatory	O
Th1	O
and	O
Th17	O
response	O
was	O
clearly	O
seen	O
in	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
with	O
markedly	O
increased	O
concentrations	O
of	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
15	O
and	O
IL	O
-	O
17	O
compared	O
to	O
controls	O
.	O

Most	O
patients	O
died	O
from	O
causes	O
unrelated	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
48	O
.	O
7	O
%	O
of	O
nonsurvivors	O
died	O
from	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
,	O
and	O
cancer	B-DISO
or	O
brain	O
injury	O
was	O
involved	O
in	O
37	O
.	O
1	O
%	O
of	O
deaths	O
.	O

Pathophysiology	O
is	O
mainly	O
characterized	O
by	O
granulocyte	O
infiltration	B-DISO
of	O
the	O
lung	O
thereby	O
inducing	O
interstitial	O
and	O
intra	O
-	O
alveolar	O
lung	B-DISO
edema	I-DISO
with	O
surfactant	O
depletion	O
and	O
atelectasis	B-DISO
formation	O
.	O

Moreover	O
,	O
in	O
response	O
to	O
restimulation	O
with	O
the	O
PEDV	O
COE	O
antigen	O
in	O
vitro	O
,	O
a	O
significant	O
difference	O
in	O
splenocyte	O
proliferation	B-DISO
response	O
and	O
Th2	O
-	O
associated	O
cytokine	O
IL	O
-	O
4	O
level	O
was	O
observed	O
in	O
the	O
group	O
of	O
mice	O
orally	O
immunized	O
with	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
groups	O
of	O
mice	O
that	O
received	O
pPG	O
-	O
COE	O
-	O
Col	O
/	O
L393	O
and	O
pPG	O
-	O
COE	O
-	O
DCpep	O
/	O
L393	O
,	O
respectively	O
.	O

TITLE	O
:	O
Diagnosis	O
and	O
Treatment	O
of	O
Undifferentiated	O
and	O
Infectious	B-DISO
Acute	B-DISO
Diarrhea	I-DISO
in	O
the	O
Adult	O
Horse	O
.	O

Furthermore	O
,	O
VP35	O
contributes	O
to	O
EBOV	O
evasion	O
of	O
the	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
by	O
suppressing	O
RNA	O
silencing	O
and	O
blocking	B-DISO
RIG	O
-	O
I	O
like	O
receptors	O
'	O
pathways	O
that	O
lead	O
to	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
.	O

It	O
can	O
cause	O
severe	B-DISO
diarrhea	I-DISO
disease	O
in	O
pigs	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
-	O
OC43	O
,	O
-	O
229E	O
,	O
-	O
NL63	O
and	O
-	O
HKU1	O
cause	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
performance	O
of	O
laboratory	O
tests	O
in	O
the	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
We	O
compared	O
the	O
performance	O
of	O
clinicopathologic	O
and	O
molecular	O
tests	O
used	O
in	O
the	O
antemortem	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

This	O
enteric	O
virus	O
is	O
transmitted	B-DISO
via	O
the	O
feco	O
-	O
oral	O
route	O
and	O
horses	O
become	O
infected	O
by	O
ingesting	O
fecally	O
contaminated	O
feed	O
and	O
water	O
.	O

This	O
review	O
article	O
will	O
focus	O
on	O
the	O
latest	O
information	O
pertaining	O
to	O
the	O
virus	O
,	O
epidemiology	O
,	O
clinical	O
signs	O
,	O
diagnosis	O
,	O
pathology	B-DISO
,	O
treatment	O
and	O
prevention	O
of	O
ECoV	O
infection	B-DISO
in	O
adult	O
horses	O
.	O

When	O
severe	O
,	O
PVD	B-DISO
can	O
lead	O
to	O
RV	O
failure	O
which	O
is	O
associated	O
to	O
an	O
increased	O
mortality	O
.	O

His	O
symptoms	O
rapidly	O
deteriorated	O
and	O
he	O
required	O
mechanical	O
ventilation	O
for	O
respiratory	B-DISO
failure	I-DISO
.	O

White	O
blood	O
cell	O
count	O
on	O
admission	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
ARDS	B-DISO
(	O
OR	O
=	O
1	O
.	O
007	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
001	O
-	O
1	O
.	O
012	O
,	O
p	O
=	O
.	O
012	O
)	O
with	O
a	O
moderate	O
prediction	O
ability	O
(	O
AUC	O
0	O
.	O
704	O
,	O
p	O
=	O
.	O
001	O
).	O

Other	O
variables	O
were	O
associated	O
with	O
ARDS	B-DISO
in	O
univariate	O
but	O
not	O
in	O
multivariate	O
analysis	O
:	O
body	O
mass	O
index	O
(	O
p	O
=	O
.	O
06	O
),	O
transfusions	O
(	O
p	O
=	O
.	O
001	O
)	O
and	O
sepsis	B-DISO
(	O
p	O
<	O
.	O
0001	O
).	O

Subsequently	O
,	O
she	O
was	O
diagnosed	O
with	O
severe	O
myocarditis	B-DISO
caused	O
by	O
RSV	B-DISO
infection	I-DISO
,	O
which	O
was	O
diagnosed	O
by	O
abnormal	O
findings	O
of	O
cardiac	O
echography	O
and	O
ECG	O
and	O
elevated	O
biomarkers	O
for	O
myocardial	O
damage	O
.	O

ECMO	O
modality	O
should	O
be	O
chosen	O
according	O
to	O
the	O
respiratory	O
and	O
circulatory	O
condition	B-DISO
of	O
each	O
individual	O
.	O

Evoked	O
serious	O
complications	O
include	O
rhabdomyolysis	B-DISO
,	I-DISO
acute	I-DISO
kidney	O
injury	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
ultimately	O
,	O
sepsis	B-DISO
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
.	O

ABSTRACT	O
:	O
Radiographic	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
have	O
been	O
criticized	O
for	O
poor	O
reliability	O
.	O

Participant	O
recognition	O
of	O
radiographic	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
low	O
,	O
with	O
poor	O
agreement	O
.	O

This	O
was	O
not	O
impacted	B-DISO
by	O
an	O
educational	O
intervention	O
designed	O
to	O
improve	O
accuracy	O
of	O
identification	O
of	O
radiographic	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Methaemoglobinaemia	B-DISO
is	O
a	O
typical	O
acute	O
intoxication	O
disorder	O
in	O
children	O
under	O
one	O
year	O
old	O
.	O

Two	O
cases	O
of	O
15	O
-	O
month	O
-	O
old	O
infants	O
with	O
methaemoglobinaemia	B-DISO
after	O
the	O
intake	O
of	O
vegetables	O
,	O
atypical	O
by	O
the	O
age	O
of	O
the	O
patients	O
and	O
the	O
initial	O
severity	O
in	O
the	O
first	O
case	O
that	O
simulated	O
a	O
septic	B-DISO
syndrome	I-DISO
.	O

Unfortunately	O
,	O
such	O
peptide	O
mimicry	B-DISO
of	O
the	O
short	O
α	O
-	O
helical	O
region	O
in	O
the	O
CHR	B-DISO
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
has	O
been	O
thwarted	O
by	O
the	O
loss	O
of	O
the	O
peptide	O
'	O
s	O
native	O
α	O
-	O
helical	O
conformation	O
when	O
taken	O
out	O
of	O
the	O
parent	O
protein	O
structure	O
.	O

Younger	O
age	O
,	O
having	O
an	O
underlying	O
pulmonary	B-DISO
disorder	I-DISO
,	O
and	O
the	O
presence	O
of	O
respiratory	O
syncytial	O
virus	O
were	O
also	O
associated	O
with	O
LRTD	O
or	O
severe	O
LRTD	O
in	O
multivariable	O
models	O
.	O

ABSTRACT	O
:	O
Venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
has	O
been	O
gaining	O
use	O
to	O
bridge	O
the	O
recovery	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
refractory	O
to	O
conventional	O
treatment	O
.	O

CONCLUSIONS	O
:	O
As	O
future	O
advancements	O
are	O
sought	O
,	O
VV	O
-	O
ECMO	O
may	O
become	O
a	O
consideration	O
for	O
casualties	O
with	O
severe	O
ARDS	B-DISO
at	O
the	O
point	O
of	O
injury	O
and	O
at	O
lower	O
echelons	O
of	O
military	O
care	O
.	O

TITLE	O
:	O
Prognostic	O
and	O
Pathogenic	O
Role	O
of	O
Angiopoietin	O
-	O
1	O
and	O
-	O
2	O
in	O
Pneumonia	B-DISO
.	O

Serum	O
angiopoietin	O
levels	O
were	O
quantified	O
in	O
pneumonia	B-DISO
patients	O
of	O
two	O
independent	O
cohorts	O
(	O
n	O
=	O
148	O
,	O
n	O
=	O
395	O
).	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
role	O
of	O
bacteria	O
(	O
including	O
bacterial	B-DISO
resistance	I-DISO
),	O
viruses	O
(	O
including	O
those	O
recently	O
described	O
)	O
and	O
mixed	O
bacterial	O
-	O
viral	B-DISO
infections	I-DISO
in	O
adults	O
presenting	O
to	O
primary	O
care	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
LRTI	B-DISO
).	O

In	O
all	O
,	O
3104	O
adults	O
with	O
LRTI	B-DISO
were	O
enrolled	O
,	O
of	O
whom	O
141	O
(	O
4	O
.	O
5	O
%)	O
had	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
),	O
and	O
2985	O
matched	O
controls	O
in	O
a	O
prospective	O
study	O
in	O
16	O
primary	O
care	O
networks	O
in	O
Europe	O
,	O
and	O
followed	O
patients	O
up	O
at	O
28	O
-	O
35	O
days	O
.	O

In	O
the	O
sitting	O
posture	O
,	O
there	O
was	O
positional	O
worsening	O
of	O
dyspnoea	B-DISO
associated	O
with	O
an	O
increase	O
in	O
the	O
alveolar	O
-	O
arterial	O
oxygen	O
gradient	O
and	O
shunt	O
fraction	O
.	O

TITLE	O
:	O
Assessment	O
of	O
Mycoplasma	B-DISO
gallisepticum	O
vaccine	O
efficacy	O
in	O
a	O
co	B-DISO
-	I-DISO
infection	I-DISO
challenge	O
model	O
with	O
QX	O
-	O
like	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Mycoplasma	B-DISO
gallisepticum	O
(	O
MG	O
)	O
is	O
the	O
primary	O
cause	O
of	O
chronic	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
poultry	O
.	O

We	O
investigated	O
the	O
protective	O
efficacy	O
of	O
the	O
live	O
-	O
attenuated	O
ts	O
-	O
11	O
and	O
6	O
/	O
85	O
MG	O
vaccines	O
against	O
a	O
local	O
MG	O
strain	O
and	O
,	O
in	O
order	O
to	O
enhance	O
signs	O
and	O
mimic	O
a	O
typical	O
field	O
situation	O
,	O
we	O
co	O
-	O
infected	O
birds	O
with	O
a	O
virulent	O
strain	O
of	O
QX	O
-	O
like	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

Pathogen	O
infection	B-DISO
and	O
replication	O
was	O
assessed	O
by	O
qPCR	O
,	O
and	O
the	O
6	O
/	O
85	O
vaccine	O
produced	O
a	O
more	O
significant	O
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
reduction	O
in	O
MG	O
replication	O
in	O
the	O
lungs	O
,	O
kidneys	O
and	O
livers	O
but	O
enhanced	O
late	O
replication	O
in	O
bursae	O
and	O
caecal	O
tonsils	O
.	O

In	O
contrast	O
,	O
the	O
ts	O
-	O
11	O
vaccine	O
had	O
a	O
more	O
pronounced	O
reductive	O
effect	O
on	O
replication	O
in	O
tracheas	O
,	O
air	O
sacs	B-DISO
,	O
bursae	O
and	O
heart	O
at	O
days	O
28	O
and	O
31	O
,	O
yet	O
increased	O
replication	O
in	O
lungs	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
mean	O
CPP	O
during	O
the	O
first	O
7	O
days	O
of	O
admission	O
between	O
patients	O
who	O
developed	O
ARDS	B-DISO
(	O
74	O
mmHg	O
SD	O
18	O
vs	O
.	O
73	O
mmHg	O
SD	O
18	O
,	O
p	O
=	O
0	O
.	O
86	O
)	O
versus	O
those	O
who	O
did	O
not	O
.	O

We	O
did	O
not	O
observe	O
an	O
association	O
between	O
increased	O
CPP	O
and	O
ARDS	B-DISO
.	O

CONCLUSIONS	O
:	O
We	O
did	O
not	O
observe	O
an	O
association	O
between	O
increased	O
CPP	O
and	O
ARDS	B-DISO
.	O

Furthermore	O
,	O
the	O
available	O
knowledge	O
concerning	O
HCoV	O
-	O
229E	O
fusion	O
core	O
may	O
make	O
it	O
possible	O
to	O
design	O
small	O
molecule	O
or	O
polypeptide	O
drugs	O
targeting	O
membrane	O
fusion	O
,	O
a	O
crucial	O
step	O
of	O
HCoV	O
-	O
229E	O
infection	B-DISO
.	O

CoV	O
infection	B-DISO
was	O
found	O
in	O
both	O
juveniles	O
and	O
adult	O
bats	O
between	O
May	O
and	O
October	O
(	O
January	O
,	O
in	O
adults	O
only	O
and	O
April	O
,	O
in	O
juveniles	O
only	O
).	O

RESULTS	O
:	O
CoV	O
infection	B-DISO
was	O
found	O
in	O
both	O
juveniles	O
and	O
adult	O
bats	O
between	O
May	O
and	O
October	O
(	O
January	O
,	O
in	O
adults	O
only	O
and	O
April	O
,	O
in	O
juveniles	O
only	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
life	O
-	O
threatening	O
form	O
of	O
respiratory	B-DISO
failure	I-DISO
that	O
affects	O
approximately	O
200	O
000	O
patients	O
each	O
year	O
in	O
the	O
United	O
States	O
,	O
resulting	O
in	O
nearly	O
75	O
000	O
deaths	O
annually	O
.	O

Globally	O
,	O
ARDS	B-DISO
accounts	O
for	O
10	O
%	O
of	O
intensive	O
care	O
unit	O
admissions	O
,	O
representing	O
more	O
than	O
3	O
million	O
patients	O
with	O
ARDS	B-DISO
annually	O
.	O

When	O
the	O
patient	O
had	O
symptoms	O
of	O
colporrhagia	O
and	O
uterine	O
contractions	B-DISO
,	O
the	O
medical	O
team	O
decided	O
to	O
start	O
labour	O
induction	O
while	O
on	O
ECMO	O
.	O

We	O
sought	O
to	O
examine	O
the	O
relationship	O
of	O
AKI	O
duration	O
and	O
recurrent	O
AKI	O
with	O
short	O
-	O
term	O
outcomes	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
who	O
were	O
mechanically	O
ventilated	O
and	O
met	O
criteria	O
for	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
)	O
cause	O
common	B-DISO
colds	I-DISO
in	O
humans	O
,	O
but	O
are	O
also	O
responsible	O
for	O
the	O
recent	O
Severe	O
Acute	O
,	O
and	O
Middle	O
East	O
,	O
respiratory	O
syndromes	B-DISO
(	O
SARS	B-DISO
and	O
MERS	O
,	O
respectively	O
).	O

The	O
virus	O
can	O
trigger	O
severe	O
pneumonia	B-DISO
and	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Data	O
from	O
clinical	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
suggest	O
that	O
virus	O
-	O
induced	O
cytokine	O
dysregulation	O
could	O
be	O
a	O
contributory	O
factor	O
to	O
the	O
pathogenesis	B-DISO
of	O
human	O
H5N1	B-DISO
disease	O
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
events	O
at	O
the	O
earliest	O
time	O
points	O
,	O
we	O
used	O
RNA	O
-	O
Seq	O
to	O
quantify	O
and	O
compare	O
the	O
host	O
mRNA	O
and	O
miRNA	O
transcriptomes	O
induced	O
by	O
the	O
highly	O
pathogenic	O
influenza	B-DISO
A	O
H5N1	B-DISO
(	O
A	O
/	O
Vietnam	O
/	O
3212	O
/	O
04	O
)	O
or	O
low	O
virulent	O
H1N1	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
54	O
/	O
98	O
)	O
viruses	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
at	O
1	O
-,	O
3	O
-,	O
and	O
6	O
-	O
h	O
post	O
infection	B-DISO
.	O

Our	O
data	O
reveals	O
that	O
two	O
macrophage	O
populations	O
corresponding	O
to	O
M1	O
(	O
classically	O
activated	O
)	O
and	O
M2	O
(	O
alternatively	O
activated	O
)	O
macrophage	O
subtypes	O
respond	O
distinctly	O
to	O
H5N1	B-DISO
virus	B-DISO
infection	I-DISO
when	O
compared	O
to	O
H1N1	O
virus	O
or	O
mock	O
infection	B-DISO
,	O
a	O
distinction	O
that	O
could	O
not	O
be	O
made	O
from	O
previous	O
microarray	O
studies	O
.	O

When	O
this	O
confounding	O
variable	O
is	O
considered	O
in	O
our	O
statistical	O
model	O
,	O
a	O
clear	O
set	O
of	O
dysregulated	O
genes	O
and	O
pathways	O
emerges	O
specifically	O
in	O
H5N1	B-DISO
virus	O
-	O
infected	O
macrophages	O
at	O
6	O
-	O
h	O
post	O
infection	B-DISO
,	O
whilst	O
was	O
not	O
found	O
with	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
.	O

Some	O
but	O
not	O
all	O
of	O
the	O
Nidovirus	O
sg	O
mRNAs	O
also	O
have	O
a	O
common	O
5	O
'	O
leader	O
sequence	O
that	O
is	O
acquired	O
by	O
a	O
discontinuous	O
RNA	O
synthesis	O
mechanism	O
regulated	O
by	O
multiple	O
3	O
'	O
body	O
transcription	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
and	O
the	O
5	O
'	O
leader	O
TRS	B-DISO
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
a	O
disintergrin	O
and	O
metalloprotease	O
17	O
(	O
ADAM17	O
)	O
induced	O
the	O
decrease	O
of	O
PEDV	O
infection	B-DISO
in	O
HEK293	O
and	O
IPEC	O
-	O
J2	O
cells	O
and	O
the	O
downregulation	O
of	O
cell	O
surface	O
aminopeptidase	O
N	O
(	O
APN	O
)	O
expression	O
,	O
an	O
important	O
entry	O
factor	O
for	O
PEDV	O
infection	B-DISO
.	O

We	O
report	O
in	O
detail	O
two	O
cases	O
of	O
fulminant	O
idiopathic	O
acute	O
lung	O
injury	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
previously	O
healthy	O
young	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
one	O
of	O
whom	O
required	O
lung	O
transplantation	O
.	O

Biopsy	O
specimens	O
showed	O
diffuse	O
alveolar	O
injury	O
with	O
a	O
striking	O
paucity	O
of	O
alveolar	O
epithelial	O
regeneration	O
,	O
rare	O
hyaline	B-DISO
membranes	I-DISO
,	O
and	O
diffuse	O
contiguous	O
airspace	O
lining	O
by	O
macrophages	O
.	O

In	O
FIP	B-DISO
cases	O
with	O
effusions	B-DISO
,	O
cytology	O
and	O
immunostaining	O
on	O
effusion	B-DISO
samples	O
can	O
be	O
relatively	O
easy	O
to	O
perform	O
;	O
otherwise	O
obtaining	O
diagnostic	O
samples	O
is	O
more	O
challenging	O
and	O
collection	O
of	O
biopsies	O
from	O
tissues	O
with	O
gross	O
lesions	O
is	O
necessary	O
.	O

Data	O
are	O
from	O
120	O
ARDS	B-DISO
survivors	O
participating	O
in	O
a	O
multicenter	O
national	O
study	O
.	O

TITLE	O
:	O
Alpha	O
/	O
Beta	O
Interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
Signaling	O
in	O
Astrocytes	O
Mediates	O
Protection	O
against	O
Viral	O
Encephalomyelitis	B-DISO
and	O
Regulates	O
IFN	O
-	O
γ	O
-	O
Dependent	O
Responses	O
.	O

TITLE	O
:	O
Rapid	O
molecular	O
diagnosis	O
of	O
infectious	B-DISO
viruses	O
in	O
microfluidics	O
using	O
DNA	O
hydrogel	O
formation	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
caused	O
by	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
),	O
which	O
is	O
a	O
considerable	O
economic	O
threat	O
to	O
the	O
poultry	O
industry	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
infected	O
at	O
least	O
2040	O
patients	O
and	O
caused	O
712	O
deaths	O
since	O
its	O
first	O
appearance	O
in	O
2012	O
,	O
yet	O
neither	O
pathogen	O
-	O
specific	O
therapeutics	O
nor	O
approved	O
vaccines	O
are	O
available	O
.	O

DAD	O
was	O
defined	O
by	O
the	O
presence	O
of	O
a	O
hyaline	B-DISO
membrane	I-DISO
plus	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
intra	O
-	O
alveolar	B-DISO
edema	I-DISO
,	O
alveolar	O
type	O
I	O
cell	O
necrosis	O
,	O
alveolar	O
type	O
II	O
cell	O
(	O
cuboidal	O
cells	O
)	O
proliferation	B-DISO
progressively	O
covering	O
the	O
denuded	O
alveolar	O
-	O
capillary	O
membrane	O
,	O
interstitial	O
proliferation	B-DISO
of	O
fibroblasts	O
and	O
myofibroblasts	O
,	O
or	O
organizing	O
interstitial	B-DISO
fibrosis	I-DISO
.	O

We	O
found	O
that	O
nano	O
silicon	O
applied	O
with	O
inactivated	O
TGEV	O
vaccine	O
induced	O
high	O
antibody	O
titers	O
,	O
increase	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
α	O
and	O
IFN	O
-	O
γ	O
expression	O
,	O
and	O
stimulate	O
CD3	O
+	O
T	O
cell	O
proliferation	B-DISO
with	O
a	O
high	O
CD4	O
+/	O
CD8	O
+	O
T	O
lymphocyte	O
ratio	O
.	O

Of	O
191	O
eligible	O
patients	O
with	O
severe	O
or	O
moderate	O
ARDS	B-DISO
,	O
62	O
were	O
treated	O
with	O
azithromycin	O
.	O

ABSTRACT	O
:	O
Hospital	O
-	O
acquired	O
infections	B-DISO
(	O
HAIs	O
)	O
are	O
serious	O
problems	O
for	O
healthcare	O
systems	O
,	O
especially	O
in	O
developing	O
countries	O
where	O
public	O
health	O
infrastructure	O
and	O
technology	O
for	O
infection	B-DISO
preventions	O
remain	O
undeveloped	O
.	O

PEDV	O
infection	B-DISO
of	O
two	O
APN	O
-	O
knockout	O
Vero	O
cells	O
had	O
the	O
same	O
efficiency	O
as	O
the	O
Vero	O
cells	O
with	O
or	O
without	O
neuraminidase	O
treatment	O
.	O

ABSTRACT	O
:	O
Rapid	O
sequence	O
induction	O
(	O
RSI	B-DISO
)	O
is	O
a	O
specific	O
technique	O
for	O
anesthesia	B-DISO
induction	O
,	O
which	O
is	O
performed	O
in	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
pulmonary	B-DISO
aspiration	I-DISO
(	O
e	O
.	O
g	O
.	O
intestinal	B-DISO
obstruction	I-DISO
,	O
severe	O
injuries	O
and	O
cesarean	O
section	O
).	O

Before	O
surgery	O
gastric	O
emptying	O
with	O
a	O
nasogastric	O
tube	O
is	O
mandatory	O
in	O
patients	O
with	O
ileus	B-DISO
and	O
passage	O
or	O
defecation	O
disorders	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
a	O
highly	O
lethal	O
pulmonary	B-DISO
infection	I-DISO
with	O
∼	O
35	O
%	O
mortality	O
.	O

These	O
studies	O
identify	O
MAbs	O
targeting	O
different	O
antigenic	O
sites	O
on	O
S	O
that	O
will	O
be	O
useful	O
for	O
defining	O
mechanisms	O
of	O
MERS	O
-	O
CoV	O
neutralization	O
and	O
for	O
developing	O
more	O
effective	O
interventions	O
to	O
prevent	O
or	O
treat	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
uses	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	B-DISO
molecule	O
1a	O
as	O
its	O
receptor	O
for	O
cell	O
entry	O
,	O
but	O
S	O
protein	O
can	O
also	O
be	O
triggered	O
in	O
the	O
absence	O
of	O
receptor	O
by	O
pH	O
8	O
.	O
0	O
alone	O
at	O
37	O
°	O
C	O
.	O

H	O
&	O
E	O
sections	O
were	O
scored	O
on	O
the	O
level	O
of	O
infiltrate	B-DISO
in	O
the	O
anterior	O
uvea	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
200	O
patients	O
with	O
ARDS	B-DISO
were	O
included	O
,	O
4	O
patients	O
were	O
excluded	O
because	O
of	O
severe	O
pneumothorax	B-DISO
,	O
massive	B-DISO
hemorrhage	I-DISO
of	O
the	O
digestive	O
tract	O
,	O
or	O
elevated	B-DISO
intracranial	I-DISO
pressure	I-DISO
,	O
so	O
196	O
patients	O
were	O
finally	O
enrolled	O
in	O
the	O
analysis	O
.	O

Overall	O
,	O
these	O
features	O
demonstrate	O
that	O
the	O
more	O
severe	O
clinical	O
signs	O
observed	O
upon	O
infection	B-DISO
with	O
the	O
HP	O
PR40	O
strain	O
are	O
sustained	O
by	O
remarkable	O
changes	O
in	O
the	O
peripheral	O
blood	O
distribution	O
of	O
immune	O
cells	O
and	O
provide	O
further	O
insights	O
into	O
the	O
immune	O
regulation	O
/	O
immunopathogenesis	O
induced	O
by	O
PRRSV	O
-	O
1	O
subtype	O
1	O
European	O
isolates	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
an	O
important	O
pathogen	O
in	O
swine	O
that	O
is	O
responsible	O
for	O
substantial	O
economic	O
losses	O
.	O

TITLE	O
:	O
Neuromuscular	B-DISO
blockade	I-DISO
is	O
associated	O
with	O
the	O
attenuation	O
of	O
biomarkers	O
of	O
epithelial	O
and	O
endothelial	O
injury	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

CONCLUSIONS	O
:	O
NBM	O
is	O
associated	O
with	O
decreased	O
biomarkers	O
of	O
epithelial	O
and	O
endothelial	O
lung	O
injury	O
and	O
systemic	O
inflammation	B-DISO
in	O
ARDS	B-DISO
patients	O
receiving	O
low	O
tidal	O
volume	O
ventilation	O
and	O
those	O
with	O
a	O
P	O
/	O
F	O
ratio	O
less	O
than	O
or	O
equal	O
to	O
120	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
transfusion	O
-	O
transmitted	B-DISO
malaria	B-DISO
in	O
a	O
patient	O
with	O
SCD	B-DISO
presenting	O
with	O
acute	O
vaso	O
-	O
occlusive	O
crisis	O
and	O
rapidly	O
decompensating	O
to	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
(	O
MSOF	O
).	O

An	O
18	O
-	O
year	O
-	O
old	O
African	O
American	O
male	O
with	O
SCD	B-DISO
was	O
admitted	O
after	O
multiple	O
days	O
of	O
fever	O
and	O
severe	O
generalized	O
body	B-DISO
pain	I-DISO
.	O

He	O
received	O
monthly	O
blood	O
transfusions	O
as	O
stroke	B-DISO
prophylaxis	O
.	O

They	O
have	O
been	O
approved	O
for	O
treatment	O
of	O
herpes	B-DISO
simplex	I-DISO
virus	O
-	O
1	O
,	O
HIV	B-DISO
,	O
HBV	B-DISO
,	O
HCV	O
,	O
and	O
influenza	B-DISO
,	O
and	O
new	O
drugs	O
are	O
being	O
developed	O
for	O
the	O
treatment	O
of	O
RSV	O
,	O
Ebola	O
,	O
coronavirus	O
MERS	O
,	O
and	O
other	O
emerging	O
viruses	O
.	O

Her	O
sputum	O
and	O
throat	O
swabs	O
were	O
checked	O
for	O
nucleic	O
acid	O
of	O
influenza	B-DISO
A	O
and	O
the	O
result	O
was	O
positive	O
for	O
influenza	B-DISO
A	O
H7N9	O
.	O

She	O
was	O
diagnosed	O
as	O
having	O
severe	O
influenza	B-DISO
A	O
H7N9	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
was	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

However	O
,	O
some	O
symptoms	O
exacerbated	O
again	O
2	O
days	O
later	O
with	O
ground	O
-	O
glass	O
changes	O
appearing	O
in	O
upper	O
area	O
of	O
right	O
lung	O
and	O
the	O
titer	O
of	O
antibody	O
to	O
Mycoplasma	B-DISO
pneumoniae	O
rising	O
from	O
1	O
:	O
80	O
to	O
1	O
:	O
640	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
confirmed	O
influenza	B-DISO
A	O
H7N9	O
infection	B-DISO
whose	O
condition	B-DISO
worsens	O
again	O
,	O
especially	O
with	O
new	O
infiltration	B-DISO
or	O
lung	O
ground	O
-	O
glass	O
infiltration	B-DISO
,	O
one	O
should	O
suspect	O
infection	B-DISO
by	O
other	O
pathogens	O
such	O
as	O
Mycoplasma	B-DISO
pneumoniae	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
mechanically	O
ventilated	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

We	O
prospectively	O
enrolled	O
consecutive	O
mechanically	O
ventilated	O
adult	O
ICU	O
patients	O
with	O
CAP	B-DISO
over	O
20	O
years	O
,	O
and	O
compared	O
them	O
with	O
mechanically	O
ventilated	O
patients	O
without	O
ARDS	B-DISO
.	O

Based	O
on	O
the	O
baseline	O
arterial	O
oxygen	O
tension	B-DISO
/	O
inspiratory	O
oxygen	O
fraction	O
ratio	O
,	O
60	O
(	O
48	O
%),	O
49	O
(	O
40	O
%)	O
and	O
15	O
(	O
12	O
%)	O
patients	O
had	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
,	O
respectively	O
.	O

TITLE	O
:	O
Future	O
Research	O
Directions	O
in	O
Pneumonia	B-DISO
.	O

Although	O
triggered	O
by	O
a	O
pathogen	O
,	O
pneumonia	B-DISO
often	O
results	O
from	O
dysregulations	O
of	O
host	O
defense	O
that	O
likely	O
precede	O
infection	B-DISO
.	O

The	O
complete	O
S	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
4149	O
-	O
4158	O
bp	O
long	O
.	O

When	O
taking	O
the	O
previously	O
submitted	O
3	O
isolates	O
from	O
China	O
into	O
consideration	O
,	O
all	O
the	O
12	O
isolates	O
were	O
clustered	O
into	O
4	O
groups	O
,	O
i	O
.	O
e	O
.,	O
G1a	O
,	O
G1b	O
,	O
G2a	O
and	O
G2b	O
,	O
suggesting	O
that	O
a	O
highly	O
diverse	O
and	O
complex	O
clustering	O
might	O
result	O
from	O
co	B-DISO
-	I-DISO
infections	I-DISO
in	O
more	O
than	O
13	O
provinces	O
in	O
China	O
,	O
as	O
well	O
in	O
South	O
Korea	O
,	O
Japan	O
,	O
Vietnam	O
,	O
Thai	O
and	O
USA	O
.	O

AEZ	B-DISO
differential	O
did	O
not	O
influence	O
risk	O
distribution	O
and	O
plausible	O
risk	O
factors	O
for	O
spatial	O
MERS	O
-	O
CoV	O
hotspots	O
were	O
camel	O
densities	O
,	O
previous	O
cases	O
of	O
MERS	O
-	O
CoV	O
,	O
high	O
seroprevalence	O
and	O
points	O
of	O
camel	O
convergences	O
.	O

DIC	B-DISO
and	O
AKI	O
are	O
frequent	O
complications	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

ABSTRACT	O
:	O
A	O
rapid	O
and	O
specific	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
recombinase	O
polymerase	O
amplification	B-DISO
assay	O
(	O
RT	O
-	O
RPA	O
)	O
was	O
developed	O
to	O
detect	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
this	O
study	O
.	O

The	O
amplification	B-DISO
was	O
performed	O
at	O
40	O
°	O
C	O
for	O
20	O
min	O
.	O

TITLE	O
:	O
Early	O
identification	O
of	O
pneumonia	B-DISO
patients	O
at	O
increased	O
risk	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
Saudi	O
Arabia	O
.	O

This	O
risk	O
prediction	O
model	O
could	O
be	O
useful	O
for	O
the	O
early	O
identification	O
of	O
patients	O
at	O
the	O
highest	O
risk	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

RESULTS	O
:	O
A	O
risk	O
prediction	O
model	O
to	O
identify	O
pneumonia	B-DISO
patients	O
at	O
increased	O
risk	O
of	O
MERS	O
-	O
CoV	O
was	O
developed	O
.	O

New	O
data	O
suggest	O
that	O
HCoV	O
-	O
229E	O
may	O
actually	O
be	O
transferred	O
from	O
dromedary	O
camels	O
similar	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
.	O

Coronaviruses	O
,	O
including	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
fuse	O
at	O
the	O
plasma	O
membrane	O
or	O
use	O
receptor	O
-	O
mediated	O
endocytosis	O
and	O
fuse	O
with	O
endosomes	O
,	O
depending	O
on	O
the	O
cell	O
or	O
tissue	O
type	O
.	O

We	O
found	O
that	O
imatinib	O
and	O
two	O
specific	O
Abl	B-DISO
kinase	O
inhibitors	O
,	O
GNF2	O
and	O
GNF5	O
,	O
reduce	O
IBV	O
titres	O
by	O
blocking	B-DISO
the	O
first	O
round	O
of	O
virus	B-DISO
infection	I-DISO
.	O

Metabolic	O
screening	O
revealed	O
elevated	O
plasma	O
homocysteine	O
levels	O
,	O
low	O
methionine	O
levels	O
,	O
and	O
methylmalonic	B-DISO
aciduria	I-DISO
,	O
and	O
the	O
patient	O
was	O
diagnosed	O
as	O
having	O
HUS	O
secondary	O
to	O
Cbl	O
C	O
defect	O
.	O

After	O
treatment	O
,	O
the	O
homocysteine	O
and	O
methylmalonic	O
acid	O
levels	O
were	O
normalized	O
but	O
hemolysis	B-DISO
and	O
acute	B-DISO
kidney	I-DISO
failure	I-DISO
persisted	O
.	O

Calves	O
that	O
suffered	B-DISO
from	O
diarrhea	B-DISO
or	O
died	O
within	O
the	O
first	O
month	O
of	O
life	O
had	O
lower	O
serum	O
Ig	O
concentrations	O
than	O
those	O
that	O
remained	O
healthy	O
or	O
survived	O
(	O
P	O
<	O
.	O
05	O
).	O

Even	O
if	O
estimated	O
on	O
a	O
small	O
number	O
of	O
calves	O
,	O
those	O
with	O
FTPI	O
had	O
higher	O
risks	O
of	O
enteric	O
infections	B-DISO
by	O
rotavirus	O
(	O
odds	O
ratio	O
=	O
12	O
;	O

ABSTRACT	O
:	O
We	O
investigated	O
public	O
health	O
emergency	B-DISO
management	O
networks	O
during	O
the	O
recent	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
that	O
affected	O
more	O
than	O
17	O
000	O
people	O
in	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
presents	O
an	O
emerging	O
threat	O
to	O
public	O
health	O
worldwide	O
by	O
causing	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
with	O
high	O
virulence	O
and	O
case	O
fatality	O
rate	O
(	O
about	O
35	O
%)	O
since	O
2012	O
.	O

While	O
chloroquine	O
was	O
not	O
active	O
in	O
these	O
primary	O
cells	O
,	O
chlorpromazine	O
showed	O
strong	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
,	O
but	O
it	O
was	O
associated	O
with	O
high	O
cytotoxicity	B-DISO
narrowing	O
the	O
potential	O
window	O
for	O
drug	O
utilization	O
.	O

AE	O
-	O
IPF	O
shares	O
several	O
pathophysiological	O
features	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
a	O
very	O
severe	O
condition	B-DISO
commonly	O
treated	O
in	O
this	O
setting	O
.	O

A	O
review	O
of	O
the	O
literature	O
has	O
been	O
conducted	O
to	O
underline	O
similarities	O
and	O
differences	O
in	O
the	O
management	O
of	O
patients	O
with	O
AE	O
-	O
IPF	O
and	O
ARDS	B-DISO
.	O
During	O
AE	O
-	O
IPF	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
massive	O
loss	O
of	O
aeration	O
occurs	O
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

Here	O
we	O
isolated	O
a	O
strain	O
of	O
PDCoV	O
,	O
named	O
CHN	B-DISO
-	O
GD	O
-	O
2016	O
,	O
from	O
the	O
intestinal	O
content	O
of	O
a	O
diseased	O
newborn	O
piglet	O
with	O
severe	B-DISO
diarrhea	I-DISO
in	O
a	O
pig	O
farm	O
in	O
Guangdong	O
,	O
China	O
.	O

We	O
report	O
two	O
HIV	B-DISO
-	O
positive	O
patients	O
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
from	O
IRIS	O
necessitating	O
successful	O
veno	O
-	O
venous	O
ECMO	O
as	O
salvage	O
therapy	O
.	O

Overall	O
NIV	O
use	O
outside	O
the	O
PICUs	O
was	O
15	O
.	O
5	O
%	O
on	O
the	O
ward	O
,	O
20	O
%	O
in	O
the	O
emergency	B-DISO
department	O
,	O
and	O
36	O
.	O
4	O
%	O
during	O
transport	O
.	O

Areas	O
covered	O
:	O
Several	O
mechanisms	O
of	O
VILI	O
have	O
been	O
described	O
,	O
such	O
as	O
:	O
inspiratory	O
and	O
/	O
or	O
expiratory	O
stress	O
inducing	O
overdistension	O
(	O
volutrauma	O
);	O
interfaces	O
between	O
collapsed	O
or	O
edema	B-DISO
-	O
filled	O
alveoli	O
with	O
surrounding	O
open	O
alveoli	O
,	O
acting	O
as	O
stress	O
raisers	O
;	O
alveoli	O
that	O
repetitively	O
open	O
and	O
close	O
during	O
tidal	O
breathing	O
(	O
atelectrauma	O
);	O
and	O
peripheral	O
airway	O
dynamics	O
.	O

In	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
,	O
prone	O
positioning	O
can	O
reduce	O
lung	O
damage	O
and	O
improve	O
survival	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
postoperative	B-DISO
complications	I-DISO
in	O
patients	O
having	O
major	O
elective	O
surgery	O
using	O
oesophageal	O
Doppler	O
monitor	O
-	O
guided	O
goal	O
-	O
directed	O
haemodynamic	O
therapy	O
(	O
GDHT	O
),	O
in	O
which	O
administration	O
of	O
fluids	O
,	O
inotropes	O
,	O
and	O
vasopressors	O
was	O
guided	O
by	O
stroke	B-DISO
volume	O
,	O
mean	O
arterial	O
pressure	O
,	O
and	O
cardiac	O
index	O
.	O

In	O
most	O
patients	O
with	O
sepsis	B-DISO
syndrome	I-DISO
,	O
who	O
have	O
3	O
or	O
more	O
organs	O
damaged	O
,	O
lethality	O
is	O
more	O
than	O
90	O
%.	O

By	O
the	O
mentioned	O
case	O
there	O
is	O
sepsis	B-DISO
-	O
induced	O
polyorganic	O
insufficiency	O
with	O
underlying	O
severe	O
somatic	O
pathological	O
condition	B-DISO
,	O
with	O
violation	O
of	O
hemodynamics	O
.	O

Conventional	O
PCR	O
analysis	O
detected	O
diverse	O
adenovirus	B-DISO
and	O
herpesvirus	O
sequences	O
that	O
were	O
widespread	O
throughout	O
Neoromicia	O
populations	O
in	O
South	O
Africa	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
20	O
-	O
year	O
-	O
old	O
male	O
patient	O
suffering	B-DISO
from	O
motorcycle	O
accident	O
complicated	O
by	O
rapid	O
development	O
of	O
severe	O
refractory	O
hypoxemia	O
and	O
hypercapnia	B-DISO
due	O
to	O
serious	O
bilateral	O
lung	O
contusions	O
and	O
lacerations	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
form	O
,	O
known	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
are	O
caused	O
by	O
direct	O
pulmonary	O
insults	O
and	O
indirect	O
systemic	O
inflammatory	B-DISO
responses	I-DISO
that	O
result	O
from	O
conditions	O
such	O
as	O
sepsis	B-DISO
,	O
trauma	O
,	O
and	O
major	O
surgery	O
.	O

Cell	O
death	O
and	O
tissue	O
inflammation	B-DISO
form	O
a	O
positive	O
feedback	O
cycle	O
,	O
ultimately	O
leading	O
to	O
exaggerated	O
inflammation	B-DISO
and	O
development	O
of	O
disease	O
.	O

Pharmacological	O
manipulation	O
of	O
AM	O
death	O
signals	O
may	O
serve	O
as	O
a	O
logical	O
therapeutic	O
strategy	O
for	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
data	O
presented	O
herein	O
can	O
improve	O
the	O
clinical	O
knowledge	O
in	O
regions	O
with	O
low	O
vaccine	O
coverage	O
and	O
highlight	O
the	O
need	O
to	O
improve	O
the	O
methods	O
used	O
to	O
control	O
these	O
infectious	B-DISO
diseases	I-DISO
in	O
domestic	O
dogs	O
.	O

ABSTRACT	O
:	O
Nucleated	O
red	O
blood	O
cells	O
(	O
NRBCs	O
)	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
are	O
associated	O
with	O
increased	O
mortality	O
and	O
poor	O
outcome	O
.	O

A	O
total	O
of	O
404	O
critically	B-DISO
ill	I-DISO
ARDS	B-DISO
patients	O
were	O
analyzed	O
.	O

NRBCs	O
may	O
predict	O
mortality	O
in	O
ARDS	B-DISO
with	O
high	O
prognostic	O
power	O
.	O

We	O
diagnosed	O
her	O
anti	O
-	O
synthetase	O
syndrome	B-DISO
(	O
ASS	B-DISO
)	O
without	O
symptom	B-DISO
of	O
myositis	B-DISO
,	O
and	O
her	O
IP	O
was	O
considered	O
to	O
be	O
ASS	B-DISO
-	O
related	O
.	O

Among	O
the	O
24	O
MERS	O
survivors	O
,	O
17	O
(	O
70	O
.	O
8	O
%)	O
exhibited	O
psychiatric	B-DISO
symptoms	I-DISO
and	O
10	O
(	O
41	O
.	O
7	O
%)	O
received	O
a	O
psychiatric	B-DISO
diagnosis	I-DISO
and	O
medication	O
during	O
their	O
hospital	O
stay	O
.	O

Lipo	B-DISO
-	O
prostaglandin	O
E	O
For	O
these	O
five	O
patients	O
(	O
ten	O
hips	O
),	O
Harris	O
score	O
was	O
100	O
from	O
the	O
diagnosis	O
to	O
final	O
follow	O
-	O
up	O
time	O
.	O

This	O
case	O
report	O
is	O
about	O
a	O
severely	O
obese	B-DISO
poorly	O
controlled	O
asthmatic	B-DISO
man	O
,	O
who	O
turns	O
out	O
to	O
be	O
suffering	B-DISO
from	O
a	O
concomitant	O
obesity	B-DISO
-	I-DISO
hypoventilation	I-DISO
syndrome	I-DISO
.	O

Molecular	O
understanding	O
of	O
the	O
pathogenic	O
contributors	O
to	O
ARDS	B-DISO
has	O
improved	O
,	O
but	O
the	O
molecular	O
-	O
associated	O
treatments	O
are	O
still	O
under	O
development	O
.	O

followed	O
by	O
VILI	O
and	O
LPS	B-DISO
i	O
.	O
t	O
.	O

All	O
six	O
isolated	O
compounds	O
have	O
been	O
evaluated	O
firstly	O
for	O
the	O
inhibition	O
of	O
both	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
Reverse	O
Transcriptase	O
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
,	O
for	O
the	O
inhibition	O
of	O
HIV	B-DISO
-	O
1	O
integrase	O
(	O
IN	O
)	O
in	O
biochemical	O
assays	O
,	O
and	O
also	O
for	O
their	O
effect	O
on	O
viral	O
replication	O
.	O

The	O
results	O
are	O
applied	O
to	O
the	O
SARS	B-DISO
epidemic	O
in	O
Singapore	O
in	O
2003	O
,	O
where	O
it	O
is	O
shown	O
that	O
the	O
two	O
-	O
peak	O
evolution	O
of	O
the	O
infected	O
population	O
can	O
be	O
attributed	O
to	O
a	O
two	O
-	O
group	O
formulation	O
of	O
transmission	O
.	O

Accurate	O
and	O
objective	O
diagnoses	O
can	O
be	O
made	O
for	O
ARDS	B-DISO
patients	O
using	O
EVLW	O
and	O
PVPI	O
.	O

In	O
addition	O
to	O
EVLW	O
more	O
than	O
10	O
mL	O
/	O
kg	O
,	O
PVPI	O
more	O
than	O
three	O
suggests	O
increased	O
vascular	O
permeability	O
(	O
i	O
.	O
e	O
.,	O
ARDS	B-DISO
),	O
and	O
PVPI	O
less	O
than	O
2	O
represent	O
normal	O
vascular	O
permeability	O
(	O
i	O
.	O
e	O
.,	O
cardiogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
).	O

EVLW	O
and	O
PVPI	O
measurement	O
will	O
open	O
the	O
door	O
to	O
future	O
ARDS	B-DISO
clinical	O
practice	O
and	O
research	O
,	O
and	O
have	O
potential	O
to	O
be	O
included	O
in	O
the	O
future	O
ARDS	B-DISO
definition	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
sequelae	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
caused	O
by	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
:	O
Delirium	B-DISO
-	O
associated	O
cognitive	B-DISO
impairment	I-DISO
and	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
.	O

We	O
evaluated	O
delirium	B-DISO
and	O
associated	O
long	O
-	O
term	O
outcomes	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
non	O
-	O
H1N1	O
and	O
H1N1	O
-	O
associated	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
sCAP	O
)	O
who	O
had	O
been	O
recommended	O
to	O
take	O
antiviral	O
drugs	O
associated	O
with	O
delirious	B-DISO
symptoms	O
as	O
adverse	B-DISO
effects	I-DISO
.	O

During	O
follow	O
-	O
up	O
(	O
n	O
=	O
23	O
),	O
we	O
assessed	O
cognitive	O
abilities	O
,	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
),	O
physical	O
capacity	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
).	O

A	O
37	O
-	O
year	O
old	O
Caucasian	O
man	O
returning	O
home	O
from	O
Angola	O
was	O
admitted	O
for	O
ovale	B-DISO
malaria	I-DISO
to	O
the	O
National	O
Institute	O
for	O
Infectious	B-DISO
Diseases	I-DISO
Lazzaro	O
Spallanzani	O
in	O
Rome	O
,	O
Italy	O
.	O

In	O
this	O
case	O
clinical	O
failure	O
of	O
oral	O
chloroquine	O
treatment	O
with	O
clinical	O
progression	O
towards	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
described	O
.	O

ABSTRACT	O
:	O
The	O
persistent	O
public	O
health	O
threat	O
of	O
infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
highlights	O
the	O
need	O
for	O
an	O
effective	O
and	O
safe	O
MERS	O
-	O
CoV	O
vaccine	O
.	O

ABSTRACT	O
:	O
Two	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
,	O
designated	O
as	O
γCoV	O
/	O
ck	O
/	O
China	O
/	O
I0712	O
/	O
11	O
(	O
I0712	O
/	O
11	O
)	O
and	O
γCoV	O
/	O
ck	O
/	O
China	O
/	O
I0108	O
/	O
17	O
(	O
I0108	O
/	O
17	O
),	O
were	O
isolated	O
from	O
diseased	O
chicken	O
flocks	O
in	O
different	O
provinces	O
in	O
China	O
and	O
genotyped	O
as	O
Arkansas	O
(	O
Ark	O
)-	O
type	O
viruses	O
with	O
three	O
other	O
Chinese	O
Ark	O
field	O
strains	O
,	O
the	O
Jilin	O
vaccine	O
strain	O
,	O
and	O
the	O
American	O
Ark	O
-	O
and	O
Ark	O
DPI	O
-	O
like	O
viruses	O
.	O

ABSTRACT	O
:	O
Mycoplasma	B-DISO
gallinaceum	O
is	O
not	O
among	O
the	O
most	O
pathogenic	O
mycoplasmas	O
affecting	O
poultry	O
,	O
but	O
its	O
continuous	O
re	O
-	O
isolation	O
from	O
flocks	O
in	O
South	O
Africa	O
displaying	O
typical	O
signs	O
of	O
mycoplasmosis	B-DISO
prompted	O
us	O
to	O
revisit	O
its	O
role	O
in	O
respiratory	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
viruses	O
(	O
IBVs	O
)	O
with	O
the	O
TC07	O
-	O
2	O
genotype	O
have	O
spread	O
rapidly	O
in	O
East	O
Asia	O
since	O
they	O
were	O
first	O
reported	O
in	O
China	O
in	O
2007	O
.	O

In	O
2015	O
,	O
an	O
IBV	O
with	O
the	O
TC07	O
-	O
2	O
genotype	O
(	O
designated	O
KrD1515	O
)	O
was	O
isolated	O
from	O
layer	O
chickens	O
with	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
in	O
Korea	O
.	O

When	O
7	O
-	O
day	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
were	O
inoculated	O
with	O
the	O
KrD1515	O
virus	O
,	O
they	O
developed	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
and	O
tracheal	O
lesions	O
.	O

To	O
investigate	O
the	O
pathogenicity	O
of	O
a	O
representative	O
Japanese	O
PDCoV	O
,	O
we	O
performed	O
an	O
experimental	O
infection	B-DISO
using	O
hysterectomy	O
-	O
produced	O
colostrum	O
-	O
deprived	O
piglets	O
.	O

Prospective	O
cohort	O
study	O
in	O
a	O
600	O
-	O
bed	B-DISO
university	O
hospital	O
in	O
Portugal	O
including	O
all	O
patients	O
with	O
severe	O
infection	B-DISO
admitted	O
into	O
intensive	O
care	O
,	O
medical	O
,	O
surgical	O
,	O
hematology	O
and	O
nephrology	O
wards	O
over	O
one	O
-	O
year	O
period	O
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
attracted	O
attention	O
as	O
a	O
potential	O
therapy	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

At	O
the	O
same	O
time	O
,	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
increased	O
among	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
emerged	O
in	O
2012	O
as	O
an	O
important	O
respiratory	B-DISO
disease	I-DISO
with	O
high	O
fatality	O
rates	O
of	O
40	O
%-	O
60	O
%.	O

The	O
three	O
other	O
patients	O
(	O
43	O
%)	O
were	O
asymptomatic	O
and	O
were	O
in	O
contact	O
with	O
patients	O
with	O
confirmed	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
most	O
common	O
presenting	O
symptoms	O
were	O
fever	O
(	O
57	O
%),	O
cough	B-DISO
(	O
14	O
%),	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
14	O
%),	O
vomiting	B-DISO
(	O
28	O
%),	O
and	O
diarrhea	B-DISO
(	O
28	O
%).	O

ABSTRACT	O
:	O
Research	O
evidence	O
exists	O
that	O
poor	O
prognosis	O
is	O
common	O
in	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
patients	O
.	O

TITLE	O
:	O
Infection	B-DISO
,	O
genetic	O
and	O
virulence	O
characteristics	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
northwest	O
China	O
.	O

Typical	O
clinical	O
symptoms	O
of	O
the	O
disease	O
included	O
severe	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
,	O
dehydration	B-DISO
and	O
death	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
frequency	O
of	O
different	O
pathogens	O
involved	O
in	O
cases	O
of	O
recurrent	O
neonatal	B-DISO
diarrhoea	I-DISO
in	O
Spain	O
.	O

A	O
≥	O
5	O
log	O
PVP	O
-	O
I	O
gargle	O
/	O
mouthwash	O
diluted	O
1	O
:	O
30	O
(	O
equivalent	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
PVP	O
-	O
I	O
)	O
showed	O
effective	O
bactericidal	O
activity	O
against	O
Klebsiella	O
pneumoniae	O
and	O
Streptococcus	O
pneumoniae	O
and	O
rapidly	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
influenza	B-DISO
virus	O
A	O
(	O
H1N1	O
)	O
and	O
rotavirus	O
after	O
15	O
s	O
of	O
exposure	O
.	O

TITLE	O
:	O
Successful	O
Use	O
of	O
Veno	O
-	O
Venous	O
Extracorporeal	O
Membrane	O
Oxygenation	O
in	O
an	O
Adult	O
Patient	O
with	O
Sickle	B-DISO
Cell	I-DISO
Anemia	I-DISO
and	O
Severe	O
Acute	B-DISO
Chest	I-DISO
Syndrome	I-DISO
.	O

Prompt	O
initiation	O
of	O
this	O
modality	O
may	O
improve	O
outcomes	O
in	O
adult	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
complicated	O
by	O
life	O
threatening	O
ACS	O
.	O

Inhaled	O
cyclodextrins	O
have	O
potential	O
for	O
the	O
treatment	O
of	O
ARDS	B-DISO
.	O

Therefore	O
,	O
we	O
measured	O
the	O
plasma	O
lipidome	O
of	O
individuals	O
with	O
ARDS	B-DISO
at	O
two	O
time	O
-	O
points	O
to	O
determine	O
if	O
changes	O
in	O
the	O
plasma	O
lipidome	O
distinguished	O
survivors	O
from	O
non	O
-	O
survivors	O
.	O

Details	O
of	O
the	O
SARs	B-DISO
and	O
PK	O
profiles	O
of	O
these	O
analogues	O
are	O
provided	O
.	O

Using	O
chimeric	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
expressing	O
TMEV	O
L	O
*,	O
we	O
showed	O
that	O
L	O
*	O
efficiently	O
inhibits	O
RNase	O
L	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
viral	B-DISO
diseases	I-DISO
of	O
poultry	O
.	O

The	O
mucosa	O
of	O
upper	O
respiratory	O
tract	O
,	O
specially	O
the	O
trachea	B-DISO
,	O
is	O
the	O
primary	O
replication	O
site	O
for	O
this	O
virus	O
.	O

This	O
study	O
examined	O
the	O
relationship	O
between	O
short	O
-	O
term	O
variations	O
in	O
criteria	O
air	O
pollutants	O
and	O
occurrence	O
of	O
sudden	B-DISO
infant	I-DISO
death	I-DISO
syndrome	I-DISO
(	O
SIDS	B-DISO
).	O

We	O
obtained	O
daily	O
time	O
series	O
data	O
on	O
SIDS	B-DISO
mortality	O
(	O
ICD	B-DISO
-	O
9	O
:	O
798	O
.	O
0	O
or	O
ICD	B-DISO
-	O
10	O
:	O
R95	O
)	O
for	O
the	O
period	O
1996	O
-	O
2006	O
with	O
a	O
total	O
of	O
211	O
SIDS	B-DISO
events	O
.	O

Daily	O
counts	O
of	O
SIDS	B-DISO
events	O
.	O

Our	O
patient	O
'	O
s	O
clinical	O
course	O
broadens	O
the	O
phenotypic	O
spectrum	O
of	O
MMDS2	B-DISO
and	O
highlights	O
the	O
potential	O
for	O
some	O
genetic	O
leukoencephalopathies	B-DISO
to	O
spontaneously	O
improve	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
risk	O
-	O
prediction	O
model	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
dialysis	O
patients	O
.	O

ABSTRACT	O
:	O
Introduction	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
can	O
cause	O
transmission	O
clusters	O
and	O
high	O
mortality	O
in	O
hemodialysis	O
facilities	O
.	O

TITLE	O
:	O
Asymptomatic	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
using	O
a	O
serologic	O
survey	O
in	O
Korea	O
.	O

A	O
serologic	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
asymptomatic	O
MERS	O
infection	B-DISO
rate	O
in	O
healthcare	O
workers	O
and	O
non	O
-	O
healthcare	O
workers	O
by	O
exposure	O
status	O
.	O

The	O
asymptomatic	B-DISO
infection	I-DISO
rate	O
was	O
0	O
.	O
060	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
002	O
to	O
0	O
.	O
346	O
).	O

The	O
asymptomatic	B-DISO
infection	I-DISO
was	O
acquired	O
via	O
healthcare	O
-	O
associated	O
transmission	O
.	O

The	O
presence	O
of	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
),	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
septic	B-DISO
shock	I-DISO
were	O
assessed	O
and	O
documented	O
based	O
on	O
the	O
consensus	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Chest	O
Physicians	O
and	O
Society	O
of	O
Critical	O
Care	O
Medicine	O
(	O
SEPSIS	B-DISO
-	O
I	O
)	O
in	O
infected	O
patients	O
.	O

infection	B-DISO
,	O
renal	O
replacement	O
treatment	O
,	O
and	O
a	O
nurse	O
-	O
to	O
-	O
patient	O
ratio	O
of	O
1	O
:	O
4	O
(	O
compared	O
with	O
a	O
nurse	O
-	O
to	O
-	O
patient	O
ratio	O
of	O
1	O
:	O
2	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
in	O
infected	O
patients	O
.	O

infection	B-DISO
,	O
renal	O
replacement	O
treatment	O
,	O
and	O
a	O
nurse	O
-	O
to	O
-	O
patient	O
ratio	O
of	O
1	O
:	O
4	O
(	O
compared	O
with	O
a	O
nurse	O
-	O
to	O
-	O
patient	O
ratio	O
of	O
1	O
:	O
2	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
in	O
infected	O
patients	O
.	O

TITLE	O
:	O
Severe	O
Varicella	B-DISO
Pneumonia	I-DISO
in	O
Adults	O
:	O
Seven	O
Years	O
'	O
Single	O
-	O
center	O
Experience	O
from	O
India	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
clinical	O
manifestations	O
,	O
hospital	O
course	O
,	O
treatment	O
,	O
and	O
outcome	O
of	O
adult	O
patients	O
with	O
severe	O
varicella	B-DISO
pneumonia	I-DISO
.	O

The	O
cases	O
of	O
varicella	B-DISO
were	O
identified	O
by	O
a	O
computerized	O
search	O
of	O
the	O
medical	O
record	O
for	O
the	O
period	O
between	O
January	O
2010	O
and	O
December	O
2016	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
influence	O
of	O
acute	B-DISO
pancreatitis	I-DISO
in	O
pregnancy	O
(	O
APIP	O
)	O
on	O
pregnancy	O
outcomes	O
and	O
neonates	O
.	O

Obtained	O
results	O
confirmed	O
that	O
patients	O
with	O
chronic	O
underlying	O
illness	O
/	O
condition	B-DISO
and	O
older	O
than	O
15	O
years	O
had	O
the	O
highest	O
risk	O
for	O
serious	O
complications	O
from	O
influenza	B-DISO
and	O
highlighted	O
the	O
importance	O
of	O
start	O
of	O
antiviral	O
therapy	O
within	O
the	O
first	O
two	O
days	O
of	O
illness	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
for	O
the	O
most	O
severe	O
outcomes	O
of	O
influenza	B-DISO
,	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
lethal	O
outcome	O
.	O

HCoV	O
-	O
NL63	O
was	O
the	O
most	O
frequent	O
virus	O
detected	O
6	O
days	O
following	O
symptom	B-DISO
onset	O
(	O
8	O
.	O
9	O
%),	O
followed	O
by	O
rhinovirus	O
(	O
6	O
.	O
7	O
%).	O

During	O
a	O
3	O
-	O
month	O
period	O
covering	O
a	O
single	O
season	O
,	O
HCoVs	O
were	O
common	O
,	O
even	O
among	O
social	O
contacts	O
without	O
respiratory	B-DISO
symptoms	I-DISO
;	O
specific	O
symptoms	O
may	O
change	O
over	O
the	O
course	O
of	O
HCoV	O
-	O
associated	O
illness	O
and	O
were	O
similar	O
to	O
symptoms	O
from	O
influenza	B-DISO
and	O
rhinovirus	O
.	O

A	O
primary	O
sero	O
-	O
prevalence	O
study	O
of	O
MERS	O
-	O
CoV	O
preexisting	O
neutralizing	O
antibodies	O
in	O
Dromedary	O
camel	O
serum	O
was	O
conducted	O
in	O
Tabuk	O
,	O
western	O
north	O
region	O
of	O
KSA	O
,	O
in	O
order	O
to	O
assess	O
the	O
seopositivity	O
of	O
these	O
animals	O
and	O
to	O
explain	O
their	O
possible	O
role	O
in	O
the	O
transmission	O
of	O
the	O
infection	B-DISO
to	O
Human	O
.	O

Studies	O
reporting	O
information	O
about	O
the	O
treatment	O
of	O
MERS	O
coronavirus	B-DISO
infection	I-DISO
were	O
extracted	O
and	O
analyzed	O
.	O

The	O
role	O
of	O
S100A12	O
in	O
parasite	O
and	O
viral	B-DISO
infections	I-DISO
is	O
also	O
difficult	O
to	O
study	O
in	O
traditional	O
animal	O
models	O
due	O
to	O
the	O
lack	O
of	O
S100A12	O
expression	O
in	O
rodents	O
.	O

(	O
C	O
.	O
canis	O
and	O
C	O
.	O
ohioensis	O
),	O
Toxocara	O
canis	O
,	O
Giardia	B-DISO
sp	O
.,	O
as	O
well	O
as	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
and	O
parvovirus	B-DISO
(	O
CPV	O
).	O

The	O
results	O
of	O
logistic	O
regression	O
analyses	O
showed	O
that	O
age	O
,	O
urolithiasis	B-DISO
,	O
hyperuricemia	B-DISO
,	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
thiazide	O
drugs	O
intake	O
,	O
family	O
history	O
of	O
diabetes	B-DISO
and	O
hypertension	B-DISO
were	O
all	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
metabolic	B-DISO
syndrome	I-DISO
(	O
OR	O
>	O
1	O
).	O

Of	O
16928	O
NPSs	O
tested	O
for	O
the	O
common	O
viruses	O
,	O
4259	O
(	O
25	O
.	O
2	O
%)	O
were	O
positive	O
for	O
≥	O
1	O
target	O
;	O
596	O
(	O
13	O
.	O
8	O
%)	O
had	O
coinfections	B-DISO
.	O

ABSTRACT	O
:	O
Knowledge	O
of	O
risk	O
factors	O
for	O
symptomatic	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infections	B-DISO
in	O
children	O
in	O
community	O
settings	O
is	O
limited	O
.	O

We	O
estimated	O
the	O
disease	O
burden	O
and	O
impact	O
of	O
birth	O
-	O
related	O
,	O
maternal	O
,	O
household	O
,	O
and	O
seasonal	O
factors	O
on	O
HCoV	O
infections	B-DISO
among	O
children	O
from	O
birth	O
to	O
6	O
months	O
old	O
in	O
rural	O
Nepal	O
.	O

Prospective	O
,	O
active	O
,	O
weekly	O
surveillance	O
for	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
ARIs	O
)	O
was	O
conducted	O
in	O
infants	O
over	O
a	O
period	O
of	O
3	O
years	O
during	O
2	O
consecutive	O
,	O
population	O
-	O
based	O
randomized	O
trials	O
of	O
maternal	O
influenza	B-DISO
immunization	O
.	O

TITLE	O
:	O
Epidemiological	O
factors	O
and	O
worldwide	O
pattern	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
from	O
2013	O
to	O
2016	O
.	O

TITLE	O
:	O
Dairy	O
calf	O
rearing	O
unit	O
and	O
infectious	B-DISO
diseases	I-DISO
:	O
diarrhea	B-DISO
outbreak	O
by	O
bovine	O
coronavirus	O
as	O
a	O
model	O
for	O
the	O
dispersion	O
of	O
pathogenic	O
microorganisms	O
.	O

This	O
study	O
,	O
through	O
some	O
etiological	O
and	O
epidemiological	O
characteristics	O
of	O
an	O
outbreak	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
,	O
has	O
the	O
aim	O
to	O
alert	O
to	O
the	O
possibility	O
of	O
pathogenic	O
microorganism	O
spread	O
in	O
a	O
dairy	O
heifer	O
calf	O
rearing	O
unit	O
.	O

International	O
health	O
community	O
'	O
s	O
attention	O
goes	O
towards	O
this	O
mass	O
gathering	O
and	O
the	O
possibility	O
of	O
the	O
development	O
of	O
any	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
due	O
to	O
the	O
high	O
risk	O
of	O
acquisition	O
of	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Role	O
of	O
animal	O
movement	O
and	O
indirect	O
contact	O
among	O
farms	O
in	O
transmission	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

PE	O
patients	O
with	O
an	O
apnea	B-DISO
-	O
hypopnoea	O
index	O
(	O
AHI	O
)	O
≥	O
15	O
/	O
h	O
were	O
significantly	O
older	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
had	O
significantly	O
impaired	B-DISO
renal	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
left	O
ventricular	O
functions	O
(	O
p	O
=	O
0	O
.	O
003	O
),	O
showed	O
significantly	O
elevated	O
troponin	O
I	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
D	O
-	O
dimer	O
levels	O
(	O
p	O
=	O
0	O
.	O
024	O
),	O
were	O
hospitalised	O
significantly	O
longer	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
had	O
significantly	O
elevated	O
PE	O
severity	O
scores	O
(	O
p	O
=	O
0	O
.	O
015	O
).	O

TITLE	O
:	O
A	O
multiplex	O
PCR	O
method	O
for	O
the	O
simultaneous	O
detection	O
of	O
three	O
viruses	O
associated	O
with	O
canine	O
viral	O
enteric	O
infections	B-DISO
.	O

The	O
clinical	O
features	O
associated	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
are	O
not	O
MERS	O
-	O
specific	O
and	O
are	O
similar	O
to	O
other	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

A	O
thoughtful	O
approach	O
to	O
management	O
may	O
help	O
limit	O
potentially	O
harmful	O
fluid	O
administration	O
for	O
patients	O
with	O
ARDS	B-DISO
.	O

The	O
Norwegian	O
control	O
program	O
against	O
these	O
infections	B-DISO
is	O
based	O
on	O
herd	O
-	O
level	O
diagnosis	O
using	O
a	O
new	O
multiplex	O
immunoassay	O
.	O

SMA	B-DISO
stenting	O
was	O
performed	O
in	O
179	O
patients	O
,	O
of	O
whom	O
65	O
(	O
36	O
%)	O
had	O
EPDs	O
.	O

Distal	O
embolization	O
was	O
noted	O
in	O
four	O
patients	O
(	O
6	O
%),	O
of	O
whom	O
two	O
had	O
AMI	B-DISO
.	O

Two	O
patients	O
had	O
vessel	O
spasm	B-DISO
treated	O
by	O
nitroglycerin	O
.	O

The	O
high	O
levels	O
of	O
ALA	O
,	O
EPA	O
and	O
DHA	O
and	O
the	O
low	O
levels	O
of	O
myristic	O
,	O
palmitic	O
and	O
palmitoleic	O
acids	O
may	O
have	O
been	O
the	O
effect	O
of	O
flaxseed	O
feeding	O
14	O
days	O
post	O
-	O
weaning	O
and	O
may	O
have	O
had	O
a	O
reverse	O
effect	O
on	O
the	O
proliferation	B-DISO
and	O
apoptosis	O
of	O
ovarian	O
follicles	O
.	O

While	O
some	O
viruses	O
simply	O
cause	O
symptoms	O
of	O
the	O
common	B-DISO
cold	I-DISO
,	O
many	O
respiratory	O
viruses	O
induce	O
severe	O
bronchiolitis	B-DISO
,	O
pneumonia	B-DISO
,	O
and	O
even	O
death	O
following	O
infection	B-DISO
.	O

CD8	O
T	O
cells	O
are	O
critical	O
for	O
mediating	O
clearance	O
following	O
many	O
acute	O
viral	B-DISO
infections	I-DISO
in	O
the	O
lung	O
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	O
prevalence	O
and	O
outcomes	O
of	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
using	O
the	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
(	O
PALICC	O
)	O
criteria	O
and	O
Berlin	O
definitions	O
.	O

In	O
particular	O
,	O
respiratory	B-DISO
infections	I-DISO
are	O
problematic	O
;	O
in	O
early	O
2003	O
,	O
World	O
Health	O
Organization	O
issued	O
a	O
worldwide	O
alert	O
for	O
a	O
previously	O
unrecognized	O
illness	O
that	O
was	O
subsequently	O
found	O
to	O
be	O
caused	O
by	O
a	O
novel	O
coronavirus	O
[	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
].	O

BCoV	O
was	O
detected	O
in	O
22	O
.	O
72	O
%	O
(	O
10	O
/	O
44	O
)	O
of	O
the	O
animals	O
with	O
diarrhoea	B-DISO
and	O
in	O
10	O
%	O
(	O
7	O
/	O
70	O
)	O
of	O
asymptomatic	O
animals	O
.	O

Interestingly	O
,	O
blocking	B-DISO
C5a	O
production	O
by	O
targeting	O
its	O
receptor	O
,	O
C5aR	O
,	O
alleviated	O
lung	O
and	O
spleen	O
tissue	O
damage	O
and	O
reduced	O
inflammatory	B-DISO
responses	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
has	O
emerged	O
in	O
several	O
pig	O
-	O
raising	O
countries	O
and	O
has	O
been	O
a	O
causative	O
pathogen	O
associated	O
with	O
diarrheal	B-DISO
diseases	I-DISO
in	O
South	O
Korea	O
since	O
2014	O
.	O

ABSTRACT	O
:	O
The	O
recently	O
emerged	O
highly	O
virulent	O
variants	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
have	O
caused	O
colossal	O
economic	O
losses	O
to	O
the	O
worldwide	O
swine	O
industry	O
.	O

TITLE	O
:	O
Recognizing	O
and	O
managing	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
in	O
the	O
emergency	B-DISO
department	O
.	O

ABSTRACT	O
:	O
With	O
population	O
shifts	O
,	O
increased	O
travel	O
,	O
and	O
climate	O
change	O
,	O
the	O
spread	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
infections	B-DISO
is	O
increasing	O
.	O

A	O
high	O
level	O
of	O
vigilance	O
and	O
proper	O
disposition	O
will	O
enable	O
the	O
emergency	B-DISO
clinician	O
to	O
effectively	O
diagnose	O
,	O
manage	O
,	O
and	O
contain	O
these	O
diseases	O
.	O

Therefore	O
,	O
we	O
evaluated	O
extracorporeal	O
virus	O
and	O
glycoprotein	O
(	O
GP	O
)	O
elimination	O
by	O
lectin	O
affinity	O
plasmapheresis	O
(	O
LAP	B-DISO
).	O

Up	O
to	O
70	O
%	O
of	O
MARV	O
-	O
soluble	O
GPs	B-DISO
were	O
eliminated	O
at	O
the	O
same	O
time	O
.	O

Two	O
years	O
old	O
patient	O
was	O
successfully	O
disconnected	O
from	O
ECMO	O
and	O
in	O
stabile	O
condition	B-DISO
is	O
treated	O
in	O
Paediatric	O
Department	O
.	O

TITLE	O
:	O
miR	O
-	O
146a	O
-	O
5p	O
promotes	O
replication	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
by	O
targeting	O
IRAK2	O
and	O
TNFRSF18	O
.	O

A	O
discharge	O
home	O
at	O
the	O
time	O
of	O
index	O
admission	O
was	O
associated	O
an	O
increased	O
overall	O
survival	O
compared	O
with	O
any	O
other	O
discharge	O
location	O
(	O
P	O
<	O
.	O
001	O
).	O
We	O
report	O
good	O
early	O
outcomes	O
,	O
but	O
significant	O
long	O
-	O
term	O
morbidity	O
in	O
patients	O
with	O
severe	O
COPD	B-DISO
requiring	O
invasive	O
mechanical	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Autophagy	O
:	O
The	O
multi	O
-	O
purpose	O
bridge	O
in	O
viral	B-DISO
infections	I-DISO
and	O
host	O
cells	O
.	O

We	O
discuss	O
the	O
role	O
that	O
macroautophagy	O
plays	O
in	O
cells	O
infected	O
with	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
hepatitis	B-DISO
B	I-DISO
virus	O
,	O
rotavirus	B-DISO
gastroenteritis	I-DISO
,	O
immune	O
cells	O
infected	O
with	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
,	O
and	O
viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
both	O
influenza	B-DISO
virus	O
and	O
coronavirus	O
.	O

Full	O
S1	O
gene	B-DISO
amplification	I-DISO
was	O
achieved	O
using	O
primer	O
A	O
and	O
primer	O
22	O
.	O
51	O
.	O

ABSTRACT	O
:	O
Since	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
infection	B-DISO
was	O
first	O
reported	O
in	O
2012	O
,	O
many	O
studies	O
have	O
analysed	O
its	O
transmissibility	O
and	O
severity	O
.	O

We	O
searched	O
international	O
(	O
PubMed	O
,	O
ScienceDirect	O
,	O
Cochrane	O
)	O
and	O
Korean	O
databases	O
(	O
DBpia	O
,	O
KISS	O
)	O
for	O
English	O
-	O
or	O
Korean	O
-	O
language	O
articles	O
using	O
the	O
terms	O
""""	O
MERS	O
""""	O
and	O
""""	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
"""."	O

To	O
characterize	O
the	O
clinical	O
features	O
and	O
survival	O
rates	O
of	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
met	O
criteria	O
for	O
ECMO	O
but	O
were	O
managed	O
without	O
it	O
.	O

Inclusion	O
criteria	O
for	O
ECMO	O
included	O
severe	O
hypoxemia	O
,	O
uncompensated	O
hypercapnia	B-DISO
,	O
or	O
elevated	O
end	O
-	O
inspiratory	O
plateau	O
pressures	O
despite	O
low	O
tidal	O
volume	O
ventilation	O
.	O

Cough	B-DISO
Hypersensitivity	B-DISO
Syndrome	I-DISO
is	O
the	O
urge	O
to	O
cough	B-DISO
following	O
minimal	O
stimulation	O
,	O
but	O
its	O
mechanism	O
and	O
method	O
of	O
provocation	O
remain	O
unexplained	O
.	O

With	O
the	O
increasing	O
use	O
of	O
advanced	O
treatments	O
such	O
as	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
prone	O
positioning	O
,	O
and	O
continuous	O
renal	O
replacement	O
therapy	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
the	O
necessity	O
to	O
transport	O
these	O
patients	O
to	O
specialized	O
hospitals	O
will	O
correspondingly	O
increase	O
.	O

The	O
number	O
of	O
monthly	O
antibiotic	O
prescriptions	O
and	O
the	O
incidence	O
of	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
between	O
2010	O
and	O
2015	O
at	O
all	O
primary	O
care	O
clinics	O
were	O
obtained	O
from	O
the	O
Korean	O
Health	O
Insurance	O
Review	O
and	O
Assessment	O
Service	O
.	O

The	O
monthly	O
detection	O
rates	O
of	O
respiratory	O
viruses	O
,	O
including	O
adenovirus	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-DISO
virus	O
,	O
human	O
coronavirus	O
,	O
and	O
human	O
rhinovirus	O
,	O
were	O
collected	O
from	O
Korea	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O

Cross	O
-	O
correlation	O
analysis	O
was	O
conducted	O
to	O
quantify	O
the	O
temporal	O
relationship	O
between	O
antibiotic	O
use	O
and	O
respiratory	O
virus	O
activities	O
as	O
well	O
as	O
respiratory	B-DISO
infections	I-DISO
in	O
primary	O
clinics	O
.	O

TITLE	O
:	O
Pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
associated	O
with	O
human	O
metapneumovirus	O
and	O
respiratory	O
syncytial	O
virus	O
.	O

An	O
unexpected	O
pattern	O
of	O
repeat	O
infections	B-DISO
was	O
observed	O
with	O
some	O
individuals	O
showing	O
higher	O
viral	O
titers	O
during	O
their	O
second	O
infection	B-DISO
.	O

Repeat	O
infections	B-DISO
by	O
HCoV	O
-	O
NL63	O
were	O
not	O
accompanied	O
by	O
detectable	O
genotype	O
switching	O
.	O

Parainfluenza	B-DISO
virus	O
,	O
influenza	B-DISO
A	O
and	O
B	O
,	O
adenovirus	B-DISO
,	O
human	O
metapneumovirus	O
,	O
enterovirus	O
,	O
bocavirus	O
and	O
parechovirus	O
were	O
the	O
remaining	O
detected	O
agents	O
.	O

Respiratory	B-DISO
symptoms	I-DISO
(	O
cough	B-DISO
,	O
nasal	B-DISO
discharge	I-DISO
and	O
congestion	B-DISO
,	O
sneezing	O
,	O
wheezing	B-DISO
),	O
physical	O
examination	O
signs	O
(	O
rales	B-DISO
and	O
rhonchi	B-DISO
)	O
and	O
radiological	O
findings	O
were	O
significantly	O
more	O
common	O
in	O
viral	O
agent	O
positive	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Complete	O
brain	B-DISO
edema	I-DISO
was	O
prominent	O
,	O
and	O
encephalopathy	B-DISO
was	O
developing	O
.	O

ABSTRACT	O
:	O
Information	O
on	O
the	O
duration	O
of	O
replicative	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
shedding	O
is	O
important	O
for	O
infection	B-DISO
control	O
.	O

Recently	O
,	O
new	O
viruses	O
associated	O
with	O
recent	O
outbreaks	O
including	O
human	O
metapneumovirus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
have	O
been	O
discovered	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
QProbe	O
RT	O
-	O
LAMP	O
assays	O
described	O
here	O
can	O
be	O
used	O
as	O
powerful	O
diagnostic	O
tools	O
for	O
rapid	O
detection	O
and	O
surveillance	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
common	O
complication	B-DISO
in	O
patients	O
with	O
severe	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
),	O
for	O
whom	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
is	O
an	O
important	O
supportive	O
method	O
.	O

ABSTRACT	O
:	O
Early	O
pulmonary	B-DISO
interstitial	I-DISO
emphysema	I-DISO
in	O
extreme	O
preterm	O
neonates	O
is	O
closely	O
linked	O
with	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
and	O
exposure	O
to	O
mechanical	O
ventilation	O
.	O

Herein	O
,	O
we	O
report	O
on	O
very	O
low	O
birth	O
weight	O
twins	O
who	O
developed	O
early	O
pulmonary	B-DISO
interstitial	I-DISO
emphysema	I-DISO
during	O
noninvasive	O
respiratory	O
support	O
.	O

Despite	O
depicting	O
a	O
positive	O
scenario	O
,	O
the	O
development	O
of	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
-	O
focused	O
NGOs	O
in	O
China	O
generated	O
by	O
the	O
international	O
securitization	O
efforts	O
is	O
largely	O
limited	O
.	O

An	O
internal	O
and	O
external	O
factor	O
was	O
identified	O
to	O
verify	O
the	O
argument	O
,	O
namely	O
(	O
1	O
)	O
the	O
reduction	O
of	O
international	O
financial	O
commitments	O
,	O
as	O
well	O
as	O
(	O
2	O
)	O
the	O
fragmentation	B-DISO
of	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
-	O
focused	O
NGO	O
community	O
in	O
China	O
.	O

We	O
present	O
a	O
case	O
of	O
pneumoperitoneum	B-DISO
in	O
an	O
extremely	O
preterm	O
infant	O
with	O
severe	O
growth	O
restriction	O
.	O

TITLE	O
:	O
Porcine	O
Deltacoronavirus	O
Accessory	O
Protein	O
NS6	B-DISO
Antagonizes	O
Interferon	O
Beta	O
Production	O
by	O
Interfering	O
with	O
the	O
Binding	O
of	O
RIG	O
-	O
I	O
/	O
MDA5	O
to	O
Double	O
-	O
Stranded	O
RNA	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
PDCoV	O
encodes	O
three	O
accessory	O
proteins	O
,	O
NS6	B-DISO
,	O
NS7	B-DISO
,	O
and	O
NS7a	O
,	O
but	O
the	O
functions	O
of	O
these	O
proteins	O
in	O
viral	O
replication	O
,	O
pathogenesis	B-DISO
,	O
and	O
immune	O
regulation	O
remain	O
unclear	O
.	O

Further	O
analyses	O
revealed	O
that	O
NS6	B-DISO
is	O
not	O
an	O
RNA	O
-	O
binding	O
protein	O
;	O
however	O
,	O
it	O
interacts	O
with	O
RIG	O
-	O
I	O
/	O
MDA5	O
.	O

In	O
an	O
independent	O
cohort	O
of	O
subjects	O
with	O
ARDS	B-DISO
,	O
PD	O
-	O
L1	O
gene	O
expression	O
and	O
PD	O
-	O
L1	O
/	O
PD	O
-	O
1	O
pathway	O
-	O
associated	O
gene	O
sets	O
were	O
significantly	O
decreased	O
in	O
AMs	B-DISO
from	O
patients	O
who	O
experienced	O
prolonged	O
mechanical	O
ventilation	O
or	O
death	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
is	O
classified	O
into	O
two	O
biotypes	O
based	O
on	O
its	O
pathogenicity	O
in	O
cats	O
:	O
a	O
feline	O
enteric	O
coronavirus	O
of	O
low	O
pathogenicity	O
and	O
a	O
highly	O
virulent	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

The	O
GPHIN	O
'	O
s	O
early	O
adoption	O
of	O
Big	O
Data	O
has	O
increased	O
global	O
capacity	O
to	O
detect	O
international	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
and	O
other	O
public	O
health	O
events	O
.	O

Children	O
with	O
ARI	O
were	O
tested	O
for	O
influenza	B-DISO
viruses	O
by	O
polymerase	O
chain	O
reaction	O
.	O

Incidence	O
of	O
severe	O
influenza	B-DISO
-	O
associated	O
ARI	O
did	O
not	O
differ	O
(	O
IRR	O
:	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
11	O
-	O
1	O
.	O
38	O
).	O

Compared	O
to	O
high	O
-	O
risk	O
children	O
,	O
healthy	O
children	O
had	O
higher	O
incidence	O
of	O
mild	O
influenza	B-DISO
-	O
associated	O
ARI	O
but	O
not	O
severe	O
influenza	B-DISO
-	O
associated	O
ARI	O
.	O

The	O
ferret	O
had	O
a	O
2	O
-	O
wk	O
history	O
of	O
inappetence	O
,	O
weight	O
loss	O
,	O
and	O
lethargy	B-DISO
.	O

Exploratory	O
laparotomy	O
revealed	O
multiple	O
nodules	B-DISO
and	O
thickened	O
tissues	O
throughout	O
the	O
mesentery	O
,	O
a	O
thickened	O
and	O
nodular	O
pancreas	O
,	O
and	O
a	O
small	O
amount	O
of	O
free	O
abdominal	O
fluid	O
.	O

Fecal	O
pathogen	O
shedding	O
at	O
d	O
14	O
,	O
respiratory	B-DISO
disease	I-DISO
at	O
d	O
56	O
,	O
and	O
antibiotic	O
usage	O
were	O
compared	O
using	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
chi	O
-	O
squared	O
test	O
.	O

In	O
summary	O
,	O
feeding	O
anti	O
-	O
IL	O
-	O
10	O
antibodies	O
was	O
associated	O
with	O
increased	O
fecal	O
pH	O
,	O
reduced	O
risk	O
of	O
respiratory	B-DISO
disease	I-DISO
later	O
in	O
the	O
preweaning	O
period	O
,	O
and	O
decreased	O
antibiotic	O
usage	O
despite	O
higher	O
rotavirus	B-DISO
infection	I-DISO
.	O

The	O
mouse	O
macrophage	O
cell	O
line	O
(	O
J774	O
A	O
.	O
1	O
)	O
was	O
incubated	O
with	O
LPS	B-DISO
and	O
ATP	O
,	O
with	O
or	O
without	O
PFD	B-DISO
pre	O
-	O
treatment	O
.	O

Taken	O
together	O
,	O
the	O
administration	O
of	O
PFD	B-DISO
reduced	O
LPS	B-DISO
-	O
induced	O
lung	B-DISO
inflammation	I-DISO
and	O
fibrosis	B-DISO
by	O
blocking	B-DISO
NLRP3	O
inflammasome	O
activation	O
and	O
subsequent	O
IL	O
-	O
1β	O
secretion	O
.	O

These	O
findings	O
indicated	O
that	O
PFD	B-DISO
can	O
down	O
-	O
regulate	O
NLRP3	O
inflammasome	O
activation	O
and	O
that	O
it	O
may	O
offer	O
a	O
promising	O
therapeutic	O
approach	O
for	O
ARDS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
is	O
responsible	O
for	O
common	B-DISO
colds	I-DISO
.	O

At	O
3	O
and	O
12	O
months	O
after	O
hospital	O
discharge	O
,	O
we	O
assessed	O
patients	O
for	O
cognitive	B-DISO
impairment	I-DISO
,	O
disability	O
,	O
and	O
depression	B-DISO
.	O

Using	O
multivariable	O
logistic	O
regression	O
,	O
we	O
modeled	O
the	O
association	O
between	O
age	O
,	O
education	O
,	O
frailty	O
,	O
durations	O
of	O
mechanical	O
ventilation	O
,	O
delirium	B-DISO
,	O
and	O
severe	B-DISO
sepsis	I-DISO
with	O
the	O
odds	O
of	O
being	O
post	O
-	O
intensive	O
care	O
syndrome	B-DISO
free	O
.	O

In	O
this	O
multicenter	O
cohort	O
study	O
,	O
one	O
or	O
more	O
post	O
-	O
intensive	O
care	O
syndrome	B-DISO
problems	O
were	O
present	O
in	O
the	O
majority	O
of	O
survivors	O
,	O
but	O
co	O
-	O
occurring	O
problems	O
were	O
present	O
in	O
only	O
one	O
out	O
of	O
four	O
.	O

Education	O
was	O
protective	O
from	O
post	O
-	O
intensive	O
care	O
syndrome	B-DISO
problems	O
and	O
frailty	O
predictive	O
of	O
the	O
development	O
of	O
post	O
-	O
intensive	O
care	O
syndrome	B-DISO
problems	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
understand	O
better	O
the	O
heterogeneous	O
subtypes	O
of	O
post	O
-	O
intensive	O
care	O
syndrome	B-DISO
and	O
to	O
identify	O
modifiable	O
risk	O
factors	O
.	O

TITLE	O
:	O
Role	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
Viroporins	O
E	O
,	O
3a	O
,	O
and	O
8a	O
in	O
Replication	O
and	O
Pathogenesis	B-DISO
.	O

While	O
many	O
coronaviruses	O
(	O
CoVs	O
)	O
encode	O
two	O
viroporins	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
encodes	O
three	O
:	O
proteins	O
3a	O
,	O
E	O
,	O
and	O
8a	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
coinfection	B-DISO
of	O
S1	O
NTD	O
-	O
del	O
PEDV	O
variants	O
and	O
the	O
original	O
US	O
PEDV	O
strain	O
in	O
US	O
pigs	O
,	O
indicating	O
that	O
PEDV	O
continues	O
to	O
evolve	O
in	O
pigs	O
and	O
might	O
be	O
responsible	O
for	O
disease	O
pattern	O
changes	O
.	O

Additionally	O
,	O
cyclopropylquinoline	O
derivative	O
IV	O
has	O
shown	O
strong	O
growth	O
inhibitory	O
activity	O
towards	O
three	O
major	O
cancers	B-DISO
(	O
colon	O
,	O
breast	O
,	O
and	O
leukemia	B-DISO
)	O
cell	O
lines	O
and	O
moderate	O
growth	O
inhibition	O
shown	O
towards	O
other	O
cancer	B-DISO
cell	O
lines	O
screened	O
.	O

TITLE	O
:	O
Complete	O
Genome	O
Sequences	O
of	O
Four	O
Novel	O
Human	O
Coronavirus	O
OC43	O
Isolates	O
Associated	O
with	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Infection	I-DISO
.	O

TITLE	O
:	O
Monkey	O
viral	O
pathology	B-DISO
in	O
the	O
Sukhum	O
colony	O
and	O
modeling	O
human	O
viral	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
The	O
data	O
characterizing	O
spontaneous	O
infections	B-DISO
of	O
Old	O
World	O
monkeys	O
:	O
measles	B-DISO
,	O
poliomyelitis	B-DISO
,	O
hepatitis	B-DISO
A	I-DISO
(	O
HPA	O
),	O
encephalomyocarditis	O
,	O
coronavirus	B-DISO
infection	I-DISO
,	O
simian	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
(	O
SHF	O
),	O
are	O
presented	O
.	O

On	O
these	O
models	O
,	O
pathogenesis	B-DISO
and	O
epidemiology	O
of	O
these	O
diseases	O
were	O
studied	O
.	O

We	O
show	O
that	O
selected	O
human	O
genes	O
were	O
enriched	O
for	O
HIV	B-DISO
susceptibility	O
variants	O
(	O
identified	O
through	O
GWAS	O
),	O
providing	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
ancient	O
humans	O
were	O
exposed	O
to	O
lentivirus	O
pandemics	O
.	O

TITLE	O
:	O
Identification	O
and	O
application	O
of	O
self	O
-	O
binding	O
zipper	O
-	O
like	O
sequences	O
in	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

Against	O
human	O
coronavirus	O
229E	O
,	O
0	O
.	O
5	O
%	O
sodium	O
hypochlorite	O
alone	O
failed	O
disinfection	O
success	O
criteria	O
,	O
whereas	O
0	O
.	O
5	O
%	O
sodium	O
hypochlorite	O
with	O
color	O
additive	O
achieved	O
full	O
viral	O
inactivation	B-DISO
(≥	O
4	O
.	O
50	O
log	O
This	O
color	O
additive	O
can	O
be	O
combined	O
with	O
chlorine	O
disinfectants	O
without	O
adversely	O
affecting	O
antimicrobial	O
efficacy	O
or	O
skin	O
safety	O
.	O

TITLE	O
:	O
Molecular	O
dynamics	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
CoV	O
)	O
fusion	O
heptad	O
repeat	O
trimers	O
.	O

TITLE	O
:	O
Ultrapotent	O
Human	O
Neutralizing	O
Antibody	O
Repertoires	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
From	O
a	O
Recovered	O
Patient	O
.	O

TITLE	O
:	O
An	O
evaluation	O
of	O
emergency	B-DISO
guidelines	O
issued	O
by	O
the	O
World	O
Health	O
Organization	O
in	O
response	O
to	O
four	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

The	O
following	O
4	O
major	O
themes	O
emerged	O
:	O
""""	O
experiencing	O
burnout	O
owing	O
to	O
the	O
heavy	O
workload	O
","""	O
""""	O
relying	O
on	O
personal	O
protective	O
equipment	O
for	O
safety	O
","""	O
""""	O
being	O
busy	O
with	O
catching	B-DISO
up	O
with	O
the	O
new	O
guidelines	O
related	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
","""	O
and	O
""""	O
caring	O
for	O
suspected	O
or	O
infected	O
patients	O
with	O
caution	O
.	O

Unclear	O
and	O
frequently	O
changing	O
guidelines	O
were	O
1	O
of	O
the	O
common	O
causes	O
of	O
confusion	B-DISO
.	O

This	O
study	O
showed	O
that	O
creating	O
a	O
supportive	O
and	O
safe	O
work	O
environment	O
is	O
essential	O
by	O
ensuring	O
adequate	O
nurse	O
staffing	O
,	O
supplying	O
best	O
-	O
quality	O
personal	O
protective	O
equipment	O
,	O
and	O
improving	O
communication	O
to	O
provide	O
the	O
quality	O
of	O
care	O
during	O
infection	B-DISO
outbreak	O
.	O

In	O
the	O
age	O
-	O
group	O
(≥	O
2	O
,	O
<	O
5	O
),	O
Adv	O
predominated	O
with	O
37	O
/	O
147	O
samples	O
(	O
25	O
.	O
2	O
%),	O
followed	O
by	O
HRV	O
,	O
RSV	O
,	O
coronavirus	O
(	O
all	O
types	O
),	O
and	O
influenza	B-DISO
,	O
Hmpv	O
and	O
PIV	O
.	O

PHARLAP	O
is	O
a	O
phase	O
2	O
,	O
international	O
,	O
multicentre	O
,	O
prospective	O
,	O
randomised	O
,	O
controlled	O
,	O
parallel	O
-	O
group	O
clinical	O
trial	O
,	O
which	O
aims	O
to	O
determine	O
if	O
staircase	O
alveolar	O
recruitment	B-DISO
and	O
individually	O
titrated	O
PEEP	O
,	O
when	O
combined	O
with	O
permissive	O
hypercapnia	B-DISO
and	O
low	O
airway	O
pressures	O
,	O
increases	O
ventilator	O
-	O
free	O
days	O
to	O
Day	O
28	O
when	O
compared	O
with	O
conventional	O
mechanical	O
ventilation	O
(	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Clinical	O
Network	O
[	O
ARDSNet	O
]	O
strategy	O
)	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Contact	O
history	O
is	O
crucial	O
during	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
and	O
vital	O
when	O
seeking	O
to	O
understand	O
and	O
predict	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
in	O
human	O
populations	O
.	O

TITLE	O
:	O
The	O
prevalence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
antibodies	O
in	O
dromedary	O
camels	O
in	O
Israel	O
.	O

Multiple	O
studies	O
suggest	O
that	O
dromedary	O
camels	O
are	O
a	O
source	O
for	O
human	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Israel	O
'	O
s	O
geographic	O
location	O
places	O
Israel	O
at	O
risk	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
heterozygous	O
HNRNPU	O
variants	O
resulted	O
in	O
early	O
onset	O
epilepsy	B-DISO
and	O
severe	O
intellectual	B-DISO
disability	I-DISO
.	O

TITLE	O
:	O
Exploring	O
the	O
Determinants	O
of	O
Perceived	O
Risk	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Korea	O
.	O

TITLE	O
:	O
Central	B-DISO
Sleep	I-DISO
Apnea	I-DISO
-	O
a	O
Rare	O
Cause	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Insufficiency	I-DISO
in	O
Children	O
.	O

Following	O
physical	O
examination	O
,	O
laboratory	O
investigations	O
and	O
thoracic	B-DISO
radiography	O
,	O
we	O
established	O
the	O
diagnosis	O
of	O
aspiration	B-DISO
pneumonia	I-DISO
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

The	O
patient	O
underwent	O
neurosurgical	O
intervention	O
and	O
postoperatively	O
,	O
the	O
evolution	O
was	O
favorable	O
,	O
with	O
remission	B-DISO
of	O
apnea	B-DISO
crisis	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
enteropathogens	O
in	O
cats	O
with	O
and	O
without	O
diarrhea	B-DISO
in	O
four	O
different	O
management	O
models	O
for	O
unowned	O
cats	O
in	O
the	O
southeast	O
United	O
States	O
.	O

The	O
types	O
of	O
enteropathogens	O
detected	O
were	O
related	O
to	O
the	O
type	O
of	O
management	O
model	O
,	O
e	O
.	O
g	O
.,	O
viral	O
and	O
protozoal	O
infections	B-DISO
were	O
most	O
common	O
in	O
shelters	O
,	O
sanctuaries	O
,	O
and	O
foster	O
homes	O
(	O
confinement	O
systems	O
),	O
whereas	O
helminth	B-DISO
infections	I-DISO
were	O
most	O
common	O
in	O
trap	O
-	O
neuter	O
-	O
return	O
programs	O
(	O
free	O
-	O
roaming	O
cats	O
).	O

TITLE	O
:	O
Ulk1	O
Governs	O
Nerve	O
Growth	O
Factor	O
/	O
TrkA	O
Signaling	O
by	O
Mediating	O
Rab5	O
GTPase	O
Activation	O
in	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	B-DISO
Virus	O
-	O
Induced	O
Neurodegenerative	B-DISO
Disorders	I-DISO
.	O

We	O
then	O
showed	O
that	O
Ulk1	O
forms	O
a	O
multiprotein	O
complex	O
with	O
TrkA	O
and	O
the	O
early	O
endosome	O
marker	O
Rab5	O
and	O
that	O
Ulk1	O
defects	O
lead	O
to	O
either	O
blocking	B-DISO
of	O
NGF	O
/	O
TrkA	O
endocytosis	O
or	O
premature	O
degradation	O
of	O
pTrkA	O
via	O
constitutive	O
activation	O
of	O
the	O
Rab5	O
GTPase	O
.	O

TITLE	O
:	O
Nasal	O
priming	O
by	O
a	O
murine	O
coronavirus	O
provides	O
protective	O
immunity	O
against	O
lethal	O
heterologous	O
virus	O
pneumonia	B-DISO
.	O

Immunogenic	O
particles	O
in	O
inspired	O
air	O
are	O
known	O
to	O
activate	O
the	O
local	O
nasal	O
mucosal	O
immune	O
system	O
and	O
can	O
lead	O
to	O
sinonasal	O
inflammation	B-DISO
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
effect	O
of	O
this	O
activation	O
on	O
the	O
lung	O
immune	O
environment	O
.	O

ABSTRACT	O
:	O
In	O
April	O
2013	O
,	O
severe	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
outbreaks	O
first	O
appeared	O
in	O
USA	O
,	O
causing	O
significant	O
financial	O
losses	O
.	O

APN	O
and	O
EGFR	O
synergistically	O
promote	O
TGEV	O
invasion	B-DISO
.	O

The	O
mean	O
abbreviated	O
burn	O
severity	O
index	O
(	O
ABSI	O
)	O
was	O
10	O
.	O
6	O
±	O
1	O
.	O
5	O
in	O
the	O
ARDS	B-DISO
group	O
and	O
6	O
.	O
6	O
±	O
2	O
.	O
3	O
in	O
the	O
non	O
-	O
ARDS	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
)	O
group	O
.	O

In	O
addition	O
we	O
found	O
that	O
Rhinovirus	O
B14	O
,	O
C15	O
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
induce	O
significant	O
increase	O
of	O
β	O
Defensins	O
2	O
and	O
Cathelicidin	O
release	O
with	O
different	O
time	O
course	O
.	O

TITLE	O
:	O
Apigenin	O
C	O
-	O
glycosides	O
of	O
Microcos	O
paniculata	O
protects	O
lipopolysaccharide	O
induced	O
apoptosis	O
and	O
inflammation	B-DISO
in	O
acute	O
lung	O
injury	O
through	O
TLR4	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
an	O
acute	O
,	O
highly	O
contagious	B-DISO
disease	I-DISO
,	O
which	O
causes	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

TITLE	O
:	O
Immunocompromised	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
secondary	O
analysis	O
of	O
the	O
LUNG	O
SAFE	O
database	O
.	O

Of	O
2813	O
patients	O
with	O
ARDS	B-DISO
,	O
584	O
(	O
20	O
.	O
8	O
%)	O
were	O
immunocompromised	O
,	O
38	O
.	O
9	O
%	O
of	O
whom	O
had	O
an	O
unspecified	O
cause	O
.	O

Pneumonia	B-DISO
,	O
nonpulmonary	O
sepsis	B-DISO
,	O
and	O
noncardiogenic	O
shock	O
were	O
their	O
most	O
common	O
risk	O
factors	O
for	O
ARDS	B-DISO
.	O

Renal	O
failure	O
,	O
metabolic	B-DISO
acidosis	I-DISO
appeared	O
to	O
be	O
good	O
predictors	O
of	O
mortality	O
.	O

ABSTRACT	O
:	O
Recent	O
reports	O
on	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
critically	B-DISO
ill	I-DISO
burn	O
patients	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
recommended	O
against	O
the	O
use	O
of	O
ECMO	O
.	O

We	O
included	O
only	O
adult	O
patients	O
who	O
had	O
been	O
placed	O
on	O
ECMO	O
with	O
burn	O
injury	O
,	O
TEN	O
,	O
or	O
inhalation	O
injury	O
and	O
severe	O
ARDS	B-DISO
.	O

CASE	O
REPORT	O
A	O
42	O
-	O
year	O
-	O
old	O
woman	O
presented	O
to	O
a	O
rural	O
medical	O
facility	O
with	O
bilateral	O
lower	O
-	O
limb	B-DISO
swelling	I-DISO
and	O
skin	O
darkening	O
for	O
2	O
days	O
.	O

Spine	O
magnetic	O
resonance	O
imaging	O
showed	O
abnormal	O
enhancement	O
of	O
the	O
conus	O
medullaris	O
with	O
thick	O
enhanced	O
cauda	O
equina	B-DISO
nerve	O
roots	O
,	O
consistent	O
with	O
a	O
possible	O
case	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
.	O

TITLE	O
:	O
Serologic	O
Follow	O
-	O
up	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Cases	O
and	O
Contacts	O
-	O
Abu	O
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
.	O

No	O
difference	O
was	O
found	O
in	O
the	O
frequency	O
of	O
RSVA	O
(	O
16	O
.	O
1	O
%	O
vs	O
.	O
14	O
.	O
6	O
%;	O
P	O
=	O
0	O
.	O
6	O
),	O
RSVB	O
(	O
10	O
.	O
9	O
%	O
vs	O
.	O
13	O
.	O
2	O
%;	O
P	O
=	O
0	O
.	O
4	O
)	O
influenza	B-DISO
(	O
Flu	B-DISO
)	O
A	O
(	O
6	O
.	O
3	O
%	O
vs	O
.	O
5	O
.	O
1	O
%;	O
P	O
=	O
0	O
.	O
5	O
),	O
FluB	O
(	O
4	O
.	O
5	O
%	O
vs	O
.	O
1	O
.	O
8	O
%;	O
P	O
=	O
0	O
.	O
09	O
),	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
1	O
(	O
5	O
.	O
1	O
%	O
vs	O
.	O
2	O
.	O
8	O
%;	O
P	O
=	O
0	O
.	O
2	O
),	O
or	O
PIV4	O
(	O
7	O
.	O
7	O
%	O
vs	O
.	O
4	O
.	O
1	O
%;	O
P	O
=	O
0	O
.	O
08	O
),	O
when	O
children	O
with	O
multiple	O
or	O
sole	O
virus	O
detection	O
were	O
compared	O
.	O

Conversely	O
,	O
rhinovirus	O
,	O
adenovirus	B-DISO
,	O
enterovirus	O
,	O
bocavirus	O
,	O
PIV2	O
,	O
PIV3	O
,	O
metapneumovirus	O
,	O
coronavirus	O
OC43	O
,	O
NL63	O
,	O
229E	O
were	O
significantly	O
more	O
frequent	O
among	O
cases	O
with	O
multiple	O
virus	O
detection	O
.	O

We	O
studied	O
one	O
mechanism	O
by	O
which	O
vomiting	B-DISO
is	O
induced	O
in	O
pigs	O
infected	O
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
by	O
characterization	O
of	O
swine	O
EC	O
cells	O
by	O
immunohistochemistry	O
.	O

Influenza	B-DISO
viruses	O
were	O
detected	O
in	O
18	O
%	O
of	O
the	O
specimens	O
and	O
any	O
respiratory	O
virus	O
in	O
47	O
%.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
,	O
a	O
pathogen	O
first	O
detected	O
in	O
US	O
domestic	O
swine	O
in	O
2013	O
,	O
has	O
rapidly	O
spilled	O
over	O
into	O
feral	O
swine	O
populations	O
.	O

FHS	B-DISO
-	O
1	O
cells	O
were	O
positive	O
for	O
α	O
-	O
naphthyl	O
butyrate	O
esterase	O
staining	O
,	O
which	O
was	O
clearly	O
inhibited	O
by	O
sodium	O
fluoride	O
.	O

Moreover	O
,	O
FHS	B-DISO
-	O
1	O
cells	O
were	O
tested	O
for	O
susceptibility	O
to	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
strain	O
79	O
-	O
1146	O
;	O
however	O
,	O
this	O
cell	O
line	O
was	O
not	O
susceptible	O
to	O
this	O
viral	O
strain	O
.	O

Therefore	O
,	O
in	O
Africa	O
,	O
most	O
malaria	B-DISO
infections	B-DISO
are	O
by	O
P	O
.	O
falciparum	O
and	O
the	O
highest	O
burden	O
of	O
P	O
.	O
vivax	O
infection	B-DISO
is	O
in	O
Southeast	O
Asia	O
and	O
South	O
America	O
.	O

TITLE	O
:	O
[	O
The	O
incidences	O
of	O
organ	O
dysfunction	O
in	O
the	O
early	O
resuscitation	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
patients	O
:	O
a	O
retrospective	O
analysis	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
potential	O
risk	O
factors	O
of	O
organ	O
dysfunction	O
and	O
mortality	O
in	O
the	O
early	O
resuscitation	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
patients	O
.	O

TITLE	O
:	O
High	O
flow	O
nasal	O
cannula	O
oxygen	O
versus	O
noninvasive	O
ventilation	O
in	O
adult	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
:	O
a	O
systematic	O
review	O
of	O
randomized	O
-	O
controlled	O
trials	O
.	O

Patients	O
were	O
postcardiothoracic	O
surgery	O
,	O
mixed	O
medical	O
/	O
surgical	O
patients	O
and	O
those	O
with	O
pneumonia	B-DISO
.	O

Here	O
,	O
we	O
report	O
four	O
crystal	O
structures	O
,	O
including	O
wild	O
-	O
type	O
porcine	O
delta	O
coronavirus	O
(	O
PDCoV	O
)	O
nsp9	O
,	O
PDCoV	O
nsp9	O
-	O
ΔN7	O
(	O
N	O
-	O
terminal	O
7	O
amino	O
acids	O
deleted	O
),	O
wild	O
-	O
type	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
nsp9	O
,	O
and	O
PEDV	O
nsp9	O
-	O
C59A	O
mutant	B-DISO
.	O

H7N9	O
-	O
specific	O
antibody	O
concentrations	O
declined	O
over	O
time	O
,	O
and	O
protective	O
antibodies	O
persisted	O
longer	O
in	O
severely	O
ill	B-DISO
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
patients	O
presenting	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
than	O
in	O
patients	O
with	O
mild	O
disease	O
.	O

TITLE	O
:	O
Breakthrough	O
infection	B-DISO
of	O
Geotrichum	O
capitatum	O
during	O
empirical	O
caspofungin	O
therapy	O
after	O
umbilical	O
cord	B-DISO
blood	O
transplantation	O
.	O

Progressive	O
renal	O
and	O
hepatic	B-DISO
dysfunction	I-DISO
subsequently	O
developed	O
.	O

Carriage	O
was	O
shown	O
to	O
vary	O
with	O
age	O
,	O
recent	O
RTI	B-DISO
and	O
the	O
presence	O
of	O
other	O
species	O
.	O

Immunoblotting	O
and	O
magnetic	O
beads	O
immunoisolation	O
complemented	O
by	O
standardized	O
flow	O
cytometry	O
and	O
nanoparticles	O
tracking	O
analyses	O
identified	O
in	O
the	O
ARDS	B-DISO
patients	O
a	O
subset	O
of	O
EVs	O
with	O
mesenchymal	O
stem	O
cell	O
(	O
MSC	O
)	O
origin	O
(	O
CD73	O

TITLE	O
:	O
Factors	O
associated	O
with	O
severity	O
and	O
mortality	O
in	O
patients	O
with	O
confirmed	O
leptospirosis	B-DISO
at	O
a	O
regional	O
hospital	O
in	O
northern	O
Taiwan	O
.	O

The	O
major	O
complications	O
were	O
pulmonary	B-DISO
involvement	I-DISO
(	O
54	O
%),	O
shock	O
(	O
44	O
%),	O
ventilator	O
support	O
(	O
32	O
%),	O
jaundice	B-DISO
(	O
32	O
%),	O
hemorrhage	B-DISO
(	O
30	O
%),	O
acute	O
kidney	O
injury	O
(	O
30	O
%),	O
meningitis	B-DISO
(	O
11	O
%)	O
and	O
myocarditis	B-DISO
(	O
2	O
%).	O

Additionally	O
,	O
an	O
outbreak	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
may	O
have	O
occurred	O
in	O
Ras	O
Tanura	O
city	O
between	O
April	O
2015	O
and	O
February	O
2016	O
.	O

Moreover	O
,	O
cyt	O
c	O
release	O
was	O
completely	O
abrogated	O
in	O
PDCoV	O
-	O
infected	O
cells	O
in	O
the	O
presence	O
of	O
CsA	B-DISO
,	O
suggesting	O
the	O
critical	O
role	O
of	O
MPTP	O
in	O
intrinsic	O
apoptosis	O
in	O
response	O
to	O
PDCoV	O
infection	B-DISO
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
PDCoV	O
infection	B-DISO
stimulates	O
MOMP	O
either	O
via	O
Bax	O
recruitment	B-DISO
or	O
MPTP	O
opening	O
to	O
permit	O
the	O
release	O
of	O
apoptogenic	O
cyt	O
c	O
into	O
the	O
cytoplasm	O
,	O
thereby	O
leading	O
to	O
execution	O
of	O
the	O
caspase	O
-	O
dependent	O
intrinsic	O
apoptosis	O
pathway	O
to	O
facilitate	O
viral	O
replication	O
in	O
vitro	O
.	O

It	O
is	O
difficult	O
to	O
establish	O
a	O
causal	O
link	O
between	O
alcohol	O
and	O
lung	B-DISO
cancer	I-DISO
as	O
the	O
lung	B-DISO
cancer	I-DISO
risk	O
is	O
likely	O
confounded	O
by	O
the	O
effect	O
of	O
smoking	O
.	O

The	O
pulmonary	O
effects	O
of	O
alcohol	O
misuse	O
are	O
many	O
but	O
further	O
investigations	O
into	O
the	O
mechanism	O
by	O
which	O
alcohol	O
might	O
predispose	O
to	O
lung	B-DISO
cancer	I-DISO
are	O
necessary	O
.	O

CONCLUSIONS	O
:	O
The	O
pulmonary	O
effects	O
of	O
alcohol	O
misuse	O
are	O
many	O
but	O
further	O
investigations	O
into	O
the	O
mechanism	O
by	O
which	O
alcohol	O
might	O
predispose	O
to	O
lung	B-DISO
cancer	I-DISO
are	O
necessary	O
.	O

TITLE	O
:	O
Distinct	O
Gene	O
Profiles	O
of	O
Bone	O
Marrow	O
-	O
Derived	O
Macrophages	O
and	O
Microglia	O
During	O
Neurotropic	O
Coronavirus	O
-	O
Induced	O
Demyelination	B-DISO
.	O

Using	O
a	O
murine	O
model	O
of	O
demyelination	B-DISO
induced	O
by	O
a	O
gliatropic	O
coronavirus	O
,	O
in	O
which	O
BMDM	O
are	O
redundant	O
for	O
demyelination	B-DISO
,	O
we	O
herein	O
characterize	O
gene	O
expression	O
profiles	O
of	O
BMDM	O
versus	O
microglia	O
associated	O
with	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
Tonsils	O
provide	O
an	O
innovative	O
in	O
vivo	O
model	O
for	O
investigating	O
immune	O
response	O
to	O
infections	B-DISO
and	O
allergens	O
.	O

Besides	O
identified	O
risk	O
factors	O
for	O
CAP	B-DISO
,	O
there	O
may	O
be	O
a	O
phenotype	O
-	O
genotype	O
association	O
with	O
cytokines	O
,	O
resulting	O
in	O
enhanced	O
inflammatory	B-DISO
response	I-DISO
resulting	O
in	O
the	O
adverse	O
outcome	O
(	O
AO	O
),	O
namely	O
complications	O
and	O
death	O
.	O

ABSTRACT	O
:	O
We	O
identified	O
novel	O
linear	O
epitopes	O
on	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
spike	O
S2	O
region	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
IBV	O
spike	O
S2	O
epitopes	O
located	O
in	O
the	O
proximity	O
of	O
the	O
fusion	O
peptide	O
,	O
and	O
it	O
is	O
suggested	O
that	O
the	O
spike	O
fusion	O
machinery	O
of	O
IBV	O
may	O
differ	O
from	O
that	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
or	O
,	O
alternatively	O
,	O
IBV	O
may	O
have	O
another	O
mechanism	O
to	O
penetrate	O
the	O
cell	O
membrane	O
.	O

Worldwide	O
2048	O
laboratory	O
confirmed	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
were	O
reported	O
from	O
June	O
2012	O
to	O
the	O
Dec	O
2017	O
.	O

The	O
pattern	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
has	O
been	O
observed	O
to	O
have	O
seasonal	O
variations	O
.	O

TITLE	O
:	O
A	O
Novel	O
Nanobody	O
Targeting	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Receptor	O
-	O
Binding	O
Domain	O
Has	O
Potent	O
Cross	O
-	O
Neutralizing	O
Activity	O
and	O
Protective	O
Efficacy	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
infect	O
humans	O
and	O
camels	O
,	O
calling	O
for	O
efficient	O
,	O
cost	O
-	O
effective	O
,	O
and	O
broad	O
-	O
spectrum	O
strategies	O
to	O
control	O
its	O
spread	O
.	O

Nanobodies	O
(	O
Nbs	B-DISO
)	O
are	O
single	O
-	O
domain	O
antibodies	O
derived	O
from	O
camelids	O
and	O
sharks	O
and	O
are	O
potentially	O
cost	O
-	O
effective	O
antivirals	O
with	O
small	O
size	O
and	O
great	O
expression	O
yield	O
.	O

We	O
further	O
tested	O
their	O
receptor	O
-	O
binding	O
affinity	O
,	O
recognizing	O
epitopes	O
,	O
cross	O
-	O
neutralizing	O
activity	O
,	O
half	O
-	O
life	O
,	O
and	O
efficacy	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Relationship	O
between	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
,	O
outcome	O
and	O
the	O
revised	O
Atlanta	O
and	O
determinant	O
-	O
based	O
classifications	O
in	O
acute	B-DISO
pancreatitis	I-DISO
.	O

A	O
higher	O
IAH	O
grade	O
was	O
more	O
likely	O
in	O
patients	O
with	O
severe	O
AP	O
(	O
42	O
per	O
cent	O
for	O
grade	O
I	O
versus	O
84	O
per	O
cent	O
for	O
grade	O
IV	O
)	O
and	O
acute	O
critical	O
pancreatitis	B-DISO
(	O
9	O
versus	O
25	O
per	O
cent	O
;	O
P	O
=	O
0	O
·	O
001	O
).	O

0	O
·	O
73	O
to	O
0	O
·	O
84	O
),	O
respiratory	B-DISO
failure	I-DISO
(	O
AUC	O
0	O
·	O
82	O
,	O
0	O
·	O
77	O
to	O
0	O
·	O
87	O
),	O
renal	B-DISO
failure	I-DISO
(	O
AUC	O
0	O
·	O
93	O
,	O
0	O
·	O
89	O
to	O
0	O
·	O
96	O
)	O
and	O
mortality	O
(	O
AUC	O
0	O
·	O
89	O
,	O
0	O
·	O
86	O
to	O
0	O
·	O
93	O
).	O

TITLE	O
:	O
Organelle	O
dynamics	O
and	O
viral	B-DISO
infections	I-DISO
:	O
at	O
cross	O
roads	O
.	O

More	O
importantly	O
,	O
piglets	O
immunized	O
with	O
the	O
S	O
-	O
Bac	O
exhibited	O
no	O
to	O
mild	O
clinical	O
signs	O
,	O
with	O
a	O
delayed	O
,	O
minimal	O
viral	B-DISO
shedding	I-DISO
.	O

Patients	O
with	O
splenic	O
rupture	O
due	O
to	O
human	B-DISO
babesiosis	I-DISO
were	O
successfully	O
treated	O
by	O
various	O
management	O
strategies	O
,	O
such	O
as	O
conservative	O
non	O
-	O
operative	O
approach	O
,	O
splenic	O
artery	O
embolization	O
,	O
and	O
splenectomy	O
.	O

It	O
has	O
been	O
proposed	O
that	O
in	O
these	O
conditions	O
,	O
bacteria	O
from	O
the	O
gut	O
might	O
enter	O
the	O
lungs	O
via	O
translocation	B-DISO
,	O
a	O
process	O
facilitated	O
by	O
increased	O
gut	O
and	O
alveolo	O
-	O
capillary	O
permeability	O
.	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
protease	O
also	O
called	O
the	O
main	O
protease	O
is	O
an	O
essential	O
enzyme	O
for	O
the	O
completion	O
of	O
the	O
life	O
cycle	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
.	O

In	O
our	O
study	O
we	O
predicted	O
compounds	O
which	O
are	O
capable	O
of	O
inhibiting	O
3C	O
-	O
like	O
protease	O
,	O
and	O
thus	O
inhibit	O
the	O
lifecycle	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
using	O
in	O
silico	O
methods	O
.	O

Their	O
clinical	O
phenotypes	O
including	O
laboratory	O
test	O
results	O
,	O
high	O
-	O
resolution	O
lung	O
computed	O
tomography	O
data	O
,	O
response	O
to	O
therapy	O
,	O
and	O
prognosis	O
were	O
compared	O
between	O
those	O
who	O
were	O
positive	O
and	O
negative	O
for	O
MAAs	O
,	O
such	O
as	O
antinuclear	O
antibody	O
(	O
ANA	O
),	O
anti	O
-	O
cyclic	O
citrullinated	O
peptide	O
(	O
CCP	B-DISO
),	O
anti	O
-	O
SSA	O
,	O
and	O
anti	O
-	O
SSB	O
antibodies	O
.	O

Among	O
24	O
patients	O
,	O
9	O
(	O
37	O
.	O
5	O
%)	O
additionally	O
had	O
at	O
least	O
one	O
of	O
the	O
MAAs	O
examined	O
in	O
this	O
study	O
:	O
1	O
patient	O
was	O
positive	O
for	O
ANA	O
,	O
5	O
for	O
anti	O
-	O
CCP	B-DISO
,	O
5	O
for	O
either	O
anti	O
-	O
SSA	O
or	O
anti	O
-	O
SSB	O
,	O
1	O
for	O
anti	O
-	O
cardiolipin	O
,	O
and	O
1	O
for	O
anti	O
-	O
Scl	O
-	O
70	O
.	O

Endocan	O
blood	O
values	O
at	O
inclusion	O
were	O
significantly	O
lower	O
in	O
patients	O
who	O
developed	O
an	O
ARDS	B-DISO
at	O
72	O
h	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Prevention	O
,	O
early	O
recognition	O
,	O
and	O
treatment	O
of	O
ARDS	B-DISO
after	O
trauma	O
are	O
potentially	O
important	O
objectives	O
for	O
efforts	O
to	O
control	O
health	O
care	O
costs	O
in	O
this	O
population	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
heat	O
-	O
labile	O
enterotoxin	O
B	O
subunit	O
-	O
adjuvanted	O
parenteral	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
trimeric	O
spike	O
subunit	O
vaccine	O
in	O
piglets	O
.	O

TITLE	O
:	O
[	O
Development	O
of	O
Novel	O
Multiplex	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
Assays	O
for	O
Detection	O
of	O
MERS	O
-	O
CoV	O
Infection	B-DISO
].	O

It	O
was	O
another	O
coronavirus	O
which	O
resulted	O
in	O
severe	O
infection	B-DISO
of	O
humans	O
,	O
apart	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

To	O
date	O
,	O
several	O
small	O
animals	O
(	O
e	O
.	O
g	O
.,	O
mice	O
,	O
Syrian	O
hamsters	O
,	O
and	O
ferrets	O
)	O
have	O
been	O
used	O
to	O
study	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ANIMALS	O
380	O
client	O
-	O
owned	O
cats	O
with	O
a	O
diagnosis	O
of	O
pleural	B-DISO
effusion	I-DISO
from	O
January	O
1	O
,	O
2009	O
,	O
through	O
July	O
14	O
,	O
2014	O
,	O
for	O
which	O
the	O
cause	O
of	O
pleural	B-DISO
effusion	I-DISO
had	O
been	O
fully	O
investigated	O
.	O

Examination	O
revealed	O
diminished	O
bilateral	O
vesicular	B-DISO
breath	I-DISO
sounds	I-DISO
,	O
fever	O
,	O
intense	O
yellow	O
tracheal	O
secretions	O
,	O
a	O
respiratory	O
rate	O
of	O
24	O
/	O
minute	O
,	O
a	O
heart	O
rate	O
of	O
123	O
/	O
minute	O
,	O
and	O
blood	O
pressure	O
of	O
75	O
/	O
55	O
mmHg	O
.	O

TITLE	O
:	O
Post	O
-	O
Pneumonectomy	O
ARDS	B-DISO
and	O
Ogilvie	B-DISO
Syndrome	I-DISO
-	O
A	O
Case	O
Report	O
.	O

This	O
report	O
covers	O
an	O
ARDS	B-DISO
case	O
occurring	O
post	O
left	O
pneumonectomy	O
,	O
with	O
a	O
favorable	O
outcome	O
,	O
despite	O
association	O
with	O
an	O
acute	O
colonic	B-DISO
pseudo	I-DISO
-	I-DISO
obstruction	I-DISO
syndrome	B-DISO
(	O
Ogilvie	B-DISO
syndrome	I-DISO
)	O
that	O
required	O
abdominal	O
surgery	O
for	O
decompression	O
.	O

TITLE	O
:	O
Better	O
horizontal	O
transmission	O
of	O
a	O
US	O
non	O
-	O
InDel	O
strain	O
compared	O
with	O
a	O
French	O
InDel	O
strain	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
.	O

We	O
report	O
herein	O
on	O
the	O
successful	O
treatment	O
of	O
a	O
two	O
-	O
year	O
-	O
old	O
female	O
child	O
with	O
TB	O
pneumonia	B-DISO
-	O
induced	O
severe	O
ARDS	B-DISO
complicated	O
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
).	O

In	O
the	O
United	O
States	O
,	O
sepsis	B-DISO
mortality	O
approaches	O
that	O
of	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
and	O
exceeds	O
deaths	O
from	O
stroke	B-DISO
.	O

While	O
the	O
lungs	O
remain	O
the	O
principal	O
organ	O
of	O
interest	O
due	O
to	O
sepsis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
""""	O
septic	O
heart	O
""""	O
or	O
""""	O
septic	O
cardiomyopathy	B-DISO
""""	O
accelerates	O
sepsis	B-DISO
'	O
transition	B-DISO
to	O
potentially	O
lethal	O
septic	B-DISO
shock	I-DISO
.	O

NTMs	O
target	O
the	O
translocation	B-DISO
of	O
proinflammatory	O
and	O
metabolic	O
transcription	O
factors	O
to	O
the	O
cell	O
'	O
s	O
nucleus	O
while	O
also	O
enhancing	O
bacterial	O
clearance	O
in	O
experimental	O
polymicrobial	O
sepsis	B-DISO
models	O
.	O

Similarly	O
,	O
the	O
incidence	O
of	O
meningococcal	B-DISO
sepsis	I-DISO
known	O
as	O
""""	O
purpura	B-DISO
fulminans	I-DISO
""""	O
has	O
been	O
reduced	O
by	O
a	O
recently	O
approved	O
vaccine	O
thereby	O
preventing	O
hearing	B-DISO
loss	I-DISO
,	O
neurologic	O
damage	O
,	O
and	O
limb	O
amputations	O
in	O
young	O
survivors	O
of	O
septic	O
outbreaks	O
.	O

TITLE	O
:	O
Preparedness	O
and	O
response	O
against	O
diseases	O
with	O
epidemic	O
potential	O
in	O
the	O
European	O
Union	O
:	O
a	O
qualitative	O
case	O
study	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
and	O
poliomyelitis	B-DISO
in	O
five	O
member	O
states	O
.	O

Although	O
the	O
formal	O
protocols	O
for	O
inter	O
-	O
sectoral	O
collaboration	O
were	O
not	O
always	O
up	O
to	O
date	O
,	O
good	O
personal	O
relations	O
were	O
reported	O
within	O
the	O
relevant	O
professional	O
networks	O
,	O
which	O
could	O
be	O
brought	O
into	O
play	O
in	O
the	O
event	O
of	O
a	O
public	O
health	O
emergency	B-DISO
.	O

RESULTS	O
:	O
Preparedness	O
and	O
response	O
plans	O
for	O
MERS	O
and	O
poliomyelitis	B-DISO
were	O
in	O
place	O
in	O
the	O
participating	O
countries	O
,	O
with	O
a	O
high	O
level	O
of	O
technical	O
expertise	O
available	O
to	O
implement	O
them	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	O
oxide	O
mitigates	O
need	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
a	O
patient	O
with	O
refractory	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
cardiac	O
and	O
pulmonary	O
shunts	O
.	O

Nitric	O
oxide	O
has	O
not	O
demonstrated	O
any	O
statistically	O
significant	O
effect	O
on	O
mortality	O
and	O
only	O
reported	O
to	O
transiently	O
improved	O
oxygenation	O
in	O
patients	O
with	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
Co	O
V	O
)	O
is	O
a	O
RNA	O
virus	O
causing	O
serious	O
harm	O
to	O
people	O
.	O

The	O
primary	O
outcome	O
was	O
development	O
of	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
ARDS	B-DISO
.	O

Two	O
thousand	O
two	O
hundred	O
and	O
seventy	O
-	O
two	O
patients	O
who	O
did	O
not	O
develop	O
ARDS	B-DISO
served	O
as	O
controls	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
the	O
highly	O
contagious	O
,	O
causative	O
agent	O
of	O
an	O
economically	O
important	O
acute	O
enteric	O
disease	O
in	O
pigs	O
of	O
all	O
ages	O
.	O

The	O
epidemiological	O
situation	O
of	O
PEDV	O
infections	B-DISO
in	O
the	O
Netherlands	O
in	O
2014	O
was	O
unknown	O
and	O
a	O
seroprevalence	O
study	O
in	O
swine	O
was	O
performed	O
.	O

Upon	O
serial	O
passages	O
into	O
Vero	O
cells	O
,	O
PED	O
-	O
CUP	B-DISO
-	O
B2014	O
adapted	O
to	O
Vero	O
cells	O
,	O
which	O
was	O
evidenced	O
as	O
higher	O
virus	O
growth	O
in	O
Vero	O
cells	O
and	O
confirmed	O
lower	O
virulence	O
in	O
suckling	O
piglets	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PEDV	O
)	O
has	O
raised	O
growing	O
concerns	O
in	O
the	O
pig	O
-	O
breeding	O
industry	O
because	O
it	O
has	O
caused	O
significant	O
economic	O
losses	O
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
liver	O
transplant	O
patient	O
.	O

ABSTRACT	O
:	O
This	O
case	O
report	O
presents	O
a	O
46	O
-	O
year	O
old	O
man	O
with	O
a	O
failed	O
liver	O
transplant	O
who	O
presented	O
with	O
malaise	B-DISO
and	O
dyspnea	B-DISO
.	O

These	O
include	O
an	O
infectious	B-DISO
model	O
of	O
ARDS	B-DISO
driven	O
by	O
direct	O
administration	O
of	O
Streptococcus	O
pneumoniae	O
and	O
a	O
sterile	B-DISO
inflammatory	O
model	O
mediated	O
by	O
intratracheal	O
administration	O
of	O
lipopolysaccharide	O
.	O

Half	O
a	O
century	O
later	O
,	O
ARDS	B-DISO
remains	O
underrecognized	O
and	O
is	O
associated	O
with	O
high	O
mortality	O
rates	O
.	O

Discerning	O
the	O
true	O
mortality	O
attributable	O
to	O
ARDS	B-DISO
is	O
also	O
difficult	O
.	O

Unlike	O
RCTs	O
,	O
observational	O
studies	O
include	O
ARDS	B-DISO
subjects	O
with	O
severe	O
comorbidities	O
and	O
those	O
requesting	O
limited	O
care	O
.	O

ABSTRACT	O
:	O
Paroxysmal	O
sympathetic	O
hyperactivity	O
represents	O
an	O
uncommon	O
and	O
potentially	O
life	O
-	O
threatening	O
complication	B-DISO
of	O
severe	O
brain	O
injuries	O
,	O
which	O
are	O
most	O
commonly	O
traumatic	O
.	O

Fat	B-DISO
embolism	I-DISO
syndrome	I-DISO
is	O
a	O
rare	O
but	O
serious	O
complication	B-DISO
of	O
long	O
bone	O
fractures	O
.	O

The	O
results	O
showed	O
that	O
the	O
swine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
had	O
a	O
significant	O
impact	O
on	O
the	O
level	O
of	O
miRNA	O
expression	O
in	O
PK	O
-	O
15	O
cells	O
,	O
thus	O
providing	O
a	O
new	O
idea	O
for	O
the	O
further	O
study	O
of	O
the	O
miRNA	O
preparation	O
for	O
the	O
treatment	O
of	O
PEDV	O
.	O

ABSTRACT	O
:	O
Respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
Middle	O
East	O
(	O
MERS	O
-	O
Co	O
V	O
)	O
has	O
caused	O
wide	O
attention	O
since	O
it	O
was	O
discovered	O
,	O
and	O
the	O
design	O
of	O
effective	O
vaccines	O
for	O
MERS	O
-	O
Co	O
V	O
becomes	O
a	O
hot	O
area	O
at	O
present	O
.	O

TITLE	O
:	O
[	O
Identification	O
and	O
Characterzation	O
of	O
the	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
(	O
PEDV	O
)	O
Isolates	O
].	O

An	O
MCC	B-DISO
tree	O
based	O
on	O
relative	O
synonymous	O
codon	O
usage	O
(	O
RSCU	O
)	O
data	O
integrating	O
data	O
from	O
both	O
viruses	O
and	O
hosts	O
into	O
a	O
same	O
analysis	O
indicated	O
three	O
putative	O
host	O
/	O
virus	O
contact	O
dates	O
ranging	O
from	O
1	O
.	O
54E8	O
to	O
2	O
.	O
44E5	O
years	O
ago	O
,	O
suggesting	O
that	O
an	O
ancestor	O
coronavirus	O
might	O
have	O
followed	O
human	O
evolution	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
is	O
a	O
kind	O
of	O
respiratory	B-DISO
disease	I-DISO
Caused	O
by	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
Coronavirus	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
2009	O
pandemic	O
influenza	B-DISO
,	O
we	O
have	O
nationally	O
established	O
a	O
committee	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
project	O
.	O

The	O
oxygenation	O
index	O
(	O
PaO	O
A	O
total	O
of	O
32	O
patients	O
with	O
ARDS	B-DISO
were	O
selected	O
,	O
with	O
16	O
in	O
each	O
group	O
,	O
and	O
their	O
baseline	O
data	O
were	O
balanced	O
and	O
comparable	O
.	O

As	O
time	O
went	O
on	O
,	O
PaO	O
The	O
Qingfeihuayutongfu	O
prescription	O
may	O
improve	O
oxygenation	O
of	O
ARDS	B-DISO
patients	O
,	O
reduce	O
the	O
levels	O
of	O
serum	O
PC	O
III	O
and	O
PLD	O
,	O
and	O
inhibit	O
pulmonary	B-DISO
fibrosis	I-DISO
,	O
thus	O
improve	O
prognosis	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
suspected	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
should	O
be	O
hospitalized	O
in	O
isolation	O
wards	O
to	O
avoid	O
transmission	O
.	O

Therefore	O
,	O
it	O
is	O
used	O
as	O
the	O
active	O
component	O
in	O
the	O
antiviral	O
nasal	O
spray	O
Coldamaris	O
prophylactic	O
(	O
1	O
.	O
2	O
mg	O
/	O
mL	O
iota	O
-	O
carrageenan	O
in	O
0	O
.	O
5	O
%	O
NaCl	O
)	O
and	O
other	O
medical	O
device	O
nasal	O
sprays	B-DISO
that	O
are	O
approved	O
and	O
marketed	O
in	O
the	O
EU	O
.	O

Cyclophilins	O
have	O
been	O
reported	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
replication	O
of	O
several	O
other	O
RNA	O
viruses	O
,	O
including	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
-	O
1	O
,	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
and	O
influenza	B-DISO
A	O
virus	O
.	O

In	O
this	O
group	O
,	O
there	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
seizures	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hemodynamic	O
compromise	O
,	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
Hypersensitivity	B-DISO
reactions	I-DISO
(	O
HR	O
)	O
are	O
immune	O
responses	O
that	O
are	O
exaggerated	O
or	O
inappropriate	O
against	O
an	O
antigen	O
or	O
allergen	O
.	O

Antibodies	O
including	O
IgE	B-DISO
,	O
IgM	O
,	O
and	O
IgG	O
mediate	O
them	O
.[	O
1	O
]	O

Tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
-	O
3	O
(	O
TIMP	O
-	O
3	O
)	O
is	O
a	O
regulator	O
of	O
matrix	O
metalloproteinase	O
activity	O
,	O
inflammation	B-DISO
,	O
and	O
vascular	O
permeability	O
,	O
and	O
hence	O
has	O
plausibility	O
as	O
a	O
biomarker	O
for	O
the	O
systemic	O
response	O
to	O
TBI	O
.	O

Along	O
with	O
clinical	O
and	O
demographic	O
data	O
,	O
early	O
measurements	O
of	O
plasma	O
biomarkers	O
such	O
as	O
TIMP	O
-	O
3	O
may	O
help	O
identify	O
patients	O
at	O
higher	O
risk	O
of	O
ARDS	B-DISO
and	O
death	O
after	O
severe	O
isolated	O
TBI	O
.	O

TITLE	O
:	O
Vinorelbine	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
non	O
-	O
invasive	O
ventilation	O
and	O
immunosuppressive	O
therapy	O
.	O

However	O
,	O
they	O
have	O
not	O
been	O
previously	O
tested	O
as	O
ARDS	B-DISO
therapeutics	O
alone	O
or	O
in	O
combination	O
.	O

Furthermore	O
,	O
whereas	O
ET	O
alone	O
improved	O
lung	B-DISO
edema	I-DISO
,	O
it	O
did	O
not	O
increase	O
the	O
survival	O
rate	O
,	O
indicating	O
the	O
necessity	O
of	O
PSL	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
.	O

A	O
possible	O
treatment	O
to	O
suppress	O
Zika	O
replication	O
is	O
represented	O
by	O
short	O
interfering	O
RNAs	O
(	O
siRNAs	O
),	O
since	O
they	O
have	O
been	O
successfully	O
used	O
even	O
against	O
Ebola	O
,	O
H5N1	B-DISO
and	O
SARS	B-DISO
viruses	O
and	O
clinical	O
trials	O
of	O
siRNA	O
-	O
based	O
drugs	O
are	O
ongoing	O
.	O

ABSTRACT	O
:	O
Yeşilbaş	O
O	O
,	O
Şevketoğlu	O
E	O
,	O
Kıhtır	O
HS	O
,	O
Hatipoğlu	O
N	O
,	O
Yıldırım	O
HM	O
,	O
Akyol	O
MB	O
,	O
Aktay	O
-	O
Ayaz	O
N	O
,	O
Gökçe	O
İ	O
.	O
Leptospirosis	B-DISO
in	O
a	O
child	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

It	O
is	O
shown	O
that	O
neonatal	O
complications	O
(	O
Jaundice	B-DISO
,	O
infections	B-DISO
,	O
asphyxia	B-DISO
and	O
etc	O
.)	O
affect	O
development	O
more	O
than	O
prematurity	O
itself	O
,	O
it	O
is	O
very	O
important	O
to	O
conduct	O
big	O
cohort	O
studies	O
on	O
neonates	O
with	O
RDS	O
to	O
identify	O
the	O
risks	O
associated	O
with	O
RDS	O
and	O
its	O
severity	O
.	O

The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
β	O
promoter	O
,	O
and	O
NF	O
-	O
κB	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	O
,	O
following	O
the	O
challenge	O
of	O
cells	O
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
α	O
or	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
.	O

RESULTS	O
:	O
The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
β	O
promoter	O
,	O
and	O
NF	O
-	O
κB	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	O
,	O
following	O
the	O
challenge	O
of	O
cells	O
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
α	O
or	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
.	O

Cardiac	O
glycosides	O
have	O
been	O
reported	O
to	O
be	O
effective	O
against	O
both	O
DNA	O
viruses	O
such	O
as	O
cytomegalovirus	O
and	O
herpes	B-DISO
simplex	I-DISO
and	O
RNA	O
viruses	O
such	O
as	O
influenza	B-DISO
,	O
chikungunya	B-DISO
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
,	O
among	O
others	O
.	O

Although	O
we	O
recognize	O
that	O
results	O
obtained	O
in	O
robust	O
mouse	O
models	O
require	O
evaluation	O
in	O
non	O
-	O
human	O
primates	O
,	O
we	O
focus	O
this	O
review	O
on	O
the	O
current	O
state	O
of	O
hCoV	O
mouse	O
models	O
,	O
their	O
use	O
as	O
tractable	O
complex	O
genetic	O
organisms	O
for	O
untangling	O
complex	O
hCoV	O
-	O
host	O
interactions	O
,	O
and	O
as	O
pathogenesis	B-DISO
models	O
for	O
preclinical	O
evaluation	O
of	O
novel	O
therapeutic	O
interventions	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
some	O
of	O
the	O
novel	O
concepts	O
and	O
critical	O
prerequisites	O
for	O
such	O
respiratory	O
lung	O
assist	O
devices	O
that	O
can	O
be	O
used	O
with	O
an	O
adequate	O
safety	O
profile	O
,	O
in	O
the	O
intensive	O
care	O
setting	O
,	O
as	O
well	O
as	O
for	O
long	O
-	O
term	O
domiciliary	O
therapy	O
in	O
patients	O
with	O
chronic	O
ventilatory	B-DISO
failure	I-DISO
.	O

Specifically	O
,	O
we	O
describe	O
some	O
of	O
the	O
pivotal	O
steps	O
,	O
such	O
as	O
device	O
miniaturization	O
,	O
passivation	O
of	O
the	O
blood	O
-	O
contacting	O
surfaces	O
by	O
chemical	O
surface	O
modifications	O
,	O
or	O
endothelial	O
cell	O
seeding	O
,	O
all	O
of	O
which	O
are	O
required	O
for	O
converting	O
current	O
lung	O
assist	O
devices	O
into	O
ambulatory	O
lung	O
assist	O
device	O
for	O
long	O
-	O
term	O
use	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
There	O
have	O
been	O
occasional	O
reports	O
of	O
respiratory	B-DISO
dysfunction	I-DISO
associated	O
with	O
acute	O
chlorine	O
gas	O
inhalation	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
chlorine	O
gas	O
exposure	O
.	O

In	O
2014	O
-	O
2015	O
the	O
median	O
week	O
of	O
influenza	B-DISO
detection	O
was	O
week	O
7	O
/	O
2015	O
with	O
B	O
/	O
Yamagata	O
lineage	O
viruses	O
dominating	O
(	O
79	O
%);	O
in	O
2015	O
-	O
2016	O
-	O
week	O
5	O
/	O
2016	O
was	O
the	O
median	O
with	O
A	O
/	O
H1N1pdm09	O
viruses	O
prevailing	O
(	O
83	O
%);	O
and	O
in	O
2016	O
-	O
2017	O
a	O
bimodal	O
distribution	O
of	O
influenza	B-DISO
activity	O
was	O
observed	O
-	O
the	O
first	O
wave	O
was	O
caused	O
by	O
A	O
/	O
H3N2	O
(	O
55	O
%)	O
with	O
median	O
week	O
51	O
/	O
2016	O
and	O
the	O
second	O
by	O
B	O
/	O
Victoria	O
lineage	O
viruses	O
(	O
45	O
%)	O
with	O
median	O
week	O
9	O
/	O
2017	O
.	O

ABSTRACT	O
:	O
Severe	O
complications	O
after	O
reperfusion	O
therapy	O
for	O
acute	O
major	O
vessel	O
occlusion	B-DISO
are	O
not	O
well	O
described	O
.	O

This	O
case	O
has	O
similarities	O
to	O
both	O
second	O
-	O
impact	O
syndrome	B-DISO
after	O
head	O
trauma	O
and	O
perfusion	O
breakthrough	O
phenomenon	O
.	O

ABSTRACT	O
:	O
An	O
understanding	O
of	O
immune	O
responses	O
against	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
important	O
for	O
the	O
development	O
of	O
treatments	O
and	O
preventive	O
measures	O
.	O

RESULTS	O
:	O
At	O
the	O
acute	O
phase	O
of	O
infection	B-DISO
,	O
elevated	O
levels	O
of	O
plasma	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
were	O
detected	O
in	O
proportion	O
to	O
the	O
severity	O
of	O
the	O
disease	O
.	O

Risk	O
factors	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
management	O
characteristics	O
,	O
and	O
short	O
-	O
and	O
long	O
-	O
term	O
outcomes	O
were	O
assessed	O
.	O

Operative	O
mortality	O
was	O
8	O
.	O
1	O
%	O
for	O
all	O
pneumonectomies	O
,	O
43	O
.	O
8	O
%	O
(	O
n	O
=	O
39	O
/	O
89	O
)	O
in	O
intubated	O
patients	O
,	O
and	O
56	O
.	O
7	O
%	O
(	O
34	O
/	O
60	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
severe	O
early	B-DISO
complication	I-DISO
of	O
pneumonectomy	O
with	O
a	O
poor	O
outcome	O
.	O

Although	O
numerous	O
studies	O
identified	O
mutations	O
predicted	O
to	O
be	O
responsible	O
for	O
the	O
FECV	O
-	O
FIPV	O
biotype	O
switch	O
,	O
the	O
presumed	O
roles	O
of	O
specific	O
genetic	O
changes	O
in	O
FIP	B-DISO
pathogenesis	B-DISO
have	O
not	O
been	O
confirmed	O
experimentally	O
.	O

ABSTRACT	O
:	O
Avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infects	O
domestic	O
fowl	O
,	O
resulting	O
in	O
respiratory	B-DISO
disease	I-DISO
and	O
causing	O
serious	O
losses	O
in	O
unprotected	O
birds	O
.	O

In	O
vitro	O
inoculation	O
of	O
chicken	O
embryo	O
kidney	O
cells	O
with	O
recombinant	O
and	O
wild	O
-	O
type	O
viruses	O
demonstrated	O
that	O
the	O
accessory	O
protein	O
5b	O
is	O
involved	O
in	O
the	O
delayed	O
activation	O
of	O
the	O
interferon	O
response	O
of	O
the	O
host	O
after	O
IBV	O
infection	B-DISO
.	O

In	O
conclusion	O
,	O
individual	O
deletion	O
of	O
accessory	O
genes	O
in	O
IBV	O
H52	O
resulted	O
in	O
mutant	B-DISO
viruses	O
with	O
an	O
attenuated	O
phenotype	O
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
is	O
a	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
disease	O
characterized	O
by	O
chronic	O
neuroinflammation	O
,	O
demyelination	B-DISO
,	O
and	O
axonal	O
damage	O
.	O

None	O
of	O
the	O
short	O
-	O
term	O
exposures	O
averaged	O
over	O
the	O
3	O
days	O
before	O
presentation	O
was	O
associated	O
with	O
ARDS	B-DISO
,	O
except	O
sulfur	O
dioxide	O
,	O
which	O
demonstrated	O
a	O
nonlinear	O
association	O
.	O

The	O
age	O
-	O
allied	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
was	O
highest	O
amongst	O
elderly	O
people	O
with	O
chronic	O
debilitating	O
diseases	O
such	O
as	O
pulmonary	B-DISO
diseases	I-DISO
,	O
end	O
-	O
stage	O
renal	O
illness	O
,	O
diabetes	B-DISO
mellitus	I-DISO
and	O
malignancy	B-DISO
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
is	O
an	O
emerging	O
global	O
health	O
concern	O
,	O
affected	O
people	O
in	O
27	O
countries	O
in	O
the	O
various	O
continents	O
.	O

ABSTRACT	O
:	O
Laboratory	O
cats	O
were	O
infected	O
with	O
a	O
serotype	O
I	O
cat	O
-	O
passaged	O
field	O
strain	O
of	O
FIP	B-DISO
virus	O
(	O
FIPV	O
)	O
and	O
peritoneal	O
cells	O
harvested	O
2	O
-	O
3	O
weeks	O
later	O
at	O
onset	O
of	O
lymphopenia	B-DISO
,	O
fever	O
and	O
serositis	B-DISO
.	O

This	O
prospective	O
observational	O
study	O
included	O
consecutive	O
adult	O
septic	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
underwent	O
emergency	B-DISO
abdominal	O
surgery	O
prior	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
.	O

NPPV	O
is	O
a	O
viable	O
option	O
for	O
lung	O
transplant	O
recipients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

A	O
series	O
of	O
novel	O
2	O
-	O
thiazolyl	O
substituted	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
naphtho	O
[	O
1	O
,	O
2	O
-	O
e	O
][	O
1	O
,	O
3	O
]	O
oxazine	O
derivatives	O
were	O
designed	O
and	O
synthesized	O
based	O
on	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
from	O
2	O
-	O
naphthol	O
,	O
substituted	O
thiazolyl	O
amines	O
and	O
formalin	O
through	O
ring	O
closure	O
by	O
one	O
-	O
pot	B-DISO
three	O
component	O
reaction	O
.	O

Docking	O
studies	O
of	O
these	O
molecules	O
revealed	O
their	O
high	O
affinity	O
binding	O
to	O
several	O
amino	O
acids	O
of	O
HIV	B-DISO
-	O
1	O
RT	O
which	O
are	O
less	O
sensitive	O
to	O
point	O
mutations	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
coronavirus	O
circulating	O
in	O
the	O
Arabian	O
Peninsula	O
since	O
September	O
2012	O
.	O

Here	O
,	O
we	O
report	O
the	O
structure	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
glycoprotein	O
in	O
complex	O
with	O
its	O
host	O
cell	O
receptor	O
ACE2	O
revealed	O
by	O
cryo	O
-	O
electron	O
microscopy	O
(	O
cryo	O
-	O
EM	O
).	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
revealing	O
antisynthetase	B-DISO
syndrome	I-DISO
].	O

The	O
subsequent	O
diagnosis	O
of	O
antisynthetase	B-DISO
syndrome	I-DISO
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
unusual	O
,	O
even	O
more	O
so	O
when	O
a	O
veino	O
-	O
veinous	O
(	O
VV	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
required	O
.	O

MMPs	O
may	O
play	O
a	O
role	O
in	O
the	O
pathobiology	O
of	O
children	O
with	O
ARDS	B-DISO
.	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
may	O
serve	O
as	O
a	O
rescue	O
therapy	O
in	O
refractory	O
ARDS	B-DISO
but	O
has	O
still	O
not	O
been	O
studied	O
in	O
predominantly	O
leuco	O
-	O
and	O
thrombocytopenic	O
cancer	B-DISO
patients	O
.	O

4	O
patients	O
experienced	O
severe	O
bleeding	B-DISO
events	O
.	O

In	O
this	O
study	O
,	O
for	O
the	O
first	O
time	O
we	O
investigated	O
the	O
role	O
of	O
DCs	B-DISO
in	O
porcine	O
PPs	B-DISO
after	O
oral	O
administration	O
inactivated	O
PEDV	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
for	O
the	O
first	O
time	O
we	O
investigated	O
the	O
role	O
of	O
DCs	B-DISO
in	O
porcine	O
PPs	B-DISO
after	O
oral	O
administration	O
inactivated	O
PEDV	O
.	O

Firstly	O
,	O
a	O
method	O
to	O
isolate	O
DCs	B-DISO
from	O
porcine	O
PPs	B-DISO
was	O
established	O
,	O
in	O
which	O
the	O
purity	O
of	O
SWC3a	O

TITLE	O
:	O
Epidemiology	O
and	O
patterns	O
of	O
tracheostomy	O
practice	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
ICUs	O
across	O
50	O
countries	O
.	O

Most	O
patients	O
that	O
receive	O
tracheostomy	O
do	O
so	O
after	O
the	O
first	O
week	O
of	O
critical	B-DISO
illness	I-DISO
.	O

Binding	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
to	O
dipeptidyl	O
peptidase	O
4	O
is	O
the	O
critical	O
step	O
in	O
MERS	O
-	O
CoV	O
infection	B-DISO
of	O
a	O
host	O
cell	O
.	O

TITLE	O
:	O
Risk	O
Factors	O
on	O
Hospital	O
Arrival	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Following	O
Pediatric	O
Trauma	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurred	O
in	O
1	O
.	O
8	O
%	O
of	O
146	O
,	O
058	O
critically	O
injured	O
children	O
(	O
n	O
=	O
2	O
,	O
590	O
).	O

Clinical	O
variables	O
included	O
abnormal	O
respiratory	O
status	O
(	O
intubated	O
relative	O
risk	O
,	O
1	O
.	O
67	O
;	O
1	O
.	O
23	O
-	O
2	O
.	O
26	O
and	O
hypopnea	O
relative	O
risk	O
,	O
1	O
.	O
23	O
;	O
1	O
.	O
05	O
-	O
1	O
.	O
45	O
and	O
tachypnea	B-DISO
relative	O
risk	O
,	O
1	O
.	O
26	O
;	O
1	O
.	O
10	O
-	O
1	O
.	O
44	O
)	O
and	O
lower	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
(	O
relative	O
risk	O
,	O
5	O
.	O
61	O
for	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
3	O
vs	O
15	O
;	O
4	O
.	O
44	O
-	O
7	O
.	O
07	O
).	O

Transporting	O
ARDS	B-DISO
patients	O
to	O
ECMO	O
centers	O
for	O
treatment	O
can	O
be	O
dangerous	O
because	O
of	O
the	O
risk	O
of	O
hypoxemia	O
during	O
transport	O
.	O

ABSTRACT	O
:	O
As	O
the	O
major	O
causative	O
agent	O
of	O
swine	O
viral	B-DISO
diarrhea	I-DISO
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
caused	O
massive	O
losses	O
to	O
the	O
economies	O
of	O
swine	O
raising	O
countries	O
.	O

Balb	O
/	O
cJ	O
mice	O
died	O
in	O
3	O
to	O
6	O
days	O
post	O
MHV	O
-	O
3	O
infection	B-DISO
,	O
with	O
severe	O
hepatic	B-DISO
necrosis	I-DISO
and	O
significant	O
augmentation	O
of	O
serum	O
ALT	O
and	O
AST	O
levels	O
.	O

Antemortem	O
evaluation	O
revealed	O
severe	O
neurologic	B-DISO
signs	I-DISO
,	O
including	O
disorientation	B-DISO
,	O
torticollis	B-DISO
,	O
and	O
opisthotonos	B-DISO
.	O

Histologically	O
,	O
severe	O
sinusitis	B-DISO
,	O
cranial	O
osteomyelitis	B-DISO
,	O
otitis	B-DISO
media	I-DISO
and	O
interna	O
,	O
and	O
meningoencephalitis	B-DISO
were	O
noted	O
,	O
explaining	O
the	O
clinical	O
signs	O
described	O
.	O

Structural	O
information	O
on	O
this	O
crucial	O
protein	O
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
is	O
lethally	O
pathogenic	O
and	O
has	O
caused	O
severe	O
respiratory	B-DISO
diseases	I-DISO
worldwide	O
,	O
is	O
lacking	O
.	O

In	O
contrast	O
,	O
mutant	B-DISO
D39A	O
exhibits	O
increased	O
activity	O
and	O
a	O
higher	O
substrate	O
binding	O
capacity	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
risk	O
of	O
hospitalization	O
from	O
different	O
viruses	O
in	O
children	O
presenting	O
with	O
an	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
).	O

After	O
controlling	O
for	O
potential	O
confounders	O
(	O
age	O
,	O
sex	O
,	O
recruitment	B-DISO
site	O
,	O
days	O
from	O
symptom	B-DISO
onset	O
to	O
enrollment	O
,	O
and	O
underlying	O
illnesses	O
),	O
children	O
with	O
RSV	O
and	O
metapneumovirus	O
infections	B-DISO
showed	O
a	O
greater	O
likelihood	O
of	O
hospitalization	O
than	O
those	O
infected	O
by	O
parainfluenza	B-DISO
viruses	O
(	O
OR	O
2	O
.	O
7	O
and	O
1	O
.	O
9	O
,	O
respectively	O
),	O
rhinovirus	O
/	O
enterovirus	O
(	O
OR	O
3	O
.	O
1	O
and	O
2	O
.	O
1	O
,	O
respectively	O
),	O
coronaviruses	O
(	O
OR	O
4	O
.	O
9	O
and	O
3	O
.	O
4	O
,	O
respectively	O
),	O
adenovirus	B-DISO
(	O
OR	O
4	O
.	O
6	O
and	O
3	O
.	O
2	O
,	O
respectively	O
),	O
and	O
influenza	B-DISO
(	O
OR	O
6	O
.	O
3	O
and	O
4	O
.	O
4	O
,	O
respectively	O
).	O

It	O
can	O
cause	O
extreme	O
dehydration	B-DISO
and	O
death	O
in	O
neonatal	O
piglets	O
.	O

TITLE	O
:	O
Management	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
with	O
H1N1	B-DISO
Influenza	I-DISO
Virus	O
in	O
Pregnancy	O
:	O
Successful	O
Mechanical	O
Ventilation	O
and	O
Weaning	O
with	O
Airway	O
Pressure	O
Release	O
Ventilation	O
.	O

In	O
2008	O
a	O
coronavirus	O
(	O
Fr	O
-	O
TCoV	O
080385d	O
)	O
was	O
isolated	O
in	O
France	O
from	O
turkey	O
poults	O
exhibiting	O
clinical	O
signs	O
compatible	O
with	O
this	O
syndrome	B-DISO
.	O

TITLE	O
:	O
Modulation	O
of	O
the	O
immune	O
response	O
by	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

In	O
addition	O
,	O
uncontrolled	O
secretion	O
of	O
interferon	O
ɣ	O
-	O
induced	O
protein	O
10	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
can	O
suppress	O
proliferation	B-DISO
of	O
human	O
myeloid	O
progenitor	O
cells	O
.	O

TITLE	O
:	O
Enhanced	O
pathogenicity	O
of	O
low	O
-	O
pathogenic	O
H9N2	O
avian	B-DISO
influenza	I-DISO
virus	O
after	O
vaccination	O
with	O
infectious	B-DISO
bronchitis	B-DISO
live	O
attenuated	O
vaccine	O
.	O

In	O
experiment	O
1	O
,	O
Groups	O
1	O
and	O
2	O
were	O
inoculated	O
with	O
H9N2	O
AIV	O
through	O
nasal	O
route	O
in	O
1	O
day	O
old	O
,	O
Groups	O
1	O
and	O
3	O
were	O
vaccinated	O
with	O
live	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
(	O
IBV	O
)	O
vaccine	O
in	O
5	O
days	O
old	O
,	O
and	O
Group	O
4	O
was	O
left	O
as	O
a	O
negative	O
control	O
.	O

As	O
a	O
result	O
,	O
laboratories	O
are	O
building	O
capacity	O
,	O
conducting	O
more	O
advanced	O
and	O
sophisticated	O
research	O
,	O
increasing	O
their	O
staff	O
,	O
and	O
establishing	O
reference	O
collections	O
of	O
dangerous	O
pathogens	O
in	O
an	O
attempt	O
to	O
reduce	O
the	O
impact	O
of	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
and	O
to	O
characterise	O
disease	O
-	O
causing	O
agents	O
.	O

The	O
global	O
community	O
needs	O
to	O
increase	O
its	O
investment	O
in	O
early	O
warning	O
and	O
detection	O
systems	O
that	O
can	O
provide	O
information	O
that	O
enables	O
action	O
to	O
be	O
taken	O
at	O
the	O
national	O
,	O
regional	O
and	O
global	O
levels	O
in	O
the	O
event	O
of	O
an	O
outbreak	O
of	O
a	O
transboundary	O
animal	B-DISO
disease	I-DISO
(	O
TAD	O
).	O

Each	O
year	O
,	O
livestock	O
,	O
and	O
the	O
people	O
who	O
rely	O
upon	O
them	O
for	O
their	O
livelihoods	O
,	O
are	O
confronted	O
with	O
animal	B-DISO
disease	I-DISO
and	O
crises	O
.	O

Swabs	O
from	O
surface	O
samples	O
,	O
and	O
air	O
samples	O
were	O
tested	O
by	O
real	O
-	O
time	O
PCR	O
for	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	B-DISO
,	O
rhinovirus	O
and	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
NL63	O
and	O
OC43	O
).	O

We	O
report	O
a	O
case	O
of	O
profound	O
,	O
long	O
-	O
lasting	O
unexplained	O
hypotension	O
during	O
and	O
after	O
anaesthesia	B-DISO
in	O
a	O
patient	O
presented	O
for	O
emergency	B-DISO
vocal	O
cord	B-DISO
surgery	O
(	O
cordectomy	O
).	O

Fifteen	O
pilgrims	O
had	O
fever	O
(>	O
38	O
°	O
C	O
)	O
accompanied	O
by	O
respiratory	B-DISO
symptoms	I-DISO
;	O
of	O
these	O
,	O
12	O
patients	O
were	O
diagnosed	O
with	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
and	O
three	O
patients	O
with	O
pneumonia	B-DISO
.	O

Although	O
rare	O
,	O
GBS	B-DISO
has	O
been	O
reported	O
as	O
a	O
complication	B-DISO
of	O
surgery	O
.	O

The	O
main	O
gastrointestinal	O
side	O
effects	O
are	O
fulminant	B-DISO
hepatitis	I-DISO
that	O
may	O
be	O
fatal	O
,	O
colitis	B-DISO
that	O
may	O
be	O
complicated	O
by	O
hemorrhage	B-DISO
,	O
and	O
perforation	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
emerging	O
as	O
a	O
pathogenic	O
coronavirus	O
that	O
causes	O
a	O
huge	O
economic	O
burden	O
to	O
the	O
swine	O
industry	O
.	O

ABSTRACT	O
:	O
Six	O
series	O
of	O
semisynthetic	O
lipophilic	O
glycopeptide	O
antibiotic	O
derivatives	O
were	O
evaluated	O
for	O
in	O
vitro	O
activity	O
against	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
.	O

ABSTRACT	O
:	O
Congenital	B-DISO
myasthenic	I-DISO
syndromes	I-DISO
are	O
a	O
group	O
of	O
genetically	O
determined	O
rare	B-DISO
diseases	I-DISO
resulting	O
from	O
ultrastructural	O
alterations	O
in	O
synaptic	O
proteins	O
.	O

目的	O
：	O
人类乳头瘤病毒	O
(	O
HPV	O
)	O
是女性发生宫颈癌的必要病因	O
，	O
也与男性阴茎癌	O
、	O
口咽癌	O
、	O
肛门癌等密切相关	O
，	O
但是目前对男性HPV的研究较少	O
。	O
本文研究配偶宫颈HPV感染男性外生殖器HPV感染状况	O
，	O
为临床制定HPV相关性疾病的防治措施提供科学依据	O
。	O
方法	O
：	O
收集2016年8	O
~	O
12月因配偶宫颈HPV感染阳性	O
，	O
南京医科大学附属妇产医院泌尿男科门诊就诊男性的相关资料	O
。	O
尼龙棉签拭子在阴茎头	O
、	O
冠状沟	O
、	O
包皮内板	O
、	O
阴茎体等处取样	O
，	O
运用凯普生物HPV分型检测试剂盒	O
，	O
采用PCR	O
和膜杂交的方法	O
，	O
检测不同型别HPV	O
感染情况	O
。	O
结果	O
：	O
去除不合格	O
?#	O
177	O
;	O
材扇	O
?	O
39例患者信息	O
。	O
139例配偶宫颈HPV感染男性外生殖器HPV感染率为83	O
.	O
5	O
%。	O
HPV感染类型以6	O
，	O
16	O
，	O
39	O
，	O
18	O
，	O
58	O
，	O
52型为主	O
，	O
分别占43	O
.	O
2	O
%(	O
60	O
/	O
139	O
)、	O
19	O
.	O
4	O
%(	O
27	O
/	O
139	O
)、	O
10	O
.	O
1	O
%(	O
14	O
/	O
139	O
)、	O
9	O
.	O
4	O
%(	O
13	O
/	O
139	O
)、	O
9	O
.	O
4	O
%(	O
13	O
/	O
139	O
)、	O
9	O
.	O
4	O
%(	O
13	O
/	O
139	O
)。	O
在配偶宫颈HPV感染阳性的男性中	O
，	O
包皮过长比率高达75	O
.	O
5	O
%，	O
但包皮正常和包皮过长男性HPV感染率没有显著差异	O
（	O
P	O
>	O
0	O
.	O
05	O
）。	O
结论	O
:	O
配偶宫颈HPV感染阳性的男性是HPV感染的高危人群	O
，	O
有必要对此类人群进行筛查和治疗	O
，	O
以降低男女双方的HPV感染	O
。.	O
RESULTS	O
:	O
Valid	O
data	O
were	O
collected	O
from	O
140	O
males	O
,	O
which	O
showed	O
83	O
.	O
5	O
%	O
of	O
HPV	O
infection	B-DISO
of	O
the	O
external	O
genitalia	O
,	O
including	O
60	O
cases	O
of	O
HPV6	O
(	O
43	O
.	O
2	O
%),	O
27	O
cases	O
of	O
HPV16	O
(	O
19	O
.	O
4	O
%),	O
14	O
cases	O
of	O
HPV39	O
(	O
10	O
.	O
1	O
%),	O
13	O
cases	O
of	O
HPV18	O
(	O
9	O
.	O
4	O
%),	O
13	O
cases	O
of	O
HPV58	O
(	O
9	O
.	O
4	O
%),	O
and	O
13	O
cases	O
of	O
HPV52	O
(	O
9	O
.	O
4	O
%).	O

TITLE	O
:	O
Comparative	O
Pathogenicity	O
of	O
Malaysian	O
QX	O
-	O
like	O
and	O
Variant	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
Strains	O
in	O
Chickens	O
at	O
Different	O
Age	O
of	O
Exposure	O
to	O
the	O
Viruses	O
.	O

TITLE	O
:	O
Viral	B-DISO
infection	I-DISO
in	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
patients	O
with	O
fever	O
:	O
a	O
prospective	O
observational	O
study	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
(	O
CAP	B-DISO
)	O
caused	O
by	O
viruses	O
can	O
develop	O
severe	O
complications	O
,	O
which	O
result	O
in	O
hospitalization	O
and	O
death	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
aetiology	O
,	O
incidence	O
,	O
clinical	O
characteristics	O
,	O
and	O
outcomes	O
of	O
CAP	B-DISO
patients	O
with	O
fever	O
during	O
non	O
-	O
pandemics	O
,	O
and	O
then	O
to	O
provide	O
theoretical	O
basis	O
for	O
accurate	O
diagnosis	O
and	O
treatment	O
in	O
CAP	B-DISO
patients	O
.	O

Among	O
them	O
,	O
23	O
.	O
4	O
%	O
were	O
viral	O
-	O
positive	O
by	O
mPCR	O
,	O
with	O
influenza	B-DISO
virus	O
most	O
prominent	O
followed	O
by	O
picornavirus	O
.	O

ABSTRACT	O
:	O
Elevated	O
driving	O
pressure	O
(	O
ΔP	O
)	O
may	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
patients	O
admitted	O
via	O
the	O
emergency	B-DISO
department	O
and	O
with	O
post	O
-	O
operative	O
pulmonary	B-DISO
complications	I-DISO
in	O
surgical	O
patients	O
.	O

CHIKV	O
and	O
dengue	B-DISO
virus	O
serotype	O
1	O
infections	B-DISO
were	O
more	O
common	O
in	O
older	O
children	O
,	O
with	O
a	O
complaint	O
of	O
arthralgia	B-DISO
serving	O
as	O
a	O
significant	O
predictor	O
for	O
infection	B-DISO
with	O
CHIKV	O
(	O
odds	O
ratio	O
,	O
16	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
8	O
.	O
0	O
-	O
34	O
.	O
4	O
;	O
positive	O
predictive	O
value	O
,	O
66	O
%;	O
negative	O
predictive	O
value	O
,	O
80	O
%).	O

TITLE	O
:	O
SARS	B-DISO
-	O
Coronavirus	O
Open	O
Reading	O
Frame	O
-	O
3a	O
drives	O
multimodal	O
necrotic	O
cell	O
death	O
.	O

While	O
previously	O
implicated	O
in	O
a	O
non	O
-	O
inflammatory	O
apoptotic	O
cell	O
death	O
pathway	O
,	O
here	O
we	O
extend	O
the	O
range	O
of	O
SARS	B-DISO
3a	O
pathophysiologic	O
targets	O
by	O
examining	O
its	O
effects	O
on	O
necrotic	O
cell	O
death	O
pathways	O
.	O

Dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
)	O
inhibitors	O
,	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	B-DISO
mellitus	I-DISO
,	O
have	O
been	O
reported	O
to	O
have	O
possible	O
anti	O
-	O
inflammatory	O
effects	O
.	O

He	O
developed	O
a	O
fever	O
of	O
39	O
°	O
C	O
with	O
respiratory	B-DISO
distress	I-DISO
and	O
was	O
transported	O
by	O
ambulance	O
to	O
his	O
usual	O
doctor	O
.	O

We	O
observed	O
significantly	O
decreased	O
plasma	O
HRG	O
levels	O
in	O
an	O
acute	B-DISO
pancreatitis	I-DISO
mouse	O
model	O
.	O

Histidine	O
-	O
rich	O
glycoprotein	O
treatment	O
inhibited	O
lung	B-DISO
edema	I-DISO
and	O
the	O
accumulation	O
of	O
neutrophil	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
,	O
but	O
HRG	O
did	O
not	O
directly	O
affect	O
pancreatitis	B-DISO
.	O

The	O
patients	O
with	O
ultrasound	O
integrated	O
management	O
received	O
a	O
more	O
appropriate	O
pharmacological	O
therapy	O
(	O
p	O
0	O
.	O
01	O
),	O
as	O
well	O
as	O
non	O
-	O
invasive	O
ventilation	O
(	O
CPAP	O
)	O
was	O
used	O
more	O
frequently	O
in	O
those	O
with	O
an	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
p	O
0	O
.	O
011	O
).	O

In	O
a	O
sub	O
-	O
analysis	O
of	O
the	O
patients	O
with	O
an	O
A	O
profile	O
,	O
we	O
observed	O
a	O
significant	O
lower	O
concentration	O
of	O
PCO	B-DISO

ABSTRACT	O
:	O
Recent	O
,	O
large	O
trials	O
of	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
versus	O
conventional	O
ventilation	O
(	O
CV	O
)	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
reported	O
negative	O
results	O
.	O

We	O
studied	O
17	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
[	O
PaO	O
The	O
mean	O
""""	O
study	O
HFO	O
mPaw	O
""""	O
was	O
8	O
-	O
10	O
cmH	B-DISO
In	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
,	O
""""	O
short	O
-	O
term	O
""""	O
4	O
-	O
Hz	O
HFO	O
strategies	O
resulted	O
in	O
better	O
RV	O
function	O
versus	O
7	O
-	O
Hz	O
HFO	O
,	O
partly	O
attributable	O
to	O
improved	O
PaCO	O
This	O
study	O
was	O
registered	O
40	O
days	O
prior	O
to	O
the	O
enrollment	O
of	O
the	O
first	O
patient	O
at	O
ClinicalTrials	O
.	O
gov	O
,	O
ID	O
no	O
.	O
NCT02027129	O
,	O
Principal	O
Investigator	O
Spyros	O
D	O
.	O
Mentzelopoulos	O
,	O
date	O
of	O
registration	O
January	O
3	O
,	O
2014	O
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
outcome	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
revealing	O
anti	O
-	O
synthetase	O
or	O
anti	O
-	O
MDA	O
-	O
5	O
dermato	O
-	O
pulmonary	O
syndrome	B-DISO
:	O
a	O
French	O
multicenter	O
retrospective	O
study	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
synthetase	O
(	O
AS	O
)	O
and	O
dermato	O
-	O
pulmonary	O
associated	O
with	O
anti	O
-	O
MDA	O
-	O
5	O
antibodies	O
(	O
aMDA	O
-	O
5	O
)	O
syndromes	B-DISO
are	O
near	O
one	O
of	O
the	O
other	O
autoimmune	B-DISO
inflammatory	B-DISO
myopathies	I-DISO
potentially	O
responsible	O
for	O
severe	O
acute	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

From	O
2005	O
to	O
2017	O
,	O
47	O
patients	O
(	O
23	O
males	O
;	O
median	O
age	O
60	O
[	O
1st	O
-	O
3rd	O
quartiles	O
52	O
-	O
69	O
]	O
years	O
,	O
no	O
comorbidity	O
85	O
%)	O
were	O
admitted	O
to	O
the	O
ICU	O
for	O
ARF	B-DISO
revealing	O
AS	O
(	O
n	O
=	O
28	O
,	O
60	O
%)	O
or	O
aMDA	O
-	O
5	O
(	O
n	O
=	O
19	O
,	O
40	O
%)	O
syndromes	B-DISO
.	O

RESULTS	O
:	O
From	O
2005	O
to	O
2017	O
,	O
47	O
patients	O
(	O
23	O
males	O
;	O
median	O
age	O
60	O
[	O
1st	O
-	O
3rd	O
quartiles	O
52	O
-	O
69	O
]	O
years	O
,	O
no	O
comorbidity	O
85	O
%)	O
were	O
admitted	O
to	O
the	O
ICU	O
for	O
ARF	B-DISO
revealing	O
AS	O
(	O
n	O
=	O
28	O
,	O
60	O
%)	O
or	O
aMDA	O
-	O
5	O
(	O
n	O
=	O
19	O
,	O
40	O
%)	O
syndromes	B-DISO
.	O

TITLE	O
:	O
The	O
effect	O
of	O
chemical	O
clarification	O
of	O
oral	O
fluids	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
antibody	O
responses	O
.	O

ABSTRACT	O
:	O
Routine	O
testing	O
of	O
breeding	O
herd	O
oral	O
fluid	O
(	O
OF	O
)	O
samples	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
IgG	O
and	O
/	O
or	O
IgA	O
is	O
used	O
to	O
track	O
levels	O
of	O
PEDV	O
immunity	O
over	O
time	O
.	O

Deterioration	O
of	O
her	O
clinical	O
status	O
prompted	O
an	O
emergency	B-DISO
hysterectomy	O
that	O
led	O
to	O
rapid	O
improvement	O
.	O

With	O
recent	O
studies	O
refuting	O
uterine	O
size	O
and	O
leiomyoma	B-DISO
location	O
as	O
risk	O
factors	O
,	O
further	O
research	O
is	O
needed	O
to	O
help	O
select	O
appropriate	O
uterine	O
artery	O
embolization	O
candidates	O
.	O

Here	O
we	O
characterize	O
replication	O
kinetics	O
and	O
plaque	B-DISO
formation	O
of	O
a	O
model	O
type	O
I	O
strain	O
FIPV	O
Black	O
in	O
Fcwf	O
-	O
4	O
cells	O
established	O
at	O
Cornell	O
University	O
(	O
Fcwf	O
-	O
4	O
CU	O
).	O

The	O
histopathological	O
examinations	O
revealed	O
villi	O
fused	O
with	O
denuded	O
tips	O
and	O
severe	O
villus	O
atrophy	B-DISO
,	O
leading	O
to	O
extensive	O
epithelial	O
flattening	O
in	O
middle	O
and	O
lower	O
small	O
intestine	O
.	O

ABSTRACT	O
:	O
Fowl	B-DISO
typhoid	I-DISO
(	O
FT	O
),	O
a	O
septicemic	O
disease	O
caused	O
by	O
Salmonella	B-DISO
Gallinarum	O
(	O
SG	O
),	O
and	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
are	O
two	O
economically	O
important	O
avian	B-DISO
diseases	I-DISO
that	O
affect	O
poultry	O
industry	O
worldwide	O
.	O

Here	O
,	O
we	O
incorporate	O
an	O
epidemic	O
model	O
into	O
a	O
game	O
theoretical	O
framework	O
to	O
investigate	O
the	O
effects	O
of	O
travel	O
strategies	O
on	O
infection	B-DISO
control	O
.	O

Many	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoVs	O
)	O
have	O
been	O
detected	O
in	O
bats	O
,	O
particularly	O
those	O
that	O
reside	O
in	O
China	O
,	O
Europe	O
,	O
and	O
Africa	O
.	O

Over	O
the	O
past	O
few	O
years	O
,	O
there	O
has	O
been	O
an	O
increase	O
in	O
the	O
use	O
of	O
ECMO	O
for	O
ARDS	B-DISO
in	O
children	O
.	O

Early	O
diagnosis	O
and	O
appropriate	O
clinical	O
management	O
of	O
ARDS	B-DISO
are	O
still	O
great	O
challenges	O
for	O
pediatric	O
critical	O
care	O
medicine	O
.	O

TITLE	O
:	O
Recent	O
advances	O
in	O
understanding	O
and	O
treating	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Low	O
tidal	O
volume	O
ventilation	O
remains	O
the	O
predominant	O
mainstay	O
of	O
the	O
ventilatory	O
strategy	O
in	O
ARDS	B-DISO
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
advances	O
in	O
the	O
diagnosis	O
,	O
epidemiology	O
,	O
and	O
treatment	O
of	O
ARDS	B-DISO
over	O
the	O
past	O
decade	O
.	O

Over	O
the	O
previous	O
centuries	O
,	O
global	O
pandemics	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
smallpox	B-DISO
,	O
cholera	B-DISO
,	O
and	O
influenza	B-DISO
,	O
periodically	O
threatened	O
the	O
survival	O
of	O
entire	O
populations	O
.	O

Left	O
untreated	O
,	O
the	O
condition	B-DISO
may	O
rapidly	O
progress	O
to	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
death	O
.	O

The	O
herpesviruses	O
identified	O
were	O
related	O
to	O
the	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
(	O
Gallid	O
herpesvirus	O
1	O
)	O
of	O
the	O
genus	O
Iltovirus	O
(	O
bootstrap	O
clade	O
support	O
=	O
99	O
%).	O

Adult	O
patients	O
with	O
acute	O
severe	O
poisoning	O
in	O
the	O
emergency	B-DISO
intensive	O
care	O
unit	O
(	O
EICU	O
)	O
of	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
from	O
January	O
2008	O
to	O
December	O
2017	O
were	O
enrolled	O
.	O

(	O
1	O
)	O
Clinical	O
features	O
:	O
compared	O
with	O
the	O
youth	O
group	O
,	O
the	O
elderly	O
group	O
had	O
higher	O
proportion	O
of	O
basic	O
diseases	O
included	O
hypertension	B-DISO
,	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
and	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
,	O
higher	O
the	O
initial	O
APACHE	O
II	O
scores	O
at	O
admission	O
,	O
higher	O
the	O
proportion	O
of	O
invasive	O
mechanical	O
ventilation	O
and	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
longer	O
the	O
length	O
of	O
EICU	O
stay	O
and	O
the	O
length	O
of	O
hospital	O
stay	O
.	O

There	O
were	O
67	O
patients	O
died	O
(	O
26	O
.	O
38	O
%)	O
in	O
the	O
youth	O
group	O
and	O
the	O
cause	O
of	O
death	O
were	O
respiratory	B-DISO
failure	I-DISO
(	O
59	O
.	O
70	O
%),	O
MODS	B-DISO
(	O
20	O
.	O
90	O
%)	O
and	O
circulatory	B-DISO
failure	I-DISO
(	O
19	O
.	O
40	O
%).	O

(	O
2	O
)	O
Risk	O
factors	O
of	O
deaths	O
:	O
the	O
APACHE	O
II	O
score	O
,	O
incidence	O
of	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
and	O
MODS	B-DISO
in	O
the	O
elderly	O
death	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
elderly	O
survival	O
group	O
.	O

TITLE	O
:	O
Salvage	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
induction	O
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
acute	B-DISO
leukemia	I-DISO
patients	O
:	O
A	O
case	O
series	O
.	O

However	O
,	O
the	O
prognosis	O
in	O
hematologic	B-DISO
malignancies	I-DISO
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
remained	O
poor	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
patients	O
with	O
acute	B-DISO
leukemia	I-DISO
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
at	O
our	O
facility	O
from	O
July	O
2015	O
through	O
August	O
2017	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
visual	O
triage	O
for	O
screening	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
patients	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
this	O
cutoff	O
score	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
were	O
74	O
.	O
1	O
%	O
and	O
18	O
.	O
6	O
%,	O
respectively	O
.	O

Clinicians	O
should	O
consider	O
human	O
coronavirus	O
NL63	O
for	O
patients	O
in	O
similar	O
settings	O
with	O
respiratory	B-DISO
disease	I-DISO
.	O

Background	O
information	O
on	O
infectious	B-DISO
diseases	I-DISO
in	O
Zhejiang	O
province	O
was	O
collected	O
,	O
and	O
the	O
brainstorming	O
and	O
expert	O
consultation	O
methods	O
were	O
used	O
to	O
identify	O
the	O
risks	O
.	O

With	O
risk	O
management	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
was	O
not	O
occurred	O
during	O
the	O
G20	O
summit	O
,	O
and	O
the	O
epidemic	O
situation	O
of	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
with	O
middle	O
or	O
low	O
risks	O
was	O
almost	O
the	O
same	O
with	O
that	O
of	O
past	O
years	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
has	O
re	O
-	O
emerged	O
in	O
recent	O
years	O
and	O
has	O
already	O
caused	O
huge	O
economic	O
losses	O
to	O
the	O
porcine	O
industry	O
all	O
over	O
the	O
world	O
.	O

Infection	B-DISO
of	O
mice	O
with	O
RV1B	O
2	O
days	O
before	O
PR8	O
reduced	O
the	O
severity	O
of	O
infection	B-DISO
by	O
a	O
low	O
or	O
medium	O
,	O
but	O
not	O
high	O
,	O
dose	O
of	O
PR8	O
.	O

Disease	O
attenuation	O
was	O
associated	O
with	O
an	O
early	O
inflammatory	B-DISO
response	I-DISO
in	O
the	O
lungs	O
and	O
enhanced	O
clearance	O
of	O
PR8	O
.	O

Management	O
of	O
the	O
condition	B-DISO
remains	O
a	O
major	O
challenge	O
for	O
pediatric	O
intensive	O
care	O
specialists	O
.	O

To	O
perform	O
a	O
descriptive	O
assessment	O
of	O
pARDS	O
based	O
on	O
the	O
modified	O
Berlin	O
Definition	O
by	O
using	O
the	O
SpO	O
The	O
data	O
of	O
all	O
children	O
on	O
mechanical	O
ventilation	O
for	O
respiratory	B-DISO
failure	I-DISO
admitted	O
between	O
2005	O
and	O
2012	O
were	O
reviewed	O
retrospectively	O
for	O
this	O
study	O
.	O

Intracranial	O
Inoculation	O
Is	O
More	O
Potent	O
Than	O
Intranasal	O
Inoculation	O
for	O
Inducing	O
Optic	B-DISO
Neuritis	I-DISO
in	O
the	O
Mouse	B-DISO
Hepatitis	I-DISO
Virus	O
-	O
Induced	O
Model	O
of	O
Multiple	B-DISO
Sclerosis	I-DISO
.	O

TITLE	O
:	O
Viral	O
etiological	O
causes	O
of	O
febrile	B-DISO
seizures	I-DISO
for	O
respiratory	O
pathogens	O
(	O
EFES	O
Study	O
).	O

Its	O
use	O
in	O
patients	O
with	O
obstructive	B-DISO
pulmonary	I-DISO
diseases	I-DISO
has	O
been	O
rare	O
since	O
obstructions	B-DISO
could	O
not	O
be	O
monitored	O
on	O
a	O
regional	O
level	O
at	O
the	O
bedside	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	B-DISO
infection	I-DISO
decreases	O
arginine	O
uptake	O
by	O
downregulating	O
CAT	O
-	O
1	O
expression	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
a	O
coronavirus	O
that	O
causes	O
severe	B-DISO
diarrhea	I-DISO
in	O
suckling	O
piglets	O
.	O

However	O
,	O
the	O
effects	O
of	O
TGEV	O
infection	B-DISO
on	O
nutrient	O
absorption	O
in	O
swine	O
have	O
not	O
yet	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
impact	O
of	O
TGEV	O
infection	B-DISO
on	O
arginine	O
uptake	O
using	O
the	O
porcine	O
small	O
intestinal	O
epithelial	O
cell	O
line	O
IPEC	O
-	O
J2	O
as	O
a	O
model	O
system	O
.	O

The	O
results	O
provide	O
insights	O
into	O
the	O
evolution	O
of	O
the	O
viruses	O
and	O
co	B-DISO
-	I-DISO
infection	I-DISO
of	O
chickens	O
with	O
different	O
virus	O
serotypes	O
.	O

HCoV	O
clinical	O
symptoms	O
were	O
more	O
severe	O
than	O
those	O
of	O
RSV	B-DISO
infections	I-DISO
but	O
milder	O
than	O
influenza	B-DISO
symptoms	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
sensitive	O
and	O
specific	O
xMAP	O
assay	O
for	O
detection	O
of	O
antibodies	O
against	O
infectious	B-DISO
laryngotracheitis	B-DISO
and	O
bronchitis	B-DISO
viruses	O
.	O

In	O
the	O
OLA	O
group	O
,	O
5	O
cmH	B-DISO
OLA	O
significantly	O
improved	O
lung	O
aeration	O
,	O
arterial	O
oxygenation	O
,	O
and	O
gas	O
exchange	O
.	O

In	O
this	O
study	O
,	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
with	O
the	O
size	O
range	O
of	O
700	O
-	O
900	O
μm	O
in	O
diameter	O
were	O
developed	O
by	O
centrifugal	O
granulation	O
-	O
fluidized	O
bed	B-DISO
coating	O
and	O
demonstrated	O
as	O
an	O
effective	O
oral	O
delivery	O
system	O
to	O
protect	O
PEDV	O
antigens	O
against	O
the	O
complex	O
gastrointestinal	O
environment	O
by	O
detecting	O
the	O
live	O
virus	O
particles	O
in	O
microspheres	O
after	O
the	O
simulated	O
gastric	O
fluid	O
treatment	O
and	O
the	O
PEDV	O
RNA	O
in	O
fecal	O
swabs	O
collected	O
from	O
all	O
weaned	O
piglets	O
(	O
100	O
%)	O
orally	O
inoculated	O
with	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
.	O

In	O
both	O
preventive	O
and	O
therapeutic	O
approaches	O
,	O
TA	O
attenuated	O
LPS	B-DISO
-	O
induced	O
histopathological	O
alterations	O
,	O
lipid	O
peroxidation	O
,	O
lung	O
permeability	O
,	O
infiltration	B-DISO
of	O
inflammatory	O
cells	O
,	O
and	O
the	O
expression	O
of	O
proinflammatory	O
mediators	O
.	O

We	O
searched	O
the	O
PubMed	O
database	O
for	O
clinical	O
trials	O
,	O
observational	O
studies	O
,	O
and	O
review	O
articles	O
describing	O
treatment	O
adjuncts	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
,	O
including	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
strategies	O
,	O
recruitment	B-DISO
maneuvers	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
prone	O
positioning	O
,	O
inhaled	O
pulmonary	O
vasodilators	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
glucocorticoids	O
,	O
and	O
renal	O
replacement	O
therapy	O
.	O

For	O
severe	O
hypoxemia	O
,	O
first	O
-	O
line	O
treatment	O
adjuncts	O
include	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
strategies	O
,	O
recruitment	B-DISO
maneuvers	O
,	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
and	O
prone	O
positioning	O
.	O

TITLE	O
:	O
Burden	O
of	O
exposure	O
to	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
Mycoplasma	B-DISO
gallisepticum	O
,	O
and	O
intestinal	B-DISO
parasites	I-DISO
in	O
introduced	O
broiler	O
chickens	O
on	O
the	O
Galapagos	O
.	O

TITLE	O
:	O
First	O
retrospective	O
studies	O
with	O
etiological	O
confirmation	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
Argentina	O
.	O

Results	O
indicated	O
that	O
AIF	O
translocated	O
from	O
the	O
mitochondria	O
to	O
nucleus	O
during	O
TGEV	O
infection	B-DISO
,	O
and	O
the	O
AIF	O
inhibitor	O
,	O
N	O
-	O
phenylmaleimide	O
(	O
NP	O
),	O
significantly	O
attenuated	O
the	O
apoptosis	O
.	O

TITLE	O
:	O
Predictors	O
of	O
survival	O
in	O
patients	O
with	O
influenza	B-DISO
pneumonia	I-DISO
-	O
related	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
prone	O
positioning	O
.	O

They	O
were	O
monitored	O
for	O
infections	B-DISO
with	O
predefined	O
intervals	O
and	O
on	O
extra	O
visits	O
during	O
the	O
first	O
year	O
,	O
the	O
total	O
follow	O
-	O
up	O
period	O
ranged	O
between	O
5	O
and	O
8	O
years	O
.	O

Viral	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
during	O
the	O
first	O
year	O
was	O
identified	O
as	O
a	O
risk	O
factor	O
for	O
long	O
-	O
term	O
CLAD	O
development	O
(	O
This	O
study	O
suggests	O
that	O
VRTI	O
during	O
the	O
first	O
year	O
after	O
lung	O
transplantation	O
is	O
associated	O
with	O
long	O
-	O
term	O
CLAD	O
development	O
and	O
that	O
coronavirus	B-DISO
infections	I-DISO
in	O
particular	O
might	O
be	O
a	O
risk	O
factor	O
.	O

Additionally	O
,	O
the	O
resistance	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
directly	O
correlated	O
with	O
increased	O
serum	O
shDPP4	O
and	O
serum	O
virus	O
neutralizing	O
activity	O
.	O

Additionally	O
,	O
it	O
offers	O
a	O
validated	O
pair	O
of	O
Tg	O
mice	O
strains	O
for	O
characterizing	O
the	O
effect	O
of	O
shDPP4	O
on	O
MERS	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
First	O
identification	O
of	O
a	O
single	O
amino	O
acid	O
change	O
in	O
the	O
spike	O
protein	O
region	O
of	O
feline	O
coronavirus	O
detected	O
from	O
a	O
coronavirus	O
-	O
associated	O
cutaneous	B-DISO
nodule	I-DISO
in	O
a	O
cat	O
.	O

Real	O
-	O
time	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
of	O
a	O
cutaneous	O
sample	O
revealed	O
a	O
single	O
nucleotide	O
substitution	O
in	O
the	O
spike	O
protein	O
gene	O
of	O
FCoV	O
(	O
mutation	O
M1058L	O
),	O
which	O
is	O
consistent	O
with	O
an	O
FCoV	O
genotype	O
commonly	O
associated	O
with	O
FIP	B-DISO
.	O

The	O
infection	B-DISO
was	O
introduced	O
by	O
import	O
of	O
two	O
breeding	O
boars	O
which	O
were	O
placed	O
in	O
provisional	O
quarantine	O
in	O
a	O
unit	O
not	O
strictly	O
separated	O
from	O
other	O
healthy	O
pigs	O
in	O
the	O
same	O
building	O
.	O

ABSTRACT	O
:	O
We	O
report	O
an	O
unusual	O
case	O
of	O
severe	O
hepatopulmonary	B-DISO
syndrome	I-DISO
with	O
previously	O
unrecognized	O
cirrhosis	B-DISO
,	O
presenting	O
with	O
acute	O
on	O
chronic	O
dyspnoea	B-DISO
,	O
extreme	O
hypoxemia	O
,	O
secondary	B-DISO
polycythemia	I-DISO
as	O
well	O
as	O
direct	O
identification	O
of	O
arteriovenous	O
communications	O
on	O
computed	O
tomography	O
angiography	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
human	O
infections	B-DISO
caused	O
by	O
severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	B-DISO
virus	O
(	O
SFTSV	O
),	O
which	O
can	O
lead	O
to	O
fatality	O
,	O
have	O
dramatically	O
increased	O
in	O
East	O
Asia	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
an	O
acute	O
,	O
highly	O
contagious	O
,	O
and	O
economically	O
important	O
viral	B-DISO
disease	I-DISO
of	O
chickens	O
.	O

ABSTRACT	O
:	O
Ever	O
since	O
the	O
development	O
of	O
the	O
first	O
vaccine	O
more	O
than	O
200	O
years	O
ago	O
,	O
vaccinations	O
have	O
greatly	O
decreased	O
the	O
burden	O
of	O
infectious	B-DISO
diseases	I-DISO
worldwide	O
,	O
famously	O
leading	O
to	O
the	O
eradication	O
of	O
small	O
pox	O
and	O
allowing	O
the	O
restriction	O
of	O
diseases	O
such	O
as	O
polio	B-DISO
,	O
tetanus	B-DISO
,	O
diphtheria	B-DISO
,	O
and	O
measles	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
a	O
highly	O
contagious	O
,	O
acute	O
enteric	O
tract	O
infectious	B-DISO
disease	I-DISO
of	O
pigs	O
(	O
Sus	O
domesticus	O
)	O
caused	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

Chlordecone	O
also	O
accelerated	O
the	O
death	O
of	O
mice	O
infected	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
and	O
enhanced	O
the	O
entry	O
of	O
the	O
virus	O
into	O
the	O
cervical	O
spinal	O
cord	B-DISO
in	O
infected	O
mice	O
,	O
leading	O
to	O
considerable	O
neurological	O
damage	O
.	O

In	O
the	O
present	O
study	O
,	O
an	O
infectious	B-DISO
cDNA	O
clone	O
of	O
an	O
attenuated	O
G2b	O
PEDV	O
strain	O
was	O
successfully	O
generated	O
for	O
the	O
first	O
time	O
,	O
and	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
indicate	O
that	O
iPEDVPT	O
-	O
P96	O
is	O
further	O
attenuated	O
but	O
remains	O
immunogenic	O
compared	O
to	O
its	O
parental	O
PEDVPT	O
-	O
P96	O
viral	O
stock	O
.	O

The	O
successful	O
development	O
of	O
the	O
iPEDVPT	O
-	O
P96	O
cDNA	O
clone	O
could	O
allow	O
for	O
the	O
manipulation	O
of	O
the	O
viral	O
genome	O
to	O
study	O
viral	B-DISO
pathogenesis	I-DISO
and	O
facilitate	O
the	O
rapid	O
development	O
of	O
effective	O
vaccines	O
.	O

Viral	B-DISO
diseases	I-DISO
are	O
highly	O
infectious	B-DISO
and	O
capable	O
of	O
causing	O
pandemics	O
as	O
evidenced	O
by	O
outbreaks	O
of	O
diseases	O
like	O
Ebola	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
,	I-DISO
West	I-DISO
Nile	O
,	O
SARS	B-DISO
-	O
Corona	O
,	O
Nipah	O
,	O
Hendra	O
,	O
Avian	B-DISO
influenza	I-DISO
and	O
Swine	B-DISO
influenza	I-DISO
.	O

Hendra	O
virus	O
(	O
HeV	O
)	O
causes	O
respiratory	O
and	O
neurological	B-DISO
disease	I-DISO
and	O
death	O
in	O
man	O
and	O
horses	O
.	O

Using	O
SARS	B-DISO
and	O
the	O
International	O
Health	O
Regulations	O
(	O
IHR	O
)	O
as	O
a	O
starting	O
point	O
,	O
this	O
article	O
examines	O
negotiated	O
information	O
orders	O
in	O
global	O
public	O
health	O
governance	O
and	O
the	O
irregularities	O
in	O
the	O
supply	O
of	O
data	O
that	O
underlie	O
them	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
2	O
patients	O
with	O
persistent	O
and	O
progressive	B-DISO
coccidioidomycosis	I-DISO
who	O
demonstrated	O
a	O
dramatic	O
response	O
to	O
adjunctive	O
corticosteroid	O
therapy	O
.	O

Serial	O
chest	O
radiographies	O
(	O
CXRs	O
)	O
were	O
obtained	O
from	O
viral	O
exposure	O
until	O
death	O
or	O
discharge	O
in	O
35	O
patients	O
with	O
laboratory	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Among	O
35	O
patients	O
(	O
22	O
men	O
,	O
13	O
women	O
;	O
median	O
age	O
:	O
48	O
years	O
),	O
25	O
demonstrated	O
abnormal	O
opacity	B-DISO
on	O
CXR	O
(	O
MERS	O
pneumonia	B-DISO
),	O
whereas	O
no	O
abnormality	O
was	O
detected	O
in	O
10	O
patients	O
(	O
MERS	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
).	O

ABSTRACT	O
:	O
A	O
majority	O
of	O
viruses	O
that	O
have	O
caused	O
recent	O
epidemics	O
with	O
high	O
lethality	O
rates	O
in	O
people	O
,	O
are	O
zoonoses	B-DISO
originating	O
from	O
wildlife	O
.	O

We	O
describe	O
isolation	O
of	O
infectious	B-DISO
MERS	O
-	O
CoV	O
from	O
the	O
upper	O
respiratory	O
tract	O
of	O
a	O
mildly	O
ill	B-DISO
27	O
-	O
year	O
-	O
old	O
female	O
in	O
Saudi	O
Arabia	O
15	O
days	O
after	O
illness	O
onset	O
.	O

In	O
mechanically	O
ventilated	O
moderate	O
-	O
severe	O
ARDS	B-DISO
,	O
2D	O
speckle	O
tracking	O
is	O
feasible	O
even	O
though	O
difficult	O
acoustic	O
windows	O
are	O
common	O
.	O

ABSTRACT	O
:	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
is	O
a	O
filovirus	O
that	O
causes	O
a	O
severe	O
and	O
rapidly	O
progressing	O
hemorrhagic	O
syndrome	B-DISO
;	O
a	O
recent	O
epidemic	O
illustrated	O
the	O
urgent	O
need	O
for	O
novel	O
therapeutic	O
agents	O
because	O
no	O
drugs	O
have	O
been	O
approved	O
for	O
treatment	O
of	O
Ebola	O
virus	O
.	O

The	O
study	O
was	O
conducted	O
in	O
the	O
outpatient	O
examination	O
rooms	O
and	O
emergency	B-DISO
departments	O
of	O
three	O
types	O
of	O
hospitals	O
in	O
the	O
Eastern	O
region	O
of	O
Saudi	O
Arabia	O
where	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
endemic	O
and	O
is	O
observed	O
in	O
routine	O
cases	O
and	O
outbreaks	O
.	O

TITLE	O
:	O
Acute	B-DISO
Megakaryoblastic	I-DISO
Leukemia	I-DISO
With	O
Diffuse	O
Periosteal	O
Reaction	O
of	O
Bilateral	O
Lower	O
Extremities	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
3	O
-	O
year	O
-	O
old	O
girl	O
diagnosed	O
with	O
acute	B-DISO
megakaryoblastic	I-DISO
leukemia	I-DISO
,	O
who	O
presented	O
after	O
>	O
1	O
year	O
of	O
bilateral	O
leg	B-DISO
pain	I-DISO
.	O

However	O
,	O
it	O
was	O
not	O
until	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
occurred	O
with	O
subsequent	O
hospitalization	O
in	O
the	O
pediatric	O
intensive	O
care	O
unit	O
that	O
severe	B-DISO
anemia	I-DISO
and	O
thrombocytopenia	O
were	O
discovered	O
and	O
the	O
diagnosis	O
of	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
was	O
made	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
leukocytosis	B-DISO
,	O
hyperkalemia	O
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
pneumonia	B-DISO
/	O
ARDS	B-DISO
,	O
seizure	B-DISO
/	O
encephalopathy	B-DISO
,	O
need	O
for	O
ICU	O
support	O
,	O
and	O
dialysis	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
died	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
leukocytosis	B-DISO
,	O
hyperkalemia	O
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
pneumonia	B-DISO
/	O
ARDS	B-DISO
,	O
seizure	B-DISO
/	O
encephalopathy	B-DISO
,	O
need	O
for	O
ICU	O
support	O
,	O
and	O
dialysis	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
died	O
.	O

He	O
was	O
diagnosed	O
with	O
myocardial	B-DISO
infarction	I-DISO
complicated	O
with	O
ventricular	B-DISO
septal	I-DISO
perforation	I-DISO
(	O
VSP	O
),	O
and	O
intraaortic	O
balloon	O
pumping	O
support	O
and	O
intensive	O
care	O
were	O
started	O
.	O

Here	O
we	O
engineered	O
full	O
,	O
partially	O
deleted	O
(-	O
29	O
nt	O
),	O
and	O
fully	O
deleted	O
ORF8	O
into	O
a	O
SARS	B-DISO
-	O
CoV	O
infectious	B-DISO
cDNA	O
clone	O
,	O
strain	O
Frankfurt	O
-	O
1	O
.	O

These	O
results	O
have	O
important	O
implications	O
for	O
the	O
retrospective	O
assessment	O
of	O
the	O
threat	O
posed	O
by	O
SARS	B-DISO
.	O

We	O
conducted	O
a	O
cost	O
-	O
utility	O
analysis	O
with	O
a	O
cohort	O
state	O
transition	B-DISO
decision	O
model	O
using	O
a	O
lifetime	O
time	O
horizon	O
,	O
1	O
.	O
5	O
%	O
discount	O
rate	O
,	O
and	O
outcomes	O
reported	O
as	O
cost	O
per	O
quality	O
-	O
adjusted	O
life	O
year	O
.	O

As	O
subepithelial	O
myofibroblasts	O
secrete	O
extracellular	O
matrix	O
and	O
growth	O
factors	O
contributing	O
to	O
the	O
attachment	O
,	O
proliferation	B-DISO
and	O
differentiation	O
of	O
epithelial	O
cells	O
,	O
co	O
-	O
cultures	O
of	O
primary	O
porcine	O
enterocytes	O
(	O
ileocytes	O
and	O
colonocytes	O
)	O
with	O
myofibroblasts	O
were	O
developed	O
and	O
evaluated	O
for	O
their	O
susceptibility	O
to	O
enteric	O
viruses	O
.	O

ABSTRACT	O
:	O
Because	O
the	O
Berlin	O
definition	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
only	O
moderate	O
reliability	O
,	O
physicians	O
disagree	O
about	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
in	O
some	O
patients	O
.	O

To	O
characterize	O
patients	O
with	O
diagnostic	O
disagreement	O
about	O
ARDS	B-DISO
among	O
critical	O
-	O
care	O
-	O
trained	O
physicians	O
and	O
compare	O
them	O
with	O
patients	O
with	O
a	O
consensus	O
that	O
ARDS	B-DISO
developed	O
.	O

Patients	O
with	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
arterial	O
oxygen	O
tension	B-DISO
/	O
pressure	O
[	O
Pa	O
Among	O
738	O
patients	O
reviewed	O
,	O
110	O
(	O
15	O
%)	O
had	O
consensus	O
-	O
ARDS	B-DISO
,	O
100	O
(	O
14	O
%)	O
had	O
disagreement	O
,	O
and	O
528	O
(	O
72	O
%)	O
did	O
not	O
have	O
ARDS	B-DISO
.	O

Patients	O
with	O
disagreement	O
had	O
baseline	O
comorbidity	O
rates	O
similar	O
to	O
those	O
of	O
patients	O
with	O
consensus	O
-	O
ARDS	B-DISO
,	O
but	O
lower	O
rates	O
of	O
ARDS	B-DISO
risk	O
factors	O
and	O
less	O
severe	O
measures	O
of	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
diseases	I-DISO
continue	O
to	O
have	O
a	O
major	O
impact	O
on	O
poultry	O
health	O
,	O
welfare	O
and	O
productivity	O
.	O

After	O
the	O
seizure	B-DISO
resolved	O
,	O
she	O
was	O
intubated	O
due	O
to	O
respiratory	O
deterioration	O
.	O

Our	O
findings	O
may	O
thus	O
provide	O
insight	O
into	O
the	O
development	O
of	O
TTC	O
and	O
prompt	O
further	O
studies	O
regarding	O
the	O
relationship	O
between	O
prolonged	O
seizures	B-DISO
and	O
TTC	O
.	O

Identifying	O
events	O
that	O
trigger	O
negative	O
emotions	O
in	O
hospital	O
workers	O
has	O
important	O
implications	O
for	O
hospitals	O
'	O
management	O
guidance	O
in	O
relation	O
to	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

For	O
fast	O
and	O
reliable	O
diagnosis	O
of	O
the	O
causative	O
agent	O
associated	O
with	O
viral	B-DISO
diarrhea	I-DISO
in	O
pigs	O
,	O
an	O
inexpensive	O
and	O
easy	O
to	O
perform	O
gel	O
-	O
based	O
multiplex	O
PCR	O
assay	O
was	O
developed	O
in	O
this	O
study	O
to	O
detect	O
and	O
differentiate	O
the	O
different	O
viruses	O
by	O
amplicon	O
size	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
recruitment	B-DISO
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
titrated	O
according	O
to	O
minimal	O
static	O
elastance	O
of	O
the	O
respiratory	O
system	O
(	O
PEEP	O
Thirteen	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
were	O
studied	O
at	O
PEEP	O
7	O
out	O
of	O
13	O
patients	O
showed	O
negative	O
end	O
-	O
expiratory	O
transpulmonary	O
pressures	O
(	O
Ptp	B-DISO
-)	O
with	O
both	O
strategies	O
(	O
PEEP	O
In	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
,	O
PEEP	O
titrated	O
according	O
to	O
the	O
minimal	O
static	O
elastance	O
of	O
the	O
respiratory	O
system	O
or	O
according	O
to	O
the	O
ARDSNetwork	O
table	O
did	O
not	O
prevent	O
negative	O
end	O
-	O
expiratory	O
transpulmonary	O
pressure	O
.	O

RESULTS	O
:	O
7	O
out	O
of	O
13	O
patients	O
showed	O
negative	O
end	O
-	O
expiratory	O
transpulmonary	O
pressures	O
(	O
Ptp	B-DISO
-)	O
with	O
both	O
strategies	O
(	O
PEEP	O

Individualized	O
vancomycin	O
dosing	O
regimens	O
and	O
therapeutic	O
drug	O
monitoring	O
are	O
necessary	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
receiving	O
CVVH	O
and	O
ECMO	O
to	O
ensure	O
that	O
the	O
target	O
serum	O
vancomycin	O
levels	O
are	O
reached	O
to	O
adequately	O
treat	O
the	O
infection	B-DISO
and	O
avoid	O
nephrotoxicity	O
.	O

TITLE	O
:	O
White	O
-	O
nose	O
syndrome	B-DISO
is	O
associated	O
with	O
increased	O
replication	O
of	O
a	O
naturally	O
persisting	O
coronaviruses	O
in	O
bats	O
.	O

TITLE	O
:	O
A	O
newly	O
isolated	O
Chinese	O
virulent	O
genotype	O
GIIb	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
:	O
Biological	O
characteristics	O
,	O
pathogenicity	O
and	O
immune	O
protective	O
effects	O
as	O
an	O
inactivated	O
vaccine	O
candidate	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
we	O
report	O
a	O
parallel	O
application	O
of	O
both	O
docking	O
-	O
and	O
shape	O
-	O
based	O
virtual	O
screening	O
(	O
VS	O
)	O
methods	O
,	O
followed	O
by	O
Molecular	O
Dynamics	O
simulations	O
(	O
MDs	B-DISO
),	O
for	O
discovering	O
new	O
compounds	O
able	O
to	O
inhibit	O
the	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
RNA	O
-	O
dependent	O
DNA	O
polymerase	O
activity	O
.	O

Transferrin	O
receptor	O
1	O
(	O
TfR1	O
),	O
which	O
is	O
highly	O
expressed	O
in	O
piglets	O
with	O
anemia	B-DISO
,	O
may	O
play	O
a	O
role	O
in	O
TGEV	O
infection	B-DISO
.	O

TGEV	O
infection	B-DISO
and	O
replication	O
were	O
inhibited	O
by	O
occluding	B-DISO
TfR1	O
with	O
antibodies	O
or	O
by	O
decreasing	O
TfR1	O
expression	O
.	O

ABSTRACT	O
:	O
Ferret	O
and	O
mink	O
coronaviruses	O
typically	O
cause	O
catarrhal	O
diarrhea	B-DISO
in	O
ferrets	O
and	O
minks	O
,	O
respectively	O
.	O

In	O
the	O
second	O
assessment	O
of	O
the	O
high	O
-	O
risk	O
group	O
,	O
the	O
sleep	O
and	O
numbness	B-DISO
subscale	O
scores	O
from	O
the	O
IES	O
-	O
R	O
differed	O
depending	O
on	O
the	O
implementation	O
of	O
home	O
quarantine	O
,	O
and	O
the	O
intrusion	O
subscale	O
scores	O
differed	O
depending	O
on	O
the	O
performance	O
of	O
MERS	O
-	O
related	O
tasks	O
.	O

Viral	O
infectious	B-DISO
agents	O
were	O
found	O
in	O
449	O
(	O
87	O
.	O
2	O
%)	O
of	O
515	O
specimens	O
.	O

Natural	O
infection	B-DISO
by	O
ECoV	O
has	O
been	O
reported	O
in	O
adult	O
horses	O
worldwide	O
,	O
whereas	O
experimental	O
infection	B-DISO
has	O
only	O
been	O
reported	O
in	O
juvenile	O
horses	O
.	O

Longitudinal	O
observational	O
retrospective	O
study	O
,	O
with	O
patients	O
aged	O
0	O
-	O
18	O
years	O
,	O
admitted	O
to	O
11	O
PICUs	O
in	O
Rio	O
de	O
Janeiro	O
,	O
with	O
suspected	O
H1N1	O
infection	B-DISO
,	O
from	O
June	O
to	O
November	O
,	O
2009	O
.	O

However	O
,	O
because	O
of	O
various	O
concerns	O
,	O
ECMO	O
has	O
rarely	O
been	O
used	O
in	O
patients	O
who	O
have	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
infection	I-DISO
with	O
or	O
without	O
acquired	B-DISO
immune	I-DISO
deficiency	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Including	O
793	O
/	O
B	O
type	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
vaccine	O
in	O
1	O
-	O
day	O
-	O
old	O
chicken	O
increased	O
the	O
protection	O
against	O
QX	O
genotype	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
),	O
a	O
highly	O
lethal	O
respiratory	B-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
),	O
is	O
an	O
emerging	O
disease	O
with	O
high	O
potential	O
for	O
epidemic	O
spread	O
.	O

A	O
nucleotide	O
sequence	O
alignment	O
showed	O
that	O
the	O
whole	O
genome	O
of	O
CHN	B-DISO
-	O
HG	O
-	O
2017	O
is	O
97	O
.	O
6	O
%-	O
99	O
.	O
1	O
%	O
identical	O
to	O
other	O
PDCoV	O
strains	O
.	O

Our	O
analysis	O
of	O
the	O
full	O
genome	O
sequence	O
of	O
a	O
recombinant	O
PDCoV	O
and	O
its	O
virulence	O
in	O
suckling	O
piglets	O
might	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	B-DISO
of	O
PDCoV	O
and	O
facilitate	O
further	O
investigation	O
of	O
this	O
newly	O
emerged	O
pathogen	O
.	O

The	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
alone	O
)	O
was	O
detected	O
with	O
highest	O
frequency	O
in	O
60	O
farms	O
,	O
and	O
separately	O
or	O
combined	O
with	O
other	O
agents	O
,	O
in	O
110	O
farms	O
;	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
separately	O
,	O
was	O
detected	O
in	O
28	O
farms	O
,	O
and	O
in	O
63	O
farms	O
separately	O
or	O
combined	O
with	O
other	O
infectious	B-DISO
agents	O
;	O
and	O
avian	B-DISO
influenza	I-DISO
H9N2	O
was	O
detected	O
in	O
22	O
farms	O
separately	O
and	O
in	O
51	O
farms	O
separately	O
or	O
concomitant	O
with	O
other	O
infectious	B-DISO
agents	O
.	O

TITLE	O
:	O
MicroRNA	O
-	O
221	O
-	O
5p	O
Inhibits	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Replication	O
by	O
Targeting	O
Genomic	O
Viral	O
RNA	O
and	O
Activating	O
the	O
NF	O
-	O
κB	O
Pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulatory	O
relationship	O
between	O
miRNA	O
-	O
221	O
-	O
5p	O
and	O
PEDV	O
infection	B-DISO
,	O
finding	O
that	O
miR	O
-	O
221	O
-	O
5p	O
overexpression	O
inhibited	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
that	O
silencing	O
endogenous	O
miR	O
-	O
221	O
-	O
5p	O
enhanced	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Stochastic	O
epidemic	O
models	O
with	O
two	O
groups	O
are	O
formulated	O
and	O
applied	O
to	O
emerging	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
recent	O
emerging	O
diseases	O
,	O
disease	O
spread	O
has	O
been	O
attributed	O
to	O
superspreaders	O
,	O
highly	O
infectious	B-DISO
individuals	O
that	O
infect	O
a	O
large	O
number	O
of	O
susceptible	O
individuals	O
.	O

We	O
apply	O
a	O
continuous	O
-	O
time	O
Markov	O
chain	O
(	O
CTMC	O
)	O
model	O
to	O
study	O
disease	O
emergence	O
or	O
re	O
-	O
emergence	O
from	O
different	O
groups	O
,	O
where	O
the	O
transmission	O
rates	O
depend	O
on	O
either	O
the	O
infectious	B-DISO
host	O
or	O
the	O
susceptible	O
host	O
.	O

TITLE	O
:	O
Incidence	O
,	O
significance	O
,	O
and	O
persistence	O
of	O
human	O
coronavirus	B-DISO
infection	I-DISO
in	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
.	O

Annual	O
epidemics	O
of	O
seasonal	O
influenza	B-DISO
cause	O
an	O
estimated	O
3	O
-	O
5	O
million	O
cases	O
of	O
severe	O
illness	O
and	O
more	O
than	O
500	O
000	O
deaths	O
,	O
with	O
the	O
prospect	O
of	O
pandemic	O
influenza	B-DISO
viruses	O
causing	O
far	O
greater	O
impact	O
.	O

ABSTRACT	O
:	O
An	O
acute	O
epidemic	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
has	O
affected	O
the	O
USA	O
since	O
2013	O
and	O
spread	O
all	O
around	O
the	O
world	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
continues	O
to	O
drive	O
seasonal	O
morbidity	O
,	O
particularly	O
in	O
settings	O
with	O
low	O
vaccine	O
coverage	O
.	O

A	O
prospective	O
study	O
based	O
on	O
active	O
surveillance	O
of	O
inpatients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
from	O
a	O
tertiary	O
hospital	O
in	O
Bucharest	O
,	O
Romania	O
,	O
in	O
the	O
season	O
2016	O
/	O
17	O
.	O

Of	O
the	O
281	O
confirmed	O
cases	O
,	O
160	O
(	O
56	O
.	O
9	O
%)	O
involved	O
comorbidities	O
,	O
wherein	O
diabetes	B-DISO
mellitus	I-DISO
,	O
hypertension	B-DISO
,	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
,	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
,	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
and	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
were	O
significantly	O
associated	O
with	O
mortality	O
from	O
MERS	O
-	O
CoV	O
and	O
two	O
or	O
three	O
comorbidities	O
significantly	O
affected	O
the	O
fatality	O
rates	O
from	O
MERS	O
-	O
CoV	O
.	O
The	O
findings	O
of	O
this	O
study	O
show	O
that	O
old	O
age	O
and	O
the	O
existence	O
of	O
underlying	O
comorbidities	O
significantly	O
increase	O
mortality	O
from	O
MERS	O
-	O
CoV	O
.	O

Neuromuscular	O
blocking	B-DISO
agents	O
(	O
NMBAs	O
)	O
have	O
been	O
prescribed	O
to	O
patients	O
with	O
ARDS	B-DISO
as	O
they	O
are	O
thought	O
to	O
decrease	O
inflammation	B-DISO
,	O
oxygen	O
consumption	O
,	O
and	O
cardiac	O
output	O
and	O
help	O
facilitate	O
ventilator	O
synchrony	O
.	O

ABSTRACT	O
:	O
Continuous	O
Positive	O
Airway	O
Pressure	O
(	O
CPAP	O
)	O
is	O
a	O
form	O
of	O
non	O
-	O
invasive	O
ventilatory	O
support	O
which	O
is	O
increasingly	O
used	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
to	O
treat	O
neonates	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
.	O

Providing	O
care	O
under	O
constrained	O
circumstances	O
left	O
staff	O
feeling	B-DISO
powerless	I-DISO
to	O
provide	O
good	O
quality	O
care	O
for	O
neonates	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
.	O

Mutant	B-DISO
icΔ10aa	O
caused	O
less	O
severe	B-DISO
diarrhea	I-DISO
rate	O
and	O
significantly	O
milder	O
intestinal	O
lesions	O
than	O
icPC22A	O
,	O
icΔ5aa	O
,	O
and	O
icYA	O
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
Spike	O
Protein	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Transmitted	B-DISO
in	O
Korea	O
Increase	O
Resistance	O
to	O
Antibody	O
-	O
Mediated	O
Neutralization	O
.	O

TITLE	O
:	O
An	O
unusual	O
case	O
of	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Patients	O
that	O
survive	O
past	O
the	O
age	O
of	O
2	O
have	O
seen	O
respiratory	B-DISO
complications	I-DISO
resolve	O
due	O
to	O
less	O
pronounced	O
thoracic	B-DISO
malformations	B-DISO
,	O
but	O
in	O
our	O
case	O
the	O
main	O
cause	O
of	O
worsening	O
pulmonary	O
function	O
was	O
the	O
degree	O
of	O
pulmonary	B-DISO
arterial	I-DISO
hypertension	I-DISO
and	O
right	B-DISO
heart	I-DISO
failure	I-DISO
.	O

However	O
,	O
these	O
surgeries	O
only	O
add	B-DISO
a	O
few	O
years	O
to	O
survival	O
without	O
a	O
definitive	O
cure	O
.	O

Samples	O
from	O
18	O
seronegative	O
non	O
-	O
FIP	B-DISO
control	O
cats	O
and	O
7	O
/	O
8	O
samples	O
from	O
seropositive	O
non	O
-	O
FIP	B-DISO
control	O
cats	O
contained	O
no	O
detectable	O
viral	O
RNA	O
.	O

With	O
the	O
emergence	O
of	O
global	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
Ebola	O
and	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
there	O
is	O
a	O
need	O
for	O
increased	O
and	O
more	O
clinically	O
competent	O
use	O
of	O
respiratory	O
protection	O
among	O
healthcare	O
workers	O
.	O

TITLE	O
:	O
Elevated	O
IL	O
-	O
33	O
promotes	O
expression	O
of	O
MMP2	O
and	O
MMP9	O
via	O
activating	O
STAT3	O
in	O
alveolar	O
macrophages	O
during	O
LPS	B-DISO
-	O
induced	O
acute	O
lung	O
injury	O
.	O

MERS	O
-	O
CoV	O
is	O
now	O
included	O
on	O
the	O
WHO	O
list	O
of	O
priority	O
blueprint	O
diseases	O
for	O
which	O
there	O
which	O
is	O
an	O
urgent	O
need	O
for	O
accelerated	O
research	O
and	O
development	O
as	O
they	O
have	O
the	O
potential	O
to	O
cause	O
a	O
public	O
health	O
emergency	B-DISO
while	O
there	O
is	O
an	O
absence	O
of	O
efficacious	O
drugs	O
and	O
/	O
or	O
vaccines	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
a	O
rigid	B-DISO
sequence	O
requirement	O
for	O
S	O
protein	O
activation	O
by	O
TMPRSS2	O
but	O
not	O
cathepsin	O
L	O
.	O

These	O
viral	O
agents	O
are	O
leading	O
causes	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
every	O
year	O
affecting	O
mainly	O
children	O
under	O
5	O
years	O
old	O
and	O
also	O
the	O
elderly	O
.	O

To	O
evaluate	O
the	O
potential	O
for	O
improvement	O
in	O
management	O
of	O
patients	O
with	O
ARDS	B-DISO
,	O
this	O
study	O
was	O
designed	O
to	O
describe	O
the	O
incidence	O
and	O
management	O
of	O
ARDS	B-DISO
in	O
mainland	O
China	O
.	O

TITLE	O
:	O
Cell	O
therapy	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
case	O
illustrates	O
that	O
tuberculosis	B-DISO
should	O
always	O
be	O
suspected	O
in	O
patients	O
from	O
high	O
-	O
incidence	O
countries	O
in	O
case	O
of	O
lung	O
involvement	O
and	O
that	O
an	O
interdisciplinary	O
approach	O
including	O
long	O
-	O
term	O
intensive	O
care	O
management	O
can	O
enable	O
successful	O
treatment	O
of	O
tuberculosis	B-DISO
with	O
severe	O
,	O
near	O
-	O
fatal	O
complications	O
.	O

TITLE	O
:	O
A	O
Fulminant	O
Case	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Associated	O
with	O
Mycoplasma	B-DISO
Pneumonia	I-DISO
Treated	O
with	O
Nasal	O
High	O
-	O
Flow	O
Oxygen	O
Therapy	O
.	O

Consequently	O
,	O
with	O
this	O
treatment	O
,	O
he	O
recovered	O
from	O
severe	O
mycoplasma	B-DISO
pneumonia	I-DISO
.	O

In	O
patients	O
with	O
severe	O
pneumonia	B-DISO
who	O
experience	O
respiratory	B-DISO
failure	I-DISO
,	O
it	O
has	O
been	O
reported	O
that	O
nasal	O
high	O
-	O
flow	O
oxygen	O
therapy	O
is	O
not	O
inferior	O
to	O
noninvasive	O
positive	O
pressure	O
ventilation	O
therapy	O
regarding	O
intubation	O
rate	O
.	O

Respiratory	O
illness	O
was	O
defined	O
as	O
having	O
any	O
of	O
the	O
following	O
:	O
fever	O
,	O
cough	B-DISO
,	O
wheeze	B-DISO
,	O
difficulty	B-DISO
breathing	I-DISO
,	O
and	O
/	O
or	O
a	O
draining	O
ear	O
.	O

Exposure	O
to	O
other	O
children	O
and	O
male	O
sex	O
were	O
each	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
primary	B-DISO
infection	I-DISO
(	O
risk	O
ratios	O
,	O
1	O
.	O
13	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
06	O
-	O
1	O
.	O
20	O
]	O
and	O
1	O
.	O
14	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
27	O
],	O
respectively	O
),	O
whereas	O
higher	O
maternal	O
education	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
both	O
primary	O
and	O
repeated	O
infections	B-DISO
(	O
risk	O
ratio	O
,	O
0	O
.	O
96	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
95	O
-	O
0	O
.	O
98	O
]).	O

RESULTS	O
:	O
Of	O
3528	O
infants	O
,	O
1726	O
(	O
49	O
%)	O
had	O
a	O
primary	B-DISO
infection	I-DISO
,	O
and	O
419	O
(	O
12	O
%)	O
had	O
a	O
repeated	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Myocarditis	B-DISO
,	O
inflammation	B-DISO
of	O
the	O
heart	O
muscle	O
,	O
can	O
be	O
caused	O
by	O
infections	B-DISO
,	O
autoimmune	B-DISO
disease	I-DISO
or	O
exposure	O
to	O
toxins	O
.	O

The	O
major	O
cause	O
of	O
myocarditis	B-DISO
in	O
the	O
paediatric	O
population	O
is	O
viral	B-DISO
infection	I-DISO
,	O
including	O
coxsackievirus	O
B3	O
,	O
adenovirus	B-DISO
,	O
herpesvirus	O
,	O
parvovirus	B-DISO
,	O
influenza	B-DISO
A	O
and	O
B	O
,	O
and	O
hepatitis	B-DISO
.	O

RNA	O
was	O
extracted	O
from	O
serum	O
and	O
two	O
nasal	O
swabs	O
,	O
and	O
tested	O
with	O
conventional	O
PCR	O
at	O
the	O
family	O
level	O
for	O
viruses	O
including	O
enterovirus	O
,	O
dengue	B-DISO
,	O
chikungunya	B-DISO
,	O
influenza	B-DISO
,	O
herpesvirus	O
,	O
paramyxovirus	O
and	O
coronavirus	O
.	O

A	O
lumbar	O
puncture	O
revealed	O
what	O
appeared	O
to	O
be	O
bacterial	B-DISO
meningitis	I-DISO
,	O
yet	O
cerebrospinal	O
fluid	O
cultures	O
,	O
Gram	O
stains	O
and	O
a	O
meningitis	B-DISO
/	I-DISO
encephalitis	I-DISO
panel	O
were	O
inconclusive	O
.	O

TITLE	O
:	O
Rescue	O
therapy	O
for	O
hypercapnia	B-DISO
due	O
to	O
high	O
PEEP	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
ARDS	B-DISO
and	O
renal	B-DISO
failure	I-DISO
.	O

To	O
analyze	O
the	O
epidemiological	O
characteristics	O
and	O
disease	O
spectrum	O
distribution	O
of	O
emergency	B-DISO
critically	B-DISO
ill	I-DISO
patients	O
,	O
annual	O
and	O
daily	O
24	O
-	O
hour	O
emergency	B-DISO
visits	O
in	O
2017	O
were	O
analyzed	O
.	O

Death	O
resulted	O
in	O
8	O
/	O
32	O
(	O
25	O
%)	O
HCWs	O
including	O
all	O
5	O
HCWs	O
with	O
chronic	B-DISO
renal	I-DISO
impairment	I-DISO
at	O
baseline	O
.	O

CONCLUSIONS	O
:	O
Approximately	O
10	O
%	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
MERS	O
were	O
HCWs	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
problems	I-DISO
are	O
common	O
in	O
Morquio	O
-	O
A	O
syndrome	B-DISO
(	O
MPS	B-DISO
IVA	I-DISO
)	O
but	O
objective	O
data	O
on	O
sleep	B-DISO
-	I-DISO
disordered	I-DISO
breathing	I-DISO
are	O
scarce	O
.	O

TITLE	O
:	O
Design	O
of	O
novel	O
multi	O
-	O
epitope	O
vaccines	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
validated	O
through	O
multistage	O
molecular	O
interaction	O
and	O
dynamics	O
.	O

ABSTRACT	O
:	O
We	O
established	O
a	O
cold	B-DISO
-	O
adapted	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
BP	O
-	O
caKII	O
)	O
by	O
passaging	O
a	O
field	O
virus	O
through	O
specific	O
pathogen	O
-	O
free	O
embryonated	O
eggs	O
20	O
times	O
at	O
32	O
°	O
C	O
.	O

Patients	O
with	O
immunodeficiency	B-DISO
(	O
e	O
.	O
g	O
.	O
SCID	B-DISO
with	O
T	O
and	O
B	O
cell	O
deficiency	O
)	O
are	O
particularly	O
susceptible	O
to	O
the	O
development	O
of	O
severe	O
ARDS	B-DISO
.	O

RAG2	O
CONCLUSIONS	O
:	O
Following	O
LPS	B-DISO
instillation	O
,	O
lung	O
mechanics	O
deteriorate	O
within	O
the	O
first	O
4	O
days	O
and	O
recover	O
towards	O
day	O
10	O
.	O

ABSTRACT	O
:	O
Sepsis	B-DISO
is	O
a	O
leading	O
cause	O
of	O
death	O
and	O
long	O
-	O
term	O
disability	O
in	O
developed	O
countries	O
.	O

In	O
total	O
,	O
1184	O
patients	O
(	O
median	O
age	O
73	O
years	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
64	O
-	O
81	O
)	O
with	O
severe	B-DISO
sepsis	I-DISO
were	O
admitted	O
to	O
the	O
ICU	O
during	O
the	O
study	O
period	O
.	O

The	O
most	O
common	O
site	O
of	O
infection	B-DISO
was	O
the	O
lung	O
(	O
31	O
%).	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
new	O
pathogens	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
poses	O
serious	O
challenges	O
to	O
global	O
public	O
health	O
and	O
highlights	O
the	O
urgent	O
need	O
for	O
methods	O
to	O
rapidly	O
identify	O
and	O
characterize	O
potential	O
therapeutic	O
or	O
prevention	O
options	O
,	O
such	O
as	O
neutralizing	O
antibodies	O
.	O

Our	O
results	O
demonstrated	O
that	O
PEDV	O
infection	B-DISO
regulated	O
lncRNA	O
expression	O
patterns	O
in	O
both	O
the	O
IPEC	O
-	O
J2	O
cell	O
line	O
and	O
piglet	O
ileum	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
a	O
major	O
pathogen	O
of	O
the	O
domestic	O
fowl	O
,	O
exhibits	O
extensive	O
antigenic	O
variation	O
.	O

Keywords	O
:	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
;	O
Iran	O
;	O
virus	O
neutralization	O
.	O

However	O
,	O
the	O
infection	B-DISO
pattern	O
of	O
the	O
two	O
isolates	O
were	O
different	O
.	O

In	O
addition	O
,	O
TGEV	O
-	O
induced	O
the	O
changes	O
in	O
mRNA	O
levels	O
of	O
TRIF	O
,	O
TRAM	O
,	O
MDA5	O
,	O
RIG	O
-	O
I	O
,	O
IPS	B-DISO
-	O
1	O
,	O
IRF9	O
,	O
IRF3	O
,	O
ISG15	O
and	O
ISG20	O
were	O
notably	O
hindered	O
in	O
p53	O
-/-	O
PK	O
-	O
15	O
cells	O
before	O
36	O
h	O
post	O
infection	B-DISO
(	O
p	O
.	O
i	O
.).	O

TITLE	O
:	O
Improved	O
Detection	O
of	O
Culprit	O
Pathogens	O
by	O
Bacterial	O
DNA	O
Sequencing	O
Affects	O
Antibiotic	O
Management	O
Decisions	O
in	O
Severe	O
Pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
A	O
boy	O
aged	O
6	O
years	O
and	O
3	O
months	O
developed	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
and	O
pyrexia	O
2	O
months	O
ago	O
and	O
was	O
given	O
oral	O
administration	O
of	O
nimesulide	O
by	O
his	O
parents	O
according	O
to	O
directions	O
.	O

Half	O
an	O
hour	O
later	O
,	O
the	O
boy	O
experienced	O
convulsions	B-DISO
and	O
cardiopulmonary	B-DISO
arrest	I-DISO
,	O
and	O
emergency	B-DISO
examination	O
found	O
hypoketotic	O
hypoglycemia	B-DISO
,	O
metabolic	B-DISO
acidosis	I-DISO
,	O
significant	O
increases	O
in	O
serum	O
aminotransferases	O
and	O
creatine	O
kinase	O
,	O
and	O
renal	O
damage	O
.	O

The	O
boy	O
had	O
a	O
significant	O
reduction	O
in	O
free	O
carnitine	O
in	O
blood	O
and	O
significant	O
increases	O
in	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acyl	O
carnitine	O
,	O
urinary	O
glutaric	O
acid	O
,	O
3	O
-	O
hydroxy	O
glutaric	O
acid	O
,	O
isovalerylglycine	O
,	O
and	O
ethylmalonic	O
acid	O
,	O
suggesting	O
the	O
possibility	O
of	O
multiple	B-DISO
acyl	I-DISO
-	I-DISO
CoA	I-DISO
dehydrogenase	I-DISO
deficiency	I-DISO
.	O

Independent	O
risk	O
factors	O
for	O
VTE	O
included	O
H1N1	O
,	O
culture	O
-	O
positive	O
bacterial	B-DISO
pneumonia	I-DISO
,	O
and	O
vasopressor	O
requirement	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
the	O
hotel	O
industry	O
in	O
the	O
response	O
to	O
emerging	O
epidemics	O
:	O
a	O
case	O
study	O
of	O
SARS	B-DISO
in	O
2003	O
and	O
H1N1	O
swine	B-DISO
flu	I-DISO
in	O
2009	O
in	O
Hong	O
Kong	O
.	O

The	O
traditional	O
focus	O
on	O
border	O
screening	O
,	O
and	O
by	O
airline	O
and	O
cruise	O
industries	O
may	O
be	O
inadequate	O
due	O
to	O
the	O
incubation	O
period	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Ischemia	B-DISO
-	O
reperfusion	O
injury	O
(	O
IRI	O
)	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
primary	B-DISO
graft	I-DISO
dysfunction	I-DISO
that	O
accounts	O
for	O
25	O
%	O
of	O
mortality	O
after	O
lung	O
transplantation	O
.	O

Furthermore	O
,	O
two	O
recent	O
clinical	O
randomized	O
,	O
placebo	O
-	O
controlled	O
pilot	O
studies	O
demonstrated	O
that	O
treatment	O
of	O
ARDS	B-DISO
with	O
MSCs	O
appears	O
to	O
be	O
safe	O
and	O
feasible	O
.	O

Administration	O
of	O
Muse	O
cell	O
through	O
the	O
left	O
pulmonary	O
artery	O
immediately	O
after	O
reperfusion	O
more	O
significantly	O
improved	O
lung	O
oxygenation	O
capacity	O
,	O
compliance	O
,	O
and	O
histological	O
damage	O
on	O
days	O
1	O
and	O
3	O
after	O
reperfusion	O
compared	O
with	O
MSCs	O
,	O
and	O
this	O
was	O
associated	O
with	O
higher	O
expression	O
levels	O
of	O
proteins	O
related	O
with	O
anti	O
-	O
inflammation	B-DISO
and	O
tissue	O
repair	O
in	O
the	O
lung	O
.	O

Admissions	O
for	O
trauma	O
or	O
pneumonia	B-DISO
,	O
higher	O
nonpulmonary	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
,	O
lower	O
partial	O
pressure	O
of	O
alveolar	O
oxygen	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
and	O
higher	O
peak	O
inspiratory	O
pressure	O
were	O
independently	O
associated	O
with	O
worsening	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
with	O
prone	O
position	O
ventilation	O
successfully	O
rescues	O
infantile	O
pertussis	B-DISO
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

During	O
ECMO	O
support	O
period	O
,	O
prone	O
position	O
ventilation	O
and	O
care	O
bundle	O
nursing	O
strategy	O
contributed	O
to	O
the	O
relief	O
of	O
continuous	O
airway	O
spasm	B-DISO
.	O

Etiology	O
of	O
infections	B-DISO
is	O
poorly	O
characterized	O
at	O
the	O
course	O
of	O
clinical	O
management	O
,	O
and	O
hence	O
empirical	O
antimicrobial	O
agents	O
are	O
used	O
.	O

A	O
total	O
of	O
175	O
throat	O
swab	O
specimens	O
of	O
influenza	B-DISO
-	O
positive	O
cases	O
collected	O
at	O
National	O
Influenza	B-DISO
Center	O
,	O
Nepal	O
,	O
during	O
the	O
2015	O
/	O
16	O
winter	O
season	O
were	O
selected	O
for	O
detecting	O
other	O
respiratory	O
copathogens	O
.	O

Respiratory	O
syncytial	O
virus	O
is	O
the	O
most	O
important	O
viral	O
pathogen	O
causing	O
acute	O
lower	B-DISO
respiratory	I-DISO
infection	I-DISO
and	O
infants	O
hospitalizations	O
.	O

Other	O
viruses	O
are	O
also	O
identified	O
(	O
métapneumovirus	O
,	O
rhino	O
/	O
enterovirus	O
,	O
coronavirus	O
,	O
influenza	B-DISO
,	O
parainfluenza	B-DISO
,	O
adenovirus	B-DISO
…).	O

Rhinovirus	O
is	O
most	O
frequently	O
-	O
detected	O
pathogen	O
;	O
followed	O
by	O
respiratory	O
syncytial	O
virus	O
;	O
metapneumovirus	O
;	O
parainfluenza	B-DISO
virus	O
;	O
enterovirus	O
and	O
coronavirus	O
.	O

To	O
understand	O
underlying	O
mechanisms	O
of	O
viral	O
-	O
induced	O
airways	B-DISO
disease	I-DISO
;	O
investigators	O
have	O
studied	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
small	O
animals	O
.	O

TITLE	O
:	O
Recent	O
advances	O
in	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

A	O
lower	O
incidence	O
of	O
acute	O
,	O
degenerated	B-DISO
ovaries	O
was	O
found	O
in	O
groups	O
given	O
one	O
injection	O
of	O
inactivated	O
vaccine	O
following	O
live	O
priming	O
,	O
and	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
groups	O
given	O
only	O
live	O
priming	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
veno	I-DISO
-	I-DISO
occlusive	I-DISO
disease	I-DISO
(	O
PVOD	B-DISO
)	O
is	O
a	O
rare	O
cause	O
of	O
pulmonary	B-DISO
arterial	I-DISO
hypertension	I-DISO
(	O
PAH	B-DISO
)	O
in	O
humans	O
and	O
can	O
be	O
classified	O
in	O
idiopathic	O
,	O
heritable	O
,	O
drug	O
and	O
radiation	O
-	O
induced	O
,	O
and	O
associated	O
with	O
connective	B-DISO
tissue	I-DISO
disease	I-DISO
or	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
infection	I-DISO
.	O

Whole	O
genome	O
sequencing	O
analysis	O
was	O
performed	O
on	O
the	O
case	O
and	O
a	O
healthy	O
GSD	B-DISO
.	O

Validation	O
was	O
performed	O
by	O
Sanger	O
sequencing	O
of	O
five	O
additional	O
GSD	B-DISO
'	O
s	O
unknown	O
for	O
any	O
form	O
of	O
respiratory	O
stress	O
and	O
aged	O
≥	O
10	O
years	O
.	O

TITLE	O
:	O
Comparative	O
features	O
of	O
infections	B-DISO
of	O
two	O
Massachusetts	O
(	O
Mass	O
)	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
variants	O
isolated	O
from	O
Western	O
Canadian	O
layer	O
flocks	O
.	O

Although	O
variant	O
IBV	O
isolates	O
with	O
major	O
genetic	O
differences	O
have	O
been	O
subjected	O
to	O
comparative	O
studies	O
,	O
it	O
is	O
unknown	O
whether	O
minor	O
genetic	O
differences	O
in	O
IBV	O
variants	O
within	O
a	O
serotype	O
are	O
different	O
in	O
terms	O
of	O
pathogenesis	B-DISO
and	O
eliciting	O
host	O
responses	O
.	O

Nevertheless	O
,	O
both	O
IBV	O
isolates	O
elicited	O
host	O
responses	O
characterized	O
by	O
significant	O
macrophage	O
recruitment	B-DISO
to	O
the	O
respiratory	O
tract	O
and	O
there	O
was	O
evidence	O
that	O
both	O
IBV	O
isolates	O
replicated	O
within	O
tracheal	O
and	O
lung	O
macrophages	O
.	O

ABSTRACT	O
:	O
Increased	O
extravascular	O
lung	O
water	O
(	O
EVLW	O
)	O
correlates	O
with	O
pulmonary	O
morbidity	O
and	O
mortality	O
in	O
critical	B-DISO
illness	I-DISO
.	O

EVLWI	O
began	O
to	O
abnormally	O
increase	O
(>	O
7ml	O
/	O
kg	O
)	O
on	O
day	O
3	O
and	O
up	O
to	O
PBD	B-DISO
9	O
,	O
indicating	O
that	O
a	O
supranormal	O
EVLWI	O
developed	O
in	O
the	O
fluid	O
reabsorption	O
stage	O
.	O

Compared	O
with	O
neurotypical	O
subjects	O
,	O
subjects	O
with	O
cognitive	B-DISO
impairment	I-DISO
were	O
older	O
(	O
median	O
,	O
years	O
,	O
6	O
.	O
2	O
vs	O
1	O
.	O
4	O
;	O
P	O
<	O
.	O
001	O
)	O
with	O
more	O
severe	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
40	O
%	O
vs	O
33	O
%;	O
P	O
=	O
.	O
009	O
).	O

Three	O
nonverbal	O
subjects	O
with	O
cognitive	B-DISO
impairment	I-DISO
received	O
no	O
analgesia	B-DISO
or	O
sedation	B-DISO
.	O

Furthermore	O
,	O
TRIM8	O
knockdown	O
evidently	O
improved	O
nuclear	O
factor	O
-	O
erythroid	O
2	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
and	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
expressions	O
in	O
lung	O
of	O
LPS	B-DISO
-	O
treated	O
mice	O
.	O

The	O
anti	O
-	O
inflammation	B-DISO
and	O
anti	O
-	O
oxidant	O
role	O
of	O
TRIM8	O
-	O
silence	B-DISO
might	O
be	O
associated	O
with	O
AMPKα	O
phosphorylation	O
.	O

The	O
diagnosis	O
can	O
be	O
difficult	O
as	O
excessive	O
urine	O
output	O
and	O
high	O
serum	O
sodium	O
can	O
often	O
be	O
attributed	O
to	O
high	O
insensible	O
water	O
loss	O
in	O
the	O
extremely	O
premature	B-DISO
newborn	I-DISO
.	O

DPP4	O
was	O
expressed	O
in	O
the	O
five	O
bat	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
with	O
significantly	O
higher	O
mRNA	O
expression	O
levels	O
than	O
those	O
in	O
non	O
-	O
susceptible	O
cells	O
(	O
P	O
=	O
0	O
.	O
0174	O
),	O
supporting	O
that	O
DPP4	O
expression	O
is	O
critical	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
bats	O
.	O

She	O
died	O
because	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
on	O
the	O
third	O
day	O
of	O
hospitalization	O
.	O

However	O
,	O
students	O
expressed	O
their	O
reluctance	O
to	O
work	O
in	O
healthcare	O
facilities	O
with	O
inadequate	O
MERS	O
infection	B-DISO
control	O
isolation	O
policies	O
.	O

TITLE	O
:	O
Driving	O
pressure	O
and	O
long	O
-	O
term	O
outcomes	O
in	O
moderate	O
/	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
obtained	O
serial	O
measurements	O
of	O
plasma	O
NT	O
-	O
PCP	B-DISO
-	O
III	O
levels	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
development	O
of	O
multi	O
-	O
epitope	O
vaccine	O
against	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
using	O
in	O
silico	O
approach	O
.	O

ARDS	B-DISO
was	O
detected	O
in	O
10	O
patients	O
on	O
enrolment	O
and	O
associated	O
with	O
90	O
%	O
case	O
fatality	O
.	O

TITLE	O
:	O
The	O
Human	O
Sodium	O
Iodide	O
Symporter	O
as	O
a	O
Reporter	O
Gene	O
for	O
Studying	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Pathogenesis	B-DISO
.	O

The	O
associated	O
pathogens	O
comprise	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
coronavirus	O
,	O
enterovirus	O
/	O
rhinovirus	O
,	O
influenza	B-DISO
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
adenovirus	B-DISO
,	O
and	O
human	O
bocavirus	O
.	O

With	O
global	O
-	O
ization	O
,	O
the	O
risk	O
of	O
emergence	O
of	O
new	O
diseases	O
is	O
increasing	O
since	O
humans	O
have	O
more	O
chan	O
-	O
ces	B-DISO
to	O
be	O
exposed	O
to	O
new	O
pathogens	O
.	O

Also	O
,	O
the	O
risk	O
of	O
international	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
is	O
increasing	O
because	O
of	O
increased	O
international	O
travel	O
.	O

During	O
2002	O
-	O
2003	O
,	O
a	O
new	O
coronavirus	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
was	O
found	O
to	O
be	O
the	O
cause	O
of	O
an	O
acute	O
,	O
severe	O
frequently	O
fatal	O
respiratory	B-DISO
disease	I-DISO
with	O
prominent	O
systemic	O
symptoms	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
).	O

TITLE	O
:	O
Avian	B-DISO
influenza	I-DISO
.	O

Asymptomatic	O
individuals	O
were	O
less	O
likely	O
to	O
have	O
underlying	O
condition	B-DISO
compared	O
to	O
fatal	O
cases	O
.	O

Takotsubo	B-DISO
syndrome	I-DISO
,	O
a	O
transient	O
cardiac	O
dysfunction	O
caused	O
by	O
emotional	O
or	O
physical	B-DISO
stress	I-DISO
,	O
is	O
characterized	O
by	O
ST	O
-	O
segment	O
elevation	O
and	O
negative	O
T	O
waves	O
in	O
electrocardiogram	O
,	O
transient	O
left	O
ventricular	B-DISO
asynergy	I-DISO
,	O
and	O
absence	O
of	O
obstructive	O
coronary	B-DISO
disease	I-DISO
.	O

Herein	O
,	O
we	O
report	O
the	O
case	O
of	O
AAV	O
complicated	O
with	O
takotsubo	B-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Conservation	O
implications	O
of	O
primate	O
trade	O
in	O
China	O
over	O
18	O
years	O
based	O
on	O
web	B-DISO
news	O
reports	O
of	O
confiscations	O
.	O

ABSTRACT	O
:	O
While	O
influenza	B-DISO
-	O
like	O
-	O
illness	O
(	O
ILI	O
)	O
surveillance	O
is	O
well	O
-	O
organized	O
at	O
primary	O
care	O
level	O
in	O
Europe	O
,	O
few	O
data	O
are	O
available	O
on	O
more	O
severe	O
cases	O
.	O

Influenza	B-DISO
epidemic	I-DISO
periods	O
were	O
retrieved	O
from	O
primary	O
care	O
sentinel	O
influenza	B-DISO
surveillance	O
data	O
.	O

TITLE	O
:	O
Genetic	O
Evidence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
Cov	O
)	O
and	O
Widespread	O
Seroprevalence	O
among	O
Camels	O
in	O
Kenya	O
.	O

The	O
pregnant	O
females	O
had	O
a	O
lower	O
median	O
age	O
(	O
25	O
[	O
22	O
-	O
28	O
]	O
vs	O
.	O
32	O
[	O
22	O
-	O
42	O
]	O
years	O
,	O
p	O
=	O
0	O
.	O
003	O
),	O
higher	O
proportion	O
of	O
severe	O
ARDS	B-DISO
(	O
40	O
.	O
8	O
%	O
vs	O
.	O
10	O
.	O
3	O
%,	O
p	O
<	O
0	O
.	O
0001	O
),	O
and	O
higher	O
driving	O
pressure	O
(	O
18	O
.	O
2	O
vs	O
.	O
15	O
.	O
5	O
cm	O
H	O
ARDS	B-DISO
complicating	B-DISO
pregnancy	I-DISO
is	O
severe	O
and	O
is	O
associated	O
with	O
high	O
perinatal	O
mortality	O
.	O

However	O
,	O
the	O
outcomes	O
of	O
ARDS	B-DISO
in	O
pregnant	O
females	O
were	O
similar	O
to	O
non	O
-	O
pregnant	O
females	O
.	O

ABSTRACT	O
:	O
The	O
emerging	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	O
,	O
a	O
subtype	O
of	O
influenza	B-DISO
viruses	O
,	O
was	O
first	O
discovered	O
in	O
March	O
2013	O
in	O
China	O
.	O

These	O
patients	O
were	O
confirmed	O
to	O
have	O
H7N9	O
infection	B-DISO
soon	O
after	O
admission	O
followed	O
by	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
various	O
severe	O
bacterial	O
and	O
fungal	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Several	O
viruses	O
cause	O
pulmonary	B-DISO
infections	I-DISO
due	O
to	O
their	O
shared	O
tropism	O
with	O
cells	O
of	O
the	O
respiratory	O
tract	O
.	O

Network	O
centrality	O
metrics	O
were	O
used	O
to	O
characterize	O
hospital	O
-	O
acquired	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
HA	O
-	O
MERS	O
)	O
outbreaks	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
between	O
2012	O
and	O
2016	O
.	O

TITLE	O
:	O
Survey	O
of	O
Respiratory	O
Virus	O
in	O
Patients	O
Hospitalised	O
for	O
Acute	O
Exacerbations	O
of	O
Heart	B-DISO
Failure	I-DISO
-	O
A	O
Prospective	O
Observational	O
Study	O
.	O

A	O
nasopharyngeal	O
swab	O
was	O
taken	O
for	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
detection	O
of	O
influenza	B-DISO
virus	O
,	O
rhinovirus	O
,	O
parainfluenza	B-DISO
virus	O
(	O
HPIV	O
),	O
human	O
coronavirus	O
(	O
HcoV	O
),	O
adenoviurs	O
,	O
human	O
bocavirus	O
(	O
HboV	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
).	O

There	O
comprised	O
9	O
rhinoviruses	O
(	O
36	O
%),	O
4	O
influenza	B-DISO
A	O
viruses	O
(	O
16	O
%),	O
3	O
HPIV	O
(	O
12	O
%),	O
3	O
HCoV	O
(	O
12	O
%),	O
2	O
adenoviruses	O
(	O
8	O
%),	O
1	O
human	O
HBoV	O
(	O
4	O
%),	O
1	O
hMPV	O
(	O
4	O
%),	O
and	O
1	O
RSV	O
(	O
4	O
%).	O

Communication	O
is	O
very	O
important	O
in	O
the	O
prevention	O
and	O
control	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

From	O
SARS	B-DISO
to	O
H7N9	O
,	O
the	O
progress	O
had	O
been	O
made	O
in	O
information	O
disclosure	O
.	O

TITLE	O
:	O
Ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
in	O
extracorporeal	O
membrane	O
oxygenation	O
-	O
assisted	O
patients	O
.	O

ABSTRACT	O
:	O
China	O
has	O
made	O
substantial	O
progress	O
in	O
tackling	O
its	O
HIV	B-DISO
and	O
AIDS	O
epidemic	O
.	O

But	O
the	O
changing	O
patterns	O
of	O
HIV	B-DISO
and	O
AIDS	O
incidence	O
based	O
on	O
the	O
longitudinal	O
observation	O
data	O
were	O
rarely	O
studied	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
483	O
,	O
010	O
newly	O
HIV	B-DISO
infections	I-DISO
and	O
214	O
,	O
205	O
AIDS	O
cases	O
were	O
reported	O
between	O
2004	O
and	O
2014	O
nationwide	O
.	O

Forty	O
-	O
five	O
patients	O
(	O
7	O
.	O
5	O
%)	O
presented	O
with	O
flail	B-DISO
chest	I-DISO
.	O

CONCLUSIONS	O
:	O
Flail	B-DISO
chest	I-DISO
had	O
no	O
independent	O
influence	O
in	O
addition	O
to	O
injury	O
severity	O
on	O
post	O
-	O
traumatic	O
morbidity	O
and	O
mortality	O
in	O
multiply	O
injured	O
patients	O
with	O
blunt	O
thoracic	B-DISO
trauma	O
.	O

To	O
explore	O
whether	O
the	O
inhibition	O
of	O
MK2	O
activation	O
has	O
the	O
same	O
effect	O
in	O
experimental	O
animals	O
,	O
MMI	O
-	O
0100	O
,	O
a	O
peptide	O
-	O
mediated	O
inhibitor	O
of	O
MK2	O
,	O
was	O
used	O
to	O
verify	O
whether	O
MMI	O
-	O
0100	O
can	O
ameliorate	O
lung	B-DISO
inflammation	I-DISO
in	O
a	O
mouse	O
model	O
of	O
ARDS	B-DISO
by	O
reducing	O
endothelial	O
expression	O
of	O
ICAM	O
-	O
1	O
.	O

CONCLUSIONS	O
:	O
ANNs	O
model	O
is	O
a	O
valuable	O
tool	O
in	O
dealing	O
with	O
risk	O
prediction	O
of	O
ARDS	B-DISO
following	O
SAP	O
.	O

Compared	O
with	O
non	O
-	O
SIRS	B-DISO
group	O
,	O
more	O
severe	O
symptoms	O
were	O
observed	O
in	O
the	O
temporary	O
and	O
persistent	O
SIRS	B-DISO
groups	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
variants	O
having	O
a	O
large	O
deletion	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
S1	O
subunit	O
of	O
spike	O
(	O
S	O
)	O
protein	O
were	O
designated	O
as	O
S1	O
NTD	O
-	O
del	O
PEDVs	O
.	O

This	O
observation	O
may	O
be	O
explained	O
partially	O
by	O
the	O
fact	O
that	O
mucin	O
,	O
bile	O
and	O
bile	O
acids	O
in	O
gastrointestinal	O
tract	O
had	O
facilitating	O
effects	O
on	O
the	O
infection	B-DISO
of	O
S	O
-	O
intact	O
PEDV	O
,	O
but	O
no	O
/	O
inhibition	O
effects	O
on	O
S1	O
NTD	O
-	O
del	O
PEDV	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
7	O
,	O
14	O
,	O
21	O
days	O
post	O
infection	B-DISO
(	O
dpi	O
)	O
and	O
subjected	O
for	O
the	O
analyses	O
of	O
serum	O
antibody	O
production	O
,	O
T	O
cell	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
frequencies	O
,	O
NK	O
cytotoxicity	B-DISO
and	O
serum	O
cytokine	O
levels	O
.	O

TITLE	O
:	O
The	O
Sudden	B-DISO
Infant	I-DISO
Death	I-DISO
Syndrome	I-DISO
mechanism	O
of	O
death	O
may	O
be	O
a	O
non	O
-	O
septic	O
hyper	O
-	O
dynamic	O
shock	O
.	O

To	O
analyse	O
the	O
usefulness	O
of	O
alternative	O
non	O
-	O
invasive	O
samples	O
for	O
the	O
diagnosis	O
of	O
emerging	O
infectious	B-DISO
viral	B-DISO
diseases	I-DISO
,	O
a	O
literature	O
search	O
was	O
performed	O
on	O
PubMed	O
for	O
alternative	O
sampling	O
for	O
these	O
viral	B-DISO
infections	I-DISO
.	O

He	O
had	O
myocarditis	B-DISO
causing	O
left	B-DISO
ventricular	I-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

CONCLUSIONS	O
:	O
Rickettsial	O
infections	B-DISO
can	O
present	O
with	O
diverse	O
manifestations	O
.	O

Overall	O
,	O
4	O
(	O
24	O
%)	O
of	O
17	O
HCP	B-DISO
cases	O
and	O
3	O
(	O
3	O
%)	O
of	O
114	O
HCP	B-DISO
contacts	O
of	O
cases	O
were	O
seropositive	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
a	O
high	O
index	O
of	O
suspicion	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
any	O
febrile	O
patients	O
who	O
present	O
after	O
a	O
trip	O
to	O
the	O
Middle	O
East	O
.	O

TITLE	O
:	O
The	O
Complexity	O
of	O
Pulmonary	B-DISO
Complications	I-DISO
in	O
Acute	O
Kidney	O
Injury	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complications	I-DISO
often	O
occur	O
in	O
patients	O
with	O
acute	O
kidney	O
injury	O
,	O
and	O
represent	O
an	O
important	O
cause	O
of	O
death	O
.	O

Most	O
pulmonary	B-DISO
complications	I-DISO
(	O
over	O
50	O
%)	O
occurred	O
in	O
sepsis	B-DISO
-	O
induced	O
acute	O
kidney	O
injury	O
.	O

Regarding	O
the	O
clinical	O
aspects	O
of	O
pulmonary	B-DISO
complications	I-DISO
,	O
the	O
most	O
frequent	O
were	O
ARDS	B-DISO
,	O
atelectasisand	O
bronchopneumopathies	B-DISO
,	O
determined	O
by	O
the	O
etiological	O
factors	O
that	O
had	O
caused	O
the	O
acute	O
kidney	O
injury	O
in	O
the	O
first	O
place	O
,	O
and	O
by	O
the	O
acute	O
kidney	O
injury	O
-	O
induced	O
physiological	O
effects	O
.	O

Several	O
factors	O
signal	O
poor	O
short	O
-	O
term	O
outcome	O
for	O
patients	O
who	O
present	O
to	O
the	O
ED	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
BMT	O
:	O
low	O
blood	O
pH	O
,	O
high	O
serum	O
lactate	O
level	O
,	O
presence	O
of	O
TBI	O
,	O
severe	O
hemorrhage	B-DISO
,	O
coagulopathy	B-DISO
,	O
organ	B-DISO
failure	I-DISO
(	O
respiratory	O
,	O
renal	O
,	O
and	O
MOF	B-DISO
),	O
and	O
ARDS	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
shed	O
greater	O
light	O
on	O
early	O
steps	O
in	O
IBV	O
infection	B-DISO
.	O

Functional	O
inactivation	B-DISO
of	O
Rab5	O
and	O
Rab7	O
significantly	O
inhibited	O
IBV	O
infection	B-DISO
.	O

The	O
lifestyle	O
gradually	O
transformed	O
from	O
Bedouin	O
life	O
to	O
urban	O
sedentary	O
life	O
,	O
along	O
with	O
a	O
sharp	O
increase	O
in	O
obesity	B-DISO
and	O
other	O
comorbidities	O
.	O

TITLE	O
:	O
Depression	B-DISO
as	O
a	O
Mediator	O
of	O
Chronic	O
Fatigue	B-DISO
and	O
Post	O
-	O
Traumatic	O
Stress	B-DISO
Symptoms	I-DISO
in	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Survivors	O
.	O

Bootstrap	O
analyses	O
indicated	O
no	O
direct	O
effects	O
of	O
T1	O
FSS	B-DISO
on	O
T2	O
IES	O
-	O
R	O
but	O
significant	O
positive	O
indirect	O
effects	O
of	O
T1	O
FSS	B-DISO
on	O
T2	O
IESR	O
through	O
T1	O
PHQ	O
-	O
9	O
and	O
T2	O
PHQ	O
-	O
9	O
(	O
B	O
=	O
2	O
.	O
1601	O
,	O
SE	O
=	O
1	O
.	O
3268	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
0	O
.	O
4250	O
-	O
6	O
.	O
1307	O
).	O

In	O
other	O
words	O
,	O
both	O
T1	O
PHQ	O
-	O
9	O
and	O
T2	O
PHQ	O
-	O
9	O
fully	O
mediated	O
the	O
relationship	O
between	O
T1	O
FSS	B-DISO
and	O
T2	O
IES	O
.	O

Chronic	O
fatigue	B-DISO
12	O
months	O
after	O
MERS	O
had	O
indirect	O
effects	O
on	O
prolonged	O
PTSSs	O
18	O
months	O
after	O
MERS	O
via	O
persisting	O
depression	B-DISO
in	O
MERS	O
survivors	O
.	O

RESULTS	O
:	O
Bootstrap	O
analyses	O
indicated	O
no	O
direct	O
effects	O
of	O
T1	O
FSS	B-DISO
on	O
T2	O
IES	O
-	O
R	O
but	O
significant	O
positive	O
indirect	O
effects	O
of	O
T1	O
FSS	B-DISO
on	O
T2	O
IESR	O
through	O
T1	O
PHQ	O
-	O
9	O
and	O
T2	O
PHQ	O
-	O
9	O
(	O
B	O
=	O
2	O
.	O
1601	O
,	O
SE	O
=	O
1	O
.	O
3268	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
0	O
.	O
4250	O
-	O
6	O
.	O
1307	O
).	O

ABSTRACT	O
:	O
Lymphography	O
with	O
Lipiodol	O
is	O
useful	O
for	O
chylothorax	B-DISO
.	O

A	O
75	O
-	O
year	O
-	O
old	O
man	O
with	O
esophageal	B-DISO
cancer	I-DISO
developed	O
chylothorax	B-DISO
after	O
esophagectomy	O
.	O

Clinical	O
features	O
of	O
MERS	O
range	O
from	O
asymptomatic	O
or	O
mild	O
disease	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
resulting	O
in	O
death	O
,	O
especially	O
in	O
individuals	O
with	O
underlying	O
comorbidities	O
.	O

This	O
ncRNA	B-DISO
consists	O
of	O
563	O
nucleotides	O
excluding	O
a	O
poly	O
(	O
A	O
)	O
tail	O
,	O
is	O
mainly	O
derived	O
from	O
the	O
3	O
'-	O
untranslated	O
region	O
of	O
IBV	O
genome	O
,	O
and	O
contains	O
a	O
63	O
-	O
nt	O
-	O
long	O
of	O
terminal	O
leader	O
sequence	O
derived	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
viral	O
genome	O
.	O

These	O
infections	B-DISO
maintain	O
a	O
similar	O
seasonal	O
pattern	O
to	O
those	O
of	O
immunocompetent	O
patients	O
.	O

Defining	O
effective	O
prophylactic	O
and	O
therapeutic	O
strategies	O
is	O
challenging	O
,	O
especially	O
considering	O
,	O
the	O
spectrum	O
of	O
immunocompromised	O
patients	O
,	O
the	O
variety	O
of	O
respiratory	O
viruses	O
,	O
and	O
the	O
presence	O
of	O
other	O
opportunistic	B-DISO
infections	I-DISO
and	O
medical	O
problems	O
.	O

This	O
balance	O
between	O
effective	O
virus	O
control	O
with	O
limited	O
pathology	B-DISO
is	O
especially	O
important	O
due	O
to	O
the	O
highly	O
specialized	O
functions	O
and	O
limited	O
regenerative	O
capacity	O
of	O
neurons	O
,	O
which	O
can	O
be	O
targets	O
of	O
direct	O
virus	O
cytolysis	O
or	O
bystander	O
damage	O
.	O

The	O
overall	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
contact	O
structure	O
and	O
animal	O
movement	O
patterns	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
case	O
herds	O
and	O
matched	O
control	O
herds	O
during	O
the	O
initial	O
incursion	O
of	O
PEDV	O
in	O
Canada	O
,	O
and	O
to	O
evaluate	O
possible	O
mechanisms	O
of	O
spread	O
during	O
this	O
period	O
.	O

All	O
respiratory	O
specimens	O
from	O
patients	O
enrolled	O
through	O
SARI	O
surveillance	O
were	O
also	O
routinely	O
tested	O
by	O
multiplex	O
reverse	O
transcription	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
for	O
adenovirus	B-DISO
;	O
enterovirus	O
;	O
human	O
metapneumovirus	O
;	O
parainfluenza	B-DISO
virus	O
types	O
1	O
,	O
2	O
,	O
and	O
3	O
;	O
respiratory	O
syncytial	O
virus	O
;	O
rhinovirus	O
;	O
influenza	B-DISO
A	O
,	O
and	O
influenza	B-DISO
B	O
.	O
Human	O
bocavirus	O
,	O
hCoV	O
-	O
229E	O
,	O
and	O
hPyV	O
-	O
WU	O
were	O
detected	O
in	O
3	O
.	O
7	O
%	O
(	O
25	O
/	O
680	O
),	O
4	O
.	O
1	O
%	O
(	O
28	O
/	O
680	O
),	O
and	O
4	O
.	O
1	O
%	O
(	O
28	O
/	O
680	O
)	O
of	O
respiratory	O
specimens	O
,	O
respectively	O
.	O

Five	O
out	O
of	O
six	O
newborns	O
required	O
hospitalization	O
,	O
three	O
of	O
them	O
due	O
to	O
neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

However	O
,	O
the	O
immunopathology	B-DISO
in	O
young	O
and	O
adult	O
Tg	O
mice	O
was	O
different	O
.	O

The	O
mouse	O
model	O
described	O
here	O
will	O
increase	O
our	O
understanding	O
of	O
disease	O
pathogenesis	B-DISO
and	O
host	O
mediators	O
that	O
protect	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
TMPRSS2	O
Contributes	O
to	O
Virus	O
Spread	O
and	O
Immunopathology	B-DISO
in	O
the	O
Airways	O
of	O
Murine	O
Models	O
after	O
Coronavirus	B-DISO
Infection	I-DISO
.	O

Most	O
common	O
presenting	O
complaints	O
were	O
fever	O
and	O
colic	B-DISO
and	O
were	O
similar	O
across	O
groups	O
.	O

These	O
data	O
indicate	O
that	O
MERS	O
-	O
CoV	O
infection	B-DISO
induces	O
overactivation	O
of	O
complement	O
,	O
which	O
may	O
contribute	O
to	O
pyroptosis	O
and	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
respiratory	O
pathogens	O
in	O
infants	O
diagnosed	O
with	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

Tidal	O
volume	O
,	O
based	O
on	O
both	O
actual	O
body	O
weight	O
and	O
ideal	O
body	O
weight	O
,	O
was	O
not	O
associated	O
with	O
either	O
increased	O
mortality	O
or	O
decreased	O
probability	O
of	O
extubation	O
after	O
adjusting	O
for	O
oxygenation	O
index	O
in	O
the	O
whole	O
cohort	O
,	O
whereas	O
associations	O
between	O
higher	O
tidal	O
volume	O
and	O
poor	O
outcomes	O
were	O
seen	O
in	O
subgroup	O
analyses	O
in	O
overweight	B-DISO
children	O
and	O
in	O
severe	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Both	O
patients	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
and	O
were	O
previously	O
diagnosed	O
with	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
).	O

However	O
,	O
the	O
efficacy	O
of	O
venovenous	O
ECMO	O
in	O
people	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
uncertain	O
according	O
to	O
the	O
most	O
recent	O
data	O
.	O

TITLE	O
:	O
Structure	O
and	O
oligomerization	O
state	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
nucleoprotein	O
.	O

In	O
addition	O
to	O
serving	O
as	O
an	O
obstacle	O
to	O
the	O
zoonotic	O
transmission	O
of	O
influenza	B-DISO
,	O
these	O
ISG15	O
species	O
-	O
species	O
differences	O
have	O
also	O
long	O
been	O
shown	O
to	O
have	O
an	O
impact	O
on	O
the	O
function	O
of	O
viral	O
deISGylases	O
.	O

TITLE	O
:	O
Single	O
Chain	O
Fragment	O
Variable	O
(	O
scFv	O
)	O
Antibodies	O
Targeting	O
the	O
Spike	O
Protein	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Provide	O
Protection	O
against	O
Viral	B-DISO
Infection	I-DISO
in	O
Piglets	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
our	O
current	O
understanding	O
of	O
the	O
epidemiology	O
,	O
pathogenesis	B-DISO
,	O
prevention	O
,	O
and	O
treatment	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
provides	O
details	O
on	O
the	O
pivotal	O
structure	O
and	O
function	O
of	O
the	O
spike	O
proteins	O
(	O
S	O
proteins	O
)	O
on	O
the	O
surface	O
of	O
each	O
of	O
these	O
viruses	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
is	O
an	O
infectious	B-DISO
virus	O
that	O
was	O
first	O
reported	O
in	O
2012	O
.	O

The	O
continuous	O
net	O
reclassification	O
improvement	O
(	O
NRI	O
)	O
in	O
the	O
ARDS	B-DISO
group	O
resulting	O
from	O
AGPT2	O
inclusion	O
was	O
64	O
.	O
1	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
integrated	O
discrimination	O
improvement	O
(	O
IDI	O
)	O
index	O
was	O
0	O
.	O
057	O
(	O
P	O
=	O
0	O
.	O
003	O
).	O

CONCLUSIONS	O
:	O
AGPT2	O
and	O
AGPT2	O
/	O
AGPT1	O
ratio	O
are	O
associated	O
with	O
severe	O
AKI	O
and	O
there	O
was	O
only	O
a	O
need	O
of	O
renal	O
replacement	O
therapy	O
(	O
RRT	O
)	O
in	O
patients	O
with	O
or	O
at	O
risk	O
of	O
ARDS	B-DISO
,	O
not	O
in	O
other	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

To	O
this	O
end	O
,	O
we	O
utilized	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
as	O
a	O
model	O
coronavirus	O
to	O
comprehensively	O
characterize	O
the	O
host	O
cell	O
lipid	O
response	O
upon	O
coronavirus	B-DISO
infection	I-DISO
with	O
an	O
ultra	O
-	O
high	O
performance	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
UPLC	O
⁻	O
MS	O
)-	O
based	O
lipidomics	O
approach	O
.	O

ABSTRACT	O
:	O
The	O
study	O
objective	O
was	O
to	O
compare	O
titration	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
with	O
electrical	O
impedance	O
tomography	O
(	O
EIT	O
)	O
and	O
with	O
ventilator	O
-	O
embedded	O
pressure	O
-	O
volume	O
loop	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

For	O
further	O
analysis	O
the	O
retrieved	O
AE	O
reports	O
were	O
selected	O
according	O
to	O
the	O
keywords	O
corresponding	O
to	O
hypersensitivity	B-DISO
symptoms	I-DISO
.	O

To	O
improve	O
patient	O
safety	O
,	O
healthcare	O
professionals	O
,	O
including	O
pharmacists	O
,	O
can	O
identify	O
warning	O
signs	O
of	O
severe	O
hypersensitivity	B-DISO
reactions	I-DISO
to	O
paracetamol	O
.	O

ABSTRACT	O
:	O
Efforts	O
towards	O
developing	O
a	O
vaccine	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
yielded	O
promising	O
results	O
.	O

TITLE	O
:	O
A	O
new	O
immunochromatographic	O
assay	O
for	O
on	O
-	O
site	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
based	O
on	O
monoclonal	O
antibodies	O
prepared	O
by	O
using	O
cell	O
surface	O
fluorescence	O
immunosorbent	O
assay	O
.	O

These	O
include	O
SARS	B-DISO
coronavirus	O
,	O
Hendra	O
virus	O
and	O
Nipah	O
virus	O
.	O

TITLE	O
:	O
Genetic	O
evolution	O
analysis	O
and	O
pathogenicity	O
assessment	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strains	O
circulating	O
in	O
part	O
of	O
China	O
during	O
2011	O
-	O
2017	O
.	O

Compared	O
with	O
oral	B-DISO
infection	I-DISO
,	O
intramuscular	O
infection	B-DISO
could	O
also	O
cause	O
typical	O
clinical	O
signs	O
but	O
with	O
a	O
slightly	O
delayed	O
onset	O
,	O
confirming	O
that	O
the	O
variant	O
PEDV	O
isolate	O
FJzz1	O
was	O
highly	O
pathogenic	O
to	O
suckling	O
piglets	O
.	O

Occupational	O
risk	O
for	O
customs	O
officers	O
also	O
includes	O
noise	O
-	O
induced	O
hearing	B-DISO
loss	I-DISO
,	O
exposure	O
to	O
diesel	O
engine	O
emission	O
and	O
stored	O
tobacco	O
and	O
occupational	O
stress	O
due	O
to	O
their	O
increased	O
time	O
-	O
schedule	O
and	O
decision	O
-	O
making	O
duties	O
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
treatment	O
with	O
LCA60	O
resulted	O
in	O
reduced	O
disease	O
and	O
virus	O
titers	O
in	O
mouse	O
models	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Univariate	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
evaluate	O
the	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ARDS	B-DISO
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
an	O
elevated	O
RDW	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ARDS	B-DISO
and	O
RDW	O
is	O
an	O
independent	O
risk	O
factor	O
in	O
the	O
prediction	O
of	O
ARDS	B-DISO
after	O
severe	O
burns	O
.	O

The	O
3	O
most	O
prevalent	O
viruses	O
were	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
(	O
33	O
.	O
1	O
%),	O
parainfluenza	B-DISO
(	O
PI	O
)	O
(	O
18	O
.	O
7	O
%),	O
and	O
coronavirus	O
(	O
CoV	O
)	O
(	O
14	O
.	O
8	O
%).	O

In	O
conclusion	O
,	O
we	O
report	O
our	O
3	O
-	O
year	O
experience	O
about	O
the	O
frequency	O
and	O
seasonality	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
cancer	B-DISO
.	O

On	O
admission	O
to	O
ICU	O
,	O
the	O
baseline	O
characteristics	O
of	O
patients	O
who	O
received	O
and	O
did	O
not	O
receive	O
macrolides	O
were	O
similar	O
,	O
including	O
demographic	O
data	O
and	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
.	O

RESULTS	O
:	O
Of	O
349	O
critically	B-DISO
ill	I-DISO
MERS	O
patients	O
,	O
136	O
(	O
39	O
%)	O
received	O
macrolide	O
therapy	O
.	O

The	O
respiratory	O
signs	O
,	O
post	O
-	O
mortem	O
lesions	O
(	O
tracheitis	B-DISO
and	O
pneumonia	B-DISO
)	O
and	O
histopathological	O
findings	O
of	O
lungs	O
,	O
trachea	B-DISO
,	O
and	O
air	O
sacs	B-DISO
in	O
the	O
experimentally	O
infected	O
broiler	O
chickens	O
appeared	O
to	O
be	O
more	O
prominent	O
in	O
the	O
chickens	O
of	O
group	O
1	O
than	O
group	O
2	O
.	O

Natural	O
initial	O
enteric	O
FCoV	O
infection	B-DISO
may	O
remain	O
subclinical	O
,	O
or	O
result	O
in	O
mild	O
enteric	O
signs	O
or	O
the	O
development	O
of	O
FIP	B-DISO
;	O
cats	O
may	O
also	O
carry	O
the	O
virus	O
systemically	O
with	O
no	O
adverse	B-DISO
effect	I-DISO
.	O

Among	O
cats	O
without	O
FIP	B-DISO
,	O
there	O
were	O
few	O
differences	O
between	O
virus	O
-	O
positive	O
and	O
virus	O
-	O
negative	O
MLNs	B-DISO
;	O
however	O
,	O
TLR9	O
and	O
STAT2	O
expression	O
were	O
higher	O
with	O
infection	B-DISO
,	O
suggesting	O
a	O
direct	O
viral	O
effect	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
an	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
in	O
the	O
lung	O
parenchyma	O
leading	O
to	O
severe	O
hypoxemia	O
.	O

Histopathology	O
of	O
biopsies	O
of	O
the	O
lesions	O
detected	O
nodular	O
pyogranulomatous	B-DISO
dermatitis	I-DISO
with	O
vasculitis	B-DISO
and	O
necrosis	O
,	O
leading	O
to	O
a	O
suspicion	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

TITLE	O
:	O
[	O
Bilateral	O
diaphragmatic	O
palsy	O
due	O
to	O
Lyme	B-DISO
neuroborreliosis	I-DISO
].	O

ABSTRACT	O
:	O
Tension	B-DISO
pneumoperitoneum	B-DISO
is	O
a	O
severe	O
and	O
rare	O
form	O
of	O
pneumoperitoneum	B-DISO
with	O
concomitant	O
hemodynamic	B-DISO
instability	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

High	O
visibility	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
cases	O
7	O
days	O
later	O
(	O
OR	O
=	O
1	O
.	O
26	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
01	O
-	O
1	O
.	O
57	O
),	O
while	O
wind	B-DISO
speed	O
also	O
showed	O
statistically	O
significant	O
associations	O
with	O
cases	O
5	O
-	O
6	O
days	O
later	O
.	O

We	O
update	O
and	O
summarize	O
the	O
role	O
of	O
spontaneous	O
breathing	O
during	O
mechanical	O
ventilation	O
in	O
ARDS	B-DISO
,	O
which	O
can	O
be	O
beneficial	O
or	O
deleterious	O
,	O
depending	O
on	O
the	O
strength	O
of	O
spontaneous	O
activity	O
and	O
severity	O
of	O
lung	O
injury	O
.	O

We	O
investigated	O
the	O
presence	O
of	O
short	O
-	O
lived	O
relative	O
cross	O
-	O
protection	O
conferred	O
by	O
specific	O
prior	O
viral	B-DISO
infections	I-DISO
against	O
subsequent	O
febrile	O
respiratory	O
illness	O
(	O
FRI	O
).	O

ResPlex	O
II	O
assays	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assays	O
were	O
used	O
to	O
detect	O
viral	O
pathogens	O
in	O
nasal	O
wash	O
samples	O
,	O
and	O
survival	O
analyses	O
were	O
performed	O
to	O
determine	O
whether	O
infection	B-DISO
with	O
particular	O
viruses	O
conferred	O
short	O
-	O
lived	O
relative	O
cross	O
-	O
protection	O
against	O
FRI	O
.	O

Protective	O
ventilation	O
(	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
low	O
tidal	O
volume	O
,	O
limited	O
peak	O
pressure	O
)	O
improve	O
the	O
survival	O
of	O
ARDS	B-DISO
patients	O
(	O
QoE	O
:	O
high	O
).	O

TITLE	O
:	O
Molecular	O
characteristics	O
of	O
a	O
novel	O
recombinant	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

In	O
this	O
case	O
,	O
the	O
patient	O
experienced	O
a	O
left	O
main	O
bronchial	O
rupture	O
,	O
bilateral	O
traumatic	B-DISO
wet	I-DISO
lung	I-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
because	O
of	O
severe	O
thoracic	B-DISO
trauma	O
.	O

The	O
aim	O
here	O
was	O
to	O
screen	O
symptomatic	O
pilgrims	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
other	O
viral	O
etiologies	O
.	O

Among	O
the	O
detected	O
viruses	O
,	O
64	O
.	O
2	O
%	O
of	O
the	O
cases	O
were	O
due	O
to	O
a	O
single	O
-	O
virus	B-DISO
infection	I-DISO
and	O
35	O
.	O
8	O
%	O
were	O
due	O
to	O
the	O
coinfections	B-DISO
with	O
up	O
to	O
four	O
viruses	O
.	O

The	O
observed	O
high	O
prevalence	O
of	O
influenza	B-DISO
viruses	O
underscores	O
the	O
need	O
for	O
more	O
effective	O
surveillance	O
during	O
the	O
Hajj	O
and	O
adoption	O
of	O
stringent	O
vaccination	O
requirements	O
from	O
all	O
pilgrims	O
.	O

TITLE	O
:	O
Recent	O
Advances	O
in	O
Pathology	B-DISO
:	O
the	O
2019	O
Annual	O
Review	O
Issue	O
of	O
The	O
Journal	O
of	O
Pathology	B-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
Annual	O
Review	O
Issue	O
of	O
The	O
Journal	O
of	O
Pathology	B-DISO
,	O
we	O
present	O
15	O
invited	O
reviews	O
on	O
topical	O
aspects	O
of	O
pathology	B-DISO
,	O
ranging	O
from	O
the	O
impacts	O
of	O
the	O
microbiome	O
in	O
human	O
disease	O
through	O
mechanisms	O
of	O
cell	O
death	O
and	O
autophagy	O
to	O
recent	O
advances	O
in	O
immunity	O
and	O
the	O
uses	O
of	O
genomics	O
for	O
understanding	O
,	O
classifying	O
and	O
treating	O
human	O
cancers	B-DISO
.	O

About	O
80	O
%	O
of	O
malaria	B-DISO
infections	B-DISO
in	O
Mangaluru	O
and	O
its	O
surrounding	O
areas	O
are	O
caused	O
by	O

<	O
strong	O
>	O
MATERIAL	O
AND	O
METHODS	O
</	O
strong	O
>	O
We	O
used	O
an	O
LPS	B-DISO
-	O
induced	O
mouse	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
model	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
HIPK1	O
in	O
ALI	O
pathophysiology	O
.	O

Sarcoidosis	B-DISO
can	O
present	O
with	O
an	O
acute	O
onset	O
(	O
usually	O
Löfgren	O
'	O
s	O
syndrome	B-DISO
(	O
LS	B-DISO
))	O
or	O
a	O
gradual	O
onset	O
(	O
non	O
-	O
LS	B-DISO
).	O

Adjusting	O
for	O
patient	O
and	O
hospital	O
demographics	O
,	O
patients	O
with	O
comorbidities	O
were	O
more	O
likely	O
to	O
develop	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
/	O
pulmonary	B-DISO
embolism	I-DISO
(	O
adjusted	O
odds	O
ratio	O
,	O
2	O
.	O
44	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
28	O
,	O
4	O
.	O
65	O
)	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
adjusted	O
odds	O
ratio	O
,	O
2	O
.	O
26	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
21	O
,	O
4	O
.	O
23	O
).	O

While	O
their	O
clinical	O
manifestations	O
may	O
vary	O
,	O
severe	O
morbidity	O
and	O
mortality	O
is	O
most	O
frequently	O
the	O
result	O
of	O
neuromuscular	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
severity	O
of	O
ARDS	B-DISO
was	O
mild	O
in	O
42	O
patients	O
,	O
moderate	O
in	O
71	O
,	O
and	O
severe	O
in	O
40	O
.	O

Forty	O
-	O
two	O
(	O
27	O
.	O
5	O
%)	O
patients	O
were	O
deceased	O
within	O
30	O
days	O
,	O
and	O
the	O
30	O
-	O
day	O
mortality	O
was	O
10	O
%	O
in	O
mild	O
ARDS	B-DISO
,	O
23	O
%	O
in	O
moderate	O
,	O
and	O
55	O
%	O
in	O
severe	O
,	O
which	O
were	O
significantly	O
different	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Development	O
of	O
a	O
recombinant	O
Newcastle	B-DISO
disease	I-DISO
virus	O
-	O
vectored	O
vaccine	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
variant	O
strains	O
circulating	O
in	O
Egypt	O
.	O

In	O
order	O
to	O
circumvent	O
these	O
issues	O
,	O
and	O
to	O
develop	O
a	O
vaccine	O
that	O
is	O
more	O
relevant	O
to	O
Egypt	O
and	O
its	O
neighboring	O
countries	O
,	O
a	O
recombinant	O
avirulent	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
rNDV	O
)	O
strain	O
LaSota	O
was	O
constructed	O
to	O
express	O
the	O
codon	O
-	O
optimized	O
S	O
glycoprotein	O
of	O
the	O
Egyptian	O
IBV	O
variant	O
strain	O
IBV	O
/	O
Ck	O
/	O
EG	O
/	O
CU	O
/	O
4	O
/	O
2014	O
belonging	O
to	O
GI	O
-	O
23	O
lineage	O
,	O
that	O
is	O
prevalent	O
in	O
Egypt	O
and	O
in	O
the	O
Middle	O
East	O
.	O

Single	O
-	O
dose	O
vaccination	O
of	O
1	O
-	O
day	O
-	O
old	O
SPF	O
White	O
Leghorn	O
chicks	O
with	O
the	O
rNDVs	O
expressing	O
IBV	O
S	O
protein	O
provided	O
significant	O
protection	O
against	O
clinical	O
disease	O
after	O
IBV	O
challenge	O
but	O
did	O
not	O
show	O
reduction	O
in	O
tracheal	O
viral	B-DISO
shedding	I-DISO
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
HKU1	O
(	O
HCoV	O
-	O
HKU1	O
)	O
was	O
first	O
detected	O
in	O
a	O
patient	O
with	O
viral	B-DISO
pneumonia	I-DISO
from	O
Hong	O
Kong	O
in	O
2004	O
.	O

It	O
is	O
usually	O
caused	O
by	O
A	O
young	O
Romanian	O
male	O
presented	O
with	O
fever	O
and	O
rigors	B-DISO
,	O
mild	O
tachypnea	B-DISO
,	O
hypoxia	B-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
decayed	B-DISO
teeth	I-DISO
,	O
and	O
tenderness	B-DISO
of	O
the	O
left	O
carotid	O
triangle	O
.	O

Because	O
of	O
the	O
syndrome	B-DISO
'	O
s	O
rarity	O
and	O
the	O
atypical	O
microorganisms	O
isolated	O
in	O
this	O
case	O
,	O
increased	O
awareness	O
is	O
advised	O
for	O
its	O
diagnosis	O
and	O
the	O
underlying	O
mechanisms	O
involved	O
in	O
its	O
genesis	O
.	O

ABSTRACT	O
:	O
Worldwide	O
,	O
there	O
is	O
growing	O
concern	O
about	O
the	O
burden	O
of	O
pneumonia	B-DISO
.	O

RESULTS	O
:	O
We	O
obtained	O
89	O
nasopharyngeal	O
swabs	O
from	O
patients	O
with	O
pediatric	B-DISO
cancer	I-DISO
(	O
mean	O
age	O
,	O
5	O
.	O
8	O
±	O
4	O
.	O
2	O
years	O
).	O

TITLE	O
:	O
Immunoprofiling	O
of	O
peripheral	O
blood	O
from	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccinated	O
MHC	O
-	O
B	O
chicken	O
lines	O
-	O
Monocyte	O
MHC	O
-	O
II	O
expression	O
as	O
a	O
potential	O
correlate	O
of	O
protection	O
.	O

ABSTRACT	O
:	O
Panton	O
-	O
Valentine	O
leukocidin	O
-	O
producing	O
Staphylococcus	O
aureus	O
necrotizing	B-DISO
pneumonia	I-DISO
is	O
an	O
unusual	O
cause	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
although	O
associated	O
with	O
a	O
high	O
case	O
fatality	O
.	O

This	O
infection	B-DISO
mainly	O
affects	O
young	O
individuals	O
,	O
without	O
any	O
history	O
,	O
and	O
is	O
most	O
often	O
preceded	O
by	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
.	O

We	O
performed	O
a	O
retrospective	O
study	O
based	O
on	O
data	O
collected	O
from	O
laboratory	O
registers	O
and	O
medical	O
files	O
of	O
patients	O
presenting	O
with	O
Staphylococcus	O
aureus	O
necrotizing	B-DISO
pneumonia	I-DISO
in	O
Reunion	O
between	O
December	O
2014	O
and	O
December	O
2017	O
.	O

More	O
than	O
half	O
of	O
patients	O
had	O
previously	O
been	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
severe	B-DISO
sepsis	I-DISO
.	O

Biological	O
endotypes	O
using	O
(	O
n	O
=	O
464	O
patients	O
and	O
controls	O
),	O
mBALF	O
and	O
serum	O
samples	O
were	O
identified	O
by	O
high	O
-	O
resolution	O
NMR	O
spectroscopy	O
from	O
two	O
clinically	O
diagnosed	O
ARDS	B-DISO
subtypes	O
grouped	O
under	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	B-DISO
as	O
subphenotype1and	O
pulmonary	O
and	O
extra	O
-	O
pulmonary	O
ARDS	B-DISO
as	O
subphenotype2	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
pose	O
a	O
major	O
clinical	O
challenge	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
naturally	O
occurring	O
flavonoid	O
kaempferol	O
(	O
KPF	O
)	O
reduces	O
endotoxin	O
-	O
induced	O
inflammatory	B-DISO
responses	I-DISO
in	O
mice	O
.	O

Our	O
study	O
shows	O
that	O
KPF	O
is	O
effective	O
in	O
reducing	O
lung	O
damage	O
induced	O
by	O
LPS	B-DISO
by	O
modulating	O
TRAF6	O
polyubiquitination	O
.	O

TITLE	O
:	O
Longitudinal	O
active	O
sampling	O
for	O
respiratory	O
viral	B-DISO
infections	I-DISO
across	O
age	O
groups	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
neutralizing	O
activity	O
in	O
serum	O
from	O
three	O
patients	O
>	O
1	O
year	O
after	O
recovery	O
from	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
associated	O
with	O
mild	O
pneumonia	B-DISO
treated	O
with	O
antivirals	O
during	O
the	O
MERS	B-DISO
outbreak	O
in	O
South	O
Korea	O
at	O
2015	O
.	O

To	O
determine	O
whether	O
PEEP	O
titration	O
guided	O
by	O
esophageal	O
pressure	O
(	O
PES	O
),	O
an	O
estimate	O
of	O
pleural	O
pressure	O
,	O
was	O
more	O
effective	O
than	O
empirical	O
high	O
PEEP	O
-	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio2	O
)	O
in	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

Of	O
these	O
,	O
3361	O
were	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
27	O
253	O
pneumonia	B-DISO
,	O
18	O
ARDS	B-DISO
,	O
2603	O
febrile	B-DISO
seizure	I-DISO
and	O
159	O
encephalitis	B-DISO
/	O
encephalopathy	B-DISO
.	O

For	O
pneumonia	B-DISO
,	O
the	O
incidence	O
was	O
highest	O
for	O
influenza	B-DISO
-	O
positive	O
patients	O
aged	O
0	O
-	O
5	O
years	O
and	O
65	O
years	O
or	O
more	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
inhibition	O
of	O
viral	B-DISO
infection	I-DISO
by	O
p53	O
was	O
mediated	O
via	O
p53	O
-	O
dependent	O
IFN	O
signaling	O
,	O
leading	O
to	O
IFN	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
activation	O
,	O
as	O
well	O
as	O
the	O
upregulation	O
of	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
and	O
IFN	O
-	O
β	O
released	O
from	O
infected	O
cells	O
.	O

The	O
viral	B-DISO
infection	I-DISO
surveillance	O
method	O
using	O
metagenomics	O
technology	O
enables	O
the	O
monitoring	O
of	O
multiple	O
viral	B-DISO
infections	I-DISO
,	O
which	O
allows	O
the	O
detection	O
of	O
main	O
infectious	B-DISO
viruses	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
impact	O
of	O
body	O
temperature	O
on	O
disease	O
severity	O
,	O
implementation	O
of	O
sepsis	B-DISO
bundles	O
,	O
and	O
outcomes	O
in	O
severe	B-DISO
sepsis	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
),	O
an	O
infectious	B-DISO
coronavirus	O
first	O
reported	O
in	O
2012	O
,	O
has	O
a	O
mortality	O
rate	O
greater	O
than	O
35	O
%.	O

Therapeutic	O
antibodies	O
are	O
key	O
tools	O
for	O
preventing	O
and	O
treating	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
but	O
to	O
date	O
no	O
such	O
agents	O
have	O
been	O
approved	O
for	O
treatment	O
of	O
this	O
virus	O
.	O

Lung	O
-	O
protective	O
mechanical	O
ventilation	O
strategies	O
remain	O
the	O
cornerstone	O
in	O
the	O
management	O
of	O
ARDS	B-DISO
.	O

Infections	B-DISO
appear	O
associated	O
with	O
increased	O
disease	O
severity	O
and	O
higher	O
mortality	O
in	O
infected	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
nsp4	O
induces	O
pro	O
-	O
inflammatory	O
cytokine	O
and	O
chemokine	O
expression	O
inhibiting	O
viral	O
replication	O
in	O
vitro	O
.	O

TITLE	O
:	O
An	O
infant	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
an	O
opportunistic	O
polymicrobial	O
pulmonary	B-DISO
infection	I-DISO
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
A	O
7	O
-	O
month	O
-	O
old	O
male	O
baby	O
presented	O
to	O
the	O
pediatric	O
hematology	O
unit	O
for	O
investigations	O
of	O
recurrent	O
episodes	O
of	O
neutropenia	O
associated	O
with	O
fever	O
and	O
respiratory	B-DISO
distress	I-DISO
.	O

However	O
,	O
Myong	O
Ji	O
Hospital	O
has	O
under	O
-	O
estimated	O
the	O
communication	O
problem	O
;	O
inadequate	O
communication	O
during	O
the	O
MERS	O
period	O
caused	O
a	O
lot	O
of	O
confusion	B-DISO
among	O
people	O
.	O

After	O
storage	O
at	O
20	O
°	O
C	O
for	O
2	O
weeks	O
no	O
infectious	B-DISO
PEDV	O
was	O
re	O
-	O
isolated	O
from	O
SDPP	O
anymore	O
(	O
LRF	O
≥	O
4	O
·	O
0	O
).	O

ABSTRACT	O
:	O
Diagnostics	O
play	O
a	O
central	O
role	O
in	O
the	O
early	O
detection	O
and	O
control	O
of	O
outbreaks	O
and	O
can	O
enable	O
a	O
more	O
nuanced	O
understanding	O
of	O
the	O
disease	O
kinetics	O
and	O
risk	O
factors	O
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
one	O
of	O
the	O
high	O
-	O
priority	O
pathogens	O
identified	O
by	O
the	O
WHO	O
.	O

A	O
more	O
detailed	O
understanding	O
of	O
the	O
kinetics	O
of	O
infection	B-DISO
of	O
MERS	O
-	O
CoV	O
is	O
needed	O
in	O
order	O
to	O
optimise	O
the	O
use	O
of	O
existing	O
assays	O
.	O

Herein	O
,	O
the	O
morpholine	O
ring	O
of	O
GLS4	O
was	O
replaced	O
with	O
substituted	O
sulfonamides	O
and	O
triazoles	O
to	O
generate	O
novel	O
non	O
-	O
nucleoside	O
HBV	B-DISO
inhibitors	O
with	O
desirable	O
potency	O
.	O

Antibiotics	O
were	O
commonly	O
prescribed	O
in	O
the	O
setting	O
of	O
a	O
viral	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
protective	O
effect	O
and	O
curative	O
effect	O
of	O
early	O
treatment	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
severe	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
acute	O
phosgene	O
poisoning	O
.	O

Oxygenation	O
was	O
improved	O
obviously	O
after	O
treatment	O
,	O
ventilator	O
support	O
conditions	O
could	O
be	O
obviously	O
reduced	O
,	O
including	O
3	O
-	O
6	O
mL	O
/	O
kg	O
of	O
the	O
small	O
tidal	O
volume	O
,	O
8	O
-	O
10	O
cmH	B-DISO
Early	O
treatment	O
with	O
ECMO	O
can	O
significantly	O
improve	O
the	O
oxygenation	O
of	O
severe	O
ARDS	B-DISO
caused	O
by	O
acute	O
phosgene	O
poisoning	O
,	O
eliminate	O
excessive	O
CO	O
RESULTS	O
:	O
After	O
admitted	O
in	O
hospital	O
,	O
the	O
4	O
patients	O
were	O
all	O
put	O
on	O
tracheal	O
intubation	O
and	O
ventilator	O
,	O
but	O
the	O
ventilator	O
support	O
conditions	O
were	O
high	O
,	O
the	O
oxygenation	O
and	O
internal	O
environment	O
were	O
unstable	O
.	O

Oxygenation	O
was	O
improved	O
obviously	O
after	O
treatment	O
,	O
ventilator	O
support	O
conditions	O
could	O
be	O
obviously	O
reduced	O
,	O
including	O
3	O
-	O
6	O
mL	O
/	O
kg	O
of	O
the	O
small	O
tidal	O
volume	O
,	O
8	O
-	O
10	O
cmH	B-DISO

In	O
addition	O
,	O
the	O
immunologic	O
effect	O
of	O
CAV	O
provokedthe	O
development	O
of	O
clinical	O
signs	O
of	O
LPAI	O
-	O
H9N2	O
and	O
IB	O
virus	O
infections	B-DISO
.	O

TITLE	O
:	O
Evaluation	O
and	O
comparison	O
of	O
immunogenicity	O
and	O
cross	O
-	O
protective	O
efficacy	O
of	O
two	O
inactivated	O
cell	O
culture	O
-	O
derived	O
GIIa	O
-	O
and	O
GIIb	O
-	O
genotype	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
vaccines	O
in	O
suckling	O
piglets	O
.	O

Sequences	O
of	O
amplified	O
S2	O
fragments	O
differed	O
between	O
trachea	B-DISO
and	O
kidney	O
samples	O
.	O

TITLE	O
:	O
Anti	O
-	O
spike	O
IgG	O
causes	O
severe	O
acute	O
lung	O
injury	O
by	O
skewing	O
macrophage	O
responses	O
during	O
acute	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Newly	O
emerging	O
viruses	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
CoVs	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
H7N9	O
,	O
cause	O
fatal	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
by	O
driving	O
hypercytokinemia	O
and	O
aggressive	B-DISO
inflammation	B-DISO
through	O
mechanisms	O
that	O
remain	O
elusive	O
.	O

The	O
viruses	O
included	O
canine	O
adenovirus	B-DISO
type	O
2	O
(	O
CAV	O
-	O
2	O
),	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
CDV	O
),	O
canine	O
influenza	B-DISO
virus	O
(	O
CIV	O
),	O
canine	O
parainfluenza	B-DISO
virus	O
(	O
CPIV	O
),	O
canine	O
circovirus	O
(	O
CanineCV	O
),	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
and	O
canine	O
parvovirus	B-DISO
(	O
CPV	O
).	O

Twenty	O
nasal	O
swabs	O
(	O
NS	O
)	O
and	O
20	O
anal	O
swabs	O
(	O
AS	O
)	O
collected	O
from	O
dogs	O
with	O
symptoms	O
of	O
respiratory	B-DISO
disease	I-DISO
or	O
enteric	O
disease	O
were	O
evaluated	O
using	O
the	O
novel	O
mPCR	O
methods	O
as	O
a	O
clinical	O
test	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
leptospirosis	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
is	O
a	O
major	O
complication	B-DISO
of	O
leptospirosis	B-DISO
,	O
leading	O
to	O
the	O
majority	O
of	O
fatalities	O
.	O

Of	O
172	O
leptospirosis	B-DISO
patients	O
from	O
January	O
2004	O
to	O
October	O
2017	O
,	O
39	O
(	O
23	O
%)	O
presented	O
a	O
moderate	O
or	O
severe	O
ARDS	B-DISO
with	O
a	O
mortality	O
rate	O
of	O
23	O
%	O
(	O
9	O
cases	O
).	O

Dromedary	O
camels	O
are	O
the	O
primary	O
zoonotic	O
reservoir	O
for	O
human	O
infections	B-DISO
.	O

Through	O
different	O
inoculation	O
routes	O
,	O
MHV	O
-	O
A59	O
can	O
provide	O
animal	O
models	O
for	O
encephalitis	B-DISO
,	O
hepatitis	B-DISO
and	O
pneumonia	B-DISO
to	O
explore	O
viral	O
life	O
machinery	O
and	O
virus	O
-	O
host	O
interactions	O
.	O

TITLE	O
:	O
Pneumonia	B-DISO
severity	O
index	O
in	O
viral	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
in	O
adults	O
.	O

However	O
,	O
there	O
is	O
a	O
lack	O
of	O
research	O
on	O
whether	O
this	O
scoring	O
system	O
can	O
be	O
applied	O
to	O
viral	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
.	O

This	O
retrospective	O
cohort	O
study	O
included	O
1	O
,	O
434	O
adult	O
patients	O
(	O
aged	O
≥	O
18	O
years	O
)	O
who	O
were	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
of	O
a	O
university	O
hospital	O
during	O
2013	O
-	O
2015	O
because	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Growth	O
enhancement	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
E6	O
cells	O
expressing	O
PEDV	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
More	O
recently	O
emerging	O
strains	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
cause	O
severe	B-DISO
diarrhea	I-DISO
and	O
especially	O
high	O
mortality	O
rates	O
in	O
infected	O
piglets	O
,	O
leading	O
to	O
substantial	O
economic	O
loss	O
to	O
worldwide	O
swine	O
industry	O
.	O

ABSTRACT	O
:	O
Beyond	O
its	O
current	O
function	O
as	O
a	O
rescue	O
therapy	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
may	O
be	O
applied	O
in	O
ARDS	B-DISO
patients	O
with	O
less	O
severe	O
hypoxemia	O
to	O
facilitate	O
lung	O
protective	O
ventilation	O
.	O

The	O
human	O
SARS	B-DISO
-	O
CoVs	O
and	O
civet	O
SARSr	O
-	O
CoVs	O
were	O
collected	O
in	O
2003	O
/	O
2004	O
,	O
while	O
bat	O
SARSr	O
-	O
CoVs	O
were	O
continuously	O
isolated	O
in	O
the	O
past	O
13	O
years	O
even	O
after	O
the	O
cessation	O
of	O
the	O
SARS	B-DISO
epidemic	O
.	O

It	O
is	O
evident	O
from	O
both	O
multiple	O
alignment	O
and	O
phylogenetic	O
analyses	O
that	O
some	O
genes	O
of	O
a	O
particular	O
SARSr	O
-	O
CoV	O
from	O
bats	O
may	O
possess	B-DISO
higher	O
while	O
other	O
genes	O
possess	B-DISO
much	O
lower	O
nucleotide	O
identity	O
to	O
the	O
corresponding	O
genes	O
of	O
SARSr	O
-	O
CoV	O
from	O
human	O
/	O
civets	O
,	O
resulting	O
in	O
the	O
shift	O
of	O
phylogenetic	O
position	O
in	O
different	O
phylogenetic	O
trees	O
.	O

This	O
review	O
supports	O
RSV	O
,	O
Flu	B-DISO
,	O
PIV	O
,	O
HMPV	O
,	O
AdV	O
,	O
RV	O
,	O
and	O
CoV	O
as	O
important	O
causes	O
of	O
ARI	O
in	O
older	O
adults	O
and	O
provides	O
quantitative	O
estimates	O
of	O
the	O
absolute	O
proportion	O
of	O
virus	O
-	O
associated	O
ARI	O
cases	O
to	O
which	O
a	O
viral	O
cause	O
can	O
be	O
attributed	O
.	O

Areas	O
covered	O
:	O
The	O
risks	O
of	O
re	O
-	O
emergence	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
bat	O
reservoir	O
hosts	O
,	O
the	O
persistence	O
of	O
MERS	O
-	O
CoV	O
circulation	O
,	O
and	O
the	O
potential	O
for	O
future	O
emergence	O
of	O
novel	O
coronaviruses	O
indicate	O
antiviral	O
drug	O
discovery	O
will	O
require	O
activity	O
against	O
multiple	O
coronaviruses	O
.	O

In	O
addition	O
,	O
numerous	O
pathogens	O
have	O
been	O
found	O
to	O
encode	O
Ub	O
(	O
l	O
)-	O
ligases	O
and	O
deconjugating	O
enzymes	O
in	O
order	O
to	O
facilitate	O
infection	B-DISO
and	O
fight	O
the	O
host	O
immune	O
response	O
.	O

In	O
the	O
present	O
report	O
we	O
discuss	O
a	O
fatal	O
case	O
of	O
18	O
-	O
years	O
-	O
old	O
boy	O
,	O
who	O
had	O
smoked	O
SCs	B-DISO
since	O
several	O
months	O
and	O
an	O
overuse	O
of	O
SCs	B-DISO
during	O
last	O
48	O
h	O
of	O
his	O
life	O
has	O
been	O
apprised	O
.	O

ABSTRACT	O
:	O
Due	O
to	O
the	O
inconsistent	O
development	O
of	O
enteric	O
signs	O
associated	O
with	O
ECoV	O
infection	B-DISO
in	O
adult	O
horses	O
,	O
many	O
practitioners	O
collect	O
nasal	O
secretions	O
rather	O
than	O
feces	O
for	O
the	O
molecular	O
diagnostic	O
work	O
-	O
up	O
of	O
such	O
horses	O
.	O

Feces	O
were	O
tested	O
for	O
ECoV	O
and	O
nasal	O
secretions	O
for	O
common	O
respiratory	O
pathogens	O
(	O
equine	O
herpesvirus	O
(	O
EHV	O
)-	O
1	O
,	O
EHV	O
-	O
4	O
,	O
equine	B-DISO
influenza	I-DISO
virus	O
(	O
EIV	O
),	O
equine	O
rhinitis	B-DISO
viruses	O
(	O
ERVs	O
)	O
and	O
The	O
total	O
number	O
of	O
horses	O
testing	O
qPCR	O
-	O
positive	O
for	O
ECoV	O
in	O
feces	O
was	O
20	O
(	O
7	O
.	O
2	O
%),	O
4	O
of	O
which	O
also	O
tested	O
qPCR	O
-	O
positive	O
for	O
ECoV	O
in	O
nasal	O
secretions	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
a	O
high	O
tidal	O
volume	O
(	O
odds	O
ratio	O
=	O
1	O
.	O
448	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
033	O
-	O
2	O
.	O
030	O
;	O
p	O
=	O
0	O
.	O
032	O
)	O
and	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
)	O
score	O
(	O
odds	O
ratio	O
=	O
1	O
.	O
233	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
029	O
-	O
1	O
.	O
478	O
;	O
p	O
=	O
0	O
.	O
023	O
)	O
were	O
the	O
risk	O
factors	O
of	O
hospital	O
mortality	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrates	O
that	O
although	O
not	O
essential	O
for	O
replication	O
,	O
glycosylation	O
in	O
the	O
IBV	O
M	O
protein	O
ectodomain	O
plays	O
important	O
roles	O
in	O
activating	O
ER	O
stress	O
,	O
apoptosis	O
and	O
proinflammatory	O
response	O
,	O
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
IBV	O
.	O

After	O
extracorporeal	O
membrane	O
oxygenation	O
weaning	O
,	O
duplex	O
sonography	O
or	O
CT	O
was	O
conducted	O
to	O
detect	O
cannula	O
-	O
related	O
thrombosis	B-DISO
.	O

ABSTRACT	O
:	O
Gamma	O
irradiation	O
using	O
a	O
cobalt	O
-	O
60	O
source	O
is	O
a	O
commonly	O
used	O
method	O
for	O
the	O
inactivation	B-DISO
of	O
infectious	B-DISO
specimens	O
to	O
be	O
handled	O
safely	O
in	O
subsequent	O
laboratory	O
procedures	O
.	O

Transfusion	O
transmitted	B-DISO
-	O
diseases	O
(	O
TTD	O
)	O
comprise	O
several	O
pathologies	O
that	O
are	O
transmitted	B-DISO
by	O
blood	O
transfusions	O
.	O

No	O
evidence	O
of	O
relapse	B-DISO
or	O
reinfection	O
was	O
found	O
.	O

No	O
evidence	O
of	O
relapse	B-DISO
or	O
reinfection	O
was	O
found	O
.	O

Sera	O
were	O
screened	O
using	O
virus	O
microneutralization	O
tests	O
and	O
positive	O
sera	O
(	O
where	O
available	O
)	O
were	O
confirmed	O
using	O
plaque	B-DISO
reduction	O
neutralization	O
tests	O
(	O
PRNT	O
).	O

TITLE	O
:	O
The	O
Infectious	B-DISO
Bronchitis	B-DISO
Coronavirus	O
Envelope	O
Protein	O
Alters	O
Golgi	O
pH	O

In	O
conclusion	O
,	O
the	O
combination	O
of	O
live	O
attenuated	O
vaccine	O
containing	O
the	O
Massachusetts	O
strain	O
with	O
a	O
booster	O
dose	O
of	O
an	O
inactivated	O
vaccine	O
,	O
containing	O
a	O
BR	O
-	O
I	O
IBV	O
strain	O
,	O
confers	O
effective	O
protection	O
against	O
infection	B-DISO
with	O
nephropathogenic	O
homologous	O
IBV	O
strain	O
because	O
of	O
the	O
induction	O
of	O
consistent	O
memory	O
immune	O
responses	O
mediated	O
by	O
IgG	O
antibodies	O
and	O
TCD8	O
cells	O
in	O
the	O
mucosal	O
and	O
systemic	O
compartments	O
of	O
chickens	O
submitted	O
to	O
this	O
vaccination	O
regime	O
.	O

ABSTRACT	O
:	O
Louse	B-DISO
-	I-DISO
borne	I-DISO
relapsing	I-DISO
fever	I-DISO
(	O
LBRF	O
)	O
is	O
an	O
epidemic	B-DISO
disease	I-DISO
with	O
a	O
fascinating	O
history	O
from	O
Hippocrates	O
'	O
times	O
,	O
through	O
the	O
6th	O
century	O
'	O
Yellow	O
Plague	B-DISO
',	O
to	O
epidemics	O
in	O
Ireland	O
,	O
Scotland	O
and	O
England	O
in	O
the	O
19th	O
century	O
and	O
two	O
large	O
Afro	O
-	O
Middle	O
Eastern	O
pandemics	O
in	O
the	O
20th	O
century	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
are	O
two	O
poultry	O
pathogens	O
seriously	O
affecting	O
the	O
poultry	O
industry	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
clinical	O
predictors	O
of	O
mortality	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Obesity	B-DISO
hypoventilation	I-DISO
syndrome	I-DISO
.	O

Pathological	O
specimens	O
from	O
patients	O
with	O
ARDS	B-DISO
frequently	O
reveal	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
and	O
laboratory	O
studies	O
have	O
demonstrated	O
both	O
alveolar	O
epithelial	O
and	O
lung	O
endothelial	O
injury	O
,	O
resulting	O
in	O
accumulation	O
of	O
protein	O
-	O
rich	O
inflammatory	O
oedematous	B-DISO
fluid	O
in	O
the	O
alveolar	O
space	O
.	O

TITLE	O
:	O
Respiratory	O
viruses	O
identified	O
in	O
western	O
Canadian	O
beef	O
cattle	O
by	O
metagenomic	O
sequencing	O
and	O
their	O
association	O
with	O
bovine	O
respiratory	B-DISO
disease	I-DISO
.	O

A	O
prospective	O
,	O
observational	O
study	O
of	O
adults	O
with	O
ARDS	B-DISO
(	O
January	O
2013	O
to	O
December	O
2015	O
)	O
was	O
conducted	O
at	O
a	O
single	O
center	O
.	O

Non	O
-	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
had	O
lower	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
scores	O
and	O
higher	O
rates	O
of	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
.	O

We	O
report	O
severe	O
T	O
.	O
foetus	O
infection	B-DISO
of	O
the	O
colon	O
,	O
cecum	O
and	O
ileum	O
with	O
concurrent	O
feline	O
enteric	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
feline	B-DISO
panleukopenia	I-DISO
virus	O
(	O
FPV	O
)	O
in	O
a	O
3	O
-	O
month	O
-	O
old	O
Bengal	O
kitten	O
with	O
an	O
8	O
-	O
day	O
history	O
of	O
vomiting	B-DISO
,	O
diarrhoea	B-DISO
,	O
failure	B-DISO
to	I-DISO
thrive	I-DISO
and	O
coughing	B-DISO
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
a	O
novel	O
linear	O
epitope	O
in	O
the	O
spike	O
protein	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Mucormycosis	B-DISO
is	O
an	O
uncommonly	O
encountered	O
fungal	B-DISO
infection	I-DISO
in	O
solid	O
-	O
organ	O
transplantation	O
,	O
occurring	O
most	O
often	O
gastrointestinally	O
.	O

Preemptive	O
therapy	O
,	O
which	O
included	O
liposomal	O
amphotericin	O
B	O
and	O
posaconazole	O
,	O
was	O
adminstered	O
when	O
voriconazole	O
proved	O
to	O
be	O
unhelpful	O
and	O
before	O
histologic	O
reports	O
of	O
gastric	O
mucormycosis	B-DISO
.	O

TITLE	O
:	O
Dynamic	O
changes	O
of	O
pulmonary	O
arterial	O
pressure	O
in	O
perinatal	O
neonates	O
with	O
pulmonary	O
and	O
extrapulmonary	O
acute	O
lung	O
injury	O
/	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
dynamic	O
changes	O
of	O
PAP	B-DISO
were	O
observed	O
in	O
these	O
neonates	O
.	O

ABSTRACT	O
:	O
The	O
protocol	O
aims	O
to	O
generate	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
fusion	O
protein	O
pseudotyped	O
particles	O
with	O
a	O
murine	O
leukemia	B-DISO
virus	O
(	O
MLV	O
)	O
core	O
and	O
luciferase	O
reporter	O
,	O
using	O
a	O
simple	O
transfection	O
procedure	O
of	O
the	O
widely	O
available	O
HEK	O
-	O
293T	O
cell	O
line	O
.	O

In	O
patients	O
with	O
MERS	O
and	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
NIV	O
failure	O
was	O
very	O
high	O
.	O

Their	O
knowledge	O
was	O
evaluated	O
against	O
facts	O
published	O
by	O
Mayo	O
Clinic	O
Foundation	O
,	O
and	O
its	O
percentage	O
mean	O
score	O
(	O
PMS	B-DISO
)	O
±	O
standard	O
deviation	O
was	O
calculated	O
.	O

Initial	O
experimentation	O
in	O
small	O
-	O
volume	O
samples	O
showed	O
that	O
both	O
types	O
of	O
particles	O
readily	O
adsorbed	O
to	O
the	O
positively	O
charged	O
glass	O
wool	O
but	O
were	O
poorly	O
detached	O
from	O
it	O
through	O
standard	O
elution	O
with	O
0	O
.	O
05	O
M	O
glycine	O
with	O
3	O
%	O
of	O
beef	O
extract	O
buffer	O
,	O
pH	O
9	O
.	O
5	O
,	O
with	O
elution	O
efficiencies	O
of	O
7	O
.	O
2	O
%	O
and	O
2	O
.	O
6	O
%,	O
for	O
HAV	B-DISO
and	O
TGEV	O
,	O
respectively	O
.	O

Nowadays	O
,	O
as	O
a	O
result	O
of	O
traffic	O
accidents	O
,	O
following	O
high	O
energy	O
deceleration	O
,	O
lung	O
contusion	O
may	O
present	O
without	O
an	O
actual	O
tissue	O
damage	O
in	O
the	O
chest	O
wall	O
as	O
a	O
condition	B-DISO
initiating	O
an	O
independent	O
,	O
life	O
-	O
threatening	O
generalised	O
process	O
.	O

Although	O
lung	O
contusion	O
shows	O
similarities	O
to	O
blast	O
injury	O
of	O
the	O
lung	O
with	O
respect	O
to	O
clinical	O
consequences	O
,	O
other	O
factors	O
play	O
a	O
role	O
in	O
its	O
aetiology	O
and	O
pathology	B-DISO
.	O

Therefore	O
,	O
we	O
conducted	O
a	O
systematic	O
literature	O
review	O
of	O
animal	O
models	O
combining	O
features	O
of	O
experimental	O
ARDS	B-DISO
with	O
ECMO	O
to	O
better	O
understand	O
this	O
situation	O
.	O

TITLE	O
:	O
Antagonism	O
of	O
dsRNA	O
-	O
Induced	O
Innate	O
Immune	O
Pathways	O
by	O
NS4a	O
and	O
NS4b	O
Accessory	O
Proteins	O
during	O
MERS	O
Coronavirus	B-DISO
Infection	I-DISO
.	O

Our	O
study	O
describes	O
the	O
functions	O
of	O
two	O
accessory	O
proteins	O
unique	O
to	O
MERS	O
-	O
CoV	O
and	O
related	O
viruses	O
,	O
NS4a	O
and	O
NS4b	O
,	O
during	O
infection	B-DISO
in	O
human	O
airway	O
epithelium	O
-	O
derived	O
A549	O
cells	O
.	O

Facial	B-DISO
palsy	I-DISO
in	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
is	O
usually	O
bilateral	O
.	O

On	O
presentation	O
,	O
diagnosis	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
was	O
supported	O
by	O
areflexia	O
and	O
albuminocytologic	O
dissociation	B-DISO
.	O

To	O
search	O
for	O
effective	O
inhibitory	O
agents	O
,	O
we	O
performed	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	B-DISO
)	O
of	O
a	O
2	O
,	O
000	O
-	O
compound	O
library	O
of	O
approved	O
drugs	O
and	O
pharmacologically	O
active	O
compounds	O
using	O
the	O
established	O
genetically	O
engineered	O
human	O
CoV	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
strain	O
expressing	O

ABSTRACT	O
:	O
Hyperbilirubinemia	B-DISO
occurs	O
in	O
up	O
to	O
40	O
%	O
of	O
critically	B-DISO
ill	I-DISO
.	O

Jaundice	B-DISO
can	O
reflect	O
the	O
course	O
of	O
disease	O
or	O
be	O
caused	O
by	O
treatment	O
(	O
e	O
.	O
g	O
.	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)),	O
thus	O
can	O
be	O
difficult	O
to	O
differentiate	O
.	O

ABSTRACT	O
:	O
Lower	O
extremity	O
necrotizing	B-DISO
fasciitis	I-DISO
(	O
NF	O
)	O
is	O
a	O
severe	O
infection	B-DISO
requiring	O
immediate	O
surgery	O
.	O

Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
highly	O
pathogenic	O
human	O
corona	O
virus	O
with	O
38	O
%	O
fatality	O
rate	O
of	O
infected	O
patients	O
.	O

TITLE	O
:	O
Surgical	O
lung	O
biopsy	O
in	O
onco	O
-	O
hematological	O
patients	O
with	O
diffuse	O
pulmonary	B-DISO
infiltrates	I-DISO
and	O
mechanical	O
ventilation	O
in	O
the	O
ICU	O
.	O

Mycoplasma	B-DISO
pneumonia	I-DISO
is	O
a	O
common	O
type	O
of	O
pneumonia	B-DISO
in	O
the	O
community	O
,	O
but	O
only	O
a	O
small	O
percentage	O
of	O
patients	O
require	O
hospitalization	O
.	O

The	O
N	O
-	O
Terminal	O
Domain	O
of	O
Spike	O
Protein	O
Is	O
Not	O
the	O
Enteric	O
Tropism	O
Determinant	O
for	O
Transmissible	O
Gastroenteritis	B-DISO
Virus	O
in	O
Piglets	O
.	O

TITLE	O
:	O
Fatal	O
Exsanguination	B-DISO
Following	O
Rupture	O
of	O
an	O
Iliac	B-DISO
Artery	I-DISO
Aneurysm	I-DISO
in	O
an	O
Infant	O
With	O
Menkes	B-DISO
Disease	I-DISO
.	O

The	O
RT	O
-	O
PCR	O
detection	O
indicated	O
that	O
the	O
infection	B-DISO
of	O
PDCoV	O
was	O
high	O
up	O
to	O
23	O
.	O
49	O
%	O
(	O
101	O
/	O
430	O
),	O
and	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
PEDV	O
were	O
common	O
(	O
60	O
.	O
40	O
%,	O
61	O
/	O
101	O
)	O
in	O
Henan	O
pigs	O
.	O

Seventeen	O
patients	O
were	O
treated	O
with	O
VV	O
-	O
ECMO	O
(	O
nine	O
males	O
,	O
median	O
age	O
33	O
years	O
,	O
range	O
14	O
-	O
74	O
),	O
the	O
indication	O
for	O
16	O
patients	O
was	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
most	O
often	O
following	O
pneumonia	B-DISO
(	O
n	O
=	O
6	O
),	O
H1N1	O
-	O
infection	B-DISO
(	O
n	O
=	O
3	O
)	O
or	O
drowning	O
(	O
n	O
=	O
2	O
).	O

This	O
deficiency	O
prevents	O
the	O
evaluation	O
of	O
how	O
well	O
therapeutic	O
agents	O
reach	O
the	O
most	O
injured	O
regions	O
and	O
precludes	O
many	O
regenerative	O
medicine	O
studies	O
since	O
it	O
is	O
not	O
possible	O
to	O
know	O
which	O
apparently	O
healing	O
regions	O
suffered	B-DISO
severe	O
injury	O
initially	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
is	O
a	O
key	O
factor	O
in	O
virus	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
host	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
Equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
and	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
represent	O
two	O
members	O
of	O
the	O
family	O

Access	O
to	O
viral	O
diagnostics	O
are	O
very	O
necessary	O
for	O
medical	O
staff	O
to	O
determine	O
appropriate	O
pneumonia	B-DISO
treatments	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
features	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
are	O
highly	O
variable	O
,	O
according	O
to	O
the	O
type	O
of	O
antecedent	O
infection	B-DISO
.	O

Frequent	O
antecedent	O
infections	B-DISO
among	O
this	O
study	O
of	O
70	O
FS	O
patients	O
included	O
Haemophilus	O
influenzae	O
[	O
n	O
=	O
15	O
(	O
21	O
%)],	O
Campylobacter	O
jejuni	O
[	O
n	O
=	O
10	O
(	O
14	O
%)],	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
[	O
n	O
=	O
6	O
(	O
8	O
.	O
6	O
%)].	O

Both	O
patients	O
tragically	O
died	O
following	O
suffocation	B-DISO
from	O
solid	O
food	O
aspiration	B-DISO
of	O
full	O
meals	O
that	O
were	O
ingested	O
6	O
and	O
8	O
hours	O
before	O
delivery	O
,	O
respectively	O
.	O

Machine	O
learning	O
algorithms	O
can	O
be	O
used	O
to	O
generate	O
dynamic	O
prediction	O
after	O
injury	O
while	O
avoiding	O
the	O
risk	O
of	O
over	O
-	O
and	O
under	O
-	O
fitting	B-DISO
inherent	O
in	O
ad	O
hoc	O
statistical	O
approaches	O
.	O

RESULTS	O
:	O
SuperLearner	O
fits	B-DISO
demonstrated	O
excellent	O
cross	O
-	O
validated	O
prediction	O
of	O
death	O
(	O
overall	O
AUC	O
0	O
.	O
94	O
-	O
0	O
.	O
97	O
),	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
(	O
overall	O
AUC	O
0	O
.	O
84	O
-	O
0	O
.	O
90	O
),	O
and	O
transfusion	O
(	O
overall	O
AUC	O
0	O
.	O
87	O
-	O
0	O
.	O
9	O
)	O
across	O
multiple	O
post	O
-	O
injury	O
time	O
points	O
,	O
and	O
good	O
prediction	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
overall	O
AUC	O
0	O
.	O
84	O
-	O
0	O
.	O
89	O
)	O
and	O
venous	B-DISO
thromboembolism	I-DISO
(	O
overall	O
AUC	O
0	O
.	O
73	O
-	O
0	O
.	O
83	O
).	O

The	O
three	O
-	O
day	O
program	O
was	O
focused	O
on	O
therapeutics	O
towards	O
seasonal	O
and	O
pandemic	O
influenza	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
coronaviruses	O
including	O
MERS	O
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
human	O
rhinovirus	O
,	O
and	O
other	O
respiratory	O
viruses	O
.	O

Leptospirosis	B-DISO
is	O
associated	O
with	O
exposure	O
to	O
water	O
,	O
soil	O
,	O
or	O
other	O
matter	O
contaminated	O
with	O
urine	O
of	O
carrier	O
animals	O
.	O

TITLE	O
:	O
Effect	O
of	O
Fc	O
Fusion	O
on	O
Folding	O
and	O
Immunogenicity	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Spike	O
Protein	O
.	O

TITLE	O
:	O
Infectious	B-DISO
Disease	I-DISO
Threats	O
in	O
the	O
Twenty	O
-	O
First	O
Century	O
:	O

Whether	O
the	O
global	O
health	O
system	O
as	O
currently	O
constituted	O
can	O
provide	O
effective	O
protection	O
against	O
a	O
dynamic	O
array	O
of	O
infectious	B-DISO
disease	I-DISO
threats	O
has	O
been	O
called	O
into	O
question	O
by	O
recent	O
outbreaks	O
of	O
Ebola	O
,	O
Zika	O
,	O
dengue	B-DISO
,	O
Middle	O
East	O
respiratory	B-DISO
syndrome	I-DISO
,	I-DISO
severe	I-DISO
acute	I-DISO
respiratory	O
syndrome	B-DISO
,	O
and	O
influenza	B-DISO
and	O
by	O
the	O
looming	O
threat	O
of	O
rising	O
antimicrobial	O
resistance	O
.	O

The	O
concern	O
is	O
magnified	O
by	O
rapid	O
population	O
growth	O
in	O
areas	O
with	O
weak	O
health	O
systems	O
,	O
urbanization	O
,	O
globalization	O
,	O
climate	O
change	O
,	O
civil	O
conflict	O
,	O
and	O
the	O
changing	O
nature	O
of	O
pathogen	B-DISO
transmission	I-DISO
between	O
human	O
and	O
animal	O
populations	O
.	O

This	O
Council	O
would	O
strengthen	O
the	O
global	O
health	O
system	O
by	O
improving	O
collaboration	O
and	O
coordination	O
across	O
organizations	O
(	O
e	O
.	O
g	O
.,	O
the	O
WHO	O
,	O
Gavi	O
,	O
CEPI	O
,	O
national	O
centers	O
for	O
disease	O
control	O
,	O
pharmaceutical	O
manufacturers	O
,	O
etc	O
.);	O
filling	O
in	O
knowledge	O
gaps	O
with	O
respect	O
to	O
(	O
for	O
example	O
)	O
infectious	B-DISO
disease	I-DISO
surveillance	O
,	O
research	O
and	O
development	O
needs	O
,	O
financing	O
models	O
,	O
supply	O
chain	O
logistics	O
,	O
and	O
the	O
social	O
and	O
economic	O
impacts	O
of	O
potential	O
threats	O
;	O
and	O
making	O
high	O
-	O
level	O
,	O
evidence	O
-	O
based	O
recommendations	O
for	O
managing	O
global	O
risks	O
associated	O
with	O
infectious	B-DISO
disease	I-DISO
.	O

The	O
novel	O
coronavirus	O
(	O
nCoV	O
),	O
or	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
is	O
a	O
particular	O
strain	O
different	O
from	O
any	O
other	O
known	O
hCoV	O
with	O
the	O
possibility	O
of	O
human	O
and	O
also	O
zoonotic	O
transmissions	O
.	O

Personal	O
protective	O
equipment	O
to	O
be	O
used	O
when	O
seeing	O
suspected	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
were	O
mainly	O
the	O
mask	O
(	O
94	O
.	O
1	O
%),	O
gloves	O
(	O
78	O
.	O
8	O
%),	O
the	O
gown	O
(	O
60	O
%),	O
goggles	O
(	O
31	O
.	O
8	O
%),	O
and	O
the	O
cap	B-DISO
(	O
22	O
.	O
4	O
%).	O

TITLE	O
:	O
Improvement	O
in	O
Oxygenation	O
Utilizing	O
Transpulmonary	O
Pressure	O
Monitoring	O
for	O
Optimal	O
Positive	O
End	O
-	O
Expiratory	O
Pressure	O
in	O
Pediatric	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
A	O
Case	O
Report	O
.	O

Our	O
case	O
suggests	O
that	O
transpulmonary	O
pressure	O
monitoring	O
should	O
be	O
studied	O
as	O
an	O
adjunct	O
to	O
improve	O
outcomes	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

More	O
particle	O
-	O
laden	O
macrophages	O
and	O
even	O
greater	O
chronic	B-DISO
inflammation	I-DISO
were	O
observed	O
in	O
the	O
UFP	O
-	O
exposed	O
mice	O
lungs	O
.	O

TITLE	O
:	O
Visual	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
using	O
a	O
novel	O
reverse	O
transcription	O
polymerase	O
spiral	O
reaction	O
method	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
a	O
novel	O
reverse	O
transcription	O
polymerase	O
spiral	O
reaction	O
(	O
RT	O
-	O
PSR	O
)	O
assay	O
for	O
the	O
rapid	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

Historically	O
thought	O
to	O
be	O
limited	O
to	O
pandemic	O
viruses	O
,	O
improved	O
detection	O
of	O
hRV	O
has	O
led	O
to	O
its	O
implication	O
in	O
serious	O
respiratory	B-DISO
disorders	I-DISO
extending	O
beyond	O
the	O
oropharynx	O
in	O
immunocompetent	O
hosts	O
.	O

ABSTRACT	O
:	O
Continuously	O
emerging	O
highly	O
pathogenic	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
remain	O
a	O
major	O
threat	O
to	O
human	O
health	O
,	O
as	O
illustrated	O
in	O
past	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
outbreaks	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
Model	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
in	O
Microminipigs	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
induces	O
an	O
often	O
fatal	O
gastrointestinal	B-DISO
disease	I-DISO
in	O
piglets	O
.	O

The	O
infected	O
Microminipig	O
showed	O
the	O
typical	O
signs	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
),	O
such	O
as	O
watery	B-DISO
diarrhea	I-DISO
,	O
loss	B-DISO
of	I-DISO
appetite	I-DISO
and	O
weight	O
loss	O
.	O

We	O
also	O
examined	O
the	O
representation	O
of	O
major	O
etiologies	O
for	O
ARDS	B-DISO
across	O
the	O
Berlin	O
definition	O
classifications	O
.	O

Normal	O
hematologic	O
function	O
and	O
the	O
absence	O
of	O
standard	O
exclusion	O
criteria	O
used	O
for	O
therapeutic	O
clinical	O
trials	O
in	O
ARDS	B-DISO
were	O
protective	O
.	O

Patients	O
with	O
asthma	B-DISO
or	O
allergies	B-DISO
are	O
apparently	O
more	O
at	O
risk	O
for	O
severe	O
symptoms	O
.	O

Bats	O
are	O
reservoirs	O
for	O
a	O
high	O
diversity	O
of	O
coronaviruses	O
,	O
and	O
focused	O
surveillance	O
detected	O
several	O
strains	O
genetically	O
similar	O
to	O
MERS	O
-	O
coronavirus	O
,	O
SARS	B-DISO
-	O
coronavirus	O
,	O
and	O
the	O
human	O
coronaviruses	O
229E	O
and	O
NL63	O
.	O

ABSTRACT	O
:	O
Camel	O
contact	O
is	O
a	O
recognized	O
risk	O
factor	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Complex	O
encephalopathy	B-DISO
arising	O
from	O
the	O
combination	O
of	O
opioids	O
and	O
gabapentin	O
.	O

TITLE	O
:	O
Fifteen	O
years	O
post	O
-	O
SARS	B-DISO
:	O
Key	O
milestones	O
in	O
Canada	O
'	O
s	O
public	O
health	O
emergency	B-DISO
response	O
.	O

While	O
SARS	B-DISO
was	O
a	O
wake	O
-	O
up	O
-	O
call	O
to	O
strengthen	O
infection	B-DISO
prevention	O
and	O
control	O
capacity	O
in	O
health	O
care	O
settings	O
and	O
led	O
to	O
the	O
formation	O
of	O
the	O
Public	O
Health	O
Agency	O
of	O
Canada	O
,	O
it	O
also	O
strengthened	O
our	O
Federal	O
/	O
Provincial	O
/	O
Territorial	O
(	O
FPT	O
)	O
senior	O
-	O
level	O
governance	O
and	O
led	O
to	O
agreements	O
for	O
pan	O
-	O
Canadian	O
mutual	O
aid	O
and	O
infectious	B-DISO
disease	I-DISO
information	O
sharing	O
.	O

TITLE	O
:	O
An	O
overview	O
of	O
the	O
National	O
Microbiology	O
Laboratory	O
emergency	B-DISO
management	O
program	O
.	O

Parent	O
-	O
administered	O
surveillance	O
is	O
a	O
useful	O
mechanism	O
for	O
understanding	O
infectious	B-DISO
disease	I-DISO
in	O
healthy	O
children	O
in	O
the	O
community	O
.	O

Many	O
strains	O
of	O
type	O
I	O
FIPV	O
do	O
not	O
cause	O
FIP	B-DISO
by	O
inoculation	O
through	O
the	O
oral	O
route	O
in	O
cats	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
outcomes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
:	O
a	O
retrospective	O
study	O
.	O

The	O
mortality	O
rate	O
and	O
duration	O
of	O
mechanical	O
ventilation	O
were	O
compared	O
in	O
ARDS	B-DISO
patients	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
(	O
OR	O
3	O
.	O
4316	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
3130	O
-	O
8	O
.	O
9686	O
;	O
P	O
=	O
0	O
.	O
0119	O
),	O
number	O
of	O
organ	B-DISO
failure	I-DISO
(	O
OR	O
3	O
.	O
4928	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
9775	O
-	O
6	O
.	O
1693	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
(	O
OR	O
5	O
.	O
1049	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
8317	O
-	O
14	O
.	O
2274	O
;	O
P	O
=	O
0	O
.	O
0018	O
),	O
driving	O
pressure	O
(	O
OR	O
6	O
.	O
0017	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
1746	O
-	O
16	O
.	O
5641	O
;	O
P	O
=	O
0	O
.	O
0005	O
)	O
and	O
lactate	O
level	O
(	O
OR	O
4	O
.	O
0754	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6114	O
-	O
10	O
.	O
3068	O
;	O
P	O
=	O
0	O
.	O
0030	O
)	O
were	O
influence	O
factors	O
for	O
survival	O
;	O
severity	O
of	O
ARDS	B-DISO
(	O
OR	O
1	O
.	O
6715	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
0307	O
-	O
2	O
.	O
7108	O
;	O
P	O
=	O
0	O
.	O
0373	O
),	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
VAP	O
)	O
(	O
OR	O
7	O
.	O
3746	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
9799	O
-	O
18	O
.	O
2505	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
transfusion	O
history	O
(	O
OR	O
2	O
.	O
2822	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
0462	O
-	O
4	O
.	O
9783	O
;	O
P	O
=	O
0	O
.	O
0381	O
)	O
were	O
influence	O
factors	O
for	O
duration	O
of	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
current	O
study	O
investigated	O
the	O
protective	O
efficacy	O
of	O
a	O
formalin	O
-	O
inactivated	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccine	O
derived	O
from	O
the	O
field	O
strain	O
KP729422	O
,	O
which	O
exhibits	O
low	O
S1	O
spike	O
protein	O
sequence	O
homology	O
(	O
77	O
.	O
1	O
-	O
79	O
.	O
8	O
%)	O
with	O
the	O
currently	O
used	O
vaccine	O
strains	O
in	O
Egypt	O
.	O

There	O
is	O
limited	O
information	O
regarding	O
the	O
prevalence	O
of	O
pathogens	O
related	O
to	O
CIRD	O
in	O
the	O
United	O
States	O
as	O
well	O
as	O
the	O
role	O
of	O
co	B-DISO
-	I-DISO
infections	I-DISO
in	O
the	O
pathogenesis	B-DISO
of	O
the	O
syndrome	B-DISO
.	O

In	O
addition	O
,	O
a	O
novel	O
probe	O
-	O
based	O
multiplex	O
real	O
-	O
time	O
PCR	O
was	O
developed	O
to	O
simultaneously	O
detect	O
and	O
differentiate	O
two	O
species	O
of	O
Mycoplasma	B-DISO
(	O
M	O
.	O
canis	O
and	O
M	O
.	O
cynos	O
).	O

Statistical	O
modeling	O
analyses	O
of	O
CIRD	O
pathogens	O
emphasized	O
the	O
impact	O
of	O
co	B-DISO
-	I-DISO
infections	I-DISO
on	O
the	O
severity	O
of	O
clinical	O
presentation	O
,	O
and	O
showed	O
that	O
host	O
factors	O
,	O
such	O
as	O
animal	O
age	O
,	O
are	O
the	O
most	O
important	O
predictors	O
of	O
disease	O
severity	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
transmission	O
from	O
dromedaries	O
to	O
humans	O
has	O
resulted	O
in	O
major	O
outbreaks	O
in	O
the	O
Middle	O
East	O
.	O

TITLE	O
:	O
P53	O
supports	O
endothelial	O
barrier	O
function	O
via	O
APE1	O
/	O
Ref1	O
suppression	B-DISO
.	O

To	O
develop	O
a	O
simple	O
,	O
rapid	O
,	O
accurate	O
,	O
and	O
high	O
-	O
throughput	O
detection	O
method	O
for	O
diagnosis	O
and	O
differential	O
diagnosis	O
on	O
swine	O
enteric	O
coronaviruses	O
,	O
specific	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
highly	O
conserved	O
regions	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
N	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
M	O
,	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
M	O
,	O
and	O
porcine	O
enteric	O
alphacoronavirus	O
(	O
PEAV	O
)	O
N	O
genes	O
respectively	O
.	O

ABSTRACT	O
:	O
Blastomyces	O
is	O
a	O
dimorphic	O
fungus	O
endemic	O
to	O
regions	O
of	O
North	O
America	O
,	O
which	O
can	O
lead	O
to	O
pneumonia	B-DISO
and	O
fatal	O
severe	O
acute	O
respiratory	B-DISO
diseases	I-DISO
syndrome	B-DISO
in	O
up	O
to	O
89	O
%	O
of	O
patients	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
life	O
support	O
can	O
effectively	O
provide	O
prolonged	O
support	O
for	O
patients	O
with	O
blastomycosis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
that	O
is	O
safe	O
and	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
outcomes	O
.	O

CONCLUSIONS	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
life	O
support	O
can	O
effectively	O
provide	O
prolonged	O
support	O
for	O
patients	O
with	O
blastomycosis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
that	O
is	O
safe	O
and	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
outcomes	O
.	O

Additionally	O
,	O
we	O
provided	O
data	O
suggesting	O
that	O
UBXN1	O
negatively	O
regulates	O
IFN	O
-	O
β	O
expression	O
after	O
TGEV	O
infection	B-DISO
.	O

ROS	O
and	O
p53	O
play	O
key	O
roles	O
in	O
regulating	O
many	O
kinds	O
of	O
cell	O
process	O
during	O
viral	B-DISO
infection	I-DISO
,	O
however	O
,	O
the	O
exact	O
function	O
in	O
PEDV	O
-	O
induced	O
apoptosis	O
remains	O
unclear	O
.	O

TITLE	O
:	O
Extended	O
thoracic	B-DISO
lymph	O
node	O
dissection	O
in	O
robotic	O
-	O
assisted	O
minimal	O
invasive	O
esophagectomy	O
(	O
RAMIE	O
)	O
for	O
patients	O
with	O
superior	O
mediastinal	O
lymph	B-DISO
node	I-DISO
metastasis	I-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
ORF3a	O
protein	O
activates	O
the	O
NLRP3	O
inflammasome	O
by	O
promoting	O
TRAF3	O
-	O
dependent	O
ubiquitination	O
of	O
ASC	O
.	O

Among	O
positive	O
samples	O
,	O
120	O
(	O
19	O
.	O
2	O
%)	O
samples	O
were	O
positive	O
for	O
H1N1	O
,	O
61	O
(	O
9	O
.	O
8	O
%)	O
for	O
H3N2	O
and	O
19	O
(	O
3	O
%)	O
were	O
positive	O
for	O
Influenza	B-DISO
B	O
.	O
Highest	O
number	O
of	O
positive	O
cases	O
occurred	O
in	O
the	O
month	O
of	O
January	O
,	O
i	O
.	O
e	O
.	O
148	O
(	O
74	O
%)	O
cases	O
.	O

The	O
dominant	O
subtype	O
in	O
our	O
set	O
-	O
up	O
,	O
during	O
winter	O
of	O
2017	O
-	O
2018	O
,	O
was	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
association	O
between	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
comorbidities	O
and	O
clinical	O
characteristics	O
,	O
and	O
to	O
explore	O
the	O
inflammation	B-DISO
mechanism	O
.	O

The	O
relationship	O
among	O
the	O
number	O
and	O
type	O
of	O
comorbidities	O
,	O
Charlson	O
comorbidity	O
index	O
(	O
CCI	O
),	O
clinical	O
characteristics	O
and	O
the	O
levels	O
of	O
plasma	O
inflammatory	O
markers	O
[	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
high	O
sensitivity	O
C	O
-	O
reaction	O
protein	O
(	O
hs	O
-	O
CRP	O
),	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
),	O
IL	O
-	O
8	O
]	O
were	O
studied	O
.	O

The	O
top	O
five	O
comorbidities	O
were	O
hypertension	B-DISO
,	O
metabolic	B-DISO
syndrome	I-DISO
and	O
diabetes	B-DISO
osteoporosis	B-DISO
,	O
bronchiectasis	B-DISO
and	O
peripheral	B-DISO
vascular	I-DISO
diseases	I-DISO
.	O

The	O
level	O
of	O
plasma	O
IL	O
-	O
6	O
was	O
greater	O
in	O
higher	O
CCI	O
score	O
(≥	O
4	O
)	O
group	O
compared	O
with	O
lower	O
CCI	O
score	O
(<	O
4	O
)	O
group	O
(	O
Patients	O
with	O
a	O
higher	O
CCI	O
score	O
had	O
more	O
severe	O
symptoms	O
,	O
functional	O
impairment	B-DISO
and	O
higher	O
level	O
of	O
inflammatory	O
factors	O
and	O
high	O
frequency	O
of	O
hospital	O
admission	O
due	O
to	O
acute	O
exacerbation	O
.	O

Thus	O
,	O
the	O
development	O
of	O
highly	O
effective	O
and	O
specific	O
antiviral	O
drugs	O
for	O
pre	O
-	O
exposure	O
prophylaxis	O
and	O
/	O
or	O
treatment	O
of	O
RSV	B-DISO
infections	I-DISO
is	O
a	O
compelling	O
need	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
pathological	O
lesions	O
in	O
the	O
chicken	O
oviduct	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
identify	O
peptides	O
within	O
the	O
polyprotein	O
(	O
Pp	O
)	O
1	O
ab	O
that	O
are	O
differentially	O
recognised	O
by	O
cats	O
with	O
either	O
enteric	O
or	O
systemic	B-DISO
disease	I-DISO
following	O
infection	B-DISO
with	O
feline	O
coronavirus	O
.	O

Current	O
findings	O
showed	O
a	O
correlation	O
between	O
IAP	O
hospitalised	O
patients	O
in	O
ICU	O
and	O
shock	O
,	O
SIRS	B-DISO
,	O
APACHE	O
II	O
,	O
central	O
venous	O
oxygen	O
saturation	O
and	O
GCS	O
.	O

TITLE	O
:	O
Influenza	B-DISO
virus	O
RNA	O
recovered	O
from	O
droplets	O
and	O
droplet	O
nuclei	O
emitted	O
by	O
adults	O
in	O
an	O
acute	O
care	O
setting	O
.	O

ABSTRACT	O
:	O
Transmission	O
in	O
hospital	O
settings	O
of	O
seasonal	O
influenza	B-DISO
viruses	O
and	O
novel	O
agents	O
such	O
as	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
well	O
-	O
described	O
but	O
poorly	O
understood	O
.	O

The	O
control	O
group	O
consisted	O
of	O
children	O
without	O
lesions	O
of	O
oral	O
cavity	B-DISO
(	O
66	O
people	O
).	O

We	O
performed	O
a	O
multicenter	O
,	O
prospective	O
data	O
collection	O
study	O
and	O
retrospectively	O
analyzed	O
the	O
data	O
to	O
confirm	O
the	O
role	O
of	O
DIC	B-DISO
in	O
severe	B-DISO
sepsis	I-DISO
.	O

The	O
overall	O
mortality	O
rate	O
of	O
severe	B-DISO
sepsis	I-DISO
was	O
21	O
.	O
5	O
%,	O
and	O
the	O
prevalence	O
of	O
DIC	B-DISO
was	O
50	O
.	O
9	O
%	O
(	O
516	O
/	O
1013	O
).	O

DIC	B-DISO
patients	O
were	O
more	O
seriously	O
ill	B-DISO
and	O
exhibited	O
a	O
higher	O
prevalence	O
of	O
MODS	B-DISO
(	O
32	O
.	O
0	O
%	O
vs	O
.	O
13	O
.	O
1	O
%)	O
on	O
day	O
0	O
and	O
worse	O
mortality	O
rate	O
(	O
24	O
,	O
8	O
%	O
vs	O
.	O
17	O
.	O
5	O
%)	O
than	O
non	O
-	O
DIC	B-DISO
patients	O
.	O

Logistic	O
regression	O
analyses	O
after	O
propensity	O
score	O
adjustment	O
for	O
potential	O
confounders	O
confirmed	O
a	O
significant	O
association	O
between	O
DIC	B-DISO
and	O
MODS	B-DISO
and	O
hospital	O
death	O
in	O
the	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

RESULTS	O
:	O
The	O
overall	O
mortality	O
rate	O
of	O
severe	B-DISO
sepsis	I-DISO
was	O
21	O
.	O
5	O
%,	O
and	O
the	O
prevalence	O
of	O
DIC	B-DISO
was	O
50	O
.	O
9	O
%	O
(	O
516	O
/	O
1013	O
).	O

TITLE	O
:	O
Molecular	O
characteristics	O
and	O
pathogenic	O
assessment	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
isolates	O
from	O
the	O
2018	O
endemic	O
outbreaks	O
on	O
Jeju	O
Island	O
,	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Serum	O
troponin	O
is	O
a	O
marker	O
of	O
cardiac	O
myocyte	O
damage	O
that	O
is	O
typically	O
used	O
to	O
assess	O
for	O
myocardial	B-DISO
infarction	I-DISO
in	O
the	O
setting	O
of	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

These	O
symptoms	O
were	O
associated	O
with	O
fevers	O
,	O
and	O
24	O
hours	O
prior	O
to	O
admission	O
,	O
he	O
developed	O
intermittent	O
chest	B-DISO
pain	I-DISO
at	I-DISO
rest	I-DISO
,	O
radiating	O
to	O
the	O
back	O
,	O
worsening	O
in	O
the	O
supine	O
position	O
.	O

Based	O
on	O
his	O
presentation	O
and	O
age	O
,	O
there	O
was	O
a	O
high	O
suspicion	O
of	O
viral	B-DISO
myocarditis	I-DISO
.	O

A	O
coronary	O
angiogram	O
showed	O
severe	O
CAD	B-DISO
and	O
he	O
underwent	O
staged	O
a	O
percutaneous	O
coronary	O
intervention	O
with	O
the	O
resolution	O
of	O
symptoms	O
.	O

The	O
Berlin	O
Definition	O
of	O
ARDS	B-DISO
specifies	O
three	O
severity	O
classifications	O
:	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
based	O
on	O
the	O
PaO	O

TITLE	O
:	O
Mechanical	O
power	O
normalized	O
to	O
predicted	O
body	O
weight	O
as	O
a	O
predictor	O
of	O
mortality	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
causes	O
considerable	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
worldwide	O
,	O
including	O
Taiwan	O
.	O

Therefore	O
,	O
the	O
development	O
of	O
a	O
sensitive	O
,	O
specific	O
,	O
and	O
easily	O
performed	O
assay	O
is	O
crucial	O
for	O
the	O
rapid	O
detection	O
and	O
surveillance	O
of	O
IBV	O
infections	B-DISO
.	O

TITLE	O
:	O
Endocan	O
,	O
a	O
Risk	O
Factor	O
for	O
Developing	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
among	O
Severe	O
Pneumonia	B-DISO
Patients	O
.	O

ABSTRACT	O
:	O
Severe	O
pneumonia	B-DISO
(	O
SP	O
)	O
has	O
been	O
widely	O
accepted	O
as	O
a	O
major	O
cause	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
the	O
development	O
of	O
ARDS	B-DISO
is	O
significantly	O
associated	O
with	O
increased	O
mortality	O
.	O

A	O
total	O
of	O
145	O
SP	O
patients	O
were	O
eventually	O
enrolled	O
into	O
the	O
final	O
analysis	O
,	O
of	O
which	O
37	O
developed	O
ARDS	B-DISO
during	O
the	O
hospital	O
stay	O
.	O

Few	O
data	O
exist	O
regarding	O
the	O
risk	O
factors	O
for	O
poor	O
outcomes	O
in	O
pediatric	O
postsurgical	O
sepsis	B-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
556	O
patients	O
were	O
included	O
:	O
138	O
with	O
postsurgical	O
and	O
418	O
with	O
medical	O
sepsis	B-DISO
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
a	O
conserved	O
segment	O
containing	O
one	O
SNP	O
A4408C	O
of	O
parvovirus	B-DISO
was	O
used	O
for	O
real	O
-	O
time	O
PCR	O
amplification	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
a	O
co	O
-	O
occurrence	O
case	O
of	O
ocular	B-DISO
myasthenia	I-DISO
gravis	I-DISO
with	O
exacerbation	O
leading	O
to	O
myasthenic	B-DISO
crisis	I-DISO
in	O
addition	O
to	O
pharyngeal	O
-	O
cervical	O
-	O
brachial	O
variant	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
in	O
a	O
patient	O
with	O
severe	O
oropharyngeal	B-DISO
dysphagia	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Pathogenicity	O
of	O
a	O
GI	O
-	O
22	O
genotype	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolated	O
in	O
China	O
and	O
protection	O
against	O
it	O
afforded	O
by	O
GI	O
-	O
19	O
vaccine	O
.	O

Moreover	O
,	O
the	O
ER	O
stress	O
sensor	O
inositol	O
requiring	O
enzyme	O
1	O
(	O
IRE1	O
),	O
but	O
not	O
its	O
substrate	O
X	O
-	O
box	O
protein	O
1	O
(	O
XBP1	O
),	O
was	O
also	O
essential	O
for	O
the	O
induction	O
of	O
autophagy	O
during	O
IBV	O
infection	B-DISO
.	O

TITLE	O
:	O
Occurrence	O
of	O
infectious	B-DISO
bronchitis	B-DISO
in	O
layer	O
birds	O
in	O
Plateau	O
state	O
,	O
north	O
central	O
Nigeria	O
.	O

Mortality	O
was	O
in	O
the	O
range	O
of	O
1	O
%-	O
2	O
%	O
with	O
post	O
-	O
mortem	O
lesions	O
revealing	O
cloudy	O
air	O
sacs	B-DISO
,	O
frothy	O
,	O
and	O
congested	O
lungs	O
.	O

TITLE	O
:	O
Comparative	O
Analysis	O
of	O
Eleven	O
Healthcare	O
-	O
Associated	O
Outbreaks	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
Mers	O
-	O
Cov	O
)	O
from	O
2015	O
to	O
2017	O
.	O

Venous	O
blood	O
oxygenation	O
through	O
the	O
ECMO	O
circuit	O
may	O
drive	O
the	O
PO2	O
stimulus	O
of	O
pulmonary	O
hypoxic	B-DISO
vasoconstriction	B-DISO
to	O
normal	O
values	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
series	O
of	O
dihydroquinazolin	O
-	O
2	O
-	O
amine	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
activity	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

All	O
of	O
the	O
molecules	O
were	O
active	O
against	O
wild	O
-	O
type	O
HIV	B-DISO
-	O
1	O
with	O
EC	O

A	O
dust	O
-	O
free	O
clumping	O
Fuller	O
'	O
s	O
earth	O
litter	O
appeared	O
to	O
fare	O
best	O
,	O
but	O
virus	B-DISO
shedding	I-DISO
also	O
varied	O
on	O
the	O
control	O
litters	O
,	O
complicating	O
interpretation	O
.	O

Specifically	O
,	O
knockdown	O
of	O
two	O
abundantly	O
expressed	O
PARPs	O
,	O
PARP12	O
and	O
PARP14	O
,	O
led	O
to	O
increased	O
replication	O
of	O
mutant	B-DISO
but	O
did	O
not	O
significantly	O
affect	O
wild	O
-	O
type	O
virus	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
developed	O
and	O
the	O
patient	O
was	O
oxygenated	O
via	O
veno	O
-	O
venous	O
ECMO	O
due	O
to	O
the	O
failure	O
of	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Malaria	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
MA	O
-	O
ARDS	B-DISO
)	O
is	O
a	O
lethal	O
complication	B-DISO
of	O
severe	O
malaria	B-DISO
,	O
characterized	O
by	O
marked	O
pulmonary	B-DISO
inflammation	I-DISO
.	O

Within	O
the	O
last	O
decade	O
,	O
increasing	O
reports	O
of	O
severe	O
influenza	B-DISO
pneumonia	I-DISO
resulting	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
complicated	O
by	O
Aspergillus	B-DISO
infection	I-DISO
were	O
published	O
.	O

If	O
influenza	B-DISO
pneumonia	I-DISO
is	O
diagnosed	O
,	O
neuraminidase	O
inhibitors	O
are	O
the	O
preferred	O
approved	O
drugs	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
(	O
A	O
/	O
H1N1	O
),	O
influenza	B-DISO
A	O
H3N2	O
,	O
and	O
influenza	B-DISO
B	O
were	O
tested	O
in	O
all	O
patients	O
by	O
RT	O
-	O
PCR	O
.	O

Hospital	O
mortality	O
associated	O
with	O
influenza	B-DISO
H1N1	O
-	O
associated	O
SARI	O
and	O
ARDS	B-DISO
continued	O
to	O
be	O
high	O
years	O
after	O
the	O
2009	O
pandemic	O
in	O
a	O
population	O
with	O
low	O
vaccine	O
coverage	O
.	O

Nonsurvivors	O
had	O
a	O
more	O
intense	O
inflammatory	B-DISO
response	I-DISO
than	O
did	O
survivors	O
at	O
48	O
h	O
(	O
C	O
-	O
reactive	O
protein	O
:	O
31	O
.	O
0	O
±	O
17	O
.	O
5	O
vs	O
.	O
14	O
.	O
6	O
±	O
8	O
.	O
9	O
mg	O
/	O
dl	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
as	O
well	O
as	O
a	O
more	O
positive	O
fluid	O
balance	O
.	O

Heart	O
tissue	O
from	O
pediatric	O
/	O
juvenile	O
and	O
adult	O
dogs	O
was	O
tested	O
with	O
a	O
comprehensive	O
panel	O
of	O
conventional	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
targeting	O
recognized	O
agents	O
of	O
canine	O
myocarditis	B-DISO
based	O
on	O
a	O
literature	O
review	O
and	O
informed	O
by	O
the	O
comparative	O
epidemiology	O
of	O
human	O
myocarditis	B-DISO
.	O

The	O
AUC	O
of	O
alkaline	O
phosphatase	O
for	O
the	O
prognosis	O
of	O
ARDS	B-DISO
patients	O
caused	O
by	O
abdominal	B-DISO
infection	I-DISO
was	O
0	O
.	O
813	O
;	O
when	O
the	O
cut	O
-	O
off	O
value	O
was	O
19	O
.	O
72	O
μmol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
75	O
.	O
0	O
%,	O
and	O
the	O
specificity	O
was	O
87	O
.	O
5	O
%.	O

Our	O
aim	O
is	O
to	O
determine	O
indicators	O
of	O
survival	O
in	O
children	O
with	O
severe	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
(	O
HRF	O
)	O
after	O
transition	B-DISO
to	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
).	O

TITLE	O
:	O
Early	O
Neuromuscular	B-DISO
Blockade	I-DISO
in	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

Co	O
-	O
detection	O
of	O
BCV	O
and	O
H	O
.	O
somni	O
at	O
the	O
time	O
of	O
the	O
disease	O
outbreak	O
suggests	O
that	O
these	O
pathogens	O
contributed	O
to	O
disease	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
antiviral	O
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
challenge	O
of	O
laboratory	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
).	O

Differences	O
in	O
disease	O
outcome	O
provided	O
an	O
opportunity	O
to	O
investigate	O
the	O
role	O
of	O
T	O
cell	O
immunity	O
to	O
FIP	B-DISO
determined	O
by	O
T	O
cell	O
subset	O
proliferation	B-DISO
after	O
stimulation	O
with	O
different	O
viral	O
antigens	O
.	O

Antiviral	O
T	O
cell	O
responses	O
during	O
early	O
primary	B-DISO
infection	I-DISO
were	O
also	O
similar	O
between	O
cats	O
that	O
developed	O
FIP	B-DISO
and	O
cats	O
remaining	O
healthy	O
.	O

Cats	O
that	O
survived	O
primary	B-DISO
infection	I-DISO
were	O
challenged	O
a	O
second	O
time	O
to	O
pathogenic	O
FIPV	O
and	O
tested	O
for	O
antiviral	O
T	O
cell	O
responses	O
over	O
a	O
four	O
week	O
period	O
.	O

Virus	O
host	O
interactions	O
during	O
very	O
early	O
stages	O
of	O
FIPV	O
infection	B-DISO
warrant	O
further	O
investigation	O
to	O
elucidate	O
host	O
resistance	O
to	O
FIP	B-DISO
.	O

This	O
review	O
will	O
discuss	O
the	O
role	O
of	O
two	O
cellular	O
eukaryotic	O
processes	O
that	O
are	O
vital	O
for	O
maintenance	O
of	O
cellular	O
homeostasis	O
-	O
1	O
)	O
the	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	B-DISO
(	O
NMD	O
)	O
pathway	O
and	O
2	O
)	O
the	O
transient	O
formation	O
of	O
stress	O
granules	O
(	O
SG	O
)	O
-	O
and	O
explore	O
the	O
current	O
literature	O
on	O
their	O
roles	O
in	O
antiviral	O
defence	O
.	O

O	O
.	O
Mühlemann	O
and	O
Volker	O
Thiel	O
teamed	O
up	O
to	O
unravel	O
the	O
roles	O
of	O
NMD	O
and	O
SGs	B-DISO
,	O
and	O
their	O
interconnections	O
in	O
defending	O
cells	O
from	O
alphavirus	O
and	O
coronavirus	B-DISO
infections	I-DISO
.	O

It	O
carries	O
a	O
very	O
poor	O
prognosis	O
,	O
particularly	O
if	O
kidney	B-DISO
replacement	I-DISO
therapy	O
is	O
required	O
,	O
with	O
mortality	O
rates	O
exceeding	O
75	O
%.	O

Other	O
new	O
-	O
world	O
camelids	O
,	O
alpacas	O
and	O
llamas	O
,	O
are	O
also	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	B-DISO
infections	I-DISO
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
morbidity	O
and	O
mortality	O
,	O
especially	O
in	O
children	O
,	O
elderly	O
and	O
immunocompromised	O
patients	O
.	O

The	O
most	O
frequently	O
observed	O
co	B-DISO
-	I-DISO
infections	I-DISO
with	O
double	O
causative	O
agents	O
were	O
HRV	O
and	O
INF	O
-	O
B	O
,	O
HRV	O
and	O
PIV	O
,	O
HRV	O
and	O
HBoV	O
,	O
HRV	O
and	O
AdV	O
combinations	O
.	O

Age	O
<	O
15	O
years	O
old	O
,	O
infection	B-DISO
with	O
influenza	B-DISO
B	O
,	O
pre	O
-	O
existence	O
of	O
chronic	B-DISO
diseases	I-DISO
,	O
and	O
admission	O
to	O
Aden	O
site	O
were	O
significantly	O
associated	O
with	O
higher	O
fatality	O
rate	O
among	O
patients	O
.	O

The	O
demographic	O
features	O
associated	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
related	O
coronavirus	B-DISO
infections	I-DISO
are	O
specifically	O
analyzed	O
for	O
a	O
better	O
understanding	O
of	O
the	O
epidemiology	O
of	O
this	O
virus	O
.	O

I	O
,	O
all	O
6	O
WT	O
piglets	O
and	O
only	O
1	O
of	O
6	O
KO	O
piglets	O
died	O
at	O
72	O
hpi	B-DISO
.	O

Fever	O
and	O
dyspnea	B-DISO
were	O
mentioned	O
to	O
be	O
present	O
the	O
last	O
5	O
days	O
.	O

The	O
detection	O
of	O
HCoV	O
alone	O
or	O
in	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
RV	O
-	O
C	O
was	O
independently	O
associated	O
with	O
PICU	O
admission	O
in	O
young	O
children	O
hospitalized	O
for	O
ALRI	O
.	O

TITLE	O
:	O
Disease	O
severity	O
and	O
clinical	O
outcomes	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
caused	O
by	O
non	O
-	O
influenza	B-DISO
respiratory	O
viruses	O
in	O
adults	O
:	O
a	O
multicentre	O
prospective	O
registry	O
study	O
from	O
the	O
CAP	B-DISO
-	O
China	O
Network	O
.	O

ABSTRACT	O
:	O
Although	O
broad	O
knowledge	O
of	O
influenza	B-DISO
viral	B-DISO
pneumonia	I-DISO
has	O
been	O
established	O
,	O
the	O
significance	O
of	O
non	O
-	O
influenza	B-DISO
respiratory	O
viruses	O
in	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
and	O
their	O
impact	O
on	O
clinical	O
outcomes	O
remains	O
unclear	O
,	O
especially	O
in	O
the	O
non	O
-	O
immunocompromised	O
adult	O
population	O
.	O

Comparisons	O
were	O
conducted	O
between	O
influenza	B-DISO
and	O
non	O
-	O
influenza	B-DISO
viral	B-DISO
infection	I-DISO
groups	O
.	O

The	O
occurrence	O
of	O
complications	O
such	O
as	O
sepsis	B-DISO
(	O
40	O
.	O
1	O
%	O

All	O
children	O
(	O
age	O
>	O
1	O
mo	O
to	O
<	O
14	O
yr	O
)	O
admitted	O
in	O
PICU	O
with	O
a	O
diagnosis	O
of	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
as	O
per	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
definition	O
)	O
from	O
August	O
1	O
,	O
2015	O
,	O
to	O
November	O
2016	O
.	O

On	O
multiple	O
logistic	O
regressions	B-DISO
,	O
Lung	O
Injury	O
Score	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
pneumothorax	B-DISO
(	O
p	O
=	O
0	O
.	O
012	O
),	O
acute	O
kidney	O
injury	O
at	O
enrollment	O
(	O
p	O
=	O
0	O
.	O
033	O
),	O
FIO2	O
-	O
D1	O
(	O
p	O
=	O
0	O
.	O
018	O
),	O
and	O
PaO2	O
/	O
FIO2	O
ratio	O
-	O
D7	O
(	O
p	O
=	O
0	O
.	O
020	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
.	O

Infection	B-DISO
remains	O
the	O
most	O
common	O
etiology	O
.	O

TITLE	O
:	O
Susceptibility	O
of	O
porcine	O
IPI	O
-	O
2I	O
intestinal	O
epithelial	O
cells	O
to	O
infection	B-DISO
with	O
swine	O
enteric	O
coronaviruses	O
.	O

The	O
small	O
intestines	O
,	O
particularly	O
the	O
jejunum	O
and	O
ileum	O
,	O
are	O
the	O
most	O
common	O
targets	O
of	O
these	O
four	O
CoVs	O
in	O
vivo	O
,	O
and	O
co	B-DISO
-	I-DISO
infections	I-DISO
by	O
these	O
CoVs	O
are	O
frequently	O
observed	O
in	O
clinically	O
infected	O
pigs	O
.	O

Effects	O
of	O
maternal	O
buprenorphine	O
dose	O
and	O
other	O
substance	O
exposures	O
on	O
maternal	O
measures	O
were	O
examined	O
,	O
as	O
were	O
neonatal	B-DISO
abstinence	I-DISO
syndrome	I-DISO
(	O
NAS	O
)	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
a	O
devastating	O
clinical	O
syndrome	B-DISO
,	O
is	O
one	O
of	O
the	O
most	O
severe	O
complications	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

TITLE	O
:	O
Sustained	O
safe	O
and	O
effective	O
anticoagulation	O
using	O
Edoxaban	O
via	O
percutaneous	O
endoscopic	O
gastrostomy	B-DISO
.	O

However	O
,	O
MERS	O
survivors	O
of	O
critical	B-DISO
illness	I-DISO
reported	O
lower	O
quality	O
of	O
life	O
than	O
survivors	O
of	O
less	O
severe	O
illness	O
.	O

TITLE	O
:	O
History	O
and	O
Future	O
of	O
Nucleic	O
Acid	O
Amplification	B-DISO
Technology	O
Blood	O
Donor	O
Testing	O
.	O

German	O
transfusion	O
centres	O
were	O
the	O
first	O
to	O
start	O
in	O
-	O
house	O
NAT	O
testing	O
of	O
their	O
donations	O
in	O
pools	O
of	O
up	O
to	O
96	O
samples	O
for	O
HCV	O
,	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
),	O
and	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
-	O
1	O
(	O
HIV	B-DISO
-	O
1	O
).	O

In	O
conjunction	O
with	O
animal	O
and	O
patient	O
studies	O
,	O
we	O
have	O
learned	O
more	O
about	O
the	O
minimal	O
infectious	B-DISO
dose	O
and	O
the	O
epidemics	O
in	O
the	O
donor	O
population	O
.	O

Inhaled	O
corticosteroids	O
and	O
other	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
very	O
effective	O
in	O
patients	O
with	O
inflammatory	O
lung	B-DISO
disorders	I-DISO
,	O
but	O
their	O
long	O
-	O
term	O
use	O
is	O
associated	O
with	O
severe	O
side	O
effects	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
not	O
been	O
a	O
described	O
complication	B-DISO
of	O
hypothermia	O
.	O

Chest	O
imaging	O
may	O
reveal	O
a	O
peripheral	O
distribution	O
of	O
bilateral	O
infiltrates	B-DISO
with	O
no	O
evidence	O
of	O
excessive	O
pulmonary	O
vasculature	O
congestion	B-DISO
or	O
cardiomegaly	O
.	O

An	O
echocardiogram	O
may	O
also	O
be	O
used	O
to	O
confirm	O
a	O
lack	O
of	O
acute	O
systolic	O
or	O
diastolic	B-DISO
dysfunction	I-DISO
.	O

The	O
scope	O
of	O
noncardiogenic	O
pulmonary	B-DISO
edema	I-DISO
is	O
much	O
broader	O
than	O
ARDS	B-DISO
and	O
includes	O
other	O
etiologies	O
which	O
include	O
high	B-DISO
altitude	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
neurogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
opioid	O
overdose	O
,	O
salicylate	O
toxicity	O
,	O
pulmonary	B-DISO
embolism	I-DISO
,	O
reexpansion	B-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
reperfusion	O
pulmonary	B-DISO
edema	I-DISO
,	O
and	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
).	O

Influenza	B-DISO
virus	O
was	O
predominating	O
(	O
22	O
.	O
6	O
%),	O
followed	O
by	O
human	O
rhinoviruses	O
(	O
HRVs	O
)	O
(	O
9	O
.	O
5	O
%),	O
and	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
(	O
5	O
%).	O

While	O
males	O
had	O
higher	O
rates	O
of	O
HRVs	O
(	O
11	O
.	O
9	O
%),	O
enteroviruses	O
(	O
1	O
.	O
1	O
%)	O
and	O
MERS	O
CoV	O
(	O
0	O
.	O
2	O
%),	O
females	O
had	O
higher	O
proportions	O
of	O
influenza	B-DISO
(	O
26	O
.	O
3	O
%),	O
HPIVs	O
(	O
3	O
.	O
2	O
%)	O
and	O
RSV	O
(	O
3	O
.	O
6	O
%)	O
infections	B-DISO
.	O

Four	O
recommendations	O
(	O
low	O
tidal	O
volume	O
,	O
plateau	O
pressure	O
limitation	O
,	O
no	O
oscillatory	O
ventilation	O
,	O
and	O
prone	O
position	O
)	O
had	O
a	O
high	O
level	O
of	O
proof	O
(	O
GRADE	O
1	O
+	O
or	O
1	O
-);	O
four	O
(	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
[	O
PEEP	O
]	O
in	O
moderate	O
and	O
severe	O
ARDS	B-DISO
,	O
muscle	O
relaxants	O
,	O
recruitment	B-DISO
maneuvers	O
,	O
and	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
[	O
ECMO	O
])	O
a	O
low	O
level	O
of	O
proof	O
(	O
GRADE	O
2	O
+	O
or	O
2	O
-);	O
seven	O
(	O
surveillance	O
,	O
tidal	O
volume	O
for	O
non	O
ARDS	B-DISO
mechanically	O
ventilated	O
patients	O
,	O
tidal	O
volume	O
limitation	O
in	O
the	O
presence	O
of	O
low	O
plateau	O
pressure	O
,	O
PEEP	O
>	O
5	O
cmH2O	O
,	O
high	O
PEEP	O
in	O
the	O
absence	O
of	O
deleterious	O
effect	O
,	O
pressure	O
mode	O
allowing	O
spontaneous	O
ventilation	O
after	O
the	O
acute	O
phase	O
,	O
and	O
nitric	O
oxide	O
)	O
corresponded	O
to	O
a	O
level	O
of	O
proof	O
that	O
did	O
not	O
allow	O
use	O
of	O
the	O
GRADE	O
classification	O
and	O
were	O
expert	O
opinions	O
.	O

The	O
APACHE	O
II	O
and	O
ISS	B-DISO
scores	O
of	O
the	O
non	O
-	O
survival	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
survival	O
group	O
[	O
APACHE	O
II	O
score	O
:	O
25	O
.	O
7	O
±	O
2	O
.	O
7	O
vs	O
.	O
20	O
.	O
6	O
±	O
2	O
.	O
2	O
,	O
ISS	B-DISO
score	O
:	O
22	O
.	O
1	O
±	O
3	O
.	O
1	O
vs	O
.	O
18	O
.	O
1	O
±	O
2	O
.	O
1	O
,	O
both	O
P	O
<	O
0	O
.	O
05	O
].	O

Dynamic	O
observation	O
of	O
EVLWI	O
could	O
improve	O
the	O
accuracy	O
of	O
death	O
forecasting	O
for	O
severe	O
multiple	O
trauma	O
patients	O
with	O
ARDS	B-DISO
.	O

Here	O
we	O
report	O
our	O
new	O
finding	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
similar	O
to	O
Vpu	O
,	O
is	O
capable	O
of	O
antagonizing	O
the	O
BST2	O
tethering	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
HCoV	O
-	O
229E	O
,	O
and	O
HIV	B-DISO
-	O
1	O
virus	O
-	O
like	O
particles	O
via	O
BST2	O
downregulation	O
.	O

ABSTRACT	O
:	O
Human	O
infection	B-DISO
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
driven	O
by	O
recurring	O
dromedary	O
-	O
to	O
-	O
human	O
spill	O
-	O
over	O
events	O
,	O
leading	O
decision	O
-	O
makers	O
to	O
consider	O
dromedary	O
vaccination	O
.	O

We	O
aim	O
to	O
bring	O
together	O
existing	O
measures	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
dromedary	O
camels	O
to	O
assess	O
the	O
distribution	O
of	O
infection	B-DISO
,	O
highlighting	O
knowledge	O
gaps	O
and	O
implications	O
for	O
animal	O
vaccination	O
.	O

We	O
tested	O
16	O
different	O
respiratory	O
virus	O
infections	B-DISO
in	O
post	O
-	O
surgery	O
mild	O
symptomatic	O
PSP	B-DISO
group	O
and	O
asymptomatic	O
PSP	B-DISO
group	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
panel	O
.	O

We	O
analyzed	O
symptom	B-DISO
data	O
and	O
quantitative	O
viral	O
load	O
to	O
investigate	O
the	O
association	O
between	O
viruses	O
,	O
symptoms	O
and	O
viral	O
quantity	O
in	O
qRT	O
-	O
PCR	O
-	O
positive	O
PSPs	O
.	O

PIV3	O
infection	B-DISO
with	O
a	O
higher	O
viral	O
load	O
was	O
frequently	O
found	O
in	O
PSPs	O
presenting	O
with	O
mild	O
symptoms	O
,	O
progressing	O
to	O
pneumonia	B-DISO
with	O
radiographic	O
evidence	O
after	O
surgery	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
influence	O
of	O
opening	O
the	O
lung	O
strategy	O
ventilation	O
on	O
burned	O
patients	O
complicated	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Vaccination	O
with	O
a	O
live	O
bivalent	O
vaccine	O
of	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
routine	O
practice	O
in	O
poultry	O
industry	O
in	O
China	O
.	O

Although	O
early	O
evidence	O
supported	O
birth	O
seasonality	O
differences	O
in	O
PWS	B-DISO
,	O
a	O
larger	O
number	O
of	O
individuals	O
in	O
our	O
recent	O
study	O
using	O
advanced	O
genetic	O
testing	O
methods	O
did	O
not	O
find	O
this	O
observation	O
.	O

Activation	O
of	O
critical	O
signaling	O
pathways	O
during	O
HCoV	O
infection	B-DISO
modulates	O
the	O
induction	O
of	O
antiviral	O
immune	O
response	O
and	O
contributes	O
to	O
the	O
pathogenesis	B-DISO
of	O
HCoV	O
.	O
Recent	O
studies	O
have	O
begun	O
to	O
reveal	O
some	O
fundamental	O
aspects	O
of	O
the	O
intricate	O
HCoV	O
-	O
host	O
interaction	O
in	O
mechanistic	O
detail	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
of	O
host	O
factors	O
co	O
-	O
opted	O
and	O
signaling	O
pathways	O
activated	O
during	O
HCoV	O
infection	B-DISO
,	O
with	O
an	O
emphasis	O
on	O
HCoV	O
-	O
infection	B-DISO
-	O
induced	O
stress	O
response	O
,	O
autophagy	O
,	O
apoptosis	O
,	O
and	O
innate	O
immunity	O
.	O

The	O
prototype	O
compound	O
of	O
this	O
family	O
is	O
a	O
derivative	O
of	O
pentaerythritol	O
with	O
12	O
peripheral	O
Trp	O
groups	O
and	O
trivalent	O
spacer	O
arms	B-DISO
.	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
is	O
the	O
leading	O
cause	O
of	O
child	O
death	O
worldwide	O
.	O

RSV	O
,	O
adenovirus	B-DISO
,	O
rhinovirus	O
,	O
FluA	O
,	O
HMPV	O
,	O
HCoV	O
-	O
OC43	O
,	O
and	O
HCoV	O
-	O
NL63	O
were	O
detected	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Here	O
,	O
we	O
identify	O
several	O
mechanisms	O
by	O
which	O
a	O
SARS	B-DISO
-	O
CoV	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
activates	O
intracellular	O
stress	O
pathways	O
and	O
targets	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
a	O
newly	O
emerging	O
enteropathogenic	O
swine	O
coronavirus	O
causing	O
acute	O
diarrhea	B-DISO
and	I-DISO
vomiting	I-DISO
in	O
pigs	O
.	O

The	O
apoptosis	O
of	O
ST	O
cells	O
induced	O
by	O
PDCoV	O
infection	B-DISO
was	O
studied	O
in	O
this	O
research	O
.	O

TITLE	O
:	O
Dexmedetomidine	O
as	O
adjunctive	O
therapy	O
for	O
the	O
treatment	O
of	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
:	O
a	O
systematic	O
review	O
protocol	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
evaluate	O
the	O
effectiveness	O
and	O
safety	O
of	O
dexmedetomidine	O
as	O
adjunctive	O
therapy	O
to	O
the	O
standard	O
of	O
care	O
(	O
benzodiazepines	O
)	O
compared	O
to	O
either	O
the	O
standard	O
of	O
care	O
or	O
other	O
adjunctive	O
treatment	O
approaches	O
(	O
e	O
.	O
g	O
.	O
benzodiazepines	O
plus	O
propofol	O
)	O
for	O
the	O
treatment	O
of	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
(	O
AWS	B-DISO
).	O

Moreover	O
,	O
benzodiazepine	O
use	O
is	O
burdened	O
by	O
excessive	O
sedation	B-DISO
,	O
confusion	B-DISO
and	O
respiratory	B-DISO
depression	I-DISO
.	O

However	O
AAV	O
-	O
Pck2	O
overexpression	O
reduced	O
TA	O
muscle	O
weights	O
(	O
p	O
=	O
0	O
.	O
0434	O
),	O
particularly	O
in	O
the	O
Control	O
(	O
vehicle	O
treated	O
)	O
mice	O
(	O
p	O
=	O
0	O
.	O
059	O
for	O
AAV	O
x	O
Clenbuterol	O
interaction	O
)	O
and	O
increased	O
the	O
expression	O
of	O
Seryl	O
-	O
tRNA	O
Synthetase	O
(	O
Sars	B-DISO
)	O
mRNA	O
(	O
p	O
=	O
0	O
.	O
0477	O
).	O

ABSTRACT	O
:	O
This	O
report	O
discusses	O
the	O
neurological	O
involvement	O
in	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infection	B-DISO
in	O
neonates	O
.	O

In	O
presence	O
of	O
neurological	O
involvement	O
during	O
RSV	O
-	O
infection	B-DISO
must	O
be	O
taken	O
in	O
consideration	O
to	O
performing	O
instrumental	O
test	O
to	O
detect	O
cerebral	B-DISO
edema	I-DISO
.	O

The	O
majority	O
of	O
MBL	O
-	O
positive	O
EACs	O
express	O
the	O
CD83	O
antigen	O
,	O
providing	O
evidence	O
that	O
coronavirus	B-DISO
infection	I-DISO
facilitated	O
the	O
maturation	O
of	O
dendritic	O
cell	O
precursors	O
.	O

ABSTRACT	O
:	O
Like	O
all	O
coronaviruses	O
,	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
possesses	B-DISO
a	O
long	O
,	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	O
RNA	O
genome	O
(∼	O
27	O
kb	O
)	O
and	O
has	O
a	O
complex	O
replication	O
strategy	O
that	O
includes	O
the	O
production	O
of	O
a	O
nested	O
set	O
of	O
subgenomic	O
mRNAs	O
(	O
sgmRNAs	O
).	O

TITLE	O
:	O
Dynamics	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
development	O
due	O
to	O
smoke	O
inhalation	O
injury	O
:	O
Implications	O
for	O
prolonged	O
field	O
care	O
.	O

CONCLUSIONS	O
:	O
Smoke	O
inhalation	O
injury	O
leads	O
to	O
early	O
development	O
of	O
shunt	O
,	O
V	O
/	O
Q	O
mismatch	O
,	O
lung	B-DISO
consolidation	I-DISO
,	O
and	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

ABSTRACT	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
level	O
of	O
knowledge	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
among	O
Hajj	O
pilgrims	O
before	O
and	O
after	O
an	O
education	O
health	O
programme	O
during	O
international	O
vaccine	O
consultations	O
in	O
France	O
.	O

TITLE	O
:	O
A	O
Systematic	O
Review	O
of	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
NETs	O
may	O
aggravate	O
ALI	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
inflammation	B-DISO
by	O
promoting	O
alveolar	O
macrophage	O
polarization	O
to	O
the	O
M1	O
type	O
.	O

TITLE	O
:	O
Viral	O
and	O
Atypical	O
Bacterial	O
Respiratory	B-DISO
Infections	I-DISO
in	O
a	O
University	O
Teaching	O
Hospital	O
.	O

The	O
British	O
Thoracic	B-DISO
Society	O
supports	O
the	O
recommendations	O
in	O
this	O
guideline	O
.	O

ABSTRACT	O
:	O
In	O
epidemics	O
of	O
highly	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
Ebola	B-DISO
Virus	I-DISO
Disease	I-DISO
(	O
EVD	O
)	O
or	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
healthcare	O
workers	O
(	O
HCW	O
)	O
are	O
at	O
much	O
greater	O
risk	O
of	O
infection	B-DISO
than	O
the	O
general	O
population	O
,	O
due	O
to	O
their	O
contact	O
with	O
patients	O
'	O
contaminated	O
body	O
fluids	O
.	O

Finally	O
,	O
245	O
patients	O
who	O
were	O
diagnosed	O
with	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
were	O
included	O
in	O
the	O
study	O
,	O
with	O
an	O
incidence	O
rate	O
of	O
2	O
.	O
3	O
%.	O

The	O
results	O
of	O
the	O
present	O
study	O
will	O
deepen	O
our	O
understanding	O
of	O
PHEP	O
by	O
identifying	O
key	O
factors	O
that	O
influence	O
the	O
public	O
'	O
s	O
behavioral	O
responses	O
as	O
well	O
as	O
providing	O
information	O
to	O
public	O
health	O
emergency	B-DISO
management	O
and	O
health	O
risk	O
communication	O
officials	O
to	O
implement	O
strategies	O
necessary	O
in	O
improving	O
PHEP	O
.	O

TITLE	O
:	O
Viral	O
and	O
Bacterial	O
Etiology	O
of	O
Acute	O
Febrile	O
Respiratory	O
Syndrome	B-DISO
among	O
Patients	O
in	O
Qinghai	O
,	O
China	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
in	O
PaO	O
Inhaled	O
streptokinase	O
serves	O
as	O
rescue	O
therapy	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
with	O
improving	O
oxygenation	O
and	O
lung	O
mechanics	O
more	O
quickly	O
than	O
heparin	O
or	O
conventional	O
management	O
.	O

Efforts	O
to	O
reduce	O
the	O
global	O
MERS	O
threat	O
are	O
working	O
,	O
but	O
countries	O
must	O
maintain	O
vigilance	O
to	O
prevent	O
further	O
infections	B-DISO
.	O

TITLE	O
:	O
Simultaneous	O
and	O
visual	O
detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
Newcastle	B-DISO
disease	I-DISO
virus	O
by	O
multiple	O
LAMP	O
and	O
lateral	O
flow	O
dipstick	O
.	O

TITLE	O
:	O
Incidence	O
of	O
post	O
-	O
traumatic	O
pneumonia	B-DISO
in	O
poly	O
-	O
traumatized	O
patients	O
:	O
identifying	O
the	O
role	O
of	O
traumatic	O
brain	O
injury	O
and	O
chest	O
trauma	O
.	O

Chest	O
trauma	O
alone	O
and	O
especially	O
its	O
combination	O
with	O
TBI	O
represent	O
high	O
-	O
risk	O
injury	O
patterns	O
for	O
the	O
development	O
of	O
pneumonia	B-DISO
,	O
which	O
forms	O
the	O
strongest	O
predictor	O
of	O
mortality	O
in	O
poly	O
-	O
traumatized	O
patients	O
.	O

CFR	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
HIV	B-DISO
than	O
in	O
HIV	B-DISO
-	O
negative	O
controls	O
(	O
OR	O
4	O
.	O
10	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
63	O
-	O
6	O
.	O
27	O
,	O
I²	O
:	O
93	O
.	O
7	O
%).	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
lung	B-DISO
cancer	I-DISO
has	O
been	O
increasing	O
in	O
healthy	O
elderly	O
patients	O
with	O
preserved	O
pulmonary	O
function	O
and	O
without	O
underlying	O
lung	B-DISO
diseases	I-DISO
.	O

Amibara	O
S	O
recombinants	O
replicated	O
more	O
slowly	O
in	O
cultured	O
cells	O
than	O
in	O
EMC	B-DISO
S	O
recombinants	O
.	O

In	O
neutralizing	O
assays	O
,	O
Amibara	O
S	O
recombinants	O
were	O
neutralized	O
by	O
lower	O
concentrations	O
of	O
sera	O
from	O
both	O
Ethiopian	O
dromedaries	O
and	O
EMC	B-DISO
isolate	O
(	O
wild	O
-	O
type	O
)-	O
immunized	O
mouse	O
sera	O
,	O
relative	O
to	O
the	O
EMC	B-DISO
S	O
recombinants	O
,	O
indicating	O
that	O
viruses	O
coated	O
in	O
the	O
Amibara	O
S	O
protein	O
were	O
easier	O
to	O
neutralize	O
than	O
the	O
EMC	B-DISO
S	O
protein	O
.	O

Influenza	B-DISO
viruses	O
have	O
been	O
affecting	O
the	O
human	O
population	O
for	O
a	O
long	O
time	O
now	O
;	O
however	O
,	O
their	O
ability	O
to	O
rapidly	O
evolve	O
through	O
antigenic	O
drift	O
and	O
antigenic	O
shift	O
causes	O
the	O
emergence	O
of	O
new	O
strains	O
.	O

Infection	B-DISO
with	O
RSV	O
can	O
cause	O
severe	O
disease	O
and	O
even	O
death	O
,	O
imposing	O
a	O
severe	O
burden	O
for	O
pediatric	O
and	O
geriatric	O
health	O
systems	O
worldwide	O
.	O

The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerging	O
respiratory	O
virus	O
.	O

The	O
virus	O
was	O
first	O
recognized	O
in	O
2012	O
and	O
it	O
is	O
associated	O
with	O
a	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
that	O
is	O
more	O
severe	O
in	O
patients	O
with	O
comorbidities	O
.	O

His	O
wife	O
and	O
son	O
were	O
also	O
recently	O
sick	O
with	O
an	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

His	O
medical	O
history	O
included	O
hypertension	B-DISO
managed	O
with	O
amlodipine	O
;	O
he	O
denied	O
any	O
history	O
of	O
TB	O
,	O
recent	O
travel	O
,	O
or	O
canned	O
food	O
ingestion	O
.	O

ABSTRACT	O
:	O
Midkine	O
has	O
been	O
reported	O
to	O
play	O
a	O
crucial	O
role	O
in	O
inflammatory	O
,	O
hypoxia	B-DISO
,	O
and	O
tissue	O
injury	O
processes	O
.	O

ABSTRACT	O
:	O
Our	O
aims	O
are	O
to	O
determine	O
the	O
clinical	O
and	O
preclinical	O
characteristics	O
and	O
outcome	O
of	O
ARDS	B-DISO
among	O
burn	O
patients	O
with	O
inhalation	O
injury	O
.	O

In	O
conclusion	O
,	O
compared	O
to	O
cutaneous	O
burn	O
-	O
induced	O
ARDS	B-DISO
,	O
ARDS	B-DISO
in	O
patients	O
with	O
inhalation	O
injury	O
has	O
earlier	O
onset	O
,	O
causes	O
more	O
severe	O
oxygenation	O
disorder	O
and	O
has	O
a	O
higher	O
mortality	O
rate	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
cytokine	O
storms	O
are	O
directly	O
associated	O
with	O
influenza	B-DISO
-	O
induced	O
fatal	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Currently	O
,	O
there	O
are	O
no	O
immunomodulatory	O
drugs	O
for	O
influenza	B-DISO
available	O
for	O
clinical	O
use	O
.	O

Dendritic	O
cells	O
(	O
DCs	B-DISO
)	O
are	O
specialised	O
cells	O
responsible	O
for	O
sampling	O
antigens	O
and	O
presenting	O
them	O
to	O
T	O
cells	O
,	O
which	O
also	O
play	O
an	O
essential	O
role	O
in	O
recognising	O
and	O
neutralising	O
viruses	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
non	O
-	O
coding	O
RNAs	O
may	O
regulate	O
the	O
functional	O
program	O
of	O
DCs	B-DISO
.	O

The	O
questionnaire	O
investigated	O
participants	O
'	O
knowledge	O
about	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
transmission	O
,	O
consequences	O
,	O
patient	O
identification	O
and	O
history	O
taking	O
practices	O
.	O

The	O
analysis	O
was	O
carried	O
using	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
for	O
Windows	O
,	O
version	O
22	O
.	O
0	O
(	O
IBM	B-DISO
Corp	O
.,	O
Armonk	O
,	O
NY	O
,	O
USA	O
)	O
logistic	O
regression	O
,	O
odds	O
ratio	O
and	O
confidence	O
intervals	O
to	O
identify	O
the	O
relationship	O
between	O
variables	O
.	O

TITLE	O
:	O
A	O
30	O
-	O
year	O
retrospective	O
study	O
on	O
causes	O
of	O
death	O
in	O
childhood	O
-	O
onset	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
in	O
a	O
tertiary	O
care	O
centre	O
in	O
Southern	O
Thailand	O
.	O

ABSTRACT	O
:	O
We	O
set	O
out	O
to	O
determine	O
the	O
causes	O
of	O
death	O
in	O
childhood	O
-	O
onset	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
cSLE	O
).	O

Sepsis	B-DISO
was	O
the	O
most	O
common	O
cause	O
of	O
death	O
and	O
,	O
together	O
with	O
sepsis	B-DISO
-	O
related	O
organ	B-DISO
failure	I-DISO
,	O
was	O
the	O
most	O
common	O
condition	B-DISO
at	O
the	O
time	O
of	O
death	O
.	O

Exposure	O
of	O
rodents	O
to	O
hyperoxia	B-DISO
mimics	O
many	O
of	O
the	O
features	O
of	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Staphylococcus	O
aureus	O
is	O
frequently	O
isolated	O
from	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
usually	O
avoided	O
in	O
ICH	B-DISO
.	O

Nevertheless	O
,	O
evidence	O
-	O
based	O
recommendation	O
on	O
use	O
of	O
ECMO	O
in	O
ICH	B-DISO
is	O
lacking	O
.	O

High	O
index	O
of	O
suspicion	O
for	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
in	O
ICH	B-DISO
,	O
early	O
antiviral	O
therapy	O
,	O
and	O
treatment	O
of	O
coinfection	B-DISO
is	O
recommended	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
in	O
ICH	B-DISO
may	O
remain	O
clinically	O
silent	O
or	O
mild	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
this	O
clinical	O
trial	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
zinc	O
supplementation	O
on	O
diarrhea	B-DISO
and	O
average	O
daily	O
weight	O
gain	O
(	O
ADG	O
)	O
in	O
pre	O
-	O
weaned	O
dairy	O
calves	O
.	O

Logistic	O
regression	O
showed	O
that	O
the	O
odds	O
of	O
microbiological	O
cure	O
at	O
diarrhea	B-DISO
resolution	O
for	O
rotavirus	O
,	O
C	O
.	O
parvum	O
,	O
or	O
any	O
single	O
fecal	O
pathogen	O
was	O
not	O
different	O
between	O
treatment	O
groups	O
.	O

TITLE	O
:	O
Endocan	O
regulates	O
acute	O
lung	B-DISO
inflammation	I-DISO
through	O
control	O
of	O
leukocyte	O
diapedesis	O
.	O

We	O
hypothesized	O
that	O
serum	O
SP	O
-	O
D	O
levels	O
would	O
be	O
elevated	O
in	O
CDH	B-DISO
infants	O
and	O
that	O
the	O
levels	O
would	O
correlate	O
to	O
the	O
amount	O
of	O
lung	O
injury	O
present	O
.	O

These	O
results	O
demonstrate	O
that	O
CDH	B-DISO
infants	O
experience	O
lung	O
injury	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
around	O
the	O
time	O
of	O
surgery	O
,	O
and	O
at	O
the	O
time	O
of	O
ECMO	O
termination	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
observational	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
ACE	O
levels	O
as	O
a	O
prognostic	O
marker	O
in	O
thoracic	B-DISO
trauma	O
.	O

Our	O
study	O
demonstrates	O
that	O
serum	O
ACE	O
levels	O
are	O
increased	O
in	O
thoracic	B-DISO
trauma	O
patients	O
with	O
higher	O
levels	O
,	O
indicating	O
the	O
severe	O
nature	O
of	O
trauma	O
in	O
concordance	O
with	O
increased	O
TTSS	O
scores	O
.	O

ABSTRACT	O
:	O
Although	O
low	O
tidal	O
volume	O
is	O
strongly	O
recommended	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
whether	O
or	O
not	O
the	O
benefit	O
varies	O
according	O
to	O
the	O
severity	O
of	O
ARDS	B-DISO
remains	O
unclear	O
.	O

TITLE	O
:	O
Genotyping	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
Iran	O
:	O
Detection	O
of	O
D274	O
and	O
changing	O
in	O
the	O
genotypes	O
rate	O
.	O

TITLE	O
:	O
Viral	O
interference	O
between	O
H9N2	O
-	O
low	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
virus	O
and	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
vaccine	O
strain	O
H120	O
in	O
vivo	O
.	O

Prospectively	O
,	O
nasal	O
and	O
tonsillar	O
swabs	O
from	O
214	O
dogs	O
affected	O
with	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
,	O
and	O
50	O
healthy	O
control	O
dogs	O
were	O
tested	O
for	O
nucleic	O
acids	O
specific	O
to	O
the	O
various	O
viral	B-DISO
infections	I-DISO
.	O

Canine	O
respiratory	O
coronavirus	O
(	O
7	O
.	O
5	O
%)	O
and	O
canine	O
parainfluenza	B-DISO
virus	O
(	O
6	O
.	O
5	O
%)	O
were	O
the	O
most	O
commonly	O
detected	O
viruses	O
in	O
samples	O
from	O
the	O
upper	O
airways	O
of	O
dogs	O
with	O
respiratory	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Diarrhea	B-DISO
,	O
caused	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
is	O
a	O
catastrophic	O
gastrointestinal	B-DISO
disease	I-DISO
among	O
suckling	O
piglets	O
,	O
with	O
high	O
infectivity	O
,	O
morbidity	O
,	O
and	O
mortality	O
,	O
causing	O
huge	O
economic	O
losses	O
to	O
the	O
pig	O
industry	O
.	O

Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
increased	O
the	O
proportion	O
of	O
harmful	O
bacteria	O
and	O
decreased	O
the	O
proportion	O
of	O
beneficial	O
bacteria	O
in	O
the	O
cecal	O
mucosa	O
and	O
contents	O
of	O
suckling	O
piglets	O
.	O

The	O
present	O
study	O
investigated	O
the	O
role	O
of	O
the	O
CXCL5	O
/	O
Cxc	O
chemokine	O
receptor	O
2	O
(	O
CXCR2	O
)	O
bio	O
-	O
axis	O
in	O
ARDS	B-DISO
,	O
and	O
explored	O
the	O
underlying	O
molecular	O
mechanism	O
.	O

ABSTRACT	O
:	O
Overview	O
of	O
influenza	B-DISO
infection	B-DISO
,	O
focusing	O
on	O
outcome	O
and	O
complications	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
is	O
around	O
20	O
%,	O
independent	O
of	O
influenza	B-DISO
subtypes	O
.	O

Antiviral	O
therapy	O
within	O
48	O
h	O
after	O
onset	O
,	O
avoidance	O
of	O
corticosteroids	O
and	O
rescue	O
therapies	O
for	O
ARF	B-DISO
or	O
myocarditis	B-DISO
,	O
such	O
as	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
improve	O
survival	O
.	O

HCV	O
infection	B-DISO
should	O
be	O
screened	O
in	O
high	O
-	O
risk	O
patients	O
to	O
prevent	O
silent	O
progression	O
of	O
the	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
and	O
its	O
potentially	O
severe	O
extra	O
-	O
hepatic	O
manifestations	O
.	O

TITLE	O
:	O
Successful	O
use	O
of	O
VV	O
-	O
ECMO	O
in	O
a	O
pregnant	O
patient	O
with	O
severe	O
ARDS	B-DISO
.	O

A	O
previously	O
healthy	O
30	O
-	O
year	O
-	O
old	O
P1G2	O
at	O
26	O
weeks	O
and	O
6	O
days	O
of	O
gestation	O
was	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
because	O
of	O
a	O
severe	O
respiratory	B-DISO
infection	I-DISO
.	O

To	O
emulate	O
such	O
distinct	O
surface	O
patterns	O
on	O
macromolecules	O
,	O
we	O
used	O
rigid	B-DISO
spherical	O
synthetic	O
dendrimers	O
(	O
polyphenylene	O
dendrimers	O
)	O
to	O
provide	O
controlled	O
amphiphilic	O
surface	O
patches	O
with	O
molecular	O
precision	O
.	O

Risk	O
factors	O
independently	O
associated	O
with	O
ARDS	B-DISO
are	O
age	O
between	O
36	O
and	O
55	O
years	O
old	O
,	O
pregnancy	O
,	O
and	O
obesity	B-DISO
,	O
while	O
protective	O
factors	O
are	O
female	O
sex	O
,	O
influenza	B-DISO
vaccination	O
,	O
and	O
infections	B-DISO
with	O
Influenza	B-DISO
A	O
(	O
H3N2	O
)	O
or	O
Influenza	B-DISO
B	O
viruses	O
.	O

In	O
the	O
ICU	O
,	O
particularly	O
during	O
the	O
winter	O
season	O
,	O
influenza	B-DISO
should	O
be	O
suspected	O
not	O
only	O
in	O
patients	O
with	O
typical	O
symptoms	O
and	O
epidemiology	O
,	O
but	O
also	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
,	O
ARDS	B-DISO
,	O
sepsis	B-DISO
with	O
or	O
without	O
bacterial	O
co	B-DISO
-	I-DISO
infection	I-DISO
,	O
as	O
well	O
as	O
in	O
patients	O
with	O
encephalitis	B-DISO
,	O
myocarditis	B-DISO
,	O
and	O
rhabdomyolysis	B-DISO
.	O

A	O
number	O
of	O
biomarkers	O
are	O
used	O
to	O
evaluate	O
coagulopathy	B-DISO
on	O
sepsis	B-DISO
.	O

The	O
fibrinogen	O
level	O
and	O
antithrombin	O
activity	O
should	O
be	O
reconsidered	O
as	O
unique	O
biomarkers	O
for	O
sepsis	B-DISO
and	O
sepsis	B-DISO
-	O
induced	O
DIC	B-DISO
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
activation	O
of	O
pituitary	O
axis	O
early	O
after	O
ICU	O
admission	O
in	O
patients	O
with	O
critical	B-DISO
illnesses	I-DISO
of	O
different	O
etiology	O
and	O
its	O
association	O
with	O
outcome	O
.	O

Activation	O
of	O
the	O
hypothalamic	O
pituitary	O
adrenal	O
axis	O
was	O
a	O
predictor	O
of	O
ICU	O
mortality	O
independently	O
from	O
the	O
underlying	O
critical	B-DISO
illness	I-DISO
[	O
OR	O
3	O
.	O
952	O
(	O
C	O
.	O
I	O
.	O
95	O
%	O
1	O
.	O
129	O
-	O
13	O
.	O
838	O
)].	O

Recent	O
studies	O
on	O
human	O
medicine	O
report	O
that	O
gut	O
microbiota	O
is	O
involved	O
in	O
the	O
development	O
of	O
systemic	O
disorders	O
and	O
could	O
influence	O
the	O
immune	O
response	O
to	O
viral	B-DISO
diseases	I-DISO
.	O

Cats	O
were	O
equally	O
grouped	O
as	O
healthy	O
FCoV	O
-	O
negative	O
,	O
healthy	O
FCoV	O
-	O
positive	O
or	O
FIP	B-DISO
affected	O
(	O
total	O
n	O
=	O
15	O
).	O

TITLE	O
:	O
Aspiration	B-DISO
Pneumonia	I-DISO
:	O
a	O
Shadow	O
in	O
Post	O
-	O
Bariatric	O
Patient	O
:	O
Correlation	O
between	O
aspiration	B-DISO
and	O
minigrastric	O
bypass	O
.	O

Cases	O
who	O
were	O
>	O
18	O
years	O
old	O
and	O
were	O
confirmed	O
by	O
a	O
respiratory	O
viral	O
panel	O
to	O
have	O
viral	B-DISO
pneumonia	I-DISO
either	O
MERS	O
-	O
CoV	O
or	O
influenza	B-DISO
viruses	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Viral	B-DISO
pneumonia	I-DISO
caused	O
by	O
influenza	B-DISO
and	O
MERS	O
-	O
CoV	O
carries	O
a	O
high	O
mortality	O
rate	O
,	O
particularly	O
among	O
MERS	O
-	O
CoV	O
infected	O
cases	O
.	O

Based	O
on	O
the	O
reported	O
imaging	O
findings	O
,	O
we	O
propose	O
that	O
Leigh	B-DISO
Syndrome	I-DISO
should	O
be	O
added	O
to	O
the	O
differential	O
diagnosis	O
of	O
acute	O
cerebellitis	B-DISO
.	O

TITLE	O
:	O
Risk	O
factor	O
analysis	O
of	O
postoperative	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
type	B-DISO
A	I-DISO
aortic	I-DISO
dissection	I-DISO
repair	O
surgery	O
.	O

The	O
ARDS	B-DISO
group	O
had	O
lower	O
mean	O
oxygenation	O
index	O
(	O
OI	O
)	O
than	O
the	O
non	O
-	O
ARDS	B-DISO
group	O
in	O
the	O
first	O
3	O
days	O
post	O
-	O
surgery	O
and	O
demonstrated	O
an	O
improvement	O
in	O
lung	O
function	O
after	O
the	O
fourth	O
day	O
.	O

According	O
to	O
the	O
high	O
-	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
examination	O
,	O
the	O
patients	O
were	O
divided	O
into	O
an	O
ARDS	B-DISO
group	O
and	O
an	O
ARDS	B-DISO
pulmonary	B-DISO
fibrosis	I-DISO
(	O
ARDS	B-DISO
-	O
PF	O
)	O
group	O
.	O

The	O
difference	O
between	O
mechanical	O
power	O
and	O
28	O
-	O
day	O
survival	O
rate	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
.	O
05	O
),	O
while	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curves	O
of	O
TGF	O
-	O
β1	O
and	O
CTGF	O
for	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
pulmonary	B-DISO
fibrosis	I-DISO
was	O
0	O
.	O
838	O
and	O
0	O
.	O
884	O
,	O
respectively	O
(	O
P	O
<	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
A	O
significant	O
correlation	O
between	O
mechanical	O
power	O
and	O
serum	O
fibrosis	B-DISO
biomarkers	O
TGF	O
-	O
β1	O
and	O
CTGF	O
in	O
ARDS	B-DISO
patients	O
was	O
found	O
,	O
and	O
its	O
level	O
was	O
related	O
to	O
the	O
survival	O
prognosis	O
of	O
patients	O
.	O

TITLE	O
:	O
Increasing	O
the	O
translation	O
of	O
mouse	O
models	O
of	O
MERS	O
coronavirus	O
pathogenesis	B-DISO
through	O
kinetic	O
hematological	O
analysis	O
.	O

We	O
recently	O
generated	O
a	O
mouse	O
model	O
for	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
through	O
the	O
humanization	O
of	O
the	O
orthologous	O
entry	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

ABSTRACT	O
:	O
Tuberculosis	B-DISO
(	O
TB	O
)	O
is	O
a	O
rare	O
but	O
known	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
a	O
high	O
mortality	O
.	O

All	O
patients	O
had	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Plasma	O
levels	O
of	O
procalcitonin	O
were	O
higher	O
in	O
patients	O
with	O
bacterial	O
coinfection	B-DISO
(	O
18	O
.	O
2	O
vs	O
0	O
.	O
54	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

Human	O
metapneumovirus	O
was	O
associated	O
with	O
severe	O
CAP	B-DISO
requiring	O
ICU	O
admission	O
among	O
elderly	O
patients	O
or	O
patients	O
with	O
comorbidities	O
,	O
but	O
also	O
in	O
healthy	O
young	O
subjects	O
.	O

Avian	B-DISO
influenza	I-DISO
and	O
Newcastle	B-DISO
disease	I-DISO
have	O
been	O
reported	O
in	O
Myanmar	O
,	O
but	O
no	O
scientific	O
information	O
is	O
available	O
for	O
other	O
respiratory	O
pathogens	O
,	O
such	O
as	O
mycoplasmas	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

In	O
this	O
study	O
,	O
we	O
detected	O
Mycoplasma	B-DISO
gallisepticum	O
(	O
MG	O
),	O
M	O
.	O
synoviae	O
(	O
MS	O
),	O
and	O
IBV	O
in	O
several	O
poultry	O
farms	O
in	O
Myanmar	O
.	O

Blood	O
and	O
fecal	O
samples	O
were	O
collected	O
twice	O
from	O
the	O
same	O
animals	O
;	O
17	O
post	O
-	O
weaned	O
calves	O
with	O
diarrhea	B-DISO
(	O
first	O
)	O
and	O
15	O
post	O
-	O
weaned	O
calves	O
that	O
recovered	O
from	O
diarrhea	B-DISO
(	O
second	O
).	O

Post	O
-	O
weaned	O
calves	O
with	O
diarrhea	B-DISO
had	O
a	O
significantly	O
higher	O
Hp	O
concentration	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
diarrhea	B-DISO
-	O
recovered	O
calves	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
sex	O
on	O
mortality	O
,	O
intensive	O
care	O
unit	O
and	O
hospital	O
length	O
of	O
stay	O
,	O
and	O
duration	O
of	O
invasive	O
mechanical	O
ventilation	O
(	O
IMV	O
)	O
in	O
patients	O
with	O
ARDS	B-DISO
who	O
underwent	O
IMV	O
,	O
adjusting	O
for	O
plausible	O
clinical	O
and	O
geographic	O
confounders	O
.	O

No	O
substantial	O
changes	O
were	O
detected	O
for	O
the	O
highest	O
-	O
acuity	O
diseases	O
,	O
with	O
increases	O
of	O
3	O
.	O
5	O
%	O
for	O
cardiac	B-DISO
arrest	I-DISO
and	O
2	O
.	O
4	O
%	O
for	O
hemorrhagic	B-DISO
stroke	I-DISO
.	O

Aspiration	B-DISO
of	O
sodium	O
polystyrene	O
sulfonate	O
is	O
not	O
common	O
but	O
can	O
be	O
lethal	O
.	O

Clinicians	O
should	O
be	O
cautious	O
and	O
appropriately	O
inform	O
patients	O
of	O
the	O
aspiration	B-DISO
risk	O
while	O
administering	O
this	O
drug	O
.	O

TITLE	O
:	O
Structure	O
-	O
aided	O
optimization	O
of	O
3	O
-	O
O	O
-	O
β	O
-	O
chacotriosyl	O
ursolic	O
acid	O
as	O
novel	O
H5N1	B-DISO
entry	O
inhibitors	O
with	O
high	O
selective	O
index	O
.	O

TITLE	O
:	O
Differential	O
neurodegenerative	O
phenotypes	O
are	O
associated	O
with	O
heterogeneous	O
voiding	O
dysfunction	O
in	O
a	O
coronavirus	O
-	O
induced	O
model	O
of	O
multiple	B-DISO
sclerosis	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
causes	O
a	O
highly	O
fatal	O
lower	O
-	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

The	O
incidences	O
of	O
AKI	O
in	O
group	O
A	O
(	O
score	O
0	O
-	O
2	O
,	O
n	O
=	O
9	O
),	O
group	B-DISO
B	I-DISO
(	O
score	O
3	O
-	O
4	O
,	O
n	O
=	O
16	O
),	O
group	O
C	O
(	O
score	O
5	O
-	O
6	O
,	O
n	O
=	O
33	O
),	O
and	O
group	O
D	O
(	O
score	O
≥	O
7	O
,	O
n	O
=	O
72	O
)	O
were	O
10	O
.	O
98	O
%,	O
16	O
.	O
00	O
%,	O
31	O
.	O
13	O
%,	O
and	O
49	O
.	O
66	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Median	O
(	O
IQR	O
)	O
age	O
was	O
8	O
(	O
5	O
-	O
10	O
.	O
3	O
)	O
y	O
.	O
Fever	O
was	O
present	O
for	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
5	O
.	O
3	O
(	O
2	O
.	O
1	O
)	O
d	O
.	O
Vomiting	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
pain	O
abdomen	O
and	O
hepatomegaly	B-DISO
were	O
other	O
clinical	O
features	O
.	O

Steroids	O
were	O
used	O
in	O
4	O
cases	O
with	O
HLH	B-DISO
and	O
all	O
survived	O
,	O
whereas	O
among	O
3	O
who	O
did	O
not	O
receive	O
steroids	O
,	O
2	O
died	O
(	O
p	O
=	O
0	O
.	O
23	O
).	O

ABSTRACT	O
:	O
The	O
highly	O
pathogenic	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
related	O
coronavirus	O
(	O
CoV	O
)	O
is	O
transmitted	B-DISO
from	O
dromedary	O
camels	O
,	O
the	O
natural	O
reservoir	O
,	O
to	O
humans	O
.	O

The	O
research	O
findings	O
showed	O
that	O
serum	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
-	O
α	O
),	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
diamine	O
oxidase	O
(	O
DAO	O
),	O
endotoxin	O
,	O
D	O
-	O
lactic	O
acid	O
levels	O
and	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
II	O
)	O
and	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
scores	O
of	O
group	B-DISO
B	I-DISO
were	O
lower	O
than	O
those	O
of	O
group	O
A	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
)	O
after	O
treatment	O
.	O

The	O
approach	O
used	O
in	O
this	O
study	O
included	O
the	O
following	O
4	O
steps	O
:	O
(	O
1	O
)	O
job	O
hazard	O
analysis	O
,	O
(	O
2	O
)	O
infectious	B-DISO
disease	I-DISO
hazard	O
analysis	O
,	O
(	O
3	O
)	O
selection	O
of	O
PPE	O
,	O
and	O
(	O
4	O
)	O
evaluation	O
of	O
selected	O
PPE	O
.	O

Owing	O
to	O
the	O
complexity	O
of	O
PPE	O
ensemble	O
selection	O
and	O
evaluation	O
,	O
a	O
team	O
with	O
expertise	O
in	O
infectious	O
diseases	B-DISO
,	I-DISO
occupational	I-DISO
health	O
,	O
the	O
health	O
care	O
activity	O
,	O
and	O
related	O
disciplines	O
,	O
such	O
as	O
human	O
factors	O
,	O
should	O
be	O
engaged	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
an	O
important	O
life	O
-	O
saving	O
technology	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Generation	O
and	O
protective	O
efficacy	O
of	O
a	O
cold	B-DISO
-	O
adapted	O
attenuated	O
genotype	O
2b	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

The	O
seasonality	O
of	O
all	O
viruses	O
included	O
was	O
compared	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
influenza	B-DISO
A	O
virus	O
using	O
cross	O
-	O
correlations	O
.	O

RSV	O
circulated	O
an	O
average	O
of	O
6	O
weeks	O
before	O
influenza	B-DISO
A	O
.	O
Co	B-DISO
-	I-DISO
infection	I-DISO
with	O
another	O
respiratory	O
virus	O
was	O
less	O
common	O
with	O
picornavirus	O
,	O
RSV	O
or	O
influenza	B-DISO
A	O
infection	B-DISO
.	O

Randomized	O
clinical	O
trials	O
of	O
interventions	O
for	O
adults	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
that	O
used	O
lung	O
protective	O
ventilation	O
.	O

Here	O
,	O
we	O
report	O
our	O
work	O
on	O
using	O
human	O
breath	O
to	O
differentiate	O
ARDS	B-DISO
and	O
non	O
-	O
ARDS	B-DISO
causes	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

A	O
fully	O
automated	O
portable	O
2	O
-	O
dimensional	O
gas	O
chromatography	O
device	O
with	O
high	O
peak	O
capacity	O
(>	O
200	O
at	O
the	O
resolution	O
of	O
1	O
),	O
high	O
sensitivity	O
(	O
sub	O
-	O
ppb	B-DISO
),	O
and	O
rapid	O
analysis	O
capability	O
(~	O
30	O
min	O
)	O
was	O
designed	O
and	O
made	O
in	O
-	O
house	O
for	O
on	O
-	O
site	O
analysis	O
of	O
patients	O
'	O
breath	O
.	O

Several	O
reported	O
studies	O
have	O
shown	O
visible	O
bubbling	O
of	O
air	O
at	O
the	O
surgical	O
site	O
as	O
the	O
first	O
clinical	O
indication	O
of	O
VAE	O
-	O
induced	O
cardiovascular	B-DISO
collapse	I-DISO
during	O
prone	O
-	O
position	O
spine	O
surgery	O
.	O

We	O
found	O
that	O
single	O
strand	O
RNA	O
(	O
termed	O
RNA	O
adjuvant	O
)	O
derived	O
from	O
cricket	O
paralysis	O
virus	O
intergenic	O
region	O
internal	O
ribosome	O
entry	O
site	O
induced	O
the	O
expression	O
of	O
various	O
adjuvant	O
-	O
function	O
-	O
related	O
genes	O
,	O
such	O
as	O
type	O
1	O
and	O
2	O
interferon	O
(	O
IFN	O
)	O
and	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
),	O
T	O
cell	O
activation	O
,	O
and	O
leukocyte	O
chemotaxis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
;	O
furthermore	O
,	O
its	O
innate	O
and	O
IFN	O
transcriptome	O
profile	O
patterns	O
were	O
similar	O
to	O
those	O
of	O
a	O
live	O
-	O
attenuated	O
yellow	B-DISO
fever	I-DISO
vaccine	O
.	O

Application	O
of	O
the	O
RNA	O
adjuvant	O
in	O
mouse	O
enhanced	O
the	O
efficacy	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
spike	O
protein	O
,	O
a	O
protein	O
-	O
subunit	O
vaccine	O
and	O
human	O
papillomavirus	O
L1	O
protein	O
,	O
a	O
virus	O
-	O
like	O
particle	O
vaccine	O
,	O
by	O
activating	O
innate	B-DISO
immune	I-DISO
response	I-DISO
through	O
TLR7	O
and	O
enhancing	O
pAPC	O
chemotaxis	O
,	O
leading	O
to	O
a	O
balanced	O
Th1	O
/	O
Th2	O
responses	O
.	O

The	O
therapy	O
is	O
based	O
on	O
early	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
dexamethasone	O
,	O
in	O
order	O
to	O
counteract	O
the	O
cytokine	B-DISO
storm	I-DISO
responsible	O
for	O
the	O
DS	O
.	O

This	O
is	O
a	O
rare	O
condition	B-DISO
,	O
not	O
well	O
known	O
among	O
nephrologists	O
,	O
where	O
early	O
recognition	O
and	O
treatment	O
are	O
crucial	O
for	O
the	O
prognosis	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
G29	O
was	O
critical	O
for	O
the	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
triggered	O
by	O
either	O
receptor	O
binding	O
or	O
high	O
pH	O
.	O
Replacement	O
of	O
G29	O
with	O
A	O
,	O
D	O
,	O
F	O
,	O
K	O
,	O
M	O
,	O
and	O
T	O
,	O
to	O
different	O
extents	O
,	O
caused	O
spontaneous	O
dissociation	B-DISO
of	O
S1	O
from	O
the	O
S	O
protein	O
,	O
resulting	O
in	O
an	O
enhancement	O
of	O
high	O
-	O
pH	O
-	O
triggered	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
in	O
HEK293T	O
cells	O
,	O
compared	O
to	O
the	O
wild	O
type	O
(	O
WT	O
).	O

We	O
successfully	O
generated	O
recombinant	O
virus	O
(	O
rC3663	O
)	O
from	O
Fcwf	O
-	O
4	O
cells	O
transfected	O
with	O
infectious	B-DISO
cDNA	O
that	O
showed	O
growth	O
kinetics	O
similar	O
to	O
those	O
shown	O
by	O
the	O
parental	O
virus	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
member	O
of	O
the	O
family	O
Coronaviridae	O
,	O
causes	O
lethal	O
watery	B-DISO
diarrhea	I-DISO
in	O
piglets	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
ORF3	O
protein	O
causes	O
endoplasmic	O
reticulum	O
stress	O
to	O
facilitate	O
autophagy	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IFN	O
-	O
γ	O
inhibited	O
TGEV	O
infection	B-DISO
directly	O
in	O
ST	O
cells	O
and	O
intestine	O
epithelial	O
IPEC	O
-	O
J2	O
cells	O
and	O
that	O
the	O
anti	O
-	O
TGEV	O
activity	O
of	O
IFN	O
-	O
γ	O
was	O
independent	O
of	O
IFN	O
-	O
α	O
/	O
β	O
.	O

The	O
impact	O
on	O
serum	O
and	O
pulmonary	O
biotrauma	O
markers	O
of	O
the	O
transition	B-DISO
to	O
ultra	O
-	O
protective	O
ventilation	O
settings	O
following	O
extracorporeal	O
membrane	O
oxygenation	O
implantation	O
,	O
and	O
different	O
mechanical	O
ventilation	O
strategies	O
while	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
were	O
investigated	O
.	O

Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
on	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Time	O
-	O
course	O
of	O
upper	O
respiratory	O
tract	O
viral	B-DISO
infection	I-DISO
and	O
COPD	B-DISO
exacerbation	I-DISO
.	O

Swabs	O
were	O
taken	O
during	O
stable	O
periods	O
(	O
n	O
=	O
1909	O
),	O
at	O
URTI	B-DISO
onset	O
(	O
n	O
=	O
391	O
),	O
10	O
days	O
after	O
the	O
URTI	B-DISO
(	O
n	O
=	O
356	O
)	O
and	O
during	O
an	O
AECOPD	O
(	O
n	O
=	O
177	O
)	O
and	O
tested	O
using	O
a	O
multiplex	O
nucleic	O
acid	O
amplification	B-DISO
test	O
.	O

Rhinovirus	O
and	O
coronavirus	O
were	O
the	O
most	O
frequently	O
detected	O
viruses	O
during	O
AECOPD	O
visits	O
,	O
accounting	O
for	O
35	O
.	O
7	O
%	O
and	O
25	O
.	O
9	O
%	O
of	O
all	O
viral	B-DISO
infections	I-DISO
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
systematically	O
and	O
quantitatively	O
update	O
and	O
assess	O
the	O
association	O
between	O
DP	O
and	O
mortality	O
among	O
ventilated	O
patients	O
with	O
ARDS	B-DISO
.	O

We	O
designed	O
a	O
multicentre	O
,	O
single	O
-	O
blind	B-DISO
,	O
stratified	O
,	O
parallel	O
-	O
group	O
,	O
randomised	O
controlled	O
trial	O
enrolling	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
in	O
20	O
university	O
or	O
non	O
-	O
university	O
intensive	O
care	O
units	O
in	O
France	O
.	O

Furthermore	O
,	O
HY	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	O
in	O
CEK	O
cells	O
,	O
and	O
significantly	O
reduced	O
the	O
mRNA	O
expression	O
levels	O
of	O
Fas	B-DISO
,	O
FasL	O
,	O
JNK	O
,	O
Bax	O
,	O
Caspase	O
3	O
,	O
and	O
Caspase	O
8	O
,	O
and	O
significantly	O
increased	O
Bcl	O
-	O
2	O
mRNA	O
expression	O
level	O
in	O
CEK	O
cells	O
.	O

As	O
the	O
evidence	O
supporting	O
the	O
use	O
of	O
extracorporeal	O
life	O
support	O
increases	O
,	O
its	O
indications	O
are	O
expanding	O
to	O
being	O
a	O
bridge	O
to	O
lung	O
transplantation	O
and	O
the	O
management	O
of	O
patients	O
with	O
pulmonary	O
vascular	B-DISO
disease	I-DISO
who	O
have	O
right	B-DISO
-	I-DISO
sided	I-DISO
heart	I-DISO
failure	I-DISO
.	O

Multivariable	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
with	O
nonlinear	O
restricted	O
cubic	O
spline	O
including	O
a	O
two	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
each	O
score	O
)	O
and	O
three	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
ISTH	O
overt	O
DIC	B-DISO
score	O
×	O
APACHE	O
II	O
score	O
)	O
was	O
performed	O
.	O

The	O
regression	O
model	O
including	O
the	O
two	O
-	O
way	O
interaction	O
term	O
showed	O
significant	O
interaction	O
between	O
intervention	O
and	O
disease	O
severity	O
as	O
indicated	O
by	O
the	O
ISTH	O
overt	O
DIC	B-DISO
score	O
and	O
APACHE	O
II	O
score	O
(	O
CONCLUSIONS	O
:	O
Anticoagulant	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
according	O
to	O
the	O
deterioration	O
of	O
both	O
DIC	B-DISO
and	O
disease	O
severity	O
,	O
suggesting	O
that	O
anticoagulant	O
therapy	O
should	O
be	O
restricted	O
to	O
patients	O
having	O
DIC	B-DISO
and	O
high	O
disease	O
severity	O
simultaneously	O
.	O

Consideration	O
of	O
various	O
differential	O
diagnoses	O
and	O
finally	O
narrowing	O
down	O
to	O
that	O
of	O
stress	O
-	O
induced	O
reversible	O
cardiomyopathy	B-DISO
(	O
Takotsubo	B-DISO
syndrome	I-DISO
)	O
following	O
his	O
intracranial	B-DISO
bleed	I-DISO
,	O
versus	O
that	O
of	O
coexisting	O
dual	O
pathology	B-DISO
-	O
acute	O
brain	O
injury	O
with	O
concomitant	O
acute	O
viral	B-DISO
myocarditis	I-DISO
,	O
deepened	O
our	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
each	O
disease	O
process	O
,	O
and	O
how	O
it	O
possibly	O
interlinks	O
between	O
different	O
organ	O
systems	O
.	O

A	O
healthy	O
child	O
can	O
contract	O
a	O
series	O
of	O
infections	B-DISO
which	O
contribute	O
to	O
the	O
maturation	O
of	O
the	O
immune	O
system	O
during	O
the	O
pre	O
-	O
pubertal	O
period	O
.	O

However	O
,	O
ITP	B-DISO
in	O
association	O
with	O
coronavirus	B-DISO
infection	I-DISO
has	O
not	O
previously	O
been	O
reported	O
.	O

An	O
infection	B-DISO
screen	O
revealed	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
With	O
reports	O
of	O
vancomycin	O
-	O
resistant	O
enterococci	O
recently	O
emerging	O
in	O
hospital	O
settings	O
,	O
renewed	O
focus	O
is	O
turning	O
to	O
the	O
importance	O
of	O
multifaceted	O
infection	B-DISO
prevention	O
efforts	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
clinical	O
,	O
laboratory	O
and	O
computed	O
tomography	O
features	O
of	O
patients	O
with	O
hospitalized	O
COPD	B-DISO
exacerbations	O
in	O
which	O
respiratory	O
viruses	O
were	O
detected	O
using	O
a	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
epidemiology	O
and	O
disease	O
prognosis	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
have	O
not	O
yet	O
been	O
fully	O
elucidated	O
in	O
Vietnam	O
.	O

The	O
mean	O
(	O
standard	O
deviation	O
)	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
)	O
score	O
was	O
9	O
.	O
5	O
(	O
3	O
.	O
4	O
)	O
in	O
non	O
-	O
survivors	O
and	O
7	O
.	O
4	O
(	O
3	O
.	O
4	O
)	O
in	O
survivors	O
(	O
p	O
=	O
0	O
.	O
002	O
).	O

Many	O
highly	O
pathogenic	O
viruses	O
such	O
as	O
SARS	B-DISO
-	O
CoV	O
and	O
rabies	B-DISO
-	O
related	O
lyssaviruses	O
have	O
crossed	O
species	O
barriers	O
to	O
infect	O
humans	O
and	O
other	O
animals	O
.	O

ABSTRACT	O
:	O
Quantification	O
of	O
potential	O
for	O
lung	O
recruitment	B-DISO
may	O
guide	O
the	O
ventilatory	O
strategy	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

However	O
,	O
there	O
was	O
still	O
no	O
consensus	O
on	O
GBS	B-DISO
treatment	O
systematically	O
all	O
over	O
the	O
world	O
.	O

After	O
conducting	O
univariate	O
analysis	O
of	O
risk	O
factors	O
,	O
statistically	O
significant	O
risk	O
factors	O
affecting	O
the	O
development	O
of	O
ROP	B-DISO
in	O
our	O
study	O
were	O
:	O
low	O
gestational	O
age	O
,	O
low	O
birth	O
weight	O
,	O
type	O
of	O
multiple	B-DISO
gestation	I-DISO
,	O
the	O
presence	O
of	O
affected	O
sibling	O
,	O
low	O
level	O
of	O
Hemoglobin	O
at	O
birth	O
,	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
low	O
Hemoglobin	O
level	O
,	O
blood	O
transfusion	O
and	O
days	O
on	O
oxygen	O
supplements	O
with	O
either	O
mechanical	O
,	O
non	O
-	O
mechanical	O
methods	O
or	O
both	O
combined	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
ROP	B-DISO
and	O
severe	O
type	O
1	O
ROP	B-DISO
that	O
require	O
treatment	O
was	O
23	O
.	O
5	O
and	O
11	O
.	O
3	O
%	O
respectively	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
,	O
Saudi	O
Arabia	O
,	O
2017	O
-	O
2018	O
.	O

All	O
patients	O
with	O
serology	O
proven	O
dengue	B-DISO
fever	I-DISO
admitted	O
to	O
MICU	O
between	O
1st	O
July	O
2015	O
and1st	O
December	O
2015	O
were	O
included	O
in	O
the	O
study	O
.	O

TITLE	O
:	O
Catastrophic	O
Antiphospholid	O
Syndrome	B-DISO
-	O
An	O
Unusual	O
Case	O
Report	O
.	O

A	O
positive	O
lupus	B-DISO
anticoagulant	I-DISO
confirmed	O
the	O
diagnosis	O
of	O
CAPS	O
.	O

TITLE	O
:	O
Chlamydia	B-DISO
psittaci	I-DISO
infection	I-DISO
as	O
a	O
cause	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
neonatal	O
foals	O
.	O

For	O
example	O
,	O
we	O
demonstrate	O
how	O
the	O
sub	O
-	O
epidemic	O
wave	O
model	O
successfully	O
captures	O
the	O
2	O
-	O
peak	O
pattern	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
Singapore	O
.	O

These	O
preliminary	O
results	O
using	O
sub	O
-	O
epidemic	O
models	O
can	O
help	O
guide	O
future	O
efforts	O
to	O
better	O
understand	O
the	O
heterogenous	O
spatial	O
and	O
social	O
factors	O
shaping	O
sub	O
-	O
epidemic	O
patterns	O
for	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Coumarin	O
-	O
based	O
molecules	O
already	O
proved	O
to	O
act	O
as	O
HIV	B-DISO
-	O
1	O
Protease	O
(	O
PR	O
)	O
or	O
Integrase	O
(	O
IN	O
)	O
inhibitors	O
and	O
also	O
to	O
target	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
),	O
blocking	B-DISO
the	O
DNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
or	O
the	O
RNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
working	O
as	O
common	O
NNRTIs	O
.	O

TITLE	O
:	O
Tension	B-DISO
pneumoperitoneum	B-DISO
caused	O
by	O
rupture	O
of	O
intraabdominal	O
soft	B-DISO
tissue	I-DISO
emphysema	I-DISO
in	O
a	O
child	O
supported	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
:	O
a	O
case	O
report	O
.	O

A	O
12	O
-	O
month	O
-	O
old	O
Thai	O
girl	O
presented	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
septic	B-DISO
shock	I-DISO
,	O
and	O
bacterial	B-DISO
pneumonia	I-DISO
.	O

Subsequently	O
,	O
to	O
exclude	O
hollow	O
viscus	O
perforation	O
,	O
diaphragmatic	O
injury	O
caused	O
by	O
intercostal	O
drainage	O
,	O
or	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
,	O
she	O
was	O
transferred	O
for	O
surgery	O
.	O

ABSTRACT	O
:	O
The	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
can	O
lead	O
to	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
which	O
the	O
precise	O
cause	O
is	O
still	O
unknown	O
.	O

Despite	O
the	O
heterogeneous	O
etiologies	O
that	O
lead	O
to	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
this	O
rapidly	O
progressing	O
form	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
characterized	O
by	O
severe	O
hypoxemia	O
and	O
nonhydrostatic	O
pulmonary	B-DISO
edema	I-DISO
,	O
has	O
a	O
recognizable	O
pattern	O
of	O
lung	O
injury	O
.	O

TITLE	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Novel	O
Therapies	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
first	O
described	O
in	O
1967	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
-	O
encoded	O
ORF8b	O
strongly	O
antagonizes	O
IFN	O
-	O
β	O
promoter	O
activation	O
:	O
its	O
implication	O
for	O
vaccine	O
design	O
.	O

TITLE	O
:	O
[	O
Coronaviruses	O
as	O
the	O
cause	O
of	O
respiratory	B-DISO
infections	I-DISO
].	O

The	O
four	O
endemic	O
human	O
CoVs	O
(	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
HKU1	O
)	O
mainly	O
cause	O
mild	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

In	O
addition	O
to	O
these	O
four	O
endemic	O
HCoV	O
,	O
the	O
two	O
epidemic	O
CoV	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
can	O
cause	O
severe	O
pneumonia	B-DISO
.	O

In	O
current	O
clinical	O
practice	O
SARS	B-DISO
-	O
CoV	O
has	O
no	O
importance	O
as	O
it	O
has	O
not	O
been	O
detected	O
in	O
humans	O
for	O
15	O
years	O
;	O
however	O
,	O
a	O
possible	O
MERS	O
-	O
CoV	O
infection	B-DISO
should	O
be	O
taken	O
into	O
account	O
in	O
patients	O
with	O
typical	O
symptoms	O
and	O
travel	O
history	O
to	O
endemic	O
regions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
BCoV	O
infections	B-DISO
and	O
their	O
genetic	O
diversity	O
in	O
Uruguayan	O
calves	O
and	O
to	O
describe	O
the	O
evolutionary	O
history	O
of	O
the	O
virus	O
in	O
South	O
America	O
.	O

TITLE	O
:	O
[	O
Viral	O
etiology	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
a	O
pediatric	O
intensive	O
care	O
unit	O
].	O

Nosocomial	B-DISO
pneumonia	I-DISO
was	O
found	O
in	O
40	O
.	O
6	O
%,	O
there	O
were	O
no	O
fatal	B-DISO
outcomes	I-DISO
from	O
this	O
complication	B-DISO
.	O

The	O
leading	O
cause	O
of	O
mortality	O
was	O
ARDS	B-DISO
(	O
mortality	O
rate	O
15	O
.	O
1	O
%	O
in	O
mild	O
and	O
moderate	O
syndrome	B-DISO
,	O
75	O
%	O
in	O
severe	O
course	O
of	O
ARDS	B-DISO
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
implementation	O
of	O
a	O
dedicated	O
multiprofessional	O
acute	O
trauma	O
health	O
care	O
(	O
mPATH	O
)	O
team	O
would	O
decrease	O
length	O
of	O
stay	O
without	O
adversely	O
impacting	O
outcomes	O
of	O
patients	O
with	O
severe	O
traumatic	O
brain	O
and	O
spinal	O
cord	B-DISO
injuries	O
.	O

Coinfection	B-DISO
was	O
detected	O
in	O
58	O
.	O
7	O
%	O
of	O
the	O
patients	O
.	O

Haemophilus	O
influenzae	O
(	O
11	O
.	O
7	O
%)	O
and	O
adenovirus	B-DISO
(	O
9	O
.	O
1	O
%)	O
were	O
the	O
predominant	O
bacterial	O
and	O
viral	O
pathogens	O
isolated	O
,	O
respectively	O
.	O

TITLE	O
:	O
Serum	O
Exosomal	O
MicroRNAs	O
Predict	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Events	O
in	O
Patients	O
with	O
Severe	O
Community	O
-	O
Acquired	O
Pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
SCAP	O
)	O
requiring	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
treatment	O
commonly	O
causes	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
high	O
mortality	O
.	O

TITLE	O
:	O
Use	O
of	O
extracorporeal	O
membranous	O
oxygenation	O
in	O
the	O
management	O
of	O
refractory	O
trauma	O
-	O
related	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
national	O
survey	O
of	O
the	O
Eastern	O
Association	O
for	O
the	O
Surgery	O
of	O
Trauma	O
.	O

There	O
are	O
an	O
increasing	O
number	O
of	O
studies	O
that	O
suggest	O
that	O
ECMO	O
is	O
a	O
safe	O
and	O
viable	O
treatment	O
option	O
for	O
trauma	O
patients	O
with	O
ARDS	B-DISO
.	O

Based	O
on	O
the	O
results	O
of	O
this	O
survey	O
,	O
ECMO	O
use	O
remains	O
limited	O
by	O
trauma	O
providers	O
that	O
care	O
for	O
patients	O
with	O
refractory	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
and	O
ARDS	B-DISO
,	O
likely	O
due	O
to	O
a	O
combination	O
of	O
knowledge	O
gaps	O
and	O
lack	O
of	O
access	O
to	O
ECMO	O
.	O

The	O
development	O
of	O
prophylactics	O
and	O
therapeutics	O
is	O
urgently	O
needed	O
to	O
prevent	O
and	O
control	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
influence	O
of	O
accidental	O
hypothermia	O
on	O
pulmonary	B-DISO
complications	I-DISO
in	O
multiply	O
injured	O
patients	O
with	O
blunt	O
chest	O
trauma	O
.	O

Multiply	O
injured	O
patients	O
[	O
injury	O
severity	O
score	O
(	O
ISS	B-DISO
)	O
≥	O
16	O
]	O
with	O
severe	O
blunt	O
chest	O
trauma	O
[	O
abbreviated	O
injury	O
scale	O
of	O
the	O
chest	O
(	O
AISchest	O
)	O
≥	O
3	O
]	O
were	O
analyzed	O
.	O

However	O
,	O
there	O
were	O
no	O
differences	O
in	O
occurrence	O
of	O
ARDS	B-DISO
and	O
VAP	O
.	O

Hypothermia	O
was	O
not	O
identified	O
as	O
an	O
independent	O
predictor	O
of	O
ARDS	B-DISO
and	O
VAP	O
.	O

The	O
lymphocytes	O
isolated	O
from	O
the	O
blood	O
and	O
spleen	O
were	O
analyzed	O
for	O
proliferation	B-DISO
,	O
cytotoxic	O
activities	O
,	O
and	O
populations	O
of	O
CD4	O

Literature	O
search	O
and	O
analysis	O
of	O
national	O
and	O
international	O
guidelines	O
for	O
the	O
epidemiology	O
,	O
diagnostics	O
,	O
treatment	O
and	O
prevention	O
of	O
IV	O
infections	B-DISO
.	O

Seasonal	O
influenza	B-DISO
vaccination	O
is	O
an	O
efficient	O
preventive	O
method	O
.	O

In	O
the	O
NIV	O
group	O
,	O
PaO	O
Treatment	O
with	O
NIV	O
did	O
not	O
reduce	O
the	O
need	O
for	O
intubation	O
among	O
patients	O
with	O
pneumonia	B-DISO
-	O
induced	O
early	O
mild	O
ARDS	B-DISO
,	O
despite	O
the	O
improved	O
PaO	O
NCT01581229	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
claimed	O
the	O
lives	O
of	O
286	O
Hong	O
Kong	O
people	O
in	O
2003	O
.	O

PCR	O
method	O
,	O
Taqman	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
method	O
,	O
sequencing	O
,	O
histopathology	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
were	O
conducted	O
with	O
the	O
collected	O
samples	O
,	O
and	O
the	O
results	O
showed	O
that	O
PDCoV	O
was	O
detected	O
among	O
the	O
suckling	O
piglets	O
,	O
commercial	O
fattening	O
pigs	O
and	O
sows	O
with	O
diarrhea	B-DISO
.	O

Lower	O
GCS	O
scores	O
,	O
higher	O
ISSs	O
,	O
and	O
emergency	B-DISO
room	O
hypotension	O
predicted	O
poorer	O
outcomes	O
.	O

We	O
used	O
isolated	O
peptides	O
and	O
giant	B-DISO
unilamellar	O
vesicles	B-DISO
(	O
GUV	O
)	O
to	O
demonstrate	O
membrane	O
binding	O
for	O
a	O
peptide	O
located	O
near	O
the	O
N	O
-	O
terminus	O
of	O
the	O
S2	O
domain	O
.	O

TITLE	O
:	O
Myocardial	B-DISO
calcification	I-DISO
in	O
a	O
patient	O
with	O
B	O
-	O
lymphoblastic	B-DISO
leukemia	I-DISO
accompanied	O
by	O
tumor	B-DISO
lysis	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Myocardial	B-DISO
calcification	I-DISO
,	O
a	O
rare	B-DISO
disease	I-DISO
that	O
leads	O
to	O
chronic	O
or	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
and	O
with	O
a	O
poor	O
prognosis	O
,	O
occurs	O
in	O
patients	O
with	O
abnormal	O
calcium	O
-	O
phosphorus	O
metabolism	O
.	O

Prednisolone	O
was	O
administered	O
for	O
tumor	B-DISO
reduction	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	O
RNA	O
virus	O
that	O
belongs	O
to	O
the	O
Coronaviridae	O
.	O

Stress	O
granules	O
(	O
SGs	B-DISO
)	O
are	O
sites	O
of	O
mRNA	O
storage	O
that	O
are	O
formed	O
under	O
various	O
stress	O
conditions	O
including	O
viral	B-DISO
infections	I-DISO
.	O

Depletion	O
of	O
G3BP1	O
inhibits	O
SGs	B-DISO
formation	O
and	O
overexpression	O
of	O
G3BP1	O
nucleates	O
SGs	B-DISO
assembly	O
.	O

An	O
increase	O
in	O
the	O
levels	O
of	O
mRNAs	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	O
-	O
1β	O
(	O
IL	O
-	O
1β	O
)	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
was	O
also	O
observed	O
in	O
PEDV	O
-	O
infected	O
G3BP1	O
depleted	O
cells	O
compared	O
to	O
PEDV	O
-	O
infected	O
control	O
cells	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
use	O
of	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
rapidly	O
increasing	O
,	O
the	O
benefit	O
of	O
ECMO	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
unclear	O
.	O

The	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
was	O
12	O
.	O
8	O
±	O
3	O
.	O
4	O
in	O
the	O
ECMO	O
group	O
and	O
13	O
.	O
7	O
±	O
3	O
.	O
5	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
0848	O
).	O

RESULTS	O
:	O
Ninety	O
-	O
nine	O
patients	O
with	O
severe	O
ARDS	B-DISO
supported	O
by	O
VV	O
-	O
ECMO	O
and	O
72	O
patients	O
without	O
ECMO	O
were	O
included	O
in	O
this	O
study	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
occurrence	O
of	O
hepatitis	B-DISO
by	O
establishing	O
a	O
model	O
for	O
infected	O
mice	O
for	O
three	O
different	O
subtypes	O
of	O
respiratory	O
IAVs	O
(	O
H1N1	O
,	O
H5N1	B-DISO
,	O
and	O
H7N2	O
).	O

All	O
these	O
data	O
showed	O
that	O
the	O
mouse	O
model	O
suitably	O
contributed	O
valuable	O
information	O
about	O
the	O
mechanism	O
underlying	O
the	O
occurrence	O
of	O
hepatitis	B-DISO
induced	O
by	O
respiratory	O
influenza	B-DISO
virus	O
.	O

We	O
then	O
did	O
a	O
series	O
of	O
experiments	O
in	O
mice	O
in	O
which	O
we	O
systematically	O
varied	O
the	O
pneumococcal	O
inoculum	O
and	O
the	O
timing	O
of	O
antibiotics	O
while	O
measuring	O
systemic	O
and	O
lung	O
-	O
specific	O
end	O
points	O
,	O
producing	O
a	O
range	O
of	O
models	O
that	O
mirrors	O
the	O
spectrum	O
of	O
pneumococcal	O
lung	B-DISO
disease	I-DISO
in	O
patients	O
,	O
from	O
mild	O
self	O
-	O
resolving	O
infection	B-DISO
to	O
severe	O
pneumonia	B-DISO
refractory	O
to	O
antibiotics	O
.	O

However	O
,	O
effective	O
vaccination	O
and	O
antiviral	O
treatment	O
is	O
only	O
emerging	O
for	O
non	O
-	O
influenza	B-DISO
CARVs	O
,	O
placing	O
emphasis	O
on	O
infection	B-DISO
control	O
and	O
supportive	O
measures	O
.	O

ABSTRACT	O
:	O
Acute	O
pulmonary	O
injury	O
,	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
has	O
a	O
high	O
incidence	O
in	O
elderly	O
individuals	O
and	O
high	O
mortality	O
in	O
its	O
most	O
severe	O
degree	O
,	O
becoming	O
a	O
challenge	O
to	O
public	O
health	O
due	O
to	O
pathophysiological	O
complications	O
and	O
increased	O
economic	O
burden	O
.	O

It	O
is	O
crucial	O
to	O
keep	O
in	O
mind	O
the	O
possibility	O
of	O
ARDS	B-DISO
after	O
gadolinium	O
injection	O
,	O
as	O
missing	O
the	O
diagnosis	O
leads	O
to	O
a	O
high	O
mortality	O
.	O

,	O
the	O
goal	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
is	O
to	O
protect	O
healthcare	O
personnel	O
(	O
HCP	B-DISO
)	O
and	O
patients	O
from	O
body	O
fluids	O
and	O
infectious	B-DISO
organisms	O
via	O
contact	O
,	O
droplet	O
,	O
or	O
airborne	O
transmission	O
.	O

In	O
the	O
present	O
work	O
,	O
a	O
novel	O
biotinylated	O
nanobody	O
-	O
based	O
blocking	B-DISO
ELISA	O
(	O
bELISA	O
)	O
was	O
developed	O
to	O
detect	O
anti	O
-	O
PEDV	O
antibodies	O
in	O
clinical	O
pig	O
serum	O
.	O

It	O
is	O
imperative	O
to	O
continue	O
surveillance	O
for	O
the	O
spread	O
of	O
antimicrobial	O
resistance	O
and	O
occurrence	O
of	O
all	O
infectious	B-DISO
diseases	I-DISO
causing	O
outbreaks	O
across	O
the	O
globe	O
in	O
the	O
last	O
year	O
,	O
like	O
Zika	O
virus	O
,	O
MDR	O
-	O
Typhoid	B-DISO
,	O
Nipah	O
,	O
Ebola	O
,	O
cholera	B-DISO
,	O
chikungunya	B-DISO
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
.	O

To	O
overcome	O
these	O
physiochemical	O
limitations	O
and	O
uncover	O
the	O
full	O
therapeutic	O
potential	O
of	O
curcumin	O
in	O
lung	B-DISO
inflammation	I-DISO
,	O
in	O
this	O
study	O
we	O
utilized	O
a	O
novel	O
water	O
-	O
soluble	O
curcumin	O
formulation	O
(	O
CDC	O
)	O
and	O
delivered	O
it	O
directly	O
into	O
the	O
lungs	O
of	O
C57BL	O
/	O
6	O
mice	O
inoculated	O
with	O
a	O
lethal	O
dose	O
of	O

ABSTRACT	O
:	O
Widespread	O
geographic	O
movement	O
and	O
extensive	O
comingling	O
of	O
exhibition	O
swine	O
facilitates	O
the	O
spread	O
and	O
transmission	O
of	O
infectious	B-DISO
pathogens	O
.	O

The	O
pathogenic	O
mechanisms	O
that	O
lead	O
to	O
respiratory	B-DISO
complications	I-DISO
,	O
such	O
as	O
vascular	O
leakage	B-DISO
,	O
remain	O
unclear	O
.	O

This	O
case	O
report	O
describes	O
an	O
early	O
presentation	O
of	O
a	O
cat	O
with	O
primarily	O
neurologic	O
FIP	B-DISO
,	O
with	O
molecular	O
characterization	O
of	O
the	O
virus	O
within	O
various	O
tissues	O
.	O

We	O
hope	O
the	O
review	O
could	O
give	O
a	O
guide	O
to	O
develop	O
new	O
anti	O
-	O
cancer	B-DISO
agents	O
with	O
greater	O
potency	O
against	O
drug	O
-	O
sensitive	O
and	O
drug	O
-	O
resistant	O
cancers	B-DISO
in	O
the	O
future	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
pulmonary	B-DISO
embolism	I-DISO
(	O
PE	O
)	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
requiring	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
ECMO	O
)	O
and	O
in	O
those	O
managed	O
with	O
conventional	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Despite	O
its	O
efficacy	O
,	O
low	O
tidal	O
volume	O
ventilation	O
(	O
LTVV	O
)	O
remains	O
severely	O
underutilized	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
propose	O
a	O
computational	O
method	O
that	O
addresses	O
some	O
of	O
the	O
limitations	O
of	O
the	O
current	O
approaches	O
to	O
automated	O
measurement	O
of	O
whether	O
ARDS	B-DISO
is	O
recognized	O
by	O
physicians	O
.	O

Hypoxemia	O
severity	O
and	O
ARDS	B-DISO
documentation	O
in	O
physicians	O
'	O
notes	O
were	O
associated	O
with	O
lower	O
standardized	O
tidal	O
volumes	O
in	O
the	O
ARDS	B-DISO
cohort	O
.	O

The	O
recognition	O
model	O
yielded	O
a	O
mean	O
(	O
99	O
%	O
confidence	O
interval	O
)	O
physician	O
recognition	O
of	O
ARDS	B-DISO
of	O
22	O
%	O
(	O
9	O
%-	O
42	O
%)	O
for	O
mild	O
,	O
34	O
%	O
(	O
19	O
%-	O
49	O
%)	O
for	O
moderate	O
,	O
and	O
67	O
%	O
(	O
41	O
%-	O
100	O
%)	O
for	O
severe	O
ARDS	B-DISO
.	O

At	O
ICU	O
discharge	O
,	O
all	O
patients	O
showed	O
RV	B-DISO
hypertrophy	I-DISO
.	O

However	O
,	O
additional	O
research	O
should	O
be	O
performed	O
to	O
elucidate	O
the	O
spectrum	O
of	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
the	O
genesis	O
of	O
RV	B-DISO
hypertrophy	I-DISO
.	O

Proteomic	O
analysis	O
was	O
then	O
conducted	O
to	O
assess	O
the	O
expression	O
dynamics	O
of	O
the	O
host	O
proteins	O
in	O
the	O
PDCoV	O
NS7	B-DISO
-	O
expressing	O
cells	O
.	O

Because	O
it	O
is	O
a	O
subclinical	B-DISO
infection	I-DISO
in	O
camels	O
,	O
epidemiological	O
measures	O
other	O
than	O
prevalence	O
are	O
challenging	O
to	O
assess	O
.	O

TITLE	O
:	O
Comorbid	O
diabetes	B-DISO
results	O
in	O
immune	O
dysregulation	O
and	O
enhanced	O
disease	O
severity	O
following	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Among	O
patients	O
who	O
had	O
a	O
response	O
to	O
induction	O
therapy	O
with	O
ustekinumab	O
and	O
underwent	O
a	O
second	O
randomization	O
,	O
the	O
percentage	O
of	O
patients	O
who	O
had	O
clinical	O
remission	B-DISO
at	O
week	O
44	O
was	O
significantly	O
higher	O
among	O
patients	O
assigned	O
to	O
90	O
mg	O
of	O
subcutaneous	O
ustekinumab	O
every	O
12	O
weeks	O
(	O
38	O
.	O
4	O
%)	O
or	O
every	O
8	O
weeks	O
(	O
43	O
.	O
8	O
%)	O
than	O
among	O
those	O
assigned	O
to	O
placebo	O
(	O
24	O
.	O
0	O
%)	O
(	O
P	O
=	O
0	O
.	O
002	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

TITLE	O
:	O
Risk	O
of	O
Introduction	O
of	O
Infectious	B-DISO
Animal	B-DISO
Diseases	I-DISO
for	O
Europe	O
Based	O
on	O
the	O
Health	O
Situation	O
of	O
North	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	O
.	O

Risk	O
analysis	O
is	O
the	O
tool	O
that	O
allows	O
the	O
identification	O
of	O
the	O
factors	O
involved	O
in	O
the	O
introduction	O
and	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
results	O
show	O
that	O
,	O
among	O
the	O
infectious	B-DISO
diseases	I-DISO
analyzed	O
in	O
this	O
study	O
,	O
avian	B-DISO
influenza	I-DISO
and	O
Newcastle	B-DISO
disease	I-DISO
are	O
the	O
ones	O
with	O
a	O
higher	O
risk	O
of	O
entry	O
in	O
the	O
European	O
Union	O
and	O
the	O
wild	O
bird	O
'	O
s	O
migration	O
is	O
the	O
route	O
with	O
greater	O
impact	O
.	O

A	O
model	O
of	O
vectors	O
dispersion	O
in	O
wind	B-DISO
currents	O
has	O
been	O
established	O
to	O
assess	O
the	O
risk	O
of	O
introduction	O
of	O
vector	O
borne	O
diseases	O
.	O

(	O
47	O
.	O
6	O
%),	O
Clostridium	O
perfringens	O
(	O
81	O
.	O
3	O
%),	O
Giardia	B-DISO
spp	O
.	O

ABSTRACT	O
:	O
Human	O
infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
poses	O
an	O
ongoing	O
threat	O
to	O
public	O
health	O
worldwide	O
.	O

ABSTRACT	O
:	O
An	O
immunocompetent	O
adult	O
with	O
asthma	B-DISO
developed	O
severe	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
illness	O
complicated	O
by	O
group	O
A	O
Streptococcus	O
coinfection	B-DISO
,	O
progressing	O
to	O
ARDS	B-DISO
and	O
shock	O
.	O

Ten	O
out	O
of	O
75	O
children	O
contracted	O
severe	O
infections	B-DISO
(	O
PVL	O
-	O
methicillin	O
resistant	O
S	O
aureus	O
n	O
=	O
4	O
)	O
including	O
necrotizing	B-DISO
pneumonia	I-DISO
(	O
n	O
=	O
4	O
),	O
necrotizing	B-DISO
fasciitis	I-DISO
(	O
n	O
=	O
2	O
),	O
pyomyositis	B-DISO
(	O
n	O
=	O
2	O
;	O
including	O
1	O
patient	O
who	O
also	O
had	O
pneumonia	B-DISO
),	O
mastoiditis	B-DISO
with	O
cerebellitis	B-DISO
(	O
n	O
=	O
1	O
),	O
preorbital	O
cellulitis	B-DISO
(	O
n	O
=	O
1	O
),	O
and	O
recurrent	O
deep	O
furunculosis	B-DISO
in	O
an	O
immunosuppressed	O
patient	O
(	O
n	O
=	O
1	O
).	O

ABSTRACT	O
:	O
This	O
study	O
will	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
blood	O
purification	O
(	O
BP	O
)	O
for	O
severe	O
pancreatitis	B-DISO
(	O
SP	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

To	O
determine	O
the	O
effect	O
of	O
intravenous	O
vitamin	O
C	O
infusion	O
on	O
organ	B-DISO
failure	I-DISO
scores	O
and	O
biological	O
markers	O
of	O
inflammation	B-DISO
and	O
vascular	O
injury	O
in	O
patients	O
with	O
sepsis	B-DISO
and	O
ARDS	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
report	O
our	O
findings	O
on	O
identifying	O
the	O
alterations	O
of	O
host	O
cell	O
innate	B-DISO
immune	I-DISO
response	I-DISO
affected	O
by	O
PDCoV	O
infection	B-DISO
and	O
exploring	O
the	O
gene	O
expression	O
profiles	O
of	O
PK	O
-	O
15	O
cells	O
at	O
0	O
,	O
24	O
,	O
and	O
36	O
h	O
PDCoV	O
post	O
infection	B-DISO
by	O
RNA	O
sequencing	O
.	O

Pig	O
infection	B-DISO
studies	O
showed	O
that	O
the	O
P7	O
strain	O
caused	O
typical	O
watery	B-DISO
diarrhea	I-DISO
,	O
while	O
the	O
P83	O
strain	O
induced	O
none	O
-	O
to	O
-	O
mild	O
,	O
delayed	O
and	O
transient	O
diarrhea	B-DISO
.	O

High	O
-	O
titre	O
anti	O
-	O
influenza	B-DISO
plasma	O
conferred	O
no	O
significant	O
benefit	O
over	O
non	O
-	O
immune	O
plasma	O
.	O

Our	O
previous	O
study	O
revealed	O
a	O
potential	O
correlation	O
between	O
integrin	O
αvβ3	O
and	O
PEDV	O
infection	B-DISO
.	O

We	O
have	O
previously	O
reported	O
the	O
synthesis	O
of	O
potent	O
coronavirus	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
inhibitors	O
and	O
the	O
efficacy	O
of	O
a	O
protease	O
inhibitor	O
,	O
GC376	O
,	O
in	O
client	O
-	O
owned	O
cats	O
with	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Diarrhea	B-DISO
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
neonatal	O
mortality	O
in	O
pigs	O
.	O

In	O
conclusion	O
,	O
the	O
large	O
diversity	O
of	O
agent	O
combinations	O
and	O
disease	O
situations	O
detected	O
in	O
neonatal	B-DISO
diarrhea	I-DISO
outbreaks	O
of	O
this	O
study	O
stand	O
for	O
a	O
more	O
personalized	O
diagnosis	O
and	O
management	O
advice	O
at	O
a	O
farm	O
level	O
.	O

CONCLUSIONS	O
:	O
Our	O
modeling	O
results	O
informed	O
by	O
historic	O
outbreak	O
data	O
for	O
SARS	B-DISO
and	O
MERS	O
suggest	O
that	O
vaccination	O
strategies	O
targeting	O
patients	O
could	O
be	O
an	O
effective	O
measure	O
to	O
mitigate	O
and	O
prevent	O
outbreaks	O
in	O
the	O
healthcare	O
setting	O
.	O

Pre	O
-	O
exanthem	B-DISO
transmission	O
of	O
measles	B-DISO
from	O
airport	O
staff	O
to	O
HCWs	O
with	O
secondary	O
vaccine	O
failure	O
poses	O
a	O
grave	O
challenge	O
to	O
hospital	B-DISO
infection	I-DISO
control	O
.	O

CONCLUSIONS	O
:	O
Despite	O
good	O
herd	O
immunity	O
with	O
overall	O
seroprevalence	O
of	O
>	O
95	O
%	O
against	O
measles	B-DISO
,	O
major	O
outbreaks	O
of	O
measles	B-DISO
occurred	O
among	O
HKIA	O
staff	O
having	O
daily	O
contact	O
with	O
many	O
international	O
pssengers	O
.	O

TGEV	O
infection	B-DISO
provokes	O
mitochondrial	B-DISO
damage	I-DISO
of	O
porcine	O
intestinal	O
epthelial	O
cell	O
(	O
IPEC	O
),	O
which	O
is	O
responsible	O
for	O
inflammation	B-DISO
and	O
cell	O
death	O
.	O

Mitochondrial	O
permeability	O
transition	B-DISO
pore	O
(	O
mPTP	O
)	O
opening	O
is	O
a	O
key	O
reason	O
for	O
mitochondrial	B-DISO
damage	I-DISO
.	O

TITLE	O
:	O
Isolation	O
and	O
growth	O
characterization	O
of	O
novel	O
full	O
length	O
and	O
deletion	O
mutant	B-DISO
human	O
MERS	O
-	O
CoV	O
strains	O
from	O
clinical	O
specimens	O
collected	O
during	O
2015	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
serves	O
multiple	O
functions	O
in	O
viral	O
replication	O
,	O
transcription	O
,	O
and	O
assembly	O
of	O
the	O
viral	O
genome	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
novel	O
in	O
vivo	O
cell	O
-	O
based	O
assay	O
for	O
examining	O
this	O
interaction	O
between	O
the	O
N	O
-	O
protein	O
and	O
packaging	O
signal	O
RNA	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
as	O
well	O
as	O
other	O
viruses	O
within	O
the	O
coronaviridae	O
family	O
.	O

A	O
31	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
due	O
to	O
high	O
fever	O
,	O
continuous	O
uterine	O
contractions	B-DISO
and	O
fetal	B-DISO
bradycardia	I-DISO
at	O
31	O
weeks	O
of	O
gestation	O
.	O

The	O
patient	O
was	O
freed	O
from	O
V	O
-	O
A	O
ECMO	O
on	O
the	O
5th	O
day	O
and	O
was	O
discharged	O
on	O
the	O
25th	O
day	O
without	O
permanent	O
impairment	B-DISO
.	O

ABSTRACT	O
:	O
In	O
Brazil	O
the	O
implementation	O
of	O
the	O
Sentinel	O
Surveillance	O
System	O
of	O
Influenza	B-DISO
began	O
in	O
2000	O
.	O

ABSTRACT	O
:	O
Various	O
objective	O
scoring	O
systems	O
were	O
developed	O
to	O
standardize	O
the	O
approach	O
to	O
the	O
designation	O
of	O
severity	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
).	O

Treatment	O
is	O
focused	O
on	O
withdrawal	B-DISO
of	O
medication	O
,	O
supportive	O
care	O
and	O
immunosuppression	O
such	O
as	O
high	O
-	O
dose	O
corticosteroid	O
therapy	O
.	O

Other	O
causes	O
of	O
hypereosinophilia	B-DISO
were	O
normal	O
.	O

Given	O
the	O
widespread	O
prevalence	O
,	O
a	O
general	O
lack	O
of	O
natural	O
sterilizing	O
immunity	O
,	O
and	O
/	O
or	O
high	O
morbidity	O
and	O
lethality	O
rates	O
of	O
diseases	O
caused	O
by	O
influenza	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
coronaviruses	O
,	O
and	O
rhinoviruses	O
,	O
this	O
difficult	O
situation	O
is	O
a	O
genuine	O
societal	O
challenge	O
.	O

Many	O
,	O
if	O
not	O
all	O
,	O
viruses	O
,	O
including	O
the	O
respiratory	O
viruses	O
listed	O
above	O
,	O
suppress	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
to	O
gain	O
a	O
window	O
of	O
opportunity	O
for	O
efficient	O
virus	O
replication	O
and	O
setting	O
-	O
up	O
of	O
the	O
infection	B-DISO
.	O

Subsequently	O
,	O
viral	O
enzymatic	O
activities	O
that	O
suppress	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
will	O
be	O
discussed	O
,	O
including	O
activities	O
causing	O
host	O
shut	O
-	O
off	O
and	O
manipulation	O
of	O
stress	O
granule	O
formation	O
.	O

By	O
surfactant	O
treatment	O
and	O
mechanical	O
extrusion	O
using	O
S	O
protein	O
-	O
or	O
three	O
structural	O
protein	O
-	O
expressing	O
Bm5	O
cells	O
,	O
S	O
protein	O
-	O
displaying	O
nanovesicles	O
with	O
diameters	O
of	O
approximately	O
100	O
-	O
200	O
nm	O
were	O
prepared	O
and	O
confirmed	O
by	O
immuno	O
-	O
TEM	B-DISO
.	O

We	O
also	O
demonstrate	O
the	O
utility	O
of	O
employing	O
multiple	O
network	O
approaches	O
for	O
analyzing	O
host	O
response	O
data	O
from	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Peripheral	O
blood	O
leukocyte	O
telomere	O
length	O
is	O
associated	O
with	O
survival	O
of	O
sepsis	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Shorter	O
peripheral	O
blood	O
leukocyte	O
(	O
PBL	O
)	O
telomere	O
length	O
(	O
TL	O
)	O
has	O
been	O
associated	O
with	O
poor	O
outcomes	O
in	O
various	O
chronic	O
lung	B-DISO
diseases	I-DISO
.	O

She	O
developed	O
very	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
which	O
was	O
treated	O
with	O
rescue	O
high	O
-	O
frequency	O
oscillation	O
),	O
hemodynamic	B-DISO
instability	I-DISO
,	O
acute	O
kidney	O
injury	O
,	O
rhabdomyolysis	B-DISO
,	O
and	O
remained	O
comatose	B-DISO
with	O
a	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
of	O
3	O
and	O
gasping	B-DISO
respirations	O
for	O
67	O
hours	O
(	O
when	O
the	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
improved	O
to	O
6	O
,	O
with	O
tachypnea	B-DISO
to	O
Paco	O

TITLE	O
:	O
Immune	O
Predictors	O
of	O
Mortality	O
After	O
Ribonucleic	O
Acid	O
Virus	B-DISO
Infection	I-DISO
.	O

We	O
demonstrate	O
how	O
pathogen	O
transmissibility	O
can	O
be	O
inferred	O
appropriately	O
using	O
datasets	O
from	O
outbreaks	O
of	O
H1N1	B-DISO
influenza	I-DISO
,	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
and	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	B-DISO
.	O

We	O
present	O
a	O
tool	O
for	O
estimating	O
the	O
reproduction	O
number	O
in	O
real	O
-	O
time	O
during	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
accurately	O
,	O
which	O
is	O
available	O
as	O
an	O
R	O
software	O
package	O
(	O
EpiEstim	O
2	O
.	O
2	O
).	O

""""	O
Elucidation	O
of	O
better	O
biomarkers	O
to	O
determine	O
the	O
underlying	O
pathogenic	O
phenotype	O
will	O
significantly	O
advance	O
our	O
understanding	O
and	O
prediction	O
of	O
which	O
critically	B-DISO
ill	I-DISO
patients	O
will	O
benefit	O
from	O
GC	O
and	O
who	O
would	O
experience	O
a	O
deleterious	O
effect	O
from	O
its	O
use	O
.	O

Therefore	O
,	O
a	O
need	O
exists	O
for	O
a	O
safer	O
and	O
more	O
effective	O
method	O
of	O
oxygenation	O
for	O
patients	O
with	O
ARDS	B-DISO
.	O

In	O
this	O
work	O
,	O
the	O
feasibility	O
of	O
using	O
intraperitoneal	O
perfusions	O
of	O
oxygen	O
microbubbles	O
-	O
peritoneal	O
microbubble	O
oxygenation	O
(	O
PMO	O
)-	O
to	O
treat	O
lipopolysaccharide	O
-	O
induced	O
ARDS	B-DISO
was	O
explored	O
with	O
the	O
objective	O
of	O
showing	O
restoration	O
of	O
normoxic	O
conditions	O
after	O
a	O
single	O
bolus	O
infusion	O
of	O
oxygen	O
microbubbles	O
.	O

While	O
overexpression	O
of	O
GILT	O
inhibited	O
the	O
entry	O
mediated	O
by	O
envelope	O
glycoproteins	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
and	O
Lassa	B-DISO
fever	I-DISO
virus	O
(	O
LASV	O
),	O
depletion	O
of	O
GILT	O
enhanced	O
the	O
entry	O
mediated	O
by	O
these	O
viral	O
envelope	O
glycoproteins	O
.	O

On	O
the	O
basis	O
of	O
its	O
success	O
in	O
that	O
population	O
,	O
ECMO	O
began	O
to	O
be	O
used	O
in	O
the	O
early	O
1970s	O
to	O
treat	O
adult	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

Adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
often	O
the	O
final	O
common	O
pathway	O
of	O
various	O
pathologies	O
affecting	O
adults	O
and	O
causing	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

No	O
specific	O
therapy	O
for	O
ARDS	B-DISO
has	O
been	O
found	O
,	O
and	O
current	O
care	O
is	O
supportive	O
,	O
primarily	O
by	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
this	O
report	O
is	O
to	O
analyze	O
and	O
summarize	O
the	O
current	O
literature	O
of	O
ischemic	B-DISO
optic	I-DISO
neuropathy	I-DISO
(	O
ION	O
),	O
a	O
rare	O
complication	B-DISO
in	O
severe	O
burn	O
and	O
trauma	O
victims	O
,	O
while	O
presenting	O
an	O
urban	O
burn	O
center	O
'	O
s	O
experience	O
with	O
the	O
condition	B-DISO
.	O

A	O
fundoscopic	O
examination	O
demonstrated	O
bilateral	O
pale	B-DISO
optic	O
nerves	O
with	O
sparing	O
of	O
the	O
remaining	O
peripheral	O
retina	O
consistent	O
with	O
ION	O
.	O

He	O
had	O
multiple	O
factors	O
that	O
could	O
have	O
instigated	O
the	O
development	O
of	O
ION	O
,	O
including	O
several	O
episodes	O
of	O
septicemia	B-DISO
,	O
hypovolemic	B-DISO
shock	I-DISO
and	O
severe	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
refractory	O
hypoxemia	O
requiring	O
a	O
prolong	O
ventilation	O
support	O
and	O
vasopressor	O
therapy	O
.	O

In	O
this	O
work	O
,	O
the	O
antiviral	O
activity	O
of	O
seven	O
different	O
carbon	O
quantum	O
dots	O
(	O
CQDs	O
)	O
for	O
the	O
treatment	O
of	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
infections	B-DISO
was	O
investigated	O
.	O

We	O
estimated	O
associations	O
between	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
outcome	O
using	O
generalized	O
linear	O
Poisson	O
regression	O
adjusted	O
for	O
age	O
,	O
injury	O
mechanism	O
,	O
Injury	O
Severity	O
Score	O
,	O
and	O
serious	O
brain	O
and	O
chest	O
injuries	O
.	O

Among	O
survivors	O
,	O
77	O
.	O
1	O
%	O
of	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
had	O
functional	O
disability	O
at	O
discharge	O
versus	O
30	O
.	O
7	O
%	O
of	O
patients	O
without	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
only	O
17	O
.	O
5	O
%	O
of	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
discharged	O
home	O
without	O
ongoing	O
care	O
versus	O
86	O
.	O
4	O
%	O
of	O
patients	O
without	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
adjusted	O
relative	O
risk	O
,	O
1	O
.	O
5	O
;	O
1	O
.	O
1	O
-	O
2	O
.	O
1	O
).	O

We	O
further	O
show	O
the	O
inhibitory	O
potential	O
of	O
non	O
-	O
immunosuppressive	O
CsA	B-DISO
derivatives	O
Alisporivir	O
,	O
NIM811	O
,	O
compound	O
3	O
on	O
HCoV	O
-	O
229E	O
-	O
GFP	O
and	O
-	O
Luciferase	O
replication	O
in	O
human	O
Huh	O
-	O
7	O
.	O
5	O
hepatoma	B-DISO
cells	O
at	O
18	O
and	O
48	O
h	O
time	O
points	O
post	O
infection	B-DISO
with	O
EC	O

TITLE	O
:	O
Midaortic	O
Syndrome	B-DISO
due	O
to	O
Takayasu	B-DISO
Arteritis	I-DISO
in	O
a	O
Child	O
with	O
Acute	O
Decompensated	B-DISO
Cardiac	I-DISO
Failure	I-DISO
Managed	O
by	O
an	O
Emergency	B-DISO
Axillo	O
-	O
External	O
Iliac	O
Artery	O
Bypass	O
:	O

Incidences	O
of	O
5	O
chicken	O
respiratory	O
viruses	O
:	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
),	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
/	O
AAVV	O
-	O
1	O
),	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
avian	O
metapneumovirus	O
(	O
aMPV	O
)	O
and	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
(	O
ILTV	O
)	O
were	O
assessed	O
on	O
commercial	O
Pakistani	O
farms	O
with	O
respiratory	B-DISO
problems	I-DISO
from	O
2014	O
through	O
to	O
2016	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
with	O
AIV	O
and	O
AAVV	O
-	O
1	O
were	O
common	O
and	O
wild	O
type	O
AAVV	O
-	O
1	O
was	O
detected	O
despite	O
the	O
use	O
of	O
vaccines	O
.	O

The	O
BCoV	O
antigen	O
distribution	O
was	O
prominent	O
within	O
the	O
necrotic	O
crypts	O
in	O
the	O
jejunum	O
and	O
cryptic	O
micro	O
-	O
abscesses	B-DISO
in	O
the	O
colon	O
and	O
ileum	O
.	O

CONCLUSIONS	O
:	O
Hospital	O
mortality	O
was	O
25	O
%;	O
septic	B-DISO
shock	I-DISO
/	O
organ	B-DISO
failure	I-DISO
at	O
admittance	O
was	O
a	O
significant	O
predictor	O
of	O
mortality	O
.	O

TITLE	O
:	O
LiverTox	O
:	O
Clinical	O
and	O
Research	O
Information	O
on	O
Drug	B-DISO
-	I-DISO
Induced	I-DISO
Liver	I-DISO
Injury	I-DISO
ABSTRACT	O
:	O
The	O
opioids	O
are	O
a	O
large	O
class	O
of	O
medications	O
related	O
in	O
structure	O
to	O
the	O
natural	O
plant	O
alkaloids	O
found	O
in	O
opium	O
that	O
are	O
derived	O
from	O
the	O
resin	O
of	O
the	O
opium	O
poppy	O
,	O
Papaver	O
somniferum	O
.	O

Opioids	O
also	O
have	O
direct	O
cardiovascular	O
effects	O
,	O
decreasing	O
blood	O
pressure	O
,	O
causing	O
vasodilation	B-DISO
and	O
decreasing	O
cardiac	O
work	O
.	O

These	O
agents	O
(	O
naldemedine	O
,	O
naloxegol	O
)	O
are	O
generally	O
modified	O
so	O
as	O
not	O
to	O
cross	O
the	O
blood	O
brain	O
and	O
reverse	O
the	O
central	O
nervous	B-DISO
system	O
effects	O
of	O
opiates	B-DISO
.	O

If	O
taken	O
too	O
frequently	O
,	O
acetaminophen	O
doses	O
may	O
reach	O
toxic	O
levels	O
,	O
particularly	O
with	O
overuse	O
for	O
several	O
days	O
in	O
the	O
face	B-DISO
of	O
malnutrition	B-DISO
,	O
alcohol	B-DISO
abuse	I-DISO
or	O
intercurrent	O
illness	O
.	O

References	O
to	O
the	O
opioids	O
and	O
the	O
opiate	O
antagonists	O
used	O
to	O
treat	O
substance	B-DISO
abuse	I-DISO
are	O
given	O
separately	O
with	O
each	O
agent	O
(	O
buprenorphine	O
,	O
methadone	O
,	O
nalmefene	O
,	O
naloxone	O
,	O
naltrexone	O
).	O

The	O
injury	O
is	O
usually	O
mild	O
-	O
to	O
-	O
moderate	O
in	O
severity	O
,	O
although	O
fatal	O
cases	O
of	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
have	O
been	O
described	O
,	O
and	O
there	O
have	O
been	O
several	O
reports	O
of	O
vanishing	B-DISO
bile	I-DISO
duct	I-DISO
syndrome	I-DISO
or	O
prolonged	O
cholestasis	B-DISO
following	O
amoxicillin	O
or	O
ampicillin	O
related	O
cholestatic	O
liver	O
injury	O
.	O

Amoxicillin	O
/	O
clavulanate	O
is	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
of	O
drug	B-DISO
induced	I-DISO
liver	I-DISO
disease	I-DISO
,	O
but	O
the	O
liver	O
injury	O
is	O
usually	O
attributed	O
to	O
the	O
clavulanate	O
rather	O
than	O
the	O
aminopenicillin	O
,	O
and	O
the	O
pattern	O
of	O
injury	O
may	O
be	O
slightly	O
different	O
than	O
that	O
described	O
with	O
penicillin	O
,	O
ampicillin	O
and	O
amoxicillin	O
alone	O
.	O

Exacerbations	O
are	O
major	O
contributors	O
to	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
),	O
and	O
respiratory	O
bacterial	O
and	O
viral	B-DISO
infections	I-DISO
are	O
an	O
important	O
trigger	O
.	O

To	O
study	O
the	O
respiratory	O
virome	O
in	O
nasopharyngeal	O
samples	O
during	O
COPD	B-DISO
exacerbations	O
using	O
mNGS	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
IBV	O
-	O
induced	O
neural	O
symptoms	O
in	O
chickens	O
with	O
encephalitis	B-DISO
and	O
the	O
furin	O
-	O
S2	O
'	O
site	O
as	O
a	O
determinant	O
of	O
neurotropism	B-DISO
.	O

Characterization	O
of	O
the	O
different	O
passages	O
revealed	O
that	O
compared	O
with	O
P10	O
and	O
P64	O
,	O
P120	O
had	O
a	O
higher	O
viral	O
titer	O
and	O
more	O
obvious	O
cytopathic	B-DISO
effects	I-DISO
,	O
thereby	O
demonstrating	O
better	O
cell	O
adaptability	O
.	O

ABSTRACT	O
:	O
Despite	O
the	O
use	O
of	O
lung	O
protective	O
ventilation	O
(	O
LPV	O
)	O
strategies	O
,	O
a	O
severe	O
form	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
unfortunately	O
associated	O
with	O
high	O
mortality	O
rates	O
,	O
which	O
sometimes	O
exceed	O
60	O
%.	O

TITLE	O
:	O
Pulmonary	O
Manifestations	O
of	O
Drug	O
Reaction	O
with	O
Eosinophilia	B-DISO
and	O
Systemic	O
Symptoms	O
(	O
DRESS	O
)	O
Syndrome	B-DISO
:	O
A	O
Systematic	O
Review	O
.	O

Symptoms	O
of	O
cough	B-DISO
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
SOB	O
)	O
were	O
present	O
in	O
72	O
%	O
of	O
patients	O
at	O
the	O
time	O
of	O
presentation	O
.	O

SOB	O
was	O
the	O
more	O
common	O
presenting	O
symptom	B-DISO
(	O
81	O
%)	O
compared	O
to	O
cough	B-DISO
(	O
19	O
%).	O

The	O
main	O
mode	O
of	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
through	O
inhalation	O
of	O
respiratory	O
droplets	O
.	O

Strict	O
infection	B-DISO
control	O
procedures	O
with	O
respiratory	O
and	O
contact	O
precautions	O
are	O
essential	O
.	O

Person	O
-	O
to	O
-	O
person	O
spread	O
causes	O
hospital	O
and	O
household	O
outbreaks	O
,	O
and	O
thus	O
improved	O
compliance	O
with	O
internationally	O
recommended	O
infection	B-DISO
control	O
protocols	O
and	O
rapid	O
implementation	O
of	O
infection	B-DISO
control	O
measures	O
are	O
required	O
.	O

TITLE	O
:	O
Detecting	O
Emerging	B-DISO
Infectious	I-DISO
Diseases	I-DISO
:	O
An	O
Overview	O
of	O
the	O
Laboratory	O
Response	O
Network	O
for	O
Biological	O
Threats	O
.	O

Many	O
differentially	O
expressed	O
lncRNAs	O
act	O
as	O
elements	O
to	O
competitively	O
attach	O
microRNAs	O
(	O
miRNAs	O
)	O
which	O
target	O
to	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
to	O
mediate	O
expression	O
of	O
genes	O
that	O
related	O
to	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
),	O
NOD	B-DISO
-	O
like	O
receptors	O
(	O
NLRs	O
),	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
),	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
pathways	O
.	O

On	O
day	O
7	O
after	O
treatment	O
,	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
6	O
,	O
CRP	O
and	O
CD8	O
CONCLUSIONS	O
:	O
EFR	O
can	O
effectively	O
eliminate	O
inflammatory	O
factors	O
,	O
improve	O
immune	O
function	O
,	O
maintain	O
the	O
stability	O
of	O
blood	O
components	O
,	O
reduce	O
the	O
incidences	O
of	O
ARDS	B-DISO
and	O
MODS	B-DISO
,	O
and	O
elevate	O
the	O
successful	O
rescue	O
rate	O
in	O
patients	O
with	O
SPF	O
.	O

The	O
most	O
common	O
pathogens	O
in	O
dogs	O
with	O
UMRD	O
were	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
canine	O
coronavirus	O
,	O
canine	O
parvovirus	B-DISO
2	O
,	O
and	O
Detection	O
of	O
nucleic	O
acids	O
from	O
selected	O
cardiotropic	O
pathogens	O
in	O
myocardial	O
tissue	O
from	O
dogs	O
with	O
UMRD	O
suggested	O
a	O
possible	O
association	O
between	O
the	O
2	O
.	O

The	O
most	O
common	O
pathogens	O
in	O
dogs	O
with	O
UMRD	O
were	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
canine	O
coronavirus	O
,	O
canine	O
parvovirus	B-DISO
2	O
,	O
and	O

In	O
this	O
unconventional	O
approach	O
,	O
a	O
fine	O
-	O
tuning	O
of	O
the	O
dihedral	O
angle	O
between	O
the	O
C4	O
phenyl	O
and	O
the	O
dihydropyrimidine	O
core	O
of	O
the	O
heteroaryldihydropyrimidine	O
(	O
HAP	O
)	O
class	O
of	O
capsid	O
inhibitors	O
successfully	O
altered	O
the	O
structure	O
-	O
activity	O
-	O
relationships	O
(	O
SARs	B-DISO
)	O
of	O
the	O
unwanted	O
CYP3A4	O
induction	O
and	O
the	O
desired	O
HBV	B-DISO
capsid	O
inhibition	O
to	O
more	O
favorable	O
values	O
.	O

It	O
infects	O
pigs	O
of	O
all	O
ages	O
,	O
and	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
high	O
mortality	O
rates	O
in	O
newborn	O
pigs	O
,	O
leading	O
to	O
devastating	O
economic	O
losses	O
in	O
the	O
pork	O
industry	O
worldwide	O
.	O

We	O
previously	O
developed	O
potent	O
fully	O
human	O
monoclonal	O
antibodies	O
and	O
inhibitory	O
peptides	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
novel	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
illness	O
with	O
high	O
mortality	O
.	O

The	O
findings	O
of	O
this	O
study	O
will	O
support	O
the	O
development	O
of	O
vaccines	O
against	O
severe	O
pneumonia	B-DISO
-	O
associated	O
coronaviruses	O
.	O

TITLE	O
:	O
Epidemiological	O
status	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
2019	O
:	O
an	O
update	O
from	O
January	O
1	O
to	O
March	O
31	O
,	O
2019	O
.	O

ABSTRACT	O
:	O
This	O
study	O
represents	O
the	O
current	O
epidemiological	O
status	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
worldwide	O
in	O
the	O
first	O
three	O
months	O
of	O
2019	O
.	O

TITLE	O
:	O
The	O
Porcine	O
Deltacoronavirus	O
Replication	O
Organelle	O
Comprises	O
Double	O
-	O
Membrane	O
Vesicles	B-DISO
and	O
Zippered	O
Endoplasmic	O
Reticulum	O
with	O
Double	O
-	O
Membrane	O
Spherules	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infects	O
ciliated	O
epithelial	O
cells	O
in	O
the	O
chicken	O
respiratory	O
tract	O
.	O

While	O
removal	O
of	O
sialic	O
acids	O
from	O
tissues	O
prevented	O
binding	O
of	O
all	O
proteins	O
to	O
all	O
tissues	O
,	O
binding	O
of	O
QX	O
-	O
RBD	O
to	O
trachea	B-DISO
and	O
kidney	O
could	O
not	O
be	O
blocked	O
by	O
preincubation	O
with	O
synthetic	O
alpha	O
-	O
2	O
,	O
3	O
-	O
linked	O
sialic	O
acids	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
burn	O
patients	O
:	O
a	O
case	O
series	O
and	O
literature	O
update	O
.	O

The	O
use	O
and	O
experience	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
burn	O
patients	O
developing	O
ARDS	B-DISO
are	O
still	O
limited	O
.	O

A	O
retrospective	O
analysis	O
of	O
burn	O
patients	O
treated	O
with	O
ECMO	O
for	O
ARDS	B-DISO
between	O
January	O
2017	O
and	O
January	O
2019	O
was	O
performed	O
.	O

Larger	O
studies	O
will	O
allow	O
for	O
distinguishing	O
between	O
sequential	O
and	O
simultaneous	O
infection	B-DISO
and	O
for	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
each	O
virus	O
during	O
the	O
evolution	O
of	O
acute	O
respiratory	O
episodes	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
treatment	O
option	O
considered	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
who	O
are	O
refractory	O
to	O
conventional	O
treatments	O
.	O

Hospital	O
stay	O
and	O
hospital	O
-	O
acquired	O
infections	B-DISO
were	O
the	O
same	O
between	O
the	O
groups	O
.	O

TITLE	O
:	O
Epitope	O
-	O
based	O
peptide	O
vaccine	O
design	O
and	O
target	O
site	O
depiction	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
:	O
an	O
immune	O
-	O
informatics	O
study	O
.	O

This	O
infectious	B-DISO
single	O
-	O
stranded	O
,	O
positive	O
(+)	O
sense	O
RNA	O
virus	O
enters	O
the	O
host	O
by	O
binding	O
to	O
dipeptidyl	O
-	O
peptide	O
receptors	O
.	O

High	O
-	O
resolution	O
computed	O
tomography	O
of	O
the	O
chest	O
demonstrated	O
bilateral	O
patchy	O
ground	O
-	O
glass	O
opacities	B-DISO
and	O
infiltrative	O
shadows	O
.	O

We	O
initiated	O
the	O
administration	O
of	O
cyclosporin	O
A	O
and	O
therapeutic	O
plasma	O
exchange	O
(	O
TPE	O
),	O
but	O
his	O
respiratory	O
condition	B-DISO
did	O
not	O
improve	O
satisfactorily	O
.	O

Patients	O
with	O
normal	O
immune	O
system	O
may	O
have	O
an	O
asymptomatic	O
course	O
or	O
clinical	O
presentation	O
such	O
as	O
acute	O
watery	B-DISO
diarrhea	I-DISO
without	O
blood	O
and	O
persistent	B-DISO
diarrhea	I-DISO
.	O

Cryptosporidium	O
spp	O
.	O
may	O
cause	O
asymptomatic	B-DISO
infection	I-DISO
,	O
mild	O
diarrheal	B-DISO
disease	I-DISO
or	O
severe	B-DISO
diarrhea	I-DISO
with	O
high	O
volume	O
,	O
which	O
may	O
be	O
accompanied	O
by	O
nausea	B-DISO
,	O
vomiting	B-DISO
,	O
abdominal	B-DISO
pain	I-DISO
and	O
fever	O
,	O
following	O
a	O
1	O
-	O
7	O
day	O
incubation	O
period	O
.	O

Hepatobiliary	O
involvement	O
is	O
not	O
expected	O
in	O
patients	O
without	O
immunodeficiency	B-DISO
.	O

We	O
would	O
like	O
to	O
emphasize	O
that	O
Cryptosporodium	O
spp	O
.	O
may	O
be	O
the	O
cause	O
of	O
severe	O
acute	B-DISO
diarrhea	I-DISO
in	O
non	O
-	O
immunocompromised	O
patients	O
and	O
may	O
also	O
involve	O
hepatobiliary	O
system	O
involvement	O
.	O

In	O
a	O
prospective	O
investigation	O
we	O
searched	O
the	O
presence	O
of	O
DNA	O
from	O
5	O
herpes	B-DISO
viruses	O
(	O
HSV	O
-	O
1	O
,	O
HSV	O
-	O
2	O
,	O
VZV	O
,	O
EBV	O
and	O
HHV6	O
)	O
in	O
CSF	O
and	O
blood	O
lymphocytes	O
from	O
54	O
patients	O
with	O
ON	O
,	O
patients	O
were	O
followed	O
62	O
±	O
3	O
months	O
;	O
those	O
who	O
developed	O
MS	O
were	O
separated	O
from	O
those	O
with	O
ephemeral	O
ON	O
.	O

The	O
symptomatology	O
was	O
dominated	O
by	O
:	O
fever	O
(	O
100	O
%),	O
cough	B-DISO
(	O
83	O
%),	O
and	O
chest	B-DISO
pain	I-DISO
(	O
79	O
%).	O

TITLE	O
:	O
Changes	O
of	O
Extravascular	O
Lung	O
Water	O
as	O
an	O
Independent	O
Prognostic	O
Factor	O
for	O
Early	O
Developed	O
ARDS	B-DISO
in	O
Severely	O
Burned	O
Patients	O
.	O

Although	O
ARDS	B-DISO
is	O
known	O
as	O
an	O
early	O
,	O
common	O
,	O
and	O
life	O
-	O
threatening	O
complication	B-DISO
in	O
major	O
burns	O
,	O
the	O
issue	O
of	O
whether	O
or	O
how	O
the	O
EVLW	O
index	O
(	O
EVLWI	O
)	O
correlates	O
with	O
its	O
prognosis	O
has	O
not	O
been	O
identified	O
yet	O
.	O

ABSTRACT	O
:	O
We	O
hypothesized	O
that	O
the	O
recent	O
change	O
of	O
sepsis	B-DISO
definition	O
by	O
sepsis	B-DISO
-	O
3	O
would	O
facilitate	O
the	O
measurement	O
of	O
timing	O
of	O
sepsis	B-DISO
for	O
trauma	O
patients	O
presenting	O
with	O
initial	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
.	O

Because	O
of	O
pulmonary	B-DISO
hemorrhage	I-DISO
during	O
ECMO	O
support	O
,	O
heparin	O
was	O
stopped	O
for	O
3	O
days	O
and	O
then	O
restarted	O
.	O

In	O
the	O
most	O
severe	O
forms	O
of	O
the	O
syndrome	B-DISO
,	O
extracorporeal	O
life	O
support	O
is	O
increasingly	O
being	O
deployed	O
for	O
severe	O
hypoxemia	O
or	O
hypercapnic	B-DISO
acidosis	I-DISO
refractory	O
to	O
conventional	O
ventilator	O
management	O
strategies	O
.	O

The	O
most	O
SEYLL	O
related	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
was	O
in	O
the	O
early	O
four	O
years	O
of	O
the	O
onset	O
of	O
the	O
pandemic	O
(	O
2012	O
to	O
2015	O
)	O
and	O
in	O
the	O
last	O
four	O
years	O
of	O
the	O
MERS	O
-	O
CoV	O
pandemic	O
(	O
216	O
to	O
2019	O
),	O
a	O
significant	O
reduction	O
was	O
observed	O
in	O
the	O
SEYLL	O
related	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
the	O
MERS	O
patients	O
.	O

We	O
report	O
an	O
8	O
-	O
month	O
-	O
old	O
boy	O
,	O
who	O
presented	O
with	O
recurrent	B-DISO
fever	I-DISO
,	O
mild	O
to	O
moderate	O
anemia	B-DISO
,	O
and	O
severe	O
neutropenia	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
been	O
known	O
to	O
occur	O
in	O
children	O
since	O
early	O
descriptions	O
of	O
the	O
disease	O
,	O
but	O
pediatric	O
specific	O
diagnostic	O
criteria	O
were	O
first	O
established	O
in	O
2015	O
with	O
the	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
(	O
PALICC	O
)	O
definition	O
of	O
pediatric	O
ARDS	B-DISO
(	O
PARDS	O
).	O

TITLE	O
:	O
Transfusion	O
in	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
in	O
paediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
overrated	O
or	O
underutilized	O
?	O

TITLE	O
:	O
Feline	O
coronavirus	O
with	O
and	O
without	O
spike	O
gene	O
mutations	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCRs	O
in	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

FCoV	O
spike	O
(	O
Fine	O
-	O
needle	O
aspirates	O
(	O
FNAs	O
)	O
and	O
incisional	O
biopsies	O
(	O
IBs	B-DISO
)	O
of	O
popliteal	O
and	O
mesenteric	O
lymph	O
nodes	O
,	O
liver	O
,	O
spleen	O
,	O
omentum	O
and	O
kidneys	O
(	O
each	O
n	O
=	O
20	O
),	O
EDTA	O
blood	O
(	O
n	O
=	O
13	O
),	O
buffy	O
coat	O
smears	O
(	O
n	O
=	O
13	O
),	O
serum	O
(	O
n	O
=	O
11	O
),	O
effusion	B-DISO
(	O
n	O
=	O
14	O
),	O
cerebrospinal	O
fluid	O
(	O
n	O
=	O
16	O
),	O
aqueous	O
humour	O
(	O
n	O
=	O
20	O
)	O
and	O
peritoneal	O
lavage	O
(	O
n	O
=	O
6	O
)	O
were	O
obtained	O
from	O
20	O
cats	O
with	O
FIP	B-DISO
diagnosed	O
by	O
immunohistochemistry	O
.	O

MERS	O
-	O
CoV	O
transmission	O
in	O
healthcare	O
facility	O
mainly	O
results	O
from	O
laps	O
in	O
infection	B-DISO
control	O
measures	O
and	O
late	O
isolation	O
of	O
suspected	O
cases	O
.	O

ABSTRACT	O
:	O
Despite	O
great	O
advances	O
in	O
mechanical	O
ventilation	O
and	O
surfactant	O
administration	O
for	O
the	O
newborn	O
infant	O
with	O
life	O
-	O
threatening	O
respiratory	B-DISO
failure	I-DISO
no	O
specific	O
therapies	O
are	O
currently	O
established	O
to	O
tackle	O
major	O
pro	O
-	O
inflammatory	O
pathways	O
.	O

A	O
systematic	O
review	O
of	O
the	O
newborn	O
piglet	O
meconium	B-DISO
aspiration	I-DISO
model	O
and	O
the	O
repeated	O
airway	O
lavage	O
model	O
is	O
finally	O
presented	O
.	O

TITLE	O
:	O
Assessment	O
of	O
respiratory	O
drive	O
with	O
esophageal	O
diaphragmatic	O
electromyography	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
prone	O
position	O
ventilation	O
.	O

We	O
found	O
that	O
12	O
/	O
100	O
camel	O
handlers	O
and	O
their	O
family	O
members	O
in	O
Pakistan	O
,	O
a	O
country	O
with	O
extensive	O
camel	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
were	O
seropositive	O
,	O
indicating	O
that	O
MERS	O
-	O
CoV	O
infection	B-DISO
of	O
these	O
populations	O
extends	O
beyond	O
the	O
Arabian	O
Peninsula	O
.	O

MERS	O
-	O
CoV	O
antibodies	O
were	O
abundant	O
in	O
Sudan	O
camels	O
,	O
but	O
we	O
found	O
no	O
evidence	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
camel	O
workers	O
,	O
other	O
livestock	O
,	O
or	O
bats	O
.	O

Compared	O
with	O
patients	O
diagnosed	O
in	O
the	O
emergency	B-DISO
department	O
[	O
90	O
min	O
(	O
IQR	O
,	O
48	O
-	O
164	O
min	O
)],	O
time	O
to	O
antibiotic	O
administration	O
was	O
shortest	O
in	O
patients	O
diagnosed	O
in	O
ICUs	O
[	O
60	O
min	O
(	O
39	O
-	O
180	O
min	O
)]	O
and	O
longest	O
in	O
patients	O
transferred	O
from	O
wards	O
[	O
120	O
min	O
(	O
62	O
-	O
226	O
)].	O

Overall	O
,	O
there	O
were	O
18	O
632	O
admission	O
encounters	O
with	O
a	O
discharge	O
diagnosis	O
of	O
sepsis	B-DISO
in	O
14	O
780	O
unique	O
patients	O
.	O

Additionally	O
,	O
SOT	O
patients	O
had	O
higher	O
odds	O
of	O
hospital	O
readmission	O
within	O
30	O
days	O
(	O
OR	O
=	O
1	O
.	O
25	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
1	O
.	O
51	O
],	O
P	O
=	O
.	O
020	O
),	O
and	O
higher	O
odds	O
for	O
DIC	B-DISO
compared	O
with	O
non	O
-	O
SOT	O
patients	O
(	O
OR	O
=	O
1	O
.	O
76	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
2	O
.	O
86	O
],	O
P	O
=	O
.	O
021	O
).	O

CONCLUSIONS	O
:	O
Sepsis	B-DISO
in	O
solid	O
organ	O
transplants	O
and	O
non	O
-	O
solid	O
organ	O
transplant	O
patients	O
have	O
similar	O
mortality	O
;	O
however	O
,	O
the	O
subset	O
of	O
heart	O
and	O
lung	O
transplant	O
recipients	O
with	O
sepsis	B-DISO
has	O
a	O
higher	O
rate	O
of	O
mortality	O
compared	O
with	O
the	O
non	O
-	O
solid	O
organ	O
transplant	O
recipients	O
.	O

Results	O
from	O
this	O
study	O
give	O
insights	O
into	O
functional	O
compatibilities	O
and	O
evolutionary	O
relationship	O
between	O
CoV	O
viral	O
proteins	O
during	O
viral	O
co	B-DISO
-	I-DISO
infection	I-DISO
and	O
co	O
-	O
evolution	O
.	O

The	O
Society	O
of	O
Critical	O
Care	O
Medicine	O
recently	O
published	O
their	O
updated	O
clinical	O
practice	O
guidelines	O
for	O
analgesia	B-DISO
,	O
agitation	B-DISO
,	O
sedation	B-DISO
,	O
delirium	B-DISO
,	O
immobility	O
,	O
and	O
sleep	O
in	O
adult	O
patients	O
in	O
the	O
ICU	O
.	O

Dexmedetomidine	O
may	O
prevent	O
ICU	O
delirium	B-DISO
when	O
administered	O
nocturnally	O
at	O
low	O
doses	O
;	O
however	O
,	O
it	O
was	O
not	O
shown	O
to	O
improve	O
mortality	O
when	O
used	O
as	O
the	O
primary	O
sedative	O
early	O
in	O
the	O
course	O
of	O
mechanical	O
ventilation	O
,	O
though	O
the	O
majority	O
of	O
patients	O
in	O
the	O
informing	O
study	O
failed	O
to	O
achieve	O
the	O
prescribed	O
light	O
level	O
of	O
sedation	B-DISO
.	O

Both	O
DUB	O
and	O
deISG	O
activities	O
are	O
implicated	O
in	O
suppressing	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
;	O
however	O
,	O
the	O
precise	O
role	O
of	O
each	O
activity	O
in	O
this	O
process	O
is	O
still	O
unclear	O
due	O
in	O
part	O
to	O
the	O
difficulties	O
in	O
separating	O
each	O
activity	O
.	O

The	O
virus	B-DISO
shedding	I-DISO
in	O
feces	O
and	O
viral	O
antigens	O
in	O
intestinal	O
tract	O
were	O
markedly	O
reduced	O
in	O
P100	O
-	O
inoculated	O
piglets	O
.	O

These	O
results	O
reveal	O
a	O
new	O
function	O
of	O
mortalin	O
in	O
inhibiting	O
endocytosis	O
,	O
and	O
provide	O
a	O
novel	O
strategy	O
for	O
treating	O
PEDV	O
infections	B-DISO
.	O

We	O
collected	O
nasopharyngeal	O
specimens	O
from	O
282	O
children	O
aged	O
≤	O
5	O
years	O
with	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
ARI	O
)	O
during	O
2005	O
to	O
2006	O
in	O
one	O
of	O
the	O
largest	O
Brazilian	O
slums	O
.	O

Viruses	O
were	O
common	O
causes	O
of	O
respiratory	B-DISO
disease	I-DISO
;	O
with	O
≥	O
1	O
virus	O
being	O
detected	O
in	O
65	O
.	O
2	O
%	O
of	O
patients	O
.	O

Thus	O
,	O
gene	O
examination	O
can	O
help	O
to	O
understand	O
the	O
etiology	O
of	O
repetitive	O
nontraumatic	O
rhabdomyolysis	B-DISO
.	O

Accurate	O
diagnosis	O
can	O
be	O
beneficial	O
for	O
providing	O
an	O
individualized	O
treatment	O
for	O
patients	O
with	O
repeated	O
and	O
progressive	O
rhabdomyolysis	B-DISO
.	O

TITLE	O
:	O
Development	O
and	O
comparison	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
based	O
on	O
recombinant	O
trimeric	O
full	O
-	O
length	O
and	O
truncated	O
spike	O
proteins	O
for	O
detecting	O
antibodies	O
against	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

TITLE	O
:	O
Developing	O
vaccines	O
against	O
epidemic	O
-	O
prone	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Outbreaks	O
of	O
EIDs	B-DISO
,	O
like	O
the	O
2013	O
-	O
2016	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
or	O
the	O
current	O
Ebola	O
outbreak	O
in	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
(	O
DRC	O
),	O
have	O
not	O
only	O
put	O
populations	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
(	O
LMIC	O
)	O
at	O
risk	O
in	O
terms	O
of	O
morbidity	O
and	O
mortality	O
,	O
but	O
they	O
also	O
have	O
had	O
a	O
significant	O
impact	O
on	O
economic	O
growth	O
in	O
affected	O
regions	O
and	O
beyond	O
.	O

The	O
Coalition	O
for	O
Epidemic	O
Preparedness	O
Innovation	O
(	O
CEPI	O
)	O
is	O
an	O
innovative	O
global	O
partnership	O
between	O
public	O
,	O
private	O
,	O
philanthropic	O
,	O
and	O
civil	O
society	O
organizations	O
that	O
was	O
launched	O
as	O
the	O
result	O
of	O
a	O
consensus	O
that	O
a	O
coordinated	O
,	O
international	O
,	O
and	O
intergovernmental	O
plan	B-DISO
was	O
needed	O
to	O
develop	O
and	O
deploy	O
new	O
vaccines	O
to	O
prevent	O
future	O
epidemics	O
.	O

CEPI	O
is	O
focusing	O
on	O
supporting	O
candidate	O
vaccines	O
against	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Blueprint	O
priority	O
pathogens	O
MERS	O
-	O
CoV	O
,	O
Nipah	O
virus	O
,	O
Lassa	B-DISO
fever	I-DISO
virus	O
,	O
and	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
virus	O
,	O
as	O
well	O
as	O
Chikungunya	B-DISO
virus	O
,	O
which	O
is	O
on	O
the	O
WHO	O
watch	O
list	O
.	O

TITLE	O
:	O
Human	O
bocavirus	O
in	O
children	O
hospitalized	O
for	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
Rome	O
.	O

Despite	O
the	O
health	O
benefits	O
of	O
the	O
influenza	B-DISO
vaccine	O
,	O
vaccination	O
rates	O
around	O
the	O
world	O
remain	O
well	O
below	O
targets	O
.	O

Infants	O
with	O
multiviral	O
bronchiolitis	B-DISO
have	O
higher	O
odds	O
of	O
PICU	O
admission	O
compared	O
with	O
those	O
with	O
a	O
single	O
or	O
nondetectable	O
viral	B-DISO
infection	I-DISO
.	O

Early	O
FO	O
also	O
predicted	O
severe	O
acute	O
kidney	O
injury	O
,	O
respiratory	B-DISO
morbidity	I-DISO
,	O
and	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
after	O
reimplantation	O
procedure	O
.	O

Viral	B-DISO
shedding	I-DISO
studies	O
of	O
asymptomatic	O
MERS	O
infections	B-DISO
have	O
demonstrated	O
the	O
potential	O
to	O
transmit	O
MERS	O
-	O
CoV	O
to	O
others	O
.	O

Involvement	O
of	O
adrenal	O
glands	O
associated	O
with	O
any	O
type	O
of	O
APS	B-DISO
results	O
in	O
Addison	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
.	O

Subsequent	O
review	O
of	O
the	O
patient	O
'	O
s	O
medical	O
history	O
and	O
correlation	O
with	O
autopsy	O
findings	O
confirmed	O
the	O
presence	O
of	O
multiple	O
organ	O
involvement	O
,	O
consistent	O
with	O
APS	B-DISO
type	I-DISO
1	I-DISO
.	O

Prone	O
position	O
is	O
a	O
key	O
component	O
of	O
lung	O
protective	O
mechanical	O
ventilation	O
in	O
association	O
with	O
low	O
tidal	O
volume	O
and	O
neuromuscular	O
blocking	B-DISO
agents	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

The	O
anatomical	O
positions	O
of	O
pressure	B-DISO
sores	I-DISO
were	O
as	O
follows	O
:	O
face	B-DISO
/	O
chin	O
,	O
5	O
%	O
(	O
n	O
=	O
8	O
);	O
face	B-DISO
/	O
cheekbones	O
,	O
6	O
%	O
(	O
n	O
=	O
11	O
);	O
thorax	O
,	O
2	O
%	O
(	O
n	O
=	O
3	O
);	O
trochanter	O
,	O
1	O
%	O
(	O
n	O
=	O
1	O
);	O
and	O
other	O
sites	O
,	O
5	O
%	O
(	O
n	O
=	O
8	O
).	O

ABSTRACT	O
:	O
There	O
has	O
been	O
rapid	O
adoption	O
of	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
in	O
adult	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
used	O
to	O
rescue	O
patients	O
with	O
severe	O
hypoxemic	O
and	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
refractory	O
to	O
optimal	O
therapy	O
and	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO2R	O
)	O
supports	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
allows	O
very	O
low	O
tidal	O
volume	O
ventilation	O
to	O
minimize	O
the	O
risk	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

LUS	O
in	O
the	O
initial	O
assessment	O
of	O
patients	O
'	O
with	O
ARDS	B-DISO
yielded	O
significant	O
findings	O
in	O
the	O
three	O
clinically	O
designated	O
categories	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
became	O
a	O
global	O
human	O
health	O
threat	O
since	O
its	O
first	O
documentation	O
in	O
humans	O
in	O
2012	O
.	O

Routine	O
chest	O
x	O
-	O
ray	O
is	O
not	O
recommended	O
-	O
except	O
if	O
pulmonary	B-DISO
edema	I-DISO
is	O
suspected	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
infection	B-DISO
requires	O
life	O
-	O
long	O
treatment	O
that	O
is	O
associated	O
with	O
chronic	O
toxicity	O
and	O
possible	O
selection	O
of	O
drug	O
-	O
resistant	O
strains	O
.	O

TITLE	O
:	O
Climate	O
factors	O
and	O
incidence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Our	O
understanding	O
of	O
climate	O
factors	O
and	O
their	O
links	O
to	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreaks	O
is	O
incomplete	O
.	O

The	O
recent	O
clinical	O
trial	O
to	O
reevaluate	O
systemic	O
early	O
neuromuscular	B-DISO
blockade	I-DISO
in	O
moderate	O
-	O
severe	O
ARDS	B-DISO
(	O
i	O
.	O
e	O
.,	O
reevaluation	O
of	O
systemic	O
early	O
neuromuscular	B-DISO
blockade	I-DISO
(	O
ROSE	O
)	O
trial	O
)	O
support	O
that	O
a	O
higher	O
PEEP	O
strategy	O
can	O
facilitate	O
'	O
safe	O
'	O
spontaneous	O
breathing	O
under	O
the	O
light	O
sedation	B-DISO
targets	O
(	O
i	O
.	O
e	O
.,	O
no	O
increase	O
in	O
barotrauma	O
nor	O
90	O
days	O
mortality	O
versus	O
early	O
muscle	O
paralysis	O
).	O

Based	O
on	O
these	O
findings	O
,	O
CTD	O
may	O
be	O
a	O
promising	O
target	O
for	O
development	O
of	O
an	O
effective	O
vaccine	O
against	O
PDCoV	O
infection	B-DISO
in	O
pigs	O
.	O

The	O
findings	O
of	O
this	O
study	O
highlight	O
the	O
enormous	O
expenses	O
incurred	O
by	O
the	O
Saudi	O
health	O
care	O
system	O
due	O
to	O
the	O
MERS	O
-	O
CoV	O
outbreak	O
and	O
the	O
importance	O
of	O
developing	O
an	O
enforceable	O
nationwide	O
policy	O
to	O
control	O
MERS	O
-	O
CoV	O
transmission	O
and	O
infection	B-DISO
.	O

At	O
hatch	O
,	O
birds	O
were	O
inoculated	O
with	O
QX	O
vaccine	O
or	O
its	O
virulent	O
progenitor	O
IBV	O
-	O
D388	O
,	O
and	O
postmortem	O
swabs	O
and	O
tissues	O
were	O
collected	O
each	O
day	O
up	O
to	O
eight	O
days	O
post	O
infection	B-DISO
to	O
assess	O
viral	O
replication	O
and	O
morphological	O
changes	O
.	O

Studies	O
focused	O
on	O
occupational	O
exposures	O
to	O
infectious	B-DISO
agents	O
,	O
dust	O
and	O
allergens	O
,	O
pesticides	O
,	O
and	O
occupational	O
injury	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
primarily	O
detected	O
in	O
2012	O
and	O
still	O
causing	O
disease	O
in	O
human	O
and	O
camel	O
.	O

This	O
statistical	O
framework	O
enables	O
a	O
community	O
ecology	O
perspective	O
to	O
be	O
applied	O
to	O
infectious	B-DISO
disease	I-DISO
epidemiology	O
with	O
important	O
utility	O
for	O
public	O
health	O
planning	O
and	O
preparedness	O
.	O

TITLE	O
:	O
Feline	B-DISO
Infectious	I-DISO
Peritonitis	I-DISO
as	O
a	O
Systemic	O
Inflammatory	B-DISO
Disease	I-DISO
:	O
Contribution	O
of	O
Liver	O
and	O
Heart	O
to	O
the	O
Pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
fatal	O
immune	O
-	O
mediated	O
disease	O
of	O
cats	O
,	O
induced	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
).	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
share	O
a	O
collated	O
MERS	O
-	O
CoV	O
database	O
and	O
extraction	O
protocol	O
that	O
can	O
be	O
utilized	O
in	O
future	O
mapping	O
efforts	O
for	O
both	O
MERS	O
-	O
CoV	O
and	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
addition	O
,	O
we	O
observed	O
histopathological	O
signs	O
indicative	O
of	O
progressive	O
pulmonary	B-DISO
fibrosis	I-DISO
,	O
including	O
thickened	O
alveolar	O
septa	O
,	O
infiltration	B-DISO
of	O
inflammatory	O
monocytes	O
,	O
and	O
macrophage	O
polarization	O
as	O
well	O
as	O
elevated	O
expression	O
of	O
profibrotic	O
molecules	O
and	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
in	O
the	O
lung	O
of	O
MERS	O
-	O
CoV	O
-	O
infected	O
hDPP4	O
-	O
transgenic	O
mice	O
.	O

We	O
studied	O
the	O
genetic	O
diversity	O
,	O
geographical	O
structure	O
,	O
infection	B-DISO
prevalence	O
,	O
and	O
age	O
-	O
associated	O
prevalence	O
among	O
camels	O
at	O
the	O
largest	O
entry	O
port	O
of	O
camels	O
from	O
Africa	O
into	O
the	O
Arabian	O
Peninsula	O
.	O

We	O
determined	O
the	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
age	O
-	O
associated	O
patterns	O
of	O
infection	B-DISO
,	O
and	O
undertook	O
phylogeographical	O
and	O
migration	O
analyses	O
to	O
determine	O
intercountry	O
virus	O
transmission	O
after	O
local	O
lineage	O
establishment	O
.	O

Infection	B-DISO
prevalence	O
peaked	O
among	O
camels	O
older	O
than	O
1	O
year	O
and	O
aged	O
up	O
to	O
2	O
years	O
in	O
both	O
groups	O
,	O
with	O
255	O
(	O
66	O
·	O
9	O
%)	O
of	O
381	O
positive	O
cases	O
in	O
this	O
age	O
group	O
.	O

This	O
disease	O
is	O
one	O
of	O
the	O
most	O
important	O
infectious	B-DISO
diseases	I-DISO
in	O
cats	O
,	O
and	O
it	O
is	O
associated	O
with	O
high	O
mortality	O
,	O
particularly	O
among	O
younger	O
cats	O
.	O

Further	O
,	O
we	O
developed	O
an	O
EvaGreen	O
-	O
based	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
accurate	O
detection	O
of	O
FCoV	O
based	O
on	O
the	O
amplification	B-DISO
of	O
the	O
highly	O
conserved	O
FIPV	O
N	O
gene	O
.	O

Then	O
,	O
using	O
a	O
combination	O
of	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
approach	O
and	O
a	O
serum	O
chemistry	O
assay	O
,	O
we	O
performed	O
an	O
epidemiological	O
survey	O
of	O
FIPV	O
infection	B-DISO
in	O
cats	O
living	O
in	O
Harbin	O
City	O
,	O
Northeast	O
China	O
.	O

TITLE	O
:	O
SKP2	O
attenuates	O
autophagy	O
through	O
Beclin1	O
-	O
ubiquitination	O
and	O
its	O
inhibition	O
reduces	O
MERS	O
-	O
Coronavirus	B-DISO
infection	I-DISO
.	O

Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
multiplication	O
results	O
in	O
reduced	O
BECN1	O
levels	O
and	O
blocks	O
the	O
fusion	O
of	O
autophagosomes	O
and	O
lysosomes	O
.	O

TITLE	O
:	O
Genetic	O
manipulation	O
of	O
porcine	O
deltacoronavirus	O
reveals	O
insights	O
into	O
NS6	B-DISO
and	O
NS7	B-DISO
functions	O
:	O
a	O
novel	O
strategy	O
for	O
vaccine	O
design	O
.	O

TITLE	O
:	O
Minimum	O
Determinants	O
of	O
Transmissible	O
Gastroenteritis	B-DISO
Virus	O
Enteric	O
Tropism	O
Are	O
Located	O
in	O
the	O
N	O
-	O
Terminus	O
of	O
Spike	O
Protein	O
.	O

TITLE	O
:	O
Human	O
Coronaviruses	O
and	O
Other	O
Respiratory	O
Viruses	O
:	O
Underestimated	O
Opportunistic	O
Pathogens	O
of	O
the	O
Central	O
Nervous	B-DISO
System	O
?	O

Furthermore	O
,	O
as	O
they	O
can	O
adapt	O
fast	O
and	O
cross	O
the	O
species	O
barrier	O
,	O
some	O
of	O
these	O
pathogens	O
,	O
like	O
influenza	B-DISO
A	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
have	O
occasionally	O
caused	O
epidemics	O
or	O
pandemics	O
,	O
and	O
were	O
associated	O
with	O
more	O
serious	O
clinical	O
diseases	O
and	O
even	O
mortality	O
.	O

For	O
a	O
few	O
decades	O
now	O
,	O
data	O
reported	O
in	O
the	O
scientific	O
literature	O
has	O
also	O
demonstrated	O
that	O
several	O
respiratory	O
viruses	O
have	O
neuroinvasive	O
capacities	O
,	O
since	O
they	O
can	O
spread	O
from	O
the	O
respiratory	O
tract	O
to	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
).	O

Viruses	O
infecting	O
human	O
CNS	O
cells	O
could	O
then	O
cause	O
different	O
types	O
of	O
encephalopathy	B-DISO
,	O
including	O
encephalitis	B-DISO
,	O
and	O
long	O
-	O
term	O
neurological	O
diseases	O
.	O

TITLE	O
:	O
In	O
silico	O
and	O
in	O
vitro	O
analysis	O
of	O
small	O
molecules	O
and	O
natural	O
compounds	O
targeting	O
the	O
3CL	O
protease	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
interleukin	O
-	O
11	O
as	O
a	O
response	O
to	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Influenza	B-DISO
A	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
among	O
pregnant	O
women	O
in	O
a	O
tertiary	O
hospital	O
in	O
Belgrade	O
,	O
Serbia	O
.	O

Two	O
women	O
(	O
18	O
.	O
2	O
%)	O
died	O
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
this	O
present	O
study	O
,	O
we	O
developed	O
a	O
detection	O
system	O
of	O
microbes	O
from	O
porcine	O
respiratory	O
by	O
using	O
TaqMan	O
real	O
-	O
time	O
PCR	O
(	O
referred	O
to	O
as	O
Dempo	O
-	O
PCR	O
)	O
to	O
screen	O
a	O
broad	O
range	O
of	O
pathogens	O
associated	O
with	O
porcine	O
respiratory	B-DISO
diseases	I-DISO
in	O
a	O
single	O
run	O
.	O

More	O
than	O
60	O
years	O
later	O
,	O
many	O
medical	O
professionals	O
have	O
observed	O
and	O
voiced	O
its	O
deficiencies	O
following	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

RESULTS	O
:	O
During	O
a	O
5	O
-	O
year	O
period	O
,	O
123	O
non	O
-	O
immunocompromised	O
patients	O
with	O
a	O
severe	O
ARDS	B-DISO
requiring	O
a	O
veno	O
-	O
venous	O
ECMO	O
were	O
included	O
.	O

Disease	O
involving	O
all	O
three	O
Yang	O
channels	O
is	O
the	O
core	O
of	O
the	O
pathogenesis	B-DISO
of	O
Chaige	O
Jieji	O
Decoction	O
syndrome	B-DISO
,	O
in	O
which	O
headache	B-DISO
is	O
the	O
key	O
indications	O
.	O

A	O
coronary	O
angiogram	O
then	O
revealed	O
triple	B-DISO
vessel	I-DISO
disease	I-DISO
.	O

A	O
diagnosis	O
of	O
Kounis	B-DISO
syndrome	I-DISO
was	O
made	O
.	O

Extracorporeal	O
CO2	O
removal	O
can	O
minimize	O
acidosis	B-DISO
and	O
enable	O
the	O
use	O
of	O
ultra	O
-	O
protective	O
lung	O
ventilation	O
strategies	O
when	O
hypoxemia	O
is	O
not	O
a	O
major	O
issue	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
all	O
adult	O
patients	O
admitted	O
to	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
H1N1	O
viral	B-DISO
pneumonia	I-DISO
having	O
severe	O
ARDS	B-DISO
and	O
requiring	O
prone	O
ventilation	O
as	O
a	O
rescue	O
therapy	O
for	O
severe	O
hypoxemia	O
were	O
reviewed	O
.	O

The	O
worst	O
PaO	O
PPV	O
improves	O
oxygenation	O
when	O
started	O
early	O
with	O
adequate	O
duration	O
and	O
should	O
be	O
considered	O
in	O
all	O
severe	O
ARDS	B-DISO
cases	O
secondary	O
to	O
H1N1	O
viral	B-DISO
infection	I-DISO
.	O

Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
most	O
frequently	O
detected	O
virus	O
with	O
prevalence	O
rates	O
between	O
50	O
.	O
21	O
and	O
62	O
.	O
10	O
%	O
in	O
samples	O
,	O
and	O
96	O
.	O
43	O
%	O
(	O
162	O
/	O
168	O
)	O
in	O
premises	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
describe	O
methods	O
for	O
in	O
vitro	O
serial	O
passaging	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
select	O
for	O
mutations	O
which	O
increase	O
replication	O
on	O
semi	O
-	O
permissive	O
cell	O
lines	O
as	O
described	O
in	O
Letko	O
et	O
al	O
.,	O
Cell	O
Rep	O
24	O
,	O
1730	O
-	O
1737	O
,	O
2018	O
.	O

Here	O
,	O
we	O
present	O
a	O
method	O
based	O
on	O
western	O
blot	O
analysis	O
to	O
investigate	O
spike	O
protein	O
proteolytic	O
cleavage	O
by	O
transient	O
transfection	O
of	O
HEK	O
-	O
293	O
T	O
cells	O
allowing	O
expression	O
of	O
the	O
spike	O
protein	O
of	O
the	O
highly	O
pathogenic	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
cellular	O
trypsin	O
-	O
like	O
transmembrane	O
serine	O
protease	O
,	O
matriptase	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
more	O
than	O
2280	O
confirmed	O
human	O
infections	B-DISO
and	O
800	O
associated	O
deaths	O
had	O
been	O
reported	O
to	O
the	O
World	O
Health	O
Organization	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
isolation	O
,	O
amplification	B-DISO
,	O
and	O
titration	O
of	O
MERS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
detailed	O
MN	O
assay	O
to	O
measure	O
nAb	O
levels	O
in	O
sera	O
from	O
different	O
mammalian	O
species	O
.	O

An	O
animal	O
model	O
that	O
supports	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
causes	O
severe	O
lung	B-DISO
disease	I-DISO
is	O
useful	O
to	O
study	O
pathogenesis	B-DISO
and	O
evaluate	O
therapies	O
and	O
vaccines	O
.	O

Here	O
we	O
describe	O
the	O
MPLEx	O
protocol	O
,	O
highlight	O
the	O
step	O
of	O
inactivation	B-DISO
,	O
and	O
describe	O
the	O
details	O
of	O
downstream	O
processing	O
,	O
instrumental	O
analysis	O
of	O
the	O
three	O
separate	O
analytes	O
,	O
and	O
their	O
subsequent	O
informatics	O
pipelines	O
.	O

Myeloid	O
cells	O
such	O
as	O
neutrophils	O
and	O
monocyte	O
-	O
macrophages	O
are	O
major	O
innate	O
leukocytes	O
that	O
orchestrate	O
protective	O
immunity	O
to	O
viral	O
lung	O
infections	B-DISO
.	O

In	O
this	O
chapter	O
,	O
we	O
report	O
useful	O
markers	O
to	O
identify	O
lung	O
infiltrating	B-DISO
innate	O
immune	O
cells	O
and	O
define	O
their	O
activation	O
status	O
.	O

We	O
also	O
describe	O
a	O
simple	O
method	O
to	O
measure	O
intracellular	O
cytokine	O
production	O
to	O
evaluate	O
the	O
inflammatory	O
activity	O
of	O
neutrophils	O
and	O
IMMs	O
in	O
a	O
mouse	O
model	O
of	O
human	O
coronavirus	B-DISO
infection	I-DISO
.	O

She	O
developed	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
was	O
strongly	O
considered	O
for	O
being	O
placed	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
immediately	O
following	O
the	O
removal	O
of	O
an	O
aspirated	B-DISO
foreign	O
body	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
form	O
of	O
diffuse	O
lung	O
injury	O
with	O
many	O
potential	O
etiologies	O
,	O
pneumonia	B-DISO
being	O
the	O
most	O
common	O
cause	O
developing	O
outside	O
of	O
the	O
hospital	O
.	O

Although	O
these	O
associations	O
exist	O
,	O
the	O
development	O
of	O
ARDS	B-DISO
immediately	O
following	O
the	O
removal	O
of	O
an	O
aspirated	B-DISO
FB	O
appears	O
quite	O
rare	O
.	O

TITLE	O
:	O
Adenovirus	B-DISO
Type	O
7	O
causing	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
immunocompetent	O
adults	O
:	O
a	O
comparison	O
of	O
two	O
contrasting	O
cases	O
from	O
an	O
intensive	O
care	O
unit	O
in	O
North	O
West	O
England	O
.	O

Adenovirus	B-DISO
type	O
7	O
was	O
identified	O
in	O
bronchoalveolar	O
lavages	O
and	O
plasma	O
samples	O
of	O
both	O
patients	O
,	O
each	O
of	O
whom	O
received	O
cidofovir	O
.	O

We	O
explored	O
the	O
temporal	O
correlations	O
between	O
respiratory	O
illness	O
outbreaks	O
and	O
acute	O
flaccid	O
myelitis	B-DISO
during	O
autumn	O
season	O
between	O
2016	O
and	O
2018	O
using	O
questionnaire	O
surveys	O
.	O

Although	O
the	O
number	O
of	O
patients	O
hospitalized	O
with	O
respiratory	O
illness	O
did	O
not	O
correlate	O
with	O
the	O
number	O
of	O
those	O
admitted	O
with	O
myelitis	B-DISO
,	O
increases	O
in	O
children	O
aged	O
7	O
-	O
12	O
and	O
13	O
-	O
19	O
years	O
requiring	O
ICU	O
admission	O
correlated	O
temporally	O
with	O
an	O
outbreak	O
of	O
acute	O
flaccid	O
myelitis	B-DISO
.	O

According	O
to	O
our	O
previous	O
study	O
,	O
type	O
I	O
FCoV	O
infection	B-DISO
is	O
inhibited	O
by	O
compounds	O
inducing	O
intracellular	O
cholesterol	O
accumulation	O
,	O
whereas	O
type	O
II	O
FCoV	O
infection	B-DISO
is	O
not	O
inhibited	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
describe	O
the	O
statistical	O
analysis	O
plan	B-DISO
for	O
the	O
MIRACLE	O
trial	O
.	O

Mechanistically	O
,	O
the	O
nsp5	O
-	O
mediated	O
NEMO	O
cleavage	O
disrupted	O
the	O
recruitment	B-DISO
of	O
the	O
TRAF	O
family	O
member	O
-	O
associated	O
NF	O
-	O
κB	O
activator	O
(	O
TANK	O
)	O
to	O
NEMO	O
,	O
which	O
reduced	O
the	O
phosphorylation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
),	O
leading	O
to	O
the	O
inhibition	O
of	O
type	O
I	O
IFN	O
production	O
.	O

Therefore	O
,	O
supportive	O
management	O
of	O
symptoms	O
is	O
necessary	O
in	O
the	O
cases	O
with	O
PTTM	O
and	O
hence	O
we	O
believe	O
that	O
the	O
information	O
presented	O
here	O
is	O
of	O
great	O
significance	O
for	O
the	O
diagnosis	O
and	O
management	O
of	O
symptoms	O
of	O
PTTM	O
with	O
HCC	B-DISO
.	O

A	O
39	O
-	O
year	O
-	O
old	O
man	O
who	O
lives	O
in	O
Bangkok	O
presented	O
with	O
fever	O
,	O
severe	O
myalgia	B-DISO
and	O
haemoptysis	B-DISO
.	O

Patients	O
with	O
lung	B-DISO
cancer	I-DISO
with	O
dorsal	O
subpleural	O
fibrotic	O
changes	O
occupying	O
three	O
or	O
more	O
segments	O
of	O
both	O
lower	O
lobes	O
and	O
planned	O
anatomical	O
lung	O
resection	O
were	O
enrolled	O
.	O

There	O
are	O
no	O
approved	O
treatments	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
although	O
a	O
combination	O
of	O
lopinavir	O
,	O
ritonavir	O
and	O
interferon	O
beta	O
(	O
LPV	O
/	O
RTV	O
-	O
IFNb	O
)	O
is	O
currently	O
being	O
evaluated	O
in	O
humans	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
Calf	O
diarrhea	B-DISO
causes	O
severe	O
economic	O
losses	O
in	O
the	O
cattle	O
industry	O
worldwide	O
.	O

BNoV	O
(	O
84	O
/	O
689	O
,	O
12	O
.	O
2	O
%)	O
was	O
the	O
most	O
prevalent	O
regardless	O
of	O
diarrhea	B-DISO
,	O
followed	O
by	O
BCoV	O
(	O
37	O
/	O
689	O
,	O
5	O
.	O
4	O
%),	O
BToV	O
(	O
15	O
/	O
689	O
,	O
2	O
.	O
2	O
%),	O
and	O
BoRVA	O
(	O
13	O
/	O
689	O
,	O
1	O
.	O
9	O
%).	O

Infection	B-DISO
by	O
the	O
four	O
pathogens	O
had	O
no	O
relationship	O
with	O
calf	O
age	O
;	O
BoRVA	O
was	O
detected	O
only	O
in	O
calves	O
aged	O
<	O
30	O
days	O
,	O
but	O
this	O
finding	O
was	O
not	O
statistically	O
significant	O
.	O

Consequently	O
,	O
our	O
results	O
highlight	O
the	O
importance	O
of	O
rapid	O
diagnosis	O
against	O
these	O
viruses	O
in	O
calf	O
diarrhea	B-DISO
.	O

TITLE	O
:	O
Sero	O
-	O
prevalence	O
,	O
cross	O
-	O
species	O
infection	B-DISO
and	O
serological	O
determinants	O
of	O
prevalence	O
of	O
Bovine	O
Coronavirus	O
in	O
Cattle	O
,	O
Sheep	O
and	O
Goats	O
in	O
Ghana	O
.	O

ABSTRACT	O
:	O
Cattle	O
,	O
goats	O
and	O
sheep	O
are	O
dominant	O
livestock	O
species	O
in	O
sub	O
-	O
Saharan	O
Africa	O
,	O
with	O
sometimes	O
limited	O
information	O
on	O
the	O
prevalence	O
of	O
major	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Posterior	O
Reversible	O
Encephalopathy	B-DISO
in	O
a	O
Patient	O
with	O
Severe	O
Leptospirosis	B-DISO
Complicated	O
with	O
Pulmonary	B-DISO
Haemorrhage	I-DISO
,	O
Myocarditis	B-DISO
,	O
and	O
Acute	O
Kidney	O
Injury	O
.	O

Leptospirosis	B-DISO
is	O
a	O
biphasic	B-DISO
disease	I-DISO
characterised	O
by	O
leptospiraemic	O
phase	O
and	O
immunological	O
phase	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
displayed	O
that	O
lnc	O
-	O
MALAT1	O
high	O
expression	O
,	O
increased	O
age	O
,	O
higher	O
proportion	O
of	O
smoking	O
and	O
COPD	B-DISO
were	O
independent	O
factors	O
for	O
predicting	O
elevated	O
ARDS	B-DISO
risk	O
.	O

ABSTRACT	O
:	O
In	O
2015	O
,	O
we	O
experienced	O
the	O
largest	O
in	O
-	O
hospital	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
outside	O
the	O
Arabian	O
Peninsula	O
.	O

It	O
is	O
anticipated	O
that	O
such	O
data	O
will	O
assist	O
researchers	O
and	O
clinicians	O
to	O
develop	O
appropriate	O
diagnostic	O
strategies	O
for	O
timely	O
and	O
effective	O
detection	O
of	O
respiratory	O
virus	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
There	O
are	O
few	O
studies	O
on	O
the	O
safety	O
and	O
respiratory	O
consequences	O
of	O
the	O
use	O
of	O
a	O
skeletal	O
traction	O
(	O
ST	O
)	O
device	O
in	O
the	O
management	O
of	O
femoral	O
shaft	O
fractures	O
with	O
damage	O
control	O
orthopaedics	O
(	O
DCO	B-DISO
)	O
strategy	O
,	O
particularly	O
in	O
cases	O
of	O
prolonged	O
use	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
influence	O
of	O
ST	O
compared	O
with	O
an	O
external	O
fixator	O
(	O
EF	O
)	O
on	O
respiratory	B-DISO
complications	I-DISO
and	O
mechanical	O
ventilation	O
requirements	O
in	O
patients	O
with	O
severe	O
trauma	O
with	O
a	O
femoral	O
shaft	O
fracture	O
managed	O
by	O
DCO	B-DISO
strategy	O
.	O

In	O
addition	O
to	O
trauma	O
severity	O
,	O
global	O
management	O
of	O
respiratory	B-DISO
complications	I-DISO
,	O
the	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
mechanical	O
ventilation	O
requirements	O
and	O
outcome	O
were	O
compared	O
.	O

In	O
contrast	O
,	O
ARDS	B-DISO
was	O
found	O
more	O
frequently	O
in	O
the	O
DCO	B-DISO
-	O
ST	O
group	O
(	O
81	O
%	O
versus	O
54	O
%;	O
P	O
=	O
0	O
.	O
035	O
).	O

Therefore	O
,	O
our	O
findings	O
suggest	O
that	O
EF	O
is	O
preferable	O
to	O
ST	O
in	O
the	O
DCO	B-DISO
setting	O
for	O
femoral	O
shaft	O
fracture	O
,	O
especially	O
in	O
trauma	O
patients	O
at	O
high	O
risk	O
of	O
developing	O
delayed	O
respiratory	B-DISO
failure	I-DISO
.	O

A	O
seasonal	O
effect	O
was	O
shown	O
for	O
bRSV	O
only	O
{	O
more	O
in	O
winter	O
compared	O
with	O
autumn	O
[	O
OR	O
=	O
10	O
.	O
3	O
(	O
2	O
.	O
8	O
-	O
37	O
.	O
5	O
)]}.	O
Other	O
factors	O
associated	O
with	O
bRSV	O
were	O
PI	O
-	O
3	O
detection	O
[	O
OR	O
=	O
13	O
.	O
4	O
(	O
2	O
.	O
1	O
-	O
86	O
.	O
0	O
)],	O
prevalence	O
of	O
calves	O
with	O
respiratory	B-DISO
disease	I-DISO
[	O
OR	O
=	O
1	O
.	O
02	O
(	O
1	O
.	O
00	O
-	O
1	O
.	O
04	O
)	O
per	O
1	O
%	O
increase	O
],	O
and	O
number	O
of	O
days	O
with	O
respiratory	O
signs	O
before	O
sampling	O
[	O
OR	O
=	O
0	O
.	O
99	O
(	O
0	O
.	O
98	O
-	O
0	O
.	O
99	O
)	O
per	O
day	O
increase	O
].	O

ABSTRACT	O
:	O
The	O
long	O
-	O
term	O
dynamics	O
of	O
antibody	O
responses	O
in	O
patients	O
with	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	B-DISO
infection	I-DISO
are	O
not	O
well	O
understood	O
.	O

TITLE	O
:	O
[	O
Update	O
and	O
Comment	O
on	O
the	O
German	O
S3	O
""""	O
Clinical	O
Guideline	O
for	O
Treating	O
Acute	B-DISO
Respiratory	I-DISO
Insufficiency	I-DISO
with	O
Invasive	O
Ventilation	O
and	O
Extracorporeal	O
Membrane	O
Oxygenation	O
:	O
Evidence	O
-	O
Based	O
Recommendations	O
"""]."	O

The	O
bobcat	O
made	O
a	O
full	O
recovery	O
within	O
72	O
hours	O
after	O
treatment	O
for	O
ticks	O
,	O
and	O
a	O
presumptive	O
diagnosis	O
of	O
tick	B-DISO
paralysis	I-DISO
was	O
made	O
.	O

We	O
also	O
found	O
NMBAs	O
did	O
not	O
affect	O
total	O
PEEP	O
,	O
plateau	O
pressure	O
,	O
days	O
free	O
of	O
ventilation	O
at	O
day	O
28	O
and	O
ICU	O
-	O
acquired	O
weakness	B-DISO
.	O

In	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
,	O
the	O
administration	O
of	O
NMBAs	O
could	O
reduce	O
21	O
to	O
28	O
-	O
day	O
mortality	O
and	O
barotrauma	O
,	O
and	O
improve	O
oxygenation	O
at	O
48	O
hours	O
,	O
but	O
have	O
no	O
significant	O
effects	O
on	O
90	O
-	O
day	O
/	O
ICU	O
mortality	O
,	O
days	O
free	O
of	O
ventilation	O
at	O
day	O
28	O
and	O
the	O
risk	O
of	O
ICU	O
-	O
acquired	O
weakness	B-DISO
.	O

Registration	O
:	O
PROSPERO	O
(	O
ID	O
:	O
CRD	B-DISO
42019139656	O
).	O

We	O
also	O
found	O
NMBAs	O
did	O
not	O
affect	O
total	O
PEEP	O
,	O
plateau	O
pressure	O
,	O
days	O
free	O
of	O
ventilation	O
at	O
day	O
28	O
and	O
ICU	O
-	O
acquired	O
weakness	B-DISO
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
a	O
core	O
component	O
of	O
PDCoV	O
,	O
is	O
essential	O
for	O
virus	O
replication	O
and	O
is	O
a	O
significant	O
candidate	O
in	O
the	O
development	O
of	O
diagnostics	O
for	O
PDCoV	O
.	O
In	O
this	O
study	O
,	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
were	O
generated	O
and	O
tested	O
for	O
reactivity	O
with	O
three	O
truncations	O
of	O
the	O
full	O
protein	O
(	O
N1	O
,	O
N2	O
,	O
N3	O
)	O
that	O
contained	O
partial	O
overlaps	O
;	O
of	O
the	O
five	O
monoclonals	O
chosen	O
tested	O
,	O
each	O
reacted	O
with	O
only	O
the	O
N3	O
truncation	B-DISO
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
and	O
comorbidities	O
in	O
adult	B-DISO
-	I-DISO
onset	I-DISO
Still	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
using	O
a	O
large	O
US	O
administrative	O
claims	O
database	O
.	O

Outcomes	O
of	O
interest	O
and	O
a	O
novel	O
claims	O
-	O
based	O
set	O
of	O
Yamaguchi	O
criteria	O
were	O
identified	O
by	O
relevant	O
ICD	B-DISO
9th	O
revision	O
(	O
ICD	B-DISO
-	O
9	O
)	O
and	O
ICD	B-DISO
-	O
10	O
codes	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
whether	O
electromyographical	O
findings	O
could	O
predict	O
intensive	O
care	O
unit	O
mortality	O
among	O
mechanically	O
ventilated	O
septic	O
patients	O
under	O
profound	O
sedation	B-DISO
.	O

Both	O
may	O
be	O
clinically	O
indistinguishable	O
and	O
present	O
as	O
an	O
acute	O
icterohemorrhagic	O
febrile	B-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
is	O
an	O
acute	O
,	O
high	O
-	O
mortality	O
-	O
rate	O
,	O
severe	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
an	O
emerging	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
that	O
causes	O
severe	O
respiratory	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
The	O
popularity	O
of	O
e	O
-	O
cigarettes	O
(	O
vaping	O
)	O
has	O
been	O
on	O
the	O
rise	O
in	O
recent	O
years	O
,	O
but	O
the	O
adverse	B-DISO
effects	I-DISO
of	O
vaping	O
have	O
been	O
greatly	O
unknown	O
.	O

TITLE	O
:	O
A	O
Novel	O
Coronavirus	O
from	O
Patients	O
with	O
Pneumonia	B-DISO
in	O
China	O
,	O
2019	O
.	O

Gaining	O
a	O
deeper	O
understanding	O
of	O
the	O
interaction	O
between	O
Coronaviruses	O
and	O
the	O
innate	O
immune	O
systems	O
of	O
the	O
hosts	O
may	O
shed	O
light	O
on	O
the	O
development	O
and	O
persistence	O
of	O
inflammation	B-DISO
in	O
the	O
lungs	O
and	O
hopefully	O
can	O
reduce	O
the	O
risk	O
of	O
lung	B-DISO
inflammation	I-DISO
caused	O
by	O
CoVs	O
.	O

In	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
gga	O
-	O
miR	O
-	O
30d	O
in	O
the	O
process	O
of	O
IBV	O
infection	B-DISO
of	O
HD11	O
cell	O
line	O
in	O
vitro	O
.	O

Further	O
studies	O
need	O
to	O
be	O
performed	O
to	O
determine	O
whether	O
this	O
recombinant	O
IBV	O
strain	O
is	O
pathogenic	O
and	O
whether	O
it	O
is	O
transmitted	B-DISO
between	O
chickens	O
and	O
turkeys	O
.	O

ECMO	O
support	O
in	O
ARDS	B-DISO
is	O
specifically	O
associated	O
with	O
an	O
increased	O
number	O
of	O
circulating	O
MSC	O
,	O
most	O
likely	O
due	O
to	O
enhanced	O
mobilization	O
,	O
but	O
not	O
with	O
a	O
higher	O
numbers	O
of	O
EPC	O
or	O
serum	O
concentrations	O
of	O
VEGF	O
and	O
Ang2	O
.	O

Of	O
the	O
1531	O
individuals	O
with	O
ARDS	B-DISO
alive	O
on	O
the	O
second	O
study	O
day	O
after	O
enrollment	O
,	O
232	O
(	O
15	O
%)	O
had	O
persistent	O
severe	O
ARDS	B-DISO
.	O

Patients	O
with	O
persistent	O
severe	O
ARDS	B-DISO
have	O
distinct	O
baseline	O
characteristics	O
and	O
poor	O
prognosis	O
.	O

ABSTRACT	O
:	O
An	O
ongoing	O
outbreak	O
of	O
pneumonia	B-DISO
associated	O
with	O
a	O
novel	O
coronavirus	O
was	O
reported	O
in	O
Wuhan	O
city	O
,	O
Hubei	O
province	O
,	O
China	O
.	O

We	O
prospectively	O
collected	O
and	O
analysed	O
data	O
on	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

Dyspnoea	B-DISO
developed	O
in	O
22	O
(	O
55	O
%)	O
of	O
40	O
patients	O
(	O
median	O
time	O
from	O
illness	O
onset	O
to	O
dyspnoea	B-DISO
8	O
·	O
0	O
days	O
[	O
IQR	O
5	O
·	O
0	O
-	O
13	O
·	O
0	O
]).	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
Reye	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
induced	O
by	O
influenza	B-DISO
A	O
virus	O
with	O
use	O
of	O
ibuprofen	O
in	O
an	O
adult	O
.	O

A	O
56	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
with	O
disturbance	B-DISO
of	I-DISO
consciousness	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
diagnosed	O
the	O
patient	O
with	O
RS	O
induced	O
by	O
influenza	B-DISO
A	O
and	O
use	O
of	O
ibuprofen	O
.	O

TITLE	O
:	O
Ebola	O
in	O
the	O
Eastern	O
Democratic	O
Republic	O
of	O
Congo	O
:	O
One	O
Health	O
approach	O
to	O
infectious	B-DISO
disease	I-DISO
control	O
.	O

A	O
phylogenetic	O
tree	O
has	O
been	O
built	O
using	O
the	O
15	O
available	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
,	O
12	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
,	O
and	O
12	O
highly	O
similar	O
whole	O
genome	O
sequences	O
available	O
in	O
gene	O
bank	O
(	O
five	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
two	O
from	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
and	O
five	O
from	O
bat	O
SARS	B-DISO
-	O
like	O
coronavirus	O
).	O

The	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
is	O
spreading	O
and	O
its	O
incidence	O
is	O
increasing	O
nationwide	O
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
subgenotype	O
of	O
human	O
coronavirus	O
NL63	O
associated	O
with	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
China	O
,	O
2018	O
.	O

Here	O
we	O
report	O
a	O
cluster	O
of	O
HCoV	O
-	O
NL63	O
cases	O
with	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
that	O
arose	O
in	O
Guangzhou	O
,	O
China	O
,	O
in	O
2018	O
.	O

TITLE	O
:	O
Receptor	O
Recognition	O
by	O
the	O
Novel	O
Coronavirus	O
from	O
Wuhan	O
:	O
an	O
Analysis	O
Based	O
on	O
Decade	O
-	O
Long	O
Structural	O
Studies	O
of	O
SARS	B-DISO
Coronavirus	O
.	O

Second	O
,	O
several	O
critical	O
residues	O
in	O
2019	O
-	O
nCoV	O
RBM	O
(	O
particularly	O
Gln493	O
)	O
provide	O
favorable	O
interactions	O
with	O
human	O
ACE2	O
,	O
consistent	O
with	O
2019	O
-	O
nCoV	O
'	O
s	O
capacity	O
for	O
human	O
cell	O
infection	B-DISO
.	O

SIRS	B-DISO
can	O
progress	O
to	O
septic	B-DISO
shock	I-DISO
if	O
not	O
identified	O
early	O
.	O

Herein	O
,	O
we	O
present	O
the	O
first	O
case	O
of	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
diagnosed	O
at	O
the	O
American	O
University	O
of	O
Beirut	O
Medical	O
Center	O
(	O
AUBMC	O
)	O
-	O
Lebanon	O
in	O
June	O
2017	O
presenting	O
without	O
any	O
respiratory	B-DISO
symptoms	I-DISO
.	O

The	O
first	O
case	O
presented	O
with	O
a	O
febrile	O
respiratory	B-DISO
infection	I-DISO
with	O
persistent	O
symptoms	O
despite	O
antibiotic	O
treatment	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
multiple	O
trauma	O
patients	O
with	O
post	O
-	O
traumatic	O
respiratory	B-DISO
failure	I-DISO
can	O
be	O
quite	O
challenging	O
because	O
of	O
the	O
need	O
for	O
systemic	O
anticoagulation	O
,	O
which	O
may	O
lead	O
to	O
excessive	O
bleeding	B-DISO
.	O

TITLE	O
:	O
Efficacy	O
and	O
safety	O
of	O
early	O
prone	O
positioning	O
combined	O
with	O
HFNC	O
or	O
NIV	O
in	O
moderate	O
to	O
severe	O
ARDS	B-DISO
:	O
a	O
multi	O
-	O
center	O
prospective	O
cohort	O
study	O
.	O

The	O
main	O
causes	O
of	O
ARDS	B-DISO
were	O
pneumonia	B-DISO
due	O
to	O
influenza	B-DISO
(	O
9	O
cases	O
,	O
45	O
%)	O
and	O
other	O
viruses	O
(	O
2	O
cases	O
,	O
10	O
%).	O

All	O
7	O
patients	O
with	O
a	O
PaO	O
Early	O
application	O
of	O
PP	O
with	O
HFNC	O
,	O
especially	O
in	O
patients	O
with	O
moderate	O
ARDS	B-DISO
and	O
baseline	O
SpO	O
ChiCTR	O
,	O
ChiCTR1900023564	O
.	O

However	O
,	O
the	O
number	O
of	O
accessed	O
resources	O
,	O
as	O
per	O
students	O
,	O
has	O
borderline	O
significant	O
correlation	O
with	O
higher	O
self	O
-	O
reported	O
anxiety	O
from	O
MERS	O
-	O
CoV	O
.	O
Medical	O
students	O
'	O
psychological	B-DISO
needs	O
during	O
the	O
MERS	O
-	O
CoV	O
outbreak	O
should	O
be	O
addressed	O
appropriately	O
.	O

TITLE	O
:	O
Management	O
of	O
hypoxaemia	O
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
coronavirus	O
causing	O
severe	O
pneumonia	B-DISO
in	O
human	O
:	O
a	O
descriptive	O
study	O
.	O

The	O
virus	O
is	O
phylogenetically	O
closest	O
to	O
a	O
bat	O
SARS	B-DISO
-	O
like	O
CoV	O
(	O
SL	O
-	O
ZC45	O
,	O
GenBank	O
MG772933	O
)	O
with	O
87	O
.	O
6	O
%	O
to	O
87	O
.	O
7	O
%	O
nucleotide	O
identity	O
,	O
but	O
is	O
in	O
a	O
separate	O
clade	O
.	O

However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
tentative	O
receptor	O
-	O
binding	O
domain	O
resembles	O
that	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
indicating	O
that	O
these	O
viruses	O
might	O
use	O
the	O
same	O
receptor	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
close	O
coordination	O
between	O
clinicians	O
and	O
public	O
health	O
authorities	O
at	O
the	O
local	O
,	O
state	O
,	O
and	O
federal	O
levels	O
,	O
as	O
well	O
as	O
the	O
need	O
for	O
rapid	O
dissemination	O
of	O
clinical	O
information	O
related	O
to	O
the	O
care	O
of	O
patients	O
with	O
this	O
emerging	O
infection	B-DISO
.	O

Although	O
no	O
cases	O
of	O
MERS	O
were	O
identified	O
,	O
the	O
majority	O
of	O
patients	O
had	O
Influenza	B-DISO
infection	B-DISO
for	O
which	O
oseltamivir	O
treatment	O
was	O
indicated	O
and	O
isolation	O
warranted	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
associated	O
with	O
human	O
to	O
human	O
transmission	O
and	O
severe	O
human	O
infection	B-DISO
has	O
been	O
recently	O
reported	O
from	O
the	O
city	O
of	O
Wuhan	O
in	O
China	O
.	O

This	O
includes	O
19	O
vaccine	O
candidates	O
against	O
its	O
priority	O
pathogens	O
(	O
Lassa	B-DISO
fever	I-DISO
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
Nipah	O
virus	O
,	O
Chikungunya	B-DISO
,	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
)	O
and	O
three	O
vaccine	O
platforms	O
to	O
develop	O
vaccines	O
against	O
Disease	O
X	O
,	O
a	O
novel	O
or	O
unanticipated	O
pathogen	O
.	O

Current	O
evidence	O
confirms	O
the	O
role	O
of	O
dromedaries	O
in	O
primary	O
human	O
infections	B-DISO
but	O
does	O
not	O
explain	O
the	O
sporadic	O
community	O
cases	O
.	O

The	O
Clinical	O
utilisation	O
of	O
respiratory	O
elastance	O
(	O
CURE	O
)	O
trial	O
is	O
a	O
two	O
-	O
arm	O
,	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
investigating	O
the	O
performance	O
of	O
PEEP	O
selected	O
at	O
an	O
objective	O
,	O
model	O
-	O
based	O
minimal	O
respiratory	O
system	O
elastance	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

50	O
(	O
51	O
%)	O
patients	O
had	O
chronic	B-DISO
diseases	I-DISO
.	O

The	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
was	O
of	O
clustering	O
onset	O
,	O
is	O
more	O
likely	O
to	O
affect	O
older	O
males	O
with	O
comorbidities	O
,	O
and	O
can	O
result	O
in	O
severe	O
and	O
even	O
fatal	O
respiratory	B-DISO
diseases	I-DISO
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Further	O
investigation	O
is	O
needed	O
to	O
explore	O
the	O
applicability	O
of	O
the	O
MuLBSTA	O
score	O
in	O
predicting	O
the	O
risk	O
of	O
mortality	O
in	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
In	O
late	O
December	O
,	O
2019	O
,	O
patients	O
presenting	O
with	O
viral	B-DISO
pneumonia	I-DISO
due	O
to	O
an	O
unidentified	O
microbial	O
agent	O
were	O
reported	O
in	O
Wuhan	O
,	O
China	O
.	O

Positive	O
immunoglobulin	O
M	O
antibodies	O
for	O
EBV	O
were	O
supportive	O
of	O
an	O
acute	O
EBV	B-DISO
infection	I-DISO
,	O
which	O
was	O
the	O
most	O
probable	O
trigger	O
of	O
HLH	B-DISO
.	O

TITLE	O
:	O
Effect	O
of	O
isolation	O
practice	O
on	O
the	O
transmission	O
of	O
middle	O
east	O
respiratory	O
syndrome	B-DISO
coronavirus	O
among	O
hemodialysis	O
patients	O
:	O
A	O
2	O
-	O
year	O
prospective	O
cohort	O
study	O
.	O

During	O
a	O
mean	O
isolation	O
period	O
of	O
15	O
days	O
,	O
no	O
further	O
cases	O
of	O
secondary	B-DISO
transmission	I-DISO
were	O
detected	O
among	O
HD	O
patients	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
can	O
cause	O
respiratory	O
syndrome	B-DISO
which	O
to	O
date	O
has	O
affected	O
about	O
twelve	O
thousand	O
individuals	O
,	O
especially	O
in	O
China	O
.	O

We	O
used	O
data	O
from	O
Dec	O
31	O
,	O
2019	O
,	O
to	O
Jan	O
28	O
,	O
2020	O
,	O
on	O
the	O
number	O
of	O
cases	O
exported	O
from	O
Wuhan	O
internationally	O
(	O
known	O
days	O
of	O
symptom	B-DISO
onset	O
from	O
Dec	O
25	O
,	O
2019	O
,	O
to	O
Jan	O
19	O
,	O
2020	O
)	O
to	O
infer	O
the	O
number	O
of	O
infections	B-DISO
in	O
Wuhan	O
from	O
Dec	O
1	O
,	O
2019	O
,	O
to	O
Jan	O
25	O
,	O
2020	O
.	O

We	O
estimated	O
that	O
in	O
the	O
baseline	O
scenario	O
,	O
Chongqing	O
,	O
Beijing	O
,	O
Shanghai	O
,	O
Guangzhou	O
,	O
and	O
Shenzhen	O
had	O
imported	O
461	O
(	O
95	O
%	O
CrI	O
227	O
-	O
805	O
),	O
113	O
(	O
57	O
-	O
193	O
),	O
98	O
(	O
49	O
-	O
168	O
),	O
111	O
(	O
56	O
-	O
191	O
),	O
and	O
80	O
(	O
40	O
-	O
139	O
)	O
infections	B-DISO
from	O
Wuhan	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
new	O
coronavirus	O
associated	O
with	O
human	O
respiratory	B-DISO
disease	I-DISO
in	O
China	O
.	O

TITLE	O
:	O
Isolated	O
Pauci	O
-	O
Immune	O
Pulmonary	O
Capillaritis	B-DISO
Associated	O
with	O
Hydrocarbon	O
Inhalation	O
and	O
Marijuana	B-DISO
Smoking	O
:	O
An	O
Unusual	O
Case	O
of	O
Severe	O
Hypoxemia	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
case	O
report	O
of	O
a	O
patient	O
with	O
Isolated	O
pauci	O
-	O
immune	O
pulmonary	O
capillaritis	B-DISO
(	O
IPIPC	O
).	O

He	O
was	O
hypotensive	B-DISO
,	O
and	O
his	O
chest	O
imaging	O
showed	O
bilateral	O
dependent	O
infiltrates	B-DISO
.	O

Given	O
the	O
lack	O
of	O
other	O
findings	O
and	O
risk	O
factors	O
,	O
his	O
IPIPC	O
was	O
likely	O
associated	O
with	O
occupational	O
exposures	O
to	O
hydrocarbons	O
as	O
a	O
cabinetmaker	O
compounded	O
by	O
marijuana	B-DISO
smoking	O
.	O

The	O
impact	O
of	O
chronic	O
comorbidities	O
on	O
clinical	O
outcomes	O
,	O
in	O
particular	O
,	O
pulmonary	B-DISO
disease	I-DISO
and	O
immunosuppression	O
,	O
were	O
analyzed	O
.	O

Notably	O
,	O
lung	B-DISO
cavitation	I-DISO
,	O
discrete	O
pulmonary	O
nodules	B-DISO
,	O
pleural	B-DISO
effusions	I-DISO
,	O
and	O
lymphadenopathy	O
were	O
absent	O
.	O

ABSTRACT	O
:	O
On	O
10	O
January	O
2020	O
,	O
a	O
new	O
coronavirus	O
causing	O
a	O
pneumonia	B-DISO
outbreak	O
in	O
Wuhan	O
City	O
in	O
central	O
China	O
was	O
denoted	O
as	O
2019	O
-	O
nCoV	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

As	O
of	O
24	O
January	O
2020	O
,	O
there	O
were	O
887	O
confirmed	O
cases	O
of	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
,	O
including	O
26	O
deaths	O
,	O
reported	O
in	O
China	O
and	O
other	O
countries	O
.	O

TITLE	O
:	O
SARS	B-DISO
to	O
novel	O
coronavirus	O
-	O
old	O
lessons	O
and	O
new	O
lessons	O
.	O

In	O
vitro	O
,	O
LPS	B-DISO
induced	O
decreased	O
cell	O
viability	O
coupled	O
with	O
activated	O
Nox2	O
,	O
high	O
level	O
of	O
ROS	O
,	O
and	O
destroyed	O
ZO	O
-	O
1	O
distribution	O
.	O

ABSTRACT	O
:	O
Protective	O
ventilation	O
is	O
the	O
cornerstone	O
of	O
treatment	O
of	O
patients	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
however	O
,	O
no	O
studies	O
have	O
yet	O
established	O
the	O
best	O
ventilatory	O
strategy	O
to	O
adopt	O
when	O
patients	O
with	O
acute	O
exacerbation	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
AE	O
-	O
ILD	O
)	O
are	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

TITLE	O
:	O
Learning	O
from	O
the	O
Past	O
:	O
Possible	O
Urgent	O
Prevention	O
and	O
Treatment	O
Options	O
for	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Infections	I-DISO
Caused	O
by	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
With	O
the	O
current	O
trajectory	O
of	O
the	O
2019	O
-	O
nCoV	O
outbreak	O
unknown	O
,	O
public	O
health	O
and	O
medicinal	O
measures	O
will	O
both	O
be	O
needed	O
to	O
contain	O
spreading	O
of	O
the	O
virus	O
and	O
to	O
optimize	O
patient	O
outcomes	O
.	O

TITLE	O
:	O
[	O
Diagnosis	O
and	O
clinical	O
management	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
:	O
an	O
operational	O
recommendation	O
of	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
(	O
V2	O
.	O
0	O
)].	O

,	O
China	O
has	O
been	O
experiencing	O
an	O
outbreak	O
of	O
new	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
).	O

On	O
January	O
30	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Director	O
-	O
General	O
declared	O
that	O
the	O
2019	O
-	O
nCoV	O
outbreak	O
constitutes	O
a	O
Public	O
Health	O
Emergency	B-DISO
of	O
International	O
Concern	O
.	O

ABSTRACT	O
:	O
The	O
individual	O
and	O
combined	O
contribution	O
of	O
viral	O
prevalence	O
in	O
the	O
community	O
to	O
Emergency	B-DISO
Department	O
(	O
ED	O
)	O
visits	O
and	O
hospitalizations	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
RTIs	O
),	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
and	O
asthma	B-DISO
is	O
unclear	O
.	O

Viral	O
data	O
was	O
collected	O
from	O
the	O
Centre	O
for	O
Immunization	O
and	O
Respiratory	O
Infectious	B-DISO
Diseases	I-DISO
(	O
CIRID	O
).	O

There	O
were	O
4	O
,	O
365	O
,	O
578	O
ED	O
visits	O
with	O
RTIs	O
of	O
which	O
321	O
,	O
719	O
(	O
7	O
.	O
4	O
%)	O
were	O
admitted	O
to	O
hospital	O
;	O
817	O
,	O
141	O
ED	O
visits	O
for	O
COPD	B-DISO
of	O
which	O
260	O
,	O
665	O
(	O
31	O
.	O
9	O
%)	O
were	O
admitted	O
and	O
649	O
,	O
666	O
ED	O
visits	O
with	O
asthma	B-DISO
of	O
which	O
68	O
,	O
626	O
(	O
10	O
.	O
6	O
%)	O
were	O
admitted	O
.	O

The	O
further	O
addition	O
of	O
human	O
metapneumovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
over	O
the	O
final	O
3	O
years	O
accounted	O
for	O
66	O
.	O
7	O
%	O
of	O
ED	O
visits	O
and	O
74	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
RTI	B-DISO
,	O
52	O
.	O
5	O
%	O
of	O
visits	O
and	O
48	O
.	O
2	O
%	O
of	O
hospitalizations	O
for	O
COPD	B-DISO
,	O
and	O
only	O
13	O
.	O
3	O
%	O
of	O
visits	O
and	O
10	O
.	O
4	O
%	O
of	O
hospitalizations	O
for	O
asthma	B-DISO
.	O

TITLE	O
:	O
2019	O
-	O
nCoV	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
,	O
Australia	O
:	O
Epidemiology	O
Report	O
1	O
(	O
Reporting	O
week	O
26	O
January	O
-	O
1	O
February	O
2020	O
).	O

In	O
rare	O
cases	O
,	O
AIHA	O
is	O
comorbid	O
with	O
other	O
immunological	O
disorders	O
;	O
for	O
instance	O
,	O
when	O
AIHA	O
is	O
complicated	O
with	O
immunologic	O
thrombocytopenic	B-DISO
purpura	I-DISO
(	O
ITP	B-DISO
)	O
it	O
is	O
called	O
Evans	B-DISO
Syndrome	I-DISO
(	O
ES	O
).	O

And	O
there	O
are	O
no	O
estimation	O
of	O
the	O
risk	O
for	O
thromboembolism	B-DISO
in	O
the	O
""""	O
immunological	B-DISO
tolerance	I-DISO
loss	O
""""	O
case	O
.	O

On	O
the	O
fourth	O
day	O
of	O
refractory	O
treatment	O
following	O
AIHA	O
recurrence	B-DISO
,	O
the	O
patient	O
had	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
severe	O
hypoxia	B-DISO
and	O
died	O
.	O

TITLE	O
:	O
A	O
rapid	O
advice	O
guideline	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infected	O
pneumonia	B-DISO
(	O
standard	O
version	O
).	O

TITLE	O
:	O
[	O
Application	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
technique	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
caused	O
by	O
ammonia	O
poisoning	O
].	O

After	O
23	O
days	O
,	O
his	O
condition	B-DISO
improved	O
and	O
was	O
discharged	O
without	O
complaining	O
of	O
any	O
discomfort	B-DISO
during	O
the	O
follow	O
-	O
up	O
till	O
March	O
2019	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
prognostic	O
capacity	O
of	O
changes	O
in	O
PaO	O
This	O
was	O
a	O
post	O
hoc	O
analysis	O
of	O
the	O
conveniently	O
-	O
sized	O
'	O
Molecular	O
Diagnosis	O
and	O
Risk	O
Stratification	O
of	O
Sepsis	B-DISO
'	O
study	O
(	O
MARS	O
).	O

The	O
current	O
analysis	O
included	O
ARDS	B-DISO
patients	O
who	O
were	O
placed	O
in	O
the	O
PP	O
.	O

Lymphopenia	B-DISO
(	O
lymphocyte	O
count	O
,	O
0	O
.	O
8	O
×	O
109	O
/	O
L	O
[	O
interquartile	O
range	O
{	O
IQR	O
},	O
0	O
.	O
6	O
-	O
1	O
.	O
1	O
])	O
occurred	O
in	O
97	O
patients	O
(	O
70	O
.	O
3	O
%),	O
prolonged	O
prothrombin	O
time	O
(	O
13	O
.	O
0	O
seconds	O
[	O
IQR	O
,	O
12	O
.	O
3	O
-	O
13	O
.	O
7	O
])	O
in	O
80	O
patients	O
(	O
58	O
%),	O
and	O
elevated	O
lactate	O
dehydrogenase	O
(	O
261	O
U	O
/	O
L	O
[	O
IQR	O
,	O
182	O
-	O
403	O
])	O
in	O
55	O
patients	O
(	O
39	O
.	O
9	O
%).	O

This	O
virus	O
is	O
genetically	O
similar	O
to	O
SARS	B-DISO
coronavirus	O
and	O
bat	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
.	O

TITLE	O
:	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)-	O
associated	O
severe	O
complications	O
;	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
,	O
myocarditis	B-DISO
,	O
acute	B-DISO
necrotizing	I-DISO
encephalopathy	I-DISO
.	O

The	O
first	O
case	O
,	O
a	O
3	O
-	O
year	O
-	O
old	O
girl	O
,	O
had	O
respiratory	B-DISO
distress	I-DISO
,	O
anemia	B-DISO
,	O
thrombocytopenia	O
and	O
renal	B-DISO
failure	I-DISO
at	O
admission	O
,	O
and	O
was	O
diagnosed	O
with	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
.	O

The	O
second	O
case	O
,	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
admitted	O
with	O
lethargia	O
and	O
flu	B-DISO
-	O
like	O
symtoms	O
and	O
was	O
diagnosed	O
with	O
myocarditis	B-DISO
and	O
cardiogenic	B-DISO
shock	I-DISO
.	O

The	O
third	O
case	O
,	O
a	O
21	O
-	O
month	O
-	O
old	O
boy	O
,	O
presented	O
with	O
decreased	O
level	O
of	O
consciousness	O
and	O
was	O
diagnosed	O
with	O
acute	B-DISO
necrotizing	I-DISO
encephalopathy	I-DISO
with	O
the	O
aid	O
of	O
cranial	O
magnetic	O
resonance	O
imagining	O
(	O
MRI	O
).	O

TITLE	O
:	O
[	O
Interpretation	O
of	O
""""	O
Guidelines	O
for	O
the	O
Diagnosis	O
and	O
Treatment	O
of	O
Novel	O
Coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
Infection	B-DISO
by	O
the	O
National	O
Health	O
Commission	O
(	O
Trial	O
Version	O
5	O
")""]."	O

In	O
this	O
study	O
,	O
we	O
determined	O
whether	O
symptomatic	O
respiratory	O
viral	B-DISO
infections	I-DISO
after	O
lung	O
transplantation	O
induce	O
circulating	O
exosomes	O
that	O
contain	O
lung	O
-	O
associated	O
self	O
-	O
antigens	O
and	O
assessed	O
whether	O
these	O
exosomes	O
activate	O
immune	O
responses	O
to	O
self	O
-	O
antigens	O
.	O

RESULTS	O
:	O
Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	O
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	B-DISO
infections	I-DISO
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

Mice	O
immunized	O
with	O
exosomes	O
from	O
recipients	O
with	O
respiratory	O
viral	B-DISO
infections	I-DISO
developed	O
immune	O
responses	O
to	O
self	O
-	O
antigens	O
,	O
fibrosis	B-DISO
,	O
small	O
airway	O
occlusion	B-DISO
,	O
and	O
significant	O
cellular	O
infiltration	B-DISO
;	O
mice	O
immunized	O
with	O
exosomes	O
from	O
controls	O
did	O
not	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Since	O
the	O
outbreak	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
(	O
2019	O
-	O
nCoV	O
)	O
in	O
Wuhan	O
City	O
,	O
China	O
,	O
by	O
January	O
30	O
,	O
2020	O
,	O
a	O
total	O
of	O
9692	O
confirmed	O
cases	O
and	O
15	O
,	O
238	O
suspected	O
cases	O
have	O
been	O
reported	O
around	O
31	O
provinces	O
or	O
cities	O
in	O
China	O
.	O

This	O
statement	O
is	O
based	O
on	O
the	O
Novel	O
Coronavirus	B-DISO
Infection	I-DISO
Pneumonia	B-DISO
Diagnosis	O
and	O
Treatment	O
Standards	O
(	O
the	O
fourth	O
edition	O
)	O
(	O
National	O
Health	O
Committee	O
)	O
and	O
other	O
previous	O
diagnosis	O
and	O
treatment	O
strategies	O
for	O
pediatric	O
virus	O
infections	B-DISO
.	O

TITLE	O
:	O
[	O
Recommendations	O
on	O
extracorporeal	O
life	O
support	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
novel	O
coronavirus	O
pneumonia	B-DISO
].	O

ABSTRACT	O
:	O
Along	O
with	O
the	O
sharp	O
increase	O
of	O
confirmed	O
cases	O
novel	O
coronavirus	B-DISO
infection	I-DISO
,	O
more	O
critically	B-DISO
ill	I-DISO
cases	O
require	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
.	O

Ruscogenin	O
(	O
RUS	O
)	O
has	O
been	O
found	O
to	O
exert	O
significant	O
protective	O
effect	O
on	O
ALI	O
induced	O
by	O
lipopolysaccharides	O
(	O
LPS	B-DISO
),	O
but	O
there	O
is	O
little	O
information	O
about	O
its	O
role	O
in	O
LPS	B-DISO
-	O
induced	O
pulmonary	O
endothelial	O
cell	O
apoptosis	O
.	O

Mice	O
were	O
challenged	O
with	O
LPS	B-DISO
(	O
5	O
mg	O
/	O
kg	O
)	O
by	O
intratracheal	O
instillation	O
for	O
24	O
h	O
to	O
induce	O
apoptosis	O
of	O
pulmonary	O
endothelial	O
cells	O
in	O
model	O
group	O
.	O

The	O
results	O
showed	O
that	O
RUS	O
could	O
attenuate	O
LPS	B-DISO
-	O
induced	O
lung	O
injury	O
and	O
pulmonary	O
endothelial	O
apoptosis	O
significantly	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
and	O
therapeutic	O
procedure	O
for	O
four	O
cases	O
with	O
2019	O
novel	O
coronavirus	O
pneumonia	B-DISO
receiving	O
combined	O
Chinese	O
and	O
Western	O
medicine	O
treatment	O
.	O

ABSTRACT	O
:	O
Pneumonia	B-DISO
associated	O
with	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
is	O
continuously	O
and	O
rapidly	O
circulating	O
at	O
present	O
.	O

Two	O
recombinant	O
IBVs	O
(	O
rIBVs	O
)	O
harboring	O
EIC	O
-	O
inactivating	O
mutations	O
-	O
rT16A	O
and	O
rA26F	O
-	O
were	O
serially	O
passaged	O
,	O
and	O
several	O
compensatory	O
mutations	O
were	O
identified	O
in	O
the	O
transmembrane	O
domain	O
(	O
TMD	B-DISO
).	O

Along	O
with	O
decompensation	O
of	O
cirrhosis	B-DISO
,	O
the	O
concept	O
of	O
acute	O
-	O
on	O
-	O
chronic	B-DISO
liver	I-DISO
failure	I-DISO
(	O
ACLF	O
)	O
has	O
emerged	O
.	O

However	O
,	O
patients	O
with	O
a	O
Chronic	B-DISO
Liver	I-DISO
Failure	I-DISO
Consortium	O
ACLF	O
score	O
greater	O
than	O
70	O
at	O
48	O
to	O
72	O
hours	O
post	O
-	O
ICU	O
admission	O
do	O
not	O
seem	O
to	O
benefit	O
from	O
ongoing	O
intensive	O
support	O
and	O
a	O
palliative	O
approach	O
may	O
be	O
more	O
appropriate	O
.	O

Limited	O
existing	O
knowledge	O
highlights	O
the	O
need	O
for	O
data	O
regarding	O
supportive	O
care	O
and	O
adjunctive	O
pharmacologic	O
therapy	O
that	O
is	O
specific	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
severe	O
RVI	O
.	O

TITLE	O
:	O
[	O
Be	O
alert	O
to	O
superposed	O
effect	O
of	O
seasonal	O
influenza	B-DISO
while	O
fighting	O
against	O
novel	O
coronavirus	O
pneumonia	B-DISO
].	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
)	O
continues	O
to	O
spread	O
throughout	O
the	O
country	O
,	O
and	O
the	O
prevention	O
and	O
control	O
of	O
the	O
epidemic	O
has	O
entered	O
a	O
critical	O
period	O
.	O

TITLE	O
:	O
Identifying	O
factors	O
and	O
target	O
preventive	O
therapies	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
sucsibtable	O
patients	O
.	O

ABSTRACT	O
:	O
There	O
is	O
no	O
proven	O
specific	O
pharmacological	O
treatment	O
for	O
patients	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
most	O
common	O
adverse	O
events	O
were	O
hyperglycaemia	B-DISO
in	O
the	O
ICU	O
(	O
105	O
[	O
76	O
%]	O
patients	O
in	O
the	O
dexamethasone	O
group	O
vs	O
97	O
[	O
70	O
%]	O
patients	O
in	O
the	O
control	O
group	O
),	O
new	O
infections	B-DISO
in	O
the	O
ICU	O
(	O
eg	O
,	O
pneumonia	B-DISO
or	O
sepsis	B-DISO
;	O
33	O
[	O
24	O
%]	O
vs	O
35	O
[	O
25	O
%]),	O
and	O
barotrauma	O
(	O
14	O
[	O
10	O
%]	O
vs	O
10	O
[	O
7	O
%]).	O

To	O
assess	O
bronchial	O
and	O
lung	O
recruitment	B-DISO
and	O
distension	B-DISO
during	O
an	O
incremental	O
positive	O
end	O
-	O
expiratory	O
pressure	O
trial	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

With	O
increasing	O
positive	O
end	O
-	O
expiratory	O
pressure	O
from	O
0	O
to	O
20	O
cmH	B-DISO
In	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
Functional	O
Respiratory	O
Imaging	O
gives	O
an	O
innovative	O
insight	O
into	O
the	O
relationship	O
between	O
positive	O
end	O
-	O
expiratory	O
pressure	O
-	O
induced	O
bronchial	O
distension	B-DISO
and	O
recruitment	B-DISO
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
-	O
induced	O
lung	O
recruitment	B-DISO
and	O
hyperinflation	B-DISO
and	O
lung	O
morphology	O
.	O

RESULTS	O
:	O
With	O
increasing	O
positive	O
end	O
-	O
expiratory	O
pressure	O
from	O
0	O
to	O
20	O
cmH	B-DISO

Nearly	O
80	O
%	O
of	O
the	O
patients	O
had	O
normal	O
or	O
decreased	O
white	O
blood	O
cell	O
counts	O
,	O
and	O
72	O
.	O
3	O
%	O
(	O
99	O
/	O
137	O
)	O
had	O
lymphocytopenia	B-DISO
.	O

It	O
is	O
essential	O
to	O
assess	O
how	O
the	O
expensive	O
,	O
resource	O
-	O
intensive	O
measures	O
implemented	O
by	O
the	O
Chinese	O
authorities	O
can	O
contribute	O
to	O
the	O
prevention	O
and	O
control	O
of	O
the	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
,	O
and	O
how	O
long	O
they	O
should	O
be	O
maintained	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
the	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
began	O
in	O
December	O
2019	O
in	O
Wuhan	O
,	O
Hubei	O
province	O
,	O
and	O
rapidly	O
spread	O
to	O
many	O
provinces	O
in	O
China	O
as	O
well	O
as	O
other	O
countries	O
.	O

All	O
12	O
cases	O
of	O
the	O
2019	O
-	O
nCoV	O
-	O
infected	O
patients	O
developed	O
pneumonia	B-DISO
and	O
half	O
of	O
them	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
most	O
common	O
laboratory	O
abnormalities	O
were	O
hypoalbuminemia	O
,	O
lymphopenia	B-DISO
,	O
decreased	O
percentage	O
of	O
lymphocytes	O
(	O
LYM	O
)	O
and	O
neutrophils	O
(	O
NEU	O
),	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
and	O
decreased	O
CD8	O
count	O
.	O

Based	O
on	O
the	O
susceptible	O
-	O
exposed	O
-	O
infected	O
-	O
removed	O
(	O
SEIR	O
)	O
compartment	O
model	O
and	O
the	O
assumption	O
that	O
the	O
infectious	B-DISO
cases	O
with	O
symptoms	O
occurred	O
before	O
26	O
January	O
,	O
2020	O
are	O
resulted	O
from	O
free	O
propagation	O
without	O
intervention	O
,	O
we	O
estimate	O
the	O
basic	O
reproduction	O
number	O
of	O
2019	O
-	O
nCoV	O
according	O
to	O
the	O
reported	O
confirmed	O
cases	O
and	O
suspected	O
cases	O
,	O
as	O
well	O
as	O
the	O
theoretical	O
estimated	O
number	O
of	O
infected	O
cases	O
by	O
other	O
research	O
teams	O
,	O
together	O
with	O
some	O
epidemiological	O
determinants	O
learned	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

All	O
five	O
patients	O
had	O
typical	O
imaging	O
findings	O
,	O
including	O
ground	O
-	O
glass	O
opacity	B-DISO
(	O
GGO	B-DISO
)	O
(	O
5	O
patients	O
)	O
and	O
/	O
or	O
mixed	O
GGO	B-DISO
and	O
mixed	O
consolidation	O
(	O
2	O
patients	O
).	O

A	O
combination	O
of	O
repeated	O
swab	O
tests	O
and	O
CT	O
scanning	O
may	O
be	O
helpful	O
when	O
for	O
individuals	O
with	O
high	O
clinical	O
suspicion	O
of	O
nCoV	O
infection	B-DISO
but	O
negative	O
RT	O
-	O
PCR	O
screening	O
.	O

Person	O
-	O
to	O
-	O
person	O
transmission	O
may	O
occur	O
through	O
droplet	O
or	O
contact	O
transmission	O
and	O
jeopardized	O
first	O
-	O
line	O
healthcare	O
workers	O
if	O
lack	O
of	O
stringent	O
infection	B-DISO
control	O
or	O
no	O
proper	O
personal	O
protective	O
equipment	O
available	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
Australia	O
:	O
Epidemiology	O
Report	O
2	O
(	O
Reporting	O
week	O
ending	O
19	O
:	O
00	O
AEDT	O
8	O
February	O
2020	O
).	O

This	O
observational	O
study	O
prospectively	O
enrolled	O
patients	O
with	O
multiple	O
bicortical	O
rib	O
fractures	O
with	O
hemothorax	B-DISO
caused	O
by	O
severe	O
blunt	O
chest	O
trauma	O
.	O

Rates	O
of	O
pneumonia	B-DISO
and	O
length	O
of	O
hospital	O
stay	O
constituted	O
secondary	O
outcomes	O
.	O

During	O
the	O
epidemic	O
of	O
2019	O
-	O
nCoV	O
,	O
the	O
emergency	B-DISO
response	O
plan	B-DISO
for	O
the	O
NICU	O
should	O
be	O
based	O
on	O
the	O
actual	O
situation	O
,	O
including	O
diagnosis	O
,	O
isolation	O
,	O
and	O
treatment	O
,	O
as	O
well	O
as	O
available	O
equipment	O
and	O
staffing	O
,	O
and	O
take	O
into	O
account	O
the	O
psychosocial	O
needs	O
of	O
the	O
families	O
and	O
neonatal	O
care	O
staff	O
.	O

Anti	O
-	O
PDCoV	O
IgA	O
antibodies	O
in	O
152	O
serum	O
samples	O
and	O
65	O
milk	O
samples	O
collected	O
from	O
six	O
farms	O
that	O
had	O
experienced	O
diarrhea	B-DISO
outbreaks	O
within	O
previous	O
last	O
two	O
years	O
were	O
detected	O
by	O
this	O
assay	O
,	O
and	O
62	O
.	O
5	O
%	O
of	O
the	O
serum	O
samples	O
and	O
100	O
%	O
of	O
the	O
milk	O
samples	O
were	O
positive	O
for	O
PDCoV	O
.	O
The	O
indirect	O
ELISA	O
method	O
established	O
in	O
this	O
study	O
will	O
provide	O
a	O
convenient	O
tool	O
for	O
measurement	O
of	O
serum	O
and	O
milk	O
IgA	O
levels	O
against	O
PDCoV	O
in	O
pig	O
herds	O
,	O
rapid	O
detection	O
of	O
PDCoV	O
infection	B-DISO
in	O
pigs	O
,	O
and	O
evaluation	O
of	O
the	O
immunogenicity	O
of	O
vaccines	O
.	O

ABSTRACT	O
:	O
A	O
global	O
health	O
emergency	B-DISO
has	O
been	O
declared	O
by	O
the	O
World	O
Health	O
Organization	O
as	O
the	O
2019	O
-	O
nCoV	O
outbreak	O
spreads	O
across	O
the	O
world	O
,	O
with	O
confirmed	O
patients	O
in	O
Canada	O
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
all	O
the	O
potential	O
interventions	O
be	O
implemented	O
to	O
control	O
the	O
emerging	O
COVID	B-DISO
-	I-DISO
19	I-DISO
if	O
the	O
infection	B-DISO
is	O
uncontrollable	O
.	O

Results	O
Twenty	O
one	O
patients	O
(	O
6	O
males	O
and	O
15	O
females	O
,	O
age	O
25	O
-	O
63	O
years	O
)	O
with	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
were	O
evaluated	O
.	O

On	O
January	O
17	O
,	O
CDC	O
and	O
the	O
U	O
.	O
S	O
.	O
Department	O
of	O
Homeland	O
Security	O
'	O
s	O
Customs	O
and	O
Border	O
Protection	O
began	O
health	O
screenings	O
at	O
U	O
.	O
S	O
.	O
airports	O
to	O
identify	O
ill	B-DISO
travelers	O
returning	O
from	O
Wuhan	O
City	O
(	O
4	O
).	O

Data	O
describing	O
the	O
times	O
from	O
symptom	B-DISO
onset	O
to	O
hospitalisation	O
for	O
47	O
patients	O
infected	O
early	O
in	O
the	O
current	O
outbreak	O
are	O
used	O
to	O
generate	O
an	O
estimate	O
for	O
the	O
probability	O
that	O
an	O
imported	O
case	O
is	O
followed	O
by	O
sustained	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
the	O
presence	O
of	O
common	O
respiratory	O
viruses	O
in	O
the	O
lower	O
respiratory	O
tract	O
without	O
causing	O
symptomatic	O
infection	B-DISO
,	O
even	O
in	O
carefully	O
collected	O
lower	O
samples	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
contemporary	O
clincial	O
case	O
management	O
of	O
patients	O
with	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
.	O

A	O
narrative	O
review	O
from	O
a	O
clinical	O
perspective	O
of	O
clinical	O
features	O
,	O
diagnostic	O
tests	O
,	O
treatments	O
and	O
outcomes	O
of	O
patients	O
with	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
.	O

RESULTS	O
:	O
Substantial	O
advances	O
have	O
been	O
made	O
in	O
the	O
care	O
of	O
patients	O
with	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
(	O
EVD	O
),	O
precipitated	O
by	O
the	O
unprecedented	O
extent	O
of	O
the	O
2014	O
-	O
2016	O
outbreak	O
.	O

A	O
RV	O
global	O
LSS	B-DISO
value	O
>	O
-	O
13	O
.	O
7	O
%	O
differentiated	O
patients	O
with	O
a	O
TAPSE	O
<	O
vs	O
>	O
12	O
mm	O
with	O
a	O
sensitivity	O
of	O
88	O
%	O
and	O
a	O
specificity	O
of	O
83	O
%.	O

NIRV	O
are	O
common	O
in	O
adults	O
admitted	O
with	O
ILI	O
during	O
influenza	B-DISO
seasons	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
since	O
December	O
2019	O
in	O
Wuhan	O
,	O
the	O
major	O
transportation	O
hub	O
in	O
central	O
China	O
,	O
became	O
an	O
emergency	B-DISO
of	O
major	O
international	O
concern	O
.	O

TITLE	O
:	O
Case	O
of	O
the	O
Index	O
Patient	O
Who	O
Caused	O
Tertiary	O
Transmission	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Infection	I-DISO
in	O
Korea	O
:	O
the	O
Application	O
of	O
Lopinavir	O
/	O
Ritonavir	O
for	O
the	O
Treatment	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Infected	O
Pneumonia	B-DISO
Monitored	O
by	O
Quantitative	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Human	O
BK	O
virus	O
(	O
BKV	O
)	O
infection	B-DISO
is	O
known	O
to	O
occur	O
mostly	O
during	O
childhood	O
with	O
the	O
establishment	O
of	O
latent	B-DISO
infection	I-DISO
with	O
no	O
tissue	O
damage	O
or	O
clinical	O
manifestations	O
.	O

After	O
multiple	O
antibiotic	O
courses	O
,	O
he	O
developed	O
acute	O
kidney	O
injury	O
,	O
a	O
hemophagocytic	B-DISO
syndrome	I-DISO
,	O
and	O
eventually	O
respiratory	B-DISO
failure	I-DISO
,	O
which	O
led	O
to	O
his	O
death	O
a	O
year	O
later	O
.	O

Combination	O
of	O
Ribavirin	O
and	O
Interferon	O
-	O
α	O
is	O
recommended	O
by	O
the	O
5	O
(	O
th	O
)	O
edition	O
National	O
Health	O
Commission	O
'	O
s	O
Regimen	O
(	O
Revised	O
Edition	O
)	O
because	O
of	O
the	O
effect	O
on	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
),	O
and	O
the	O
effectiveness	O
of	O
Lopinavir	O
/	O
Ritonavir	O
and	O
Remdisivir	O
needs	O
to	O
be	O
confirmed	O
by	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
),	O
given	O
the	O
situation	O
of	O
no	O
specific	O
antivirus	O
drug	O
on	O
NCP	O
is	O
unavailable	O
.	O

TITLE	O
:	O
[	O
Recommendations	O
for	O
general	O
surgery	O
clinical	O
practice	O
in	O
novel	O
coronavirus	O
pneumonia	B-DISO
situation	O
].	O

TITLE	O
:	O
A	O
realistic	O
two	O
-	O
strain	O
model	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
uncovers	O
the	O
high	O
risk	O
for	O
epidemic	O
propagation	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
announcement	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
in	O
2018	O
,	O
the	O
Wuhan	O
pneumonia	B-DISO
caused	O
by	O
an	O
unknown	O
etiology	O
should	O
be	O
recognized	O
as	O
the	O
first	O
Disease	O
X	O
.	O
Later	O
,	O
the	O
pathogen	O
was	O
identified	O
to	O
be	O
a	O
novel	O
coronavirus	O
denoted	O
2019	O
-	O
nCoV	O
,	O
which	O
has	O
79	O
.	O
5	O
%	O
and	O
96	O
%	O
whole	O
genome	O
sequence	O
identify	O
to	O
SARS	B-DISO
-	O
CoV	O
and	O
bat	O
SARS	B-DISO
-	O
related	O
coronavirus	O
(	O
SARSr	O
-	O
CoV	O
-	O
RaTG13	O
),	O
respectively	O
,	O
suggesting	O
its	O
potential	O
bat	O
origin	O
.	O

Here	O
we	O
suggest	O
renaming	O
2019	O
-	O
nCoV	O
as	O
""""	O
transmissible	O
acute	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
TARS	O
-	O
CoV	O
")"""	O
and	O
briefly	O
review	O
the	O
advancement	O
of	O
research	O
and	O
development	O
of	O
neutralizing	O
antibodies	O
and	O
vaccines	O
targeting	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
and	O
viral	O
fusion	O
inhibitors	O
targeting	O
the	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
domain	O
in	O
spike	O
protein	O
of	O
2019	O
-	O
nCoV	O
.	O

TITLE	O
:	O
[	O
Inhibitors	O
of	O
RAS	O
Might	O
Be	O
a	O
Good	O
Choice	O
for	O
the	O
Therapy	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Pneumonia	I-DISO
].	O

Respiratory	O
support	O
is	O
the	O
most	O
important	O
therapy	O
for	O
SARI	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

Based	O
on	O
international	O
experiences	O
with	O
pandemic	O
control	O
,	O
the	O
world	O
should	O
emphasize	O
improving	O
the	O
system	O
of	O
emergency	B-DISO
reserve	O
medical	O
supplies	O
in	O
the	O
process	O
of	O
establishing	O
and	O
improving	O
public	O
health	O
emergency	B-DISO
response	O
systems	O
,	O
and	O
it	O
should	O
promote	O
the	O
establishment	O
of	O
international	O
cooperative	O
programs	O
to	O
jointly	O
deal	O
with	O
public	O
health	O
emergencies	B-DISO
of	O
international	O
concern	O
in	O
the	O
future	O
.	O

ABSTRACT	O
:	O
Porcine	O
delta	O
coronavirus	O
(	O
PDCoV	O
)	O
is	O
a	O
novel	O
emerging	O
enterocytetropic	O
virus	O
causing	O
diarrhea	B-DISO
,	O
vomiting	B-DISO
,	O
dehydration	B-DISO
,	O
and	O
mortality	O
in	O
suckling	O
piglets	O
.	O

Our	O
study	O
provided	O
comprehensive	O
information	O
about	O
lncRNAs	O
that	O
would	O
be	O
a	O
useful	O
resource	O
for	O
studying	O
the	O
pathogenesis	B-DISO
of	O
and	O
designing	O
antiviral	O
therapy	O
for	O
PDCoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
epidemiological	O
history	O
and	O
clinical	O
characteristics	O
of	O
7	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
1	O
case	O
of	O
close	O
contact	O
in	O
the	O
first	O
family	O
aggregation	O
epidemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Gansu	O
Province	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
While	O
there	O
has	O
been	O
increasing	O
attention	O
to	O
the	O
role	O
of	O
social	O
media	O
during	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
underlying	O
mechanisms	O
by	O
which	O
social	O
media	O
use	O
affects	O
risk	O
perception	O
and	O
preventive	O
behaviors	O
during	O
such	O
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
identified	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
has	O
caused	O
more	O
than	O
11	O
,	O
900	O
laboratory	O
-	O
confirmed	O
human	O
infections	B-DISO
,	O
including	O
259	O
deaths	O
,	O
posing	O
a	O
serious	O
threat	O
to	O
human	O
health	O
.	O

These	O
results	O
suggest	O
that	O
CR3022	O
may	O
have	O
the	O
potential	O
to	O
be	O
developed	O
as	O
candidate	O
therapeutics	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
neutralizing	O
antibodies	O
,	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
2019	O
-	O
nCoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
an	O
emerging	O
porcine	O
coronavirus	O
that	O
causes	O
a	O
tremendous	O
economic	O
burden	O
on	O
the	O
swine	O
industry	O
.	O

We	O
evaluated	O
the	O
performance	O
of	O
a	O
PEDV	O
imaging	O
cytometry	O
-	O
based	O
high	O
-	O
throughput	O
neutralization	O
test	O
(	O
HTNT	O
)	O
and	O
compared	O
the	O
HTNT	O
to	O
a	O
fluorescent	O
focus	O
neutralization	O
(	O
FFN	O
)	O
assay	O
using	O
serum	O
samples	O
from	O
pigs	O
of	O
known	O
PEDV	O
infection	B-DISO
status	O
(	O

It	O
was	O
believed	O
that	O
2019	O
-	O
nCoV	O
was	O
transmitted	B-DISO
through	O
respiratory	O
tract	O
and	O
then	O
induced	O
pneumonia	B-DISO
,	O
thus	O
molecular	O
diagnosis	O
based	O
on	O
oral	O
swabs	O
was	O
used	O
for	O
confirmation	O
of	O
this	O
disease	O
.	O

However	O
,	O
many	O
coronaviruses	O
can	O
also	O
be	O
transmitted	B-DISO
through	O
oral	O
-	O
fecal	O
route	O
by	O
infecting	O
intestines	O
.	O

For	O
prevention	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
23	O
provinces	O
in	O
China	O
issued	O
CM	O
programs	O
.	O

TITLE	O
:	O
Effect	O
of	O
Intravenous	O
Interferon	O
β	O
-	O
1a	O
on	O
Death	O
and	O
Days	O
Free	O
From	O
Mechanical	O
Ventilation	O
Among	O
Patients	O
With	O
Moderate	O
to	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
is	O
an	O
acute	O
,	O
highly	O
infectious	B-DISO
and	O
contagious	O
viral	B-DISO
disease	I-DISO
of	O
chickens	O
caused	O
by	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
belonging	O
to	O
the	O
genus	O
Coronavirus	O
and	O
family	O
Coronaviridae	O
.	O

The	O
TLRs	O
are	O
essential	O
for	O
initiation	O
of	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
and	O
in	O
the	O
development	O
of	O
adaptive	O
immune	O
responses	O
.	O

The	O
ECEs	O
of	O
9	O
-	O
11	O
days	O
old	O
were	O
treated	O
with	O
different	O
doses	O
(	O
high	O
,	O
intermediate	O
and	O
low	O
)	O
of	O
TLR	O
-	O
2	O
(	O
Pam3CSK4	O
),	O
TLR	O
-	O
4	O
(	O
LPS	B-DISO
)	O
and	O
TLR	O
-	O
21	O
(	O
CpG	O
ODN	O
)	O
ligands	O
.	O

The	O
present	O
study	O
pointed	O
towards	O
the	O
novel	O
opportunities	O
for	O
rational	O
design	O
of	O
LPS	B-DISO
as	O
immuno	O
-	O
stimulatory	O
agent	O
in	O
chickens	O
with	O
reference	O
to	O
IBV	O
.	O

CONCLUSIONS	O
:	O
The	O
use	O
of	O
NMBAs	O
could	O
significantly	O
decrease	O
mortality	O
in	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
patients	O
and	O
decrease	O
the	O
incidence	O
of	O
barotrauma	O
during	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
A	O
familial	O
cluster	O
of	O
infection	B-DISO
associated	O
with	O
the	O
2019	O
novel	O
coronavirus	O
indicating	O
potential	O
person	O
-	O
to	O
-	O
person	O
transmission	O
during	O
the	O
incubation	O
period	O
.	O

During	O
chemotherapy	O
the	O
child	O
had	O
a	O
persistent	O
HCoV	O
-	O
OC43	O
respiratory	B-DISO
infection	I-DISO
and	O
later	O
developed	O
progressive	O
encephalitis	B-DISO
.	O

TITLE	O
:	O
Driving	O
Pressure	O
-	O
Limited	O
Strategy	O
for	O
Patients	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
):	O

ABSTRACT	O
:	O
Necrosis	O
with	O
inflammation	B-DISO
plays	O
a	O
crucial	O
role	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
•	O
Novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)-	O
infected	O
pneumonia	B-DISO
usually	O
manifests	O
as	O
bilateral	O
ground	O
-	O
glass	O
opacities	B-DISO
in	O
the	O
lung	O
periphery	O
on	O
chest	O
CT	O
scans	O
.	O

Only	O
16	O
(	O
35	O
.	O
7	O
%)	O
of	O
RI	O
with	O
increases	O
in	O
binding	O
antibodies	O
also	O
had	O
increases	O
in	O
neutralizing	O
antibodies	O
to	O
HCoV	O
.	O
Increases	O
in	O
binding	O
antibodies	O
with	O
RI	O
were	O
more	O
frequent	O
than	O
increased	O
neutralizing	O
antibodies	O
and	O
virus	B-DISO
shedding	I-DISO
,	O
and	O
more	O
frequent	O
in	O
younger	O
compared	O
to	O
older	O
adults	O
.	O

RESULTS	O
:	O
The	O
overall	O
mortality	O
was	O
11	O
.	O
5	O
%,	O
the	O
non	O
-	O
survivors	O
revealed	O
significantly	O
higher	O
D	O
-	O
dimer	O
and	O
fibrin	O
degradation	O
product	O
(	O
FDP	O
)	O
levels	O
,	O
longer	O
prothrombin	O
time	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
compared	O
to	O
survivors	O
on	O
admission	O
(	O
P	O
<	O
.	O
05	O
);	O
71	O
.	O
4	O
%	O
of	O
non	O
-	O
survivors	O
and	O
0	O
.	O
6	O
%	O
survivors	O
met	O
the	O
criteria	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
during	O
their	O
hospital	O
stay	O
.	O

Many	O
airline	O
travelers	O
moved	O
between	O
Wuhan	O
and	O
Japan	O
at	O
that	O
time	O
,	O
suggesting	O
that	O
Japan	O
is	O
at	O
high	O
risk	O
of	O
invasion	B-DISO
by	O
the	O
virus	O
.	O

For	O
the	O
patients	O
with	O
gastrointestinal	B-DISO
tumors	I-DISO
,	O
pre	O
-	O
admission	O
screening	O
should	O
be	O
done	O
in	O
order	O
to	O
rule	O
out	O
NCP	O
.	O

Transcatheter	O
arterial	B-DISO
embolization	I-DISO
for	O
hemostasis	O
is	O
an	O
alternative	O
choice	O
for	O
gastrointestinal	B-DISO
tumor	I-DISO
with	O
bleeding	B-DISO
.	O

Preventive	O
enterostomy	B-DISO
is	O
preferable	O
in	O
lower	O
digestive	O
tract	O
surgery	O
.	O

The	O
most	O
common	O
symptoms	O
at	O
onset	O
of	O
illness	O
were	O
fever	O
in	O
48	O
(	O
77	O
%)	O
patients	O
,	O
cough	B-DISO
in	O
50	O
(	O
81	O
%),	O
expectoration	O
in	O
35	O
(	O
56	O
%),	O
headache	B-DISO
in	O
21	O
(	O
34	O
%),	O
myalgia	B-DISO
or	O
fatigue	B-DISO
in	O
32	O
(	O
52	O
%),	O
diarrhoea	B-DISO
in	O
3	O
(	O
8	O
%),	O
and	O
haemoptysis	B-DISO
in	O
2	O
(	O
3	O
%).	O

We	O
also	O
provide	O
biophysical	O
and	O
structural	O
evidence	O
that	O
the	O
2019	O
-	O
nCoV	O
S	O
protein	O
binds	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
with	O
higher	O
affinity	O
than	O
does	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
S	O
.	O
Additionally	O
,	O
we	O
tested	O
several	O
published	O
SARS	B-DISO
-	O
CoV	O
RBD	O
-	O
specific	O
monoclonal	O
antibodies	O
and	O
found	O
that	O
they	O
do	O
not	O
have	O
appreciable	O
binding	O
to	O
2019	O
-	O
nCoV	O
S	O
,	O
suggesting	O
that	O
antibody	O
cross	O
-	O
reactivity	O
may	O
be	O
limited	O
between	O
the	O
two	O
RBDs	O
.	O

Silicone	O
embolization	O
syndrome	B-DISO
(	O
SES	O
)	O
can	O
rapidly	O
progress	O
to	O
pneumonitis	B-DISO
as	O
a	O
consequence	O
of	O
the	O
injection	O
of	O
nonmedical	O
-	O
grade	O
liquid	O
silicone	O
.	O

We	O
describe	O
a	O
case	O
of	O
severe	O
silicone	O
pneumonitis	B-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
bilateral	O
pneumothorax	B-DISO
secondary	O
to	O
silicone	O
gluteal	O
augmentation	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
caused	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
infection	B-DISO
has	O
been	O
widely	O
spread	O
.	O

Electronic	O
medical	O
records	O
including	O
demographics	O
,	O
clinical	O
manifestation	O
,	O
comorbidities	O
,	O
laboratory	O
data	O
,	O
and	O
radiological	O
materials	O
of	O
140	O
hospitalized	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
,	O
with	O
confirmed	O
result	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
viral	B-DISO
infection	I-DISO
,	O
were	O
extracted	O
and	O
analyzed	O
.	O

Due	O
to	O
the	O
systemic	O
immunosuppressive	O
of	O
lung	B-DISO
cancer	I-DISO
patients	O
caused	O
by	O
the	O
malignancy	B-DISO
and	O
anticancer	O
treatments	O
,	O
lung	B-DISO
cancer	I-DISO
patients	O
are	O
more	O
susceptible	O
to	O
infection	B-DISO
than	O
healthy	O
individuals	O
.	O

Lung	B-DISO
cancer	I-DISO
patients	O
should	O
be	O
the	O
priority	O
group	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
prevention	O
.	O

Comprehensive	O
measures	O
and	O
suggestions	O
for	O
protection	O
and	O
disinfection	O
are	O
put	O
forward	O
from	O
perspectives	O
of	O
functional	O
areas	O
in	O
key	O
places	O
,	O
such	O
as	O
hotels	O
,	O
mobile	O
cabin	O
hospitals	O
,	O
passenger	O
transport	O
stations	O
and	O
public	O
transport	O
facilities	O
,	O
environment	O
and	O
facilities	O
,	O
personal	O
protection	O
,	O
operation	O
management	O
system	O
,	O
etc	O
.,	O
so	O
as	O
to	O
provide	O
technical	O
support	O
for	O
the	O
prevention	O
and	O
control	O
of	O
new	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
.	O

In	O
this	O
paper	O
,	O
combining	O
with	O
the	O
key	O
clinical	O
problems	O
of	O
prevention	O
and	O
control	O
in	O
hospital	O
during	O
the	O
epidemic	O
period	O
of	O
NCP	O
infection	B-DISO
,	O
medical	O
evidence	O
,	O
and	O
clinical	O
and	O
management	O
experience	O
,	O
the	O
author	O
formulates	O
prevention	O
and	O
control	O
management	O
strategy	O
of	O
the	O
author	O
'	O
s	O
unit	O
in	O
order	O
to	O
provide	O
reference	O
for	O
prevention	O
and	O
control	O
of	O
burn	O
and	O
wound	O
care	O
ward	O
.	O

TITLE	O
:	O
Chest	O
CT	O
Findings	O
in	O
Coronavirus	B-DISO
Disease	I-DISO
-	I-DISO
19	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
):	O
Relationship	O
to	O
Duration	O
of	O
Infection	B-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
retrospective	O
study	O
,	O
chest	O
CTs	B-DISO
of	O
121	O
symptomatic	O
patients	O
infected	O
with	O
coronavirus	B-DISO
disease	I-DISO
-	I-DISO
19	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
from	O
four	O
centers	O
in	O
China	O
from	O
January	O
18	O
,	O
2020	O
to	O
February	O
2	O
,	O
2020	O
were	O
reviewed	O
for	O
common	O
CT	O
findings	O
in	O
relationship	O
to	O
the	O
time	O
between	O
symptom	B-DISO
onset	O
and	O
the	O
initial	O
CT	O
scan	O
(	O
i	O
.	O
e	O
.	O
early	O
,	O
0	O
-	O
2	O
days	O
(	O
36	O
patients	O
),	O
intermediate	O
3	O
-	O
5	O
days	O
(	O
33	O
patients	O
),	O
late	O
6	O
-	O
12	O
days	O
(	O
25	O
patients	O
)).	O

ABSTRACT	O
:	O
The	O
geographic	O
spread	O
of	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
infections	B-DISO
from	O
the	O
epicenter	O
of	O
Wuhan	O
,	O
China	O
,	O
has	O
provided	O
an	O
opportunity	O
to	O
study	O
the	O
natural	O
history	O
of	O
the	O
recently	O
emerged	O
virus	O
.	O

The	O
mean	O
time	O
from	O
illness	O
onset	O
to	O
hospital	O
admission	O
(	O
for	O
treatment	O
and	O
/	O
or	O
isolation	O
)	O
was	O
estimated	O
at	O
3	O
-	O
4	O
days	O
without	O
truncation	B-DISO
and	O
at	O
5	O
-	O
9	O
days	O
when	O
right	O
truncated	O
.	O

The	O
median	O
time	O
delay	O
of	O
13	O
days	O
from	O
illness	O
onset	O
to	O
death	O
(	O
17	O
days	O
with	O
right	O
truncation	B-DISO
)	O
should	O
be	O
considered	O
when	O
estimating	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
case	O
fatality	O
risk	O
.	O

However	O
,	O
inappropriate	O
administration	O
of	O
diuretic	O
drugs	O
can	O
result	O
in	O
clinical	O
treatment	O
failure	O
and	O
cause	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
.	O

To	O
date	O
,	O
the	O
clinical	O
phenomenon	O
of	O
inappropriate	O
use	O
of	O
diuretics	O
leading	O
to	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
remains	O
unexplored	O
and	O
unrecognized	O
.	O

A	O
71	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
was	O
intubated	O
and	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
due	O
to	O
respiratory	B-DISO
failure	I-DISO
was	O
initially	O
diagnosed	O
with	O
pneumonia	B-DISO
as	O
a	O
complication	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

After	O
treatments	O
including	O
antibiotics	O
,	O
lung	O
protective	O
ventilation	O
strategies	O
,	O
and	O
restrictive	O
fluid	O
management	O
,	O
his	O
respiratory	B-DISO
symptoms	I-DISO
improved	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
pulmonary	B-DISO
edema	I-DISO
following	O
diuretic	O
therapy	O
to	O
stress	O
the	O
need	O
of	O
physicians	O
to	O
follow	O
guidelines	O
of	O
clinical	O
practice	O
.	O

The	O
meta	O
-	O
analysis	O
results	O
showed	O
that	O
corticosteroid	O
therapy	O
was	O
associated	O
with	O
significantly	O
higher	O
mortality	O
(	O
OR	O
1	O
.	O
53	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
16	O
,	O
2	O
.	O
01	O
])	O
and	O
incidence	O
of	O
nosocomial	B-DISO
infection	I-DISO
(	O
OR	O
3	O
.	O
15	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
54	O
,	O
6	O
.	O
45	O
]).	O

TITLE	O
:	O
Structure	O
analysis	O
of	O
the	O
receptor	O
binding	O
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
2019	O
-	O
nCoV	O
is	O
a	O
newly	O
identified	O
coronavirus	O
with	O
high	O
similarity	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
performed	O
a	O
structural	O
analysis	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
spike	O
glycoprotein	O
responsible	O
for	O
entry	O
of	O
coronaviruses	O
into	O
host	O
cells	O
.	O

TITLE	O
:	O
Community	O
pharmacist	O
in	O
public	O
health	O
emergencies	B-DISO
:	O
Quick	O
to	O
action	O
against	O
the	O
coronavirus	O
2019	O
-	O
nCoV	O
outbreak	O
.	O

TITLE	O
:	O
COVID	O
-	O
2019	O
:	O
The	O
role	O
of	O
the	O
nsp2	O
and	O
nsp3	O
in	O
its	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Processing	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
pp1a	O
/	O
ab	O
nsp7	O
-	O
10	O
region	O
.	O

To	O
date	O
,	O
CT	O
findings	O
have	O
been	O
recommended	O
as	O
major	O
evidence	O
for	O
clinical	O
diagnosis	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Hubei	O
,	O
China	O
.	O

The	O
current	O
situation	O
of	O
prevention	O
and	O
control	O
of	O
new	O
coronavirus	O
pneumonia	B-DISO
is	O
severe	O
.	O

By	O
summarizing	O
the	O
research	O
progress	O
and	O
guidelines	O
in	O
recent	O
years	O
in	O
the	O
fields	O
of	O
colorectal	B-DISO
cancer	I-DISO
disease	O
screening	O
,	O
treatment	O
strategies	O
(	O
including	O
early	O
colorectal	B-DISO
cancer	I-DISO
,	O
locally	O
advanced	O
colorectal	B-DISO
cancer	I-DISO
,	O
obstructive	O
colorectal	B-DISO
cancer	I-DISO
,	O
metastatic	B-DISO
colorectal	I-DISO
cancer	I-DISO
and	O
the	O
treatment	O
of	O
patients	O
after	O
neoadjuvant	O
therapy	O
),	O
the	O
choice	O
of	O
medication	O
and	O
time	O
limit	O
for	O
adjuvant	O
therapy	O
,	O
the	O
protective	O
measures	O
for	O
patients	O
undergoing	O
emergency	B-DISO
surgery	O
,	O
the	O
re	O
-	O
examination	O
of	O
postoperative	O
patients	O
and	O
the	O
protection	O
of	O
medical	O
staff	O
,	O
etc	O
.,	O
authors	O
improve	O
treatment	O
strategies	O
in	O
order	O
to	O
provide	O
more	O
choices	O
for	O
patients	O
to	O
obtain	O
the	O
best	O
treatment	O
under	O
the	O
severe	O
epidemic	O
situation	O
of	O
new	O
coronavirus	O
pneumonia	B-DISO
.	O

(	O
3	O
)	O
The	O
colorectal	B-DISO
cancer	I-DISO
patients	O
with	O
suspected	O
or	O
confirmed	O
NCP	O
should	O
be	O
placed	O
in	O
the	O
isolated	O
room	O
with	O
separate	O
medical	O
devices	O
,	O
and	O
the	O
operative	O
room	O
with	O
negative	O
pressure	O
(	O
under	O
-	O
5	O
Pa	O
)	O
must	O
be	O
separated	O
.	O

(	O
4	O
)	O
The	O
surgical	O
medical	O
workers	O
who	O
process	O
colorectal	B-DISO
cancer	I-DISO
patients	O
with	O
NCP	O
must	O
be	O
protected	O
by	O
three	O
-	O
level	O
.	O

Delay	O
of	O
non	O
-	O
emergency	B-DISO
dental	O
service	O
will	O
have	O
a	O
potential	O
impact	O
on	O
the	O
experience	O
,	O
cognition	O
,	O
treatment	O
and	O
rehabilitation	O
of	O
patients	O
with	O
oral	O
diseases	O
.	O

Intensive	O
research	O
on	O
the	O
novel	O
emerging	O
human	O
infectious	B-DISO
coronaviruses	O
is	O
urgently	O
needed	O
to	O
elucidate	O
their	O
route	O
of	O
transmission	O
and	O
pathogenic	O
mechanisms	O
,	O
and	O
to	O
identify	O
potential	O
drug	O
targets	O
,	O
which	O
would	O
promote	O
the	O
development	O
of	O
effective	O
preventive	O
and	O
therapeutic	O
countermeasures	O
.	O

ABSTRACT	O
:	O
Statistics	O
show	O
that	O
76	O
.	O
74	O
%	O
(	O
4	O
688	O
)	O
of	O
6	O
109	O
patients	O
with	O
chronic	O
wounds	O
are	O
those	O
over	O
50	O
years	O
of	O
age	O
;	O
the	O
proportion	O
of	O
patients	O
with	O
underlying	O
diseases	O
in	O
all	O
age	O
groups	O
above	O
50	O
years	O
ranges	O
from	O
78	O
.	O
25	O
%	O
to	O
100	O
.	O
00	O
%;	O
among	O
the	O
underlying	O
diseases	O
of	O
chronic	O
wound	O
patients	O
,	O
the	O
top	O
four	O
diseases	O
are	O
diabetes	B-DISO
mellitus	I-DISO
,	O
cardiovascular	O
and	O
cerebrovascular	B-DISO
diseases	I-DISO
,	O
hypertension	B-DISO
,	O
and	O
respiratory	B-DISO
diseases	I-DISO
.	O

Here	O
we	O
evaluate	O
the	O
preparedness	O
and	O
vulnerability	O
of	O
African	O
countries	O
against	O
their	O
risk	O
of	O
importation	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Many	O
countries	O
in	O
Africa	O
are	O
stepping	B-DISO
up	O
their	O
preparedness	O
to	O
detect	O
and	O
cope	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
importations	O
.	O

It	O
is	O
secondary	O
to	O
pulmonary	B-DISO
disease	I-DISO
or	O
a	O
disorder	O
of	O
the	O
pulmonary	O
circulation	O
.	O

Certain	O
precipitating	O
factors	O
,	O
such	O
as	O
infection	B-DISO
of	O
any	O
origin	O
,	O
have	O
been	O
reported	O
,	O
leading	O
to	O
acute	O
on	O
chronic	B-DISO
cor	I-DISO
pulmonale	I-DISO
that	O
has	O
a	O
particularly	O
high	O
mortality	O
.	O

A	O
more	O
consistent	O
and	O
evidence	O
driven	O
approach	O
to	O
adjunct	O
use	O
may	O
reduce	O
costs	O
and	O
improve	O
outcomes	O
in	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Only	O
a	O
month	O
after	O
the	O
outbreak	O
of	O
pneumonia	B-DISO
caused	O
by	O
2019	O
-	O
nCoV	O
,	O
more	O
than	O
forty	O
-	O
thousand	O
people	O
were	O
infected	O
.	O

This	O
experience	O
will	O
provide	O
China	O
and	O
other	O
countries	O
with	O
valuable	O
lessons	O
for	O
quickly	O
coordinating	O
and	O
coping	O
with	O
future	O
public	O
health	O
emergencies	B-DISO
.	O

TITLE	O
:	O
First	O
respiratory	O
transmitted	B-DISO
food	O
borne	O
outbreak	O
?	O

TITLE	O
:	O
Potential	O
Presymptomatic	O
Transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
Zhejiang	O
Province	O
,	O
China	O
,	O
2020	O
.	O

Totally	O
80	O
patients	O
diagnosed	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
included	O
.	O

The	O
common	O
chest	O
CT	O
findings	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
are	O
multiple	O
GGO	O
,	O
consolidation	O
and	O
interlobular	O
septal	O
thickening	O
in	O
both	O
lungs	O
,	O
which	O
are	O
mostly	O
distributed	O
under	O
the	O
pleura	O
.	O

RESULTS	O
:	O
Totally	O
80	O
patients	O
diagnosed	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
included	O
.	O

A	O
variety	O
of	O
chest	O
imaging	O
features	O
have	O
been	O
reported	O
,	O
similar	O
to	O
those	O
found	O
in	O
other	O
types	O
of	O
coronavirus	O
syndromes	B-DISO
.	O

One	O
possible	O
answer	O
is	O
antibody	B-DISO
dependent	I-DISO
enhancement	I-DISO
(	O
ADE	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
due	O
to	O
prior	O
exposure	O
to	O
other	O
coronaviruses	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
Real	O
-	O
time	O
dissemination	O
of	O
scientific	O
information	O
to	O
fight	O
a	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
.	O

Therefore	O
,	O
although	O
SARS	B-DISO
,	O
MERS	O
,	O
and	O
COVID	B-DISO
-	I-DISO
19	I-DISO
are	O
all	O
the	O
result	O
of	O
coronaviral	O
infections	B-DISO
,	O
the	O
causes	O
of	O
the	O
coronaviruses	O
differ	O
dramatically	O
in	O
their	O
transmissibility	O
.	O

We	O
estimate	O
the	O
dependence	B-DISO
of	O
the	O
risk	O
of	O
a	O
major	O
outbreak	O
in	O
a	O
country	O
from	O
imported	O
cases	O
on	O
key	O
parameters	O
such	O
as	O
:	O
(	O
i	O
)	O
the	O
evolution	O
of	O
the	O
cumulative	O
number	O
of	O
cases	O
in	O
mainland	O
China	O
outside	O
the	O
closed	O
areas	O
;	O
(	O
ii	O
)	O
the	O
connectivity	O
of	O
the	O
destination	O
country	O
with	O
China	O
,	O
including	O
baseline	O
travel	O
frequencies	O
,	O
the	O
effect	O
of	O
travel	O
restrictions	O
,	O
and	O
the	O
efficacy	O
of	O
entry	O
screening	O
at	O
destination	O
;	O
and	O
(	O
iii	O
)	O
the	O
efficacy	O
of	O
control	O
measures	O
in	O
the	O
destination	O
country	O
(	O
expressed	O
by	O
the	O
local	O
reproduction	O
number	O
R	O
loc	O
).	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
cases	O
of	O
unidentified	O
pneumonia	B-DISO
with	O
a	O
history	O
of	O
exposure	O
in	O
the	O
Huanan	O
Seafood	O
Market	O
were	O
reported	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
.	O

Human	O
-	O
to	O
-	O
human	O
transmission	O
is	O
confirmed	O
,	O
and	O
this	O
disease	O
(	O
named	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
World	O
Health	O
Organization	O
(	O
WHO	O
))	O
spread	O
rapidly	O
around	O
the	O
country	O
and	O
the	O
world	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
resulted	O
in	O
a	O
much	O
lower	O
case	O
-	O
fatality	O
rate	O
(	O
about	O
2	O
.	O
67	O
%)	O
among	O
the	O
confirmed	O
cases	O
,	O
compared	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
).	O

The	O
source	O
of	O
the	O
virus	O
and	O
the	O
pathogenesis	B-DISO
of	O
this	O
disease	O
are	O
still	O
unconfirmed	O
.	O

These	O
findings	O
suggest	O
that	O
glycopyrronium	O
,	O
formoterol	O
,	O
and	O
a	O
combination	O
of	O
glycopyrronium	O
,	O
formoterol	O
,	O
and	O
budesonide	O
inhibit	O
HCoV	O
-	O
229E	O
replication	O
partly	O
by	O
inhibiting	O
receptor	O
expression	O
and	O
/	O
or	O
endosomal	O
function	O
and	O
that	O
these	O
drugs	O
modulate	O
infection	B-DISO
-	O
induced	O
inflammation	B-DISO
in	O
the	O
airway	O
.	O

RESULTS	O
:	O
Pretreatment	O
of	O
HNE	O
and	O
HTE	O
cells	O
with	O
glycopyrronium	O
or	O
formoterol	O
decreased	O
viral	O
RNA	O
levels	O
and	O
/	O
or	O
titers	O
,	O
the	O
expression	O
of	O
the	O
HCoV	O
-	O
229E	O
receptor	O
CD13	O
,	O
the	O
number	O
and	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
where	O
HCoV	O
-	O
229E	O
RNA	O
enters	O
the	O
cytoplasm	O
,	O
and	O
the	O
infection	B-DISO
-	O
induced	O
production	O
of	O
cytokines	O
,	O
including	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IFN	O
-	O
β	O
.	O

To	O
investigate	O
the	O
potential	O
route	O
of	O
2019	B-DISO
-	I-DISO
nCov	I-DISO
infection	I-DISO
on	O
the	O
mucosa	O
of	O
oral	O
cavity	B-DISO
,	O
bulk	O
RNA	O
-	O
seq	O
profiles	O
from	O
two	O
public	O
databases	O
including	O
The	O
Cancer	B-DISO
Genome	O
Atlas	O
(	O
TCGA	O
)	O
and	O
Functional	O
Annotation	O
of	O
The	O
Mammalian	O
Genome	O
Cap	B-DISO
Analysis	O
of	O
Gene	O
Expression	O
(	O
FANTOM5	O
CAGE	O
)	O
dataset	O
were	O
collected	O
.	O

RNA	O
-	O
seq	O
profiling	O
data	O
of	O
13	O
organ	O
types	O
with	O
para	O
-	O
carcinoma	B-DISO
normal	O
tissues	O
from	O
TCGA	O
and	O
14	O
organ	O
types	O
with	O
normal	O
tissues	O
from	O
FANTOM5	O
CAGE	O
were	O
analyzed	O
in	O
order	O
to	O
explore	O
and	O
validate	O
the	O
expression	O
of	O
ACE2	O
on	O
the	O
mucosa	O
of	O
oral	O
cavity	B-DISO
.	O

TITLE	O
:	O
Functional	O
assessment	O
of	O
cell	O
entry	O
and	O
receptor	O
usage	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
and	O
other	O
lineage	O
B	O
betacoronaviruses	O
.	O

Early	O
antiviral	O
treatment	O
could	O
alleviate	O
disease	O
severity	O
and	O
prevent	O
illness	O
progression	O
,	O
and	O
we	O
found	O
lopinavir	O
/	O
ritonavir	O
combined	O
with	O
abidol	O
showed	O
antiviraleffects	O
in	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Moreover	O
,	O
it	O
also	O
favoredthe	O
balance	O
of	O
fluid	O
,	O
electrolyte	O
and	O
acid	O
-	O
base	O
and	O
thus	O
improved	O
treatment	O
efficacy	O
in	O
critical	B-DISO
illness	I-DISO
.	O

Antimicrobial	O
prophylaxis	O
should	O
be	O
prescribed	O
rationally	O
and	O
was	O
not	O
recommended	O
except	O
for	O
patients	O
with	O
long	O
course	O
of	O
disease	O
,	O
repeated	O
fever	O
and	O
elevated	O
procalcitonin	O
(	O
PCT	B-DISO
),	O
meanwhile	O
secondary	O
fungal	B-DISO
infection	I-DISO
should	O
be	O
concerned	O
.	O

Besides	O
,	O
we	O
should	O
select	O
the	O
appropriate	O
therapy	O
and	O
optimize	O
treatment	O
process	O
so	O
as	O
to	O
prevent	O
the	O
propagation	O
and	O
cross	B-DISO
infection	I-DISO
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
as	O
well	O
as	O
manage	O
the	O
breast	B-DISO
diseases	I-DISO
without	O
delay	O
.	O

Therefore	O
,	O
we	O
carried	O
out	O
some	O
management	O
proposals	O
of	O
the	O
patients	O
with	O
breast	B-DISO
diseases	I-DISO
in	O
the	O
central	O
epidemic	O
area	O
during	O
the	O
epidemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
on	O
the	O
basis	O
of	O
conventional	O
treatment	O
guidelines	O
and	O
clinical	O
experiences	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
occurred	O
in	O
Wuhan	O
,	O
Hubei	O
province	O
of	O
China	O
,	O
at	O
the	O
end	O
of	O
2019	O
,	O
and	O
spread	O
rapidly	O
across	O
the	O
country	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
a	O
series	O
of	O
unexplained	O
pneumonia	B-DISO
cases	O
have	O
been	O
reported	O
in	O
Wuhan	O
,	O
China	O
.	O

TITLE	O
:	O
Analysis	O
of	O
Severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	B-DISO
in	O
critical	O
ill	B-DISO
patients	O
in	O
central	O
China	O
.	O

ABSTRACT	O
:	O
Severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	B-DISO
(	O
SFTS	O
)	O
is	O
an	O
emerging	O
zoonosis	B-DISO
infected	O
by	O
virus	O
(	O
SFTSV	O
)	O
in	O
central	O
and	O
eastern	O
China	O
,	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
.	O

We	O
applied	O
""""	O
projections	O
""""	O
package	O
in	O
R	O
to	O
simulate	O
the	O
plausible	O
cumulative	O
epidemic	O
trajectories	O
and	O
future	O
daily	O
incidence	O
by	O
fitting	B-DISO
the	O
data	O
of	O
existing	O
daily	O
incidence	O
,	O
a	O
serial	O
interval	O
distribution	O
,	O
and	O
the	O
estimated	O
R0	O
into	O
a	O
model	O
based	O
on	O
the	O
assumption	O
that	O
daily	O
incidence	O
obeys	O
approximately	O
Poisson	O
distribution	O
determined	O
by	O
daily	O
infectiousness	O
.	O

We	O
applied	O
""""	O
projections	O
""""	O
package	O
in	O
R	O
to	O
simulate	O
the	O
plausible	O
cumulative	O
epidemic	O
trajectories	O
and	O
future	O
daily	O
incidence	O
by	O
fitting	B-DISO
the	O
data	O
of	O
existing	O
daily	O
incidence	O
,	O
a	O
serial	O
interval	O
distribution	O
,	O
and	O
the	O
estimated	O
R0	O
into	O
a	O
model	O
based	O
on	O
the	O
assumption	O
that	O
daily	O
incidence	O
obeys	O
approximately	O
Poisson	O
distribution	O
determined	O
by	O
daily	O
infectiousness	O
.	O

CONCLUSIONS	O
:	O
The	O
median	O
with	O
95	O
%	O
CI	O
of	O
R0	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
was	O
about	O
2	O
.	O
28	O
(	O
2	O
.	O
06	O
-	O
2	O
.	O
52	O
)	O
during	O
the	O
early	O
stage	O
experienced	O
on	O
the	O
Diamond	O
Princess	O
cruise	O
ship	O
.	O

Many	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
part	O
of	O
patients	O
,	O
adults	O
or	O
children	O
,	O
diagnosed	O
with	O
glioblastoma	B-DISO
will	O
suffer	B-DISO
from	O
cognitive	O
deficiency	O
during	O
their	O
clinical	O
course	O
,	O
especially	O
in	O
long	O
-	O
term	O
survivors	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
severity	O
of	O
infection	B-DISO
for	O
a	O
given	O
disease	O
,	O
it	O
is	O
common	O
epidemiological	O
practice	O
to	O
estimate	O
the	O
case	O
fatality	O
risk	O
,	O
defined	O
as	O
the	O
risk	O
of	O
death	O
among	O
cases	O
.	O

The	O
collaborative	O
efforts	O
of	O
researchers	O
are	O
needed	O
to	O
fill	O
the	O
knowledge	O
gaps	O
about	O
this	O
new	O
virus	O
,	O
to	O
develop	O
the	O
proper	O
diagnostic	O
tools	O
,	O
and	O
effective	O
treatment	O
to	O
combat	O
this	O
infection	B-DISO
.	O

The	O
goal	O
of	O
this	O
work	O
is	O
to	O
systematically	O
review	O
and	O
compare	O
between	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
the	O
context	O
of	O
their	O
virus	O
incubation	O
,	O
originations	O
,	O
diagnosis	O
and	O
treatment	O
methods	O
,	O
genomic	O
and	O
proteomic	O
sequences	O
,	O
and	O
pathogenic	O
mechanisms	O
.	O

TITLE	O
:	O
[	O
What	O
are	O
the	O
highlights	O
of	O
""""	O
Diagnosis	O
and	O
treatment	O
of	O
Disease	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
suitable	O
for	O
Military	O
support	O
Hubei	O
medical	O
team	O
"""]."	O

According	O
to	O
""""	O
the	O
Diagnosis	O
and	O
Treatment	O
of	O
New	O
Coronavirus	O
Pneumonia	B-DISO
"""("	O
6th	O
edition	O
)	O
of	O
the	O
National	O
Health	O
Commission	O
of	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
,	O
a	O
new	O
guideline	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
suitable	O
for	O
the	O
military	O
(	O
first	O
trial	O
version	O
)	O
was	O
established	O
.	O

With	O
the	O
spreading	O
of	O
the	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	B-DISO
,	O
the	O
reproduction	O
number	O
has	O
been	O
found	O
to	O
vary	O
,	O
reflecting	O
the	O
dynamics	O
of	O
transmission	O
of	O
the	O
coronavirus	O
outbreak	O
as	O
well	O
as	O
the	O
case	O
reporting	O
rate	O
.	O

ABSTRACT	O
:	O
This	O
study	O
presents	O
a	O
preliminary	O
report	O
on	O
the	O
chest	O
radiographic	O
and	O
computed	O
tomography	O
(	O
CT	O
)	O
findings	O
of	O
the	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
pneumonia	B-DISO
in	O
Korea	O
.	O

TITLE	O
:	O
2019	O
Novel	O
Coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
Pneumonia	B-DISO
:	O
Serial	O
Computed	O
Tomography	O
Findings	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
presence	O
of	O
novel	O
coronavirus	O
in	O
tears	O
and	O
conjunctival	O
secretions	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
infected	O
patients	O
.	O

We	O
speculate	O
that	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
may	O
be	O
detected	O
in	O
the	O
tears	O
and	O
conjunctival	O
secretions	O
in	O
NCP	O
patients	O
with	O
conjunctivitis	B-DISO
.	O

ABSTRACT	O
:	O
From	O
the	O
beginning	O
of	O
2002	O
and	O
2012	O
,	O
severe	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
crossed	O
the	O
species	O
barriers	O
to	O
infect	O
humans	O
,	O
causing	O
thousands	O
of	O
infections	B-DISO
and	O
hundreds	O
of	O
deaths	O
,	O
respectively	O
.	O

This	O
paper	O
discusses	O
how	O
to	O
realize	O
scientific	O
health	O
management	O
of	O
breast	B-DISO
cancer	I-DISO
patients	O
outside	O
the	O
hospital	O
based	O
on	O
the	O
existing	O
epidemic	O
situation	O
,	O
characteristics	O
of	O
breast	B-DISO
cancer	I-DISO
patients	O
and	O
public	O
health	O
safety	O
factors	O
.	O

Conclusion	O
Chest	O
CT	O
has	O
a	O
high	O
sensitivity	O
for	O
diagnosis	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Here	O
we	O
aimed	O
to	O
describe	O
ARDS	B-DISO
incidence	O
and	O
severity	O
among	O
patients	O
evacuated	O
from	O
war	O
zones	O
and	O
admitted	O
to	O
French	O
intensive	O
care	O
units	O
(	O
ICUs	O
).	O

Analyzed	O
parameters	O
included	O
invasive	O
ventilation	O
duration	O
,	O
ARDS	B-DISO
treatments	O
,	O
ICU	O
stay	O
length	O
,	O
and	O
30	O
-	O
day	O
and	O
90	O
-	O
day	O
mortality	O
.	O

The	O
infection	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
has	O
been	O
reported	O
in	O
the	O
brains	O
from	O
both	O
patients	O
and	O
experimental	O
animals	O
,	O
where	O
the	O
brainstem	O
was	O
heavily	O
infected	O
.	O

Following	O
the	O
SARS	B-DISO
outbreak	O
,	O
5	O
additional	O
coronaviruses	O
have	O
been	O
discovered	O
in	O
humans	O
,	O
most	O
recently	O
the	O
novel	O
coronavirus	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
believed	O
to	O
have	O
originated	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
.	O

SARS	B-DISO
-	O
CoV	O
and	O
MERSCoV	O
are	O
particularly	O
pathogenic	O
in	O
humans	O
and	O
are	O
associated	O
with	O
high	O
mortality	O
.	O

In	O
this	O
review	O
,	O
the	O
epidemiology	O
,	O
pathophysiology	O
,	O
and	O
management	O
of	O
the	O
recently	O
discovered	O
COVID	B-DISO
-	I-DISO
19	I-DISO
are	O
reviewed	O
,	O
with	O
a	O
focus	O
on	O
best	O
practices	O
and	O
the	O
public	O
health	O
implications	O
.	O

The	O
interface	O
formed	O
a	O
conserved	O
hydrophobic	O
cavity	B-DISO
suitable	O
for	O
targeted	O
drug	O
screening	O
.	O

TITLE	O
:	O
Clinical	O
course	O
and	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
pneumonia	B-DISO
in	O
Wuhan	O
,	O
China	O
:	O
a	O
single	O
-	O
centered	O
,	O
retrospective	O
,	O
observational	O
study	O
.	O

The	O
mean	O
age	O
of	O
the	O
52	O
patients	O
was	O
59	O
·	O
7	O
(	O
SD	O
13	O
·	O
3	O
)	O
years	O
,	O
35	O
(	O
67	O
%)	O
were	O
men	O
,	O
21	O
(	O
40	O
%)	O
had	O
chronic	B-DISO
illness	I-DISO
,	O
51	O
(	O
98	O
%)	O
had	O
fever	O
.	O

TITLE	O
:	O
Radiological	O
findings	O
from	O
81	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
in	O
Wuhan	O
,	O
China	O
:	O
a	O
descriptive	O
study	O
.	O

The	O
predominant	O
pattern	O
of	O
abnormality	O
observed	O
was	O
bilateral	O
(	O
64	O
[	O
79	O
%]	O
patients	O
),	O
peripheral	O
(	O
44	O
[	O
54	O
%]),	O
ill	B-DISO
-	O
defined	O
(	O
66	O
[	O
81	O
%]),	O
and	O
ground	O
-	O
glass	O
opacification	O
(	O
53	O
[	O
65	O
%]),	O
mainly	O
involving	O
the	O
right	O
lower	O
lobes	O
(	O
225	O
[	O
27	O
%]	O
of	O
849	O
affected	O
segments	O
).	O

Lesions	O
quickly	O
evolved	O
to	O
bilateral	O
(	O
19	O
[	O
90	O
%]),	O
diffuse	O
(	O
11	O
[	O
52	O
%])	O
ground	O
-	O
glass	O
opacity	B-DISO
predominance	O
(	O
17	O
[	O
81	O
%])	O
in	O
group	O
2	O
(	O
n	O
=	O
21	O
).	O

ABSTRACT	O
:	O
Fast	O
point	O
-	O
of	O
-	O
use	O
detection	O
of	O
,	O
for	O
example	O
,	O
early	O
-	O
stage	O
zoonoses	B-DISO
,	O
e	O
.	O
g	O
.,	O
Q	B-DISO
-	I-DISO
fever	I-DISO
,	O
bovine	B-DISO
tuberculosis	I-DISO
,	O
or	O
the	O
Covid	B-DISO
-	I-DISO
19	I-DISO
coronavirus	O
,	O
is	O
beneficial	O
for	O
both	O
humans	O
and	O
animal	O
husbandry	O
as	O
it	O
can	O
save	O
lives	O
and	O
livestock	O
.	O

Tests	O
with	O
real	O
zoonoses	B-DISO
and	O
DNA	O
specific	O
amplification	B-DISO
reactions	O
still	O
need	O
to	O
be	O
done	O
.	O

As	O
no	O
mutation	O
has	O
been	O
observed	O
in	O
these	O
identified	O
epitopes	O
among	O
the	O
120	O
available	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
sequences	O
(	O
as	O
of	O
21	O
February	O
2020	O
),	O
immune	O
targeting	O
of	O
these	O
epitopes	O
may	O
potentially	O
offer	O
protection	O
against	O
this	O
novel	O
virus	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
:	O
Coronaviruses	O
and	O
Blood	O
Safety	O
.	O

Of	O
all	O
included	O
patients	O
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
presented	O
with	O
ground	O
glass	O
opacities	B-DISO
in	O
65	O
(	O
72	O
%),	O
consolidation	O
in	O
12	O
(	O
13	O
%),	O
crazy	O
paving	O
pattern	O
in	O
11	O
(	O
12	O
%),	O
interlobular	O
thickening	O
in	O
33	O
(	O
37	O
%),	O
adjacent	O
pleura	B-DISO
thickening	I-DISO
in	O
50	O
(	O
56	O
%),	O
and	O
linear	O
opacities	B-DISO
combined	O
in	O
55	O
(	O
61	O
%).	O

Pleural	O
effusion	B-DISO
,	I-DISO
pericardial	I-DISO
effusion	B-DISO
,	O
and	O
lymphadenopathy	O
were	O
uncommon	O
findings	O
.	O

TITLE	O
:	O
Impact	O
of	O
corticosteroid	O
treatment	O
on	O
clinical	O
outcomes	O
of	O
influenza	B-DISO
-	O
associated	O
ARDS	B-DISO
:	O
a	O
nationwide	O
multicenter	O
study	O
.	O

Among	O
the	O
241	O
patients	O
with	O
influenza	B-DISO
-	O
associated	O
ARDS	B-DISO
,	O
85	O
(	O
35	O
.	O
3	O
%)	O
patients	O
receiving	O
early	O
corticosteroid	O
treatment	O
had	O
similar	O
baseline	O
characteristics	O
,	O
but	O
a	O
significantly	O
higher	O
hospital	O
mortality	O
rate	O
than	O
those	O
without	O
early	O
corticosteroid	O
treatment	O
[	O
43	O
.	O
5	O
%	O
(	O
37	O
/	O
85	O
)	O
vs	O
.	O
19	O
.	O
2	O
%	O
(	O
30	O
/	O
156	O
),	O
p	O
<	O
0	O
.	O
001	O
].	O

Early	O
corticosteroid	O
treatment	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
hospital	O
mortality	O
in	O
adult	O
patients	O
with	O
influenza	B-DISO
-	O
associated	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
epidemic	O
situation	O
and	O
spatiotemporal	O
changes	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Anhui	O
].	O

We	O
mapped	O
the	O
spatiotemporal	O
changes	O
of	O
confirmed	O
cases	O
,	O
fitted	B-DISO
the	O
epidemic	O
situation	O
by	O
the	O
population	O
growth	O
curve	O
at	O
different	O
stages	O
and	O
took	O
statistical	O
description	O
and	O
analysis	O
of	O
the	O
epidemic	O
situation	O
in	O
Anhui	O
province	O
.	O

ABSTRACT	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
been	O
in	O
epidemic	O
for	O
nearly	O
two	O
months	O
.	O

Compared	O
with	O
that	O
of	O
during	O
SARS	B-DISO
period	O
in	O
2003	O
,	O
China	O
has	O
the	O
stronger	O
capability	O
to	O
carry	O
out	O
clinical	O
trials	O
of	O
new	O
drugs	O
in	O
emergency	B-DISO
period	O
.	O

TITLE	O
:	O
[	O
Treatment	O
strategies	O
of	O
Budd	B-DISO
-	I-DISO
Chiari	I-DISO
syndrome	I-DISO
during	O
the	O
epidemic	O
period	O
of	O
2019	O
coronavirus	O
disease	O
].	O

ABSTRACT	O
:	O
Genome	O
Detective	O
is	O
a	O
web	B-DISO
-	O
based	O
,	O
user	O
-	O
friendly	O
software	O
application	O
to	O
quickly	O
and	O
accurately	O
assemble	O
all	O
known	O
virus	O
genomes	O
from	O
next	O
generation	O
sequencing	O
datasets	O
.	O

The	O
tool	O
also	O
allows	O
tracking	O
of	O
new	O
viral	O
mutations	O
as	O
the	O
outbreak	O
expands	O
globally	O
,	O
which	O
may	O
help	O
to	O
accelerate	O
the	O
development	O
of	O
novel	O
diagnostics	O
,	O
drugs	O
and	O
vaccines	O
to	O
stop	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
disease	O
.	O

During	O
the	O
first	O
2	O
months	O
of	O
the	O
current	O
outbreak	O
,	O
Covid	B-DISO
-	I-DISO
19	I-DISO
spread	O
rapidly	O
throughout	O
China	O
and	O
caused	O
varying	O
degrees	O
of	O
illness	O
.	O

The	O
proportion	O
of	O
patients	O
having	O
liver	B-DISO
dysfunction	I-DISO
and	O
abnormal	O
CT	O
imaging	O
was	O
relatively	O
lower	O
than	O
that	O
of	O
Wuhan	O
.	O

A	O
retrospective	O
analysis	O
was	O
performed	O
on	O
the	O
imaging	O
findings	O
of	O
patients	O
confirmed	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
who	O
had	O
chest	O
CT	O
scanning	O
and	O
treatment	O
after	O
disease	O
onset	O
.	O

The	O
density	O
of	O
lesion	O
was	O
mostly	O
uneven	O
with	O
ground	O
glass	O
opacity	B-DISO
as	O
the	O
primary	O
presentation	O
accompanied	O
by	O
partial	O
consolidation	O
and	O
fibrosis	B-DISO
.	O

TITLE	O
:	O
[	O
The	O
keypoints	O
in	O
treatment	O
of	O
the	O
critical	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
patient	O
].	O

TITLE	O
:	O
[	O
Recommendations	O
for	O
the	O
regulation	O
of	O
medical	O
practices	O
of	O
burn	O
treatment	O
during	O
the	O
outbreak	O
of	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
].	O

The	O
next	O
generation	O
matrix	O
approach	O
was	O
adopted	O
to	O
calculate	O
the	O
basic	O
reproduction	O
number	O
(	O
R	O
The	O
value	O
of	O
R	O
Our	O
model	O
showed	O
that	O
the	O
transmissibility	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
was	O
higher	O
than	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
in	O
the	O
Middle	O
East	O
countries	O
,	O
similar	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
but	O
lower	O
than	O
MERS	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

In	O
most	O
provinces	O
,	O
a	O
high	O
proportion	O
of	O
older	O
men	O
develop	O
infections	B-DISO
after	O
exposure	O
to	O
camels	O
.	O

ABSTRACT	O
:	O
The	O
December	O
,	O
2019	O
coronavirus	O
disease	O
outbreak	O
has	O
seen	O
many	O
countries	O
ask	O
people	O
who	O
have	O
potentially	O
come	O
into	O
contact	O
with	O
the	O
infection	B-DISO
to	O
isolate	O
themselves	O
at	O
home	O
or	O
in	O
a	O
dedicated	O
quarantine	O
facility	O
.	O

On	O
the	O
basis	O
of	O
this	O
study	O
,	O
we	O
provided	O
the	O
ratio	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
on	O
the	O
severe	O
cases	O
to	O
the	O
mild	O
,	O
asymptomatic	O
and	O
non	O
-	O
pneumonia	B-DISO
cases	O
in	O
Beijing	O
.	O

Another	O
uncommon	O
element	O
was	O
the	O
presence	O
of	O
mediastinal	B-DISO
lymphadenopathy	I-DISO
with	O
short	O
-	O
axis	O
oval	O
nodes	O
.	O

Finally	O
,	O
the	O
pulmonary	O
vessels	O
enlargement	B-DISO
in	O
areas	O
where	O
new	O
lung	O
infiltrates	B-DISO
develop	O
in	O
the	O
follow	O
-	O
up	O
CT	O
scan	O
,	O
could	O
describe	O
an	O
early	O
predictor	O
radiological	O
sign	O
of	O
lung	O
impairment	B-DISO
.	O

TITLE	O
:	O
World	O
Health	O
Organization	O
declares	O
global	O
emergency	B-DISO
:	O
A	O
review	O
of	O
the	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

In	O
response	O
to	O
this	O
global	O
outbreak	O
,	O
we	O
summarise	O
the	O
current	O
state	O
of	O
knowledge	O
surrounding	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Evaluation	O
of	O
novel	O
multiplex	O
qPCR	O
assays	O
for	O
diagnosis	O
of	O
pathogens	O
associated	O
with	O
the	O
bovine	B-DISO
respiratory	I-DISO
disease	I-DISO
complex	I-DISO
.	O

Pathogenic	O
bacteria	O
(	O
Mannheimia	O
haemolytica	O
(	O
Mh	O
),	O
Pasteurella	O
multocida	O
(	O
Pm	O
),	O
Histophilus	O
somni	O
(	O
Hs	O
),	O
and	O
Mycoplasma	B-DISO
bovis	O
)	O
and	O
a	O
range	O
of	O
viruses	O
(	O
bovine	O
respiratory	O
syncytial	O
virus	O
,	O
bovine	O
coronavirus	O
,	O
bovine	O
parainfluenza	B-DISO
virus	O
type	O
3	O
,	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
and	O
bovine	O
herpesvirus	O
type	O
1	O
)	O
are	O
associated	O
with	O
this	O
complex	O
.	O

Of	O
these	O
125	O
herbs	O
,	O
26	O
are	O
classically	O
catalogued	O
as	O
treating	O
viral	O
respiratory	B-DISO
infections	I-DISO
.	O

Network	O
pharmacology	O
analysis	O
predicted	O
that	O
the	O
general	O
in	O
vivo	O
roles	O
of	O
these	O
26	O
herbal	O
plants	O
were	O
related	O
to	O
regulating	O
viral	B-DISO
infection	I-DISO
,	O
immune	O
/	O
inflammation	B-DISO
reactions	O
and	O
hypoxia	B-DISO
response	O
.	O

ABSTRACT	O
:	O
An	O
ongoing	O
outbreak	O
of	O
severe	O
respiratory	O
pneumonia	B-DISO
associated	O
with	O
the	O
2019	O
novel	O
coronavirus	O
has	O
recently	O
emerged	O
in	O
China	O
.	O

We	O
compared	O
the	O
positive	O
ratio	O
of	O
2019	O
-	O
nCoV	O
nucleic	O
acid	O
amplification	B-DISO
test	O
results	O
from	O
different	O
samples	O
including	O
oropharyngeal	O
swab	O
,	O
blood	O
,	O
urine	O
and	O
stool	O
with	O
3	O
different	O
fluorescent	O
RT	O
-	O
PCR	O
kits	O
.	O

Ten	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
30	O
patients	O
with	O
other	B-DISO
viral	I-DISO
pneumonia	I-DISO
(	O
non	O
-	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
admitted	O
to	O
Shanghai	O
Jiao	O
Tong	O
University	O
Affiliated	O
Sixth	O
People	O
'	O
s	O
Hospital	O
and	O
Jinshan	O
Branch	O
Hospital	O
from	O
January	O
22	O
to	O
February	O
17	O
,	O
2020	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

We	O
analyzed	O
the	O
data	O
of	O
patients	O
who	O
received	O
corticosteroids	O
within	O
7	O
days	O
of	O
the	O
onset	O
of	O
ARDS	B-DISO
between	O
June	O
2006	O
and	O
December	O
2015	O
at	O
a	O
single	O
tertiary	O
teaching	O
hospital	O
.	O

There	O
is	O
currently	O
no	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
can	O
be	O
transmitted	B-DISO
transplacentally	O
from	O
mother	O
to	O
the	O
newborn	O
.	O

Mice	O
were	O
then	O
placed	O
on	O
high	O
-	O
volume	O
MV	O
(	O
30	O
ml	O
/	O
kg	O
with	O
3	O
cmH	B-DISO

ABSTRACT	O
:	O
With	O
the	O
increasing	O
number	O
of	O
cases	O
and	O
widening	O
geographical	O
spread	O
,	O
the	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
been	O
classified	O
as	O
one	O
of	O
the	O
class	O
B	O
infectious	B-DISO
diseases	I-DISO
but	O
prevented	O
and	O
controlled	O
as	O
class	O
A	O
infectious	B-DISO
disease	I-DISO
by	O
the	O
National	O
Health	O
Commission	O
of	O
China	O
.	O

Strict	O
protection	O
for	O
lung	B-DISO
cancer	I-DISO
patients	O
is	O
needed	O
to	O
avoid	O
infection	B-DISO
.	O

Lung	B-DISO
cancer	I-DISO
patients	O
are	O
difficult	O
to	O
differentiate	O
from	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
terms	O
of	O
clinical	O
symptoms	O
,	O
which	O
will	O
bring	O
great	O
trouble	O
to	O
the	O
clinical	O
work	O
and	O
physical	O
and	O
mental	O
health	O
of	O
lung	B-DISO
cancer	I-DISO
patients	O
.	O

This	O
review	O
will	O
demonstrate	O
how	O
to	O
applicate	O
appropriate	O
and	O
individual	O
management	O
for	O
lung	B-DISO
cancer	I-DISO
patients	O
to	O
protect	O
them	O
from	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Compared	O
with	O
the	O
ordinary	O
patients	O
,	O
the	O
severe	O
/	O
critical	O
patients	O
had	O
older	O
ages	O
,	O
higher	O
incidence	O
of	O
comorbidities	O
,	O
cough	B-DISO
,	O
expectoration	O
,	O
chest	B-DISO
pain	I-DISO
and	O
dyspnea	B-DISO
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
ordinary	O
patients	O
,	O
the	O
severe	O
/	O
critical	O
patients	O
had	O
older	O
ages	O
,	O
higher	O
incidence	O
of	O
comorbidities	O
,	O
cough	B-DISO
,	O
expectoration	O
,	O
chest	B-DISO
pain	I-DISO
and	O
dyspnea	B-DISO
.	O

TITLE	O
:	O
Analysis	O
of	O
factors	O
associated	O
with	O
disease	O
outcomes	O
in	O
hospitalized	O
patients	O
with	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Since	O
early	O
December	O
2019	O
,	O
the	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
caused	O
pneumonia	B-DISO
epidemic	O
in	O
Wuhan	O
,	O
Hubei	O
province	O
of	O
China	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
factors	O
affecting	O
the	O
progression	O
of	O
pneumonia	B-DISO
in	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
.	O

For	O
all	O
the	O
78	O
patients	O
,	O
fever	O
was	O
the	O
most	O
common	O
initial	O
symptom	B-DISO
,	O
and	O
the	O
maximum	O
body	O
temperature	O
at	O
admission	O
was	O
significantly	O
higher	O
in	O
the	O
progression	O
group	O
than	O
in	O
the	O
improvement	O
/	O
stabilization	O
group	O
(	O
38	O
.	O
2	O
[	O
37	O
.	O
8	O
,	O
38	O
.	O
6	O
]	O
vs	O
.	O
37	O
.	O
5	O
[	O
37	O
.	O
0	O
,	O
38	O
.	O
4	O
]°	O
C	O
,	O
U	O
=	O
2	O
.	O
057	O
,	O
P	O
=	O
0	O
.	O
027	O
).	O

RESULTS	O
:	O
Seventy	O
-	O
eight	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
induced	O
pneumonia	B-DISO
met	O
the	O
inclusion	O
criteria	O
and	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
official	O
case	O
report	O
on	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
was	O
collected	O
as	O
of	O
January	O
30	O
,	O
2020	O
.	O

Time	O
and	O
location	O
information	O
on	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
was	O
extracted	O
and	O
analyzed	O
using	O
ArcGIS	O
and	O
WinBUGS	O
software	O
.	O

We	O
developed	O
a	O
stochastic	O
transmission	O
model	O
,	O
parameterised	O
to	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
.	O

In	O
this	O
study	O
,	O
sequence	O
analysis	O
,	O
modeling	O
,	O
and	O
docking	O
are	O
used	O
to	O
build	O
a	O
model	O
for	O
Wuhan	O
COVID	B-DISO
-	I-DISO
19	I-DISO
RdRp	O
.	O

The	O
present	O
study	O
presents	O
a	O
perfect	O
model	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
RdRp	O
enabling	O
its	O
testing	O
in	O
silico	O
against	O
anti	O
-	O
polymerase	O
drugs	O
.	O

This	O
is	O
being	O
emphasised	O
as	O
the	O
outbreak	O
gains	O
ground	O
in	O
other	O
countries	O
,	O
leading	O
towards	O
a	O
global	O
health	O
emergency	B-DISO
,	O
and	O
as	O
global	O
collaboration	O
is	O
sought	O
in	O
numerous	O
quarters	O
.	O

TITLE	O
:	O
Epidemiological	O
Identification	O
of	O
A	O
Novel	O
Pathogen	O
in	O
Real	O
Time	O
:	O
Analysis	O
of	O
the	O
Atypical	B-DISO
Pneumonia	I-DISO
Outbreak	O
in	O
Wuhan	O
,	O
China	O
,	O
2019	O
-	O
2020	O
.	O

TITLE	O
:	O
Eco	B-DISO
-	O
Virological	O
Preliminary	O
Study	O
of	O
Potentially	O
Emerging	O
Pathogens	O
in	O
Hedgehogs	O
(	O
ABSTRACT	O
:	O
The	O
Western	O
European	O
Hedgehog	O
(	O

In	O
order	O
to	O
minimise	O
cross	O
-	O
infection	B-DISO
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
a	O
triage	O
system	O
was	O
set	O
up	O
to	O
identify	O
patients	O
with	O
fever	O
,	O
respiratory	B-DISO
symptoms	I-DISO
,	O
acute	B-DISO
conjunctivitis	I-DISO
or	O
recent	O
travel	O
to	O
outbreak	O
areas	O
and	O
to	O
encourage	O
these	O
individuals	O
to	O
postpone	O
their	O
appointments	O
for	O
at	O
least	O
14	O
days	O
.	O

Infection	B-DISO
control	O
training	O
was	O
provided	O
to	O
all	O
clinical	O
staff	O
.	O

In	O
West	O
China	O
Hospital	O
,	O
Emergency	B-DISO
Department	O
(	O
ED	O
)	O
undertook	O
the	O
mission	O
of	O
clinical	O
reception	O
,	O
primary	O
diagnosis	O
,	O
and	O
interim	O
treatment	O
for	O
the	O
suspected	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
The	O
emergence	O
and	O
spread	O
of	O
2019	O
novel	O
coronavirus	O
-	O
infected	O
pneumonia	B-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
from	O
Wuhan	O
,	O
China	O
,	O
it	O
has	O
spread	O
globally	O
.	O

We	O
found	O
that	O
compared	O
to	O
pharyngeal	O
swab	O
specimens	O
,	O
nucleic	O
acid	O
detection	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
fecal	O
specimens	O
was	O
equally	O
accurate	O
.	O

It	O
is	O
difficult	O
to	O
control	O
source	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
[	O
Expert	O
recommendations	O
on	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
during	O
epidemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
Trial	O
version	O
)].	O

Four	O
of	O
the	O
5	O
patients	O
treated	O
with	O
lopinavir	O
-	O
ritonavir	O
developed	O
nausea	B-DISO
,	O
vomiting	B-DISO
,	O
and	O
/	O
or	O
diarrhea	B-DISO
,	O
and	O
3	O
developed	O
abnormal	B-DISO
liver	I-DISO
function	I-DISO
test	O
results	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
various	O
mechanisms	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
mediated	O
inflammation	B-DISO
.	O

Results	O
from	O
the	O
current	O
study	O
showed	O
that	O
pretreatment	O
with	O
nafithromycin	O
significantly	O
reduced	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
MPO	O
,	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
levels	O
in	O
BAL	O
fluid	O
compared	O
to	O
LPS	B-DISO
control	O
group	O
.	O

As	O
a	O
result	O
of	O
immunomodulatory	O
activity	O
,	O
nafithromycin	O
is	O
expected	O
to	O
provide	O
additional	O
clinical	O
benefits	O
by	O
resolving	O
the	O
secondary	O
complications	O
associated	O
with	O
severe	O
pneumonia	B-DISO
and	O
thereby	O
improving	O
survival	O
in	O
such	O
patients	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
craniotomy	O
(	O
CO	O
)	O
and	O
decompressive	O
craniectomy	O
(	O
DC	O
)	O
for	O
evacuation	O
of	O
acute	B-DISO
subdural	I-DISO
hematoma	I-DISO
(	O
SDH	B-DISO
)	O
on	O
pulmonary	B-DISO
complications	I-DISO
and	O
sepsis	B-DISO
.	O

Some	O
differences	O
were	O
found	O
between	O
the	O
CO	O
and	O
DC	O
groups	O
regarding	O
age	O
(	O
mean	O
[	O
standard	O
deviation	O
(	O
SD	O
)]:	O
47	O
.	O
9	O
years	O
[	O
22	O
.	O
8	O
]	O
versus	O
39	O
.	O
6	O
years	O
[	O
20	O
.	O
1	O
];	O
Although	O
most	O
of	O
the	O
patients	O
underwent	O
CO	O
for	O
acute	O
SDH	B-DISO
,	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
incidence	O
of	O
ARDS	B-DISO
,	O
pneumonia	B-DISO
,	O
PE	O
,	O
or	O
systemic	O
sepsis	B-DISO
when	O
compared	O
with	O
patients	O
who	O
underwent	O
DC	O
.	O

ABSTRACT	O
:	O
We	O
report	O
two	O
cases	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
travellers	O
from	O
Wuhan	O
,	O
China	O
to	O
Thailand	O
.	O

The	O
participants	O
in	O
dental	O
practice	O
expose	O
to	O
tremendous	O
risk	O
of	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
due	O
to	O
the	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
communication	O
and	O
the	O
exposure	O
to	O
saliva	O
,	O
blood	O
,	O
and	O
other	O
body	O
fluids	O
,	O
and	O
the	O
handling	O
of	O
sharp	O
instruments	O
.	O

Eighty	O
medical	O
staff	O
contracted	O
SARS	B-DISO
in	O
2003	O
.	O

A	O
tentative	O
suggestion	O
based	O
on	O
existing	O
therapeutics	O
,	O
which	O
would	O
likely	O
be	O
resistant	O
to	O
new	O
coronavirus	O
mutations	O
,	O
is	O
to	O
use	O
available	O
angiotensin	O
receptor	O
1	O
(	O
AT1R	O
)	O
blockers	O
,	O
such	O
as	O
losartan	O
,	O
as	O
therapeutics	O
for	O
reducing	O
the	O
aggressiveness	B-DISO
and	O
mortality	O
from	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
virus	O
infections	B-DISO
.	O

Pulmonary	O
function	O
testing	O
procedures	O
have	O
been	O
associated	O
with	O
an	O
increasing	O
risk	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
transmission	O
among	O
patients	O
/	O
subjects	O
and	O
medical	O
staffs	O
.	O

It	O
is	O
strongly	O
recommended	O
to	O
suspend	O
the	O
test	O
for	O
the	O
confirmed	O
or	O
suspected	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
during	O
the	O
contagious	O
stage	O
,	O
and	O
to	O
postpone	O
the	O
test	O
for	O
other	O
patients	O
if	O
it	O
is	O
not	O
imperative	O
.	O

TITLE	O
:	O
[	O
Prediction	O
modeling	O
with	O
data	O
fusion	O
and	O
prevention	O
strategy	O
analysis	O
for	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
].	O

The	O
FPASSA	O
-	O
ANFIS	O
model	O
is	O
evaluated	O
using	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
official	O
data	O
of	O
the	O
outbreak	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
to	O
forecast	O
the	O
confirmed	O
cases	O
of	O
the	O
upcoming	O
ten	O
days	O
.	O

ABSTRACT	O
:	O
Hospital	O
-	O
associated	O
transmission	O
is	O
an	O
important	O
route	O
of	O
spreading	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	B-DISO
and	O
pneumonia	B-DISO
(	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
[	O
1	O
].	O

Appropriate	O
hospital	B-DISO
infection	I-DISO
control	O
measures	O
could	O
prevent	O
nosocomial	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
recognition	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
by	O
full	O
-	O
length	O
human	O
ACE2	O
.	O

TITLE	O
:	O
Improved	O
molecular	O
diagnosis	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
the	O
novel	O
,	O
highly	O
sensitive	O
and	O
specific	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
RdRp	O
/	O
Hel	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
validated	O
ABSTRACT	O
:	O
On	O
31	O

Levels	O
of	O
anxiety	O
,	O
self	O
-	O
efficacy	O
,	O
stress	O
,	O
sleep	O
quality	O
,	O
and	O
social	O
support	O
were	O
measured	O
using	O
the	O
and	O
the	O
Self	O
-	O
Rating	O
Anxiety	O
Scale	O
(	O
SAS	O
),	O
the	O
General	O
Self	O
-	O
Efficacy	O
Scale	O
(	O
GSES	O
),	O
the	O
Stanford	O
Acute	B-DISO
Stress	I-DISO
Reaction	I-DISO
(	O
SASR	O
)	O
questionnaire	O
,	O
the	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
(	O
PSQI	O
),	O
and	O
the	O
Social	O
Support	O
Rate	O
Scale	O
(	O
SSRS	O
),	O
respectively	O
.	O

The	O
intubation	O
procedure	O
,	O
anesthetic	O
regimen	O
,	O
and	O
complication	B-DISO
were	O
collected	O
and	O
analyzed	O
.	O

The	O
detection	O
of	O
oropharyngeal	O
swab	O
virus	O
nucleic	O
acid	O
were	O
negative	O
in	O
all	O
9	O
healthcare	O
workers	O
,	O
none	O
of	O
them	O
had	O
fever	O
or	O
any	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Non	O
-	O
tuberculous	B-DISO
mycobacteria	O
were	O
not	O
isolated	O
,	O
whereas	O
infection	B-DISO
with	O
Bcc	O
and	O
Mycobacterium	O
tuberculosis	B-DISO
was	O
observed	O
,	O
which	O
could	O
probably	O
have	O
a	O
role	O
in	O
CF	O
morbidity	O
.	O

The	O
clinical	O
,	O
laboratory	O
,	O
and	O
chest	O
CT	O
features	O
of	O
20	O
pediatric	O
inpatients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
confirmed	O
by	O
pharyngeal	O
swab	O
COVID	B-DISO
-	I-DISO
19	I-DISO
nucleic	O
acid	O
test	O
were	O
retrospectively	O
analyzed	O
during	O
23	O
January	O
and	O
8	O
February	O
2020	O
.	O

The	O
disease	O
is	O
officially	O
named	O
as	O
Coronavirus	O
Disease	O
-	O
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
by	O
WHO	O
on	O
February	O
11	O
,	O
2020	O
).	O

Person	O
-	O
to	O
-	O
person	O
transmission	O
may	O
occur	O
through	O
droplet	O
or	O
contact	O
transmission	O
and	O
if	O
there	O
is	O
a	O
lack	O
of	O
stringent	O
infection	B-DISO
control	O
or	O
if	O
no	O
proper	O
personal	O
protective	O
equipment	O
available	O
,	O
it	O
may	O
jeopardize	O
the	O
first	O
-	O
line	O
healthcare	O
workers	O
.	O

Currently	O
,	O
there	O
is	O
no	O
definite	O
treatment	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
although	O
some	O
drugs	O
are	O
under	O
investigation	O
.	O

This	O
article	O
will	O
review	O
the	O
new	O
knowledge	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
COVID	B-DISO
-	I-DISO
19	I-DISO
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
,	O
and	O
summarise	O
its	O
clinical	O
features	O
.	O

TITLE	O
:	O
Influence	O
of	O
trust	O
on	O
two	O
different	O
risk	O
perceptions	O
as	O
an	O
affective	O
and	O
cognitive	O
dimension	O
during	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
South	O
Korea	O
:	O
serial	O
cross	O
-	O
sectional	O
surveys	O
.	O

ABSTRACT	O
:	O
The	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
has	O
issued	O
a	O
warning	O
that	O
,	O
although	O
the	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
from	O
Wuhan	O
City	O
(	O
China	O
),	O
is	O
not	O
pandemic	O
,	O
it	O
should	O
be	O
contained	O
to	O
prevent	O
the	O
global	O
spread	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
virus	O
was	O
known	O
earlier	O
as	O
2019	O
-	O
nCoV	O
.	O
As	O
of	O
12	O
February	O
2020	O
,	O
WHO	O
reported	O
45	O
,	O
171	O
cases	O
and	O
1115	O
deaths	O
related	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Comparison	O
of	O
the	O
genome	O
sequences	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
showed	O
that	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
a	O
better	O
sequence	O
identity	O
with	O
SARS	B-DISO
-	O
CoV	O
compared	O
to	O
MERS	O
CoV	O
.	O
However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
differs	O
from	O
other	O
coronaviruses	O
specifically	O
in	O
the	O
regions	O
of	O
1ab	O
polyprotein	O
and	O
surface	O
glycoprotein	O
or	O
S	O
-	O
protein	O
.	O

This	O
mini	O
-	O
review	O
aims	O
at	O
investigating	O
the	O
most	O
recent	O
trend	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Novel	O
coronavirus	O
2019	O
-	O
nCoV	O
:	O
prevalence	O
,	O
biological	O
and	O
clinical	O
characteristics	O
comparison	O
with	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Human	O
infections	B-DISO
with	O
zoonotic	O
coronavirus	O
contain	O
emerging	O
and	O
reemerging	O
pathogenic	O
characteristics	O
which	O
have	O
raised	O
great	O
public	O
health	O
concern	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
outbreak	O
:	O
preparedness	O
and	O
readiness	O
of	O
countries	O
in	O
the	O
Eastern	O
Mediterranean	O
Region	O
.	O

The	O
detection	O
of	O
this	O
new	O
virus	O
in	O
humans	O
without	O
knowing	O
the	O
source	O
of	O
the	O
infection	B-DISO
has	O
raised	O
greatly	O
heightened	O
concerns	O
not	O
only	O
in	O
China	O
,	O
but	O
also	O
internationally	O
.	O

By	O
simulation	O
and	O
data	O
fitting	B-DISO
,	O
the	O
model	O
showed	O
the	O
peak	O
existing	O
confirmed	O
cases	O
of	O
59	O
769	O
arriving	O
on	O
15	O
February	O
2020	O
,	O
with	O
the	O
coefficient	O
of	O
determination	O
close	O
to	O
1	O
and	O
the	O
fitting	B-DISO
bias	O
3	O
.	O
02	O
%,	O
suggesting	O
high	O
precision	O
of	O
the	O
data	O
-	O
fitting	B-DISO
results	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
Cell	O
Entry	O
Depends	O
on	O
ACE2	O
and	O
TMPRSS2	O
and	O
Is	O
Blocked	O
by	O
a	O
Clinically	O
Proven	O
Protease	O
Inhibitor	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
the	O
novel	O
,	O
pathogenic	O
SARS	B-DISO
-	O
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
in	O
China	O
and	O
its	O
rapid	O
national	O
and	O
international	O
spread	O
pose	O
a	O
global	O
health	O
emergency	B-DISO
.	O

Unravelling	O
which	O
cellular	O
factors	O
are	O
used	O
by	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
for	O
entry	O
might	O
provide	O
insights	O
into	O
viral	O
transmission	O
and	O
reveal	O
therapeutic	O
targets	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
travel	O
restrictions	O
on	O
the	O
spread	O
of	O
the	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
outbreak	O
.	O

TITLE	O
:	O
Serial	O
interval	O
of	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
infections	B-DISO
.	O

This	O
suggests	O
that	O
a	O
substantial	O
proportion	O
of	O
secondary	B-DISO
transmission	I-DISO
may	O
occur	O
prior	O
to	O
illness	O
onset	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
serial	O
interval	O
is	O
also	O
shorter	O
than	O
the	O
serial	O
interval	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
indicating	O
that	O
calculations	O
made	O
using	O
the	O
SARS	B-DISO
serial	O
interval	O
may	O
introduce	O
bias	O
.	O

TITLE	O
:	O
[	O
Screening	O
and	O
management	O
of	O
asymptomatic	B-DISO
infection	I-DISO
of	O
corona	B-DISO
virus	I-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)].	O

ABSTRACT	O
:	O
Since	O
the	O
middle	O
of	O
December	O
2019	O
,	O
human	O
-	O
to	O
-	O
human	O
transmission	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
)	O
has	O
occurred	O
among	O
close	O
contacts	O
.	O

The	O
month	O
of	O
February	O
,	O
however	O
,	O
has	O
been	O
dominated	O
by	O
two	O
large	O
clusters	O
of	O
outbreaks	O
in	O
Northern	O
Italy	O
,	O
south	O
of	O
Milan	O
,	O
with	O
mainly	O
local	O
transmission	O
the	O
source	O
of	O
infections	B-DISO
.	O

It	O
will	O
be	O
important	O
to	O
develop	O
point	O
-	O
of	O
-	O
care	O
devices	O
to	O
aid	O
clinicians	O
in	O
stratifying	O
elderly	O
patients	O
as	O
early	O
as	O
possible	O
to	O
determine	O
the	O
potential	O
level	O
of	O
care	O
they	O
will	O
require	O
to	O
improve	O
their	O
chances	O
of	O
survival	O
from	O
COVID	B-DISO
-	I-DISO
19	I-DISO
disease	O
.	O

The	O
data	O
showed	O
that	O
58	O
.	O
73	O
%	O
of	O
imported	O
camels	O
and	O
25	O
%	O
of	O
traders	O
had	O
antibodies	O
specific	O
to	O
MERS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
like	O
seroreactive	O
camels	O
,	O
all	O
seropositive	O
humans	O
were	O
apparently	O
healthy	O
without	O
any	O
history	O
of	O
developing	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
the	O
14	O
days	O
prior	O
to	O
sampling	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
showed	O
clinical	O
characteristics	O
of	O
patients	O
with	O
the	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
and	O
the	O
evidence	O
of	O
person	O
-	O
to	O
-	O
person	O
transmission	O
.	O

Epidemiological	O
investigations	O
were	O
conducted	O
among	O
all	O
close	O
contacts	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
(	O
or	O
suspected	O
patients	O
)	O
in	O
Nanjing	O
,	O
Jiangsu	O
Province	O
,	O
China	O
,	O
from	O
Jan	O
28	O
to	O
Feb	O
9	O
,	O
2020	O
,	O
both	O
in	O
clinic	O
and	O
in	O
community	O
.	O

Five	O
cases	O
(	O
20	O
.	O
8	O
%)	O
developed	O
symptoms	O
(	O
fever	O
,	O
cough	B-DISO
,	O
fatigue	B-DISO
,	O
etc	O
.)	O
during	O
hospitalization	O
.	O

None	O
of	O
the	O
24	O
cases	O
developed	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
or	O
died	O
.	O

We	O
report	O
a	O
confirmed	O
case	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
whose	O
oropharyngeal	O
swab	O
test	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
RNA	O
turned	O
positive	O
in	O
convalescence	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
dynamic	O
surveillance	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
RNA	O
for	O
infectivity	O
assessment	O
.	O

This	O
article	O
summarizes	O
agents	O
with	O
potential	O
efficacy	O
against	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

ABSTRACT	O
:	O
While	O
erythromycin	O
has	O
caused	O
numerous	O
cases	O
of	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
(	O
ALF	B-DISO
),	O
clarithromycin	O
,	O
a	O
similar	O
macrolide	O
antibiotic	O
,	O
has	O
caused	O
only	O
six	O
reported	O
cases	O
of	O
ALF	B-DISO
.	O

Of	O
the	O
28	O
cases	O
,	O
16	O
were	O
index	O
cases	O
imported	O
from	O
abroad	O
,	O
with	O
10	O
cases	O
of	O
secondary	B-DISO
infection	I-DISO
originating	O
in	O
Korea	O
,	O
and	O
the	O
route	O
of	O
transmission	O
still	O
under	O
investigation	O
for	O
2	O
patients	O
.	O

To	O
overcome	O
these	O
limitations	O
,	O
methods	O
that	O
can	O
objectively	O
verify	O
the	O
patient	O
'	O
s	O
claims	O
(	O
medical	O
facility	O
records	O
,	O
Global	O
Positioning	O
System	O
,	O
card	O
transactions	O
,	O
and	O
closed	O
-	O
circuit	O
television	O
)	O
were	O
used	O
for	O
the	O
recent	O
ongoing	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
contact	O
investigations	O
in	O
South	O
Korea	O
.	O

However	O
,	O
discrimination	O
and	O
prejudice	O
driven	O
by	O
fear	O
or	O
misinformation	O
have	O
been	O
flowing	O
globally	O
,	O
superseding	O
evidence	O
and	O
jeopardizing	O
the	O
anti	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
efforts	O
.	O

The	O
study	O
provides	O
evidence	O
that	O
the	O
MERS	O
-	O
CoV	O
epidemic	O
in	O
the	O
subject	O
regions	O
has	O
specific	O
characteristics	O
that	O
might	O
help	O
future	O
plans	O
for	O
the	O
prevention	O
and	O
management	O
of	O
such	O
a	O
contagious	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Radiation	O
induced	O
apoptosis	O
and	O
pulmonary	B-DISO
fibrosis	I-DISO
:	O
curcumin	O
an	O
effective	O
intervention	O
?	O

ABSTRACT	O
:	O
Idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
)	O
is	O
a	O
fatal	O
lung	B-DISO
disease	I-DISO
characterized	O
by	O
interstitial	O
remodeling	O
,	O
leading	O
to	O
compromised	O
lung	O
function	O
.	O

TITLE	O
:	O
Repurposing	O
of	O
clinically	O
approved	O
drugs	O
for	O
treatment	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
in	O
a	O
2019	O
-	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
related	O
coronavirus	O
model	O
.	O

The	O
pangolin	O
coronavirus	O
model	O
was	O
used	O
to	O
identify	O
drug	O
candidates	O
for	O
treating	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
.	O

Furthermore	O
,	O
we	O
found	O
CEP	B-DISO
has	O
potent	O
antiviral	O
activities	O
against	O
both	O
viral	O
entry	O
(	O
1	O
.	O
00	O
±	O
0	O
.	O
37	O
vs	O
.	O
0	O
.	O
46	O
±	O
0	O
.	O
12	O
,	O
t	O
=	O
2	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
viral	O
replication	O
(	O
1	O
.	O
00	O
±	O
0	O
.	O
43	O
vs	O
.	O
[	O
6	O
.	O
18	O
±	O
0	O
.	O
95	O
]	O
×	O
10	O
,	O
t	O
=	O
3	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
this	O
study	O
,	O
we	O
hope	O
to	O
discover	O
evidence	O
either	O
supporting	O
or	O
opposing	O
the	O
systemic	O
therapeutic	O
administration	O
of	O
glucocorticoids	O
in	O
severe	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
patients	O
.	O

In	O
the	O
last	O
twenty	O
years	O
,	O
several	O
viral	O
epidemics	O
such	O
as	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
to	O
2003	O
,	O
and	O
H1N1	B-DISO
influenza	I-DISO
in	O
2009	O
,	O
have	O
been	O
recorded	O
.	O

In	O
a	O
timeline	O
that	O
reaches	O
the	O
present	O
day	O
,	O
an	O
epidemic	O
of	O
cases	O
with	O
unexplained	O
low	O
respiratory	B-DISO
infections	I-DISO
detected	O
in	O
Wuhan	O
,	O
the	O
largest	O
metropolitan	O
area	O
in	O
China	O
'	O
s	O
Hubei	O
province	O
,	O
was	O
first	O
reported	O
to	O
the	O
WHO	O
Country	O
Office	O
in	O
China	O
,	O
on	O
December	O
31	O
,	O
2019	O
.	O

As	O
they	O
were	O
unable	O
to	O
identify	O
the	O
causative	O
agent	O
,	O
these	O
first	O
cases	O
were	O
classified	O
as	O
""""	O
pneumonia	B-DISO
of	O
unknown	O
etiology	O
.	O

SARS	B-DISO
-	O
CoV	O
provoked	O
a	O
large	O
-	O
scale	O
epidemic	O
beginning	O
in	O
China	O
and	O
involving	O
two	O
dozen	O
countries	O
with	O
approximately	O
8000	O
cases	O
and	O
800	O
deaths	O
,	O
and	O
the	O
MERS	O
-	O
CoV	O
that	O
began	O
in	O
Saudi	O
Arabia	O
and	O
has	O
approximately	O
2	O
,	O
500	O
cases	O
and	O
800	O
deaths	O
and	O
still	O
causes	O
as	O
sporadic	O
cases	O
.	O

Interestingly	O
,	O
these	O
latter	O
viruses	O
have	O
probably	O
originated	O
from	O
bats	O
and	O
then	O
moving	O
into	O
other	O
mammalian	O
hosts	O
—	O
the	O
Himalayan	O
palm	O
civet	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
the	O
dromedary	O
camel	O
for	O
MERS	O
-	O
CoV	O
—	O
before	O
jumping	O
to	O
humans	O
.	O

The	O
dynamics	O
of	O
SARS	B-DISO
-	O
Cov	O
-	O
2	O
are	O
currently	O
unknown	O
,	O
but	O
there	O
is	O
speculation	O
that	O
it	O
also	O
has	O
an	O
animal	O
origin	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
and	O
validated	O
2	O
species	O
-	O
independent	O
protein	O
-	O
based	O
assays	O
to	O
detect	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
functional	O
antibodies	O
that	O
can	O
block	O
virus	O
receptor	O
-	O
binding	O
or	O
sialic	O
acid	O
-	O
attachment	O
.	O

TITLE	O
:	O
In	O
Vitro	O
Antiviral	O
Activity	O
and	O
Projection	O
of	O
Optimized	O
Dosing	O
Design	O
of	O
Hydroxychloroquine	O
for	O
the	O
Treatment	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
).	O

Currently	O
,	O
there	O
is	O
no	O
evidence	O
to	O
support	O
the	O
use	O
of	O
hydroxychloroquine	O
in	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
.	O

The	O
pharmacological	O
activity	O
of	O
chloroquine	O
and	O
hydroxychloroquine	O
was	O
tested	O
using	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
infected	O
Vero	O
cells	O
.	O

Based	O
on	O
PBPK	O
models	O
results	O
,	O
a	O
loading	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
of	O
hydroxychloroquine	O
sulfate	O
given	O
orally	O
,	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
200	O
mg	O
given	O
twice	O
daily	O
for	O
4	O
days	O
is	O
recommended	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
,	O
as	O
it	O
reached	O
three	O
times	O
the	O
potency	O
of	O
chloroquine	O
phosphate	O
when	O
given	O
500	O
mg	O
twice	O
daily	O
5	O
days	O
in	O
advance	O
.	O

Fetal	B-DISO
distress	I-DISO
was	O
monitored	O
in	O
two	O
cases	O
.	O

The	O
most	O
promising	O
compound	O
is	O
remdesivir	O
(	O
GS	O
-	O
5734	O
),	O
a	O
nucleotide	O
analog	O
prodrug	O
currently	O
in	O
clinical	O
trials	O
for	O
treating	O
Ebola	O
virus	O
infections	B-DISO
.	O

Thus	O
,	O
the	O
infectious	B-DISO
contact	O
network	O
exhibited	O
small	O
-	O
world	O
dynamics	O
characterised	O
by	O
locally	O
clustered	O
contacts	O
exposed	O
to	O
transmission	O
paths	O
via	O
short	O
path	O
lengths	O
.	O

The	O
diagnosis	O
and	O
differential	O
diagnosis	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
was	O
facing	O
challenges	O
not	O
only	O
because	O
of	O
large	O
number	O
of	O
tourists	O
increasing	O
dramatically	O
after	O
the	O
relieving	O
of	O
epidemic	O
,	O
but	O
also	O
patients	O
with	O
other	O
diseases	O
return	O
from	O
different	O
areas	O
to	O
search	O
for	O
medical	O
care	O
.	O

We	O
were	O
trying	O
to	O
find	O
the	O
similarities	O
and	O
differences	O
among	O
them	O
,	O
and	O
to	O
identify	O
clues	O
to	O
the	O
diagnosis	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
,	O
so	O
as	O
to	O
ensure	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O

This	O
article	O
makes	O
a	O
brief	O
analysis	O
and	O
reflection	O
on	O
the	O
relevant	O
legal	O
issues	O
faced	O
and	O
raised	O
by	O
oral	O
medical	O
institutions	O
and	O
practioners	O
,	O
taking	O
cases	O
from	O
the	O
emergent	O
crisis	O
caused	O
by	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
China	O
since	O
December	O
2019	O
,	O
with	O
the	O
hope	O
to	O
provide	O
legal	O
help	O
and	O
guidance	O
to	O
the	O
oral	O
medical	O
industry	O
in	O
dealing	O
with	O
public	O
health	O
emergencies	B-DISO
.	O

TITLE	O
:	O
[	O
Medical	O
management	O
and	O
prevention	O
instruction	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
during	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
epidemic	O
].	O

ABSTRACT	O
:	O
Currently	O
,	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O

TITLE	O
:	O
MiR	O
-	O
10a	O
-	O
5p	O
-	O
Mediated	O
Syndecan	O
1	O
Suppression	B-DISO
Restricts	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	B-DISO
Virus	O
Replication	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
)	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
coronavirus	O
that	O
causes	O
nervous	B-DISO
dysfunction	O
in	O
the	O
infected	O
hosts	O
and	O
leads	O
to	O
widespread	O
alterations	O
in	O
the	O
host	O
transcriptome	O
by	O
modulating	O
specific	O
microRNA	O
(	O
miRNA	O
)	O
levels	O
.	O

Perinatal	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
may	O
have	O
adverse	B-DISO
effects	I-DISO
on	O
newborns	O
,	O
causing	O
problems	O
such	O
as	O
fetal	B-DISO
distress	I-DISO
,	O
premature	B-DISO
labor	I-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
thrombocytopenia	O
accompanied	O
by	O
abnormal	B-DISO
liver	I-DISO
function	I-DISO
,	O
and	O
even	O
death	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
has	O
resulted	O
in	O
>	O
90	O
,	O
000	O
infections	B-DISO
and	O
>	O
3	O
,	O
000	O
deaths	O
.	O

TITLE	O
:	O
Rapid	O
establishment	O
of	O
laboratory	O
diagnostics	O
for	O
the	O
novel	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
Bavaria	O
,	O
Germany	O
,	O
February	O
2020	O
.	O

Multiple	O
bilateral	O
lobular	O
and	O
subsegmental	O
areas	O
of	O
consolidation	O
or	O
bilateral	O
ground	O
-	O
glass	O
opacities	B-DISO
were	O
the	O
main	O
reported	O
radiological	O
features	O
of	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
,	O
at	O
least	O
in	O
the	O
early	O
phases	O
of	O
the	O
disease	O
.	O

CONCLUSIONS	O
:	O
The	O
new	O
2019	O
-	O
nCoV	O
epidemic	O
is	O
mainly	O
associated	O
with	O
respiratory	B-DISO
disease	I-DISO
and	O
few	O
extrapulmonary	O
signs	O
.	O

TITLE	O
:	O
CT	O
Manifestations	O
of	O
Novel	O
Coronavirus	O
Pneumonia	B-DISO
:	O
A	O
Case	O
Report	O
ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
the	O
outbreak	O
of	O
the	O
novel	O
coronavirus	O
has	O
impacted	B-DISO
nearly	O
>	O
90	O
,	O
000	O
people	O
in	O
more	O
than	O
75	O
countries	O
.	O

In	O
this	O
case	O
report	O
,	O
we	O
aim	O
to	O
define	O
the	O
chest	O
computed	O
tomography	O
findings	O
of	O
2019	O
-	O
novel	O
coronavirus	O
associated	O
with	O
pneumonia	B-DISO
and	O
its	O
successful	O
resolution	O
after	O
treatment	O
.	O

This	O
model	O
was	O
built	O
with	O
the	O
data	O
and	O
used	O
to	O
assess	O
the	O
detection	O
rate	O
during	O
the	O
study	O
period	O
,	O
considering	O
the	O
differences	O
between	O
the	O
true	O
infections	B-DISO
,	O
detectable	O
and	O
detected	O
cases	O
.	O

TITLE	O
:	O
Identification	O
of	O
coronavirus	O
sequences	O
in	O
carp	B-DISO
cDNA	O
from	O
Wuhan	O
,	O
China	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
like	O
coronavirus	O
sequences	O
were	O
identified	O
in	O
two	O
separate	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
pools	O
.	O

This	O
institution	O
is	O
very	O
close	O
in	O
proximity	O
to	O
the	O
Wuhan	O
South	O
China	O
Seafood	O
Wholesale	O
Market	O
where	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
first	O
amplified	O
in	O
the	O
human	O
population	O
.	O

The	O
genome	O
composition	O
,	O
nucleotide	O
analysis	O
,	O
codon	O
usage	O
indices	O
,	O
relative	O
synonymous	O
codons	O
usage	O
,	O
and	O
effective	O
number	O
of	O
codons	O
(	O
ENc	O
)	O
were	O
analyzed	O
in	O
the	O
four	O
structural	O
genes	O
;	O
Spike	O
(	O
S	O
),	O
Envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
Nucleocapsid	O
(	O
N	O
)	O
genes	O
,	O
and	O
two	O
of	O
the	O
most	O
important	O
nonstructural	O
genes	O
comprising	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
main	O
protease	O
(	O
Mpro	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
Beta	O
-	O
CoV	O
from	O
pangolins	O
,	O
bat	O
SARS	B-DISO
,	O
MERS	O
,	O
and	O
SARS	B-DISO
CoVs	O
.	O

In	O
her	O
view	O
,	O
a	O
central	O
problem	O
is	O
that	O
the	O
definition	O
of	O
pandemics	O
is	O
based	O
solely	O
on	O
disease	B-DISO
transmission	I-DISO
across	O
several	O
countries	O
,	O
and	O
not	O
on	O
spread	O
and	O
severity	O
together	O
,	O
which	O
conflates	O
two	O
very	O
different	O
situations	O
:	O
emergency	B-DISO
and	O
nonemergency	O
disease	O
outbreaks	O
.	O

We	O
noted	O
low	O
sensitivity	O
of	O
upper	O
respiratory	O
specimens	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
which	O
could	O
further	O
complicate	O
recognition	O
of	O
the	O
full	O
extent	O
of	O
disease	O
.	O

TITLE	O
:	O
Geographical	O
tracking	O
and	O
mapping	O
of	O
coronavirus	O
disease	O
COVID	B-DISO
-	I-DISO
19	I-DISO
/	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
epidemic	O
and	O
associated	O
events	O
around	O
the	O
world	O
:	O
how	O
21st	O
century	O
GIS	O
technologies	O
are	O
supporting	O
the	O
global	O
fight	O
against	O
outbreaks	O
and	O
epidemics	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
virus	O
(	O
initially	O
called	O
'	O
Novel	O
Coronavirus	O
2019	O
-	O
nCoV	O
'	O
and	O
later	O
renamed	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
causing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
coronavirus	O
disease	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
emerged	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
,	O
and	O
rapidly	O
spread	O
to	O
other	O
parts	O
of	O
China	O
and	O
other	O
countries	O
around	O
the	O
world	O
,	O
despite	O
China	O
'	O
s	O
massive	O
efforts	O
to	O
contain	O
the	O
disease	O
within	O
Hubei	O
.	O

Patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
also	O
have	O
lower	O
level	O
of	O
regulatory	O
T	O
cells	O
,	O
and	O
more	O
obviously	O
damaged	O
in	O
severe	O
cases	O
.	O

We	O
report	O
a	O
case	O
of	O
neonatal	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
in	O
China	O
with	O
pharyngeal	O
swabs	O
tested	O
positive	O
by	O
rRT	O
-	O
PCR	O
assay	O
36	O
hours	O
after	O
birth	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
fever	O
and	O
cough	B-DISO
.	O

The	O
proportions	O
of	O
hypertension	B-DISO
,	O
cardia	O
-	O
cerebrovascular	O
disease	O
and	O
diabetes	B-DISO
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
17	O
.	O
1	O
%,	O
16	O
.	O
4	O
%	O
and	O
9	O
.	O
7	O
%,	O
respectively	O
.	O

The	O
clinical	O
data	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
from	O
December	O
2019	O
to	O
February	O
2020	O
were	O
retrieved	O
from	O
four	O
databases	O
.	O

Although	O
the	O
efficacy	O
of	O
AHCC	O
has	O
not	O
yet	O
been	O
specifically	O
evaluated	O
with	O
respect	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
disease	I-DISO
,	O
its	O
action	O
in	O
promoting	O
a	O
protective	O
response	O
to	O
a	O
wide	O
range	O
of	O
viral	B-DISO
infections	I-DISO
,	O
and	O
the	O
current	O
absence	O
of	O
effective	O
vaccines	O
,	O
could	O
support	O
its	O
use	O
in	O
the	O
prevention	O
of	O
diseases	O
provoked	O
by	O
human	O
pathogenic	O
coronavirus	O
,	O
including	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
ARTI	O
),	O
including	O
the	O
common	B-DISO
cold	I-DISO
,	O
pharyngitis	B-DISO
,	O
sinusitis	B-DISO
,	O
otitis	B-DISO
media	I-DISO
,	O
bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
are	O
the	O
most	O
common	O
diagnoses	O
among	O
patients	O
seeking	O
medical	O
care	O
in	O
western	O
countries	O
,	O
and	O
account	O
for	O
most	O
antibiotic	O
prescriptions	O
.	O

ABSTRACT	O
:	O
The	O
new	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
),	O
also	O
named	O
as	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
WHO	O
on	O
Feb	O
11	O
2020	O
,	O
is	O
now	O
causing	O
a	O
severe	O
public	O
health	O
emergency	B-DISO
in	O
China	O
since	O
.	O

We	O
have	O
also	O
reviewed	O
the	O
clinical	O
evidence	O
generated	O
from	O
SARS	B-DISO
and	O
H1N1	O
management	O
with	O
hypothesized	O
mechanisms	O
and	O
latest	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
the	O
role	O
of	O
mass	O
gatherings	O
.	O

However	O
,	O
the	O
events	O
surrounding	O
the	O
latest	O
threat	O
to	O
global	O
health	O
,	O
the	O
PHEIC	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
may	O
be	O
sufficient	O
to	O
highlight	O
the	O
role	O
of	O
mass	O
gatherings	O
,	O
mass	O
migration	O
,	O
and	O
other	O
forms	O
of	O
dense	O
gatherings	O
of	O
people	O
on	O
the	O
emergence	O
,	O
sustenance	O
,	O
and	O
transmission	O
of	O
novel	O
pathogens	O
.	O

However	O
,	O
the	O
recent	O
report	O
on	O
asymptomatic	O
contact	O
transmission	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
travelers	O
who	O
passed	O
the	O
symptoms	O
-	O
based	O
screening	O
and	O
tested	O
positive	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
using	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
challenges	O
this	O
approach	O
as	O
body	O
temperature	O
screening	O
may	O
miss	O
travelers	O
incubating	O
the	O
disease	O
or	O
travelers	O
concealing	O
fever	O
during	O
travel	O
.	O

TITLE	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
a	O
multifactorial	O
diffuse	O
alveolar	O
haemorrhage	B-DISO
.	O

We	O
describe	O
patient	O
characteristics	O
,	O
mortality	O
,	O
and	O
frequency	O
of	O
complications	O
(	O
such	O
as	O
skin	O
breakdown	B-DISO
and	O
accidental	O
extubation	O
)	O
at	O
our	O
center	O
.	O

China	O
has	O
been	O
making	O
unprecedented	O
efforts	O
in	O
treating	O
the	O
confirmed	O
cases	O
,	O
identifying	O
and	O
isolating	O
their	O
close	O
contacts	O
and	O
suspected	O
cases	O
to	O
control	O
the	O
source	O
of	O
infection	B-DISO
and	O
cut	O
the	O
route	O
of	O
transmission	O
.	O

The	O
disease	O
is	O
transmitted	B-DISO
by	O
inhalation	O
or	O
contact	O
with	O
infected	O
droplets	O
and	O
the	O
incubation	O
period	O
ranges	O
from	O
2	O
to	O
14	O
d	O
.	O
The	O
symptoms	O
are	O
usually	O
fever	O
,	O
cough	B-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
breathlessness	B-DISO
,	O
fatigue	B-DISO
,	O
malaise	B-DISO
among	O
others	O
.	O

ABSTRACT	O
:	O
Despite	O
multiple	O
importations	O
resulting	O
in	O
local	O
chains	O
of	O
transmission	O
,	O
Singapore	O
has	O
been	O
able	O
to	O
control	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
without	O
major	O
disruption	O
to	O
daily	O
living	O
.	O

TITLE	O
:	O
An	O
exclusive	O
42	O
amino	O
acid	O
signature	O
in	O
pp1ab	O
protein	O
provides	O
insights	O
into	O
the	O
evolutive	O
history	O
of	O
the	O
2019	O
novel	O
human	O
-	O
pathogenic	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
).	O

In	O
this	O
short	O
communication	O
,	O
we	O
performed	O
phylogenetic	O
-	O
structural	O
sequence	O
analysis	O
of	O
pp1ab	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

While	O
comparing	O
pp1ab	O
protein	O
with	O
other	O
betacoronaviruses	O
,	O
we	O
found	O
a	O
42	O
amino	O
acid	O
signature	O
that	O
is	O
only	O
present	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(	O
AS	O
-	O
SCoV2	O
).	O

In	O
this	O
study	O
,	O
we	O
screened	O
these	O
chemical	O
structures	O
from	O
traditional	O
Chinese	O
medicinal	O
compounds	O
proven	O
to	O
show	O
antiviral	O
activity	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
the	O
similar	O
chemical	O
structures	O
through	O
a	O
molecular	O
docking	O
study	O
to	O
target	O
RdRp	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

A	O
new	O
coronavirus	O
,	O
named	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
by	O
the	O
Coronavirus	O
Study	O
Group	O
of	O
the	O
International	O
Committee	O
on	O
Taxonomy	O
of	O
Viruses	O
was	O
soon	O
found	O
to	O
be	O
the	O
cause	O
.	O

These	O
findings	O
suggested	O
that	O
there	O
may	O
be	O
selective	O
mutations	O
in	O
SARS	B-DISO
-	O
COV	O
-	O
2	O
,	O
and	O
it	O
is	O
necessary	O
to	O
avoid	O
certain	O
regions	O
when	O
designing	O
primers	O
and	O
probes	O
.	O

ABSTRACT	O
:	O
With	O
an	O
increasing	O
number	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
cases	O
outside	O
of	O
Hubei	O
,	O
emergency	B-DISO
departments	O
(	O
EDs	B-DISO
)	O
and	O
fever	O
clinics	O
are	O
facing	O
challenges	O
posed	O
by	O
the	O
large	O
number	O
of	O
admissions	O
of	O
patients	O
suspected	O
to	O
have	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

The	O
development	O
of	O
ARDS	B-DISO
and	O
death	O
.	O

Older	O
age	O
was	O
associated	O
with	O
greater	O
risk	O
of	O
development	O
of	O
ARDS	B-DISO
and	O
death	O
likely	O
owing	O
to	O
less	O
rigorous	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
coronavirus	O
infectious	B-DISO
disease	I-DISO
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
gripped	O
the	O
world	O
with	O
apprehension	O
and	O
has	O
evoked	O
a	O
scare	O
of	O
epic	O
proportion	O
regarding	O
its	O
potential	O
to	O
spread	O
and	O
infect	O
humans	O
worldwide	O
.	O

As	O
we	O
are	O
in	O
the	O
midst	O
of	O
an	O
ongoing	O
pandemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
scientists	O
are	O
struggling	O
to	O
understand	O
how	O
it	O
resembles	O
and	O
differs	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
at	O
the	O
genomic	O
and	O
transcriptomic	O
level	O
.	O

TITLE	O
:	O
A	O
Diabetic	O
Patient	O
With	O
2019	O
-	O
nCoV	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
Infection	B-DISO
Who	O
Recovered	O
and	O
Was	O
Discharged	O
From	O
Hospital	O
.	O

TITLE	O
:	O
Estimating	O
Risk	O
for	O
Death	O
from	O
2019	B-DISO
Novel	I-DISO
Coronavirus	I-DISO
Disease	I-DISO
,	O
China	O
,	O
January	O
-	O
February	O
2020	O
.	O

In	O
this	O
review	O
,	O
we	O
summarized	O
the	O
latest	O
research	O
progress	O
of	O
the	O
epidemiology	O
,	O
pathogenesis	B-DISO
,	O
and	O
clinical	O
characteristics	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
and	O
discussed	O
the	O
current	O
treatment	O
and	O
scientific	O
advancements	O
to	O
combat	O
the	O
epidemic	O
novel	O
coronavirus	O
.	O

TITLE	O
:	O
Vicarious	O
traumatization	O
in	O
the	O
general	O
public	O
,	O
members	O
,	O
and	O
non	O
-	O
members	O
of	O
medical	O
teams	O
aiding	O
in	O
COVID	B-DISO
-	I-DISO
19	I-DISO
control	O
.	O

Psychological	B-DISO
stress	I-DISO
,	O
especially	O
vicarious	O
traumatization	O
caused	O
by	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
,	O
should	O
not	O
be	O
ignored	O
.	O

Moreover	O
,	O
lung	O
cells	O
that	O
have	O
ACE2	O
expression	O
may	O
be	O
the	O
main	O
target	O
cells	O
during	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
.	O

Insufficient	O
and	O
excessive	O
protection	O
will	O
have	O
adverse	B-DISO
effects	I-DISO
on	O
the	O
skin	O
and	O
mucous	O
membrane	O
barrier	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
):	O
What	O
we	O
know	O
?	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
is	O
spreading	O
in	O
China	O
and	O
all	O
over	O
the	O
world	O
now	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
primarily	O
to	O
review	O
the	O
pathogen	O
,	O
clinical	O
features	O
,	O
diagnosis	O
,	O
and	O
treatment	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
but	O
also	O
to	O
comment	O
briefly	O
on	O
the	O
epidemiology	O
and	O
pathology	B-DISO
based	O
on	O
the	O
current	O
evidences	O
.	O

To	O
estimate	O
the	O
early	O
dynamics	O
of	O
transmission	O
in	O
Wuhan	O
,	O
we	O
fitted	B-DISO
a	O
stochastic	O
transmission	O
dynamic	O
model	O
to	O
multiple	O
publicly	O
available	O
datasets	O
on	O
cases	O
in	O
Wuhan	O
and	O
internationally	O
exported	O
cases	O
from	O
Wuhan	O
.	O

When	O
COVI	B-DISO
-	I-DISO
19	I-DISO
infect	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
it	O
can	O
cause	O
mild	O
or	O
highly	O
acute	O
respiratory	O
syndrome	B-DISO
with	O
consequent	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1β	O
and	O
IL	O
-	O
6	O
.	O

ABSTRACT	O
:	O
Cases	O
of	O
2019	O
-	O
nCoV	O
are	O
now	O
being	O
reported	O
in	O
different	O
regions	O
around	O
the	O
globe	O
,	O
concerning	O
for	O
a	O
possible	O
SARS	B-DISO
like	O
epidemic	O
that	O
infected	O
for	O
than	O
8000	O
people	O
in	O
2002	O
-	O
03	O
.	O

TITLE	O
:	O
Clinical	O
and	O
CT	O
imaging	O
features	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
:	O
Focus	O
on	O
pregnant	O
women	O
and	O
children	O
.	O

This	O
is	O
a	O
retrospective	O
study	O
of	O
patients	O
with	O
new	O
coronavirus	O
pneumonia	B-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
who	O
were	O
hospitalized	O
in	O
Hainan	O
Provincial	O
People	O
'	O
s	O
Hospital	O
from	O
January	O
15	O
,	O
2020	O
to	O
February	O
18	O
,	O
2020	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
we	O
included	O
adults	O
(	O
age	O
≥	O
18years	O
)	O
with	O
laboratory	O
-	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
without	O
Invasive	O
ventilation	O
,	O
diagnosed	O
between	O
Jan	O
17	O
,	O
2020	O
,	O
and	O
Feb	O
13	O
,	O
2020	O
.	O

The	O
primary	O
endpoint	O
was	O
a	O
negative	O
conversion	O
rate	O
of	O
coronavirus	O
from	O
the	O
date	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
diagnosis	O
(	O
day7	O
,	O
day14	O
),	O
and	O
assessed	O
whether	O
the	O
pneumonia	B-DISO
was	O
progressing	O
or	O
improving	O
by	O
chest	O
CT	O
(	O
day7	O
).	O

The	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
could	O
not	O
be	O
detected	O
for	O
12	O
(	O
75	O
%)	O
of	O
16	O
patients	O
'	O
nasopharyngeal	O
specimens	O
in	O
the	O
combination	O
group	O
after	O
seven	O
days	O
,	O
compared	O
with	O
6	O
(	O
35	O
%)	O
of	O
17	O
in	O
the	O
monotherapy	O
group	O
(	O
p	O
<	O
0	O
·	O
05	O
).	O

After	O
14	O
days	O
,	O
15	O
(	O
94	O
%)	O
of	O
16	O
and	O
9	O
(	O
52	O
·	O
9	O
%)	O
of	O
17	O
,	O
respectively	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
could	O
not	O
be	O
detected	O
(	O
p	O
<	O
0	O
·	O
05	O
).	O

Up	O
to	O
now	O
,	O
clinical	O
features	O
and	O
treatment	O
of	O
patients	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
have	O
been	O
reported	O
in	O
detail	O
.	O

TITLE	O
:	O
Diagnosis	O
and	O
clinical	O
management	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
Coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
infection	B-DISO
:	O
an	O
operational	O
recommendation	O
of	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
(	O
V2	O
.	O
0	O
).	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
clinical	O
presentation	O
of	O
horses	O
diagnosed	O
with	O
ECoV	O
infection	B-DISO
that	O
were	O
not	O
associated	O
with	O
an	O
outbreak	O
.	O

The	O
Spanish	O
Paediatric	O
Association	O
appointed	O
a	O
Working	O
Group	O
of	O
the	O
Societies	O
of	O
Paediatric	O
Infectious	B-DISO
Diseases	I-DISO
and	O
Paediatric	O
Intensive	O
Care	O
to	O
prepare	O
the	O
present	O
recommendations	O
with	O
the	O
evidence	O
available	O
at	O
the	O
time	O
of	O
preparing	O
them	O
.	O

TITLE	O
:	O
Applications	O
of	O
google	O
search	O
trends	O
for	O
risk	O
communication	O
in	O
infectious	B-DISO
disease	I-DISO
management	O
:	O
A	O
case	O
study	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
in	O
Taiwan	O
.	O

Searches	O
related	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
face	B-DISO
masks	O
in	O
Taiwan	O
increased	O
rapidly	O
,	O
following	O
the	O
announcements	O
of	O
Taiwan	O
'	O
first	O
imported	O
case	O
and	O
reached	O
its	O
peak	O
as	O
local	O
cases	O
were	O
reported	O
.	O

A	O
literature	O
search	O
was	O
conducted	O
using	O
the	O
databases	O
PubMed	O
,	O
EMBASE	O
,	O
and	O
Web	B-DISO
of	O
sciences	O
until	O
February	O
25	O
,	O
2020	O
.	O

Risk	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	B-DISO
)	O
were	O
pooled	O
using	O
random	O
-	O
effects	O
models	O
.	O

Increasing	O
eosinophils	O
may	O
be	O
an	O
indicator	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
improvement	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
may	O
benefit	O
from	O
sustained	O
lopinavir	O
using	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
of	O
refractory	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
in	O
Wuhan	O
,	O
China	O
.	O

TITLE	O
:	O
False	O
-	O
Negative	O
Results	O
of	O
Real	O
-	O
Time	O
Reverse	O
-	O
Transcriptase	O
Polymerase	O
Chain	O
Reaction	O
for	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
2	O
:	O
Role	O
of	O
Deep	O
-	O
Learning	O
-	O
Based	O
CT	O
Diagnosis	O
and	O
Insights	O
from	O
Two	O
Cases	O
.	O

ABSTRACT	O
:	O
The	O
epidemic	O
of	O
2019	O
novel	O
coronavirus	O
,	O
later	O
named	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
is	O
still	O
gradually	O
spreading	O
worldwide	O
.	O

Coinfection	B-DISO
with	O
SARS	B-DISO
-	O
COV	O
-	O
2	O
and	O
other	O
viruses	O
has	O
been	O
discussed	O
as	O
well	O
.	O

Owing	O
to	O
the	O
complications	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
,	O
the	O
first	O
symptom	B-DISO
and	O
imaging	O
features	O
of	O
patients	O
can	O
be	O
very	O
atypical	O
and	O
early	O
diagnosis	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infections	B-DISO
remains	O
a	O
challenge	O
.	O

TITLE	O
:	O
[	O
Advances	O
in	O
the	O
research	O
of	O
mechanism	O
of	O
pulmonary	B-DISO
fibrosis	I-DISO
induced	O
by	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
and	O
the	O
corresponding	O
therapeutic	O
measures	O
].	O

Pulmonary	B-DISO
fibrosis	I-DISO
is	O
a	O
pulmonary	B-DISO
disease	I-DISO
with	O
progressive	O
fibrosis	B-DISO
,	O
which	O
is	O
the	O
main	O
factor	O
leading	O
to	O
pulmonary	O
dysfunction	O
and	O
quality	O
of	O
life	O
decline	O
in	O
SARS	B-DISO
survivors	O
after	O
recovery	O
.	O

ABSTRACT	O
:	O
Unexplained	O
pneumonia	B-DISO
(	O
UP	O
)	O
caused	O
by	O
a	O
novel	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
)	O
emerged	O
in	O
China	O
in	O
late	O
December	O
2019	O
and	O
has	O
infected	O
more	O
than	O
9000	O
cases	O
by	O
31	O
January	O
2020	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
purely	O
data	O
-	O
driven	O
statistical	O
method	O
to	O
estimate	O
the	O
CFR	O
in	O
the	O
early	O
phase	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
.	O

Our	O
early	O
estimates	O
suggest	O
that	O
the	O
CFR	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
is	O
lower	O
than	O
the	O
previous	O
coronavirus	O
epidemics	O
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
Shadows	O
of	O
MERS	O
-	O
CoV	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

Recently	O
,	O
at	O
the	O
end	O
of	O
December	O
2019	O
,	O
a	O
cluster	O
of	O
pneumonia	B-DISO
cases	O
were	O
reported	O
from	O
Wuhan	O
city	O
,	O
Hubei	O
Province	O
,	O
China	O
,	O
linked	O
to	O
a	O
wet	O
seafood	O
market	O
with	O
a	O
new	O
coronavirus	O
identified	O
as	O
the	O
etiologic	O
agent	O
currently	O
named	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

As	O
it	O
relates	O
to	O
countries	O
with	O
the	O
ongoing	O
MERS	O
-	O
CoV	O
community	O
cases	O
and	O
hospital	O
acquired	O
infections	B-DISO
,	O
there	O
will	O
be	O
a	O
huge	O
challenge	O
for	O
HCWs	O
to	O
deal	O
with	O
both	O
coronaviruses	O
,	O
especially	O
with	O
the	O
lack	O
of	O
standardized	O
and	O
approved	O
point	O
of	O
care	O
testing	O
.	O

This	O
virus	O
causes	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

Since	O
then	O
,	O
there	O
have	O
been	O
anecdotal	O
reports	O
of	O
ocular	B-DISO
infection	I-DISO
.	O

Data	O
from	O
routine	O
diagnostics	O
show	O
a	O
strong	O
and	O
consistent	O
seasonal	O
variation	O
of	O
the	O
four	O
endemic	O
coronaviruses	O
(	O
229E	O
,	O
HKU1	O
,	O
NL63	O
,	O
OC43	O
)	O
and	O
we	O
parameterise	O
our	O
model	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
using	O
these	O
data	O
.	O

While	O
the	O
uncertainty	O
in	O
parameters	O
is	O
large	O
,	O
the	O
scenarios	O
we	O
explore	O
show	O
that	O
transient	O
reductions	O
in	O
the	O
incidence	O
rate	O
might	O
be	O
due	O
to	O
a	O
combination	O
of	O
seasonal	O
variation	O
and	O
infection	B-DISO
control	O
efforts	O
but	O
do	O
not	O
necessarily	O
mean	O
the	O
epidemic	O
is	O
contained	O
.	O

The	O
likely	O
aggregated	O
effect	O
of	O
seasonal	O
variation	O
,	O
infection	B-DISO
control	O
measures	O
,	O
and	O
transmission	O
rate	O
variation	O
is	O
a	O
prolonged	O
pandemic	O
wave	O
with	O
lower	O
prevalence	O
at	O
any	O
given	O
time	O
,	O
thereby	O
providing	O
a	O
window	O
of	O
opportunity	O
for	O
better	O
preparation	O
of	O
health	O
care	O
systems	O
.	O

We	O
also	O
predict	O
the	O
unique	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
sites	O
of	O
spike	O
glycoprotein	O
that	O
distinguish	O
it	O
from	O
the	O
SARS	B-DISO
and	O
underlines	O
shielding	O
and	O
camouflage	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
from	O
the	O
host	O
the	O
defence	O
system	O
.	O

TITLE	O
:	O
First	O
known	O
person	O
-	O
to	O
-	O
person	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
in	O
the	O
USA	O
.	O

Overall	O
,	O
372	O
contacts	O
of	O
both	O
cases	O
were	O
identified	O
;	O
347	O
underwent	O
active	O
symptom	B-DISO
monitoring	O
,	O
including	O
152	O
community	O
contacts	O
and	O
195	O
health	O
-	O
care	O
personnel	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
whether	O
platelet	O
count	O
could	O
differentiate	O
between	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
with	O
or	O
without	O
severe	O
disease	O
.	O

Additionally	O
,	O
we	O
evaluate	O
if	O
thrombocytopenia	O
is	O
associated	O
with	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

A	O
meta	O
-	O
analysis	O
was	O
performed	O
,	O
with	O
calculation	O
of	O
weighted	O
mean	O
difference	O
(	O
WMD	O
)	O
of	O
platelet	O
number	O
in	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
with	O
or	O
without	O
severe	O
disease	O
and	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
thrombocytopenia	O
for	O
severe	O
form	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Clinical	O
,	O
laboratory	O
and	O
imaging	O
features	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

We	O
performed	O
a	O
systematic	O
literature	O
review	O
with	O
meta	O
-	O
analysis	O
,	O
using	O
three	O
databases	O
to	O
assess	O
clinical	O
,	O
laboratory	O
,	O
imaging	O
features	O
,	O
and	O
outcomes	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
confirmed	O
cases	O
.	O

ABSTRACT	O
:	O
An	O
ongoing	O
epidemic	O
of	O
respiratory	B-DISO
diseases	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
COVID	O
2019	O
,	O
SARS	B-DISO
-	O
CoV2	O
)	O
started	O
in	O
Wuhan	O
,	O
Hubei	O
,	O
in	O
China	O
at	O
the	O
end	O
of	O
December	O
2019	O
.	O

All	O
the	O
tests	O
for	O
SARS	B-DISO
-	O
CoV2	O
were	O
negative	O
.	O

Teicoplanin	O
,	O
an	O
antibiotic	O
used	O
to	O
treat	O
staphylococci	O
infection	B-DISO
,	O
previously	O
showed	O
efficacy	O
to	O
inhibit	O
the	O
first	O
stage	O
of	O
MERS	O
-	O
coronarivus	O
viral	O
cycle	O
in	O
human	O
cells	O
.	O

ABSTRACT	O
:	O
Estimation	O
of	O
the	O
prevalence	O
and	O
contagiousness	O
of	O
undocumented	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV2	O
)	O
infections	B-DISO
is	O
critical	O
for	O
understanding	O
the	O
overall	O
prevalence	O
and	O
pandemic	O
potential	O
of	O
this	O
disease	O
.	O

These	O
findings	O
explain	O
the	O
rapid	O
geographic	O
spread	O
of	O
SARS	B-DISO
-	O
CoV2	O
and	O
indicate	O
containment	O
of	O
this	O
virus	O
will	O
be	O
particularly	O
challenging	O
.	O

Here	O
we	O
report	O
that	O
GA	O
inhibits	O
Herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
by	O
inhibition	O
of	O
both	O
fusion	O
and	O
viral	O
protein	O
synthesis	O
.	O

Our	O
experiments	O
suggest	O
that	O
GA	O
inhibits	O
virion	O
entry	O
by	O
blocking	B-DISO
the	O
initial	O
fusion	O
event	O
.	O

Data	O
showing	O
inhibition	O
of	O
HSV	O
-	O
1	O
and	O
CMV	O
replication	O
,	O
when	O
GA	O
is	O
administered	O
post	O
-	O
infection	B-DISO
,	O
suggest	O
a	O
possible	O
secondary	O
mechanism	O
targeting	O
protein	O
and	O
DNA	O
synthesis	O
.	O

The	O
two	O
confirmed	O
children	O
only	O
presented	O
with	O
mild	O
respiratory	O
or	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

Pediatric	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
are	O
mostly	O
owing	O
to	O
family	O
cluster	O
or	O
with	O
a	O
close	O
contact	O
history	O
.	O

ABSTRACT	O
:	O
We	O
found	O
a	O
strong	O
correlation	O
between	O
travel	O
volumes	O
departing	O
from	O
Wuhan	O
,	O
Hubei	O
Province	O
before	O
the	O
Spring	O
Festival	O
and	O
the	O
extent	O
of	O
amplification	B-DISO
of	O
the	O
outbreak	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
China	O
in	O
2020	O
,	O
with	O
100	O
top	O
cities	O
.	O

According	O
to	O
the	O
Chest	O
computed	O
tomography	O
scans	O
,	O
67	O
.	O
03	O
%	O
cases	O
had	O
bilateral	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
Preparing	O
for	O
public	O
health	O
emergencies	B-DISO
is	O
an	O
ongoing	O
process	O
and	O
involves	O
a	O
variety	O
of	O
approaches	O
and	O
tools	O
.	O

The	O
specificity	O
of	O
predicting	O
the	O
severity	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
during	O
IL	O
-	O
6	O
and	O
D	O
-	O
Dimer	O
tandem	O
testing	O
was	O
up	O
to	O
93	O
.	O
3	O
%,	O
while	O
the	O
sensitivity	O
of	O
IL	O
-	O
6	O
and	O
D	O
-	O
Dimer	O
by	O
parallel	O
test	O
in	O
the	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
was	O
96	O
.	O
4	O
%.	O

Its	O
pathophysiology	O
includes	O
the	O
release	O
of	O
damage	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
),	O
which	O
propagate	O
tissue	O
injuries	O
by	O
triggering	O
neutrophil	O
extracellular	O
traps	B-DISO
(	O
NETs	O
).	O

This	O
treatment	O
may	O
facilitate	O
ventilator	O
weaning	O
,	O
reduce	O
the	O
burden	O
of	O
trauma	O
-	O
induced	O
lung	B-DISO
inflammation	I-DISO
and	O
facilitate	O
recovery	O
and	O
rehabilitation	O
in	O
severe	O
trauma	O
patients	O
.	O

We	O
conducted	O
statistical	O
modelling	O
to	O
derive	O
the	O
delay	O
-	O
adjusted	O
asymptomatic	O
proportion	O
of	O
infections	B-DISO
,	O
along	O
with	O
the	O
infections	B-DISO
'	O
timeline	O
.	O

Most	O
infections	B-DISO
occurred	O
before	O
the	O
quarantine	O
start	O
.	O

TITLE	O
:	O
Post	O
-	O
discharge	O
surveillance	O
and	O
positive	O
virus	O
detection	O
in	O
two	O
medical	O
staff	O
recovered	O
from	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
),	O
China	O
,	O
January	O
to	O
February	O
2020	O
.	O

ABSTRACT	O
:	O
The	O
peak	O
of	O
Internet	O
searches	O
and	O
social	O
media	O
data	O
about	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
outbreak	O
occurred	O
10	O
-	O
14	O
days	O
earlier	O
than	O
the	O
peak	O
of	O
daily	O
incidences	O
in	O
China	O
.	O

TITLE	O
:	O
A	O
Sequence	O
Homology	O
and	O
Bioinformatic	O
Approach	O
Can	O
Predict	O
Candidate	O
Targets	O
for	O
Immune	O
Responses	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

This	O
includes	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
has	O
high	O
sequence	O
similarity	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
and	O
is	O
the	O
best	O
-	O
characterized	O
coronavirus	O
in	O
terms	O
of	O
epitope	O
responses	O
.	O

The	O
independent	O
identification	O
of	O
the	O
same	O
regions	O
using	O
two	O
approaches	O
reflects	O
the	O
high	O
probability	O
that	O
these	O
regions	O
are	O
promising	O
targets	O
for	O
immune	O
recognition	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Decision	O
making	O
in	O
the	O
time	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Many	O
survivors	O
develop	O
new	O
functional	O
limitations	O
and	O
health	O
problems	O
,	O
and	O
in	O
cases	O
of	O
sepsis	B-DISO
,	O
approximately	O
40	O
%	O
of	O
patients	O
are	O
rehospitalized	O
within	O
three	O
months	O
.	O

Due	O
to	O
the	O
extensive	O
spread	O
and	O
high	O
transmission	O
ability	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
there	O
is	O
a	O
possibility	O
of	O
virus	O
infections	B-DISO
among	O
malaria	B-DISO
cases	O
during	O
the	O
medical	O
care	O
-	O
seeking	O
behaviors	O
and	O
among	O
healthcare	O
professionals	O
during	O
clinical	O
diagnosis	O
and	O
treatment	O
,	O
sample	O
collection	O
and	O
testing	O
and	O
epidemiological	O
surveys	O
.	O

Close	O
monitoring	O
of	O
oxygenation	O
,	O
reducing	O
patients	O
'	O
oxygen	O
consumption	O
,	O
active	O
psychological	B-DISO
intervention	O
,	O
and	O
rapidly	O
dealing	O
with	O
severe	O
hypoxemia	O
events	O
are	O
the	O
key	O
factors	O
for	O
the	O
successful	O
treatment	O
of	O
NIV	O
.	O

There	O
were	O
more	O
case	O
fatalities	O
among	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
without	O
comorbidities	O
than	O
in	O
the	O
reference	O
cohort	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
licensed	O
antiviral	O
treatment	O
or	O
vaccine	O
exists	O
for	O
MERS	O
and	O
SARS	B-DISO
.	O

Better	O
understanding	O
transmission	O
dynamics	O
associated	O
with	O
SSEs	O
,	O
identifying	O
and	O
mitigating	O
high	O
-	O
risk	O
settings	O
,	O
strict	O
adherence	O
to	O
healthcare	O
infection	B-DISO
prevention	O
and	O
control	O
measures	O
,	O
and	O
timely	O
implementation	O
of	O
nonpharmaceutical	O
interventions	O
can	O
help	O
prevent	O
and	O
control	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
,	O
as	O
well	O
as	O
future	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

The	O
result	O
of	O
this	O
phase	O
I	O
clinical	O
trial	O
showed	O
that	O
a	O
single	O
-	O
dose	O
IV	O
infusion	O
of	O
human	O
umbilical	O
cord	B-DISO
-	O
derived	O
mesenchymal	O
stem	O
cells	O
was	O
safe	O
with	O
favorable	O
outcome	O
in	O
nine	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

ARDS	B-DISO
is	O
a	O
serious	O
pulmonary	O
inflammatory	O
process	O
with	O
alveolar	O
damage	O
and	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
;	O
Adenovirus	B-DISO
pneumonia	B-DISO
in	O
children	O
may	O
manifest	O
as	O
severe	O
pulmonary	O
morbidity	O
and	O
respiratory	B-DISO
failure	I-DISO
that	O
may	O
require	O
prolonged	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
The	O
Cholera	B-DISO
Epidemics	O
in	O
Hamburg	O
and	O
What	O
to	O
Learn	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
).	O

The	O
virus	O
is	O
highly	O
infectious	B-DISO
and	O
pathogenic	O
,	O
causing	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

TITLE	O
:	O
[	O
Countermeasures	O
and	O
treatment	O
for	O
aortic	O
acute	O
syndrome	B-DISO
with	O
2019	O
coronavirus	O
disease	O
].	O

ABSTRACT	O
:	O
The	O
2019	O
coronavirus	O
disease	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
cost	O
a	O
great	O
loss	O
to	O
the	O
health	O
and	O
economic	O
property	O
of	O
Chines	O
people	O
.	O

PEDV	O
infection	B-DISO
causes	O
watery	B-DISO
diarrhea	I-DISO
and	O
a	O
mortality	O
of	O
up	O
to	O
100	O
%	O
in	O
piglets	O
.	O

TITLE	O
:	O
Structure	O
-	O
Guided	O
Mutagenesis	O
Alters	O
Deubiquitinating	O
Activity	O
and	O
Attenuates	O
Pathogenesis	B-DISO
of	O
a	O
Murine	O
Coronavirus	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
host	O
transcriptional	O
response	O
to	O
infection	B-DISO
with	O
murine	O
coronaviruses	O
encoding	O
independent	O
mutations	O
in	O
one	O
of	O
two	O
different	O
viral	O
antagonists	O
:	O
the	O
deubiquitinase	O
(	O
DUB	O
)	O
within	O
nonstructural	O
protein	O
3	O
or	O
the	O
endoribonuclease	O
(	O
EndoU	O
)	O
within	O
nonstructural	O
protein	O
15	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
Knowns	O
,	O
Unknowns	O
,	O
and	O
Questions	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
myelodysplastic	B-DISO
syndrome	I-DISO
/	O
myeloproliferative	B-DISO
neoplasm	I-DISO
(	O
MDS	B-DISO
/	O
MPN	O
)	O
are	O
often	O
asymptomatic	O
and	O
thus	O
can	O
remain	O
undiagnosed	O
until	O
they	O
become	O
symptomatic	O
due	O
to	O
progression	O
to	O
the	O
accelerated	O
phase	O
(	O
AP	O
)	O
or	O
transformation	B-DISO
to	O
acute	B-DISO
leukemia	I-DISO
(	O
leukemic	O
transformation	B-DISO
;	O
LT	O
).	O

In	O
conclusions	O
The	O
infection	B-DISO
spread	O
in	O
Japan	O
will	O
be	O
gradually	O
contained	O
by	O
reducing	O
the	O
time	O
spent	O
in	O
the	O
crowded	O
zone	O
to	O
less	O
than	O
4	O
hours	O
.	O

Severe	O
ARDS	B-DISO
reflects	O
the	O
hallmark	O
of	O
a	O
critical	O
course	O
of	O
the	O
disease	O
.	O

However	O
,	O
unlike	O
other	O
healthcare	O
issues	O
,	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
to	O
detect	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
AI	O
-	O
driven	O
tools	O
are	O
expected	O
to	O
have	O
active	O
learning	O
-	O
based	O
cross	O
-	O
population	O
train	O
/	O
test	O
models	O
that	O
employs	O
multitudinal	O
and	O
multimodal	O
data	O
,	O
which	O
is	O
the	O
primary	O
purpose	O
of	O
the	O
paper	O
.	O

Our	O
case	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
showed	O
multiple	O
subpleural	O
GGOs	O
in	O
bilateral	O
lung	O
,	O
rapid	O
progression	O
,	O
and	O
it	O
also	O
accompanied	O
nodular	O
GGOs	O
on	O
chest	O
CT	O
.	O

These	O
findings	O
were	O
consistent	O
with	O
the	O
previous	O
reports	O
,	O
and	O
they	O
might	O
be	O
useful	O
for	O
early	O
detection	O
and	O
evaluation	O
of	O
severity	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
resulted	O
in	O
a	O
worldwide	O
crisis	O
,	O
with	O
large	O
populations	O
locked	O
down	O
and	O
transportation	O
links	O
severed	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
the	O
novel	O
beta	O
Coronavirus	O
,	O
recently	O
renamed	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
has	O
raised	O
serious	O
concerns	O
due	O
to	O
the	O
virus	O
rapid	O
dissemination	O
worldwide	O
.	O

Nevertheless	O
,	O
there	O
is	O
limited	O
information	O
about	O
the	O
genomic	O
epidemiology	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
circulating	O
in	O
Italy	O
from	O
surveillance	O
studies	O
.	O

Continued	O
genomic	O
surveillance	O
strategies	O
are	O
needed	O
to	O
improve	O
monitoring	O
and	O
understanding	O
of	O
the	O
currently	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
epidemics	O
,	O
which	O
might	O
help	O
to	O
attenuate	O
public	O
health	O
impact	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

This	O
modified	O
3I	O
Tool	O
will	O
assist	O
emergency	B-DISO
and	O
primary	O
care	O
clinicians	O
,	O
as	O
well	O
as	O
out	O
-	O
of	O
-	O
hospital	O
providers	O
,	O
in	O
effectively	O
managing	O
persons	O
with	O
suspected	O
or	O
confirmed	O
2019	O
-	O
nCoV	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
:	O
the	O
harms	O
of	O
exaggerated	O
information	O
and	O
non	O
-	O
evidence	O
-	O
based	O
measures	O
.	O

We	O
hereby	O
would	O
like	O
to	O
discuss	O
a	O
few	O
additional	O
points	O
with	O
regards	O
to	O
the	O
challenges	O
encountered	O
while	O
managing	O
pregnant	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

It	O
is	O
desirable	O
to	O
develop	O
automatic	O
and	O
accurate	O
detection	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
using	O
chest	O
CT	O
.	O

TITLE	O
:	O
Natural	O
small	O
molecules	O
as	O
inhibitors	O
of	O
coronavirus	O
lipid	O
-	O
dependent	O
attachment	O
to	O
host	O
cells	O
:	O
a	O
possible	O
strategy	O
for	O
reducing	O
SARS	B-DISO
-	O
COV	O
-	O
2	O
infectivity	O
?	O

This	O
report	O
describes	O
findings	O
from	O
the	O
initial	O
phase	O
of	O
the	O
cruise	O
ship	O
investigation	O
into	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
among	O
crew	O
members	O
during	O
February	O
4	O
-	O
12	O
,	O
2020	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
Effectiveness	O
of	O
Surveillance	O
and	O
Containment	O
Measures	O
for	O
the	O
First	O
100	O
Patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Singapore	O
-	O
January	O
2	O
-	O
February	O
29	O
,	O
2020	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
was	O
first	O
reported	O
in	O
Wuhan	O
,	O
China	O
,	O
in	O
December	O
2019	O
,	O
and	O
has	O
since	O
spread	O
globally	O
,	O
resulting	O
in	O
>	O
95	O
,	O
000	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
worldwide	O
by	O
March	O
5	O
,	O
2020	O
(	O
1	O
).	O

In	O
this	O
article	O
,	O
we	O
explain	O
why	O
the	O
testing	O
strategy	O
in	O
Switzerland	O
should	O
be	O
strengthened	O
urgently	O
,	O
as	O
a	O
core	O
component	O
of	O
a	O
combination	O
approach	O
to	O
control	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
what	O
should	O
anaethesiologists	O
and	O
intensivists	O
know	O
about	O
it	O
?	O

We	O
describe	O
a	O
patient	O
presenting	O
to	O
an	O
Emergency	B-DISO
Department	O
in	O
Rhode	O
Island	O
on	O
March	O
12	O
,	O
2020	O
with	O
cough	B-DISO
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
after	O
a	O
trip	O
to	O
Jamaica	O
.	O

SARS	B-DISO
-	O
CoV	O
-	O
2	O
RT	O
-	O
PCR	O
came	O
back	O
positive	O
24	O
hours	O
later	O
.	O

The	O
radical	O
operation	O
of	O
colorectal	B-DISO
cancer	I-DISO
is	O
semi	O
-	O
elective	O
operation	O
.	O

2019	O
-	O
nCoV	O
virus	O
can	O
be	O
transmitted	B-DISO
by	O
asymptomatic	O
infectors	O
,	O
and	O
it	O
has	O
been	O
confirmed	O
to	O
be	O
transmitted	B-DISO
by	O
droplets	O
and	O
contact	O
.	O

(	O
4	O
)	O
The	O
surgical	O
medical	O
workers	O
who	O
process	O
colorectal	B-DISO
cancer	I-DISO
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
must	O
be	O
protected	O
by	O
three	O
-	O
level	O
.	O

The	O
median	O
incubation	O
period	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
was	O
4	O
days	O
(	O
IQR	O
3	O
-	O
6	O
).	O

Different	O
CT	O
features	O
are	O
seen	O
according	O
to	O
disease	O
severity	O
,	O
which	O
can	O
help	O
COVID	B-DISO
-	I-DISO
19	I-DISO
stratification	O
.	O

RESULTS	O
:	O
Six	O
patients	O
(	O
8	O
%)	O
were	O
diagnosed	O
as	O
mild	O
type	O
pneumonia	B-DISO
;	O
these	O
patients	O
had	O
no	O
obvious	O
abnormal	O
CT	O
findings	O
or	O
manifested	O
mild	O
changes	O
of	O
lung	B-DISO
infection	I-DISO
.	O

Based	O
on	O
a	O
comprehensive	O
literature	O
review	O
and	O
the	O
experience	O
in	O
the	O
frontline	O
,	O
we	O
aim	O
to	O
review	O
the	O
typical	O
and	O
relatively	O
atypical	O
CT	O
manifestations	O
with	O
representative	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
at	O
our	O
hospital	O
,	O
and	O
hope	O
to	O
strengthen	O
the	O
recognition	O
of	O
these	O
features	O
with	O
radiologists	O
and	O
help	O
them	O
make	O
a	O
quick	O
and	O
accurate	O
diagnosis	O
.	O

Key	O
Points	O
•	O
Ground	O
glass	O
opacities	B-DISO
,	O
consolidation	O
,	O
reticular	O
pattern	O
,	O
and	O
crazy	O
paving	O
pattern	O
are	O
typical	O
CT	O
manifestations	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

•	O
CT	O
manifestations	O
may	O
associate	O
with	O
the	O
progression	O
and	O
prognosis	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
severe	O
pediatric	O
patients	O
with	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
in	O
Wuhan	O
:	O
a	O
single	O
center	O
'	O
s	O
observational	O
study	O
.	O

We	O
included	O
eight	O
severe	O
or	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
who	O
were	O
treated	O
at	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
),	O
Wuhan	O
Children	O
'	O
s	O
Hospital	O
from	O
January	O
24	O
to	O
February	O
24	O
.	O

Common	O
imaging	O
changes	O
included	O
multiple	O
patch	O
-	O
like	O
shadows	O
and	O
ground	O
-	O
glass	O
opacity	B-DISO
;	O
and	O
a	O
cytokine	B-DISO
storm	I-DISO
was	O
found	O
in	O
these	O
patients	O
,	O
which	O
appeared	O
more	O
serious	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

For	O
safe	O
and	O
efficient	O
screening	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
drive	O
-	O
through	O
(	O
DT	O
)	O
screening	O
centers	O
have	O
been	O
designed	O
and	O
implemented	O
in	O
Korea	O
.	O

It	O
could	O
be	O
implemented	O
in	O
other	O
countries	O
to	O
cope	O
with	O
the	O
global	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
and	O
transformed	O
according	O
to	O
their	O
own	O
situations	O
.	O

TITLE	O
:	O
First	O
Pediatric	O
Case	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
in	O
Korea	O
.	O

ABSTRACT	O
:	O
The	O
large	O
outbreak	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
that	O
started	O
in	O
Wuhan	O
,	O
China	O
has	O
now	O
spread	O
to	O
many	O
countries	O
worldwide	O
.	O

The	O
10	O
-	O
year	O
-	O
old	O
girl	O
was	O
a	O
close	O
contact	O
of	O
her	O
uncle	O
and	O
her	O
mother	O
who	O
were	O
confirmed	O
to	O
have	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Transmission	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
terminal	O
stage	O
of	O
incubation	O
period	O
:	O
a	O
familial	O
cluster	O
.	O

However	O
,	O
there	O
are	O
currently	O
no	O
effective	O
drugs	O
targeting	O
2019	O
-	O
nCoV	O
/	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Phylogenetic	O
analyses	O
of	O
15	O
HCoV	O
whole	O
genomes	O
reveal	O
that	O
2019	O
-	O
nCoV	O
/	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
shares	O
the	O
highest	O
nucleotide	O
sequence	O
identity	O
with	O
SARS	B-DISO
-	O
CoV	O
(	O
79	O
.	O
7	O
%).	O

TITLE	O
:	O
The	O
outbreak	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
pneumonia	B-DISO
calls	O
for	O
viral	O
vaccines	O
.	O

This	O
work	O
aims	O
to	O
share	O
strategies	O
and	O
candidate	O
antigens	O
to	O
develop	O
safe	O
and	O
effective	O
vaccines	O
against	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Here	O
,	O
the	O
authors	O
review	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pathogenesis	B-DISO
,	O
presentation	O
,	O
diagnosis	O
,	O
and	O
potential	O
therapeutics	O
,	O
with	O
a	O
focus	O
on	O
management	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
associated	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
,	O
named	O
COVID	B-DISO
-	I-DISO
19	I-DISO
officially	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
Geneva	O
,	O
Switzerland	O
)	O
on	O
February	O
12	O
,	O
2020	O
,	O
has	O
spread	O
at	O
unprecedented	O
speed	O
.	O

Approximately	O
3	O
.	O
2	O
%	O
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
required	O
intubation	O
and	O
invasive	O
ventilation	O
at	O
some	O
point	O
in	O
the	O
disease	O
course	O
.	O

Lung	O
-	O
protective	O
ventilation	O
,	O
prone	O
position	O
ventilation	O
,	O
and	O
adequate	O
sedation	B-DISO
and	O
analgesia	B-DISO
are	O
essential	O
components	O
of	O
ventilation	O
management	O
.	O

ABSTRACT	O
:	O
Clinical	O
,	O
laboratory	O
,	O
and	O
computed	O
tomography	O
(	O
CT	O
)	O
findings	O
of	O
5	O
cases	O
of	O
the	O
novel	B-DISO
Coronavirus	I-DISO
Disease	I-DISO
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
pneumonia	B-DISO
from	O
patients	O
outside	O
of	O
Wuhan	O
were	O
reviewed	O
.	O

Our	O
results	O
suggested	O
that	O
although	O
PMX	O
-	O
HP	O
did	O
not	O
reduce	O
in	O
-	O
hospital	O
mortality	O
among	O
overall	O
septic	B-DISO
shock	I-DISO
patients	O
,	O
it	O
may	O
benefit	O
a	O
limited	O
population	O
with	O
high	O
age	O
and	O
higher	O
disease	O
severity	O
.	O

All	O
of	O
them	O
accepted	O
mechanical	O
ventilation	O
,	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
),	O
blood	O
transfusion	O
,	O
glucocorticoid	O
,	O
and	O
multi	O
-	O
anti	O
-	O
infectious	B-DISO
therapy	O
.	O

The	O
patients	O
'	O
demographic	O
information	O
,	O
cancer	B-DISO
history	O
,	O
treatment	O
pattern	O
,	O
information	O
about	O
MERS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
,	O
history	O
of	O
travel	O
,	O
clinical	O
symptoms	O
,	O
test	O
results	O
,	O
and	O
outcome	O
were	O
collected	O
and	O
analyzed	O
as	O
part	O
of	O
a	O
quality	O
improvement	O
project	O
to	O
improve	O
the	O
care	O
and	O
safety	O
of	O
our	O
patients	O
.	O

The	O
most	O
common	O
underlying	O
disease	O
was	O
hematologic	B-DISO
malignancies	I-DISO
(	O
47	O
.	O
4	O
%),	O
followed	O
by	O
colorectal	B-DISO
cancer	I-DISO
(	O
21	O
%)	O
and	O
lung	B-DISO
cancer	I-DISO
(	O
15	O
.	O
8	O
%).	O

All	O
patients	O
contracted	O
the	O
infection	B-DISO
during	O
their	O
hospitalization	O
for	O
other	O
reasons	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
Coronavirus	O
).	O

The	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
in	O
humans	O
remains	O
unclear	O
.	O

This	O
article	O
reviews	O
the	O
immunological	O
changes	O
of	O
coronaviruses	O
like	O
SARS	B-DISO
,	O
MERS	O
and	O
other	B-DISO
viral	I-DISO
pneumonia	I-DISO
similar	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Laboratory	O
Diagnosis	O
of	O
Emerging	O
Human	O
Coronavirus	B-DISO
Infections	I-DISO
-	O
The	O
State	O
of	O
the	O
Art	O
.	O

Several	O
integrated	O
,	O
random	O
-	O
access	O
,	O
point	O
-	O
of	O
-	O
care	O
molecular	O
devices	O
are	O
currently	O
under	O
development	O
for	O
fast	O
and	O
accurate	O
diagnosis	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
infections	B-DISO
.	O

TITLE	O
:	O
Point	O
-	O
of	O
-	O
Care	O
Lung	O
Ultrasound	O
findings	O
in	O
novel	B-DISO
coronavirus	I-DISO
disease	I-DISO
-	O
19	O
pnemoniae	O
:	O
a	O
case	O
report	O
and	O
potential	O
applications	O
during	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
.	O

Lung	O
ultrasound	O
allowed	O
the	O
identification	O
of	O
nCoV	O
-	O
19	O
infection	B-DISO
at	O
bed	B-DISO
-	O
side	O
.	O

CONCLUSIONS	O
:	O
Currently	O
,	O
there	O
is	O
no	O
clear	O
evidence	O
regarding	O
optimal	O
delivery	O
timing	O
,	O
the	O
safety	O
of	O
vaginal	O
delivery	O
,	O
or	O
whether	O
cesarean	O
delivery	O
prevents	O
vertical	B-DISO
transmission	I-DISO
at	O
the	O
time	O
of	O
delivery	O
;	O
therefore	O
,	O
route	O
of	O
delivery	O
and	O
delivery	O
timing	O
should	O
be	O
individualized	O
based	O
on	O
obstetrical	O
indications	O
and	O
maternal	O
-	O
fetal	O
status	O
.	O

The	O
clinical	O
course	O
of	O
the	O
eleven	O
cases	O
demonstrated	O
the	O
complexity	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
profile	O
with	O
different	O
clinical	O
presentations	O
.	O

Clinical	O
manifestations	O
range	O
from	O
asymptomatic	O
cases	O
to	O
patients	O
with	O
mild	O
and	O
severe	O
symptoms	O
,	O
with	O
or	O
without	O
pneumonia	B-DISO
.	O

All	O
different	O
clinical	O
characteristics	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
should	O
be	O
taken	O
into	O
consideration	O
to	O
identify	O
patients	O
that	O
need	O
to	O
be	O
in	O
strict	O
quarantine	O
for	O
the	O
efficient	O
containment	O
of	O
the	O
pandemic	O
.	O

RESULTS	O
:	O
The	O
clinical	O
course	O
of	O
the	O
eleven	O
cases	O
demonstrated	O
the	O
complexity	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
profile	O
with	O
different	O
clinical	O
presentations	O
.	O

ABSTRACT	O
:	O
In	O
2014	O
,	O
the	O
worst	O
outbreak	O
of	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
(	O
EVD	O
)	O
emerged	O
in	O
sub	O
-	O
Saharan	O
Africa	O
(	O
SSA	O
)	O
causing	O
fear	O
and	O
panic	O
.	O

5	O
out	O
of	O
the	O
115	O
patients	O
confirmed	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
also	O
diagnosed	O
with	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
,	O
with	O
three	O
cases	O
being	O
influenza	B-DISO
A	O
and	O
two	O
cases	O
being	O
influenza	B-DISO
B	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
the	O
clinical	O
characteristics	O
of	O
those	O
patients	O
who	O
got	O
infected	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
as	O
well	O
as	O
influenza	B-DISO
virus	O
.	O

,	O
the	O
Lombardy	O
region	O
of	O
Italy	O
has	O
become	O
one	O
of	O
the	O
areas	O
of	O
highest	O
incidence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
Coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
).	O

TITLE	O
:	O
Navigating	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
Covid	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
Physiatry	O
:	O
A	O
CAN	O
report	O
for	O
Inpatient	O
Rehabilitation	O
Facilities	O
.	O

TITLE	O
:	O
Probable	O
Pangolin	O
Origin	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
Associated	O
with	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Outbreak	O
.	O

The	O
S1	O
protein	O
of	O
Pangolin	O
-	O
CoV	O
is	O
much	O
more	O
closely	O
related	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
than	O
to	O
RaTG13	O
.	O

Conclusively	O
,	O
this	O
study	O
suggests	O
that	O
pangolin	O
species	O
are	O
a	O
natural	O
reservoir	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
like	O
CoVs	O
.	O

TITLE	O
:	O
Managing	O
Cancer	B-DISO
Care	O
During	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Pandemic	O
:	O
Agility	O
and	O
Collaboration	O
Toward	O
a	O
Common	O
Goal	O
.	O

ABSTRACT	O
:	O
At	O
the	O
end	O
of	O
2019	O
,	O
the	O
novel	B-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
),	O
a	O
fast	O
-	O
spreading	O
respiratory	B-DISO
disease	I-DISO
caused	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
was	O
reported	O
in	O
Wuhan	O
,	O
China	O
and	O
has	O
now	O
affected	O
over	O
123	O
countries	O
globally	O
[...].	O

TITLE	O
:	O
A	O
case	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
pneumonia	B-DISO
returning	O
from	O
Macau	O
in	O
Taiwan	O
:	O
Clinical	O
course	O
and	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
IgG	O
dynamic	O
.	O

ABSTRACT	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
woman	O
presented	O
to	O
the	O
emergency	B-DISO
department	O
with	O
2	O
-	O
day	O
fever	O
and	O
cough	B-DISO
at	O
seven	O
days	O
after	O
returning	O
from	O
Macau	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
identified	O
on	O
Jan	O
20	O
,	O
2020	O
in	O
South	O
Korea	O
,	O
the	O
number	O
of	O
cases	O
rapidly	O
increased	O
,	O
resulting	O
in	O
6	O
,	O
284	O
cases	O
including	O
42	O
deaths	O
as	O
of	O
March	O
6	O
,	O
2020	O
.	O

Singapore	O
'	O
s	O
health	O
ministry	O
has	O
responded	O
with	O
enhanced	O
surveillance	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
for	O
all	O
suspected	O
pneumonia	B-DISO
cases	O
,	O
further	O
increasing	O
the	O
volume	O
of	O
testing	O
via	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
,	O
as	O
well	O
as	O
samples	O
necessitating	O
stringent	O
infectious	B-DISO
control	O
.	O

ABSTRACT	O
:	O
The	O
first	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
case	O
was	O
reported	O
in	O
United	O
States	O
(	O
US	O
),	O
in	O
the	O
state	O
of	O
Washington	O
,	O
approximately	O
three	O
months	O
after	O
the	O
outbreak	O
in	O
Wuhan	O
,	O
China	O
.	O

Three	O
weeks	O
later	O
,	O
the	O
US	O
federal	O
government	O
declared	O
the	O
pandemic	O
a	O
national	O
emergency	B-DISO
.	O

The	O
number	O
of	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
positive	O
cases	O
increased	O
rather	O
rapidly	O
and	O
changed	O
routine	O
daily	O
activities	O
of	O
the	O
community	O
.	O

Common	O
symptoms	O
included	O
fever	O
(	O
120	O
[	O
88	O
.	O
9	O
%]),	O
cough	B-DISO
(	O
102	O
[	O
76	O
.	O
5	O
%]),	O
and	O
fatigue	B-DISO
(	O
44	O
[	O
32	O
.	O
5	O
%]).	O

Compared	O
with	O
the	O
mild	O
cases	O
,	O
the	O
severe	O
cases	O
had	O
lower	O
lymphocyte	O
counts	O
and	O
higher	O
plasma	O
levels	O
of	O
Pt	O
,	O
APTT	O
,	O
D	O
-	O
dimer	O
,	O
LDH	O
,	O
PCT	B-DISO
,	O
ALB	O
,	O
CRP	O
,	O
and	O
AST	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
,	O
the	O
clinic	O
features	O
and	O
therapies	O
of	O
135	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
were	O
demonstrated	O
.	O

It	O
has	O
been	O
a	O
good	O
8	O
years	O
since	O
I	O
'	O
ve	O
graduated	O
medical	O
school	O
,	O
with	O
nary	O
an	O
exposure	O
to	O
emergency	B-DISO
medicine	O
since	O
my	O
intern	O
days	O
.	O

The	O
lung	O
injury	O
and	O
repair	O
caused	O
by	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
many	O
similarities	O
with	O
the	O
onset	O
and	O
progression	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ILD	O
)	O
.	O

TITLE	O
:	O
Health	O
security	O
capacities	O
in	O
the	O
context	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
:	O
an	O
analysis	O
of	O
International	O
Health	O
Regulations	O
annual	O
report	O
data	O
from	O
182	O
countries	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
characteristics	O
and	O
clinical	O
value	O
of	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
images	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
).	O

The	O
main	O
clinical	O
manifestations	O
were	O
fever	O
,	O
dry	B-DISO
cough	I-DISO
,	O
fatigue	B-DISO
,	O
a	O
little	O
white	O
sputum	O
,	O
or	O
diarrhoea	B-DISO
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
2	O
months	O
since	O
the	O
first	O
case	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
was	O
reported	O
in	O
Wuhan	O
.	O

CNGOF	O
.]	O
ABSTRACT	O
:	O
A	O
new	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
highlighted	O
at	O
the	O
end	O
of	O
2019	O
in	O
China	O
is	O
spreading	O
across	O
all	O
continents	O
.	O

Pregnancy	O
is	O
known	O
as	O
a	O
period	O
at	O
higher	O
risk	O
for	O
the	O
consequences	O
of	O
respiratory	B-DISO
infections	I-DISO
,	O
as	O
for	O
influenza	B-DISO
,	O
so	O
it	O
seems	O
important	O
to	O
screen	O
for	O
Covid	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
presence	O
of	O
symptoms	O
and	O
to	O
monitor	O
closely	O
pregnant	O
women	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
turned	O
positive	O
in	O
a	O
discharged	O
patient	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
arouses	O
concern	O
regarding	O
the	O
present	O
standard	O
for	O
discharge	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
gastrointestinal	B-DISO
symptoms	I-DISO
and	O
potential	O
sources	O
of	O
2019	O
-	O
nCoV	O
transmission	O
.	O

At	O
the	O
genetic	O
level	O
,	O
2019	O
-	O
nCoV	O
is	O
closely	O
related	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
MERS	O
-	O
CoV	O
,	O
which	O
appeared	O
as	O
epidemiological	O
threats	O
in	O
recent	O
years	O
in	O
China	O
and	O
the	O
Middle	O
East	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
As	O
the	O
infection	B-DISO
of	O
2019	O
-	O
nCoV	O
coronavirus	O
is	O
quickly	O
developing	O
into	O
a	O
global	O
pneumonia	B-DISO
epidemic	O
,	O
the	O
careful	O
analysis	O
of	O
its	O
transmission	O
and	O
cellular	O
mechanisms	O
is	O
sorely	O
needed	O
.	O

Second	O
,	O
infection	B-DISO
has	O
been	O
associated	O
with	O
multiple	O
direct	O
and	O
indirect	O
cardiovascular	O
complications	O
including	O
acute	O
myocardial	O
injury	O
,	O
myocarditis	B-DISO
,	O
arrhythmias	B-DISO
and	O
venous	B-DISO
thromboembolism	I-DISO
.	O

This	O
review	O
in	O
the	O
hope	O
of	O
helping	O
the	O
public	O
effectively	O
recognize	O
and	O
deal	O
with	O
the	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
and	O
providing	O
a	O
reference	O
for	O
future	O
studies	O
.	O

STAT3	O
exhibits	O
a	O
proviral	O
function	O
in	O
several	O
viral	B-DISO
infections	I-DISO
,	O
including	O
those	O
of	O
HBV	B-DISO
,	O
HCV	O
,	O
HSV	O
-	O
1	O
,	O
varicella	B-DISO
zoster	I-DISO
virus	O
,	O
human	O
CMV	O
and	O
measles	B-DISO
virus	O
.	O

This	O
review	O
summarizes	O
the	O
roles	O
of	O
STAT3	O
in	O
viral	B-DISO
infection	I-DISO
and	O
pathogenesis	B-DISO
,	O
and	O
briefly	O
discusses	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
these	O
processes	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
:	O
pathogenesis	B-DISO
and	O
therapeutic	O
developments	O
.	O

TITLE	O
:	O
Dermatology	O
staff	O
participate	O
in	O
fight	O
against	O
Covid	B-DISO
-	I-DISO
19	I-DISO
in	O
China	O
.	O

We	O
also	O
discuss	O
issues	O
related	O
to	O
transplant	O
-	O
related	O
research	O
during	O
the	O
pandemic	O
,	O
the	O
role	O
of	O
transplant	O
infectious	B-DISO
diseases	I-DISO
and	O
the	O
influence	O
of	O
transplant	O
societies	O
for	O
education	O
and	O
disseminating	O
current	O
information	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
cytokines	O
and	O
immunosuppression	O
:	O
what	O
can	O
we	O
learn	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
?	O

The	O
two	O
previously	O
reported	O
coronavirus	O
epidemics	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
]	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
[	O
MERS	O
])	O
share	O
similar	O
pathogenetic	O
,	O
epidemiological	O
and	O
clinical	O
features	O
as	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Lopinavir	O
/	O
ritonavir	O
combination	O
therapy	O
amongst	O
symptomatic	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
patients	O
in	O
India	O
:	O
Protocol	O
for	O
restricted	O
public	O
health	O
emergency	B-DISO
use	O
.	O

Hospitalized	O
adult	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
with	O
any	O
one	O
of	O
the	O
following	O
criteria	O
will	O
be	O
eligible	O
to	O
receive	O
lopinavir	O
/	O
ritonavir	O
for	O
14	O
days	O
after	O
obtaining	O
written	O
informed	O
consent	O
:	O
(	O
i	O
)	O
respiratory	B-DISO
distress	I-DISO
with	O
respiratory	O
rate	O
≥	O
22	O
/	O
min	O
or	O
SpO2	O
of	O
<	O
94	O
per	O
cent	O
;	O
(	O
ii	O
)	O
lung	O
parenchymal	O
infiltrates	B-DISO
on	O
chest	O
X	O
-	O
ray	O
;	O
(	O
iii	O
)	O
hypotension	O
defined	O
as	O
systolic	O
blood	O
pressure	O
<	O
90	O
mmHg	O
or	O
need	O
for	O
vasopressor	O
/	O
inotropic	O
medication	O
;	O
(	O
iv	O
)	O
new	O
-	O
onset	O
organ	O
dysfunction	O
;	O
and	O
(	O
v	O
)	O
high	O
-	O
risk	O
groups	O
-	O
age	O
>	O
60	O
yr	O
,	O
diabetes	B-DISO
mellitus	I-DISO
,	O
renal	B-DISO
failure	I-DISO
,	I-DISO
chronic	I-DISO
lung	B-DISO
disease	I-DISO
and	O
immunocompromised	O
persons	O
.	O

While	O
there	O
remained	O
important	O
uncertainties	O
in	O
the	O
natural	O
history	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
using	O
hypothetical	O
epidemic	O
curves	O
,	O
some	O
key	O
findings	O
were	O
illustrated	O
that	O
appeared	O
insensitive	O
to	O
model	O
assumptions	O
,	O
as	O
well	O
as	O
highlighting	O
critical	O
data	O
gaps	O
.	O

COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
occurred	O
in	O
children	O
,	O
but	O
they	O
seemed	O
to	O
have	O
a	O
milder	O
disease	O
course	O
and	O
better	O
prognoses	O
than	O
adults	O
.	O

A	O
panel	O
of	O
Italian	O
urologists	O
has	O
agreed	O
on	O
possible	O
strategies	O
for	O
the	O
reorganization	O
of	O
urological	O
routine	O
practice	O
and	O
on	O
a	O
set	O
of	O
recommendations	O
that	O
should	O
facilitate	O
the	O
process	O
of	O
rescheduling	O
both	O
surgical	O
and	O
outpatient	O
activities	O
during	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
and	O
in	O
the	O
subsequent	O
phases	O
.	O

TITLE	O
:	O
Changing	O
the	O
editorial	O
process	O
at	O
JCI	O
and	O
JCI	O
Insight	O
in	O
response	O
to	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
.	O

Health	O
care	O
workers	O
in	O
hospitals	O
equipped	O
with	O
fever	O
clinics	O
or	O
wards	O
for	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
eligible	O
.	O

Frontline	O
health	O
care	O
workers	O
engaged	O
in	O
direct	O
diagnosis	O
,	O
treatment	O
,	O
and	O
care	O
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
symptoms	B-DISO
of	I-DISO
depression	I-DISO
(	O
OR	O
,	O
1	O
.	O
52	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
-	O
2	O
.	O
09	O
;	O
P	O
=	O
.	O
01	O
),	O
anxiety	O
(	O
OR	O
,	O
1	O
.	O
57	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
22	O
-	O
2	O
.	O
02	O
;	O
P	O
<	O
.	O
001	O
),	O
insomnia	B-DISO
(	O
OR	O
,	O
2	O
.	O
97	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
92	O
-	O
4	O
.	O
60	O
;	O
P	O
<	O
.	O
001	O
),	O
and	O
distress	O
(	O
OR	O
,	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
25	O
-	O
2	O
.	O
04	O
;	O
P	O
<	O
.	O
001	O
).	O

In	O
this	O
survey	O
of	O
heath	O
care	O
workers	O
in	O
hospitals	O
equipped	O
with	O
fever	O
clinics	O
or	O
wards	O
for	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Wuhan	O
and	O
other	O
regions	O
in	O
China	O
,	O
participants	O
reported	O
experiencing	O
psychological	B-DISO
burden	O
,	O
especially	O
nurses	O
,	O
women	O
,	O
those	O
in	O
Wuhan	O
,	O
and	O
frontline	O
health	O
care	O
workers	O
directly	O
engaged	O
in	O
the	O
diagnosis	O
,	O
treatment	O
,	O
and	O
care	O
for	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Public	O
Mental	O
Health	O
Crisis	O
during	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Pandemic	O
,	O
China	O
.	O

China	O
has	O
been	O
implementing	O
emergency	B-DISO
psychological	B-DISO
crisis	O
interventions	O
to	O
reduce	O
the	O
negative	O
psychosocial	O
impact	O
on	O
public	O
mental	O
health	O
,	O
but	O
challenges	O
exist	O
.	O

TITLE	O
:	O
Planning	O
and	O
provision	O
of	O
ECMO	O
services	O
for	O
severe	O
ARDS	B-DISO
during	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
and	O
other	O
outbreaks	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
WHO	O
interim	O
guidelines	O
recommend	O
offering	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
eligible	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
related	O
to	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

We	O
calculated	O
word	O
frequency	O
,	O
scores	O
of	O
emotional	O
indicators	O
(	O
e	O
.	O
g	O
.,	O
anxiety	O
,	O
depression	B-DISO
,	O
indignation	O
,	O
and	O
Oxford	O
happiness	O
)	O
and	O
cognitive	O
indicators	O
(	O
e	O
.	O
g	O
.,	O
social	O
risk	O
judgment	O
and	O
life	O
satisfaction	O
)	O
from	O
the	O
collected	O
data	O
.	O

The	O
results	O
contribute	O
to	O
the	O
knowledge	O
gaps	O
of	O
short	O
-	O
term	O
individual	O
changes	O
in	O
psychological	B-DISO
conditions	O
after	O
the	O
outbreak	O
.	O

Here	O
the	O
management	O
guideline	O
for	O
pediatric	O
wards	O
of	O
hematology	O
and	O
oncology	O
during	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
is	O
established	O
based	O
on	O
the	O
features	O
of	O
children	O
with	O
hematological	B-DISO
tumors	I-DISO
.	O

Preventive	O
treatment	O
has	O
an	O
important	O
role	O
to	O
control	O
and	O
avoid	O
the	O
spread	O
of	O
severe	O
respiratory	B-DISO
disease	I-DISO
,	O
but	O
often	O
is	O
difficult	O
to	O
obtain	O
and	O
sometimes	O
cannot	O
be	O
effective	O
to	O
reduce	O
the	O
risk	O
of	O
deterioration	O
of	O
the	O
underlining	O
lung	O
pathology	B-DISO
.	O

TITLE	O
:	O
[	O
Perinatal	O
and	O
neonatal	O
management	O
plan	B-DISO
for	O
prevention	O
and	O
control	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
(	O
2nd	O
Edition	O
)].	O

At	O
the	O
end	O
of	O
January	O
2020	O
,	O
the	O
Working	O
Group	O
for	O
the	O
Prevention	O
and	O
Control	O
of	O
Neonatal	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
Infection	I-DISO
in	O
the	O
Perinatal	O
Period	O
of	O
the	O
Editorial	O
Committee	O
of	O
Chinese	O
Journal	O
of	O
Contemporary	O
Pediatrics	O
worked	O
out	O
the	O
perinatal	O
and	O
neonatal	O
management	O
plan	B-DISO
for	O
prevention	O
and	O
control	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
(	O
1st	O
Edition	O
).	O

TITLE	O
:	O
[	O
Response	O
plan	B-DISO
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
during	O
epidemic	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
(	O
2nd	O
Edition	O
)].	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
infection	B-DISO
has	O
occurred	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
.	O

A	O
retrospective	O
analysis	O
was	O
performed	O
for	O
the	O
clinical	O
data	O
and	O
chest	O
CT	O
images	O
of	O
9	O
children	O
,	O
aged	O
0	O
to	O
3	O
years	O
,	O
who	O
were	O
diagnosed	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
nucleic	O
acid	O
detection	O
between	O
January	O
20	O
and	O
February	O
10	O
,	O
2020	O
.	O

As	O
the	O
special	O
population	O
with	O
immature	O
immune	O
function	O
,	O
newborns	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
have	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
analyze	O
the	O
chest	O
imaging	O
findings	O
in	O
patients	O
with	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
on	O
thin	O
-	O
section	O
CT	O
.	O

Among	O
the	O
47	O
cases	O
,	O
78	O
.	O
7	O
%	O
involved	O
both	O
lungs	O
,	O
and	O
93	O
.	O
6	O
%	O
had	O
peripheral	O
infiltrates	B-DISO
distributed	O
along	O
the	O
subpleural	O
area	O
.	O

Neither	O
enlarged	O
mediastinal	O
lymph	O
nodes	O
nor	O
pleural	B-DISO
effusion	I-DISO
were	O
present	O
.	O

TITLE	O
:	O
Interrupting	O
COVID	B-DISO
-	I-DISO
19	I-DISO
transmission	O
by	O
implementing	O
enhanced	O
traffic	O
control	O
bundling	O
:	O
Implications	O
for	O
global	O
prevention	O
and	O
control	O
efforts	O
.	O

COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
with	O
and	O
without	O
travel	O
history	O
to	O
China	O
were	O
divided	O
into	O
cohorts	O
according	O
to	O
the	O
Healthcare	O
Access	O
and	O
Quality	O
Index	O
(	O
HAQ	O
-	O
Index	O
)	O
of	O
each	O
country	O
.	O

Further	O
analyses	O
demonstrate	O
a	O
significantly	O
lower	O
proportion	O
of	O
reported	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
without	O
travel	O
history	O
to	O
China	O
in	O
countries	O
with	O
lower	O
HAQ	O
(	O
HAQ	O
I	O
vs	O
.	O
HAQ	O
II	O
,	O
posthoc	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
index	O
case	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
Scotland	O
:	O
a	O
case	O
report	O
.	O

COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
is	O
certainly	O
conditioning	O
the	O
treatment	O
strategy	O
of	O
a	O
complex	O
disorder	O
as	O
rheumatoid	B-DISO
arthritis	I-DISO
(	O
RA	O
),	O
whose	O
infectious	B-DISO
risk	O
is	O
increased	O
compared	O
to	O
the	O
general	O
population	O
because	O
of	O
an	O
overall	O
impairment	B-DISO
of	O
immune	O
system	O
typical	O
of	O
autoimmune	B-DISO
diseases	I-DISO
combined	O
with	O
the	O
iatrogenic	O
effect	O
generated	O
by	O
corticosteroids	O
and	O
immunosuppressive	O
drugs	O
.	O

French	O
Confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
were	O
included	O
in	O
a	O
single	O
arm	O
protocol	O
from	O
early	O
March	O
to	O
March	O
16	O
Six	O
patients	O
were	O
asymptomatic	O
,	O
22	O
had	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
symptoms	O
and	O
eight	O
had	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
symptoms	O
.	O

ABSTRACT	O
:	O
Rapid	O
virological	O
diagnosis	O
is	O
needed	O
to	O
limit	O
the	O
length	O
of	O
isolation	O
for	O
suspected	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
.	O

We	O
managed	O
the	O
first	O
280	O
patients	O
suspected	O
to	O
have	O
COVID	B-DISO
-	I-DISO
19	I-DISO
through	O
a	O
rapid	O
care	O
circuit	O
and	O
virological	O
diagnosis	O
in	O
our	O
infectious	B-DISO
disease	I-DISO
reference	O
hospital	O
in	O
Marseille	O
,	O
France	O
.	O

Other	O
viral	B-DISO
infections	I-DISO
were	O
identified	O
in	O
49	O
%	O
of	O
the	O
patients	O
,	O
with	O
most	O
common	O
pathogens	O
being	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
,	O
rhinovirus	O
,	O
metapneumovirus	O
and	O
common	O
coronaviruses	O
,	O
notably	O
HKU1	O
and	O
NL63	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
lies	O
behind	O
the	O
ongoing	O
outbreak	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

TITLE	O
:	O
Insilico	O
Alpha	O
-	O
Helical	O
Structural	O
Recognition	O
of	O
Temporin	O
Antimicrobial	O
Peptides	O
and	O
Its	O
Interactions	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
Coronavirus	O
.	O

ABSTRACT	O
:	O
Since	O
2012	O
and	O
to	O
date	O
,	O
outbreak	O
/	O
new	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
related	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
were	O
always	O
reported	O
in	O
Saudi	O
Arabia	O
.	O

Our	O
data	O
suggests	O
that	O
2019	O
-	O
nCoV	O
is	O
newly	O
spilled	O
coronavirus	O
into	O
humans	O
in	O
China	O
is	O
closely	O
related	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
has	O
only	O
12	O
.	O
8	O
%	O
of	O
difference	O
with	O
SARS	B-DISO
-	O
CoV	O
in	O
S	O
protein	O
and	O
has	O
83	O
.	O
9	O
%	O
similarity	O
in	O
minimal	O
receptor	O
-	O
binding	O
domain	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Addition	O
of	O
a	O
novel	O
glycosylation	O
sites	O
were	O
observed	O
in	O
2019	O
-	O
nCoV	O
.	O
In	O
addition	O
,	O
antigenic	O
analysis	O
proposes	O
that	O
great	O
antigenic	O
differences	O
exist	O
between	O
both	O
the	O
viral	O
strains	O
,	O
but	O
some	O
of	O
the	O
epitopes	O
were	O
found	O
to	O
be	O
similar	O
between	O
both	O
the	O
S	O
proteins	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
assessing	O
impact	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
on	O
mortality	O
have	O
shown	O
conflicting	O
results	O
.	O

ARDS	B-DISO
was	O
independently	O
associated	O
with	O
ICU	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
(	O
LOS	O
),	O
ICU	O
LOS	O
,	O
and	O
ventilator	O
-	O
free	O
days	O
.	O

Clinical	O
trials	O
targeting	O
patients	O
with	O
severe	O
ARDS	B-DISO
will	O
be	O
best	O
poised	O
to	O
detect	O
measurable	O
differences	O
in	O
these	O
outcomes	O
.	O

RESULTS	O
:	O
ARDS	B-DISO
occurred	O
in	O
195	O
EARLI	O
patients	O
(	O
41	O
%)	O
and	O
99	O
VALID	O
patients	O
(	O
29	O
%).	O

A	O
total	O
of	O
25	O
confirmed	O
pediatric	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
collected	O
.	O

It	O
was	O
concluded	O
that	O
children	O
were	O
susceptible	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
like	O
adults	O
,	O
while	O
the	O
clinical	O
presentations	O
and	O
outcomes	O
were	O
more	O
favorable	O
in	O
children	O
.	O

The	O
experience	O
of	O
the	O
Lombardy	O
underlines	O
the	O
need	O
for	O
gathering	O
and	O
sharing	O
our	O
data	O
to	O
increase	O
our	O
knowledge	O
and	O
support	O
common	O
,	O
initially	O
experience	O
-	O
based	O
,	O
and	O
as	O
soon	O
as	O
possible	O
evidence	O
-	O
based	O
position	O
to	O
face	B-DISO
this	O
overwhelming	O
crisis	O
.	O

Furthermore	O
,	O
complications	O
such	O
as	O
mediastinal	B-DISO
emphysema	I-DISO
,	O
giant	B-DISO
bulla	B-DISO
,	O
and	O
pneumothorax	B-DISO
were	O
also	O
observed	O
during	O
the	O
course	O
of	O
the	O
disease	O
.	O

Based	O
on	O
a	O
VSV	O
pseudovirus	O
production	O
system	O
,	O
a	O
pseudovirus	O
-	O
based	O
neutralization	O
assay	O
has	O
been	O
developed	O
for	O
evaluating	O
neutralizing	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
biosafety	O
level	O
2	O
facilities	O
.	O

Recommendations	O
for	O
clinical	O
researchers	O
working	O
with	O
older	O
adults	O
during	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
are	O
discussed	O
.	O

Assess	O
the	O
psychological	B-DISO
and	O
social	O
impact	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
How	O
are	O
participants	O
coping	O
?	O

CT	O
images	O
of	O
ordinary	O
patients	O
were	O
mainly	O
manifested	O
as	O
solid	O
plaque	B-DISO
shadow	O
and	O
halo	B-DISO
sign	I-DISO
(	O
18	O
/	O
35	O
,	O
51	O
.	O
4	O
%);	O
while	O
fibrous	O
strip	O
shadow	O
with	O
ground	O
glass	O
shadow	O
was	O
more	O
frequent	O
in	O
severe	O
cases	O
(	O
7	O
/	O
22	O
,	O
31	O
.	O
8	O
%).	O

CT	O
images	O
in	O
patients	O
with	O
different	O
clinical	O
types	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
have	O
characteristic	O
manifestations	O
,	O
and	O
solid	O
shadow	O
may	O
predict	O
severe	O
and	O
critical	B-DISO
illness	I-DISO
.	O

Consolidation	O
shadow	O
as	O
the	O
main	O
lesion	O
was	O
observed	O
in	O
7	O
cases	O
,	O
and	O
all	O
of	O
them	O
were	O
severe	O
or	O
critical	O
ill	B-DISO
patients	O
.	O

This	O
paper	O
reports	O
a	O
pregnant	O
woman	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
for	O
whom	O
a	O
cesarean	O
section	O
was	O
successfully	O
performed	O
in	O
our	O
hospital	O
on	O
February	O
8	O
,	O
2020	O
.	O

A	O
total	O
of	O
691	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
had	O
been	O
confirmed	O
as	O
of	O
February	O
23	O
.	O

Passengers	O
confirmed	O
to	O
free	O
from	O
infection	B-DISO
began	O
disembarking	O
on	O
Day	O
15	O
of	O
quarantine	O
(	O
February	O
19	O
).	O

TITLE	O
:	O
Novel	O
2019	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
):	O
An	O
updated	O
overview	O
for	O
emergency	B-DISO
clinicians	O
ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
has	O
quickly	O
become	O
a	O
worldwide	O
threat	O
to	O
health	O
,	O
travel	O
,	O
and	O
commerce	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
strategy	O
and	O
the	O
emergency	B-DISO
management	O
and	O
infection	B-DISO
control	O
procedures	O
of	O
our	O
radiology	O
department	O
during	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
.	O

Our	O
health	O
system	O
has	O
confirmed	O
prior	O
and	O
current	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

UC	O
San	O
Diego	O
Health	O
built	O
multiple	O
COVID	B-DISO
-	I-DISO
19	I-DISO
-	O
specific	O
tools	O
to	O
support	O
outbreak	O
management	O
,	O
including	O
scripted	O
triaging	O
,	O
electronic	O
check	O
-	O
in	O
,	O
standard	O
ordering	O
and	O
documentation	O
,	O
secure	O
messaging	O
,	O
real	O
-	O
time	O
data	O
analytics	O
,	O
and	O
telemedicine	O
capabilities	O
.	O

TITLE	O
:	O
Clinical	O
observation	O
and	O
management	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
.	O

TITLE	O
:	O
All	O
Feet	O
On	O
Deck	O
-	O
The	O
Role	O
of	O
Podiatry	O
During	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Pandemic	O
:	O
ABSTRACT	O
:	O
The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
is	O
driving	O
significant	O
change	O
in	O
the	O
healthcare	O
system	O
and	O
disrupting	O
the	O
best	O
practices	O
for	O
diabetic	O
limb	O
preservation	O
,	O
leaving	O
large	O
numbers	O
of	O
patients	O
without	O
care	O
.	O

Podiatric	O
care	O
is	O
associated	O
with	O
fewer	O
diabetes	B-DISO
-	O
related	O
amputations	O
,	O
ER	O
visits	O
,	O
hospitalizations	O
,	O
length	O
-	O
of	O
-	O
stay	O
,	O
and	O
costs	O
.	O

This	O
includes	O
patients	O
with	O
hypertension	B-DISO
,	O
heart	B-DISO
disease	I-DISO
,	O
diabetes	B-DISO
mellitus	I-DISO
,	O
and	O
clearly	O
the	O
elderly	O
.	O

SARS	B-DISO
-	O
CoV	O
-	O
2	O
with	O
potential	O
origin	O
of	O
bat	O
is	O
still	O
circulating	O
in	O
China	O
.	O

The	O
smooth	O
distance	O
curve	O
for	O
SARS	B-DISO
-	O
CoV	O
suggests	O
that	O
its	O
close	O
relatives	O
still	O
exist	O
in	O
nature	O
and	O
public	O
health	O
is	O
challenged	O
as	O
usual	O
.	O

ABSTRACT	O
:	O
The	O
first	O
case	O
of	O
coronavirus	O
disease	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
Finland	O
was	O
confirmed	O
on	O
29	O
January	O
2020	O
.	O

ABSTRACT	O
:	O
Data	O
concerning	O
the	O
transmission	O
of	O
the	O
novel	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
in	O
paucisymptomatic	O
patients	O
are	O
lacking	O
.	O

TITLE	O
:	O
Publishing	O
in	O
the	O
time	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
This	O
paper	O
concerns	O
study	O
of	O
the	O
genome	O
of	O
the	O
Wuhan	O
Seafood	O
Market	O
isolate	O
believed	O
to	O
represent	O
the	O
causative	O
agent	O
of	O
the	O
disease	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

This	O
study	O
is	O
performed	O
to	O
analyze	O
the	O
clinical	O
characteristics	O
of	O
patients	O
who	O
succumbed	O
to	O
and	O
who	O
recovered	O
from	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

On	O
admission	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
symptoms	O
of	O
dyspnea	B-DISO
(	O
70	O
.	O
6	O
%	O
vs	O
.	O
24	O
.	O
7	O
%,	O
χ	O
=	O
60	O
.	O
905	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
expectoration	O
(	O
32	O
.	O
1	O
%	O
vs	O
.	O
15	O
.	O
7	O
%,	O
χ	O
=	O
13	O
.	O
250	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
was	O
significantly	O
higher	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
intensive	O
care	O
.	O

It	O
is	O
not	O
uncommon	O
for	O
IC	O
-	O
HCPs	O
to	O
get	O
carried	O
away	O
during	O
an	O
emergent	O
situation	O
,	O
such	O
as	O
that	O
posed	O
by	O
a	O
suddenly	O
deteriorating	O
patient	O
,	O
and	O
forgo	O
the	O
protective	O
barriers	O
that	O
protect	O
them	O
from	O
contracting	O
a	O
communicable	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Pneumonitis	B-DISO
and	O
pneumonia	B-DISO
after	O
non	O
-	O
fatal	O
drowning	O
are	O
common	O
and	O
the	O
pathogens	O
involved	O
are	O
numerous	O
.	O

The	O
diagnosis	O
was	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
caused	O
by	O
aspiration	B-DISO
pneumonitis	I-DISO
as	O
a	O
result	O
of	O
non	O
-	O
fatal	O
drowning	O
and	O
septic	B-DISO
shock	I-DISO
.	O

Microscopic	O
analysis	O
revealed	O
diffuse	O
filamentous	O
fungi	O
throughout	O
the	O
lungs	O
,	O
heart	O
,	O
stomach	O
,	O
thyroid	O
gland	O
,	O
and	O
the	O
pulmonary	B-DISO
embolus	I-DISO
,	O
which	O
were	O
identified	O
as	O
Invasive	B-DISO
aspergillosis	I-DISO
should	O
also	O
be	O
considered	O
in	O
immunocompetent	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
after	O
non	O
-	O
fatal	O
drowning	O
who	O
do	O
not	O
respond	O
to	O
broad	O
-	O
spectrum	O
antibiotics	O
.	O

The	O
most	O
recent	O
of	O
these	O
zoonotic	O
events	O
that	O
have	O
caused	O
an	O
ongoing	O
epidemic	O
of	O
high	O
magnitude	O
is	O
the	O
Covid	B-DISO
-	I-DISO
19	I-DISO
epidemics	O
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

However	O
,	O
information	O
on	O
cardiac	O
injury	O
in	O
patients	O
affected	O
by	O
COVID	B-DISO
-	I-DISO
19	I-DISO
is	O
limited	O
.	O

TITLE	O
:	O
Analysis	O
of	O
Epidemiological	O
and	O
Clinical	O
features	O
in	O
older	O
patients	O
with	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
out	O
of	O
Wuhan	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
epidemiological	O
and	O
clinical	O
characteristics	O
of	O
older	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
out	O
of	O
Wuhan	O
.	O

Significantly	O
increased	O
CT	O
score	O
may	O
indicate	O
the	O
aggravation	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
progressive	O
stage	O
.	O

ABSTRACT	O
:	O
The	O
world	O
must	O
act	O
fast	O
to	O
contain	O
wider	O
international	O
spread	O
of	O
the	O
epidemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
now	O
.	O

To	O
avoid	O
any	O
airway	O
manipulation	O
,	O
regional	O
anesthesia	B-DISO
should	O
be	O
considered	O
whenever	O
surgery	O
is	O
planned	O
for	O
a	O
suspect	O
or	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patient	O
or	O
any	O
patient	O
who	O
poses	O
an	O
infection	B-DISO
risk	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
is	O
not	O
the	O
first	O
,	O
and	O
certainly	O
will	O
not	O
be	O
the	O
last	O
novel	O
virus	O
that	O
will	O
lead	O
to	O
worldwide	O
outbreaks	O
.	O

TITLE	O
:	O
Why	O
is	O
COVID	B-DISO
-	I-DISO
19	I-DISO
so	O
mild	O
in	O
children	O
?	O

TITLE	O
:	O
The	O
Trial	O
of	O
Chloroquine	O
in	O
the	O
Treatment	O
of	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
（	B-DISO
COVID	I-DISO
-	I-DISO
19	O
）	O
and	O
Its	O
Research	O
Progress	O
in	O
Forensic	O
Toxicology	O
.	O

